id	species	ncrna	ncrna_type	ef	phenotype	sample	ef_condition	evidence	pmid
1	Aedes aegypti mosquitoe	aae-miR-286b	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	Aedes aegypti	infect with ZIKV treatment	dysregulated	28715413
2	Aedes aegypti mosquitoe	aae-miR-2940	miRNA	wolbachia	wolbachia infection	aedes aegypti mosquitoes	wolbachia-infected treatment	upregulated	25158106
3	Aedes aegypti mosquitoe	aae-miR-2941	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	Aedes aegypti	infect with ZIKV treatment	dysregulated	28715413
4	Aedes aegypti mosquitoe	aae-miR-308	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	Aedes aegypti	infect with ZIKV treatment	dysregulated	28715413
5	Aedes aegypti mosquitoe	aae-miR-309a	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	Aedes aegypti	infect with ZIKV treatment	dysregulated	28715413
6	Aedes aegypti mosquitoe	aae-miR-989	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	Aedes aegypti	infect with ZIKV treatment	dysregulated	28715413
24	Anopheles anthropophagus	aan-miR-275	miRNA	plasmodium	plasmodium infection	anopheles anthropophagus midgut	plasmodium treatment	downregulated in midgut	28209211
25	Anopheles anthropophagus	aan-miR-92a	miRNA	plasmodium	plasmodium infection	anopheles anthropophagus midgut	plasmodium treatment	upregulated in midgut	28209211
26	Anopheles gambiae	aga-miR-133	miRNA	rodent malaria parasite Plasmodium berghei	expression regulation	de novo A. gambiae	infect with rodent malaria parasite Plasmodium berghei treatment	upregulated	24997592
27	Anopheles gambiae	aga-miR-1891	miRNA	rodent malaria parasite Plasmodium berghei	expression regulation	de novo A. gambiae	infect with rodent malaria parasite Plasmodium berghei treatment	upregulated	24997592
28	Anopheles gambiae	aga-miR-278	miRNA	rodent malaria parasite Plasmodium berghei	expression regulation	de novo A. gambiae	infect with rodent malaria parasite Plasmodium berghei treatment	upregulated	24997592
29	Anopheles gambiae	aga-miR-281	miRNA	rodent malaria parasite Plasmodium berghei	expression regulation	de novo A. gambiae	infect with rodent malaria parasite Plasmodium berghei treatment	upregulated	24997592
30	Anopheles gambiae	aga-miR-305	miRNA	P. falciparum	anti-Plasmodium response	mosquito	P. falciparum infected treatment	upregulated	25445902
31	Anopheles gambiae	aga-miR-929	miRNA	rodent malaria parasite Plasmodium berghei	expression regulation	de novo A. gambiae	infect with rodent malaria parasite Plasmodium berghei treatment	upregulated	24997592
32	Anopheles gambiae	aga-miR-965	miRNA	rodent malaria parasite Plasmodium berghei	expression regulation	de novo A. gambiae	infect with rodent malaria parasite Plasmodium berghei treatment	upregulated	24997592
33	Anopheles gambiae	aga-miR-989	miRNA	P. falciparum	anti-Plasmodium response	mosquito	P. falciparum infected treatment	upregulated	25445902
34	Apostichopus japonicus	spu-miR-137	miRNA	lipopolysaccharide (LPS)	apoptosis	sea cucumber primary cell	1 mg mL-1 of LPS from Escherichia coli	downregulated	27832949
35	Apostichopus japonicus	spu-miR-138	miRNA	vibrio splendidus	apoptosis	healthy adult sea cucumber Apostichopus japonicus	infect with Vibrio splendiduss treatment	downregulated	27832949
36	Apple	MLNC3.2	lncRNA	light	anthocyanin biosynthetic	apple peels from the 'Red Fuji' cultivar	light treatment	dysregulated	31344284
37	Apple	MLNC4.6	lncRNA	light	anthocyanin biosynthetic	apple peels from the 'Red Fuji' cultivar	light treatment	dysregulated	31344284
38	Apple	mdm-miR156a	miRNA	light	anthocyanin biosynthetic	apple peels from the 'Red Fuji' cultivar	light treatment	dysregulated	31344284
39	Arabidopsis thaliana	AK221488	lncRNA	fusarium oxysporum	infection of Fusarium oxysporum	Arabidopsis thaliana	Fusarium oxysporum infection treatment	dysregulated	24117540
40	Arabidopsis thaliana	AK226818	lncRNA	fusarium oxysporum	infection of Fusarium oxysporum	Arabidopsis thaliana	Fusarium oxysporum infection treatment	dysregulated	24117540
41	Arabidopsis thaliana	At2g30770	lncRNA	fusarium oxysporum	infection of Fusarium oxysporum	Arabidopsis thaliana	Fusarium oxysporum infection treatment	dysregulated	24117540
42	Arabidopsis thaliana	ath-miR156	miRNA	salt and drought stress	adaptation to the environment	Arabidopsis	under stress conditions treatment	upregulated	25345491
43	Arabidopsis thaliana	ath-miR156	miRNA	recurring heat stress (HS memory)	heat stress	arabidopsis thaliana	HS treatment	upregulated	24769482
44	Arabidopsis thaliana	ath-miR156a	miRNA	glucose	extended juvenile development	Arabidopsis seedlings	MS medium containing 10 mM Glucose	downregulated	28108181
45	Arabidopsis thaliana	ath-miR156a	miRNA	sugar	vegetative phase change	Arabidopsis thaliana	Sugar?treatment treatment	downregulated	23538384
46	Arabidopsis thaliana	ath-miR156c	miRNA	glucose	extended juvenile development	Arabidopsis seedlings	MS medium containing 10 mM Glucose	downregulated	28108181
47	Arabidopsis thaliana	ath-miR156c	miRNA	sugar	vegetative phase change	Arabidopsis thaliana	Sugar?treatment treatment	downregulated	23538384
48	Arabidopsis thaliana	ath-miR156h	miRNA	root knot nematodes (RKN)	root-knot nematodes (RKNs) infection	Arabidopsis root	RKN treatment	strong activity within galls	28906559
49	Arabidopsis thaliana	ath-miR160	miRNA	sulfur dioxide (SO2)	botrytis cinerea (B. cinerea) infection	arabidopsis plants	sulfur dioxide (SO2) treatment	upregulated	28917191
50	Arabidopsis thaliana	ath-miR163	miRNA	root knot nematodes (RKN)	root-knot nematodes (RKNs) infection	Arabidopsis root	RKN treatment	strong activity within galls	28906559
51	Arabidopsis thaliana	ath-MIR165a	miRNA	abscisic acid (ABA)	xylem patterning and maturation	Arabidopsis protoxylem (PX)	abscisic acid (ABA) treatment	upregulated	31399468
52	Arabidopsis thaliana	ath-MIR166b	miRNA	abscisic acid (ABA)	xylem patterning and maturation	Arabidopsis protoxylem (PX)	abscisic acid (ABA) treatment	upregulated	31399468
53	Arabidopsis thaliana	ath-miR167	miRNA	sulfur dioxide (SO2)	botrytis cinerea (B. cinerea) infection	arabidopsis plants	sulfur dioxide (SO2) treatment	upregulated	28917191
54	Arabidopsis thaliana	ath-miR2111a-3p	miRNA	root knot nematodes (RKN)	root-knot nematodes (RKNs) infection	Arabidopsis root	RKN treatment	strong activity within galls	28906559
55	Arabidopsis thaliana	ath-miR393	miRNA	salt	acclimation to salinity	arabidopsis thaliana seeds	culture at salt (ATS) medium treatment	upregulated	25222737
56	Arabidopsis thaliana	ath-miR393	miRNA	sulfur dioxide (SO2)	botrytis cinerea (B. cinerea) infection	arabidopsis plants	sulfur dioxide (SO2) treatment	upregulated	28917191
57	Arabidopsis thaliana	ath-miR395	miRNA	sulfur dioxide (SO2)	sulfur dioxide (SO2) stress and oxidative stress	Arabidopsis shoots	SO2 treatment	downregulated(miR-398) and upregulated (miR-395)	28819808
58	Arabidopsis thaliana	ath-miR396	miRNA	ultraviolet (UV) irradiation	cell proliferation	proliferating tissues	UV-B radiation treatment	upregulated	24076976
59	Arabidopsis thaliana	ath-MIR398	miRNA	boron	boron toxicity	Arabidopsis thaliana seedlings	boron treatment	upregulated	27794275
60	Arabidopsis thaliana	ath-miR398	miRNA	sulfur dioxide (SO2)	sulfur dioxide (SO2) stress and oxidative stress	Arabidopsis shoots	SO2 treatment	downregulated(miR-398) and upregulated (miR-395)	28819808
61	Arabidopsis thaliana	ath-miR414c	miRNA	Salinity	plant salinity tolerance	Arabidopsis	Salinity stress induce treatment	downregulated	30676211
62	Arabidopsis thaliana	ath-miR5090	miRNA	duplication of AOP2	nitrogen starvation	Arabidopsis thaliana	duplication of AOP2 treatment	upregulated	24367020
63	Arabidopsis thaliana	ath-miR826	miRNA	duplication of AOP2	nitrogen starvation	Arabidopsis thaliana	duplication of AOP2 treatment	upregulated	24367020
64	Arabidopsis thaliana	ath-miR831	miRNA	root knot nematodes (RKN)	root-knot nematodes (RKNs) infection	Arabidopsis root	RKN treatment	strong activity within galls	28906559
65	Arabidopsis thaliana	ath-miR861-5p	miRNA	root knot nematodes (RKN)	root-knot nematodes (RKNs) infection	Arabidopsis root	RKN treatment	strong activity within galls	28906559
66	Arabidopsis thaliana	DRIR	lncRNA	abscisic acid (ABA)	response to abiotic stress	arabidopsis	abscisic acid (ABA) treatment	downregulated	28887353
67	Arabidopsis thaliana	DRIR	lncRNA	salt	response to abiotic stress	arabidopsis	salt stress	downregulated	28887353
68	Arabidopsis thaliana	T5120	lncRNA	nitrate	nitrate regulation	Arabidopsis seedling roots	nitrate treatment	upregulated	31264223
69	Asian tiger mosquito	aal-miR-252	miRNA	dengue virus serotype 2 (DENV-2)	dengue virus (DENV) infection	Ae. albopictus C6/36 cellline	wih dengue virus serotype 2 (DENV-2) infection treatment	upregulated	25025105
70	Atlantic cod	gmo-miR-128-3-5p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	antiviral immune response	Atlantic cod (Gadus morhua) macrophages	poly (I:C) treatment	upregulated	29190475
71	Atlantic cod	gmo-miR-199-1-3p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	antiviral immune response	Atlantic cod (Gadus morhua) macrophages	poly (I:C) treatment	downregulated	29190475
72	Atlantic cod	gmo-miR-214-1-5p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	antiviral immune response	Atlantic cod (Gadus morhua) macrophages	poly (I:C) treatment	upregulated	29190475
73	Atlantic cod	gmo-miR-30b-3p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	antiviral immune response	Atlantic cod (Gadus morhua) macrophages	poly (I:C) treatment	downregulated	29190475
74	Atlantic cod	gmo-miR-451-3p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	antiviral immune response	Atlantic cod (Gadus morhua) macrophages	poly (I:C) treatment	upregulated	29190475
75	Baboon	pan-miR-124	miRNA	¦Ã-rays	hematological acute radiation syndrome (HARS)	baboons peripheral blood on day 1 after exposure	irradiated with 2.5 or 5 Gy	upregulated in the peripheral blood on day 1 after exposure	28236054
76	Baboon	pan-miR-150-5p	miRNA	simvastatin	endometriosis	serum	simvastatin treatment	downregulated	29587611
77	Baboon	pan-miR-29c	miRNA	¦Ã-rays	hematological acute radiation syndrome (HARS)	baboons peripheral blood on day 1 after exposure	irradiated with 2.5 or 5 Gy	upregulated in the peripheral blood on day 1 after exposure	28236054
78	Baboon	pan-miR-3613-5p	miRNA	simvastatin	endometriosis	serum	simvastatin treatment	upregulated	29587611
79	Baboon	pan-miR-378	miRNA	¦Ã-rays	hematological acute radiation syndrome (HARS)	baboons peripheral blood on day 1 after exposure	irradiated with 2.5 or 5 Gy	upregulated in the peripheral blood on day 1 after exposure	28236054
80	Baboon	pan-miR-451a	miRNA	simvastatin	endometriosis	serum	simvastatin treatment	downregulated	29587611
81	Baboon	pan-miR-574-3p	miRNA	¦Ã-rays	hematological acute radiation syndrome (HARS)	baboons peripheral blood on day 1 after exposure	irradiated with 2.5 or 5 Gy	upregulated in the peripheral blood on day 1 after exposure	28236054
82	Baboon	pan-miR-7	miRNA	¦Ã-rays	hematological acute radiation syndrome (HARS)	baboons peripheral blood on day 1 after exposure	irradiated with 2.5 or 5 Gy	upregulated in the peripheral blood on day 1 after exposure	28236054
83	Barley	Hv-miR1432	miRNA	drought	abiotic stress response	barley	drought treatments	dysregulated	27155357
84	Barley	Hv-mir160a	miRNA	heat stress	heat-responsive	barley	high temperature treatment	upregulated	25183744
85	Barley	Hv-mir166a	miRNA	heat stress	heat-responsive	barley	high temperature treatment	upregulated	25183744
86	Barley	Hv-miR166b	miRNA	drought	abiotic stress response	barley	drought treatments	dysregulated	27155357
87	Barley	Hv-miR166b	miRNA	aluminum (Al)	aluminum (Al) toxicity	barley	Al treatment	downregulated	32588054
88	Barley	Hv-miR166c	miRNA	drought	abiotic stress response	barley	drought treatments	dysregulated	27155357
89	Barley	Hv-mir167h	miRNA	heat stress	heat-responsive	barley	high temperature treatment	upregulated	25183744
90	Barley	Hv-miR169b	miRNA	drought	abiotic stress response	barley	drought treatments	dysregulated	27155357
91	Barley	Hv-mir5175a	miRNA	heat stress	heat-responsive	barley	high temperature treatment	upregulated	25183744
92	Barley	Hv-miRx5	miRNA	drought	abiotic stress response	barley	drought treatments	dysregulated	27155357
93	Barley	TCONS_00002619	lncRNA	boric acid	barley development and environmental response	Barley	boric acid treatment	"Compared to the untreated control, the abundance of TCONS_00002619 transcripts dramatically increased in the root of Sahara exposed by excess-B."	31730798
94	Barley	TCONS_00006186	lncRNA	boric acid	barley development and environmental response	Barley	boric acid treatment	"Compared to the untreated control, the abundance of TCONS_00006186 transcripts dramatically increased in the leaf of Sahara exposed by excess-B."	31730798
95	Barley	TCONS_00045190	lncRNA	boric acid	barley development and environmental response	Barley	boric acid treatment	"Compared to the untreated control, the abundance of TCONS_00045190 transcripts dramatically increased in the root of Sahara exposed by excess-B."	31730798
96	Barley	TCONS_00056415	lncRNA	boric acid	barley development and environmental response	Barley	boric acid treatment	"Compared to the untreated control, the abundance of TCONS_00056415 transcripts dramatically increased in the leaf of Sahara exposed by excess-B."	31730798
97	Barley	TCONS_00077802	lncRNA	boric acid	barley development and environmental response	Barley	boric acid treatment	"Compared to the untreated control, the abundance of TCONS_00077802 transcripts dramatically increased in the leaf of Sahara exposed by excess-B."	31730798
99	Bombus terrestris	bte-miR-100	miRNA	"slow bee paralysis virus (SBPV), Israeli acute paralysis virus (IAPV)"	bee-virus interaction	bumblebee	"SBPV,IAPV treatment"	dysregulated	28374846
100	Bombus terrestris	bte-miR-281	miRNA	"slow bee paralysis virus (SBPV), Israeli acute paralysis virus (IAPV)"	bee-virus interaction	bumblebee	"SBPV,IAPV treatment"	dysregulated	28374846
101	Bombus terrestris	bte-miR-34	miRNA	"slow bee paralysis virus (SBPV), Israeli acute paralysis virus (IAPV)"	bee-virus interaction	bumblebee	"SBPV,IAPV treatment"	dysregulated	28374846
102	Bombus terrestris	bte-miR-87	miRNA	"slow bee paralysis virus (SBPV), Israeli acute paralysis virus (IAPV)"	bee-virus interaction	bumblebee	"SBPV,IAPV treatment"	dysregulated	28374846
7	Branchiostoma belcheri	bbe-miR-10b-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
8	Branchiostoma belcheri	bbe-miR-10c-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	downregulated	28069432
9	Branchiostoma belcheri	bbe-miR-125a-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
10	Branchiostoma belcheri	bbe-miR-190-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	downregulated	28069432
11	Branchiostoma belcheri	bbe-miR-2063-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	downregulated	28069432
12	Branchiostoma belcheri	bbe-miR-29a-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
13	Branchiostoma belcheri	bbe-miR-31-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
14	Branchiostoma belcheri	bbe-miR-33-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	downregulated	28069432
15	Branchiostoma belcheri	bbe-miR-34a-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	downregulated	28069432
16	Branchiostoma belcheri	bbe-miR-34b-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
17	Branchiostoma belcheri	bbe-miR-4866-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
18	Branchiostoma belcheri	bbe-miR-4874-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
19	Branchiostoma belcheri	bbe-miR-4877-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	downregulated	28069432
20	Branchiostoma belcheri	bbe-miR-92a-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
21	Branchiostoma belcheri	bbe-miR-92b-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
22	Branchiostoma belcheri	bbe-miR-92c-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	upregulated	28069432
23	Branchiostoma belcheri	bbe-miR-92d-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	gills of amphioxus Branchiostoma belcheri	lipopolysaccharide (LPS) treatment	downregulated	28069432
24120	Bread wheat	tae-miR10004	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24121	Bread wheat	tae-miR10008	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24122	Bread wheat	tae-miR10009	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24123	Bread wheat	tae-miR1130c	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24124	Bread wheat	tae-miR156	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	downregulated	28241738
24125	Bread wheat	tae-miR159	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24126	Bread wheat	tae-miR159a	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24127	Bread wheat	tae-miR160	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24128	Bread wheat	tae-miR160b	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24129	Bread wheat	tae-miR165a	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24130	Bread wheat	tae-miR166	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24131	Bread wheat	tae-miR167	miRNA	angiostrongylus cantonensis (A. cantonensis)	rhizobium infection	wheat between shoots and roots	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	27858182
24132	Bread wheat	tae-miR169	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	downregulated	28241738
24133	Bread wheat	tae-miR169	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24134	Bread wheat	tae-miR171	miRNA	angiostrongylus cantonensis (A. cantonensis)	rhizobium infection	wheat between shoots and roots	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	27858182
24135	Bread wheat	tae-miR171a	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	downregulated	28241738
24136	Bread wheat	tae-miR171c	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24137	Bread wheat	tae-miR172	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24138	Bread wheat	tae-miR1858	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24139	Bread wheat	tae-miR2118	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24140	Bread wheat	tae-miR2118a	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24141	Bread wheat	tae-miR319a	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	upregulated	28241738
24142	Bread wheat	tae-miR393	miRNA	angiostrongylus cantonensis (A. cantonensis)	rhizobium infection	wheat between shoots and roots	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	27858182
24143	Bread wheat	tae-miR395	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24144	Bread wheat	tae-miR396	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24145	Bread wheat	tae-miR408	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24146	Bread wheat	tae-miR444c	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	downregulated	28241738
24147	Bread wheat	tae-miR472	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24148	Bread wheat	tae-miR477	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24149	Bread wheat	tae-miR482	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24150	Bread wheat	tae-miR5048a	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	downregulated	28241738
24151	Bread wheat	tae-miR5049	miRNA	drought	crop growth	leaf and root	drought treatments	dysregulated	26141043
24152	Bread wheat	tae-miR827	miRNA	low temperature	cold stress	seeds of common wheat cultivar JM22	germinated and grown in a 4 ¡ãC chamber for vernalization	downregulated	28241738
153	Caenorhabditis elegans	cel-miR-124	miRNA	polysaccharide (APS)	longevity	Caenorhabditis elegans	polysaccharide (APS) treatment	upregulated	25186652
154	Caenorhabditis elegans	cel-miR-228	miRNA	dietary restriction (DR)	prolong longevity	OP50 E. coli	Dietary restriction (DR) induce	upregulated	25242029
155	Caenorhabditis elegans	cel-miR-235	miRNA	dietary restriction (DR)	dietary restriction (DR)-induced longevity in Caenorhabditis elegans	Caenorhabditis elegans	Dietary restriction (DR) induce	upregulated	30872315
156	Caenorhabditis elegans	cel-mir-237	miRNA	¦Ã-rays	enhance radiation sensitivity	Caenorhabditis elegans	¦Ã-irradiation treatment	downregulated	27321180
157	Caenorhabditis elegans	cel-mir-237	miRNA	ionizing radiation (IR)	ionizing radiation (IR) injury	vulval cell	ionizing radiation (IR) treatment	downregulated	27321180
158	Caenorhabditis elegans	cel-miR-34-5p	miRNA	enoxacin	aging	Caenorhabditis elegans	enoxacin treatment	Enoxacin treatment downregulated miR-34-5p.	29986212
159	Caenorhabditis elegans	cel-miR-35	miRNA	multiwalled carbon nanotubes (MWCNT)	multi-walled carbon nanotubes (MWCNTs) toxicity	intestine	multi-walled carbon nanotubes (MWCNTs) exposure	upregulated	31434956
160	Caenorhabditis elegans	cel-miR-67	miRNA	P. aeruginosa PA14	P. aeruginosa PA14 infection	worms	Exposure to P. aeruginosa PA14 treatment	upregulated	29050943
161	Caenorhabditis elegans	cel-miR-71	miRNA	dietary restriction (DR)	prolong longevity	OP50 E. coli	Dietary restriction (DR) induce	upregulated	25242029
162	Caenorhabditis elegans	linc-18	lncRNA	nanopolystyrene	nanopolystyrene toxicity	Caenorhabditis elegans	nanopolystyrene exposure	upregulated	31541829
163	Caenorhabditis elegans	linc-2	lncRNA	nanopolystyrene	nanopolystyrene toxicity	Caenorhabditis elegans	nanopolystyrene exposure	upregulated	31541829
164	Caenorhabditis elegans	linc-50	lncRNA	nanopolystyrene	nanopolystyrene toxicity	Caenorhabditis elegans	nanopolystyrene exposure	downregulated	31541829
165	Caenorhabditis elegans	linc-61	lncRNA	nanopolystyrene	nanopolystyrene toxicity	Caenorhabditis elegans	nanopolystyrene exposure	upregulated	31541829
166	Caenorhabditis elegans	linc-9	lncRNA	nanopolystyrene	nanopolystyrene toxicity	Caenorhabditis elegans	nanopolystyrene exposure	upregulated	31541829
179	Cat	fca-miR-101	miRNA	feline herpesvirus 1 (FHV-1)	feline herpesvirus 1 (FHV-1) infection	F81 cells	feline herpesvirus 1 (FHV-1) infection	FHV-1 infection upregulated the expression level of miR-101 in a cGAS-dependent manner.	32456815
103	Cattle	bta-miR-106a	miRNA	TGF-¦Â1	cell proliferation	bovine granulosa cells	TGF-¦Â1 treatment	upregulated	29665451
104	Cattle	bta-miR-106a	miRNA	interferon tau (IFNT)	IFNT effect on endometrium	bovine endometrial cells	interferon tau (IFNT) treatment	upregulated	27091464
105	Cattle	bta-miR-125b	miRNA	escherichia coli lipopolysaccharides and staphylococcus aureus enterotoxin B	inflammatory response	CD14(+) bovine monocytes	Escherichia coli lipopolysaccharides and Staphylococcus aureus enterotoxin B treatment	downregulated	22033210
106	Cattle	bta-miR-1434-5p	miRNA	TGF-¦Â1	cell proliferation	bovine granulosa cells	TGF-¦Â1 treatment	upregulated	29665451
107	Cattle	bta-miR-146a	miRNA	quercetin	bovine mastitis	bovine neutrophil	quercetin treatment	downregulated	28507412
108	Cattle	bta-miR-146a	miRNA	escherichia coli lipopolysaccharides and staphylococcus aureus enterotoxin B	inflammatory response	CD14(+) bovine monocytes	Escherichia coli lipopolysaccharides and Staphylococcus aureus enterotoxin B treatment	downregulated	22033210
109	Cattle	bta-miR-146a	miRNA	lipopolysaccharide (LPS)	smooth muscle cell differentiation	CD14(+) bovine monocytes	lipopolysaccharide (LPS) treatment	upregulated	22033210
110	Cattle	bta-miR-148a	miRNA	lipopolysaccharide (LPS)	endometriosis	primary bovine endometrial epithelial cells (bEECs)	lipopolysaccharide (LPS) treatment	upregulated	31756048
111	Cattle	bta-miR-148b	miRNA	IFN-¦Ó	innate immune response	primary bovine endometrial epithelial cells (bEECs) and an endometrial epithelial cell line (BEND)	IFN-¦Ó treatment	downregulated	29456541
112	Cattle	bta-miR-152	miRNA	IFN-¦Ó	innate immune response	primary bovine endometrial epithelial cells (bEECs) and an endometrial epithelial cell line (BEND)	IFN-¦Ó treatment	downregulated	29456541
113	Cattle	bta-miR-155	miRNA	escherichia coli lipopolysaccharides and staphylococcus aureus enterotoxin B	inflammatory response	CD14(+) bovine monocytes	Escherichia coli lipopolysaccharides and Staphylococcus aureus enterotoxin B treatment	downregulated	22033210
114	Cattle	bta-miR-155	miRNA	lipopolysaccharide (LPS)	smooth muscle cell differentiation	CD14(+) bovine monocytes	LPS treatment	upregulated	22033210
115	Cattle	bta-miR-15a	miRNA	trichostatin A (TSA)	cell cycle arrest	Bovine donor cells	50 nM TSA-ed cells were synchronized at G0/G1 stage treatment	upregulated	25151601
116	Cattle	bta-miR-16	miRNA	trichostatin A (TSA)	cell cycle arrest	Bovine donor cells	50 nM TSA-ed cells were synchronized at G0/G1 stage treatment	upregulated	25151601
117	Cattle	bta-miR-181c	miRNA	quercetin	bovine mastitis	bovine neutrophil	quercetin treatment	downregulated	28507412
118	Cattle	bta-miR-183	miRNA	lipopolysaccharide (LPS)	inflammation	bovine endometrial cells	treated with 1 ¦Ìg/mL LPS for 24 h	upregulated	29191705
119	Cattle	bta-miR-19a	miRNA	lipopolysaccharide (LPS)	endometriosis	bovine endometrial epithelial cells (bEECs)	lipopolysaccharide (LPS) treatment	downregulated	30673803
120	Cattle	bta-miR-20a	miRNA	lipopolysaccharide (LPS)	inflammation	bovine endometrial cells	treated with 1 ¦Ìg/mL LPS for 24 h	downregulated	29191705
121	Cattle	bta-miR-221	miRNA	TGF-¦Â1	corpus luteum regression	bovine luteal endothelial cells (LECs)	transforming growth factor (TGF)¦Â1 treatment	downregulated	29228113
122	Cattle	bta-miR-221	miRNA	fibroblast growth factor 2 (FGF2)	corpus luteum regression	bovine luteal endothelial cells (LECs)	fibroblast growth factor-2 (FGF2) treatment	upregulated	29228113
123	Cattle	bta-miR-223	miRNA	Staphylococcus aureus	bovine mastitis	mastitic udder tissues	(Staphylococcus aureus) S. aureus infection treatment	upregulated	33195489
124	Cattle	bta-miR-223	miRNA	escherichia coli lipopolysaccharides and staphylococcus aureus enterotoxin B	inflammatory response	CD14(+) bovine monocytes	Escherichia coli lipopolysaccharides and Staphylococcus aureus enterotoxin B treatment	downregulated	22033210
125	Cattle	bta-miR-24-2	miRNA	quercetin	bovine mastitis	bovine neutrophil	quercetin treatment	downregulated	28507412
126	Cattle	bta-miR-26b	miRNA	lipopolysaccharide (LPS)	inflammatory response	bovine alveolar macrophages (bAMs)	lipopolysaccharide (LPS) treatment	upregulated	26503952
127	Cattle	bta-miR-34a	miRNA	trichostatin A (TSA)	cell cycle arrest	Bovine donor cells	50 nM TSA-ed cells were synchronized at G0/G1 stage treatment	upregulated	25151601
128	Cattle	bta-miR-365-3p	miRNA	lipopolysaccharide (LPS)	inflammation	bovine endometrial cells	treated with 1 ¦Ìg/mL LPS for 24 h	downregulated	29191705
129	Cattle	bta-miR-375	miRNA	lipopolysaccharide (LPS)	inflammation	bovine endometrial cells	treated with 1 ¦Ìg/mL LPS for 24 h	upregulated	29191705
130	Cattle	bta-miR-448	miRNA	lipopolysaccharide (LPS)	endometriosis	"Bovine endometrial epithelial cell line (bEECs, BEND cells)"	lipopolysaccharides (LPS) treatment	downregulated	31674024
131	Cattle	bta-miR-449b	miRNA	doxycycline	apoptosis	bovine fetal fibroblasts	doxycycline (DXC) treatment	upregulated	29042680
132	Cattle	bta-miR-9	miRNA	escherichia coli lipopolysaccharides and staphylococcus aureus enterotoxin B	inflammatory response	CD14(+) bovine monocytes	Escherichia coli lipopolysaccharides and Staphylococcus aureus enterotoxin B treatment	downregulated	22033210
133	Cattle	bta-miR-98	miRNA	caprine parainfluenza virus type 3 (CPIV3)	viral replication	Madin-Darby bovine kidney (MDBK) cells	caprine parainfluenza virus type 3 (CPIV3) infection	Bta-miR-98 Suppresses Replication of Caprine Parainfluenza Virus Type 3 Through Inhibiting Apoptosis by Targeting Caspase-3	32983081
134	Cattle	H19	lncRNA	lipopolysaccharide (LPS)	cell proliferation	bovine mammary epithelial cells (MAC-T).	lipopolysaccharide (LPS) treatment	upregulated	30984483
135	Cattle	XIST	lncRNA	escherichia coli (E.coli)	bovine mastitis	bovine mammary alveolar cell-T (MAC-T)	Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) infection	upregulated	30362186
136	Cattle	XIST	lncRNA	Staphylococcus aureus	bovine mastitis	bovine mammary alveolar cell-T (MAC-T)	Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) infection treatment	upregulated	30362186
149	Cattle	bta-miR-35a	miRNA	either toxic or non-toxic fescue seed diets	fescue toxicosis	Angus bulls sperm	s of either toxic or non-toxic fescue seed diets treatment	upregulated	25462855
150	Cattle	bta-miR-36a	miRNA	either toxic or non-toxic fescue seed diets	fescue toxicosis	Angus bulls sperm	s of either toxic or non-toxic fescue seed diets treatment	upregulated	25462855
151	Cattle	bta-miR-37a	miRNA	either toxic or non-toxic fescue seed diets	fescue toxicosis	Angus bulls sperm	s of either toxic or non-toxic fescue seed diets treatment	upregulated	25462855
152	Cattle	bta-miR-38a	miRNA	either toxic or non-toxic fescue seed diets	fescue toxicosis	Angus bulls sperm	s of either toxic or non-toxic fescue seed diets treatment	upregulated	25462855
328	Cattle	bta-miR-132	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	upregulated	31722768
329	Cattle	bta-miR-143	miRNA	metabolizable energy (ME)	adipogenesis	low body condition score (BCS) cows subcutaneous adipose tissue	overfed ME	upregulated in subcutaneous adipose tissue	28088407
330	Cattle	bta-miR-145	miRNA	Staphylococcus aureus	dairy cow mastitis	dairy cows mammary gland tissue	Staphylococcus aureus infection treatment	downregulated	30974481
331	Cattle	bta-miR-145	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	downregulated	31722768
332	Cattle	bta-miR-15a	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	"Differential expression of miR-15a and interleukin-1 receptor-associated kinase-like 2 (IRAK2), were evaluated by western blot and luciferase reporter assays"	31722768
333	Cattle	bta-miR-184	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	upregulated	31722768
334	Cattle	bta-miR-196a	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	downregulated	31722768
335	Cattle	bta-miR-200b	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	downregulated	31722768
336	Cattle	bta-miR-205	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	downregulated	31722768
337	Cattle	bta-miR-223	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	upregulated	31722768
338	Cattle	bta-miR-31	miRNA	Staphylococcus aureus	mastitis	Chinese Holstein cows	Staphylococcus aureus infection treatment	downregulated	31722768
339	Cattle	bta-miR-378	miRNA	metabolizable energy (ME)	adipogenesis	low body condition score (BCS) cows subcutaneous adipose tissue	overfed ME	upregulated in subcutaneous adipose tissue	28088407
137	Chicken	ENSGALG00000053559	lncRNA	cadmium (Cd)	cadmium pollution	liver tissues	cadmium (Cd) treatment	upregulated	33078306
138	Chicken	ENSGALG00000053926	lncRNA	cadmium (Cd)	cadmium pollution	liver tissues	cadmium (Cd) treatment	upregulated	33078306
139	Chicken	ENSGALG00000054404	lncRNA	cadmium (Cd)	cadmium pollution	liver tissues	cadmium (Cd) treatment	downregulated	33078306
140	Chicken	gga-miR-128-1-5p	miRNA	selenium (Se)	selenium (Se) deficiency symptoms	Vein endothelial cells (VECs)	Se deficiency treatment	upregulated	29904913
141	Chicken	gga-miR-33-3p	miRNA	selenium (Se)	apoptosis	vein tissues	Selenium (Se) deficiency treatment	upregulated	31249647
142	Chicken	gga-miR-429	miRNA	avian pathogenic escherichia coli (APEC)	avian pathogenic Escherichia coli (APEC) infection	broilers spleen of three groups of broilers	APEC-challenge	upregulated in spleen of three groups of broilers	27795362
180	Chicken	ALDBGALG0000005049	lncRNA	Se-deficient diet	inflammation	chicken muscles	Se-deficient diet treatment	downregulated	28881768
181	Chicken	circVav3	circRNA	avian leukosis virus (ALV-J)	hepatocellular carcinoma (HCC)	vascular smooth muscle cells from high-fat diet fed ApoE-/- mice	avian leukosis virus subgroup J (ALV-J) infection	circ-Vav3 was upregulated in the liver tumors of chickens infected with ALV-J.	30608205
182	Chicken	GALMD1	lncRNA	Marek's disease virus (MDV)	Marek's disease (MD)	MD-resistant line of birds	marek's disease virus (MDV) infection	downregulated	31798630
183	Chicken	GALMD3	lncRNA	Marek's disease virus (MDV)	Marek's disease (MD)	White Leghorn chickens CD4+ T cells	MDV was injected intra-abdominally with 500 plaque-forming units (pfu) at the fifth day after hatching	upregulated in CD4+ T cells	28860661
184	Chicken	gga_circ_0002209	circRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen	marek's disease virus (MDV) infection	upregulated	31948317
185	Chicken	gga_circ_0003618	circRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen	marek's disease virus (MDV) infection	downregulated	31948317
186	Chicken	gga_circ_0008071	circRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen	marek's disease virus (MDV) infection	downregulated	31948317
187	Chicken	gga_circ_0009435	circRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen	marek's disease virus (MDV) infection	upregulated	31948317
188	Chicken	gga_circ_0009437	circRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen	marek's disease virus (MDV) infection	upregulated	31948317
189	Chicken	gga_circ_0015132	circRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen	marek's disease virus (MDV) infection	downregulated	31948317
190	Chicken	gga-let-7b	miRNA	subgroup J avian leukosis virus (ALV-J)	subgroup J avian leukosis virus (ALV-J) infection	liver and bone marrow tissues	subgroup J avian leukosis virus (ALV-J) infection	upregulated	28190219
191	Chicken	gga-let-7d	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	chicken skin	infect with MDV	upregulated in the skin	28410454
192	Chicken	gga-let-7i	miRNA	subgroup J avian leukosis virus (ALV-J)	subgroup J avian leukosis virus (ALV-J) infection	liver and bone marrow tissues	subgroup J avian leukosis virus (ALV-J) infection	upregulated	28190219
193	Chicken	gga-miR-122	miRNA	arsenite	arseniasis	chicken liver tissues and primary chicken liver cells (PCLCs)	arsenic (As) exposure	upregulated	31546213
194	Chicken	gga-miR-1306-5p	miRNA	lipopolysaccharide (LPS)	immune response	HD11 cells	lipopolysaccharide (LPS) treatment	upregulated	31338187
195	Chicken	gga-miR-1306-5p	miRNA	Salmonella enteritidis (SE)	immune response	"spleen, caecum, cecal tonsil, and bursa fabricius tissues"	Salmonella enteritidis (SE) infection treatment	upregulated	31338187
196	Chicken	gga-miR-130b-3p	miRNA	infectious bursal disease virus (IBDV)	infectious bursal disease virus (IBDV) infection	DF-1 cells	infect with IBDV	upregulated	29046449
197	Chicken	gga-mir-133	miRNA	brain-derived neurotrophic factor (BDNF)	retinocollicular/tectal map formation	retinal ganglion cell (RGC)	brain-derived neurotrophic factor (BDNF) treatment	upregulated	24431456
198	Chicken	gga-miR-138	miRNA	high temperature	high-temperature stress	chicks	heat challenge of 10-day-old previously high-temperature-conditioned chicks treatment	downregulated	25086319
199	Chicken	gga-miR-140*	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and lymphocytes	Marek's disease virus (MDV) infection	downregulated	23226446
200	Chicken	gga-miR-146a	miRNA	lipid associated membrane proteins (LAMP)	inflammation	chicken tracheal epithelial cells (TEC)	LAMP treatment	upregulated	25401327
201	Chicken	gga-miR-146c	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and lymphocytes	Marek's disease virus (MDV) infection	upregulated	23226446
202	Chicken	gga-miR-148a-3p	miRNA	ammonia (NH3)	necroptosis	Broiler chicken trachea tissues	ammonia (NH3) treatment	upregulated	31791863
203	Chicken	gga-miR-148a-3p	miRNA	ammonia (NH3)	respiratory system injury	chicken trachea	ammonia (NH3) treatment	lncRNA-107053293 regulated necroptosis by acting as a competing endogenous RNA of miR-148a-3p.	31791863
204	Chicken	gga-miR-15	miRNA	NaHS	respiratory toxicity	LMH cells; tracheal tissues	NaHS stimulation	LncRNA3037 is downregulated and miR-15a is upregulated in tracheal tissue and LMH cells under H 2S exposure.	31683218
205	Chicken	gga-miR-155	miRNA	reticuloendotheliosis virus (REV)	hepatocellular carcinoma (HCC)	chicken B-cell lymphomas	reticuloendotheliosis virus strain T (REV-T) infection treatment	reticuloendotheliosis virus strain T (REV-T) upregulates miR-155 in chicken embryo fibroblasts	19759154
206	Chicken	gga-miR-155	miRNA	lipopolysaccharide (LPS)	liver necroptosis	liver tissues	lipopolysaccharide (LPS) treatment	"Compared with the C group and Se group, the expression level of miR-155 and TRAF3 in the LPS group was upregulated."	33151563
207	Chicken	gga-miR-155	miRNA	polychlorinated biphenyls (PCBs)	polychlorinated biphenyls (PCBs) toxicity	primary chicken fibroblasts	PCBs (Arochlor-1250) treatment	"A significant downregulated of miR-155 and NF-kB was found in both groups exposed to A1250, regardless of being stimulated with Poly I:C or not, when compared to the virus stimulated group only"	29380441
208	Chicken	gga-miR-155	miRNA	reticuloendotheliosis virus (REV)	reticuloendotheliosis virus (REV) infection	chicken embryo fibroblasts (CEFs)	Reticuloendotheliosis virus (REV) treatment	miR-155 in CEFs after REV infection was upregulated in a time- and dose-dependent manner	32122614
209	Chicken	gga-miR-155	miRNA	reticuloendotheliosis virus (REV)	rev-T infection	primary chicken spleen and bone marrow cells	infect with Rev-T treatment	upregulated	28113043
210	Chicken	gga-mir-1551	miRNA	high temperature	heat stress	embryonic hearts	32 ¡ãC high temperatures treated maternal	upregulated	31466753
211	Chicken	gga-miR-1551	miRNA	manganese (Mn)	heat stress	embryonic hearts	manganese (Mn) feed	downregulated	31466753
212	Chicken	gga-miR-1586	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
213	Chicken	gga-miR-1594	miRNA	selenium (Se)	selenium (Se)-deficient cardiomyocytes injury	?chicken heart tissues	Selenium deficiency treatment	"TNNT2 suppression induced cardiac calcium overload in vivo and in vitro miR-1594 activates cardiac calcium overload by targeting TNNT2 Moreover, lnc-3215 regulates miR-1594, and thus influences the TNNT2 expression in vivo and in vitro"	31479920
214	Chicken	gga-miR-1594	miRNA	selenium (Se)	selenium (Se)-deficient cardiomyocytes injury	cardiomyocytes cells	Selenium deficiency treatment	"TNNT2 suppression induced cardiac calcium overload in vivo and in vitro miR-1594 activates cardiac calcium overload by targeting TNNT2 Moreover, lnc-3215 regulates miR-1594, and thus influences the TNNT2 expression in vivo and in vitro"	31479920
215	Chicken	gga-miR-15a	miRNA	hypoxia	adaptation to hypoxia	chicks embryonic lung tissue	were incubated in low oxygen (hypoxia) treatment	upregulated	24887070
216	Chicken	gga-miR-15a	miRNA	hydrogen sulfide (H2S)	respiratory toxicity	tracheal tissue	H2S?exposure	H2S exposure mediates apoptosis and necroptosis through lncRNA3037/miR-15/A20-BCL2.	31683218
217	Chicken	gga-miR-15b	miRNA	Marek's disease virus (MDV)	lymphoma	splenic tumor cells	Marek's disease virus infection	downregulated	22178800
218	Chicken	gga-miR-1610	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
219	Chicken	gga-miR-1618	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
220	Chicken	gga-miR-1627	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
221	Chicken	gga-miR-1633	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
222	Chicken	gga-miR-1646	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
223	Chicken	gga-miR-1647	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
224	Chicken	gga-miR-1649	miRNA	IFN-¦Ã	macrophage differentiation and activation	peripheral blood derived monocytes	IFN¦Ã treatment	dysregulated	27897122
225	Chicken	gga-miR-16-5p	miRNA	lead (Pb)	lead (Pb) toxicity	neutrophils	lead (Pb) treatment	Pb up-regulates miR-16-5p and leads to the subsequent downregulated of the target genes phosphoinositide-3-kinase regulatory subunit 1 (PiK3R1).	31918102
226	Chicken	gga-miR-16-5p	miRNA	hydrogen sulfide (H2S)	neutrophil extracellular traps (NETs) generation	neutrophil	hydrogen sulfide (H2S) treatment	H2S upregulated miR-16-5p.	32155482
227	Chicken	gga-miR-16-5p	miRNA	lipopolysaccharide (LPS)	tracheal injury	tracheal	lipopolysaccharide (LPS) treatment	upregulated	32125337
228	Chicken	gga-miR181a	miRNA	forskolin (FSK)	endothelial cell migration and angiogenesis	chicken auditory epithelium	Forskolin treatment	upregulated	20634979
229	Chicken	gga-miR-181a	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and lymphocytes	Marek's disease virus (MDV) infection	downregulated	23226446
230	Chicken	gga-miR-181a	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	"MD lymphoma cell line, MSB1"	Marek's disease virus (MDV) treatment	downregulated	26500265
231	Chicken	gga-miR-194	miRNA	¦Á-melanocyte-stimulating hormone (¦Á-MSH)	blinding ischemic retinopathies	retina	¦Á-melanocyte-stimulating hormone (¦Á-MSH) treatment	downregulated	26507936
232	Chicken	gga-miR-199*	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and lymphocytes	Marek's disease virus (MDV) infection	downregulated	23226446
233	Chicken	gga-miR-205a	miRNA	ammonia (NH3)	intestinal toxicity	jejunum	ammonia (NH3) treatment	Cooperative application of transcriptomics and ceRNA hypothesis: LncRNA-107052630/miR-205a/G0S2 crosstalk is involved in ammonia-induced intestinal apoptotic injury in chicken	32334290
234	Chicken	gga-miR-215-5p	miRNA	selenium (Se)	myocardial differentiation and development	myocardial tissues and primary cardiomyocyte cultures	Selenium (Se) deficiency treatment	upregulated	30565618
235	Chicken	gga-miR-216	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and intestinal intraepithelial lymphocytes (IEL) from 2 inbred chicken lines	host response to pathogen challenge treatment	upregulated	24879688
236	Chicken	gga-miR-221	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and lymphocytes	Marek's disease virus (MDV) infection	downregulated	23226446
237	Chicken	gga-miR-222	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and lymphocytes	Marek's disease virus (MDV) infection	downregulated	23226446
238	Chicken	gga-miR-26a	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleen and lymphocytes	Marek's disease virus (MDV) infection	downregulated	23226446
239	Chicken	gga-miR-26a	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	spleens of chickens MDV-infected spleens at cytolytic infection	MDV-infected treatment	downregulated	24795301
240	Chicken	gga-miR-29a-3p	miRNA	selenium (Se)	hepatocellular carcinoma (HCC)	chicken hepatocellular carcinoma cell line (LMH)	Selenium (Se) treatment	miR-29a-3p in LMH cells was decreased by Se supplementation	32039426
241	Chicken	gga-mir-33	miRNA	cadmium (Cd)	ion homeostasis	chickens chicken spleen	"cadmium chloride (CdCl2, 10 mg/kg) was administered in the diet of chickens for 90 days"	downregulated in	29223809
242	Chicken	gga-mir-33-5q	miRNA	cadmium (Cd)	cadmium-induced toxicity	spleen tissues	cadmium (Cd) treatment	Cd exposure suppressed miR-33-5q.	29223809
243	Chicken	gga-miR-34b-5p	miRNA	avian leukosis virus (ALV-J)	avian leukosis virus subgroup J (ALV-J) infection	chicken spleens	avian leukosis virus subgroup J (ALV-J) infection	upregulated	28194372
244	Chicken	gga-mir-34c	miRNA	high temperature	heat stress	embryonic hearts	32 ¡ãC high temperatures treated maternal	upregulated	31466753
245	Chicken	gga-miR-34c	miRNA	manganese (Mn)	heat stress	embryonic hearts	manganese (Mn) feed	downregulated	31466753
246	Chicken	gga-miR-375	miRNA	avian leukosis virus (ALV-J)	avian leukosis virus subgroup J (ALV-J) infection	DF-1 cell line	avian leukosis virus subgroup J (ALV-J) infection	downregulated	24694742
247	Chicken	gga-miR-375	miRNA	avian leukosis virus (ALV-J)	avian leukosis virus subgroup J (ALV-J) infection	DF-1 cells	avian leukosis virus (ALV-J) inhection	gga-miR-375 was downregulated by ALV-J infection.	32537011
248	Chicken	gga-miR-375	miRNA	avian leukosis virus (ALV-J)	hepatocellular carcinoma (HCC)	liver tumors of chickens	avian leukosis virus subgroup J (ALV-J) infection	gga-miR-375 was downregulated in the liver tumors of chickens infected with avian leukosis virus subgroup J (ALV-J).	30608205
249	Chicken	gga-miR-451	miRNA	mycoplasma gallisepticum (MG)	chronic respiratory disease (CRD)	chicken type II pneumocytes (CP-II)	Mycoplasma gallisepticum (MG) treatment	"exosomes from MG-infected CP-II cells alter the dynamics of the DF-1 cells, and may contribute to pathology of the MG infection via exosomal gga-miR-451 targeting YWHAZ involving in inflammation."	32307881
250	Chicken	gga-mir-548s	miRNA	daidzein (DA)	immune response	chicken liver tissues	daidzein (DA) treatment	downregulated	31057556
251	Chicken	gga-miR-6615-5p	miRNA	ammonia (NH3)	ammonia (NH3) toxicity	broiler	ammonia (NH3) treatment	"After NH3 exposure, miR-6615-5p expression was elevated."	33142454
252	Chicken	gga-miR-M11-5p	miRNA	gallid alphaherpesvirus 2 (GaHV2)	Marek's disease (MD)	chickens	infect with GaHV2	downregulated	28510513
253	Chicken	gga-miR-M4-5p	miRNA	Marek's disease virus (MDV)	Marek's disease (MD)	chicken embryo fibroblast (CEF)	marek's disease virus serotype 1 (MDV-1) treatment	"In lymphoblastoid cell lines derived from MDV-induced T-cell lymphomas, miR-M4-5p has been shown to be highly expressed."	33191002
254	Chicken	lnc2315	lncRNA	selenium (Se)	selenium (Se)-deficient cardiomyocytes injury	?chicken heart tissues	Selenium deficiency treatment	"TNNT2 suppression induced cardiac calcium overload in vivo and in vitro miR-1594 activates cardiac calcium overload by targeting TNNT2 Moreover, lnc-3215 regulates miR-1594, and thus influences the TNNT2 expression in vivo and in vitro"	31479920
255	Chicken	lncRNA107052630	lncRNA	ammonia (NH3)	intestinal toxicity	jejunum	ammonia (NH3) treatment	Cooperative application of transcriptomics and ceRNA hypothesis: LncRNA-107052630/miR-205a/G0S2 crosstalk is involved in ammonia-induced intestinal apoptotic injury in chicken	32334290
256	Chicken	lncRNA107053293	lncRNA	ammonia (NH3)	respiratory system injury	chicken trachea	ammonia (NH3) treatment	lncRNA-107053293 regulated necroptosis by acting as a competing endogenous RNA of miR-148a-3p.	31791863
257	Chicken	lncRNA3037	lncRNA	NaHS	respiratory toxicity	LMH cells; tracheal tissues	NaHS stimulation	LncRNA3037 is downregulated and miR-15a is upregulated in tracheal tissue and LMH cells under H 2S exposure.	31683218
258	Chicken	lncRNA3037	lncRNA	hydrogen sulfide (H2S)	respiratory toxicity	tracheal tissue	H2S?exposure	H2S exposure mediates apoptosis and necroptosis through lncRNA3037/miR-15/A20-BCL2.	31683218
259	Chicken	MG066601	lncRNA	avian leukosis virus (ALV-J)	hematopoietic malignancy in myeloid leukemia and hemangioma	chickens CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	29198037
260	Chicken	MG066609	lncRNA	avian leukosis virus (ALV-J)	hematopoietic malignancy in myeloid leukemia and hemangioma	chickens CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	29198037
261	Chicken	MG066616	lncRNA	avian leukosis virus (ALV-J)	hematopoietic malignancy in myeloid leukemia and hemangioma	chickens CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	29198037
262	Chicken	MG066617	lncRNA	avian leukosis virus (ALV-J)	hematopoietic malignancy in myeloid leukemia and hemangioma	chickens CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	29198037
263	Chicken	MG066618	lncRNA	avian leukosis virus (ALV-J)	hematopoietic malignancy in myeloid leukemia and hemangioma	chickens CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	29198037
264	Chicken	MG066629	lncRNA	avian leukosis virus (ALV-J)	hematopoietic malignancy in myeloid leukemia and hemangioma	chickens CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	29198037
265	Chicken	NONGGAT001975.2	lncRNA	avian leukosis virus (ALV-J)	avian leukosis virus subgroup J (ALV-J) infection	HD11 and CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	28673822
266	Chicken	NONGGAT005832.2	lncRNA	avian leukosis virus (ALV-J)	avian leukosis virus subgroup J (ALV-J) infection	HD11 and CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	28673822
267	Chicken	NONGGAT009792.2	lncRNA	avian leukosis virus (ALV-J)	avian leukosis virus subgroup J (ALV-J) infection	HD11 and CEF cells	avian leukosis virus subgroup J (ALV-J) infection	upregulated	28673822
268	Chicken	satb1	lncRNA	Marek's disease virus (MDV)	T cell tumorigenesis	T cell	marek's disease virus treatment	"linc-satb1, was found to play a crucial role in MD immune response by regulating a nearby protein-coding gene SATB1"	26471251
269	Chicken	XLOC_098131	lncRNA	daidzein (DA)	immune response	chicken liver tissues	daidzein (DA) treatment	upregulated	31057556
384	Chicken	gga-miR-155	miRNA	methionine selenium	necroptosis	chicken liver tissues	methionine selenium treatment	"The current results suggested that methionine selenium antagonizes oxidative stress, inflammation, and the MAPK pathway, thereby antagonizing the occurrence of necroptosis through multiple mechanisms. At the same time, methionine selenium affects miR-155/TRAF3/MAPK signaling, reduces miR-155 expression, and upregulates TRAF3 expression to inhibit necroptosis."	33151563
279	Citrus	cj-miR152	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	upregulated	28165059
280	Citrus	cj-miR156b	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	upregulated	28165059
281	Citrus	cj-miR197	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	downregulated	28165059
282	Citrus	cj-miR203	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	upregulated	28165059
283	Citrus	cj-miR219	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	upregulated	28165059
284	Citrus	cj-miR3946	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	downregulated	28165059
285	Citrus	cj-miR3951	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	downregulated	28165059
286	Citrus	cj-miR395a	miRNA	boron	boron toxicity	11-week-old citrus seedlings	boron treatment	upregulated	26962011
287	Citrus	cj-miR397a	miRNA	boron	boron toxicity	11-week-old citrus seedlings	boron treatment	upregulated	26962011
288	Citrus	cj-miR408	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	upregulated	28165059
289	Citrus	cj-miR472	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	upregulated	28165059
290	Citrus	cj-miR482b	miRNA	dehydration and salt	drought and salinity stresses	citrus roots	subjected to dehydration and salt treatment	upregulated	28165059
178	Common carp	ccr-miR-155	miRNA	lead (Pb)	inflammation	head kidney tissues	Lead (Pb) poisoning	upregulated	32781208
291	Common carp	ccr-miR-122	miRNA	cadmium (Cd)	toxicity of cadmium (Cd)	head kidney	cadmium (Cd) treatment	downregulated	31951951
292	Common carp	ccr-miR-144	miRNA	vibrio harveyi and lipopolysaccharide (LPS)	teleost inflammatory responses	miiuy croaker macrophages	vibrio harveyi and lipopolysaccharide (LPS) treatment	upregulated	32815068
293	Common carp	ccr-miR-146a	miRNA	selenium (Se)	inflammation	head kidney of carp	Selenium (Se) deficiency treatment	downregulated	31125664
294	Common carp	ccr-miR-148a	miRNA	simvastatin	detoxification-related metabolism	Mugilogobius abei	Simvastatin treatment	upregulated	30240922
295	Common carp	ccr-miR-155	miRNA	cadmium (Cd)	immunotoxicity	Cyprinus carpio (C. carpio) kidneys	cadmium (Cd) treatment	upregulated	31693945
296	Common carp	ccr-miR-181-5p	miRNA	atrazine (2-chloro-4-ethylamino-6-isopropylamino-s-triazine; ATR)	inflammation	carp lymphocytes	atrazine (ATR)?exposure	downregulated	31580934
297	Common carp	ccr-miR-181a	miRNA	cadmium (Cd)	immunotoxicity	Cyprinus carpio (C. carpio) kidneys	cadmium (Cd) treatment	upregulated	31693945
298	Common carp	ccr-miR-193a-3p	miRNA	cadmium (Cd)	toxicity of cadmium (Cd)	head kidney	cadmium (Cd) treatment	downregulated	31951951
299	Common carp	ccr-miR-21	miRNA	lipopolysaccharide (LPS)	bacterial infection	"miiuy croaker liver, spleen, macrophage"	lipopolysaccharide (LPS) treatment	upregulated	31379828
300	Common carp	ccr-miR-216a	miRNA	cadmium (Cd)	cadmium-induced toxicity	splenic lymphocytes	cadmium (Cd) treatment	upregulated	32563067
301	Common carp	ccr-miR-217	miRNA	vibrio harveyi and lipopolysaccharide (LPS)	teleost inflammatory responses	miiuy croaker macrophages	vibrio harveyi and lipopolysaccharide (LPS) treatment	upregulated	32815068
302	Common carp	ccr-miR-2188-3p	miRNA	chlorpyrifos (CPF)	head kidney injury in common carp	head kidney of common carp	chlorpyrifos (CPF) exposure	downregulated	31479757
303	Common carp	ccr-miR-27a-5p	miRNA	cadmium (Cd)	toxicity of cadmium (Cd)	head kidney	cadmium (Cd) treatment	upregulated	31951951
304	Common carp	ccr-miR-27b-3p	miRNA	bisphenol A (BPA)	Bisphenol A (BPA) toxicity	spleen lymphocytes	bisphenol A (BPA) treatment	"BPA exposure can target up regulate CYP1B1 expression by down regulating miR-27b-3p expression, thus causing oxidative stress and inducing apoptosis of carp spleen lymphocytes through mitochondrial pathway."	32430284
305	Common carp	ccr-miR-31-12-5p	miRNA	cadmium (Cd)	cadmium-induced toxicity	spleens	cadmium (Cd) treatment	downregulated	32070891
306	Common carp	ccr-miR-375-4-3p	miRNA	cadmium (Cd)	cadmium-induced toxicity	spleens	cadmium (Cd) treatment	upregulated	32070891
307	Common carp	ccr-miR-6	miRNA	cadmium (Cd)	toxicity of cadmium (Cd)	head kidney	cadmium (Cd) treatment	downregulated	31951951
308	Common carp	ccr-miR-731	miRNA	chlorpyrifos (CPF)	head kidney injury in common carp	head kidney of common carp	chlorpyrifos (CPF) exposure	downregulated	31479757
309	Common carp	ccr-miR-9-6-5p	miRNA	cadmium (Cd)	cadmium-induced toxicity	spleens	cadmium (Cd) treatment	downregulated	32070891
310	Common carp	MSTRG.16320.2	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	upregulated	32147374
311	Common carp	rna19947	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	downregulated	32147374
312	Common carp	XLOC_024184	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	downregulated	32147374
313	Common carp	XLOC_069999	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	upregulated	32147374
314	Common carp	XLOC_115571	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	upregulated	32147374
315	Common carp	XLOC_133815	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	downregulated	32147374
316	Common carp	XLOC_142217	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	upregulated	32147374
317	Common carp	XLOC_147893	lncRNA	bisphenol A (BPA)	toxicity in aquatic organisms	head kidney (HK) macrophages	bisphenol A (BPA) treatment	upregulated	32147374
24153	Coregonus lavaretus	cla-miR-122-5p	miRNA	microcystin-leucine arginine (MC-LR)	liver damage	liver tissues	microcystin-LR treatment	upregulated	26345281
24154	Coregonus lavaretus	cla-let-7c	miRNA	microcystin-leucine arginine (MC-LR)	cyanobacterial hepatotoxin microcystin-LR (MC-LR) toxicity	liver tissues	microcystin-LR (MC-LR) treatment	upregulated	22819808
24155	Coregonus lavaretus	cla-miR-122	miRNA	microcystin-leucine arginine (MC-LR)	cyanobacterial hepatotoxin microcystin-LR (MC-LR) toxicity	liver tissues	microcystin-LR (MC-LR) treatment	upregulated	22819808
24156	Coregonus lavaretus	cla-miR-16a	miRNA	microcystin-leucine arginine (MC-LR)	cyanobacterial hepatotoxin microcystin-LR (MC-LR) toxicity	liver tissues	microcystin-LR (MC-LR) treatment	upregulated	22819808
24157	Coregonus lavaretus	cla-miR-21a	miRNA	microcystin-leucine arginine (MC-LR)	cyanobacterial hepatotoxin microcystin-LR (MC-LR) toxicity	liver tissues	microcystin-LR (MC-LR) treatment	upregulated	22819808
24158	Coregonus lavaretus	cla-miR-34a	miRNA	microcystin-leucine arginine (MC-LR)	cyanobacterial hepatotoxin microcystin-LR (MC-LR) toxicity	liver tissues	microcystin-LR (MC-LR) treatment	upregulated	22819808
24159	Coregonus lavaretus	cla-miR-9b	miRNA	microcystin-leucine arginine (MC-LR)	cyanobacterial hepatotoxin microcystin-LR (MC-LR) toxicity	liver tissues	microcystin-LR (MC-LR) treatment	upregulated	22819808
322	Cotton	ghr-miR-156	miRNA	high-temperature (HT)	male sterility	anthers of HT-insensitive (84021)	HT stress	downregulated	28635129
323	Cotton	ghr-miR-156	miRNA	high-temperature (HT)	male sterility	anthers of HT-sensitive (H05) cotton cultivars	HT stress	dysregulated	28635129
324	Cotton	ghr-miR-160	miRNA	high-temperature (HT)	male sterility	anthers of HT-insensitive (84021)	HT stress	downregulated	28635129
325	Cotton	ghr-miR-160	miRNA	high-temperature (HT)	male sterility	anthers of HT-sensitive (H05) cotton cultivars	HT stress	dysregulated	28635129
326	Cotton	ghr-miR414c	miRNA	Salinity	plant salinity tolerance	cotton cv. SF06 plants	Salinity stress induce treatment	downregulated	30676211
327	Cotton	lncRNA973	lncRNA	salt	salt stress	"cotyledons, stems and roots from Upland cotton ¡®SN91¨C11¡¯ plants"	salt treatment	upregulated	31666019
353	Crab-eating macaque	cad-miR-125b	miRNA	formaldehyde	apoptosis	nasal epithelium	Formaldehyde treatment	upregulated	23322811
354	Crab-eating macaque	cad-miR-142-3p	miRNA	formaldehyde	apoptosis	nasal epithelium	Formaldehyde treatment	downregulated	23322811
12647	Crab-eating macaque	cad-miR-1228	miRNA	ethylene glycol monomethyl ether (EGME)	testicular toxicity	testis	ethylene glycol monomethyl ether (EGME) treatment	upregulated	25972197
12657	Crab-eating macaque	cad-miR-2861	miRNA	ethylene glycol monomethyl ether (EGME)	testicular toxicity	testis	ethylene glycol monomethyl ether (EGME) treatment	upregulated	25972197
19129	Crassostrea gigas	cgi-miR-365	miRNA	norepinephrine (NE)	against intertidal stress	Oyster Crassostrea gigas during desiccation	norepinephrine treatment	upregulated	28286314
19130	Crassostrea gigas	cgi-miR-92d	miRNA	lipopolysaccharide (LPS)	inflammation	oyster Crassostrea gigas	lipopolysaccharide (LPS) treatment	upregulated	27346152
340	Creeping bentgrass	ast-miR396	miRNA	long-day (LD) photoperiod and vernalization	flower development	creeping bentgrass (Agrostis stolonifera L.)	long-day (LD) photoperiod and vernalization	Gene expression analysis reveals that miR396 is induced by long-day (LD) photoperiod and vernalization.	33328434
341	Cucumber	csa-miR172c	miRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	upregulated	31125116
342	Cucumber	csa-miR261	miRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
343	Cucumber	csa-miR6196	miRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	upregulated	31125116
344	Cucumber	csa-miR8597	miRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
345	Cucumber	TCONS_00000311	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
346	Cucumber	TCONS_00005674	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
347	Cucumber	TCONS_00007594	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
348	Cucumber	TCONS_00011359	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	upregulated	31125116
349	Cucumber	TCONS_00014332	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
350	Cucumber	TCONS_00014717	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
351	Cucumber	TCONS_00031790	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	downregulated	31125116
352	Cucumber	TCONS_00031790	lncRNA	high temperature	effects of high-temperature on Cucumis sativus L.	cucumber	high-temperature	upregulated	31125116
98	Dog	cfa-miR-122	miRNA	NP260	hepatotoxicity	dogs	NP260 treatment	upregulated	24699182
167	Dog	cfa-miR-107	miRNA	calorie restriction (CR)	obesity	overweight pet dogs	calorie restriction (CR) treatment	"downregulated (miR-23 , miR-107) and upregulation (miR-21) in muscle biopsies"	26701817
168	Dog	cfa-miR-143	miRNA	canine influenza virus (CIV) H3N2	apoptosis	canine kidney (MDCK) cells	infect with CIV H3N2	upregulated	29186842
169	Dog	cfa-miR-15b	miRNA	gentamicin	acute kidney injury (AKI)	Urine	gentamicin treatment	downregulated	33290828
170	Dog	cfa-miR-15b-3p	miRNA	gentamicin	acute kidney injury (AKI)	Urine	gentamicin treatment	downregulated	33290828
171	Dog	cfa-miR-16	miRNA	gentamicin	acute kidney injury (AKI)	Urine	gentamicin treatment	downregulated	33290828
172	Dog	cfa-miR-21	miRNA	calorie restriction (CR)	obesity	overweight pet dogs	calorie restriction (CR) treatment	"downregulated (miR-23 , miR-107) and upregulation (miR-21) in muscle biopsies"	26701817
173	Dog	cfa-miR-23	miRNA	calorie restriction (CR)	obesity	overweight pet dogs	calorie restriction (CR) treatment	"downregulated (miR-23 , miR-107) and upregulation (miR-21) in muscle biopsies"	26701817
174	Dog	cfa-miR-26a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	Madin-Darby canine kidney cell line MDCK	influenza A virus(IAV) infection	downregulated	28674773
175	Dog	cfa-miR-30a	miRNA	gentamicin	acute kidney injury (AKI)	Urine	gentamicin treatment	upregulated	33290828
176	Dog	cfa-miR-30a-3p	miRNA	gentamicin	acute kidney injury (AKI)	Urine	gentamicin treatment	upregulated	33290828
177	Dog	cfa-miR-30c-2-3p	miRNA	gentamicin	acute kidney injury (AKI)	Urine	gentamicin treatment	upregulated	33290828
355	Dog	cfa-miR-192	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	upregulated	26081562
356	Dog	cfa-miR-21	miRNA	matrix metalloproteinases inhibitor (MMPi)	fibrodysplasia (FD)	cervical subcutaneous tissue	MMP-inhibitor (MMPi) treatment	miR-21 expression in the cervical subcutaneous tissue was a sensitive and specific biomarker of FD incidence	23688202
357	Dog	cfa-miR-210	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	downregulated	26081562
358	Dog	cfa-miR-212	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	downregulated	26081562
359	Dog	cfa-miR-216a	miRNA	cerulein	acute pancreatic injury	pancreas	cerulein treatment	upregulated	30301227
360	Dog	cfa-miR-219-5p	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	downregulated	26081562
361	Dog	cfa-miR-22	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	upregulated	26081562
362	Dog	cfa-miR-338	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	downregulated	26081562
363	Dog	cfa-miR-34a	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	upregulated	26081562
364	Dog	cfa-miR-34a*	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	upregulated	26081562
365	Dog	cfa-miR-34c	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	upregulated	26081562
366	Dog	cfa-miR-375	miRNA	cerulein	acute pancreatic injury	pancreas	cerulein treatment	upregulated	30301227
367	Dog	cfa-miR-503	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	downregulated	26081562
368	Dog	cfa-miR-505*	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	downregulated	26081562
369	Dog	cfa-miR-877	miRNA	X-rays	injury in retinal ganglion	retinal ganglion cell line (RGC-5 cells)	X-rays treatment	upregulated	26081562
398	Domestic guinea pig	ssc-miR-1	miRNA	arsenic trioxide (ATO)	acute promyelocytic leukemia (APL)	the heart of guinea pig	arsenic trioxide (As2O3) treatment	upregulated	22889704
399	Domestic guinea pig	ssc-miR-103-2	miRNA	uterine artery ablation	low birth weight (LBW)	guinea pig	uterine artery ablation and fed a control diet from weaning to 145 days treatment	upregulated	24926663
400	Domestic guinea pig	ssc-miR-133	miRNA	arsenic trioxide (ATO)	acute promyelocytic leukemia (APL)	the heart of guinea pig	arsenic trioxide (As2O3) treatment	upregulated	22889704
401	Domestic guinea pig	ssc-miR-24	miRNA	uterine artery ablation	low birth weight (LBW)	guinea pig	uterine artery ablation and fed a control diet from weaning to 145 days treatment	upregulated	24926663
23957	Domestic silkworm	bmo-miR-275	miRNA	20-hydroxyecdysone (20-HE)	insects development	BmE cells	20-Hydroxyecdysone (20-HE) treatment	upregulated	32482109
23958	Domestic silkworm	bmo-miR-305	miRNA	20-hydroxyecdysone (20-HE)	insects development	BmE cells	20-Hydroxyecdysone (20-HE) treatment	upregulated	32482109
376	Eutrema salsugineum	esa-miR165	miRNA	red light (RL)	effects of red light (RL) on plants	eutrema salsugineum	red light (RL) treatment	downregulated	33301852
377	Eutrema salsugineum	esa-miR395	miRNA	red light (RL)	effects of red light (RL) on plants	eutrema salsugineum	red light (RL) treatment	downregulated	33301852
378	Eutrema salsugineum	esa-miR408	miRNA	red light (RL)	effects of red light (RL) on plants	eutrema salsugineum	red light (RL) treatment	downregulated	33301852
370	Fruit fly	dme-miR-12	miRNA	wolbachia	wolbachia infection	testes tissues	Wolbachia infection treatment	upregulated	31491378
371	Fruit fly	dme-miR-8-5p	miRNA	drosophila C virus (DCV)	drosophila C virus (DCV) infection	drosophila S2 cells	Drosophila C virus (DCV) treatment	downregulated	28691661
372	Fruit fly	dme-miR-956-3p	miRNA	drosophila C virus (DCV)	drosophila C virus (DCV) infection	Fly	Drosophila C virus (DCV) treatment	upregulated	27960110
373	Fruit fly	dme-miR-956-3p	miRNA	drosophila C virus (DCV)	drosophila C virus (DCV) infection	Drosophila S2 cells	Drosophila C virus (DCV) treatment	"Comparison of the miRNA expression profiles in DCV-infected and uninfected Fly showed altered miRNA levels due to DCV infection, with the largest change in abundance observed for miR-956-3p."	27960110
379	Fruit fly	dme-miR-1008-5p	miRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	fly heads	¦Á-synuclein treatment	upregulated	26361355
380	Fruit fly	dme-miR-133-3p	miRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	fly heads	¦Á-synuclein treatment	upregulated	26361355
381	Fruit fly	dme-miR-137-3p	miRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	fly heads	¦Á-synuclein treatment	upregulated	26361355
382	Fruit fly	dme-miR-13b-3p	miRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	fly heads	¦Á-synuclein treatment	upregulated	26361355
383	Fruit fly	dme-miR-932-5p	miRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	fly heads	¦Á-synuclein treatment	upregulated	26361355
385	Goat	chi-miR-1	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	NK cells	peste des petits ruminants virus (PPRV) infection treatment	PPRV infection induced TWEAK expression in goat NK cells involving post-transcription by suppressing miR-1	32038620
386	Goat	chi-miR-1246	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	goats lung and spleen	infect with PPR treatment	dysregulated inin lung and spleen	28694795
387	Goat	chi-miR-135b	miRNA	prolactin (PRL)	lactogenesis	goat mammary epithelial cells	Prolactin treatment	downregulated	28332185
388	Goat	chi-miR-135b	miRNA	"prolactin,IGF-1"	lactogenesis	goat mammary gland	2.5 ¦Ìg/ml prolactin and 2.5 ¦Ìg/ml IGF-1 treatment	upregulated in the goat mammary gland	28332185
389	Goat	chi-miR-21-3p	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	goats lung and spleen	infect with PPR treatment	dysregulated inin lung and spleen	28694795
390	Goat	chi-miR-218	miRNA	petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	goat peripheral blood mononuclear cells (PBMCs)	petits ruminants virus (PPRV) infection treatment	downregulated	31616415
391	Goat	chi-miR-27a-5p	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	goats lung and spleen	infect with PPR treatment	dysregulated inin lung and spleen	28694795
392	Goat	chi-miR-3	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants virus (PPRV) infection	peripheral blood mononuclear cells (PBMCs)	peste des petits ruminants virus (PPRV) infection treatment	"We report that a novel microRNA in goat PBMCs, novel miR-3, was upregulated by PPRV to facilitate virus infection"	33504605
393	Goat	chi-miR-320a	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	goats lung and spleen	infect with PPR treatment	dysregulated inin lung and spleen	28694795
394	Goat	chi-miR-363	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	goats lung and spleen	infect with PPR treatment	dysregulated inin lung and spleen	28694795
395	Goat	chi-miR-760-3p	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	goats lung and spleen	infect with PPR treatment	dysregulated inin lung and spleen	28694795
396	Green monkey	mml-miR-30c-5p	miRNA	porcine epidemic diarrhea virus (PEDV)	porcine epidemic diarrhea virus (PEDV) infection	Vero E6 cells	Porcine epidemic diarrhea virus (PEDV) treatment	PEDV infection increased SOCS1 expression by decreasing host miR-30c-5p expression	32574254
397	Green monkey	NEAT1	lncRNA	HTNV strain 76-118	hantaan virus (HTNV) infection	Vero E6 cells	treat with HTNV strain 76-118 was	upregulated	28202761
12648	Green monkey	mml-miR-127	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	MARC145 cells	infect with PRRSV treatment	different regulation	25077995
12651	Green monkey	mml-miR-145	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	MARC145 cells	infect with PRRSV treatment	different regulation	25077995
12652	Green monkey	mml-miR-181a	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	MARC145 cells	infect with PRRSV treatment	different regulation	25077995
12654	Green monkey	mml-miR-204	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	MARC145 cells	infect with PRRSV treatment	different regulation	25077995
12656	Green monkey	mml-miR-21	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	MARC145 cells	infect with PRRSV treatment	different regulation	25077995
12658	Green monkey	mml-miR-29	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	MARC145 cells	infect with PRRSV treatment	different regulation	25077995
12659	Green monkey	mml-miR-373	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	MARC-145	infect with PRRSV treatment	upregulated	27881653
405	Horse	eca-miR-140-3p	miRNA	metformin (Met)	horses equine metabolic syndrome	adipose-derived stromal cells isolated from equine metabolic syndrome horses (EqASCEMS)	metformin (MF) treatment	downregulated	30678275
406	Horse	eca-miR-145-5p	miRNA	cladophora glomerata methanolic extract	chondrogenesis	equine metabolic syndrome adipose-derived mesenchymal stromal stem cells (ASCsEMS)	Cladophora glomerata methanolic extract treatment	downregulated	31847882
407	Horse	eca-miR-145-5p	miRNA	metformin (Met)	horses equine metabolic syndrome	adipose-derived stromal cells isolated from equine metabolic syndrome horses (EqASCEMS)	metformin (MF) treatment	downregulated	30678275
408	Horse	eca-miR-146-3p	miRNA	cladophora glomerata methanolic extract	chondrogenesis	equine metabolic syndrome adipose-derived mesenchymal stromal stem cells (ASCsEMS)	Cladophora glomerata methanolic extract treatment	downregulated	31847882
409	Horse	eca-miR-155	miRNA	lipopolysaccharide (LPS)	endotoxemia	equine peripheral blood mononuclear cells	lipopolysaccharide (LPS) treatment	upregulated	28552958
410	Horse	eca-miR-16-5p	miRNA	metformin (Met)	horses equine metabolic syndrome	adipose-derived stromal cells isolated from equine metabolic syndrome horses (EqASCEMS)	metformin (MF) treatment	downregulated	30678275
411	Horse	eca-miR-21-5p	miRNA	metformin (Met)	horses equine metabolic syndrome	adipose-derived stromal cells isolated from equine metabolic syndrome horses (EqASCEMS)	metformin (MF) treatment	downregulated	30678275
412	Horse	eca-miR-29a-3p	miRNA	metformin (Met)	horses equine metabolic syndrome	adipose-derived stromal cells isolated from equine metabolic syndrome horses (EqASCEMS)	metformin (MF) treatment	downregulated	30678275
413	Horse	eca-miR-34a	miRNA	cladophora glomerata methanolic extract	chondrogenesis	equine metabolic syndrome adipose-derived mesenchymal stromal stem cells (ASCsEMS)	Cladophora glomerata methanolic extract treatment	downregulated	31847882
414	Horse	eca-miR-449a	miRNA	cladophora glomerata methanolic extract	chondrogenesis	equine metabolic syndrome adipose-derived mesenchymal stromal stem cells (ASCsEMS)	Cladophora glomerata methanolic extract treatment	downregulated	31847882
19331	Horse	eca-let-7d-3p	miRNA	sprint training	training responses	thoroughbred racehorses skeletal muscle samples	sprint training treatment	dysregulated	29166903
19332	Horse	eca-let-7d-5p	miRNA	sprint training	training responses	thoroughbred racehorses skeletal muscle samples	sprint training treatment	dysregulated	29166903
19333	Horse	eca-miR-21-5p	miRNA	sprint training	training responses	thoroughbred racehorses skeletal muscle samples	sprint training treatment	dysregulated	29166903
19334	Horse	eca-miR-30b-5p	miRNA	sprint training	training responses	thoroughbred racehorses skeletal muscle samples	sprint training treatment	dysregulated	29166903
19335	Horse	eca-miR-30e-5p	miRNA	sprint training	training responses	thoroughbred racehorses skeletal muscle samples	sprint training treatment	dysregulated	29166903
415	Human	4631405K08Rik	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
416	Human	A2M-AS1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human neonatal cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	LncRNA A2M-AS1 lessens the injury of cardiomyocytes caused by hypoxia and reoxygenation via regulating IL1R2.	33057899
417	Human	AC003092.1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	temozolomide (TMZ) treatment	lncRNA AC0030921 expression was significantly down- regulated in both U87TR and U251TR cells	30442884
418	Human	AC005523.2-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
419	Human	AC005550.3	lncRNA	homocysteine (Hcy)	homocysteine (HCY)-induced vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	homocysteine (HCY) treatment	downregulated	30093949
420	Human	AC006050.3-003	lncRNA	cisplatin (DDP)	lung squamous cell carcinoma (LSQCC)	advanced lung squamous cell carcinoma patients	cisplatin treatment	downregulated	25250788
421	Human	AC006262.5	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
422	Human	AC007283.5	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
423	Human	AC007952.1.1-3:1	lncRNA	nigericin	pancreatic cancer (PC)	PANC-4 cells	nigericin treatment	downregulated	32850392
424	Human	AC013451.2	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	upregulated	32326576
425	Human	AC015849.2	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
426	Human	AC023115.3	lncRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	human glioblastoma cells	cisplatin treatment	upregulated	28499919
427	Human	AC026904.1	lncRNA	TGF-¦Â	breast cancer	MCF-7 cells	TGF-¦Â treatment	"TGF-¦Â induced genome-wide changes in lncRNA levels in breast cancer cells, among which AC0269041 and UCA1 were highly expressed in metastatic breast cancer and closely associated with poor prognosis"	29774079
428	Human	AC068039.4	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	"Consistent with microarray analysis, quantitative PCR verified that AC068039.4 was obviously upregulated in hypoxia-induced PASMCs."	33026218
429	Human	AC068580.3	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	upregulated	32326576
430	Human	AC078883.3	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"lung tissues, A549 and H460 cells"	?cisplatin treatment	?the low expression of lncRNA-AC0788833 contributed to the development of chemoresistance against cisplatin	31111480
431	Human	AC092620.3	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	Cr(VI)-treated 16HBE cells	Cr(VI) exposure	dysregulated	30476843
432	Human	AC092620.3	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	16HBE cells	hexavalent chromium [Cr(VI)] treatment	upregulated	30476843
433	Human	AC105052.4	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
434	Human	AC133485	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	downregulated	31514003
435	Human	AC145676.2.1-6	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	whole blood samples	Mycobacterium tuberculosis (MTB) infection	downregulated	31028876
436	Human	ADAMTS9-AS2	lncRNA	tamoxifen (TAM)	breast cancer	Human MCF-7 cells	Tamoxifen (TAM) treatment	downregulated	30840279
437	Human	ADAMTS9-AS2	lncRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells; BGC823C cells	cisplatin treatment	downregulated	32516127
438	Human	ADAMTS9-AS2	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"GBM cell lines (T98G, U118)"	temozolomide (TMZ) treatment	upregulated	31632968
439	Human	AF085935	lncRNA	chrysin	hepatocellular carcinoma (HCC)	HepG2 cells	chrysin treatment	chrysin against HCC through the suppression of the GPC3/SULF2 axis along with the downregulated of lncRNA-AF085935 expression.	33076548
440	Human	AF085935	lncRNA	epigallocatechin-3-gallate (EGCG) and metformin	hepatocellular carcinoma (HCC)	HepG2 cells	epigallocatechin-3-gallate (EGCG) and metformin treatment	downregulated	30710234
441	Human	AF086415	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
442	Human	AF086415	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	downregulated	24379026
443	Human	AF131217.1	lncRNA	laminar shear stress	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	Laminar shear stress induce	upregulated	30905197
444	Human	AF131217.1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30905197
445	Human	AF147447	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	tumor tissues	H. pylori treatment	downregulated	27835575
446	Human	AFAP1-AS1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	upregulated	32020881
447	Human	AFAP1-AS1	lncRNA	oridonin	epithelial-mesenchymal transition (EMT)	?BxPC-3 and PANC-1 cells	oridonin treatment	"the combination of oridonin and siAFAP1-AS1 inhibited pancreatic cancer cell proliferation, induced apoptosis, arrested cell cycle progression, prevented the migration, regulated EMT-related protein expression in BxPC-3 and PANC-1 cells, and inhibited pancreatic cancer cell tumorigenicity and EMT in nude mice."	31314060
448	Human	AFAP1-AS1	lncRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	BxPC-3 cells; HPAC cells	cucurbitacin B (CuB) treatment	CuB inhibits proliferation of PC cells by downregulating AFAP1-AS1 expression.	30206930
449	Human	AFAP1-AS1	lncRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	"Human PC cell lines, ASPC©\1, BxPC©\3, HPAC, MiaPaCa©\2"	cucurbitacin B (CuB) treatment	CuB-induced high miR-146b-5p expression and inhibited the expression of AFAP1-AS1.	30206930
450	Human	AFAP1-AS1	lncRNA	oridonin	pancreatic cancer (PC)	BxPC-3 and PANC-1 cells	oridonin treatment	"the combination of oridonin and siAFAP1-AS1 inhibited pancreatic cancer cell proliferation, induced apoptosis, arrested cell cycle progression, prevented the migration, regulated EMT-related protein expression in BxPC-3 and PANC-1 cells, and inhibited pancreatic cancer cell tumorigenicity and EMT in nude mice."	31314060
451	Human	AGAP2-AS1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	upregulated	30157918
452	Human	AIRN	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
453	Human	AK001796	lncRNA	resveratrol	lung cancer	lung cancer tissues	resveratrol (RS) treatment	reduced lncRNA AK001796 level potentially impaired the inhibitory effect of resveratrol on cell proliferation	25888808
454	Human	AK021021	lncRNA	baicalin (BAI)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	baicalin (BAI) treatment	upregulated	26885187
455	Human	AK027294	lncRNA	glycyrrhiza glabra	nasopharyngeal carcinoma (NPC)	C666-1 cells	glycyrrhiza glabra treatment	downregulated of AK027294 contributes to the anti-cancer function of G. glabra.	31589096
456	Human	AK027294	lncRNA	glycyrrhiza glabra	nasopharyngeal carcinoma (NPC)	C666-1 cells	Glycyrrhiza glabra treatment	AK027294 had a strongest downregulated upon G. glabra treatment.	31589096
457	Human	AK056098	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
458	Human	AK056098	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
459	Human	AK056155	lncRNA	TGF-¦Â1	loeys-Dietz syndrome (LDS)	peripheral blood circulating endothelial cells	TGF-¦Â1 treatment	upregulated	26617788
460	Human	AK058003	lncRNA	hypoxia	gastric cancer (GC)	GC cell lines	hypoxia-induced GC treatment	upregulated	25499222
461	Human	AK077216	lncRNA	high glucose (HG)	diabetic retinopathy (DR)		high glucose treatment	AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of ARPE-19 cells by downregulating miR-383.	31391356
462	Human	AK092074	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
463	Human	AK094457	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (hVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	"LncRNA AK094457 downregulated by shRNA-AK094457-1 have inhibiting effects on proliferation, migration, ROS level and inflammation level in OX-LDL induced vascular smooth muscle cells (VSMCs)."	31632534
464	Human	AK094457	lncRNA	angiotensin II (Ang II)	hypertension	human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	The expression of the lncRNA AK094457 in the angiotensin II (Ang II) treatment groups were higher than the control group.	32027625
465	Human	AK094629	lncRNA	IL-1¦Â	temporomandibular joint osteoarthritis	synovial-derived mesenchymal stem cells (SMSCs)	IL-1¦Â treatment	IL-1¦Â upregulated the expression of AK094629 in the SMSCs in vitro.	32468015
466	Human	AK095147	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
467	Human	AK095147	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	downregulated	24379026
468	Human	AK294004	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
469	Human	AK294004	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
470	Human	AK309872	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
471	Human	AL049437	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	32057949
472	Human	AL645940.1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
473	Human	ALT1	lncRNA	hypoxia	regulation of cell cycle	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	upregulated	28977802
474	Human	ANCR	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"MCF10A,MDA-MB-231,MCF7,T47D,BT549,HEK293T"	TGF-¦Â1 down-regulates ANCR treatment	downregulated	28978036
475	Human	ANPODRT	lncRNA	tert-butyl hydroperoxide (TBHP)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cell	?tert-butyl hydroperoxide (TBHP) treatment	We found that ANPODRT was downregulated in degenerative NP tissues and in NP cells treated with tert-butyl hydroperoxide	33603950
476	Human	ANRIL	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	lipopolysaccharide (LPS) treatment	The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells	32069473
477	Human	ANRIL	lncRNA	human T-cell leukemia virus type 1 (HTLV-1)	adult T-cell leukemia (ATL)	ATL cells	human T-cell leukemia virus type 1 (HTLV-1) infection	The expression level of the lncRNA ANRIL was elevated in HTLV-1-infected cell lines and clinical ATL samples.	30258009
478	Human	ANRIL	lncRNA	tanshinone IIA (Tan IIA)	age-related nuclear cataract	H2O2 treated human lens epithelial cell line SRA01/04	Tanshinone IIA treatment	upregulated	30701534
479	Human	ANRIL	lncRNA	IL-13	allergic rhinitis (AR)	Human nasal epithelial cells (HNECs)	IL-13 treatment	"The expression levels of ANRIL and JAK2 were also upregulated in IL-13-induced HNECs, while the expression levels of miR-15a-5p were downregulated."	33325534
480	Human	ANRIL	lncRNA	oxygen glucose deprivation (OGD)	angiogenesis	Human umbilical vein endothelial cells (HUVECs)	oxygen glucose deprivation (OGD) treatment	OGD remarkably decreased lncRNA-ANRIL expression level.	32400082
481	Human	ANRIL	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta vascular smooth muscle cells (HA-VSMCs); human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ANRIL promoted AS progression by sponging miR-399-5p and regulating RAS/RAF/ERK signal pathway.	32141564
482	Human	ANRIL	lncRNA	H2O2	cataract	HLECs	H2O2 treatment	lncRNA ANRIL attenuated H2O2-induced cell injury in HELCs via up-regulating miR-21 via the activation of AMPK and ¦Â-catenin.	32310822
483	Human	ANRIL	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	kidney tissues	high glucose (HG) treatment	ANRIL and TXNIP were elevated in DN kidney tissues and HG-treated HK-2 cells while miR-497 was reduced.?miR-497 mimics inhibited caspase-1-dependent pyroptosis while co-overexpression of TXNIP blocked its effects in HG-treated HK-2 cells.	33160992
484	Human	ANRIL	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial cell cells (HK-2)	high glucose (HG) treatment	ANRIL promotes pyroptosis and kidney injury in DN via acting as miR-497 sponge to disinhibit TXNIP expression.	33160992
485	Human	ANRIL	lncRNA	Rhein-8-O-¦Â-D-glucopyranoside (Rg)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	Rhein-8-O-¦Â-D-glucopyranoside (Rg) treatment	Rg attenuated HG-induced apoptosis of HMCs by regulating the lincRNA ANRIL/let-7a/TGF-¦Â1/Smad signaling pathway	32256771
486	Human	ANRIL	lncRNA	high glucose (HG)	diabetic wound healing	Human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	downregulated	30565672
487	Human	ANRIL	lncRNA	H2O2	glaucoma	human trabecular meshwork (TM) cells	"For the stimulation with H2 O2 , the cells were cultured in Trabecular Meshwork Cell Medium (TMCM) containing 50-400 ¦ÌM H2O2 (Sigma-Aldrich, St. Louis, MO, USA) for 24 h after they reached 80-85% confluence."	H2O2-induced decrease of cell viability and the increases in apoptosis and ROS generation were significantly attenuated by lncRNA ANRIL overexpression	31081068
488	Human	ANRIL	lncRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	all-trans retinoic acid (ATRA) treatment	downregulated	31186810
489	Human	ANRIL	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	ANRIL knockdown inhibited the development of DDP resistance by upregulating miR-98.	32705261
490	Human	ANRIL	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	U2-OS and Saos-2 osteosarcoma cell lines	cisplatin (DPP) treatment	ANRIL-silenced cells were more sensitive to cisplatin: apoptotic ratio was increased and cleaved caspase-3 level was upregulated.	30777616
491	Human	ANRIL	lncRNA	hypoxia	osteosarcoma (OS)	osteosarcoma cells (MNNG and U2OS)	hypoxia treatment	upregulated	28588425
492	Human	ANRIL	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells	cisplatin treatment	upregulated	31189742
493	Human	ANRIL	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
494	Human	ANRIL	lncRNA	propofol (PPF)	papillary thyroid cancer (PTC)	Human PTC cell lines TPC-1 and IHH-4	Propofol treatment	downregulated	30703346
495	Human	ANRIL	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	downregulated	31974617
496	Human	ANRIL	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	downregulated	31974617
497	Human	ANRIL	lncRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	fetal human cells (FHCs)	lipopolysaccharide (LPS) treatment	upregulated	30477744
498	Human	ANRIL	lncRNA	ursolic acid (UA)	uric acid nephropathy (UAN)	HK-2?cells	uric acid treatment	Uric acid increased the expression levels of ANRIL in HK-2 cells	30347231
499	Human	ANRIL	lncRNA	high glucose (HG)	wound healing	human dermal lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"ANRIL was downregulated, whereas miR-181a was upregulated in high glucose (HG)-induced LECs."	30565672
500	Human	ANRIL	lncRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells	irradiation treatment	Irradiation significantly decreased cell viability and ANRIL expression in a dose-dependent manner.	33529508
501	Human	AP000769.1-2:10	lncRNA	celecoxib	lung squamous cell carcinoma (LSQCC)	The human LSQCC cell line SK-MES-1	celecoxib treatment	downregulated	29512696
502	Human	APAP2-AS1	lncRNA	trastuzumab	breast cancer	HER2-positive SKBR-3 and BT474 cells	Trastuzumab treatment	upregulated	30910994
503	Human	APPAT	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	APPAT showed significant reduction in ox-LDL treated human VSMCs in vitro.	29372117
504	Human	ARAP1-AS2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	32969198
505	Human	ARAP1-AS2	lncRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	HK-2 cells	high glucose (HG) treatment	upregulated	31975379
506	Human	Arid2-IR	lncRNA	advanced glycation end product (AGE)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	advanced glycation end product (AGE) treatment	upregulated	31912402
507	Human	ARSR	lncRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; SW620 cells	oxaliplatin (OXA) treatment	upregulated of lncARSR promoted OXA resistance in CRC.	32558022
508	Human	ARSR	lncRNA	atorvastatin	hypercholesterolemia	peripheral blood samples	atorvastatin treatment	Atorvastatin increased the expression of lncRNAs ARSR after treatment.	33198086
509	Human	ARSR	lncRNA	fatty acid	nonalcoholic fatty liver disease (NAFLD)	human hepatocarcinoma cell line (HepG2)	fatty acid treatment	upregulated	29555473
510	Human	ARSR	lncRNA	high fatty acid	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high fatty acid treatment	upregulated	32169080
511	Human	AT102202	lncRNA	epigallocatechin-3-gallate (EGCG)	cholesterol metabolism	"human hepatoblastoma cell line, HepG2"	epigallocatechin-3-gallate (EGCG) treatment	upregulated	25563320
512	Human	ATB	lncRNA	TGF-¦Â1	atherosclerosis (AS)	human umbilical vein endothelial cell (HUVEC) line	TGF-¦Â1 treatment	upregulated	30942415
513	Human	ATB	lncRNA	angiotensin II (Ang II)	endothelial cell injury	human umbilical vein endothelial cell (HUVECs)	angiotensin II (Ang II) treatment	Ang II treatment downregulated the lncRNA-ATB level in HUVECs.	32581029
514	Human	ATB	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells	TGF-¦Â1 induces EMT process and elevates treatment	upregulated	29113749
515	Human	ATB	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; Beas-2B cells	TGF-¦Â1 treatment	TGF-¦Â1 induces EMT process and elevates lncRNA-ATB levels in pulmonary epithelial cells	30010033
516	Human	ATB	lncRNA	TGF-¦Â	glioblastoma multiforme (GBM)	LN-18 and U251 cells	TGF-¦Â treatment	upregulated	31140621
517	Human	ATB	lncRNA	hepatitis B virus (HBV)	HBV-associated hepatocellular carcinoma (HCC)	HepG2 cell lines	hepatitis B virus (HBV) infection	upregulated	31746419
518	Human	ATB	lncRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	SMMC-7721 cells	astragaloside (AS-IV) treatment	downregulated	29331759
519	Human	ATB	lncRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	hepatoma cells	SMMC-7721 continuously with TGF-¦Â for 21 days treatment	different experssion	24768205
520	Human	ATB	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	HBx treatment	HBx-induced autophagy could upregulate the expression of TGF-¦Â and lncRNA-ATB.	31746419
521	Human	ATB	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human ATDC5 cells	lipopolysaccharide (LPS) treatment	"lncRNA-ATB expression was downregulated in LPS-injured cells, and lncRNA-ATB overexpression significantly alleviated LPS-induced inflammatory injury in ATDC5 cells."	30771739
522	Human	ATB	lncRNA	TGF-¦Â1	renal fibrosis	human kidney 2 (HK-2) cells	TGF-?1 treatment	LncRNA-ATB was highly expressed in TGF-?1 induced HK-2 cells	32447340
523	Human	ATXN8OS	lncRNA	ginsenoside Rg3	breast cancer	MCF-7 breast cancer cells	ginsenoside Rg3 treatment	"Here, a lncRNA (ATXN8OS) was found to be downregulated via Rg3-mediated promoter hypermethylation in MCF-7 breast cancer cells."	33477683
524	Human	AU015836	lncRNA	glyoxylate	kidney damage and kidney stones	HK-2 cells	glyoxylate	upregulated	29160413
525	Human	AV310809	lncRNA	TGF-¦Â1	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	TGF-¦Â1 treatment	upregulated	30935692
526	Human	AWPPH	lncRNA	bone morphogenetic protein 2 (BMP2)	non-traumatic osteonecrosis of femoral head (ONFH)	human MSCs from bone marrow (hMSC-BM)	bone morphogenetic protein 2 (BMP2) treatment	BMP-2 significantly upregulated the expression of lncRNA AWPPH in a dose-dependent manner.	31853285
527	Human	AWPPH	lncRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis	Human MSCs from bone marrow (hMSC-BM)	bone morphogenetic protein 2 (BMP2) treatment	"BMP-2 treatment significantly increased the expression level of AWPPH in human MSCs from bone marrow (hMSC-BM). AWPPH overexpression promoted, while AWPPH short hairpin RNA silencing inhibited the expression of Runx2 expression in hMSC-BM cells."	31853285
528	Human	AWPPH	lncRNA	carboplatin (CBP)	triple negative breast cancer (TNBC)	o human TNBC cell lines MDA©\MB©\231 and BT©\ 20	carboplatin (CBP) treatment	LncRNA AWPPH overexpression led to promoted cancer cells proliferation and improved cancer cell viability under carboplatin treatment.	31033015
529	Human	AX747207	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	upregulated	29749447
530	Human	AX800134	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	blood; liver tissues	hepatitis B virus (HBV) infection	AX800134 was upregulated in HBV-positive HCC compared with HBV-negative HCC.	29789998
531	Human	BACE1	lncRNA	anisomycin	ovarian cancer (OC)	human ovarian cancer stem cells (OCSCs)	anisomycin treatment	upregulated	26783004
532	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	"The BACE1-AS level was found to be upregulated in serum samples of AD patients, brain tissues of AD transgenic (Tg) mice and A¦Â1-42-treated SH-SY5Y cells."	33197504
533	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease.	33197504
534	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	HPN; SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	31898085
535	Human	BACE1-AS	lncRNA	berberine (BBR)	Alzheimer's disease (AD)	HPN; SK-N-SH cells	berberine (BBR) treatment	downregulated	31898085
536	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	senile plaque (SP) AD SH-SY5Y cell	synthetic amyloid ¦Â-protein( A¦Â1-42) treatment	up-regulate	24970022
537	Human	BACE1-AS	lncRNA	HIV-1 transactivator of transcription (Tat) protein	HIV-associated neurocognitive disorders (HAND)	human primary astrocytes (HPAs)	HIV-1 transactivator of transcription (Tat) protein treatment	HIV-1 Tat-mediated astrocytic amyloidosis involves the HIF-1¦Á/lncRNA BACE1-AS axis.	32453744
538	Human	BANCR	lncRNA	IFN-¦Ã	age-related macular degeneration (AMD)	ARPE-19 cells	IFN-¦Ã treatment	IFN-¦Ã by itself increases BANCR expression in RPE cells.	29054724
539	Human	BANCR	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial cell line ARPE-19	high-glucose (HG) treatment	"In vitro, high-glucose treatment failed to affect the expression of lncRNA BANCR in the human retinal pigment epithelial cell line ARPE-19. However, lncRNA BANCR overexpression inhibited the apoptosis of ARPE-19 cells under high-glucose conditions."	31007747
540	Human	BANCR	lncRNA	IFN-¦Ã	inflammation	ARPE-19 cells	IFN¦Ã treatment	upregulated	29054724
541	Human	BANCR	lncRNA	IFN-¦Â	myocardial injury	iPS cell-derived cardiomyocytes	IFN-¦Â treatment	BANCR promotes interferon-¦Â-induced cardiomyocyte apoptosis by targeting signal transducer and activator of transcription 1 in vitro.	33284897
542	Human	BANCR	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
543	Human	BC005927	lncRNA	hypoxia	gastric cancer (GC)	SGC7901 cells; MKN45 cells; MKN28 cells	hypoxia treatment	"BC005927 was strongly induced by hypoxia in SGC7901 cells, MKN45 cells and MKN28 cells in a time- dependent method."	29383777
544	Human	BC064139	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
545	Human	BC200	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
546	Human	BC200	lncRNA	doxorubicin (DOX)	cellular defense against genotoxic agents	human glioma cell lines	doxorubicin (DOX) treatment	downregulated	25645334
547	Human	BC200	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	H1299/DDP cells	cisplatin treatment	the IC50 in H1299/DDP cells transfected with si-BC200 was lower than in those transfected with si-NC.	30779077
548	Human	BC200	lncRNA	carboplatin (CBP)	ovarian cancer (OC)	SKOV3 and A2780 ovarian cancer cells	carboplatin (CBP) treatment	"it was observed that carboplatin induced BC200 expression in the cell lines, and that the inhibition of BC200 decreased the sensitivity of the cells to the drug"	26893717
549	Human	BCAR42	lncRNA	Yes-associated protein (YAP)	breast cancer	"human breast cancer cell lines MDA©\MB©\231, MDA©\MB©\468, and human embryonic kidney cell line HEK293T"	YAP treatment	upregulated	28963395
550	Human	BDLNR	lncRNA	baicalin (BAI)	cervical cancer (CC)	HeLa cells; SiHa cells	baicalin (BAI) treatment	BDLNR is downregulated by baicalein in a dose- and time-dependent manner in cervical cancer.	29175387
551	Human	BDLNR	lncRNA	baicalin (BAI)	cervical cancer (CC)	"HeLa, SiHa, ME-180 cells"	baicalin (BAI) treatment	upregulated	291753872
552	Human	BDNF-AS	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial (RPE) cells	50 mM D-glucose	upregulated	28657668
553	Human	BDNF-AS	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	"With treatment of 50?mM D-glucose, BDNF was markedly downregulated whereas BDNF-AS upregulated in ARPE-19 cells."	28657668
554	Human	BDNF-AS	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	32057951
555	Human	BDNF-AS	lncRNA	lithium (Li)	spinal cord injury (SCI)	SH-SY5Y cells	lithium treatment	Lithium treatment rescued the upregulation of BDNF-AS expression and downregulated of miR-9-5p expression induced by H2O2 in SH-SY5Y cells.	33464390
556	Human	BFAL1	lncRNA	enterotoxigenic bacteroides fragilis (ETBF)	colorectal cancer (CRC)	HCT-116 and DLD-1 cells	Enterotoxigenic Bacteroides fragilis (ETBF) infection	upregulated	31515468
557	Human	BLACAT1	lncRNA	ketamine	anesthesia-induced neural cytotoxicity	human induced pluripotent stem cells (hiPSCs)-derived neurons	"HiPSC-derived neurons were incubated with ketamine (MilliporeSigma, Shanghai, China) at various concentrations of 0, 0.001, 0.01, 0.1, 0.5, 1, 2 and 5 mM for 24 h."	"ketamine induced neuronal apoptosis, neurite degeneration, and upregulated BLACAT1 gene expression. Inversely, lentiviral-induced BLACAT1 downregulated rescued ketamine-induced neural cytotoxicity in hiPSCs-derived neurons. In addition, BLACAT1 downregulated was demonstrated to prevent ketamine-induced mitochondrial dysregulations by suppressing ROS and caspase 3/7 activities in hiPSCs-derived neurons."	31622594
558	Human	BLACAT1	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	SCC25 cell; FaDu cells	radiation treatment	BLACAT1 knockdown enhanced radioresistance of HNSCC cells via regulating PSEN1	31944856
559	Human	BLACAT1	lncRNA	afatinib	non-small cell lung cancer (NSCLC)	NSCLC cell lines Calu3 and H1975	afatinib treatment	BLACAT1 was upregulated in afatinib-resistant NSCLC cells.	31359792
560	Human	Blnc1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	31632538
561	Human	BMP5	lncRNA	oestrogen (E2)	phallus development	urethral epithelium of male phalluses	oestrogen (E2) treatment	Lnc-ZBTB16 was downregulated by oestrogen treatment in male phalluses at day 50 post-partum (pp).	30598023
562	Human	C0100223	lncRNA	estrogen (ES)	epithelial ovarian cancer (EOC)	E2 receptor (ER) ¦Á-positive EOC cells	Estrogen (E2) treatment	dysregulated	24481591
563	Human	C2dat1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor (PDGF)-BB treatment	C2dat1 was higher in coronary artery disease (CAD) tissues than in normal arterial tissues and the C2dat1 expression level was upregulated in the proliferating VSMC after being treated with PDGF-bb	30474870
564	Human	C2dat1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	C2dat1 was higher in coronary artery disease (CAD) tissues than in normal arterial tissues and the C2dat1 expression level was upregulated in the proliferating VSMC after being treated with TNF-¦Á	30474870
565	Human	C3orf67-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	Ginsenoside Rh2-treated MCF-7 cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31645124
566	Human	C3orf67-AS1	lncRNA	ginsenoside Rh2	breast cancer	MCF-7 cancer cells	Ginsenoside Rh2 treatment	downregulated	31645124
567	Human	C5orf66-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"gastric cardia adenocarcinoma (GCA) cell lines MGC-803, BGC-823, HGC-27, SGC-7901, NCI-N87"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29566283
568	Human	C7orf30-2	lncRNA	IFN-¦Ã and TNF-¦Á	atopic dermatitis (AD)	human keratinocytes (HaCaT cells)	IFN-¦Ã/TNF-¦Á treatment	upregulated	31181406
569	Human	C7orf30-2	lncRNA	quercetin	atopic dermatitis (AD)	IFN-¦Ã/TNF-¦Á-treated human keratinocytes (HaCaT cells)	Quercetin (Que) treatment	downregulated	31181406
570	Human	CA7-4	lncRNA	high glucose (HG)	autophagy	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680.	30957640
571	Human	CA7-4	lncRNA	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO)	vascular endothelial cells (VECs) autophagy and apoptosis	human vascular endothelial cells (VECs)	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment	3BDO restrained the upregulation of CA7-4 induced by high glucose in VECs.	30957640
572	Human	CAIF	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human CHON-001 cells	lipopolysaccharide (LPS) treatment	"CAIF overexpression inhibited the apoptosis of CHON-001 cells under LPS treatment, while miR-1246 overexpression attenuated the effects of CAIF overexpression."	31653823
573	Human	CASC15	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	CIHP-1 cells	high glucose (HG) treatment	CASC15 is upregulated in DCRF patients and promotes the apoptosis of podocytes by sponging miR-34c.	32053576
574	Human	CASC15	lncRNA	hypoxia	non-small cell lung cancer (NSCLC)	"NSCLC cell lines (A549, H1299, H1650, H1975, H520)"	hypoxia treatment	?Further analysis showed that hypoxia-induced CASC15 transactivation was mainly dependent on hypoxia-inducible factor 1¦Á (HIF-1¦Á) and hypoxia response elements (HREs) located in CASC15 promoter.	33407675
575	Human	CASC2	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32323747
576	Human	CASC2	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	29492259
577	Human	CASC2	lncRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells and MDA-MB-231 cells	paclitaxel (PTX) treatment	upregulated	31352515
578	Human	CASC2	lncRNA	berberine (BBR)	colorectal cancer (CRC)	The human colorectal cancer cell lines HT29 and HCT116	berberine (BBR) treatment	"LncRNA CASC2 was upregulated in cells treated with berberine, and knockdown of lncRNA CASC2 reversed the berberine-induced apoptosis."	30681073
579	Human	CASC2	lncRNA	berberine (BBR)	colorectal cancer (CRC)	"Five human CRC cell lines (HT-29, HCT116, SW480, SW620 and LoVo)"	berberine (BBR) treatment	lncRNA CASC2 was upregulated by berberine treatment	31173223
580	Human	CASC2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	"CASC2 upregulation suppressed HG-induced proliferation, ECM accumulation and oxidative stress of HMCs through miR-133b /FOXP1 regulatory axis."	32016985
581	Human	CASC2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal mesangial cells (HRMCs)	high glucose (HG) treatment	"CASC2 could alleviate the degree and process of apoptosis, inflammation, and fibrosis in diabetic nephropathic models by regulating the miR-144/SOCS2 axis."	33227790
582	Human	CASC2	lncRNA	sanguinarine	epithelial ovarian cancer (EOC)	SKOV3 cells	sanguinarine treatment	upregulated	29571014
583	Human	CASC2	lncRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901 cells	cisplatin treatment	downregulated	30372881
584	Human	CASC2	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U257 cells; U87 cells	temozolomide (TMZ) treatment	downregulated	29136760
585	Human	CASC2	lncRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	TPC-1 cells; IHH-4 cells	Radioiodine (131I) treatment	CASC2 increases 131I sensitivity in PTC by sponging miR-155	33134385
586	Human	CASC2	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	CASC2 attenuated hypoxia-induced PASMC proliferation and migration by regulating the miR-222/ING5 axis to prevent vascular remodeling and the development of PAH.	32206065
587	Human	CASC7	lncRNA	corticosteroid	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	corticosteroid treatment	CASC7 increased corticosteroid sensitivity by inhibiting the PI3K/AKT signaling pathway via targeting miR-21.	31412983
588	Human	CASC7	lncRNA	dexamethasone (DEX)	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	dexamethasone (DEX) treatment	Overexpression of CASC7 suppressed the PI3K/AKT signaling pathway and promoted the inhibition effects of dexamethasone on cell proliferation and cytokines secretion via targeting miR-21.	31412983
589	Human	CASC7	lncRNA	NaSH	spinal cord ischemia/reperfusion injury (SCII)	SH5Y-SY cells	NaSH treatment	NaSH preprocessing upregulated CasC7 and downregulated miR-30c in OGD/R-induced SH5Y-SY cells.	29571256
590	Human	CASC9	lncRNA	lipopolysaccharide (LPS)	lung injury	human small airway epithelial cells (HSAECs)	Lipopolysaccharide (LPS) treatment	CASC9 protects lung epithelial cells from sepsis-induced injury via regulating miR-195-5p/PDK4 axis.	32221619
591	Human	CASC9	lncRNA	hypoxia	pancreatic cancer (PC)	"human pancreatic cancer cell lines (SW1990, PANC-1, BxPC-3, and MiaPaCa-2)"	hypoxia treatment	"Additionally, our findings showed that hypoxia induced the expression of CASC9 and enhanced the binding of HIF-1¦Á to its promoter."	33520364
592	Human	CCAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS administration reduced CCAT1 in tubular epithelial cells in vitro.	32243922
593	Human	CCAT1	lncRNA	radiation	breast cancer	MCF-7 cells; MDA-MB-231 cells	radiation treatment	Radiation treatment triggered a significant increase in CCAT1 and an obvious decrease in miR-148b	29024383
594	Human	CCAT1	lncRNA	X-rays	breast cancer	human breast cancer cell lines MCF-7 and MDA-MB-231	radiation treatment	upregulated	29024383
595	Human	CCAT1	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	A2780; SKOV3	cisplatin treatment	CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.	32124583
596	Human	CCAT1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"HCT 116, SW1417, HT-29, and KM12 cell lines and NCM460 cell line"	5-fluorouracil (5-FU) treatment	the expression levels of CCAT1 were high in HCT 116/5-FU and HT-29/5-FU cell lines	31039730
597	Human	CCAT1	lncRNA	dandelion	gastric cancer (GC)	human GC cells	dandelion treatment	downregulated	28724210
598	Human	CCAT1	lncRNA	solasonine (SS)	hepatocellular carcinoma (HCC)	"HepG2 cells, QGY-7703 cells"	Solasonine (SS) treatment	downregulated	31681610
599	Human	CCAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	skin keratinocyte HaCaT cells	lipopolysaccharide (LPS) treatment	upregulated	31356903
600	Human	CCAT1	lncRNA	Sinomenine (SIN)	inflammation	skin keratinocyte HaCaT cells	sinomenine treatment	downregulated	31356903
601	Human	CCAT1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Human colorectal cancer cell line Caco-2	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30615124
602	Human	CCAT1	lncRNA	dexmedetomidine (DEX)	ischemia/reperfusion (I/R) injury	HL7702 cells	dexamethasone (DEX) treatment	Dex partially reversed the OGD-inhibited expression of lncRNA CCAT1.	29851220
603	Human	CCAT1	lncRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cell	cigarette smoke extract (CSE) treatment	upregulated	28184029
604	Human	CCAT1	lncRNA	baicalin (BAI)	melanoma	A375 and SK-MEL-28 cells	baicalin (BAI) treatment	downregulated	31778440
605	Human	CCAT1	lncRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	L02 cells	oleic acid (OA) treatment	"CCAT1 increases LXR¦Á transcription by serving as a competing endogenous RNA for miR-613 in an LXRE-dependent manner, thereby promoting lipid droplet formation and NAFLD."	32413192
606	Human	CCAT1	lncRNA	hyperoside	non-small cell lung cancer (NSCLC)	H1975 cells	hyperoside treatment	downregulated	31894285
607	Human	CCAT1	lncRNA	hyperoside	non-small cell lung cancer (NSCLC)	The adenocarcinoma lung cancer cell line PC-9 and the T790M-positive NSCLC cell line NCI-H1975	Hyperoside treatment	downregulated	31894285
608	Human	CCAT1	lncRNA	paclitaxel (PTX)	paclitaxel (PTX) resistance	PC3-TXR cells; DU145-TXR cells	Paclitaxel (PTX) treatment	Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1	32089062
609	Human	CCAT2	lncRNA	X-rays	esophageal cancer (EC)	TE-3 cells; ECA109 cells	X-ray radiation treatment	lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR-145/p70S6K1 and p53 pathway	31789385
610	Human	CCAT2	lncRNA	calcitriol	ovarian cancer (OC)	SKOV3 cells; A2780 cells	calcitriol treatment	calcitriol inhibited CCAT2 expression in ovarian cancer cells.	32230936
611	Human	CCDC26	lncRNA	imatinib	gastrointestinal stromal tumor (GIST)	GIST-882 cells; GIST- T1 cells	imatinib treatment	downregulated	29423012
612	Human	CCNB1IP1-1:2	lncRNA	nigericin	pancreatic cancer (PC)	PANC-5 cells	nigericin treatment	upregulated	32850392
613	Human	Ccnd1	lncRNA	polyunsaturated fatty acids (PUFAs)	glioblastoma multiforme (GBM)	Glioblastoma cells (U373; GBM2;GBM5)	polyunsaturated fatty acids (PUFAs) treatment	downregulated	21961478
614	Human	CD160	lncRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	CD8+ T cells	hepatitis B virus (HBV) infection	lncRNA-CD160 is positively associated with CD160 in CD8+ T cells with HBV infection.	32565950
615	Human	CD1D-2:1	lncRNA	melanin	melanoma	Primary melanocytes	melanin treatment	upregulated	26596215
616	Human	CDKN2B-AS	lncRNA	gemcitabine (GEM)	gemcitabine sensitivity	T24 cells	gemcitabine treatment	The expression of CDKN2B-AS gene in Gemcitabine-resistant T24/Gem cells was much higher than that in T24 cells.	29937935
617	Human	CDKN2B-AS1	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
618	Human	CDKN2B-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	"Knockdown of CDKN2B-AS1 suppressed proliferation, ECM accumulation and PI3K/AKT signaling by increasing miR-424-5p and decreasing HMGA2 in high glucose-treated HMGC cells."	31707340
619	Human	CDKN2B-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	upregulated	31707340
620	Human	CDKN2B-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis	33298110
621	Human	CDKN2B-AS1	lncRNA	¦Â-Elemene	esophageal squamous cell carcinoma (ESCC)		¦Â-Elemene treatment	The chemotherapeutic drug ¦Â-elemene suppressed the proliferation of esophageal carcinoma ECA-109 cells by regulating the inhibition of hTERT expression by lncRNA CDKN2B-AS1	25646744
622	Human	CDKN2B-AS1	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
623	Human	CERNA1	lncRNA	"annexin A7 inhibitor, ABO (6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine)"	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	"annexin A7 inhibitor, ABO (6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine) treatment"	upregulated	30911960
624	Human	CETP-3	lncRNA	medroxyprogesterone acetate (MPA)	endometrial cancer (EC)	Ishikawa cells (PRB+)	medroxyprogesterone acetate (MPA) treatment	upregulated	31718641
625	Human	CF129	lncRNA	hypoxia	pancreatic cancer (PC)	The PANC-1 and BxPC-3 cell lines	hypoxia induce	downregulated	31367258
626	Human	CHCHD4P4	lncRNA	glyoxylate	kidney damage and kidney stones	HK-2 cells	glyoxylate	upregulated	29160413
627	Human	chr13:50054355-50057699	circRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	downregulated	31818729
628	Human	chr13:50054355-50057699+	circRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	downregulated	31818729
629	Human	chr14:101402109-101464448+	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells	gemcitabine (GEM) treatment	chr14:101402109- 101464448+ was found significantly upregulated in non-responsive group.	29922161
630	Human	chr18:21644104-21649235	circRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	downregulated	31818729
631	Human	chr18:21644104-21649235+	circRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	downregulated	31818729
632	Human	chr2:15629018-15651474	circRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	upregulated	31818729
633	Human	chr4:52729603-52780244+	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells	gemcitabine (GEM) treatment	chr4:52729603-52780244+ was found significantly upregulated in non-responsive group.	29922161
634	Human	chr7:2330794-22357656	circRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	upregulated	31818729
635	Human	chr7:2330794-22357656-	circRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	upregulated	31818729
636	Human	CHRF	lncRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â1 treatment	CHRF and L1CAM expression were significantly upregulated and promoted the EMT process in A549 after treatment of TGF-¦Â1	33754922
637	Human	CHRF	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
638	Human	CILinc02	lncRNA	ibuprofen	osteoarthritis (OA)	cartilage tissues of osteoarthritis	Ibuprofen treatment	downregulated	30548658
639	Human	CILinc02	lncRNA	methylene blue (MB)	osteoarthritis (OA)	cartilage tissues of osteoarthritis	methylene blue treatment	downregulated	30548658
640	Human	circABCB10	circRNA	paclitaxel (PTX)	breast cancer	BC tissues; MCF-7 cells MDA-MB-231	Paclitaxel (PTX) treatment	upregulated	32273769
641	Human	circABCB10	circRNA	cisplatin (DDP)	lung cancer	A549 cells; NCl H292 cells	cisplatin treatment	downregulated	31931771
642	Human	circACTR2	circRNA	glucose	diabetic nephropathy (DN)	HK-2 cells	glucose treatment	"CircACTR2 regulates high glucose-induced pyroptosis, inflammation and fibrosis in proximal tubular cells."	32115515
643	Human	circADAM9	circRNA	high glucose (HG)	dysfunction of endothelial progenitor cells (EPCs)	human endothelial progenitor cells (EPCs)	high glucose (HG) treatment	Circ-ADAM9 targeting PTEN and ATG7 promotes autophagy and apoptosis of diabetic endothelial progenitor cells by sponging mir-20a-5p.	32661238
644	Human	circANKRD11	circRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human pulmonary microvascular endothelial cells HPMECs	cigarette smoke extract (CSE) treatment	"CircANKRD11 and BRD4 expression were increased, whereas miR-145-5p expression was decreased in the lung tissues of smokers with or without COPD and CSE-induced HPMECs"	33833509
645	Human	circANKRD36	circRNA	lipopolysaccharide (LPS)	bedsore	HaCaT cells	lipopolysaccharide (LPS) treatment	upregulated	31692058
646	Human	circANKRD36	circRNA	lipopolysaccharide (LPS)	inflammatory injury	HaCaT cells	lipopolysaccharide (LPS) treatment	circANKRD36 remitted cell inflammatory damage upregulating miR-15/MyD88 via the NF-¦ÊB pathway in HaCaT cells.	31692058
647	Human	circANKRD36	circRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	circANKRD36 sponge miR-599 to up-regulate the expression of Casz1 and thus prevent apoptosis and inflammation in OA.	33205602
648	Human	circANKRD36	circRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	LPS irritation raised the level of circANKRD36 in MRC-5 cells.	31793082
649	Human	circANKRD36	circRNA	sepsis	pneumonia	human embryonic lung fibroblast MRC-5 cell	human embryonic lung fibroblast MRC-5 cell injury irritated by lipopolysaccharide (LPS) treatment	"LPS aroused a decrease in viability, increases in apoptosis, ROS, and IL-6, IL-8, and TNF-¦Á, along with circANKRD36, and activation of NF-¦ÊB pathway Silencing circANKRD36 weakened the above-mentioned influences of LPS"	31793082
650	Human	circANRIL	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"The expression of circ_ANRIL in OGD/R-induced human brain microvascular endothelial cells (HBMECs) was significantly upregulated, while that of miR-622 was significantly downregulated"	32616043
651	Human	circANRIL	circRNA	lipopolysaccharide (LPS)	inflammation	HK-2 cells	lipopolysaccharides (LPS) treatment	upregulated	31432701
652	Human	circARF3	circRNA	tumor necrosis factor alpha (TNF-¦Á) 	encephalitis	SH-SY5Y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á inducement also markedly reduced circARF3 expression.	32329660
653	Human	circARL3	circRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HCC tissues	hepatitis B virus (HBV) infection	upregulated	33372396
654	Human	circATP2B4	circRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	CircATP2B4 potentiated hypoxia-induced proliferation and migration of PASMCs through the miR-223/ATR axis.	32926932
655	Human	circAtp9b	circRNA	lipopolysaccharide (LPS)	inflammation	MRC-5 cells	lipopolysaccharide (LPS) treatment	LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression.	31735661
656	Human	circAtp9b	circRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression.	31735661
657	Human	circBCRC4	circRNA	gambogic acid (GA)	bladder cancer	T24T and UMUC3 cells	Gallic acid (GA) treatment	upregulated	29270748
658	Human	circBPTF	circRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	CircBPTF knockdown protected against HG-induced inflammatory injuries and oxidative stress by mediating the miR-384/LIN28B axis in HUVECs.	32524321
659	Human	circCamk4	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	circ-camk4 (hsa-circ-camk4) are elevated in SH-SY5Y cells exposed to OGD/R treatment	32332879
660	Human	circCCDC66	circRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells; HT-29 cells	oxaliplatin (OXA) treatment	circCCDC66 is elevated in colorectal cancer cells with resistance to oxaliplatin	32187976
661	Human	circCCDC66	circRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells; HT-29 cells	oxaliplatin treatment	circCCDC66 is elevated in colorectal cancer cells with resistance to oxaliplatin	32187976
662	Human	circCDK8	circRNA	CoCl2	periodontitis	human Periodontal ligament stem cells (PDLSCs)	CoCl2 treatment	upregulated	32978798
663	Human	circCDR1as	circRNA	cisplatin (DDP)	bladder cancer	"human bladder cancer cell lines TCCSUP, 5367, T24 and EJ"	cisplatin treatment	Cdr1as induced the apoptosis and enhanced the cisplatin chemosensitivity of bladder cancer cells both in vitro and in vivo.	31131537
664	Human	circCDR1as	circRNA	3-methyladenine (3-MA)	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	3-Methyladenine (3-MA) treatment	upregulated	31582727
665	Human	circCDR1as	circRNA	hypoxia	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	hypoxia induce	upregulated	31582727
666	Human	circCDR1as	circRNA	rapamycin	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	rapamycin treatment	upregulated	31582727
667	Human	circCDR1as	circRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	32018039
668	Human	circCDR1as	circRNA	cisplatin (DDP)	ovarian cancer (OC)	Human ovarian cancer cell lines (A2780 and SKOV-3)	cisplatin treatment	there was a decreasing trend in Cdr1as levels from normal ovarian tissues to cisplatinsensitive ovarian cancer tissues and then to cisplatin-resistant ovarian cancer tissues. Cdr1as Enhances the Cisplatin Chemosensitivity of Ovarian Cancer In Vitro.	31479922
669	Human	circCDR1as	circRNA	lipopolysaccharide (LPS)	periodontitis	Human periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	"CDR1as was significantly downregulated in LPS-treated PDLSCs compared to untreated cells, as well as in normal periodontal ligament tissues compared to periodontitis tissues."	31582895
670	Human	circCDR1as	circRNA	hypoxia	pulmonary hypertension (PH)	Human pulmonary artery smooth muscle cell (HPASMC)	hypoxia treatment	CDR1as/miR-7-5p/CNN3 and CAMK2D regulatory axis mediates HPASMC osteoblastic differentiation and calcification induced by hypoxia.	33230455
671	Human	circCDR1as	circRNA	silica	silicosis	HBE cells; A549 cells	silica treatment	The increase of circRNA CDR1as was observed after treatment of silica	30202956
672	Human	circCHFR	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circ_CHFR contributed to the progression of AS through the miR-214-3p/Wnt3/¦Â-catenin signals.	32271446
673	Human	circChr19	circRNA	ebola virus (EBOV)	Ebola virus (EBOV) therapy	293T cells	EBOV treatment	upregulated	29209594
674	Human	circCIDN	circRNA	compression force (CF)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	compression treatment	CircRNA-CIDN was significantly downregulated in compression-treated human NP cells.	32114390
675	Human	circCILinc02	circRNA	methylene blue (MB)	osteoarthritis (OA)	chondrocytes	methylene blue treatment	CILinc02 was increased in primary cells of OA but was reduced in primary OA cells treated with MB.	30548658
676	Human	circCircNFIX	circRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	LN229 cells; U251 cells	temozolomide (TMZ) treatment	Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma	32194140
677	Human	circCLASP2	circRNA	high glucose (HG)	diabetic-associated vascular injury	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	High glucose (HG) exposure downregulated the expression of circ_CLASP2 in HUVECs	33776760
678	Human	circCOG8	circRNA	mechanical stress	intervertebral disc degeneration (IDD)	NP cells	mechanical stress treatment	circCOG8 expression was obviously downregulated by the mechanical stress in disk NP cells.	33195225
679	Human	circCOL1A2	circRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	Circular RNA COL1A2 promotes angiogenesis via regulating miR-29b/VEGF axis in diabetic retinopathy.	32497630
680	Human	circDHRS3	circRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	Circ_DHRS3 expression was elevated in OA cartilage tissues and IL-1¦Â-treated chondrocytes.	33360372
681	Human	circDHRS3	circRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	Circ_DHRS3 expression was elevated in OA cartilage tissues and IL-1¦Â-treated chondrocytes.	33360372
682	Human	circDLGAP4	circRNA	hypoxia	ischemia/reperfusion (I/R) injury	Human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	31607223
683	Human	circDLGAP4	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	circDLGAP4 expression was decreased in MPTP-induced PD mouse model and MPP+-induced PD cell models.	31761328
684	Human	circDLGAP4	circRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y Cells	1-methyl-4-phenylpyridinium (MPP+) treatment	circDLGAP4 expression was decreased in MPP+-induced PD cell models.	31761328
685	Human	circDNMT3B	circRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	High Glucose (HG) treatment	downregulated	31636010
686	Human	circDONSON	circRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC cells	cisplatin treatment	circDONSON promoted cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis.	32581651
687	Human	circDROSHA	circRNA	magnesium-free extracellular fluid	temporal lobe epilepsy (TLE)	SK-N-SH cells; IMR-32 cells	magnesium-free extracellular solution	downregulated	33370579
688	Human	circDYM	circRNA	repetitive transcranial magnetic stimulation (rTMS)	breast cancer	plasma	repetitive transcranial magnetic stimulation (rTMS) treatment	circDYM expression was upregulated after rTMS treatment	32663980
689	Human	circERCC2	circRNA	tert-butyl hydroperoxide (TBHP)	intervertebral disc degeneration (IDD)	nucleus pulposus cells (NPCs)	tert-butyl hydroperoxide (TBHP) treatment	downregulated	31582722
690	Human	circFAM172A	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	upregulated	33308021
691	Human	circFANCA	circRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	Circ-FANCA was upregulated in septic AKI serum specimens and LPS-treated HK2 cells.	33468219
692	Human	circFBXW7	circRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells; colorectal cancer (CRC) tissues	oxaliplatin treatment	circ-FBXW7 was measured and results showed circ-FBXW7 was lower in oxaliplatin-resistant CRC patients and resistant CRC cells than that in controls	33147048
693	Human	circFLNA	circRNA	fucoidan	oral squamous cell carcinoma (OSCC)	SCC15 cells; SCC25 cells	fucoidan treatment	upregulated	31495936
694	Human	circFLNA	circRNA	fucoidan	oral squamous cell carcinoma (OSCC)	Human tongue squamous carcinoma cells (SCC15 and SCC25)	fucoidan treatment	upregulated	31495936
695	Human	circFN1	circRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells; BGC823C cells	cisplatin treatment	circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5p.	31898357
696	Human	circFOXM1	circRNA	naringenin	lung cancer	A549 cells; PC9 cells	naringenin treatment	Naringenin hindered cell metastasis in vitro and tumor growth in vivo by reducing circFOXM1 and SPAG5 expression and inducing the expression of miR-3619-5p in lung cancer.	32598178
697	Human	circGCN1L1	circRNA	tumor necrosis factor alpha (TNF-¦Á) 	temporomandibular joint osteoarthritis	synoviocyte	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32332704
698	Human	circGRN	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	"In this study, we found that circ_GRN was elevated in the serum of AS and oxidized low-density lipoprotein (ox-LDL)-induced HVSMCs."	33818550
699	Human	circHDAC9	circRNA	amyloid-¦Â (A¦Â) 42	Alzheimer's disease (AD)	HN cells	amyloid-¦Â (A¦Â) 42 treatment	Berberine attenuates A¦Â42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells	32251633
700	Human	circHECTD1	circRNA	silicon dioxide (SiO2)	macrophage activation	Primary cultures of alveolar macrophages from healthy donors and patients	silicon dioxide (SiO2) treatment	downregulated	29290828
701	Human	circHECTD1	circRNA	SiO2	silicosis	HPF-a cells	SiO2 treatment	"After exposure to SiO2, the circHECTD1 level was decreased, which was associated with an increase in HECTD1 in HPF-a cells SiO2-induced autophagy was reversed by either circHECTD1 overexpression or HECTD1 knockdown in HPF-a cells"	31832126
702	Human	circHIAT1	circRNA	baicalin (BAI)	cervical cancer (CC)	Human CC cell lines (HeLa and SiHa)	baicalin (BAI) treatment	upregulated	33603395
703	Human	circHIPK3	circRNA	platelet-derived growth factor (PDGF)	airway remodeling	airway smooth muscle cells (ASMCs)	platelet-derived growth factor (PDGF) treatment	circHIPK3 was significantly upregulated in platelet-derived growth factor (PDGF) induced ASMCs	32450169
704	Human	circHIPK3	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	The expression of circHIPK3 was downregulated in ox-LDL treated HUVECs.	33378035
705	Human	circHIPK3	circRNA	H2O2	cytotoxicity	OB-6 cells	Hydrogen peroxide (H2O2) treatment	downregulated	31955154
706	Human	circHIPK3	circRNA	oleic acid (OA)	diabetes-associated metabolic disorders	HepG2 cells	oleate treatment	circHIPK3 contributes to hyperglycemia and insulin resistance by sponging miR-192-5p and up-regulating FOXO1.	31875589
707	Human	circHIPK3	circRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	Expression level of circHIPK3 in HK-2 cells was remarkably decreased after the treatment of HG.	33628038
708	Human	circHIPK3	circRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	A172 cells; U251 cells	temozolomide (TMZ) treatment	"Circ-HIPK3 was obviously increased in TMZ-resistant glioma cells and their exosomes, miR-421, was downregulated in TMZ-resistant glioma"	32644821
709	Human	circHIPK3	circRNA	oleic acid (OA)	hyperglycemia and insulin resistance	HepG2 cells	oleate treatment	upregulated	31875589
710	Human	circHIPK3	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Human-derived cardiomyocytes HCM	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	CircHIPK3 was highly expressed in HCM cells with simulated myocardial I/R relative to those with normoxic treatment	31799682
711	Human	circHIPK3	circRNA	dexamethasone (DEX)	osteoblast injury	OB-6 osteoblastic cells and primary human osteoblasts	dexamethasone (DEX) treatment	circHIPK3 expression was downregulated in DEX-treated human osteoblasts and circHIPK3 levels decreased in human necrotic femoral head tissues. In OB-6 osteoblastic cells and primary human osteoblasts ectopic overexpression of circHIPK3 potently suppressed DEX-induced apoptosis and programmed necrosis.	31242973
712	Human	circHIPK3	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	Pancreatic cancer tissues; PANC-1 cells; SW-1990 cells	Gemcitabine (GEM) treatment	circHIPK3 was also increased in GEM-resistant PC tumors tissues and GEM-resistant PC cells.	32104074
713	Human	circHIPK3	circRNA	CoCl2	spinal cord injury (SCI)	AGE1.HN	CoCl2 treatment	circ-HIPK3 relieves the neuronal cell apoptosis through regulating miR-588/DPYSL5 axis in SCI.	32247616
714	Human	circHIPK3	circRNA	CoCl2	spinal cord injury (SCI)	AGE1.HN cells	?CoCl2 treatment	Circ_HIPK3 expression was inhibited by CoCl2?in AGE1.HN cells.	33770577
715	Human	circHIPK3	circRNA	high glucose (HG)	vascular injury	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	30454897
716	Human	circHMGCS1	circRNA	sevoflurane (SEV)	colorectal cancer (CRC)	SW480 cells; LOVO cells	sevoflurane treatment	sevoflurane inhibited colon cancer progression by modulating the exosome-transmitted circ-HMGCS1/miR-34a-5p/SGPP1 axis	33125091
717	Human	circINO80	circRNA	Nel-like molecule type 1 (NELL-1)	osteogenesis	human adipose-derived stem cells (hASCs)	"recombinant nel-like molecule, type 1 (NELL-1) treatment"	upregulated	31633307
718	Human	circIQGAP1	circRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	"Circ-IQGAP1 abundance was enhanced in the cartilage tissues from OA patients compared with normal subjects (n = 32), and its expression was increased in CHON-001 cells after treatment of IL-1¦Â in a dose-dependent pattern."	33675175
719	Human	circITCH	circRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)	doxorubicin treatment	"The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a"	32392088
720	Human	circITCH	circRNA	lidocaine	hepatocellular carcinoma (HCC)	HCC cells	?lidocaine treatment	"circ_ITCH and CPEB3 levels were decreased in hepatocellular carcinoma tissues and cells, and were restored in cells via lidocaine treatment"	33433806
721	Human	circLARP4	circRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells	cisplatin treatment	"Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma."	31642110
722	Human	circLARP4	circRNA	cisplatin and doxorubicin	osteosarcoma (OS)	MG63 cells	cisplatin and doxorubicin treatment	"Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma."	31642110
723	Human	circLARP4	circRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells	doxorubicin treatment	"Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma."	31642110
724	Human	circLRP6	circRNA	arsenite	arsenite-induced carcinogenesis	human keratinocyte (HaCaT) cells	arsenite exposure	upregulated	29216394
725	Human	circMCTP2	circRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823	cisplatin (DPP) treatment	CircMCTP2 sensitizes GC to CDDP through the upregulation of MTMR3 by sponging miR-99a-5p.	33198772
726	Human	circMTHFD2	circRNA	pemetrexed	gastric cancer (GC)	Human gastric cancer MGC-803 cells	pemetrexed (MTA) treatment	"Compared with MGC-803/MTA resistant cells, the drug resistance of cells increased significantly in circ MTHFD2 overexpression group"	31841184
727	Human	circMTO1	circRNA	TGF-¦Â1	liver fibrosis	LX©\2 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	31148365
728	Human	circNFXL1_009	circRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (hPASMCs)	hypoxia treatment	exposure to hypoxia markedly reduced the hsa_circNFXL1_009 level in cultured hPASMCs.	33614247
729	Human	circNRIP1	circRNA	hypoxia	gastric cancer (GC)	SGC-7901; AGS; MKN-45; BGC-823	hypoxia treatment	upregulated	32425596
730	Human	circNSUN2	circRNA	aloperine	colorectal cancer (CRC)	SW480 and HT29 cells	aloperine treatment	downregulated	33664565
731	Human	circOSBPL2	circRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	cigarette smoke extract (CSE) treatment	"Circ-OSBPL2 was highly expressed in lung tissues of smokers without or with COPD, particularly in smokers with COPD."	33854310
732	Human	circPAN3	circRNA	doxorubicin (DOX)	acute myeloid leukemia (AML)	human AML cells THP-1 and K562	doxorubicin treatment	"circPAN3 is most likely a key mediator in the development of AML drug resistance, evidenced by the increased expression in ADM-resistant cell lines and BM samples from relapsed patients."	31401408
733	Human	circPHC3	circRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	human brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	CircPHC3 was highly expressed in human BMECs after OGD	33519202
734	Human	circPostn	circRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	human cardiomyocytes	hypoxia and reoxygenation (H/R) treatment	"We identified that the expression of circPostn was elevated in the plasma of MI patients, MI mouse model, and hypoxia and reoxygenation (H/R)-treated human cardiomyocytes."	33681183
735	Human	circPRKCA	circRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	"NSCLC cells (H1650, H1299, H460, A549)"	curcumin treatment	"After curcumin treatment, the expression tendency of circ-PRKCA, miR-384, and ITGB1 in NSCLC cells was overturned."	33684690
736	Human	circPRKCB	circRNA	hypoxia/reoxygenation (H/R)	intestinal ischemia/reperfusion (I/R) injury	Caco-2 cells	hypoxia/reoxygenation (H/R) treatment	circ-PRKCB/miR-339-5p/p66Shc signaling pathway in regulating oxidative stress in the I/R intestine.	32929374
737	Human	circPRKCI	circRNA	lipopolysaccharide (LPS)	HK-2 cells injury	HK-2 cells	Lipopolysaccharide (LPS) treatment	highly expressed circPRKCI relieved inflammatory injury induced by LPS in HK2 cells by suppressing miR-545/ZEBs and depressing the briskness of NF-kB pathway.	32104945
738	Human	circPRKCI	circRNA	H2O2	oxidative stress	SH-SY5Y neuronal cells	H2O2 treatment	downregulated	31053300
739	Human	circPRMT5	circRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H460 cells	cisplatin treatment	Circ-PRMT5 promoted DDP resistance via REV3L by sponging miR-4458 in NSCLC	32808744
740	Human	circPTPRA	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human vascular smooth muscle cell line (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33336764
741	Human	circPUM1	circRNA	insulin	polycystic ovarian syndrome (PCOS)	KGN cells; SVOG cells	insulin treatment	upregulated	32540374
742	Human	circPVT1	circRNA	paclitaxel (PTX)	gastric cancer (GC)	"Human GC tissues and tumor cell lines (MKN-45, HGC-27, MGC-803, and AGS)"	paclitaxel (PTX) treatment	circ-PVT1 expression was upregulated in PTX-resistant GC tissues and cells. Circ-PVT1 downregulated enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p.	31793989
743	Human	circPVT1	circRNA	propofol (PPF)	gastric cancer (GC)	HGC-27 cells; AGS cells	Propofol treatment	"Propofol inhibited the proliferation and invasion, but enhanced the apoptosis of GC cells by regulating the circ-PVT1/miR-195-5p/ETS1 axis"	32945521
744	Human	circPVT1	circRNA	cisplatin and pemetrexed	lung adenocarcinoma (LUAD)	A549/DR cells	cisplatin and pemetrexed treatment	circPVT1 contributes to cisplatin and pemetrexed chemotherapy resistance through miR-145-5p/ABCC1 axis.	31986409
745	Human	circPWWP2A	circRNA	mycobacterium tuberculosis (Mtb)	apoptosis	primary human monocyte-derived macrophages	Mycobacterium tuberculosis (MTB) infection	downregulated	31434611
746	Human	circPWWP2A	circRNA	dexamethasone (DEX)	cytotoxicity	DEX-treated human OB-6 osteoblastic cells	dexamethasone (Dex) treatment	cPWWP2A is downregulated in the necrotic femoral head tissues of DEX-taking human patients as well as in DEX-treated human osteoblasts. cPWWP2A silencing or forced miR-579 overexpression induced significant cytotoxicity in human osteoblasts.	31376935
747	Human	circPWWP2A	circRNA	lipopolysaccharide (LPS)	liver fibrosis	human HSC line LX2 cells	lipopolysaccharide (LPS) treatment	upregulated	31719209
748	Human	circPWWP2A	circRNA	TGF-¦Â	liver fibrosis	Human HSC line LX2 cells	TGF-¦Â treatment	upregulated	31719209
749	Human	circRACGAP1	circRNA	apatinib	advanced gastric cancers (AGCs)	BGC-823 and HGC-27	apatinib treatment	Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7	32139670
750	Human	circRELL1	circRNA	oxidized low density lipoprotein (ox-LDL)	endothelial inflammation	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ-RELL1 modulate inflammatory response by miR-6873-3p/MyD88/NF-¦ÊB axis in ox-LDL induced endothelial cells.	33008595
751	Human	circRFWD2	circRNA	Nel-like molecule type 1 (NELL-1)	osteogenesis	human adipose-derived stem cells (hASCs)	recombinant nel-like molecule type 1 (NELL-1) treatment	upregulated	31633307
752	Human	circRHOT1	circRNA	propofol (PPF)	non-small cell lung cancer (NSCLC)	human bronchial epithelioid(16HBE)	Propofol treatment	"?Importantly, treatment with Propofol inhibited circ-RHOT1 expression in NSCLC cells"	33515563
753	Human	circRIMS2	circRNA	aerobic exercise	vascular cognitive impairment (VCI)	serum	aerobic exercise training (AET) treatment	"Aerobic exercise could shorten the average time that mice reached the platform in the Morris water maze, increase the expression level of circRIMS2 and BDNF, reduce miR-186 expression, and inhibit neuronal apoptosis."	33413076
754	Human	circRSF	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	CircRSF1 could protect against ox-LDL-induced endothelial cell injury in vitro via miR-758/CCND2 axis	32791147
755	Human	circRSF1	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"In this study, ox-LDL inhibited circRSF1 and HDAC1 expression while upregulated miR-135b-5p expression in Human umbilical vein endothelial cells (HUVECs)."	33757583
756	Human	circRSF1	circRNA	radiation	radiation-induced liver disease (RILD)	LX2 cells	radiation treatment	CircRNA RSF1 (circRSF1) was upregulated in irradiated LX2 cells	31960423
757	Human	circS-7	circRNA	IL-1¦Â	osteoarthritis (OA)	Human OA chondrocytes (C28/12 cell line)	IL-1¦Â treatment	downregulated	30925324
758	Human	circS-7	circRNA	ultraviolet (UV) irradiation	pigmented skin diseases	HaCaT cells; FB cells	Ultraviolet B (UVB)? treatment	upregulated	33687273
759	Human	circSEC24A	circRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	"CircSEC24A and SOX5 expression were enhanced, while miR-142-5p level was reduced in OA cartilage tissues and chondrocytes."	33751650
760	Human	circSEMA4B	circRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	NPC	IL-1¦Â treatment	IL-1¦Â stimulation also dramatically inhibited circSEMA4B expression.	30251693
761	Human	circSERPINE2	circRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	CircSERPINE2 could mediate TGFBR2 expression by binding with miR-495.	33094798
762	Human	circSFMBT2	circRNA	platelet derived growth factor-BB (PDGF-BB)	proliferative vascular diseases	Human VSMCs	platelet derived growth factor-BB (PDGF-BB) treatment	circSFMBT2 plays a vital role in VSMC proliferation and migration through the miR-331/HDAC5/Aggf1 axis	33166591
763	Human	circSFMBT2	circRNA	platelet derived growth factor-BB (PDGF-BB)	proliferative vascular diseases	vascular smooth muscle cell (VSMC)	platelet derived growth factor-BB (PDGF-BB) treatment	upregulated	33166591
764	Human	circSLC7A6	circRNA	matrine	colorectal cancer (CRC)	cancer-associated fibroblasts	matrine treatment	circRNAs (circSLC7A6) was significantly downregulated in CM of CAFs with matrine treatment.	32423804
765	Human	circSMARCA5	circRNA	cisplatin and gemcitabine	non-small cell lung cancer (NSCLC)	NCI©\H1299 cells; NCI©\H1437 cells	cisplatin and gemcitabine treatment	Circular RNA SMARCA5 may serve as a tumor suppressor in non-small cell lung cancer.	31944395
766	Human	circSMARCA5	circRNA	double hydrogen testosterone (DHT)	prostate cancer	LNCaP cells	double hydrogen testosterone (DHT) treatment	upregulated	28765045
767	Human	circSORE	circRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SKhep1 cells; Huh7 cells; LM3 cells	sorafenib treatment	upregulated	33222692
768	Human	circTADA2A	circRNA	platelet derived growth factor-BB (PDGF-BB) and insulin-like growth factor (IGF)-1	idiopathic pulmonary fibrosis (IPF)	human fibroblastic cell line (LL-24)	PDGF-BB and IGF-1 treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2	32694556
769	Human	circTIMP2	circRNA	TNF-¦Á and IL-1¦Â	intervertebral disc degeneration (IDD)	NP cells	TNF-¦Á and IL-1¦Â treatment	circ-TIMP2 promoted TNF-¦Á- and IL-1¦Â-induced NP cell imbalance between ECM anabolism and catabolism via miR-185-5p-MMP2 signaling	32626912
770	Human	circTM7SF3	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1-derived macrophages and differentiated human monocyte-derived macrophages (hMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	CircTM7SF3 level was markedly increased in the serum samples of AS patients and ox-LDL-induced THP-1-derived macrophages compared with their matching counterparts.	33526034
771	Human	circTMBIM6	circRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	Chondrocytes	IL-1¦Â and TNF-¦Á treatment	CircTMBIM6 promotes osteoarthritis-induced chondrocyte extracellular matrix degradation via miR-27a/MMP13 axis.	32767318
772	Human	circTtc3	circRNA	hypoxia	pressure ulcer (PU)	HaCaT cells	hypoxia treatment	circ-Ttc3 alleviated hypoxic injury and activated NF-¦ÊB and PI3K/AKT pathways by downregulating miR-449a in HaCaT cells.	32043754
773	Human	circTUBD1	circRNA	irradiation and lipopolysaccharide (LPS)	radiation-induced liver disease (RILD)	LX-2 cells	irradiation and lipopolysaccharide (LPS) treatment	Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway.	32097101
774	Human	circUBE2G1	circRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	circRNA-UBE2G1 facilitates the progression in the LPS-induced OA cell model via regulating the miR-373/HIF-1a axis.	32476580
775	Human	circUSP36	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein smooth muscle cells (HUVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Knockdown of circ_USP36 alleviated ox-LDL-mediated injury of HUVSMCs by modulating miR-182-5p/KLF5 axis	33437365
776	Human	circUSP36	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Ox-LDL exposure induced the upregulation of circ-USP36 in HUVEC cells.	33249762
777	Human	circUSP36	circRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Ox-LDL exposure induced the upregulation of circ-USP36 in HUVEC cells.	33249762
778	Human	circUSP45	circRNA	glucocorticoid (GC)	glucocorticoid-induced osteonecrosis of femoral head (GIONFH)	femoral heads	glucocorticoids (GCs) treatment	upregulated	30579595
779	Human	circUSP45	circRNA	glucocorticoid (GC)	glucocorticoid-induced osteonecrosis of femoral head (GIONFH)	human Bone mesenchymal stem cells (BMSCs)	glucocorticoids (GCs) treatment	upregulated	30579595
780	Human	circVEGFC	circRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32680978
781	Human	circVIRF4	circRNA	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV)	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	primary effusion lymphoma (PEL) cell lines	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	upregulated	31911496
782	Human	circVMA21	circRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	"CircVMA21 and NRP1 were decreased, and miR-199a-5p was increased in LPS-induced THP-1 cells."	33647793
783	Human	circVPS13C	circRNA	propofol (PPF)	ovarian cancer (OC)	ovarian cancer cell lines (A2780 and SKOV3)	Propofol treatment	Propofol suppressed the progression of ovarian cancer through up-regulating miR-145 via suppressing circVPS13C	33563314
784	Human	circVPS18	circRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells; LN229 cells; glioma tissues	temozolomide (TMZ) treatment	Circ-VPS18 expression was upregulated in TMZ-resistant glioma tissues and glioma cells	33188501
785	Human	circWBSCR17	circRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	Circ_WBSCR17 aggravates inflammatory responses and fibrosis by targeting miR-185-5p/SOX6 regulatory axis in high glucose-induced human kidney tubular cells	32798559
786	Human	circWDR77	circRNA	high glucose (HG)	diabetes mellitus (DM)	human vascular smooth muscle cells (VSMCs)		upregulated	29042195
787	Human	circZC3H4	circRNA	SiO2	epithelial-mesenchymal transition (EMT)	MLE-12 cells	SiO2 treatment	upregulated	30826420
788	Human	circZC3H4	circRNA	silicon dioxide (SiO2)	lung fibrosis	lung tissues	silicon dioxide (SiO2) treatment	upregulated	29401612
789	Human	circZNF292	circRNA	hypoxia	hepatocellular carcinoma (HCC)	hepatoma SMMC7721 cells	hypoxia induce	upregulated	31028816
790	Human	circZNF609	circRNA	bovine serum albumin (BSA)	focal segmental glomerulosclerosis (FSGS)	HK-2 cells	bovine serum albumin (BSA) treatment	upregulated	32800553
791	Human	circZNF609	circRNA	H2O2	oxidative stress	HaCaT cells	H2O2 treatment	Anti-antioxidant impacts of circZNF609 silence in HaCaT cells through regulating miR-145	33821719
792	Human	circZNF652	circRNA	lipopolysaccharide (LPS)	infantile pneumonia (IP)	WI-38 cells	lipopolysaccharide (LPS) treatment	LPS inducement remarkably enhanced the expression of circZNF652.	31889339
793	Human	circZNF652	circRNA	lipopolysaccharide (LPS)	infantile pneumonia (IP)	WI-38 cells	lipopolysaccharide (LPS) treatment	upregulated	31889339
794	Human	CLDN10-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28316063
795	Human	CMPK2	lncRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	primary human hepatocytes	IFN-¦Á treatment	upregulation	25122750
796	Human	COX2	lncRNA	polyunsaturated fatty acids (PUFAs)	glioblastoma multiforme (GBM)	Glioblastoma cells (U373; GBM2;GBM5)	polyunsaturated fatty acids (PUFAs) treatment	downregulated	21961478
797	Human	COX2	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (PASMCs)	hypoxia exposure	lincRNA-COX2 expression was upregulated in hypoxic PASMCs.	32803651
798	Human	COX2	lncRNA	lipopolysaccharide (LPS)	postoperative peritoneal adhesion (PPA)	The human peritoneal mesothelium cells (HPMCs)	lipopolysaccharide (LPS) treatment	"Suppression of Cox-2 ameliorated LPS induced HMPCs injury as cell viability was promoted, and cell apoptosis and the production of inflammatory factors were inhibited."	31885500
799	Human	CPS1-IT1	lncRNA	CoCl2	colorectal cancer (CRC)	LoVo and HCT116	CoCl2 treatment	downregulated	29017924
800	Human	CPS1-IT1	lncRNA	melatonin	hepatocellular carcinoma (HCC)	HepG2 cells;Huh7 cells	Melatonin treatment	downregulated	29137263
801	Human	CRAL	lncRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901 cells	cisplatin treatment	downregulated	31885317
802	Human	CRART16	lncRNA	cetuximab	colorectal cancer (CRC)	Caco-2 cells	cetuximab treatment	lncRNA CRART16 was upregulated in Caco-2 CR cells.	32158358
803	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	"si-CRNDE-1 and miR-181a-5p mimic were able to reverse the promoting effects of LPS on production of NF-kB, TNF-a, IL-1b and IL-6 by THP-1 cells."	31604377
804	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	32399391
805	Human	CRNDE	lncRNA	paclitaxel (PTX)	colorectal cancer (CRC)	SW480 cells; SW620 cells	Paclitaxel (PTX) treatment	?CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis	32581554
806	Human	CRNDE	lncRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	"human colonic epithelial cell lines (HT-29, LOVO, and Caco-2)"	dextran sulfate sodium (DSS) treatment	CRNDE in the colonic epithelial cell lines.	31251902
807	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	liver damage	L02 cells	lipopolysaccharide (LPS) treatment	LPS significantly suppressed CRNDE expression in L02 cells.	32031750
808	Human	CRNDE	lncRNA	cisplatin (DDP)	medulloblastoma	"Medulloblastoma cell lines D283, Daoy, D425, and D341"	cisplatin treatment	upregulated	31753063
809	Human	CRNDE	lncRNA	cisplatin (DDP)	medulloblastoma	Daoy; D341	cisplatin (DDP) treatment	upregulated	31753063
810	Human	CRNDE	lncRNA	palmitic acid (PA)	obesity	Human umbilical vein endothelial cells (HUVECs)	palmitic acid (PA) treatment	upregulated	31863035
811	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	LPS exposure induced cell injuries and increased CRNDE expression in WI-38 cells.	29864958
812	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	CRNDE expression was induced in LPS-induced MRC-5 cells.	32317619
813	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis.	31604377
814	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	sepsis-induced renal injury	HK-2 and HEK293 cells	lipopolysaccharide (LPS) treatment	CRNDE was markedly downregulated in sepsis models.	31877497
815	Human	CTA	lncRNA	doxorubicin (DOX)	osteosarcoma (OS)	"osteosarcoma cell lines Saos-2, U-2OS and MG-63"	doxorubicin treatment	upregulated	28415557
816	Human	CTB-60E11.4-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
817	Human	CTBP1-AS2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA CTBP1-AS2 may serve a role in AS by inhibiting the proliferation and promoting the autophagy of VSMCs through ATG14 modulation via miR-195-5p.	32626936
818	Human	CTBP1-AS2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	"CTBP1-AS2 attenuated HG-induced HGMC proliferation, oxidative stress, ECM accumulation, and inflammation through miR-155-5p/FOXO1 signaling."	32868076
819	Human	CTBP1-AS2	lncRNA	microwave ablation (MWA)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues; HCC cell lines	microwave ablation (MWA) treatment	upregulated	32988587
820	Human	CTC-276P9.1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines TE1, TE13, T.Tn, YES2, Eca109, and Kyse170"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29524086
821	Human	CTC-276P9.1	lncRNA	histone deacetylase inhibitor trichostatin A (TSA)	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines TE1, TE13, T.Tn, YES2, Eca109, and Kyse170"	histone deacetylase (HDAC) inhibitor TSA treatment	upregulated	29524086
822	Human	CTC-459I6.1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28316063
823	Human	CTD1-2003C8	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
824	Human	CTD-2201E18	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
825	Human	CTD-2215E18.3	lncRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	ginsenoside Rh2 treatment	upregulated	30394104
826	Human	CTD-2639E6.9	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
827	Human	CUST_40243	lncRNA	benzene	benzene-induced hematotoxicity	peripheral lymphocytes	benzene treatment	upregulated	32730034
828	Human	CYTOR	lncRNA	tamoxifen (TAM)	breast cancer	tamoxifen resistant MCF7 cell lines (MCF7/TAM1 and MCF7/TAM2)	tamoxifen treatment	upregulated	31894257
829	Human	CYTOR	lncRNA	tamoxifen (TAM)	breast cancer	MCF7 / TAM2; MCF7 / TAM1	tamoxifen treatment	lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a-5p	31894257
830	Human	D63785	lncRNA	doxorubicin (DOX)	gastric cancer (GC)	BGC823 cells	doxorubicin (DOX) treatment	lncR-D63785 was downregulated in BGC823 cells treated by DOX.	30195778
831	Human	D63785	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuron apoptosis	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32999283
832	Human	DANCR	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	Lipopolysaccharide (LPS) treatment	DANCR Suppressed Lipopolysaccharide-Induced Septic Acute Kidney Injury by Regulating miR-214 in HK-2 Cells	32222722
833	Human	DANCR	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	downregulated	32714991
834	Human	DANCR	lncRNA	compression force (CF)	cell differentiation	root resorption tissues	orthodontic tooth movement (OTM)	upregulated	31213122
835	Human	DANCR	lncRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cells	cisplatin treatment	upregulated	32766131
836	Human	DANCR	lncRNA	doxorubicin (DOX)	colorectal cancer (CRC)	HCT116 and RKO cells	doxorubicin (DOX) treatment	we found DANCR was suppressed by Doxorubicin and it acted as an important repressor of apoptosis in colorectal cancer.	33414433
837	Human	DANCR	lncRNA	cisplatin (DDP)	gastric cancer (GC)	"GC cell lines (SGC7901, BGC823) and cisplatin (DDP)-resistant cell lines (SGC7901/DDP, BGC823/DDP)"	cisplatin treatment	upregulated	31002130
838	Human	DANCR	lncRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	cisplatin treatment	DANCR highly expressed LN18 and U138MG cells were less sensitive to cisplatin than DANCR lowly expressed U87MG and U251MG cells.	29572052
839	Human	DANCR	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HEK-293T; Huh7; Hep3B cells	sorafenib treatment	LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells	32103983
840	Human	DANCR	lncRNA	resveratrol	nasopharyngeal carcinoma (NPC)	SUNE-1 cells; 5-8F cells	resveratrol (RS) treatment	Resveratrol downregulated the expression of DANCR	32683392
841	Human	DANCR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human primary chondrocytes	lipopolysaccharide (LPS) treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
842	Human	DANCR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	primary chondrocytes	lipopolysaccharide (LPS)? treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
843	Human	DANCR	lncRNA	TGF-¦Â	ovarian cancer (OC)	A2780 cells; SKOV3 cells	TGF-¦Â treatment	Knockdown of DANCR Suppressed the Biological Behaviors of Ovarian Cancer Cells Treated with Transforming Growth Factor-¦Â (TGF-¦Â) by Sponging MiR-214	32417846
844	Human	DANCR	lncRNA	paclitaxel (PTX)	prostate cancer	"Human prostate cancer cells (PC3, C4-2 and DU145)"	Paclitaxel treatment	downregulated of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a	31486484
845	Human	DARS-AS1	lncRNA	hypoxia	myeloma	"RPMI 8226, LP-1, U266, H929 cells"	hypoxia induce	upregulated	31289203
846	Human	DDIT4-AS1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
847	Human	DGCR5	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells	aurora kinase inhibitor (CCT137690) treatment	upregulated	31319040
848	Human	DGCR5	lncRNA	hypoxia	spinal cord injury (SCI)	AGE1.HN cells	hypoxia treatment	DGCR5 was downregulated in AGE1.HN cells treated with hypoxia.	30146926
849	Human	DICER1-AS1	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
850	Human	DICER1-AS1	lncRNA	arsenite	cell proliferation	A549 cells	arsenite exposure	we found that the expression of lncRNA DICER1-AS1 was significantly inhibited by sodium arsenite in a dose-dependent manner.	33609750
851	Human	DILC	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	30365067
852	Human	DIO3OS	lncRNA	resveratrol	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	resveratrol (RS) treatment	downregulated	33718067
853	Human	DIO3OS	lncRNA	TGF-¦Â1	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	TGF-¦Â1 treatment	upregulated	33718067
854	Human	DKK3-1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
855	Human	DLX6-AS1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	SH-SY5Ycells; N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33216728
856	Human	DLX6-AS1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS induced DLX6-AS1 expression in HK-2 cells	32666494
857	Human	DNM3OS	lncRNA	palmitic acid (PA)	diabetes mellitus (DM)	THP1 macrophages (TMC) and human primary macrophages	palmitic acid (PA) treatment	upregulated	29930005
858	Human	DNM3OS	lncRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"DNM3OS expression was the most upregulated lncRNA in PrSCs induced by TGF¦Â1, DNM3OS silencing decreases the protein level of COL3A1 upon TGF¦Â1 stimulation"	31694982
859	Human	DPP10-AS1	lncRNA	tetramethylpyrazine (TMP)	prostate cancer	PC3 cells; DU145 cells	Tetramethylpyrazine (TMP) treatment	upregulated	32319592
860	Human	DYNLRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	24493833
861	Human	DYN-LRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28815701
862	Human	DYN-LRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	cholesterol efflux	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LincRNA DYN-LRB2-2 was upregulated in oxLDL-treated THP-1 cells.	28815701
863	Human	EBF3-AS	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	Ab25¨C35 induced the upregulation of EBF3-AS.	29298096
864	Human	EBLN3P	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	upregulated	30314355
865	Human	EFNA3	lncRNA	hypoxia	breast cancer	MDA-MB231-EphrinA3-Luc cells;MDA-MB231-Luc cells	"cells were placed in a 1% O2, 5% CO2?and 94% N2?gas mixture treatment"	upregulated	25023702
866	Human	EGFR-AS1	lncRNA	gemcitabine and cisplatin	non small cell lung cancer (NSCLC)	plasma	gemcitabine and cisplatin treatment	"the plasma levels of EGFR-AS1 were increased in patients with NSCLC, particularly in GP-resistant patient plasma."	30431074
867	Human	EGFR-AS1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"The human NLCLC cell lines, A549, NCI-H460, NCI-H1299 and NCI-H358"	cisplatin (DPP) treatment	upregulated	30431074
868	Human	EGOT	lncRNA	hypoxia	autophagy	HK-2 cells	hypoxia treatment	The lncRNA EGOT expression was significantly downregulated in renal tubular cells during hypoxia-induced autophagy.	32030803
869	Human	ELIT-1	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	"Huh7, A549, HepG2, HaCaT cells"	TGF¦Â treatment	upregulated	30952633
870	Human	LINC01480	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
871	Human	DSCAM-AS1	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	upregulated	32547604
872	Human	LINC00843	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32689997
873	Human	ANKRD20A8P	lncRNA	cadmium (Cd)	cadmium-induced toxicity	16HBE cells	cadmium (Cd) treatment	upregulated	33447366
874	Human	NALT1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
875	Human	lncRNA 74.1	lncRNA	TGF-¦Â	renal fibrosis	HK2 cells	TGF-¦Â treatment	LncRNA ENST000004537741 was significantly downregulated in the TGF-¦Â-induced HK-2 cell fibrosis	30317629
876	Human	lncRNA 74.1	lncRNA	TGF-¦Â	renal fibrosis	human HK-2 cell	TGF-¦Â treatment	The expression of LncRNA 741 was significantly downregulated in the TGF-¦Â-induced HK-2 cell fibrosis and clinical renal fibrosis specimens	30317629
877	Human	DSCAM-AS1	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	downregulated	32547604
878	Human	ANKRD18DP	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	downregulated	32547604
879	Human	LINC02577	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	upregulated	28487500
880	Human	BG772796.1	lncRNA	paclitaxel (PTX)	lung cancer	A549 human lung cancer cells	paclitaxel (PTX) treatment	downregulated	31516584
881	Human	BE779106.1	lncRNA	coal tar pitch (CTP)	lung cancer	human bronchial epithelial cells (BAES-2B)	coal tar pitch (CTP) treatment	LncRNA-ENST00000501520 could promote the proliferation in malignant-transformed BEAS-2B cells induced with CTP extract which may be mediated by target genes.	31033183
882	Human	BE779106.1	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	upregulated	32470693
883	Human	uc063pbz.2	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
884	Human	C1RL-AS1	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	upregulated	32470693
885	Human	uc058qvk.1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells; LoVo cells	5-fluorouracil (5-FU) treatment	ENST00000547547 was downregulated in 5-FU-resistant CRC cells in comparison with the parental cells.	29115526
886	Human	CB852161.1	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	upregulated	32470693
887	Human	ENST00000567668.1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
888	Human	BX116192.1	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
889	Human	ENST00000570843.1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
890	Human	ENST00000574654.1	lncRNA	hypoxia	renal cell carcinoma (RCC)	SW839 cells; OSRC cells	hypoxia treatment	hypoxia promoted RCC cell invasion through HIF-1¦Á/lncRNA (ENST00000574654.1)/hnRNP/VEGF-A pathway.	32774742
891	Human	NARF-AS1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
892	Human	ZNF667-AS1	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	upregulated	32547604
893	Human	ZNF528-AS1	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32689997
894	Human	ENST00000602478.1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
895	Human	ZNF658B	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
896	Human	BC028413.1	lncRNA	¦Á-melanocyte-stimulating hormone (¦Á-MSH)	skin pigmentation disorders	human skin primary melanocytes (MCs)	¦Á-MSH treatment	upregulated	33318297
897	Human	BF244201.1	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
898	Human	BF244201.1	lncRNA	dexamethasone (DEX)	steatosis	?HepG2 cell lines	dexamethasone (DEX) treatment	"ENST00000608794 plays an important role in dexamethasone induced steatosis, which was partly mediated by derepressing of PDK4 through competitively binding to miR-15b-5p."	31330194
899	Human	BF244201.1	lncRNA	dexamethasone (DEX)	steatosis	hepatocytes	dexamethasone (DEX) treatment	upregulated	31330194
900	Human	BC017676.1	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32689997
901	Human	AK123910.1	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32689997
902	Human	EPB41L4A-AS1	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
903	Human	EPB41L4A-AS2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	downregulated	29683761
904	Human	EPEL	lncRNA	carboplatin (CBP)	ovarian endometrioid adenocarcinoma	human ovarian endometrioid adenocarcinoma cell line SNU-251	carboplatin (CBP) treatment	"EPEL overexpression increased, whereas small interfering RNA (siRNA) silencing reduced the viability of SNU-251 cells under carboplatin treatment."	31621389
905	Human	EPIC1	lncRNA	dexamethasone (DEX)	osteoblast injury	OB-6 osteoblastic cells; primary human osteoblasts	dexamethasone (Dex) treatment	"In OB-6 osteoblastic cells and primary human osteoblasts, treatment with Dex increased expression of Lnc-EPIC1."	29959919
906	Human	EPIC1	lncRNA	H2O2	neuronal cell injury	SH-SY5Y neuronal cells and primary human neuron cultures	hydrogen peroxide (H2O2) treatment	downregulated	31812951
907	Human	EPR	lncRNA	TGF-¦Â	cell proliferation	human mammary gland adenocarcinoma cells MDAMB-231	TGF-¦Â treatment	TGF-¦Â induced a small increase in EPR levels followed by rapid downregulated	31036808
908	Human	ERLR	lncRNA	TGF-¦Â1	cell proliferation	ARPE-19 cells; phRPE cells	TGF-¦Â1 treatment	ERLR was upregulated in RPE cells stimulated with transforming growth factor (TGF)-¦Â1 as detected by lncRNA microarray and RT-PCR	33664479
909	Human	ES3	lncRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	upregulated	32483833
910	Human	ES3	lncRNA	high glucose (HG)	vascular calcification (VC)	human aorta vascular smooth muscle cells (HA-VSMCs)	high glucose treatment	lncRNA-ES3 inhibited miR-34c-5p expression by direct interaction and its knockdown suppressed the calcification/senescence of HA-VSMCs.	30654331
911	Human	F11-AS1	lncRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2.2.15 cells	HBx-induce	downregulated	31880390
912	Human	F11-AS1	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV) infection	downregulated	31880390
913	Human	FA2H-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	"human umbilical vein endothelial cells (ECs; ATCC CRL-1730), and human aorta vascular smooth muscle cells (SMCs; ATCC CRL-1999)"	oxidized low-density lipoprotein (OX-LDL) treatment	downregulated	30683918
914	Human	FAL1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	brain endothelial cell damage	human primary brain microvascular endothelial cells (HBMVECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The lncRNA FAL1 protects against hypoxia-reoxygenation- induced brain endothelial damages through regulating PAK1	31927658
915	Human	FAL1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetic atherosclerosis	HUVECs	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30338819
916	Human	FAM133B-2	lncRNA	X-rays	nasopharyngeal carcinoma (NPC)	CNE-2 cells; 6-10B cells	X-ray radiation treatment	FAM133B-2 is highly expressed in the radio-resistant nasopharyngeal carcinoma cells.	32889799
917	Human	FAM225A	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells	sorafenib treatment	FAM225A expression is dramatically upregulated in sorafenib-resistant HepG2/SOR cells	33245102
918	Human	FAM83H-AS1	lncRNA	TGF-¦Â	oesophageal squamous cell carcinoma (ESCC)	Eca109 cells	TGF-¦Â treatment	upregulated	32583631
919	Human	FAM83H-AS1	lncRNA	staphylococcal protein A (SpA)	osteomyelitis	Human bone mesenchymal stem cells (hBMSCs)	staphylococcal protein A (SpA) treatment	FAM83H-AS1/miR-541-3p/WNT3A ameliorated SpA-mediated inhibition of the osteogenic differentiation of hBMSCs	31871129
920	Human	FANCI-2	lncRNA	human papilloma virus (HPV)	cervical cancer (CC)	human foreskin keratinocytes (HFK)K-derived organotypic raft cultures	HPV infectionn	upregulated	33436409
921	Human	FAS-AS1	lncRNA	hydroquinone (HQ)	benzene-induced carcinogenesis	TK6 cells	Hydroquinone (HQ) treatment	downregulated	32088430
922	Human	FBXL19-AS1	lncRNA	sophorae Fructus	hepatocellular carcinoma (HCC)	Huh7 cells	sophorae Fructus treatment	"Flavonoids of Sophorae Fructus could inhibite the proliferation, migration and invasion of hepatoma cells by regulating LncRNA FBXL19-AS1/miR-342-3p pathway"	33164374
923	Human	FENDRR	lncRNA	adriamycin (ADR)	chronic lymphocytic leukemia (CLL)	human chronic myeloid leukemia cell line K562 and KCL22	adriamycin (ADR) treatment	downregulated	31180580
924	Human	FENDRR	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	upregulated	30700211
925	Human	FENDRR	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	downregulated	31925944
926	Human	FENDRR	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
927	Human	FER1L4	lncRNA	compression force (CF)	orthodontic tooth movement	human periodontal ligament stem cells (PDLSCs)	compressive force treatment	"After the application of compressive force, lncRNA FER1L4 was strongly upregulated."	33604341
928	Human	FER1L4	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells	paclitaxel (PTX) treatment	downregulated	30444026
929	Human	FEZF1-AS1	lncRNA	hypoxia	pancreatic cancer (PC)	human PC cell lines PANC©\1;SW1990	hypoxic condition induce	"In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1¦Á axis under hypoxic condition."	30693518
930	Human	FEZF1-AS1	lncRNA	normoxia	pancreatic cancer (PC)	"human PC cell lines PANC©\1, SW1990"	normoxia condition induce	upregulated	30693518
931	Human	FEZF1-AS1	lncRNA	TGF-¦Â2	posterior capsular opacification (PCO)	Human Lens Epithelial Cells SRA01/04	?TGF-¦Â2 treatment	upregulated	31281667
932	Human	FGD5-AS1	lncRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; Hcc827 cells; lung adenocarcinoma (LAD) tissues	cisplatin treatment	FGD5-AS1 was highly expressed in DDP-resistant LAD tissues and cells.	33416094
933	Human	FGD5-AS1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells; Non-small cell lung cancer (NSCLC) tissues	cisplatin treatment	FGD5-AS1 was upregulated in DDP-resistant tumors and cells compared with DDP-sensitive ones.	32534055
934	Human	FGD5-AS1	lncRNA	lipopolysaccharide (LPS)	periodontitis	primary human periodontal ligament cells (PDLC	lipopolysaccharide (LPS) treatment	upregulated of lncRNA FGD5-AS1 could protect against periodontitis via regulating the miR-142-3p/SOCS6/NF-¦ÊB signals.	31144533
935	Human	FLJ46906	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
936	Human	FLJ46906	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	AGS cells	Helicobacter pylori (H. pylori) infection	upregulated	32457731
937	Human	FLJ46906	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
938	Human	FLJ46906	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
939	Human	FOXD2-AS1	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	TE-1/DDP	cisplatin treatment	Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis	31558183
940	Human	FOXD2-AS1	lncRNA	cisplatin (DDP)	esophageal squamous cell carcinoma (ESCC)	The human ESCC cell line TE-1	cisplatin treatment	upregulated	31558183
941	Human	FoxD2-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	The human glioma cell lines U251 and A172	temozolomide (TMZ) treatment	"Knockdown of FoxD2-AS1 decreased the proliferation, metastatic ability of glioma cells and promote the sensitivity to TMZ in glioma cells"	31680769
942	Human	FOXD2-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"human glioma cell lines (U87, U251, LN229, A172)"	temozolomide (TMZ) treatment	"downregulated FOXD2-AS1 repressed invasion, proliferation, migration and drug resistance of drug-resistant glioma cells while stimulating their apoptosis via increasing miR-98-5p and inhibiting CPEB4 expression."	31770107
943	Human	FOXD2-AS1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 and HUH7 cells	sorafenib treatment	downregulated	31210410
944	Human	FOXD2-AS1	lncRNA	IL-1¦Â and/or TNF-¦Á	osteoarthritis (OA)	Human cartilage C28/I2 cells	IL-1¦Â and/or TNF-¦Á treatment	"IL-1¦Â and/or TNF-¦Á treatment could increase FOXD2-AS1 expression in chondrocytes. FOXD2-AS1 overexpression induced cell proliferation, inflammation and extracellular matrix (ECM) degradation in chondrocytes."	30945573
945	Human	FOXD2-AS1	lncRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	osteosarcoma (OS)	"Normal osteoblastic cell line (hFOB); osteosarcoma cell lines (MG63, Saos-2, 143B, U2-OS)"	HIF-1¦Á overexpression	upregulated	31228799
946	Human	FOXD3-AS1	lncRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	Hypoxia exposure caused an upregulation of FOXD3-AS1 in AC16 cells.	32973515
947	Human	FOXD3-AS1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	FOXD3-AS1 was upregulated in cisplatin-resistant NSCLC cells (A549/DDP and H1299/DDP cells) in comparison with their parental cell lines.	32742197
948	Human	FR075921	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
949	Human	FR324124	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
950	Human	FTH1P3	lncRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells; MDA-MB-231 cells	paclitaxel (PTX) treatment	lncRNA FTH1P3 was upregulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells)	29971911
951	Human	GABPB1-AS1	lncRNA	human papilloma viruses 16 (HPV16) E6	cervical cancer (CC)	C33A cells; SiHa cells; CaSki cells	human papillomaviruses 16 (HPV16) E6 infection	upregulated	32844486
952	Human	GABPB1-AS1	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
953	Human	GABPB1-AS1	lncRNA	erastin	ferroptosis	HepG2 hepatocellular carcinoma cells	erastin treatment	upregulated	31700067
954	Human	GABPB1-AS1	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
955	Human	GABPB1-AS1	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
956	Human	GABPB1-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
957	Human	GACAT3	lncRNA	IL-6	gastric cancer (GC)	gastric cancer SGC-7901 cells	IL-6 treatment	upregulated	27644247
958	Human	GAEA	lncRNA	connective tissue growth factor (CTGF)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	CTGF treatment	upregulated	30631154
959	Human	GAEA	lncRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	high glucose treatment	upregulated	30631154
960	Human	GAEA	lncRNA	IL-6	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	IL-6 treatment	upregulated	30631154
961	Human	GAEA	lncRNA	sonic hedgehog(SHH)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	SHH treatment	upregulated	30631154
962	Human	GAEA	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	TGF-¦Â treatment	upregulated	30631154
963	Human	GAPLINC	lncRNA	hypoxia	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia induce	upregulated	31589383
964	Human	GAPLINC	lncRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia-inducible factor 1¦Á (HIF-1¦Á) treatment	upregulated	31589383
965	Human	GAS5	lncRNA	C-terminal Hsp90 inhibitor KU758	adrenocortical carcinoma	NCI-H295R and SW13 cells	C-terminal Hsp90 inhibitor KU758 treatment	upregulated	31561992
966	Human	GAS5	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	nasal epithelial cells secreted exosomes	ovalbumin (OVA) treatment	upregulated	31841965
967	Human	GAS5	lncRNA	amygdalin	anti-cancer therapy	"human cancer cells (A549, MCF7, AGS)"	amygdalin treatment	upregulated	30725348
968	Human	GAS5	lncRNA	2-o-methylmagnolol (MM1)	apoptosis	A375 (melanoma) and A431 (squamous cell carcinoma) cells	2-O-methylmagnolol (MM1) treatment	upregulated	28252643
969	Human	GAS5	lncRNA	TGF-¦Â1	asthma	human bronchial epithelial cells BEAS-2B	TGF-¦Â1 treatment	"TGF-¦Â1, GAS5, HDAC4 were upregulated, while miR-217 was downregulated in bronchial mucosal tissues of asthmatic children and TGF-¦Â1-treated BEAS-2B cells"	33864612
970	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 was enriched in atherosclerotic plaques and THP-1 macrophage exposed to oxidized low-density lipoprotein (ox-LDL).	29859752
971	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	"We found that the abundance of GAS5 was markedly increased, and miR-135a was decreased in AS patient serums and ox-LDL-induced human THP-1 cells dose and time dependently. Interference of GAS5 suppressed inflammation and oxidative stress induced by ox-LDL in THP-1 cells."	33128668
972	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 knockdown suppresses inflammation and oxidative stress induced by oxidized low-density lipoprotein in macrophages by sponging miR-135a	33128668
973	Human	GAS5	lncRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	downregulated	32160712
974	Human	GAS5	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
975	Human	GAS5	lncRNA	chemotherapeutic agents£¨rapamycin; temsirolimus and everolimus; BEZ235 and AZD8055; and imatinib £©	breast cancer	breast cancer cell	chemotherapeutic agents treatment	downregulated	24789445
976	Human	GAS5	lncRNA	dendrosomal curcumin (DNC)	breast cancer	MCF7 cells; MDA-MB231 cells; SKBR3 cells	dendrosomal curcumin (DNC) treatment	"GAS5 was upregulated in DNC treatment of MCF7, MDA-MB231, and SKBR3 cells."	29655698
977	Human	GAS5	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7?cells	tamoxifen treatment	lncRNA GAS5 was downregulated in MCF-7R cells	29969658
978	Human	GAS5	lncRNA	high glucose (HG)	cell damage	human renal tubular epithelial HK-2	high glucose (HG) treatment	HG enhances the expression of GAS5 in HK-2 cells; Silence of GAS5 alleviates the HG-caused HK-2 cell toxicity.	31159592
979	Human	GAS5	lncRNA	cisplatin (DDP)	cervical cancer (CC)	Human cervical adenocarcinoma cell Hela and human cervical squamous cancer cell line Siha	cisplatin treatment	upregulated	30352127
980	Human	GAS5	lncRNA	radiation	cervical cancer (CC)	SiHa cells	radiation treatment	GAS5 was low expressed in the radio-resistant SiHa cells	30579899
981	Human	GAS5	lncRNA	X-rays	cervical cancer (CC)	CC tissues and cell lines (SiHa and ME180)	6 MV X-ray irradiation	downregulated	30579899
982	Human	GAS5	lncRNA	lipopolysaccharide (LPS)	chronic nonbacterial prostatitis (CNP)	Human prostate epithelial cell line RWPE-1	lipopolysaccharide (LPS) treatment	downregulated	30892130
983	Human	GAS5	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model."	33865922
984	Human	GAS5	lncRNA	glucocorticoid (GC)	diabetes mellitus (DM)	EndoC-¦ÂH1 cells	glucocorticoid (GC) treatment	Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA	32029226
985	Human	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cardiomyocytes	high glucose (HG) treatment	GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model	33682891
986	Human	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	HG increased GAS5 expression in AC16 cells and knockdown of GAS5 protected AC16 cells from HG-induced injury.	31865425
987	Human	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human cardiomyocyte-like AC16 cells	high glucose (HG) treatment	upregulated	31865425
988	Human	GAS5	lncRNA	mevastatin (MEV)	diabetic foot ulcer (DFU)	skin samples were used to generate acute wounds	"treat daily with 50 ¦Ìm ZGA, 10 ¦Ìm MEV, or both ZGA and MEV treatment"	upregulated	29158265
989	Human	GAS5	lncRNA	zaragozic acid (ZGA)	diabetic foot ulcer (DFU)	skin samples were used to generate acute wounds	"treat daily with 50 ¦Ìm ZGA, 10 ¦Ìm MEV, or both ZGA and MEV treatment"	upregulated	29158265
990	Human	GAS5	lncRNA	high fat diet (HFD)	diabetic nephropathy (DN)	kidney tissues	high fat diet (HFD) feed	LncRNA Gas5 (GAS5) expression was increased in kidneys of the DKD mouse model.	31810140
991	Human	GAS5	lncRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	LncRNA Gas5(GAS5) expression was increased in TGF-¦Â1-induced HK-2 cells	31810140
992	Human	GAS5	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial HK-2	high glucose (HG) treatment	HG enhances the expression of GAS5 in HK-2 cells; Silence of GAS5 alleviates the HG-caused HK-2 cell toxicity.	31159592
993	Human	GAS5	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose treatment	downregulated	31849505
994	Human	GAS5	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	downregulated	32467994
995	Human	GAS5	lncRNA	high glucose (HG)	endometrial cancer (EC)	"Human endometrial carcinoma cell lines (HEC1-B, HEC1-A and Ishikawa)"	high glucose (HG) treatment	downregulated	31105847
996	Human	GAS5	lncRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	thapsigargin (Tg) treatment	downregulated	30753838
997	Human	GAS5	lncRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	tunicamycin (TM)? treatment	downregulated	30753838
998	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cells injury and autophagy dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 expression was upregulated and miR-26a was downregulated in the plasma samples of patients with atherosclerosis and ox-LDL-treated HAECs.	30468731
999	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"GAS5 knockdown inhibited cell apoptosis and activated autophagy flux, whereas inhibition of miR-26a reversed the effect of GAS5 in HAECs."	30468731
1000	Human	GAS5	lncRNA	radiation	esophageal squamous cell carcinoma (ESCC)	TE-1 cells; esophageal squamous cell carcinoma (ESCC) tissues	radiation treatment	GAS5 expression is far higher in radiation sensitive ESCC tissues/cells than radiation resistant tissues/cells	31866421
1001	Human	GAS5	lncRNA	X-rays	esophageal squamous cell carcinoma (ESCC)	ESCC tissues and TE-1 celss	2 Gy X-ray treatment	upregulated	31866421
1002	Human	GAS5	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	SGC-7901 and SGC-7901/ADM cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27466992
1003	Human	GAS5	lncRNA	combination of rapamycin plus MP	gastric cancer (GC)	peripheral blood mononuclear cells (PBMCs)	combination of rapamycin plus MP treatment	downregulated	27001230
1004	Human	GAS5	lncRNA	steroids	glucocorticoids effects	HeLa cells; LoVo cells	steroids treatment	GAS5 was upregulated in GC-resistant cells	28722800
1005	Human	GAS5	lncRNA	dexamethasone (DEX)	glucocorticoid (GC)-mediated beta cell dysfunction	Human pancreatic islets and the human beta cell line EndoC-¦ÂH1	dexamethasone (DEX) treatment	Increasing GAS5 levels using GAS5 HREM alleviated the inhibitory effects of dexamethasone on insulin secretion.	32029226
1006	Human	GAS5	lncRNA	corylin	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	Corylin treatment	upregulated	29382035
1007	Human	GAS5	lncRNA	lipopolysaccharide (LPS)	hepatocellular carcinoma (HCC)	HepG2 cells	lipopolysaccharide (LPS) treatment	LPS stimulation promotes GNAS expression in HCC cells through increasing m6A methylation of GNAS mRNA.	32123532
1008	Human	GAS5	lncRNA	platelet derived growth factor-BB (PDGF-BB)	hypertension	vascular smooth muscle cells (VSMCs)	PDGF©\bb treatment	"?GAS5 inhibits PDGF-bb-induced VSMC proliferation and migration, partly through acting as a competing endogenous RNA of miR-21"	31069831
1009	Human	GAS5	lncRNA	hypoxic/ischemic	hypoxic/ischemic brain damage (HIBD)	neonatal brain tissues;hippocampal neurons tissues	hypoxic/ischemic treatment	GAS5 expression was significantly upregulated in hypoxic/ischemic-injured neonatal brain and hippocampal neurons.	29428721
1010	Human	GAS5	lncRNA	X-rays	improved radiosensitivity	NSCLC cell lines (A549 and H1975)	X-ray irradiation treatment	upregulated	28117028
1011	Human	GAS5	lncRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	NCI-H460 cells; A549 cells	ionizing radiation (IR) treatment	IR enhanced the interaction between lncRNA GAS5 and the miR-21/PTEN/Akt axis.	32020207
1012	Human	GAS5	lncRNA	propofol (PPF)	oral squamous cell carcinoma (OSCC)	UM-SCC6 and SCC090 cells	Propofol treatment	upregulated	31583913
1013	Human	GAS5	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
1014	Human	GAS5	lncRNA	androgen	prostate cancer	"LNCaP, 22RV1, DU145, PC3"	androgen treatment	downregulated	28771526
1015	Human	GAS5	lncRNA	¦Á-solanine	prostate cancer	Human normal prostate epithelial cell line RWPE-1 and PCa cell lines DU145 and PC-3	¦Á-Solanine treatment	upregulated	30970507
1016	Human	GAS5	lncRNA	sorafenib (SOR)	renal cell carcinoma (RCC)	"Human RCC cell lines, OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P"	sorafenib treatment	GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis	29895198
1017	Human	GAS5	lncRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	lncRNA GAS5 was upregulated in TGF-¦Â1-treated HK-2 cells	31810140
1018	Human	GAS5	lncRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	HK2 cells	hypoxia induce	upregulated	30129267
1019	Human	GAS5	lncRNA	tanshinone IIA (Tan IIA)	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLS)	tanshinone IIA (Tan IIA) treatment	"Long non-coding RNA (lncRNA) GAS5 expression was significantly decreased in the synovial tissues and RAFLS, while Tan IIA treatment resulted in an upregulated of GAS5"	30232236
1020	Human	GAS5	lncRNA	ribavirin	ribavirin-induced cardiac developmental toxicity	human induced pluripotent stem cells (hiPSCs)	ribavirin treatment	Exposuring to ribavirin (5 and 10 ¦ÌM) markedly upregulated the expression of lncRNAs Gas5 in both mid-phase and late phase of differentiation and HBL1 in the mid-phase	32112805
1021	Human	GAS5	lncRNA	dexamethasone (DEX)	severe asthma (SA)	Human bronchial epithelial cells (HBECs)	dexamethasone (DEX) treatment	downregulated	32642099
1022	Human	GAS5	lncRNA	IL-2 and IL-4	severe asthma (SA)	Human bronchial epithelial cells (HBECs)	IL-2 and IL-4 treatment	upregulated	32642099
1023	Human	GAS5	lncRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	The TNBC cell lines MDA©\MB©\231 and BT549	cisplatin treatment	"the expression of lncRNA GAS5 was significantly downregulated in TNBC cells treated with paclitaxel (PTX) or cisplatin (CIS). More interestingly, the expression level of lncRNA GAS5 in TNBC patients was associated with tumor resistance to PTX and CIS."	31692053
1024	Human	GAS5	lncRNA	paclitaxel (PTX)	triple negative breast cancer (TNBC)	The TNBC cell lines MDA©\MB©\231 and BT549	paclitaxel (PTX) treatment	"the expression of lncRNA GAS5 was significantly downregulated in TNBC cells treated with paclitaxel (PTX) or cisplatin (CIS) More interestingly, the expression level of lncRNA GAS5 in TNBC patients was associated with tumor resistance to PTX and CIS"	31692053
1025	Human	GAS5	lncRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HASMCs)	phosphorus treatment	downregulated	32347320
1026	Human	GAS5-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27489122
1027	Human	GAS6-AS1	lncRNA	ultraviolet (UV) irradiation	DNA damage	CD4 cells	ultraviolet-C (UVC) treatment	upregulated	32258156
1028	Human	GAS6-AS2	lncRNA	heat stress	hepatocellular carcinoma (HCC)	Huh7 cells; MHCC97 cells	heating treatment	GAS6-AS2 was upregulated in Huh7-H and MHCC97-H cells relative to Huh7 and MHCC97 cells.	32799553
1029	Human	GATA6-AS	lncRNA	hypoxia	oxidative stress	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	29339785
1030	Human	GBCDRlnc1	lncRNA	doxorubicin (DOX)	gallbladder cancer (GBC)	The NOZ and GBC-SD human gallbladder cancer cell lines	doxorubicin (Dox) treatment	upregulated	30953511
1031	Human	GHET1	lncRNA	hypoxia	triple negative breast cancer (TNBC)	MDA-MB-468 cells; HCC1937 cells	hypoxia treatment	Highly expressed lncRNA GHET1 in TNBC tissues and cells and induction of lncRNA GHET1 by hypoxia were proved.	33869194
1032	Human	GIHCG	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	LoVo cells	5-fluorouracil (5-FU) treatment	upregulated	30799935
1033	Human	GIHCG	lncRNA	oxaliplatin	colorectal cancer (CRC)	LoVo cells	Oxaliplatin (Oxa) treatment	upregulated	30799935
1034	Human	GIRGL	lncRNA	glutamine starvation	glutamine metabolism	(HEK) 293T cells	glutamine starvation treatment	"Here, we characterize a long noncoding RNA, GIRGL (glutamine insufficiency regulator of glutaminase lncRNA), that is induced upon glutamine starvation."	33762340
1035	Human	GKN2-1:1	lncRNA	melanin	melanoma	Primary melanocytes	melanin treatment	upregulated	26596215
1036	Human	Gm15834	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	human AC-16 cell lines	angiotensin II (Ang II) treatment	upregulated	33130312
1037	Human	Gm15834	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	AC16 cells	angiotensin II (Ang II) treatment	upregulated	33130312
1038	Human	Gm22	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
1039	Human	Gm26945	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	upregulated	30314355
1040	Human	GNAS-AS1	lncRNA	IL-4	macrophage polarization	peripheral blood mononuclear cells (PBMCs)	IL-4 treatment	upregulated	31267263
1041	Human	GNAT1-1	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	SGC-7901 and MNK45 cells	Helicobacter (H.) pylori infection	downregulated	30132541
1042	Human	GOLGA2P10	lncRNA	actinomycin D (actD)	endoplasmic reticulum stress (ERS)	MHCC-97H cells	actinomycin D (actD) treatment	Treatment with actinomycin D abrogated tunicamycin-induced GOLGA2P10 expression.	32332695
1043	Human	GPX3-AS	lncRNA	H2O2	age-related cataract (ARC)	SRA01/04 cells	H2O2 treatment	"GPX3-AS downregulated the apoptosis of LECs via promoting GPX3 expression, implying a novel therapeutic target for ARCs."	31814699
1044	Human	GS1-600G8.5	lncRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	primary human skin fibroblasts; keratinocytes; fresh human explant whole skin	ultraviolet radiation (UVA) treatment	upregulated	29496359
1045	Human	H19	lncRNA	curcumin (Cur)	breast cancer	tamoxifen-resistant breast cancer cells MCF-7/TAMR	curcumin treatment	"In addition, following treatment with curcumin for 48 h, H19 expression was decreased in a dose-dependent manner."	33179087
1046	Human	H19	lncRNA	hesperetin	breast cancer	MDA-MB-231 and MCF-7 cells	hesperetin treatment	"?Hesperetin restored the expression of miR-486-5p, inhibited H19 lncRNA and ICAM-1 expression and selectively regressed mBC cell aggressiveness."	33882812
1047	Human	H19	lncRNA	high glucose (HG)	inflammation	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
1048	Human	H19	lncRNA	dexamethasone (DEX)	pulmonary inflammatory response	IL-1¦Â-treated A549 cells	dexamethasone (Dex) treatment	upregulated	33413425
1049	Human	H19	lncRNA	IL-1¦Â	pulmonary inflammatory response	A549 cells	IL-1¦Â treatment	downregulated	33413425
1050	Human	H19	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	upregulated	33716779
1051	Human	H19	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4- LR1 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29703210
1052	Human	H19	lncRNA	levonorgestrel (LNG)	adenomyosis	endometrial stromal cells (ESCs)	levonorgestrel (LNG) treatment	LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway.	32921982
1053	Human	H19	lncRNA	ultraviolet (UV) irradiation	age-related cataract (ARC)	Human lens epithelial cells (HLECs)	ultraviolet irradiation treatment	"the interaction among lncRNA H19, miR-29a and TDG is involved in early ARC lncRNA H19 could be a useful marker of early ARC and oxidative damage repair pathway of lncRNA H19/miR-29a/TDG may be a promising target for the treatment of ARC"	31282110
1054	Human	H19	lncRNA	¦Â-glycerophosphate (¦Â-GP)	arterial calcification	vascular smooth muscle cells (VSMCs)	¦Â-glycerophosphate treatment	upregulated	32355545
1055	Human	H19	lncRNA	astragaloside IV (AS-IV)	atherosclerosis (AS)	¦Â-Glycerophosphate-treated human vascular smooth muscle cells (VSMCs)	astragaloside (AS-IV) treatment	upregulated	30529164
1056	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs).	oxidized low-density lipoprotein (ox-LDL) treatment	The level of H19 was increased and miR-148b expression was decreased in human AS patient serums and oxidized low-density lipoprotein (ox-LDL)-stimulated human aorta vascular smooth muscle cells (HA-VSMCs).	29415742
1057	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"the expression of H19 in the serum of patients with AS and in the ox-LDL-treated human umbilical vein endothelial cells (HUVECs) was significantly upregulated. H19 knockdown by transfection with H19 siRNAs in ox-LDL-treated HUVECs remarkably promoted cell viability, suppressed the secretion of interleukin (IL)-1¦Â, IL-6, and tumour necrosis factor (TNF)-¦Á, decreased the expression of vascular cell adhesion molecule 1 (VCAM1), intercellular adhesion molecule 1 (ICAM1) and E-selectin, reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), increased superoxide dismutase (SOD) levels, and reduced cell apoptosis."	31054453
1058	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
1059	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Our results showed that H19 expression was elevated in serum samples of patients with AS and ox-LDL-treated HA-VSMC.	33235026
1060	Human	H19	lncRNA	¦Â-glycerophosphate (¦Â-GP)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	¦Â-Glycerophosphate treatment	downregulated	30529164
1061	Human	H19	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1062	Human	H19	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	downregulated	30251663
1063	Human	H19	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	Quantitative real-time PCR (qRT-PCR) analyzed H19 expression in chemotherapy-resistant and sensitive breast cancer tissues.	32345117
1064	Human	H19	lncRNA	huaier extract	breast cancer	"breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF7"		upregulated	29145193
1065	Human	H19	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
1066	Human	H19	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells; SK-BR-3 cells	tamoxifen treatment	lncRNA H19 in tamoxifen-resistance cells (MCF-7-R and SK-BR-3-R) was much higher than normal breast cancer cells (MCF-7 and SK-BR-3)	30519041
1067	Human	H19	lncRNA	valproic acid (VPA)	apoptosis	A549 cells	VPA treatment	downregulated	28328238
1068	Human	H19	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	H19 was upregulated whereas miR-19a-3p was downregulated in I/R tissues and OGD/R induced cells	32335212
1069	Human	H19	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	28203482
1070	Human	H19	lncRNA	platelet lysate (PL)	chondrogenesis	human umbilical cord-derived mesenchymal stem cells (hUCMSCs)	Platelet lysate (PL) treatment	PL induced chondrogenic differentiation of hUCMSCs by regulating the H19/miR-29b-3p/SOX9 axis	33058414
1071	Human	H19	lncRNA	5-fluorouracil (5-Fu)	chondrosarcoma	human CC cell line JEG-3	5-fluorouracil (5-FU) treatment	upregulated	31020694
1072	Human	H19	lncRNA	methotrexate (MTX)	chondrosarcoma	human CC cell line JEG-3	Methotrexate (MTX) treatment	upregulated	31020694
1073	Human	H19	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	SW1116 cells; HCT8Fu cells	5-fluorouracil (5-FU) treatment	H19 expression was obviously upregulated both in primary 5-Fu resistant SW1116 cell line and acquired 5-Fu resistant HCT8Fu cell line.	30451820
1074	Human	H19	lncRNA	hypoxia	colorectal cancer (CRC)	SW620 cells; HCT116 cells	hypoxia treatment	"During hypoxic stimulation, colorectal cancer cell lines upregulated the levels of both the lncH19 and its intragenic miR-675-5p."	32481626
1075	Human	H19	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	downregulated	31362245
1076	Human	H19	lncRNA	¦Á-Mangostin	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	¦Á-Mangostin treatment	¦Á-Mangostin restored the high glucose-induced inhibition of H19	31362245
1077	Human	H19	lncRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	30815865
1078	Human	H19	lncRNA	early growth response protein 1 (EGR1)	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	early growth response protein 1 (EGR1) treatment	upregulated	30815865
1079	Human	H19	lncRNA	TGF-¦Â2	diabetic nephropathy (DN)	human dermal microvascular endothelial cells (HMVECs)	TGF-¦Â2 treatment	Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT	32346618
1080	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	H19 played an important role in regulating inflammatory processes in retinal endothelial cells under high-glucose condition through modulating miR-93/XBP1s axis.	31953562
1081	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression.	33022863
1082	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	"Our results showed that lncRNA H19 and SIRT1 were reduced, while miR-19b was increased in ARPE-19 cells with HG condition."	33022863
1083	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose conditions (25 mmol/l) treatment	downregulated	30612136
1084	Human	H19	lncRNA	human MSC Growth Medium	cell differentiation	human adipose-derived stem cells (ASCs)	human MSC Growth Medium containing 10% MSCs-Qualified Fetal Bovine Serum (FBS)	upregulated	28662497
1085	Human	H19	lncRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	upregulated	30692507
1086	Human	H19	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	SKOV-3 cells; OVCAR3 cells	TGF-¦Â treatment	TGF-¦Â treatment upregulated H19 and downregulated miR-370-3p	29403287
1087	Human	H19	lncRNA	epstein-barr virus (EBV)	Epstein-Barr virus (EBV) infection	human peripheral blood monocular cells	infecting with Epstein-Barr Virus	upregulated	27956246
1088	Human	H19	lncRNA	cigarette smoke extract (CSE)	esophageal squamous cell carcinoma (ESCC)	SHEE cells	cigarette smoke?extract?(CSE) treatment	upregulated	32739445
1089	Human	H19	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GC tissues and cells	Helicobacter pylori (H. pylori) infection	upregulated	31787851
1090	Human	H19	lncRNA	metformin (Met)	gastric cancer (GC)	AGS and SGC7901 cell lines	metformin treatment	downregulated	30192003
1091	Human	H19	lncRNA	metformin (Met)	gastric cancer (GC)	SGC7901 cells	metformin treatment	downregulated	30192003
1092	Human	H19	lncRNA	benzo(a)pyrene (BaP)	gene-methylation alterations by carcinogen BaP	16HBE cells; BEAS-2B cells; VA13 cells	benzo(a)pyrene (BaP) exposure	BaP-treated cells H19 expressions were increased in a dose- and time-dependent manner.	29772428
1093	Human	H19	lncRNA	TGF-¦Â	glaucoma filtration surgery (GFS)	primary human Tenon's capsule fibroblasts (HTFs)	TGF-¦Â treatment	TGF-¦Â promoted the expression of H19 in HTFs and that suppression of H19 inhibited the effect of TGF-¦Â on HTFs	31877306
1094	Human	H19	lncRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	31468534
1095	Human	H19	lncRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	curcumin (CUR) treatment	downregulated	31468534
1096	Human	H19	lncRNA	hypoxia	glioblastoma multiforme (GBM)	"human glioma cell lines U87, U251, Ln229, U373 and U118"	hypoxia treatment	upregulated	28327666
1097	Human	H19	lncRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	glioblastoma cells	TGF-¦Â1 treatment	?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling	32813021
1098	Human	H19	lncRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	"1,25(OH) 2 D3 downregulated the expression of H19."	31468534
1099	Human	H19	lncRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	curcumin (CUR) treatment	CUR downregulated the expression of H19.	31468534
1100	Human	H19	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U-251 cells; M059 cells	Temozolomide (TMZ) treatment	H19 was significantly increased in U-251TMZ and M059JTMZ cells	29391808
1101	Human	H19	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	downregulated	32998396
1102	Human	H19	lncRNA	hepatitis B virus (HBV)	hepatoblastoma	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	30367502
1103	Human	H19	lncRNA	apigenin	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	apigenin treatment	H19 was downregulated by API.	33345859
1104	Human	H19	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	hepatoma carcinoma cells (Hep G2 and HCCLM3 cells)	hypoxia induce	upregulated	31196153
1105	Human	H19	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU©\449; SNU©\387	sorafenib treatment	Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675	32627034
1106	Human	H19	lncRNA	sorafenib or doxorubicin	hepatocellular carcinoma (HCC)	"human hepatoma cell lines (HepG2, Plc/Prf5, and Huh7)"	sorafenib or doxorubicin treatment	upregulated	31225433
1107	Human	H19	lncRNA	hypoxia	hypoxia-induced injury	human hepatic sinusoidal endothelial cells (HHSEC)	hypoxia induce	upregulated	31082428
1108	Human	H19	lncRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	MRC-5 cells	TGF-¦Â treatment	the level of lncRNA H19 was significantly increased in activated fibroblasts compared with untreated cells	29411215
1109	Human	H19	lncRNA	H2O2	intervertebral disc degeneration (IDD)	nucleus pulposus cells (NPCs)	H2O2 treatment	"In response to H2O2 treatment, H19 expression was dramatically increased."	29520849
1110	Human	H19	lncRNA	cisplatin (DDP)	laryngeal squamous cell carcinoma (LSCC)	TU-177 cells; AMC-HN-8 cells	cisplatin treatment	H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo.	33314408
1111	Human	H19	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells	carbon tetrachloride (CCl4) treatment	upregulated	32445757
1112	Human	H19	lncRNA	hepatitis B virus X protein (HBx)	liver damage	L02 cells	hepatitis B X protein (HBx) treatment	"the expression of lncRNA H19 and miR-675 was upregulated in patients with chronic hepatitis B. Inhibition of lncRNA H19 or miR-675 in L02 cells increased cell viability, suppressed hepatitis B X protein (HBx)-induced cell apoptosis, inflammatory cytokine production, and oxidative stress, and remodelled energy metabolism."	31574452
1113	Human	H19	lncRNA	first-generation EGFR tyrosine kinase inhibitors (TKIs)	lung cancer	HCC827 cells; PC9 cells	First-generation EGFR tyrosine kinase inhibitors (TKIs) treatment	downregulated	32439420
1114	Human	H19	lncRNA	lipopolysaccharide (LPS)	lung injury	MRC-5 cells	lipopolysaccharide (LPS) treatment	upregulated	29315794
1115	Human	H19	lncRNA	cisplatin (DDP)	melanoma	A375/DDP; M8/DDP cells	cisplatin treatment	lncRNA H19 could influence DDP-resistance by modulating the miR-18b/IGF axis in melanoma cells.	32265386
1116	Human	H19	lncRNA	bortezomib	multiple myeloma (MM)	"Human MM cell lines H929, U266"	bortezomib? treatment	"H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis."	30728351
1117	Human	H19	lncRNA	hypoxia	multiple myeloma (MM)	MM cell lines (RPMI and MM1.S)	hypoxia induce	upregulated	30781795
1118	Human	H19	lncRNA	hypoxia	myocardial infarction (MI)	peripheral blood	hypoxia treatment	Downregulated H19 and upregulated CYP1B1 were observed in MI patients.	33389498
1119	Human	H19	lncRNA	angelica polysaccharide (AP)	neuroblastoma (NB)	SH-SY5Y cells	angelica polysaccharide (AP) treatment	downregulated	29465760
1120	Human	H19	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; HCC4006 cells	gefitinib treatment	H19 was increased in gefitinib-resistant cells when compared to sensitive parent cells.	30542738
1121	Human	H19	lncRNA	ghrelin	obesity-induced myocardial injury	human cardiac myocytes	ghrelin treatment	Ghrelin protects against PA-induced injury in cardiomyocytes via upregulating the expression of lncRNA H19.	32084395
1122	Human	H19	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	31894109
1123	Human	H19	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	A notably dose-dependent elevation of H19 levels was observed in LPS-treated C28/I2 cells.	30900425
1124	Human	H19	lncRNA	mechanical stimulation	osteochondral activity	primary umbilical cord mesenchymal stem cells (U-MSCs)	mechanical stimulation	Exosomes derived from umbilical cord mesenchymal stem cells in mechanical environment show improved osteochondral activity via upregulation of LncRNA H19	33437630
1125	Human	H19	lncRNA	"mechanical tension (10%, 0.5Hz)"	osteogenesis	human BMMSCs (hBMMSCs)	"mechanical tension (10%, 0.5Hz)"	upregulated	29253550
1126	Human	H19	lncRNA	tension	osteogenic capability	Bone marrow mesenchymal stem cells (BMMSCs)	tension treatment	mechanical tension could enhance osteogenic differentiation and increase H19 expression	29253550
1127	Human	H19	lncRNA	valproic acid (VPA)	ovarian cancer (OC)	A2780 cells	valproic acid (VPA) treatment	downregulated	29468525
1128	Human	H19	lncRNA	high glucose (HG)	oxidative stress	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
1129	Human	H19	lncRNA	sulforaphane (SFN)	pancreatic ductal adenocarcinoma (PDAC)	"human PDAC cell lines BxPc-3, AsPC-1, PANC-1, and MIA-PaCa2"	sulforaphane treatment	"Sulforaphane regulated the expression of all of five examined lncRNAs, but basal expression, biological function and inhibition of H19 were of highest significance"	33669381
1130	Human	H19	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y Cells	1-methyl-4-phenylpyridinium (MPP+) treatment	H19 was downregulated in MPP+ treated SH-SY5Y cells.	32356199
1131	Human	H19	lncRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity	HTR-8/SVneo cells	Perfluorooctane sulfonic acid (PFOS) treatment	upregulated	32738709
1132	Human	H19	lncRNA	estrogen (ES)	postmenopausal osteoporosis (PMOP)	human bone marrow mesenchymal stem cells (BMSCs)	estrogen treatment	upregulated	33577975
1133	Human	H19	lncRNA	metformin (Met)	preeclampsia (PE)	Trophoblast and HUVEC cells	Metformin (Met) treatment	downregulated	31203154
1134	Human	H19	lncRNA	H2O2	premature senescence	C-kit(+) cardiac progenitor cells (CPCs)	H2 O2 treatment	downregulated	27062045
1135	Human	H19	lncRNA	ginsenoside Rh2	cell proliferation	MC3T3-E1 cells	treat with Rh2	upregulated	28886306
1136	Human	H19	lncRNA	dihydrotestosterone (DHT)	prostate cancer	LNCaP cells	dihydrotestosterone (DHT) treatment	downregulated	32356434
1137	Human	H19	lncRNA	enzalutamide (Enz)	prostate cancer	LNCaP cells	enzalutamide treatment	upregulated	32356434
1138	Human	H19	lncRNA	estradiol-17¦Â (E2)	prostate cancer	prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM)	estradiol-17¦Â (E2) treatment	upregulated	31426484
1139	Human	H19	lncRNA	estradiol-17¦Â (E2)	prostate cancer	prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM)	estradiol-17¦Â (E2) treatment	downregulated	31426484
1140	Human	H19	lncRNA	hypoxia	prostate cancer	prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM)	hypoxia induce	upregulated	31426484
1141	Human	H19	lncRNA	arsenite	lung fibrosis	THP-1 cells	arsenic (As) exposure	downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages.	33162208
1142	Human	H19	lncRNA	arsenite	lung fibrosis	THP-1 cells	arsenite exposure	upregulated	33162208
1143	Human	H19	lncRNA	phorbol-12-myristate-13-acetate(PMA)	rheumatoid arthritis (RA)	peripheral blood mononuclear cells (PBMCs)	PMA treatment	The level of lncRNA H19 was higher in RA patients than in healthy volunteers	33540246
1144	Human	H19	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32525617
1145	Human	H19	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	human astrocyte (NHA)	lipopolysaccharide (LPS) treatment	lncRNA H19 expression was increased by LPS in NHAs.	32371379
1146	Human	H19	lncRNA	melatonin	subarachnoid hemorrhage (SAH)	U87 cells; U251 cells	melatonin (MT) treatment	Melatonin increased H19 expression level by enhancing H19 transcriptional efficiency in a concentration-dependent manner.	29367587
1147	Human	H19	lncRNA	estradiol	thyroid cancer (TC)	TPC-1cells; K-1 cells	estradiol (E2) treatment	upregulated	30389909
1148	Human	H19	lncRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	ARK2 and MCF-7 cells	metformin treatment	downregulated	27775072
1149	Human	H19	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
1150	Human	H19	lncRNA	vincristine (VCR)	vincristine (VCR) resistance	RPMI 8226/VCR	vincristine (VCR) treatment	"The lnc-RNA H19/Akt pathway is closely related to the occurrence of VCR resistance in MM cells, and the downregulated of H19 can significantly improve the sensitivity of VCR in MM."	33040789
1151	Human	H19	lncRNA	ginsenoside 20(S)-Rg3	warburg effect	SKOV3 cells; A2780 cells	ginsenoside 20(S)-Rg3 treatment	H19 was found to be decreased by 50% in 20(S)-Rg3-treated cells compared to control cells.	30481782
1152	Human	H19	lncRNA	TGF-¦Â1	lung fibrosis	HBE and A549 cells	TGF-¦Â1 treatment	H19 knockdown attenuated pulmonary fibrosis via the regulatory network of lncRNA H19-miR-140-TGF-¦Â/Smad3 signaling	30988156
1153	Human	H19	lncRNA	cigarette smoke extract (CSE)	smoke-induced lung injury (SILI)	A549 cells; H460 cells	cigarette smoke extract (CSE) treatment	upregulated	33523607
1154	Human	H19	lncRNA	Rb3	smoke-induced lung injury (SILI)	A549 cells; H460 cells	Rb3 treatment	downregulated	33523607
1155	Human	H19X	lncRNA	TGF-¦Â	fibrosis	primary dermal fibroblasts	TGF-¦Â treatment	upregulated	32603313
1156	Human	HABON	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	human hepatocarcinoma cell SMMC-7721; Huh-7;MHCC-97 h;MHCC-97 L;Hep-G2; Hep-3B	hypoxia? treatment	"Among them, a hypoxia-activated lncRNA that we identified and termed Hypoxia-Activated BNIP3 Overlapping Non-coding RNA (HABON), was not only regulated by hypoxic-induced factor-1¦Á (HIF-1¦Á) but its expression increased significantly under hypoxia in tumour cells."	33478328
1157	Human	HAGLR	lncRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	SH-SY5Y cells	lipopolysaccharide (LPS) treatment	HAGLR displayed high levels in spinal cords of CCI rats and in LPS treated SH-SY5Y cells.	33626373
1158	Human	HAGLROS	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cell	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31298038
1159	Human	HAGLROS	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38?cells	lipopolysaccharide (LPS) treatment	LPS caused WI-38?cell injury and increased HAGLROS levels.	29673591
1160	Human	HAND2-AS1	lncRNA	low glucose (LG)	osteosarcoma (OS)	MG-63 cells; SAOS- 2 cells; U-2OS cells; HOS cells; SW1353 cells	1mM glucose treatment	lncRNA HAND2-AS1 was significantly upregulated in glucose starved-cells	29637006
1161	Human	HAS2-AS1	lncRNA	resveratrol	hyaluronan (HA) accumulation	human aortic smooth muscle cells (AoSMCs)	resveratrol (RS) treatment	downregulated	31932306
1162	Human	HAS2-AS1	lncRNA	SIRT1 activators (SRT1720)	hyaluronan (HA) accumulation	human aortic smooth muscle cells (AoSMCs)	SIRT1 activators (SRT1720) treatment	downregulated	31932306
1163	Human	HAS2-AS1	lncRNA	hypoxia	oral squamous cell carcinoma (OSCC)	"human OSCC cell lines, SCC-9 and CAL-27"	treat with hypoxia	upregulated	28485478
1164	Human	HBBP1	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
1165	Human	HCCL5	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human HCC cell lines HepG2, SMMC-7721 and HCCLM3"	TGF-¦Â1 treatment	upregulated	30482773
1166	Human	HCG11	lncRNA	"oxidized low-density lipoprotein (ox-LDL), IL-6 and TNF-¦Á)"	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	"oxidation Low Lipoprotein (Ox-LDL), interleukin-6 (IL-6) and tumor necrosis factor ¦Á (TNF ¦Á) radiation"	LncRNA HCG11 regulates proliferation and apoptosis of vascular smooth muscle cell through targeting miR-144-3p/FOXF1 axis.	33008472
1167	Human	HCG11	lncRNA	high glucose (HG)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	LncRNA HCG11/miR-26b-5p/QKI5 feedback loop reversed high glucose-induced proliferation and angiogenesis inhibition of HUVECs.	33128346
1168	Human	HCG18	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
1169	Human	HCP5	lncRNA	cisplatin (DDP)	breast cancer	MDA-MB-231 cells	cisplatin treatment	upregulated	31028999
1170	Human	HCP5	lncRNA	geniposide (GEN)	diffuse large B-cell lymphoma (DLBCL)	OCI-LY7; OCI-LY3 cells	geniposide treatment	Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis	33162801
1171	Human	HCP5	lncRNA	5-fluorouracil (5-FU)	gastric cancer (GC)	AGS cell; MKN45 cells	5-fluorouracil (5-FU) treatment	upregulated	32300102
1172	Human	HCP5	lncRNA	oxaliplatin	gastric cancer (GC)	AGS cell; MKN45 cells	oxaliplatin (OXA) treatment	upregulated	32300102
1173	Human	HCP5	lncRNA	TGF-¦Â	lung adenocarcinoma (LUAD)	A549 cell	TGF¦Â treatment	upregulated	31131047
1174	Human	HCP5	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 and SW 1990 cells	gemcitabine (GEM) treatment	upregulated	31632071
1175	Human	HEAL	lncRNA	human immunodeficiency virus (HIV)-1	acquired immune deficiency syndrome (AIDS)	"MT4, H9, E4 Jurkat, MDMs were prepared by culture of PBMCs cells"	?Human immunodeficiency virus (HIV)-1 infection treatment	upregulated	31551335
1176	Human	HEIH	lncRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	serum; exosomes	hepatitis C virus (HCV) infection	"In patients with HCV-related HCC, lncRNA-HEIH expression in serum and exosomes was increased, but the ratio of lncRNA-HEIH expression in serum versus exosomes was decreased compared to patients with CHC."	29286922
1177	Human	HEIH	lncRNA	paclitaxel (PTX)	endometrial cancer (EC)	"Human endometrial cancer cell lines (Ishikawa, HHUA) and hESC (Human endometrial stromal cells)"	paclitaxel (PTX) treatment	"LncRNA HEIH, the dysregulation of which involved in production of drug-resistance, was overexpressed in PTX-resistant endometrial cancer cells"	31650338
1178	Human	HEIH	lncRNA	paclitaxel (PTX)	endometrial cancer (EC)	Ishikawa cells; HHUA cells	paclitaxel (PTX) treatment	Down-regulating lncRNA HEIH expression reversed the PTX-resistance of endometrial cancer cells through MAPK signaling pathway	31650338
1179	Human	HEIH	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells	sorafenib treatment	HEIH was upregulated in sorafenib-resistant HCC tissues and cell lines	32821157
1180	Human	HEIPP	lncRNA	hypoxia	preeclampsia (PE)	HTR-8 / Svneo cellsHTR-8/SVneo human trophoblast cells	hypoxia treatment	upregulated	33424915
1181	Human	HIF1A-AS1	lncRNA	TGF-¦Â1	activation of hepatic stellate cells (HSCs)	HSCs LX-2	TGF-¦Â1 treatment	downregulated	25550811
1182	Human	HIF1A-AS1	lncRNA	clopidogrel	cardiovascular disease (CVD)	HUVECs	clopidogrel treatment	clopidogrel rescues apoptosis and promotes proliferation of PA-induced damage model of HUVECs through inhibiting the mediator LncRNA HIF1A-AS1	25761653
1183	Human	HIF1A-AS1	lncRNA	arecoline	oral submucous fibrosis (OSF)	fibrotic buccal mucosal fibroblasts (fBMFs)	arecoline treatment	Administration of arecoline induced the elevation of HIF1A-AS1 in BMFs.	31959495
1184	Human	HIF1A-AS2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human coronary artery endothelial cells (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulated.	33133688
1185	Human	HIF1A-AS2	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1186	Human	HIF1A-AS2	lncRNA	cisplatin (DDP)	bladder cancer	T24 cells; 5937 cells; SW780 cells	cisplatin treatment	"hypoxia inducible factor 1¦Á-antisense RNA 2 (HIF1A-AS2), as a subtype-specific hypoxia inducible lncRNA, is upregulated in bladder cancer cells."	30216500
1187	Human	HIF1A-AS2	lncRNA	cisplatin (DDP)	bladder cancer	"Bladder cancer cell lines, T24, 5637, and SW780"	cisplatin (DPP) treatment	upregulated	30216500
1188	Human	HIF1A-AS2	lncRNA	hypoxia	ischemic stroke (IS)	HUVECs	hypoxia treatment	upregulated	28985553
1189	Human	HIF1A-AS2	lncRNA	hypoxia	myocardial infarction (MI)	human cardiomyocytes (HMCs)	hypoxia treatment	HIF1A-AS2 is upregulated in hypoxia-treated human cardiomyocytes (HMCs) compared with normal cardiomyocytes.	32222118
1190	Human	HIFCAR	lncRNA	hypoxia	oral cancer	Hela cells; HEK293T cells	hypoxia conditions (1% oxygen)	upregulated	28639619
1191	Human	HIPK1-AS	lncRNA	Sipi soup (SPS)	cervical cancer (CC)	HeLa	Sipi soup (SPS) treatment	"HIPK1-AS expression levels were upregulated in response to HeLa CM, but were decreased under SPS treatment"	29901171
1192	Human	HITT	lncRNA	hypoxia	colorectal cancer (CRC)	HCT116 cells	hypoxia treatment	"The enrichment of HITT was significantly decreased, while that of the 5¡ä-UTR was increased in response to the hypoxic switch."	31700144
1193	Human	HITT	lncRNA	Hypoxia	hypoxia-induced injury	HCT116 cells;HeLa cells	hypoxia induce	downregulated	31784651
1194	Human	HITT	lncRNA	hypoxia	hypoxia-induced injury	HCT116 cells; Hela cells	hypoxia treatment	downregulated	31784651
1195	Human	HMGCR	lncRNA	epigallocatechin-3-gallate (EGCG)	cholesterol metabolism	"human hepatoblastoma cell line, HepG2"	epigallocatechin-3-gallate (EGCG) treatment	downregulated	25563320
1196	Human	HMGN1-1:12	lncRNA	nigericin	pancreatic cancer (PC)	PANC-2 cells	nigericin treatment	upregulated	32850392
1197	Human	HOATIR	lncRNA	oestrogen (E2)	osteoporosis	HFOB and MG63 cells	oestrogen (E2) treatment	a dose-dependent upregulated of HOTAIR was observed in cells treated with oestrogen	33733597
1198	Human	HORAS5	lncRNA	cabazitaxel	prostate cancer	LNCaP cells; DU145 cells	cabazitaxel treatment	HORAS5 stimulates the expression of BCL2A1 thereby decreasing apoptosis and enhancing cabazitaxel resistance in CRPC cells.	32618200
1199	Human	HOST2	lncRNA	sinomenine hydrochloride (SH)	ovarian cancer (OC)	"Human ovarian epithelial cell line (HOEpiC), Caov3 and SKOV3 cells"	sinomenine hydrochloride (SH) treatment	downregulated	31701766
1200	Human	HOST2	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	Hs766T cells; AsPC-1 cells	gemcitabine (GEM) treatment	upregulated	30406400
1201	Human	HOST2	lncRNA	gemcitabine (GEM)	pancreatic neoplasms	Hs766T; AsPC-1 cells	gemcitabine treatment	down- expression of HOST2 observably enhanced sensibility of pancreatic cancer cell lines to gemcitabine.	30406400
1202	Human	HOTAIR	lncRNA	metformin (Met)	breast cancer	MDA-MB-231 breast cancer cells	?metformin treatment	"Reduction in the expression of vimentin, ¦Â-catenin, and HOTAIR was detected as the result of metformin treatment"	33164274
1203	Human	HOTAIR	lncRNA	tanshinone IIA (Tan IIA)	acetaminophen (APAP)-induced liver injury (AILI)	L02 cells	Tanshinone IIA (Tan IIA) treatment	Tan IIA induced the expression of Nrf2-MRP2/4 pathway by downregulating HOTAIR	32777703
1204	Human	HOTAIR	lncRNA	all-trans retinoic acid (ATRA)	acute myeloid leukemia (AML)	HL-60 cells	all-trans retinoic acid (ATRA) treatment	upregulated	33241756
1205	Human	HOTAIR	lncRNA	ethanol (EtOH)	alcohol-induced tumor angiogenesis	HUVECs endothelial extracellular vesicles (EVs)	ethanol treatment	upregulated in endothelial extracellular vesicles (EVs)	29062004
1206	Human	HOTAIR	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	HOTAIR was significantly increased in THP-1 cells treated with ox-LDL.	29698635
1207	Human	HOTAIR	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	HOTAIR was significantly increased in THP-1 cells treated with ox-LDL.	30187491
1208	Human	HOTAIR	lncRNA	sunitinib (SU)	autophagy	786-O-R cells; ACHN-R cells	sunitinib treatment	HOTAIR expression in sunitinib-resistant cells is higher than that in parental cells	32760216
1209	Human	HOTAIR	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1210	Human	HOTAIR	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1211	Human	HOTAIR	lncRNA	bisphenol-A (BPA) and diethylstilbestrol (DES)	breast cancer	human breast cancer cells (MCF7)	BPA and DES treatment	upregulation	24533973
1212	Human	HOTAIR	lncRNA	delphinidin	breast cancer	"Breast cancer cells MDA©\MB©\231, MCF©\7, and MDA©\MB©\453 w"	delphinidin treatment	downregulated	31325197
1213	Human	HOTAIR	lncRNA	estradiol	breast cancer	breast cancer cells	estradiol treatment	HOTAIR is crucial for cell growth and viability and its knockdown induced apoptosis in breast cancer cells	23375982
1214	Human	HOTAIR	lncRNA	hypoxia	breast cancer	MDA-MB-231 cells	hypoxia treatment	HOTAIR levels was upregulated after 48 h hypoxia relative to normoxia in breast cancer cell lines.	32466537
1215	Human	HOTAIR	lncRNA	ionizing radiation (IR)	breast cancer	breast cancer cells and tissues	ionizing radiation treatment	upregulated	30429228
1216	Human	HOTAIR	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	downregulated	30619763
1217	Human	HOTAIR	lncRNA	hypoxia	tumorigenesis	"colon adenocarcinoma,cervical cancer,breast cancer,neuroblastoma"	hypoxia treatment	downregulated	28756022
1218	Human	HOTAIR	lncRNA	polyphyllin I (PPI)	castration-resistant prostate cancer (CRPC)	castration-resistant prostate cancer (CRPC) cells	Polyphyllin I (PPI) treatment	downregulated	29221985
1219	Human	HOTAIR	lncRNA	polyphyllin I (PPI)	castration-resistant prostate cancer (CRPC)	DU145 cells; PC3 cells	polyphyllin I (PPI) treatment	PPI also decreased HOTAIR expression	29807357
1220	Human	HOTAIR	lncRNA	LiCl	cervical cancer (CC)	radioresistant HeLa cells	LiCl treatment	"the short interfering ribonucleic acid (siRNA)-mediated knockdown of HOTAIR disturbed the Wnt signaling pathway, reduced autophagy, inhibited EMT, decreased cell proliferation, and induced apoptosis in radioresistant HeLa cells."	30367473
1221	Human	HOTAIR	lncRNA	direct-acting antivirals (DAAs)	chronic hepatitis C virus (HCV) infection	polymorphonuclear leucocytes (PMNLs)	direct-acting antivirals (DAAs) treatment	upregulated	33074585
1222	Human	HOTAIR	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	31128153
1223	Human	HOTAIR	lncRNA	propofol (PPF)	colorectal cancer (CRC)	LOVO cells; SW480 cells	propofol treatment	Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WIF-1 and suppressing Wnt pathway	31953926
1224	Human	HOTAIR	lncRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells; HCT116 cells	ionizing radiation (IR) treatment	HOTAIR expression was markedly upregulated in plasma from CRC patients after radiotherapy and CRC cells after irradiation.	32144238
1225	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	cytokines expression	"C3A, HepG2, and SMMC-7721"	lipopolysaccharide (LPS) treatment	HOTAIR exerted a crucial role in cytokines expression by activating JAK/STAT and NF-¦ÊB.	31621909
1226	Human	HOTAIR	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	30542437
1227	Human	HOTAIR	lncRNA	cisplatin (DDP)	endometrial cancer (EC)	arental Ishikawa cells	cisplatin treatment	downregulated	28721581
1228	Human	HOTAIR	lncRNA	TGF-¦Â1	endometrial fibrosis	endometrial stromal cells (ESCs)	TGF-¦Â1 treatment	HOTAIR was significantly elevated in ESCs that had been treated with TGF-¦Â1	33313721
1229	Human	HOTAIR	lncRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	metformin (Met) treatment	downregulated	33164274
1230	Human	HOTAIR	lncRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	TE-1 cells	5-fluorouracil (5-FU) treatment	LncRNA HOTAIR-mediated MTHFR methylation inhibits 5-fluorouracil sensitivity in esophageal cancer cells.	32653028
1231	Human	HOTAIR	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U-87 cells; A172 cells	temozolomide (TMZ) treatment	upregulated	32279420
1232	Human	HOTAIR	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	A172 ; LN229	temozolomide (TMZ) treatment	Exosomal lncRNA HOTAIR mediated TMZ resistance through miR-519a-3p/RRM1 axis in GB	32721218
1233	Human	HOTAIR	lncRNA	polyphyllin I (PPI)	growth of CRPC cells	castration-resistant prostate cancer cells	Polyphyllin I (PPI) treatment	downregulated	29221985
1234	Human	HOTAIR	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	hepatic insulin resistance	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30536334
1235	Human	HOTAIR	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2; Huh7	hypoxia treatment	knockdown of HOTAIR suppressed glycolysis by regulating miR-130a-3p and HIF1A in HCC cells treated by hypoxia	32062551
1236	Human	HOTAIR	lncRNA	orafenib	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU-387; SNU-449	orafenib treatment	Lnc HOTAIR could increase sorafenib resistance in HCC by inhibiting miR-217.	32462038
1237	Human	HOTAIR	lncRNA	taxol	hepatocellular carcinoma (HCC)	HepG2/Taxol; SMMC7721/Taxol	Taxol treatment	LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a	32700738
1238	Human	HOTAIR	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
1239	Human	HOTAIR	lncRNA	cigarette smoke extract (CSE)	inflammation	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	25447409
1240	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	inflammation	"L02, C3A, HepG2, and SMMC-7721 cells."	lipopolysaccharide (LPS) treatment	"LPS induced the overexpression of HOTAIR in L02, C3A, HepG2, and SMMC-7721 cells."	31621909
1241	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	kidney damage	HK-2 cells	lipopolysaccharide (LPS) treatment	HOTAIR was also upregulated in LPS-induced human renal tubular epithelial cells (HK-2).	30130540
1242	Human	HOTAIR	lncRNA	X-rays	laryngeal cancer	"Laryngeal cancer cell lines TU212, LLN and TU686"	X-ray radiation treatment	HOTAIR overexpression reduced laryngeal cancer cell radiosensitivity	31849488
1243	Human	HOTAIR	lncRNA	TGF-¦Â1	multidrug resistance (MDR)	The HepG2 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30698830
1244	Human	HOTAIR	lncRNA	doxorubicin (DOX)	multidrug resistance (MDR)	K562/A02 cells	doxorubicin treatment	Overexpression of LncRNA-HOTAIR promotes chemoresistance in acute leukemia cells.	33425105
1245	Human	HOTAIR	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NCI-H1299 cells	criplatin treatment	upregulated	29805510
1246	Human	HOTAIR	lncRNA	crizotinib	non-small cell lung cancer (NSCLC)	A549?cells	crizotinib treatment	upregulated	29470986
1247	Human	HOTAIR	lncRNA	type I collagen (Col-1)	non-small cell lung cancer (NSCLC)	NSCLC cells	type I collagen (Col-1) treatment	upregulated	23668363
1248	Human	HOTAIR	lncRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 and H1650 cells	Xiaoji decoction (XJD) treatment	downregulated	30910577
1249	Human	HOTAIR	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	nucleus pulposus cell (NPC)	tumor necrosis factor alpha (TNF-¦Á) treatment	31 HOTAIR is downregulated in NPCs induced by TNF-¦Á	30138895
1250	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human articular chondrocyte C28/I2 cells	lipopolysaccharide (LPS) treatment	upregulated	31966787
1251	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	CHON-001 chondrocytes	lipopolysaccharide (LPS) treatment	"HOTAIR and SGTB were upregulated, while miR-1277-5p was downregulated in OA cartilages and LPS-stimulated CHON-001 chondrocytes."	33721916
1252	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteosarcoma (OS)	The cell lines MG63 and Saos-2	lipopolysaccharides (LPS) treatment	upregulated	30240881
1253	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteosarcoma (OS)	MG63 and Saos-2 cells	lipopolysaccharides (LPS) treatment	upregulated	30240881
1254	Human	HOTAIR	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells; A2780 cells	cisplatin treatment	HOTAIR was upregulated in DDP-resistant cells.	32349783
1255	Human	HOTAIR	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	pancreatic cancer stem-like cells (CSCs)	gemcitabine treatment	upregulated	29201179
1256	Human	HOTAIR	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	28445933
1257	Human	HOTAIR	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	HOTAIR promoted MPP+-induced neuronal injury via modulating the miR-874-5p/ATG10 axis in SK-N-SH cells.	33013268
1258	Human	HOTAIR	lncRNA	TGF-¦Â2	posterior capsular opacification (PCO)	SRA01/04 cells	transforming growth factor ¦Â2 (TGF-¦Â2) treatment	TGF-¦Â2 induces EMT in SRA01/04 cells via the upregulated of the long non-coding RNA (lncRNA) HOTAIR	30239553
1259	Human	HOTAIR	lncRNA	androgen	prostate cancer	prostate cancer cell	low androgen treatment	upregulated	26411689
1260	Human	HOTAIR	lncRNA	bufalin	prostate cancer	prostate cancer DU145 and PC3 cells	bufalin treatment	downregulated	31028291
1261	Human	HOTAIR	lncRNA	radiation	radiation resistance of breast cancer (BRCA)	MCF©\7; T47D; LM©\MCF©\7; BT©\474;SKBR©\3; MDA©\MB©\231	radiation treatment	LncRNA HOTAIR facilitates the expression of HSPA1A by sequestering miR-449b-5p post-transcriptionally and thereby endows BRCA with radiation resistance	32374522
1262	Human	HOTAIR	lncRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	upregulated	29717517
1263	Human	HOTAIR	lncRNA	arsenite	toxicity of arsenic	A549 cells	arsenic (As) exposure	upregulated	32816178
1264	Human	HOTAIR	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
1265	Human	HOTAIR	lncRNA	ultraviolet (UV) irradiation	UVB-induced apoptosis and inflammatory	HaCaT cells	UVB treatment	UVB also promoted the expression of HOTAIR	29898032
1266	Human	HOTTIP	lncRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	platelet derived growth factor-BB (PDGF-BB) treatment	The expression level of HOTTIP was upregulated in the proliferating endothelial cells induced by TNF-¦Á or PDGF-BB	29058802
1267	Human	HOTTIP	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	tumor necrosis factor alpha (TNF-¦Á) treatment	The expression level of HOTTIP was upregulated in the proliferating endothelial cells induced by TNF-¦Á or PDGF-BB	29058802
1268	Human	HOTTIP	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1269	Human	HOTTIP	lncRNA	"TNF-¦Á,PDGF-BB"	coronary artery disease (CAD)	HU-VECs	TNF-¦Á or PDGF-BB treatment	upregulated	29058802
1270	Human	HOTTIP	lncRNA	hypoxia	epithelial-mesenchymal transition (EMT)	U87 and U251 cell lines	hypoxia treatment	upregulated	28886531
1271	Human	HOTTIP	lncRNA	salinomycin	gastric cancer (GC)	SGC7901/cisplatin (CDDP) gastric cancer cell	salinomycin treatment	downregulated	30882398
1272	Human	HOTTIP	lncRNA	hypoxia	non-small cell lung cancer (NSCLC)	two NSCLC cell lines (A549 and H1299)	hypoxia induce	upregulated	31422060
1273	Human	HOTTIP	lncRNA	IL-1¦Â	osteoarthritis (OA)	cultured chondrocytes	interleukin-1¦Â (IL-1¦Â) treatment	upregulated	31508417
1274	Human	HOTTIP	lncRNA	IL-1¦Â	osteoarthritis (OA)	OA cartilage tissues	IL-1¦Â treatment	"The expression of HOTTIP and FRK were upregulated, while miR-663a was downregulated in OA cartilage tissues."	33435956
1275	Human	HOTTIP	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
1276	Human	HOTTIP	lncRNA	cisplatin (DDP)	pancreatic cancer (PC)	PANC-1 cells; HS766T cells; AsPC-1 cells	cisplatin treatment	upregulated	32280243
1277	Human	HOX	lncRNA	TGF-¦Â1	liver fibrosis	hepatic stellate cells (HSCs)	TGF-¦Â1 treatment	upregulated	27979710
1278	Human	HOXA11-AS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells; MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1279	Human	HOXA11-AS	lncRNA	calcium oxalate (CaOx)	calcium oxalate (CaOx) nephrolithiasis	HK-2 cell	calcium oxalate (CaOx) treatment	HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis.	31878844
1280	Human	HOXA11-AS	lncRNA	calcium oxalate monohydrate (COM)	calcium oxalate (CaOx) nephrolithiasis	calcium oxalate monohydrate (COM)-treated HK-2 cells	calcium oxalate monohydrate (COM)-treatment	HOXA11-AS was significantly upregulated in calcium oxalate monohydrate (COM)-treated HK-2 cells.	31680444
1281	Human	HOXA11-AS	lncRNA	propofol (PPF)	colorectal cancer (CRC)	Colo205; SW620 cells	"Propofol (2,6-diisopropylphenol) treatment"	Propofol suppresses colorectal cancer tumorigenesis by modulating the HOXA11-AS-let-7i-ABCC10 regulatory network	31013434
1282	Human	HOXA11-AS	lncRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B cells	propofol treatment	Propofol suppressed the expression of HOXA11-AS in HCC cells	32705160
1283	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; H157 cells	cisplatin treatment	The expression of HOXA11-AS was much stronger in cisplatin-resistant LUAD cells.	30099826
1284	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	lung cancer	A549 cell line	cisplatin treatment	upregulated	31144606
1285	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	C666-1 cells; HNE1 cells	cisplatin treatment	elevated HOXA11-AS and reduced miR-454-3p were found in NPC tissue and cisplatin-resistant NPC cells.	33115978
1286	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	"The normal human oral keratinocyte (NHOK) and OSCC cell lines, including TSCCA, CAL-27, SCC-9, and Tca8113"	cisplatin treatment	upregulated	31275988
1287	Human	HOXA6-AS	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	HNSCC cell lines	radiation treatment	downregulated	30441874
1288	Human	HOXA-AS2	lncRNA	prednisone	acute lymphoblastic leukemia (ALL)	Jurkat cells; CEM/C1 cells	prednisone treatment	lncRNA HOXA-AS2 was highly expressed both in prednisone insensitive ALL cell lines.	30551418
1289	Human	HOXA-AS2	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	upregulated	30466095
1290	Human	HOXA-AS2	lncRNA	adriamycin (ADR)	breast cancer	T47D cells	adriamycin (ADR) treatment	upregulated	32163894
1291	Human	HOXA-AS2	lncRNA	oxidized low density lipoprotein (ox-LDL)	human aortic vascular smooth muscle cells (HA-VSMCs) injury	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31957850
1292	Human	HOXA-AS3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32982172
1293	Human	HOXD10-35	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	upregulated	28487500
1294	Human	HOXD-AS2	lncRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	glioblastoma cells	TGF-¦Â1 treatment	?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling	32813021
1295	Human	hsa_circ_0000109	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1296	Human	hsa_circ_0000199	circRNA	cisplatin (DDP)	gastric cancer (GC)	"GC tissues and cells SGC7901, BGC823"	cisplatin treatment	upregulated	30927924
1297	Human	hsa_circ_0000260	circRNA	cisplatin (DDP)	gastric adenocarcinoma (GAC)	HGC27; AGS	cisplatin treatment	Circ_0000260 Regulates the Development and Deterioration of Gastric Adenocarcinoma with Cisplatin Resistance by Upregulating MMP11 via Targeting MiR-129-5p.	33122949
1298	Human	hsa_circ_0000285	circRNA	cisplatin (DDP)	bladder cancer	bladder cancer tissues	cisplatin treatment	hsa_circ_0000285 expression was lower in cisplatin-resistant bladder cancer patients than in those who were cisplatin-sensitive.	30509102
1299	Human	hsa_circ_0000285	circRNA	cisplatin (DDP)	bladder cancer	serum	cisplatin treatment	hsa_circ_0000285 expression was lower in cisplatin-resistant bladder cancer patients than in those who were cisplatin-sensitive.	30509102
1300	Human	hsa_circ_0000376	circRNA	hypoxia	non-small cell lung cancer (NSCLC)	H522; H1975; BEAS-2B	hypoxia treatment	Circ_0000376 promoted NSCLC progression by regulating the miR-1182/NOVA2 axis	32922073
1301	Human	hsa_circ_000042	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	downregulated	31793078
1302	Human	hsa_circ_0000504	circRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"human CRC cell line, HCT116"	5-fluorouracil (5-FU) treatment	upregulated	28656150
1303	Human	hsa_circ_0000524	circRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	podocytes	angiotensin II (Ang II) treatment	"AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p, and induced cell apoptosis in podocytes."	32974919
1304	Human	hsa_circ_0000524	circRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	AB8/13 podocytes	angiotensin II (Ang II) treatment	"AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p."	32974919
1305	Human	hsa_circ_0000567	circRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC9 cells	gefitinib treatment	upregulated	32328186
1306	Human	hsa_circ_0000592	circRNA	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)	gastric cancer (GC)	malignant-transformed gastric epithelial cells (GES-1-T); normal gastric epithelial cells (GES-1-N)	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment	upregulated	31189743
1307	Human	hsa_circ_0000638	circRNA	neodymium oxide (Nd2O3)	inflammation	human bronchial epithelial (16HBE) cells	neodymium oxide treatment	circRNA_0000638 was downregulated in neodymium oxide-treated 16HBE cells.	32199215
1308	Human	hsa_circ_0000657	circRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line (HL7702)	MC-LR exposure	downregulated	31825292
1309	Human	hsa_circ_0000659	circRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line (HL7702)	MC-LR exposure	downregulated	31825292
1310	Human	hsa_circ_0000735	circRNA	docetaxel (DTX)	prostate cancer	PC-3 cells; DU145 cells	docetaxel (DTX) treatment	Hsa_circ_0000735 was upregulated in DTX-resistant PCa tissues and cells.	32714093
1311	Human	hsa_circ_0000977	circRNA	hypoxia	pancreatic cancer (PC)	NK cells	hypoxia induce	upregulated	31402756
1312	Human	hsa_circ_0001013	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	upregulated	33308021
1313	Human	hsa_circ_0001085	circRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	interferon-¦Ã (IFN-¦Ã) treatment	downregulated in PC-3M IE8 cells in the EMT induction model	31882179
1314	Human	hsa_circ_0001085	circRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	downregulated	31882179
1315	Human	hsa_circ_0001165	circRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	interferon-¦Ã (IFN-¦Ã) treatment	upregulated in PC-3M IE8 cells in the EMT induction model	31882179
1316	Human	hsa_circ_0001165	circRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	Hsa_circ_0001165 was upregulated in PC-3M IE8 cells treatment with IFN-¦Ã.	31882179
1317	Human	hsa_circ_0001173	circRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8 cellsS;Vneo cells	high-glucose (HG) treatment	"In GDM patients, the expression of circ_0008285 was significantly upregulated, while that of circ_0001173 was decreased."	33879262
1318	Human	hsa_circ_0001204	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human monocyte derived macrophages (MDMs)	infect with Mtb	dysregulated	29057952
1319	Human	hsa_circ_0001313	circRNA	radiation	colorectal cancer (CRC)	colon cancer tissues	radiation treatment	circ_0001313 was significantly upregulated and miR-338-3p was downregulated in radio-resistant colon cancer tissues compared to radio-sensitive tissues	30630646
1320	Human	hsa_circ_0001313	circRNA	X-rays	colorectal cancer (CRC)	SW480 and SW620 cells	6-MV X-ray exposure	Radiation treatment in colon cells triggered a remarkable upregulation of circ_0001313 and a downregulated of miR-338-3p.	30630646
1321	Human	hsa_circ_000139	circRNA	XAV939	non-small cell lung cancer (NSCLC)	NCL-H1299?cells	XAV939 treatment	"Circ_MDM2_000139, Circ_ATF2_001418, Circ_CDC25C_002079, and Circ_BIRC6_001271 Are Involved in the Functions of XAV939 in Non-Small Cell Lung Cancer"	31885751
1322	Human	hsa_circ_0001445	circRNA	oxidized low density lipoprotein (ox-LDL)	inflammatory injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Hsa_ circ_0001445 expression was gradually decreased with the increase of OX-LDL concentration.	33300444
1323	Human	hsa_circ_0001535	circRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line (HL7702)	MC-LR exposure	upregulated	31825292
1324	Human	hsa_circ_0001946	circRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"human normal lung fibroblasts cell line MRC-5, human NSCLC cell line A549, cisplatin-resistant cell line A549/DDP"	cisplatin treatment	hsa_circ_0001946 can affect the sensitivity of NSCLC cells to the chemotherapeutic drug cisplatin via modulation of the NER signaling pathway.	31249811
1325	Human	hsa_circ_0001953	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30214434
1326	Human	hsa_circ_0002142	circRNA	hypoxia	glioblastoma multiforme (GBM)	"The normal human astrocyte line SVGp12 and two human glioma cell lines, U87MG and A172"	hypoxia induce	upregulated	30988674
1327	Human	hsa_circ_0002317	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1328	Human	hsa_circ_0002468	circRNA	retinoic acid (RA)	human neuronal differentiation	SH-SY5Y cells	retinoic acid (RA) treatment	The expression of hsa_circ_0002468 was increased during SH-SY5Y differentiation and was inversely correlated with miR-561 expression.	30951518
1329	Human	hsa_circ_0002570	circRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose treatment	circ_0002570 could upregulate angiomotin by targeting miR-1243 to mediate the dysfunction of hRMECs induced by high glucose.	32319024
1330	Human	hsa_circ_0002594	circRNA	corticosteroid	allergic asthma (AA)	CD4+ T cells	inhaled corticosteroids (ICS) treatment	Hsa_circ_0002594 was decreased after inhaled corticosteroids (ICS) treatment.	33326955
1331	Human	hsa_circ_0002755	circRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	A-172; SHG-44	Sevoflurane (Sev) treatment	Sev mediated glioma progression via circ_0002755/miR-628-5p/MAGT1 axis	32669871
1332	Human	hsa_circ_0003204	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31900142
1333	Human	hsa_circ_0003247	circRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line (HL7702)	MC-LR exposure	upregulated	31825292
1334	Human	hsa_circ_0003250	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1335	Human	hsa_circ_0003418	circRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	"Human HCC cell lines (Hep-3B, Huh-7, Sk-hep-1, SMMC7721 and PLC)"	cisplatin treatment	suppression of circ_0003418 enhanced cisplatin resistance of HCC cells in vivo and vitro.	31807029
1336	Human	hsa_circ_0003420	circRNA	lipopolysaccharide (LPS)	sepsis-induced liver injury	Kupffer cells	lipopolysaccharide (LPS) treatment	We observed circ_0003420 upregulation accompanied by NPAS4 downregulated in liver samples from patients with sepsis-associated damage and in Kupffer cells treated with LPS.	33719821
1337	Human	hsa_circ_0003489	circRNA	hypoxia	osteogenesis	periodontitis tissues	hypoxia treatment	"The expression levels of circCDK8 and hypoxia-inducible factor-1¦Á were significantly increased in periodontitis tissues, and the expression of circCDK8 was further confirmed in a hypoxia model using cobalt chloride (CoCl2?)."	32978798
1338	Human	hsa_circ_0003524	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30214434
1339	Human	hsa_circ_0003528	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30214434
1340	Human	hsa_circ_0003546	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
1341	Human	hsa_circ_0003575	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28946214
1342	Human	hsa_circ_0003645	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32554046
1343	Human	hsa_circ_0003865	circRNA	melatonin	osteoporosis	human bone marrow mesenchymal stem cell (hBMSC)	melatonin (MEL) treatment	Circ_0003865 expression in BMSCs was significantly decreased by MEL treatment.	33632317
1344	Human	hsa_circ_0003928	circRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	Hsa_circ_0003928 was increased in HG-induced HK-2 cells.	32982348
1345	Human	hsa_circ_0004018	circRNA	salvianolic acid B (Sal B)	liver fibrosis	hepatic stellate cells (HSCs)	salvianolic acid B treatment	Hsa_circ_0004018 were significantly upregulated over time as the HSCs were treated with 100 ug/L of Sal B	32584784
1346	Human	hsa_circ_0004018	circRNA	salvianolic acid B (Sal B)	liver fibrosis	primary hepatic stellate cells (HSCs)	salvianolic acid B treatment	hsa_circ_0004018 were significantly upregulated over time as the HSCs were treated with 100 ug/L of Sal B	32584784
1347	Human	hsa_circ_0004058	circRNA	H2O2	age-related cataract (ARC)	human lens epithelial B3 (HLE-B3) cells	H2O2 treatment	Our data showed that circZNF292 was downregulated in ARC tissues and H2O2-treated human lens epithelial B3 (HLE-B3) cells.	33851769
1348	Human	hsa_circ_0004812	circRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	Huh7 cells; HepG2 cells	pHBV1.3 infection	The level of circ_0004812 was significantly increased in the pHBV1.3-infected cells.	32188476
1349	Human	hsa_circ_0004872	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	Circ_0004872 expression was elevated in PDGF-BB-induced human aortic vascular smooth muscle cells (HA-VSMCs) and carotid plaque tissues	33592319
1350	Human	hsa_circ_0004916	circRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	interferon-¦Ã (IFN-¦Ã) treatment	downregulated in PC-3M IE8 cells in the EMT induction model	31882179
1351	Human	hsa_circ_0004916	circRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	downregulated	31882179
1352	Human	hsa_circ_0005105	circRNA	IL-1¦Â	osteoarthritis (OA)	human Chondrocytes-articular	IL-1¦Â treatment	upregulated	28276108
1353	Human	hsa_circ_0005263	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1354	Human	hsa_circ_0005694	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	downregulated	33308021
1355	Human	hsa_circ_0005741	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1356	Human	hsa_circ_0005941	circRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	downregulated	32767026
1357	Human	hsa_circ_0005963	circRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells	oxaliplatin treatment	upregulated	31901148
1358	Human	hsa_circ_0006294	circRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh-7 cells; HepG2 cells	sorafenib treatment	downregulated	32226514
1359	Human	hsa_circ_0006393	circRNA	dexamethasone (DEX)	glucocorticoid-induced osteoporosis (GIOP)	Bone tissue	dexamethasone (DEX) treatment	"the expression level of hsa_circ_0006393 was decreased in patients with GIOP. Furthermore, the overexpression of hsa_circ_0006393 increased the expression level of genes associated with osteogenesis."	31322188
1360	Human	hsa_circ_0006766	circRNA	ultraviolet (UV) irradiation	photoaging	human dermal fibroblasts (HDFs)	ultraviolet A (UVA)-irradiated treatment	downregulated	33093901
1361	Human	hsa_circ_0006867	circRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC9 cells	gefitinib treatment	downregulated	32328186
1362	Human	hsa_circ_0006872	circRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human pulmonary microvascular endothelial cells HPMECs and bronchial epithelial cells BEAS-2B	cigarette smoke extract (CSE) treatment	upregulated	33248690
1363	Human	hsa_circ_0006872	circRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HPMECs and BEAS-2B cells	cigarette smoke extract (CSE) exposure	"Hsa_circ_0006872 facilitated CSE-triggered apoptosis, inflammation and oxidative stress in HPMECs and BEAS-2B cells by regulating miR-145-5p/NF-¦ÊB pathway."	33248690
1364	Human	hsa_circ_0006892	circRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	The bronchial epithelial cells (BEAS-2B and 16HBE)	cigarette smoke extract (CSE) treatment	Circ_0006892 expression was reduced in lung tissues of smokers with COPD and CSE-stimulated bronchial epithelial cells.	33734482
1365	Human	hsa_circ_0007006	circRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"human CRC cell line, HCT116"	5-fluorouracil (5-FU) treatment	upregulated	28656150
1366	Human	hsa_circ_0007031	circRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"human CRC cell line, HCT116"	5-fluorouracil (5-FU) treatment	upregulated	28656150
1367	Human	hsa_circ_0007031	circRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells; Caco2 cells	5-fluorouracil (5-FU) treatment	Circ_0007031 expression was markedly increased in CRC resistant cells.	32982440
1368	Human	hsa_circ_0007386	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	downregulated	33308021
1369	Human	hsa_circ_0007623	circRNA	hypoxia	myocardial ischaemic injury	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	"hsa_circ_0007623 can bind to miR-297, promote cardiac repair after acute myocardial ischemia, and protect cardiac function."	31973814
1370	Human	hsa_circ_0007976	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1371	Human	hsa_circ_0008285	circRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8 cellsS;Vneo cells	high-glucose (HG) treatment	"In GDM patients, the expression of circ_0008285 was significantly upregulated, while that of circ_0001173 was decreased."	33879262
1372	Human	hsa_circ_0008297	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30214434
1373	Human	hsa_circ_0008305	circRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	A549 cells; H226 cells	TGF-¦Â1 treatment	circ_0008305 was significantly downregulated in NSCLC cells undergoing EMT induced by TGF-¦Â	30261900
1374	Human	hsa_circ_0008360	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1375	Human	hsa_circ_0008362	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	downregulated	33308021
1376	Human	hsa_circ_0008450	circRNA	hypoxia	hepatocellular carcinoma (HCC)	SNU-387 cells; Huh7 cells	hypoxia treatment	Circ_0008450 was upregulated in hypoxia-disposed HCC cells.	33193848
1377	Human	hsa_circ_0009024	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30214434
1378	Human	hsa_circ_000926	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SWl990 cells	gemcitabine (GEM) treatment	downregulated	29781033
1379	Human	hsa_circ_0009910	circRNA	imatinib	chronic myeloid leukemia (CML)	K562 cells; serum	imatinib treatment	The expression of circ_0009910 was upregulated in the serum of imatinib-resistance CML patients and K562/R cells.	31923418
1380	Human	hsa_circ_0010283	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ_0010283 mediated cell viability and migration via a miR-370-3p/HMGB1 axis in ox-LDL-induced VSMCs.	32945389
1381	Human	hsa_circ_0010283	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human VSMCs (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ_0010283 participated in ox-LDL-induced dysfunctions of HVSMCs by modulating the miR-133a-3p/PAPPA pathway.	33162460
1382	Human	hsa_circ_0010729	circRNA	hypoxia	ischemic heart disease (IHD)	AC16 cell	hypoxia exposure	circ_0010729 knockdown alleviated hypoxia-induced AC16 cell injuries by mediating the miR-27a-3p/TRAF5 axis.	33010282
1383	Human	hsa_circ_0010729	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic heart disease (IHD)	human cardiomyocytes (HCM)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"OGD treatment enhanced circ_0010729 expression and evoked cell injury in HCM Moreover, OGD-induced injury was aggrandized by circ_0010729 overexpression via suppressing cell growth and migration in HCM"	31482388
1384	Human	hsa_circ_0010729	circRNA	hypoxia	"vascular endothelial cell proliferation , apoptosis"	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	upregulated	28571741
1385	Human	hsa_circ_0011129	circRNA	ultraviolet (UV) irradiation	photoaging	human dermal fibroblasts (HDFs)	ultraviolet A (UVA)-irradiated treatment	downregulated	33093901
1386	Human	hsa_circ_00116639	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	upregulated	33308021
1387	Human	hsa_circ_001175	circRNA	high glucose (HG)	high glucose (HG) disease	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	Glucose treatments gradually decreased the expressions of circRNA-001175 in a concentration dependent manner.	30521417
1388	Human	hsa_circ_0012129	circRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	T98G cell; LN229 cells	sevoflurane (Sev) treatment	Circ_0012129 was downregulated in sevoflurane-treated glioma cells	32495888
1389	Human	hsa_circ_001271	circRNA	XAV939	non-small cell lung cancer (NSCLC)	NCL-H1299?cells	XAV939 treatment	"Circ_MDM2_000139, Circ_ATF2_001418, Circ_CDC25C_002079, and Circ_BIRC6_001271 Are Involved in the Functions of XAV939 in Non-Small Cell Lung Cancer"	31885751
1390	Human	hsa_circ_001418	circRNA	XAV939	non-small cell lung cancer (NSCLC)	NCL-H1299?cells	XAV939 treatment	"Circ_MDM2_000139, Circ_ATF2_001418, Circ_CDC25C_002079, and Circ_BIRC6_001271 Are Involved in the Functions of XAV939 in Non-Small Cell Lung Cancer"	31885751
1391	Human	hsa_circ_0015879	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30214434
1392	Human	hsa_circ_0020394	circRNA	puerarin	bladder cancer	T24 cells; UM-UC-3 cells	puerarin treatment	circ_0020394 was downregulated in puerarin-treated bladder cancer cells	33016781
1393	Human	hsa_circ_002079	circRNA	XAV939	non-small cell lung cancer (NSCLC)	NCL-H1299?cells	XAV939 treatment	"Circ_MDM2_000139, Circ_ATF2_001418, Circ_CDC25C_002079, and Circ_BIRC6_001271 Are Involved in the Functions of XAV939 in Non-Small Cell Lung Cancer"	31885751
1394	Human	hsa_circ_0026344	circRNA	CCL20 and CXCL8	colorectal cancer (CRC)	human CRC cell lines SW480 and Caco-2	?CCL20 and CXCL8 co-stimulation	"Highlights CCL20 and CXCL8 synergize to decrease the expression of circ_0026344; Silence of circ_0026344 promotes CRC cells migration, invasion and EMT process"	31608699
1395	Human	hsa_circ_0027492	circRNA	doxorubicin (DOX)	DNA damage	HCT116 cells; RKO cells; SW48 cells	Doxorubicin (DOXO) treatment	Hsa_circ_0027492 is upregulated in a p53-dependent manner in response to DNA damage.	32041821
1396	Human	hsa_circ_0028198	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
1397	Human	hsa_circ_0029589	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circ_0029589 silence might inhibit the progression of AS by regulating miR-424-5p/IGF2 axis	32860985
1398	Human	hsa_circ_0030411	circRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	upregulated	32767026
1399	Human	hsa_circ_0031250	circRNA	genistein	non-small cell lung cancer (NSCLC)	human NSCLC cell lines (H292 and A549)	genistein treatment	"circ_0031250 abundance was elevated in NSCLC samples and cell lines, and it was reduced via genistein exposure."	33159503
1400	Human	hsa_circ_0031250	circRNA	genistein	non-small cell lung cancer (NSCLC)	H292 cells; A549 cells	Genistein treatment	"circ_0031250 abundance was elevated in NSCLC samples and cell lines, and it was reduced via genistein exposure."	33159503
1401	Human	hsa_circ_003211	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	downregulated	31793078
1402	Human	hsa_circ_003251	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SWl990 cells	gemcitabine (GEM) treatment	upregulated	29781033
1403	Human	hsa_circ_0032821	circRNA	oxaliplatin	gastric cancer (GC)	HGC-27 cells; AGS cells	oxaliplatin (OXA) treatment	Circ_0032821 was highly expressed in OXA-resistant GC cells	33123829
1404	Human	hsa_circ_0034616	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	upregulated	33308021
1405	Human	hsa_circ_0035266	circRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS)	inflammation	BEAS-2B cells	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS) treatment	"We identified a novel circRNA, circ_0035266, which was strongly upregulated in NNK+LPS-induced BEAS-2B cells and enhanced the inflammatory responses to NNK+LPS by regulating the secretion of pro-inflammatory cytokines interleukin (IL)-6 and IL-8."	33107911
1406	Human	hsa_circ_0035483	circRNA	gemcitabine (GEM)	renal cell carcinoma (RCC)	renal tissues or TK10 and UO31 cells	gemcitabine treatment	"Hsa_circ_0035483 can facilitate gemcitabine-induced autophagy, and enhance the resistance of RCC to gemcitabine."	31492499
1407	Human	hsa_circ_0035944	circRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh-7 cells; HepG2 cells	sorafenib treatment	downregulated	32226514
1408	Human	hsa_circ_0038467	circRNA	lipopolysaccharide (LPS)	pneumonia	16HBE cells	lipopolysaccharide (LPS) treatment	Circ_0038467 was upregulated and miR-338-3p was downregulated in LPS-treated 16HBE cells.	32181994
1409	Human	hsa_circ_0039411	circRNA	neodymium oxide (Nd2O3)	inflammation	human bronchial epithelial cells (16HBE)	neodymium oxide (Nd2O3) treatment	upregulation of circ_0039411 mediated Nd2O3-induced inflammation and dysfunction by sponging miR-93-5p.	30903189
1410	Human	hsa_circ_0040768	circRNA	caffeic acid phenethyl ester (CAPE)	cadmium-induced toxicity	HepG2 cells	caffeic acid phenethyl ester (CAPE) treatment	"CAPE significantly (P < 0.05) increased cell viability via inhibiting CdCl2-induced autophagy, and this process was regulated by hsa_circ_0040768/MAP1LC3B axis."	32298858
1411	Human	hsa_circ_004077	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SWl990 cells	gemcitabine (GEM) treatment	upregulated	29781033
1412	Human	hsa_circ_0040824	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Our data showed that circ-BANP expression was upregulated in AS blood and ox-LDL-induced HUVECs.	33298736
1413	Human	hsa_circ_0041795	circRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	hsa_circ_0041795 contributes to human retinal pigment epithelial cells (ARPE 19) injury induced by high glucose via sponging miR-646 and activating VEGFC	32259632
1414	Human	hsa_circ_0043256	circRNA	cinnamaldehyde (CA)	non-small cell lung cancer (NSCLC)	NCI-H460;A549 cell lines	Cinnamaldehyde (CA) treatment	upregulated	28958934
1415	Human	hsa_circ_0043497	circRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human monocyte derived macrophages (MDMs)	infect with Mtb	dysregulated	29057952
1416	Human	hsa_circ_0044073	circRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs) and human umbilical vein smooth muscle cells (HUVSMCs)	lipopolysaccharide (LPS) treatment	LPS treatment significantly increased the levels of circRNA-0044073 in HUVSMCs but downregulated the levels of circRNA-0044073 in HUVECs. CircRNA-0044073 activates the JAK/STAT signaling pathway of HUVSMCs and HUVECs.	30864721
1417	Human	hsa_circ_0044226	circRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	The human lung fibroblasts (WI-38 cells)	TGF-¦Â1 treatment	upregulated	31786325
1418	Human	hsa_circ_0045462	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1419	Human	hsa_circ_0046366	circRNA	free fatty acids (FFAs; 2:1 oleate:palmitate)	hepatocellular steatosis	HepG2 cells	free fatty acids (FFAs; 2:1 oleate:palmitate) treatment	downregulated	29391755
1420	Human	hsa_circ_0047814	circRNA	H2O2	diabetic retinopathy (DR)	ACBRI-183 cells	H2O2 treatment	upregulated	32343678
1421	Human	hsa_circ_0047814	circRNA	high glucose (HG)	diabetic retinopathy (DR)	ACBRI-183 cells	high glucose (HG) treatment	upregulated	32343678
1422	Human	hsa_circ_0047814	circRNA	IL-6	diabetic retinopathy (DR)	ACBRI-183 cells	IL-6?treatment	upregulated	32343678
1423	Human	hsa_circ_0047814	circRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetic retinopathy (DR)	ACBRI-183 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32343678
1424	Human	hsa_circ_0047814	circRNA	vascular endothelial growth factor (VEGF)	diabetic retinopathy (DR)	ACBRI-183 cells	VEGF treatment	upregulated	32343678
1425	Human	hsa_circ_0054633	circRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	29693114
1426	Human	hsa_circ_0058097	circRNA	excessive mechanical tension	intervertebral disc degeneration (IDD)	primary human endplate chondrocytes culture	Excessive mechanical tension induce	"circRNA_0058097 can upregulate the expression of downstream target gene histone deacetylase 4 by sponge adsorption of miR-365a-5p, which promoted morphological changes of endplate chondrocytes, and increased extracellular matrix degradation and degeneration of endplate cartilage."	31222836
1427	Human	hsa_circ_0060060	circRNA	cisplatin (DDP)	anaplastic thyroid carcinoma (ATC)	TPC1 cells; BHT101 cells	cisplatin (DPP) treatment	upregulated	30540564
1428	Human	hsa_circ_0060927	circRNA	vitamin D	vitamin D metabolism	HCT-116; HT-29 cells	vitamin D treatment	upregulated	32803502
1429	Human	hsa_circ_0061012	circRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	Interleukin-22 (IL-22) treatment increased the expression of circ_0061012 in a dose-dependent manner.	33393621
1430	Human	hsa_circ_0061052	circRNA	cigarette smoke (CS)	epithelial-mesenchymal transition (EMT)	human bronchial epithelial (HBE) cells	Cigarette smoke (CS) exposure	upregulated	32768781
1431	Human	hsa_circ_0063809	circRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells; HeyA-8 cells	paclitaxel (PTX) treatment	The expression of circ_0063809 in PTX-resistant ovarian cancer cells (SKOV3/PTX and HeyA-8/ PTX) was upregulated	31945729
1432	Human	hsa_circ_0063809	circRNA	paclitaxel (PTX)	ovarian cancer (OC)	ovarian cancer cells (SKOV3/PTX and HeyA-8/PTX)	paclitaxel (PTX) treatment	"circCELSR1 was highly expressed in PTX-resistant ovarian cancer cell lines, and circCELSR1 silencing enhanced PTX-induced cytotoxicity in ovarian cancer cells"	31945729
1433	Human	hsa_circ_0064772	circRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	?high glucose (HG) induce treatment	dysregulated	31369204
1434	Human	hsa_circ_006660	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
1435	Human	hsa_circ_0067717	circRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Huh7-HBV;Hep3B-HBV cells	hepatitis B virus (HBV) infection	"Circ-RNF13 was upregulated in HBV-infected human HCC tissues and HBV-expressing cells (Huh7-HBV and Hep3B-HBV), accompanied with TGIF2 upregulation and miR-424-5p downregulated."	33714261
1436	Human	hsa_circ_0068087	circRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31108165
1437	Human	hsa_circ_0068655	circRNA	hypoxia	myocardial infarction (MI)	human induced pluripotent stem-derived cardiomyocytes (HCMs)	hypoxia treatment	Circ_0068655 Promotes Cardiomyocyte Apoptosis via miR-498/PAWR Axis	32767028
1438	Human	hsa_circ_0068888	circRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	Decreased hsa_circ_0068888 expression was observed in AKI cell model.	33429194
1439	Human	hsa_circ_00699	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	30756390
1440	Human	hsa_circ_0073237	circRNA	radiation	glioblastoma multiforme (GBM)	U87 cells; U251 cells	radiation treatment	circ_VCAN expression was significantly downregulated in U87 and U251 cells following irradiation	32080097
1441	Human	hsa_circ_0073817	circRNA	5-fluorouracil (5-Fu)	osteosarcoma (OS)	MG63 cells	5-fluorouracil (5-FU) treatment	downregulated	33308021
1442	Human	hsa_circ_0076305	circRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"NSCLC tissues and cells (A549, H1650, A549/DDP, H1650/DDP)"	cisplatin treatment	upregulated	31647948
1443	Human	hsa_circ_0076631	circRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose treatment	circRNA-0076631 was increased both in high-glucose-treated cardiomyocytes and in the serum of diabetic patients.	31400606
1444	Human	hsa_circ_0077930	circRNA	high glucose (HG)	vascular smooth muscle aging	human umbilical vein endothelial cell (HUVEC)	high glucose (HG) treatment	HG-HUVECs derived exosomes induced the VSMCs senescence by circRNA0077930-miR622-Kras CeRNA network.	32307741
1445	Human	hsa_circ_007874	circRNA	monastrol	breast cancer	MCF-7 cells; MDA-MB-231 cells	monastrol treatment	circRNA-MTO1 (hsa-circRNA-007874) was validated as a circRNA that exhibited elevated expression levels in monastrol-resistant cells.	30015883
1446	Human	hsa_circ_0079662	circRNA	oxaliplatin	colorectal cancer (CRC)	HT29 cells; HCT116 cells; HCT8 cells	oxaliplatin treatment	"hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-¦Á pathway in human colon cancer"	32243061
1447	Human	hsa_circ_0081001	circRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells; KHOS cells; U2OS cells	doxorubicin (Dox) treatment	hsa_circ_0081001 was upregulated with 12 fold change in the chemo-resistant OS cell lines.	30263004
1448	Human	hsa_circ_0084043	circRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	Loss of circRNA_0084043 depressed HG-induced damage via sponging miR-140-3p and regulating TGFA.	32259630
1449	Human	hsa_circ_0086720	circRNA	radiation	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) tissues	radiation treatment	upregulated	32940043
1450	Human	hsa_circ_0088364	circRNA	nitidine chloride (NC)	hepatocellular carcinoma (HCC)	HCC xenograft tumour tissues	Nitidine chloride (NC)?treatment	hsa_circ_0088364 dysregulated.	31506425
1451	Human	hsa_circ_008913	circRNA	arsenite	arsenite-induced carcinogenesis	HaCaT cells	arsenite exposure	downregulated	30167605
1452	Human	hsa_circ_0090049	circRNA	nitidine chloride (NC)	hepatocellular carcinoma (HCC)	HCC xenograft tumour tissues	Nitidine chloride (NC)?treatment	hsa_circ_0090049 dysregulated.	31506425
1453	Human	hsa_circ_0091223	circRNA	¦Á-melanocyte-stimulating hormone (¦Á-MSH)	skin pigmentation disorders	human skin primary melanocytes (MCs)	¦Á-MSH treatment	upregulated	33318297
1454	Human	hsa_circ_0092317	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
1455	Human	hsa_circ_0092493	circRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	serum	hepatitis B virus (HBV) infection	"?In this study, we performed circRNA microarray profile and found an HBV-related circRNA, circ-ARL3 (hsa_circ_0092493)."	33372396
1456	Human	hsa_circ_0096157	circRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	upregulated	32767026
1457	Human	hsa_circ_0109320	circRNA	gefitinib	non-small cell lung cancer (NSCLC)	plasma	gefitinib treatment	Elevated hsa_circ_0109320 was associated with longer PFS in gefitinib-treated NSCLC patients. hsa_circ_0109320 may be a potential biomarker for the efficacy of EGFR-TKI in NSCLC patients.	31285870
1458	Human	hsa_circ_0110805	circRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC-27 cells	cisplatin (DPP) treatment	"circ_0110805 knockdown increased the sensitivity of gastric cancer to cisplatin, which also repressed gastric cancer progression by sponging miR-299-3p to downregulate ENDOPDI expression."	33192077
1459	Human	hsa_circ_0113656	circRNA	platelet derived growth factor-BB (PDGF-BB)	vascular restenosis	human aortic vascular smooth muscle cell (HA-VSMC)	platelet derived growth factor-BB (PDGF-BB) treatment	upregulated	32736703
1460	Human	hsa_circ_0114427	circRNA	gentamicin	acute kidney injury (AKI)	HK-2 cells	gentamicin treatment	"Circ-0114427 dramatically increased 727 in LPS-, H202-, and gentamicin-induced AKI cell models."	31930399
1461	Human	hsa_circ_0114427	circRNA	H2O2	acute kidney injury (AKI)	HK-2 cells	H2O2 treatment	"Circ-0114427 dramatically increased 727 in LPS-, H202-, and gentamicin-induced AKI cell models."	31930399
1462	Human	hsa_circ_0114427	circRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	LPS treatment	"Circ-0114427 dramatically increased 727 in LPS-, H202-, and gentamicin-induced AKI cell models."	31930399
1463	Human	hsa_circ_0114428	circRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	upregulated	33830389
1464	Human	hsa_circ_0114876	circRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	The expression of circ_0114876 was increased in OA tissues and inhibition of circ_0114876 could induce cell viability and suppress inflammation as well as inhibit cell apoptosis in IL-1¦Â induced CHON-001 cells.	33404903
1465	Human	hsa_circ_01183	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	30756390
1466	Human	hsa_circ_0124644	circRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circular RNA circ_0124644 exacerbates the ox-LDL-induced endothelial injury in human vascular endothelial cells through regulating PAPP-A by acting as a sponge of miR-149-5p.	32500475
1467	Human	hsa_circ_0127305	circRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	29953413
1468	Human	hsa_circ_0127305	circRNA	pramipexole (PPX)	parkinson's disease (PD)	1-methyl-4-phenylpyridinium (MMP+) treated SH-SY5Y cells	pramipexole (PPX) treatment	downregulated	29953413
1469	Human	hsa_circ_0134111	circRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	Circ_0134111 was overexpressed in OA cartilage tissues and IL-1¦Â-induced chondrocytes.	33684877
1470	Human	hsa_circ_0134501	circRNA	gefitinib	non-small cell lung cancer (NSCLC)	plasma	gefitinib treatment	dysregulated	31285870
1471	Human	hsa_circ_01536	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30756390
1472	Human	hsa_circ_01536	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"Network analysis uncovered three potential key circRNAs, that is, circRNA_05432, circRNA_08441, and circRNA_01536."	30756390
1473	Human	hsa_circ_01978	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	30756390
1474	Human	hsa_circ_04411	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30756390
1475	Human	hsa_circ_05432	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"Network analysis uncovered three potential key circRNAs, that is, circRNA_05432, circRNA_08441, and circRNA_01536."	30756390
1476	Human	hsa_circ_08441	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"Network analysis uncovered three potential key circRNAs, that is, circRNA_05432, circRNA_08441, and circRNA_01536."	30756390
1477	Human	hsa_circ_09169	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30756390
1478	Human	hsa_circ_09905	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30756390
1479	Human	hsa_circ_100284	circRNA	arsenite	acceleration of the cell cycle and carcinogenesis	HaCaT cells	arsenic exposure	upregulated	28062277
1480	Human	hsa_circ_100284	circRNA	arsenite	bladder cancer	Normal bladder SV-HUC-1 cells	?arsenite treatment	"With prolonged contact time with arsenite, the expression level of circRNA-100284 in cells increased continuously"	33386469
1481	Human	hsa_circ_100284	circRNA	arsenite	cell cycle and proliferation	human hepatic epithelial (L-02) cells	arsenite exposure	circRNA_100284 is involved in the malignant transformation of L-02 cells induced by arsenite.	29674685
1482	Human	hsa_circ_100338	circRNA	hypoxia/reoxygenation (H/R)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (H/R) treatment	The expression of circ-100338 was decreased in HUAECs after H/R treatment.	32572929
1483	Human	hsa_circ_100797	circRNA	ultraviolet (UV) irradiation	cell senescence	human fibroblast	"the UVB irradiation output was monitored using a Waldmann UV meter (Waldmann, Villigen©\Schwenningen, Germany). UVB dose = UVB irradiance ¡Á time in second (s), with a distance of 15 cm between the lamp and cell culture dish. The UVB with 10 mJ/cm2 was delivered to cells daily for 5 days and at 48 hr after the last irradiation treatment"	circRNA_100797 had a low expression in ultraviolet B stress-induced human fibroblast premature senescence (UVB-SIPS)	30908647
1484	Human	hsa_circ_101237	circRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	serum of patients; Huh7 cells	cisplatin treatment	upregulated	32226487
1485	Human	hsa_circ_101237	circRNA	bortezomib	multiple myeloma (MM)	MM.1S cells; H929 cells	bortezomib? treatment	upregulated	32256118
1486	Human	hsa_circ_101505	circRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	The cisplatin-resistant Hep3B (Hep3B-R) and Huh7 (Huh7-R) cells	cisplatin treatment	"Gain-of-function investigations showed that overexpression of circRNA_101505 suppressed cancer cell growth in vivo and in vitro, and enhanced cisplatin toxicity in HCC cells."	31372241
1487	Human	hsa_circ_101543	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SWl990 cells	gemcitabine (GEM) treatment	downregulated	29781033
1488	Human	hsa_circ_101672	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SWl990 cells	gemcitabine (GEM) treatment	upregulated	29781033
1489	Human	hsa_circ_102115	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"circ_102115 was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression."	32127962
1490	Human	hsa_circ_102610	circRNA	TGF-¦Â1	crohn disease (CD)	human intestinal epithelial cells (HIECs); normal-derived colon mucosa cell line 460 (NCM460) cells	TGF-¦Â1 treatment	Hsa_circRNA_102610 upregulation in CD patients could promote the proliferation and EMT of intestinal epithelial cells via sponging of hsa-miR-130a-3p	32587447
1491	Human	hsa_circ_102747	circRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SWl990 cells	gemcitabine (GEM) treatment	downregulated	29781033
1492	Human	hsa_circ_103572	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"circ_103572 was downregulated in CNE-2 cells after treatment by radiation, while curcumin treatment upregulated the expression."	32127962
1493	Human	hsa_circ_103765	circRNA	tumor necrosis factor alpha (TNF-¦Á) 	crohn disease (CD)	Caco2 and HIEC cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	33436852
1494	Human	hsa_circ_103809	circRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	upregulated	33276753
1495	Human	hsa_circ_104057	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"circ_104057 was downregulated in CNE-2 cells after treatment by radiation, while curcumin treatment upregulated the expression."	32127962
1496	Human	hsa_circ_104075	circRNA	matrine	glioblastoma multiforme (GBM)	Glioma cell line U251?cells	Matrine treatment	Matrine decreased circRNA-104075 expression significantly. Overexpression of circRNA-104075 was found to counteract the inhibitory effects of matrine on cell proliferation and promoting effects on apoptosis and autophagy in U251?cells.	31112718
1497	Human	hsa_circ_104250	circRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-2B"	particulate matter 2.5 (PM2.5) exosure treatment	upregulated	31864925
1498	Human	hsa_circ_104250	circRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-2B"	particulate matter 2.5 (PM2.5) exposure treatment	upregulated	31864925
1499	Human	hsa_circ_104883	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	downregulated	31793078
1500	Human	hsa_circ_13360	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	32547599
1501	Human	hsa_circ_14411	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	32547599
1502	Human	hsa_circ_16804	circRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	5-aza induced the differentiation of human umbilical cord-derived mesenchymal stem cells (hUCMSCs) into cardiomyocyte-like cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	30756390
1503	Human	hsa_circ_1698	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	32547599
1504	Human	hsa_circ_1848	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	32547599
1505	Human	hsa_circ_2858	circRNA	escherichia coli (E.coli)	meningitis	human brain microvascular endothelial cells (hBMECs)	escherichia coli (E. coli) infection	circ_2858 was upregulated in human brain microvascular endothelial cells (hBMECs) upon meningitic E. coli infection.	33230468
1506	Human	hsa_circ_3041	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	32547599
1507	Human	hsa_circ_3046	circRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	KMB17 cells	herpes simplex virus 1 (HSV-1) treatment	upregulated	29972822
1508	Human	hsa_circ_3140	circRNA	mechanical force (MF)	osteogenesis	human periodontal ligament stem cells (PDLSCs)	mechanical force (MF)?induce	"circRNA3140 was highly and widely associated with microRNA-21, which plays a critical role in MF-induced osteogenic differentiation of PDLSCs."	30422310
1509	Human	hsa_circ_33287	circRNA	bone morphogenetic protein 2 (BMP2)	cell differentiation	maxillary sinus membrane stem cells (MSMSCs)	bone morphogenetic protein 2 (BMP2) treatment	Hsa_circRNA_33287 promotes the osteogenic differentiation of maxillary sinus membrane stem cells via miR-214-3p/Runx3.	30551425
1510	Human	hsa_circ_3875	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	32547599
1511	Human	hsa_circ_402801	circRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"circ_402801 was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression."	32127962
1512	Human	hsa_circ_403658	circRNA	hypoxia	bladder cancer	hypoxia-induced 5637;T24 cells	hypoxia-induce	"hsa-circ_403658 was an important circRNA that upregulated in bladder cancer cells under hypoxia, and higher hsa-circ_403658 levels were associated with poorer survival outcome."	31814891
1513	Human	hsa_circ_406961	circRNA	particulate matter (PM2.5)	airway inflammation	BEAS-2B cells	Fine particulate matter (PM2.5) treatment	"circ_406961 inhibited activation of STAT3/JNK pathways via interacting with ILF2 protein, thereby inhibiting the PM25-induced inflammatory reaction"	32388272
1514	Human	hsa_circ_4099	circRNA	H2O2	hepatitis	L02 cells	H2O2 treatment	circRNA-4099 was stimulated by H2O2. Plentiful circRNA-4099 augmented H2O2-resulted damage.	31479678
1515	Human	hsa_circ_4099	circRNA	H2O2	hepatitis	L02 cells	H2O2 treatment	upregulated	31479678
1516	Human	hsa_circ_4099	circRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	NP cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á treatment increased circ-4099 expression in NP cells	29651107
1517	Human	hsa_circ_4452	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	32547599
1518	Human	hsa_circ_51217	circRNA	R-2-hydroxyglutarate (R-2HG)	prostate cancer	"C4-2, PC3, DU145, LNCaP cells"	R-2-hydroxyglutarate (R-2HG) treatment	upregulated	31846689
1519	Human	hsa_circ_5780	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	32547599
1520	Human	hsa_circ_6783	circRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	KMB17 cells	herpes simplex virus 1 (HSV-1) treatment	upregulated	29972822
1521	Human	hsa_circ_859267	circRNA	ultraviolet (UV) irradiation	photoaging	human dermal fibroblasts (HDFs)	UVA irradiated treatment	downregulated	28286269
1522	Human	hsa_circ_8979	circRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	primary human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	32547599
1523	Human	hsa_circ_9119	circRNA	polyinosinic-polycytidilic acid (Poly(I:C))	orchitis	testicular cells	poly I:C treatment	upregulated	31195953
1524	Human	hsa_circ_9119	circRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 cells	IL-1¦Â treatment	downregulated	32522568
1525	Human	hsa-let-2b-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
1526	Human	hsa-let-7	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
1527	Human	hsa-let-7	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
1528	Human	hsa-let-7	miRNA	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	colorectal cancer (CRC)	HCT116 cells£»HT29 cells£»SW480 cells£» SW620 cells	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	upregulated	22983985
1529	Human	hsa-let-7	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	downregulated	30692507
1530	Human	hsa-let-7	miRNA	epstein-barr virus EBNA1 protein	EBV infection	nasopharyngeal carcinoma cell lines	EBNA1 treatment	downregulated	25031339
1531	Human	hsa-let-7	miRNA	HT-3O sulfate (HT-3Os)	epithelial-mesenchymal transition (EMT)	IL-1¦Â-treated human umbilical endothelial cells (HUVEC) and human retinal endothelial cells (HREC)	HT-3O sulfate (HT-3Os) treatmment	upregulated	30725211
1532	Human	hsa-let-7	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	human umbilical endothelial cells (HUVEC) and human retinal endothelial cells (HREC)	interleukin-1¦Â (IL-1¦Â) treatment	downregulated	30725211
1533	Human	hsa-let-7	miRNA	HT-3O sulfate (HT-3Os)	epithelial-mesenchymal transition (EMT)	human umbilical EC (HUVEC); human retinal EC (HREC)	HT-3O sulfate (HT-3Os) treatment	Exposure of HUVEC and HREC to IL-1¦Â alone led to a sig- nificant reduction of let-7 miRNA levels which were restored in the presence of HT-3Os.	30725211
1534	Human	hsa-let-7	miRNA	H2O2	gastric cancer (GC)	GC cells	H2O2 treatment	Hsa-let-7 g miRNA increased the sensitivity of GC to oxidative stress by repression activation of DDR indirectly. Let-7 g improved the effects of X-rays on GC cells involving in DDR regulation as well.	25972194
1535	Human	hsa-let-7	miRNA	phenformin	glioblastoma multiforme (GBM)	glioma stem cells (GSCs)	Phenformin treatment	upregulated	27486821
1536	Human	hsa-let-7	miRNA	secretin	human primary sclerosing cholangitis (PSC)	"PSC liver tissue biopsies, serum, and bile"	secretin? treatment	downregulated	27115285
1537	Human	hsa-let-7	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?9 cells	heme treatment	upregulated	23538684
1538	Human	hsa-let-7	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
1539	Human	hsa-let-7	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
1540	Human	hsa-let-7	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	human non-small cell lung cancer cells A549	cisplatin treatment	downregulated	28235063
1541	Human	hsa-let-7	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	human non-small cell lung cancer cells A549	2 Gy of irradiation once a week	downregulated	28235063
1542	Human	hsa-let-7	miRNA	tankyrase inhibitor JW74	osteosarcoma (OS)	"OS cell lines (KPD, U2OS, and SaOS-2)"	JW74 treatment	upregulated	24403055
1543	Human	hsa-let-7	miRNA	metformin (Met)	ovarian cancer (OC)	ovarian cancer cells	metformin treatment	upregulated	27775072
1544	Human	hsa-let-7	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human endometrial cell-lines	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	28499250
1545	Human	hsa-let-7	miRNA	fractionated radiation	prostate cancer	Human Prostate Cancer Cells	radiation treatment	Tumor suppressor miR-34a and let-7 miRNAs were upregulated by fractionated radiation in radiosensitive LNCaP (p53 positive) and PC3 (p53-null) cells indicating	22827214
1546	Human	hsa-let-7	miRNA	simvastatin	prostate cancer	human castration-resistant prostate cancer (CRPC) cells	simvastatin treatment	upregulated	28910332
1547	Human	hsa-let-7	miRNA	TGF-¦Â1	Pancreatic ductal adenocarcinoma (PDAC)	Panc1 cells	?TGF-¦Â1 treatment	downregulated	21057545
1548	Human	hsa-let-7	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	ARK2 and MCF-7 cells	metformin treatment	upregulated	27775072
1549	Human	hsa-let-7	miRNA	cryptosporidium parvum	cryptosporidium parvum infection	"C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)"	cryptosporidium parvum? infection	downregulated	20486857
1550	Human	hsa-let-7	miRNA	cryptosporidium parvum	cryptosporidium parvum infection	"C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)"	cryptosporidium parvum? infection	downregulated	20486857
1551	Human	hsa-let-7	miRNA	sorafenib (SOR)	human immunodeficiency virus (HIV)-1 infection	Huh7 hepatoma cells	sorafenib treatment	downregulated	20347499
1552	Human	hsa-let-7a	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
1553	Human	hsa-let-7a	miRNA	"sulforaphane, quercetin and GTC"	pancreatic ductal adenocarcinoma (PDAC)	BxPc-3 and MIA-PaCa2 and human hTERT-HPNE	"sulforaphane, quercetin and GTC complement treatment"	upregulated	25017900
1554	Human	hsa-let-7a	miRNA	antidiabetic	glycemic control	ment-na?ve diabetic patients with poor metabolic control	12 months of antidiabetic treatment	upregulated	24937531
1555	Human	hsa-let-7a	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	acute myeloid leukemia (AML)	"human myeloid leukemic cell line, AML-193"	GM-CSF treatment	downregulated	22015065
1556	Human	hsa-let-7a	miRNA	lipopolysaccharide (LPS) and TGF-¦Â	alcoholic liver disease (ALD)	human hepatic stellate cells (HSCs)	lipopolysaccharide (LPS) and TGF-¦Â treatment	downregulated	28536261
1557	Human	hsa-let-7a	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
1558	Human	hsa-let-7a	miRNA	high glucose-induced endothelial microparticles (EMPs)	apoptosis	human umbilical vein endothelial cells (HUVECs)	high glucose EMPs	downregulated	28942148
1559	Human	hsa-let-7a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"let-7a, which directly targets the 3'-UTR of periostin mRNA. In addition, periostin overexpression partly reversed the biological effects of H19 knockdown in ox-LDL-treated HUVECs, which were almost recapitulated by let-7 overexpression."	31054453
1560	Human	hsa-let-7a	miRNA	androgen	breast cancer	"MCF-7, MDA-MB-453 , MDA-MB-231"	androgen treatment	upregulated	24172884
1561	Human	hsa-let-7a	miRNA	arsenic trioxide (ATO)	breast cancer	MCF-7 and SK-BR-3 cell lines	arsenic trioxide (ATO) treatment	upregulated	28980872
1562	Human	hsa-let-7a	miRNA	benzo(a)pyrene (BaP)	breast cancer	MDA-MB-231 cells	benzo(a)pyrene (BaP) exposure	downregulated	30155724
1563	Human	hsa-let-7a	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1564	Human	hsa-let-7a	miRNA	metformin (Met)	breast cancer	MCF-7 cells	metformin?treatment	upregulated	21368581
1565	Human	hsa-let-7a	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells; MDA-MB-231 cells	paclitaxel treatment	downregulated	30019863
1566	Human	hsa-let-7a	miRNA	paclitaxel (PTX)	breast cancer	BT-474 cells	paclitaxel treatment	upregulated	30019863
1567	Human	hsa-let-7a	miRNA	nanoparticle (NP)	colorectal cancer (CRC)	Human colon cancer HCT-116 cells	Nanoparticle (NP) technology	"Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulated of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms,"	21929751
1568	Human	hsa-let-7a	miRNA	honeysuckle aqueous extract	dengue virus (DENV) infection	human blood	aqueous extract treatment	upregulated	28052239
1569	Human	hsa-let-7a	miRNA	honeysuckle aqueous extract	dengue virus (DENV) infection	mouse blood	aqueous extract treatment	upregulated	28052239
1570	Human	hsa-let-7a	miRNA	Rhein-8-O-¦Â-D-glucopyranoside (Rg)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	Rhein-8-O-¦Â-D-glucopyranoside (Rg) treatment	Rg attenuated HG-induced apoptosis of HMCs by regulating the lincRNA ANRIL/let-7a/TGF-¦Â1/Smad signaling pathway	32256771
1571	Human	hsa-let-7a	miRNA	acrolein	environmental pollutants	human umbilical vein endothelial cells	acrolein treatment	upregulated	24812010
1572	Human	hsa-let-7a	miRNA	curcumin (Cur)	fat	esophageal cancer cell lines	curcumin treatment	downregulated	22363450
1573	Human	hsa-let-7a	miRNA	urolithin A (UA)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	urolithin A treatment	upregulated	29742265
1574	Human	hsa-let-7a	miRNA	honeysuckle (HS)	enterovirus 71 (EV71) infection	human muscle rhabdomyosarcoma RD cells	Honeysuckle treatment	"Moreover, honeysuckle-induced?let-7a?suppression of EV71 RNA and protein expression as well as viral replication were investigated both in vitro and in vivo."	33669264
1575	Human	hsa-let-7a	miRNA	estradiol-17¦Â (E2)	inflammation	human macrophages	estradiol-17¦Â (E2) treatment	"LPS induces let-7a and inhibits miR-125b expression in human macrophages, and pretreatment with estradiol abrogates these effects"	20351193
1576	Human	hsa-let-7a	miRNA	sepsis	liver damage	liver tissues	sepsis induce treatment	The expression of let-7a in liver tissue of patients with sepsis-induced liver injury was clearly decreased	31344555
1577	Human	hsa-let-7a	miRNA	particulate matter (PM2.5)	lung cancer	human non-small cell lung cancer cell line A549	chronic (five passages) PM2.5 exposure treatment	downregulated	28846189
1578	Human	hsa-let-7a	miRNA	ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE)	metastasized melanoma	A375 melanoma cells	SLE treatment	upregulated	31514083
1579	Human	hsa-let-7a	miRNA	"pan-JAK inhibitor, INC424"	myeloproliferative neoplasms	Ton.JAK2.V617F cells	"pan-JAK inhibitor, INC424 treatment"	upregulated	28057739
1580	Human	hsa-let-7a	miRNA	pan-HDAC inhibitor ITF2357	non-Hodgkin lymphoma (NHL)	human B-cell non-Hodgkin lymphomas (B-NHLs)	pan-HDAC inhibitor ITF2357 treatment	upregulated	24648290
1581	Human	hsa-let-7a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells	cisplatin treatment	downregulated	31189742
1582	Human	hsa-let-7a	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
1583	Human	hsa-let-7a	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
1584	Human	hsa-let-7a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	preeclampsia (PE)	JEG-3 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	Let-7a inhibits Bcl-xl and YAP1 expression to induce apoptosis of trophoblast cells in early-onset severe preeclampsia	32721616
1585	Human	hsa-let-7a	miRNA	CXCR4	pregnancy disease	AML cells	CXCR4 treatment	downregulated	23676502
1586	Human	hsa-let-7a	miRNA	Yangzheng Sanjie decoction (YZSJD)	gastric cancer (GC)	AGS and HS-746T GC cells	YZSJD treatment	downregulated	28852313
1587	Human	hsa-let-7a	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (PASMCs)	hypoxia exposure	miR-let-7a was downregulated in hypoxic PASMCs.	32803651
1588	Human	hsa-let-7a	miRNA	arsenite	lung fibrosis	THP-1 cells	arsenic (As) exposure	downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages.	33162208
1589	Human	hsa-let-7a	miRNA	arsenite	lung fibrosis	lung tissues; bone marrow-derived macrophages (BMDMs)	arsenite exposure	downregulated	33162208
1590	Human	hsa-let-7a	miRNA	anti-citrullinated protein antibodies (ACPAs)	rheumatoid arthritis (RA)	macrophages isolated from patients with RA	ACPAs treatment (160IU/mL)	downregulated	28802150
1591	Human	hsa-let-7a	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	upregulated	30182520
1592	Human	hsa-let-7a	miRNA	melatonin	subarachnoid hemorrhage (SAH)	U87 cells; U251 cells	melatonin (MT) treatment	downregulated	29367587
1593	Human	hsa-let-7a	miRNA	IL-22	systemic sclerosis (SSc)	normal human dermal fibroblast	IL-22	downregulated	29336866
1594	Human	hsa-let-7a	miRNA	IL-22	systemic sclerosis (SSc)	Human dermal fibroblasts	IL-22 treatment	downregulated	29336866
1595	Human	hsa-let-7a	miRNA	arsenite	tumorigenesis of arsenite	human keratinocyte HaCaT cells	arsenic exposure	downregulated	24704393
1596	Human	hsa-let-7a1	miRNA	listeria monocytogenes (L. monocytogenes)	Listeria infection	Human epithelial cells (Caco-2)	Listeria infection	downregulated	22312311
1597	Human	hsa-let-7a-2	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	muscarinic M(1) receptor dysfunction	A549 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	23469214
1598	Human	hsa-let-7a-3	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
1599	Human	hsa-let-7a-5p	miRNA	paclitaxel (PTX)	breast cancer	BC tissues; MCF-7 cells MDA-MB-231	Paclitaxel (PTX) treatment	downregulated	32273769
1600	Human	hsa-let-7a-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	downregulated	30503955
1601	Human	hsa-let-7a-5p	miRNA	silica	pneumoconiosis	THP-1 cells	silica treatment	downregulated	29516679
1602	Human	hsa-let-7a-5p	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	human lens epithelial cells (LECs)	TGF-¦Â2 treatment	TGF-¦Â2 upregulated Smad2 expression and reduced let-7a-5p expression in LECs	32345785
1603	Human	hsa-let-7a-5p	miRNA	doxorubicin (DOX)	prostate cancer	prostate cancer DU-145 cells	doxorubicin (DOX) treatment	upregulated	31188543
1604	Human	hsa-let-7a-5p	miRNA	radiation	prostate cancer	serum	curative radiotherapy (RT) treatment	upregulated	30103771
1605	Human	hsa-let-7b	miRNA	hypoxia	acute myocardial infarction (AMI)	AC16	hypoxia treatment	downregulated	32922590
1606	Human	hsa-let-7b	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	Cryopreserved primary human hepatocytes (cPHH)	ethanol (EtOH) exposure	upregulated	30103265
1607	Human	hsa-let-7b	miRNA	lipopolysaccharide (LPS) and TGF-¦Â	alcoholic liver disease (ALD)	human hepatic stellate cells (HSCs)	lipopolysaccharide (LPS) and TGF-¦Â treatment	downregulated	28536261
1608	Human	hsa-let-7b	miRNA	curcumin (Cur)	breast cancer	MCF-10F cells	curcumin (Cur) treatment	upregulated	31894298
1609	Human	hsa-let-7b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1610	Human	hsa-let-7b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1611	Human	hsa-let-7b	miRNA	electrode	cervical cancer (CC)	HeLa cells	electric treatment	upregulated	16503596
1612	Human	hsa-let-7b	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	colonic epithelial cells	adherent invasive escherichia coli (AIEC) treatment	AIEC elicits/exacerbate gut inflammation in WT/IL-10 KO mice that correlates with increased expression of TLR4 and decreased level of let-7b in IECs.	30142321
1613	Human	hsa-let-7b	miRNA	mycolactone	expression regulation	human primary T cells	Mycolactone treatment	mycolactone-induced suppression of CD62-L expression by human primary T cells was induced rapidly at both the mRNA and protein levels and correlated with the reduced expression of one miRNA: let-7b.	21768364
1614	Human	hsa-let-7b	miRNA	preoperative radiotherapy	esophageal squamous cell carcinoma (ESCC)	ESCC tissues	preoperative radiotherapy treatment	dysregulated	24576011
1615	Human	hsa-let-7b	miRNA	helicobacter pylori (H. pylori)	hepatitis B virus (HBV) infection	gastric mucosa specimens and two gastric epithelial cell lines	Helicobacter pylori infection	downregulated	23437218
1616	Human	hsa-let-7b	miRNA	oleic acid (OA)	inflammation	LPS-activated human acute monocytic leukemia cells (THP-1)	oleic acid (OA) treatment	upregulated	29790117
1617	Human	hsa-let-7b	miRNA	palmitic acid (PA)	inflammation	LPS-activated human acute monocytic leukemia cells (THP-1)	palmitic acid (PA) treatment	upregulated	29790117
1618	Human	hsa-let-7b	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
1619	Human	hsa-let-7b	miRNA	"RESMENA (reduction of metabolic syndrome in Navarra, Spain)"	metabolic syndrome	MetS patients white blood cells (WBC)	RESMENA treatment	"miR-155-3p was decreased ,miR-Let-7b was strongly upregulated in white blood cells (WBC)"	26421388
1620	Human	hsa-let-7b	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
1621	Human	hsa-let-7b	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
1622	Human	hsa-let-7b	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
1623	Human	hsa-let-7b	miRNA	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á)	renal fibrosis	HK-2 cell lines	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) overexpression treatment	upregulated	31614978
1624	Human	hsa-let-7b	miRNA	arsenite	tumorigenesis of arsenite	human keratinocyte HaCaT cells	arsenic exposure	downregulated	24704393
1625	Human	hsa-let-7b*	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
1626	Human	hsa-let-7b-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
1627	Human	hsa-let-7b-5p	miRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"LINC00987 Ameliorates COPD by Regulating LPS-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Autophagy Through Let-7b-5p/SIRT1 Axis."	33311978
1628	Human	hsa-let-7b-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC 7901cells; AGC cells	cisplatin treatment	downregulated	33009035
1629	Human	hsa-let-7b-5p	miRNA	fibroblast growth factor receptor (FGFR) 1	mitochondrial dynamics	normal human dermal microvascular endothelial cells (HMVECs)	Fibroblast growth factor receptor (FGFR) 1 treatment	downregulated	29269295
1630	Human	hsa-let-7b-5p	miRNA	N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP)	mitochondrial dynamics	normal human dermal microvascular endothelial cells (HMVECs)	N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) treatment	upregulated	29269295
1631	Human	hsa-let-7b-5p	miRNA	"triple cytokines (TGF-¦Â2, interleukin-1¦Â, tumor necrosis factor-¦Á)"	mitochondrial dynamics	normal human dermal microvascular endothelial cells (HMVECs)	"triple cytokines (TGF-¦Â2, interleukin-1¦Â, tumor necrosis factor-¦Á) treatment"	downregulated	29269295
1632	Human	hsa-let-7b-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
1633	Human	hsa-let-7b-5p	miRNA	trichloroethylene (TCE)	non-Hodgkin lymphoma (NHL)	serum	trichloroethylene (TCE) exposure treatment	downregulated	31161417
1634	Human	hsa-let-7b-5p	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	"NEAT1 regulated TRAF6 expression by sponging let-7b-5p in HK-2 cells, which promotes LPS-induced injury and inflammation in HK-2 cells."	32724027
1635	Human	hsa-let-7b-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 human macrophages	?Mycobacterium tuberculosis (Mtb) infection	upregulated	29471394
1636	Human	hsa-let-7c	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
1637	Human	hsa-let-7c	miRNA	androgen	prostate cancer	prostate cancer cells	androgen treatment	downregulated	23503464
1638	Human	hsa-let-7c	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
1639	Human	hsa-let-7c	miRNA	all-trans retinoic acid (ATRA)	acute myeloid leukemia (AML)	"human leukemic cell lines NB4, HEL, HL-60, KG1, K562, SKNO-1, THP-1, and UF-1"	all-trans retinoic acid (ATRA) treatment	upregulated	24637061
1640	Human	hsa-let-7c	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1641	Human	hsa-let-7c	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
1642	Human	hsa-let-7c	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	human umbilical cord vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	22917031
1643	Human	hsa-let-7c	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	ARPE-19 cells	TGF-¦Â2 treatment	The expression of miR-let7c was dramatically reduced after induction by TGF-¦Â2	32420214
1644	Human	hsa-let-7c	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
1645	Human	hsa-let-7c	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
1646	Human	hsa-let-7c	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cell	cigarette smoke extract (CSE) treatment	downregulated	28184029
1647	Human	hsa-let-7c	miRNA	fulvestrant	non-small cell lung cancer (NSCLC)	H1975 NSCLC cells	fulvestrant treatment	upregulated	24268810
1648	Human	hsa-let-7c	miRNA	H2O2	osteoporosis	Adipose-derived mesenchymal stem cells (ADMSCs)	H2O2 treatment	upregulated	30379578
1649	Human	hsa-let-7c	miRNA	H2O2	osteoporosis	human adipose-derived mesenchymal stem cells (hADMSCs)	H2O2 treatment	upregulated	30379578
1650	Human	hsa-let-7c	miRNA	N-acetyl-L-cysteine (NAC)	osteoporosis	H2O2-treated human adipose-derived mesenchymal stem cells (hADMSCs)	N-acetyl-L-cysteine (NAC) treatment	downregulated	30379578
1651	Human	hsa-let-7c	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
1652	Human	hsa-let-7c	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
1653	Human	hsa-let-7c	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
1654	Human	hsa-let-7c	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
1655	Human	hsa-let-7c	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
1656	Human	hsa-let-7c	miRNA	quercetin	pancreatic ductal adenocarcinoma (PDAC)	PDA cells	quercetin treatment	upregulated	27521217
1657	Human	hsa-let-7c	miRNA	lipoxins	premature ovarian failure (POF)	HK-2 cells	Lipoxins?treatment	upregulated	23520204
1658	Human	hsa-let-7c	miRNA	fulvestrant	progesterone production in rat granulosa cells	H1975 NSCLC cells	Fulvestrant treatment	let-7c plays an important role in fulvestrant-induced upregulation of gefitinib sensitivity in H1975 cells	24268810
1659	Human	hsa-let-7c	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
1660	Human	hsa-let-7c	miRNA	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á)	renal fibrosis	HK-2 cell lines	peroxisome proliferator-activated receptor ¦Ã coactivator-1¦Á (PGC-1¦Á) overexpression treatment	upregulated	31614978
1661	Human	hsa-let-7c	miRNA	arsenite	tumorigenesis of arsenite	human keratinocyte HaCaT cells	arsenic exposure	downregulated	24704393
1662	Human	hsa-let-7c-3p	miRNA	H2O2	age-related cataract (ARC)	Human lens epithelial cells (LECs)	H2O2 treatment	the expression of let-7c-3p was also lower under oxidative stress.	32258130
1663	Human	hsa-let-7c-3p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
1664	Human	hsa-let-7c-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
1665	Human	hsa-let-7c-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
1666	Human	hsa-let-7c-5p	miRNA	olive oil polyphenol hydroxytyrosol (HT)	inflammation	TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	olive oil polyphenol hydroxytyrosol (HT) treatment	upregulated	31627295
1667	Human	hsa-let-7c-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31627295
1668	Human	hsa-let-7c-5p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	upregulated	31176168
1669	Human	hsa-let-7c-5p	miRNA	oleacein (OA)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleacein (OA) treatment	upregulated	31766503
1670	Human	hsa-let-7c-5p	miRNA	oleocanthal (OC)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleocanthal (OC) treatment	upregulated	31766503
1671	Human	hsa-let-7c-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31766503
1672	Human	hsa-let-7c-5p	miRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp cells (HDPCs)	lipopolysaccharide (LPS) treatment	LPS exposure upregulated the expression of NUTM2A-AS1 and High-Mobility Group Box 1 (HMGB1) and downregulated the level of let-7c-5p.	33831808
1673	Human	hsa-let-7d	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1674	Human	hsa-let-7d	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
1675	Human	hsa-let-7d	miRNA	platelet-derived growth factor (PDGF)	glioblastoma and ovarian cancer	U118-MG cells£»U87-MG glioblastoma cells£» human WI-38 fibroblasts?£» ovarian cells C272/hTert/E7	Platelet derived growth factor (PDGF)? treatment	downregulated	21266476
1676	Human	hsa-let-7d	miRNA	ficus carica	glioblastoma multiforme (GBM)	"T98G, U-138 MG, and U-87 MG human GBM cell lines"	ficus carica treatment	upregulated	25212824
1677	Human	hsa-let-7d	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
1678	Human	hsa-let-7d	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
1679	Human	hsa-let-7d	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
1680	Human	hsa-let-7d	miRNA	diesel exhaust particle (DEP)	pulmonary inflammatory response	16HBE and Beas-2B cells	diesel exhaust particle (DEP) exposure	downregulated	30172002
1681	Human	hsa-let-7d	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
1682	Human	hsa-let-7d-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
1683	Human	hsa-let-7d-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
1684	Human	hsa-let-7d-5p	miRNA	house dust mite (HDM)	lung fibrosis	serum	dust exposure	upregulated	30090591
1685	Human	hsa-let-7e	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
1686	Human	hsa-let-7e	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
1687	Human	hsa-let-7e	miRNA	olive leaf extract (OLE)	atherosclerosis (AS)	Serum amyloid A (SAA)-induced human coronary artery endothelial cells (HCAEC)	Olive leaf extract (OLE) treatment	downregulated	31157238
1688	Human	hsa-let-7e	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28195197
1689	Human	hsa-let-7e	miRNA	serum amyloid A (SAA)	atherosclerosis (AS)	human coronary artery endothelial cells (HCAEC)	Serum amyloid A (SAA) treatment	upregulated	31157238
1690	Human	hsa-let-7e	miRNA	cisplatin (DDP)	breast cancer	Human umbilical vein endothelial cells (HUVECs)	cisplatin (DPP) treatment	downregulated	30670152
1691	Human	hsa-let-7e	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1692	Human	hsa-let-7e	miRNA	D-glucose	epithelial-mesenchymal transition (EMT)	peritoneal mesothelial cells (PMCs)	D-glucose treatment	downregulated	25683944
1693	Human	hsa-let-7e	miRNA	IL-1¦Â	inflammatory response	monocytes	IL-1¦Â treatment	upregulated	30245693
1694	Human	hsa-let-7e	miRNA	lipopolysaccharide (LPS)	inflammatory response	monocytes	lipopolysaccharide (LPS) treatment	upregulated	30245693
1695	Human	hsa-let-7e	miRNA	TLR2 agonist pam3CSK4	inflammatory response	monocytes	TLR2 agonist pam3CSK4 treatment	upregulated	30245693
1696	Human	hsa-let-7e	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
1697	Human	hsa-let-7e	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
1698	Human	hsa-let-7e	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
1699	Human	hsa-let-7e	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
1700	Human	hsa-let-7e	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
1701	Human	hsa-let-7e-5p	miRNA	insulin and high glucose (HG)	insulin resistance (IR)	HepG2 cells	insulin and high glucose treatment	upregulated	32710190
1702	Human	hsa-let-7f	miRNA	antidiabetic	glycemic control	ment-na?ve diabetic patients with poor metabolic control	12 months of antidiabetic treatment	upregulated	24937531
1703	Human	hsa-let-7f	miRNA	¦Â 2-Adrenergic receptors (¦Â 2ARs)	asthma	human airway smooth muscle (HASM) cells	¦Â 2-Adrenergic receptors (¦Â 2ARs) treatment	"In cultured HASM cells from nonasthmatic and asthmatic lungs, 18 h of ¦Â-agonist exposure increased let-7f by 2-3-fold"	29455573
1704	Human	hsa-let-7f	miRNA	aromatase inhibitors (AIs)	breast cancer	MCF-7; SK-BR-3 cells	Aromatase inhibitors (AIs) treatment	upregulated	22407818
1705	Human	hsa-let-7f	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1706	Human	hsa-let-7f	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
1707	Human	hsa-let-7f	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
1708	Human	hsa-let-7f	miRNA	TLR9 and RIG-I	immune tolerance	Endocervical cells (End1/E6E7)	ligands of TLR9 and RIG-I once or after pre-stimulation with same ligand treatment	"Stimulation with TLR9 downregulated let-7f , RIG-I stimulation upregulated let-7f"	24405266
1709	Human	hsa-let-7f	miRNA	ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE)	metastasized melanoma	A376 melanoma cells	SLE treatment	upregulated	31514083
1710	Human	hsa-let-7f	miRNA	cigarette smoke extract (CSE)	neovascularization	HUVECs	cigarette smoke extracts (CSE) exposure	downregulated	28345812
1711	Human	hsa-let-7f	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	downregulated	20110569
1712	Human	hsa-let-7f-1	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
1713	Human	hsa-let-7f-1	miRNA	lycopene	prostate cancer	Human prostate carcinoma cells PC3	lycopene treatment	upregulated	26847233
1714	Human	hsa-let-7f-1-3p	miRNA	smoking	smoke-induced lung injury (SILI)	Human small airway epithelial cells (HSAEC) and human pulmonary alveolar epithelial cells (HPAEpiC)	Smoke was generated by heating 500 mg of degreasing cotton at about 400 ¡ãC for 15 min in a tube furnace with air stream of 1L/min for combustion in a non-flaming fashion and 10 L/min for dilution treatment	downregulated	31301310
1715	Human	hsa-let-7f-2	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
1716	Human	hsa-let-7f-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	downregulated	30503955
1717	Human	hsa-let-7f-5p	miRNA	adriamycin (ADR)	leukemia	K562 cells	adriamycin (ADR) treatment	downregulated	31793054
1718	Human	hsa-let-7f-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
1719	Human	hsa-let-7f-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells; WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	33300070
1720	Human	hsa-let-7f-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells; WI-38 cells	lipopolysaccharide (LPS) treatment	let-7f-5p expression levels was significantly decreased in lipopolysaccharide (LPS) induced A549 and WI-38 cells.	33300070
1721	Human	hsa-let-7g	miRNA	disulfiram (DSF)	atypical teratoid/rhabdoid tumors (AT/RT)	human ALDH(+) AT/RT cells	DSF treatment	upregulated	25378634
1722	Human	hsa-let-7g	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1723	Human	hsa-let-7g	miRNA	hepatitis B X-interacting protein (HBXIP)	breast cancer	MCF-7 cells	hepatitis B X-interacting protein (HBXIP) treatment	downregulated	29174803
1724	Human	hsa-let-7g	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
1725	Human	hsa-let-7g	miRNA	angiotensin II (Ang II)	endothelial senescence	Human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	downregulated	29393358
1726	Human	hsa-let-7g	miRNA	aspirin	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 cell lines	aspirin treatment	upregulated	31278071
1727	Human	hsa-let-7g	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
1728	Human	hsa-let-7g	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
1729	Human	hsa-let-7g	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
1730	Human	hsa-let-7g	miRNA	kallistatin	oxidative stress	human umbilical vein endothelial cells (HUVECs)	Kallistatin treatment	upregulated	29992759
1731	Human	hsa-let-7g	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
1732	Human	hsa-let-7g	miRNA	diesel exhaust particle (DEP)	pulmonary inflammatory response	16HBE and Beas-2B cells	diesel exhaust particle (DEP) exposure	downregulated	30172002
1733	Human	hsa-let-7g	miRNA	IFN-¦Á	cell senescence	HeLa cells	24-h of IFN¦Á treatment	downregulated	24942926
1734	Human	hsa-let-7g	miRNA	lipopolysaccharide (LPS)	sepsis	Neonatal Polymorphonuclear Leukocytes	lipopolysaccharide (LPS) treatment	dysregulated	28655995
1735	Human	hsa-let-7g-5p	miRNA	mitogen activated-protein kinase pathway inhibitors (MAPKis)	cutaneous malignant melanoma (CMM)	extracellular microvesicle in matched plasma	Mitogen activated-protein kinase pathway inhibitors (MAPKis) treatment	upregulated	30399176
1736	Human	hsa-let-7g-5p	miRNA	verbascoside (VB)	glioblastoma multiforme (GBM)	A172 cells; SHG139 cells; SHG-44 cells; U87 cells; U251 cells	verbascoside (VB) treatment	let-7g-5p expression was upregulated upon VB treatment	32000296
1737	Human	hsa-let-7g-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
1738	Human	hsa-let-7i	miRNA	recombinant tissue plasminogen activator (rt-PA)	acute ischemic stroke (AIS)	AIS patients blood samples	rt-PA treatment	upregulation of let-7i and downregulated of miR-15a	28892656
1739	Human	hsa-let-7i	miRNA	propofol (PPF)	anti-cancer therapy	human EOC cells	expression in OVCAR-3 with or without propofol treatment	upregulated	25556276
1740	Human	hsa-let-7i	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1741	Human	hsa-let-7i	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
1742	Human	hsa-let-7i	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-let-7i was downregulated in resistant patients when compared with sensitive patients	33072545
1743	Human	hsa-let-7i	miRNA	propofol (PPF)	colorectal cancer (CRC)	Colo205; SW620 cells	"Propofol (2,6-diisopropylphenol) treatment"	Propofol suppresses colorectal cancer tumorigenesis by modulating the HOXA11-AS-let-7i-ABCC10 regulatory network	31013434
1744	Human	hsa-let-7i	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
1745	Human	hsa-let-7i	miRNA	oxygen glucose deprivation (OGD)	inflammation	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation (OGD) treatment	downregulated	28844675
1746	Human	hsa-let-7i	miRNA	cryptosporidium parvum	innate immune response	H69 cells	cryptosporidium parvum? infection	downregulated	24862934
1747	Human	hsa-let-7i	miRNA	oxygen glucose deprivation (OGD)	post-stroke cognitive impairment (PSCI)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	MicroRNA Let-7i Is a Promising Serum Biomarker for Post-stroke Cognitive Impairment and Alleviated OGD-Induced Cell Damage in vitro by Regulating Bcl-2	32265630
1748	Human	hsa-let-7i	miRNA	IFN-¦Á	cell senescence	HeLa cells	24-h of IFN¦Á treatment	downregulated	24942926
1749	Human	hsa-let-7i-3p	miRNA	melatonin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	melatonin treatment	melatonin treatment markedly induced the expression of the miRNA let7i-3p in cells.	30201903
1750	Human	hsa-let-7i-3p	miRNA	cyclic mechanical stretch (CMS)	osteogenesis	human adipose-derived stem cells (hASCs)	cyclic strain induce	downregulated	31753039
1751	Human	hsa-let-7i-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
1752	Human	hsa-let-7i-5p	miRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	downregulated	32926961
1753	Human	hsa-let-7i-5p	miRNA	silica	pneumoconiosis	THP-1 cells	silica treatment	downregulated	29516679
1754	Human	hsa-let-7i-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
1755	Human	hsa-miR-1	miRNA	coronary artery bypass graft (CABG)	acute coronary syndrome (ACS)	acute coronary syndrome patients heart	CABG treatment	upregulated	29506853
1756	Human	hsa-miR-1	miRNA	myocardin	andes hantavirus (ANDV) infection	human smooth muscle cells (SMCs)	myocardin treatment	myocardin was reported to induce the expression of microRNA-1 (miR-1) in cardiomyocytes.miR-1 participates in myocardin-dependent of SMC proliferation inhibition.	21051663
1757	Human	hsa-miR-1	miRNA	IL-13	asthma	human lung endothelium	IL-13 treatment	IL-13 stimulation decreased miR-1 levels in human lung endothelium.	32035607
1758	Human	hsa-miR-1	miRNA	IFN-¦Â	autophagy	HeLa cells	IFN-¦Â treatment	upregulated	31799933
1759	Human	hsa-miR-1	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
1760	Human	hsa-miR-1	miRNA	angiotensin-converting enzyme 2 (ACE2) inhibitor	cardiovascular disease (CVD)	H9c2 cardiac myoblast cells	ACE2 (angiotensin-converting enzyme 2) treatment	upregulated	26400542
1761	Human	hsa-miR-1	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
1762	Human	hsa-miR-1	miRNA	bortezomib	congenital muscular dystrophy	congenital muscular dystrophy type 1A muscle cells	bortezomib? treatment	downregulated	24631023
1763	Human	hsa-miR-1	miRNA	myocardin	contractility of  vascular smooth muscle cells	human aortic SMCs	myocardin treatment	upregulated	20458751
1764	Human	hsa-miR-1	miRNA	glucose	diabetes mellitus (DM)	human retinal microvascular endothelial cells	25mM glucose treatment	downregulated	24394957
1765	Human	hsa-miR-1	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	"LN15, LN18, LN229, U138, U87, U251 cell lines"	TGF-¦Â treatment	downregulated	25256711
1766	Human	hsa-miR-1	miRNA	carvedilol	heart failure (HF)	serum	carvedilol treatment	upregulated	32943906
1767	Human	hsa-miR-1	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells	sorafenib treatment	downregulated	32560747
1768	Human	hsa-miR-1	miRNA	oxidized low density lipoprotein (ox-LDL)	hyperlipidemia	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	24792518
1769	Human	hsa-miR-1	miRNA	multiwalled carbon nanotubes (MWCNT)	liver fibrosis	A549 cells	MWCNT (20 or 50 ?g/mL) for 6 or 24 h	downregulated after 6 or 24 h of treatment regardless of the dose	28128526
1770	Human	hsa-miR-1	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	upregulated	29899866
1771	Human	hsa-miR-1	miRNA	active pterocarpanquinone LQB-118 	active pterocarpanquinone LQB-118 cytotoxicity	"PC3, LNCaP, and LAPC4 PCa cells"	LQB-118	downregulated	29105806
1772	Human	hsa-miR-1	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	downregulated	19748927
1773	Human	hsa-miR-1	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
1774	Human	hsa-miR-1	miRNA	(-)-epigallocatechin gallate (EGCG)	osteosarcoma (OS)	MG-63 and U-2OS	(-)-Epigallocatechin gallate (EGCG) treatment	upregulated	26499783
1775	Human	hsa-miR-1	miRNA	prednisolone	polymyositis (PM)	serum	prednisolone (PSL) treatment	the serum miR-1 level is significantly reduced by treatment	31483179
1776	Human	hsa-miR-1	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	29167124
1777	Human	hsa-miR-1	miRNA	H2O2	sepsis	A549 cell line and HKC cell line	H2O2 treatment	upregulated	28673002
1778	Human	hsa-miR-1	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1779	Human	hsa-miR-1	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
1780	Human	hsa-miR-100	miRNA	"androgen receptor (AR) agonist, CI-4AS-1"	breast cancer	luminal MCF-7 and T47D cells and the molecular apocrine MDA-MB-453 cells.	CI-4AS-1 treatment	downregulated	28816390
1781	Human	hsa-miR-100	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
1782	Human	hsa-miR-100	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-100 was upregulated in resistant patients when compared with sensitive patients	33072545
1783	Human	hsa-miR-100	miRNA	arsenic trioxide (ATO)	epithelial-mesenchymal transition (EMT)	BEAS-2B cells	arsenic trioxide (As2O3) treatment	downregulated	28956730
1784	Human	hsa-miR-100	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
1785	Human	hsa-miR-100	miRNA	docetaxel (DTX)	head and neck squamous cell carcinoma (HNSCC)	UMSCC-1 cells;SQ20B cells	docetaxel (DTX) treatment	downregulated	21560177
1786	Human	hsa-miR-100	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
1787	Human	hsa-miR-100	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG-63 cells	cisplatin (DPP) treatment	downregulated	30280766
1788	Human	hsa-miR-100	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
1789	Human	hsa-miR-100	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cell	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	31298038
1790	Human	hsa-miR-100	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38?cells	lipopolysaccharide (LPS) treatment	downregulated	29673591
1791	Human	hsa-miR-100	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	prostate cancer	?primary prostatic epithelial cells (PrE)	"?1,25-dihydroxyvitamin D"	downregulated	23503652
1792	Human	hsa-miR-100	miRNA	mifepristone (MIF)	prostate cancer	prostate cells	Mifepristone treatment	upregulated	27340920
1793	Human	hsa-miR-100	miRNA	iodine-131 (131I)	thyroid cancer (TC)	A follicular thyroid carcinoma cell line (FTC-133)	I131 treatment	downregulated	24785011
1794	Human	hsa-miR-100*	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
1795	Human	hsa-miR-100-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
1796	Human	hsa-miR-100-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	downregulated	33194074
1797	Human	hsa-miR-100-5p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells; Hep3B cells; HepG2 cells	hypoxia treatment	The expression of miR-100-5p expression was significantly suppressed in HCC cell lines under 1% O2-induced hypoxia.	32152275
1798	Human	hsa-miR-100-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
1799	Human	hsa-miR-100-5p	miRNA	rapamycin	osteoarthritis (OA)	Chondrocytes	Rapamycin treatment	upregulated	31358056
1800	Human	hsa-miR-101	miRNA	hypoxia	angiogenesis	HUVECs	2¡À1% O2 treatment	upregulated	24844779
1801	Human	hsa-miR-101	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	apoptosis 	breast cancer cells	HIF1¦Á treatment	upregulated	26841847
1802	Human	hsa-miR-101	miRNA	H2O2	apoptosis	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	upregulated	33226571
1803	Human	hsa-miR-101	miRNA	melatonin	apoptosis	H2O2 treated human umbilical vein endothelial cells (HUVECs)	melatonin treatment	downregulated	33226571
1804	Human	hsa-miR-101	miRNA	lipopolysaccharide (LPS)	autophagy	intestinal epithelial cell line Caco-2	lipopolysaccharide (LPS) treatment	downregulated	31185236
1805	Human	hsa-miR-101	miRNA	octreotide (OCT)	autophagy	LPS-treated Caco-2 cells	Octreotide (OCT) treatment	upregulated	31185236
1806	Human	hsa-miR-101	miRNA	gambogic acid (GA) and methyl jasmonate (MJ)	bladder cancer	human bladder cancer cells	GA and MJ treatment	upregulated	24490857
1807	Human	hsa-miR-101	miRNA	histone deacetylase inhibitor (HDACi)	burkitt lymphoma (BL)	Raji B-cell lymphoma	HDACi treatment	upregulated	24577510
1808	Human	hsa-miR-101	miRNA	cadmium (Cd)	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	cadmium (Cd) treatment	CdCl2-induced abnormal angiogenesis is mediated by miR-101/COX-2/VEGF-axis-dependent ER stress.	32783891
1809	Human	hsa-miR-101	miRNA	Sphingosine-1-phosphate (S1P)	chondrosarcoma	human chondrosarcoma cells	S1P treatment	downregulated	28672103
1810	Human	hsa-miR-101	miRNA	hypoxia	clear cell renal cell carcinoma (ccRCC)	ACHN and HK-2 cells	hypoxia treatment	upregulated	28138701
1811	Human	hsa-miR-101	miRNA	jasmonate	colorectal cancer (CRC)	SW620 human colorectal cancer cells	jasmonate treatment	"Compared with control, the anticancer effect of methyl jasmonate inhibited Enhancer of zeste homolog 2 (EZH2) protein expression and activated microRNA (miR)-101 expression in SW620 cells."	28000868
1812	Human	hsa-miR-101	miRNA	methyl jasmonate (MeJA)	colorectal cancer (CRC)	SW620 human colorectal cancer cells	"were treated with 0, 0.5, 0.75, 1.5 and 2.0 mM methyl jasmonate for 12, 24 and 48 h"	upregulated	28000868
1813	Human	hsa-miR-101	miRNA	etoposide (VP-16)	DNA damage	MCF7 cells	1 ?M/5 ?M etoposide treatment	upregulated	25353636
1814	Human	hsa-miR-101	miRNA	melatonin	apoptosis	human umbilical vein endothelial cells (HUVECs)	Melatonin treatment	Melatonin upregulates DNA-PKcs to suppress apoptosis of human umbilical vein endothelial cells via inhibiting miR-101 under H 2 O 2-induced oxidative stress	33226571
1815	Human	hsa-miR-101	miRNA	nicotine	epithelial-mesenchymal transition (EMT)	"head and neck squamous cell carcinoma cell lines, UMSCC-10B and HN-1"	nicotine treatment	downregulated	23300583
1816	Human	hsa-miR-101	miRNA	cyclooxygenase-2 (COX-2)	gastric cancer (GC)	Human gastric cancer cell lines SGC-7901; BGC-823;matched normal tissue	Cyclooxygenase-2 (COX-2)? treatment	downregulated	23013439
1817	Human	hsa-miR-101	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	Expression of miR-101 largely decreased in U-251/ TMZ compared with the parental cell	29479863
1818	Human	hsa-miR-101	miRNA	Sinomenine (SIN)	glucocorticoids dermatitis	HaCaT cells	Sinomenine (SIN) treatment	downregulated	29501764
1819	Human	hsa-miR-101	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	downregulated	28797462
1820	Human	hsa-miR-101	miRNA	apigenin	hepatocellular carcinoma (HCC)	doxorubicin-resistant hepatocellular carcinoma cell line BEL-7402/ADM	apicidin treatment	upregulated	29137246
1821	Human	hsa-miR-101	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	human liver cancer cells (HepG2)	cisplatin (DDP) treatment	"Cell proliferation, apoptosis, intracellular reactive oxygen species and comet assay results indicated that the upregulation of miR-101 sensitized HepG2 cells to CDDP, and downregulated of miR-101 reduced chemosensitivity."	31516578
1822	Human	hsa-miR-101	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
1823	Human	hsa-miR-101	miRNA	lipopolysaccharide (LPS)	inflammation	pancreatic ¦Â cell Min6	lipopolysaccharide (LPS) treatment	upregulated	31213095
1824	Human	hsa-miR-101	miRNA	tetramethylpyrazine (TMP)	inflammation	LPS-treated pancreatic ¦Â cell Min6	Tetramethylpyrazine (TMP) treatment	downregulated	31213095
1825	Human	hsa-miR-101	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
1826	Human	hsa-miR-101	miRNA	octreotide (OCT)	intestinal mucositis	Caco-2 cells	octreotide (OCT) treatment	OCT affected autophagy through up-regulating miR-101 in LPS-treated cells.	30205395
1827	Human	hsa-miR-101	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	HSCs	carbon tetrachloride (CCl4) treatment	downregulated	24817606
1828	Human	hsa-miR-101	miRNA	active pterocarpanquinone LQB-118 	active pterocarpanquinone LQB-118 cytotoxicity	"PC3, LNCaP, and LAPC4 PCa cells"	LQB-118	downregulated	29105806
1829	Human	hsa-miR-101	miRNA	IL-1¦Â	lung cancer	lung	IL-1¦Â treatment	the interleukin 1 receptor antagonist and interleukin-1¦Â antibody can reduce silica particle-induced downregulated of mir-101	25428391
1830	Human	hsa-miR-101	miRNA	silica particle	lung cancer	Xuan Wei lung cancer cell line	silica particle treatment	downregulated	25428391
1831	Human	hsa-miR-101	miRNA	curcumin (Cur)	multiple myeloma (MM)	MM cell lines RPMI8226 and U266	curcumin treatment	upregulated	28322158
1832	Human	hsa-miR-101	miRNA	IL-1¦Â	osteoarthritis (OA)	primary OA chondrocytes	IL-1¦Â treatment	"LINC00623/miR-101/HRAS axis modulates OA chondrocyte apoptosis, senescence and ECM degradation through MAPK signaling"	32062610
1833	Human	hsa-miR-101	miRNA	zoledronic acid (ZA)	osteoporosis	serum	ZOL treatment	"?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment"	33637048
1834	Human	hsa-miR-101	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
1835	Human	hsa-miR-101	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
1836	Human	hsa-miR-101	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
1837	Human	hsa-miR-101	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	parkinson's disease (PD)	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
1838	Human	hsa-miR-101	miRNA	sunitinib (SU)	renal cell carcinoma (RCC)	RCC cells	sunitinib treatment	downregulated	27487138
1839	Human	hsa-miR-101	miRNA	ultraviolet (UV) irradiation	skin senescence	skin fibroblasts	UVB treatment	microRNA-mRNA functional interactions in UVB-induced senescence of human diploid fibroblasts	23557329
1840	Human	hsa-miR-101	miRNA	TPA (12-O-tetradecanoylphorbol 13-acetate)	hepatocellular carcinoma (HCC)	HepG2 cells	TPA (12-O-tetradecanoylphorbol 13-acetate) treatment	"TPA not only upregulated miR-101 expression, but also reduced protein level of EZH2, EED and H3K27me3 in HepG2 cells"	20444294
1841	Human	hsa-miR-101-3p	miRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	thyroid papillary cell line TPC-1 (BNCC337912) and B-CPAP (BNCC338685)	131I treatment	NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo.	30596336
1842	Human	hsa-miR-101-3p	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	autophagy	human HTR-8/SVneo (HTR) cells	Titanium dioxide nanoparticles (TiO2 NPs) treatment	upregulated	30345998
1843	Human	hsa-miR-101-3p	miRNA	cisplatin (DDP)	bladder cancer	The 5637 and EJ-M3 cells	cisplatin treatment	MALAT1 affected the cisplatin resistance of the BC cells via regulating the miR-101-3p/VEGF-C pathway.	31650173
1844	Human	hsa-miR-101-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
1845	Human	hsa-miR-101-3p	miRNA	serum deprivation	endothelial cell death associated with vascular disorders	HUVECs	serum deprivation treatment	downregulated	28518140
1846	Human	hsa-miR-101-3p	miRNA	cigarette smoke extract (CSE)	esophageal squamous cell carcinoma (ESCC)	human immortalized non-tumorigenic esophageal epithelial cell line (Het-1A)	cigarette smoking extract (CSE) treatment	downregulated	26530100
1847	Human	hsa-miR-101-3p	miRNA	cigarette smoke extract (CSE)	esophageal squamous cell carcinoma (ESCC)	Eca109 cancer cells	cigarette smoking extract (CSE) treatment	downregulated	26530100
1848	Human	hsa-miR-101-3p	miRNA	bupivacaine	neurotoxicity	Primary dorsal root ganglion (DRG) neurons	bupivacaine treatment	miR-101-3p was decreased with increasing concentrations of bupivacaine exposure.	31254586
1849	Human	hsa-miR-101-3p	miRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	SH-SY5Y cells	abnormal accumulation of ¦Á-Syn treatment	Overexpressed lncRNA-T199678 significantly downregulated the expression in SH-SY5Y cells	33328976
1850	Human	hsa-miR-101-3p	miRNA	docetaxel (DTX)	prostate cancer	LNCaP and CWR22Rv1 cells	docetaxel (DTX) treatment	downregulated	30621625
1851	Human	hsa-miR-101-3p	miRNA	Treponema pallidum (Tp)	treponema pallidum (Tp) infection	THP-1 cells	Treponema pallidum (Tp) infection treatment	Stimulation of THP-1 cells with Tp increased miR-101-3p expression	31930972
1852	Human	hsa-miR-101a	miRNA	cyclooxygenase-2 (COX-2)	bladder cancer	human bladder cancer cells	COX-2 treatment	downregulated	25109742
1853	Human	hsa-miR-101a-3p	miRNA	osthole	Alzheimer's disease (AD)	SH-SY5Y cells	osthole treatment	"osthole had a protective effect on APP-SH-SY5Y cells, and it could raise miRNA-101a-3p expression and inhibit APP mRNA/protein expression, the formation of A¦Â protein was inhibited too."	30951743
1854	Human	hsa-miR-101a-3p	miRNA	osthole	Alzheimer's disease (AD)	SH-SY5Y cells	osthole treatment	Osthole inhibits the expression of APP by up-regulating miR-101a-3p in AD cell model.	30693688
1855	Human	hsa-miR-103	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
1856	Human	hsa-miR-103	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	K562 cells	adriamycin (ADR) treatment	upregulated	29058777
1857	Human	hsa-miR-103	miRNA	tetrabromobisphenol-A (TBBPA)	adipogenesis	human adipose-derived primary MSCs	TBBPA treatment	upregulated	28329833
1858	Human	hsa-miR-103	miRNA	human immunodeficiency virus (HIV)-1	antiviral immune response	monocyte-derived macrophage (MDM)	human immunodeficiency virus type 1 (HIV-1) treatment	upregulated	32994328
1859	Human	hsa-miR-103	miRNA	IL-1¦Â	antiviral immune response	monocyte-derived macrophage (MDM)	IL-1¦Â treatment	Treatment of MDMs with interleukin-1¦Â (IL-1¦Â) enhanced microRNA 103 expression.	32994328
1860	Human	hsa-miR-103	miRNA	glucocorticoid (GC)	apoptosis	"CEM-C7H2 , CUTLL, MOLT-4, Loucy, BJAB, SUD-H6 , DAUDI cell lines"	GC	upregulated	27888798
1861	Human	hsa-miR-103	miRNA	H2O2	atherosclerosis (AS)	human coronary artery endothelial cells	H2O2 treatment	"Under the stimulation of H 2O 2, the expression of miR-103 decreased."	32190178
1862	Human	hsa-miR-103	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31232476
1863	Human	hsa-miR-103	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 6¡ã HDT bed rest experiment	downregulated	28261104
1864	Human	hsa-miR-103	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1865	Human	hsa-miR-103	miRNA	H2O2	cardiovascular disease (CVD)	HUVEC	H2O2 treatment	downregulated	26000071
1866	Human	hsa-miR-103	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	The cisplatin-resistant Hep3B (Hep3B-R) and Huh7 (Huh7-R) cells	cisplatin treatment	"circRNA_101505 could sensitize HCC cells to cisplatin by sponging miR-103, and thereby promoting oxidored-nitro domain-containing protein 1 (NOR1) expression."	31372241
1867	Human	hsa-miR-103	miRNA	lipopolysaccharide (LPS)	inflammation	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31284776
1868	Human	hsa-miR-103	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	human umbilical vein endothelial cells (HUVECs)	oxygen-glucose deprivation (OGD) treatment	downregulated	29511499
1869	Human	hsa-miR-103	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30007440
1870	Human	hsa-miR-103	miRNA	morphine	morphine tolerance	"human embryonic kidney 293 (HEK293) cells, Be(3)C cells"	chronic morphine men treatment	upregulated	24302561
1871	Human	hsa-miR-103	miRNA	retinoic acid (RA)	nervous system cancers	SK-N-BE(2)-C £»SH SY5Y??cells?;SH-EP cells£» HEK 293T cells	retinoic acid treatment	upregulated	22848373
1872	Human	hsa-miR-103	miRNA	IL-1¦Â	osteoarthritis (OA)	Human primary chondrocyte	IL-1¦Â treatment	upregulated	31302420
1873	Human	hsa-miR-103	miRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	CD4 + cells from PTC patients	131?I treatment	downregulated	30267584
1874	Human	hsa-miR-103	miRNA	Shenmai injection (SMI)	papillary thyroid cancer (PTC)	CD4 + cells from PTC patients	131?I and Shenmai injection (SMI) dual treatment	upregulated	30267584
1875	Human	hsa-miR-103	miRNA	hypoxia	prostate cancer	colorectal cancer (CRC) cells	Hypoxia treatment	upregulated	22593189
1876	Human	hsa-miR-103	miRNA	hypoxia	retinal pigment epithelium (RPE) cells injuries	ARPE-19 human RPE cells	hypoxia treatment	hypoxia downregulated microRNA-103 (miR-103).	30144973
1877	Human	hsa-miR-103	miRNA	lipopolysaccharide (LPS)	sepsis	Monocytes	lipopolysaccharide (LPS) treatment	downregulated	32455124
1878	Human	hsa-miR-103-3p	miRNA	lipopolysaccharide (LPS)	liver fibrosis	THP-1 cells	lipopolysaccharide (LPS)	Exosomal miR-103-3p from LPS-activated THP-1 macrophage contributes to the activation of hepatic stellate cells.	32061112
1879	Human	hsa-miR-103-3p	miRNA	salidroside (SAL)	non small cell lung cancer (NSCLC)	A549 cells; H460 cells	salidroside (SAL) treatment	"Salidroside could inhibit the proliferation of nonsmall cell lung cancer (NSCLC) cells, and elevated the level of miR-103-3p"	32304408
1880	Human	hsa-miR-103a-2-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SKhep1 cells; Huh7 cells; LM3 cells	sorafenib treatment	downregulated	33222692
1881	Human	hsa-miR-103a-3p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
1882	Human	hsa-miR-103a-3p	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	gastric cancer (GC)	MGC-803 and MKN-45 cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	downregulated	31606381
1883	Human	hsa-miR-103a-3p	miRNA	hyperbaric oxygen (HBO)	hepatocellular carcinoma (HCC)	Hepatoma cell lines (BEL-7402 and SK-Hep1)	HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment	downregulated	24956259
1884	Human	hsa-miR-103a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
1885	Human	hsa-miR-103a-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
1886	Human	hsa-miR-103a-3p	miRNA	L-dopa	parkinson's disease (PD)	peripheral blood	L-dopa-treated treatment	the results suggest a role of L-dopa treatment in miR-103a-3p expression only	25596505
1887	Human	hsa-miR-103b	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
1888	Human	hsa-miR-103b	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
1889	Human	hsa-miR-103b	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
1890	Human	hsa-miR-103b	miRNA	fibroblast growth factor 2 (FGF2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fibroblast growth factor 2 (FGF2) treatment	downregulated	30414893
1891	Human	hsa-miR-103b	miRNA	TGF-¦Â	angiogenesis	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â treatment	downregulated	30414893
1892	Human	hsa-miR-103b	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	vascular endothelial cell growth factor (VEGF) treatment	downregulated	30414893
1893	Human	hsa-miR-105	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	"human colon epithelial cell line FHC and CRC cell lines including LS174T, LoVo, HT29, SW620, SW480, HCT116"	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29238068
1894	Human	hsa-miR-105	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	upregulated	32807750
1895	Human	hsa-miR-105	miRNA	fibroblast growth factor 2 (FGF2)	osteoarthritis (OA)	chondrocytes	Fibroblast growth factor 2 (FGF2) treatment	downregulated	27998273
1896	Human	hsa-miR-106	miRNA	baicalin (BAI)	bladder cancer	T24 cells	baicalin (BAI) treatment	downregulated	30257376
1897	Human	hsa-miR-106	miRNA	diet	obesity	Plasma	diet treatment	"Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss."	32439373
1898	Human	hsa-miR-106	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
1899	Human	hsa-miR-106	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	K562 cells	cisplatin (DPP) treatment	miR-106 and miR-150 were downregulated	20428827
1900	Human	hsa-miR-106	miRNA	high glucose (HG)	vascular endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	downregulated	30055307
1901	Human	hsa-miR-106?b-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
1902	Human	hsa-miR-106-5p	miRNA	H2O2	cell senescence	multipotent stromal cells	H2O2 treatment	downregulated	32174776
1903	Human	hsa-miR-106a	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
1904	Human	hsa-miR-106a	miRNA	lipopolysaccharide (LPS)	breast cancer	HeLa cells	lipopolysaccharide (LPS) treatment	the expression of miR-17-3p and miR-106a is regulated by  LPS in HeLa cells	21370248
1905	Human	hsa-miR-106a	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	malignant human bronchial epithelial cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide treatment"	upregulated	20889678
1906	Human	hsa-miR-106a	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells; HT-29 cells	oxaliplatin (OXA) treatment	upregulated	31897182
1907	Human	hsa-miR-106a	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 and HT-29 CELLS	oxaliplatin treatment	"Elevation of miR-106a and a decrease of FOXQ1 expression levels were detected in tumor tissues from patients with oxaliplatin-sensitive colorectal cancer, compared with patients with oxaliplatin-resistant colorectal cancer"	31897182
1908	Human	hsa-miR-106a	miRNA	5-fluorouracil (5-Fu)	diabetic nephropathy (DN)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
1909	Human	hsa-miR-106a	miRNA	platelet-derived growth factor-D (PDGF-D)	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 cells	platelet-derived growth factor-D (PDGF-D) treatment	downregulated	25760076
1910	Human	hsa-miR-106a	miRNA	TGF-¦Â	inflammatory bowel disease (IBD)	Jurkat T cells	TGF-¦Â treatment	downregulated	30327532
1911	Human	hsa-miR-106a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Jurkat T cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30327532
1912	Human	hsa-miR-106a	miRNA	Src-TKIs (saracatinib or dasatinib)	lung cancer	"A549, H460, and H1299 NSCLC cells"	Src-TKIs treatment	downregulated	27372519
1913	Human	hsa-miR-106a	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
1914	Human	hsa-miR-106a	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells	lipopolysaccharide (LPS) treatment	upregulated	23562609
1915	Human	hsa-miR-106a	miRNA	5-fluorouracil (5-Fu)	metastatic colorectal cancer (mCRC)	mCRC patients	5-fluorouracil (5-FU) treatment	upregulated	24119443
1916	Human	hsa-miR-106a	miRNA	IL-6	ovarian cancer (OC)	SKOV3 and OVCAR3 cell lines	IL-6 treatment	downregulated	275100942
1917	Human	hsa-miR-106a	miRNA	radiation	prostate cancer	PC3 cells; DU145 cells	radiation treatment	upregulated	29191361
1918	Human	hsa-miR-106a	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
1919	Human	hsa-miR-106a-363	miRNA	estrogen receptor-¦Á	breast cancer	breast cancer cells	The estrogen receptor-¦Á treatment	upregulated	19706389
1920	Human	hsa-miR-106a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	miR-106a-3p was increased in exosomes from ox-LDL induced THP-1.	32633398
1921	Human	hsa-miR-106a-5p	miRNA	melatonin	intervertebral disc degeneration (IDD)	human annulus fibrosus (AF)	melatonin treatment	downregulated	30992660
1922	Human	hsa-miR-106a-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
1923	Human	hsa-miR-106a-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	MGC-803 cells	5-fluorouracil (5-FU) treatment	upregulated	31115533
1924	Human	hsa-miR-106a-5p	miRNA	cryptotanshinone	osteoarthritis (OA)	priamry cultured chondrocytes	Cryptotanshinone (CTS) treatment	upregulated	29858052
1925	Human	hsa-miR-106a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	31894109
1926	Human	hsa-miR-106b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32130290
1927	Human	hsa-miR-106b	miRNA	prolactin and estradiol	breast cancer	"human breast cancer cell lines, T47D and MCF-7, the human prostate cancer cell line, PC3, and human ovarian cancer cell lines, TOV-112D, OV-90 and TOV-21G"	prolactin and estradiol treatment	upregulated	28422740
1928	Human	hsa-miR-106b	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells	docosahexaenoic acid (DHA) fatty acids treatment	MDA-MB-231 cells with DHA caused a decrease in the miR-106b expression.	31713924
1929	Human	hsa-miR-106b	miRNA	TGF-¦Â	breast cancer	"MDA-MB-231, MCF-7 and MCF-10A cell lines"	TGF-¦Â treatment	upregulated	24292682
1930	Human	hsa-miR-106b	miRNA	radiation	cervical cancer (CC)	SiHa cells	radiation treatment	miR-106b expression was highly expressed in the radio-resistant SiHa cells	30579899
1931	Human	hsa-miR-106b	miRNA	X-rays	cervical cancer (CC)	CC tissues and cell lines (SiHa and ME180)	6 MV X-ray irradiation	upregulated	30579899
1932	Human	hsa-miR-106b	miRNA	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC)	chronic inflammatory diseases	human umbilical vein endothelial cells (HUVECs) exosomes	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment	upregulated	29161413
1933	Human	hsa-miR-106b	miRNA	butyrate	colorectal cancer (CRC)	HCT-116 cells	butyrate treatment	"Butyrate decreased HCT-116 proliferation, an effect reversed with the addition of the miR-106b mimic"	21283757
1934	Human	hsa-miR-106b	miRNA	shikonin	endometrial cancer (EC)	Ishikawa cells	Shikonin treatment	downregulated	29449346
1935	Human	hsa-miR-106b	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
1936	Human	hsa-miR-106b	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	gastric epithelial cells	lipopolysaccharide (LPS) treatment	downregulated	25307786
1937	Human	hsa-miR-106b	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	"human gastric epithelial cell lines, AGS and MKN45"	LPS from H. pylori 26695 treatment	downregulated	25307786
1938	Human	hsa-miR-106b	miRNA	shikonin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	Shikonin treatment	Shikonin suppresses cell progression and EMT and accelerates cell death of HCC cells via modulating miR-106b/SMAD7/TGF-¦Â signaling pathway	31617643
1939	Human	hsa-miR-106b	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
1940	Human	hsa-miR-106b	miRNA	TGF-¦Â	innate immune response	MDA-MB-231 cells; MCF-7 cells; MCF-10A cells	TGF-¦Â treatment	upregulated	24292682
1941	Human	hsa-miR-106b	miRNA	grape seed proanthocyanidins (GSPs)	lung cancer	"human NSCLC lines, A549 (Adenocarcinoma), H520 (squamous cell carcinoma), H1299 (Metastatic NSCLC), DMS114 (small cell lung cancer), H23 (adenocarcinoma)"	grape seed procyanidin extract (GSE) treatment	downregulated	29643994
1942	Human	hsa-miR-106b	miRNA	leucoselect phytosome (LP)	lung cancer	human lung tumor xenografts	leucoselect phytosome (LP) treatment	downregulated	29643994
1943	Human	hsa-miR-106b	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
1944	Human	hsa-miR-106b	miRNA	grape seed proanthocyanidins (GSPs)	melanoma	A375 and Hs294t cells	with GSPs treatment	downregulated	25361006
1945	Human	hsa-miR-106b	miRNA	H2O2	mitophagy	HeLa and HEK 293T cells	H2O2 treatment	"We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions."	33627622
1946	Human	hsa-miR-106b	miRNA	berberine (BBR)	multiple myeloma (MM)	"human multiple myeloma cell, RPMI-8266 and U266"	berberine (BBR) treatment	downregulated	27647143
1947	Human	hsa-miR-106b	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	cancer-associated fibroblasts (CAFs) and the exosomes derived from CAFs	Gemcitabine (GEM) treatment	upregulated	31374207
1948	Human	hsa-miR-106b	miRNA	hypoxia	prostate cancer	PCa cell lines (LNCaP£» PC3)£»neural crest (NC) cells	hypoxia treatment	downregulated	24135225
1949	Human	hsa-miR-106b	miRNA	hypoxia	prostate cancer	LNCaP cells	5% O2 treatment	upregulated	24135225
1950	Human	hsa-miR-106b	miRNA	salvianolic acid B (Sal B)	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	Sal B treatment	upregulated	25094038
1951	Human	hsa-miR-106b	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	TGF-¦Â1 treatment	downregulated	25094038
1952	Human	hsa-miR-106b	miRNA	toxoplasma gondii (T. gondii)	toxoplasma gondii infection	primary human foreskin fibroblasts (HFFs)	toxoplasma gondii (T. gondii) infection treatment	upregulated	20090903
1953	Human	hsa-miR-106b	miRNA	docosahexaenoic acid (DHA)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	Docosahexaenoic acid (DHA) treatment	downregulated	31713924
1954	Human	hsa-miR-106b	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
1955	Human	hsa-miR-106b-25	miRNA	natalizumab	B lymphocytic leukemia	whole blood  lymphocytes	natalizumab treatment	downregulated	22659298
1956	Human	hsa-miR-106b-25	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
1957	Human	hsa-miR-106b-3p	miRNA	matrine	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	matrine treatment	downregulated	29045804
1958	Human	hsa-miR-106b-3p	miRNA	BIX01294	lung cancer	human NSCLC cells	BIX01294 treatment	downregulated	24932239
1959	Human	hsa-miR-106b-5p	miRNA	TGF-¦Â1	asthma	human bronchial epithelial cells BEAS-2B	TGF-¦Â1 treatment	The present study revealed downregulated miR-106b-5p expression and upregulated SIX1 expression in asthmatic mice and TGF-¦Â1-induced BEAS-2B cells	33495833
1960	Human	hsa-miR-106b-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
1961	Human	hsa-miR-106b-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
1962	Human	hsa-miR-106b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	cardiac dysfunction	SH-SY5Y cells; HCN-2 cells	MPP+ (1-methyl-4-phenylpyridinium) treatment	Inhibition of miR-6862 induces SphK1 elevation and protects neuronal cells from MPP+-induced cell death.	33414358
1963	Human	hsa-miR-106b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-106b-5p expression was increased in OGD/R induced SH-SY5Y cells	32407850
1964	Human	hsa-miR-106b-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
1965	Human	hsa-miR-106b-5p	miRNA	magnesium-free extracellular fluid	temporal lobe epilepsy (TLE)	SK-N-SH cells; IMR-32 cells	magnesium-free extracellular solution	upregulated	33370579
1966	Human	hsa-miR-106b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
1967	Human	hsa-miR-106b-93-25	miRNA	trichostatin A (TSA)	inflammation	human endometrial cancer (EMC) cells	trichostatin (TSA)? treatment	downregulated	23028803
1968	Human	hsa-miR-107	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2£» PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
1969	Human	hsa-miR-107	miRNA	hyperbaric oxygen (HBO)	intervertebral disc degeneration (IDD)	nucleus pulposus cells (NPCs)	Hyperbaric oxygen (HBO) treatment	upregulated	30704538
1970	Human	hsa-miR-107	miRNA	tetrabromobisphenol-A (TBBPA)	adipogenesis	human adipose-derived primary MSCs	TBBPA treatment	upregulated	28329833
1971	Human	hsa-miR-107	miRNA	6-hydroxydopamine (6-OHDA)	Alzheimer's disease (AD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	31778666
1972	Human	hsa-miR-107	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y; SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	"NEAT1 expression was enhanced in A¦Â-treated SH-SY5Y and SK-N-SH cells, miR-107 abundance was reduced in A¦Â-treated cells, and its overexpression reversed A¦Â-induced injury. Moreover, interference of miR-107 abated silencing of NEAT1-mediated inhibition of neuronal damage in A¦Â-treated SH-SY5Y and SK-N-SH cells."	31250578
1973	Human	hsa-miR-107	miRNA	6-hydroxydopamine (6-OHDA)	Alzheimer's disease (AD)	SH-SY5Y Cells	6-hydroxydopamine (6-OHDA) treatment	6-OHDA suppressed miR-107 expression.	31778666
1974	Human	hsa-miR-107	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y; SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	SOX21-AS1 silencing could attenuate A¦Â1-42-induced neuronal damage by sponging miR-107	32124921
1975	Human	hsa-miR-107	miRNA	metformin (Met)	anti-cancer therapy	CD8 + T cells	Metformin treatment	downregulated	32221038
1976	Human	hsa-miR-107	miRNA	human immunodeficiency virus (HIV)-1	antiviral immune response	monocyte-derived macrophage (MDM)	human immunodeficiency virus type 1 (HIV-1) treatment	upregulated	32994328
1977	Human	hsa-miR-107	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs) and human umbilical vein smooth muscle cells (HUVSMCs)	lipopolysaccharide (LPS) treatment	"The expression of miR-107 was significantly decreased in the blood cells of patients with atherosclerosis compared with the controls. In addition, miR-107 mimics significantly inhibited the proliferation of HUVECs and HUVSMCs, compared with the control groups, at 48 and 72 h, which was in contrast to the observed effects of circRNA-0044073."	30864721
1978	Human	hsa-miR-107	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
1979	Human	hsa-miR-107	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
1980	Human	hsa-miR-107	miRNA	hypoxia	colorectal cancer (CRC)	Bone marrow mononuclear cells (BMMCs)	hypoxia treatment	MiR-107 expression were increased in EPCs under hypoxic conditions	22792280
1981	Human	hsa-miR-107	miRNA	dichloroacetate (DCA) and oxaliplatin (L-OHP)	colorectal cancer (CRC)	HCT-116 cells	dichloroacetate (DCA) and oxaliplatin (L-OHP) treatment	upregulated	31919406
1982	Human	hsa-miR-107	miRNA	Skullcapflavone I (SF I)	colorectal cancer (CRC)	HCT116 cells	Skullcapflavone I treatment	downregulated	30509103
1983	Human	hsa-miR-107	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma extracellular vesicle (EV)	doxorubicin (Dox) treatment	downregulated	32255536
1984	Human	hsa-miR-107	miRNA	rapamycin	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	downregulated	29579170
1985	Human	hsa-miR-107	miRNA	extract of Stellerachamaejasme L(ESC)	hepatocellular carcinoma (HCC)	HepG2 and MHCC97H cells	extract of Stellerachamaejasme L(ESC) treatment	upregulated	29554896
1986	Human	hsa-miR-107	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
1987	Human	hsa-miR-107	miRNA	ischemia/reperfusion (I/R) 	ischemic stroke (IS)	brain tissues	ischemia/reperfusion (I/R) treatment	upregulated in rat hippocampal cultures	24943094
1988	Human	hsa-miR-107	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30007440
1989	Human	hsa-miR-107	miRNA	cisplatin (DDP)	laryngeal squamous cell carcinoma (LSCC)	TU-177 cells; AMC-HN-8 cells	cisplatin treatment	H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo.	33314408
1990	Human	hsa-miR-107	miRNA	morphine	morphine tolerance	"human embryonic kidney 293 (HEK293) cells, Be(2)C cells"	chronic morphine men treatment	upregulated	24302561
1991	Human	hsa-miR-107	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
1992	Human	hsa-miR-107	miRNA	hyperbaric oxygen (HBO)	osteoarthritis (OA)	osteoarthritic (OA) chondrocytes	Hyperbaric oxygen (HBO) treatment	upregulated	31146014
1993	Human	hsa-miR-107	miRNA	dexamethasone (DEX)	oxidative stress	OB-6 human osteoblastic cells	dexamethasone (DEX) treatment	miR-107 inhibition upregulates CAB39 and activates AMPK-Nrf2 signaling to protect osteoblasts from dexamethasone-induced oxidative injury and cytotoxicity	32527986
1994	Human	hsa-miR-107	miRNA	hypoxia	prostate cancer	colorectal cancer (CRC) cells	Hypoxia treatment	upregulated	22593189
1995	Human	hsa-miR-107	miRNA	hypoxia	tumor angiogenesis	HCT116 cells	Hypoxia treatment	upregulated	20308559
1996	Human	hsa-miR-10a	miRNA	alcohol	alcohol stress	alcohol consumption in heavy drinkers	were allowed to drink up to 750 cc of beer? treatment	upregulated	25421511
1997	Human	hsa-miR-10a	miRNA	tamoxifen (TAM)	breast cancer	tumour samples of breast cancer	tamoxifen treatment	upregulated	23968733
1998	Human	hsa-miR-10a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	?SH-SY5Y cell	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30798122
1999	Human	hsa-miR-10a	miRNA	trametenolic acid B (TAB)	cerebral ischemia/reperfusion (I/R) injury	oxygen glucose deprivation/reoxygenation (OGD/R) induced?SH-SY5Y cell	Trametenolic acid B (TAB) treatment	downregulated	30798122
2000	Human	hsa-miR-10a	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
2001	Human	hsa-miR-10a	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-10a was upregulated in resistant patients when compared with sensitive patients	33072545
2002	Human	hsa-miR-10a	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma-derived exosomes (GDEs)	hypoxia treatment	The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN).	29713056
2003	Human	hsa-miR-10a	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	human glioma cell	transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	24100613
2004	Human	hsa-miR-10a	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
2005	Human	hsa-miR-10a	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
2006	Human	hsa-miR-10a	miRNA	infliximab	inflammatory bowel disease (IBD)	IBD patients	infliximab treatment	downregulated	25281418
2007	Human	hsa-miR-10a	miRNA	cisplatin (DDP)	lung cancer	A549 cells; H1299 cells	cisplatin treatment	CTCs treated with cisplatin demonstrated higher miR-10a expression and lower PIK3CA expression than that in A549 and H1299 cells.	32186774
2008	Human	hsa-miR-10a	miRNA	icariin (ICA)	lung cancer	A549 cells	Icaritin treatment	downregulated	31829310
2009	Human	hsa-miR-10a	miRNA	retinoic acid (RA)	neuroblastoma (NB)	SH-SY5Y (ATCC CRL-2266); HeLa (ATCC CCL-2) cells	Retinoic acid treatment	upregulated	21118818
2010	Human	hsa-miR-10a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
2011	Human	hsa-miR-10a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid treatment	downregulated	32143184
2012	Human	hsa-miR-10a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
2013	Human	hsa-miR-10a	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	peripheral blood	methotrexate treatment	circulating miR-10a was upregulated in RA patients treated with MTX.	29667551
2014	Human	hsa-miR-10a-3p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
2015	Human	hsa-miR-10a-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human articular chondrocyte	?IL-6?treatment treatment	"?IL-6 downregulated miR-10a-5p, which subsequently derepressed IL-6R expression"	33166496
2016	Human	hsa-miR-10a-5p	miRNA	lipopolysaccharide (LPS)	apical periodontitis (AP)	K-562 cells	lipopolysaccharide (LPS) treatment	upregulated	33245973
2017	Human	hsa-miR-10a-5p	miRNA	S-equol	breast cancer	MCF-7?cells	S-equol treatment	upregulated	31390527
2018	Human	hsa-miR-10a-5p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
2019	Human	hsa-miR-10a-5p	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
2020	Human	hsa-miR-10a-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
2021	Human	hsa-miR-10a-5p	miRNA	heparin-binding EGF-like growth factor (HB-EGF)	keratinocytes (KCs) diferentiation	human primary KCs	heparin-binding EGF-like growth factor (HB-EGF) treatment	upregulated	31049964
2022	Human	hsa-miR-10a-5p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
2023	Human	hsa-miR-10a-5p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
2024	Human	hsa-miR-10a-5p	miRNA	cyclosporine A (CsA)	nephrotoxicity	human proximal tubule cells	cyclosporine A treatment	dysregulated	28925592
2025	Human	hsa-miR-10a-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	downregulated	26298803
2026	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	interleukin-1¦Â treatment	upregulated	30731321
2027	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	upregulated	30731321
2028	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	LncRNA SNHG5 promotes chondrocyte proliferation and inhibits apoptosis in osteoarthritis by regulating miR-10a-5p/H3F3B axis	32967481
2029	Human	hsa-miR-10a-5p	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	downregulated	32028542
2030	Human	hsa-miR-10a-5p	miRNA	tyrosine kinase inhibitors (TKI)	renal cell carcinoma (RCC)	patients with advanced renal cell carcinoma (RCC)	tyrosine kinase inhibitors (TKI) treatment	downregulated	28746769
2031	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	SW982 cells	IL-5¦Â treatment	downregulated	28782180
2032	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	human synovial sarcoma cell line SW982	IL-1¦Â treatment	downregulated	28782180
2033	Human	hsa-miR-10a-5p	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	SW982 cells	IL-1¦Â treatment	downregulated	29545315
2034	Human	hsa-miR-10b	miRNA	fenretinide	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fenretinide treatment	downregulated	31925643
2035	Human	hsa-miR-10b	miRNA	propofol (PPF)	bladder cancer	T24 cells	"2,6-diisopropylphenol (propofol) treatment"	downregulated	31788099
2036	Human	hsa-miR-10b	miRNA	hyperthermia	breast cancer	BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231	Hyperthermia treatment	downregulated	27380148
2037	Human	hsa-miR-10b	miRNA	linifanib	breast cancer	"MCF-7, MM231, MM468, T47D cells"	Linifanib treatment	downregulated	30166612
2038	Human	hsa-miR-10b	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
2039	Human	hsa-miR-10b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	chondrosarcoma	JJ012 and SW1353 chondrosarcoma cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	26549320
2040	Human	hsa-miR-10b	miRNA	acidic microenvironment	early-stage hepatocellular carcinoma (E-HCC)	The human HCC cell lines SMMC-7721 and Hep3B	acidic microenvironment treatment	upregulated	31037150
2041	Human	hsa-miR-10b	miRNA	TGF-¦Â	esophageal squamous cell carcinoma (ESCC)	"Esophageal cancer cells, TE-1 and EC9706"	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	31602239
2042	Human	hsa-miR-10b	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	downregulated	33285269
2043	Human	hsa-miR-10b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	GC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24481854
2044	Human	hsa-miR-10b	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
2045	Human	hsa-miR-10b	miRNA	lidocaine	gastric cancer (GC)	MGC-803 cells	lidocaine (Lido) treatment	Lido declined cisplatin resistance by down-regulating miR-10b.	32892697
2046	Human	hsa-miR-10b	miRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	human glioma cell lines U87 and U251	5 ng/ml of TGF-¦Â treatment	upregulated	28393237
2047	Human	hsa-miR-10b	miRNA	neferine (NEF)	glioblastoma multiforme (GBM)	human glioma cell line U251	neferine (NEF) treatment	downregulated	30551353
2048	Human	hsa-miR-10b	miRNA	neferine (NEF)	glioblastoma multiforme (GBM)	human glioma cell line U251	neferine (NEF) treatment	downregulated	30551353
2049	Human	hsa-miR-10b	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	human glioma cell	transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	24100613
2050	Human	hsa-miR-10b	miRNA	heparin	angiogenesis	human microvascular endothelial cells (HMEC-1)	Heparin treatment	downregulated	21642433
2051	Human	hsa-miR-10b	miRNA	B cell lymphoma/lewkmia-2 (Bcl2)	medulloblastoma	medulloblastoma cell	B cell lymphoma/lewkmia-2 (Bcl2) treatment	high expression of miRNA-10b in medulloblastoma cell lines compared to a normal cerebellar control	26394044
2052	Human	hsa-miR-10b	miRNA	retinoic acid (RA)	neuroblastoma (NB)	SH-SY5Y (ATCC CRL-2266); HeLa (ATCC CCL-2) cells	Retinoic acid treatment	upregulated	21118818
2053	Human	hsa-miR-10b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
2054	Human	hsa-miR-10b	miRNA	hyaluronan-CD44	thymic atrophy and alterations in T cell differentiation	breast tumor cells (MDA-MB-231 cells)	Hyaluronan-CD44? treatment	upregulated	20843787
2055	Human	hsa-miR-10b	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
2056	Human	hsa-miR-10b	miRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	human nasopharyngeal carcinoma cells	Epstein-Barr virus (EBV) infection	upregulated	20732742
2057	Human	hsa-miR-10b-3p	miRNA	hypoxia	esophageal squamous cell carcinoma (ESCC)	ECA109 cells; KYSE410 cells	hypoxia induce	upregulated	31772141
2058	Human	hsa-miR-10b-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
2059	Human	hsa-miR-10b-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
2060	Human	hsa-miR-10b-3p	miRNA	hypoxia	preeclampsia (PE)	human trophoblast HTR-8/SVneo cells	hypoxia induce	downregulated	30552989
2061	Human	hsa-miR-10b-3p	miRNA	hypoxia	preeclampsia (PE)	HTR-8/SVneo cells	hypoxia treatment	Lower levels of miR-10b-3p but higher expression of WDR86-AS1 and LITAF were observed in PE-affected placentas and trophoblast cells under hypoxia.	30552989
2062	Human	hsa-miR-10b-5p	miRNA	Kv channel blocker 4-aminopyridine (4-AP)	cell proliferation and apoptosis	U87-MG cells; U251 cells	Kv channel blocker 4-aminopyridine (4-AP) treatment	"4-AP altered the miRNA expression in glioma cells, and the downregulated of miR-10b-5p induced by 4-AP was verified by real-time PCR."	29514931
2063	Human	hsa-miR-10b-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
2064	Human	hsa-miR-10b-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
2065	Human	hsa-miR-10b-5p	miRNA	hypoxia	ischemic injury	endothelial colony-forming cells (ECFCs) exosomes	hypoxia induce	downregulated	30183690
2066	Human	hsa-miR-10b-5p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
2067	Human	hsa-miR-1178	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human macrophages (HTP-1 and U937 cells)	Mycobacterium tuberculosis (M.tb) infection	upregulated	29781535
2068	Human	hsa-miR-1179	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
2069	Human	hsa-miR-1180	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
2070	Human	hsa-miR-1180	miRNA	paclitaxel (PTX)	triple negative breast cancer (TNBC)	HCC38 (paclitaxel-sensitive) and MDA-MB436 (paclitaxel-resistant) TNBC cells	paclitaxel treatment	downregulated	29416635
2071	Human	hsa-miR-1181	miRNA	platelet derived growth factor-BB (PDGF-BB)	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	Platelet-derived growth factor BB (PDGFBB) treatment	downregulated	30211651
2072	Human	hsa-miR-1181	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2073	Human	hsa-miR-1182	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
2074	Human	hsa-miR-1182	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
2075	Human	hsa-miR-1182	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	H522; H1975; BEAS-2B	hypoxia treatment	Circ_0000376 promoted NSCLC progression by regulating the miR-1182/NOVA2 axis	32922073
2076	Human	hsa-miR-1183	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
2077	Human	hsa-miR-1183	miRNA	radiation	glioblastoma multiforme (GBM)	U87 cells; U251 cells	radiation treatment	miR-1183 expression was significantly upregulated in U87 and U251 cells following irradiation	32080097
2078	Human	hsa-miR-1183	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
2079	Human	hsa-miR-1184	miRNA	lipopolysaccharide (LPS)	neonatal sepsis (NS)	serum	lipopolysaccharide (LPS) treatment	The results indicated that the serum levels of miR-1184 in neonates with sepsis were decreased	33732323
2080	Human	hsa-miR-1193	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	MH7A cells	IL-1¦Â treatment	downregulated	32597556
2081	Human	hsa-miR-12	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
2082	Human	hsa-miR-1202	miRNA	antidepressant	major depressive disorder (MDD)	cohorts of depressed patients	received 8 weeks of antidepressant therapy	upregulated	28520926
2083	Human	hsa-miR-1202	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuroinflammation	human microglial cells (HM cells)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated of miR-1202 and upregulated of Rab1a were found in OGD/R induced HM cells.	32124161
2084	Human	hsa-miR-1203	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	T-HESC and primary human endometrial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-1203 targets and silences CypD to protect human endometrial cells from OGDR	32041924
2085	Human	hsa-miR-1205	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
2086	Human	hsa-miR-1207-3p	miRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells; PANC-1 cells	Gemcitabine treatment	"Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)."	30341811
2087	Human	hsa-miR-1207-5p	miRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells; PANC-1 cells	Gemcitabine treatment	"Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)."	30341811
2088	Human	hsa-miR-1207-5p	miRNA	lucidum	breast cancer	MCF-7 breast cancer cells	lucidum treatment	upregulated	25954907
2089	Human	hsa-miR-1207-5p	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
2090	Human	hsa-miR-1207-5p	miRNA	tanshinol (TAN)	melanoma	"Human melanoma cell lines (M14, A375)"	Tanshinol treatment	upregulated	31828417
2091	Human	hsa-miR-1207-5p	miRNA	tanshinol (TAN)	melanoma	A375 cells; M14 cells	Tanshinol treatment	Tanshinol induced miR-1207-5p expression and suppressed cell growth and mobility of melanoma cells	31828417
2092	Human	hsa-miR-122	miRNA	N-3 polyunsaturated fatty acids (PUFA)	nonalcoholic fatty liver disease (NAFLD)	blood	n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) treatment	 n-3 PUFA were effective in reducing ALP and liver fibrosis without altering the expression of circulating miR-122 in individuals with NAFLD.	33147705
2093	Human	hsa-miR-122	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	primary human hepatocytes (PHH)	acetaminophen (APAP) treatment	upregulated	32379794
2094	Human	hsa-miR-122	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
2095	Human	hsa-miR-122	miRNA	coptisine (COP)	acute liver failure (ALF)	HepG2 cells and LO2 cells	COP treatment for 7d	upregulated	29253766
2096	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	acute lymphoblastic leukemia (ALL)	liver and serum	hepatitis C virus (HCV) infection	downregulated	23085648
2097	Human	hsa-miR-122	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19 cells	H2O2 treatment	downregulated	31784665
2098	Human	hsa-miR-122	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	Both lncRNA Rpph1 and miR-122 were upregulated in AD mouse and Rpph1 activated Wnt/¦Â-catenin signaling to ameliorate amyloid-¦Â induced neuronal apoptosis in SK-N-SH cells via direct targeting miR-122.	31718352
2099	Human	hsa-miR-122	miRNA	amoxicillin or clavulanate	amoxicillin/clavulanate-induced liver injury (AC-DILI)	healthy subjects liver	administered amoxicillin/clavulanate for 14 days	upregulated	27785887
2100	Human	hsa-miR-122	miRNA	PAX8/PPAR¦Ã fusion protein (PPFP)	anaplastic thyroid carcinoma (ATC)	"ATC cell lines: BHT-101; FRO, C-643; KTC-2;KTC-3"	PAX8/PPAR¦Ã fusion protein (PPFP) treatment	upregulated	23598436
2101	Human	hsa-miR-122	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
2102	Human	hsa-miR-122	miRNA	rhinoviruses (RVs)	asthma	human airway epithelial cells	rhinoviruses (RVs) infection treatment	"Here, we found that RV infection induced the expression of miRNA 122 (miR-122) in mouse lungs and in human airway epithelial cells"	33830082
2103	Human	hsa-miR-122	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic Endothelial cell (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31228514
2104	Human	hsa-miR-122	miRNA	benzimidazotriazin	breast cancer	breast cancer (BC) tissues	benzimidazotriazin treatment	miR-122 was significantly higher in both groups treated with benzimidazotriazine compared to the cisplatin group.	33232730
2105	Human	hsa-miR-122	miRNA	bile duct ligation (BDL)	breast cancer	serum	bile-duct ligation (BDL) treatment	Serum miR-122 increased significantly after BDL-induced cholestatic injury	24086271
2106	Human	hsa-miR-122	miRNA	trichostatin A (TSA)	cell differentiation	hepatocyte-like cells (HLCs) generated from human adipose tissue-derived mesenchymal stem cells (hAT-MSCs)	hepatocyte-like cells (HLCs) generated from human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) treatment	upregulation	26360933
2107	Human	hsa-miR-122	miRNA	hepatitis B virus (HBV)	cell-intrinsic angiogenic activity of ECs	liver tissue	hepatitis B virus (HBV) infection	downregulated	22105316
2108	Human	hsa-miR-122	miRNA	leptin	cholangiocarcinoma (CCA)	The human cholangiocarcinoma cell lines SK-ChA-1 and TFK-1	Leptin treatment	downregulated	31115511
2109	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV) direct-acting antiviral agents (DAAs)	chronic hepatitis C virus (HCV) infection	Plasma HCV RNA	DAAs treatment	downregulated	26436610
2110	Human	hsa-miR-122	miRNA	IFN-¦Ã	chronic hepatitis C virus (HCV) infection	HCV-infected hepatocytes	IFN-¦Ë treatment	downregulated	24385435
2111	Human	hsa-miR-122	miRNA	transarterial chemoembolization (TACE)	chronic hepatitis and hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	upregulated in plasma	27194671
2112	Human	hsa-miR-122	miRNA	PEG-interferon plus ribavirin therapy	chronic hepatitis C virus (HCV) infection	Blood and plasma	PEG-interferon plus ribavirin therapy treatment	upregulated	27054010
2113	Human	hsa-miR-122	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells	oxaliplatin treatment	downregulated	31901148
2114	Human	hsa-miR-122	miRNA	H2O2	crohn disease (CD)	HT-29 cells	H2O2 treatment	downregulated	31019652
2115	Human	hsa-miR-122	miRNA	ionic liquids (ILs) 1-decyl-3-methylimidazolium bromide	cytotoxicity	HepG2 cells	Ionic liquids (ILs) 1-decyl-3-methylimidazolium bromide treatment	upregulated	31702098
2116	Human	hsa-miR-122	miRNA	H2O2	deep vein thrombosis (DVT)	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	downregulated	33195700
2117	Human	hsa-miR-122	miRNA	trichostatin A (TSA)	differentiated phenotype in hepatocytes	hepatocyte-like cells (HLCs)	trichostatin A (TSA) treatment	upregulated	26360933
2118	Human	hsa-miR-122	miRNA	acetaminophen (APAP)	drug hepatotoxicity	healthy men and women	acetaminophen (APAP) treatment	upregulated	24118944
2119	Human	hsa-miR-122	miRNA	grape pomace extract (GPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape pomace extract (GPE) treatment	GPE reduced miR-122 but increased miR-33a expression.	24165878
2120	Human	hsa-miR-122	miRNA	grape seed proanthocyandin extract (GSPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape seed proanthocyandin extract (GSPE) treatment	GSPE reduced both miR-122 and miR-33a levels.	24165878
2121	Human	hsa-miR-122	miRNA	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P)	early non-genotoxic events	HepaRG cells	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) treatment	downregulated	26609139
2122	Human	hsa-miR-122	miRNA	2-octynoic acid	endometrial cancer (EC)	human hepatocytes HepG2.2.15	2-octynoic acid treatment	over expression	23741428
2123	Human	hsa-miR-122	miRNA	H2O2	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs); human aortic endothelial cells (HAECs)	H2O2 treatment	miR-122 was markedly upregulated after treatment with H2O2 for 48 h.	33278397
2124	Human	hsa-miR-122	miRNA	cisplatin (DDP)	gastric cancer (GC)	MKN74 cells	cisplatin treatment	downregulated	31152437
2125	Human	hsa-miR-122	miRNA	aflatoxin B1 (AFB1)	genotoxicity	HepaRG cells	aflatoxin B1 (AFB1) treatment	downregulated	26609139
2126	Human	hsa-miR-122	miRNA	peginterferon alfa-2a (PEG-IFN)	HBV/HCV dually infection	HBV/HCV patients serum	PEG-IFN treatment	upregulated	25788377
2127	Human	hsa-miR-122	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	upregulated	27874954
2128	Human	hsa-miR-122	miRNA	FeSO4	hepatic inflammation	Huh7 cells	100 ?¦¬ FeSO4 treatment	downregulated	29176318
2129	Human	hsa-miR-122	miRNA	holo-transferrin (holo-Tf)	hepatic inflammation	Huh7 cells	holo-transferrin (holo-Tf) treatment	downregulated	29176318
2130	Human	hsa-miR-122	miRNA	alcohol	liver damage	Huh-7.5 cells; Huh-7.5 cells;CYP2E1 expressing cells	alcohol exposure	upregulated	23126531
2131	Human	hsa-miR-122	miRNA	miravirsen?(SPC3649)	hepatitis C virus (HCV) infection	HeLa cells; Huh-7 cells	Miravirsen (SPC3649) treatment	downregulated	24068553
2132	Human	hsa-miR-122	miRNA	miravirsen?(SPC3649)	hepatitis C virus (HCV) infection	HeLa cells;Huh-7 cells	miravircsen?(SPC3649) treatment	upregulated	24068553
2133	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	ML-1 human thyroid cells	hepatitis C virus (HCV) infection	upregulated	31784757
2134	Human	hsa-miR-122	miRNA	ribavirin and interferon ¦Â	hepatitis C virus (HCV) infection	The human hepatoma cell line Huh7	ribavirin and interferon ¦Â treatment	downregulated	20428788
2135	Human	hsa-miR-122	miRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	HepG2 cells	astragaloside IV (AS-IV) treatment	upregulated	28179291
2136	Human	hsa-miR-122	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	HepG2 cells	curcumin treatment	upregulated	28179291
2137	Human	hsa-miR-122	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
2138	Human	hsa-miR-122	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	hepatitis B virus (HBV) infection	downregulated	31485598
2139	Human	hsa-miR-122	miRNA	radiofrequency ablation (RFA)	hepatocellular carcinoma (HCC)	plasma	radiofrequency ablation (RFA) treatment	upregulated	26129878
2140	Human	hsa-miR-122	miRNA	TP-1	hepatocellular carcinoma (HCC)	SMMC-7721 cells	TP-1 treatment	upregulated	25787750
2141	Human	hsa-miR-122	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
2142	Human	hsa-miR-122	miRNA	ochratoxin A (OTA)	hepatocyte apoptosis	"human hepatoblastoma cell line, HepG2"	ochratoxin A treatment	inhibited	30090334
2143	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	liver damage	monocytes	hepatitis C virus (HCV) infection	Serum levels of miR-122 were elevated in cHCV patients and correlated with increased ALT and AST levels and serum miR-155 levels	22846613
2144	Human	hsa-miR-122	miRNA	tolvaptan	idiosyncratic drug-induced liver injury (IDILI)	primary hepatocytes	tolvaptan treatment	upregulated	29029277
2145	Human	hsa-miR-122	miRNA	pginterferon (PEG IFN)	hepatitis C virus (HCV) infection	patients liver	IFN treatment	upregulated	24612050
2146	Human	hsa-miR-122	miRNA	lipopolysaccharide (LPS)	inflammation	HaCaT cells	lipopolysaccharide (LPS) treatment	upregulated	30632205
2147	Human	hsa-miR-122	miRNA	tanshinol (TAN)	inflammation	LPS-treated HaCaT cells	tanshinol (TAN) treatment	downregulated	30632205
2148	Human	hsa-miR-122	miRNA	ionic liquids (ILs)	Ionic liquids (ILs)-related human health risks	HepG2 cells	Ionic liquids (ILs) treatment	ILs increased the expression of miR-122.	31702098
2149	Human	hsa-miR-122	miRNA	anoxia/reoxygenation (A/R)	ischemia/reperfusion (I/R) injury	LO2 cell	anoxia/reoxygenation (A/R) treatment	downregulated	28093198
2150	Human	hsa-miR-122	miRNA	citrus peel flavonoid extracts (CPFE)	lipid metabolism	HepG2 cells	citrus peel flavonoid extracts (CPFE) treatment	downregulated	31017523
2151	Human	hsa-miR-122	miRNA	daphnane diterpenoid genkwanine M (GENK)	hepatocellular carcinoma (HCC)	Huh-7 cells	daphnane diterpenoid genkwanine M (GENK) treatment	downregulated	22761847
2152	Human	hsa-miR-122	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?13 cells	heme treatment	upregulated	23538684
2153	Human	hsa-miR-122	miRNA	IFN-¦Á	hepatocellular carcinoma (HCC)	;Huh-7 ; HepG2	Alpha Interferon (IFN-¦Á) treatment	downregulated	23055569
2154	Human	hsa-miR-122	miRNA	microcystin-leucine arginine (MC-LR)	hepatocellular carcinoma (HCC)	WRL-70 cells	microcystin-LR treatment	downregulated	22265967
2155	Human	hsa-miR-122	miRNA	P body protein LSm1	hepatocellular carcinoma (HCC)	Huh7 cells; Huh7.5 cells	P body protein LSm1 treatment	The P body protein LSm1 contributes to stimulation of hepatitis C virus translation by microRNA-122	24141094
2156	Human	hsa-miR-122	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	upregulated	32656599
2157	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	liver cirrhosis and hepatocellular carcinoma	human hepatocellular carcinoma-derived Huh7; Hep3B; HepG2; embryonic kidney-derived HEK293 ; 293T; lung-derived RERF-LC-AI;NCI-H-2030; A-427; kidney-derived Caki-2 and 769-P; neuron-derived MC-IXC ;SK-PN-DW; uterus-derived Hec1B; ovary-derived SK-OV3; colon-derived SW620; urinary bladder-derived SW780 cells	hepatitis C virus (HCV) infection	Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus	22593164
2158	Human	hsa-miR-122	miRNA	coptisine (COP)	liver damage	HepG2 cells; L02 cells	coptisine (COP) treatment	COP increased the miR-122 level in LPS-treated HepG2 and L02 cells.	29253766
2159	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	liver fibrosis	hepatoma cells	hepatitis C virus (HCV) infection	upregulated	26157120
2160	Human	hsa-miR-122	miRNA	amoxicillin/clavulanate-induced liver injury (AC-DILI)	liver damage	Blood and urine	amoxicillin/clavulanate-induced liver injury (AC-DILI) treatment	upregulated	27785887
2161	Human	hsa-miR-122	miRNA	IFN and ribavirin	liver damage	HIV-HCV co-infected patients	interferon and ribavirin treatment	downregulated	24895202
2162	Human	hsa-miR-122	miRNA	paraquat (PQ)	liver damage	paraquat-exposed individuals liver tissue	paraquat (PQ) treatment	downregulated	22427142
2163	Human	hsa-miR-122	miRNA	oleanolic acid (OLA)	lung cancer	"human lung cancer cell lines, A549, NCI-H460, and NCI_x0002_H1299"	oleanolic acid (OLA) treatment	upregulated	25472877
2164	Human	hsa-miR-122	miRNA	oleanolic acid (OLA)	lung cancer	lung carcinoma cell lines	Oleanolic acid treatment	upregulated	25472877
2165	Human	hsa-miR-122	miRNA	ethanol (EtOH)	mitochondrial dysfunction	human hepatoma cells	Ethanol?treatment	downregulated	22898980
2166	Human	hsa-miR-122	miRNA	amyloid-¦Â (A¦Â)	neuronal cell injury	SK-N-SH cells	amyloid-¦Â (A¦Â) treatment	LncRNA Rpph1 protects amyloid-¦Â induced neuronal injury in SK-N-SH cells via miR-122/Wnt1 axis	31718352
2167	Human	hsa-miR-122	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
2168	Human	hsa-miR-122	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
2169	Human	hsa-miR-122	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	human liver cell line (L02)	free fatty acid (FFA) treatment	upregulated	31126802
2170	Human	hsa-miR-122	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 and Huh-7 cells	free fatty acids (FFA) treatment	upregulated	31195981
2171	Human	hsa-miR-122	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Huh7 cells exosomes	palmitic acid (PA) treatment	upregulated in exosomes	28623272
2172	Human	hsa-miR-122	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	downregulated	32143184
2173	Human	hsa-miR-122	miRNA	post-bariatric surgery	obesity	obesity patients serum	a 3 months post-bariatric surgery treatment	upregulated in serum	29103239
2174	Human	hsa-miR-122	miRNA	propofol (PPF)	papillary thyroid cancer (PTC)	TPC-1 cells; IHH-4 cells	propofol treatment	Propofol promoted the expression of miR-122	32432774
2175	Human	hsa-miR-122	miRNA	acetaminophen (APAP)	prostate cancer	serum	acetaminophen (APAP) treatment	?Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients	22045675
2176	Human	hsa-miR-122	miRNA	docetaxel (DTX)	prostate cancer	LNCaP cells	docetaxel (DTX) treatment	downregulated	33178345
2177	Human	hsa-miR-122	miRNA	silica	lung fibrosis	HBE cells	silica treatment	downregulated	33297121
2178	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	short bowel syndrome (SBS)	human liver	hepatitis C virus (HCV) infection	downregulated	20625373
2179	Human	hsa-miR-122	miRNA	noncanonical polymerase Gld2	stabilizes specific miRNA populations in human fibroblasts	Human primary fibroblasts	The noncanonical polymerase Gld2 treatment	The noncanonical polymerase Gld2 has been implicated in the stabilization of miR-122	23200856
2180	Human	hsa-miR-122	miRNA	free fatty acids (FFA)	steatotic hepatocytes	human HCC cell lines HepG2 and Huh7	free fatty acid treatment	downregulated	29216638
2181	Human	hsa-miR-122	miRNA	lipopolysaccharide (LPS)	triple negative breast cancer (TNBC)	HT-29 cells	lipopolysaccharide (LPS) treatment	downregulated	23872065
2182	Human	hsa-miR-122	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
2183	Human	hsa-miR-122	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	downregulated	23537271
2184	Human	hsa-miR-122*	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
2185	Human	hsa-miR-1222-5p	miRNA	M¦ÂCD-cholesterol	nonalcoholic steatohepatitis (NASH)	Huh7 cells secreted exosomes	M¦ÂCD-cholesterol treatment	upregulated	31759057
2186	Human	hsa-miR-122-3p	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	downregulated	29590087
2187	Human	hsa-miR-1224	miRNA	H2O2	acute liver injury (ALI)	L02 cells	H2O2 treatment	upregulated	30848506
2188	Human	hsa-miR-1224-3p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	upregulated	32438192
2189	Human	hsa-miR-1224-3p	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
2190	Human	hsa-miR-1224-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
2191	Human	hsa-miR-1224-3p	miRNA	proanthocyanidin extract (GSPE)	hepatocellular carcinoma (HCC)	HepG2 cells	proanthocyanidin extract (GSPE) treatment	upregulated	21998738
2192	Human	hsa-miR-1224-5p	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	upregulated	32362797
2193	Human	hsa-miR-1224-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
2194	Human	hsa-miR-1225-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2195	Human	hsa-miR-1225-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
2196	Human	hsa-miR-122-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
2197	Human	hsa-miR-122-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen (APAP) treatment	upregulated	32779042
2198	Human	hsa-miR-122-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	upregulated	33782973
2199	Human	hsa-miR-122-5p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
2200	Human	hsa-miR-122-5p	miRNA	resveratrol	breast cancer	adriamycin-resistant breast cancer cells MCF-7 cells	resveratrol (RSV) treatment	upregulated	31155753
2201	Human	hsa-miR-122-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	downregulated	31198949
2202	Human	hsa-miR-122-5p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	cyclosporine A (CYCA) treatment	downregulated	31198949
2203	Human	hsa-miR-122-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
2204	Human	hsa-miR-122-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
2205	Human	hsa-miR-122-5p	miRNA	glucosamine	insulin resistance (IR)	HepG2 hepatic cells	glucosamine treatment	upregulated	30958584
2206	Human	hsa-miR-122-5p	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	downregulated	29899866
2207	Human	hsa-miR-122-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
2208	Human	hsa-miR-122-5p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
2209	Human	hsa-miR-122-5p	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	pancreatic cancer (PC)	THP-1 cells	lipopolysaccharide; interferon-¦Ã treatment	"lncRNA SBF2-AS1 in M2 macrophage-derived exosomes increases miR-122-5p expression to restrain XIAP expression, which further inhibits PC progression."	32301277
2210	Human	hsa-miR-122-5p	miRNA	IL-22	psoriatic lesions	HaCaT cells	IL-22	upregulated	27943426
2211	Human	hsa-miR-122-5p	miRNA	radiation	rectal injury	human intestinal epithelial crypt (HIEC) cells	radiation treatment	miR-122-5p aggravates radiation-induced rectal injury through targeting CCAR1	32422326
2212	Human	hsa-miR-122-5p	miRNA	cadmium (Cd)	renal toxic	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
2213	Human	hsa-miR-122-5p	miRNA	curcumin (Cur)	schwannoma	RT4 schwannoma cells	curcumin treatment	upregulated	30534000
2214	Human	hsa-miR-122-5p	miRNA	coal-burning type fluoride	skeletal fluorosis	plasma	coal-burning type fluoride exposure	"In human populations with coal-burning type fluoride exposure, the results showed that miR-122-5p was downregulated"	32572801
2215	Human	hsa-miR-122-5p	miRNA	cadmium (Cd)	toxic effects of cadmium	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
2216	Human	hsa-miR-122-5p	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
2217	Human	hsa-miR-122-5p	miRNA	ursolic acid (UA)	uric acid nephropathy (UAN)	HK-2?cells	uric acid treatment	miR-122-5p was reduced uric acid-treated HK-2 cells	30347231
2218	Human	hsa-miR-1228-3p	miRNA	TGF-¦Â1	chronic kidney disease (CKD)	HK-2 cells	TGF-¦Â1 treatment	Upregulation of miRNA-1228-3p markedly inhibited the progression of renal fibrosis in vitro	32720699
2219	Human	hsa-miR-1228-5p	miRNA	particulate matter (PM2.5)	non-small cell lung cancer (NSCLC)	human A549 cells	particulate matter (PM2.5) treatment	downregulated	26867688
2220	Human	hsa-miR-1229	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
2221	Human	hsa-miR-1229	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2222	Human	hsa-miR-1229-5p	miRNA	occupational noise	occupational noise-induced hearing loss (ONIHL)	serum	occupational noise exposure	upregulated	29340520
2223	Human	hsa-miR-1229-5p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
2224	Human	hsa-miR-122a	miRNA	"chenodeoxycholic acid, GW4064"	bile acid synthesis	human primary hepatocytes	"chenodeoxycholic acid, GW4064 treatment"	upregulated	20351063
2225	Human	hsa-miR-122a	miRNA	fibroblast growth factor ( FGF)19	bile acid synthesis	human primary hepatocytes	fibroblast growth factor ( FGF)19 treatment	upregulated	20351063
2226	Human	hsa-miR-122a	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	upregulated	24396484
2227	Human	hsa-miR-122a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intestinal inflammation	Caco-2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	21763238
2228	Human	hsa-miR-122a	miRNA	adenovirus (ADV)	hepatocellular carcinoma (HCC)	Huh7.5 cells; N52.E6 cell line48; CCL-185 cells; CCL 243 cells; CRL 1772	adenovirus vectors treatment	miRNA-mediated regulation of antigen expression in the context of adenovirus vectors can significantly improve transgene product-directed immune responses	21556053
2229	Human	hsa-miR-122a	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
2230	Human	hsa-miR-1231	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
2231	Human	hsa-miR-1234	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 8¡ã HDT bed rest experiment	downregulated	28261104
2232	Human	hsa-miR-1234	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2233	Human	hsa-miR-1236	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
2234	Human	hsa-miR-1236	miRNA	hypoxia	epithelial-mesenchymal transition (EMT)	"Human breast cancer (MCF7), lung cancer (H1299), head and neck cancer (SAS) and embryonic kidney (293T) cell lines"	hypoxia treatment	downregulated	27177472
2235	Human	hsa-miR-1236-3p	miRNA	cisplatin (DDP)	lung cancer	lung cancer tissues and A549 cell line	cisplatin treatment	downregulated	30805558
2236	Human	hsa-miR-1237	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2237	Human	hsa-miR-1237-3p	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-1237-3p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
2238	Human	hsa-miR-1237-3p	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-1237-3p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
2239	Human	hsa-miR-1238	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
2240	Human	hsa-miR-1238	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human thyroid	infect with HHV-6A	upregulated	28081700
2241	Human	hsa-miR-1238-2	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
2242	Human	hsa-miR-1238-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
2243	Human	hsa-miR-124	miRNA	H2O2	acute lung injury (ALI)	Beas2B cells	H2O2 treatment	downregulated	31938089
2244	Human	hsa-miR-124	miRNA	hyperoxia	acute lung injury (ALI)	Beas2B cells	hyperoxia treatment	downregulated	31938089
2245	Human	hsa-miR-124	miRNA	Mito-TEMPO	acute lung injury (ALI)	hyperoxia-/H2O2-treated Beas2B cells	Mito-TEMPO treatment	upregulated	31938089
2246	Human	hsa-miR-124	miRNA	N-acetyl-L-cysteine (NAC)	acute lung injury (ALI)	hyperoxia-/H2O2-treated Beas2B cells	N-acetyl-L-cysteine (NAC) treatment	upregulated	31938089
2247	Human	hsa-miR-124	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
2248	Human	hsa-miR-124	miRNA	estradiol	breast cancer	BC cell lines MCF7 and MDA-MB-231	estradiol treatment	downregulated	27175587
2249	Human	hsa-miR-124	miRNA	paclitaxel (PTX)	breast cancer	"Human breast cancer cells, BT474, SKBR3 and MCF7"	paclitaxel (PTX) treatment	"The miR-124, a tumor suppressive miRNA, was significantly downregulated in Taxol resistant cells."	31367191
2250	Human	hsa-miR-124	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Myeloid-derived suppressor cells (MDSCs)	chronic hepatitis C virus (HCV) infection	downregulated	27753084
2251	Human	hsa-miR-124	miRNA	quercetin	chronic kidney disease (CKD)	HK-2 cells	quercetin (QUE) treatment	MyD88 and miR-124 expression was elevated by LPS and alleviated by Quercetin	31804760
2252	Human	hsa-miR-124	miRNA	lipopolysaccharide (LPS)	chronic kidney disease (CKD)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31804760
2253	Human	hsa-miR-124	miRNA	quercetin	chronic kidney disease (CKD)	LPS-treated HK-2 cells	quercetin treatment	downregulated	31804760
2254	Human	hsa-miR-124	miRNA	IFN-¦Ã and TNF-¦Á	chronic skin inflammation in atopic eczema	human keratinocyte	IFN-¦Ã and TNF-¦Á	downregulated	28847568
2255	Human	hsa-miR-124	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	Caco-2 cells and HT-29 cells	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	"downregulated or upregulation of miR-124 in TNBS-induced colitic colon alleviated or aggravated experimental colitis, respectively."	26802080
2256	Human	hsa-miR-124	miRNA	5-aza-2'-deoxycytidine and trichostatin A	colonic inflammation	Squamous cell carcinoma (SCC) cell line	5-aza-deoxycytidine and trichostatin A treatment	downregulated	22828925
2257	Human	hsa-miR-124	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	colorectal cancer (CRC)	Hct-116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-124 expression was upregulated after 5-AZA-CdR treatment in the Hct-116 cells.	32552060
2258	Human	hsa-miR-124	miRNA	high-intensity focused ultrasound (HIFU)	colorectal cancer (CRC)	HCT-116 cells	High-intensity focused ultrasound (HIFU) induce	upregulated	30980700
2259	Human	hsa-miR-124	miRNA	H2O2	cytotoxicity	OB-6 cells	Hydrogen peroxide (H2O2) treatment	upregulated	31955154
2260	Human	hsa-miR-124	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
2261	Human	hsa-miR-124	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
2262	Human	hsa-miR-124	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human RPE cells	TGF-¦Â1 treatment	downregulated	26746014
2263	Human	hsa-miR-124	miRNA	fluoride	fluorosis	sodium fluoride (NaF) treated human osteosarcoma (HOS) cells	fluoride treatment	miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor ¦Ê-B ligand (RANKL) genes	26339601
2264	Human	hsa-miR-124	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	AGS human gastric cancer cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27041578
2265	Human	hsa-miR-124	miRNA	pemetrexed	gastric cancer (GC)	Human gastric cancer MGC-803 cells	pemetrexed (MTA) treatment	"In MGC-803/MTA cells, miR-124 could remarkably increase the resistance of MGC-803/MTA cells to MTA"	31841184
2266	Human	hsa-miR-124	miRNA	phenformin	glioblastoma multiforme (GBM)	glioma stem cells (GSCs)	Phenformin treatment	upregulated	27486821
2267	Human	hsa-miR-124	miRNA	H2O2	H2O2-induced apoptosis and oxidative stress	human lens epithelial cells (hLEC)	H2O2 treatment	The H2O2-induced hLEC showed reductions in cell viability with decreased miRNA-124 but increased p-p65 in a dose-/time-dependent manner.	30099456
2268	Human	hsa-miR-124	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	"Hela,HEK293FT,SK-N-SH,SHSY5Y"	infect with EV71	upregulated	29120300
2269	Human	hsa-miR-124	miRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2 cells	Hepatitis B virus X protein (HBx) infection	HBx upregulated lncRNA-MALAT1 expression while downregulating miR-124 expression in HepG2-X cells.	30500989
2270	Human	hsa-miR-124	miRNA	glucocorticoid (GC)	hematological malignancies	human embryonic kidney (HEK) 293 and DLBCL cell lines	Glucocorticoids (GCs) treatment	Our study supports the notion that miR-124 could be an attractive therapeutic target for overcoming GC resistance in DLBCL	25576220
2271	Human	hsa-miR-124	miRNA	citalopram	major depressive disorder (MDD)	plasma	citalopram treatment	Plasma miR-124 in the treatment-free MDD and citalopram-treated MDD groups was 1.8-fold and 4-fold that in the control group.	29689690
2272	Human	hsa-miR-124	miRNA	alpinumisoflavone (AIF)	melanoma	A375 and SK-MEL-1 human melanoma cells	alpinumisoflavone (AIF) treatment	upregulated	28386327
2273	Human	hsa-miR-124	miRNA	high glucose (HG)	diabetes mellitus (DM)	human vascular smooth muscle cells (VSMCs)		downregulated	29042195
2274	Human	hsa-miR-124	miRNA	mycobacterium bovis bacille Calmette-Gu¨¦rin (BCG)	mycobacterium tuberculosis (Mtb) infection	A549 alveolar epithelial cells	infect with Mycobacterium bovis BCG treatment	upregulated	24705038
2275	Human	hsa-miR-124	miRNA	TGF-¦Â	nasopharyngeal carcinoma (NPC)	6-10B cells	TGF-¦Â treatment	TGF-¦Â-induced the suppression of miR-124 in NPC cells	29710466
2276	Human	hsa-miR-124	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	SH-SY5Y Cells	oxygen glucose deprivation (OGD) treatment	downregulated	31916069
2277	Human	hsa-miR-124	miRNA	niclosamide	oral cancer	HN6 cells	niclosamide treatment	upregulated	29251334
2278	Human	hsa-miR-124	miRNA	niclosamide	oral cancer	WSU-HN6 cells	5 ?M niclosamide	upregulated	29251334
2279	Human	hsa-miR-124	miRNA	icariin (ICA)	oral squamous cell carcinoma (OSCC)	human oral squamous cell carcinoma cells	Icaritin?treatment	upregulated	27889233
2280	Human	hsa-miR-124	miRNA	dexamethasone (DEX)	osteoblast injury	OB-6 osteoblastic cells and primary human osteoblasts	dexamethasone (DEX) treatment	miR-124 accumulated following DEX treatment in OB-6?cells and primary osteoblasts. miR-124 inhibitor attenuated cell death in human osteoblasts.	31242973
2281	Human	hsa-miR-124	miRNA	dihydroartemisinin (DHA) and curcumin (Cur)	ovarian cancer (OC)	human ovarian cancer SKOV3 cells	dihydroartemisinin (DHA) and curcumin (Cur)	upregulated	28934730
2282	Human	hsa-miR-124	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	1-methyl-4-phenylpyridinium (MPP+) treatment	miR-124 was a target of NEAT1. Anti-miR-124 could reverse the effects caused by NEAT1 knockdown in MPP+ treated SH-SY5Y cells.	31228597
2283	Human	hsa-miR-124	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	human neuroblastoma cell lines SH-SY5Y (SH-SY5Y) cells	lipopolysaccharide (LPS) treatment	downregulated	30995872
2284	Human	hsa-miR-124	miRNA	hypoxia	prostate cancer	prostate cancer cell lines (DU145 and PC3)	hypoxia treatment	downregulated	26990493
2285	Human	hsa-miR-124	miRNA	TGF-¦Â	prostate cancer	"MKN-45, MDA-MB-231, HCT15 and PA1 cell lines"	TGF-¦Á treatment	downregulated	24969691
2286	Human	hsa-miR-124	miRNA	baicalin (BAI)	renal fibrosis	HK-2 cells	baicalin (BAI) treatment	Baicalin prevented renal fibrosis by increasing miR-124 and inactivating downstream TLR4/NF-¦ÊB pathway in DN.	32500512
2287	Human	hsa-miR-124	miRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	downregulated	29717517
2288	Human	hsa-miR-124	miRNA	ultraviolet (UV) irradiation	Skin senescence	human epidermal keratinocytes (NHEKs)	UVB treatment	upregulated	27818465
2289	Human	hsa-miR-124	miRNA	ultraviolet (UV) irradiation	skin senescence	normal human epidermal keratinocytes (NHEKs)	UVB-irradiated treatment	upregulated	27818465
2290	Human	hsa-miR-124	miRNA	acute stress	stress response	mice amygdala	acute Stress treatment	downregulated	24023867
2291	Human	hsa-miR-124	miRNA	TGF-¦Â1	tongue squamous cell carcinoma (TSCC)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
2292	Human	hsa-miR-124	miRNA	nicotine	ulcerative colitis (UC)	human ulcerative colonic mucosa	Nicotine treatment	upregulated	27709266
2293	Human	hsa-miR-124	miRNA	high glucose (HG)	vascular injury	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	30454897
2294	Human	hsa-miR-124	miRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2-X cell line was induced by transfect HBx into HepG2 cells.	HBx-induce	HBx downregulating miR-124 expression in HepG2-X cells.	30500989
2295	Human	hsa-miR-124-2	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
2296	Human	hsa-miR-1243	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose treatment	circ_0002570 could upregulate angiomotin by targeting miR-1243 to mediate the dysfunction of hRMECs induced by high glucose.	32319024
2297	Human	hsa-miR-124-3	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
2298	Human	hsa-miR-124-3	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	28958159
2299	Human	hsa-miR-124-3p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	"SNHG14 was boosted in renal tissues of I/R-stimulated rats and H/R-induced HK-2 cells, while miR-124-3p was diminished in H/R-stimulated HK-2 cells."	33490282
2300	Human	hsa-miR-124-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	"LPS induced A549 cells apoptosis and inflammation, wherein SNHG14 was upregulated and miR-124-3p was downregulated."	33652176
2301	Human	hsa-miR-124-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	"VSMCs were treated with different doses of ox-LDL (0, 25, 50, and 100 mg/L) and for different time points (0, 12, 24, and 48 h) to mimic an in vitro environment of hyperlipidemia."	miRNA-124-3p was gradually upregulated in ox-LDL-treated VSMCs.	31696492
2302	Human	hsa-miR-124-3p	miRNA	calcium oxalate (CaOx)	calcium oxalate (CaOx) nephrolithiasis	HK-2 cell	calcium oxalate (CaOx) treatment	HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis.	31878844
2303	Human	hsa-miR-124-3p	miRNA	calcium oxalate monohydrate (COM)	calcium oxalate (CaOx) nephrolithiasis	calcium oxalate monohydrate (COM)-treated HK-2 cells	calcium oxalate monohydrate (COM)-treatment	miR©\124©\3p was down©\regulated in calcium oxalate monohydrate (COM)-treated HK-2 cells.	31680444
2304	Human	hsa-miR-124-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
2305	Human	hsa-miR-124-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	MGC803 cells	cisplatin treatment	upregulated	33337849
2306	Human	hsa-miR-124-3p	miRNA	hydrogen gas (H2)	gastric cancer (GC)	MGC-803 cells;and BGC-823 cells	?hydrogen treatment	"H2?gas significantly inhibited gastric tumor growth in vivo and the proliferation, migration, and lncRNA MALAT1 and EZH2 expression of gastric cancer cells while upregulated miR-124-3p expression"	33482814
2307	Human	hsa-miR-124-3p	miRNA	paclitaxel (PTX)	gastric cancer (GC)	"Human GC tissues and tumor cell lines (MKN-45, HGC-27, MGC-803, and AGS)"	paclitaxel (PTX) treatment	circ-PVT1 expression was upregulated in PTX-resistant GC tissues and cells. Circ-PVT1 downregulated enhanced PTX sensitivity in PTX-resistant GC cells by negatively regulating miR-124-3p.	31793989
2308	Human	hsa-miR-124-3p	miRNA	amentoflavone (AF)	glioblastoma multiforme (GBM)	"The glioma cell lines U87, LV229, U251, LN18 and U373"	amentoflavone (AF) treatment	upregulated	30153494
2309	Human	hsa-miR-124-3p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	human glioma cell lines U251 and U87	sevoflurane (SEVO) treatment	upregulated	30915607
2310	Human	hsa-miR-124-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U251 cells; U87MG cells; A172 cells	hypoxia treatment	Hypoxia-induced lncRNA PDIA3P1 promotes mesenchymal transition via sponging of miR-124-3p in glioma.	32127518
2311	Human	hsa-miR-124-3p	miRNA	midazolam (MDZ)	hepatocellular carcinoma (HCC)	HepG2 human HCC cells	midazolam (MDZ) treatment	upregulated	31651086
2312	Human	hsa-miR-124-3p	miRNA	suberoylanilide hydroxamic acid (SAHA)	hepatocellular carcinoma (HCC)	Hep3B and Huh7 HCC cell lines	suberanilohydroxamic acid (SAHA) treatment	upregulated	31092334
2313	Human	hsa-miR-124-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
2314	Human	hsa-miR-124-3p	miRNA	sevoflurane (SEV)	malignant glioma	U251 cells; U87 cells	sevoflurane treatment	Sevoflurane Inhibits Glioma Cells Proliferation and Metastasis through miRNA-124-3p/ROCK1 Axis	30915607
2315	Human	hsa-miR-124-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Human-derived cardiomyocytes HCM	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	circHIPK3 overexpression reversed the protective effects of miRNA-124-3p on myocardial I/R and cardiomyocyte apoptosis	31799682
2316	Human	hsa-miR-124-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	The human cardiac myocyte (HCM) cell line	HCMs were exposed to hypoxic conditions for 2?h followed by re-oxygenation (H/R) treatment.	"miR-124-3p was significantly downregulated in both MIRI rat model and H/R treated HCMs.?Overexpression of miR-124-3p reversed the H/R-induced cell apoptosis and upregulation of TNF-¦Á, IL-6, and IL-1¦Â."	31768721
2317	Human	hsa-miR-124-3p	miRNA	¦Ã- Mangostin (¦Ã-MS)	osteoarthritis (OA)	SW984 cells	¦Ã- Mangostin (¦Ã-MS) treatment	upregulated	32302289
2318	Human	hsa-miR-124-3p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28543594
2319	Human	hsa-miR-124-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"We demonstrated that, in SH-SY5Y cells treated with MPP+, NEAT1 and PDE4B expression levels were raised, while miR-124-3p expression was repressed"	33522352
2320	Human	hsa-miR-124-3p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28543594
2321	Human	hsa-miR-124-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
2322	Human	hsa-miR-124-3p	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
2323	Human	hsa-miR-124-3p.1	miRNA	propofol (PPF)	colorectal cancer (CRC)	RKO cell; HCT116 cells	Propofol treatment	Propofol treatment evidently enhanced the expression of miR- 124-3p1	31894425
2324	Human	hsa-miR-1244	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
2325	Human	hsa-miR-1244	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	downregulated	29510375
2326	Human	hsa-miR-1244	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
2327	Human	hsa-miR-1244	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC patients NSCLC tissue	cisplatin treatment	downregulated	28498474
2328	Human	hsa-miR-124-5p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
2329	Human	hsa-miR-124-5p	miRNA	5-fluorouracil (5-Fu)	non-small cell lung cancer (NSCLC)	A549 cells	5-fluorouracil (5-FU) treatment	A decrease in miR-124-5p expression level was observed in A549/5-FU cells compared with the parental A549 cells.	33240411
2330	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	30253370
2331	Human	hsa-miR-1246	miRNA	ultraviolet (UV) irradiation	apoptosis	HaCaT cells	UV irradiation treatment	upregulated	24880483
2332	Human	hsa-miR-1246	miRNA	curcumin (Cur)	bladder cancer	"T24 cells, SV-HUC-1 cells, HT-1376 cells"	curcumin treatment	downregulated	31236854
2333	Human	hsa-miR-1246	miRNA	curcumin (Cur)	corneal neovascularization (CNV)	HUVECs	curcumin treatment	upregulated	27625050
2334	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	corneal neovascularization (CNV)	human corneal fibroblasts (HCFs)	lipopolysaccharide (LPS) treatment	downregulated	30328354
2335	Human	hsa-miR-1246	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	U87 cells; U118 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-1246 was increased in the glioma cell lines treated with 5-Aza.	33153768
2336	Human	hsa-miR-1246	miRNA	hypoxia	glioblastoma multiforme (GBM)	The human GBM cell lines U87MG and U251 exosomes	hypoxia induce	upregulated	31485019
2337	Human	hsa-miR-1246	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87 cells; U251 cells	hypoxia treatment	upregulated	31485019
2338	Human	hsa-miR-1246	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO2 cells	hypoxia induce	downregulated	31709894
2339	Human	hsa-miR-1246	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
2340	Human	hsa-miR-1246	miRNA	tetrandrine	hypertrophic scars (HS)	human hypertrophic scar fibroblasts (HSFs)	tetrandrine treatment	downregulated	26909951
2341	Human	hsa-miR-1246	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
2342	Human	hsa-miR-1246	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
2343	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	lung injury	human PMVECs	lipopolysaccharide (LPS) treatment	upregulated	28386354
2344	Human	hsa-miR-1246	miRNA	metformin (Met)	melanoma	"The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951"	Metformin treatment	upregulated	30754729
2345	Human	hsa-miR-1246	miRNA	radiation	non-small cell lung cancer (NSCLC)	A549 cells; PC9 cells	radiation treatment	Both intracellular and extracellular miR-1246 was found to be upregulated after irradiation in a time-dependent pattern	32064170
2346	Human	hsa-miR-1246	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human CHON-001 cells	lipopolysaccharide (LPS) treatment	"CAIF overexpression inhibited the apoptosis of CHON-001 cells under LPS treatment, while miR-1246 overexpression attenuated the effects of CAIF overexpression."	31653823
2347	Human	hsa-miR-1246	miRNA	hypoxia	preeclampsia (PE)	primary human cytotrophoblasts	hypoxia induce	downregulated	29546425
2348	Human	hsa-miR-1246	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
2349	Human	hsa-miR-1246	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
2350	Human	hsa-miR-1246	miRNA	enterovirus 71 (EV71)	viral encephalitis in children	human neuroblastoma SH-SY5Y cells	HEV71-infected treatment	upregulated	24739954
2351	Human	hsa-miR-1247	miRNA	lipopolysaccharide (LPS)	acute pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	miR-1247 was decreased expression after LPS treatment.	30378300
2352	Human	hsa-miR-1247	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	upregulated	29172709
2353	Human	hsa-miR-1247	miRNA	curcumin (Cur)	prostate cancer	HuPCaSC lines DU145 and 22Rv1	curcumin treatment	dysregulated	29172709
2354	Human	hsa-miR-1247-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HepG2 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28586038
2355	Human	hsa-miR-1247-5p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
2356	Human	hsa-miR-1247-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
2357	Human	hsa-miR-1248	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
2358	Human	hsa-miR-1249	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2359	Human	hsa-miR-124a	miRNA	lipopolysaccharide (LPS)	acute-on-chronic liver failure (ACLF)	U937 and HepG2 cells	lipopolysaccharide (LPS) treatment	upregulated	31628069
2360	Human	hsa-miR-124a	miRNA	lipopolysaccharide (LPS)	acute-on-chronic liver failure (ACLF)	U937 cells; HepG2 cells	lipopolysaccharide (LPS) treatment	upregulated	31628069
2361	Human	hsa-miR-124a	miRNA	atorvastatin	hypercholesterolemia	HepG2 cells	atorvastatin treatment	downregulated	25926069
2362	Human	hsa-miR-124a	miRNA	laquinimod	multiple sclerosis (MS)	human microglia	laquinimod treatment	upregulated	25356411
2363	Human	hsa-miR-124a	miRNA	glucocorticoid (GC)	neuronal development	NS1 cells;A549 cells;COS-1cells	Glucocorticoids (GCs) treatment	upregulated	19131573
2364	Human	hsa-miR-124a	miRNA	CoCl2	neuronal differentiation	human mesenchymal stem cells	CoCl2 treatment	upregulated	24491559
2365	Human	hsa-miR-124a	miRNA	liraglutide	nonalcoholic fatty liver disease (NAFLD)	palmitate-treated normal human liver cell line (HL-7702)	liraglutide treatment	downregulated	30861258
2366	Human	hsa-miR-124a	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	normal human liver cell line (HL-7702)	palmitate treatment	upregulated	30861258
2367	Human	hsa-miR-124a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLS)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27824863
2368	Human	hsa-miR-124a	miRNA	geniposide (GEN)	rheumatoid arthritis (RA)	MH7A cells	geniposide (GE) treatment	GE upregulated the expression of miRNA-124a and decreased the expression of Itg¦Â1 at the mRNA and protein levels.	30342345
2369	Human	hsa-miR-125	miRNA	"androgen receptor (AR) agonist, CI-4AS-1"	breast cancer	luminal MCF-7 and T47D cells and the molecular apocrine MDA-MB-453 cells.	CI-4AS-1 treatment	downregulated	28816390
2370	Human	hsa-miR-125	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U-87 cells; A172 cells	temozolomide (TMZ) treatment	downregulated	32279420
2371	Human	hsa-miR-1252	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells; HeyA-8 cells	paclitaxel (PTX) treatment	downregulated	31945729
2372	Human	hsa-miR-1252	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	ovarian cancer cells (SKOV3/PTX and HeyA-8/PTX)	paclitaxel (PTX) treatment	circCELSR1 acts as a sponge for miR-1252 and verified that forkhead box 2 (FOXR2) is a novel target of miR-1252	31945729
2373	Human	hsa-miR-125-3p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
2374	Human	hsa-miR-125-3p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
2375	Human	hsa-miR-1255a	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
2376	Human	hsa-miR-1255b-5p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
2377	Human	hsa-miR-1256	miRNA	isoflavone	apoptosis	PCa cells	isoflavone? treatment	downregulated	22805767
2378	Human	hsa-miR-1257	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
2379	Human	hsa-miR-1257	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-miR-1257 was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
2380	Human	hsa-miR-125a	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
2381	Human	hsa-miR-125a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	miR-125a expression was markedly lower in HL60/ADR cells than HL60 cells.	29663500
2382	Human	hsa-miR-125a	miRNA	macrophage colony stimulating factor (M-CSF)	bone formation	CD14+ peripheral blood mononuclear cells (PBMCs)	macrophage colony stimulating factor (M-CSF) treatment	downregulated	24360988
2383	Human	hsa-miR-125a	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	bone formation	CD14+ peripheral blood mononuclear cells (PBMCs)	receptor activator of nuclear factor-¦ÊB ligand (RANKL) treatment	downregulated	24360988
2384	Human	hsa-miR-125a	miRNA	cisplatin (DDP)	breast cancer	Human umbilical vein endothelial cells (HUVECs)	cisplatin (DPP) treatment	downregulated	30670152
2385	Human	hsa-miR-125a	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
2386	Human	hsa-miR-125a	miRNA	entinostat	breast cancer	MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells	entinostat treatment	downregulated	23519125
2387	Human	hsa-miR-125a	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
2388	Human	hsa-miR-125a	miRNA	paclitaxel (PTX)	cervical cancer (CC)	CC cell lines	paclitaxel treatment	downregulated	26878391
2389	Human	hsa-miR-125a	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	"LN15, LN18, LN229, U138, U87, U251 cell lines"	TGF-¦Â treatment	downregulated	25256711
2390	Human	hsa-miR-125a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HuH-7 and HepG2 HCC cells	sorafenib treatment	upregulated	27982429
2391	Human	hsa-miR-125a	miRNA	hepatitis B virus X protein (HBx)	hepatocyte death and liver damage	immortalized liver (L-O2) and HepG2 cell lines	Hepatitis B virus X protein (HBx) treatment	upregulated	25993287
2392	Human	hsa-miR-125a	miRNA	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2)"	angiogenesis	human umbilical vein endothelial cells	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2) treatment"	upregulated	27836539
2393	Human	hsa-miR-125a	miRNA	IL-1¦Â	inflammatory response	monocytes	IL-1¦Â treatment	upregulated	30245693
2394	Human	hsa-miR-125a	miRNA	lipopolysaccharide (LPS)	inflammatory response	monocytes	lipopolysaccharide (LPS) treatment	upregulated	30245693
2395	Human	hsa-miR-125a	miRNA	TLR2 agonist pam3CSK4	inflammatory response	monocytes	TLR2 agonist pam3CSK4 treatment	upregulated	30245693
2396	Human	hsa-miR-125a	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
2397	Human	hsa-miR-125a	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	nasopharyngeal tissues and matched adjacent nasopharyngeal tissues	cisplatin treatment	upregulated	26017674
2398	Human	hsa-miR-125a	miRNA	radiation	non-small cell lung cancer (NSCLC)	A549; LTEP-a2 cells	radiation exposure treatment	MicroRNA-125a-5p modulates radioresistance in LTEP-a2 non-small cell lung cancer cells by targeting SIRT7	31683458
2399	Human	hsa-miR-125a	miRNA	curcumin (Cur)	osteosarcoma (OS)	osteosarcoma cell lines U2OS and MG63	curcumin in indicated concentrations	upregulated	27231954
2400	Human	hsa-miR-125a	miRNA	curcumin (Cur)	osteosarcoma (OS)	U2OS cells	curcumin treatment	upregulated	27231954
2401	Human	hsa-miR-125a	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	H2O2 induced TrxR1 expression partly through downregulated of miR-125a.	30225271
2402	Human	hsa-miR-125a-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
2403	Human	hsa-miR-125a-3p	miRNA	nonylphenol (NP)	tumorigenesis	Sertoli TM4 cells	nonylphenol (NP) treatment	upregulated	21914226
2404	Human	hsa-miR-125a-3p	miRNA	LukS-PV	cell differentiation and apoptosis	human monocytic leukaemia cell line THP-1	LukS-PV	upregulated	29179212
2405	Human	hsa-miR-125a-3p	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	NCI-H460 cells and another kind of NSCLC cells	EGCG treatment	upregulated	24712372
2406	Human	hsa-miR-125a-3p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
2407	Human	hsa-miR-125a-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
2408	Human	hsa-miR-125a-3p	miRNA	hypoxia	pancreatic cancer (PC)	"pancreatic cancer cell lines SW1990, Capan-1, PANC-1, AsPC-1, CFPAC-1, MIAPaCa-2, and BxPC-3"	1% O2	downregulated	29121972
2409	Human	hsa-miR-125a-3p	miRNA	TGF-¦Â1	lung fibrosis	MRC-5 cells	TGF-¦Â1 treatment	downregulated	30658076
2410	Human	hsa-miR-125a-5p	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
2411	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (oxLDL) treatment	upregulated	30370524
2412	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30370524
2413	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human vascular smooth muscle cells (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31410121
2414	Human	hsa-miR-125a-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
2415	Human	hsa-miR-125a-5p	miRNA	histone deacetylase inhibitor (HDACi)	breast cancer	human breast cancer cells	Histone deacetylase inhibitors (HDACi) treatment	downregulated	25531695
2416	Human	hsa-miR-125a-5p	miRNA	histone deacetylase inhibitor (HDACi)	breast cancer	MDA-MB-231 human breast cancer cell line	HDACi treatment	downregulated	25531695
2417	Human	hsa-miR-125a-5p	miRNA	tamoxifen (TAM)	breast cancer	tamoxifen resistant MCF7 cell lines (MCF7/TAM1 and MCF7/TAM2)	tamoxifen treatment	downregulated	31894257
2418	Human	hsa-miR-125a-5p	miRNA	tamoxifen (TAM)	breast cancer	MCF7 / TAM2; MCF7 / TAM1	tamoxifen treatment	downregulated	31894257
2419	Human	hsa-miR-125a-5p	miRNA	propofol (PPF)	cervical cancer (CC)	A2780 cells; SKOV3 cells	propofol treatment	Propofol significantly upregulated miR-125a-5p to exert its antitumor activity	32627014
2420	Human	hsa-miR-125a-5p	miRNA	schisandrin B (Sch B)	glioblastoma multiforme (GBM)	U251 and U87 cells	Sch B treatment	upregulated	27977512
2421	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	Marek's disease (MD)	primary peripheral blood monocytes	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	19377067
2422	Human	hsa-miR-125a-5p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
2423	Human	hsa-miR-125a-5p	miRNA	IFNs	monocytic differentiation	monocyte	IFNs treatment	dysregulated	25148686
2424	Human	hsa-miR-125a-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
2425	Human	hsa-miR-125a-5p	miRNA	gefitinib	nasopharyngeal carcinoma (NPC)	"HNE-1 cells,HK-1 cells"	geftinib treatment	upregulated	24602316
2426	Human	hsa-miR-125a-5p	miRNA	cisplatin (DDP)	osteosarcoma (OS)	U2-OS and Saos-2 osteosarcoma cell lines	cisplatin (DPP) treatment	MiR-125a-5p inhibitor attenuated ANRIL knockdown-induced chemosensitivity to cisplatin.	30777616
2427	Human	hsa-miR-125a-5p	miRNA	imiquimod (IMQ)	psoriasis	HaCaT cells	?imiquimod treatment	downregulated	33948156
2428	Human	hsa-miR-125a-5p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-125a-5p was upregulated in treated patients when compared with untreated patients.	29523324
2429	Human	hsa-miR-125a-5p	miRNA	cisplatin (DDP) and?thiosemicarbazone compound 4	triple negative breast cancer (TNBC)	MDA-MB 231 breast cancer cell line	Cisplatin?+?thiosemicarbazone compound 4 treatment	upregulated	31541355
2430	Human	hsa-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	insulin-treated HepG2 cells	dioscin treatment	upregulated	31881477
2431	Human	hsa-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	palmitic acid-treated AML12 cells	dioscin treatment	upregulated	31881477
2432	Human	hsa-miR-125a-5p	miRNA	insulin	type 2 diabetes mellitus (T2DM)	HepG2 cells	insulin treatment	downregulated	31881477
2433	Human	hsa-miR-125a-5p	miRNA	palmitic acid (PA)	type 2 diabetes mellitus (T2DM)	AML12 cells	palmitic acid treatment	downregulated	31881477
2434	Human	hsa-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	HepG2 cells	dioscin treatment	Dioscin was found to markedly elevate miR-125a-5p level and decrease STAT3 expression.	31881477
2435	Human	hsa-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular disease	human brain microvessel endothelial cells (HBMEC)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	27903586
2436	Human	hsa-miR-125b	miRNA	"1,24-dihydroxyvitamin D 3 (tacalcitol)"	breast cancer	MCF-7 cells	"1,24-dihydroxyvitamin D3 (tacalcitol) treatment"	downregulated	30503385
2437	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	breast cancer	MCF-7 cells	"1,25-dihydroxyvitamin D3 (calcitriol) treatment"	downregulated	30503385
2438	Human	hsa-miR-125B	miRNA	transcription factor NRF2	acute myeloid leukemia (AML)	peripheral blood	Transcription factor NRF2 treatment	upregulated	25323587
2439	Human	hsa-miR-125b	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
2440	Human	hsa-miR-125b	miRNA	H2O2	age-related macular degeneration (AMD)	human retinal pigment epithelial (RPE) cell	H2O2 treatment	miR-125b is induced by H2O2 treatments in RPE cells.	29631677
2441	Human	hsa-miR-125b	miRNA	lipopolysaccharide (LPS)	allergic airway inflammation	normal human tracheal epithelial (HTEpC) and A549 cells	lipopolysaccharide (LPS) treatment	downregulated	27112664
2442	Human	hsa-miR-125b	miRNA	epigallocatechin-3-gallate (EGCG)	Alzheimer's disease (AD)	SH-SY5Y cells	32mol/L EGCG	downregulated	28731435
2443	Human	hsa-miR-125b	miRNA	metal	Alzheimer's disease (AD)	human astroglial (HAG)	metal sulfate treatment	upregulated	22099153
2444	Human	hsa-miR-125b	miRNA	metal	Alzheimer's disease (AD)	human astroglial (HAG)	metal sulfate treatment	upregulated	22099153
2445	Human	hsa-miR-125b	miRNA	platelet derived growth factor-BB (PDGF-BB)	arteriosclerosis obliterans (ASO)	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	29689557
2446	Human	hsa-miR-125b	miRNA	dexamethasone (DEX)	B-cell malignant multiple myeloma£¨MM£©	MM cells	dexamethasone (DEX) treatment	upregulated	23759586
2447	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	breast cancer	MCF-7 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	30503385
2448	Human	hsa-miR-125b	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
2449	Human	hsa-miR-125b	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
2450	Human	hsa-miR-125b	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
2451	Human	hsa-miR-125b	miRNA	entinostat	breast cancer	MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells	entinostat treatment	downregulated	23519125
2452	Human	hsa-miR-125b	miRNA	trastuzumab	breast cancer	SKBR-3-TR and BT474-TR cell lines	Trastuzumab treatment	downregulated	30621694
2453	Human	hsa-miR-125b	miRNA	proteinase activated receptor 2 (PAR2)	tumorigenesis	human colorectal carcinoma	Proteinase activated-receptor 2 (PAR2) treatment	downregulated	26354435
2454	Human	hsa-miR-125b	miRNA	camptothecin	cancer cell apoptosis	PC3 cells; K562 cells; CCRF-CEM cells; NCI-H1299 cells; HCT-15 cells;HBE cells; RBE cells	camptothecin treatment	downregulated	22252650
2455	Human	hsa-miR-125b	miRNA	ultraviolet (UV) irradiation	cataract	SRA01/04 cell	15W UVB lamps treatment	downregulated	25312242
2456	Human	hsa-miR-125b	miRNA	ultraviolet (UV) irradiation	cell cycle arrest	"Human embryonic kidney cell line HEK293, human colon cancer cell line HCT116,human osteosarcoma cell line U2OS and Human keratinocyte cell line HaCaT"	ultraviolet radiation (UV) treatment	UV radiation induces upregulated of miR-125b	22854965
2457	Human	hsa-miR-125b	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	upregulated	24178909
2458	Human	hsa-miR-125b	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	HCV replicon cells Con1 (type 1b) and Huh7/Ava5 (type 1b) and sera from HCV-infected patients	hepatitis C virus (HCV) infection	upregulated	29541414
2459	Human	hsa-miR-125b	miRNA	rituximab (RTX)	chronic lymphocytic leukemia (CLL)	CD19 cells of CML patients	rituximab treatment	downregulated	28126961
2460	Human	hsa-miR-125b	miRNA	granulocyte-colony stimulating factor (G-CSF)	colorectal cancer (CRC)	"human CRC cell line HCT-8, SW480, SW620, HCT-116, LOVO"	Granulocyte colony-stimulating factor?treatment	upregulated	28881590
2461	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 renal tubular epithelial cells	high glucose treatment	upregulated	27775793
2462	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
2463	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retina microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	downregulated	30988072
2464	Human	hsa-miR-125b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial (RPE) cells	high glucose (HG) treatment	miR-125b expressions were significantly downregulated by the high glucose treatments.	31938439
2465	Human	hsa-miR-125b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	encephalitis	SH-SY5Y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	Overexpression of circARF3 mitigates TNF-¦Á-induced inflammatory damage by up-regulating miR-125b.	32329660
2466	Human	hsa-miR-125b	miRNA	cocaine	viral replication	CD4+ T cells	Cocaine treatment	downregulated	23251514
2467	Human	hsa-miR-125b	miRNA	reactive oxygen species (ROS)	Epstein-Barr virus (EBV) infection	ovarian cancer cells	reactive oxygen species (ROS) treatment	downregulated	23146892
2468	Human	hsa-miR-125b	miRNA	phorbol-12-myristate-13-acetate(PMA)	functions of human macrophages	U937 cells	phorbol 12-myristate 13-acetate (PMA) treatment	upregulated	33268675
2469	Human	hsa-miR-125b	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
2470	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	MCF-7 cells	"1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))?treatment"	upregulated	19437538
2471	Human	hsa-miR-125b	miRNA	arsenic trioxide (ATO)	glioblastoma multiforme (GBM)	human glioma U251 cells	arsenic trioxide (As2O3) treatment	downregulated	24479808
2472	Human	hsa-miR-125b	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
2473	Human	hsa-miR-125b	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
2474	Human	hsa-miR-125b	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
2475	Human	hsa-miR-125b	miRNA	propranolol (PRO)	infantile hemangioma (IH)	hemangioma endothelial cells	propranolol treatment	upregulated	30986805
2476	Human	hsa-miR-125b	miRNA	estradiol-17¦Â (E2)	inflammation	human macrophages	estradiol-17¦Â (E2) treatment	"LPS induces let-7a and inhibits miR-125b expression in human macrophages, and pretreatment with estradiol abrogates these effects"	20351193
2477	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	leukemia	U937 and HL60 cells2	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	28389358
2478	Human	hsa-miR-125b	miRNA	daunorubicin	leukemia	leukemia cell lines	on the resistance to the chemotherapeutic agent treatment	upregulated	24604579
2479	Human	hsa-miR-125b	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
2480	Human	hsa-miR-125b	miRNA	TGF-¦Â	liver fibrosis	LX2 cells	TGF-¦Â treatment	downregulated	31548167
2481	Human	hsa-miR-125b	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
2482	Human	hsa-miR-125b	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
2483	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	macrophage polarization	LPS-treated THP-1 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	30540970
2484	Human	hsa-miR-125b	miRNA	lipopolysaccharide (LPS)	macrophage polarization	THP-1 cells	lipopolysaccharide (LPS) treatment	upregulated	30540970
2485	Human	hsa-miR-125b	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	nasopharyngeal tissues and matched adjacent nasopharyngeal tissues	cisplatin treatment	upregulated	26017674
2486	Human	hsa-miR-125b	miRNA	tanshinone IIA (Tan IIA)	nasopharyngeal carcinoma (NPC)	HK1 cells	tanshinone IIA treatment	the present study demonstrates that tanshinone IIA enhances pyroptosis and inhibits the proliferation of HK1 cells by modulating miR-125b/foxp3/caspase-1/GSDMD signaling	33760137
2487	Human	hsa-miR-125b	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
2488	Human	hsa-miR-125b	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
2489	Human	hsa-miR-125b	miRNA	osimertinib	non-small cell lung cancer (NSCLC)	H1975 cells	osimertinib treatment	The relative expression levels of miR-125b was significantly upregulated after treated with 100 nM osimertinib for 24 h.	32375124
2490	Human	hsa-miR-125b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
2491	Human	hsa-miR-125b	miRNA	"dexamethasone (DEX), ascorbic acid, and ¦Â-glycerol phosphate"	PDLCs osteoblastic differentiation	periodontal ligament cells (PDLCS)	"dexamethasone, ¦Â-glycerol phosphate and ¦Á-ascorbic acid treatment"	miR-125b was downregulated during the process of ostoblast differentiation of PDLCs.	30078007
2492	Human	hsa-miR-125b	miRNA	decitabine	precursor B-cell acute lymphoblastic leukemia (B-ALL)	Nalm6 cell line	decitabine treatment	downregulated	30912184
2493	Human	hsa-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	prostate cancer	?primary prostatic epithelial cells (PrE)	"?1,25-dihydroxyvitamin D"	downregulated	23503652
2494	Human	hsa-miR-125b	miRNA	capecitabine	rectal cancer	rectal cancer tissue	capecitabine treatment	upregulated	18695884
2495	Human	hsa-miR-125b	miRNA	trichostatin A (TSA)	systemic sclerosis (SSc)	primary dermal fibroblasts	trichostatin A treatment	downregulated	31309742
2496	Human	hsa-miR-125b	miRNA	tubastatin A	systemic sclerosis (SSc)	primary dermal fibroblasts	tubastatin A treatment	downregulated	31309742
2497	Human	hsa-miR-125b	miRNA	glucosamine	type 2 diabetes mellitus (T2DM)	HepG2 cells	glucosamine treatment	upregulated	29319168
2498	Human	hsa-miR-125b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	type 2 diabetes mellitus (T2DM)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29319168
2499	Human	hsa-miR-125b	miRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells	high levels of phosphate treatment	downregulated	28522697
2500	Human	hsa-miR-125b	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	keratinocytes HaCaT	lipopolysaccharide (LPS) treatment	downregulated	27133077
2501	Human	hsa-miR-125b	miRNA	homocysteine (Hcy)	vascular smooth muscle cell proliferation	vascular smooth muscle cells	homocysteine treatment	downregulated	27426728
2502	Human	hsa-miR-125b-1*	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
2503	Human	hsa-miR-125b-1-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
2504	Human	hsa-miR-125b-1-3p	miRNA	cortisol	schizophrenia (SZ)	"The immortalized multipotent, human hippocampal progenitor cell line, HPC0A07/03C (propriety of ReNeuron)"	HPC0A07/03C cells were treated with the stress hormone cortisol (100 ¦ÌM) or vehicle for 3 days during the proliferation stage (to mimic the early stress exposure)	downregulated	30057098
2505	Human	hsa-miR-125b-2	miRNA	androgen	prostate cancer	prostate cancer cells	androgen treatment	downregulated	23503464
2506	Human	hsa-miR-125b-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
2507	Human	hsa-miR-125b-5p	miRNA	IL-1¦Â	arthritis	human osteoarthritic (OA) chondrocytes	IL-1¦Â treatment	downregulated	31053727
2508	Human	hsa-miR-125b-5p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
2509	Human	hsa-miR-125b-5p	miRNA	brucella.suis	brucellosis	HEK293T cell lines	Brucella infection treatment	downregulated	27473222
2510	Human	hsa-miR-125b-5p	miRNA	sevoflurane (SEV)	cognitive impairment	SH-SY5Y cells	Sevoflurane treatment	upregulated	31490755
2511	Human	hsa-miR-125b-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells; HCT8 cells; HT29 cells	5-fluorouracil (5-FU) treatment	downregulated	31746054
2512	Human	hsa-miR-125b-5p	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cells	cisplatin treatment	downregulated	32766131
2513	Human	hsa-miR-125b-5p	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells; HCT8 cells; HT29 cells	oxaliplatin treatment	downregulated	31746054
2514	Human	hsa-miR-125b-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE©\19 cells	high glucose treatment	downregulated	31094072
2515	Human	hsa-miR-125b-5p	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
2516	Human	hsa-miR-125b-5p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
2517	Human	hsa-miR-125b-5p	miRNA	IL-1¦Â	lumbar disc degeneration (LDD)	human lumbar degenerative NP specimens and IL-1¦Â-treated NP cells	IL-1¦Â? treatment	miR-125b-5p was markedly upregulated in both human lumbar degenerative NP specimens and IL-1¦Â-treated NP cells.	33123835
2518	Human	hsa-miR-125b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY6Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	32057951
2519	Human	hsa-miR-125b-5p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
2520	Human	hsa-miR-125b-5p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
2521	Human	hsa-miR-125b-5p	miRNA	bortezomib	cutaneous T-cell lymphoma (CTCL)	MyLa2000 and SeAx	?bortezomib treatment	upregulated	23527180
2522	Human	hsa-miR-126	miRNA	arsenic trioxide (ATO)	acute promyelocytic leukemia (APL)	HUVECs	arsenic trioxide (ATO) treatment	upregulated	26274316
2523	Human	hsa-miR-126	miRNA	cysteine-rich 61 (CCN1)	angiogenesis	"human osteoblast-like cell line MG-63, human fetal osteoblastic cell line hFOB"	cysteine-rich 61 (CCN1) treatment	downregulated	27465842
2524	Human	hsa-miR-126	miRNA	fenretinide	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fenretinide treatment	upregulated	31925643
2525	Human	hsa-miR-126	miRNA	palmitic acid (PA)	antiapoptotic	HUVECs	palmitic acid (PA) treatment	downregulated	25318608
2526	Human	hsa-miR-126	miRNA	actinomycin X2 (AX2)	apoptosis	human prostate cancer cells (PC-3)	actinomycin X2 (AX2) treatment	miR-144 was decreased ; smiR-126 was increased	26645890
2527	Human	hsa-miR-126	miRNA	palmitate	apoptosis	HUVECs	palmitate treatment	downregulated	25318608
2528	Human	hsa-miR-126	miRNA	resveratrol	apoptosis	CRL-1730 cells	resveratrol (RS) treatment	upregulated	24107596
2529	Human	hsa-miR-126	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
2530	Human	hsa-miR-126	miRNA	curcumin (Cur)	arteriosclerosis (AS)	Human microvascular endothelial HMEC-1 cells	curcumin treatment	upregulated	31016760
2531	Human	hsa-miR-126	miRNA	asbestos	asbestos-related malignancies	serum	asbestos treatment	upregulated	30257964
2532	Human	hsa-miR-126	miRNA	inhaled corticosteroids	asthma	bronchial epidermal cells from asthma patients	inhaled corticosteroids treatment	downregulated	24995087
2533	Human	hsa-miR-126	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-126 level was significantly reduced in ox-LDL-treated HUVECs.	29203244
2534	Human	hsa-miR-126	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29203244
2535	Human	hsa-miR-126	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	HUVEC	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	24870014
2536	Human	hsa-miR-126	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
2537	Human	hsa-miR-126	miRNA	arachidonic acid (AA)	breast cancer	platelet microvesicle (MV)	arachidonic acid (AA) treatment	upregulated	31665654
2538	Human	hsa-miR-126	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
2539	Human	hsa-miR-126	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
2540	Human	hsa-miR-126	miRNA	tamoxifen (TAM)	breast cancer	tumour samples of breast cancer	tamoxifen treatment	upregulated	23968733
2541	Human	hsa-miR-126	miRNA	hypoxia	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	22282338
2542	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	cell damage	HK-2 cells	lipopolysaccharide (LPS) treatment	LncRNA?Mirt2 prohibits lipopolysaccharide-evoked HK-2 cell injury via modulation of?microRNA-126.	31889348
2543	Human	hsa-miR-126	miRNA	benzo(a)pyrene (BaP)	cell proliferation	primary cell cultures from normal and malignant endometrial tissue	benzo(a)pyrene (BaP) exposure	downregulated	30811740
2544	Human	hsa-miR-126	miRNA	high glucose (HG)	cell senescence	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	downregulated	30717558
2545	Human	hsa-miR-126	miRNA	tea polyphenols (TP)	cell senescence	high glucose (HG)-treated human glomerular mesangial cells (HGMCs)	tea polyphenols (TP) treatment	upregulated	30717558
2546	Human	hsa-miR-126	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell-to-cell communication	human aortic endothelial cells (ECs) and their transfer to recipient cells	tumor necrosis factor alpha (TNF-¦Á) treatment	differently regulation	25315114
2547	Human	hsa-miR-126	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	human umbilical vein endothelial cells (HUVECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-126 expression was markedly reduced in HUVECs subjected to OGD/R treatment	33355373
2548	Human	hsa-miR-126	miRNA	naringin	chondrosarcoma	human chondrosarcoma cell line JJ012	naringin treatment	upregulated	24975661
2549	Human	hsa-miR-126	miRNA	HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA)	chronic heart failure (CHF)	human aortic endothelial cells	HDLNYHA treatment	downregulated	24958738
2550	Human	hsa-miR-126	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patient cells	ibrutinib treatment	upregulated	28299881
2551	Human	hsa-miR-126	miRNA	capecitabine	colorectal cancer (CRC)	colon cancer cells	capecitabine treatment	upregulated	22397399
2552	Human	hsa-miR-126	miRNA	oxaliplatin	colorectal cancer (CRC)	colon cancer cells	oxaliplatin treatment	upregulated	22397399
2553	Human	hsa-miR-126	miRNA	docosahexaenoic acid (DHA)	colorectal cancer (CRC)	HCT116 and Caco2 cell lines	Docosahexaenoic acid (DHA) treatment	upregulated	30598703
2554	Human	hsa-miR-126	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
2555	Human	hsa-miR-126	miRNA	IL-1¦Â and TNF-¦Á	cystic fibrosis (CF)	cystic fibrosis airway epithelial cells	IL-1¦Â and TNF-¦Á treatment	downregulated	20083669
2556	Human	hsa-miR-126	miRNA	glucose plus advanced glycation end product-BSA	diabetes mellitus (DM)	human cavernous endothelial cells (hCECs)	glucose plus advanced glycation end product-BSA treatment	downregulated	29942117
2557	Human	hsa-miR-126	miRNA	icariside II (ICA II)	diabetes mellitus (DM)	glucose plus advanced glycation end product-BSA-treated human cavernous endothelial cells (hCECs)	icariside II (ICA II) treatment	upregulated	29942117
2558	Human	hsa-miR-126	miRNA	hyperglycemia and advanced glycation end products (AGE)	diabetic vasculopathy	Endothelial Progenitor Cells	Hyperglycemia and Advanced Glycation End Products treatment	downregulated	27673690
2559	Human	hsa-miR-126	miRNA	maggot debridement therapy (MDT)	diabetic foot ulcer (DFU)	patients with DFUs	maggot debridement therapy (MDT) treatment	upregulated	27623390
2560	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose treatment	downregulated	30341510
2561	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose treatment	downregulated	31608649
2562	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	miR-126 was downregulated in high-glucose-induced HRECs.	31608649
2563	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal capillary endothelial cells (HRCECs)	high glucose (HG) treatment	downregulated	33416109
2564	Human	hsa-miR-126	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	serum	streptozotocin (STZ) treatment	downregulated	33416109
2565	Human	hsa-miR-126	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal capillary endothelial cells (HRCECs)	high glucose (HG) treatment	The diabetic rats were found to exhibit downregulated serum and retinal miR-126 levels compared with the non-diabetic rats.	33416109
2566	Human	hsa-miR-126	miRNA	palmitate	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	palmitate treatment	MicroRNA-126 Modulates Palmitate-Induced Migration in HUVECs by Downregulating Myosin Light Chain Kinase via the ERK/MAPK Pathway	32850751
2567	Human	hsa-miR-126	miRNA	aspirin	fetal neural stem cells (NSCs)maturation	?plasma	aspirin treatment	downregulated	23386708
2568	Human	hsa-miR-126	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
2569	Human	hsa-miR-126	miRNA	Cl-amidine	glioblastoma multiforme (GBM)	LN18 and LN229 cells	Cl-amidine treatment	upregulated	30597867
2570	Human	hsa-miR-126	miRNA	high glucose (HG)	hyperglycemia-induced senescence	human glomerular mesangial cells (HGMCs)	high glucose treatment	downregulated	31089945
2571	Human	hsa-miR-126	miRNA	tea polyphenols (TP)	hyperglycemia-induced senescence	High glucose-treated human glomerular mesangial cells (HGMCs)	tea polyphenols (TPs) treatment	upregulated	31089945
2572	Human	hsa-miR-126	miRNA	training	hypertension and skeletal muscle microcirculation rarefaction	heart tissues	training treatment	upregulated	33105326
2573	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	IgA nephropathy (IgAN)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31889348
2574	Human	hsa-miR-126	miRNA	polychlorinated biphenyls (PCBs)	inflammation	HUVECs	polychlorinated biphenyls (PCBs) treatment	upregulated	27288564
2575	Human	hsa-miR-126	miRNA	angiopoietin-1 (Ang-1)	inflammatory injury	HPDE6-C7 treated with LPS (10 ?g/mL)	angiopoietin-1 (Ang-1) treatment	upregulated	31966500
2576	Human	hsa-miR-126	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	OGD induced downregulated of miR-126 in HBMECs.	32591985
2577	Human	hsa-miR-126	miRNA	a?a¨ª (Ac) and red muscadine grape (Gp)	lipid accumulation and inflammatory response	human vascular endothelial cells (HUVEC)	a?a¨ª (Ac) and red muscadine grape (Gp)treatment	?microRNA-126 expression was found to be modulated by Ac and Gp	21682256
2578	Human	hsa-miR-126	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
2579	Human	hsa-miR-126	miRNA	exercise and diet	microvascular endothelial dysfunction	serum	exercise and diet treatment	"After 6-weeks intervention, microRNA-126 was significantly decreased."	30472037
2580	Human	hsa-miR-126	miRNA	exercise and diet	microvascular endothelial dysfunction	serum from obese adolescents	food and exercise treatment	downregulated	30472037
2581	Human	hsa-miR-126	miRNA	natalizumab	multiple sclerosis (MS)	CD4+T lymphocytes	natalizumab treatment	downregulated	24598267
2582	Human	hsa-miR-126	miRNA	dimethyloxalylglycine (DMOG)	myocardial angiogenesis	human umbilical vein endothelial cells (HUVECs)	dimethyloxalylglycine (DMOG) treatment	DMOG significantly increased the expression level of HIF-1¦Á and miR-126 in a concentration-dependent manner in normoxia.	32939968
2583	Human	hsa-miR-126	miRNA	danhong injection (DHI)	myocardial infarction (MI)	hypoxia-induced human umbilical vein endothelial cells (HUVECs)	danhong injection (DHI) treatment	upregulated	31629250
2584	Human	hsa-miR-126	miRNA	hypoxia	myocardial infarction (MI)	human cardiosphere-derived cells (CDCs) exosomes	hypoxia induce	upregulated	29243842
2585	Human	hsa-miR-126	miRNA	hypoxia	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	31629250
2586	Human	hsa-miR-126	miRNA	"TNF¦Á , IFN¦Ã"	neuroinflammation	human brain endothelial cell line	"TNF¦Á , IFN¦Ã treatment"	downregulated	28358058
2587	Human	hsa-miR-126	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
2588	Human	hsa-miR-126	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
2589	Human	hsa-miR-126	miRNA	matrine	non-small cell lung cancer (NSCLC)	A549 NSCLC cell line	matrine treatment	"matrine induced cell cycle arrest and apoptosis, and recovered the expression of miR-126 in the A549 NSCLC cell line."	27665734
2590	Human	hsa-miR-126	miRNA	radiation	non-small cell lung cancer (NSCLC)	non-small cell lung cancer tissue	radiation treatment	upregulated	20728239
2591	Human	hsa-miR-126	miRNA	total flavonoids (TFs)	non-small cell lung cancer (NSCLC)	human lung cancer cell line A549	TFS treatment	downregulated	28404902
2592	Human	hsa-miR-126	miRNA	high glucose (HG)	obesity	obesity subjects' adipose tissue-derived stem cells (ASCs)	high glucose (HG) treatment	downregulated in cell-derived extracellular vesicles (EVs)	26122028
2593	Human	hsa-miR-126	miRNA	palmitic acid (PA)	obesity	obesity subjects' adipose tissue-derived stem cells (ASCs)	palmitic acid (PA) treatment	downregulated in cell-derived extracellular vesicles (EVs)	26122028
2594	Human	hsa-miR-126	miRNA	baicalin (BAI)	osteoarthritis (OA)	IL-1¦Â-treated CHON-001 cells	baicalin (BAI) treatment	downregulated	29331857
2595	Human	hsa-miR-126	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	upregulated	29331857
2596	Human	hsa-miR-126	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocyte cell line CHON-001	IL-1¦Â treatment	upregulated	30034795
2597	Human	hsa-miR-126	miRNA	ailanthone (AIL)	osteosarcoma (OS)	MG63 cells	ailanthone (AIL) treatment	upregulated	31571500
2598	Human	hsa-miR-126	miRNA	angelica polysaccharide (AP)	oxidative stress	H2O2-treated HaCaT cells	angelica polysaccharide (AP) treatment	upregulated	31288012
2599	Human	hsa-miR-126	miRNA	H2O2	oxidative stress	HaCaT cells	H2O2 treatment	downregulated	31288012
2600	Human	hsa-miR-126	miRNA	high glucose (HG)	periodontitis with diabetes	THP-1 cells	high glucose (HG) treatment	High glucose condition can inhibit the proliferation of THP-1-derived macrophages and increase the expression of miR-126.	33280362
2601	Human	hsa-miR-126	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
2602	Human	hsa-miR-126	miRNA	carbon black (CB) particles	lung fibrosis	human bronchial epithelial cell line (16HBE)	carbon black (CB) particles treatment	downregulated	31502903
2603	Human	hsa-miR-126	miRNA	carbon black (CB) particles	lung fibrosis	16HBE cells	carbon black (CB) particles treatment	miR-126 in 16HBE cells after treatment with different concentration of CB was statistically decreased.	31502903
2604	Human	hsa-mir-126	miRNA	carbon black (CB) particles	lung fibrosis	16HBE cells	carbon black (CB) particles treatment	pri-miR-126 in 16HBE cells after treatment with different concentration of CB was statistically increased.	31502903
2605	Human	hsa-miR-126	miRNA	oxygen glucose deprivation (OGD)	remote ischemic preconditioning (RIPC)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	upregulated	32380415
2606	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	sepsis-induced severe cardiomyopathy	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharides (LPS) treatment	upregulated	32411123
2607	Human	hsa-miR-126	miRNA	naringin	small-cell lung cancer (SCLC)	human small cell lung cancer H69AR cells	naringin treatment	upregulated	30197681
2608	Human	hsa-miR-126	miRNA	Buyang Huanwu decoction (BYHWD)	stroke	mesenchymal stem cell (MSC)	Buyang Huanwu decoction (BYHWD) treatment	upregulated	25796380
2609	Human	hsa-miR-126	miRNA	"diet control and exercise in IGT/IFG subjects, insulin plus diet control and exercise"	type 2 diabetes mellitus (T2DM)	type 2 diabetes mellitus (T2DM) patients	six months of treatment	upregulated	24927146
2610	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	CCD-18Co cells	lipopolysaccharide (LPS) treatment	downregulated	27061150
2611	Human	hsa-miR-126	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	CCD-18Co cells	lipopolysaccharide (LPS) treatment	downregulated	27061150
2612	Human	hsa-miR-126	miRNA	mango extract	ulcerative colitis (UC)	CCD-18Co cells	mango extract treatment	upregulated	27061150
2613	Human	hsa-miR-126	miRNA	polyphenolics extracted from mango (var. Keitt)	ulcerative colitis (UC)	LPS-treated CCD-18Co cells	polyphenolics extracted from mango (var. Keitt) treatment	upregulated	27061150
2614	Human	hsa-miR-126	miRNA	asbestos	asbestos toxicity	BEAS-2B cells	asbestos exposure	upregulated	32006662
2615	Human	hsa-miR-126	miRNA	red wine polyphenolics	chronic intestinal inflammation and colon cancer	CCD-18Co myofibroblast cells	red wine polyphenolics treatment	downregulated	22572890
2616	Human	hsa-miR-126*	miRNA	"TNF¦Á , IFN¦Ã"	neuroinflammation	human brain endothelial cell line	"TNF¦Á , IFN¦Ã treatment"	downregulated	28358058
2617	Human	hsa-miR-1260	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
2618	Human	hsa-miR-1260	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
2619	Human	hsa-miR-1260b	miRNA	hypoxia	pathological proliferation of VSMCs	human primary pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	Hypoxia-induced miR-1260b promotes VSMC proliferation.	31818357
2620	Human	hsa-miR-1261	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
2621	Human	hsa-miR-126-3p	miRNA	etanercept	ankylosing spondylitis (AS)	Blood	etanercept treatment	upregulated	26273623
2622	Human	hsa-miR-126-3p	miRNA	high-intensity interval training (HIIT)	atherosclerosis (AS)	individuals	three exercise sessions/week of 4 ¡Á 30 s at maximum speed (all-out) with one extra session every week (up to 7 ¡Á 30 s)	upregulated	28611681
2623	Human	hsa-miR-126-3p	miRNA	low-intensity training	atherosclerosis (AS)	individuals	three exercise sessions/week for 25 min <75% of maximum heart rate	upregulated	28611681
2624	Human	hsa-miR-126-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	downregulated	31722571
2625	Human	hsa-miR-126-3p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
2626	Human	hsa-miR-126-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
2627	Human	hsa-miR-126-3p	miRNA	high-intensity interval training (HIIT)	endothelial dysfunction	blood	high-intensity interval (HII) cycling exercise bouts treatment	upregulated	31487226
2628	Human	hsa-miR-126-3p	miRNA	hydroquinone (HQ)	erythroid cell differentiation	CD34 + hematopoietic progenitor cells	hydroquinone (HQ) treatment	downregulated	28733890
2629	Human	hsa-miR-126-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
2630	Human	hsa-miR-126-3p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
2631	Human	hsa-miR-126-3p	miRNA	hydroquinone (HQ)	hematotoxicity	CD34 hematopoietic progenitor cells	treat with HQ	downregulated	28733890
2632	Human	hsa-miR-126-3p	miRNA	Traumatic brain injury (TBI)	hypopituitarism	blood	Traumatic brain injury (TBI) treatment	downregulated	27027233
2633	Human	hsa-miR-126-3p	miRNA	dabrafenib	melanoma	The BRAF-mutant human melanoma cell lines A375 and SK-Mel28	?dabrafenib treatment	downregulated	31227006
2634	Human	hsa-miR-126-3p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
2635	Human	hsa-miR-126-3p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oxidative stress	HTR-8/SVneo cell line	mono-(2-ethylhexyl) phthalate (MEHP) treatment	upregulation	26871967
2636	Human	hsa-miR-126-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	preeclampsia (PE)	HUVECs	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	31323164
2637	Human	hsa-miR-126-3p	miRNA	adalimumab(ADA)	psoriasis	circulating angiogenic cells (CACs)	adalimumab treatment	upregulated	26943583
2638	Human	hsa-miR-126-3p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
2639	Human	hsa-miR-126-3p	miRNA	high glucose (HG)	wound healing defects and vascular dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	"High glucose decreased the endogenous H2S and miR-126-3p levels and increased the DNMT1 expression, thus inducing the migration dysfunction of HUVECs."	32186933
2640	Human	hsa-miR-126-3p	miRNA	hydrogen sulfide (H2S)	wound healing defects and vascular dysfunction	human umbilical vein endothelial cells (HUVECs)	hydrogen sulfide (H2S) treatment	upregulated	32186933
2641	Human	hsa-miR-1264	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
2642	Human	hsa-miR-126-5p	miRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	human aortic smooth muscle cells (hAoSMCs)	angiotensin II (Ang II) treatment	miR-126-5p expression significantly decreased in primary hAoSMCs stimulated with Ang II.	32612287
2643	Human	hsa-miR-126-5p	miRNA	bone morphogenetic protein 4 (BMP4)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	bone morphogenetic protein 4 (BMP4) treatment	upregulated(miR-126-5p) ;downregulated (miR-494 )	28124060
2644	Human	hsa-miR-126-5p	miRNA	baicalin (BAI)	atherosclerosis (AS)	ox-LDL-treated HA-VSMCs	baicalin (BAI) treatment	upregulated	31204352
2645	Human	hsa-miR-126-5p	miRNA	high-intensity interval training (HIIT)	atherosclerosis (AS)	individuals	three exercise sessions/week of 4 ¡Á 30 s at maximum speed (all-out) with one extra session every week (up to 7 ¡Á 30 s)	upregulated	28611681
2646	Human	hsa-miR-126-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HA-VSMCs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31204352
2647	Human	hsa-miR-126-5p	miRNA	IL-1¦Â	chondrocyte inflammation	cartilage cells	IL-1¦Â treatment	upregulated	33098220
2648	Human	hsa-miR-126-5p	miRNA	paclitaxel (PTX)	colorectal cancer (CRC)	SW480 cells; SW620 cells	Paclitaxel (PTX) treatment	?CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis	32581554
2649	Human	hsa-miR-126-5p	miRNA	high-intensity interval training (HIIT)	endothelial dysfunction	blood	high-intensity interval (HII) cycling exercise bouts treatment	upregulated	31487226
2650	Human	hsa-miR-126-5p	miRNA	proresolution lipid mediator lipoxin (LX)A4	inflammation	HUVECs and EMVs	LXA4 treatment	upregulated in HUVECs and in EMVs	28100645
2651	Human	hsa-miR-126-5p	miRNA	lipopolysaccharide (LPS)	liver damage	L02 cells	lipopolysaccharide (LPS) treatment	LPS significantly elevated the expression of miR-126-5p in L02 cells.	32031750
2652	Human	hsa-miR-126-5p	miRNA	Tubeimoside-1 (TBMS1)	non-small cell lung cancer (NSCLC)	NCI-H1299 cells	Tubeimoside-1 (TBMS1) treatment	upregulated	29363720
2653	Human	hsa-miR-126-5p	miRNA	Tubeimoside-1 (TBMS1)	non-small cell lung cancer (NSCLC)	NCI-H1299 cells	Tubeimoside-1 (TBMS1) treatment	upregulated	30127904
2654	Human	hsa-miR-1268a	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
2655	Human	hsa-miR-1268a	miRNA	hypoxia	cell proliferation	human primary pulmonary artery smooth muscle cells	hypoxia induce	upregulated	31370272
2656	Human	hsa-miR-1268a	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2657	Human	hsa-miR-1268b	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
2658	Human	hsa-miR-1268b	miRNA	steviol	gastrointestinal cancer	MKN-45 cells	steviol treatment	upregulated	29899860
2659	Human	hsa-miR-1269b	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	miR-1269b expression was upregulated in cisplatin-resistant NSCLC specimens and NSCLC cell lines.	32021259
2660	Human	hsa-miR-1269b	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV)? treatment	upregulated	27349221
2661	Human	hsa-miR-126a-5p	miRNA	H2O2 and hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	H9C2 cells	myocardial ischemia-reperfusion (M-I/R)	upregulated	29212219
2662	Human	hsa-miR-127	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	"Human bladder carcinoma cell line,T24 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	16766263
2663	Human	hsa-miR-127	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
2664	Human	hsa-miR-127	miRNA	schizandrin A (SchA)	inflammatory skin diseases	HaCaT cells	schizandrin A (SchA) treatment	miR-127 expression was upregulated in LPS-treated HaCaT cells but downregulated after SchA treatment.	30257250
2665	Human	hsa-miR-127	miRNA	TGF-¦Â	lung cancer	HCC cell	TGF-¦Â? treatment	TGF¦Â decreases miR-127 expression by enhancing c-Jun-mediated inhibition of miR-127 promoter activity	23762330
2666	Human	hsa-miR-127	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
2667	Human	hsa-miR-127	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	"miR-127 was repressed by overexpressed TUG1, meanwhile the protective impacts of TUG1 against LPS-evoked inflammatory injury in MRC-5 cells were overturned by overexpressed miR-127."	31017717
2668	Human	hsa-miR-127	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
2669	Human	hsa-miR-1270	miRNA	cisplatin (DDP)	ovarian cancer (OC)	Human ovarian cancer cell lines (A2780 and SKOV-3)	cisplatin treatment	miR-1270 Plays an Oncogenic Role in Ovarian Cancer Cells and Reduces Their Cisplatin Chemosensitivity.	31479922
2670	Human	hsa-miR-1271	miRNA	huaier extract	acute kidney injury (AKI)	HK-2 cells	Huaier extract (HE) treatment	HE Downregulates CHOP and GRP78 and Upregulates miR-1271 in HK-2 Cells.	33457422
2671	Human	hsa-miR-1271	miRNA	hepatitis B virus (HBV)	HBV-associated hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues and cells	hepatitis B virus (HBV) infection	downregulated	30565670
2672	Human	hsa-miR-1271	miRNA	dietary saturated fatty acids (SFA)	insulin resistance (IR)	HepG2 cells	Dietary saturated fatty acids (SFA) treatment	upregulated	27613089
2673	Human	hsa-miR-1271-5p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
2674	Human	hsa-miR-1273c	miRNA	XAV939	non-small cell lung cancer (NSCLC)	"The NSCLC cell line, NCI-H1299"	10 ?M XAV939 for 12 h treatment	The downregulated of lncRNA?MIR503HG?induced by XAV939 may serve an important role in NSCLC suppression via sponging?miR-1273c?and regulating?SOX4?expression	31186710
2675	Human	hsa-miR-1273d	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
2676	Human	hsa-miR-1273d	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
2677	Human	hsa-miR-1273f	miRNA	hypoxia	hepatocellular carcinoma (HCC)	exosomes from Huh7 cells	hypoxia induce	upregulated	31562861
2678	Human	hsa-miR-127-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
2679	Human	hsa-miR-127-3p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	downregulated	32742197
2680	Human	hsa-miR-1274a	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
2681	Human	hsa-miR-1274a	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	upregulated	23159985
2682	Human	hsa-miR-1274b	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	upregulated	23159985
2683	Human	hsa-miR-1275	miRNA	curcumin (Cur)	corneal neovascularization (CNV)	HUVECs	curcumin treatment	upregulated	27625050
2684	Human	hsa-miR-1275	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
2685	Human	hsa-miR-1275	miRNA	"tamarix articulata, quercetin , epigallocatechin gallate (EGCG)"	hepatocellular carcinoma (HCC)	Huh-7 cells	"T. articulata, quercetin and EGCG treatment"	downregulated	28817968
2686	Human	hsa-miR-1275	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
2687	Human	hsa-miR-127-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
2688	Human	hsa-miR-127-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteonecrosis of femoral head (GIONFH)	human Bone mesenchymal stem cells (BMSCs)	glucocorticoids (GCs) treatment	upregulated	30579595
2689	Human	hsa-miR-127-5p	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
2690	Human	hsa-miR-1276	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
2691	Human	hsa-miR-1276	miRNA	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL)	osteoclast differentiation	THP-1 cells	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL) treatment	NF-¦ÊB promotes osteoclast differentiation by overexpressing MITF via down regulating microRNA-1276 expression	32673666
2692	Human	hsa-miR-1277-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	articular chondrocytes (ACs)	IL-1¦Â treatment	downregulated	31198977
2693	Human	hsa-miR-1277-5p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	CHON-001 chondrocytes	lipopolysaccharide (LPS) treatment	"HOTAIR and SGTB were upregulated, while miR-1277-5p was downregulated in OA cartilages and LPS-stimulated CHON-001 chondrocytes."	33721916
2694	Human	hsa-miR-1277-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30671473
2695	Human	hsa-miR-1277-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	30671473
2696	Human	hsa-miR-1277-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MMP+) treatment	downregulated	33069733
2697	Human	hsa-miR-128	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
2698	Human	hsa-miR-128	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	particulate matter (PM)treatment treatment	upregulated	24515752
2699	Human	hsa-miR-128	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	PM-ed A549 pulmonary cell lines in v treatment	upregulated	24515752
2700	Human	hsa-miR-128	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
2701	Human	hsa-miR-128	miRNA	TGF-¦Â1	cell differentiation	human hair follicle mesenchymal stem cells (hHFMSCs)	human hair follicle mesenchymal stem cells (hHFMSCs) treatment	downregulated	27087048
2702	Human	hsa-miR-128	miRNA	H2O2	extracellular matrices (ECMs) homeostasis	"human prostate cancer epithelial cell lines, LNCaP, C4-2, PC3, PC3M, and DU145"	hydrogen peroxide	upregulated	28831065
2703	Human	hsa-miR-128	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	SGC-7901 cells	Helicobacter pylori £¨H. pylori£©infection	downregulated	29604247
2704	Human	hsa-miR-128	miRNA	radiation	glioblastoma multiforme (GBM)	U87 cells	radiation treatment	MicroRNA-128 increases glioma cell radio-sensitivity by suppressing senescent evasion through oncogene Bmi-1	31938239
2705	Human	hsa-miR-128	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
2706	Human	hsa-miR-128	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	human glioma-derived cell lines U251 and U87	TMZ treatment	downregulated	25017996
2707	Human	hsa-miR-128	miRNA	ginsenoside Rh2	glioblastoma multiforme (GBM)	U251 cells	ginsenoside Rh2 (Rh2) treatment	The anti-proliferative effect of Rh2 in human glioma cells was mediated in part through upregulated of miRNA-128 expression	21372826
2708	Human	hsa-miR-128	miRNA	insulin	glycolysis	human HepG2 hepatocellular carcinoma cells	insulin treatment	dysregulated	24895527
2709	Human	hsa-miR-128	miRNA	NPV-LDE-225 (Erismodegib)	human immunodeficiency virus (HIV)-1 infection	Glioblastoma initiating cells (GICs)	NPV-LDE-225 (Erismodegib) treatment	downregulated	23482671
2710	Human	hsa-miR-128	miRNA	opiate	neuroblastoma (NB)	neuroblastoma SH-SY5Y cell line	chronic opiate administration treatment	"low doses of morphine (10nM) reduced the expression levels of miR133b, higher doses (1¦ÌM) downregulated levels of miR133b and miR128"	24440526
2711	Human	hsa-miR-128	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG5 cells	high glucose (HG) treatment	downregulated	31889412
2712	Human	hsa-miR-128	miRNA	adipogenesis medium	osteogenesis	human mesenchymal stem cells	adipogenic	upregulated	27485180
2713	Human	hsa-miR-128	miRNA	P. gingivalis	periodontitis	THP-1 cells and CA9-22 cells	P. gingivalis treatment	upregulated	27240473
2714	Human	hsa-miR-1281	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
2715	Human	hsa-miR-1281	miRNA	high glucose (HG)	diabetes microvascular complications	ARPE-19 cells	high glucose (HG) treatment	upregulated	32849308
2716	Human	hsa-miR-1281	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
2717	Human	hsa-miR-1281	miRNA	asbestos fibers	malignant pleural mesothelioma (MPM)	serum	ex-exposed to asbestos fibers (WEA)	upregulated	27716620
2718	Human	hsa-miR-1281	miRNA	radiation	nasopharyngeal carcinoma (NPC)	serum	radiation treatment	downregulated	32198434
2719	Human	hsa-miR-1281	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	primary human macrophages differentiated from PBMCs	Mycobacterium tuberculosis (MTB) infection	"microRNA-1281 inhibition in human macrophages, by the anti-sense sequence, increased CypD expression and potentiated MTB-induced cytotoxicity."	31884421
2720	Human	hsa-miR-128-1-5P	miRNA	liraglutide	atherosclerosis (AS)	human vascular smooth muscle cells	liraglutide treatment	Liraglutide could curb the expression of inflammatory cytokines and apoptosis related protein in coronary atherosclerosis by regulating RMRP/miR-128-1-5P/Gadd45g signaling pathway	32196624
2721	Human	hsa-miR-128-1-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
2722	Human	hsa-miR-1282	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
2723	Human	hsa-miR-1282	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	downregulated	31359311
2724	Human	hsa-miR-1283	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	Human embryonic cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	"GADD45A and miR-1283 were upregulated or downregulated in myocardial infarction, respectively"	33293495
2725	Human	hsa-miR-1283	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	human embryonic cardiomyocytes	hypoxia /reoxygenation (H/R) treatment	The miR-1283-GADD45A axis may protect against H/R -induced cardiomyocyte injury by suppressing the JNK and p38 MAPK pathways.	33293495
2726	Human	hsa-miR-128-3p	miRNA	laminar shear stress	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	Laminar shear stress induce	downregulated	30905197
2727	Human	hsa-miR-128-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30905197
2728	Human	hsa-miR-128-3p	miRNA	angiotensin II (Ang II)	atrial fibrosis	human atrial fibroblasts	angiotensin II (Ang II) treatment	LncRNA PVT1 promotes atrial fibrosis via miR-128-3p-SP1-TGF-¦Â1-Smad axis in atrial fibrillation.	30894138
2729	Human	hsa-miR-128-3p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
2730	Human	hsa-miR-128-3p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
2731	Human	hsa-miR-128-3p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
2732	Human	hsa-miR-128-3p	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells; colorectal cancer (CRC) tissues	oxaliplatin treatment	miR-18b-5p was increased in oxaliplatin-resistant CRC cells and tissues	33147048
2733	Human	hsa-miR-128-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	High-level glucose (HG) treatment significantly upregulated miRNA-128- 3p expression in HRECs.	32572899
2734	Human	hsa-miR-128-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Seven HCC cell lines PLC/PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC©\7721, and HCCLM3"	sorafenib treatment	downregulated	30132868
2735	Human	hsa-miR-128-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human bone marrow mesenchymal stem cells (BMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31635801
2736	Human	hsa-miR-128-3p	miRNA	gypenoside LI	melanoma	A375 cells; SK-MEL-28 cells	gypenoside LI treatment	Gypenoside LI can induce the upregulation of the tumor suppressor miR-128-3p during melanoma apoptosis.	32022984
2737	Human	hsa-miR-128-3p	miRNA	all-trans retinoic acid (ATRA)	neurogenesis	amniotic epithelial cells (AECs)	all-trans retinoic acid (ATRA) treatment	"lncRNA MEG3 is upregulated by the ATRA/cAMP/CREB pathway, and it, in turn, is directly downregulated by miR-128-3p to increase the amount of neuron differentiation."	31921854
2738	Human	hsa-miR-128-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	C28/I2 cells	IL-1¦Â treatment	miR-128-3p was downregulated in chondrocytes stimulated with interleukin (IL)-1¦Â.	32830547
2739	Human	hsa-miR-128-3p	miRNA	hydrochloric acid	reflux esophagitis	Het-1A cells	hydrochloric acid (HCl) treatment	miR-128-3p was upregulated in Het-1A cells after HCl treatment.	30223934
2740	Human	hsa-miR-128-3p	miRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMEC-1)	lipopolysaccharide (LPS) treatment	HULC knockdown partially reversed LPS-induced sepsis via the regulation of miR-128-3p/RAC1 axis.	33174038
2741	Human	hsa-miR-1284	miRNA	propofol (PPF)	lung cancer	A549 cells	propofol treatment	upregulated	29402342
2742	Human	hsa-miR-1284	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
2743	Human	hsa-miR-1285	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
2744	Human	hsa-miR-1285	miRNA	methylmercury (MeHg)	neurotoxicity	human neural progenitor cells (ihNPCs)	methylmercury (MeHg) treatment	downregulated	27941687
2745	Human	hsa-miR-1285-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cervical cancer (CC)	HeLa cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"TNF-¦Á-induced lncRNA LOC105374902 may function as a ceRNA for miR-1285-3p to promote the expression of RPL14, promoting the migration, invasion and EMT of CC cells."	30935691
2746	Human	hsa-miR-1285-3p	miRNA	herapy with transarterial chemoembolisation (TACE)	hepatocellular carcinoma (HCC)	HCC patients	TACE treatment	dysregulated	25230788
2747	Human	hsa-miR-1285-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
2748	Human	hsa-miR-1286	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
2749	Human	hsa-miR-1286	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
2750	Human	hsa-miR-1286	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
2751	Human	hsa-miR-1287	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
2752	Human	hsa-miR-1287-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
2753	Human	hsa-miR-1287-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
2754	Human	hsa-miR-1287-5p	miRNA	TGF-¦Â	angiogenesis	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â treatment	downregulated	30414893
2755	Human	hsa-miR-1287-5p	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	vascular endothelial cell growth factor (VEGF) treatment	downregulated	30414893
2756	Human	hsa-miR-1287-5p	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	Huh7 cells; HepG2 cells	pHBV1.3 infection	The expression of miR-1287-5p was significantly decreased in the circ_0004812 overexpressing cells.	32188476
2757	Human	hsa-miR-1287-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
2758	Human	hsa-miR-1287-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
2759	Human	hsa-miR-128a	miRNA	X-rays	glioblastoma multiforme (GBM)	U-87 MG glioblastoma cells	X-ray radiation treatment	"High doses of X-ray radiation increased the expression levels of Bmi-1, which may be associated with the evasion of cellular senescence miRNA-128a and its downstream target gene Bmi-1 may have an important role in the radioresistance of U-87 MG glioma cells"	26238021
2760	Human	hsa-miR-128a	miRNA	"haloperidol, clozapine and olanzapine"	schizophrenia (SZ)	"HepG2 (ATCC,CRL-1573)"	"haloperidol, clozapine , olanzapine treatment"	downregulated	28429622
2761	Human	hsa-miR-129	miRNA	piceatannol (PIC)	colorectal cancer (CRC)	HCT116 and HT29 cells	piceatannol treatment	upregulated	25218158
2762	Human	hsa-miR-129	miRNA	gefitinib	esophageal squamous cell carcinoma (ESCC)	TE1 cells; KYSE-450 cells	gefitinib treatment	miR-129 is downregulated in both gefitinib-resistant cell lines in contrast with their respective parental cell lines.	30049286
2763	Human	hsa-miR-129	miRNA	cisplatin (DDP)	gastric cancer (GC)	MGC-803 cells	cisplatin treatment	downregulated	31378887
2764	Human	hsa-miR-129	miRNA	histone deacetylase (HDAC)	histone deacetylase resistance in nasopharyngeal cancer (NPC)	CNE1; CNE2; C666¨C1	Histone deacetylase treatment	downregulated	32692721
2765	Human	hsa-miR-129	miRNA	magnolol	multiple myeloma (MM)	MM cells U266 and LP1	Magnolol treatment	And magnolol increased the miR-129 expression in MM cells.	33440989
2766	Human	hsa-miR-129	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	A549 cells	TGF-¦Â treatment	TGF-¦Â induced EMT accompanied by the reduction of miR-129 and elevating of SOX4	30475081
2767	Human	hsa-miR-129	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Human neuroblastoma cell line SH©\SY5Y	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30260025
2768	Human	hsa-miR-129	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
2769	Human	hsa-miR-129	miRNA	resveratrol	parkinson's disease (PD)	MPTP-treated human neuroblastoma cell line SH©\SY5Y	resveratrol (RS) treatment	upregulated	30260025
2770	Human	hsa-miR-129	miRNA	resveratrol	parkinson's disease (PD)	SH©\SY5Y cells	resveratrol (RS) treatment	upregulated	30260025
2771	Human	hsa-miR-129	miRNA	perioglas (PG) and P-15	promote bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
2772	Human	hsa-miR-129	miRNA	TGF-¦Â1	renal fibrosis	HK-3 cells	TGF-¦Â1 treatment	downregulated	32475133
2773	Human	hsa-miR-1290	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
2774	Human	hsa-miR-1290	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 9¡ã HDT bed rest experiment	downregulated	28261104
2775	Human	hsa-miR-1290	miRNA	asiatic acid (AA)	cardiomyocyte apoptosis	human AC16 cardiomyocytes under hypoxia	treat with various doses of AA for 24 h	upregulated	28686797
2776	Human	hsa-miR-1290	miRNA	polygonatum odoratum lectin (POL)	cell apoptosis and autophagy	A549 cells	Polygonatum odoratum lectin (POL) treatment	downregulated	26562549
2777	Human	hsa-miR-1290	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
2778	Human	hsa-miR-1290	miRNA	polygonatum odoratum lectin (POL)	lung adenocarcinoma (LUAD)	A549 cells	Polygonatum odoratum lectin (POL) treatment	downregulated	26562549
2779	Human	hsa-miR-1290	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	31173947
2780	Human	hsa-miR-1290	miRNA	platinum	lung adenocarcinoma (LUAD)	LADC tissues	platinum-based doublet chemotherapy treatment	dysregulated	25142144
2781	Human	hsa-miR-1290	miRNA	asiatic acid (AA)	non-small cell lung cancer (NSCLC)	A549 NSCLC cells	asiatic acid treatment	upregulated	25016979
2782	Human	hsa-miR-1290	miRNA	TGF-¦Â1	lung fibrosis	A549 cells	TGF-¦Â1 treatment	upregulated	32319530
2783	Human	hsa-miR-1290	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
2784	Human	hsa-miR-1290	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
2785	Human	hsa-miR-1291	miRNA	¦Á-melanocyte-stimulating hormone (¦Á-MSH)	skin pigmentation disorders	human skin primary melanocytes (MCs)	¦Á-MSH treatment	downregulated	33318297
2786	Human	hsa-miR-129-2	miRNA	progesterone (P4)	breast cancer	"T47D, BT474, MDA-MB-231 and MCF7 breast cancer cell lines"	2.5 mg/ml Amphotericin-B (Abbott) and 1.25 ?l/ml Gentamycin (Abbott) treatment	upregulated	28876975
2787	Human	hsa-miR-129-2	miRNA	neuron-glial antigen 2 (NG2) protein	diffuse intrinsic pontine gliomas (DIPGs)	Human DIPG cells	neuron-glial antigen 2 (NG2) protein treatment	downregulated	25987129
2788	Human	hsa-miR-129-2	miRNA	trichostatin A (TSA)	glioblastoma multiforme (GBM)	GBM patient specimens and cultured cell lines	trichostatin A treatment	miR-129-2 expression could be restored upon treatment with a histone deadetylase inhibitor (trichostatin A) but not a DNA methylation inhibitor (5-Aza-2'-deoxycytidine)	26320507
2789	Human	hsa-miR-129-3p	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
2790	Human	hsa-miR-129-3p	miRNA	histone deacetylase inhibitor (HDACi)	cell death	"Huh7 cells, MGC-803 cells"	Histone deacetylase inhibitors (HDACis) treatment	upregulated	30852137
2791	Human	hsa-miR-129-3p	miRNA	avenanthramide A (AVN A)	colorectal cancer (CRC)	"human colon carcinoma cell lines HCT-8, HCT-116"	avenanthramide A (AVN A) treatment	upregulated	30888162
2792	Human	hsa-miR-129-3p	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
2793	Human	hsa-miR-129-3p	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
2794	Human	hsa-miR-129-3p	miRNA	chidamide	non-small cell lung cancer (NSCLC)	H1355 and A549 cells	chidamide treatment	Chidamide repressed telomerase activity through ROS accumulation and cell cycle arrest by miR-129-3p upregulation in both H1355 and A549 cells.	30668358
2795	Human	hsa-miR-129-3p	miRNA	chidamide	non-small cell lung cancer (NSCLC)	H1355 cells; A549 cells	Chidamide treatment	Chidamide upregulates miR-129-3p expression in lung cancer cells.	30668358
2796	Human	hsa-miR-1294	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	SMMC7721 cells; HepG2 cells	arsenic trioxide (ATO) treatment	miR-1294 was found to be significantly upregulated in ATO-treated HCC cells.	32280078
2797	Human	hsa-miR-1294	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
2798	Human	hsa-miR-129-5p	miRNA	CoCl2	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	CoCl2 treatment	downregulated	33175458
2799	Human	hsa-miR-129-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	33175458
2800	Human	hsa-miR-129-5p	miRNA	alcohol	alcoholic liver disease (ALD)	differentiated Caco-2 cells	alcohol treatment	upregulated	31814565
2801	Human	hsa-miR-129-5p	miRNA	physical exercise	Alzheimer's disease (AD)	serum	physical exercise treatment	miR-129-5p is significantly upregulated by physical exercise	32434194
2802	Human	hsa-miR-129-5p	miRNA	suberoylanilide hydroxamic acid (SAHA)	apoptosis	"human lung adenocarcinoma (A549 and SL-LU-1), squamous cell carcinoma (HCC-95 and HCC-1588), large cell carcinoma (NCI-H460 and NCI-H1299), and small cell lung cancer (SCLC; HCC-33, NCI-H69, and Calu-6) cells ,human small airway epithelial cells (HSAEC), human bronchial epithelial cells (HBEC), human pulmonary artery endothelial cells (HPEC) and human pulmonary fibroblast (HPF) cells"	SAHA treatment	upregulated	28667779
2803	Human	hsa-miR-129-5p	miRNA	CoCl2	apoptosis	HK-2 cells	CoCl2 treatment	downregulated	33175458
2804	Human	hsa-miR-129-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	Human cardiac myocytes (HCMs)	angiotensin II (Ang II) treatment	downregulated	33569456
2805	Human	hsa-miR-129-5p	miRNA	IFN-¦Â	cervical intraepithelial neoplasia (CIN) and cancer	Hela cells;HPV 16-negative Siha cells;HPV-negative C33A cells; HCC94 cells	Interferon-¦Â treatment	Interferon-b Induced microRNA-129-5p Down-Regulates HPV-18 E6 and E7 Viral Gene Expression by Targeting SP1 in Cervical Cancer Cells	24358111
2806	Human	hsa-miR-129-5p	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	MCF-7 and MDA-MB-231 cells	cisplatin treatment	lncRNA ZEB1-AS1 silencing protects against drug resistance in breast cancer by promoting miR-129-5p-dependent ZEB1 downregulated.	33430826
2807	Human	hsa-miR-129-5p	miRNA	toxic acetaminophen (APAP)	drug metabolizing enzymes (DMEs) expression	HepaRG cells	toxic acetaminophen (APAP) treatment	APAP treatment increased the level of hsa-miR-129-5p	32273307
2808	Human	hsa-miR-129-5p	miRNA	cisplatin (DDP)	gastric adenocarcinoma (GAC)	HGC27; AGS	cisplatin treatment	Circ_0000260 Regulates the Development and Deterioration of Gastric Adenocarcinoma with Cisplatin Resistance by Upregulating MMP11 via Targeting MiR-129-5p.	33122949
2809	Human	hsa-miR-129-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	SGC7901/VCR gastric cancer multi-drug resistant cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25344911
2810	Human	hsa-miR-129-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	Pri GBM; Rec GBM; N3S; N3T3rd; U251; U251T3rd; glioblastoma (GBM) tissues	temozolomide (TMZ) treatment	downregulated	32039732
2811	Human	hsa-miR-129-5p	miRNA	osteopontin (OPN)	liver fibrosis	human hepatic stellate cells (HSCs) LX-2 cells	Osteopontin (OPN) treatment	downregulated	29196165
2812	Human	hsa-miR-129-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
2813	Human	hsa-miR-129-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteosarcoma (OS)	OS tissues with pulmonary metastasis	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25566966
2814	Human	hsa-miR-129-5p	miRNA	lipopolysaccharide (LPS)	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	lipopolysaccharide (LPS) treatment	downregulated	30855347
2815	Human	hsa-miR-129-5p	miRNA	matrine	peritoneal fibrosis	LPS-treated human peritoneal mesothelial cells (HPMCs)	matrine treatment	upregulated	30855347
2816	Human	hsa-miR-129-5p	miRNA	docetaxel (DTX)	prostate cancer	PC-3 cells	docetaxel (DTX) treatment	upregulated	31876385
2817	Human	hsa-miR-129-5p	miRNA	royal jelly	skin senescence	human dermal microvascular endothelial cells (HDMEC)	royal jelly treatment	downregulated	31723098
2818	Human	hsa-miR-129-5p	miRNA	ultraviolet (UV) irradiation	skin senescence	human dermal microvascular endothelial cells (HDMEC)	UVB radiation treatment	upregulated	31723098
2819	Human	hsa-miR-129-5p	miRNA	histone deacetylase inhibitor (HDACi)	thyroid cancer (TC)	TPC-1 cells;BCPAP cells;8505C clls;CAL62 cells	histone deacetylase inhibitors (HDACi) treatment	miR-129-5p is involved in the antitumor activity of HDACi and highlight a miRNA-driven cell death mechanism.	21946411
2820	Human	hsa-miR-1296	miRNA	genistein	renal fibrosis	PC3 cells	Genistein treatment	downregulated	29967188
2821	Human	hsa-miR-1296	miRNA	trichostatin A (TSA)	renal fibrosis	PC3 cells	TSA treatment	downregulated	29967188
2822	Human	hsa-miR-1297	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"We predicted and verified miR-1297 as the regulatory miRNA of COL1A2, and the expression of miR-1297 was decreased in DN tissues and HG-stimulated HK-2 cells."	33811432
2823	Human	hsa-miR-1297	miRNA	propofol (PPF)	oral squamous cell carcinoma (OSCC)	UM-SCC6 and SCC090 cells	Propofol treatment	downregulated	31583913
2824	Human	hsa-miR-130	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
2825	Human	hsa-miR-1301	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	upregulated	28797462
2826	Human	hsa-miR-1301-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated of NEAT1 repressed ¦Á-syn-induced activation of NLRP3 inflammasome via inhibiting the expression of GJB1 by targeting miR-1301-3p.	32712773
2827	Human	hsa-miR-1301-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	32712773
2828	Human	hsa-miR-1303	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-1303 was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
2829	Human	hsa-miR-1303	miRNA	coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human umbilical vein endothelial cell (HUVECs)	Coxsackievirus A16 (CA16) infection	downregulated	30228270
2830	Human	hsa-miR-1305	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HCC tissues	hepatitis B virus (HBV) infection	downregulated	33372396
2831	Human	hsa-miR-1305	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
2832	Human	hsa-miR-1305	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
2833	Human	hsa-miR-1306	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	upregulated	33197057
2834	Human	hsa-miR-1306-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	"SNHG7-003 may inhibit the proliferation, migration and invasion of VSMCs via the miR-1306-5p/SIRT7 signaling pathway."	33416100
2835	Human	hsa-miR-1306-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	31460837
2836	Human	hsa-miR-1307	miRNA	cisplatin (DDP)	breast cancer	MCF-7 cells; MDA-MB-468 cells	cisplatin treatment	MiR-1307 was downregulated while MDM4 was upregulated in MCF-7/cisplatin (CDDP) and MDA-MB-468/CDDP cells compared with parental MCF-7 and MDA-MB-468 cells.	29697201
2837	Human	hsa-miR-1308	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
2838	Human	hsa-miR-130a	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	downregulated	33716779
2839	Human	hsa-miR-130a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL-60 cells	adriamycin (ADR) treatment	miR-130a expression was decreased in increasing Adr concentrations.	32945422
2840	Human	hsa-miR-130a	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	U251 cells	amyloid-¦Â (A¦Â) treatment	upregulated	29238290
2841	Human	hsa-miR-130a	miRNA	hypoxia	angiogenesis	human primary endothelial colony-forming cells (ECFCs)	hypoxia induce	"Here, we identify miR-130a as a mediator of the hypoxic response in human primary endothelial colony-forming cells (ECFCs)."	33614244
2842	Human	hsa-miR-130a	miRNA	high glucose (HG)	cell damage	ARPE-19 cells	high glucose (HG) treatment	high-glucose (50 mM) significantly decreased the levels of miR-130a.	32018221
2843	Human	hsa-miR-130a	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 7¡ã HDT bed rest experiment	downregulated	28261104
2844	Human	hsa-miR-130a	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
2845	Human	hsa-miR-130a	miRNA	imatinib	chronic myeloid leukemia (CML)	CML patients	imatinib (IM) treatment	differently regulated	24629639
2846	Human	hsa-miR-130a	miRNA	nilotinib	chronic myeloid leukemia (CML)	HL-60.BCR-ABL cells	nilotinib (NIL) treatment	differently regulated	24629639
2847	Human	hsa-miR-130a	miRNA	curcumin (Cur)	colorectal cancer (CRC)	SW480 cells	curcumin treatment	downregulated	29225578
2848	Human	hsa-miR-130a	miRNA	mesalazine (MSLZ)	colorectal cancer (CRC)	CaCo2 cell line	Mesalazine (5-ASA) treatment	downregulated	29794245
2849	Human	hsa-miR-130a	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	intestinal epithelial cells T84 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	24148619
2850	Human	hsa-miR-130a	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	T85 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	32583714
2851	Human	hsa-miR-130a	miRNA	docetaxel (DTX)	head and neck squamous cell carcinoma (HNSCC)	UMSCC-1 cells;SQ20B cells	docetaxel (DTX) treatment	downregulated	21560177
2852	Human	hsa-miR-130a	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cells	cisplatin treatment	upregulated	22846564
2853	Human	hsa-miR-130a	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	Blood samples	cisplatin treatment	upregulated	22846564
2854	Human	hsa-miR-130a	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
2855	Human	hsa-miR-130a	miRNA	IL-2	immunotherapy	NK-92 cells	IL-2 treatment	upregulated	31883616
2856	Human	hsa-miR-130a	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
2857	Human	hsa-miR-130a	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
2858	Human	hsa-miR-130a	miRNA	radiation	lung cancer	A549 cells	radiation treatment	upregulated	32968458
2859	Human	hsa-miR-130a	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
2860	Human	hsa-miR-130a	miRNA	apicidin	myocardial infarction (MI)	human bone marrow-derived MSC	apicidin treatment	downregulated	28498815
2861	Human	hsa-miR-130a	miRNA	hypoxia	myocardial infarction (MI)	human cardiosphere-derived cells (CDCs) exosomes	hypoxia induce	upregulated	29243842
2862	Human	hsa-miR-130a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
2863	Human	hsa-miR-130a	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	hypoxia treatment	downregulated	32450163
2864	Human	hsa-miR-130a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	H19 negatively regulated the expression of miR-130a via acting as a molecular sponge for miR-130a. The stimulatory effects of H19 on cell damage were abolished following the restoration of miR-130a.	30900425
2865	Human	hsa-miR-130a	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
2866	Human	hsa-miR-130a	miRNA	human immunodeficiency virus (HIV)-1 and cocaine	pulmonary vascular remodeling	human monocyte derived macrophages	HIV-infected and cocaine treatment	upregulated	29672222
2867	Human	hsa-miR-130a	miRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	HK-2 cells (human renal proximal tubule cells)	lipopolysaccharide (LPS) treatment	upregulated	29441906
2868	Human	hsa-miR-130a	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	serum	liraglutide treatment	upregulated	33008044
2869	Human	hsa-miR-130a*	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
2870	Human	hsa-miR-130a-3p	miRNA	indoxyl sulfate (IS)	chronic kidney disease (CKD)	human coronary artery endothelial cells (HCAECs)	indoxyl sulfate (IS) treatment	"Consistent with the clinical data, treatment with the uremia toxin indoxyl sulfate (IS) reduced miR-130a-3p levels in HCAEC-derived EVs."	33135066
2871	Human	hsa-miR-130a-3p	miRNA	TGF-¦Â1	crohn disease (CD)	human intestinal epithelial cells (HIECs); normal-derived colon mucosa cell line 460 (NCM460) cells	TGF-¦Â1 treatment	Hsa_circRNA_102610 upregulation in CD patients could promote the proliferation and EMT of intestinal epithelial cells via sponging of hsa-miR-130a-3p	32587447
2872	Human	hsa-miR-130a-3p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2; Huh7	hypoxia treatment	knockdown of HOTAIR suppressed glycolysis by regulating miR-130a-3p and HIF1A in HCC cells treated by hypoxia	32062551
2873	Human	hsa-miR-130a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	26669941
2874	Human	hsa-miR-130a-3p	miRNA	tobacco smoke	lung cancer	"bronchial epithelial BEAS-2B cells that were malignantly transformed into S30 cells, human lung cancer cell lines A549 and H1299"	tobacco smoke exposure	downregulated	31526129
2875	Human	hsa-miR-130a-3p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
2876	Human	hsa-miR-130a-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	downregulated	31678554
2877	Human	hsa-miR-130a-3p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	downregulated	27018851
2878	Human	hsa-miR-130a-3p	miRNA	TGF-¦Â1	renal fibrosis	"human renal proximal tubular epithelial cells (HRPTEpiCs, HK-2 and primary HRPTEpiCs)"	TGF-¦Â1 treatment	upregulated	31836508
2879	Human	hsa-miR-130a-3p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells; HRPTEpiCs	TGF-¦Â1 treatment	"After TGF-¦Â1 treatment, miR-130a-3p was highly expressed in renal tubular epithelial cells"	31836508
2880	Human	hsa-miR-130a-3p	miRNA	metformin (Met)	cell senescence	HK-2 cells	Metformin treatment	Metformin Increased the Stability of miR-130a-3p by Upregulating MBNL1 and Thus Reduced the High-Glucose- Induced Senescence of Renal Tubular Epithelial Cells.	32104542
2881	Human	hsa-miR-130a-5p	miRNA	tamoxifen (TAM)	breast cancer	Human MCF-7 cells	Tamoxifen (TAM) treatment	Low expression of ADAMTS9-AS2 inhibits PTEN expression and enhances tamoxifen resistance through targeting microRNA-130a-5p	30840279
2882	Human	hsa-miR-130a-5p	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	podocyte cell line AB8/13	angiotensin II (Ang II) treatment	downregulated	30394845
2883	Human	hsa-miR-130a-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
2884	Human	hsa-miR-130b	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	THP-1 cells	Tanshinone IIA (Tan) treatment	upregulated	31512787
2885	Human	hsa-miR-130b	miRNA	5-fluorouracil (5-Fu)	diabetic nephropathy (DN)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
2886	Human	hsa-miR-130b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HMCs)	high glucose treatment	upregulated	30260005
2887	Human	hsa-miR-130b	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
2888	Human	hsa-miR-130b	miRNA	lipopolysaccharide (LPS)	hepatolithiasis	Human intrahepatic biliary epithelial cells (HIBEpiCs)	lipopolysaccharide (LPS) treatment	Molecular mechanism underlying miR-130b-Sp1 transcriptional regulation in LPS-induced upregulation of MUC5AC in the bile duct epithelium	33300069
2889	Human	hsa-miR-130b	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	downregulated	28347920
2890	Human	hsa-miR-130b	miRNA	5-fluorouracil (5-Fu)	metastatic colorectal cancer (mCRC)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
2891	Human	hsa-miR-130b	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx7 treatment"	downregulated	21572246
2892	Human	hsa-miR-130b	miRNA	lipopolysaccharide (LPS)	vascular injury	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharides (LPS) treatment	downregulated	28759810
2893	Human	hsa-miR-130b-3p	miRNA	high glucose (HG)	diabetic pregnancy	BeWo cells	high glucose	upregulated	28433632
2894	Human	hsa-miR-130b-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
2895	Human	hsa-miR-132	miRNA	aspergillus fumigatus (A. fumigatus)	Aspergillus fumigatus infection	human monocytes and dendritic cells (DCs)	infect with A. fumigatus	upregulated	24841251
2896	Human	hsa-miR-132	miRNA	notoginsenoside R1 (NGR1)	atherosclerosis (AS)	Human umbilical vascular endothelial cells (HUVECs)	Notoginsenoside R1 (NGR1) treatment	downregulated	30504696
2897	Human	hsa-miR-132	miRNA	hypoxia	blood-brain barrier (BBB) dysfunction	human brain microvascular endothelial cells (BMEC)	hypoxia induce	upregulated	30617994
2898	Human	hsa-miR-132	miRNA	co-nanoencapsulated curcumin (Cur) and chrysin (Chr)	breast cancer	MDA-MB-231 breast cancer cells	co-nanoencapsulated Curcumin (Cur) and Chrysin (Chr) treatment	upregulated	30955355
2899	Human	hsa-miR-132	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
2900	Human	hsa-miR-132	miRNA	luteolin	bronchopneumonia	BEAS-2B cells	Luteolin treatment	luteolin alleviated the LPS-induced miR-132 expression increase in BEAS-2B cells.	30119240
2901	Human	hsa-miR-132	miRNA	doxorubicin (DOX)	cardiotoxicity	human iPSC-derived cardiomyocytes	doxorubicin treatment	"In vitro, overexpression of the pro-hypertrophic miR-212/132 cluster in primary rodent and human iPSC-derived cardiomyocytes inhibited doxorubicin-induced toxicity."	30527757
2902	Human	hsa-miR-132	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
2903	Human	hsa-miR-132	miRNA	recombinant human thymic stromal lymphopoietin (rhTSLP)	cervical cancer (CC)	HeLa and SiHa cells	rhTSLP were significantly impaired inwith treatment	upregulated	29250181
2904	Human	hsa-miR-132	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	THP-1 cells	cigarette smoke extract (CSE) treatment	upregulated	30292646
2905	Human	hsa-miR-132	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	LncRNA SNHG5 regulates cell apoptosis and inflammation by miR-132/PTEN axis in COPD	32145584
2906	Human	hsa-miR-132	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	We revealed that HG-treated ARPE-19 cells exhibited significantly increased miR-132 expression	33563844
2907	Human	hsa-miR-132	miRNA	fluid shear stress (FSS)	epairing the oral cavity	human periodontal ligament (PDL) cells	fluid shear stress? treatment	dysregulated	24556727
2908	Human	hsa-miR-132	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8/SVneo cell	high glucose (HG) treatment	downregulated	31653266
2909	Human	hsa-miR-132	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	LN229 cells; U251 cells	temozolomide (TMZ) treatment	exosome-mediated transfer of CircNFIX enhances TMZ resistance in glioma at least partially through sponging miR-132	32194140
2910	Human	hsa-miR-132	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	Human glioma cell lines U87MG	TGF treatment	upregulated	25983322
2911	Human	hsa-miR-132	miRNA	TGF-¦Â1	hard-to-heal skin wounds	human dermal fibroblasts (HDFs)	TGF-¦Â1 treatment	upregulated	28798331
2912	Human	hsa-miR-132	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	HCC cells	hepatitis C virus (HCV) infection	downregulated	23376496
2913	Human	hsa-miR-132	miRNA	angiotensin II (Ang II)	hypertension	human breast artery tissues	angiotensin II (Ang II) treatment	upregulated	23712358
2914	Human	hsa-miR-132	miRNA	notoginsenoside R1 (NGR1)	inflammation	human lung fibroblast MRC-5 cell	Notoginsenoside R1 (NGR1) treatment	upregulated	30622031
2915	Human	hsa-miR-132	miRNA	palmitate	inflammation	THP-1 cells	PA treatment	upregulated	29258239
2916	Human	hsa-miR-132	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Colon mucosa	dextran sulfate sodium treatment	upregulated	26878986
2917	Human	hsa-miR-132	miRNA	oxygen glucose deprivation (OGD)	hepatocellular carcinoma (HCC)	HepG2 cells	OGD treatment	downregulated	24661879
2918	Human	hsa-miR-132	miRNA	citalopram	major depressive disorder (MDD)	plasma	citalopram treatment	Plasma miR-132 in the treatment-free MDD group was 2.4-fold that in the control group and significantly higher than that in the citalopram-treated MDD group.	29689690
2919	Human	hsa-miR-132	miRNA	nanocurcumin	multiple sclerosis (MS)	blood	nanocurcumin treatment	downregulated	30340096
2920	Human	hsa-miR-132	miRNA	basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF)	neurogenesis	periodontal ligament-derived neural crest stem cells (NCSCs)	basic fibroblast growth factor and epidermal growth factor treatment	upregulated	30352481
2921	Human	hsa-miR-132	miRNA	Toll-like receptor (TLR)	neurological diseases	U251 human astrocytoma cell line	Toll-like receptor (TLR) treatment	upregulated	25957996
2922	Human	hsa-miR-132	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
2923	Human	hsa-miR-132	miRNA	bupivacaine	neurotoxicity	SH-SY5Y cells	bupivacaine treatment	upregulated	30850243
2924	Human	hsa-miR-132	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
2925	Human	hsa-miR-132	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
2926	Human	hsa-miR-132	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	CAL-27cells	cisplatin treatment	miR-132 expression was significantly decreased in the OSCC tissues and CDDP resistant OSCC cell line (CAL-27/CDDP).	31906769
2927	Human	hsa-miR-132	miRNA	dexamethasone (DEX)	pancreatic cancer (PC)	AsPC-1 CELLS; PANC-1 cells; ASAN-PaCa cells	dexamethasone (Dex) treatment	DEX inhibits miR-132 expression by promoter hypermethylation.	30387838
2928	Human	hsa-miR-132	miRNA	dexamethasone (DEX)	pancreatic ductal adenocarcinoma (PDAC)	"human primary pancreatic cancer cell line ASAN-PaCa, AsPC-1 and PANC-1 pancreatic cancer cell lines"	dexamethasone (DEX) treatment	downregulated	30387838
2929	Human	hsa-miR-132	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
2930	Human	hsa-miR-132	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	"TUG1 had a decreased expression in both periodontal ligament (PDL) tissues with periodontitis and PDLCs under a LPS-induced inflammatory condition, and TUG1 expression was negatively correlated with miR-132 expression in periodontitis-affected PDL tissues."	31735958
2931	Human	hsa-miR-132	miRNA	melatonin	primary biliary cholangitis (PBC)	H69 cells	melatonin treatment	downregulated	33352965
2932	Human	hsa-miR-132	miRNA	platelet-derived growth factor (PDGF)	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	platelet-derived growth factor treatment	upregulated	30896881
2933	Human	hsa-miR-132	miRNA	sevoflurane (SEV)	sevoflurane-induced neuronal apoptosis	human H4 neuroglioma cell line	sevoflurane treatment	downregulated	30272258
2934	Human	hsa-miR-132*	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
2935	Human	hsa-miR-132*	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
2936	Human	hsa-miR-1323	miRNA	¦Â-elemene	gastric cancer (GC)	SGC7901 cells	¦Â-Elemene treatment	downregulated	32199253
2937	Human	hsa-miR-1323	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8/SVneo cells; BeWo cells	high-glucose (HG) treatment	HG upregulated the miR-1323 expression and inhibited trophoblast cell viability.	33603839
2938	Human	hsa-miR-132-3p	miRNA	5-fluorouracil (5-Fu)	advanced colorectal cancer (CRC)	HCT-15 cells	5-fluorouracil (5-FU) treatment	"HF inhibited the proliferation, invasion and migration of HCT-15/FU cells by upregulating the expression levels of miR-132-3p."	33154782
2939	Human	hsa-miR-132-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	HPN; SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31898085
2940	Human	hsa-miR-132-3p	miRNA	berberine (BBR)	Alzheimer's disease (AD)	HPN; SK-N-SH cells	berberine (BBR) treatment	upregulated	31898085
2941	Human	hsa-miR-132-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
2942	Human	hsa-miR-132-3p	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
2943	Human	hsa-miR-132-3p	miRNA	influenza A virus (IAV)	innate immune response	peripheral blood samples from IAV patients and A549 cells	H1N1 influenza A virus (IAV) infection	upregulated	31746331
2944	Human	hsa-miR-132-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
2945	Human	hsa-miR-132-3p	miRNA	nephrotoxicants	kidney injury and fibrosis	Primary human proximal tubular epithelial cells (HPTECs)	nephrotoxicants treatment	upregulated	26707937
2946	Human	hsa-miR-132-3p	miRNA	liposomal bupivacaine (BUP)	neurotoxicity	SH-SY5Y cells	liposomal bupivacaine (BUP) treatment	upregulated	32335807
2947	Human	hsa-miR-132-3p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	whole-blood	methotrexate (MTX) treatment	downregulated	30511295
2948	Human	hsa-miR-132-3p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	RA patients whole-blood	methotrexate (MTX) treatment	upregulated	30511295
2949	Human	hsa-miR-132-5p	miRNA	candida albicans (C. albicans) and aspergillus fumigatus (A. fumigatus)	fungal infection	human monocyte-derived dendritic cells	6 and 12 h of infection with C. albicans and A. fumigatus as well as treatment with lipopolysaccharides (LPS)	dysregulated	28280489
2950	Human	hsa-miR-133	miRNA	hypoxia	cardiac fibrosis	human endothelial progenitor cell (EPC) and EPCs-derived exosomes	hypoxia induce	upregulated	31443679
2951	Human	hsa-miR-133	miRNA	nicotine	cardiomyocyte apoptosis	Human embryonic kidney cell line (HEK293)	nicotine treatment	downregulated	24190542
2952	Human	hsa-miR-133	miRNA	nicotine	cardiomyocyte apoptosis	human embryonic kidney cell line	nicotine treatment	downregulated	24190542
2953	Human	hsa-miR-133	miRNA	angiotensin-converting enzyme 2 (ACE2) inhibitor	cardiovascular disease (CVD)	H9c2 cardiac myoblast cells	ACE2 (angiotensin-converting enzyme 2) treatment	upregulated	26400542
2954	Human	hsa-miR-133	miRNA	neurotensin (NT)	colonic inflammation	HCT-116 cells	Neurotensin (NT) treatment	upregulated	25112884
2955	Human	hsa-miR-133	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human renal proximal tubular epithelial cell line human kidney-2 (HK-2)	high glucose (HG) treatment	upregulated	31858564
2956	Human	hsa-miR-133a	miRNA	brazilein	acoustic neuroma	The vestibular schwannoma (VS) cells	brazilein treatment	upregulated	30610843
2957	Human	hsa-miR-133a	miRNA	coronary artery bypass graft (CABG)	acute coronary syndrome (ACS)	acute coronary syndrome patients heart	CABG treatment	upregulated	29506853
2958	Human	hsa-miR-133a	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
2959	Human	hsa-miR-133a	miRNA	IL-13	asthma	human BSM cells (hBSMCs)	interleukin-13 (IL-13) treatment	the level of miR-133a was significantly decreased in BSMs of the diseased animals.	33132251
2960	Human	hsa-miR-133a	miRNA	high glucose (HG)	hyperglycemia-induced beta-cell dysfunction	human islet	?high glucose exposure	Prolonged high-glucose exposure down-regulates PTB levels and insulin biosynthesis rates in human islets by increasing miR-133a levels	20520763
2961	Human	hsa-miR-133a	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	airway epithelial cells of smokers	cigarette smoke (CS) exposure	upregulated	30341388
2962	Human	hsa-miR-133a	miRNA	bortezomib	congenital muscular dystrophy	congenital muscular dystrophy type 1A muscle cells	bortezomib? treatment	downregulated	24631023
2963	Human	hsa-miR-133a	miRNA	aortic valve replacement (AVR)	aortic stenosis	plasma	aortic valve replacement (AVR) treatmenr	upregulated	23948643
2964	Human	hsa-miR-133a	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
2965	Human	hsa-miR-133a	miRNA	paclitaxel (PTX)	esophageal squamous cell carcinoma (ESCC)	esophageal squamous cell carcinoma (ESCC) tissues	the patients received four cycles of paclitaxel-based chemotherapy treatment	downregulated	25280517
2966	Human	hsa-miR-133a	miRNA	ursolic acid (UA)	gastric cancer (GC)	BGC-823 cells	UA treatment	upregulated	26629938
2967	Human	hsa-miR-133a	miRNA	benzene	hematotoxicity	workers	benzene treatment	downregulated	26435271
2968	Human	hsa-miR-133a	miRNA	homocysteine (Hcy)	hyperhomocysteinemia (HHcy)	HL-1 cardiomyocytes	100 ¦ÌM homocysteine treatment	downregulated	24495916
2969	Human	hsa-miR-133a	miRNA	angiotensin II (Ang II)	hypertension	Human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	downregulated	31524252
2970	Human	hsa-miR-133a	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	downregulated	31926162
2971	Human	hsa-miR-133a	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	human lung fibroblasts (HFL)	transforming growth factor (TGF)-¦Â1 treatment	upregulated	31511493
2972	Human	hsa-miR-133a	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
2973	Human	hsa-miR-133a	miRNA	TGF-¦Â	liver fibrosis	hepatic stellate cells(HSC)	TGF-¦Â treatment	Treatment of primary murine and human HSC with transforming growth factor (TGF)-¦Â resulted in a significant downregulated of miR-133a in these cells	23183523
2974	Human	hsa-miR-133a	miRNA	matrine	lung cancer	NCI-H1299 cells	Matrine treatment	upregulated	26379863
2975	Human	hsa-miR-133a	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
2976	Human	hsa-miR-133a	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
2977	Human	hsa-miR-133a	miRNA	Vitamin K2	osteogenesis	human bone marrow stromal cells (hBMSCs)	Vitamin K2 treatment	downregulated	28447758
2978	Human	hsa-miR-133a	miRNA	astragalus polysaccharide (APS)	osteosarcoma (OS)	MG63 cells	astragalus polysaccharide (APS) treatment	APS enhanced the expression of miR-133a in MG63 cells.	30462772
2979	Human	hsa-miR-133a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
2980	Human	hsa-miR-133a	miRNA	normoxia	pancreatic cancer (PC)	"human PC cell lines PANC©\1, SW1990"	normoxia condition induce	downregulated	30693518
2981	Human	hsa-miR-133a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
2982	Human	hsa-miR-133a	miRNA	propofol (PPF)	pancreatic cancer (PC)	peripheral blood	Propofol treatment	upregulated	26214431
2983	Human	hsa-miR-133a	miRNA	lactoferrin (LF)	prostate cancer	DU-145 cells	lactoferrin (LF) treatment	upregulated	30285009
2984	Human	hsa-miR-133a	miRNA	¦Â-glycerophosphate (¦Â-GP)	prostate cancer	vascular smooth muscle cells (VSMCs)	?¦Â-glycerophosphate treatment	downregulated	23798596
2985	Human	hsa-miR-133a	miRNA	estrogen (ES)	pulmonary arterial hypertension (PAH)	human pulmonary smooth muscle cell (HPASMC)	estrogen (ES) treatment	upregulated	31562386
2986	Human	hsa-miR-133a	miRNA	20-hydroxyeicosatetraeonic acid (20-HETE)	pulmonary hypertension (PH)	vascular smooth muscle cell	20-Hydroxyeicosatetraeonic acid (20-HETE) treatment	downregulated	26921441
2987	Human	hsa-miR-133a	miRNA	endothelin-1 (ET-1)	renal cytotoxicity	human renal proximal tubule cells (RPTECs)	endothelin-1 (ET-1) treatment	upregulated	25871823
2988	Human	hsa-miR-133a	miRNA	artesunate (ART)	rhabdomyosarcoma (RMS)	ERMS cell lines	artesunate (ARS) treatment	downregulated	26153023
2989	Human	hsa-miR-133a	miRNA	high-intensity interval training (HIIT)	skeletal muscle adaptation	human	human treatment	downregulated	27101297
2990	Human	hsa-miR-133a	miRNA	nuclear factor 90 (NF90)-NF45 complex	skeletal muscle atrophy	Mouse myoblast C2C12 cells	nuclear factor 90 (NF90)-NF45 complex treatment	downregulated	25918244
2991	Human	hsa-miR-133a	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
2992	Human	hsa-miR-133a	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	human dermal fibroblasts (HDFs)	ultraviolet radiation (UVA) treatment	downregulated	30378537
2993	Human	hsa-miR-133a	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HAVSMC)	inorganic phosphate (Pi) treatment	downregulated	27419135
2994	Human	hsa-miR-133a-3p	miRNA	puerarin	breast cancer	HCC38 cells	Puerarin treatment	upregulated	30483784
2995	Human	hsa-miR-133a-3p	miRNA	IL-17A	asthma	human BSM cells (hBSMCs)	IL-17A treatment	upregulated	28267638
2996	Human	hsa-miR-133a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human VSMCs (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ_0010283 participated in ox-LDL-induced dysfunctions of HVSMCs by modulating the miR-133a-3p/PAPPA pathway.	33162460
2997	Human	hsa-miR-133a-3p	miRNA	puerarin	breast cancer	HCC38 cells	Puerarin treatment	upregulated	30483784
2998	Human	hsa-miR-133a-3p	miRNA	bufothionine	gastric cancer (GC)	MGC-803 cells; BGC-823 cells	bufothionine treatment	miR-133a-3p was upregulated by Bufothionine.	32758622
2999	Human	hsa-miR-133a-3p	miRNA	cigarette smoke extract (CSE)	oropharyngeal squamous cell carcinoma (OPSCC)	lymph node and serum	cigarette smoke extract (CSE) treatment	HPV(+) smokers exhibit lymph node metastasis and reduced miR-133a-3p in both lymph node and serum.	30289952
3000	Human	hsa-miR-133a-3p	miRNA	warfarin	 anticoagulation	Peripheral Blood Mononuclear Cells (PBMCs)	warfarin treatment	miR-133a-3p is involved in the coagulation pathway	29296264
3001	Human	hsa-miR-133a-5p	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	QSG-7701 cells	hypoxia condition for 15 h and then in reoxygenation condition for 6 h	downregulated	28198596
3002	Human	hsa-miR-133b	miRNA	thyroid hormone	hepatocellular carcinoma (HCC)	skeletal muscle	thyroid hormone (TH) treatment	downregulated	19567520
3003	Human	hsa-miR-133b	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	downregulated	29393545
3004	Human	hsa-miR-133b	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31572518
3005	Human	hsa-miR-133b	miRNA	dihydrotestosterone (DHT)	androgenetic alopecia (AGA)	human hair follicles (HFs)	dihydrotestosterone (DHT) treatment	upregulated	33290799
3006	Human	hsa-miR-133b	miRNA	KHCO3	bone resorption of alkali	human serum	potassium bicarbonate [(KHCO3); 81 mmol/d; n = 12] vs placebo (n = 12) for 84 days	upregulated in serum	29264553
3007	Human	hsa-miR-133b	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
3008	Human	hsa-miR-133b	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	SW 780 cells	cisplatin treatment	MST1P2 serves as a competing endogenous RNA for miR-133b to counteract miR-133b-induced suppression on Sirt1.	32052927
3009	Human	hsa-miR-133b	miRNA	¦Á-mangostin	colorectal cancer (CRC)	human colon cancer DLD-1 cell line	¦Á-mangostin treatment	downregulated	26304927
3010	Human	hsa-miR-133b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	"CASC2 upregulation suppressed HG-induced proliferation, ECM accumulation and oxidative stress of HMCs through miR-133b /FOXP1 regulatory axis."	32016985
3011	Human	hsa-miR-133b	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	miR-133b was highly expressed in TGF-¦Â1-treated HK-2 cells	30125566
3012	Human	hsa-miR-133b	miRNA	paclitaxel (PTX)	esophageal squamous cell carcinoma (ESCC)	esophageal squamous cell carcinoma (ESCC) tissues	the patients received four cycles of paclitaxel-based chemotherapy treatment	downregulated	25280517
3013	Human	hsa-miR-133b	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
3014	Human	hsa-miR-133b	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) tissues	criplatin (DPP) treatment	downregulated	29344640
3015	Human	hsa-miR-133b	miRNA	insulin-like growth factor 1 (IGF-1)	infertility	oocytes at MI stage were obtained from patients who received intra-cytoplasmic sperm injection (ICSI) ments	IGF-1 treatment	upregulated	24959893
3016	Human	hsa-miR-133b	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	upregulated	29899866
3017	Human	hsa-miR-133b	miRNA	opiate	neuroblastoma (NB)	neuroblastoma SH-SY5Y cell line	chronic opiate administration treatment	"low doses of morphine (10nM) reduced the expression levels of miR133b, higher doses (1¦ÌM) downregulated levels of miR133b and miR128"	24440526
3018	Human	hsa-miR-133b	miRNA	methadone	opioid use disorder (OUD)	blood	methadone treatment	downregulated	31349687
3019	Human	hsa-miR-133b	miRNA	hydrostatic pressure (HP)	osteogenesis	adipose-derived mesenchymal stem cells (AMSCs)	hydrostatic pressure (HP) treatment	miR-133b was downregulated during osteogenic differentiation of AMSCs.	32661199
3020	Human	hsa-miR-133b	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cell line	cisplatin treatment	upregulated	29399170
3021	Human	hsa-miR-133b	miRNA	procaine (PCA)	osteosarcoma (OS)	osteosarcoma MG63 cells	2 ¦ÌM PCA treatment	upregulated	28251881
3022	Human	hsa-miR-133b	miRNA	NaHS and l-cysteine	preeclampsia (PE)	human placenta	NaHS and l-cysteine treatment	upregulated	28454695
3023	Human	hsa-miR-133b	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
3024	Human	hsa-miR-133b	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
3025	Human	hsa-miR-133¦Á	miRNA	neurotensin (NT)	colonic inflammation	NCM-460	neurotensin (NT) treatment	upregulated	25112884
3026	Human	hsa-miR-133¦Á	miRNA	neurotensin (NT)	inflammatory bowel disease (IBD)	human colonocytes NCM460 cells	Neurotensin (NT) treatment	upregulated	26005712
3027	Human	hsa-miR-133¦Á	miRNA	neurotensin (NT)	neurotensin receptor 1 recycling	human NCM460 colonocytes	neurotensin (NT) treatment	upregulation	26902265
3028	Human	hsa-miR-134	miRNA	penicillin-binding protein?1A (PBP1A) mutation-positive H.?pylori (H.?pyloriCagA+/P+)	gastric cancer (GC)	SGC-7901 cells	penicillin-binding protein?1A (PBP1A) mutation-positive H.?pylori (H.?pyloriCagA+/P+)?infection treatment	downregulated	30569124
3029	Human	hsa-miR-134	miRNA	lambertianic acid (LA)	apoptosis	MCF-7 cells	lambertianic acid (LA) treatment	upregulated	31248140
3030	Human	hsa-miR-134	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
3031	Human	hsa-miR-134	miRNA	astragaloside IV (AS-IV)	colorectal cancer (CRC)	colorectal cancer cell line SW-480	astragaloside (AS-IV) treatment	upregulated	29041002
3032	Human	hsa-miR-134	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells	TGF-¦Â1 treatment	"the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2,"	24258346
3033	Human	hsa-miR-134	miRNA	propofol (PPF)	glioblastoma multiforme (GBM)	glioma U87 cells	?propofol treatment	"Compared with the blank group, the proliferation, invasion and migration capacity of U87 cells were reduced in the positive control group and the propofol groups after 48 hours (all?P<005), along with the decreased expression of Ki-67, MMP-2 and MMP-9 and the ratio of p-PI3K/PI3K and p-Akt/Akt (all?P<005), while the level of miR-134 was increased significantly"	33678632
3034	Human	hsa-miR-134	miRNA	pyrogallol	hepatocellular carcinoma (HCC)	Hep3B and Huh7 hepatocellular carcinoma cells	pyrogallol treatment	upregulated	31426282
3035	Human	hsa-miR-134	miRNA	TGF-¦Â1	liver fibrosis	immortalized human hepatic stellate cell line LX-2	TGF-¦Â1 treatment	downregulated	30645141
3036	Human	hsa-miR-134	miRNA	TGF-¦Â1	lung adenocarcinoma (LUAD)	human adenocarcinoma cell lines	transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment	upregulated	24258346
3037	Human	hsa-miR-134	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
3038	Human	hsa-miR-134	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
3039	Human	hsa-miR-134	miRNA	glargine	pancreatic cancer (PC)	pancreatic cancer cells	glargine treatment	upregulated	22690071
3040	Human	hsa-miR-134	miRNA	valproic acid (VPA)	temporal lobe epilepsy (TLE)	epilepsy patients	VPA treatment	downregulated	29069823
3041	Human	hsa-miR-134	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
3042	Human	hsa-miR-134-5p	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	AC16 cells; human cardiomyocytes (HCM)	hypoxia/reoxygenation (H/R) treatment	Expression of miR-134-5p was upregulated in serum of AMI patients and hypoxia/reoxygenation (H/R)-induced cardiomyocytes (AC16 and HCM).	32797709
3043	Human	hsa-miR-134-5p	miRNA	resveratrol	autism spectrum disorder (ASD)	peripheral blood	resveratrol (Res) treatment	downregulated	29510222
3044	Human	hsa-miR-134-5p	miRNA	cisplatin (DDP)	cervical cancer (CC)	Cervical cancer HeLa cells	cisplatin treatment	si-NCK1-AS1 and miR-134-5p mimic both reduced MSH2 activity and increased cisplatin-induced apoptosis in cervical cancer cells.	30221354
3045	Human	hsa-miR-134-5p	miRNA	high glucose (HG)	diabetes mellitus (DM)	Endothelial colony forming cells (ECFCs)	high glucose treatment	upregulated	26799933
3046	Human	hsa-miR-134-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes	high glucose (HG) treatment	miR-134-5p was upregulated in high-glucose (HG)-treated podocytes.	29636888
3047	Human	hsa-miR-134-5p	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	downregulated	29899866
3048	Human	hsa-miR-134-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"circDLGAP4 exerted its functions via regulating miR-134-5p, circDLGAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway both in human and mouse."	31761328
3049	Human	hsa-miR-134-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y Cells	1-methyl-4-phenylpyridinium (MPP+) treatment	miR-134-5p was verified to be increased in PD cell models.	31761328
3050	Human	hsa-miR-135	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	28484287
3051	Human	hsa-miR-135	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	tissue regeneration	Human adult DPSCs	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	26351742
3052	Human	hsa-miR-135a	miRNA	L©\arginine	acute edematous pancreatitis (AEP)	pancreatic acinar cell line (AR43J)	introperitoneal injection of L-arginine (150 mg/kg) treatment	upregulated	24710937
3053	Human	hsa-miR-135a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	25230140
3054	Human	hsa-miR-135a	miRNA	visfatin	acute myeloid leukemia (AML)	HL60 cells	visfatin treatment	downregulated	30876976
3055	Human	hsa-miR-135a	miRNA	prostaglandin E2 (PGE2)	Alzheimer's disease (AD)	human umbilical vein endothelial cells (HUVECs)	PGE2 treatment	upregulated	25554493
3056	Human	hsa-miR-135a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	atherosclerosis (AS)	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 knockdown suppresses inflammation and oxidative stress induced by oxidized low-density lipoprotein in macrophages by sponging miR-135a	33128668
3057	Human	hsa-miR-135a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33128668
3058	Human	hsa-miR-135a	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells; liver tissues	hepatitis C virus (HCV) infection	miR-135a hepatic abundance is upregulated by HCV infection in both cultured hepatocytes and human liver.	30456659
3059	Human	hsa-miR-135a	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Caco-2 and HT-29 cells	dextran sodium sulfate (DSS) treatment	downregulated	30476915
3060	Human	hsa-miR-135a	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
3061	Human	hsa-miR-135a	miRNA	paclitaxel (PTX)	prostate cancer	"Human prostate cancer cells (PC3, C4-2 and DU145)"	Paclitaxel treatment	downregulated of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a	31486484
3062	Human	hsa-miR-135a	miRNA	acute stress	stress response	mice amygdala	acute Stress treatment	downregulated	24023867
3063	Human	hsa-miR-135a*	miRNA	platinum	lung adenocarcinoma (LUAD)	LADC tissues	platinum-based doublet chemotherapy treatment	dysregulated	25142144
3064	Human	hsa-miR-135a*	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
3065	Human	hsa-miR-135a-3p	miRNA	tanshinone I and TRAIL	prostate cancer	"PC-3, M2182 and DU145 cells"	co- of Tanshinone I and TRAIL treatment	upregulated	25015549
3066	Human	hsa-miR-135a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-135a-5p was decreased in oxidized low-density lipoprotein (ox-LDL)-treated HUVECs.	31921409
3067	Human	hsa-miR-135a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (T/G HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	LINC00299 regulated ox-LDL-induced T/G HA-VSMCs injury through the miR-135a-5p/XBP1 axis.	32700888
3068	Human	hsa-miR-135a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33778018
3069	Human	hsa-miR-135a-5p	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	upregulated	32705273
3070	Human	hsa-miR-135b	miRNA	hypoxia	cell proliferation	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	30576641
3071	Human	hsa-miR-135b	miRNA	ligustrazine (Lig)	cell proliferation	hypoxia-induced human umbilical vein endothelial cells (HUVECs)	Ligustrazine (Lig) treatment	upregulated	30576641
3072	Human	hsa-miR-135b	miRNA	mesalazine (MSLZ)	colorectal cancer (CRC)	CaCo2 cell line	Mesalazine (5-ASA) treatment	downregulated	29794245
3073	Human	hsa-miR-135b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
3074	Human	hsa-miR-135b	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
3075	Human	hsa-miR-135b	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	29883713
3076	Human	hsa-miR-135b	miRNA	X-rays	improved radiosensitivity	NSCLC cell lines (A549 and H1975)	X-ray irradiation treatment	downregulated	28117028
3077	Human	hsa-miR-135b	miRNA	5-aza-2'-deoxycytidine and trichostatin A	leukemia	human leukemia cell lines	5-aza-deoxycytidine and trichostatin A treatment	upregulated	27570640
3078	Human	hsa-miR-135b	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
3079	Human	hsa-miR-135b	miRNA	morin	lung cancer	A549 cells	Morin treatment	downregulated	28975847
3080	Human	hsa-miR-135b	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
3081	Human	hsa-miR-135b	miRNA	transcriptional co-activator with PDZ-binding motif (TAZ)	osteosarcoma (OS)	U2OS and HOS cell lines	TAZ treatment	upregulated	28823959
3082	Human	hsa-miR-135b	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	31036506
3083	Human	hsa-miR-135b	miRNA	ligustrazine (Lig)	pressure ulcer (PU)	human umbilical vein endothelial cells (HUVECs)	ligustrazine (Lig) treatment	miR-135b was upregulated by the treatment of Lig.	30576641
3084	Human	hsa-miR-135b	miRNA	E. senticosus extract (ESE)	cell proliferation	normal human keratinocytes	normal human keratinocytes treatment	downregulated	27042261
3085	Human	hsa-miR-135b-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"In this study, ox-LDL inhibited circRSF1 and HDAC1 expression while upregulated miR-135b-5p expression in Human umbilical vein endothelial cells (HUVECs)."	33757583
3086	Human	hsa-miR-135b-5p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	downregulated	30665445
3087	Human	hsa-miR-135b-5p	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	downregulated	32362797
3088	Human	hsa-miR-135b-5p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"Human gastric cancer cell lines (MKN45, SNU601 and SNU1)"	Helicobacter pylori (H. pylori) infection	upregulated	29985646
3089	Human	hsa-miR-135b-5p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"Human gastric cancer cell lines (MKN45, SNU601 and SNU1)"	Helicobacter pylori infection	upregulated	29985646
3090	Human	hsa-miR-135b-5p	miRNA	sulforaphane (SFN)	pancreatic ductal adenocarcinoma (PDAC)	"The established human PDA cell lines AsPC-1, BxPC-3, PANC-1"	sulforaphane treatment	upregulated	31044154
3091	Human	hsa-miR-136	miRNA	platelet-derived growth factor (PDGF)	atherosclerosis (AS)	vascular smooth muscle cells	platelet-derived growth factor (PDGF) treatment	upregulated	25409743
3092	Human	hsa-miR-136	miRNA	TGF-¦Â1	skin wound healing	HaCaT cells	TGF-¦Â1 treatment	downregulated	25654102
3093	Human	hsa-miR-136	miRNA	hypoxia	spinal cord ischemia injury (SCII)	human neuronal cell line AGE1.NH	hypoxia for 3 day supplemented with 1% O2	upregulated	28753453
3094	Human	hsa-miR-136	miRNA	rapamycin complex (mTOR)	tuberous sclerosis complex (TSC)	serum	rapamycin complex (mTOR) treatment	upregulated	27680012
3095	Human	hsa-miR-136*	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
3096	Human	hsa-miR-136-3p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
3097	Human	hsa-miR-136-5p	miRNA	lipopolysaccharide (LPS)	LPS-induced inflammation and damage	ARPE-19 cells	lipopolysaccharide (LPS) treatment	"After the treatment of ripasudil, the expression levels of miR-136-5p was suppressed."	32252692
3098	Human	hsa-miR-136-5p	miRNA	ripasudil	LPS-induced inflammation and damage	ARPE-19 cells	ripasudil treatment	"After the treatment of ripasudil, the expression levels of ROCK1, ROCK2 and miR-136-5p were suppressed"	32252692
3099	Human	hsa-miR-136-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells; CFPAC-1 cells	gemcitabine treatment	"MicroRNA-136-5p can reduce the proliferation rate and metastasis ability of PCa cells via regulating ZNF32, and thus alleviates gemcitabine resistance in PCa cells."	33155203
3100	Human	hsa-miR-136-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
3101	Human	hsa-miR-137	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y and human primary neuron (HPN) cells	amyloid-¦Â (A¦Â) 25-35 treatment	"A¦Â25-35 inhibited cell viability, induced cell apoptosis and increased the expression of SNHG1 in SH-SY5Y and human primary neuron (HPN) cells."	31447119
3102	Human	hsa-miR-137	miRNA	hypoxia	apoptosis	human embryonic kidney 293 (HEK-293) cells	"5% O2, 90% N2 and 5% CO2,"	downregulated	29286063
3103	Human	hsa-miR-137	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
3104	Human	hsa-miR-137	miRNA	osteogenic differentiation medium	calcific aortic valve disease (CAVD)	valve interstitial cells (VICs) isolated from human calcific aortic valves	"a-minimal essential medium (Gibco, Carlsbad, CA, USA) containing 0.1% FBS, bioactive recombinant human bone morphogenetic protein-2 (BMP-2; 50 ng/mL), dexamethasone (100 nmol/L), ascorbic acid (50 mg/mL), and b-glycerophosphate (5 mmol/L) treatment"	upregulated	30846207
3105	Human	hsa-miR-137	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human renal mesangial cells (HRMCs)	high glucose treatment	downregulated	28695984
3106	Human	hsa-miR-137	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	high glucose-treated human renal mesangial cells (HRMCs)	triptolide (TPL) treatment	upregulated	28695984
3107	Human	hsa-miR-137	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HRMCs	high glucose treatment	downregulated	28695984
3108	Human	hsa-miR-137	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	HG-treat HRMCs	high glucose treatment	upregulated	28695984
3109	Human	hsa-miR-137	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
3110	Human	hsa-miR-137	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
3111	Human	hsa-miR-137	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	upregulated	29505767
3112	Human	hsa-miR-137	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	HTR-8/SVneo cells	high glucose (HG) treatment	upregulated	29786111
3113	Human	hsa-miR-137	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	trophoblast cell line HTR-8/Svneo	high glucose (HG) treatment	upregulated	31109274
3114	Human	hsa-miR-137	miRNA	H2O2	glaucoma	RGCs	H2O2 treatment	We show that miR-137 was downregulated in H2O2-induced human trabecular meshwork cells (HTMCs)	33865939
3115	Human	hsa-miR-137	miRNA	phenformin	glioblastoma multiforme (GBM)	glioma stem cells (GSCs)	Phenformin treatment	upregulated	27486821
3116	Human	hsa-miR-137	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 and A172 cells	temozolomide (TMZ) treatment	downregulated	31750728
3117	Human	hsa-miR-137	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
3118	Human	hsa-miR-137	miRNA	olea europaea leaf extract (OLE)	glioblastoma multiforme (GBM)	GBM cell lines	olea europaea leaf extract (OLE) treatment	upregulation	25232498
3119	Human	hsa-miR-137	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251; A172 cells	temozolomide (TMZ) treatment	NCK1-AS1 could increase drug resistance of glioma cells to TMZ by modulating miR-137/TRIM24 pathway	31750728
3120	Human	hsa-miR-137	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	HEK293 cells	transfection with pHBV1.3	upregulated	29441983
3121	Human	hsa-miR-137	miRNA	aspirin	hepatocellular carcinoma (HCC)	Huh-7 cells	Aspirin treatment	upregulated	32627038
3122	Human	hsa-miR-137	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
3123	Human	hsa-miR-137	miRNA	propofol (PPF)	melanoma	Melanoma cells A2058 and WM793B	Propofol treatment	upregulated	31134615
3124	Human	hsa-miR-137	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC patient tissue samples	criplatin treatment	microRNA-137 in cisplatin-treated NSCLC patient tissue samples was markedly lower than that in healthy tissue samples.	30008879
3125	Human	hsa-miR-137	miRNA	oxaliplatin	oxaliplatin (L-OHP) resistance	HCT116; W480 cells	oxaliplatin (L-OHP) treatment	Silencing OIP5-AS1 reversed the resistance of CC cells to L-OHP by promoting the expression of miR-137	32308348
3126	Human	hsa-miR-137	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	PANC-1 cells; HS766T cells; AsPC-1 cells	cisplatin treatment	downregulated	32280243
3127	Human	hsa-miR-137	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation and migration	VSMCs cell lines (human aortic smooth muscle cells)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	29016699
3128	Human	hsa-miR-137	miRNA	bicalutamide	prostate cancer	human prostate cancer LNCaP cells	bicalutamide treatment	miR-137 modulate the response of human prostate cancer LNCaP cells to the antiandrogen bicalutamide.	31217891
3129	Human	hsa-miR-137	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
3130	Human	hsa-miR-138	miRNA	adipogenesis medium	adipogenesis	adipose tissue-derived mesenchymal stem cells (AMSCs)	adipogenic differentiation medium culture	downregulated	31769250
3131	Human	hsa-miR-138	miRNA	platelet-derived growth factor (PDGF)	bone homeostasis disorders	Multipotent mesenchymal stromal cells	PDGF treatment	upregulated	24792185
3132	Human	hsa-miR-138	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
3133	Human	hsa-miR-138	miRNA	hypoxia	tumorigenesis	EA.hy926 endothelial cells ATCC (CRL-2922)	?hypoxia treatment	upregulated	24244340
3134	Human	hsa-miR-138	miRNA	hypoxia	cardiac dysfunction	human cardiac cells	hypoxia treatment	downregulated	28899927
3135	Human	hsa-miR-138	miRNA	hypoxia	cardiomyocyte apoptosis	Myocardial samples of patients with congenital heart disease (CHD)	hypoxia treatment	upregulated	24211202
3136	Human	hsa-miR-138	miRNA	imatinib	chronic myeloid leukemia (CML)	K562 cells and primary CML samples	1 mmol/l imatinib for 24 or 48 h treatment	downregulated	23208504
3137	Human	hsa-miR-138	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cardiomyocytes	high glucose (HG) treatment	GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model	33682891
3138	Human	hsa-miR-138	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high-glucose (HG) treatment	upregulated	31251107
3139	Human	hsa-miR-138	miRNA	salidroside (SAL)	diabetic retinopathy (DR)	high-glucose (HG)-treated ARPE-19 cells	salidroside (SAL) treatment	downregulated	31251107
3140	Human	hsa-miR-138	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	LC006 cells; LC021 cells	TGF-¦Â1 treatment	"Among those dysregulated miRNAs, the expression of microRNA-138 was time-dependently downregulated by TGF¦Â1 treatment"	29407170
3141	Human	hsa-miR-138	miRNA	¦Á-solanine	esophageal cancer (EC)	human EC cells lines EC9706 and KYSE30	human EC cells lines EC9706 and KYSE30 treatment	upregulation	27536892
3142	Human	hsa-miR-138	miRNA	¦Á-solanine	esophageal squamous cell carcinoma (ESCC)	EC9706 and KYSE30 cells	¦Á-solanine treatment	upregulated	29328459
3143	Human	hsa-miR-138	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	T-cell	hepatitis B virus (HBV)?treatment	"We found that PD-1 was upregulated and miR-138 was downregulated in patients with CHB, LC, and HCC."	33410459
3144	Human	hsa-miR-138	miRNA	hepatitis B virus (HBV)	hepatoblastoma	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	30367502
3145	Human	hsa-miR-138	miRNA	resveratrol	low extremity deep vein thrombosis	Endothelial progenitor cells (EPCs)	resveratrol (Res) treatment	downregulated	29447140
3146	Human	hsa-miR-138	miRNA	"MS-275, a histone deacetylase inhibitor"	lung adenocarcinoma (LUAD)	A549 and HCC827 cell lines	MS-275 treatment	upregulated	31090206
3147	Human	hsa-miR-138	miRNA	¦Á-solanine	lung cancer	human lung adenocarcinoma cell lines (A549 and H1299)	human lung adenocarcinoma cell lines (A549 and H1299) treatment	upregulation	26631041
3148	Human	hsa-miR-138	miRNA	triptolide (TPL)	medulloblastoma	Daoy cells	triptolide (TPL) treatment	upregulated	30156009
3149	Human	hsa-miR-138	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
3150	Human	hsa-miR-138	miRNA	lentivirus	non-small cell lung cancer (NSCLC)	NSCLC cell lines H460 and SPC-A1 cells	Lentivirus treatment	upregulated	26201895
3151	Human	hsa-miR-138	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	human OA chondrocytes	"TNF¦Á for 3, 6, and 12 h treatment"	downregulated	28537665
3152	Human	hsa-miR-138	miRNA	"mechanical tension (10%, 0.5Hz)"	osteogenesis	human BMMSCs (hBMMSCs)	"mechanical tension (10%, 0.5Hz)"	downregulated	29253550
3153	Human	hsa-miR-138	miRNA	tension	osteogenic capability	Bone marrow mesenchymal stem cells (BMMSCs)	tension treatment	mechanical tension could suppress miR-138 expression	29253550
3154	Human	hsa-miR-138	miRNA	oestrogen (E2)	osteoporosis	HFOB and MG63 cells	oestrogen (E2) treatment	a dose-dependent upregulated of HOTAIR was observed in cells treated with oestrogen	33733597
3155	Human	hsa-miR-138	miRNA	curcumin (Cur)	osteosarcoma (OS)	human osteosarcoma cell line MG-63	curcumin treatment	upregulated	26823826
3156	Human	hsa-miR-138	miRNA	desflurane	ovarian cancer (OC)	SKOV3 cells	desflurane treatment	"miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane."	33673181
3157	Human	hsa-miR-138	miRNA	sevoflurane (SEV)	ovarian cancer (OC)	SKOV3 cells	sevoflurane treatment	"miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane"	33673181
3158	Human	hsa-miR-138	miRNA	lipopolysaccharide (LPS)	periodontal disease	periodontal progenitors	lipopolysaccharide (LPS) treatment	upregulated	26518300
3159	Human	hsa-miR-138	miRNA	¦Á-solanine	prostate cancer	human prostate cancer cell PC-3	¦Á-solanine treatment	upregulated	25116803
3160	Human	hsa-miR-138	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLS)	lipopolysaccharides (LPS) treatment	upregulated	31492495
3161	Human	hsa-miR-138	miRNA	cyanidin-3-glucoside (C3G)	triple negative breast cancer (TNBC)	TNBC lines MDA-MB-231 and BT-549	Cyanidin-3-glucoside (C3G) treatment	downregulated	30876970
3162	Human	hsa-miR-138-5p	miRNA	phenytoin	antiepileptic drug (AED) resistance	human brain microvascular endothelial cells (HBMECs)	phenytoin treatment	downregulated	31920517
3163	Human	hsa-miR-138-5p	miRNA	manganese chloride (MnCl2 )	autophagy	SH-SY5Y cells	manganese chloride (MnCl2 ) treatment	MnCl2 could induce autophagic dysregulation and inhibit expression of miR-138-5p.	30672645
3164	Human	hsa-miR-138-5p	miRNA	bruceine D (BD)	gastric cancer (GC)	HGC27 cells; MKN45 cells	bruceine D (BD) treatment	upregulated	33390953
3165	Human	hsa-miR-138-5p	miRNA	hypoxia	gastric cancer (GC)	SGC-7901; BGC-823	hypoxia treatment	downregulated	32425596
3166	Human	hsa-miR-138-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells; U87 cells	temozolomide (TMZ) treatment	LINC00174 downregulated decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis	31713817
3167	Human	hsa-miR-138-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	insulin resistance (IR)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30442237
3168	Human	hsa-miR-138-5p	miRNA	resolvin D1 (RvD1)	non small cell lung cancer (NSCLC)	"A549 cells, H1299 and LLC cells"	resolvin D1 (RvD1) treatment	upregulated	31783879
3169	Human	hsa-miR-138-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	MiR-138-5p was downregulated in CHON-001 cells.	31486753
3170	Human	hsa-miR-138-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells; A2780 cells	cisplatin treatment	miR-138-5p was downregulated in DDP-resistant cells.	32349783
3171	Human	hsa-miR-138-5p	miRNA	hypoxia	pancreatic cancer (PC)	"AsPC-1, BxPC-3, and PANC-1 cell lines"	hypoxia treatment	downregulated	28052003
3172	Human	hsa-miR-138-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31737212
3173	Human	hsa-miR-138-5p	miRNA	lipopolysaccharide (LPS)	preeclampsia (PE)	HTR-8/SVneo cells; JEG-3 cells	lipopolysaccharide (LPS) treatment	downregulated	33550900
3174	Human	hsa-miR-138-5p	miRNA	docetaxel (DTX)	prostate cancer	LNCaP and CWR22Rv1 cells	docetaxel (DTX) treatment	downregulated	30621625
3175	Human	hsa-miR-139	miRNA	hyperthermia	breast cancer	BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231	Hyperthermia treatment	downregulated	27380148
3176	Human	hsa-miR-139	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-139 was significantly downregulated whereas c-Jun was obviously upregulated after OGD/R treatment.	32807449
3177	Human	hsa-miR-139	miRNA	resveratrol	osteosarcoma (OS)	U20S and MG63 cells	resveratrol (RS) treatment	upregulated	31881225
3178	Human	hsa-miR-139	miRNA	a moderate-carbohydrate and high glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and high glycemic index diet	downregulated	29233589
3179	Human	hsa-miR-139	miRNA	low fat diet (LFD)	overweight and obese	plasma	low fat diet (LFD) treatment	downregulated in plasma	29233590
3180	Human	hsa-miR-139	miRNA	TGF-¦Â	scar formation after the glaucoma filtration surgery	human Tenon's fibroblasts (HTFs)	TGF-¦Â treatment	downregulated	30648255
3181	Human	hsa-miR-139-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
3182	Human	hsa-miR-139-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	downregulated	24589211
3183	Human	hsa-miR-139-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
3184	Human	hsa-miR-139-5p	miRNA	sevoflurane (SEV)	breast cancer	MDA-MB-231 and MCF-7 cells	sevoflurane (SEV) treatment	MiR-139-5p was upregulated in BC cells treated with SEV	33317757
3185	Human	hsa-miR-139-5p	miRNA	T-helper type 2 (Th2)-biased cytokine environment 	allergic asthma (AA)	Bronchial epithelial cells	T-helper type 2 (Th2)-biased cytokine environment treatment	downregulated	26289417
3186	Human	hsa-miR-139-5p	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	asthma	human airway smooth muscle cells	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	downregulated	28711603
3187	Human	hsa-miR-139-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human arterial smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33331071
3188	Human	hsa-miR-139-5p	miRNA	sevoflurane (SEV)	breast cancer	MCF-10A cells	Sevoflurane (SEV) treatment	MiR-139-5p was upregulated in BC cells treated with SEV	33317757
3189	Human	hsa-miR-139-5p	miRNA	high glucose (HG)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	miR-139-5p expression was elevated in human umbilical vein endothelial cells (HUVECs) cultured in high glucose media.	33293476
3190	Human	hsa-miR-139-5p	miRNA	ginsenoside Rg3	epithelial-mesenchymal transition (EMT)	iE-DAP-treated human umbilical vein endothelial cells (HUVEC)	Ginsenoside Rg3 (Rg3) treatment	upregulated	32148412
3191	Human	hsa-miR-139-5p	miRNA	¦Ã-d-glutamyl-meso-diaminopimelic acid (iE-DAP)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVEC)	¦Ã-d-glutamyl-meso-diaminopimelic acid (iE-DAP) treatment	downregulated	32148412
3192	Human	hsa-miR-139-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
3193	Human	hsa-miR-139-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
3194	Human	hsa-miR-139-5p	miRNA	particulate matter (PM2.5)	lung cancer	16HBE cells	PM2.5 stimulation treatment	downregulated	32913469
3195	Human	hsa-miR-139-5p	miRNA	ultraviolet (UV) irradiation	lupus erythematosus (LE)	HaCaT cells	30 mJ/cm2 UVB irradiation treatment	upregulated	31966801
3196	Human	hsa-miR-139-5p	miRNA	morphine	morphine addiction	HEK 293 cells	morphine treatment	Chronic morphine pretreatment alone elevated both c-Jun protein and miR-139-5p expression levels.	29916183
3197	Human	hsa-miR-139-5p	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	HNE1 cells	cisplatin (DPP) treatment	downregulated	29337244
3198	Human	hsa-miR-139-5p	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
3199	Human	hsa-miR-139-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
3200	Human	hsa-miR-139-5p	miRNA	hyaluronic acid (HA)	primary ovarian insufficiency (POI)	ovarian granulosa cells (GCs)	HA treatment	downregulated	25232020
3201	Human	hsa-miR-139-5p	miRNA	X-rays	prostate cancer	PC-3 cells; DU145 cells	X-ray radiation treatment	Knockdown of lncRNA TUG1 enhanced radiosensitivity in PCa via the TUG1/miR-139-5p/SMC1A axis	32256083
3202	Human	hsa-miR-1-3p	miRNA	PI3K/mTOR dual inhibitor BEZ235	acute myeloid leukemia (AML)	HL-60/VCR cells	BEZ235 treatment	upregulated	28042875
3203	Human	hsa-miR-1-3p	miRNA	hepatocyte growth factor (HGF)	lung cancer	lung cancer cells PC-9 and HCC-827	Hepatocyte growth factor (HGF) treatment	downregulated	29664235
3204	Human	hsa-miR-1-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
3205	Human	hsa-miR-1-3p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
3206	Human	hsa-miR-140	miRNA	lipopolysaccharide (LPS)	colorectal cancer (CRC)	SW480 cells; HCT116 cells	lipopolysaccharide (LPS) treatment	LPS could increase miR-140 expression in a time- and concentration-dependent manner.	31882548
3207	Human	hsa-miR-140	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	31362245
3208	Human	hsa-miR-140	miRNA	¦Á-Mangostin	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	¦Á-Mangostin treatment	H19 exerted its function via the modulation of H19/miR-140/HE4 in hyperglycemia with ¦Á-Mangostin	31362245
3209	Human	hsa-miR-140	miRNA	Bie Jia Jian Pill (BJJP)	hepatocellular carcinoma (HCC)	cancer stem cells (CSCs)	Bie Jia Jian Pill (BJJP) treatment	?BJJP or BMSCs treatment alone on CSCs lead to increased miR-140 expression and cell apoptosis	33632990
3210	Human	hsa-miR-140	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCC cells	hypoxia treatment	?NR2F1-AS1 level was enhanced in HCC tissues and cells.	33488124
3211	Human	hsa-miR-140	miRNA	lipopolysaccharide (LPS)	inflammation	CD14©\positive cells	lipopolysaccharides (LPS) treatment	downregulated	30321456
3212	Human	hsa-miR-140	miRNA	aucubin	intervertebral disc degeneration (IDD)	IL©\1¦Â or TNF©\¦Á-induced human nucleus pulposus cells (HNPCs)	aucubin treatment	upregulated	30637726
3213	Human	hsa-miR-140	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPCs)	IL-1¦Â treatment	downregulated	30637726
3214	Human	hsa-miR-140	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30637726
3215	Human	hsa-miR-140	miRNA	estradiol-17¦Â (E2)	menopausal arthritis	chondrocytes	estradiol-17¦Â (E2) treatment	upregulated	27165343
3216	Human	hsa-miR-140	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	NEAT1 and miR-140 are upregulated in hepacytes under the NAFLD conditions. The NEAT1-miR-140 axis play a crucial role in modulation of NAFLD via inactivation of AMPK/SREBP1 signaling.	31239155
3217	Human	hsa-miR-140	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	erlotinib-sensitive PC9 cells	TGF¦Â treatment	dysregulated	28646226
3218	Human	hsa-miR-140	miRNA	carnosic acid (CA)	osteoarthritis (OA)	human articular chondrocytes	Carnosic acid (CA) treatment	upregulated	29678719
3219	Human	hsa-miR-140	miRNA	IL-1¦Â	osteoarthritis (OA)	Human Chondrocytes	IL-1¦Â treatment	downregulated	31915516
3220	Human	hsa-miR-140	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	downregulated	32520081
3221	Human	hsa-miR-140	miRNA	IL-1¦Â	osteoarthritis (OA)	human cartilage cells line C28/I2	IL-1¦Â treatment	Expression of miRNA-140 and MMP-13 was elevated in IL-1b-stimulated C28/I2 cells	22273691
3222	Human	hsa-miR-140	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
3223	Human	hsa-miR-140	miRNA	melatonin	osteoarthritis (OA)	Human Chondrocytes	melatonin treatment	upregulated	31915516
3224	Human	hsa-miR-140	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
3225	Human	hsa-miR-140	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
3226	Human	hsa-miR-140	miRNA	insulin	polycystic ovarian syndrome (PCOS)	human granulosa cells (GCs)	insulin treatment	High miR-140 expression was observed in insulin-treated granulosa cells compared to that in unstimulated cells.	32024547
3227	Human	hsa-miR-140	miRNA	TGF-¦Â1	lung fibrosis	HBE and A549 cells	TGF-¦Â1 treatment	H19 knockdown attenuated pulmonary fibrosis via the regulatory network of lncRNA H19-miR-140-TGF-¦Â/Smad3 signaling	30988156
3228	Human	hsa-miR-140-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	"Human retinal vascular endothelial cells (HRVECs), human umbilical vein endothelial cells (HUVECs), human coronary artery endothelial cells (HCAECs) and human coronary artery endothelial cells (EA.hy.926)"	high glucose treatment	downregulated	30862410
3229	Human	hsa-miR-140-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	Loss of circRNA_0084043 depressed HG-induced damage via sponging miR-140-3p and regulating TGFA.	32259630
3230	Human	hsa-miR-140-3p	miRNA	astragaloside IV (AS-IV)	endothelial dysfunction	Oxidized low-density lipoprotein (ox-LDL)-treated human umbilical vein endothelial cells (HUVECs)	astragaloside IV (AS-IV) treatment	upregulated	31257467
3231	Human	hsa-miR-140-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31257467
3232	Human	hsa-miR-140-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (H/R) induce	downregulated	31792649
3233	Human	hsa-miR-140-3p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
3234	Human	hsa-miR-140-3p	miRNA	epigallocatechin-3-gallate (EGCG)	osteoarthritis (OA)	interleukin-1¦Â-stimulated human osteoarthritis chondrocytes	EGCG	downregulated	28110479
3235	Human	hsa-miR-140-3p	miRNA	epigallocatechin-3-gallate (EGCG)	osteoarthritis (OA)	human chondrocytes	Epigallocatechin-3-O-gallate (EGCG) treatment	EGCG inhibited IL-1¦Â-induced ADAMTS5 expression and upregulated the expression of hsa-miR-140-3p.	28110479
3236	Human	hsa-miR-140-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
3237	Human	hsa-miR-140-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-8¦Â treatment	dysregulated	29123165
3238	Human	hsa-miR-140-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 chondrocyte cells	IL-1¦Â treatment	MiR-140-3p Ameliorates the Progression of Osteoarthritis via Targeting CXCR4.	32101839
3239	Human	hsa-miR-140-3p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	downregulated	27018851
3240	Human	hsa-miR-140-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	asthma	human airway smooth muscle cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	22773691
3241	Human	hsa-miR-140-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	30344669
3242	Human	hsa-miR-140-5p	miRNA	particulate matter (PM2.5)	airway inflammation	16HBE cells	fine particulate matter (PM2.5) exposure treatment	MiR-140-5p/TLR4 /NF-¦ÊB signaling pathway: Crucial role in inflammatory response in 16HBE cells induced by dust fall PM 25	33080424
3243	Human	hsa-miR-140-5p	miRNA	particulate matter (PM2.5)	airway inflammation	human bronchial epithelial cells (16HBE)	fine particulate matter (PM2.5) exposure treatment	"In conclusion, this study revealed a new mechanism by which the miR-140-5p/TLR4 signaling pathway mediated the inflammatory response of 16HBE cells induced by PM25"	33080424
3244	Human	hsa-miR-140-5p	miRNA	simvastatin	breast cancer	MDA-MB-231 cells	Simvastatin treatment	upregulated	31138773
3245	Human	hsa-miR-140-5p	miRNA	hypoxia	cerebral ischemia injury (CII)	HUVECs	hypoxia treatment	downregulated	27035554
3246	Human	hsa-miR-140-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	downregulated	32073611
3247	Human	hsa-miR-140-5p	miRNA	high glucose (HG)	diabetic-associated vascular injury	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	High glucose (HG) exposure downregulated the expression of circ_CLASP2 in HUVECs	33776760
3248	Human	hsa-miR-140-5p	miRNA	propofol (PPF)	gastric cancer (GC)	SGC-7901 and MKN45 cells	propofol?treatment treatment	upregulated	31819507
3249	Human	hsa-miR-140-5p	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
3250	Human	hsa-miR-140-5p	miRNA	catalpol	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells	catalpol treatment	Catalpol increased the expression levels of E-cadherin and miR-140-5p.	33179108
3251	Human	hsa-miR-140-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2/SOR cell line	sorafenib treatment	"miR-140-5p overexpression also increases the sensitivity of HepG2/SOR cells to sorafenib, and the effects of SNHG16 knockdown on sorafenib resistance could be blocked by miR-140-5p inhibitor"	30655679
3252	Human	hsa-miR-140-5p	miRNA	TGF-¦Â1	hepatocellular carcinoma (HCC)	MHCC-97H and SMMC-7721 cells	TGF¦Â1 treatment	downregulated	31402791
3253	Human	hsa-miR-140-5p	miRNA	simvastatin	hypercholesterolemia	HepG2 cells; LO2 cells	simvastatin treatment	"Palmitic acid and simvastatin suppressed, whereas LDL-C upregulated the expression of miR-140-5p in HepG2 cells"	32109664
3254	Human	hsa-miR-140-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
3255	Human	hsa-miR-140-5p	miRNA	hypoxia	hypoxic brain injury	SH-SY5Y cells	hypoxia treatment	"LncRNA SNHG1-modulated miR-140-5p inhibition regulates Bcl-XL expression, thereby reducing cell apoptosis and recovering cell viability of SH-SY5Y cells."	32186226
3256	Human	hsa-miR-140-5p	miRNA	oxygen glucose deprivation (OGD)	hypoxic brain injury	SH-SY5Y cells	Oxygen glucose deprivation (OGD) treatment	Oxygen glucose deprivation (OGD) treatment inhibited SNHG1 and Bcl-XL expression and enhanced miR-140-5p expression	32186226
3257	Human	hsa-miR-140-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	lipopolysaccharides (LPS) treatment	downregulated	29901170
3258	Human	hsa-miR-140-5p	miRNA	pioglitazone	metabolic syndrome	endothelial progenitor cells (EPCs)	Pioglitazone treatment	downregulated	26898430
3259	Human	hsa-miR-140-5p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC cell lines (A549 and H1299)	cisplatin treatment	downregulated	31288529
3260	Human	hsa-miR-140-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteoarthritis (OA)	OA chondrocytes and synoviocytes	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31077718
3261	Human	hsa-miR-140-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	The normal human chondrocytes C28/I2	IL-1¦Â treatment	downregulated	31712854
3262	Human	hsa-miR-140-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes C28/I2	IL-1¦Â treatment	upregulated	31712854
3263	Human	hsa-miR-140-5p	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cell lines PANC-1 and BxPC-3	Metformin treatment	dysregulated	28875433
3264	Human	hsa-miR-140-5p	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	The human renal epithelial cells (294T cells)	metformin treatment	differently regulated in circulating	24478399
3265	Human	hsa-miR-141	miRNA	ultraviolet (UV) irradiation	DNA damage	U2OS;EH1; EH2 cell lines	ultraviolet light treatment	upregulated	24163379
3266	Human	hsa-miR-141	miRNA	esomeprazole	adeno and squamous-cell-carcinoma	human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines	esomeprazole treatment	upregulated	25175076
3267	Human	hsa-miR-141	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
3268	Human	hsa-miR-141	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	26823756
3269	Human	hsa-miR-141	miRNA	influenza A virus (IAV)	avian influenza virus (AIV) infection	NCI-H292 cells	avian influenza viruses treatment	the modulation of TGF-¦Â2 expression by different influenza subtypes via miR-141 might be a critical step for determining the outcome of either normal or excessive inflammation progression	23663545
3270	Human	hsa-miR-141	miRNA	arsenic trioxide (ATO)	breast cancer	MDA-MB-231 cells	arsenic trioxide (As2O3) treatment	upregulated	24729530
3271	Human	hsa-miR-141	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 breast cancer cells	Glabridin treatment	upregulated	24754877
3272	Human	hsa-miR-141	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
3273	Human	hsa-miR-141	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
3274	Human	hsa-miR-141	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
3275	Human	hsa-miR-141	miRNA	decabromodiphenyl ether (BDE-209)	cardiovascular disease (CVD)	THP-1 monocytes to human aortic endothelial cells (HAECs)	decabromodiphenyl ether (BDE-209) treatment	downregulated	30419430
3276	Human	hsa-miR-141	miRNA	decabromodiphenyl ether (BDE-209)	cardiovascular disease (CVD)	human aortic endothelial cells (HAECs)	decabromodiphenyl ether (BDE-209) treatment	downregulated	30419430
3277	Human	hsa-miR-141	miRNA	paeonol (PAE)	chondrosarcoma	human chondrosarcoma cell line JJ012	paeonol treatment	upregulated	24992595
3278	Human	hsa-miR-141	miRNA	leukemia inhibitory factor(LIF)	choriocarcinoma	JEG-3 cells	leukemia inhibitory factor(LIF) treatment	downregulated	21726338
3279	Human	hsa-miR-141	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 119 cells	RM (Root methanol) treatment	upregulated	32691634
3280	Human	hsa-miR-141	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	The results showed that SNHG15 was remarkably upregulated in pediatric DN tissues and HG-induced HGMCs.	33506255
3281	Human	hsa-miR-141	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
3282	Human	hsa-miR-141	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-141 towards the control level.	32387379
3283	Human	hsa-miR-141	miRNA	decitabine	gastric cancer (GC)	SGC-7902 cells	decitabine treatment	upregulated	25502084
3284	Human	hsa-miR-141	miRNA	decitabine	gastric cancer (GC)	SGC-7901 cells	the chemotherapeutic agent decitabine treatment	upregulated	25502084
3285	Human	hsa-miR-141	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	people	Helicobacter pylori infected treatment	downregulated	24732377
3286	Human	hsa-miR-141	miRNA	TGF-¦Â	gastric cancer (GC)	SGC-7902 cells	TGF-¦Â treatment	downregulated	25502084
3287	Human	hsa-miR-141	miRNA	high glucose (HG)	hepatic steatosis	HepG2 cells	high glucose (HG) treatment	upregulated	31256424
3288	Human	hsa-miR-141	miRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	5-fluorouracil (5-FU) treatment	miR-141 was sig- nificantly increased in 5-FU-resistant HCC cells.	30119680
3289	Human	hsa-miR-141	miRNA	lipopolysaccharide (LPS)	infantile pneumonia (IP)	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	30500550
3290	Human	hsa-miR-141	miRNA	lipopolysaccharide (LPS)	inflammation	WI-38 fibroblasts	lipopolysaccharides (LPS) treatment	downregulated	30500550
3291	Human	hsa-miR-141	miRNA	TGF-¦Â1	liver fibrosis	LX2 cells	TGF-¦Â1 treatment	downregulated of miR-141 deactivates hepatic stellate cells by targeting the PTEN/AKT/mTOR pathway	32319536
3292	Human	hsa-miR-141	miRNA	arsenite	melanoma	human keratinocyte HaCaT cell line	arsenic (As) exposure	upregulated	27054085
3293	Human	hsa-miR-141	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
3294	Human	hsa-miR-141	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose treatment	upregulated	31256424
3295	Human	hsa-miR-141	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	erlotinib-sensitive PC9 cells	TGF¦Â treatment	dysregulated	28646226
3296	Human	hsa-miR-141	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-19B cells	human papillomaviruses (HPVs) 19 treatment	downregulated	31911577
3297	Human	hsa-miR-141	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	miR-141 expression was low in LPS-induced MRC-5 cells.	32317619
3298	Human	hsa-miR-141	miRNA	hypoxia	preeclampsia (PE)	HTR-8/SVneo cells	hypoxia induce	upregulated	31004838
3299	Human	hsa-miR-141	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (hPASMCs)	hypoxia treatment	The miR-141 expression was decreased under hypoxia culture.	32559140
3300	Human	hsa-miR-141	miRNA	honokiol	renal cell carcinoma (RCC)	A-498 cell line	honokiol treatment	upregulated	24810210
3301	Human	hsa-miR-141	miRNA	ginsenoside Rh3	retinal injury	ARPE-19 cells; retinal ganglion cells (RGCs)	ginsenoside Rh3 treatment	Rh3 dose-dependently increased expression of miR-141.	29427790
3302	Human	hsa-miR-141	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
3303	Human	hsa-miR-141	miRNA	p16 INK4A	cell senescence	human fibroblast and epithelial cells	p16 INK4A treatment	upregulated	27596953
3304	Human	hsa-miR-141-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 enhanced the progression of AS in vitro by regulating the miR-141-3p/ROR2 axis.	32565910
3305	Human	hsa-miR-141-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-141-3p was decreased in oxidized low-density lipoprotein (ox-LDL)-treated human vascular smooth muscle cells (VSMCs)	33818249
3306	Human	hsa-miR-141-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells	high glucose	upregulated	29246323
3307	Human	hsa-miR-141-3p	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	human mesangial cells	triptolide (TPL) treatment	downregulated	29246323
3308	Human	hsa-miR-141-3p	miRNA	trans-nonachlor (TNC)	melanoma	melanoma cell lines	trans-nonachlor (TNC) treatment	downregulated	27616325
3309	Human	hsa-miR-141-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	Long non-coding RNA SNHG15 is a competing endogenous RNA of miR-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression	32247266
3310	Human	hsa-miR-141-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
3311	Human	hsa-miR-141-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	"SNHG16 and sushi domain containing 2 (SUSD2) were upregulated, and miRNA (miR)-141-3p was downregulated in the serum of acute pneumonia patients and lipopolysaccharide (LPS)-challenged human lung fibroblasts WI-38."	33836533
3312	Human	hsa-miR-141-3p	miRNA	hypoxia	preeclampsia (PE)	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	MiR-141-3p expression was upregulated in the HUVECs isolated from PE tissues and hypoxia-induced HUVECs.	33631423
3313	Human	hsa-miR-141-3p	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	transforming growth factor (TGF)-¦Â1 treatment	downregulated	33135476
3314	Human	hsa-miR-141-3p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	synovial fibroblasts (SFs)	lipopolysaccharide (LPS) treatment	miR-141-3p was significantly decreased at the gene level ln LPS induced SFs.	32373221
3315	Human	hsa-miR-141-3p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
3316	Human	hsa-miR-141-5p	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
3317	Human	hsa-miR-141-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	peripheral blood cells	imatinib treatment	miR-141-5p was remarkably elevated in patients after treatment with imatinib.	32038235
3318	Human	hsa-miR-141-5p	miRNA	nilotinib	chronic myeloid leukemia (CML)	peripheral blood cells	nilotinib treatment	miR-141-5p was remarkably elevated in patients after treatment with nilotinib.	32038235
3319	Human	hsa-miR-141-5p	miRNA	lectin	prostate cancer	Prostate cancer (PC) cell lines	lectin treatment	upregulated	26417675
3320	Human	hsa-miR-142	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	chronic periodontitis	human gingival epithelial cells (hGECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28123644
3321	Human	hsa-miR-142	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HCC cell lines HepG2 and SMMC7721	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28963738
3322	Human	hsa-miR-142	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; Hcc827 cells; lung adenocarcinoma (LAD) tissues	cisplatin treatment	downregulated	33416094
3323	Human	hsa-miR-142	miRNA	hypoxia	pancreatic cancer (PC)	human PC cell lines PANC©\1;SW1990	hypoxic condition induce	"In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1¦Á axis under hypoxic condition."	30693518
3324	Human	hsa-miR-142	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	lung fibrosis	"The OHS cell line (IOR/OS14, IOR/OS10, IOR/SARG and IOR/MOS) and cell lines HOS, U-2 OS, MG-63 ;K562 leukemia cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	mir-142 is epigenetically repressed by DNA methylation	24236112
3325	Human	hsa-miR-142-3p	miRNA	respected serum exosomes	acute cellular rejection	human Umbilical Vein Endothelial Cells (HUVECs)	respected serum exosomes treatment	upregulated	28073833
3326	Human	hsa-miR-142-3p	miRNA	bone morphogenetic protein 7 (BMP7)	apoptosis	HA-VSMCs	bone morphogenetic protein 7 (BMP7) treatment	upregulated	29435112
3327	Human	hsa-miR-142-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-142-3p expression was substantially upregulated during the ox-LDL-elicited apoptosis in HAECs.	29949787
3328	Human	hsa-miR-142-3p	miRNA	macrophage migration inhibitory factor (MIF)	cardioprotective therapy	human adipose-derived MSCs (ADMSCs); Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes	macrophage migration inhibitory factor (MIF) treatment	LncRNA-NEAT1/miR-142-3p/FOXO1 at least partially mediates the cardioprotective roles of exosomeMIF in protecting cardiomyocytes from apoptosis.	31964409
3329	Human	hsa-miR-142-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	downregulated	31722571
3330	Human	hsa-miR-142-3p	miRNA	aspergillus fumigatus (A. fumigatus)	cell activation	CD4+?T cells	"CD4+ T cells were activated by co-culturing with dendritic cells (DCs), which were pre-treated with AFE"	"Forced expression of miRNA-142-3P dramatically suppressed RICTOR levels, phosphorylated AKT and IFN-¦Ã in AFE activated T cells."	31930050
3331	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	cell death	The dermal microvascular endothelial cells (HMVEC-D)£» the human skin fibroblasts (ATCC)£»breast cancer cell line MCF7£» prostate cancer cell line PC-3	lipopolysaccharide (LPS) treatment	miR-142-3p in regulating DC responses to LPS	21474672
3332	Human	hsa-miR-142-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	HA-VSMCs	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	29435112
3333	Human	hsa-miR-142-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	neuronal cell line SH-SY5Y	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31863884
3334	Human	hsa-miR-142-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-142-3p expression was decreased after OGD/R induction.	31863884
3335	Human	hsa-miR-142-3p	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	downregulated	20460641
3336	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	downregulated	32269710
3337	Human	hsa-miR-142-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
3338	Human	hsa-miR-142-3p	miRNA	antrodia cinnamomea	colorectal cancer (CRC)	"The human colon cancer cell lines (SW480, SW620 and HCT116)"	antrodia cinnamomea treatment	upregulated	31349708
3339	Human	hsa-miR-142-3p	miRNA	trichosanthes kirilowii extract (TKE)	DNA damage	HaCaT cells	Trichosanthes kirilowii extract (TKE) treatment	"TKE significantly upregulated the expression of the core clock protein, brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein-1 (BMAL1), and downregulated the expression of miRNA (miR)-142-3p"	29115465
3340	Human	hsa-miR-142-3p	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
3341	Human	hsa-miR-142-3p	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
3342	Human	hsa-miR-142-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	Sorafenib treatment	downregulated	29472524
3343	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	hirschsprung's disease (HSCR)	human 293T cells	lipopolysaccharides (LPS) treatment	downregulated	29956457
3344	Human	hsa-miR-142-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
3345	Human	hsa-miR-142-3p	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
3346	Human	hsa-miR-142-3p	miRNA	FTY-720	leukemia	OCI-AML3 cells	FTY-720 treatment	downregulated	24858343
3347	Human	hsa-miR-142-3p	miRNA	licochalcone A (LA)	melanoma	A375 cells	licochalcone A (LCA) treatment	MiR- 142-3p level was significantly upregulated in LCA-treated A375 cells in a time- and dose-dependent manner.	31793097
3348	Human	hsa-miR-142-3p	miRNA	licochalcone A (LA)	melanoma	A375 and B16 melanoma cells	Licochalcone A (LCA) treatment	upregulated	31793097
3349	Human	hsa-miR-142-3p	miRNA	autologous hematopoietic SCT(AHSCT)	multiple sclerosis (MS)	MS patients	AHSCT treatment	upregulated in T- and B-cell	25486582
3350	Human	hsa-miR-142-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
3351	Human	hsa-miR-142-3p	miRNA	high glucose (HG)	cardiac fibrosis	primary human aortic endothelial cells (HAECs)	high glucose (HG) treatment	MiR-142-3p screened by miRNA microarray was significantly downregulated in HAECs under HG stimulation in a dose and time dependent manner.	31938215
3352	Human	hsa-miR-142-3p	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
3353	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human chondrocytes	lipopolysaccharide (LPS) treatment	downregulated	31836002
3354	Human	hsa-miR-142-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	"Pancreatic cancer cell lines including AsPC-1, HPAC, BxPC-3, and PANC-1"	gemcitabine treatment	knock-down of SBF2-AS1 inhibits the expression of TWF1 by competitively binding with miR-142-3p to induce gemcitabine resistance in pancreatic cancer.	31619579
3355	Human	hsa-miR-142-3p	miRNA	triptolide and quercetin	pancreatic ductal adenocarcinoma (PDAC)	MIA PaCa-2; Capan-1; HEK-293 lines ;S2-013 cells	triptolide and quercetin treatment	upregulated	23635652
3356	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	primary human periodontal ligament cells (PDLC	lipopolysaccharide (LPS) treatment	upregulated of lncRNA FGD5-AS1 could protect against periodontitis via regulating the miR-142-3p/SOCS6/NF-¦ÊB signals.	31144533
3357	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	Human rheumatoid fibroblast-like synoviocytes (MH7?A)	lipopolysaccharide (LPS) treatment	downregulated	31022596
3358	Human	hsa-miR-142-3p	miRNA	salvianolic acid B (Sal B)	rheumatoid arthritis (RA)	LPS-treated Human rheumatoid fibroblast-like synoviocytes (MH7?A)	salvianolic acid B (Sal B) treatment	upregulated	31022596
3359	Human	hsa-miR-142-3p	miRNA	lipopolysaccharide (LPS)	sepsis	Neonatal Polymorphonuclear Leukocytes	lipopolysaccharide (LPS) treatment	dysregulated	28655995
3360	Human	hsa-miR-142-3p	miRNA	Trichosanthes kirilowii extract (TKE)	skin diseases	human keratinocytes	TKE treatment	downregulated	29115465
3361	Human	hsa-miR-142-3p	miRNA	mycophenolic acid (MPA)	systemic lupus erythematosus (SLE)	lupus CD4(+)T cells	Mycophenolic acid (MPA) treatment	upregulated	25661834
3362	Human	hsa-miR-142-3p	miRNA	curcumin (Cur)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	curcumin treatment	curcumin suppressed p300/miR-142-3p/PSMB5 axis leading to the inhibition of the CT-l activity of 20S proteasome.	32866906
3363	Human	hsa-miR-142-3p	miRNA	rapamycin complex (mTOR)	tuberous sclerosis complex (TSC)	serum	rapamycin complex (mTOR) treatment	upregulated	27680012
3364	Human	hsa-miR-142-5p	miRNA	CoCl2	acute kidney injury (AKI)	HK-2 cells	CoCl2 treatment	downregulated of XIST ameliorates acute kidney injury by sponging miR-142-5p and targeting PDCD4.	32347551
3365	Human	hsa-miR-142-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	28769761
3366	Human	hsa-miR-142-5p	miRNA	amyloid-¦Â (A¦Â) 42	Alzheimer's disease (AD)	HN cells	amyloid-¦Â (A¦Â) 42 treatment	Berberine attenuates A¦Â42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells	32251633
3367	Human	hsa-miR-142-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	peripheral blood; bone marrow	imatinib treatment	miR-365a-3p showing the most significant downregulated in non-responders treatment by imatinib.	32999756
3368	Human	hsa-miR-142-5p	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	downregulated	31226416
3369	Human	hsa-miR-142-5p	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	upregulated	31226416
3370	Human	hsa-miR-142-5p	miRNA	rotavirus (RV)	colorectal cancer (CRC)	colon cancer cells	rotavirus (SA11 or KU)treatment treatment	upregulated	26572508
3371	Human	hsa-miR-142-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cell (HREC)	high glucose (HG) treatment	miR-142-5p level was downregulated in high glucose (HG)-treated HRECs.	32116075
3372	Human	hsa-miR-142-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec3A cells	Progesterone treatment	upregulated	22543862
3373	Human	hsa-miR-142-5p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
3374	Human	hsa-miR-142-5p	miRNA	triptolide (TPL)	multiple myeloma (MM)	the dexamethasone-sensitive MM.1S human MM cell line	triptolide (TPL)? treatment	downregulated	22260163
3375	Human	hsa-miR-142-5p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
3376	Human	hsa-miR-142-5p	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose (HG) treatment	upregulated	31889412
3377	Human	hsa-miR-142-5p	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG3 cells	high glucose (HG) treatment	upregulated	31889412
3378	Human	hsa-miR-142-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 cells	IL-1¦Â treatment	miR-142-5p was downregulated in IL-1¦Â-treated chondrocytes.	31903636
3379	Human	hsa-miR-142-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	"CircSEC24A and SOX5 expression were enhanced, while miR-142-5p level was reduced in OA cartilage tissues and chondrocytes."	33751650
3380	Human	hsa-miR-142-5p	miRNA	SDF-1	osteoarthritis (OA)	primary human OA chondrocytes	SDF-1 treatment	miR-142-5p as a CXCR4-Targeted MicroRNA Attenuates SDF-1-Induced Chondrocyte Apoptosis and Cartilage Degradation via Inactivating MAPK Signaling Pathway	32047668
3381	Human	hsa-miR-142-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	"OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells"	cisplatin treatment	"in OVCAR3, SKOV3, and primary epithelial ovarian cancer (EOC) cells, overexpression or inhibition of miR-142-5p increased or suppressed their sensitivities to cisplatin respectively."	30639456
3382	Human	hsa-miR-142-5p	miRNA	neurofibromatosis type 1 (NF1)	ovarian cancer (OC)	OVCAR3 and SKOV3 cells	Neurofibromatosis type 1 (NF1) deficiency	downregulated	30543142
3383	Human	hsa-miR-142-5p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
3384	Human	hsa-miR-142-5p	miRNA	rotavirus (RV)	rotavirus (RV) infection	blood	rotavirus (SA11 or KU) infection treatment	upregulated	26572508
3385	Human	hsa-miR-142-5p	miRNA	sulforaphane (SFN)	staphylococcus aureus infection	THP-1 cells	sulforaphane (SFN) treatment	SFN pretreatment of the THP-1-derived macrophages significantly attenuated the S aureus-mediated increased expression levels of miR-142-5p	32323751
3386	Human	hsa-miR-142-5p	miRNA	mycophenolic acid (MPA)	systemic lupus erythematosus (SLE)	lupus CD4(+)T cells	Mycophenolic acid (MPA) treatment	upregulated	25661834
3387	Human	hsa-miR-142-5p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
3388	Human	hsa-miR-142-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	HT-29 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TUG1 negatively regulated inflammation in ulcerative colitis through miR-142-5p/SOCS1 axis	32173492
3389	Human	hsa-miR-142-5p	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	Human umbilical cord mesenchymal stem cells (hUCMSCs)	Zika virus (ZIKV) infection treatment	miR-142-5p was significantly downregulated upon ZIKV infection	32902370
3390	Human	hsa-miR-143	miRNA	IFN-¦Â	asthma	airway smooth muscle (ASM)	IFN-beta? treatment	upregulated	20382746
3391	Human	hsa-miR-143	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	Human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	31607223
3392	Human	hsa-miR-143	miRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	U937 cells; HL60 cells	cytarabine treatment	MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.	33077697
3393	Human	hsa-miR-143	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	"miR-143 regulation of IL-13-induced inflammatory cytokine and mucus production in NECs from AR patients probably partly depends on inhibition of IL13R¦Á1. Therefore, the IL13R¦Á1 signaling pathway may be a potential target for the prevention and treatment of AR by miR-143."	25529447
3394	Human	hsa-miR-143	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs) from AR patients	IL-13 treatment	upregulated	25529447
3395	Human	hsa-miR-143	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	vascular smooth muscle cell (VSMC)	homocysteine (Hcy) treatment	downregulated	26573388
3396	Human	hsa-miR-143	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	vascular smooth muscle cell (VSMC)	homocysteine (Hcy) treatment	downregulated	26573388
3397	Human	hsa-miR-143	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
3398	Human	hsa-miR-143	miRNA	estradiol	breast cancer	MCF-7 cells	estradiol (E?) treatment	"E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells"	22260523
3399	Human	hsa-miR-143	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
3400	Human	hsa-miR-143	miRNA	TGF-¦Â1	breast cancer	human coronary artery smooth muscle cells	TGF-¦Â1 treatment	downregulated	21712382
3401	Human	hsa-miR-143	miRNA	histone deacetylase inhibitor (HDACi)	burkitt lymphoma (BL)	Raji B-cell lymphoma	HDACi treatment	upregulated	24577510
3402	Human	hsa-miR-143	miRNA	arsenite	tumorigenesis	derivative normal stem cell (SC) line	arsenite exposure	downregulated	24431212
3403	Human	hsa-miR-143	miRNA	conditioned media (CM)	cardiovascular disease (CVD)	human vascular smooth muscle cells (hVSMC)	exposure to CM from primary human subcutaneous adipocytes treatment	upregulated	24333576
3404	Human	hsa-miR-143	miRNA	taxol	cervical squamous cell carcinoma (SCC)	patients of cervical SCC	taxol treatment	upregulated	24774218
3405	Human	hsa-miR-143	miRNA	epidermal growth factor receptor (EGFR)	colorectal cancer (CRC)	colorectal cancer cells	epidermal growth factor receptor (EGFR) treatment	miRNA-143 expression levels serve as an independent prognostic biomarker for CRC in KRAS wild-type patients. No role for miRNA-143 expression as a predictive biomarker for EGFR-targeted agents could be identified	22549179
3406	Human	hsa-miR-143	miRNA	fluoropyrimidine	colorectal cancer (CRC)	colorectal cancer (CRC) cells	Fluoropyrimidine treatment	upregulated	26392389
3407	Human	hsa-miR-143	miRNA	¦Á-Mangostin	colorectal cancer (CRC)	human colorectal cancer DLD-1 cells	¦Á-Mangostin treatment	?increased miR-143 expression in human colorectal cancer DLD-1 cells	17553685
3408	Human	hsa-miR-143	miRNA	baccharin and drupanin	colorectal cancer (CRC)	human colon cancer DLD-1 cells	baccharin and drupanin treatment	upregulated	24854570
3409	Human	hsa-miR-143	miRNA	hexavalent chromium [Cr(VI)]	Cr(VI)-induced carcinogenesis	blood samples of Cr(VI)-exposing workers and human bronchial epithelial cells (BEAS-2B cells)	Hexavalent chromium [Cr(VI)] exposure	downregulated	31152816
3410	Human	hsa-miR-143	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
3411	Human	hsa-miR-143	miRNA	IL-1¦Â	endothelial activation	human umbilical endothelial cells (HUVECs)	IL-1¦Â treatment	upregulated	28527816
3412	Human	hsa-miR-143	miRNA	endothelial growth medium©\2 (EGM©\2) plus VEGF	endothelial dysfunction	Adipose-derived stem cells (ADSCs)	endothelial growth medium©\2 (EGM©\2) supplemented with 15 ng/mL VEGF innduce	downregulated	31264280
3413	Human	hsa-miR-143	miRNA	shikonin	glioblastoma multiforme (GBM)	glioblastoma stem cells (GSCs)	Shikonin treatment	downregulated	26541455
3414	Human	hsa-miR-143	miRNA	TGF-¦Â	glomerular diseases	human podocytes	TGF-¦Â treatment	"a time dependent, TGF-¦Â inducible expression of miR-143 in human podocytes"	27941332
3415	Human	hsa-miR-143	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	primary liver cells	hepatitis B virus (HBV) infection	upregulated	29236306
3416	Human	hsa-miR-143	miRNA	hexavalent chromium [Cr(VI)]	lung cancer	BEAS-2B cells	Hexavalent chromium [Cr (VI)]?treatment	downregulated	23748240
3417	Human	hsa-miR-143	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	downregulated	19748927
3418	Human	hsa-miR-143	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	downregulated	26356996
3419	Human	hsa-miR-143	miRNA	inorganic phosphate (Pi)	migration of vascular smooth muscle cells	human aortic vascular smooth muscle cells (VSMCs)	inorganic phosphate (Pi) treatment	downregulated	23094093
3420	Human	hsa-miR-143	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	CD34(+) marrow cells	lenalidomide? treatment	upregulated	22929976
3421	Human	hsa-miR-143	miRNA	hypoxia	myocardial infarction (MI)	human cardiac cells	hypoxia induce	upregulated	29728596
3422	Human	hsa-miR-143	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	downregulated	29619741
3423	Human	hsa-miR-143	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
3424	Human	hsa-miR-143	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	The NSCLC cell lines (HCC827 and PC9)	gefitinib treatment	"repressed UCA1 promoted the miR-143 expression, and miR-143 could bind to the predicted binding site of UCA1."	31951852
3425	Human	hsa-miR-143	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC9 cells	gefitinib treatment	lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer.	31951852
3426	Human	hsa-miR-143	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	TGF-¦Â treatment	upregulated	25175415
3427	Human	hsa-miR-143	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
3428	Human	hsa-miR-143	miRNA	cisplatin (DDP)	osteosarcoma (OS)	Sarcoma Osteogenic-2 (Saos-2) cells	cisplatin treatment	upregulated	32508321
3429	Human	hsa-miR-143	miRNA	TGF-¦Â1	osteosarcoma (OS)	osteosarcoma cell	TGF-¦Â1 treatment	downregulated	25562163
3430	Human	hsa-miR-143	miRNA	cisplatin (DDP)	ovarian cancer (OC)	Human ovarian cancer cell lines (A2780 and SKOV-3) and normal ovarian epithelial cell line (IOSE-80)	cisplatin treatment	downregulated	31234009
3431	Human	hsa-miR-143	miRNA	H2O2	oxidative stress	human normal liver cell line L02	H2O2 treatment	upregulated	29258429
3432	Human	hsa-miR-143	miRNA	human mesenchymal stem cell conditioned medium (MSC-CM)	oxidative stress	human normal liver cell line L02	MSC-CM	downregulated	29258429
3433	Human	hsa-miR-143	miRNA	everolimus	pancreatic cancer (PC)	Panc-1 human pancreatic cancer cells	everolimus treatment	upregulated	23251295
3434	Human	hsa-miR-143	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
3435	Human	hsa-miR-143	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
3436	Human	hsa-miR-143	miRNA	curcumin (Cur)	prostate cancer	"DU145, PC3, and RPWE-1 cells"	curcumin treatment	upregulated	28391351
3437	Human	hsa-miR-143	miRNA	curcumin (Cur)	prostate cancer	"PC3, DU145 and LNCaP cells"	curcumin treatment	upregulated	28391715
3438	Human	hsa-miR-143	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	30195228
3439	Human	hsa-miR-143	miRNA	20-hydroxyeicosatetraeonic acid (20-HETE)	pulmonary hypertension (PH)	vascular smooth muscle cell	20-Hydroxyeicosatetraeonic acid (20-HETE) treatment	downregulated	26921441
3440	Human	hsa-miR-143	miRNA	acidic bile salt	reflux esophagitis	Het-1A cells	acidic bile salt treatment	upregulated	24006894
3441	Human	hsa-miR-143	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	sepsis	mesenchymal stem cells (MSCs)	poly(I:C) treatment	downregulated	24105952
3442	Human	hsa-miR-143	miRNA	TGF-¦Â1	subconjunctival fibrosis	Human tenon's capsule fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	31081880
3443	Human	hsa-miR-143	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	tissue regeneration	Human adult DPSCs	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	26351742
3444	Human	hsa-miR-143	miRNA	TGF-¦Â	type 2 diabetes mellitus (T2DM)	Vascular smooth muscle cells (SMC) from T2DM	exposure of ND-SMC to transforming growth factor beta (TGF¦Â) treatment	upregulated	24927876
3445	Human	hsa-miR-143	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HAVSMC)	inorganic phosphate (Pi) treatment	downregulated	27419135
3446	Human	hsa-miR-143-1	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
3447	Human	hsa-miR-143-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	32337953
3448	Human	hsa-miR-143-3p	miRNA	angiotensin II (Ang II)	aortic dissection (AD)	human aortic endothelial cells (HAECs); human aortic smooth muscle cells (HASMCs)	angiotensin II (Ang II) treatment	"We found that lnc-OIP5-AS1 was upregulated, whereas miR-143-3p was downregulated in cells treated with angiotensin II (AngII) and AD tissues."	33577845
3449	Human	hsa-miR-143-3p	miRNA	Resibufogenin (RES)	breast cancer	MDA-MB-453 cells; MCF-7 cells	Resibufogenin (RES) treatment	RES notably enhanced the expression of miR- 143-3p in both MDA-MB-453 and MCF-7 cells compared with the control group	32006291
3450	Human	hsa-miR-143-3p	miRNA	dermatophagoides pteronyssinus peptidase 1 (Der p1)	bronchial asthma	BEAS-2B cells	Dermatophagoides pteronyssinus peptidase 1 (Der p1) treatment	OIP5-AS1 exacerbated Der p1-induced inflammation and apoptosis in BEAS-2B cells by targeting miR-143-3p via HMGB1.	33174035
3451	Human	hsa-miR-143-3p	miRNA	cadmium (Cd)	cadmium-induced toxicity	human bone marrow mesenchymal stem cells (hBMSCs)	cadmium (Cd) treatment	Concentrations of CdCl 2 (2.5 and 5.0 ¦ÌM) increased miR-143-3p levels.	32522577
3452	Human	hsa-miR-143-3p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
3453	Human	hsa-miR-143-3p	miRNA	"hyperglycemia, insulin and lipopolysaccharide (LPS)"	dyslipidemia	HepG2 cells	"hyperglycemia, insulin, and LPS treatment"	"Levels of miR-143-3p increase in response to hyperglycemia, insulin, and LPS treatment."	30261196
3454	Human	hsa-miR-143-3p	miRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	?progesterone (P4) treatment	upregulated	29661100
3455	Human	hsa-miR-143-3p	miRNA	TGF-¦Â1	epithelial ovarian cancer (EOC)	human ovarian tumour cells	TGF-¦Â1 treatment	upregulated	29238081
3456	Human	hsa-miR-143-3p	miRNA	dexamethasone (DEX)	esophageal cancer (EC)	KYSE150 cells	dexamethasone (DEX) treatment	MiR-143-3p could be induced by DEX treatment in esophageal cancer cells.	32701250
3457	Human	hsa-miR-143-3p	miRNA	high glucose (HG)	hyperglycemia	HepG2 cells	high glucose induce	upregulated	30261196
3458	Human	hsa-miR-143-3p	miRNA	insulin	hyperinsulinemic	HepG2 cells	insulin treatment	upregulated	30261196
3459	Human	hsa-miR-143-3p	miRNA	lipopolysaccharide (LPS)	inflammatory response	HepG2 cells	lipopolysaccharide (LPS) treatment	upregulated	30261196
3460	Human	hsa-miR-143-3p	miRNA	TGF-¦Â1	myocardial infarction (MI)	human cardiac fibroblasts (HCFs)	transforming growth ¦Â1 (TGF¦Â1) treatment	upregulated	30878395
3461	Human	hsa-miR-143-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	miR-143-3p level was upregulated in LPS-treated PDLCs.	32520926
3462	Human	hsa-miR-143-3p	miRNA	sulfur mustard (SM)	sulfur mustard induced lung disease	serum	sulfur mustard exposure treatment	upregulated	29566027
3463	Human	hsa-miR-143-3p	miRNA	TGF-¦Â1	asthma	airway smooth muscle cells (ASMCs)	TGF-¦Â1 treatment	over expression	27639060
3464	Human	hsa-miR-143-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
3465	Human	hsa-miR-144	miRNA	actinomycin X2 (AX2)	apoptosis	human prostate cancer cells (PC-3)	actinomycin X2 (AX2) treatment	miR-144 was decreased ; smiR-126 was increased	26645890
3466	Human	hsa-miR-144	miRNA	7-chlorokynurenic acid (7-CTKA)	cardiovascular disease (CVD)	human aortic endothelial cells (HAECs)	7-CTKA intraperitoneal injection	upregulated	24642088
3467	Human	hsa-miR-144	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
3468	Human	hsa-miR-144	miRNA	nanoparticle (NP)	colorectal cancer (CRC)	Human colon cancer HCT-116 cells	Nanoparticle (NP) technology	"Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulated of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms,"	21929751
3469	Human	hsa-miR-144	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	"MiR-144 expression level was enhanced, while CTRP3 expression was reduced in HG-induced AC16 cardiomyocytes."	32211094
3470	Human	hsa-miR-144	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal mesangial cells (HRMCs)	high glucose (HG) treatment	"CASC2 could alleviate the degree and process of apoptosis, inflammation, and fibrosis in diabetic nephropathic models by regulating the miR-144/SOCS2 axis."	33227790
3471	Human	hsa-miR-144	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
3472	Human	hsa-miR-144	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
3473	Human	hsa-miR-144	miRNA	rapamycin	hepatitis	HT29 cells	rapamycin treatment	downregulated	22983984
3474	Human	hsa-miR-144	miRNA	human immunodeficiency virus (HIV)-1	HIV-1 infection-induced pneumonia	human monocyte-derived macrophages (MDMs)	HIV-1 infection	MiR-144 expression was increased in AMs from HIV-1 Tg rats and in HIV-1-infected human MDMs compared to cells from WT rats and non-infected human MDMs.	32773107
3475	Human	hsa-miR-144	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	L. casei LC01 decreased the expression of miR-144 in IECs.	32807750
3476	Human	hsa-miR-144	miRNA	baohuoside-I	melanoma	Human melanoma cell lines M14 and MV3	baohuoside-I treatment	upregulated	29260980
3477	Human	hsa-miR-144	miRNA	triptolide (TPL)	nasopharyngeal carcinoma (NPC)	Epstein-Barr virus-negative human NPC cell lines (NPC-TW 039 and NPC-TW 076)	triptolide (TPL) treatment	downregulated	31059711
3478	Human	hsa-miR-144	miRNA	smoky coal	non-small cell lung cancer (NSCLC)	non-small cell lung cancers (NSCLCs) cells	smoky coal treatment	downregulated	26395400
3479	Human	hsa-miR-144	miRNA	patulin (PAT)	oxidative stress	HEK293 cells	Patulin (PAT)? treatment	PAT significantly decreased miR-144	33403569
3480	Human	hsa-miR-144	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
3481	Human	hsa-miR-144	miRNA	cyclosporine A (CsA)	cell proliferation and invasion	human trophoblast (HT) cells	CsA treatment	downregulated	24453045
3482	Human	hsa-miR-144	miRNA	cisplatin (DDP)	prostate cancer	prostate cancer (PC) cells	cisplatin treatment	downregulated	26566625
3483	Human	hsa-miR-144	miRNA	hypoxia	prostate cancer	prostate cancer cell lines (DU145 and PC3)	hypoxia treatment	downregulated	26990493
3484	Human	hsa-miR-144-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	29492259
3485	Human	hsa-miR-144-3p	miRNA	cisplatin (DDP)	anaplastic thyroid carcinoma (ATC)	TPC1 cells; BHT101 cells	cisplatin (DPP) treatment	downregulated	30540564
3486	Human	hsa-miR-144-3p	miRNA	licochalcone A (LA)	apoptosis	H292 cells	Natural compound licochalcone A (lico A) treatment	lico A significantly promoted the tumor-suppressor miR-144-3p expression.	30709582
3487	Human	hsa-miR-144-3p	miRNA	"oxidized low-density lipoprotein (ox-LDL), IL-6 and TNF-¦Á)"	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	"oxidation Low Lipoprotein (Ox-LDL), interleukin-6 (IL-6) and tumor necrosis factor ¦Á (TNF ¦Á) radiation"	LncRNA HCG11 regulates proliferation and apoptosis of vascular smooth muscle cell through targeting miR-144-3p/FOXF1 axis.	33008472
3488	Human	hsa-miR-144-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	Our data indicated that LOC729178 was underexpressed in COPD tissues and CSE-treated 16HBE cells.	33847879
3489	Human	hsa-miR-144-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Human umbilical vein endothelial cells (HUVEC) and Human Retinal Endothelial Cells (HREC)	high glucose treatment	downregulated	31292167
3490	Human	hsa-miR-144-3p	miRNA	hemin	inflammation	"Neutrophils isolated from human peripheral blood, dHL-60 cells"	hemin treatment	upregulated	30499593
3491	Human	hsa-miR-144-3p	miRNA	licochalcone A (LA)	lung cancer	Human Lung Cancer Cell Line H292	licochalcone A (lico A) treatment	upregulated	30108506
3492	Human	hsa-miR-144-3p	miRNA	TGF-¦Â1	lung cancer	A549 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	31038242
3493	Human	hsa-miR-144-3p	miRNA	hypoxia	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	hypoxia induce	upregulated	31590045
3494	Human	hsa-miR-144-3p	miRNA	tert-butyl hydroperoxide (TBHP)	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
3495	Human	hsa-miR-144-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	27329039
3496	Human	hsa-miR-144-3p	miRNA	hemin	inflammation	Neutrophils isolated from human peripheral blood	hemin treatment	upregulated	30499593
3497	Human	hsa-miR-144-3p	miRNA	tert-butyl hydroperoxide (TBHP)	retinal dysfunction	retinal pigment epithelium (RPE) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
3498	Human	hsa-miR-144-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	abdominal aortic aneurysm (AAA)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32278833
3499	Human	hsa-miR-144-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-144-5p overexpression could inhibit proliferation and induce apoptosis in HUVECs.	31853287
3500	Human	hsa-miR-144-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-144-5p serves an important role in the development of atherosclerosis through regulating the function of HUVECs by targeting SMAD1.	31853287
3501	Human	hsa-miR-144-5p	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-144-5p was downregulated in resistant patients when compared with sensitive patients	33072545
3502	Human	hsa-miR-144-5p	miRNA	hypoxia	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	hypoxia induce	upregulated	31590045
3503	Human	hsa-miR-144-5p	miRNA	tert-butyl hydroperoxide (TBHP)	oxidative stress	Human retinal pigment epithelial (ARPE-19) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
3504	Human	hsa-miR-144-5p	miRNA	tert-butyl hydroperoxide (TBHP)	retinal dysfunction	retinal pigment epithelium (RPE) cells	tert-butyl hydroperoxide (t-BHP) treatment	upregulated	31590045
3505	Human	hsa-miR-144-5p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	THP-1 macrophages	lipopolysaccharide (LPS) treatment	downregulated	31853295
3506	Human	hsa-miR-144-5p	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	THP-1 cell differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	31853295
3507	Human	hsa-miR-145	miRNA	IFN-¦Â	asthma	airway smooth muscle (ASM)	IFN-beta? treatment	upregulated	20382746
3508	Human	hsa-miR-145	miRNA	basic fibroblast growth factor (bFGF)	adipose-derived stem cells (ASCs) differentiation	Adipose-derived stem cells (ASCs)	ASCs were isolated from clinical lipoaspirates and cultured with DMEM or endothelial cell-conditioned medium. bFGF (basic fibroblast growth factor) released by ECs as inducer of ASCs differentiation.	downregulated	31219744
3509	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	anti-proliferative action	human aortic vascular smooth muscle cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	27412561
3510	Human	hsa-miR-145	miRNA	genistein	apoptosis	human retinoblastoma cell line Y79	genistein treatment	upregulated	28706438
3511	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	apoptosis	GES-1cells	lipopolysaccharides (LPS) treatment	MiR-145 inhibited lipopolysaccharide-induced apoptosis of gastric mucosal via up-regulating JNK-mediated cytoprotective autophagy.	30829205
3512	Human	hsa-miR-145	miRNA	arsenite	arsenic-induced liver injury	L-02 cells	arsenic exposure	upregulated	29705342
3513	Human	hsa-miR-145	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
3514	Human	hsa-miR-145	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
3515	Human	hsa-miR-145	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	upregulated	24396484
3516	Human	hsa-miR-145	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
3517	Human	hsa-miR-145	miRNA	TGF-¦Â1	breast cancer	human coronary artery smooth muscle cells	TGF-¦Â1 treatment	downregulated	21712382
3518	Human	hsa-miR-145	miRNA	histone deacetylase inhibitor (HDACi)	burkitt lymphoma (BL)	Raji B-cell lymphoma	HDACi treatment	upregulated	24577510
3519	Human	hsa-miR-145	miRNA	cortisol	tumorigenesis	cervical cancer cells	Cortisol?treatment	downregulated	22287315
3520	Human	hsa-miR-145	miRNA	TGF-¦Â	cancer-associated fibroblasts (CAFs) activation	primary normal human fibroblasts	TGF-¦Â treatment	upregulated	29506142
3521	Human	hsa-miR-145	miRNA	conditioned media (CM)	cardiovascular disease (CVD)	human vascular smooth muscle cells (hVSMC)	exposure to CM from primary human subcutaneous adipocytes treatment	upregulated	24333576
3522	Human	hsa-miR-145	miRNA	(-)-epigallocatechin gallate (EGCG)	cell proliferation	Ang II-treated human coronary artery smooth muscle cells (HCASMCs)	(-)-epigallocatechin gallate (EGCG) treatment	upregulated	29127880
3523	Human	hsa-miR-145	miRNA	angiotensin II (Ang II)	cell proliferation	Human coronary artery smooth muscle cells (HCASMCs)	angiotensin II (Ang II) treatment	downregulated	29127880
3524	Human	hsa-miR-145	miRNA	homocysteine (Hcy)	cell proliferation	Human aortic vascular smooth muscle cells (HAVSMCs)	homocysteine (HCY) treatment	downregulated	31757424
3525	Human	hsa-miR-145	miRNA	tanshinone IIA (Tan IIA)	cell proliferation	Homocysteine (Hcy)-treated Human aortic vascular smooth muscle cells (HAVSMCs)	Tanshinone IIA (Tan IIA) treatment	upregulated	31757424
3526	Human	hsa-miR-145	miRNA	tanshinone IIA (Tan IIA)	cervical cancer (CC)	HeLa cells	tanshinone II A treatment	Treatment of tanshinone II A significantly upregulated the expression of GSDMD and miR-145	32232409
3527	Human	hsa-miR-145	miRNA	nilotinib	chronic myeloid leukemia (CML)	HL-60.BCR-ABL cells	nilotinib (NIL) treatment	differently regulated	24629639
3528	Human	hsa-miR-145	miRNA	pomegranate beverage (PG)	colitis	CCD-18Co colon-myofibroblastic cells treated with lipopolysaccharide (LPS)	PG treatment	upregulated	28282584
3529	Human	hsa-miR-145	miRNA	troglitazone	collagen synthesis	human dermal fibroblasts	troglitazone treatment	upregulated	25704091
3530	Human	hsa-miR-145	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	parental 5-FU- sensitive DLD-1 cells	5-fluorouracil (5-FU) treatment	upregulated	24447928
3531	Human	hsa-miR-145	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
3532	Human	hsa-miR-145	miRNA	rosiglitazone	colorectal cancer (CRC)	"CaCo2, SW480, HCT116, and HT-29 cell lines"	azone-mediated activation of PPAR¦Ã treatment	upregulated	24631504
3533	Human	hsa-miR-145	miRNA	atorvastatin	cytotoxicity	HepG2 cells	atorvastatin (Ato) treatment	upregulated	29630879
3534	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic atherosclerosis	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	miR-145 was downregulated in cultured human VSMCs exposed to high glucose.	29324316
3535	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human AC16 cardiomyocytes	high glucose (HG) treatment	"the role of MEG3 in HG-treated human cardiomyocytes is to serve as a competing endogenous RNA (ceRNA), which negatively regulates miR-145"	31085717
3536	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	hyperglycemia significantly increased the level of MALAT1 but decreased miR-145 expression in a time-dependent manner in HK-2 cells.	31081103
3537	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells (HMCs)	high glucose treatment	downregulated	31737219
3538	Human	hsa-miR-145	miRNA	baicalin (BAI)	diabetic retinopathy (DR)	ARPE-19 cells and HRMECs	high glucose (HG) and Baicalin (BAI) co-treatment	the expression level of miR-145 was upregulated in HG-and BAI-co-treated cells.	30625293
3539	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
3540	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells (RECs)	high glucose (HG) treatment	miR-145 was significantly downregulated in high glucose (HG)-treated RECs.	29883722
3541	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells and HRMECs	high glucose (HG) and Baicalin (BAI) co-treatment	the expression level of miR-145 was upregulated in HG-and BAI-co-treated cells.	30625293
3542	Human	hsa-miR-145	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high-glucose (HG) treatment	downregulated	31794890
3543	Human	hsa-miR-145	miRNA	schizandrin A (SchA)	diabetic retinopathy (DR)	ARPE-19 cells	schizandrin A (SchA) treatment	upregulated	31794890
3544	Human	hsa-miR-145	miRNA	schizandrin A (SchA)	diabetic retinopathy (DR)	high-glucose (HG)-induced ARPE-19 cells	Schizandrin A (SchA) treatment	upregulated	31794890
3545	Human	hsa-miR-145	miRNA	hypoxia	cell differentiation	umbilical cord mesenchymal stem cells (UCMSCs)	hypoxia treatment	upregulated	28789953
3546	Human	hsa-miR-145	miRNA	TGF-¦Â1 or bone morphogenetic protein-4 (BMP4)	cell differentiation	hASCs to smooth muscle cells (SMCs)	"TGF-¦Â1,BMP4 treatment"	upregulated	28440409
3547	Human	hsa-miR-145	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
3548	Human	hsa-miR-145	miRNA	quercetin	endometrial fibrosis	human endometrial stromal cells (hESCs)	quercetin treatment	The decreased expression of miR-145 induced by TGF-¦Â1 was upregulated with the increase of the concentration of quercetin	33066828
3549	Human	hsa-miR-145	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human renal proximal tubular epithelial (HK-2) cells	TGF-¦Â1 treatment	MIAT served as an endogenous sponge for miR-145 in the TGF-¦Â1-induced-EMT in HK-2 cells	31863776
3550	Human	hsa-miR-145	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	endothelial progenitor cells (EPCs)	treat with TGF-¦Â1 treatment	downregulated	28535533
3551	Human	hsa-miR-145	miRNA	X-rays	esophageal cancer (EC)	TE-3 cells; ECA109 cells	X-ray radiation treatment	lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR-145/p70S6K1 and p53 pathway	31789385
3552	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	facial nerve damage	SH-SY5Y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	miR-145 was revealed to be significantly increased in response to TNF¦Á treatment	30551550
3553	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	facial neuritis	SH-SY5Y cell	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30551550
3554	Human	hsa-miR-145	miRNA	isorhapontigenin (ISO)	glioblastoma multiforme (GBM)	?glioma stem cells (GSCs)	Isorhapontigenin treatment	downregulated	26681767
3555	Human	hsa-miR-145	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
3556	Human	hsa-miR-145	miRNA	dendrosomal curcumin (DNC)	glioblastoma multiforme (GBM)	U87MG cells	dendrosomal curcumin r treatment	downregulated	24531649
3557	Human	hsa-miR-145	miRNA	olea europaea leaf extract (OLE)	glioblastoma multiforme (GBM)	GBM cell lines	olea europaea leaf extract (OLE) treatment	upregulation	25232498
3558	Human	hsa-miR-145	miRNA	insulin	glycolysis	human HepG2 hepatocellular carcinoma cells	insulin treatment	dysregulated	24895527
3559	Human	hsa-miR-145	miRNA	H2O2	granulosa cell (GC) apoptosis	KGN cells	H2O2 treatment	downregulated	28564582
3560	Human	hsa-miR-145	miRNA	carboplatin (CBP)	head and neck squamous cell carcinoma (HNSCC)	Hep-2 cells; FaDu cells	carboplatin treatment	carboplatin induced the expression of miR-145 in a dose-dependent manner.	31886905
3561	Human	hsa-miR-145	miRNA	5-aminolevulinic acid photodynamic therapy(ALA-PDT)	head and neck squamous cell carcinoma (HNSCC)	Two oral cancer cell lines SAS (tongue squamous cell carcinoma) and GNM (neck metastasis of gingival carcinoma)	5-Aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) treatment	upregulated	29936107
3562	Human	hsa-miR-145	miRNA	carboplatin (CBP)	head and neck squamous cell carcinoma (HNSCC)	The human LSCC Hep-2 cell line and the human HSCC FaDu cell line	carboplatin (CBP) treatment	upregulated	31886905
3563	Human	hsa-miR-145	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells £¬ HepG2.2.15 cells.	plasmid transfected treatment	downregulated	25260533
3564	Human	hsa-miR-145	miRNA	emodin	hepatitis	LPS-treated L-02 cell	Emodin treatment	upregulated	31079494
3565	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	hepatitis	L-02 cell	lipopolysaccharide (LPS) treatment	downregulated	31079494
3566	Human	hsa-miR-145	miRNA	compound astragalus and salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	DEN-induced HCC in rats	Compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	upregulated	30412748
3567	Human	hsa-miR-145	miRNA	compound Astragalus and Salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	HepG2 cells	compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	CASE upregulated miR-145 expression in TGF-¦Â 1-stimulated HepG2 cells.	30412748
3568	Human	hsa-miR-145	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells	Hepatitis B virus X protein (HBX)treatment	downregulated	26512974
3569	Human	hsa-miR-145	miRNA	tanshinone IIA (Tan IIA)	human aortic vascular smooth muscle cells (HA-VSMCs) injury	vascular smooth muscle cells (VSMCs)	Tanshinone IIA (Tan IIA) treatment	"The miR-145 expression was downregulated and its targeted gene CD40 was upregulated in Hcy-treating VSMCs, while the Tan IIA reversed the effect of Hcy"	31757424
3570	Human	hsa-miR-145	miRNA	decabromodiphenyl ether (BDE-209)	human embryonic development	human embryonic stem cell lines FY-hES-10 and FY-hES-26	Decabromodiphenyl ether (BDE-209) treatment	upregulated	26206603
3571	Human	hsa-miR-145	miRNA	high glucose (HG)	hyperglycemia	Human coronary artery smooth muscle cells (HCASMCs)	high glucose treatment	downregulated	26181633
3572	Human	hsa-miR-145	miRNA	baicalin (BAI)	hypertension	TNF-¦Á-treated human aortic endothelial cells (HAECs)	baicalin (BAI) treatment	upregulated	31793706
3573	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	hypertension	human aortic endothelial cells (HAECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31793706
3574	Human	hsa-miR-145	miRNA	TGF-¦Â1	hypertrophic scars (HS)	skin myofibroblasts	TGF-¦Â1 treatment	upregulated	25876136
3575	Human	hsa-miR-145	miRNA	IL-1¦Â	osteoarthritis (OA)	OA chondrocytes	IL-1¦Â treatment	upregulated	24873879
3576	Human	hsa-miR-145	miRNA	platelet derived growth factor-BB (PDGF-BB)	juvenile lupus nephritis (JLN)	human vascular smooth muscle cells (HVSMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	31430759
3577	Human	hsa-miR-145	miRNA	TGF-¦Â1	cornea scarring	light-scattering myofibroblasts	TGF-¦Â1 treatment	upregulated	26165705
3578	Human	hsa-miR-145	miRNA	listeria monocytogenes (L. monocytogenes)	Listeria infection	Human epithelial cells (Caco-2)	Listeria infection	downregulated	22312311
3579	Human	hsa-miR-145	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	miR-145 was downregulated in transforming growth factor-¦Â1 induced HSCs	29375381
3580	Human	hsa-miR-145	miRNA	pemetrexed	lung adenocarcinoma (LUAD)	serum	pemetrexed treatment	"Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations"	26687391
3581	Human	hsa-miR-145	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
3582	Human	hsa-miR-145	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
3583	Human	hsa-miR-145	miRNA	inorganic phosphate (Pi)	migration of vascular smooth muscle cells	human aortic vascular smooth muscle cells (VSMCs)	inorganic phosphate (Pi) treatment	downregulated	23094093
3584	Human	hsa-miR-145	miRNA	cerivastatin	mitochondrial dysfunction	RD cells	cerivastatin (1 ¦ÌM for 48 h) treatment	downregulated	28438533
3585	Human	hsa-miR-145	miRNA	TGF-¦Â1	multidrug resistance (MDR)	The HepG2 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30698830
3586	Human	hsa-miR-145	miRNA	IFN-¦Â	multiple sclerosis (MS)	blood	IFN-¦Â treatment	downregulated	27752929
3587	Human	hsa-miR-145	miRNA	nanocurcumin	multiple sclerosis (MS)	blood	nanocurcumin treatment	downregulated	30340096
3588	Human	hsa-miR-145	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	CD34(+) marrow cells	lenalidomide? treatment	upregulated	22929976
3589	Human	hsa-miR-145	miRNA	angiotensin II (Ang II)	neointimal formation	human coronary artery smooth muscle cells (HCASMCs)	angiotensin II (Ang II) treatment	downregulated	29127880
3590	Human	hsa-miR-145	miRNA	epigallocatechin-3-gallate (EGCG)	neointimal formation	human coronary artery smooth muscle cells (HCASMCs)	EGCG	upregulated	29127880
3591	Human	hsa-miR-145	miRNA	flavonoids (TFs)	neointimal formation	human coronary artery smooth muscle cells (HCASMCs)	100 nM flavonoids treatment	upregulated	29127880
3592	Human	hsa-miR-145	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	downregulated	29619741
3593	Human	hsa-miR-145	miRNA	ethanol (EtOH)	neuropsychological disorders	human embryonic stem cells	ethanol treatment	upregulated	28833141
3594	Human	hsa-miR-145	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
3595	Human	hsa-miR-145	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
3596	Human	hsa-miR-145	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	The human NSCLC cell line A549	erlotinib treatment	Pretreatment with miRNA-145 synergistically enhanced the sensitivity of the lung cancer cells to erlotinib. Results of apoptosis assay revealed that miRNA-145 can induce apoptosis and increase the erlotinib-mediated apoptosis.	31554377
3597	Human	hsa-miR-145	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
3598	Human	hsa-miR-145	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
3599	Human	hsa-miR-145	miRNA	CoCl2	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	HK-2 cells	CoCl2 treatment	CoCl2 induced expression of miR-145 while ROR overexpression downregulated expression of miR-145.	31164009
3600	Human	hsa-miR-145	miRNA	cigarette smoke condensate (CSC)	oral cancer	SCC4 cells; H357 cells; primary normal oral fibroblasts (NOF)	Cigarette smoke condensate(CSC) treatment	downregulated	23173553
3601	Human	hsa-miR-145	miRNA	prednisolone	oral submucous fibrosis (OSF)	OSF-fibroblast cells	were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment	upregulated	24921400
3602	Human	hsa-miR-145	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	downregulated	31637891
3603	Human	hsa-miR-145	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	upregulated	32028542
3604	Human	hsa-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	human OA cartilage	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29072705
3605	Human	hsa-miR-145	miRNA	osteogenic differentiation medium	osteogenesis	Human jaw bone marrow mesenchymal stem cells (h-JBMMSCs)	osteogenic medium culture	downregulated	31305177
3606	Human	hsa-miR-145	miRNA	ossotide	osteogenesis imperfecta (OI)	osteoblasts	Ossotide treatment	upregulated	27551756
3607	Human	hsa-miR-145	miRNA	zoledronic acid (ZA)	osteoporosis	serum	ZOL treatment	"?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment"	33637048
3608	Human	hsa-miR-145	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	ovarian cancer (OC)	"paclitaxel-resistant cell lines (A2780/PTX, SKOV3/PTX)"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24510775
3609	Human	hsa-miR-145	miRNA	propofol (PPF)	ovarian cancer (OC)	ovarian cancer cell lines (A2780 and SKOV3)	Propofol treatment	Propofol suppressed the progression of ovarian cancer through up-regulating miR-145 via suppressing circVPS13C	33563314
3610	Human	hsa-miR-145	miRNA	quercetin	ovarian cancer (OC)	SKOV-3 and A2780 cells	quercetin treatment	upregulated	25937243
3611	Human	hsa-miR-145	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
3612	Human	hsa-miR-145	miRNA	TGF-¦Â1	peritoneal fibrosis	human peritoneal mesothelial cells (i.e. HMrSV5 cells)	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31431501
3613	Human	hsa-miR-145	miRNA	curcumin (Cur)	prostate cancer	"PC3, DU145 and LNCaP cells"	curcumin treatment	upregulated	28391715
3614	Human	hsa-miR-145	miRNA	curcumin (Cur)	prostate cancer	HuPCaSCs	curcumin treatment	upregulated	28843521
3615	Human	hsa-miR-145	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	30195228
3616	Human	hsa-miR-145	miRNA	TGF-¦Â1	renal fibrosis	human renal proximal tubular epithelial (HK2) cells	TGF-¦Â1 treatment	MALAT1 functions by acting as a miR-145 sponge in HK2 cells treated with TGF-¦Â1	32203053
3617	Human	hsa-miR-145	miRNA	hypoxia	renal injury	human renal inner medullary CD133+ progenitors	hypoxia treatment	downregulated	21900452
3618	Human	hsa-miR-145	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	TGF-¦Â1 treatment	downregulated	31863776
3619	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	human fibroblast-like synoviocyte line MH7A	lipopolysaccharides (LPS) treatment	downregulated	30191608
3620	Human	hsa-miR-145	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
3621	Human	hsa-miR-145	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
3622	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	30784922
3623	Human	hsa-miR-145	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	BEAS-2B cells	lipopolysaccharide (LPS) treatment	downregulated	30841464
3624	Human	hsa-miR-145	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
3625	Human	hsa-miR-145	miRNA	TGF-¦Â1	subconjunctival fibrosis	Human tenon's capsule fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	31081880
3626	Human	hsa-miR-145	miRNA	ultraviolet (UV) irradiation	systemic lupus erythematosus (SLE)	HaCaT cells	UVB treatment	miR-145 was upregulated by UVB irradiation	30198366
3627	Human	hsa-miR-145	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
3628	Human	hsa-miR-145	miRNA	acetylated Low density lipoprotein (Ac-LDL)	type 2 diabetes mellitus (T2DM)	THP-1 cells; peripheral blood mononuclear cells (PBMCs)	acetylated Low density lipoprotein (Ac-LDL) treatment	upregulated	30941422
3629	Human	hsa-miR-145	miRNA	acetylated Low density lipoprotein (Ac-LDL) and high glucose (HG)	type 2 diabetes mellitus (T2DM)	THP-1 cells; peripheral blood mononuclear cells (PBMCs)	acetylated Low density lipoprotein (Ac-LDL) treatment	upregulated	30941422
3630	Human	hsa-miR-145	miRNA	free fatty acids (FFA)	type 2 diabetes mellitus (T2DM)	THP-1 cells;peripheral blood mononuclear cells	free fatty acid (FFA) treatment	upregulated	30941422
3631	Human	hsa-miR-145	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	THP-1 cells;peripheral blood mononuclear cells	high glucose (HG) treatment	upregulated	30941422
3632	Human	hsa-miR-145	miRNA	TGF-¦Â	type 2 diabetes mellitus (T2DM)	Vascular smooth muscle cells (SMC) from T2DM	exposure of ND-SMC to transforming growth factor beta (TGF¦Â) treatment	upregulated	24927876
3633	Human	hsa-miR-145	miRNA	mechanical stretch	vascular disease	HASMCs	mechanical stretch treatment	downregulated	24848371
3634	Human	hsa-miR-145	miRNA	high glucose (HG)	vascular injury	smooth muscle cells (VSMCs)	high glucose treatment	downregulated	26181633
3635	Human	hsa-miR-145	miRNA	homocysteine (Hcy)	vascular smooth muscle cell proliferation	Human vascular smooth muscle cell line (VSMCs)	Homocysteine (Hcy) treatment	Hcy decreased the expression of miR-145 in VSMCs.	32124010
3636	Human	hsa-miR-145	miRNA	TGF-¦Â and bleomycin A5	venous malformations (VMs)	human umbilical vein endothelial cells (HUVECs)	recombinant human TGF-¦Â and bleomycin A5 treatment	upregulated	28104472
3637	Human	hsa-miR-145-3p	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	macrophage polarization	THP1-derived macrophages	IFN-gamma and LPS treatment	downregulated	30634164
3638	Human	hsa-miR-145-3p	miRNA	IL-4 and IL-13	macrophage polarization	THP1-derived macrophages	IL-4 and IL-13 treatment	upregulated	30634164
3639	Human	hsa-miR-145-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	downregulated	33602903
3640	Human	hsa-miR-145-5p	miRNA	cigarette smoke (CS)	airway diseases	Normal human bronchial epithelial (NHBE) air-liquid interface (ALI) cultures	cigarette smoke (CS) exposure	upregulated	30595527
3641	Human	hsa-miR-145-5p	miRNA	TGF-¦Â	airway diseases	Normal human bronchial epithelial (NHBE) air-liquid interface (ALI) cultures	TGF-¦Â treatment	upregulated	30595527
3642	Human	hsa-miR-145-5p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	human lung tissues samples	cigarette smoke (CS) exposure	downregulated	30639269
3643	Human	hsa-miR-145-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human pulmonary microvascular endothelial cells HPMECs and bronchial epithelial cells BEAS-2B	cigarette smoke extract (CSE) treatment	downregulated	33248690
3644	Human	hsa-miR-145-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HPMECs and BEAS-2B cells	cigarette smoke extract (CSE) exposure	"Hsa_circ_0006872 facilitated CSE-triggered apoptosis, inflammation and oxidative stress in HPMECs and BEAS-2B cells by regulating miR-145-5p/NF-¦ÊB pathway."	33248690
3645	Human	hsa-miR-145-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human pulmonary microvascular endothelial cells HPMECs	cigarette smoke extract (CSE) treatment	"CircANKRD11 and BRD4 expression were increased, whereas miR-145-5p expression was decreased in the lung tissues of smokers with or without COPD and CSE-induced HPMECs"	33833509
3646	Human	hsa-miR-145-5p	miRNA	TGF-¦Â	chronic obstructive pulmonary disease (COPD)	Primary human bronchial epithelial cells	Transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	30595527
3647	Human	hsa-miR-145-5p	miRNA	puerarin	diabetic nephropathy (DN)	HK2 cells	puerarin treatment	upregulated	33122931
3648	Human	hsa-miR-145-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	?progesterone (P4) treatment	upregulated	29661100
3649	Human	hsa-miR-145-5p	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
3650	Human	hsa-miR-145-5p	miRNA	rapamycin	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	upregulated	29579170
3651	Human	hsa-miR-145-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	freshly-frozen specimens in the ESCC tumors	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26254350
3652	Human	hsa-miR-145-5p	miRNA	TGF-¦Â1	gastric cancer (GC)	AGS and MKN45 cancer cells	transforming growth factor ¦Â1 (TGF-¦Â1) secretion by MSCs treatment	downregulated	30742067
3653	Human	hsa-miR-145-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
3654	Human	hsa-miR-145-5p	miRNA	dexamethasone (DEX)	glucocorticoid-induced osteoporosis (GIOP)	Bone tissue	dexamethasone (DEX) treatment	hsa_circ_0006393 increases the expression levels of osteogenic genes during bone remodeling by sponging miR-145-5p and upregulating FOXO1.	31322188
3655	Human	hsa-miR-145-5p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
3656	Human	hsa-miR-145-5p	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	human peripheral blood mononuclear cells (PBMC)	HIV-1 infection treatment	downregulated	25295610
3657	Human	hsa-miR-145-5p	miRNA	dihydroartemisinin (DHA)	hypertrophic scars (HS)	human Tenon's capsule fibroblasts (HTFs)	dihydroartemisinin (DHA) treatment	DHA notably increased the expression of microRNA (miR)-145-5p in HTFs in a dose-dependent manner.	33688170
3658	Human	hsa-miR-145-5p	miRNA	high fat diet (HFD)	inflammation	plasma	high fat diet (HFD) feed	upregulated	30885503
3659	Human	hsa-miR-145-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic heart disease (IHD)	human cardiomyocytes (HCM)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-145-5p inhibition reversed the effects of silencing circ_0010729 on OGD-induced injury and mTOR and MEK/ERK pathways	31482388
3660	Human	hsa-miR-145-5p	miRNA	cisplatin and pemetrexed	lung adenocarcinoma (LUAD)	A549/DR cells	cisplatin and pemetrexed treatment	circPVT1 contributes to cisplatin and pemetrexed chemotherapy resistance through miR-145-5p/ABCC1 axis.	31986409
3661	Human	hsa-miR-145-5p	miRNA	particulate matter (PM2.5)	PM2.5-induced carcinogenesis	human bronchial epithelial (HBE) cells	fine particulate matter (PM2.2) treatment	downregulated	33545377
3662	Human	hsa-miR-145-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	preeclampsia (PE)	HTR-8/SVneo cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30081007
3663	Human	hsa-miR-145-5p	miRNA	bromocriptine	prolactinoma	prolactinoma clinical samples and prolactinoma cell line MMQ/BRC	bromocriptine treatment	downregulated	30370446
3664	Human	hsa-miR-145-5p	miRNA	docetaxel (DTX)	prostate cancer	PC-3 cells	docetaxel (DTX) treatment	miR-145-5p in PC3-DTX cell was markedly lower than that of PC3 cells.	29633510
3665	Human	hsa-miR-145-5p	miRNA	hantaan virus (HTNV)	hemorrhagic fever with renal syndrome (HFRS)	exosomes derived from HTNV-infected human vascular endothelial cells (HUVECs) (Exo-HV)	Hantaan virus (HTNV) infection	upregulated	32808389
3666	Human	hsa-miR-145-5p	miRNA	valproic acid (VPA)	thyroid cancer (TC)	TC1889 cells	VPA treatment	upregulated	28486946
3667	Human	hsa-miR-145-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	VSMCs proliferation and migration	vascular smooth muscle cells (VSMCs)	PDGF-bb treatment	miR-145-5p is downregulated in PDGF-mediated VSMCs in both time- and dose-dependent manners	30007992
3668	Human	hsa-miR-146	miRNA	docosahexaenoic acid (DHA)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	docosahexaenoic acid (DHA) treatment	upregulated	25182732
3669	Human	hsa-miR-146	miRNA	gamma-linolenic acid (GLA)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	GLA treatment	upregulated	25182732
3670	Human	hsa-miR-146	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	irradiation treatment	upregulated	25182732
3671	Human	hsa-miR-146	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
3672	Human	hsa-miR-146	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
3673	Human	hsa-miR-146	miRNA	carbamylated albumin	renal cell carcinoma (RCC)	human renal cell carcinoma cells	Carbamylated albumin treatment	upregulated	21472233
3674	Human	hsa-miR-146	miRNA	lipopolysaccharide (LPS)	inflammation	human vascular endothelial cell line EA. hy926 cells	lipopolysaccharide (LPS) treatment	downregulated	29442046
3675	Human	hsa-miR-146	miRNA	thrombin	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	were transfect miRNA mimics or antimiRs and thrombin treatment	upregulated	24985472
3676	Human	hsa-miR-146	miRNA	TNF-a and MMP13	osteoarthritis (OA)	human OA cartilage and bone	TNF-a and MMP13 treatment	downregulated	19008124
3677	Human	hsa-miR-146	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
3678	Human	hsa-miR-1468-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
3679	Human	hsa-miR-1468-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
3680	Human	hsa-miR-1468-5p	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	vascular endothelial cell growth factor (VEGF) treatment	downregulated	30414893
3681	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	falls and fractures among the elderly	THP-1 cells	lipopolysaccharide (LPS)	lipopolysaccharide (LPS) induces a reactive oxygen species-/NF-kappaB-dependent pathway which increases the expression of the anti-inflammatory miR-146a	19390647
3682	Human	hsa-miR-146a	miRNA	6-mer HA oligosaccharides as sodium salt	6-mer HA-induced inflammation	chondrocytes	6-mer HA oligosaccharides as sodium salt treatment	upregulated	31583475
3683	Human	hsa-miR-146a	miRNA	cutibacterium acnes (C. acnes)	acne	acne lesions or human keratinocytes	cutibacterium acnes (C. acnes) infection	upregulated	31194941
3684	Human	hsa-miR-146a	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
3685	Human	hsa-miR-146a	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
3686	Human	hsa-miR-146a	miRNA	IL-1¦Â	acute inflammatory response	Human Lung Alveolar Epithelial Cells	IL-1¦Â treatment	upregulated	18390754
3687	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32399391
3688	Human	hsa-miR-146a	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	The human promyelocytic cell line NB4£» humanembryonic kidney cell line 293T	retinoid acid? treatment	downregulated	20577838
3689	Human	hsa-miR-146a	miRNA	human T-cell leukemia virus type 1 (HTLV-1)	adult T-cell leukemia (ATL)	CD4£«T cell	human T-cell leukemia virus type 1 (HTLV-1) infection	upregulated	20017139
3690	Human	hsa-miR-146a	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-146a was inversely associated with PM25 exposure during the 2nd trimester of pregnancy	27104955
3691	Human	hsa-miR-146a	miRNA	chitin	allergic airway diseases (AAD)	bronchial epithelial cells and in A549 and H292 lung carcinoma cells	chitin treatment	upregulated	27463381
3692	Human	hsa-miR-146a	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	N9 microglial cell line	amyloid-¦Â (A¦Â) treatment	upregulated	27797173
3693	Human	hsa-miR-146a	miRNA	amyloid-¦Â (A¦Â) 42	Alzheimer's disease (AD)	human neuronal-glial primary cell	amyloid-¦Â (A¦Â) 42 peptide metal treatment	upregulated	22043907
3694	Human	hsa-miR-146a	miRNA	dipeptidyl vinyl sulfone (VS)	Alzheimer's disease (AD)	N9 microglial cell line treated with A¦Â	VS treatment	downregulated	27797173
3695	Human	hsa-miR-146a	miRNA	neurotoxic metal	Alzheimer's disease (AD)	human neuronal-glial primary cell	neurotoxic metal treatment	upregulated	22043907
3696	Human	hsa-miR-146a	miRNA	proinflammatory cytokines	Alzheimer's disease (AD)	human neuronal-glial primary cell	pro-inflammatory cytokine treatment	upregulated	22043907
3697	Human	hsa-miR-146a	miRNA	herpes simplex virus 1 (HSV-1)	alzheimer-type inflammatory	HN cells	Herpes simplex virus type-1 (HSV-1) infection	upregulated	19801956
3698	Human	hsa-miR-146a	miRNA	nanocurcumin	ankylosing spondylitis (AS)	peripheral blood mononuclear cells (PBMCs)	nanocurcumin treatment	upregulated	31074089
3699	Human	hsa-miR-146a	miRNA	"dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)"	anti-inflammatory responses	primary astrocyte cultures derived from human brains stimulated with IL-1¦Â	"pretreat with DMF, MMF"	downregulated	28589165
3700	Human	hsa-miR-146a	miRNA	immunoglobulin	anti-inflammatory responses	LPS-activated human monocytes	intravenous immunoglobulin (IVIG)	downregulated	28288804
3701	Human	hsa-miR-146a	miRNA	mechanical pressure of 10 MPa	apoptosis	human chondrocytes	mechanical pressure of 10 Mpa for 60 min treatment	upregulated	24939082
3702	Human	hsa-miR-146a	miRNA	epstein-barr virus (EBV)	asthma	"U2932,BL28 and BL41, BL28 E95A and BL41 E95C,BL28 EHRA and BL41 EHRA,Oma 4 ,Bjab and the B95-8"	Epstein-Barr virus (EBV)	downregulated	22614176
3703	Human	hsa-miR-146a	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	asthma	human airway smooth muscle cells (hASMCs)	"cytomix (IL-1¦Â, TNF-¦Á, and IFN¦Ã) treatment"	upregulated	25217662
3704	Human	hsa-miR-146a	miRNA	IL-17A	asthma	primary conventional human bronchial epithelial cells (HBECs) culture	IL-17A treatment	upregulated	31798831
3705	Human	hsa-miR-146a	miRNA	IL-1¦Â	asthma	airway smooth muscle cells (ASMCs) from asthmatic patients	IL-1¦Â treatment	downregulated	29946002
3706	Human	hsa-miR-146a	miRNA	IL-4	asthma	primary conventional human bronchial epithelial cells (HBECs) culture	IL-4 treatment	upregulated	31798831
3707	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	asthma	primary conventional human bronchial epithelial cells (HBECs) culture	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31798831
3708	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharides (LPS) treatment	upregulated	30710793
3709	Human	hsa-miR-146a	miRNA	olive leaf extract (OLE)	atherosclerosis (AS)	Serum amyloid A (SAA)-induced human coronary artery endothelial cells (HCAEC)	Olive leaf extract (OLE) treatment	downregulated	31157238
3710	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
3711	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human macrophage THP-1 cells exosomes	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31416388
3712	Human	hsa-miR-146a	miRNA	serum amyloid A (SAA)	atherosclerosis (AS)	human coronary artery endothelial cells (HCAEC)	Serum amyloid A (SAA) treatment	upregulated	31157238
3713	Human	hsa-miR-146a	miRNA	TNF-¦Á£¬IGF-1	atherosclerosis (AS)	smooth muscle cell	TNF-¦Á£¬IGF-1 treatment	upregulated	26047583
3714	Human	hsa-miR-146a	miRNA	ortho-silicic acid	bone defects	human mesenchymal stem cells (hMSCs)	orthosilicic acid (Si(OH)4) treatment	upregulated	27163405
3715	Human	hsa-miR-146a	miRNA	coenzyme Q10 (CoQ10)	breast cancer	primary human umbilical vein endothelial cells (HUVECs)	coenzyme Q10 (CoQ10H?) treatment	downregulated	23727324
3716	Human	hsa-miR-146a	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
3717	Human	hsa-miR-146a	miRNA	quercetin	breast cancer	human breast cancer cell lines MCF-7 and MDA-MB-231	quercetin treatment	upregulated	25596948
3718	Human	hsa-miR-146a	miRNA	triptolide (TPL)	breast cancer	MDA-MB-231 breast cancer cells	triptolide (TPL) treatment	upregulated	31072418
3719	Human	hsa-miR-146a	miRNA	atorvastatin	coronary artery disease (CAD)	PBMCs (peripheral blood mononuclear cells)	atorvastatin and telmisartan or atorvastatin treatment	downregulated	20524934
3720	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cardiac dysfunction	cardiomyocyte cell line of human origin (AC16)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26112171
3721	Human	hsa-miR-146a	miRNA	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)	cardiac hypertrophy	human breast cancer? cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23647548
3722	Human	hsa-miR-146a	miRNA	doxorubicin (DOX)	cardiotoxicity	AC16 cardiomyocytes	Doxorubicin (DOX) treatment	upregulated	31511497
3723	Human	hsa-miR-146a	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
3724	Human	hsa-miR-146a	miRNA	gliadinN	celiac disease (CD)	PBMCs; monocytes	gliadinN treatment	upregulated	31781909
3725	Human	hsa-miR-146a	miRNA	CoCl2	cell-based therapies	human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)	CoCl2 treatment	CoCl2 leads to increased expression of microRNA- (miR-) 146a.	30254683
3726	Human	hsa-miR-146a	miRNA	chikungunya virus	chronic infection	human synovial fibroblasts	infect with chikungunya virus treatment	upregulated	25083878
3727	Human	hsa-miR-146a	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	upregulated	20460641
3728	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	corticosteroid-dependent dermatitis (CDD)	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	29913408
3729	Human	hsa-miR-146a	miRNA	tripterine	corticosteroid-dependent dermatitis (CDD)	LPS-treated HaCaT cells	Tripterine treatment	upregulated	29913408
3730	Human	hsa-miR-146a	miRNA	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV)	cryptosporidium parvum infection	Human Umbilical Vein Endothelial Cells (HUVEC)	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) treatment	upregulated	20023696
3731	Human	hsa-miR-146a	miRNA	bisphenol A (BPA)	cytotoxicity	human placental cells	bisphenol A (BPA) treatment	upregulated	20417706
3732	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	dementia	human gastric epithelial cells	Helicobacter pylori (H. pylori) infection	?H. pylori infection upregulated the expression of miR-146a in gastric epithelial cells	20542134
3733	Human	hsa-miR-146a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human REC	high glucose (HG) treatment	downregulated	26997759
3734	Human	hsa-miR-146a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
3735	Human	hsa-miR-146a	miRNA	portland cement (PC)	cell differentiation	human periodontal ligament cells	PC treatment	upregulated	28528141
3736	Human	hsa-miR-146a	miRNA	portland cement (PC)	cell differentiation	PDL cells	Portland cement (PC) treatment	"PC enhances the differentiation of PDL cells, especially osteogenic through miR-146a upregulation"	28528141
3737	Human	hsa-miR-146a	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma extracellular vesicle (EV)	doxorubicin (Dox) treatment	downregulated	32255536
3738	Human	hsa-miR-146a	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
3739	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell migration	THP-1 cell	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	21329689
3740	Human	hsa-miR-146a	miRNA	phorbol-12-myristate-13-acetate(PMA)	angiogenesis 	HMVECs	PMA treatment	PMA induced miR-146a expression in human microvascular endothelial cells	19944095
3741	Human	hsa-miR-146a	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
3742	Human	hsa-miR-146a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	L02 hepatocytes	TGF-¦Â1 treatment	downregulated	30711634
3743	Human	hsa-miR-146a	miRNA	cyanobacterial lipopolysaccharide antagonist (CyP)	endotoxin cross-tolerance	THP-1 cells and human monocytes	cyanobacterial lipopolysaccharide antagonist (CyP) treatment	upregulated	30054544
3744	Human	hsa-miR-146a	miRNA	enterovirus 71 (EV71)	enterovirus infection	human rhabdomyosarcoma cells line (RD)	EV71 infection treatment	upregulated	24561744
3745	Human	hsa-miR-146a	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	human RPE cells	interferon-¦Ã treatment	upregulated	23592910
3746	Human	hsa-miR-146a	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	human RPE cells	IL-1¦Â treatment	upregulated	23592910
3747	Human	hsa-miR-146a	miRNA	Kr¨¹ppel-like factor 8 (KLF8)	epithelial-mesenchymal transition (EMT)	"MCF-10A, MCF-7 , T47D, MDA-MB-231, Hs578T and BT-549 cell lines and the MCF-10A line"	Kr¨¹ppel-like factor 8 treatment	upregulated	23977446
3748	Human	hsa-miR-146a	miRNA	"TGF-¦Â1 plus cytomix (a mixture of IL-1beta, IFN-gamma and TNF-alpha)"	epithelial-mesenchymal transition (EMT)	HBECs	cytokine treatment	"miRNA-146a was upregulated in human bronchial epithelial cells (HBECs) in response to stimulation by TGF-?1 plus cytomix (a mixture of IL-1?, IFN-c and TNF-a)"	19167348
3749	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	epithelial-mesenchymal transition (EMT)	human RPE cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23592910
3750	Human	hsa-miR-146a	miRNA	epstein-barr virus (EBV)	Epstein-Barr virus (EBV) infection	B-cells	Epstein-Barr virus (EBV) infection	downregulated	19001862
3751	Human	hsa-miR-146a	miRNA	porphyromonas gingivalis	experimental periodontal disease	human THP-1 monocytes	Porphyromonas gingivalis treatment	downregulated	21263019
3752	Human	hsa-miR-146a	miRNA	purified lipooligosaccharides (LOS)	facilitate bacterial survival and dissemination	human monocytic THP-1 cells and primary monocytes	LOS re of cells treatment	upregulated	24442429
3753	Human	hsa-miR-146a	miRNA	neutrophil elastase (NE)	fat	16HBE cells	neutrophil elastase (NE) treatment	NE exerts a dose- and time-dependent induction of both MUC5AC and miR-146a in human bronchial epithelial cells (16HBE)	21773870
3754	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	gastritis	gastric lesions	Helicobacter pylori treatment	upregulated	30219037
3755	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	gingival inflammation	Human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	29407755
3756	Human	hsa-miR-146a	miRNA	monosodium urate (MSU)	gouty tophus	human monocytic THP-1 cells	monosodium urate (MSU) treatment	downregulated	25646371
3757	Human	hsa-miR-146a	miRNA	IL-1¦Â	graves' orbitopathy (GO)	GO orbital adipose	IL-1¦Âtreatment	upregulated	27494344
3758	Human	hsa-miR-146a	miRNA	TGF-¦Â	graves' orbitopathy (GO)	orbital fibroblasts from patients with Graves' orbitopathy (GO)	TGF-¦Â treatment	upregulated	29101123
3759	Human	hsa-miR-146a	miRNA	TGF-¦Â	graves' orbitopathy (GO)	orbital fibroblasts from patients with GO	TGF-¦Â treatment	upregulated	29101123
3760	Human	hsa-miR-146a	miRNA	IL-10	hepatocellular carcinoma (HCC)	NK cells from CHB and HCC patients	"IL-10 ,transforming growth factor-¦Â treatment"	upregulated	26996068
3761	Human	hsa-miR-146a	miRNA	"IL-12, IFN-¦Á and IFN-¦Â"	hepatocellular carcinoma (HCC)	NK cells from CHB and HCC patients	"IL-12,IFN-¦Á , IFN-¦Â treatment"	downregulated	26996068
3762	Human	hsa-miR-146a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	NK cells from CHB and HCC patients	"IL-10 ,transforming growth factor-¦Â treatment"	upregulated	26996068
3763	Human	hsa-miR-146a	miRNA	recombinant Schistosoma japonicum protein P40 (rSjP40)	liver fibrosis	LX-2 cells	recombinant Schistosoma japonicum protein P40 (rSjP40) treatment	rSjP40 could induce miR-146a expression in LX-2 cells	29953648
3764	Human	hsa-miR-146a	miRNA	angiotensin-(1-7)	hepatocellular carcinoma (HCC)	human aortic endothelial cells (HAECs)	angiotensin-(1-7) treatment	downregulated	23246834
3765	Human	hsa-miR-146a	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	HCC cell	Paclitaxe treatment	upregulated	25973036
3766	Human	hsa-miR-146a	miRNA	hantaan virus (HTNV)	hantaan virus (HTNV) infection	human umbilical vein endothelial cells (HUVECs)	infect with HTNV	upregulated	28843856
3767	Human	hsa-miR-146a	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells (PBMCs)	human immunodeficiency virus (HIV)-1 infection	upregulated	31827152
3768	Human	hsa-miR-146a	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
3769	Human	hsa-miR-146a	miRNA	simvastatin	hyperlipidemia	blood	Simvastatin treatment	downregulated	25727911
3770	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	upregulated	24863965
3771	Human	hsa-miR-146a	miRNA	type I interferon (IFN)	hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	type I interferon (IFN) treatment	upregulated	23650597
3772	Human	hsa-miR-146a	miRNA	vibrio cholerae O1	infection of Vibrio cholerae O1	colon carcinoma cell line T84	infect with Vibrio cholerae O1 treatment	upregulated at acute stage of V cholerae infection and declined to normal at convalescent stage	28319200
3773	Human	hsa-miR-146a	miRNA	alternariol (AOH)	inflammation	THP-1 cells	alternariol (AOH) treatment	downregulated	30175388
3774	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	inflammation	human gastric epithelial cells	Helicobacter pylori (H. pylori) infection	upregulated	21947847
3775	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	inflammation	human gastric mucosa	Helicobacter pylori (H. pylori) infection	upregulated	30535468
3776	Human	hsa-miR-146a	miRNA	helicobacter pylori (H. pylori)	inflammation	human gastric mucosa	Helicobacter pylori (H. pylori) infection	upregulated	30535468
3777	Human	hsa-miR-146a	miRNA	IL-17A	inflammation	SGC-7901 cells	IL-17A treatment	upregulated	30535468
3778	Human	hsa-miR-146a	miRNA	IL-17A	inflammation	SGC-7901 cells	interleukin (IL)-17A treatment	upregulated	30535468
3779	Human	hsa-miR-146a	miRNA	IL-1¦Â	inflammation	human lung fibroblasts	IL-1¦Â treatment	downregulated	30619270
3780	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	inflammation	human microvascular endothelial cells (HMECs)	lipopolysaccharides (LPS) treatment	upregulated	31291804
3781	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	inflammation	THP-1 monocytes	lipopolysaccharide (LPS) treatment	upregulated	21178010
3782	Human	hsa-miR-146a	miRNA	outer membrane vesicles (OMVs)	inflammation	human intestinal epithelial cells T84	Vibrio cholerae outer membrane vesicles (OMVs) treatment	upregulated	31076615
3783	Human	hsa-miR-146a	miRNA	particulate matter (PM1)	inflammation	human lung bronchial epithelial BEAS-2B cells	particulate matter (PM1) treatment	upregulated	29667303
3784	Human	hsa-miR-146a	miRNA	"PD98059, TPCA-1 and LY294002"	inflammation	A549 cells	"exposure to PD98059, TPCA-1 and LY294002 treatment"	downregulated	25183503
3785	Human	hsa-miR-146a	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	human adipocytes	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
3786	Human	hsa-miR-146a	miRNA	Tnf¦Á and Gm-csf	heart failure (HF)	cardiomyocyte cell line H9C2	Tnf¦Á and Gm-csf treatment	upregulated	29258606
3787	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	colonic epithelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26752469
3788	Human	hsa-miR-146a	miRNA	IL-1¦Â	inflammatory diseases	THP-1 cells	IL-1¦Â treatment	upregulated	25896300
3789	Human	hsa-miR-146a	miRNA	IL-1¦Â	inflammatory injury	human umbilical cord-derived mesenchymal stem cells (MSCs)	IL-1¦Â treatment	upregulated	28090688
3790	Human	hsa-miR-146a	miRNA	candida albicans (C. albicans)	inflammatory response	THP-1 cells	candida albicans infection	upregulated	28454101
3791	Human	hsa-miR-146a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	Influenza A virus (IAV) infection	upregulated	30611999
3792	Human	hsa-miR-146a	miRNA	"TLR2 ligand zymosan, the TLR3 ligand poly(I:C) or the TLR5 ligand flagellin"	innate immune response	keratinocytes	"TLR2 ligand zymosan, the TLR3 ligand poly(I:C) or the TLR5 ligand flagellin treatment"	upregulated	24588688
3793	Human	hsa-miR-146a	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
3794	Human	hsa-miR-146a	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
3795	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	downregulated	28161709
3796	Human	hsa-miR-146a	miRNA	IL-1¦Â	intestinal inflammation	Caco-2 cells	IL-1¦Â treatment	upregulated	30478292
3797	Human	hsa-miR-146a	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	serum	Japanese encephalitis virus (JEV) infection	miR-146a was found significantly decreased (p?=?0.0008) in JEV infected patients as compared to healthy controls.	30196835
3798	Human	hsa-miR-146a	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	human microglial CHME3 cells	JEV-infected treatment	upregulated	24885259
3799	Human	hsa-miR-146a	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
3800	Human	hsa-miR-146a	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
3801	Human	hsa-miR-146a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	linesprostate cancer	LNCaP£¬PC3 cell	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24885368
3802	Human	hsa-miR-146a	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	upregulated	24431000
3803	Human	hsa-miR-146a	miRNA	TGF-¦Â1	liver fibrosis	L02 hepatocytes	TGF-¦Â1 treatment	downregulated	30711634
3804	Human	hsa-miR-146a	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
3805	Human	hsa-miR-146a	miRNA	IL-1¦Â	lung cancer	human airway smooth muscle (HASM) cells	IL-1¦Â treatment	upregulated	20525168
3806	Human	hsa-miR-146a	miRNA	M2000 (¦Â-d-mannuronic acid)	inflammatory response	HEK-Blue hTLR2 cells	M2000 at low and high doses (5 and 25¦Ìg/well)	downregulated	28324845
3807	Human	hsa-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	macrophage maturation	Human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	"oxLDL positively regulates miR-146a via the JNK and NF-¦ÊB pathways in macrophages, and that miR-146a inhibits inflammatory activation."	26718614
3808	Human	hsa-miR-146a	miRNA	mechanotransduction and pressure	mechanically induced inflammation	Primary human small airway epithelial cells (HSAEpCs)	mechanotransduction and pressure treatment	MiR-146a is a mechanosensitive miRNA that is rapidly upregulated by oscillatory pressure and plays an important role in regulating mechanically induced inflammation in lung epithelia.	22593544
3809	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	migration of human dental pulp cells	human dental pulp cells	lipopolysaccharide (LPS) treatment	upregulated	23146644
3810	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	monocytic differentiation	monocyte	lipopolysaccharide (LPS) treatment	dysregulated	25148686
3811	Human	hsa-miR-146a	miRNA	"TNF¦Á , IFN¦Ã"	multiple sclerosis (MS)	human cerebral microvascular endothelial cells (hCMEC/D3)	TNF¦Á and IFN¦Ã treatment	upregulated	25515214
3812	Human	hsa-miR-146a	miRNA	Toll-like receptor (TLR)	neurological diseases	U251 human astrocytoma cell line	Toll-like receptor (TLR) treatment	upregulated	25957996
3813	Human	hsa-miR-146a	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
3814	Human	hsa-miR-146a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
3815	Human	hsa-miR-146a	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
3816	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	HaCaT cells	lipopolysaccharide (LPS) treatment	The expression of miR-146a was upregulated in OLP tissues and in lipopolysaccharide (LPS)-incubated HaCaT cells.	30125971
3817	Human	hsa-miR-146a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteoarthritis (OA)	OA chondrocytes and synoviocytes	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31077718
3818	Human	hsa-miR-146a	miRNA	dendrobine	osteoarthritis (OA)	synovial cells (OA-FLS) isolated from stage-IV-OA patients	dendrobine treatment	upregulated	25052989
3819	Human	hsa-miR-146a	miRNA	H2O2	osteoarthritis (OA)	human OA chondrocytes	H2O2 treatment	downregulated (miR-146a) ; upregulated(miR-34a)	29292727
3820	Human	hsa-miR-146a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	hydrostatic pressure (HP) treatment	upregulated	32455798
3821	Human	hsa-miR-146a	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
3822	Human	hsa-miR-146a	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
3823	Human	hsa-miR-146a	miRNA	resistin	osteoarthritis (OA)	human OA synovial fibroblasts	resistin treatment	upregulated	31635187
3824	Human	hsa-miR-146a	miRNA	visfatin	osteoarthritis (OA)	human OA synovial fibroblasts	visfatin treatment	upregulated	31635187
3825	Human	hsa-miR-146a	miRNA	IL-1¦Â	osteoporosis	A549 cells	IL-1¦Â treatment	downregulated	19786024
3826	Human	hsa-miR-146a	miRNA	proinflammatory cytokines	otitis media (OM)	Human middle ear epithelial cells	proinflammatory cytokines treatment	upregulated	27497395
3827	Human	hsa-miR-146a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	oxygen-glucose deprivation/reoxygenation (OGD/R) injury	SK-N-SH cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	27449900
3828	Human	hsa-miR-146a	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	Colo357; Panc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	20124483
3829	Human	hsa-miR-146a	miRNA	BxPC-3-conditioned medium (BxCM)	pancreatic cancer (PC)	human CD14£«monocyte-derived DCs	BxPC-3-conditioned medium (BxCM) treatment	"aberrant miRNA-146a expression is one of main factors responsible for inhibition of DC maturation and antigen presentation function, and this inhibitory effect on DCs may be due to the repression of Smad4 mediated signal pathway by BxCM"	22311263
3830	Human	hsa-miR-146a	miRNA	curcumin-derived analogue CDF	pancreatic cancer (PC)	"human PC cell lines AsPC-1, BxPC-3, COLO-357, L3.6pl, PANC-1, PANC-28, MIAPaCa-2, MIAPaCa-2-GR"	curcumin-derived analogue CDF treatment	upregulated	24839931
3831	Human	hsa-miR-146a	miRNA	isoflavone	pancreatic cancer (PC)	Colo357; Panc-1 cells	isoflavone treatment	upregulated	20124483
3832	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	pancreatic ductal adenocarcinoma (PDAC)	THP-1 cells	lipopolysaccharide (LPS) treatment	upregulated	19840932
3833	Human	hsa-miR-146a	miRNA	paraquat poisoning	paraquat poisoning-induced lung injury	"pulmonary macrophages, PBMCs and serum"	paraquat poisoning treatment	downregulated	29896267
3834	Human	hsa-miR-146a	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
3835	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide (LPS) treatment	upregulated	25948157
3836	Human	hsa-miR-146a	miRNA	porphyromonas gingivalis	periodontitis	Human periodontal ligament fibroblasts (HPDLFs)	Porphyromonas gingivialis (P. gingivalis) infection treatment	upregulated	30378773
3837	Human	hsa-miR-146a	miRNA	porphyromonas gingivalis	periodontitis	Human periodontal ligament fibroblasts (HPDLFs)	Porphyromonas gingivialis (P. gingivalis) infection treatment	upregulated	30378773
3838	Human	hsa-miR-146a	miRNA	Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS)	periodontitis	Human periodontal ligament fibroblasts (HPDLFs)	Porphyromonas gingivialis (P. gingivalis) LPS treatment	upregulated	30378773
3839	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	peripheral inflammation	mesenchymal stem cells (MSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	over expression	20049872
3840	Human	hsa-miR-146a	miRNA	TGF-¦Â1	cell differentiation	human dermal fibroblasts	TGF-¦Â1 treatment	upregulated	21968601
3841	Human	hsa-miR-146a	miRNA	TGF-¦Â1	podocyte injury	Alexa Fluor 568-labeled phalloidin and HCS CellMask blue	TGF-¦Â1 treatment	downregulated	27913625
3842	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	preeclampsia (PE)	HTR8 cells; SVneo cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TRAIL downregulated the expressions of miR-146a	32090966
3843	Human	hsa-miR-146a	miRNA	TPCA-1	pro-inflammatory activity	human gingival fibroblasts (HGFs)	high concentration (10 ¦ÌM) of IRAK1/4 inhibitor or the NF-¦ÊB inhibitor treatment	downregulated	25598707
3844	Human	hsa-miR-146a	miRNA	hepatitis C virus (HCV)	promote regulatory T-cell development	Human peripheral blood mononuclear cells (PBMCs)	hepatitis C virus (HCV) infection	upregulated	27004559
3845	Human	hsa-miR-146a	miRNA	ascorbic acid	angiogenesis	?I-PDL cells and primary PDL cells	ascorbic acid?treatment	upregulated	20110513
3846	Human	hsa-miR-146a	miRNA	epstein-barr virus (EBV)	prostate cancer	Burkitt's lymphoma cells	Epstein-Barr Virus (EBV)?infection	upregulated	18347435
3847	Human	hsa-miR-146a	miRNA	IL-17A	psoriasis	human primary keratinocytes	IL-17A treatment	upregulated	31630447
3848	Human	hsa-miR-146a	miRNA	methotrexate (MTX)	psoriasis	Blood	methotrexate treatment	downregulated	26604920
3849	Human	hsa-miR-146a	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in plasma	27535005
3850	Human	hsa-miR-146a	miRNA	NB-UVB	psoriasis	Blood	NB-UVB treatment	downregulated	26604920
3851	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	human primary keratinocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31630447
3852	Human	hsa-miR-146a	miRNA	ionizing radiation (IR)	radiation-induced acute and chronic complications	EA.hy926 cells	ionizing radiation (IR) treatment	downregulated	32532422
3853	Human	hsa-miR-146a	miRNA	iguratimod	rheumatoid arthritis (RA)	rheumatoid arthritis-fibroblast-like synoviocytes (RA-FLS)	iguratimod treatment	upregulated	32662411
3854	Human	hsa-miR-146a	miRNA	quercetin	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLSs)	quercetin treatment	Quercetin treatment elevated the RNA level of miR-146a.	32216502
3855	Human	hsa-miR-146a	miRNA	tripterygium wilfordii Hook F (TwHF)	rheumatoid arthritis (RA)	RA patients peripheral blood mononuclear cells (PBMCs)	TwHF treatment	downregulated in peripheral blood mononuclear cells (PBMCs)	28514293
3856	Human	hsa-miR-146a	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
3857	Human	hsa-miR-146a	miRNA	severe fever with thrombocytopenia syndrome virus (SFTSV)	severe fever with thrombocytopenia syndrome (SFTS)	Human monocyte cell line (THP-1)-derived macrophages	Severe fever with thrombocytopenia syndrome virus (SFTSV) infection treatment	upregulated	31156641
3858	Human	hsa-miR-146a	miRNA	hydroxychloroquine	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	hydroxychloroquine treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs."	24121037
3859	Human	hsa-miR-146a	miRNA	prednisone	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	prednisone treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs"	24121037
3860	Human	hsa-miR-146a	miRNA	IFN	systemic lupus erythematosus (SLE)	THP-1 cells	interferon (IFN) treatment	downregulated	26315540
3861	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	31572547
3862	Human	hsa-miR-146a	miRNA	mycophenolic acid (MPA)	systemic lupus erythematosus (SLE)	lupus CD4(+)T cells	Mycophenolic acid (MPA) treatment	upregulated	25661834
3863	Human	hsa-miR-146a	miRNA	IL-15	T cell immunotherapy	na?ve CD8+ T cells	IL-15 treatment	upregulated	25331734
3864	Human	hsa-miR-146a	miRNA	IL-2	T cell immunotherapy	na?ve CD8+ T cells	IL-2 treatment	upregulated	25331734
3865	Human	hsa-miR-146a	miRNA	human immunodeficiency virus (HIV)-1	thyroid cancer (TC)	primary human fetal microglial cells	HIV-1 infection	upregulated	20181935
3866	Human	hsa-miR-146a	miRNA	thyroid stimulating hormone	thyroid eye disease (TED)	orbital fibroblasts (OFs)	thyroid stimulating hormone treatment	upregulated	31622470
3867	Human	hsa-miR-146a	miRNA	IL-1¦Â	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	interleukin (IL)-1¦Â treatment	downregulated	29467762
3868	Human	hsa-miR-146a	miRNA	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	LPS-treated primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) treatment	downregulated	29467762
3869	Human	hsa-miR-146a	miRNA	lipopolysaccharide (LPS)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	lipopolysaccharide (LPS) treatment	upregulated	29467762
3870	Human	hsa-miR-146a	miRNA	acyclovir	type 2 diabetes mellitus (T2DM)	human primary brain cells	acyclovir treatment	downregulated	20683212
3871	Human	hsa-miR-146a	miRNA	amyloid-¦Â (A¦Â) 42	type 2 diabetes mellitus (T2DM)	human primary brain cells	amyloid-¦Â (A¦Â) 44 peptide metal treatment	downregulated	20683212
3872	Human	hsa-miR-146a	miRNA	butyrate and inulin	type 2 diabetes mellitus (T2DM)	peripheral blood mononuclear cells (PBMCs)	butyrate and inulin treatment	butyrate and concomitant use of butyrate and inulin caused a significant increase in the fold change of miR-146a and miR-9 compared with the placebo group.	32315958
3873	Human	hsa-miR-146a	miRNA	IL-1¦Â and TNF-¦Á	type 2 diabetes mellitus (T2DM)	human pancreatic islets	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
3874	Human	hsa-miR-146a	miRNA	chuyou yuyang granule (CYYY)	ulcer relapse	Helicobacter pylori (HP) infected Peptic ulcert patients blood	Chuyou Yuyang granule (CYYY) four weeks or six weeks treatment	downregulated	31034651
3875	Human	hsa-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	urethral stricture	human umbilical cord-derived mesenchymal stem cells (MSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	"Exosomes derived from MSCs pretreated with TNF-¦Á were more effective in suppressing urethral fibrosis and stricture than exosomes from untreated MSCs We found that miR-146a, an anti-inflammatory miRNA, was strongly upregulated in TNF-¦Á-stimulated MSCs and was selectively packaged into exosomes"	31144307
3876	Human	hsa-miR-146a	miRNA	baicalin (BAI)	influenza A virus (IAV) infection	IVA-infected A549 cells	baicalin (BAI) treatment	downregulated	31638222
3877	Human	hsa-miR-146a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	H1N1 and H3N2 viruses infection	upregulated	31638222
3878	Human	hsa-miR-146a	miRNA	zinc	zinc deficiency illnesses	Jurkat T cells	zinc deficiency treatment	downregulated	30316032
3879	Human	hsa-miR-146a	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	primary human monocytes; THP-1 cells	dengue virus (DENV)infection	upregulated	23685241
3880	Human	hsa-miR-146a	miRNA	histone deacetylase inhibitor (HDACi)	osteoarthritis (OA)	fibroblast-like synoviocytes (OA-FLS)	Histone deacetylase inhibitors?treatment	upregulated	24107356
3881	Human	hsa-miR-146a	miRNA	hepatitis B virus (HBV)	vascular smooth muscle cell calcification	HepG2.2.15 cells	hepatitis B virus (HBV) infection	MiR146a was upregulated in HBV+ HepG2.2.15 cells	23890093
3882	Human	hsa-miR-146a-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Human normal lung epithelial cell line BEAS-2B	lipopolysaccharide (LPS) treatment	Reduced SIRT1 and raised miR-146a-3p were found in LPS-induced BEAS-2B cells and ALI rats.	33185125
3883	Human	hsa-miR-146a-3p	miRNA	lipoteichoic acid (LTA)	lower respiratory tract infections	BEAS-2B cells	lipoteichoic acid (LTA) treatment	upregulated	31837465
3884	Human	hsa-miR-146a-3p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	lower respiratory tract infections	BEAS-2B cells	poly(I:C) treatment	upregulated	31837465
3885	Human	hsa-miR-146a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	lower respiratory tract infections	BEAS-2B cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31837465
3886	Human	hsa-miR-146a-5p	miRNA	zhenbao pill	acute spinal cord injury (ASCI)	hypoxia-induced SH-SY5Y cells	zhenbao pill treatment	upregulated	29187582
3887	Human	hsa-miR-146a-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	LINC01311 was downregulated whereas hsa-miR-146a-5p upregulated in AB1-42 treated SH-SY5Y cells.	33830627
3888	Human	hsa-miR-146a-5p	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	asthma	A549 cells	"cytokine mixture containing IFN-¦Ã, IL-1¦Â and TNF-¦Á treatment"	upregulated	31698144
3889	Human	hsa-miR-146a-5p	miRNA	long-chain polyunsaturated fatty acids (LCPUFAs)	asthma	"cytokine mixture containing IFN-¦Ã, IL-1¦Â and TNF-¦Á-treated A549 cells"	long-chain polyunsaturated fatty acids (LCPUFAs) treatment	upregulated	31698144
3890	Human	hsa-miR-146a-5p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	downregulated	30245930
3891	Human	hsa-miR-146a-5p	miRNA	doxorubicin (DOX)	breast cancer	MDA-MB-231 cells	doxorubicin treatment	downregulated	30245930
3892	Human	hsa-miR-146a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MCF-7 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	downregulated	30245930
3893	Human	hsa-miR-146a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MDA-MB-231 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	downregulated	30245930
3894	Human	hsa-miR-146a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
3895	Human	hsa-miR-146a-5p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
3896	Human	hsa-miR-146a-5p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	downregulated	28749179
3897	Human	hsa-miR-146a-5p	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	"Human hepatic cell line, THLE-2"	hepatitis B virus (HBV) infection	upregulated	31018043
3898	Human	hsa-miR-146a-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	dental pulp in?ammation	human dental pulp cells (hDPCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30952010
3899	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	dental pulp in?ammation	human dental pulp cells (hDPCs)	lipopolysaccharide (LPS) treatment	upregulated	30952010
3900	Human	hsa-miR-146a-5p	miRNA	hypoxia	diabetic retinopathy (DR)	ARPE©\19 cells	hypoxia treatment	downregulated	31094072
3901	Human	hsa-miR-146a-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
3902	Human	hsa-miR-146a-5p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
3903	Human	hsa-miR-146a-5p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	30197683
3904	Human	hsa-miR-146a-5p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â1 treatment	CHRF and L1CAM expression were significantly upregulated and promoted the EMT process in A549 after treatment of TGF-¦Â1	33754922
3905	Human	hsa-miR-146a-5p	miRNA	dexamethasone (DEX)	inflammation	"TNF-¦Á-treated A549 human lung carcinoma cell, NuLi-1 immortalized, normal human bronchial epithelial cells"	dexamethasone (DEX) treatment	downregulated	30300399
3906	Human	hsa-miR-146a-5p	miRNA	particulate matter (PM2.5)	inflammation	THP-1 cells	particulate matter (PM2.5) treatment	upregulated	33160737
3907	Human	hsa-miR-146a-5p	miRNA	particulate matter (PM2.5)	inflammation	human monocytic leukemia cell line (THP-1)	PM2.5?extracts?treatment treatment	"?we observed expression of miR-146a-5p was significantly increased, with the maximal response of six folds in WN group"	33160737
3908	Human	hsa-miR-146a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	"A549 human lung carcinoma cell, NuLi-1 immortalized, normal human bronchial epithelial cells"	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30300399
3909	Human	hsa-miR-146a-5p	miRNA	high glucose (HG)	diabetic vasculopathy	human aortic endothelial cells (HAECs)	high glucose (HG)	downregulated	28824448
3910	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	inflammatory response	macrophages	lipolysaccharide (LPS) treatment	upregulated	25805648
3911	Human	hsa-miR-146a-5p	miRNA	hepatitis A virus (HAV)	innate immune response	The human embryonic lung fbroblast cell line KMB17	hepatitis A virus (HAV) infection	HAV infection upregulates the expression of hsa-miR-146a-5p	33459883
3912	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	liver fibrosis	human HSC line LX-2	LPS treatment	downregulated	28739486
3913	Human	hsa-miR-146a-5p	miRNA	TGF-¦Â1	liver fibrosis	human HSC line LX-2	TGF¦Â1 treatment	downregulated	28739486
3914	Human	hsa-miR-146a-5p	miRNA	TGF-¦Â1	liver fibrosis	human hepatic stellate cell line LX2	TGF-¦Â1 treatment	downregulated	31560641
3915	Human	hsa-miR-146a-5p	miRNA	X rays	liver fibrosis	human hepatic stellate cell line LX2	LX2 cells were stimulated with 8 Gy of X rays treatment	downregulated	31560641
3916	Human	hsa-miR-146a-5p	miRNA	BRAF and MEK inhibitor	melanoma	LM16R cells; LM69 cells; LM70 cells	BRAF and MEK inhibitor treatment	miR-146a-5p expression was reduced in BRAF and MEK inhibitor-resistant melanoma cells and tissues.	31915008
3917	Human	hsa-miR-146a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
3918	Human	hsa-miR-146a-5p	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	downregulated	31484042
3919	Human	hsa-miR-146a-5p	miRNA	CXCR4 antagonist TN14003	osteoarthritis (OA)	SDF-1-treated OA chondrocytes	CXCR4 antagonist TN14003 treatment	upregulated	30942441
3920	Human	hsa-miR-146a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-9¦Â treatment	dysregulated	29123165
3921	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	human lung fibroblasts cell WI-38	lipopolysaccharide (LPS) treatment	SNHG16 regulated LPS-induced inflammation injury in WI-38 cells through competitively binding miR-146a-5p with CCL5 further mediating JNK and NF-¦ÊB pathways	31071307
3922	Human	hsa-miR-146a-5p	miRNA	ethanol (EtOH)	prostate cancer	cancer-associated fibroblasts (CAFs)	ethanol (ETOH) treatment	MiR-146a-5p level in exosomes from ETOH-treated CAFs was significantly reduced.	33317606
3923	Human	hsa-miR-146a-5p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
3924	Human	hsa-miR-146a-5p	miRNA	adalimumab(ADA)	psoriasis	circulating angiogenic cells (CACs)	adalimumab treatment	downregulated	26943583
3925	Human	hsa-miR-146a-5p	miRNA	ionizing radiation (IR)	radiation-induced liver disease (RILD)	LX-2 cells	ionizing radiation (IR) treatment	upregulated	29348414
3926	Human	hsa-miR-146a-5p	miRNA	irradiation and lipopolysaccharide (LPS)	radiation-induced liver disease (RILD)	LX-2 cells	irradiation and lipopolysaccharide (LPS) treatment	Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway.	32097101
3927	Human	hsa-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	radiation-induced liver disease (RILD)	LX-2 cells	lipopolysaccharide (LPS) treatment	upregulated	29348414
3928	Human	hsa-miR-146a-5p	miRNA	radiation	radiation-induced liver disease (RILD)	LX2 cells	radiation treatment	downregulated	31960423
3929	Human	hsa-miR-146a-5p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
3930	Human	hsa-miR-146a-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	whole-blood	methotrexate (MTX) treatment	downregulated	30511295
3931	Human	hsa-miR-146a-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	RA patients whole-blood	methotrexate (MTX) treatment	upregulated	30511295
3932	Human	hsa-miR-146a-5p	miRNA	resolvin D1 (RvD1)	rheumatoid arthritis (RA)	fibroblast-like synoviocyte (FLS)	resolvin D1 (RvD1) treatment	RvD1 upregulated miRNA-146a-5p	32216830
3933	Human	hsa-miR-146a-5p	miRNA	sulforaphane (SFN)	staphylococcus aureus infection	THP-1 cells	sulforaphane (SFN) treatment	SFN pretreatment of the THP-1-derived macrophages significantly attenuated the S aureus-mediated increased expression levels of miR-146a-5p	32323751
3934	Human	hsa-miR-146a-5p	miRNA	ultraviolet (UV) irradiation	skin photoaging	human dermal fibroblasts (HDFs)	UVA irradiation treatment	downregulated	33025709
3935	Human	hsa-miR-146b	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
3936	Human	hsa-miR-146b	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	asthma	human airway smooth muscle cells (hASMCs)	"cytomix (IL-1¦Â, TNF-¦Á, and IFN¦Ã) treatment"	upregulated	25217662
3937	Human	hsa-miR-146b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31479774
3938	Human	hsa-miR-146b	miRNA	atorvastatin	coronary artery disease (CAD)	PBMCs (peripheral blood mononuclear cells)	atorvastatin and telmisartan or atorvastatin treatment	downregulated	20524934
3939	Human	hsa-miR-146b	miRNA	suberoylanilide hydroxamic acid (SAHA)	tumorigenesis	MEG-01 cells; HEK-293 cells	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	23543665
3940	Human	hsa-miR-146b	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
3941	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	gingival inflammation	Human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	29407755
3942	Human	hsa-miR-146b	miRNA	TGF-¦Â	intestinal cell differentiation	intestinal epithelial cell (IEC-6)	Growth factor TGF-¦Â?treatment treatment	miR-146b expression increased rapidly	22570175
3943	Human	hsa-miR-146b	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
3944	Human	hsa-miR-146b	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
3945	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	Human renal mesangial cells (HRMCs)	lipopolysaccharide (LPS) treatment	"NEAT1 accelerated renal mesangial cell injury via directly targeting miR-146b, promoting the expression of TRAF6, and activating the NF-¦ÊB signaling in lupus nephritis."	32710276
3946	Human	hsa-miR-146b	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
3947	Human	hsa-miR-146b	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
3948	Human	hsa-miR-146b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid (PA) treatment	downregulated	32143184
3949	Human	hsa-miR-146b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	downregulated	32143184
3950	Human	hsa-miR-146b	miRNA	TNF-¦Á and IL-6	obesity	mature human adipocytes	TNF-¦Á and IL-6 treatment	upregulated	24428800
3951	Human	hsa-miR-146b	miRNA	platelet-derived growth factor (PDGF)	oral cavity cancer	U118-MG cells£»U87-MG glioblastoma cells£» human WI-38 fibroblasts?£» ovarian cells C272/hTert/E7	Platelet derived growth factor (PDGF)? treatment	upregulated	21266476
3952	Human	hsa-miR-146b	miRNA	IL-1¦Â	osteoporosis	A549 cells	IL-1¦Â treatment	downregulated	19786024
3953	Human	hsa-miR-146b	miRNA	proinflammatory cytokines	otitis media (OM)	Human middle ear epithelial cells	proinflammatory cytokines treatment	upregulated	27497395
3954	Human	hsa-miR-146b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
3955	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 human lung fibroblasts cells	lipopolysaccharide (LPS) treatment	downregulated	31583932
3956	Human	hsa-miR-146b	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	miR-146b was downregulated in WI-38 cells treated with LPS.	31583932
3957	Human	hsa-miR-146b	miRNA	TPCA-1	pro-inflammatory activity	human gingival fibroblasts (HGFs)	high concentration (10 ¦ÌM) of IRAK1/4 inhibitor or the NF-¦ÊB inhibitor treatment	downregulated	25598707
3958	Human	hsa-miR-146b	miRNA	Salmonella Typhimurium	salmonella typhimurium infection	human HeLa cells	Salmonella Typhimurium infection treatment	upregulated	21468030
3959	Human	hsa-miR-146b	miRNA	severe fever with thrombocytopenia syndrome virus (SFTSV)	severe fever with thrombocytopenia syndrome (SFTS)	Human monocyte cell line (THP-1)-derived macrophages	Severe fever with thrombocytopenia syndrome virus (SFTSV) infection treatment	upregulated	31156641
3960	Human	hsa-miR-146b	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	plasma and myocardial cells	coxsackievirus B3 (CVB3) treatment	upregulated	25815880
3961	Human	hsa-miR-146b-3p	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
3962	Human	hsa-miR-146b-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	thrombosis	THP-1 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32337281
3963	Human	hsa-miR-146b-5p	miRNA	ultraviolet (UV) irradiation	DNA damage	U2OS;EH1; EH2 cell lines	ultraviolet light treatment	upregulated	24163379
3964	Human	hsa-miR-146b-5p	miRNA	TNF-¦Á£¬IGF-1	atherosclerosis (AS)	smooth muscle cell	TNF-¦Á£¬IGF-1 treatment	upregulated	26047583
3965	Human	hsa-miR-146b-5p	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
3966	Human	hsa-miR-146b-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell differentiation	THP-1 cells stimulated with phorbol 12-myristate 13-acetate (100 nM)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29201219
3967	Human	hsa-miR-146b-5p	miRNA	"cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)"	diffuse large B-cell lymphoma (DLBCL)	patients with DLBCL	CHOP treatment	downregulated	24931464
3968	Human	hsa-miR-146b-5p	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
3969	Human	hsa-miR-146b-5p	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
3970	Human	hsa-miR-146b-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	human Ishikawa cells	Progesterone treatment	miR-146b-5p was notably decreased in Ishikawa cells while upregulated after treatment with progesterone	30452118
3971	Human	hsa-miR-146b-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	progesterone treatment	miR-146b-5p was notably decreased in Ishikawa cells	30452118
3972	Human	hsa-miR-146b-5p	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec4A cells	Progesterone treatment	upregulated	22543862
3973	Human	hsa-miR-146b-5p	miRNA	p-cresol (PcEMV)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	p-cresol (PcEMV) treatment	upregulated	32606426
3974	Human	hsa-miR-146b-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	human RPE cells	interferon-¦Ã treatment	upregulated	23592910
3975	Human	hsa-miR-146b-5p	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	human RPE cells	IL-1¦Â treatment	upregulated	23592910
3976	Human	hsa-miR-146b-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	papillary thyroid carcinoma cell line BCPAP	TGF-¦Â1 treatment	upregulated	24946010
3977	Human	hsa-miR-146b-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	epithelial-mesenchymal transition (EMT)	human RPE cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23592910
3978	Human	hsa-miR-146b-5p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	U87-MG and U251 cells	Sevoflurane (Sev) treatment	upregulated	31385537
3979	Human	hsa-miR-146b-5p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	A172 cells; U251 cells	sevoflurane (Sev) treatment	"KCNQ1OT1 knockdown mediated the role of Sev in glioma cell proliferation, apoptosis, migration, and invasion both in vitro and in vivo through miR-146b-5p/STC1 pathway"	32996777
3980	Human	hsa-miR-146b-5p	miRNA	IL-6	hepatocarcinogenesis	non-transformed liver-derived PH5CH8 and THLE2 cells and in Huh-7 hepatoma cells	Interleukin-6 (IL-6) treatment	upregulated	30145833
3981	Human	hsa-miR-146b-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
3982	Human	hsa-miR-146b-5p	miRNA	EGFR tyrosine kinase inhibitors (TKIs)	lung cancer	lung cancer cells	EGFR tyrosine kinase inhibitors (TKIs) treatment	miR-146b-5p expression in lung cancer cells isolated from pleural effusions of treatment-naive patients was significantly higher than that after acquiring resistance to EGFR TKI treatment.	33230450
3983	Human	hsa-miR-146b-5p	miRNA	hypoxia	myocardial infarction (MI)	serum	hypoxia treatment	"Herein, miR-146b-5p was found to be upregulated in the infarcted myocardium of mice and the serum of myocardial ischemia patients."	32845445
3984	Human	hsa-miR-146b-5p	miRNA	dioxin	neuroblastoma (NB)	SK-N-SH cells	dioxin treatment	upregulated	29406108
3985	Human	hsa-miR-146b-5p	miRNA	dioxin	neuroblastoma (NB)	SK-N-SH cells	dioxin treatment	upregulated	29406108
3986	Human	hsa-miR-146b-5p	miRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	BxPC-3 cells; HPAC cells	cucurbitacin B (CuB) treatment	MiR-146b-5p is expressed differentially after CuB treatment and is associated with the EGFR.	30206930
3987	Human	hsa-miR-146b-5p	miRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	"Human PC cell lines, ASPC©\1, BxPC©\3, HPAC, MiaPaCa©\2"	cucurbitacin B (CuB) treatment	CuB-induced high miR-146b-5p expression and inhibited the expression of AFAP1-AS1.	30206930
3988	Human	hsa-miR-146b-5p	miRNA	p16 INK4A	cell senescence	human fibroblast and epithelial cells	p16 INK4A treatment	upregulated	27596953
3989	Human	hsa-miR-147	miRNA	hypoxia	breakdown of blood-brain barrier (BBB)	PC12 cells	hypoxia treatment	downregulated	29130945
3990	Human	hsa-miR-147	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
3991	Human	hsa-miR-147	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
3992	Human	hsa-miR-147	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	blood	Metformin treatment	upregulated	30297296
3993	Human	hsa-miR-1470	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose treatment	downregulated	30784065
3994	Human	hsa-miR-1471	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
3995	Human	hsa-miR-147a	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	cervical cancer (CC)	HeLa cells; ATCC cells; CCL-2 cells	HIF1¦Á treatment	upregulated	27260617
3996	Human	hsa-miR-147a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	downregulated	33009725
3997	Human	hsa-miR-147a	miRNA	sodium new houttuyfonate (SNH)	non-small cell lung cancer (NSCLC)	A549 and NCI-H1299 cells	sodium new houttuyfonate (SNH) treatment	upregulated	30971296
3998	Human	hsa-miR-147b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	MiR-147b was downregulated in lipopolysaccharide (LPS)-induced ALI rats and LPS-treated A549 cells	33660808
3999	Human	hsa-miR-147b	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (VSMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	30060075
4000	Human	hsa-miR-148-3p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	downregulated	29901102
4001	Human	hsa-miR-148-3p	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	upregulated	32028542
4002	Human	hsa-miR-148-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
4003	Human	hsa-miR-148a	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
4004	Human	hsa-miR-148a	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	human monocyte leukemia cell line THP-1	homocysteine	upregulated	28472596
4005	Human	hsa-miR-148a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	tamoxifen sensitive (TamS) MCF-7 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28063929
4006	Human	hsa-miR-148a	miRNA	ailanthone (AIL)	breast cancer	DA-MB-231 cells	ailanthone (AIL) treatment	upregulated	30551356
4007	Human	hsa-miR-148a	miRNA	ailanthone (AIL)	breast cancer	MDA-MB-231 cells	ailanthone (AIL) treatment	upregulated	30551356
4008	Human	hsa-miR-148a	miRNA	estradiol	breast cancer	breast cancer cells	Estradiol treatment	downregulated	25928008
4009	Human	hsa-miR-148a	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-7 and MDA-MB-231 cells	estradiol-17¦Â (E2) treatment	upregulated	25063027
4010	Human	hsa-miR-148a	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
4011	Human	hsa-miR-148a	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 and Hs-578T breast cancer cell lines	Glabridin (GLA) treatment	upregulated	25980823
4012	Human	hsa-miR-148a	miRNA	glabridin (GLA)	breast cancer	human breast cancer (MDA-MB-231 and Hs-578T) cells	glabridin (GLA)	downregulated	28464803
4013	Human	hsa-miR-148a	miRNA	caffeic acid	tumorigenesis	Human TNBC cell line	caffeic acid (CA) treatment	upregulated	26106521
4014	Human	hsa-miR-148a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human bone mesenchymal stromal cells (hBMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28656724
4015	Human	hsa-miR-148a	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
4016	Human	hsa-miR-148a	miRNA	radiation	cervical cancer (CC)	SiHa cells; Hela cells	radiation treatment	LncRNA SNHG12 promoted CDK1 expression to regulate the sensitivity of CC cells to radiation through sponging miR-148a	33292254
4017	Human	hsa-miR-148a	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	p53-mutant MEG-01 cells	fludarabine treatment	specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets	20504344
4018	Human	hsa-miR-148a	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cell line	cisplatin treatment	MicroRNA (miRNA) array and qRT-PCR assay identified the downregulated of miR-148a in cisplatin-resistant SW480 cells.	30551544
4019	Human	hsa-miR-148a	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cells	criplatin (DPP) treatment	downregulated	30551544
4020	Human	hsa-miR-148a	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
4021	Human	hsa-miR-148a	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	SGC-7901 cells	Helicobacter pylori £¨H. pylori£©infection	downregulated	29604247
4022	Human	hsa-miR-148a	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
4023	Human	hsa-miR-148a	miRNA	nuclear factor kappa-B (NF-¦ÊB)	glioblastoma multiforme (GBM)	glioblastoma cells	NF-¦ÊB treatment	upregulated	25971746
4024	Human	hsa-miR-148a	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	drug resistant (MDR) Bel-7402 cells (BelMDR) cells	arsenic trioxide (ATO) treatment	upregulated	31759055
4025	Human	hsa-miR-148a	miRNA	rhamnetin	hepatocellular carcinoma (HCC)	HCC cells	rhamnetin treatment	rhamnetin increased expression of miR-148a (which is tumor-suppressive) in a P53-dependent manner	33570057
4026	Human	hsa-miR-148a	miRNA	serum-free MSCM	inflammation	human adipose tissue-derived mesenchymal stem cells (hMSCs-Ad)	human adipose tissue-derived mesenchymal stem cells (hMSCs-Ad) treatment	upregulation	27878286
4027	Human	hsa-miR-148a	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	downregulated	30186499
4028	Human	hsa-miR-148a	miRNA	estradiol	intrahepatic cholestasis of pregnancy (ICP)	LO2 cells	estradiol treatment	upregulated	28575098
4029	Human	hsa-miR-148a	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) X protein (HBx) treatment	downregulated	23321675
4030	Human	hsa-miR-148a	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	Dendritic cells (DCs)	lipopolysaccharide (LPS) treatment	downregulated	27714813
4031	Human	hsa-miR-148a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
4032	Human	hsa-miR-148a	miRNA	Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS)	periodontitis	periodontal ligament stem cells (PDLSCs)	Porphyromonas gingivalis lipopolysaccharide (LPS) treatment	upregulated	31809209
4033	Human	hsa-miR-148a	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	hepatocellular carcinoma (HCC)	CD14+ peripheral blood mononuclear cells (PBMCs)	receptor activator of nuclear factor-¦ÊB ligand (RANKL) treatment	upregulated	23225151
4034	Human	hsa-miR-148a	miRNA	macrophage colony stimulating factor (M-CSF)	osteoporosis	CD14+ PBMCs	macrophage colony stimulating factor (M-CSF) treatment	upregulated	23225151
4035	Human	hsa-miR-148a-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
4036	Human	hsa-miR-148a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRECs)	high glucose (HG) treatment	HG treatment reduced miR-148a-3p level in HRECs.	32661705
4037	Human	hsa-miR-148a-3p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
4038	Human	hsa-miR-148a-3p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	upregulated	31176168
4039	Human	hsa-miR-148a-5p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	upregulated	32582989
4040	Human	hsa-miR-148a-5p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	upregulated	31176168
4041	Human	hsa-miR-148a-5p	miRNA	metformin (Met)	preeclampsia (PE)	Trophoblast and HUVEC cells	Metformin (Met) treatment	upregulated	31203154
4042	Human	hsa-miR-148b	miRNA	statins	asthma	Immortalized lymphoblastoid cell lines (LCLs)	statins? treatment	upregulated	25266681
4043	Human	hsa-miR-148b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs).	oxidized low-density lipoprotein (ox-LDL) treatment	The level of H19 was increased and miR-148b expression was decreased in human AS patient serums and oxidized low-density lipoprotein (ox-LDL)-stimulated human aorta vascular smooth muscle cells (HA-VSMCs).	29415742
4044	Human	hsa-miR-148b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human VSMC; human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 knockdown attenuated ox-LDL-induced injury through regulating proliferation and apoptosis of VSMC and HUVEC by miR-148b/IGF2 axis	31926240
4045	Human	hsa-miR-148b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Proliferation and migration were modified by MIAT/miR-148b/PAPPA axis in ox-LDL induced AS cell model.	32470448
4046	Human	hsa-miR-148b	miRNA	radiation	breast cancer	MCF-7 cells; MDA-MB-231 cells	radiation treatment	Radiation treatment triggered a significant increase in CCAT1 and an obvious decrease in miR-148b	29024383
4047	Human	hsa-miR-148b	miRNA	X-rays	breast cancer	human breast cancer cell lines MCF-7 and MDA-MB-231	radiation treatment	downregulated	29024383
4048	Human	hsa-miR-148b	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
4049	Human	hsa-miR-148b	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	patients with chronic myeloid leukemia (CML)	discontinuing imatinib mesylate (IM) treatment	downregulated	25187697
4050	Human	hsa-miR-148b	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
4051	Human	hsa-miR-148b	miRNA	remnant-like lipoproteins (RLPs)	ePCs senescence	Total peripheral mononuclear cells (PB-MNCs)	Remnant-like lipoproteins (RLPs) treatment	miR-148b and miR-155 were upregulated while miR-574-3p was downregulated	23044309
4052	Human	hsa-miR-148b	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
4053	Human	hsa-miR-148b	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	Dendritic cells (DCs)	lipopolysaccharide (LPS) treatment	downregulated	27714813
4054	Human	hsa-miR-148b-3p	miRNA	hypoxia	hypoxia-induced injury	human hepatic sinusoidal endothelial cells (HHSEC)	hypoxia induce	downregulated	31082428
4055	Human	hsa-miR-148b-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
4056	Human	hsa-miR-148b-3p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
4057	Human	hsa-miR-148b-3p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-148b-3p was downregulated in treated patients when compared with untreated patients.	29523324
4058	Human	hsa-miR-149	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	33428703
4059	Human	hsa-miR-149	miRNA	platelet activating factor (PAF)	asthma	Human small airway epithelial cells (HSAECs)	platelet activating factor (PAF) treatment	LncRNA PVT1 exacerbates the inflammation and cell-barrier injury during asthma by regulating miR-149	32830409
4060	Human	hsa-miR-149	miRNA	TmPyP4 (Porphyrin)	breast cancer	MCF-7 breast cancer cells	TmPyP4 (Porphyrin) treatment	upregulated	30585723
4061	Human	hsa-miR-149	miRNA	formononetin	colorectal cancer (CRC)	colon carcinoma cell lines SW1116 and HCT116	Formononetin (Form) treatment	upregulated	29620230
4062	Human	hsa-miR-149	miRNA	bisphenol A (BPA)	endometrial cancer (EC)	human endometrial cancer RL95-2 cells	bisphenol A (BPA) treatment	downregulated	28238728
4063	Human	hsa-miR-149	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	Eahy926 and HUVEC	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	24299952
4064	Human	hsa-miR-149	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	Eahy926 endothelial cells and HUVEC	TNF¦Á treatment	downregulated	24299952
4065	Human	hsa-mir-149	miRNA	fibroblast growth factor 2 (FGF2)	fine tunes the angiogenic	endothelial cells (ECs)	FGF2 treatment	upregulated	24463821
4066	Human	hsa-miR-149	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer (GC) tissues; AGS cells	5-fluorouracil (5-FU) treatment	miR-149 was significantly increased in 5-FU resistant tumor tissues and cells.	32977944
4067	Human	hsa-miR-149	miRNA	paeoniflorin	gastric cancer (GC)	Paired gastric normal fifbroblast (GNF) and gastric cancer associated fibroblasts (GCAFs) cultures	Paeoniflorin (PF) treatment	upregulated	30361813
4068	Human	hsa-miR-149	miRNA	paeoniflorin	gastric cancer (GC)	gastric cancer associated fibroblasts (GCAFs)	Paeoniflorin (PF) treatment	Paeoniflorin suppressed IL-6 production and secretion by up-regulating microRNA149 expression in GCAFs	30361813
4069	Human	hsa-miR-149	miRNA	triptolide (TPL)	gastric cancer (GC)	gastric cancer-associated fibroblasts (GCAFs)	triptolide (TPL) treatment	downregulated miR-301a expression and upregulated miR-149	29049979
4070	Human	hsa-miR-149	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	human glioma-derived cell lines U251 and U87	TMZ treatment	downregulated	25017996
4071	Human	hsa-miR-149	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hypermethylation	U87MG cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"Treatment of U87MG cells with 5-aza-dC reversed the hypermethylation status of miR-149,"	27783537
4072	Human	hsa-miR-149	miRNA	glucocorticoid (GC)	myeloma	sensitive RPMI-8226 cell line	chronic glucocorticoid exposure	downregulated	28035377
4073	Human	hsa-miR-149	miRNA	"N,N'-dinitrosopiperazine (DNP)"	nasopharyngeal carcinoma (NPC)	6-10B cells	"N,N'-dinitrosopiperazine (DNP) treatment"	upregulated	30144176
4074	Human	hsa-miR-149	miRNA	long-chain fatty acid	nonalcoholic fatty liver disease (NAFLD)	liver cells genotyped as TT	long-chain fatty acid treatment	upregulated	28507283
4075	Human	hsa-miR-149	miRNA	IL-1¦Â	osteoarthritis (OA)	Human normal chondrocytes	IL-1¦Â treatment	downregulated	29524885
4076	Human	hsa-miR-149	miRNA	Silica	lung fibrosis	"A549 , HBE cell"	silica treatment	downregulated	24641842
4077	Human	hsa-miR-149*	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
4078	Human	hsa-miR-149-3p	miRNA	quinidine	cell proliferation and apoptosis	human glioma U87-MG cells	quinidine treatment	the upregulation of miR-149-3p and downregulated of miR-424-5p	25420507
4079	Human	hsa-miR-149-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HBE135-E6E7 cells	cigarette smoke extract (CSE) treatment	MEG3 promoted proliferation and inhibited apoptosis by regulating the NF-¦ÊB signal pathway via miR-149-3p in CSE-treated HBE cells.	33365060
4080	Human	hsa-miR-149-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	THP-1 cells	cigarette smoke?extract?(CSE) treatment	downregulated	28260877
4081	Human	hsa-miR-149-3p	miRNA	cisplatin (DDP)	colorectal cancer (CRC)	"HCT116, SW480 and SW620 cells"	?cisplatin treatment	downregulated	31866582
4082	Human	hsa-miR-149-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
4083	Human	hsa-miR-149-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
4084	Human	hsa-miR-149-3p	miRNA	maimendong and qianjinweijing tang (Jin formula)	lung cancer	A549 cells; H1299 cells	Maimendong and Qianjinweijing Tang (Jin formula) treatment	Maimendong and Qianjinweijing Tang (Jin formula) suppresses lung cancer by regulation of miR-149-3p.	32344160
4085	Human	hsa-miR-149-3P	miRNA	dioscin	pancreatic cancer (PC)	ASPC-1 and PANC-1 cell	dioscin treatment	upregulated	28095588
4086	Human	hsa-miR-149-5p	miRNA	oxaliplatin	advanced colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer	33251049
4087	Human	hsa-miR-149-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circular RNA circ_0124644 exacerbates the ox-LDL-induced endothelial injury in human vascular endothelial cells through regulating PAPP-A by acting as a sponge of miR-149-5p.	32500475
4088	Human	hsa-miR-149-5p	miRNA	ursolic acid (UA)	breast cancer	MDA-MB-231 (231) and MDA-MB-231/PTX-resistance (231/PTX) cells	ursolic acid (UA) treatment	upregulated	31259152
4089	Human	hsa-miR-149-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	vascular smooth muscle cells (VSMCs)	PDGF-bb treatment	downregulated	31595884
4090	Human	hsa-miR-149-5p	miRNA	serum samples from patients with T2DM	endoplasmic reticulum stress (ERS)	human umbilical vein endothelial cells (HUVECs)	incubated with serum samples from patients with T2DM treatment	downregulated	28848152
4091	Human	hsa-miR-149-5p	miRNA	lipoteichoic acid (LTA)	inflammation	BEAS-2B cells	?lipoteichoic acid treatment	downregulated	31837465
4092	Human	hsa-miR-149-5p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	inflammation	BEAS-2B cells	viral dsRNA analogue poly(I:C) treatment	downregulated	31837465
4093	Human	hsa-miR-149-5p	miRNA	lipoteichoic acid (LTA)	lower respiratory tract infections	BEAS-2B cells	lipoteichoic acid (LTA) treatment	downregulated	31837465
4094	Human	hsa-miR-149-5p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	lower respiratory tract infections	BEAS-2B cells	poly(I:C) treatment	downregulated	31837465
4095	Human	hsa-miR-149-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	lower respiratory tract infections	BEAS-2B cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31837465
4096	Human	hsa-miR-149-5p	miRNA	IL-6	osteoarthritis (OA)	human chondrocyte-articular (HC-a) cells	IL-6?treatment	downregulated	32141427
4097	Human	hsa-miR-149-5p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human ¦Â-cells	cytokines IL-1¦Â plus IFN-¦Ã treatment	dysregulated	27737950
4098	Human	hsa-miR-149-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	vascular restenosis	human aortic vascular smooth muscle cell (HA-VSMC)	platelet derived growth factor-BB (PDGF-BB) treatment	downregulated	32736703
4099	Human	hsa-miR-15	miRNA	ginsenoside Rg1	angiogenesis	human umbilical vein endothelial cells (HUVECs)	ginsenoside-Rg1 treatment	downregulated	23688497
4100	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	bedsore	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	31692058
4101	Human	hsa-miR-15	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
4102	Human	hsa-miR-15	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells	5-fluorouracil (5-FU) treatment	miR-15 expression was significantly upregulated in HCT116 cells treated with 5-Fu.	29467857
4103	Human	hsa-miR-15	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells	oxaliplatin (OXA) treatment	miR-15 expression was significantly upregulated in HCT116 cells treated with OX.	29467857
4104	Human	hsa-miR-15	miRNA	fibroblast growth factor 4 (FGF4)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	FGF4 treatment	upregulated	30753902
4105	Human	hsa-miR-15	miRNA	hepatocyte growth factor (HGF)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	HGF treatment	upregulated	30753902
4106	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	inflammation	Human WI©\38 cells	lipopolysaccharide (LPS) treatment	"MIAT2 reversely regulated miR-15 and miR-15 mimic could reverse the effects of MIAT2. Finally, MIAT2 restrained the p38MAPK and NF-¦ÊB pathways by downregulating miR-15."	31566734
4107	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	inflammatory injury	HaCaT cells	lipopolysaccharide (LPS) treatment	circANKRD36 remitted cell inflammatory damage upregulating miR-15/MyD88 via the NF-¦ÊB pathway in HaCaT cells.	31692058
4108	Human	hsa-miR-15	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	MIAT2 restrained the p38MAPK and NF-¦ÊB pathways by downregulating miR-15.	31566734
4109	Human	hsa-miR-15	miRNA	IL-1¦Â	rheumatoid arthritis (RA)	human RA fibroblast-like synoviocyte (FLS) cell line MH7A cells	IL-1¦Â treatment	downregulated	31611200
4110	Human	hsa-miR-150	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	nucleus pulposus cells	IL-1¦Â treatment	downregulated	31726456
4111	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cell	lipopolysaccharide (LPS) treatment	downregulated	31398659
4112	Human	hsa-miR-150	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
4113	Human	hsa-miR-150	miRNA	oxidized low density lipoprotein (ox-LDL)	angiogenesis	human umbilical vein endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28254813
4114	Human	hsa-miR-150	miRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	airway smooth muscle cells (ASMCs)	platelet-derived growth factor BB (PDGF-BB) treatment	downregulated	31695627
4115	Human	hsa-miR-150	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	27216461
4116	Human	hsa-miR-150	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical cord vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28110404
4117	Human	hsa-miR-150	miRNA	ozone (O3)	cardiovascular disease (CVD)	plasma samples	ozone (O3) exopusure	upregulated	32414303
4118	Human	hsa-miR-150	miRNA	dextran sodium sulfate (DSS)	chronic inflammatory bowel diseases (IBDs)	colonic epithelial HT29 cells	dextran sulphate sodium (DSS)? treatment	upregulated	21590770
4119	Human	hsa-miR-150	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	upregulated	20460641
4120	Human	hsa-miR-150	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	BEAS-2B airway epithelial cells	cigarette smoke extract (CSE) treatment	downregulated	29205062
4121	Human	hsa-miR-150	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human airway epithelial cells BEAS-2B cells	cigarette smoke extract (CSE) treatment	downregulated	29205062
4122	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	sepsis	HUVECs	lipopolysaccharide (LPS) treatment	miR-150 affects sepsis-induced endothelial injury by regulating ER stress and inflammation via MALAT1-mediated NF-¦ÊB pathway.	33181172
4123	Human	hsa-miR-150	miRNA	Marek's disease virus (MDV)	diabetes mellitus (DM)	seven independentCD4+T-lymphoma cell line	Marek's disease virus (MDV) treatment	downregulated	19297609
4124	Human	hsa-miR-150	miRNA	TGF-¦Â	"fibrotic diseases, myofibroblast activation"	"human fetal lung fibroblast (HFL1, ECACC)"	"human fetal lung fibroblast (HFL1, ECACC) treatment"	upregulation	27226027
4125	Human	hsa-miR-150	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissues	5-fluorouracil (5-FU) treatment	upregulated	27081844
4126	Human	hsa-miR-150	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
4127	Human	hsa-miR-150	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
4128	Human	hsa-miR-150	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
4129	Human	hsa-miR-150	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	human cardiomyocytes (HCMs)	hypoxia treatment	downregulated	29328381
4130	Human	hsa-miR-150	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	human adipocytes	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
4131	Human	hsa-miR-150	miRNA	celastrol	insulin resistance (IR)	palmitic acid (PA) treated HepG2 cells	celastrol treatment	upregulated	30287053
4132	Human	hsa-miR-150	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
4133	Human	hsa-miR-150	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
4134	Human	hsa-miR-150	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
4135	Human	hsa-miR-150	miRNA	rapamycin	malignancies of the lymphocyte lineage	human Jurkat T-cell acute lymphoblastic leukemia (T-ALL) cells	rapamycin treatment	upregulated	30269036
4136	Human	hsa-miR-150	miRNA	natalizumab	multiple sclerosis (MS)	MS patients	natalizumab treatment	downregulated in cell-free CSF	27144214
4137	Human	hsa-miR-150	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	Ionizing irradiation treatment	upregulated	29516971
4138	Human	hsa-miR-150	miRNA	carbon disulfide (CS2)	nerve system injury	workers	experienced injury to nerve system from carbon disulfide (CS2) treatment	upregulated	25224332
4139	Human	hsa-miR-150	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	human hepatocarcinoma cell line (HepG2)	oleic acid (OA) treatment	upregulated	31966555
4140	Human	hsa-miR-150	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	K562 cells	cisplatin (DPP) treatment	miR-106 and miR-150 were downregulated	20428827
4141	Human	hsa-miR-150	miRNA	hpoxia	pancreatic cancer (PC)	pancreatic	Hypoxia treatment	downregulated	26622579
4142	Human	hsa-miR-150	miRNA	hypoxia	pancreatic cancer (PC)	CaPan2 human pancreatic cancer cell line	hypoxia treatment	downregulated	26622579
4143	Human	hsa-miR-150	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
4144	Human	hsa-miR-150	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
4145	Human	hsa-miR-150	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	downregulated	28715868
4146	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	29689269
4147	Human	hsa-miR-150	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	MiR-150 was downregulated in LPS-induced HUVECs.	33181172
4148	Human	hsa-miR-150-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	bone loss	human bone marrow cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26935950
4149	Human	hsa-miR-150-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	MALAT1 silencing can potentially suppress HPMEC apoptosis and alleviate lung injury in ARDS via miR-150-5p-targeted ICAM-1.	32315984
4150	Human	hsa-miR-150-5p	miRNA	oxaliplatin	advanced colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer	33251049
4151	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33278458
4152	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis	33278458
4153	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs.	33278458
4154	Human	hsa-miR-150-5p	miRNA	Trypanosoma cruzi (T. cruzi)	cardiac fibrosis	human AC16 cardiomyocytes	Trypanosoma cruzi (T. cruzi) infection treatment	downregulated	31122130
4155	Human	hsa-miR-150-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell proliferation and migration	human aortic smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31468685
4156	Human	hsa-miR-150-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16	high glucose (HG) treatment	Overexpression of NORAD protects DCM development via miRNA-150-5p/ZEB1 axis.	33215445
4157	Human	hsa-miR-150-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"Our results showed that NEAT1 and Drp1 levels were upregulated, while miR-150-5p level was downregulated in HK-2 cells in response to HG."	33914383
4158	Human	hsa-miR-150-5p	miRNA	simvastatin	endometriosis	Serum	simvastatin treatment	downregulated	29587611
4159	Human	hsa-miR-150-5p	miRNA	free fatty acids (FFA)	hepatic steatosis	LO2 cells	free fatty acid (FFA) treatment	upregulated	31191607
4160	Human	hsa-miR-150-5p	miRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	SMMC-7721 cells; Huh7 cells	astragaloside IV (AS-IV) treatment	AS-IV treatment was supposed to significantly increase miR-150-5p level.	32417721
4161	Human	hsa-miR-150-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 and HUH7 cells	sorafenib treatment	upregulated	31210410
4162	Human	hsa-miR-150-5p	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	Hypoxia exposure caused a downregulated of miR-150-5p in AC16 cells.	32973515
4163	Human	hsa-miR-150-5P	miRNA	marathon	inflammation	blood	marathon treatment	upregulated	25997943
4164	Human	hsa-miR-150-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
4165	Human	hsa-miR-150-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	liver fibrosis	LX-2 cells	platelet derived growth factor-BB (PDGF-BB) treatment	downregulated	31833387
4166	Human	hsa-miR-150-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	31833387
4167	Human	hsa-miR-150-5p	miRNA	physical exercise	myasthenia gravis (MG)	MG patients serum	performed supervised aerobic and resistance training twice weekly for 12 weeks treatment	downregulated	27935072
4168	Human	hsa-miR-150-5p	miRNA	rituximab (RTX)	myasthenia gravis (MG)	serum exosome	rituximab (RTX) treatment	RTX decreased the serum exosomal miR-150-5p	32961347
4169	Human	hsa-miR-150-5p	miRNA	trichloroethylene (TCE)	non-Hodgkin lymphoma (NHL)	serum	trichloroethylene (TCE) exposure treatment	downregulated	31161417
4170	Human	hsa-miR-150-5p	miRNA	adipokine apelin (APLN)	osteoarthritis (OA)	human OA synovial fibroblasts (OASFs)	adipokine apelin (APLN) treatment	APLN inhibited levels of microRNA-150-5p (miR-150-5p).	32131466
4171	Human	hsa-miR-150-5p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	CAOV3 cells; SKOV3 cells	paclitaxel (Tax) treatment	downregulated	33156701
4172	Human	hsa-miR-150-5p	miRNA	TGF-¦Â1	lung fibrosis	HFL1 cells	TGF-¦Â1 treatment	upregulated	32453709
4173	Human	hsa-miR-151	miRNA	genistein	head and neck squamous cell carcinoma (HNSCC)	LNCaP cells;PC-3 cells; DU145 cells; RWPE-1 cells	Genistein? treatment	downregulated	22928040
4174	Human	hsa-miR-151-3p	miRNA	dexamethasone (DEX)	Alzheimer's disease (AD)	SH-SY5Ycells	dexamethasone (DEX) treatment	upregulated of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against ¦Â-amyloid by targeting DAPK-1 and TP53.	33275947
4175	Human	hsa-miR-151-3p	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 11¡ã HDT bed rest experiment	downregulated	28261104
4176	Human	hsa-miR-151-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	miR-151-3p was decreased in HG-induced HK-2 cells.	32982348
4177	Human	hsa-miR-151-3p	miRNA	hydroxyurea	sickle cell anemia (SCA)	Circulating erythroid cells	Hydroxyurea treatment	upregulated	21921042
4178	Human	hsa-miR-151-5p	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 10¡ã HDT bed rest experiment	downregulated	28261104
4179	Human	hsa-miR-151-5p	miRNA	hantaan virus (HTNV)	hantaan virus (HTNV) infection	A549 cells	hantavirus(HTNV)treatment	upregulated	24074584
4180	Human	hsa-miR-151-5p	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
4181	Human	hsa-miR-15-16	miRNA	hypoxia	colorectal cancer (CRC)	colorectal carcinoma cell lines	hypoxia treatment	upregulated	24704828
4182	Human	hsa-miR-151a	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
4183	Human	hsa-miR-151a-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"Five human GBM cell lines (U87, LN229, A172, T98, U251)"	temozolomide (TMZ) treatment	downregulated	30992025
4184	Human	hsa-miR-151a-3p	miRNA	BIX01294	lung cancer	human NSCLC cells	BIX01294 treatment	downregulated	24932239
4185	Human	hsa-miR-151a-5p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	downregulated	28749179
4186	Human	hsa-miR-151a-5p	miRNA	l-carnitine	male infertility	sperm	l-carnitine treatment	upregulated	31749176
4187	Human	hsa-miR-151b	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	downregulated	32587527
4188	Human	hsa-miR-152	miRNA	statins	asthma	Immortalized lymphoblastoid cell lines (LCLs)	statins? treatment	upregulated	25266681
4189	Human	hsa-miR-152	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	human monocyte leukemia cell line THP-1	homocysteine	upregulated	28472596
4190	Human	hsa-miR-152	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	lipopolysaccharide (LPS) treatment	downregulated	22295098
4191	Human	hsa-miR-152	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	tamoxifen sensitive (TamS) MCF-7 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28063929
4192	Human	hsa-miR-152	miRNA	insulin-like growth factor 1 (IGF-1)	breast cancer	"human breast cancer cells MCF7, MDA-MB-231, T47D, MDA-MB-453"	IGF-1 treatment	upregulated	29162853
4193	Human	hsa-miR-152	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high glucose treatment	miR-152/LIN28B axis modulates high-glucose-induced angiogenesis in human retinal endothelial cells via VEGF signaling	31609010
4194	Human	hsa-miR-152	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs) and retinal microvascular endothelial cell line (hRMECs)	high-glucose (HG) treatment	downregulated	31609010
4195	Human	hsa-miR-152	miRNA	progesterone (P4)	endometrial cancer (EC)	"human endometrial cancer cell lines (Ishikawa, HEC-1-b, and KLE)"	P4 treatment	upregulated	28122483
4196	Human	hsa-miR-152	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
4197	Human	hsa-miR-152	miRNA	TGF-¦Â	gastric cancer (GC)	BGC823 and SGC7901	TGF-¦Âtreatment treatment	downregulated	26627200
4198	Human	hsa-miR-152	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	human gastric carcinoma (AGS) cells	infect with HP	downregulated	28056089
4199	Human	hsa-miR-152	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
4200	Human	hsa-miR-152	miRNA	nickel sulfide (NiS)	inflammation	human bronchial epithelial (16HBE) cells	nickel sulfide (NiS) treatment	downregulated	23125218
4201	Human	hsa-miR-152	miRNA	TGF-¦Â	liver fibrosis	LX2 cells	TGF-¦Â treatment	downregulated	31258681
4202	Human	hsa-miR-152	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
4203	Human	hsa-miR-152	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	downregulated	31611969
4204	Human	hsa-miR-152	miRNA	gemcitabine (GEM)	osteosarcoma (OS)	LncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells.	gemcitabine treatment	"lncRNA PVT1 played a contributory role in chemoresistance of osteosarcoma cells through c-MET/PI3K/AKT pathway activation, which was largely dependent on miR-152."	30661902
4205	Human	hsa-miR-152	miRNA	"dietary 3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	"human pancreatic adenocarcinoma cell lines CaPan-1, CaPan-2, AsPC-1, BxPC-3, Hs766T, MiaPaCa-2, PANC-1, PANC-28, PANC-48, PaTu8902, FG, Colo357, L3.7"	diet containing 2000 ppm of Bio-DIM for 6w	upregulated	28659310
4206	Human	hsa-miR-152	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
4207	Human	hsa-miR-152	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	prostate cancer	AA and CA derived prostate cancer cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25004396
4208	Human	hsa-miR-152	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
4209	Human	hsa-miR-152	miRNA	TGF-¦Â	renal fibrosis	"human HK2, HEK293 cells"	TGF¦Â treatment	downregulated	28285987
4210	Human	hsa-miR-152	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	miR-152 expression was significantly reduced in TGF-¦Â1-treated HK-2 cells	29620271
4211	Human	hsa-miR-152	miRNA	vitamin D	type 2 diabetes mellitus (T2DM)	type 2 diabetes patients	vitamin D treatment	dysregulated	28945992
4212	Human	hsa-miR-152-3p	miRNA	melatonin	breast cancer	MDA-MB-231 cells	melatonin treatment	melatonin treatment increases the gene expression of miR-152-3p.	29990486
4213	Human	hsa-miR-152-3p	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	Paclitaxel treatment	downregulated	32913475
4214	Human	hsa-miR-152-3p	miRNA	high glucose (HG)	diabetic foot ulcer (DFU)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	Inhibition of miRNA-152-3p enhances diabetic wound repair via upregulation of PTEN	32620711
4215	Human	hsa-miR-152-3p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
4216	Human	hsa-miR-152-3p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
4217	Human	hsa-miR-152-3p	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cell lines PANC-1 and BxPC-3	Metformin treatment	dysregulated	28875433
4218	Human	hsa-miR-152-3p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
4219	Human	hsa-miR-153	miRNA	estradiol	breast cancer	human breast cell lines	estradiol treatment	upregulated	27012032
4220	Human	hsa-miR-153	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
4221	Human	hsa-miR-153	miRNA	4-phenylbutyric acid and 5-aza-2-deoxycytidine	glioblastoma multiforme (GBM)	DBTRG-05MG cells; T98G cells	4-phenylbutyric acid and 5-aza-20-deoxycytidine treatment	upregulated	21213215
4222	Human	hsa-miR-153	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
4223	Human	hsa-miR-153	miRNA	olea europaea leaf extract (OLE)	glioblastoma multiforme (GBM)	GBM cell lines	olea europaea leaf extract (OLE) treatment	upregulation	25232498
4224	Human	hsa-miR-153	miRNA	paraquat (PQ)	neurotoxicity	SH-SY5Y neuroblastoma cells	paraquat (PQ) treatment	upregulated	24866057
4225	Human	hsa-miR-153	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG4 cells	high glucose (HG) treatment	downregulated	31889412
4226	Human	hsa-miR-153	miRNA	hypoxia	pancreatic cancer (PC)	NK cells	hypoxia induce	downregulated	31402756
4227	Human	hsa-miR-153	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	SH-SY5Y cells treatment	miR-153 was significantly increased in MPP+-induced SH-SY5Y cells.	31949812
4228	Human	hsa-miR-153	miRNA	mechanical stretch	cell proliferation	vascular smooth muscle cells (VSMCs)	mechanical stretch-stimulated treatment	downregulated	23046980
4229	Human	hsa-miR-153	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
4230	Human	hsa-miR-153	miRNA	mifepristone (MIF)	triple negative breast cancer (TNBC)	MCF10A cells	mifepristone (MIF) treatment	upregulation	26941846
4231	Human	hsa-miR-153	miRNA	arsenic trioxide (ATO)	glioblastoma and ovarian cancer	K562 cells	arsenic trioxide (As2O3) treatment	downregulated	21267675
4232	Human	hsa-miR-153-3p	miRNA	nutritional stress	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	low nutritional (LN) condition induce	Upregulation of LINC00641 and downregulated of miR-153-3p are detected in NP cells under nutritional stress.	30378116
4233	Human	hsa-miR-153-3p	miRNA	imatinib	chronic myeloid leukemia (CML)	KBM5 cells; K562 cells	imatinib (IM) treatment	miR-153-3p was identified to be downregulated in IM-resistant CML cells.	32342278
4234	Human	hsa-miR-153-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
4235	Human	hsa-miR-153-3p	miRNA	hypoxia	ischemic stroke (IS)	HUVECs	hypoxia treatment	downregulated	28985553
4236	Human	hsa-miR-153-3p	miRNA	cisplatin (DDP)	osteosarcoma (OS)	"OS tissues, MG63/DDP, and U2OS/DDP cells."	cisplatin treatment	downregulated	31539112
4237	Human	hsa-miR-153-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	SNHG1 aggravates MPP+-induced cellular toxicity in SH-SY5Y cells by regulating PTEN/AKT/mTOR signaling via sponging miR-153-3p.	31907031
4238	Human	hsa-miR-1539	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
4239	Human	hsa-miR-1539	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
4240	Human	hsa-miR-1539	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
4241	Human	hsa-miR-154	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	downregulated	27709720
4242	Human	hsa-miR-154	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	downregulated	31359876
4243	Human	hsa-miR-155	miRNA	francisella tularensis	microbial infection	PBMCs (peripheral blood mononuclear cells)	Francisella tularensis infection	induction of miR-155	22919664
4244	Human	hsa-miR-155	miRNA	aspergillus fumigatus (A. fumigatus)	Aspergillus fumigatus infection	human monocytes and dendritic cells (DCs)	infect with A. fumigatus	upregulated	24841251
4245	Human	hsa-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	active tuberculosis (ATB)	PBMCs (peripheral blood mononuclear cells)	Mycobacterium tuberculosis (MTB) infection	upregulated	22037148
4246	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute coronary syndrome (ACS)	peripheral blood mononuclear cell (PBMC) of ACS patients	lipopolysaccharide (LPS) treatment	upregulated	28407320
4247	Human	hsa-miR-155	miRNA	rosuvastatin	acute coronary syndrome (ACS)	patients with ACS	rosuvastatin treatment	downregulated in serum	25319951
4248	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	acute graft-versus-host disease (aGVHD)	human umbilical vein endothelial cells (EA.hy926)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28423578
4249	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	human monocytic cells	lipopolysaccharide (LPS) treatment	upregulated	19596814
4250	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS administration increased miR-155 levels in tubular epithelial cells in vitro.	32243922
4251	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	32323747
4252	Human	hsa-miR-155	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	upregulated	32359033
4253	Human	hsa-miR-155	miRNA	sulforaphane (SFN)	acute myeloid leukemia (AML)	"acute myelogenous leukemia cells U937, KG-1, HL-60, and NB-4"	sulforaphane treatment	downregulated	30350234
4254	Human	hsa-miR-155	miRNA	"IFN-¦Ã, IL-1¦Â and TNF-¦Á"	age-related macular degeneration (AMD)	human retinal pigment epithelial (HRPE) cell	"IFN-¦Ã, TNF-¦Á and IL-1¦Â treatment"	upregulated	20950585
4255	Human	hsa-miR-155	miRNA	chitin	allergic airway diseases (AAD)	bronchial epithelial cells and in A549 and H292 lung carcinoma cells	chitin treatment	upregulated	27463381
4256	Human	hsa-miR-155	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	N9 microglial cell line	amyloid-¦Â (A¦Â) treatment	upregulated	27797173
4257	Human	hsa-miR-155	miRNA	dipeptidyl vinyl sulfone (VS)	Alzheimer's disease (AD)	N9 microglial cell line treated with A¦Â	VS treatment	downregulated	27797173
4258	Human	hsa-miR-155	miRNA	arsenic trioxide (ATO)	anti-cancer therapy	human prostate cancer PC-3 and LNCaP cells	arsenic trioxide (As2O3) treatment	upregulated	25283513
4259	Human	hsa-miR-155	miRNA	oxysophocarpine (OSC)	anti-inflammatory responses	NCI-H292 and human primary airway epithelial cells	Oxysophocarpine (OSC) treatment	"The expression of miR-155 could be dramatically induced by LPS treatment in NCI-H292 cells, which could be attenuated by OSC treatment"	32603606
4260	Human	hsa-miR-155	miRNA	"dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)"	anti-inflammatory responses	primary astrocyte cultures derived from human brains stimulated with IL-1¦Â	"pretreat with DMF, MMF"	downregulated	28589165
4261	Human	hsa-miR-155	miRNA	M2000 (¦Â-d-mannuronic acid)	anti-inflammatory responses	LPS treated PBMCs	5 and 25 ¦Ìg/ml of M2000 in duplicates	downregulated	28090274
4262	Human	hsa-miR-155	miRNA	pitavastatin (Pit)	anti-inflammatory responses	LPS pretreated HUVECs	"Pit (0.01, 0.1, 1 ¦Ìmol/L) treatment"	downregulated	28664667
4263	Human	hsa-miR-155	miRNA	H2O2	apoptosis	Human umbilical vein endothelial cells (HUVEC)	H2O2 treatment	"endothelial cell proliferation was promoted, and oxidant-induced injury was decreased when the expression of miR-155 was inhibited."	30675289
4264	Human	hsa-miR-155	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
4265	Human	hsa-miR-155	miRNA	cockroach extract (CRE)	asthma	human bronchial epithelial cells	cockroach extract (CRE) treatment	upregulated	29967100
4266	Human	hsa-miR-155	miRNA	glucocorticoid (GC)	asthma	CD4+ T-cells	glucocorticoids treatment	Mir-155 is dysregulated in allergic T-cells exposed to DM extract compared to in non-allergic cells and it is inhibited by glucocorticoids.	30245919
4267	Human	hsa-miR-155	miRNA	"toluene 2,4-diisocyanate (TDI)"	asthma	human bronchial epithelial cells (HBEC)	"toluene 2,4-diisocyanate (TDI) treatment"	upregulated	32499335
4268	Human	hsa-miR-155	miRNA	imatinib	atheroprotective	Macrophages	imatinib treatment	upregulated	26721343
4269	Human	hsa-miR-155	miRNA	conjugated linoleic acid (CLA)	atherosclerosis (AS)	THP-1 cells	conjugated linoleic acid (CLA) treatment	CLA blend also decreased miR-155 expression in vitro in human THP-1 polarized macrophages.	33391256
4270	Human	hsa-miR-155	miRNA	genistein	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	"genistein (10, 100, and 1000 nM) for 6 h"	downregulated	28550396
4271	Human	hsa-miR-155	miRNA	imatinib	atherosclerosis (AS)	human macrophages	imatinib treatment	upregulated	26721343
4272	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human endothelial cells surrogate EA.hy926 lines (EA.hy926 cells)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29017169
4273	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	HUVECs	TNF¦Á ed HUVECs treatment	upregulated	24905663
4274	Human	hsa-miR-155	miRNA	TNF-¦Á£¬IGF-1	atherosclerosis (AS)	smooth muscle cell	TNF-¦Á£¬IGF-1 treatment	upregulated	26047583
4275	Human	hsa-miR-155	miRNA	H2O2	autophagy	Human umbilical vein endothelial cells (HUVEC)	H2O2 treatment	"endothelial cell proliferation was promoted, and oxidant-induced injury was decreased when the expression of miR-155 was inhibited."	30675289
4276	Human	hsa-miR-155	miRNA	hypoxia	autophagy	CNE (human nasopharyngeal cancer) or HeLa (human cervical cancer) cells	1% O2 treatment	upregulated	24262949
4277	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28659666
4278	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30015881
4279	Human	hsa-miR-155	miRNA	wogonin	B lymphoma	human cell line Raji	wogonin treatment	downregulated	28222771
4280	Human	hsa-miR-155	miRNA	camptothecin	biologic and molecular activity of camptothecin	hypoxic-human cancer cells	camptothecin treatment	upregulated	24252850
4281	Human	hsa-miR-155	miRNA	hedyotis diffusa plus scutellaria barbata	bladder cancer	human bladder cancer cell lines 5637 and T24	Hedyotis diffusa plus Scutellaria barbata treatment	Further experiments showed that miR-155 was reduced by the herb-pair and miRNA-155 inhibitor induced cell apoptosis and suppressed Akt activation.	26989427
4282	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	blood-brain barrier (BBB) dysfunction	human brain endothelium	lipopolysaccharide (LPS) treatment	upregulated	24604078
4283	Human	hsa-miR-155	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-7 cells	estradiol-17¦Â (E2) treatment	upregulated	23568502
4284	Human	hsa-miR-155	miRNA	genistein	breast cancer	MDA-MB-435 and Hs578t breast cancer cells	genistein treatment	downregulated	26771440
4285	Human	hsa-miR-155	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
4286	Human	hsa-miR-155	miRNA	mastectomy	breast cancer	breast cancer tissues	mastectomy treatment	upregulated	25503185
4287	Human	hsa-miR-155	miRNA	oleuropein (OL)	breast cancer	MCF-7 cells	oleuropein treatment	Oleuropein significantly decreased expression of both miR-21 and miR-155 over time in a dose-dependent manner.	29905007
4288	Human	hsa-miR-155	miRNA	pomegranate polyphenolics	breast cancer	Human mammary carcinoma cell lines BT474 and MDA-MB-231	pomegranate polyphenolics treatment	downregulated	22941571
4289	Human	hsa-miR-155	miRNA	schizandrin A (SchA)	breast cancer	MDA-MB-231 cells	schizandrin A (SchA) treatment	SchA strikingly decreases miR-155.	32623835
4290	Human	hsa-miR-155	miRNA	silibinin (SB)	breast cancer	MCF-7 breast cancer cells	Silibinin treatment	downregulated	27066095
4291	Human	hsa-miR-155	miRNA	tamoxifen (TAM)	breast cancer	Human breast cancer tissues	Tamoxifen treatment	upregulated	26692956
4292	Human	hsa-miR-155	miRNA	wound fluids (WFs) from breast cancer patients	breast cancer	human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line	WFs treatment	upregulated	28943910
4293	Human	hsa-miR-155	miRNA	brucella Omp25	brucellosis	human Monocyte/Macrophages	brucella Omp25 treatment	upregulated	28694807
4294	Human	hsa-miR-155	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
4295	Human	hsa-miR-155	miRNA	polycyclic aromatic hydrocarbons (PAHs)	cardiovascular disease (CVD)	human umbilical cord vein cells (HUVECs)	polycyclic aromatic hydrocarbons (PAHs) treatment	upregulated	30144390
4296	Human	hsa-miR-155	miRNA	gliadinN	celiac disease (CD)	PBMCs; monocytes	gliadinN treatment	upregulated	31781909
4297	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell-to-cell communication	human aortic endothelial cells (ECs) and their transfer to recipient cells	tumor necrosis factor alpha (TNF-¦Á) treatment	differently regulation	25315114
4298	Human	hsa-miR-155	miRNA	diesel exhaust particle (DEP)	cellular protection and tumorigenesis	"A549, H358 and 293 T cell lines"	diesel exhaust particle (DEP) exposure	downregulated	28315615
4299	Human	hsa-miR-155	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32090104
4300	Human	hsa-miR-155	miRNA	telbivudine	chronic hepatitis B virus (HBV) infection	CHB patients peripheral blood mononuclear cells (PBMCs)	telbivudine treatment	upregulated in peripheral blood mononuclear cells (PBMCs)	29018442
4301	Human	hsa-miR-155	miRNA	telbivudine or peg-IFN-¦Á-2a	chronic hepatitis B virus (HBV) infection	CHB patients peripheral blood mononuclear cells (PBMCs)	telbivudine or peg-IFN-¦Á-2a treatment	downregulated in peripheral blood mononuclear cells (PBMCs)	29018442
4302	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	chronic inflammatory diseases	human bronchial epithelial cells 16HBE	lipopolysaccharide (LPS) treatment	upregulated	30905633
4303	Human	hsa-miR-155	miRNA	hypoxia	chronic kidney disease (CKD)	HK-2 cells	chronic intermittent hypoxia (CIH) treatment	upregulated	29953588
4304	Human	hsa-miR-155	miRNA	IL-4	chronic lymphocytic leukemia (CLL)	MEC-1 cells	interleukin (IL)-4 treatment	upregulated	31289477
4305	Human	hsa-miR-155	miRNA	smoking	chronic obstructive pulmonary disease (COPD)	lung tissues	smoking treatment	MiR-155 expression was significantly increased in lung tissue of smokers and patients with COPD compared to never smokers	31819170
4306	Human	hsa-miR-155	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	human colorectal cancer HCT-116 and HT-29 cells	5-fluorouracil (5-FU) treatment	downregulated	28515355
4307	Human	hsa-miR-155	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
4308	Human	hsa-miR-155	miRNA	TGF-¦Â1	colorectal cancer (CRC)	colorectal cancer cells	TGF-¦Â1 treatment	upregulated	27626488
4309	Human	hsa-miR-155	miRNA	surgery and chemotherapy	colorectal cancer (CRC)	patients blood	surgery and chemotherapy for 3years treatment	upregulated	24310813
4310	Human	hsa-miR-155	miRNA	NOD2-agonist muramyl dipeptide	crohn disease (CD)	Crohn's disease patients without NOD2 mutations monocytes	NOD2-agonist muramyl dipeptide treatment	downregulated in monocytes	29263823
4311	Human	hsa-miR-155	miRNA	Staphylococcus aureus enterotoxins (SE)	cutaneous T-cell lymphoma (CTCL)	primary malignant T cells	Staphylococcus aureus enterotoxins (SE) treatment	"Here, we show that SE induce expression of the oncogenic microRNA mir-155 in primary malignant T cells"	33862068
4312	Human	hsa-miR-155	miRNA	oligosaccharide nanomedicine of alginate sodium (ONAS)	degenerative lumbar disease (DLD)	serum	oral administration of 100 mg ONAS daily)	downregulated	29200854
4313	Human	hsa-miR-155	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	Huh-7 cells	dengue virus (DENV) infection	downregulated	32277848
4314	Human	hsa-miR-155	miRNA	high glucose (HG)	diabetic foot ulcer (DFU)	primary endothelial progenitor cells (EPCs)	high glucose treatment	upregulated	29545091
4315	Human	hsa-miR-155	miRNA	angiotensin II (Ang II)	diabetic nephropathy (DN)	human vascular endothelial cells	angiotensin II (Ang II) treatment	downregulated	23174997
4316	Human	hsa-miR-155	miRNA	high glucose and free fatty acids (HG-FFA)	diabetic osteoporosis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	high glucose and free fatty acids (HG-FFA) treatment	miR-155 levels in hBMSCs increased corresponding to the time of exposure to HG-FFA treatment.	32248286
4317	Human	hsa-miR-155	miRNA	vincristine (VCR)	diffuse large B-cell lymphoma (DLBCL)	DLBCL cell lines	vincristine treatment	miR-155 as highly expressed in vincristine-sensitive DLBCL cell lines compared with resistant ones	30967394
4318	Human	hsa-miR-155	miRNA	hydroquinone (HQ)	DNA damage	TK6 lymphoblastoid cells	Hydroquinone (HQ) treatment	upregulated	30448557
4319	Human	hsa-miR-155	miRNA	hydroquinone (HQ)	DNA damage	TK6 lymphoblastoid cells	Hydroquinone (HQ) treatment	miR-155 was significantly increased.	30448557
4320	Human	hsa-miR-155	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
4321	Human	hsa-miR-155	miRNA	angiotensin II (Ang II)	endothelial inflammation and migration	human umbilical vein endothelial cells (HUVECs) ;vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	upregulated	21310411
4322	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial senescence	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31752013
4323	Human	hsa-miR-155	miRNA	TGF-¦Â	cardiac fibrosis	human coronary artery endothelial cells (HCAECs)	TGF-¦Â treatment	upregulated	28607031
4324	Human	hsa-miR-155	miRNA	dexamethasone (DEX)	eosinophilic chronic rhinosinusitis with nasal polyps	rhinal tissues	dexamethasone (DEX) treatment	DEX treatment inhibited the expression of cytokines and decreased the relapse rate of Eos CRSwNP via inhibiting NF-kappaB/miR-155.	32614806
4325	Human	hsa-miR-155	miRNA	remnant-like lipoproteins (RLPs)	ePCs senescence	Total peripheral mononuclear cells (PB-MNCs)	Remnant-like lipoproteins (RLPs) treatment	miR-148b and miR-155 were upregulated while miR-574-3p was downregulated	23044309
4326	Human	hsa-miR-155	miRNA	F. novicida	F. novicida?infection	Human peripheral blood monocytes (PBM)	F. novicida?infection	downregulated	20041145
4327	Human	hsa-miR-155	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
4328	Human	hsa-miR-155	miRNA	fluoride	fluorosis	sodium fluoride (NaF) treated human osteosarcoma (HOS) cells	fluoride treatment	miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor ¦Ê-B ligand (RANKL) genes	26339601
4329	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	follicle development and oocyte maturation	human endothelial cells	TNF¦Á treatment	upregulated	21982894
4330	Human	hsa-miR-155	miRNA	phorbol-12-myristate-13-acetate(PMA)	functions of human macrophages	U937 cells	phorbol 12-myristate 13-acetate (PMA) treatment	upregulated	33268675
4331	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GES-1 cells	Helicobacter pylori (H. pylori) infection	upregulated	31162747
4332	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	gastritis	Blood	H. pylori treatment	upregulated	26191144
4333	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	gastritis	gastric lesions	Helicobacter pylori treatment	upregulated	30219037
4334	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	gingival inflammation	Human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	29407755
4335	Human	hsa-miR-155	miRNA	metformin (Met)	glioblastoma multiforme (GBM)	U87 cells	metformin(Met) treatment	downregulated	33059952
4336	Human	hsa-miR-155	miRNA	melatonin	glioblastoma multiforme (GBM)	"human glioma cell lines U87, U373 and U251"	"melatonin (100¦ÌM, 1¦ÌM and 1nM)"	downregulated	28724215
4337	Human	hsa-miR-155	miRNA	monosodium urate (MSU)	gout	Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) from acute gouty arthritis patients	monosodium urate (MSU) treatment	upregulated	24708712
4338	Human	hsa-miR-155	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	human	hepatitis B virus (HBV)infection	downregulated	27110261
4339	Human	hsa-miR-155	miRNA	borna disease virus (BDV)	borna disease virus (BDV) infection	human oligodendroglial	borna disease virus (BDV)?infection	downregulated	23428672
4340	Human	hsa-miR-155	miRNA	recombinant Schistosoma japonicum egg antigen P40 (rSjP40)	liver fibrosis	LX-2 cells	recombinant Schistosoma japonicum egg antigen P40 (rSjP40) treatment	microRNA-155 was raised in rSjP40-treated HSCs	30091834
4341	Human	hsa-miR-155	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	HepG2 cells	hepatitis B virus (HBV) infection	miR-155 was inhibited on HBV infection.	31930529
4342	Human	hsa-miR-155	miRNA	arsenite	hepatocellular carcinoma (HCC)	L-02 cells	arsenite exposure	upregulated	29240254
4343	Human	hsa-miR-155	miRNA	pegylated interferon-¦Á (PEG-IFN)	hepatocellular carcinoma (HCC)	HepG2 cells	pegylated interferon-¦Á (PEG-IFN) treatment	downregulated	31036495
4344	Human	hsa-miR-155	miRNA	hepatitis C virus (HCV)	liver damage	monocytes	hepatitis C virus (HCV) infection	Serum levels of miR-122 were elevated in cHCV patients and correlated with increased ALT and AST levels and serum miR-155 levels	22846613
4345	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	herpes simplex virus 1 (HSV-1) infection	human umbilical vein endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23108656
4346	Human	hsa-miR-155	miRNA	Shenqi pollen capsules (SPCs)	high-altitude deacclimatization syndrome (HADAS)	serum	Shenqi pollen capsules (SPCs) treatment	downregulated	31828172
4347	Human	hsa-miR-155	miRNA	follicle stimulating hormone (FSH)	high-grade serous ovarian carcinomas (HGSOC)	fallopian tube secretory epithelial cells (FTSECs)	follicular fluid (FF) treatment	upregulated	32614381
4348	Human	hsa-miR-155	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
4349	Human	hsa-miR-155	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
4350	Human	hsa-miR-155	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
4351	Human	hsa-miR-155	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
4352	Human	hsa-miR-155	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
4353	Human	hsa-miR-155	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
4354	Human	hsa-miR-155	miRNA	S-amlodipine	hypertension	human umbilical vein endothelial cells (HUVECs)	S-amlodipine treatment	downregulated	30951948
4355	Human	hsa-miR-155	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	upregulated	29516639
4356	Human	hsa-miR-155	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	downregulated	29516639
4357	Human	hsa-miR-155	miRNA	Ig-like transcript 3 (ILT3)	immune inflammatory	human CD8(+) T suppressor cells	Ig-like transcript 3 (ILT3) treatment	upregulated	22387553
4358	Human	hsa-miR-155	miRNA	IFN-¦Ã	immunoregulatory function	MSCs	IFN¦Ã treatment	upregulated	23449975
4359	Human	hsa-miR-155	miRNA	IL-1¦Â	immunoregulatory function	MSCs	IL-1¦Â treatment	upregulated	23449975
4360	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	immunoregulatory function	MSCs	TNF¦Á treatment	upregulated	23449975
4361	Human	hsa-miR-155	miRNA	steroids	immune thrombocytopenic purpura (ITP)	peripheral blood mononuclear cells of ITP patients	steroid therapy treatment	downregulated	25413124
4362	Human	hsa-miR-155	miRNA	corticosterone	immunosuppression	Su-DHL4 cells	corticosterone (CORT) treatment	downregulated	30414952
4363	Human	hsa-miR-155	miRNA	cocaine	HIV-induced immunopathogenesis	peripheral blood mononuclear cells (PBMC)	Cocaine treatment	downregulated	24391808
4364	Human	hsa-miR-155	miRNA	vibrio cholerae O1	infection of Vibrio cholerae O1	colon carcinoma cell line T84	infect with Vibrio cholerae O1 treatment	upregulated at acute stage of V cholerae infection and declined to normal at convalescent stage	28319200
4365	Human	hsa-miR-155	miRNA	alternariol (AOH)	inflammation	THP-1 cells	alternariol (AOH) treatment	upregulated	30175388
4366	Human	hsa-miR-155	miRNA	cold	inflammation	LPS-induced human monocytes	exposure to cold (32¡ãC) treatment	upregulated	25231976
4367	Human	hsa-miR-155	miRNA	crataegus special extract WS 1442	inflammation	Human umbilical vein endothelial cells (HUVECs)	Crataegus Special Extract WS 1442 treatment	upregulated	29660753
4368	Human	hsa-miR-155	miRNA	curcumin (Cur)	inflammation	LPS-induced THP-1 cells	curcumin treatment	downregulated	28264607
4369	Human	hsa-miR-155	miRNA	glucocorticoid (GC)	inflammation	RAW264.7 cells	Glucocorticoids (GCs) treatment	downregulated	22326887
4370	Human	hsa-miR-155	miRNA	helicobacter pylori (H. pylori)	inflammation	Human gastric cancer cell line AGS and human embryonickidney HEK-293 cell	Helicobacter pylori infection	upregulated	20219467
4371	Human	hsa-miR-155	miRNA	interferon regulatory factor 3 (IRF3)	inflammation	primary human astrocytes	Interferon regulatory factor 3 (IRF3) treatment	downregulated	22170100
4372	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	HUVECs	lipopolysaccharide (LPS) treatment	upregulated	28664667
4373	Human	hsa-miR-155	miRNA	nitric oxide (NO)	inflammation	human liver epithelial (HepG2) cells	the NO-releasing S-nitroso-N-acetylpenicillamine (SNAP) 100 ¦ÌM for 4 h treatment	MiR-155 was the only miRNA of the 887 arrayed that showed a change in expression after SNAP ment.	24687397
4374	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	PMA-preprocessed THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	"overexpression of miR-155 promoted the activation of the ox-LDL-induced NLRP3 inflammasome, which could also be blocked by the ERK inhibitor U0126."	31865729
4375	Human	hsa-miR-155	miRNA	IFN-¦Ã and TNF-¦Á	inflammation	human dermal lymphatic endothelial cells (HDLECs)	HDLECs with the treatment	upregulated	29066622
4376	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	Human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29660753
4377	Human	hsa-miR-155	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	human adipocytes	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
4378	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	colonic epithelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26752469
4379	Human	hsa-miR-155	miRNA	IFN-¦Ã and TNF-¦Á	inflammatory response	Normal human mesangial cells	IFN-¦Ã and TNF-¦Á treatment	upregulated	20948191
4380	Human	hsa-miR-155	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human pulmonary microvascular endothelial cells (HPMECs)	influenza A virus strain H1N1 infection	MiR-155 was elevated in response to the H1N1 infection in HPMECs (24 h post-infection.	32889908
4381	Human	hsa-miR-155	miRNA	candida albicans (C. albicans)	innate immune response	monocytes derived dendritic cells (DCs)	candida albicans infection	upregulated	32042774
4382	Human	hsa-miR-155	miRNA	"ferrylhemoglobin (ferrylHb, Fe4+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"ferrylhemoglobin (ferrylHb, Fe4+) treatment"	upregulated	32961661
4383	Human	hsa-miR-155	miRNA	heme	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	heme treatment	upregulated	32961661
4384	Human	hsa-miR-155	miRNA	"methemoglobin (metHb, Fe3+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"methemoglobin (metHb, Fe3+) treatment"	upregulated	32961661
4385	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32961661
4386	Human	hsa-miR-155	miRNA	panax notoginseng saponins (PNS)	ischemic stroke (IS)	SH-SY5Y cells	panax notoginseng saponins (PNS) treatment	"In OGD/R-induced SH-SY5Y cells, 160??g/mL PNS treatment promoted cell proliferation and cell cycle progression, as well as decreased inhibited apoptosis and miR-155 expression"	30587668
4387	Human	hsa-miR-155	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells	JEV infection treatment	upregulated	24522920
4388	Human	hsa-miR-155	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	human microglial CHME3 cells	JEV-infected treatment	upregulated	24885259
4389	Human	hsa-miR-155	miRNA	epstein-barr virus (EBV)	large B-cell lymphomas (DLBCLs)	"EBV-positive BL cell lines Mutu I; Mutu III; Namalwa; Raji,;the EBV-positive DLBCL cell line IBL-1; EBV-negative BJAB cell line;EBV-infected human peripheral blood mononuclear cells (PBMCs) and 293T cells"	Epstein-Barr virus (EBV) treatment	upregulated	20844043
4390	Human	hsa-miR-155	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
4391	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6e	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6e treatment	upregulated	29970309
4392	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6g	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6g treatment	downregulated	29970309
4393	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6u	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6u treatment	upregulated	29970309
4394	Human	hsa-miR-155	miRNA	anthraquinone-chalcone hybrids containing amide function compounds 6v	leukemia	K562 cells	anthraquinone-chalcone hybrids containing amide function compounds 6v treatment	downregulated	29970309
4395	Human	hsa-miR-155	miRNA	listeria monocytogenes (L. monocytogenes)	Listeria infection	Human epithelial cells (Caco-2)	Listeria infection	downregulated	22312311
4396	Human	hsa-miR-155	miRNA	arsenite	hepatocellular carcinoma (HCC)	L-02 and THLE-3 cells	arsenite exposure	upregulated	27913196
4397	Human	hsa-miR-155	miRNA	arsenite	hepatocellular carcinoma (HCC)	L-02 cells	arsenite exposure	upregulated	29240254
4398	Human	hsa-miR-155	miRNA	hypoxia	hepatocellular carcinoma (HCC)	A549 cells	hypoxia trreatment	upregulated	22027557
4399	Human	hsa-miR-155	miRNA	NO-releasing S-nitroso-N-acetylpenicillamine	liver inflammation and cancer	human liver epithelial (HepG2) cells	NO-releasing S-nitroso-N-acetylpenicillamine (SNAP) 100 ¦ÌM for 4 h a treatment	differerntlly expressed	24687397
4400	Human	hsa-miR-155	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
4401	Human	hsa-miR-155	miRNA	arsenic trioxide (ATO)	lung cancer	human lung adenocarcinoma cell line A549 cells	arsenic trioxide (ATO) treatment	downregulated	29260515
4402	Human	hsa-miR-155	miRNA	poly-lactic acid nanoparticles (PLA-NP)	lung cancer	human lung epithelial A549 cells	"PLA-NP for 24, 48 and 72 h treatment"	downregulated	28143572
4403	Human	hsa-miR-155	miRNA	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	NCI cells; FaDu cells	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment	upregulated	32326378
4404	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	Dendritic cells (DCs)	lipopolysaccharide (LPS) treatment	upregulated	27714813
4405	Human	hsa-miR-155	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
4406	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	monocytic differentiation	monocyte	lipopolysaccharide (LPS) treatment	dysregulated	25148686
4407	Human	hsa-miR-155	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	myeloma cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	in vitro methylation of part of the promoter and first exon abrogated the miR-155 expression	25497370
4408	Human	hsa-miR-155	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
4409	Human	hsa-miR-155	miRNA	autologous hematopoietic SCT(AHSCT)	multiple sclerosis (MS)	MS patients	AHSCT treatment	upregulated in T- and B-cell	25486582
4410	Human	hsa-miR-155	miRNA	torpedo acetylcholine receptor (T-AChR)	myasthenia gravis (MG)	B cells of MG patients	T-AChR treatment	upregulated	24387321
4411	Human	hsa-miR-155	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	myeloma	MM cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25497370
4412	Human	hsa-miR-155	miRNA	RNA-directed DNA methylation	myeloma	MM cell lines	Nucleofection with 141 siRNAs at a 20 nM concentration treatment	downregulated	25497370
4413	Human	hsa-miR-155	miRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma cell	EBV?infection	upregulated	24241359
4414	Human	hsa-miR-155	miRNA	latent membrane protein 1 (LMP1)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	latent membrane protein 1 (LMP1) treatment	upregulated	27123134
4415	Human	hsa-miR-155	miRNA	calcium oxalate (CaOx)	nephrolithiasis	HK-2 cells	calcium oxalate (CaOx) treatment	CaOx treatment caused upregulated of miR-155 and induced autophagy in renal tubular epithelial cells.	32417393
4416	Human	hsa-miR-155	miRNA	Toll-like receptor (TLR)	neurological diseases	U251 human astrocytoma cell line	Toll-like receptor (TLR) treatment	upregulated	25957996
4417	Human	hsa-miR-155	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
4418	Human	hsa-miR-155	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
4419	Human	hsa-miR-155	miRNA	chemoradiation therapy (CRT)	non-small cell lung cancer (NSCLC)	patients with stage IIIB-IV NSCLC	CRT treatment	upregulated	25466375
4420	Human	hsa-miR-155	miRNA	IFN-¦Ã	oral lichen planus (OLP)	EOLP CD4(+) T cells	IFN-¦Ã treatment	upregulated	26594049
4421	Human	hsa-miR-155	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human OA chondrocyte	"exposure to three hours of a cyclic HP (1-5 MPa, frequency 0.25 Hz)"	downregulated	29150345
4422	Human	hsa-miR-155	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	chondrocytes	hydrostatic pressure (HP) treatment	miR-155 and miR-181a resulted significantly downregulated immediately after pressurization (T0) in OA cells.	29150345
4423	Human	hsa-miR-155	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	The expression level of miR-155 in primary chondrocytes was drastically induced upon IL-1¦Â treatment.	32562373
4424	Human	hsa-miR-155	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
4425	Human	hsa-miR-155	miRNA	"rapamycin,2-deoxyglucose (2-DG)"	osteoarthritis (OA)	primary human articular chondrocytes and the T/C28a2 human chondrocyte cell line	primary human articular chondrocytes and the T/C28a2 human chondrocyte cell line treatment	upregulation	26805019
4426	Human	hsa-miR-155	miRNA	tanshinone IIA (Tan IIA)	osteoarthritis (OA)	human articular chondrocytes	?tanshinone IIA treatment	tanshinone IIA ameliorates inflammation response in OA via inhibition of the miR-155/FOXO3 axis	33395681
4427	Human	hsa-miR-155	miRNA	hepatitis C virus (HCV)	osteoblastic differentiation	Human hepatic tis-sues	hepatitis C virus (HCV) infection	upregulated	22610915
4428	Human	hsa-miR-155	miRNA	IFN-¦Â	osteoclast-mediated diseases	HEK293T cells	Interferon-¦Â treatment	upregulated	22771905
4429	Human	hsa-miR-155	miRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis from preosteoblasts	preosteoblast cell line MC3T3-E1	bone morphogenetic protein 2 (BMP2) treatment	downregulated	28473977
4430	Human	hsa-miR-155	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx9 treatment"	downregulated	21572246
4431	Human	hsa-miR-155	miRNA	adriamycin (ADR)	osteosarcoma (OS)	MG-63 cells	adriamycin (ADR) treatment	upregulated	29412697
4432	Human	hsa-miR-155	miRNA	cisplatin (DDP)	osteosarcoma (OS)	Human osteosarcoma cell lines (Saos-2 and MG-63)	cisplatin (DDP) treatment	upregulated	25009614
4433	Human	hsa-miR-155	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	Human osteosarcoma cell lines (Saos-2 and MG-63)	?doxorubicin (DOX) treatment	upregulated	25009614
4434	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteosarcoma (OS)	U2OS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31669646
4435	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteosarcoma (OS)	U2OS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á upregulated the miR-155 expression in U2OS cells	31669646
4436	Human	hsa-miR-155	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	human pancreatic cancer PANC-1 cells	gemcitabine (GEM) treatment	upregulated	20871480
4437	Human	hsa-miR-155	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
4438	Human	hsa-miR-155	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"PDAC cell lines (Panc1, MiaPaCa2, and PSN1 cell lines)"	long-term exposure of GEM	upregulated	28198398
4439	Human	hsa-miR-155	miRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	TPC-1 cells; IHH-4 cells	Radioiodine (131I) treatment	CASC2 increases 131I sensitivity in PTC by sponging miR-155	33134385
4440	Human	hsa-miR-155	miRNA	sevoflurane (SEV)	papillary thyroid cancer (PTC)	Human PTC cell lines (TPC-1 and IHH-4)	?Sevoflurane treatment	downregulated	31378899
4441	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	periodontitis	THP-1 cells	lipopolysaccharide (LPS) from porphyromonas gingivalis (Pg-LPS) treatment	downregulated	30012943
4442	Human	hsa-miR-155	miRNA	Staphylococcus aureus	post-viral bacterial pneumonia	lung macrophages	staphylococcus aureus (CA-MRSA) infection treatment	upregulated	26589478
4443	Human	hsa-miR-155	miRNA	aspirin	preeclampsia (PE)	TNF-¦Á-mediated human umbilical vein endothelial cells (HUVECs)	aspirin treatment	downregulated	28087411
4444	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	preeclampsia (PE)	HTR-8 cells;SVneo cells	?injection of lipopolysaccharides (LPS)	upregulated	21515911
4445	Human	hsa-miR-155	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
4446	Human	hsa-miR-155	miRNA	arsenite	pro-inflammatory activity	human hepatic epithelial (L-02) cells	arsenic exposure	upregulated	27913196
4447	Human	hsa-miR-155	miRNA	paclitaxel (PTX)	prostate cancer	DU145 and PC-3 cells	paclitaxel treatment	downregulated	28599307
4448	Human	hsa-miR-155	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in PBMCs	27535005
4449	Human	hsa-miR-155	miRNA	TGF-¦Â	lung fibrosis	human pulmonary fibroblasts	TGF-¦Â treatment	miR-155 expression was decreased in human pulmonary fibroblasts by TGF-¦Â treatment	31556264
4450	Human	hsa-miR-155	miRNA	porphyromonas gingivalis	pyroptosis	The immortalized human monocyte cell line U937	Porphyromonas gingivalis infection treatment	upregulated	31529565
4451	Human	hsa-miR-155	miRNA	hypoxia	renal fibrosis	HK-2 cells	Hypoxia treatment	upregulated	25672593
4452	Human	hsa-miR-155	miRNA	tanshinone IIA (Tan IIA)	renal fibrosis	HCT116 cells; HT-29 cells	TanshinoneIIA treatment	upregulated	22982040
4453	Human	hsa-miR-155	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	30080287
4454	Human	hsa-miR-155	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	28006785
4455	Human	hsa-miR-155	miRNA	particulate matter (PM2.5)	respiratory injury	human bronchial epithelial (HBE) cells	"fine particulate matter (PM2.5, particles <2.5?¦Ìm in size) exposure treatment"	upregulated	31185220
4456	Human	hsa-miR-155	miRNA	hepatitis C virus (HCV)	rheumatoid arthritis (RA)	serum	hepatitis C virus (HCV) infection	The exo-miR-155 levels were significantly increased in RA patients with HCV infection compared with those without infection	29575671
4457	Human	hsa-miR-155	miRNA	silibinin (SB)	rheumatoid arthritis (RA)	peripheral blood T lymphocytes	silibinin treatment	downregulated	30174672
4458	Human	hsa-miR-155	miRNA	TGF-¦Â	rheumatoid arthritis (RA)	RA fibroblast-like synoviocytes (FLS)	50 ng/mL of tumor necrosis factor alpha (TNF-¦Á) for 1 h treatment	downregulated	28401267
4459	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29693176
4460	Human	hsa-miR-155	miRNA	triptolide (TPL)	rheumatoid arthritis (RA)	monocytes pre-stimulated by lipopolysaccharide (LPS) from rheumatoid arthritis (RA) patients	triptolide (TPL) treatment	downregulated	24909288
4461	Human	hsa-miR-155	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
4462	Human	hsa-miR-155	miRNA	Salmonella Typhimurium	salmonella typhimurium infection	human HeLa cells	Salmonella Typhimurium infection treatment	upregulated	21468030
4463	Human	hsa-miR-155	miRNA	valproic acid (VPA)	seizure	cerebrospinal fluid (CSF)	valproic acid (VPA) treatment	downregulated	29115566
4464	Human	hsa-miR-155	miRNA	dexamethasone (DEX)	septic shock	T lymphocytes	dexamethasone (DEX) treatment	downregulated	28105104
4465	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	septic shock	human internal mammary artery (hIMA) rings	lipopolysaccharide (LPS) treatment	upregulated	29979224
4466	Human	hsa-miR-155	miRNA	hydroxychloroquine	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	hydroxychloroquine treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs."	24121037
4467	Human	hsa-miR-155	miRNA	prednisone	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	prednisone treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs"	24121037
4468	Human	hsa-miR-155	miRNA	IFN-¦Á	systemic lupus erythematosus (SLE)	HUVECs	IFN-¦Á treatment	upregulated	28779021
4469	Human	hsa-miR-155	miRNA	thyroid stimulating hormone	thyroid eye disease (TED)	orbital fibroblasts (OFs)	thyroid stimulating hormone treatment	upregulated	31622470
4470	Human	hsa-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	serum	Mycobacterium tuberculosis (M.TB) treatment	downregulated	28061948
4471	Human	hsa-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human primary dendritic cells (DC)	?Mycobacterium tuberculosis (Mtb) infection	upregulated	29300789
4472	Human	hsa-miR-155	miRNA	IL-1¦Â	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	interleukin (IL)-1¦Â treatment	downregulated	29467762
4473	Human	hsa-miR-155	miRNA	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	LPS-treated primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	inositol-requiring enzyme 1 (IRE1) inhibitor (4u8C) treatment	downregulated	29467762
4474	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	tumor necrosis factor (TNF)-receptor-associated periodic fever syndrome (TRAPS)	Primary dermal fibroblasts (DFs) were isolated from skin biopsies of healthy controls (HC)	lipopolysaccharide (LPS) treatment	upregulated	29467762
4475	Human	hsa-miR-155	miRNA	lipopolysaccharide (LPS)	type 2 diabetes mellitus (T2DM)	peripheral blood mononuclear cells (PBMC)	lipopolysaccharide (LPS) treatment	downregulated	23616185
4476	Human	hsa-miR-155	miRNA	propofol (PPF)	unilateral ureteral obstruction (UUO)	HK-2 cells	HK-2 cells treatment	downregulated	27158339
4477	Human	hsa-miR-155	miRNA	alprostadil	uremia	peripheral blood	alprostadil treatment	downregulated	26267685
4478	Human	hsa-miR-155	miRNA	palmitate	vascular endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	palmitate treatment	downregulated	31485611
4479	Human	hsa-miR-155	miRNA	adrenaline	vascular injury	HT29 cells	adrenaline treatment	upregulated	23036199
4480	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	vascular injury	human endothelial	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	24769202
4481	Human	hsa-miR-155	miRNA	everolimus	waldenstrom macroglobulinemia	Primary Waldenstrom macroglobulinemia cells	Everolimus treatment	downregulated	23048077
4482	Human	hsa-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	21030878
4483	Human	hsa-miR-155	miRNA	hypoxia	autophagy	CNE cells ;HeLa cells	hypoxia treatment	upregulated	24262949
4484	Human	hsa-miR-155	miRNA	IL-10	breast cancer	human bronchial epithelial cells (hBECs)	IL-10 treatment	downregulated	23967196
4485	Human	hsa-miR-155	miRNA	IL-4	cell differentiation	human embryonic stem cells	IL-4 ? treatment	downregulated	21388667
4486	Human	hsa-miR-155	miRNA	IL-1¦Â	epithelial-mesenchymal transition (EMT)	lung fibroblasts	IL-1¦Â treatment	upregulated	19701459
4487	Human	hsa-miR-155	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	lung fibroblasts	?TGF-¦Â? treatment	downregulated	19701459
4488	Human	hsa-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	epithelial-mesenchymal transition (EMT)	lung fibroblasts	tumor necrosis factor alpha (TNF-¦Á) treatment	up regulation	19701459
4489	Human	hsa-miR-155	miRNA	type I interferon (IFN)	hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	type I interferon (IFN) treatment	upregulated	23650597
4490	Human	hsa-miR-155*	miRNA	mycobacterium tuberculosis (Mtb)	active tuberculosis (ATB)	PBMCs (peripheral blood mononuclear cells)	Mycobacterium tuberculosis (MTB) infection	upregulated	22037148
4491	Human	hsa-miR-155*	miRNA	lipopolysaccharide (LPS)	B-cell lymphomas	HTR-8/SVneo cells	lipopolysaccharide (LPS)? treatment	upregulated	23684381
4492	Human	hsa-miR-155*	miRNA	interferon regulatory factor 3 (IRF3)	inflammation	primary human astrocytes	Interferon regulatory factor 3 (IRF3) treatment	downregulated	22170100
4493	Human	hsa-miR-155-2	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human thyroid	infect with HHV-6A	downregulated	28081700
4494	Human	hsa-miR-155-3p	miRNA	lithium (Li)	bipolar disorder (BD)	lymphoblastoid cell lines	Lithium treatment	dysregulated	31801218
4495	Human	hsa-miR-155-3p	miRNA	lipopolysaccharide (LPS)	innate immune response	primary human monocyte-derived macrophages (1¡ãMDMs)	lipopolysaccharide (LPS) treatment	upregulated	31641696
4496	Human	hsa-miR-155-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	mantle cell lymphoma (MCL)	MCL cell line (REC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25211095
4497	Human	hsa-miR-155-3p	miRNA	"RESMENA (reduction of metabolic syndrome in Navarra, Spain)"	metabolic syndrome	MetS patients white blood cells (WBC)	RESMENA treatment	"miR-155-3p was decreased ,miR-Let-7b was strongly upregulated in white blood cells (WBC)"	26421388
4498	Human	hsa-miR-155-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
4499	Human	hsa-miR-155-5p	miRNA	H2O2	abdominal aortic aneurysm (AAA)	vascular smooth muscle cells (VSMCs)	H2O2 treatment	upregulated	30898623
4500	Human	hsa-miR-155-5p	miRNA	NaAsO2	abdominal aortic aneurysm (AAA)	vascular smooth muscle cells (VSMCs)	NaAsO2 treatment	upregulated	30898623
4501	Human	hsa-miR-155-5p	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
4502	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atopic dermatitis (AD)	HaCaT cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31767859
4503	Human	hsa-miR-155-5p	miRNA	lipopolysaccharide (LPS)	bronchopneumonia	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"NEAT1 and MyD88 were upregulated in BEAS-2B cells by LPS, while miR-155-5p was downregulated."	33719773
4504	Human	hsa-miR-155-5p	miRNA	oxalate and calcium	calcium oxalate (CaOx) stone	HK-2 cells	Oxalate and calcium treatment	miR-155-5p was significantly upregulated after oxalate and COM treated in HK-2 cells.	32215174
4505	Human	hsa-miR-155-5p	miRNA	(-)-epigallocatechin gallate (EGCG)	colorectal cancer (CRC)	"human colon carcinoma cell line-HCT-116, DLD1"	(-)-Epigallocatechin gallate (EGCG) treatment	upregulated	30741544
4506	Human	hsa-miR-155-5p	miRNA	enterotoxigenic bacteroides fragilis (ETBF)	colorectal cancer (CRC)	HCT-116 and DLD-1 cells	Enterotoxigenic Bacteroides fragilis (ETBF) infection	downregulated	31515468
4507	Human	hsa-miR-155-5p	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	human monocyte-derived macrophages (MDM) differentiated in absence or presence of vitamin D (D3-MDM)	dengue virus (DENV) infection	vitamin D in the control of inflammatory cytokine responses during DENV infection of human macrophages via the TLR4/NF-¦ÊB/miR-155-5p/SOCS-1 axis	30639520
4508	Human	hsa-miR-155-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	"CTBP1-AS2 attenuated HG-induced HGMC proliferation, oxidative stress, ECM accumulation, and inflammation through miR-155-5p/FOXO1 signaling."	32868076
4509	Human	hsa-miR-155-5p	miRNA	BAY11-7082	EBV-associated gastric cancer (EBVaGC)	GT39 cells	NF-¦ÊB inhibitor (BAY 11-7082) treatment	downregulated	31469179
4510	Human	hsa-miR-155-5p	miRNA	epstein-barr virus (EBV)	EBV-associated gastric cancer (EBVaGC)	SGC7901 cells	EBV-encoded latent membrane protein 2A (LMP2A) treatment	upregulated	31469179
4511	Human	hsa-miR-155-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal cancer (EC)	KYSE-30 cells; KYSE-140 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-155-5p was upregulated in the indicated ESCC cell lines following treatment with 5-aza-dC for 72 h.	32323857
4512	Human	hsa-miR-155-5p	miRNA	epstein-barr virus (EBV)	gastric cancer (GC)	GT38 cells; GT39 cells; SNU719 cells	Epstein-Barr virus (EBV) infection	The expression level of miR-155-5p in the EBV-positive cell lines was significantly higher than that in the EBV-negative cell lines	31469179
4513	Human	hsa-miR-155-5p	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	serum	Enterovirus 71 (EV71) infection	microRNA-155-5p (miR-155-5p) was found to be significantly upregulated in serum from patients with EV71 infection.	31856677
4514	Human	hsa-miR-155-5p	miRNA	R-pulegone (PUL)	hepatotoxicity	liver tissues	R-pulegone (PUL) treatment	downregulated	29921785
4515	Human	hsa-miR-155-5p	miRNA	olive oil polyphenol hydroxytyrosol (HT)	inflammation	TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	olive oil polyphenol hydroxytyrosol (HT) treatment	downregulated	31627295
4516	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31627295
4517	Human	hsa-miR-155-5p	miRNA	carbon monoxide-releasing compound CORM-2	inflammatory vascular disorders	TNF-¦Á-stimulated HUVECs	200?¦Ìm CORM-2 treatment	downregulated	29170479
4518	Human	hsa-miR-155-5p	miRNA	enterovirus 71 (EV71)	innate immune response	"serum from patients with EV71 infection, Vero, RD, HT-29, HeLa, and THP-1 cells"	Enterovirus 71 (EV71) infection	upregulated	31856677
4519	Human	hsa-miR-155-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-155-5p was upregulated in OGD/R-induced SH-SY5Y cells.	32096190
4520	Human	hsa-miR-155-5p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
4521	Human	hsa-miR-155-5p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
4522	Human	hsa-miR-155-5p	miRNA	X-rays	non-small cell lung cancer (NSCLC)	Human NSCLC A549 and H460 cells	"cells were irradiated using experimental X-ray irradiator (Gulmay Medical Inc., Atlanta, GA, xstrahl.com) at a rate of 2.4 Gy/min for the time required treatment"	upregulated	30901121
4523	Human	hsa-miR-155-5p	miRNA	oleacein (OA)	obesity	TNF-¦Á-treated Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleacein (OA) treatment	downregulated	31766503
4524	Human	hsa-miR-155-5p	miRNA	oleocanthal (OC)	obesity	TNF-¦Á-treated Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleocanthal (OC) treatment	downregulated	31766503
4525	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31766503
4526	Human	hsa-miR-155-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-10¦Â treatment	dysregulated	29123165
4527	Human	hsa-miR-155-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
4528	Human	hsa-miR-155-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oxidative stress	HTR-8/SVneo cell line	mono-(2-ethylhexyl) phthalate (MEHP) treatment	upregulation	26871967
4529	Human	hsa-miR-155-5p	miRNA	sulforaphane (SFN)	pancreatic cancer (PC)	Monocyte-Derived Dendritic Cells	sulforaphane (SFN) treatment	upregulated	33193420
4530	Human	hsa-miR-155-5p	miRNA	porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS)	periodontitis	The exosomes were extracted from periodontal ligament stem cells (PDLSCs)	Porphyromonas gingivalis lipopolysaccharide (LPS) treatment	downregulated	31016751
4531	Human	hsa-miR-155-5p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
4532	Human	hsa-miR-155-5p	miRNA	radiation	radiation-induced pulmonary fibrosis (RIPF)	BEAS-2B cells	radiation treatment	adiation downregulates miR-155-5p in alveolar epithelial cells that induces EMT	33259794
4533	Human	hsa-miR-155-5p	miRNA	radiation	radiation-induced pulmonary fibrosis (RIPF)	A549 cells; BEAS-2B cells	radiation treatment	we found that miR-155-5p was significantly downregulated through high-throughput sequencing	33259794
4534	Human	hsa-miR-155-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	whole-blood	methotrexate (MTX) treatment	downregulated	30511295
4535	Human	hsa-miR-155-5p	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	RA patients whole-blood	methotrexate (MTX) treatment	upregulated	30511295
4536	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	Fibroblast-like synoviocytes (FLSs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-¦Á	32289665
4537	Human	hsa-miR-155-5p	miRNA	Korean Red ginseng extract (KRGE)	cell senescence	human umbilical vein endothelial cells (HUVECs)	Korean Red ginseng extract (KRGE) treatment	"miR-155-5p levels were increased in senescent HUVECs compared to young cells, and this increase was blocked by KRGE."	33841015
4538	Human	hsa-miR-155-5p	miRNA	nuclear factor kappa-B (NF-¦ÊB) inhibitor Bay11-708211	cell senescence	human umbilical vein endothelial cells (HUVECs)	NF-kB inhibitor Bay11-708211 treatment	"miR-155-5p levels were increased in senescent HUVECs compared to young cells, and this increase was blocked by the NF-kB inhibitor Bay11-708211."	33841015
4539	Human	hsa-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	rheumatoid synovial fibroblasts (RASFs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28807007
4540	Human	hsa-miR-155-5p	miRNA	ARS labeled titanium dioxide nanoparticles (nano-TiO 2-ARS)	toxicity of nanoparticles	THP-1 cells	ARS labeled Titanium dioxide nanoparticles (nano-TiO 2-ARS) treatment	downregulated	32284792
4541	Human	hsa-miR-155-5p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
4542	Human	hsa-miR-155-5p	miRNA	bufalin	triple negative breast cancer (TNBC)	MDA-MB-231 and MCF-7/ADR TNBC cell lines	bufalin treatment	upregulated	26398931
4543	Human	hsa-miR-155-5p	miRNA	Indoxyl sulfate (IS)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	Indoxyl sulfate (IS) treatment	upregulated	32979364
4544	Human	hsa-miR-155-5p	miRNA	Korean Red ginseng extract (KRGE)	vascular disease	human umbilical vein endothelial cells (HUVECs)	korean red ginseng extract (KRGE)? treatment	The beneficial effects of KRGE were due to the induction of HO-1 and the inhibition of NF-¦ÊB-dependent biogenesis of miR-155-5p that led to the downregulated of eNOS.	33841015
4545	Human	hsa-miR-155a	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	hepatitis C virus (HCV) infection	miR-155a expression was upregulated in HCV-infected PBMC.	31696995
4546	Human	hsa-miR-155a	miRNA	chuyou yuyang granule (CYYY)	ulcer relapse	Helicobacter pylori (HP) infected Peptic ulcert patients blood	Chuyou Yuyang granule (CYYY) four weeks or six weeks treatment	downregulated	31034651
4547	Human	hsa-miR-1587	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
4548	Human	hsa-miR-1587	miRNA	botulinum toxin A (BTXA)	keloids	human skin keloid fibroblasts (HSFBs)	botulinum toxin A (BTXA) treatment	upregulated	31652445
4549	Human	hsa-miR-15a	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
4550	Human	hsa-miR-15a	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
4551	Human	hsa-miR-15a	miRNA	recombinant tissue plasminogen activator (rt-PA)	acute ischemic stroke (AIS)	AIS patients blood samples	rt-PA treatment	upregulation of let-7i and downregulated of miR-15a	28892656
4552	Human	hsa-miR-15a	miRNA	prednisolone	acute lymphoblastic leukemia (ALL)	CCRF-CEM cell line	Prednisolone treatment	upregulated	27281445
4553	Human	hsa-miR-15a	miRNA	resveratrol	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	resveratrol (RS) treatment	upregulated	26434860
4554	Human	hsa-miR-15a	miRNA	H2O2	age-related cataract (ARC)	"human lens epithelial B3 cells, HLE-B3 cells"	H2O2 treatment	upregulated	31737898
4555	Human	hsa-miR-15a	miRNA	BL-8040	apoptosis	human acute myeloid leukemia (AML) blasts	BL-8040 treatment	upregulated	28280274
4556	Human	hsa-miR-15a	miRNA	aloe-emodin (AE)	breast cancer	MCF-10AT cells; MCF-7 cells	aloe-emodin (AE) treatment	upregulated	32190086
4557	Human	hsa-miR-15a	miRNA	bleomycin (BLM)	breast cancer	human breast cancer cell lines MCF-7 cells and/or MDA-MB-231 cells	bleomycin (BLM) treatment	upregulated	28337296
4558	Human	hsa-miR-15a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin (diferuloylmethane)? treatment	upregulated	19908170
4559	Human	hsa-miR-15a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
4560	Human	hsa-miR-15a	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
4561	Human	hsa-miR-15a	miRNA	tripterine	breast cancer	MDA-MB-231 cells	Tripterine treatment	upregulated	30913029
4562	Human	hsa-miR-15a	miRNA	IL-23	cardiomyocyte apoptosis	B-acute lymphoblastic leukemia cells	IL-23 treatment	upregulated	20671120
4563	Human	hsa-miR-15a	miRNA	doxorubicin (DOX)	chemoresistance of lymphoma	Daudi and Namalwa cells	doxorubicin treatment	MCM3AP-AS1/miR-15a/EIF4E axis plays a role in the chemoresistance of Burkitt lymphoma	32765087
4564	Human	hsa-miR-15a	miRNA	imatinib	chronic myeloid leukemia (CML)	CML patients	imatinib (IM) treatment	differently regulated	24629639
4565	Human	hsa-miR-15a	miRNA	taxol	colorectal cancer (CRC)	HCT116 cells	taxol treatment	downregulated	30126852
4566	Human	hsa-miR-15a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Primary human retinal endothelial cells (REC)	high glucose (HG) treatment	downregulated	29339083
4567	Human	hsa-miR-15a	miRNA	resveratrol	diabetic retinopathy (DR)	high glucose-treated primary human retinal endothelial cells (REC)	resveratrol (RSV) treatment	upregulated	29339083
4568	Human	hsa-miR-15a	miRNA	D-glucose	epithelial-mesenchymal transition (EMT)	peritoneal mesothelial cells (PMCs)	D-glucose treatment	downregulated	25683944
4569	Human	hsa-miR-15a	miRNA	H2O2	gastric cancer (GC)	HGC-27 cells	H2O2 treatment	upregulated	33329376
4570	Human	hsa-miR-15a	miRNA	Helicobacter pylori (H. pylori) extract (HPE)	gastric cancer (GC)	HGC-27 cells	Helicobacter pylori (H. pylori) infection	upregulated	33065487
4571	Human	hsa-miR-15a	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
4572	Human	hsa-miR-15a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	30103211
4573	Human	hsa-miR-15a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; HepG2.2.15 cells; human normal liver cell line L-02	hepatitis B virus (HBV) infection	upregulated	24089558
4574	Human	hsa-miR-15a	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
4575	Human	hsa-miR-15a	miRNA	curcumin (Cur)	laryngeal cancer	human laryngeal cancer cells	curcumin treatment	upregulated	29085504
4576	Human	hsa-miR-15a	miRNA	curcumin (Cur)	leukemia	primary acute myeloid leukemia (AML) cells	Pure curcumin treatment	downregulated	22449094
4577	Human	hsa-miR-15a	miRNA	bortezomib	multiple myeloma (MM)	The human multiple myeloma cell lines U266 and NCI-H929	bortezomib? treatment	"via suppressing miRNA-15a expression, BMSCs provide survival support and protect myeloma cells from bortezomib induced apoptosis"	21534877
4578	Human	hsa-miR-15a	miRNA	IL-6	multiple myeloma (MM)	bone marrow mesenchymal stem cells(BMSCs)	interleukin-6 (IL-6) treatment	"via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells"	21936961
4579	Human	hsa-miR-15a	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
4580	Human	hsa-miR-15a	miRNA	hypoxia	osteosarcoma (OS)	MG63 human osteosarcoma cell line	hypoxia induce	downregulated	29484432
4581	Human	hsa-miR-15a	miRNA	lipopolysaccharide (LPS)	pneumonia	Human lung bronchial epithelial cell line BEAS-2B	lipopolysaccharide (LPS) treatment	upregulated	29710526
4582	Human	hsa-miR-15a	miRNA	xianyu decoction (XD)	pneumonia	LPS-treated human lung bronchial epithelial cell line BEAS-2B	Xianyu decoction (XD) treatment	downregulated	29710526
4583	Human	hsa-miR-15a	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
4584	Human	hsa-miR-15a	miRNA	protein kinase C (PKC) ¦Á	renal cell carcinoma (RCC)	"renal clear-cell carcinoma cells,CP renal carcinoma cells, renal papillary cell carcinoma cells, renal oncocytoma cells and Normal renal tissue cells"	protein kinase C (PKC) ¦Á treatment	upregulated	22429968
4585	Human	hsa-miR-15a	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
4586	Human	hsa-miR-15a	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
4587	Human	hsa-miR-15a	miRNA	retinoic acid (RA)	epithelial-mesenchymal transition (EMT)	NB4 cells£» HL-60U937 cells£»primary leukemic cells	retinoic acid treatment	upregulated	21838537
4588	Human	hsa-miR-15a-5p	miRNA	IL-13	allergic rhinitis (AR)	Human primary nasal epithelial cells (NECs)	IL-13 treatment	downregulated	31104300
4589	Human	hsa-miR-15a-5p	miRNA	IL-13	allergic rhinitis (AR)	Human nasal epithelial cells (HNECs)	IL-13 treatment	knockdown of ANRIL may suppress the production of inflammatory cytokines and mucin in IL-13-treated HNECs via regulation of the miR-15a-5p/JAK2 axis.	33325534
4590	Human	hsa-miR-15a-5p	miRNA	IL-13	allergic rhinitis (AR)	Human nasal epithelial cells (HNECs)	IL-13 treatment	"The expression levels of ANRIL and JAK2 were also upregulated in IL-13-induced HNECs, while the expression levels of miR-15a-5p were downregulated."	33325534
4591	Human	hsa-miR-15a-5p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
4592	Human	hsa-miR-15a-5p	miRNA	advanced glycation end product (AGE)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	advanced glycation end (AGE) product treatment	downregulated	30362573
4593	Human	hsa-miR-15a-5p	miRNA	high glucose (HG)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	high glucose (HG) treatment	downregulated	30362573
4594	Human	hsa-miR-15a-5p	miRNA	advanced glycation end product (AGE)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	advanced glycation end (AGE) product treatment	downregulated	30362573
4595	Human	hsa-miR-15a-5p	miRNA	high glucose (HG)	long-term peritoneal dialysis (PD) ultrafiltration failure	human peritoneal mesothelial cells (HPMCs)	high glucose treatment	downregulated	30362573
4596	Human	hsa-miR-15a-5p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
4597	Human	hsa-miR-15a-5p	miRNA	simvastatin	apoptosis	Myocardial tissue biopsies	Simvastatin treatment	downregulated	29985281
4598	Human	hsa-miR-15b	miRNA	paeoniflorin	breast cancer	MCF-7/4-hydroxytamoxifen (4-OHT)	paeoniflorin (Pae) treatment	downregulated	33519190
4599	Human	hsa-miR-15b	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
4600	Human	hsa-miR-15b	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	human T-ALL cell	Glucocorticoids (GCs) treatment	downregulated	19148136
4601	Human	hsa-miR-15b	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
4602	Human	hsa-miR-15b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
4603	Human	hsa-miR-15b	miRNA	hyperthermia	breast cancer	BC lines MCF-7;BT474;SK-BR-3;MDA-MB-231	Hyperthermia treatment	downregulated	27380148
4604	Human	hsa-miR-15b	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
4605	Human	hsa-miR-15b	miRNA	triamcinolone	cell differentiation	hepatic induced stem cells	triamcinolone treatment	upregulated	29101812
4606	Human	hsa-miR-15b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells (REC)	high-glucose treatment	downregulated	25888955
4607	Human	hsa-miR-15B	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
4608	Human	hsa-miR-15b	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
4609	Human	hsa-miR-15b	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-15b was downregulated in propofol-treated group	24454982
4610	Human	hsa-miR-15b	miRNA	geniposide (GEN)	inflammation and apoptosis	Human umbilical vein endothelial cells (HUVECs)	ginsenosides treatment	upregulated	21872652
4611	Human	hsa-miR-15b	miRNA	morphine	inflammation and oxidative stress	peripheral blood mononuclear cells (PBMCs)	Morphine treatment	upregulated	20564181
4612	Human	hsa-miR-15b	miRNA	epigallocatechin-3-gallate (EGCG)	inflammation	human Jurkat E6.1 Cell Line	10 ¦ÌM EGCG	upregulated	27851983
4613	Human	hsa-miR-15b	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus cells	IL-1¦Â treatment	upregulated	28039556
4614	Human	hsa-miR-15b	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	NP cells	IL-1¦Â treatment	upregulated	28039556
4615	Human	hsa-miR-15b	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	?The expression of miR-15bwas decreased in TGF-¦Â1-stimulated LX-2 cells	33545201
4616	Human	hsa-miR-15b	miRNA	dexamethasone (DEX)	miRNA biogenesis	human endothelial cells	dexamethasone (Dex) treatment	downregulated	28523344
4617	Human	hsa-miR-15b	miRNA	ginsenoside Rg1	miRNA biogenesis	human endothelial cells	ginsenoside-Rg1 treatment	downregulated	28523344
4618	Human	hsa-mir-15b	miRNA	Copper(II) complex of quercetin Cu+Q	osteogenesis and angiogenesis	human osteoblast-like cells (MG-63)	Cu+Q(Neo)	upregulated	29208278
4619	Human	hsa-miR-15b	miRNA	lipopolysaccharide (LPS)	placentation	HTR-8/SVneo cell	lipopolysaccharides (LPS) treatment	upregulated	27208409
4620	Human	hsa-miR-15b	miRNA	ionizing radiation (IR)	radiation-induced lung disease	human bronchial epithelial cells	IR treatment	expression was highest after 2 h of IR and downregulated gradually	25092292
4621	Human	hsa-miR-15b	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
4622	Human	hsa-miR-15b	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
4623	Human	hsa-miR-15b*	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	upregulated	27709720
4624	Human	hsa-miR-15b-3p	miRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line HL7702	"treatment with MC-LR at concentrations of 1, 2.5, 5 or 10 ¦ÌM"	upregulated	29265921
4625	Human	hsa-miR-15b-3p	miRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	human normal liver cell line HL7702	icrocystin-LR (MC-LR) treatment	upregulated	29265921
4626	Human	hsa-miR-15b-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
4627	Human	hsa-miR-15b-5p	miRNA	benzyl butyl phthalate (BBP)	acute myeloid leukemia (AML)	"The human acute monocytic leukemia AML U937 (isolated from the histiocytic lymph), Raji (lymphoblast Burkitt's lymph), and HL-60 (a promyelocytic cell line) cell lines"	benzyl butyl phthalate (BBP) treatment	downregulated	31629899
4628	Human	hsa-miR-15b-5p	miRNA	benzyl butyl phthalate (BBP)	acute Myeloid Leukemia (AML)	U937 cells	benzyl butyl phthalate (BBP) treatment	BBP can decrease the expression of miR-15b-5p in AML cells.	31629899
4629	Human	hsa-miR-15b-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
4630	Human	hsa-miR-15b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	downregulated	30842352
4631	Human	hsa-miR-15b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis	33298110
4632	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated lncRNA SNHG1 promotes MPP+ -induced cytotoxicity and ROS production through the miR-15b-5p/GSK3¦Â axis in human dopaminergic SH-SY5Y cells	30302821
4633	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	29217406
4634	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	29217406
4635	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	30302821
4636	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	miR-15b-5p level was nota- bly reduced in MPP+-challenged SK-N-SH cells in dose- and time-dependent patterns	33208053
4637	Human	hsa-miR-15b-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells.	33208053
4638	Human	hsa-miR-15b-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
4639	Human	hsa-miR-15b-5p	miRNA	dexamethasone (DEX)	steatosis	HepG5 cells	dexamethasone (Dex) treatment	downregulated	29409992
4640	Human	hsa-miR-15b-5p	miRNA	dexamethasone (DEX)	steatosis	?HepG2 cell lines	dexamethasone (DEX) treatment	"ENST00000608794 plays an important role in dexamethasone induced steatosis, which was partly mediated by derepressing of PDK4 through competitively binding to miR-15b-5p."	31330194
4641	Human	hsa-miR-15b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
4642	Human	hsa-miR-16	miRNA	hyperoxia	acute lung injury (ALI)	primary human alveolar type II epithelial cells (AECII)	hyperoxia induce	downregulated	29484411
4643	Human	hsa-miR-16	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	30784935
4644	Human	hsa-miR-16	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	human T-ALL cell	Glucocorticoids (GCs) treatment	downregulated	19148136
4645	Human	hsa-miR-16	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	acute myeloid leukemia (AML)	"human myeloid leukemic cell line, AML-193"	GM-CSF treatment	downregulated	22015065
4646	Human	hsa-miR-16	miRNA	IL-13	allergic rhinitis (AR)	human nasal epithelial cells (JME/CF15)	IL-13 treatment	Interleukin (IL)-13 stimulation gradually decreased the levels of miR-16 in JME/CF15 cells.	30132525
4647	Human	hsa-miR-16	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
4648	Human	hsa-miR-16	miRNA	epigallocatechin-3-gallate (EGCG)	apoptosis	human hepatocellular carcinoma HepG2 cells	Epigallocatechin gallate (EGCG)?treatment	upregulated	19269153
4649	Human	hsa-miR-16	miRNA	puerarin	bladder cancer	T24 cells	Puerarin treatment	upregulated	29422113
4650	Human	hsa-miR-16	miRNA	estradiol	breast cancer	MCF-7 cells	estradiol (E?) treatment	"E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells"	22260523
4651	Human	hsa-miR-16	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
4652	Human	hsa-miR-16	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
4653	Human	hsa-miR-16	miRNA	hesperidin	breast cancer	MCF-7 cells	hesperidin treatment	upregulated	33050842
4654	Human	hsa-miR-16	miRNA	lipopolysaccharide (LPS)	breast cancer	human neonatal cardiomyocytes	lipopolysaccharide (LPS) treatment	downregulated	32369253
4655	Human	hsa-miR-16	miRNA	luteolin	breast cancer	MCF-7 cells	luteolin treatment	upregulated	33050842
4656	Human	hsa-miR-16	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
4657	Human	hsa-miR-16	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
4658	Human	hsa-miR-16	miRNA	VEGF or basic fibroblast growth factor (bFGF)	tumorigenesis	endothelial vascellum	VEGF or basic fibroblast growth factor (bFGF) treatment	upregulated	21885851
4659	Human	hsa-miR-16	miRNA	bothrops moojeni snake venom (BmooLAAO-I)	chronic myeloid leukemia (CML)	"Bcr-Abl+ cell lines (HL-60.Bcr-Abl, K562-S, and K562-R)"	bothrops moojeni snake venom (BmooLAAO-I) treatment	upregulated	33354202
4660	Human	hsa-miR-16	miRNA	nilotinib	chronic myeloid leukemia (CML)	HL-60.BCR-ABL cells	nilotinib (NIL) treatment	differently regulated	24629639
4661	Human	hsa-miR-16	miRNA	Protein Arginine Deiminases (PADs)	colorectal cancer (CRC)	HCT 116 wild-type (WT) colon cancer cells	Protein Arginine Deiminases (PADs)treatment treatment	"p53-dependent G1 arrest associated with PAD inhibition was, in turn, dependent on miRNA-16 expression"	23308284
4662	Human	hsa-miR-16	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-16 was downregulated in resistant patients when compared with sensitive patients	33072545
4663	Human	hsa-miR-16	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells (REC)	high-glucose treatment	downregulated	25888955
4664	Human	hsa-miR-16	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
4665	Human	hsa-miR-16	miRNA	nicotine	gastric cancer (GC)	Human gastric adenocarcinoma cells (AGS)	Nicotine treatment	"EP2 or EP4 siRNA or antagonists impaired the nicotine-mediated NF-kB activity, upregulation of miR-16 and miR-21 and cell proliferation."	21081469
4666	Human	hsa-miR-16	miRNA	osthole	glioblastoma multiforme (GBM)	"common glioma cell line, U87"	osthole treatment	upregulated	26082082
4667	Human	hsa-miR-16	miRNA	paeoniflorin	glioblastoma multiforme (GBM)	human glial cells	Paeoniflorin (PF) treatment	upregulated	25954855
4668	Human	hsa-miR-16	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	Human glioblastoma cell lines (U-138MG and A172)	Temozolomide (TMZ) treatment	downregulated	26722459
4669	Human	hsa-miR-16	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
4670	Human	hsa-miR-16	miRNA	microcystin-leucine arginine (MC-LR)	hepatitis	HepG2 cells	Microcystin-LR (MC-LR) treatment	miR-16 may play a vital role in the cell cycle alteration of HepG2 cells after MC-LR exposure.	32066005
4671	Human	hsa-miR-16	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; HepG2.2.15 cells; human normal liver cell line L-02	hepatitis B virus (HBV) infection	upregulated	24089558
4672	Human	hsa-miR-16	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	The human HepG2;SK-HEP-1; Huh7 HCC cell lines	Hepatitis B virus X protein (HBx)?treatment	downregulated	21629246
4673	Human	hsa-miR-16	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	serum	hepatitis C virus (HCV) infection	upregulated	29333940
4674	Human	hsa-miR-16	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
4675	Human	hsa-miR-16	miRNA	Pien Tze Huang (PZH)	hepatocellular carcinoma (HCC)	BEL-7402 HCC	PZH treatment	upregulated	29344256
4676	Human	hsa-miR-16	miRNA	sanguinarine	hepatocellular carcinoma (HCC)	"HepG2, Huh7, Hep3B cells"	sanguinarine treatment	"sanguinarine (SG), was capable of activating miR-16 in HCC cells with wildtype or mutated p53 expression but not in p53-deleted HCC cells"	31163195
4677	Human	hsa-miR-16	miRNA	fibroblast growth factor 4 (FGF4)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	FGF4 treatment	upregulated	30753902
4678	Human	hsa-miR-16	miRNA	hepatocyte growth factor (HGF)	hepatocyte differentiation	primary ccultured human amniotic epithelial cells (AECs)	HGF treatment	upregulated	30753902
4679	Human	hsa-miR-16	miRNA	hepatitis C virus (HCV)	liver cirrhosis	liver	hepatitis C virus (HCV) infection	Serum miR-16 was significantly lower in HCC than in HCV patients (P = 0.033).	26133725
4680	Human	hsa-miR-16	miRNA	hepatitis C virus (HCV)	liver fibrosis	"liver cell line, QSG-7701"	hepatitis C virus (HCV) infection	upregulated	26071245
4681	Human	hsa-miR-16	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	?The expression of miR-16 was decreased in TGF-¦Â1-stimulated LX-2 cells	33545201
4682	Human	hsa-miR-16	miRNA	quercetin	lung adenocarcinoma (LUAD)	lung adenocarcinoma A549 cells	Quercetin treatment	upregulated	26061016
4683	Human	hsa-miR-16	miRNA	particulate matter (PM2.5)	lung cancer	human non-small cell lung cancer cell line A549	chronic (five passages) PM2.5 exposure treatment	downregulated	28846189
4684	Human	hsa-miR-16	miRNA	arctigenin	mechanical trauma injury	scratch-induced injury of human SH-SY5Y cells	arctigenin (ARC) treatment	upregulated	27389368
4685	Human	hsa-miR-16	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	monocytic differentiation	"HL60 cells,"	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	31232026
4686	Human	hsa-miR-16	miRNA	IL-6	multiple myeloma (MM)	bone marrow mesenchymal stem cells(BMSCs)	interleukin-6 (IL-6) treatment	"via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells"	21936961
4687	Human	hsa-miR-16	miRNA	autologous hematopoietic SCT(AHSCT)	multiple sclerosis (MS)	MS patients	AHSCT treatment	upregulated in T- and B-cell	25486582
4688	Human	hsa-miR-16	miRNA	nanocurcumin	multiple sclerosis (MS)	blood	nanocurcumin treatment	downregulated	30340096
4689	Human	hsa-miR-16	miRNA	hypoxia	expression regulation	ARPE-19 cells	hypoxia	downregulated	29237295
4690	Human	hsa-miR-16	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SH-SY5Y human neuroblastoma cells	Perfluorooctane sulfonate (PFOS) treatment	downregulated	26649298
4691	Human	hsa-miR-16	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SK-N-SH cells	PFOS treatment	upregulated	28441774
4692	Human	hsa-miR-16	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	compound C treatment	downregulated	32143184
4693	Human	hsa-miR-16	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	downregulated	32143184
4694	Human	hsa-miR-16	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
4695	Human	hsa-miR-16	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid treatment	downregulated	32143184
4696	Human	hsa-miR-16	miRNA	paclitaxel (PTX)	non-small cell lung cancer (NSCLC)	lung cancer cells	Paclitaxel treatment	downregulated	25435430
4697	Human	hsa-miR-16	miRNA	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np)	non-small cell lung cancer (NSCLC)	A549 cells	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) treatment	upregulated	31411213
4698	Human	hsa-miR-16	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	"human NSCLC cell lines A549, NCI-H1299 and HCC827"	TGF-¦Â treatment	downregulated	29138833
4699	Human	hsa-miR-16	miRNA	quercetin	oral cancer	"Oral cancer cell line HSC-6, SCC-9"	quercetin treatment	upregulated	30639311
4700	Human	hsa-miR-16	miRNA	cisplatin (DDP)	osteosarcoma (OS)	"osteosarcoma cell lines (SAOS2, U2OS)"	cisplatin (DPP) treatment	"SNHG16 enhanced the cisplatin resistance in osteosarcoma cell lines, while miR-16 reversed this impact."	31427084
4701	Human	hsa-miR-16	miRNA	p-glycoprotein	osteosarcoma (OS)	HepG2 cells; SK-HEP-1 cells ;MiHa cells	P-glycoprotein treatment	upregulated	21336967
4702	Human	hsa-miR-16	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	placental apoptosis	HTR-8/SVneo cell line	Mono-(2-ethylhexyl) phthalate treatment	upregulated	26597031
4703	Human	hsa-miR-16	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	placental apoptosis	HTR-8/SVneo cell line	Mono-(2-ethylhexyl) phthalate£¨MEHP£© treatment	"our study demonstrates for the first time that MEHP induces miR-16, which in turn, alters BCL-2/BAX ratio leading to increased apoptosis."	26597031
4704	Human	hsa-miR-16	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	selenium nanoparticles (SeNPs) treatment	upregulated	32357938
4705	Human	hsa-miR-16	miRNA	ionizing radiation (IR)	radiation-induced intestinal fibrosis (RIF)	human intestinal CCD-18Co fibroblasts cell lines;subepithelial SEMFs	"Ionizing radiation (IR) was done with 6 MV photons, 8 Gy/min by a linear accelerator (Varian, America) at room temperature."	downregulated	31262262
4706	Human	hsa-miR-16	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
4707	Human	hsa-miR-16	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
4708	Human	hsa-miR-16	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	serum	Mycobacterium tuberculosis (M.TB) treatment	upregulated	28061948
4709	Human	hsa-miR-16	miRNA	hypoxia	expression regulation	RPE-19 cells	hypoxia treatment	"After cultivating under hypoxia, the expression of microRNA-16 in ARPE-19 cells decreased."	29237295
4710	Human	hsa-miR-16	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin (diferuloylmethane)? treatment	upregulated	19908170
4711	Human	hsa-miR-16-1	miRNA	prednisolone	acute lymphoblastic leukemia (ALL)	CCRF-CEM cell line	Prednisolone treatment	upregulated	27281445
4712	Human	hsa-miR-16-1	miRNA	resveratrol	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	resveratrol (RS) treatment	upregulated	26434860
4713	Human	hsa-miR-16-1	miRNA	triptolide (TPL)	anastomotic fibrosis	primary fibroblasts were obtained from strictured anastomosis tissue (SAT) samples	triptolide (TPL) treatment	downregulated	30942423
4714	Human	hsa-miR-16-1	miRNA	BL-8040	apoptosis	human acute myeloid leukemia (AML) blasts	BL-8040 treatment	upregulated	28280274
4715	Human	hsa-miR-16-1	miRNA	aloe-emodin (AE)	breast cancer	MCF-10AT cells; MCF-7 cells	aloe-emodin (AE) treatment	upregulated	32190086
4716	Human	hsa-miR-16-1	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	colorectal cancer (CRC)	HCT-116 cells	Omega-3 fatty acid DHA treatment	upregulated	29619114
4717	Human	hsa-miR-16-1	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	30103211
4718	Human	hsa-miR-16-1	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
4719	Human	hsa-miR-16-1	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
4720	Human	hsa-miR-16-1	miRNA	candida albicans (C. albicans)	invasive candidiasis	respiratory epithelial cells	candida albicans infection	upregulated	26313489
4721	Human	hsa-miR-16-1	miRNA	curcumin (Cur)	leukemia	primary acute myeloid leukemia (AML) cells	Pure curcumin treatment	downregulated	22449094
4722	Human	hsa-miR-16-1	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
4723	Human	hsa-miR-16-1	miRNA	retinoic acid (RA)	epithelial-mesenchymal transition (EMT)	NB4 cells£» HL-60U937 cells£»primary leukemic cells	retinoic acid treatment	upregulated	21838537
4724	Human	hsa-miR-16-1*	miRNA	triptolide (TPL)	lymphocytic leukemia	Molt-4 cells	triptolide (TPL) treatment	downregulated	21441948
4725	Human	hsa-miR-16-1-3p	miRNA	particulate matter (PM2.5)	hepatocellular carcinoma (HCC)	human HCC cell line SMMC-7721	PM2.5 (particulate matter with an aerodynamic diameter less than 2.5 ¦Ìm) exposure treatment	downregulated	31572802
4726	Human	hsa-miR-16-2	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
4727	Human	hsa-miR-16-2-3p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
4728	Human	hsa-miR-16-5p	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	AC16 cells	hypoxia/re-oxygenation (H/R) treatment	miR-16-5p was elevated in H/R-treated AC16 cells.	31870262
4729	Human	hsa-miR-16-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) treatment	The expression levels of miR-16-5p and miR-19b-3p were reduced but BACE1 protein expression was enhanced in SH-SY5Y cells after treatment of amyloid ¦Â.	31876684
4730	Human	hsa-miR-16-5p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
4731	Human	hsa-miR-16-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
4732	Human	hsa-miR-16-5p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
4733	Human	hsa-miR-16-5p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
4734	Human	hsa-miR-16-5p	miRNA	ketogenic	cell differentiation	adipogenic induced stem cells	Ketorolac treatment	upregulated	29101812
4735	Human	hsa-miR-16-5p	miRNA	etoposide (VP-16)	cell senescence	A549 and MCF-7 cells	etoposide treatment	downregulated	33141998
4736	Human	hsa-miR-16-5p	miRNA	radiation	cervical cancer (CC)	SiHa cells; Hela cells	radiation treatment	miR-16-5p expression was low in radio-resistant CC cells	31872565
4737	Human	hsa-miR-16-5p	miRNA	X-rays	cervical cancer (CC)	"Human cervical cancer cell lines (HeLa, C©\33A, CaSki, HeLa229, SiHa)"	X-ray exposure treatment	downregulated	31872565
4738	Human	hsa-miR-16-5p	miRNA	resistin	chondrosarcoma	The human chondrosarcoma cell line JJ012 and SW1353	resistin treatment	downregulated	30631040
4739	Human	hsa-miR-16-5p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
4740	Human	hsa-miR-16-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes (HPDCs)	high glucose (HG) treatment	downregulated	31568645
4741	Human	hsa-miR-16-5p	miRNA	melatonin	gastric cancer (GC)	BSG823 cells; SGC-7901	Melatonin treatment	melatonin administration enhanced the expression of miR-16-5p.	29359963
4742	Human	hsa-miR-16-5p	miRNA	tanshinone IIA (Tan IIA)	glioblastoma multiforme (GBM)	T98G cells; A172 cells	Tanshinone IIA (TIIA) treatment	"TIIA induced anti-glioma role, wherein miR-16-5p was upregulated"	33192091
4743	Human	hsa-miR-16-5p	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells and human astrocytoma (CCF-STTG1) cells	infect with EV71	upregulated	29180670
4744	Human	hsa-miR-16-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Bel7404; HepG2 cells	sorafenib treatment	LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1	33378944
4745	Human	hsa-miR-16-5p	miRNA	silybin	hepatoprotective	HepG2 cells	Silybin treatment	upregulated	31058823
4746	Human	hsa-miR-16-5p	miRNA	etoposide (VP-16)	lung adenocarcinoma (LUAD)	human senescent cells	etoposide treatment	?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells.	33141998
4747	Human	hsa-miR-16-5p	miRNA	lipopolysaccharide (LPS)	lung cancer	A549 cells	lipopolysaccharides (LPS) treatment	downregulated	30957556
4748	Human	hsa-miR-16-5p	miRNA	anti-programmed cell death protein 1 (anti-PD-1) antibody	malignant melanoma (MM)	serum	anti-programmed cell death protein 1 (anti-PD-1) antibody treatment	Serum expression levels of miR-16-5p was significantly higher in responders than in non-responders.	31843231
4749	Human	hsa-miR-16-5p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	upregulated	33071785
4750	Human	hsa-miR-16-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human articular chondrocytes-knee cells	IL-1¦Â treatment	SNHG1 alleviates the inflammation of IL-1¦Â-induced OA through the activation of miR-16-5p-mediated p38MAPK and NF-¦ÊB signaling pathway.	31383786
4751	Human	hsa-miR-16-5p	miRNA	ionizing radiation (IR)	prostate cancer	CaP LNCaP cells	ionizing radiation (IR) treatment	upregulated	30536619
4752	Human	hsa-miR-16-5p	miRNA	X-rays and heavy ions	prostate cancer	LNCaP cells	X-rays and heavy ions treatment	upregulated	30536619
4753	Human	hsa-miR-16-5p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
4754	Human	hsa-miR-16-5p	miRNA	etoposide (VP-16)	cell senescence	A549; MCF-7 cells	etoposide treatment	downregulated	33141998
4755	Human	hsa-miR-16-5p	miRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	¦Â-TC-tet cells	high glucose treatment	downregulated	32797474
4756	Human	hsa-miR-16a-5p	miRNA	IL-6	intervertebral disc degeneration (IDD)	Primary human chondrocytes	IL-6 treatment	downregulated	32746985
4757	Human	hsa-miR-17	miRNA	levonorgestrel (LNG)	adenomyosis	endometrial stromal cells (ESCs)	levonorgestrel (LNG) treatment	LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway.	32921982
4758	Human	hsa-miR-17	miRNA	phosphatase of regenerating liver-3 (PRL-3)	angiogenesis	colon cancer cells	Phosphatase of regenerating liver-3 (PRL-3) treatment	"overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3"	22677902
4759	Human	hsa-miR-17	miRNA	nanocurcumin	ankylosing spondylitis (AS)	peripheral blood mononuclear cells (PBMCs)	nanocurcumin treatment	downregulated	31074089
4760	Human	hsa-miR-17	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
4761	Human	hsa-mir-17	miRNA	estrogen receptor-¦Á	breast cancer	breast cancer cells	The estrogen receptor-¦Á treatment	upregulated	19706389
4762	Human	hsa-miR-17	miRNA	phenethyl isothiocyanate	breast cancer	PCa cells	Phenethyl isothiocyanate treatment	downregulated	23661605
4763	Human	hsa-miR-17	miRNA	oridonin and the antileukemia drugs Ara-C and VP-16	chemoresistant leukemia	human leukemia cells	oridonin and the antileukemia drugs Ara-C and VP-16 treatment	downregulated	24872388
4764	Human	hsa-miR-17	miRNA	IL-6	chronic lymphocytic leukemia (CLL)	chronic lymphocytic leukemia (CLL) cells	IL-6 treatment	upregulated	26041742
4765	Human	hsa-miR-17	miRNA	calycosin	colorectal cancer (CRC)	HCT-116 cells	Calycosin treatment	downregulated	26215320
4766	Human	hsa-miR-17	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary heart disease (CHD)	Human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31296440
4767	Human	hsa-miR-17	miRNA	"IRE1¦Á, an ER bifunctional kinase/endoribonuclease (RNase)"	diabetes mellitus (DM)	Human THP-1 cells	IRE1¦Á treatment	downregulated	22883233
4768	Human	hsa-miR-17	miRNA	ruxolitinib	glioblastoma multiforme (GBM)	U87-MG cells	ruxolitinib treatment	Uxolitinib (195 nM) significantly increased miR-17 and miR-20a expression	31452174
4769	Human	hsa-miR-17	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) induced liver fibrosis	serum	hepatitis B virus (HBV) infection	Serum miR-17 level is highly expressed in HBV patients.	32572891
4770	Human	hsa-mir-17	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
4771	Human	hsa-miR-17	miRNA	lipopolysaccharide (LPS)	inflammation	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	29704506
4772	Human	hsa-miR-17	miRNA	resveratrol	inflammation	LPS-treated HaCaT cells	resveratrol (Res) treatment	upregulated	29704506
4773	Human	hsa-miR-17	miRNA	VEGF-immobilized microparticles (VEGF-MPs)	ischemic injury	outgrowth endothelial progenitor cells (OEPCs)	outgrowth endothelial progenitor cells (OEPCs) from human UCB sample treatment	downregulated	28963481
4774	Human	hsa-miR-17	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
4775	Human	hsa-miR-17	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells	lipopolysaccharide (LPS) treatment	upregulated	23562609
4776	Human	hsa-miR-17	miRNA	high glucose (HG)	myocardial infarction (MI)	myocardial infarction (MI)	high-glucose (HG) treatment	upregulated	31075259
4777	Human	hsa-miR-17	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; L02 cells	free fatty acids (FFA) treatment	downregulated	30338914
4778	Human	hsa-miR-17	miRNA	keratinocyte-derived exosomes (Ker-Exo)	osteoclast differentiation	osteoclast precursor cells	keratinocyte-derived exosomes (Ker-Exo) treatment	exosomes miRNA-17 secreted by keratinocytes in patients with middle ear cholesteatoma can up-regulate the expression of RANKL in fibroblasts and induce osteoclast differentiation.	32093888
4779	Human	hsa-miR-17	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
4780	Human	hsa-miR-17	miRNA	Sphingosine-1-phosphate (S1P)	papillary thyroid cancer (PTC)	thyroid follicular cancer cell lines (ML-1 and FTC-133)	Sphingosine-1-phosphate (S1P) treatment	downregulated	25748447
4781	Human	hsa-miR-17	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
4782	Human	hsa-miR-17	miRNA	natalizumab	multiple sclerosis (MS)	CD4+ T cells	natalizumab treatment	downregulated	24901013
4783	Human	hsa-miR-17	miRNA	decitabine	precursor B-cell acute lymphoblastic leukemia (B-ALL)	Nalm6 cell line	decitabine treatment	downregulated	30912184
4784	Human	hsa-miR-17	miRNA	hypoxia	pulmonary hypertension (PH)	human plasma	hypoxia treatment	upregulated	28971974
4785	Human	hsa-miR-17	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	rhabdomyosarcoma (RMS)	RD and Rh30 rhabdomyosarcoma (RMS) cells	"Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment"	downregulated	30610105
4786	Human	hsa-miR-17	miRNA	toxoplasma gondii (T. gondii)	toxoplasma gondii infection	primary human foreskin fibroblasts (HFFs)	toxoplasma gondii (T. gondii) infection treatment	upregulated	20090903
4787	Human	hsa-miR-17	miRNA	imatinib	chronic myeloid leukemia (CML)	chronic myeloid leukemia cells	imatinib? treatment	upregulated	23818358
4788	Human	hsa-miR-17?	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
4789	Human	hsa-miR-17-3p	miRNA	methyl-3-O-methyl gallate (M3OMG)	antioxidant enzymes	peripheral blood mononuclear cells and EVC-304 cells	M3OMG treatment	downregulated	24975036
4790	Human	hsa-miR-17-3p	miRNA	lipopolysaccharide (LPS)	breast cancer	HeLa cells	lipopolysaccharide (LPS) treatment	the expression of miR-17-3p and miR-106a is regulated by  LPS in HeLa cells	21370248
4791	Human	hsa-miR-17-3p	miRNA	racemate	endogenous antioxidant defenses	Caco-2 cells	subtoxic concentrations of racemate treatment	upregulated	28264488
4792	Human	hsa-miR-17-3p	miRNA	lipopolysaccharide (LPS)	inflammation	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"In HUVECs, LPS caused upregulation of miR-17-3p."	33623121
4793	Human	hsa-miR-17-3p	miRNA	candida albicans (C. albicans)	invasive candidiasis	respiratory epithelial cells infected by invasive Candida species	candida albicans infection	downregulated	26313489
4794	Human	hsa-miR-17-3p	miRNA	polyphenols	"iron bioavailability,iron absorption"	Caco-2 cells	polyphenols treatment	upregulated	25058155
4795	Human	hsa-miR-17-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human articular chondrocyte C28/I2 cells	lipopolysaccharide (LPS) treatment	downregulated	31966787
4796	Human	hsa-miR-17-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	miR-17-5p expression was downregulated and FOXA1 expression was upregulated in LPS-treated A549 cells	31257497
4797	Human	hsa-miR-17-5p	miRNA	influenza A virus (IAV)	acute respiratory distress syndrome (ARDS)	acute respiratory distress syndrome (ARDS) patients' BALF and in EVs of IAV-infected lung epithelial cells (A549)	Influenza A virus (IAV) infection	upregulated	30239899
4798	Human	hsa-miR-17-5p	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
4799	Human	hsa-miR-17-5p	miRNA	bortezomib	apoptosis	human endometrial cancer cells HTB-111£» Ishikawa cells	bortezomib? treatment	downregulated	23716467
4800	Human	hsa-miR-17-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophage-derived foam cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31646601
4801	Human	hsa-miR-17-5p	miRNA	hypoxia	autophagy	VSMCs	hypoxia treatment	upregulated	28450922
4802	Human	hsa-miR-17-5p	miRNA	sunitinib (SU)	autophagy	786-O-R cells; ACHN-R cells	sunitinib treatment	downregulated	32760216
4803	Human	hsa-miR-17-5p	miRNA	camptothecin	biologic and molecular activity of camptothecin	hypoxic-human cancer cells	camptothecin treatment	upregulated	24252850
4804	Human	hsa-miR-17-5p	miRNA	brown seaweed fucoidan	breast cancer	Human Breast Cancer Cells	brown seaweed fucoidan treatment	downregulated	27994679
4805	Human	hsa-miR-17-5p	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
4806	Human	hsa-miR-17-5p	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
4807	Human	hsa-miR-17-5p	miRNA	casiopeina II-gly (Cas-II-gly)	cervical cancer (CC)	HeLa and CaSki cells	Casiopeina II-gly (Cas-II-gly) treatment	upregulated	31524268
4808	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	chondrosarcoma	SW1353 human chondrosarcoma cells	IL-1¦Â treatment	downregulated	29434766
4809	Human	hsa-miR-17-5p	miRNA	curcumin (Cur)	colorectal cancer (CRC)	RKO; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts	curcumin treatment	downregulated	23194063
4810	Human	hsa-miR-17-5p	miRNA	diabetes mellitus macrophage-conditioned media (DM-MCM)	diabetes mellitus (DM)	HASMC	DM-MCM treatment	upregulated	25409512
4811	Human	hsa-miR-17-5p	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29786752
4812	Human	hsa-miR-17-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	miR-17-5p expression is upregulated in SGC7901/DDP cells compared with SGC7901 cells.	29541229
4813	Human	hsa-miR-17-5p	miRNA	H2O2	glaucoma	Human trabecular meshwork cells (HTMCs)	H2O2 treatment	downregulated	30816540
4814	Human	hsa-miR-17-5p	miRNA	X-rays	glioblastoma multiforme (GBM)	glioma patients serum samples	irradiation at a dose of 6.4 Gy with a high-energy X-ray accelerator (2 Gy/min) treatment	downregulated	28081732
4815	Human	hsa-miR-17-5p	miRNA	angiotensin II (Ang II)	glomerulonephritis	podocytes	angiotensin II (Ang II) treatment	RT-qPCR analysis showed that miR-17-5p was downregulated in Ang II-induced podocytes.	33835671
4816	Human	hsa-miR-17-5p	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	patients who were infected with hepatitis C virus genotype 1b	pegylated interferon-alpha and ribavirin combination therapy treatment	downregulated	24819603
4817	Human	hsa-miR-17-5p	miRNA	hypoglycemic	hepatocellular carcinoma (HCC)	HepG2 cells	hypoglycemic treatment	downregulated	27629773
4818	Human	hsa-miR-17-5p	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary arterial smooth muscle cell (PASMC)	hypoxia induce	upregulated	30305109
4819	Human	hsa-miR-17-5p	miRNA	anti-programmed cell death protein 1 (anti-PD-1) antibody	malignant melanoma (MM)	serum	anti-programmed cell death protein 1 (anti-PD-1) antibody treatment	Serum expression levels of miR-17-5p was significantly higher in responders than in non-responders.	31843231
4820	Human	hsa-miR-17-5p	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	A549 cells	erlotinib	downregulated	27633093
4821	Human	hsa-miR-17-5p	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	A549 cells	erlotinib treatment	downregulated	27633093
4822	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	downregulated	32765678
4823	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocytes	IL-1¦Â treatment	miR-17-5p was downregulated and FUT1 upregulated in OA cartilage tissues and IL-1¦Â-induced chondrocytes.	33093892
4824	Human	hsa-miR-17-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 human chondrosarcoma cells	interleukin-1¦Â treatment	downregulated	29434766
4825	Human	hsa-miR-17-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oxidative stress	HTR-8/SVneo cell line	mono-(2-ethylhexyl) phthalate (MEHP) treatment	upregulation	26871967
4826	Human	hsa-miR-17-5p	miRNA	ionizing radiation (IR)	pancreatic cancer (PC)	oral carcinoma cell line OC3	ionizing radiation treatment	upregulated	23780339
4827	Human	hsa-miR-17-5p	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
4828	Human	hsa-miR-17-5p	miRNA	hypoxia	pulmonary hypertension (PH)	hPASMCs	1% O2 for 48 h treatment	upregulated	24879052
4829	Human	hsa-miR-17-5p	miRNA	fractionated radiation	radiation-induced injury	human peripheral blood mononuclear cells	fractionated radiation treatment	upregulated	25313363
4830	Human	hsa-miR-17-5p	miRNA	lipopolysaccharide (LPS)	rhinitis	nasal epithelial RPMI2650 cells	lipopolysaccharide (LPS) treatment	upregulated	29433423
4831	Human	hsa-miR-17-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	32099901
4832	Human	hsa-miR-17-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
4833	Human	hsa-miR-17-92	miRNA	high iodine blocked BRAF(V600E)	iodine intake on BRAF-mediated oncogenesis	PCCl3 line	V600E treatment	upregulated	23998804
4834	Human	hsa-miR-17-92	miRNA	dexamethasone (DEX)	acute lymphoblastic leukemia (ALL)	"Pre-B ALL cell lines RS4;11, REH ;SUP-B15"	dexamethasone (DEX) treatment	downregulated	22475310
4835	Human	hsa-miR-17-92	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	downregulated	31264378
4836	Human	hsa-miR-17-92	miRNA	prostaglandin E2 (PGE2)	apoptosis	"human squamous cell carcinoma NSCLC cell line H157, H460 and RH2"	PGE2 treatment	upregulated	24469837
4837	Human	hsa-miR-17-92	miRNA	natalizumab	B lymphocytic leukemia	whole blood  lymphocytes	natalizumab treatment	downregulated	22659298
4838	Human	hsa-miR-17-92	miRNA	E. faecalis	bacterial infection	human gastric adenocarcinoma cell line MKN74	E. faecalis infection treatment	downregulated	25170597
4839	Human	hsa-miR-17-92	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
4840	Human	hsa-miR-17-92	miRNA	estrogen receptor ¦Â	colorectal cancer (CRC)	Cell lines (SW480;HT29 ;SW620)	Estrogen receptor ¦Â treatment	the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated	23436804
4841	Human	hsa-miR-17-92	miRNA	hypoxia	colorectal cancer (CRC)	Caco-2 ; HCT116 p53+/+?cells	Hypoxia treatment	downregulated	19696742
4842	Human	hsa-miR-17-92	miRNA	cycle-dependent kinase (CDK) inhibitor SNS-032	acute myeloid leukemia (AML)	AML HL-60 cells	cycle-dependent kinase (CDK) inhibitor SNS-032 treatment	downregulated	26038136
4843	Human	hsa-miR-17-92	miRNA	glucocorticoid (GC)	impair skeletal development	HCS-2/8 cells	GCs treatment	downregulated	24859019
4844	Human	hsa-miR-17-92	miRNA	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV)	kaposi's sarcoma (KS)	endothelial cells	KSHV treatment	upregulated	26545119
4845	Human	hsa-miR-17-92	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
4846	Human	hsa-miR-17-92	miRNA	dexamethasone (DEX)	lymphocyte apoptosis	The Jurkat GR¦Á cell line	dexamethasone (DEX) treatment	upregulated	20847043
4847	Human	hsa-miR-17-92a	miRNA	estrogen (ES)	estrogen protection of osteoblasts against apoptosis	osteoblasts	Estrogen treatment	upregulated	23264746
4848	Human	hsa-miR-18	miRNA	adherent-invasive escherichia coli (AIEC)	autophagy	human intestinal epithelial T84 cells	AIEC LF82 reference strain infection	upregulated	30634511
4849	Human	hsa-miR-18	miRNA	glucocorticoid (GC)	neuronal development	NS1 cells;A549 cells; COS-1cells	Glucocorticoids (GCs) treatment	upregulated	19131573
4850	Human	hsa-miR-181	miRNA	TGF-¦Â	breast cancer	breast cancer cells	Transforming growth factor (TGF)-¦Â treatment	upregulated	21102523
4851	Human	hsa-miR-181	miRNA	imatinib	chronic myeloid leukemia (CML)	MYL; MYL-R human CML cells;K562-R cells;HL-60 cells; HEK293T cells	?imatinib treatment	upregulated	20693279
4852	Human	hsa-miR-181	miRNA	tetra-arsenic tetra-sulfide (As4S4)	chronic myeloid leukemia (CML)	K562 cells	As4S4 treatment	downregulated	28072759
4853	Human	hsa-miR-181	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
4854	Human	hsa-miR-181	miRNA	aplysin	glioblastoma multiforme (GBM)	"human glioma cell lines U87 MG, U251 MG, U373 MG and M059J"	aplysin treatment	upregulated	33104845
4855	Human	hsa-miR-181	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
4856	Human	hsa-miR-181	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
4857	Human	hsa-miR-181	miRNA	high fat diet (HFD)	inflammation	human CD14? monocytes	high fat diet (HFD) feed	downregulated	24870697
4858	Human	hsa-miR-181	miRNA	lipopolysaccharide (LPS)	inflammation	TLR4/2+ primary human dental pulp fibroblasts	were stimulat Pg LPS treatment	downregulated	24848932
4859	Human	hsa-miR-181	miRNA	lipopolysaccharide (LPS)	inflammation	astrocytes	lipopolysaccharide (LPS) treatment	over expression	23650073
4860	Human	hsa-miR-181	miRNA	"anti-CD3, anti-CD28, IL-12, , IL-18"	innate and adaptive immune responses	PB CD4+ T cells	"co-stimulating with anti-CD3, anti-CD28, IL-12, and IL-18 treatment"	downregulated	24704866
4861	Human	hsa-miR-181	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
4862	Human	hsa-miR-181	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
4863	Human	hsa-miR-181	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human endometrial cell-lines	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	28499250
4864	Human	hsa-miR-181	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
4865	Human	hsa-miR-181-5p	miRNA	chlorpyrifos (CPF)	parkinson's disease (PD)	SH-SY5Y cells	chlorpyrifos (CPF) treatment	upregulated	30835941
4866	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
4867	Human	hsa-miR-181a	miRNA	5-fluorouracil (5-Fu)	5-fluorouracil (5-FU) induced nephrotoxicity	The immortalized human mesangial cell (HMC) line	5-fluorouracil (5-FU) treatment	upregulated	29795190
4868	Human	hsa-miR-181a	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	APL blasts and NB4 leukemia cells	all-trans retinoic acid (ATRA) treatment	downregulated	26041820
4869	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	apoptosis	HK-2 cells	cisplatin treatment	One pathway of DDP induces apoptosis of tubular epithelial cell by suppressing Bcl-2 expression is achieved by regulating the target gene of MicroRNA-181a.	22490414
4870	Human	hsa-miR-181a	miRNA	H2O2	atherosclerosis (AS)	HUVECs	H2O2 treatment	upregulated	27460740
4871	Human	hsa-miR-181a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29737518
4872	Human	hsa-miR-181a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30938884
4873	Human	hsa-miR-181a	miRNA	IFN-¦Ã	autophagy	human hepatoma Huh7 cells	IFN-¦Ë treatment	upregulated	28131804
4874	Human	hsa-miR-181a	miRNA	metformin (Met)	breast cancer	MCF-7 cells	metformin?treatment	downregulated	21368581
4875	Human	hsa-miR-181a	miRNA	IL-1¦Â	colorectal cancer (CRC)	colon cancer cell	IL-1¦Â treatment	upregulated	27264420
4876	Human	hsa-miR-181a	miRNA	high glucose (HG)	diabetic wound healing	Human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	upregulated	30565672
4877	Human	hsa-miR-181a	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	human hepatocyte cell line PH5CH8	TGF-¦Âtreatment treatment	upregulated	24576072
4878	Human	hsa-miR-181a	miRNA	kaempferol	gastric cancer (GC)	SNU-216 cells	kaempferol treatment	upregulated	30785478
4879	Human	hsa-miR-181a	miRNA	H2O2	glaucoma	trabecular meshwork (TM) cells	H2O2 treatment	"After the TM cells were treated with H2O2, miR-181a expression was significantly lower."	29616751
4880	Human	hsa-miR-181a	miRNA	docosahexaenoic acid (DHA)	glioblastoma multiforme (GBM)	human U87 MG glioma cell line	docosahexaenoic acid (DHA) treatment	upregulated	25182732
4881	Human	hsa-miR-181a	miRNA	TGF-¦Â	granular corneal dystrophy type 2 (GCD2)	Primary corneal fibroblasts	TGF-¦Âtreatment treatment	upregulated	26915797
4882	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	downregulated	21274007
4883	Human	hsa-miR-181a	miRNA	dichlorvos (DDVP)	hepatic cell toxicity	HepaRG cells	DDVP treatment	upregulated	31966431
4884	Human	hsa-miR-181a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells	HepG2 cells treatment	downregulated	273849772
4885	Human	hsa-miR-181a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	human hepatocyte cell line PH5CH8	TGF-¦Â treatment	upregulated	24576072
4886	Human	hsa-miR-181a	miRNA	"IFN-¦Á, IFN-¦Ã"	human immunodeficiency virus (HIV)-1 infection	astrocytes;microglia	IFN-¦Á and IFN-¦Ã treatment	downregulated	27219130
4887	Human	hsa-miR-181a	miRNA	8-bromo-cyclic adenosine monophosphate (8-bromo-cAMP) and medroxyprogesterone acetate (MPA)	human endometrial stromal cell decidualization	human endometrial stromal cell (hESC)	8-Br-cAMP and MPA treatment	upregulated	25889210
4888	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	infantile pneumonia (IP)	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	31889339
4889	Human	hsa-miR-181a	miRNA	type III interferon (IFN¦Ë)	inflammation	human epithelial cells	type III interferon (IFN¦Ë) treatment	upregulated	24098127
4890	Human	hsa-miR-181a	miRNA	adriamycin (ADR)	leukemia	HL-60 cells	adriamycin (ADR) treatment	downregulated	30964176
4891	Human	hsa-miR-181a	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
4892	Human	hsa-miR-181a	miRNA	TGF-¦Â	liver fibrosis	LX2 cells	TGF-¦Â treatment	upregulated	31166951
4893	Human	hsa-miR-181a	miRNA	piceatannol (PIC)	melanoma	"WM266-4 , A2058 cells"	treat with piceatannol treatment	upregulated	29187907
4894	Human	hsa-miR-181a	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell line RPMI8226	bortezomib? treatment	downregulated	26032093
4895	Human	hsa-miR-181a	miRNA	triptolide (TPL)	multiple myeloma (MM)	the dexamethasone-sensitive MM.1S human MM cell line	triptolide (TPL)? treatment	downregulated	22260163
4896	Human	hsa-miR-181a	miRNA	triptolide (TPL)	neuroblastoma (NB)	SH-SY5Y cells	triptolide (TPL) treatment	microRNA-181a (miR-181a) was upregulated after TPL treatment	29426375
4897	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	neuroinflammation	tongue squamous cell	cisplatin (DPP) treatment	downregulated	24148247
4898	Human	hsa-miR-181a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	LO-2 cells	palmitic acid (PA) treatment	upregulated	30558790
4899	Human	hsa-miR-181a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	The human normal liver cell line L02 cells	palmitic acid (PA) treatment	upregulated	30558790
4900	Human	hsa-miR-181a	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) A549 cells	cisplatin treatment	upregulated	20145152
4901	Human	hsa-miR-181a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human OA chondrocyte	"exposure to three hours of a cyclic HP (1-5 MPa, frequency 0.25 Hz)"	downregulated	29150345
4902	Human	hsa-miR-181a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	chondrocytes	hydrostatic pressure (HP) treatment	miR-155 and miR-181a resulted significantly downregulated immediately after pressurization (T0) in OA cells.	29150345
4903	Human	hsa-miR-181a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	hydrostatic pressure (HP) treatment	upregulated	32455798
4904	Human	hsa-miR-181a	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
4905	Human	hsa-miR-181a	miRNA	resistin	osteoarthritis (OA)	human OA synovial fibroblasts	resistin treatment	upregulated	31635187
4906	Human	hsa-miR-181a	miRNA	visfatin	osteoarthritis (OA)	human OA chondrocytes	visfatin treatment	"upregulated, all the visfatin-caused effects were suppressed by using miR-34a and miR-181a inhibitors."	31405216
4907	Human	hsa-miR-181a	miRNA	triptolide (TPL)	osteosarcoma (OS)	SAOS2 and U2OS cells	"150?mol/L triptolide for 24, 48, and 72 h treatment"	upregulated	28381158
4908	Human	hsa-miR-181a	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
4909	Human	hsa-miR-181a	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
4910	Human	hsa-miR-181a	miRNA	H2O2	oxidative stress	KGN cells	H2O2 treatment	upregulated	31359035
4911	Human	hsa-miR-181a	miRNA	sphingosine-1-phosphate (S1P)	oxidative stress	H2O2 treated KGN cells	sphingosine-1-phosphate (S1P) treatment	downregulated	31359035
4912	Human	hsa-miR-181a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human SK-N-SH neuroblastoma cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	28365714
4913	Human	hsa-miR-181a	miRNA	bufalin	prostate cancer	Human prostate carcinoma PC-3 cells	?bufalin treatment	Bufalin was found to induce the expression of miR-181a	24267199
4914	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	sepsis	Monocytes	lipopolysaccharide (LPS) treatment	LPS stimulation in monocytes also led to a decrease in the expression of miR-181a.	32104257
4915	Human	hsa-miR-181a	miRNA	high glucose (HG)	wound healing	human dermal lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"ANRIL was downregulated, whereas miR-181a was upregulated in high glucose (HG)-induced LECs."	30565672
4916	Human	hsa-miR-181a	miRNA	lipopolysaccharide (LPS)	pancreatic cancer (PC)	Pancreatic cancer cells	lipopolysaccharide (LPS) treatment	downregulated	24532253
4917	Human	hsa-miR-181a*	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
4918	Human	hsa-miR-181a-1?3p	miRNA	benzo(a)pyrene (BaP)	hepatocellular carcinoma (HCC)	HepG2	benzo(a)pyrene (BaP) exposure	upregulated	25690898
4919	Human	hsa-miR-181a-2*	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	downregulated	26640557
4920	Human	hsa-miR-181a-2-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
4921	Human	hsa-miR-181a-2-3p	miRNA	cadmium (Cd)	cadmium (Cd)-induced inflammatory responses	human bronchial epithelial cell line (BEAS-2B) and normal human bronchial epithelial (NHBE) cells	cadmium (Cd) treatment	downregulated	31463135
4922	Human	hsa-miR-181a-2-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	MEG3 expression was enhanced while miR-181a-2-3p abundance was reduced in the serum of patients with COPD and CSE-treated 16HBE cells.	33262837
4923	Human	hsa-miR-181a-2-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
4924	Human	hsa-miR-181a-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
4925	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	"si-CRNDE-1 and miR-181a-5p mimic were able to reverse the promoting effects of LPS on production of NF-kB, TNF-a, IL-1b and IL-6 by THP-1 cells."	31604377
4926	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33197806
4927	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33197806
4928	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33407436
4929	Human	hsa-miR-181a-5p	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells	irradiation treatment	upregulated	33529508
4930	Human	hsa-miR-181a-5p	miRNA	cisplatin (DDP)	esophageal adenocarcinoma (EAC)	OE19 cells	cisplatin treatment	miR-181a-5p was highly expressed while CBLB was lowly expressed in OE19 cell lines compared with OE19/CDDP cells.	32612385
4931	Human	hsa-miR-181a-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	downregulated	32968457
4932	Human	hsa-miR-181a-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCC patients serum	3 months after the initiation of sorafenib treatment	upregulated in serum	28275578
4933	Human	hsa-miR-181a-5p	miRNA	IL-17	non-small cell lung cancer (NSCLC)	H226 and H460 cells	interleukin-17 (IL-17) treatment	downregulated	28535543
4934	Human	hsa-miR-181a-5p	miRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 and H1975 cells	Xiaoji decoction (XJD) treatment	upregulated	31707347
4935	Human	hsa-miR-181a-5p	miRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 cells; H1975 cells	xiaoji decoction (XJD) treatment	XJD increased miR-181a-5p expressions.	31707347
4936	Human	hsa-miR-181a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 cells	IL-1¦Â treatment	IL-1¦Â increased hsa-miR-181a-5p and decreased SBP2 in a time- and dose-dependent manner.	30286747
4937	Human	hsa-miR-181a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Hyperplastic synovial fibroblasts (SFs)	interleukin-1¦Â treatment	upregulated	31777535
4938	Human	hsa-miR-181a-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells; SK-N- AS cessl	1-methyl-4-phenylpyridinium (MPP+) treatment	"We discovered that SNHG1 was significantly elevated, while miR-181a-5p was decreased in N-methyl-4-phenylpyridinium (MPP+)-treated neuroblastoma cells in dose-dependent manners."	33389428
4939	Human	hsa-miR-181a-5p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	downregulated	32921988
4940	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis.	31604377
4941	Human	hsa-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	sepsis-induced renal injury	HK-2 and HEK293 cells	lipopolysaccharide (LPS) treatment	miR-181a-5p was significantly upregulated in sepsis models.	31877497
4942	Human	hsa-miR-181a-5p	miRNA	cisplatin (DDP) and?thiosemicarbazone compound 5	triple negative breast cancer (TNBC)	MDA-MB 231 breast cancer cell line	Cisplatin?+?thiosemicarbazone compound 4 treatment	upregulated	31541355
4943	Human	hsa-miR-181a-5p	miRNA	high glucose (HG)	tubulointerstitial fibrosis (TIF)	HK-2 cells	high glucose	downregulated	28077323
4944	Human	hsa-miR-181b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	upregulated	26622531
4945	Human	hsa-miR-181b	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	APL blasts and NB4 leukemia cells	all-trans retinoic acid (ATRA) treatment	downregulated	26041820
4946	Human	hsa-miR-181b	miRNA	arsenite	angiogenesis	EA.hy926 cells	arsenic (As) exposure	downregulated	21503876
4947	Human	hsa-miR-181b	miRNA	celastrol	apoptosis	A549 cells	celastrol treatment	upregulated	29434967
4948	Human	hsa-miR-181b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29136944
4949	Human	hsa-miR-181b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 suppression protects the endothelium from oxLDL-induced inflammation and oxidative stress in endothelial cells by upregulation of miR-181b and downregulated of TOX.	31949884
4950	Human	hsa-miR-181b	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
4951	Human	hsa-miR-181b	miRNA	curcumin (Cur)	breast cancer	human metastatic breast cancer cells MDA©\MB©\231	curcumin treatment	upregulated	24484937
4952	Human	hsa-miR-181b	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
4953	Human	hsa-miR-181b	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
4954	Human	hsa-miR-181b	miRNA	everolimus	endothelial dysfunction	TNF-¦Á treated human umbilical vein endothelial cell (HUVECs)	everolimus treatment	upregulated	29889836
4955	Human	hsa-miR-181b	miRNA	TGF-¦Â	endothelial dysfunction	HCC cell lines	TGFbeta treatment	upregulated	20023698
4956	Human	hsa-miR-181b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	human umbilical vein endothelial cell (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29889836
4957	Human	hsa-miR-181b	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissues	5-fluorouracil (5-FU) treatment	upregulated	27081844
4958	Human	hsa-miR-181b	miRNA	S-1/oxaliplatin	gastric cancer (GC)	gastric tumor specimens	?S-1/Oxaliplatin?(intravenous injection) treatment	miR-181b and miR-21 was significantly overexpressed in gastric tumors	21876743
4959	Human	hsa-miR-181b	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	T98G cells	temozolomide (TMZ) treatment	upregulated	22722712
4960	Human	hsa-miR-181b	miRNA	oleuropein (OL)	glioblastoma multiforme (GBM)	GBM cell line T98G	oleuropein (OL) treatment or OL+temozolomide (TMZ) combined treatment	upregulated	31169033
4961	Human	hsa-miR-181b	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	upregulated	28797462
4962	Human	hsa-miR-181b	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	upregulated	25837671
4963	Human	hsa-miR-181b	miRNA	hypoxia	hypoxia-induced injury	HK-2 cells	hypoxia induce	downregulated	30860638
4964	Human	hsa-miR-181b	miRNA	morphine	inflammation and oxidative stress	peripheral blood mononuclear cells (PBMCs)	Morphine treatment	downregulated	20564181
4965	Human	hsa-miR-181b	miRNA	"ferrylhemoglobin (ferrylHb, Fe4+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"ferrylhemoglobin (ferrylHb, Fe4+) treatment"	upregulated	32961661
4966	Human	hsa-miR-181b	miRNA	heme	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	heme treatment	upregulated	32961661
4967	Human	hsa-miR-181b	miRNA	"methemoglobin (metHb, Fe3+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"methemoglobin (metHb, Fe3+) treatment"	upregulated	32961661
4968	Human	hsa-miR-181b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32961661
4969	Human	hsa-miR-181b	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
4970	Human	hsa-miR-181b	miRNA	TGF-¦Â1	liver fibrosis	human LX-2 cell	transforming growth factor-¦Â1 treatment	upregulated	25148875
4971	Human	hsa-miR-181b	miRNA	celastrol	lung cancer	A549 cells; LTEP-a-2 cells	celastrol treatment	miR-181b was upregulated in celastrol-treated LTEP-a-2 cells.	29434967
4972	Human	hsa-miR-181b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	upregulated	28899784
4973	Human	hsa-miR-181b	miRNA	epidermal growth factor (EGF)	oral carcinogenesis	"HSC-3£¬OECM-1,SAS£¬NOK"	EGF treatment	upregulated	25229239
4974	Human	hsa-miR-181b	miRNA	decitabine	precursor B-cell acute lymphoblastic leukemia (B-ALL)	Nalm6 cell line	decitabine treatment	downregulated	30912184
4975	Human	hsa-miR-181b	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
4976	Human	hsa-miR-181b	miRNA	methotrexate (MTX)	vascular disease	human umbilical vein endothelial cells (HUVECs)	methotrexate (MTX) treatment	upregulated	33416495
4977	Human	hsa-miR-181b	miRNA	TGF-¦Â1	apoptosis	serum of cirrhosis patients	TGF-¦Â1 treatment	?miR-181b could be induced by TGF-¦Â1 and promote the growth of HSCs by directly targeting p27	22446332
4978	Human	hsa-miR-181b	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	retinoic acid treatment	downregulated	17260024
4979	Human	hsa-miR-181b1	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVEC)	TNF¦Á treatment	upregulated	29666964
4980	Human	hsa-miR-181b-5p	miRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	A549 cells	TGF-¦Â1 treatment	upregulated	28534939
4981	Human	hsa-miR-181b-5p	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	spontaneous preterm birth (SPB)	human syncytiotrophoblast	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	"miR-181b-5p and miR-26b-5p in term human syncytiotrophoblast were increased in response to treatment with 1,25(OH)2D."	30395535
4982	Human	hsa-miR-181c	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
4983	Human	hsa-miR-181c	miRNA	hypoxia	acute ischemic stroke (AIS)	Plasma	hypoxia treatment	downregulated	28053821
4984	Human	hsa-miR-181c	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
4985	Human	hsa-miR-181c	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
4986	Human	hsa-miR-181c	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
4987	Human	hsa-miR-181c	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	cigarette smoke (CS) exposure	downregulated	28806967
4988	Human	hsa-miR-181c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric and colorectal cancer	KATO-III cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	20080834
4989	Human	hsa-miR-181c	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	liver biopsy specimens and Huh7.5 cells	hepatitis C virus (HCV) infection	downregulated	31400158
4990	Human	hsa-miR-181c	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
4991	Human	hsa-miR-181c	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?12 cells	heme treatment	upregulated	23538684
4992	Human	hsa-miR-181c	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
4993	Human	hsa-miR-181c*	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
4994	Human	hsa-miR-181c-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29605252
4995	Human	hsa-miR-181c-5p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29605252
4996	Human	hsa-miR-181c-5p	miRNA	melatonin	osteogenic differentiation and calcification	Human jawbone-derived osteoblastic (hOB) cells	melatonin (MEL) treatment	upregulated	32945514
4997	Human	hsa-miR-181c-5p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
4998	Human	hsa-miR-181d	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
4999	Human	hsa-miR-181d	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
5000	Human	hsa-miR-181d	miRNA	garcinol	glioblastoma multiforme (GBM)	U87MG or GBM8401 cells	garcinol treatment	upregulated	31783691
5001	Human	hsa-miR-181d	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	glioblastoma CD133+ cancer stem cell	ionizing radiation (IR) treatment	downregulated	31226325
5002	Human	hsa-miR-181d	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	glioblastoma CD133+ cancer stem cell	temozolomide (TMZ) treatment	downregulated	31226325
5003	Human	hsa-miR-181d	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
5004	Human	hsa-miR-181d	miRNA	Vitamin D and phorbol 12-myristate 13-acetate	leukemia	AML cell line (HL60 and NB4)	Vitamin D and phorbol 12-myristate 13-acetate treatment	downregulated	20981674
5005	Human	hsa-miR-181d-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney ischemia/reperfusion injury (IRI)	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	"miR-181d-5p in the H/R group increased at 6¨C12 h, but started to decrease at 24 h."	32581828
5006	Human	hsa-miR-181d-5p	miRNA	t-butylhydroperoxide (t-BHP)	atherosclerotic coronary heart disease (CHD)	Primary HUVECs	t-butylhydroperoxide (t-BHP) treatment	downregulated	31352814
5007	Human	hsa-miR-181d-5p	miRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS)	inflammation	BEAS-2B cells	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and lipopolysaccharide (LPS) treatment	"We identified a novel circRNA, circ_0035266, which was strongly upregulated in NNK+LPS-induced BEAS-2B cells and enhanced the inflammatory responses to NNK+LPS by regulating the secretion of pro-inflammatory cytokines interleukin (IL)-6 and IL-8."	33107911
5008	Human	hsa-miR-182	miRNA	isorhapontigenin (ISO)	bladder cancer	T24 cells	isorhapontigenin (ISO) treatment	downregulated	29409027
5009	Human	hsa-miR-182	miRNA	curcumin (Cur)	breast cancer	T47D breast cancer cells	curcumin treatment	48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells.	30467667
5010	Human	hsa-miR-182	miRNA	TGF-¦Â	cancer cell epithelial-mesenchymal transition (EMT)	breast tumour	TGF-¦Âtreatment treatment	"TGF¦Â activates the expression of microRNA-182 (miR-182), which suppresses SMAD7 protein"	27996004
5011	Human	hsa-miR-182	miRNA	fentanyl	colorectal cancer (CRC)	human colorectal carcinoma (HCT116) cells	Fentanyl treatment	downregulated	25755709
5012	Human	hsa-miR-182	miRNA	TGF-¦Â	gallbladder cancer (GBC)	GBC cells	TGF-¦Â induces expression in treatment	upregulated	24445397
5013	Human	hsa-miR-182	miRNA	metformin (Met)	glioblastoma multiforme (GBM)	U87 cells	metformin(Met) treatment	downregulated	33059952
5014	Human	hsa-miR-182	miRNA	TGF-¦Â1	liver fibrosis	human hepatocellular cell line LX-2	TGF-¦Â1 treatment	upregulated	29323718
5015	Human	hsa-miR-182	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	patients with advanced hepatocellular carcinoma (HCC)	cisplatin treatment	upregulated	24447717
5016	Human	hsa-miR-182	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCC cells	hypoxia treatment	upregulated	26126858
5017	Human	hsa-miR-182	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	293A and 293T cells	infect with HSV-1	upregulated	28783105
5018	Human	hsa-miR-182	miRNA	mangiferin	prostate cancer	PC3 human prostate cancer cells	Mangiferin treatment	upregulated	26870290
5019	Human	hsa-miR-182	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
5020	Human	hsa-miR-182	miRNA	glucocorticoid (GC)	lymphoblastic malignancies	Th e mouse myeloma cell line SP2/0; lymphocytic leu-kemia line L1210;T-lymphoma line EL-4 ;acute pre-B lym-phoblastic leukemia line SUP-B15; acute T-lymphoblastic leukemia line CCRF-CEM; cutaneous T-lymphocyte line HUT-78; Burkitt lymphoma line Daudi; acute T-cell leukemia line Molt-4 ; acute T-cell leukemia line J	Glucocorticoid (GC)treatment	upregulated	22582938
5021	Human	hsa-miR-182	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
5022	Human	hsa-miR-182	miRNA	low intensity pulsed ultrasound (LIPUS)	periodontal bone defect	human primary periodontal ligament cells (hPDLCs)	Low intensity pulsed ultrasound (LIPUS) treatment	downregulated	31401188
5023	Human	hsa-miR-182	miRNA	atorvastatin	prostate cancer	PC3 prostate cancer cells	atorvastatin? treatment	upregulated	23936432
5024	Human	hsa-miR-182	miRNA	mangiferin	prostate cancer	PC3 human prostate cancer cells	Mangiferin treatment	upregulated	26870290
5025	Human	hsa-miR-182	miRNA	light	retinal injury	retinal pigment epithelial (RPE) cells	light treatment	upregulated	25955435
5026	Human	hsa-miR-182	miRNA	curcumin (Cur)	schwannoma	RT4 schwannoma cells	curcumin treatment	upregulated	30534000
5027	Human	hsa-miR-182	miRNA	iodine-131 (131I)	thyroid cancer (TC)	FTC-133 cells; TPC-1 cells	iodine-131 (131I) treatment	MEG3 expression appeared a decline and miR-182 expression displayed an increase in 131I-resistant FTC-133 (res-FTC-133) and TPC-1 (res-TPC-1) cells.	30021359
5028	Human	hsa-miR-182-3p	miRNA	asymmetrical dimethylarginine	atherosclerosis (AS)	human aortic artery smooth muscle cell (SMC)	asymmetrical dimethylarginine treatment	downregulated	27199451
5029	Human	hsa-miR-182-3p	miRNA	vibrio parahaemolyticus flagellin	innate immune response	grouper spleen (GS) cells	Vibrio parahaemolyticus flagellin treatment	"miR-182-3p expression significantly downregulated at 3h and 6h, compared with control group After stimulation for 12h and 24h, the expression of miR-182-3p was significantly upregulated"	31351112
5030	Human	hsa-miR-1825	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
5031	Human	hsa-miR-182-5p	miRNA	tert-butyl hydroperoxide (TBHP)	intervertebral disc degeneration (IDD)	nucleus pulposus cells (NPCs)	tert-butyl hydroperoxide (TBHP) treatment	upregulated	31582722
5032	Human	hsa-miR-182-5p	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	cisplatin treatment	upregulated	33647908
5033	Human	hsa-miR-182-5p	miRNA	H2O2	age-related cataract (ARC)	HLE-B3 cells	H2O2 treatment	miR-182-5p expression was significantly decreased by the H2O2 exposure.	32552665
5034	Human	hsa-miR-182-5p	miRNA	ropivacaine	apoptosis	umbilical cord mesenchymal stem cells (UCMSCs)	ropivacaine treatment	downregulated	30773504
5035	Human	hsa-miR-182-5p	miRNA	Sufentanil	apoptosis	umbilical cord mesenchymal stem cells (UCMSCs)	Sufentanil treatment	upregulated	30773504
5036	Human	hsa-miR-182-5p	miRNA	arsenite	arsenic carcinogenesis	HK-2 human renal epithelial cells	arsenic exposure	downregulated	30334557
5037	Human	hsa-miR-182-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein smooth muscle cells (HUVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Knockdown of circ_USP36 alleviated ox-LDL-mediated injury of HUVSMCs by modulating miR-182-5p/KLF5 axis	33437365
5038	Human	hsa-miR-182-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	"The expression level of miR-182-5p decreased, while the expression level of PAPPA increased significantly in the ox-LDL treated HA-VSMC cells."	32684596
5039	Human	hsa-miR-182-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	human-induced pluripotent stem cell (hiPSC)	doxorubicin treatment	upregulated	26842497
5040	Human	hsa-miR-182-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
5041	Human	hsa-miR-182-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells; BGC823C cells	cisplatin treatment	circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5p.	31898357
5042	Human	hsa-miR-182-5p	miRNA	trichloroethylene (TCE)	hepatocarcinogenesis	human hepatoma cell line HepG2	Trichloroethylene (TCE) treatment	upregulated	31524101
5043	Human	hsa-miR-182-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B; SNU©\387; SNU©\449 cells	Sorafenib (SOR) treatment	lncRNA-POIR promotes EMT progression and suppresses SOR sensitivity simultaneously by sponging miR-182-5p	32951268
5044	Human	hsa-miR-182-5p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	human embryonic lung fibroblasts	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31884830
5045	Human	hsa-miR-182-5p	miRNA	human metapneumovirus (HMPV)	innate immune response	human dendritic cells	Human metapneumovirus (HMPV) infection	upregulated	29970194
5046	Human	hsa-miR-182-5p	miRNA	mechanical stress	intervertebral disc degeneration (IDD)	NP cells	mechanical stress treatment	upregulated	33195225
5047	Human	hsa-miR-182-5p	miRNA	TGF-¦Â1	lung fibrosis	human embryonic lung fibroblasts	TGF-¦Â1 treatment	miR-182-5p was upregulated in pulmonary fibrosis	31884830
5048	Human	hsa-miR-182-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
5049	Human	hsa-miR-182-5p	miRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	SH-SY5Y cells	lipopolysaccharide (LPS) treatment	HAGLR displayed high levels in spinal cords of CCI rats and in LPS treated SH-SY5Y cells.	33626373
5050	Human	hsa-miR-182-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
5051	Human	hsa-miR-182-5p	miRNA	matrine	papillary thyroid cancer (PTC)	TPC-1 cells; BCPAP cells	Matrine treatment	Matrine inhibited the expression of miR-182-5p.	32505823
5052	Human	hsa-miR-1826	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
5053	Human	hsa-miR-1827	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
5054	Human	hsa-miR-182a	miRNA	morphine	neurogenesis	hippocampal neural progenitor cell (hNPC) lineages	morphine treatment	upregulated	24964979
5055	Human	hsa-miR-183	miRNA	quinacrine	apoptosis	U937 cells	quinacrine treatment	upregulated	28867437
5056	Human	hsa-miR-183	miRNA	curcumin (Cur)	breast cancer	T47D breast cancer cells	curcumin treatment	48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells.	30467667
5057	Human	hsa-miR-183	miRNA	oxidized low density lipoprotein (ox-LDL)	cell damage	human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31210063
5058	Human	hsa-miR-183	miRNA	IL-8	cholesterol efflux	THP-1 macrophage-derived foam cells	IL-8 treatment	upregulated	29703573
5059	Human	hsa-miR-183	miRNA	CCL20 and CXCL8	colorectal cancer (CRC)	human CRC cell lines SW480 and Caco-2	?CCL20 and CXCL8 co-stimulation	"miR-183 was negatively regulated by circ_0026344, and the inhibitory effects of circ_0026344 overexpression on Wnt/¦Â-catenin pathway were reversed when miR-183 was overexpressed."	31608699
5060	Human	hsa-miR-183	miRNA	elevated CO(2) concentrations (hypercapnia)	helicobacter pylori infection	fibroblasts (N12); A549 cells	CO(2) treatment	upregulated	21903582
5061	Human	hsa-miR-183	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HCC cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28321157
5062	Human	hsa-miR-183	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	293A and 293T cells	infect with HSV-1	upregulated	28783105
5063	Human	hsa-miR-183	miRNA	TGF-¦Â	immunosuppression	human NK cells	TGF-¦Â treatment	upregulated	24586048
5064	Human	hsa-miR-183	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
5065	Human	hsa-miR-183	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
5066	Human	hsa-miR-183	miRNA	baicalin (BAI)	osteosarcoma (OS)	MG-63 and Saos-2 cells	baicalin (BAI) treatment	upregulated	29845278
5067	Human	hsa-miR-183	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	PDAC cells	gemcitabine treatment	downregulated	28849150
5068	Human	hsa-miR-183	miRNA	light	retinal injury	retinal pigment epithelial (RPE) cells	light treatment	upregulated	25955435
5069	Human	hsa-miR-183*	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
5070	Human	hsa-miR-183-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG15 knockdown protected against cerebral I/R injury via targeting miR-183-5p/FOXO1 axis	33194027
5071	Human	hsa-miR-183-5p	miRNA	cytomegalovirus (CMV)	cytomegalovirus infection	plasma	Cytomegalovirus (CMV) treatment	upregulated	27684416
5072	Human	hsa-miR-183-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
5073	Human	hsa-miR-183-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	Circ_DHRS3 expression was elevated in OA cartilage tissues and IL-1¦Â-treated chondrocytes.	33360372
5074	Human	hsa-miR-184	miRNA	adriamycin (ADR)	chronic lymphocytic leukemia (CLL)	human chronic myeloid leukemia cell line K562 and KCL22	adriamycin (ADR) treatment	upregulated	31180580
5075	Human	hsa-miR-184	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-184 was upregulated in resistant patients when compared with sensitive patients	33072545
5076	Human	hsa-miR-184	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	HLE-B3 cells	TGF-¦Â2 treatment	upregulated	32356563
5077	Human	hsa-miR-184	miRNA	cadmium (Cd)	keratinocytes (KCs) diferentiation	human primary epidermal keratinocytes (HPEK)	exogenous Ca2+ treatment	upregulated	31985037
5078	Human	hsa-miR-184	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	TGF-¦Â could induce miR-31 and suppress miR-184 levels in A549 cells	31874165
5079	Human	hsa-miR-184	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	downregulated	31874165
5080	Human	hsa-miR-184	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	BEAS-2B cells; A549 cells	TGF-¦Â1 treatment	downregulated	32989231
5081	Human	hsa-miR-184	miRNA	IL-22	inflammatory skin diseases	RHE cells; HaCaT cells	IL-22 treatment	cytokine-induced miR-184 attenuates AGO2 expression in keratinocytes	23696368
5082	Human	hsa-miR-184	miRNA	retinoic acid (RA)	neuroblastoma (NB)	Neuroblastoma tissue and cell lines	retinoic acid treatment	downregulated	17283129
5083	Human	hsa-miR-184	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	OS cell line U-2 OS and MG-63	Doxorubicin treatment	Doxorubicin induced time-dependent expression of miR-184 in OS cell line U-2 OS and MG-63.	27222034
5084	Human	hsa-miR-184	miRNA	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA)"	ovarian cancer (OC)	ovarian cancer cell lines SKOV-3 and A2780	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA) treatment"	upregulated	29324748
5085	Human	hsa-miR-184	miRNA	artesunate (ART)	prostate cancer	"DU145,LNCaP cells"	artesunate (ART) treatment	downregulated	28209917
5086	Human	hsa-miR-184	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
5087	Human	hsa-miR-185	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
5088	Human	hsa-miR-185	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
5089	Human	hsa-miR-185	miRNA	angiotensin II (Ang II)	HAVSMC dysfunction and hypertension	human aortic vascular smooth muscle cells (HAVSMCs)	angiotensin II (Ang II) treatment	downregulated	28277742
5090	Human	hsa-miR-185	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	29499960
5091	Human	hsa-miR-185	miRNA	TGF-¦Â1	liver fibrosis	LX-2 Cells	TGF-¦Â1 treatment	downregulated	29499960
5092	Human	hsa-miR-185	miRNA	CdSe/ZnS-GSH	lung cancer	A549 cells	CdSe/ZnS-GSH treatment	upregulated	31883144
5093	Human	hsa-miR-185	miRNA	CdSe/ZnS-MPA	lung cancer	A549 cells	CdSe/ZnS-MPA treatment	upregulated	31883144
5094	Human	hsa-miR-185	miRNA	hypoxia	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	30450725
5095	Human	hsa-miR-185	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	human HepG2 hepatocytes	palmitic acid treatment	downregulated	25548489
5096	Human	hsa-miR-185	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx4 treatment"	downregulated	21572246
5097	Human	hsa-miR-185	miRNA	dexmedetomidine (DEX)	ovarian cancer (OC)	"SKOV3 , HO-8910 cells"	dexamethasone (DEX) treatment	DEX promoted miR-185 but suppressed SOX9 expression in OC cells.	33818283
5098	Human	hsa-miR-185	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH5Y-SY cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	miR-185 was significantly downregulated in SH-SY5Y cells treated with MPTP.	29115479
5099	Human	hsa-miR-185	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH5Y-SY cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31814881
5100	Human	hsa-miR-185	miRNA	radiation	renal cell carcinoma (RCC)	renal cell carcinoma cells	radiation treatment	downregulated	23807228
5101	Human	hsa-miR-185	miRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	downregulated	30095214
5102	Human	hsa-miR-185-3p	miRNA	ursolic acid (UA)	breast cancer	MCF-7 cells	usnic acid treatment	downregulated	31549595
5103	Human	hsa-miR-185-3p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	upregulated	24927770
5104	Human	hsa-miR-185-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Human colorectal cancer cell line Caco-2	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30615124
5105	Human	hsa-miR-185-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
5106	Human	hsa-miR-185-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	Circ_WBSCR17 aggravates inflammatory responses and fibrosis by targeting miR-185-5p/SOX6 regulatory axis in high glucose-induced human kidney tubular cells	32798559
5107	Human	hsa-miR-185-5p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
5108	Human	hsa-miR-185-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
5109	Human	hsa-miR-185-5p	miRNA	palmitate	insulin resistance (IR)	Human HepG2 cells and primary hepatocytes	"To establish an insulin-resistant hepatocyte cell model, hepatocytes were stimulated by palmitate (0.25 mM, Sigma-Aldrich, St. Louis, MO, USA) for 24 h, and treated with insulin (100 nM) for 20 min before harvest. treatment"	but miR-185-5p was downregulated in palmitate-treated insulin resistance hepatocytes and HFD mice	31298399
5110	Human	hsa-miR-185-5p	miRNA	TNF-¦Á and IL-1¦Â	intervertebral disc degeneration (IDD)	NP cells	TNF-¦Á and IL-1¦Â treatment	circ-TIMP2 promoted TNF-¦Á- and IL-1¦Â-induced NP cell imbalance between ECM anabolism and catabolism via miR-185-5p-MMP2 signaling	32626912
5111	Human	hsa-miR-185-5p	miRNA	hypoxia	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	30450725
5112	Human	hsa-miR-185-5p	miRNA	noise	noise-induced hearing loss (NIHL)	plasma	noise treatment	downregulated	26278637
5113	Human	hsa-miR-185-5p	miRNA	fractionated radiation	radiation-induced injury	human peripheral blood mononuclear cells	fractionated radiation treatment	upregulated	25313363
5114	Human	hsa-miR-185-5p	miRNA	IFN-¦Â	relapsing-remitting multiple sclerosis (RRMS)	whole blood	IFN-¦Â treatment	miR-185¨C5p was downregulated in responders to IFN-¦Â therapy in RRMS patients.	32554287
5115	Human	hsa-miR-185-5p	miRNA	escitalopram	side effects of antidepressant drugs	peripheral	escitalopram treatment	upregulated	31819986
5116	Human	hsa-miR-186	miRNA	resistin	chondrosarcoma	lymphatic endothelial cells (LECs)	resistin treatment	downregulated	29730230
5117	Human	hsa-miR-186	miRNA	methotrexate (MTX)	colorectal cancer (CRC)	human colorectal cancer cell lines HT-29-P/HT-29-R cell and HCT-8 cells	methotrexate treatment	downregulated	28805722
5118	Human	hsa-miR-186	miRNA	hypoxia	hypoxia-induced injury	Human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	31511208
5119	Human	hsa-miR-186	miRNA	curcumin (Cur)	lung cancer	The A549 human lung adenocarcinoma cell line	curcumin treatment	Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186*signaling pathway	20878113
5120	Human	hsa-miR-186	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	renal tissue and podocyte cells	angiotensin II (Ang II) treatment	downregulated	26382839
5121	Human	hsa-miR-186	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	AC16 cells	hypoxia/reoxygenation (H/R) treatment	Knockdown of long non-coding RNA PVT1 protects human AC16 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis and autophagy by regulating miR-186/Beclin-1 axis.	32428696
5122	Human	hsa-miR-186	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
5123	Human	hsa-miR-186	miRNA	cyclosporine A (CsA)	nephrotoxicity	HEK293	cyclosporine A treatment	upregulated	28414804
5124	Human	hsa-miR-186	miRNA	lycorine	non-small cell lung cancer (NSCLC)	"NSCLC cell lines including A549, H1299 and H460, normal cell BEAS-2B"	Lycorine treatment	upregulated	31176784
5125	Human	hsa-miR-186	miRNA	repeatedly passed	premature senescence	lung fibroblast IMR-90 cells	repeatedly passed until a senescence-like state was observed treatment	upregulated	25139266
5126	Human	hsa-miR-186	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
5127	Human	hsa-miR-186	miRNA	aerobic exercise	vascular cognitive impairment (VCI)	serum	aerobic exercise training (AET) treatment	"Aerobic exercise could shorten the average time that mice reached the platform in the Morris water maze, increase the expression level of circRIMS2 and BDNF, reduce miR-186 expression, and inhibit neuronal apoptosis."	33413076
5128	Human	hsa-miR-186	miRNA	hypoxia	"vascular endothelial cell proliferation , apoptosis"	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	28571741
5129	Human	hsa-miR-186-5p	miRNA	ethanol (EtOH)	alcoholic cardiomyopathy (ACM)	AC16 cardiomyocytes	ethanol treatment	upregulated	30816481
5130	Human	hsa-miR-186-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	E2F1/SNHG7/miR-186-5p/MMP2 axis modulates the proliferation and migration of vascular endothelial cell in atherosclerosis	32603818
5131	Human	hsa-miR-186-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32735135
5132	Human	hsa-miR-186-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs); human mononuclear cells (U938)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32876518
5133	Human	hsa-miR-186-5p	miRNA	propofol (PPF)	heart failure (HF)	Human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs)	Propofol (PPF) treatment	miR-186-5p was downregulated in HiPSC-CMs treated by propofol (PPF)	32968636
5134	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	29399065
5135	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	miR-186-5p expression was downregulated in HG-treated cardiomyocytes.	30506923
5136	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	Human cardiomyocyte AC16 cells	high glucose (HG) treatment	downregulated	30506923
5137	Human	hsa-miR-186-5p	miRNA	hypoxia	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated of TTTY15 ameliorated hypoxia-induced cell injury by targeting miR-186-5p in HUVECs.	32271447
5138	Human	hsa-miR-186-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
5139	Human	hsa-miR-186-5p	miRNA	high glucose (HG)	high glucose (HG)-induced cytotoxicity and apoptosis	AC16 cells	HG	downregulated	29399065
5140	Human	hsa-miR-186-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30443183
5141	Human	hsa-miR-186-5p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	Expression of miR-186-5p was downregulated in DDP resistant NSCLC tissues and cells (A549/DDP and H1299/DDP).	31686523
5142	Human	hsa-miR-186-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
5143	Human	hsa-miR-186-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	IL-1¦Â treatment significantly upregulated miR-186-5p expression in CHON-001 cells.	33537828
5144	Human	hsa-miR-187	miRNA	IL-10	anti-inflammatory responses	primary human monocytes	IL-10 treatment	downregulated	23071313
5145	Human	hsa-miR-187	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
5146	Human	hsa-miR-187	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
5147	Human	hsa-miR-187	miRNA	IL-17A	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
5148	Human	hsa-miR-187	miRNA	IL-1¦Â	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
5149	Human	hsa-miR-187	miRNA	IL-22	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
5150	Human	hsa-miR-187	miRNA	IL-6	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	IL-6 treatment	downregulated	30607907
5151	Human	hsa-miR-187	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	HaCaT cells and primary cultured normal human keratinocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30607907
5152	Human	hsa-miR-187-3p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	interferon-¦Ã (IFN-¦Ã) treatment	downregulated in PC-3M IE8 cells in the EMT induction model	31882179
5153	Human	hsa-miR-187-3p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	Hsa-miR-187-3p was downregulated in PC-3M IE8 cells treatment with IFN-¦Ã.	31882179
5154	Human	hsa-miR-187-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
5155	Human	hsa-miR-187a	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
5156	Human	hsa-miR-188	miRNA	iodixanol	contrast-induced acute kidney injury (CIAKI)	HK-2 cells	iodixanol treatment	upregulated	31555692
5157	Human	hsa-miR-188	miRNA	erythropoietin (EPO)	erythroid cell differentiation	The original UT-7 cell line	erythropoietin treatment	upregulated	18492109
5158	Human	hsa-miR-188-5p	miRNA	hypoxia	cardiomyocyte apoptosis	AC16 cells	hypoxia treatment	downregulated	32970504
5159	Human	hsa-miR-188-5p	miRNA	morin	chronic myeloid leukemia (CML)	CML cell lines K562 and KCL22	Morin treatment	downregulated	31515296
5160	Human	hsa-miR-188-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
5161	Human	hsa-miR-188-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose treatment	upregulated	30263007
5162	Human	hsa-miR-188-5p	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	high glucose-treated HK-2 cells	triptolide (TPL) treatment	downregulated	30263007
5163	Human	hsa-miR-188-5p	miRNA	berberine (BBR)	melanoma	A375 cells	berberine (BBR) treatment	The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression.	32915362
5164	Human	hsa-miR-188-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
5165	Human	hsa-miR-188-5p	miRNA	oxygen glucose deprivation (OGD)	stroke	human neural cell line HNC	oxygen glucose deprivation (OGD) treatment	The expressions of miR-188-5p and PTEN got increased with increasing OGD treatment time.	32745469
5166	Human	hsa-miR-189	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
5167	Human	hsa-miR-18a	miRNA	camptothecin	biologic and molecular activity of camptothecin	hypoxic-human cancer cells	camptothecin treatment	upregulated	24252850
5168	Human	hsa-miR-18a	miRNA	polyphyllin VI (PP-VI)	breast cancer	MDA-MB-231 cells	Polyphyllin VI (PP-VI) treatment	downregulated	30817902
5169	Human	hsa-miR-18a	miRNA	trastuzumab	breast cancer	SKBR-3 cells	trastuzumab treatment	downregulated	29408336
5170	Human	hsa-miR-18a	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
5171	Human	hsa-miR-18a	miRNA	AVM-derived brain endothelial cells Conditioned media (AVM-BEC-CM)	cerebral arteriovenous malformation (AVM)	brain-derived endothelial cells	AVM-BEC-CM treatment	upregulated	24837588
5172	Human	hsa-miR-18a	miRNA	radiation	cervical cancer (CC)	cervical cancer cells	radiation treatment	Higher expression of miR-18a in cervical cancer cells leads to more radiosensitivity	30308669
5173	Human	hsa-miR-18a	miRNA	hypoxia	gastric cancer (GC)	"Human gastric carcinoma cell lines, MGC-803 and HGC-27,"	Hypoxia treatment	downregulated	26622381
5174	Human	hsa-miR-18a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
5175	Human	hsa-miR-18a	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
5176	Human	hsa-miR-18a	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
5177	Human	hsa-miR-18a	miRNA	hypoxia	lymphoma	Human Burkitt lymphomas cell lines P3HR-1; Raji(EBV positive)	hypoixa induce	upregulated	30594162
5178	Human	hsa-miR-18a	miRNA	ultraviolet (UV) irradiation	lymphoma	"Human Burkitt lymphomas cell lines P3HR-1, Raji(EBV positive)"	UV irradiation treatment	upregulated	30594162
5179	Human	hsa-miR-18a	miRNA	¦Á-mangostin (¦ÁM) and ¦Ã-mangostin (¦ÃM)	pancreatic cancer (PC)	human pancreatic cancer cell lines MIA PaCa-2 and PANC-1	¦ÁM or ¦ÃM treatment	downregulated	28822990
5180	Human	hsa-miR-18a	miRNA	fractional CO(2) laser	prostate cancer	types I and III procollagen	treatment with a fractional CO(2) laser	miR-18a and miR-19a were dramatically upregulated	22907286
5181	Human	hsa-miR-18a	miRNA	¦Á-solanine	prostate cancer	Human normal prostate epithelial cell line RWPE-1 and PCa cell lines DU145 and PC-3	¦Á-Solanine treatment	downregulated	30970507
5182	Human	hsa-miR-18a-5p	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells and MDA-MB-231 cells	paclitaxel (PTX) treatment	downregulated	31352515
5183	Human	hsa-miR-18a-5p	miRNA	PXR ligand rifampicin	expression regulation	HepG2 cells	PXR ligand rifampicin treatment	upregulated	31998607
5184	Human	hsa-miR-18a-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
5185	Human	hsa-miR-18a-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	32585247
5186	Human	hsa-miR-18a-5p	miRNA	bleomycin (BLM)	lung fibrosis	human PMC line MeT-5A	bleomycin (BLM) treatment	downregulated	28131417
5187	Human	hsa-miR-18b	miRNA	bone morphogenetic protein 2 (BMP2)	tumorigenesis	NT2/D1 cells	"BMP-2 at 6, 12, and 24 h, and on days 6 and 10 treatment"	upregulated	24383669
5188	Human	hsa-miR-18b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	KCNQ1OT1 expression was increased and miR-18b expression was decreased in DN patients and HG-challenged HMCs.	32989627
5189	Human	hsa-miR-18b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose treatment	downregulated	26851511
5190	Human	hsa-miR-18b	miRNA	TGF-¦Â	cell differentiation	Human hair follicle mesenchymal stem cells (hHF-MSCs)	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	23916701
5191	Human	hsa-miR-18b	miRNA	cisplatin (DDP)	melanoma	A375/DDP; M8/DDP cells	cisplatin treatment	lncRNA H19 could influence DDP-resistance by modulating the miR-18b/IGF axis in melanoma cells.	32265386
5192	Human	hsa-miR-18b	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
5193	Human	hsa-miR-18b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
5194	Human	hsa-miR-19	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
5195	Human	hsa-miR-19	miRNA	estradiol-17¦Â (E2)	innate immune response	"THP-1 (human acute monocytic leukaemia cell line), U937 (Human monocytic [histiocytic lymphoma] cell line)"	estradiol-17¦Â (E2) treatment	upregulated	31266011
5196	Human	hsa-miR-19	miRNA	hydatid cyst fluid (HCF)	liver fibrosis	LX-2 cells	LX-2 cells treatment	downregulated	27177776
5197	Human	hsa-miR-19	miRNA	estradiol-17¦Â (E2)	lung diseases	human monocytic cells	estradiol-17¦Â (E2) treatment	E2 downregulated SLPI and upregulated miR-19 expression in monocytes.	31266011
5198	Human	hsa-miR-19	miRNA	aluminum maltolate (Al-malt)	neurodegenerative pathogenesis	neuroblastoma SH-SY5Y cells	aluminum maltolate (Al-malt) treatment	upregulated	26836165
5199	Human	hsa-miR-190	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
5200	Human	hsa-miR-190	miRNA	hypoxia	pulmonary hypertension (PH)	human plasma	hypoxia treatment	upregulated	28971974
5201	Human	hsa-miR-1907	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28804559
5202	Human	hsa-miR-1908	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
5203	Human	hsa-miR-1908	miRNA	adipokines	obesity-related complications	mature human adipocytes	resistin and leptin treatment	downregulated	24898511
5204	Human	hsa-miR-1908	miRNA	TNF-¦Á and IL-6	obesity-related complications	mature human adipocytes	TNF-¦Á and IL-6 treatment	upregulated	24898511
5205	Human	hsa-miR-1909*	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
5206	Human	hsa-miR-190a	miRNA	benzo(a)pyrene (BaP)	cell proliferation	primary cell cultures from normal endometrial tissue	benzo(a)pyrene (BaP) exposure	upregulated	30811740
5207	Human	hsa-miR-190a	miRNA	dichlorodiphenyltrichloroethane (DDT)	dichlorodiphenyltrichloroethane (DDT) exposure	normal endometrial cells	dichlorodiphenyltrichloroethane (DDT) exposure	upregulated	30421125
5208	Human	hsa-miR-190a	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
5209	Human	hsa-miR-190a-5p	miRNA	hypoxia	chronic obstructive pulmonary disease (COPD)	human pulmonary endothelial cells (HPECs)	hypoxia induce	upregulated	30538440
5210	Human	hsa-miR-190b	miRNA	tocotrienols (¦Ã and ¦ÄT3)	apoptosis	HeLa cells	tocotrienols (¦Ã and ¦ÄT3) treatment	Involvement of miR-190b in Xbp1 mRNA Splicing upon Tocotrienol Treatment	33396504
5211	Human	hsa-miR-190b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33378035
5212	Human	hsa-miR-190b	miRNA	single-walled carbon nanotubes (SWCNTs)	immune response	normal human astrocytes (line NHA/TS)	single-walled carbon nanotubes (SWCNTs) treatment	upregulated	29906516
5213	Human	hsa-miR-190b	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	LO-2 cells	free fatty acid treatment	upregulated	29575055
5214	Human	hsa-miR-191	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
5215	Human	hsa-miR-191	miRNA	inorganic arsenic (iAs)	arsenic poisoning	human liver epithelial L-02 cells	acute or chronic exposure to arsenite	upregulated	29277653
5216	Human	hsa-miR-191	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
5217	Human	hsa-miR-191	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenite exposure	upregulated	31775542
5218	Human	hsa-miR-191	miRNA	arsenite	arsenic-induced renal dysfunction	Plasma	arsenic (As) exposure	upregulated	31775542
5219	Human	hsa-miR-191	miRNA	arsenite	arsenicism	L-02 cells	arsenite exposure	upregulated	33743404
5220	Human	hsa-miR-191	miRNA	estradiol	breast cancer	MCF7 and T-47D cells	estradiol treatment	upregulated	29247596
5221	Human	hsa-miR-191	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
5222	Human	hsa-miR-191	miRNA	triptolide (TPL)	colorectal cancer (CRC)	Human CRC cell lines HT-29 and SW480	Triptolide (TPL) treatment	downregulated	30684462
5223	Human	hsa-miR-191	miRNA	¦Â-elemene	colorectal cancer (CRC)	colorectal carcinoma cells (HCT116 and HT29)	beta-elemene treatment	downregulated	29737579
5224	Human	hsa-miR-191	miRNA	cisplatin (DDP)	DNA damage	HeLa cells	cisplatin treatment	MicroRNA-191 modulates cisplatin-induced DNA damage response by targeting RCC2.	32803782
5225	Human	hsa-miR-191	miRNA	cigarette smoke extract (CSE)	hepatic insulin resistance	L-02 cells	cigarette smoke extract (CSE) exposure	CSE also increased miR-191 levels in L-02 cells.	28963693
5226	Human	hsa-miR-191	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO-2 cells	hypoxia induce	upregulated	29769640
5227	Human	hsa-miR-191	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO-2 cells	hypoxia/reperfusion (H/R)?induce	upregulated	29769640
5228	Human	hsa-miR-191	miRNA	arsenite	hepatocellular carcinoma (HCC)	human liver epithelial L-02 cells	arsenite exposure	upregulated	29277653
5229	Human	hsa-miR-191	miRNA	hypoxia inducible factor (HIF)-1	hypoxic breast tumors	MCF7 cells;MM231 cells; breast adenocarcinoma cells	hypoxia-inducible factor (HIF) treatment	upregulated	25867965
5230	Human	hsa-miR-191	miRNA	dioxin	kidney fibrosis	"Hep3B, SNU423, andHepG2 cell lines"	dioxin treatment	upregulated	20924108
5231	Human	hsa-miR-191	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
5232	Human	hsa-miR-191	miRNA	arsenite	lung cancer	human bronchial epithelial (HBE) cells	arsenite exposure	upregulated	25252218
5233	Human	hsa-miR-191	miRNA	arsenite	lung cancer	HBE cells	arsenite exposure	upregulated	25252218
5234	Human	hsa-miR-191	miRNA	radiation	lung cancer	A549 cells	radiation treatment	upregulated	32968458
5235	Human	hsa-miR-191	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	SK-MES-1cells; A549 cells; NCI-H460 cells;NSCLC cells	chronic hypoxia	upregulated	28075452
5236	Human	hsa-miR-191	miRNA	hypoxia	rheumatoid arthritis (RA)	rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)	hypoxia induce	upregulated	30894209
5237	Human	hsa-miR-191	miRNA	cigarette smoke (CS)	type 2 diabetes mellitus (T2DM)	L-02 cells	cigarette smoke (CS)?exposure	upregulated	28963693
5238	Human	hsa-miR-1910-3p	miRNA	metformin (Met)	polycystic ovarian syndrome (PCOS)	human Ishikawa cells	metformin treatment	downregulated	30599813
5239	Human	hsa-miR-1910-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
5240	Human	hsa-miR-191-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
5241	Human	hsa-miR-1914*	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
5242	Human	hsa-miR-1914-5p	miRNA	heptapeptide angiotensin-(1-7) [ang-(1-7)]	liver fibrosis	LX-2 cells	heptapeptide angiotensin-(1-7) [ang-(1-7)] treatment	upregulated	29524604
5243	Human	hsa-miR-1915	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GC tissues and GC cells SGC-7901 and MKN45	Helicobacter pylori (HP) infection	downregulated	30554489
5244	Human	hsa-miR-1915-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
5245	Human	hsa-miR-191-5p	miRNA	FTY-720	leukemia	OCI-AML3 cells	FTY-720 treatment	upregulated	24858343
5246	Human	hsa-miR-191-5p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	upregulated	27018851
5247	Human	hsa-miR-191-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	neutrophil	M.tb infection	downregulated	29477867
5248	Human	hsa-miR-192	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
5249	Human	hsa-miR-192	miRNA	silver nanoparticles (AgNPs)	apoptosis	lung cancer cell line (A549)	Silver nanoparticles (AgNPs) treatment	upregulated	30479160
5250	Human	hsa-miR-192	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
5251	Human	hsa-miR-192	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
5252	Human	hsa-miR-192	miRNA	TGF-¦Â1	breast cancer	Primary human renal epithelial PTCs (	Transforming growth factor ¦Â1 treatment	downregulated	22264233
5253	Human	hsa-miR-192	miRNA	lipopolysaccharide (LPS)	cervical cancer (CC)	HeLa cells	lipopolysaccharide (LPS) treatment	upregulated	31450920
5254	Human	hsa-miR-192	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	upregulated	24178909
5255	Human	hsa-miR-192	miRNA	suberoylanilide hydroxamic acid (SAHA)	chronic myeloid leukemia (CML)	K562 cells	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	29343029
5256	Human	hsa-miR-192	miRNA	simvastatin	colorectal cancer (CRC)	colon cancer HCT-116 cells	Simvastatin treatment	upregulated	30628692
5257	Human	hsa-miR-192	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
5258	Human	hsa-miR-192	miRNA	exendin-4 and high glucose (Ex-HG)	diabetic nephropathy (DN)	HK-2 cells	exendin-4 and high glucose (Ex-HG) treatment	HG and exendin-4 may have contributed to a decrease in miR-192 in both HK-2 cells and EVs in a p53-dependent manner.	29717107
5259	Human	hsa-miR-192	miRNA	bisphenol A (BPA)	hepatic steatosis and lipid accumulation	human HepG2 cells	bisphenol A (BPA) treatment	downregulated	28483554
5260	Human	hsa-miR-192	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV)-mediated hepatic fibrosis	human hepatic stellate cells (HSCs) line LX-2	hepatitis C virus (HCV) infection	upregulated	30753992
5261	Human	hsa-miR-192	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
5262	Human	hsa-miR-192	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	upregulated	29516639
5263	Human	hsa-miR-192	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	downregulated	29516639
5264	Human	hsa-miR-192	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
5265	Human	hsa-miR-192	miRNA	IL-17	multiple myeloma (MM)	MM cells	IL-17 treatment	downregulated	25489847
5266	Human	hsa-miR-192	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Huh7 cells exosomes	palmitic acid (PA) treatment	upregulated in exosomes	28623272
5267	Human	hsa-miR-192	miRNA	nicotine	non-small cell lung cancer (NSCLC)	A549 and NCI-H460 cells	nicotine treatment	downregulated	29518612
5268	Human	hsa-miR-192	miRNA	opisthorchis viverrini	opisthorchis viverrini infection	human urine	infect with Opisthorchis viverrini	upregulated in the urine	26456596
5269	Human	hsa-miR-192	miRNA	acetaminophen (APAP)	prostate cancer	serum	acetaminophen (APAP) treatment	?Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients	22045675
5270	Human	hsa-miR-192	miRNA	acidic bile salt	reflux esophagitis	Het-1A cells	acidic bile salt treatment	upregulated	24006894
5271	Human	hsa-miR-192	miRNA	astragaloside IV (AS-IV)	renal fibrosis	TGF-¦Â1-treated HK-2 cells	astragaloside (AS-IV) treatment	downregulated	31497219
5272	Human	hsa-miR-192	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	31497219
5273	Human	hsa-miR-192	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
5274	Human	hsa-miR-192	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
5275	Human	hsa-miR-192	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	The human renal epithelial cells (293T cells)	metformin treatment	differently regulated in circulating	24478399
5276	Human	hsa-miR-192-5p	miRNA	vancomycin (VAN)	acute kidney injury (AKI)	human renal tubular +H57epithelial cell line (HK-2)	human renal tubular +H57epithelial cell line (HK-2) treatment	upregulation	27941921
5277	Human	hsa-miR-192-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
5278	Human	hsa-miR-192-5p	miRNA	oleic acid (OA)	diabetes-associated metabolic disorders	HepG2 cells	oleate treatment	circHIPK3 contributes to hyperglycemia and insulin resistance by sponging miR-192-5p and up-regulating FOXO1.	31875589
5279	Human	hsa-miR-192-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
5280	Human	hsa-miR-192-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	downregulated	30854110
5281	Human	hsa-miR-192-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
5282	Human	hsa-miR-192-5p	miRNA	"N,N-dimethylformamide (DMF)"	hepatotoxicity	HL-7702 liver cells	"N,N-dimethylformamide (DMF) treatment"	"Aberrant expression of miRNA-192-5p contributes to N,N-dimethylformamide-induced hepatic apoptosis."	32648274
5283	Human	hsa-miR-192-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
5284	Human	hsa-miR-192-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
5285	Human	hsa-miR-192-5p	miRNA	oleic acid (OA)	hyperglycemia and insulin resistance	HepG2 cells	oleate treatment	downregulated	31875589
5286	Human	hsa-miR-192-5p	miRNA	metformin (Met)	melanoma	"The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951"	Metformin treatment	upregulated	30754729
5287	Human	hsa-miR-192-5p	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Huh7 cells	palmitic acid (PA) treatment	upregulated	29290651
5288	Human	hsa-miR-192-5p	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer cells	curcumin treatment	upregulated	26351877
5289	Human	hsa-miR-192-5p	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	A427 cells; A549 cells	curcumin treatment	Curcumin treatment promoting the expression levels of miR-192-5p.	32626956
5290	Human	hsa-miR-192-5p	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	H460 and A427 cells	curcumin treatment	upregulated	25444916
5291	Human	hsa-miR-192-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
5292	Human	hsa-miR-192-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
5293	Human	hsa-miR-192b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
5294	Human	hsa-miR-193	miRNA	cisplatin (DDP)	esophageal cancer (EC)	TE-1 cells	cisplatin treatment	upregulated	32369495
5295	Human	hsa-miR-193	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 and T98G cells	temozolomide (TMZ) treatment	miR-93 and -193 decreased cell cycling quiescence and induced resistance to TMZ.	30853911
5296	Human	hsa-miR-193-5p	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
5297	Human	hsa-miR-193-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
5298	Human	hsa-miR-193-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
5299	Human	hsa-miR-193a	miRNA	high glucose (HG)	diabetic podocytopathy	Human podocytes (PDs)	high glucose (HG) treatment	upregulated	29357419
5300	Human	hsa-miR-193a	miRNA	D-glucose	epithelial-mesenchymal transition (EMT)	peritoneal mesothelial cells (PMCs)	D-glucose treatment	upregulated	25683944
5301	Human	hsa-miR-193a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	lung cancer	NSCLC A549 cells	5-aza-20-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A treatment	upregulated	22282464
5302	Human	hsa-miR-193a-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31857133
5303	Human	hsa-miR-193a-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	miR-193a-3p was significantly downregulated in SH-SY5Y cells.	31857133
5304	Human	hsa-miR-193a-3p	miRNA	dextran sodium sulfate (DSS)	colitis	Human intestinal epithelial Caco2	dextran sodium sulfate (DSS) treatment	"Intracolonic delivery of miR-193a-3p significantly ameliorated dextran sodium sulfate-induced colitis, whereas the overexpression of colonic PepT1 via PepT1 3'-untranslated region mutant lentivirus vector abolished the anti-inflammatory effect of miR-193a-3p"	25931122
5305	Human	hsa-miR-193a-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
5306	Human	hsa-miR-193a-3p	miRNA	activin A	liver fibrosis	LX-2 cells	activin A treatment	downregulated	30945448
5307	Human	hsa-miR-193a-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	30945448
5308	Human	hsa-miR-193a-3p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	upregulated	33071785
5309	Human	hsa-miR-193a-3p	miRNA	intermittent hypoxia (IH)	obstructive sleep apnea (OSA)	human umbilical vein endothelial cells (HUVECs)	intermittent hypoxia(IH) treatment	miR-193a-3p was upregulated in HUVECs exposed to IH.	32003752
5310	Human	hsa-miR-193a-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	31632562
5311	Human	hsa-miR-193a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31210318
5312	Human	hsa-miR-193a-5p	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
5313	Human	hsa-miR-193a-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	cigarette smoke extract (CSE) treatment	"Circ-OSBPL2 was highly expressed in lung tissues of smokers without or with COPD, particularly in smokers with COPD."	33854310
5314	Human	hsa-miR-193a-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U257 cells; U87 cells	temozolomide (TMZ) treatment	upregulated	29136760
5315	Human	hsa-miR-193a-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
5316	Human	hsa-miR-193a-5p	miRNA	docetaxel (DTX)	prostate cancer	PC3 cells	docetaxel (DTX) treatment	upregulated	29216925
5317	Human	hsa-miR-193b	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	upregulated	33197057
5318	Human	hsa-miR-193b	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
5319	Human	hsa-miR-193b	miRNA	TGF-¦Â1	gastric cancer (GC)	BGC-823 cells; SGC7901 cells; MKN28 cell	TGF-¦Â1 treatment	downregulated	23372348
5320	Human	hsa-miR-193b	miRNA	metformin (Met)	triple negative breast cancer (TNBC)	triple-negative breast cancer (TNBC) cell lines	metformin treatment	upregulated	25213330
5321	Human	hsa-miR-193b	miRNA	IL-4	monocytic differentiation	monocyte	IL-4 treatment	dysregulated	25148686
5322	Human	hsa-miR-193b	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec8A cells	Progesterone treatment	downregulated	22543862
5323	Human	hsa-miR-193b*	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
5324	Human	hsa-miR-193b-3p	miRNA	IL-1¦Â	chondrogenesis and metabolism	primary human chondrocytes (PHCs)	IL-1¦Â treatment	IL-1¦Â stimulation resulted in decreased miR-193b-3p expression.	29344280
5325	Human	hsa-miR-193b-3p	miRNA	activin A	liver fibrosis	LX-2 cells	activin A treatment	downregulated	30945448
5326	Human	hsa-miR-193b-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	30945448
5327	Human	hsa-miR-193b-3p	miRNA	triptolide (TPL)	nephroblastoma	human nephroblastoma cells (G-401 and WiT49)	triptolide (TPL) treatment	upregulated	30978333
5328	Human	hsa-miR-193b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	downregulated	29323744
5329	Human	hsa-miR-193b-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes (PHCs)	IL-1¦Â treatment	downregulated	30854734
5330	Human	hsa-miR-19-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
5331	Human	hsa-miR-194	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	LO2 cells	ethanol treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)."	33068587
5332	Human	hsa-miR-194	miRNA	yangonin (Yan)	alcoholic liver disease (ALD)	LO2 cells	Yangonin (Yan) treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yan"	33068587
5333	Human	hsa-miR-194	miRNA	yangonin (Yan)	alcoholic liver disease (ALD)	ethanol-induced LO2 cells	Yangonin (Yan) treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)"	33068587
5334	Human	hsa-miR-194	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
5335	Human	hsa-miR-194	miRNA	neutral bile mixture	barrett's esophagus	Het-1A cells	neutral bile mixture treatment	upregulated	24006894
5336	Human	hsa-miR-194	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells	docosahexaenoic acid (DHA) fatty acids treatment	MDA-MB-231 cells with DHA caused an increase in the miR-194 expression.	31713924
5337	Human	hsa-miR-194	miRNA	trastuzumab	breast cancer	BT474 cells;SKBr3 cells; MDA-MB-361 cells;MDA-MB-231 cells	Trastuzumab treatment	trastuzumab treatment upregulates miR-194 expression and may exert its cell migration-inhibitory effect through miR-194-mediated downregulated of cytoskeleton protein talin2 in HER2-overexpressing human breast cancer cells	22829924
5338	Human	hsa-miR-194	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	plasma or liver tissues of CHB patients	hepatitis B virus (HBV)infection	upregulated	30044042
5339	Human	hsa-miR-194	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
5340	Human	hsa-miR-194	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
5341	Human	hsa-miR-194	miRNA	palmitic acid (PA)	inflammatory response	Human THP-1 cells	palmitic acid (PA) treatment	downregulated	25984739
5342	Human	hsa-miR-194	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 alveolar epithelial cells (AECs)	infec with IAV/Beijing/501/2009 (BJ501)	downregulated	29163456
5343	Human	hsa-miR-194	miRNA	high glucose (HG)	lung cancer	Human lung cancer cell lines A549 and H1299	high glucose (HG) treatment	downregulated	30900402
5344	Human	hsa-miR-194	miRNA	green tea (GT)	nonalcoholic fatty liver disease (NAFLD)	TNF-¦Á-treated HepG2 cells	green tea (GT) treatment	upregulated	31885789
5345	Human	hsa-miR-194	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	human derived HepG2 cell	palmitic acid treatment	upregulated	28951211
5346	Human	hsa-miR-194	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31885789
5347	Human	hsa-miR-194	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3ip1 cells; HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
5348	Human	hsa-miR-194	miRNA	acidic bile salt	reflux esophagitis	Het-1A cells	acidic bile salt treatment	upregulated	24006894
5349	Human	hsa-miR-194	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK-2 cells	hypoxia/reperfusion (H/R) treatment	miR-194 was decreased in H/R-induced HK-2 cells.	30485514
5350	Human	hsa-miR-194	miRNA	lycium barbarum polysaccharide (LBP)	spinal cord injury (SCI)	SH-SY5Y cells	Lycium barbarum polysaccharides (LBPs) treatment	downregulated	30308510
5351	Human	hsa-miR-194	miRNA	docosahexaenoic acid (DHA)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	Docosahexaenoic acid (DHA) treatment	upregulated	31713924
5352	Human	hsa-miR-194	miRNA	hepatocyte nuclear factor-1 ¦Á	intestinal cell differentiation	Caco-2 cells	hepatocyte nuclear factor-1 ¦Á	upregulated	18492795
5353	Human	hsa-miR-194-3p	miRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	Human bronchial epithelial cells (HBEpiCs)	Fine particulate matter (PM2.5) exposure treatment	downregulated	30122914
5354	Human	hsa-miR-194-3p	miRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	blood	Fine particulate exposure (PM2.5) treatment	miR-194-3p was decreased significantly after fine particulate exposure (PM25) exposure	30746254
5355	Human	hsa-miR-194-3p	miRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	embryo implantation	human trophoblast Swan 71 cells	"benzo[a]pyrene-7, 8-diol-9, 10-epoxide (BPDE) treatment"	upregulated	30011042
5356	Human	hsa-miR-194-5p	miRNA	IL-6 and TNF-¦Á	intervertebral disc degeneration (IDD)	"human osteoblast cells (hFOB1.19), nucleus pulposus cells (hNPCs), and annulus fibrosus cells (hAFCs)"	IL-6 and TNF-¦Á treatment	downregulated	30945295
5357	Human	hsa-miR-194-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary alveolar epithelial cells (HPAEpiC)	lipopolysaccharide (LPS) treatment	MALAT1 knockdown alleviated HPAEpiC apoptosis by competitively binding to miR-194-5p and then elevating the inhibitory effect on its target FOXP2.	33117815
5358	Human	hsa-miR-194-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	bladder cancer	bladder cancer cell lines T24 and 5637	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30925453
5359	Human	hsa-miR-194-5p	miRNA	cisplatin (DDP)	bladder cancer	bladder cancer cell lines T24 and 5637	?cisplatin treatment	upregulated	30925453
5360	Human	hsa-miR-194-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
5361	Human	hsa-miR-194-5p	miRNA	histone deacetylase inhibitor SAHA	leukemogenesis and drug resistance	"U937, NB4, K562 and Molm-14 cells"	SAHA	upregulated	28216661
5362	Human	hsa-miR-194-5p	miRNA	lipopolysaccharide (LPS)	neurodegenerative diseases	human astrocytes	lipopolysaccharide (LPS) treatment	miR-194-5p was downregulated in LPS-induced astrocytes.	32533463
5363	Human	hsa-miR-194-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin treatment	"Compared to cisplatin-sensitive ovarian cancer cells, higher miR-194-5p expression and lower SLC40A1 expression were found in cisplatin-resistant ovarian cancer cells."	32534701
5364	Human	hsa-miR-194-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
5365	Human	hsa-miR-194-5p	miRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	downregulated	33393621
5366	Human	hsa-miR-195	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute stroke	SH-SY5Y neural cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30775405
5367	Human	hsa-miR-195	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
5368	Human	hsa-miR-195	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	22802111
5369	Human	hsa-miR-195	miRNA	aidi injection (ADI)	breast cancer	MCF-7 cells	aidi Injection (ADI)	upregulated	21563499
5370	Human	hsa-miR-195	miRNA	mastectomy	breast cancer	breast cancer tissues	mastectomy treatment	upregulated	25503185
5371	Human	hsa-miR-195	miRNA	H2O2	cardiomyocyte apoptosis	human cardiomyocytes (HCMs)	Hydrogen peroxide (H2O2) treatment	upregulated	30355909
5372	Human	hsa-miR-195	miRNA	doxorubicin (DOX)	cardiotoxicity	human AC16 cardiomyocytes	Doxorubicin (DOX)? treatment	"SNHG1 could counteract the inhibitory effect of miR-195 on Bcl-2, and miR-195 restoration blocked the beneficial effect of SNHG1 against DOX toxicity in AC16 cells"	31300525
5373	Human	hsa-miR-195	miRNA	triamcinolone	cell differentiation	hepatic induced stem cells	triamcinolone treatment	upregulated	29101812
5374	Human	hsa-miR-195	miRNA	hypoxia	cerebral ischemia injury (CII)	HUVECs	hypoxia treatment	downregulated	28849133
5375	Human	hsa-miR-195	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissues	cigarette smoke (CS) exposure	upregulated	29223853
5376	Human	hsa-miR-195	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	TE-1/DDP	cisplatin treatment	Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis	31558183
5377	Human	hsa-miR-195	miRNA	Schizandrin A (SchA)	colorectal cancer (CRC)	HCT116 and SW480 cells	Schizandrin A (SchA) treatment	upregulated	29331856
5378	Human	hsa-miR-195	miRNA	hypoxia	deep vein thrombosis (DVT)	human EPCs (hEPCs)	hypoxia treatment	upregulated	27623937
5379	Human	hsa-miR-195	miRNA	astragalus polysaccharide (APS)	diabetic retinopathy (DR)	high glucose (HG)-treated ARPE-19 cells	astragalus polysaccharide (APS) treatment	downregulated	31117931
5380	Human	hsa-miR-195	miRNA	H2O2	diabetic retinopathy (DR)	human umbilical vein endothelial cells (HUVECs); human retinal endothelial cells (HMRECs)	H2O2 treatment	upregulated	28487236
5381	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human umbilical vein endothelial cells (HUVECs); human retinal endothelial cells (HMRECs)	high glucose (HG) treatment	upregulated	28487236
5382	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	upregulated	31117931
5383	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic retinopathy (DR)	"human retinal and dermal microvascular ECs (HRECs, HMECs)"	"exposure to 25 mmol/l glucose (high glucose, HG) treatment"	upregulation	24570140
5384	Human	hsa-miR-195	miRNA	H2O2	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HMRECs)	H2O2 treatment	We confirmed that over-expression of SNGH16 attenuated H2O2-induced angiogenesis by HMRECs.	33530902
5385	Human	hsa-miR-195	miRNA	high glucose (HG)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31115479
5386	Human	hsa-miR-195	miRNA	cisplatin (DDP)	esophageal squamous cell carcinoma (ESCC)	The human ESCC cell line TE-1	cisplatin treatment	downregulated	31558183
5387	Human	hsa-miR-195	miRNA	propofol (PPF)	gastric cancer (GC)	MKN45 cells	propofol treatment	The expression of miR-195 was increased after propofol treatment	30171944
5388	Human	hsa-miR-195	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	temozolomide (TMZ) treatment	The expression levels of miR-195 were drastically higher in both U87TR and U251TR cell lines	30442884
5389	Human	hsa-miR-195	miRNA	cyclosporine A (CsA)	glioblastoma multiforme (GBM)	human glioblastoma cells	cyclosporine A treatment	downregulated	26537083
5390	Human	hsa-miR-195	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell line U87	glioma cell line U87 treatment	"downregulated(miR-205), upregulation(miR-195)"	27574009
5391	Human	hsa-miR-195	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
5392	Human	hsa-miR-195	miRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	"human hepatocellular carcinoma cell line, BEL-7402"	5-fluorouracil (5-FU) treatment	upregulated	21947305
5393	Human	hsa-miR-195	miRNA	enterovirus 71 (EV71)	infant encephalitis	SH-SY5Y cells	Enterovirus 71 (EV71) infection	MicroRNA-195 suppresses enterovirus A71-induced pyroptosis in human neuroblastoma cells through targeting NLRX1	33253716
5394	Human	hsa-miR-195	miRNA	"MS-275, a histone deacetylase inhibitor"	lung adenocarcinoma (LUAD)	A549 and HCC827 cell lines	MS-275 treatment	upregulated	31090206
5395	Human	hsa-miR-195	miRNA	ailanthone (AIL)	lung cancer	A549 cells	ailanthone (AIL) treatment	upregulated	30565729
5396	Human	hsa-miR-195	miRNA	chronic brain hypoperfusion (CBH)	murine atherosclerosis and vascular smooth muscle cell proliferation	plasma	chronic brain hypoperfusion (CBH) treatment	downregulated	23447608
5397	Human	hsa-miR-195	miRNA	paraquat (PQ)	neural degenerative diseases	"human embryonic stem cell-derived neural progenitor cells, hESC-NPCs"	paraquat (PQ) treatment	upregulated	23807224
5398	Human	hsa-miR-195	miRNA	salidroside (SAL)	non-small cell lung cancer (NSCLC)	A549 cells	Salidroside treatment	upregulated	30880481
5399	Human	hsa-miR-195	miRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	primary chondrocytes	interleukin-1 beta (IL-1¦Â) and tumor necrosis factor-alpha (TNF-¦Á) treatment	downregulated	30575896
5400	Human	hsa-miR-195	miRNA	enterovirus 71 (EV71)	pyroptosis	SH-SY5Y cells	Enterovirus 71 (EV71) infection	miR-195 was significantly down-regulate in EV-A71-infected SH-SY5Y human neuroblastoma cells.	33253716
5401	Human	hsa-miR-195	miRNA	lipopolysaccharide (LPS)	sepsis	NCM460 cells	lipopolysaccharide (LPS) treatment	upregulated	31894250
5402	Human	hsa-miR-195	miRNA	lipopolysaccharide (LPS)	sepsis	human intestinal epithelial cells	lipopolysaccharide (LPS) treatment	miR-195 was significantly upregulated following LPS treatment.	31894250
5403	Human	hsa-miR-195	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-195 expression in CMS-treated PLL cells was restored by a demethylation reagent 5-aza-2'-deoxycytidine (AZA).	32432317
5404	Human	hsa-miR-195	miRNA	cyclic mechanical stretch (CMS)	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	cyclic mechanical stress (CMS) treatment	miR-195 was downregulated in treated PLL cells.	32432317
5405	Human	hsa-miR-195	miRNA	transretinoic acid/hydrocortisone (tRA/H)	thyroid cancer (TC)	MCF-7 human breast cancer cells	tRA/H treatment	downregulated	25404690
5406	Human	hsa-miR-195	miRNA	resistanceor endurance training	type 2 diabetes mellitus (T2DM)	middle-aged Polynesian men and women with morbid obesity (44 kg/m(2) ¡À 10) and Type 2 diabetes	16 wk of resistanceor endurance training treatment	dysregulated	25138607
5407	Human	hsa-miR-195-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
5408	Human	hsa-miR-195-5p	miRNA	caerulein (Cae)	acute pancreatitis (AP)	Human pancreatic duct epithelial cells (HPDE)	caerulein (Cae) treatment	"As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased."	32856219
5409	Human	hsa-miR-195-5p	miRNA	homocysteine (Hcy)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	homocysteine (HCY) treatment	downregulated	31629816
5410	Human	hsa-miR-195-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA CTBP1-AS2 may serve a role in AS by inhibiting the proliferation and promoting the autophagy of VSMCs through ATG14 modulation via miR-195-5p.	32626936
5411	Human	hsa-miR-195-5p	miRNA	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT)	cervical cancer (CC)	serum	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) treatment	upregulated	32851067
5412	Human	hsa-miR-195-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
5413	Human	hsa-miR-195-5p	miRNA	propofol (PPF)	gastric cancer (GC)	HGC-27 cells; AGS cells	Propofol treatment	"Propofol inhibited the proliferation and invasion, but enhanced the apoptosis of GC cells by regulating the circ-PVT1/miR-195-5p/ETS1 axis"	32945521
5414	Human	hsa-miR-195-5p	miRNA	microwave ablation (MWA)	hepatocellular carcinoma (HCC)	HCC cell lines	microwave ablation (MWA) treatment	SP1-induced upregulation of lncRNA CTBP1-AS2 accelerates the hepatocellular carcinoma tumorigenesis through targeting CEP55 via sponging miR-195-5p.	32988587
5415	Human	hsa-miR-195-5p	miRNA	lipopolysaccharide (LPS)	lung injury	human small airway epithelial cells (HSAECs)	Lipopolysaccharide (LPS) treatment	CASC9 protects lung epithelial cells from sepsis-induced injury via regulating miR-195-5p/PDK4 axis.	32221619
5416	Human	hsa-miR-195-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
5417	Human	hsa-miR-195-5p	miRNA	simulated tension strain	osteogenic differentiation and bone formation	human periodontal ligament cells (PDLCs)	simulated tension strain treatment	downregulated	28181691
5418	Human	hsa-miR-195-5p	miRNA	treponema pallidum (T. pallidum) infection	treponema pallidum (Tp) infection	peripheral blood mononuclear cells (PBMCs)	treponema pallidum (T. pallidum) infection treatment	upregulated	32087699
5419	Human	hsa-miR-195a	miRNA	endothelin-1 (ET-1)	sickle cell disease (SCD)	THP-1 cells and human peripheral blood monocytes	Endothelin-1 treatment	downregulated	20952681
5420	Human	hsa-miR-195a	miRNA	advanced glycation end product (AGE)	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPC)	advanced glycation end product (AGE) treatment	downregulated	32850952
5421	Human	hsa-miR-196	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
5422	Human	hsa-miR-196	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
5423	Human	hsa-miR-196	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?8 cells	heme treatment	upregulated	23538684
5424	Human	hsa-miR-196-5p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	"HCC (HCCLM3, SMMC7721, HepG2, Huh7, and Hep3B) cell lines"	hypoxia induce	downregulated	31713780
5425	Human	hsa-miR-196a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA SNHG1 regulates vascular endothelial cell proliferation and angiogenesis via miR-196a	32297149
5426	Human	hsa-miR-196a	miRNA	hemin	erythropoiesis	K562 cells	hemin treatment	miR-196a overexpression inhibits apoptosis in hemin-induced K562 cells through downregulating p27kip1.	31913716
5427	Human	hsa-miR-196a	miRNA	hypoxia	glioblastoma multiforme (GBM)	Glioblastoma (GBM)	hypoxia treatment	We identified miR-196a as a hypoxia-inducible and hypoxia-inducible factor (HIF)-regulated miRNA that plays an oncogenic role in GBM.	33469841
5428	Human	hsa-miR-196a	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
5429	Human	hsa-miR-196a	miRNA	hepatitis C virus (HCV) core protein	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 HCC cell lines	hepatitis C virus (HCV) core protein treatment	upregulated	27108614
5430	Human	hsa-miR-196a	miRNA	vascular endothelial growth factor (VEGF)	hepatocellular carcinoma (HCC)	Human umbilical vein endothelial cells (HUVECs)	treatment treatment	downregulated	22773844
5431	Human	hsa-miR-196a	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-196a was upregulated in propofol-treated group	24454982
5432	Human	hsa-miR-196a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
5433	Human	hsa-miR-196a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
5434	Human	hsa-miR-196a	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	upregulated	30182520
5435	Human	hsa-miR-196a-1	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cervical cancer (CC)	"cervical cell lines SiHa, CaSki and HeLa"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31326568
5436	Human	hsa-miR-196a2	miRNA	cisplatin (DDP)	myeloproliferative disorder	Blood samples	gemcitabine or cisplatin treatment	the SNP might affect mature?miR©\196a?expression and binding of mature?hsa©\miR©\196a2¨C3p	23143626
5437	Human	hsa-miR-196a2	miRNA	gemcitabine (GEM)	myeloproliferative disorder	Blood samples	gemcitabine or cisplatin treatment	the SNP might affect mature?miR©\196a?expression and binding of mature?hsa©\miR©\196a2¨C3p	23143626
5438	Human	hsa-miR-196a-5p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
5439	Human	hsa-miR-196a-5p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
5440	Human	hsa-miR-196a-5p	miRNA	anti-microbial peptide LL-37	rosacea	skin tissues	LL37 treatment	downregulated	33678493
5441	Human	hsa-miR-196b	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
5442	Human	hsa-miR-196b	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
5443	Human	hsa-miR-196b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
5444	Human	hsa-miR-196b	miRNA	curcumin (Cur)	chronic myeloid leukemia (CML)	Chronic Myelogenous Leukemia (CML) cells	curcumin treatment	upregulated	26116834
5445	Human	hsa-miR-196b	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	downregulated	31744065
5446	Human	hsa-miR-196b	miRNA	5-aza-2'-deoxycytidine and trichostatin A	leukemia	human leukemia cell lines	5-aza-deoxycytidine and trichostatin A treatment	upregulated	27570640
5447	Human	hsa-miR-196b	miRNA	platinum	lung adenocarcinoma (LUAD)	LADC tissues	platinum-based doublet chemotherapy treatment	dysregulated	25142144
5448	Human	hsa-miR-196b	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
5449	Human	hsa-miR-196b	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
5450	Human	hsa-miR-196b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	primary gastric tumors	U937;K562; HL60; Hep3B; HepG2;Huh-7; HT29; MDA-MB231; MCF-7; HeLa;LNCap; MRC5; H1299; GBM-8901; GBM-8401;U87; SHY5Y; HCS3; Cal27; MIA paca2; NCCIT;293T; GM05387; AGS; AZ-521; HR; TSGH;NUGC	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	20662076
5451	Human	hsa-miR-196b	miRNA	bacillus calmette-guerin (BCG)	tuberculosis (TB)	TB patients	bacillus calmette-guerin (BCG) treatment	downregulated	24586438
5452	Human	hsa-miR-196-b	miRNA	suberoylanilide hydroxamic acid (SAHA)	neuroblastoma (NB)	SH-SY5Y cells	suberoylanilide hydroxamic acid (SAHA) treatment	downregulated	30091530
5453	Human	hsa-miR-196b-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer (GC) tissues	Helicobacter pylori (H. pylori) infection	Patients with H. pylori infection had a higher expression of hsa-miR-196b-3p and CALML4 than those without H. pylori infection.	32802507
5454	Human	hsa-miR-196b-5p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
5455	Human	hsa-miR-196b-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	interferon-¦Ã (IFN-¦Ã) treatment	upregulated in PC-3M IE8 cells in the EMT induction model	31882179
5456	Human	hsa-miR-196b-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	Hsa-miR-196b-5p was upregulated in PC-3M IE8 cells treatment with IFN-¦Ã.	31882179
5457	Human	hsa-miR-196b-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
5458	Human	hsa-miR-196b-5p	miRNA	aldosterone	renal injury	HK-2 cells	aldosterone treatment	upregulated	32727744
5459	Human	hsa-miR-197	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
5460	Human	hsa-miR-197	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
5461	Human	hsa-miR-197	miRNA	aspirin	atherothrombotic risk in type 2 diabetes mellitus	blood	aspirin treatment	Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p?=?0.039) or prasugrel.	31910903
5462	Human	hsa-miR-197	miRNA	prasugrel	atherothrombotic risk in type 2 diabetes mellitus	blood	prasugrel treatmrnt treatment	Circulating miR-197 was lower in those cardiovascular disease during therapy with aspirin (p?=?0039) or prasugrel	31910903
5463	Human	hsa-miR-197	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	Peripheral Blood Mononuclear Cells(PBMC)	hepatitis B virus (HBV) infection	downregulated	23710316
5464	Human	hsa-miR-197	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
5465	Human	hsa-miR-197	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	31108165
5466	Human	hsa-miR-197	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
5467	Human	hsa-miR-197	miRNA	docetaxel (DTX)	head and neck squamous cell carcinoma (HNSCC)	UMSCC-1 cells;SQ20B cells	docetaxel (DTX) treatment	downregulated	21560177
5468	Human	hsa-miR-197	miRNA	IL-6 and signal transducers and activators of transcription 3 (STAT3)	hepatocellular carcinoma (HCC)	human HCC cell lines HepG2	IL-6/STAT3 treatment	downregulated	26451302
5469	Human	hsa-miR-197	miRNA	proanthocyanidin extract (GSPE)	hepatocellular carcinoma (HCC)	HepG2 cells	proanthocyanidin extract (GSPE) treatment	upregulated	21998738
5470	Human	hsa-miR-197	miRNA	quercetin	meningioma	HBL-52 meningioma cells	quercetin treatment	Quercetin treatment increases miR-197 mRNA	32585423
5471	Human	hsa-miR-197	miRNA	taxol	ovarian cancer (OC)	ovarian cancer cells	Taxol resistance treatment	upregulated	25833695
5472	Human	hsa-miR-197	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
5473	Human	hsa-miR-197	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
5474	Human	hsa-miR-197	miRNA	enterovirus 71 (EV71)	severe central nervous system complications	"Human rhabdomyosarcoma (RD) cells,human embryonic kidney (HEK293T) cells"	Enterovirus 71 (EV71) treatment	downregulated	26581983
5475	Human	hsa-miR-1972	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
5476	Human	hsa-miR-1972	miRNA	cisplatin (DDP)	ovarian cancer (OC)	OC lines (SKOV-3 and A2780)	cisplatin treatment	upregulated	31865363
5477	Human	hsa-miR-1973	miRNA	hantaan virus (HTNV)	hantaan virus (HTNV) infection	A549 cells	hantavirus(HTNV)treatment	upregulated	24074584
5478	Human	hsa-miR-1973	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
5479	Human	hsa-miR-1973	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
5480	Human	hsa-miR-197-3p	miRNA	asbestos fibers	malignant pleural mesothelioma (MPM)	serum	ex-exposed to asbestos fibers (WEA)	downegulated	27716620
5481	Human	hsa-miR-197-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	neutrophil	M.tb infection	downregulated	29477867
5482	Human	hsa-miR-1975	miRNA	influenza A virus (IAV)	innate immune response	A549 cells	Influenza virus A (IVA) infection	upregulated	31416454
5483	Human	hsa-miR-198	miRNA	bortezomib	diffuse large B-cell lymphoma (DLBCL)	DLBCL CRL-2630 cells	bortezomib? treatment	upregulated	30216798
5484	Human	hsa-miR-198	miRNA	cisplatin (DDP)	gastric cancer (GC)	"GC tissues and cells SGC7901, BGC823"	cisplatin treatment	downregulated	30927924
5485	Human	hsa-miR-198	miRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	glioblastoma cells	TGF-¦Â1 treatment	?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling	32813021
5486	Human	hsa-miR-198	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
5487	Human	hsa-miR-199	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	human nucleus pulposus cells injury	Human nucleus pulposus cells	tumor necrosis factor alpha (TNF-¦Á) treatment	miR-199 was extremely decreased in Human nucleus pulposus cells after TNF-¦Á treatment	30309653
5488	Human	hsa-miR-199	miRNA	molecular hydrogen	inflammatory injury	Retinal Microglia cells	Molecular hydrogen?treatment	upregulated	23826519
5489	Human	hsa-miR-199	miRNA	TGF-¦Â1	myofibroblast proliferation	foreskins of unidentified normal neonates tissue	Transforming growth factor-¦Â1 treatment	"TGF-¦Â1 downregulated HGF in primary human adult pulmonary fibroblasts (HLFb) and increased the expression of miR-199a-3p, a microRNA (miRNA) associated with fibrotic remodeling"	23657814
5490	Human	hsa-miR-199a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	lipopolysaccharide (LPS) treatment	The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells	32069473
5491	Human	hsa-miR-199a	miRNA	propofol (PPF)	apoptosis	HepG2 cells	Propofol?treatment treatment	Propofol significantly elevated the expression of miR-199a and inhibited the invasiveness of HepG2 cells	23742776
5492	Human	hsa-miR-199a	miRNA	dacarbazine and interferon-alfa-2b	breast cancer	circulating endothelial cells	dacarbazine and interferon-alfa-2b treatment	Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a	23217102
5493	Human	hsa-miR-199a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	"high glucose (25 mmol/L, 1-7 days)"	"downregulated (miR-124,miR-125b,miR-135b,miR-199a);upregulated (miR-145,miR-146a)"	28706953
5494	Human	hsa-miR-199a	miRNA	hypoxia	epithelial ovarian cancer (EOC)	EOCC	1-3% O2 treatment	upregulated	24706848
5495	Human	hsa-miR-199a	miRNA	reactive oxygen species (ROS)	Epstein-Barr virus (EBV) infection	ovarian cancer cells	reactive oxygen species (ROS) treatment	downregulated	23146892
5496	Human	hsa-miR-199a	miRNA	hypoxia	fat	non-small cell lung cancer cells	hypoxia treatment	downregulated	22119803
5497	Human	hsa-miR-199a	miRNA	dauricine (Dau)	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 HCC cells	Dauricine (Dau) treatment	upregulated	30171973
5498	Human	hsa-miR-199a	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma cells	Propofol treatment	upregulated	23319430
5499	Human	hsa-miR-199a	miRNA	hypoxia	hypoxia-induced injury	human dermal microvascular endothelial cells (hDMECs)	hypoxia induce	downregulated	31537150
5500	Human	hsa-miR-199a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
5501	Human	hsa-miR-199a	miRNA	sodium selenite and Se-methylselenocysteine (MSC)	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite and Se-methylselenocysteine (MSC) treatment	downregulated	32656599
5502	Human	hsa-miR-199a	miRNA	hepatitis C virus (HCV)	liver cirrhosis	liver	hepatitis C virus (HCV) infection	The serum level of miR-199a in chronic HCV patients was significantly lower than in healthy controls (P = 0.001).	26133725
5503	Human	hsa-miR-199a	miRNA	chemokine CCL5	malignant bone cancer	JJ012/CCL5 cells	CCL5 treatment	downregulated	25444917
5504	Human	hsa-miR-199a	miRNA	arctigenin	mechanical trauma injury	scratch-induced injury of human SH-SY5Y cells	arctigenin (ARC) treatment	upregulated	27389368
5505	Human	hsa-miR-199a	miRNA	nitric oxide donors	nitrate tolerance	human umbilical vein endothelial cells	nitric oxide donors treatment	upregulated	29431644
5506	Human	hsa-miR-199a	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
5507	Human	hsa-miR-199a	miRNA	curcumin (Cur)	pancreatic cancer (PC)	The BxPC-3 human pancreatic carcinoma cell line	curcumin (diferuloylmethane)? treatment	downregulated	18347134
5508	Human	hsa-miR-199a	miRNA	dexamethasone (DEX)	steatosis	HepG3 cells	dexamethasone (Dex) treatment	downregulated	29409992
5509	Human	hsa-miR-199a	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	testicular germ cell tumors (TGCTs)	NTERA2 and NCCIT cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	upregulated	31802647
5510	Human	hsa-miR-199a	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	testicular germ cell tumors (TGCTs)	NTERA2 cells; NCCIT cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	miR-199a was decreased in TGCTs but was increased by PG in a dose-dependent manner.	31802647
5511	Human	hsa-miR-199a*	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
5512	Human	hsa-miR-199a*	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
5513	Human	hsa-miR-199a2	miRNA	placenta growth factor (PlGF)	hypertension	endothelial cells	PlGF treatment	downregulated	25389292
5514	Human	hsa-miR-199a-3p	miRNA	p53	acute kidney injury (AKI)	HK-2 human renal tubular epithelial cells	p53 deficiency treatment	downregulated	31148231
5515	Human	hsa-miR-199a-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human epithelial cell line A549 and the human macrophage cell line U937	?lipopolysaccharide (LPS) treatment	downregulated	31754335
5516	Human	hsa-miR-199a-3p	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 12¡ã HDT bed rest experiment	downregulated	28261104
5517	Human	hsa-miR-199a-3p	miRNA	CL 316243 disodium salt	brown adipocyte differentiation	human brown adipocyte	CL 316243 disodium salt treatment	downregulated	29753771
5518	Human	hsa-miR-199a-3p	miRNA	forskolin (FSK)	brown adipocyte differentiation	human brown adipocyte	forskolin (FSK) treatment	downregulated	29753771
5519	Human	hsa-miR-199a-3p	miRNA	H2O2	brown adipocyte differentiation	human brown adipocyte	H2O2 treatment	upregulated	29753771
5520	Human	hsa-miR-199a-3p	miRNA	norepinephrine (NE)	brown adipocyte differentiation	human brown adipocyte	norepinephrine treatment	downregulated	29753771
5521	Human	hsa-miR-199a-3p	miRNA	lipopolysaccharide (LPS)	cervical remodeling	ect1/e6e7 cells; end1/e6e7 cells	lipopolysaccharide (LPS) treatment	downregulated	32468045
5522	Human	hsa-miR-199a-3p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
5523	Human	hsa-miR-199a-3p	miRNA	bone morphogenetic protein 2 (BMP2)	glioblastoma multiforme (GBM)	Glioblastoma stem-like cells (GSCs) cell U87S	bone morphogenetic protein 2 (BMP2) treatment	upregulated	32884997
5524	Human	hsa-miR-199a-3p	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	Hepatic stem-like epithelial cells (LE/6)	hepatitis B virus X protein (HBx) treatment	upregulated	31740785
5525	Human	hsa-miR-199a-3p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	SNU-182 cells; HUH7 cells	hypoxia treatment	downregulated	32670881
5526	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â1	hepatocellular carcinoma (HCC)	Hepatic stem-like epithelial cells (LE/6)	TGF-¦Â1 treatment	upregulated	31740785
5527	Human	hsa-miR-199a-3p	miRNA	dapagliflozin	hypertensive patients with type 2 diabetes	plasma	dapagliflozin treatment	downregulated	31162549
5528	Human	hsa-miR-199a-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
5529	Human	hsa-miR-199a-3p	miRNA	dextran-capped nanosized europium(III) hydroxides [Eu(OH)3] nanoclusters (NCs)	ischemic heart/limb diseases and tissue regeneration	human umbilical vein endothelial cells (HUVECs)	dextran-capped nanosized europium(III) hydroxides [Eu(OH)3] nanoclusters (NCs) treatment	upregulated	30148600
5530	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
5531	Human	hsa-miR-199a-3p	miRNA	gambogic acid (GA)	melanoma	A375 cells	gambogic acid (GA) treatment	upregulated	29959879
5532	Human	hsa-miR-199a-3p	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	Hepa1-6 cells	oleic acid treatment	downregulated	28469795
5533	Human	hsa-miR-199a-3p	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Hepa1-6 cells	palmitic acid (PA) treatment	downregulated	28469795
5534	Human	hsa-miR-199a-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	33494069
5535	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â and EGF	pterygium	human conjunctival epithelial cells (HCEs)	TGF-¦Â and EGF treatment	TGF-¦Â and EGF induce EMT of HCEs through miR-199a-3p/5p-DUSP5/MAP3K11 axes	32867783
5536	Human	hsa-miR-199a-3p	miRNA	high glucose (HG)	renal tubular epithelial cells (RTEC) injury	HK-2 cells	high glucose (HG) treatment	miR-199a-3p expression was time-dependently decreased in the HG-induced cell damage model.	33125105
5537	Human	hsa-miR-199a-3p	miRNA	Bt2cAMP	type II pneumocyte differentiation	cultured human fetal lung (HFL) epithelial cells	Bt2cAMP treatment	downregulated	29507184
5538	Human	hsa-miR-199a-3p	miRNA	TGF-¦Â1	unilateral ureteral obstruction (UUO)	human kidney tubular epithelial cells (HK-2)	TGF-¦Â1 treatment	upregulated	28240316
5539	Human	hsa-miR-199a-5p	miRNA	human serum albumin (HSA)	diabetic nephropathy (DN)	extracellular vesicles from HSA-induced HK-2 cells	human serum albumin (HSA) treatment	upregulated	31208912
5540	Human	hsa-miR-199a-5p	miRNA	alpha-1 antitrypsin (AAT)	anti-inflammatory responses	monocytes of AAT deficient (ZZ) individuals	alpha-1 antitrypsin (AAT) treatment	downregulated	29062067
5541	Human	hsa-miR-199a-5p	miRNA	peroxisome proliferator activated receptor gamma (PPAR¦Ã)	aplastic anemia (AA)	bone marrow-derived mesenchymal stem cells (BM-MSCs)	PPAR gamma (PPAR¦Ã) treatment	upregulated	31400610
5542	Human	hsa-miR-199a-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	arsenite-induced carcinogenesis	arsenic-exposured lung epithelial cells (BEAS-2B and HLF1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31170415
5543	Human	hsa-miR-199a-5p	miRNA	arsenite	arsenite-induced carcinogenesis	lung epithelial cells (BEAS-2B and HLF1)	arsenic exposure	downregulated	31170415
5544	Human	hsa-miR-199a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32339345
5545	Human	hsa-miR-199a-5p	miRNA	hypoxia	cardiac dysfunction	serum	chronic hypoxia at high altitudes	"The level of miR-199a-5p was significantly higher in individuals with poor exercise capacity at 3,800 m, compared with those with good exercise capacity"	33633582
5546	Human	hsa-miR-199a-5p	miRNA	human cytomegalovirus (HCMV)	cell migration and tube formation	Human umbilical vein endothelial cells (HUVECs)	human cytomegalovirus infection	upregulated	23760629
5547	Human	hsa-miR-199a-5p	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	K562 cells	Imatinib (IM) treatment	downregulated	29890129
5548	Human	hsa-miR-199a-5p	miRNA	steroids	endometriosis	ovarian endometrial	steroid hormones treatment	upregulated	26819477
5549	Human	hsa-miR-199a-5p	miRNA	hypoxia	endoplasmic reticulum stress (ERS)	Human umbilical vein endothelial cells (HUVECs) and derived exosomes	hypoxia induce	upregulated	31634452
5550	Human	hsa-miR-199a-5p	miRNA	hypoxia/reoxygenation (H/R)	endoplasmic reticulum stress (ERS)	human umbilical vein endothelial cells (HUVEC)	hypoxia/re-oxygenation (H/R) treatment	H/R administration increased miR-199a-5p levels both in HUVECs and exosomes.	31634452
5551	Human	hsa-miR-199a-5p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells; SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
5552	Human	hsa-miR-199a-5p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
5553	Human	hsa-miR-199a-5p	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	?human HCC cell lines	cisplatin (DPP) treatment	downregulated	22713463
5554	Human	hsa-miR-199a-5p	miRNA	hypoxia	multiple myeloma (MM)	multiple myeloma (MM) cells	hypoxia treatment	downregulated	24839982
5555	Human	hsa-miR-199a-5p	miRNA	deoxycholic acid (DCA)	non-small cell lung cancer (NSCLC)	human primary colonic epithelial cells	The deoxycholic acid? treatment	downregulated	22903020
5556	Human	hsa-miR-199a-5p	miRNA	visfatin	osteoarthritis (OA)	human OA synovial fibroblasts (OASFs)	visfatin treatment	downregulated	29316707
5557	Human	hsa-miR-199a-5p	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cell lines PANC-1 and BxPC-3	Metformin treatment	dysregulated	28875433
5558	Human	hsa-miR-199a-5p	miRNA	high glucose (HG)	peritoneal dialysis (PD)	human peritoneal mesothelial cells (HPMCs)	high-glucose (HG)	upregulated	28428333
5559	Human	hsa-miR-199a-5p	miRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	LUCAT1 likely promotes HG-induced EMT through ZEB1 by sponging miR-199a-5p.	33426083
5560	Human	hsa-miR-199a-5p	miRNA	hypoxia	seizure	epileptic brain	hypoxia treatment	downregulated	25539181
5561	Human	hsa-miR-199a-5p	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
5562	Human	hsa-miR-199a-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
5563	Human	hsa-miR-199a-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
5564	Human	hsa-miR-199a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	"CircVMA21 and NRP1 were decreased, and miR-199a-5p was increased in LPS-induced THP-1 cells."	33647793
5565	Human	hsa-miR-199a-5p	miRNA	arsenite	arsenite-induced carcinogenesis	human lung epithelial BEAS-2B cells	arsenic exposure	upregulated	24413338
5566	Human	hsa-miR-199a-5p	miRNA	Bt2cAMP	type II pneumocyte differentiation	cultured human fetal lung (HFL) epithelial cells	Bt2cAMP treatment	downregulated	29507184
5567	Human	hsa-miR-199b	miRNA	lipopolysaccharide (LPS)	acute spinal cord injury (ASCI)	primary microglia	lipopolysaccharide (LPS) treatment	miR-199b was significantly decreased in microglia stimulated by LPS.	29631367
5568	Human	hsa-miR-199b	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	miR-199b was highly expressed in TGF-¦Â1-treated HK-2 cells	30125566
5569	Human	hsa-miR-199b	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
5570	Human	hsa-miR-199b	miRNA	trichloroethylene (TCE)	liver damage	human HL-7702 cells	Trichloroethylene (TCE) treatment	downregulated	31140026
5571	Human	hsa-miR-199b	miRNA	5-fluorouracil (5-Fu)	locally advanced rectal cancer (LARC)	SW480 cells	5-fluorouracil (5-FU) treatment	downregulated	32580513
5572	Human	hsa-miR-199b	miRNA	nitric oxide donors	nitrate tolerance	human umbilical vein endothelial cells	nitric oxide donors treatment	upregulated	29431644
5573	Human	hsa-miR-199b-5p	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	K562 cells	Imatinib (IM) treatment	downregulated	29890129
5574	Human	hsa-miR-199b-5p	miRNA	atrasentan	diabetic nephropathy (DN)	Human renal proximal tubular epithelial HK-2 cells	atractylon (Atr)?treatment	downregulated	29623952
5575	Human	hsa-miR-199b-5p	miRNA	tigecycline (TGC)	malignant glioma	U87 glioma cells	tigecycline treatment	upregulated	26823491
5576	Human	hsa-miR-199b-5p	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
5577	Human	hsa-miR-199b-5p	miRNA	lipopolysaccharide (LPS)	rejection after lung transplantation	THP-1 monocytes	lipopolysaccharide (LPS) treatment	downregulated	29779167
5578	Human	hsa-miR-199b-5p	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	Peripheral blood cells	imatinib mesylate treatment	downregulated	20460641
5579	Human	hsa-miR-19a	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver failure (ALF)	primary hepatocyte and hepatocytes line HL-7702	D-GalN and LPS treatment	upregulated	28586153
5580	Human	hsa-miR-19a	miRNA	phosphatase of regenerating liver-3 (PRL-3)	angiogenesis	colon cancer cells	Phosphatase of regenerating liver-3 (PRL-3) treatment	"overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3"	22677902
5581	Human	hsa-miR-19a	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	autophagy	primary human hepatocytes; HL-7702 cells	D-galactosamine (D-GalN) and lipopolysaccharide (LPS) treatment	upregulated	28586153
5582	Human	hsa-miR-19a	miRNA	arsenic trioxide (ATO)	bladder cancer	T24 human bladder carcinoma cells	arsenic trioxide?treatment	downregulated	20857258
5583	Human	hsa-miR-19a	miRNA	bisphenol A (BPA)	breast cancer	MCF-7 human breast cancer cells	bisphenol A (BPA) treatment	upregulated	24831732
5584	Human	hsa-miR-19a	miRNA	butyl benzyl phthalate (BBP)	breast cancer	MCF-7 cells; MDA-MB-231 cells	Butyl benzyl phthalate (BBP) treatment	BBP significantly induced the expression of miR-19a.	29864457
5585	Human	hsa-miR-19a	miRNA	cold atmospheric plasma (CAP)	breast cancer	MCF-7 breast cancer cell	Cold atmospheric plasma (CAP) treatment	downregulated	27445062
5586	Human	hsa-miR-19a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	downregulated	29189128
5587	Human	hsa-miR-19a	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
5588	Human	hsa-miR-19a	miRNA	hypoxia	cell proliferation and migration	human pulmonary arterial smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	31682848
5589	Human	hsa-miR-19a	miRNA	IL-6	chronic lymphocytic leukemia (CLL)	chronic lymphocytic leukemia (CLL) cells	IL-6 treatment	upregulated	26041742
5590	Human	hsa-miR-19a	miRNA	hepatitis C virus (HCV)	cognitive impairment	monocyte-derived exosome	hepatitis C virus (HCV) infection	upregulated	32157304
5591	Human	hsa-miR-19a	miRNA	human immunodeficiency virus (HIV)-1	cognitive impairment	monocyte-derived exosome	human immunodeficiency virus (HIV)-1 infectiom	upregulated	32157304
5592	Human	hsa-miR-19a	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HT29 cells	Oxaliplatin treatment	miR-19a was significantly increased in SW480/R and HT29/R compared to their parental SW480 and HT29	32209726
5593	Human	hsa-miR-19a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	colorectal cancer (CRC) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26302825
5594	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	apoptosis	HUVECs and EAhy926 cells	lipopolysaccharide (LPS) treatment	downregulated	25982447
5595	Human	hsa-miR-19a	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell	Deacetylase inhibitors (DACi)treatment	downregulated	24375802
5596	Human	hsa-miR-19a	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell lines	Deacetylase inhibitors (DACi) treatment	downregulated	24375802
5597	Human	hsa-miR-19a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
5598	Human	hsa-miR-19a	miRNA	pterostilbene	hepatocellular carcinoma (HCC)	SMMC-7721 HCC cells	Pterostilbene (Pter) treatment	miR-19a expression was decreased by Pter treatment in a dose-depen-dent manner in SMMC-7721 cells	29393488
5599	Human	hsa-miR-19a	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
5600	Human	hsa-miR-19a	miRNA	berberine (BBR)	multiple myeloma (MM)	RPMI-8266 cells; U266 cells	berberine (BBR) treatment	Berberine downregulated miR-19a expression in multiple myeloma (MM) cells.	29687521
5601	Human	hsa-miR-19a	miRNA	aluminum maltolate (Al-malt)	neurodegenerative pathogenesis	neuroblastoma SH-SY5Y cells	aluminum maltolate (Al-malt) treatment	downregulated	26836165
5602	Human	hsa-miR-19a	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"lung tissues, A549 and H460 cells"	?cisplatin treatment	lncRNA-AC0788833/miR-19a/PTEN/AKT pathway contributed to the development of chemoresistance against cisplatin	31111480
5603	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human primary chondrocytes	lipopolysaccharide (LPS) treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
5604	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human primary chondrocytes	lipopolysaccharide (LPS)? treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
5605	Human	hsa-miR-19a	miRNA	Rh-endostatin	pancreatic cancer (PC)	ASPC-1 cells	Rh-endostatin treatment	downregulated	26041879
5606	Human	hsa-miR-19a	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity	HTR-8/SVneo cells	Perfluorooctane sulfonic acid (PFOS) treatment	downregulated	32738709
5607	Human	hsa-miR-19a	miRNA	fractional CO(2) laser	prostate cancer	types I and III procollagen	treatment with a fractional CO(2) laser	miR-18a and miR-19a were dramatically upregulated	22907286
5608	Human	hsa-miR-19a	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
5609	Human	hsa-miR-19a	miRNA	lipopolysaccharide (LPS)	sepsis	human bronchial epithelial cells (HBEpCs)	lipopolysaccharide (LPS) treatment	"THRIL is upregulated in sepsis and may sponge miR-19a to upregulate TNF-¦Á, thereby promoting lung cell apoptosis."	32944003
5610	Human	hsa-miR-19a	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	human colon tissue with UC and DSS-treated mice colitis tissues	dextran sodium sulfate (DSS) treatment	downregulated	23795660
5611	Human	hsa-miR-19a-3p	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
5612	Human	hsa-miR-19a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	H19 was upregulated whereas miR-19a-3p was downregulated in I/R tissues and OGD/R induced cells	32335212
5613	Human	hsa-miR-19a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-19a-3p was significantly upregulated in rat I/R brain tissues and OGD/R induced SH-SY5Y cells.	32312329
5614	Human	hsa-miR-19a-3p	miRNA	baicalin (BAI)	cervical cancer (CC)	Human CC cell lines (HeLa and SiHa)	baicalin (BAI) treatment	downregulated	33603395
5615	Human	hsa-miR-19a-3p	miRNA	TGF-¦Â1	fibrogenesis	human cardiac fibroblasts	TGF-¦Â1? treatment	downregulated	27098600
5616	Human	hsa-miR-19a-3p	miRNA	shock wave therapy (SWT)	ischemic heart disease (IHD)	human umbilical vein endothelial cells (HUVECs)	shock wave therapy (SWT) treatment	miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy	31410448
5617	Human	hsa-miR-19b	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
5618	Human	hsa-miR-19b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	Endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	26459935
5619	Human	hsa-miR-19b	miRNA	bisphenol A (BPA)	breast cancer	MCF-7 human breast cancer cells	bisphenol A (BPA) treatment	upregulated	24831732
5620	Human	hsa-miR-19b	miRNA	butyl benzyl phthalate (BBP)	breast cancer	MCF-7 cells; MDA-MB-231 cells	Butyl benzyl phthalate (BBP) treatment	BBP significantly induced the expression of miR-19b.	29864457
5621	Human	hsa-miR-19b	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	downregulated	29189128
5622	Human	hsa-miR-19b	miRNA	glucagon-like peptide-1 (GLP-1)	cholesterol-induced lipotoxicity	HepG2 cells	Glucagon-like peptide-1 (GLP-1) treatment	downregulated	30308521
5623	Human	hsa-miR-19b	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	upregulated	31226416
5624	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	downregulated	31226416
5625	Human	hsa-miR-19b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	upregulated	32519748
5626	Human	hsa-miR-19b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression.	33022863
5627	Human	hsa-miR-19b	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	human LO2 cells	?acetaminophen (APAP) treatment	downregulated	31077331
5628	Human	hsa-miR-19b	miRNA	mechanical stretch	epithelial-mesenchymal transition (EMT)	primary human alveolar epithelial type II (AEII) cells	mechanical stretch	upregulated	27508324
5629	Human	hsa-miR-19b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
5630	Human	hsa-miR-19b	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
5631	Human	hsa-miR-19b	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells of LTNPs	Human immunodeficiency virus (HIV) infection	The levels of microRNA-19b (miR-19b) were found to be significantly increased in peripheral blood mononuclear cells of LTNPs with lower rather than higher viral load.	30687333
5632	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	upregulated	28213977
5633	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	upregulated	28213977
5634	Human	hsa-miR-19b	miRNA	alcohol	liver damage	LX2 cells	alcohol exposure	downregulated	27291156
5635	Human	hsa-miR-19b	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	downregulated	25552929
5636	Human	hsa-miR-19b	miRNA	AZD8055	neuroblastoma (NB)	neuroblastoma cells	AZD8055 treatment	downregulated	27492819
5637	Human	hsa-miR-19b	miRNA	rapamycin	neuroblastoma (NB)	neuroblastoma cells	rapamycin treatment	upregulated	27492819
5638	Human	hsa-miR-19b	miRNA	aluminum maltolate (Al-malt)	neurodegenerative pathogenesis	neuroblastoma SH-SY5Y cells	aluminum maltolate (Al-malt) treatment	downregulated	26836165
5639	Human	hsa-miR-19b	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity	HTR-8/SVneo cells	Perfluorooctane sulfonic acid (PFOS) treatment	downregulated	32738709
5640	Human	hsa-miR-19b	miRNA	herbal formula HQT	rheumatoid arthritis (RA)	fibroblast-like synoviocytes	herbal formula HQT treatment	downregulated	32696503
5641	Human	hsa-mir-19b	miRNA	Tongbi formula (HQT)	rheumatoid arthritis (RA)	RA-derived human fibroblast-like synoviocytes (HFLS-RA)	Tongbi formula (HQT) treatment	downregulated	32696503
5642	Human	hsa-miR-19b	miRNA	H2O2	skin wound healing	Human adipose-derived mesenchymal stem cells (ADMSCs)	H2O2 treatment	"Exosomal miR-19b derived from ADMSCs regulates the TGF-¦Â pathway by targeting CCL1, thereby promoting the healing of skin wounds."	33364805
5643	Human	hsa-miR-19b	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	Caco2 cells	lipopolysaccharide (LPS) treatment	"LPS significantly induced Caco2 cell inflammatory injury, downregulated miR-19b expression."	30178853
5644	Human	hsa-miR-19b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	"Our results showed that lncRNA H19 and SIRT1 were reduced, while miR-19b was increased in ARPE-19 cells with HG condition."	33022863
5645	Human	hsa-miR-19b1	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell	Deacetylase inhibitors (DACi)treatment	downregulated	24375802
5646	Human	hsa-miR-19b-1	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
5647	Human	hsa-miR-19b1	miRNA	deacetylase inhibitors (DACi)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell lines	Deacetylase inhibitors (DACi) treatment	downregulated	24375802
5648	Human	hsa-miR-19b-1-5p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
5649	Human	hsa-miR-19b-3p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) treatment	The expression levels of miR-16-5p and miR-19b-3p were reduced but BACE1 protein expression was enhanced in SH-SY5Y cells after treatment of amyloid ¦Â.	31876684
5650	Human	hsa-miR-19b-3p	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
5651	Human	hsa-miR-19b-3p	miRNA	hypoxia	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	31933110
5652	Human	hsa-miR-19b-3p	miRNA	TGF-¦Â1	fibrogenesis	human cardiac fibroblasts	TGF-¦Â1? treatment	downregulated	27098600
5653	Human	hsa-miR-19b-3p	miRNA	matrine	melanoma	A375 cells; SK-MEL-2 melanoma cells	Matrine treatment	downregulated	29845233
5654	Human	hsa-miR-19b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	miR-19b-3p prevent osteoarthritis progression by targeting EZH2.	32765678
5655	Human	hsa-miR-2	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	colorectal cancer (CRC)	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28100780
5656	Human	hsa-miR-20	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
5657	Human	hsa-miR-200	miRNA	busulfan	anti-osteosarcoma effect	human osteosarcoma U2OS and MG63 cells lines	busulfan treatment	upregulated	24815002
5658	Human	hsa-miR-200	miRNA	retinoic acid (RA)	breast cancer	MDA-MB-231 breast cancer cells	retinoic acid treatment	upregulated	23904188
5659	Human	hsa-miR-200	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells	Tamoxifen treatment	upregulated	29738694
5660	Human	hsa-miR-200	miRNA	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	colorectal cancer (CRC)	HCT116 cells£»HT29 cells£»SW480 cells£» SW620 cells	3-acetyl-11-keto-¦Â-boswellic acid (AKBA)	upregulated	22983985
5661	Human	hsa-miR-200	miRNA	catalpol	colorectal cancer (CRC)	human HCT116 colorectal cancer cells	catalpol treatment	upregulated	28927141
5662	Human	hsa-miR-200	miRNA	NPV-LDE-225 (Erismodegib)	human immunodeficiency virus (HIV)-1 infection	Glioblastoma initiating cells (GICs)	NPV-LDE-225 (Erismodegib) treatment	downregulated	23482671
5663	Human	hsa-miR-200	miRNA	"3,3'-diindolylmethane (DIM)"	human cytomegalovirus (HCMV) infection	Breast cancer cell lines SKBR3£» MDA-MB-468 cells	"?3, 3'-diindolylmethane (DIM) treatment"	upregulated	23372748
5664	Human	hsa-miR-200	miRNA	high fat diet (HFD)	inflammation	plasma	high fat diet (HFD) feed	upregulated	30885503
5665	Human	hsa-miR-200	miRNA	triacetyl resveratrol (TCRV)	pancreatic cancer (PC)	human pancreatic cancer AsPC-1 and PANC-1 cells	triacetyl resveratrol (TCRV) treatment	upregulated	30720134
5666	Human	hsa-miR-200	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
5667	Human	hsa-miR-200	miRNA	tamoxifen (TAM)	epithelial-mesenchymal transition (EMT)	Endometrial epithelial cancer ECC-1 cells	Although tamoxifen treatment	TAM can repress the miR-200 family and induce EMT via the upregulated of c-Myc in endometrial cancer cells	23295740
5668	Human	hsa-miR-200-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	miR-200-3p suppresses cell proliferation and reduces apoptosis in diabetic retinopathy via blocking the TGF-¦Â2/Smad pathway	33150936
5669	Human	hsa-miR-200a	miRNA	Pien Tze Huang (PZH)	anti-cancer therapy	human colorectal carcinoma HCT-8 cells	PZH treatment	upregulated	25422078
5670	Human	hsa-miR-200a	miRNA	curcumin (Cur)	breast cancer	MCF-10F cells	curcumin (Cur) treatment	upregulated	31894298
5671	Human	hsa-miR-200a	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
5672	Human	hsa-miR-200a	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 breast cancer cells	Glabridin treatment	upregulated	24754877
5673	Human	hsa-miR-200a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
5674	Human	hsa-miR-200a	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
5675	Human	hsa-miR-200a	miRNA	estrogen receptor ¦Â	colorectal cancer (CRC)	Cell lines (SW480;HT29 ;SW620)	Estrogen receptor ¦Â treatment	the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated	23436804
5676	Human	hsa-miR-200a	miRNA	astaxanthin	colorectal cancer (CRC)	The human colon cancer cell HCT116	astaxanthin (ATX) treatment	upregulated	31263239
5677	Human	hsa-miR-200a	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human colorectal carcinoma HCT-8 cells	Pien Tze Huang (PZH) treatment	upregulated	25422078
5678	Human	hsa-miR-200a	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 116 cells	RM (Root methanol) treatment	upregulated	32691634
5679	Human	hsa-miR-200a	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HCT-8 cells	Ursolic acid (UA) treatment	upregulated	31452805
5680	Human	hsa-miR-200a	miRNA	LEFTY2	endometrial cancer (EC)	Ishikawa cells	LEFTY2 treatment	upregulated	27497669
5681	Human	hsa-miR-200a	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
5682	Human	hsa-miR-200a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-200a towards the control level.	32387379
5683	Human	hsa-miR-200a	miRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	SW480 cells; HCT116 cells	metformin treatment	upregulated	30017802
5684	Human	hsa-miR-200a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	HK-2 cells	treat with TGF ¦Â1 treatment	downregulated	28817830
5685	Human	hsa-miR-200a	miRNA	dexamethasone (DEX)	femoral head necrosis (FHN)	human osteoblasts	dexamethasone (DEX) treatment	downregulated	29285219
5686	Human	hsa-miR-200a	miRNA	allopurinol	fructose-induced hepatic inflammation	fructose-induced rats HepG2 cells	allopurinol treatemnt	upregulated	30248460
5687	Human	hsa-miR-200a	miRNA	curcumin (Cur)	fructose-induced hepatic inflammation	fructose-induced rats HepG2 cells	curcumin treatment	upregulated	30248460
5688	Human	hsa-miR-200a	miRNA	fructose	fructose-induced hepatic inflammation	HepG2 cells	fructose treatment	downregulated	30248460
5689	Human	hsa-miR-200a	miRNA	toosendanin (TSN)	gastric cancer (GC)	SGC-7901 cells	TSN treatment	upregulated	29048657
5690	Human	hsa-miR-200a	miRNA	TGF-¦Â	glaucoma filtration surgery (GFS)	primary human Tenon's capsule fibroblasts (HTFs)	TGF-¦Â treatment	H19 exerted its effects by interacting with miR-200a in TGF-¦Â-treated HTFs	31877306
5691	Human	hsa-miR-200a	miRNA	radiotherapy	head and neck squamous cell carcinoma (HNSCC)	neck squamous cell carcinoma patients saliva samples	radiotherapy treatment	upregulated in saliva samples	28677748
5692	Human	hsa-miR-200a	miRNA	TGF-¦Â1	liver fibrosis	Hepatic stellate cell (HSC)	TGF-¦Â1 treatment	downregulated	24242045
5693	Human	hsa-miR-200a	miRNA	HepG2-CORE cells conditioned media (CM)	hepatitis C virus (HCV)-related liver fibrosis	LX-2 cells	treated with HepG2-CORE CM	downregulated	28302418
5694	Human	hsa-miR-200a	miRNA	histone deacetylase 4 (HDAC4)	hepatocellular carcinoma (HCC)	Human HCC Tissues	histone deacetylase 4 (HDAC4)? treatment	downregulated	21837748
5695	Human	hsa-miR-200a	miRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia induce	"LncRNA MALAT1 was involved in proliferation, migration, invasion, and apoptosis by interacting with miR-200a in hypoxic Hep3B cells, revealing a new mechanism of MALAT1 involved in hypoxic HCC progression."	31347327
5696	Human	hsa-miR-200a	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
5697	Human	hsa-miR-200a	miRNA	angiotensin II (Ang II)	hypertension and diabetes	AB8/13 cells	angiotensin II (Ang II) treatment	upregulated	32887498
5698	Human	hsa-miR-200a	miRNA	high glucose (HG)	hypertension and diabetes	AB8/13 cells	high glucose (HG) treatment	upregulated	32887498
5699	Human	hsa-miR-200a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
5700	Human	hsa-miR-200a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	LX-2 cells	carbon tetrachloride (CCl4) treatment	miR-200a was significantly reduced in liver tissues of a carbon tetrachloride (CCl4)- activated LX2 cells.	32319630
5701	Human	hsa-miR-200a	miRNA	gefitinib	lung cancer	A549 cells	gefitinib treatment	"MALAT1 promoted the proliferation and gefitinib resistance of lung cancer cells by sponging miR-200a, which regulates expression of ZEB1 in the A549 cells."	31133357
5702	Human	hsa-miR-200a	miRNA	arsenite	melanoma	human keratinocyte HaCaT cell line	arsenic (As) exposure	upregulated	27054085
5703	Human	hsa-miR-200a	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
5704	Human	hsa-miR-200a	miRNA	beraprost sodium	metabolic disorders	C57BL/7JNju mice	beraprost sodium	downregulated	28732575
5705	Human	hsa-miR-200a	miRNA	beraprost sodium	metabolic disorders	human-derived HepG3 cells	beraprost sodium	downregulated	28732575
5706	Human	hsa-miR-200a	miRNA	thymosin ¦Â4 (T¦Â4)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced cardiac microvascular endothelial cells (CMECs)	Thymosin ¦Â-4 (T¦Â4) treatment	upregulated	31265170
5707	Human	hsa-miR-200a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	neurodegenerative diseases	SH5Y-SY cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	29936262
5708	Human	hsa-miR-200a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
5709	Human	hsa-miR-200a	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
5710	Human	hsa-miR-200a	miRNA	high fructose	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high fructose treatment	downregulated	30014902
5711	Human	hsa-miR-200a	miRNA	polydatin (PD)	nonalcoholic fatty liver disease (NAFLD)	high fructose-induced HepG2 cells	"Polydatin (3,4',5-trihydroxy-stilbene-3-¦Â-D-glucoside) treatment"	upregulated	30014902
5712	Human	hsa-miR-200a	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-16B cells	human papillomaviruses (HPVs) 16 treatment	downregulated	31911577
5713	Human	hsa-miR-200a	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
5714	Human	hsa-miR-200a	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
5715	Human	hsa-miR-200a	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
5716	Human	hsa-miR-200a	miRNA	IL-9	pancreatic cancer (PC)	PANC-1;AsPC-1 cells line	IL-9 treatment	downregulated	28349057
5717	Human	hsa-miR-200a	miRNA	TGF-¦Â1	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	transforming growth factor (TGF)-¦Â1 treatment	downregulated	29357421
5718	Human	hsa-miR-200a	miRNA	docetaxel (DTX)	prostate cancer	CRP patients	docetaxel (DTX) treatment	"miR-200b levels, miR-20a levels, were independent predictors of overall survival"	24714754
5719	Human	hsa-miR-200a	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
5720	Human	hsa-miR-200a	miRNA	arsenite	urothelial carcinoma	HUC1 cells	arsenic (As) exposure	downregulated	25586904
5721	Human	hsa-miR-200a-3p	miRNA	hypoxia/reoxygenation (H/R)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (H/R) treatment	upregulated	32572929
5722	Human	hsa-miR-200a-3p	miRNA	enterotoxigenic bacteroides fragilis (ETBF)	colorectal cancer (CRC)	HCT-116 and DLD-1 cells	Enterotoxigenic Bacteroides fragilis (ETBF) infection	downregulated	31515468
5723	Human	hsa-miR-200a-3p	miRNA	hepatitis B virus X protein (HBx)	HBV-associated tumorigenesis	LO2 cells	hepatitis B virus X protein (HBx) treatment	HBX downregulated miR-200a-3p mRNA expression	29231260
5724	Human	hsa-miR-200a-3p	miRNA	metformin (Met)	HBV-associated tumorigenesis	LO2 cells	metformin treatment	Metformin enhanced miR-200a-3p mRNA expression	29231260
5725	Human	hsa-miR-200a-3p	miRNA	free fatty acids (FFA)	hepatic steatosis	LO2 cells	free fatty acid (FFA) treatment	upregulated	31191607
5726	Human	hsa-miR-200a-3p	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	upregulated	30100735
5727	Human	hsa-miR-200a-3p	miRNA	TGF-¦Â	lung cancer	A549	Transforming growth factor ¦Â (TGF¦Â) treatment	LINC00273 promoted TGF¦Â-induced lung cancer EMT through miR-200a-3p/ZEB1 feedback loop	32017082
5728	Human	hsa-miR-200a-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced brain injury (SIBI)	human brain microvascular endothelial cells	lipopolysaccharide (LPS) treatment	overexpression of miRNA-200a-3p promoted inflammation in sepsis-induced brain injury through reactive oxygen species-induced NLRP3.	31485604
5729	Human	hsa-miR-200a-c	miRNA	XMD8-92	pancreatic ductal adenocarcinoma (PDAC)	human pancreatic cancer AsPC-1 cells	XMD8-92 treatment	upregulated	24880079
5730	Human	hsa-miR-200b	miRNA	esomeprazole	adeno and squamous-cell-carcinoma	human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines	esomeprazole treatment	upregulated	25175076
5731	Human	hsa-miR-200b	miRNA	Pien Tze Huang (PZH)	anti-cancer therapy	human colorectal carcinoma HCT-8 cells	PZH treatment	upregulated	25422078
5732	Human	hsa-miR-200b	miRNA	TGF-¦Â1	bladder cancer	HTB9 and T24 bladder cancer cells	TGF-¦Â1 treatment	downregulated	25017509
5733	Human	hsa-miR-200b	miRNA	artemisinin (ART)	breast cancer	MCF-7/DDP cells	artemisinin treatment	upregulated	28361857
5734	Human	hsa-miR-200b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
5735	Human	hsa-miR-200b	miRNA	epstein-barr virus (EBV)	tumorigenesis	EBV-positive B-lymphocytic cell lines;Epithelial gastric carcinoma AGSB95.8 cells;MCF-7 cells (ATCC)	Epstein-Barr Virus (EBV) infection	downregulated	20668090
5736	Human	hsa-miR-200b	miRNA	suberoylanilide hydroxamic acid (SAHA)	tumorigenesis	MEG-01 cells; HEK-293 cells	suberoylanilide hydroxamic acid (SAHA) treatment	downregulated	23543665
5737	Human	hsa-miR-200b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
5738	Human	hsa-miR-200b	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
5739	Human	hsa-miR-200b	miRNA	5-fluorouracil (5-Fu)	tumorigenesis	human colon cancer cells	5-fluorouracil (5-FU) treatment	downregulated	17702597
5740	Human	hsa-miR-200b	miRNA	carbon tetrachloride (CCl4)	chondrosarcoma	human chondrosarcoma cell line (JJ012)	CCl4 treatment	downregulated	25301739
5741	Human	hsa-miR-200b	miRNA	hypoxia	chronic hypoxia	human endothelial cells	binder CO2/O2 incubator treatment	upregulated	25550463
5742	Human	hsa-miR-200b	miRNA	bone morphogenetic protein 2 (BMP2)	chronic pancreatitis (CP)	human primary pancreatic stellate cells; human primary pancreatic fibroblast (hPFBs)	bone morphogenetic protein 2 (BMP2) treatment	upregulated	29303912
5743	Human	hsa-miR-200b	miRNA	TGF-¦Â	chronic pancreatitis (CP)	human primary pancreatic fibroblast (hPFBs)	TGF-¦Â treatment	downregulated	29303912
5744	Human	hsa-miR-200b	miRNA	estrogen receptor ¦Â	colorectal cancer (CRC)	Cell lines (SW480;HT29 ;SW620)	Estrogen receptor ¦Â treatment	the oncogenic miR-17¨C92 cluster and miR-200a/b are strongly downregulated	23436804
5745	Human	hsa-miR-200b	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human colorectal carcinoma HCT-8 cells	Pien Tze Huang (PZH) treatment	upregulated	25422078
5746	Human	hsa-miR-200b	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 117 cells	RM (Root methanol) treatment	upregulated	32691634
5747	Human	hsa-miR-200b	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HCT-8 cells	Ursolic acid (UA) treatment	upregulated	31452805
5748	Human	hsa-miR-200b	miRNA	cyclosporine A (CsA)	cyclosporine A (CsA)-induced gingival overgrowth	normal human gingival fibroblasts (HGFs)	cyclosporine A (CsA) treatment	downregulated	30449457
5749	Human	hsa-miR-200b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	We found that SNHG4 was downregulated in DR.	33822671
5750	Human	hsa-miR-200b	miRNA	hyperglycemia	diabetic wound angiogenesis	human microvascular endothelial cells (HMECs)	HG	downregulated	29037594
5751	Human	hsa-miR-200b	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
5752	Human	hsa-miR-200b	miRNA	glucose and TGF¦Â1	epithelial-mesenchymal transition (EMT)	human retinal microvascular endothelial cells	25 mM glucose with TGF¦Â1 treatment	upregulated	25335984
5753	Human	hsa-miR-200b	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
5754	Human	hsa-miR-200b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-200b towards the control level.	32387379
5755	Human	hsa-miR-200b	miRNA	erythropoietin (EPO)	epithelial-mesenchymal transition (EMT)	HK-2 cells	EPO treatment	upregulated	28535509
5756	Human	hsa-miR-200b	miRNA	TGF-¦Â1	fibrosis	human Tenon's fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	30512998
5757	Human	hsa-miR-200b	miRNA	TGF-¦Â1	fibrosis	human Tenon's fibroblasts (HTFs)	TGF-¦Â1 treatment	upregulated	30512998
5758	Human	hsa-miR-200b	miRNA	diallyl disulfide (DADS)	gastric cancer (GC)	Five gastric cancer cell lines (MGC-803; BGC-823; MKN-28; SGC-7901; HGC-27; AGS)	diallyl disulfide treatment	upregulated	23851184
5759	Human	hsa-miR-200b	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	human gastric carcinoma (AGS) cells	infect with HP	downregulated	28056089
5760	Human	hsa-miR-200b	miRNA	TGF-¦Â1	glaucoma	human Tenon's capsule fibroblasts	were various doses of TGF-¦Â1 for 24 hours treatment	upregulated	24667864
5761	Human	hsa-miR-200b	miRNA	TGF-¦Â1	hepatic steatosis	intestinal epithelial cells (IECs)	TGF-¦Â1 treatment	downregulated	23492772
5762	Human	hsa-miR-200b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	HCC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26919246
5763	Human	hsa-miR-200b	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	downregulated	26500110
5764	Human	hsa-miR-200b	miRNA	hypoxia	hypoxic-related diseases	primary human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	miR-200b and miR-429 are upregulated in response to hypoxia.	29737439
5765	Human	hsa-miR-200b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Caco-2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	27979826
5766	Human	hsa-miR-200b	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	upregulated	28347920
5767	Human	hsa-miR-200b	miRNA	tobacco carcinogens	lung cancer	HBECs	tobacco carcinogens treatment	"EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205"	21363915
5768	Human	hsa-miR-200b	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
5769	Human	hsa-miR-200b	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
5770	Human	hsa-miR-200b	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
5771	Human	hsa-miR-200b	miRNA	arecoline	oral submucous fibrosis (OSF)	human buccal mucosal fibroblasts (BMFs)	arecoline treatment	downregulated	29893466
5772	Human	hsa-miR-200b	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-17B cells	human papillomaviruses (HPVs) 17 treatment	downregulated	31911577
5773	Human	hsa-miR-200b	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human chondrocytes	lipopolysaccharide (LPS) treatment	"The expression level of miR-200b was downregulated, and that of FUT4 was upregulated in OA cartilage tissues and LPS-treated normal chondrocytes compared with normal cartilage tissues and chondrocytes."	33692838
5774	Human	hsa-miR-200b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
5775	Human	hsa-miR-200b	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
5776	Human	hsa-miR-200b	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	"Capan-1, Capan-2, Panc-1, MIAPaCa-2, BxPC-3 and PL45 cells"	Gemcitabine (GEM) treatment	the expression of miR-200b correlated positively with chemosensitivity.	30628651
5777	Human	hsa-miR-200b	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
5778	Human	hsa-miR-200b	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
5779	Human	hsa-miR-200b	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	PDAC cells	gemcitabine treatment	downregulated	28849150
5780	Human	hsa-miR-200b	miRNA	hypoxia	proangiogenic function	human endothelial cells	a CO2/O2 incubator for hypoxia research (Tri-gas Binder CB150)	upregulated	29042072
5781	Human	hsa-miR-200b	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
5782	Human	hsa-miR-200b	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
5783	Human	hsa-miR-200b	miRNA	docetaxel (DTX)	prostate cancer	CRP patients	docetaxel (DTX) treatment	"miR-200b levels, miR-20a levels, were independent predictors of overall survival"	24714754
5784	Human	hsa-miR-200b	miRNA	lactoferrin (LF)	prostate cancer	DU-145 cells	lactoferrin (LF) treatment	upregulated	30285009
5785	Human	hsa-miR-200b	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	human retinal endothelial cells (HRECs)	high glucose	downregulated	28122089
5786	Human	hsa-miR-200b	miRNA	arsenite	urothelial carcinoma	HUC1 cells	arsenic (As) exposure	downregulated	25586904
5787	Human	hsa-miR-200b	miRNA	hypoxia	inflammatory bowel disease (IBD)	human microvascular endothelial cells (HMECs)	hypoxia? treatment	downregulated	21081489
5788	Human	hsa-miR-200b-3p	miRNA	copper (Cu)	Alzheimer's disease (AD)	human primary microvascular endothelial cells (MVECs)	chronic exposure to copper	"In human primary microvascular endothelial cells (MVECs), microRNA-200b-3p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure."	30923833
5789	Human	hsa-miR-200b-3p	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	Immortalized primary bronchial epithelial cell line (BEAS-2B cells)	transforming growth factor-¦Â (TGF-¦Â) treatment	downregulated	31283671
5790	Human	hsa-miR-200b-3p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
5791	Human	hsa-miR-200b-3p	miRNA	xiaoai Jiedu recipe (XJR)	hepatocellular carcinoma (HCC)	HepG2 cells	Xiaoai Jiedu recipe (XJR) treatment	XJR could effectively inhibit HCC and might exert its antitumor effect through the miR-200b-3p/Notch1 axis	33173345
5792	Human	hsa-miR-200b-3p	miRNA	oridonin	pancreatic cancer (PC)	The BxPC-3 and PANC-1 human pancreatic cancer cell lines	Oridonin treatment	downregulated	27878247
5793	Human	hsa-miR-200b-3p	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells; KHOS cells; U2OS cells	doxorubicin treatment	miR-200b-3p expression was greatly downregulated in the chemo-resistant OS tissues.	30204936
5794	Human	hsa-miR-200b-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
5795	Human	hsa-miR-200b-3p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
5796	Human	hsa-miR-200b-3p	miRNA	¦Â-glycerophosphate (¦Â-GP)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	¦Â-glycerophosphate (¦Â-GP) treatment	upregulated	32818704
5797	Human	hsa-miR-200b-5p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	30197683
5798	Human	hsa-miR-200c	miRNA	H2O2	endothelial cell apoptosis and senescence	Human umbilical vein endothelial cells (HUVEC)	H2O2 treatment	upregulated	21527937
5799	Human	hsa-miR-200c	miRNA	Pien Tze Huang (PZH)	anti-cancer therapy	human colorectal carcinoma HCT-8 cells	PZH treatment	upregulated	25422078
5800	Human	hsa-miR-200c	miRNA	arsenic trioxide (ATO)	breast cancer	breast cancer cells	arsenic trioxide (As(2)O(3)) treatment	upregulated	24729530
5801	Human	hsa-miR-200c	miRNA	arsenic trioxide (ATO)	breast cancer	MDA-MB-231 cells	arsenic trioxide (As2O3) treatment	upregulated	24729530
5802	Human	hsa-miR-200c	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
5803	Human	hsa-miR-200c	miRNA	glabridin (GLA)	breast cancer	MDA-MB-231 breast cancer cells	Glabridin treatment	upregulated	24754877
5804	Human	hsa-miR-200c	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
5805	Human	hsa-miR-200c	miRNA	SK228	breast cancer	MDA-MB-231 human breast cancer cell lines	SK228 treatment	upregulated	24967704
5806	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cancer-associated fibroblasts (CAFs) activation	cultured cancer-associated fibroblasts (CAFs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30851420
5807	Human	hsa-miR-200c	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	downregulated	30851420
5808	Human	hsa-miR-200c	miRNA	doxorubicin (DOX)	cardiotoxicity	human cardiac mesenchymal progenitor cells	DOXO	upregulated	28837147
5809	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	clear cell renal cell carcinoma (ccRCC)	ccRCC cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27123083
5810	Human	hsa-miR-200c	miRNA	Clostridium butyricum (C. butyricum)	colitis-associated colon cancer (CAC)	human intestinal cell line Vaco2-BBE	infect with C. butyricum	upregulated	28478805
5811	Human	hsa-miR-200c	miRNA	bicotine	colorectal cancer (CRC)	SW620 and HT-29 cells	nicotine treatment	downregulated	30076725
5812	Human	hsa-miR-200c	miRNA	nicotine	colorectal cancer (CRC)	CRC tissues and cell lines SW620 and HT-29	cigarette smoking exposure	downregulated	30076725
5813	Human	hsa-miR-200c	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human colorectal carcinoma HCT-8 cells	Pien Tze Huang (PZH) treatment	upregulated	25422078
5814	Human	hsa-miR-200c	miRNA	resveratrol	colorectal cancer (CRC)	NA-anti-miR-200c transfected HCT-116 cells	resveratrol (RS) treatment	upregulated	27918105
5815	Human	hsa-miR-200c	miRNA	RM (Root methanol)	colorectal cancer (CRC)	HT-29 cells; HCT 118 cells	RM (Root methanol) treatment	upregulated	32691634
5816	Human	hsa-miR-200c	miRNA	Short-chain fatty acid sodium butyrate (NaB)	colorectal cancer (CRC)	HCT116 and LOVO CRC cells	Short-chain fatty acid sodium butyrate (NaB) treatment	upregulated	29418071
5817	Human	hsa-miR-200c	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HCT-8 cells	Ursolic acid (UA) treatment	upregulated	31452805
5818	Human	hsa-miR-200c	miRNA	surgery and chemotherapy	colorectal cancer (CRC)	patients blood	surgery and chemotherapy for 3years treatment	upregulated	24310813
5819	Human	hsa-miR-200c	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
5820	Human	hsa-miR-200c	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
5821	Human	hsa-miR-200c	miRNA	antcin A (ATA)	epithelial-mesenchymal transition (EMT)	"Human breast cancer cell lines, MCF-7 and MDA-MB-231"	Antcin-A (ATA) treatment	upregulated	31185503
5822	Human	hsa-miR-200c	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
5823	Human	hsa-miR-200c	miRNA	insulin-like growth factor 1 (IGF-1)	epithelial-mesenchymal transition (EMT)	human gastric cell lines MGC803;SGC-7901	IGF-I treatment	downregulated	24885194
5824	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial-mesenchymal transition (EMT)	human conjunctival epithelial (HCjE) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-AzaC treatment induced increased expression of miR-200c towards the control level.	32387379
5825	Human	hsa-miR-200c	miRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	SW480 cells; HCT116 cells	metformin treatment	upregulated	30017802
5826	Human	hsa-miR-200c	miRNA	platinum-based chemotherapy	esophageal squamous cell carcinoma (ESCC)	Venous blood samples	platinum-based chemotherapy treatment	upregulated	24349623
5827	Human	hsa-miR-200c	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
5828	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human GC cell lines NCI-N87, SGC7901 ,AGS ,HGC27 and MGC803"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27498672
5829	Human	hsa-miR-200c	miRNA	decitabine	gastric cancer (GC)	SGC-7902 cells	decitabine treatment	upregulated	25502084
5830	Human	hsa-miR-200c	miRNA	decitabine	gastric cancer (GC)	SGC-7901 cells	the chemotherapeutic agent decitabine treatment	upregulated	25502084
5831	Human	hsa-miR-200c	miRNA	TGF-¦Â	gastric cancer (GC)	SGC-7902 cells	TGF-¦Â treatment	downregulated	25502084
5832	Human	hsa-miR-200c	miRNA	hepatocyte growth factor (HGF)	head and neck squamous cell carcinoma (HNSCC)	HNSCC; adjacent normal squamous epithelial tissues	Hepatocyte growth factor (HGF) treatment	downregulated	21899661
5833	Human	hsa-miR-200c	miRNA	lanthionine	lanthionine toxicity	EA.hy926 cell cultures	lanthionine treatment	upregulated	31071929
5834	Human	hsa-miR-200c	miRNA	hypoxia	lung cancer	"The human cell lines A549 (lung carcinoma), NCI-H460 (lung carcinoma)"	hypoxia induce	downregulated	31061665
5835	Human	hsa-miR-200c	miRNA	paclitaxel (PTX)	lung cancer	A549 cells	paclitaxel treatment	"miRNA-200c was significantly lower in A549/TAX cells, which are paclitaxel-resistant A549 cells"	29219949
5836	Human	hsa-miR-200c	miRNA	tobacco carcinogens	lung cancer	HBECs	tobacco carcinogens treatment	"EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205"	21363915
5837	Human	hsa-miR-200c	miRNA	silica	lung function decline	blood	silica treatment	downregulated	29280772
5838	Human	hsa-miR-200c	miRNA	dacarbazine (DTIC)	melanoma	FEMX-1 melanoma cell line	dacarbazine (DTIC) treatment	upregulated	28387914
5839	Human	hsa-miR-200c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
5840	Human	hsa-miR-200c	miRNA	free fatty acids (FFAs) and TNF-¦Á and IL-6	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells and human hepatocytes	free fatty acids (FFAs) and proinflammatory factors (tumour necrosis factor-alpha (TNF-¦Á) and interleukin-6 (IL-6) treatment	upregulated	25562147
5841	Human	hsa-miR-200c	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	erlotinib-sensitive PC9 cells	TGF¦Â treatment	dysregulated	28646226
5842	Human	hsa-miR-200c	miRNA	sulforaphane (SFN)	oral squamous cell carcinoma (OSCC)	OSCC cancer stem cells (CSCs)isolated from SAS and GNM cells	sulforaphane treatment	upregulated	26879838
5843	Human	hsa-miR-200c	miRNA	arecoline	oral submucous fibrosis (OSF)	fibrotic buccal mucosal fibroblasts (fBMFs	arecoline treatment	downregulated	29958727
5844	Human	hsa-miR-200c	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-18B cells	human papillomaviruses (HPVs) 18 treatment	downregulated	31911577
5845	Human	hsa-miR-200c	miRNA	methotrexate (MTX)	osteosarcoma (OS)	MG63 cells; HOS cells	methotrexate (MTX) treatment	miR-200c was downregulated in methotrexate resistance osteosarcoma cells	29170124
5846	Human	hsa-miR-200c	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines (MG-63, U2OS, HOS and SAOS-2)"	methotrexate treatment	downregulated	29170124
5847	Human	hsa-miR-200c	miRNA	olaparib	ovarian cancer (OC)	UWB cells; UWB-BRCA cells	olaparib treatment	downregulated	31898520
5848	Human	hsa-miR-200c	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3ip1 cells	paclitaxel (PTX) treatment	downregulated	33028939
5849	Human	hsa-miR-200c	miRNA	H2O2	oxidative stress	human renal tubular epithelium (HK-2) cells	hydrogen peroxide (H2O2) treatment	upregulated	31199854
5850	Human	hsa-miR-200c	miRNA	"3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	"3,3'-diindolylmethane (DIM) treatment"	upregulated	19654291
5851	Human	hsa-miR-200c	miRNA	garcinol	pancreatic cancer (PC)	PANC-1 SP cells	Garcinol treatment	upregulated	26400206
5852	Human	hsa-miR-200c	miRNA	isoflavone	pancreatic cancer (PC)	MiaPaCa-2; Panc-1; Aspc-1 cells	isoflavone treatment	upregulated	19654291
5853	Human	hsa-miR-200c	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
5854	Human	hsa-miR-200c	miRNA	TGF-¦Â1	peritoneal fibrosis	Immortalized human mesothelial cells (Met-5A cells)	TGF-¦Â1 treatment	downregulated	31226520
5855	Human	hsa-miR-200c	miRNA	hydrogen sulfide (H2S)	preeclampsia (PE)	placental cells obtained from pregnant women with preeclampsia	placental cells obtained from pregnant women with preeclampsia treatment	downregulated	26992682
5856	Human	hsa-miR-200c	miRNA	endothelin-1 (ET-1)	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	endothelin-1 (ET-1) treatment	upregulated	29044995
5857	Human	hsa-miR-200c	miRNA	neoadjuvant chemoradiotherapy (CRT)	rectal cancer	patients with rectal cancer	received neoadjuvant chemoradiotherapy treatment	downregulated	24617665
5858	Human	hsa-miR-200c	miRNA	docetaxel (DTX)	tongue squamous cell carcinoma (TSCC)	HSC-3 cells	docetaxel (DTX) treatment	downregulated	32310826
5859	Human	hsa-miR-200c	miRNA	isoliquiritigenin	triple negative breast cancer (TNBC)	BT-549 cells; MDA-MB-231 cells	isoliquiritigenin (ISL)?treatment	"In this study, PCR array screened a significant increase of miR-200c in BT-549 and MDA-MB-231 cells after ISL treatment, and ISH exerted that miR-200c was expressed at a low level in breast cancer tissue of patients."	33641651
5860	Human	hsa-miR-200c	miRNA	tamoxifen (TAM)	triple negative breast cancer (TNBC)	TNBC cells (MCF-7/ADR and MDA-MB-231)	TAM treatment	downregulated	28724364
5861	Human	hsa-miR-200c	miRNA	arsenite	urothelial carcinoma	HUC1 cells	arsenic (As) exposure	downregulated	25586904
5862	Human	hsa-miR-200c	miRNA	sulforaphane (SFN)	oral squamous cell carcinoma (OSCC)	"normal oral epithelial cells (SG) and SAS or GNM cells,OSCC-CSCs"	sulforaphane treatment	upregulated	26879838
5863	Human	hsa-miR-200c*	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
5864	Human	hsa-miR-200c-3p	miRNA	influenza virus	acute respiratory distress syndrome (ARDS)	A549 cells	infect with H5N1	upregulated	28690868
5865	Human	hsa-miR-200c-3p	miRNA	copper (Cu)	Alzheimer's disease (AD)	human primary microvascular endothelial cells (MVECs)	chronic exposure to copper	"In human primary microvascular endothelial cells (MVECs), microRNA-200c-3p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure."	30923833
5866	Human	hsa-miR-200c-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
5867	Human	hsa-miR-200c-3p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
5868	Human	hsa-miR-200c-3p	miRNA	yin yang 1 (YY1)	cholangiocarcinoma (CCA)	CCLP-1 and QBC939 cells	yin yang 1 (YY1) treatment	downregulated	33040228
5869	Human	hsa-miR-200c-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
5870	Human	hsa-miR-200c-3p	miRNA	H2O2	glaucoma	human trabecular meshwork (HTM) cells	H2O2 treatment	downregulated	32626945
5871	Human	hsa-miR-200c-3p	miRNA	ferulic acid (FA)	intestinal barrier dysfunction	Caco-2 cells	Ferulic acid (FA) treatment	"LPS stimulation decreased miR-200c-3p expression, whereas this decrease was inhibited by FA pretreatment."	32308620
5872	Human	hsa-miR-200c-3p	miRNA	IL-1B	intestinal inflammation	Caco-2 cells	IL-1B treatment	MIR200C-3p was rapidly increased in Caco-2 cells incubated with IL-1B.	32569770
5873	Human	hsa-miR-200c-3p	miRNA	ultrasound (US)	multidrug resistance (MDR)	MCF-7/ADR and HEPG2/ADM cells	ultrasound (US) irradiation treatment	upregulated	30231924
5874	Human	hsa-miR-200c-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
5875	Human	hsa-miR-200c-3p	miRNA	NaF	skeletal fluorosis	SaoS2 cells	NaF treatment	upregulated	29471239
5876	Human	hsa-miR-200s	miRNA	estradiol-17¦Â (E2)	endometriosis	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	downregulated	30500775
5877	Human	hsa-miR-200s	miRNA	estradiol-17¦Â (E2)	epithelial-mesenchymal transition (EMT)	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	downregulated	30500775
5878	Human	hsa-miR-200s	miRNA	TGF-¦Â	tumorigenicity	glioma stem-like cell (GSC)	TGF-¦Â treatment	downregulated	31599491
5879	Human	hsa-miR-201	miRNA	catalpol	proliferation and apoptosis	OVCAR-3 cells	catalpol treatment	upregulated	25347277
5880	Human	hsa-miR-202	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
5881	Human	hsa-miR-202	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
5882	Human	hsa-miR-202	miRNA	angiotensin II (Ang II)	liver fibrosis	hepatic stellate cells (HSC)	angiotensin II (Ang II) treatment	The expression level of miR-202 significantly increased after hepatic stellate cells (HSC) were stimulated by AngII.	32270431
5883	Human	hsa-miR-202	miRNA	TGF-¦Â1	osteosarcoma (OS)	high grade osteosarcom	TGF-¦Â1 treatment	upregulated	26276504
5884	Human	hsa-miR-202	miRNA	bone morphogenetic protein 4 (BMP4)	varicose vein	human venous smooth muscle cells (HUVSMCs)	bone morphogenetic protein 4 (BMP4) treatment	downregulated	30556158
5885	Human	hsa-miR-202	miRNA	platelet-derived growth factor (PDGF)	varicose vein	human venous smooth muscle cells (HUVSMCs)	platelet-derived growth factor (PDGF) treatment	upregulated	30556158
5886	Human	hsa-miR-202	miRNA	TGF-¦Â	varicose vein	human venous smooth muscle cells (HUVSMCs)	TGF©\¦Â treatment	upregulated	30556158
5887	Human	hsa-miR-202-3p	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP)	interleukin-1¦Â (IL-1¦Â) treatment	downregulated	30458287
5888	Human	hsa-miR-202-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary heart disease (CHD)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	Oxidized low-density lipoprotein (ox-LDL) induced miR-202-3p expression.	31956131
5889	Human	hsa-miR-202-3p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
5890	Human	hsa-miR-202-3p	miRNA	angiotensin II (Ang II)	essential hypertension (EH)	THP-1 cells	angiotensin II (Ang II) treatment	upregulated	32338289
5891	Human	hsa-miR-202-3p	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	IL-1¦Â treatment	downregulated	30458287
5892	Human	hsa-miR-202-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
5893	Human	hsa-miR-203	miRNA	nickel	esophageal cancer (EC)	NSTCs	nickel treatment	downregulated	23968727
5894	Human	hsa-miR-203	miRNA	curcumin (Cur)	bladder cancer	"Non-malignant human uroepithelial cell line (SV-HUC-1)£» bladder cancer cell lines (T24, J82£»TCCSUP)"	curcumin (CUR) treatment	downregulated	21836020
5895	Human	hsa-miR-203	miRNA	lead (Pb)	blood-cerebrospinal fluid barrier (BCB)	choroidal epithelial cells	(Pb) exposure	upregulated	25975750
5896	Human	hsa-miR-203	miRNA	estradiol	breast cancer	MCF-7 cells	estradiol (E?) treatment	"E? significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells"	22260523
5897	Human	hsa-miR-203	miRNA	estradiol	breast cancer	ER¦Á-positive breast cancer MCF-7 cells	estradiol treatment	downregulated	28962215
5898	Human	hsa-miR-203	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
5899	Human	hsa-miR-203	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
5900	Human	hsa-miR-203	miRNA	huaier extract	breast cancer	tamoxifen-resistant cells (M7-TR) and fulvestrant-resistant cells (M7-FR)	Huaier extract	downregulated	28779143
5901	Human	hsa-miR-203	miRNA	luteolin	breast cancer	MDA-MB-453 and MCF-7 cells	luteolin treatment	upregulated	31368817
5902	Human	hsa-miR-203	miRNA	paclitaxel (PTX)	breast cancer	"HER2-positive cell lines, BT-474 and SKBR3"	paclitaxel treatment	upregulated	28509576
5903	Human	hsa-miR-203	miRNA	sevoflurane (SEV)	breast cancer	MDA-MB-231 cells	sevoflurane treatment	upregulated	29750301
5904	Human	hsa-miR-203	miRNA	folic acid	cervical cancer (CC)	CaSki cells	folic acid treatment	upregulated	27313708
5905	Human	hsa-miR-203	miRNA	adriamycin (ADR)	colorectal cancer (CRC)	HCT116	adriamycin (ADR) treatment	upregulated	26397233
5906	Human	hsa-miR-203	miRNA	sevoflurane (SEV)	colorectal cancer (CRC)	SW620 and HCT116 cells	sevoflurane treatment	upregulated	30685432
5907	Human	hsa-miR-203	miRNA	sodium butyrate (NaB)	colorectal cancer (CRC)	HT-29 and Caco-2 cell lines	sodium butyrate (NaBt) treatment	upregulated	27771718
5908	Human	hsa-miR-203	miRNA	AZD6244	cytotoxicity	breast cancer cell lines MDA-MB-231 and HCC1937	10¦ÌM AZD6244 for 24 h treatment	upregulated	24938872
5909	Human	hsa-miR-203	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
5910	Human	hsa-miR-203	miRNA	glycolaldehyde-modified advanced glycation end product (AGE)	diabetic foot ulcer (DFU)	The immortalized human keratinocyte lines HaCaT and HFF1	glycolaldehyde-modified advanced glycation end product (AGE) treatment	upregulated	31707396
5911	Human	hsa-miR-203	miRNA	human papilloma virus (HPV)	cell differentiation	Normal human foreskin keratinocytes (NHKs)	Human papillomaviruses (HPV)?infection	downregulated	20219920
5912	Human	hsa-miR-203	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
5913	Human	hsa-miR-203	miRNA	berberine (BBR)	gastric cancer (GC)	Gastric cancer cell lines SGC-7901 and BGC-823	berberine (BBR) treatment	upregulated	27142767
5914	Human	hsa-miR-203	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	GBM patients tissues and serum	TMZ treatment	upregulated	28187000
5915	Human	hsa-miR-203	miRNA	bufalin	glioblastoma multiforme (GBM)	U251 and U87 cells	bufalin treatment	upregulated	29169175
5916	Human	hsa-miR-203	miRNA	TGF-¦Â	head and neck squamous cell carcinoma (HNSCC)	MSCC-1 and MSCC-inv1 cells	TGF-¦Â treatment	downregulated	26882562
5917	Human	hsa-miR-203	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
5918	Human	hsa-miR-203	miRNA	lipopolysaccharide (LPS)	liver fibrosis	Human HSC line LX2 cells	lipopolysaccharide (LPS) treatment	downregulated	31719209
5919	Human	hsa-miR-203	miRNA	TGF-¦Â	liver fibrosis	Human HSC line LX2 cells	TGF-¦Â treatment	downregulated	31719209
5920	Human	hsa-miR-203	miRNA	human papilloma viruses (HPVs) 16	human papillomaviruses (HPV) infection	human foreskin keratinocytes(HFKs)	human papillomavirus type 16 (HPV16) infection	downregulated	20702634
5921	Human	hsa-miR-203	miRNA	platelet derived growth factor-BB (PDGF-BB) and insulin-like growth factor (IGF)-1	idiopathic pulmonary fibrosis (IPF)	human fibroblastic cell line (LL-24)	PDGF-BB and IGF-1 treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2	32694556
5922	Human	hsa-miR-203	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	Primary human lung fibroblasts	TGF¦Â1 treatment	upregulated	31488543
5923	Human	hsa-miR-203	miRNA	sulfur mustard (SM)	impaired tissue regeneration	normal human epidermal keratinocytes (NHEK)	sulfur mustard (SM) treatment	upregulated	26383628
5924	Human	hsa-miR-203	miRNA	kaempferol	inflammation	LPS or AngII-disposed human aortic endothelial cells (HAECs)	Kaempferol (KAE)?treatment	upregulated	31022599
5925	Human	hsa-miR-203	miRNA	TGF-¦Â	inflammation	breast cancer cells	transforming growth factor ¦Â (TGF-¦Â)? treatment	downregulated	23447531
5926	Human	hsa-miR-203	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	29717211
5927	Human	hsa-miR-203	miRNA	oleic acid (OA)	keratinocytes (KCs) diferentiation	neonatal human epidermal keratinocytes (HEKn)	oleic acid (OA) treatment	OA increased the expression of miR-203.	29638027
5928	Human	hsa-miR-203	miRNA	imatinib	leukemia	The K562 cells; HL-60 cells; the KU812 cells	imatinib treatment	demethylation of miR-203 is one of the molecular mechanisms of imatinib-induced inhibition of BCR-ABL1-positive leukemic cells	23953880
5929	Human	hsa-miR-203	miRNA	TGF-¦Â	lung adenocarcinoma (LUAD)	A549 cell	TGF¦Â treatment	upregulated	31131047
5930	Human	hsa-miR-203	miRNA	Sendai virus (SeV)	lung cancer	A549 cells	Sendai Virus treatment	"miR-203isanIFN-inducible miRNA that can negatively regulate a number of cellular mRNAs,including an IFN-stimulated gene target,IFIT1/ISG56,by destabilizing its mRNA transcript"	23785202
5931	Human	hsa-miR-203	miRNA	temozolomide (TMZ)	malignant melanoma (MM)	human MM cells	TMZ treatment	downregulated	28597996
5932	Human	hsa-miR-203	miRNA	aspirin	nasopharyngeal carcinoma (NPC)	"Human NPC cell line C666-1, C2089"	aspirin treatment	upregulated	31265948
5933	Human	hsa-miR-203	miRNA	X-rays	nasopharyngeal carcinoma (NPC)	5-8F; SUNE-1 cells	4 Gy radiation treatment	LINC00114 contributed to NPC development and radioresistance through the regulation of ERK/JNK signaling pathway and the mediation of miR-203	32196600
5934	Human	hsa-miR-203	miRNA	riboflavin (RF)	neuroprotective effects	SH-SY5Y neuroblostoma cell line	RF treatment	upregulated	24884571
5935	Human	hsa-miR-203	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	Tca8113 cells	cisplatin treatment	downregulated	26946357
5936	Human	hsa-miR-203	miRNA	arecoline	oral submucous fibrosis (OSF)	human buccal mucosal fibroblasts	arecoline treatment	downregulated	25872484
5937	Human	hsa-miR-203	miRNA	prednisolone	oral submucous fibrosis (OSF)	OSF-fibroblast cells	were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment	upregulated	24921400
5938	Human	hsa-miR-203	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	IL-1¦Â stimulation induced the expression of miR-203.	31894489
5939	Human	hsa-miR-203	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human cartilage C28/I2 cells	lipopolysaccharide (LPS) treatment	upregulated	28764893
5940	Human	hsa-miR-203	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	SW1990 cells	cisplatin treatment	downregulated	31696470
5941	Human	hsa-miR-203	miRNA	hypoxia	pathological retinal neovascularization disease	human retinal microvascular endothelial cells (HRMECs)	hypoxia treatment	downregulated	32084532
5942	Human	hsa-miR-203	miRNA	IL-17	psoriasis	HaCaT cells	IL-17 treatment	upregulated	29039484
5943	Human	hsa-miR-203	miRNA	Kr¨¹ppel-like factor 4 (KLF4)	cell senescence	pluripotent stem (iPS) cells	Kr¨¹ppel-like factor 4 (KLF4) treatment	upregulated	27531889
5944	Human	hsa-miR-203	miRNA	COTI-2	T-cell acute lymphoblastic leukemia (T-ALL)	Jurkat cells	COTI-2 treatment	upregulated	32063077
5945	Human	hsa-miR-203	miRNA	sulfur mustard (SM)	tissue injury	human epidermal keratinocytes (NHEK)	sulfur mustard (SM) treatment	upregulated	26383628
5946	Human	hsa-miR-203	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	type 2 diabetes mellitus (T2DM)	"human hepatocytes (JHH5, JHH7, and HepG2)"	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	28955777
5947	Human	hsa-miR-203a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	esophageal cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
5948	Human	hsa-miR-203a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, Yes-2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
5949	Human	hsa-miR-203a	miRNA	hepatitis C virus (HCV) core protein	hepatocellular carcinoma (HCC)	"human hepatoblastoma cell line, HepG2"	Hepatitis C virus (HCV) Core protein treatment	downregulated	26210453
5950	Human	hsa-miR-203a	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2 cells	hypoxia treatment	downregulated	32468055
5951	Human	hsa-miR-203a	miRNA	cadmium (Cd)	epidermal development	HaCaT Cells	cadmium (Cd) treatment	upregulated	28754589
5952	Human	hsa-miR-203a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	murine chondrogenic ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	29679904
5953	Human	hsa-miR-203a	miRNA	tanshinone IIA (Tan IIA)	osteoarthritis (OA)	LPS-treated murine chondrogenic ATDC5 cells	Tanshinone IIA (Tan IIA) treatment	downregulated	29679904
5954	Human	hsa-miR-203a-3p	miRNA	acidosis	acidosis	R3327-AT-1 prostate	incubated at pH 6.6	downregulated	28685435
5955	Human	hsa-miR-203a-3p	miRNA	TGF-¦Â1	asthma	BEAS-2B cells; 16HBE cells	TGF-¦Â1 treatment	Transforming growth factor-¦Â1 (TGF-¦Â1) treatment induced the reduction of miR-203a-3p in BEAS-2B and 16HBE cells in a time-dependent manner	32065213
5956	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	MALAT1 affect angiogenesis by sponging miR-203a-3p in DR.	31689123
5957	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31689123
5958	Human	hsa-miR-203a-3p	miRNA	atorvastatin	endothelial senescence	ox-LDL treated HUVECs	atorvastatin treatment	downregulated	29248491
5959	Human	hsa-miR-203a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial senescence	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
5960	Human	hsa-miR-203a-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
5961	Human	hsa-miR-203a-3p	miRNA	steviol	gastrointestinal cancer	HCT-116 cells	steviol treatment	upregulated	29899860
5962	Human	hsa-miR-203a-3p	miRNA	atorvastatin	hyperlipidemia	HUVECs	atorvastatin treatment	downregulated	29248491
5963	Human	hsa-miR-203a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	hyperlipidemia	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
5964	Human	hsa-miR-203a-3p	miRNA	carnosic acid (CA)	liver fibrosis	LX-2 cells	carnosic acid (CA) treatment	Inhibition of p66Shc Oxidative Signaling via CA-Induced Upregulation of miR-203a-3p Alleviates Liver Fibrosis Progression.	32781430
5965	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	proliferative diabetic retinopathy (PDR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31408201
5966	Human	hsa-miR-203a-3p	miRNA	high glucose (HG)	proliferative diabetic retinopathy (PDR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31408201
5967	Human	hsa-miR-203a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell senescence	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28347692
5968	Human	hsa-miR-203b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	esophageal cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
5969	Human	hsa-miR-203b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, Yes-2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26577858
5970	Human	hsa-miR-204	miRNA	arsenic trioxide (ATO)	acute myeloid leukemia (AML)	"Human AML cell lines, AML-5 and HL-60"	arsenic trioxide (ATO) treatment	upregulated	30982490
5971	Human	hsa-miR-204	miRNA	high inorganic phosphate (Pi)	arterial calcification	Human aorta vascular smooth muscle cells (HA-VSMCs)	high phosphate treatment	downregulated	29850805
5972	Human	hsa-miR-204	miRNA	trichostatin A (TSA)	breast cancer	MCF-7 and ;MDA-MB-231 cells	Trichostatin A (TSA) treatment	downregulated	26436206
5973	Human	hsa-miR-204	miRNA	triiodo-l-thyronine (T3)	breast cancer	BC cell lines MCF-7 and T47-D	Triiodothyronine (T3) treatment	downregulated	30406874
5974	Human	hsa-miR-204	miRNA	TGF-¦Â1 or bone morphogenetic protein 2 (BMP-2)	calcific aortic valve disease (CAVD)	human aortic valve interstitial cells (AVICs)	"TGF-¦Â1,BMP-2 treatment"	dysregulated	28377507
5975	Human	hsa-miR-204	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
5976	Human	hsa-miR-204	miRNA	hypoxia	cervical spondylotic	Human neuronal cell lines	hypoxia treatment	upregulated	26350953
5977	Human	hsa-miR-204	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116; HT-29; SW620; SW480; DLD-1; RKO; LoVo cells	5-fluorouracil (5-FU) treatment	PCAT6 knockdown attenuated CRC chemoresistance to 5-FU through miR-204/HMGA2/PI3K; miR-204 inhibition could partially reverse the effect of PCAT6 knockdown.	30938104
5978	Human	hsa-miR-204	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	downregulated	30131392
5979	Human	hsa-miR-204	miRNA	melatonin	diabetic retinopathy (DR)	MIO-M1 cells	melatonin (MEL) treatment	miR-204 increased in HG-treated MIO-M1 cells and that melatonin (MEL) inhibited miR-204 expression	32324260
5980	Human	hsa-miR-204	miRNA	particulate matter (PM2.5)	epithelial-mesenchymal transition (EMT)	human bronchial epithelial cell lines (HBE and BEAS-2B)	Organic extracts of PM2.5 treatment	"NF-¦ÊB transcriptionally regulates MALAT1, which, by binding with miR-204 and releasing ZEB1, promotes the EMT"	31042084
5981	Human	hsa-miR-204	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human LECs (HLECs)	TGF-¦Â2 treatment	"TGF-¦Â2 induces NEAT1 overexpression, which in turn suggests that NEAT1 acts as a ceRNA targeting Snail1 or Zeb1 by binding miR-34a or miR-204"	32596382
5982	Human	hsa-miR-204	miRNA	Sinomenine (SIN)	gastric cancer (GC)	MKN45 and SGC-7901 cells	Sinomenine (SIN) treatment	upregulated	31243880
5983	Human	hsa-miR-204	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	miR-204 was downregulated in U251MG-resistant (-R) cells	29725461
5984	Human	hsa-miR-204	miRNA	hypoxia	hepatocellular carcinoma (HCC)	LO2 cells;Hep3B cells;Huh7 cells	hypoxia induce	downregulated	30279729
5985	Human	hsa-miR-204	miRNA	vemurafenib	melanoma	A375 melanoma cells	vemurafenib treatment	upregulated	28445987
5986	Human	hsa-miR-204	miRNA	IL-1¦Â	osteoarthritis (OA)	human OA chondrocytes;chondrogenic SW1353 cells	IL-12¦Â treatment	downregulated	29441883
5987	Human	hsa-miR-204	miRNA	metformin (Met)	preeclampsia (PE)	HUVEC and HPASMC cells	Metformin treatment	upregulated	31582211
5988	Human	hsa-miR-204	miRNA	propofol (PPF)	expression regulation	human adipocyte stem cells	"50 ?M propofol, or 100 ?M propofol in culture media for 3 hours treatment"	"The lowest expression was seen for miR-204, The highest expression was seen for miR-208b"	25568843
5989	Human	hsa-miR-204	miRNA	oxibendazole (OBZ)	prostate cancer	22Rv1 cells; PC-3 cells	oxibendazole (OBZ) treatment	OBZ increased the expression of microRNA-204 (miR-204)	29434928
5990	Human	hsa-miR-204	miRNA	dehydroepiandrosterone (DHEA)	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cell (PASMC)	Dehydroepiandrosterone (DHEA) treatment	upregulated	21890685
5991	Human	hsa-miR-204	miRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary artery endothelial cells (HPAECs)	hypoxia induce	downregulated	31542480
5992	Human	hsa-miR-204	miRNA	lipopolysaccharide (LPS)	sepsis	rats lung tissues	lipopolysaccharide (LPS) treatment	downregulated	28901393
5993	Human	hsa-miR-204	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
5994	Human	hsa-miR-204	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN cells; P12 cells	hypoxia treatment	"The expression of MALAT1 and Bcl-2 was decreased, while miRNA-204 (miR-204) was upregulated in rats SCIRI model and neurocyte lines under hypoxic conditions."	29998804
5995	Human	hsa-miR-2042	miRNA	IL-6	epithelial ovarian cancer (EOC)	human ovarian cancer cell line A2780;its related cDDP-resistant cell lines (ACRP)	interleukin-6 (IL-6) treatment	downregulated	28388577
5996	Human	hsa-miR-204-3p	miRNA	lipopolysaccharide (LPS)	familial Mediterranean fever	THP-1 cells	lipopolysaccharide (LPS) treatment	The expression of miR-204-3p was suppressed by LPS stimulation in the macrophages derived from THP-1 cells	29294109
5997	Human	hsa-miR-204-5p	miRNA	TGF-¦Â1	asthma	human airway smooth muscle cells	TGF-¦Â1 treatment	MiR-204-5p was downregulated notably in asthmatic airway smooth muscle cells as well as cells stimulated with TGF-¦Â1	31955160
5998	Human	hsa-miR-204-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"silence of XIST displayed a protective role in ox-LDL-induced injury in HUVECs by regulating miR-204-5p/TLR4 axis, providing a novel mechanism for understanding the pathogenesis of atherosclerosis."	32345778
5999	Human	hsa-miR-204-5p	miRNA	¦Ã-rays	ionizing radiation (IR) injury	whole blood samples from healthy donors extracellular vesicles (ELVs)	irradiate with 2 Gy gamma rays treatment	upregulated	28264626
6000	Human	hsa-miR-204-5p	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
6001	Human	hsa-miR-204-5p	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	human lens epithelial cells (LECs)	TGF-¦Â2 treatment	downregulated	33327804
6002	Human	hsa-miR-204-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HBMEC;bEnd.3 cells	oxygen-glucose deprivation (OGD) treatment	downregulated	33607153
6003	Human	hsa-miR-204-5p	miRNA	vemurafenib	melanoma	A375 cells	vemurafenib treatment	upregulated	29229605
6004	Human	hsa-miR-204-5p	miRNA	triptolide (TPL)	non-small cell lung cancer (NSCLC)	A549 cells	triptolide (TPL) treatment	TL upregulated miR204-5p mRNA expression in NSCLC	32733649
6005	Human	hsa-miR-204-5p	miRNA	docetaxel (DTX)	prostate cancer	PCa samples; PC3 cells; DU145 cells	docetaxel (DTX) treatment	downregulated	31672604
6006	Human	hsa-miR-204-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	RA-FLS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"We found that NEAT1 was upregulated, and miR-204-5p was downregulated in the RA patients' synovial tissue and TNF-¦Á treated RA-FLSs"	33394349
6007	Human	hsa-miR-204-5p	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"LPS impaired cell viability, and promoted cell apoptosis, inflammatory response and oxidative stress in HUVECs by regulating HULC/miR-204-5p/TRPM7 axis."	32484206
6008	Human	hsa-miR-204-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	B cells	M.tb infection	upregulated	29477867
6009	Human	hsa-miR-205	miRNA	garcinol	acute myocardial infarction (AMI)	Human myocardial cell line (AC16)	Garcinol treatment	garcinol enhanced the expression of microRNA-205	33809417
6010	Human	hsa-miR-205	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells	lipopolysaccharide (LPS) treatment	"SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice."	33170429
6011	Human	hsa-miR-205	miRNA	transglutaminase 2 (TG2)	breast cancer	"MCF-7, MDA-MB-231 breast cancer cells"	transglutaminase 2 (TG2) overexpression	downregulated	30949413
6012	Human	hsa-miR-205	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	upregulated	24396484
6013	Human	hsa-miR-205	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
6014	Human	hsa-miR-205	miRNA	entinostat	breast cancer	MDA-MB-453 cells£»BT474 cells£»SKBR3 cells£»MDA-MB-435 cells	entinostat treatment	downregulated	23519125
6015	Human	hsa-miR-205	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
6016	Human	hsa-miR-205	miRNA	MEK inhibitor U0126 or PD98059	breast cancer	ErbB2-overexpressing nontumorigenic human breast epithelial cell line MCF10A	U0126 or PD98059	upregulated	28781955
6017	Human	hsa-miR-205	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells; MDA-MB-231 cells	paclitaxel treatment	downregulated	30019863
6018	Human	hsa-miR-205	miRNA	paclitaxel (PTX)	breast cancer	BT-474 cells	paclitaxel treatment	upregulated	30019863
6019	Human	hsa-miR-205	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
6020	Human	hsa-miR-205	miRNA	arsenite	tumorigenesis	derivative normal stem cell (SC) line	arsenite exposure	downregulated	24431212
6021	Human	hsa-miR-205	miRNA	particulate matter (PM2.5)	cardiovascular disease (CVD)	AC16 cells	fine particulate matter (PM 2.5) treatment	miR-205 was decreased in the PM25 group	32880505
6022	Human	hsa-miR-205	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (HASMC)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	31441592
6023	Human	hsa-miR-205	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
6024	Human	hsa-miR-205	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cellular stress response	prostate cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-205 and miR-31	21368878
6025	Human	hsa-miR-205	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
6026	Human	hsa-miR-205	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
6027	Human	hsa-miR-205	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
6028	Human	hsa-miR-205	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	glioblastoma U87MG cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28792704
6029	Human	hsa-miR-205	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell line U87	glioma cell line U87 treatment	"downregulated(miR-205), upregulation(miR-195)"	27574009
6030	Human	hsa-miR-205	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Hepatoma cell lines HepG2	hepatitis B virus (HBV) infection	downregulated	24339740
6031	Human	hsa-miR-205	miRNA	gemcitabine (GEM)	hepatocellular carcinoma (HCC)	HuCCT1 cells; HuH28 cells	Gemcitabine treatment	upregulated	24147037
6032	Human	hsa-miR-205	miRNA	carboplatin (CBP)	lung cancer	A549 and H1975 lung cancer cells	carboplatin (CBP) treatment	upregulated	25917317
6033	Human	hsa-miR-205	miRNA	tobacco carcinogens	lung cancer	HBECs	tobacco carcinogens treatment	"EMT induction was epigenetically driven, initially by chromatin remodeling through H3K27me3 enrichment and later by ensuing DNA methylation to sustain silencing of tumor-suppressive miR-200b, miR-200c, and miR-205"	21363915
6034	Human	hsa-miR-205	miRNA	oleacein (OA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	oleic acid (OA) treatment	upregulated	31799678
6035	Human	hsa-miR-205	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
6036	Human	hsa-miR-205	miRNA	¦Â-glycerophosphate (¦Â-GP)	osteogenesis	human aortic smooth muscle cells (HASMCs)	¦Â-glycerophosphate treatment	downregulated	25012146
6037	Human	hsa-miR-205	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
6038	Human	hsa-miR-205	miRNA	cancer-associated fibroblasts (CAFs)	prostate cancer	prostate cancer (PCa) cells	PCa cells upon CAF stimulation treatment	downregulated	23924028
6039	Human	hsa-miR-205	miRNA	hypoxia	prostate cancer	DU145 and LNCaP cells	hypoxia treatment	downregulated	27160121
6040	Human	hsa-miR-205	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
6041	Human	hsa-miR-205	miRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	HK-2 cells	hypoxia induce	downregulated	31934284
6042	Human	hsa-miR-205	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
6043	Human	hsa-miR-205	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	TapSAKI was upregulated and miR-205 was downregulated in LPS-induced HK-2 cells.	33869780
6044	Human	hsa-miR-205	miRNA	tumor resection	squamous cell carcinoma (SQCC) and adenocarcinoma (ADC£©	SQCC and ADC patients	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28634901
6045	Human	hsa-miR-205	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
6046	Human	hsa-miR-205-3p	miRNA	ultraviolet (UV) irradiation	corneal damage	human corneal epithelial cells	ultraviolet (UV) radiation treatment	upregulated	32633336
6047	Human	hsa-miR-205-3p	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell lines	TGF-¦Â treatment	downregulated	31558707
6048	Human	hsa-miR-205-3p	miRNA	ionizing radiation (IR)	low doses hyper-radiosensitivity (LDHRS)	DLD-1 cells	ionizing radiation (IR) treatment	upregulated	29899866
6049	Human	hsa-miR-205-5p	miRNA	copper (Cu)	Alzheimer's disease (AD)	human primary microvascular endothelial cells (MVECs)	chronic exposure to copper	"In human primary microvascular endothelial cells (MVECs), microRNA-205-5p was significantly elevated within the 24-h exposure to copper and returned to baseline after 48-h postexposure."	30923833
6050	Human	hsa-miR-205-5p	miRNA	anabolic-androgenic ateroids (AASs)	anabolic-Androgenic Steroids (AASs)-induced renal damage	kidney tissues	anabolic-androgenic ateroids (AASs) treatment	upregulated	33041804
6051	Human	hsa-miR-205-5p	miRNA	H2O2	angiogenesis	The ARPE-19 human cell line	H2O2 treatment	upregulated	31863632
6052	Human	hsa-miR-205-5p	miRNA	N-acetyl-L-cysteine (NAC)	angiogenesis	H2O2-treated the ARPE-19 human cell line	N-acetylcysteine (NAC) treatment	downregulated	31863632
6053	Human	hsa-miR-205-5p	miRNA	gemcitabine (GEM)	breast cancer	MDA-MB-231 and BT549 cells	Gemcitabine (GEM) treatment	Overexpression of miR-205-5p significantly augmented cytotoxicity effects of gemcitabine treatment in MDA-MB-231 and BT549 cells.	31602229
6054	Human	hsa-miR-205-5p	miRNA	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT)	cervical cancer (CC)	serum	low molecular weight heparin (LWMH) and concurrent chemoradiotherapy (CCRT) treatment	upregulated	32851067
6055	Human	hsa-miR-205-5p	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
6056	Human	hsa-miR-205-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
6057	Human	hsa-miR-205-5p	miRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	Bel-7402 (Bel) cells	5-fluorouracil (5-FU) treatment	upregulated	28979703
6058	Human	hsa-miR-205-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
6059	Human	hsa-miR-205-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	32057949
6060	Human	hsa-miR-205-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30853343
6061	Human	hsa-miR-205-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32217110
6062	Human	hsa-miR-20-5p	miRNA	H2O2	cell senescence	multipotent stromal cells	H2O2 treatment	downregulated	32174776
6063	Human	hsa-miR-206	miRNA	thyroid hormone	hepatocellular carcinoma (HCC)	skeletal muscle	thyroid hormone (TH) treatment	downregulated	19567520
6064	Human	hsa-miR-206	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33635017
6065	Human	hsa-miR-206	miRNA	IL-1¦Â and forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	IL-1¦Â and forskolin (Fsk) treatment	downregulated	33508847
6066	Human	hsa-miR-206	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cell line	oxidized low-density lipoprotein (ox-LDL) treatment	"miR-206 was predicted as a target of UCA1 and knockdown of UCA1 was able to repress miR-206 expression. Furthermore, overexpression of miR-206 inhibited oxidative stress process and it was reversed by UCA1 upregulation in vitro."	30633352
6067	Human	hsa-miR-206	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1-derived macrophages and differentiated human monocyte-derived macrophages (hMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33526034
6068	Human	hsa-miR-206	miRNA	IL-1¦Â	autoimmune thyroiditis (AIT)	Nthy-ori 3-1 cells	IL-1¦Â treatment	downregulated	33452572
6069	Human	hsa-miR-206	miRNA	ursolic acid (UA)	autoimmune thyroiditis (AIT)	IL-1¦Â-treated Nthy-ori 3-1 cells	ursolic acid (UA) treatment	upregulated	33452572
6070	Human	hsa-miR-206	miRNA	acetyl-11-keto-¦Â-boswellic acid (AKBA)	breast cancer	MCF-10AT cells	Acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment	AKBA could induce cell apoptosis and G1-phase arrest and inhibit ER-¦Á expression via LINC00707/miR-206 in MCF-10AT cells.	32013235
6071	Human	hsa-miR-206	miRNA	physical activity	breast cancer	MCF-7 cells	physical activity treatment	upregulated	32547708
6072	Human	hsa-miR-206	miRNA	antrodia cinnamomea	cancer treatment	"THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68"	antrodia cinnamomea treatment	downregulated	28602756
6073	Human	hsa-miR-206	miRNA	tocotrienol-rich fraction (TRF)	cell differentiation	senescent human skeletal muscle myoblasts (HSMM)	senescent human skeletal muscle myoblasts (HSMM) were treated with 50 ¦Ìg/mL TRF for 24 h treatment	upregulated	30519366
6074	Human	hsa-miR-206	miRNA	high glucose (HG)	cell proliferation and extracellular matrix (ECM) deposition	?human glomerular mesangial cells (hMCs)	high glucose (HG) treatment	downregulated	31880296
6075	Human	hsa-miR-206	miRNA	amphiregulin	chondrosarcoma	human chondrosarcoma cells	amphiregulin treatment	downregulated	27826039
6076	Human	hsa-miR-206	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cells (HPMECs)	cigarette smoke extract (CSE) treatment	upregulated	30335896
6077	Human	hsa-miR-206	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cells (HPMECs)	cigarette smoke extract (CSE) exposure	upregulated	30335896
6078	Human	hsa-miR-206	miRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	MRC-5 cells	lipopolysaccharide (LPS) treatment	upregulated	31279225
6079	Human	hsa-miR-206	miRNA	prostaglandin E2 (PGE2)	colorectal cancer (CRC)	HCT-116 and Caco-2 cells	prostaglandin E2 (PGE2) treatment	downregulated	30135139
6080	Human	hsa-miR-206	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	31608712
6081	Human	hsa-miR-206	miRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	OV2008 cells	cisplatin treatment	miR-206 expression was increased in primary platinum-resistant EOC.	33292230
6082	Human	hsa-miR-206	miRNA	propofol (PPF)	glioblastoma multiforme (GBM)	U251 cells; LN229 cells	propofol treatment	"MiR-206 was decreased in glioma tissues and cells, while propofol exposure induced the upregulation of miR-206 in glioma cells."	32021281
6083	Human	hsa-miR-206	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
6084	Human	hsa-miR-206	miRNA	high fat diet (HFD)	hepatosteatosis and hyperglycemia	human hepatocytes	high fat diet (HFD) feed	downregulated	28025059
6085	Human	hsa-miR-206	miRNA	lipopolysaccharide (LPS)	inflammation	human astrocytes	lipopolysaccharide (LPS) treatment	upregulated	25452104
6086	Human	hsa-miR-206	miRNA	dexamethasone (DEX)	legg Calve Perthes disease (LCPD)	chondrocytes obtained from patients with LCPD	dexamethasone (DEX) treatment	upregulated	29387248
6087	Human	hsa-miR-206	miRNA	dexamethasone (DEX)	left ventricular hypertrophy (LVH)	primary chondrocytes of the LCPD and normal control group	dexamethasone (DEX) treatment	upregulated	29387248
6088	Human	hsa-miR-206	miRNA	active pterocarpanquinone LQB-118 	active pterocarpanquinone LQB-118 cytotoxicity	"PC3, LNCaP, and LAPC4 PCa cells"	LQB-118	downregulated	29105806
6089	Human	hsa-miR-206	miRNA	hepatocyte growth factor (HGF)	lung cancer	lung cancer cells PC-9 and HCC-827	Hepatocyte growth factor (HGF) treatment	downregulated	29664235
6090	Human	hsa-miR-206	miRNA	l-carnitine	male infertility	sperm	l-carnitine treatment	upregulated	31749176
6091	Human	hsa-miR-206	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
6092	Human	hsa-miR-206	miRNA	GW501516	nasopharyngeal carcinoma (NPC)	C666-1 cells	GW501516 treatment	upregulated	30982495
6093	Human	hsa-miR-206	miRNA	propofol (PPF)	neurotoxicity	human embryonic stem cells (hESCs)	expose to propofol (50 ¦ÌM) for 6 hr treatment	upregulated	28869449
6094	Human	hsa-miR-206	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	A549 cells	curcumin treatment	"Curcumin significantly inhibited migration and invasion in A549 cells, accompanied by significantly elevated miR-206 expression."	32074070
6095	Human	hsa-miR-206	miRNA	prednisolone	oral submucous fibrosis (OSF)	OSF-fibroblast cells	were cultur Salvia (90 g/mL) combin low-dose prednisolone treatment	upregulated	24921400
6096	Human	hsa-miR-206	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	upregulated	22366961
6097	Human	hsa-miR-206	miRNA	particulate matter (PM2.5)	pulmonary arterial hypertension (PAH)	plasma	particulate matter (PM2.5) treatment	"Based on microarray analyses, we found that microRNA-206 may be involved in asthma induced PAH stimulated by PM25"	33086901
6098	Human	hsa-miR-206	miRNA	hypoxia	pulmonary hypertension (PH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	downregulated	23628900
6099	Human	hsa-miR-206	miRNA	artesunate (ART)	rhabdomyosarcoma (RMS)	ERMS cell lines	artesunate (ARS) treatment	downregulated	26153023
6100	Human	hsa-miR-206	miRNA	tin protoporphyrin	rhabdomyosarcoma (RMS)	RD and SMS-CTR cells	RD and SMS-CTR cells treatment	downregulated	27488535
6101	Human	hsa-miR-206	miRNA	"vincristine, dactinomycin, cyclophosphamide (VAC)"	rhabdomyosarcoma (RMS)	rhabdomyosarcoma patients	VAC treatment	upregulated	28834127
6102	Human	hsa-miR-206	miRNA	triiodo-l-thyronine (T3)	thyroid hormone-induced disorders of lipid metabolism	HepG2 cells	triiodothyronine (T3) treatment	downregulated	29484422
6103	Human	hsa-miR-206	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (M.tb) treatment	upregulated	27291149
6104	Human	hsa-miR-206	miRNA	mesalamine	ulcerative colitis (UC)	HT29 colon cells	mesalamine treatment	downregulated	30204869
6105	Human	hsa-miR-206	miRNA	mood stabilizers	bipolar disorder type I (BD-I)	blood	mood stabilizers treatment	downregulated	24767015
6106	Human	hsa-miR-206-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	THP-1 cells	"4,4'-methylene diphenyl diisocyanate (MDI) treatment"	Both in vivo murine MDI aerosol exposure and in vitro MDI-GSH exposures in THP-1 macrophages result in downregulated of endogenous miR-206-3p and miR-381-3p and upregulation of PPP3CA and iNOS expression.	31609387
6107	Human	hsa-miR-208	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
6108	Human	hsa-miR-208a	miRNA	coronary artery bypass graft (CABG)	acute coronary syndrome (ACS)	acute coronary syndrome patients heart	CABG treatment	upregulated	29506853
6109	Human	hsa-miR-208a	miRNA	caffeine	cardiovascular disease (CVD)	HL-1 and primary embryonic cardiomyocytes	exposure to physiologically relevant doses of caffeine treatment	downregulated	25354728
6110	Human	hsa-miR-208a	miRNA	cyclic mechanical stretch (CMS)	cardiovascular disease (CVD)	human cardiac fibroblasts-adult atrial (HCF-aa)	cyclic stretching treatment	"MiR208a was upregulated early by stretching and returned to normal levels with longer stretching cycles, whereas the expression of miR499 and Bcl-2 was upregulated by longer stretching times."	33605072
6111	Human	hsa-miR-208a	miRNA	H2O2	myocardial injury	AC16 cardiomyocytes	H2O2 treatment	"miR-208a mimic aggravated H2O2-induced apoptosis and oxidative injury in cardiomyocytes, while miR-208a inhibitor hadan inverse effect."	31545986
6112	Human	hsa-miR-208b	miRNA	caffeine	cardiovascular disease (CVD)	HL-1 and primary embryonic cardiomyocytes	exposure to physiologically relevant doses of caffeine treatment	upregulated	25354728
6113	Human	hsa-miR-208b	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7 cells	hepatitis C virus (HCV) infection	upregulated	24241692
6114	Human	hsa-miR-208b	miRNA	propofol (PPF)	expression regulation	human adipocyte stem cells	"50 ?M propofol, or 100 ?M propofol in culture media for 3 hours treatment"	"The lowest expression was seen for miR-204, The highest expression was seen for miR-208b"	25568843
6115	Human	hsa-miR-20a	miRNA	hypoxia	paracrine function	Primary human adipose-derived stem cells (ADSCs)	hypoxia induce	downregulated	31368162
6116	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	31874343
6117	Human	hsa-miR-20a	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
6118	Human	hsa-miR-20a	miRNA	hypoxia	acute tubular injury	HK-2 cells-derived exosomes	hypoxia treatment	upregulated	32808649
6119	Human	hsa-miR-20a	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-20a was positively associated with 1st trimester exposure	27104955
6120	Human	hsa-miR-20a	miRNA	hypoxia	angiogenesis	adipose-derived stem cells (ADSCs)	hypoxia treatment	miR-20a expression was significantly downregulated compared to that under normoxia.	31368162
6121	Human	hsa-miR-20a	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	HUVECs	vascular endothelial growth factor (VEGF) treatment	upregulated	28097093
6122	Human	hsa-miR-20a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29653364
6123	Human	hsa-miR-20a	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 13¡ã HDT bed rest experiment	downregulated	28261104
6124	Human	hsa-miR-20a	miRNA	rapamycin	breast cancer	breast cancer cells	rapamycin treatment	over expression	26829385
6125	Human	hsa-miR-20a	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
6126	Human	hsa-miR-20a	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
6127	Human	hsa-miR-20a	miRNA	oridonin and the antileukemia drugs Ara-C and VP-16	chemoresistant leukemia	human leukemia cells	oridonin and the antileukemia drugs Ara-C and VP-16 treatment	downregulated	24872388
6128	Human	hsa-miR-20a	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	upregulated	24178909
6129	Human	hsa-miR-20a	miRNA	curcumin (Cur)	colorectal cancer (CRC)	RKO ; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts	curcumin treatment	downregulated	23194063
6130	Human	hsa-miR-20a	miRNA	hypoxia	colorectal cancer (CRC)	The human colon cancer cell lines LoVo and SW48	hypoxia induce	downregulated	30883936
6131	Human	hsa-miR-20a	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
6132	Human	hsa-miR-20a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose treatment	downregulated	32868134
6133	Human	hsa-miR-20a	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN45 cells	docetaxel (DTX) treatment	downregulated	31368060
6134	Human	hsa-miR-20a	miRNA	ruxolitinib	glioblastoma multiforme (GBM)	U87-MG cells	ruxolitinib treatment	upregulated	31452174
6135	Human	hsa-miR-20a	miRNA	endothelial-monocyte-activating polypeptide-II (EMAP-II)	glioblastoma multiforme (GBM)	U-87 and U-251 cells	endothelial-monocyte-activating polypeptide-II (EMAP-II) treatment	downregulated	27242439
6136	Human	hsa-miR-20a	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	LO2 cells	hypoxia induce	downregulated	31566731
6137	Human	hsa-miR-20a	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
6138	Human	hsa-miR-20a	miRNA	vascular endothelial growth factor (VEGF)	inflammation	endothelial cell	vascular endothelial growth factor (VEGF)treatment treatment	?miR-20a expression is increased by VEGF	22696064
6139	Human	hsa-miR-20a	miRNA	sulfur mustard (SM)	lung diseases	plasma and serum	Sulfur mustard (SM) treatment	downregulated	26525353
6140	Human	hsa-miR-20a	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
6141	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	HL-60 cells; U937 cells; THP-1 cells; HT-29 cells; 293T cells; HeLa cells; HepG2 cells; MDB231 cells; MCF7 cells; SH-SY5Y cells; C2C12 cells	lipopolysaccharide (LPS) treatment	upregulated	23562609
6142	Human	hsa-miR-20a	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell line RPMI8226	bortezomib? treatment	downregulated	26032093
6143	Human	hsa-miR-20a	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; L02 cells	free fatty acids (FFA) treatment	downregulated	30338914
6144	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	cultured chondrocytes	lipopolysaccharides (LPS) treatment	upregulated	31451219
6145	Human	hsa-miR-20a	miRNA	"phorbol-12-myristate-13-acetate (PMA), macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-¦ÊB ligand RANKL"	osteoclastogenesis	THP-1 human acute monocytic leukemia cells	"phorbol-12-myristate-13-acetate (PMA), macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-¦ÊB ligand RANKL treatment"	downregulated	31545439
6146	Human	hsa-miR-20a	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx2 treatment"	downregulated	21572246
6147	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	pediatric pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	29115456
6148	Human	hsa-miR-20a	miRNA	hypoxia	pelvic endometriosis	stromal cells	Hypoxia treatment	Levels of miR20a were upregulated in endometriotic stromal cells. Elevation of miR20a was upregulated by hypoxia inducible factor-1¦Á	22648654
6149	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	periodontal inflammation	Primary human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	downregulated	31552681
6150	Human	hsa-miR-20a	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	29115456
6151	Human	hsa-miR-20a	miRNA	hydrogen sulfide (H2S)	preeclampsia (PE)	placental cells obtained from pregnant women with preeclampsia	placental cells obtained from pregnant women with preeclampsia treatment	downregulated	26992682
6152	Human	hsa-miR-20a	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
6153	Human	hsa-miR-20a	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	rhabdomyosarcoma (RMS)	RD and Rh30 rhabdomyosarcoma (RMS) cells	"Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment"	downregulated	30610105
6154	Human	hsa-miR-20a-3p	miRNA	IL-22	psoriasis	HaCaT cells (human keratinocyte cell line)	Interleukin-22 (IL-22) treatment	downregulated	29886071
6155	Human	hsa-miR-20a-5p	miRNA	phorbol-12-myristate-13-acetate(PMA)	allergic inflammation	HMC-1 mast cells	PMA/A23187 treatment	downregulated	30684894
6156	Human	hsa-miR-20a-5p	miRNA	mycobacterium tuberculosis (Mtb)	active tuberculosis (ATB)	human macrophages	Mycobacterium tuberculosis (Mtb) infection	downregulated	27494776
6157	Human	hsa-miR-20a-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	"PVT1 expression was significantly increased, whereas miR-20a-5p expression was significantly decreased in sepsis model mice and LPS-induced HK-2 cells compared with sham mice and control HK-2 cells"	33576456
6158	Human	hsa-miR-20a-5p	miRNA	TGF-¦Â1	asthma	BEAS-2B cells	TGF-¦Â1 treatment	MiR-20a-5p was downregulated in TGF-¦Â1-treated human bronchial epithelial cells	31883454
6159	Human	hsa-miR-20a-5p	miRNA	TGF-¦Â1	asthma	human bronchial epithelial BEAS-2B cells	transforming growth factor (TGF)-¦Â1 treatment	downregulated	31883454
6160	Human	hsa-miR-20a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
6161	Human	hsa-miR-20a-5p	miRNA	SD or MF radiation	breast cancer	MDA-MB-361 cells	SD (10 Gy) or MF radiation (2 Gy x 5 MF) treatment	"upregulated(miR-17-92) downregulated(miR-19a-3p, miR-20a-5p, miR-19b-3p)"	24626680
6162	Human	hsa-miR-20a-5p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
6163	Human	hsa-miR-20a-5p	miRNA	pks+ E. coli	colorectal cancer (CRC)	HCT116 cells	colonised by pks+ E. coli treatment	upregulated	24658599
6164	Human	hsa-miR-20a-5p	miRNA	high glucose (HG)	dysfunction of endothelial progenitor cells (EPCs)	human endothelial progenitor cells (EPCs)	high glucose (HG) treatment	Circ-ADAM9 targeting PTEN and ATG7 promotes autophagy and apoptosis of diabetic endothelial progenitor cells by sponging mir-20a-5p.	32661238
6165	Human	hsa-miR-20a-5p	miRNA	IFN-¦Ã	epithelial-mesenchymal transition (EMT)	PC-3M IE8 cells	IFN-¦Ã treatment	Hsa-miR-196b-5p was downregulated in PC-3M IE8 cells treatment with IFN-¦Ã.	31882179
6166	Human	hsa-miR-20a-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
6167	Human	hsa-miR-20a-5p	miRNA	hypoglycemic	hepatocellular carcinoma (HCC)	HepG2 cells	hypoglycemic treatment	downregulated	27629773
6168	Human	hsa-miR-20a-5p	miRNA	anti-programmed cell death protein 1 (anti-PD-1) antibody	malignant melanoma (MM)	serum	anti-programmed cell death protein 1 (anti-PD-1) antibody treatment	Serum expression levels of miR-20a-5p was significantly higher in responders than in non-responders.	31843231
6169	Human	hsa-miR-20a-5p	miRNA	IFN-¦Â	multiple sclerosis (MS)	RRMS patients blood sample	IFN-¦Â treatment	downregulated	27752929
6170	Human	hsa-miR-20a-5p	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acid (FFA) treatment	downregulated	33344451
6171	Human	hsa-miR-20b	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
6172	Human	hsa-miR-20b	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
6173	Human	hsa-miR-20b	miRNA	propofol (PPF)	autophagic cell death	Human umbilical vein endothelial cells (HUVECs)	propofol treatment	Propofol promoted the expression of miR-20b	32826852
6174	Human	hsa-miR-20b	miRNA	BAY11-7082	autophagy	Mycobacterium tuberculosis (Mtb)-infected THP-1 cells	BAY 11-7082 treatment	upregulated	30011088
6175	Human	hsa-miR-20b	miRNA	rapamycin	breast cancer	breast cancer cells	rapamycin treatment	over expression	26829385
6176	Human	hsa-miR-20b	miRNA	hypoxia	cerebral ischemia injury (CII)	Human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	30628668
6177	Human	hsa-miR-20b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial senescence	human pulmonary microvascular endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28595801
6178	Human	hsa-miR-20b	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-20b was upregulated in propofol-treated group	24454982
6179	Human	hsa-miR-20b	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
6180	Human	hsa-miR-20b	miRNA	resveratrol	lymph node cancer of prostate	Lymph node cancer of prostate (LNCaP)£»Du145 cells	resveratrol (Res) treatment	upregulated	21714127
6181	Human	hsa-miR-20b	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
6182	Human	hsa-miR-20b	miRNA	triptolide (TPL)	osteoarthritis (OA)	LPS-induced human monocytic cell line THP-1	triptolide (TPL) treatment	downregulated	29974310
6183	Human	hsa-miR-20b	miRNA	triptolide (TPL)	osteoarthritis (OA)	LPS-treated human monocytic cell line THP-1	triptolide (TPL) treatment	downregulated	29974310
6184	Human	hsa-miR-20b	miRNA	hydrogen sulfide (H2S)	preeclampsia (PE)	placental cells obtained from pregnant women with preeclampsia	placental cells obtained from pregnant women with preeclampsia treatment	downregulated	26992682
6185	Human	hsa-miR-20b	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (Mtb) infection	downregulated	30011088
6186	Human	hsa-miR-20b-3p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
6187	Human	hsa-miR-20b-3p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
6188	Human	hsa-miR-20b-3p	miRNA	temozolomide (TMZ)	temozolomide (TMZ) resistance in glioblastoma (GBM)	"LN229, U251, 551 W, and HG7 cells"	temozolomide (TMZ) treatment	lnc-TALC correlated with TMZ resistance via competitively binding miR-20b-3p to facilitate c-Met expression	31053733
6189	Human	hsa-miR-20b-5p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
6190	Human	hsa-miR-20b-5p	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
6191	Human	hsa-miR-20b-5p	miRNA	platelet-derived growth factor (PDGF)	asthma	fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	downregulated	29549727
6192	Human	hsa-miR-20b-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	High Glucose (HG) treatment	upregulated	31636010
6193	Human	hsa-miR-20b-5p	miRNA	propofol (PPF)	ischemia/reperfusion (I/R) injury	human umbilical vein endothelial cells (HUVECs)	propofol treatment	miR-20b-5p was significantly higher and ULK1 was lower in propofol-preconditioned HUVECs with HR injury than in HUVECs with HR injury only	32098914
6194	Human	hsa-miR-20b-5p	miRNA	fractionated radiation	radiation-induced injury	human peripheral blood mononuclear cells	fractionated radiation treatment	upregulated	25313363
6195	Human	hsa-miR-21	miRNA	"3,3'-diindolylmethane (DIM)"	adipogenesis	MCF-7 cells	"3,3'-Diindolylmethane (DIM) treatment"	treatment of MCF-7 cells with DIM increased miR-21 expression and downregulated Cdc25A	21761201
6196	Human	hsa-miR-21	miRNA	taxol	breast cancer	The human breast adenocarcinoma MCF-7 cells	taxol treatment	downregulated	20082533
6197	Human	hsa-miR-21	miRNA	thymic stromal lymphopoietin (TSLP)	fungal keratitis	dendritic cells (DCs) from peripheral blood of healthy volunteers	thymic stromal lymphopoietin (TSLP)?treatment treatment	miR-21 was highly expressed in exosomes from TSLP-treated DCs	33253708
6198	Human	hsa-miR-21	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
6199	Human	hsa-miR-21	miRNA	resveratrol	inflammation	glioma cells	resveratrol (Res) treatment	downregulated	23793554
6200	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	cell division	human peripheral blood mononuclear cells	LPS treatment	upregulated	17700064
6201	Human	hsa-miR-21	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	?SSc fibroblasts	TGF-¦Â treatment	upregulated	23657402
6202	Human	hsa-miR-21	miRNA	docosahexaenoic acid (DHA)	osteogenesis	human breast cancer cell lines MDA-MB-231 ;MCF-7	docosahexaenoic acid (DHA) treatment	downregulated	22678116
6203	Human	hsa-miR-21	miRNA	5-fluorouracil (5-Fu)	pancreatic cancer (PC)	HT-29 cells	5-fluorouracil (5-FU) treatment	downregulated	24275137
6204	Human	hsa-miR-21	miRNA	statins	active hepatitis or cirrhosis	HepG2 cells	statins? treatment	upregulated	26429200
6205	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	acute coronary syndrome (ACS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30233677
6206	Human	hsa-miR-21	miRNA	CoCl2	acute kidney injury (AKI)	Human proximal tubular cell lines (HK-2 cells)	CoCl2 treatment	upregulated	30013485
6207	Human	hsa-miR-21	miRNA	CoCl2	acute kidney injury (AKI)	human umbilical vein endothelial cells (HUVECs)	treated with CoCl2	upregulated	28677811
6208	Human	hsa-miR-21	miRNA	hypoxia	acute kidney injury (AKI)	Human proximal tubular cell lines (HK-2 cells)	hypoxia induce	upregulated	30013485
6209	Human	hsa-miR-21	miRNA	L-mimosine	acute kidney injury (AKI)	Human proximal tubular cell lines (HK-2 cells)	L-Mimosine treatment	upregulated	30013485
6210	Human	hsa-miR-21	miRNA	kanglaite	advanced lung cancer	serum	Kanglaite treatment	Kanglaite injection on serum miRNA-21 in patients with advanced lung cancer was shown to significantly reduce the expression of miRNA-21.	29735968
6211	Human	hsa-miR-21	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-21 was inversely associated with PM25 exposure during the 2nd trimester of pregnancy	27104955
6212	Human	hsa-miR-21	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-21 was positively associated with 1st trimester exposure	27104955
6213	Human	hsa-miR-21	miRNA	budesonide	airway remodeling	Human bronchial fibroblasts	?budesonide treatment	downregulated	31204163
6214	Human	hsa-miR-21	miRNA	calcitriol	airway remodeling	Human bronchial fibroblasts	calcitriol treatment	downregulated	31204163
6215	Human	hsa-miR-21	miRNA	receptor inhibitor (SB431542)	airway remodeling	human bronchial fibroblasts (HBFs)	receptor inhibitor (SB431542) treatment	The high expression of miR-21 induced by TGF¦Â1 was reduced following the treatment with the SB431542 in HBFs.	29621415
6216	Human	hsa-miR-21	miRNA	SB431542	airway remodeling	TGF¦Â1-treated human bronchial fibroblasts (HBFs)	SB431542 treatment	downregulated	29621415
6217	Human	hsa-miR-21	miRNA	TGF-¦Â1	airway remodeling	human bronchial fibroblasts (HBFs)	TGF-¦Â3 treatment	upregulated	29621415
6218	Human	hsa-miR-21	miRNA	alcohol	alcohol stress	alcohol consumption in heavy drinkers	were allowed to drink up to 750 cc of beer? treatment	upregulated	25421511
6219	Human	hsa-miR-21	miRNA	chitin	allergic airway diseases (AAD)	bronchial epithelial cells and in A549 and H292 lung carcinoma cells	chitin treatment	upregulated	27463381
6220	Human	hsa-miR-21	miRNA	hepatitis C virus (HCV)	allergies and bronchial asthma	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	23633945
6221	Human	hsa-miR-21	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	29635890
6222	Human	hsa-miR-21	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
6223	Human	hsa-miR-21	miRNA	propofol (PPF)	anesthesia-induced neural cytotoxicity	human embryonic stem cell	propofol treatment	downregulated	24950164
6224	Human	hsa-miR-21	miRNA	ionizing radiation (IR)	angiogenesis	HUVEC cells	ionizing radiation (IR) treatment	upregulated	31128066
6225	Human	hsa-miR-21	miRNA	phosphatase of regenerating liver-3 (PRL-3)	angiogenesis	colon cancer cells	Phosphatase of regenerating liver-3 (PRL-3) treatment	"overexpression of PRL-3 in colon cancer cells induced the expression of miR-21, miR-17 and miR-19a by activating STAT3"	22677902
6226	Human	hsa-miR-21	miRNA	sulfasalazine	ankylosing spondylitis (AS)	patients blood	sulfasalazine treatment	upregulated	24786924
6227	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	ankylosing spondylitis (AS)	fibroblasts	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32009856
6228	Human	hsa-miR-21	miRNA	metformin (Met)	anti-cancer therapy	"human skin keratinocyte cell line, HaCaT"	metformin treatment	downregulated	29286158
6229	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	anti-inflammatory responses	myocardial cell line H9c2(2-1)	exposed to LPS treatment	upregulated	25131238
6230	Human	hsa-miR-21	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
6231	Human	hsa-miR-21	miRNA	CC2238/¦ÁANP	apoptosis	CASMCs	CC2238/¦ÁANP treatment	downregulated	25401746
6232	Human	hsa-miR-21	miRNA	contrast medium (CM)	apoptosis	human renal proximal tubular epithelial (HK-2) cells	contrast medium (CM) treatment	downregulated	28901491
6233	Human	hsa-miR-21	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31966898
6234	Human	hsa-miR-21	miRNA	temozolomide (TMZ)	apoptosis	human glioblastoma U87MG cells	temozolomide treatment	over-express miR-21 in U87MG cells could significantly reduce TMZ-induced apoptosis	20633539
6235	Human	hsa-miR-21	miRNA	resveratrol	apoptosis	pancreatic cancers cells	resveratrol (RS) treatment	downregulated	23359184
6236	Human	hsa-miR-21	miRNA	arsenite	arsenic-induced multiorgan damage	plasma	arsenic exposure	upregulated	31085440
6237	Human	hsa-miR-21	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
6238	Human	hsa-miR-21	miRNA	arsenic trioxide (ATO)	As2O3 cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
6239	Human	hsa-miR-21	miRNA	inhaled corticosteroids	asthma	bronchial epidermal cells from asthma patients	inhaled corticosteroids treatment	downregulated	24995087
6240	Human	hsa-miR-21	miRNA	angiotensin II (Ang II)	atherosclerosis (AS)	human microvascular endothelial cells (HMECs)	angiotensin II (Ang II) treatment	upregulated	30950039
6241	Human	hsa-miR-21	miRNA	dihydromyricetin (DHM)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	dihydromyricetin (DMY) treatment	DMY decreases microRNA-21 (miR-21).	32301289
6242	Human	hsa-miR-21	miRNA	geniposide (GEN)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	geniposide treatment	geniposide pretreatment significantly increased miR-21 level in human umbilical vein endothelial cells (HUVECs) under ox-LDL condition.	32323738
6243	Human	hsa-miR-21	miRNA	teniposide	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HASMCs)	teniposide treatment	upregulated	30409428
6244	Human	hsa-miR-21	miRNA	tongxinluo (TXL)	atherosclerosis (AS)	normal human proximal tubular epithelial cells (HKCs) £» serum	Tongxinluo? treatment	downregulated	24370587
6245	Human	hsa-miR-21	miRNA	angiotensin II (Ang II)	atrial fibrosis	Neonatal cardiac fibroblasts	angiotensin II (Ang II) treatment	upregulated	22760500
6246	Human	hsa-miR-21	miRNA	connective tissue growth factor (CTGF)	atrial fibrosis	Neonatal cardiac fibroblasts	CTGF treatment	upregulated	22760500
6247	Human	hsa-miR-21	miRNA	arsenite	autophagy	L-02 cells	arsenite exposure	upregulated	27107786
6248	Human	hsa-miR-21	miRNA	isoflavone formononetin	bladder cancer	T24 cells	formononetin	downregulated	28139790
6249	Human	hsa-miR-21	miRNA	resveratrol	bladder cancer	T24 and 5637 cells	resveratrol (RS) treatment	downregulated	24535223
6250	Human	hsa-miR-21	miRNA	benzo(a)pyrene (BaP)	breast cancer	MDA-MB-231 cells	benzo(a)pyrene (BaP) exposure	downregulated	30155724
6251	Human	hsa-miR-21	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	upregulated	25120778
6252	Human	hsa-miR-21	miRNA	collagenase-2	breast cancer	breast cancer cells	collagenase-2?treatment	downregulated	23851508
6253	Human	hsa-miR-21	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	downregulated	28599484
6254	Human	hsa-miR-21	miRNA	DDT and BPA	breast cancer	MCF-7 breast cancer cells	DDT and BPA treatment	upregulated	22403704
6255	Human	hsa-miR-21	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
6256	Human	hsa-miR-21	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
6257	Human	hsa-miR-21	miRNA	hesperidin	breast cancer	MCF-7 cells	hesperidin treatment	downregulated	33050842
6258	Human	hsa-miR-21	miRNA	luteolin	breast cancer	MCF-7 cells	luteolin treatment	downregulated	33050842
6259	Human	hsa-miR-21	miRNA	oleuropein (OL)	breast cancer	MCF-7 cells	oleuropein treatment	Oleuropein significantly decreased expression of both miR-21 and miR-155 over time in a dose-dependent manner.	29905007
6260	Human	hsa-miR-21	miRNA	paclitaxel (PTX)	breast cancer	"HER2-positive cell lines, BT-474 and SKBR3"	paclitaxel treatment	upregulated	28509576
6261	Human	hsa-miR-21	miRNA	propofol (PPF)	breast cancer	MCF-7 cells	Propofol treatment	downregulated	30942630
6262	Human	hsa-miR-21	miRNA	silibinin (SB)	breast cancer	MCF-7 breast cancer cells	Silibinin treatment	downregulated	27066095
6263	Human	hsa-miR-21	miRNA	silibinin (SB)	breast cancer	T47D breast cancer cell line	silibinin treatment	"upregulated(miR-200c) ;downregulated (miR-21, miR-15a and miR-141)"	28509572
6264	Human	hsa-miR-21	miRNA	TGF-¦Â	breast cancer	tumor samples of breast cancer	transforming growth factor-beta (TGF-beta) treatment	upregulated	18932017
6265	Human	hsa-miR-21	miRNA	TGF-¦Â1	breast cancer	MCF-7 cell line	TGF-¦Â1 treatment	upregulated	29151919
6266	Human	hsa-miR-21	miRNA	trastuzumab	breast cancer	BT474 cells	trastuzumab treatment	upregulated	29981261
6267	Human	hsa-miR-21	miRNA	trastuzumab	breast cancer	serum	Trastuzumab treatment	downregulated	30246355
6268	Human	hsa-miR-21	miRNA	trastuzumab or lapatinib	breast cancer	patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer	chemotherapy combin either trastuzumab or lapatinib treatment	upregulated	25086636
6269	Human	hsa-miR-21	miRNA	wound fluids (WFs) from breast cancer patients	breast cancer	human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line	WFs treatment	upregulated	28943910
6270	Human	hsa-miR-21	miRNA	zoledronic acid (ZA)	breast cancer	human breast cancer cell lines	zoledronic acid (ZA) treatment	downregulated	26905520
6271	Human	hsa-miR-21	miRNA	¦Á-linolenic acid (ALA)	breast cancer	MCF-7 cells	¦Á-linolenic acid (ALA) treatment	ALA reduced miR-21 expression	29342901
6272	Human	hsa-miR-21	miRNA	X-irradiated	bystander effect	HaCaT cells	X-irradiated treatment	downregulated	26080011
6273	Human	hsa-miR-21	miRNA	radiation	bystander effect	human fetal lung MRC-5 fibroblasts	different types of radiation treatment	upregulation	25483031
6274	Human	hsa-miR-21	miRNA	arsenite	tumorigenesis	HBE cells; A549 cells;HUVEC cells	arsenite exposure	upregulated	24012885
6275	Human	hsa-miR-21	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells by a low concentration (1.0¦ÌM) of arsenite	arsenic exposure	upregulated	25445583
6276	Human	hsa-miR-21	miRNA	high glucose (HG)	cardiac fibrosis	Human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31680453
6277	Human	hsa-miR-21	miRNA	polychlorinated biphenyls (PCBs)	cardiac injury	HUVECs	polychlorinated biphenyls (PCBs) treatment	upregulated	27288564
6278	Human	hsa-miR-21	miRNA	IFN	cardiomyocyte apoptosis	prostate cancer cells	IFN? treatment	cytokine IFN rapidly induces miR-21 expression in cells	20813833
6279	Human	hsa-miR-21	miRNA	kaempferol	cardioprotective therapy	vascular smooth muscle cell (VSMC)	Bioflavonoids treatment	"Kaempferol activates the BMP signaling pathway, induces miR-21 expression and downregulates DOCK4, 5, and 7, leading to inhibition of cell migration."	26048714
6280	Human	hsa-miR-21	miRNA	arsenic trioxide (ATO)	cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
6281	Human	hsa-miR-21	miRNA	hypoxia	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated	22282338
6282	Human	hsa-miR-21	miRNA	H2O2	cataract	HLECs	H2O2 treatment	lncRNA ANRIL attenuated H2O2-induced cell injury in HELCs via up-regulating miR-21 via the activation of AMPK and ¦Â-catenin.	32310822
6283	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell differentiation	human dental pulp stem cells (DPSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	"the expression of miR-21 and STAT3 increased gradually in low concentration (1-10?ng/mL) of TNF-¦Á, while they were suppressed in high concentration (50-100?ng/mL)"	29620442
6284	Human	hsa-miR-21	miRNA	high glucose (HG)	cell proliferation	human aortic vascular smooth muscle cells (HASMCs)	high glucose treatment	upregulated	31672498
6285	Human	hsa-miR-21	miRNA	metformin (Met)	cell proliferation	"human skin keratinocyte cell line, HaCaT"	Metformin treatment	downregulated	29286158
6286	Human	hsa-miR-21	miRNA	substance P (SP)	cell proliferation	exosomes from human colonic epithelial cells (NCM460 and NCM460-NK1R)	substance P (SP) treatment	upregulated	31545921
6287	Human	hsa-miR-21	miRNA	tanshinone IIA (Tan IIA)	cell proliferation	high glucose-treated human aortic vascular smooth muscle cells (HASMCs)	Tanshinone IIA treatment	downregulated	31672498
6288	Human	hsa-miR-21	miRNA	arsenite	cell transformation	Immortalized HELF cells	arsenic exposure	upregulated	22387281
6289	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell-to-cell communication	human aortic endothelial cells (ECs) and their transfer to recipient cells	tumor necrosis factor alpha (TNF-¦Á) treatment	differently regulation	25315114
6290	Human	hsa-miR-21	miRNA	H2O2	cellular oxidative injury	human umbilical vein endothelial cells (HUVECs)	hydrogen peroxide (H2O2) treatment	upregulated	30037352
6291	Human	hsa-miR-21	miRNA	high glucose (HG)	cellular oxidative injury	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	30037352
6292	Human	hsa-miR-21	miRNA	oscillating glucose	cellular oxidative injury	human umbilical vein endothelial cells (HUVECs)	oscillating glucose treatment	upregulated	30037352
6293	Human	hsa-miR-21	miRNA	cisplatin (DDP)	cervical cancer (CC)	Human cervical adenocarcinoma cell Hela;human cervical squamous cancer cell line Siha	cisplatin treatment	downregulated	30352127
6294	Human	hsa-miR-21	miRNA	human papilloma viruses 16 (HPV16) E6	cervical cancer (CC)	SiHa cells	human papillomavirus E6 oncoprotein treatment	dysregulated	25539644
6295	Human	hsa-miR-21	miRNA	N-nitroso carcinogen N-methyl-N-nitro-N'-nitrosoguanidine (MNNG)	chemical carcinogenesis	GES-1 cells	MNNG treatment	upregulated	24821435
6296	Human	hsa-miR-21	miRNA	prostaglandin E2 (PGE2)	cholangiocarcinoma (CCA)	human cholangiocarcinoma cells	PGE2 treatment	upregulated	24699315
6297	Human	hsa-miR-21	miRNA	galangin	cholangiocarcinoma (CCA)	HCCC9810 cells	Galangin treatment	downregulated	32626749
6298	Human	hsa-miR-21	miRNA	HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA)	chronic heart failure (CHF)	human aortic endothelial cells	HDLNYHA treatment	downregulated	24958738
6299	Human	hsa-miR-21	miRNA	quercetin	chronic kidney disease (CKD)	HK-2 cells	quercetin treatment	Quercetin treatment significantly inhibited TGF-¦Â-induced miR-21 upregulation	30210596
6300	Human	hsa-miR-21	miRNA	berberine (BBR)	chronic lymphocytic leukemia (CLL)	peripheral blood mononuclear cells (PBMCs)	berberine (BBR) treatment	berberine could reduce the expression of miR-21 in comparison to the untreated group.	33174291
6301	Human	hsa-miR-21	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	p53-mutant MEG-01 cells	fludarabine treatment	specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets	20504344
6302	Human	hsa-miR-21	miRNA	berberine (BBR)	chronic lymphocytic leukemia (CLL)	peripheral blood mononuclear cells (PBMCs) of CLL patients	berberine (BBR) treatment	"Interestingly, berberine could reduce the expression of miR-21 in comparison to the untreated group."	33174291
6303	Human	hsa-miR-21	miRNA	curcumin (Cur)	chronic myeloid leukemia (CML)	K562 and LAMA84 cells	curcumin treatment	upregulated	27050372
6304	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (16HBE) cells	cigarette smoke extract (CSE) exposure	upregulated	29543496
6305	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells; bronchial fibroblasts (MRC-5 cells)	cigarette smoke extract (CSE) exposure	miR-21 levels were increased in CSE-treated HBE cells and in MRC-5 cells	30555555
6306	Human	hsa-miR-21	miRNA	bone morphogenetic protein 2 (BMP2)	chronic pancreatitis (CP)	human primary pancreatic stellate cells; human primary pancreatic fibroblast (hPFBs)	bone morphogenetic protein 2 (BMP2) treatment	downregulated	29303912
6307	Human	hsa-miR-21	miRNA	TGF-¦Â1	chronic rhinosinusitis with nasal polyps (CRSwNP)	Primary human nasal epithelial cells (PHNECs)	TGF-¦Â1 treatment	upregulated	30982052
6308	Human	hsa-miR-21	miRNA	TGF-¦Â1	chronic rhinosinusitis with nasal polyps (CRSwNP)	epithelial-mesenchymal transition (EMT)	TGF-¦Â1 treatment	upregulated	30982052
6309	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL"	23725219
6310	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL."	23725219
6311	Human	hsa-miR-21	miRNA	p-Cresyl sulfate (pCS)	clear cell renal cell carcinoma (ccRCC)	A498 and 786-O cells of ccRCC	p-Cresyl sulfate (pCS) treatment	upregulated	30824757
6312	Human	hsa-miR-21	miRNA	berberine (BBR)	colorectal cancer (CRC)	HCT116 cells	berberine (BBR) treatment	Berberine inhibited miR-21 expression.	29564000
6313	Human	hsa-miR-21	miRNA	epidermal growth factor (EGF)	colorectal cancer (CRC)	colon cancer cells (HT29; SW480; Caco-2)	epidermal growth factor (EGF) treatment	downregulated	23827854
6314	Human	hsa-miR-21	miRNA	TGF-¦Â	colorectal cancer (CRC)	OVCAR3 cells; Hela cells; HCT116 cells; MRC-5 cells; OSE cells; Human ovarian cancer tissue specimens and Primary fibroblast	TGF-¦Â treatment	upregulated	20533548
6315	Human	hsa-miR-21	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	U251 cells	Ursolic acid treatment	downregulated	22028478
6316	Human	hsa-miR-21	miRNA	butylcycloheptyl prodiginine (bPGN)	colorectal cancer (CRC)	HCT-116 colorectal cancer cells	butylcycloheptyl prodiginine (bPGN) treatment	downregulated	31155509
6317	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	colorectal cancer (CRC)	human colorectal adenocarcinoma cell line (Caco-2)	cigarette smoke extract (CSE) exposure	upregulated	31574306
6318	Human	hsa-miR-21	miRNA	curcumol	colorectal cancer (CRC)	"Human colorectal cancer cells lines LoVo, HCT-116, SW480"	curcumol treatment	downregulated	30811964
6319	Human	hsa-miR-21	miRNA	docosahexaenoic acid (DHA)	colorectal cancer (CRC)	HCT-116 and HCT-8 cells	docosahexaenoic acid (DHA) treatment	downregulated	26853468
6320	Human	hsa-miR-21	miRNA	fusobacterium nucleatum (F. nucleatum)	colorectal cancer (CRC)	"HCT116, HT29, LoVo, and SW480 CRC cell lines"	Fusobacterium nucleatum	upregulated	27876571
6321	Human	hsa-miR-21	miRNA	gambogic acid (GA)	colorectal cancer (CRC)	HT-29 cells	gambogic acid (GA) treatment	treatment with GA significantly decreased miR-21 expression in these cells.	30186399
6322	Human	hsa-miR-21	miRNA	hypoxia	colorectal cancer (CRC)	"CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)"	1 and 0.2% oxygen	upregulated	28207045
6323	Human	hsa-miR-21	miRNA	"JQ-1, Bromodoamin and extraterminal (BET) protein inhibitor"	colorectal cancer (CRC)	SW480 colon cancer cells	"JQ-1, Bromodoamin and extraterminal (BET) protein inhibitor treatment"	downregulated	29600711
6324	Human	hsa-miR-21	miRNA	pomegranate juice (PJ)	colorectal cancer (CRC)	?prostate cancer cells	Pomegranate juice (PJ) treatment	downregulated	21594291
6325	Human	hsa-miR-21	miRNA	sulforaphane (SFN)	colorectal cancer (CRC)	Human RKO colon cancer cells	Sulforaphane (SFN) treatment	downregulated	28176652
6326	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	HT29 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28192117
6327	Human	hsa-miR-21	miRNA	COX-2 inhibitor NS398	colorectal cancer (CRC)	HCA-7 cell	COX-2 inhibitor NS398 significantly decreased treatment	downregulated	25310697
6328	Human	hsa-miR-21	miRNA	metformin and 5-fluorouracil and oxaliplatin (FuOx)	colorectal cancer (CRC)	human colon cancer cells HT-29 and HCT-116	combinatorial treatment	upregulated	24465408
6329	Human	hsa-miR-21	miRNA	acute exercise	congestive heart failure (CHF)	CHF patients	acute exercise treatment	upregulated	26799589
6330	Human	hsa-miR-21	miRNA	AS1411	corneal neovascularization (CNV)	human limbus stroma (HLSC)	AS1411 treatment	AS1411 treatment also significantly reduced VEGF-stimulated induction of miR-21 and miR-221 in HLSC.	32081668
6331	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	coronary artery disease (CAD)	human endothelial cell from umbilical vein (HU-VECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28804550
6332	Human	hsa-miR-21	miRNA	thrombospondin-1 (TSP-1)	coronary heart disease (CHD)	Human aortic VSMCs	Thrombospondin-1 (TSP-1)?treatment treatment	?Acute inhibition of miR-21 led to a decrease in VSMC migration and proliferation caused by TSP-1	24314882
6333	Human	hsa-miR-21	miRNA	corticosteroid	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	corticosteroid treatment	CASC7 increased corticosteroid sensitivity by inhibiting the PI3K/AKT signaling pathway via targeting miR-21.	31412983
6334	Human	hsa-miR-21	miRNA	dexamethasone (DEX)	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	dexamethasone (DEX) treatment	Overexpression of CASC7 suppressed the PI3K/AKT signaling pathway and promoted the inhibition effects of dexamethasone on cell proliferation and cytokines secretion via targeting miR-21.	31412983
6335	Human	hsa-miR-21	miRNA	coxsackievirus B3 (CVB3)	coxsackievirus B3 (CVB3) infection disease	Hela cells	CVB3 infection	upregulated	31585536
6336	Human	hsa-miR-21	miRNA	matrine	sorafenib-induced cytotoxicity	HepG2 cells;Hep3B cells	exposure to matrine treatment	downregulated	25721136
6337	Human	hsa-miR-21	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	HepG2 (liver) cells	DENV infection	dysregulated	28365456
6338	Human	hsa-miR-21	miRNA	hyperglycemia	diabetes-induced retinal pathology	ARPE-19 cells	"hyperglycemic condition (high glucose, 33mM)"	upregulated	28465657
6339	Human	hsa-miR-21	miRNA	atrasentan	diabetic nephropathy (DN)	high glucose (HG)-induced podocytes	atractylon (Atr)?treatment	downregulated	30876973
6340	Human	hsa-miR-21	miRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	upregulated	30876973
6341	Human	hsa-miR-21	miRNA	tongxinluo (TXL)	diabetic nephropathy (DN)	human proximal tubular epithelial cell (HKCs) line	TXL treatment	downregulated	24370587
6342	Human	hsa-miR-21	miRNA	paclitaxel (PTX)	drug resistance	Human Gastric Adenocarcinoma Cell Line	paclitaxel treatment	expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901	27040946
6343	Human	hsa-miR-21	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	downregulated	30692507
6344	Human	hsa-miR-21	miRNA	acidic microenvironment	early-stage hepatocellular carcinoma (E-HCC)	The human HCC cell lines SMMC-7721 and Hep3B	acidic microenvironment treatment	upregulated	31037150
6345	Human	hsa-miR-21	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec2A cells	Progesterone treatment	upregulated	22543862
6346	Human	hsa-miR-21	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
6347	Human	hsa-miR-21	miRNA	high glucose (HG)	endothelial cytotoxicity	The blood samples from diabetes patients	high glucose treatment	upregulated	23771797
6348	Human	hsa-miR-21	miRNA	dihydromyricetin (DHM)	endothelial dysfunction	TNF-¦Á treated human umbilical vein endothelial cells (HUVECs)	dihydromyricetin (DMY) treatment	downregulated	29682517
6349	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29682517
6350	Human	hsa-miR-21	miRNA	propofol (PPF)	epithelial-mesenchymal transition (EMT)	MCF-7 cells	Propofol treatment	downregulated	30942630
6351	Human	hsa-miR-21	miRNA	Smilax glabra Roxb (PTFS)	epithelial-mesenchymal transition (EMT)	TGF-¦Â1-treated HK-2 cells	Smilax glabra Roxb (PTFS) treatment	downregulated	30304552
6352	Human	hsa-miR-21	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	High glucose (HG) upregulated miR-21 and induced EndMT in ECs	31680453
6353	Human	hsa-miR-21	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	Human umbilical vein endothelial cells (HUVECs)	TGF-¦Â treatment	upregulated	22095988
6354	Human	hsa-miR-21	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	HT-29 cells	TGF-¦Â treatment	upregulated	23483606
6355	Human	hsa-miR-21	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
6356	Human	hsa-miR-21	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human peritoneal mesothelial cells (HPMCs)	high glucose (HG) treatment	HG upregulated miRNA-21 expression and downregulated PTEN expression.	30210695
6357	Human	hsa-miR-21	miRNA	nicotine	esophageal cancer (EC)	human esophageal cells	nicotine treatment	upregulated	24756761
6358	Human	hsa-miR-21	miRNA	zinc deficiency	esophageal cancer (EC)	human ESCC and OSCC	zinc deficiency? treatment	upregulated	22689922
6359	Human	hsa-miR-21	miRNA	isoalantolactone	esophageal squamous cell carcinoma (ESCC)	ECA-109 cells; KYSE30 cells	Isoalantolactone treatment	downregulated	29781054
6360	Human	hsa-miR-21	miRNA	radiation	esophageal squamous cell carcinoma (ESCC)	TE-1 cells; esophageal squamous cell carcinoma (ESCC) tissues	radiation treatment	miR-21 expression is much lower in radiation sensitive ESCC tissues than radiation resistant tissues	31866421
6361	Human	hsa-miR-21	miRNA	radiation	esophageal squamous cell carcinoma (ESCC)	esophageal squamous cell carcinoma (ESCC) tumor tissues; ESCC TE-1 cells	radiation treatment	MiR-21 levels were increased in radiation-resistant compared with radiation-sensitive patients	32268810
6362	Human	hsa-miR-21	miRNA	X-rays	esophageal squamous cell carcinoma (ESCC)	ESCC tissues and TE-1 celss	2 Gy X-ray treatment	downregulated	31866421
6363	Human	hsa-miR-21	miRNA	curcumin (Cur)	fat	esophageal cancer cell lines	curcumin treatment	downregulated	22363450
6364	Human	hsa-miR-21	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
6365	Human	hsa-miR-21	miRNA	TGF-¦Â	fibrosis	Dermal fibroblasts	TGF-¦Â treatment	upregulated	31155965
6366	Human	hsa-miR-21	miRNA	matrine	follicular thyroid cancer	FTC-133 follicular thyroid cancer cells	Matrine treatment	downregulated	31579406
6367	Human	hsa-miR-21	miRNA	thrombospondin-1 (TSP-1)	fungal keratitis	exosomes of dendritic cells (DCs)	Thymic stromal lymphopoietin (TSLP) treatment	miR-21 was highly expressed in exosomes from TSLP-treated DCs	33253708
6368	Human	hsa-miR-21	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
6369	Human	hsa-miR-21	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	31572012
6370	Human	hsa-miR-21	miRNA	celastrol	gastric cancer (GC)	human gastric cancer cell line MKN45	celastrol treatment	downregulated	30989726
6371	Human	hsa-miR-21	miRNA	celastrol	gastric cancer (GC)	"human gastric adenocarcinoma cell line BGC-823, gastric mucinous adenocarcinoma cell line MGC-803"	celastrol treatment	upregulated	24434352
6372	Human	hsa-miR-21	miRNA	chidamide	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	chidamide treatment	downregulated	31572012
6373	Human	hsa-miR-21	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells	cisplatin treatment	DDP-resistant GC cells expressed higher levels of miR-21 compared with the parent cells.	31913198
6374	Human	hsa-miR-21	miRNA	curcumin (Cur)	gastric cancer (GC)	MGC-803 cell line	curcumin treatment	downregulated	30727807
6375	Human	hsa-miR-21	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN-45 cells	docetaxel (DTX) treatment	upregulated	33416185
6376	Human	hsa-miR-21	miRNA	H2O2	gastric cancer (GC)	HGC-27 cells	H2O2 treatment	upregulated	33329376
6377	Human	hsa-miR-21	miRNA	nicotine	gastric cancer (GC)	Human gastric adenocarcinoma cells (AGS)	Nicotine treatment	"EP2 or EP4 siRNA or antagonists impaired the nicotine-mediated NF-kB activity, upregulation of miR-16 and miR-21 and cell proliferation."	21081469
6378	Human	hsa-miR-21	miRNA	S-1/oxaliplatin	gastric cancer (GC)	gastric tumor specimens	?S-1/Oxaliplatin?(intravenous injection) treatment	miR-181b and miR-21 was significantly overexpressed in gastric tumors	21876743
6379	Human	hsa-miR-21	miRNA	myricetin-loaded mixed micelles (MYR-MCs)	glioblastoma multiforme (GBM)	human glioblastoma cells	myricetin-loaded mixed micelles (MYR-MCs) treatment	downregulated	27757032
6380	Human	hsa-miR-21	miRNA	temozolomide and irradiation	glioblastoma multiforme (GBM)	primary glioblastoma cells; U87MG cells; U251MG cells; U118MG cells	temozolomide and irradiation treatment	upregulated	33082482
6381	Human	hsa-miR-21	miRNA	type I interferon (IFN)	glioblastoma multiforme (GBM)	T98 cells; SKMG1 cells; U251MG cells; U87MG cells	Type I IFNs treatment	The Modulation of MicroRNAs by Type I IFN through the Activation of Signal Transducers and Activators of Transcription 3 in Human Glioma	19934272
6382	Human	hsa-miR-21	miRNA	Cl-amidine	glioblastoma multiforme (GBM)	LN18 and LN229 cells	Cl-amidine treatment	downregulated	30597867
6383	Human	hsa-miR-21	miRNA	metformin (Met)	glioblastoma multiforme (GBM)	U87 cells	metformin(Met) treatment	downregulated	33059952
6384	Human	hsa-miR-21	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma-derived exosomes (GDEs)	hypoxia treatment	The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN).	29713056
6385	Human	hsa-miR-21	miRNA	si wei xiao xiu yin	glioblastoma multiforme (GBM)	U87 cells	Si wei xiao xiu yin treatment	downregulated	32448616
6386	Human	hsa-miR-21	miRNA	TGF-¦Â	granular corneal dystrophy type 2 (GCD2)	Primary corneal fibroblasts	TGF-¦Âtreatment treatment	upregulated	26915797
6387	Human	hsa-miR-21	miRNA	sophocarpine (SC)	head and neck squamous cell carcinoma (HNSCC)	UM-SCC-22B and UM-SCC-47 cells	SC treatment	downregulated	28571917
6388	Human	hsa-miR-21	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	downregulated	27874954
6389	Human	hsa-miR-21	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells £¬ HepG2.2.15 cells.	hepatitis B virus X protein (HBx) treatment	downregulated	25260533
6390	Human	hsa-miR-21	miRNA	mineral pitch (MP)	hepatocellular carcinoma (HCC)	Huh-7 cells	Mineral Pitch (MP) treatment	downregulated	27233240
6391	Human	hsa-miR-21	miRNA	TGF-¦Â1	liver fibrosis	QSG-7701 cells	TGF-¦Â1 treatment	upregulated	25661333
6392	Human	hsa-miR-21	miRNA	"3,3'-diindolylmethane (DIM)"	liver fibrosis	HSC-T6 cell line and primary hepatic stellate cells (HSCs)	"3,3'-Diindolylmethane (DIM) treatment"	downregulated	23902531
6393	Human	hsa-miR-21	miRNA	compound astragalus and salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	TGF-¦Â1-stimulated HepG2 cells	Compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	downregulated	30412748
6394	Human	hsa-miR-21	miRNA	compound Astragalus and Salvia miltiorrhiza extract (CASE)	hepatocellular carcinoma (HCC)	HepG2 cells	compound Astragalus and Salvia miltiorrhiza extract (CASE) treatment	CASE downregulated miR-21 expression in TGF-¦Â 1-stimulated HepG2 cells.	30412748
6395	Human	hsa-mir-21	miRNA	dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S)	hepatocellular carcinoma (HCC)	HepG2 human hepatoma cells	10nM DHEA and DHEA-S treatment	upregulated	24845419
6396	Human	hsa-miR-21	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
6397	Human	hsa-miR-21	miRNA	indole-3-carbinol (I3C)	hepatocellular carcinoma (HCC)	"human HCC cell lines, SK-Hep-1 and SNU-449"	I3C treatment	downregulated	25447674
6398	Human	hsa-miR-21	miRNA	kaempferol	hepatocellular carcinoma (HCC)	HepG2 cells	kaempferol treatment	downregulated	30477356
6399	Human	hsa-miR-21	miRNA	mycobacterium leprae	hepatocellular carcinoma (HCC)	monocytes	Mycobacterium leprae treatment	"The most dysregulated miRNA in L-lep lesions, hsa-mir-21, was upregulated in Mycobacterium leprae-infected monocytes"	22286305
6400	Human	hsa-miR-21	miRNA	notoginsenoside R1 (NGR1)	hepatocellular carcinoma (HCC)	"human HCC cell lines MHCC97H, BEL7402, Huh7, HepG2, PLC/PRF/5 (PLC), and SMMC7721"	Notoginsenoside R1 (NG-R1) treatment	downregulated	31559550
6401	Human	hsa-miR-21	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
6402	Human	hsa-miR-21	miRNA	polysaccharides (PRP1£©	hepatocellular carcinoma (HCC)	HepG2 cells	polysaccharides (PRP1£©treatment	downregulated	32380108
6403	Human	hsa-miR-21	miRNA	pSG5-HBx plasmid	hepatocellular carcinoma (HCC)	Huh 7 and Hep G2 cells	transfect treatment	upregulated	24633222
6404	Human	hsa-miR-21	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Human HCC HepG2 and Huh7 cells, and SR-HCC cells"	sorafenib treatment	"Sorafenib induced translocation of miR-21 to the nucleus, where it promoted the expression of SNHG1"	31053148
6405	Human	hsa-miR-21	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
6406	Human	hsa-miR-21	miRNA	visfatin	hepatocellular carcinoma (HCC)	HepG2 cells	visfatin treatment	upregulated	29808800
6407	Human	hsa-miR-21	miRNA	Shenqi pollen capsules (SPCs)	high-altitude deacclimatization syndrome (HADAS)	serum	Shenqi pollen capsules (SPCs) treatment	upregulated	31828172
6408	Human	hsa-miR-21	miRNA	NPV-LDE-225 (Erismodegib)	human immunodeficiency virus (HIV)-1 infection	Glioblastoma initiating cells (GICs)	NPV-LDE-225 (Erismodegib) treatment	downregulated	23482671
6409	Human	hsa-miR-21	miRNA	epigallocatechin-3-gallate (EGCG)	hormone refractory prostate cancer (HRPC)	LNCaP and 22R¦Í cells	Green tea polyphenol EGCG treatment	downregulated	21177307
6410	Human	hsa-miR-21	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
6411	Human	hsa-miR-21	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
6412	Human	hsa-miR-21	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
6413	Human	hsa-miR-21	miRNA	platelet derived growth factor-BB (PDGF-BB)	hypertension	vascular smooth muscle cells (VSMCs)	PDGF©\bb treatment	"?GAS5 inhibits PDGF-bb-induced VSMC proliferation and migration, partly through acting as a competing endogenous RNA of miR-21"	31069831
6414	Human	hsa-miR-21	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	upregulated	26500110
6415	Human	hsa-miR-21	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	upregulated	29516639
6416	Human	hsa-miR-21	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	downregulated	29516639
6417	Human	hsa-miR-21	miRNA	intermittent hypoxia (IH)	hypoxemia	blood	intermittent (HI) hypoxia treatment	miR-21 was upregulated in intermittent (HI) hypoxia treatment group.	30416683
6418	Human	hsa-miR-21	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary artery smooth muscle cells	hypoxia treatment	miR-21 expression was upregulated in hypoxia cell models.	29198701
6419	Human	hsa-miR-21	miRNA	hypoxia	hypoxic brain injury	human neural stem cells (hNSCs)	oxygen and glucose deprivation (OGD) treatment	upregulated	30291880
6420	Human	hsa-miR-21	miRNA	imatinib	imatinib resistance	human acute lymphoblastic leukemia cell line Sup-b15	imatinib treatment	upregulated	25451263
6421	Human	hsa-miR-21	miRNA	Ig-like transcript 3 (ILT3)	immune inflammatory	human CD8(+) T suppressor cells	Ig-like transcript 3 (ILT3) treatment	upregulated	22387553
6422	Human	hsa-miR-21	miRNA	medroxyprogesterone acetate (MPA)	impaired decidualization	human endometrial stromal cell (hESC)	medroxyprogesterone acetate (MPA) treatment	downregulated	30772912
6423	Human	hsa-miR-21	miRNA	collagen IV and vascular endothelial growth factor (VEGF)	cell differentiation	pluripotent stem cells (iPSC)	collagen IV and VEGF treatment	upregulated	24356956
6424	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	infantile pneumonia (IP)	MRC5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	NKILA weakens TNF-¦Á-induced inflammation of MRC-5 cells by miR-21 upregulated	32013579
6425	Human	hsa-miR-21	miRNA	progesterone (P4)	infertility	"human endometrial carcinoma cell line, SNU-1077"	progesterone treatment	dysregulated	30603515
6426	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	inflammation	Airway normal and cancer epithelial cells (16HBE and A549)	cigarette smoke extracts (CSE) exposure	upregulated	31054160
6427	Human	hsa-miR-21	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
6428	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
6429	Human	hsa-miR-21	miRNA	molecular hydrogen	inflammatory injury	Retinal Microglia cells	Molecular hydrogen?treatment	downregulated	23826519
6430	Human	hsa-miR-21	miRNA	propofol (PPF)	inflammatory response	human umbilical vein endothelial cells (HUVECs)	propofol treatment	upregulated	29039542
6431	Human	hsa-miR-21	miRNA	retinoic acid (RA)	inflammatory response	"breast carcinoma cells,MCF-7 Cells"	retinoic acid? treatment	upregulated	21131358
6432	Human	hsa-miR-21	miRNA	extract of Celastrus orbiculatus (COE)	inflammatory response	H. pylori-infected GES-1 cells	The extract of Celastrus orbiculatus (COE) treatment	downregulated	31035975
6433	Human	hsa-miR-21	miRNA	helicobacter pylori (H. pylori)	inflammatory response	GES-1 cells	Helicobacter pylori (H. pylori) infection	upregulated	31035975
6434	Human	hsa-miR-21	miRNA	gemcitabine (GEM)	insulin resistance accompanies obesity	?serum	gemcitabine treatment	downregulated	23177026
6435	Human	hsa-miR-21	miRNA	galla chinensis ointment	keloids	human keloid-derived fibroblasts	Galla chinensis ointment treatment	Galla chinensis inhibited the expression of miR-21.	32216491
6436	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	kidney damage	HK-2 cell	lipopolysaccharide (LPS) treatment	upregulated	28821165
6437	Human	hsa-miR-21	miRNA	calcium oxalate monohydrate (COM)	kidney stone disease	HK-2 cells	calcium oxalate monohydrate (COM) treatment	MiR-21 promotes calcium oxalate-induced renal tubular cell injury by targeting PPARA.	32628541
6438	Human	hsa-miR-21	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
6439	Human	hsa-miR-21	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
6440	Human	hsa-miR-21	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
6441	Human	hsa-miR-21	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
6442	Human	hsa-miR-21	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
6443	Human	hsa-miR-21	miRNA	leukemia microvesicles	leukemia	healthy hematopoietic stem cells	leukemia microvesicles transformation	upregulated	28218044
6444	Human	hsa-miR-21	miRNA	leukemia microvesicles	leukemia	hematopoietic stem progenitor cells (HSPCs)	leukemia microvesicles treatment	upregulated	31429853
6445	Human	hsa-miR-21	miRNA	decabromodiphenyl ether (BDE-209)	lipid accumulation	THP-1 macrophages	decabromodiphenyl ether (BDE-209) treatment	downregulated	30597220
6446	Human	hsa-miR-21	miRNA	decabromodiphenyl ether (BDE-209)	lipid uptake	THP-1 cells	decabromodiphenyl ether (BDE-209) treatment	"miR-21 were significantly suppressed by BDE-209?at concentrations of 6.25, 12.5 and 25?¦ÌM."	30597220
6447	Human	hsa-miR-21	miRNA	berberine (BBR)	inflammation	human dental pulp fibroblast	berberine (BBR) treatment	downregulated	31837588
6448	Human	hsa-miR-21	miRNA	antrodia cinnamomea	hepatocellular carcinoma (HCC)	SK-Hep-1 liver cancer cell	antrodia cinnamomea treatment	"oncomirs miR-21,miR-191 and major oncogenic clusters miR-17-92 and miR-106b-25 among the most severely downregulated"	24358224
6449	Human	hsa-miR-21	miRNA	coptidis rhizoma aqueous extract	hepatocellular carcinoma (HCC)	human hcc mhcc97-l cells	Coptidis rhizoma aqueous extract treatment	upregulated	22977465
6450	Human	hsa-miR-21	miRNA	microcystin-leucine arginine (MC-LR)	hepatocellular carcinoma (HCC)	WRL-68 cells	microcystin-LR treatment	upregulated	22265967
6451	Human	hsa-miR-21	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	downregulated	24431000
6452	Human	hsa-miR-21	miRNA	trichloroethylene (TCE)	liver damage	human HL-7702 cells	Trichloroethylene (TCE) treatment	downregulated	31140026
6453	Human	hsa-miR-21	miRNA	angiotensin-(1-7)	liver fibrosis	HEK-293 cells	angiotensin-(1-7) treatment	downregulated	27502441
6454	Human	hsa-miR-21	miRNA	corilagin	liver fibrosis	hepatic stellate LX2 cell line	Corilagin treatment	downregulated	31752524
6455	Human	hsa-miR-21	miRNA	5-fluorouracil (5-Fu)	lung cancer	A549 cells	5-fluorouracil (5-FU) treatment	"Our findings demonstrated that the overexpression of miR-21 decreased 5-fluorouracil-induced apoptosis and necrosis, and the opposite effects were obtained by the suppression of miR-21."	31934061
6456	Human	hsa-miR-21	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	29501572
6457	Human	hsa-miR-21	miRNA	cisplatin (DDP)	lung cancer	A549 cells	cisplatin treatment	upregulated	30644017
6458	Human	hsa-miR-21	miRNA	clopidogrel	lung cancer	NCI cells; FaDu cells	clopidogrel treatment	upregulated	32326378
6459	Human	hsa-miR-21	miRNA	curcumin (Cur)	lung cancer	Human lung adenocarcinoma A549 cells	curcumin treatment	downregulated	24293118
6460	Human	hsa-miR-21	miRNA	curcumin (Cur)	lung cancer	A549 cells	curcumin treatment	upregulated	24293118
6461	Human	hsa-miR-21	miRNA	lidocaine	lung cancer	A549/DDP cells	Lidocaine (Lido) treatment	downregulated	30644017
6462	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	lung cancer	primary human lung cancer cells	lipopolysaccharide (LPS) treatment	upregulated	27286259
6463	Human	hsa-miR-21	miRNA	Sinomenine (SIN)	lung cancer	A549 cells; H1299 cells	Sinomenine treatment	Sinomenine downregulates oncogenic microRNA-21 (miR-21)	32349289
6464	Human	hsa-miR-21	miRNA	Skullcapflavone I (SF I)	lung cancer	A549 and H1975 cells	Skullcapflavone I treatment	downregulated	31301304
6465	Human	hsa-miR-21	miRNA	solasonine (SS)	lung cancer	human lung cancer cell A5492	solasodine treatment	downregulated	28283413
6466	Human	hsa-miR-21	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
6467	Human	hsa-miR-21	miRNA	¦Â-adrenergic agonist and Epac activator	malignant astrocytic gliomas	human glioblasoma cell line U87MG and human astrocytoma cell line 1321N1	¦Â-adrenergic agonist and Epac activator treatment	downregulated	27504157
6468	Human	hsa-miR-21	miRNA	prolactin (PRL)	mammary development	HC11 mammary cells	levels increased in upon prolactin treatment	upregulated	24497923
6469	Human	hsa-miR-21	miRNA	Penetratin-tagged STAT3-NTD inhibitor (S3-NTDi)	medulloblastoma	"MB cell lines DAOY (SHH-TP53-mutated) and D341 (Group 3, Non-WNT/SHH), HD-MB03 cells (Group 3, Non-WNT/SHH, MYC amplified)"	Penetratin-tagged STAT3-NTD inhibitor (S3-NTDi) treatment	downregulated	29280516
6470	Human	hsa-miR-21	miRNA	Akt inhibitor and the EGFR inhibitor (Gefitinib)	melanogenesis	A375.S2 cells	gefitinib	downregulated	28398611
6471	Human	hsa-miR-21	miRNA	ultraviolet (UV) irradiation	melanogenesis	A375.S2 cells	UV treatment	upregulated	28398611
6472	Human	hsa-miR-21	miRNA	arsenite	melanoma	human keratinocyte HaCaT cell line	arsenic (As) exposure	upregulated	27054085
6473	Human	hsa-miR-21	miRNA	cantharidin (CTD)	melanoma	A375 cells	cantharidin (CTD) treatment	CTD treatment reduced microRNA (miR)-21 expression.	30221692
6474	Human	hsa-miR-21	miRNA	cordycepin	migration of renal cell carcinoma	Caki-1 cells	cordycepin	downregulated	29070781
6475	Human	hsa-miR-21	miRNA	ibrutinib	multiple myeloma (MM)	"Human MM cell lines, LP-1, U266, MM.1S, and MM.1R, Primary patient MM (ppMM) cells"	ibrutinib treatment	downregulated	29320977
6476	Human	hsa-miR-21	miRNA	berberine (BBR)	multiple myeloma (MM)	human multiple myeloma cells	berberine (BBR) treatment	downregulated	23247593
6477	Human	hsa-miR-21	miRNA	berberine (BBR)	multiple myeloma (MM)	multiple myeloma cells	berberine (BBR) treatment	upregulated	25000828
6478	Human	hsa-miR-21	miRNA	hypoxia	multiple myeloma (MM)	U266 cells	hypoxia treatment	upregulated	29158801
6479	Human	hsa-miR-21	miRNA	fumaric acid esters	multiple sclerosis (MS)	T helper-17 cells	fumaric acid esters treatment	downregulated	30698680
6480	Human	hsa-miR-21	miRNA	TGF-¦Â	myelodysplastic syndrome (MDS)	MDS marrow samples	?TGF-¦Â treatment	upregulated	23390194
6481	Human	hsa-miR-21	miRNA	arsenic trioxide (ATO)	myeloid leukemia	HL60 cells;K562 cells	arsenic trioxide (ATO) treatment	"pre-miR-21 expression increased resistance to ATO, nevertheless not affecting cell growth alone. miRNA-21 by targeting PDCD4 may play a functional role in modulating ATO-induced cell death."	20143188
6482	Human	hsa-miR-21	miRNA	hypoxia	myocardial ischaemic injury	H9c2 cells;HL-1 cells;HCM cells	cells under hypoxic conditions (2% O2 or CoCl2) treatment	upregulated	24983504
6483	Human	hsa-miR-21	miRNA	graphene oxide (GO)	nanoparticles toxicity	MCF-7 cells	graphene oxide (GO) treatment	upregulated	32070776
6484	Human	hsa-miR-21	miRNA	graphene oxide (GO)	nanoparticles toxicity	KMBC/71 cells	graphene oxide (GO) treatment	downregulated	32070776
6485	Human	hsa-miR-21	miRNA	graphene oxide (GO)	nanoparticles toxicity	human umbilical vein endothelial cells (HUVECs)	graphene oxide (GO) treatment	upregulated	32070776
6486	Human	hsa-miR-21	miRNA	graphene quantum dots (GQDs)	nanoparticles toxicity	MCF-7 cells	graphene quantum dots (GQDs) treatment	downregulated	32070776
6487	Human	hsa-miR-21	miRNA	graphene quantum dots (GQDs)	nanoparticles toxicity	KMBC/71 cells	graphene quantum dots (GQDs) treatment	downregulated	32070776
6488	Human	hsa-miR-21	miRNA	latent membrane protein 1 (LMP1)	nasopharyngeal carcinoma (NPC)	cancer stem cells (CSCs) in NPC	latent membrane protein 1 (LMP1) treatment	upregulated	26568302
6489	Human	hsa-miR-21	miRNA	cyclosporine A (CsA)	nephrotoxicity	HEK293	cyclosporine A treatment	upregulated	28414804
6490	Human	hsa-miR-21	miRNA	cyclosporine A (CsA)	nephrotoxicity	human proximal tubular epithelial cells (HPTECs)	exposure to cyclosporine A (CsA) treatment	upregulated	25266172
6491	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	bladder cancer	"bladder cancer cells,T24 cells"	doxorubicin treatment	upregulated	21468550
6492	Human	hsa-miR-21	miRNA	lycopene	nonalcoholic fatty liver disease (NAFLD)	Hepa 1¨C6 cells	Lycopene treatment	downregulated	22968990
6493	Human	hsa-miR-21	miRNA	epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)	non-small cell lung cancer (NSCLC)	NSCLC patients	EGFR-TKI treatment	upregulated	24331411
6494	Human	hsa-miR-21	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	NCI-H460 cells; A549 cells	ionizing radiation (IR) treatment	IR enhanced the interaction between lncRNA GAS5 and the miR-21/PTEN/Akt axis.	32020207
6495	Human	hsa-miR-21	miRNA	osimertinib	non-small cell lung cancer (NSCLC)	H1975 cells	osimertinib treatment	The relative expression levels of miR-21 was significantly upregulated after treated with 100 nM osimertinib for 24 h.	32375124
6496	Human	hsa-miR-21	miRNA	propofol (PPF)	non-small cell lung cancer (NSCLC)	A549 cells	Propofol treatment	Propofol inhibited miR-21 expression	32925348
6497	Human	hsa-miR-21	miRNA	triptolide (TPL)	non-small cell lung cancer (NSCLC)	The human lung cancer cell line PC-9	triptolide (TPL) treatment	upregulated	26847601
6498	Human	hsa-miR-21	miRNA	oxidized low density lipoprotein (ox-LDL)	breast cancer	human mammary epithelial cells (MCF10A)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	23091604
6499	Human	hsa-miR-21	miRNA	"TNF-¦Á, IL-6, leptin, resistin , free fatty acids (FFAs)"	obesity and obesity-associated insulin resistance	human mature adipocytes	"TNF-¦Á, IL-6, leptin, resistin , FFAs treatment"	upregulated	28627656
6500	Human	hsa-miR-21	miRNA	thyroid hormone	opioid tolerance	hepatoma cells	Thyroid hormone (T(3))? treatment	over expression	23442323
6501	Human	hsa-miR-21	miRNA	opisthorchis viverrini	opisthorchis viverrini infection	human urine	infect with Opisthorchis viverrini	upregulated in the urine	26456596
6502	Human	hsa-miR-21	miRNA	curcumin (Cur)	oral cancer	oral cancer stem cells of UD-SCC2 (HPV+ve) and UPCI:SCC131 and UPCI: SCC 84(HPV¨Cve) cell lines	curcumin treatment	downregulated	30319975
6503	Human	hsa-miR-21	miRNA	hypoxia	oral squamous cell carcinoma (OSCC)	oral squamous cell carcinoma (OSCC) cells	hypoxia treatment	upregulated	26992424
6504	Human	hsa-miR-21	miRNA	porphyromonas gingivalis	oral squamous cell carcinoma (OSCC)	OSCC Tca8113 cells	Porphyromonas gingivalis infection treatment	upregulated	31243990
6505	Human	hsa-miR-21	miRNA	arecoline	oral submucous fibrosis (OSF)	buccal mucosal fibroblasts (BMFs)	arecoline treatment	MiR-21 expression was induced in BMFs by arecoline treatment in a dose-dependent manner.	33191095
6506	Human	hsa-miR-21	miRNA	hypoxia	orthodontic tooth movement	Periodontal ligament cells (PDLCs)	hypoxia induce	upregulated	30930976
6507	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	orthopedic diseases	osteoblastic hFOB1.19 cells	lipopolysaccharide (LPS) treatment	downregulated	26516113
6508	Human	hsa-miR-21	miRNA	mechanical stretch	osteogenesis	human periodontal ligament stem cells (PDLSCs)	exposed to mechanical stretch treatment	upregulated	25203845
6509	Human	hsa-miR-21	miRNA	honokiol	osteosarcoma (OS)	Saos-2 cells; Mg-63 cells	honokiol (HNK) treatment	"HNK was able to induce aberrant expression of miRNAs in human OS cells, and miR-21 was one of the miRNAs that was most significantly downregulated."	29393336
6510	Human	hsa-miR-21	miRNA	Piceatannol (Pice)	osteosarcoma (OS)	MG-63; Saos-2 cells	Piceatannol (Pice) treatment	downregulated	32901863
6511	Human	hsa-miR-21	miRNA	celastrol	ovarian cancer (OC)	human ovarian carcinoma cells	celastrol treatment	downregulated	27840916
6512	Human	hsa-miR-21	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
6513	Human	hsa-miR-21	miRNA	TGF-¦Â1	ovarian cancer (OC)	human fibroblasts	TGF-¦Â1 treatment	"In primary cultured fibroblasts, mature miR-21 increases after TGF-¦Â1 treatment"	23784029
6514	Human	hsa-miR-21	miRNA	caudatin	oxidative stress	human gastric carcinoma cell lines	caudatin? treatment	downregulated	23708208
6515	Human	hsa-miR-21	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	oxidative stress	human lung carcinoma cell line (A549)	NPs treatment	downregulated	28400205
6516	Human	hsa-miR-21	miRNA	hypoxia	pancreatic cancer (PC)	human pancreatic cancer (PC) cells	Hypoxia treatment	upregulated	23272057
6517	Human	hsa-miR-21	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
6518	Human	hsa-miR-21	miRNA	propofol (PPF)	pancreatic cancer (PC)	PANC-1 pancreatic cancer cells	Propofol treatment	downregulated	27829997
6519	Human	hsa-miR-21	miRNA	epidermal growth factor (EGF)	pancreatic ductal adenocarcinoma (PDAC)	PANC-1 cells	epidermal growth factor (EGF) treatment	upregulated	30464258
6520	Human	hsa-miR-21	miRNA	H2O2	pancreatic ductal adenocarcinoma (PDAC)	primary human pancreatic stellate cells (PSCs)	?H2O2 treatment	upregulated	29854071
6521	Human	hsa-miR-21	miRNA	N-acetyl-L-cysteine (NAC)	pancreatic ductal adenocarcinoma (PDAC)	?H2O2-treated primary human pancreatic stellate cells (PSCs)	N-acetyl-L-cysteine (NAC) treatment	downregulated	29854071
6522	Human	hsa-miR-21	miRNA	resveratrol	pancreatic ductal adenocarcinoma (PDAC)	?H2O2-treated primary human pancreatic stellate cells (PSCs)	resveratrol (Res) treatment	downregulated	29854071
6523	Human	hsa-miR-21	miRNA	matrine	papillary thyroid cancer (PTC)	TPC-1 cells	matrine treatment	downregulated	30127885
6524	Human	hsa-miR-21	miRNA	docosahexaenoic acid (DHA)	parkinson's disease (PD)	SH-Y5Y cells	docosahexaenoic acid (DHA) treatment	downregulated	28346830
6525	Human	hsa-miR-21	miRNA	high glucose (HG)	peritoneal fibrosis	human peritoneal mesothelial cell lines HMrSV5 cells	high glucose (HG) treatment	upregulated	29207016
6526	Human	hsa-miR-21	miRNA	glucocorticoid (GC)	polymyositis (PM)	PM patients	glucocorticoids	upregulated	26873848
6527	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	postoperative peritoneal adhesion (PPA)	The human peritoneal mesothelium cells (HPMCs)	lipopolysaccharide (LPS) treatment	the effect of Cox-2 on LPS induced HPMCs injury was achieved by negatively regulation of miR-21 and targeted TLR4 through NF-¦ÊB pathway axis.	31885500
6528	Human	hsa-miR-21	miRNA	vitamin D	preeclampsia (PE)	HTR-8/SVneo cells	Vitamin D treatment	downregulated	31068287
6529	Human	hsa-miR-21	miRNA	emodin	pressure ulcer (PU)	HaCaT cells	Emodin treatment	upregulated	31250665
6530	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	pressure ulcer (PU)	HaCaT cells	lipopolysaccharide (LPS) treatment	downregulated	31250665
6531	Human	hsa-miR-21	miRNA	"4', 5, 7-trihydroxy-3', 5'-dimethoxyflavone (Tricin)"	prostate cancer	PC3 cell line	"4', 5, 7-Trihydroxy-3', 5'-dimethoxyflavone (Tricin) treatment"	downregulated	29447469
6532	Human	hsa-miR-21	miRNA	docetaxel (DTX)	prostate cancer	"The human androgen-insensitive prostate carcinoma cell line, PC3"	docetaxel (DTX) treatment	upregulated	20581857
6533	Human	hsa-miR-21	miRNA	hyperoside and quercetin in combination (QH; 1:1)	prostate cancer	human prostate cancer cells	QH treatment	downregulated	25354548
6534	Human	hsa-miR-21	miRNA	methylated urolithin A	prostate cancer	human prostate cancer cells	Methylated urolithin A treatment	downregulated	27725205
6535	Human	hsa-miR-21	miRNA	TGF-¦Â	prostate cancer	HASCs	TGF-¦Â treatment	upregulated	19816956
6536	Human	hsa-miR-21	miRNA	¦Á-solanine	prostate cancer	human prostate cancer cell PC-3	¦Á-solanine treatment	downregulated	25116803
6537	Human	hsa-miR-21	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in plasma	27535005
6538	Human	hsa-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	HaCaT and NHEKs cell lines	tumor necrosis factor alpha (TNF-¦Á) treatment	"MEG3/miR-21 axis may regulate the expression of caspase-8, and further influence the proliferation and apoptosis of psoriasis keratinocyte, Act-HaCaT and Act- HHEK"	31660855
6539	Human	hsa-miR-21	miRNA	SB431542	lung fibrosis	IMR-90 cells	SB431542 treatment	"miR-21 expression was promoted by single TGF¦Â1 treatment, whereas reduced by SB431542"	30213983
6540	Human	hsa-miR-21	miRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary artery smooth muscle cell	hypoxia treatment	upregulated	29198701
6541	Human	hsa-miR-21	miRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary microvascular endothelial cells (HPECs)	hypoxia treatment	miR-21 was upregulated in the hypoxia-treated HPECs and its conditioned media in a time-dependent manner.	30449992
6542	Human	hsa-miR-21	miRNA	berberine (BBR)	pulpitis	LPS treated human dental pulp fibroblast (HDPF)	berberine (BBR) treatment	upregulated	31837588
6543	Human	hsa-miR-21	miRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp fibroblast (HDPF)	lipopolysaccharide (LPS) treatment	downregulated	31837588
6544	Human	hsa-miR-21	miRNA	gemcitabine (GEM)	renal cell carcinoma (RCC)	Panc-1 cells	gemcitabine treatment	downregulated	23564788
6545	Human	hsa-miR-21	miRNA	eupatilin	renal cell carcinoma (RCC)	786-O cells	Eupatilin treatment	downregulated	31179326
6546	Human	hsa-miR-21	miRNA	insulin-like growth factor 1 (IGF-1)	renal cell carcinoma (RCC)	human renal cell carcinoma cell	IGF-I treatment	upregulated	28453463
6547	Human	hsa-miR-21	miRNA	metformin (Met)	renal cell carcinoma (RCC)	CAKI-1 and CAKI-2 cells	Metformin (MET) treatment	downregulated	26496641
6548	Human	hsa-miR-21	miRNA	sorafenib (SOR)	renal cell carcinoma (RCC)	"Human RCC cell lines, OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P"	sorafenib treatment	GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis	29895198
6549	Human	hsa-miR-21	miRNA	angiotensin II (Ang II)	renal fibrosis	HK-2 cells	angiotensin II (Ang II) treatment	upregulated	31611175
6550	Human	hsa-miR-21	miRNA	bone morphogenetic protein 4 (BMP4)	renal fibrosis	vascular smooth muscle cell (vSMC)	?bone morphogenetic protein 4 (BMP4)? treatment	upregulated	22158624
6551	Human	hsa-miR-21	miRNA	high glucose (HG)	renal interstitial fibrosis (RIF)	human kidney-2 (HK-2) cells	high glucose (HG) treatment	upregulated	31389582
6552	Human	hsa-miR-21	miRNA	pure total flavonoids from Smilax glabra Roxb (PTFS)	renal interstitial fibrosis (RIF)	HK-2 cells	pure total flavonoids from Smilax glabra Roxb (PTFS) treatment	PTFS treatment inhibited TGF-¦Â1-induced EMT progress by blocking miR-21/PTEN/PI3K/Akt signaling	30304552
6553	Human	hsa-miR-21	miRNA	Smilax glabra Roxb (PTFS)	renal interstitial fibrosis (RIF)	TGF-¦Â1-treated HK-2 cells	Smilax glabra Roxb (PTFS) treatment	downregulated	30304552
6554	Human	hsa-miR-21	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK-2 cell	hypoxia/reoxygenation	upregulated	27030384
6555	Human	hsa-miR-21	miRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	human umbilical vein endothelial cells	hypoxia (1% O2 for 24 hours)	upregulated	28737660
6556	Human	hsa-miR-21	miRNA	aspirin	residual platelet reactivity	DAMI cell	aspirin treatment	Aspirin induces the modulation of platelet miR-21 expression levels.	30046765
6557	Human	hsa-miR-21	miRNA	doxorubicin (DOX)	glioblastomas (GBMs)	"GBM cell lines A172, U87MG"	DOX treatment	downregulated	25628933
6558	Human	hsa-miR-21	miRNA	IL-34	rheumatoid arthritis (RA)	fibroblast-like synovial cells (FLS) of RA and OA patients	IL-34 treatment	upregulated	27084907
6559	Human	hsa-miR-21	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
6560	Human	hsa-miR-21	miRNA	mitomycin C (MMC)	scar adhesion after joint surgery	primary fibroblasts	mitomycin C (MMC) treatment	MMC induced apoptosis of fibroblasts and decreased the expression of miR-21.	31669961
6561	Human	hsa-miR-21	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
6562	Human	hsa-miR-21	miRNA	cardio-pulmonary bypass (CPB)	severe lung injury	lung	cardiopulmonary bypass (CPB) treatment	upregulated	25347932
6563	Human	hsa-miR-21	miRNA	hepatitis C virus (HCV)	short bowel syndrome (SBS)	human liver	hepatitis C virus (HCV) infection	downregulated	20625373
6564	Human	hsa-miR-21	miRNA	arsenite	skin cancer	HaCaT	arsenic (As) exposure	upregulated	28069514
6565	Human	hsa-miR-21	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	downregulated	30182520
6566	Human	hsa-miR-21	miRNA	ultraviolet (UV) irradiation	skin pigmentation disorders	melanocytes exosome	ultraviolet (UV) irradiation treatment	upregulated	31909885
6567	Human	hsa-miR-21	miRNA	TGF-¦Â1	skin wound healing	HaCaT cells	TGF-¦Â1 treatment	upregulated	27735045
6568	Human	hsa-miR-21	miRNA	rapamycin	squamous cell carcinoma (SCC)	HUVECs	Rapamycin treatment	Rapamycin treatment increased the expression of miR-21 in HUVECs	23313253
6569	Human	hsa-miR-21	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
6570	Human	hsa-miR-21	miRNA	rapamycin	subependymal giant cell astrocytoma (SEGA)	primary cultures of SEGA-derived cells	rapamycin (mTOR) treatment	upregulated	30509037
6571	Human	hsa-miR-21	miRNA	hydroxychloroquine	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	hydroxychloroquine treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs."	24121037
6572	Human	hsa-miR-21	miRNA	prednisone	systemic lupus erythematosus (SLE)	"mesangial cells, T cells, pDCs, PBMCs, and the urine"	prednisone treatment	"lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs"	24121037
6573	Human	hsa-miR-21	miRNA	IL-1¦Â	systemic sclerosis (SSc)	fibroblasts	IL-1¦Â treatment	"Performing microRNA (miRNA) inhibition experiments in the presence of TGF-¦Â1, we showed that the pro-fibrotic effect of IL-1¦Â may be mediated by a miRNA-21/TGF-¦Â receptor II axis"	33662666
6574	Human	hsa-miR-21	miRNA	TGF-¦Â	testicular lesion	human renal glomerular mesangial cells	TGF¦Â treatment	upregulated	22879939
6575	Human	hsa-miR-21	miRNA	baicalin (BAI)	cell differentiation	human lung fibroblasts	baicalin (BAI) treatment	"Baicalein diminished the expression of miR-21, and miR-21 mimics partially antagonized the effects of baicalein."	30201452
6576	Human	hsa-miR-21	miRNA	hypoxia	transplacental clastogenic and epigenetic effects	pancreatic cancer cells	hypoxia treatment	Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells	23726431
6577	Human	hsa-miR-21	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
6578	Human	hsa-miR-21	miRNA	carboplatin (CBP)	triple negative breast cancer (TNBC)	human TNBC cell lines MDA©\MB©\231 and BT©\ 20	carboplatin (CBP) treatment	miR-21 overexpression led to promoted cancer cells proliferation and improved cancer cell viability under carboplatin treatment.	31033015
6579	Human	hsa-miR-21	miRNA	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO)	triple negative breast cancer (TNBC)	TNBC cell line MDA-MB-231	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) treatment	downregulated	33405856
6580	Human	hsa-miR-21	miRNA	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO)	triple negative breast cancer (TNBC)	"TNBC cell line ,MDAMB-231"	folic-acid-adorned PEGylated graphene oxide (FA-PEG-GO) treatment	downregulated	33405856
6581	Human	hsa-miR-21	miRNA	rapamycin	tuberous sclerosis complex (TSC)	serum	rapamycin (mTOR) treatment	upregulated	30509037
6582	Human	hsa-miR-21	miRNA	TGF-¦Â	renal fibrosis	tubular epithelial cells (TECs)	TGF-¦Â treatment	upregulated	21852586
6583	Human	hsa-miR-21	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	type 1 diabetes mellitus (T1DM)	INS-1 832/13 beta cells	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	upregulated	28280903
6584	Human	hsa-miR-21	miRNA	IL-1¦Â and TNF-¦Á	type 2 diabetes mellitus (T2DM)	human pancreatic islets	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
6585	Human	hsa-miR-21	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	metformin treatment	downregulated	28230206
6586	Human	hsa-miR-21	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
6587	Human	hsa-miR-21	miRNA	ailanthone (AIL)	vestibular schwannomas (VSs)	human primary vestibular schwannomas (VSs) cells	ailanthone (AIL) treatment	miR-21 was lowly expressed in AIL-treated cells.	29298734
6588	Human	hsa-miR-21	miRNA	centrin gene deleted Leishmania donovani parasites (LdCen?/?)	visceral leishmaniasis	human macrophages	LdCen-/- parasites infection	LdCen-/- infection suppresses the expression of microRNA-21 (miR-21) in human macrophages compared to LdWT infection.	31608064
6589	Human	hsa-miR-21	miRNA	TGF-¦Â1	wound healing	mesenchymal stem cells (MSCs)	TGF-¦Â1 treatment	Higher TGF-¦Â1concentrations (1¨C10 ng/ml) in the culture medium led to reduced miR-21 expression	32080965
6590	Human	hsa-miR-21	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19264808
6591	Human	hsa-miR-21	miRNA	TGF-¦Â1	cardiac hypertrophy	HaCaT cell	TGF-¦Â1 treatment	upregulated	21647251
6592	Human	hsa-miR-21	miRNA	arsenite	epithelial-mesenchymal transition (EMT)	human bronchial epithelial cells	?Arsenite treatment	upregulated	24004609
6593	Human	hsa-miR-21	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	Rko cells; HCT116 cells	curcumin (diferuloylmethane)? treatment	downregulated	20815812
6594	Human	hsa-miR-21	miRNA	cisplatin (DDP)	liver fibrosis	A549 cell	cisplatin (DPP) treatment	downregulated	23485110
6595	Human	hsa-miR-21	miRNA	hypoxia	pulmonary artery smooth muscle cell proliferation and migration	pulmonary artery smooth muscle cell (PASMC)	hypoxia treatment	upregulated	20693317
6596	Human	hsa-miR-21*	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	allergic inflammation	Peripheral blood eosinophils	GM-CSF treatment	"the increased in vitro viability of GM-CSF-treated eosinophils and upregulated expression of miRNA-21* (miR-21*), a complementary miRNA of miR-21, in GM-CSF-treated eosinophils."	22698984
6597	Human	hsa-miR-210	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HEK (humanembryonic kidney) 293T;SMMC-7721; Huh-7 cells	Hypoxia treatment	upregulated	22144109
6598	Human	hsa-miR-210	miRNA	radiation	radiation enteropathy	intestinal samples;fibrotic cultured cells	radiation treatment	miR-210 overexpression	24290534
6599	Human	hsa-miR-210	miRNA	sulfated polysaccharide that inhibits angiogenesis(WSS25)	adipogenesis	HMEC-1 cells	WSS25 treatment	down-regulating microRNA-210	23322395
6600	Human	hsa-miR-210	miRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells	gemcitabine (GEM) treatment	Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.	31713003
6601	Human	hsa-miR-210	miRNA	connective tissue growth factor (CTGF)	angiogenesis	human synovial fibroblasts	CTGF treatment	upregulated	25341039
6602	Human	hsa-miR-210	miRNA	hypoxia	angiogenesis	K562 cells£» ¦Â-thalassemia/HbE progenitor cells	?hypoxia treatment	upregulated	23623309
6603	Human	hsa-miR-210	miRNA	rosuvastatin	apoptosis	factor-¦Á induced human mesenchymal stem cells (MSCs)	rosuvastatin treatment	upregulated	25620256
6604	Human	hsa-miR-210	miRNA	IL-13	asthma	human bronchial epithelial cells (NHBE)	IL-13 treatment	upregulated	31386204
6605	Human	hsa-miR-210	miRNA	hypoxia	autophagy	human colon cancer cell lines SW480;SW620 cells	hypoxia treatment	upregulated	25385144
6606	Human	hsa-miR-210	miRNA	hypoxia	breast cancer	SKBR-3 cells; MCF-7 cells; MDA-MB-231 cells	hypoxia treatment	upregulated	32945512
6607	Human	hsa-miR-210	miRNA	hypoxia	breast cancer	breast adenocarcinoma cell line MCF7£» hepatoblastoma cell line Hep3B; uterine cervix adenocarcinoma cell line HeLa£» renal cancer cell line RCC4	Hypoxia treatment	upregulated	18316553
6608	Human	hsa-miR-210	miRNA	trastuzumab or lapatinib	breast cancer	patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer	chemotherapy combin either trastuzumab or lapatinib treatment	upregulated	25086636
6609	Human	hsa-miR-210	miRNA	hypoxia	tumorigenesis	neural progenitor cells (NPCs)	?hypoxia treatment	upregulated	23039253
6610	Human	hsa-miR-210	miRNA	natural compound 1'S-1'-acetoxychavicol acetate (ACA)	cervical cancer (CC)	human cervical cancer cells Ca Ski and SiHa	ACA	downregulated	28401751
6611	Human	hsa-miR-210	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	peripheral blood monocytes (PBMs) and serum of patients with CHB	hepatitis B virus (HBV) infection	downregulated	30592291
6612	Human	hsa-miR-210	miRNA	acute exercise	chronic kidney disease (CKD)	blood	acute exercise treatment	downregulated	26475583
6613	Human	hsa-miR-210	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	cigarette smoke extract (CSE) treatment	upregulated	26563733
6614	Human	hsa-miR-210	miRNA	hypoxia	colorectal cancer (CRC)	"CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)"	1 and 0.2% oxygen	upregulated	28207045
6615	Human	hsa-miR-210	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
6616	Human	hsa-miR-210	miRNA	surgery and chemotherapy	colorectal cancer (CRC)	patients blood	surgery and chemotherapy for 3years treatment	upregulated	24310813
6617	Human	hsa-miR-210	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32498701
6618	Human	hsa-miR-210	miRNA	hypoxia	endometriosis	CRL-7566 cells	hypoxia treatment	upregulated	26914112
6619	Human	hsa-miR-210	miRNA	paraquat (PQ)	epithelial-mesenchymal transition (EMT)	human lung adenocarcinoma epithelial cells (A549)	paraquat (PQ) treatment	upregulated	28699703
6620	Human	hsa-miR-210	miRNA	erythropoietin (EPO)	erythroid cell differentiation	The original UT-7 cell line	erythropoietin treatment	upregulated	18492109
6621	Human	hsa-miR-210	miRNA	hypoxia	esophageal cancer (EC)	Eca-109 and HEK 293t/17 cells	under hypoxic conditions in ESCC treatment	upregulated	25069478
6622	Human	hsa-miR-210	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
6623	Human	hsa-miR-210	miRNA	hypoxia	gastric cancer (GC)	gastric cancer cell line AGS cells	hypoxia treatment	upregulated	26548949
6624	Human	hsa-miR-210	miRNA	phosphatase of regenerating liver-3 (PRL-3)	gastric cancer (GC)	Gastric cancer cell line AGS	Phosphatase of regenerating liver-3 (PRL-3) treatment	upregulated	26548949
6625	Human	hsa-miR-210	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
6626	Human	hsa-miR-210	miRNA	hypoxia	glioblastoma multiforme (GBM)	human glioma cell lines U87;SHG44	hypoxia treatment	upregulated	24930954
6627	Human	hsa-miR-210	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	L02 cells	hypoxia treatment	downregulated	32155285
6628	Human	hsa-miR-210	miRNA	zeaxanthin dipalmitate (ZD)	hepatic tissue-repairing	human adipose-derived mesenchymal stem cells (hADMSCs)	ZD treatment	upregulated	27983913
6629	Human	hsa-miR-210	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	neural progenitor cells (NPCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	23039253
6630	Human	hsa-miR-210	miRNA	nickel oxide nanoparticles (NiO NPs)	hepatocellular carcinoma (HCC)	HepG2 cells	Nickel oxide nanoparticles (NiO-NPs) treatment	upregulated	31812053
6631	Human	hsa-miR-210	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	transarterial chemoembolization treatment	upregulated in serum	24935355
6632	Human	hsa-miR-101	miRNA	influenza A virus (IAV) 	host-Influenza A virus (IAV) infection	A549 cells	"The X-31 virus, a reassortant between PR8 and A/Aichi/68(H3N2) IAV strain ifection"	downregulated	32326380
6633	Human	hsa-miR-210	miRNA	hypoxia	cell proliferation	Primary human pulmonary arterial smooth muscle cells (HPASMC)	hypoxia treatment	"miR-210 as a hypoxia-inducible miRNA both in vitro and in vivo, which inhibits pulmonary vascular smooth muscle cell apoptosis in hypoxia by specifically repressing E2F3 expression."	22886504
6634	Human	hsa-miR-210	miRNA	hypoxia	hypoxia-induced injury	C28/I2 human chondrocytes	hypoxia treatment	upregulated	24790587
6635	Human	hsa-miR-210	miRNA	hypoxia	hypoxia-induced cell death	human umbilical vein endothelial cells (HUVEC)	hypoxia treatment	both ROD1 mRNA and protein were down-modulated upon hypoxia in a miR-210 dependent manner. ROD1 targeting by miR-210 was biologically significant: the rescue of ROD1 inhibition significantly increased hypoxia-induced cell death	23024754
6636	Human	hsa-miR-210	miRNA	hypoxia	hypoxia-induced renal tubular cell apoptosis	human renal tubular HK-2 cells	hypoxia treatment	upregulated	29387863
6637	Human	hsa-miR-210	miRNA	hypoxia	idiopathic pulmonary fibrosis (IPF)	IPF fibroblasts	hypoxia treatment	upregulated	24951777
6638	Human	hsa-miR-210	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	HNSCC	hypoxia?treatment	the level of hsa-miR-210 was significantly correlated with other markers of hypoxia	20187102
6639	Human	hsa-miR-210	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
6640	Human	hsa-miR-210	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
6641	Human	hsa-miR-210	miRNA	leishmania	leishmaniasis	?human primary macrophages	Leishmania (L.) infection	upregulated	24098824
6642	Human	hsa-miR-210	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
6643	Human	hsa-miR-210	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	"miR-210 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM"	32656599
6644	Human	hsa-miR-210	miRNA	pemetrexed	lung adenocarcinoma (LUAD)	serum	pemetrexed treatment	"Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations"	26687391
6645	Human	hsa-miR-210	miRNA	epigallocatechin-3-gallate (EGCG)	lung cancer	lung cancer cells	Green tea polyphenol EGCG treatment	upregulated	21965273
6646	Human	hsa-miR-210	miRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	HK-2 cells	lipopolysaccharide (LPS) treatment	miR-210 level in LPS-treated cells was elevated by ALK.	30372870
6647	Human	hsa-miR-210	miRNA	hypoxia	myocardial infarction (MI)	human mesenchymal stem cells (hMSCs)	hypoxia treatment	upregulated	23388440
6648	Human	hsa-miR-210	miRNA	hypoxia	myocardial infarction (MI)	human cardiosphere-derived cells (CDCs) exosomes	hypoxia induce	upregulated	29243842
6649	Human	hsa-miR-210	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
6650	Human	hsa-miR-210	miRNA	melatonin	nickel toxicity	BEAS-2B cells	melatonin treatment	"NiCl2 induced a sharp increase in miR210 expression, while melatonin treatment signifi- cantly repressed miR210 overexpression."	32566089
6651	Human	hsa-miR-210	miRNA	vascular endothelial growth factor (VEGF)	obesity	haematopoietic stem cells (HSCs)	vascular endothelial growth factor? treatment	upregulated	22360314
6652	Human	hsa-miR-210	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	apoptosis	primary cardiomyocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	29461605
6653	Human	hsa-miR-210	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteonecrosis of femoral head (ONFH)	SONFH tissues (ONs) and the adjacent normal tissues (NLs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26805628
6654	Human	hsa-miR-210	miRNA	lipopolysaccharide (LPS)	otitis media with effusion (OME)	human middle ear epithelial cells (HMEECs)	lipopolysaccharide (LPS) treatment	the miR-210 level is significantly reduced in culture supernatant of lipopolysaccharide (LPS) treated human middle ear epithelial cells (HMEECs).	33248692
6655	Human	hsa-miR-210	miRNA	lipopolysaccharide (LPS)	otitis media with effusion (OME)	human middle ear epithelial cells (HMEECs)	lipopolysaccharides (LPS) treatment	downregulated	33248692
6656	Human	hsa-miR-210	miRNA	hypoxia	ovarian cancer (OC)	"OVCAR-3 , SK-OV-3 EOC cell lines"	hypoxia treatment	upregulated	24715221
6657	Human	hsa-miR-210	miRNA	sevoflurane (SEV)	ovarian cancer (OC)	SKOV3 cells	sevoflurane treatment	"miR-138 expression was suppressed by both sevoflurane and desflurane, while miR-210 expression was suppressed only by sevoflurane"	33673181
6658	Human	hsa-miR-210	miRNA	CoCl2	ovulation and corpus luteum (CL) formation	human primary (hGLCs) and immortalized (SVOG) granulosa-lutein cells	CoCl2 treatment	upregulated	29301980
6659	Human	hsa-miR-210	miRNA	hypoxia	ovulation and corpus luteum (CL) formation	human primary (hGLCs) and immortalized (SVOG) granulosa-lutein cells	hypoxia induce	upregulated	29301980
6660	Human	hsa-miR-210	miRNA	ginsenoside Rb1	oxidative stress	H2O2-treated human endothelial EA.hy926 cells	Ginsenoside Rb1 (Rb1) treatment	upregulated	31359794
6661	Human	hsa-miR-210	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2	upregulated	28367268
6662	Human	hsa-miR-210	miRNA	H2O2	oxidative stress	Human endothelial EA.hy926 cells	H2O2 treatment	downregulated	31359794
6663	Human	hsa-miR-210	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
6664	Human	hsa-miR-210	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
6665	Human	hsa-miR-210	miRNA	curcumin-derived analogue CDF	pancreatic cancer (PC)	human pancreatic cancer (PC) cells	curcumin-derived analogue CDF treatment	downregulated	23272057
6666	Human	hsa-miR-210	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	BxS and PANC-1 cells	Gemcitabine (GEM) treatment	upregulated	31713003
6667	Human	hsa-miR-210	miRNA	hypoxia	pancreatic cancer (PC)	"PC cell lines (AsPC-1, BxPC-3, MIAPaCa-2, PANC-1, Su86.86 and SW1990)"	hypoxia treatment	upregulated	22672828
6668	Human	hsa-miR-210	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells	hypoxia induce	upregulated	31875764
6669	Human	hsa-miR-210	miRNA	lapatinib and 5-fluorouracil (5-Fu)	pancreatic cancer (PC)	PANC-1 and MIA PaCa-2 cells	lapatinib and 5-FU treatment	upregulated	26998056
6670	Human	hsa-miR-210	miRNA	hypoxia	preeclampsia (PE)	placental	hypoxia treatment	upregulated	27746364
6671	Human	hsa-miR-210	miRNA	hypoxia	pregnancy complication preeclampsia	trophoblasts	hypoxia treatment	upregulated	31616934
6672	Human	hsa-miR-210	miRNA	hypoxia	prostate cancer	"NCaP, 22RV1, and PC3"	hypoxia treatment	Hypoxia-induced miR-210 expression can contribute to prostate cancer.	31975433
6673	Human	hsa-miR-210	miRNA	hypoxia	prostate cancer	human prostate fibroblasts (HPFs)	hypoxia treatment	upregulated	25091736
6674	Human	hsa-miR-210	miRNA	radiation	radiation enteropathy	enteropathy and fibrotic cultured cells	radiation treatment	upregulated	24290534
6675	Human	hsa-miR-210	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
6676	Human	hsa-miR-210	miRNA	hypoxia	squamous cell carcinoma (SCC)	SCC2 and SCC38 cell lines	hypoxia treatment	upregulated	28099149
6677	Human	hsa-miR-210	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
6678	Human	hsa-miR-210	miRNA	hypoxia	tumor-initiating cells (TICs) activation	HCT116 cells;HT29 cells;LS174t cells	hypoxia treatment	upregulated	27589845
6679	Human	hsa-miR-210	miRNA	propranolol (PRO)	Von Hippel-Lindau (VHL) disease	VHL patients plasma	administered 120 mg propranolol daily treatment	downregulated	28662711
6680	Human	hsa-miR-210	miRNA	trastuzumab	H1N1 influenza virus infection	Plasma	trastuzumab treatment	upregulated	22370716
6681	Human	hsa-miR-210	miRNA	hypoxia	cardiac hypertrophy	SMMC-7721 cells; HepG2 cells; HuH7 cells	hypoxia?treatment	downregulated	22387901
6682	Human	hsa-miR-210-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	angiogenesis	Endothelial progenitor cells (EPCs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31164807
6683	Human	hsa-miR-210-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31680642
6684	Human	hsa-miR-210-3p	miRNA	cytomegalovirus (CMV)	cytomegalovirus infection	plasma	Cytomegalovirus (CMV) treatment	upregulated	27684416
6685	Human	hsa-miR-210-3p	miRNA	hypoxia	elective intrauterine growth restriction (sIUGR)	The human extravillous trophoblast cell line HTR©\8/SVneo	hypoxia induce	upregulated	30993882
6686	Human	hsa-miR-210-3p	miRNA	hypoxia	endometriosis	primary endometrial stromal cells (ESCs) and Ishikawa cells	hypoxia induce	upregulated	30760709
6687	Human	hsa-miR-210-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
6688	Human	hsa-miR-210-3p	miRNA	candida albicans (C. albicans)	inflammatory response	THP-1 cells	candida albicans infection	upregulated	28454101
6689	Human	hsa-miR-210-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV-3 cells	cisplatin treatment	downregulated	30957179
6690	Human	hsa-miR-210-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
6691	Human	hsa-miR-210a	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	serum	liraglutide treatment	upregulated	33008044
6692	Human	hsa-miR-211	miRNA	hypoxia	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia induce	downregulated	31589383
6693	Human	hsa-miR-211	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia-inducible factor 1¦Á (HIF-1¦Á) treatment	downregulated	31589383
6694	Human	hsa-miR-211	miRNA	vemurafenib	melanoma	A375 melanoma cells	vemurafenib treatment	upregulated	28445987
6695	Human	hsa-miR-211	miRNA	4-nitroquinoline 1-oxide (4NQO)	oral squamous cell carcinoma (OSCC)	human oral squamous cell carcinoma (OSCC) cells	4-nitroquinoline 1-oxide (4NQO) treatment	upregulated	27221705
6696	Human	hsa-miR-211	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	miR-211 expression could be significantly inhibited by IL-1¦Â stimulation.	30005876
6697	Human	hsa-miR-211	miRNA	ligustrazine (Lig)	ovarian cancer (OC)	"SK-OV-3 , OVCAR-3 cells"	Ligustrazine (Lig) treatment	LSZ could significantly increase the expression of miR-211 in both SK-OV-3 and OVCAR-3	33245099
6698	Human	hsa-miR-211	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	human Pancreatic Cancer tissue	gemcitabine treatment	upregulated	23155457
6699	Human	hsa-miR-211	miRNA	ultraviolet (UV) irradiation	repigmentation outcomes	human melanocytes	UVB treatment	downegulated	31985026
6700	Human	hsa-miR-211	miRNA	lipopolysaccharide (LPS)	sepsis	rats lung tissues	lipopolysaccharide (LPS) treatment	downregulated	28901393
6701	Human	hsa-miR-211	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	normal human astrocytes (NHAs)	lipopolysaccharide (LPS) treatment	downregulated	28790168
6702	Human	hsa-miR-2113	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	downregulated	29393545
6703	Human	hsa-miR-2113	miRNA	high glucose (HG)	diabetic retinopathy (DR)	MIO-M1 cells	high glucose (HG) treatment	downregulated	29654764
6704	Human	hsa-miR-211-3p	miRNA	lipopolysaccharide (LPS)	endoplasmic reticulum stress (ERS)	ccultured human skin fibroblasts	lipopolysaccharide (LPS) treatment	downregulated	31221950
6705	Human	hsa-miR-2115?	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
6706	Human	hsa-miR-211-5p	miRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2.2.15 cells	HBx-induce	upregulated	31880390
6707	Human	hsa-miR-211-5p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV) infection	upregulated	31880390
6708	Human	hsa-miR-211-5p	miRNA	BRAF	melanoma	melanoma cell lines MML-1 and A375	BRAF treatment	upregulated	28684402
6709	Human	hsa-miR-211-5p	miRNA	vemurafenib	melanoma	A375 cells	vemurafenib treatment	upregulated	29229605
6710	Human	hsa-miR-211-5p	miRNA	alpinetin (ALP)	oral squamous cell carcinoma (OSCC)	Human OSCC cell lines (CAL-27 and TCA-8113)	alpinetin (ALP) treatment	upregulated	31403340
6711	Human	hsa-miR-211-5p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	"KCNQ1OT1 and TCF4 were highly expressed in the cartilage tissues of patients with OA and C28/I2 cells treated with LPS (OA cells), whereas miR-211-5p was downregulated concomitantly in OA tissues and cells."	33747189
6712	Human	hsa-miR-211-5p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
6713	Human	hsa-miR-211-5p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human islets	(IL-1¦Â+IFN-¦Ã) treatment	downregulated	31277072
6714	Human	hsa-miR-2116-3p	miRNA	omeprazole	barrett's esophagus	Barrett's esophagus (BE) organoids	omeprazole treatment	upregulated	30705106
6715	Human	hsa-miR-2116-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
6716	Human	hsa-miR-212	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y; IMR-32 cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	32474742
6717	Human	hsa-miR-212	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29174964
6718	Human	hsa-miR-212	miRNA	hypoxia	blood-brain barrier (BBB) dysfunction	human brain microvascular endothelial cells (BMEC)	hypoxia induce	upregulated	30617994
6719	Human	hsa-miR-212	miRNA	4?-12-O-tetradecanoylphorbol-13-acetate (TPA)	carcinoma of nasopharyngeal epithelial (CNE)	NSCLC cell lines	4?-12-O-tetradecanoylphorbol-13-acetate (TPA) treatment	upregulated	22357618
6720	Human	hsa-miR-212	miRNA	doxorubicin (DOX)	cardiotoxicity	human iPSC-derived cardiomyocytes	doxorubicin treatment	"In vitro, overexpression of the pro-hypertrophic miR-212/132 cluster in primary rodent and human iPSC-derived cardiomyocytes inhibited doxorubicin-induced toxicity."	30527757
6721	Human	hsa-miR-212	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
6722	Human	hsa-miR-212	miRNA	imatinib	chronic myeloid leukemia (CML)	human immortalized myelogenous leukemia line K-562 cells	imatinib treatment	downregulated	22241070
6723	Human	hsa-miR-212	miRNA	lipopolysaccharide (LPS)	delayed union of femoral neck fracture	MG-63 cells	lipopolysaccharide (LPS) treatment	downregulated	33725277
6724	Human	hsa-miR-212	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human gastric cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	21053104
6725	Human	hsa-miR-212	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	U251 cells	irradiation treatment	miR-212 is downregulated in human glioma U251 cells following irradiation.	29286157
6726	Human	hsa-miR-212	miRNA	hepatitis B virus (HBV)	HBV-infection-related liver diseases	serum	hepatitis B virus (HBV) infection	upregulated	31608838
6727	Human	hsa-miR-212	miRNA	lactobacillus plantarum dy-1 (LFBE)	hepatocellular carcinoma (HCC)	HepG2 cells	Lactobacillus plantarum dy-1 (LFBE) treatment	LFBE and VA normalized the upregulaton of miR-212.	30369345
6728	Human	hsa-miR-212	miRNA	angiotensin II (Ang II)	hypertension	human breast artery tissues	angiotensin II (Ang II) treatment	upregulated	23712358
6729	Human	hsa-miR-212	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
6730	Human	hsa-miR-212	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	29611404
6731	Human	hsa-miR-212	miRNA	alcohol	gut leakiness	Caco-2 cells; colon biopsy tissue	alcohol exposure	upregulated	18162065
6732	Human	hsa-miR-212*	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal development	HeLa? cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	20307261
6733	Human	hsa-miR-212-3p	miRNA	macrocalyxin C	gastric cancer (GC)	"AGS, MKN45, SGC7901 cells"	macrocalyxin C treatment	upregulated	31726103
6734	Human	hsa-miR-212-3p	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	Huh7 cells	paclitaxel (PTX) treatment	downregulated	32774496
6735	Human	hsa-miR-212-3p	miRNA	mycobacterium tuberculosis (Mtb)	latent tuberculosis infection (LTBI)	peripheral blood mononuclear cells (PBMCs) of TB patients and individuals with LTBI	Mycobacterium tuberculosis (M.tb) infection	upregulated	31082644
6736	Human	hsa-miR-212-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1-treatment treatment	upregulated	29557526
6737	Human	hsa-miR-212-3p	miRNA	zoledronic acid (ZA)	osteosarcoma (OS)	The KHOS/NP and U2OS OS cell lines	Zoledronic acid (ZOL) treatment	upregulated	31752184
6738	Human	hsa-miR-212-3p	miRNA	IL-1¦Â	preterm labour	human myometrial smooth muscle cells	interleukin (IL)1B treatment	upregulated	30892651
6739	Human	hsa-miR-212-3p	miRNA	IL-6	preterm labour	human myometrial smooth muscle cells	IL-6 treatment	upregulated	30892651
6740	Human	hsa-miR-212-3p	miRNA	helicobacter pylori (H. pylori)	sophageal carcinogenesis	human esophageal cell line HET-1A	Helicobacter pylori infection	miR-212-3p was significantly decreased in HET-1A cells exposure to H. pylor.	30783439
6741	Human	hsa-miR-212-5p	miRNA	H2O2	abdominal aortic aneurysm (AAA)	human vascular smooth muscle cells (VSMCs)	H2O2 treatment	LINC00473 inhibits vascular smooth muscle cell viability to promote aneurysm formation via miR-212-5p/BASP1 axis.	31954705
6742	Human	hsa-miR-212-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	NCI-H292 cells	cigarette smoke extract (CSE) treatment	downregulated	30695677
6743	Human	hsa-miR-212-5p	miRNA	candida albicans (C. albicans) and aspergillus fumigatus (A. fumigatus)	fungal infection	human monocyte-derived dendritic cells	6 and 12 h of infection with C. albicans and A. fumigatus as well as treatment with lipopolysaccharides (LPS)	dysregulated	28280489
6744	Human	hsa-miR-21-3p	miRNA	lipopolysaccharide (LPS)	age-related macular degeneration (AMD)	human retinal pigment epithelial (ARPE-19) cells	lipopolysaccharide (LPS) treatment	upregulated	31330059
6745	Human	hsa-miR-21-3p	miRNA	berberine (BBR)	breast cancer	estrogen receptor (ER)¦Á(+) MCF-7 breast cancer cells	berberine (BBR) treatment	upregulated	29143794
6746	Human	hsa-miR-21-3p	miRNA	IL-4	chronic lymphocytic leukemia (CLL)	Peripheral blood	Interleukin 4 (IL-4) treatment	upregulated	25909590
6747	Human	hsa-miR-21-3p	miRNA	TGF-¦Â	chronic obstructive pulmonary disease (COPD)	primary parenchymal lung fibroblasts	TGF-¦Â treatment	upregulated	28910321
6748	Human	hsa-miR-21-3p	miRNA	high glucose (HG)	diabetic atherosclerosis	Human aortic VSMCs; vascular endothelial cells (VECs)	high glucose (HG) treatment	The high-glucose medium induced the downregulated of ADAM10 via excessive production of miR-21-3p in the vascular endothelial cells (VECs).	32196704
6749	Human	hsa-miR-21-3p	miRNA	D-glucose	diabetic foot ulcer (DFU)	Human skin fibroblasts	D-glucose treatment	miR-21-3p may treat DFU by reducing SPRY1.	32634115
6750	Human	hsa-miR-21-3p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
6751	Human	hsa-miR-21-3p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) cyclosporine A (CYCA) treatment	upregulated	31198949
6752	Human	hsa-miR-21-3p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
6753	Human	hsa-miR-21-3p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
6754	Human	hsa-miR-21-3p	miRNA	oxidized glycerophospholipids (oxGPs) and IL-1¦Â	inflammation	human aortic endothelial cells (HAECs)	oxGPs and interleukin 1¦Â (IL-1¦Â) treatment	upregulated	25327529
6755	Human	hsa-miR-21-3p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
6756	Human	hsa-miR-21-3p	miRNA	platinum-based chemotherapy	ovarian tumours	ovarian cancer cell line A2780	cisplatin and carboplatin treatment	upregulated	25579119
6757	Human	hsa-miR-21-3p	miRNA	ultraviolet (UV) irradiation	skin inflammation	epidermis	UV exposure treatment	upregulated	27250636
6758	Human	hsa-miR-214	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	Lipopolysaccharide (LPS) treatment	DANCR Suppressed Lipopolysaccharide-Induced Septic Acute Kidney Injury by Regulating miR-214 in HK-2 Cells	32222722
6759	Human	hsa-miR-214	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
6760	Human	hsa-miR-214	miRNA	berberine (BBR)	alveolar bone regeneration	human alveolar osteoblasts (HAOBs)	berberine (BBR) treatment	miR-214 was reduced as BBR concentrations increased.	32688361
6761	Human	hsa-miR-214	miRNA	berberine (BBR)	alveolar bone regeneration	primary human alveolar osteoblasts (HAOBs)	berberine (BBR) treatment	downregulated	32688361
6762	Human	hsa-miR-214	miRNA	isoflurane	anesthesia-induced neural cytotoxicity	human neuroblastoma cell line SH-SY5Y	Isoflurane treatment	downregulated	31704096
6763	Human	hsa-miR-214	miRNA	ginsenoside Rg1	angiogenesis	human umbilical vein endothelial cells (HUVECs)	ginsenoside-Rg1 treatment	downregulated	19733659
6764	Human	hsa-miR-214	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
6765	Human	hsa-miR-214	miRNA	IFN-¦Ã	autophagy	human hepatoma Huh7 cells	IFN-¦Ë treatment	upregulated	28131804
6766	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	upregulated	31678133
6767	Human	hsa-miR-214	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
6768	Human	hsa-miR-214	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
6769	Human	hsa-miR-214	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
6770	Human	hsa-miR-214	miRNA	lipopolysaccharide (LPS)	calcific aortic valve disease (CAVD)	aortic valve interstitial cells (AVICs)	lipopolysaccharide (LPS) treatment	upregulated	30519780
6771	Human	hsa-miR-214	miRNA	H2O2	cataract	SRA01/04 cell lines	H2O2 treatment	downregulated	28535504
6772	Human	hsa-miR-214	miRNA	hypoxia	chronic obstructive pulmonary disease (COPD)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	27381447
6773	Human	hsa-miR-214	miRNA	hypoxia	chronic obstructive pulmonary disease (COPD)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	28684904
6774	Human	hsa-miR-214	miRNA	5-aza-2'-deoxycytidine and trichostatin A	colonic inflammation	Squamous cell carcinoma (SCC) cell line	5-aza-deoxycytidine and trichostatin A treatment	downregulated	22828925
6775	Human	hsa-miR-214	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	Two colon cancer cell lines were used: HT-29 and LoVo	5-fluorouracil (5-FU) treatment	"miR-214 is downregulated in 5-FU-resistant colon cancer cells compared to normal cells. In vitro, miR-214 could sensitize non-resistant colon cancer cells and 5-FU-resistant colon cancer cellsto 5-FU."	30915129
6776	Human	hsa-miR-214	miRNA	high glucose (HG)	diabetic corneal endothelial keratopathy	HCEC-B4G12 cells	treatment	downregulated	31693400
6777	Human	hsa-miR-214	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human proximal tubular epithelial cells HK2	high glucose (HG) treatment	upregulated	31240704
6778	Human	hsa-miR-214	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
6779	Human	hsa-miR-214	miRNA	steroids	eosinophilic esophagitis (EoE)	esophageal mucosal tissue	Steroids treatment	upregulated	22815788
6780	Human	hsa-miR-214	miRNA	astragaloside IV (AS-IV)	gastric cancer (GC)	gastric cancer-associated fibroblast (GCAF)	astragaloside (AS-IV) treatment	upregulated	29358859
6781	Human	hsa-miR-214	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	upregulated	29456019
6782	Human	hsa-miR-214	miRNA	hypoxia	gastric cancer (GC)	human gastric cancer cells	hypoxia treatment	upregulated	29129783
6783	Human	hsa-miR-214	miRNA	hypoxia	gastric cancer (GC)	MKN-45 cells	hypoxia induce	upregulated	29129783
6784	Human	hsa-miR-214	miRNA	carvedilol	heart failure (HF)	serum	carvedilol treatment	upregulated	32943906
6785	Human	hsa-miR-214	miRNA	H2O2	cardiac dysfunction	human cardiomyocyte (HCM)	H2O2 treatment	downregulated	28849090
6786	Human	hsa-miR-214	miRNA	heat shock factor 1 (HSF1)	huntington's disease (HD)	Blood	Heat shock factor 1 (HSF1) treatment	downregulated	26634350
6787	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	left ventricular hypertrophy (LVH)	human articular chondrocytes and immortalized costal chondrocytes (TC28 cells)	dexamethasone (DEX) treatment	downregulated	31180556
6788	Human	hsa-miR-214	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
6789	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	miRNA biogenesis	human endothelial cells	dexamethasone (Dex) treatment	downregulated	28523344
6790	Human	hsa-miR-214	miRNA	ginsenoside Rg1	miRNA biogenesis	human endothelial cells	ginsenoside-Rg1 treatment	downregulated	28523344
6791	Human	hsa-miR-214	miRNA	¦Â-glycerophosphate + ascorbic acid + dexamethasone	osteogenesis	human Bone marrow mesenchymal stem cells (BMSCs)	"10 mM ¦Â-glycerophosphate (Sigma-Aldrich, USA), 200 ¦ÌM ascorbic acid (Sigma-Aldrich, USA) and 100 nM dexamethasone (Sigma-Aldrich, USA) treatment"	KCNQ1OT1 was significantly upregulated during the process of osteogenic induction while miR-214 was contrarily downregulated	30703347
6792	Human	hsa-miR-214	miRNA	curcumin (Cur)	ovarian cancer (OC)	cisplatin-resistant A2780cp cells	curcumin treatment	downregulated	28175963
6793	Human	hsa-miR-214	miRNA	TGF-¦Â	ovarian cancer (OC)	A2780 cells; SKOV3 cells	TGF-¦Â treatment	Knockdown of DANCR Suppressed the Biological Behaviors of Ovarian Cancer Cells Treated with Transforming Growth Factor-¦Â (TGF-¦Â) by Sponging MiR-214	32417846
6794	Human	hsa-miR-214	miRNA	ethanol (EtOH)	oxidative stress	"human hepatoma cell (Bel7402), human embryonic kidney 293 cell (HEK293),"	ethanol (EtOH) treatment	upregulated	23905773
6795	Human	hsa-miR-214	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	downregulated	30896848
6796	Human	hsa-miR-214	miRNA	advanced glycation end product (AGE)	apoptosis	THP-1 cells	advanced glycation end products (AGEs) treatment	"Overexpression of pre¨CmiR-214 led to impaired PTEN expression and delayed apoptosis of THP-1 cells, whereas knockdown of miR-214 level largely abolished AGE-induced cell survival."	21228352
6797	Human	hsa-miR-214	miRNA	dexamethasone (DEX)	steroid-induced avascular necrosis of femoral head (SANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	upregulated	31678133
6798	Human	hsa-miR-214	miRNA	Bt2cAMP	type II pneumocyte differentiation	cultured human fetal lung (HFL) epithelial cells	Bt2cAMP treatment	downregulated	29507184
6799	Human	hsa-miR-214	miRNA	IL-6	ulcerative colitis (UC)	NCM460 cells	IL-6 treatment	upregulated	31382166
6800	Human	hsa-miR-214	miRNA	limonin	ulcerative colitis (UC)	IL-6-treated NCM460 cells	limonin treatment	downregulated	31382166
6801	Human	hsa-miR-214	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	plasma and myocardial cells	coxsackievirus B3 (CVB3) treatment	upregulated	25815880
6802	Human	hsa-miR-214	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	Pulmonary artery smooth muscle cells (hPASMCs)	hypoxia treatment	upregulated	27144530
6803	Human	hsa-miR-214-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	33197504
6804	Human	hsa-miR-214-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease.	33197504
6805	Human	hsa-miR-214-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circ_CHFR contributed to the progression of AS through the miR-214-3p/Wnt3/¦Â-catenin signals.	32271446
6806	Human	hsa-miR-214-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (HVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33818550
6807	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	brain injury in diabetes mellitus (DM)	SH-SY5Y cells	high glucose (HG) treatment	MicroRNA-214-3p (miR-214-3p) was decreased in HG-treated cells.	32910484
6808	Human	hsa-miR-214-3p	miRNA	melatonin	brain injury in diabetes mellitus (DM)	SH-SY5Y cells	melatonin (MEL) treatment	"MicroRNA-214-3p (miR-214-3p) was decreased in DM mice and HG-treated cells, and such a downregulated was corrected by melatonin"	32910484
6809	Human	hsa-miR-214-3p	miRNA	bone morphogenetic protein 2 (BMP2)	cell differentiation	maxillary sinus membrane stem cells (MSMSCs)	bone morphogenetic protein 2 (BMP2) treatment	Hsa_circRNA_33287 promotes the osteogenic differentiation of maxillary sinus membrane stem cells via miR-214-3p/Runx3.	30551425
6810	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	30355944
6811	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	?high glucose (HG) induce treatment	lncRNA?PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via miR-214-3p/MMP2 axis	31755246
6812	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	high glucose (HG) treatment	downregulated	31755246
6813	Human	hsa-miR-214-3p	miRNA	"3,3'5-tri-iodo-L-thyronine (T3)"	hepatocellular carcinoma (HCC)	HepG2 cells	"3,3'5-tri-iodo-L-thyronine (T3) treatment"	upregulated	29093516
6814	Human	hsa-miR-214-3p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	downregulated	33071785
6815	Human	hsa-miR-214-3p	miRNA	bisphenol A (BPA)	nasopharyngeal carcinoma (NPC)	CNE1 cell; 5-8F cells	bisphenol A (BPA) treatment	BPA treatment also decreased the expression of miR-214-3p in both CNE1 and 5-8F cells.	32360864
6816	Human	hsa-miR-214-3p	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neuroblastoma (NB)	neuroblastoma cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
6817	Human	hsa-miR-214-3p	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neurological disorders	SK-N-SH cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
6818	Human	hsa-miR-214-3p	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	"The normal human oral keratinocyte (NHOK) and OSCC cell lines, including TSCCA, CAL-27, SCC-9, and Tca8113"	cisplatin treatment	downregulated	31275988
6819	Human	hsa-miR-214-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 and SW 1990 cells	gemcitabine (GEM) treatment	downregulated	31632071
6820	Human	hsa-miR-214-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	33071725
6821	Human	hsa-miR-214-3p	miRNA	high glucose (HG)	peritoneal dialysis (PD)	human peritoneal mesothelial cells (HPMCs)	high-glucose (HG)	upregulated	28428333
6822	Human	hsa-miR-214-3p	miRNA	hypoxia	renal fibrosis	HK-2 cells	hypoxia treatment	upregulated	29277613
6823	Human	hsa-miR-214-3p	miRNA	hypoxia	renal fibrosis	?HK-2?cells	hypoxia induce	upregulated	29277613
6824	Human	hsa-miR-214-5p	miRNA	hypoxia	cervical cancer (CC)	HeLa and C-33A cells	hypoxia induce	downregulated	33394293
6825	Human	hsa-miR-214-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
6826	Human	hsa-miR-214-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human primary chondrocytes	IL-1¦Â treatment	"The results showed that SNHG7 was distinctly downregulated, while miR-214-5p was significantly upregulated in OA patients and primary chondrocytes treated with IL-1¦Â."	33296783
6827	Human	hsa-miR-214-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary chondrocytes	IL-1¦Â treatment	SNHG7 prevents IL-1¦Â induced OA by inhibiting NLRP3 inflammasome and apoptosis through miR-214-5p/PPARGC1B axis.	33296783
6828	Human	hsa-miR-214-5p	miRNA	dexamethasone (DEX)	postmenopausal osteoporosis (PMOP)	human bone marrow stem cells (BMSCs)	dexamethasone (DEX) treatment	upregulated	29532880
6829	Human	hsa-miR-215	miRNA	hypoxia	colorectal cancer (CRC)	"Cancer stem cells, also known as tumor-initiating cells (TICs)"	hypoxia induce	upregulated	30790680
6830	Human	hsa-miR-215	miRNA	adriamycin (ADR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) subcel	adriamycin (ADR) treatment	upregulated	26135967
6831	Human	hsa-miR-215	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	H460 and A427 cells	curcumin treatment	upregulated	25444916
6832	Human	hsa-miR-215	miRNA	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA)"	ovarian cancer (OC)	ovarian cancer cell lines SKOV-3 and A2780	"Trans10,cis12 conjugated linoleic acid (t10,c12 CLA) treatment"	upregulated	29324748
6833	Human	hsa-miR-215	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
6834	Human	hsa-miR-215	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	CCD-18Co cells	lipopolysaccharide (LPS) treatment	knockdown of miR-215 alleviated oxidative stress and inflammatory response in LPS-treated CCD-18Co cells by upregulating GDF11 expression and inactivating the TLR4/NF-¦ÊB and JNK/p38 signaling pathways.	33146403
6835	Human	hsa-miR-215-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
6836	Human	hsa-miR-215-5p	miRNA	melatonin	colorectal cancer (CRC)	"Human colon cancer cell lines HCT116, SW480, COLO320, DLD-1, HT29, RKO, CaCO2, and SW620"	melatonin treatment	upregulated	30590435
6837	Human	hsa-miR-215-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
6838	Human	hsa-miR-215-5p	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	upregulated	32587527
6839	Human	hsa-miR-215-5p	miRNA	particulate matter (PM2.5)	PM2.5-induced carcinogenesis	human bronchial epithelial (HBE) cells	fine particulate matter (PM2.4) treatment	upregulated	33545377
6840	Human	hsa-miR-215-5p	miRNA	IL-17A	psoriasis	HaCaT cells	IL-17A treatment	downregulated	32881074
6841	Human	hsa-miR-215-5p	miRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	downregulated	32881074
6842	Human	hsa-miR-215-5p	miRNA	IL-6	psoriasis	HaCaT cells	IL-6?treatment	downregulated	32881074
6843	Human	hsa-miR-215-5p	miRNA	imiquimod (IMQ)	psoriasis	skin tissues	imiquimod (IMQ) treatment	The expression of miR-215-5p was downregulated in imiquimod (IMQ)-treated skin tissues.	32881074
6844	Human	hsa-miR-21-5p	miRNA	immunoglobulin E (IgE)	airway remodeling	human primary airway smooth muscle cell (ASMC)	immunoglobulin E (IgE) treatment	upregulated	30781615
6845	Human	hsa-miR-21-5p	miRNA	anabolic-androgenic ateroids (AASs)	anabolic-Androgenic Steroids (AASs)-induced renal damage	kidney tissues	anabolic-androgenic ateroids (AASs) treatment	upregulated	33041804
6846	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	angiogenesis	human retinal microvascular endothelial cells (HRMECs)	high glucose treatment	upregulated	29658404
6847	Human	hsa-miR-21-5p	miRNA	KHCO3	bone resorption of alkali	human serum	potassium bicarbonate [(KHCO3); 81 mmol/d; n = 12] vs placebo (n = 12) for 84 days	upregulated in serum	29264553
6848	Human	hsa-miR-21-5p	miRNA	ethanol extract of antrodia cinnamomea (AC)	breast cancer	MCF-7 and tamoxifen-resistant MCF-7 cells	ethanol extract of antrodia cinnamomea (AC) treatment	upregulated	29743060
6849	Human	hsa-miR-21-5p	miRNA	brucella Omp25	brucellosis	human Monocyte/Macrophages	brucella Omp25 treatment	upregulated	28694807
6850	Human	hsa-miR-21-5p	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	"hepatic tissues from HCV-infected patients, Huh-7 cells"	hepatitis C virus (HCV) infection	upregulated	30938910
6851	Human	hsa-miR-21-5p	miRNA	IL-4	chronic lymphocytic leukemia (CLL)	Peripheral blood	Interleukin 4 (IL-4) treatment	upregulated	25909590
6852	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	GAS5 could competitively bind with miR-21-5p and miR-21-5p inhibition alleviated the beneficial effects of GAS5 knockdown against HG stimulation.	31865425
6853	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human cardiomyocyte-like AC16 cells	high glucose (HG) treatment	downregulated	31865425
6854	Human	hsa-miR-21-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial ARPE-19 cells	high-glucose (HG) treatment	"XIST, likely through competitive binding of hsa-miR-21-5p, provides protection against hyperglycemia-associated injury in human retinal pigment epithelial cells."	32106367
6855	Human	hsa-miR-21-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
6856	Human	hsa-miR-21-5p	miRNA	saponin extract	endometriosis	human endometrial stromal cells (HESCs) obtained from patients with endometriosis	saponin extract treatment	downregulated	28558522
6857	Human	hsa-miR-21-5p	miRNA	atorvastatin	endothelial senescence	ox-LDL treated HUVECs	atorvastatin treatment	downregulated	29248491
6858	Human	hsa-miR-21-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial senescence	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
6859	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
6860	Human	hsa-miR-21-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
6861	Human	hsa-miR-21-5p	miRNA	hypoxia	flap surgeries	human umbilical vein endothelial cells (HUVEC)	hypoxia treatment	upregulated	28880208
6862	Human	hsa-miR-21-5p	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
6863	Human	hsa-miR-21-5p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
6864	Human	hsa-miR-21-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
6865	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
6866	Human	hsa-miR-21-5p	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	Hep3B cells; Huh-7 cells	curcumin treatment	miR-21-5p level was decreased in curcumin-treated cells.	32757994
6867	Human	hsa-miR-21-5p	miRNA	atorvastatin	hyperlipidemia	HUVECs	atorvastatin treatment	downregulated	29248491
6868	Human	hsa-miR-21-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	hyperlipidemia	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29248491
6869	Human	hsa-miR-21-5p	miRNA	metformin (Met)	hypopharyngeal cancer	human hypopharyngeal carcinoma cell line (FaDu)	metformin treatment	downregulated	27688683
6870	Human	hsa-miR-21-5p	miRNA	electron beam (EB) irradiation	keloids	keloid fibroblast	Electron beam (EB) irradiation	downregulated	31558773
6871	Human	hsa-miR-21-5p	miRNA	electron beam (EB) irradiation	keloids	keloid fibroblasts	Electron beam (EB) irradiation treatment	MiR-21-5p expression was found to be significantly downregulated after keloid fibroblasts were exposed to 20 Gy of EB irradiation.	31558773
6872	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	liver fibrosis	NTCP-Huh7.5.1 cells	TGF-¦Â1 treatment	TGF-¦Â1 incubation significantly increased miR-21-5p levels	33456536
6873	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	TGF-¦Â1 incubation significantly increased miR-21-5p levels	33456536
6874	Human	hsa-miR-21-5p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
6875	Human	hsa-miR-21-5p	miRNA	physical exercise	myasthenia gravis (MG)	MG patients serum	performed supervised aerobic and resistance training twice weekly for 12 weeks treatment	downregulated	27935072
6876	Human	hsa-miR-21-5p	miRNA	prednisone	myasthenia gravis (MG)	serum	prednisone treatment	Levels of miR-21-5p displayed a negative correlation with the prednisone dose within the prednisone-only group	29511707
6877	Human	hsa-miR-21-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
6878	Human	hsa-miR-21-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
6879	Human	hsa-miR-21-5p	miRNA	ovatodiolide (OV)	oral squamous cell carcinoma (OSCC)	cancer stem cell-derived extracellular vesicles (CSC_EVs) generated from CAL27 and SCC-15 OSCC cells	ovatodiolide (OV) treatment	downregulated	31878245
6880	Human	hsa-miR-21-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	downregulated	31053150
6881	Human	hsa-miR-21-5p	miRNA	pulsed electromagnetic field (PEMF)	osteoblastic differentiation	human bone marrow stromal cells (hBMSCs)	PEMFs treatment	upregulated	28512472
6882	Human	hsa-miR-21-5p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	upregulated	26987780
6883	Human	hsa-miR-21-5p	miRNA	lectin	prostate cancer	Prostate cancer (PC) cell lines	lectin treatment	upregulated	26417675
6884	Human	hsa-miR-21-5p	miRNA	radiation	prostate cancer	serum	curative radiotherapy (RT) treatment	upregulated	30103771
6885	Human	hsa-miR-21-5p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-21-5p was downregulated in treated patients when compared with untreated patients.	29523324
6886	Human	hsa-miR-21-5p	miRNA	lipopolysaccharide (LPS)	pulpal inflammation	human dental pulp cells (hDPCs)	lipopolysaccharide (LPS) treatment	upregulated	31042008
6887	Human	hsa-miR-21-5p	miRNA	pioglitazone	renal fibrosis	TGF-¦Â1-treated HK-2 cells	Pioglitazone treatment	downregulated	31254585
6888	Human	hsa-miR-21-5p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	31254585
6889	Human	hsa-miR-21-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	cell senescence	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28347692
6890	Human	hsa-miR-21-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
6891	Human	hsa-miR-21-5p	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	type 1 diabetes mellitus (T1DM)	EndoC-¦ÂH1 beta cell lines and human islets	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	upregulated	29445851
6892	Human	hsa-miR-21-5p	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	"SUM159PT, MCF-7, BT-474 and BT-549"	metformin treatment	downregulated	28698800
6893	Human	hsa-miR-216	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
6894	Human	hsa-miR-216	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
6895	Human	hsa-miR-216	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
6896	Human	hsa-miR-216	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
6897	Human	hsa-miR-216	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
6898	Human	hsa-miR-216-3p	miRNA	metformin (Met)	preeclampsia (PE)	Trophoblast and HUVEC cells	Metformin (Met) treatment	upregulated	31203154
6899	Human	hsa-miR-216a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS)	downregulated	31784954
6900	Human	hsa-miR-216a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	31784954
6901	Human	hsa-miR-216a	miRNA	ginsenoside Rb2	inflammation	human umbilical vein endothelial cells (HUVECs); human aortic endothelial cells	Ginsenoside Rb2 (Rb2) treatment	Rb2 decreased the expression of endogenous miR-216a.	33786633
6902	Human	hsa-miR-216a	miRNA	lipopolysaccharide (LPS)	macrophage polarization	THP-1 derived macrophage	1 ng/ml lipopolysaccharide (LPS) and 20 ng/ml interferon (IFN)-¦Ã treatment	upregulated	29940270
6903	Human	hsa-miR-216a	miRNA	dihydrotestosterone (DHT)	prostate cancer	LNCaP cells	dihydrotestosterone treatment	upregulated	26506397
6904	Human	hsa-miR-216a-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
6905	Human	hsa-miR-216a-5p	miRNA	H2O2	asthma	human bronchial epithelial cell (16HBE)	H2O2 treatment	downregulated	30502088
6906	Human	hsa-miR-216a-5p	miRNA	H2O2	asthma	16HBE cells	H2O2 treatment	downregulated	30502088
6907	Human	hsa-miR-216a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31029709
6908	Human	hsa-miR-216a-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose treatment	ZEB1-AS1 suppressed HG-induced EMT and fibrogenesis by regulating miR-216a-5p and BMP-7.	32294702
6909	Human	hsa-miR-216a-5p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	upregulated	24927770
6910	Human	hsa-miR-216a-5p	miRNA	treponema pallidum (T. pallidum) infection	syphilis	plasma	Treponema pallidum (T. pallidum) infectionn treatment	downregulated	31358689
6911	Human	hsa-miR-216b	miRNA	Cetuximab	colorectal cancer (CRC)	CRC cells	cetuximab treatment	downregulated	27158405
6912	Human	hsa-miR-216b	miRNA	ethanol extract of Salviamiltiorrhiza (SM)	endoplasmic reticulum stress (ERS)	U266 and U937 cells	ethanol extract of Salviamiltiorrhiza (SM) treatment	upregulated	29671785
6913	Human	hsa-miR-216b	miRNA	cigarette smoke condensate (CSC)	non-small cell lung cancer (NSCLC)	HPL1A cells	cigarette smoke condensate (CSC) treatment	upregulated	32668597
6914	Human	hsa-miR-216b	miRNA	paclitaxel (PTX)	non-small cell lung cancer (NSCLC)	NSCLC cells	paclitaxel treatment	downregulated	26852748
6915	Human	hsa-miR-216b	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrosarcoma cells (SW1353)	IL-1¦Â treatment	upregulated	28356485
6916	Human	hsa-miR-216b	miRNA	oxygen glucose deprivation (OGD)	spinal cord injury (SCI)	human SY-SH-5Y cells	oxygen-glucose deprivation treatment	"TCTN2 was downregulated in the spinal cord tissues of a rat model of SCI and in oxygen-glucose deprivation-induced hypoxic SY-SH-5Y cells, while microRNA-216b (miR-216b) was upregulated"	31050183
6917	Human	hsa-miR-217	miRNA	arsenite	acceleration of the cell cycle and carcinogenesis	HaCaT cells	arsenic exposure	upregulated	28062277
6918	Human	hsa-miR-217	miRNA	human cytomegalovirus (HCMV)	acute myeloid leukemia (AML)	endothelial cells(ECs)	Human cytomegalovirus(HCMV)? infection	upregulated	24376725
6919	Human	hsa-miR-217	miRNA	TGF-¦Â1	asthma	Human airway smooth muscle cells (ASMCs)	transforming growth factor-¦Â (TGF-¦Â1) treatment	downregulated	30212709
6920	Human	hsa-miR-217	miRNA	TGF-¦Â1	asthma	human bronchial epithelial cells BEAS-2B	TGF-¦Â1 treatment	"TGF-¦Â1, GAS5, HDAC4 were upregulated, while miR-217 was downregulated in bronchial mucosal tissues of asthmatic children and TGF-¦Â1-treated BEAS-2B cells"	33864612
6921	Human	hsa-miR-217	miRNA	high glucose (HG)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	miR-217 was found to be upregulated in VSMCs treated by high glucose and aorta VSMCs of diabetic rats.	33283391
6922	Human	hsa-miR-217	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 acute monocytic leukemia cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31432137
6923	Human	hsa-miR-217	miRNA	arsenite	bladder cancer	Normal bladder SV-HUC-1 cells	?arsenite treatment	downregulated	33386469
6924	Human	hsa-miR-217	miRNA	dasatinib	chronic myeloid leukemia (CML)	K562 cells	dasatinib treatment	miR-217 was significantly downregulated in K562 cells.	30195077
6925	Human	hsa-miR-217	miRNA	baicalin (BAI)	colorectal cancer (CRC)	DLD1 and HCT-116 cells	baicalin (BAI) treatment	downregulated	30737617
6926	Human	hsa-miR-217	miRNA	high glucose (HG)	diabetes mellitus (DM)	human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model."	33865922
6927	Human	hsa-miR-217	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	upregulated	31702814
6928	Human	hsa-miR-217	miRNA	rapamycin	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	upregulated	29579170
6929	Human	hsa-miR-217	miRNA	cigarette smoke condensate (CSC)	esophageal adenocarcinoma (EAC)	esophageal adenocarcinoma (EAC) cells	cigarette smoke condensate (CSC) treatment	downregulated	25703328
6930	Human	hsa-miR-217	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	HCV patients	IFN/RBV for 12 months treatment	upregulated	24033414
6931	Human	hsa-miR-217	miRNA	orafenib	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU-387; SNU-449	orafenib treatment	Lnc HOTAIR could increase sorafenib resistance in HCC by inhibiting miR-217.	32462038
6932	Human	hsa-miR-217	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammatory injury	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-217 ameliorates inflammatory damage of endothelial cells induced by oxidized LDL by targeting EGR1.	32737769
6933	Human	hsa-miR-217	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	downregulated	26415832
6934	Human	hsa-miR-217	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	Conditionally immortalized human podocyte cell line AB8/13	angiotensin II (Ang II) treatment	downregulated	30414341
6935	Human	hsa-miR-217	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
6936	Human	hsa-miR-217	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
6937	Human	hsa-miR-217	miRNA	TGF-¦Â1	pancreatic cancer (PC)	"The human pancreatic cancer cell lines BxPC-3, PANC-1"	TGF-¦Â1 treatment	downregulated	25172416
6938	Human	hsa-miR-217	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31737212
6939	Human	hsa-miR-217	miRNA	dasatinib and 5-Aza-2'-deoxycytidine	chronic myeloid leukemia (CML)	K562 cells	exposure to dasatinib (10 nM) together with 5-AzadC(0.1 ¦ÌM) treatment	upregulated	24350829
6940	Human	hsa-miR-217-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells	oxidized low-density lipoprotein (OX-LDL) treatment	downregulated	31744714
6941	Human	hsa-miR-217-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y Cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The level of miR-217-5p was significantly decreased in SH-SY5Y cells following OGD/R treatment	32683553
6942	Human	hsa-miR-218	miRNA	cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC)	advanced gastric cancers (AGCs)	advanced gastric cancers patients	CRS and HIPEC treatment	upregulated	25170221
6943	Human	hsa-miR-218	miRNA	triptolide (TPL)	benign prostatic hypertrophy (BPH)	BPH-1 cells	triptolide (TPL) treatment	upregulated	30453799
6944	Human	hsa-miR-218	miRNA	ionizing radiation (IR)	breast cancer	breast cancer cells and tissues	ionizing radiation treatment	upregulated	30429228
6945	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	carcinogenesis of cigarette smoke	human bronchial epithelial (HBE) cells	cigarette smoke?extract?(CSE) treatment	upregulated	25526925
6946	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells	cigarette smoke?extract?(CSE) treatment	downregulated	28864214
6947	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	downregulated	31668807
6948	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	CSE-treated 16HBE cells	cigarette smoke extract (CSE) treatment	MiR-218 was downregulated in COPD tissues and CSE-treated or MEG3 overexpressed 16HBE cells. MiR-218 overexpression attenuated CSE-blocked proliferation and CSE-induced apoptosis or inflammation.	31668807
6949	Human	hsa-miR-218	miRNA	smoking	chronic obstructive pulmonary disease (COPD)	lung tissues	smoking treatment	MiR-218 was downregulated in COPD tissues	31668807
6950	Human	hsa-miR-218	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	miR-218 was highly expressed in renal proximal tubule under high-glucose conditions.	32028854
6951	Human	hsa-miR-218	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelium (RPE) cells (ARPE-19)	high glucose (HG) treatment	upregulated	31830266
6952	Human	hsa-miR-218	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
6953	Human	hsa-miR-218	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	29693114
6954	Human	hsa-miR-218	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)		"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26610476
6955	Human	hsa-miR-218	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	criplatin treatment	miR-218 was decreased in cisplatin resistant SGC7901/DDP cells.	30542435
6956	Human	hsa-miR-218	miRNA	thermo-chemotherapy	gastric cancer (GC)	SGC7901 cells	thermo-chemotherapy treatment	upregulated	25694126
6957	Human	hsa-miR-218	miRNA	propofol (PPF)	glioblastoma multiforme (GBM)	U373 glioblastoma cell	Propofol treatment	upregulated	26133092
6958	Human	hsa-miR-218	miRNA	genistein	gliosarcoma	human gliosarcoma cells (U251)	exposed to genistein (12.5-200 ¦Ìg) for 24 h	upregulated	28776680
6959	Human	hsa-miR-218	miRNA	cigarette smoke condensate (CSC)	glomerulosclerosis	primary bronchial epithelial cells and H1299 cells	cigarette smoke condensate (CSC) treatment	mir-218 expression is reduced in primary bronchial epithelium exposed to cigarette smoke condensate (CSC)	19168627
6960	Human	hsa-miR-218	miRNA	benzophenone-3 (BP-3)	hirschsprung's disease (HSCR)	maternal urine	benzophenone-3 (BP-3) treatment	BP-3 influenced cell migration via SLIT2/ROBO1-miR-218-RET/PLAG1 pathway	26454118
6961	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	human bronchial epithelial (HBE) cells injury	human bronchial epithelial (HBE) cells	cigarette smoke?extract?(CSE) treatment	downregulated	25526925
6962	Human	hsa-miR-218	miRNA	Legionella pneumophila (L. pneumophila)	Legionella pneumophila (L. pneumophila) infection	u937 cells	L. pneumophila infection	L. pneumophila infection upregulated the expression of miR-218.	30509489
6963	Human	hsa-miR-218	miRNA	"1,6,7-trihydroxyxanthone (THA)"	hepatocellular carcinoma (HCC)	liver cancer cell lines HepG2	"1,6,7-trihydroxyxanthone (THA) treatment"	upregulated	25416134
6964	Human	hsa-miR-218	miRNA	andes hantavirus (ANDV)	liver damage	human endothelial cells (ECs)	andes hantavirus (ANDV) infection	downregulated	20844033
6965	Human	hsa-miR-218	miRNA	andrographolide	lung cancer	human alveolar epithelial A549 cells	andrographolide treatment	upregulated	24298938
6966	Human	hsa-miR-218	miRNA	carboplatin (CBP)	lung cancer	A549 and H1975 lung cancer cells	carboplatin (CBP) treatment	downregulated	25917317
6967	Human	hsa-miR-218	miRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	downregulated	27212446
6968	Human	hsa-miR-218	miRNA	human papilloma virus (HPV)	malignant transformation of esophageal epithelial cells	Het-1A cells	HPV and MNNG treatment	downregulated	33189795
6969	Human	hsa-miR-218	miRNA	andrographolide	oral cancer	human oral cancer stem cells (OCSCs)	andrographolide treatment	upregulated	27926533
6970	Human	hsa-miR-218	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
6971	Human	hsa-miR-218	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells	gemcitabine (GEM) treatment	downregulated	26157323
6972	Human	hsa-miR-218	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament progenitor cells	lipopolysaccharide (LPS) treatment	downregulated	30444938
6973	Human	hsa-miR-218	miRNA	Legionella pneumophila (L. pneumophila)	pneumonia	The human macrophage-like cell line U937	Legionella pneumophila infection	upregulated	30509489
6974	Human	hsa-miR-218	miRNA	hypoxia	preeclampsia (PE)	cell line HTR-8/Svneo;the trophoblast-derived choriocarcinoma cell line JEG-3	exposed to 0.5% O2	upregulated	28412444
6975	Human	hsa-miR-218	miRNA	hypoxia	renal cell carcinoma (RCC)	renal cell carcinoma cell lines	hypoxia treatment	downregulated	27133059
6976	Human	hsa-miR-218	miRNA	cisplatin (DDP)	small-cell lung cancer (SCLC)	NCI-H69 cells	cisplatin treatment	Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression	31477834
6977	Human	hsa-miR-218-2*	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
6978	Human	hsa-miR-218-5p	miRNA	IL-13	asthma	human bronchial epithelial (HBE) cells; BEAS-2B cells	IL-13 treatment	downregulated	31520422
6979	Human	hsa-miR-218-5p	miRNA	IL-13	asthma	HBE and BEAS-2B cells	interleukin 13 (IL-13) treatment	downregulated	31520422
6980	Human	hsa-miR-218-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
6981	Human	hsa-miR-218-5p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	plasma	cigarette smoke (CS) treatment	downregulated	30024625
6982	Human	hsa-miR-218-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cell (HPMECs)	cigarette smoke extract (CSE) treatment	downregulated	32129458
6983	Human	hsa-miR-218-5p	miRNA	KSHV-encoded viral interferon regulatory factor 1 (vIRF1)	kaposi's sarcoma (KS)	endothelial cell	KSHV-encoded viral interferon regulatory factor 1 (vIRF1) treatment	downregulated	30699189
6984	Human	hsa-miR-219	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
6985	Human	hsa-miR-219	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
6986	Human	hsa-miR-219	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	upregulated	32807750
6987	Human	hsa-miR-219-2-3p	miRNA	5-aza-2'-deoxycytidine and trichostatin A	gastric cancer (GC)	human GC cell lines MGC-803; HGC-27; MKN-45; SGC-7901	5-aza-2'-deoxycytidine and trichostatin A treatment	downregulated	23637748
6988	Human	hsa-miR-219-5p	miRNA	paraquat (PQ)	acute paraquat (PQ) poisoning	serum	paraquat (PQ) treatment	Serum miR-219-5p level was decreased and negatively correlated with TLR4 level in MODS patients.	33233960
6989	Human	hsa-miR-219-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial (RPE) cells	high glucose (HG) treatment	miR-219-5p was significantly upregulated by high glucose (HG) treatment.	29749515
6990	Human	hsa-miR-219-5p	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	Huh7 and SMMC7721 cells	Propofol treatment	upregulated	31104336
6991	Human	hsa-miR-219-5p	miRNA	AgNPs	toxicity of silver (Ag)	Jurkat T cells	AgNPs treatment	downregulated	24974767
6992	Human	hsa-miR-219-5p	miRNA	hypoxia	wound healing	HaCaTs	hypoxia treatment	MiR-219-5p was markedly increased in hypoxia group.	30338788
6993	Human	hsa-miR-21a-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
6994	Human	hsa-miR-22	miRNA	paclitaxel (PTX)	colorectal cancer (CRC)	HT-29 cells; HCT-15 cells	Paclitaxel treatment	over expression	21594648
6995	Human	hsa-miR-22	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
6996	Human	hsa-miR-22	miRNA	L©\arginine	acute edematous pancreatitis (AEP)	pancreatic acinar cell line (AR42J)	introperitoneal injection of L-arginine (150 mg/kg) treatment	upregulated	24710937
6997	Human	hsa-miR-22	miRNA	hypoxia	acute kidney injury (AKI)	Distal convoluted tubule cells (DCT)	hypoxia induce	upregulated	29791781
6998	Human	hsa-miR-22	miRNA	sodium butyrate (NaB)	apoptosis	Huh 7 cells	sodium butyrate treatment	upregulated	28288414
6999	Human	hsa-miR-22	miRNA	high glucose (HG)	atherosclerosis (AS)	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
7000	Human	hsa-miR-22	miRNA	myeloperoxidase oxidized LDL (Mox-LDL)	atherosclerosis (AS)	HUVEC Cells	Mox-LDL treatment	upregulated	25530680
7001	Human	hsa-miR-22	miRNA	lipopolysaccharide (LPS)	breast cancer	182R-6 fulvestrant-resistant breast cancer line	LPS treatment	downregulated	30057418
7002	Human	hsa-miR-22	miRNA	sc-514 (a selective IKK¦Â inhibitor)	breast cancer	LPS-treated 182R-6 fulvestrant-resistant breast cancer line	"sc-514, a selective IKK¦Â inhibitor treatment"	upregulated	30057418
7003	Human	hsa-miR-22	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	human bronchial epithelial cells 16HBE	"anti-benzo[a]pyrene-7,8-diol-9,10-epoxide treatment"	upregulated	20170724
7004	Human	hsa-miR-22	miRNA	high glucose (HG)	cell pyroptosis	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
7005	Human	hsa-miR-22	miRNA	salidroside (SAL)	cell senescence	50 population doubling (PD) of the 2BS cell line isolated from human fetal lung fibroblasts	salidroside (SAL) treatment	downregulated	31612074
7006	Human	hsa-miR-22	miRNA	ultraviolet (UV) irradiation	cellular stress response	Human embryonic kidney cell line HEK293T	UV radiation treatment	?UV radiation induces a significant increase of miR-22 expression	22166214
7007	Human	hsa-miR-22	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
7008	Human	hsa-miR-22	miRNA	phorbol-12-myristate-13-acetate(PMA)	chronic myeloid leukemia (CML)	CML cell line K562	20 nM PMA for 48 h in a 25 mm petri dish treatment	downregulated	27889568
7009	Human	hsa-miR-22	miRNA	phorbol-12-myristate-13-acetate(PMA)	chronic myeloid leukemia (CML)	CML cell line K562	CML cell line K562 treatment	upregulation	27889568
7010	Human	hsa-miR-22	miRNA	butyrate	colorectal cancer (CRC)	HCT116 and DLD-1 cells	butyrate treatment	upregulated	30252536
7011	Human	hsa-miR-22	miRNA	butyrate	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	butyrate treatment	upregulated	30252536
7012	Human	hsa-miR-22	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	human CRC cell line (HCT-8/5-FU)	PZH treatment	upregulated	29042944
7013	Human	hsa-miR-22	miRNA	propionate	colorectal cancer (CRC)	HCT116 and DLD-1 cells	propionate treatment	upregulated	30252536
7014	Human	hsa-miR-22	miRNA	propionate	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	propionate treatment	upregulated	30252536
7015	Human	hsa-miR-22	miRNA	retinoic acid (RA)	colorectal cancer (CRC)	HCT116 and DLD-1 cells	retinoic acid (RA) treatment	upregulated	30252536
7016	Human	hsa-miR-22	miRNA	retinoic acid (RA)	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	retinoic acid (RA) treatment	upregulated	30252536
7017	Human	hsa-miR-22	miRNA	SAHA	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	SAHA treatment	upregulated	30252536
7018	Human	hsa-miR-22	miRNA	suberoylanilide hydroxamic acid (SAHA)	colorectal cancer (CRC)	HCT116 and DLD-1 cells	suberanilohydroxamic acid (SAHA) treatment	upregulated	30252536
7019	Human	hsa-miR-22	miRNA	valerate	colorectal cancer (CRC)	HCT116 and DLD-1 cells	valerate treatment	upregulated	30252536
7020	Human	hsa-miR-22	miRNA	valerate	colorectal cancer (CRC)	human colon cancer HCT116 and DLD-1 cells	valerate treatment	upregulated	30252536
7021	Human	hsa-miR-22	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	serum	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) treatment"	We showed a significant modulation of serum miR-22 after R-CHOP treatment.	29716630
7022	Human	hsa-miR-22	miRNA	endosulfan	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	endosulfan	upregulated	28161397
7023	Human	hsa-miR-22	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
7024	Human	hsa-miR-22	miRNA	simulated microgravity (SMG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	simulated microgravity (SMG) treatment	upregulated	30017544
7025	Human	hsa-miR-22	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
7026	Human	hsa-miR-22	miRNA	diallyl disulfide (DADS)	gastric cancer (GC)	Five gastric cancer cell lines (MGC-803; BGC-823; MKN-28; SGC-7901; HGC-27; AGS)	diallyl disulfide treatment	upregulated	23851184
7027	Human	hsa-miR-22	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"BGC-823, AGS and THP-1 cells"	Helicobacter pylori (H. pylori) infection	downregulated	29059152
7028	Human	hsa-miR-22	miRNA	IL-1¦Â	gastric cancer (GC)	"BGC-823, AGS and THP-1 cells"	IL-1¦Â treatment	downregulated	29059152
7029	Human	hsa-miR-22	miRNA	mineral pitch (MP)	hepatocellular carcinoma (HCC)	Huh-7 cells	Mineral Pitch (MP) treatment	upregulated	27233240
7030	Human	hsa-miR-22	miRNA	lipopolysaccharide (LPS)	kidney damage	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	30130540
7031	Human	hsa-miR-22	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 leukemia cell line	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	20214878
7032	Human	hsa-miR-22	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	"miR-22 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM"	32656599
7033	Human	hsa-miR-22	miRNA	haloperidol	neuroblastoma (NB)	SK-N-SH cell lines	haloperidol at 10¦Ìm concentration for 24 hours	downregulated	28886082
7034	Human	hsa-miR-22	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
7035	Human	hsa-miR-22	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SK-N-SH cells	PFOS treatment	upregulated	28441774
7036	Human	hsa-miR-22	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	L02 cells	free fatty acids (FFAs) treatment	Free fatty acids induced miR-22 upregulation and lipogenesis in human hepatocytes.	33159388
7037	Human	hsa-miR-22	miRNA	pemetrexed	non-small cell lung cancer (NSCLC)	NSCLC tissue	pemetrexed treatment	upregulated	23794259
7038	Human	hsa-miR-22	miRNA	quercetin	oral lichen planus (OLP)	human oral keratinocytes (HOKs)	quercetin treatment	"Quercetin can mitigate LPS-induced injury in HOKs by downregulating miR-22, thereby activating PI3K/AKT and JAK1/STAT3 cascades"	32329368
7039	Human	hsa-miR-22	miRNA	arecoline	oral squamous cell carcinoma (OSCC)	ORL-48(T) and ORL-136(T) cell lines	arecoline treatment	downregulated	29385191
7040	Human	hsa-miR-22	miRNA	quercetin	oral squamous cell carcinoma (OSCC)	Human normal oral keratinocytes (hNOK) and OSCC cell line Tca8113 and SAS cells	Quercetin (Que) treatment	upregulated	31257059
7041	Human	hsa-miR-22	miRNA	IL-1	osteoarthritis (OA)	primary cultured chondrocytes	?IL-1 treatment	miR-22 downregulated in patients with OA	30887601
7042	Human	hsa-miR-22	miRNA	osteogenic inductive cocktail	osteogenesis	human periodontal ligament stem cells (PDLSCs)	osteogenic inductive cocktail	upregulated	28195408
7043	Human	hsa-miR-22	miRNA	cisplatin (DDP)	osteosarcoma (OS)	human osteosarcoma cell lines (U-2 OS and MG-63)	cisplatin (DDP) treatment	upregulated	24609901
7044	Human	hsa-miR-22	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	human osteosarcoma cell lines (U-2 OS and MG-63)	doxorubicin (DOX) treatment	upregulated	24609901
7045	Human	hsa-miR-22	miRNA	isoflurane	ovarian cancer (OC)	SKOV3 cells;TOV21G cells	isoflurane treatments at 1 and 2 h	upregulated	28951521
7046	Human	hsa-miR-22	miRNA	curcumin (Cur)	pancreatic cancer (PC)	The BxPC-3 human pancreatic carcinoma cell line	curcumin (diferuloylmethane)? treatment	upregulated	18347134
7047	Human	hsa-miR-22	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
7048	Human	hsa-miR-22	miRNA	Hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	downregulated	20110569
7049	Human	hsa-mir-22	miRNA	hypoxia/reoxygenation (H/R)	reperfusion injury	Human iPS-derived cardiomyocytes (iPS-CM)	hypoxia and hypoxia-reoxygenation treatment	upregulated	32826883
7050	Human	hsa-miR-22	miRNA	curcumin (Cur)	retinoblastoma (RB)	human Y79 retinoblastoma cells	curcumin (CUR) treatment	upregulated	22510010
7051	Human	hsa-miR-22	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	"TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway."	30666657
7052	Human	hsa-miR-22	miRNA	IL-21	systemic lupus erythematosus (SLE)	normal and SLE B cells	IL-21 treatment	upregulated	25101889
7053	Human	hsa-miR-22	miRNA	perfluorooctane sulfonic acid (PFOS)	toxicity of perfluorooctane sulfonate (PFOS)	SH-SY5Y human neuroblastoma cells	Perfluorooctane sulfonate (PFOS) treatment	upregulated	26649298
7054	Human	hsa-miR-22	miRNA	vitamin D	colorectal cancer (CRC)	Human colon cancer SW480-ADH£»HCT116£»HT29£» LS174T£»DLD-1£»SW620£» SW1417£» SW480-R cell lines	?vitamin D? treatment	upregulated	22328083
7055	Human	hsa-miR-22*	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
7056	Human	hsa-miR-221	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	HUVECs	human immunodeficiency virus-1 (HIV-1) infection	downregulated	23555914
7057	Human	hsa-miR-221	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
7058	Human	hsa-miR-221	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
7059	Human	hsa-miR-221	miRNA	metformin (Met)	angiogenesis	human endothelial progenitor cells (EPCs)	metformin treatment	downregulated	31581911
7060	Human	hsa-miR-221	miRNA	resveratrol	anti-inflammatory responses	HUVECs treated with TNF-¦Á	resveratrol (RS) treatment	upregulated	28338009
7061	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	anti-inflammatory responses	HUVECs	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28338009
7062	Human	hsa-miR-221	miRNA	TGF-¦Â	asthma	ASM cells (ASMCs) from patients with severe asthma	TGF-¦Â treatment	upregulated	23944957
7063	Human	hsa-miR-221	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29859752
7064	Human	hsa-miR-221	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31565033
7065	Human	hsa-miR-221	miRNA	hydroquinone (HQ)	benzene-induced carcinogenesis	hydroquinone (HQ)-transformed 16HBE cells secreted exosomes	Hydroquinone (HQ) treatment	upregulated	31468561
7066	Human	hsa-miR-221	miRNA	IFN-¦Ã	biliary inflammation	H69 cells	interferon-gamma treatment	downregulated	20110463
7067	Human	hsa-miR-221	miRNA	necrosis factor related apoptosis-inducing ligand (TRAIL)	bladder cancer	T24 cells; RT4 cells;SV-HUC-1 cells	necrosis factor related apoptosis-inducing ligand (TRAIL) treatment	upregulated	19767219
7068	Human	hsa-miR-221	miRNA	leptin	borna disease virus (BDV)?infection	human pre-adipocytes	leptin treatment	downregulated	23756832
7069	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	borna disease virus (BDV)?infection	human pre-adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	23756832
7070	Human	hsa-miR-221	miRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	upregulated	31899608
7071	Human	hsa-miR-221	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
7072	Human	hsa-miR-221	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
7073	Human	hsa-miR-221	miRNA	TGF-¦Â	breast cancer	MCF-7 cells	MCF-7 cells treatment	upregulation	27174021
7074	Human	hsa-miR-221	miRNA	wound fluids (WFs) from breast cancer patients	breast cancer	human epidermal growth factor receptor 2-positive breast cancer SK-BR-3 cell line	WFs treatment	upregulated	28943910
7075	Human	hsa-miR-221	miRNA	TGF-¦Â1	cancer-associated fibroblasts (CAFs) activation	cultured normal fibroblasts (NFs)	TGF¦Â1 treatment	upregulated	30851420
7076	Human	hsa-miR-221	miRNA	minocycline (MNC)	cell proliferation	PDGF-BB-treated human aortic smooth muscle cell (SMC)	Minocycline treatment	downregulated	30716386
7077	Human	hsa-miR-221	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (SMC)	platelet-derived growth factor BB homodimer (PDGF-BB) treatment	upregulated	30716386
7078	Human	hsa-miR-221	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	25019494
7079	Human	hsa-miR-221	miRNA	TGF-¦Â1	chronic kidney disease (CKD)	?renal tubule epithelial cells	TGF-¦Â1 treatment	downregulated	26806834
7080	Human	hsa-miR-221	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	CML cell lines (K562 and imatinib-resistant K562/G)	imatinib treatment	"MiR-221 expression was markedly decreased in K562/G cells and peripheral blood mononuclear cells from patients with treatment failure, when compared to imatinib-sensitive CML cells and patients with optimal responses respectively."	30516071
7081	Human	hsa-miR-221	miRNA	hepatitis C virus (HCV)	cognitive impairment	monocyte-derived exosome	hepatitis C virus (HCV) infection	upregulated	32157304
7082	Human	hsa-miR-221	miRNA	human immunodeficiency virus (HIV)-1	cognitive impairment	monocyte-derived exosome	human immunodeficiency virus (HIV)-1 infectiom	upregulated	32157304
7083	Human	hsa-miR-221	miRNA	temozolomide (TMZ)	colorectal cancer (CRC)	"U87MG cells;T98G cells; LN428 cells; LN308 cells; A172 cells; HEK-293 cells cells;LN229 cells;T98G, U87MG, and LN229 ,LN428 cells; LN308 cells; A172 cells"	temozolomide (TMZ) treatment	upregulated	24147153
7084	Human	hsa-miR-221	miRNA	microcystin-leucine arginine (MC-LR)	colorectal cancer (CRC)	colon cell line DLD-1	microcystin-LR (MC-LR) treatment	upregulated	30312888
7085	Human	hsa-miR-221	miRNA	microcystin-leucine arginine (MC-LR)	colorectal cancer (CRC)	colon cell line DLD-1	microcystin-LR (MC-LR) treatment	upregulated	30312888
7086	Human	hsa-miR-221	miRNA	AS1411	corneal neovascularization (CNV)	human limbus stroma (HLSC)	AS1411 treatment	AS1411 treatment also significantly reduced VEGF-stimulated induction of miR-21 and miR-221 in HLSC.	32081668
7087	Human	hsa-miR-221	miRNA	estradiol	depression	MCF7 cells	estradiol (E2) treatment	miR-221/222 expression is increased in antiestrogen-resistant breast cancer cell lines and is upregulated by fulvestrant in antiestrogen-sensitive MCF7 cells	21057537
7088	Human	hsa-miR-221	miRNA	diabetes mellitus macrophage-conditioned media (DM-MCM)	diabetes mellitus (DM)	HASMC	DM-MCM treatment	upregulated	25409512
7089	Human	hsa-miR-221	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
7090	Human	hsa-miR-221	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	miR-221 in EVs mediated proximal tubule cells injury through Wnt/¦Â-catenin signaling.	32926967
7091	Human	hsa-miR-221	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMEC)	high glucose (HG) treatment	High glucose (HG) treatment enhanced expression of miR-221.	32698791
7092	Human	hsa-miR-221	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	"ox-LDL-induced apoptotic human umbilical cord vein endothelial cells. MiR-221/222 inhibition enhanced apoptosis in ECs, whereas over-expression of miR-221/222 could partly alleviate apoptotic cell death mediated by ox-LDL through suppression of Ets-1 and its downstream target p21."	25893733
7093	Human	hsa-miR-221	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	19351599
7094	Human	hsa-miR-221	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
7095	Human	hsa-miR-221	miRNA	atorvastatin	endothelial dysfunction	Human umbilical vein endothelial cells (HUVEC)	atorvastatin treatment	downregulated	25517390
7096	Human	hsa-miR-221	miRNA	ezetimibe	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	exposed to ezetimibe (0 to 5.0 ¦ÌM) treatment	downregulated	25517390
7097	Human	hsa-miR-221	miRNA	simvastatin	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	exposed to simvastatin (0 to 5.0 ¦ÌM) treatment	downregulated	25517390
7098	Human	hsa-miR-221	miRNA	angiotensin II (Ang II)	endothelial inflammation and migration	human umbilical vein endothelial cells (HUVECs) ;vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	upregulated	21310411
7099	Human	hsa-miR-221	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	upregulated	27081844
7100	Human	hsa-miR-221	miRNA	propofol (PPF)	gastric cancer (GC)	gastric cancer cells	Propofol treatment	downregulated	26214494
7101	Human	hsa-miR-221	miRNA	radiation	glioblastoma multiforme (GBM)	glioablastoma cells	radiation treatment	upregulated	24295494
7102	Human	hsa-miR-221	miRNA	platelet-derived growth factor (PDGF)	glioblastoma multiforme (GBM)	pancreatic cancer cells	platelet-derived growth factor (PDGF)?treatment treatment	downregulated	23967190
7103	Human	hsa-miR-221	miRNA	si wei xiao xiu yin	glioblastoma multiforme (GBM)	U87 cells	Si wei xiao xiu yin treatment	downregulated	32448616
7104	Human	hsa-miR-221	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
7105	Human	hsa-miR-221	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	HCV patients	IFN/RBV for 12 months treatment	upregulated	24033414
7106	Human	hsa-miR-221	miRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	HepG2 cells	astragaloside IV (AS-IV) treatment	downregulated	28179291
7107	Human	hsa-miR-221	miRNA	curcumin (Cur)	hepatocellular carcinoma (HCC)	HepG2 cells	curcumin treatment	downregulated	28179291
7108	Human	hsa-miR-221	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	HepG2 and Hep3B cell lines	doxorubicin treatment	upregulated	24324033
7109	Human	hsa-miR-221	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	serum	hepatitis C virus (HCV) infection	upregulated	29333940
7110	Human	hsa-miR-221	miRNA	indole-3-carbinol (I3C)	hepatocellular carcinoma (HCC)	"human HCC cell lines, SK-Hep-1 and SNU-449"	I3C treatment	downregulated	25447674
7111	Human	hsa-miR-221	miRNA	myrothecine A	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell line SMMC-7721	Myrothecine A treatment	downregulated	31376622
7112	Human	hsa-miR-221	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
7113	Human	hsa-miR-221	miRNA	¦Á-pinene	hepatocellular carcinoma (HCC)	HepG2 cells	¦Á-pinene treatment	¦Á-pinene treatment led to miR-221 and CDK1 downregulated.	30473536
7114	Human	hsa-miR-221	miRNA	hepatitis E virus (HEV)	hepatitis	HEK 293 cells(human embryonic kidney 293 cell line)	Hepatitis E virus (HEV)? infection	downregulated	23579640
7115	Human	hsa-miR-221	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	Neural Precursor Cells (NPCs)	Human cytomegalovirus (HCMV) infection	upregulated	31550968
7116	Human	hsa-miR-221	miRNA	"13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3)"	pancreatic ductal adenocarcinoma (PDAC)	pancreatic ductal adenocarcinoma (PDAC) cells	"13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3) treatment"	"Moreover, treatment of SP600125 (a specific inhibitor of JNK pathway) or cotreatment of 13-cis RA and 1,25-VD3 significantly induced a decreased expression of miR-221 and an increased expression of TIMP-3 protein."	33730072
7117	Human	hsa-miR-221	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
7118	Human	hsa-miR-221	miRNA	cryptosporidium parvum	IgA nephropathy (IgAN)	biliary epithelial cells	cryptosporidium parvum? infection	downregulated	21236259
7119	Human	hsa-miR-221	miRNA	extracts from wild bitter gourd fruit (WBGE)	inflammation	TNF-¦Á-treated alveolar epithelial (A549) cells	extracts from wild bitter gourd fruit (WBGE) treatment	upregulated	29655703
7120	Human	hsa-miR-221	miRNA	lipopolysaccharide (LPS)	inflammation	WI-38 lung fibroblasts	lipopolysaccharide (LPS) treatment	upregulated	30849307
7121	Human	hsa-miR-221	miRNA	quercetin	inflammation	LPS-induced WI-38 lung fibroblasts	quercetin treatment	downregulated	30849307
7122	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVEC)	TNF¦Á treatment	upregulated	29666964
7123	Human	hsa-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	alveolar epithelial (A549) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29655703
7124	Human	hsa-miR-221	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
7125	Human	hsa-miR-221	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
7126	Human	hsa-miR-221	miRNA	eicosapentaenoic acid (EPA)	ischemic injury	human endothelial progenitor cells	EPA treatment	downregulated	24927915
7127	Human	hsa-miR-221	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
7128	Human	hsa-miR-221	miRNA	emodin	leukemia	K562 cells	Emodin treatment	downregulated	23744534
7129	Human	hsa-miR-221	miRNA	xenotropic murine leukemia virus-related retrovirus (XMRV)	leukemia	LNCaPcells; DU145 cells	Xenotropic murine leukemia virus-related retrovirus (XMRV) infection treatment	upregulated of miR-221 and miR-222 expression	21932423
7130	Human	hsa-miR-221	miRNA	gemcitabine (GEM)	hepatocellular carcinoma (HCC)	HuCCT1 cells; HuH28 cells	Gemcitabine treatment	upregulated	24147037
7131	Human	hsa-miR-221	miRNA	microcystin-leucine arginine (MC-LR)	hepatocellular carcinoma (HCC)	WRL-69 cells	microcystin-LR treatment	upregulated	22265967
7132	Human	hsa-miR-221	miRNA	hyperoxia	lung injury	human epithelial cells	human epithelial cells treatment	upregulation in derived microvesicles (MVs)	27731391
7133	Human	hsa-miR-221	miRNA	resveratrol	melanoma	melanoma cell lines (A375 and MV3)	resveratrol (Res) treatment	downregulated	28936555
7134	Human	hsa-miR-221	miRNA	dexamethasone (DEX)	multiple myeloma (MM)	"Human MM cell lines MM.1S, MM.1R, RPMI-8226, U266, NCIH929, and ARH-77"	dexamethasone (DEX) treatment	downregulated	30765325
7135	Human	hsa-miR-221	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human cardiomyocytes (HCM) cells	hypoxia/reoxygenation (H/R) induce	upregulated	31115025
7136	Human	hsa-miR-221	miRNA	organosulfur garlic compounds	neovasculogenesis	Human endothelial progenitor cells (EPCs)	Organosulfur garlic compounds treatment	downregulated	23663050
7137	Human	hsa-miR-221	miRNA	chemoradiation therapy (CRT)	non-small cell lung cancer (NSCLC)	patients with stage IIIB-IV NSCLC	CRT treatment	upregulated	25466375
7138	Human	hsa-miR-221	miRNA	palmitic acid (PA)	obesity	HepG2 cells	palmitic acid (PA) treatment	upregulated	31828133
7139	Human	hsa-miR-221	miRNA	adriamycin (ADR)	oral squamous cell carcinoma (OSCC)	Tca8113 and UM2 cells	adriamycin (ADR) treatment	upregulated	26796268
7140	Human	hsa-miR-221	miRNA	doxorubicin (DOX)	oral squamous cell carcinoma (OSCC)	SCC4 and SCC9 cells	doxorubicin treatment	upregulated	28677788
7141	Human	hsa-miR-221	miRNA	ginsenoside Rg3	oral squamous cell carcinoma (OSCC)	human OSCC SCC-9 and HSC-5?cells	Ginsenoside Rg3 treatment	downregulated	30928631
7142	Human	hsa-miR-221	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
7143	Human	hsa-miR-221	miRNA	lapatinib and 5-fluorouracil (5-Fu)	pancreatic cancer (PC)	PANC-1 and MIA PaCa-2 cells	lapatinib and 5-FU treatment	upregulated	26998056
7144	Human	hsa-miR-221	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer PANC-1 cells	metformin treatment	downregulated	25955843
7145	Human	hsa-miR-221	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
7146	Human	hsa-miR-221	miRNA	ovalbumin (OVA)	pediatric asthma	Lymphocytes	ovalbumin (OVA) treatment	Upregulated	22895815
7147	Human	hsa-miR-221	miRNA	"androgen receptor (AR) agonist, CI-4AS-1"	prostate cancer	prostate cancer cell line	AR agonists treatment	downregulated	25846647
7148	Human	hsa-miR-221	miRNA	IFN-¦Á	renal fibrosis	glioblastoma U251 cells	IFN-¦Á	downregulated	20428775
7149	Human	hsa-miR-221	miRNA	hydroxyurea	sickle cell disease (SCD)	human umbilical vein endothelial cell (HUVEC)	hydroxyurea treatment	dysregulated	24925859
7150	Human	hsa-miR-221	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN and SY-SH-5Y neuronal cell lines	oxygen-glucose deprivation (OGD) treatment	downregulated	29596155
7151	Human	hsa-miR-221	miRNA	Buyang Huanwu decoction (BYHWD)	stroke	mesenchymal stem cell (MSC)	Buyang Huanwu decoction (BYHWD) treatment	downregulated	25796380
7152	Human	hsa-miR-221	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	upregulated	24396484
7153	Human	hsa-miR-221	miRNA	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG)	triple negative breast cancer (TNBC)	MDA-MB-157 and HCC1806 cells	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) dual treatment	downregulated	30591655
7154	Human	hsa-miR-221	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
7155	Human	hsa-miR-221-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL significantly inhibited the expression of miR-221-3p.	32401923
7156	Human	hsa-miR-221-3p	miRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	upregulated	32160712
7157	Human	hsa-miR-221-3p	miRNA	paroxetine	depression	serum	paroxetine treatment	downregulated	29791588
7158	Human	hsa-miR-221-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
7159	Human	hsa-miR-221-3p	miRNA	conditioned media (CM)	metabolic disease	human adipocytes	conditioned medium of lipopolysaccharide-stimulated macrophages	upregulated	28938482
7160	Human	hsa-miR-221-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-2¦Â treatment	downregulated	28236026
7161	Human	hsa-miR-221-5p	miRNA	P. longifolia leaf extract	apoptosis 	HeLa cells	P. longifolia leaf extract treatment	downregulated	32850286
7162	Human	hsa-miR-221-5p	miRNA	polyalthia longifolia	apoptosis 	HeLa cells	Polyalthia longifolia treatment	downregulated miR-221-5p was involved in regulating apoptosis in HeLa cancer cells	32110879
7163	Human	hsa-miR-221-5p	miRNA	polyalthia longifolia leaf extract	cell death	HeLa cells	Polyalthia longifolia leaf extract treatment	downregulated	31383043
7164	Human	hsa-miR-221-5p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
7165	Human	hsa-miR-222	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	HUVECs	human immunodeficiency virus-1 (HIV-1) infection	downregulated	23555914
7166	Human	hsa-miR-222	miRNA	neoadjuvant multimodality ment	adenocarcinomas	serum	received neoadjuvant therapy and subsequently underwent surgical resection treatment	upregulation	25429911
7167	Human	hsa-miR-222	miRNA	particulate matter (PM2.5)	air pollution-induced placental epigenetic alterations	placental tissue	Particulate matter (PM2.5) exposure treatment	miR-222 was inversely associated with PM25 exposure during the 2nd trimester of pregnancy	27104955
7168	Human	hsa-miR-222	miRNA	curcumin (Cur)	anaplastic thyroid carcinoma (ATC)	SW1736 and 8505C	curcumin treatment	downregulated	29197967
7169	Human	hsa-miR-222	miRNA	resveratrol	anti-inflammatory responses	HUVECs treated with TNF-¦Á	resveratrol (RS) treatment	upregulated	28338009
7170	Human	hsa-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	anti-inflammatory responses	HUVECs	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28338009
7171	Human	hsa-miR-222	miRNA	asbestos	asbestos toxicity	BEAS-2B cells	asbestos exposure	upregulated	32006662
7172	Human	hsa-miR-222	miRNA	asbestos	asbestos-related malignancies	serum	asbestos treatment	upregulated	30257964
7173	Human	hsa-miR-222	miRNA	TGF-¦Â	asthma	ASM cells (ASMCs) from patients with severe asthma	TGF-¦Â treatment	upregulated	23944957
7174	Human	hsa-miR-222	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
7175	Human	hsa-miR-222	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cancer cells	doxorubicin (DOX) treatment	upregulated	31273056
7176	Human	hsa-miR-222	miRNA	ionizing radiation (IR)	breast cancer	Blood	The radiation scheduled could be normofractionated RT (50 Gy at 2 Gy/day on the affected breast and 16 Gy at 2 Gy/day on the tumour bed for 5 days/week) or hypofractionated RT (40 Gy at 2.67 Gy/day for 5 days/week). The dose rate of all schedules was 4.5 Gy/min (400 MU/min)	upregulated	31150454
7177	Human	hsa-miR-222	miRNA	helicobacter pylori (H. pylori)	tumorigenesis	Human gastric cancer cell line A	Helicobacter pylori (H. pylori) infection	upregulated	22321642
7178	Human	hsa-miR-222	miRNA	inorganic arsenic (iAs)	tumorigenesis	human Jurkat leukemic T cell	"Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment"	upregulated	24317173
7179	Human	hsa-miR-222	miRNA	minocycline (MNC)	cell proliferation	PDGF-BB-treated human aortic smooth muscle cell (SMC)	Minocycline treatment	downregulated	30716386
7180	Human	hsa-miR-222	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (SMC)	platelet-derived growth factor BB homodimer (PDGF-BB) treatment	upregulated	30716386
7181	Human	hsa-miR-222	miRNA	HDL isolated from CHF patients in NYHA-IIIb (HDLNYHA)	chronic heart failure (CHF)	human aortic endothelial cells	HDLNYHA treatment	downregulated	24958738
7182	Human	hsa-miR-222	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	p53-mutant MEG-01 cells	fludarabine treatment	specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets	20504344
7183	Human	hsa-miR-222	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
7184	Human	hsa-miR-222	miRNA	temozolomide (TMZ)	colorectal cancer (CRC)	"U87MG cells;T98G cells; LN428 cells; LN308 cells; A172 cells; HEK-293 cells cells;LN229 cells;T98G, U87MG, and LN229 ,LN428 cells; LN308 cells; A172 cells"	temozolomide (TMZ) treatment	upregulated	24147153
7185	Human	hsa-miR-222	miRNA	estradiol	depression	MCF7 cells	estradiol (E2) treatment	miR-221/222 expression is increased in antiestrogen-resistant breast cancer cell lines and is upregulated by fulvestrant in antiestrogen-sensitive MCF7 cells	21057537
7186	Human	hsa-miR-222	miRNA	mammosphere culture	epithelial-mesenchymal transition (EMT)	MCF-7 cells	mammosphere culture treatment	"suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221"	21553120
7187	Human	hsa-miR-222	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	"ox-LDL-induced apoptotic human umbilical cord vein endothelial cells. MiR-221/222 inhibition enhanced apoptosis in ECs, whereas over-expression of miR-221/222 could partly alleviate apoptotic cell death mediated by ox-LDL through suppression of Ets-1 and its downstream target p21."	25893733
7188	Human	hsa-miR-222	miRNA	ionizing radiation (IR)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	Human umbilical vein endothelial cells (HUVECs) were exposed to 2 Gy RT	"2 Gy significantly increased the expression of miRNA-221 and miRNA-222, and reduced the level of miRNA-155 after 2 h; whereas miRNA-146a and miRNA-155 were significantly overexpressed and miRNA-222 was significantly downregulated at 24 h."	30711956
7189	Human	hsa-miR-222	miRNA	atorvastatin	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	exposed to atorvastatin (0 to 5.0 ¦ÌM) treatment	downregulated	25517390
7190	Human	hsa-miR-222	miRNA	streptozocin (STZ)	gestational diabetes mellitus (GDM)	placenta tissues	streptozocin treatment	MiR-222 was increased while CXCR4 was decreased in GDM patients and mice	33278386
7191	Human	hsa-miR-222	miRNA	radiation	glioblastoma multiforme (GBM)	glioablastoma cells	radiation treatment	upregulated	24295494
7192	Human	hsa-miR-222	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
7193	Human	hsa-miR-222	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2 cells £¬ HepG2.2.15 cells.	hepatitis B virus X protein (HBx) treatment	downregulated	25260533
7194	Human	hsa-miR-222	miRNA	indole-3-carbinol (I3C)	hepatocellular carcinoma (HCC)	"human HCC cell lines, SK-Hep-1 and SNU-449"	I3C treatment	downregulated	25447674
7195	Human	hsa-miR-222	miRNA	hepatitis E virus (HEV)	hepatitis	HEK 293 cells(human embryonic kidney 293 cell line)	Hepatitis E virus (HEV)? infection	downregulated	23579640
7196	Human	hsa-miR-222	miRNA	extracts from wild bitter gourd fruit (WBGE)	inflammation	TNF-¦Á-treated alveolar epithelial (A549) cells	extracts from wild bitter gourd fruit (WBGE) treatment	upregulated	29655703
7197	Human	hsa-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human umbilical vein endothelial cells (HUVEC)	TNF¦Á treatment	upregulated	29666964
7198	Human	hsa-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	alveolar epithelial (A549) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29655703
7199	Human	hsa-miR-222	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human intervertebral disc nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	upregulated	31432092
7200	Human	hsa-miR-222	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
7201	Human	hsa-miR-222	miRNA	emodin	leukemia	K562 cells	Emodin treatment	downregulated	23744534
7202	Human	hsa-miR-222	miRNA	xenotropic murine leukemia virus-related retrovirus (XMRV)	leukemia	LNCaP cells; DU145 cells	Xenotropic murine leukemia virus-related retrovirus (XMRV) infection treatment	upregulated of miR-221 and miR-222 expression	21932423
7203	Human	hsa-miR-222	miRNA	metformin (Met)	medulloblastoma	lung cancer cells	Metformin? treatment	downregulated	23974492
7204	Human	hsa-miR-222	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
7205	Human	hsa-miR-222	miRNA	IL-4	monocytic differentiation	monocyte	IL-4 treatment	dysregulated	25148686
7206	Human	hsa-miR-222	miRNA	dexamethasone (DEX)	multiple myeloma (MM)	"Human MM cell lines MM.1S, MM.1R, RPMI-8226, U266, NCIH929, and ARH-77"	dexamethasone (DEX) treatment	downregulated	30765325
7207	Human	hsa-miR-222	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
7208	Human	hsa-miR-222	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	palmitic acid (PA) treatment	downregulated	32143184
7209	Human	hsa-miR-222	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
7210	Human	hsa-miR-222	miRNA	ozone (O3)	air pollution	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
7211	Human	hsa-miR-222	miRNA	epidermal growth factor (EGF)	oral carcinogenesis	"HSC-3£¬OECM-1,SAS£¬NOK"	EGF treatment	upregulated	25229239
7212	Human	hsa-miR-222	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx10 treatment"	downregulated	21572246
7213	Human	hsa-miR-222	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
7214	Human	hsa-miR-222	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
7215	Human	hsa-miR-222	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
7216	Human	hsa-miR-222	miRNA	adenovirus (ADV)	prostate cancer	human prostate Cancer Cells	adenovirus treatment	downregulated	28114818
7217	Human	hsa-miR-222	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
7218	Human	hsa-miR-222	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	CASC2 attenuated hypoxia-induced PASMC proliferation and migration by regulating the miR-222/ING5 axis to prevent vascular remodeling and the development of PAH.	32206065
7219	Human	hsa-miR-222	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
7220	Human	hsa-miR-222	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
7221	Human	hsa-miR-222	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
7222	Human	hsa-miR-222	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
7223	Human	hsa-miR-222	miRNA	hydroxyurea	sickle cell disease (SCD)	human umbilical vein endothelial cell (HUVEC)	hydroxyurea treatment	dysregulated	24925859
7224	Human	hsa-miR-222	miRNA	Buyang Huanwu decoction (BYHWD)	stroke	mesenchymal stem cell (MSC)	Buyang Huanwu decoction (BYHWD) treatment	downregulated	25796380
7225	Human	hsa-miR-222	miRNA	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG)	triple negative breast cancer (TNBC)	MDA-MB-157 and HCC1806 cells	Suberoylanilide hydroxamic acid (SAHA)/epigallocatechin-3-gallate (EGCG) dual treatment	downregulated	30591655
7226	Human	hsa-miR-222	miRNA	arsenite	arsenite-induced carcinogenesis	human lung epithelial BEAS-2B cells	arsenic (As) exposure	upregulated	26909602
7227	Human	hsa-miR-222	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	The human renal epithelial cells (295T cells)	metformin treatment	differently regulated in circulating	24478399
7228	Human	hsa-miR-222*	miRNA	arsenic trioxide (ATO)	bladder cancer	T24 human bladder carcinoma cells	arsenic trioxide?treatment	upregulated	20857258
7229	Human	hsa-miR-222-3p	miRNA	H2O2	age-related cataract (ARC)	human lens epithelial B3 (HLE-B3) cells	H2O2 treatment	upregulated	33851769
7230	Human	hsa-miR-222-3p	miRNA	dexamethasone (DEX)	airway epithelial injury	9HTE cells	dexamethasone (Dex) treatment	downregulated	32202184
7231	Human	hsa-miR-222-3p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	upregulated	28749179
7232	Human	hsa-miR-222-3p	miRNA	doxorubicin (DOX)	colorectal cancer (CRC)	LoVo cells	Doxorubicin (DOX) treatment	miR-222-3p was upregulated in LoVo/ADR compared with the expression in LoVo/S cells.	30904920
7233	Human	hsa-miR-222-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells	high glucose (HG) treatment	Real-time PCR was performed to detect the relative NEAT1 and miR-222-3p expressions and further confirmed the relationship between NEAT1 and miR-222-3p.	33585566
7234	Human	hsa-miR-222-3p	miRNA	high glucose (HG)	endometrial cancer (EC)	"Human endometrial carcinoma cell lines (HEC1-B, HEC1-A and Ishikawa)"	high glucose (HG) treatment	upregulated	31105847
7235	Human	hsa-miR-222-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	Gastric cancer tissues and cells	Helicobacter pylori (H. pylori)?infection	upregulated	29227536
7236	Human	hsa-miR-222-3p	miRNA	cigarette smoke (CS)	lung cancer	NCI-H292 cells	cigarette smoke (CS) treatment	"upregulated(miR-155-5p,miR-196a-5p,miR-222-3p); downregulated(miR-21-5p)"	28692419
7237	Human	hsa-miR-222-3p	miRNA	osteogenic differentiation medium	osteogenesis	Adipose-derived mesenchymal stem cells (ADSCs)	osteogenic differentiation media induce	downregulated	30511267
7238	Human	hsa-miR-222-3p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
7239	Human	hsa-miR-222-3p	miRNA	CoCl2	spinal cord injury (SCI)	AGE1.HN cells	?CoCl2 treatment	upregulated	33770577
7240	Human	hsa-miR-222-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	downregulated	28046107
7241	Human	hsa-miR-223	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
7242	Human	hsa-miR-223	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	human T-ALL cell	Glucocorticoids (GCs) treatment	downregulated	19148136
7243	Human	hsa-miR-223	miRNA	H2O2	age-related cataract (ARC)	SRA01/04 cells	H2O2 treatment	MEG3 promoted ARC progression by up-regulating TP53INP1 expression through suppressing miR-223 and promoting P53 expression.	32841649
7244	Human	hsa-miR-223	miRNA	baicalin (BAI)	age-related macular degeneration (AMD)	ARPE-19 cells	baicalin (BAI) treatment	Baicalin significantly induced upregulation of miR-223.	31578016
7245	Human	hsa-miR-223	miRNA	baicalin (BAI)	age-related macular degeneration (AMD)	A¦Â-envoked ARPE-19 cells	baicalin (BAI) treatment	upregulated	31578016
7246	Human	hsa-miR-223	miRNA	melatonin	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	melatonin treatment	upregulated	29024030
7247	Human	hsa-miR-223	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29024030
7248	Human	hsa-miR-223	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	33373321
7249	Human	hsa-miR-223	miRNA	arachidonic acid (AA)	breast cancer	platelet microvesicle (MV)	arachidonic acid (AA) treatment	upregulated	31665654
7250	Human	hsa-miR-223	miRNA	IL-4	breast cancer	CD4+ T cells;breast cancer cells	interleukin-4 (IL-4) treatment	upregulated	21939504
7251	Human	hsa-miR-223	miRNA	celastrol	breast cancer	human breast cancer cell line MCF-7 and prostate cancer PC3	celastrol treatment	upregulated	26552919
7252	Human	hsa-miR-223	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	NCI-H292 cells	cigarette smoke extract (CSE) treatment	downregulated	30695677
7253	Human	hsa-miR-223	miRNA	hepatitis C virus (HCV)	cognitive impairment	monocyte-derived exosome	hepatitis C virus (HCV) infection	upregulated	32157304
7254	Human	hsa-miR-223	miRNA	human immunodeficiency virus (HIV)-1	cognitive impairment	monocyte-derived exosome	human immunodeficiency virus (HIV)-1 infectiom	upregulated	32157304
7255	Human	hsa-miR-223	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	downregulated	31744065
7256	Human	hsa-miR-223	miRNA	clopidogrel	coronary artery disease (CAD)	patients with coronary artery disease (CAD)	clopidogrel treatment	upregulated	25350775
7257	Human	hsa-miR-223	miRNA	prasugrel/ticagrelor	coronary artery disease (CAD)	patients with coronary artery disease (CAD)	prasugrel/ticagrelor treatment	upregulated	25350775
7258	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	crohn disease (CD)	HT-29 colonic epithelial cell line	lipopolysaccharide (LPS) treatment	downregulated	30299179
7259	Human	hsa-miR-223	miRNA	high protein diet	diet-induced weight loss	human HDL constituents	high protein diet treatment	downregulated	26962854
7260	Human	hsa-miR-223	miRNA	acrolein	environmental pollutants	human umbilical vein endothelial cells	acrolein treatment	upregulated	24812010
7261	Human	hsa-miR-223	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
7262	Human	hsa-miR-223	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
7263	Human	hsa-miR-223	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 and U118 cells	TMZ treatment	upregulated	28035389
7264	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	liver fibrosis	Human HSC line LX2 cells	lipopolysaccharide (LPS) treatment	downregulated	31719209
7265	Human	hsa-miR-223	miRNA	TGF-¦Â	liver fibrosis	Human HSC line LX2 cells	TGF-¦Â treatment	downregulated	31719209
7266	Human	hsa-miR-223	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	"Human HCC cell lines (HepG2, Huh7, SNU387, and SNU449)"	doxorubicin treatment	downregulated	31695022
7267	Human	hsa-miR-223	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
7268	Human	hsa-miR-223	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Huh7, SNU387 and SNU449 cells"	sorafenib treatment	upregulated	30535501
7269	Human	hsa-miR-223	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
7270	Human	hsa-miR-223	miRNA	fibroblast growth factor (FGF) and the insulin-like growth factor receptor (IGF-1R)	human embryonic stem cell differentiation	human embryonic stem cells (hESCs)	fibroblast growth factor (FGF) and the insulin-like growth factor receptor (IGF-1R)? treatment	upregulated	24250812
7271	Human	hsa-miR-223	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6A	dysregulated	29163428
7272	Human	hsa-miR-223	miRNA	human herpesvirus 6B (HHV-6B)	human herpesvirus 6A (HHV-6A) infection	human NK cell line (NK-92)	infected with HHV-6B	dysregulated	29163428
7273	Human	hsa-miR-223	miRNA	medium prepared with pIgA from patients with glomerular endothelial proliferation	IgA nephropathy (IgAN)	glomerular endothelial cells (GEnCs)	incubate with the medium prepar pIgA from patients with glomerular endothelial proliferation treatment	downregulated	24284509
7274	Human	hsa-miR-223	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Colon mucosa	dextran sulfate sodium treatment	upregulated	26878986
7275	Human	hsa-miR-223	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	BEAS-2B cells; serum	Influenza A virus (IAV) infection	downregulated	33278394
7276	Human	hsa-miR-223	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
7277	Human	hsa-miR-223	miRNA	celastrol	insulin resistance (IR)	palmitic acid (PA) treated HepG2 cells	celastrol treatment	upregulated	30287053
7278	Human	hsa-miR-223	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
7279	Human	hsa-miR-223	miRNA	palmitic acid (PA)	insulin resistance (IR)	HepG2 cells	palmitic acid (PA) treatment	downregulated	30287053
7280	Human	hsa-miR-223	miRNA	"ferrylhemoglobin (ferrylHb, Fe4+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"ferrylhemoglobin (ferrylHb, Fe4+) treatment"	upregulated	32961661
7281	Human	hsa-miR-223	miRNA	heme	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	heme treatment	upregulated	32961661
7282	Human	hsa-miR-223	miRNA	"methemoglobin (metHb, Fe3+)"	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	"methemoglobin (metHb, Fe3+) treatment"	upregulated	32961661
7283	Human	hsa-miR-223	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intraventricular hemorrhage (IVH)	human choroid plexus epithelial cell (HCPEpiC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32961661
7284	Human	hsa-miR-223	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
7285	Human	hsa-miR-223	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
7286	Human	hsa-miR-223	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
7287	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	HK2 cells	lipopolysaccharide (LPS) treatment	LPS treatment significantly enhanced the ex- pression of miR-223 in HK-2 cells.	29800915
7288	Human	hsa-miR-223	miRNA	mycobacterium tuberculosis (Mtb)	macrophage apoptosis	Human macrophages	Mycobacterium tuberculosis (Mtb) treatment	upregulated	26505221
7289	Human	hsa-miR-223	miRNA	estrogen (ES)	estrogen-mediated immune regulation	Splenic lymphocytes	Estrogen treatment	upregulated	18791161
7290	Human	hsa-miR-223	miRNA	inorganic phosphate (Pi)	migration of vascular smooth muscle cells	human aortic vascular smooth muscle cells (VSMCs)	inorganic phosphate (Pi) treatment	upregulated	23094093
7291	Human	hsa-miR-223	miRNA	radiation	nasopharyngeal carcinoma (NPC)	NP460; CNE2; CNE2R cells	radiation treatment	"MINCR diminished NPC cell radiosensitivity by sponging miR-223, increasing ZEB1 and activating the AKT/PI3K axis"	33290841
7292	Human	hsa-miR-223	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"The human NLCLC cell lines, A549, NCI-H460, NCI-H1299 and NCI-H358"	cisplatin (DPP) treatment	downregulated	30431074
7293	Human	hsa-miR-223	miRNA	clopidogrel	non-ST elevation acute coronary syndrome (NSTE-ACS)	patients with coronary heart disease	300 mg (for at least 24 h) or 75 mg clopidogel (for at least 5 days) plus aspirin treatment	downregulated	24202700
7294	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human ATDC5 cells	lipopolysaccharide (LPS) treatment	miR-223 expression was downregulated by lncRNA-ATB and miR-223 overexpression declined the protective effect of lncRNA-ATB on LPS-injured ATDC5 cells.	30771739
7295	Human	hsa-miR-223	miRNA	mud-bath therapy (MBT)	osteoarthritis (OA)	patients with bilateral knee osteoarthritis (OA)	"daily treated with a combination of local mud-packs at 42 ¡ãC and baths in mineral water, at 37 ¡ãC for 15 min, for 12 applications over a period of 2 weeks"	downregulated	28785809
7296	Human	hsa-miR-223	miRNA	cisplatin (DDP)	pancreatic cancer (PC)	BXPC3 cells	cisplatin treatment	upregulated	31599414
7297	Human	hsa-miR-223	miRNA	genistein	pancreatic cancer (PC)	pancreatic cancer cells	Genistein? treatment	downregulated	23834147
7298	Human	hsa-miR-223	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
7299	Human	hsa-miR-223	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
7300	Human	hsa-miR-223	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
7301	Human	hsa-miR-223	miRNA	mechanical stretch	cell proliferation	vascular smooth muscle cells (VSMCs)	mechanical stretch-stimulated treatment	downregulated	23046980
7302	Human	hsa-miR-223	miRNA	methotrexate (MTX)	psoriasis	chronic plaque-type psoriasis patients PBMCs	methotrexate (MTX) treatment	downregulated in plasma	27535005
7303	Human	hsa-miR-223	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	CircATP2B4 potentiated hypoxia-induced proliferation and migration of PASMCs through the miR-223/ATR axis.	32926932
7304	Human	hsa-miR-223	miRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp fibroblasts (HDPFs)	lipopolysaccharide (LPS) treatment	downregulated	32966618
7305	Human	hsa-miR-223	miRNA	IL-6	traumatic brain injury (TBI)	Glomerular endothelial cells (GEnCs)	IL-6 treatment	downregulated	24284509
7306	Human	hsa-miR-223	miRNA	ellagic acid (EA)	type 2 diabetes mellitus (T2DM)	high glucose-exposed HepG2 cells	ellagic acid (EA) treatment	upregulated	30466006
7307	Human	hsa-miR-223	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	HepG2 cells	high glucose (HG) treatment	downregulated	30466006
7308	Human	hsa-miR-223	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	HepG2 cells	high glucose treatment	downregulated	30466006
7309	Human	hsa-miR-223	miRNA	ellagic acid (EA)	type 2 diabetes mellitus (T2DM)	HepG2 cells	Ellagic acid (EA) treatment	upregulated	30466006
7310	Human	hsa-miR-223	miRNA	clopidogrel	colorectal cancer (CRC)	purified platelets	clopidogrel treatment	downregulated	23498169
7311	Human	hsa-miR-223	miRNA	Marek's disease virus (MDV)	diabetes mellitus (DM)	seven independentCD4+T-lymphoma cell line	Marek's disease virus (MDV) treatment	downregulated	19297609
7312	Human	hsa-miR-223*	miRNA	clopidogrel	platelet inhibition	serum	clopidogrel treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
7313	Human	hsa-miR-223*	miRNA	ticagrelor	platelet inhibition	serum	ticagrelor treatment	"Endotoxin administration in volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 h after endotoxin administration volunteers markedly reduced levels of leukocyte-enriched miR-150 at 6 hours after endotoxin (6 h), while platelet-enriched miR-197, miR-223 and miR-223* showed an increase."	32326325
7314	Human	hsa-miR-223-3p	miRNA	colchicine	acute gouty arthritis (AGA)	plasma	colchicine treatment	Comparison of differences between pre- and 5-day post-treatment values confirmed that the upregulation of miR-223-3p and downregulated of IL-1¦Â induced by colchicine were more significant than etoricoxib.	31360199
7315	Human	hsa-miR-223-3p	miRNA	colchicine	acute gouty arthritis (AGA)	plasma	Colchicine treatment	"Colchicine could upregulate miR-223-3p and downregulate IL-1¦Â in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2."	31360199
7316	Human	hsa-miR-223-3p	miRNA	etoricoxib	acute gouty arthritis (AGA)	plasma	etoricoxib treatment	"Colchicine could upregulate miR-223-3p and downregulate IL-1¦Â in the plasma, while etoricoxib may treat AGA by upregulating miR-451a and downregulating COX-2."	31360199
7317	Human	hsa-miR-223-3p	miRNA	baicalin (BAI)	acute kidney injury (AKI)	HK-2 cells	baicalin (BAI) treatment	Baicalin attenuates lipopolysaccharide-induced renal tubular epithelial cell injury by inhibiting the TXNIP/NLRP3 signalling pathway via increasing miR-223-3p expression	32392921
7318	Human	hsa-mir-223-3p	miRNA	high-density lipoproteins (HDL)	atherosclerosis (AS)	Polymorphonuclear neutrophils (PMNs) and human monocyte derived macrophages (HMDMs)	high-density lipoproteins (HDL) treatment	upregulated	31096070
7319	Human	hsa-miR-223-3p	miRNA	ginkgolide B (GB)	bladder cancer	bladder cancer cells	Ginkgolide B (GB) treatment	downregulated	27744452
7320	Human	hsa-miR-223-3p	miRNA	H2O2	cataract	human lens epithelial cells (SRA01/04)	H2O2 treatment	downregulated	33744257
7321	Human	hsa-miR-223-3p	miRNA	p-cresol (PcEMV)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	p-cresol (PcEMV) treatment	upregulated	32606426
7322	Human	hsa-miR-223-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells; BGC823C cells	cisplatin treatment	miR-223-3p was higher in cisplatin-resistant GC (CR-GC) cells than their parental cisplatin-sensitive GC (CS-GC) cells.	32516127
7323	Human	hsa-miR-223-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"AGS, BGC-823 and SGC-7901 cells"	Helicobacter pylori (H. pylori) infection	upregulated	29317648
7324	Human	hsa-miR-223-3p	miRNA	monosodium urate (MSU)	gouty inflammation	THP-1 cells	monosodium urate treatment	downregulated	33650318
7325	Human	hsa-miR-223-3p	miRNA	helicobacter pylori (H. pylori)	H. pylori infection	human immune cells	Helicobacter pylori infection	upregulated	29145789
7326	Human	hsa-miR-223-3p	miRNA	silybin	hepatoprotective	HepG2 cells	Silybin treatment	upregulated	31058823
7327	Human	hsa-miR-223-3p	miRNA	lipopolysaccharide (LPS)	inflammation	human adipose stem cells	lipopolysaccharide (LPS) treatment	downregulated	30807577
7328	Human	hsa-miR-223-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	kaposi's sarcoma (KS)	human coronary artery endothelial cells (HCAECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31396494
7329	Human	hsa-miR-223-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
7330	Human	hsa-miR-223-3p	miRNA	dexamethasone (DEX)	neuroprotective effects	human hippocampal neuronal cells	dexamethasone (DEX) treatment	upregulated	30569136
7331	Human	hsa-miR-223-3p	miRNA	dexamethasone (DEX)	neuroprotective effects	human hippocampal neuronal cells	dexamethasone (DEX) treatment	DEX enhanced the expression of miR-223-3p.	30569136
7332	Human	hsa-miR-223-3p	miRNA	dexmedetomidine (DEX)	oxidative stress	H2O2 treated human hippocampal neuronal cells	dexamethasone (DEX) treatment	upregulated	30569136
7333	Human	hsa-miR-223-3p	miRNA	H2O2	oxidative stress	human hippocampal neuronal cells	H2O2 treatment	downregulated	30569136
7334	Human	hsa-miR-223-3p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
7335	Human	hsa-miR-223-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32666494
7336	Human	hsa-miR-223-3p	miRNA	Treponema pallidum subsp pallidum (T pallidum)	syphilis	human umbilical vein endothelial cells (HUVECs)	Treponema pallidum subsp pallidum (T pallidum) infection treatment	MiR-223-3p inhibits rTp17-induced inflammasome activation and pyroptosis by targeting NLRP3	33145937
7337	Human	hsa-miR-223-3p	miRNA	polystyrene (PSNPs)	toxicity of nanoparticles	THP-1 cells	polystyrene (PSNPs) treatment	downregulated	32284792
7338	Human	hsa-miR-223-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (MTB) treatment	downregulated	32048448
7339	Human	hsa-miR-223-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	"?LINC00707 was increased, and miR-223-5p was decreased in LPS-treated MRC-5 cells."	33604647
7340	Human	hsa-miR-22-3p	miRNA	calcium oxalate monohydrate (COM)	kidney stone disease	human renal proximal tubular epithelial (HK-2) cells	?calcium oxalate monohydrate (COM)?treatment treatment	lncRNA LINC00339 promotes cell pyroptosis by sponging miR-22-3p to regulate NLRP3 expression in COM-treated HK-2 cells	30614043
7341	Human	hsa-miR-22-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	miR-22-3p was downregulated in LPS-stimulated HK-2 cells.	33335994
7342	Human	hsa-miR-22-3p	miRNA	lipopolysaccharide (LPS)	age-related macular degeneration (AMD)	"Human retinal pigment epithelial cell line, ARPE©\19 cells"	LPS combined with rotenone treatment	downregulated	30927257
7343	Human	hsa-miR-22-3p	miRNA	rotenone (ROT)	age-related macular degeneration (AMD)	"Human retinal pigment epithelial cell line, ARPE©\19 cells"	LPS combined with rotenone treatment	downregulated	30927257
7344	Human	hsa-miR-22-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	downregulated	31722571
7345	Human	hsa-miR-22-3p	miRNA	vinyl chloride monomer (VCM)	chromosomal damage	workers peripheral blood lymphocytes	high VCM-expose treatment	downregulated	28749179
7346	Human	hsa-miR-22-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	downregulated	31722571
7347	Human	hsa-miR-22-3p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) cyclosporine A (CYCA) treatment	upregulated	31198949
7348	Human	hsa-miR-22-3p	miRNA	TGF-¦Â2	fibrotic cataract	human lens epithelial explants	TGF-¦Â2 treatment	miR-22-3p prevents lens fibrotic progression by targeting HDAC6 thereby promoting ¦Á-tubulin acetylation.	32985730
7349	Human	hsa-miR-22-3p	miRNA	oxaliplatin	gastric cancer (GC)	"GC tissues;Normal cells (GES-1); GC cells (SGC-7901, BGC-823); GC/OXA cells (SGC-7901/OXA; BCG-823/OXA"	oxaliplatin (OXA) treatment	MALAT1 modulates ZFP91 to promote GC cells OXA resistance via sponging miR-22-3p	32104001
7350	Human	hsa-miR-22-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
7351	Human	hsa-miR-22-3p	miRNA	monosodium urate (MSU)	gouty inflammation	THP-1 cells	monosodium urate treatment	downregulated	33650318
7352	Human	hsa-miR-22-3p	miRNA	betulinic acid (BA)	hepatocellular carcinoma (HCC)	PLC/PRF/5; MHCC97L	betulinic acid (BA) treatment	lncRNA MALAT1 functioned as a ceRNA (competing endogenous RNA) to contribute to BA-mediated degradation of IAPs by sponging miR-22-3p.	33135336
7353	Human	hsa-miR-22-3p	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HCC cells	?hepatitis B virus-encoded X (HBx) protein treatment	we found that translation regulatory lncRNA 1 (TRERNA1) upregulation by HBx not only promoted HCC cell proliferation by regulating the cell cycle in vitro and in vivo but also correlated positively with poor prognosis in HCC	33839325
7354	Human	hsa-miR-22-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
7355	Human	hsa-miR-22-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29505299
7356	Human	hsa-miR-22-3p	miRNA	nicotinamide	periodontitis	periodontal ligament stem cell (PDLSC)	nicotinamide treatment	upregulated	31769563
7357	Human	hsa-miR-22-3p	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	miR-22-3p was significantly downregulated LPS-induced sepsis model in HK-2 cells.	32412059
7358	Human	hsa-miR-224	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC) and EA.hy926 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	25463084
7359	Human	hsa-miR-224	miRNA	paclitaxel (PTX)	cervical cancer (CC)	SiHa cells	paclitaxel treatment	downregulated	26390698
7360	Human	hsa-miR-224	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
7361	Human	hsa-miR-224	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	upregulated	27081844
7362	Human	hsa-miR-224	miRNA	hypoxia	gastric cancer (GC)	human gastric cancer cell lines SGC-7901; MGC-803	"maintained with 5% CO2, 1% O2"	upregulated	28173803
7363	Human	hsa-miR-224	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	U87 MG cells	irradiation at a dose of 6Gy treatment	downregulated	24785373
7364	Human	hsa-miR-224	miRNA	pegylated interferon-¦Á and ribavirin (IFN/RBV)	hepatitis C virus (HCV) infection	HCV patients	IFN/RBV for 12 months treatment	upregulated	24033414
7365	Human	hsa-miR-224	miRNA	geniposide (GEN)	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	geniposide (GEN) treatment	downregulated	31778668
7366	Human	hsa-miR-224	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues	sorafenib treatment	dysregulated	28049231
7367	Human	hsa-miR-224	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCC patients	Sorafenib treatment	upregulated	24804874
7368	Human	hsa-miR-224	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
7369	Human	hsa-miR-224	miRNA	oxygen glucose deprivation (OGD)	neuronal cell injury	HCN-2 cells	oxygen/glucose deprivation (OGD) treatment	upregulated	27165196
7370	Human	hsa-miR-224	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
7371	Human	hsa-miR-224	miRNA	palliative chemotherapy	non-small cell lung cancer (NSCLC)	NSCLC tissues	platinum derivatives in combination with paclitaxel or gemcitabine treatment	upregulated	29387235
7372	Human	hsa-miR-224	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
7373	Human	hsa-miR-224	miRNA	hypoxia	prostate cancer	NK cells	oxygen-glucose deprivation (OGD) treatment	upregulated	29885835
7374	Human	hsa-miR-224	miRNA	zinc(II) ions	prostate cancer	22Rv1 cell line	zinc(II) ions treatment	upregulated	23064315
7375	Human	hsa-miR-224-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic ECs (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33510945
7376	Human	hsa-miR-224-3p	miRNA	hypoxia	autophagy	Human glioblastoma multiforme	hypoxia treatment	downregulated	26536662
7377	Human	hsa-miR-224-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
7378	Human	hsa-miR-224-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma LN229 and astrocytoma U-251MG cell lines	hypoxia induce	downregulated	30569180
7379	Human	hsa-miR-224-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	glioma LN229 and astrocytoma U-251MG cell lines	hypoxia induce	downregulated	30569180
7380	Human	hsa-miR-224-3p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	30197683
7381	Human	hsa-miR-224-3p	miRNA	thymosin ¦Á1 (T¦Á1)	non-segmental vitiligo (NSV)	peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV)	thymosin ¦Á1 (T¦Á1) treatment	upregulated	25495156
7382	Human	hsa-miR-224-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
7383	Human	hsa-miR-224-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	Human colorectal carcinoma HCT116 and human colorectal adenocarcinoma DLD-1 cells	5-fluorouracil (5-FU) treatment	he decrease in miR-224-5p expression in the 5-fluorouracil-resistant cells correlated with drug insensitivity due to its overexpression-induced drug-dependent apoptosis.	31810268
7384	Human	hsa-miR-224-5p	miRNA	transarterial chemoembolization (TACE)	hepatocellular carcinoma (HCC)	HCC patients plasma	TACE treatment	differently regulated	25275448
7385	Human	hsa-miR-224-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
7386	Human	hsa-miR-22-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
7387	Human	hsa-miR-2278	miRNA	cardenolide analog 3¦Â-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG)	renal cell carcinoma (RCC)	"renal cell carcinoma cell lines (786-O, Caki-2)"	AMANTADIG treatment	downregulated	28099931
7388	Human	hsa-miR-23	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human mesotheial peritoneal cells(HPMCs)	high glucose treatment	upregulated	28942023
7389	Human	hsa-miR-23	miRNA	intermittent hypoxia (IH)	hypoxemia	blood	intermittent (HI) hypoxia treatment	miR-23 was upregulated in intermittent (HI) hypoxia treatment group.	30416683
7390	Human	hsa-miR-23-3p	miRNA	infliximab	rheumatoid arthritis (RA)	serological	infliximab treatment	upregulated	25860297
7391	Human	hsa-miR-2355-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	upregulated	30817728
7392	Human	hsa-miR-2392	miRNA	botulinum toxin A (BTXA)	keloids	human skin keloid fibroblasts (HSFBs)	botulinum toxin A (BTXA) treatment	upregulated	31652445
7393	Human	hsa-miR-2392	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	SH-SY5Y human neuroblastoma cells	GDNF	downregulated	28829278
7394	Human	hsa-miR-23a	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	downregulated	27158236
7395	Human	hsa-miR-23a	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
7396	Human	hsa-miR-23a	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	downregulated	27158236
7397	Human	hsa-miR-23a	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
7398	Human	hsa-miR-23a	miRNA	arsenic trioxide (ATO)	As2O3 cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
7399	Human	hsa-miR-23a	miRNA	IL-4	asthma	BEAS©\2B cells	IL©\4 treatment	upregulated	31020662
7400	Human	hsa-miR-23a	miRNA	thymic stromal lymphopoietin (TSLP)	asthma	"Human lung fibroblasts, HFL©\1"	TSLP treatment	upregulated	31020662
7401	Human	hsa-miR-23a	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
7402	Human	hsa-miR-23a	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
7403	Human	hsa-miR-23a	miRNA	arsenic trioxide (ATO)	cardiotoxicity	hERG-HEK293 cells and neonatal cardiomyocytes	arsenic trioxide (As2O3) treatment	upregulated	25395240
7404	Human	hsa-miR-23a	miRNA	heat stress	cellular stress response	PErTA70 cells	circulating water bath at 43?¡ãC for 1?h treatment	upregulated	25429623
7405	Human	hsa-miR-23a	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
7406	Human	hsa-miR-23a	miRNA	hypoxia	colorectal cancer (CRC)	HT29 cells; SW480 cells; Caco2 cells	hypoxia treatment	upregulated	30393198
7407	Human	hsa-miR-23a	miRNA	hypoxia	colorectal cancer (CRC)	"HT-29, Caco2 and SW480 cells"	hypoxia induce	upregulated	30393198
7408	Human	hsa-miR-23a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	human HCT116 and HT29 colon carcinoma cell lines	5-fluorouracil (5-FU) treatment	upregulated	24249161
7409	Human	hsa-miR-23a	miRNA	IL-2	cytotoxicity	PBMCs or tumor cell line K562; lymphoblastoid cell line R69	IL-2 treatment	downregulated	24440757
7410	Human	hsa-miR-23a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	28707079
7411	Human	hsa-miR-23a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	human primary endothelial cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	22038739
7412	Human	hsa-miR-23a	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	HK2 cells	high glucose treatment	upregulated	28707079
7413	Human	hsa-miR-23a	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	A549 cells;PC9 cells; PC14 cells; LC2/ad; RERF-LC-KJ; RERF-LC-OK adenocarcinoma (AC) cell lines; PC1; PC10; LK2; SQ5 squamous cell carcinoma cell lines (SCC)	TGF-¦Â treatment	upregulated	22752005
7414	Human	hsa-miR-23a	miRNA	fas ligand (FasL)	gastric cancer (GC)	human GI cancer cell lines	Fas ligand (FasL) treatment	upregulated	23929433
7415	Human	hsa-miR-23a	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
7416	Human	hsa-miR-23a	miRNA	berberine (BBR)	hepatocellular carcinoma (HCC)	human HCC cells	berberine (BBR) treatment	upregulated	24942805
7417	Human	hsa-miR-23a	miRNA	estrogen (ES)	hepatocellular carcinoma (HCC)	human liver cancer cell lines	Estrogen (E2)treatment	upregulated	26439986
7418	Human	hsa-miR-23a	miRNA	etoposide (VP-16)	hepatocellular carcinoma (HCC)	HCC cells	etoposide treatment	upregulated	24103454
7419	Human	hsa-miR-23a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	downregulated	31769216
7420	Human	hsa-miR-23a	miRNA	TGF-¦Â	endometrial endometrioid adenocarcinoma (EEC)	HEC-1-A cells	TGF-¦Â treatment	downregulated	27601936
7421	Human	hsa-miR-23a	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
7422	Human	hsa-miR-23a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
7423	Human	hsa-miR-23a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
7424	Human	hsa-miR-23a	miRNA	TGF-¦Â	immunoregulatory function	human CD8(+) T cells	TGF-¦Â treatment	upregulation	25030422
7425	Human	hsa-miR-23a	miRNA	coptidis rhizoma aqueous extract	hepatocellular carcinoma (HCC)	human hcc mhcc97-l cells	Coptidis rhizoma aqueous extract treatment	upregulated	22977465
7426	Human	hsa-miR-23a	miRNA	pristimerin	lung cancer	A549 and NCI-H446 cells	Pristimerin treatment	downregulated	30664149
7427	Human	hsa-miR-23a	miRNA	dexamethasone (DEX)	miRNA biogenesis	human endothelial cells	dexamethasone (Dex) treatment	downregulated	28523344
7428	Human	hsa-miR-23a	miRNA	ginsenoside Rg1	miRNA biogenesis	human endothelial cells	ginsenoside-Rg1 treatment	downregulated	28523344
7429	Human	hsa-miR-23a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoblasts apoptosis	"The clonal murine osteoblastic cell line, MC3T3-E1 £»Human embryonic kidney cell line (HEK-293)"	tumor necrosis factor alpha (TNF-¦Á) treatment	microRNA-23a depletion significantly enhances TNF-alpha-induced MC3T3-E1 cell apoptosis and over-expressing microRNA-23a remarkably attenuates this phenomenon	23804233
7430	Human	hsa-miR-23a	miRNA	dexamethasone (DEX)	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	dexamethasone (DEX) treatment	upregulated	24802236
7431	Human	hsa-miR-23a	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
7432	Human	hsa-miR-23a	miRNA	H2O2	oxidative stress	ARPE-19 cells	ARPE-19 cells treatment	upregulated	27411920
7433	Human	hsa-miR-23a	miRNA	Sinomenine (SIN)	prostate cancer	PC3 and LNCaP cells	Sinomenine (SIN) treatment	downregulated	30784907
7434	Human	hsa-miR-23a	miRNA	zinc(II) ions	prostate cancer	NCaP cells£» PC-3 human cell line£» 22Rv1 cell line	zinc(II) ions treatment	upregulated	23064315
7435	Human	hsa-miR-23a	miRNA	lipopolysaccharide (LPS)	psoriatic arthritis (PsA)	primary synovial fibroblasts (SFC)	lipopolysaccharide (LPS) treatment	downregulated	30181004
7436	Human	hsa-miR-23a	miRNA	lipopolysaccharide (LPS)	psoriatic arthritis (PsA)	PsA synovial fibroblasts (SFC)	lipopolysaccharide (LPS) treatment	downregulated	30181004
7437	Human	hsa-miR-23a	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	psoriatic arthritis (PsA)	PsA synovial fibroblasts (SFC)	poly I:C treatment	downregulated	30181004
7438	Human	hsa-miR-23a	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	psoriatic arthritis (PsA)	primary synovial fibroblasts (SFC)	poly(I:C) treatment	downregulated	30181004
7439	Human	hsa-miR-23a	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	29864909
7440	Human	hsa-miR-23a	miRNA	X-rays	stress response	human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A	a single dose of 5Gy ?-radiation	downregulated	28851536
7441	Human	hsa-miR-23a	miRNA	ultraviolet (UV) irradiation	UVB-induced injury	human keratinocyte cell line (HaCaT) cells	UVB-irradiated? treatment	upregulated	23158364
7442	Human	hsa-miR-23a	miRNA	2-deoxy glucose (2-DG) and thapsigargin (TG)	warburg effect	HeLa cells	2-Deoxy glucose (2-DG); Thapsigargin (TG) treatment	downregulated	29377281
7443	Human	hsa-miR-23a	miRNA	1'-acetoxychavicol acetate	extracellular signal-regulated kinase (ERK) phosphorylation	HN4 cells	1'-acetoxychavicol acetate treatment	downregulated	24317043
7444	Human	hsa-miR-23a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	Huh-7 cells	Transforming growth factor-beta (TGF-beta) treatment	upregulated	18508316
7445	Human	hsa-miR-23a-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
7446	Human	hsa-miR-23a-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
7447	Human	hsa-miR-23a-3p	miRNA	H2O2	cataract	human lens epithelial cells HLE-B3	H2O2 treatment	"The results of the present study revealed that the expression levels of miR-23a-3p were significantly upregulated, while the expression levels of BCL2 were significantly downregulated in H2O2-induced HLE-B3 cells compared to untreated control cells."	33777189
7448	Human	hsa-miR-23a-3p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
7449	Human	hsa-miR-23a-3p	miRNA	IL-17C	colorectal cancer (CRC)	DLD-1 cells	IL-17C treatment	"The expression of miR-23a-3p is higher in IL-17C (100 ng/mL, 3 h)-treated DLD-1 cells."	32492770
7450	Human	hsa-miR-23a-3p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
7451	Human	hsa-miR-23a-3p	miRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	33049089
7452	Human	hsa-miR-23a-3p	miRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	cardiomyocytes	high-glucose (HG) treatment	We observed that PVT1 and CASP10 were upregulated while miR-23a-3p was downregulated in high glucose-induced cardiomyocytes.	33049089
7453	Human	hsa-miR-23a-3p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
7454	Human	hsa-miR-23a-3p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	TSN upregulated the expression of miR-23a-3p	32582989
7455	Human	hsa-miR-23a-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
7456	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	downregulated	27143365
7457	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
7458	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
7459	Human	hsa-miR-23a-3p	miRNA	osthole	prostate cancer	The PC3 and DU145 human AIPC cell lines	Osthole treatment	downregulated	26110567
7460	Human	hsa-miR-23a-3p	miRNA	dexamethasone (DEX)	steatosis	HepG4 cells	dexamethasone (Dex) treatment	downregulated	29409992
7461	Human	hsa-miR-23a-3p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human ¦Â-cells	cytokines IL-1¦Â plus IFN-¦Ã treatment	dysregulated	27737950
7462	Human	hsa-miR-23a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
7463	Human	hsa-miR-23a-5p	miRNA	ultraviolet (UV) irradiation	cell senescence	human fibroblast	"the UVB irradiation output was monitored using a Waldmann UV meter (Waldmann, Villigen©\Schwenningen, Germany). UVB dose = UVB irradiance ¡Á time in second (s), with a distance of 15 cm between the lamp and cell culture dish. The UVB with 10 mJ/cm2 was delivered to cells daily for 5 days and at 48 hr after the last irradiation treatment"	"circRNA_100797 could target miR-23a-5p, their expression levels were inversely associated in fibroblasts, and the miR-23a-5p overexpression blocked the effect of the overexpression of circRNA_100797 in UVB-SIPS"	30908647
7464	Human	hsa-miR-23a-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	GEnCs	high glucose (HG) treatment	LncOR13C9 could regulate ABCA1 by inhibiting the action of miR-23a-5p in the LXR pathway.	33192550
7465	Human	hsa-miR-23a-5p	miRNA	prostaglandin E2 (PGE2)	liver fibrosis	TGF-¦Â1-treated LX-2 cells	PGE2 treatment	downregulated	29109031
7466	Human	hsa-miR-23a-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	upregulated	29109031
7467	Human	hsa-miR-23a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	The results of the present study revealed that the expression levels of miR-23a-5p were significantly downregulated in the plasma of patients with RA and in MH7A cells	33767774
7468	Human	hsa-miR-23b	miRNA	pulsatile shear (PS) flow	retinoblastoma (RB)	vascular endothelial cells (ECs)	pulsatile shear (PS) flow treatment	downregulated	20133741
7469	Human	hsa-miR-23b	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	downregulated	28886127
7470	Human	hsa-miR-23b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	"LINC01140 was downregulated, while p53 and miR-23b were upregulated in oxLDL-induced inflammatory response of macrophages."	31748847
7471	Human	hsa-miR-23b	miRNA	IL-17	autoimmune inflammation	human fibroblast-like synoviocytes£»astrocytes	IL-17 treatment	downregulated	22660635
7472	Human	hsa-miR-23b	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	downregulated	33197057
7473	Human	hsa-miR-23b	miRNA	genistein	breast cancer	MCF-7 cell	Genistein treatment	upregulated	26199568
7474	Human	hsa-miR-23b	miRNA	genistein	breast cancer	"MCF-7 cell, line"	genistein treatment	miR-23b was found to be upregulated 56.69 fold	26199568
7475	Human	hsa-miR-23b	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
7476	Human	hsa-miR-23b	miRNA	brucella Omp25	brucellosis	human Monocyte/Macrophages	brucella Omp25 treatment	upregulated	28694807
7477	Human	hsa-miR-23b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cervical cancer (CC)	"HeLa, SiHa, CaSki and C33A cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26622315
7478	Human	hsa-miR-23b	miRNA	oxaliplatin	colorectal cancer (CRC)	Human colorectal carcinoma HCT116 and human colorectal adenocarcinoma DLD-1 cells	oxaliplatin treatment	"miR-23b/27b/24-1 cluster was overexpressed in oxaliplatin-resistant cells The knockout of miR-23b led to the partial restoration of oxaliplatin susceptibility, showing the essential role of miR-23b in the development of drug resistance by this cluster"	31810268
7479	Human	hsa-miR-23b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	"human kidney proximal tubular epithelial cells ,HK2"	"human kidney proximal tubular epithelial cells ,HK2 treatment"	downregulated	26646104
7480	Human	hsa-miR-23b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human kidney proximal tubular epithelial cells (HK2)	high glucose (HG) treatment	downregulated	26646104
7481	Human	hsa-miR-23b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	HK-2 cells treatment	downregulated	26839366
7482	Human	hsa-miR-23b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	"glioma stem cells (GSCs) ,U87 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	22982144
7483	Human	hsa-miR-23b	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
7484	Human	hsa-miR-23b	miRNA	BAY11-7082	osteogenesis	TNF-¦Á-treated bone marrow mesenchymal stem cell (BMSC)	BAY 11-7082 treatment	downregulated	29234953
7485	Human	hsa-miR-23b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	bone marrow mesenchymal stem cell (BMSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29234953
7486	Human	hsa-miR-23b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	human bone marrow mesenchymal stem cell (BMSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29234953
7487	Human	hsa-miR-23b	miRNA	r-rays	pancreatic cancer (PC)	pancreatic cancer cell lines	radiation treatment	"In pancreatic cancer cells, reduced levels of the miRNA MIR23B increase levels of ATG12 and autophagy to promote radioresistance MIR23B might be used to increase the sensitivity of pancreatic cancer cells to radiation therapy"	23916944
7488	Human	hsa-miR-23b	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
7489	Human	hsa-miR-23b	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	31780861
7490	Human	hsa-miR-23b	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	downregulated	30182520
7491	Human	hsa-miR-23b	miRNA	low-dose ionizing radiation (LDIR)	stress response	human Epstein-Barr virus-infected B-cells (EBV-B)	low-dose ionizing radiation (LDIR) treatment	upregulated	26809544
7492	Human	hsa-miR-23b	miRNA	retinoic acid (RA)	rhinovirus 1B (RV1B) infection	hela cells	Retinoic acid treatment	downregulated	21642441
7493	Human	hsa-miR-23b-3p	miRNA	angiotensin II (Ang II)	atrial fibrillation (AF)	Human atrial fibroblasts (HAFs)	angiotensin II (Ang II) treatment	upregulated	30729664
7494	Human	hsa-miR-23b-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	breast epithelial cell line	bone morphogenetic protein 4 (BMP4) treatment	upregulated	26684238
7495	Human	hsa-miR-23b-3p	miRNA	bone morphogenetic protein 4 (BMP4)	breast cancer	BT-474 cell	bone morphogenetic protein 4 (BMP4) treatment	"four miRNAs (miR-16-5p, miR-106b-5p, miR-23a-3p, and miR-23b-3p) were commonly induced in a subset of breast cancer cells upon BMP4 treatment."	26684238
7496	Human	hsa-miR-23b-3p	miRNA	TGF-¦Â	cataract	lens epithelial cells (LECs)	TGF-¦Â treatment	upregulated	31235073
7497	Human	hsa-miR-23b-3p	miRNA	5-fluorouracil (5-Fu)	chemoresistance of 5-fluorouracil (5-FU)	SW480 and SW620	5-fluorouracil (5-FU) treatment	UCA1 mediated 5-FU resistance of CRC cells through facilitating autophagy and inhibiting apoptosis via miR-23b-3p/ZNF281 axis in vivo and in vitro.	32801774
7498	Human	hsa-miR-23b-3p	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
7499	Human	hsa-miR-23b-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (MCs)	high glucose (HG) treatment	downregulated	32322310
7500	Human	hsa-miR-23b-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose treatment	upregulated	26687158
7501	Human	hsa-miR-23b-3p	miRNA	10-hydroxycamptothecin (HCPT)	epidural fibrosis	human fibroblasts	10-Hydroxycamptothecin (HCPT) treatment	upregulated	30720099
7502	Human	hsa-miR-23b-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
7503	Human	hsa-miR-23b-3p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
7504	Human	hsa-miR-23b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
7505	Human	hsa-miR-23b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocyte cell line CHON-001	IL-1¦Â treatment	upregulated	31440033
7506	Human	hsa-miR-23b-3p	miRNA	IL-1¦Â and IFN-¦Ã	type 1 diabetes mellitus (T1DM)	human ¦Â-cells	cytokines IL-1¦Â plus IFN-¦Ã treatment	dysregulated	27737950
7507	Human	hsa-miR-23b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
7508	Human	hsa-miR-23c	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	downregulated	29393545
7509	Human	hsa-miR-23c	miRNA	oxLDL and pitavastatin	cholesterol homeostasis	THP-1 cells	oxLDL and pitavastatin treatment	downregulated	27415822
7510	Human	hsa-miR-23c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells		downregulated	27964927
7511	Human	hsa-miR-23c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	streptozotocin treatment	downregulated	27964927
7512	Human	hsa-miR-23c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	high glucose (HG) treatment	downregulated	32096162
7513	Human	hsa-miR-23c	miRNA	steviol	gastrointestinal cancer	MKN-45 cells	steviol treatment	downregulated	29899860
7514	Human	hsa-miR-24	miRNA	H2O2	age-related cataract (ARC)	human lens epithelial cells (LECs)	H2O2 treatment	upregulated	29393409
7515	Human	hsa-miR-24	miRNA	celastrol	apoptosis	A549 cells	celastrol treatment	upregulated	29434967
7516	Human	hsa-miR-24	miRNA	etoposide (VP-16)	apoptosis	highly differentiated CD8(+) T cells	etoposide treatment	upregulated	22435726
7517	Human	hsa-miR-24	miRNA	cholesterol	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	cholesterol treatment	downregulated	33755271
7518	Human	hsa-miR-24	miRNA	theaflavin (TF)	atherosclerosis (AS)	cholesterol-treated human umbilical vein endothelial cells (HUVECs)	theaflavin (TF)?treatment treatment	upregulated	33755271
7519	Human	hsa-miR-24	miRNA	hypoxia	brain injury	SH-SY5Y cells	hypoxia treatment	downregulated	27349868
7520	Human	hsa-miR-24	miRNA	propofol (PPF)	breast cancer	MDA-MB-435 cells	propofol treatment	downregulated	29103019
7521	Human	hsa-miR-24	miRNA	TGF-¦Â	breast cancer	"Human HaCaT keratinocytes, human embryonic kidney cells(HEK293) and thehuman cancer cell lines (MDAMB231, T47D, DU145, BT474,SKBR3 and MCF7)"	TGF-¦Â treatment	over expression	21986943
7522	Human	hsa-miR-24	miRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes	Phenylephrine (PE) treatment	upregulated	32898528
7523	Human	hsa-miR-24	miRNA	hypoxia/reoxygenation (H/R)	cerebral ischemia/reperfusion (I/R) injury	human umbilical cord MSCs (HMCs)-derived exosome	hypoxia/reoxygenation (H/R) treatment	upregulated	33258087
7524	Human	hsa-miR-24	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	The bronchial epithelial cells (BEAS-2B and 16HBE)	cigarette smoke extract (CSE) treatment	Circ_0006892 expression was reduced in lung tissues of smokers with COPD and CSE-stimulated bronchial epithelial cells.	33734482
7525	Human	hsa-miR-24	miRNA	melatonin	colorectal cancer (CRC)	HCT 116 and MCF-7 cells	melatonin treatment	downregulated	26967561
7526	Human	hsa-miR-24	miRNA	hypoxia	colorectal cancer (CRC)	"HT-29, Caco2 and SW480 cells"	hypoxia induce	upregulated	30393198
7527	Human	hsa-miR-24	miRNA	hypoxia	colorectal cancer (CRC)	HT29 cells; SW480 cells; Caco2 cells	hypoxia treatment	upregulated	30393198
7528	Human	hsa-miR-24	miRNA	Helicobacter pylori (H. pylori) extract (HPE)	gastric cancer (GC)	HGC-27 cells	Helicobacter pylori (H. pylori) infection	upregulated	33065487
7529	Human	hsa-miR-24	miRNA	cyclic mechanical stretch (CMS)	glaucoma	human trabecular meshwork cells	cyclic mechanical stress (CMS) treatment	downregulated	20945401
7530	Human	hsa-miR-24	miRNA	TGF-¦Â1	hypertrophic scars (HS)	fibroblasts	TGF-¦Â1 treatment	downregulated	25837671
7531	Human	hsa-miR-24	miRNA	nicotine	idiopathic pulmonary fibrosis (IPF)	Normal human lung epithelial cells	nicotine treatment	downregulated	30446578
7532	Human	hsa-miR-24	miRNA	nicotine	idiopathic pulmonary fibrosis (IPF)	Primary human lung epithelial cells	nicotine treatment	downregulated	30446578
7533	Human	hsa-miR-24	miRNA	"anti-CD3, anti-CD28, IL-12, , IL-18"	innate and adaptive immune responses	PB CD4+ T cells	"co-stimulating with anti-CD3, anti-CD28, IL-12, and IL-18 treatment"	downregulated	24704866
7534	Human	hsa-miR-24	miRNA	trinitrobenzene sulfonic acid (TNBS)	irritable bowel syndrome (IBS)		trinitro-benzene-sulfonic acid (TNBS) treatment	upregulated	26631964
7535	Human	hsa-miR-24	miRNA	kidney transplantation	kidney transplantation	patients kidney	kidney transplantation treatment	upregulated	24854275
7536	Human	hsa-miR-24	miRNA	sodium selenite	hepatocellular carcinoma (HCC)	HLF cells	sodium selenite treatment	"miR-24 was downregulated at a dose of 5 ¦ÌM, but increased at a dose of 10 ¦ÌM"	32656599
7537	Human	hsa-miR-24	miRNA	celastrol	lung cancer	A549 cells; LTEP-a-2 cells	celastrol treatment	miR-24 was upregulated in celastrol-treated LTEP-a-2 cells.	29434967
7538	Human	hsa-miR-24	miRNA	noise	noise-induced hearing loss (NIHL)	plasma	noise treatment	downregulated	26278637
7539	Human	hsa-miR-24	miRNA	fatty acid	nonalcoholic fatty liver disease (NAFLD)	human hepatocytes	incubat fatty acid treatment	upregulated	24677249
7540	Human	hsa-miR-24	miRNA	pemetrexed	non-small cell lung cancer (NSCLC)	NSCLC tissue	pemetrexed treatment	upregulated	23794259
7541	Human	hsa-miR-24	miRNA	oleic acid (OA)	obesity	HepG2 cells	oleic acid (OA) treatment	downregulated	29787826
7542	Human	hsa-miR-24	miRNA	palmitic acid (PA)	obesity	HepG2 cells	palmitic acid (PA) treatment	upregulated	29787826
7543	Human	hsa-miR-24	miRNA	¦Ã- Mangostin (¦Ã-MS)	osteoarthritis (OA)	SW982 cells	¦Ã- Mangostin (¦Ã-MS) treatment	upregulated	32302289
7544	Human	hsa-miR-24	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
7545	Human	hsa-miR-24	miRNA	H2O2	periodontal tissue damage and repair	periodontal ligament cells (PDLCs)	H2O2 treatment	upregulated	27188727
7546	Human	hsa-miR-24	miRNA	zirconia and titanium	preosteoblast differentiation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	downregulated	18241218
7547	Human	hsa-miR-24	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	prostate cancer	AfA cell line (MDA-PCa-2b)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28157714
7548	Human	hsa-miR-24	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
7549	Human	hsa-miR-24	miRNA	Staphylococcus aureus	staphylococcus aureus infection	human macrophage cell lines	infect with S. aureus treatment	downregulated	28303416
7550	Human	hsa-miR-24	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
7551	Human	hsa-mir-24	miRNA	stress	cell senescence	CD138+ plasma cells	stress treatment	mir-24 activity propagates stress-induced senescence by down regulating TOP1	26748253
7552	Human	hsa-miR-24	miRNA	IL-1¦Â	terminal chondrogenesis	primary OA chondrocytes;mesenchymal stem cells	IL-1-¦Â treatment	downregulated	24572376
7553	Human	hsa-miR-24-1	miRNA	ionizing radiation (IR)	anti-cancer therapy	SCC-4;SCC-25;CAL-27;LN229;T98G;U-87 MG	ionizing radiation treatment	upregulated	21453501
7554	Human	hsa-miR-24-1	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
7555	Human	hsa-miR-24-1-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
7556	Human	hsa-miR-24-2	miRNA	X-rays	stress response	human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A	a single dose of 5Gy ?-radiation	downregulated	28851536
7557	Human	hsa-miR-24-2-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
7558	Human	hsa-miR-24-2-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
7559	Human	hsa-miR-24-3p	miRNA	IL-6	spermatogonial differentiation	"primary B cells, plasma blasts, plasma cells, and in plasmacytoma cells"	interleukin-6 treatment	upregulated	23934711
7560	Human	hsa-miR-24-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	arteriosclerosis obliterans (ASO)	HASMCs	Platelet-derived growth factor BB (PDGF-BB) treatment	downregulated	26159387
7561	Human	hsa-miR-24-3p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
7562	Human	hsa-miR-24-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33675584
7563	Human	hsa-miR-24-3p	miRNA	etoposide (VP16) and cisplatin (DDP)	advanced-stage small-cell lung cancer (SCLC)	VP16-DDP-resistant SCLC cells (H446/EP)	etoposide (VP16) and cisplatin (DDP) treatment	dysregulated	25426560
7564	Human	hsa-miR-24-3p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
7565	Human	hsa-miR-24-3p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
7566	Human	hsa-miR-24-3p	miRNA	azacitidine (AZA)	myelodysplastic syndrome (MDS)	bone marrow CD34+ cells	azacitidine (AZA) treatment	downregulated	29630523
7567	Human	hsa-miR-24-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
7568	Human	hsa-miR-24-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	human ovarian cancer cells OVCAR-8R	cisplatin treatment	dysregulated	28861582
7569	Human	hsa-miR-24-3p	miRNA	paclitaxel (PTX)	paclitaxel (PTX) resistance	PC3-TXR cells; DU145-TXR cells	Paclitaxel (PTX) treatment	Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1	32089062
7570	Human	hsa-miR-24-3p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
7571	Human	hsa-miR-2467	miRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	cisplatin treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel.	31581131
7572	Human	hsa-miR-2467	miRNA	paclitaxel (PTX)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	paclitaxel treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel	31581131
7573	Human	hsa-miR-24a-3p	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	lower respiratory tract infections	BEAS-2B cells	poly(I:C) treatment	downregulated	31837465
7574	Human	hsa-miR-25	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis and coronary heart disease	vascular smooth muscle cell	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	25672882
7575	Human	hsa-miR-25	miRNA	epigallocatechin-3-gallate (EGCG)	breast cancer	MCF-7 cells	epigallocatechin-3-gallate (EGCG) treatment	downregulated	31431131
7576	Human	hsa-miR-25	miRNA	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC)	chronic inflammatory diseases	human umbilical vein endothelial cells (HUVECs) exosomes	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment	upregulated	29161413
7577	Human	hsa-miR-25	miRNA	helicobacter pylori (H. pylori)	coronary heart disease (CHD)	gastric epithelial cells	Helicobacter pylori infection	upregulated	31750260
7578	Human	hsa-miR-25	miRNA	cyclopamine	cholangiocarcinoma (CCA)	human cholangiocyte cell line H69£»KMCH cells £»Mz-ChA-1 cells	cyclopamine treatment	downregulated	21953056
7579	Human	hsa-miR-25	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human kidney (HK-2) cells	high glucose treatment	downregulated	29031207
7580	Human	hsa-miR-25	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
7581	Human	hsa-miR-25	miRNA	suberoylanilide hydroxamic acid (SAHA)	hepatocellular carcinoma (HCC)	Hep3B and Huh7 HCC cell lines	suberanilohydroxamic acid (SAHA) treatment	upregulated	31092334
7582	Human	hsa-mir-25	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
7583	Human	hsa-miR-25	miRNA	oxygen glucose deprivation (OGD)	ischemia/reperfusion (I/R) injury	Human SH-SY5Y and IMR-32 cells	oxygen-glucose deprivation (OGD) treatment	downregulated	26768135
7584	Human	hsa-miR-25	miRNA	K. pneumoniae reference strains (K. pneumoniae ATCC 10031)	klebsiella pneumoniae infection	BEAS 2B cells	K. pneumoniae reference strains (K. pneumoniae ATCC 10031) infection	upregulated	33322147
7585	Human	hsa-miR-25	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	KPC-producing K. pneumoniae infection	upregulated	33322147
7586	Human	hsa-miR-25	miRNA	klebsiella pneumoniae	klebsiella pneumoniae infection	BEAS 2B cells	MS K. pneumoniae infection	upregulated	33322147
7587	Human	hsa-miR-25	miRNA	pemetrexed	lung adenocarcinoma (LUAD)	serum	pemetrexed treatment	"Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations"	26687391
7588	Human	hsa-miR-25	miRNA	radiation	lung cancer	A549 cells	radiation treatment	upregulated	32968458
7589	Human	hsa-miR-25	miRNA	berberine (BBR)	multiple myeloma (MM)	"human multiple myeloma cell, RPMI-8266 and U266"	berberine (BBR) treatment	downregulated	27647143
7590	Human	hsa-miR-25	miRNA	methylmercury (MeHg)	neurotoxicity	human neural progenitor cells (ihNPCs)	methylmercury (MeHg) treatment	downregulated	27941687
7591	Human	hsa-miR-25	miRNA	diet	obesity	Plasma	diet treatment	"Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss."	32439373
7592	Human	hsa-miR-25	miRNA	ginsenoside Rb1	ovarian cancer (OC)	"human ovarian cancer cell lines, SKOV3 and 3AO"	Ginsenoside Rb1	downregulated	28928801
7593	Human	hsa-miR-25	miRNA	hypoxia	ovarian cancer (OC)	"human ovarian cancer cell lines, SKOV3 ;3AO"	hypoxia treatment	upregulated	28928801
7594	Human	hsa-miR-25	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	ovarian cancer (OC)	SKOV3 and OVCAR-3 cells	Physcion 8-O-¦Â-Glucopyranoside (PG) treatment	downregulated	31298363
7595	Human	hsa-miR-25	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	downregulated	21093163
7596	Human	hsa-miR-25	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
7597	Human	hsa-miR-25	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
7598	Human	hsa-miR-25	miRNA	hypoxia	prostate cancer	PCa cell lines (LNCaP£» PC3)£»neural crest (NC) cells	hypoxia treatment	downregulated	24135225
7599	Human	hsa-miR-25	miRNA	hypoxia	prostate cancer	LNCaP cells	5% O2 treatment	upregulated	24135225
7600	Human	hsa-miR-25	miRNA	salvianolic acid B (Sal B)	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	Sal B treatment	upregulated	25094038
7601	Human	hsa-miR-25	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	TGF-¦Â1 treatment	downregulated	25094038
7602	Human	hsa-miR-25	miRNA	lipopolysaccharide (LPS)	sepsis	peripheral blood mononuclear cells (PBMCs) derived macrophages	lipopolysaccharide (LPS) treatment	downregulated	30250569
7603	Human	hsa-miR-25	miRNA	ginkgolide A (GA)	sepsis-induced renal injury	NRK-52E cells	Ginkgolide A (GA) treatment	The sepsis-induced decrease of miR-25 was enhanced by GA treatment.	33677255
7604	Human	hsa-miR-25	miRNA	lipopolysaccharide (LPS)	sepsis-induced renal injury	NRK-52E cells	lipopolysaccharide (LPS) treatment	The sepsis-induced decrease of miR-25 was enhanced by GA treatment.	33677255
7605	Human	hsa-miR-25	miRNA	ginsenoside Rb1	skin wrinkle formation	human dermal fibroblasts	Ginsenoside Rb1 treatemnt	downregulated	22692056
7606	Human	hsa-miR-25	miRNA	IL-23	thyroid cancer (TC)	thyroid cancer cells	IL-23 treatment	upregulated	26437444
7607	Human	hsa-miR-25	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
7608	Human	hsa-miR-25-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
7609	Human	hsa-miR-25-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
7610	Human	hsa-miR-25-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High-glucose inhibited METTL3 and miR-25-3p expressions in RPE cells.	32365051
7611	Human	hsa-miR-25-3p	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	NP cells	IL-1¦Â treatment	MicroRNA-25-3p therapy for intervertebral disc degeneration by targeting the IL-1¦Â/ZIP8/MTF1 signaling pathway with a novel thermo-responsive vector	33313245
7612	Human	hsa-miR-25-3p	miRNA	H2O2	mitophagy	HeLa and HEK 293T cells	H2O2 treatment	"We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions."	33627622
7613	Human	hsa-miR-25-3p	miRNA	cigarette smoke condensate (CSC)	pancreatic cancer (PC)	HPDE6-C7 cells	cigarette smoke condensate (CSC) treatment	upregulated	31015415
7614	Human	hsa-miR-25-3p	miRNA	particulate matter (PM2.5)	PM2.5-induced carcinogenesis	human bronchial epithelial (HBE) cells	fine particulate matter (PM2.3) treatment	upregulated	33545377
7615	Human	hsa-miR-25-5p	miRNA	thrombospondin-1 (TSP-1)	angiogenesis	vascular smooth muscle cell (VSMC)	Thrombospondin-1 (TSP-1) treatment	downregulated	26728995
7616	Human	hsa-miR-25-5p	miRNA	racemate	endogenous antioxidant defenses	Caco-2 cells	subtoxic concentrations of racemate treatment	upregulated	28264488
7617	Human	hsa-miR-25-5p	miRNA	curcumin (Cur)	lung cancer	human non-small cell lung cancer A549 cell line	curcumin treatment	dysregulated	28660665
7618	Human	hsa-miR-25-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
7619	Human	hsa-miR-25-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular disease	human brain microvessel endothelial cells (HBMECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31365884
7620	Human	hsa-miR-26	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
7621	Human	hsa-miR-26	miRNA	oxaliplatin	gastric cancer (GC)	HGC-27 cells; BGC-823 cells	oxaliplatin (OXA) treatment	downregulated	31617275
7622	Human	hsa-miR-26	miRNA	hypoxia	hypoxemia	blood	chronic hypoxia (CH)	miR-26 was upregulated in chronic hypoxia (CH) treatment group.	30416683
7623	Human	hsa-miR-26	miRNA	bushen yijing decoction (BSYJ)	systemic sclerosis (SSc)	primary skin fibroblasts	Bushen Yijing decoction (BSYJ)? treatment	BSYJ-containing rat serum suppressed miR-26a expression	33843426
7624	Human	hsa-miR-26-5p	miRNA	ethanol extract of antrodia cinnamomea (AC)	breast cancer	MCF-7 and tamoxifen-resistant MCF-7 cells	ethanol extract of antrodia cinnamomea (AC) treatment	upregulated	29743060
7625	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK-2 cells	cisplatin treatment	downregulated	31887787
7626	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK2 cells	cisplatin treatment	miR-26a was significantly downregulated during cisplatin-induced AKI and during cisplatin co-cultured HK2 cells.	31887787
7627	Human	hsa-miR-26a	miRNA	H2O2	acute respiratory distress syndrome (ARDS)	Type II alveolar epithelial cells (AEC-II)	H2O2 treatment	downregulated	29424907
7628	Human	hsa-miR-26a	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	HUVECs	VEGF treatment	downregulated	28602162
7629	Human	hsa-miR-26a	miRNA	mechanical stretch	asthma	human airway smooth muscle cells (HASMCs)	Mechanical stretch up treatment	upregulated	20525681
7630	Human	hsa-miR-26a	miRNA	tanshinol (TAN)	atherosclerosis (AS)	endothelial cells	tanshinol treatment	upregulated	27508018
7631	Human	hsa-miR-26a	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
7632	Human	hsa-miR-26a	miRNA	metformin (Met)	breast cancer	MCF-7 breast cancer cell lines	metformin treatment	upregulated	27517917
7633	Human	hsa-miR-26a	miRNA	trastuzumab	breast cancer	HER2-positive (SKBR3£» BT474) £» HER2-negetive (MCF7 £» MDA-MB-231) cells	Trastuzumab treatment	upregulated	22384020
7634	Human	hsa-miR-26a	miRNA	trastuzumab	breast cancer	BT474 wt cells	trastuzumab treatment	upregulated	28120942
7635	Human	hsa-miR-26a	miRNA	"dexamethasone (DEX), ascorbic acid, and ¦Â-glycerol phosphate"	cell differentiation	human adipose tissue¨Cderived stem cells(hADSCs)	"dexametha-sone, ascorbic acid, and ¦Â-glycerol phosphate treatment"	upregulated	18197755
7636	Human	hsa-miR-26a	miRNA	estrogen (ES)	cell proliferation	"MCF-7¡¢T47D¡¢MDA-MB-231 , BT549 cell"	estrogen treatment	downregulated	24735615
7637	Human	hsa-miR-26a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31486504
7638	Human	hsa-miR-26a	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	cholangiocarcinoma (CCA)	human cholangiocarcinoma cell	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) treatment	downregulated	25691459
7639	Human	hsa-miR-26a	miRNA	ginsenoside Rg1	diabetic retinopathy (DR)	high glucose (HG)-treated human retinal pigment epithelium cells (ARPE-19)	Ginsenoside Rg1 (Rg1) treatment	upregulated	30763577
7640	Human	hsa-miR-26a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelium cells (ARPE-19)	high glucose (HG) treatment	downregulated	30763577
7641	Human	hsa-miR-26a	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	HepG2 cells	thapsigargin (Tg) treatment	upregulated	32567701
7642	Human	hsa-miR-26a	miRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	HepG2 cells	tunicamycin (Tu) treatment	upregulated	32567701
7643	Human	hsa-miR-26a	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cells injury and autophagy dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 expression was upregulated and miR-26a was downregulated in the plasma samples of patients with atherosclerosis and ox-LDL-treated HAECs.	30468731
7644	Human	hsa-miR-26a	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"GAS5 knockdown inhibited cell apoptosis and activated autophagy flux, whereas inhibition of miR-26a reversed the effect of GAS5 in HAECs."	30468731
7645	Human	hsa-miR-26a	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human lens epithelial cells (LECs)	TGF-¦Â2 treatment	downregulated	31143769
7646	Human	hsa-miR-26a	miRNA	curcumin (Cur)	thyroid cancer (TC)	"human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101"	curcumin treatment	downregulated	28265769
7647	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC-7901 / DDP	cisplatin-resistant treatment	downregulated	26458859
7648	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	human glioblastoma cells	cisplatin treatment	downregulated	28499919
7649	Human	hsa-miR-26a	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia induce	upregulated	30425242
7650	Human	hsa-miR-26a	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	"HepG2,Huh-7, 293T"	DOX at a range of 0.5¨C25?¦ÌM over a period of 10 months	downregulated	28079894
7651	Human	hsa-miR-26a	miRNA	lipopolysaccharide (LPS)	inflammation	"Human renal proximal tubular epithelial cell lines, HK-2 and RPTECs"	lipopolysaccharide (LPS) treatment	downregulated	31158334
7652	Human	hsa-miR-26a	miRNA	notoginsenoside R1 (NGR1)	inflammation	"LPS-treated Human renal proximal tubular epithelial cell lines, HK-2 and RPTECs"	Notoginsenoside R1 (NGR1) treatment	upregulated	31158334
7653	Human	hsa-miR-26a	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	human mesenchymal stem cells (MSCs)	hypoxia treatment	"miRNA-26a was significantly increased in EV(HM), compared with EV(NM)."	29978610
7654	Human	hsa-miR-26a	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	upregulated	18648749
7655	Human	hsa-miR-26a	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	upregulated	24431000
7656	Human	hsa-miR-26a	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	31432162
7657	Human	hsa-miR-26a	miRNA	TLR9 ligand CpG-oligodeoxynucleotides (CpG-ODN)	lung cancer	H460 human lung cancer cells	CpG-ODN treatment	upregulated	24788552
7658	Human	hsa-miR-26a	miRNA	water-extracted PM10 (WE-PM10)	lung cancer	human lung adenocarcinoma A549 cells	exposure to 25 and 50 ¦Ìg/ml of WE-PM10 for 48 h treatment	downregulated	29222745
7659	Human	hsa-miR-26a	miRNA	IFN-¦Â	multiple sclerosis (MS)	MS patients	interferon-¦Â treatment	downregulated	28962897
7660	Human	hsa-miR-26a	miRNA	palmitic acid (PA)	myocardial lipotoxic injury	human cardiomyocytes (AC16 cells)	palmitic acid (PA) treatment	downregulated	31123414
7661	Human	hsa-miR-26a	miRNA	A23187	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	A23187 treatment	upregulated	32567701
7662	Human	hsa-miR-26a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
7663	Human	hsa-miR-26a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	compound C treatment	downregulated	32143184
7664	Human	hsa-miR-26a	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	oleate acid (OA) treatment	upregulated	32567701
7665	Human	hsa-miR-26a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	palmitate acid (PA) treatment	upregulated	32567701
7666	Human	hsa-miR-26a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid treatment	downregulated	32143184
7667	Human	hsa-miR-26a	miRNA	particulate matter (PM2.5)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	particular matters (PM) PM2.5 treatment	downregulated	30798028
7668	Human	hsa-miR-26a	miRNA	thapsigargin (Tg)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	thapsigargin (Tg) treatment	upregulated	32567701
7669	Human	hsa-miR-26a	miRNA	tunicamycin (TM)	nonalcoholic fatty liver disease (NAFLD)	"HepG2, Huh7, 786-O cells"	tunicamycin (Tu) treatment	upregulated	32567701
7670	Human	hsa-miR-26a	miRNA	pan-HDAC inhibitor ITF2357	non-Hodgkin lymphoma (NHL)	human B-cell non-Hodgkin lymphomas (B-NHLs)	pan-HDAC inhibitor ITF2357 treatment	upregulated	24648290
7671	Human	hsa-miR-26a	miRNA	metformin (Met)	oral cancer	KB human oral cancer cells	metformin treatment	upregulated	27082123
7672	Human	hsa-miR-26a	miRNA	IL-1¦Â	osteoarthritis (OA)	human Chondrocytes-articular	IL-1¦Â treatment	downregulated	28276108
7673	Human	hsa-miR-26a	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	downregulated	29208566
7674	Human	hsa-miR-26a	miRNA	IL-1¦Â	osteoarthritis (OA)	SW1353 cells	IL-1¦Â treatment	upregulated	32522568
7675	Human	hsa-miR-26a	miRNA	metformin (Met)	pancreatic cancer (PC)	Human pancreatic cancer cell lines AsPC-1£» AsPC-1-GTR£» MiaPaCa-2£» MiaPaCa-2-GTR	Metformin? treatment	downregulated	22086681
7676	Human	hsa-miR-26a	miRNA	cadmium (Cd)	preeclampsia (PE)	JEG-3 cells	cadmium (Cd) treatment	upregulated	28774740
7677	Human	hsa-miR-26a	miRNA	metformin (Met)	renal cancer	786-O cells	metformin treatment	upregulated	25419360
7678	Human	hsa-miR-26a	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	upregulated	17653614
7679	Human	hsa-miR-26a	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	downregulated	18573151
7680	Human	hsa-miR-26a	miRNA	S-adenosylhomocysteine hydrolase (AHCY)	prostate cancer	LNCaP-hr cells	AHCY treatment	upregulated	28705714
7681	Human	hsa-miR-26a	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	30542439
7682	Human	hsa-miR-26a	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	upregulated	21030674
7683	Human	hsa-miR-26a	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	caco-2?cell line	high glucose treatment	upregulated	31493868
7684	Human	hsa-miR-26a	miRNA	¦Â-glycerophosphate (¦Â-GP)	vascular calcification (VC)	vascular smooth muscle cells (VSMCs)	incubated with 10 mmol/L ¦Â-glycerol phos_x0002_phate (¦Â-GP) for 7 and 14 days treatment	downregulated	29050490
7685	Human	hsa-miR-26a	miRNA	TGF-¦Â1	wound healing	HaCaT cells; NHEK cells	TGF-¦Â1 treatment	The RNA expression of miR-26a was downregulated and ITGA5 protein expression was upregulated by TGF-¦Â1 treatment in HaCaT and NHEK cells in a time-dependent manner	32955094
7686	Human	hsa-miR-26a-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	32102754
7687	Human	hsa-miR-26a-5p	miRNA	IL-1¦Â	adrenal steroid production	NCI-H295R cells	IL-1¦Â treatment	downregulated	33508847
7688	Human	hsa-miR-26a-5p	miRNA	kaempferol	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	kaempferol treatment	Kaempferol upregulated miR-26a-5p expression in ox-LDL-stimulated HAECs.	30372882
7689	Human	hsa-miR-26a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31865360
7690	Human	hsa-miR-26a-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	RKO cells	5-fluorouracil (5-FU) treatment	SNHG6 may promote chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in CRC cells.	31516391
7691	Human	hsa-miR-26a-5p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	Di (2-ethylhexyl) phthalate (DEHP)-induced lung toxicity	A549 cells	di(2-ethylhexyl) phthalate (DEHP) treatment	MiR-26a-5p was significantly enriched in DEHP-elicited sEV.	33229049
7692	Human	hsa-miR-26a-5p	miRNA	high glucose (HG)	diabetic cataract (DC)	SRA01/04 cells	high glucose treatment	downregulated	32950535
7693	Human	hsa-miR-26a-5p	miRNA	bovine serum albumin (BSA)	diabetic nephropathy (DN)	HK-2 cells	bovine serum albumin (BSA) treatment	miR-26a-5p expression in exosomes secreted by BSA-treated HK-2 cells was significantly increased.	32853650
7694	Human	hsa-miR-26a-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
7695	Human	hsa-miR-26a-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
7696	Human	hsa-miR-26a-5p	miRNA	IFN-¦Â	multiple sclerosis (MS)	RRMS patients	IFN-¦Â treatment	upregulated	24885345
7697	Human	hsa-miR-26a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
7698	Human	hsa-miR-26a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
7699	Human	hsa-miR-26a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	synovial fibroblast	IL-1¦Â treatment	downregulated	31784400
7700	Human	hsa-miR-26a-5p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	upregulated	27018851
7701	Human	hsa-miR-26a-5p	miRNA	dexamethasone (DEX)	steroid-induced osteonecrosis of femoral head (ONFH)	human bone marrow-derived mesenchymal stem cells (hBMSCs)	dexamethasone (DEX) treatment	"NORAD expression was downregulated in SONFH tissues, while miR-26a-5p expression was upregulated."	33413642
7702	Human	hsa-miR-26b	miRNA	yin yang 1 (YY1)	acute myeloid leukemia (AML)	"Human AML cells U937, KG-1, THP-1, and HL-60"	yin yang 1 (YY1) treatment	downregulated	33318617
7703	Human	hsa-miR-26b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
7704	Human	hsa-miR-26b	miRNA	ionizing radiation (IR)	breast cancer	MCF7 breast cancer cells	"Cells were given for IR 24 h after transfection and harvested by centrifugation at 13,201 x g for 3 min at room temperature for analysis. IR was delivered at a rate of 0.38 Gy/min (180 kV; 18 mA) using an XSZ-Z20/20 X-ray generator (Kang Jia Instrument Equipment Co., Ltd., Dandong, China)."	downregulated	29399189
7705	Human	hsa-miR-26b	miRNA	radiation	breast cancer	MCF7 breast cancer cells	radiation treatment	downregulated	29399189
7706	Human	hsa-miR-26b	miRNA	estrogen (ES)	cell proliferation	"MCF-7¡¢T47D¡¢MDA-MB-231 , BT549 cell"	estrogen treatment	downregulated	24735615
7707	Human	hsa-miR-26b	miRNA	chloroquine	chloroquine in inducing apoptosis of human hepatocellular carcinoma cells	HepG2 cells	chloroquine treatment	chloroquine significantly increased the expression of miR-26b and downregulated the expression of Mcl-1 in HepG2 cells.	29735440
7708	Human	hsa-miR-26b	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	cholangiocarcinoma (CCA)	human cholangiocarcinoma cell	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA) treatment	downregulated	25691459
7709	Human	hsa-miR-26b	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
7710	Human	hsa-miR-26b	miRNA	etanercept	gastric cancer (GC)	?serum	Etanercept treatment	downregulated	23600954
7711	Human	hsa-miR-26b	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	"HepG2,Huh-7, 293T"	DOX at a range of 0.5¨C25?¦ÌM over a period of 10 months	downregulated	28079894
7712	Human	hsa-miR-26b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	cell differentiation	Human preadipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	23275201
7713	Human	hsa-miR-26b	miRNA	arsenite	liver fibrosis	human hepatic (L-02) cells	arsenite exposure	exosomal MALAT1 derived from arsenite-treated L-02 cells promoted the activation of LX-2 cells via microRNA-26b regulation of COL1A2.	31513886
7714	Human	hsa-miR-26b	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	31432162
7715	Human	hsa-miR-26b	miRNA	¦Ã-rays	lung cancer	H1299 lung cancer cells	¦Ã-rays treatment	downregulated	21901137
7716	Human	hsa-miR-26b	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
7717	Human	hsa-miR-26b	miRNA	tacrolimus or high glucose	new-onset diabetes after liver transplantation (NODALT)	human hepatocytes	tacrolimus or high glucose treatment	dysregulated	27458792
7718	Human	hsa-miR-26b	miRNA	high glucose (HG)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	high-glucose (HG) treatment	downregulated	31625803
7719	Human	hsa-miR-26b	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	downregulated	29208566
7720	Human	hsa-miR-26b	miRNA	pioglitazone	osteoarthritis (OA)	high-glucose (HG) treated human osteoarthritis (OA) chondrocytes	pioglitazone (PGZ) treatment	upregulated	31625803
7721	Human	hsa-miR-26b	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	human PCO-attached lens epithelial cells (LECs) and SRA01/04 cells	TGF-¦Â2 treatment	downregulated	25063219
7722	Human	hsa-miR-26b	miRNA	epidermal growth factor (EGF)	posterior capsular opacification (PCO)	primary human lens epithelial cells (HLECs)	epidermal growth factor (EGF) treatment	downregulated	29977916
7723	Human	hsa-miR-26b	miRNA	lipopolysaccharide (LPS)	sepsis	Neonatal Polymorphonuclear Leukocytes	lipopolysaccharide (LPS) treatment	dysregulated	28655995
7724	Human	hsa-miR-26b	miRNA	hydroxyurea	sickle cell anemia (SCA)	Circulating erythroid cells	Hydroxyurea treatment	upregulated	21921042
7725	Human	hsa-miR-26b	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	caco-2?cell line	high glucose treatment	upregulated	31493868
7726	Human	hsa-miR-26b	miRNA	desferrioxamine (DFOM)	immune response	carcinoma of nasopharyngeal epithelial (CNE) cells	desferrioxamine (DFOM)	upregulated	20100477
7727	Human	hsa-miR-26b-3p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	downregulated	30197683
7728	Human	hsa-miR-26b-5p	miRNA	huaier	anti-cancer therapy	pulmonary adenocarcinoma A549 cells	huaier treatment	upregulated	24815696
7729	Human	hsa-miR-26b-5p	miRNA	high glucose (HG)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	LncRNA HCG11/miR-26b-5p/QKI5 feedback loop reversed high glucose-induced proliferation and angiogenesis inhibition of HUVECs.	33128346
7730	Human	hsa-miR-26b-5p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
7731	Human	hsa-miR-26b-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
7732	Human	hsa-miR-26b-5p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
7733	Human	hsa-miR-26b-5p	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	spontaneous preterm birth (SPB)	human syncytiotrophoblast	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	"miR-181b-5p and miR-26b-5p in term human syncytiotrophoblast were increased in response to treatment with 1,25(OH)2D."	30395535
7734	Human	hsa-miR-26b-5p	miRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HASMCs)	phosphorus treatment	upregulated	32347320
7735	Human	hsa-miR-27	miRNA	nanocurcumin	ankylosing spondylitis (AS)	peripheral blood mononuclear cells (PBMCs)	nanocurcumin treatment	downregulated	31074089
7736	Human	hsa-miR-27	miRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Huh7.5 cells	hepatitis C virus (HCV) infection	upregulated	23897856
7737	Human	hsa-miR-27	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	HT-29 cells	TGF-¦Â treatment	upregulated	23483606
7738	Human	hsa-miR-27	miRNA	hepatitis C virus (HCV)	hepatic steatosis	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	23897856
7739	Human	hsa-miR-27a	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
7740	Human	hsa-miR-27a	miRNA	alcohol	alcoholic liver disease (ALD)	monocyte	alcohol exposure	upregulated	25716995
7741	Human	hsa-miR-27a	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
7742	Human	hsa-miR-27a	miRNA	betulinic acid (BA)	atherosclerosis (AS)	The RKO and SW480 colon cancer cell lines	betulinic acid (BA) treatment	downregulated	21864401
7743	Human	hsa-miR-27a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1-derived macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31518965
7744	Human	hsa-miR-27a	miRNA	C8 fluoride derivative of cheliensisin A (ChlA-F)	bladder cancer	T24 cells	ChlA-F treatment	downregulated	30118841
7745	Human	hsa-miR-27a	miRNA	arsenic trioxide (ATO)	breast cancer	breast cancer cells	arsenic trioxide (ATO) treatment	downregulated	26592661
7746	Human	hsa-miR-27a	miRNA	arsenic trioxide (ATO)	breast cancer	MDA-MB-231 and SK-BR-3	arsenic trioxide (ATO) treatment	downregulated	26592661
7747	Human	hsa-miR-27a	miRNA	betulinic acid (BA)	breast cancer	Human mammary carcinoma cell lines MDA-MB-231£»MDA-MB-435£» BT474£»MDA-MB-468£»MDA-MB-453£»HS-578T	betulinic acid (BA) treatment	downregulated	22407812
7748	Human	hsa-miR-27a	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	upregulated	25120778
7749	Human	hsa-miR-27a	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
7750	Human	hsa-miR-27a	miRNA	liraglutide	breast cancer	MCF-7 cells	liraglutide treatment	liraglutide treatment downregulated miR-27a expression in MCF-7 cells.	29393459
7751	Human	hsa-miR-27a	miRNA	metformin (Met)	breast cancer	breast cancer MCF-7 cells	metformin treatment	downregulated	27779715
7752	Human	hsa-miR-27a	miRNA	pomegranate polyphenolics	breast cancer	Human mammary carcinoma cell lines BT474 and MDA-MB-231	pomegranate polyphenolics treatment	downregulated	22941571
7753	Human	hsa-miR-27a	miRNA	tamoxifen (TAM)	breast cancer	MCF7 cells; T47D luminal A breast cancer cells	tamoxifen treatment	Tamoxifen-resistant cells showed decreased expression of ER¦Á and miR-27a.	30415143
7754	Human	hsa-miR-27a	miRNA	tamoxifen (TAM)	breast cancer	MCF7 and T47D luminal A breast cancer cell lines	tamoxifen treatment	downregulated	30415143
7755	Human	hsa-miR-27a	miRNA	vascular endothelial growth factor (VEGF)	breast cancer	breast cancer stem like cells (BCSLCs)	vascular endothelial growth factor (VEGF) treatment	upregulated	23752185
7756	Human	hsa-miR-27a	miRNA	vascular endothelial growth factor (VEGF)	breast cancer	MDA-MB-231 breast cancer cell line	VEGF treatment	upregulated	23752185
7757	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	bronchopneumonia	BEAS-2B cells	lipopolysaccharide (LPS) treatment	upregulated	29772436
7758	Human	hsa-miR-27a	miRNA	tanshinone IIA (Tan IIA)	bronchopneumonia	LPS-treated BEAS-2B cells	Tanshinone IIA (Tan) treatment	downregulated	29772436
7759	Human	hsa-miR-27a	miRNA	SV40 small T antigen	tumorigenesis	human bronchial epithelial cells(HBERST)	SV40 small T antigen treatment	upregulated	21460851
7760	Human	hsa-miR-27a	miRNA	"ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094)"	candida albicans infection	RKO and SW480 colon cancer cells	"Ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094) treatment"	downregulated	21156786
7761	Human	hsa-miR-27a	miRNA	high glucose (HG)	cell damage	human renal tubular epithelial HK-2	high glucose (HG) treatment	miR-27a participates in the effects of GAS5 silencing on HG-stimulated HK-2 cells; BNIP3 is regulated by miR-27a and related to the HG toxicity to HK-2 cells.	31159592
7762	Human	hsa-miR-27a	miRNA	cholesterol	clear cell renal cell carcinoma (ccRCC)	The human ccRCC cell line 786-O	cholesterol treatment	upregulated	29782853
7763	Human	hsa-miR-27a	miRNA	"2,3-dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)]"	colorectal cancer (CRC)	colon cancer cells	"2,3-Dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)] treatment"	downregulated	24030632
7764	Human	hsa-miR-27a	miRNA	curcumin (Cur)	colorectal cancer (CRC)	RKO ; SW480 human colon carcinoma cell lines ; CCD-18Co colon fibroblasts	curcumin treatment	downregulated	23194063
7765	Human	hsa-miR-27a	miRNA	curcuminoids	colorectal cancer (CRC)	colon cancer SW-480 cells	curcuminoids treatment	downregulated	23471840
7766	Human	hsa-miR-27a	miRNA	resveratrol and quercetin	colorectal cancer (CRC)	HT-29 cells	Resveratrol and quercetin treatment	downregulated	23530649
7767	Human	hsa-miR-27a	miRNA	hypoxia	colorectal cancer (CRC)	"HT-29, Caco2 and SW480 cells"	hypoxia induce	upregulated	30393198
7768	Human	hsa-miR-27a	miRNA	hypoxia	colorectal cancer (CRC)	HT29 cells; SW480 cells; Caco2 cells	hypoxia treatment	upregulated	30393198
7769	Human	hsa-miR-27a	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
7770	Human	hsa-miR-27a	miRNA	arbutin (ARB)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) and Arbutin (ARB) co-treatment	"MiR-27a expression was reduced in HG-treated cells, but was accelerated in HG and ARB co-treated HK-2 cells with the increased concentration."	31319730
7771	Human	hsa-miR-27a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial HK-2	high glucose (HG) treatment	miR-27a participates in the effects of GAS5 silencing on HG-stimulated HK-2 cells; BNIP3 is regulated by miR-27a and related to the HG toxicity to HK-2 cells.	31159592
7772	Human	hsa-miR-27a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"MiR-27a expression was reduced in HG-treated cells, but was accelerated in HG and ARB co-treated HK-2 cells with the increased concentration."	31319730
7773	Human	hsa-miR-27a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	RPE-1 cells	high glucose (HG) treatment	downregulated	29896271
7774	Human	hsa-miR-27a	miRNA	hemin	erythroid cell differentiation	K562 cells	hemin treatment	miR-27a levels gradually increased after 0 hours and decreased after the 24- hour time point during hemin-induced erythroid differentiation.	29590650
7775	Human	hsa-miR-27a	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
7776	Human	hsa-miR-27a	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	hepatic stellate cells (HSC) transdifferentiate into myofibroblasts	colon cancer cells	"Methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate (CDODA-Me) treatment"	downregulated	19582879
7777	Human	hsa-miR-27a	miRNA	genistein	hepatocellular carcinoma (HCC)	human uveal melanoma cells	Genistein?treatment	downregulated	19639204
7778	Human	hsa-miR-27a	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
7779	Human	hsa-miR-27a	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs)	human immunodeficiency virus (Human immunodeficiency virus (HIV)) infection	upregulated	31371699
7780	Human	hsa-miR-27a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein gp120	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein gp120 treatment	upregulated	31371699
7781	Human	hsa-miR-27a	miRNA	recombinant Human immunodeficiency virus (HIV) viral protein Tat	HIV-associated neurocognitive disorders (HAND)	human monocyte-derived macrophages (MDMs) and THP-1 cells	recombinant Human immunodeficiency virus (HIV) viral protein Tat treatment	upregulated	31371699
7782	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	hypothyroidism	The human thyroid follicular epithelial cells (Nthy-ori 3-1)	lipopolysaccharide (LPS) treatment	downregulated	30300656
7783	Human	hsa-miR-27a	miRNA	salidroside (SAL)	hypothyroidism	LPS-treated the human thyroid follicular epithelial cells (Nthy-ori 3-1)	salidroside (SAL) treatment	upregulated	30300656
7784	Human	hsa-miR-27a	miRNA	mycobacterium tuberculosis (Mtb)	immune response	THP-1 cells	infect with Mtb	downregulated	31966878
7785	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	inflammation	MRC-5 cells	lipopolysaccharide (LPS) treatment	LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression.	31735661
7786	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	inflammation	BMDMs	lipopolysaccharide (LPS) treatment	downregulated	24835395
7787	Human	hsa-miR-27a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human mitral valve interstitial cells (hMVICs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29694513
7788	Human	hsa-miR-27a	miRNA	quercetin and hyperoside (QH)	injury in vascular smooth muscle cells	renal cancer cells	quercetin and hyperoside treatment	downregulated	24173369
7789	Human	hsa-miR-27a	miRNA	doxorubicin (DOX)	leukemia	myeloid leukemic cell lines NB4; human promyelocytic leukaemia cell line;HL60	doxorubicin (DOX)? treatment	downregulated	21070600
7790	Human	hsa-miR-27a	miRNA	genistein	lung cancer	A549 cells	Genistein treatment	upregulated	27602162
7791	Human	hsa-miR-27a	miRNA	glucagon-like peptide-1 (GLP-1)	lung fibrosis	human embryonic lung fibroblast (MRC-5) cells	Glucagon-like peptide-1 (GLP-1) treatment	"After pretreating MRC-5 cells via GLP-1, with or without compound C (AMPK inhibitor), the expression of miR-27a in the GLP-1 treated group was significantly lower than that in Vehicle group."	33850889
7792	Human	hsa-miR-27a	miRNA	alcohol	macrophage activation	plasma	alcohol exposure	upregulated	26527689
7793	Human	hsa-miR-27a	miRNA	alcohol	macrophage activation	THP-1	alcohol exposure	upregulated	26527689
7794	Human	hsa-miR-27a	miRNA	metformin (Met)	pancreatic cancer (PC)	Panc1 cells;L3.6pL cells;Panc28 cells	Metformin? treatment	downregulated	23803693
7795	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	monocytic differentiation	monocyte	lipopolysaccharide (LPS) treatment	dysregulated	25148686
7796	Human	hsa-miR-27a	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose (HG) treatment	upregulated	31889412
7797	Human	hsa-miR-27a	miRNA	high glucose (HG)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high glucose (HG) treatment	upregulated	31889412
7798	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	human oral keratinocytes (HOKs)	lipopolysaccharide (LPS) treatment	downregulated	31942011
7799	Human	hsa-miR-27a	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrosarcoma (SW1353) cells and primary cultured articular chondrocytes	IL-1¦Â treatment	upregulated	31460867
7800	Human	hsa-miR-27a	miRNA	IL-1¦Â	osteoarthritis (OA)	OA cartilage tissues and primary human articular chondrocyte	IL-1¦Â treatment	upregulated	31520995
7801	Human	hsa-miR-27a	miRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	Chondrocytes	IL-1¦Â and TNF-¦Á treatment	CircTMBIM6 promotes osteoarthritis-induced chondrocyte extracellular matrix degradation via miR-27a/MMP13 axis.	32767318
7802	Human	hsa-miR-27a	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
7803	Human	hsa-miR-27a	miRNA	glucocorticoid (GC)	osteogenesis	human bone marrow stromal cells ( hBMSCs)	glucocorticoid (GC) treatment	miR-27a expression profiles were found to be downregulated in ONFH samples and GC-induced hBMSCs using microarray analysis and real-time quantitative polymerase chain reaction	33532936
7804	Human	hsa-miR-27a	miRNA	astragalus polysaccharide (APS)	ovarian cancer (OC)	OV-90 cells	astragalus polysaccharide (APS) treatment	APS dose-dependently decreased the levels of miR-27a in OV-90 cells.	32159214
7805	Human	hsa-miR-27a	miRNA	hypoxia	ovarian cancer (OC)	Skov3 cells	hypoxia treatment	The expression of the miR-27a was obviously upregulated under hypoxia and involved in hypoxia-induced paclitaxel resistance.	32190895
7806	Human	hsa-miR-27a	miRNA	H2O2	oxidative stress	human trabecular meshwork (HTM) cells	H2O2 treatment	downregulated	31062616
7807	Human	hsa-miR-27a	miRNA	salidroside (SAL)	oxidative stress	H2O2-treated human trabecular meshwork (HTM) cells	salidroside (SAL) treatment	upregulated	31062616
7808	Human	hsa-miR-27a	miRNA	genistein	pancreatic cancer (PC)	BxPC-3 and PANC-1 cell	genistein treatment	downregulated	24479798
7809	Human	hsa-miR-27a	miRNA	paraquat (PQ)	paraquat poisoning	serum	paraquat treatment	Decreased serum miR-27a level and increased IL-10 expression levels were detected in patients with paraquat poisoning compared with healthy controls	32104255
7810	Human	hsa-miR-27a	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	LPS triggered adverse inflammation response by elevating the biogenesis of circAtp9b which caused a repressive role in miR-27a expression.	31735661
7811	Human	hsa-miR-27a	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	downregulated	27915273
7812	Human	hsa-miR-27a	miRNA	hemin	pulmonary hypertension (PH)	human pulmonary artery endothelial cells (HPAECs)	hemin for 72 hours	upregulated	27612006
7813	Human	hsa-miR-27a	miRNA	hypoxia	pulmonary hypertension (PH)	Human pulmonary artery endothelial cells (HPAECs)	hypoxia treatment	downregulated	24244514
7814	Human	hsa-miR-27a	miRNA	rosiglitazone	pulmonary hypertension (PH)	mouse	"rosiglitazone (RSG), 10 mg/kg/day treatment"	upregulated	27612006
7815	Human	hsa-miR-27a	miRNA	quercetin and hyperoside (QH)	renal cell carcinoma (RCC)	786-O renal cancer cells	quercetin and hyperoside (QH) in combination (1:1 ratio) treatment	downregulated	24173369
7816	Human	hsa-miR-27a	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	rhabdomyosarcoma (RMS)	RD and Rh30 rhabdomyosarcoma (RMS) cells	"Methyl 2-trifluoromethyl-3,11-dioxo-18¦Â-olean-1,12-dien-3-oate (CF3DODA-Me) treatment"	downregulated	30610105
7817	Human	hsa-miR-27a	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
7818	Human	hsa-miR-27a	miRNA	"haloperidol, clozapine and olanzapine"	schizophrenia (SZ)	"HepG2 (ATCC,CRL-1573)"	"haloperidol, clozapine , olanzapine treatment"	downregulated	28429622
7819	Human	hsa-miR-27a	miRNA	folate	squamous cell carcinoma (SCC)	HeLa cells; SiHa cells	Folate treatment	"There was a highly significant difference between the 200 and 500 nM folate groups, in which miR-27a expression levels were significantly downregulated between the 200 and 500 nM concentration groups."	31918266
7820	Human	hsa-miR-27a	miRNA	X-rays	stress response	human endothelial cell-line EA.hy926 and the mammary epithelial cell-line MCF10A	a single dose of 5Gy ?-radiation	downregulated	28851536
7821	Human	hsa-miR-27a	miRNA	hypoxia	urothelial bladder carcinoma	human bladder cancer cell line (J82)	hypoxia treatment	upregulated	24462738
7822	Human	hsa-miR-27a-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells; BEAS-2B cells	lipopolysaccharide (LPS) treatment	MiR-27a-3p was downregulated in LPS-induced alveolar epithelial cells.	32993961
7823	Human	hsa-miR-27a-3p	miRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	Significantly higher miR-27a-3p expression was confirmed in MCF-7/ADR as compared with sensitive cell line MCF-7.	32764979
7824	Human	hsa-miR-27a-3p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
7825	Human	hsa-miR-27a-3p	miRNA	folate	cervical cancer (CC)	HeLa-GFP and SiHa cells	500nM Folate treatment	downregulated	31918266
7826	Human	hsa-miR-27a-3p	miRNA	lipopolysaccharide (LPS)	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"TUG1 could repress cell apoptosis, autophagy, and inflammatory response in LPS-treated HUVECs by sponging miR-27a-3p to target SLIT2."	32738556
7827	Human	hsa-miR-27a-3p	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	downregulated	30503955
7828	Human	hsa-miR-27a-3p	miRNA	dihydrotestosterone (DHT)	cardiovascular disease (CVD)	EA.hy926	dihydrotestosterone treatment	downregulated	28240250
7829	Human	hsa-miR-27a-3p	miRNA	hypoxia	ischemic heart disease (IHD)	AC16 cell	hypoxia exposure	circ_0010729 knockdown alleviated hypoxia-induced AC16 cell injuries by mediating the miR-27a-3p/TRAF5 axis.	33010282
7830	Human	hsa-miR-27a-3p	miRNA	TGF-¦Â1	lung fibrosis	human lung fibroblasts	transforming growth factor-¦Â1 treatment	upregulated	26600197
7831	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	downregulated	27143365
7832	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
7833	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
7834	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	29749508
7835	Human	hsa-miR-27a-3p	miRNA	IL-1¦Â and/or TNF-¦Á	osteoarthritis (OA)	Human cartilage C28/I2 cells	IL-1¦Â and/or TNF-¦Á treatment	FOXD2-AS1 upregulated the expression level of TLR4 by sponging miR-27a-3p.	30945573
7836	Human	hsa-miR-27a-3p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
7837	Human	hsa-miR-27a-3p	miRNA	insulin	polycystic ovarian syndrome (PCOS)	human granulosa-like tumor cell line (KGN)	insulin treatment	downregulated	29029022
7838	Human	hsa-miR-27a-3p	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32084559
7839	Human	hsa-miR-27a-3p	miRNA	adalimumab(ADA)	rheumatoid arthritis (RA)	plasma	adalimumab(ADA) treatment	"In the ADA group, a higher pretreatment level of miR-27a-3p was significantly associated with remission at 12 months. The level decreased in remitting patients between pretreatment and 3 months, and increased in nonremitting patients."	29142030
7840	Human	hsa-miR-27a-3p	miRNA	CoCl2	acute kidney injury (AKI)	human kidney tubular cells (HK-2)	CoCl2?-stimulated HK-2 cells	miR-27a-3p was downregulated in AKI patients compared with healthy control.	31090110
7841	Human	hsa-miR-27a-3p	miRNA	ischemia	acute kidney injury (AKI)	serum from AKI patients	ischemia©\induced AKI	The level of miR©\27a©\3p in HK©\2 cells treated with CoCl2 was decreased in a dose©\dependent manner.	31090110
7842	Human	hsa-miR-27a-5p	miRNA	TGF-¦Â1	against cancer	human natural killer (NK) cells	TGF-¦Â1 treatment	upregulated	28791023
7843	Human	hsa-miR-27a-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
7844	Human	hsa-miR-27a-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	upregulated	31198949
7845	Human	hsa-miR-27a-5p	miRNA	cyclosporine A (CsA)	drug-induced liver injury (DILI)	upcyte hepatocytes	cyclosporine A (CYCA) treatment	upregulated	31198949
7846	Human	hsa-miR-27a-5p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
7847	Human	hsa-miR-27a-5p	miRNA	oxidized glycerophospholipids (oxGPs) and IL-1¦Â	inflammation	human aortic endothelial cells (HAECs)	oxGPs and interleukin 1¦Â (IL-1¦Â) treatment	upregulated	25327529
7848	Human	hsa-miR-27a-5p	miRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte primary cells (HCM)	hypoxia treatment	downregulated	32528555
7849	Human	hsa-miR-27a-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
7850	Human	hsa-miR-27a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	32546573
7851	Human	hsa-miR-27a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	sepsis	human pulmonary microvascular endothelial cells (HPMECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32546573
7852	Human	hsa-miR-27a-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
7853	Human	hsa-miR-27-a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine protects SH-SY5Y cells against oxygen-glucose deprivation and reoxygenation-induced injury partly through the inhibition of microRNA-27-a-5p and promotion of the Bach1/HO-1 signaling pathway.	32706194
7854	Human	hsa-miR-27b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
7855	Human	hsa-miR-27b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	fibroblast-like synoviocytes (FLSs) cells (MH7A)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31124343
7856	Human	hsa-miR-27b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1-derived macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31518965
7857	Human	hsa-miR-27b	miRNA	leptin	bone malignancy	chondrosarcoma cells	Leptin treatment	"the expression of microRNA-27b was negatively regulated by leptin via the FAK, PI3K and Akt cascade."	27345723
7858	Human	hsa-miR-27b	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	downregulated	25120778
7859	Human	hsa-miR-27b	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
7860	Human	hsa-miR-27b	miRNA	IL-6	breast cancer	MCF-7 and MDA-MB-231 cells	interleukin-6 (IL-6) treatment	downregulated	31515600
7861	Human	hsa-miR-27b	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	ARPE-19 cells	platelet-derived growth factor (PDGF)-BB treatment	downregulated	29858119
7862	Human	hsa-miR-27b	miRNA	adiponectin	chondrosarcoma	human lymphatic endothelial cells	adiponectin (ApN) treatment	downregulated	27252405
7863	Human	hsa-miR-27b	miRNA	IL-6	colorectal cancer (CRC)	HCT116 and SW480 cells	IL-6 treatment	downregulated	25333344
7864	Human	hsa-miR-27b	miRNA	oxidized low density lipoprotein (ox-LDL)	Dendritic cell (DC) maturation	Human peripheral blood monocytes differentiated DCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29617044
7865	Human	hsa-miR-27b	miRNA	alagebrium chloride (ALT711)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	alagebrium chloride (ALT711) treatment	upregulated	30972183
7866	Human	hsa-miR-27b	miRNA	N¦Å-carboxymethyl-lysine (CML)-BSA	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	N¦Å-carboxymethyl-lysine (CML)-BSA treatment	downregulated	30972183
7867	Human	hsa-miR-27b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high-glucose treatment	downregulated	29786744
7868	Human	hsa-miR-27b	miRNA	TGF-¦Â	fibrosis	A549 human alveolar epithelial cells	TGF-¦Â treatment	downregulated	24633904
7869	Human	hsa-miR-27b	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31046802
7870	Human	hsa-miR-27b	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	human glioma U251 cells	infect with HCMV	upregulated	28343438
7871	Human	hsa-miR-27b	miRNA	hepatocyte growth factor (HGF)	head and neck squamous cell carcinoma (HNSCC)	HNSCC; adjacent normal squamous epithelial tissues	Hepatocyte growth factor (HGF) treatment	downregulated	21899661
7872	Human	hsa-miR-27b	miRNA	tetrandrine	hypertrophic scars (HS)	human hypertrophic scar fibroblasts (HSFs)	tetrandrine treatment	upregulated	26909951
7873	Human	hsa-miR-27b	miRNA	insulin	insulin resistance (IR)	human mesenchymal stem cell (hMSC)-derived adipocytes	insulin treatment	upregulated	29455245
7874	Human	hsa-miR-27b	miRNA	fumonisin B?	hepatocellular carcinoma (HCC)	human hepatoma cell line (HepG2)	Fumonisin B? treatment	downregulated	24614526
7875	Human	hsa-miR-27b	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	upregulated	28347920
7876	Human	hsa-miR-27b	miRNA	(6)-gingerol (6G)	myeloid leukemia	U937 cells; K562 cells	(6)-gingerol (6G) treatment	upregulated	24378438
7877	Human	hsa-miR-27b	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	human oral keratinocytes (HOKs)	lipopolysaccharide (LPS) treatment	downregulated	31942011
7878	Human	hsa-miR-27b	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
7879	Human	hsa-miR-27b	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
7880	Human	hsa-miR-27b	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial endothelial cells (HPAECs)	hypoxia treatment	The results revealed that PPAR¦Ã expression was downregulated and miR-27b expression was upregulated in the HPAECs exposed to hypoxia.	33907846
7881	Human	hsa-miR-27b	miRNA	lipopolysaccharide (LPS)	transitional cell carcinomas (TCCs)	primary human macrophages	lipopolysaccharide (LPS) treatment	upregulated	20164187
7882	Human	hsa-miR-27b	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	serum	liraglutide treatment	upregulated	33008044
7883	Human	hsa-miR-27b	miRNA	bisphenol A (BPA)	vascular endothelial dysfunction	primary cultured human endometrial stromal cells (HESCs)	bisphenol A (BPA) treatment	downregulated	30328349
7884	Human	hsa-miR-27b	miRNA	estradiol-17¦Â (E2)	vascular endothelial dysfunction	primary cultured human endometrial stromal cells (HESCs)	estradiol-17¦Â (E2) treatment	downregulated	30328349
7885	Human	hsa-miR-27b-3p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
7886	Human	hsa-miR-27b-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	aortic dissection (AD)	Human aortic smooth muscle cells (HASMCs)	platelet derived growth factor-BB (PDGF-BB) treatment	"In AD, PVT1 expression was upregulated, yet that of miR-27b-3p was downregulated"	33106979
7887	Human	hsa-miR-27b-3p	miRNA	house dust mite (HDM)	asthma	human	dust mite treatment	downregulated	30406061
7888	Human	hsa-miR-27b-3p	miRNA	angiotensin II (Ang II)	atrial fibrillation (AF)	Human atrial fibroblasts (HAFs)	angiotensin II (Ang II) treatment	upregulated	30729664
7889	Human	hsa-miR-27b-3p	miRNA	tamoxifen (TAM)	breast cancer	MCF-7/TAM-1 and T47D/TAM-1 cells	tamoxifen treatment	downregulated	27809310
7890	Human	hsa-miR-27b-3p	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; HCT116 cells	Oxaliplatin (OXA) treatment	miR-27b-3p expression was significantly downregulated in oxaliplatin-resistant cell lines (SW480-OxR and HCT116-OxR)	32104496
7891	Human	hsa-miR-27b-3p	miRNA	geniposide (GEN)	diffuse large B-cell lymphoma (DLBCL)	OCI-LY7; OCI-LY3 cells	geniposide treatment	Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis	33162801
7892	Human	hsa-miR-27b-3p	miRNA	Rg3-enhanced red ginseng extract (Rg3E)	endometriosis	human endometrial stromal cells (HESCs)	400??L/mL Rg3E and cultured for 48?h treatment	downregulated	29247225
7893	Human	hsa-miR-27b-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	MKN-45 and SGC-7901 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31539861
7894	Human	hsa-miR-27b-3p	miRNA	radiation	gastric cancer (GC)	MKN-45 and AGS cells	radiation treatment	NEAT1 depletion enhanced radio-sensitivity of GC by negatively regulating miR-27b-3p in vitro and in vivo	33292252
7895	Human	hsa-miR-27b-3p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
7896	Human	hsa-miR-27b-3p	miRNA	dihydrotestosterone (DHT)	cardiovascular disease (CVD)	EA.hy926	dihydrotestosterone treatment	downregulated	28240250
7897	Human	hsa-miR-27b-3p	miRNA	l-carnitine	male infertility	sperm	l-carnitine treatment	upregulated	31749176
7898	Human	hsa-miR-27b-3p	miRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	oral squamous cell carcinoma (OSCC) cells	cisplatin treatment	downregulated	33191714
7899	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	downregulated	27143365
7900	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
7901	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
7902	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-7¦Â treatment	dysregulated	29123165
7903	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-11¦Â treatment	dysregulated	29123165
7904	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	31863917
7905	Human	hsa-miR-27b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human transformed chondrocytes C28/I2	IL-1¦Â treatment	downregulated	31863917
7906	Human	hsa-miR-27b-5p	miRNA	sulforaphane (SFN)	cancer treatment	NCI-60 cells	sulforaphane treatment	downregulated	32429039
7907	Human	hsa-miR-27b-5p	miRNA	IL-10	hemangioma (HA)	human primary HDEC	recombinant IL-10 (rIL-10) treatment	rIL-10 can increase expression of miR-27b-5p	32416101
7908	Human	hsa-miR-27b-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oral squamous cell carcinoma (OSCC)	SCC-4 cells	Mono-2-ethyhexyl phthalate (MEHP) treatment	downregulated	30858031
7909	Human	hsa-miR-27b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
7910	Human	hsa-miR-28	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
7911	Human	hsa-miR-28	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
7912	Human	hsa-miR-281	miRNA	platelet derived growth factor-BB (PDGF-BB)	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	29514810
7913	Human	hsa-miR-28-3p	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
7914	Human	hsa-miR-28-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
7915	Human	hsa-miR-28-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
7916	Human	hsa-miR-28-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
7917	Human	hsa-miR-28-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	myeloma	human myeloma cell lines (HMCLs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28775176
7918	Human	hsa-miR-28-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
7919	Human	hsa-miR-28-5p	miRNA	"glucose,hydrogen peroxide"	oxidative stress	primary human tenocytes	high (17.5 mM) and 100 ¦ÌM hydrogen peroxide treatment	upregulated	24556689c
7920	Human	hsa-miR-28-5p	miRNA	hydrocarbons (PAHs)	hydrocarbons (PAHs) toxic action	20 exposed workers pooled plasma samples	exposed to PAHs treatment	dysregulated	24633190
7921	Human	hsa-miR-28-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
7922	Human	hsa-miR-28-5p	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
7923	Human	hsa-miR-2861	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
7924	Human	hsa-miR-28a	miRNA	lithocholic acid (LCA)	glutathione synthesis and antioxidant capacity	Huh-7 cells	lithocholic acid (LCA) treatment	upregulated	25226452
7925	Human	hsa-miR-28a-5p	miRNA	prostaglandin E2 (PGE2)	liver fibrosis	TGF-¦Â1-treated LX-2 cells	PGE2 treatment	downregulated	29109031
7926	Human	hsa-miR-28a-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	upregulated	29109031
7927	Human	hsa-miR-28b	miRNA	dexamethasone (DEX)	central fat accumulation	primary SVF cells derived from human SAT and VAT	dexamethasone (DEX) treatment	upregulated	25187367
7928	Human	hsa-miR-28b	miRNA	lithocholic acid (LCA)	glutathione synthesis and antioxidant capacity	Huh-7 cells	lithocholic acid (LCA) treatment	upregulated	25226452
7929	Human	hsa-miR-28b	miRNA	ERK1/2 inhibitor	leukemia	TIB152 human leukemia cell line	ER¦Á-neutralizing antibody or ERK1/2 inhibitor treatment	downregulated	24974218
7930	Human	hsa-miR-28b	miRNA	ER¦Á-neutralizing antibody	leukemia	TIB152 human leukemia cell line	ER¦Á-neutralizing antibody or ERK1/2 inhibitor treatment	downregulated	24974218
7931	Human	hsa-miR-29	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
7932	Human	hsa-miR-29	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	burkitt lymphoma (BL)	The BL cell lines: Raji (EBV+) and BL41 (EBV-)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31173259
7933	Human	hsa-miR-29	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial cells (RPEs)	high glucose treatment	upregulated	32447557
7934	Human	hsa-miR-29	miRNA	progesterone (P4)	esophageal cancer (EC)	T47D cells; MCF7 cells	Progesterone treatment	progestin treatment decreases miR-29	22330642
7935	Human	hsa-miR-29	miRNA	TGF-¦Â	fibrosis	Dermal fibroblasts	TGF-¦Â treatment	downregulated	31155965
7936	Human	hsa-miR-29	miRNA	cisplatin and docetaxel	gastric cancer (GC)	gastric cancer cell	cisplatin and docetaxel treatment	upregulated	25634213
7937	Human	hsa-miR-29	miRNA	TGF-¦Â	glioblastoma multiforme (GBM)	human trabecular meshwork (HTM) cells	transforming growth factor-betas treatment	downregulated	21273536
7938	Human	hsa-miR-29	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
7939	Human	hsa-miR-29	miRNA	high glucose (HG)	hyperglycemia	human retinal pigment epithelial (RPE)	high glucose treatment	upregulated	26822433
7940	Human	hsa-miR-29	miRNA	TGF-¦Â2	innate immunity	trabecular meshwork (TM)	TGF-¦Â2 treatment	the incubation of TM cells with TGF-¦Â2 induced miR-29a and suppressed miR-29b levels	21330653
7941	Human	hsa-miR-29	miRNA	TGF-¦Â1	leprosy	human lung fibroblasts	TGF-¦Â1 treatment	Treatment of the human embryonic lung fibroblast cell line IMR90 with TGF¦Â1 caused a decrease in expression of miR-29a/b/c	23238947
7942	Human	hsa-miR-29	miRNA	TGF-¦Â1	lung cancer	proximal tubular cells; primary mesangial cells; podocytes	TGF-¦Â1 treatment	downregulated	22095944
7943	Human	hsa-miR-29	miRNA	IFN-¦Ã	melanoma	melanoma cell lines	?IFN-¦Ã?treatment treatment	downregulated	23245396
7944	Human	hsa-miR-29	miRNA	IFN-¦Â	multiple sclerosis (MS)	Peripheral blood mononuclear cells (PBMC)	Interferon-¦Â treatment	downregulated	23921681
7945	Human	hsa-miR-29	miRNA	TGF-¦Â1	orbital fibrosis	human orbital fibroblasts (OFs)	TGF-¦Â1 treatment	downregulated	25550793
7946	Human	hsa-miR-29	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human endometrial cell-lines	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	28499250
7947	Human	hsa-miR-29	miRNA	Salmonella	salmonella typhimurium infection	human monocytes	Salmonella Typhimurium infection treatment	upregulated	22248082
7948	Human	hsa-miR-29	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	upregulated	30182520
7949	Human	hsa-miR-29	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	hepatic stellate cell (HSC)	hepatitis C virus (HCV) infection	downregulated	21606534
7950	Human	hsa-miR-29?b-1-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
7951	Human	hsa-miR-29*	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec7A cells	Progesterone treatment	upregulated	22543862
7952	Human	hsa-miR-2909	miRNA	lipopolysaccharide (LPS)	inflammation	human adipose stem cells	lipopolysaccharide (LPS) treatment	downregulated	30807577
7953	Human	hsa-miR-291	miRNA	"WIN55,212-2 (WIN)"	osteosarcoma (OS)	Human osteosarcoma MG63 cells	"WIN55,212-2 (WIN) treatment"	upregulated	31652569
7954	Human	hsa-miR-296	miRNA	5-fluorouracil and ixabepilone	breast cancer	MDA-MB-453?cells;MDA-kb2 cells	5-FU and ixabepilone treatment	downregulated	24396484
7955	Human	hsa-miR-296	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
7956	Human	hsa-miR-296	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
7957	Human	hsa-miR-296	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
7958	Human	hsa-miR-296	miRNA	epigallocatechin-3-gallate (EGCG)	nasopharyngeal carcinoma (NPC)	TW01 cells; TW06 cells	Epigallocatechin gallate (EGCG) treatment	Involvement of MicroRNA-296 in the Inhibitory Effect of Epigallocatechin Gallate against the Migratory Properties of Anoikis-Resistant Nasopharyngeal Carcinoma Cells	32326395
7959	Human	hsa-miR-296	miRNA	5-fluorouracil and ixabepilone	triple negative breast cancer (TNBC)	MDA-MB-453 LAR-type TNBC tumor cells	5-fluorouracil together with ixabepilone treatment	downregulated	24396484
7960	Human	hsa-miR-296-3p	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	HONE1 and SUNE1 cells	cisplatin treatment	downregulated	29525743
7961	Human	hsa-miR-296-3p	miRNA	nicotine	nasopharyngeal carcinoma (NPC)	HONE1 and SUNE1 cells	nicotine treatment	downregulated	29525743
7962	Human	hsa-miR-2965p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
7963	Human	hsa-miR-296-5p	miRNA	aloperine	colorectal cancer (CRC)	SW480 and HT29 cells	aloperine treatment	upregulated	33664565
7964	Human	hsa-miR-296-5p	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?11 cells	heme treatment	upregulated	23538684
7965	Human	hsa-miR-296-5p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"NSCLC tissues and cells (A549, H1650, A549/DDP, H1650/DDP)"	cisplatin treatment	downregulated	31647948
7966	Human	hsa-miR-296-5p	miRNA	Fusobacterium nucleatum (F. nucleatum)	oral squamous cell carcinoma (OSCC)	human immortalized oral epithelial cells (HIOECs); SCC-9 cells; HSC-4 cells	F. nucleatum infection	downregulated	31997506
7967	Human	hsa-miR-296-5p	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	vascular smooth muscle cell (VSMC)	high glucose (HG) treatment	upregulated	29386225
7968	Human	hsa-miR-296-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	type 2 diabetes mellitus (T2DM)	vascular smooth muscle cell (VSMC)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	29386225
7969	Human	hsa-miR-297	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	miR-297 was decreased in LPS-induced A549 cells.	31945608
7970	Human	hsa-miR-297	miRNA	hypoxia	myocardial ischaemic injury	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	"hsa_circ_0007623 can bind to miR-297, promote cardiac repair after acute myocardial ischemia, and protect cardiac function."	31973814
7971	Human	hsa-miR-297	miRNA	aluminum oxide nanoparticles (Al2O3 NPs)	pulmonary inflammation	human bronchial epithelial (HBE) cells	aluminum oxide nanoparticles (Al2O3 NPs) treatment	upregulated	31918133
7972	Human	hsa-miR-297	miRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	30921508
7973	Human	hsa-miR-298	miRNA	bufalin	gastric cancer (GC)	gastric cancer cells	bufalin treatment	downregulated	26064232
7974	Human	hsa-miR-299	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
7975	Human	hsa-miR-299	miRNA	hypoxia	ovarian cancer (OC)	human ovarian cancer cell lines Caov3;Skov3	hypoxia treatment	upregulated	28726915
7976	Human	hsa-miR-299	miRNA	oleuropein (OL)	ovarian cancer (OC)	Caov3 cells	oleuropein	upregulated	28726915
7977	Human	hsa-miR-299-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC-27 cells	cisplatin (DPP) treatment	"circ_0110805 knockdown increased the sensitivity of gastric cancer to cisplatin, which also repressed gastric cancer progression by sponging miR-299-3p to downregulate ENDOPDI expression."	33192077
7978	Human	hsa-miR-299-3p	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
7979	Human	hsa-miR-299-5p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	downregulated	30131392
7980	Human	hsa-miR-299-5p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
7981	Human	hsa-miR-299-5p	miRNA	6'-O-galloylpaeoniflorin (GPF)	non-small cell lung cancer (NSCLC)	A549 cells	6'-O-galloylpaeoniflorin (GPF) treatment	GPF up-regulates miR-299-5p expression via the AMPK pathway.	32014006
7982	Human	hsa-miR-29a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
7983	Human	hsa-miR-29a	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
7984	Human	hsa-miR-29a	miRNA	ultraviolet (UV) irradiation	age-related cataract (ARC)	Human lens epithelial cells (HLECs)	ultraviolet irradiation treatment	"the interaction among lncRNA H19, miR-29a and TDG is involved in early ARC lncRNA H19 could be a useful marker of early ARC and oxidative damage repair pathway of lncRNA H19/miR-29a/TDG may be a promising target for the treatment of ARC"	31282110
7985	Human	hsa-miR-29a	miRNA	klotho	Alzheimer's disease (AD)	human peripheral blood mononuclear cells (PBMCs) of AD patients	klotho treatment	upregulated	31197641
7986	Human	hsa-miR-29a	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29386999
7987	Human	hsa-miR-29a	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	29386999
7988	Human	hsa-miR-29a	miRNA	¦Â-hydroxybutyrate	Alzheimer's disease (AD)	SH-SY5Y cells	¦Â-hydroxybutyrate treatment	"microRNA-29a expression was downregulated in 2 ¦ÌM A¦Â25-35-exposed SH-SY5Y cells, but respectively decreased and upregulated in 10 ¦ÌM A¦Â25-35-exposed cells, which were all reversed by ¦Â-hydroxybutyrate"	29386999
7989	Human	hsa-miR-29a	miRNA	etanercept	ankylosing spondylitis (AS)	Blood	etanercept treatment	upregulated	26273623
7990	Human	hsa-miR-29a	miRNA	arsenite	arsenic induced senescence (AIS)	HEK 293 cells	arsenic (As) exposure	upregulated	29107899
7991	Human	hsa-miR-29a	miRNA	platelet derived growth factor-BB (PDGF-BB)	arteriosclerosis obliterans (ASO)	human arterial smooth muscle cells (HASMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	31614351
7992	Human	hsa-miR-29a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29074464
7993	Human	hsa-miR-29a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HASMCs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29074464
7994	Human	hsa-miR-29a	miRNA	insulin	breast cancer	"human breast cancer cells, namely, MCF-7 and T47D cells"	human insulin treatment	upregulated	28427228
7995	Human	hsa-miR-29a	miRNA	isoflavone	apoptosis	PCa cells	isoflavone? treatment	downregulated	22805767
7996	Human	hsa-miR-29a	miRNA	dexamethasone (DEX)	cell differentiation	human multipotent adipose stem (hMADS) cells	dexamethasone (DEX) treatment	upregulated	30742779
7997	Human	hsa-miR-29a	miRNA	human papilloma virus (HPV)	cervical cancer (CC)	human foreskin keratinocytes (HFK)K-derived organotypic raft cultures	HPV infectionn	downregulated	33436409
7998	Human	hsa-miR-29a	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	downregulated	31226416
7999	Human	hsa-miR-29a	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	upregulated	31226416
8000	Human	hsa-miR-29a	miRNA	doxorubicin (DOX)	colorectal cancer (CRC)	HT29 cells	doxorubicin (DOX) treatment	miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via upregulated of PTEN in colon cancer cells	32416187
8001	Human	hsa-miR-29a	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
8002	Human	hsa-miR-29a	miRNA	photodynamic therapy (PDT)	colorectal cancer (CRC)	HCT116 cells	PDT treatment	downregulated	29807108
8003	Human	hsa-miR-29a	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	High Glucose (HG) treatment	downregulated	30520097
8004	Human	hsa-miR-29a	miRNA	high glucose (HG)	diabetes mellitus (DM)	HepG2 cells	high glucose (HG) treatment	upregulated	30296791
8005	Human	hsa-miR-29a	miRNA	morin	diabetes mellitus (DM)	high glucose (HG)-induced HepG2 cells	Morin treatment	downregulated	30296791
8006	Human	hsa-miR-29a	miRNA	TGF-¦Â2	diabetic nephropathy (DN)	human dermal microvascular endothelial cells (HMVECs)	TGF-¦Â2 treatment	Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT	33324218
8007	Human	hsa-miR-29a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
8008	Human	hsa-miR-29a	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
8009	Human	hsa-miR-29a	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
8010	Human	hsa-miR-29a	miRNA	high glucose (HG) and TGF-¦Â1	excess collagen deposition in PTCs	?HK-2 cells	high glucose /TGF-¦Â1 treatment	downregulated	20067797
8011	Human	hsa-miR-29a	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
8012	Human	hsa-miR-29a	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
8013	Human	hsa-miR-29a	miRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	T98G cells; U87MG cells	cisplatin (DPP) treatment	Cisplatin increased CD133 expression by suppressing miR-29a levels.	30267383
8014	Human	hsa-miR-29a	miRNA	sevoflurane (SEV)	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	sevoflurane (SEVO) treatment	upregulated	31190353
8015	Human	hsa-miR-29a	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	human HCC cell lines	human HCC cell lines with TGF-¦Â treatment	downregulated	23789939
8016	Human	hsa-miR-29a	miRNA	xiaoai jiedu recipe (XJR)	hepatocellular carcinoma (HCC)	SK-Hep-1 cells; Hep3B cells	Xiaoai Jiedu Recipe (XJR) treatment	XJR treatment significantly increased the expression of miR-29a	32848411
8017	Human	hsa-miR-29a	miRNA	Intestinal Salmonella typhimurium	intestinal Salmonella typhimurium infection	human intestinal cells	Intestinal Salmonella typhimurium infection	upregulated	23826261
8018	Human	hsa-miR-29a	miRNA	leukemia microvesicles	leukemia	healthy hematopoietic stem cells	leukemia microvesicles transformation	upregulated	28218044
8019	Human	hsa-miR-29a	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	HepG-2 cells	arsenic trioxide?treatment	upregulated	21175813
8020	Human	hsa-miR-29a	miRNA	rosiglitazone	liver fibrosis	human hepatic stellate cell line LX-2	rosiglitazone (RSG) treatment	upregulated	30781750
8021	Human	hsa-miR-29a	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	upregulated	32933544
8022	Human	hsa-miR-29a	miRNA	graphene oxide (GO)	nanoparticles toxicity	MCF-7 cells	graphene oxide (GO) treatment	upregulated	32070776
8023	Human	hsa-miR-29a	miRNA	graphene oxide (GO)	nanoparticles toxicity	KMBC/71 cells	graphene oxide (GO) treatment	downregulated	32070776
8024	Human	hsa-miR-29a	miRNA	graphene quantum dots (GQDs)	nanoparticles toxicity	KMBC/71 cells	graphene quantum dots (GQDs) treatment	downregulated	32070776
8025	Human	hsa-miR-29a	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	"A radio-resistant sub-cell line, CNE-2R"	irradiation (IR) exposure	downregulated	31034464
8026	Human	hsa-miR-29a	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	upregulated	29619741
8027	Human	hsa-miR-29a	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	JFH-I-infected Huh-7 cells	oleic acid (OA) treatment	upregulated	28097097
8028	Human	hsa-miR-29a	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines, MG-63 and U2OS"	methotrexate (MTX) treatment	downregulated	30518744
8029	Human	hsa-miR-29a	miRNA	ischemia	peripheral arterial disease (PAD)	human umbilical vein endothelial cells (HUVEC)	"exposed to simulated ischemia (2% oxygen, BioSpherix, Lacona, NY and starvation medium)"	downregulated	28637396
8030	Human	hsa-miR-29a	miRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"miR-29a expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR-29a"	31694982
8031	Human	hsa-miR-29a	miRNA	TGF-¦Â1	pulmonary fibroblasts proliferation	IMR-90	TGF-¦Â1 treatment	downregulated	26410313
8032	Human	hsa-miR-29a	miRNA	radiation	radiation-induced lung injury (RILI)	HFL-1; WI-38	TGF-¦Â1 and radiation treatment	downregulated	33117089
8033	Human	hsa-miR-29a	miRNA	fibroblast growth factor 2 (FGF2)	regeneration of skeletal muscle	human myoblasts	fibroblast growth factor-2 (FGF2) treatment	we demonstrate using microRNA (miRNA) profiling in mouse and human myoblasts that the capacity of FGF2 to stimulate myoblast proliferation is mediated by miR-29a. FGF2 induces miR-29a expression and inhibition of miR-29a using pharmacological or genetic deletion decreases myoblast proliferation.	26731484
8034	Human	hsa-miR-29a	miRNA	arsenite	cell senescence	HEK 293 cells	arsenite exposure	upregulated	29107899
8035	Human	hsa-miR-29a	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	upregulated	21030674
8036	Human	hsa-miR-29a	miRNA	glucose	type 2 diabetes mellitus (T2DM)	INS-1E beta-cells; human islets of Langerhans	glucose treatment	upregulated	22940552
8037	Human	hsa-miR-29a	miRNA	resistanceor endurance training	type 2 diabetes mellitus (T2DM)	middle-aged Polynesian men and women with morbid obesity (44 kg/m(2) ¡À 10) and Type 2 diabetes	16 wk of resistanceor endurance training treatment	dysregulated	25138607
8038	Human	hsa-miR-29a	miRNA	phosphorus (Pi)	vascular calcification (VC)	vascular smooth muscle cell (VSMC)	phosphorus (Pi) treatment	upregulated	26610870
8039	Human	hsa-miR-29a	miRNA	high glucose (HG)	vascular injury	human umbilical vein endothelial cells (HUVEC)	high glucose (HG) treatment	72-hour exposure to HG-decreased hsa-miRNA-29a.	30520097
8040	Human	hsa-miR-29a	miRNA	"3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064)"	liver fibrosis	hepatic stellate cells (HSCs)	"3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064) treatment"	upregulated	21511916
8041	Human	hsa-miR-29a-3p	miRNA	tamoxifen and metformin	breast cancer	MCF-7 and MDA-MB-231 cell lines	MCF-7 and MDA-MB-231 cell lines treatment	dysregulated	27329603
8042	Human	hsa-miR-29a-3p	miRNA	hypoxia	cell differentiation	human (P3 and U87) glioma cell lines	hypoxia induce	upregulated	30536597
8043	Human	hsa-miR-29a-3p	miRNA	astaxanthin	colorectal cancer (CRC)	The human colon cancer cell HCT116	astaxanthin (ATX) treatment	upregulated	31263239
8044	Human	hsa-miR-29a-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ACBRI-183 cells	high glucose (HG) treatment	upregulated	32343678
8045	Human	hsa-miR-29a-3p	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
8046	Human	hsa-miR-29a-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric mucosa tissues and gastric cells BGC-823 and GES-1	Helicobacter pylori (H. pylori)?infection	upregulated	30485838
8047	Human	hsa-miR-29a-3p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
8048	Human	hsa-miR-29a-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	miR-29a-3p expression in LX-2 cells showed the greatest decrease among four candidate microRNAs in response to TGF-¦Â1 treatment	32819600
8049	Human	hsa-miR-29a-3p	miRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	downregulated	33165134
8050	Human	hsa-miR-29a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
8051	Human	hsa-miR-29a-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (Mtb) infection	upregulated	30711160
8052	Human	hsa-miR-29a-3p	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
8053	Human	hsa-miR-29a-5p	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	Ginsenoside Rh2 (Rh2) treatment	downregulated	30197683
8054	Human	hsa-miR-29a-5p	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary alveolar epithelial cells (HPAECS)	hypoxia treatment	"MIAT was upregulated in both in vivo and in vitro HPH models, while miR-29a-5p was downregulated."	32964992
8055	Human	hsa-miR-29b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
8056	Human	hsa-miR-29b	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
8057	Human	hsa-miR-29b	miRNA	high glucose (HG)	inflammation	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
8058	Human	hsa-miR-29b	miRNA	AR-42	osteoblastic differentiation	Increased anti-leukemic activity of decitabine	AR-42 treatment	upregulated	23178755
8059	Human	hsa-miR-29b	miRNA	prostaglandin E2 (PGE2)	abdominal aortic aneurysm (AAA)	human aortic smooth muscle cells (HASMCs)	prostaglandin E2 (PGE2) treatment	upregulated	29896234
8060	Human	hsa-miR-29B	miRNA	transcription factor NRF2	acute myeloid leukemia (AML)	peripheral blood	Transcription factor NRF2 treatment	downregulated	25323587
8061	Human	hsa-miR-29b	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
8062	Human	hsa-miR-29b	miRNA	wear particles	adverse biological responses to prostheses wear particles	THP-1 cells	wear particles treatment	upregulated	27812842
8063	Human	hsa-miR-29b	miRNA	ethanol (EtOH)	alcoholic liver fibrosis (ALF)	Human HSC cells (LX-2)	ethanol treatment	downregulated	31418997
8064	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	angiotensin II (Ang II)-induced human glomerular mesangial cell (HGMC) activation	Human glomerular mesangial cells (HGMCs)	angiotensin II (Ang II) treatment	Treatment with Ang II led to upregulated of miR-29b in a time-dependent manner.	31630337
8065	Human	hsa-miR-29b	miRNA	epigallocatechin-3-gallate (EGCG)	anti-cancer therapy	AGS and SGC7901 GC cells	Epigallocatechin gallate (EGCG) treatment	Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis	32512188
8066	Human	hsa-miR-29b	miRNA	alginate oligosaccharide (AOS)	aortic aneurysmal disease	aortic aneurysm patients	oral administration 10-mg AOS daily	downregulated	28919708
8067	Human	hsa-miR-29b	miRNA	glucocorticoid (GC)	apoptosis	human plasmacytoid dendritic cells(pDCs)	Glucocorticoids (GCs) treatment	both of these miRNAs promoted pDC apoptosis by directly targeting Mcl-1 and Bcl-2 in human primary pDCs	23894561
8068	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	upregulated	29398368
8069	Human	hsa-miR-29b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	primary human aortic smooth muscle cell (HASMC)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	21266537
8070	Human	hsa-miR-29b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29398368
8071	Human	hsa-miR-29b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29398368
8072	Human	hsa-miR-29b	miRNA	IFN-¦Ã	atopic dermatitis (AD)	human keratinocytes	"treat with IFN-¦Ã (10 ng/ml for 12 h, 24 h and 48 h)"	upregulated	31966903
8073	Human	hsa-miR-29b	miRNA	benzo(a)pyrene (BaP)	breast cancer	MDA-MB-231 cells	benzo(a)pyrene (BaP) exposure	downregulated	30155724
8074	Human	hsa-miR-29b	miRNA	gemcitabinepoly and ADP-ribose polymerase-1 (PARP1) inhibitor	breast cancer	BRCA1 wild-type cells (MDA-MB-231)	gemcitabine-alone and in combination with PARP1 inhibitor treatment	upregulated	25202071
8075	Human	hsa-miR-29b	miRNA	anthracycline (AC)	cardiotoxicity	children plasma	anthracycline (AC) treatment	upregulated	28377429
8076	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HEK293N (AT1R-HEK) cells	angiotensin II (Ang II) treatment	upregulated	21449976
8077	Human	hsa-miR-29b	miRNA	lovastatin	cardiovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	lovastatin	upregulated in time/dose-dependently	28061433
8078	Human	hsa-miR-29b	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
8079	Human	hsa-miR-29b	miRNA	cisplatin (DDP)	cervical cancer (CC)	human cervical caner cell lines (HeLa and Caski cells)	cisplatin treatment	upregulated	28122338
8080	Human	hsa-miR-29b	miRNA	indoxyl sulfate (IS)	chronic kidney disease (CKD)	human aortic smooth muscle cells (HASMCs)	indoxyl sulfate (IS) treatment	upregulated	29195902
8081	Human	hsa-miR-29b	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HBE cells	cigarette smoke extract (CSE) treatment	downregulated	30652495
8082	Human	hsa-miR-29b	miRNA	N-acetyl-L-cysteine (NAC)	chronic obstructive pulmonary disease (COPD)	cigarette smoke extract (CSE)-treated HBE cells	N-acetylcysteine treatment	upregulated	30652495
8083	Human	hsa-miR-29b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
8084	Human	hsa-miR-29b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	Circular RNA COL1A2 promotes angiogenesis via regulating miR-29b/VEGF axis in diabetic retinopathy.	32497630
8085	Human	hsa-miR-29b	miRNA	quercetin	diabetic retinopathy (DR)	ARPE-19 cells	quercetin treatment	"miR-29b was low expressed in high glucose-treated cell, but quercetin elevated its expression"	31960917
8086	Human	hsa-miR-29b	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
8087	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	endothelial cell injury	human umbilical vein endothelial cells (HUVEC)	lipopolysaccharide (LPS) treatment	MiR-29b was upregulated in LPS-treated HUVEC and Eahy926 cells.	29665646
8088	Human	hsa-miR-29b	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	30936982
8089	Human	hsa-miR-29b	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial (RPE) cells	TGF-¦Â2 treatment	downregulated	31850164
8090	Human	hsa-miR-29b	miRNA	H2O2	epithelial ovarian cancer (EOC)	human ovarian cancer cell lines SKOV3 and A2780	H2O2	downregulated	29050034
8091	Human	hsa-miR-29b	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
8092	Human	hsa-miR-29b	miRNA	TGF-¦Â	extracellular-matrix (ECM) and fibril formation	LX-2 cells	TGF-¦Â treatment	downregulated	24650661
8093	Human	hsa-miR-29b	miRNA	TGF-¦Â	fibrosis	human Tenon's fibroblasts (HTFs)	TGF-¦Â treatment	miR-29b in TGF-b treatment group was significantly decreased compared to that in blank group	32124130
8094	Human	hsa-miR-29b	miRNA	ochratoxin A (OTA)	fibrosis	human embryonic kidney cells (HEK293) cells	OTA treatment	downregulated	25091173
8095	Human	hsa-miR-29b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human gastric cancer cell lines including AGS, BGC-823, SGC-7901, and MGC-803"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29221174
8096	Human	hsa-miR-29b	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
8097	Human	hsa-miR-29b	miRNA	lithium chloride (LiCl)	glaucoma	human TM cells	incubat lithium chloride (LiCl) treatment	upregulated	25352117
8098	Human	hsa-miR-29b	miRNA	TGF-¦Â1	glaucoma	human subconjunctival fibroblasts	TGF-¦Â1 treatment	miR-29b acted as a suppressor of type I collagen gene by repressing the PI3K/Akt/Sp1 pathway in HTFs	22297492
8099	Human	hsa-miR-29b	miRNA	TGF-¦Â2	glaucoma	Tenon's capsule fibroblasts	TGF-¦Â2 treatment	downregulated	26191170
8100	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	henoch Sch?nlein purpura nephritis (HSPN)	human glomerular mesangial cell (HGMC)	angiotensin II (Ang II) treatment	upregulated	31630337
8101	Human	hsa-miR-29b	miRNA	fusaric acid (FA)	hepatocellular carcinoma (HCC)	HepG2 cells	Fusaric acid (FA) treatment	upregulated	31060424
8102	Human	hsa-miR-29b	miRNA	brucea javanica oil (BJO)	hepatocellular carcinoma (HCC)	HCC cells	brucea javanica oil (BJO) treatment	BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level and p53 expression.	33341052
8103	Human	hsa-miR-29b	miRNA	brusatol	hepatocellular carcinoma (HCC)	HCC cells	brusatol treatment	BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level and p53 expression.	33341052
8104	Human	hsa-miR-29b	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	plasma	HIV-1 infection	upregulated	25808800
8105	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
8106	Human	hsa-miR-29b	miRNA	dexamethasone (DEX)	ischemic brain injury	SK-N-SH cells	dexamethasone (DEX) treatment	Dex treatment could reduce miR-29b expression.	29087603
8107	Human	hsa-miR-29b	miRNA	dexmedetomidine (DEX)	ischemic brain injury	human neuroblastoma SK-N-SH cells subjected to oxygen-glucose deprivation (OGD)	dexamethasone (DEX) treatment	downregulated	29087603
8108	Human	hsa-miR-29b	miRNA	angiotensin II (Ang II)	kidney damage	human podocytes	angiotensin II (Ang II) treatment	upregulated	26867059
8109	Human	hsa-miR-29b	miRNA	gemcitabine (GEM)	hepatocellular carcinoma (HCC)	HuCCT1 cells; HuH28 cells	Gemcitabine treatment	upregulated	24147037
8110	Human	hsa-miR-29b	miRNA	astaxanthin	liver fibrosis	human hepatic stellate cell (HSC) line LX-2	astaxanthin (AST) treatment	upregulated	30896849
8111	Human	hsa-miR-29b	miRNA	curcumin (Cur)	liver fibrosis	activated HSCs	curcumin? treatment	upregulated	24138392
8112	Human	hsa-miR-29b	miRNA	high glucose (HG)	memory impairment in diabetes	SH-SY5Y cells	high glucose (HG) treatment	downregulated	32198621
8113	Human	hsa-miR-29b	miRNA	bortezomib	multiple myeloma (MM)	Bone marrow	bortezomib? treatment	upregulated	30967527
8114	Human	hsa-miR-29b	miRNA	genistein	multiple myeloma (MM)	human MM cell line U266	Genistein treatment	upregulated	26718793
8115	Human	hsa-miR-29b	miRNA	genistein	multiple myeloma (MM)	U266 cells	genistein treatment	upregulated	26718793
8116	Human	hsa-miR-29b	miRNA	paeoniflorin	multiple myeloma (MM)	SKO-007 cells	Paeoniflorin (PF) treatment	upregulated	27430753
8117	Human	hsa-miR-29b	miRNA	berberine (BBR)	myocardial infarction (MI)	human umbilical vein endothelial cells (HUVECs)	berberine (BBR) treatment	upregulated	28722488
8118	Human	hsa-miR-29b	miRNA	haloperidol	neuroblastoma (NB)	SK-N-SH cell lines	haloperidol at 10¦Ìm concentration for 24 hours	downregulated	28886082
8119	Human	hsa-miR-29b	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	upregulated	29619741
8120	Human	hsa-miR-29b	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines, MG-63 and U2OS"	methotrexate (MTX) treatment	downregulated	30518744
8121	Human	hsa-miR-29b	miRNA	oxymatrine	ovarian cancer (OC)	OVCAR-3 ovary cancer cell line	Oxymatrine treatment	upregulated	26099492
8122	Human	hsa-miR-29b	miRNA	high glucose (HG)	oxidative stress	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
8123	Human	hsa-miR-29b	miRNA	corticosteroid	pancreatic cancer (PC)	PC12 cells	corticosterone (CORT) treatment	downregulated	27501468
8124	Human	hsa-miR-29b	miRNA	lipopolysaccharide (LPS)	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	lipopolysaccharide (LPS) treatment	downregulated	30855347
8125	Human	hsa-miR-29b	miRNA	matrine	peritoneal fibrosis	LPS-treated human peritoneal mesothelial cells (HPMCs)	matrine treatment	upregulated	30855347
8126	Human	hsa-miR-29b	miRNA	TGF-¦Â1	cell proliferation	ARPE-19 cells	TGF-¦Â1 treatment	downregulated	25263462
8127	Human	hsa-miR-29b	miRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"miR-29b expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR29b"	31694982
8128	Human	hsa-miR-29b	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	29662889
8129	Human	hsa-miR-29b	miRNA	TGF-¦Â1	pulmonary fibroblasts proliferation	IMR-90	TGF-¦Â1 treatment	downregulated	26410313
8130	Human	hsa-miR-29b	miRNA	infliximab	rheumatoid arthritis (RA)	peripheral blood monocytes (PBMs) from RA patients	infliximab treatment	downregulated	31473844
8131	Human	hsa-miR-29b	miRNA	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA)	cell senescence	SH-SY5Y cells	brain-derived neurotrophic factor (BDNF) and retinoic acid (RA) treatment	upregulated	27525675
8132	Human	hsa-miR-29b	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	retinoic acid (RA) treatment	upregulated	27525675
8133	Human	hsa-miR-29b	miRNA	retinoic acid (RA)	cell senescence	SH-SY5Y cells	SH-SY5Y cells treatment	upregulation	27525675
8134	Human	hsa-miR-29b	miRNA	silica	silicosis	A549 cells	silica treatment	miRNA-29b (miR-29b) was dynamically downregulated by silica	30529807
8135	Human	hsa-miR-29b	miRNA	indoxyl sulfate (IS)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	Indoxyl sulfate (IS) treatment	downregulated	29195902
8136	Human	hsa-miR-29b	miRNA	phosphorus (Pi)	vascular calcification (VC)	vascular smooth muscle cell (VSMC)	phosphorus (Pi) treatment	upregulated	26610870
8137	Human	hsa-miR-29b-1-5p	miRNA	sulforaphane (SFN)	cancer treatment	NCI-60 cells	sulforaphane treatment	downregulated	32429039
8138	Human	hsa-miR-29b-2	miRNA	"CK2 inhibitor TBB (4,5,6,7-tetrabromobenzotriazole)"	breast cancer	MCF-7 cells	TBB treatment	upregulated	25120778
8139	Human	hsa-miR-29b-2-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (hPASMCs)	hypoxia treatment	hsa_circNFXL1_009 directly sponged hsa-miR-29b-2-5p (miR-29b) and positively regulated the expression of voltage-gated potassium (K+) channel subfamily B member 1 (KCNB1) at the mRNA level.	33614247
8140	Human	hsa-miR-29b-3p	miRNA	walnut	benefits of walnuts	Plasma exosomes	walnuts treatment	upregulated	32979076
8141	Human	hsa-miR-29b-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	upregulated	29154802
8142	Human	hsa-miR-29b-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
8143	Human	hsa-miR-29b-3p	miRNA	platelet lysate (PL)	chondrogenesis	human umbilical cord-derived mesenchymal stem cells (hUCMSCs)	platelet lysate (PL) treatment	PL induced chondrogenic differentiation of hUCMSCs by regulating the H19/miR-29b-3p/SOX9 axis	33058414
8144	Human	hsa-miR-29b-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
8145	Human	hsa-miR-29b-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells; HL-7702 cells	TGF-¦Â1 treatment	Transforming growth factor beta 1 (TGF-¦Â1)-induced hepatic stellate cell (HSC) activation significantly decreased miR-29b-3p expression	32653922
8146	Human	hsa-miR-29b-3p	miRNA	bortezomib	multiple myeloma (MM)	"Human MM cell lines H929, U266"	bortezomib? treatment	"H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis."	30728351
8147	Human	hsa-miR-29b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
8148	Human	hsa-miR-29b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models.	32037864
8149	Human	hsa-miR-29b-3p	miRNA	Bone morphogenetic protein 1 (BMP1)	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	BMP1 treatment	NEAT1 promotes osteogenic differentiation in hBMSCs by regulating miR-29b-3p/BMP1 axis.	30638953
8150	Human	hsa-miR-29b-3p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	A2780 cells; SK-OV-3 cells	Paclitaxel (PTX) treatment	TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells	32189969
8151	Human	hsa-miR-29b-3p	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	Human pancreatic cancer cell lines PANC-1 and BxPC-3	gemcitabine treatment	MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14.	30915884
8152	Human	hsa-miR-29b-3p	miRNA	radiation	prostate cancer	LNCaP cells	radiation treatment	miR-29b-3p expression is increased in response to IR in LNCaP cells	33033519
8153	Human	hsa-miR-29b-3p	miRNA	cigarette smoke extract (CSE)	smoke-induced lung injury (SILI)	A549 cells; H460 cells	cigarette smoke extract (CSE) treatment	upregulated	33523607
8154	Human	hsa-miR-29b-3p	miRNA	Rb3	smoke-induced lung injury (SILI)	A549 cells; H460 cells	Rb3 treatment	downregulated	33523607
8155	Human	hsa-miR-29c	miRNA	IFN-¦Ã	graft-versus-host disease (GVHD)	Cord blood (CB)	interferon-¦Ã treatment	downregulated	21913990
8156	Human	hsa-miR-29c	miRNA	glucocorticoid (GC)	apoptosis	human plasmacytoid dendritic cells(pDCs)	Glucocorticoids (GCs) treatment	both of these miRNAs promoted pDC apoptosis by directly targeting Mcl-1 and Bcl-2 in human primary pDCs	23894561
8157	Human	hsa-miR-29c	miRNA	SGI-1027	biliary atresia-related fibrosis	HIBEpiC cells	SGI-1027 treatment	upregulated	30906331
8158	Human	hsa-miR-29c	miRNA	TGF-¦Â1	biliary atresia-related fibrosis	HIBEpiC cells	TGF-¦Â1 treatment	downregulated	30906331
8159	Human	hsa-miR-29c	miRNA	brown seaweed fucoidan	breast cancer	Human Breast Cancer Cells	brown seaweed fucoidan treatment	upregulated	27994679
8160	Human	hsa-miR-29c	miRNA	paclitaxel (PTX)	breast cancer	"The breast cancer cell lines (MDA-MB-231, MCF-7, Hs-578T, and T47D) and the immortalized breast epithelial cell line MCF-10A"	paclitaxel treatment	LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells by upregulating miR-29c	31047896
8161	Human	hsa-miR-29c	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	upregulated	20346162
8162	Human	hsa-miR-29c	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patient cells	ibrutinib treatment	upregulated	28299881
8163	Human	hsa-miR-29c	miRNA	astragaloside IV (AS-IV)	colorectal cancer (CRC)	CRC cell lines (SW620 and HCT116)	astragaloside (AS-IV) treatment	upregulated	29710520
8164	Human	hsa-miR-29c	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec6A cells	Progesterone treatment	upregulated	22543862
8165	Human	hsa-miR-29c	miRNA	celecoxib	gastric cancer (GC)	AGS cells; MKN45 cells	celecoxib treatment	downregulated	23001726
8166	Human	hsa-miR-29c	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	plasma	hepatitis B virus (HBV) infection	downregulated	22105822
8167	Human	hsa-miR-29c	miRNA	tumor necrosis factor alpha-induced protein 3 (TNFAIP3)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell line (HepG2)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	21763284
8168	Human	hsa-miR-29c	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	Influenza A virus treatment	upregulated	22850539
8169	Human	hsa-miR-29c	miRNA	influenza A virus (IAV)	innate immune response	human CRC cell lines SW620 and RKO	infect with IAVs treatment	upregulated	24953694
8170	Human	hsa-miR-29c	miRNA	"tranilast (N-3,4-dimethoxycinnamoyl anthranilic acid)"	leiomyoma	leiomyoma smooth muscle cells (LSMC) of leiomyoma patients	tranilast treatment	upregulated	28114878
8171	Human	hsa-miR-29c	miRNA	methamphetamine (METH)	locomotor sensitization	mouse nucleus accumbens (NAc) tissues	methamphetamine (METH) treatment	downregulated	30639389
8172	Human	hsa-miR-29c	miRNA	silica	lung function decline	blood	silica treatment	downregulated	29280772
8173	Human	hsa-miR-29c	miRNA	mycoplasma pneumoniae (M. pneumoniae)	mycoplasma pneumoniae pneumonia(MPP)	peripheral blood monouclear cells	Mycoplasma pneumoniae (M. pneumoniae) infection	downregulated	31088519
8174	Human	hsa-miR-29c	miRNA	paclitaxel (PTX)	nasopharyngeal carcinoma (NPC)	"human NPC cell lines, SUNE-1 and C666-1"	Paclitaxel (Taxol) treatment	downregulated	30779921
8175	Human	hsa-miR-29c	miRNA	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF)	neuronal development	SH-SY5Y cells	retinoic acid ; brain-derived neurotrophic factor (RA+BDNF) treatment	upregulated	29619741
8176	Human	hsa-miR-29c	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
8177	Human	hsa-miR-29c	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid treatment	downregulated	32143184
8178	Human	hsa-miR-29c	miRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines, MG-63 and U2OS"	methotrexate (MTX) treatment	downregulated	30518744
8179	Human	hsa-miR-29c	miRNA	palmitic acid (PA)	pancreatic cancer (PC)	human PC cells	palmitic acid (PA) treatment	downregulated	28088520
8180	Human	hsa-miR-29c	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	31732967
8181	Human	hsa-miR-29c	miRNA	TGF-¦Â1	pulmonary fibroblasts proliferation	IMR-90	TGF-¦Â1 treatment	downregulated	26410313
8182	Human	hsa-miR-29c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	triple negative breast cancer (TNBC)	MCF10A cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28160548
8183	Human	hsa-miR-29c	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	human dermal fibroblasts (HDFs)	ultraviolet radiation (UVA) treatment	upregulated	30378537
8184	Human	hsa-miR-29c	miRNA	tranilast	leiomyoma	leiomyoma smooth muscle cells (LSMC)	tranilast treatment	downregulated	28114878
8185	Human	hsa-miR-29c-3p	miRNA	TGF-¦Â2	age-related cataract (ARC)	SRA01/04 cells	TGF-¦Â2 traetment treatment	"miR-29c-3p regulated FOS to repress EMT, cell proliferation and facilitate apoptosis in TGF-¦Â2-treated SRA01/04 cells mediated by KCNQ1OT1"	32534225
8186	Human	hsa-miR-29c-3p	miRNA	sanguinarine	gastric cancer (GC)	BGC-823 cells	sanguinarine treatment	downregulated	31243669
8187	Human	hsa-miR-29c-3p	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
8188	Human	hsa-miR-29c-3p	miRNA	cisplatin (DDP)	medulloblastoma	"Medulloblastoma cell lines D283, Daoy, D425, and D341"	cisplatin treatment	downregulated	31753063
8189	Human	hsa-miR-29c-3p	miRNA	cisplatin (DDP)	medulloblastoma	Daoy; D341	cisplatin (DDP) treatment	downregulated	31753063
8190	Human	hsa-miR-29c-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
8191	Human	hsa-miR-30	miRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	peripheral blood mononuclear cells (PBMCs)	interferon alpha treatment	upregulated	21070682
8192	Human	hsa-miR-30	miRNA	cadmium (Cd)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	cadmium (Cd) treatment	Cd exposure repressed miR-30 levels	33756289
8193	Human	hsa-miR-30	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	crohn disease (CD)	Caco2 and HIEC cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	33436852
8194	Human	hsa-miR-30	miRNA	TGF-¦Â	endothelium-dependent vasorelaxation	HT-29 cells	TGF-¦Â treatment	downregulated	23483606
8195	Human	hsa-miR-30	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	human gastric cell line SNU-5	5-fluorouracil (5-FU) treatment	downregulated	26209295
8196	Human	hsa-miR-30	miRNA	cadmium (Cd)	lung diseases	BEAS-2B cells	cadmium (Cd) treatment	downregulated	30998937
8197	Human	hsa-miR-30	miRNA	high glucose (HG)	podocyte injury	?human podocyte cell	high glucose (HG) treatment	downregulated	33490186
8198	Human	hsa-miR-30	miRNA	lipopolysaccharide (LPS)	podocytopathy	human podocytes	lipopolysaccharide (LPS) treatment	downregulated	24029422
8199	Human	hsa-miR-30	miRNA	puromycin aminonucleoside (PAN)	podocytopathy	human podocytes	PAN treatment	downregulated	24029422
8200	Human	hsa-miR-30	miRNA	TGF-¦Â	podocytopathy	human podocytes	TGF-¦Â treatment	downregulated	24029422
8201	Human	hsa-miR-30	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	downregulated	20110569
8202	Human	hsa-miR-300	miRNA	Shikimic acid (SA)	breast cancer	MCF-7 and T47D cells	Shikimic acid (SA) treatment	upregulated	31048002
8203	Human	hsa-miR-300	miRNA	X-rays	gastric cancer (GC)	human gastric cancer tissue samples	"4 Gy of X-rays (6 MV, 0.8 Gy/min) treatment"	downregulated	24919435
8204	Human	hsa-miR-300	miRNA	ionizing radiation (IR)	lung cancer	human lung cancer cells	ionizing radiation (IR) treatment	upregulated	28895780
8205	Human	hsa-miR-300	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx3 treatment"	downregulated	21572246
8206	Human	hsa-miR-301	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
8207	Human	hsa-miR-301	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human cartilage ATDC5 cells	lipopolysaccharide (LPS) treatment	downregulated	29414810
8208	Human	hsa-miR-301	miRNA	emodin	ovarian cancer (OC)	A2780 cells	emodin treatment	upregulated	29512773
8209	Human	hsa-miR-301	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	Capan-2 and Panc-1	Gemcitabine (GEM) treatment	gemcitabine-resistant cells (Capan-2 and Panc-1) exhibited upregulated miR-301 expression and downregulated gemcitabine-induced apoptosis.	30628651
8210	Human	hsa-miR-301	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
8211	Human	hsa-miR-301	miRNA	luteolin	prostate cancer	PC3 and LNCaP cells	luteolin treatment	downregulated	27307749
8212	Human	hsa-miR-301a	miRNA	plasminogen activator inhibitor-1 (PAI-1)	apoptosis	human pulmonary endothelial cells	PAI-1 (plasminogen activator inhibitor-1) ? treatment	downregulated	21175428
8213	Human	hsa-miR-301a	miRNA	arsenite	arsenite-induced carcinogenesis	BEAS-2B cells	arsenic (As) exposure	upregulated	30185897
8214	Human	hsa-miR-301a	miRNA	astragaloside IV (AS-IV)	gastric cancer (GC)	gastric cancer-associated fibroblast (GCAF)	astragaloside (AS-IV) treatment	downregulated	29358859
8215	Human	hsa-miR-301a	miRNA	triptolide (TPL)	gastric cancer (GC)	gastric cancer-associated fibroblasts (GCAFs)	triptolide (TPL) treatment	downregulated miR-301a expression and upregulated miR-149	29049979
8216	Human	hsa-miR-301a	miRNA	placenta growth factor (PlGF)	lung fibrosis	endothelial cells	placenta growth factor (PlGF) treatment	downregulated	26460070
8217	Human	hsa-miR-301a	miRNA	hypoxia	pancreatic cancer (PC)	PaCa-2 and BxPC-3 cells	hypoxia induce	upregulated	29772221
8218	Human	hsa-miR-301a	miRNA	hypoxia	prostate cancer	Caco2-BBE cells	hypoxia treatment	upregulated	26813459
8219	Human	hsa-miR-301a	miRNA	TGF-¦Â	lung fibrosis	HFL1 cells	TGF-¦Â treatment	upregulated	32788629
8220	Human	hsa-miR-301a	miRNA	Japanese encephalitis virus (JEV)	viral-induced neuroinflammation	The human cell line of fetal microglial origin CHME3 and human brains	Japanese encephalitis virus (JEV) infection	upregulated	31527198
8221	Human	hsa-miR-301a-3p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29901102
8222	Human	hsa-miR-301a-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-301a-3p expression is highly expressed in ox-LDL-induced HUVECs.	33850541
8223	Human	hsa-miR-301a-3p	miRNA	¦Â-elemene	non-small cell lung cancer (NSCLC)	A549 cells	¦Â-elemene treatment	¦Â-elemene suppressed the expression of miR-301a-3p	32463461
8224	Human	hsa-miR-301a-3p	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells and cell-derived exosomes	hypoxia induce	upregulated	29880482
8225	Human	hsa-miR-301b	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
8226	Human	hsa-miR-301b	miRNA	caffeine	inflammatory response	MLE-12 and MH-S cells	caffeine treatment	downregulated	27670114
8227	Human	hsa-miR-301b	miRNA	pseudomonas aeruginosa (PA)	inflammatory response	MLE-12 and MH-S cells	Pseudomonas aeruginosa treatment	upregulated	27670114
8228	Human	hsa-miR-301b	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
8229	Human	hsa-miR-301b	miRNA	isoliquiritigenin	melanoma	"Human melanoma cell line(A375, A2058)"	Isoliquiritigenin (ISL) treatment	downregulated	30081934
8230	Human	hsa-miR-301b	miRNA	hypoxia	prostate cancer	Caco2-BBE cells	hypoxia treatment	upregulated	26813459
8231	Human	hsa-miR-301b-3p	miRNA	hypoxia	prostate cancer	"Human prostate cancer cell lines (DU145, PC-3, LNCaP and IA8)"	hypoxia induce	upregulated	31442444
8232	Human	hsa-miR-302	miRNA	pulsatile shear stress	cerebral ischemia injury (CII)	SH-SY5Y cells	pulsatile shear stress?treatment treatment	downregulated	31096001
8233	Human	hsa-miR-302	miRNA	enterovirus 71 (EV71)	innate immune response	THP-1¨Cderived macrophages	Enterovirus 71 (EV71) infection	downregulated	29777028
8234	Human	hsa-miR-302	miRNA	zoledronic acid (ZA)	osteoporosis	serum	ZOL treatment	"?Mechanistically, the expression of miR-302, miR-101, miR-145, RANKL, SMAD3 and PRKACB in the serum was remarkably activated by ZOL treatment"	33637048
8235	Human	hsa-miR-302	miRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin treatment	miR-302 is downregulated in cisplatin-resistant ovarian cancer cells and involved in chemosensitivity.	32835657
8236	Human	hsa-miR-302	miRNA	sodium butyrate (NaB)	somatic cell reprogramming	human foreskin fibroblasts (HFFs)	NaB treatment	upregulated	24568633
8237	Human	hsa-miR-302a	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19 cells	H2O2 treatment	downregulated	31784665
8238	Human	hsa-miR-302a	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
8239	Human	hsa-miR-302a	miRNA	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep)	gastric cancer (GC)	gastric and liver cancer cells	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) treatment	upregulated	24861464
8240	Human	hsa-miR-302a	miRNA	radiation	non-small cell lung cancer (NSCLC)	NCI-H1299 ; NCI-H1299R cells	radiation treatment	downregulated	31928130
8241	Human	hsa-miR-302a	miRNA	rapamycin	reperfusion injury in diabetic heart	human-pluripotent-stem-cells-derived cardiomyocytes (HG-hiPSC-CMs)	rapamycin (RAPA) treatment	Rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling	33319180
8242	Human	hsa-miR-302a-3p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	downregulated	25526515
8243	Human	hsa-miR-302a-3p	miRNA	brahma (BRM)	pancreatic cancer (PC)	BxPC-3 and T3M4 cells	brahma (BRM) dificiency	"silencing BRM reduced PC cell migration and invasion both in vivo and in vitro, accompanied by reduced level of miR-302a-3p."	30790683
8244	Human	hsa-miR-302a-3p	miRNA	cisplatin (DDP)	testicular germ cell tumors (TGCTs)	TGCT cell lines NT2-D1 and 833?K	cisplatin treatment	downregulated	31235829
8245	Human	hsa-miR-302b	miRNA	fentanyl	esophageal squamous cell carcinoma (ESCC)	ESCC Eca109 and TE1 cell lines	Fentanyl treatment	upregulated	29928433
8246	Human	hsa-miR-302b	miRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 MG cells	all-trans retinoic acid (ATRA) treatment	upregulated	25040912
8247	Human	hsa-miR-302b	miRNA	monosodium urate (MSU)	gouty arthritis	THP-1 cells	monosodium urate (MSU) crystal treatment	upregulated	29482609
8248	Human	hsa-miR-302b	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	Human OA chondrocytes (C28/12 cell line)	lipopolysaccharide (LPS) treatment	upregulated	29414803
8249	Human	hsa-miR-302b	miRNA	epirubicin	osteosarcoma (OS)	osteosarcoma MG-63cells; SAOS-2 cells; hFOB119 cells	Epirubicin treatment	"miR-302b, which is stably low-expressed in osteosarcoma, could be induced by the epirubicin"	23845851
8250	Human	hsa-miR-302b	miRNA	tetramethylpyrazine (TMP)	Periodontitis	human periodontal ligament stem cells (hPDLSCs)	tetramethylpyrazine (TMP) treatment	TMP downregulated microRNA (miR)-302b levels in LPS-stimulated cells.	32236610
8251	Human	hsa-miR-302b	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	cisplatin (DDP) treatment	miR-302b was significantly downregulated in UUO mouse kidney tissue and TGF-¦Â1-treated HK-2 cells	33503202
8252	Human	hsa-miR-302b	miRNA	ethanol (EtOH)	neuronal cell death	SH-SY5Y cells	ethanol treatment	upregulated	21878650
8253	Human	hsa-miR-302b*	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
8254	Human	hsa-miR-302b-3p	miRNA	cisplatin (DDP)	testicular germ cell tumors (TGCTs)	TGCT cell lines NT2-D1 and 833?K	cisplatin treatment	downregulated	31235829
8255	Human	hsa-miR-302c	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
8256	Human	hsa-miR-302c	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	particulate matter (PM)treatment treatment	upregulated	24515752
8257	Human	hsa-miR-302c	miRNA	particulate matter (PM)	cardiovascular disease (CVD)	A549 pulmonary cell lines	PM-ed A549 pulmonary cell lines in v treatment	upregulated	24515752
8258	Human	hsa-miR-302c	miRNA	inositol hexaphosphate (IP6)	colorectal cancer (CRC)	Caco-2 colon cancer cells	5 mM IP6 treatment	upregulated	31744065
8259	Human	hsa-miR-302c	miRNA	IL-8	gastric cancer (GC)	"Human gastric cancer cell lines, HGC-27, MGC80-3, AGS, NCI-N87, SGC-7901, and BGC-823"	IL8 expression	downregulated	26199092
8260	Human	hsa-miR-302c	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251MG-TMZ cells and LN229-TMZ cells	temozolomide (TMZ) treatment	downregulated	31409725
8261	Human	hsa-miR-302c	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
8262	Human	hsa-miR-302c	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	Human lung epithelial cells A549	influenza A virus (IAV) treatment	downregulated	26602079
8263	Human	hsa-miR-302c	miRNA	TGF-¦Â	liver fibrosis	LX-2 cells; primary hepatic stellate cells (HSCs)	TGF-¦Â treatment	Induction of E6AP by microRNA-302c dysregulation inhibits TGF-¦Â-dependent fibrogenesis in hepatic stellate cells	33037648
8264	Human	hsa-miR-302c	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	lung fibrosis	Kasumi-1 cells; K562 cells;MCF7 cells; MDA-MB-231 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	23820258
8265	Human	hsa-miR-302c	miRNA	TGF-¦Â1	mesothelial/epithelial-mesenchymal transition (MMT/EMT)	human peritoneal mesothelial cell line (HMrSV5)	TGF-¦Â1 treatment	downregulated	30693641
8266	Human	hsa-miR-302c	miRNA	proline-rich polypeptide 1 (PRP-1)	metastatic chondrosarcoma	human chondrosarcoma JJ012 cell line	"proline-rich polypeptide 1, (PRP-1) treatment"	downregulated	26094604
8267	Human	hsa-miR-302c-3p	miRNA	hepatitis B virus (HBV)	chronic hepatitis B virus (HBV) infection	HepG2©\hNTCP©\C4 cells	hepatitis B virus (HBV) infection	miR-302c-3p suppresses HBV replication and HBsAg production	30828831
8268	Human	hsa-miR-302c-3p	miRNA	cisplatin (DDP)	testicular germ cell tumors (TGCTs)	TGCT cell lines NT2-D1 and 833?K	cisplatin treatment	downregulated	31235829
8269	Human	hsa-miR-302e	miRNA	phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA)	allergic inflammation	HMC-1 cells	phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA) treatment	miR-302e was significantly decreased in response to phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 or ovalbumin (OVA) stimulation	29748238
8270	Human	hsa-miR-302e	miRNA	sevoflurane (SEV)	neurotoxicity	human hippocampal cells (HN-h)	sevoflurane treatment	upregulated	30221705
8271	Human	hsa-miR-302f	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8272	Human	hsa-miR-302f	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8273	Human	hsa-miR-30-5p	miRNA	ethanol extract of antrodia cinnamomea (AC)	breast cancer	MCF-7 and tamoxifen-resistant MCF-7 cells	ethanol extract of antrodia cinnamomea (AC) treatment	upregulated	29743060
8274	Human	hsa-miR-30-5p	miRNA	candida albicans (C. albicans)	inflammatory response	THP-1 cells	candida albicans infection	upregulated	28454101
8275	Human	hsa-miR-3065-5p	miRNA	antrodia cinnamomea	cancer treatment	"THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68"	antrodia cinnamomea treatment	downregulated	28602756
8276	Human	hsa-miR-30a	miRNA	hypoxia	acute myocardial infarction (AMI)	Blood samples	hypoxia treatment	upregulated	26857375
8277	Human	hsa-miR-30a	miRNA	low-frequency electromagnetic fields (LF-EMF)	Alzheimer's disease (AD)	human neuroblastoma SH-SY5Y cells	low-frequency electromagnetic fields (LF-EMF) treatment	downregulated	24676932
8278	Human	hsa-miR-30a	miRNA	hepatitis B virus X protein (HBx)	autophagosome formation	liver	hepatitis B virus X protein treatment	"HBx induces autophagosome formation via beclin-1 expression, whereas miRNA-30a overexpression could successfully inhibit the beclin-1 expression induced by HBx, thereby modulating autophagosome formation in hepatic cells."	25620738
8279	Human	hsa-miR-30a	miRNA	cisplatin (DDP)	autophagy	HeLa cells£» MCF-7 cells£» HepG2 cells	cis-dichloro-diamine platinum (cis-DDP) treatment	upregulated	22157765
8280	Human	hsa-miR-30a	miRNA	taxol	autophagy	HeLa cells£» MCF-7 cells£» HepG2 cells	taxol treatment	upregulated	22157765
8281	Human	hsa-miR-30a	miRNA	BAY11-7082	bladder cancer	HTB-1 and T24 cells	The addition of BAY11-7082 into the tumor-associated macrophages (TAMs)/HTB-1 or T24 co-culture system	downregulated	31002892
8282	Human	hsa-miR-30a	miRNA	androgen	breast cancer	MDA-MB-453 breast cancer cells	androgen treatment	downregulated	29085503
8283	Human	hsa-miR-30a	miRNA	imatinib mesylate	chronic myeloid leukemia (CML)	peripheral blood mononuclear cells	Imatinib Mesylate treatment	miR-30a was over expressed and Beclin 1 was under expressed in imatinib responders compared to resistant cases.	31945609
8284	Human	hsa-miR-30a	miRNA	imatinib	chronic myeloid leukemia (CML)	?human chronic myeloid leukemia cells	?imatinib? treatment	upregulated	22395361
8285	Human	hsa-miR-30a	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC-7901 cells	cisplatin (DPP) treatment		29375703
8286	Human	hsa-miR-30a	miRNA	norcantharidin (NCTD)	giant cell tumor of bone (GCTB)	GCTB stromal tumor cells	norcantharidin (NCTD) treatment	Expression of miR-30a was significantly upregulated by NCTD treatment.	29710674
8287	Human	hsa-miR-30a	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	TMZ led to a significant reduction in miR-30a levels in a dose-dependent manner in U251 cells	29805498
8288	Human	hsa-miR-30a	miRNA	alcohol	head and neck squamous cell carcinoma (HNSCC)	normal oral keratinocytes	alcohol exposure	upregulated	26472042
8289	Human	hsa-miR-30a	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
8290	Human	hsa-miR-30a	miRNA	TGF-¦Â1	liver fibrosis	HSCs and LX-2 exosomes	TGF-¦Â1 treatment	downregulated in exosomes	28766848
8291	Human	hsa-miR-30a	miRNA	mycobacterium tuberculosis (Mtb)	mycobacterium tuberculosis (Mtb) infection	THP-1 human monocytes cells during infection	infect with MTB H37Rv	upregulated	28912881
8292	Human	hsa-miR-30a	miRNA	carbon disulfide (CS2)	nerve system injury	workers	experienced injury to nerve system from carbon disulfide (CS2) treatment	upregulated	25224332
8293	Human	hsa-miR-30a	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 and NCI-H292 cells	low-dose radiation (50 mGy) exposure	upregulated	30424954
8294	Human	hsa-miR-30a	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 cells	low-dose radiation (LDR) radiation	upregulated	30424954
8295	Human	hsa-miR-30a	miRNA	IL-1¦Â	osteoarthritis (OA)	human osteoarthritis	human osteoarthritis treatment	downregulated	27067395
8296	Human	hsa-miR-30a	miRNA	beclin-1	osteosarcoma (OS)	human osteosarcoma MG-63 cell	Beclin-1 treatment	downregulated	26708607
8297	Human	hsa-miR-30a	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	oxidative stress	human lung carcinoma cell line (A549)	NPs treatment	downregulated	28400205
8298	Human	hsa-miR-30a	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	The human lens epithelial cell line SRA01/04 and HLE B-3 cells	TGF-¦Â2 treatment	downregulated	31049834
8299	Human	hsa-miR-30a	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
8300	Human	hsa-miR-30a	miRNA	hypoxia	prostate cancer	DU145 and LNCaP cells	hypoxia treatment	downregulated	27160121
8301	Human	hsa-miR-30a	miRNA	metformin (Met)	prostate cancer	Vcap and PC-3 cells	metformin treatment	downregulated	25201727
8302	Human	hsa-miR-30a	miRNA	TGF-¦Â	renal fibrosis	"human HK2, HEK293 cells"	TGF¦Â treatment	downregulated	28285987
8303	Human	hsa-miR-30a	miRNA	dexamethasone (DEX)	steatosis	HepG2 cells	dexamethasone (Dex) treatment	downregulated	29409992
8304	Human	hsa-miR-30a-3p	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
8305	Human	hsa-miR-30a-3p	miRNA	metformin (Met)	anti-cancer therapy	CD8 + T cells	Metformin treatment	downregulated	32221038
8306	Human	hsa-miR-30a-3p	miRNA	recombinant early secreted antigenic target 6 (rESAT-6)	autophagy	Calcimycin-treated dTHP-1 cells	recombinant early secreted antigenic target 6 (rESAT-6) treatment	upregulated	31181223
8307	Human	hsa-miR-30a-3p	miRNA	TGF-¦Â	angiogenesis 	Human umbilical vein endothelial cells	TGF-¦Â treatment	downregulated	23960241
8308	Human	hsa-miR-30a-3p	miRNA	IFN-¦Ã	systemic sclerosis (SSc)	arthritis fibroblasts;SSc HDF	IFN-¦Ã treatment	downregulated	25360821
8309	Human	hsa-miR-30a-5p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
8310	Human	hsa-miR-30a-5p	miRNA	recombinant early secreted antigenic target 6 (rESAT-6)	autophagy	Calcimycin-treated dTHP-1 cells	recombinant early secreted antigenic target 6 (rESAT-6) treatment	downregulated	31181223
8311	Human	hsa-miR-30a-5p	miRNA	paclitaxel (PTX)	tumorigenesis	NCI60 cancer cell line£¬Ovarian cancer (OVCA) cell lines and Human stem cell lines (H9)	paclitaxel treatment	miR-367 upregulated and miR-30a-5p downregulated	24220856
8312	Human	hsa-miR-30a-5p	miRNA	curcumol	colorectal cancer (CRC)	HCT116 cells	curcumol treatment	Curcumol treatment was identified to increase miR-30a-5p expression	33732375
8313	Human	hsa-miR-30a-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	upregulated	25526515
8314	Human	hsa-miR-30a-5p	miRNA	steroids	focal segmental glomerulosclerosis (FSGS)	urine	steroid treatment	downregulated	25107948
8315	Human	hsa-miR-30a-5p	miRNA	valproic acid (VPA)	hepatic differentiation	human umbilical cord Wharton's jelly derived mesenchymal stem cells (hUC-MSCs)	valproic acid (VPA) treatment	upregulated	27001466
8316	Human	hsa-miR-30a-5p	miRNA	respiratory syncytial virus (RSV)	innate immune response	human dendritic cells	respiratory syncytial virus (RSV) infection treatment	upregulated	29970194
8317	Human	hsa-miR-30a-5p	miRNA	deoxycholic acid (DCA)	intestinal metaplasia	GES-1 cells	deoxycholic acid treatment	deoxycholic acid-induced macrophage-derived exosomes (D-Exos) may promote intestinal metaplasia and suppress proliferation of GES-1 cells via hsa-miR-30a-5p targeting FOXD1.	32950501
8318	Human	hsa-miR-30a-5p	miRNA	trichostatin A (TSA)	keloids	cultured keloid fibroblasts	Trichostatin A (TSA) treatment	downregulated	31059100
8319	Human	hsa-miR-30a-5p	miRNA	lithium (Li) and valproic acid (VPA)	neurodegeneration (ND)	human neuroblastoma cell line (SH-SY5Y)	L-glutamate and Li-VPA treatment	both L-glutamate and Li-VPA caused an increase in miR-30a-5p expression at 24 h of incubation and a downregulated at 48 h	25149854
8320	Human	hsa-miR-30a-5p	miRNA	perfluorooctane sulfonic acid (PFOS)	neurotoxicity	SK-N-SH cells	PFOS treatment	upregulated	28441774
8321	Human	hsa-miR-30a-5p	miRNA	IL-6 and TNF-¦Á	osteoarthritis (OA)	chondrocytes	IL-6 and TNF-¦Á treatment	LINC00461 may modulate the development of OA by suppressing miR-30a-5p expression in chondrocytes.	32155130
8322	Human	hsa-miR-30a-5p	miRNA	L-dopa	parkinson's disease (PD)	Plasma and White Blood Cells	L-dopa-treated treatment	upregulated	28540642
8323	Human	hsa-miR-30a-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (HPAECs)	hypoxia induce	downregulated	31115541
8324	Human	hsa-miR-30a-5p	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
8325	Human	hsa-miR-30b	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	29635893
8326	Human	hsa-miR-30b	miRNA	oxalic acid poisoning	acute kidney injury (AKI)	urinary	oxalic acid poisoning	upregulated	32910981
8327	Human	hsa-miR-30b	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
8328	Human	hsa-miR-30b	miRNA	androgen	breast cancer	MDA-MB-453 breast cancer cells	androgen treatment	downregulated	29085503
8329	Human	hsa-miR-30b	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
8330	Human	hsa-miR-30b	miRNA	kynurenine	breast cancer	95D cells	Kynurenine (Kyn) treatment	downregulated	31093946
8331	Human	hsa-miR-30b	miRNA	trastuzumab	breast cancer	HER2-positive (SKBR3£» BT474)£» HER2-negetive (MCF7£» MDA-MB-231) cells	Trastuzumab treatment	upregulated	22384020
8332	Human	hsa-miR-30b	miRNA	trastuzumab	breast cancer	BT474 wt cells	trastuzumab treatment	upregulated	28120942
8333	Human	hsa-miR-30b	miRNA	vascular endothelial growth factor (VEGF)	capillary morphogenesis	human umbilical vein endothelial cells (HUVECs)	VEGF treatment	downregulated	28977001
8334	Human	hsa-miR-30b	miRNA	homocysteine (Hcy)	cardiovascular disease (CVD)	HCAECs	Homocysteine (Hcy) treatment	downregulated	26263983
8335	Human	hsa-miR-30b	miRNA	¦Ã-rays	cell senescence	CD34+ cells	¦Ã-radiation treatment	upregulated	23144934
8336	Human	hsa-miR-30b	miRNA	cisplatin (DDP)	gastric cancer (GC)	"The human GC cell line AGS,;HGC-27 cells"	cisplatin treatment	downregulated	30365113
8337	Human	hsa-miR-30b	miRNA	bone morphogenetic protein 2 (BMP2)	hepatocellular carcinoma (HCC)	vascular smooth muscle cell (VSMC)	bone morphogenetic protein 2 (BMP2) treatment	BMP-2 downregulates miR-30b and miR-30c to increase Runx2 expression in CASMCs and promote mineralization	23316327
8338	Human	hsa-miR-30b	miRNA	tanshinone IIA (Tan IIA)	hepatocellular carcinoma (HCC)	HepG2 cell	Tanshinone IIA treatment	downregulated	27894814
8339	Human	hsa-miR-30b	miRNA	tanshinone IIA (Tan IIA)	hepatocellular carcinoma (HCC)	HepG2 cells	Tanshinone IIA treatment	downregulated	27894814
8340	Human	hsa-miR-30b	miRNA	propofol (PPF)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cells(HUVECs)	propofol treatment	miR-30b was upregulated in propofol-treated group	24454982
8341	Human	hsa-miR-30b	miRNA	hypoxia	hypoxic-ischemic encephalopathy (HIE)	Human brain microvascular endothelial cells (HBMECs)	hypoxia treatment	"In hypoxia-induced HBMECs, the mRNA and protein expression levels of PAI-1 were significantly upregulated, while the miR-30b expression level was significantly downregulated."	33360521
8342	Human	hsa-miR-30b	miRNA	Ig-like transcript 3 (ILT3)	immune inflammatory	human CD8(+) T suppressor cells	Ig-like transcript 3 (ILT3) treatment	upregulated	22387553
8343	Human	hsa-miR-30b	miRNA	L-kynurenine (L-Kyn)	immune response	BCL-1 cells	L-kynurenine (L-Kyn) treatment	downregulated	26590946
8344	Human	hsa-miR-30b	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
8345	Human	hsa-miR-30b	miRNA	kynurenine	lung cancer	95D cells	50 ¦ÌM Kyn	downregulated	28905195
8346	Human	hsa-miR-30b	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
8347	Human	hsa-miR-30b	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	compound C treatment	downregulated	32143184
8348	Human	hsa-miR-30b	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
8349	Human	hsa-miR-30b	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid treatment	downregulated	32143184
8350	Human	hsa-miR-30b	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 and NCI-H292 cells	low-dose radiation (50 mGy) exposure	upregulated	30424954
8351	Human	hsa-miR-30b	miRNA	low-dose ionizing radiation (LDIR)	non-small cell lung cancer (NSCLC)	A549 cells	low-dose radiation (LDR) radiation	upregulated	30424954
8352	Human	hsa-miR-30b	miRNA	TGF-¦Â1	ovarian cancer (OC)	SKOV3 and 3AO cells	TGF-¦Â1 treatment	downregulated	26501435
8353	Human	hsa-miR-30b	miRNA	perioglas (PG) and P-15	bone formation	osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	upregulated	17653614
8354	Human	hsa-miR-30b	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HAVSMC)	inorganic phosphate (Pi) treatment	downregulated	27419135
8355	Human	hsa-miR-30b*	miRNA	hypoxia	gastroesophageal cancer (GEC)	ESCC and AC cell lines	Hypoxia treatment	upregulated	26851030
8356	Human	hsa-miR-30b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	AC16 cells	angiotensin II (Ang II) treatment	upregulated	33130312
8357	Human	hsa-miR-30b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	human AC-16 cell lines	angiotensin II (Ang II) treatment	downregulated	33130312
8358	Human	hsa-miR-30b-3p	miRNA	ebola virus (EBOV)	Ebola virus (EBOV) therapy	293T cells	EBOV treatment	downregulated	29209594
8359	Human	hsa-miR-30b-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	Glioma stem-like cells (GSCs)	hypoxia treatment	The miRNA profiling revealed that miR-30b-3p was significantly upregulated in the EVs from hypoxic GSCs.	33408780
8360	Human	hsa-miR-30b-3p	miRNA	respiratory syncytial virus (RSV)	respiratory syncytial virus (RSV)-associated pneumonia	whole blood	respiratory syncytial virus (RSV) infection treatment	upregulated	32410870
8361	Human	hsa-miR-30b-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cell line HAEC cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33812169
8362	Human	hsa-miR-30b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	renal tissues	high glucose (HG) treatment	"In high glucose induced HK-2 cells, expression levels of miR-30b-5p and E-cadherin were decreased, while SNAI1, a-SMA and Vimentin were increased."	33383483
8363	Human	hsa-miR-30b-5p	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
8364	Human	hsa-miR-30b-5p	miRNA	hypoxia	hypoxia-induced injury	AC16 human cardiomyocytes	hypoxia induce	upregulated	31768184
8365	Human	hsa-miR-30b-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
8366	Human	hsa-miR-30b-5p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	downregulated	33817304
8367	Human	hsa-miR-30b-5p	miRNA	selenium nanoparticles (SeNPs)	prostate cancer	LNCaP cells; LNCaP-A cells	Selenium nanoparticles (SeNPs) treatment	upregulated	33604641
8368	Human	hsa-miR-30c	miRNA	hypoxia	acute myeloid leukemia (AML)	human renal cell carcinoma	Hypoxia treatment	downregulated	24112779
8369	Human	hsa-miR-30c	miRNA	plasminogen activator inhibitor-1 (PAI-1)	apoptosis	human pulmonary endothelial cells	PAI-1 (plasminogen activator inhibitor-1) ? treatment	downregulated	21175428
8370	Human	hsa-miR-30c	miRNA	adriamycin (ADR)	breast cancer	"MCF-10A, MCF-7, and ZR-75-1 cells"	adriamycin (ADR) treatment	upregulated	31511498
8371	Human	hsa-miR-30c	miRNA	androgen	breast cancer	MDA-MB-453 breast cancer cells	androgen treatment	downregulated	29085503
8372	Human	hsa-miR-30c	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
8373	Human	hsa-miR-30c	miRNA	¦Ã-rays	cell senescence	CD34+ cells	¦Ã-radiation treatment	upregulated	23144934
8374	Human	hsa-miR-30c	miRNA	¦Ã-rays	cell senescence	human fetal osteoblast cell line (hFOB)	¦Ã-radiation treatment	downregulated	23144934
8375	Human	hsa-miR-30c	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
8376	Human	hsa-miR-30c	miRNA	coffee	colorectal cancer (CRC)	Caco-2 human colon carcinoma cells	coffee treatment	upregulated	28693281
8377	Human	hsa-miR-30c	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	intestinal epithelial cells T84 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	24148619
8378	Human	hsa-miR-30c	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	T84 cells	adherent invasive escherichia coli (AIEC) treatment	upregulated	32583714
8379	Human	hsa-miR-30c	miRNA	estradiol-17¦Â (E2)	endometrial cancer (EC)	ER-positive Ishikawa and ER-negative HEC-1-B cells	estradiol-17¦Â (E2) treatment	downregulated	24595016
8380	Human	hsa-miR-30c	miRNA	hyperthermia	heat shock	human OSCC cell lines HSC-2;HSC-3;HSC-4	HT at 44?C for 60 min treatment	dysregulated	24789751
8381	Human	hsa-miR-30c	miRNA	bone morphogenetic protein 2 (BMP2)	hepatocellular carcinoma (HCC)	vascular smooth muscle cell (VSMC)	bone morphogenetic protein 2 (BMP2) treatment	BMP-2 downregulates miR-30b and miR-30c to increase Runx2 expression in CASMCs and promote mineralization	23316327
8382	Human	hsa-miR-30c	miRNA	hepatitis C virus (HCV) core protein	hepatocellular carcinoma (HCC)	"human hepatoblastoma cell line, HepG2"	Hepatitis C virus (HCV) Core protein treatment	downregulated	26210453
8383	Human	hsa-miR-30c	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	downregulated	28213977
8384	Human	hsa-miR-30c	miRNA	lipopolysaccharide (LPS)	inflammation	human aortic endothelial cells	lipopolysaccharide (LPS) treatment	downregulated	28213977
8385	Human	hsa-miR-30c	miRNA	pravastatin	lipid homeostasis	subjects recruited from a lipid clinic	pravastatin for 1year treatment	upregulated	28062296
8386	Human	hsa-miR-30c	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
8387	Human	hsa-miR-30c	miRNA	cisplatin (DDP)	nephrotoxicity	HK-2 and NRK-52E cells	cisplatin treatment	downregulated	28796263
8388	Human	hsa-miR-30c	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
8389	Human	hsa-miR-30c	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	palmitic acid treatment	downregulated	32143184
8390	Human	hsa-miR-30c	miRNA	bevacizumab	non-small cell lung cancer (NSCLC)	Serum	bevacizumab treatment	Serum miR-30c level is elevated during bevacizumab chemotherapy.	29737469
8391	Human	hsa-miR-30c	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	Paclitaxel-resistant NSCLC cell lines of A549 and H460	curcumin treatment	upregulated	28443468
8392	Human	hsa-miR-30c	miRNA	TGF-¦Â1	ovarian cancer (OC)	SKOV3 and 3AO cells	TGF-¦Â1 treatment	downregulated	26501435
8393	Human	hsa-miR-30c	miRNA	NaSH	spinal cord ischemia/reperfusion injury (SCII)	SH5Y-SY cells	NaSH treatment	NaSH preprocessing upregulated CasC7 and downregulated miR-30c in OGD/R-induced SH5Y-SY cells.	29571256
8394	Human	hsa-miR-30c-1-3p	miRNA	benzo(a)pyrene (BaP)	lung fibrosis	BEAS-2B cells	benzo(a)pyrene (BaP) exposure	downregulated	30543962
8395	Human	hsa-miR-30c-1-3p	miRNA	benzo(a)pyrene (BaP)	lung fibrosis	BEAS-2B cells	benzo(a)pyrene (BaP) exposure	downregulated	30543962
8396	Human	hsa-miR-30c-1-3p	miRNA	sulfur dioxide (SO2)	lung fibrosis	BEAS-2B cells	SO2 treatment	downregulated	30543962
8397	Human	hsa-miR-30c-1-3p	miRNA	sulfur dioxide (SO2)	lung fibrosis	BEAS-2B cells	sulfur dioxide (SO2)?exposure treatment	downregulated	30543962
8398	Human	hsa-miR-30c-2*	miRNA	epidermal growth factor (EGF)	tumorigenesis	OVCAR-3;SKOV-3;A549 cells	The epidermal growth factor treatment	upregulated	22024689
8399	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophage line	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29016810
8400	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30119891
8401	Human	hsa-miR-30c-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	MiR-30c-5p was downregulated and JAK1 was upregulated in renal fibrosis tissue and HG stimulated HK2 cells.	32096183
8402	Human	hsa-miR-30c-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"Compared with the controls, DN tissues and high glucose-induced HK-2 cells had significantly reduced miR-30c-5p levels."	33817282
8403	Human	hsa-miR-30c-5p	miRNA	chlorpromazine (CHLO)	drug-induced liver injury (DILI)	upcyte hepatocytes	chlorpromazine (CHLO) treatment	downregulated	31198949
8404	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	"Silence of LINC00657 repressed ox-LDL-induced injury via inhibiting EndMT, inflammatory response, and apoptosis in HUVEC cells by regulating miR-30c-5p/Wnt7b/¦Â-catenin."	32577947
8405	Human	hsa-miR-30c-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	"PTEN was a target of miR-30c-5p, and its interference led to great inhibition of cell apoptosis and inflammatory response induced by ox-LDL in HUVEC, while this effect was attenuated by miR-30c-5p deficiency or XIST overexpression."	31539155
8406	Human	hsa-miR-30c-5p	miRNA	sodium oxalate	kidney stone disease	HK-2 cells	sodium oxalate treatment	downregulated	31894301
8407	Human	hsa-miR-30c-5p	miRNA	sodium oxalate	sodium oxalate-induced kidney stones	HK-2 cells	sodium oxalate treatment	miR-30c-5p expression was significantly downregulated by exposure to 750 ?M sodium oxalate.	31894301
8408	Human	hsa-miR-30d	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
8409	Human	hsa-miR-30d	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
8410	Human	hsa-miR-30d	miRNA	¦Ã-rays	cell senescence	CD34+ cells	¦Ã-radiation treatment	upregulated	23144934
8411	Human	hsa-miR-30d	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL"	23725219
8412	Human	hsa-miR-30d	miRNA	doxorubicin (DOX)	classical hodgkin lymphoma	L428 cells	doxorubicin (DOX) treatment	"in L428 cells showed increased sensitivity to doxorubicin-induced apoptosis, pointing towards abnormalities of mitochondrial intrinsic and TP53-CDKN1A pathways as related to miRNA deregulation in cHL"	23725219
8413	Human	hsa-miR-30d	miRNA	hypoxia	colorectal cancer (CRC)	"CRC cell lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S)"	1 and 0.2% oxygen	upregulated	28207045
8414	Human	hsa-miR-30d	miRNA	lipopolysaccharide (LPS)	epithelial-mesenchymal transition (EMT)	hippocampus	lipopolysaccharide (LPS) treatment	The treatment of HBMECs with Meth or LPS significantly increased the circHECW2 expression in HBMECs.	29260931
8415	Human	hsa-miR-30d	miRNA	methamphetamine (METH)	epithelial-mesenchymal transition (EMT)	primary human brain microvascular endothelial cells (HBMECs)	methamphetamine (Meth) treatment	miR-30d was significantly downregulated	29260931
8416	Human	hsa-miR-30d	miRNA	methamphetamine (METH)	epithelial-mesenchymal transition (EMT)	primary human brain microvascular endothelial cells (HBMECs)	methamphetamine (Meth) treatment	The treatment of HBMECs with Meth or LPS significantly increased the circHECW2 expression in HBMECs.	29260931
8417	Human	hsa-miR-30d	miRNA	ricolinostat (ACY-1215)	esophageal squamous cell carcinoma (ESCC)	"The human cell lines EC109, KYSE150, TE-1, TE-13"	Ricolinostat (ACY-1215) treatment	upregulated	30050135
8418	Human	hsa-miR-30d	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Li-7 cells; Hep3B cells; HepG2 cells; Huh7 cells	sorafenib (SOR) treatment	upregulated	32724415
8419	Human	hsa-miR-30d	miRNA	methylmercury (MeHg)	neurotoxicity	human neural progenitor cells (ihNPCs)	methylmercury (MeHg) treatment	downregulated	27941687
8420	Human	hsa-miR-30d	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx5 treatment"	downregulated	21572246
8421	Human	hsa-miR-30d	miRNA	TGF-¦Â1	ovarian cancer (OC)	SKOV3 and 3AO cells	TGF-¦Â1 treatment	downregulated	26501435
8422	Human	hsa-miR-30d	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	downregulated	18573151
8423	Human	hsa-miR-30d	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
8424	Human	hsa-miR-30d	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	human AGS cells and GES-1 cells	Helicobacter pylori (H. pylori) infection	upregulated	27099441
8425	Human	hsa-miR-30d-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
8426	Human	hsa-miR-30d-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
8427	Human	hsa-miR-30d-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	upregulated	27018851
8428	Human	hsa-miR-30e	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-30e was downregulated in resistant patients when compared with sensitive patients	33072545
8429	Human	hsa-miR-30e	miRNA	propofol (PPF)	gastric cancer (GC)	SGC7901/CDDP	propofol treatment	lncRNA MALAT1/miR-30e/ATG5 mediated autophagy-related chemoresistance in GC	32302291
8430	Human	hsa-miR-30e	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 cells	hepatitis C virus (HCV) infection	downregulated	31334444
8431	Human	hsa-miR-30e	miRNA	IFN-¦Á	immune tolerance of maternal-fetal interface	peripheral blood NK cells (PB-NK cells) and decidua NK cells (D-NK cells)	IFN-¦Á treatment	downregulated	30551399
8432	Human	hsa-miR-30e	miRNA	mycobacterium tuberculosis (Mtb)	mycobacterium tuberculosis (Mtb) infection	THP-1 human monocytes cells during infection	infect with MTB H37Rv	upregulated	28912881
8433	Human	hsa-miR-30e	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
8434	Human	hsa-miR-30e	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
8435	Human	hsa-miR-30e	miRNA	schisandrin B (Sch B)	tubulointerstitial fibrosis (TIF)	TGF-¦Â1-treated HK-2 cells	Schisandrin B (Sch B) treatment	upregulated	31697999
8436	Human	hsa-miR-30e	miRNA	TGF-¦Â1	tubulointerstitial fibrosis (TIF)	HK-2 cells	TGF-¦Â1 treatment	downregulated	31697999
8437	Human	hsa-miR-30e	miRNA	dexamethasone (DEX)	intestinal cell differentiation	?IEC-6 cells	dexamethasone (DEX) treatment	upregulated	20372961
8438	Human	hsa-miR-30e*	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	human monocyte cell line U937	DENV infection	upregulated	25122182
8439	Human	hsa-miR-30e*	miRNA	insect cell-derived anionic septapeptide	innate immune response	Primary human monocyte cultures	insect cell-derived anionic septapeptide treatment	upregulated	31075349
8440	Human	hsa-miR-30e-3p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
8441	Human	hsa-miR-30e-5p	miRNA	hypoxia	coronary microembolization	human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)	hypoxia induce	downregulated	31182924
8442	Human	hsa-miR-30e-5p	miRNA	demethoxycurcumin	glioblastoma multiforme (GBM)	LN-229 and A172 cells	demethoxycurcumin treatment	upregulated	30305611
8443	Human	hsa-miR-30e-5p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
8444	Human	hsa-miR-30e-5p	miRNA	dapagliflozin	hypertensive patients with type 2 diabetes	plasma	dapagliflozin treatment	upregulated	31162549
8445	Human	hsa-miR-31	miRNA	puerarin	acute kidney injury (AKI)	HK-2 cells	puerarin treatment	Puerarin alleviates cisplatin-induced acute renal damage and upregulates microRNA-31-related signaling	32855680
8446	Human	hsa-miR-31	miRNA	vascular endothelial growth factor (VEGF)	angiogenesis	HUVECs	vascular endothelial growth factor (VEGF) treatment	upregulated	28097093
8447	Human	hsa-miR-31	miRNA	arsenite	arsenite-induced carcinogenesis	Beas-2B cells	arsenic (As) exposure	Arsenic downregulated miRNA-31.	29603397
8448	Human	hsa-miR-31	miRNA	promoted in platelet-derived growth factor (PDGF)-BB	arteriosclerosis obliterans (ASO)	human ASMCs (HASMCs)	(PDGF)-BB treatment	upregulated	29403548
8449	Human	hsa-miR-31	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	MDA-MB-231 cell	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27593563
8450	Human	hsa-miR-31	miRNA	halofuginone (HF)	breast cancer	MCF-7 cell	Halofuginone (HF) treatment	"miRNAs knockdown experiment in exosomes and the MCF-7 growth inhibition assay showed that exosomal microRNA-31 (miR-31) modulates MCF-7 cells growth by specially targeting the histone deacetylase 2 (HDAC2), which increases the levels of cyclin-dependent kinases 2 (CDK2) and cyclin D1 and suppresses the expression of p21."	30916359
8451	Human	hsa-miR-31	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cellular stress response	prostate cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-205 and miR-31	21368878
8452	Human	hsa-miR-31	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	downregulated	31226416
8453	Human	hsa-miR-31	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	upregulated	31226416
8454	Human	hsa-miR-31	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	RKO cells	kaempferol-3- O-glycoside treatment	downregulated	31441682
8455	Human	hsa-miR-31	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	Human colorectal malignant cell lines DLD©\1 and SW480	5-fluorouracil (5-FU) treatment	upregulated	31162779
8456	Human	hsa-miR-31	miRNA	baicalin (BAI)	colorectal cancer (CRC)	HT29 cells	baicalin (BAI) treatment	downregulated	30262902
8457	Human	hsa-miR-31	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	colon cancer cell line (RKO)	kaempferol-3-O-glycoside treatment	downregulated	31441682
8458	Human	hsa-miR-31	miRNA	TGF-¦Â1	cutaneous lupus erythematosus	primary adult keratinocytes and PBMCs isolated from discoid lupus erythematosus (DLE) patients	TGF-¦Â1 treatment	upregulated	30130620
8459	Human	hsa-miR-31	miRNA	ultraviolet (UV) irradiation	cutaneous lupus erythematosus	primary adult keratinocytes and PBMCs isolated from discoid lupus erythematosus (DLE) patients	UV irradiation treatment	upregulated	30130620
8460	Human	hsa-miR-31	miRNA	TGF-¦Â1	discoid lupus erythematosus (DLE)	keratinocyte	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30130620
8461	Human	hsa-miR-31	miRNA	ultraviolet (UV) irradiation	discoid lupus erythematosus (DLE)	keratinocyte	UV radiation treatment	upregulated	30130620
8462	Human	hsa-miR-31	miRNA	high glucose (HG)	endothelial dysfunction	primary endothelial progenitor cells (EPCs)	high glucose treatment	upregulated	29566115
8463	Human	hsa-miR-31	miRNA	cigarette smoke condensate (CSC)	cell differentiation	normal human respiratory epithelia and lung cancer cells	cigarette smoke condensate (CSC) treatment	Cigarette smoke induces expression of miR-31 targeting several antagonists of cancer stem cell signaling in normal respiratory epithelia and lung cancer cells	21048943
8464	Human	hsa-miR-31	miRNA	zinc deficiency	esophageal cancer (EC)	human ESCC and OSCC	zinc deficiency? treatment	upregulated	22689922
8465	Human	hsa-miR-31	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
8466	Human	hsa-miR-31	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	TGF-¦Â could induce miR-31 and suppress miR-184 levels in A549 cells	31874165
8467	Human	hsa-miR-31	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â treatment	upregulated	31874165
8468	Human	hsa-miR-31	miRNA	polychlorinated biphenyls (PCBs)	inflammation	HUVECs	polychlorinated biphenyls (PCBs) treatment	upregulated	27288564
8469	Human	hsa-miR-31	miRNA	neoadjuvant chemoradiotherapy (CRT)	locally advanced rectal cancer (LARC)	Rectal Cancer tissues	neoadjuvant chemoradiotherapy (CRT) treatment	upregulation	27271609
8470	Human	hsa-miR-31	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
8471	Human	hsa-miR-31	miRNA	ginsenoside Rh2	medulloblastoma	human medulloblastoma cell line Daoy	ginsenoside Rh2 treatment	downregulated	29377269
8472	Human	hsa-miR-31	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
8473	Human	hsa-miR-31	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
8474	Human	hsa-miR-31	miRNA	epidermal growth factor (EGF)	oral carcinogenesis	"HSC-3£¬OECM-1,SAS£¬NOK"	EGF treatment	upregulated	25229239
8475	Human	hsa-miR-31	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	bone marrow stromal stem cells (BMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30132874
8476	Human	hsa-miR-31	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	ethanol-induced osteonecrosis bone marrow stromal stem cells (BMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30132874
8477	Human	hsa-miR-31	miRNA	estramustine phosphate	prostate cancer	PC3 cells	Estramustine phosphate treatment	MiR-31 level decreased after estramustine phosphate treatment.	29364469
8478	Human	hsa-miR-31	miRNA	mocetinostat	prostate cancer	primary prostate cancer stem cells	mocetinostat treatment	activation of miR-31 and downregulated of E2F6 constitute an important mechanism in mocetinostat-induced apoptosis in prostate cancer.	27551526
8479	Human	hsa-miR-31	miRNA	"high-fluence light-emitting diode-generated red light (HF-LED-RL, 633?¡À?15?nm)"	skin fibrosis	human skin fibroblast	HF-LED-RL at 320 and 640?J/cm2 radiation	downregulated	30182520
8480	Human	hsa-mir-31	miRNA	aminosulfonylarylisoxazole	transgenerational pancreatic impairment 	human embryonic kidney cells (HEK-293T)	aminosulfonylarylisoxazole	upregulated	28867213
8481	Human	hsa-miR-31	miRNA	aminosulfonylarylisoxazole	transgenerational pancreatic impairment 	human embryonic kidney cells (HEK-293T)	aminosulfonylarylisoxazole	downregulated	28867213
8482	Human	hsa-miR-31*	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
8483	Human	hsa-miR-3121-3p	miRNA	nilotinib	chronic myeloid leukemia (CML)	human umbilical vein derived EA.hy926 cells and human umbilical vein endothelial cells (HUVECs)	nilotinib treatment	downregulated	28501737
8484	Human	hsa-miR-3126-5p	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
8485	Human	hsa-miR-3126-5p	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
8486	Human	hsa-miR-3129-5p	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	Human HCC cell line HepG2 and Huh7	Doxorubicin (DOX) treatment	downregulated	30615851
8487	Human	hsa-miR-3129-5p	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	Huh-7 cell; Hep3B cells	doxorubicin treatment	downregulated	32965597
8488	Human	hsa-miR-3131	miRNA	ganoderma lucidum polysaccharides (GLPs)	anti-cancer therapy	human hepatocarcinoma cells (HepG2)	GLPs treatment	upregulated	24528735
8489	Human	hsa-miR-3131	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8490	Human	hsa-miR-3131	miRNA	ganoderma lucidum polysaccharides (GLPs)	hepatocellular carcinoma (HCC)	human hepatocarcinoma cells (HepG2)	Ganoderma lucidum polysaccharides (GLPs) treatment	upregulated	24528735
8491	Human	hsa-miR-3131	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
8492	Human	hsa-miR-3135b	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	upregulated	31824817
8493	Human	hsa-miR-3138	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
8494	Human	hsa-miR-31-3p	miRNA	ultraviolet (UV) irradiation	chronic actinic dermatitis (CAD)	HaCaT cells	ultraviolet (UV) irradiation treatment	The expression of hsa-miR-31-3p was increased after treated with UV irradiation for 48 h	32907715
8495	Human	hsa-miR-31-3p	miRNA	IFN-¦Ã	colitis	human colonic epithelial cells NCM460 cells	interferon-¦Ã(IFN-¦Ã) treatment	upregulated	29253460
8496	Human	hsa-miR-31-3p	miRNA	IL-6	colitis	human colonic epithelial cells NCM460 cells	IL-6 treatment	upregulated	29253460
8497	Human	hsa-miR-31-3p	miRNA	IL-8	colitis	human colonic epithelial cells NCM460 cells	IL8 treatment	upregulated	29253460
8498	Human	hsa-miR-31-3p	miRNA	jun N-terminal kinase inhibitor	colitis	Substance P (SP)-treated human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R)	Jun N-terminal kinase inhibitor treatment	downregulated	29253460
8499	Human	hsa-miR-31-3p	miRNA	substance P (SP)	colitis	human colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R)	substance P (SP) treatment	upregulated	29253460
8500	Human	hsa-miR-31-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colitis	human colonic epithelial cells NCM460 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29253460
8501	Human	hsa-miR-31-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	downregulated	31793082
8502	Human	hsa-miR-31-3p	miRNA	sepsis	pneumonia	human embryonic lung fibroblast MRC-5 cell	human embryonic lung fibroblast MRC-5 cell injury irritated by lipopolysaccharide (LPS) treatment	"Silencing miR-31-3p mitigated the impacts of circANKRD36 silence on LPS-irritated MRC-5 cells Besides, MyD88 was a downstream target of miR-31-3p, and 3'UTR of IL-34 mRNA was targeted by miR-31-5p"	31793082
8503	Human	hsa-miR-31-3p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
8504	Human	hsa-miR-3148	miRNA	atropine	myopia	Human corneal epithelial cells	0.003% atropine treatment	dysregulated	31540331
8505	Human	hsa-miR-3148	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	downregulated	29409992
8506	Human	hsa-miR-3149	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8507	Human	hsa-miR-3150a-3p	miRNA	melatonin	rheumatoid arthritis (RA)	human rheumatoid fibroblast-like synoviocytes	melatonin treatment	upregulated	30648758
8508	Human	hsa-miR-3150b-5p	miRNA	paclitaxel (PTX)	laryngeal cancer	laryngeal cancer cell line hep2	Paclitaxel treatment	the most markedly expression-changed	23826416
8509	Human	hsa-miR-3154	miRNA	CCAAT/enhancer binding protein delta (CEBPD)	leukemia	human monocytic leukemic cell line THP-1 and the human myeloid cell line U937	CEBPD treatment	upregulated	29120412
8510	Human	hsa-miR-3156-5p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
8511	Human	hsa-miR-31-5p	miRNA	low-intensity pulsed ultrasound (LIPUS)	bone regeneration	hMSCs	low-intensity pulsed ultrasound (LIPUS) induce	upregulated	30925808
8512	Human	hsa-miR-31-5p	miRNA	¦Ã-rays	ionizing radiation (IR) injury	whole blood samples from healthy donors extracellular vesicles (ELVs)	irradiate with 2 Gy gamma rays treatment	upregulated	28264626
8513	Human	hsa-miR-31-5p	miRNA	IL-6	colitis-associated colon cancer (CAC)	THP-1 and Caco2 cells	IL-6 treatment	upregulated	31100679
8514	Human	hsa-miR-31-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colitis-associated colon cancer (CAC)	THP-1 and Caco2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31100679
8515	Human	hsa-miR-31-5p	miRNA	water extract of I. rotunda (WIR)	colitis-associated colon cancer (CAC)	IL-6/TNF-¦Á-treated THP-1 and Caco2 cells	water extract of I. rotunda (WIR) treatment	downregulated	31100679
8516	Human	hsa-miR-31-5p	miRNA	epidermal growth factor receptor (EGFR)	colorectal cancer (CRC)	FFPE tissues or colon cancer cell lines	epidermal growth factor receptor (EGFR) treatment	upregulated	25472647
8517	Human	hsa-miR-31-5p	miRNA	anti-EGFR therapy	colorectal cancer (CRC)	patients with CRC	anti-EGFR therapeutics treatment	upregulated	25472647
8518	Human	hsa-miR-31-5p	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells and Huh7 cells	cisplatin treatment	"When miR-31-5p was downregulated, the proliferation and invasion of HepG2 cells and Huh7 cells were enhanced and the cisplatin-induced apoptosis was inhibited, while LINC01234 knockdown could diminish the effects caused by miR-31-5p depletion."	31838274
8519	Human	hsa-miR-31-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	preeclampsia (PE)	human placental arterial vessels	tumor necrosis factor alpha (TNF-¦Á) treatment	miR-31-5p was upregulated in human endothelial cells treated with TNF¦Á	30279269
8520	Human	hsa-miR-31-5p	miRNA	protein kinase C inhibitor GF109203X	wound healing and regeneration of skin tissues.	human keratinocytes	GF109203X treatment	"upregulated ( hsa-miR-1-3p , hsa-miR-181c-5p); downregulated( hsa-miR-31-5p , hsa-let-7c-3p )"	28901412
8521	Human	hsa-miR-3162	miRNA	CCAAT/enhancer binding protein delta (CEBPD)	leukemia	human monocytic leukemic cell line THP-1 and the human myeloid cell line U937	CEBPD treatment	upregulated	29120412
8522	Human	hsa-miR-3162-3p	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	IIIB-MT2 cells	human immunodeficiency virus (HIV)-1 infection	downregulated	29627523
8523	Human	hsa-miR-3170	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
8524	Human	hsa-miR-3171	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	downregulated	31549595
8525	Human	hsa-miR-3178	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
8526	Human	hsa-miR-3178	miRNA	H2O2	primary open angle glaucoma (POAG)	Human trabecular meshwork cells (HTMCs)	H2O2 induced oxidative stress	"lncRNA-RP11-820 directly binds miR-3178, through which the expression of MYOD1 is regulated."	31495061
8527	Human	hsa-miR-318	miRNA	propofol (PPF)	pancreatic cancer (PC)	pancreatic cell lines Panc1 and Bxpc3	Propofol treatment	upregulated	30861616
8528	Human	hsa-miR-3180-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
8529	Human	hsa-miR-3182	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
8530	Human	hsa-miR-3182	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
8531	Human	hsa-miR-3182	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
8532	Human	hsa-miR-3184-5p	miRNA	p53 activator mithramycin A	cervical cancer (CC)	HeLa cells; SiHa cells	p53 activator Mithramycin A treatment	p53 activator Mithramycin A stimulated p53 and miR-3184-5p expression	33416166
8533	Human	hsa-miR-3188	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 derived macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29442044
8534	Human	hsa-miR-3189-3p	miRNA	fenofibrate	glioblastoma multiforme (GBM)	LN-229 and U87MG cells	fenofibrate treatment	upregulated	25645911
8535	Human	hsa-miR-3195	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
8536	Human	hsa-miR-3195	miRNA	melatonin	prostate cancer	hypoxic PC-3 cells	melatonin treatment	upregulated	25553085
8537	Human	hsa-miR-3197	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
8538	Human	hsa-miR-3197	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	downregulated	28534445
8539	Human	hsa-miR-3198	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	downregulated	31549595
8540	Human	hsa-miR-3198	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
8541	Human	hsa-miR-31a-5p	miRNA	high temperature	hypertrophic scars (HS)	human dermal fibroblast cells (CC-2511 cells)	CC-2511 cells were incubated at high temperature conditions (41?¡ãC-43?¡ãC for 1-3?h).	upregulated	30075370
8542	Human	hsa-miR-32	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	acute myeloid leukemia (AML)	HL60-G cells and U937 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	21816906
8543	Human	hsa-miR-32	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	AML cell lines	adriamycin (ADR) treatment	miR-32 was identified as the downstream target of SNHG5 and miR-32 inhibitor abrogated the inhibiting effects of downregulated SNHG5 on AML cell viability.	31884339
8544	Human	hsa-miR-32	miRNA	oridonin	colorectal cancer (CRC)	"Human colorectal carcinoma cell lines HCT-116, SW620 and HT-29"	Oridonin treatment	downregulated	26054686
8545	Human	hsa-miR-32	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
8546	Human	hsa-miR-32	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
8547	Human	hsa-miR-32	miRNA	particulate matter (PM2.5)	lung cancer	human lung cancer cells	PM2.5 treatment	upregulated	28601662
8548	Human	hsa-miR-32	miRNA	isoliquiritigenin	nasopharyngeal carcinoma (NPC)	"nasopharyngeal carcinoma cell lines, including C666-1 and CNE2"	isoliquiritigenin treatment	downregulated	31004603
8549	Human	hsa-miR-320	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cholangiocarcinoma (CCA)	Two human pancreatic cancer cell lines - MiaPACA-2 £»PANC-1	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	19407485
8550	Human	hsa-miR-320	miRNA	cardio-pulmonary bypass (CPB)	acute lung injury (ALI)	blood	cardio-pulmonary bypass (CPB) treatment	upregulated	25972997
8551	Human	hsa-miR-320	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29902461
8552	Human	hsa-miR-320	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	miR-320 expression was significantly downregulated.	31449822
8553	Human	hsa-miR-320	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	31449822
8554	Human	hsa-miR-320	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	M¨¹ller cells	streptozotocin (STZ) treatment	DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas	33762162
8555	Human	hsa-miR-320	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	MKN28 (human gastric epithelial cells)£»AGS (human gastric epithelial cells)	Helicobacter pylori infection	downregulated	24136787
8556	Human	hsa-miR-320	miRNA	ionizing radiation (IR)	glioblastoma multiforme (GBM)	glioma tissues; U251 cells; U87 cells	ionizing radiation (IR) treatment	downregulated	29331678
8557	Human	hsa-miR-320	miRNA	IL-1¦Â	osteoarthritis (OA)	primary chondrocytes	IL-1¦Â treatment	downregulated	30280762
8558	Human	hsa-miR-320	miRNA	high-dose steroid	steroid-induced avascular necrosis of femoral head (SANFH)	bone tissues	high-dose steroid treatment	downregulated	29551500
8559	Human	hsa-miR-3200-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
8560	Human	hsa-miR-3202	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human T lymphocyte	cigarette smoke?extract?(CSE) treatment	downregulated	29208459
8561	Human	hsa-miR-3202	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	T lymphocytes	cigarette smoke extract (CSE) exposure	downregulated	29208459
8562	Human	hsa-miR-3202	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
8563	Human	hsa-miR-320a	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	children serum samples	acetaminophen(APAP) treatment	upregulated in serum samples	29067470
8564	Human	hsa-miR-320a	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
8565	Human	hsa-miR-320a	miRNA	acetaminophen (APAP)	acute liver failure (ALF)	serum	acetaminophen (APAP) treatment	hsa-miR-320a and hsa-miR-877-5p levels were significantly elevated in serum samples obtained from children with APAP overdose compared to health controls.	29067470
8566	Human	hsa-miR-320a	miRNA	alpha-1 antitrypsin (AAT)	anti-inflammatory responses	monocytes of AAT deficient (ZZ) individuals	alpha-1 antitrypsin (AAT) treatment	downregulated	29062067
8567	Human	hsa-miR-320a	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
8568	Human	hsa-miR-320a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	OIP5-AS1 knockdown modulated cell progression via regulating miR-320a/LOX1 axis in ox-LDL-treated HUVECs.	32072428
8569	Human	hsa-miR-320a	miRNA	lithium (Li)	bipolar disorder (BD)	lymphoblastoid cell lines	Lithium treatment	dysregulated	31801218
8570	Human	hsa-miR-320a	miRNA	artemisinin (ART)	breast cancer	MCF-7/Dox cells	artemisinin treatment	upregulated	28361857
8571	Human	hsa-miR-320a	miRNA	tamoxifen (TAM)	breast cancer	breast cancer cells	Tamoxifen treatment	downregulated	25736597
8572	Human	hsa-miR-320a	miRNA	¦¤Np63¦Á	cancer invasion	HaCaT and A431 cells	¦¤Np63¦Á deficiency treatment	downregulated	31515469
8573	Human	hsa-miR-320a	miRNA	oxidized low density lipoprotein (ox-LDL)	electrophilic stress response	human umbilical vein endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	24786516
8574	Human	hsa-miR-320a	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8575	Human	hsa-miR-320a	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8576	Human	hsa-miR-320a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	GC cell lines and tissues	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31662823
8577	Human	hsa-miR-320a	miRNA	rebamipide	gastric cancer (GC)	cancer-initiating cells (C-IC)	Rebamipide treatment	upregulated	27265143
8578	Human	hsa-miR-320a	miRNA	hydroxygenkwanin (HGK)	hepatocellular carcinoma (HCC)	The hepatocellular carcinoma cell lines HepG2 and Huh7	hydroxygenkwanin (HGK) treatment	upregulated	31877715
8579	Human	hsa-miR-320a	miRNA	high glucose (HG)	hyperglycemia	human umbilical vein endothelial cells	high glucose treatment	upregulated	27070575
8580	Human	hsa-miR-320a	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cell (HUVEC)	hypoxia/reoxygenation (H/R) treatment	MALAT1 represses H/R-stimulated HUVEC injury by targeting the miR-320a/RAC1 axis.	31408432
8581	Human	hsa-miR-320a	miRNA	IL-33	inflammatory bowel disease (IBD)	Caco2 colonic intestinal epithelial cell (IEC) line	IL-33 treatment	upregulated	30224451
8582	Human	hsa-miR-320a	miRNA	hyperoxia	lung injury	human epithelial cells	human epithelial cells treatment	upregulation in derived microvesicles (MVs)	27731391
8583	Human	hsa-miR-320a	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
8584	Human	hsa-miR-320a	miRNA	IL-1¦Â	osteoarthritis (OA)	human cartilage cells (C28/I2)	IL-4¦Â treatment	upregulated	28404547
8585	Human	hsa-miR-320a	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx6 treatment"	downregulated	21572246
8586	Human	hsa-miR-320a	miRNA	follicle stimulating hormone (FSH)	ovarian steroidogenesis	human granulosa cell line KGN	follicle-stimulating hormone (FSH) treatment	dysregulated	26773729
8587	Human	hsa-miR-320a	miRNA	insulin-like growth factor 1 (IGF-1)	polycystic ovarian syndrome (PCOS)	cumulus cells (CCs) of PCOS patients	IGF1 (10-8 M) treatment	upregulated	27965096
8588	Human	hsa-mir-320a	miRNA	ionizing radiation (IR)	radiosensitivity of cancer cells	HeLa cells	ionizing radiation (IR) treatment	Pri-miR-320a expression increased linearly with the IR dose and treatment duration.	30066913
8589	Human	hsa-miR-320a	miRNA	ionizing radiation (IR)	radiosensitivity of cancer cells	HeLa cells; HCT116 cells	ionizing radiation (IR) treatment	miR-320a expression increased linearly with the IR dose and treatment duration.	30066913
8590	Human	hsa-miR-320a	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	B cells	M.tb infection	upregulated	29477867
8591	Human	hsa-miR-320a	miRNA	Roux-en-Y gastric bypass (RYGB)	type 2 diabetes mellitus (T2DM)	patients with T2DM peripheral blood	on the peripheral blood microRNAs (miRNAs) of treatment	downregulated in the peripheral blood	28273212
8592	Human	hsa-miR-320a-3p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	upregulated	30245930
8593	Human	hsa-miR-320a-3p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MCF-7 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	upregulated	30245930
8594	Human	hsa-miR-320a-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
8595	Human	hsa-miR-320a-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
8596	Human	hsa-miR-320b	miRNA	intermittent hypoxia (IH)	lung cancer	A549 cells; H1650 cells	intermittent hypoxia (IH) treatment	downregulated	33898105
8597	Human	hsa-miR-320b	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
8598	Human	hsa-miR-320b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
8599	Human	hsa-miR-320b	miRNA	androgen	prostate cancer	Human prostate cancer cell lines DU145	androgen stimulation	"the silencing of MALAT1 inactivated AR signaling by sponging miR-320b, and inhibited proliferation and cell cycle progression in prostate cancer cells"	30642743
8600	Human	hsa-miR-320c	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	The human pancreatic cell lines MiaPaCa2;PSN1	gemcitabine treatment	upregulated	23799850
8601	Human	hsa-miR-320c	miRNA	lipopolysaccharide (LPS)	pulmonary diseases	HL60 cells	lipopolysaccharide (LPS) treatment	lipopolysaccharide (LPS) showed increase in miR-320c expression in HL60 cells.	32439252
8602	Human	hsa-miR-320c	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
8603	Human	hsa-miR-320d	miRNA	"cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)"	diffuse large B-cell lymphoma (DLBCL)	patients with DLBCL	CHOP treatment	downregulated	24931464
8604	Human	hsa-miR-320d	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
8605	Human	hsa-miR-320d	miRNA	norcantharidin (NCTD)	prostate cancer	human prostate cancer cells	intraperitoneal injection of different concentration of NCTD treatment	upregulated	28760656
8606	Human	hsa-miR-320d	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	Exosomes derived from human primary melanocytes	ultraviolet B (UVB) irradiation treatment	upregulated	32785244
8607	Human	hsa-miR-322	miRNA	aluminum maltolate (Al-malt)	Alzheimer's disease (AD)	"human neuroblastoma cell line, SH-SY5Y"	treat with Al-Malt for 3 day	downregulated	28656195
8608	Human	hsa-miR-322	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	upregulated	20110569
8609	Human	hsa-miR-322/424	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	human liver tissue	CCl4 treatment	"miR-322/424 level in liver cirrhosis patients, mouse liver fibrosis induced by CCl4?and BDL, and rat liver fibrosis induced by CCl4?and dimethylnitrosamine was increased."	33333053
8610	Human	hsa-miR-323a-5p	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-323a-5p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
8611	Human	hsa-miR-323a-5p	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-323a-5p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
8612	Human	hsa-miR-323b-5p	miRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	fetal human cells (FHCs)	lipopolysaccharide (LPS) treatment	downregulated	30477744
8613	Human	hsa-miR-32-3p	miRNA	asbestos fibers	malignant pleural mesothelioma (MPM)	serum	ex-exposed to asbestos fibers (WEA)	downregulated	27716620
8614	Human	hsa-miR-324	miRNA	hypoxia	prostate cancer	LNCaP cells; LNCaP cells exosomes	hypoxia treatment	upregulated	29568403
8615	Human	hsa-miR-324-3p	miRNA	dexamethasone (DEX)	pulmonary inflammatory response	IL-1¦Â-treated A549 cells	dexamethasone (Dex) treatment	downregulated	33413425
8616	Human	hsa-miR-324-3p	miRNA	IL-1¦Â	pulmonary inflammatory response	A549 cells	IL-1¦Â treatment	upregulated	33413425
8617	Human	hsa-miR-324-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	29956723
8618	Human	hsa-miR-324-3p	miRNA	oxaliplatin	colorectal cancer (CRC)	CRC tissues; HCT116 cells; HCT8 cells	oxaliplatin (OXA) treatment	miR-324-3p was downregulated in Ox-resistant CRC tissues and cells	33005106
8619	Human	hsa-miR-324-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	HK-2 cells	High Glucose (HG) treatment	downregulated	31430717
8620	Human	hsa-miR-324-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
8621	Human	hsa-miR-324-5p	miRNA	oxaliplatin	colorectal cancer (CRC)	HT29 cells; HCT116 cells; HCT8 cells	oxaliplatin treatment	"hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-¦Á pathway in human colon cancer"	32243061
8622	Human	hsa-miR-324-5p	miRNA	high glucose (HG)	inflammatory response	VSMCs	high glucose (HG) treatment	MiRNA-324-5p exerts an inhibitory effect on T2DM-induced inflammation in blood vessels by negatively regulating CPT1A level and reducing the release of inflammatory factors.	33378033
8623	Human	hsa-miR-324-5p	miRNA	high glucose (HG)	inflammatory response	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	miRNA-324-5p was dose-dependently downregulated.	33378033
8624	Human	hsa-miR-324-5p	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
8625	Human	hsa-miR-324-5p	miRNA	H2O2	myocardial infarction (MI)	Endothelial progenitor cells (EPCs) derived from peripheral blood	H2O2 treatment	downregulated	31066044
8626	Human	hsa-miR-325	miRNA	cisplatin (DDP)	bladder cancer	5637 cells; T24 cells	cisplatin treatment	miR-325 was downregulated in 5637/R and T24/R cells compared to their parental 5637 and T24 cells.	33015771
8627	Human	hsa-miR-325-3p	miRNA	sevoflurane (SEV)	sevoflurane-induced neurotoxicity	HCN-2 cells	sevoflurane treatment	miR-325-3p is downregulated in HCN-2 cells exposed to sevoflurane	32191629
8628	Human	hsa-miR-32-5p	miRNA	walnut	benefits of walnuts	Plasma exosomes	walnuts treatment	upregulated	32979076
8629	Human	hsa-miR-32-5p	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-32-5p was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
8630	Human	hsa-miR-32-5p	miRNA	high glucose (HG)	cardiac fibrosis	human cardiac fibroblasts (CFs)	high glucose (HG) treatment	upregulated	31438862
8631	Human	hsa-miR-32-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	occupational workers serum	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
8632	Human	hsa-miR-32-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
8633	Human	hsa-miR-32-5p	miRNA	vmycobacterium tuberculosis (M.tb)	mycobacterium tuberculosis (Mtb) infection	THP-1 and U937 cells	infect with M.tb treatment	upregulated	28215633
8634	Human	hsa-miR-32-5p	miRNA	helicobacter pylori (H. pylori)	pediatric enteritis	"serum, human intestinal epithelial cell line HIEC-6"	Helicobacter pylori (H. pylori) infection	upregulated	31749593
8635	Human	hsa-miR-326	miRNA	H2O2	age-related cataract (ARC)	HLEC-B3 human lens epithelial cells	H2O2 treatment	upregulated	30268497
8636	Human	hsa-miR-326	miRNA	platelet-derived growth factor (PDGF)	airway remodeling	airway smooth muscle cells (ASMCs)	platelet-derived growth factor (PDGF) treatment	downregulated	32450169
8637	Human	hsa-miR-326	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	32336203
8638	Human	hsa-miR-326	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â25-35-induced ERS and apoptosis in SH-SY5Y cells can be attenuated by lncRNA RPPH1 through regulating miR-326/PKM2 axis.	32336203
8639	Human	hsa-miR-326	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
8640	Human	hsa-miR-326	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
8641	Human	hsa-miR-326	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	upregulated	31597953
8642	Human	hsa-miR-326	miRNA	sulforaphane (SFN)	gastric cancer (GC)	MKN45 cells	sulforaphane treatment	upregulated	30096452
8643	Human	hsa-miR-326	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	curcumin (Cur) treatment	Curcumin promoted the expression of miR-326.	27819521
8644	Human	hsa-miR-326	miRNA	pyruvate kinase M2(PKM2)	glioblastoma multiforme (GBM)	"U87MG, U251MG, T98G, U373MG, and A172"	Pyruvate kinase M2(PKM2) treatment	"cells with high levels of PKM2 expressed lower levels of miR-326, suggestive of endogenous regulation of PKM2 by miR-326"	20667897
8645	Human	hsa-miR-326	miRNA	sevoflurane (SEV)	lung cancer	H446 cells; H1975 cells	sevoflurane (Sev) treatment	upregulated	33987473
8646	Human	hsa-miR-326	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
8647	Human	hsa-miR-326	miRNA	propofol (PPF)	non-small cell lung cancer (NSCLC)	human bronchial epithelioid(16HBE)	Propofol treatment	"?Importantly, treatment with Propofol inhibited circ-RHOT1 expression in NSCLC cells"	33515563
8648	Human	hsa-miR-326	miRNA	resveratrol	cell proliferation and apoptosis	various tumor cells	resveratrol (Res) treatment	upregulated	27960279
8649	Human	hsa-miR-326-3p	miRNA	cadmium (Cd)	renal toxic	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
8650	Human	hsa-miR-326-3p	miRNA	cadmium (Cd)	toxic effects of cadmium	HK-2 cells	cadmium (Cd) treatment	upregulated	31626960
8651	Human	hsa-miR-328	miRNA	H2O2	apoptosis	H9c2 cells	H2O2 treatment	downregulated	28544404
8652	Human	hsa-miR-328	miRNA	sodium selenite	apoptosis	H9c2 cells	sodium selenite treatment	downregulated	28544404
8653	Human	hsa-miR-328	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30324654
8654	Human	hsa-miR-328	miRNA	arsenic trioxide (ATO)	breast cancer	MCF-7 cells	arsenic trioxide (As2O3) treatment	upregulated	25824027
8655	Human	hsa-miR-328	miRNA	imatinib	chronic lymphocytic leukemia (CLL)	K562 cells	Imatinib treatment	downregulated	31701195
8656	Human	hsa-miR-328	miRNA	imatinib	chronic myeloid leukemia (CML)	human immortalized myelogenous leukemia line K-562 cells	imatinib treatment	downregulated	22241070
8657	Human	hsa-miR-328	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	29859985
8658	Human	hsa-miR-328	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric mucosa	H. pylori treatment	downregulated	25479940
8659	Human	hsa-miR-328	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin (DPP) treatment	upregulated	30221716
8660	Human	hsa-miR-328	miRNA	resveratrol	osteosarcoma (OS)	osteosarcoma cells	resveratrol (Res) treatment	upregulated	25605016
8661	Human	hsa-miR-328	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	TGF-¦Â1 could induce EMT expression and fibrogenesis and significantly downregulated the expression of miR-328	30160133
8662	Human	hsa-miR-328-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-328-3p expression was downregulated in oxidized low-density lipoprotein (ox-LDL) induced human umbilical vein endothelial cells (HUVECs).	32329448
8663	Human	hsa-miR-328-3p	miRNA	puerarin	bladder cancer	T24 cells; UM-UC-3 cells	puerarin treatment	upregulated	33016781
8664	Human	hsa-miR-328-3p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
8665	Human	hsa-miR-328-3p	miRNA	5¦Á©\dihydrotestosterone (DHT)	triple negative breast cancer (TNBC)	MDA-MB-231 cells	5¦Á-dihydrotestosterone (DHT) treatment	upregulated	29964098
8666	Human	hsa-miR-328-5p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	APL cell line NB4	all-trans retinoic acid (ATRA) treatment	downregulated	30453015
8667	Human	hsa-miR-328-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	downregulated	32462517
8668	Human	hsa-miR-328-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	lipid accumulation	human acute monocytic leukemia cel (THP-1)	oxidized low-density lipoprotein (ox-LDL) treatment	The results showed that miR-328-5p expression was robustly decreased in oxidized low-density lipoprotein (ox-LDL)-treated macrophages.	33663010
8669	Human	hsa-miR-329-3p	miRNA	high glucose (HG)	endothelial cell injury	Human umbilical vein endothelial cells (HUVECs)	high glucose treatment	downregulated	33262815
8670	Human	hsa-miR-329-3p	miRNA	X-rays	glioblastoma multiforme (GBM)	U251 cells	X-ray radiation treatment	"XIST accelerates cell proliferation, invasion and inhibits cell apoptosis by repressing radio-sensitivity of glioma via enhancing CREB1 expression through sponging miR-329-3p"	32271437
8671	Human	hsa-miR-329-3p	miRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS;  LAN-6 cells	cisplatin (DPP) treatment	LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis.	32329857
8672	Human	hsa-miR-329-3p	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	"The results revealed that plasma miR-329-3p expression was decreased patients with T2DM compared with healthy controls, and in HUVECs treated with high glucose concentrations."	33262815
8673	Human	hsa-miR-33	miRNA	betulinic acid (BA)	alcoholic fatty liver disease	Human THP-1 macrophages	betulinic acid (BA) treatment	BA promoted ABCA1 expression via downregulated of miR-33s	24086374
8674	Human	hsa-miR-33	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid-¦Â (A¦Â) 25-35 treatment	miR-33 expression level was markedly upregulated in SH-SY5Y cells treated with A?25-35.	32119650
8675	Human	hsa-miR-33	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31933767
8676	Human	hsa-miR-33	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	ox-LDL-induced THP-1 macrophages	Tanshinone IIA (Tan) treatment	downregulated	31933767
8677	Human	hsa-miR-33	miRNA	citrus peel flavonoid extracts (CPFE)	lipid metabolism	HepG2 cells	citrus peel flavonoid extracts (CPFE) treatment	downregulated	31017523
8678	Human	hsa-miR-33	miRNA	resveratrol and epigallocatechin	hepatocellular carcinoma (HCC)	hepatic cell lines	resveratrol and epigallocatechin treatment		24165878
8679	Human	hsa-miR-330	miRNA	epigallocatechin-3-gallate (EGCG)	hormone refractory prostate cancer (HRPC)	LNCaP and 22R¦Í cells	Green tea polyphenol EGCG treatment	upregulated	21177307
8680	Human	hsa-miR-330	miRNA	fructose	kidney damage	HK-2 cells	fructose treatment	downregulated	28205387
8681	Human	hsa-miR-330-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
8682	Human	hsa-miR-330-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	temporomandibular joint osteoarthritis	synoviocyte	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	32332704
8683	Human	hsa-miR-330-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
8684	Human	hsa-miR-330-5p	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
8685	Human	hsa-miR-330-5p	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
8686	Human	hsa-miR-330-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-330-5p was greatly decreased in THP-1 cells incubated with ox-LDL.	29698635
8687	Human	hsa-miR-330-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-330-5p was greatly decreased in THP-1 cells incubated with ox-LDL and overexpression of miR-330-5p was able to inhibit oxidative stress and inflammation process.	30187491
8688	Human	hsa-miR-330-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)	doxorubicin treatment	"The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a"	32392088
8689	Human	hsa-miR-330-5p	miRNA	curcumin (Cur)	lung cancer	human non-small cell lung cancer A549 cell line	curcumin treatment	dysregulated	28660665
8690	Human	hsa-miR-330-5p	miRNA	arsenic trioxide (ATO)	pancreatic cancer (PC)	Human PC cell lines Patu8988 and Panc-1	arsenic trioxide (ATO) treatment	upregulated	30847385
8691	Human	hsa-miR-330-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	Pancreatic cancer tissues	Gemcitabine (GEM) treatment	downregulated	32104074
8692	Human	hsa-miR-330-5p	miRNA	lipopolysaccharide (LPS)	pulmonary vascular endothelial cell (PVEC) injury	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	PRNCR1 was upregulated in LPS-induced PVEC and aggravated its injury via modulating the miR-330-5p/TLR4 axis.	33049095
8693	Human	hsa-miR-330-5p	miRNA	H2O2	thoracic aortic aneurysm (TAA)	mouse aortic smooth muscle cells (SMCs)	H2O2 treatment	long noncoding RNA (lncRNA) Sox2ot modulates the progression of TAA by regulating miR-330-5p/Myh11 axis.	32578852
8694	Human	hsa-miR-331	miRNA	particulate matter (PM2.5)	airway epithelial injury	human airway epithelial Beas-2B (B2B) cells	PM2.5 treatment	downregulated	28192748
8695	Human	hsa-miR-331	miRNA	platelet derived growth factor-BB (PDGF-BB)	proliferative vascular diseases	Human VSMCs	platelet derived growth factor-BB (PDGF-BB) treatment	circSFMBT2 plays a vital role in VSMC proliferation and migration through the miR-331/HDAC5/Aggf1 axis	33166591
8696	Human	hsa-miR-331-3p	miRNA	amyloid-¦Â (A¦Â) 1-40	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 1-40 treatment	"In AD patients and A¦Â1-40?treated SH-SY5Y cells, the expression of miR-331-3p was significantly downregulated."	33279668
8697	Human	hsa-miR-331-3p	miRNA	amyloid-¦Â (A¦Â) 1-40	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 1-40 treatment	"In A¦Â1-40 treated SH-SY5Y cells, the expression of miR-331-3p was significantly downregulated."	33279668
8698	Human	hsa-miR-331-3p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
8699	Human	hsa-miR-331-3p	miRNA	rapamycin and methylprednisolone (MP)	glucocorticoids (GCs) resistance	CCL-119 cells	rapamycin and methylprednisolone (MP) treatment	upregulated	32776229
8700	Human	hsa-miR-331-3p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HCC cell lines	hepatitis B virus (HBV) infection	upregulated	25750939
8701	Human	hsa-miR-331-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC1 cells; MIAPaCa2 cells; plasma	gemcitabine treatment	miR-331-3p is upregulated in gemcitabine-treated pancreatic cancer cells and plasma from chemotherapy patients.	32924881
8702	Human	hsa-miR-331-3p	miRNA	¦Ã-rays	prostate cancer	22RV1; DU145 cells	Gy radiation treatement	LncRNA UCA1 deletion suppressed the radioresistance to PCa by suppressing EIF4G1 expression via miR-331-3p.	32943997
8703	Human	hsa-miR-331-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	B cells	M.tb infection	upregulated	29477867
8704	Human	hsa-miR-331-5p	miRNA	doxorubicin (DOX)	leukemia	myeloid leukemic cell lines NB4; human promyelocytic leukaemia cell line;HL60	doxorubicin (DOX)? treatment	downregulated	21070600
8705	Human	hsa-miR-335	miRNA	glucocorticoid (GC)	acute lymphoblastic leukemia (ALL)	Mononuclear cells	glucocorticoid (GC) treatment	downregulated	23888996
8706	Human	hsa-miR-335	miRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	bone marrow aspirates	cytarabine (Ara-C) treatment	upregulated	26287405
8707	Human	hsa-miR-335	miRNA	hypoxia	aging	hMSCs	"hypoxia (3% O2, for 7 days) treatment"	downregulated	24648336
8708	Human	hsa-miR-335	miRNA	pro-inflammatory growth factors	aging	hMSCs	pro-inflammatory growth factors treatment	downregulated	24648336
8709	Human	hsa-miR-335	miRNA	¦Ã-rays	aging	hMSCs	¦Ã-irradiation (0.5¨C10 Gy) treatment	upregulated	24648336
8710	Human	hsa-miR-335	miRNA	platycodin D (PD)	bladder cancer	T24; RT4	Platycodin D (PD) treatment	"PD inhibited LncRNA-XIST expressions, while increased miR-335 expression levels in bladder cancer cells"	32919956
8711	Human	hsa-miR-335	miRNA	NT21MP2	breast cancer	MCF-7 and SKBR-3 cells	NT21MP2 treatment	downregulated	28731125
8712	Human	hsa-miR-335	miRNA	"TCDD and 6-methyl-1,3,-trichlorodibenzofuran (MCDF)"	breast cancer	MDA-MB-231 ;BT474 cells	"TCDD and 6-methyl-1,3,-trichlorodibenzofuran (MCDF)?treatment treatment"	Both TCDD and MCDF induced miR-335 in MDA-MB-231 and BT474 cells	22034498
8713	Human	hsa-miR-335	miRNA	"leptin, resistin, TNF-¦Á, and IL-6"	fat	human mature adipocytes	"leptin, resistin, TNF-¦Á, and IL-6 treatment"	upregulated	23801157
8714	Human	hsa-miR-335	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	gastric cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25520857
8715	Human	hsa-miR-335	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 or Bel7404	sorafenib (Sora) treatment	"lncRNA NEAT1 mediates Sora resistance of HCC cells by suppressing miR-335 expression, and disinhibition on c-Met-Akt signaling pathway"	30937906
8716	Human	hsa-miR-335	miRNA	decabromodiphenyl ether (BDE-209)	human embryonic development	human embryonic stem cell lines FY-hES-10 and FY-hES-26	Decabromodiphenyl ether (BDE-209) treatment	upregulated	26206603
8717	Human	hsa-miR-335	miRNA	Pomegranate juice (PJ)	prostate cancer	?prostate cancer cells	Pomegranate juice (PJ) treatment	upregulated	21594291
8718	Human	hsa-miR-335	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
8719	Human	hsa-miR-335	miRNA	gemcitabine (GEM)	renal cell carcinoma (RCC)	renal tissues or TK10 and UO31 cells	gemcitabine treatment	"Hsa-miR-335 is the target regulatory point of hsa_circ_0035483. In addition, hsa_circ_0035483 promotes autophagy and tumor growth and enhances gemcitabine resistance in RCC by regulating hsa-miR-335/CCNB1."	31492499
8720	Human	hsa-miR-335-3p	miRNA	H2O2	age-related nuclear cataract	human lens epithelial B3 (HLE-B3) cell	H2O2 treatment	downregulated	29653565
8721	Human	hsa-miR-335-3p	miRNA	TGF-¦Â	hereditary gingival fibromatosis (HGF)	human gingival fibroblasts (NHGFs)	transforming growth factor ¦Â (TGF-¦Â) treatment	downregulated	31323181
8722	Human	hsa-miR-335-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"miR-335-3p was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression."	32127962
8723	Human	hsa-miR-335-5p	miRNA	H2O2	atherosclerosis (AS)	human umbilical vein endothelial cells	H2O2 treatment	upregulated	30785341
8724	Human	hsa-miR-335-5p	miRNA	H2O2	preeclampsia (PE)	JEG-3 cells	H2O2 treatment	H2O2 significantly increased the intracellular ROS levels and miR-335-5p expression.	31894323
8725	Human	hsa-miR-335-5p	miRNA	H2O2	preeclampsia (PE)	JEG-3 cells	H2O2 treatment	upregulated	31894323
8726	Human	hsa-miR-337	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
8727	Human	hsa-miR-337	miRNA	high glucose (HG)	osteogenesis		?high-glucose (HG) treatment	High glucose inhibited osteogenic differentiation but increased the level of miR-337	33748908
8728	Human	hsa-miR-337	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
8729	Human	hsa-miR-337	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
8730	Human	hsa-miR-337-3p	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
8731	Human	hsa-miR-337-3p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	upregulated	33276753
8732	Human	hsa-miR-337-5p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
8733	Human	hsa-miR-338	miRNA	Iodine-125 (125I)	hepatocellular carcinoma (HCC)	HCCLM3 and SMMC-7721 cells	125I irradiation treatment	upregulated	31514072
8734	Human	hsa-miR-338-3p	miRNA	silver nanoparticles (AgNPs)	breast cancer	"MCF7, T47D and MDA-MB-231 cells"	silver nanoparticles (AgNPs)?treatment treatment	upregulated	33613979
8735	Human	hsa-miR-338-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	"RPMI-2650 cells, a human nasal epithelial cell line"	fine particulate matter (PM2.5) exposure treatment	The results showed that miR-338-3p was downregulated in both nasal mucosa of PM25-exacerbated AR rat models and PM25-treated RPMI-2650 cells	33770685
8736	Human	hsa-miR-338-3p	miRNA	mepolizumab	asthma	serum	6 patients with mepolizumab after 8 weeks of treatment	upregulated	33808110
8737	Human	hsa-miR-338-3p	miRNA	reslizumab	asthma	serum	10 patients treated with reslizumab for 8 weeks treatment	upregulated	33808110
8738	Human	hsa-miR-338-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVEC cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30556591
8739	Human	hsa-miR-338-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miR-338-3p was increased in patients with AS and oxidized low-density lipoprotein (ox-LDL)-induced HUVEC cells.	30556591
8740	Human	hsa-miR-338-3p	miRNA	baicalin (BAI)	breast cancer	"MCF-10A, MCF-7 and MDA-MB-231 cells"	baicalin (BAI) treatment	upregulated	31908485
8741	Human	hsa-miR-338-3p	miRNA	hypoxia	breast cancer	MCF7 cells; HCC1937 cells	hypoxia treatment	miR-338-3p level was decreased in a dose- and time-dependent manner after hypoxia treatment.	32726486
8742	Human	hsa-miR-338-3p	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
8743	Human	hsa-miR-338-3p	miRNA	radiation	colorectal cancer (CRC)	colon cancer tissues	radiation treatment	circ_0001313 was significantly upregulated and miR-338-3p was downregulated in radio-resistant colon cancer tissues compared to radio-sensitive tissues	30630646
8744	Human	hsa-miR-338-3p	miRNA	X-rays	colorectal cancer (CRC)	SW480 and SW620 cells	6-MV X-ray exposure	Radiation treatment in colon cells triggered a remarkable upregulation of circ_0001313 and a downregulated of miR-338-3p.	30630646
8745	Human	hsa-miR-338-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32680978
8746	Human	hsa-miR-338-3p	miRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS cells; SK-N-SH cells	cisplatin treatment	downregulated	32164348
8747	Human	hsa-miR-338-3p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
8748	Human	hsa-miR-338-3p	miRNA	resveratrol	osteoporosis	human osteoblast (HOB) cells	"Resveratrol (3,5,4-tri-hydroxystilbene; RESV) treatment"	downregulated	25845653
8749	Human	hsa-miR-338-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	16HBE cells	lipopolysaccharide (LPS) treatment	Circ_0038467 was upregulated and miR-338-3p was downregulated in LPS-treated 16HBE cells.	32181994
8750	Human	hsa-miR-338-5p	miRNA	hypoxia	colorectal cancer (CRC)	The human colon cancer cell lines HCT116 and HCT8	hypoxia induce	downregulated	31208913
8751	Human	hsa-miR-338-5p	miRNA	anticancer bioactive peptide-3 (ACBP-3)	gastric cancer (GC)	GC MKN45 cells	anticancer bioactive peptide-3 (ACBP-3) treatment	ACBP-3 induced the expression of miR-338-5p and the BAK and BIM proteins and promoted GCSC apoptosis.	27688872
8752	Human	hsa-miR-339	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
8753	Human	hsa-miR-339	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
8754	Human	hsa-miR-339-3p	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
8755	Human	hsa-miR-339-5p	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
8756	Human	hsa-miR-339-5p	miRNA	prolactin (PRL)	breast cancer	MCF-7 and T47D breast cancer cells	Prolactin (PRL) treatment	upregulated	27066093
8757	Human	hsa-miR-339-5p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
8758	Human	hsa-miR-339-5p	miRNA	high glucose (HG)	diabetic vasculopathy	human aortic endothelial cells (HAECs)	high glucose (HG)	downregulated	28824448
8759	Human	hsa-miR-339-5p	miRNA	hypoxia/reoxygenation (H/R)	intestinal ischemia/reperfusion (I/R) injury	Caco-2 cells	hypoxia/reoxygenation (H/R) treatment	circ-PRKCB/miR-339-5p/p66Shc signaling pathway in regulating oxidative stress in the I/R intestine.	32929374
8760	Human	hsa-miR-339-5p	miRNA	ionizing radiation (IR)	lung cancer	A549 cells; H460 cells	ionizing radiation (IR) treatment	upregulated	30462625
8761	Human	hsa-miR-339-5p	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	downregulated	26640557
8762	Human	hsa-miR-33a	miRNA	metformin (Met)	breast cancer	ALDHbright cells	metformin treatment	upregulated	24980829
8763	Human	hsa-miR-33a	miRNA	xuezhikang (XZK)	cellular cholesterol export	participating patients with low baseline levels of HDL cholesterol	"XZK capsule, 600 mg twice daily for 6 months treatment"	upregulated	24591767
8764	Human	hsa-miR-33a	miRNA	cholesterol	colorectal cancer (CRC)	HT-29 and SW480 cells	cholesterol treatment	downregulated	30827510
8765	Human	hsa-miR-33a	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
8766	Human	hsa-miR-33a	miRNA	grape pomace extract (GPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape pomace extract (GPE) treatment	GPE reduced miR-122 but increased miR-33a expression.	24165878
8767	Human	hsa-miR-33a	miRNA	grape seed proanthocyandin extract (GSPE)	dyslipidemia and insulin resistance	rat hepatoma cell line (ECACC); FAO cells	grape seed proanthocyandin extract (GSPE) treatment	GSPE reduced both miR-122 and miR-33a levels.	24165878
8768	Human	hsa-miR-33a	miRNA	curcumin (Cur)	formation of foam cells	THP-1 cells	curcumin treatment	"ox-LDL significantly promoted the expression of miR33a, while the expression of miR33a mRNA was significantly decreased in curcumin pre-treated cells."	32782494
8769	Human	hsa-miR-33a	miRNA	TGF-¦Â2	liver fibrosis	Lx-2 cells	TGF-¦Â2 treatment	upregulated	24100264
8770	Human	hsa-miR-33a	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2 cells;BEL-7402 cells	hypoxia treatment	downregulated	27460728
8771	Human	hsa-miR-33a	miRNA	H2O2	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
8772	Human	hsa-miR-33a	miRNA	lipopolysaccharide (LPS)	oxidative stress	human umbilical endothelial cells (HUVECs) and peripheral blood mononuclear cells	LPS (20 ng/mL) or H2O2 (1%) for 8 hours at 37¡ãC	dysregulated	28403739
8773	Human	hsa-miR-33a	miRNA	aflatoxin B1 (AFB1)	ischemic injury	hepatocellular carcinoma (HCC) cells	aflatoxin B1 (AFB1) treatment	upregulated	24015284
8774	Human	hsa-miR-33a	miRNA	resistin	osteoarthritis (OA)	THP-1 cells	resistin treatment	downregulated	30845380
8775	Human	hsa-miR-33a	miRNA	"bone morphogenetic protein 2 (BMP2), Osteocalcin, and Runx2"	osteogenesis	osteoclast-like cells (OLCs)	"BMP2, Osteocalcin, and Runx8 treatment"	downregulated	21572246
8776	Human	hsa-miR-33a	miRNA	lovastatin	osteosarcoma (OS)	MG63 cells; SaOS2 cells	lovastatin treatment	lovastatin increased the expression of SREBP-2 and miR-33a.	30466075
8777	Human	hsa-miR-33a	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"Human pancreatic carcinoma cells, SW1990 and MiaPaCa-2, and human embryonic kidney (HEK) 293 T cells"	gemcitabine (GEM) treatment	downregulated	26113407
8778	Human	hsa-miR-33a	miRNA	TGF-¦Â1	liver fibrosis	hepatic stellate cells (HSCs)	TGF-¦Â1? treatment	upregulated	24100264
8779	Human	hsa-miR-33a*	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
8780	Human	hsa-miR-33a-5p	miRNA	celastrol	lung adenocarcinoma (LUAD)	A549 and LTEP-a-2 cells	celastrol treatment	upregulated	29484434
8781	Human	hsa-miR-33a-5p	miRNA	PD-L1 inhibitor	glioblastoma multiforme (GBM)	U87 MG cells; U251 cells	PD-L1 inhibitor treatment	"PD-L1 inhibitor significantly decreased the expression of the target gene, miR-33a-5p"	32537433
8782	Human	hsa-miR-33a-5p	miRNA	high glucose (HG)	hyperglycemic ST-segment elevation myocardial infarction (STEMI)	Human aortic endothelial cells (HAECs; PCS©\100©\011?) and pulmonary artery endothelial cells (CPAEs; CCL©\209)	high glucose treatment	upregulated	31294459
8783	Human	hsa-miR-33a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	Human bonemarrow stromal cells (hBMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26785690
8784	Human	hsa-miR-33a-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
8785	Human	hsa-miR-33a-5p	miRNA	chidamide	triple negative breast cancer (TNBC)	The MDA-MB-231 and BT-20 TNBC cell lines	chidamide treatment	upregulated	31257519
8786	Human	hsa-miR-33b	miRNA	xuezhikang (XZK)	cellular cholesterol export	participating patients with low baseline levels of HDL cholesterol	"XZK capsule, 600 mg twice daily for 6 months treatment"	upregulated	24591767
8787	Human	hsa-miR-33b	miRNA	high glucose (HG)	hyperglycemic ST-segment elevation myocardial infarction (STEMI)	Human aortic endothelial cells (HAECs; PCS©\100©\011?) and pulmonary artery endothelial cells (CPAEs; CCL©\209)	high glucose treatment	upregulated	31294459
8788	Human	hsa-miR-33b	miRNA	MLN9708/2238	ischemia/reperfusion (I/R) injury	multiple myeloma (MM) cellls	proteasome inhibitor? treatment	upregulated	22983447
8789	Human	hsa-miR-33b	miRNA	high glucose (HG)	lipid accumulation	HepG2 cells	high glucose treatment	upregulated	31686542
8790	Human	hsa-miR-33b	miRNA	metformin (Met)	lipid accumulation	high glucose-induced HepG2 cells	Metformin treatment	downregulated	31686542
8791	Human	hsa-miR-33b	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
8792	Human	hsa-miR-33b	miRNA	cordycepin	malignant melanoma (MM)	highly-metastatic melanoma cell lines	cordycepin treatment	upregulated	25868853
8793	Human	hsa-miR-33b	miRNA	lovastatin	medulloblastoma	"HEK293T, D283;Daoy cells"	lovastatin? treatment	upregulated	22887866
8794	Human	hsa-miR-33b	miRNA	resistin	osteoarthritis (OA)	THP-1 cells	resistin treatment	downregulated	30845380
8795	Human	hsa-miR-33b-3p	miRNA	cisplatin (DDP)	lung cancer	A549 cells	cisplatin treatment	downregulated	27559850
8796	Human	hsa-miR-33b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	downregulated	31522815
8797	Human	hsa-miR-33b-3p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
8798	Human	hsa-miR-33b-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
8799	Human	hsa-miR-33b-5p	miRNA	rosuvastatin	atherosclerosis (AS)	atherosclerotic plaques	rosuvastatin treatment	downregulated	31409515
8800	Human	hsa-miR-33b-5p	miRNA	rosuvastatin	atherosclerosis (AS)	atherosclerotic plaques	rosuvastatin treatment	downregulated	31409515
8801	Human	hsa-miR-33b-5p	miRNA	arsenite	tumorigenesis	human bronchial epithelial (HBE) cells	arsenic exposure	"upregulated (miR-141-3p, miR-106b-5p, miR-200b-3p) and downregulated(miR-192b-5p, miR-15b-5p, miR-33b-5p)"	28972549
8802	Human	hsa-miR-34	miRNA	IL-13	autophagy	BEAS-2B cells	IL-13 treatment	upregulated	28796252
8803	Human	hsa-miR-34	miRNA	resveratrol	chronic obstructive pulmonary disease (COPD)	Peripheral blood	resveratrol (RS) treatment	upregulated	26191210
8804	Human	hsa-miR-34	miRNA	corticosteroid	erythroid cell differentiation	bronchial epithelial? cells	corticosteroids treatment	downregulated	22955319
8805	Human	hsa-miR-34	miRNA	curcumin (Cur)	ischemia/reperfusion (I/R) injury	colon cancer cell lines	curcumin (CUR) treatment	CDF was very effective in the re-expression of miR-34a and miR-34c	22992310
8806	Human	hsa-miR-34	miRNA	melatonin	primary biliary cholangitis (PBC)	H69 cells	melatonin treatment	downregulated	33352965
8807	Human	hsa-miR-34	miRNA	¦Ã-rays	renal disease	HeLa? cells	gamma radiation treatment	miR-34 is significantly induced by ¦Ã-radiation in HeLa cells	23091481
8808	Human	hsa-miR-340	miRNA	lipopolysaccharide (LPS)	acute liver injury (ALI)	Kupffer cells (KCs)	lipopolysaccharides (LPS) treatment	downregulated	33155227
8809	Human	hsa-miR-340	miRNA	tetrachloromethane (CCl4)	acute liver injury (ALI)	Kupffer cells (KCs)	tetrachloromethane (CCl4) treatment	downregulated	33155227
8810	Human	hsa-miR-340	miRNA	kaempferol	lung cancer	A549 cells	kaempferol treatment	miR-340 was upregulated by kaempferol treatment.	30253373
8811	Human	hsa-miR-340	miRNA	lentinan (LNT)	osteosarcoma (OS)	human OS MG63 cells	lentinan (LNT) treatment	upregulated	31949775
8812	Human	hsa-miR-340	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells	criplatin (DPP) treatment	downregulated	29494357
8813	Human	hsa-miR-340	miRNA	a moderate-carbohydrate and high glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and high glycemic index diet	downregulated	29233589
8814	Human	hsa-miR-340	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
8815	Human	hsa-miR-340	miRNA	curcumin (Cur)	pancreatic cancer (PC)	human pancreatic cancer cells	curcumin treatment	upregulated	28789415
8816	Human	hsa-miR-340	miRNA	ultraviolet (UV) irradiation	pigmentation	Pig-1 cells	ultraviolet B (UVB) irradiation treatment	Expression of miR-340 was reduced in human Pig-1 cells after UVB irradiation	33179560
8817	Human	hsa-miR-340	miRNA	ultraviolet (UV) irradiation	UVB-mediated retinal damage	retinal pigment epithelium (RPE) cells	ultraviolet B (UVB) treatment	UVB significantly increased miR-340 levels	29982095
8818	Human	hsa-miR-340-5p	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 and HepG2/CDDP	cisplatin treatment	downregulated	30030687
8819	Human	hsa-miR-340-5p	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus infection	downregulated	30753994
8820	Human	hsa-miR-340-5p	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	downregulated	25552929
8821	Human	hsa-miR-340-5p	miRNA	hypoxia	melanoma	melanoma stem-like cells	hypoxia treatment	downregulated	26554847
8822	Human	hsa-miR-340-5p	miRNA	Hypoxia	oesophageal squamous cell carcinoma (ESCC)	"human OSCC cell lines (Te13, Te1 , Eca109)"	Hypoxia treatment	miR-340-5p was highly expressed in hypoxic exosomes	33485367
8823	Human	hsa-miR-340-5p	miRNA	ferulic acid (FA)	osteogenesis	human bone marrow-derived mesenchymal stem cell (MSC)	FA	downregulated	28764862
8824	Human	hsa-miR-340-5p	miRNA	silver nanoparticles (AgNPs)	silver nanoparticles (SNPs) induced cytotoxicity	human dermal fibroblasts (HDFs)	silver nanoparticles (SNPs) treatment	upregulated	30305212
8825	Human	hsa-miR-342	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	MiR-342 attenuates lipopolysaccharide-induced acute lung injury via inhibiting MAPK1 expression.	32248545
8826	Human	hsa-miR-342	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
8827	Human	hsa-miR-342	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
8828	Human	hsa-miR-342	miRNA	all-trans retinoic acid (ATRA)	crohn disease (CD)	acute promyelocytic leukemia cells	?all-trans-retinoic acid (ATRA) treatment	upregulated	19151778
8829	Human	hsa-miR-342	miRNA	retinoic acid (RA)	acute promyelocytic leukemia (APL)	human promyelocytic cell line NB4	Retinoic acid treatment	upregulated	17260024
8830	Human	hsa-miR-342	miRNA	paraquat (PQ)	lung injury	Beas-2B cells	paraquat (PQ) treatment	downregulated	32758486
8831	Human	hsa-miR-342	miRNA	palliative chemotherapy	non-small cell lung cancer (NSCLC)	NSCLC tissues	platinum derivatives in combination with paclitaxel or gemcitabine treatment	downregulated	29387235
8832	Human	hsa-miR-342-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 was significantly increased in THP-1 cells incubated with ox-LDL and meanwhile miR-342-3p was greatly decreased.	30259979
8833	Human	hsa-miR-342-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30259979
8834	Human	hsa-miR-342-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse renal mesangial cells (MCs)	high glucose (HG) treatment	miR-342-3p suppresses the progression of DKD by inducing the degradation of SOX6.	31746345
8835	Human	hsa-miR-342-3p	miRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	"MIAT and CASP1 expression were substantially increased, while that of miR-342-3p was decreased in AGE-BSA-treated HRPCs."	33065089
8836	Human	hsa-miR-342-3p	miRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	primary human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by mdulating miR-342-3p targeting of CASP1 in diabetic retinopathy.	33065089
8837	Human	hsa-miR-342-3p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
8838	Human	hsa-miR-342-3p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
8839	Human	hsa-miR-342-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	upregulated	27081844
8840	Human	hsa-miR-342-3p	miRNA	sophorae Fructus	hepatocellular carcinoma (HCC)	Huh7 cells	sophorae Fructus treatment	"Flavonoids of Sophorae Fructus could inhibite the proliferation, migration and invasion of hepatoma cells by regulating LncRNA FBXL19-AS1/miR-342-3p pathway"	33164374
8841	Human	hsa-miR-342-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	"KMS-12-PE , RPMI-8226R cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29242101
8842	Human	hsa-miR-342-3p	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"The human PDAC cell lines PANC-1, MiaPaCa-2 and the normal pancreatic ductal epithelial cell line HPDE6c7"	gemcitabine (GEM) treatment	"expression levels of obesity-associated miR-342-3p were significantly upregulated in gemcitabine (GEM)-resistant PDAC tissues and cells, and this upregulation was associated with poor postchemotherapy prognosis."	30638935
8843	Human	hsa-miR-342-5p	miRNA	5-fluorouracil/cisplatin (CDDP-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	CDDP-CRTX treatment	dysregulated	28347920
8844	Human	hsa-miR-344a-3p	miRNA	curcumin (Cur)	schwannoma	RT4 schwannoma cells	curcumin treatment	upregulated	30534000
8845	Human	hsa-miR-345	miRNA	"trans-3,5,4-trimethoxystilbene (TMS)"	non-small cell lung cancer (NSCLC)	H1299 and PC©\9/GR cells	"trans-3,5,4-trimethoxystilbene (TMS) treatment"	upregulated	30701693
8846	Human	hsa-miR-345-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (oxLDL) treatment	downregulated	31825793
8847	Human	hsa-miR-345-3p	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	upregulated	31824817
8848	Human	hsa-miR-345-5p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
8849	Human	hsa-miR-345-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
8850	Human	hsa-miR-346	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	colorectal cancer (CRC)	human colon cancer cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	25192497
8851	Human	hsa-miR-346	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	HeLa cells	thapsigargin (Tg) treatment	upregulated	29107113
8852	Human	hsa-miR-346	miRNA	leishmania	leishmaniasis	U937 and/or THP-1 human monocytic cells	leishmania infection	upregulated	29867904
8853	Human	hsa-miR-346	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	oral lichen planus (OLP)	HaCat cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29335479
8854	Human	hsa-miR-34a	miRNA	TGF-¦Â	colitis	HepG2 cells; Hepa1-6 cells; WRL68 cells; CD4+CD25+ T cells;CD4+CD25- T cells	TGF-¦Â treatment	downregulated	22975373
8855	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT8; SW480 cells	5-fluorouracil (5-FU) treatment	LncRNA NEAT1 could target miR-34a and promote autophagy to facilitate 5-FU chemoresistance in CRC.	31802650
8856	Human	hsa-miR-34a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	Human bone marrow stromal cell line HS-5 and human AML cell line HL60	adriamycin (ADR) treatment	downregulated	30551433
8857	Human	hsa-miR-34a	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	downregulated	30551433
8858	Human	hsa-miR-34a	miRNA	all-trans retinoic acid (ATRA)	acute myeloid leukemia (AML)	KG-1 cells	all-trans retinoic acid (ATRA) treatment	upregulated	32006898
8859	Human	hsa-miR-34a	miRNA	decitabine	acute myeloid leukemia (AML)	KG-1 cells	decitabine (DAC) treatment	upregulated	32006898
8860	Human	hsa-miR-34a	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19 cells	H2O2 treatment	upregulated	31249522
8861	Human	hsa-miR-34a	miRNA	flavonoids (TFs)	aging	human umbilical vein endothelial cells (HUVEC)	flavonoids (TFs) treatment	downregulated	31106472
8862	Human	hsa-miR-34a	miRNA	ethanol (EtOH) and lipopolysaccharide (LPS)	alcoholic liver injury	Normal human hepatocytes (N-Heps) £» human intrahepatic biliary epithelial cells (HiBECs)	ethanol and lipopolysaccharide treatment	upregulated	22841474
8863	Human	hsa-miR-34a	miRNA	amyloid-¦Â (A¦Â) 1-40	Alzheimer's disease (AD)	Human neuroblastoma SH-SY5Y cells	amyloid-¦Â (A¦Â) 1-40 treatment	downregulated	31281568
8864	Human	hsa-miR-34a	miRNA	advanced glycation end product (AGE)	apoptosis	endothelial progenitor cells	advanced glycation end products (AGEs) treatment	upregulated	31397599
8865	Human	hsa-miR-34a	miRNA	capsaicin	apoptosis	"human lung cancer cell lines, A549 and H1299"	capsaicin treatment	upregulated	24444609
8866	Human	hsa-miR-34a	miRNA	hyperthermia	apoptosis	colorectal carcinoma (CRC) HCT116 cells	exposure to hyperthermia (42¡ãC for 2-4 h)	upregulated	29285066
8867	Human	hsa-miR-34a	miRNA	hypofractionated radiotherapy	apoptosis	human NPC cells	hypofractionated radiotherapy treatment	upregulated	25231528
8868	Human	hsa-miR-34a	miRNA	metformin (Met)	apoptosis	MCF-7 cells	metformin treatment	upregulated	24970682
8869	Human	hsa-miR-34a	miRNA	temozolomide (TMZ)	apoptosis	peripheral blood lymphocytes (PBLs) obtained from oncology nurses handling antineoplastic drugs	TMZ treatment	upregulated	28944882
8870	Human	hsa-miR-34a	miRNA	thymosin ¦Â4 (T¦Â4)	apoptosis	advanced glycation endproducts (AGEs)-treated endothelial progenitor cells	thymosin beta 4 (T¦Â4) treatment	downregulated	31397599
8871	Human	hsa-miR-34a	miRNA	IL-13	asthma	human bronchial epithelial cells (NHBE)	IL-13 treatment	upregulated	31386204
8872	Human	hsa-miR-34a	miRNA	genistein	atherosclerosis (AS)	ox-LDL-treat human umbilical vein endothelial cells (HUVECs)	"pretreated with genistein at different concentrations (10nM, 100nM and 1000nM) for 6h"	downregulated	28688900
8873	Human	hsa-miR-34a	miRNA	H2O2	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	"miR-34a upregulation was accompanied with reduced SIRT1 expression in HUVECs, following H2O2?treatment."	33488795
8874	Human	hsa-miR-34a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29328474
8875	Human	hsa-miR-34a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29704100
8876	Human	hsa-miR-34a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL treatment significantly increased the levels of miR-34a in a dose-dependent manner in the HUVECs.	29750293
8877	Human	hsa-miR-34a	miRNA	sulforaphane (SFN)	atherosclerosis (AS)	H2O2-treated human umbilical vein endothelial cells (HUVECs)	sulforaphane (SFN) treatment	downregulated	33488795
8878	Human	hsa-miR-34a	miRNA	indoxyl sulfate (IS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs); human aortic vascular smooth muscle cells (HA-VSMCs)	indoxyl sulfate (IS) treatment	IS up-regulates the expression of miR-34a in vitro.	32593718
8879	Human	hsa-miR-34a	miRNA	dexamethasone (DEX)	B-cell malignant multiple myeloma£¨MM£©	MM cells	dexamethasone (DEX) treatment	downregulated	23759586
8880	Human	hsa-miR-34a	miRNA	benzene	benzene toxicity	workers blood	benzene treatment	upregulated	27939626
8881	Human	hsa-miR-34a	miRNA	etoposide (VP-16)	brain tumour	MHH-Med1 cells	etoposide? treatment	upregulated	25250818
8882	Human	hsa-miR-34a	miRNA	"3,6-dihydroxyflavone (3,6-DHF)"	breast cancer	MDA-MB-231 cells	"3,6-dihydroxyflavone (3,6-DHF) treatment"	upregulated	28870206
8883	Human	hsa-miR-34a	miRNA	adoMet	breast cancer	MCF-7 cells	adoMet treatment	upregulated	30533999
8884	Human	hsa-miR-34a	miRNA	artemisinin (ART)	breast cancer	MCF-7/S cells	artemisinin treatment	upregulated	28361857
8885	Human	hsa-miR-34a	miRNA	artemisinin and artesunate	breast cancer	Human breast cancer cells	artemisinin and artesunate treatment	upregulated	25789847
8886	Human	hsa-miR-34a	miRNA	curcumin (Cur)	breast cancer	MCF-7 cells	curcumin treatment	upregulated	29189128
8887	Human	hsa-miR-34a	miRNA	curcumin (Cur)	breast cancer	MCF-10F and MDA-MB-231 breast cell lines	curcumin treatment	upregulated	31894298
8888	Human	hsa-miR-34a	miRNA	curcumin (Cur)	breast cancer	MCF-10F cells	curcumin (Cur) treatment	upregulated	31894298
8889	Human	hsa-miR-34a	miRNA	delphinidin	breast cancer	"Breast cancer cells MDA©\MB©\231, MCF©\7, and MDA©\MB©\453 w"	delphinidin treatment	upregulated	31325197
8890	Human	hsa-miR-34a	miRNA	diallyl disulfide (DADS)	breast cancer	MDA-MB-231 cells	Diallyl disulfide (DADS) treatment	upregulated	25396727
8891	Human	hsa-miR-34a	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	upregulated	33159957
8892	Human	hsa-miR-34a	miRNA	hesperidin	breast cancer	MCF-7 cells	hesperidin treatment	upregulated	33050842
8893	Human	hsa-miR-34a	miRNA	IL-6	breast cancer	DLD-1 cells;HT-29 CRC;MCF7 breast cancer cells	exposure to IL-6 treatment	downregulated	24642471
8894	Human	hsa-miR-34a	miRNA	Indolo-pyrido-isoquinolin based?alkaloid	breast cancer	breast cancer cells	Indolo-pyrido-isoquinolin based?alkaloid treatment	upregulated	27259808
8895	Human	hsa-miR-34a	miRNA	luteolin	breast cancer	MCF-7 cells	luteolin treatment	upregulated	33050842
8896	Human	hsa-miR-34a	miRNA	microsciadia	breast cancer	MDA-MB-231 cells	microsciadia treatment	upregulated	32603285
8897	Human	hsa-miR-34a	miRNA	rhamnetin	breast cancer	MCF-7 cell	rhamnetin treatment	upregulated	30655816
8898	Human	hsa-miR-34a	miRNA	rhamnetin	breast cancer	MCF-7 cells	rhamnetin treatment	miR-34a expression in MCF-7 cells was significantly increased following treatment with 20 and 25 ¦ÌM rhamnetin for 48 h compared with the untreated cells	30655816
8899	Human	hsa-miR-34a	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
8900	Human	hsa-miR-34a	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
8901	Human	hsa-miR-34a	miRNA	"3,6-dihydroxyflavone (3,6-DHF)"	breast cancer	human breast epithelial MCF10A cells	"3,6-dihydroxyflavone (3,6-DHF) treatment"	upregulated	25784176
8902	Human	hsa-miR-34a	miRNA	radiation	cardiac radiation-associated injury	human cardiomyocytes	radiation treatment	miR-34a was significantly increased in HCMs exposed to radiation	30226567
8903	Human	hsa-miR-34a	miRNA	H2O2	cataract	HLE-B3 cells	H2O2 treatment	upregulated	27990356
8904	Human	hsa-miR-34a	miRNA	silver nanoparticles (AgNPs)	cell toxicity	human dermal fibroblasts (HDFs)	"200 nM SNPs on HDFs after1, 4 and 8h treatment"	upregulated	26000389
8905	Human	hsa-miR-34a	miRNA	5-aminolevulinic acid photodynamic therapy(ALA-PDT)	cervical cancer (CC)	"HPV-positive Hela, SiHa, Caski and HPV-negative C33?A cervical cancer cell lines"	5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment	downregulated	30118903
8906	Human	hsa-miR-34a	miRNA	high-risk human papillomavirus (hrHPV)	cervical cancer (CC)	cervical epithelium	high-risk human papillomavirus (HR-HPV) infection	downregulated	20442590
8907	Human	hsa-miR-34a	miRNA	"(1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI)"	cervical cancer (CC)	HeLa cells	"(1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI) treatment"	upregulated	30362332
8908	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	cervical cancer (CC)	HeLa cells	cisplatin (DPP) treatment	upregulated	30362332
8909	Human	hsa-miR-34a	miRNA	doxorubicin (DOX)	cervical cancer (CC)	HeLa cells	doxorubicin (DOX) treatment	upregulated	30362332
8910	Human	hsa-miR-34a	miRNA	selective S-adenosyl-methionine-competitive small-molecule (GSK126) or 5-Aza-2'-deoxycytidine	cholangiocarcinoma (CCA)	human cholangiocarcinoma (CCA)	GSK126 or 5-Aza-2'-deoxycytidine treatment	upregulated	28923203
8911	Human	hsa-miR-34a	miRNA	cyclophosphamide (CP)	chronic lymphocytic leukemia (CLL)	"WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines"	cyclophosphamide treatment	upregulated	30111844
8912	Human	hsa-miR-34a	miRNA	fludarabine	chronic lymphocytic leukemia (CLL)	"WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines"	fludarabine treatment	upregulated	30111844
8913	Human	hsa-miR-34a	miRNA	rituximab (RTX)	chronic lymphocytic leukemia (CLL)	"WSU-NHL, RAMOS, RAJI, MEC-1, 293FT, SW-48 cell lines"	rituximab treatment	upregulated	30111844
8914	Human	hsa-miR-34a	miRNA	ibrutinib	chronic lymphocytic leukemia (CLL)	CLL patients paired LN and PB samples	ibrutinib treatment	downregulated in paired LN and PB samples	27431016
8915	Human	hsa-miR-34a	miRNA	H2O2	chronic obstructive pulmonary disease (COPD)	BEAS2B cells (human airway epithelial)	BEAS2B cells (human airway epithelial) treatment	upregulated	27767101
8916	Human	hsa-miR-34a	miRNA	trichostatin A (TSA)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cells (HPMVEC)	trichostatin A (TSA) treatment	upregulated	21224215
8917	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	colon cancer cells	5-fluorouracil (5-FU) treatment	downregulated	25333573
8918	Human	hsa-miR-34a	miRNA	"epigallocatechin-3-gallate (EGCG), resveratrol (RES) and ¦Á-mangostin (¦Á-M)"	colorectal cancer (CRC)	Human colon cancer cell lines DLD-1;SW480 ;COLO201	"epigallocatechin-3-gallate (EGCG), resveratrol (RES) and ¦Á-mangostin (¦Á-M) treatment"	upregulated	23954321
8919	Human	hsa-miR-34a	miRNA	proteinase activated receptor 2 (PAR2)	colorectal cancer (CRC)	The human colonic epithelial cell line HT-29; Caco-2; HCT-116;RKO ;human lung adenocarcinoma A549 cell line	proteinase activated receptor 2 (PAR2) treatment	downregulated	23991105
8920	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"Human normal colonic epithelial cell line, FHC, and colorectal carcinoma cell lines, HT29, HCT8, HCT116, SW480, SW620"	5-fluorouracil (5-FU) treatment	Inhibition of miR-34a or overexpression of HMGB1 could effectively reverse elevated 5-FU sensitivity upon NEAT1 knockdown.	31802650
8921	Human	hsa-miR-34a	miRNA	desflurane	colorectal cancer (CRC)	DLD-1 cells	desflurane treatment	downregulated of miR-34a and upregulation of LOXL3 were required for desflurane-induced EMT in CRC cells.	32658033
8922	Human	hsa-miR-34a	miRNA	ethanol extract of Spica Prunellae (EESP)	colorectal cancer (CRC)	human colon carcinoma HCT-8 cells	EESP	upregulated	28713966
8923	Human	hsa-miR-34a	miRNA	melatonin	colorectal cancer (CRC)	HCT116 cells	melatonin treatment	"Compared with the control group, melatonin significantly enhanced the expression levels of the miR-34a/449a cluster"	33398374
8924	Human	hsa-miR-34a	miRNA	oxaliplatin	colorectal cancer (CRC)	CRC patients colorectal cancer (CRC) tissues	treated with OXA-based chemotherapy treatment	downregulated in colorectal cancer (CRC) tissues	28348487
8925	Human	hsa-miR-34a	miRNA	oxaliplatin	colorectal cancer (CRC)	Human colon cancer cell lines HCT116 and SW480	oxaliplatin (L-OHP) treatment	downregulated	31040703
8926	Human	hsa-miR-34a	miRNA	Scutellaria barbata D. Don (SB)	colorectal cancer (CRC)	human colon cancer HCT-8 cells	ECSB treatment	upregulated	28498458
8927	Human	hsa-miR-34a	miRNA	sevoflurane (SEV)	colorectal cancer (CRC)	HCT116 and SW480 cells	sevoflurane treatment	upregulated	31305122
8928	Human	hsa-miR-34a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	colorectal cancer (CRC)	LOVO colorectal cancer cell line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25422210
8929	Human	hsa-miR-34a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	parental 5-FU- sensitive DLD-1 cells	5-fluorouracil (5-FU) treatment	upregulated	24447928
8930	Human	hsa-miR-34a	miRNA	cyclin-dependent kinase 1 (CDK1)	neuroblastoma (NB)	Human SH-SY5Y£»BE(2)-M17neuroblastoma cells	Cyclin-dependent kinase 1 (CDK1) treatment	CDK1 inhibition caused elevation of microRNA-34a	22703967
8931	Human	hsa-miR-34a	miRNA	X-rays	dental pulp repair and regeneration	MCF-10A cells; T-47D cells; MCF-7 cells	"low dose, low energy X-ray? treatment"	upregulated	24094113
8932	Human	hsa-miR-34a	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
8933	Human	hsa-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cultured human adult cardiomyocytes	high glucose (HG) treatment	upregulated	29302057
8934	Human	hsa-miR-34a	miRNA	advanced glycation end product (AGE)	diabetic nephropathy (DN)	serum	advanced glycation end (AGE) treatment	"The expression of acetylated p53 and miR-34a was upregulated, SIRT1was downregulated in glomeruli from patients with DN and STZ induced diabetic mice, as well as in human podocytes treated with advanced glycation end (AGE)."	33932899
8935	Human	hsa-miR-34a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	HG stimulation notably upregulated miR-34a expression	33536772
8936	Human	hsa-miR-34a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression.	30529346
8937	Human	hsa-miR-34a	miRNA	yiqichutan	diffuse large B-cell lymphoma (DLBCL)	SUDHL-6 cells	Yiqichutan treatment	"Yiqichutan treatment increased miR-34a expression levels and induced apoptosis, as well as reducing Foxp1 expression level in SUDHL-6 cells"	32765691
8938	Human	hsa-miR-34a	miRNA	arsenite	DNA methylation	human keratinocytes	arsenic exposure	produces cumulative disruptions to epigenetic regulation of miR-34a expression	25281835
8939	Human	hsa-miR-34a	miRNA	cigarette smoke extract (CSE)	apoptosis	human pulmonary microvascular endothelial cells (HPMECs)	cigarette smoke extract (CSE) treatment	miR-34a was significantly increased in CSE-treated HPMECs.	29373969
8940	Human	hsa-miR-34a	miRNA	ionizing radiation (IR)	endothelial dysfunction	A172 glioblastoma cells	irradiation treatment	downregulated	23155233
8941	Human	hsa-miR-34a	miRNA	laminar shear stress	cell differentiation	human umbilical cord blood-derived EPCs	parallel plate flow chamber system treatment	upregulated	24792364
8942	Human	hsa-miR-34a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	XIST promotes TGF-¦Â1-induced EMT by regulating the miR-34a-YAP-EGFR axis in PC	31013436
8943	Human	hsa-miR-34a	miRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Human lens epithelial cells (LECs)	transforming growth factor (TGF)-¦Â2 treatment	downregulated	31158382
8944	Human	hsa-miR-34a	miRNA	bleomycin (BLM)	epithelial-mesenchymal transition (EMT)	A549/ABCA3 cells	bleomycin (BLM) treatment	upregulated	31603744
8945	Human	hsa-miR-34a	miRNA	methotrexate (MTX)	epithelial-mesenchymal transition (EMT)	A549/ABCA3 cells	methotrexate (MTX) treatment	upregulated	31603744
8946	Human	hsa-miR-34a	miRNA	curcumin (Cur)	fat	esophageal cancer cell lines	curcumin treatment	downregulated	22363450
8947	Human	hsa-miR-34a	miRNA	pterostilbene	fructose-induced hepatic lipid accumulation	HepG2 cells	Pterostilbene treatment	Pterostilbene recovered the fructose-disturbed miR-34a expression	31927917
8948	Human	hsa-miR-34a	miRNA	curcumin (Cur)	gastric cancer (GC)	Human gastric cancer cell line SGC-7901	curcumin treatment	upregulated	31539270
8949	Human	hsa-miR-34a	miRNA	diallyl disulfide (DADS)	gastric cancer (GC)	SGC-7901 cells	Diallyl disulfide (DADS) treatment	upregulated	27073535
8950	Human	hsa-miR-34a	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN-45 cells	docetaxel (DTX) treatment	downregulated	33416185
8951	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	gastric cancer cells	Luteolin treatment	upregulated	24988056
8952	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	AGS cells; BGC823 cells; SGC7901 cells	luteolin (LTL) treatment	miR-34a was found to be markedly upregulated in GC cells induced by luteolin and decreased miR-34a level was found in the artificial luteolin-resistant GC cells.	29054762
8953	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	"human gastric cancer cell lines AGS, BGC823 and SGC7901"	luteolin treatment	upregulated	29054762
8954	Human	hsa-miR-34a	miRNA	luteolin	gastric cancer (GC)	BGC-823 and SGC-7901 human gastric carcinoma cell lines	luteolin treatment	upregulated	24988056
8955	Human	hsa-miR-34a	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
8956	Human	hsa-miR-34a	miRNA	dexamethasone (DEX)	glucocorticoid-induced osteonecrosis of femoral head (GIONFH)	human umbilical vein endothelial cells (HUVECs)	dexamethasone (Dex) treatment	Dex inhibited mMSC proliferation and mir-34a expression.	28543623
8957	Human	hsa-miR-34a	miRNA	genistein	head and neck squamous cell carcinoma (HNSCC)	HNC-TICs -1; HNC-TICs-2	genistein treatment	Genistein induced ROS production through upregulation of miR-34a.	32610494
8958	Human	hsa-miR-34a	miRNA	benzene	hematotoxicity	workers	benzene treatment	upregulated	27939626
8959	Human	hsa-miR-34a	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	upregulated	28708282
8960	Human	hsa-miR-34a	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	downregulated	28708282
8961	Human	hsa-miR-34a	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	human HCC cell lines HepG2	aflatoxin B1 (AFB1) treatment	upregulated	26567713
8962	Human	hsa-miR-34a	miRNA	"DNA-damaging compound, 0404"	hepatocellular carcinoma (HCC)	HepG2 cells	404	downregulated	28667294
8963	Human	hsa-miR-34a	miRNA	emodin	hepatocellular carcinoma (HCC)	HepG2 cells	Emodin?treatment	upregulated	30976957
8964	Human	hsa-miR-34a	miRNA	emodin	hepatocellular carcinoma (HCC)	HepG2 cells	emodin treatment	Emodin inhibited the expression of SMAD2/4 in HepG2 cells by inducing the miR-34a level.	30976957
8965	Human	hsa-miR-34a	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	serum	hepatitis C virus (HCV) infection	upregulated	29333940
8966	Human	hsa-miR-34a	miRNA	low-intensity ultrasound (LIUS)	hepatocellular carcinoma (HCC)	Huh7 and HCCLM3 cell	low-intensity ultrasound (LIUS) treatment	upregulated	31115495
8967	Human	hsa-miR-34a	miRNA	nanocurcumin	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	nanocurcumin treatment	upregulation	27165229
8968	Human	hsa-miR-34a	miRNA	taxol	hepatocellular carcinoma (HCC)	HepG2/Taxol; SMMC7721/Taxol	Taxol treatment	LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a	32700738
8969	Human	hsa-miR-34a	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
8970	Human	hsa-miR-34a	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
8971	Human	hsa-miR-34a	miRNA	lithium (Li)	hyperglycemia	lymphoblastoid cell lines (LCLs)	Lithium (Li) treatment	significant changes in miR-34a£¬miR-152£¬miR-155 and miR-221	19254429
8972	Human	hsa-miR-34a	miRNA	angiotensin II (Ang II)	hypertension and diabetes	AB8/13 cells	angiotensin II (Ang II) treatment	upregulated	32887498
8973	Human	hsa-miR-34a	miRNA	high glucose (HG)	hypertension and diabetes	AB8/13 cells	high glucose (HG) treatment	upregulated	32887498
8974	Human	hsa-miR-34a	miRNA	curcumin with emodin	hypertension	breast cancer cells	curcumin with emodin treatment	upregulated	23771315
8975	Human	hsa-miR-34a	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	downregulated	29516639
8976	Human	hsa-miR-34a	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	upregulated	29516639
8977	Human	hsa-miR-34a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus-infected	downregulated	27610823
8978	Human	hsa-miR-34a	miRNA	"2,4,5-trihydroxybenzaldehyde (TDB)"	ischemic vascular injuries	HUVEC cells following OGD/R	"2,4,5-trihydroxybenzaldehyde (TDB) treatment"	downregulated	27885275
8979	Human	hsa-miR-34a	miRNA	ingenol-mebutate	keloids	keloid fibroblasts	Ingenol-mebutate treatment	"In particular, the upregulation of miR-34a was detected in keloid fibroblasts during and following Ingenol-mebutate exposure."	29568916
8980	Human	hsa-miR-34a	miRNA	phorbol-12-myristate-13-acetate(PMA)	leukemia	human chronic myelocytic leukemia cell line K562	Phorbol 12-myristate 13-acetate (PMA) treatment	upregulated	20299489
8981	Human	hsa-miR-34a	miRNA	resistin	lipid metabolism	HepG2	resistin treatment	upregulated	29197627
8982	Human	hsa-miR-34a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	human HCC and adjacent non-tumoral liver tissues	sorafenib treatment	downregulated	23862748
8983	Human	hsa-miR-34a	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	expression and chemoresistance has not been explored in HCC	sorafenib treatment	downregulated	23862748
8984	Human	hsa-miR-34a	miRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HepG2 cells	UV irradiation treatment	upregulated	24431000
8985	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	lung cancer	"NSCLC cancer cells, including H226, H1299, A549, H1975 and HCC827"	cisplatin treatment	upregulated	27836543
8986	Human	hsa-miR-34a	miRNA	particulate matter (PM2.5)	lung cancer	human non-small cell lung cancer cell line A549	chronic (five passages) PM2.5 exposure treatment	downregulated	28846189
8987	Human	hsa-miR-34a	miRNA	PRIMA-1	lung cancer	human lung cancer cells	PRIMA-1 treatment	upregulated	19921694
8988	Human	hsa-miR-34a	miRNA	radiation	malignant mesothelioma (MM)	epithelial type M28K cells	radiation treatment	upregulated	22237142
8989	Human	hsa-miR-34a	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood CD14+ monocytes	lenalidomide treatment	upregulated	25287904
8990	Human	hsa-miR-34a	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood	Lenalidomide treatment	upregulated	25287904
8991	Human	hsa-miR-34a	miRNA	estradiol-17¦Â (E2)	myofibroblast differentiation	MCF-7 cells	estradiol-17¦Â (E2) treatment	"in MCF-7, which is an ER¦Á-positive breast cancer cell line, miR-34a is remarkably downregulated after E2 treatment"	24050776
8992	Human	hsa-miR-34a	miRNA	ethanol (EtOH)	neural differentiation	Neural crest cells (NCCs)	ethanol exposure	upregulated	31247197
8993	Human	hsa-miR-34a	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
8994	Human	hsa-miR-34a	miRNA	retinoic acid (RA)	neuroblastoma (NB)	SK-N-BE cell line	retinoic acid treatment	"miR-34a expression increases during retinoic acid-induced differentiation of the SK-N-BE cell line, whereas E2F3 protein levels decrease"	17297439
8995	Human	hsa-miR-34a	miRNA	compound C	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	compound C treatment	downregulated	32143184
8996	Human	hsa-miR-34a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmitic acid (PA) treatment	downregulated	32143184
8997	Human	hsa-miR-34a	miRNA	ursodeoxycholic acid (UDCA)	nonalcoholic fatty liver disease (NAFLD)	morbidly obese NAFLD-patients vesicle-free fraction in serum	UDCA treatment	downregulated in the vesicle-free fraction in serum	28853202
8998	Human	hsa-miR-34a	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	NSCLC cells	erlotinib treatment	upregulated	24551227
8999	Human	hsa-miR-34a	miRNA	nutlin-3a	non-small cell lung cancer (NSCLC)	normal human fibroblasts	Nutlin-3a treatment	upregulated	18451145
9000	Human	hsa-miR-34a	miRNA	palliative chemotherapy	non-small cell lung cancer (NSCLC)	NSCLC tissues	platinum derivatives in combination with paclitaxel or gemcitabine treatment	upregulated	29387235
9001	Human	hsa-miR-34a	miRNA	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np)	non-small cell lung cancer (NSCLC)	A549 cells	PEGylated PLGA thymoquinone nanoparticles with transferrin (TF-TQ-Np) treatment	upregulated	31411213
9002	Human	hsa-miR-34a	miRNA	pemetrexed	non-small cell lung cancer (NSCLC)	NSCLC tissue	pemetrexed treatment	upregulated	23794259
9003	Human	hsa-miR-34a	miRNA	Rhamnetin and cirsiliol	non-small cell lung cancer (NSCLC)	"NSCLC cells, NCI-H1299 and NCI-H460"	Rhamnetin and cirsiliol treatment	upregulated	23902763
9004	Human	hsa-miR-34a	miRNA	Delta-tocotrienol	non-small cell lung cancer (NSCLC)	Human NSCLC cell lines (A549 and H1650)	Delta-tocotrienol treatment	upregulated	22438124
9005	Human	hsa-miR-34a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	nucleus pulposus cell (NPC)	tumor necrosis factor alpha (TNF-¦Á) treatment	MiR-34a is upregulated in TNF-¦Á- induced NPCs	30138895
9006	Human	hsa-miR-34a	miRNA	hypoxia	oropharyngeal squamous cell carcinoma (OPSCC)	SCC25 cells; SCC090 cells	hypoxia treatment	upregulated	32102296
9007	Human	hsa-miR-34a	miRNA	H2O2	osteoarthritis (OA)	human OA chondrocytes	H2O2 treatment	downregulated (miR-146a) ; upregulated(miR-34a)	29292727
9008	Human	hsa-miR-34a	miRNA	hydrostatic pressure (HP)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	hydrostatic pressure (HP) treatment	upregulated	32455798
9009	Human	hsa-miR-34a	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	upregulated	29236314
9010	Human	hsa-miR-34a	miRNA	resistin	osteoarthritis (OA)	human OA synovial fibroblasts	resistin treatment	upregulated	31635187
9011	Human	hsa-miR-34a	miRNA	visfatin	osteoarthritis (OA)	human OA chondrocytes	visfatin treatment	"upregulated, all the visfatin-caused effects were suppressed by using miR-34a and miR-181a inhibitors."	31405216
9012	Human	hsa-miR-34a	miRNA	visfatin	osteoarthritis (OA)	human OA synovial fibroblasts	visfatin treatment	upregulated	31635187
9013	Human	hsa-miR-34a	miRNA	etoposide (VP-16)	osteosarcoma (OS)	human osteosarcoma cell lines	etoposide treatment	upregulated	25490093
9014	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells	cisplatin (DPP) treatment	downregulated	29561664
9015	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
9016	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
9017	Human	hsa-miR-34a	miRNA	H2O2	oxidative stress	Human bone marrow mesenchymal stromal/stem cells (hMSCs)	H2O2 treatment	upregulated	29331104
9018	Human	hsa-miR-34a	miRNA	H2O2	oxidative stress	Human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	upregulated	29992759
9019	Human	hsa-miR-34a	miRNA	kallistatin	oxidative stress	HEK293T cells	Kallistatin treatment	downregulated	28544111
9020	Human	hsa-miR-34a	miRNA	kallistatin	oxidative stress	H2O2-treated human umbilical vein endothelial cells (HUVECs)	Kallistatin treatment	downregulated	29992759
9021	Human	hsa-miR-34a	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
9022	Human	hsa-miR-34a	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
9023	Human	hsa-miR-34a	miRNA	genistein	pancreatic cancer (PC)	"Human PC cell lines, including AsPC-1 and MiaPaCa-2"	Genistein treatment	upregulated	21301871
9024	Human	hsa-miR-34a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
9025	Human	hsa-miR-34a	miRNA	propofol (PPF)	pancreatic cancer (PC)	PANC-1 cells	propofol treatment	"Propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression"	32303144
9026	Human	hsa-miR-34a	miRNA	TGF-¦Â1	pancreatic cancer (PC)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	XIST promotes TGF-¦Â1-induced EMT by regulating the miR-34a-YAP-EGFR axis in PC	31013436
9027	Human	hsa-miR-34a	miRNA	rotenone (ROT)	parkinson's disease (PD)	SH-SY5Y cell	rotenone treatment	downregulated	28259991
9028	Human	hsa-miR-34a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	30221494
9029	Human	hsa-miR-34a	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	Human lens epithelial cells (LECs)	transforming growth factor (TGF)-¦Â2 treatment	downregulated	31158382
9030	Human	hsa-miR-34a	miRNA	doxorubicin (DOX)	posterior capsular opacification (PCO)	human lens epithelial cell line HLE B3	doxorubicin treatment	upregulated	30980790
9031	Human	hsa-mir-34a	miRNA	hypoxia	preeclampsia (PE)	JEG-3 cells	hypoxia treatment	upregulated	24081307
9032	Human	hsa-miR-34a	miRNA	propofol (PPF)	propofol-induced neurotoxicity and cognitive dysfunction	SH-SY5Y cells	propofol treatment	microRNA-34a was upregulated after propofol treatment	29578002
9033	Human	hsa-miR-34a	miRNA	butyl benzyl phthalate (BBP)	prostate cancer	Human prostate cancer LNCaP and PC-3 cells	butyl benzyl phthalate (BBP) treatment	downregulated	30243731
9034	Human	hsa-miR-34a	miRNA	butyl benzyl phthalate (BBP)	prostate cancer	LNCaP and PC-3 cells	butyl benzyl phthalate (BBP) treatment	downregulated	30243731
9035	Human	hsa-miR-34a	miRNA	"codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone"	prostate cancer	"LNCaP, C4-2 , DU145 , and PC3 cells"	"codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone treatment"	upregulated	28428276
9036	Human	hsa-miR-34a	miRNA	curcumin (Cur)	prostate cancer	"Human prostate cancer 22RV1, PC©\3, and DU145 cells"	curcumin treatment	upregulated	31042325
9037	Human	hsa-miR-34a	miRNA	fractionated radiation	prostate cancer	Human Prostate Cancer Cells	radiation treatment	Tumor suppressor miR-34a and let-7 miRNAs were upregulated by fractionated radiation in radiosensitive LNCaP (p53 positive) and PC3 (p53-null) cells indicating	22827214
9038	Human	hsa-miR-34a	miRNA	genistein	prostate cancer	LNCaP cells£» PC3 cells£» DU145 cells£» RWPE-1 cells	genistein treatment	genistein inhibited PCa cell growth through downregulated of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a	23936419
9039	Human	hsa-miR-34a	miRNA	hypermethylation	prostate cancer	PCa tissues and cell lines	hypermethylation treatment	downregulated	26499184
9040	Human	hsa-miR-34a	miRNA	hypoxia	renal cell carcinoma (RCC)	HK-2 cells	hypoxia treatment	downregulated	22363487
9041	Human	hsa-miR-34a	miRNA	dihydromyricetin (DHM)	renal fibrosis	TGF-¦Â1-treated HK-2 cells	Dihydromyricetin (DHM) treatment	downregulated	30853453
9042	Human	hsa-miR-34a	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	transforming growth factor ¦Â1 (TGF-¦Â1) treatment	upregulated	30853453
9043	Human	hsa-miR-34a	miRNA	dioscin	renal injury	cisplatin (CDDP)-induced NRK-52E and HK-2 cells	dioscin treatment	upregulated	28514495
9044	Human	hsa-miR-34a	miRNA	vascular endothelial growth factor (VEGF)	retinal angiogenesis	human retinal microvascular endothelial cells (HRMECs)	vascular endothelial growth factor (VEGF) treatment	downregulated	30571142
9045	Human	hsa-miR-34a	miRNA	vascular endothelial growth factor (VEGF)	retinal angiogenesis	human retinal microvascular endothelial cells (HRMECs)	vascular endothelial growth factor (VEGF) treatment	downregulated	30571142
9046	Human	hsa-miR-34a	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
9047	Human	hsa-miR-34a	miRNA	lipopolysaccharide (LPS)	sepsis	U937 cells	lipopolysaccharide (LPS) treatment	miR-34a was upregulated in Lipopolysaccharide (LPS)-induced U937 cell lines.	30021364
9048	Human	hsa-miR-34a	miRNA	cisplatin (DDP)	sinonasal squamous cell carcinoma	Tumor samples	cis-diamminedichloroplatinum treatment	downregulated	22624980
9049	Human	hsa-miR-34a	miRNA	high glucose (HG)	stress-associated premature senescence (SAPS)	Human retinal microvascular endothelial cells (HuREC)	high glucose (HG) treatment	upregulated	31443378
9050	Human	hsa-miR-34a	miRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	HK2 cells	lipopolysaccharide (LPS) treatment	LPS reduced the expression of miR-34a.	30414207
9051	Human	hsa-miR-34a	miRNA	IL-1¦Â and TNF-¦Á	type 2 diabetes mellitus (T2DM)	human pancreatic islets	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
9052	Human	hsa-miR-34a	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	"ACHN, 769-P, and A498 cells"	metformin treatment	upregulated	28045889
9053	Human	hsa-miR-34a	miRNA	lopinavir	vascular aging	vascular endothelial cells (ECs)	lopinavir treatment	upregulated	27889708
9054	Human	hsa-miR-34a	miRNA	ritonavir	vascular aging	vascular endothelial cells (ECs)	ritonavir treatment	upregulated	27889708
9055	Human	hsa-miR-34a	miRNA	high glucose (HG)	vascular endothelial dysfunction	human microvascular endothelial cell-1 (HMEC-1) cells	high glucose (HG) treatment	upregulated	31533227
9056	Human	hsa-miR-34a	miRNA	vaccarin (VAC)	vascular endothelial dysfunction	high glucose (HG)-treated human microvascular endothelial cell-1 (HMEC-1) cells	Vaccarin (VAC) treatment	downregulated	31533227
9057	Human	hsa-miR-34a	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
9058	Human	hsa-miR-34a	miRNA	hypoxia	wet age-related macular degeneration (wAMD)	ARPE-19 cells	hypoxia induce	HIF-1¦Á-dependent p53 activation upregulated miRNA-34a expression in ARPE-19 cells following hypoxia.	33438362
9059	Human	hsa-miR-34a	miRNA	adriamycin (ADR)	colorectal cancer (CRC)	human colon cancer cell line HCT 116	adriamycin (ADR) treatment	upregulated	17875987
9060	Human	hsa-miR-34a	miRNA	phorbol ester	megakaryocytic differentiation	K562 cells	phorbol ester treatment	upregulated	19584398
9061	Human	hsa-miR-34a	miRNA	thyroid hormone	renal tubular epithelial to mesenchymal transition	human proximal tubular epithelial cell line HK-2	Thyroid hormone?treatment treatment	downregulated	23770290
9062	Human	hsa-miR-34a*	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood CD14+ monocytes	lenalidomide treatment	upregulated	25287904
9063	Human	hsa-miR-34a*	miRNA	lenalidomide	myelodysplastic syndrome (MDS)	peripheral blood	Lenalidomide treatment	upregulated	25287904
9064	Human	hsa-miR-34a-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer (GC) tissues	Helicobacter pylori (HP) treatment	downregulated	30242897
9065	Human	hsa-miR-34a-3p	miRNA	ultrasound (US)	multidrug resistance (MDR)	MCF-7/ADR and HEPG2/ADM cells	ultrasound (US) irradiation treatment	upregulated	30231924
9066	Human	hsa-miR-34a-3p	miRNA	metformin (Met)	cell senescence	dental pulp stem cells (DPSCs)	Metformin (Met) treatment	metformin significantly suppressed microRNA-34a-3p (miR-34a-3p) expression	33505470
9067	Human	hsa-miR-34a-5p	miRNA	H2O2	age-related nuclear cataract	human lens epithelial B3 (HLE-B3) cell	H2O2 treatment	upregulated	29653565
9068	Human	hsa-miR-34a-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
9069	Human	hsa-miR-34a-5p	miRNA	hypoxia	autophagy	"human coronary artery endothelial cells (HCAECs),"	?chronic intermittent hypoxia (CIH) induce	upregulated	31218746
9070	Human	hsa-miR-34a-5p	miRNA	doxorubicin (DOX)	breast cancer	MDA-MB-231 cells	doxorubicin treatment	downregulated	30245930
9071	Human	hsa-miR-34a-5p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (Dox) treatment	upregulated	30245930
9072	Human	hsa-miR-34a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MCF-7 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	upregulated	30245930
9073	Human	hsa-miR-34a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC)	breast cancer	MDA-MB-231 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) treatment	upregulated	30245930
9074	Human	hsa-miR-34a-5p	miRNA	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin	breast cancer	MDA-MB-231 cells	methyl 2-(5-fluoro-2-hydroxyphenyl)-1H- benzo[d]imidazole-5-carboxylate (MBIC) and doxorubicin treatment	upregulated	30245930
9075	Human	hsa-miR-34a-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	K562 cells	imatinib treatment	downregulated	31923418
9076	Human	hsa-miR-34a-5p	miRNA	sevoflurane (SEV)	colorectal cancer (CRC)	SW480 cells; LOVO cells	sevoflurane treatment	sevoflurane inhibited colon cancer progression by modulating the exosome-transmitted circ-HMGCS1/miR-34a-5p/SGPP1 axis	33125091
9077	Human	hsa-miR-34a-5p	miRNA	paroxetine	depression	serum	paroxetine treatment	downregulated	29791588
9078	Human	hsa-miR-34a-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	diffuse large B-cell lymphoma (DLBCL)	HT and U2932 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24722400
9079	Human	hsa-miR-34a-5p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
9080	Human	hsa-miR-34a-5p	miRNA	steroids	endometriosis	ovarian endometrial	steroid hormones treatment	upregulated	26819477
9081	Human	hsa-miR-34a-5p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	upregulated	32582989
9082	Human	hsa-miR-34a-5p	miRNA	"cisplatin, N-ethyl-N-nitrosourea, etoposide, mitomycin C, methyl methanesulphonate, taxol, and X-ray radiation"	genotoxicity	TK6 cells	"cisplatin, N-ethyl-N-nitrosourea, etoposide, mitomycin C, methyl methanesulphonate, taxol, and X-ray radiation"	upregulated	32929177
9083	Human	hsa-miR-34a-5p	miRNA	olive oil polyphenol hydroxytyrosol (HT)	inflammation	TNF-¦Á treated human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	olive oil polyphenol hydroxytyrosol (HT) treatment	downregulated	31627295
9084	Human	hsa-miR-34a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes and exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31627295
9085	Human	hsa-miR-34a-5p	miRNA	compression force (CF)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	compression treatment	upregulated	32114390
9086	Human	hsa-miR-34a-5p	miRNA	hypoxia/reoxygenation (H/R)	intestinal hypoxia/reoxygenation injury	caco-2 cells	hypoxia-reoxygeneration (H/R) treatment	upregulated	26935288
9087	Human	hsa-miR-34a-5p	miRNA	lipopolysaccharide (LPS)	LPS-induced injury	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	MiR-34a-5p expression was significantly enhanced in HUVECs after 24 h of LPS treatment.	33155244
9088	Human	hsa-miR-34a-5p	miRNA	oleacein (OA)	melanoma	501Mel melanoma cells	oleacein (OA) treatment	upregulated	33071785
9089	Human	hsa-miR-34a-5p	miRNA	hypoxia	myocardial infarction (MI)	human cardiac myocytes	hypoxia induce	upregulated	30312158
9090	Human	hsa-miR-34a-5p	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	human NPC cell lines CNE-1 and CNE-2	ionizing radiation	upregulated	28985197
9091	Human	hsa-miR-34a-5p	miRNA	luteolin	non-small cell lung cancer (NSCLC)	A549 cells; H460 cells	luteolin (LTL) treatment	miR-34a-5p was dramatically upregulated upon LTL treatment in tumor tissues.	29393891
9092	Human	hsa-miR-34a-5p	miRNA	oleacein (OA)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleacein (OA) treatment	downregulated	31766503
9093	Human	hsa-miR-34a-5p	miRNA	oleocanthal (OC)	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	oleocanthal (OC) treatment	downregulated	31766503
9094	Human	hsa-miR-34a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	Simpson-Golabi-Behmel syndrome (SGBS) adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31766503
9095	Human	hsa-miR-34a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Hyperplastic synovial fibroblasts (SFs)	interleukin-1¦Â treatment	upregulated	31777535
9096	Human	hsa-miR-34a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	"SNHG7 sponged miR-34a-5p to affect cell proliferation, apoptosis and autophagy through targeting SYVN1"	32066502
9097	Human	hsa-miR-34a-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells; A2780 cells	cisplatin treatment	miR-34a-5p was decreased in DDP-resistant cells.	31777260
9098	Human	hsa-miR-34a-5p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 and A2780 ovarian cancer cell lines	cisplatin treatment	downregulated	31777260
9099	Human	hsa-miR-34a-5p	miRNA	docetaxel (DTX)	prostate cancer	PCa samples; PC3 cells; DU145 cells	docetaxel (DTX) treatment	downregulated	31672604
9100	Human	hsa-miR-34a-5p	miRNA	high glucose (HG)	tubulointerstitial fibrosis (TIF)	human proximal tubule cell line(HK-2) cells	high glucose treatment	upregulated	29371016
9101	Human	hsa-miR-34a-c	miRNA	cisplatin (DDP)	apoptosis	K562 cells	cisplatin treatment	upregulated	20428827
9102	Human	hsa-miR-34b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	acute lymphoblastic leukemia (ALL)	HL-60 and K562 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26861642
9103	Human	hsa-miR-34b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	chronic lymphocytic leukemia (CLL)	MEC1 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24559316
9104	Human	hsa-miR-34b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"miR-34b overexpression inhibited apoptosis and expression levels of TNF-alpha, IL-1?, IL-6, and caspase-3 in HG-treated HK-2 cells."	31665127
9105	Human	hsa-miR-34b	miRNA	nanocurcumin	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	nanocurcumin treatment	upregulation	27165229
9106	Human	hsa-miR-34b	miRNA	CdSe/ZnS-GSH	lung cancer	A549 cells	CdSe/ZnS-GSH treatment	upregulated	31883144
9107	Human	hsa-miR-34b	miRNA	CdSe/ZnS-MPA	lung cancer	A549 cells	CdSe/ZnS-MPA treatment	upregulated	31883144
9108	Human	hsa-miR-34b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	melanoma	melanoma tissue	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	21949788
9109	Human	hsa-miR-34b	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegeneration (ND)	SH-SY5Y human neuroblastoma cells	ELF-MFs	downregulated	29039021
9110	Human	hsa-miR-34b	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegenerative diseases	SH-SY5Y human neuroblastoma cells	extremely low-frequency magnetic fields (ELF-MFs) treatment	downregulated	29039021
9111	Human	hsa-miR-34b	miRNA	nutlin-3a	non-small cell lung cancer (NSCLC)	normal human fibroblasts	Nutlin-3a treatment	upregulated	18451145
9112	Human	hsa-miR-34b	miRNA	sirolimus	osteosarcoma (OS)	Human OS cell line MG63/ADM	sirolimus treatment	upregulated	26924291
9113	Human	hsa-miR-34b-5p	miRNA	melatonin	oral cancer	SAS cells; SCC9 cells	Melatonin treatment	Melatonin reduced the drug resistance and promoted the apoptosis of VCR-resistant oral cancer cells through the upregulation of microRNA-892a (miR-892a) and miR-34b-5p expressions.	31982774
9114	Human	hsa-miR-34b-5p	miRNA	melatonin	vincristine (VCR) resistance	SAS cells; SCC9 cells	Melatonin treatment	upregulated	31982774
9115	Human	hsa-miR-34c	miRNA	high glucose (HG)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	MicroRNA-34c suppresses proliferation of vascular smooth muscle cell via modulating high mobility group box protein 1	32157741
9116	Human	hsa-miR-34c	miRNA	adoMet	breast cancer	MCF-7 cells	adoMet treatment	upregulated	30533999
9117	Human	hsa-miR-34c	miRNA	benzo(a)pyrene (BaP)	cell transformation	human bronchial epithelial (HBE) cells	benzo(a)pyrene (BaP) exposure	downregulated	24362009
9118	Human	hsa-miR-34c	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	cigarette smoke extract (CSE) treatment	LncRNA TUG1 knockdown mitigates inflammatory injury induced by cigarette smoke extract in chronic obstructive pulmonary disease via miR-34c/BRD4 axis	32812639
9119	Human	hsa-miR-34c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	CIHP-1 cells	high glucose (HG) treatment	CASC15 is upregulated in DCRF patients and promotes the apoptosis of podocytes by sponging miR-34c.	32053576
9120	Human	hsa-miR-34c	miRNA	bisphenol A (BPA)	female fertility	cumulus oocyte complex (COC)	bisphenol A (BPA) treatment	upregulated	33285269
9121	Human	hsa-miR-34c	miRNA	zika virus (ZIKV)	glioblastoma multiforme (GBM)	glioblastoma stem cells (GSCs)	Zika virus (ZIKV) infection treatment	upregulated	30890698
9122	Human	hsa-miR-34c	miRNA	nanocurcumin	hepatocellular carcinoma (HCC)	HepG2 and Huh7 cells	nanocurcumin treatment	upregulation	27165229
9123	Human	hsa-miR-34c	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegeneration (ND)	SH-SY5Y human neuroblastoma cells	ELF-MFs	downregulated	29039021
9124	Human	hsa-miR-34c	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegenerative diseases	SH-SY5Y human neuroblastoma cells	extremely low-frequency magnetic fields (ELF-MFs) treatment	downregulated	29039021
9125	Human	hsa-miR-34c	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9126	Human	hsa-miR-34c	miRNA	nutlin-3a	non-small cell lung cancer (NSCLC)	normal human fibroblasts	Nutlin-3a treatment	upregulated	18451145
9127	Human	hsa-miR-34c	miRNA	radiation	prostate cancer	LNCaP cells;C4-2 cells	radiation treatment	upregulated	18668526
9128	Human	hsa-miR-34c	miRNA	doxycycline	reprogramming activity of somatic cell nuclear transfer (SCNT) embryos	Primary fibroblast cell cultures	doxycycline (DXC) treatment	upregulated	25437869
9129	Human	hsa-miR-34c	miRNA	S-adenosyl-L-methionine (AdoMet)	triple negative breast cancer (TNBC)	MDA-MB-231; MDA-MB-468 cells	S-adenosyl-L-methionine (AdoMet) treatment	AdoMet exerts its antitumor effects in TNBC cells through upregulating the expression of miR-34c and miR-449a	33396625
9130	Human	hsa-miR-34c-3p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
9131	Human	hsa-miR-34c-3p	miRNA	glargine	pancreatic cancer (PC)	pancreatic cancer cells	glargine treatment	upregulated	22690071
9132	Human	hsa-miR-34c-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
9133	Human	hsa-miR-34c-5p	miRNA	sodium valproate (VPA)	autophagy	SH-SY5Y cells	sodium valproate (VPA) treatment	upregulated	30613007
9134	Human	hsa-miR-34c-5p	miRNA	ultraviolet (UV) irradiation	breast cancer	normal human primary dermal fibroblasts	ultraviolet irradiation treatment	upregulated	23983607
9135	Human	hsa-miR-34c-5p	miRNA	arsenite	tumorigenesis	derivative normal stem cell (SC) line	arsenite exposure	downregulated	24431212
9136	Human	hsa-miR-34c-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	human-induced pluripotent stem cell (hiPSC)	doxorubicin treatment	upregulated	26842497
9137	Human	hsa-miR-34c-5p	miRNA	pirarubicin (THP)	cervical cancer (CC)	cervical cancer cells	Pirarubicin (THP)treatment	downregulated	27097054
9138	Human	hsa-miR-34c-5p	miRNA	Pien Tze Huang (PZH)	colorectal cancer (CRC)	HCT-8 cells	PZH treatment	upregulated	29042999
9139	Human	hsa-miR-34c-5p	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
9140	Human	hsa-miR-34c-5p	miRNA	high glucose (HG)	vascular calcification (VC)	human aorta vascular smooth muscle cells (HA-VSMCs)	high glucose treatment	"Overexpression of miR-34c-5p alleviated calcification/senescence of HA-VSMCs, whereas inhibition of miR-34c-5p received the opposite results."	30654331
9141	Human	hsa-miR-351	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
9142	Human	hsa-miR-3605-5p	miRNA	coxsackievirus A16 (CVA16) and enterovirus 71(EV71)	hand-foot-mouth disease (HFMD)	human embryonic kidney 293T cells	infect with CVA16 and EV71	downregulated	28198671
9143	Human	hsa-miR-3607-3p	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular cells (HK-2)	TGF-¦Â1 treatment	downregulated	31455266
9144	Human	hsa-miR-3607-5p	miRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-4B"	particulate matter 2.5 (PM2.5) exosure treatment	"CircRNA104250 and lncRNAuc001dgp1 target miR-3607-5p and affect expression of interleukin 1 receptor 1 (IL1R1), which influences the nuclear factor ¦ÊB (NF-¦ÊB) signaling pathway"	31864925
9145	Human	hsa-miR-3609	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
9146	Human	hsa-miR-3609	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
9147	Human	hsa-miR-361	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
9148	Human	hsa-miR-361	miRNA	Somatostatin (SRIF)	antiangiogenic	human umbilical vein endothelial cells	Somatostatin (SRIF)? treatment	downregulated	23128854
9149	Human	hsa-miR-361	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
9150	Human	hsa-miR-361	miRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"miR-361 expression was significantly downregulated in BPH tissues, compared to normal prostate tissues Moreover, DNM3OS was negatively correlated with miR-361"	31694982
9151	Human	hsa-miR-3610	miRNA	Traumatic brain injury (TBI)	hypopituitarism	blood	Traumatic brain injury (TBI) treatment	upregulated	27027233
9152	Human	hsa-miR-3613	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
9153	Human	hsa-miR-3613-3p	miRNA	palbociclib	triple negative breast cancer (TNBC)	MDA-MB-231 cells	palbociclib treatment	Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib	33330073
9154	Human	hsa-miR-3613-5p	miRNA	simvastatin	endometriosis	Serum	simvastatin treatment	upregulated	29587611
9155	Human	hsa-miR-3613-5p	miRNA	ursolic acid (UA)	malignant pleural mesothelioma (MPM)	H2452 cells	ursolic acid treatment	upregulated	28090191
9156	Human	hsa-miR-361-3p	miRNA	resveratrol	Alzheimer's disease (AD)	SK-N-SH cells; CHP-212 cells	resveratrol (Res) treatment	upregulated	32741808
9157	Human	hsa-miR-361-3p	miRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cell (HUVEC)	high glucose (HG) treatment	Knockdown of MALAT1 inhibits HG-induced vascular endothelial injury through regulating miR-361-3p/SOCS3 axis.	32509100
9158	Human	hsa-miR-361-3p	miRNA	enzalutamide (Enz)	prostate cancer	C4-2 cells	enzalutamide (Enz) treatment	downregulated	32978369
9159	Human	hsa-miR-361-3p	miRNA	helicobacter pylori (H. pylori)	sophageal carcinogenesis	human esophageal cell line HET-1A	Helicobacter pylori infection	miR-361-3p was significantly decreased in HET-1A cells exposure to H. pylor.	30783439
9160	Human	hsa-miR-361-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31312370
9161	Human	hsa-miR-361-5p	miRNA	dexmedetomidine (DEX)	osteoporosis	human umbilical vein endothelial cells (HUVECs)	dexamethasone (DEX) treatment	"After Dex treatment, the expressions of miR-361-5p, VEGFA, BMD related indexes were increased in OP rats."	33631172
9162	Human	hsa-miR-361-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	Human pulmonary artery smooth muscle cells (hPASMCs)	hypoxia induce	upregulated	29339076
9163	Human	hsa-miR-3619-5p	miRNA	platelet-derived growth factor (PDGF)	asthma	Human fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	downregulated	31014672
9164	Human	hsa-miR-3619-5p	miRNA	5-fluorouracil (5-FU)	gastric cancer (GC)	AGS cell; MKN45 cells	5-fluorouracil (5-FU) treatment	downregulated	32300102
9165	Human	hsa-miR-3619-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS/DPP; NUGC-3/DPP cells	cisplatin treatment	PVT1 silencing attenuated the DPP resistance in GC by downregulating TBL1XR1 via sponging miR-3619-5p.	32407172
9166	Human	hsa-miR-3619-5p	miRNA	oxaliplatin	gastric cancer (GC)	AGS cell; MKN45 cells	oxaliplatin (OXA) treatment	downregulated	32300102
9167	Human	hsa-miR-3619-5p	miRNA	heat stress	hepatocellular carcinoma (HCC)	Huh7 cells; MHCC97 cells	heating treatment	downregulated	32799553
9168	Human	hsa-miR-3619-5p	miRNA	naringenin	lung cancer	A549 cells; PC9 cells	naringenin treatment	Naringenin hindered cell metastasis in vitro and tumor growth in vivo by reducing circFOXM1 and SPAG5 expression and inducing the expression of miR-3619-5p in lung cancer.	32598178
9169	Human	hsa-miR-3619-5p	miRNA	isoimperatorin (ISO)	melanin metabolism disorders	HaCaT cells	Isoimperatorin (ISO) treatment	downregulated	32299303
9170	Human	hsa-miR-362	miRNA	erythropoietin (EPO)	erythroid cell differentiation	The original UT-7 cell line	erythropoietin treatment	upregulated	18492109
9171	Human	hsa-miR-3620-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
9172	Human	hsa-miR-362-3p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	downregulated	30131392
9173	Human	hsa-miR-362-3p	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
9174	Human	hsa-miR-362-3p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
9175	Human	hsa-miR-362-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-362-3p expression increased while methylation of its promoter significantly decreased in human HCC cells and tissues compared with normal cells and adjacent noncancerous tissues.	25649327
9176	Human	hsa-miR-362-5p	miRNA	"chlorpromazine, haloperidol and clozapine"	psychosis	JM-Jurkat T-lymphocytes	"chlorpromazine, haloperidol and clozapine treatment"	dysregulated	24480591
9177	Human	hsa-miR-362-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	downregulated	31790802
9178	Human	hsa-miR-362-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	GC cell line SGC7901	cisplatin treatment	downregulated	31423228
9179	Human	hsa-miR-362-5p	miRNA	crizotinib	non-small cell lung cancer (NSCLC)	ALK-positive NSCLC patients plasma	crizotinib treatment	upregulated	28514730
9180	Human	hsa-miR-363	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
9181	Human	hsa-miR-363	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 14¡ã HDT bed rest experiment	downregulated	28261104
9182	Human	hsa-miR-363	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	downregulated	26143754
9183	Human	hsa-miR-363	miRNA	oxaliplatin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	oxaliplatin (OXA) treatment	miR-363 expression levels were downregulated in oxaliplatin-resis- tant HCC cell lines compared with parental cell lines	29602203
9184	Human	hsa-miR-363	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
9185	Human	hsa-miR-363-3p	miRNA	dual MEK/Aurora kinase inhibitor BI-847325	anaplastic thyroid carcinoma (ATC)	ATC cell lines (C643 and SW1736)	dual MEK/Aurora kinase inhibitor BI-847325 treatment	upregulated	31077090
9186	Human	hsa-miR-363-3p	miRNA	clopidogrel	gastric mucosal injury	GES-1 cells	clopidogrel treatment	The expression of miR-363-3p in gastric mucosal injury caused by clopidogrel was higher than that in normal samples.	33208005
9187	Human	hsa-miR-363-3p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	The level of miR-363-3p was significantly decreased in TGF-¦Â1-treated HK-2 cells	33630202
9188	Human	hsa-miR-363-3p	miRNA	cadmium (Cd)	renal injury	serum	cadmium (Cd) treatment	We tested five dysregulated miRNAs and determined a significant increase of sera miR-363-3p.	33857584
9189	Human	hsa-miR-3648	miRNA	thapsigargin (TG) and tunicamycin (TM)	cell proliferation	HeLa and HEK293T cells	Thapsigargin (TG) and Tunicamycin (TM)s treatment	upregulated	28661420
9190	Human	hsa-miR-365	miRNA	intermittent cyclic mechanical tension (ICMT)	intervertebral disc degeneration (IDD)	primary human end plate chondrocytes	intermittent cyclic mechanical tension (ICMT) treatment	downregulated	31472300
9191	Human	hsa-miR-365	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
9192	Human	hsa-miR-365	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
9193	Human	hsa-miR-365	miRNA	crocin	cervical cancer (CC)	sensitive human cervical cancer cell line (OV2008) and resistant one (C13)	crocin treatment	downregulated	28763753
9194	Human	hsa-miR-365	miRNA	chondrogenic medium	chondrogenesis	"articular cartilage-derived mesenchymal stem cells from osteoarthritis patients (OA-MSC), bone marrow-derived mesenchymal stem cells (BMSC)"	chondrogenic medium cultures	upregulated	31287025
9195	Human	hsa-miR-365	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose treatment	"High glucose treatment led to downregulated RPSAP52 and Timp3, but upregulated miR-365 in RPE cells."	33178344
9196	Human	hsa-miR-365	miRNA	hydatid cyst fluid (HCF)	melanoma	human melanoma cell A375	Hydatid cyst fluid (HCF) treatment	"The fold change of Bax/Bcl-2 ratio, Caspase-9, miR-365 and Caspase-3 activity was higher in the fertile HCF-treated melanoma cells compared to infertile fluid treated A375 cells and human normal epithelial cell (as control cell)."	33609644
9197	Human	hsa-miR-365	miRNA	mechanical loading and hydrostatic pressure (HP)	osteoarthritis (OA)	OA human chondrocytes	mechanical loading and hydrostatic pressure (HP) treatment	upregulated	28085114
9198	Human	hsa-miR-365	miRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	30233734
9199	Human	hsa-miR-365	miRNA	oxidized low density lipoprotein (ox-LDL)	focal cerebral ischemia	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	21640710
9200	Human	hsa-miR-3651	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
9201	Human	hsa-miR-3651	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
9202	Human	hsa-miR-3652	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
9203	Human	hsa-miR-3653-3p	miRNA	melatonin	osteoporosis	human bone marrow mesenchymal stem cell (hBMSC)	melatonin (MEL) treatment	Circ_0003865 expression in BMSCs was significantly decreased by MEL treatment.	33632317
9204	Human	hsa-miR-3656	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
9205	Human	hsa-miR-3659	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9206	Human	hsa-miR-3659	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
9207	Human	hsa-miR-365a-3p	miRNA	toosendanin (TSN)	gastric cancer (GC)	MKN-45 cells	toosendanin (TSN) treatment	upregulated	32582989
9208	Human	hsa-miR-365a-3p	miRNA	sulforaphane (SFN)	pancreatic ductal adenocarcinoma (PDAC)	AsPC-1 cells	sulforaphane treatment	upregulated	30910589
9209	Human	hsa-miR-365a-5p	miRNA	excessive mechanical tension	intervertebral disc degeneration (IDD)	primary human endplate chondrocytes culture	Excessive mechanical tension induce	"circRNA_0058097 can upregulate the expression of downstream target gene histone deacetylase 4 by sponge adsorption of miR-365a-5p, which promoted morphological changes of endplate chondrocytes, and increased extracellular matrix degradation and degeneration of endplate cartilage."	31222836
9210	Human	hsa-miR-365b-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	coronary atherosclerosis (CAS)	human coronary artery smooth muscle cells (HCASMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	30402161
9211	Human	hsa-miR-3663	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
9212	Human	hsa-miR-3663-3p	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
9213	Human	hsa-miR-3666	miRNA	all-trans retinoic acid (ATRA)	colorectal cancer (CRC)	Human CRC HCT116 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29772445
9214	Human	hsa-miR-3666	miRNA	palmitic acid (PA)	hepatic steatosis	HepG2 cells	palmitic acid (PA) treatment	In PA treated HepG2 cells during development of hepatic steatosis PPAR¦Ã was significantly upregulated concomitant with downregulated of miR-3666	32755726
9215	Human	hsa-miR-367	miRNA	c-reactive protein (CRP)	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	CRP treatment	upregulated	31646586
9216	Human	hsa-miR-367	miRNA	hypoxia	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	hypoxia induce	upregulated	31646586
9217	Human	hsa-miR-367	miRNA	paclitaxel (PTX)	tumorigenesis	NCI60 cancer cell line£¬Ovarian cancer (OVCA) cell lines and Human stem cell lines (H9)	paclitaxel treatment	miR-367 upregulated and miR-30a-5p downregulated	24220856
9218	Human	hsa-miR-367	miRNA	sodium butyrate (NaB)	somatic cell reprogramming	human foreskin fibroblasts (HFFs)	NaB treatment	upregulated	24568633
9219	Human	hsa-miR-3675-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9220	Human	hsa-miR-3676	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	downregulated	25722110
9221	Human	hsa-miR-3676-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9222	Human	hsa-miR-3679-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9223	Human	hsa-miR-3682-3p	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
9224	Human	hsa-miR-3687	miRNA	lucidum	breast cancer	MCF-7 breast cancer cells	lucidum treatment	upregulated	25954907
9225	Human	hsa-miR-369	miRNA	azacitidine (AZA)	gastric cancer (GC)	"HGC27, SGC7091, MGC803, and MKN45 cell lines"	azacitidine (AZA) treatment	upregulated	31162777
9226	Human	hsa-miR-369-3p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
9227	Human	hsa-miR-369-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
9228	Human	hsa-miR-369-3p	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	A549 cells	bleomycin (BLM) treatment	TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells. DLEU2 directly targeted miR-369-3p.	33760118
9229	Human	hsa-miR-369-3p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â1 treatment	TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells DLEU2 directly targeted miR-369-3p	33760118
9230	Human	hsa-miR-37	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	acute myeloid leukemia (AML)	THP-1 line	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26191124
9231	Human	hsa-miR-370	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31900142
9232	Human	hsa-miR-370	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33298736
9233	Human	hsa-miR-370	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y Cells	oxygen glucose deprivation (OGD) treatment	miR-370 expression was significantly promoted in SH-SY5Y cells after OGD treated.	32311231
9234	Human	hsa-miR-370	miRNA	homoharringtonine (HHT)	chronic myeloid leukemia (CML)	chronic myeloid leukemia K562 cells	Homoharringtonine (HHT) treatment	upregulated	24148180
9235	Human	hsa-miR-370	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
9236	Human	hsa-miR-370	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells; LN229 cells;glioma tissues	temozolomide (TMZ) treatment	miR-370 expression was significantly downregulated in TMZ-resistant glioma tissues and glioma cells	33188501
9237	Human	hsa-miR-370	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	Glioblastoma cells	Japanese encephalitis virus (JEV) infection	downregulated	27703358
9238	Human	hsa-miR-370	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteosarcoma (OS)	human osteosarcoma cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28539830
9239	Human	hsa-miR-370-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ_0010283 mediated cell viability and migration via a miR-370-3p/HMGB1 axis in ox-LDL-induced VSMCs.	32945389
9240	Human	hsa-miR-370-3p	miRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	downregulated	33376537
9241	Human	hsa-miR-370-3p	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	SKOV-3 cells; OVCAR3 cells	TGF-¦Â treatment	TGF-¦Â treatment upregulated H19 and downregulated miR-370-3p	29403287
9242	Human	hsa-miR-370-3p	miRNA	baohuoside-I	nasopharyngeal carcinoma (NPC)	CNE1 cells; CNE2 cells	baohuoside-I treatment	upregulated	32945196
9243	Human	hsa-miR-370-3p	miRNA	osteogenic differentiation medium	osteogenesis	human bone marrow-derived mesenchymal stem cells (HBMSCs)	"osteogenic differentiation medium with 100 mmol/L dexamethasone, 0.05 mmol/L ascorbic acid, and 10 mmol/L ¦Â-glycerophosphate treatment"	downregulated	30795799
9244	Human	hsa-miR-370-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 human lung fibroblasts cells	lipopolysaccharide (LPS) treatment	downregulated	31066476
9245	Human	hsa-miR-370-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	LPS treatment	"SNHG16 impeded cell viability and promoted apoptosis, inflammatory injury by targeting IGF2 mediated by miR-370-3p in LPS-induced A549 cells."	31841752
9246	Human	hsa-miR-370-3p	miRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	lipopolysaccharides (LPS) treatment	downregulated	31841752
9247	Human	hsa-miR-370-3p	miRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	Exosomes were isolated from MDA-MB-231 cells	cisplatin treatment	upregulated	31424364
9248	Human	hsa-miR-371a-3p	miRNA	orchiectomy	germ cell tumour (GCT)	serum	orchiectomy treatment	downregulated in serum	25187505
9249	Human	hsa-miR-371a-5p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	tumor tissue and serum from HCC patients	hepatitis B virus (HBV) infection	upregulated	29928866
9250	Human	hsa-miR-371a-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
9251	Human	hsa-miR-371b-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	SH-SY5Y human neuroblastoma cells	GDNF	downregulated	28829278
9252	Human	hsa-miR-372	miRNA	cadmium (Cd)	cell cycle and proliferation	hepatoma cell line (HepG2)	cadmium (Cd) treatment	upregulated	25101185
9253	Human	hsa-miR-372	miRNA	chemotherapy	colorectal cancer (CRC)	serum	" modified folfox6 (oxaliplatin 85 mg/m2, day 1; 5-fluorouracil as a continuous intravenous infusion at 46 h dose 2400 mg/m2; 5-fluorouracil intravenous infusion at 30 min dose 300 mg/m2
, day 1; CF 400 mg/m2 intravenous infusion at 2 h, day 1) treatment"	dysregulated	24304648
9254	Human	hsa-miR-372	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	hepatocellular carcinoma (HCC)	Huh7 or HCCLM3 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-372 expression was restored upon 5-aza-dCyd treatment	25880458
9255	Human	hsa-miR-372	miRNA	propofol (PPF)	lung cancer	A549 cells	propofol treatment	downregulated	30547768
9256	Human	hsa-miR-372	miRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	"Two NPC cell lines, 5©\8F and C666©\1"	ionization radiation treatment	upregulated	30656832
9257	Human	hsa-miR-372	miRNA	caudatin	oxidative stress	human gastric carcinoma cell lines	caudatin? treatment	downregulated	23708208
9258	Human	hsa-miR-372	miRNA	IL-1¦Â	spinal cord injury (SCI)	human neural stem cells (hNSC)	IL-3¦Â treatment	upregulated	28298306
9259	Human	hsa-miR-372-3p	miRNA	rapamycin	dyslipidemia	serum	rapamycin treatment	hsa-miR-372-3p was filtered using RNA sequencing and identified as a key regulator in rapamycin-induced TGs accumulation	33705959
9260	Human	hsa-miR-372-3p	miRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	serum	Dox treatment	We found a significantly higher level of miR-372-3p in the blood of the responder group of HCC patients who received TACE with Dox than of non-responders	32416702
9261	Human	hsa-miR-372-3p	miRNA	fructose	liver fibrosis	primary human hepatocytes	fructose treatment	downregulated	31299062
9262	Human	hsa-miR-372-3p	miRNA	high glucose (HG)	liver fibrosis	LX-2 and HepG2 cells	high glucose treatment	downregulated	31299062
9263	Human	hsa-miR-372-3p	miRNA	palmitate	liver fibrosis	primary human hepatocytes	palmitate treatment	downregulated	31299062
9264	Human	hsa-miR-372-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
9265	Human	hsa-miR-372-5p	miRNA	mono-(2-ethylhexyl) phthalate (MEHP)	oral squamous cell carcinoma (OSCC)	SCC-4 cells	Mono-2-ethyhexyl phthalate (MEHP) treatment	downregulated	30858031
9266	Human	hsa-miR-373	miRNA	berberine (BBR)	abnormal lipid accumulation	MIHA cells; HepG2 cells	berberine (BBR) treatment	MicroRNA-373 (MiR-373) was consistently upregulated in both cell lines upon berberine treatments.	29477657
9267	Human	hsa-miR-373	miRNA	trastuzumab or lapatinib	breast cancer	patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer	chemotherapy combin either trastuzumab or lapatinib treatment	upregulated	25086636
9268	Human	hsa-miR-373	miRNA	arsenite	tumorigenesis	RWPE-1 human prostate epithelial line	arsenite exposure	downregulated	24431212
9269	Human	hsa-miR-373	miRNA	pomegranate juice (PJ)	colorectal cancer (CRC)	?prostate cancer cells	Pomegranate juice (PJ) treatment	downregulated	21594291
9270	Human	hsa-miR-373	miRNA	suberoylanilide hydroxamic acid (SAHA)	non-small cell lung cancer (NSCLC)	Calu-6 non-small cell lung cancer (NSCLC) cell line	SAHA treatment	upregulated	25063738
9271	Human	hsa-miR-373	miRNA	trichostatin A (TSA)	non-small cell lung cancer (NSCLC)	A549 and Calu-6 cells	trichostatin A treatment	downregulated	25063738
9272	Human	hsa-miR-373	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	circRNA-UBE2G1 facilitates the progression in the LPS-induced OA cell model via regulating the miR-373/HIF-1a axis.	32476580
9273	Human	hsa-miR-373	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
9274	Human	hsa-miR-373	miRNA	TGF-¦Â1	renal fibrosis	human kidney-2 cells	TGF-¦Â1 treatment	upregulated	29723660
9275	Human	hsa-miR-373	miRNA	TGF-¦Â1	renal fibrosis	human kidney-2 cells	TGF-¦Â1 treatment	upregulated	29723660
9276	Human	hsa-miR-373	miRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	Exosomes were isolated from MDA-MB-231 cells	cisplatin treatment	upregulated	31424364
9277	Human	hsa-miR-373-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	lncRNA SNHG16 knockdown significantly limited the progression of OA by sponging miR-373-3p in vitro	33300061
9278	Human	hsa-miR-373-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
9279	Human	hsa-miR-373-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute hepatic injury	THLE-3 cells	Lipopolysaccharide (LPS) treatment	downregulated of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis.	33129786
9280	Human	hsa-miR-374a	miRNA	isoliquiritigenin	breast cancer	"MDA-MB-231, MCF-7, BT474, 4T1, MCF-10A and 293 T"	isoliquiritigenin treatment	downregulated	28827662
9281	Human	hsa-miR-374a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 human renal tubular epithelial cells	high glucose (HG) treatment	downregulated	30147653
9282	Human	hsa-miR-374a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	"Serum miR-374a was progressively accelerated in patients with NDR, NPDR and PDR than in healthy controls."	33941051
9283	Human	hsa-miR-374a	miRNA	etoposide (VP-16)	glioblastoma multiforme (GBM)	"Human glioma cell lines A172, U118-MG and LN-18"	Etoposide (VP-16) treatment	knockdown of miR-374a was able to enhance the etoposide-induced cytotoxicity against glioma cells.	30841958
9284	Human	hsa-miR-374a	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	downregulated	21274007
9285	Human	hsa-miR-374a	miRNA	ferric ammonium citrate (FAC)	liver fibrosis	LO-2 cells	ferric ammonium citrate (FAC) treatment	downregulated	31171361
9286	Human	hsa-miR-374a	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	HepG2 and SMMC-7721 cells	Propofol treatment	downregulated	30257238
9287	Human	hsa-miR-374a	miRNA	¦Ã-rays	irradiation-induced ischemic stroke	HA-1800 cells	¦Ã-radiation treatment	downregulated	29984671
9288	Human	hsa-miR-374a	miRNA	propofol (PPF)	ovarian cancer (OC)	A2780 cells	propofol treatment	Propofol decreased miR-374a expression levels in A2780 cells	32016462
9289	Human	hsa-miR-374a-5p	miRNA	TGF-¦Â1	hepatocarcinogenesis	Hep3B cells	TGF-¦Â1 treatment	upregulated	32269736
9290	Human	hsa-miR-374b	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
9291	Human	hsa-miR-374b	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"human HCC cell lines (Hep3B, HepG2, and HCCLM3)"	sorafenib treatment	The suppression of PKM2 by miR-374b re-sensitizes sorafenib-resistant HCC cells and mouse xenografts to sorafenib treatment by antagonizing glycolysis pathway.	31106002
9292	Human	hsa-miR-374b	miRNA	melatonin	prostate cancer	hypoxic PC-3 cells	melatonin treatment	upregulated	25553085
9293	Human	hsa-miR-374b	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
9294	Human	hsa-miR-374b-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35."	33279663
9295	Human	hsa-miR-374b-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y	amyloid-¦Â (A¦Â) 25-35 treatment	MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells.	33279663
9296	Human	hsa-miR-374c-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	cervical squamous cell	TGF¦Â1 treatment	downregulated	28810526
9297	Human	hsa-miR-375	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	allergic rhinitis (AR)	Human nasal mucosa cells HNEpC	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29677549
9298	Human	hsa-miR-375	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"Overexpression of WT1-AS can inhibit the miR-375/SIX4 axis, OSI and neuronal apoptosis in AD by inhibiting WT1 expression."	33234729
9299	Human	hsa-miR-375	miRNA	PAX8/PPAR¦Ã fusion protein (PPFP)	anaplastic thyroid carcinoma (ATC)	"ATC cell lines: BHT-101; FRO, C-643; KTC-2;KTC-3"	PAX8/PPAR¦Ã fusion protein (PPFP) treatment	upregulated	23598436
9300	Human	hsa-miR-375	miRNA	ketamine	anesthesia-induced neural cytotoxicity	human embryonic stem cell (hESC)-derived neuron	Ketamine treatment	upregulated	30500346
9301	Human	hsa-miR-375	miRNA	phytoestrogens	anti-cancer therapy	"human osteosarcoma cell line, U2OS"	Phytoestrogens treatment	upregulated	26381132
9302	Human	hsa-miR-375	miRNA	platelet-derived growth factor (PDGF)	asthma	airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	miR-375 expression was significantly decreased in fetal ASM cells that were treated with PDGF	29245068
9303	Human	hsa-miR-375	miRNA	biochanin A	breast cancer	breast cancer cells	biochanin A treatment	upregulated	25613180
9304	Human	hsa-miR-375	miRNA	biochanin A	breast cancer	"ER¦Á-positive breast cancer cells (T47D, MCF-7)"	biochanin A treatment	upregulated	25613180
9305	Human	hsa-miR-375	miRNA	formononetin	breast cancer	"HUVEC cells, MCF-7 cells"	Formononetin treatment	upregulated	25663261
9306	Human	hsa-miR-375	miRNA	tamoxifen (TAM)	breast cancer	"The human breast cancer cell lines, MCF-7 and MDA-MB-231, and lung cancer cell lines, H1703 and H1299 ;HEK-293FT cells and The human ovarian cancer cell line, Ovcar-5"	tamoxifen treatment	downregulated	22508479
9307	Human	hsa-miR-375	miRNA	formononetin	cell proliferation	"HUVEC, MCF-7"	Formononetin treatment	upregulated	25663261
9308	Human	hsa-miR-375	miRNA	doxorubicin (DOX)	cell senescence	K562 cells	Doxorubicin (DOX) treatment	upregulated	22606351
9309	Human	hsa-miR-375	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cervical cancer (CC)	"cervical cell lines SiHa, CaSki and HeLa"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31326568
9310	Human	hsa-miR-375	miRNA	folic acid	cervical cancer (CC)	CaSki cells	folic acid treatment	upregulated	27313708
9311	Human	hsa-miR-375	miRNA	paclitaxel (PTX)	cervical cancer (CC)	SiHa and Caski cells	paclitaxel treatment	upregulated	23778521
9312	Human	hsa-miR-375	miRNA	paclitaxel (PTX)	cervical cancer (CC)	"two human cervical cancer cell lines, SiHa and CaSki"	paclitaxel treatment	upregulated	25330011
9313	Human	hsa-miR-375	miRNA	high-risk human papillomavirus (hrHPV)	cervical cancer (CC)	The HPV16-immortalized keratinocyte cellline FK16A	high-risk human papillomavirus (hrHPV)infection	downregulated	22987659
9314	Human	hsa-miR-375	miRNA	formaldehyde	chronic respiratory disease (CRD)	human bronchial epithelial cells 16HBE	formaldehyde treatment	downregulated	31172816
9315	Human	hsa-miR-375	miRNA	high glucose (HG)	diabetic nephropathy (DN)	enteric glia cell (EGC)	high glucose treatment	upregulated	30140011
9316	Human	hsa-miR-375	miRNA	cyclic hydroxamic acid-containing peptide 31 (CHAP31)	esophageal squamous cell carcinoma (ESCC)	The human ESCC cell lines ( T.Tn cells; TE2 cells; CHAP31 )	cyclic hydroxamic acid-containing peptide 31 (CHAP31) treatment	upregulated	22752059
9317	Human	hsa-miR-375	miRNA	imatinib and lapatinib	fulvestrant-resistant breast cancer	fulvestrant-resistant breast cancer (FRBC) MCF-7 cells	imatinib+lapatinib dual treatment	upregulated	29522716
9318	Human	hsa-miR-375	miRNA	cisplatin (DDP)	gastric cancer (GC)	human gastric cancer cells	cisplatin treatment	downregulated	26893657
9319	Human	hsa-miR-375	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	gastric epithelial cells	lipopolysaccharide (LPS) treatment	downregulated	25307786
9320	Human	hsa-miR-375	miRNA	lipopolysaccharide (LPS)	gastric cancer (GC)	"human gastric epithelial cell lines, AGS and MKN45"	LPS from H. pylori 26695 treatment	downregulated	25307786
9321	Human	hsa-miR-375	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
9322	Human	hsa-miR-375	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
9323	Human	hsa-miR-375	miRNA	everolimus	hepatocellular carcinoma (HCC)	"Human HCC cell lines PLC/PRF/5, and JHH-6"	everolimus (EVE) treatment	downregulated	31406139
9324	Human	hsa-miR-375	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCCs	hypoxia treatment	"MiR-375 presented an obviously differential expression in human HCCs versus background livers (BLs) and HCCs versus normal liver tissues (NLTs). In rat models, miR-375 was gradually declined during hepatocarcinogenesis."	32215815
9325	Human	hsa-miR-375	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells	Sorafenib treatment	downregulated	32431510
9326	Human	hsa-miR-375	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Hep3B cells; HepG2 cells	sorafenib treatment	downregulated	32616906
9327	Human	hsa-miR-375	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	human papillomaviruses (HPV) infection	Ca Ski and SiHa cell	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28521287
9328	Human	hsa-miR-375	miRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	human foreskin keratinocytes	Using CD4+ T-cells expressing only Human immunodeficiency virus (HIV)-1 envelope inoculated on human adult foreskin tissues	upregulated	28443609
9329	Human	hsa-miR-375	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	downregulated	29516639
9330	Human	hsa-miR-375	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	upregulated	29516639
9331	Human	hsa-miR-375	miRNA	helicobacter pylori (H. pylori)	helicobacter pylori (H. pylori) infection	GES-1 and BGC-823 cells	H. pylori infection treatment	downregulated	24718681
9332	Human	hsa-miR-375	miRNA	ketamine	ketamine-induced neurotoxicity	human embryonic stem cell (hESC)	ketamine treatment	upregulated	30500346
9333	Human	hsa-miR-375	miRNA	ASH1	lung cancer	CLC cell line; ACC-LC-172; A549 cells	The transcription factor ASH1 treatment	upregulated	21856745
9334	Human	hsa-miR-375	miRNA	SGI-110 and/or trichostatin A	multiple myeloma (MM)	human myeloma cell lines (HMCLs)	SGI-110 and/or trichostatin A treatment	upregulated	28439875
9335	Human	hsa-miR-375	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9336	Human	hsa-miR-375	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	palmiticacid (PA) treatment	upregulated	29569260
9337	Human	hsa-miR-375	miRNA	radiation	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) tissues	radiation treatment	downregulated	32940043
9338	Human	hsa-miR-375	miRNA	teriparatide (TP)	osteoporosis	human marrow mesenchymal cells (hMSCs)	teriparatide (TP) treatment	downregulated	31858576
9339	Human	hsa-miR-375	miRNA	platelet-derived growth factor (PDGF)	pediatric asthma	human fetal airway smooth muscle cells	PDGF treatment	downregulated	29245068
9340	Human	hsa-miR-375	miRNA	docetaxel (DTX)	prostate cancer	DU145 and PC-3 cells	docetaxel (DTX) treatment	upregulated	27832783
9341	Human	hsa-miR-375	miRNA	TGF-¦Â	lung fibrosis	human lung fibroblasts	TGF-¦Â treatment	miR-375 was markedly upregulated in human lung fibroblasts after TGF-¦Â stimulation	32582987
9342	Human	hsa-miR-375	miRNA	trichostatin A (TSA)	tongue squamous cell carcinoma (TSCC)	human tongue cancer cell lines SCC-15 and CAL27	human tongue cancer cell lines SCC-15 and CAL27 treatment	upregulated	27878285
9343	Human	hsa-miR-375	miRNA	trichostatin A (TSA)	tongue squamous cell carcinoma (TSCC)	human tongue cancer cell lines SCC-15 and CAL27	TSA treatment	upregulated	27878285
9344	Human	hsa-miR-375	miRNA	"polycistronic viral vector expressing Sox2, Klf4, c-Myc, and Oct4"	type 1 diabetes mellitus (T1DM)	hiPSCs from human foreskin fibroblasts	polycistronic viral vector treatment	upregulated	24469711
9345	Human	hsa-miR-375	miRNA	formononetin	vascular endothelial cells (ECs) proliferation	human umbilical vein endothelial cells (HUVECs)	Formononetin (Form) treatment	upregulated	29722068
9346	Human	hsa-miR-375	miRNA	androgen	adipogenic differentiation	mature adipocytes	androgen treatment	downregulated	26219823
9347	Human	hsa-miR-375	miRNA	particulate matter (PM) and diesel exhaust particles (DEP)	asthma	?human bronchial epithelial cells	particulate matter (PM) and diesel exhaust particles (DEP) treatment	upregulated	23455502
9348	Human	hsa-miR-375	miRNA	radiation and etoposide	gastric cancer (GC)	gastric cancer cell lines(BGC823; MGC803; SGC7901;AGS; N87;MKN45)	radiation and etoposide treatment	upregulated	23835407
9349	Human	hsa-miR-375-3p	miRNA	hypoxia	congenital heart disease (CHD)	serum	hypoxia induce	miR-375-3p was upregulated and FOXP1/Bcl2l2 was downregulated in maternal serum of women with fetal CHD and hypoxia-induced rat cardiomyocyte h9c2 cells.	33128129
9350	Human	hsa-miR-375-3p	miRNA	solasonine (SS)	hepatocellular carcinoma (HCC)	"HepG2 cells, QGY-7703 cells"	Solasonine (SS) treatment	upregulated	31681610
9351	Human	hsa-miR-376	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	hepatocellular carcinoma (HCC)	"everolimus (EVE) resistant PLC/PRF/5, and JHH-6 cells"	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	31406139
9352	Human	hsa-miR-376	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	HFF cells	infect with HCMV	upregulated	24586166
9353	Human	hsa-miR-376a	miRNA	esomeprazole	adeno and squamous-cell-carcinoma	human adeno-(OE19) and squamous-cell-carcinoma (KYSE410) cell lines	esomeprazole treatment	downregulated	25175076
9354	Human	hsa-miR-376a	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HCMEC/D3 cells	Oxygen-glucose deprivation (OGD) treatment	LncRNA SNHG1 depressed apoptosis and inflammation of IS cell model via inhibiting miR-376a and upregulating CBS/H2S signal	32532171
9355	Human	hsa-miR-376a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9356	Human	hsa-miR-376a	miRNA	N-succinimidyl N-methylcarbamate	pancreatic cancer (PC)	Normal human pancreatic ductal epithelial (HPDE-6) cells	Cells were a fixed 0.005 mmol/L concentration of N-succinimidyl N-methylcarbamate	upregulated	24563415
9357	Human	hsa-miR-376a	miRNA	arsenic trioxide (ATO)	retinoblastoma (RB)	retinoblastoma cells	arsenic trioxide?treatment	downregulated	23373993
9358	Human	hsa-miR-376b-3p	miRNA	matrine	acute lymphoblastic leukemia (ALL)	CCRF-CEM cells	matrine treatment	downregulated	29045804
9359	Human	hsa-miR-376c	miRNA	IL-1¦Â	osteosarcoma (OS)	hFOB;Saos2;MG63;U2OS;SW1353	IL-1¦Â?treatmrnt	upregulated	29441940
9360	Human	hsa-miR-376c	miRNA	Thrombospondin-1 (TSP-1)	prostate cancer	human PCa cells	TSP-1 treatment	downregulated	28122633
9361	Human	hsa-miR-376c	miRNA	bacillus calmette-guerin (BCG)	tuberculosis (TB)	TB patients	bacillus calmette-guerin (BCG) treatment	upregulated	24586438
9362	Human	hsa-miR-376c-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
9363	Human	hsa-miR-376c-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	upregulated	25129238
9364	Human	hsa-miR-376c-3p	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	31844418
9365	Human	hsa-miR-376C-3p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
9366	Human	hsa-miR-377	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	downregulated	27158236
9367	Human	hsa-miR-377	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	HUVECs	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
9368	Human	hsa-miR-377	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	downregulated	27158236
9369	Human	hsa-miR-377	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
9370	Human	hsa-miR-377	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Primary cultures of normal human mesangial cells (NHMCs)	high glucose treatment	upregulated	18716028
9371	Human	hsa-miR-377	miRNA	TGF-¦Â	diabetic nephropathy (DN)	Primary cultures of normal human mesangial cells (NHMCs)	transforming growth factor-¦Â treatment	?upregulated	18716028
9372	Human	hsa-miR-377	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose treatment	upregulated	30706373
9373	Human	hsa-miR-377	miRNA	hypoxia	diabetic retinopathy (DR)	human retinal endothelial cells	hypoxia induce	upregulated	30706373
9374	Human	hsa-miR-377	miRNA	hypoxia	ischemic heart disease (IHD)	Hypoxic MSCs	"cultured in DMEM without glucose and with 1% FBS under hypoxic conditions of 1% O2, 5% CO2 treatment"	downregulated	25251394
9375	Human	hsa-miR-377	miRNA	gefitinib	lung adenocarcinoma (LUAD)	PC9 cells; A549 cells	gefitinib treatment	upregulated	29592872
9376	Human	hsa-miR-377	miRNA	carbamate	lung cancer	Normal human bronchial epithelial (NHBE) cells	carbamate treatment	upregulated	19748927
9377	Human	hsa-miR-377	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischaemic injury	human neonatal cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	miR-377 expression was downregulated in cardiomyocyte exposed to H/R.	32647500
9378	Human	hsa-miR-377	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
9379	Human	hsa-miR-377	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
9380	Human	hsa-miR-377	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
9381	Human	hsa-miR-377	miRNA	titanium (Ti) particle	wear particle-induced osteolysis (PIO)	Bone marrow macrophages (BMMs)	titanium (Ti) particle treatment	downregulated	30958621
9382	Human	hsa-miR-377-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-377-3p inhibits atherosclerosis-associated vascular smooth muscle cell proliferation and migration via targeting neuropilin2.	32373927
9383	Human	hsa-miR-377-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Normal human articular chondrocytes	IL-1¦Â treatment	downregulated	31831175
9384	Human	hsa-miR-377-3p	miRNA	oleanolic acid (OLA)	osteoarthritis (OA)	chondrocytes	oleanolic acid (OLA) treatment	downregulated	32028542
9385	Human	hsa-miR-377-3p	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells; Saos-2 cells	cisplatin treatment	OIP5-AS1 positively modulated FOSL2 expression to decrease CDDP sensitivity in OS by sponging miR-377-3p.	32440152
9386	Human	hsa-miR-377-3p	miRNA	tuberculosis (MTB)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (MTB) infection treatment	downregulated	33271233
9387	Human	hsa-miR-378	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
9388	Human	hsa-miR-378	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) exposure	downregulated	31696490
9389	Human	hsa-miR-378	miRNA	acute exercise	congestive heart failure (CHF)	CHF patients	acute exercise treatment	upregulated	26799589
9390	Human	hsa-miR-378	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
9391	Human	hsa-miR-378	miRNA	Fatty acid	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	Fatty acid treatment	miR-378 was significantly increased in Fatty acid treated human hepatoma HepG2 cells.	29625129
9392	Human	hsa-miR-378	miRNA	oleacein (OA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	oleate treatment	upregulated	30281809
9393	Human	hsa-miR-378	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
9394	Human	hsa-miR-378	miRNA	IL-6	obesity	matured human adipocytes	"TNF-¦Á, IL-6, leptin, or resistin treatment"	upregulated	24771406
9395	Human	hsa-miR-378	miRNA	leptin	obesity	matured human adipocytes	"TNF-¦Á, IL-6, leptin, or resistin treatment"	upregulated	24771406
9396	Human	hsa-miR-378	miRNA	resistin	obesity	matured human adipocytes	"TNF-¦Á, IL-6, leptin, or resistin treatment"	upregulated	24771406
9397	Human	hsa-miR-378	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	matured human adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	24771406
9398	Human	hsa-miR-378	miRNA	high-intensity interval training (HIIT)	skeletal muscle adaptation	human	human treatment	downregulated	27101297
9399	Human	hsa-miR-378	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	downregulated	21030674
9400	Human	hsa-miR-378	miRNA	adipokines	systemic adipose tissue inflammation	human visceral preadipocytes	adipokines and inflammatory cytokines on treatment	upregulated	24923530
9401	Human	hsa-miR-378-3p	miRNA	morphine	morphine tolerance	Be(2)C cells	morphine treatment	Chronic morphine treatment significantly increased the miR-378-3p level in Be(2)C cells.	31999011
9402	Human	hsa-miR-378a-3p	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
9403	Human	hsa-miR-378a-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7; HCCLM3; SK-HEP-1	sorafenib treatment	downregulated	32754282
9404	Human	hsa-miR-378a-3p	miRNA	radiation	tumor radiotherapy	U87 cells-derived exosome	radiation treatment	upregulated	32267172
9405	Human	hsa-miR-378a-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	upregulated	28951593
9406	Human	hsa-miR-378a-5p	miRNA	forskolin (FSK)	choriocarcinoma	human choriocarcinoma cell line BeWo	forskolin treatment	downregulated	25122062
9407	Human	hsa-miR-378a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	OA synovial explants	IL-1¦Âtreatment	upregulated	27143365
9408	Human	hsa-miR-378b	miRNA	arctiin	antiviral immune response	normal human dermal fibroblasts (nHDFs)	arctiin treatment	downregulated	28990056
9409	Human	hsa-miR-378b	miRNA	ultraviolet (UV) irradiation	dermal fibroblasts aging	human dermal fibroblasts (HDFs)	UVB-exposed treatment	upregulated	28983623
9410	Human	hsa-miR-378b	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
9411	Human	hsa-miR-378b	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	TiO2-NPs-mediated colonic cytotoxicity	NCM460 cells; HCT116 cells	Titanium dioxide nanoparticles (TiO2-NPs) treatment	upregulated	32423014
9412	Human	hsa-miR-378c	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
9413	Human	hsa-miR-378c	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
9414	Human	hsa-miR-378d	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
9415	Human	hsa-miR-378d	miRNA	sodium fluoride (NaF)	female reproductive dysfunction	KGN cells	sodium fluoride (NaF) treatment	The miR-378d was the most significantly upregulated one dose dependently by NaF	33405077
9416	Human	hsa-miR-378f	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
9417	Human	hsa-miR-378g	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
9418	Human	hsa-miR-378g	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-378g was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
9419	Human	hsa-miR-378g	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-miR-378g was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
9420	Human	hsa-miR-378g	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	TiO2-NPs-mediated colonic cytotoxicity	HCT116 cells	Titanium dioxide nanoparticles (TiO2-NPs) treatment	upregulated	32423014
9421	Human	hsa-miR-378g	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	TiO2-NPs-mediated colonic cytotoxicity	NCM460 cells	Titanium dioxide nanoparticles (TiO2-NPs) treatment	downregulated	32423014
9422	Human	hsa-miR-378h	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
9423	Human	hsa-miR-378h	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	downregulated	29510375
9424	Human	hsa-miR-378h	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
9425	Human	hsa-miR-378i	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
9426	Human	hsa-miR-379	miRNA	coenzyme Q10 (CoQ10)	atherosclerosis (AS)	human THP-1 macrophages	CoQ10 treatment	downregulated	24675663
9427	Human	hsa-miR-379	miRNA	genistein	hepatocellular carcinoma (HCC)	HepG2 cells	Genistein (GNT) treatment	downregulated	25781341
9428	Human	hsa-miR-379	miRNA	rifampicin	hepatocellular carcinoma (HCC)	HepG2 cells	rifampicin treatment	a miRNA negatively regulating ABCC2 on the post-transcriptional level and provide evidence that this miRNA impedes overexpression of ABCC2 protein after a PXR-mediated external transcriptional stimulus	21540293
9429	Human	hsa-miR-379-5p	miRNA	arsenite	arsenite-induced liver damage	L-02 cells	arsenite exposure	downregulated	30643918
9430	Human	hsa-miR-380	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human Bronchial Epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	miR-380 showed a tendency of high expression in COPD patients and CSE models.	31821848
9431	Human	hsa-miR-380	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Human Bronchial Epithelial cells	cigarette smoke extract (CSE) exposure	upregulated	31821848
9432	Human	hsa-miR-380-3p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissue	cigarette smoke (CS) exposure	upregulated	31819170
9433	Human	hsa-miR-381	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
9434	Human	hsa-miR-381	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary heart disease (CHD)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Protective effect of microRNA-381 against inflammatory damage of endothelial cells during coronary heart disease by targeting CXCR4.	32016478
9435	Human	hsa-miR-381	miRNA	periostin	epithelial-mesenchymal transition (EMT)	human lung adenocarcinoma cell line A549	periostin treatment	downregulated	28977942
9436	Human	hsa-miR-381	miRNA	radiotherapy	esophageal cancer (EC)	tissues from primary ESCC and recurrent ESCC in situ after radiotherapy	radiotherapy treatment	downregulated	25628936
9437	Human	hsa-miR-381	miRNA	metformin (Met)	non-small cell lung cancer (NSCLC)	A549 cells	metformin treatment	Metformin dose- and time- dependently increased the RNA level of miR-381.	31906986
9438	Human	hsa-miR-381	miRNA	lipopolysaccharide (LPS)	respiratory infections	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	26688820
9439	Human	hsa-miR-381	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9440	Human	hsa-miR-381-3p	miRNA	kartogenin	chondrogenesis	Small extracellular vesicles (sEVs) derived from human umbilical cord mesenchymal stem cells (hUCMSCs)	kartogenin preconditioned	upregulated	31864017
9441	Human	hsa-miR-381-3p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
9442	Human	hsa-miR-381-3p	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	Caco-2 cells	hypoxia induce	upregulated	29706629
9443	Human	hsa-miR-381-3p	miRNA	Hypoxia	nasopharyngeal carcinoma (NPC)	HK-1 and C666-1	hypoxia treatment	"XIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis, providing new insights into the pathogenesis of NPC."	32196601
9444	Human	hsa-miR-381-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	THP-1 cells	"4,4'-methylene diphenyl diisocyanate (MDI) treatment"	Both in vivo murine MDI aerosol exposure and in vitro MDI-GSH exposures in THP-1 macrophages result in downregulated of endogenous miR-206-3p and miR-381-3p and upregulation of PPP3CA and iNOS expression.	31609387
9445	Human	hsa-miR-381-3p	miRNA	fingolimod	relapsing-remitting multiple sclerosis (RRMS)	peripheral blood	Fingolimod treatment	upregulated	32215780
9446	Human	hsa-miR-382	miRNA	hypoxia	gastric cancer (GC)	MKN1 human gastric cancer cells	hypoxia treatment	upregulated	24914051
9447	Human	hsa-miR-382	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
9448	Human	hsa-miR-382	miRNA	polydatin (PD)	colorectal cancer (CRC)	The CRC cell lines (Caco-2 and HCT 116)	Polydatin treatment	upregulated	31755739
9449	Human	hsa-miR-382	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human kidney epithelial cell HK-2	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	"Knockdown of miR-382, which was upregulated by TGF-¦Â1,attenuated TGF-¦Â1-induced loss of the epithelial marker E-cadherin"	20716515
9450	Human	hsa-miR-382	miRNA	heroin	human immunodeficiency virus (HIV)-1 infection	Peripheral blood	Heroin treatment	downregulated	26583016
9451	Human	hsa-miR-382	miRNA	morphine	human immunodeficiency virus (HIV)-1 infection	peripheral blood mononuclear cells(PBMCs)	morphine treatment	downregulated	21224041
9452	Human	hsa-miR-382	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	downregulated	29172709
9453	Human	hsa-miR-382	miRNA	propranolol (PRO)	infantile hemangioma (IH)	XPTS-1 cells	propranolol treatment	downregulated	28112362
9454	Human	hsa-miR-382	miRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells	high levels of phosphate treatment	downregulated	28522697
9455	Human	hsa-miR-382-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human OA chondrocytes	IL-1¦Â treatment	downregulated	31144313
9456	Human	hsa-miR-382-5p	miRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	upregulated	30453015
9457	Human	hsa-miR-382-5p	miRNA	TGF-¦Â	epidural fibrosis	Primary human fibroblasts	TGF-¦Â treatment	upregulated	29949138
9458	Human	hsa-miR-382-5p	miRNA	diesel exhaust particle (DEP)	PM 2.5 or DEPs-induced inflammatory response	HBE cells	diesel exhaust particle (DEP) exposure	The expression level of miR-382-5p was downregulated after exposure to DEPs.	32146367
9459	Human	hsa-miR-382-5p	miRNA	particulate matter (PM2.5)	PM 2.5 or DEPs-induced inflammatory response	HBE cells	fine particulate matter (PM 2.5) exposure treatment	The expression level of miR-382-5p was downregulated in HBE cells after exposure to PM 25	32146367
9460	Human	hsa-miR-382-5p	miRNA	TGF-¦Â1	primary myelofibrosis (PMF)	PMF CD34+ cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30259659
9461	Human	hsa-miR-383	miRNA	high glucose (HG)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31994599
9462	Human	hsa-miR-383	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 human RPE cell lines	high glucose	upregulated	28559987
9463	Human	hsa-miR-383	miRNA	high glucose (HG)	diabetic retinopathy (DR)		high glucose treatment	AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of ARPE-19 cells by downregulating miR-383.	31391356
9464	Human	hsa-miR-383	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	downregulated	24589211
9465	Human	hsa-miR-383-5p	miRNA	resveratrol	diabetic nephropathy (DN)	human podocytes	resveratrol (RS) treatment	downregulated	28374806
9466	Human	hsa-miR-384	miRNA	luteolin	colorectal cancer (CRC)	HT-29 cells	"Luteolin (3,4,5,7-tetrahydroxyflavone) treatment"	upregulated	31059061
9467	Human	hsa-miR-384	miRNA	high glucose (HG)	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	CircBPTF knockdown protected against HG-induced inflammatory injuries and oxidative stress by mediating the miR-384/LIN28B axis in HUVECs.	32524321
9468	Human	hsa-miR-384	miRNA	curcumin (Cur)	non-small cell lung cancer (NSCLC)	"NSCLC cells (H1650, H1299, H460, A549)"	curcumin treatment	"After curcumin treatment, the expression tendency of circ-PRKCA, miR-384, and ITGB1 in NSCLC cells was overturned."	33684690
9469	Human	hsa-miR-3907	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
9470	Human	hsa-miR-3911	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9471	Human	hsa-miR-3923	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	downregulated	30100735
9472	Human	hsa-miR-3928	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
9473	Human	hsa-miR-3928-5p	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-3928-5p was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
9474	Human	hsa-miR-3928-5p	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-3928-5p was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
9475	Human	hsa-miR-3928v	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HBV (+) HCC tissues	hepatitis B virus (HBV) infection	upregulated	29378599
9476	Human	hsa-miR-3929	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
9477	Human	hsa-miR-3935	miRNA	sodium butyrate (NaB)	lung cancer	A549 cells	sodium butyrate(NaB) treatment	upregulated	29231270
9478	Human	hsa-miR-3940-5p	miRNA	thymosin ¦Á1 (T¦Á1)	non-segmental vitiligo (NSV)	peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV)	thymosin ¦Á1 (T¦Á1) treatment	downregulated	25495156
9479	Human	hsa-miR-3941	miRNA	lipopolysaccharide (LPS)	acute pancreatitis (AP)	A549 cells	lipopolysaccharides (LPS) treatment	downregulated	29328418
9480	Human	hsa-miR-3941	miRNA	lipopolysaccharide (LPS)	acute pneumonia	A549 cells	lipopolysaccharide (LPS) treatment	LPS treatment also resulted in a significantly decreased expression of miR-3941 in A549 cells.	29328418
9481	Human	hsa-miR-399-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta vascular smooth muscle cells (HA-VSMCs); human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ANRIL promoted AS progression by sponging miR-399-5p and regulating RAS/RAF/ERK signal pathway.	32141564
9482	Human	hsa-miR-409-3p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
9483	Human	hsa-miR-409-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
9484	Human	hsa-miR-410	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29518604
9485	Human	hsa-miR-410	miRNA	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P)	early non-genotoxic events	HepaRG cells	human genotoxic carcinogens aflatoxin B1 (AFB1) and benzo[a]pyrene (B[a]P) treatment	upregulated	26609139
9486	Human	hsa-miR-410	miRNA	aflatoxin B1 (AFB1)	genotoxicity	HepaRG cells	aflatoxin B1 (AFB1) treatment	upregulated	26609139
9487	Human	hsa-miR-410	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
9488	Human	hsa-miR-410	miRNA	andes hantavirus (ANDV)	liver damage	human endothelial cells (ECs)	andes hantavirus (ANDV) infection	downregulated	20844033
9489	Human	hsa-miR-410	miRNA	TGF-¦Â3	osteoarthritis (OA)	human bone marrow mesenchymal stem cells	TGF-¦Â3 treatment	upregulated	28123640
9490	Human	hsa-miR-410	miRNA	"rapamycin, doxorubicin , cisplatin"	osteosarcoma (OS)	U2OS and MG-63 human osteosarcoma cell lines	"rapamycin, doxorubicin , cisplatin treatment"	upregulated	28138700
9491	Human	hsa-miR-410	miRNA	vascular endothelial growth factor (VEGF)	osteosarcoma (OS)	OS cell lines	VEGF treatment	"restoration of VEGF reversed the effect of miR-410 on OS cells, and upregulated the expression of phosphorylated AKT"	25385479
9492	Human	hsa-miR-410	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	31067440
9493	Human	hsa-miR-410	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
9494	Human	hsa-miR-410	miRNA	vascular endothelial growth factor (VEGF)	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (hPAECs)	vascular endothelial growth factor (VEGF) treatment	downregulated	31289307
9495	Human	hsa-miR-410-3p	miRNA	vemurafenib	melanoma	A375 cells; G361 cells; SKMEL1 cells	vemurafenib treatment	miR-410-3p is induced by vemurafenib.	32555626
9496	Human	hsa-miR-410-3p	miRNA	calcium chloride or osteogenic medium	osteogenic-like differentiation	human renal interstitial fibroblasts (hRIFs)	calcium chloride or osteogenic medium treatment	Suppression of osteogenic-like differentiation in human renal interstitial fibroblasts by miRNA-410-3p through MSX2	33209671
9497	Human	hsa-miR-410-3p	miRNA	magnoflorine	osteosarcoma (OS)	MG-63 cells; U-2 OS cells	Magnoflorine treatment	"Magnoflorine significantly suppressed HMGB1 expression and NF-¦ÊB activation, but upregulated miR-410-3p level."	32553931
9498	Human	hsa-miR-410-3p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	human pancreatic cancer xenograft (HPCx) in mouse	gemcitabine treatment	downregulated	29296182
9499	Human	hsa-miR-411	miRNA	curcumin (Cur)	prostate cancer	22Rv1 cells	curcumin treatment	upregulated	29172709
9500	Human	hsa-miR-411	miRNA	IL-1¦Â	osteoarthritis (OA)	C28/I2 cells	IL-1¦Â treatment	miRNA-411 Regulates Chondrocyte Autophagy in Osteoarthritis by Targeting Hypoxia-Inducible Factor 1 alpha (HIF-1¦Á)	32072994
9501	Human	hsa-miR-411	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
9502	Human	hsa-miR-421	miRNA	"chlorpromazine, haloperidol and clozapine"	psychosis	JM-Jurkat T-lymphocytes	"chlorpromazine, haloperidol and clozapine treatment"	dysregulated	24480591
9503	Human	hsa-miR-421	miRNA	lidocaine	cervical cancer (CC)	HeLa cells	lidocaine treatment	lidocaine inhibited the growth of cervical cancer cells by modulating the lncRNA-MEG3/miR-421/BTG1 signaling pathway	31632519
9504	Human	hsa-miR-421	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	human GC MGC-803 cells	5-fluorouracil (5-FU) treatment	upregulated	31115533
9505	Human	hsa-miR-421	miRNA	Helicobacter pylori (H. pylori) extract (HPE)	gastric cancer (GC)	HGC-27 cells	Helicobacter pylori (H. pylori) infection	upregulated	33065487
9506	Human	hsa-miR-421	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	A172 cells; U251 cells	temozolomide (TMZ) treatment	"Circ-HIPK3 was obviously increased in TMZ-resistant glioma cells and their exosomes, miR-421, was downregulated in TMZ-resistant glioma"	32644821
9507	Human	hsa-miR-421	miRNA	lidocaine	hepatocellular carcinoma (HCC)	HCC cells	?lidocaine treatment	"circ_ITCH and CPEB3 levels were decreased in hepatocellular carcinoma tissues and cells, and were restored in cells via lidocaine treatment"	33433806
9508	Human	hsa-miR-421	miRNA	bitter melon seed water extract (BMSW)	hepatocellular carcinoma (HCC)	HepG2 cells	Bitter melon seed water extract (BMSW) treatment	The expression level of miR-421 in HepG2 was distinctly downregulated by 13.74 fold with 600 ?g/ml of BMSW.	33844303
9509	Human	hsa-miR-421	miRNA	tunicamycin (TM)	vitiligo	human melanocytes	tunicamycin (TM) treatment	upregulated	31974624
9510	Human	hsa-miR-422a	miRNA	"chenodeoxycholic acid, GW4064"	bile acid synthesis	human primary hepatocytes	"chenodeoxycholic acid, GW4064 treatment"	upregulated	20351063
9511	Human	hsa-miR-422a	miRNA	fibroblast growth factor 19 ( FGF19)	bile acid synthesis	human primary hepatocytes	fibroblast growth factor ( FGF)19 treatment	upregulated	20351063
9512	Human	hsa-miR-422a	miRNA	doxorubicin (DOX)	gastric cancer (GC)	BGC823 cells	doxorubicin (DOX) treatment	The results showed that the miR-422a level was markedly elevated 6 hr after DOX stimulation.	30195778
9513	Human	hsa-miR-422a	miRNA	IFN-¦Á	human immunodeficiency virus (HIV)-1 infection	PBMC	TNF-¦Á treatment	downregulated	25275557
9514	Human	hsa-miR-422a	miRNA	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	NCI cells; FaDu cells	tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment	downregulated	32326378
9515	Human	hsa-miR-422a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuron apoptosis	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32999283
9516	Human	hsa-miR-422a	miRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	metformin treatment	upregulated	32143184
9517	Human	hsa-miR-422a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells; primary human hepatocytes (HH)	palmitic acid (PA) treatment	downregulated	32143184
9518	Human	hsa-miR-422a	miRNA	TGF-¦Â1	oral squamous cell carcinoma (OSCC)	"human OSCC cell lines (Te13, Te1 , Eca109)"	TGF-¦Â1 treatment	Microarray analysis revealed that miR-422a exhibited the greatest downregulated (fold change: 022) in the presence of TGF-¦Â1	33107637
9519	Human	hsa-miR-422a	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-422a was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
9520	Human	hsa-miR-422a	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-422a was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
9521	Human	hsa-miR-422a	miRNA	high iodine	thyroid cancer (TC)	"TPC-1cells, K1 cells and Nthy-3 cells"	high iodine	downregulated	28992617
9522	Human	hsa-miR-423	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	HMEEC	lipopolysaccharide (LPS) treatment	upregulated	21377743
9523	Human	hsa-miR-423	miRNA	zirconia and titanium	bone formation	Osteoblast-like cells (MG63)	zirconia and titanium? treatment	upregulated	18241218
9524	Human	hsa-miR-423	miRNA	lanthionine	lanthionine toxicity	EA.hy926 cell cultures	lanthionine treatment	downregulated	31071929
9525	Human	hsa-miR-423	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
9526	Human	hsa-miR-423	miRNA	low fat diet (LFD)	overweight and obese	plasma	low fat diet (LFD) treatment	downregulated in plasma	29233590
9527	Human	hsa-miR-423	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
9528	Human	hsa-miR-423	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	upregulated	28534445
9529	Human	hsa-miR-423-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
9530	Human	hsa-miR-423-5	miRNA	IL-1¦Â	disc degeneration	NP cells	IL-1¦Â treatment	upregulated	32467560
9531	Human	hsa-miR-423-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	human kidney (HK-2) cells	hypoxia/reoxygenation (H/R) treatment	upregulated	29137244
9532	Human	hsa-miR-423-5p	miRNA	T-helper type 2 (Th2)-biased cytokine environment 	allergic asthma (AA)	Bronchial epithelial cells	T-helper type 2 (Th2)-biased cytokine environment treatment	downregulated	26289417
9533	Human	hsa-miR-423-5p	miRNA	doxorubicin (DOX)	"cardiotoxicity,cardiomyopathy and heart failure"	female patients from the placebo arm	doxorubicin treatment	upregulated	28052002
9534	Human	hsa-miR-423-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	upregulated	31455213
9535	Human	hsa-miR-423-5p	miRNA	chaenomeles speciosa (CSTT)	gastric injury	GES-1 cells	Chaenomeles speciosa (CSTT) treatment	CSTT obviously downregulated miR-423-5p mRNA.	31895380
9536	Human	hsa-miR-423-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Hepatocellular carcinoma (HCC) cells	sorafenib treatment	upregulated	25782064
9537	Human	hsa-miR-423-5p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
9538	Human	hsa-miR-423-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
9539	Human	hsa-miR-423-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	Our data showed that MPP+?induced UCA1 expression in SK-N-SH cells.	33464446
9540	Human	hsa-miR-423-5p	miRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	Exosomes were isolated from MDA-MB-231 cells	cisplatin treatment	upregulated	31424364
9541	Human	hsa-miR-424	miRNA	lipopolysaccharide (LPS)	graft-versus-host disease (GVHD)	Cord blood (CB)	lipopolysaccharide (LPS) treatment	upregulated	21913990
9542	Human	hsa-miR-424	miRNA	CoCl2	acute mountain sickness (AMS)	Human pulmonary microvascular ECs (HPMECs) and HUVECs	CoCl2 treatment	upregulated	31461385
9543	Human	hsa-miR-424	miRNA	hypoxia	acute mountain sickness (AMS)	Human pulmonary microvascular ECs (HPMECs) and HUVECs	hypoxia induce	upregulated	31461385
9544	Human	hsa-miR-424	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human alveolar epithelial cells A549 and BEAS-2B	lipopolysaccharide (LPS) treatment	downregulated	31881228
9545	Human	hsa-miR-424	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells; BEAS-2B cells	lipopolysaccharide (LPS) treatment	downregulated	31881228
9546	Human	hsa-miR-424	miRNA	hypoxia	apoptosis	A375;U251;HCT116;HEK293T cells	hypoxia treatment	upregulated	24967963
9547	Human	hsa-miR-424	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
9548	Human	hsa-miR-424	miRNA	VEGF or basic fibroblast growth factor (bFGF)	tumorigenesis	endothelial vascellum	VEGF or basic fibroblast growth factor (bFGF) treatment	upregulated	21885851
9549	Human	hsa-miR-424	miRNA	TGF-¦Â	cell cycle arrest	MCF-10A and MCF-12 cells	TGF-¦Â treatment	upregulated	25266660
9550	Human	hsa-miR-424	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA SNHG1 regulates OGD/R-induced cell death through serving as a ceRNA for miR-424 in SH-SY5Y cells	31900069
9551	Human	hsa-miR-424	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
9552	Human	hsa-miR-424	miRNA	TGF-¦Â1	lung fibrosis	human lung fibroblasts (HLFs)	TGF-¦Â1 treatment	miR-424 expression was increased by 26-fold in HLFs in response to TGF-¦Â1	32712053
9553	Human	hsa-miR-424	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
9554	Human	hsa-miR-424	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
9555	Human	hsa-miR-424	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	obesity	human visceral preadipocytes (HPA©\V cells)	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á treatment significantly downregulated the expression levels of miR-424 via binding to its promoter region and reducing its transcriptional activity	33179089
9556	Human	hsa-miR-424	miRNA	recombinant lentivirus	cell differentiation	hDPCs	recombinant lentivirus?infection treatment	downregulated	24331995
9557	Human	hsa-miR-424	miRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells	cisplatin treatment	"Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma."	31642110
9558	Human	hsa-miR-424	miRNA	cisplatin and doxorubicin	osteosarcoma (OS)	MG63 cells	cisplatin and doxorubicin treatment	"Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma."	31642110
9559	Human	hsa-miR-424	miRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells	doxorubicin treatment	"Circ-LARP4 high expression correlates with decreased Enneking stage and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging miR-424 in osteosarcoma."	31642110
9560	Human	hsa-miR-424	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
9561	Human	hsa-miR-424	miRNA	H2O2	oxidative stress	hTERT-transduced human adipose derived mesenchymal stem cells (hASCs)	H2O2 treatment	downregulated	28186136
9562	Human	hsa-miR-424	miRNA	IL-13	pulmonary arterial hypertension (PAH)	primary human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
9563	Human	hsa-miR-424	miRNA	IL-13	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
9564	Human	hsa-miR-424	miRNA	hypoxia	wilson's disease	human endothelial cells	Hypoxia treatment	downregulated	20972335
9565	Human	hsa-miR-424-3p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
9566	Human	hsa-miR-424-3p	miRNA	baicalin (BAI)	non-small cell lung cancer (NSCLC)	A549 and H460 cells	baicalin (BAI) treatment	downregulated	29392841
9567	Human	hsa-miR-424-5p	miRNA	ginsenoside Rg3	breast cancer	MCF-7 breast cancer cells	ginsenoside Rg3 treatment	upregulated	33477683
9568	Human	hsa-miR-424-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	Human cerebral microvascular endothelia cells (hCMEC/D3)	amyloid-¦Â (A¦Â) treatment	upregulated	31375213
9569	Human	hsa-miR-424-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Circ_0029589 silence might inhibit the progression of AS by regulating miR-424-5p/IGF2 axis	32860985
9570	Human	hsa-miR-424-5p	miRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	downregulated	33376537
9571	Human	hsa-miR-424-5p	miRNA	quinidine	cell proliferation and apoptosis	human glioma U87-MG cells	quinidine treatment	the upregulation of miR-149-3p and downregulated of miR-424-5p	25420507
9572	Human	hsa-miR-424-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	"Knockdown of CDKN2B-AS1 suppressed proliferation, ECM accumulation and PI3K/AKT signaling by increasing miR-424-5p and decreasing HMGA2 in high glucose-treated HMGC cells."	31707340
9573	Human	hsa-miR-424-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	downregulated	31707340
9574	Human	hsa-miR-424-5p	miRNA	ropivacaine	glioblastoma multiforme (GBM)	T98G cells; LN229 cells	ropivacaine treatment	upregulated	33817285
9575	Human	hsa-miR-424-5p	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Huh7-HBV;Hep3B-HBV cells	hepatitis B virus (HBV) infection	"Circ-RNF13 was upregulated in HBV-infected human HCC tissues and HBV-expressing cells (Huh7-HBV and Hep3B-HBV), accompanied with TGIF2 upregulation and miR-424-5p downregulated."	33714261
9576	Human	hsa-miR-424-5p	miRNA	saturated fatty acids (SFA) palmitate (PA)	obesity-induced hepatic insulin resistance	HepG2 cells	saturated fatty acids (SFA) palmitate (PA) treatment	miR-424-5p was upregulated in PA-treated HepG2 cells	30033101
9577	Human	hsa-miR-424-5p	miRNA	silver nanoparticles (AgNPs)	silver nanoparticles (SNPs) induced cytotoxicity	human dermal fibroblasts (HDFs)	silver nanoparticles (SNPs) treatment	upregulated	30305212
9578	Human	hsa-miR-424-5p	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
9579	Human	hsa-miR-425	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	acute respiratory distress syndrome (ARDS)	A549 and HFL-1 cells	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	downregulated	31934088
9580	Human	hsa-miR-425	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
9581	Human	hsa-miR-425	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
9582	Human	hsa-miR-425	miRNA	IL-1¦Â	gastric cancer (GC)	AGS cells	IL-1¦Â treatment	upregulated	24571667
9583	Human	hsa-miR-425	miRNA	angiotensin II (Ang II)	heart failure (HF)	Human adult atrial fibroblast primary cultures (NHCF-A)	angiotensin II (Ang II) treatment	downregulated	30392569
9584	Human	hsa-miR-425	miRNA	glucose	obesity and diabetes	Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and HepG2 cells	glucose treatment	upregulated	26892417
9585	Human	hsa-miR-425	miRNA	CuO nanowire fabricated with folic acid (CuO-Nw-FA)	triple negative breast cancer (TNBC)	MDAMB-231 cells	MDAMB-231 cells treatment	downregulated	26520043
9586	Human	hsa-miR-425-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCC cell lines	sorafenib treatment	upregulation	25040368
9587	Human	hsa-miR-425-3p	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells secreted exosomes	cisplatin (DPP) treatment	upregulated	31632022
9588	Human	hsa-miR-425-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9589	Human	hsa-miR-425-5p	miRNA	sodium arsenite (NaAsO2)	cardiovascular disease (CVD)	HUVECs	sodium arsenite (NaAsO2) treatment	downregulated	27132035
9590	Human	hsa-miR-425-5p	miRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	31711985
9591	Human	hsa-miR-425-5p	miRNA	high glucose (HG) and IL-1¦Â	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) and interleukin-1¦Â (IL-1¦Â) treatment	miR-425-5p was significantly upregulated in diabetic patients and human umbilical vein endothelial cells (HUVECs) treated with high glucose (HG) and interleukin-1¦Â (IL-1¦Â).	31711985
9592	Human	hsa-miR-425-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
9593	Human	hsa-miR-425-5p	miRNA	TGF-¦Â1	liver fibrosis	LX©\2 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31148365
9594	Human	hsa-miR-4257	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
9595	Human	hsa-miR-4262	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human lung fibroblast WI-38 cells and human PMVECs	lipopolysaccharide (LPS) treatment	MEG3 was downregulated by LPS and its knockdown aggravated LPS-induced injury of human lung cells through miR-4262-mediated downregulated of KLF4.	31184231
9596	Human	hsa-miR-4262	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	Caco-2 cells	dextran sulfate sodium (DSS) treatment	miR-4262 is upregulated in 2% DSS©\stimulated Caco-2 cells.	32765699
9597	Human	hsa-miR-4267	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
9598	Human	hsa-miR-4269	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
9599	Human	hsa-miR-4271	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9600	Human	hsa-miR-4274	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
9601	Human	hsa-miR-4274	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
9602	Human	hsa-miR-4275	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
9603	Human	hsa-miR-4281	miRNA	IL-2	immunological self-tolerance and suppress	human PBMCs	IL-2 treatment	upregulated	29282311
9604	Human	hsa-miR-4284	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
9605	Human	hsa-miR-4286	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32141990
9606	Human	hsa-miR-4287	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	downregulated	29806389
9607	Human	hsa-miR-4288	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
9608	Human	hsa-miR-4289	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	upregulated	26151338
9609	Human	hsa-miR-4289	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
9610	Human	hsa-miR-4289	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
9611	Human	hsa-miR-429	miRNA	Vitamin E ¦Ä-tocotrienol	breast cancer	TNBC cell lines (MDA-MB-231 and MDA-MB-468)	Vitamin E ¦Ä-tocotrienol treatment	upregulated	26629059
9612	Human	hsa-miR-429	miRNA	epstein-barr virus (EBV)	tumorigenesis	EBV-positive B-lymphocytic cell lines;Epithelial gastric carcinoma AGSB95.8 cells;MCF-7 cells (ATCC)	Epstein-Barr Virus (EBV) infection	downregulated	20668090
9613	Human	hsa-miR-429	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-429 expression levels were upregulated in cultured neurons with OGD/R treatment	29624520
9614	Human	hsa-miR-429	miRNA	hypoxia	chronic hypoxia	human endothelial cells	binder CO2/O2 incubator treatment	upregulated	25550463
9615	Human	hsa-miR-429	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	chronic hypoxia	endothelial cells	HIF1A treatment	"miR-429 attenuates HIF-1 activity by decreasing HIF1A message during the early stages of hypoxia before HIF-2 is activated, and this regulatory network helps explain the HIF-1 transition to HIF-2 during chronic hypoxia in endothelial cells."	25550463
9616	Human	hsa-miR-429	miRNA	high glucose (HG)	endothelial inflammation	human aortic endothelial cells (HAECs)	high glucose (HG) treatment	downregulated	29720943
9617	Human	hsa-miR-429	miRNA	tacrolimus (FK506)	epidural fibrosis	human fibroblasts	FK506 treatment	downregulated	28669722
9618	Human	hsa-miR-429	miRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	SW480 cells; HCT116 cells	metformin treatment	upregulated	30017802
9619	Human	hsa-miR-429	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	human GC AGS cells	soft-shelled turtle peptide treatment	differentlly regulated	29435044
9620	Human	hsa-miR-429	miRNA	hypoxia	hypoxic-related diseases	primary human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	miR-200b and miR-429 are upregulated in response to hypoxia.	29737439
9621	Human	hsa-miR-429	miRNA	hypoxia	myocardial ischaemic injury	human cardiomyocytes	hypoxia treatment	upregulated	27082497
9622	Human	hsa-miR-429	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	MiR-429 expression level was increased in LPS-stimulated WI-38 cells.	32003671
9623	Human	hsa-miR-429	miRNA	human papilloma viruses (HPVs) 16	oropharyngeal squamous cell carcinoma (OPSCC)	HOK-20B cells	human papillomaviruses (HPVs) 20 treatment	downregulated	31911577
9624	Human	hsa-miR-429	miRNA	H2O2	osteogenesis	human adipose-derived mesenchymal stem cells	hydrogen peroxid (H2O2) treatment	upregulated	31885708
9625	Human	hsa-miR-429	miRNA	H2O2	osteogenesis	hADMSCs	H2O2 treatment	upregulated	31885708
9626	Human	hsa-miR-429	miRNA	H2O2	renal cell carcinoma (RCC)	ACHN and Caki-1 cells	H2O2 treatment	downregulated	31550675
9627	Human	hsa-miR-429	miRNA	metformin (Met)	cell senescence	BJ-1 human diploid fibroblasts (HDFs)	metformin treatment	upregulated	22356767
9628	Human	hsa-miR-429	miRNA	Schizandrin A (SchA)	thyroid cancer (TC)	TC cell line TPC-1	Schizandrin A (SchA) treatment	downregulated	30909188
9629	Human	hsa-miR-429	miRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	hepatoma cells	Hepatitis B virus X protein (HBx)? treatment	downregulated	23471881
9630	Human	hsa-miR-429	miRNA	hypoxia	hypoxia-induced injury	primary human umbilical vein endothelial cells	hypoxia treatment	downregulated	26954587
9631	Human	hsa-miR-4291	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
9632	Human	hsa-miR-4295	miRNA	H2O2	glaucoma	human trabecular meshwork (HTM) cells	H2O2 treatment	downregulated	30594603
9633	Human	hsa-miR-4295	miRNA	H2O2 and Lycium barbarum polysaccharides (LBPs)	glaucoma	human trabecular meshwork (HTM) cells	H2O2 and Lycium barbarum polysaccharides (LBPs)  treatment	MiR-4295 expression was upregulated in H 2O 2 and LBPs treated cells.	30594603
9634	Human	hsa-miR-4295	miRNA	lycium barbarum polysaccharide (LBP)	glaucoma	H2O2 treated human trabecular meshwork (HTM) cells	Lycium barbarum polysaccharides (LBPs) treatment	upregulated	30594603
9635	Human	hsa-miR-4295	miRNA	propranolol (PRO)	infantile hemangioma (IH)	Human umbilical vein endothelial cells (HUVECs)	propranolol treatment	downregulated	30368887
9636	Human	hsa-miR-4295	miRNA	propranolol (PRO)	infantile hemangioma (IH)	human umbilical vein endothelial cells (HUVECs)	propranolol treatment	Propranolol treatment downregulated miR-4295 expression in HUVECs.	30368887
9637	Human	hsa-miR-4295	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
9638	Human	hsa-miR-4298	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9639	Human	hsa-miR-4298	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	downregulated	28534445
9640	Human	hsa-miR-4299	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
9641	Human	hsa-miR-4306	miRNA	MnCl2	neurodegeneration (ND)	SH-SY5Y cells	MnCl2 treatment	upregulated	28302480
9642	Human	hsa-miR-431	miRNA	IFN-¦Â	cell proliferation	human embryo-derived fibroblasts	IFN-¦Â? treatment	downregulated	22293894
9643	Human	hsa-miR-431	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
9644	Human	hsa-miR-431	miRNA	hypoxia	hepatocellular carcinoma (HCC)	SNU-387 cells; Huh7 cells	hypoxia treatment	miR-431 expression was reduced in SNU-387 and Huh7 cells under hypoxia treatment.	33193848
9645	Human	hsa-miR-431	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	downregulated	32807750
9646	Human	hsa-miR-431	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
9647	Human	hsa-miR-4310	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9648	Human	hsa-miR-4313	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
9649	Human	hsa-miR-431-5p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
9650	Human	hsa-miR-4317	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
9651	Human	hsa-miR-4319	miRNA	IL-4	macrophage polarization	peripheral blood mononuclear cells (PBMCs)	IL-4 treatment	downregulated	31267263
9652	Human	hsa-miR-432	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
9653	Human	hsa-miR-432	miRNA	thermal stress	heat shock	HeLa cells	were subjected to heat shock at 42C for 60 min and kept at 37C for 4 h treatment	upregulated	25280995
9654	Human	hsa-miR-432	miRNA	dopamine cocktail and retinoic acid	neuronal differentiation	SH-SY5Y and IMR-32 cells	were dopamine cocktail and retinoic acid treatment	dysregulated	24657437
9655	Human	hsa-miR-432	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
9656	Human	hsa-miR-432	miRNA	low fat diet (LFD)	overweight and obese	plasma	low fat diet (LFD) treatment	downregulated in plasma	29233590
9657	Human	hsa-miR-432	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9658	Human	hsa-miR-4320	miRNA	hypoxia	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	human KS-derived SLK and SLKK cells	hypoxia treatment	upregulated	28046107
9659	Human	hsa-miR-4324	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
9660	Human	hsa-miR-4327	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	downregulated	28397044
9661	Human	hsa-miR-4328	miRNA	everolimus	lung cancer	A549 cells	everolimus (EVE) treatment	downregulated	31612036
9662	Human	hsa-miR-433	miRNA	hypoxia	cerebral infarction (CI)	HUVECs	hypoxia treatment	downregulated	27815672
9663	Human	hsa-miR-433	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
9664	Human	hsa-miR-433	miRNA	manganese (Mn)	idiopathic Parkinson's disease	human neuroblastoma SH-SY5Y cells	manganese (100¦ÌM) treatment	downregulated	28986288
9665	Human	hsa-miR-433	miRNA	manganese (Mn)	manganese induced neurotoxic	SH-SY5Y cells	manganese treatment	The expressions of miR-7 and miR-433 significantly reduced upon manganese exposure.	28986288
9666	Human	hsa-miR-433	miRNA	hypoxia	neuron proliferation and migration	human umbilical vein vascular endothelial cells (HUVECs)	hypoxia treatment	downregulated	27815672
9667	Human	hsa-miR-433	miRNA	andrographolide	oxidative stress	HepG2 cells	andrographolide treatment	downregulated	30414976
9668	Human	hsa-miR-433	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
9669	Human	hsa-miR-4417	miRNA	nickel	epithelial-mesenchymal transition (EMT)	BEAS-2B and A549	nickel	upregulated	29127306
9670	Human	hsa-miR-4417	miRNA	TGF-¦Â inhibitor SB525334	epithelial-mesenchymal transition (EMT)	TGF-¦Â-treated BEAS-2B and A549	SB525334 treatment	downregulated	29127306
9671	Human	hsa-miR-4421	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
9672	Human	hsa-miR-4422	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"miR-4422 was downregulated in CNE-2 cells after treatment by radiation, while curcumin treatment upregulated the expression."	32127962
9673	Human	hsa-miR-4423-3p	miRNA	doxorubicin (DOX)	cardiotoxicity	human-induced pluripotent stem cell (hiPSC)	doxorubicin treatment	upregulated	26842497
9674	Human	hsa-miR-4425	miRNA	ginsenoside 20(S)-Rg3	ovarian cancer (OC)	SKOV3 cells; 3AO cells	ginsenoside 20(S)-Rg3 treatment	20(S)-Rg3 reduced miR-4425 to alleviate the malignant phenotypes of ovarian cancer cells.	32877662
9675	Human	hsa-miR-4428	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	downegulated	32323778
9676	Human	hsa-miR-4428	miRNA	hyperbaric oxygen (HBO)	hepatocellular carcinoma (HCC)	Hepatoma cell lines (BEL-7402 and SK-Hep1)	HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment	upregulated	24956259
9677	Human	hsa-miR-4430	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	upregulated	31549595
9678	Human	hsa-miR-4433	miRNA	suberoylanilide hydroxamic acid (SAHA)	chronic lymphocytic leukemia (CLL)	CML cells K562	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	31737104
9679	Human	hsa-miR-4433	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
9680	Human	hsa-miR-4433-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9681	Human	hsa-miR-4434	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
9682	Human	hsa-miR-4442	miRNA	prednisolone	polymyositis (PM)	plasma	prednisolone treatment	downregulated	29321815
9683	Human	hsa-miR-4446-3p	miRNA	mechanical compression	breast cancer	MDA-MB-231 cells and CAFs	mechanical compression treatment	upregulated	27027350
9684	Human	hsa-miR-4448	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
9685	Human	hsa-miR-4448	miRNA	IFN-¦Ã	corneal allograft rejection	human corneal epithelial cells (HCECs)	IFN-¦Ã treatment	downregulated	30013574
9686	Human	hsa-miR-4448	miRNA	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep)	gastric cancer (GC)	gastric and liver cancer cells	suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep) treatment	upregulated	24861464
9687	Human	hsa-miR-4448	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
9688	Human	hsa-miR-4448	miRNA	respiratory syncytial virus (RSV)	innate immune response	human dendritic cells	respiratory syncytial virus (RSV) infection treatment	upregulated	29970194
9689	Human	hsa-miR-4448	miRNA	titanium (Ti)	osteoblastic differentiation	human bone marrow mesenchymal stem cells (hMSCs)	Ti treatment	downregulated	24619927
9690	Human	hsa-miR-4455	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	downregulated	29435044
9691	Human	hsa-miR-4455	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
9692	Human	hsa-miR-4455	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	downregulated	25722110
9693	Human	hsa-miR-4458	miRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B cells	propofol treatment	miR-4458 was significantly increased by propofol	32705160
9694	Human	hsa-miR-4458	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H460 cells	cisplatin treatment	Circ-PRMT5 promoted DDP resistance via REV3L by sponging miR-4458 in NSCLC	32808744
9695	Human	hsa-miR-4459	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
9696	Human	hsa-miR-446	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
9697	Human	hsa-miR-4463	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33245416
9698	Human	hsa-miR-4463	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2	upregulated	28713907
9699	Human	hsa-miR-4463	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	30244253
9700	Human	hsa-miR-4463	miRNA	hypoxia	type 2 diabetes mellitus (T2DM)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	30244253
9701	Human	hsa-miR-4463	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular smooth muscle cell (VSMC) phenotypic switching	human aortic smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	Ox-LDL decreased the level of miR-4463.	33245416
9702	Human	hsa-miR-4465	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 and Hey-8	Paclitaxel (PTX) treatment	SDHAP1 was upregulated in PTX-resistant SKOV3 and Hey-8 ovarian cancer cell lines while the level of miR-4465 was downregulated	32211849
9703	Human	hsa-miR-4468	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
9704	Human	hsa-miR-4474	miRNA	fusobacterium nucleatum (F. nucleatum)	colorectal cancer (CRC)	The human epithelial colorectal cell line Caco-2	Fusobacterium nucleatum (F. nucleatum) infection	upregulated	30951563
9705	Human	hsa-miR-4478	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
9706	Human	hsa-miR-4478	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
9707	Human	hsa-miR-448	miRNA	hypoxia	antiarrhythmic	RL14 cells	hypoxia treatment	upregulated	33108349
9708	Human	hsa-miR-448	miRNA	"IFN-¦Á, IFN-¦Â, IFN-¦Ã, IFN-¦Ë1"	chronic hepatitis C virus (HCV) infection	Huh7 cells	"types I (IFN-¦Á, IFN-¦Â), II (IFN-¦Ã) and III (IFN-¦Ë1) interferons (IFNs) treatment"	dysregulated	24844965
9709	Human	hsa-miR-448	miRNA	platelet derived growth factor-BB (PDGF-BB)	coronary artery disease (CAD)	human VSMCs	PDGF-bb (20 ng/ml) treatment	upregulated	28799067
9710	Human	hsa-miR-448	miRNA	IL-1¦Â	osteoarthritis (OA)	Chondrocytes	IL-1¦Â treatment	The level of miR-448 was significantly higher in IL-1¦Â-induced chondrocytes.	29483929
9711	Human	hsa-miR-448	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN cells	hypoxia induce	upregulated	29561961
9712	Human	hsa-miR-448	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	plasma	Mycobacterium tuberculosis (MTB) treatment	downregulated	32048448
9713	Human	hsa-miR-4484	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	downregulated	30100735
9714	Human	hsa-miR-4485-3p	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	upregulated	33197057
9715	Human	hsa-miR-4485-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
9716	Human	hsa-miR-4485-5p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
9717	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	allergic asthma (AA)	16HBE cells	TGF-¦Â1 treatment	miR-448-5p was dramatically decreased in TGF-¦Â1-stimulated bronchial epithelial cells	30362537
9718	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	asthma	"Human bronchial epithelial cells, 16HBE"	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30362537
9719	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human bronchial epithelial cells, 16HBE"	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30362537
9720	Human	hsa-miR-448-5p	miRNA	TGF-¦Â1	lung fibrosis	"Human bronchial epithelial cells, 16HBE"	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	30362537
9721	Human	hsa-miR-4487	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH5Y-SY cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â 25-35 downregulated hsa-miR-4487 in SH-SY5Y cell lines associated with A¦Â-mediated pathophysiology.	30547775
9722	Human	hsa-miR-4488	miRNA	adeno-associated virus (AAV)	cellular physiology	Huh-7 cells; ARPE-19 cells	adeno-associated virus (AAV) serotypes 2 and 3 infection	downregulated	31629820
9723	Human	hsa-miR-4488	miRNA	adeno-associated virus (AAV)	adeno-associated virus (AAV) infection	ARPE-19 cells	adeno-associated virus (AAV) treatment	downregulated	31629820
9724	Human	hsa-miR-4488	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	Exosomes derived from human primary melanocytes	ultraviolet B (UVB) irradiation treatment	upregulated	32785244
9725	Human	hsa-miR-449	miRNA	IL-13	autophagy	BEAS-2B cells	IL-13 treatment	upregulated	28796252
9726	Human	hsa-miR-449	miRNA	corticosteroid	erythroid cell differentiation	bronchial epithelial? cells	corticosteroids treatment	downregulated	22955319
9727	Human	hsa-miR-449	miRNA	doxorubicin (DOX)	triple negative breast cancer (TNBC)	"The MDA-MB-231, MDA-MB-468, and MCF-7 breast cancer cell lines"	doxorubicin treatment	upregulated	30926829
9728	Human	hsa-miR-4496	miRNA	rebamipide	gastric cancer (GC)	cancer-initiating cells (C-IC)	Rebamipide treatment	upregulated	27265143
9729	Human	hsa-miR-4499	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9730	Human	hsa-miR-449a	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
9731	Human	hsa-miR-449a	miRNA	IL-1¦Â	cartilage destruction	chondrocytes	IL-1¦Â treatment	upregulated	27421775
9732	Human	hsa-miR-449a	miRNA	E2F transcription factor 1 (E2F1)	cell proliferation and apoptosis	HCT116 cells;H1299;U2OS;GH;833KE ;Saos-2 cells	E2F1 treatment	upregulated	19960022
9733	Human	hsa-miR-449a	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	human air-liquid-interface (ALI) airway cultures	cigarette smoke (CS)?exposure	"In particular, a time-dependent decrease in the expression of miR-449a, a conserved miRNA highly enriched in ciliated airway epithelia and implicated in motile ciliogenesis, was observed in CS-exposed cultures. Similar alterations in miR-449a have been reported in smokers with COPD."	33704509
9734	Human	hsa-miR-449a	miRNA	melatonin	colorectal cancer (CRC)	HCT116 cells	melatonin treatment	"Compared with the control group, melatonin significantly enhanced the expression levels of the miR-34a/449a cluster"	33398374
9735	Human	hsa-miR-449a	miRNA	neferine (NEF)	gastrointestinal stromal tumor (GIST)	GIST cell line GIST-T1	Neferin (Nef) treatment	upregulated	30551450
9736	Human	hsa-miR-449a	miRNA	bromopyruvate (3-BrPA)	glioblastoma multiforme (GBM)	Malignantly transformed macrophages (tM?); dendritic cells (tDC)	bromopyruvate (3-BrPA) treatment	upregulated	31710894
9737	Human	hsa-miR-449a	miRNA	bromopyruvate (3-BrPA)	glioblastoma multiforme (GBM)	Malignantly transformed macrophages (tM?) and dendritic cells (tDC) induced by glioma stem cells in the glioma microenvironment	bromopyruvate (3-BrPA) treatment	upregulated	31710894
9738	Human	hsa-miR-449a	miRNA	hepatitis C virus (HCV)	liver fibrosis	human Primary Hepatocytes£» HEPG2 Cell Line	hepatitis C virus (HCV) infection	downregulated	23226395
9739	Human	hsa-miR-449a	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	downregulated	31824817
9740	Human	hsa-miR-449a	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	A549 cells	at doses ranging from 4 to 8 Gy at 24 h	upregulated	28800787
9741	Human	hsa-miR-449a	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	A549 cells	ionizing radiation (IR) treatment	upregulated	28800787
9742	Human	hsa-miR-449a	miRNA	hypoxia	organs hypoxia	Primary human fibroblasts	hypoxia treatment	downregulated	20356416
9743	Human	hsa-miR-449a	miRNA	hypoxia	pressure ulcer (PU)	HaCaT cells	hypoxia treatment	circ-Ttc3 alleviated hypoxic injury and activated NF-¦ÊB and PI3K/AKT pathways by downregulating miR-449a in HaCaT cells.	32043754
9744	Human	hsa-miR-449a	miRNA	S-adenosyl-L-methionine (AdoMet)	triple negative breast cancer (TNBC)	MDA-MB-231; MDA-MB-468 cells	S-adenosyl-L-methionine (AdoMet) treatment	AdoMet exerts its antitumor effects in TNBC cells through upregulating the expression of miR-34c and miR-449a	33396625
9745	Human	hsa-miR-449b	miRNA	E2F transcription factor 1 (E2F1)	cell proliferation and apoptosis	HCT116 cells;H1299;U2OS;GH;833KE ;Saos-2 cells	E2F1 treatment	upregulated	19960022
9746	Human	hsa-miR-449b	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
9747	Human	hsa-miR-449b	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	NP69 cells	cisplatin (DPP) treatment	downregulated	29795279
9748	Human	hsa-miR-449b	miRNA	hypoxia	organs hypoxia	Primary human fibroblasts	hypoxia treatment	downregulated	20356416
9749	Human	hsa-miR-449b-3p	miRNA	acupuncture	in vitro fertilization and embryo transplantation	endometrial tissues	acupuncture treatment	downregulated	31824817
9750	Human	hsa-miR-449b-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	LN229 cells	hypoxia treatment	downregulated	32849915
9751	Human	hsa-miR-449b-5p	miRNA	radiation	radiation resistance of breast cancer (BRCA)	MCF©\7; T47D; LM©\MCF©\7; BT©\474;SKBR©\3; MDA©\MB©\231	radiation treatment	LncRNA HOTAIR facilitates the expression of HSPA1A by sequestering miR-449b-5p post-transcriptionally and thereby endows BRCA with radiation resistance	32374522
9752	Human	hsa-miR-449c	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteosarcoma tumorigenesis	human osteosarcoma cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28924385
9753	Human	hsa-miR-4500	miRNA	ursolic acid (UA)	colorectal cancer (CRC)	HCT116 and HT29 colorectal cancer cells	ursolic acid (UA) treatment	upregulated	30597956
9754	Human	hsa-miR-4505	miRNA	lipopolysaccharide (LPS)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	miR-4505 was highly expressed in HUVECs stimulated by LPS.	29115487
9755	Human	hsa-miR-4505	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9756	Human	hsa-miR-4505	miRNA	lipopolysaccharide (LPS)	vascular endothelial cell injury	HUVECs	lipopolysaccharide (LPS) treatment	upregulated	29115487
9757	Human	hsa-miR-4508	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9758	Human	hsa-miR-4508	miRNA	MnCl2	neurodegeneration (ND)	SH-SY5Y cells	MnCl2 treatment	upregulated	28302480
9759	Human	hsa-miR-450a	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
9760	Human	hsa-miR-450a	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
9761	Human	hsa-miR-450a	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
9762	Human	hsa-miR-450b-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
9763	Human	hsa-miR-450b-5p	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
9764	Human	hsa-miR-450b-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
9765	Human	hsa-miR-450b-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT-29 cells and HCT-116 cells	5-fluorouracil (5-FU) treatment	downregulated	26845645
9766	Human	hsa-miR-450b-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2 cells	curcumin treatment	"miR-450b-5p was upregulated in CNE-2 cells after treatment by radiation, while curcumin treatment downregulated the expression."	32127962
9767	Human	hsa-miR-451	miRNA	erythropoietin (EPO)	apoptosis	SH-SY5Y neuronal-like cells	EPO treatment	downregulated	25324845
9768	Human	hsa-miR-451	miRNA	tamoxifen (TAM)	breast cancer	breast cancer cell	Tamoxifen treatment	downregulated	21666713
9769	Human	hsa-miR-451	miRNA	hypoxia	cerebral ischemia injury (CII)	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	downregulated	31173234
9770	Human	hsa-miR-451	miRNA	docetaxel (DTX)	gastric cancer (GC)	MKN-45 cells	docetaxel (DTX) treatment	downregulated	33416185
9771	Human	hsa-miR-451	miRNA	propofol (PPF)	gastric cancer (GC)	SGC-7901 cell	Propofol treatment	upregulated	27173190
9772	Human	hsa-miR-451	miRNA	erythropoietin (EPO)	glioblastoma multiforme (GBM)	U87 human glioblastoma cell line	EPO treatment	downregulated	28629521
9773	Human	hsa-miR-451	miRNA	¦Â2 adrenergic agonist	glioblastoma multiforme (GBM)	1321N1 astrocytoma cells	a selective ¦Â2 adrenergic agonist treatment	upregulated	24714982
9774	Human	hsa-miR-451	miRNA	valproic acid (VPA)	hematopoietic differentiation	hematopoietic stem cells (HSCs)	VPA treatment	different regulation	25241289
9775	Human	hsa-miR-451	miRNA	microcystin-leucine arginine (MC-LR)	liver damage	HL7702 cells	Microcystin-LR treatment	downregulated	30875960
9776	Human	hsa-miR-451	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	upregulated	28347920
9777	Human	hsa-miR-451	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC tissues and cell lines	cisplatin treatment	"?TATDN1 and TRIM66 was significantly upregulated while miR-451 was downregulated in NSCLC tissues and cell lines, especially in DDP-resistant tumor tissues and cells."	30481109
9778	Human	hsa-miR-451	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H157 cells	cisplatin treatment	downregulated	30481109
9779	Human	hsa-miR-451	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	HepG2 cells	Hypoxia treatment	upregulated	20110569
9780	Human	hsa-miR-451	miRNA	resistance exercise training	skeletal muscle hypertrophy	Vastus lateralis biopsies	resistance exercise training treatment	upregulated	21030674
9781	Human	hsa-miR-451	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
9782	Human	hsa-miR-451-1	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	human T-cell lines	infect with HHV-6A	upregulated	28081700
9783	Human	hsa-miR-4516	miRNA	BET inhibitors (JQ1)	anaplastic thyroid carcinoma (ATC)	ATC-derived cell lines (SW1736 and 8505c)	treat with either 5 ?M JQ1	downregulated	29251329
9784	Human	hsa-miR-4516	miRNA	BET inhibitors (JQ1)	anaplastic thyroid carcinoma (ATC)	SW1736 cells; 8505c cells	BET inhibitors (JQ1) treatment	upregulated	29251329
9785	Human	hsa-miR-4516	miRNA	melatonin	chronic kidney disease (CKD)	mesenchymal stem/stromal cell (MSC)	melatonin treatment	upregulated	31989677
9786	Human	hsa-miR-4516	miRNA	coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	16HBE cells	coxsackievirus A16 (CV-A16) treatment	upregulated	29686973
9787	Human	hsa-miR-4516	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	16HBE cells	Enterovirus 71 (EV71) infection	downregulated	29686973
9788	Human	hsa-miR-4516	miRNA	cyclosporine A (CsA)	nephrotoxicity	human proximal tubule cells	cyclosporine A treatment	dysregulated	28925592
9789	Human	hsa-miR-4516	miRNA	particulate matter (PM2.5)	non-small cell lung cancer (NSCLC)	A549 cells	particulate matter (PM2.5) treatment	upregulated	27329587
9790	Human	hsa-miR-4516	miRNA	photochemotherapy with psoralens and ultraviolet A (PUVA)	psoriasis	human keratinocytes (HaCaT cells)	PUVA treatment	upregulated	24610393
9791	Human	hsa-miR-4516	miRNA	house dust mite (HDM)	lung fibrosis	serum	dust exposure	upregulated	30090591
9792	Human	hsa-miR-451a	miRNA	common aeroallergens	asthma	peripheral blood lymphocytes	common aeroallergens treatment	downregulated of miRNA-451a Promotes the Differentiation of CD4+ T Cells towards Th2 Cells by Upregulating ETS1 in Childhood Asthma	33271553
9793	Human	hsa-miR-451a	miRNA	head-down tilt (HDT) bed rest	bone loss	male volunteers	invited to participate in the 45 days of 15¡ã HDT bed rest experiment	downregulated	28261104
9794	Human	hsa-miR-451a	miRNA	microcystin-leucine arginine (MC-LR)	cytoskeletal reorganization	HL7702 liver cells	microcystin (MC)-LR treatment	downregulated	30422063
9795	Human	hsa-miR-451a	miRNA	paroxetine	depression	serum	paroxetine treatment	upregulated	29791588
9796	Human	hsa-miR-451a	miRNA	4-hydroxynonenal (4-HNE)	diabetic retinopathy (DR)	RPE cells	4-hydroxynonenal (4-HNE) treatment	The expression of miR-451a was downregulated both in the retina of Akita mice and 4-hydroxynonenal (4-HNE)-treated RPE cells.	30576241
9797	Human	hsa-miR-451a	miRNA	simvastatin	endometriosis	Serum	simvastatin treatment	downregulated	29587611
9798	Human	hsa-miR-451a	miRNA	hydroquinone (HQ)	erythroid cell differentiation	CD34 + hematopoietic progenitor cells	hydroquinone (HQ) treatment	downregulated	28733890
9799	Human	hsa-miR-451a	miRNA	glucocorticoid (GC)	glucocorticoid-induced osteoporosis (GIOP)	vertebral samples	treatment	upregulated	30503955
9800	Human	hsa-miR-451a	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
9801	Human	hsa-miR-451a	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
9802	Human	hsa-miR-451a	miRNA	hydroquinone (HQ)	hematotoxicity	CD34 hematopoietic progenitor cells	treat with HQ	downregulated	28733890
9803	Human	hsa-miR-451a	miRNA	endothelin-1 (ET-1)	cardiac dysfunction	Cor.4U human inducible pluripotent stem cell-derived cardiomyocytes (hiPS-CMs)	endothelin-1 (ET-1) treatment	downregulated	31618079
9804	Human	hsa-miR-451a	miRNA	hypoxia	cardiac dysfunction	Cor.4U human inducible pluripotent stem cell-derived cardiomyocytes (hiPS-CMs)	hypoxia induce	downregulated	31618079
9805	Human	hsa-miR-451a	miRNA	acidic bile	hypopharyngeal cancer	human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	acidic bile exposure	downregulated	29516639
9806	Human	hsa-miR-451a	miRNA	BAY11-7082	hypopharyngeal cancer	Acidic bile-exposed human hypopharyngeal primary cells (HHPC) (2nd passage) and telomerase-immortalized human hypopharyngeal keratinocytes (HHK) (4th passage)	BAY 11-7082 treatment	upregulated	29516639
9807	Human	hsa-miR-451a	miRNA	doxorubicin (DOX)	lung cancer	A549 cells; PC9 cells	doxorubicin (Dox) treatment	upregulated	32106373
9808	Human	hsa-miR-451a	miRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	human normal liver cell line HL7702	icrocystin-LR (MC-LR) treatment	downregulated	29265921
9809	Human	hsa-miR-451a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
9810	Human	hsa-miR-451a	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
9811	Human	hsa-miR-451a	miRNA	noise	noise-induced hearing loss (NIHL)	plasma	noise treatment	downregulated	26278637
9812	Human	hsa-miR-451a	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	"free fatty acids (FFAs; oleate/palmitate, 2:1 ratio) treatment"	downregulated	29604329
9813	Human	hsa-miR-451a	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	upregulated	31452742
9814	Human	hsa-miR-451a	miRNA	radiation	oesophageal adenocarcinoma (OAC)	OE19 cells	radiation treatment	Inhibition of miR-451a in the radiation resistant OAC cell line OE19 increased radiosensitivity	33255413
9815	Human	hsa-miR-451a	miRNA	4-hydroxynonenal (4-HNE)	proliferative diabetic retinopathy (PDR)	ARPE-19 cells and primary human RPE cells	4-hydroxynonenal (4-HNE) treatment	downregulated	30576241
9816	Human	hsa-miR-451a	miRNA	radon radiation	ionizing radiation (IR) injury	Blood samples	radon radiation treatment	downregulated	32165872
9817	Human	hsa-miR-452	miRNA	adriamycin (ADR)	breast cancer	adriamycin-resistant MCF-7 cells (MCF-7/ADR)	adriamycin (ADR) treatment	downregulated	25040964
9818	Human	hsa-miR-452	miRNA	hypoxia	sleep apnea syndrome (SAS)	human SW872 adipocytes	hypoxia treatment	downregulated	31013606
9819	Human	hsa-miR-4521	miRNA	hypoxia	gastric cancer (GC)	GC cells	hypoxia treatment	Further studies showed that hypoxia repressed miR-4521 expression via inducing ETS1 and miR-4521 mitigated hypoxia-mediated metastasis	33407516
9820	Human	hsa-miR-4521	miRNA	microcystin-leucine arginine (MC-LR)	hepatotoxicity	human normal liver cell line HL7702	"treatment with MC-LR at concentrations of 1, 2.5, 5 or 10 ¦ÌM"	downregulated	29265921
9821	Human	hsa-miR-4521	miRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	human normal liver cell line HL7702	icrocystin-LR (MC-LR) treatment	downregulated	29265921
9822	Human	hsa-miR-452-3p	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
9823	Human	hsa-miR-4525	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9824	Human	hsa-miR-452-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose treatment	upregulated	31849505
9825	Human	hsa-miR-452-5p	miRNA	sunitinib (SU)	metastatic renal cell carcinoma (mRCC)	OSRC-2 and SW839 cells	sunitinib treatment	downregulated	30419914
9826	Human	hsa-miR-453	miRNA	cisplatin (DDP)	cell death	A549 cell	cisplatin (DPP) treatment	downregulated	21880462
9827	Human	hsa-miR-4530	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	downregulated	31359311
9828	Human	hsa-miR-4532	miRNA	ultraviolet (UV) irradiation	cataract	human lens epithelial cells (HLECs)	Ultra-violet radiation (UVR) exposure treatment	"Functional studies show that UVR-induced cytotoxicity and apoptosis in HLECs were potentiated by miR-4532 overexpression, Nrf2 depletion or SIRT6 shRNA"	31079921
9829	Human	hsa-miR-454	miRNA	cisplatin (DDP)	cisplatin (DDP) resistance	A2780; SKOV3	cisplatin treatment	CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.	32124583
9830	Human	hsa-miR-454	miRNA	advanced glycation end product (AGE)	epithelial-mesenchymal transition (EMT)	primary human peritoneal mesothelial cells (HPMCs)	advanced glycation end products (AGEs) treatment	"iRNA-454, potentially targeting STAT3, was downregulated in AGEs-treated HPMCs. Overexpression of miRNA-454 prevented AGEs- induced EMT in HPMCs."	30820783
9831	Human	hsa-miR-454	miRNA	placenta growth factor (PlGF)	lung fibrosis	endothelial cells	placenta growth factor (PlGF) treatment	downregulated	26460070
9832	Human	hsa-miR-454	miRNA	TGF-¦Â1	schistosomiasis	LX-2 cells	TGF-¦Â1 treatment	downregulated	24685242
9833	Human	hsa-miR-454-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	?human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"In the present study, the results revealed that miR-454-3p expression was substantially downregulated in human aortic endothelial cells (HAECs) following oxidized low-density lipoprotein (ox-LDL) treatment."	33732296
9834	Human	hsa-miR-454-3p	miRNA	X-rays	laryngeal cancer	"Laryngeal cancer cell lines TU212, LLN and TU686"	X-ray radiation treatment	HOTAIR knockdown reduced laryngeal cancer cell radiosensitivity by sponging miR-454-3p to silence E2F2	31849488
9835	Human	hsa-miR-454-3p	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
9836	Human	hsa-miR-454-3p	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; H157 cells	cisplatin treatment	miR-454-3p was expressed lower in cisplatin-resistant LUAD cells than that in the parental LUAD cells.	30099826
9837	Human	hsa-miR-454-3p	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	C666-1 cells; HNE1 cells	cisplatin treatment	elevated HOXA11-AS and reduced miR-454-3p were found in NPC tissue and cisplatin-resistant NPC cells.	33115978
9838	Human	hsa-miR-455	miRNA	arsenite	arsenite-induced carcinogenesis	human keratinocyte (HaCaT) cells	arsenite exposure	downregulated	29216394
9839	Human	hsa-miR-455	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â1 treatment	UCA1 exerted its role via regulating the UCA1/miR-455/ZEB1 regulatory axis in HUVECs treated with TGF-¦Â1	32584608
9840	Human	hsa-miR-455	miRNA	CoCl2	hypoxia-induced injury	Human lung epithelial cells BEAS-2B	CoCl2 treatment	downregulated	30193773
9841	Human	hsa-miR-455	miRNA	hydrogen sulfide (H2S)	hypoxia-induced injury	CoCl2-induced human lung epithelial cells BEAS-2B	hydrogen sulfide (H2S) treatment	upregulated	30193773
9842	Human	hsa-miR-455	miRNA	H2O2	oxidative stress	human endometrial stromal cells (HESCs)	hydrogen peroxide (H2O2) treatment	downregulated	31638263
9843	Human	hsa-miR-455-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	human neuroblastoma cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	28934394
9844	Human	hsa-miR-455-3p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
9845	Human	hsa-miR-455-3p	miRNA	TGF-¦Â	chronic obstructive pulmonary disease (COPD)	primary parenchymal lung fibroblasts	TGF-¦Â treatment	upregulated	28910321
9846	Human	hsa-miR-455-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMC) and human proximal tubule epithelial cells (HK-2)	high glucose (HG) treatment	downregulated	29932921
9847	Human	hsa-miR-455-3p	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	human mesangial cells (HMC) and human proximal tubule epithelial cells (HK-2)	transforming growth factor beta 1 (TGF-¦Â1) treatment	downregulated	29932921
9848	Human	hsa-miR-455-3p	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
9849	Human	hsa-miR-455-3p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
9850	Human	hsa-miR-455-3p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
9851	Human	hsa-miR-455-3p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
9852	Human	hsa-miR-455-3p	miRNA	bicyclol	idiopathic pulmonary fibrosis (IPF)	human lung epithelial cells HPAEpiC	bicyclol treatment	upregulated	31407409
9853	Human	hsa-miR-455-3p	miRNA	vehicle and bicyclol	idiopathic pulmonary fibrosis (IPF)	human pulmonary alveolar epithelial cells (HPAEpiCs)	vehicle and bicyclol treatment	upregulated	31407409
9854	Human	hsa-miR-455-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
9855	Human	hsa-miR-455-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	transforming growth factor ¦Â1 (TGF-¦Â1) treatment	downregulated	31150929
9856	Human	hsa-miR-455-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	cultured chondrocytes	interleukin-1¦Â (IL-1¦Â) treatment	downregulated	31508417
9857	Human	hsa-miR-455-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocyte cell line CHON-001	IL-1¦Â treatment	upregulated	31809639
9858	Human	hsa-miR-455-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	"miR-455-3p continued to increase in the first 21 days during chondrogenesis, peaked at day 21, and then declined."	32343998
9859	Human	hsa-miR-455-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32982172
9860	Human	hsa-miR-455-5p	miRNA	MLN4924/Pevonedistat	breast cancer	MCF-7 cells	MLN4924/Pevonedistat treatment	miR-455-5p was significantly decreased after MLN4924 treatment in breast cancer cells.	32360865
9861	Human	hsa-miR-455-5p	miRNA	intermittent cyclic mechanical tension (ICMT)	degeneration of endplate chondrocytes	human endplate cartilage tissues	Intermittent cyclic mechanical tension (ICMT)	downregulated	30132981
9862	Human	hsa-miR-455-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	human brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	CircPHC3 was highly expressed in human BMECs after OGD	33519202
9863	Human	hsa-miR-455-5p	miRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte	hypoxia induce	Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p.	30898696
9864	Human	hsa-miR-455-5p	miRNA	total flavonoids (TFs)	oxLDL-induced vascular smooth muscle cell inflammation	vascular smooth muscle cells	total flavones of Clematis filamentosa Dunn treatment	The total flavones of Clematis filamentosa Dunn promoted the expression of miR-455-5p.	33040830
9865	Human	hsa-miR-4634	miRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	downregulated	26151338
9866	Human	hsa-miR-4634	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	upregulated	27893811
9867	Human	hsa-miR-4634	miRNA	Human metapneumovirus (HMPV)	innate immune response	human dendritic cells	Human metapneumovirus (HMPV) infection	upregulated	29970194
9868	Human	hsa-miR-4634	miRNA	respiratory syncytial virus (RSV)	innate immune response	human dendritic cells	respiratory syncytial virus (RSV) infection treatment	upregulated	29970194
9869	Human	hsa-miR-4650	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	downregulated	25722110
9870	Human	hsa-miR-4651	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
9871	Human	hsa-miR-4653-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9872	Human	hsa-miR-4654	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
9873	Human	hsa-miR-4654	miRNA	alternariol (AOH)	cytotoxicity	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
9874	Human	hsa-miR-4654	miRNA	resveratrol	hypertrophic scars (HS)	HS-derived fibroblasts (HSFBs)	resveratrol (RS) treatment	microRNA-4654 (miR-4654) was significantly decreased in the HSFBs and re-upregulated by resveratrol treatment dose-dependently	32945452
9875	Human	hsa-miR-4656	miRNA	heat stress	heat-induced pathophysiology	human umbilical vein endothelial cells	cultured in the incubator at 43¡ãC for 1 h	"downregulated (miR-1281, miR-34c-5p , miR-140-5p) ;upregulated (miR-4448, miR-1231 , miR-4656)"	29039486
9876	Human	hsa-miR-466	miRNA	p53	esophageal squamous cell carcinoma (ESCC)	ESCC cell lines	?p53 overexpression treatment	downregulated	31185143
9877	Human	hsa-miR-4665-3p	miRNA	arsenic sulfide	gastric cancer (GC)	AGS cells	arsenic sulfide treatment	upregulated	31692505
9878	Human	hsa-miR-4665-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9879	Human	hsa-miR-4667-5p	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
9880	Human	hsa-miR-4668	miRNA	fluticasone	eosinophilic esophagitis (EoE)	salivary	fluticasone treatment	downregulated	32923026
9881	Human	hsa-miR-4669	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9882	Human	hsa-miR-467	miRNA	high glucose (HG)	angiogenesis	HUVECs;HDMECs;HAECs	?high glucose treatment	upregulated	23316333
9883	Human	hsa-miR-4680-3p	miRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	human embryonic palatal mesenchymal (HEPM) cells	all-trans retinoic acid (ATRA) treatment	We found that?all-trans?retinoic acid (atRA) specifically induces?miR-4680-3p?in cultured human embryonic palatal mesenchymal (HEPM) cells.	33585479
9884	Human	hsa-miR-4689	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
9885	Human	hsa-miR-4701-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
9886	Human	hsa-miR-4708	miRNA	titanium (Ti)	osteoblastic differentiation	human bone marrow mesenchymal stem cells (hMSCs)	Ti treatment	downregulated	24619927
9887	Human	hsa-miR-4709-3p	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular cells (HK-2)	TGF-¦Â1 treatment	upregulated	31455266
9888	Human	hsa-miR-4710	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
9889	Human	hsa-miR-4712-3p	miRNA	thymosin ¦Á1 (T¦Á1)	non-segmental vitiligo (NSV)	peripheral blood mononuclear cells (PBMC) of patients with non-segmental vitiligo (NSV)	thymosin ¦Á1 (T¦Á1) treatment	upregulated	25495156
9890	Human	hsa-miR-4715-3p	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
9891	Human	hsa-miR-4715-3p	miRNA	alternariol (AOH)	cytotoxicity	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
9892	Human	hsa-miR-4716-5p	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	downregulated	29860902
9893	Human	hsa-miR-4717	miRNA	fusobacterium nucleatum (F. nucleatum)	colorectal cancer (CRC)	The human epithelial colorectal cell line Caco-2	Fusobacterium nucleatum (F. nucleatum) infection	upregulated	30951563
9894	Human	hsa-miR-4717-3p	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9895	Human	hsa-miR-4726-5p	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
9896	Human	hsa-miR-4728-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
9897	Human	hsa-miR-4734	miRNA	aspirin	heart repair	mesenchymal stem cells (MSCs)	aspirin treatment	upregulated	32044414
9898	Human	hsa-miR-4739	miRNA	bleomycin (BLM)	pleural fibrosis	The human pleural mesothelial cells (PMCs)	bleomycin (BLM) treatment	upregulated	30850350
9899	Human	hsa-miR-4739	miRNA	TGF-¦Â1	pleural fibrosis	The human pleural mesothelial cells (PMCs)	TGF-¦Â1 treatment	upregulated	30850350
9900	Human	hsa-miR-4741	miRNA	herapy with transarterial chemoembolisation (TACE)	hepatocellular carcinoma (HCC)	HCC patients	TACE treatment	dysregulated	25230788
9901	Human	hsa-miR-4747-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
9902	Human	hsa-miR-4749-5p	miRNA	xanthohumol (XN)	glioblastoma multiforme (GBM)	A172 cells; U87-MG cells	xanthohumol (XN) treatment	upregulated	32422304
9903	Human	hsa-miR-4750	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
9904	Human	hsa-miR-4756	miRNA	albumin	diabetic nephropathy (DN)	HK-2 cells	albumin treatment	upregulated	30145827
9905	Human	hsa-miR-4756	miRNA	albumin	diabetic nephropathy (DN)	HK-2 cells	albumin treatment	Albumin stimulation significantly increased miR-4756 levels in HK-2 cells.	30145827
9906	Human	hsa-miR-4763-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
9907	Human	hsa-miR-4769-5p	miRNA	mechanical compression	breast cancer	MDA-MB-231 cells and CAFs	mechanical compression treatment	upregulated	27027350
9908	Human	hsa-miR-4773	miRNA	titanium (Ti)	osteoblastic differentiation	human bone marrow mesenchymal stem cells (hMSCs)	Ti treatment	downregulated	24619927
9909	Human	hsa-miR-4784	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
9910	Human	hsa-miR-4785	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	downregulated	25959385
9911	Human	hsa-miR-4788	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
9912	Human	hsa-miR-4792	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	upregulated	30100735
9913	Human	hsa-miR-4795-5p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	downregulated	26397152
9914	Human	hsa-miR-483	miRNA	sera from acute KD patients	acute Kawasaki disease (KD)	human umbilical vein endothelial cell	sera from acute KD patients treatment	downregulated	27923814
9915	Human	hsa-miR-483	miRNA	TGF-¦Â1	anaplastic thyroid carcinoma (ATC)	8505C cells; FRO cells	TGF-¦Â1 treatment	TGF-¦Â1 increases miR-483 expression and decreases Pard3 expression	30171257
9916	Human	hsa-miR-483	miRNA	tunicamycin (TM)	apoptosis	HEK293 cells	tunicamycin treatment	upregulated	31792031
9917	Human	hsa-miR-483	miRNA	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1)"	hepatocellular carcinoma (HCC)	Hep3B cells	"3¦Â,16¦Â,17¦Á-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-¦Â-D-xylopyranosyl)-(1¡ú3)- (2-O-acetyl-¦Á-L-arabinopyranoside) (OSW-1) treatment"	upregulated	23588479
9918	Human	hsa-miR-483	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29218085
9919	Human	hsa-miR-483-3p	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
9920	Human	hsa-miR-483-3p	miRNA	black raspberry (BRB) anthocyanins	colorectal cancer (CRC)	LoVo cells; SW480 cells; HCT116 cells	black raspberry (BRB) anthocyanins treatment	downregulated	31763724
9921	Human	hsa-miR-483-3p	miRNA	black raspberry (BRB) anthocyanins	colorectal cancer (CRC)	"Human HCT116 and HT29 CRC cell lines, LoVo cells and SW480 cells"	black raspberry (BRB) anthocyanins treatment	downregulated	31763724
9922	Human	hsa-miR-483-3p	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
9923	Human	hsa-miR-483-3p	miRNA	heartmate II left ventricular assist device (LVAD) implantation	heartmate II left ventricular assist device (LVAD) implantation therapy effect	plasma and myocardial samples	LVAD treatment	upregulated	24961598
9924	Human	hsa-miR-483-3p	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
9925	Human	hsa-miR-483-5p	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
9926	Human	hsa-miR-483-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	AC16 cells	hypoxia treatment	miR-483-5p were also upregulated in hypoxia-induced AC16 cell injury.	32206064
9927	Human	hsa-miR-483-5p	miRNA	statins	atherosclerosis (AS)	peripheral blood mononuclear cells (PBMCs)	statins? treatment	upregulated	32885808
9928	Human	hsa-miR-483-5p	miRNA	retinoic acid (RA)	breast cancer	Human embryonic kidney cells (HEK293T) ;HepG2 cells; Huh7  cells; adjacent non-tumor tissues	retinoic acid treatment	downregulated	22971576
9929	Human	hsa-miR-483-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
9930	Human	hsa-miR-483-5p	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
9931	Human	hsa-miR-483-5p	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
9932	Human	hsa-miR-483-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
9933	Human	hsa-miR-483-5p	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine (GEM) treatment	upregulated	25722110
9934	Human	hsa-miR-483-5p	miRNA	benzo(a)pyrene (BaP)	toxicity of Benzo[a]pyrene (BaP)	THBEc1 cells	benzo(a)pyrene (BaP) exposure	downregulated	32681969
9935	Human	hsa-miR-484	miRNA	forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	forskolin (Fsk) treatment	upregulated	33508847
9936	Human	hsa-miR-484	miRNA	polyalthia longifolia leaf extract	cell death	HeLa cells	Polyalthia longifolia leaf extract treatment	downregulated	31383043
9937	Human	hsa-miR-484	miRNA	5-fluorouracil (5-Fu)	diabetic nephropathy (DN)	?plasma	5-fluorouracil (5-FU) treatment	upregulated	24119443
9938	Human	hsa-miR-484	miRNA	5-fluorouracil (5-Fu)	metastatic colorectal cancer (mCRC)	mCRC patients	5-fluorouracil (5-FU) treatment	upregulated	24119443
9939	Human	hsa-miR-484	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
9940	Human	hsa-miR-484	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	downregulated	26298803
9941	Human	hsa-miR-484	miRNA	intercept (amotosalen+ ultraviolet-A [UVA] light)	pathogen reduction	platelet	gamma irradiation treatment	downregulated	24749844
9942	Human	hsa-miR-485	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SK-N-SH; SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Long Noncoding RNA MIR210HG Promotes the Warburg Effect and Tumor Growth by Enhancing HIF-1¦Á Translation in Triple-Negative Breast Cancer	31794744
9943	Human	hsa-miR-485	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	downregulated	31727371
9944	Human	hsa-miR-485	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	miR-485 expression is significantly decreased in HG-stimulated HMCs.	31727371
9945	Human	hsa-miR-485	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	human neuroblastoma cell lines SK-N-SH and SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31794744
9946	Human	hsa-miR-485	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	downregulated	30182373
9947	Human	hsa-miR-485	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	A549/cisplatin (A549/CDDP) cells	epigallocatechin-3-gallate (EGCG) treatment	upregulated	30182373
9948	Human	hsa-miR-485-3p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	SH-SY5Y Cells	amyloid-¦Â (A¦Â) treatment	upregulated	33220166
9949	Human	hsa-miR-485-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	33220166
9950	Human	hsa-miR-485-3p	miRNA	hypoxia	angiogenesis	Human Brain Microvascular Endothelial Cells (HBMEC)	hypoxia induce	downregulated	31737200
9951	Human	hsa-miR-485-3p	miRNA	paclitaxel (PTX)	breast cancer	SK-BR-3 cells	paclitaxel (PTX) treatment	downregulated	32897218
9952	Human	hsa-miR-485-3p	miRNA	IL-1¦Á	cutaneous lupus erythematosus	primary PBMCs isolated from discoid lupus erythematosus (DLE) patients	IL-1¦Á treatment	upregulated	30130620
9953	Human	hsa-miR-485-3p	miRNA	TGF-¦Â1	cutaneous lupus erythematosus	primary PBMCs isolated from discoid lupus erythematosus (DLE) patients	TGF-¦Â1 treatment	upregulated	30130620
9954	Human	hsa-miR-485-3p	miRNA	IL-1¦Á	discoid lupus erythematosus (DLE)	peripheral mononuclear blood cells from DLE patients	IL-1¦Á treatment	upregulated	30130620
9955	Human	hsa-miR-485-3p	miRNA	TGF-¦Â1	discoid lupus erythematosus (DLE)	peripheral mononuclear blood cells from DLE patients	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30130620
9956	Human	hsa-miR-485-3p	miRNA	ovalbumin (OVA)	pediatric asthma	Lymphocytes	ovalbumin (OVA) treatment	Upregulated	22895815
9957	Human	hsa-miR-485-3p	miRNA	fludarabine	prostate cancer	DU-145 cells	Fludarabine treatment	"?in fludarabine treated cells the release of miR-485-3p, as well as its association with exosomes, was reduced suggesting that miR-485-3p was retained by surviving cells"	23734815
9958	Human	hsa-miR-485-5p	miRNA	resveratrol	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	resveratrol (RS) treatment	upregulated	33718067
9959	Human	hsa-miR-485-5p	miRNA	TGF-¦Â1	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	TGF-¦Â1 treatment	downregulated	33718067
9960	Human	hsa-miR-485-5p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	upregulated	24927770
9961	Human	hsa-miR-485-5p	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	"A549, H1299, H460 cells"	epigallocatechin-3-gallate (EGCG) treatment	upregulated	30058740
9962	Human	hsa-miR-485-5p	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
9963	Human	hsa-miR-486	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
9964	Human	hsa-miR-486	miRNA	TGF-¦Â1 or bone morphogenetic protein 2 (BMP-2)	calcific aortic valve disease (CAVD)	human aortic valve interstitial cells (AVICs)	"TGF-¦Â1,BMP-2 treatment"	dysregulated	28377507
9965	Human	hsa-miR-486	miRNA	tocotrienol-rich fraction (TRF)	cell differentiation	senescent human skeletal muscle myoblasts (HSMM)	senescent human skeletal muscle myoblasts (HSMM) were treated with 50 ¦Ìg/mL TRF for 24 h treatment	upregulated	30519366
9966	Human	hsa-miR-486	miRNA	hypoxia	erythroid cell differentiation	TF-1 cells	hypoxia treatment	upregulated	28043832
9967	Human	hsa-miR-486	miRNA	hypoxia	erythroid cell differentiation	erythroleukemia TF-1 cells	hypoxia treatment	upregulated	28043832
9968	Human	hsa-miR-486	miRNA	cigarette smoke extract (CSE)	head and neck squamous cell carcinoma (HNSCC)	HaCaT	cigarette smoke?extract?(CSE) treatment	upregulated	28797462
9969	Human	hsa-miR-486	miRNA	hypoxia	hypoxic/ischemic injury	bone marrow-derived mesnechymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	26801559
9970	Human	hsa-miR-486	miRNA	propofol (PPF)	lung cancer	lung cancer cell lines H1299 and H1792	propofol treatment	upregulated	28076456
9971	Human	hsa-miR-486	miRNA	high-intensity interval training (HIIT)	skeletal muscle adaptation	human	human treatment	downregulated	27101297
9972	Human	hsa-miR-486	miRNA	lidocaine	skin healing process	denatured skin tissues	Lidocaine treatment	"lidocaine treatment promoted the skin healing after thermal injury through up-regulating miR-486 and miR-663 expression, and partially explained how lidocaine modulates wound healing processes."	31815358
9973	Human	hsa-miR-486	miRNA	sprint interval training (SIT)	training responses	skeletal muscle and heart	acute exercise and short-term sprint interval training (SIT) three times a week for 6 weeks treatment	downregulated	29126336
9974	Human	hsa-miR-486-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
9975	Human	hsa-miR-486-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
9976	Human	hsa-miR-486-3p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
9977	Human	hsa-miR-486-3p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
9978	Human	hsa-miR-486-3p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
9979	Human	hsa-miR-486-3p	miRNA	nintedanib	idiopathic pulmonary fibrosis (IPF)	Human IPF lung fibroblasts	nintedanib treatment	downregulated	30841487
9980	Human	hsa-miR-486-3p	miRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells;DDP cells	cisplatin treatment	upregulated	24589211
9981	Human	hsa-miR-486-5p	miRNA	hesperetin	breast cancer	MDA-MB-231 and MCF-7 cells	hesperetin treatment	"?Hesperetin restored the expression of miR-486-5p, inhibited H19 lncRNA and ICAM-1 expression and selectively regressed mBC cell aggressiveness."	33882812
9982	Human	hsa-miR-486-5p	miRNA	cisplatin (DDP)	bladder cancer	5637 cells; EJ138 cancer cells	cisplatin treatment	MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and downregulated of metastatic genes.	32527702
9983	Human	hsa-miR-486-5p	miRNA	adoMet	breast cancer	MCF-7 cells	adoMet treatment	downregulated	30533999
9984	Human	hsa-miR-486-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"XIST and GAB2 were significantly highly expressed, while miR-486-5p was low expressed in SH-SY5Y cells under I/R"	33660813
9985	Human	hsa-miR-486-5p	miRNA	hydroquinone (HQ)	erythroid cell differentiation	CD34 + hematopoietic progenitor cells	hydroquinone (HQ) treatment	downregulated	28733890
9986	Human	hsa-miR-486-5p	miRNA	solasonine (SS)	gastric cancer (GC)	SNU1 cells; SNU5 cells	solasonine treatment	Solasonine increased the expression of miR-486-5p significantly.	32774717
9987	Human	hsa-miR-486-5p	miRNA	hydroquinone (HQ)	hematotoxicity	CD34 hematopoietic progenitor cells	treat with HQ	downregulated	28733890
9988	Human	hsa-miR-486-5p	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh-7 cells	hepatitis C virus (HCV) infection	downregulated	27698829
9989	Human	hsa-miR-486-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	lipopolysaccharides (LPS) treatment	downregulated	30790508
9990	Human	hsa-miR-486-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29505299
9991	Human	hsa-miR-486-5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	non-small cell lung cancer (NSCLC)	human NSCLC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28965852
9992	Human	hsa-miR-486-5p	miRNA	estrogen (ES)	ovarian cancer (OC)	SKOV3 cells	SKOV3 cells treatment	downregulated	26871282
9993	Human	hsa-miR-486-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
9994	Human	hsa-miR-486-5p	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	upregulated	32587527
9995	Human	hsa-miR-486-5p	miRNA	TGF-¦Â2	posterior capsular opacification (PCO)	SRA01/04 cells	TGF-¦Â2 treatment	downregulated	29229876
9996	Human	hsa-miR-487a	miRNA	TGF-¦Â1	breast cancer	MCF-7 and MDA-MB-231	MCF-7 and MDA-MB-231 treatment	upregulation	27019625
9997	Human	hsa-miR-487a-3p	miRNA	5-fluorouracil (5-FU)	locally advanced rectal cancer (LARC)	tumor tissues	5-fluorouracil (5-FU) treatment	upregulated	32345666
9998	Human	hsa-miR-487a-3p	miRNA	capecitabine	locally advanced rectal cancer (LARC)	tumor tissues	capecitabine treatment	upregulated	32345666
9999	Human	hsa-miR-487a-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	Expression level of circHIPK3 in HK-2 cells was remarkably decreased after the treatment of HG.	33628038
10000	Human	hsa-miR-487a-5p	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
10001	Human	hsa-miR-487b	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
10002	Human	hsa-miR-487b	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
10003	Human	hsa-miR-487b	miRNA	cigarette smoke condensate (CSC)	breast cancer	Primary lung cancer specimens and adjacent histologically normal lung parenchyma	cigarette smoke condensate (CSC) treatment	downregulated	23426183
10004	Human	hsa-miR-487b	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells	TGF-¦Â1 treatment	"the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2,"	24258346
10005	Human	hsa-miR-487b	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
10006	Human	hsa-miR-487b	miRNA	TGF-¦Â1	lung adenocarcinoma (LUAD)	human adenocarcinoma cell lines	transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment	upregulated	24258346
10007	Human	hsa-miR-487b	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
10008	Human	hsa-miR-487b-3p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
10009	Human	hsa-miR-487b-5p	miRNA	temozolomide (TMZ)	lung cancer	A549 and H1299 cells	Temozolomide (TMZ) treatment	downregulated	27097129
10010	Human	hsa-miR-488	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells (HMCs)	high glucose (HG) treatment	upregulated	31173306
10011	Human	hsa-miR-488	miRNA	BAY11-7082	helicobacter pylori infection	H. pylori infected gastric epithelial cells	treated with 10 ¦ÌM Bay 11-7082	upregulated	28208005
10012	Human	hsa-miR-488	miRNA	18¦Â-glycyrrhetinic acid (GA)	prostate cancer	LNCaP cells	18¦Â-glycyrrhetinic acid (GA) treatment	miR-488 was markedly induced by GA treatment.	32219716
10013	Human	hsa-miR-488-3p	miRNA	aristolochic acid	chronic kidney disease (CKD) and upper urinary tract carcinoma (UUC)	paraffin-embedded tissue	aristolochic acid (AA) treatment	upregulated	26397152
10014	Human	hsa-miR-489	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	downregulated	27158236
10015	Human	hsa-miR-489	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	downregulated	27158236
10016	Human	hsa-miR-489	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SK-N-SH cell lines	fluoxetine treatment	upregulated	27716787
10017	Human	hsa-miR-489	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
10018	Human	hsa-miR-489	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	downregulated	17653614
10019	Human	hsa-miR-489	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
10020	Human	hsa-miR-489-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells; HSC-T6 cells	TGF-¦Â1 treatment	downregulated	32144602
10021	Human	hsa-miR-489-3p	miRNA	bupivacaine	spinal cord injury (SCI)	"human neural cell lines, AGE1.HN and SY-SH-5Y"	bupivacaine treatment	upregulated	29441872
10022	Human	hsa-miR-490	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	human HCC cell lines HepG2 and Hep3B	hepatitis C virus (HCV) infection	upregulated	28781655
10023	Human	hsa-miR-490	miRNA	hepatitis C virus E2 envelope glycoprotein (HCV-E2)	hepatocellular carcinoma (HCC)	mast cells (MCs) line HMC-1	HCV-E2	upregulated	28781655
10024	Human	hsa-miR-490	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	downregulated	31435813
10025	Human	hsa-miR-490-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	HPAEpiC (human type II alveolar epithelial cell)	lipopolysaccharide (LPS) treatment	downregulated	33456519
10026	Human	hsa-miR-490-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells; HPAEpiC (human type II alveolar epithelial cell)	lipopolysaccharide (LPS) treatment	downregulated	33456519
10027	Human	hsa-miR-490-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	"The HepG2 cell, hCASMC, and human coronary artery endothelial cell (hCAEC)"	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	23821525
10028	Human	hsa-miR-490-3p	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
10029	Human	hsa-miR-490-3p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	AGS cells	Helicobacter pylori (H. pylori) infection	downregulated	32735911
10030	Human	hsa-miR-490-3p	miRNA	TGF-¦Â	invasive ductal carcinoma (IDC)	MCF10A cells	TGF-¦Â treatment	The expression of miR-490-3p was induced following transforming growth factor (TGF)-¦Â-induced epithelial-to-mesenchymal transition (EMT) in MCF10A cells	33416185
10031	Human	hsa-miR-490-3p	miRNA	TGF-¦Â1	silicosis	MRC-5 cells	TGF-¦Â1treatment treatment	MiR-490-3p was significantly downregulated in silica-induced fibrotic mouse lung tissues and TGF-¦Â1 treated fibroblasts	33482250
10032	Human	hsa-miR-490-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
10033	Human	hsa-miR-491	miRNA	curcumin (Cur)	colorectal cancer (CRC)	human HCT-116 cells	curcumin treatment	upregulated	29058812
10034	Human	hsa-miR-491	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	human hepatocellular carcinoma (HCC)	arsenic trioxide (As2O3) treatment	upregulated	25304214
10035	Human	hsa-miR-491	miRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	SMMC-7721 cells	Ginsenoside Rh2 treatment	upregulated	25561284
10036	Human	hsa-miR-491	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	human liver cancer cells	arsenic trioxide (As2O3) treatment	upregulated	24680928
10037	Human	hsa-miR-491	miRNA	ginsenoside Rh2	lung adenocarcinoma (LUAD)	hypoxia-induced A549 and H1299 cells	Ginsenoside Rh2 (Rh2) treatment	upregulated	31272362
10038	Human	hsa-miR-491	miRNA	hypoxia	lung adenocarcinoma (LUAD)	A549 and H1299 cells	hypoxia induce	downregulated	31272362
10039	Human	hsa-miR-491	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	The hepatoma-derived cell line Huh7	hepatitis C virus (HCV) infection	suppression of HCV replication by miR-491 was dependent on the PI3 kinase/Akt pathway. miRNAs altered by HCV infection would then affect HCV replication	21802413
10040	Human	hsa-miR-491-3p	miRNA	atorvastatin	hypercholesterolemia	HepG2 cells	atorvastatin treatment	downregulated	27575876
10041	Human	hsa-miR-491-3p	miRNA	metformin (Met)	polycystic ovarian syndrome (PCOS)	human Ishikawa cells	metformin treatment	downregulated	30599813
10042	Human	hsa-miR-492	miRNA	glucose	atherosclerosis (AS)	HUVEC CRL-1730 cells	high glucose stress treatment	downregulated	24526524
10043	Human	hsa-miR-492	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	upregulated	32362797
10044	Human	hsa-miR-492	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	clear cell renal cell carcinoma (ccRCC)	ccRCC tissues and matched adjacent normal tissues	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25815441
10045	Human	hsa-miR-492	miRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells	cisplatin treatment	miR-492 was upregulated in SGC7901-CDDP Cells.	32065219
10046	Human	hsa-miR-493	miRNA	lidocaine	melanoma	melanoma cell line SK-MEL-2	(0-100 uM) lidocaine	upregulated	29442040
10047	Human	hsa-miR-493	miRNA	radiation	premature senescence	WI-38 cells (human embryonic lung diploid fibroblasts)	radiation treatment	upregulated	21093163
10048	Human	hsa-miR-493	miRNA	hypoxia	renal fibrosis	HK2 cells	hypoxia induce	upregulated	30183377
10049	Human	hsa-miR-493	miRNA	Shear stress	ruptured intracranial aneurysm (IA)	human umbilical vein endothelial cells (HUVECs)	Shear stress treatment	miR-493 was significantly downregulated in HUVECs exposed to shear stress	33332775
10050	Human	hsa-miR-493	miRNA	nicotine	head and neck squamous cell carcinoma (HNSCC)	head and neck cancer cell lines UPCI:SCC131 and SCC172	Nicotine treatment	downregulated	27956702
10051	Human	hsa-miR-493-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
10052	Human	hsa-miR-493-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
10053	Human	hsa-miR-493-5p	miRNA	imatinib	chronic myeloid leukemia (CML)	CML cell line (K562)	imatinib in a CML cell line (K562) treatment	upregulated	25506832
10054	Human	hsa-miR-493-5p	miRNA	acrolein	environmental pollutants	human umbilical vein endothelial cells	acrolein treatment	upregulated	24812010
10055	Human	hsa-miR-494	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK-2 cells	cisplatin treatment	downregulated	31930399
10056	Human	hsa-miR-494	miRNA	bone morphogenetic protein 4 (BMP4)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	bone morphogenetic protein 4 (BMP4) treatment	upregulated(miR-126-5p) ;downregulated (miR-494 )	28124060
10057	Human	hsa-miR-494	miRNA	ionizing radiation (IR)	apoptosis	medulloblastoma (MB) cells	ionizing radiation (IR) treatment	upregulated	23728345
10058	Human	hsa-miR-494	miRNA	"N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99)"	arthritis	Human mononuclear suspension cells THP-1	"N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99) treatment"	upregulated	31881378
10059	Human	hsa-miR-494	miRNA	C8 fluoride derivative of cheliensisin A (ChlA-F)	bladder cancer	"Human BC cell lines (UMUC3, T24T and HT1197)"	ChlA-F treatment	upregulated	31167152
10060	Human	hsa-miR-494	miRNA	diesel exhaust particle (DEP)	bronchial epithelial cell cancer	Primary human bronchial epithelial cells	diesel exhaust particle (DEP) exposure	upregulated	20049127
10061	Human	hsa-miR-494	miRNA	ethanol extract of spica prunellae (EESP)	colorectal cancer (CRC)	HCT-8/5-FU cells	ethanol extract of Spica Prunellae (EESP) treatment with 48h	upregulated	31662984
10062	Human	hsa-miR-494	miRNA	nerve growth factor (NGF)	cornea epithelial diseases	hCECs	NGF	downregulated	28765880
10063	Human	hsa-miR-494	miRNA	cinobufacini	gastric cancer (GC)	BGC-823 cells; SGC-7901	cinobufacini treatment	"miR-494 and BAG-1 exhibited opposing trends of in cinobufacini-treated cells, with miR-494 was upregulated and BAG-1 downregu- lated by cinobufacini."	29568970
10064	Human	hsa-miR-494	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	plasma	enterovirus 71 treatment	Circulating miR-494 was abnormally upregulated in plasma of the children with EV71-induced HFMD.	32985212
10065	Human	hsa-miR-494	miRNA	estrogen (ES)	hepatocellular carcinoma (HCC)	HuH-7 cells	Estrogen treatment	miR-494 levels are upregulated following estrogen treatment in HuH-7 liver cells in association with downregulated PROS1 mRNA and PS levels.	23789915
10066	Human	hsa-miR-494	miRNA	hepatitis C virus (HCV)	liver fibrosis	Huh 7.5.1 cells	hepatitis C virus (HCV) infection	downregulated	26157120
10067	Human	hsa-miR-494	miRNA	hexavalent chromium [Cr(VI)]	lung cancer	human bronchial epithelial cells BEAS-2B	Hexavalent chromium [Cr(VI)] exposure	downregulated	31504995
10068	Human	hsa-miR-494	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
10069	Human	hsa-miR-494	miRNA	compound 331	malignant glioma	glioma cells	compound 331 treatment	upregulated	26153143
10070	Human	hsa-miR-494	miRNA	silibinin (SB)	neck squamous cell carcinomas (HNC)	neck squamous cell carcinomas (HNC)	silibinin (SB) treatment	upregulated	26090866
10071	Human	hsa-miR-494	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
10072	Human	hsa-miR-494	miRNA	silybin	osteosarcoma (OS)	Saos-2 cells	silybin treatment	upregulated	29068478
10073	Human	hsa-miR-494	miRNA	TGF-¦Â3	preeclampsia (PE)	Decidual mesenchymal stem cells (dMSCs)	TGF-¦Â3 treatment	upregulated	27149081
10074	Human	hsa-miR-494	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
10075	Human	hsa-miR-494	miRNA	amB with copper (II) ions (AmB-Cu2+)	renal fibrosis	normal human renal proximal tubule epithelial cells (RPTEC)	complex of AmB with copper (II) ions (AmB-Cu2+) exhibits a lower	downregulated	28534445
10076	Human	hsa-miR-494	miRNA	titanium surface	implant-host tissue interactions	osteoblastic cells from human alveolar bone	osteoblastic cells from human alveolar bone treatment	dysregulated	27200092
10077	Human	hsa-miR-494	miRNA	TGF-¦Â	tumor immune evasion in gastric cancer (GC)	T cells	TGF-¦Â treatment	upregulated	33247701
10078	Human	hsa-miR-494-3p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	lncRNA TUG1 was decreased while miR-494-3p was elevated in vivo and in vitro.	33663500
10079	Human	hsa-miR-494-3p	miRNA	hypoxia/reoxygenation (H/R)	cardiac surgery-associated acute kidney injury (CSA-AKI)	human kidney tubular epithelial (HK2) cells	hypoxia/reoxygenation (H/R) treatment	"Our result showed that Hsa-miR-494-3p was elevated in the serum of patients with CSA-AKI, and also induced in hypoxic reoxygenated HK2 cells."	33462352
10080	Human	hsa-miR-494-3p	miRNA	enterovirus 71 (EV71)	endometrial cancer (EC)	Rhabdomyosarcoma (RD) and human embryonic kidney (HEK) 293 cells	Enterovirus 71 (EV71) infection	upregulated	30234021
10081	Human	hsa-miR-494-3p	miRNA	sodium butyrate (NaB)	lung cancer	A549 cells	sodium butyrate(NaB) treatment	upregulated	29231270
10082	Human	hsa-miR-494-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	29567426
10083	Human	hsa-miR-494-3p	miRNA	pramipexole (PPX)	parkinson's disease (PD)	SK-N-SH cells; CHP 212 cells	Pramipexole (PPX) treatment	PPX inhibited MPP+-induced neurotoxicity in SK-N-SH and CHP 212 cells by decreasing miR-494-3p and increasing BDNF	31811458
10084	Human	hsa-miR-494-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH and CHP 212 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31811458
10085	Human	hsa-miR-494-3p	miRNA	pramipexole (PPX)	parkinson's disease (PD)	1-Methyl-4-phenylpyridinium (MPP+) treated SK-N-SH and CHP 212 cells	Pramipexole (PPX) treatment	downregulated	31811458
10086	Human	hsa-miR-494-3p	miRNA	rotenone (ROT)	RPE mitochondrial dysfunction	ARPE-19 cells	rotenone treatment	Elevated levels of miR-494-3p in EVs released by ARPE-19 cells indicate diminished capacity of the mitochondria within these cells	32240720
10087	Human	hsa-miR-495	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	"human BC cell lines MCF-7 , HCC1973, the immortalized breast epithelial MCF10A,human embryonic kidney 293T"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28498478
10088	Human	hsa-miR-495	miRNA	high glucose (HG)	cardiac fibrosis	human cardiac fibroblasts (CFs)	high glucose treatment	downregulated	29760746
10089	Human	hsa-miR-495	miRNA	propofol (PPF)	chondrosarcoma	JEG-3 cells	propofol treatment	upregulated	31046467
10090	Human	hsa-miR-495	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	upregulated	31226416
10091	Human	hsa-miR-495	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	downregulated	31226416
10092	Human	hsa-miR-495	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
10093	Human	hsa-miR-495	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	"human colonic epithelial cell lines (HT-29, LOVO, and Caco-2)"	dextran sulfate sodium (DSS) treatment	miR-495 was lowly expressed in the colonic epithelial cell lines.	31251902
10094	Human	hsa-miR-495	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	The cisplatin-R group exhibited lower levels of UCA1 and NRF2 expression but a higher level of miR-495 expression than the cisplatin-S group	31583720
10095	Human	hsa-miR-495	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	CircSERPINE2 could mediate TGFBR2 expression by binding with miR-495.	33094798
10096	Human	hsa-miR-495-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33856026
10097	Human	hsa-miR-495-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33830389
10098	Human	hsa-miR-495-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	AGS cells; SNU484 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28991363
10099	Human	hsa-miR-495-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"AGS, MKN28, MKN45 , SNU216, SNU484 cancer cell lines"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	restore miR-495-3p expression	28991363
10100	Human	hsa-miR-495-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human Nucleus Pulposus Cells	tumor necrosis factor alpha (TNF-¦Á) treatment	MiRNA-495-3p Attenuates TNF-¦Á Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Targeting IL5RA	32445070
10101	Human	hsa-miR-495-3p	miRNA	hypoxia/reoxygenation (H/R)	intestinal hypoxia/reoxygenation injury	caco-2 cells	hypoxia-reoxygeneration (H/R) treatment	upregulated	26935288
10102	Human	hsa-miR-495-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
10103	Human	hsa-miR-496	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30597231
10104	Human	hsa-miR-496	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30597231
10105	Human	hsa-miR-496	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	human cardiomyocyte (HCM)	hypoxia/reoxygenation (H/R) treatment	miR-496 was lowly expressed in H/R-treated human cardiomyocyte (HCM).	31436348
10106	Human	hsa-miR-496	miRNA	IL-1¦Â	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMMSC)	IL-1¦Â treatment	upregulated	28509407
10107	Human	hsa-miR-496	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
10108	Human	hsa-miR-496	miRNA	oxidized low density lipoprotein (ox-LDL)	vascular endothelial dysfunction	human umbilical vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30811087
10109	Human	hsa-miR-497	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	27918592
10110	Human	hsa-miR-497	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28653788
10111	Human	hsa-miR-497	miRNA	cisplatin (DDP)	tumorigenesis	A549 cells	cisplatin treatment	downregulated	21258880
10112	Human	hsa-miR-497	miRNA	hypoxia	cell proliferation	human primary pulmonary artery smooth muscle cells	hypoxia induce	upregulated	31370272
10113	Human	hsa-miR-497	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	downregulated	31696986
10114	Human	hsa-miR-497	miRNA	bufalin	colorectal cancer (CRC)	human colorectal cancer HCT116 cells	bufalin treatment	upregulated	24375248
10115	Human	hsa-miR-497	miRNA	probucol	coronary artery disease (CAD)	HUVECs	probucol treatment	upregulated	26897284
10116	Human	hsa-miR-497	miRNA	high glucose (HG)	diabetic foot ulcer (DFU)	human dermal fibroblasts cells	high glucose treatment	downregulated	31707336
10117	Human	hsa-miR-497	miRNA	lipopolysaccharide (LPS)	diabetic foot ulcer (DFU)	human dermal fibroblasts cells	lipopolysaccharide (LPS) treatment	downregulated	31707336
10118	Human	hsa-miR-497	miRNA	high glucose (HG)	diabetic nephropathy (DN)	kidney tissues	high glucose (HG) treatment	ANRIL and TXNIP were elevated in DN kidney tissues and HG-treated HK-2 cells while miR-497 was reduced.?miR-497 mimics inhibited caspase-1-dependent pyroptosis while co-overexpression of TXNIP blocked its effects in HG-treated HK-2 cells.	33160992
10119	Human	hsa-miR-497	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial cell cells (HK-2)	high glucose (HG) treatment	ANRIL promotes pyroptosis and kidney injury in DN via acting as miR-497 sponge to disinhibit TXNIP expression.	33160992
10120	Human	hsa-miR-497	miRNA	melatonin	diabetic nephropathy (DN)	glomerular endothelial cells (GEnCs)	melatonin (MT) treatment	MiR-497 expression was increased in melatonin-treated glomerular endothelial cells (GEnCs).	30212830
10121	Human	hsa-miR-497	miRNA	high glucose (HG) and lipopolysaccharide (LPS)	diabetic retinopathy (DR)	HDF; WI38 cells	high glucose (HG) and LPS treatment	downregulated	31707336
10122	Human	hsa-miR-497	miRNA	metformin (Met)	esophageal squamous cell carcinoma (ESCC)	KYSE510 cells	metformin treatment	upregulated	30771436
10123	Human	hsa-miR-497	miRNA	hypoxia	glioblastoma multiforme (GBM)	Glioma cells U87 and U251 and HEK293T cells	1% oxygen for 12 h treatment	upregulated	25080009
10124	Human	hsa-miR-497	miRNA	cigarette smoke extract (CSE)	human bronchial epithelial (HBE) cells injury	HBE cells	cigarette smoke extract (CSE) exposure	CSE treatment decreased miR-497 level in HBE cells.	31696986
10125	Human	hsa-miR-497	miRNA	vincristine (VCR)	lung cancer	human gastric cancer cell line SGC7901	vincristine (VCR) treatment	downregulated	21258880
10126	Human	hsa-miR-497	miRNA	ethanol (EtOH)	neuronal cell death	SH-SY5Y cells	ethanol treatment	upregulated	21878650
10127	Human	hsa-miR-497	miRNA	amikacin	neuronal cell death	SH-SY5Y cells	treat with amikacin	downregulated	27209189
10128	Human	hsa-miR-497	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
10129	Human	hsa-miR-497	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated of miR-497 in CMS-treated PLL cells was restored by a demethylation reagent 5-aza-2'-deoxycytidine (AZA).	32432317
10130	Human	hsa-miR-497	miRNA	cyclic mechanical stretch (CMS)	spinal ossification of the posterior longitudinal ligament (OPLL)	posterior longitudinal ligament (PLL) cells	cyclic mechanical stress (CMS) treatment	miR-497 was downregulated in treated PLL cells.	32432317
10131	Human	hsa-miR-497-5p	miRNA	mitogen activated-protein kinase pathway inhibitors (MAPKis)	cutaneous malignant melanoma (CMM)	extracellular microvesicle in matched plasma	Mitogen activated-protein kinase pathway inhibitors (MAPKis) treatment	upregulated	30399176
10132	Human	hsa-miR-497-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901	cisplatin treatment	downregulated	33149605
10133	Human	hsa-miR-497-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human Osteoarthritis Chondrocytes	IL-1¦Â treatment	dysregulated	27152662
10134	Human	hsa-miR-497-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	Chondrocytes	IL-1¦Â treatment	downregulated	31934153
10135	Human	hsa-miR-497-5p	miRNA	X-rays	radiosensitivity	"KYSE-30, KYSE-180, KYSE-150 and TE-5"	X-ray radiation treatment	LINC00473 reduces the radiosensitivity of ESCC cells by modulating the miR-497-5p/CDC25A axis	32468021
10136	Human	hsa-miR-498	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	upregulated	31315126
10137	Human	hsa-miR-498	miRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	"Linc00632 inhibited IL-13-induced GM-CSF, eotaxin, and MUAC5AC production in IL-13-treated NECs by targeting miR-498"	31315126
10138	Human	hsa-miR-498	miRNA	propofol (PPF)	esophageal cancer (EC)	EC109; KYSE70 cells	Propofol treatment	"Propofol suppresses hypoxia-induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO-AS1/miR-498 axis"	32643321
10139	Human	hsa-miR-498	miRNA	hypoxia	myocardial infarction (MI)	human induced pluripotent stem-derived cardiomyocytes (HCMs)	hypoxia treatment	Circ_0068655 Promotes Cardiomyocyte Apoptosis via miR-498/PAWR Axis	32767028
10140	Human	hsa-miR-498	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	CNE-2R cells	curcumin treatment	upregulated	31793078
10141	Human	hsa-miR-498	miRNA	"trans-3,5,4-trimethoxystilbene (TMS)"	non-small cell lung cancer (NSCLC)	H1299 and PC©\9/GR cells	"trans-3,5,4-trimethoxystilbene (TMS) treatment"	upregulated	30701693
10142	Human	hsa-miR-498	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
10143	Human	hsa-miR-498	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	upregulated	26987780
10144	Human	hsa-miR-498	miRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide (LPS) treatment	?TUG1 was downregulated upon LPS stimulation in hPDLCs.	32762066
10145	Human	hsa-miR-498	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	tissue injury	OVCAR3 cells; A2780 cells;A2780-CP cells; C13 cells;OV2008 cells; CAOV3 cells; MCF-7 cells; Ishikawa cells;HeLa cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	"miR-498 induced by 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3)) decreases the mRNA expression of the human telomerase reverse transcriptase"	23055531
10146	Human	hsa-miR-498-5p	miRNA	neodymium oxide (Nd2O3)	inflammation	human bronchial epithelial (16HBE) cells	neodymium oxide treatment	upregulated	32199215
10147	Human	hsa-miR-499	miRNA	hemodialysis	cardiac hypertrophy	cardiac patients on hemodialysis plasma	treat with high-flux or low-flux dialysis	downregulated	29064177
10148	Human	hsa-miR-499	miRNA	anthracycline (AC)	cardiotoxicity	children plasma	anthracycline (AC) treatment	upregulated	28377429
10149	Human	hsa-miR-499	miRNA	caffeine	cardiovascular disease (CVD)	HL-1 and primary embryonic cardiomyocytes	exposure to physiologically relevant doses of caffeine treatment	upregulated	25354728
10150	Human	hsa-miR-499	miRNA	cyclic mechanical stretch (CMS)	cardiovascular disease (CVD)	human cardiac fibroblasts-adult atrial (HCF-aa)	cyclic stretching treatment	"MiR208a was upregulated early by stretching and returned to normal levels with longer stretching cycles, whereas the expression of miR499 and Bcl-2 was upregulated by longer stretching times."	33605072
10151	Human	hsa-miR-499	miRNA	homocysteine (Hcy)	hyperhomocysteinemia (HHcy)	HL-1 cardiomyocytes	100 ¦ÌM homocysteine treatment	downregulated	24495916
10152	Human	hsa-miR-499-5p	miRNA	exercise (Ex)	muscle injury	muscle	exercise treatment	upregulated	26472872
10153	Human	hsa-miR-499-5p	miRNA	statins	muscle injury	plasma	statins? treatment	upregulated	26472872
10154	Human	hsa-miR-499a-5p	miRNA	ursolic acid (UA)	breast cancer	"breast CSCs enriched from breast cancer cell lines, MCF7, MDA-MB-231 and T47D"	ursolic acid (UA) treatment	"UA can target breast CSCs via Wnt by suppressing miR-499a-5p and upregulating the Wnt antagonist, sFRP4"	33278391
10155	Human	hsa-miR-499a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (NPC)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30856535
10156	Human	hsa-miR-499a-5p	miRNA	forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	forskolin (Fsk) treatment	upregulated	33508847
10157	Human	hsa-miR-499a-5p	miRNA	IL-1¦Â and forskolin (Fsk)	adrenal steroid production	NCI-H295R cells	IL-1¦Â and forskolin (Fsk) treatment	downregulated	33508847
10158	Human	hsa-miR-499a-5p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7 cells	hepatitis C virus (HCV) infection	upregulated	24241692
10159	Human	hsa-miR-499b-5p	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	UCA1 inhibition protected WI-38 cells against LPS-managed inflammatory injury and apoptosis process via miR-499b-5p/TLR4 crosstalk.	33368965
10160	Human	hsa-miR-499b-5p	miRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	?We displayed that UCA1 was elevated in LPS-injured WI-38 cells.	33368965
10161	Human	hsa-miR-4a-5p	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
10162	Human	hsa-miR-500	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
10163	Human	hsa-miR-5001-5p	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
10164	Human	hsa-miR-5006-5p	miRNA	kynurenine	bone loss	bone marrow stromal cells (BMSCs)	kynurenine treatment	upregulated	31790802
10165	Human	hsa-miR-5006-5p	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	upregulated	31549595
10166	Human	hsa-miR-500a-3p	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK2 cell	cisplatin treatment	downregulated	30365367
10167	Human	hsa-miR-500a-3P	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	HK-2 cells	cisplatin treatment	hsa-miR-500a-3P was significantly suppressed in cisplatin-treated human tubular epithelial (HK2) cells.	30365367
10168	Human	hsa-miR-500a-3p	miRNA	cisplatin (DDP)	gastric cancer (GC)	MGC803 cells; MKN45 cells	cisplatin treatment	Exosomal miR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer	32588541
10169	Human	hsa-miR-500a-5p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
10170	Human	hsa-miR-500a-5p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
10171	Human	hsa-miR-500a-5p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
10172	Human	hsa-miR-500a-5p	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	AB8/13 podocytes	angiotensin II (Ang II) treatment	"AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p."	32974919
10173	Human	hsa-miR-500a-5p	miRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	human podocyte cell line AB8/13 podocytes	angiotensin II (Ang II) treatment	"AngII treatment induced the overexpression of circ_0000524 and CXCL16, a decrease of miR-500a-5p, and induced cell apoptosis in podocytes."	32974919
10174	Human	hsa-miR-501	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
10175	Human	hsa-miR-501	miRNA	doxorubicin (DOX)	gastric cancer (GC)	SGC7901 cells	doxorubicin treatment	"Endogenous miR-501 was higher, whereas BLID was lower, in doxorubicin-resistant gastric cancer SGC7901/ADR cells compared with their parental SGC7901 cells."	30195794
10176	Human	hsa-miR-501	miRNA	doxorubicin (DOX)	gastric cancer (GC)	doxorubicin-resistant gastric cancer (GC) SGC7901/ADR cell-secreted exosomes (ADR Exo)	doxorubicin treatment	upregulated	31173853
10177	Human	hsa-miR-501-3p	miRNA	estradiol	endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	estradiol treatment	upregulated	29510375
10178	Human	hsa-miR-501-3p	miRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	U251 cells	cisplatin treatment	Cisplatin treatment inhibited the level of miR-501-3p in a time-dependent way.	30221699
10179	Human	hsa-miR-501-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
10180	Human	hsa-miR-501-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV)-induced liver disease and hepatocarcinogenesis	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
10181	Human	hsa-miR-501-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
10182	Human	hsa-miR-501-5p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
10183	Human	hsa-miR-502	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma extracellular vesicle (EV)	doxorubicin (Dox) treatment	upregulated	32255536
10184	Human	hsa-miR-502	miRNA	BAY11-7082	intervertebral disc degeneration (IDD)	TNF-¦Á treated human nucleus pulposus (NP) cell	BAY 11-7082 treatment	"Moreover, both TNF-¦Á?and BAY 11-7082 treatments were associated with marked miRNA dysregulation, with miR-502 being upregulated by TNF-¦Á?treatment and downregulated by BAY 11-7082 treatment, respectively."	33869626
10185	Human	hsa-miR-502	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cell	tumor necrosis factor alpha (TNF-¦Á) treatment	"Moreover, both TNF-¦Á?and BAY 11-7082 treatments were associated with marked miRNA dysregulation, with miR-502 being upregulated by TNF-¦Á?treatment and downregulated by BAY 11-7082 treatment, respectively"	33869626
10186	Human	hsa-miR-502-3p	miRNA	niacin	insulin resistance (IR)	hMADS adipocytes	niacin treatment	upregulated	30482933
10187	Human	hsa-miR-502-3p	miRNA	niacin	insulin resistance (IR)	human adipocytes	niacin treatment	upregulated	30482933
10188	Human	hsa-miR-502-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human primary chondrocytes	IL-1¦Â treatment	downregulated	26861148
10189	Human	hsa-miR-502c	miRNA	co-nanoencapsulated curcumin (Cur) and chrysin (Chr)	breast cancer	MDA-MB-231 breast cancer cells	co-nanoencapsulated Curcumin (Cur) and Chrysin (Chr) treatment	upregulated	30955355
10190	Human	hsa-miR-503	miRNA	hypoxia	tumor angiogenesis and growth	Cell lines HepG2 and LO2	?hypoxia treatment	downregulated	23352645
10191	Human	hsa-miR-503	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
10192	Human	hsa-miR-503	miRNA	ionizing radiation (IR)	tumorigenesis	Human dermal microvascular endothelial cells(HDMEC)	ionizing radiation treatment	downregulated	20346162
10193	Human	hsa-miR-503	miRNA	TGF-¦Â	cell cycle arrest	MCF-10A and MCF-12 cells	TGF-¦Â treatment	upregulated	25266660
10194	Human	hsa-miR-503	miRNA	TGF-¦Â	liver fibrosis	LX-2 cells	TGF-¦Â treatment	upregulated	32648079
10195	Human	hsa-miR-503	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	hepatocellular apoptosis	Hep-nonstructural protein 5A (Hep-NS5A) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28343379
10196	Human	hsa-miR-503	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	downregulated	32807750
10197	Human	hsa-miR-503	miRNA	ezetimibe	monocytic differentiation	Human monocytic cell lineTHP-1	Ezetimibe trratment	downregulated	22989505
10198	Human	hsa-miR-503	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	non-small cell lung cancer (NSCLC)	NSCLC cell lines from patients with NSCLC	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24486548
10199	Human	hsa-miR-503	miRNA	high glucose (HG)	proximal tubular cell apoptosis	Human proximal tubular (HK-2) cells	high glucose (HG) treatment	MIR503HG indirectly regulates Bcl-2 by promoting the co-transcription of miRNA-503 to participate high-glucose-induced proximal tubular cell apoptosis.	33262626
10200	Human	hsa-miR-503	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (hPASMCs)	hypoxia treatment	lncRNA MALAT1 promotes the proliferation and migration of hPASMCs and inhibits their apoptosis by inhibiting the miR-503/TLR4 signal axis.	32712618
10201	Human	hsa-miR-503	miRNA	IL-13	pulmonary arterial hypertension (PAH)	primary human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
10202	Human	hsa-miR-503	miRNA	IL-13	pulmonary arterial hypertension (PAH)	human pulmonary artery endothelial cells (HPAECs)	Interleukin-13 (IL-13) treatment	downregulated	29102771
10203	Human	hsa-miR-503-5p	miRNA	microgravity	apoptosis	human pulmonary microvascular endothelial cells (HPMECs)	microgravity treatment	upregulated	30216505
10204	Human	hsa-miR-503-5p	miRNA	microgravity	endothelial dysfunction	human pulmonary microvascular endothelial cells (HPMECs)	microgravity treatment	miR-503-5p is dramatically upregulated in HPMECs in simulated microgravity.	30216505
10205	Human	hsa-miR-503-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	downegulated	32323778
10206	Human	hsa-miR-504	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
10207	Human	hsa-miR-504	miRNA	IFN-¦Â	multiple sclerosis (MS)	whole blood	IFN-¦Â treatment	"The expression level of miR-504 was significantly higher in patients who respond to IFN-¦Â therapy, compared with non-responders."	32199199
10208	Human	hsa-miR-505	miRNA	prednisolone	active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV)	prednisolone treatment	downregulated	24215168
10209	Human	hsa-miR-505	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	exosomes from human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31768526
10210	Human	hsa-miR-505	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	nasopharyngeal carcinoma cell HK-1	TGF-¦Âtreatment	upregulated	26032086
10211	Human	hsa-miR-505	miRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901 cells	cisplatin treatment	upregulated	31885317
10212	Human	hsa-miR-505	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
10213	Human	hsa-miR-505	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30025813
10214	Human	hsa-miR-505	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
10215	Human	hsa-miR-506	miRNA	TGF-¦Â1	lung fibrosis	MRC-5 cells	TGF-¦Â1 treatment	downregulated	31214773
10216	Human	hsa-miR-506	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
10217	Human	hsa-miR-506	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells and the control untransformed cell line 16HBE-N cells	"anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide (anti-BPDE) treatment"	expression of miR-506 was reduced in 16HBE-T transformed malignant human bronchial epithelial cells compared with 16HBE normal human bronchial epithelial cells	21726609
10218	Human	hsa-miR-506	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	SK-HEP-1 cells; Huh-7 cells; HCC tissues	sorafenib treatment	miR-506 was downregulated in sorafenib-resistant HCC tissues and cells	33000204
10219	Human	hsa-miR-506	miRNA	H2O2	cardiac dysfunction	human cardiomyocyte (HCM)	H2O2 treatment	downregulated	28849090
10220	Human	hsa-miR-506	miRNA	¦Ã-rays	laryngeal cancer	human larynx squamous carcinoma cell line Hep-2	637 cGy 60Co rays radiation	downregulated	30980388
10221	Human	hsa-miR-506	miRNA	IL-1¦Â	osteosarcoma (OS)	"human OS cell line(Saos2, MG63, U2OS, and SW1353)"	IL-6¦Â treatment	downregulated	28926924
10222	Human	hsa-miR-506	miRNA	rosmarinic acid (RA)	pancreatic cancer (PC)	Pancreatic cancer cell lines (Panc-1 and SW1990)	rosmarinic acid treatment	upregulated	31060006
10223	Human	hsa-miR-506-3p	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	HCC4006 cells	erlotinib treatment	miR-506-3p expression was markedly reduced in erlotinib-resistant (ER) cells.	33291316
10224	Human	hsa-miR-506-3p	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	PC-9 cells	gefitinib treatment	downregulated	30535506
10225	Human	hsa-miR-506-3p	miRNA	high glucose (HG)	oxidative stress	HK-2 cells	high glucose (HG) treatment	"downregulated of KCNQ1OT1 inhibited the inflammation, oxidative stress and pyroptosis of HG-induced HK-2 cells by up-regulating the expression of miR-506-3p."	32104033
10226	Human	hsa-miR-506-5p	miRNA	estradiol-17¦Â (E2)	endometriosis	ectopic endometrial tissue	estradiol-17¦Â (E2) treatment	LINC01541 functions as a ceRNA that modulates the Wnt/¦Â-catenin pathway by decoying miR-506-5p.	32833189
10227	Human	hsa-miR-508-3p	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
10228	Human	hsa-miR-508-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ZNF295-AS1 inhibits autophagy via the ZNF295-AS1/miR-508-5p/ATG7 axis in AS	32633396
10229	Human	hsa-miR-508-5p	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
10230	Human	hsa-miR-509-3p	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
10231	Human	hsa-miR-509-3p	miRNA	respiratory syncytial virus (RSV)	respiratory syndrome virus (PRRSV) infection	sputum specimens; A549 cells; BEAS-2B cells	respiratory syncytial virus (RSV) infection treatment	upregulated	32102886
10232	Human	hsa-miR-5094	miRNA	X-rays	cellular radiation response	HeLa cells	X-ray irradiation treatment	"upregulated of miR-5094 downregulated the expression of STAT5b, thereby suppressing cell proliferation after X-ray irradiation"	32127949
10233	Human	hsa-miR-5095	miRNA	X-rays	cervical cancer (CC)	Hela cells	irradiated with 6?Gy of X-ray treatment	downregulated	31169309
10234	Human	hsa-miR-5096	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
10235	Human	hsa-miR-512	miRNA	prostaglandin E1 (PGE1)	contrast-induced nephropathy (CIN)	THP-1 cells; peripheral blood samples	PGE1 treatment	MiR-512 could directly bind to and negatively regulate the expression of PTGS1 and HULC	32678165
10236	Human	hsa-miR-512	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
10237	Human	hsa-miR-512-3p	miRNA	thrombospondin-1 (TSP-1)	angiogenesis	vascular smooth muscle cell (VSMC)	Thrombospondin-1 (TSP-1) treatment	upregulated	26728995
10238	Human	hsa-miR-512-3p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia treatment	Hypoxia could elevate miR-512-3p levels in HCC cells.	32612368
10239	Human	hsa-miR-512-5p	miRNA	radiation	cervical cancer (CC)	cervical cancer tissues	radiation treatment	miR-512-5p expression was dramatically downregulated in the radiotherapy resistant group	32126879
10240	Human	hsa-miR-512-5p	miRNA	retinoic acid (RA)	non-small cell lung cancer (NSCLC)	NSCLC cell lines A549 and H1299	retinoic acid treatment	downregulated	26648284
10241	Human	hsa-miR-512-5p	miRNA	retinoic acid (RA)	non-small cell lung cancer (NSCLC)	A549 and H1299 cell lines	retinoic acid treatment	upregulated	26648284
10242	Human	hsa-miR-513	miRNA	cryptosporidium parvum	human biliary cryptosporidiosis	cholangiocytes H69 cells	cryptosporidium parvum? infection	downregulated	19916867
10243	Human	hsa-miR-513	miRNA	IFN-¦Ã	immune response	H69 cells	IFN-¦Ã treatment	downregulated	19155478
10244	Human	hsa-miR-513a-5p	miRNA	5-fluorouracil (5-Fu)	retinoblastoma (RB)	retinoblastoma cells	5-fluorouracil (5-Fu) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
10245	Human	hsa-miR-513a-5p	miRNA	carboplatin (CBP)	retinoblastoma (RB)	retinoblastoma cells	carboplatin (CBP) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
10246	Human	hsa-miR-513a-5p	miRNA	cisplatin (DDP)	retinoblastoma (RB)	retinoblastoma cells	cisplatin treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
10247	Human	hsa-miR-513a-5p	miRNA	vincristine (VCR)	retinoblastoma (RB)	retinoblastoma cells	vincristine (VCR) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells.	31264280
10248	Human	hsa-miR-513a-5p	miRNA	etoposide (VP-16)	retinoblastoma (RB)	retinoblastoma cells	Etoposide (VP-16) treatment	silence of miR-513a-5p or STMN1 overexpression could partly reverse UCA1 knockdown-induced inhibitory effects on proliferation and multidrug resistance of retinoblastoma cells	31264280
10249	Human	hsa-miR-513a-5p	miRNA	dichlorvos (DDVP)	apoptosis	human kidney cell line HK-2	dichlorvos treatment	upregulated	30372899
10250	Human	hsa-miR-513a-5p	miRNA	TNF-¦Á and lipopolysaccharide (LPS)	apoptosis	human umbilical vein endothelial cells (HUVECs)	?tumour necrosis factor-¦Á (TNF-¦Á) and lipopolysaccharide (LPS) treatment	upregulated	22504158
10251	Human	hsa-miR-513a-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	downregulated	33592319
10252	Human	hsa-miR-513a-5p	miRNA	diesel exhaust particle (DEP)	bronchial epithelial cell cancer	Primary human bronchial epithelial cells	diesel exhaust particle (DEP) exposure	upregulated	20049127
10253	Human	hsa-miR-513a-5p	miRNA	etoposide (VP-16)	cardioprotective therapy	retinoblastoma cells	etoposide treatment	downregulated	22886978
10254	Human	hsa-miR-513a-5p	miRNA	4-aminobiphenyl (4-ABP)	DNA damage	HepG2 cells	4-Aminobiphenyl (4-ABP) treatment	upregulation	24857880
10255	Human	hsa-miR-513a-5p	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	?Insulin-like growth factor (IGF)-1 treatment	upregulated	31805126
10256	Human	hsa-miR-513a-5p	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?7 cells	heme treatment	downregulated	23538684
10257	Human	hsa-miR-513a-5p	miRNA	carboplatin (CBP)	retinoblastoma (RB)	SO-RB50 cells	carboplatin (CBP) treatment	downregulated	31702387
10258	Human	hsa-miR-513a-5p	miRNA	vincristine (VCR)	retinoblastoma (RB)	SO-RB50 cells	vincristine (VCR) treatment	downregulated	31702387
10259	Human	hsa-miR-513b	miRNA	lipopolysaccharide (LPS)	procalcitonin (PCT) production	HepG2 cells	lipopolysaccharide (LPS) treatment	downregulated	29891911
10260	Human	hsa-miR-515-3p	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
10261	Human	hsa-miR-515-5p	miRNA	estrogen receptor	breast cancer	Human breast cancer cell lines (MCF7; ZR-75-1; MDA-MB-231)	estrogen receptor treatment	downregulated	23928990
10262	Human	hsa-miR-515-5p	miRNA	cigarette smoke (CS)	epithelial-mesenchymal transition (EMT)	human bronchial epithelial (HBE) cells	Cigarette smoke (CS) exposure	downregulated	32768781
10263	Human	hsa-miR-515-5p	miRNA	oxaliplatin	gastric cancer (GC)	HGC-27 cells; AGS cells	oxaliplatin (OXA) treatment	"A marked upregulation of miR- 515-5p was viewed in HGC-27 and AGS cells compared with HGC-27/OXA, and AGS/OXA cells"	33123829
10264	Human	hsa-miR-515-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	Circ_0134111 was overexpressed in OA cartilage tissues and IL-1¦Â-induced chondrocytes.	33684877
10265	Human	hsa-miR-515-5p	miRNA	radiation	radioresistance	C666-1; 5¨C8F cells	radiation exposure treatment	"PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis"	33116864
10266	Human	hsa-miR-516	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
10267	Human	hsa-miR-516b	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	upregulated	22366961
10268	Human	hsa-miR-516b-5p	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
10269	Human	hsa-miR-517c	miRNA	human immunodeficiency virus (HIV)-1	pregnancy	peripheral plasmas	human immunodeficiency virus (HIV)-1 infection	upregulated	26757431
10270	Human	hsa-miR-517c	miRNA	plasmodium falciparum	pregnancy	peripheral plasmas	Plasmodium falciparum infection treatment	upregulated	26757431
10271	Human	hsa-miR-518a-5p	miRNA	dasatinib	chronic myeloid leukemia (CML)	CML cell line K562	dasatinib treatment	upregulated	30814857
10272	Human	hsa-miR-518a-5p	miRNA	hypoxia	periodontitis	human periodontal ligament cells (hPDLCs)	hypoxia treatment	"We selected LINC01126, which was the most highly expressed lncRNA, to further verify its functions in periodontitis-induced hypoxia."	33231338
10273	Human	hsa-miR-518a-5p	miRNA	cysteine-rich 61 (CCN1)	rheumatoid arthritis (RA)	"human osteoblast-like cell line MG63, human fetal osteoblastic cell line hFOB"	cysteine-rich 61 (CCN1) treatment	downregulated	28341837
10274	Human	hsa-miR-518b	miRNA	gambogic acid (GA)	apoptosis	SW1353 cells	GA treatment	upregulated	24173143
10275	Human	hsa-miR-518b	miRNA	bone morphogenetic protein 2 (BMP2)	tumorigenesis	NT2/D1 cells	"BMP-2 at 6, 12, and 24 h, and on days 6 and 10 treatment"	upregulated	24383669
10276	Human	hsa-miR-518b	miRNA	gambogic acid (GA)	chondrosarcoma	SW1353 human chondrosarcoma cells	Gallic acid (GA) treatment	upregulated	24173143
10277	Human	hsa-miR-518b	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
10278	Human	hsa-miR-518d-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
10279	Human	hsa-miR-519	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 and SW1990 cell	hypoxia induce	downregulated	31966071
10280	Human	hsa-miR-519	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells; SW1990 cells	hypoxia treatment	downregulated	31966071
10281	Human	hsa-miR-5194	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	downregulated	31549595
10282	Human	hsa-miR-5194	miRNA	melatonin	osteosarcoma (OS)	SaOS2 cells; MG63 cells	Melatonin treatment	upregulated	32592723
10283	Human	hsa-miR-5195	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
10284	Human	hsa-miR-5195-3p	miRNA	paclitaxel (PTX)	triple negative breast cancer (TNBC)	BT549 and MDA-MB-231 cells	paclitaxel (PTX) treatment	downregulated	31308851
10285	Human	hsa-miR-519a	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	downregulated	21274007
10286	Human	hsa-miR-519a-3p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	A172 ; LN229	temozolomide (TMZ) treatment	Exosomal lncRNA HOTAIR mediated TMZ resistance through miR-519a-3p/RRM1 axis in GB	32721218
10287	Human	hsa-miR-519b	miRNA	TGF-¦Â1	osteoarthritis (OA)	human osteoarthritic synovial fibroblasts (OASFs)	TGF-¦Â1 treatment	downregulated	28423042
10288	Human	hsa-miR-519c-5p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
10289	Human	hsa-miR-519c-5p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
10290	Human	hsa-miR-519d	miRNA	resistin	chondrosarcoma	human chondrosarcoma cells	resistin treatment	downregulated	25404641
10291	Human	hsa-miR-519d	miRNA	connective tissue growth factor (CTGF)	osteosarcoma (OS)	human osteosarcoma	CTGF/CCN2 treatment	downregulated	25003330
10292	Human	hsa-miR-519d-3p	miRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
10293	Human	hsa-miR-519e-5p	miRNA	human papilloma viruses 16 (HPV16) E6	cervical cancer (CC)	C33A cells; SiHa cells; CaSki cells	human papillomaviruses 16 (HPV16) E6 infection	downregulated	32844486
10294	Human	hsa-miR-520	miRNA	oxymatrine	lung cancer	A549 cells	Oxymatrine (OMT) treatment	upregulated	31091971
10295	Human	hsa-miR-520-3p	miRNA	CH12	hepatocellular carcinoma (HCC)	HCC cells	CH12 treatment	upregulated	24007863
10296	Human	hsa-miR-520a-3p	miRNA	lidocaine	colorectal cancer (CRC)	SW480 cells; HCT116 cells	Lidocaine treatment	upregulated	30262429
10297	Human	hsa-miR-520a-3p	miRNA	lidocaine	retinoblastoma (RB)	"The RB cell line, Y79"	Lidocaine treatment	upregulated	31173241
10298	Human	hsa-miR-520b	miRNA	apigenin	hepatocellular carcinoma (HCC)	doxorubicin-resistant hepatocellular carcinoma cell line BEL-7402/ADM	apigenin treatment	upregulated	29191453
10299	Human	hsa-miR-520b	miRNA	apigenin	hepatocellular carcinoma (HCC)	hepatocellular carcinoma cell line BEL-7402/ADM	apicidin treatment	upregulated	29191453
10300	Human	hsa-miR-520b	miRNA	bufalin	prostate cancer	prostate cancer DU145 and PC3 cells	bufalin treatment	upregulated	31028291
10301	Human	hsa-miR-520b-3p	miRNA	thapsigargin (Tg)	cellular stress response	HeLa cells	thapsigargin (Tg) treatment	Diverse stress conditions trigger a rapid and dramatic decrease in miR-520b-3p and a corresponding increase in ATF5 mRNA over time in HeLa cells.	32603335
10302	Human	hsa-miR-520c	miRNA	glucocorticoid (GC)	myeloma	sensitive RPMI-8226 cell line	chronic glucocorticoid exposure	upregulated	28035377
10303	Human	hsa-miR-520c	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	lung fibrosis	Kasumi-1 cells; K562 cells;MCF7 cells; MDA-MB-231 cells?	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	23820258
10304	Human	hsa-miR-520c-3p	miRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	downregulated	30466095
10305	Human	hsa-miR-520c-3p	miRNA	hypoxia	preeclampsia (PE)	HTR8/SVneo cells	hypoxia induce	downregulated	31143973
10306	Human	hsa-miR-520d-3p	miRNA	monoclonal antibody CH12	inflammatory breast cancer (IBC)	HCC cells	The monoclonal antibody CH12 treatment	CH12 treatment upregulated miR-520-3p and downregulated E2F-1 and TS at the mRNA and protein levels	24007863
10307	Human	hsa-miR-520d-3p	miRNA	"rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)"	diffuse large B-cell lymphoma (DLBCL)	diffuse large B cell lymphoma (DLBCL) patients serum	6 cycles of R-CHOP treatment	dysregulated	24858372
10308	Human	hsa-miR-520d-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial hypoxia/reoxygenation (H/R) injury	human myocardial cell (HCM)	Hypoxia/reoxygenation (H/R)? treatment	"Hypoxia/reoxygenation (H/R) injury could inhibit cell viability, apoptosis and inhibited microRNA-520d-3p expression in HCM."	33389611
10309	Human	hsa-miR-520d-5p	miRNA	midazolam (MDZ)	non-small cell lung cancer (NSCLC)	A549 cells	midazolam treatment	upregulated	31938232
10310	Human	hsa-miR-520e	miRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	A549 cells	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	30475986
10311	Human	hsa-miR-520g	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell lines RPMI-8266 and H929	bortezomib? treatment	miR-520g were significantly downregulated in bortezomib-resistant MM cell lines	31204563
10312	Human	hsa-miR-520g	miRNA	asbestos	non-small cell lung cancer (NSCLC)	serum	asbestos exposure	upregulated	30257964
10313	Human	hsa-miR-520h	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
10314	Human	hsa-miR-520h	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
10315	Human	hsa-miR-520h	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	gastric cancer tissue	5-fluorouracil (5-FU) treatment	downregulated	27081844
10316	Human	hsa-miR-520h	miRNA	bortezomib	multiple myeloma (MM)	Human MM cell lines RPMI-8266 and H929	bortezomib? treatment	miR-520h were significantly downregulated in bortezomib-resistant MM cell lines	31204563
10317	Human	hsa-miR-521	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
10318	Human	hsa-miR-521	miRNA	hypoxia	prostate cancer	LNCaP cells; LNCaP cells exosomes	hypoxia treatment	upregulated	29568403
10319	Human	hsa-miR-521	miRNA	radiation	prostate cancer	LNCaP cells;C4-2 cells	radiation treatment	upregulated	18668526
10320	Human	hsa-miR-522	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	hepatitis B virus (HBV) infection	upregulated	32128112
10321	Human	hsa-miR-522-3p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3ip1 cells; HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
10322	Human	hsa-miR-523	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	hepatitis B virus (HBV) infection	upregulated	32128112
10323	Human	hsa-miR-524*	miRNA	ginsenoside Rg3	angiogenesis	HUVECs	ginsenoside-Rg3 (Rg3) treatment	upregulated	27158236
10324	Human	hsa-miR-524*	miRNA	ginsenoside Rg3	angiomodulation	HUVECs	Ginsenoside-Rg3 treatment	upregulated	27158236
10325	Human	hsa-miR-524-5p	miRNA	nifedipine	angina and hypertension	MDA-MB-231 cells	nifedipine treatment	downregulated	25436889
10326	Human	hsa-miR-524-5p	miRNA	PLX4032 (vemurafenib)	melanoma	SK-Mel-19 cells	PLX4032 (vemurafenib) treatment	downregulated	33142243
10327	Human	hsa-miR-525-3p	miRNA	ionizing radiation (IR)	tumorigenesis	RPE£» HUVEC£»tumor-derived cell lines (HeLa;U2-Os;EA.hy926) cell lines	Ionizing radiation (IR)?treatment	upregulated	24147004
10328	Human	hsa-miR-525-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
10329	Human	hsa-miR-525-3p	miRNA	RV (human Wa RV or Rhesus RV) strains	rotavirus (RV) infection	"human colon cancer Caco-2, HT-29, and HEK293 cells"	infect with RV treatment	downregulated	28890396
10330	Human	hsa-miR-525-5p	miRNA	lipopolysaccharide (LPS)	inflammation	monocytes£» U937 cells	liposaccharide (LPS) treatment	upregulated	20706588
10331	Human	hsa-miR-526b	miRNA	CoCl2	breast cancer	MCF-7 cells	CoCl2 treatment	upregulated	32707933
10332	Human	hsa-miR-526b	miRNA	platelet derived growth factor-BB (PDGF-BB) and insulin-like growth factor (IGF)-1	idiopathic pulmonary fibrosis (IPF)	human fibroblastic cell line (LL-24)	PDGF-BB and IGF-1 treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2	32694556
10333	Human	hsa-miR-527	miRNA	dasatinib	chronic myeloid leukemia (CML)	CML cell line K562	dasatinib treatment	upregulated	30814857
10334	Human	hsa-miR-532	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
10335	Human	hsa-miR-532-3p	miRNA	rituximab (RTX)	chronic lymphocytic leukemia (CLL)	CD19 cells of CML patients	rituximab treatment	downregulated	28126961
10336	Human	hsa-miR-532-3p	miRNA	proanthocyanidin extract (GSPE)	hepatocellular carcinoma (HCC)	HepG2 cells	proanthocyanidin extract (GSPE) treatment	upregulated	21998738
10337	Human	hsa-miR-532-3p	miRNA	ginsenoside 20(S)-Rg3	ovarian cancer (OC)	SKOV3 ovarian cancer cells	Ginsenoside 20(S)-Rg3 treatment	upregulated	29558748
10338	Human	hsa-miR-532-3p	miRNA	estrogen (ES)	postmenopausal osteoporosis (PMOP)	human bone marrow mesenchymal stem cells (BMSCs)	estrogen treatment	downregulated	33577975
10339	Human	hsa-miR-532-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33867350
10340	Human	hsa-miR-532-5p	miRNA	tripterine	hepatocellular carcinoma (HCC)	HCCLM3 celsl; MHCC97H cells	tripterine treatment	"Under tripterine treatment, the level of miR-532-5p was strikingly raised"	32308429
10341	Human	hsa-miR-532-5p	miRNA	5-fluorouracil/mitomycin C (MMC-CRTX)	locally advanced head and neck squamous cell carcinoma (HNSCC)	HNSCC patients head and neck squamous cell carcinoma (HNSCC)	MMC-CRTX treatment	downregulated	28347920
10342	Human	hsa-miR-539	miRNA	lidocaine	lung cancer	A549 and NCI-H1299 cells	Lidocaine treatment	upregulated	31299862
10343	Human	hsa-miR-539-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	HCN-2 cells	oxygen glucose deprivation (OGD) treatment	downregulated	32491927
10344	Human	hsa-miR-539-5p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
10345	Human	hsa-miR-541-3p	miRNA	carfilzomib	familial dysautonomia(FD)	FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs)	carfilzomib treatment	dysregulated	28404519
10346	Human	hsa-miR-541-3p	miRNA	staphylococcal protein A (SpA)	osteomyelitis	Human bone mesenchymal stem cells (hBMSCs)	staphylococcal protein A (SpA) treatment	FAM83H-AS1/miR-541-3p/WNT3A ameliorated SpA-mediated inhibition of the osteogenic differentiation of hBMSCs	31871129
10347	Human	hsa-miR-541-6p	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	Human normal pulmonary fibroblasts MRC-5 and hFL1 and HEK-293 cells	treat with TGF-¦Â treatment	downregulated	28816543
10348	Human	hsa-miR-542-3p	miRNA	T-helper type 2 (Th2)-biased cytokine environment 	allergic asthma (AA)	Bronchial epithelial cells	T-helper type 2 (Th2)-biased cytokine environment treatment	downregulated	26289417
10349	Human	hsa-miR-542-3p	miRNA	aristolochic acid	aristolochic acid nephropathy	Primary human renal PTCs	aristolochic acid (AA) treatment	upregulated	24508230
10350	Human	hsa-miR-542-3p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
10351	Human	hsa-miR-542-3p	miRNA	angiopoietin-1 (Ang-1)	breast cancer	HUVECs	angiopoietin-1 (Ang-1) treatment	downregulated	26272182
10352	Human	hsa-miR-542-3p	miRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	upregulated	30245930
10353	Human	hsa-miR-542-3p	miRNA	resveratrol	breast cancer	breast cancer cell	resveratrol (RS) treatment	downregulated	26890143
10354	Human	hsa-miR-542-3p	miRNA	trastuzumab	breast cancer	SKBR3 and MCF7/Her2 breast cancer cell lines	Trastuzumab treatment	Trastuzumab induced miRNA-542-3p expression in SKBR3 and MCF7/Her2 cells	25586125
10355	Human	hsa-miR-542-3p	miRNA	TGF-¦Â1	liver fibrosis	LX©\2 cells	transforming growth factor ¦Â1 (TGF¦Â1) treatment	upregulated	30368874
10356	Human	hsa-miR-542-3p	miRNA	8-bromo-cyclic adenosine monophosphate (8-bromo-cAMP) and medroxyprogesterone acetate (MPA)	migration and invasion of endometriotic cells	human ectopic endometrial stromal cells (HEcESCs)	8-Br-cAMP and MPA treatment	downregulated	29259466
10357	Human	hsa-miR-542-3p	miRNA	resveratrol	recanalization of thrombi	Endothelial progenitor cells (EPCs)	resveratrol (RSV) treatment	downregulated	31606730
10358	Human	hsa-miR-542-3p	miRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	upregulated	32470449
10359	Human	hsa-miR-542-5p	miRNA	pristimerin	breast cancer	MCF-7 cells; MDA-MB-231 cells	pristimerin treatment	upregulated	32753899
10360	Human	hsa-miR-542-5p	miRNA	pristimerin	ectopic pregnancy (EP)	HTR-8/SVneo cells	pristimerin treatment	downregulated	33173276
10361	Human	hsa-miR-542-5p	miRNA	pristimerin	glioblastoma multiforme (GBM)	Human U373 glioma cells	Pristimerin treatment	downregulated	31015365
10362	Human	hsa-miR-542-5p	miRNA	forskolin and dexamethasone (FSK/DEX)	hyperglycemia and hyperlipoidemia	HepG2 cells	forskolin/dexamethasone (FSK/DEX) treatment	downregulated	32882762
10363	Human	hsa-miR-542-5p	miRNA	oleic acid (OA)	hyperglycemia and hyperlipoidemia	HepG2 cells	oleate treatment	downregulated	32882762
10364	Human	hsa-miR-542-5p	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
10365	Human	hsa-miR-542¨C5p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
10366	Human	hsa-miR-543	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
10367	Human	hsa-miR-543	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT8 cells	5-fluorouracil (5-FU) treatment	upregulated	30842340
10368	Human	hsa-miR-543	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	The L-OHP-resistant cell line HCT-8/L and its parental cell line HCT-8	dichloroacetate (DCA) treatment	downregulated	31762813
10369	Human	hsa-miR-543	miRNA	oxaliplatin	colorectal cancer (CRC)	The L-OHP-resistant cell line HCT-8/L and its parental cell line HCT-8	oxaliplatin (L-OHP) treatment	upregulated	31762813
10370	Human	hsa-miR-543	miRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high glucose (HG) treatment	upregulated	31056258
10371	Human	hsa-miR-543	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
10372	Human	hsa-miR-543	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
10373	Human	hsa-miR-543	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"human gastric cancer tissue, the human gastric cancer cell lines SNU1, AGS, MGC803, and MKN1"	Helicobacter pylori (H. pylori) infection	upregulated	31423013
10374	Human	hsa-miR-543	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	hypertension	insulin-resistant HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26562529
10375	Human	hsa-miR-543	miRNA	suberoylanilide hydroxamic acid (SAHA)	neuroblastoma (NB)	SH-SY5Y cells	suberoylanilide hydroxamic acid (SAHA) treatment	downregulated	30091530
10376	Human	hsa-miR-543	miRNA	TGF-¦Â2	cell proliferation	ARPE-19 cells	TGF-¦Â2 treatment	"miR-543 was found in exosomes from EMTed RPE cells, and miR-543-enriched exosomes significantly induced the EMT of recipient RPE cells"	33047885
10377	Human	hsa-miR-543	miRNA	H2O2	cell senescence	hMSCs	400 ¦ÌM hydrogen peroxide solution treatment	downregulated	25465621
10378	Human	hsa-miR-543	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
10379	Human	hsa-miR-543*	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	upregulated	25552929
10380	Human	hsa-miR-544	miRNA	cisplatin (DDP)	esophageal squamous cell carcinoma (ESCC)	"The EC9706, KYSE450 and TE-1 human ESCC cell lines and the human immortalized normal esophageal epithelial cell line HET-1A"	cisplatin treatment	"overexpression of miR-544 led to increased sensitivity of ESCC cells to cisplatin, an anticancer drug."	31579422
10381	Human	hsa-miR-544a-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
10382	Human	hsa-miR-545	miRNA	lipopolysaccharide (LPS)	HK-2 cells injury	HK-2 cells	Lipopolysaccharide (LPS) treatment	highly expressed circPRKCI relieved inflammatory injury induced by LPS in HK2 cells by suppressing miR-545/ZEBs and depressing the briskness of NF-kB pathway.	32104945
10383	Human	hsa-miR-545	miRNA	H2O2	oxidative stress	SH-SY5Y neuronal cells	H2O2 treatment	upregulated	31053300
10384	Human	hsa-miR-545-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10385	Human	hsa-miR-548a-3p	miRNA	IL-22	psoriasis	human keratinocytes (HaCaT)	Interleukin-22 (IL-22) treatment	upregulated	29181737
10386	Human	hsa-miR-548a-5p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	upregulated	26987780
10387	Human	hsa-miR-548aa	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
10388	Human	hsa-miR-548ah-5p	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HT29 cells	5-fluorouracil (5-FU) treatment	downregulated	25526515
10389	Human	hsa-miR-548an	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
10390	Human	hsa-miR-548as-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	non-small cell lung cancer (NSCLC)	H1299 NSCLC cell line	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30727918
10391	Human	hsa-miR-548c-3p	miRNA	doxorubicin (DOX)	breast cancer	MDA-MB-231;MDA-MB-468;MCF-10A;MCF-7 cell lines	doxorubicin treatment	miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability	25802200
10392	Human	hsa-miR-548d-3p	miRNA	BET inhibitors (JQ1)	breast cancer	MDA-MB-231 cells; BT549 cells	BET bromodomain inhibitors (BETi)-JQ1 treatment	"JQ1 treatment evicts BRD4 from the FOXD3-localized MIR548D1 gene promoter, leading to repression of miR-548d-3p."	31937753
10393	Human	hsa-miR-548d-5p	miRNA	dexamethasone (DEX)	corticosteroid-induced osteonecrosis	hBMSCs	dexamethasone (DEX) treatment	downregulated	24929254
10394	Human	hsa-miR-548d-5p	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
10395	Human	hsa-miR-548d-5p	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
10396	Human	hsa-miR-548j	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
10397	Human	hsa-miR-548z	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
10398	Human	hsa-miR-549	miRNA	neoadjuvant multimodality ment	adenocarcinomas	serum	received neoadjuvant therapy and subsequently underwent surgical resection treatment	upregulation	25429911
10399	Human	hsa-miR-550	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
10400	Human	hsa-miR-550	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
10401	Human	hsa-miR-550	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	upregulated	22366961
10402	Human	hsa-miR-550a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetes mellitus (DM)	B cells of diabetic patients	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulation	27935135
10403	Human	hsa-miR-550a	miRNA	"glucose deprived, galactose enriched (GAL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
10404	Human	hsa-miR-550a	miRNA	"lipid reduced, cholesterol deficient (RL)"	distinct metabolic stressors	human dermal fibroblasts	"glucose deprived, galactose enriched (GAL) or lipid reduced, cholesterol deficient (RL) treatment"	dysregulated	24246224
10405	Human	hsa-miR-550a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human retinal pigment epithelial cells	TGF-¦Â1 treatment	downregulated	25263462
10406	Human	hsa-miR-550a-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10407	Human	hsa-miR-551a	miRNA	5-fluorouracil (5-Fu)	drug resistance	Hep3B cells	5-fluorouracil (5-FU) treatment	"miR-551a-expressing cells (Hep3B-lenti-miR-551a) were resistant to 5-FU-induced cell death, and after 5-FU treatment, and showed significant increases in cell viability, cell survival, and sphere formation."	30703870
10408	Human	hsa-miR-551a	miRNA	oral zinc gluconate	esophageal cancer (EC)	barrett's esophagus (BE)	oral zinc gluconate treatment	upregulated	32415564
10409	Human	hsa-miR-551a	miRNA	demethoxycurcumin	ovarian cancer (OC)	human epithelia ovarian cancer cells	demethoxycurcumin treatment	upregulated	28345465
10410	Human	hsa-miR-551b-5p	miRNA	mechanical stretch	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	"mechanical stretch for 3 h (60 cycles/min, 15% elongation)"	upregulated	28639574
10411	Human	hsa-miR-552-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
10412	Human	hsa-miR-552-3p	miRNA	dichloroacetate (DCA)	colorectal cancer (CRC)	HCT116 cells	dichloroacetate (DCA) treatment	downregulated	31597953
10413	Human	hsa-miR-556-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32536864
10414	Human	hsa-miR-557	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
10415	Human	hsa-miR-557	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
10416	Human	hsa-miR-557	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
10417	Human	hsa-miR-557	miRNA	fibroblast growth factor 2 (FGF2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	fibroblast growth factor 2 (FGF2) treatment	downregulated	30414893
10418	Human	hsa-miR-558	miRNA	IL-1¦Â	osteoarthritis (OA)	human articular chondrocytes and OA chondrocytes	IL-1¦Â treatment	downregulated	23611898
10419	Human	hsa-miR-558	miRNA	CoCl2	spinal cord injury (SCI)	AGE1.HN	CoCl2 treatment	circ-HIPK3 relieves the neuronal cell apoptosis through regulating miR-588/DPYSL5 axis in SCI.	32247616
10420	Human	hsa-miR-5583-5p	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	downregulated	28007639
10421	Human	hsa-miR-5583-5p	miRNA	altertoxin II (ATX II)	cytotoxicity	HepG2	altertoxin II (ATX II) treatment	downregulated	28007639
10422	Human	hsa-miR-561	miRNA	acetaminophen (APAP)	hepatotoxicity	HepG2 cells	acetaminophen (APAP) treatment	upregulated	24104199
10423	Human	hsa-miR-561	miRNA	retinoic acid (RA)	human neuronal differentiation	SH-SY5Y cells	retinoic acid (RA) treatment	downregulated	30951518
10424	Human	hsa-miR-561	miRNA	acetaminophen (APAP)	macular degeneration	HepG2 cells and primary human hepatocytes	acetaminophen (APAP) treatment	upregulated	24104199
10425	Human	hsa-miR-564	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	hPC and HEK 293	TGF-¦Â treatment	TMEM63C Is Regulated by MicroRNA-564 and Transforming Growth Factor beta in Human Renal Cells	33080601
10426	Human	hsa-miR-564	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
10427	Human	hsa-miR-565	miRNA	hepatitis C virus (HCV)	hepatocellular carcinoma (HCC)	Huh7.5 parental hepatoma cells	hepatitis C virus (HCV) infection	downregulated	23418453
10428	Human	hsa-miR-5680	miRNA	high glucose (HG)	autophagy	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680.	30957640
10429	Human	hsa-miR-5680	miRNA	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO)	vascular endothelial cells (VECs) autophagy and apoptosis	human vascular endothelial cells (VECs)	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment	3BDO promoted the expression of miR-5680 in VECs under high glucose conditions.	30957640
10430	Human	hsa-miR-569	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	upregulated	30100735
10431	Human	hsa-miR-5701	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y cells	6-hydroxydopamine (6-OHDA) treatment	The level of miR-5701 was significantly downregulated in the presence of 6-OHDA.	28710704
10432	Human	hsa-miR-5701	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	SH-SY5Y Cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28710704
10433	Human	hsa-miR-5703	miRNA	luteolin and gefitinib	prostate cancer	PC-3 cells	luteolin and/or gefitinib treatment	upregulated	24971999
10434	Human	hsa-miR-570-3p	miRNA	metformin (Met)	osteosarcoma (OS)	143B and U2OS cells	Metformin treatment	upregulated	29795113
10435	Human	hsa-miR-571	miRNA	alcohol	liver cirrhosis	blood	alcohol exposure	upregulated	22412969
10436	Human	hsa-miR-572	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SK-N-SH cell lines	fluoxetine treatment	upregulated	27716787
10437	Human	hsa-miR-572	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
10438	Human	hsa-miR-572	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
10439	Human	hsa-miR-573	miRNA	hyperbaric oxygen (HBO)	intervertebral disc degeneration (IDD)	human degenerative nucleus pulposus (NP) cells	hyperbaric oxygen (HBO)?induce	MiR-573 was induced by HBO and simultaneous suppression of Bax was observed in NP cells.	33413477
10440	Human	hsa-miR-574	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune defense	Human nasal epithelial cells (HNECs)	poly I:C treatment	upregulated	25959385
10441	Human	hsa-miR-574-3p	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
10442	Human	hsa-miR-574-3p	miRNA	remnant-like lipoproteins (RLPs)	ePCs senescence	Total peripheral mononuclear cells (PB-MNCs)	Remnant-like lipoproteins (RLPs) treatment	miR-148b and miR-155 were upregulated while miR-574-3p was downregulated	23044309
10443	Human	hsa-miR-574-3p	miRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	SKOV3 and CAOV3 cells	cisplatin treatment	downregulated	31396325
10444	Human	hsa-miR-574-3p	miRNA	paclitaxel (PTX)	epithelial ovarian cancer (EOC)	SKOV3 and CAOV3 cells	paclitaxel treatment	downregulated	31396325
10445	Human	hsa-miR-574-3p	miRNA	TGF-¦Â1	gastric cancer (GC)	AGS cells	TGF-¦Â1 treatment	upregulated	28042090
10446	Human	hsa-miR-574-3p	miRNA	X-rays	genotoxicity	the lung cancer cell line A549	X-ray irradiation treatment	upregulated	24566139
10447	Human	hsa-miR-574-3p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
10448	Human	hsa-miR-574-3p	miRNA	"myclobutanil, propiconazole, and triadimefon"	hepatocellular carcinoma (HCC)	HepG2 cells	"myclobutanil, propiconazole, and triadimefon treatment"	downregulated	23159985
10449	Human	hsa-miR-574-3p	miRNA	sodium butyrate (NaB)	lung cancer	A549 cells	sodium butyrate(NaB) treatment	upregulated	29231270
10450	Human	hsa-miR-574-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	HK1 cell line	concentration treatment	dysregulated	24896104
10451	Human	hsa-miR-574-3p	miRNA	TGF-¦Â1	gastric cancer (GC)	AGS cells	induced upregulation in treatment	upregulated	28042090
10452	Human	hsa-miR-574-3p	miRNA	genistein	prostate cancer	"Human PCa cell lines, PC3£» DU145£»non-malignant epithelial prostate cell line, RWPE-1"	Genistein? treatment	upregulated	23554959
10453	Human	hsa-miR-574-3p	miRNA	lectin	prostate cancer	Prostate cancer (PC) cell lines	lectin treatment	upregulated	26417675
10454	Human	hsa-miR-574-5p	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
10455	Human	hsa-miR-574-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	"In ARDS models, microRNA-574-5p (miR-574-5p) expression could be induced by the TLR4/NF-¦ÊB pathway upon LPS stimulation."	33202146
10456	Human	hsa-miR-574-5p	miRNA	TGF-¦Â	cardiac fibrosis	human cardiac fibroblasts (HCFs)	TGF-¦Â treatment	upregulated	31672272
10457	Human	hsa-miR-574-5p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
10458	Human	hsa-miR-575	miRNA	5-fluorouracil (5-Fu)	actinobacillus pleuropneumoniae infection	MCF-7 cells	5-fluorouracil (5-FU) treatment	upregulated	21506117
10459	Human	hsa-miR-575	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
10460	Human	hsa-miR-575	miRNA	angiopoietin-1 (Ang-1)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	downregulated	30414893
10461	Human	hsa-miR-575	miRNA	angiopoietin-2 (Ang-2)	angiogenesis	human umbilical vein endothelial cells (HUVECs)	angiopoietin-2 (Ang-2) treatment	downregulated	30414893
10462	Human	hsa-miR-575	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	downregulated	19022373
10463	Human	hsa-miR-576-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87 and U251 cells	hypoxia induce	downregulated	31017266
10464	Human	hsa-miR-576-3p	miRNA	granulocyte-colony stimulating factor (G-CSF)	leukemia	CD34+ cells	Granulocyte colony-stimulating factor?treatment	upregulated	24056818
10465	Human	hsa-miR-577	miRNA	TGF-¦Â	gastric cancer (GC)	human GC cell lines (MKN45 and MGC803)	Transforming growth factor ¦Â (TGF-¦Â) treatment	upregulated	30879950
10466	Human	hsa-miR-579	miRNA	mycobacterium tuberculosis (Mtb)	apoptosis	primary human monocyte-derived macrophages	Mycobacterium tuberculosis (MTB) infection	upregulated	31434611
10467	Human	hsa-miR-579	miRNA	dexamethasone (DEX)	cytotoxicity	DEX-treated human OB-6 osteoblastic cells	dexamethasone (Dex) treatment	miR-579 is upregulated in the necrotic femoral head tissues of DEX-taking human patients as well as in DEX-treated human osteoblasts. Forced miR-579 overexpression induced significant cytotoxicity in human osteoblasts.	31376935
10468	Human	hsa-miR-580-3p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
10469	Human	hsa-miR-582-3p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	osteogenesis	human adipose-derived Mesenchymal stem cells (hAMSCs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	29218085
10470	Human	hsa-miR-582-5p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	NNT-AS1 played a promoting role in smoking-induced COPD via modulating miR-582-5p/FBXO11 signaling.	32768929
10471	Human	hsa-miR-582-5p	miRNA	ozone (O3)	epigenetic regulation of responses to O3 exposure	healthy adult human sputum	exposed to 0.4 ppm O3 for 2 h treatment	upregulated	24771714
10472	Human	hsa-miR-582-5p	miRNA	heroin	immunosuppression	monocytes	heroin treatment	downregulated	26978739
10473	Human	hsa-miR-582-5p	miRNA	particulate matter (PM2.5)	lung cancer	BEAS-2B and HBE cells	particulate matter (PM2.5) treatment	Loss of NEAT1 represses the malignant transformation of BEAS-2B and HBE cells induced by PM25	33829382
10474	Human	hsa-miR-582-5p	miRNA	berberine (BBR)	melanoma	A375 cells	berberine (BBR) treatment	The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression.	32915362
10475	Human	hsa-miR-584	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	downregulated	28886127
10476	Human	hsa-miR-584	miRNA	porphyromonas gingivalis	anti-inflammatory responses	OBA-9(immortalized HGECs)	Pg treatment	upregulated	24228808
10477	Human	hsa-miR-584	miRNA	TGF-¦Â	breast cancer	breast cancer cells	?TGF-¦Â treatment	downegulated	23479725
10478	Human	hsa-miR-584	miRNA	porphyromonas gingivalis	destructive periodontitis	Human Gingival Epithelial Cells(HGECs)	Porphyromonas gingivalis treatment	upregulated	24228808
10479	Human	hsa-miR-584	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neuroblastoma (NB)	neuroblastoma cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
10480	Human	hsa-miR-584	miRNA	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf)	neurological disorders	SK-N-SH cells	bovine lactoferrin (bLf) and iron saturated lactoferrin (Fe-bLf) treatment	downregulated	25498991
10481	Human	hsa-miR-584-3p	miRNA	metformin (Met)	melanoma	"The human melanoma cell lines A375, A2058, HS695T, MeWo and RPMI7951"	Metformin treatment	upregulated	30754729
10482	Human	hsa-miR-584-5p	miRNA	radix tetrastigma hemsleyani (RTH)	lung cancer	A549 cells	radix tetrastigma hemsleyani (RTH) treatment	downregulated	30100735
10483	Human	hsa-miR-585-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y Cells	1-methyl-4-phenylpyridinium (MPP+) treatment	H19 knockdown markedly increased miR-585-3p expression.	32356199
10484	Human	hsa-miR-589	miRNA	antrodia cinnamomea	cancer treatment	"THP-1, GBM 8401,A549,MDA-MB-231,HepG2,SW620,HS68"	antrodia cinnamomea treatment	downregulated	28602756
10485	Human	hsa-miR-589	miRNA	proline-rich polypeptide 1 (PRP-1)	chondrosarcoma	human JJ012 chondrosarcoma cell line	PRP-1 treatment	downregulated	24178909
10486	Human	hsa-miR-589	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	HMrSV5 cells	TGF-¦Â1 treatment	The changes were accompanied with notably decreased level of miRNA589 in HMrSV5 cells treated with TGF¦Â1	23118514
10487	Human	hsa-miR-589	miRNA	H2O2	oxidative stress	SH-SY5Y neuronal cells	H2O2 treatment	upregulated	31053300
10488	Human	hsa-miR-589-3p	miRNA	lipopolysaccharide (LPS)	lumbar disc degeneration (LDD)	human NP cell line	lipopolysaccharide (LPS) treatment	upregulated	29434746
10489	Human	hsa-miR-589-3p	miRNA	lipopolysaccharide (LPS)	lumbar disc degeneration (LDD)	Nucleus pulposus (NP) cells	Lipopolysaccharide (LPS) treatment	upregulated	29434746
10490	Human	hsa-miR-590	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	upregulated	30602960
10491	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	26648441
10492	Human	hsa-miR-590	miRNA	nobiletin	atherosclerosis (AS)	human THP-1 macrophages	Nobiletin treatment	upregulated	30471854
10493	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	The human umbilical vascular endothelial cell (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	26648441
10494	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30799593
10495	Human	hsa-miR-590	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein ECs (HUVECs); human coronary artery ECs (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33022677
10496	Human	hsa-miR-590	miRNA	Ag¨CTiO2 photocatalyst particles	nasopharyngeal carcinoma (NPC)	5-8F human NPC cell derived exosomes	Ag¨CTiO2 treatment	upregulated	27598726
10497	Human	hsa-miR-590	miRNA	hydroxychloroquine plus prednisone	systemic lupus erythematosus (SLE)	Th17 cells	Hydroxychloroquine (HCQ) plus prednisone treatment	upregulated	29545450
10498	Human	hsa-miR-590-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29436491
10499	Human	hsa-miR-590-3p	miRNA	melatonin	apoptosis	human fetal osteoblastic cell line hFOB 1.19	Melatonin treatment	downregulated	29568931
10500	Human	hsa-miR-590-3p	miRNA	radiation	colorectal cancer (CRC)	HCT116 cells	radiation treatment	upregulated	33738143
10501	Human	hsa-miR-590-3p	miRNA	hypoxia	coronary artery disease (CAD)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	Long non-coding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR-590-3p under hypoxic conditions.	32323787
10502	Human	hsa-miR-590-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	downregulated	31618425
10503	Human	hsa-miR-590-3p	miRNA	hypoxia	angiogenesis 	Primary human ADSCs (ADSCs)	hypoxia treatment	downregulated	32277427
10504	Human	hsa-miR-590-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	The immortalized human chondrocytes cell lines C20/A4	IL-1¦Â treatment	upregulated	31571401
10505	Human	hsa-miR-590-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	MES23.5 and SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	27064872
10506	Human	hsa-miR-590-3p	miRNA	YKL-40	rheumatoid arthritis (RA)	human osteoblast-like cell line MG-63	stimulated with YKL-40 for 24 h treatment	downregulated	28448439
10507	Human	hsa-miR-590-3p	miRNA	H2O2	cell senescence	hMSCs	400 ¦ÌM hydrogen peroxide solution treatment	downregulated	25465621
10508	Human	hsa-miR-590-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	human airway smooth muscle cells (ASMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	downregulated	33825599
10509	Human	hsa-miR-590-5p	miRNA	platelet-derived growth factor (PDGF)	asthma	fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	downregulated	30154893
10510	Human	hsa-miR-590-5p	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	HUVEC	angiotensin II (Ang II) treatment	downregulated	26906623
10511	Human	hsa-miR-590-5p	miRNA	galacto-oligosaccharides (GOS)	colitis	normal and LPS-stimulated human colon epithelial FHC cells	galacto-oligosaccharides (GOS) treatment	upregulated	31226416
10512	Human	hsa-miR-590-5p	miRNA	lipopolysaccharide (LPS)	colitis	human colon epithelial FHC cells	lipopolysaccharide (LPS) treatment	downregulated	31226416
10513	Human	hsa-miR-590-5p	miRNA	hypoxia	colorectal cancer (CRC)	human colorectal cancer cell lines RKO and HCT116	hypoxia treatment	upregulated	29247825
10514	Human	hsa-miR-590-5p	miRNA	hypoxia	colorectal cancer (CRC)	"colorectal cancer (CRC) cell lines RKO, HCT116, SW480, HT29, SW620, LS174T, LoVo, SW403, Colo205, DLD-1, HCT15"	hypoxia induce	upregulated	29247825
10515	Human	hsa-miR-590-5p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
10516	Human	hsa-miR-590-5p	miRNA	human papillomavirus E6 and E7	human papillomaviruses (HPV) infection	K16 and K38 supernatants	Human papillomavirus E6 and E7 treatment	"HPV-16 and/or HPV-38 E6 and E7 single proteins can modify the expression of selected miRNAs involved in the tumorigenesis, in particular miR-18a, -19a, -34a and -590-5p."	27300513
10517	Human	hsa-miR-590-5p	miRNA	heroin	immunosuppression	monocytes	heroin treatment	downregulated	26978739
10518	Human	hsa-miR-590-5p	miRNA	TGF-¦Â1	intrauterine adhesion (IUA)	human embryonic stem cells (hESCs)	TGF-¦Â1 treatment	lncRNA TUG1 promotes endometrial fibrosis and inflammation by sponging miR-590-5p to regulate Fasl in intrauterine adhesions	32599321
10519	Human	hsa-miR-590-5p	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	MRC-5 cells	IAV/Hong Kong/498/97 (H3N2) treatment	Viral infection up-regulates miR-590-5p expression.	30291142
10520	Human	hsa-miR-592	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	upregulated	26298803
10521	Human	hsa-miR-593	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	NPC cells	curcumin treatment	upregulated	27313684
10522	Human	hsa-miR-593-3p	miRNA	insulin	hepatocellular carcinoma (HCC)	hepatocellular carcinoma HepG2 and Bel7402 cells	Insulin treatment	upregulated	27613819
10523	Human	hsa-miR-593-5p	miRNA	cisplatin (DDP)	rectal cancer	SW837 cells; HR8348 cells	cisplatin treatment	"LINC00461 mediates cisplatin resistance of rectal cancer by targeting miR-593-5p/CCND1 axis, shedding new light on the treatment of rectal cancer."	31972361
10524	Human	hsa-miR-593-5p	miRNA	cisplatin (DDP)	tongue squamous cell carcinoma (TSCC)	tongue squamous cell carcinoma (TSCC) cells	cisplatin treatment	downregulated	25912308
10525	Human	hsa-miR-596	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
10526	Human	hsa-miR-596	miRNA	steroids	non-traumatic osteonecrosis of femoral head (ONFH)	bone marrow	steroid treatment	upregulated	32410637
10527	Human	hsa-miR-598	miRNA	alpha-1 antitrypsin (AAT)	anti-inflammatory responses	monocytes of AAT deficient (ZZ) individuals	alpha-1 antitrypsin (AAT) treatment	downregulated	29062067
10528	Human	hsa-miR-599	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	32248560
10529	Human	hsa-miR-599	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33235026
10530	Human	hsa-miR-599	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33566259
10531	Human	hsa-miR-599	miRNA	IL-1¦Â	osteoarthritis (OA)	human chondrocytes	IL-1¦Â treatment	circANKRD36 sponge miR-599 to up-regulate the expression of Casz1 and thus prevent apoptosis and inflammation in OA.	33205602
10532	Human	hsa-miR-599	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	30720180
10533	Human	hsa-miR-601	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
10534	Human	hsa-miR-601	miRNA	H2O2	oxidative stress	ARPE-19?cells and primary human RPE cells	H2O2 treatment	upregulated	31178131
10535	Human	hsa-miR-601	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
10536	Human	hsa-miR-602	miRNA	troxerutin	alopecia	HDP cells	troxerutin treatment	has-miR-602 was the most markedly upregulated by troxerutin in the H2O2-treated HDP cells	25955790
10537	Human	hsa-miR-605	miRNA	"anthranilamide-pyrazolo[1,5-a]pyrimidine"	neuroblastoma (NB)	neuronalcancer cells lines MR-32; SK-N-SH	"anthranilamide-pyrazolo[1,5-a]pyrimidine treatment"	upregulated	23992861
10538	Human	hsa-miR-608	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	neuroblastoma (NB)	SK-N-SH neuroblastoma cells	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	28860601
10539	Human	hsa-miR-608	miRNA	doxorubicin (DOX)	non-small cell lung cancer (NSCLC)	NSCLC cell lines A549 and HCC4006	doxorubicin treatment	"overexpression of miR-608 promoted doxorubicin-induced apoptosis in NSCLC cell lines A549 and HCC4006 by inhibiting the expression of transcription factor activating enhancer-binding protein 4 (TFAP4), and high expression levels of TFAP4 were observed in NSCLC tissues."	31552102
10540	Human	hsa-miR-608	miRNA	physcion 8-O-¦Â-glucopyranoside (PG)	ovarian cancer (OC)	SKOV3 cells	physcion 8-O-¦Â-glucopyranoside (PG) treatment	downregulated	31299866
10541	Human	hsa-miR-6086	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	TNF¦Á-induced endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29605606
10542	Human	hsa-miR-6088	miRNA	steviol	gastrointestinal cancer	HCT-116 cells	steviol treatment	downregulated	29899860
10543	Human	hsa-miR-6088	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
10544	Human	hsa-miR-612	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MCF-7 cells	anacardic acid (AnAc) treatment	upregulated	28886127
10545	Human	hsa-miR-612	miRNA	anacardic acid (AnAc)	anacardic acid (AnAc) activity	MDA-MB-231 cells	anacardic acid (AnAc) treatment	upregulated	28886127
10546	Human	hsa-miR-6126	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	upregulated	29337256
10547	Human	hsa-miR-6127	miRNA	cyclosporine A (CsA)	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	cyclosporine A (CsA) treatment	downregulated	31371743
10548	Human	hsa-miR-6127	miRNA	rapamycin	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	rapamycin (RAPA) treatment	upregulated	31371743
10549	Human	hsa-miR-613	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	paclitaxel (PTX) treatment	Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis	32425595
10550	Human	hsa-miR-613	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	L02 cells	oleic acid (OA) treatment	"CCAT1 increases LXR¦Á transcription by serving as a competing endogenous RNA for miR-613 in an LXRE-dependent manner, thereby promoting lipid droplet formation and NAFLD."	32413192
10551	Human	hsa-miR-613	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	MiRNA-613 alleviates IL-1¦Â-induced injury in chondrogenic CHON-001 cells by targeting fibronectin 1.	33042421
10552	Human	hsa-miR-6132	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
10553	Human	hsa-miR-615	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
10554	Human	hsa-miR-615-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	myocardial infarction (MI)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31355606
10555	Human	hsa-miR-615-3p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
10556	Human	hsa-miR-615-3p	miRNA	hypoxia	non-small cell lung cancer (NSCLC)	two NSCLC cell lines (A549 and H1299)	hypoxia induce	downregulated	31422060
10557	Human	hsa-miR-615-5p	miRNA	bovine serum albumin (BSA)	focal segmental glomerulosclerosis (FSGS)	HK-2 cells	bovine serum albumin (BSA) treatment	downregulated	32800553
10558	Human	hsa-miR-615-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	upregulated	23525256
10559	Human	hsa-miR-616	miRNA	tissue factor pathway inhibitor TFPI-2	metabolic syndrome	prostate cancer cells	tissue factor pathway inhibitor TFPI-2 treatment	"reexpression of TFPI-2 in LNCaP cells with stable miR-616 overexpression rescued the AD phenotype, TFPI-2 expression to be inversely correlated to miR-616 in a series of prostate cell lines"	21224345
10560	Human	hsa-miR-616-5p	miRNA	sulforaphane (SFN)	lung cancer	"human NSCLC cell lines H1299, 95C and 95D"	sulforaphane treatment	upregulated	27890917
10561	Human	hsa-miR-616-5p	miRNA	sulforaphane (SFN)	non-small cell lung cancer (NSCLC)	"human H1299, 95C, and 95D NSCLC cell lines"	100 ¦Ìg/mL streptomycin treatment	downregulated	27890917
10562	Human	hsa-miR-616¨C5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	SH-SY5Y human neuroblastoma cells	GDNF	downregulated	28829278
10563	Human	hsa-miR-617	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
10564	Human	hsa-miR-617	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
10565	Human	hsa-miR-619	miRNA	arsenite	arsenic-induced skin lesions	plasma	arsenic exposure	upregulated	31359311
10566	Human	hsa-miR-619-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
10567	Human	hsa-miR-619-3p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV)-induced liver disease and hepatocarcinogenesis	Huh7.5.1 cells	hepatitis C virus (HCV) infection	upregulated	31076402
10568	Human	hsa-miR-620	miRNA	TGF-¦Â1	asthma	human airway smooth muscle cells (ASMCs)	TGF-¦Â1 treatment	upregulated	32583575
10569	Human	hsa-miR-622	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"The expression of circ_ANRIL in OGD/R-induced human brain microvascular endothelial cells (HBMECs) was significantly upregulated, while that of miR-622 was significantly downregulated"	32616043
10570	Human	hsa-miR-622	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
10571	Human	hsa-miR-622	miRNA	5-fluorouracil (5-Fu)	locally advanced rectal cancer (LARC)	Tumor tissues	5-fluorouracil (5-FU) treatment	upregulated	25961730
10572	Human	hsa-miR-622	miRNA	FOXO3a	lung cancer	U0126-treated A549 cells	FOXO3a treatment	upregulated	26528854
10573	Human	hsa-miR-622	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	downregulated	27524914
10574	Human	hsa-miR-622	miRNA	high glucose (HG)	vascular smooth muscle aging	human umbilical vein endothelial cell (HUVEC)	high glucose (HG) treatment	HG-HUVECs derived exosomes induced the VSMCs senescence by circRNA0077930-miR622-Kras CeRNA network.	32307741
10575	Human	hsa-miR-623	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
10576	Human	hsa-miR-623	miRNA	hypoxia	myocardial infarction (MI)	human cardiomyocytes (HMCs)	hypoxia treatment	downregulated	32222118
10577	Human	hsa-miR-625	miRNA	1-methyl-4-phenylpyridinium (MPP+)	neuronal cell injury	human neuroblastoma SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	lnc-p21 regulated MPP + -induced neuronal injury by sponging miR-625 and upregulating TRPM2 in SH-SY5Y cells	31004593
10578	Human	hsa-miR-625	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human neuroblastoma SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	lnc-p21 regulated MPP + -induced neuronal injury by sponging miR-625 and upregulating TRPM2 in SH-SY5Y cells	31004593
10579	Human	hsa-miR-625*	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec1A cells	Progesterone treatment	upregulated	22543862
10580	Human	hsa-miR-625-3p	miRNA	oxaliplatin	metastatic colorectal cancer (mCRC)	HCT116 cells; LoVo cells	oxaliplatin? treatment	High expression of microRNA-625-3p	23506979
10581	Human	hsa-miR-625-3p	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC-9 cells	Gefitinib treatment	miR-625-3p expression was downregulated in the HCC827GR cells.	32319651
10582	Human	hsa-miR-625-3p	miRNA	icariin (ICA)	thyroid cancer (TC)	SW579 cells;TPC1 cells	icariin (ICA) treatment	downregulated	30551506
10583	Human	hsa-miR-625-3p	miRNA	icariin (ICA)	thyroid cancer (TC)	SW579 and TPC1 cells	icariin (ICA) treatment	downregulated	30551506
10584	Human	hsa-miR-625-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (hNPC) and annulus fibrosus cells (hAFC)	lipopolysaccharide (LPS) treatment	upregulated	30972168
10585	Human	hsa-miR-625-5p	miRNA	lipopolysaccharide (LPS)	asthma	human bronchial epithelial cells (HBECs) 16HBEC	lipopolysaccharide (LPS) treatment	upregulated	30628701
10586	Human	hsa-miR-625-5p	miRNA	hypoxia	glioblastoma multiforme (GBM)	"The normal human astrocyte line SVGp12 and two human glioma cell lines, U87MG and A172"	hypoxia induce	downregulated	30988674
10587	Human	hsa-miR-625-5p	miRNA	hypoxia	hypoxia-induced injury	?12 soft tissue sarcoma cell lines	was exposed to 1% oxygen (hypoxia) for up to 48 h treatment	downregulated	24927770
10588	Human	hsa-miR-626	miRNA	H2O2	age-related macular degeneration (AMD)	ARPE-19?cells and primary human RPE cells	H2O2 treatment	downregulated	31446056
10589	Human	hsa-miR-627	miRNA	TGF-¦Â1	lung fibrosis	normal human lung fibroblast	TGF-¦Â1 treatment	downregulated	30536600
10590	Human	hsa-miR-627	miRNA	TGF-¦Â1	lung fibrosis	normal human lung fibroblast (NHLF)	TGF-¦Â1 treatment	downregulated	30536600
10591	Human	hsa-miR-627	miRNA	TGF-¦Â1	lung fibrosis	normal human primary lung fibroblasts (NHLFs)	TGF-¦Â1 treatment	downregulated	33482190
10592	Human	hsa-miR-627-5p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
10593	Human	hsa-miR-627-5p	miRNA	palbociclib	glioblastoma multiforme (GBM)	"HMC3 cells, temozolomide-resistant (TMZ-R) cells"	palbociclib treatment	"SNHG15 to promote GBM tumorigenesis was by inhibiting tumor suppressor, miR-627-5p which leads to activation of CDK6"	31462285
10594	Human	hsa-miR-628-5p	miRNA	acute bout of resistance exercise	"ageing, activation of Rho signalling"	older (60-75 years) people	acute bout of resistance exercise	upregulated	27739650
10595	Human	hsa-miR-628-5p	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	A-172; SHG-44	Sevoflurane (Sev) treatment	Sev mediated glioma progression via circ_0002755/miR-628-5p/MAGT1 axis	32669871
10596	Human	hsa-miR-629	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	31240850
10597	Human	hsa-miR-629-3p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	human bronchial epithelial (16HBE) cells	infect with EV71 and CA16	dysregulated	27890633
10598	Human	hsa-miR-629-3p	miRNA	enterovirus 71 (EV71) and coxsackievirus A16 (CA16)	hand-foot-mouth disease (HFMD)	Human bronchial epithelial (16HBE) cells	Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) treatment	dysregulated	27890633
10599	Human	hsa-miR-629-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	glioblastoma multiforme (GBM)	human U251 glioma cells	50 ng/mL GDNF for 24 h	upregulated	29224008
10600	Human	hsa-miR-630	miRNA	4-aminobiphenyl (4-ABP)	4-Aminobiphenyl (4-ABP)-induced liver injury	Hep3B cells; L-02 cells	4-Aminobiphenyl (4-ABP) treatment	4-ABP induced miR-630 expression in Hep3B and L-02 cells.	32433928
10601	Human	hsa-miR-630	miRNA	H2O2	age-related nuclear cataract	human lens epithelial B3 (HLE-B3) cell	H2O2 treatment	upregulated	29653565
10602	Human	hsa-miR-630	miRNA	H2O2	cataract	HLE-B3 cells	H2O2 treatment	miR-630 was significantly upregulated in HLE-B3 after H2O2 treatment.	31869263
10603	Human	hsa-miR-630	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
10604	Human	hsa-miR-630	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	"Human colorectal cancer cell lines Ls174T, SW480, HCT116, SW837, HR8348, and HT29"	ionic radiation (IR) treatment	"After IR treatment, miR-630 induced apoptosis in cells"	26263387
10605	Human	hsa-miR-630	miRNA	4-aminobiphenyl (4-ABP)	DNA damage	HepG2 cells	4-Aminobiphenyl (4-ABP) treatment	upregulation	24857880
10606	Human	hsa-mir-630	miRNA	cisplatin (DDP)	DNA damage	human lung cancer A549 cells	cisplatin treatment	upregulated	24909689
10607	Human	hsa-miR-630	miRNA	cisplatin (DDP)	head and neck squamous cell carcinoma (HNSCC)	Head and neck squamous cell carcinoma (HNSCC) cells	cisplatin treatment	upregulated	21274007
10608	Human	hsa-miR-630	miRNA	bone morphogenetic protein 4 (BMP4) and TGF-¦Â2	heterotopic ossification (HO)	HD-MVECs	bone morphogenetic protein 4 (BMP4) and TGF-¦Â2 treatment	downregulated	26940839
10609	Human	hsa-miR-630	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
10610	Human	hsa-miR-630	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) A549 cells	cisplatin treatment	upregulated	20145152
10611	Human	hsa-miR-630	miRNA	H2O2	oxidative stress	human lens epithelium cell line HLE-B3	H2O2 treatment	upregulated	31869263
10612	Human	hsa-miR-630	miRNA	luteolin and gefitinib	prostate cancer	PC-3 cells	luteolin and/or gefitinib treatment	upregulated	24971999
10613	Human	hsa-miR-630	miRNA	radiation	radioresistance	"human glioma cell lines BT325, U373, U87 and U251"	radiation treatment	downregulated	28386351
10614	Human	hsa-miR-630	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10615	Human	hsa-miR-630	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
10616	Human	hsa-miR-633	miRNA	progesterone (P4)	endometrial cancer (EC)	Hec5A cells	Progesterone treatment	upregulated	22543862
10617	Human	hsa-miR-633	miRNA	anacardic acid (AnAc)	rheumatoid arthritis (RA)	RA fibroblast-like synoviocytes (RA-FLSs)	anacardic acid (AnAc) treatment	upregulated	30273785
10618	Human	hsa-miR-634	miRNA	photodynamic therapy (PDT)	skin cancer	ATCC-No. CRL-1555 cells	Photodynamic therapy (PDT) treatment	upregulated	23466801
10619	Human	hsa-miR-636	miRNA	Bu-Shen-Huo-Xue-Fang (BSHXF)	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	Bu-Shen-Huo-Xue-Fang (BSHXF) treatment	upregulated	29393545
10620	Human	hsa-miR-636	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	upregulated	32438192
10621	Human	hsa-miR-636	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
10622	Human	hsa-miR-636	miRNA	brain-derived neurotrophic factor (BDNF)	proangiogenic function	CFU-Hill cells	brain-derived neurotrophic factor (BDNF) treatment	upregulated	29860902
10623	Human	hsa-miR-637	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cell line (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	MiR-637 expression was decreased in a dose- and time-dependent manner in animal models with ox-LDL-induced atherosclerosis.	32399056
10624	Human	hsa-miR-637	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	U251 cell	Sevoflurane treatment	upregulated	27840895
10625	Human	hsa-miR-637	miRNA	heme	hepatocellular carcinoma (HCC)	Huh?10 cells	heme treatment	upregulated	23538684
10626	Human	hsa-miR-638	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 adjusted the AKT/mTOR signaling pathway via miR-638 in ox-LDL-induced HAECs to accelerate their proliferation and impede their apoptosis.	32377692
10627	Human	hsa-miR-638	miRNA	PhIP and 17-¦Â-estradiol	breast cancer	MCF-7 human breast adenocarcinoma cell line	PhIP and 17-¦Â-estradiol (E2) treatment	dysregulated	24877718
10628	Human	hsa-miR-638	miRNA	inorganic arsenic (iAs)	tumorigenesis	human Jurkat leukemic T cell	"Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment"	upregulated	24317173
10629	Human	hsa-miR-638	miRNA	platelet-derived growth factor (PDGF)	cell proliferation and migration	human vascular smooth muscle cells(SMCs)	platelet-derived growth factor (PDGF) treatment	downregulated	23554459
10630	Human	hsa-miR-638	miRNA	extract of Stellerachamaejasme L(ESC)	hepatocellular carcinoma (HCC)	HepG2 and MHCC97H cells	extract of Stellerachamaejasme L(ESC) treatment	upregulated	29554896
10631	Human	hsa-miR-638	miRNA	benzo(a)pyrene (BaP)	leukemia	peripheral lymphocytes	benzo(a)pyrene (BaP) exposure	miR-638 is involved in the BaP-induced carcinogenesis by targeting BRCA1	22048643
10632	Human	hsa-miR-638	miRNA	bostrycin	lung cancer	human lung carcinoma A549 cells	bostrycin treatment	upregulated	21303527
10633	Human	hsa-miR-638	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human cardiomyocytes (HCMs)	hypoxia/reoxygenation (H/R) treatment	"Hypoxia/reoxygenation (H/R) treatment suppressed cell viability, increased cell apoptotic rate and suppressed miR-638 expression in the HCMs."	30556888
10634	Human	hsa-miR-638	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
10635	Human	hsa-miR-638	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC cell line SPC-A1	cisplatin treatment	upregulated	25952770
10636	Human	hsa-miR-638	miRNA	SMPD3 inhibitor GW4869	release of microRNAs into extracellular spaces	SW480 and HuH-7 cells	the SMPD3 inhibitor GW4869 treatment	extracellular and intracellular miR-638 were dose-dependently downregulated and upregulated	25394686
10637	Human	hsa-miR-638	miRNA	ginsenoside Rh2	retinoblastoma (RB)	Human RB Y79 and RBL-13 cells	Ginsenoside Rh2 (GRh2) treatment	downregulated	30853612
10638	Human	hsa-miR-638	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
10639	Human	hsa-miR-638	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
10640	Human	hsa-miR-639	miRNA	TGF-¦Â	tongue cancer	TSCC cell lines SCC9 and CAL27	human recombinant TGF¦Â1 for 48 h treatment	?downregulated	25130698
10641	Human	hsa-miR-640	miRNA	hydrogen sulfide (H2S)	angiogenesis	vascular endothelial cells (ECs)	hydrogen sulfide (H2S) treatment	downregulated	26879375
10642	Human	hsa-miR-640	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	Nucleus pulposus (NP) cells	IL©\1¦Â treatment	upregulated	31343104
10643	Human	hsa-miR-640	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	Nucleus pulposus (NP) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31343104
10644	Human	hsa-miR-640	miRNA	angiopoietin-1 (Ang-1)	Ang-1-induced endothelial cell migration and differentiation	human umbilical vein endothelial cells (HUVECs)	angiopoietin-1 (Ang-1) treatment	Exposure to Ang-1 (300 ng/mL) from 6 to 72 h significantly decreased expression of mature miR-640.	32630670
10645	Human	hsa-miR-640	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammatory injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	miRNA-640 expression was gradually increased in HUVECs treatment with OX-LDL.	33300444
10646	Human	hsa-miR-640	miRNA	hydrogen sulfide (H2S)	proangiogenic function	vascular endothelial cells (ECs)	hydrogen sulfide (H2S) treatment	downregulated	26879375
10647	Human	hsa-miR-641	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
10648	Human	hsa-miR-642	miRNA	X-rays	gastric cancer (GC)	human gastric cancer tissue samples	"4 Gy of X-rays (6 MV, 0.8 Gy/min) treatment"	downregulated	24919435
10649	Human	hsa-miR-642	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
10650	Human	hsa-miR-642-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
10651	Human	hsa-miR-642a	miRNA	organophosphorus(OP)	acute organophosphorus(OP) pesticide poisoning	serum	organophosphorus(OP) pesticide poisoning	downregulated	30602960
10652	Human	hsa-miR-642a-3p	miRNA	vorinostat (SAHA)	breast cancer	BT474 cells	vorinostat (SAHA) treatment	upregulated	29620153
10653	Human	hsa-miR-642a-3p	miRNA	rosmarinic acid (RA)	gastric cancer (GC)	SGC7901 cells	rosmarinic acid (RA) treatment	RA treated SGC7901/5-Fu cells showed reduced expression levels of miR-642a-3p and miR-6785-5p compared to untreated SGC7901/5-Fu cells	30551491
10654	Human	hsa-miR-642a-5p	miRNA	lipopolysaccharide (LPS)	acute Lung Injury (ALI)/acute respiratory distress syndrome (ARDS)	pulmonary microvascular endothelial cells (PMVECs)	lipopolysaccharide (LPS) treatment	miR-642a-5p levels are significantly upregulated in LPS-stimulated PMVECs.	32881411
10655	Human	hsa-miR-642a-5p	miRNA	glucocorticoid (GC)	inflammatory bowel disease (IBD)	serum	Glucocorticoids (GCs) treatment	downregulated	31938187
10656	Human	hsa-miR-643	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	SW1990 pancreatic cancer cells	gemcitabine treatment	upregulated	25722110
10657	Human	hsa-miR-643	miRNA	entamoeba histolytica	parasites infection	SW-480 colon cells	Entamoeba histolytica infection	upregulated	30671387
10658	Human	hsa-miR-646	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	hsa_circ_0041795 contributes to human retinal pigment epithelial cells (ARPE 19) injury induced by high glucose via sponging miR-646 and activating VEGFC	32259632
10659	Human	hsa-miR-646	miRNA	TGF-¦Â1	gastric cancer (GC)	human GC cell lines	TGF-¦Â1 treatment	upregulated	28632723
10660	Human	hsa-miR-646	miRNA	hypoxia	pancreatic cancer (PC)	PANC-1 cells	hypoxia treatment	MiR-646 is critical for downregulated of MIIP under hypoxia.	29343850
10661	Human	hsa-miR-646	miRNA	ischemia	preeclampsia (PE)	endothelial progenitor cells	ischemia treatment	microRNA-646 inhibits angiogenesis of endothelial progenitor cells in pre-eclamptic pregnancy by targeting the VEGF-A/HIF-1¦Á axis	32782496
10662	Human	hsa-miR-646	miRNA	R-2-hydroxyglutarate (R-2HG)	prostate cancer	"C4-2, PC3, DU145, LNCaP cells"	R-2-hydroxyglutarate (R-2HG) treatment	downregulated	31846689
10663	Human	hsa-miR-647	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31486513
10664	Human	hsa-miR-647	miRNA	argon-helium cryoablation treatment	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	argon-helium cryoablation treatment	miR-647 was high expression in tumor that under argon-helium cryoablation treatment in contrast to the tumor under non argon-helium cryoablation treatment and inhibited cell proliferation of A549 and H1299 cells by inducing G1-S transition.	30349310
10665	Human	hsa-miR-647	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid (GC) treatment	upregulated	29590087
10666	Human	hsa-miR-648	miRNA	placenta growth factor (PlGF)	sickle cell anemia (SCA)	human umbilical vein endothelial cells (HUVEC)	placenta growth factor (PlGF) treatment	downregulated	25403488
10667	Human	hsa-miR-649	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	HeLa cells	infect with HSV-1	downregulated	27813118
10668	Human	hsa-miR-649	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	HeLa cells	infect wirh HSV-1	downregulated	27813118
10669	Human	hsa-miR-650	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer (GC) tissues; HGC-27 cells; MKN-45 cells	helicobacter pylori (HP) treatment	upregulated	33147052
10670	Human	hsa-miR-650	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GC cells	Helicobacter pylori (HP) treatment	miR-650 was upregulated in HP+ tissues and cells	33147052
10671	Human	hsa-miR-651-3p	miRNA	atropine	myopia	Human corneal epithelial cells	0.003% atropine treatment	dysregulated	31540331
10672	Human	hsa-miR-652	miRNA	acidity	pancreatic cancer (PC)	"human pancreatic cancer cell lines AsPC-1, BxPC-3, PANC-1, SW1990 and MIAPaCa-2"	acidity treatment	downregulated	26498682
10673	Human	hsa-miR-652-3p	miRNA	simvastatin	aberrant endothelial function	human umbilical vein endothelial cells (HUVECs)	Simvastatin treatment	Simvastatin blocked oxidized LDL (ox-LDL)-induced increases in miR-652-3p and ox-LDL-induced decreases in ISL1 protein expression.	32277945
10674	Human	hsa-miR-652-3p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
10675	Human	hsa-miR-653-5p	miRNA	IL-1¦Â	chondrocyte apoptosis	CHON-001 cells	IL-1¦Â treatment	upregulated	32517436
10676	Human	hsa-miR-654-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32349937
10677	Human	hsa-miR-654-3p	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	downregulated	29172709
10678	Human	hsa-miR-654-3p	miRNA	IFN-¦Ã	immunoregulatory function	human mesenchymal stem cells (MSCs)	"150 U/mL of IFN ¦Ã (Sigma, USA) for 24 h"	upregulated	28397044
10679	Human	hsa-miR-654-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10680	Human	hsa-miR-654-3p	miRNA	silver ions Ag+	toxicity of silver (Ag)	Jurkat T cells	Ag ions treatment	downregulated	24974768
10681	Human	hsa-miR-654-5p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells; HeyA8 cells	paclitaxel (PTX) treatment	downregulated	32016960
10682	Human	hsa-miR-655	miRNA	CoCl2	breast cancer	MCF-7 cells	CoCl2 treatment	upregulated	32707933
10683	Human	hsa-miR-655	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; PC3 cells;PC9 cells; RERF-LCKJ cells; RERF-LCMS cells; PC14 cells; ABC-1 cells	TGF-¦Â1 treatment	"the miR-134/487b/655 cluster contributed to the TGF-¦Â1-induced EMT phenomenon and affected the resistance to gefitinib by directly targeting MAGI2,"	24258346
10684	Human	hsa-miR-655	miRNA	benzyl butyl phthalate (BBP)	hemangioma (HA)	The human HA HDEC and CRL-2586 EOMA cells	benzyl butyl phthalate (BBP) treatment	downregulated	31212022
10685	Human	hsa-miR-655	miRNA	TGF-¦Â1	lung adenocarcinoma (LUAD)	human adenocarcinoma cell lines	transforming growth factor ¦Â1 (TGF-¦Â1) exposure in cell lines with or without EMT treatment	upregulated	24258346
10686	Human	hsa-miR-655-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epigenetic regulation	HCT116 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30538122
10687	Human	hsa-miR-655-3p	miRNA	echinacea purpurea (EP)	hepatoblastoma	human hepatoblastoma HepG2 cells	50 ?g/mL methanolic extract of commercial EP capsules	downregulated	28990842
10688	Human	hsa-miR-656-3p	miRNA	resveratrol	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	resveratrol (RS) treatment	upregulated	33718067
10689	Human	hsa-miR-656-3p	miRNA	TGF-¦Â1	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	TGF-¦Â1 treatment	downregulated	33718067
10690	Human	hsa-miR-657	miRNA	Spatholobus suberectus Dunn (SSD)	apoptosis	U266 and U937 cells	Spatholobus suberectus Dunn (SSD) treatment	downregulated	30696076
10691	Human	hsa-miR-657	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	gestational diabetes mellitus (GDM)	THP-1 cells	LPS and IFN-¦Ã treatment	upregulated	31915414
10692	Human	hsa-miR-658	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
10693	Human	hsa-miR-658	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
10694	Human	hsa-miR-660	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
10695	Human	hsa-miR-660	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
10696	Human	hsa-miR-660-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SKhep1 cells; Huh7 cells; LM3 cells	sorafenib treatment	downregulated	33222692
10697	Human	hsa-miR-660-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	primary hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	upregulated	32584784
10698	Human	hsa-miR-660-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	multiple sclerosis (MS)	serum exosomes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29505299
10699	Human	hsa-miR-663	miRNA	waltonitone	apoptosis	H460 and H3255 lung cancer cells	waltonitone treatment	upregulated	25301444
10700	Human	hsa-miR-663	miRNA	oscillatory shear stress (OS)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oscillatory shear stress (OS) treatment	miR-663 plays a key role in OS-induced inflammatory responses by mediating the expression of inflammatory gene network in HUVECs	21378144
10701	Human	hsa-miR-663	miRNA	vascular endothelial growth factor (VEGF)	atherosclerosis (AS)	Human umbilical vein ECs (HUVECs) and human coronary artery ECs (HCAECs)	VEGF treatment	"miR-663 is critically important for 2 key events induced in ECs by stress agents and oxidized lipids, namely induction of transcription factor ATF4 and its downstream gene VEGF"	22776647
10702	Human	hsa-miR-663	miRNA	PhIP and 17-¦Â-estradiol	breast cancer	MCF-7 human breast adenocarcinoma cell line	PhIP and 17-¦Â-estradiol (E2) treatment	dysregulated	24877718
10703	Human	hsa-miR-663	miRNA	inorganic arsenic (iAs)	tumorigenesis	human Jurkat leukemic T cell	"Jurkat cells were exposed to 2 ¦Ìmol/l sodium arsenite and incubated for 0, 24 and 144 hours treatment"	upregulated	24317173
10704	Human	hsa-miR-663	miRNA	arsenite	chronic arsenic toxicity	skin cancer tissues	arsenic (As) exposure	miR-663 was significantly reduced in arsenic induced skin cancer tissues compared to control tissue.	32563914
10705	Human	hsa-miR-663	miRNA	4-hydroxynonenal (4-HNE)	leukemia	HL-60 leukemic cells	4-Hydroxynonenal (HNE) treatment	upregulated	19022373
10706	Human	hsa-miR-663	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	multiple myeloma (MM)	Human MM Cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26164366
10707	Human	hsa-miR-663	miRNA	rotenone (ROT)	oxidative stress	human fibroblasts of different age	0.6 ¦ÌM rotenone in stressed conditions treatment	upregulated	24664125
10708	Human	hsa-miR-663	miRNA	metformin (Met)	pancreatic cancer (PC)	BxPC-3 cells; MIAPaCa-2 cells	metformin treatment	miR-663 was upregulated after treatment of metformin.	33116621
10709	Human	hsa-miR-663	miRNA	lidocaine	skin healing process	denatured skin tissues	Lidocaine treatment	"lidocaine treatment promoted the skin healing after thermal injury through up-regulating miR-486 and miR-663 expression, and partially explained how lidocaine modulates wound healing processes."	31815358
10710	Human	hsa-miR-663a	miRNA	ultraviolet (UV) irradiation	cell senescence	primary human dermal fibroblasts	UVB-irradiated treatment	"RP11-670E136/miR-663a/CDK4?and?RP11-670E136/miR-663a/CDK6?axis, which may function as competitive endogenous RNA networks, played important roles in UVB-induced cellular senescence"	31444317
10711	Human	hsa-miR-663a	miRNA	antimicrobial peptides (AMPs)	colorectal cancer (CRC)	HCT116 cells	administration of the human cathelicidin AMP	upregulated	28061765
10712	Human	hsa-miR-663a	miRNA	"irbesartan, fenofibrate, omeprazole"	drug-induced liver injury (DILI)	human HepG2 cells	"irbesartan, fenofibrate, omeprazole"	upregulated	28179883
10713	Human	hsa-miR-663a	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	thapsigargin (Tg) treatment	upregulated	30753838
10714	Human	hsa-miR-663a	miRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	tunicamycin (TM)? treatment	upregulated	30753838
10715	Human	hsa-miR-663a	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
10716	Human	hsa-miR-663a	miRNA	graphene oxide (GO)	graphene oxide (GO) toxicity	GLC-82 cells	GO treatment	dysregulated	24512264
10717	Human	hsa-miR-663a	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SK-N-SH cell lines	fluoxetine treatment	upregulated	27716787
10718	Human	hsa-miR-663a	miRNA	fluoxetine (Prozac)	neurodevelopmental processes	SH-SY5Y cell lines	fluoxetine treatment	upregulated	27716787
10719	Human	hsa-miR-663a	miRNA	IL-1¦Â	osteoarthritis (OA)	OA cartilage tissues	IL-1¦Â treatment	"The expression of HOTTIP and FRK were upregulated, while miR-663a was downregulated in OA cartilage tissues."	33435956
10720	Human	hsa-miR-663a	miRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	"Human PDAC cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2)"	Gemcitabine (GEM) treatment	upregulated	30788003
10721	Human	hsa-miR-663a	miRNA	OSI-027	pancreatic ductal adenocarcinoma (PDAC)	"Human PDAC cell lines (Panc-1, BxPC-3, T3-M4, MIApaca-2)"	OSI-027 treatment	downregulated	30788003
10722	Human	hsa-miR-663b	miRNA	beryllium sulfate (BeSO4 )	beryllium toxicity	16HBE cells	beryllium sulfate (BeSO4 ) treatment	downregulated	33197057
10723	Human	hsa-miR-663b	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
10724	Human	hsa-miR-663b	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells	tamoxifen (TAM) treatment	miRNA-663b was upregulated in breast cancer with TAM resistance	29845295
10725	Human	hsa-miR-663b	miRNA	pterostilbene	endometrial cancer (EC)	HTB-111 and Ishikawa cells	PT (25-100 ¦Ìmol/L) treatment	downregulated	28552912
10726	Human	hsa-miR-664	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
10727	Human	hsa-miR-664-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10728	Human	hsa-miR-664a-3p	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	Beas-2B cells	cigarette smoke extract (CSE) exposure	upregulated	31632001
10729	Human	hsa-miR-664a-5p	miRNA	all-trans retinoic acid (ATRA)	neuronal differentiation	SH-SY5Y cells	all-trans retinoic acid (ATRA) treatment	upregulated	29341475
10730	Human	hsa-miR-665	miRNA	hypoxia	cell proliferation	human primary pulmonary artery smooth muscle cells	hypoxia induce	upregulated	31370272
10731	Human	hsa-miR-665	miRNA	propofol (PPF)	neurotoxicity	human stem cell-derived neurons	Propofol treatment	upregulated	31656124
10732	Human	hsa-miR-665	miRNA	high fat diet (HFD)	prostate cancer	PCa cells	high fat diet (HFD) feed	upregulated	27915273
10733	Human	hsa-miR-665	miRNA	olmesartan (OMST)	vascular senescence	vascular smooth muscle cells (VSMCs)	Olmesartan (OMST) treatment	downregulated	33042414
10734	Human	hsa-miR-665-3p	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	Caco-2 cells	hypoxia induce	upregulated	29706629
10735	Human	hsa-miR-671	miRNA	muramyl dipeptide	crohn disease (CD)	?HCT116 cells	Muramyl dipeptide treatment	downregulated	24297055
10736	Human	hsa-miR-671	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes CHON-001	IL-1¦Â treatment	downregulated	31085006
10737	Human	hsa-miR-671	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	The expression of circ_0114876 was increased in OA tissues and inhibition of circ_0114876 could induce cell viability and suppress inflammation as well as inhibit cell apoptosis in IL-1¦Â induced CHON-001 cells.	33404903
10738	Human	hsa-miR-671-3p	miRNA	bisphenol A (BPA)	arterial hypertension	urine; whole blood	bisphenol A (BPA) treatment	downregulated	32438192
10739	Human	hsa-miR-671-5p	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
10740	Human	hsa-miR-671-5p	miRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia induce	downregulated	30250300
10741	Human	hsa-miR-671-5p	miRNA	lipopolysaccharide (LPS)	inflammation	OFSCs (OFSCs-CM)	upon co-culture with activated macrophages treatment	downregulated	25124290
10742	Human	hsa-miR-671-5p	miRNA	3-methyladenine (3-MA)	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	3-Methyladenine (3-MA) treatment	downregulated	31582727
10743	Human	hsa-miR-671-5p	miRNA	hypoxia	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	hypoxia induce	downregulated	31582727
10744	Human	hsa-miR-671-5p	miRNA	rapamycin	oral squamous cell carcinoma (OSCC)	Tca-8113 cells	rapamycin treatment	downregulated	31582727
10745	Human	hsa-miR-671-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	"Circ-IQGAP1 abundance was enhanced in the cartilage tissues from OA patients compared with normal subjects (n = 32), and its expression was increased in CHON-001 cells after treatment of IL-1¦Â in a dose-dependent pattern."	33675175
10746	Human	hsa-miR-671-5p	miRNA	bromocriptine	pituitary adenoma	pituitary adenoma tissue	bromocriptine treatment	downregulated	22366961
10747	Human	hsa-miR-6720-3p	miRNA	alternariol (AOH)	antagonistic cytotoxic	HepG2 cells	alternariol (AOH) treatment	upregulated	28007639
10748	Human	hsa-miR-6720-3p	miRNA	alternariol (AOH)	cytotoxicity	HepG2	alternariol (AOH) treatment	upregulated	28007639
10749	Human	hsa-miR-6731-5p	miRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	downregulated	29339075
10750	Human	hsa-miR-6732-3p	miRNA	radon	lung cancer	BEAS-2B cells	radon treatment	upregulated	33447367
10751	Human	hsa-miR-6732-3p	miRNA	radiation	nasopharyngeal carcinoma (NPC)	serum	radiation treatment	downregulated	32198434
10752	Human	hsa-miR-6734-3p	miRNA	arsenic resistance protein 2 (Ars2)	acute myeloid leukemia (AML)	U937 cells	Ars2 deficiency	downregulated	30518811
10753	Human	hsa-miR-6734-5p	miRNA	arsenic trioxide (ATO)	bladder cancer	T24 cells	arsenic trioxide (As2O3) treatment	lncRNA OTUD6B-AS1 Exacerbates As 2 O 3-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2	32952848
10754	Human	hsa-miR-6740	miRNA	stiff (50 kPa) hydrogel substrates	cardiovascular disease (CVD)	human umbilical vein endothelial cells	stiff (50 kPa) hydrogel substrates cultures treatment	downregulated	31606530
10755	Human	hsa-miR-6746-5p	miRNA	cyclosporine A (CsA)	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	cyclosporine A (CsA) treatment	downregulated	31371743
10756	Human	hsa-miR-6746-5p	miRNA	rapamycin	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	rapamycin (RAPA) treatment	upregulated	31371743
10757	Human	hsa-miR-675	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	30815865
10758	Human	hsa-miR-675	miRNA	early growth response protein 1 (EGR1)	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	early growth response protein 1 (EGR1) treatment	upregulated	30815865
10759	Human	hsa-miR-675	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	upregulated	30692507
10760	Human	hsa-miR-675	miRNA	lipopolysaccharide (LPS)	gestational diabetes mellitus (GDM)	Human leukemia cell line THP©\1 cells	lipopolysaccharide (LPS) treatment	upregulated	30362558
10761	Human	hsa-miR-675	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	31468534
10762	Human	hsa-miR-675	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	curcumin (CUR) treatment	downregulated	31468534
10763	Human	hsa-miR-675	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	curcumin (CUR) treatment	CUR downregulated the expression of miR-675.	31468534
10764	Human	hsa-miR-675	miRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	curcumin (CUR) treatment	"1,25(OH) 2 D3 downregulated the expression of H19 and miR-675."	31468534
10765	Human	hsa-miR-675	miRNA	hepatitis B virus (HBV)	hepatoblastoma	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	30367502
10766	Human	hsa-miR-675	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU©\449; SNU©\387	sorafenib treatment	Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675	32627034
10767	Human	hsa-miR-675	miRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	Hep3B cells	2 ng/ml TGF-¦Â for 48 h treatment	upregulation	24703882
10768	Human	hsa-miR-675	miRNA	hepatitis B virus X protein (HBx)	liver damage	L02 cells	hepatitis B X protein (HBx) treatment	"the expression of lncRNA H19 and miR-675 was upregulated in patients with chronic hepatitis B. Inhibition of lncRNA H19 or miR-675 in L02 cells increased cell viability, suppressed hepatitis B X protein (HBx)-induced cell apoptosis, inflammatory cytokine production, and oxidative stress, and remodelled energy metabolism."	31574452
10769	Human	hsa-miR-675	miRNA	angelica polysaccharide (AP)	neuroblastoma (NB)	SH-SY5Y cells	angelica polysaccharide (AP) treatment	downregulated	29465760
10770	Human	hsa-miR-675	miRNA	hypoxia	osteoarthritis (OA)	human cartilage cells	Hypoxia treatment	upregulated	22527881
10771	Human	hsa-miR-675	miRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	human cartilage cells	IL-1¦Â and TNF-¦Á?treatment	downregulated	22527881
10772	Human	hsa-miR-675	miRNA	H2O2	premature senescence	C-kit(+) cardiac progenitor cells (CPCs)	H2 O2 treatment	downregulated	27062045
10773	Human	hsa-miR-675	miRNA	melatonin	subarachnoid hemorrhage (SAH)	U87 cells; U251 cells	melatonin (MT) treatment	upregulated	29367587
10774	Human	hsa-miR-6751	miRNA	triptolide (TPL)	ovarian cancer (OC)	cisplatin-resistant ovarian cancer cell line A2780/CP70	triptolide (TPL) treatment	upregulated	29966441
10775	Human	hsa-miR-6752-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
10776	Human	hsa-miR-675-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocytes	IL-1¦Â treatment	The overexpression of miR-675-3p inhibited apoptosis and cartilage matrix degradation and promoted cell proliferation in human chondrocytes.	32336544
10777	Human	hsa-miR-675-3p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	upregulated	28707489
10778	Human	hsa-miR-675-5p	miRNA	hypoxia	bone ossification	hMSCs	hypoxia treatment	upregulated	29111380
10779	Human	hsa-miR-675-5p	miRNA	huaier extract	breast cancer	"breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF8"		downregulated	29145193
10780	Human	hsa-miR-675-5p	miRNA	hypoxia	colorectal cancer (CRC)	SW620 cells; HCT116 cells	hypoxia treatment	Hypoxia-Induced miR-675-5p Supports ¦Â-Catenin Nuclear Localization by Regulating GSK3-¦Â Activity in Colorectal Cancer Cell Lines	32481626
10781	Human	hsa-miR-675-5p	miRNA	Prostaglandin E2 (PGE2)	colorectal cancer (CRC)	LS174T colorectal cancer cells	Prostaglandin E2 (PGE2) treatment	upregulated	31734182
10782	Human	hsa-miR-675-5p	miRNA	prostaglandin E2 (PGE2)	colorectal cancer (CRC)	LS174T cells	Prostaglandin E2 (PGE2) treatment	Prostaglandin E 2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression	31734182
10783	Human	hsa-miR-6776-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
10784	Human	hsa-miR-6779-5p	miRNA	yhexamethylene guanidine phosphate (PHMG-phosphate)	lung fibrosis	A549 cells	yhexamethylene guanidine phosphate (PHMG-phosphate) treatment	downregulated	29337256
10785	Human	hsa-miR-6785-5p	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC7901 cells	5-fluorouracil (5-FU) treatment	upregulated	30551491
10786	Human	hsa-miR-6785-5p	miRNA	rosmarinic acid (RA)	gastric cancer (GC)	SGC7901/5-Fu cells	Rosmarinic acid (RA) treatment	downregulated	30551491
10787	Human	hsa-miR-6785-5p	miRNA	rosmarinic acid (RA)	gastric cancer (GC)	SGC7901 cells	rosmarinic acid (RA) treatment	RA treated SGC7901/5-Fu cells showed reduced expression levels of miR-642a-3p and miR-6785-5p compared to untreated SGC7901/5-Fu cells	30551491
10788	Human	hsa-miR-6787-5p	miRNA	cyclosporine A (CsA)	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	cyclosporine A (CsA) treatment	downregulated	31371743
10789	Human	hsa-miR-6787-5p	miRNA	rapamycin	colorectal cancer (CRC)	HCT116 and SW480 cell extracellular vesicle (EV)	rapamycin (RAPA) treatment	upregulated	31371743
10790	Human	hsa-miR-6794-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
10791	Human	hsa-miR-6797-5p	miRNA	parathyroid hormone (PTH)	cell differentiation	human bone marrow stromal cells (hBMSCs)	Parathyroid hormone (PTH) treatment	upregulated	30562548
10792	Human	hsa-miR-6797-5p	miRNA	parathyroid hormone (PTH)	osteoblastic differentiation	human bone marrow stromal cells (hBMSCs)	parathyroid hormone (PTH) treatment	PTH-treatment increased the expression of miR-6797-5p in hBMSCs	30562548
10793	Human	hsa-miR-6808-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
10794	Human	hsa-miR-6808-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
10795	Human	hsa-miR-6809-5p	miRNA	luteolin	hepatocellular carcinoma (HCC)	"Huh7 cells, HepG2 cells"	"Luteolin (3,4,5,7-tetrahydroxy flavone) treatment"	upregulated	30668319
10796	Human	hsa-miR-6809-5p	miRNA	luteolin	hepatocellular carcinoma (HCC)	"Huh7 cells, HepG2 cells"	"Luteolin (3,4,5,7-tetrahydroxy flavone) treatment"	upregulated	30668319
10797	Human	hsa-miR-6810-5p	miRNA	gefitinib	lung cancer	PC-9 cells	gefitinib treatment	upregulated	32052182
10798	Human	hsa-miR-6813-5p	miRNA	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC)"	breast cancer	MCF-7 cells	"(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) treatment"	Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells.	33652854
10799	Human	hsa-miR-6816	miRNA	suberoylanilide hydroxamic acid (SAHA)	chronic myeloid leukemia (CML)	K562 cells	suberoylanilide hydroxamic acid (SAHA) treatment	upregulated	29343029
10800	Human	hsa-miR-6817-5p	miRNA	Nel-like molecule type 1 (NELL-1)	osteogenesis	human adipose-derived stem cells (hASCs)	"recombinant nel-like molecule, type 1 (NELL-1) treatment"	downregulated	31633307
10801	Human	hsa-miR-682	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	human colonic epithelial cells	hypoxia treatment	upregulated	27124584
10802	Human	hsa-miR-6825-5p	miRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	downregulated	28166203
10803	Human	hsa-miR-6832-5p	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
10804	Human	hsa-miR-6839-5p	miRNA	radiation	chondrosarcoma	SW1353 cells	radiation treatment	upregulated	32362797
10805	Human	hsa-miR-684	miRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	low-dose metronomic (LDM) paclitaxel treatment	upregulated	25552929
10806	Human	hsa-miR-6842-5p	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
10807	Human	hsa-miR-6845-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH5Y-SY cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â 25-35 upregulated hsa-miR-6845-3p in SH-SY5Y cell lines associated with A¦Â-mediated pathophysiology.	30547775
10808	Human	hsa-miR-6845-5p	miRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	downregulated	28166203
10809	Human	hsa-miR-6873-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial inflammation	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	circ-RELL1 modulate inflammatory response by miR-6873-3p/MyD88/NF-¦ÊB axis in ox-LDL induced endothelial cells.	33008595
10810	Human	hsa-miR-6886-3p	miRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	downregulated	28166203
10811	Human	hsa-miR-6889-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
10812	Human	hsa-miR-7	miRNA	hepatocyte growth factor (HGF)	breast cancer	MCF-10A cells	HGF	upregulated	29133945
10813	Human	hsa-miR-7	miRNA	trichostatin A (TSA)	breast cancer	lapatinib-ed triple-negative breast cancer cells	TSA treatment	upregulated	24707474
10814	Human	hsa-miR-7	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-7 cells	estradiol-17¦Â (E2) treatment	upregulated	23227519
10815	Human	hsa-miR-7	miRNA	estrogen (ES)	breast cancer	MCF-7 cells; SK-BR-3 cells	estrogen treatment	miRNAs were significantly induced by E2 treatment in the MCF-7 cell line.miR-7 suppress epidermal growth factor receptor (EGFR) expression in several human malignancies.	23227519
10816	Human	hsa-miR-7	miRNA	photodynamic therapy (PDT)	cervical cancer (CC)	HeLa cells	photody-namic therapy (PDT) treatment	upregulated	19953537
10817	Human	hsa-miR-7	miRNA	oleic acid (OA)	cervical cancer (CC)	HeLa cells	OA induces production in	upregulated	28483648
10818	Human	hsa-miR-7	miRNA	gefitinib	drug resistance	A549 sub-clone	gefitinib-resistant was established by exposure to escalating gefitinib concentrations over a period of 16-24 months treatment	downregulated	25339453
10819	Human	hsa-miR-7	miRNA	alcohol	gastric cancer (GC)	HEK293T cells;SH SY5Y cells;1321 N1 cells	?alcohol? treatment	upregulated	24961422
10820	Human	hsa-miR-7	miRNA	IL-1¦Â and TNF-¦Á	gastric cancer (GC)	gastric tumor cells	IL-1¦Â and TNF-¦Á treatment	downregulated	22139078
10821	Human	hsa-miR-7	miRNA	soft-shelled turtle peptide	gastric cancer (GC)	AGS cells	soft-shelled turtle peptide treatment	upregulated	29435044
10822	Human	hsa-miR-7	miRNA	yangzheng sanjie decoction (YZSJD)	gastric cancer (GC)	GC MKN-45 cell line	yangzheng Sanjie Decoction (YZSJD) treatment	upregulated	29467883
10823	Human	hsa-miR-7	miRNA	H2O2	glaucoma	human trabecular meshwork (TM) cells	"For the stimulation with H2 O2 , the cells were cultured in Trabecular Meshwork Cell Medium (TMCM) containing 50-400 ¦ÌM H2O2 (Sigma-Aldrich, St. Louis, MO, USA) for 24 h after they reached 80-85% confluence."	miR-7 overexpression abrogated the effects of lncRNA ANRIL on H2O2-treated TM cells. Phosphorylation levels of the key kinases in the mTOR and MEK/ERK pathways were enhanced by lncRNA ANRIL via down-regulating miR-7 in H2O2-treated TM cells.	31081068
10824	Human	hsa-miR-7	miRNA	lapatinib	HER2-positive breast cancer	primary human breast cancer cells	lapatinib treatment	"microRNA-7 directly binds and inhibits Raf-1 3'UTR activity, and that downregulated of miR-7 by lapatinib contributes to the activation of Raf-1 signaling pathway and the induction of IL-6 expression"	26513016
10825	Human	hsa-miR-7	miRNA	manganese (Mn)	idiopathic Parkinson's disease	human neuroblastoma SH-SY5Y cells	manganese (100¦ÌM) treatment	downregulated	28986288
10826	Human	hsa-miR-7	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	The human lung fibroblasts (WI-38 cells)	TGF-¦Â1 treatment	downregulated	31786325
10827	Human	hsa-miR-7	miRNA	single-walled carbon nanotubes (SWCNTs)	immune response	normal human astrocytes (line NHA/TS)	single-walled carbon nanotubes (SWCNTs) treatment	upregulated	29906516
10828	Human	hsa-miR-7	miRNA	docetaxel (DTX)	lung cancer	NSCLC cell lines A549 and H460	docetaxel (DTX) treatment	upregulated	26464649
10829	Human	hsa-miR-7	miRNA	gefitinib	lung cancer	A549 human lung cancer cell	gefitinib treatment	downregulated	25339453
10830	Human	hsa-miR-7	miRNA	manganese (Mn)	manganese induced neurotoxic	SH-SY5Y cells	manganese treatment	The expressions of miR-7 and miR-433 significantly reduced upon manganese exposure.	28986288
10831	Human	hsa-miR-7	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
10832	Human	hsa-miR-7	miRNA	metformin (Met)	non-small cell lung cancer (NSCLC)	A549 cells	metformin (Met) treatment	"Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells."	31789625
10833	Human	hsa-miR-7	miRNA	IL-1¦Â	osteoarthritis (OA)	Human OA chondrocytes (C28/12 cell line)	IL-1¦Â treatment	upregulated	30925324
10834	Human	hsa-miR-7	miRNA	curcumin (Cur)	pancreatic cancer (PC)	pancreatic carcinoma PANC-1 cells	curcumin treatment	upregulated	28259961
10835	Human	hsa-miR-7	miRNA	curcumin (Cur)	pancreatic cancer (PC)	human AsPC-1 and BxPC-3 PC cells	curcumin treatment	upregulated	25256401
10836	Human	hsa-miR-7	miRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 cells	gemcitabine treatment	miR-7 expression was decreased in gemcitabine-resistant pancreatic cancer cells.	33552258
10837	Human	hsa-miR-7	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	29953413
10838	Human	hsa-miR-7	miRNA	pramipexole (PPX)	parkinson's disease (PD)	1-methyl-4-phenylpyridinium (MMP+) treated SH-SY5Y cells	pramipexole (PPX) treatment	upregulated	29953413
10839	Human	hsa-miR-7	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
10840	Human	hsa-miR-7	miRNA	astaxanthin	parkinson's disease (PD)	SH-SY5Y Cells	astaxanthin (AST) treatment	AST reverses the dysregulation of miR-7 and SNCA in SH-SY5Y cells induced by MPP+.	32333925
10841	Human	hsa-miR-7	miRNA	lipopolysaccharide (LPS)	periodontitis	Human periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	"CDR1as was significantly downregulated in LPS-treated PDLSCs compared to untreated cells, as well as in normal periodontal ligament tissues compared to periodontitis tissues."	31582895
10842	Human	hsa-miR-7	miRNA	ultraviolet (UV) irradiation	pigmented skin diseases	HaCaT cells; FB cells	Ultraviolet B (UVB)? treatment	downregulated	33687273
10843	Human	hsa-miR-7	miRNA	docetaxel (DTX)	prostate cancer	PC-3 cells; DU145 cells	docetaxel (DTX) treatment	miR-7 was downregulated in DTX-resistant PCa tissues and cells.	32714093
10844	Human	hsa-miR-7	miRNA	lapatinib	triple negative breast cancer (TNBC)	triple-negative MDA-MB-231 breast cancer cells	Lapatinib treatment	downregulated	23355539
10845	Human	hsa-miR-7	miRNA	"antipsychotic(olanzapine, quetiapine, ziprasidone and risperidone)"	schizophrenia (SZ)	schizophrenia patients	six-week antipsychotic treatment	upregulated	24694668
10846	Human	hsa-miR-7	miRNA	silica	silicosis	HBE cells; A549 cells	silica treatment	miR-7 was downregulated in HBE and A549 cells treated with silica	30202956
10847	Human	hsa-miR-7	miRNA	IL-21	systemic lupus erythematosus (SLE)	normal and SLE B cells	IL-21 treatment	upregulated	25101889
10848	Human	hsa-miR-7	miRNA	vitamin D	type 2 diabetes mellitus (T2DM)	type 2 diabetes patients	vitamin D treatment	dysregulated	28945992
10849	Human	hsa-miR-7	miRNA	Roux-en-Y gastric bypass (RYGB)	weight loss	obese subjects without exercise program plasma	RYGB treatment	dysregulatedin plasma	28344345
10850	Human	hsa-miR-7	miRNA	nicotine	wound healing	periodontal ligament-derived stem cells (PDLSC)	nicotine treatment	upregulated	23030247
10851	Human	hsa-miR-7013-3p	miRNA	hydroxyurea	melanoma	B16 melanoma cells	Hydroxyurea (HU) treatment	We found that miR-7013-3p exhibited increased expression after HU treatment and could bind to MITF.	33746605
10852	Human	hsa-miR-706	miRNA	H2O2	hepatitis	L02 cells	H2O2 treatment	miR-706 mimic partly abolished the influence of H2O2-resulted damage on L02 cells.	31479678
10853	Human	hsa-miR-706	miRNA	H2O2	hepatitis	L02 cells	H2O2 treatment	downregulated	31479678
10854	Human	hsa-miR-708	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	L0-2 cells	ethanol treatment	downregulated	32721464
10855	Human	hsa-miR-708	miRNA	maritoclax	apoptosis	"renal carcinoma (Caki, ACHN and A498), lung cancer (A549) and hepatocellular carcinoma (SK-Hep1) cells"	Maritoclax treatment	upregulated	30463333
10856	Human	hsa-miR-708	miRNA	antcin A (ATA)	breast cancer	human breast cancer cells MCF-7 and MDA-MB-231	antcin A (ATA) treatment	upregulated	30726934
10857	Human	hsa-miR-708	miRNA	dexamethasone (DEX)	breast cancer	human breast cancer cells MCF-7 and MDA-MB-231	dexamethasone (DEX) treatment	upregulated	30726934
10858	Human	hsa-miR-708	miRNA	dexamethasone (DEX)	breast cancer	MDA-MB-231 cells	dexamethasone (DEX) treatment	The dose dependent induction of miR-708 by DEX was observed in the MDA-MB-231 cells from 1 nM to 100 nM.	33065150
10859	Human	hsa-miR-708	miRNA	carnosic acid (CA)	chronic lymphocytic leukemia (CLL)	CML KBM-7 cell line	Carnosic acid (CA) treatment	downregulated	30003745
10860	Human	hsa-miR-708	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	human neuroblastoma cells (SH-SY5Y)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29128627
10861	Human	hsa-miR-708	miRNA	glucocorticoid (GC)	osteonecrosis of femoral head (ONFH)	mesenchymal stem cells (MSCs)	glucocorticoid (GC) treatment	upregulated	26932538
10862	Human	hsa-miR-708	miRNA	deubiquitinases inhibitor (WP1130)	renal cell carcinoma (RCC)	Caki cells	WP1130 treatment	upregulated	30862047
10863	Human	hsa-miR-708-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	human macrophages (HTP-1 and U937 cells)	Mycobacterium tuberculosis (M.tb) infection	upregulated	31599428
10864	Human	hsa-miR-709	miRNA	cyclosporine A (CsA)	nephrotoxicity	HEK293	cyclosporine A treatment	upregulated	28414804
10865	Human	hsa-miR-710	miRNA	carbon monoxide (CO)	colonic inflammation	The YAMC (Young Adult Mouse Colon) cell	carbon monoxide (CO) treatment	downregulated	20005208
10866	Human	hsa-miR-7109-5p	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
10867	Human	hsa-miR-711	miRNA	dexamethasone (DEX)	ischemic liver injury	L-02 cells	dexamethasone (DEX) treatment	"Dexmedetomidine attenuated OGD-induced apoptosis and inflammation, and dexmedetomidine downregulated the expression of miR-711."	30338821
10868	Human	hsa-miR-7-1-3p	miRNA	rapamycin	glioblastoma multiforme (GBM)	U87MG and T98G	rapamycin (RAPA) treatment	upregulated	26573275
10869	Human	hsa-miR-718	miRNA	toluene	toluene-induced toxicity	HL-60 human promyelocytic leukemia cells	toluene treatment	dysregulated	28245982
10870	Human	hsa-miR-720	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
10871	Human	hsa-miR-744	miRNA	lactic acid (LA)	cervical cancer (CC)	HPV16 positive SiHa cells	lactic acid treatment	upregulated	30423314
10872	Human	hsa-miR-744	miRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 cells	oxaliplatin treatment	upregulated	31884801
10873	Human	hsa-miR-744	miRNA	oxaliplatin	colorectal cancer (CRC)	colorectal cancer tissues; HCT116 cells	oxaliplatin (OXA) treatment	upregulated	31884801
10874	Human	hsa-miR-744	miRNA	angiotensin II (Ang II)	heart failure (HF)	Human adult atrial fibroblast primary cultures (NHCF-A)	angiotensin II (Ang II) treatment	downregulated	30392569
10875	Human	hsa-miR-744	miRNA	CCAAT/enhancer binding protein delta (CEBPD)	leukemia	human monocytic leukemic cell line THP-1 and the human myeloid cell line U937	CEBPD treatment	upregulated	29120412
10876	Human	hsa-miR-744	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
10877	Human	hsa-miR-744-5p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10878	Human	hsa-miR-758	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs or HAECs (human artery cells)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29660520
10879	Human	hsa-miR-758	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	CircRSF1 could protect against ox-LDL-induced endothelial cell injury in vitro via miR-758/CCND2 axis	32791147
10880	Human	hsa-miR-758	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
10881	Human	hsa-miR-758	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
10882	Human	hsa-miR-7-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human alveolar epithelial cell line A549	lipopolysaccharide (LPS) treatment	upregulated	27331901
10883	Human	hsa-miR-7-5p	miRNA	ccrriizottiiniib	anaplastic lymphoma kinase positive anaplastic large cell lymphomas	Karpas-299 cells; SU-DHL-1 cells	ccrriizottiiniib treatment	downregulated	31626878
10884	Human	hsa-miR-7-5p	miRNA	hydroquinone (HQ)	cell proliferation and apoptosis	TK6 cells	Hydroquinone (HQ) treatment	downregulated	29421518
10885	Human	hsa-miR-7-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-7-5p expression was upregulated in OGD/R-treated SH-SY5Y cells.	32453073
10886	Human	hsa-miR-7-5p	miRNA	hyperoxia	experimental retinopathy	human umbilical vein endothelial cells	incubated at 2% oxygen	upregulated	28353063
10887	Human	hsa-miR-7-5p	miRNA	2-deoxy-d-glucose (2-DG)	glioblastoma multiforme (GBM)	U87MG cells; LN229 cells; A172 cells; T98G cells	2-Deoxy-d-glucose (2-DG) treatment	2-DG treatment downregulates the tumor suppressive miR-7-5p in GBM cell lines in vitro.	29621542
10888	Human	hsa-miR-7-5p	miRNA	verbascoside (VB)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	Verbascoside (VB) treatment	VB promoted the expression of miR-7-5p in GBM	33768139
10889	Human	hsa-miR-7-5p	miRNA	aspirin	hepatocellular carcinoma (HCC)	Huh-7 cells	Aspirin treatment	downregulated	32627038
10890	Human	hsa-miR-7-5p	miRNA	honokiol	non-small cell lung cancer (NSCLC)	NSCLC A549 cells	honokiol treatment	downregulated	31176168
10891	Human	hsa-miR-7-5p	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	32018039
10892	Human	hsa-miR-7-5p	miRNA	activin A	prostate cancer	PC3 cells	activin A treatment	downregulated	27018851
10893	Human	hsa-miR-7-5p	miRNA	hypoxia	pulmonary hypertension (PH)	Human pulmonary artery smooth muscle cell (HPASMC)	hypoxia treatment	CDR1as/miR-7-5p/CNN3 and CAMK2D regulatory axis mediates HPASMC osteoblastic differentiation and calcification induced by hypoxia.	33230455
10894	Human	hsa-miR-760	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells; Caco2 cells	5-fluorouracil (5-FU) treatment	miR-760 expression was markedly increased in CRC resistant cells.	32982440
10895	Human	hsa-miR-760	miRNA	methotrexate (MTX)	colorectal cancer (CRC)	The human CRC cell line HT29 and Caco2 cells	methotrexate (MTX) treatment	KCNQ1OT1 enhanced the MTX resistance of CRC cells by regulating miR-760-mediated PPP1R1B expression via the cAMP signalling pathway	30997746
10896	Human	hsa-miR-760	miRNA	peiminine	colorectal cancer (CRC)	SW620 and HT29 cells	peiminine treatment	"Peiminine notably downregulated the expression of LINC00659, while the expression of miR-760 was upregulated by peiminine treatment"	32740014
10897	Human	hsa-miR-760	miRNA	rituximab (RTX)	neuromyelitis optica (NMO)	NMO patients	NMO patients treatment	dysregulated in the blood	27393339
10898	Human	hsa-miR-760	miRNA	X-rays	non-small cell lung cancer (NSCLC)	Human NSCLC A549 and H460 cells	"cells were irradiated using experimental X-ray irradiator (Gulmay Medical Inc., Atlanta, GA, xstrahl.com) at a rate of 2.4 Gy/min for the time required treatment"	upregulated	30901121
10899	Human	hsa-miR-760	miRNA	insulin	polycystic ovarian syndrome (PCOS)	KGN cells; SVOG cells	insulin treatment	"miR-760 expression was decreased in PCOS tissues insulin treated GCs, KGN and SVOG cells."	32540374
10900	Human	hsa-miR-760	miRNA	repeatedly passed	premature senescence	lung fibroblast IMR-90 cells	repeatedly passed until a senescence-like state was observed treatment	upregulated	25139266
10901	Human	hsa-miR-760	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cell (hPASMC)	hypoxia induce	downregulated	30226538
10902	Human	hsa-miR-761	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32772311
10903	Human	hsa-miR-761	miRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	T98G cell; LN229 cells	sevoflurane (Sev) treatment	miR-761 was upregulated in sevoflurane-treated glioma cells	32495888
10904	Human	hsa-miR-761	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	downregulated	28619522
10905	Human	hsa-miR-762	miRNA	vorinostat (SAHA)	breast cancer	BT474 cells	vorinostat (SAHA) treatment	upregulated	29620153
10906	Human	hsa-miR-762	miRNA	pseudomonas aeruginosa (PA)	infection and excessive inflammation	human corneal epithelial cells	Pseudomonas aeruginosa treatment	upregulated	23469087
10907	Human	hsa-miR-762	miRNA	tear fluid	infection and excessive inflammation	human corneal epithelial cells	tear fluid treatment	upregulated	23469087
10908	Human	hsa-miR-762	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
10909	Human	hsa-miR-762	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	"Human NSCLC cell lines, including A549, NCI-H820, NCI-H2170, NCI-H1650, NCI-H1993, NCI-H2126, NCI-H1975, NCIH1299, NCI-H1648, NCI-H1703, NCI-H2347, PC-9 and a normal human lung epithelial cell line NuLi-1 ATCC-CRL-4011)"	gefitinib treatment	upregulated	31823748
10910	Human	hsa-miR-7641	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
10911	Human	hsa-miR-765	miRNA	capecitabine-oxaliplatin and radiotherapy	colorectal cancer (CRC)	human fresh biopsies of rectal tumors	capecitabine-oxaliplatin and radiotherapy	upregulated	22172905
10912	Human	hsa-miR-765	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87MG cells	Temozolomide (TMZ) treatment	downregulated	27893811
10913	Human	hsa-miR-765	miRNA	hyperbaric oxygen (HBO)	hepatocellular carcinoma (HCC)	Hepatoma cell lines (BEL-7402 and SK-Hep1)	HBO at 2 atmosphere absolute pressure for 80 min per day or combin sorafenib or cisplatin treatment	upregulated	24956259
10914	Human	hsa-miR-765	miRNA	vincristine (VCR)	multidrug resistance (MDR)	SGC7901 cells	vincristine (VCR) treatment	upregulated	32166887
10915	Human	hsa-miR-765	miRNA	cisplatin (DDP)	osteosarcoma (OS)	9901 cells	cisplatin treatment	upregulated	28775773
10916	Human	hsa-miR-765	miRNA	fulvestrant	prostate cancer	DU145 cells; PC-3 cells	Fulvestrant treatment	upregulated	24837491
10917	Human	hsa-miR-765	miRNA	fulvestrant	prostate cancer	prostate cancer patients	a single dose (250 mg) of fulvestrant 28 days before prostatectomy treatment	downregulated	24837491
10918	Human	hsa-miR-766	miRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	EAC cells;SCC cells	5-fluorouracil (5-FU) treatment	downregulated	21743970
10919	Human	hsa-miR-766	miRNA	cisplatin (DDP)	esophageal cancer (EC)	EAC cells;SCC cells	cisplatin (DPP) treatment	downregulated	21743970
10920	Human	hsa-miR-766	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
10921	Human	hsa-miR-766	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
10922	Human	hsa-miR-766-3p	miRNA	baicalin (BAI)	osteoarthritis (OA)	primary chondrocytes	baicalin (BAI) treatment	Baicalin protects human OA chondrocytes against IL-1¦Â-induced apoptosis and the degradation of ECM through activating autophagy via miR-766-3p/AIFM1 axis.	32753846
10923	Human	hsa-miR-766-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10924	Human	hsa-miR-766-3p	miRNA	abatacept	rheumatoid arthritis (RA)	plasma	abatacept treatment	downregulated	30769772
10925	Human	hsa-miR-769-5p	miRNA	hypoxia	lung cancer	A549 cells	hypoxia treatment	upregulated	27524914
10926	Human	hsa-miR-769-5p	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation-induced bystander effects (UV-RIBEs)	Human skin fibroblasts	ultraviolet radiation treatment	Exosomal MiR-769-5p Exacerbates Ultraviolet-Induced Bystander Effect by Targeting TGFBR1	33329055
10927	Human	hsa-miR-770	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human gastric cancer cell lines MKN45, SGC7901, BGC823, and AGS"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28345805
10928	Human	hsa-miR-7704	miRNA	MnCl2	neurodegeneration (ND)	SH-SY5Y cells	MnCl2 treatment	upregulated	28302480
10929	Human	hsa-miR-7704	miRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	Exosomes derived from human primary melanocytes	ultraviolet B (UVB) irradiation treatment	upregulated	32785244
10930	Human	hsa-miR-770-5p	miRNA	X-rays	breast cancer	MCF7 cells	"2, 8, and 24 h post irradiation"	upregulated	28333152
10931	Human	hsa-miR-770-5p	miRNA	methotrexate (MTX)	colorectal cancer (CRC)	HT-29 cells	Methotrexate (MTX) treatment	Upregulation of miR-770-5p significantly decreased the sensitivity of HT-29 cells to MTX.	31853309
10932	Human	hsa-miR-770-5p	miRNA	dexamethasone (DEX)	cytotoxicity	primary human osteoblasts	dexamethasone (DEX) treatment	upregulated	31313024
10933	Human	hsa-miR-770-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes	high glucose (HG) treatment	upregulated	32696822
10934	Human	hsa-miR-770-5p	miRNA	curcumin (Cur)	prostate cancer	DU145 cells; 22Rv1 cells	curcumin treatment	upregulated	29172709
10935	Human	hsa-miR-770-5p	miRNA	methotrexate (MTX)	methotrexate (MTX) resistance	HT-29 cells	Methotrexate (MTX) treatment	miR-770-5p modulates resistance to methotrexate in human colorectal adenocarcinoma cells by downregulating HIPK1.	31853309
10936	Human	hsa-miR-770-5p	miRNA	curcumin (Cur)	prostate cancer	HuPCaSC lines DU145 and 22Rv1	curcumin treatment	dysregulated	29172709
10937	Human	hsa-miR-7845-5p	miRNA	tensile	hepatocellular carcinoma (HCC)	HepG2 cells	tensile treatment	upregulated	32323778
10938	Human	hsa-miR-7a-2-3p	miRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	downregulated	26987780
10939	Human	hsa-miR-801	miRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Plasma	hepatitis B virus (HBV) infection	?upregulated	22105822
10940	Human	hsa-miR-802	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A547 cells	lipopolysaccharide (LPS) treatment	downregulated	31696241
10941	Human	hsa-miR-802	miRNA	arsenite	arsenic carcinogenesis	HK-2 human renal epithelial cells	arsenic exposure	downregulated	30334557
10942	Human	hsa-miR-802	miRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC cells	cisplatin treatment	circDONSON promoted cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis.	32581651
10943	Human	hsa-miR-802	miRNA	hepatitis B virus (HBV)	HBV-associated hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV) infection	upregulated	31611549
10944	Human	hsa-miR-802	miRNA	high fat diet (HFD)	insulin resistance (IR)	human liver tissues	high fat diet (HFD) treatment	upregulated	23389544
10945	Human	hsa-miR-802	miRNA	lipopolysaccharide (LPS)	oral lichen planus (OLP)	human oral keratinocytes	lipopolysaccharide (LPS) treatment	upregulated	30074824
10946	Human	hsa-miR-802	miRNA	vitamin D	oral lichen planus (OLP)	LPS-treated human oral keratinocytes	Vitamin D treatment	downregulated	30074824
10947	Human	hsa-miR-8055	miRNA	H2O2	oxidative stress	human umbilical vein endothelial cells (HUVECs)	H2O2 treatment	miR-8055 was downregulated in the HUVEcs induced by H2O2 compared to those in the control HUVEcs.	33125125
10948	Human	hsa-miR-8055	miRNA	vitamin C	oxidative stress	human umbilical vein endothelial cells (HUVECs)	vitamin C treatment	miR-8055 was upregulated in the HUVEcs treated with vitamin C and H2O2 compared to those in the HUVEcs exposed to H2O2.	33125125
10949	Human	hsa-miR-8056	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
10950	Human	hsa-miR-8485	miRNA	bone marrow mesenchymal stem cells (BMSCs)	chondrogenesis	chondrocytes	bone marrow mesenchymal stem cells (BMSCs) treatment	chondrocytes-derived exosomal miR-8485 regulated the Wnt/¦Â-catenin pathways to promote chondrogenic differentiation of BMSCs	31898972
10951	Human	hsa-miR-873	miRNA	norcantharidin (NCTD)	breast cancer	MCF-7 and ZR75-1 cells	Norcantharidin (NCTD) treatment	upregulated	31120927
10952	Human	hsa-miR-873-5p	miRNA	genistein	non-small cell lung cancer (NSCLC)	human NSCLC cell lines (H292 and A549)	genistein treatment	"circ_0031250 abundance was elevated in NSCLC samples and cell lines, and it was reduced via genistein exposure."	33159503
10953	Human	hsa-miR-874	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	asthma	human fetal airway smooth muscle (fASM) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á treatment significantly downregulated the expression of miR-874 in fASM cells	29448029
10954	Human	hsa-miR-874	miRNA	psoralen	diabetic nephropathy (DN)	HK-2 cells	psoralen treatment	Psoralen could significantly alleviate HG-induced HK-2 cell injury via upregulation of miR-874	32698907
10955	Human	hsa-miR-874	miRNA	rifampicin	drug metabolism and pharmacokinetics	human hepatocytes	10 ?M rifampicin treatment	dysregulated	24552687
10956	Human	hsa-miR-874	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	Jurkat cells	Enterovirus 71 (EV71) infection	EV71 infection significantly decreased the expression of miR-874 in Jurkat cells.	32851429
10957	Human	hsa-miR-874	miRNA	¦Ä-opioid receptor (DOR)	hepatocellular carcinoma (HCC)	Bel-7402 cells; SK-hep-1 cells; HepG2 cells; Huh7 cells; Li-7 cells; LO2 cells	¦Ä-opioid receptor (DOR) treatment	upregulated	29374140
10958	Human	hsa-miR-874-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced renal podocyte injury	human podocytes	doxorubicin (DOX) treatment	upregulated	32908641
10959	Human	hsa-miR-874-3p	miRNA	high glucose (HG)	diabetic vasculopathy	human aortic endothelial cells (HAECs)	high glucose (HG)	downregulated	28824448
10960	Human	hsa-miR-874-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31200256
10961	Human	hsa-miR-874-5p	miRNA	atropine	myopia	Human corneal epithelial cells	0.003% atropine treatment	dysregulated	31540331
10962	Human	hsa-miR-874-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	HOTAIR promoted MPP+-induced neuronal injury via modulating the miR-874-5p/ATG10 axis in SK-N-SH cells.	33013268
10963	Human	hsa-miR-876	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28723693
10964	Human	hsa-miR-876-3p	miRNA	rosiglitazone	insulin resistance (IR)	adipocytes	rosiglitazone treatment	Rosiglitazone treatment in CI-induced IR adipocytes drastically reduced miR-876-3p expression	30307150
10965	Human	hsa-miR-877	miRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	SGC-7901 cells	5-fluorouracil (5-FU) treatment	downregulated	23525256
10966	Human	hsa-miR-877	miRNA	paclitaxel (PTX)	hepatocellular carcinoma (HCC)	The HepG2 human HCC cell line	Paclitaxel treatment	upregulated	24060847
10967	Human	hsa-miR-877-3p	miRNA	high glucose (HG)	autophagy	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680.	30957640
10968	Human	hsa-miR-877-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	human aortic vascular smooth muscle cells (HA-VSMCs) injury	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31957850
10969	Human	hsa-miR-877-3p	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
10970	Human	hsa-miR-877-3P	miRNA	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO)	vascular endothelial cells (VECs) autophagy and apoptosis	human vascular endothelial cells (VECs)	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment	3BDO promoted the expression of miR-877-3P in VECs under high glucose conditions.	30957640
10971	Human	hsa-miR-877-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	children serum samples	acetaminophen(APAP) treatment	upregulated in serum samples	29067470
10972	Human	hsa-miR-877-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen(APAP) treatment	dysregulated	29067470
10973	Human	hsa-miR-877-5p	miRNA	acetaminophen (APAP)	acute liver failure (ALF)	serum	acetaminophen (APAP) treatment	hsa-miR-320a and hsa-miR-877-5p levels were significantly elevated in serum samples obtained from children with APAP overdose compared to health controls.	29067470
10974	Human	hsa-miR-885	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	human cardiomyocytes (HCMs)	hypoxia/reoxygenation (H/R) treatment	miR-885 in HCMs was markedly repressed after H/R stimulation.	31960416
10975	Human	hsa-miR-885	miRNA	hypoxia	prostate cancer	LNCaP cells; LNCaP cells exosomes	hypoxia treatment	upregulated	29568403
10976	Human	hsa-miR-885-3p	miRNA	radiochemotherapy	head and neck squamous cell carcinoma (HNSCC)	?blood plasma	radiochemotherapy?treatment treatment	"six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p)"	24373621
10977	Human	hsa-miR-885-5p	miRNA	erythropoietin (EPO)	apoptosis	SH-SY5Y neuronal-like cells	EPO treatment	downregulated	25324845
10978	Human	hsa-miR-885-5p	miRNA	hepatitis C virus (HCV)	liver fibrosis	hepatoma cells	hepatitis C virus (HCV) infection	upregulated	26157120
10979	Human	hsa-miR-886	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
10980	Human	hsa-miR-886-3p	miRNA	radon	lung cancer	BEAS2B cells	RADON treatment	upregulated	23294299
10981	Human	hsa-miR-886-5p	miRNA	paclitaxel (PTX)	ovarian cancer (OC)	HeyA8 cells	paclitaxel (PTX) treatment	downregulated	33028939
10982	Human	hsa-miR-888-5p	miRNA	methyl donor S-Adenosylmethionine (AdoMet)	laryngeal squamous cell carcinoma (LSCC)	JHU-SCC-011 cells; HNO210 LSCC cells	methyl donor S-Adenosylmethionine (AdoMet) treatment	miR-888-5p Is Involved in S-Adenosylmethionine Antitumor Effects in Laryngeal Squamous Cancer Cells	33297397
10983	Human	hsa-miR-889	miRNA	arsenite	arsenite-induced carcinogenesis	HaCaT cells	arsenite exposure	upregulated	30167605
10984	Human	hsa-miR-889	miRNA	paraquat (PQ)	parkinson's disease (PD)	human neural progenitor cells (hNPCs)	10¦ÌM PQ treatment	upregulated	28619522
10985	Human	hsa-miR-891a	miRNA	lipopolysaccharide (LPS)	inflammation	THP1-differentiated macrophages	lipopolysaccharide (LPS) treatment	downregulated	24062196
10986	Human	hsa-miR-891a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
10987	Human	hsa-miR-891b	miRNA	enterovirus 71 (EV71)	apoptosis	Human rhabdomyosarcoma cells (RD)	EV71 infection	"host cells suppress lnc-IRAK3-3 to relieve lnc-IRAK3-3-sequestered miR-891b, restrain GADD45¦Â, and attenuate apoptosis in EV71 infection that prevent host cells from severe damages."	31099182
10988	Human	hsa-miR-892a	miRNA	melatonin	oral cancer	SAS cells; SCC9 cells	Melatonin treatment	Melatonin reduced the drug resistance and promoted the apoptosis of VCR-resistant oral cancer cells through the upregulation of microRNA-892a (miR-892a) and miR-34b-5p expressions.	31982774
10989	Human	hsa-miR-892a	miRNA	melatonin	vincristine (VCR) resistance	SAS cells; SCC9 cells	Melatonin treatment	upregulated	31982774
10990	Human	hsa-miR-892c-3p	miRNA	ursolic acid (UA)	breast cancer	BT474 cells	usnic acid treatment	upregulated	31549595
10991	Human	hsa-miR-9	miRNA	tetramethylpyrazine (TMP)	activation of hepatic stellate cells (HSCs)	hepatic stellate cells (HSCs)	were transfect TMP treatment	upregulated	25560232
10992	Human	hsa-miR-9	miRNA	daunorubicin	acute myeloid leukemia (AML)	"The AML cell lines HL-60, KG-1, THP-1 and Kasumi-1"	Daunorubicin (Dnr) treatment	downregulated	30745844
10993	Human	hsa-miR-9	miRNA	arsenite	angiogenesis	EA.hy926 cells	arsenic (As) exposure	downregulated	21503876
10994	Human	hsa-miR-9	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
10995	Human	hsa-miR-9	miRNA	N-(4-hydoxyphenyl)-retinamide (4HPR)	apoptosis	human retinal pigment epithelial (HRPE) cell	N-(4-hydoxyphenyl)-retinamide (4HPR) treatment	upregulated	20806079
10996	Human	hsa-miR-9	miRNA	proanthocyanidin	atherosclerosis (AS)	THP-1 cells	proanthocyanidins treatment	"proanthocyanidins suppressed the expression of ACAT1 via up-regulating the expression of miR-9, thus lessening the intracellular lipid accumulation and eventually inhibiting macrophage foam cell formation"	31967154
10997	Human	hsa-miR-9	miRNA	P. aeruginosa GroEL	bacterial infection	"A549 cells (human alveolar epithelial cells), THP-1 cells (human monocytes), and U937 cells (human monocytes)"	infect with P. aeruginosa GroEL treatment	downregulated	28031262
10998	Human	hsa-miR-9	miRNA	docosahexaenoic acid (DHA)	breast cancer	MDA-MB-231 cells-derived exosomes	docosahexaenoic acid (DHA) treatment	downregulated	33159957
10999	Human	hsa-miR-9	miRNA	estradiol	breast cancer	MCF-7 breast cancer cells	Estradiol treatment	downregulated	19528081
11000	Human	hsa-miR-9	miRNA	mechanical compression	breast cancer	MDA-MB-231 and BT-474 breast cancer cell lines	mechanical compression	downregulated	28252641
11001	Human	hsa-miR-9	miRNA	cigarette smoke (CS)	cell proliferation	na?ve and desialylated human alveolar epithelial cells (A549 cells)	cigarette smoke (CS) treatment	downregulated	29492899
11002	Human	hsa-miR-9	miRNA	dexamethasone (DEX)	cell proliferation	cigarette smoke-induced na?ve and desialylated human alveolar epithelial cells (A549 cells)	dexamethasone (DEX) treatment	upregulated	29492899
11003	Human	hsa-miR-9	miRNA	lipopolysaccharide (LPS)	cell proliferation	cigarette smoke-induced na?ve and desialylated human alveolar epithelial cells (A549 cells)	lipopolysaccharide (LPS) treatment	upregulated	29492899
11004	Human	hsa-miR-9	miRNA	staurosporine	cervical cancer (CC)	iPSCs	staurosporine treatment	downregulated	24143176
11005	Human	hsa-miR-9	miRNA	lipopolysaccharide (LPS)	cervical cancer (CC)	HeLa cells	lipopolysaccharide (LPS) treatment	upregulated	31450920
11006	Human	hsa-miR-9	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	hearts	high glucose treatment	downregulated	26898797
11007	Human	hsa-miR-9	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes cells (HPCs)	high glucose (HG) treatment	SOX2OT overexpression alleviates the HG-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis.	31301307
11008	Human	hsa-miR-9	miRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	miR-9 expression remarkably decreased	33721156
11009	Human	hsa-miR-9	miRNA	dopaminergic (DA) neuron differentiation medium	dopaminergic (DA) neuron differentiation	human trabecular meshwork mesenchymal stem cells	"the induction medium was prepared by adding 10 ¦ÌM retinoic acid (RA) (Sigma, USA), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma, USA) and 0.5 mM N6,2¡ä-O-Dibutyryladenosine 3¡ä,5¡ä-cyclic monophosphate (dbcAMP) (Sigma, USA) to 10% FBS supplemented DMEM."	upregulated	31173848
11010	Human	hsa-miR-9	miRNA	enterovirus 71 (EV71)	endometrial cancer (EC)	"293T, Vero, RD, HT-29, HeLa, and THP-1 cells"	Enterovirus 71 (EV71) infection	downregulated	30186747
11011	Human	hsa-miR-9	miRNA	nicotine	epithelial-mesenchymal transition (EMT)	"head and neck squamous cell carcinoma cell lines, UMSCC-10B ;HN-1"	nicotine treatment	upregulated	23300583
11012	Human	hsa-miR-9	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, YES2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	28539329
11013	Human	hsa-miR-9	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	human GC cell lines SGC-7901 and BGC-823	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
11014	Human	hsa-miR-9	miRNA	GSK1059615	gastric cancer (GC)	AGS cells and primary human GC cells	GSK1059615 treatment	downregulated	30765226
11015	Human	hsa-miR-9	miRNA	sulforaphane (SFN)	gastric cancer (GC)	MKN45 cells	sulforaphane treatment	upregulated	30096452
11016	Human	hsa-miR-9	miRNA	sulforaphane (SFN)	gastric cancer (GC)	HF2FF cells	sulforaphane treatment	upregulated	30096452
11017	Human	hsa-miR-9	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 glioma cells	temozolomide (TMZ) treatment	upregulated	31186688
11018	Human	hsa-miR-9	miRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	SCC90 cells; SCC47 cells; SCC104 cells	human papillomavirus (HPV) treatment	miR-9 was upregulated in HPV + HNSCC cells.	32120025
11019	Human	hsa-miR-9	miRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	"exosome of SCC90 cells, SCC47 cells and SCC104 cells"	human papillomavirus (HPV) treatment	miR-9 was upregulated in HPV + HNSCC exosomes.	32120025
11020	Human	hsa-miR-9	miRNA	angiotensin II (Ang II)	hypertension	human umbilical vein endothelial cells	angiotensin II (Ang II) treatment	microRNA-9 (miR-9) suppressed angiotensin II-induced apoptosis and enhanced proliferation in human umbilical vein endothelial cells.	31345003
11021	Human	hsa-miR-9	miRNA	high glucose (HG)	inflammation	smooth muscle cell line C-12511	high glucose treatment	downregulated	31122000
11022	Human	hsa-miR-9	miRNA	lipopolysaccharide (LPS)	inflammation	HK-2 cells	lipopolysaccharides (LPS) treatment	downregulated	31432701
11023	Human	hsa-miR-9	miRNA	molecular hydrogen	inflammatory injury	Retinal Microglia cells	Molecular hydrogen?treatment	downregulated	23826519
11024	Human	hsa-miR-9	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	infect with IAV	upregulated	27322373
11025	Human	hsa-miR-9	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	The oxygen-glucose deprivation (OGD) in SH-SY5Y cells significantly reduced miR-9 expression	30539420
11026	Human	hsa-miR-9	miRNA	glucosamine	ischemic stroke (IS)	OGD-treated SH-SY5Y cells	Glucosamine treatment	upregulated	30539420
11027	Human	hsa-miR-9	miRNA	hypoxia	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	30539420
11028	Human	hsa-miR-9	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	leukemia	UoCM1 and K562 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31054042
11029	Human	hsa-miR-9	miRNA	VitB12	methylmalonic acidemia (MMA)	MMA patient	VitB12 treatment	upregulated	24798023
11030	Human	hsa-miR-9	miRNA	ultraviolet (UV) irradiation	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	UV light treatment	upregulated	25891118
11031	Human	hsa-miR-9	miRNA	retinoic acid (RA)	nervous system cancers	SK-N-BE(2)-C £»SH SY5Y??cells?;SH-EP cells£» HEK 293T cells	retinoic acid treatment	upregulated	22848373
11032	Human	hsa-miR-9	miRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	A549 cells	ionizing radiation (IR) treatment	"microRNA-9 overexpression increased the radiosensitivity of A549 cells by inhibiting cell activity and migration, and by increasing apoptosis."	31158449
11033	Human	hsa-miR-9	miRNA	prophylactic cranial irradiation (PCI)	non-small cell lung cancer (NSCLC)	A549 cells	prophylactic cranial irradiation (PCI)? treatment	levels of miR-9 secreted by irradiated M1 microglia significantly increased	33758511
11034	Human	hsa-miR-9	miRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	A549 and HCC827 cells	TGF-¦Â1 treatment	upregulated	28266181
11035	Human	hsa-miR-9	miRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	"cell lines A549, NCI-H1299 and HCC827"	5 ng/ml TGF-¦Â1 for 24 h treatment	upregulated	29118814
11036	Human	hsa-miR-9	miRNA	alkannin	oral squamous cell carcinoma (OSCC)	CAL-27 and SCC-9 cells	alkannin (ALK) treatment	downregulated	31349748
11037	Human	hsa-miR-9	miRNA	hydroxytyrosol (HT)	osteoarthritis (OA)	human primary and C-28/I2 chondrocytes	were pre-treated with 100 ¦ÌM HT 30 min before 100 ¦ÌM H2O2	upregulated	27914878
11038	Human	hsa-miR-9	miRNA	IL-1¦Â	osteoarthritis (OA)	OA chondrocytes	IL-1¦Â treatment	upregulated	25917063
11039	Human	hsa-miR-9	miRNA	TNF-a and MMP13	osteoarthritis (OA)	human OA cartilage and bone	TNF-a and MMP13 treatment	upregulated	19008124
11040	Human	hsa-miR-9	miRNA	vorinostat (SAHA)	osteoarthritis (OA)	human OA chondrocytes	SAHA treatment	downregulated	27404795
11041	Human	hsa-miR-9	miRNA	estradiol-17¦Â (E2)	osteosarcoma (OS)	Human OS cell line MG-63	estradiol-17¦Â (E2) treatment	upregulated	25592968
11042	Human	hsa-miR-9	miRNA	curcumin (Cur)	ovarian cancer (OC)	SKOV3 cells	curcumin treatment	upregulated	24870723
11043	Human	hsa-miR-9	miRNA	propofol (PPF)	ovarian cancer (OC)	ES-2 cells	propofol treatment	upregulated	27982283
11044	Human	hsa-miR-9	miRNA	platelet derived growth factor-BB (PDGF-BB)	prion infection	U87 glioblastoma cells and neonatal cardiomyocytes	PDGFR-beta treatment	upregulated	21684288
11045	Human	hsa-miR-9	miRNA	perioglas(PG)	bone formation	Osteoblast-like cells (MG63)	PerioGlas(PG) treatment	upregulated	18573151
11046	Human	hsa-miR-9	miRNA	platelet derived growth factor-BB (PDGF-BB)	prostate cancer	neuronal progenitor cells	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	24336080
11047	Human	hsa-miR-9	miRNA	tumor resection	squamous cell carcinoma (SQCC) and adenocarcinoma (ADC£©	SQCC and ADC patients	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	28634901
11048	Human	hsa-miR-9	miRNA	butyrate and inulin	type 2 diabetes mellitus (T2DM)	peripheral blood mononuclear cells (PBMCs)	butyrate and inulin treatment	butyrate and concomitant use of butyrate and inulin caused a significant increase in the fold change of miR-146a and miR-9 compared with the placebo group.	32315958
11049	Human	hsa-miR-9	miRNA	human immunodeficiency virus (HIV)-1 and methamphetamine	uveal melanoma	human frontal cortex	human immunodeficiency virus (HIV) and methamphetamine treatment	significantly increased expression of the neuron-specific miR-9	23508624
11050	Human	hsa-miR-9	miRNA	ultraviolet (UV) irradiation	vitiligo repigmentation	HaCaT keratinocytes	UVB irradiation treatment	downregulated	31499059
11051	Human	hsa-miR-9*	miRNA	hydroxychloroquine	apoptosis	cervical cancer SiHa cells	HCQ treatment	downregulated	24944668
11052	Human	hsa-miR-9*	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
11053	Human	hsa-miR-9-1	miRNA	decitabine	acute myeloid leukemia (AML)	RUNX1-RUNX1T1 (+) AML cell lines	decitabine£¬trichostatin A	upregulated	27770540
11054	Human	hsa-mir-92	miRNA	estrogen receptor-¦Á	breast cancer	breast cancer cells	The estrogen receptor-¦Á treatment	upregulated	19706389
11055	Human	hsa-mir-92	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
11056	Human	hsa-miR-92	miRNA	12-O-tetradecanoylphorbol-13-acetate (TPA)	leukemia	HL-60 cells	12-O-tetradecanoylphorbol-13-acetate (TPA)	downregulated	18648749
11057	Human	hsa-miR-92	miRNA	perioglas (PG) and P-15	bone formation	Osteoblast-like cell (MG63)	PerioGlas (PG) and P-15 treatment	upregulated	17653614
11058	Human	hsa-miR-92	miRNA	platelet derived growth factor-BB (PDGF-BB)	vascular restenosis	human vascular smooth muscle cells (VSMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	31933825
11059	Human	hsa-miR-923	miRNA	diesel exhaust particle (DEP)	bronchial epithelial cell cancer	Primary human bronchial epithelial cells	diesel exhaust particle (DEP) exposure	upregulated	20049127
11060	Human	hsa-miR-923	miRNA	bostrycin	lung cancer	human lung carcinoma A549 cells	bostrycin treatment	upregulated	21303527
11061	Human	hsa-miR-923	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	upregulated	26640557
11062	Human	hsa-miR-92-3p	miRNA	silybin	hepatoprotective	HepG2 cells	Silybin treatment	downregulated	31058823
11063	Human	hsa-miR-92a	miRNA	high glucose (HG)	acute coronary syndrome (ACS)	Human Macrophages	high glucose treatment	upregulated	27519051
11064	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	33015189
11065	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	31841757
11066	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	pulmonary microvascular endothelial cells (HPMEC); A549 cells	lipopolysaccharide (LPS) treatment	upregulated	32534035
11067	Human	hsa-miR-92a	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	Inhibition of microRNA-92a ameliorates lipopolysaccharide-induced endothelial barrier dysfunction by targeting ITGA5 through the PI3K/Akt signaling pathway in human pulmonary microvascular endothelial cells	31841757
11068	Human	hsa-miR-92a	miRNA	hyperbaric oxygen (HBO)	angiogenesis	human coronary artery endothelial cells (HCAECs)	Hyperbaric oxygen (HBO) treatment	downregulated	30301563
11069	Human	hsa-miR-92a	miRNA	triptolide (TPL)	angiogenesis	human dermal microvascular endothelial cells (HMEC-1)	triptolide (TPL) treatment	upregulated	31691162
11070	Human	hsa-miR-92a	miRNA	curcumin (Cur)	antioxidant defense	human ARPE-19 cells	curcumin (diferuloylmethane)? treatment	downregulated	23559849
11071	Human	hsa-miR-92a	miRNA	serum	apoptosis	vascular smooth muscle cell (VSMC)	serum treatment	upregulated	24705900
11072	Human	hsa-miR-92a	miRNA	ML-7 (an inhibitor of myosin light chain kinase)	atherosclerosis (AS)	Human aortic smooth muscle cells (HASMCs)	ML-7 (an inhibitor of myosin light chain kinase) treatment	downregulated	30907506
11073	Human	hsa-miR-92a	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
11074	Human	hsa-miR-92a	miRNA	butyrate	colorectal cancer (CRC)	human colon cancer cells	butyrate treatment	downregulated	26463716
11075	Human	hsa-miR-92a	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	RKO cells	kaempferol-3- O-glycoside treatment	downregulated	31441682
11076	Human	hsa-miR-92a	miRNA	kaempferol-3-O-glycoside	colorectal cancer (CRC)	colon cancer cell line (RKO)	kaempferol-3-O-glycoside treatment	downregulated	31441682
11077	Human	hsa-miR-92a	miRNA	oxaliplatin	colorectal cancer (CRC)	plasma	oxaliplatin treatment	miR-92a was downregulated in resistant patients when compared with sensitive patients	33072545
11078	Human	hsa-miR-92a	miRNA	advanced glycation end products (AGEs) and oxidized low-density lipoprotein (ox-LDL)	diabetes mellitus (DM)	human umbilical vein endothelial Cells (HUVEC£©	AGEs and oxidized low-density lipoprotein	upregulated	28683566
11079	Human	hsa-miR-92a	miRNA	"H2O2, angiotensin II (AngII) and oxidized low-density lipoprotein (ox-LDL)"	endothelial dysfunction	HUVECs	"with H2O2, Ang II, and oxidized LDL (ox-LDL) treatment"	upregulated	25550450
11080	Human	hsa-miR-92a	miRNA	swainsonine (SW)	glioblastoma multiforme (GBM)	U251 and LN444 cells	swainsonine (SW) treatment	downregulated	30890138
11081	Human	hsa-miR-92a	miRNA	alkannin	hepatocellular carcinoma (HCC)	Huh7 and Hep3B2.1-7 cells	alkannin (ALK) treatment	downregulated	30909147
11082	Human	hsa-miR-92a	miRNA	human cytomegalovirus (HCMV; human herpesvirus 5)	human cytomegalovirus (HCMV) infection	HFFF cells	human cytomegalovirus (HCMV; human herpesvirus 5) treatment	hsa-miR-92a downregulated	21471310
11083	Human	hsa-miR-92a	miRNA	sulfur mustard (SM)	lung diseases	plasma and serum	Sulfur mustard (SM) treatment	downregulated	26525353
11084	Human	hsa-miR-92a	miRNA	AZD6244	lymphoma	"Raji, MOLT4 and 293T cells w"	AZD6244 treatment	downregulated	24375836
11085	Human	hsa-miR-92a	miRNA	berberine (BBR)	multiple myeloma (MM)	RPMI-8266 cells; U266 cells	berberine (BBR) treatment	Berberine downregulated miR-92a cluster expression in multiple myeloma (MM) cells.	29687521
11086	Human	hsa-miR-92a	miRNA	TGF-¦Â1	neointimal hyperplasia	human umbilical vein endothelial cells (HUVEC)	TGF-¦Â1 treatment	TGF-¦Â1 treatment of HUVECs significantly increased miR-92a expression and induced EndMT	33253710
11087	Human	hsa-miR-92a	miRNA	hyperbaric oxygen (HBO)	neovascularization	human coronary artery endothelial cells (HCAECs)	hyperbaric oxygen (HBO) treatment	downregulated	30301563
11088	Human	hsa-miR-92a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	downregulated	26878281
11089	Human	hsa-miR-92a	miRNA	TGF-¦Â1	osteoarthritis (OA)	human osteoarthritis synovial fibroblasts (OASFs)	TGF-¦Â1 treatment	downregulated	31232696
11090	Human	hsa-miR-92a	miRNA	integrin ¦Á5	ovarian cancer (OC)	"The ovarian cancer cell lines, A2780£» CaOV3 cells£» RMUG-S£» OVISE£»and RMG-1 cell lines£»SKOV3ip1 cells £»HeyA-8 cell"	integrin ¦Á5 treatment	miR-92a overexpression	23499550
11091	Human	hsa-miR-92a	miRNA	advanced glycation end product (AGE)	oxidative stress	human umbilical vein endothelial cells (HUVECs)	advanced glycation end products (AGEs) treatment	upregulated	28683566
11092	Human	hsa-miR-92a	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28683566
11093	Human	hsa-miR-92a	miRNA	statins	unstable angina (UA)	plasma	statins? treatment	downregulated	26474612
11094	Human	hsa-miR-92a	miRNA	TGF-¦Â1	vein grafts	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â1 treatment	we show that TGF-¦Â1 treatment of HUVECs significantly increased miR-92a expression and induced EndMT	33253710
11095	Human	hsa-miR-92a-1-5p	miRNA	regorafenib	frail metastatic colorectal cancer (mCRC)	serum	regorafenib treatment	"Serum levels of miR-126-3p and miR-152-3p and tumor expression of miR-92a-1-5p were associated with treatment toxicity, particularly interesting in patients exhibiting comorbidities, and high levels of miR-362-3p were associated with asthenia"	33916610
11096	Human	hsa-miR-92a-1-5p	miRNA	bile acids	gastric intestinal metaplasia (IM)	"BGC823, GES-1, SGC7901, MKN28, MKN45 and AGS cells"	bile acids treatment	upregulated	30635407
11097	Human	hsa-miR-92a-1-5p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
11098	Human	hsa-miR-92a-3p	miRNA	H2O2	angiogenesis	human umbilical vein endothelial cells (HUVECs) exosomes	H2O2 treatment	Primary miR-92a (pri-miR-92a-1) was decreased in Exo-H2O2-treated HUVECs.	32901851
11099	Human	hsa-miR-92a-3p	miRNA	clozapine (CLZ)	cardiotoxicity	plasma	clozapine (CLZ) treatment	upregulated	31722571
11100	Human	hsa-miR-92a-3p	miRNA	hypoxia	cell differentiation	human (P3 and U87) glioma cell lines	hypoxia induce	upregulated	30536597
11101	Human	hsa-miR-92a-3p	miRNA	¦Ã-rays	ionizing radiation (IR) injury	whole blood samples from healthy donors extracellular vesicles (ELVs)	irradiate with 2 Gy gamma rays treatment	upregulated	28264626
11102	Human	hsa-miR-92a-3p	miRNA	clozapine (CLZ)	clozapine (CLZ)-induced cardiotoxicities	Plasma	clozapine (CLZ) treatment	upregulated	31722571
11103	Human	hsa-miR-92a-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	cardiomyocytes	Doxorubicin (Dox) treatment	Dox-treated cardiomyocytes expressed a higher level of miR-92a-3p.	32384281
11104	Human	hsa-miR-92a-3p	miRNA	cardiac resynchronization therapy	heart failure (HF)	plasma	cardiac resynchronization therapy treatment	upregulated	23736534
11105	Human	hsa-miR-92a-3p	miRNA	"MS-275, a histone deacetylase inhibitor"	melanoma	TRAIL-resistant or TRAIL-sensitive cutaneous and uveal melanoma cells	MS-275 treatment	downregulated	27620505
11106	Human	hsa-miR-92a-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes (PHCs)	IL-1¦Â	downregulated	29241192
11107	Human	hsa-miR-92a-3p	miRNA	"isoniazid, pyrazinamide and ethambutol"	pulmonary tuberculosis (PTB)	serum	"isoniazid, pyrazinamide and ethambutol treatment"	miR-92a-3p was downregulated in treated patients when compared with untreated patients.	29523324
11108	Human	hsa-miR-92b	miRNA	IL-13	asthma	human bronchial epithelial cells (NHBE)	IL-13 treatment	upregulated	31386204
11109	Human	hsa-miR-92b	miRNA	sulforaphane (SFN)	breast cancer	"breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3)"	SFN (5-10 ?M) treatment	downregulated	28912888
11110	Human	hsa-miR-92b-3p	miRNA	hypoxia	cell proliferation	Human primary pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	upregulated	30518907
11111	Human	hsa-miR-92b-3p	miRNA	deoxycholic acid (DCA)	gallbladder cancer (GBC)	NOZ cells; GBC-SD cells	deoxycholic acid (DCA) treatment	DCA treatment decreased miR-92b-3p expression.	32514152
11112	Human	hsa-miR-92b-3p	miRNA	hypoxia	glioblastoma multiforme (GBM)	U87MG cells	hypoxia treatment	downregulated	25129238
11113	Human	hsa-miR-92b-3p	miRNA	dipogenic differentiation mixture (MDI)	liver fibrosis	LX-2 cells	dipogenic differentiation mixture (MDI) treatment	"We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1. However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)."	33618248
11114	Human	hsa-miR-92b-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	"We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1 However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)"	33618248
11115	Human	hsa-miR-92b-3p	miRNA	bevacizumab and FOLFOX	metastatic colorectal cancer (mCRC)	mCRC patients tumor tissue	bevacizumab/FOLFOX	upregulated	28693229
11116	Human	hsa-miR-92b-3p	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	hepatocyte cell lines	palmitate treatment	downregulated	25314137
11117	Human	hsa-miR-93	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	downregulated	33505213
11118	Human	hsa-miR-93	miRNA	estradiol-17¦Â (E2)	breast cancer	MCF-10A cells;T47D cells	estradiol-17¦Â (E2) treatment	upregulated	23492819
11119	Human	hsa-miR-93	miRNA	vitamin C	breast cancer	MCF-10A cells;T47D cells	vitamin C treatment	downregulated	23492819
11120	Human	hsa-miR-93	miRNA	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC)	chronic inflammatory diseases	human umbilical vein endothelial cells (HUVECs) exosomes	oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) treatment	upregulated	29161413
11121	Human	hsa-miR-93	miRNA	5-fluorouracil (5-Fu) and oxaliplatin	colorectal cancer (CRC)	human colon cancer cells	5-Fluorouracil and oxaliplatin treatment	downregulated	19956872
11122	Human	hsa-miR-93	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells; HCT116 cells	ionizing radiation (IR) treatment	HOTAIR knockdown enhances radiosensitivity through regulating microRNA-93/ATG12 axis in colorectal cancer.	32144238
11123	Human	hsa-miR-93	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	miR-93 was dramatically decreased in TGF-¦Â1-stimulated HK2 cells	29551286
11124	Human	hsa-miR-93	miRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	H19 played an important role in regulating inflammatory processes in retinal endothelial cells under high-glucose condition through modulating miR-93/XBP1s axis.	31953562
11125	Human	hsa-miR-93	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Primary human retinal pigment epithelium (RPE) cells and ARPE-19 cells	high glucose (HG) treatment	"lncRNA MEG3 depresses HG-induced apoptosis and inflammation of RPE via miR-93/Nrf2 axis, providing a novel perspective on the genesis and development of DR."	32473920
11126	Human	hsa-miR-93	miRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	downregulated	30544204
11127	Human	hsa-miR-93	miRNA	cigarette smoke (CS)	emphysema	HBE cells	Cigarette smoke (CS) exposure	upregulated	33660100
11128	Human	hsa-miR-93	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 and T98G cells	temozolomide (TMZ) treatment	miR-93 and -193 decreased cell cycling quiescence and induced resistance to TMZ.	30853911
11129	Human	hsa-miR-93	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	human primary hepatocytes isolated from humanized chimeric uPA/SCID mice as efficient sources	hepatitis B virus (HBV) infection	downregulated	25026299
11130	Human	hsa-miR-93	miRNA	radiotherapy	head and neck squamous cell carcinoma (HNSCC)	neck squamous cell carcinoma patients saliva samples	radiotherapy treatment	upregulated in saliva samples	28677748
11131	Human	hsa-miR-93	miRNA	triptolide (TPL)	hepatocellular carcinoma (HCC)	HepG2 cells	triptolide (TPL) treatment	downregulated	29523159
11132	Human	hsa-miR-93	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	influenza A virus (IAV) infection significantly inhibited miR-93 expression in alveolar epithelial type II cells through RIG-I/JNK pathway.	32652502
11133	Human	hsa-miR-93	miRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	31432162
11134	Human	hsa-miR-93	miRNA	H2O2	mitophagy	HeLa and HEK 293T cells	H2O2 treatment	"We further demonstrate that H2O2?promotes the expression of the miR-106b-93-25 cluster and that miR-106b and miR-93 synergistically inhibit the translation of OPTN, NDP52, and MFN2 by targeting their 3' untranslated regions."	33627622
11135	Human	hsa-miR-93	miRNA	diet	obesity	Plasma	diet treatment	"Levels of miRNAs 25, 93 and 106 that are expressed from a common genomic cluster were reduced after weight loss."	32439373
11136	Human	hsa-miR-93	miRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin (DPP) treatment	upregulated	31128026
11137	Human	hsa-miR-93	miRNA	berberine (BBR)	ovarian cancer (OC)	cisplatin resistant A2780 cell lines	berberine (BBR) treatment	upregulated	26087719
11138	Human	hsa-miR-93	miRNA	L-tetrahydropalmatine (L-THP)	ovarian cancer (OC)	A2780 cells	L-Tetrahydropalmatine (L-THP) treatment	downregulated	31128026
11139	Human	hsa-miR-93	miRNA	morin	oxidative stress	A549 cells upon traffic PM2.5 exposure	Morin treatment	downregulated	31284452
11140	Human	hsa-miR-93	miRNA	particulate matter (PM2.5)	oxidative stress	A549 cells	traffic PM2.5 treatment	upregulated	31284452
11141	Human	hsa-miR-93	miRNA	curcumin (Cur)	peripheral arterial disease (PAD)	Human umbilical vein endothelial cells (HUVECs)	curcumin treatment	upregulated	30651865
11142	Human	hsa-miR-93	miRNA	hypoxia	peripheral arterial disease (PAD)	EA.hy926 endothelial cells	hypoxia induce	upregulated	31059098
11143	Human	hsa-miR-93	miRNA	green tea polysaccharide (GTP)	prostate cancer	PC-3 cells	green tea (Camellia sinensis) polysaccharide (GTP) treatment	downregulated	30342140
11144	Human	hsa-miR-93	miRNA	green tea polysaccharide (GTP)	prostate cancer	PC-3 cells	green tea polysaccharide (GTP) treatment	downregulated	30342140
11145	Human	hsa-miR-93	miRNA	hypoxia	prostate cancer	LNCaP cells	5% O2 treatment	upregulated	24135225
11146	Human	hsa-miR-93	miRNA	TGF-¦Â	renal cell carcinoma (RCC)	renal cancer cells	TGF-¦Â treatment	downregulated	25183046
11147	Human	hsa-miR-93	miRNA	salvianolic acid B (Sal B)	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	Sal B treatment	upregulated	25094038
11148	Human	hsa-miR-93	miRNA	TGF-¦Â1	renal fibrosis	human kidney proximal tubular epithelial cells (HK-2 cells)	TGF-¦Â1 treatment	downregulated	25094038
11149	Human	hsa-miR-93	miRNA	leptin	rheumatoid arthritis (RA)	human osteoblasts	leptin treatment	downregulated	25198901
11150	Human	hsa-miR-9-3	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA)"	bladder cancer	BCa cell lines (T24£»UM-UC-3£» HT-1197£» HT-1376£» SW780£»5637) £»normal urothelial cell line (SV-HUC-1)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and 4-phenylbutyric acid (PBA) treatment"	upregulated	23200812
11151	Human	hsa-miR-9-3	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	lung cancer	NSCLC A549 cells	5-aza-20-deoxycytidine (Aza-dC) and with a combination of Aza-dC and the histone deacetylase inhibitor trichostatin A treatment	upregulated	22282464
11152	Human	hsa-miR-9-3	miRNA	sulforaphane (SFN)	lung cancer	lung cancer A549 cells	Sulforaphane (SFN) treatment	upregulated	29525530
11153	Human	hsa-miR-933	miRNA	27-hydroxycholesterol (27-OHC)	Alzheimer's disease (AD)	microvascular endothelial cell (HMVEC)	27 hydroxycholesterol (27-OHC) treatment	upregulated	29966198
11154	Human	hsa-miR-933	miRNA	ursolic acid (UA)	breast cancer	MCF-7 cells	usnic acid treatment	downregulated	31549595
11155	Human	hsa-miR-933	miRNA	palmitate	diabetes mellitus (DM)	Human islets	palmitate (Pal) treatment	upregulated	30131392
11156	Human	hsa-miR-933	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
11157	Human	hsa-miR-93-3p	miRNA	human immunodeficiency virus (HIV)-1	HIV-associated neurocognitive disorders (HAND)	human primary monocyte-derived macrophages	infect with HIV-1	upregulated	28594894
11158	Human	hsa-miR-934	miRNA	alcohol	head and neck squamous cell carcinoma (HNSCC)	normal oral keratinocytes	alcohol exposure	upregulated	26472042
11159	Human	hsa-miR-935	miRNA	intermediate-sized hyaluronan (INT-HA)	macrophage polarization	Primary human macrophages derived from peripheral blood monocytes	Intermediate-sized hyaluronan (INT-HA) treatment	downregulated	30341559
11160	Human	hsa-miR-935	miRNA	intermediate-sized hyaluronan (INT-HA)	macrophage polarization	Primary human macrophages	Intermediate-sized hyaluronan (INT-HA) treatment	downregulated	30341559
11161	Human	hsa-miR-93-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	Endothelial progenitor cells-secreted extracellular vesicles containing microRNA-93-5p confer protection against sepsis-induced acute kidney injury via the KDM6B/H3K27me3/TNF-¦Á axis	32679234
11162	Human	hsa-miR-93-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	?human renal tubular epithelial HK-2 cells	?high glucose (HG) induce	silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN	31545928
11163	Human	hsa-miR-93-5p	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	"serum of patients with HCV-1b infection, Huh7 cells"	hepatitis C virus (HCV) infection	upregulated	29375208
11164	Human	hsa-miR-93-5p	miRNA	neodymium oxide (Nd2O3)	inflammation	human bronchial epithelial cells (16HBE)	neodymium oxide (Nd2O3) treatment	upregulation of circ_0039411 mediated Nd2O3-induced inflammation and dysfunction by sponging miR-93-5p.	30903189
11165	Human	hsa-miR-93-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	cultured primary chondrocyte	IL-1¦Â treatment	downregulated	30930294
11166	Human	hsa-miR-93-5p	miRNA	activin A	prostate cancer	LNCaP cells	activin A treatment	downregulated	27018851
11167	Human	hsa-miR-939	miRNA	monocyte chemoattractant protein-1 (MCP-1)	complex regional pain syndrome (CRPS)	THP-1 monocytes secreted small extracellular vesicles (sEVs)	monocyte chemoattractant protein-1 (MCP-1) treatment	upregulated	31489147
11168	Human	hsa-miR-939	miRNA	leuprolide	endometriosis	endometriotic tissues	Leuprolide treatment	downregulated	27709720
11169	Human	hsa-miR-939	miRNA	water particulate matter 2.5 (PM2.5 )	respiratory toxicity	human alveolar epithelial cell (A549)	water particulate matter 2.5 (PM2.5 ) treatment	upregulated	26791009
11170	Human	hsa-miR-93a	miRNA	H2O2	apoptosis	vascular smooth muscle cell (VSMC)	H2O2 treatment	downregulated	24705900
11171	Human	hsa-miR-9-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary artery disease (CAD)	endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	miR-9-3p was downregulated by oxLDL treatment in endothelial cell.	30485507
11172	Human	hsa-miR-9-3p	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
11173	Human	hsa-miR-9-3p	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
11174	Human	hsa-miR-940	miRNA	dasatinib	chronic myeloid leukemia (CML)	CML cell line K562	dasatinib treatment	downregulated	30814857
11175	Human	hsa-miR-940	miRNA	acute exercise	congestive heart failure (CHF)	CHF patients	acute exercise treatment	upregulated	26799589
11176	Human	hsa-miR-940	miRNA	hypoxia	epithelial ovarian cancer (EOC)	macrophages of human epithelial ovarian cancer (EOC) exosomes	hypoxia treatment	upregulated	28586039
11177	Human	hsa-miR-940	miRNA	sodium butyrate (NaB)	sickle cell anemia (SCA)	CD133 hematopoietic stem cells	sodium butyrate treatment	dysregulated	26837891
11178	Human	hsa-miR-941	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	T-HESC; primary human endometrial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-941 activates Nrf2 cascade to protect human endometrial cells from OGDR-induced oxidative stress and programmed necrosis	32102665
11179	Human	hsa-miR-941	miRNA	exercise (Ex)	physiological impairments associated with aging	circulating exosomes	exercise treatment	upregulated	32587527
11180	Human	hsa-miR-942	miRNA	"chlorpromazine, haloperidol and clozapine"	psychosis	JM-Jurkat T-lymphocytes	"chlorpromazine, haloperidol and clozapine treatment"	dysregulated	24480591
11181	Human	hsa-miR-942	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	upregulated	22647265
11182	Human	hsa-miR-942	miRNA	oxidized low density lipoprotein (ox-LDL)	carotid artery atherosclerosis	HCtAEC | Human Carotid Artery Endothelial Cells; THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LncRNA ZEB1-AS1 contributed to ox-LDL-mediated injury and apoptosis of HCtAEC cells and the oxidative stress and inflammation of THP-1 cells through up-regulating HMGB1 via sponging miR-942.	31962131
11183	Human	hsa-miR-942	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	human hepatoma cell line HLCZ01	infectious HCV isolate JFH1 treatment	downregulated	24727952
11184	Human	hsa-miR-942	miRNA	lipopolysaccharide (LPS)	liver fibrosis	human primary hepatic stellate cells; LX-2 cells	lipopolysaccharide (LPS) treatment	upregulated	30097701
11185	Human	hsa-miR-942	miRNA	TGF-¦Â1	liver fibrosis	human primary hepatic stellate cells; LX-2 cells	TGF-¦Â1 treatment	upregulated	30097701
11186	Human	hsa-miR-942-5p	miRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	MiR-942-5p expression was reduced in lipopolysaccharide (LPS)-treated HK-2 cells.	32572890
11187	Human	hsa-miR-944	miRNA	low-glycaemic load dietary	breast cancer	serum (pre-menopausal women)	low-glycaemic load dietary treatment	downregulated	22647265
11188	Human	hsa-miR-95	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	aortic stenosis	cervical cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines"	23732000
11189	Human	hsa-miR-95	miRNA	glargine	pancreatic cancer (PC)	pancreatic cancer cells	glargine treatment	upregulated	22690071
11190	Human	hsa-miR-95	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) and suberoylanilide hydroxamic acid"	renal cell carcinoma (RCC)	renal cell; carcinoma cell lines	(5-aza-2'-deoxycytidine) and (suberoylanilide hydroxamic acid) treatment	upregulated	23707942
11191	Human	hsa-miR-9500	miRNA	hematoporphyrin	glioblastoma multiforme (GBM)	U87 glioma cells	hematoporphyrin treatment	upregulated	29344634
11192	Human	hsa-miR-95-5p	miRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	downregulated	32483833
11193	Human	hsa-miR-9-5p	miRNA	traffic-originated PM2.5 organic component (tPo)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	Traffic-related air pollution particulate matter 2.5 (TRAPM2.5) treatment	LncRNA RP11-86H71 promotes airway inflammation induced by TRAPM25 by acting as a ceRNA of miRNA-9-5p to regulate NFKB1 in HBECS	32665564
11194	Human	hsa-miR-9-5p	miRNA	cocaine	drug addiction	differentiated SH-SY5Y neuroblastoma cells	cocaine treatment	downregulated	30166527
11195	Human	hsa-miR-9-5p	miRNA	"2,3,5,4'-tetrahydroxystilbene-2-O-¦Â-D-glucoside (TSG)"	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	"2,3,5,4'-Tetrahydroxystilbene-2-O-¦Â-D-Glucoside (TSG) treatment"	downregulated	33093269
11196	Human	hsa-miR-9-5p	miRNA	insulin-like growth factor 1 (IGF-1)	glioblastoma multiforme (GBM)	U87-MG cells	IGF-1 treatment	downregulated	28389653
11197	Human	hsa-miR-9-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	SH-SY5Y cells	oxygen-glucose deprivation (OGD) treatment	downregulated	31500865
11198	Human	hsa-miR-9-5p	miRNA	Japanese encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	human neuronal progenitor cells and primary neural precursor cells isolated from aborted fetuses	Japanese encephalitis virus (JEV) infection	downregulated	31578247
11199	Human	hsa-miR-9-5p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	downregulated	29073595
11200	Human	hsa-miR-9-5p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30826419
11201	Human	hsa-miR-9-5p	miRNA	"pramipexole,piribedil, L-dopa, amantadine"	parkinson's disease (PD)	patients with Parkinson's disease	"different medications (pramipexole,piribedil, L-dopa, amantadine) treatment"	upregulated	25465742
11202	Human	hsa-miR-9-5p	miRNA	lithium (Li)	spinal cord injury (SCI)	SH-SY5Y cells	lithium treatment	Lithium treatment rescued the upregulation of BDNF-AS expression and downregulated of miR-9-5p expression induced by H2O2 in SH-SY5Y cells.	33464390
11203	Human	hsa-miR-9-5p	miRNA	high glucose (HG)	vascular endothelial cell injury	human umbilical vascular endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	30716366
11204	Human	hsa-miR-96	miRNA	curcumin (Cur)	breast cancer	T47D breast cancer cells	curcumin treatment	48 h curcumin treatment prevented the autocrine GH-mediated miR-182-96-183 cluster expression stimulation in T47D cells.	30467667
11205	Human	hsa-miR-96	miRNA	coffee	colorectal cancer (CRC)	Caco-2 human colon carcinoma cells	coffee treatment	upregulated	28693281
11206	Human	hsa-miR-96	miRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1	32765688
11207	Human	hsa-miR-96	miRNA	cisplatin and doxorubicin	gastric cancer (GC)	SGC7901 cells	cisplatin and doxorubicin treatment	treatment with a low dose of either chemotherapeutic agent induced miR-96 expression.	30128023
11208	Human	hsa-miR-96	miRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	293A and 293T cells	infect with HSV-1	upregulated	28783105
11209	Human	hsa-miR-96	miRNA	mitochondrial dysfunction	insulin resistance (IR)	SK-Hep1 cells (ATCC HTB-52)	mitochondrial dysfunction treatment	upregulated	23583389
11210	Human	hsa-miR-96	miRNA	cisplatin and paclitaxel	metastatic bladder cancer	T24 bladder cancer cells	cisplatin and paclitaxel treatment	upregulated	26356996
11211	Human	hsa-miR-96	miRNA	hyperoxia	oxygen-induced retinopathy (OIR)	human retinal microvascular endothelial cells (HRMEC)	hyperoxia treatment	MicroRNA-96 Promotes Vascular Repair in Oxygen-Induced Retinopathy-A Novel Uncovered Vasoprotective Function.	32116694
11212	Human	hsa-miR-96	miRNA	hypoxia	prostate cancer	prostate cancer cell lines LNCaP;22Rv1 cells	hypoxia treatment	upregulated	25333253
11213	Human	hsa-miR-96	miRNA	carbon black nanoparticle (CBNP)	lung fibrosis	human bronchial epithelial (16HBE) cells	carbon black nanoparticle (CBNP) treatment	downregulated	31683435
11214	Human	hsa-miR-96	miRNA	light	retinal injury	retinal pigment epithelial (RPE) cells	light treatment	upregulated	25955435
11215	Human	hsa-miR-96	miRNA	running	telomere homeostasis	twenty-two healthy males white blood cells	undertook 30 minutes of treadmill running at 80% of peak oxygen uptake treatment	upregulated	24752326
11216	Human	hsa-miR-96-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32342116
11217	Human	hsa-miR-96-5p	miRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	human AML cell lines HL60 and THP-1	cytarabine (Ara-C) treatment	"miR-96 downregulated abolished the effects of MALAT1 knockdown on the proliferation, apoptosis, Ara-C sensitivity in AML cells."	30970520
11218	Human	hsa-miR-96-5p	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	autophagy	human HTR-8/SVneo (HTR) cells	Titanium dioxide nanoparticles (TiO2 NPs) treatment	upregulated	30345998
11219	Human	hsa-miR-96-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity	endothelial cells	PM2.5 exposure treatment	downregulated	30597786
11220	Human	hsa-miR-96-5p	miRNA	particulate matter (PM2.5)	cardiotoxicity of PM2.5	endothelial cells	PM2.5 treatment	downregulated	30597786
11221	Human	hsa-miR-96-5p	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	The expression of miR-96-5p were significantly increased in the GAS5 knockdown group The level of miR-96-5p was downregulated in the renal tissues of DM mice miR-96- 5p mimic downregulated GAS5 expression	31810140
11222	Human	hsa-miR-96-5p	miRNA	sanguinarine	gastric cancer (GC)	BGC-823 cells	sanguinarine treatment	downregulated	31243669
11223	Human	hsa-miR-96-5p	miRNA	"OTX015 (MK-8628, birabresib)"	lymphomagenesis	DOHH-2 cells; OCI-LY-1 cells	OTX015 treatment	OTX015 upregulates miR-96-5p in a time-dependent manner.	30076183
11224	Human	hsa-miR-96-5p	miRNA	cryptotanshinone	non-small cell lung cancer (NSCLC)	A549 cells	cryptotanshinone treatment	downregulated	31452742
11225	Human	hsa-miR-96-5p	miRNA	malathion	organophosphate-induced cytotoxicity	HK-2 cells	Malathion treatment	Malathion decreased HK-2 cell viability and the expression of miR-96-5p in a dose- and time-dependent manner.	32897819
11226	Human	hsa-miR-96-5p	miRNA	H2O2	oxidative stress	ARPE-19 cells	H2O2 treatment	downregulated	28707489
11227	Human	hsa-miR-96-5p	miRNA	hypoxia	pancreatic cancer (PC)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	hypoxic exosomal UCA1 could promote angiogenesis and tumor growth through the miR-96-5p/AMOTL2/ERK1/2 axis	32942233
11228	Human	hsa-miR-96-5p	miRNA	titanium dioxide nanoparticles (TiO2 NPs)	placental development	"human trophoblast-derived cell, HTR8-Svneo"	Titanium dioxide nanoparticles (TiO2 NPs) treatment	upregulated	31226636
11229	Human	hsa-miR-96-5p	miRNA	angiotensin II (Ang II)	"proliferation, migration, and apoptosis of VSMCs"	vascular smooth muscle cell (VSMC)	angiotensin II (Ang II) treatment	miR-96-5p was downregulated in Ang II-induced VSMCs.	32045906
11230	Human	hsa-miR-96-5p	miRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	miR-96-5p targets FN1 and alleviates TGF-¦Â1-induced fibrosis in HK-2 cells	31810140
11231	Human	hsa-miR-98	miRNA	cisplatin (DDP)	cell death	A549 cell	cisplatin (DPP) treatment	downregulated	21880462
11232	Human	hsa-miR-98	miRNA	oxidized low density lipoprotein (ox-LDL)	apoptosis	human umbilical vein ECs (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28565756
11233	Human	hsa-miR-98	miRNA	estradiol	breast cancer	MCF-7 cells	Estradiol treatment	upregulated	19528081
11234	Human	hsa-miR-98	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
11235	Human	hsa-miR-98	miRNA	tamoxifen (TAM)	breast cancer	MCF-7 breast cancer cells	tamoxifen treatment	upregulated	30072833
11236	Human	hsa-miR-98	miRNA	TGF-¦Â1	cardiac fibrosis	human cardiac fibroblasts (HCFs)	TGF-¦Â1 treatment	downregulated in a time- and concentration-dependent manner	28251559
11237	Human	hsa-miR-98	miRNA	cryptosporidium parvum	cryptosporidium parvum infection	"C. parvum oocysts,H69 cells;Non-immortalized normal human biliary epithelial cells (HIBEpiC)"	cryptosporidium parvum? infection	downregulated	20486857
11238	Human	hsa-miR-98	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	"glioma cell lines (U87, U251, U373 and SHG44)"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29436585
11239	Human	hsa-miR-98	miRNA	hypoxia	inflammation	human Aortic Smooth Muscle Cells (hASMCs)	Hypoxia treatment	downregulated	26045772
11240	Human	hsa-miR-98	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cells (BMVEC)	oxygen-glucose deprivation (OGD) treatment	downregulated	31601141
11241	Human	hsa-miR-98	miRNA	aspirin	lung cancer	A549 and H1299 cell lines	aspirin treatment	upregulated	30756509
11242	Human	hsa-miR-98	miRNA	curcumin (Cur)	lung cancer	lung cancer cell line A549	curcumin treatment	upregulated	28587210
11243	Human	hsa-miR-98	miRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	ANRIL knockdown inhibited the development of DDP resistance by upregulating miR-98.	32705261
11244	Human	hsa-miR-98	miRNA	TNF-a and MMP13	osteoarthritis (OA)	human OA cartilage and bone	TNF-a and MMP13 treatment	upregulated	19008124
11245	Human	hsa-miR-98	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	human synoviocytes (HS) cell line	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31077735
11246	Human	hsa-miR-98-5p	miRNA	H2O2	acute myocardial infarction (AMI)	Human myocardial cell line (AC16)	H2O2 treatment	downregulated	32888161
11247	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33542956
11248	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33249762
11249	Human	hsa-miR-98-5p	miRNA	epigallocatechin-3-gallate (EGCG)	non-small cell lung cancer (NSCLC)	NCI-H460 cells and another kind of NSCLC cells	EGCG treatment	upregulated	24712372
11250	Human	hsa-miR-98-5p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
11251	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"The expression of OIP5-AS1 was upregulated, while miR-98-5p was downregulated in ox-LDL-induced human umbilical vein endothelial cells (HUVECs)."	32990894
11252	Human	hsa-miR-98-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	33249762
11253	Human	hsa-miR-98-5p	miRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"human glioma cell lines (U87, U251, LN229, A172)"	temozolomide (TMZ) treatment	"downregulated FOXD2-AS1 repressed invasion, proliferation, migration and drug resistance of drug-resistant glioma cells while stimulating their apoptosis via increasing miR-98-5p and inhibiting CPEB4 expression."	31770107
11254	Human	hsa-miR-98-5p	miRNA	lauric acid	hepatocellular carcinoma (HCC)	HepG2 cells	lauric acid treatment	upregulated	32156243
11255	Human	hsa-miR-98-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells	sorafenib treatment	downregulated	32821157
11256	Human	hsa-miR-98-5p	miRNA	¦Ã- Mangostin (¦Ã-MS)	osteoarthritis (OA)	SW983 cells	¦Ã- Mangostin (¦Ã-MS) treatment	upregulated	32302289
11257	Human	hsa-miR-98-5p	miRNA	osteogenic differentiation medium	osteogenesis	bone marrow-derived mesenchymal stem cells (BMMSCs)	osteogenic-inducing medium [10% FBS; 5 mM L-glycerophosphate; 100 nM dexamethasone (Sigma-Aldrich; Merck KGaA) and 50 mg/ml ascorbic acid (Sigma-Aldrich; Merck KGaA)] treatment	downregulated	31555368
11258	Human	hsa-miR-98-5p	miRNA	osteogenic differentiation medium	osteogenesis	bone marrow-derived mesenchymal stem cells (BMMSCs) and MC3T3-E1 cells	osteogenic-inducing medium [10% FBS; 5 mM L-glycerophosphate; 100 nM dexamethasone (Sigma-Aldrich; Merck KGaA) and 50 mg/ml ascorbic acid (Sigma-Aldrich; Merck KGaA)] treatment	downregulated	31555368
11259	Human	hsa-miR-98-5p	miRNA	H2O2	ulcerative colitis (UC)	Caco-2 cells	H2O2 treatment	upregulated	33394187
11260	Human	hsa-miR-98a-5p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	drug-induced liver injury (DILI)	upcyte hepatocytes	¦Á-naphthyl isothiocyanate (ANIT) treatment	upregulated	31198949
11261	Human	hsa-miR-99a	miRNA	benzyl isothiocyanate (BITC)	bladder cancer	Human bladder cancer cell lines derived from patients (5637 and T24)	benzyl isothiocyanate (BITC) treatment	upregulated	31587482
11262	Human	hsa-miR-99a	miRNA	advanced glycation end product (AGE)	colorectal cancer (CRC)	HCT-116 cells	advanced glycation end products (AGEs) treatment	downregulated	31819515
11263	Human	hsa-miR-99a	miRNA	salidroside (SAL)	gastric cancer (GC)	GC cell lines (SNU-216 and MGC803) and gastric epithelial cell line GES-1	Salidroside (SAL) treatment	upregulated	31432697
11264	Human	hsa-miR-99a	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	Huh-7 cells	hepatitis C virus (HCV) infection	Cell-culture-derived HCV (HCVcc) infection caused downregulated of miR-99a in Huh-7 cells.	32605105
11265	Human	hsa-miR-99a	miRNA	lipopolysaccharide (LPS)	inflammation	HUVECs cells	lipopolysaccharide (LPS) treatment	downregulated	27403035
11266	Human	hsa-miR-99a	miRNA	paraquat (PQ)	neurotoxicity	human neural progenitor cells (hNPCs)	paraquat (PQ) treatment	upregulated	26878281
11267	Human	hsa-miR-99a	miRNA	radiation	non-small cell lung cancer (NSCLC)	A549 cells	radiation treatment	miR-99a was significantly upregulated in radiation-sensitive A549 cells compared with radiation-resistant A549 cells	29614485
11268	Human	hsa-miR-99a	miRNA	insulin	polycystic ovarian syndrome (PCOS)	Granulosa cells (GCs)	insulin treatment	downregulated	30374732
11269	Human	hsa-miR-99a	miRNA	insulin	premature senescence	HepG2 cells; HL7702 cells	insulin treatment	downregulated	23762265
11270	Human	hsa-miR-99a	miRNA	androgen	prostate cancer	prostate cancer cells	androgen treatment	downregulated	23503464
11271	Human	hsa-miR-99a	miRNA	mifepristone (MIF)	prostate cancer	prostate cells	Mifepristone treatment	upregulated	27340920
11272	Human	hsa-miR-99a	miRNA	curcumin (Cur)	retinoblastoma (RB)	?Two Rb cell lines SO-Rb50 and Y79	curcumin treatment	upregulated	30526546
11273	Human	hsa-miR-99a	miRNA	bafilomycin A1	hepatocellular carcinoma and ovarian cancer	BEL-7402 hepatocellular carcinoma;HO-8910 ovarian cancer cell	bafilomycin A1 treatment	downregulated	26640557
11274	Human	hsa-miR-99a*	miRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	cancer cell	5-fluorouracil treatment	upregulated	23167930
11275	Human	hsa-miR-99a*	miRNA	capecitabine	colorectal cancer (CRC)	cancer cell	capecitabine treatment	upregulated	23167930
11276	Human	hsa-miR-99a-5p	miRNA	benzyl isothiocyanate (BITC)	bladder cancer	"Human BC cell lines RT4, 5637, HT1376, HT1197, T24 and humanureter-sumian-virus-40 transformed immortalized epithelial cell line SV-HUC-1"	benzyl isothiocyanate (BITC) treatment	upregulated	30942430
11277	Human	hsa-miR-99a-5p	miRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823	cisplatin (DPP) treatment	CircMCTP2 sensitizes GC to CDDP through the upregulation of MTMR3 by sponging miR-99a-5p.	33198772
11278	Human	hsa-miR-99a-5p	miRNA	hormone	non-traumatic osteonecrosis of femoral head (ONFH)	femoral head	hormone treatment	downregulated	26298803
11279	Human	hsa-miR-99b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The expression of miR-99b was increased in the OGD/R model.	32343508
11280	Human	hsa-miR-99b	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	gastric cancer tissues; BGC-823 cells	Helicobacter pylori treatment	microRNA (miR)-99b levels increased in H. pylori-infected gastric cancer tissues and the BGC-823 gastric cancer cell line.	30250606
11281	Human	hsa-miR-99b	miRNA	IL-1¦Â	inflammatory response	monocytes	IL-1¦Â treatment	upregulated	30245693
11282	Human	hsa-miR-99b	miRNA	lipopolysaccharide (LPS)	inflammatory response	monocytes	lipopolysaccharide (LPS) treatment	upregulated	30245693
11283	Human	hsa-miR-99b	miRNA	TLR2 agonist pam3CSK4	inflammatory response	monocytes	TLR2 agonist pam3CSK4 treatment	upregulated	30245693
11284	Human	hsa-miR-99b	miRNA	lactobacillus casei (L. casei LC01)	irritable bowel syndrome with diarrhea (IBS-D)	intestinal epithelial cells (IECs)	L. casei LC01 treatment	upregulated	32807750
11285	Human	hsa-miR-99b	miRNA	nicotine	non-small cell lung cancer (NSCLC)	A549 and NCI-H460 cells	nicotine treatment	downregulated	29518612
11286	Human	hsa-miR-99b	miRNA	a moderate-carbohydrate and low glycemic index diet	overweight and obese	overweight and obese subjects plasma	a moderate-carbohydrate and low glycemic index diet	downregulated	29233588
11287	Human	hsa-miR-99b-5p	miRNA	p-Coumaric acid (p-CA)	autoimmune hepatitis (AIH)	SNU-16 cells	p-Coumaric acid (p-CA) treatment	upregulated	32462517
11288	Human	hsa-miR-99b-5p	miRNA	P. macrocarpa ethyl acetate fraction (PMEAF)	breast cancer	MDA-MB-231 cells	PMEAF treatment	downregulated	29154802
11289	Human	hsa-miR-99b-5p	miRNA	particulate matter (PM10)	cardiovascular disease (CVD)	extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	particulate matter (PM10) treatment	downregulated in extracellular vesicles (EVs) derived from monocyte/macrophage components (CD14+) and platelets (CD61+)	28899404
11290	Human	hsa-miR-99b-5p	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SMMC-7721 cells-derived exosomes	TGF-¦Â1 treatment	upregulated	33194074
11291	Human	hsa-miR-99b-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	neutrophil	M.tb infection	downregulated	29477867
11292	Human	hsa-miR-99b-5p	miRNA	ultraviolet (UV) irradiation	UVB-induced cellular response	normal human dermal papilla cells	UVB radiation of ¡Ý50 mJ/cm2 treatment	upregulated	25069581
11293	Human	hsa-miR-9a-3p	miRNA	methylglyoxal (MGO)	ascular tone regulation	HEK293 cells	methylglyoxal (MGO) treatment	upregulated	25354529
11294	Human	hsa-miR-AB40	miRNA	IL-27	human immunodeficiency virus (HIV)-1 infection	macrophages;monocytes	IL-27 treatment	Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis confirmed that IL-27 dysregulatedthe expression of 16 of the 38 miRNAs.	33525571
11295	Human	hsa-miR-B1-3p	miRNA	polyomavirus BK (BKV)	polyomavirus BK (BKV) infection	HK-2 cells	BKV infection treatment	upregulated	24735545
11296	Human	hsa-miR-B1-5p	miRNA	polyomavirus BK (BKV)	polyomavirus BK (BKV) infection	HK-2 cells	BKV infection treatment	upregulated	24735545
11297	Human	hsa-miR-hz02	miRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	miscarriage	trophoblast Swan 71 and HTR-8/SVneo cells	"BPDE (benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide) treatment"	"If trophoblast cells are exposed to BPDE, both miR-hz02 and lnc-HZ02 are upregulated"	33851497
11298	Human	hsa-miR-K12-11	miRNA	Kaposi¡¯s sarcoma-associated herpesvirus (KSHV)	kaposi¡¯s sarcoma-associated herpesvirus (KSHV) infection	BCBL1cells; JSC-1cells; BJAB cells; Ramous; Loukes ; DG75 cells	Kaposi's sarcoma-associated herpesvirus (KSHV) infection	upregulated	21221132
11299	Human	hsa-miR-SX1	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
11300	Human	hsa-miR-SX2	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
11301	Human	hsa-miR-SX3	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
11302	Human	hsa-miR-SX6	miRNA	IL-27	acute liver injury (ALI)	human macrophages	IL-27?treatment	"?Four of which were preferentially expressed in I-Mac (miR-SX1, -SX2, -SX3 and -SX6) whilst three were detected in both M-Mac and I-Mac (miR-SX4, -SX5 and -SX7)"	23535375
11303	Human	hsa-miR-U86	miRNA	human herpesvirus 6A (HHV-6A)	human herpesvirus 6A (HHV-6A) infection	Jjhan and HSB2 cells	totransform HHV-6A-BAC-containing SW102 cells for insertion by homologous recombination treatment	upregulated	25520507
11304	Human	hsa-miR-UL22A	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	"THP-1 , differentiated THP-1 , human embryo lung fibroblasts"	HCMV infection treatment	dysregulated	32275696
11305	Human	hsa-miR-UL70	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	"THP-1 , differentiated THP-1 , human embryo lung fibroblasts"	HCMV infection treatment	dysregulated	32275696
11306	Human	hsa-miR-US33	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	"THP-1 , differentiated THP-1 , human embryo lung fibroblasts"	HCMV infection treatment	dysregulated	32275696
11307	Human	HSRL	lncRNA	tanshinone IIA (Tan IIA)	hypertrophic scars (HS)	human skin fibroblast (HSF)	tanshinone IIA (TSIIA) treatment	TSIIA treatment for 24h inhibited HSRL and SNX9 gene transcription in comparison with TGF-¦Â1 group	33049375
11308	Human	HTR2A-AS1	lncRNA	patrinia herba aqueous extract	hepatocellular carcinoma (HCC)	MHCC97-H cells	P. herba aqueous extract treatment	"P herba aqueous extract may inhibit the proliferation, invasion and migration of hepatocellular carcinoma cells by up-regulating the expression of HTR2A-AS1 in hepatocellular carcinoma cells and induce apoptosis"	32538757
11309	Human	HULC	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
11310	Human	HULC	lncRNA	prostaglandin E1 (PGE1)	contrast-induced nephropathy (CIN)	THP-1 cells; peripheral blood samples	PGE1 treatment	HULC was positively correlated with the expression of PTGS1 and PGE1	32678165
11311	Human	HULC	lncRNA	¦Â-Elemene	diffuse large B-cell lymphoma (DLBCL)	SU-DHL-8; SU-DHL-10	¦Â-Elemene treatment	¦Â-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway	32010942
11312	Human	HULC	lncRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	upregulated	28166203
11313	Human	HULC	lncRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HaCaT cells	Ultraviolet radiation b (UVB) treatment	upregulated	29803927
11314	Human	HULC	lncRNA	ionizing radiation (IR)	prostate cancer	PC3 cells; LNCaP cells	ionizing radiation (IR) treatment	upregulated	29694502
11315	Human	HULC	lncRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMECs)	lipopolysaccharide (LPS) treatment	upregulated	31231228
11316	Human	HULC	lncRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"LPS impaired cell viability, and promoted cell apoptosis, inflammatory response and oxidative stress in HUVECs by regulating HULC/miR-204-5p/TRPM7 axis."	32484206
11317	Human	HUR1	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	29790592
11318	Human	HZ02	lncRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	miscarriage	trophoblast Swan 71 and HTR-8/SVneo cells	"BPDE (benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide) treatment"	"If trophoblast cells are exposed to BPDE, both miR-hz02 and lnc-HZ02 are upregulated"	33851497
11319	Human	HZ08	lncRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	recurrent miscarriage (RM)	Swan 71 and HTR-8/SVneo cell lines	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE) treatment"	upregulated	33864160
11320	Human	IGF2AS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells	aurora kinase inhibitor (CCT137690) treatment	upregulated	31319040
11321	Human	IGF2AS	lncRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	CD4+ MOLT4 Tregs	high glucose (HG) treatment	upregulated	33572095
11322	Human	IGF2-AS	lncRNA	high glucose (HG)	apoptosis	"human retinal pigment epithelial cell line, ARPE-19"	high glucose (HG) treatment	"High-glucose induced apoptosis in ARPE-19 cells, and upregulated IGF-2AS in a dose-dependent manner. SiRNA-mediated IGF2-AS downregulated ameliorated apoptosis, upregulated IGF2/AKT and decreased Casp-9, in high-glucose-treated ARPE-19 cells."	31317640
11323	Human	IGF2-AS	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	"human retinal pigment epithelial cell line, ARPE-19"	high glucose (HG) treatment	"High-glucose induced apoptosis in ARPE-19 cells, and upregulated IGF-2AS in a dose-dependent manner. SiRNA-mediated IGF2-AS downregulated ameliorated apoptosis, upregulated IGF2/AKT and decreased Casp-9, in high-glucose-treated ARPE-19 cells."	31317640
11324	Human	IHAT	lncRNA	hypoxia	breast cancer	MDA-MB-231 cells	hypoxia treatment	LncIHAT Is Induced by Hypoxia-Inducible Factor 1 and Promotes Breast Cancer Progression	33380467
11325	Human	IL7AS	lncRNA	IL-1¦Â	inflammation	human lung fibroblasts	IL-1¦Â treatment	upregulated	30619270
11326	Human	lnc-IL7R	lncRNA	lipopolysaccharide (LPS)	inflammation	human monocytic cell line	lipopolysaccharide (LPS) treatment	upregulated	24723426
11327	Human	INXS	lncRNA	three apoptosis	apoptosis	786-O kidney tumor cell line	three apoptosis treatment	upregulation	24992962
11328	Human	IPAN	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	31189112
11329	Human	IRAK3-3	lncRNA	enterovirus 71 (EV71)	apoptosis	Human rhabdomyosarcoma cells (RD)	EV71 infection	downregulated	31099182
11330	Human	IRF1-AS	lncRNA	IFNs	oesophageal squamous cell carcinoma (ESCC)	The ESCC cell lines	Interferons (IFNs) treatment	upregulated	31173852
11331	Human	ISG20	lncRNA	influenza A virus (IAV)	antiviral immune response	A549 and HEK293T cells	influenza A virus (IAV) infection	upregulated	29899085
11332	Human	ISR	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	31623059
11333	Human	IUR	lncRNA	imatinib	leukemia	Abl-transformed primary bone marrow cells	imatinib treatment	Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment.	30961617
11334	Human	JHDMD1	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
11335	Human	KAT14	lncRNA	"DAPT (N-[(3,5-Difluorophenyl)-acetyl]-L-al- anyl-2-phenyl]-glycine-1,1-dimethylethylester)"	tongue squamous cell carcinoma (TSCC)	CAL-27 cell; SCC-9 cells	"DAPT (N-[(3,5-Difluorophenyl)-acetyl]-L-al- anyl-2-phenyl]-glycine-1,1-dimethylethylester) treatment"	"Proliferation was inhibited after treatment with DAPT, and the expression of lncRNA-KAT14 was upregulated."	31957832
11336	Human	KB-1980E6.3	lncRNA	hypoxia	breast cancer	BT549 cells	hypoxia induce	"We identified a hypoxia-induced long noncoding RNA (lncRNA) KB-1980E6.3, which is aberrantly upregulated in clinical breast cancer tissues and closely correlated with poor prognosis of breast cancer patients."	33469161
11337	Human	KCNK15-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31572012
11338	Human	KCNK15-AS1	lncRNA	chidamide	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	chidamide treatment	upregulated	31572012
11339	Human	KCNQ1OT1	lncRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen (APAP) treatment	downregulated	32779042
11340	Human	KCNQ1OT1	lncRNA	TGF-¦Â2	age-related cataract (ARC)	SRA01/04 cells	TGF-¦Â2 traetment treatment	"miR-29c-3p regulated FOS to repress EMT, cell proliferation and facilitate apoptosis in TGF-¦Â2-treated SRA01/04 cells mediated by KCNQ1OT1"	32534225
11341	Human	KCNQ1OT1	lncRNA	phenytoin	antiepileptic drug (AED) resistance	human brain microvascular endothelial cells (HBMECs)	phenytoin treatment	upregulated	31920517
11342	Human	KCNQ1OT1	lncRNA	H2O2	cataract	SRA01/04 cell lines	H2O2 treatment	upregulated	28535504
11343	Human	KCNQ1OT1	lncRNA	H2O2	cataract	lens epithelial cells (SRA01/04)	H2O2 treatment	We found that KCNQ1OT1 was upregulated in cataract anterior lens capsule samples and H2O2-induced SRA01/04 cells.	33744257
11344	Human	KCNQ1OT1	lncRNA	TGF-¦Â2	cataract	SRA01/04 cells	TGF-¦Â2 treatment	KCNQ1OT1 was upregulated in transforming growth factor (TGF)-¦Â2-treated SRA01/04 cells	29749509
11345	Human	KCNQ1OT1	lncRNA	cisplatin (DDP)	colorectal cancer (CRC)	HCT8 cells	cisplatin treatment	"Compared with CRC cell line HCT8, the cisplatin-resistant CRC cell line HCT8/DDP exhibited a higher expression level of KCNQ1OT1."	32757174
11346	Human	KCNQ1OT1	lncRNA	methotrexate (MTX)	colorectal cancer (CRC)	The human CRC cell line HT29 and Caco2 cells	methotrexate (MTX) treatment	KCNQ1OT1 enhanced the MTX resistance of CRC cells by regulating miR-760-mediated PPP1R1B expression via the cAMP signalling pathway	30997746
11347	Human	KCNQ1OT1	lncRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 ; SW480 cells	oxaliplatin (L-OHP) treatment	upregulated	31040703
11348	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiac tissues	high glucose (HG) treatment	Kcnq1ot1 expression was dramatically elevated in cardiac tissue of the diabetic mice.	30250027
11349	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	upregulated	30355944
11350	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	SRA01/04 cells	high glucose treatment	upregulated	32950535
11351	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic corneal endothelial keratopathy	HCEC-B4G12 cells	high glucose (HG) treatment	upregulated	31693400
11352	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMCs) cells; human renal glomerular endothelial cells (HRGECs)	high glucose (HG) treatment	KCNQ1OT1 was upregulated in DN patients and high glucose-induced HGMCs and HRGECs.	32905431
11353	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	KCNQ1OT1 expression was increased and miR-18b expression was decreased in DN patients and HG-challenged HMCs.	32989627
11354	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose treatment	upregulated	30784065
11355	Human	KCNQ1OT1	lncRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	A172 cells; U251 cells	sevoflurane (Sev) treatment	"KCNQ1OT1 knockdown mediated the role of Sev in glioma cell proliferation, apoptosis, migration, and invasion both in vitro and in vivo through miR-146b-5p/STC1 pathway"	32996777
11356	Human	KCNQ1OT1	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	SK-HEP-1 cells	cisplatin treatment	LncRNA KCNQ1OT1 targets miR-338-3p to regulate the survival rate and autophagy of SK-HEP-1/DDP cells and improve the cisplatin sensitivity of SK-HEP-1/DDP cells.	32538770
11357	Human	KCNQ1OT1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	SK-HEP-1 cells; Huh-7 cells; HCC tissues	sorafenib treatment	KCNQ1OT1 was found to be upregulated in sorafenib-resistant HCC tissues and cells	33000204
11358	Human	KCNQ1OT1	lncRNA	¦Â-glycerophosphate + ascorbic acid + dexamethasone	osteogenesis	human Bone marrow mesenchymal stem cells (BMSCs)	"10 mM ¦Â-glycerophosphate (Sigma-Aldrich, USA), 200 ¦ÌM ascorbic acid (Sigma-Aldrich, USA) and 100 nM dexamethasone (Sigma-Aldrich, USA) treatment"	KCNQ1OT1 was significantly upregulated during the process of osteogenic induction while miR-214 was contrarily downregulated	30703347
11359	Human	KCNQ1OT1	lncRNA	high glucose (HG)	oxidative stress	HK-2 cells	high glucose (HG) treatment	"downregulated of KCNQ1OT1 inhibited the inflammation, oxidative stress and pyroptosis of HG-induced HK-2 cells by up-regulating the expression of miR-506-3p."	32104033
11360	Human	KRAL	lncRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	5-fluorouracil (5-FU) treatment	KRAL was significantly decreased in HepG2/5-FU and SMMC-7721/5-FU cells.	30119680
11361	Human	LASI	lncRNA	lipopolysaccharide (LPS)	allergic asthma (AA)	human airway epithelial cells (HAECs)	lipopolysaccharides (LPS) treatment	upregulated	33122732
11362	Human	LCPAT1	lncRNA	cigarette smoke extract (CSE)	DNA damage	Beas-2B cells	cigarette smoke extract (CSE) treatment	upregulated	30509493
11363	Human	LCPAT1	lncRNA	cigarette smoke extract (CSE)	lung cancer	Beas-2B cells	cigarette smoke extract (CSE) treatment	"With increased concentration of exposure to CSE, there was higher expression of LCPAT1."	30509493
11364	Human	LCPAT1	lncRNA	cigarette smoke extract (CSE) and particulate matter (PM2.5)	lung cancer	H1299 cells; H520 cells	cigarette smoke extract (CSE) and PM2.5 exposure	LCPAT1 was upregulated after the treatment of CSE and PM2.5.	29913439
11365	Human	LET	lncRNA	gemcitabine (GEM)	urinary bladder cancers (UBCs)	"human UBC cell lines, T24, 5637, J82, SW780, BIU87, ScaBER and UMUC3"	treat with gemcitabine	downregulated	28839463
11366	Human	LGALS9	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
11367	Human	LIFR-AS1	lncRNA	photodynamic therapy (PDT)	colorectal cancer (CRC)	HCT116 cells	PDT treatment	upregulated	29807108
11368	Human	LILRP2	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
11369	Human	LIN28B-AS1	lncRNA	lipopolysaccharide (LPS)	inflammatory response	?THP-1 macrophages	lipopolysaccharide (LPS) treatment	upregulated	31537384
11370	Human	LINC00114	lncRNA	X-rays	nasopharyngeal carcinoma (NPC)	5-8F; SUNE-1 cells	X-ray treatment	LINC00114 contributed to NPC development and radioresistance through the regulation of ERK/JNK signaling pathway and the mediation of miR-203	32196600
11371	Human	LINC00115	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
11372	Human	LINC00115	lncRNA	TGF-¦Â	tumorigenicity	glioma stem-like cell (GSC)	TGF-¦Â treatment	upregulated	31599491
11373	Human	LINC00115-201	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
11374	Human	LINC00152	lncRNA	oxidized low density lipoprotein (ox-LDL)	cardiovascular disease (CVD)	human umbilical vein VECs (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29156700
11375	Human	LINC00152	lncRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial cells 16HBE	cigarette smoke extract (CSE) exposure	upregulated	30289508
11376	Human	LINC00160	lncRNA	paclitaxel (PTX)	breast cancer	breast cancer (BC) tissues	paclitaxel (PTX) treatment	downregulated	32652877
11377	Human	LINC00162	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	?gastric cancer cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"LINC00162, as highly and frequently expressed in gastric cancer cell lines sensitive to 5-aza-2'-deoxycytidine (5-aza-dC)."	30914798
11378	Human	LINC00173	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
11379	Human	LINC00173	lncRNA	cisplatin (DDP)	small-cell lung cancer (SCLC)	NCI-H69 cells	cisplatin treatment	Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression	31477834
11380	Human	LINC00174	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells; U87 cells	temozolomide (TMZ) treatment	LINC00174 downregulated decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis	31713817
11381	Human	LINC00261	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	33481135
11382	Human	LINC00273	lncRNA	TGF-¦Â	lung cancer	A549	Transforming growth factor ¦Â (TGF¦Â) treatment	LINC00273 promoted TGF¦Â-induced lung cancer EMT through miR-200a-3p/ZEB1 feedback loop	32017082
11383	Human	LINC00294	lncRNA	bakkenolide-IIIa (Bak-IIIa)	inflammation	human umbilical vein endothelial cells (HUVECs)	bakkenolide-IIIa (Bak-IIIa) treatment	Bak-IIIa ameliorated LPS-induced inflammatory damage in HUVECs by upregulating LINC00294.	33760129
11384	Human	LINC00294	lncRNA	lipopolysaccharide (LPS)	inflammation	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	33760129
11385	Human	LINC00299	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (T/G HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	LINC00299 regulated ox-LDL-induced T/G HA-VSMCs injury through the miR-135a-5p/XBP1 axis.	32700888
11386	Human	LINC00305	lncRNA	hypoxia	VECs apoptosis	human umbilical vein endothelial cells (HUVECs)	hypoxia (1% O2) treatment	upregulated	28763747
11387	Human	LINC00324	lncRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	upregulated	33376537
11388	Human	LINC00338-008	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
11389	Human	LINC00339	lncRNA	calcium oxalate monohydrate (COM)	kidney stone disease	human renal proximal tubular epithelial (HK-2) cells	?calcium oxalate monohydrate (COM)?treatment treatment	lncRNA LINC00339 promotes cell pyroptosis by sponging miR-22-3p to regulate NLRP3 expression in COM-treated HK-2 cells	30614043
11390	Human	LINC00339	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
11391	Human	LINC00341	lncRNA	particulate matter (PM2.5)	cell cycle arrest	16HBE cell	treated with PM2.5 treatment	upregulated	28366736
11392	Human	LINC00346	lncRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	HNE1cells; CNE2 cells	cisplatin treatment	LINC00346 regulates the cisplatin resistance of NPC cells by inhibiting miR-342-5p.	32397872
11393	Human	LINC00460	lncRNA	oxaliplatin	advanced colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer	33251049
11394	Human	LINC00460	lncRNA	nicotine	lung cancer	The NSCLC cell lines A549 and H1299	nicotine treatment	upregulated	31123168
11395	Human	LINC00461	lncRNA	IL-6 and TNF-¦Á	osteoarthritis (OA)	chondrocytes	IL-6 and TNF-¦Á treatment	LINC00461 may modulate the development of OA by suppressing miR-30a-5p expression in chondrocytes.	32155130
11396	Human	LINC00461	lncRNA	cisplatin (DDP)	rectal cancer	SW837 cells; HR8348 cells	cisplatin treatment	"LINC00461 mediates cisplatin resistance of rectal cancer by targeting miR-593-5p/CCND1 axis, shedding new light on the treatment of rectal cancer."	31972361
11397	Human	LINC00467	lncRNA	signal transducers and activators of transcription 1 (STAT1)	lung adenocarcinoma (LUAD)	"Four acknowledged human LUAD cell lines (H1299, Calu, SPCA1, and A549)"	STAT1 overexpression	LINC00467 was activated by STAT1 in LUAD.	31027730
11398	Human	LINC00472	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	THLE-3 cells	Lipopolysaccharide (LPS) treatment	downregulated of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis.	33129786
11399	Human	LINC00473	lncRNA	H2O2	abdominal aortic aneurysm (AAA)	human vascular smooth muscle cells (VSMCs)	H2O2 treatment	LINC00473 inhibits vascular smooth muscle cell viability to promote aneurysm formation via miR-212-5p/BASP1 axis.	31954705
11400	Human	LINC00473	lncRNA	taxol	colorectal cancer (CRC)	HCT116 cells	taxol treatment	upregulated	30126852
11401	Human	LINC00473	lncRNA	X-rays	radiosensitivity	"KYSE-30, KYSE-180, KYSE-150 and TE-5"	X-ray radiation treatment	LINC00473 reduces the radiosensitivity of ESCC cells by modulating the miR-497-5p/CDC25A axis	32468021
11402	Human	LINC00475	lncRNA	hypoxia	glioblastoma multiforme (GBM)	LN229 cells	hypoxia treatment	LINC00475 was upregulated in hypoxic glioma samples.	32849915
11403	Human	LINC00511	lncRNA	epigallocatechin-3-gallate (EGCG)	anti-cancer therapy	AGS and SGC7901 GC cells	Epigallocatechin gallate (EGCG) treatment	Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis	32512188
11404	Human	LINC00511	lncRNA	paclitaxel (PTX)	breast cancer	"The breast cancer cell lines (MDA-MB-231, MCF-7, Hs-578T, and T47D) and the immortalized breast epithelial cell line MCF-10A"	paclitaxel treatment	LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells by upregulating miR-29c	31047896
11405	Human	LINC00511	lncRNA	paclitaxel (PTX)	cervical cancer (CC)	PTX-resistant Hela/PTX cells	paclitaxel (PTX) treatment	"silencing of LINC00511 could suppress cell resistance to PTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells"	31180057
11406	Human	LINC00511	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SPCA1 cells; H1975 cells	TGF-¦Â1 treatment	upregulated	32092827
11407	Human	LINC00518	lncRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	linc00518 level was almost 2.5 fold higher and MRP1 level was about 2 fold increased in ADR-resistant MCF-7 cells.	30001527
11408	Human	LINC00574	lncRNA	toxic acetaminophen (APAP)	drug metabolizing enzymes (DMEs) expression	HepaRG cells	toxic acetaminophen (APAP) treatment	The expression of lncRNA LINC00574 was decreased in APAP-treated HepaRG cells	32273307
11409	Human	LINC00595	lncRNA	Vitamins A and D	bacterial infection	human monocytes during A.fumigatus infections	Vitamins A and D treatment	dysregulated	28094339
11410	Human	LINC00618	lncRNA	vincristine (VCR)	acute myeloid leukemia (AML)	K562 cells; MV4-11 cells	vincristine (VCR) treatment	upregulated	33002417
11411	Human	LINC00618	lncRNA	vincristine (VCR)	leukemia	human leukemia	vincristine (VCR) treatment	"Here, we show that the expression of a nuclear long non-coding RNA (lncRNA), LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment"	33002417
11412	Human	LINC00623	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary OA chondrocytes	IL-1¦Â treatment	"LINC00623/miR-101/HRAS axis modulates OA chondrocyte apoptosis, senescence and ECM degradation through MAPK signaling"	32062610
11413	Human	LINC00632	lncRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	downregulated	31315126
11414	Human	LINC00632	lncRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	"Linc00632 inhibited IL-13-induced GM-CSF, eotaxin, and MUAC5AC production in IL-13-treated NECs by targeting miR-498"	31315126
11415	Human	LINC00641	lncRNA	nutritional stress	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	low nutritional (LN) condition induce	Upregulation of LINC00641 and downregulated of miR-153-3p are detected in NP cells under nutritional stress.	30378116
11416	Human	LINC00645	lncRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell lines	TGF-¦Â treatment	upregulated	31558707
11417	Human	LINC00657	lncRNA	oxidized low density lipoprotein (ox-LDL)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	oxLDL also upregulated LINC00657 expression.	29436491
11418	Human	LINC00657	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	"Silence of LINC00657 repressed ox-LDL-induced injury via inhibiting EndMT, inflammatory response, and apoptosis in HUVEC cells by regulating miR-30c-5p/Wnt7b/¦Â-catenin."	32577947
11419	Human	LINC00659	lncRNA	peiminine	colorectal cancer (CRC)	SW620 and HT29 cells	peiminine treatment	"Peiminine notably downregulated the expression of LINC00659, while the expression of miR-760 was upregulated by peiminine treatment"	32740014
11420	Human	LINC00665	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	lung cancer tissues and cells (Human LAD cell line PC9)	gefitinib treatment	upregulated	30889481
11421	Human	LINC00665	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
11422	Human	LINC00667	lncRNA	yin yang 1 (YY1)	cholangiocarcinoma (CCA)	CCLP-1 and QBC939 cells	yin yang 1 (YY1) treatment	"Our data indicated that LINC00667 was highly expressed in CCA tissues and cells, and transcription factor Yin Yang 1 (YY1) induced LINC00667 expression in CCA cells"	33040228
11423	Human	LINC00667:6	lncRNA	nigericin	pancreatic cancer (PC)	PANC-1 cells	nigericin treatment	upregulated	32850392
11424	Human	LINC00668	lncRNA	sodium new houttuyfonate (SNH)	non-small cell lung cancer (NSCLC)	A549 and NCI-H1299 cells	sodium new houttuyfonate (SNH) treatment	downregulated	30971296
11425	Human	LINC00673	lncRNA	benzo(a)pyrene (BaP)	non-small cell lung cancer (NSCLC)	A549 cells	benzo(a)pyrene (BaP) exposure	upregulated	31778776
11426	Human	LINC00673	lncRNA	benzo(a)pyrene (BaP)	non-small cell lung cancer (NSCLC)	A549 cells	benzo(a)pyrene (BaP) exposure	BaP significantly elevated the expression level of linc00673.	31778776
11427	Human	LINC00707	lncRNA	acetyl-11-keto-¦Â-boswellic acid (AKBA)	breast cancer	MCF-10AT cells	Acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment	AKBA could induce cell apoptosis and G1-phase arrest and inhibit ER-¦Á expression via LINC00707/miR-206 in MCF-10AT cells.	32013235
11428	Human	LINC00707	lncRNA	osteogenic differentiation medium	osteogenesis	human bone marrow-derived mesenchymal stem cells (HBMSCs)	"osteogenic differentiation medium with 100 mmol/L dexamethasone, 0.05 mmol/L ascorbic acid, and 10 mmol/L ¦Â-glycerophosphate treatment"	upregulated	30795799
11429	Human	LINC00707	lncRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	"?LINC00707 was increased, and miR-223-5p was decreased in LPS-treated MRC-5 cells."	33604647
11430	Human	LINC00844	lncRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	HepaRG cells	acetaminophen (APAP) treatment	"In HepaRG cells, LINC00844 was significantly downregulated by 5 and 10 mM APAP in a concentration-dependent manner."	31904498
11431	Human	LINC00847	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
11432	Human	LINC00847	lncRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	HL7702 cells	microcystin-LR(MC-LR) treatment	upregulated	30430930
11433	Human	LINC00882	lncRNA	"corticosteroid, dexamethasone, and fetal calf serum (FCS)."	airway diseases	primary ASM cells	"corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment"	dysregulated	24886442
11434	Human	LINC00882	lncRNA	platelet-derived growth factor (PDGF)	asthma	Human fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	upregulated	31014672
11435	Human	LINC00883	lncRNA	"corticosteroid, dexamethasone, and fetal calf serum (FCS)."	airway diseases	primary ASM cells	"corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment"	dysregulated	24886442
11436	Human	LINC00894-002	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells	Tamoxifen treatment	downregulated	29738694
11437	Human	LINC00941	lncRNA	TGF-¦Â1	papillary thyroid cancer (PTC)	"B-CPAP, TPC1, Cal62 and 8505c cells"	TGF-¦Â1 treatment	?Linc00941 was identified as transcribed starting from one of the TGF¦Â-induced ENHs Linc00941 expression was significantly higher in aggressive cancer both in the TCGA dataset and in a separate validation cohort from our institution	32495722
11438	Human	LINC00943	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells.	33208053
11439	Human	LINC00943	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells.	33208053
11440	Human	LINC00958	lncRNA	X-rays	cervical cancer (CC)	Hela cells	irradiated with 6?Gy of X-ray treatment	upregulated	31169309
11441	Human	LINC00958	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
11442	Human	LINC00961	lncRNA	c-reactive protein (CRP)	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	CRP treatment	downregulated	31646586
11443	Human	LINC00961	lncRNA	hypoxia	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	hypoxia induce	downregulated	31646586
11444	Human	LINC00968	lncRNA	oxidized low density lipoprotein (ox-LDL)	coronary artery disease (CAD)	endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	LINC00968 was upregulated by oxidized low-density lipoprotein (oxLDL) treatment in endothelial cell.	30485507
11445	Human	LINC00968	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
11446	Human	LINC00987	lncRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"LINC00987 Ameliorates COPD by Regulating LPS-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Autophagy Through Let-7b-5p/SIRT1 Axis."	33311978
11447	Human	LINC01116	lncRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	33061421
11448	Human	LINC01116	lncRNA	sulforaphane (SFN)	prostate cancer	normal human prostate epithelial cells and prostate cancer cells	treated with 15 ¦ÌM SFN treatment	downregulated	28131897
11449	Human	LINC01121	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	downregulated	30619763
11450	Human	LINC01125	lncRNA	LXR-623 (WAY-252623)	breast cancer	MDA-MB-231 cells	LXR-623 (WAY-252623) treatment	upregulated	30867411
11451	Human	LINC01125	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	OC lines (SKOV-3 and A2780)	cisplatin treatment	downregulated	31865363
11452	Human	LINC01126	lncRNA	hypoxia	periodontitis	human periodontal ligament cells (hPDLCs)	hypoxia treatment	"We selected LINC01126, which was the most highly expressed lncRNA, to further verify its functions in periodontitis-induced hypoxia."	33231338
11453	Human	LINC01133	lncRNA	periostin	pancreatic ductal adenocarcinoma (PDAC)	human PSCs cells	periostin treatment	upregulated	33824474
11454	Human	LINC01137	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
11455	Human	LINC01137	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
11456	Human	LINC01137	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
11457	Human	LINC01140	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	"LINC01140 was downregulated, while p53 and miR-23b were upregulated in oxLDL-induced inflammatory response of macrophages."	31748847
11458	Human	LINC01186	lncRNA	TGF-¦Â1	lung cancer	A549 cells	treat with TGF-¦Â1 treatment	downregulated	28119085
11459	Human	LINC01234	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells and Huh7 cells	cisplatin treatment	"When miR-31-5p was downregulated, the proliferation and invasion of HepG2 cells and Huh7 cells were enhanced and the cisplatin-induced apoptosis was inhibited, while LINC01234 knockdown could diminish the effects caused by miR-31-5p depletion."	31838274
11460	Human	LINC01297	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
11461	Human	LINC01311	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	LINC01311 was downregulated whereas hsa-miR-146a-5p upregulated in AB1-42 treated SH-SY5Y cells.	33830627
11462	Human	LINC01391	lncRNA	piplartine	hepatocellular carcinoma (HCC)	HepG2 and SMMC-7721?cells	piplartine treatment	upregulated	31207322
11463	Human	LINC01541	lncRNA	estradiol-17¦Â (E2)	endometriosis	Human endometrial stromal cells (ESCs)	estradiol-17¦Â (E2) treatment	downregulated	30608887
11464	Human	LINC01541	lncRNA	estradiol-17¦Â (E2)	endometriosis	ectopic endometrial tissue	estradiol-17¦Â (E2) treatment	LINC01541 functions as a ceRNA that modulates the Wnt/¦Â-catenin pathway by decoying miR-506-5p.	32833189
11465	Human	LINC01572	lncRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901	cisplatin treatment	upregulated	33149605
11466	Human	LINC01667	lncRNA	bruceine D (BD)	gastric cancer (GC)	HGC27 cells; MKN45 cells	bruceine D (BD) treatment	LINC01667 was significantly downregulated after BD treatment.	33390953
11467	Human	linc-p21	lncRNA	ginkgo biloba extract EGb 761	colorectal cancer (CRC)	"The human colorectal cancer cell lines SW480, SW620"	Ginkgo biloba extract EGb 761 treatment	upregulated	29207671
11468	Human	linc-p21	lncRNA	hypoxia	warburg effect	HeLa cells;MCF7 ccells; H1299 cells;IMR90 cells	culture under hypoxic conditions for 24 hr treatment	upregulated	24316222
11469	Human	linc-p21	lncRNA	hypoxia	warburg effect	HeLa cells	hypoxia treatment	LincRNA-p21 is Induced by Hypoxia and Is Essential for Hypoxia-Enhanced Glycolysis	24316222
11470	Human	LINP1	lncRNA	doxorubicin- and 5-fluorouracil	breast cancer	MDA-MB-468 cells	doxorubicin- and 5-fluorouracil treatment	LINP1 was upregulated in doxorubicin- and 5-fluorouracil-resistant cells and induced chemoresistance.	29293402
11471	Human	LINP1	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells; T47D cells	Tamoxifen (TAM) treatment	upregulated	31927036
11472	Human	LINP1	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	A549 cells; H1299 cells; H358 cells	TGF-¦Â treatment	"In three lung cancer cell lines A549, H1299, and H358, TGF-¦Â1 significantly inhibited LINP1 expression"	30416386
11473	Human	LMCD1-AS1	lncRNA	aspirin	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 cell lines	aspirin treatment	downregulated	31278071
11474	Human	lnc949	lncRNA	TGF-¦Â1	lung fibrosis	L929 cells	TGF-¦Â1 treatment	Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-¦Â1-Smad2/3 and JNK signalling pathways	33181025
11475	Human	LncDC	lncRNA	hepatitis B virus (HBV)	immune response	DC cells induced by isolated peripheral blood mononuclear cells	hepatitis B virus (HBV) infection	upregulated	30202418
11476	Human	lncIHAT	lncRNA	hypoxia	triple negative breast cancer (TNBC)	MDA-MB-231 cells	hypoxia treatment	Hypoxia-inducible factor 1 (HIF1) but not HIF2 bound to the hypoxia response element at the promoter of lncIHAT to activate its transcription in hypoxic TNBC cells. LncIHAT promoted TNBC cell survival?in vitro?and tumor growth and lung metastasis in mice.	33380467
11477	Human	linc-p21	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HCAECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28983628
11478	Human	linc-p21	lncRNA	oligo-fucoidan	hepatocellular carcinoma (HCC)	HepG2 cells	oligo-fucoidan treatment	apoptosis and cell cycle pathways could also contribute to the induction of lncRNA-Saf and lncRNA-p21 by oligo-fucoidan.	30632031
11479	Human	linc-p21	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	?human neuroblastoma SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	lnc-p21 was highly expressed in human neuroblastoma SH-SY5Y cells treated with MPP+.	31004593
11480	Human	lncRNA00364	lncRNA	IFN-¦Ã	hepatocellular carcinoma (HCC)	HCC cells	IFN¦Ã treatment	upregulated	29254221
11481	Human	lncRNA01126	lncRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide of Porphyromonas Gingivalis (LPS-PG) treatment	upregulated	32240552
11482	Human	lncRNA1403	lncRNA	7.5% hypertonic saline (HS)	traumatic brain injury (TBI)	peripheral blood mononuclear cells	7.5% hypertonic saline (HS) treatment	downregulated	30569101
11483	Human	lncRNA155	lncRNA	influenza A virus (IAV)	innate immune response	"Human lung epithelial cells (A549), human embryonic kidney cells (HEK293T/293T), human acute monocytic leukemia cells (THP-1), mouse embryonic fibroblasts (NIH/3T3), mouse Lewis lung carcinoma cells (LLC), mouse Abelson murine leukemia virus transformed macrophages (RAW 264.7)and madin-darby canine kidney cells (MDCK)"	influenza A virus (IAV) infection	expression of lncRNA-155 was markedly upregulated during influenza A virus (IAV) infection both in vitro (several cell lines) and in vivo (mouse model)	31045320
11484	Human	lncRNA2448-11	lncRNA	7.5% hypertonic saline (HS)	traumatic brain injury (TBI)	peripheral blood mononuclear cells	7.5% hypertonic saline (HS) treatment	downregulated	30569101
11485	Human	lncRNA51663	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	AGS cells	Helicobacter pylori (H. pylori) infection	upregulated	32457731
11486	Human	lncRNA8	lncRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Huh-7.5 hepatoma cells	hepatitis C virus (HCV) infection	upregulated	31200545
11487	Human	lncRNA91H	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	cell line TE-1 and Eca-109	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	24706416
11488	Human	lncRNA-p19461	lncRNA	diet	weight loss	fasting venous blood	diet treatment	upregulated	27767123
11489	Human	LOC101927497	lncRNA	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)	gastric cancer (GC)	human gastric epithelial cells	treat with MNNG	upregulated	29223541
11490	Human	LOC101927497	lncRNA	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)	gastric cancer (GC)	MKN28 cells; MGC-803 cells	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment	downregulated	29223541
11491	Human	LOC101927514	lncRNA	particulate matter (PM2.5)	respiratory inflammation	16HBE cells	fine particulate matter (PM2.5) exposure treatment	upregulated	31682869
11492	Human	LOC101927514	lncRNA	particulate matter (PM2.5)	respiratory inflammation	human normal bronchial 16HBE cells	particulate matter (PM2.5) treatment	"Inhibiting LncRNA LOC101927514 expression by RNAi, reflected in a reduction in inflammation, is driven by PM25"	31682869
11493	Human	LOC102724017	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
11494	Human	LOC105374902	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	cervical cancer (CC)	HeLa cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"TNF-¦Á-induced lncRNA LOC105374902 may function as a ceRNA for miR-1285-3p to promote the expression of RPL14, promoting the migration, invasion and EMT of CC cells."	30935691
11495	Human	loc105377478	lncRNA	neodymium oxide nanoparticles (NPs-Nd2O3)	airway inflammation	human bronchial epithelial cells (16HBE)	neodymium oxide nanoparticles (NPs-Nd2O3) exposure	upregulated	33396129
11496	Human	loc105377478	lncRNA	neodymium oxide nanoparticles (NPs-Nd2O3)	cytotoxicity	human bronchial epithelial cells (16HBE)	neodymium oxide nanoparticles (NPs-Nd2O3) treatment	upregulated	33396129
11497	Human	loc107985872	lncRNA	traffic-originated PM2.5 organic component (tPo)	toxicity of PM2.5	A549 cells; H1299 cells	Traffic-originated PM2.5 organic component (tPo) treatment	tPo treatment upregulated the expression of loc107985872	32829169
11498	Human	loc146880	lncRNA	particulate matter (PM2.5)	cytotoxicity	A549 cells	treated with PM2.5 treatment	upregulated	27836757
11499	Human	LOC285194	lncRNA	propofol (PPF)	pancreatic cancer (PC)	PANC-1 cells	propofol treatment	"Propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression"	32303144
11500	Human	LOC286367	lncRNA	propofol (PPF)	inflammation	THP-1 macrophages	propofol treatment	downregulated	30647536
11501	Human	LOC338799	lncRNA	ultraviolet (UV) irradiation	DNA damage	CD4 cells	ultraviolet-C (UVC) treatment	upregulated	32258156
11502	Human	LOC344887	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
11503	Human	LOC645166	lncRNA	adriamycin (ADR)	adriamycin (ADR) treatment in breast cancer	MCF-7 cells	adriamycin (ADR) treatment	lncRNA LOC645166 mediated adriamycin chemoresistance in breast cancer by regulating GATA3 via NF-¦ÊB.	32461377
11504	Human	LOC728228	lncRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	human bronchial epithelial cell line (16HBE-T cells)	"anti-benzo(a) pyrene-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	upregulated	25820656
11505	Human	LOC729178	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	Our data indicated that LOC729178 was underexpressed in COPD tissues and CSE-treated 16HBE cells.	33847879
11506	Human	LOXL1-AS1	lncRNA	doxorubicin (DOX)	prostate cancer	prostate cancer DU-145 cells	doxorubicin (DOX) treatment	downregulated	31188543
11507	Human	LRRC24-2:1	lncRNA	nigericin	pancreatic cancer (PC)	PANC-3 cells	nigericin treatment	downregulated	32850392
11508	Human	LSINCT5	lncRNA	B-type-natriuretic peptide (BNP)	chronic heart failure (CHF)	HCM human myocardial cells	B-type-natriuretic peptide (BNP) treatment	"lncRNA LSINCT5, upregulated by BNP, is able to regulate myocardial cell apoptosis via the activation of the caspase-1/interleukin (IL)-1¦Â signaling pathway."	26323562
11509	Human	LUADT1	lncRNA	lipopolysaccharide (LPS)	sepsis	primary cardiac endothelial cells	lipopolysaccharide (LPS) treatment	LPS treatment downregulated the expression of LUADT1 in primary cardiac endothelial cells.	33225891
11510	Human	LUCAT1	lncRNA	hypoxia	colorectal cancer (CRC)	HCT-116;RKO cells	hypoxia treatment	Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response.	31964396
11511	Human	LUCAT1	lncRNA	methotrexate (MTX)	osteosarcoma (OS)	MG63 cells; HOS cells	methotrexate (MTX) treatment	"LUCAT1 was upregulated in MTX-resistant cells (MG63/MTX, HOS/MTX) compared to that in parental cells."	29170124
11512	Human	LUCAT1	lncRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines (MG-63, U2OS, HOS and SAOS-2)"	methotrexate treatment	upregulated	29170124
11513	Human	LUCAT1	lncRNA	particulate matter (PM2.5)	PM2.5 exposure	BEAS-2B cells	PM2.5 treatment	lncLUCAT1 was increased in PM25 treated BEAS-2B cells	30231965
11514	Human	LUCAT1	lncRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	LUCAT1 likely promotes HG-induced EMT through ZEB1 by sponging miR-199a-5p.	33426083
11515	Human	MACC1-AS1	lncRNA	TGF-¦Â1	gastric cancer (GC)	AGS and MKN45 cancer cells	transforming growth factor ¦Â1 (TGF-¦Â1) secretion by MSCs treatment	upregulated	30742067
11516	Human	MACC1-AS1	lncRNA	hypoxia	ischemic stroke (IS)	human brain microvascular endothelial cells (HBMECs)	hypoxia treatment	downregulated	32793720
11517	Human	MAF-4	lncRNA	brucella.suis	brucellosis	blood samples	brucellosis infection	Linc-MAF-4 was significantly increased in the acute group in comparison to control and relapse groups.	32417631
11518	Human	MAGI2-AS3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35."	33279663
11519	Human	MAGI2-AS3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells.	33279663
11520	Human	MALAT1	lncRNA	IL-6	abdominal aortic aneurysm (AAA)	human aortic endothelial cells (HAOECs)	IL-6 treatment	upregulated	29441928
11521	Human	MALAT1	lncRNA	arsenite	accelerated glycolysis	"L-02 cells, a normal human liver cell line"	arsenite exposure	arsenite-increased MALAT1 enhances the disassociation of Von Hippel-Lindau (VHL) tumor suppressor from HIF-1¦Á	27287256
11522	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	LPS treatment upregulated MALAT1 expression and suppressed the proliferation of A549 cells.	31257497
11523	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary alveolar epithelial cells (HPAEpiC)	lipopolysaccharide (LPS) treatment	MALAT1 knockdown alleviated HPAEpiC apoptosis by competitively binding to miR-194-5p and then elevating the inhibitory effect on its target FOXP2.	33117815
11524	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33197806
11525	Human	MALAT1	lncRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	human AML cell lines HL60 and THP-1	cytarabine (Ara-C) treatment	"Knockdown of MALAT1 inhibited the proliferation, induced apoptosis, and enhanced Ara-C sensitivity of AML cells."	30970520
11526	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	MALAT1 silencing can potentially suppress HPMEC apoptosis and alleviate lung injury in ARDS via miR-150-5p-targeted ICAM-1.	32315984
11527	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	33197806
11528	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	33407436
11529	Human	MALAT1	lncRNA	ethanol (EtOH)	alcohol-induced tumor angiogenesis	HUVECs endothelial extracellular vesicles (EVs)	ethanol treatment	upregulated in endothelial extracellular vesicles (EVs)	29062004
11530	Human	MALAT1	lncRNA	tubercidin	alternative splicing	HeLa cells	tubercidin treatment	downregulated	24569078
11531	Human	MALAT1	lncRNA	dual MEK/Aurora kinase inhibitor BI-847325	anaplastic thyroid carcinoma (ATC)	ATC cell lines (C643 and SW1736)	dual MEK/Aurora kinase inhibitor BI-847325 treatment	downregulated	31077090
11532	Human	MALAT1	lncRNA	hyperbaric oxygen (HBO)	angiogenesis	human coronary artery endothelial cells (HCAECs)	Hyperbaric oxygen (HBO) treatment	upregulated	30301563
11533	Human	MALAT1	lncRNA	amygdalin	anti-cancer therapy	"human cancer cells (A549, MCF7, AGS)"	amygdalin treatment	downregulated	30725348
11534	Human	MALAT1	lncRNA	bone morphogenetic protein 7 (BMP7)	apoptosis	HA-VSMCs	bone morphogenetic protein 7 (BMP7) treatment	upregulated	29435112
11535	Human	MALAT1	lncRNA	high glucose (HG)	apoptosis	human vascular endothelial cells (HUVECs)	high glucose (HG) treatment	"MALAT1 is upregulated in HG-induced HUVECs, and inhibition of MALAT1 inhibits HG-induced apoptosis and inflammation in HUVECs by suppression of the NF-¦ÊB signaling pathway."	32502356
11536	Human	MALAT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	airway smooth muscle cells (ASMCs)	platelet-derived growth factor BB (PDGF-BB) treatment	upregulated	31695627
11537	Human	MALAT1	lncRNA	high glucose (HG)	atherosclerosis (AS)	EA.hy926?cells	high glucose (HG) treatment	lncRNA MALAT1 expression and found that it was upregulated in high glucose-treated EA.hy926?cells.	30591217
11538	Human	MALAT1	lncRNA	high glucose (HG)	atherosclerosis (AS)	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
11539	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	"VSMCs were treated with different doses of ox-LDL (0, 25, 50, and 100 mg/L) and for different time points (0, 12, 24, and 48 h) to mimic an in vitro environment of hyperlipidemia."	MALAT1 were dose-dependently downregulated in ox-LDL-treated VSMCs.	31696492
11540	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29258822
11541	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29258822
11542	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human Coronary Artery Endothelial Cells (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 expression was upregulated under oxidative low-density lipoprotein (ox-LDL) treatment.	30314869
11543	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31029709
11544	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	exosomes from Human umbilical VECs (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31305205
11545	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 suppression protects the endothelium from oxLDL-induced inflammation and oxidative stress in endothelial cells by upregulation of miR-181b and downregulated of TOX.	31949884
11546	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LncRNA MALAT1 Enhances ox-LDL-Induced Autophagy through the SIRT1/MAPK/NF-¦ÊB Pathway in Macrophages	32183682
11547	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein ECs (HUVECs); human coronary artery ECs (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 was upregulated in ECs treated with ox-LDL.	33022677
11548	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 was increased in oxLDL-treated human umbilical vein endothelial cells.	29750307
11549	Human	MALAT1	lncRNA	IL-1¦Â	autoimmune thyroiditis (AIT)	Nthy-ori 3-1 cells	IL-1¦Â treatment	upregulated	33452572
11550	Human	MALAT1	lncRNA	ursolic acid (UA)	autoimmune thyroiditis (AIT)	IL-1¦Â-treated Nthy-ori 3-1 cells	ursolic acid (UA) treatment	downregulated	33452572
11551	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 expression was markedly increased in HUVECs treated with ox-LDL.	30485490
11552	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	autophagy was upregulated and MALAT1 expression was markedly increased in HUVECs treated with ox-LDL.	30485490
11553	Human	MALAT1	lncRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	upregulated	31678133
11554	Human	MALAT1	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	downregulated	32714991
11555	Human	MALAT1	lncRNA	cisplatin (DDP)	bladder cancer	The 5637 and EJ-M3 cells	cisplatin treatment	suppression of MALAT1 enhanced the chemotherapeutic drug sensitivity and inhibited the cisplatin resistance of the BC cells.	31650173
11556	Human	MALAT1	lncRNA	TGF-¦Â	bladder cancer	bladder cancer cells	TGF-¦Â treatment	upregulation	24449823
11557	Human	MALAT1	lncRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	bone metabolism	RANKL inhibited hFOB 1.19 cells	Receptor activator of NF&mdash;&#954;B ligand (RANKL) treatment	upregulated	25817340
11558	Human	MALAT1	lncRNA	paclitaxel (PTX)	breast cancer	SK-BR-3 cells	paclitaxel (PTX) treatment	upregulated	32897218
11559	Human	MALAT1	lncRNA	cadmium (Cd)	cadmium-induced toxicity	16HBE cells	cadmium (Cd) treatment	upregulated	30090505
11560	Human	MALAT1	lncRNA	TGF-¦Â1	cardiovascular disease (CVD)	HUVECs	TGF-¦Â1 treatment	upregulated	27144026
11561	Human	MALAT1	lncRNA	androgen deprivation therapies (ADT)	castration-resistant prostate cancer (CRPC)	patients with CRPC	androgen deprivation therapies (ADT) treatment	upregulated	25189356
11562	Human	MALAT1	lncRNA	high glucose (HG)	cell function	Human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	31646587
11563	Human	MALAT1	lncRNA	high glucose (HG)	cell pyroptosis	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
11564	Human	MALAT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	HA-VSMCs	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	29435112
11565	Human	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	cerebrovascular endothelial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Under the normal culture condition, MALAT1 reached 15 times after reoxygenation treatment for 9 h, and the expression level decreased to 027 times significantly after reoxygenation treatment for 36h"	29575939
11566	Human	MALAT1	lncRNA	casiopeina II-gly (Cas-II-gly)	cervical cancer (CC)	HeLa and CaSki cells	Casiopeina II-gly (Cas-II-gly) treatment	downregulated	31524268
11567	Human	MALAT1	lncRNA	radiation	cervical cancer (CC)	CaSki cells	radiation treatment	"Comparing to radiotherapy sensitive tissues, the MALAT1 level was significantly elevated in radiotherapy resistant tissues"	30178834
11568	Human	MALAT1	lncRNA	oxaliplatin	colorectal cancer (CRC)	CRC tissues; HCT116 cells; HCT8 cells	oxaliplatin (OXA) treatment	MALAT1 was upregulated in Ox-resistant CRC tissues and cells	33005106
11569	Human	MALAT1	lncRNA	oxymatrine	colorectal cancer (CRC)	HT29 cells	oxymatrine treatment	lncRNA MALAT1 was significantly upregulated in the oxymatrine resistant cells	29328404
11570	Human	MALAT1	lncRNA	radiation	colorectal cancer (CRC)	CCL244 cells	radiation treatment	upregulated	32380053
11571	Human	MALAT1	lncRNA	radiation	colorectal cancer (CRC)	LOVO cells	radiation treatment	downregulated	32380053
11572	Human	MALAT1	lncRNA	dihydromyricetin (DHM)	cutaneous squamous cell carcinoma (CSCC)	A431 cells	Dihydromyricetin (DHM) treatment	downregulated	31413743
11573	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	delayed union of femoral neck fracture	MG-63 cells	lipopolysaccharide (LPS) treatment	MALAT1 expression was upregulated in serum of patients with delayed union of femoral neck fracture.	33725277
11574	Human	MALAT1	lncRNA	dexamethasone (DEX)	dexamethasone (DEX)-induced injuries	B-6 cells; hFOB1.19 cells; necrotic femoral head tissues	dexamethasone (Dex) treatment	Lnc-MALAT1 expression was downregulated by Dex treatment.	30439702
11575	Human	MALAT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	human lens epithelial cells (HLECs)	high glucose (HG) treatment	MALAT1 not only was aberrantly expressed in DC anterior lens capsule tissues and high glucose (HG)-treated HLECs.	29936249
11576	Human	MALAT1	lncRNA	high glucose (HG)	diabetic gastroparesis (DGP)	human gastric SMCs	high glucose (HG) treatment	upregulated	29317209
11577	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high-glucose	upregulated	27964927
11578	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	streptozotocin treatment	upregulated	27964927
11579	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	hyperglycemia significantly increased the level of MALAT1 but decreased miR-145 expression in a time-dependent manner in HK-2 cells.	31081103
11580	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human proximal tubular cells (HK-2 cells)	high glucose (HG) treatment	upregulated	31388927
11581	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells	high glucose (HG) treatment	Glucose increased LncRNA?MALAT1?levels by increasing Sp1 transcription factor binding at its promoter.	33051272
11582	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retina microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	upregulated	30988072
11583	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	MALAT1 affect angiogenesis by sponging miR-203a-3p in DR.	31689123
11584	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	upregulated	31689123
11585	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal vascular endothelial cells (RVECs)	high glucose (HG) treatment	upregulated	31986419
11586	Human	MALAT1	lncRNA	hypoxia	doxorubicin (DOX)-induced cardiotoxicity	human adipose-derived mesenchymal stem cells	hypoxia treatment	Treatment of the human adipose-derived mesenchymal stem cells with hypoxia induced lncRNA-MALAT1 accumulation in the secreted exosomes.	32384281
11587	Human	MALAT1	lncRNA	estradiol-17¦Â (E2)	endometriosis	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	upregulated	30500775
11588	Human	MALAT1	lncRNA	hypoxia	endometriosis	ectopic endometrium and cultured human endometrial stromal cells	hypoxia induce	upregulated	30324652
11589	Human	MALAT1	lncRNA	hypoxia	endometriosis	primary human endometrial stromal cells	hypoxia treatment	lncRNA-MALAT1 and autophagy were induced by hypoxia in a time-dependent manner and lncRNA-MALAT1 upregulated was dependent on HIF-1¦Á signalling.	30324652
11590	Human	MALAT1	lncRNA	hypoxia	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	upregulated	31933110
11591	Human	MALAT1	lncRNA	high glucose (HG)	endothelial dysfunction	human renal glomerular endothelial cells (HRGECs)	high glucose (HG) treatment	upregulated	30762931
11592	Human	MALAT1	lncRNA	estradiol-17¦Â (E2)	epithelial-mesenchymal transition (EMT)	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	upregulated	30500775
11593	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30871555
11594	Human	MALAT1	lncRNA	particulate matter (PM2.5)	epithelial-mesenchymal transition (EMT)	human bronchial epithelial cell lines (HBE and BEAS-2B)	Organic extracts of PM2.5 treatment	"NF-¦ÊB transcriptionally regulates MALAT1, which, by binding with miR-204 and releasing ZEB1, promotes the EMT"	31042084
11595	Human	MALAT1	lncRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human lens epithelial cells (LECs)	TGF-¦Â2 treatment	upregulated	31143769
11596	Human	MALAT1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	endothelial progenitor cells (EPCs)	treat with TGF-¦Â1 treatment	upregulated	28535533
11597	Human	MALAT1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	ARPE-19 cells	TGF-¦Â1 treatment	upregulated	27019196
11598	Human	MALAT1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	TPC-1 cells	TGF-¦Â1 treatment	upregulated	29967342
11599	Human	MALAT1	lncRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	human lens epithelial cells (LECs)	TGF-¦Â2 treatment	upregulated	33327804
11600	Human	MALAT1	lncRNA	TGF-¦Â1	esophageal squamous cell carcinoma (ESCC)	KYSE30 cells; KYSE150 cells; KYSE450 cells	TGF-¦Â1 treatment	upregulated	33123280
11601	Human	MALAT1	lncRNA	¦Ã-rays	esophageal squamous cell carcinoma (ESCC)	mice xenografted with KYSE150 cells	10 Gy dose of ¦Ã-ray irradiation by the 137Cesium irradiator at 2 Gy/1f/day for 5 days treatment	downregulated	27935117
11602	Human	MALAT1	lncRNA	cisplatin (DDP)	gastric cancer (GC)	The human GC cell line AGS;HGC-27 cells	cisplatin treatment	upregulated	30365113
11603	Human	MALAT1	lncRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC-27 cells	cisplatin treatment	MALAT1 was found to be highly expressed in CDDP-resistant AGS(AGS/CDDP) cells and CDDP-resistant HGC-27 (HGC-27/CDDP) cells.	30365113
11604	Human	MALAT1	lncRNA	hydrogen gas (H2)	gastric cancer (GC)	MGC-803 cells;and BGC-823 cells	?hydrogen treatment	"H2?gas significantly inhibited gastric tumor growth in vivo and the proliferation, migration, and lncRNA MALAT1 and EZH2 expression of gastric cancer cells while upregulated miR-124-3p expression"	33482814
11605	Human	MALAT1	lncRNA	oxaliplatin	gastric cancer (GC)	"GC tissues;Normal cells (GES-1); GC cells (SGC-7901, BGC-823); GC/OXA cells (SGC-7901/OXA; BCG-823/OXA"	oxaliplatin (OXA) treatment	MALAT1 modulates ZFP91 to promote GC cells OXA resistance via sponging miR-22-3p	32104001
11606	Human	MALAT1	lncRNA	propofol (PPF)	gastric cancer (GC)	SGC7901/CDDP	propofol treatment	lncRNA MALAT1/miR-30e/ATG5 mediated autophagy-related chemoresistance in GC	32302291
11607	Human	MALAT1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	GBM patients tissues and serum	TMZ treatment	downregulated	28187000
11608	Human	MALAT1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	MALAT1 was significantly upregulated in TMZ-resistant GBM cells	29479863
11609	Human	MALAT1	lncRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	all-trans retinoic acid (ATRA) treatment	downregulated	31186810
11610	Human	MALAT1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells	temozolomide (TMZ) treatment	upregulated	30940658
11611	Human	MALAT1	lncRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2 cells	Hepatitis B virus X protein (HBx) infection	HBx upregulated lncRNA-MALAT1 expression while downregulating miR-124 expression in HepG2-X cells.	30500989
11612	Human	MALAT1	lncRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2-X cell line was induced by transfect HBx into HepG2 cells.	HBx-induce	HBx upregulated lncRNA-MALAT1 expression in HepG2-X cells.	30500989
11613	Human	MALAT1	lncRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	human hepatocytes	hypoxia induce	upregulated	31075559
11614	Human	MALAT1	lncRNA	betulinic acid (BA)	hepatocellular carcinoma (HCC)	PLC/PRF/5; MHCC97L	betulinic acid (BA) treatment	lncRNA MALAT1 functioned as a ceRNA (competing endogenous RNA) to contribute to BA-mediated degradation of IAPs by sponging miR-22-3p.	33135336
11615	Human	MALAT1	lncRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	Huh-7 cell; Hep3B cells	doxorubicin treatment	upregulated	32965597
11616	Human	MALAT1	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia induce	"LncRNA MALAT1 was involved in proliferation, migration, invasion, and apoptosis by interacting with miR-200a in hypoxic Hep3B cells, revealing a new mechanism of MALAT1 involved in hypoxic HCC progression."	31347327
11617	Human	MALAT1	lncRNA	hypoxia-inducible factor 2¦Á (HIF-2¦Á)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cells	HIF-2¦Á treatment	upregulated	27524242
11618	Human	MALAT1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC cells	sorafenib treatment	upregulated	32220970
11619	Human	MALAT1	lncRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	CD4+ T cells	human immunodeficiency virus (HIV)-1 infection	upregulated	30788509
11620	Human	MALAT1	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cell (HUVEC)	high glucose (HG) treatment	Knockdown of MALAT1 inhibits HG-induced vascular endothelial injury through regulating miR-361-3p/SOCS3 axis.	32509100
11621	Human	MALAT1	lncRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cell (HUVEC)	hypoxia/reoxygenation (H/R) treatment	MALAT1 represses H/R-stimulated HUVEC injury by targeting the miR-320a/RAC1 axis.	31408432
11622	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	human microvascular endothelial cells (HMECs)	lipopolysaccharides (LPS) treatment	downregulated	31291804
11623	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	human lung fibroblasts WI-38	lipopolysaccharides (LPS) treatment	upregulated	31633220
11624	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	innate immune response	macrophages	lipopolysaccharide (LPS) treatment	upregulated	27434861
11625	Human	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	human brain microvascular endothelial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	28413461
11626	Human	MALAT1	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	OGD induced upregulation of MALAT1 in HBMECs.	32591985
11627	Human	MALAT1	lncRNA	arsenite	liver fibrosis	lihuman hepatic (L-02) cells	arsenite exposure	Co-cultures with arsenite-treated L-02 cells induced the activation of LX-2 cells and overexpression of MALAT1.	31513886
11628	Human	MALAT1	lncRNA	E2F transcription factor 3 (E2F3)	lung adenocarcinoma (LUAD)	"SPC-A1/docetaxel (DTX), H1299/docetaxel (DTX), and A549/docetaxel (DTX) cells"	E2F transcription factor 3 (E2F3) overexpression	upregulated	30771618
11629	Human	MALAT1	lncRNA	ZEB1	lung adenocarcinoma (LUAD)	"SPC-A1/docetaxel (DTX), H1299/docetaxel (DTX), and A549/docetaxel (DTX) cells"	ZEB1 overexpression treatment	upregulated	30771618
11630	Human	MALAT1	lncRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	26415832
11631	Human	MALAT1	lncRNA	gefitinib	lung cancer	A549 cells	gefitinib treatment	"MALAT1 promoted the proliferation and gefitinib resistance of lung cancer cells by sponging miR-200a, which regulates expression of ZEB1 in the A549 cells."	31133357
11632	Human	MALAT1	lncRNA	hypoxia	lung cancer	A549 lung adenocarcinoma cells	hypoxia induce	upregulated	29928414
11633	Human	MALAT1	lncRNA	IL-4	macrophage polarization	human PBMC-derived macrophages and THP-1-derived macrophages.	IL-4 treatment	downregulated	30676324
11634	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	macrophage polarization	human PBMC-derived macrophages and THP-1-derived macrophages.	lipopolysaccharide (LPS) treatment	upregulated	30676324
11635	Human	MALAT1	lncRNA	hypoxia	multiple myeloma (MM)	"multiple myeloma (MM) cell lines MM1S, 8226, KMS12BM, KMS11, U266"	hypoxia induce	upregulated	29444873
11636	Human	MALAT1	lncRNA	palmitic acid (PA)	myocardial lipotoxic injury	human cardiomyocytes (AC16 cells)	palmitic acid (PA) treatment	upregulated	31123414
11637	Human	MALAT1	lncRNA	hyperbaric oxygen (HBO)	neovascularization	human coronary artery endothelial cells (HCAECs)	hyperbaric oxygen (HBO) treatment	HBO at 2.5?ATA significantly increased MALAT1 expression in HCAECs and HCAECs-derived exosomes.	30301563
11638	Human	MALAT1	lncRNA	hypoxia	neuroblastoma (NB)	human neuroblastoma cell lines	hypoxia treatment	upregulated	26848616
11639	Human	MALAT1	lncRNA	bupivacaine	neurotoxicity	The human neuroblastoma cell line SH-SY5Y	bupivacaine treatment	"The expression of lncRNA MALAT1 was upregulated upon exposure to bupivacaine. Knockdown of lncRNA MALAT1 significantly increased the cell death rates, and Caspase3 activity assays revealed that the apoptosis rates were manifestly increased in the MALAT1 downregulated group."	31254586
11640	Human	MALAT1	lncRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	CAL-27 cells; SCC-9 cells	cisplatin treatment	DDP-resistant cells showed higher expression level of MALAT1 compared to cisplatin-na?ve cells.	32494159
11641	Human	MALAT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	upregulated	31637891
11642	Human	MALAT1	lncRNA	osteogenic differentiation medium	osteogenesis	Adipose-derived mesenchymal stem cells (ADSCs)	osteogenic differentiation media induce	upregulated	30511267
11643	Human	MALAT1	lncRNA	estradiol-17¦Â (E2)	osteosarcoma (OS)	U2OS cells	estradiol-17¦Â (E2) treatment	upregulated	28098894
11644	Human	MALAT1	lncRNA	IL-17A	otitis media (OM)	human middle ear epithelial cells (HMEECs)	IL-17A treatment	RT-qPCR analysis revealed that long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was verified to be upregulated in LPS- or IL-17A-stimulated HMEECs	33506040
11645	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	otitis media (OM)	human middle ear epithelial cells (HMEECs)	lipopolysaccharide (LPS) treatment	RT-qPCR analysis revealed that long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was verified to be upregulated in LPS- or IL-17A-stimulated HMEECs	33506040
11646	Human	MALAT1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
11647	Human	MALAT1	lncRNA	cisplatin (DDP)	ovarian cancer cell stemness	SKOV3 cells	cisplatin treatment	upregulated	32433460
11648	Human	MALAT1	lncRNA	high glucose (HG)	oxidative stress	retinal microvessels	high glucose (HG) treatment	upregulated	33051272
11649	Human	MALAT1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	30260025
11650	Human	MALAT1	lncRNA	resveratrol	parkinson's disease (PD)	MPTP-treated human neuroblastoma cell line SH©\SY5Y	resveratrol (RS) treatment	downregulated	30260025
11651	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	periodontal inflammation	Primary human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	31552681
11652	Human	MALAT1	lncRNA	androgen	prostate cancer	Human prostate cancer cell lines DU145	androgen stimulation	lung adenocarcinoma transcript 1 (MALAT1) was increased in prostate cancer cells after androgen stimulation	30642743
11653	Human	MALAT1	lncRNA	docetaxel (DTX)	prostate cancer	DU-145 cells; PC-3 cells	docetaxel (DTX) treatment	LncRNA MALAT1 was overexpressed in human DTX-resistant PCa.	29633510
11654	Human	MALAT1	lncRNA	enzalutamide (Enz)	prostate cancer	Pca patients	enzalutamide (Enz) treatment	upregulated	28528814
11655	Human	MALAT1	lncRNA	Paris forrestii (PCT3)	prostate cancer	PC-3 cells	Paris forrestii (PCT3) treatment	upregulated	31810132
11656	Human	MALAT1	lncRNA	quercetin	prostate cancer	PC-3 cells	Quercetin (Quer) treatment	MALAT1 expression was significantly downregulated in quercetin-treated PC cells in a dose- and time-dependent manner	32210615
11657	Human	MALAT1	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (hPASMCs)	hypoxia treatment	lncRNA MALAT1 promotes the proliferation and migration of hPASMCs and inhibits their apoptosis by inhibiting the miR-503/TLR4 signal axis.	32712618
11658	Human	MALAT1	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
11659	Human	MALAT1	lncRNA	ionizing radiation (IR)	radiation-induced acute and chronic complications	EA.hy926 cells	ionizing radiation (IR) treatment	radiation-induced DNA damage triggers cGAS signaling and subsequently increases the expression of MALAT1.	32532422
11660	Human	MALAT1	lncRNA	sunitinib (SU)	renal cell carcinoma (RCC)	769P cells; 786O cells	sunitinib (SU) treatment	MALAT1 expression was dramatically upregulated in SU-resistance RCC tissues and cell lines.	32663095
11661	Human	MALAT1	lncRNA	TGF-¦Â1	renal fibrosis	human renal proximal tubular epithelial (HK2) cells	TGF-¦Â1 treatment	TGF-¦Â1 induced fibrosis via upregulating MALAT1 expression in HK2 cells	32203053
11662	Human	MALAT1	lncRNA	CoCl2	renal ischemia/reperfusion (I/R) injury	HK-2 cells	cobalt chloride (CoCl 2) treatment	upregulated	30277425
11663	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	upregulated	30896848
11664	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	g human skeletal muscle cells (HSMKMC 3500)	lipopolysaccharide (LPS) treatment	upregulated	31830649
11665	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	HSMKMC 3500 cells	lipopolysaccharide (LPS) treatment	upregulated	32882524
11666	Human	MALAT1	lncRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN cells; P12 cells	hypoxia treatment	"The expression of MALAT1 and Bcl-2 was decreased, while miRNA-204 (miR-204) was upregulated in rats SCIRI model and neurocyte lines under hypoxic conditions."	29998804
11667	Human	MALAT1	lncRNA	dexamethasone (DEX)	steroid-induced avascular necrosis of femoral head (SANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	downregulated	31678133
11668	Human	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32217110
11669	Human	MALAT1	lncRNA	liposomal spherical nucleic acid (LSNA)	therapeutic potential of a LSNA	A549 (lung carcinoma) cells	liposomal spherical nucleic acid (LSNA)	downregulated	28026123
11670	Human	MALAT1	lncRNA	particulate matter (PM2.5)	toxicity of PM2.5	human bronchial epithelial cell lines (BEAS-2B and A549).	PM2.5 treatment	upregulated	28839203
11671	Human	MALAT1	lncRNA	high glucose (HG)	tubular injury	HK-2?cells	high glucose (HG) treatment	LncRNA MALAT1 was upregulated in HK-2?cells treated with high glucose.	29928873
11672	Human	MALAT1	lncRNA	rapamycin	vascular endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin (RPM) treatment	RPM treatment downregulates the endogenous expression of lncRNAs MALAT1 and SENCR in HUVECs	29845247
11673	Human	MALAT1	lncRNA	hypoxia	vascular growth	HUVECs	exposed to hypoxia (0.2% O2) treatment	upregulated	24602777
11674	Human	MALAT1	lncRNA	hypoxia	vascular remodeling	human pulmonary artery smooth muscle cells	hypoxia treatment	upregulated	28056547
11675	Human	MALAT-1	lncRNA	estradiol-17¦Â (E2)	breast cancer	"MCF10a, MCF7 and MB231 cells"	estradiol-17¦Â (E2) treatment	downregulated	24525122
11676	Human	MALAT-1	lncRNA	rosmarinic acid (RA)	ovarian cancer (OC)	OVCAR-3 human ovarian cancer cells	rosmarinic acid treatment	Rosmarinic acid induced upregulation of lncRNA MALAT-1 expression	30003749
11677	Human	MALAT-1	lncRNA	androgen	prostate cancer	human prostate cancer tissues and male nude mice	androgen treatment	MALAT-1 was upregulated in human prostate cancer tissues and cell lines.	23845456
11678	Human	MALAT-1	lncRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMECs)	lipopolysaccharide (LPS) treatment	upregulated	31231228
11679	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	MiR-150 was downregulated in LPS-induced HUVECs.	33181172
11680	Human	MANTIS	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
11681	Human	MANTIS	lncRNA	HSA-bound P-cresol	chronic kidney disease (CKD) and end-stage renal disease (ESRD)	human umbilical vein endothelial cells (HUVECs)	HSA-bound P-cresol treatment	HSA-bound P-cresol induced HUVECs injury and decreased MANTIS expression.	31949698
11682	Human	MATR3	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
11683	Human	MCM3AP-AS1	lncRNA	doxorubicin (DOX)	chemoresistance of lymphoma	Daudi and Namalwa cells	doxorubicin treatment	MCM3AP-AS1/miR-15a/EIF4E axis plays a role in the chemoresistance of Burkitt lymphoma	32765087
11684	Human	MCM3AP-AS1	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human chondrocytes	lipopolysaccharide (LPS) treatment	upregulated	31836002
11685	Human	MEG3	lncRNA	CoCl2	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	CoCl2 treatment	upregulated	33175458
11686	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	33175458
11687	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	upregulated	33602903
11688	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	TKPTS cells	lipopolysaccharide (LPS) treatment	MEG3 was significantly increased in TKPTS cells induced by lipopolysaccharide (LPS).	29923218
11689	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human lung fibroblast WI-38 cells and human PMVECs	lipopolysaccharide (LPS) treatment	MEG3 was downregulated by LPS and its knockdown aggravated LPS-induced injury of human lung cells through miR-4262-mediated downregulated of KLF4.	31184231
11690	Human	MEG3	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	downregulated	32359033
11691	Human	MEG3	lncRNA	caerulein (Cae)	acute pancreatitis (AP)	Human pancreatic duct epithelial cells (HPDE)	caerulein (Cae) treatment	"As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased."	32856219
11692	Human	MEG3	lncRNA	H2O2	age-related cataract (ARC)	SRA01/04 cells	H2O2 treatment	MEG3 promoted ARC progression by up-regulating TP53INP1 expression through suppressing miR-223 and promoting P53 expression.	32841649
11693	Human	MEG3	lncRNA	arsenite	apoptosis	A549 cells	arsenic (As) exposure	"Our results demonstrated that MEG3 expression was positively correlated with the concentration of three arsenic species (inorganic arsenic (iAs), monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA)"	33033900
11694	Human	MEG3	lncRNA	CoCl2	apoptosis	HK-2 cells	CoCl2 treatment	upregulated	33175458
11695	Human	MEG3	lncRNA	arsenite	arsenic-induced apoptosis	A549	arsenic (As) exposure	upregulated	33033900
11696	Human	MEG3	lncRNA	baicalin (BAI)	atherosclerosis (AS)	ox-LDL-induced human aorta vascular smooth muscle cells (HA-VSMCs)	baicalin (BAI) treatment	upregulated	30535498
11697	Human	MEG3	lncRNA	baicalin (BAI)	atherosclerosis (AS)	ox-LDL-treated human aorta vascular smooth muscle cells (HA-VSMCs)	baicalin (BAI) treatment	upregulated	30535498
11698	Human	MEG3	lncRNA	melatonin	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	melatonin treatment	downregulated	29024030
11699	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29024030
11700	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30535498
11701	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30535498
11702	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31312370
11703	Human	MEG3	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
11704	Human	MEG3	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
11705	Human	MEG3	lncRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	human umbilical vein endothelial cell (HUVECs)	angiotensin II (Ang II) treatment	downregulated	30838022
11706	Human	MEG3	lncRNA	etoposide (VP-16)	cell senescence	A549 and MCF-7 cells	etoposide treatment	?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells.	33141998
11707	Human	MEG3	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SK-N-SH; SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MEG3/miR-485/AIM2 axis contributes to pyroptosis via activating caspase1 signaling during cerebral I/R	31794744
11708	Human	MEG3	lncRNA	lidocaine	cervical cancer (CC)	HeLa cells	lidocaine treatment	"Long noncoding RNA maternally expressed gene 3 (lncRNA-MEG3) was significantly downregulated in cervical cancer cells, and lidocaine increased the expression of lncRNA-MEG3 in HeLa cells."	31632519
11709	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	MEG3 was upregulated in (CSE)-treated 16HBE cells.	31668807
11710	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cell (HPMEC)	cigarette smoke extract (CSE) treatment	upregulated	32201430
11711	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	MEG3 expression was enhanced while miR-181a-2-3p abundance was reduced in the serum of patients with COPD and CSE-treated 16HBE cells.	33262837
11712	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HBE135-E6E7 cells	cigarette smoke extract (CSE) treatment	MEG3 promoted proliferation and inhibited apoptosis by regulating the NF-¦ÊB signal pathway via miR-149-3p in CSE-treated HBE cells.	33365060
11713	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	CSE-treated 16HBE cells	cigarette smoke extract (CSE) treatment	"MEG3 was upregulated in COPD tissues and CSE-treated 16HBE cells, and knockdown of MEG3 mitigated CSE-repressed proliferation and CSE-triggered apoptosis or inflammation"	31668807
11714	Human	MEG3	lncRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	PM2.5 treatment	LncRNA maternally expressed gene 3 ( MEG3) was significantly upregulated in HBECs after PM25 treatment	29899163
11715	Human	MEG3	lncRNA	smoking	chronic obstructive pulmonary disease (COPD)	lung tissues	smoking treatment	MEG3 was upregulated in COPD tissues	31668807
11716	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	upregulated	32269710
11717	Human	MEG3	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	coronary artery disease (CAD)	human endothelial cell from umbilical vein (HU-VECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28804550
11718	Human	MEG3	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human AC16 cardiomyocytes	high glucose (HG) treatment	"MEG3 was overexpressed in HG-treated AC16 cells, and MEG3 knockdown suppressed the HG-induced apoptosis in AC16 cells"	31085717
11719	Human	MEG3	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells (HMCs)	high glucose treatment	upregulated	31737219
11720	Human	MEG3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression.	30529346
11721	Human	MEG3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression.	30529346
11722	Human	MEG3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	Primary human retinal pigment epithelium (RPE) cells and ARPE-19 cells	high glucose (HG) treatment	"lncRNA MEG3 depresses HG-induced apoptosis and inflammation of RPE via miR-93/Nrf2 axis, providing a novel perspective on the genesis and development of DR."	32473920
11723	Human	MEG3	lncRNA	melatonin	diabetic retinopathy (DR)	MIO-M1 cells	melatonin (MEL) treatment	"MEG3 level was lower in HG-treated MIO-M1 cells, and melatonin (MEL) reversed the HG-induced decrease of MEG3."	32324260
11724	Human	MEG3	lncRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	upregulated	30544204
11725	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial ovarian cancer (EOC)	"OVCAR3, SKOV3, HP8910 and ES-2 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24859196
11726	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	KYSE-410	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27778235
11727	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, YES2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28539329
11728	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human gastric cancer cell lines MKN45, SGC7901, BGC823, and AGS"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28345805
11729	Human	MEG3	lncRNA	TGF-¦Â1	glaucoma	Glaucoma Tenon's capsule fibroblasts (GTFs) from patients with glaucoma filtration surgery	TGF-¦Â2 (5ng/mL) treatment	downregulated	28081465
11730	Human	MEG3	lncRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	U87 cells	cisplatin treatment	upregulated	28677749
11731	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	"U251, U87 and A172 human glioma cell lines"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-Aza-2'-deoxycytidine (5-AzadC) decreased aberrant hypermethylation of the MEG3 promoter and prevented the loss of MEG3 expression.	26676363
11732	Human	MEG3	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	downregulated	32998396
11733	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	downregulated	28708282
11734	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	upregulated	28708282
11735	Human	MEG3	lncRNA	adenosine	hepatocellular carcinoma (HCC)	HepG2 cells	adenosine treatment	upregulated	31144362
11736	Human	MEG3	lncRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	"Four human hepatocellular carcinoma cell lines, SMMC-7721, Huh7, MHCC97H, and HCCLM3, and one human liver cell line L02"	arsenic trioxide (ATO) treatment	upregulated	31003765
11737	Human	MEG3	lncRNA	high glucose (HG)	high glucose-induced endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	high glucose (HG) treatment	MEG3 is significantly downregulated in an endothelial cell model of hyperglycemia.	31938204
11738	Human	MEG3	lncRNA	hypoxia	hypoxia-induced injury	HK-2 cells	hypoxia induce	upregulated	30860638
11739	Human	MEG3	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary artery smooth muscle cells	hypoxia treatment	lncRNA MEG3 was downregulated in human pulmonary artery smooth muscle cell in hypoxia.	29198701
11740	Human	MEG3	lncRNA	dexamethasone (DEX)	immune thrombocytopenic purpura (ITP)	peripheral blood	dexamethasone (DEX) treatment	downregulated	27522004
11741	Human	MEG3	lncRNA	palmitate	insulin resistance (IR)	Human HepG2 cells and primary hepatocytes	"To establish an insulin-resistant hepatocyte cell model, hepatocytes were stimulated by palmitate (0.25 mM, Sigma-Aldrich, St. Louis, MO, USA) for 24 h, and treated with insulin (100 nM) for 20 min before harvest. treatment"	MEG3 were upregulated in palmitate-treated insulin resistance hepatocytes and HFD mice	31298399
11742	Human	MEG3	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	human neuroblastoma cell lines SK-N-SH and SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31794744
11743	Human	MEG3	lncRNA	etoposide (VP-16)	lung adenocarcinoma (LUAD)	human senescent cells	etoposide treatment	?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells.	33141998
11744	Human	MEG3	lncRNA	curcumin (Cur)	lung cancer	lung cancer cell lines A549 and H520	curcumin treatment	Curcumin upregulated the expression of lncRNA-MEG3 and PTEN	33566305
11745	Human	MEG3	lncRNA	TGF-¦Â	lung cancer	human lung cancer cell lines	TGF-¦Â treatment	upregulated	27852821
11746	Human	MEG3	lncRNA	vincristine (VCR)	lung cancer	A549 cells; H292 cells	vincristine treatment	downregulated	29509250
11747	Human	MEG3	lncRNA	nickel	lung tumorigenesis	human bronchial epithelial cells	nickel treatment	downregulated	28263966
11748	Human	MEG3	lncRNA	respiratory syncytial virus (RSV)	nasopharyngeal carcinoma (NPC)	BEAS-2B cells	respiratory syncytial virus (RSV) infection treatment	downregulated	29257348
11749	Human	MEG3	lncRNA	all-trans retinoic acid (ATRA)	neurogenesis	amniotic epithelial cells (AECs)	all-trans retinoic acid (ATRA) treatment	"lncRNA MEG3 is upregulated by the ATRA/cAMP/CREB pathway, and it, in turn, is directly downregulated by miR-128-3p to increase the amount of neuron differentiation."	31921854
11750	Human	MEG3	lncRNA	paclitaxel (PTX)	non-small cell lung cancer (NSCLC)	A549 cells	paclitaxel (PTX) treatment	upregulated	30173893
11751	Human	MEG3	lncRNA	mineralizing solution	osteogenesis	human periodontal ligament cells (hPDLCs)	mineralizing solution treatment	downregulated	30256394
11752	Human	MEG3	lncRNA	mineralizing solution	osteogenesis	human periodontal ligament cells (hPDLCs)	mineralizing solution treatment	MEG3 was downregulated in osteogenic differentiation hPDLCs induced by mineralizing solution.	30256394
11753	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	ovarian cancer (OC)	cisplatin-resistant A2780cp cells treated with curcumin	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	28175963
11754	Human	MEG3	lncRNA	curcumin (Cur)	ovarian cancer (OC)	cisplatin-resistant A2780cp cells	curcumin treatment	upregulated	28175963
11755	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	MEG3 level was decreased in LPS-treated PDLCs.	32520926
11756	Human	MEG3	lncRNA	high glucose (HG)	podocyte injury	human podocytes	high glucose (HG) treatment	upregulated	33061608
11757	Human	MEG3	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	HaCaT and NHEKs cell lines	tumor necrosis factor alpha (TNF-¦Á) treatment	"MEG3/miR-21 axis may regulate the expression of caspase-8, and further influence the proliferation and apoptosis of psoriasis keratinocyte, Act-HaCaT and Act- HHEK"	31660855
11758	Human	MEG3	lncRNA	nickel oxide nanoparticles (NiO NPs)	lung fibrosis	A549 cells	Nickel oxide nanoparticles (NiO NPs) treatment	NiO NPs also evoked EMT and decreased MEG3 expression in a dose-dependent manner in A549 cells.	33547861
11759	Human	MEG3	lncRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary artery smooth muscle cell	hypoxia treatment	downregulated	29198701
11760	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp cells (hDPCs)	lipopolysaccharide (LPS) treatment	"Here, we performed high-throughput sequencing to identify dysregulated lncRNAs between human normal and inflamed pulp and concluded that lncMEG3 (lncRNA maternally expressed gene 3, MEG3) was signi?cantly upregulated in both inflamed pulp and LPS-treated hDPCs."	33524362
11761	Human	MEG3	lncRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	downregulated	30095214
11762	Human	MEG3	lncRNA	respiratory syncytial virus (RSV)	respiratory syndrome virus (PRRSV) infection	BEAS-2B cells	respiratory syncytial virus (RSV) infection treatment	lncRNA MEG3 was reduced in the NPA samples of RSV-infected patients and in BEAS-2B cells infected with RSV	29257348
11763	Human	MEG3	lncRNA	etoposide (VP-16)	cell senescence	A549; MCF-7 cells	etoposide treatment	upregulated	33141998
11764	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	sepsis	Human primary renal mixed epithelial cells	lipopolysaccharide (LPS) treatment	"lncRNA MEG3 overexpression and silencing using siRNA promoted and inhibited renal epithelial cell and cardiomyocyte apoptosis induced by lipopolysaccharide, respectively."	31641380
11765	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	sepsis	U937 cells	lipopolysaccharide (LPS) treatment	downregulated	33040826
11766	Human	MEG3	lncRNA	iodine-131 (131I)	thyroid cancer (TC)	FTC-133 cells; TPC-1 cells	iodine-131 (131I) treatment	MEG3 expression appeared a decline and miR-182 expression displayed an increase in 131I-resistant FTC-133 (res-FTC-133) and TPC-1 (res-TPC-1) cells.	30021359
11767	Human	MEG3	lncRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	CD4+ MOLT4 Tregs	high glucose (HG) treatment	upregulated	33572095
11768	Human	MEG3	lncRNA	H2O2	ulcerative colitis (UC)	Caco-2 cells	H2O2 treatment	downregulated	33394187
11769	Human	MEG3	lncRNA	dNK/IFN-¦Á	uterovascular transformation	vascular smooth muscle cell (VSMC)	dNK/IFN-¦Á treatment	upregulated	28161059
11770	Human	MEG3	lncRNA	dNK/IFN-¦Ã	spiral artery remodeling	human aorta VSMC (HA-VSMC) line	dNK/IFN-¦Ã treatment	upregulated	28161059
11771	Human	MEG4	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	human hepatic stellate cell lines LX-2 cells	CCl4 treatment	downregulated	25201081
11772	Human	MEG5	lncRNA	TGF-¦Â1	liver fibrosis	human hepatic stellate cell lines LX-3 cells	in response to transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	25201082
11773	Human	MEG8	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; Panc1 cells	TGF-¦Â treatment	MEG8 lncRNA expression was immediately induced during TGF-¦Â-mediated EMT of A549 and LC2/ad lung cancer and Panc1 pancreatic cancer cell lines	30262664
11774	Human	MER11C	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
11775	Human	METTL8	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
11776	Human	MFI2-AS1	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	MFI2-AS1 expression was increased in osteoarthritis tissues and LPS-treated C28/I2 cells.	31678554
11777	Human	MHRT	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
11778	Human	MHRT	lncRNA	H2O2	chronic heart failure (CHF)	human cardiomyocyte cell line AC16	H2O2 treatment	downregulated	31853247
11779	Human	MIAT	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29136944
11780	Human	MIAT	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Proliferation and migration were modified by MIAT/miR-148b/PAPPA axis in ox-LDL induced AS cell model.	32470448
11781	Human	MIAT	lncRNA	diethylstilbestrol (DES)	breast cancer	MCF-7?cells	diethylstilbestrol (DES) treatment	Activating estrogen signaling by diethylstilbestrol (DES) led to a dose- and time-dependent upregulated of MIAT in MCF-7?cells.	29792859
11782	Human	MIAT	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	upregulated	33009725
11783	Human	MIAT	lncRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	"MIAT and CASP1 expression were substantially increased, while that of miR-342-3p was decreased in AGE-BSA-treated HRPCs."	33065089
11784	Human	MIAT	lncRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	primary human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by mdulating miR-342-3p targeting of CASP1 in diabetic retinopathy.	33065089
11785	Human	MIAT	lncRNA	high glucose (HG)	angiogenesis 	diabetic retinas and endothelial cells	high glucose treatment	upregulated	25587098
11786	Human	MIAT	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human renal proximal tubular epithelial (HK-2) cells	TGF-¦Â1 treatment	"MIAT knockdown reduced cell viability, proliferation, migration, and the EMT in HK-2 cells"	31863776
11787	Human	MIAT	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2 cells	hypoxia treatment	upregulated	32468055
11788	Human	MIAT	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary alveolar epithelial cells (HPAECS)	hypoxia treatment	"MIAT was upregulated in both in vivo and in vitro HPH models, while miR-29a-5p was downregulated."	32964992
11789	Human	MIAT	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human adipose-derived stem cells (hASCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	27797128
11790	Human	MIAT	lncRNA	bortezomib	multiple myeloma (MM)	Bone marrow	bortezomib? treatment	upregulated	30967527
11791	Human	MIAT	lncRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	TGF-¦Â1 treatment	upregulated	31863776
11792	Human	MIAT	lncRNA	high glucose (HG)	renal tubules injury	human renal tubular epithelial cell line (HK-2)	high glucose treatment	downregulated	26551455
11793	Human	MIAT2	lncRNA	lipopolysaccharide (LPS)	inflammation	Human WI©\38 cells	lipopolysaccharide (LPS) treatment	?MIAT2 was negatively regulated by LPS and it alleviated LPS-induced damage.	31566734
11794	Human	MIAT2	lncRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	MIAT2 was negatively regulated by LPS and it alleviated LPS-induced damage.	31566734
11795	Human	MINCR	lncRNA	radiation	nasopharyngeal carcinoma (NPC)	NP460; CNE2; CNE2R cells	radiation treatment	"MINCR diminished NPC cell radiosensitivity by sponging miR-223, increasing ZEB1 and activating the AKT/PI3K axis"	33290841
11796	Human	MIR100HG	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
11797	Human	MIR100HG	lncRNA	CoCl2	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	CoCl2 treatment	upregulated	32391042
11798	Human	MIR155HG	lncRNA	doxorubicin (DOX)	cellular defense against genotoxic agents	human glioma cell lines	doxorubicin (DOX) treatment	downregulated	25645334
11799	Human	MIR155HG	lncRNA	resveratrol	cellular defense against genotoxic agents	human glioma cell lines	resveratrol (Res) treatment	upregulated	25645334
11800	Human	MIR155HG	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cell (HPMECs)	cigarette smoke extract (CSE) treatment	upregulated	32129458
11801	Human	MIR155HG	lncRNA	TGF-¦Â1	lung fibrosis	normal human primary lung fibroblasts (NHLFs)	TGF-¦Â1 treatment	The lncRNA MIR155 host gene (MIR155HG) was found to be abnormally upregulated in pulmonary fibrosis tissues and TGF¦Â1-stimulated normal human primary lung fibroblasts (NHLFs)	33482190
11802	Human	MIR181A2HG	lncRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
11803	Human	MIR210HG	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
11804	Human	MIR210HG	lncRNA	Hypoxia	warburg effect	MCF7; T47D; ZR-75-1 cells	hypoxia treatment	upregulated	33392077
11805	Human	MIR22	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
11806	Human	MIR22HG	lncRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	upregulated	33376537
11807	Human	MIR22HG	lncRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	HL7702 cells	microcystin-LR(MC-LR) treatment	upregulated	30430930
11808	Human	MIR22HG	lncRNA	hypoxia	myocardial infarction (MI)	AC16 cardiomyocytes	hypoxia treatment	Results showed that hypoxia treatment decreased viability and increased MIR22HG expression in AC16 cardiomyocytes.	33631962
11809	Human	MIR3142HG	lncRNA	IL-1¦Â	inflammation	human lung fibroblasts	IL-1¦Â treatment	upregulated	30619270
11810	Human	MIR31HG	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	gefitinib-resistant PC9 (PC9-R) cell lines	gefitinib	upregulated	28529576
11811	Human	MIR4435-2HG	lncRNA	Fusobacterium nucleatum (F. nucleatum)	oral squamous cell carcinoma (OSCC)	human immortalized oral epithelial cells (HIOECs); SCC-9 cells; HSC-4 cells	F. nucleatum infection	upregulated	31997506
11812	Human	MIR497HG	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	High-level glucose (HG) treatment significantly downregulated MIR497HG in HRECs.	32572899
11813	Human	MIR503HG	lncRNA	high glucose (HG)	proximal tubular cell apoptosis	Human proximal tubular (HK-2) cells	high glucose (HG) treatment	MIR503HG indirectly regulates Bcl-2 by promoting the co-transcription of miRNA-503 to participate high-glucose-induced proximal tubular cell apoptosis.	33262626
11814	Human	MIR503HG	lncRNA	XAV939	non-small cell lung cancer (NSCLC)	"The NSCLC cell line, NCI-H1299"	10 ?M XAV939 for 12 h treatment	The downregulated of lncRNA?MIR503HG?induced by XAV939 may serve an important role in NSCLC suppression via sponging?miR-1273c?and regulating?SOX4?expression	31186710
11815	Human	MIR6516	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
11816	Human	Mirt2	lncRNA	lipopolysaccharide (LPS)	cell damage	HK-2 cells	lipopolysaccharide (LPS) treatment	LncRNA?Mirt2 prohibits lipopolysaccharide-evoked HK-2 cell injury via modulation of?microRNA-126.	31889348
11817	Human	Mirt2	lncRNA	lipopolysaccharide (LPS)	IgA nephropathy (IgAN)	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS inhibited Mirt2 expression in HK-2 cells.	31889348
11818	Human	Mirt2	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
11819	Human	Mirt2	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	parkinson's disease (PD)	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
11820	Human	Mirt2	lncRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	colonic epithelial cells	lipopolysaccharide (LPS) treatment	downregulated	31687015
11821	Human	MKI67IP-3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28195197
11822	Human	MM2P	lncRNA	lipopolysaccharide- and MSU	acute gouty arthritis (AGA)	THP-1 cells	lipopolysaccharide-and MSU treatment	downregulated	32705194
11823	Human	Morrbid	lncRNA	lymphocytic choriomeningitis virus (LCMV)	lymphocytic choriomeningitis virus (LCMV) infection	CD8 T cell	lymphocytic choriomeningitis virus (LCMV) infection	upregulated	31138702
11824	Human	MPRL	lncRNA	cisplatin (DDP)	tongue squamous cell carcinoma (TSCC)	"human TSCC cell lines, CAL-27, SCC-9 and SCC-25"	cisplatin treatment	MPRL expression was significantly upregulated in TSCC cell lines treated with cisplatin and transactivated by E2F1.	30885939
11825	Human	MSC-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	LN229 cells; SHG-44 cells	temozolomide (TMZ) treatment	MSC-AS1 was upregulated in TMZ-resistant glioma tissues and cells	33106913
11826	Human	MSC-AS1	lncRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	Human pancreatic cancer cell lines PANC-1 and BxPC-3	gemcitabine treatment	MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14.	30915884
11827	Human	MST1P2	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	SW 780 cells	cisplatin treatment	MST1P2 serves as a competing endogenous RNA for miR-133b to counteract miR-133b-induced suppression on Sirt1.	32052927
11828	Human	MSTRG.292666.16	lncRNA	osimertinib	non-small cell lung cancer (NSCLC)	plasma; H1975R cells; H1975R cells-derived exosomes	osimertinib treatment	"lncRNA MSTRG.292666.16 was significantly upregulated in osimertinib-resistant plasma, osimertinib-resistant H1975R cells and their derived exosomes, compared with those in osimertinib-sensitive plasma, H1975 cells and exosomes."	32375124
11829	Human	MSX2P1	lncRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	upregulated	29339075
11830	Human	MT1DP	lncRNA	cadmium (Cd)	cadmium (Cd)-induced hepatoxicity	HepG2 cells	cadmium (Cd) treatment	upregulated	30027041
11831	Human	MT1DP	lncRNA	cadmium (Cd)	cadmium-induced toxicity	blood; blood exosomes; liver cells	cadmium (Cd) treatment	upregulated	31864927
11832	Human	MTA2TR	lncRNA	hypoxia	pancreatic cancer (PC)	PANC-1;BxPC-3;SW1990 cell;	hypoxia induce	upregulated	31410216
11833	Human	MTMR9LP	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
11834	Human	MUDENG	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
11835	Human	MUDENG	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
11836	Human	MX1-215	lncRNA	IFN-¦Á	head and neck squamous cell carcinoma (HNSCC)	Cal27 cells; HN30 cells	IFN-¦Á treatment	upregulated	31907020
11837	Human	n335586	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HCC tissues; HepG2.2.15cells	hepatitis B virus (HBV) infection	n335586 was significantly increased in HBV positive HCC tissues and cells.	29753758
11838	Human	n336098	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
11839	Human	n337041	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
11840	Human	n344988	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
11841	Human	n345751	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
11842	Human	NBR2	lncRNA	curcumin (Cur)	colorectal cancer (CRC)	"4 human CRC cell lines, including HCT116, HCT8, SW480, and SW620"	curcumin treatment	"when colorectal cancer cells were treated with curcumin, the expression of NBR2 was significantly increased."	31888414
11843	Human	NBR2	lncRNA	glucose	colorectal cancer (CRC)	"4 human CRC cell lines, including HCT116, HCT8, SW480, and SW620"	glucose starvation	"glucose deficiency increased the expression of NBR2 in colorectal cancer cells, and NBR2 knockdown affected the progression of colorectal cancer cells under glucose starvation conditions."	31888414
11844	Human	nc886	lncRNA	doxorubicin (DOX)	cytotoxicity	"HCT116 cells, Nthy-ori 3-1 cells"	doxorubicin treatment	downregulated	30948645
11845	Human	nc886	lncRNA	ultraviolet (UV) irradiation	inflammation	?human keratinocytes HaCaT cells	ultraviolet B (UVB) radiation treatment	downregulated	30685091
11846	Human	nc886	lncRNA	TGF-¦Â	ovarian cancer (OC)	SKOV3 cells	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	29563500
11847	Human	nc886	lncRNA	ultraviolet (UV) irradiation	photoaging	human keratinocyte (HaCaT) cells	UVB irradiation treatment	"UVB irradiation accelerates the methylation of the nc886 gene, therefore, reducing its expression"	32630038
11848	Human	NCK1-AS1	lncRNA	cisplatin (DDP)	cervical cancer (CC)	Cervical cancer HeLa cells	cisplatin treatment	si-NCK1-AS1 and miR-134-5p mimic both reduced MSH2 activity and increased cisplatin-induced apoptosis in cervical cancer cells.	30221354
11849	Human	NCK1-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 and A172 cells	temozolomide (TMZ) treatment	upregulated	31750728
11850	Human	NCK1-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251; A172 cells	temozolomide (TMZ) treatment	NCK1-AS1 could increase drug resistance of glioma cells to TMZ by modulating miR-137/TRIM24 pathway	31750728
11851	Human	NCRMS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells; MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
11852	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	"The human osteosarcoma cell line, MG63"	lipopolysaccharide (LPS) treatment	"?There were 427 dysregulated genes in the LPS-stimulated MG63 cells, in which NEAT1 was significantly downregulated"	33416115
11853	Human	NEAT1	lncRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus cells	IL-1¦Â treatment	TNF-¦Á/IL-1¦Â induced a time- and dose-dependent increase in the mRNA expression of lncRNA NEAT1 in the nucleus pulposus cells	33478594
11854	Human	NEAT1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á/IL-1¦Â induced a time- and dose-dependent increase in the mRNA expression of lncRNA NEAT1 in the nucleus pulposus cells	33478594
11855	Human	NEAT1	lncRNA	Iodine-131 (131I)	papillary thyroid cancer (PTC)	thyroid papillary cell line TPC-1 (BNCC337912) and B-CPAP (BNCC338685)	131I treatment	NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo.	30596336
11856	Human	NEAT1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT8; SW480 cells	5-fluorouracil (5-FU) treatment	LncRNA NEAT1 could target miR-34a and promote autophagy to facilitate 5-FU chemoresistance in CRC.	31802650
11857	Human	NEAT1	lncRNA	CoCl2	acute kidney injury (AKI)	human kidney tubular cells (HK-2)	CoCl2?-stimulated HK-2 cells	NEAT1 was upregulated in AKI patients compared with healthy control.	31090110
11858	Human	NEAT1	lncRNA	ischemia	acute kidney injury (AKI)	serum from AKI patients	ischemia©\induced AKI	The level of NEAT1 in HK©\2 cells treated with CoCl2 was higher in a dose©\dependent manner.	31090110
11859	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	NEAT1 was upregulated in LPS-stimulated HK-2 cells.	33335994
11860	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	NEAT1 was upregulated in serum of sepsis patients and LPS-induced HK2 cells.	33885954
11861	Human	NEAT1	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29111326
11862	Human	NEAT1	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y and SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	"NEAT1 expression was enhanced in A¦Â-treated SH-SY5Y and SK-N-SH cells, miR-107 abundance was reduced in A¦Â-treated cells, and its overexpression reversed A¦Â-induced injury. Moreover, interference of miR-107 abated silencing of NEAT1-mediated inhibition of neuronal damage in A¦Â-treated SH-SY5Y and SK-N-SH cells."	31250578
11863	Human	NEAT1	lncRNA	acrolein	apoptosis	vascular smooth muscle cells (VSMCs)	acrolein treatment	downregulated	31864078
11864	Human	NEAT1	lncRNA	acrolein	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	Acrolein treatment	downregulated	31864078
11865	Human	NEAT1	lncRNA	asparagus extract (AE)	atherosclerosis (AS)	Acrolein-treated vascular smooth muscle cells (VSMCs)	asparagus extract (AE) treatment	upregulated	31864078
11866	Human	NEAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 was significantly increased in THP-1 cells incubated with ox-LDL and meanwhile miR-342-3p was greatly decreased.	30259979
11867	Human	NEAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30259979
11868	Human	NEAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 adjusted the AKT/mTOR signaling pathway via miR-638 in ox-LDL-induced HAECs to accelerate their proliferation and impede their apoptosis.	32377692
11869	Human	NEAT1	lncRNA	Trimethylamine N-oxide (TMAO)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	Trimethylamine N-oxide (TMAO) exposure treatment	upregulated	31173767
11870	Human	NEAT1	lncRNA	t-butylhydroperoxide (t-BHP)	atherosclerotic coronary heart disease (CHD)	Primary HUVECs	t-butylhydroperoxide (t-BHP) treatment	upregulated	31352814
11871	Human	NEAT1	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
11872	Human	NEAT1	lncRNA	hypoxia	breast cancer	MCF-7 cells	1% O2 treatment	upregulated	26289678
11873	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	bronchopneumonia	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"NEAT1 and MyD88 were upregulated in BEAS-2B cells by LPS, while miR-155-5p was downregulated."	33719773
11874	Human	NEAT1	lncRNA	macrophage migration inhibitory factor (MIF)	cardioprotective therapy	human adipose-derived MSCs (ADMSCs); Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes	macrophage migration inhibitory factor (MIF) treatment	LncRNA-NEAT1/miR-142-3p/FOXO1 at least partially mediates the cardioprotective roles of exosomeMIF in protecting cardiomyocytes from apoptosis.	31964409
11875	Human	NEAT1	lncRNA	H2O2	cataract	human lens epithelial cells (HLECs)	H2O2 treatment	upregulated	33490165
11876	Human	NEAT1	lncRNA	resveratrol	cellular defense against genotoxic agents	human glioma cell lines	resveratrol (Res) treatment	upregulated	25645334
11877	Human	NEAT1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"Human normal colonic epithelial cell line, FHC, and colorectal carcinoma cell lines, HT29, HCT8, HCT116, SW480, SW620"	5-fluorouracil (5-FU) treatment	NEAT1 knockdown noticeably inhibited the proliferation of CRC cells and enhanced 5-FU sensitivity.	31802650
11878	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	corneal neovascularization (CNV)	human corneal fibroblasts (HCFs)	lipopolysaccharide (LPS) treatment	The expression of NEAT1 in HCFs was upregulated by LPS.	30328354
11879	Human	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells	high glucose (HG) treatment	Real-time PCR was performed to detect the relative NEAT1 and miR-222-3p expressions and further confirmed the relationship between NEAT1 and miR-222-3p.	33585566
11880	Human	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"Our results showed that NEAT1 and Drp1 levels were upregulated, while miR-150-5p level was downregulated in HK-2 cells in response to HG."	33914383
11881	Human	NEAT1	lncRNA	fenofibrate	drug-inducible neuroprotection from oxidative stress	SH-SY5Y cells	fenofibrate treatment	upregulated	31311324
11882	Human	NEAT1	lncRNA	paraquat (PQ)	drug-inducible neuroprotection from oxidative stress	SH-SY5Y cells	paraquat (PQ) treatment	upregulated	31311324
11883	Human	NEAT1	lncRNA	simvastatin	drug-inducible neuroprotection from oxidative stress	SH-SY5Y cells	simvastatin treatment	upregulated	31311324
11884	Human	NEAT1	lncRNA	rapamycin	dyslipidemia	serum	rapamycin treatment	hsa-miR-372-3p was filtered using RNA sequencing and identified as a key regulator in rapamycin-induced TGs accumulation	33705959
11885	Human	NEAT1	lncRNA	progesterone (P4)	endometrial cancer (EC)	human Ishikawa cells	Progesterone treatment	NEAT1 or LEF1 was overexpressed in endometrial cancer cells while downregulated following post-treatment with progesterone	30452118
11886	Human	NEAT1	lncRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	progesterone treatment	LncRNA nuclear enriched abundant transcript 1 (NEAT1) was the most significantly downregulated lncRNA in endometrial cancer cells treated with progesterone	30452118
11887	Human	NEAT1	lncRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human LECs (HLECs)	TGF-¦Â2 treatment	"TGF-¦Â2 induces NEAT1 overexpression, which in turn suggests that NEAT1 acts as a ceRNA targeting Snail1 or Zeb1 by binding miR-34a or miR-204"	32596382
11888	Human	NEAT1	lncRNA	adriamycin (ADR)	gastric cancer (GC)	SGC7901 cells	adriamycin (ADR) treatment	"NEAT1 was upregulated in GC tissues and cells, especially in in GC adriamycin-resistant cells."	28401449
11889	Human	NEAT1	lncRNA	oxaliplatin	gastric cancer (GC)	GC cell lines HGC-27;BGC-823	oxaliplatin treatment	upregulated	31617275
11890	Human	NEAT1	lncRNA	oxaliplatin	gastric cancer (GC)	HGC-27 cells; BGC-823 cells	oxaliplatin (OXA) treatment	upregulated	31617275
11891	Human	NEAT1	lncRNA	radiation	gastric cancer (GC)	MKN-45 and AGS cells	radiation treatment	NEAT1 depletion enhanced radio-sensitivity of GC by negatively regulating miR-27b-3p in vitro and in vivo	33292252
11892	Human	NEAT1	lncRNA	adenovirus (ADV)	glioblastoma multiforme (GBM)	FMXJ-1 cells	adenovirus (ADV) treatment	ADV infection upregulated lncRNA NEAT1.	32843056
11893	Human	NEAT1	lncRNA	estradiol-17¦Â (E2)	hepatic steatosis	HepG2 cells	estradiol-17¦Â (E2) treatment	upregulated	31062612
11894	Human	NEAT1	lncRNA	oleacein (OA)	hepatic steatosis	HepG2 cells	oleic acids treatment	upregulated	31062612
11895	Human	NEAT1	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	SNU-182 cells; HUH7 cells	hypoxia treatment	LncRNA-NEAT1 expression was significantly induced by hypoxia in SNU-182 and HUH7 cells.	32670881
11896	Human	NEAT1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 or Bel7404	sorafenib (Sora) treatment	"lncRNA NEAT1 mediates Sora resistance of HCC cells by suppressing miR-335 expression, and disinhibition on c-Met-Akt signaling pathway"	30937906
11897	Human	NEAT1	lncRNA	histone deacetylase (HDAC)	histone deacetylase resistance in nasopharyngeal cancer (NPC)	CNE1; CNE2; C666¨C1	Histone deacetylase treatment	upregulated	32692721
11898	Human	NEAT1	lncRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	HeLa cells	infect with HSV-1	upregulated	27783096
11899	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	osteoblasts inflammation	MG63 cells	lipopolysaccharide (LPS) treatment	downregulated	33416115
11900	Human	NEAT1	lncRNA	Toll-like receptor3-p38 pathway-triggered poly I:C	innate immune response	HeLa TO cells £¬ A549 cells	cells were transfect poly I:C treatment	upregulated	24507715
11901	Human	NEAT1	lncRNA	advanced glycation end product (AGE)	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPC)	advanced glycation end product (AGE) treatment	upregulated	32850952
11902	Human	NEAT1	lncRNA	sepsis	liver damage	liver tissues	sepsis induce treatment	The expression of lncRNA NEAT1 in liver tissue of patients with sepsis-induced liver injury was clearly increased	31344555
11903	Human	NEAT1	lncRNA	particulate matter (PM2.5)	lung cancer	BEAS-2B and HBE cells	particulate matter (PM2.5) treatment	Loss of NEAT1 represses the malignant transformation of BEAS-2B and HBE cells induced by PM25	33829382
11904	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	Human renal mesangial cells (HRMCs)	lipopolysaccharide (LPS) treatment	"NEAT1 accelerated renal mesangial cell injury via directly targeting miR-146b, promoting the expression of TRAF6, and activating the NF-¦ÊB signaling in lupus nephritis."	32710276
11905	Human	NEAT1	lncRNA	dexamethasone (DEX)	multiple myeloma (MM)	MM1R cell lines	dexamethasone (Dex) treatment	NEAT1 was highly expressed in DEX-resistant myeloma cell lines.	29948578
11906	Human	NEAT1	lncRNA	resveratrol	multiple T myeloma	U266 cells; LP1 cells	resveratrol (RS) treatment	"lncRNA NEAT1 was highly expressed in MM cells, which could be significantly inhibited by resveratrol"	30107344
11907	Human	NEAT1	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	NEAT1 and miR-140 are upregulated in hepacytes under the NAFLD conditions. The NEAT1-miR-140 axis play a crucial role in modulation of NAFLD via inactivation of AMPK/SREBP1 signaling.	31239155
11908	Human	NEAT1	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	upregulated	31484042
11909	Human	NEAT1	lncRNA	bone morphogenetic protein 1 (BMP1)	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	BMP1 treatment	NEAT1 promotes osteogenic differentiation in hBMSCs by regulating miR-29b-3p/BMP1 axis.	30638953
11910	Human	NEAT1	lncRNA	radioactivity iodine (RAI)	papillary thyroid cancer (PTC)	TPC-1 cells; B-CPAP cells	radioactivity iodine (RAI) treatment	upregulated	30596336
11911	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	1-methyl-4-phenylpyridinium (MPP+) treatment	?NEAT1 expression was significantly increased in SH-SY5Y cells after MPP+?treatment in dose- and time- dependent manners.	31228597
11912	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated of NEAT1 repressed ¦Á-syn-induced activation of NLRP3 inflammasome via inhibiting the expression of GJB1 by targeting miR-1301-3p.	32712773
11913	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	29287722
11914	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	29575151
11915	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	32712773
11916	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"Here, the increased lncRNA NEAT1 was discovered in MPP+-induced SH-SY5Y cells."	32712773
11917	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MMP+) treatment	upregulated	33069733
11918	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"We demonstrated that, in SH-SY5Y cells treated with MPP+, NEAT1 and PDE4B expression levels were raised, while miR-124-3p expression was repressed"	33522352
11919	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	upregulated	31632562
11920	Human	NEAT1	lncRNA	H2O2	preeclampsia (PE)	HTR-8/SVneo	H2O2 treatment	upregulated of LncRNA NEAT1 induces apoptosis of human placental trophoblasts	32998583
11921	Human	NEAT1	lncRNA	docetaxel (DTX)	prostate cancer	PCa samples; PC3 cells; DU145 cells	docetaxel (DTX) treatment	NEAT1 was upregulated in docetaxel-resistant PCa clinical samples and cell lines.	31672604
11922	Human	NEAT1	lncRNA	Paris forrestii (PCT3)	prostate cancer	PC-3 cells	Paris forrestii (PCT3) treatment	downregulated	31810132
11923	Human	NEAT1	lncRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	32475133
11924	Human	NEAT1	lncRNA	hypoxia	reperfusion injury	human iPS-derived cardiomyocytes (iPS-CM)	hypoxia treatment	downregulated	32826883
11925	Human	NEAT1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	upregulated	32326576
11926	Human	NEAT1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	RA-FLS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"We found that NEAT1 was upregulated, and miR-204-5p was downregulated in the RA patients' synovial tissue and TNF-¦Á treated RA-FLSs"	33394349
11927	Human	NEAT1	lncRNA	anti-microbial peptide LL-37	rosacea	skin tissues	LL37 treatment	?NEAT1 was upregulated in rosacea skin and in LL37-treated HaCaT cells.	33678493
11928	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	upregulated	32099901
11929	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	"NEAT1 regulated TRAF6 expression by sponging let-7b-5p in HK-2 cells, which promotes LPS-induced injury and inflammation in HK-2 cells."	32724027
11930	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	32089649
11931	Human	NEAT1	lncRNA	tuberculosis (MTB)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (MTB) infection treatment	upregulated	33271233
11932	Human	NEAT1.1	lncRNA	cisplatin (DDP)	bladder cancer	T24 cells	cisplatin (DPP) treatment	"the RNA level of NEAT1.1, one RNA variant of NEAT1, was reduced in cisplatin-sensitive T24 cells compared to cisplatin-resistant T24 (T24R) cells after both treated with cisplatin modulated through Wnt/¦Â-catenin signaling pathway using RNA-seq."	31933859
11933	Human	NEAT1_2	lncRNA	Solamargine	gastric cancer (GC)	"The GC cell lines AGS, BGC823, SGC7901, HGC27 and MGC803"	Solamargine treatment	upregulated	30864686
11934	Human	NEAT1-1	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	mycobacterium tuberculosis (Mtb) infection	Mycobacterium tuberculosis infection robustly increased the expression of NEAT1-1 and NEAT1-2 in THP-1 macrophages in vitro.	30534569
11935	Human	NEAT1-2	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	mycobacterium tuberculosis (Mtb) infection	Mycobacterium tuberculosis infection robustly increased the expression of NEAT1-1 and NEAT1-2 in THP-1 macrophages in vitro.	30534569
11936	Human	NFAT5-1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	downregulated	31925944
11937	Human	NIFK-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
11938	Human	NKILA	lncRNA	active fraction of polyrhachis vicina rogers (AFPR)	breast cancer	MCF-7 cells	active fraction of Polyrhachis vicina Rogers (AFPR) treatment	upregulated	31881485
11939	Human	NKILA	lncRNA	active fraction of Polyrhachis vicina Rogers (AFPR)	breast cancer	MCF-7 cells	active fraction of Polyrhachis vicina Rogers (AFPR) treatment	upregulated	31881485
11940	Human	NKILA	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	MCF 7 cells	TGF-¦Â treatment	lncRNA NKILA was upregulated by TGF-¦Â	29761481
11941	Human	NKILA	lncRNA	TGF-¦Â1	esophageal squamous cell carcinoma (ESCC)	KYSE30 cells	TGF-¦Â1 treatment	LncRNA NKILA is upregulated by TGF-¦Â1	29379981
11942	Human	NKILA	lncRNA	baicalin (BAI)	hepatocellular carcinoma (HCC)	SMMC-7721 cells; HepG2 cells	baicalin (BAI) treatment	downregulated	29481769
11943	Human	NKILA	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	infantile pneumonia (IP)	MRC5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	NKILA weakens TNF-¦Á-induced inflammation of MRC-5 cells by miR-21 upregulated	32013579
11944	Human	NKILA	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGDR induce NKILA upregulation in SH-SY5Y cells	30007440
11945	Human	NKILA	lncRNA	osteogenic differentiation medium	osteogenesis	Mesenchymal stem cells (MSCs)	"osteogenic medium (¦Á-MEM containing 10% FBS, 50 ¦Ìg/ml ascorbic acid, and 5 mM ¦Â-glycerophosphate) treatment"	"NKILA is functionally involved in the regulation of RXFP1/PI3K-AKT and NF-¦ÊB signalling. Knockdown of NKILA dramatically down-regulates the expression of RXFP1 and then reduces the activity of AKT, a downstream regulator of RXFP1 signalling which is widely accepted as an activator of osteogenesis."	31657882
11946	Human	NKILA	lncRNA	hypoxia	retinal pigment epithelium (RPE) cells injuries	ARPE-19 human RPE cells	hypoxia treatment	"Hypoxia induced NKILA expression, NKILA-I¦ÊB¦Á association and NF¦ÊB activation in ARPE-19?cells and primary human RPE cells."	30144973
11947	Human	NKILA	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31599426
11948	Human	NKX2-5-4	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	upregulated	31514003
11949	Human	NMR	lncRNA	IL-1¦Â and TNF-¦Á	esophageal squamous cell carcinoma (ESCC)	KYSE70 Cells	IL-1¦Â and TNF-¦Á treatment	IL-1¦Â and TNF-¦Á stimulation showed that IL-1¦Â and TNF-¦Á could significantly promote the expression of NMR in ESCC cells.	29763634
11950	Human	NNT-AS1	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	NNT-AS1 played a promoting role in smoking-induced COPD via modulating miR-582-5p/FBXO11 signaling.	32768929
11951	Human	NONHSAG024980	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
11952	Human	NONHSAG048134.2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
11953	Human	NONHSAG048135.2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
11954	Human	NONHSAG048143.2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
11955	Human	NONHSAG096479.1	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
11956	Human	NONHSAT000264	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	upregulated	32391956
11957	Human	NONHSAT057283	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	upregulated	32547604
11958	Human	NONHSAT076891	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	bone marrow (BM)	all-trans retinoic acid (ATRA) treatment	upregulated	29956795
11959	Human	NONHSAT084969.2	lncRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle cells (VSMCs)	high-phosphorus (HP) treatment	lncRNAs NONHSAT084969.2 was confirmed to increase significantly in the HP group in comparison with than that in the CON group.	32401115
11960	Human	NONHSAT089447	lncRNA	olanzapine (OLP)	schizophrenia (SZ)	Human neuroblastoma cell lines (SK-N-SH)	olanzapine (OLP) treatment	downregulated	31180069
11961	Human	NONHSAT097797	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	downregulated	32547604
11962	Human	NONHSAT105177	lncRNA	melittin	pancreatic ductal adenocarcinoma (PDAC)	PATU8988 cells; Panc1 cells; SW1990 cells	melittin treatment	melittin treatment increased NONHSAT105177 expression in PDAC cell lines	30237397
11963	Human	NONHSAT108582.2	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32689997
11964	Human	NONHSAT141593.2	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32689997
11965	Human	NONHSAT143692.2	lncRNA	H2O2	age-related cataract (ARC)	human lens epithelial cells (LECs)	oxidative stress	NONHSAT143692.2 is involved in oxidative DNA damage repair in the lens by regulating the miR-4728-5p/OGG1 axis.	33000245
11966	Human	NONHSAT161887	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	normal human liver cells L-02	PCB 156 treatment	dysregulated	31514003
11967	Human	NONHSAT172176	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	downregulated	31514003
11968	Human	NONHSAT174696	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	normal human liver cells L-02	PCB 156 treatment	dysregulated	31514003
11969	Human	NONHSAT177112.1	lncRNA	lipopolysaccharide (LPS)	inflammation	human cardiomyocytes (HCMs)	lipopolysaccharide (LPS) treatment	NONHSAT177112.1 showed dynamic expression that first increased and then decreased during LPS stimulation.	33641342
11970	Human	NONHSAT179219	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	normal human liver cells L-02	PCB 156 treatment	dysregulated	31514003
11971	Human	NONHSAT187744	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	upregulated	31514003
11972	Human	NONHSAT193411.1	lncRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle cells (VSMCs)	high-phosphorus (HP) treatment	NONHSAT193411.1 was confirmed to increase significantly in the HP group in comparison with than that in the CON group.	32401115
11973	Human	NONHSAT203881	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	upregulated	31514003
11974	Human	NONHSAT247851.1	lncRNA	particulate matter (PM2.5)	cerebrovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	PM 2.5 treatment	upregulated	32278143
11975	Human	NONMMUT008655.2	lncRNA	resveratrol	hepatic insulin resistance	Hepa cells	resveratrol (Res) treatment	RSV may improve hepatic insulin resistance and control blood glucose levels by downregulating lncRNA NONMMUT0086552	32051733
11976	Human	NONSHAT022487	lncRNA	toxoplasma gondii (T. gondii)	T. gondii infection	human foreskin fibroblast (HFF) cells	toxoplasma gondii (T. gondii) infection treatment	The transcriptional level of NONHSAT022487 was increased by more than 30-fold after T gondii infection	29530077
11977	Human	NONT087634	lncRNA	lipopolysaccharide (LPS)	sepsis	human microvascular endothelial cells	lipopolysaccharide (LPS) treatment	dysregulated	29147069
11978	Human	NONT119666	lncRNA	lipopolysaccharide (LPS)	sepsis	human microvascular endothelial cells	lipopolysaccharide (LPS) treatment	dysregulated	29147069
11979	Human	NORAD	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"lncRNA NORAD attenuates endothelial cell senescence, endothelial cell apoptosis, and atherosclerosis via NF-¦ÊB and p53-p21 signaling pathways and IL-8."	32267831
11980	Human	NORAD	lncRNA	hypoxia	coronary artery disease (CAD)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	Long non-coding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR-590-3p under hypoxic conditions.	32323787
11981	Human	NORAD	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16	high glucose (HG) treatment	Overexpression of NORAD protects DCM development via miRNA-150-5p/ZEB1 axis.	33215445
11982	Human	NORAD	lncRNA	particulate matter (PM10)	lung cancer	A549 cells	Particulate matter of 10 ¦Ìm or less in diameter (PM10) treatment	we demonstrated that PM10?treatment increased the expression levels of NORAD	33250223
11983	Human	NORAD	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	H446 cells; A549 cells	cisplatin treatment	downregulated	31894841
11984	Human	NORAD	lncRNA	physcion 8-O-¦Â-glucopyranoside (PG)	ovarian cancer (OC)	SKOV3 cells	physcion 8-O-¦Â-glucopyranoside (PG) treatment	upregulated	31299866
11985	Human	NORAD	lncRNA	hypoxia	pancreatic cancer (PC)	"pancreatic cancer cell lines SW1990, Capan-1, PANC-1, AsPC-1, CFPAC-1, MIAPaCa-2, and BxPC-3"	1% O2	upregulated	29121972
11986	Human	NORAD	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"MPP?+?induced cytotoxicity, and downregulated lncRNA NORAD in both dose- and time- dependent manners in SH-SY5Y cells."	31421205
11987	Human	NORAD	lncRNA	dexamethasone (DEX)	steroid-induced osteonecrosis of femoral head (ONFH)	human bone marrow-derived mesenchymal stem cells (hBMSCs)	dexamethasone (DEX) treatment	"NORAD expression was downregulated in SONFH tissues, while miR-26a-5p expression was upregulated."	33413642
11988	Human	NPSR1-AS1	lncRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	hepatocellular carcinoma (HCC)	Hep3B cells; Huh7 cells	hypoxia-inducible factor-1¦Á (HIF-1¦Á) treatment	Hypoxia-inducible long noncoding RNA NPSR1-AS1 promotes the proliferation and glycolysis of hepatocellular carcinoma cells by regulating the MAPK/ERK pathway.	33008585
11989	Human	NR_002733	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
11990	Human	NR_004845	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	downregulated	29409992
11991	Human	NR_024118	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	AC16 cells	lipopolysaccharide (LPS) treatment	downregulated	33846787
11992	Human	NR_024351	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
11993	Human	NR_026763	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
11994	Human	NR_028034	lncRNA	lipopolysaccharide (LPS)	inflammation	human macrophages	lipopolysaccharides (LPS) treatment	upregulated	28420462
11995	Human	NR_029399	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
11996	Human	NR_033661	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
11997	Human	NR_038323	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	HK-2 cells	High Glucose (HG) treatment	upregulated	31430717
11998	Human	NR_039985	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
11999	Human	NR_109779	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
12000	Human	NR_110586	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
12001	Human	NR_110801	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
12002	Human	NR_120420	lncRNA	oxygen glucose deprivation (OGD)	stroke	SH-SY5Y cells	oxygen and glucose deprivation (OGD) treatment	upregulated	31838253
12003	Human	NR_120420	lncRNA	oxygen glucose deprivation (OGD)	stroke	SH-SY5Y cells	oxygen and glucose deprivation (OGD) treatment	NR_120420 knockdown inhibited apoptosis after cerebral infarction by downregulating the phosphorylation of a subunit of NF-¦ÊB (P65)	31838253
12004	Human	NR_122070	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
12005	Human	NR2F1-AS1	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HCC cells	hypoxia treatment	?NR2F1-AS1 level was enhanced in HCC tissues and cells.	33488124
12006	Human	NR2F1-AS1	lncRNA	oxaliplatin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	oxaliplatin (OXA) treatment	lncRNA NR2F1-AS1 was upregulated in oxaliplatin-resistant HCC tissue and cells	29602203
12007	Human	NRAL	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 and HepG2/CDDP	cisplatin treatment	NRAL was highly expressed in HepG2 cisplatin resistant cell lines compared to their parental counterparts.	30030687
12008	Human	NRAL	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	upregulated	30030687
12009	Human	NRAV	lncRNA	respiratory syncytial virus (RSV)	respiratory syndrome virus (PRRSV) infection	sputum specimens	respiratory syncytial virus (RSV) infection treatment	lncRNA negative regulator of antiviral response (NRAV) in RSV-positive patients was significantly lower than that in uninfected patients	32102886
12010	Human	NRIR	lncRNA	lipopolysaccharide (LPS)	systemic sclerosis (SSc)	human monocytes	lipopolysaccharide (LPS) treatment	upregulated	30804934
12011	Human	NUTF2P3-001	lncRNA	CoCl2	pancreatic cancer (PC)	pancreatic cancer cell	hypoxia£¬CoCl2 treatment	upregulated	26755660
12012	Human	NUTF2P3-001	lncRNA	hypoxia	pancreatic cancer (PC)	pancreatic cancer cell	hypoxia£¬CoCl2 treatment	upregulated	26755660
12013	Human	NUTM2A-AS1	lncRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp cells (HDPCs)	lipopolysaccharide (LPS) treatment	LPS exposure upregulated the expression of NUTM2A-AS1 and High-Mobility Group Box 1 (HMGB1) and downregulated the level of let-7c-5p.	33831808
12014	Human	OBFC2A	lncRNA	"1,4-benzoquinone (1,4-BQ)"	benzene-induced hematotoxicity	AHH1 cells	"1,4-Benzoquinone (1,4-BQ) treatment"	upregulated	32087087
12015	Human	OBFC2A	lncRNA	"1,4-benzoquinone (1,4-BQ)"	benzene toxicity	human normal lymphocyte line (AHH-1)	"1,4-Benzoquinone (1,4-BQ) treatment"	upregulated	28388563
12016	Human	OGRU	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	M¨¹ller cells	streptozotocin (STZ) treatment	DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas	33762162
12017	Human	OIP5-AS1	lncRNA	angiotensin II (Ang II)	aortic dissection (AD)	human aortic endothelial cells (HAECs); human aortic smooth muscle cells (HASMCs)	angiotensin II (Ang II) treatment	"We found that lnc-OIP5-AS1 was upregulated, whereas miR-143-3p was downregulated in cells treated with angiotensin II (AngII) and AD tissues."	33577845
12018	Human	OIP5-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	OIP5-AS1 knockdown modulated cell progression via regulating miR-320a/LOX1 axis in ox-LDL-treated HUVECs.	32072428
12019	Human	OIP5-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Our data showed the significant upregulation of OIP5-AS1 in atherosclerosis serum and ox-LDL-stimulated HUVECs.	33778018
12020	Human	OIP5-AS1	lncRNA	dermatophagoides pteronyssinus peptidase 1 (Der p1)	bronchial asthma	BEAS-2B cells	Dermatophagoides pteronyssinus peptidase 1 (Der p1) treatment	OIP5-AS1 exacerbated Der p1-induced inflammation and apoptosis in BEAS-2B cells by targeting miR-143-3p via HMGB1.	33174035
12021	Human	OIP5-AS1	lncRNA	osteogenic differentiation medium	calcific aortic valve disease (CAVD)	valve interstitial cells (VICs) isolated from human calcific aortic valves	"a-minimal essential medium (Gibco, Carlsbad, CA, USA) containing 0.1% FBS, bioactive recombinant human bone morphogenetic protein-2 (BMP-2; 50 ng/mL), dexamethasone (100 nmol/L), ascorbic acid (50 mg/mL), and b-glycerophosphate (5 mmol/L) treatment"	downregulated	30846207
12022	Human	OIP5-AS1	lncRNA	radiation	colorectal cancer (CRC)	LoVo cells; SW480 cells	radiation treatment	LncRNA OIP5-AS1 and DYRK1A were downregulated in radio-resistant CRC cell lines	29773344
12023	Human	OIP5-AS1	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
12024	Human	OIP5-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"The expression of OIP5-AS1 was upregulated, while miR-98-5p was downregulated in ox-LDL-induced human umbilical vein endothelial cells (HUVECs)."	32990894
12025	Human	OIP5-AS1	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
12026	Human	OIP5-AS1	lncRNA	KSHV-encoded viral interferon regulatory factor 1 (vIRF1)	kaposi's sarcoma (KS)	endothelial cell	KSHV-encoded viral interferon regulatory factor 1 (vIRF1) treatment	upregulated	30699189
12027	Human	OIP5-AS1	lncRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models.	32037864
12028	Human	OIP5-AS1	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells; Saos-2 cells	cisplatin treatment	OIP5-AS1 positively modulated FOSL2 expression to decrease CDDP sensitivity in OS by sponging miR-377-3p.	32440152
12029	Human	OIP5-AS1	lncRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells; KHOS cells; U2OS cells	doxorubicin treatment	upregulated	30204936
12030	Human	OIP5-AS1	lncRNA	oxaliplatin	oxaliplatin (L-OHP) resistance	HCT116; W480 cells	oxaliplatin (L-OHP) treatment	upregulated	32308348
12031	Human	OIP5-AS1	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
12032	Human	OR13C9	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	GEnCs	high glucose (HG) treatment	LncOR13C9 could regulate ABCA1 by inhibiting the action of miR-23a-5p in the LXR pathway.	33192550
12033	Human	OTUD6B-AS1	lncRNA	arsenic trioxide (ATO)	bladder cancer	T24 cells	arsenic trioxide (As2O3) treatment	lncRNA OTUD6B-AS1 Exacerbates As 2 O 3-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2	32952848
12034	Human	linc-p21	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	LincRNA-p21 was significantly increased in septic model in vivo and in vitro.	32495896
12035	Human	linc-p21	lncRNA	oleanolic acid (OLA)	arteriosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oleanolic acid (OLA) treatment	upregulated	27900030
12036	Human	linc-p21	lncRNA	ginkgo biloba extract EGb 761	colorectal cancer (CRC)	HT29 cells; HCT116 cells	Ginkgo biloba extract EGb 761 treatment	lincRNA-p21 was upregulated in colon cancer cells after treatment with EGb 761.	30594943
12037	Human	linc-p21	lncRNA	X-rays	colorectal cancer (CRC)	CRC cell lines and tissue	X-ray treatment	upregulation	24573322
12038	Human	linc-p21	lncRNA	arsenite	lung cancer	A549 cells	arsenic (As) exposure	upregulated	32816178
12039	Human	linc-p21	lncRNA	hypoxia	glioblastoma multiforme (GBM)	SMMC7721 hepatoma;U251MG glioma cells	hypoxia treatment	upregulated	28689810
12040	Human	linc-p21	lncRNA	X-rays	glioblastoma multiforme (GBM)	"SMMC7721 hepatoma , U251MG glioma cells"	X-ray irradiation treatment	upregulated	28689810
12041	Human	linc-p21	lncRNA	TGF-¦Â1	liver fibrosis	Human LX-2 cell strain	TGF-¦Â1 treatment	downregulated	27610008
12042	Human	linc-p21	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30671473
12043	Human	linc-p21	lncRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	Human Jurkat T cell;THP-1 monocyte;Peripheral blood mononuclear cells (PBMCs)	methotrexate treatment	"MTX restored lincRNA-p21 expression, in vivo, in RA"	25077978
12044	Human	linc-p21	lncRNA	ultraviolet (UV) irradiation	skin cancer	keratinocytes	UV irradiation treatment	lincRNA-p21 is highly inducible by UVB	25789975
12045	Human	linc-p21	lncRNA	arsenite	toxicity of arsenic	A549 cells	arsenic (As) exposure	upregulated	32816178
12046	Human	PAAN	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	HEK293T cells	influenza A virus (IAV) infection	The level of lncRNA-PAAN increases upon infection of IAV.	29914164
12047	Human	PABPC	lncRNA	androgen deprivation therapies (ADT)	castration-resistant prostate cancer (CRPC)	patients with CRPC	androgen deprivation therapies (ADT) treatment	upregulated	25189356
12048	Human	PAGBC	lncRNA	hydrostatic pressure (HP)	osteogenesis	adipose-derived mesenchymal stem cells (AMSCs)	hydrostatic pressure (HP) treatment	lncRNA-PAGBC was upregulated during osteogenic differentiation of AMSCs.	32661199
12049	Human	PANDAR	lncRNA	arsenite	DNA damage	Peripheral blood lymphocytes	arsenic (As) exposure	arsenic exposure increased PANDAR expression and DNA damage among arsenic smelting plant laborers.	31885278
12050	Human	PANDAR	lncRNA	arsenite	DNA damage	peripheral blood lymphocytes	arsenic (As) exposure	Arsenic exposure increased PANDAR expression.	31885278
12051	Human	PANDAR	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin treatment	upregulated	30375398
12052	Human	PANDAR	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
12053	Human	PART1	lncRNA	gefitinib	esophageal squamous cell carcinoma (ESCC)	TE1 cells; KYSE-450 cells	gefitinib treatment	lncRNA PART1 was upregulated in gefitinib-resistant cells when compared to parental ESCC cells.	30049286
12054	Human	PART1	lncRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cell	lipopolysaccharide (LPS) treatment	"Expression levels of lncRNA PART1 in LPS-treated NP cells were found to be higher compared with those in the control groups.? Collectively, these results suggest that PART1 accelerates the progression of IDD."	33376513
12055	Human	PART-1	lncRNA	IL-1¦Â	osteoarthritis (OA)	The immortalized human chondrocytes cell lines C20/A4	IL-1¦Â treatment	downregulated	31571401
12056	Human	PAX8-AS1-N	lncRNA	baicalin (BAI)	breast cancer	MCF-7 cells; MDA-MB-231 cells	baicalin (BAI) treatment	upregulated	29693272
12057	Human	PCAT-1	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
12058	Human	PCAT-1	lncRNA	Paris forrestii (PCT3)	prostate cancer	LNCaP cells	Paris forrestii (PCT3) treatment	upregulated	31810132
12059	Human	PCAT6	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"Seven CRC cell lines: HCT116, HT©\29, SW620, SW480, DLD©\1, RKO, and LoVo, a normal colon fibroblast cell line CCD©\112CoN"	5-fluorouracil (5-FU) treatment	PCAT6 knockdown attenuated CRC chemoresistance to 5-FU through miR-204/HMGA2/PI3K; miR-204 inhibition could partially reverse the effect of PCAT6 knockdown.	30938104
12060	Human	PCAT6	lncRNA	sevoflurane (SEV)	lung cancer	H446 cells; H1975 cells	sevoflurane (Sev) treatment	downregulated	33987473
12061	Human	PCGEM1	lncRNA	montelukast sodium	asthma	serum	montelukast sodium treatment	PCGEM1 was highly expressed in cough-variant asthma (CVA) children with response to the treatment.	32520202
12062	Human	PCGEM1	lncRNA	hypoxia	gastric cancer (GC)	human gastric cancer cell lines SGC-7901 and BGC-823	hypoxia induce	upregulated	30690667
12063	Human	PCGEM1	lncRNA	doxorubicin (DOX)	prostate cancer	LNCaP cells	doxorubicin (DOX) treatment	PCGEM1 overexpression in LNCaP cell culture model results in the inhibition of apoptosis induced by doxorubicin (DOX)	16569192
12064	Human	PCK1-2:1	lncRNA	C-BaP-Cr-Pb-As	inflammation	Human Bronchial Epithelial Cells 16HBE	C-BaP-Cr-Pb-As treatment	downregulated	30913382
12065	Human	PCK1-2:1	lncRNA	particulate matter (PM2.5)	inflammation	Human Bronchial Epithelial Cells 16HBE	PM2.5-JN particles treatment	downregulated	30913382
12066	Human	PDIA3P1	lncRNA	hypoxia	glioblastoma multiforme (GBM)	U251 cells; U87MG cells; A172 cells	hypoxia treatment	Hypoxia-induced lncRNA PDIA3P1 promotes mesenchymal transition via sponging of miR-124-3p in glioma.	32127518
12067	Human	PDIA3P1	lncRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	SK-Hep-1 cells	doxorubicin (Dox) treatment	Dox induced PDIA3P1 expression in a dose-dependent manner.	31509261
12068	Human	PDIA3P1	lncRNA	etoposide (VP-16)	hepatocellular carcinoma (HCC)	SK-Hep-1 cells	etoposide treatment	Etoposide induced PDIA3P1 expression in a dose-dependent manner.	31509261
12069	Human	PGM5-AS1	lncRNA	p53	esophageal squamous cell carcinoma (ESCC)	ESCC cell lines	?p53 overexpression treatment	upregulated	31185143
12070	Human	PINT	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	Fibroblast-like synoviocytes (FLSs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-¦Á	32289665
12071	Human	PMS2L2	lncRNA	carboplatin (CBP)	endometrial cancer (EC)	plasma	carboplatin treatment	LncRNA PMS2L2 in endometrial cancer was downregulated during carboplatin treatment and regulates chemosensitivity.	31632150
12072	Human	PNRC2-1	lncRNA	TGF-¦Â1	nasopharyngeal carcinoma (NPC)	CNE1 nasopharyngeal carcinoma cells	TGF-¦Â1 treatment	"Sixty lncRNA genes were clustered in a heatmap, and mRNA expression of 14 dysregulated lncRNAs was consistent with RNA sequencing"	33752469
12073	Human	POIR	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B; SNU©\387; SNU©\449 cells	Sorafenib (SOR) treatment	lncRNA-POIR promotes EMT progression and suppresses SOR sensitivity simultaneously by sponging miR-182-5p	32951268
12074	Human	POTEF-AS1	lncRNA	5¦Á©\dihydrotestosterone (DHT)	prostate cancer	LNCaP and VCaP cells	DHT treatment	upregulated	28032932
12075	Human	POU5F1P4	lncRNA	cetuximab	metastatic colorectal cancer (mCRC)	NCI-H508 cells; tumor tissues	cetuximab treatment	POU5F1P4 was also downregulated in acquired cetuximab resistant cells.	29136952
12076	Human	PRINS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells; MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
12077	Human	PRINS	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
12078	Human	PRLB	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	CAOV3 cells; SKOV3 cells	paclitaxel (Tax) treatment	upregulated	33156701
12079	Human	PRNCR1	lncRNA	cisplatin (DDP)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	cisplatin treatment	downregulated	33647908
12080	Human	PRNCR1	lncRNA	lipopolysaccharide (LPS)	pulmonary vascular endothelial cell (PVEC) injury	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	PRNCR1 was upregulated in LPS-induced PVEC and aggravated its injury via modulating the miR-330-5p/TLR4 axis.	33049095
12081	Human	PSMB8-AS1	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
12082	Human	PSMG3-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
12083	Human	PSOR1C3	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
12084	Human	PTENP1	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	HNSCC cell lines	radiation treatment	upregulated	30441874
12085	Human	PTPRG-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
12086	Human	PTTG3P	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	downregulated	30619763
12087	Human	PVT	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	TPC-1 cells	TGF-¦Â1 treatment	upregulated	29967342
12088	Human	PVT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	"PVT1 expression was significantly increased, whereas miR-20a-5p expression was significantly decreased in sepsis model mice and LPS-induced HK-2 cells compared with sham mice and control HK-2 cells"	33576456
12089	Human	PVT1	lncRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells; PANC-1 cells	Gemcitabine treatment	"Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)."	30341811
12090	Human	PVT1	lncRNA	"corticosteroid, dexamethasone, and fetal calf serum (FCS)."	airway diseases	primary ASM cells	"corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment"	dysregulated	24886442
12091	Human	PVT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	aortic dissection (AD)	Human aortic smooth muscle cells (HASMCs)	platelet derived growth factor-BB (PDGF-BB) treatment	"In AD, PVT1 expression was upregulated, yet that of miR-27b-3p was downregulated"	33106979
12092	Human	PVT1	lncRNA	platelet activating factor (PAF)	asthma	Human small airway epithelial cells (HSAECs)	platelet activating factor (PAF) treatment	LncRNA PVT1 exacerbates the inflammation and cell-barrier injury during asthma by regulating miR-149	32830409
12093	Human	PVT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	human airway smooth muscle cells (ASMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	upregulated	33825599
12094	Human	PVT1	lncRNA	angiotensin II (Ang II)	atrial fibrosis	human atrial fibroblasts	angiotensin II (Ang II) treatment	"upregulated, PVT1 knockdown attenuated the Ang-II-induced mouse atrial fibrosis."	30894138
12095	Human	PVT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	?high glucose (HG) induce treatment	lncRNA?PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via miR-214-3p/MMP2 axis	31755246
12096	Human	PVT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	high glucose (HG) treatment	lncRNA PVT1 expression was upregulated in the HG-induced HLE B-3 cells	31755246
12097	Human	PVT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (MCs)	high glucose (HG) treatment	PVT1 was highly expressed in high glucose (HG)-induced mesangial cells (MCs).	32322310
12098	Human	PVT1	lncRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	upregulated	33049089
12099	Human	PVT1	lncRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	cardiomyocytes	high-glucose (HG) treatment	We observed that PVT1 and CASP10 were upregulated while miR-23a-3p was downregulated in high glucose-induced cardiomyocytes.	33049089
12100	Human	PVT1	lncRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	Human GC cell lines SGC-7901	5-fluorouracil (5-FU) treatment	PVT1 can regulate the expression of Bcl2 and enhance drug-resistance of gastric cancer to 5-Fu.	31205469
12101	Human	PVT1	lncRNA	cardamonin	gastric cancer (GC)	"The human gastric cancer cell lines (AGS, MGC-803, BGC-823)"	cardamonin treatment	downregulated	31028131
12102	Human	PVT1	lncRNA	cisplatin (DDP)	gastric cancer (GC)	AGS/DPP; NUGC-3/DPP cells	cisplatin treatment	PVT1 silencing attenuated the DPP resistance in GC by downregulating TBL1XR1 via sponging miR-3619-5p.	32407172
12103	Human	PVT1	lncRNA	paclitaxel (PTX)	glioblastoma multiforme (GBM)	SHG 44 cells	paclitaxel treatment	LncRNA PVT1 was overexpressed in glioma cells SHG-44 RE compared with parent SHG-44 cells	30347597
12104	Human	PVT1	lncRNA	IFN-¦Á	hepatocellular carcinoma (HCC)	SMMC-7721 cells	IFN-¦Á treatment	IFN-¦Á treatment further increases PVT1 expression in HCC cells by enhancing H3K4me3 modification on the promoter.	29715456
12105	Human	PVT1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	AC16 cells	hypoxia/reoxygenation (H/R) treatment	Knockdown of long non-coding RNA PVT1 protects human AC16 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis and autophagy by regulating miR-186/Beclin-1 axis.	32428696
12106	Human	PVT1	lncRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 and H1975 cells	Xiaoji decoction (XJD) treatment	downregulated	31707347
12107	Human	PVT1	lncRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 cells; H1975 cells	xiaoji decoction (XJD) treatment	XJD decreased lncRNA PVT1 expressions.	31707347
12108	Human	PVT1	lncRNA	high glucose (HG)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	high-glucose (HG) treatment	upregulated	31625803
12109	Human	PVT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	30126849
12110	Human	PVT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	31863917
12111	Human	PVT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	Human transformed chondrocytes C28/I2	IL-1¦Â treatment	upregulated	31863917
12112	Human	PVT1	lncRNA	pioglitazone	osteoarthritis (OA)	high-glucose (HG) treated human osteoarthritis (OA) chondrocytes	pioglitazone (PGZ) treatment	downregulated	31625803
12113	Human	PVT1	lncRNA	gemcitabine (GEM)	osteosarcoma (OS)	LncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells.	gemcitabine treatment	"LncRNA PVT1 overexpression promoted cell proliferation and exhibited the anti-apoptotic property in LncRNA PVT1-overexpressing MG63 cells treated with gemcitabine. While, LncRNA PVT1-depleted MG63/DOX cells treated with gemcitabine exhibited significant lower survival rate and high percentage of apoptosis."	30661902
12114	Human	PVT1	lncRNA	gemcitabine (GEM)	osteosarcoma (OS)	MG63 cells	gemcitabine treatment	lncRNA PVT1 level was upregulated about 3.3 folds in MG63/DOX cells compared to MG63 cells.	30661902
12115	Human	pvt1	lncRNA	carboplatin-docetaxel	ovarian cancer (OC)	3AO cells	carboplatin-docetaxel treatment	carboplatin-docetaxel-induced lncRNA PVT1 which may be a central downstream target of carboplatin plus docetaxel because expression of PVT1 positively correlates with anticancer action of carboplatin plus docetaxel.	26097562
12116	Human	PVT1	lncRNA	ketamine	ovarian cancer (OC)	"human ovarian cancer cell lines OVCAR-3, SKOV3, A2780, 3AO, COC1, OV-90"	ketamine treatment	"We then investigated the effect of ketamine on these lncRNAs, and found that ketamine regulated the expression of lncRNA PVT1."	33763107
12117	Human	PVT1	lncRNA	radiation	radioresistance	C666-1; 5¨C8F cells	radiation exposure treatment	"PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis"	33116864
12118	Human	PVT1	lncRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	PVT1 was upregulated in TGF-¦Â1-treated HK-2 cells	32921988
12119	Human	PVT1	lncRNA	lipopolysaccharide (LPS)	temporomandibular joint osteoarthritis	SW982 cells	lipopolysaccharide (LPS) treatment	upregulated	32171788
12120	Human	R-471B22	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
12121	Human	RAB11B-AS1	lncRNA	hypoxia	breast cancer	MDA-MB-231; MDA-MB-468; SUM159; MCF-7; T47D; BT474; ZR-75-1; HCC1954 cells	hypoxia treatment	upregulated	31900259
12122	Human	RAD51-AS1	lncRNA	Corylin	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	Corylin treatment	upregulated	29749376
12123	Human	RAD51-AS1	lncRNA	melatonin	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	Melatonin treatment	upregulated	30201872
12124	Human	RAET1K	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HCCLM3 cells; HepG2 cells	hypoxia treatment	upregulated	32152275
12125	Human	RALY-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
12126	Human	RAXIP-AS2	lncRNA	Paris forrestii (PCT3)	prostate cancer	LNCaP cells	Paris forrestii (PCT3) treatment	downregulated	31810132
12127	Human	RDH10-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
12128	Human	RGMB-AS1	lncRNA	quercetin	chronic high glucose-induced oxidative stress and mitochondrial dysfunction	HepG2 cells	quercetin treatment	Quercetin increased RGMB-AS1 ~35-fold after 6 h in high glucose-treated HepG2 cells	30266680
12129	Human	RHPN1-AS1	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	PC9 cells; HCC827 cells	gefitinib treatment	RHPN1-AS1 was observed to be downregulated in gefitinib resistant NSCLC cell lines.	30010468
12130	Human	RMEL3	lncRNA	PD98059	melanoma	"five melanoma cell lines: 4 harboring BRAFV600E mutation (WM1617, A375, Skmel19 and UACC-62) and one BRAF-wt/NRAS-mutant (WM1366)"	PD98059 treatment	downregulated	30457212
12131	Human	RMEL3	lncRNA	vemurafenib/PLX4032	melanoma	"five melanoma cell lines: 4 harboring BRAFV600E mutation (WM1617, A375, Skmel19 and UACC-62) and one BRAF-wt/NRAS-mutant (WM1366)"	Vemurafenib/PLX4032 treatment	downregulated	30457212
12132	Human	RMRP	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	RMRP was upregulated in sera from patients with AKI and in LPS-induced cells.	33635017
12133	Human	RMRP	lncRNA	silica	lung fibrosis	human bronchial epithelial (HBE) cells; BEAS2b cells	treatment treatment	RMRP is upregulated in human bronchial epithelial (HBE) and BEAS2b cells exposed to silica and activated by p53	33297121
12134	Human	RMRP	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neural ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30926681
12135	Human	RMST	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HBMEC;bEnd.3 cells	oxygen-glucose deprivation (OGD) treatment	RMST was upregulated in OGD-treated HBMEC and bEnd3 cells	33607153
12136	Human	RMST	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
12137	Human	RNCR3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	27253412
12138	Human	ROR	lncRNA	apatinib	breast cancer	breast cancer stem cells (BCSCs) were isolated from MDA-MB-231 cells	apatinib treatment	"Apatinib decreased the viability and colony numbers of BCSCs in a concentration-dependent manner, and it also reduced sphere numbers, suppressed migration, invasion and lncRNA ROR expression, and induced apoptosis of BCSCs."	33845750
12139	Human	ROR	lncRNA	homocysteine (Hcy)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	homocysteine (HCY) treatment	upregulated	31629816
12140	Human	ROR	lncRNA	denovirus type 36 (Ad36)	cell differentiation	human adipose-derived stem cells (hADSCs)	denovirus type 36 (Ad36) treatment	Ad36 may promote the differentiation of hADSCs into brown adipocytes by up-regulating LncRNA ROR.	33189825
12141	Human	ROR	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	TPC-1 cells	TGF-¦Â1 treatment	upregulated	29967342
12142	Human	ROR	lncRNA	adriamycin (ADR) and vincristine (VCR)	gastric cancer (GC)	human gastric cancer tissues	adriamycin (ADR) and vincristine (VCR) treatment	upregulated	32019330
12143	Human	ROR	lncRNA	radiation	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	radiation treatment	linc-ROR was significantly upregulated in radioresistant HCC cells	29559320
12144	Human	ROR	lncRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	HCC cells	TGF-¦Â treatment	upregulated	24918061
12145	Human	ROR	lncRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	human cardiomyocytes (HCM)	hypoxia/reoxygenation (H/R) treatment	upregulated	29694511
12146	Human	ROR	lncRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	HepG2 cells	arsenic trioxide treatment	Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression.	32017938
12147	Human	ROR	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	The human cardiac myocyte (HCM) cell line	HCMs were exposed to hypoxic conditions for 2?h followed by re-oxygenation (H/R) treatment.	lncRNA ROR were upregulated in both MIRI rat model and H/R treated HCMs.	31768721
12148	Human	ROR	lncRNA	polyphyllin I (PPI)	nasopharyngeal carcinoma (NPC)	"The normal nasopharyngeal cell line NP69 and NPC cell lines (CNE-1, CNE-2, HONE-1, and HNE-1)"	Polyphyllin I (PP I) treatment	A higher level of lncRNA regulator of reprogramming (ROR) expression was detected in NPC cell lines compared with normal nasopharyngeal cell line and PP I must significantly down-regulate the expression level of lncRNA ROR	30601067
12149	Human	ROR	lncRNA	CoCl2	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	HK-2 cells	CoCl2 treatment	CoCl2?decreased cell viability and increased apoptosis as well as increased the expression of ROR.	31164009
12150	Human	ROR	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	"OS tissues, MG63/DDP, and U2OS/DDP cells."	cisplatin treatment	upregulated	31539112
12151	Human	ROR	lncRNA	curcumin (Cur)	prostate cancer	HuPCaSCs	curcumin treatment	downregulated	28843521
12152	Human	ROR	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
12153	Human	RP11	lncRNA	artesunate (ART)	epithelial-mesenchymal transition (EMT)	SK-HEP1 and SM7721 hepatocellular carcinoma cell lines	artesunate (ART) treatment	RP11 depresses the inhibitory effect of ART on cancer cell EMT.	30335897
12154	Human	RP11	lncRNA	artesunate (ART)	epithelial-mesenchymal transition (EMT)	SK-HEP1 cells; SM7721 cells; HepG2 cells; Huh7 cells	artesunate (ART) treatment	downregulated	30335897
12155	Human	RP11	lncRNA	artesunate (ART)	hepatocellular carcinoma (HCC)	SK-HEP1 and SM7721 hepatocellular carcinoma cell lines	artesunate (ART) treatment	RP11 depresses the inhibitory effect of ART on cancer cell EMT.	30335897
12156	Human	RP11	lncRNA	radiation	radiation-induced lung injury (RILI)	HFL-1; WI-38	TGF-¦Â1 and radiation treatment	upregulated	33117089
12157	Human	RP11-1055B8.4	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
12158	Human	RP11-120K9.2	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
12159	Human	RP11-121G22.3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
12160	Human	RP11-132E11.2	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
12161	Human	RP11-134F2.2	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
12162	Human	RP11-135L22.1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	HO8910 cells	cisplatin treatment	RP11-135L22.1 level in chemotherapy-sensitive group was significantly lower than that of insensitive group.	29509240
12163	Human	RP11-154D6	lncRNA	steroids	osteonecrosis of femoral head (ONFH)	BMSCs of patients	steroid treatment	?the expression of lncRNA RP11-154D6 was significantly decreased in BMSCs of patients with ONFH	31190361
12164	Human	RP11-218C14.5	lncRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	ginsenoside Rh2 treatment	upregulated	30394104
12165	Human	RP11-23P13.6	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
12166	Human	RP11-2C24.6-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
12167	Human	RP11-347E10.1	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
12168	Human	RP11-354P11.2	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
12169	Human	RP11-354P17.15-001	lncRNA	T cell	acute kidney injury (AKI)	kidney biopsies and urine	T cell treatment	upregulated	26506996
12170	Human	RP11-381N20.2	lncRNA	paclitaxel (PTX)	cervical cancer (CC)	SiHa cells	paclitaxel treatment	The expression of RP11-381N202 was reduced with the increased paclitaxel dose	29863245
12171	Human	RP11-381O7.3	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
12172	Human	RP11-388M20.9	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	Cr(VI)-treated 16HBE cells	Cr(VI) exposure	"dysregulated. RP11-388M20.9 to regulate DNA damage by interacting with the target gene after Cr(VI) exposure, and was likely to be a potential biomarker of DNA damage in Cr(VI)-treated 16HBE cells."	30476843
12173	Human	RP11-388M20.9	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	16HBE cells	hexavalent chromium [Cr(VI)] treatment	upregulated	30476843
12174	Human	RP11-390F4.3	lncRNA	hypoxia	tumor metastasis	FADU cells; MCF7 cells; U2-OS cells	hypoxia treatment	upregulated	32353468
12175	Human	RP11-394l13.1	lncRNA	Vitamins A and D	fungal infection	human monocytes during C.albicans infections	Vitamins A and D treatment	dysregulated	28094339
12176	Human	RP11-395P13.3-001	lncRNA	T cell	acute kidney injury (AKI)	kidney biopsies and urine	T cell treatment	upregulated	26506996
12177	Human	RP1-140K8.5	lncRNA	homocysteine (Hcy)	homocysteine (HCY)-induced vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	homocysteine (HCY) treatment	upregulated	30093949
12178	Human	RP11-414H23.3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
12179	Human	RP11-415D17.3	lncRNA	homocysteine (Hcy)	homocysteine (HCY)-induced vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	homocysteine (HCY) treatment	downregulated	30093949
12180	Human	RP11-426C22.6	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
12181	Human	RP11-430L16.1	lncRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	ginsenoside Rh2 treatment	upregulated	30394104
12182	Human	RP11-442H21.2	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
12183	Human	RP11-445H22.4	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human cartilage ATDC5 cells	lipopolysaccharide (LPS) treatment	LPS significantly promoted RP11-445H22.4 expression.	29414810
12184	Human	RP11-474G23.2-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
12185	Human	RP11-48O20.4	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
12186	Human	RP11-497G19.1	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
12187	Human	RP11-504P24.3	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
12188	Human	RP11-504P24.3-005	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
12189	Human	RP11-543N12.1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
12190	Human	RP11-553L6.5	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
12191	Human	RP11-566E18.3-201	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
12192	Human	RP11-588G21.2	lncRNA	Vitamins A and D	fungal infection	human monocytes during C.albicans infections	Vitamins A and D treatment	dysregulated	28094339
12193	Human	RP11-642d21.1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
12194	Human	RP11-65M17.3	lncRNA	calycosin	breast cancer	MCF-7 and T47D cells	calycosin treatment	"Here we provide evidence for the presence of a positive feedback loop between ER¦Á and long noncoding RNA RP11-65M17.3 in both normal and cancer cells, and calycosin stimulated this feedback loop in ECs but decreased RP11-65M17.3 expression in BCCs."	33647882
12195	Human	RP11-670E13.5	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
12196	Human	RP11-670E13.6	lncRNA	ultraviolet (UV) irradiation	cell senescence	primary human dermal fibroblasts	UVB-irradiated treatment	RP11-670E136?may facilitate DNA damage repair by increasing ATM and ¦ÃH2AX levels	31444317
12197	Human	RP11-670E13.6	lncRNA	ultraviolet (UV) irradiation	skin photodamage	primary human dermal fibroblasts (HDFs)	UVB treatment	upregulated	29143326
12198	Human	RP11-798E3.2	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
12199	Human	RP1-179N16.3	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
12200	Human	RP1-179N16.3	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
12201	Human	RP11-820	lncRNA	H2O2	primary open angle glaucoma (POAG)	Human trabecular meshwork cells (HTMCs)	H2O2 induced oxidative stress	lncRNA-RP11-820 was significantly upregulated under oxidative stress in HTMCs.	31495061
12202	Human	RP11-838N2.4	lncRNA	erlotinib	non-small cell lung cancer (NSCLC)	HCC827 cells; HCC4006 cells	erlotinib treatment	lncRNA RP11-838N2.4 was upregulated in erlotinib-resistant cells when compared to normal NSCLC cells.	29845246
12203	Human	RP11-86H7.1	lncRNA	traffic-originated PM2.5 organic component (tPo)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	Traffic-related air pollution particulate matter 2.5 (TRAPM2.5) treatment	LncRNA RP11-86H71 promotes airway inflammation induced by TRAPM25 by acting as a ceRNA of miRNA-9-5p to regulate NFKB1 in HBECS	32665564
12204	Human	RP1-286D6	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
12205	Human	RP1-43E13	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
12206	Human	RP1-77H15.1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
12207	Human	RP-1-7H24.1	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
12208	Human	RP1-93H18.7	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
12209	Human	RP6-65G23.1	lncRNA	"M5 (IL-17A, TNF-¦Á, IL-1¦Á, IL-22, and Oncostatin-M)"	psoriasis	HaCaT cells; primary keratinocytes	"M5 (IL-17A, TNF-¦Á, IL-1¦Á, IL-22, and Oncostatin-M) treatment"	RP6-65G23.1 was significantly upregulated in M5-stimulated keratinocytes.	32065443
12210	Human	RPMS1	lncRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	NPC C666-1 cells	Epstein-Barr virus (EBV) infection	upregulated	31696060
12211	Human	Rpph1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	Both lncRNA Rpph1 and miR-122 were upregulated in AD mouse and Rpph1 activated Wnt/¦Â-catenin signaling to ameliorate amyloid-¦Â induced neuronal apoptosis in SK-N-SH cells via direct targeting miR-122.	31718352
12212	Human	RPPH1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	32336203
12213	Human	RPPH1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â25-35-induced ERS and apoptosis in SH-SY5Y cells can be attenuated by lncRNA RPPH1 through regulating miR-326/PKM2 axis.	32336203
12214	Human	Rpph1	lncRNA	amyloid-¦Â (A¦Â)	neuronal cell injury	SK-N-SH cells	amyloid-¦Â (A¦Â) treatment	LncRNA Rpph1 protects amyloid-¦Â induced neuronal injury in SK-N-SH cells via miR-122/Wnt1 axis	31718352
12215	Human	RPS27L-1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
12216	Human	RPSAP52	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose treatment	"High glucose treatment led to downregulated RPSAP52 and Timp3, but upregulated miR-365 in RPE cells."	33178344
12217	Human	SAF	lncRNA	human immunodeficiency virus (HIV)-1	apoptosis	human monocyte-derived macrophages (MDM)	Human immunodeficiency virus (HIV)-1 infection	upregulated	30918127
12218	Human	SAF	lncRNA	oligo-fucoidan	hepatocellular carcinoma (HCC)	HepG2 cells	oligo-fucoidan treatment	apoptosis and cell cycle pathways could also contribute to the induction of lncRNA-Saf and lncRNA-p21 by oligo-fucoidan.	30632031
12219	Human	SAMD12-AS1	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	31406141
12220	Human	SAMD12-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
12221	Human	SARCC	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	Sarcoma Osteogenic-2 (Saos-2) cells	cisplatin treatment	lncRNA-SARCC was significantly downregulated in the cisplatin-resistant OS tissues.	32508321
12222	Human	SARCC	lncRNA	sunitinib (SU)	renal cell carcinoma (RCC)	renal cell carcinoma (RCC)	treat with sunitinib treatment	upregulated	28644440
12223	Human	SBF2-AS1	lncRNA	Vitamins A and D	bacterial infection	human monocytes during A.fumigatus infections	Vitamins A and D treatment	dysregulated	28094339
12224	Human	SBF2-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"Five human GBM cell lines (U87, LN229, A172, T98, U251)"	temozolomide (TMZ) treatment	"SBF2-AS1 was upregulated in TMZ-resistant GBM cells and tissues, and overexpression of SBF2-AS1 led to the promotion of TMZ resistance, whereas its inhibition sensitized resistant GBM cells to TMZ"	30992025
12225	Human	SBF2-AS1	lncRNA	radiation	non-small cell lung cancer (NSCLC)	NCI-H1299 ; NCI-H1299R cells	radiation treatment	upregulated	31928130
12226	Human	SBF2-AS1	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	"Pancreatic cancer cell lines including AsPC-1, HPAC, BxPC-3, and PANC-1"	gemcitabine treatment	knock-down of SBF2-AS1 inhibits the expression of TWF1 by competitively binding with miR-142-3p to induce gemcitabine resistance in pancreatic cancer.	31619579
12227	Human	SBF2-AS1	lncRNA	IFN-¦Ã and lipopolysaccharide (LPS)	pancreatic cancer (PC)	THP-1 cells	lipopolysaccharide; interferon-¦Ã treatment	"lncRNA SBF2-AS1 in M2 macrophage-derived exosomes increases miR-122-5p expression to restrain XIAP expression, which further inhibits PC progression."	32301277
12228	Human	SCA8	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
12229	Human	SCAL1	lncRNA	high glucose (HG)	diabetic lung disease	Normal human lung cell line BEAS-2B	high (30 mM) glucose treatment	upregulated	31410144
12230	Human	SCAL1	lncRNA	cigarette smoke (CS)	lung cancer	A549;CL1¨C0; CL1¨C5; H1975; HCC-827; NCI-H292;PC9 cells;Normal human primary bronchial epithelial (NHBE) cells	cigarette smoke (CS) treatment	a novel long noncoding RNA (lncRNA) that is induced by cigarette smoke extract (CSE) bothin vitroandin vivoand is elevated in numerous lung cancer cell lines.	23672216
12231	Human	SCAMP1	lncRNA	H2O2	renal cell carcinoma (RCC)	ACHN and Caki-1 cells	H2O2 treatment	upregulated	31550675
12232	Human	SCARNA2	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
12233	Human	SCRG1	lncRNA	TGF-¦Â1	liver fibrosis	LX2 cells	TGF-¦Â1 treatment	upregulated	30226813
12234	Human	SDHAP1	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 and Hey-8	Paclitaxel (PTX) treatment	SDHAP1 was upregulated in PTX-resistant SKOV3 and Hey-8 ovarian cancer cell lines while the level of miR-4465 was downregulated	32211849
12235	Human	SDHAP2	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
12236	Human	SENCR	lncRNA	rapamycin	vascular endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin (RPM) treatment	RPM treatment downregulates the endogenous expression of lncRNAs MALAT1 and SENCR in HUVECs	29845247
12237	Human	SGCG-5:4	lncRNA	melanin	melanoma	Primary melanocytes	melanin treatment	upregulated	26596215
12238	Human	SIAH1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	29217406
12239	Human	SIKIAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	32342116
12240	Human	SLC7A11-AS1	lncRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	BxPC-3 cells	gemcitabine treatment	upregulated	32036249
12241	Human	SMILR	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	U937 cells	oxidized low-density lipoprotein (ox-LDL) treatment	SMILR was upregulated in ox-LDL-induced AS cell models.	32367412
12242	Human	SMILR	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (hPASMCs)	hypoxia treatment	SMILR is upregulated in vitro PAH model.	32559140
12243	Human	snaR	lncRNA	human papilloma virus (HPV)	human papillomaviruses (HPV)-negative cervical squamous cell carcinoma (CSCC)	plasma	human papillomaviruses (HPV) infection	lncRNA snaR was downregulated in HPV-negative CSCC patients comparing with healthy controls.	30249756
12244	Human	SNHG1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y and human primary neuron (HPN) cells	amyloid-¦Â (A¦Â) 25-35 treatment	"A¦Â25-35 inhibited cell viability, induced cell apoptosis and increased the expression of SNHG1 in SH-SY5Y and human primary neuron (HPN) cells."	31447119
12245	Human	SNHG1	lncRNA	resveratrol	Alzheimer's disease (AD)	SK-N-SH cells; CHP-212 cells	resveratrol (Res) treatment	SNHG1 expression was positively regulated by A¦Â and negatively regulated by resveratrol	32741808
12246	Human	SNHG1	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
12247	Human	SNHG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32536864
12248	Human	SNHG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA SNHG1 regulates vascular endothelial cell proliferation and angiogenesis via miR-196a	32297149
12249	Human	SNHG1	lncRNA	H2O2	cardiomyocyte apoptosis	human cardiomyocytes (HCMs)	Hydrogen peroxide (H2O2) treatment	Hydrogen peroxide (H2O2) treatment suppressed SNHG1 expression in HCMs.	30355909
12250	Human	SNHG1	lncRNA	doxorubicin (DOX)	cardiotoxicity	human AC16 cardiomyocytes	Doxorubicin (DOX)? treatment	"DOX treatment also reduced the expression of SNHG1 in AC16 cells, and overexpression of SNHG1 alleviated the increased apoptosis in DOX-treated AC16 cells."	31300525
12251	Human	SNHG1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA SNHG1 regulates OGD/R-induced cell death through serving as a ceRNA for miR-424 in SH-SY5Y cells	31900069
12252	Human	SNHG1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Human HCC HepG2 and Huh7 cells, and SR-HCC cells"	sorafenib treatment	upregulated	31053148
12253	Human	SNHG1	lncRNA	hypoxia	hypoxic brain injury	SH-SY5Y cells	hypoxia treatment	"LncRNA SNHG1-modulated miR-140-5p inhibition regulates Bcl-XL expression, thereby reducing cell apoptosis and recovering cell viability of SH-SY5Y cells."	32186226
12254	Human	SNHG1	lncRNA	oxygen glucose deprivation (OGD)	hypoxic brain injury	SH-SY5Y cells	Oxygen glucose deprivation (OGD) treatment	Oxygen glucose deprivation (OGD) treatment inhibited SNHG1 and Bcl-XL expression and enhanced miR-140-5p expression	32186226
12255	Human	SNHG1	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HCMEC/D3 cells	Oxygen-glucose deprivation (OGD) treatment	LncRNA SNHG1 depressed apoptosis and inflammation of IS cell model via inhibiting miR-376a and upregulating CBS/H2S signal	32532171
12256	Human	SNHG1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (H/R) induce	upregulated	31792649
12257	Human	SNHG1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC cell lines (A549 and H1299)	cisplatin treatment	upregulated	31288529
12258	Human	SNHG1	lncRNA	IL-1¦Â	osteoarthritis (OA)	human articular chondrocytes-knee cells	IL-1¦Â treatment	SNHG1 alleviates the inflammation of IL-1¦Â-induced OA through the activation of miR-16-5p-mediated p38MAPK and NF-¦ÊB signaling pathway.	31383786
12259	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated lncRNA SNHG1 promotes MPP+ -induced cytotoxicity and ROS production through the miR-15b-5p/GSK3¦Â axis in human dopaminergic SH-SY5Y cells	30302821
12260	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	SNHG1 aggravates MPP+-induced cellular toxicity in SH-SY5Y cells by regulating PTEN/AKT/mTOR signaling via sponging miR-153-3p.	31907031
12261	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	29217406
12262	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30031125
12263	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	Upregulation of SNHG1 enhanced MPP + -induced cellular toxicity in SH-SY5Y cells.	30302821
12264	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells; SK-N- AS cessl	1-methyl-4-phenylpyridinium (MPP+) treatment	"We discovered that SNHG1 was significantly elevated, while miR-181a-5p was decreased in N-methyl-4-phenylpyridinium (MPP+)-treated neuroblastoma cells in dose-dependent manners."	33389428
12265	Human	SNHG12	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32339345
12266	Human	SNHG12	lncRNA	radiation	cervical cancer (CC)	SiHa cells; Hela cells	radiation treatment	LncRNA SNHG12 promoted CDK1 expression to regulate the sensitivity of CC cells to radiation through sponging miR-148a	33292254
12267	Human	SNHG12	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	Pri GBM; Rec GBM; N3S; N3T3rd; U251; U251T3rd; glioblastoma (GBM) tissues	temozolomide (TMZ) treatment	SNHG12 was upregulated in TMZ-resistant cells and tissues.	32039732
12268	Human	SNHG12	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	vascular endothelial dysfunction	SH-SY5Y cell	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31056262
12269	Human	SNHG12	lncRNA	angiotensin II (Ang II)	vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	"As a result, LncRNA SNHG12 was downregulated in aortic primary ECs isolated from Ang II-induced hypertensive mice and 1 kidney/deoxycorticosterone acetate/salt-induced hypertensive mice."	33464650
12270	Human	SNHG14	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	"SNHG14 was boosted in renal tissues of I/R-stimulated rats and H/R-induced HK-2 cells, while miR-124-3p was diminished in H/R-stimulated HK-2 cells."	33490282
12271	Human	SNHG14	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	Increased expression of SNHG14 was observed in LPS-induced HK-2 cells.	33505213
12272	Human	SNHG14	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	upregulated	33856026
12273	Human	SNHG14	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	"LPS induced A549 cells apoptosis and inflammation, wherein SNHG14 was upregulated and miR-124-3p was downregulated."	33652176
12274	Human	SNHG14	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	he current study revealed that SNHG14 level was high in the serum of AS patients and oxidized low-density lipoprotein (ox-LDL)-induced AS cell lines.	32735135
12275	Human	SNHG14	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs); human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	SNHG14 level was high in oxidized low-density lipoprotein (ox-LDL)-induced AS cell lines.	32876518
12276	Human	SNHG14	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	lncRNA-small nucleolar RNA host gene 14 (SNHG14) was upregulated in trastuzumab-resistant cells when compared with parental breast cancer cells	30015837
12277	Human	SNHG14	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	SNHG14 was upregulated in resistant cell lines in contrast to their parental cell lines	30063126
12278	Human	SNHG14	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	33071725
12279	Human	SNHG15	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	33636173
12280	Human	SNHG15	lncRNA	hypoxia	cardiomyocyte apoptosis	AC16 cells	hypoxia treatment	upregulated	32970504
12281	Human	SNHG15	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG15 knockdown protected against cerebral I/R injury via targeting miR-183-5p/FOXO1 axis	33194027
12282	Human	SNHG15	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	The results showed that SNHG15 was remarkably upregulated in pediatric DN tissues and HG-induced HGMCs.	33506255
12283	Human	SNHG15	lncRNA	palbociclib	glioblastoma multiforme (GBM)	"HMC3 cells, temozolomide-resistant (TMZ-R) cells"	palbociclib treatment	SNHG15-silenced TMZ-R cells became significantly sensitive towards TMZ treatment and less capable of promoting M2-phenotype in the HMC3 microglial cells	31462285
12284	Human	SNHG15	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	Long non-coding RNA SNHG15 is a competing endogenous RNA of miR-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression	32247266
12285	Human	SNHG16	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophage-derived foam cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31646601
12286	Human	SNHG16	lncRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (HASMC)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	31441592
12287	Human	SNHG16	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGD/R itreatment downregulated LncRNA SNHG16 in SH-SY5Y cells	32407850
12288	Human	SNHG16	lncRNA	H2O2	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HMRECs)	H2O2 treatment	We confirmed that over-expression of SNGH16 attenuated H2O2-induced angiogenesis by HMRECs.	33530902
12289	Human	SNHG16	lncRNA	ropivacaine	glioblastoma multiforme (GBM)	T98G cells; LN229 cells	ropivacaine treatment	ropivacaine impeded SNHG16 expression in glioma cells.	33817285
12290	Human	SNHG16	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2/SOR cell line	sorafenib treatment	"SNHG16 is upregulated in HepG2/SOR cells, whereas knockdown of SNHG16 increases the sensitivity of HepG2/SOR cells to sorafenib in vitro and in vivo"	30655679
12291	Human	SNHG16	lncRNA	ketamine	ketamine-induced neurotoxicity	human embryonic stem cell (hESC)	ketamine treatment	"48-h in vitro treatment of ketamine induced significant neurotoxicity, and downregulated SNHG16 among hESC-derived neurons."	30171995
12292	Human	SNHG16	lncRNA	oxidized low density lipoprotein (ox-LDL)	myocardial infarction (MI)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31355606
12293	Human	SNHG16	lncRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS cells; SK-N-SH cells	cisplatin treatment	upregulated	32365562
12294	Human	SNHG16	lncRNA	liposomal bupivacaine (BUP)	neurotoxicity	SH-SY5Y cells	liposomal bupivacaine (BUP) treatment	BUP induced dose-dependent cell death and SNHG16 downregulated in SH-SY5Y cells.	32335807
12295	Human	SNHG16	lncRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	lncRNA SNHG16 knockdown significantly limited the progression of OA by sponging miR-373-3p in vitro	33300061
12296	Human	SNHG16	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	"osteosarcoma cell lines (SAOS2, U2OS)"	cisplatin (DPP) treatment	SNHG16 enhanced the cisplatin resistance in osteosarcoma cell lines.	31427084
12297	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	human lung fibroblasts cell WI-38	lipopolysaccharide (LPS) treatment	SNHG16 regulated LPS-induced inflammation injury in WI-38 cells through competitively binding miR-146a-5p with CCL5 further mediating JNK and NF-¦ÊB pathways	31071307
12298	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	LPS treatment	"SNHG16 impeded cell viability and promoted apoptosis, inflammatory injury by targeting IGF2 mediated by miR-370-3p in LPS-induced A549 cells."	31841752
12299	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	"SNHG16 and sushi domain containing 2 (SUSD2) were upregulated, and miRNA (miR)-141-3p was downregulated in the serum of acute pneumonia patients and lipopolysaccharide (LPS)-challenged human lung fibroblasts WI-38."	33836533
12300	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	lipopolysaccharides (LPS) treatment	upregulated	31841752
12301	Human	SNHG22	lncRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	cisplatin treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel.	31581131
12302	Human	SNHG22	lncRNA	paclitaxel (PTX)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	paclitaxel treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel	31581131
12303	Human	SNHG29	lncRNA	¦Â-glycerophosphate (¦Â-GP)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	¦Â-glycerophosphate (¦Â-GP) treatment	downregulated	32818704
12304	Human	SNHG3	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Seven HCC cell lines PLC/PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC©\7721, and HCCLM3"	sorafenib treatment	"forced expression of SNHG3 promoted cell invasion, epithelial-mesenchymal transition (EMT), and sorafenib resistance in HCC"	30132868
12305	Human	SNHG4	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	We found that SNHG4 was downregulated in DR.	33822671
12306	Human	SNHG5	lncRNA	yin yang 1 (YY1)	acute myeloid leukemia (AML)	"Human AML cells U937, KG-1, THP-1, and HL-60"	yin yang 1 (YY1) treatment	upregulated	33318617
12307	Human	SNHG5	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	AML cell lines	adriamycin (ADR) treatment	upregulated	31884339
12308	Human	SNHG5	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells	lipopolysaccharide (LPS) treatment	"SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice."	33170429
12309	Human	SNHG5	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
12310	Human	SNHG5	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	LncRNA SNHG5 regulates cell apoptosis and inflammation by miR-132/PTEN axis in COPD	32145584
12311	Human	SNHG5	lncRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	upregulated	32269710
12312	Human	SNHG5	lncRNA	high glucose (HG) and high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	NCM460 cells; DLD-1 cells	high-glucose and high-fat treatment	upregulated	32242546
12313	Human	SNHG5	lncRNA	TGF-¦Â1	intrauterine adhesion (IUA)	primary human endometrial stromal cells (HESCs)	TGF-¦Â1 treatment	upregulated	33176855
12314	Human	SNHG5	lncRNA	gefitinib	lung adenocarcinoma (LUAD)	PC9 cells; A549 cells	gefitinib treatment	downregulated	29592872
12315	Human	SNHG5	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-0¦Â treatment	LncRNA SNHG5 promotes chondrocyte proliferation and inhibits apoptosis in osteoarthritis by regulating miR-10a-5p/H3F3B axis	32967481
12316	Human	SNHG6	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	The levels of SNHG6 was increased in oxidized low-density lipoprotein (ox-LDL)-treated HUVECs.	31921409
12317	Human	SNHG6	lncRNA	propofol (PPF)	heart failure (HF)	Human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs)	Propofol (PPF) treatment	"PPF induced significant cytotoxicity, as well as SNHG6 upregulation in HiPSC-CMs"	32968636
12318	Human	SNHG6	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	RKO cells	5-fluorouracil (5-FU) treatment	SNHG6 enhanced CRC cell resistance to 5-fluorouracil (5-FU).	31516391
12319	Human	SNHG7	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA SNHG7 was remarkedly upregulated in ox-LDL exposed HUVECs.	32603818
12320	Human	SNHG7	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high glucose (HG) treatment	SNHG7 was decreased in hRECs under HG stimuli.	31056258
12321	Human	SNHG7	lncRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS;  LAN-6 cells	cisplatin (DPP) treatment	LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis.	32329857
12322	Human	SNHG7	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	"SNHG7 sponged miR-34a-5p to affect cell proliferation, apoptosis and autophagy through targeting SYVN1"	32066502
12323	Human	SNHG7	lncRNA	IL-1¦Â	osteoarthritis (OA)	human primary chondrocytes	IL-1¦Â treatment	"The results showed that SNHG7 was distinctly downregulated, while miR-214-5p was significantly upregulated in OA patients and primary chondrocytes treated with IL-1¦Â."	33296783
12324	Human	SNHG7	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary chondrocytes	IL-1¦Â treatment	SNHG7 prevents IL-1¦Â induced OA by inhibiting NLRP3 inflammasome and apoptosis through miR-214-5p/PPARGC1B axis.	33296783
12325	Human	SNHG7-003	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	"SNHG7-003 may inhibit the proliferation, migration and invasion of VSMCs via the miR-1306-5p/SIRT7 signaling pathway."	33416100
12326	Human	SNHG8	lncRNA	human papilloma virus (HPV)	cervical cancer (CC)	HeLa cells; SiHa cells; MS751 cells; CaSki cells	human papillomaviruses (HPVs) treatment	SNHG8 was upregulated in HPV-induced CC cells was found compared with HPV-negative CC cells.	31961005
12327	Human	SOX21-AS1	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y;SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	SOX21-AS1 silencing could attenuate A¦Â1-42-induced neuronal damage by sponging miR-107	32124921
12328	Human	SOX2OT	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
12329	Human	SOX2OT	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes cells (HPCs)	high glucose (HG) treatment	SOX2OT overexpression alleviates the HG-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis.	31301307
12330	Human	SOX2OT	lncRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	all-trans retinoic acid (ATRA) treatment	downregulated	31186810
12331	Human	SOX2OT	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
12332	Human	SOX2OT	lncRNA	H2O2	thoracic aortic aneurysm (TAA)	mouse aortic smooth muscle cells (SMCs)	H2O2 treatment	long noncoding RNA (lncRNA) Sox2ot modulates the progression of TAA by regulating miR-330-5p/Myh11 axis.	32578852
12333	Human	SOX2OT	lncRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte primary cells (HCM)	hypoxia treatment	lncRNA SOX2-OT expression was upregulated in hypoxic HCMs.	32528555
12334	Human	SOX2OT variant 7	lncRNA	epigallocatechin-3-gallate (EGCG)	osteosarcoma (OS)	U2OS and SaoS2 cell lines	epigallocatechin-3-gallate (EGCG) treatment	downregulated	29475441
12335	Human	SPAG5-AS1	lncRNA	high glucose (HG)	podocyte injury	human podocytes (HPCs)	high glucose (HG) treatment	upregulated	31957155
12336	Human	SPRY4-IT1	lncRNA	ketamine	neurotoxicity	human embryonic stem cells (hESCs)	ketamine treatment	"Ketamine-induced dose-dependent apoptosis, neurite degeneration, and SPRY4-IT1 upregulation in hESC-induced neurons."	33827085
12337	Human	SRA	lncRNA	resveratrol	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	resveratrol (RSV) treatment	RSV suppressed the production of SRA	30272285
12338	Human	SRA1	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
12339	Human	SRAs	lncRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	CD4+ MOLT4 Tregs	high glucose (HG) treatment	upregulated	33572095
12340	Human	SRLR	lncRNA	sorafenib (SOR)	renal cell carcinoma (RCC)	RCC cells	sorafenib treatment	upregulated	27841868
12341	Human	STAiRs15	lncRNA	IL-6	multiple myeloma (MM)	human multiple myeloma cell lines INA-6 and JK-6E	interleukin-6 (IL-6) treatment	upregulated	28801664
12342	Human	STAiRs18	lncRNA	IL-6	multiple myeloma (MM)	human multiple myeloma cell lines INA-6;JK-6E	interleukin-6 (IL-6) treatment	upregulated	28801664
12343	Human	T199678	lncRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	SH-SY5Y cells	¦Á-synuclein (¦Á-Syn) treatment	Xogenous ¦Á-Syn induced the downregulated of lncRNA-T199678 in SH-SY5Y cells	33328976
12344	Human	TALC	lncRNA	temozolomide (TMZ)	temozolomide (TMZ) resistance in glioblastoma (GBM)	"LN229, U251, 551 W, and HG7 cells"	temozolomide (TMZ) treatment	Lnc-TALC is highly expressed in TMZ-resistant GBM cells	31053733
12345	Human	TapSAKI	lncRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	TapSAKI was upregulated and miR-205 was downregulated in LPS-induced HK-2 cells.	33869780
12346	Human	TapSAKI	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	"TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway."	30666657
12347	Human	TATDN1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC tissues and cell lines	cisplatin treatment	"?TATDN1 and TRIM66 was significantly upregulated while miR-451 was downregulated in NSCLC tissues and cell lines, especially in DDP-resistant tumor tissues and cells."	30481109
12348	Human	TATDN1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H157 cells	cisplatin treatment	upregulated	30481109
12349	Human	TBILA	lncRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	A549 cells; H226 cells	TGF-¦Â1 treatment	lncRNA TBILA is upregulated in response to TGF-¦Â1 treatment	29908210
12350	Human	TBULC	lncRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	NSCLC cell lines (A549 and H226)	TGF¦Â treatment	upregulated	31921623
12351	Human	TBX2-AS1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	downregulated	31925944
12352	Human	TC0101441	lncRNA	estrogen (ES)	epithelial ovarian cancer (EOC)	E2 receptor (ER) ¦Á-positive EOC cells	Estrogen (E2) treatment	dysregulated	24481591
12353	Human	TC0101441	lncRNA	oestrogen (E2)	epithelial ovarian cancer (EOC)	The human EOC cell lines SKOV3 and A2780	oestrogen(E2) treatment	E2 modulates lncRNA expression in ER?-positive EOC cells and that this regulation is sometimes ER¦Á-mediate	24380700
12354	Human	TC0101441	lncRNA	oestrogen (E2)	ovarian cancer (OC)	The human EOC cell lines SKOV3 and A2780	the cells were ed for 24 h with 10-8 M E2 treatment	dysregulated	24380700
12355	Human	TC0101686	lncRNA	estrogen (ES)	epithelial ovarian cancer (EOC)	E2 receptor (ER) ¦Á-positive EOC cells	Estrogen (E2) treatment	dysregulated	24481591
12356	Human	TC0101686	lncRNA	oestrogen (E2)	ovarian cancer (OC)	The human EOC cell lines SKOV3 and A2780	the cells were ed for 24 h with 10-8 M E2 treatment	dysregulated	24380700
12357	Human	TCF7	lncRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	airway smooth muscle cells (ASMCs)	platelet-derived growth factor (PDGF)-BB treatment	PDGF-BB treated ASMCs exhibited elevated levels of lncTCF7	30528236
12358	Human	TCONS_00001266	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
12359	Human	TCONS_00006019	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	sorafenib treatment	upregulated	32149026
12360	Human	TCONS_00015544	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
12361	Human	TCONS_00022632-XLOC_010933	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	bone marrow (BM)	all-trans retinoic acid (ATRA) treatment	downregulated	29956795
12362	Human	TCONS_00024652	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	acute coronary syndrome (ACS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	TCONS_00024652 is highly expressed in TNF-¦Á-induced HUVECs	30233677
12363	Human	TCONS_00284048	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	sorafenib treatment	upregulated	32149026
12364	Human	TCONS-00010875	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	upregulated	28487500
12365	Human	TCONS-00018436	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	downregulated	28487500
12366	Human	TCTN2	lncRNA	oxygen glucose deprivation (OGD)	spinal cord injury (SCI)	human SY-SH-5Y cells	oxygen-glucose deprivation treatment	"TCTN2 was downregulated in the spinal cord tissues of a rat model of SCI and in oxygen-glucose deprivation-induced hypoxic SY-SH-5Y cells, while microRNA-216b (miR-216b) was upregulated"	31050183
12367	Human	TDRG1	lncRNA	hypoxia	cervical cancer (CC)	HeLa and C-33A cells	hypoxia induce	We found Lnc-TDRG1 was highly expressed in CC tissues and cells and it was upregulated in response to hypoxia.	33394293
12368	Human	TDRG1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRECs)	high glucose (HG) treatment	upregulated	32082175
12369	Human	TERRA	lncRNA	H2O2	oxidative stress	HEK-293T cells	H2O2 treatment	TERRA levels significantly increased upon incubation of cells with 500 ¦ÌM H2O2.	31917282
12370	Human	TERRA	lncRNA	compound C	subtelomeric DNA methylation	HeLa and HCT116 cells	AMPK inhibitor (compound C) treatment	upregulated	31181625
12371	Human	TERRAs	lncRNA	etoposide (VP-16)	DNA damage	HeLa cells	etoposide treatment	upregulated	31756221
12372	Human	TFDP2-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
12373	Human	TGFB2-AS1	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	Human immortalized male keratinocytes (HaCaT)	TGF-¦Â treatment	upregulated	31533040
12374	Human	TGF¦Â2-AS1	lncRNA	H2O2	open-angle glaucoma (OAG)	human trabecular meshwork cells (HTMCs)	H2O2 treatment	lnc-TGF¦Â2-AS1 promotes ECM production via TGF-¦Â2 in HTMC.	32423825
12375	Human	TGS-1	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	whole blood samples	Mycobacterium tuberculosis (MTB) infection	downregulated	31028876
12376	Human	THAP9-AS1	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"The human GC cell lines AGS, BGC-823, HGC-27, MGC803 and SGC-7901"	H. pylori infection	upregulated	32021238
12377	Human	THOR	lncRNA	triptolide (TPL)	nasopharyngeal carcinoma (NPC)	HONE-1 cells	triptolide (TPL) treatment	"THOR (¡°Lnc-THOR¡±), was significantly decreased in TN-treated cells"	30503558
12378	Human	THOR	lncRNA	triptolide (TPL)	nasopharyngeal carcinoma (NPC)	"The established human NPC cell lines, HONE-1, CNE1, CNE-2, 5¨C8F, 6¨C10B and primary culture of human NPC cells"	triptolide (TPL) treatment	downregulated	30503558
12379	Human	THRIL	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	THRIL was upregulated in both?in vitro?and?in vivo?models of brain ischemia-reperfusion injury	33675584
12380	Human	THRIL	lncRNA	lipopolysaccharide (LPS)	sepsis	human bronchial epithelial cells (HBEpCs)	lipopolysaccharide (LPS) treatment	"THRIL is upregulated in sepsis and may sponge miR-19a to upregulate TNF-¦Á, thereby promoting lung cell apoptosis."	32944003
12381	Human	THRIL	lncRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	HK2 cells	lipopolysaccharide (LPS) treatment	LncRNA THRIL was highly expressed in the LPS-stimulated cells.	30414207
12382	Human	THUMPD3-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
12383	Human	TINCR	lncRNA	trastuzumab	breast cancer	SKBR-3-TR and BT474-TR cell lines	Trastuzumab treatment	upregulated	30621694
12384	Human	TINCR	lncRNA	high glucose (HG)	cardiac hypertrophy	human cardiomyocyte cells	high glucose (HG) treatment	upregulated	30453794
12385	Human	TINCR	lncRNA	X-rays	colorectal cancer (CRC)	radioresistant CRC cell line (SW620R)	2 Gy of X-ray irradiation (120 kV and 3.5 mA for 4 min with a 0.5-mm A1 filter) treatment	upregulated	31540772
12386	Human	TINCR	lncRNA	photodynamic therapy using 5©\aminolevulinic acid (ALA-PDT)	cutaneous squamous cell carcinoma (CSCC)	CSCC cell lines A431	ALA©\PDT treatment	"ALA-PDT treatment at 32?mmol/L for 120?minutes significantly promoted TINCR expression in CSCC A431 cells, and TINCR promoted ALA-PDT-induced apoptosis and cell autophagy"	30993776
12387	Human	TLINC	lncRNA	TGF-¦Â	intrahepatic cholangiocarcinoma (iCCA)	HuCCT1 cells; Huh28 cells	TGF¦Â treatment	upregulated	29916183
12388	Human	TM1P3	lncRNA	IL-1	osteoarthritis (OA)	primary cultured chondrocytes	?IL-1 treatment	The lncRNA-TM1P3 significantly upregulated in patients with OA	30887601
12389	Human	TMPO-AS1	lncRNA	propofol (PPF)	esophageal cancer (EC)	EC109; KYSE70 cells	Propofol treatment	"Propofol suppresses hypoxia-induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO-AS1/miR-498 axis"	32643321
12390	Human	TNK2-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	cell proliferation and migration	human aortic smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31468685
12391	Human	TOCN_00011820	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	downregulated	32470693
12392	Human	tp53inp1	lncRNA	polyunsaturated fatty acids (PUFAs)	glioblastoma multiforme (GBM)	Glioblastoma cells (U373; GBM2;GBM5)	polyunsaturated fatty acids (PUFAs) treatment	downregulated	21961478
12393	Human	TP53TG1	lncRNA	glucose deprivation (GD)	cell proliferation and migration	U87 and LN18 cells	glucose deprivation treatment	upregulated	28569381
12394	Human	TP53TG1	lncRNA	ultraviolet (UV) irradiation	DNA damage	CD4 cells	ultraviolet-C (UVC) treatment	upregulated	32258156
12395	Human	TP53TG1	lncRNA	covalent inhibitor of CDK7 (THZ1)	nasopharyngeal carcinoma (NPC)	"HK1,S18, S26, SUNE1, and SUNE2 cells"	THZ1 treatment	upregulated	28951465
12396	Human	TP73-AS1	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
12397	Human	TP73-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	GBM cancer stem cells (gCSC)	temozolomide (TMZ) treatment	"Using CRISPRi to downregulate our candidate lncRNA in gCSC, we demonstrate that TP73-AS1 promotes TMZ resistance in gCSC and is linked to regulation of the expression of metabolism- related genes and ALDH1A1, a protein known to be expressed in cancer stem cell markers and protects gCSC from TMZ treatment."	30867410
12398	Human	TPTEP1	lncRNA	cisplatinum	hepatocellular carcinoma (HCC)	"The human HCC cell lines, including HepG2, SMMC-7721, QGY-7703, Huh-7, MHCC97h, SNU-449 and Sk-hep1, and L02 human normal liver cell line"	cisplatinum treatment	upregulated	31072375
12399	Human	TRERNA1	lncRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HCC cells	?hepatitis B virus-encoded X (HBx) protein treatment	we found that translation regulatory lncRNA 1 (TRERNA1) upregulation by HBx not only promoted HCC cell proliferation by regulating the cell cycle in vitro and in vivo but also correlated positively with poor prognosis in HCC	33839325
12400	Human	TRIM58	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
12401	Human	TRINGS	lncRNA	glucose starvation	glucose homeostasis	human tumor cells	glucose starvation condition	upregulated	29046333
12402	Human	TSI	lncRNA	TGF-¦Â1	renal fibrosis	HK2 and HKC8 cells	TGF-¦Â1 treatment	upregulated	30305452
12403	Human	TSPEAR-AS2	lncRNA	CoCl2	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	CoCl2 treatment	upregulated	32391042
12404	Human	TSPOAP1-AS1	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	"A549 and THP-1 cell lines, MDCK, A172, Caco-2, and SH-SY5Y cells"	influenza A virus (IAV) infection	upregulated	30968963
12405	Human	TSPOAP1-AS1	lncRNA	polyinosinic-polycytidilic acid (Poly(I:C))	influenza A virus (IAV) infection	"A549 and THP-1 cell lines, MDCK, A172, Caco-2, and SH-SY5Y cells"	poly (I:C) treatment	upregulated	30968963
12406	Human	TTN-AS1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Bel7404; HepG2 cells	sorafenib treatment	LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1	33378944
12407	Human	TTN-AS1	lncRNA	X-rays	large intestine cancer	SW620 cells; HT29 cells	X-ray radiation treatment	upregulated	32749739
12408	Human	TTTY14	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
12409	Human	TTTY15	lncRNA	H2O2	acute myocardial infarction (AMI)	Human myocardial cell line (AC16)	H2O2 treatment	upregulated	32888161
12410	Human	TTTY15	lncRNA	hypoxia	acute myocardial infarction (AMI)	AC16	hypoxia treatment	upregulated	32922590
12411	Human	TTTY15	lncRNA	hypoxia	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated of TTTY15 ameliorated hypoxia-induced cell injury by targeting miR-186-5p in HUVECs.	32271447
12412	Human	TTTY15	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
12413	Human	TTTY15	lncRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte	hypoxia induce	Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p.	30898696
12414	Human	TTTY15	lncRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	upregulated	32926961
12415	Human	TUC339	lncRNA	IL-4	hepatocellular carcinoma (HCC)	THP-1 cells	IL-4 treatment	upregulated	30274167
12416	Human	TUG1	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	lncRNA TUG1 was decreased while miR-494-3p was elevated in vivo and in vitro.	33663500
12417	Human	TUG1	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	Human bone marrow stromal cell line HS-5 and human AML cell line HL60	adriamycin (ADR) treatment	upregulated	30551433
12418	Human	TUG1	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	TUG1 was upregulated in ADR-resistant AML tissues and cells.	30551433
12419	Human	TUG1	lncRNA	rapamycin	angiogenesis	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	upregulated	30186415
12420	Human	TUG1	lncRNA	metformin (Met)	atherosclerosis (AS)	Blood Samples; HUVECs	Metformin treatment	Metformin prevent AS by activating the AMPK/mTOR pathway via lncRNA TUG1.	32099330
12421	Human	TUG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human VSMC; human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 knockdown attenuated ox-LDL-induced injury through regulating proliferation and apoptosis of VSMC and HUVEC by miR-148b/IGF2 axis	31926240
12422	Human	TUG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 enhanced the progression of AS in vitro by regulating the miR-141-3p/ROR2 axis.	32565910
12423	Human	TUG1	lncRNA	X-rays	bladder cancer	"SW780,HT1376,BIU87, T24"	X-ray treatment	upregulated	28376901
12424	Human	TUG1	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
12425	Human	TUG1	lncRNA	doxorubicin (DOX)	cellular defense against genotoxic agents	human glioma cell lines	doxorubicin (DOX) treatment	downregulated	25645334
12426	Human	TUG1	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	cigarette smoke extract (CSE) treatment	LncRNA TUG1 knockdown mitigates inflammatory injury induced by cigarette smoke extract in chronic obstructive pulmonary disease via miR-34c/BRD4 axis	32812639
12427	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	LPS treatment enhanced autophagy and promoted EndMT of LSECs by upregulating TUG1.	32269710
12428	Human	TUG1	lncRNA	methotrexate (MTX)	colorectal cancer (CRC)	human colorectal cancer cell lines HT-29-P/HT-29-R cell and HCT-8 cells	methotrexate treatment	upregulated	28805722
12429	Human	TUG1	lncRNA	high glucose (HG)	diabetic atherosclerosis	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	30402858
12430	Human	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetic atherosclerosis	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30402858
12431	Human	TUG1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocyte cell line (CIHP) cells	high glucose (HG) treatment	upregulated	30671964
12432	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"TUG1 could repress cell apoptosis, autophagy, and inflammatory response in LPS-treated HUVECs by sponging miR-27a-3p to target SLIT2."	32738556
12433	Human	TUG1	lncRNA	endothelial growth medium©\2 (EGM©\2) plus VEGF	endothelial dysfunction	Adipose-derived stem cells (ADSCs)	endothelial growth medium©\2 (EGM©\2) supplemented with 15 ng/mL VEGF innduce	upregulated	31264280
12434	Human	TUG1	lncRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	upregulated	31926162
12435	Human	TUG1	lncRNA	baicalin (BAI)	inflammation	LPS stimulated human normal liver L-02 and THLE2 cells	baicalin (BAI) treatment	upregulated	31396818
12436	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	inflammation	human normal liver L-02; THLE2 cells	lipopolysaccharide (LPS) treatment	downregulated	31396818
12437	Human	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28756222
12438	Human	TUG1	lncRNA	TGF-¦Â1	intrauterine adhesion (IUA)	human embryonic stem cells (hESCs)	TGF-¦Â1 treatment	lncRNA TUG1 promotes endometrial fibrosis and inflammation by sponging miR-590-5p to regulate Fasl in intrauterine adhesions	32599321
12439	Human	TUG1	lncRNA	TGF-¦Â	liver fibrosis	LX-2 cells	TGF-¦Â treatment	upregulated	29904430
12440	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	HK2 cells	lipopolysaccharide (LPS) treatment	TUG1 was downregulated and related with LPS-induced HK-2 cell inflammatory response.	29800915
12441	Human	TUG1	lncRNA	ultraviolet (UV) irradiation	melanogenesis	PIG1 cells	UVB irradiation exposure treatment	upregulated	30924963
12442	Human	TUG1	lncRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	upregulated	33165134
12443	Human	TUG1	lncRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocytes	IL-1¦Â treatment	TUG1 was elevated in OA cartilage tissues and interleukin (IL)-1¦Â-induced chondrocytes.	33093892
12444	Human	TUG1	lncRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	primary chondrocytes	interleukin-1 beta (IL-1¦Â) and tumor necrosis factor-alpha (TNF-¦Á) treatment	"After chondrocytes were induced by IL-1¦Â and TNF-¦Á, the expression of lncRNA-TUG1 increased."	30575896
12445	Human	TUG1	lncRNA	ionizing radiation (IR)	osteogenesis	bone marrow mesenchymal stem cells (BM-MSCs)	"For the radiation treatment, when cultured cells reached 80 % confluence, they were irradiated with Co-60 for 13min at a rate of 0.69 Gy/min"	upregulated	31149038
12446	Human	TUG1	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	"osteosarcoma cell lines (Saos-2/DDP, MG-63/DDP)"	cisplatin treatment	upregulated	31305159
12447	Human	TUG1	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	Saos-2 cells; MG-63 cells	cisplatin treatment	upregulated	31305159
12448	Human	TUG1	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	A2780 cells; SK-OV-3 cells	Paclitaxel (PTX) treatment	TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells	32189969
12449	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide (LPS) treatment	?TUG1 was downregulated upon LPS stimulation in hPDLCs.	32762066
12450	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	"TUG1 had a decreased expression in both periodontal ligament (PDL) tissues with periodontitis and PDLCs under a LPS-induced inflammatory condition, and TUG1 expression was negatively correlated with miR-132 expression in periodontitis-affected PDL tissues."	31735958
12451	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	TUG1 lightened LPS-evoked pro-inflammatory response in MRC-5 cells.	31017717
12452	Human	TUG1	lncRNA	X-rays	prostate cancer	PC-3 cells; DU145 cells	X-ray radiation treatment	Knockdown of lncRNA TUG1 enhanced radiosensitivity in PCa via the TUG1/miR-139-5p/SMC1A axis	32256083
12453	Human	TUG1	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary smooth muscle cell (HPASMC)	hypoxia induce	upregulated	31679623
12454	Human	TUG1	lncRNA	IL-6	pulmonary arterial hypertension (PAH)	human pulmonary smooth muscle cell (HPASMC)	IL-6 treatment	upregulated	31679623
12455	Human	TUG1	lncRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	transforming growth factor (TGF)-¦Â1 treatment	upregulated	33135476
12456	Human	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	HT-29 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TUG1 negatively regulated inflammation in ulcerative colitis through miR-142-5p/SOCS1 axis	32173492
12457	Human	TUSC7	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells	temozolomide (TMZ) treatment	low expression of TUSC7 in GBM cells and tissues resistant to TMZ	29397407
12458	Human	uc.173	lncRNA	lead (Pb)	lead-induced nephrotoxicity	Human proximal tubular epithelial cell line (HK-2) cells; human kidney proximal tubular epithelial cell line (HKC)	lead (Pb) exposure	Lead exposure inhibited the expression of lncRNA UC.173 in renal tubular epithelial cells.	29425744
12459	Human	uc.173	lncRNA	lead (Pb)	nerve injury	serum	lead treatment	downregulated	26683706
12460	Human	uc.187	lncRNA	lipopolysaccharide (LPS)	preeclampsia (PE)	HTR-8/SVneo cells	lipopolysaccharide (LPS) treatment	Overexpression of uc.187 could induce PE-like symptoms in a pregnant rat model by affecting the distribution of ¦Â-catenin in the cytoplasm and nucleus.	31950140
12461	Human	uc.333	lncRNA	IL-6	insulin resistance (IR)	HepG2 cells	IL-6 treatment	downregulated	32303004
12462	Human	uc.333	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	insulin resistance (IR)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	32303004
12463	Human	uc.477	lncRNA	herbal formula HQT	rheumatoid arthritis (RA)	fibroblast-like synoviocytes	herbal formula HQT treatment	upregulated	32696503
12464	Human	uc.477	lncRNA	Tongbi formula (HQT)	rheumatoid arthritis (RA)	RA-derived human fibroblast-like synoviocytes (HFLS-RA)	Tongbi formula (HQT) treatment	upregulated	32696503
12465	Human	uc001.dgp.1	lncRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-3B"	particulate matter 2.5 (PM2.5) exosure treatment	upregulated	31864925
12466	Human	uc001.dgp.1	lncRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-2B"	particulate matter 2.5 (PM2.5) exposure treatment	upregulated	31864925
12467	Human	uc002mbe.2	lncRNA	histone deacetylase inhibitor trichostatin A (TSA)	hepatocellular carcinoma (HCC)	Huh7;Bel7402; Bel7721; HepG2	"histone deacetylase inhibitor (Trichostatin A, TSA) treatment"	TSA-induced apoptosis of HCC cells is uc002mbe.2 dependent and reduced expression of uc002mbe.2 may be associated with liver carcinogenesis	23643933
12468	Human	uc007keu.1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
12469	Human	uc010vei.1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
12470	Human	UCA1	lncRNA	5-fluorouracil (5-Fu)	retinoblastoma (RB)	retinoblastoma cells	5-fluorouracil (5-Fu) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
12471	Human	UCA1	lncRNA	carboplatin (CBP)	retinoblastoma (RB)	retinoblastoma cells	carboplatin (CBP) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
12472	Human	UCA1	lncRNA	cisplatin (DDP)	retinoblastoma (RB)	retinoblastoma cells	cisplatin treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
12473	Human	UCA1	lncRNA	vincristine (VCR)	retinoblastoma (RB)	retinoblastoma cells	vincristine (VCR) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
12474	Human	UCA1	lncRNA	etoposide (VP-16)	retinoblastoma (RB)	retinoblastoma cells	Etoposide (VP-16) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
12475	Human	UCA1	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	UCA1 expression was upregul.ated following adr-based chemotherapy	29663500
12476	Human	UCA1	lncRNA	arsenite	arsenic (As) toxicities	HepG2 cells	arsenic (As) exposure	lncRNA UCA1 was markedly induced by As treatment in human hepatocytes.	29248574
12477	Human	UCA1	lncRNA	arsenite	arsenic (As) toxicities	HepG2 cells	arsenic (As) exposure	UCA1 facilitates the ubiquitination of EZH2 to upregulate NFATc2 and further antagonizes As-induced cell cycle arrest.	32537408
12478	Human	UCA1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cell line	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL increased UCA1 expression greatly in THP-1 cells.	30633352
12479	Human	UCA1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cell line (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Dysregulation of the Urothelial Cancer Associated 1 Long Noncoding RNA Promotes Proliferation of Vascular Smooth Muscle Cells by Modulating Expression of P27KIP1/CDK2.	32213082
12480	Human	UCA1	lncRNA	arsenite	autophagy	human hepatocytes	arsenic (As) exposure	upregulated	29248574
12481	Human	UCA1	lncRNA	cisplatin (DDP)	bladder cancer	patients with bladder and cancer.cisplatin-resistant bladder cancer cells	cisplatin treatment	upregulated	24495014
12482	Human	UCA1	lncRNA	metformin (Met)	bladder cancer	bladder cancer 5637 cells	metformin	downregulated	28641488
12483	Human	UCA1	lncRNA	transcription factor CCAAT/enhancer binding protein ¦Á (C/EBP¦Á)	bladder cancer	human bladder cancer cell lines 5637 and T24	C/EBP¦Á treatment	upregulated	24648007
12484	Human	UCA1	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
12485	Human	UCA1	lncRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	paclitaxel (PTX) treatment	Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis	32425595
12486	Human	UCA1	lncRNA	tamoxifen (TAM)	breast cancer	breast cancer cells (LCC2 and LCC9)	tamoxifen treatment	upregulated	30628639
12487	Human	UCA1	lncRNA	TGF-¦Â	breast cancer	MCF-7 cells	TGF-¦Â treatment	"TGF-¦Â induced genome-wide changes in lncRNA levels in breast cancer cells, among which AC0269041 and UCA1 were highly expressed in metastatic breast cancer and closely associated with poor prognosis"	29774079
12488	Human	UCA1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells	trastuzumab treatment	upregulated	29408336
12489	Human	UCA1	lncRNA	ionizing radiation (IR)	cervical cancer (CC)	SiHa cells; HeLa cells	irradiation treatment	upregulated	30015920
12490	Human	UCA1	lncRNA	5-fluorouracil (5-Fu)	chemoresistance of 5-fluorouracil (5-FU)	SW480 and SW620	5-fluorouracil (5-FU) treatment	UCA1 mediated 5-FU resistance of CRC cells through facilitating autophagy and inhibiting apoptosis via miR-23b-3p/ZNF281 axis in vivo and in vitro.	32801774
12491	Human	UCA1	lncRNA	X-rays	colorectal cancer (CRC)	CCL244 cells	X-ray irradiation treatment	UCA1 was significantly higher in CRC tissues after chemoradiotherapy	30015983
12492	Human	UCA1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	downregulated	31608712
12493	Human	UCA1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
12494	Human	UCA1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â1 treatment	UCA1 exerted its role via regulating the UCA1/miR-455/ZEB1 regulatory axis in HUVECs treated with TGF-¦Â1	32584608
12495	Human	UCA1	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	30353369
12496	Human	UCA1	lncRNA	curcumin (Cur)	lung cancer	A549 cells	curcumin treatment	curcumin inhibited the expression of UCA1.	30001775
12497	Human	UCA1	lncRNA	cetuximab	metastatic colorectal cancer (mCRC)	Caco2 cells	cetuximab treatment	upregulated	30377411
12498	Human	UCA1	lncRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	UCA1 inhibition protected WI-38 cells against LPS-managed inflammatory injury and apoptosis process via miR-499b-5p/TLR4 crosstalk.	33368965
12499	Human	UCA1	lncRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	?We displayed that UCA1 was elevated in LPS-injured WI-38 cells.	33368965
12500	Human	UCA1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	upregulated	30652341
12501	Human	UCA1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin (DPP) treatment	The cisplatin-R group exhibited lower levels of UCA1 and NRF2 expression but a higher level of miR-495 expression than the cisplatin-S group.	31583720
12502	Human	UCA1	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	The NSCLC cell lines (HCC827 and PC9)	gefitinib treatment	UCA1 was increased in both gefitinib-resistant NSCLC cells and their secreted exosomes.	31951852
12503	Human	UCA1	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC9 cells	gefitinib treatment	UCA1 was increased in both gefitinib-resistant NSCLC cells and their secreted exosomes.	31951852
12504	Human	UCA1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	Human ovarian cancer cell lines (A2780 and SKOV-3) and normal ovarian epithelial cell line (IOSE-80)	cisplatin treatment	upregulated	31234009
12505	Human	UCA1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
12506	Human	UCA1	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells; HeyA8 cells	paclitaxel (PTX) treatment	UCA1 was markedly upregulated in PTX-resistant OC cells	32016960
12507	Human	UCA1	lncRNA	hypoxia	pancreatic cancer (PC)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	hypoxic exosomal UCA1 could promote angiogenesis and tumor growth through the miR-96-5p/AMOTL2/ERK1/2 axis	32942233
12508	Human	UCA1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	30536337
12509	Human	UCA1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	Our data showed that MPP+?induced UCA1 expression in SK-N-SH cells.	33464446
12510	Human	UCA1	lncRNA	metformin (Met)	preeclampsia (PE)	HUVEC and HPASMC cells	Metformin treatment	downregulated	31582211
12511	Human	UCA1	lncRNA	oxidized low density lipoprotein (ox-LDL)	cell proliferation and migration	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32346422
12512	Human	UCA1	lncRNA	artesunate (ART)	prostate cancer	"DU145,LNCaP cells"	artesunate (ART) treatment	upregulated	28209917
12513	Human	UCA1	lncRNA	¦Ã-rays	prostate cancer	22RV1; DU145 cells	Gy radiation treatement	LncRNA UCA1 deletion suppressed the radioresistance to PCa by suppressing EIF4G1 expression via miR-331-3p.	32943997
12514	Human	UCA1	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	UCA1 was confirmed to be highly expressed under hypoxia compared with normoxia.	30353369
12515	Human	UCA1	lncRNA	carboplatin (CBP)	retinoblastoma (RB)	SO-RB50 cells	carboplatin (CBP) treatment	upregulated	31702387
12516	Human	UCA1	lncRNA	vincristine (VCR)	retinoblastoma (RB)	SO-RB50 cells	vincristine (VCR) treatment	upregulated	31702387
12517	Human	UCA1	lncRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMECs)	lipopolysaccharide (LPS) treatment	upregulated	31231228
12518	Human	UCA1	lncRNA	TGF-¦Â1	tongue squamous cell carcinoma (TSCC)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
12519	Human	UIHTC	lncRNA	H2O2	myocardial infarction (MI)	AC16 cells	H2O2 treatment	upregulated	29887450
12520	Human	UIHTC	lncRNA	hypothermia	myocardial infarction (MI)	AC16 cells	hypothermia (28 ¡ãC) treatment	upregulated	29887450
12521	Human	Unigene56159	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Huh7 cells	hepatitis B virus (HBV) infection	Unigene56159 significantly promoted cell migration/invasion and epithelial-mesenchymal transition (EMT) in HCC.	27597739
12522	Human	UPK1A-AS1	lncRNA	hypoxia	lung cancer	A549 cells;NCI-H460 cells	hypoxia treatment	upregulated	33273139
12523	Human	VCAN-AS1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
12524	Human	VIM-AS1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial cells (RPEs)	high glucose treatment	downregulated	32447557
12525	Human	VLDLR	lncRNA	adriamycin (ADR)	esophageal squamous cell carcinoma (ESCC)	Eca109 cell line	adriamycin (ADR) treatment	upregulated	30606658
12526	Human	VLDLR	lncRNA	"anticancer agents£¨sorafenib, camptothecin, and doxorubicin£©"	hepatocellular carcinoma (HCC)	malignant hepatocytes	anticancer agents treatment	upregulated	24874432
12527	Human	VNN3	lncRNA	benzene	benzene-induced hematotoxicity	serum	low-dose benzene exposure	upregulated	31541949
12528	Human	VPS9D1-AS1	lncRNA	histone deacetylase inhibitor chidamide	acute myeloid leukemia (AML)	SKM-1 cells; THP-1 cells	histone deacetylase inhibitor Chidamide treatment	Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 downregulated via MEK/ERK Signaling Pathway	33192510
12529	Human	WAKMAR2	lncRNA	TGF-¦Â	chronic wounds	cultured keratinocytes	TGF-¦Â treatment	upregulated	30594489
12530	Human	WDR86-AS1	lncRNA	hypoxia	preeclampsia (PE)	human trophoblast HTR-8/SVneo cells	hypoxia induce	upregulated	30552989
12531	Human	WISP1-AS1	lncRNA	carcinogenic nephrotoxin ochratoxin A	carcinogenic nephrotoxin ochratoxin A. toxicity	HK-2 cells	carcinogenic nephrotoxin ochratoxin A. treatment	upregulated	29282485
12532	Human	WT1-AS	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"Overexpression of WT1-AS can inhibit the miR-375/SIX4 axis, OSI and neuronal apoptosis in AD by inhibiting WT1 expression."	33234729
12533	Human	WWC2-AS1	lncRNA	ionizing radiation (IR)	radiation-induced intestinal fibrosis (RIF)	human intestinal CCD-18Co fibroblasts cell lines;subepithelial SEMFs	"Ionizing radiation (IR) was done with 6 MV photons, 8 Gy/min by a linear accelerator (Varian, America) at room temperature."	upregulated	31262262
12534	Human	X72487	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
12535	Human	X85157	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
12536	Human	XIST	lncRNA	CoCl2	acute kidney injury (AKI)	HK-2 cells	CoCl2 treatment	downregulated of XIST ameliorates acute kidney injury by sponging miR-142-5p and targeting PDCD4.	32347551
12537	Human	XIST	lncRNA	ethanol (EtOH)	alcoholic liver fibrosis (ALF)	Human HSC cells (LX-2)	ethanol treatment	upregulated	31418997
12538	Human	XIST	lncRNA	hypoxia	angiogenesis	Human Brain Microvascular Endothelial Cells (HBMEC)	hypoxia induce	upregulated	31737200
12539	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA XIST (X-inactive specific transcript) was upregulated in human umbilical vein endothelial cells (HUVECs) stimulated by ox-LDL.	29902461
12540	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
12541	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"silence of XIST displayed a protective role in ox-LDL-induced injury in HUVECs by regulating miR-204-5p/TLR4 axis, providing a novel mechanism for understanding the pathogenesis of atherosclerosis."	32345778
12542	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33542956
12543	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	"n this research, we uncovered that the XIST level was elevated in the serum of AS patients and ox-LDL-treated AS cell models."	33566259
12544	Human	XIST	lncRNA	platycodin D (PD)	bladder cancer	T24; RT4	Platycodin D (PD) treatment	"PD inhibited LncRNA-XIST expressions, while increased miR-335 expression levels in bladder cancer cells"	32919956
12545	Human	XIST	lncRNA	cyclosporine A (CsA)	cell proliferation and invasion	HT cells	cyclosporine A treatment	upregulated	28059474
12546	Human	XIST	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"XIST and GAB2 were significantly highly expressed, while miR-486-5p was low expressed in SH-SY5Y cells under I/R"	33660813
12547	Human	XIST	lncRNA	IL-1¦Â	chondrocyte apoptosis	CHON-001 cells	IL-1¦Â treatment	downregulated	32517436
12548	Human	XIST	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	?human renal tubular epithelial HK-2 cells	?high glucose (HG) induce	silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN	31545928
12549	Human	XIST	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	HG could inhibit the expression of XIST.	33332155
12550	Human	XIST	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial ARPE-19 cells	high-glucose (HG) treatment	"XIST, likely through competitive binding of hsa-miR-21-5p, provides protection against hyperglycemia-associated injury in human retinal pigment epithelial cells."	32106367
12551	Human	XIST	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	"Silencing XIST reduced the expression of YAP and suppressed transforming growth factor (TGF)-¦Â1-induced EMT, while over-expression of XIST increased the expression of YAP and promoted EMT"	31013436
12552	Human	XIST	lncRNA	cisplatin (DDP)	gastric cancer (GC)	SGC 7901cells; AGC cells	cisplatin treatment	upregulated	33009035
12553	Human	XIST	lncRNA	X-rays	glioblastoma multiforme (GBM)	U251 cells	X-ray radiation treatment	"XIST accelerates cell proliferation, invasion and inhibits cell apoptosis by repressing radio-sensitivity of glioma via enhancing CREB1 expression through sponging miR-329-3p"	32271437
12554	Human	XIST	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
12555	Human	XIST	lncRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cell	?IL-1¦Â treatment	"XIST expression was upregulated in the NP tissues of patients with IDD, and IL-1¦Â treatment resulted in a degradation of NPCs"	33722663
12556	Human	XIST	lncRNA	estradiol-17¦Â (E2)	leiomyoma	leiomyoma smooth muscle cells (LSMC)	estradiol-17¦Â (E2) treatment	"XIST levels was reduced in leiomyoma smooth muscle cells (LSMC) after treatment with 17¦Â-estradiol, progesterone."	33070965
12557	Human	XIST	lncRNA	IL-4	macrophage polarization	THP-1-differentiated macrophages	IL-4 treatment	upregulated	31632059
12558	Human	XIST	lncRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	Conditionally immortalized human podocyte cell line AB8/13	angiotensin II (Ang II) treatment	upregulated	30414341
12559	Human	XIST	lncRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	human NPC cell lines CNE-1 and CNE-2	ionizing radiation	downregulated	28985197
12560	Human	XIST	lncRNA	Hypoxia	nasopharyngeal carcinoma (NPC)	HK-1 and C666-1	hypoxia treatment	"XIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis, providing new insights into the pathogenesis of NPC."	32196601
12561	Human	XIST	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) tumors; A549 cells; SPC A1 cells; H2279 cells; H1875 cells; HC827 cells	cisplatin treatment	"XIST is upregulated in human NSCLC specimens, and is especially overexpressed in tumors previously treated with cisplatin (cis-diamminedichloroplatinum(II); DDP)."	32209729
12562	Human	XIST	lncRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	oral squamous cell carcinoma (OSCC) cells	cisplatin treatment	upregulated	33191714
12563	Human	XIST	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	upregulated	30005876
12564	Human	XIST	lncRNA	IL-1¦Â	osteoarthritis (OA)	articular chondrocytes (ACs)	IL-1¦Â treatment	upregulated	31198977
12565	Human	XIST	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells	paclitaxel treatment	XIST promoted the sensitivity of ovarian cancer stem cells to paclitaxel in a KMT2C-dependent manner	32943985
12566	Human	XIST	lncRNA	TGF-¦Â1	pancreatic cancer (PC)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	"Silencing XIST reduced the expression of YAP and suppressed transforming growth factor (TGF)-¦Â1-induced EMT, while over-expression of XIST increased the expression of YAP and promoted EMT"	31013436
12567	Human	XIST	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	33494069
12568	Human	XIST	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 human lung fibroblasts cells	lipopolysaccharide (LPS) treatment	upregulated	31066476
12569	Human	XIST	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	"Expression of XIST and CCL16 was upregulated in the serum of patients with pneumonia and LPS-induced WI-38 cells, respectively"	33817304
12570	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	"PTEN was a target of miR-30c-5p, and its interference led to great inhibition of cell apoptosis and inflammatory response induced by ox-LDL in HUVEC, while this effect was attenuated by miR-30c-5p deficiency or XIST overexpression."	31539155
12571	Human	XLOC_000620	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
12572	Human	XLOC_004122	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
12573	Human	XLOC_004562	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
12574	Human	XLOC_005912	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
12575	Human	XLOC_014388	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
12576	Human	XLOC_032768	lncRNA	cisplatin (DDP)	cisplatin (DDP)-induced nephrotoxicity	human renal proximal tubular epithelial cells (HK-2)	cisplatin treatment	lncRNA XLOC_032768 expression was significantly repressed by cisplatin treatment.	32278129
12577	Human	XLOC-006390	lncRNA	silver nanoparticles (AgNPs)	breast cancer	"MCF7, T47D and MDA-MB-231 cells"	silver nanoparticles (AgNPs)?treatment treatment	"we found that a long noncoding RNA, XLOC_006390, was decreased in AgNPs-treated breast cancer cells"	33613979
12578	Human	Z74666	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
12579	Human	ZBTB20-AS1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
12580	Human	ZEB1-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	carotid artery atherosclerosis	HCtAEC | Human Carotid Artery Endothelial Cells; THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LncRNA ZEB1-AS1 contributed to ox-LDL-mediated injury and apoptosis of HCtAEC cells and the oxidative stress and inflammation of THP-1 cells through up-regulating HMGB1 via sponging miR-942.	31962131
12581	Human	ZEB1-AS1	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	MCF-7 and MDA-MB-231 cells	cisplatin treatment	lncRNA ZEB1-AS1 silencing protects against drug resistance in breast cancer by promoting miR-129-5p-dependent ZEB1 downregulated.	33430826
12582	Human	ZEB1-AS1	lncRNA	high glucose (HG)	diabetic lung disease	BEAS©\2B cells	high glucose (HG) treatment	ZEB1-AS1 in lung cells was downregulated by high glucose treatment.	33193839
12583	Human	ZEB1-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose treatment	ZEB1-AS1 suppressed HG-induced EMT and fibrogenesis by regulating miR-216a-5p and BMP-7.	32294702
12584	Human	ZEB1-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31040785
12585	Human	ZEB1-AS1	lncRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	The expression of lnc ZEB1-AS1 was significantly suppressed by high glucose.	30121551
12586	Human	ZEB2-AS1	lncRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2	?hepatitis B virus-encoded X (HBx) protein treatment	upregulated	29258558
12587	Human	ZEB2-AS1	lncRNA	IL-6	non-small cell lung cancer (NSCLC)	A549 cells	IL-6 treatment	upregulated	32329850
12588	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	The expression of ZFAS1 was significantly upregulated in in-vitro cell model of atherosclerosis at a dose- and time-dependent manner.	32349937
12589	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33278458
12590	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis	33278458
12591	Human	ZFAS1	lncRNA	cisplatin (DDP)	cervical cancer (CC)	cervical cancer CaSki;the HeLa cell lines	cisplatin treatment	"Silencing ZFAS1 may inhibit cell proliferation, migration and invasion and enhance cisplatin chemosensitivity."	30738960
12592	Human	ZFAS1	lncRNA	cisplatin (DDP)	high-grade serous ovarian carcinomas (HGSOC)	"A2008, HeyA8, and HeyC2 cell lines"	cisplatin treatment	upregulated	28154416
12593	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs.	33278458
12594	Human	Zfhx2as	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	HNSCC cell lines	radiation treatment	downregulated	30441874
12595	Human	ZNF295-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ZNF295-AS1 inhibits autophagy via the ZNF295-AS1/miR-508-5p/ATG7 axis in AS	32633396
12596	Human	ZNF593-AS	lncRNA	phenylephrine (PE)	dilated cardiomyopathy (DCM)	cardiomyocytes	phenylephrine treatment	"ZNF593-AS, which mainly localized in the cytoplasm of cardiomyocytes, was robustly decreased in the failing heart of DCM patients, as well as in phenylephrine-treated human cardiomyocytes"	33550812
12597	Human	ZNF649-AS1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	ZNF649-AS1 was more highly expressed in trastuzumab-resistant cells compared to sensitive cells	32735773
12598	Human	ZNF667-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines (Kyse170, Eca109, TE1, and TE13)"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31804468
12599	Human	ZNF667-AS1	lncRNA	histone deacetylase inhibitor trichostatin A (TSA)	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines (Kyse170, Eca109, TE1, and TE13)"	histone deacetylase inhibitor TSA treatment	upregulated	31804468
12600	Human	ZNRD1-AS1	lncRNA	cold atmospheric plasma (CAP)	cancer treatment	MCF-7 breast cancer cells	Cold atmospheric plasma (CAP) treatment	ZNRD1 and Its Antisense Long Noncoding RNA ZNRD1-AS1 Are Oppositely Regulated by Cold Atmospheric Plasma in Breast Cancer Cells.	32454947
12601	Human	ZXF1	lncRNA	cisplatin (DDP)	lung cancer	A549 cells	cisplatin treatment	Enhanced expression of lncRNA ZXF1 promotes cisplatin resistance in lung cancer cell via MAPK axis.	32533982
24275	Human	hsa-miR-5703	miRNA	TGF-¦Â1	breast cancer	MDA-MB231 cells	TGF-¦Â1 treatment	miR-5703 expression was significantly downregulated at both precursor and mature levels upon TGF-¦Â1-treatment in human breast cancer cells.	34492519
24276	Human	hsa-miR-16-2-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	peripheral blood	SARS-CoV-2 infection	"A miRNA¡¯s high-throughput sequencing analysis in peripheral blood of 10 COVID-19 patients and 4 control donors indicated 35 upregulated and 38 downregulated miRNAs, in which changes of miR-16-2-3p is most remarkable in the upregulated list."	33675361
24277	Human	hsa-miR-183-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	peripheral blood	SARS-CoV-2 infection	"A miRNA¡¯s high-throughput sequencing analysis in peripheral blood of 10 COVID-19 patients and 4 control donors indicated 35 upregulated and 38 downregulated miRNAs, in which changes of miR-183-5p is the most remarkable in the downregulated list."	33675361
24278	Human	hsa-miR-146a-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-146a-5p was consistently downregulated."	33675361
24279	Human	hsa-miR-21-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-21-5p was consistently downregulated."	33675361
24280	Human	hsa-miR-142-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-142-3p was consistently downregulated."	33675361
24281	Human	hsa-miR-3605-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	"transcriptome sequencing of both whole blood noncoding RNAs and mRNAs for six moderate and six severe COVID-19 patients as well as and four healthy donors, in which miR-3605-3p was consistently upregulated."	33675361
24282	Human	hsa-miR-15b-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-15b-5p was upregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
24283	Human	hsa-miR-486-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-486-3p was upregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
24284	Human	hsa-miR-486-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-486-5p was upregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
24285	Human	hsa-miR-181a-2-3p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-181a-2-3p was downregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
24286	Human	hsa-miR-31-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-31-5p was downregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
24287	Human	hsa-miR-99a-5p	miRNA	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Coronavirus disease 2019 (COVID-19)	whole blood	SARS-CoV-2 infection	miR-99a-5p was downregulated only in severe COVID-19 patients compared with the healthy donors.	33675361
12602	Human cytomegalovirus	hcmv-miR-UL112-1	miRNA	human cytomegalovirus (HCMV)	human cytomegalovirus (HCMV) infection	"human embryonic lung fibroblast cell line, MRC-5"	HCMV infection	upregulated	23402302
12609	Laodelphax striatellus	lst_circ_2030	circRNA	Rice black-streaked dwarf virus (RBSDV)	rice black-streaked dwarf virus (RBSDV) infection	striatellus midgut tissues	Rice black-streaked dwarf virus (RBSDV) infection treatment	upregulated	33117326
12620	Maize	zma-miR156f	miRNA	phosphorus (Pi)	phosphorus (Pi) starvation	maize seeds	phosphorus (P) treatment	"downregulated (miR156f, miR169h , miR396a); upregulation(miR396c, miR408) in roots and leaves"	26572939
12621	Maize	zma-miR169h	miRNA	phosphorus (Pi)	phosphorus (Pi) starvation	maize seeds	phosphorus (P) treatment	"downregulated (miR156f, miR169h , miR396a); upregulation(miR396c, miR408) in roots and leaves"	26572939
12622	Maize	zma-miR396a	miRNA	phosphorus (Pi)	phosphorus (Pi) starvation	maize seeds	phosphorus (P) treatment	"downregulated (miR156f, miR169h , miR396a); upregulation(miR396c, miR408) in roots and leaves"	26572939
12623	Maize	zma-miR396c	miRNA	phosphorus (Pi)	phosphorus (Pi) starvation	maize seeds	phosphorus (P) treatment	"downregulated (miR156f, miR169h , miR396a); upregulation(miR396c, miR408) in roots and leaves"	26572939
12624	Maize	zma-miR408	miRNA	phosphorus (Pi)	phosphorus (Pi) starvation	maize seeds	phosphorus (P) treatment	"downregulated (miR156f, miR169h , miR396a); upregulation(miR396c, miR408) in roots and leaves"	26572939
12625	Malus hupehensis	Mh-miR168a	miRNA	botryosphaeria dothidea	botryosphaeria dothidea Infection	malus hupehensis	botryosphaeria dothidea infection	upregulated	28633325
12626	Malus hupehensis	Mh-miR397	miRNA	botryosphaeria dothidea	resistance of plants to pathogens	Malus hupehensis	bothrops moojeni snake venom (BmooLAAO-I) treatment	MicroRNA397b negatively regulates resistance of Malus hupehensis to Botryosphaeria dothidea by modulating MhLAC7 involved in lignin biosynthesis.	32005395
12627	Manduca sexta	mse-miR-281*	miRNA	"E. coli, M. luteus, and curdlan"	insect immunity	tobacco hornworm Manduca sexta	"E. coli, M. luteus, and curdlan was injected into day 2, 5th instar larvae treatment"	"Mse-miR-281-star, mse-miR-965-star, mse-miR-31-star, and mse-miR-9b-star were present at higher levels than their respective mature strands."	24508515
12628	Manduca sexta	mse-miR-31*	miRNA	"E. coli, M. luteus, and curdlan"	insect immunity	tobacco hornworm Manduca sexta	"E. coli, M. luteus, and curdlan was injected into day 2, 5th instar larvae treatment"	"Mse-miR-281-star, mse-miR-965-star, mse-miR-31-star, and mse-miR-9b-star were present at higher levels than their respective mature strands."	24508515
12629	Manduca sexta	mse-miR-965*	miRNA	"E. coli, M. luteus, and curdlan"	insect immunity	tobacco hornworm Manduca sexta	"E. coli, M. luteus, and curdlan was injected into day 2, 5th instar larvae treatment"	"Mse-miR-281-star, mse-miR-965-star, mse-miR-31-star, and mse-miR-9b-star were present at higher levels than their respective mature strands."	24508515
12630	Manduca sexta	mse-miR-9b*	miRNA	"E. coli, M. luteus, and curdlan"	insect immunity	tobacco hornworm Manduca sexta	"E. coli, M. luteus, and curdlan was injected into day 2, 5th instar larvae treatment"	"Mse-miR-281-star, mse-miR-965-star, mse-miR-31-star, and mse-miR-9b-star were present at higher levels than their respective mature strands."	24508515
12616	Marsupenaeus japonicus	gja-miR-100	miRNA	Vibrio alginolyticus	Vibrio alginolyticus infection	shrimp hemocytes	Vibrio alginolyticus infection for 24 h treatment	upregulated	28181552
12617	Marsupenaeus japonicus	gja-miR-100	miRNA	white spot syndrome virus (WSSV)	white spot syndrome virus (WSSV) infection	shrimp hemocytes	WSSV infection for 24 h treatment	upregulated	28181552
12618	Marsupenaeus japonicus	gja-miR-S5	miRNA	Vibrio alginolyticus	Vibrio alginolyticus infection	shrimp hemocytes	Vibrio alginolyticus infection	upregulated	28986214
12619	Marsupenaeus japonicus	gja-miR-S5	miRNA	white spot syndrome virus (WSSV)	white spot syndrome virus (WSSV) infection	shrimp hemocytes	WSSV infection	upregulated	28986214
12631	Megalobrama amblycephala	mam-miR-145	miRNA	high fat diet (HFD)	hepatic steatosis	fish	high fat diet (HFD) feed	downregulated	24788396
12632	Megalobrama amblycephala	mam-miR-15a-5p	miRNA	high fat diet (HFD)	hepatic steatosis	fish	high fat diet (HFD) feed	downregulated	24788396
12633	Megalobrama amblycephala	mam-miR-30c	miRNA	high fat diet (HFD)	hepatic steatosis	fish	high fat diet (HFD) feed	upregulated	24788396
12634	Megalobrama amblycephala	mam-miR-30e-3p	miRNA	high fat diet (HFD)	hepatic steatosis	fish	high fat diet (HFD) feed	upregulated	24788396
12635	Mi-iuy croaker	mmi-miR-3570	miRNA	rhabdovirus	host antiviral defense	miiuy croaker macrophages	rhabdovirus treatment	rhabdovirus infection significantly upregulated host miR-3570 expression in miiuy croaker macrophages.	29093090
12636	Mi-iuy croaker	mmi-miR-148	miRNA	lipopolysaccharide (LPS)	inflammation	miiuy croaker liver and spleen	LPS treatment	upregulated	28646187
12637	Mi-iuy croaker	mmi-miR-216a	miRNA	vibrio anguillarum	inflammation	spleen; kidney	Vibrio anguillarum infection	upregulated	29632247
12638	Mi-iuy croaker	mmi-miR-3570	miRNA	vibrio anguillarum	Vibrio anguillarum infection	miiuy croakers liver samples	challenged i.p. with 1 ml of V. anguillarum (1.5 3 108 CFU/ml) treatment	upregulated in liver samples	28250156
12639	Mi-iuy croaker	mmi-miR-21	miRNA	vibrio anguillarum	bacterial infection	"miiuy croaker liver, spleen"	Vibrio anguillarum infection treatment	upregulated	31379828
12640	Mi-iuy croaker	mmi-miR-216a	miRNA	lipopolysaccharide (LPS)	inflammation	spleen; kidney; macrophages	lipopolysaccharide (LPS) treatment	upregulated	29632247
12641	Mi-iuy croaker	mmi-mir-217-5p	miRNA	lipopolysaccharide (LPS)	inflammation	macrophage isolated from the head kidneys of juvenile miiuy croakers	lipopolysaccharide (LPS) treatment	upregulated	27832948
12642	Mi-iuy croaker	mmi-miR-217-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	macrophage	lipopolysaccharide (LPS) treatment	upregulated	27832948
12643	Mi-iuy croaker	mmi-mir-8159-5p	miRNA	lipopolysaccharide (LPS)	inflammation	macrophage isolated from the head kidneys of juvenile miiuy croakers	lipopolysaccharide (LPS) treatment	upregulated	27832948
12644	Mi-iuy croaker	mmi-miR-8159-5p	miRNA	lipopolysaccharide (LPS)	innate immune response	macrophage	lipopolysaccharide (LPS) treatment	upregulated	27832948
12645	Mongolian gerbil	mun-miR-155	miRNA	CTB-UE	H. pylori infection	CTB-UE	CTB-UE treatment	downregulated	25093281
12660	Mouse	RNCR3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	RF/6A cells	high glucose stress	upregulated	27876564
12661	Mouse	1110038B12Rik	lncRNA	X rays	radiation-induced injury	blood	X rays treatment	downregulated	29309266
12662	Mouse	1700009J07Rik	lncRNA	high fat diet (HFD)	male infertility	C57bl/6J mice	high fat diet (HFD) feed	dysregulated	28599310
12663	Mouse	1700020I14Rik	lncRNA	hypoxia/reoxygenation (H/R)	myocardial injury	HL-1 cells	hypoxia/reoxygenation (H/R) treatment	1700020I14Rik/miR-297a/CGRP axis suppressed myocardial cell apoptosis in myocardial I/R injury.	32298875
12664	Mouse	1700026D11Rik	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	upregulated	32246647
12665	Mouse	1700091H14Rik	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	downregulated	32246647
12666	Mouse	1810034E14Rik	lncRNA	lipopolysaccharide (LPS)	ischemic stroke (IS)	primary microglial cells	lipopolysaccharide (LPS) treatment	downregulated	30961627
12667	Mouse	1810034E14Rik	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary microglial cells	oxygen-glucose deprivation treatment	downregulated	30961627
12668	Mouse	2310069B03Rik	lncRNA	cold	obesity	white adipose tissues	cold treatment	Cold exposure increased both lncRNA 2310069B03Rik and Ucp1 expression in inguinal white adipose tissue (iWAT).	31601163
12669	Mouse	2610035D17Rik	lncRNA	rosiglitazone	diabetic nephropathy (DN)	kidney tissues	rosiglitazone treatment	upregulated	32025515
12670	Mouse	2700086A05Rik	lncRNA	paraquat (PQ)	idiopathic pulmonary fibrosis (IPF)	alveolar epithelial cells	paraquat (PQ) treatment	upregulated	26824344
12671	Mouse	2810403D21Rik	lncRNA	H2O2	acute myocardial infarction (AMI)	Neonatal mice cardiomyocytes (NMCMs)	hydrogen peroxid (H2O2) treatment	"forced expression of 2810403D21Rik/Mirf downregulated Mir26a to inhibit autophagy. In contrast, loss of 2810403D21Rik/Mirf resulted in upregulation of Mir26a to promote autophagy and alleviate cardiac injury, which in turn improved cardiac function in MI mice."	31512556
12672	Mouse	2900052N01Rik	lncRNA	lipopolysaccharide (LPS)	inflammation	B lymphocytes	lipopolysaccharide (LPS) treatment	lnc-290 was highly expressed in B cells stimulated by LPS	33773377
12673	Mouse	4930556M19Rik	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	4930556M19Rik overexpression slowed HG-induced podocyte injury by downregulating miR-27a-3p and upregulating TIMP3.	32896839
12674	Mouse	4930597A21Rik	lncRNA	dexamethasone (DEX)	asthma	lung tissues	dexamethasone (Dex) treatment	4930597A21Rik was upregulated in the Dex group compared with that in the Model group.	32222886
12675	Mouse	6430584L05Rik	lncRNA	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)"	rheumatoid arthritis (RA)	TM3 Leydig cells	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment"	upregulated	33360214
12676	Mouse	9030404E10Rik	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	upregulated	32246647
12677	Mouse	A_30_P01018532	lncRNA	albizia julibrissin (AJSAF)	cell function	RAW264.7 macrophages	albizia julibrissin (AJSAF) treatment	upregulated	31678866
12678	Mouse	A330023F24Rik	lncRNA	vorinostat (SAHA)	atherosclerosis (AS)	aortic tissues	vorinostat treatment	upregulated	30284929
12679	Mouse	AA089093	lncRNA	X-rays	radiation-induced injury	mouse thymocytes	X-ray irradiation	upregulated	27864278
12680	Mouse	AA591058	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	AA591058 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
12681	Mouse	AA591058	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	downregulated	29115403
12682	Mouse	AA591058	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	AA591058 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
12683	Mouse	ACART	lncRNA	H2O2	ischemia/reperfusion (I/R) injury	Neonatal mouse ventricular cardiomyocytes (NMVCs)	H2O2 treatment	LncRNA ACART protects cardiomyocytes from apoptosis by activating PPAR-¦Ã/Bcl-2 pathway	31749326
12684	Mouse	ACART	lncRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary cultured cardiomyocytes	H2O2 treatment	downregulated	31749326
12685	Mouse	ACOD1	lncRNA	esicular stomatitis virus (VSV)	esicular stomatitis virus (VSV) infection	macrophages	stimulated with VSV for 12 hours	upregulated	29074580
12686	Mouse	AIR	lncRNA	"diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC)"	liver preneoplastic foci and tumors	mice liver cells	"Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC) treatment"	upregulated	19362547
12687	Mouse	AK006025	lncRNA	human immunodeficiency virus (HIV)-1 Nef	HIV-associated neurocognitive disorders (HAND)	primary mouse astrocytes	Human immunodeficiency virus (HIV)-1 Nef treatment	upregulated	30382871
12688	Mouse	AK009366	lncRNA	pressure overload	heart failure (HF)	heart sissues	pressure overload treatment	upregulated	33224746
12689	Mouse	AK020546	lncRNA	H2O2	cardiomyocyte autophagy	primary cardiomyocytes	H2O2 treatment	AK020546 was decreased upon H2O2 treatment	29295976
12690	Mouse	AK028245	lncRNA	cyclophosphamide (CP)	ircadian rhythmicity	mouse	cyclophosphamide (CP) treatment	downregulated	32748687
12691	Mouse	AK028245	lncRNA	lipopolysaccharide (LPS)	ircadian rhythmicity	mouse	lipopolysaccharide (LPS) treatment	downregulated	32748687
12692	Mouse	AK038897	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	neuro-2A (N2a) neuroblastoma cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30703362
12693	Mouse	AK038898	lncRNA	radiation	radiation-induced intestinal injury	intestinal tissues	radiation treatment	downregulated	30324649
12694	Mouse	AK039862	lncRNA	paraquat (PQ)	parkinson's disease (PD)	BV2 cells	paraquat (PQ) treatment	upregulated	33120262
12695	Mouse	AK039862	lncRNA	paraquat (PQ)	parkinson's disease (PD)	BV2 cells	paraquat (PQ) treatment	PQ-induced low expression of AK039862 rescued microglia proliferation and migration inhibition via the AK039862/Pafah1b1/Foxa1 pathway.	33120262
12696	Mouse	AK043271	lncRNA	X-rays	radiation-induced injury	mouse thymocytes	X-ray irradiation	downregulated	27864278
12697	Mouse	AK045171	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	Neonatal mouse cardiomyocytes and cardiac fibroblasts	angiotensin II (Ang II) treatment	Overexpression of AK045171 attenuated cardiac hypertrophy both in vitro and in vivo.	32087602
12698	Mouse	AK054386	lncRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	BNL-CL2	hypoxia induce	upregulated	31827704
12699	Mouse	AK077216	lncRNA	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL)	osteoclastogenesis	RAW 264.7 cells and Bone marrow and spleen derived monocytes/macrophages	macrophage colony©\stimulating factor (M©\CSF) and receptor activator of nuclear factor ¦ÊB ligand (RANKL) treatment	upregulated	30132869
12700	Mouse	AK080622	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	decreased	25827714
12701	Mouse	AK081017	lncRNA	streptozocin (STZ)	diabetic neuropathic pain (DNP)	mouse brain tissues	streptozotocin treatment	dysregulated	30599267
12702	Mouse	AK081284	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	Cardiac fibroblasts (CFs)	high glucose (HG) treatment	The levels of long noncoding RNA-AK081284 were increased in the CFs treated with high glucose or IL-17.	29305939
12703	Mouse	AK081284	lncRNA	IL-17	diabetic cardiomyopathy (DCM)	Cardiac fibroblasts (CFs)	IL-17 treatment	IL-17 treatment increased the expression of AK081284 in CFs.	29305939
12704	Mouse	AK081284	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	cardiac tissues	streptozocin (STZ) treatment	upregulated	29305939
12705	Mouse	AK083162	lncRNA	X-rays	radiation-induced injury	mouse thymocytes	X-ray irradiation	downregulated	27864278
12706	Mouse	AK083183	lncRNA	radiation	radiation-induced intestinal injury	intestinal tissues	radiation treatment	downregulated	30324649
12707	Mouse	AK085865	lncRNA	dermatophagoides farinae protein 1(Der f1)	allergic asthma (AA)	M2 macrophages	Der f1 treatment	upregulated	32247269
12708	Mouse	AK085865	lncRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	M1 macrophages	coxsackievirus B3 (CVB3) treatment	upregulated	32220054
12709	Mouse	AK085865	lncRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	heart sissues	Coxsackievirus B3 (CVB3) infection	downregulated	32668391
12710	Mouse	AK089579	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	decreased	25827714
12711	Mouse	AK133602	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	AK133602 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
12712	Mouse	AK133602	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	downregulated	29115403
12713	Mouse	AK133602	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	AK133602 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
12714	Mouse	AK142426	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	upregulated	25827714
12715	Mouse	AK144841	lncRNA	"promoter (7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA)"	cutaneous squamous cell carcinoma (cSCC)	cSCC and highly tumorigenic cells	"DMBA,TPA treatment"	upregulated	28596382
12716	Mouse	AK148321	lncRNA	lipopolysaccharide (LPS)	neuroinflammation	BV2 cells	lipopolysaccharide (LPS) treatment	LPS treatment suppressed AK148321 expression in BV2 cells.	33301806
12717	Mouse	AK148321	lncRNA	lipopolysaccharide (LPS)	neuroinflammation	BV2 cells	lipopolysaccharide (LPS) treatment	LPS treatment suppressed AK148321 expression in BV2 cells. Overexpression of AK148321 inhibited LPS-induced BV2 microglial cell activation and decreased the expression of inflammatory cytokine TNF-¦Á and IL-1¦Â.	33301806
12718	Mouse	AK149641	lncRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	downregulated of lncRNA-AK149641 attenuated the airway inflammatory response in an OVA-induced asthma mouse model.	32929606
12719	Mouse	AK156531	lncRNA	propofol (PPF)	acute neurotoxicity	hippocampus	propofol treatment	downregulated	30261491
12720	Mouse	AK157361	lncRNA	radiation	radiation-induced intestinal injury	intestinal tissues	radiation treatment	upregulated	30324649
12721	Mouse	ANCR	lncRNA	¦Â-glycerophosphate (¦Â-GP)	arterial calcification	vascular smooth muscle cells (VSMCs)	¦Â-glycerophosphate (¦Â-GP) treatment	ANCR may inhibit the osteoblastic differentiation of VSMCs and attenuate mice arterial calcification through activating autophagy	31974677
12722	Mouse	ANRIL	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells	32069473
12723	Mouse	ANRIL	lncRNA	metformin (Met)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	Metformin treatment	Metformin activates AMPK to suppress the formation of atherosclerotic plaque through upregulation of lncRNA-ANRIL.	33411680
12724	Mouse	ANRIL	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	MPC5 cells	high glucose (HG) treatment	upregulated	32617859
12725	Mouse	ANRIL	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	N-2a cells	oxygen and glucose deprivation treatment	ANRIL protects N-2a cells against ischemia induced injury by elevated CAV-1 by competitively interacting with miR-199a-5p	31907708
12726	Mouse	ANRIL	lncRNA	ischemia	type 2 diabetes mellitus (T2DM)	peripheral venous blood	ligation of the left anterior descending coronary artery treatment	upregulated	31469688
12727	Mouse	ANRIL	lncRNA	streptozocin (STZ)	wound healing	granulation tissues	streptozocin (STZ) treatment	"ANRIL was downregulated, in the diabetic wound healing mouse model"	30565672
12728	Mouse	Arid2-IR	lncRNA	high fat diet (HFD)	diabetic nephropathy (DN)	mouse kidney tissues	high fat diet (HFD) feed	Arid2-IR was increased in mice with high-fat diet and streptozotocin-induced type 2 diabetes and in mouse mesangial cells cultured with high glucose to mimic diabetes	30462533
12729	Mouse	Arid2-IR	lncRNA	high fat diet (HFD) and streptozotocin (STZ)	diabetic nephropathy (DN)	kidney tissues	high fat diet (HFD) and streptozotocin (STZ) treatment	upregulated	30462533
12730	Mouse	Arid2-IR	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells	high glucose (HG) treatment	upregulated	30462533
12731	Mouse	Arid2-IR	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells	high glucose treatment	Arid2-IR was increased in mice with high-fat diet and streptozotocin-induced type 2 diabetes and in mouse mesangial cells cultured with high glucose to mimic diabetes	30462533
12732	Mouse	Arid2-IR	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	mouse kidney tissues	streptozotocin treatment	Arid2-IR was increased in mice with high-fat diet and streptozotocin-induced type 2 diabetes and in mouse mesangial cells cultured with high glucose to mimic diabetes	30462533
12733	Mouse	ASIR	lncRNA	insulin	cell metabolism	mouse primary Adipocyte culture	insulin treatment	upregulated	30948776
12734	Mouse	AU015836	lncRNA	glyoxylate	kidney damage and kidney stones	C57BL/6J mice	glyoxylate	upregulated	29160413
12735	Mouse	AU020206	lncRNA	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)"	rheumatoid arthritis (RA)	TM3 Leydig cells	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment"	upregulated	33360214
12736	Mouse	AW112010	lncRNA	H2O2	age-related hearing loss (AHL)	HEI-OC1 Cells	H2O2 treatment	upregulated	31781342
12737	Mouse	B230206L02Rik	lncRNA	propofol (PPF)	propofol-induced neurotoxicity	hippocampus	propofol treatment	downregulated	29628875
12738	Mouse	BACE1AS	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	downregulated	32626785
12739	Mouse	Bace1-as	lncRNA	memantine	Alzheimer's disease (AD)	brain and blood tissues	memantine treatment	upregulated	32648077
12740	Mouse	BC049991	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	decreased	25827714
12741	Mouse	BDNF-AS	lncRNA	hypoxia	apoptosis	C57BL/6J mice neonatal cardiomyocyte	treat with either long (Hypoxia (L)) or short (Hypoxia (S)) H/R	upregulated	28363791
12742	Mouse	Blnc1	lncRNA	oxygen glucose deprivation (OGD)	intracerebral haemorrhage (ICH)	brain tissues	oxygen and glucose deprivation (OGD) treatment	"Blnc1 was upregulated in perihematomal edema, hematoma and microvessel in the brain of ICH mice"	33359247
12743	Mouse	Blnc1	lncRNA	oxygen glucose deprivation (OGD)	intracerebral haemorrhage (ICH)	primary brain microvascular endothelial cells (BMVECs)	oxygen and glucose deprivation (OGD) treatment	upregulated	33359247
12744	Mouse	Blnc1	lncRNA	high fat diet (HFD)	mitochondrial function of white adipose tissue (WAT)	3T3-L1 pre-adipocytes	high fat diet (HFD) feed	Blnc1 Protects Against Diet-Induced Obesity by Promoting Mitochondrial Function in White Fat	32368112
12745	Mouse	Blnc1	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	30061575
12746	Mouse	Braveheart	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	upregulated	32626785
12747	Mouse	Bvht	lncRNA	hypoxia/reoxygenation (H/R)	epithelial-mesenchymal transition (EMT)	MSCs	exposure to hypoxia (1% O2) and serum deprivation for 24 h	upregulated	28095922
12748	Mouse	C0300307D09Rik	lncRNA	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)"	rheumatoid arthritis (RA)	TM3 Leydig cells	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment"	upregulated	33360214
12749	Mouse	C2dat2	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Mouse N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33833132
12750	Mouse	CASC15	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocyte	angiotensin II (Ang II) treatment	CASC15 expression was upregulated when cardiomyocytes were treated with Ang-II.	29966657
12751	Mouse	CASC2	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	29492259
12752	Mouse	CASC2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocyte cells	high glucose treatment	downregulated	29890555
12753	Mouse	CCAT-1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	Podocytes were isolated from mice	tumor necrosis factor alpha (TNF-¦Á) treatment	CCAT1 induction critically participated in apoptosis inhibition in podocytes through autophagy inhibition via increasing PI3K/Akt signaling	31468575
12754	Mouse	CCAT-1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	podocyte apoptosis	Podocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	CCAT1 induction critically participated in apoptosis inhibition in podocytes through autophagy inhibition via increasing PI3K/Akt signaling	31468575
12755	Mouse	CHCHD4P4	lncRNA	glyoxylate	kidney damage and kidney stones	C57BL/6J mice	glyoxylate	upregulated	29160413
12756	Mouse	chr15:95864225-95894541+	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	upregulated	29991023
12757	Mouse	chr18:35610871-35613502+	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	upregulated	29991023
12758	Mouse	chr19:16705875-16710941-	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	upregulated	29991023
12759	Mouse	chr19:42562552-42564341+	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	downregulated	29991023
12760	Mouse	chr3:141922094:141940965	circRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse primary kidney GEC (C57-6014G) and mouse glomerular mesangial cells (GMC) (SV40 MES 13) and derived exosomes	high glucose (HG) treatment	downregulated	31497190
12761	Mouse	chr3:72958113-72960367-	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	downregulated	29991023
12762	Mouse	chr3:96041338-96042928-	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	upregulated	29991023
12763	Mouse	chr5:32640331-32664400+	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	downregulated	29991023
12764	Mouse	chr5:64096979-64108263+	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	upregulated	29991023
12765	Mouse	chr8:79343654-79372364-	circRNA	radiation	radiation-induced injury	jejuna	radiation treatment	downregulated	29991023
12766	Mouse	CHRF	lncRNA	isoprenaline	cardiac hypertrophy	primary cardiomyocytes	isoprenaline (ISO) tteatment	CHRF expression was upregulated and miR-93 expression was downregulated in mice and cellular models of cardiac hypertrophy.	29747050
12767	Mouse	CHRF	lncRNA	valsartan (VAL)	doxorubicin (DOX)-induced cardiotoxicity	primarymyocardialcells	valsartan (VAL) treatment	The expression of CHRF was downregulated by valsartan (VAL) treatment in doxorubicin (DOX)-induced heart failure	29124661
12768	Mouse	CHRF	lncRNA	doxorubicin (DOX)	heart failure (HF)	C57BL/6 male mice	doxorubicin treatment	upregulated	29124661
12769	Mouse	CHRF	lncRNA	IL-6	osteoarthritis (OA)	ATDC5 cells	IL-6 treatment	IL©\6 upregulated lncRNA CHRF in ATDC5 cells. Overexpression of lncRNA CHRF aggravated IL©\6©\evoked inflammatory damages in ATDC5 cells.	31026064
12770	Mouse	circAkap7	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	primary astrocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Exosomes Derived From CircAkap7-Modified Adipose-Derived Mesenchymal Stem Cells Protect Against Cerebral Ischemic Injury	33123535
12771	Mouse	circARF3	circRNA	high fat diet (HFD)	adipose inflammation	mouse adipose tissues	high fat diet (HFD) feed	Overexpressing TRAF3 attenuated miR-103-induced inflammation by accelerating mitophagy.	30623853
12772	Mouse	circArhgap12	circRNA	doxorubicin (DOX)	cardiotoxicity	heart tissues	doxorubicin (DOX) treatment	CircRNA-Arhgap12 was upregulated in the mouse heart tissue upon DOX intervention.	33245966
12773	Mouse	circArhgap12	circRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart tissue	doxorubicin (DOX) treatment	"we found that a circRNA coded by the Arhgap12 gene, termed circArhgap12, was upregulated in the mouse heart tissue upon DOX intervention. circArhgap12 might play a competitive role among endogenous RNAs in mouse cardiomyocytes during DOX-induced cardiotoxicity."	33245966
12774	Mouse	circATP9b	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	32308754
12775	Mouse	circAtp9b	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse chondrocytes	IL-1¦Â treatment	circRNA_Atp9b expression was significantly upregulated in mouse chondrocytes after stimulation with interleukin-1 beta (IL-1¦Â).	29305974
12776	Mouse	circBbs9	circRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	lung tissues; blood; RAW264.7 cells	Fine particulate matter (PM2.5) treatment	upregulated	32707273
12777	Mouse	circCalm4	circRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	lung tissues	hypoxia treatment		32008463
12778	Mouse	circCalm4	circRNA	hypoxia	pulmonary hypertension (PH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	33657879
12779	Mouse	circCBFB	circRNA	acetaminophen (APAP)	liver damage	AML12 cells	acetaminophen (APAP) treatment	circ-CBFB acts as a miRNA sponge of miR-185-5p to mediate p66Shc in APAP-induced liver injury.	33159035
12780	Mouse	circCd84	circRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	downregulated	32337768
12781	Mouse	circCDH13	circRNA	destabilization of medial meniscus (DMM)	osteoarthritis (OA)	artilage tissues	destabilization of medial meniscus (DMM) treatment	CircCDH13 contributes to OA pathogenesis by functioning as a sponge of miR-296-3p and regulating the miR-296-3p-PTEN pathway.	33037617
12782	Mouse	circCDR1as	circRNA	diosbuibin B (DB)	gastric cancer (GC)	"human gastric cancer cell lines (MGC803, BGC-823 and SGC7901)"	diosbuibin B (DB) treatment	knock-down of CircRNA CDR1as specifically promoted the cytotoxic effects of low-dose DB on GC cells instead of hepatocytes by regulating miR-7-5p/REG¦Ã axis.	31542615
12783	Mouse	circCOL1A2	circRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal tissues	streptozotocin (STZ) treatment	upregulated	32497630
12784	Mouse	circDcbld2	circRNA	bisphenol A (BPA)	apoptosis	?GC-2 cells	bisphenol A (BPA) treatment	upregulated	31020848
12785	Mouse	circDdx17	circRNA	ovalbumin (OVA)	allergic rhinitis (AR)	spleen cells	ovalbumin (OVA) treatment	circDdx17 were decreased in OVA-induced AR mice.	31999672
12786	Mouse	circDLGAP4	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	"ventral midbrains, mouse dopaminergic neuronal cell line MN9D"	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	circDLGAP4 expression was decreased in MPTP-induced PD mouse model and MPP+-induced PD cell models.	31761328
12787	Mouse	circDLGAP4	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	circDLGAP4 expression was decreased in MPTP-induced PD mouse model.	31761328
12788	Mouse	circDYM	circRNA	chronic unpredictable mild stress (CUMS)	depression	plasma and hippocampus	chronic unpredictable stress (CUS) treatment	downregulated	30413800
12789	Mouse	circDYM	circRNA	lipopolysaccharide (LPS)	depression	plasma and hippocampus	lipopolysaccharide (LPS) treatment	downregulated	30413800
12790	Mouse	circDYM	circRNA	chronic unpredictable stress (CUMS) and lipopolysaccharide (LPS)	major depressive disorder (MDD)	plasma; hippocampus	chronic unpredictable stress (CUS) and lipopolysaccharide (LPS) treatment	downregulated	30413800
12791	Mouse	circEhmt1	circRNA	hypoxia	diabetic retinopathy (DR)	endotheliocytes	hypoxia treatment	We also found that hypoxia upregulated circEhmt1 expression in pericytes	33815662
12792	Mouse	circELF2	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	32308754
12793	Mouse	circEPRS	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	32308754
12794	Mouse	circFBXW4	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	32308754
12795	Mouse	circFBXW4	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	upregulated	32308754
12796	Mouse	circFoxO3	circRNA	glutamate	neurodegenerative diseases	HT22 cells	glutamate treatment	Silencing of circFoxO3 Protects HT22 Cells from Glutamate-Induced Oxidative Injury via Regulating the Mitochondrial Apoptosis Pathway	32140899
12797	Mouse	circHECTD1	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral infarction (CI)	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Circ_HECTD1 and FSTL1 were highly expressed, and miR-27a-3p was decreased in OGD/R-treated HT22 cells"	33843447
12798	Mouse	circHECTD1	circRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation (OGD) treatment	"Circ_HECTD1 knockdown inhibited the expression of TRAF3 by targeting miR-133b, thereby attenuating neuronal injury caused by cerebral ischemia"	33148417
12799	Mouse	circHECTD1	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"The results showed that the expression of circ-HECTD1 and tumor necrosis factor receptor-associated factor 3 (TRAF3) was remarkably upregulated, while miR-133b was downregulated in oxygen-glucose deprivation (OGD)-induced HT22 cells and mouse middle cerebral artery occlusion (MCAO) model circ-HECTD1 knockdown relieved OGD-caused neuronal cell death in vitro Simultaneously, circ-HECTD1 knockdown improved cerebral infarction volume and neuronal apoptosis in MCAO mice"	33148417
12800	Mouse	circHECTD1	circRNA	silicon dioxide (SiO2)	macrophage activation	RAW264.7 macrophage cell line	silicon dioxide (SiO2) treatment	downregulated	29290828
12801	Mouse	circHECTD1	circRNA	silicon dioxide (SiO2)	lung fibrosis	mouse endothelial cell line (MML1)	silicon dioxide (SiO2) treatment	SiO 2 concomitantly increased circHECTD1 expression	29540674
12802	Mouse	circHIPK3	circRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4+ Th2 cells	ovalbumin induction	upregulated	32242002
12803	Mouse	circHIPK3	circRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	"circ_HIPK3 expression markedly increased in CFs and heart tissues after the treatment of Ang II. Circ_HIPK3 silencing attenuates CFs proliferation, migration and the upregulation of a-SMA expression levels induced by Ang II in vitro"	30967276
12804	Mouse	circHIPK3	circRNA	adrenaline	heart failure (HF)	Primary NMCMs (neonatal mouse cardiomyocytes)	adrenaline treatment	upregulated	31595165
12805	Mouse	circHIPK3	circRNA	lipopolysaccharide (LPS)	myocardial dysfunction	myocardial tissues; H9c2 cells	lipopolysaccharide (LPS) treatment	circHIPK3 expression is significantly upregulated when exposed to LPS in vivo and in vitro.	33240996
12806	Mouse	circHIPK3	circRNA	H2O2	myocardial infarction (MI)	cardiac endothelial cells	H2O2 treatment	downregulated	32733638
12807	Mouse	circHIPK3	circRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	mouse cardiomyocytes	ischemia/reperfusion (I/R) treatment	The expression of circHIPK3 was upregulated during myocardial I/R injury and hypoxia/reoxygenation (H/R) injury of cardiomyocytes.	33824287
12808	Mouse	circHIPK3	circRNA	hypoxia	oxidative stress	Primary cultures of neonatal mouse cardiomyocytes	hypoxia induce	upregulated	31885817
12809	Mouse	circHIPK3	circRNA	bleomycin (BLM)	lung fibrosis	fibroblast	bleomycin (BLM) treatment	upregulated	30796204
12810	Mouse	circHomer1	circRNA	methamphetamine (METH)	neuronal cell injury	HT22 cells	Methamphetamine (METH) treatment	upregulated	32450188
12811	Mouse	circIns2	circRNA	palmitate and glucose	¦Â-cell dysfunction	¦ÂTC6 cells	palmitate and glucose treatment	upregulated	32560282
12812	Mouse	circKrt13	circRNA	Sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	skin tissues	Sheng-ji Hua-yu (SJHY) treatment	downregulated	33271241
12813	Mouse	circKrt13	circRNA	Sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	ulceration surface	sheng-ji Hua-yu (SJHY) formula treatment	"RNA-seq identified 11 DE circRNAs and 476 DE mRNAs between SJHY formula-treated and diabetic mice, including 4 upregulated and 7 downregulated circRNAs, 311 upregulated and 165 downregulated mRNAs CircRNA-Krt13/miR-665-3p/Itga3 and circRNA-Krt14/miR-706/Mylk4 pathways were built, which may contribute to the healing of SJHY formula-treated diabetic wounds"	33271241
12814	Mouse	circKrt14	circRNA	Sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	skin tissues	Sheng-ji Hua-yu (SJHY) treatment	downregulated	33271241
12815	Mouse	circKrt14	circRNA	sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	ulceration surface	sheng-ji Hua-yu (SJHY) formula treatment	"RNA-seq identified 11 DE circRNAs and 476 DE mRNAs between SJHY formula-treated and diabetic mice, including 4 upregulated and 7 downregulated circRNAs, 311 upregulated and 165 downregulated mRNAs CircRNA-Krt13/miR-665-3p/Itga3 and circRNA-Krt14/miR-706/Mylk4 pathways were built, which may contribute to the healing of SJHY formula-treated diabetic wounds"	33271241
12816	Mouse	circLRP6	circRNA	high glucose (HG)	diabetic nephropathy (DN)	The mouse mesangial SV40©\Mes13 cells	"SV40©\Mes13 cells were cultured under normal glucose condition (Con, 5.5 mM glucose), mannitol condition (MN, 5.5 mM glucose + 24.5 mM mannitol), or HG condition (30 mM glucose) for 24 hr. treatment"	"circLRP6 regulates HG©\induced proliferation, oxidative stress, ECM accumulation, and inflammation in mesangial cells via sponging miR©\205"	31087368
12817	Mouse	circMapk1	circRNA	bisphenol A (BPA)	apoptosis	?GC-2 cells	bisphenol A (BPA) treatment	upregulated	31020848
12818	Mouse	circMpp6	circRNA	bisphenol A (BPA)	apoptosis	?GC-2 cells	bisphenol A (BPA) treatment	upregulated	31020848
12819	Mouse	circNFIB	circRNA	TGF-¦Â	cardiac fibrosis	primary adult cardiac fibroblasts	TGF-¦Â treatment	"The expression of circRNA-circNFIB was decreased in mice post-myocardial infarction heart samples, as well as in primary adult cardiac fibroblasts treated with TGF-¦Â Overexpression of circNFIB attenuates cardiac fibroblast proliferation induced by TGF-¦Â"	31316543
12820	Mouse	circPAN3	circRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	mouse cardiomyocytes	ischemia/reperfusion (I/R) treatment	"?In this study, we found that the expression of circPAN3 (circular RNA PAN3) was decreased in a mouse model of myocardial I/R."	33483599
12821	Mouse	circPostn	circRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	mouse cardiomyocytes	hypoxia and reoxygenation (H/R) treatment	"We identified that the expression of circPostn was elevated in the plasma of MI patients, MI mouse model, and hypoxia and reoxygenation (H/R)-treated human cardiomyocytes."	33681183
12822	Mouse	circPPM1F	circRNA	lipopolysaccharide (LPS)	pancreatic islet injury	M1 macrophage	Lipopolysaccharide (LPS) treatment	circPPM1F is a novel positive regulator of M1 macrophage activation through the circPPM1F-HuR-PPM1F-NF-¦ÊB axis.	33042261
12823	Mouse	circPSD3	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	"For instance, the expression of circPSD3, a circRNA derived from the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene, was considerably downregulated in primary hepatic stellate cells (HSCs) and liver tissues of mice with CCl4-induced HF compared to those in the vehicle group."	33614234
12824	Mouse	circPtchd2	circRNA	prenatal alcohol exposure (PAE)	fetal alcohol spectrum disorders (FASD)	brain	prenatal alcohol exposure (PAE) treatment	upregulated	33304235
12825	Mouse	circRar1	circRNA	lead (Pb)	lead (Pb) toxicity	mouse neuroblastoma N2a cells	PbAc treatment	upregulated	27604105
12826	Mouse	circRasGEF1B	circRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	28947785
12827	Mouse	circRIC3	circRNA	melatonin	calcific aortic valve disease (CAVD)	valvular interstitial cells	melatonin treatment	melatonin ameliorates aortic valve calcification via the regulation of CircRIC3/miR-204-5p/DPP4 signaling in hVICs	32369647
12828	Mouse	circRIMS2	circRNA	aerobic exercise	vascular cognitive impairment (VCI)	HT22 cells	aerobic exercise training (AET) treatment	"Aerobic exercise could shorten the average time that mice reached the platform in the Morris water maze, increase the expression level of circRIMS2 and BDNF, reduce miR-186 expression, and inhibit neuronal apoptosis."	33413076
12829	Mouse	circRPRD1b	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	32308754
12830	Mouse	circRtn4	circRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoporosis	MC3T3-E1 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	Rtn4-Exos attenuated TNF-¦Á-induced cytotoxicity and apoptosis in murine MC3T3-E1 cells by sponging miR-146a	32400849
12831	Mouse	circS-7	circRNA	hypoxia	myocardial infarction (MI)	cardiomyocytes	hypoxia treatment	upregulated	26998750
12832	Mouse	circSAMD4A	circRNA	high fat diet (HFD)	obesity	preadipocyte	high fat diet (HFD) feed	"CircSAMD4A regulated preadipocyte differentiation by acting as a miR-138-5p sponge, and thus increasing EZH2 expression."	32292524
12833	Mouse	circSHOC2	circRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary astrocytes	oxygen glucose deprivation (OGD) treatment	circSHOC2 in IPAS-EXOs suppressed neuronal apoptosis and ameliorated neuronal damage by regulating autophagy and acting on the miR-7670-3p/SIRT1 axis	33230464
12834	Mouse	circSOS1	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	32308754
12835	Mouse	circTADA2A	circRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung tissues	bleomycin (BLM) treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2.	32694556
12836	Mouse	circTbc1d20	circRNA	bisphenol A (BPA)	apoptosis	?GC-2 cells	bisphenol A (BPA) treatment	upregulated	31020848
12837	Mouse	circTns3	circRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	downregulated	32337768
12838	Mouse	circUBE2K	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	upregulated	32308754
12839	Mouse	circUCK2	circRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HT-22 cells	oxygen-and-glucose-deprivation (OGD) treatment	Overexpression of circRNA circUCK2 Attenuates Cell Apoptosis in Cerebral Ischemia-Reperfusion Injury via miR-125b-5p/GDF11 Signaling	33230465
12840	Mouse	circWBSCR17	circRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney cortex tissues	streptozotocin (STZ) treatment	upregulated	32798559
12841	Mouse	circWdr91	circRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	downregulated	32337768
12842	Mouse	circWwp1	circRNA	isoproterenol hydrochloride	cardiac hypertrophy	left ventricular specimens	isoproterenol hydrochloride treatment	downregulated	32023551
12843	Mouse	circZC3H4	circRNA	silicon dioxide (SiO2)	lung fibrosis	RAW264.7 cells	silicon dioxide (SiO2) treatment	upregulated	29401612
12844	Mouse	circZNF609	circRNA	adriamycin (ADR)	focal segmental glomerulosclerosis (FSGS)	kidney tissues	adriamycin (ADR) treatment	upregulated	32800553
12845	Mouse	COX2	lncRNA	bacillus calmette-guerin (BCG)	apoptosis	RAW264.7 cells	bacillus calmette-guerin (BCG) treatment	upregulated	33250268
12846	Mouse	COX2	lncRNA	bacillus calmette-guerin (BCG)	apoptosis	RAW264.7 cells	bacillus calmette-guerin(BCG) infection	"In this study, we found Bacillus Calmette-Guerin(BCG)infection induced cell apoptosis with a increasing LincRNA-Cox2 expression in RAW264.7 cells.?si-LincRNA-Cox2 was capable of increased the expression of apoptosis-associated proteins and accumulation of ROS in BCG-infected RAW264.7 cells."	33250268
12847	Mouse	COX2	lncRNA	lipopolysaccharide (LPS)	cell proliferation	microglial cells	lipopolysaccharide (LPS) treatment	lincRNA-Cox2-siRNA loaded EVs also decreased LPS-induced microglial proliferation in mice.	31325121
12848	Mouse	COX2	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory response	IEC cell line	tumor necrosis factor alpha (TNF-¦Á) treatment	"lincRNA-Cox2 silencing significantly (P < 005) enhanced the transcription of Il12b, a secondary late-responsive gene induced by TNF-¦Á Mechanistically, lincRNA-Cox2 promoted the recruitment of the Mi-2/nucleosome remodeling and deacetylase (Mi-2/NuRD) repressor complex to the Il12b promoter region"	26578685
12849	Mouse	COX2	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	upregulated	32626785
12850	Mouse	COX2	lncRNA	Rhein	uric acid nephropathy (UAN)	Mouse kidney epithelial cell line (TCMK-1)	Rhein treatment	Rhein attenuates inflammatory injury of TCMK-1 cells and represses lincRNA-Cox2 expression	32504995
12851	Mouse	COX2	lncRNA	lipopolysaccharide (LPS)	hepatocellular carcinoma (HCC)	RAW264.7 macrophages	lipopolysaccharide (LPS) treatment	upregulated	29131381
12852	Mouse	COX2	lncRNA	lipopolysaccharide (LPS)	hepatocellular carcinoma (HCC)	RAW264.7 macrophages	lipopolysaccharide (LPS) treatment	upregulated	29131381
12853	Mouse	COX2	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	mouse	carbon tetrachloride (CCl4) treatment	upregulated	28259935
12854	Mouse	CRNDE	lncRNA	parathyroid hormone (PTH)	bone metabolism	MC3T3-E1 cells	parathyroid hormone induction treatment	Crnde regulates osteoblast proliferation through the Wnt/¦Â-catenin signaling pathway in mice	31622775
12855	Mouse	CRNDE	lncRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts (CFs)	TGF-¦Â1 treatment	upregulated	30748104
12856	Mouse	CRNDE	lncRNA	parathyroid hormone (PTH)	cell differentiation	MC3T3-E1 cells	Parathyroid hormone (PTH) treatment	upregulated	31622775
12857	Mouse	CRNDE	lncRNA	doxorubicin (DOX)	heart failure (HF)	HL-1 cells	doxorubicin (Dox) treatment	downregulated	33249529
12858	Mouse	CRNDE	lncRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colitis tissues	dextran sulfate sodium (DSS) treatment	CRNDE in the DSS-induced colitis tissues.	31251902
12859	Mouse	CRNDE	lncRNA	dexamethasone (DEX)	osteoporosis	human bone marrow mesenchymal stem cell (hBMSC)	Dexamethasone (Dex) treatment	"Dex downregulated CRNDE expression, whereas NBIF upregulated CRNDE."	33713471
12860	Mouse	CRNDE	lncRNA	neobavaisoflavone (NBIF)	osteoporosis	human bone marrow mesenchymal stem cell (hBMSC)	Neobavaisoflavone (NBIF)? treatment	"Dex downregulated CRNDE expression, whereas NBIF upregulated CRNDE."	33713471
12861	Mouse	CRNDE	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	mouse kidney tissues	lipopolysaccharide (LPS) treatment	upregulated	31841203
12862	Mouse	CTD-2574D22.4	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	mouse ATDC5 cells	lipopolysaccharides (LPS) treatment	upregulated	31368870
12863	Mouse	Cyrano	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	downregulated	32626785
12864	Mouse	CYTOR	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cardiomyocyte	angiotensin II (Ang II) treatment	CYTOR knockdown significantly enhanced the inducible effect of AB operation on mice myocardial hypertrophy and Angiotensin II on cardiomyocyte hypertrophy.	30794866
12865	Mouse	D63785	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuron apoptosis	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32999283
12866	Mouse	DACH1	lncRNA	hypoxia	heart failure (HF)	heart tissues	transverse aortic constriction surgery treatment	upregulated	31446800
12867	Mouse	Dlk1-Dio3	lncRNA	phenobarbital (PB)	hepatocellular carcinoma (HCC)	hepatocyte	phenobarbital (PB) treatment	Dlk1-Dio3 ncRNAs as novel candidate early biomarkers for mouse liver tumor promotion	23091169
12868	Mouse	Dlx6os1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	SV40 MES13 cells	high glucose (HG) treatment	Long non-coding RNA Dlx6os1 serves as a potential treatment target for diabetic nephropathy via regulation of apoptosis and inflammation.	32855728
12869	Mouse	DNM3OS	lncRNA	high fat diet (HFD)	diabetes mellitus (DM)	peritoneal macrophages (PMs)	high fat diet (HFD) feed	upregulated	29930005
12870	Mouse	DNM3OS	lncRNA	high glucose (HG)	diabetes mellitus (DM)	bone marrow-derived macrophages (BMDMs)	high glucose feed	upregulated	29930005
12871	Mouse	DNM3OS	lncRNA	palmitic acid (PA)	diabetes mellitus (DM)	bone marrow-derived macrophages (BMDMs)	palmitic acid (PA) treatment	upregulated	29930005
12872	Mouse	DNM3OS	lncRNA	streptozocin (STZ)	diabetes mellitus (DM)	peritoneal macrophages (PMs)	streptozotocin (STZ) treatment	upregulated	29930005
12873	Mouse	DNM3OS	lncRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	lung tissues	transforming growth factor-¦Â (TGF-¦Â) treatment	lncRNA DNM3OS was upregulated in TGF-¦Â treatment of lung fibroblastsinterfering with DNM3OS function not only prevents lung fibrosis but also improves established pulmonary fibrosis	30964696
12874	Mouse	DQ786227	lncRNA	benzo(a)pyrene (BaP)	lung cancer	BEAS-2B cells	benzo(a)pyrene (BaP) exposure	lncRNA-DQ786227 acts as an oncogene in malignantly transformed BEAS-2B cells induced by benzo(a)pyrene	24084393
12875	Mouse	DSCAM-AS1	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocytes	angiotensin II (Ang II) treatment	DSCAM-AS1 mediates pro-hypertrophy role of GRK2 in cardiac hypertrophy aggravation via absorbing miR-188-5p.	32377998
12876	Mouse	DYN-LRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Raw264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28815701
12877	Mouse	DYN-LRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	cholesterol efflux	RAW 264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LincRNA DYN-LRB2-2 was upregulated in oxLDL-treated Raw264.7 cells.	28815701
12878	Mouse	E230001N04Rik	lncRNA	propofol (PPF)	propofol-induced neurotoxicity	hippocampus	propofol treatment	upregulated	29628875
12879	Mouse	E330013P06	lncRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	C57BL/6J mice macrophage	"streptozotocin (50mg/kg) for 5 consecutive days. In diet-induced T2D models, f high-fat diet for 4 weeks and then inject a single dose of SZ (100mg/kg) treatment"	upregulated	25008173
12880	Mouse	E52329	lncRNA	Japanese encephalitis virus (JEV)	neuroinflammation	mouse brain	infect with JEV	dysregulated	29033949
12881	Mouse	Tmpo	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	downregulated	32246647
12882	Mouse	Gm15996	lncRNA	high fat diet (HFD)	male infertility	C57bl/6J mice	high fat diet (HFD) feed	dysregulated	28599310
12883	Mouse	Mthfd2	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	downregulated	32246647
12884	Mouse	BC012245.1	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	upregulated	32246647
12885	Mouse	CCDS19728.1	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	upregulated	32246647
12886	Mouse	ENSMUST00000053838	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	upregulated	25827714
12887	Mouse	Gm7816	lncRNA	X-rays	radiation-induced injury	mouse thymocytes	X-ray irradiation	upregulated	27864278
12888	Mouse	ENSMUST00000082683	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	placenta	high fat diet (HFD) feed	downregulated	29986645
12889	Mouse	Gm6166	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	downregulated	29986645
12890	Mouse	Gm11295	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	downregulated	29986645
12891	Mouse	Gm14328	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	downregulated	29986645
12892	Mouse	Hectd2os	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	ENSMUST00000129953 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
12893	Mouse	Hectd2os	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	downregulated	29115403
12894	Mouse	Hectd2os	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	ENSMUST00000129953 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
12895	Mouse	Gm13709	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	ENSMUST00000138573 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
12896	Mouse	Gm13709	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	downregulated	29115403
12897	Mouse	Gm13709	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	ENSMUST00000138573 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
12898	Mouse	Dnm3os	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	upregulated	31833538
12899	Mouse	ENSMUST00000145208	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	ENSMUST00000145208 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
12900	Mouse	ENSMUST00000145208	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	ENSMUST00000145208 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
12901	Mouse	F730043M19Rik	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	downregulated	31833538
12902	Mouse	BI665410.1	lncRNA	streptozocin (STZ)	diabetic neuropathic pain (DNP)	mouse brain tissues	streptozotocin treatment	dysregulated	30599267
12903	Mouse	Ufm1-205	lncRNA	cigarette smoke (CS)	airway inflammation	C57BL/6 mice lung tissue	cigarette smoke (CS) exposure	dysregulated	29383188
12904	Mouse	Hmcn1-205	lncRNA	cigarette smoke (CS)	airway inflammation	C57BL/6 mice lung tissue	cigarette smoke (CS) exposure	dysregulated	29383188
12905	Mouse	Matr3-ps2-201	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	upregulated	31833538
12906	Mouse	AK164970?	lncRNA	pressure overload	heart failure (HF)	heart sissues	pressure overload treatment	upregulated	33224746
12907	Mouse	AK079754.1	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	downregulated	31833538
12908	Mouse	AA079447.	lncRNA	radiation	radiation-induced intestinal injury	intestinal tissues	radiation treatment	upregulated	30324649
12909	Mouse	Gm20662-201	lncRNA	cigarette smoke (CS)	airway inflammation	C57BL/6 mice lung tissue	cigarette smoke (CS) exposure	dysregulated	29383188
12910	Mouse	Gm17501-201	lncRNA	cigarette smoke (CS)	airway inflammation	C57BL/6 mice lung tissue	cigarette smoke (CS) exposure	dysregulated	29383188
12911	Mouse	Pigbos1-201	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	upregulated	31833538
12912	Mouse	Gm10603-202	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	upregulated	31833538
12913	Mouse	Gm38077-201	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	fetal mice palates	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	31961203
12914	Mouse	BC016005.1	lncRNA	Tripterysium Glycosides Tablets (TGT)	rheumatoid arthritis (RA)	peripheral blood	Tripterysium Glycosides Tablets (TGT) treatment	downregulated	33135351
12915	Mouse	DA040518.1	lncRNA	carbon tetrachloride (CCl4)	epithelial-mesenchymal transition (EMT)	liver tissues	carbon tetrachloride (CCl4) treatment	"ENST00000530691, named Mical2, was significantly upregulated in liver fibrosis."	32659284
12916	Mouse	EPR	lncRNA	TGF-¦Â	cell proliferation	"Murine immortalized NMuMG cells, 4T1 mouse mammary gland cancer cells"	TGF-¦Â treatment	TGF-¦Â induced a small increase in EPR levels followed by rapid downregulated	31036808
12917	Mouse	EPS	lncRNA	caerulein (Cae)	acute pancreatitis (AP)	pancreases tissues	caerulein (Cae) treatment	"lincRNA-EPS was significantly downregulated in the pancreases from Cer-AP-10h mice, while it was dramatically upregulated in the pancreases from Cer-AP-22h mice."	33512718
12918	Mouse	EPS	lncRNA	sodium taurocholate	acute pancreatitis (AP)	pancreases tissues	sodium taurocholate treatment	"lincRNA-EPS was significantly downregulated in the pancreases from NaTc-SAP-2h mice, while it was dramatically upregulated in the pancreases from NaTc-SAP-24h and NaTc-SAP-36h mice"	33512718
12919	Mouse	Erbb4-IR	lncRNA	TGF-¦Â1	renal fibrosis	"mTEC,MEF cells"	TGF-¦Â1 treatment	upregulated	29102563
12920	Mouse	Erbb4-IR	lncRNA	TGF-¦Â1	renal fibrosis	mouse tubular epithelial cells (mTECs)	TGF-¦Â1 treatment	Erbb4-IR was upregulated by TGF-¦Â1 stimulation in a time- and dose-dependent manner	29102563
12921	Mouse	FAO	lncRNA	lipopolysaccharide (LPS)	inflammation	murine bone marrow-derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	lncFAO is induced late after lipopolysaccharide (LPS) stimulation of cultured macrophages and in Ly6Chi monocyte-derived macrophages in damaged tissue during the resolution and reparative phases.	32513690
12922	Mouse	Fendrr	lncRNA	high glucose (HG) and hypoxia/reoxygenation (H/R)	diabetic cerebral ischemia-reperfusion (I/R) injury	BV-2 cells	high glucose followed by hypoxia/reoxygenation (H/R) treatment	"Fendrr was significantly increased in the diabetic cerebral I/R model, and NLRC4 inflammatory complex and pyroptosis mediated inflammatory factors were increased."	33858325
12923	Mouse	FENDRR	lncRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	mouse lungs; primary lung fibroblasts	bleomycin (BLM) treatment	FENDRR reduced pulmonary fibrosis by inhibiting fibroblast activation by reducing iron concentration and acting as a competing endogenous RNA of the profibrotic microRNA-214.	31697569
12924	Mouse	FIRRE	lncRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	mouse microglial cells	lipopolysaccharide (LPS) treatment	FIRRE expression was upregulated in the spinal cord tissue of female CCI mice and LPS-induced microglial cells.	33151463
12925	Mouse	FIRRE	lncRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	mouse primary microglial cells	lipopolysaccharide (LPS) treatment	downregulated of lncRNA FIRRE relieved the neuropathic pain of female mice by suppressing HMGB1 expression.	33151463
12926	Mouse	FLRL2	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	¦Á-Mouse liver (AML) 12 cells	free fatty acids treatment	downregulated	31311301
12927	Mouse	FLRL2	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	Liver tissues	high fat diet (HFD) feed	downregulated	31311301
12928	Mouse	FOXC2-AS1	lncRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart tissues	doxorubicin (Dox) treatment	FOXC2-AS1 was downregulated in heart tissues of mice with Dox-induced cardiotoxicity.	30558506
12929	Mouse	FOXC2-AS1	lncRNA	doxorubicin (DOX)	cardiotoxicity	heart tissues	doxorubicin (Dox)?treatment	lncRNA FOXC2-AS1 may upregulate WISP1 to protect cardiomyocytes from doxorubicin-induced cardiotoxicity.	30558506
12930	Mouse	FOXD3-AS1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33068927
12931	Mouse	FOXD3-AS1	lncRNA	hyperoxia	lung injury	lung tissues	treat with ROS	upregulated	28655711
12932	Mouse	FR022494	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4 + T cells	ovalbumin (OVA) treatment	upregulated	29287883
12933	Mouse	FR169472	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4 + T cells	ovalbumin (OVA) treatment	upregulated	29287883
12934	Mouse	FR255904	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4 + T cells	ovalbumin (OVA) treatment	upregulated	29287883
12935	Mouse	FR285768	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4 + T cells	ovalbumin (OVA) treatment	downregulated	29287883
12936	Mouse	FR288904	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4 + T cells	ovalbumin (OVA) treatment	downregulated	29287883
12937	Mouse	FR301516	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4 + T cells	ovalbumin (OVA) treatment	downregulated	29287883
12938	Mouse	FTX	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse cardiac myocytes	angiotensin II (Ang II) treatment	The expression of lnc-FTX was associated with reduced hypertrophy of neonatal mouse cardiac myocytes and regulated the PTEN/PI3K/Akt signaling pathway by sponging miRNA-22	31840653
12939	Mouse	FTX	lncRNA	H2O2	cardiomyocyte apoptosis	cardiomyocytes were isolated from male mice	treat with hydrogen peroxide	downregulated	29117536
12940	Mouse	FTX	lncRNA	ischemia/reperfusion (I/R) 	cardiomyocyte apoptosis	cardiomyocytes were isolated from male mice	ischemia/reperfusion (I/R) treatment	downregulated	29117536
12941	Mouse	FTX	lncRNA	H2O2	cardiovascular disease (CVD)	cardiomyocytes	hydrogen peroxide (H2O2 ) treatment	lncRNA FTX is significantly downregulated upon ischemia/reperfusion injury and hydrogen peroxide treatment.	29117536
12942	Mouse	Galont	lncRNA	anoxia/reoxygenation (A/R)	autophagy	cardiomyocytes	anoxia/reoxygenation (A/R) treatment	Galont was upregulated by anoxia/reoxygenation (A/R) stimulus.	29247537
12943	Mouse	GAPLINC	lncRNA	lipopolysaccharide (LPS)	endotoxic shock	macrophages	lipopolysaccharide (LPS) treatment	"Upon inflammatory activation, GAPLINC is rapidly downregulated."	33568531
12944	Mouse	GAS5	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	Mouse hippocampal neuron HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33746585
12945	Mouse	GAS5	lncRNA	qingda granule (QDG)	ischemic stroke (IS)	oxygen-glucose deprivation/reoxygenation (OGD/R) treated HT22 cells	Qingda granule (QDG) treatment	downregulated	33746585
12946	Mouse	GAS5	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	MLE-12 cells; lung tissues	lipopolysaccharide (LPS) treatment	GAS5 expression was decreased in lung tissues from LPS-induced ALI mice and LPS-treated MLE-12 cells.	31837322
12947	Mouse	GAS5	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	murine alveolar epithelial cell line MLE-12	lipopolysaccharide (LPS) treatment	GAS5 suppresses inflammatory responses and apoptosis of alveolar epithelial cell MLE-12 by targeting miR-429/DUSP1 axis.	31837322
12948	Mouse	GAS5	lncRNA	adjuvant	adjuvant-induced arthritis (AIA)	cartilage	adjuvant treatment	Long noncoding RNA-GAS5 siRNA prevented cartilage destruction by inhibiting miR-103 expression.	33343265
12949	Mouse	GAS5	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4+ Th2 cells	ovalbumin induction	upregulated	32242002
12950	Mouse	GAS5	lncRNA	arsenite	arsenic-exposion	male C57BL/6J mice	arsenic (As) exposure	downregulated	29132937
12951	Mouse	GAS5	lncRNA	fasting with HIF-1¦Á inhibitor (BAY)	cardiac decompensation secondary to acute severe caloric-restriction	cardiac tissues	Fasting with HIF-1¦Á inhibitor (BAY) treatment	downregulated	32942153
12952	Mouse	GAS5	lncRNA	triiodo-l-thyronine (T3)	cardiac decompensation secondary to acute severe caloric-restriction	cardiac tissues	Triiodo-l-Thyronine (T3) treatment	downregulated	32942153
12953	Mouse	GAS5	lncRNA	isoproterenol	cardiac fibrosis	mouse heart tissues	isoproterenol (ISO)  treatment	Overexpression of GAS5 could attenuate cardiac fibrosis induced by ISO.	31173316
12954	Mouse	GAS5	lncRNA	lipopolysaccharide (LPS)	cardiac fibrosis	fibrotic heart tissues	lipopolysaccharide (LPS) treatment	downregulated	32008164
12955	Mouse	GAS5	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Primary mouse cerebral cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31278927
12956	Mouse	GAS5	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Mouse N2a neuroblastoma cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31751592
12957	Mouse	GAS5	lncRNA	streptozocin (STZ)	diabetes mellitus (DM)	skin	streptozotocin (STZ) treatment	"GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model."	33865922
12958	Mouse	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	newborn mouse cardiomyocyte (NMC)	high glucose (HG) treatment	Gas5/miR-320-3p/Tcf3 pathway was found to modulate the apoptosis of NMC.	32003049
12959	Mouse	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	HL-1 cells	high glucose (HG) treatment	LncRNA GAS5 inhibits NLRP3 inflammasome activation-mediated pyroptosis in diabetic cardiomyopathy by targeting miR-34b-3p/AHR	33092444
12960	Mouse	GAS5	lncRNA	danggui buxue tang (DBT)	diabetic nephropathy (DN)	high glucose-treated mouse mesangial cells (SV40 MES-13)	danggui buxue tang (DBT) treatment	upregulated	31481528
12961	Mouse	GAS5	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (SV40 MES-13)	high glucose treatment	downregulated	31481528
12962	Mouse	GAS5	lncRNA	magnesium-free extracellular fluid	epilepsy	primary hippocampal neuron	magnesium-free extracellular fluid culture	"lncRNA GAS5 functions as a competitive endogenous RNA of miR-135a-5p to increase expression of KCNQ3, and lncRNA GAS5 silencing inhibited the occurrence and progression of epilepsy."	31373759
12963	Mouse	GAS5	lncRNA	¦Ã-rays	gastrointestinal acute radiation syndrome	Macrophages (M?) with the M2b phenotype (Pheno2b-M?)	7-10 Gy of gamma rays treatment	downregulated	29743312
12964	Mouse	GAS5	lncRNA	arsenite	glucocorticoids (GCs) resistance	utero	arsenic (As) exposure	Total cellular Gas5 levels were lower in arsenic-exposed males with no changes seen in arsenic-exposed females at GD16 and 18.	29132937
12965	Mouse	GAS5	lncRNA	chlorogenic acid (CGA)	intestinal diseases	intestinal epithelial cells	chlorogenic acid (CGA) treatment	CGA promotes autophagy and inhibits ST infection through the GAS5/miR-23a/PTEN axis and the p38 MAPK pathway.	33240872
12966	Mouse	GAS5	lncRNA	isosteviol Sodium (STV-Na)	ischemic stroke (IS)	microglia/macrophage polarization in ischemic stroke	Isosteviol Sodium (STV-Na) treatment	downregulated	31434993
12967	Mouse	GAS5	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse primary brain neurons	oxygen-glucose deprivation (OGD) treatment	GAS5 level was elevated in neurons subjected to OGD compared with the control group	29307821
12968	Mouse	GAS5	lncRNA	hypoxia	cardiomyocytes injury	HL-1 Cells	hypoxia exposure	miR-222-3p could resume the functions of GAS5 in cell viabilities and apoptosis through protein regulation in PI3K and AKT signaling pathways.	32240616
12969	Mouse	GAS5	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	"LPS reduced cell viability and promoted cell apoptosis and secretion of inflammatory cytokines, along with downregulated of GAS5."	29448248
12970	Mouse	GAS5	lncRNA	rotenone (ROT)	parkinson's disease (PD)	brain tissues	rotenone treatment	upregulated	32470877
12971	Mouse	GAS5	lncRNA	ZCL-082	premature ovarian failure (POF)	female germline stem cell (FGSC)	ZCL-082 treatment	downregulated	31319247
12972	Mouse	GAS5	lncRNA	high fat diet (HFD) and streptozotocin (STZ)	renal fibrosis	kidney tissues	high fat diet (HFD) and streptozotocin (STZ) treatment	LncRNA Gas5(GAS5) expression was increased in kidneys of the DKD mouse model.	31810140
12973	Mouse	GAS5	lncRNA	lipopolysaccharide (LPS)	sepsis	podocyte	lipopolysaccharide (LPS) treatment	GAS5 expression decreased in a time-dependent manner in LPS-induced podocytes.	30556845
12974	Mouse	GAS5	lncRNA	dexamethasone (DEX)	severe asthma (SA)	lung tissues	dexamethasone (DEX) treatment	downregulated	32642099
12975	Mouse	GAS5	lncRNA	ovalbumin (OVA) and lipopolysaccharide (LPS)	severe asthma (SA)	lung tissues	ovalbumin (OVA) and lipopolysaccharide (LPS) treatment	upregulated	32642099
12976	Mouse	GAS5	lncRNA	TGF-¦Â	tissue fibrosis	NIH-3T3 cells	Transforming growth factor-¦Â (TGF-¦Â) treatment	LncRNA GAS5 attenuates fibroblast activation through inhibiting Smad3 signaling	32374674
12977	Mouse	GAS5	lncRNA	H2O2	traumatic brain injury (TBI)	retinal ganglion cells (RGCs)	H2O2 treatment	upregulated	30450834
12978	Mouse	GAS5	lncRNA	traditional Chinese medicine Changqin NO. 1	traumatic brain injury (TBI)	brain tissues and primary neurons	traditional Chinese medicine Changqin NO. 1 treatment	Changqin NO 1 promoted neuroprotective effects by inhibiting neuronal apoptosis via the GAS5/miR-335/Rasa1 axis in TBI	30653462
12979	Mouse	Gm11149	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	30193772
12980	Mouse	Gm11529	lncRNA	dexamethasone (DEX)	asthma	lung tissues	dexamethasone (Dex) treatment	Gm11529 was downregulated in the Dex group compared with that in the Model group.	32222886
12981	Mouse	Gm11974	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Gm11974 was mainly located in cytoplasm Knockdown of lncRNA Gm11974 alleviated the apoptosis induced by OGD and cell death rates were significantly reduced	31556305
12982	Mouse	Gm11985	lncRNA	propofol (PPF)	acute neurotoxicity	hippocampus	propofol treatment	downregulated	30261491
12983	Mouse	Gm12840	lncRNA	TGF-¦Â1	ischemia/reperfusion (I/R) injury	kidney tissues	TGF-¦Â1 treatment	LncRNA (Gm12840) could act as a sponge for miR-677-5p to mediate fibroblast activation induced by TGF-¦Â1 via the WISP1/PKB (Akt) signaling pathway	33351669
12984	Mouse	Gm13133	lncRNA	cold	obesity	mouse brown adipose	cold treatment	upregulated	28247947
12985	Mouse	Gm13133	lncRNA	"¦Â3 -adrenergic agonist ,cAMP"	obesity	mouse brown adipose	¦Â3 -adrenergic agonist and cAMP treatment	upregulated	28247947
12986	Mouse	Gm13372	lncRNA	dexamethasone (DEX)	asthma	lung tissues	dexamethasone (Dex) treatment	Gm13372 was upregulated in the Dex group compared with that in the Model group.	32222886
12987	Mouse	Gm13910	lncRNA	chronic intermittent hypoxia (CIH)	atherosclerosis (AS)	aorta tissues	Chronic intermittent hypoxia (CIH) treatment	upregulated	32328084
12988	Mouse	Gm14205	lncRNA	hormone	postpartum depression (PPD)	hippocampus	hormone treatment	Gm14205 induces astrocytic NLRP3 inflammasome activation via inhibiting oxytocin receptor in postpartum depression.	32706026
12989	Mouse	Gm14461	lncRNA	lipopolysaccharide (LPS)	trigeminal neuralgia (TN)	astrocytes	lipopolysaccharide (LPS) treatment	Silencing of lncRNA Gm14461 alleviates pain in trigeminal neuralgia through inhibiting astrocyte activation.	33141516
12990	Mouse	Gm15621	lncRNA	sevoflurane (SEV)	cognitive impairment	primary hippocampal neuron cells	sevoflurane exposure treatment	The expression of lncRNA Gm15621 was decreased with the development of sevoflurane exposure	31264218
12991	Mouse	Gm15621	lncRNA	sevoflurane (SEV)	cognitive impairment	Primary hippocampal neuron cells	"To establish an in vitro sevoflurane©\ induced neurotoxicity model, the primary hippocampal neuron cells were treated with different concentrations of sevoflurane for 6 hr treatment"	lncRNA Gm15621 located in the cytoplasm The expression of lncRNA Gm15621 was decreased with the development of sevoflurane exposure Overexpression of lncRNA Gm15621 significantly reduced the apoptosis and cell survival rates	31264218
12992	Mouse	Gm15622	lncRNA	metformin (Met)	nonalcoholic fatty liver disease (NAFLD)	AML-12 cells	metformin treatment	Metformin suppresses Gm15622 and alleviates NAFLD-associated lipid deposition in mice.	32229588
12993	Mouse	Gm15645	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	primary mouse podocyte cells	high glucose (HG) treatment	Gm15645 was significantly downregulated in podocytes under high glucose conditions.	30132544
12994	Mouse	Gm15834	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	The cardiomyocyte-like HL-1 cell lines	angiotensin II (Ang II) treatment	upregulated	33130312
12995	Mouse	Gm15834	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	HL-1 cells	angiotensin II (Ang II) treatment	upregulated	33130312
12996	Mouse	Gm15851	lncRNA	prenatal nicotine exposure (PNE)	POMC neuronal development and/or function	POMC neurons	prenatal nicotine exposure (PNE) treatment	upregulated	27609221
12997	Mouse	Gm16343	lncRNA	IL-36¦Â	colorectal cancer (CRC)	CD8+ T cells	interleukin 36¦Â treatment	upregulated	31684829
12998	Mouse	Gm16410	lncRNA	particulate matter (PM2.5)	PM2.5-induced lung inflammation	RAW264.7 cells	fine particulate matter (PM2.5) treatment	"The result showed that a significant reduction in expression of one lncRNA, identified as lncGm16410, was observed in the lung of mice and RAW2647 cells following exposure to PM25"	33796524
12999	Mouse	Gm16410	lncRNA	particulate matter (PM2.5)	lung fibrosis	mouse pulmonary vascular endothelial cells (MHCs)	PM2.5 exposure treatment	The involvement of lncRNA Gm16410 in PM25-induced EndMT highlights the potential of lncRNA to promote pulmonary fibrosis under environmental pollution	32961493
13000	Mouse	Gm17501	lncRNA	dexamethasone (DEX)	asthma	lung tissues	dexamethasone (Dex) treatment	Gm13372 was upregulated in the Dex group compared with that in the Model group.	32222886
13001	Mouse	Gm20319	lncRNA	subchronic deoxynivalenol (DON)	liver damage	liver tissues; Hepa 1-6 cells	subchronic deoxynivalenol (DON) exposure treatment	upregulated	32439590
13002	Mouse	Gm20471	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	30193772
13003	Mouse	Gm2199	lncRNA	carbon tetrachloride (CCl4)	liver damage	liver tissues; AML12 cells	carbon tetrachloride (CCl4) treatment	Gm2199 was downregulated in both damaged livers and hepatocyte lines.	29789577
13004	Mouse	Gm26917	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cell	?high glucose (HG)?treatment treatment	The expression of Gm26917 was induced by HG but weakened by RSG	33790061
13005	Mouse	Gm26917	lncRNA	rosiglitazone	diabetic nephropathy (DN)	mesangial cell	Rosiglitazone (RSG) treatment	The expression of Gm26917 was induced by HG but weakened by RSG	33790061
13006	Mouse	Gm34934	lncRNA	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)"	rheumatoid arthritis (RA)	TM3 Leydig cells	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment"	upregulated	33360214
13007	Mouse	Gm43050	lncRNA	sevoflurane (SEV)	sevoflurane-induced abnormal cognition	primary hippocampal neurons	sevoflurane treatment	Overexpression of lncRNA Gm43050 alleviates apoptosis and inflammation response induced by sevoflurane treatment by regulating miR-640/ZFP91	32913509
13008	Mouse	Gm43181	lncRNA	ventilator	ventilator-induced lung injury (VILI)	mouse lung tissues	ventilator treatment	lncRNA Gm43181 might be related to lung damage and neutrophil activation via chemokine receptor chemokine (C-X-C) receptor 2	30784114
13009	Mouse	Gm43652	lncRNA	adipogenesis medium	muscle cells during adipogenic transdifferentiation	C2C12 cells	"adipogenesis medium (DMEM-F12, 20% fetal calf serum, 10 ?g/mL insulin, 1 ?M dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 10 ?M rosiglitazone) treatment"	upregulated	31366088
13010	Mouse	Gm5091	lncRNA	alcohol	alcoholic liver fibrosis (ALF)	mouse primary hepatic stellate cells	alcohol treatment	LncRNA Gm5091 was sharply downregulated in HSCs of mouse AHF in vivo and alcohol-treated primary HSCs in vitro.	29935035
13011	Mouse	Gm5421	lncRNA	chronic intermittent hypoxia (CIH)	atherosclerosis (AS)	aorta tissues	Chronic intermittent hypoxia (CIH) treatment	upregulated	32328084
13012	Mouse	Gm5524	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	primary mouse podocyte cells	high glucose (HG) treatment	Gm5524 was additionally significantly upregulated in podocytes under high glucose conditions.	30132544
13013	Mouse	Gm9926	lncRNA	5-aminolevulinic acid photodynamic therapy(ALA-PDT)	colitis	colon tissues	5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment	downregulated	30385297
13014	Mouse	Gomafu	lncRNA	berberine (BBR)	obesity-induced chronic inflammation	RAW264.7 ; 3T3-L1 preadipocytes	berberine (BBR) treatment	Overexpression of lncRNA Gomafu partially blocked the protective effects of berberine in free fatty acids-treated adipocytes by increasing endoplasmic reticulum stress.	32650294
13015	Mouse	Gpr137b-ps	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	?lncRNA G protein-coupled receptor 137B (Gpr137b-ps) and C-X-C motif chemokine ligand 14 (CXCL14) showed to be markedly upregulated within carbon tetrachloride (CCl4)-caused hepatic fibrotic mice tissue samples and activated HSCs.	33069761
13016	Mouse	Gpr137b-ps	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis		carbon tetrachloride (CCl4) treatment	lncRNA Gpr137b-ps/miR-200a-3p/CXCL14 axis that modulates HSC activation and might exert an effect on the pathogenesis of liver fibrosis.	33069761
13017	Mouse	H19	lncRNA	hypoxia	acute myocardial infarction (AMI)	mouse HL-1 cells	hypoxia	upregulated	29179202
13018	Mouse	H19	lncRNA	benzyl butyl phthalate (BBP)	adipogenesis	Multipotent C3H10T1/2 cells	benzyl butyl phthalate (BBP) treatment	Cells treated with an 8 day BBP regimen showed that H19 expression was decreased at day 2 with 50 ¦ÌM BBP exposure	33395283
13019	Mouse	H19	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	brain tissues	amyloid-¦Â (A¦Â) 25-35 treatment	"Elevated H19, HMGB1 and decreased miR-129 were found in A¦Â25-35-treated PC12 cells as well as in brain tissues of AD mice."	33410377
13020	Mouse	H19	lncRNA	dexamethasone (DEX)	asthma	lung tissues	dexamethasone (Dex) treatment	H19 was upregulated in the Dex group compared with that in the Model group.	32222886
13021	Mouse	H19	lncRNA	astragaloside IV (AS-IV)	atherosclerosis (AS)	vascular smooth muscle cells from high-fat diet fed ApoE-/- mice	astragaloside (AS-IV) treatment	upregulated	30529164
13022	Mouse	H19	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	ApoE-/- mice vascular smooth muscle cells	high fat diet (HFD) feed	downregulated	30529164
13023	Mouse	H19	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	aortic tissues of atherosclerosis mice	high fat diet (HFD) feed	upregulated	31757932
13024	Mouse	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	Increased expression of H19 was detected in ox-LDL-treated Raw264.7 cells.	29172088
13025	Mouse	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Raw264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29172088
13026	Mouse	H19	lncRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia (Hyp) treatment	Downregulated lncRNA H19 relieved pulmonary injury via targeting miR-17 to downregulate STAT3 and reduced inflammatory response caused by p-STAT3 in BPD newborn mice.	33285606
13027	Mouse	H19	lncRNA	high glucose (HG)	cardiomyocyte senescence	Neonatal mouse ventricular cells (NMVCs)	high glucose (HG) treatment	H19 level was significantly increased in high glucose-induced senescence cardiomyocytes and aged mouse hearts.	33664669
13028	Mouse	H19	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	mouse palatal tissues	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	29081343
13029	Mouse	H19	lncRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	fetuses	all-trans retinoic acid (ATRA) treatment	"In addition, the the relationship between lncRNA H19 and IGF2 were negative correlation in the critical period of developmental palate"	27307343
13030	Mouse	H19	lncRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	C57BL/6 mice	all-trans retinoic acid (ATRA) treatment	upregulated	27307343
13031	Mouse	H19	lncRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS) AOM/DSS	colitis-associated colon cancer (CAC)	colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	H19 was highly expressed in the tumor tissues of CAC mice compared with the expression in normal colon tissues.	30083271
13032	Mouse	H19	lncRNA	streptozocin (STZ)	diabetes mellitus (DM)	hippocampal neurons	streptozotocin (STZ) treatment	"Higher lncRNA H19 expression was found in DM Upregulated lncRNA H19 significantly increased the expression of Bax and caspase-3 but decreased that of Bcl-2, thus promoting the apoptosis of hippocampal neuron"	30536889
13033	Mouse	H19	lncRNA	metformin (Met)	diabetic nephropathy (DN)	SV40-MES-13 cells	Metformin (MET) treatment	"Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-¦Â1 axis."	32391614
13034	Mouse	H19	lncRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	upregulated	30692507
13035	Mouse	H19	lncRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	tumor-initiating hepatocytes (TICs)	TGF-¦Â treatment	TGF-¦Â treatment reduced H19 expression	30014520
13036	Mouse	H19	lncRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung fibrosis tissues	bleomycin (BLM) treatment	The level of H19 was upregulated in the lung fibrosis tissue compared with the control group treated with saline.	29411215
13037	Mouse	H19	lncRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung tissues	bleomycin (BLM) treatment	upregulated	33138822
13038	Mouse	H19	lncRNA	TGF-¦Â1	inflammation	MAC-T cells	TGF-¦Â1 treatment	upregulated	29062612
13039	Mouse	H19	lncRNA	hypoxia	ischemic stroke (IS)	mouse plasma ;white blood cells;brain tissues	middle cerebral artery occlusion (MCAO) treatment	"upregulated in plasma, white blood cells, and brain"	28630232
13040	Mouse	H19	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HT22 cells	oxygen-glucose deprivation (OGD) treatment	Long non-coding RNA H19 inhibition ameliorates oxygen-glucose deprivation-induced cell apoptosis and inflammatory cytokine expression by regulating the microRNA-29b/SIRT1/PGC-1¦Á axis	33313940
13041	Mouse	H19	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse HT22 cells	oxygen-glucose deprivation (OGD) treatment	"In the present study, MCAO model mice and OGD-treated cells displayed significantly increased lncRNA H19 expression levels compared with sham mice and control cells, respectively"	33313940
13042	Mouse	H19	lncRNA	glyoxylate	kidney tubular cell injury	renal tubular epithelial cell	glyoxylate treatment	upregulated	31735555
13043	Mouse	H19	lncRNA	glyoxylate	kidney tubular cell injury	oxidative stress	glyoxylate treatment	upregulated	31735555
13044	Mouse	H19	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	30362572
13045	Mouse	H19	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	mouse liver tissue	carbon tetrachloride (CCl4) treatment	upregulated	30362572
13046	Mouse	H19	lncRNA	H2O2	liver fibrosis	AML12 cells	H2O2 treatment	upregulated	32579217
13047	Mouse	H19	lncRNA	TGF-¦Â	liver fibrosis	"mouse Primary hepatic stellate cells (PHSCs), The human immortalized HSC line LX©\2,Human L©\02 hepatocytes"	TGF-¦Â treatment	upregulated	30362572
13048	Mouse	H19	lncRNA	"diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC)"	liver preneoplastic foci and tumors	mice liver cells	"Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC) treatment"	upregulated	19362547
13049	Mouse	H19	lncRNA	high fat diet (HFD)	male infertility	C57bl/6J mice	high fat diet (HFD) feed	dysregulated	28599310
13050	Mouse	H19	lncRNA	metformin (Met)	metabolic disorders	mouse fetuses	Metformin treatment	upregulated	29215608
13051	Mouse	H19	lncRNA	CoCl2	myocardial infarction (MI)-induced heart failure (HF)	Cardiac progenitor cells (CPCs)	CoCl2 treatment	The expression of long non-coding RNA H19 was significantly downregulated in CPCs after hypoxia stimuli.	30137188
13052	Mouse	H19	lncRNA	6-Gingerol (6-G)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	HL-1 cells	6-Gingerol (6-G) treatment	we found that 6-G elevated cellular H19 expression in hypoxia/reoxygenation (H/R)-treated HL-1 cells.	33758383
13053	Mouse	H19	lncRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	H2O2 treatment	downregulated	31284127
13054	Mouse	H19	lncRNA	berberine (BBR)	nonalcoholic fatty liver disease (NAFLD)	mouse liver	berberine (BBR) treatment	BBR's beneficial effects are linked with the downregulated of microRNA34a and long noncoding RNA H19	33494295
13055	Mouse	H19	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	primary cultured hepatocytes	free fatty acids treatment	upregulated	29140550
13056	Mouse	H19	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	cultured mouse primary hepatocytes	free fatty acid (FFA) treatment	upregulated	31064820
13057	Mouse	H19	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	29140550
13058	Mouse	H19	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31064820
13059	Mouse	H19	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	H19 was upregulated during the development of high-fat diet (HFD)-induced NAFLD.	31809000
13060	Mouse	H19	lncRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	primary mouse hepatocytes	oleic acid (OA) treatment	H19 was upregulated in oleic acid-induced steatosis.	31809000
13061	Mouse	H19	lncRNA	bone morphogenetic protein 9 (BMP9)	osteogenesis	mouse mesenchymal stem cell (MSC) lines iMEFs and iMADs	bone morphogenetic protein 9 (BMP9) treatment	upregulated	28881833
13062	Mouse	H19	lncRNA	metformin (Met)	oxidative stress	N2a cells	metformin treatment	metformin inhibited the expression of lncRNA-H19 in both MCAO/R-treated mice and OGD/R-treated N2a cells.	31934270
13063	Mouse	H19	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	H19 was downregulated in brain tissues of MPTP-induced PD mice (in vivo).	32356199
13064	Mouse	H19	lncRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	dopaminergic neuron	6-hydroxydopamine (6-OHDA) treatment	LncRNA H19 diminishes dopaminergic neuron loss by mediating microRNA-301b-3p in Parkinson's disease via the HPRT1-mediated Wnt/¦Â-catenin signaling pathway.	32434961
13065	Mouse	H19	lncRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	serum; lungs tissues	monocrotaline (MCT) treatment	H19 was highly expressed in the serum and lungs of MCT-induced models.	30547791
13066	Mouse	H19	lncRNA	arsenite	lung fibrosis	murine bone marrow-derived macrophages (BMDMs)	arsenic (As) exposure	downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages.	33162208
13067	Mouse	H19	lncRNA	arsenite	lung fibrosis	lung tissues; bone marrow-derived macrophages (BMDMs)	arsenite exposure	upregulated	33162208
13068	Mouse	H19	lncRNA	dextran sodium sulfate (DSS)	regeneration of the intestinal epithelia	intestinal tissues	dextran sulfate sodium (DSS) treatment	upregulated	29621481
13069	Mouse	H19	lncRNA	lipopolysaccharide (LPS)	regeneration of the intestinal epithelia	intestinal tissues	lipopolysaccharide (LPS) treatment	upregulated	29621481
13070	Mouse	H19	lncRNA	lipopolysaccharide (LPS)	sepsis	mice cardiomyocytes UL-1 cells	lipopolysaccharide (LPS) treatment	downregulated	30021355
13071	Mouse	H19	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	BV2 cells	lipopolysaccharides (LPS) treatment	LncRNA H19 Regulates Lipopolysaccharide (LPS)-Induced Apoptosis and Inflammation of BV2 Microglia Cells Through Targeting miR-325-3p/NEUROD4 Axis.	33205379
13072	Mouse	H19	lncRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	liver tissues	high fat diet (HFD) feed	Hepatic H19 expression is chronically increased in diabetic mice.	29769440
13073	Mouse	H19	lncRNA	cinnamaldehyde (CA)	ulcerative colitis (UC)	colonic tissues	Cinnamaldehyde (CA) treatment	lncRNA H19 was increased in the colonic tissues of the DSS-treated mice compared with the normal mice at 7 days or 14 days and was significantly decreased on day 14 after CA administration.	33341041
13074	Mouse	H19	lncRNA	cigarette smoke extract (CSE)	smoke-induced lung injury (SILI)	lung tissues	cigarette smoke extract (CSE) treatment	upregulated	33523607
13075	Mouse	H19	lncRNA	Rb3	smoke-induced lung injury (SILI)	lung tissues	Rb3 treatment	downregulated	33523607
13076	Mouse	HAGLROS	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	mouse midbrain tissues	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31298038
13077	Mouse	HCG18	lncRNA	high glucose (HG)	diabetic peripheral neuropathy (DPN)	macrophage	high glucose (HG) treatment	LncRNA HCG18 was highly expressed in DPN model and HG-induced macrophages.	32996080
13078	Mouse	HCP5	lncRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	oxygen glucose deprivation (OGD) treatment	upregulation of lncRNA HCP5 may exacerbate cerebral ischemic reperfusion injury by sponging miR-652-3p	32657103
13079	Mouse	HIF1A-AS1	lncRNA	coxsackievirus B3 (CVB3)	acute viral myocarditis (VM)	mouse myocardium; primary cardiomyocytes	Coxsackievirus B3 (CVB3) infection	lncRNA HIF1A-AS1 promotes NF-¦ÊB signaling and subsequently aggravates cardiomyocyte apoptosis and inflammation via targeting miR-138.	33224748
13080	Mouse	HIF1A-AS2	lncRNA	flagellin	intestinal inflammation	ulcerative colitis samples	flagellin treatment	Flagellin induced HIF1A-AS2 expression in a dose- and time-dependent manner via p38-stat1 activation.	29772233
13081	Mouse	HOTAIR	lncRNA	coronary artery ligation	acute myocardial infarction (AMI)	C57BL/6J mice serum	subjected to coronary artery ligation	downregulated	29258067
13082	Mouse	HOTAIR	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Raw264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30402866
13083	Mouse	HOTAIR	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	primary cultured cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	upregulated	30402865
13084	Mouse	HOTAIR	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose (HG) treatment	HOTAIR was downregulated in HG-stimulated H9c2.	30216438
13085	Mouse	HOTAIR	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	mouse heart tissues	streptozotocin (STZ) treatment	HOTAIR protected against DCM via activation of the SIRT1 expression by sponging miR-34a	30216438
13086	Mouse	HOTAIR	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	conditionally immortalised mouse podocytes	high glucose (HG) treatment	upregulated	31399844
13087	Mouse	HOTAIR	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	upregulated	31399844
13088	Mouse	HOTAIR	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	Retinal endothelial cell (REC) dysfunction	high glucose treatment	upregulated	32812634
13089	Mouse	HOTAIR	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	30673982
13090	Mouse	HOTAIR	lncRNA	rosiglitazone	liver fibrosis	TGF-¦Â1 treated primary mouse hepatic stellate cells (HSCs)	Rosiglitazone (RGZ) treatment	downregulated	30673982
13091	Mouse	HOTAIR	lncRNA	rosiglitazone	liver fibrosis	carbon tetrachloride (CCl4) treated mouse liver tissues	Rosiglitazone (RGZ) treatment	downregulated	30673982
13092	Mouse	HOTAIR	lncRNA	TGF-¦Â1	liver fibrosis	Primary mouse hepatic stellate cells (HSCs)	TGF-¦Â1 treatment	upregulated	30673982
13093	Mouse	HOTAIR	lncRNA	high fat diet (HFD)	hepatic insulin resistance	liver tissues	high fat diet (HFD) feed	"HOTAIR was significantly upregulated in T2D patients, C57BL/6J mice fed with a high-fat diet."	30536334
13094	Mouse	HOTAIR	lncRNA	H2O2	hepatic ischemia/reperfusion injury (HIRI)	Primary mouse hepatocytes culture	H2O2 treatment	knockdown of the expression of HOTAIR attenuated autophagy induced by hydrogen peroxide.	30367982
13095	Mouse	HOTAIR	lncRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 macrophages	lipopolysaccharide (LPS) treatment	HOTAIR expression is induced in immune cells (macrophages) upon treatment with lipopolysaccharide (LPS).	30353135
13096	Mouse	HOTAIR	lncRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	33420270
13097	Mouse	HOTAIR	lncRNA	ischemia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Plasma	left anterior descending artery (LAD) ligation	HOTAIR aggravates myocardial IR by competitively binding SRSF1 with microRNA-126.	32964995
13098	Mouse	HOTAIR	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	32315726
13099	Mouse	HOTAIR	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	mouse brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	28445933
13100	Mouse	HOTAIR	lncRNA	arsenite	lung fibrosis	lung tissues	arsenite exposure	upregulated	33162208
13101	Mouse	HOTAIR	lncRNA	cecal ligation and puncture (CLP)	sepsis	Monocytes were isolated from the spleens	cecal ligation and puncture induce	upregulated	31656541
13102	Mouse	HOTAIR	lncRNA	silicon dioxide (SiO2)	silicosis	HBE and A549 cells	silicon dioxide (SiO2) treatment	"miR-326 is downregulated in the fibrotic lung tissues of silica-treated mice, while increased expression of miR-326 attenuates silica-induced pulmonary fibrosis in vivo"	31642316
13103	Mouse	HOTAIR	lncRNA	lipopolysaccharide (LPS)	traumatic brain injury (TBI)	BV2 cells; primary microglia	lipopolysaccharide (LPS) treatment	upregulated	32602030
13104	Mouse	HOTAIR	lncRNA	lipopolysaccharide (LPS)	traumatic brain injury (TBI)	primary mouse microglia	lipopolysaccharide (LPS) treatment	LncRNA HOTAIR was abnormally highly expressed in activated microglia.	32602030
13105	Mouse	HOTTIP	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	SV40-MES13 cells	high-glucose (HG) treatment	upregulated	31934070
13106	Mouse	HOTTIP	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary cortical neurons	oxygen-glucose deprivation (OGD) treatment	downregulated	30129112
13107	Mouse	HOTTIP	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	CCl4 treatment	upregulated	30548190
13108	Mouse	HOTTIP	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	HOTTIP expressions in fibrotic liver samples and cirrhotic liver samples were significantly upregulated compared with healthy liver controls.	30562760
13109	Mouse	HOX	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	mouse	CCl4 treatment	upregulated	27979710
13110	Mouse	HOXA11-AS	lncRNA	TGF-¦Â1	cardiac fibrosis	mouse cardiac fibroblasts (CFs)	TGF¦Â1 treatment	upregulated	30720066
13111	Mouse	HOXA11-AS1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra (SN) area	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"?HOXA11-AS promoted MPTP-mediated SH-SY5Y neuronal injury and LPS-induced microglia activation, while miR-124-3p had the opposite effects."	33839699
13112	Mouse	HOXA11-AS1	lncRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV2 cells	lipopolysaccharide (LPS) treatment	upregulated	33839699
13113	Mouse	Hoxaas3	lncRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung fibroblasts	bleomycin (BLM) treatment	upregulated	32848140
13114	Mouse	Hoxaas3	lncRNA	hypoxia	pulmonary hypertension (PH)	lung vasculature of hypoxic mice and in pulmonary artery smooth muscle cells (PASMCs) under hypoxic conditions	hypoxia induce	upregulated	30304383
13115	Mouse	Hsp4	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	MLE-12 cells	lipopolysaccharide (LPS) treatment	Hsp4 alleviates lipopolysaccharide-induced apoptosis of lung epithelial cells via miRNA-466m-3p/DNAjb6 axis.	32976821
13116	Mouse	HULC	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	?ATDC5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	?HULC protected ATDC5 cells against TNF-¦Á-induced inflammatory injury by repression of miR-101	30981080
13117	Mouse	IGF2	lncRNA	ketamine	neurotoxicity	neural stem cell culture	ketamine treatment	upregulated	27914827
13118	Mouse	IGF2AS	lncRNA	ketamine	neurotoxicity	E18.5 brain-derived neural stem cells	ketamine treatment	upregulated	27914827
13119	Mouse	IUR	lncRNA	imatinib	leukemia	Abl-transformed primary bone marrow cells	imatinib treatment	Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment.	30961617
13120	Mouse	Jak3	lncRNA	monosodium urate (MSU)	cell differentiation	RAW264.7 cells	Monosodium urate monohydrate (MSU) treatment	upregulated	30387921
13121	Mouse	KCNQ1OT1	lncRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	serums	acetaminophen (APAP) treatment	downregulated	32779042
13122	Mouse	KCNQ1OT1	lncRNA	angiotensin II (Ang II)	atrial fibrillation (AF)	heart tissues	angiotensin II (Ang II) treatment	LncRNA KCNQ1 overlapping transcript 1 (KCNQ1OT1) was found to be significantly upregulated in AF model and Ang-II-induced mice heart.	30241939
13123	Mouse	KCNQ1OT1	lncRNA	arsenic trioxide (ATO)	cardiac arrhythmia	primary cultured neonatal mouse cardiomyocytes	arsenic trioxide (ATO) treatment	"After ATO treatment, the Kcnq1ot1 and Kcnq1 expression levels were downregulated."	29675399
13124	Mouse	KCNQ1OT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary mouse cerebral cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32912499
13125	Mouse	KCNQ1OT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	mouse primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31837324
13126	Mouse	KCNQ1OT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31837324
13127	Mouse	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	primary cardiomyocytes	high glucose (HG) treatment	upregulated	30355944
13128	Mouse	KCNQ1OT1	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	heart tissues	streptozotocin (STZ) treatment	upregulated	30355944
13129	Mouse	KCNQ1OT1	lncRNA	doxorubicin (DOX)	heart failure (HF)	HL-1 cells	doxorubicin (ADR) treatment	KCNQ1OT1 facilitates cardiomyocyte apoptosis by - targeting FUS in ADR-induced HF.	32497620
13130	Mouse	KCNQ1OT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	intimal hyperplasia (IH)	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor type BB (PDGF-BB) treatment	downregulated	32146419
13131	Mouse	KCNQ1OT1	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary cultured cardiomyocyte	hypoxia induce	upregulated	31644943
13132	Mouse	KCNQ1OT1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	"KCNQ1OT1 could promote the LGALS3 expression by binding to miR-204-5p, which led to aggravated myocardial IR injury."	31644943
13133	Mouse	KCNQ1OT1	lncRNA	resveratrol	osteoblastic differentiation	mouse mesenchymal stem cells (mMSCs)	resveratrol (Res) treatment	upregulated	29541443
13134	Mouse	KCNQ1OT1	lncRNA	polymethylmethacrylate (PMMA)	particle-induced osteolysis (PIO)	primary bone marrow-derived macrophages (BMMs)	polymethylmethacrylate (PMMA) treatment	KCNQ1OT1 was suppressed in PMMA-induced cells	29252185
13135	Mouse	KCNQ1OT1	lncRNA	sublytic complement C5b-9 (sC5b-9)	renal inflammatory diseases	MPC5 cells	sublytic complement C5b-9 (sC5b-9) treatment	upregulated	33296289
13136	Mouse	KCNQ1OT1	lncRNA	sublytic complement C5b-9 (sC5b-9)	renal inflammatory diseases	MPC5 cells	sublytic complement C5b-9 (sC5b-9) treatment	Kcnq1ot1 was upregulated in sC5b-9-induced podocytes	33296289
13137	Mouse	LET	lncRNA	hypoxia	hepatocellular carcinoma (HCC) and colorectal cancer (CRC)	SMMC-7721 cells; HCCLM3 cells; SW480 cells	Hypoxia treatment	downregulated	23395002
13138	Mouse	Lethe	lncRNA	sepsis	sepsis-induced brain injury (SIBI)	cerebral cortex tissues	cecal ligation and puncture (CLP) induce treatment	upregulated	31210319
13139	Mouse	LGR	lncRNA	fasting	expression regulation	plasma	fasting treatment	upregulated	26904944
13140	Mouse	Lin28B	lncRNA	angiotensin II (Ang II)	allergic airway inflammation	murine bone marrow-derived macrophages (BMDMs)	angiotensin II (Ang II) treatment	upregulated	32458348
13141	Mouse	LINC00261	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	kidney tissues	lipopolysaccharide (LPS) treatment	"In this study, we found the expression of LINC00261 was significantly decreased in the serum of patients with sepsis than healthy controls. A similar result was also observed in the mouse model of sepsis induced by lipopolysaccharide (LPS)."	33481135
13142	Mouse	LINC00261	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	pulmonary microvascular endothelial cells (PMVECs)	lipopolysaccharide (LPS) treatment	downregulated	33481135
13143	Mouse	LINC00305	lncRNA	lipopolysaccharide (LPS)	inflammation	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	31190561
13144	Mouse	LINC00511	lncRNA	H2O2	ischemia/reperfusion (I/R) injury	Primary cardiomyocytes	H2O2 treatment	LINC00511 accelerates the proliferation of cardiomyocytes after I/R by targeting miRNA-515-5p.	32141575
13145	Mouse	LINC00968	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells	high glucose (HG) treatment	lncRNA LINC00968 expression was high-expressed in high-glucose induced mesangial cells.	30197001
13146	Mouse	LINC01093	lncRNA	carbon tetrachloride (CCl4)	apoptosis	liver tissues	CCl4 treatment	upregulated	32044992
13147	Mouse	LINC01093	lncRNA	TGF-¦Â1	apoptosis	NCTC 146	TGF-¦Â1 treatment	upregulated	32044992
13148	Mouse	LINC01152	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	"Huh7, HepG2 and Hep3B cells"	hepatitis B virus (HBV) infection	upregulated	31054511
13149	Mouse	Lincs_chr17_4383_2	lncRNA	trichloroethylene (TCE)	trichloroethylene (TCE) hepatocarcinogenesis	liver tissues	Trichloroethylene (TCE) treatment	"TCE induced extensive LincRNA expression changes in mouse liver, and the downregulated of Liver Lincs_chr17_4383_2 might contribute to TCE hepatocarcinogenesis by interacting with miR-182-5p and Cdkn1a"	31942800
13150	Mouse	LINK-A	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocyte cells	high glucose treatment	downregulated	31258644
13151	Mouse	LNC_000898	lncRNA	hypoxia	myocardial infarction (MI)	neonatal mouse ventricular cardiomyocytes (NMCMs)	hypoxia treatment	LNC_000898 could protect the heart against MI injury by regulating miR-375/PDK1.	32398474
13152	Mouse	LNC_000941	lncRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	kidney tissues	ischemia/reperfusion (I/R) treatment	dysregulated	29245971
13153	Mouse	lnc010561	lncRNA	melatonin	breast cancer	mouse breast cancer cell lines 4T1 and MA-891	Melatonin treatment	downregulated	31955008
13154	Mouse	lnc010561	lncRNA	melatonin	breast cancer	?4T1 cells; 891 cells	Melatonin treatment	Melatonin regulated breast cancer progression by the lnc010561/miR-30/FKBP3 axis.	31955008
13155	Mouse	lnc949	lncRNA	bleomycin and engeletin	lung fibrosis	myofibroblasts	bleomycin and engeletin treatment	Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-¦Â1-Smad2/3 and JNK signalling pathways	33181025
13156	Mouse	linc-p21	lncRNA	immunoglobulin E (IgE)	abdominal aortic aneurysm (AAA)	aortic tissues	asthma-induced high level of IgE	upregulated	31440377
13157	Mouse	linc-p21	lncRNA	streptozocin (STZ)	diabetes mellitus (DM)	hippocampal neuron	streptozotocin induce treatment	"lincRNA p21 were poorly expressed lincRNA p21 overexpression in the diabetes mice reduced the cell apoptosis rate, and the expression of Bax and cleaved Caspase-3, whereas increase the Bcl-2 expression"	31081202
13158	Mouse	lncRNA30245	lncRNA	TGF-¦Â1	myocardial infarction (MI)	cardiac fibroblasts (CFs)	transforming growth factor (TGF)-¦Â1 treatment	upregulated	30935639
13159	Mouse	lncRNA430945	lncRNA	angiotensin II (Ang II)	atherosclerosis (AS)	mouse vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	The downregulated of lncRNA 430945 significantly suppressed AngII-induced VSMC proliferation and migration.	30957191
13160	Mouse	lncRNA6406	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	renal tubular epithelial (PTEC) cells; kidney tissues	lipopolysaccharide (LPS) treatment	LncRNA 6406 is downregulated both in the Kidneys of mice in the LPS-induced AKI Model and LPS-stimulated in vitro Model.	32655407
13161	Mouse	lncRNA9884	lncRNA	protocatechualdehyde (PCA)	tubulointerstitial fibrosis (TIF)	primary renal tubular epithelial cells (TECs)	protocatechualdehyde (PCA) treatment	Protocatechualdehyde attenuates obstructive nephropathy through inhibiting lncRNA9884 induced inflammation	33118280
13162	Mouse	LOC102633466	lncRNA	aerobic exercise	parkinson's disease (PD)	striatal tissues	aerobic exercise training (AET) treatment	upregulated	33150124
13163	Mouse	LOC102637865	lncRNA	aerobic exercise	parkinson's disease (PD)	striatal tissues	aerobic exercise training (AET) treatment	upregulated	33150124
13164	Mouse	LOC102637887	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	downregulated	32246647
13165	Mouse	LOC102638670	lncRNA	aerobic exercise	parkinson's disease (PD)	striatal tissues	aerobic exercise training (AET) treatment	upregulated	33150124
13166	Mouse	LOC102638971	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinal tissues	oxygen treatment	upregulated	32246647
13167	Mouse	LOC102640519	lncRNA	hypoxia	cerebral ischemia injury (CII)	mice brain microvascular endothelial cells	oxygen-glucose deprivation reperfusion (OGD/R) treatment	downregulated	29842876
13168	Mouse	LOC102640519	lncRNA	vascular endothelial growth factor (VEGF)	cerebral ischemia injury (CII)	oxygen-glucose deprivation reperfusion (OGD/R) treated mice brain microvascular endothelial cells	oxygen-glucose deprivation reperfusion (OGD/R) treatment	upregulated	29842876
13169	Mouse	LOC105375913	lncRNA	complement C3a	focal segmental glomerulosclerosis (FSGS)	tubular cells	C3a treatment	upregulated	30679767
13170	Mouse	LOC146880	lncRNA	particulate matter (PM2.5)	lung cancer	lung tissue	PM2.5 treatment	upregulated	27836757
13171	Mouse	LOC498759	lncRNA	glucocorticoid-inducible kinase-1 (SGK1)	diabetic nephropathy (DN)	mouse podocytes	glucocorticoid-inducible kinase-1 (SGK1) treatment	upregulated	31564202
13172	Mouse	LOC498759	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	upregulated	31564202
13173	Mouse	LOC498759	lncRNA	Jixuepaidu Tang-1	diabetic nephropathy (DN)	high glucose (HG) treated mouse podoccytes	Jixuepaidu Tang-1 treatment	downregulated	31564202
13174	Mouse	LOC498759	lncRNA	TGF-¦Â1	diabetic nephropathy (DN)	mouse podocytes	Transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31564202
13175	Mouse	LRCF	lncRNA	propofol (PPF)	cognitive function	"Primary neonatal mouse oligodendrocyte (OLGs), microglia (MGs) and neuron cells (NCs)"	propofol treatment	?Our systematic study showed that LRCF expression differs in OLGs of mice of different ages	33411226
13176	Mouse	LRNA9884	lncRNA	cisplatin (DDP)	acute kidney injury (AKI)	murine renal proximal tubular epithelial cells (mTECs)	cisplatin treatment	upregulated	33192605
13177	Mouse	LRNA9884	lncRNA	advanced glycation end product (AGE)	diabetic nephropathy (DN)	immortalized murine kidney proximal tubular epithelial (mTEC) cells	advanced glycation end products (AGE) treatment	upregulated	31048367
13178	Mouse	Lrrc55-AS	lncRNA	herpes simplex virus 1 (HSV-1)	innate immune response	mouse peritoneal macrophages	Herpes Simplex Virus( HSV) infection	upregulated	31213650
13179	Mouse	Lrrc55-AS	lncRNA	IFN-I	innate immune response	mouse peritoneal macrophages	IFN-I treatment	upregulated	31213650
13180	Mouse	Lrrc55-AS	lncRNA	lipopolysaccharide (LPS)	innate immune response	mouse peritoneal macrophages	lipopolysaccharides (LPS) treatment	upregulated	31213650
13181	Mouse	Lrrc55-AS	lncRNA	polyinosinic-polycytidilic acid (Poly(I:C))	innate immune response	mouse peritoneal macrophages	poly (I: C)) treatment	upregulated	31213650
13182	Mouse	Lrrc55-AS	lncRNA	Sendai virus (SeV)	innate immune response	mouse peritoneal macrophages	Sendai virus (SeV) infection treatment	upregulated	31213650
13183	Mouse	MAGI2-AS3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	BV2 cells	amyloid-¦Â (A¦Â) 25-35 treatment	"The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35."	33279663
13184	Mouse	MAGI2-AS3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	BV2 cells	amyloid-¦Â (A¦Â) 25-35 treatment	MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells.	33279663
13185	Mouse	MALAT	lncRNA	hypoxia	renal proximal tubular function	kidney tissues;testis tissues	hypoxia treatment	upregulated	27774481
13186	Mouse	MALAT1	lncRNA	hypoxia	acute myocardial infarction (AMI)	Cardiomyocytes	hypoxia induce	upregulated	31783925
13187	Mouse	MALAT1	lncRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	The mouse cardiomyocyte cell line HL-1	hypoxia/reperfusion induce	upregulated	32010261
13188	Mouse	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	angiogenesis	mouse brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	the levels of lncRNA-MALAT1 and miR-145 were upregulated in OGD-induced BMECs miR-145 functioned as an anti-angiogenic and pro-apoptotic factor in OGD treated BMECs via down-regulating VEGF-A and ANGPT2 directly	30038058
13189	Mouse	MALAT1	lncRNA	insulin	brain injury	human adipose-derived stem cells (hASCs)	insulin treatment	upregulated	27841943
13190	Mouse	MALAT1	lncRNA	fasting with HIF-1¦Á inhibitor (BAY)	cardiac decompensation secondary to acute severe caloric-restriction	cardiac tissues	Fasting with HIF-1¦Á inhibitor (BAY) treatment	downregulated	32942153
13191	Mouse	MALAT1	lncRNA	triiodo-l-thyronine (T3)	cardiac decompensation secondary to acute severe caloric-restriction	cardiac tissues	Triiodo-l-Thyronine (T3) treatment	downregulated	32942153
13192	Mouse	MALAT1	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblasts	angiotensin II (Ang II) treatment	upregulated	30146700
13193	Mouse	MALAT1	lncRNA	melatonin	cardiac fibrosis	high glucose (HG)-treated cardiac fibroblasts (CFs)	Melatonin treatment	melatonin produces an antifibrotic effect via inhibiting lncR-MALAT1/miR-141-mediated NLRP3 inflammasome activation and TGF-¦Â1/Smads signaling	32067273
13194	Mouse	MALAT1	lncRNA	hypoxia/reoxygenation (H/R)	cardiomyocyte apoptosis	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	Long noncoding RNA MALAT1 enhances the apoptosis of cardiomyocytes through autophagy modulation.	31985274
13195	Mouse	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral palsy	N2A neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31500509
13196	Mouse	MALAT1	lncRNA	high glucose (HG) and hypoxia/reoxygenation (H/R)	diabetes mellitus (DM) induced cerebral ischemic reperfusion (I/R) injury	rat primary microglia; HAPI cells	high glucose (HG) and hypoxia-reoxygenation (H/R) treatment	upregulated	29844328
13197	Mouse	MALAT1	lncRNA	streptozocin (STZ)	diabetes-related microvascular complications	db/db mice retinal vasculature	STZ treatment	upregulated	25356875
13198	Mouse	MALAT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiomyocytes	high glucose (HG) treatment	upregulated	31353329
13199	Mouse	MALAT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	primary cultured cardiomyocyte	high glucose treatment	upregulated	31353329
13200	Mouse	MALAT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	mouse cardiomyocytes	high glucose (HG) treatment	MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy.	33097254
13201	Mouse	MALAT1	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	myocardium	streptozocin treatment	upregulated	31353329
13202	Mouse	MALAT1	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	myocardial tissues	streptozotocin (STZ) treatment	upregulated	31353329
13203	Mouse	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	MPC5 cells	high glucose (HG) treatment	LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy	33232688
13204	Mouse	MALAT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	C57BL/6 mice kidney	streptozocin (STZ) treatment	upregulated	28444861
13205	Mouse	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells	high glucose (HG) treatment	Glucose increased LncRNA?MALAT1?levels by increasing Sp1 transcription factor binding at its promoter.	33051272
13206	Mouse	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal microvascular endothelial cells (RMECs)	high glucose treatment	upregulated	31313295
13207	Mouse	MALAT1	lncRNA	oxygen	diabetic retinopathy (DR)	mouse retinal tissues	oxygen induce treatment	upregulated	31689123
13208	Mouse	MALAT1	lncRNA	oxygen	diabetic retinopathy (DR)	retinal tissues	oxygen treatment	MALAT1 affect angiogenesis by sponging miR-203a-3p in DR	31689123
13209	Mouse	MALAT1	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	RF/6A cell	streptozotocin treatment	upregulated	24436191
13210	Mouse	MALAT1	lncRNA	streptozotocin injection and a high-glucose/high-fat diet	diabetic retinopathy (DR)	retinal microvascular endothelial cells (RMECs)	streptozotocin injection and a high-glucose/high-fat diet treatment	"YAP1 may exert some promotive effects on the development of DR through its regulation of the MALAT1/miR-200b-3p/VEGFA axis, highlighting that YAP1 silencing may be instrumental for the therapeutic targeting of DR"	31313295
13211	Mouse	MALAT1	lncRNA	high fat diet (HFD)	epithelial-mesenchymal transition (EMT)	ApoE-/- mice arterial tissue	high fat diet (HFD) feed	upregulated	30871555
13212	Mouse	MALAT1	lncRNA	CoCl2	heart failure (HF)	cardiac progenitor cells (CPCs)	CoCl2 treatment	long non-coding RNA MALAT1 expression was significantly upregulated in the CoCl 2-induced hypoxia CPC model.	29605300
13213	Mouse	MALAT1	lncRNA	CoCl2	heart failure (HF)	cardiac stem cells (CSCs)	CoCl2 treatment	upregulated	30362213
13214	Mouse	MALAT1	lncRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	mouse primary hippocampal neurons	hypoxia induce	upregulated	31185248
13215	Mouse	MALAT1	lncRNA	exercise (Ex)	insulin resistance (IR)	serum from IR mouse	swimming	downregulated	31479923
13216	Mouse	MALAT1	lncRNA	high-fat high-fructose diet (HFHFD)	insulin resistance (IR)	subcutaneous white adipose tissue (scWAT)	high-fat-high-sucrose diet feed	downregulated	29746487
13217	Mouse	MALAT1	lncRNA	fentanyl	ischemia/reperfusion (I/R) injury	"HL-1, a cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte"	fentanyl treatment	downregulated	27862640
13218	Mouse	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	astrocyte cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MALAT1 promotes cerebral ischemia-reperfusion injury by affecting AQP4 expression through competitively binding miR-145	32138732
13219	Mouse	MALAT1	lncRNA	hypoxia	ischemic brain injury	Neuronal Cells	middle cerebral artery occlusion (MCAO) treatment	upregulated	28854438
13220	Mouse	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic brain injury	Mouse brain MEC line bEnd.3 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	29203245
13221	Mouse	MALAT1	lncRNA	CoCl2	ischemic heart disease (IHD)	cardiac stem cells (CSCs)	CoCl 2 treatment	CoCl2 induced a dose-dependent increase in MALAT1 mRNA levels.	30362213
13222	Mouse	MALAT1	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	bEnd.3 cells	Oxygen-glucose deprivation (OGD) treatment	Long noncoding RNA MALAT1 regulates apoptosis in ischemic stroke by sponging miR-205-3p and modulating PTEN expression	32655805
13223	Mouse	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	brain microvascular endothelial cell (BMEC) of C57BL/6J mice	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	28433650
13224	Mouse	MALAT1	lncRNA	palmitate	cell proliferation	hepatocytes	palmitate treatment	upregulated	26935028
13225	Mouse	MALAT1	lncRNA	arsenite	liver fibrosis	mouse liver tissues	arsenite exposure	"In mice, MALAT1 was overexpressed in the progression of liver fibrosis induced by arsenite"	31513886
13226	Mouse	MALAT1	lncRNA	myostatin	hepatic insulin resistance	mouse Hepa-1c1c7	myostatin treatment	downregulated	24882465
13227	Mouse	MALAT1	lncRNA	IL-4	macrophage polarization	Mouse bone marrow-derived macrophages (BMDMs)	IL-4 treatment	downregulated	30676324
13228	Mouse	MALAT1	lncRNA	lipopolysaccharide (LPS)	macrophage polarization	Mouse bone marrow-derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	upregulated	30676324
13229	Mouse	MALAT1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	HL-1 cardiomyocytes	hypoxia/reoxygenation (H/R) induce	upregulated	31227612
13230	Mouse	MALAT1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	HL-1 cells	hypoxia/reoxygenation (H/R) treatment	LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5	32010261
13231	Mouse	MALAT1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	HL-1 cells	hypoxia-reoxygenation (H/R)treatment	downregulated	27862640
13232	Mouse	MALAT1	lncRNA	nitrogen dioxide (NO2)	neurodevelopmental disorder	cortex	nitrogen dioxide (NO2) treatment	upregulated	32203807
13233	Mouse	MALAT1	lncRNA	bupivacaine	neurotoxicity	Primary dorsal root ganglion (DRG) neurons	bupivacaine treatment	"The expression of lncRNA MALAT1 was upregulated upon exposure to bupivacaine. Knockdown of lncRNA MALAT1 significantly increased the cell death rates, and Caspase3 activity assays revealed that the apoptosis rates were manifestly increased in the MALAT1 downregulated group."	31254586
13234	Mouse	MALAT1	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	MALAT1 was upregulated in LPS-stimulated ATDC5 cells.	30145831
13235	Mouse	MALAT1	lncRNA	streptozocin (STZ)	oxidative stress	retinal microvessels	streptozocin (STZ) treatment	upregulated	33051272
13236	Mouse	MALAT1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain samples	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	30260025
13237	Mouse	MALAT1	lncRNA	resveratrol	parkinson's disease (PD)	Parkinson's disease (PD) mice midbrain samples	resveratrol (RS) treatment	downregulated	30260025
13238	Mouse	MALAT1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"The expression levels of MALAT1 and leucine-rich repeat kinase (LRRK2) were increased, and that of miR-205-5p was decreased in the midbrains of mice in which PD was induced by MPTP."	29511451
13239	Mouse	MALAT1	lncRNA	¦Â-Asarone	parkinson's disease (PD)	midbrain	¦Â-Asarone treatment	downregulated	27470562
13240	Mouse	MALAT1	lncRNA	oxygen	pathological neovascularization	mouse ocular neovascularization	exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment	dysregulated	24623407
13241	Mouse	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	post-stroke angiogenesis	A mouse brain microvascular endothelial cell line	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30784209
13242	Mouse	MALAT1	lncRNA	oxygen glucose deprivation (OGD)	post-stroke brain damage	mouse brain microvascular endothelial cells (BMECs)	oxygen and glucose deprivation treatment	upregulated	28093478
13243	Mouse	MALAT1	lncRNA	berberine (BBR)	post-stroke inflammation	ipsilateral cortex tissues	berberine (BBR) treatment	Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation.	31431734
13244	Mouse	MALAT1	lncRNA	berberine (BBR)	post-stroke inflammation	MCAO treated ipsilateral cortex tissues	?berberine (BBR)?treatment treatment	downregulated	31431734
13245	Mouse	MALAT1	lncRNA	arsenite	lung fibrosis	lung tissues	arsenite exposure	upregulated	33162208
13246	Mouse	MALAT1	lncRNA	silica	lung fibrosis	mouse lung tissues	silica treatment	upregulated in	28900284
13247	Mouse	MALAT1	lncRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	HK-2 cells and HUVEC cells	hypoxia induce	upregulated	29467431
13248	Mouse	MALAT1	lncRNA	oxygen	retinopathy of prematurity (ROP)	retinas	oxygen treatment	upregulated	32827542
13249	Mouse	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	HL-1 cells	lipopolysaccharide (LPS) treatment	upregulated	28165557
13250	Mouse	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	mouse macrophage cell line RAW264.7	lipopolysaccharide (LPS) treatment	"MALAT1 inhibited RAW264.7?cell proliferation, while miR-346 promoted its proliferation."	31494280
13251	Mouse	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	skeletal muscle tissues	lipopolysaccharide (LPS) treatment	upregulated	31830649
13252	Mouse	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	Skeletal Muscle Tissues	lipopolysaccharide (LPS) treatment	upregulated	32882524
13253	Mouse	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	30779099
13254	Mouse	MALAT1	lncRNA	hypoxia	stroke	mouse brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) induce	the levels of lncRNA-MALAT1 and miR-145 were upregulated in OGD-induced BMECs. miR-145 functioned as an anti-angiogenic and pro-apoptotic factor in OGD treated BMECs via down-regulating VEGF-A and ANGPT2 directly.	30038058
13255	Mouse	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	testicular ischemia-reperfusion injury (IRI)	GC-1 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA MALAT1 was involved in the response to testicular IRI and cellular OGD/R	29870987
13256	Mouse	MALAT1	lncRNA	streptozocin (STZ)	tubular injury	kidney tissues	streptozotocin (STZ) treatment	LncRNA MALAT1 was upregulated in kidney tissues of diabetic mice	29928873
13257	Mouse	MALAT1	lncRNA	palmitate	¦Â-cell dysfunction	MIN6 cells	palmitate treament treatment	exendin-4 ameliorated ¦Â-cell impairment by Pdx1-mediated Malat1 upregulation	32324218
13258	Mouse	MALAT1	lncRNA	cigarette smoke extract (CSE)	¦Â-cell dysfunction	MIN6 cells	cigarette smoke extract (CSE) treatment	cigarette smoke extract (CSE) increased the levels of MALAT1.	29856480
13259	Mouse	MEG3	lncRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	mouse embryonic palate mesenchymal (MEPM) cells	all-trans retinoic acid (ATRA) treatment	upregulated	33493612
13260	Mouse	MEG3	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	MEG3 was significantly increased in kidney tissues induced by lipopolysaccharide (LPS).	29923218
13261	Mouse	MEG3	lncRNA	chronic intermittent hypoxia (CIH)	aortic endothelial function	aortic endothelial cells	chronic intermittent hypoxia (CIH) treatment	MEG3 suppresses the apoptosis of aortic endothelial cells in mice with chronic intermittent hypoxia via downregulated of HIF-1¦Á by competitively binding to microRNA-135a.	32642094
13262	Mouse	MEG3	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	endothelium	high fat diet (HFD) feed	Melatonin significantly diminished MEG3 expression.	29024030
13263	Mouse	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	mouse Raw264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL upregulated MEG3 expression and that knockdown of MEG3 inhibited the action of ox-LDL in Raw264.7 cells.	30672051
13264	Mouse	MEG3	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	Cardiomyocytes isolated from newborn mouse hearts	angiotensin II (Ang II) treatment	MEG3 was upregulated in the cardiomyocytes which were treated with Ang-II.	30679521
13265	Mouse	MEG3	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	BV-2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MEG3 could alleviate cerebral I/R injury via inhibiting M1 polarization and promoting M2 polarization through Kr¨¹ppel-like factor 4 (KLF4)	33180644
13266	Mouse	MEG3	lncRNA	hypoxia	cerebral ischemic stroke (CIS)	C57BL/6 J mice	MCAO treatment	upregulated	29238035
13267	Mouse	MEG3	lncRNA	high glucose (HG)	diabetes mellitus (DM)	primary hepatocytes	high glucagon treatment	MEG3 was highly expressed in high glucagon-treated mouse primary hepatocytes.	30260029
13268	Mouse	MEG3	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	MPC5 cells	high glucose (HG) treatment	downregulated	31799068
13269	Mouse	MEG3	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal endothelial cell	STZ treatment	downregulated	26845358
13270	Mouse	MEG3	lncRNA	atorvastatin	heart failure (HF)	cardiac progenitor cell (CPC)	atorvastatin treatment	downregulated	30481260
13271	Mouse	MEG3	lncRNA	high glucagon	hepatic gluconeogenesis	mouse primary hepatocytes	high glucagon treatment	MEG3 was highly expressed in high glucagon-treated mouse primary hepatocytes.	30260029
13272	Mouse	MEG3	lncRNA	high fat diet (HFD)	hepatic insulin resistance	primary hepatocytes	high fat diet (HFD) feed	upregulated	26603935
13273	Mouse	MEG3	lncRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	upregulated	30431065
13274	Mouse	MEG3	lncRNA	palmitate	hepatic insulin resistance	mouse primary hepatocytes	palmitate treatment	upregulated	30431065
13275	Mouse	MEG3	lncRNA	ischemia	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hepatic ischemia-reperfusion (HIR)	upregulated	28708282
13276	Mouse	MEG3	lncRNA	hyperoxia	hyperoxia-induced acute lung injury (HALI)	MLE-12 cells	hyperoxia treatment	upregulated	32084370
13277	Mouse	MEG3	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	lncRNA-MEG3 was significantly increased and primarily localized in the cytoplasm of hypoxic PASMCs. Silencing of lncRNA-MEG3 by siRNAs and gapmers attenuated proliferation and cell-cycle progression in both PASMCs from idiopathic pulmonary arterial hypertension (iPAH) patients (iPAH-PASMCs) and hypoxia-exposed PASMCs in vitro.	31477557
13278	Mouse	MEG3	lncRNA	oxygen glucose deprivation (OGD)	intracerebral haemorrhage (ICH)	Primary brain microvascular endothelial cells (BMECs)	oxygen-and-glucose-deprivation (OGD) treatment	upregulated	33836898
13279	Mouse	MEG3	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	male C57BL/6J mice	CCl4 treatment	downregulated	25201080
13280	Mouse	MEG3	lncRNA	"diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC)"	liver preneoplastic foci and tumors	mice liver cells	"Diethyl 1,4-dihydro-2,4,6,-trimethyl-3,5-pyridinedicarboxylate (DDC) treatment"	downregulated	19362547
13281	Mouse	MEG3	lncRNA	morphine	morphine addiction	HT22 cells	Morphine treatment	upregulated	31433241
13282	Mouse	MEG3	lncRNA	IL-1¦Â	osteoarthritis (OA)	"CHON-001, ATDC5 cells"	IL-1¦Â treatment	"MEG3 expression in chondrocytes was downregulated by the stimulation of IL-1¦Â, and MEG3 negatively regulated miR-9-5p expression but positively regulated KLF4 expression."	33776787
13283	Mouse	MEG3	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	"LPS decreased cell viability, increased cell apoptosis, promoted the release of pro-inflammatory factors, and downregulated MEG3 expression."	29432995
13284	Mouse	MEG3	lncRNA	streptozocin (STZ)	podocyte injury	mouse podocytes	streptozotocin (STZ) treatment	upregulated	33061608
13285	Mouse	MEG3	lncRNA	cyclophosphamide (CP)	pathological senescence	mouse ovarian granulosa cells	cyclophosphamide (CP) treatment	upregulated	27729272
13286	Mouse	MEG3	lncRNA	melatonin	protecting neural stem cells (NSCs) from reactive oxygen species (ROS)	neural stem cells	Melatonin treatment	melatonin appeared to protect NSCs from H2O2-induced ROS by modification of the MEG3/miRNA-27a-3p/MAP2K4 axis.	32599124
13287	Mouse	MEG3	lncRNA	mycobacterium tuberculosis (Mtb)	pulmonary tuberculosis (PTB)	RAW264.7 cells	mycobacterium tuberculosis (MTB) infection	MEG3 was highly expressed in PTB.	33035634
13288	Mouse	MEG3	lncRNA	light	retinal degenerative diseases	retina	light exposure	Light exposure leads to increased MEG3 expression.	29409883
13289	Mouse	MEG3	lncRNA	ultraviolet (UV) irradiation	skin damage	primary murine skin fibroblasts	UVB treatment	"The overexpression of Meg3 after UVB irradiation was observed in primary murine skin fibroblasts, and the upregulated Meg3 expression was related to the activation of the inflammatory cytokines"	31761787
13290	Mouse	MEG3	lncRNA	lipopolysaccharide + ATP	traumatic brain injury (TBI)	microglia	lipopolysaccharide + ATP treatment	upregulated	33189612
13291	Mouse	MEG3	lncRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	primary hepatocytes	high fat diet (HFD) feed	upregulated	26603935
13292	Mouse	MEG3	lncRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	macrophages	coxsackievirus B3 (CVB3) treatment	"downregulated of MEG3 leads to the inhibition of inflammation and induces M2 macrophage polarization via miR-223/TRAF6/NF-¦ÊB axis, thus alleviating VMC."	33047847
13293	Mouse	MEG3-4	lncRNA	P. aeruginosa strain PAO1	bacterial infection	lung tissues	P. aeruginosa strain PAO1 treatment	MEG3-4 is in a decreased abundance in mouse lungs after bacterial infection	29945883
13294	Mouse	MEG8	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	Mouse brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	upregulated	32627090
13295	Mouse	MEG9	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	upregulated	32626785
13296	Mouse	Mhrt	lncRNA	hearts pressure-overloaded	pathological hypertrophy	mouse	transaortic constriction (TAC)3 treatment	downregulated	25119045
13297	Mouse	Mhrt779	lncRNA	exercise (Ex)	physiological myocardial hypertrophy (PMH)	heart tissues	exercise treatment	Mhrt779?was one of the markedly upregulated long noncoding RNAs in the EHP group.	33757294
13298	Mouse	MIAT	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	primary cardiomyocytes; fibroblasts	high glucose (HG) treatment	upregulated	32351959
13299	Mouse	MIAT	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	mouse retion	STZ treatment	upregulated	28246353
13300	Mouse	MIAT	lncRNA	hypoxia	hypoxic/ischemic injury	Neuro2A cells	hypoxia treatment	lncRNA MIAT was downregulated in oxygen glucose deprivation (OGD)-induced ischemic injury of Neuro2A cells.	30563429
13301	Mouse	MIAT	lncRNA	lipopolysaccharide (LPS)	pneumonia	TC-1 cells	lipopolysaccharide (LPS) treatment	upregulated	33318298
13302	Mouse	MIAT	lncRNA	high glucose (HG)	podocyte injury	mouse podocytes	high glucose (HG) treatment	Ablation of lncRNA MIAT mitigates high glucose-stimulated inflammation and apoptosis of podocyte via miR-130a-3p/TLR4 signaling axis.	32972755
13303	Mouse	MIAT	lncRNA	collagen	rheumatoid arthritis (RA)	synovium; myocardial tissues	collagen treatment	we found that macrophage inflammation induced by LPS could up-regulate lncRNA MIAT expression.	33459112
13304	Mouse	MIAT	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	HL-1 cells	lipopolysaccharide (LPS) treatment	LncRNA MIAT Promotes Inflammation and Oxidative Stress in Sepsis-Induced Cardiac Injury by Targeting miR-330-5p/TRAF6/NF-¦ÊB Axis	32556678
13305	Mouse	MIAT	lncRNA	cinnamaldehyde (CA)	ulcerative colitis (UC)	colonic tissues	Cinnamaldehyde (CA) treatment	MIAT was reduced in the DSS-treated mice and was significantly increased after CA treatment.	33341041
13306	Mouse	MIAT	lncRNA	hypoxia	acute myocardial infarction (AMI)	The mouse cardiomyocyte cell line HL-1 cells	hypoxia induce	"MIAT and EGR2 were subsequently determined to be highly-expressed, whereas miR-10a-5p was found to be poorly-expressed in cardiomyocytes exposed to hypoxia as well as in MI mice using RT-qPCR and Western blot assay."	33819189
13307	Mouse	MIR143HG	lncRNA	rosiglitazone	diabetic nephropathy (DN)	kidney tissues	rosiglitazone treatment	upregulated	32025515
13308	Mouse	MIRF	lncRNA	H2O2	acute myocardial infarction (AMI)	primary neonatal mice ventricular cardiomyocytes	H2O2 treatment	MIRF contributed to cardiomyocyte apoptosis through modulating Bak1 by regulation of miR-26a.	32464547
13309	Mouse	Mirt1	lncRNA	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP)"	rheumatoid arthritis (RA)	TM3 Leydig cells	"phthalic acid mono-2-ethylhexyl ester (MEHP, bio-metabolite of DEHP) treatment"	downregulated	33360214
13310	Mouse	Mirt2	lncRNA	lipopolysaccharide (LPS)	inflammation	C57BL/6 mice	lipopolysaccharide (LPS) treatment	downregulated	29230038
13311	Mouse	Mirt2	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissue	high fat diet (HFD) feed	downregulated	30898698
13312	Mouse	Mirt2	lncRNA	IFN-¦Ã	sj?gren's syndrome (SS)	salivary gland epithelial cells (SGECs)	interferon gamma (IFN-¦Ã) treatment	upregulated	31198060
13313	Mouse	Mist	lncRNA	high fat diet (HFD)	obesity	macrophages	high fat diet (HFD) feed	LncRNA Mist Is Downregulated in Macrophages From HFD-Fed Obese Mice.	32078363
13314	Mouse	MM2P	lncRNA	lipopolysaccharide- and MSU	acute gouty arthritis (AGA)	RAW 264.7 cells	lipopolysaccharide-and MSU treatment	downregulated	32705194
13315	Mouse	MM2P	lncRNA	lipopolysaccharide (LPS)	chondrocyte differentiation	mouse bone marrow-derived macrophages	lipopolysaccharide (LPS) treatment	downregulated	32938906
13316	Mouse	mmu_circ_0000038	circRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	upregulated	32552669
13317	Mouse	mmu_circ_0000120	circRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts	TGF-¦Â1 treatment	upregulated	32062386
13318	Mouse	mmu_circ_0000220	circRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	upregulated	32552669
13319	Mouse	mmu_circ_0000372	circRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse primary kidney GEC (C57-6014G) and mouse glomerular mesangial cells (GMC) (SV40 MES 13) and derived exosomes	high glucose (HG) treatment	downregulated	31497190
13320	Mouse	mmu_circ_0000455	circRNA	house dust mite (HDM)	allergic asthma (AA)	lung tissues	house dust mite allergen treatment	upregulated	33173985
13321	Mouse	mmu_circ_0000468	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Parkinson's disease (PD) group	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	32344560
13322	Mouse	mmu_circ_0000491	circRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (MES13 cells)	high glucose (HG) treatment	circ_0000491 aggravates the extracellular matrix of diabetic nephropathy glomerular mesangial cells through suppressing miR-101b by targeting TGF¦ÂRI.	32901868
13323	Mouse	mmu_circ_0000505	circRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse primary kidney GEC (C57-6014G) and mouse glomerular mesangial cells (GMC) (SV40 MES 13) and derived exosomes	high glucose (HG) treatment	downregulated	31497190
13324	Mouse	mmu_circ_0000512	circRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts	TGF-¦Â2 treatment	upregulated	32062386
13325	Mouse	mmu_circ_0000517	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	striatum (ST)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	32344560
13326	Mouse	mmu_circ_0000623	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic tissue	carbon tetrachloride (CCl4) treatment	mmu_circ_0000623 expression was downregulated in CCl4-induced mice.	32633558
13327	Mouse	mmu_circ_0000629	circRNA	house dust mite (HDM)	allergic asthma (AA)	lung tissues	house dust mite allergen treatment	upregulated	33173985
13328	Mouse	mmu_circ_0000668	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with miR-203-3p	31452702
13329	Mouse	mmu_circ_0000723	circRNA	house dust mite (HDM)	allergic asthma (AA)	lung tissues	house dust mite allergen treatment	downregulated	33173985
13330	Mouse	mmu_circ_0000790	circRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxic treatment	mmu_circ_0000790 Is Involved in Pulmonary Vascular Remodeling in Mice with HPH via MicroRNA-374c-Mediated FOXC1.	32199127
13331	Mouse	mmu_circ_0000870	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	striatum (ST)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	32344560
13332	Mouse	mmu_circ_0000981	circRNA	atractylon (Atr)	asthma	asthma mouse lung tissues; TGF-¦Â1-treated TC-1 cells	atractylon (Atr)?treatment	Atr treatment suppressed OVA-induced circRNA-0000981 and TGFBR2 expression but promoted miR-211-5p expression.	33855682
13333	Mouse	mmu_circ_0000981	circRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	33855682
13334	Mouse	mmu_circ_0000981	circRNA	TGF-¦Â1	asthma	TC-1 cells	TGF-¦Â1 treatment	upregulated	33855682
13335	Mouse	mmu_circ_0001066	circRNA	bisphosphonates (BPs)	osteoclastogenesis	RAW264.7 cells	bisphosphonates (BPs) treatment	Four MRONJ-related miRNAs were upregulated in BP-treated RAW264.7 cells and the expression of mmu_circ_0001066 was negatively correlated with those of MRONJ-related miRNAs.	33837656
13336	Mouse	mmu_circ_0001204	circRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts	TGF-¦Â3 treatment	upregulated	32062386
13337	Mouse	mmu_circ_0001223	circRNA	panax notoginseng saponins (SLPN)	depression	mouse ventral medial prefrontal cortex (VMPC)	panax notoginseng saponins (SLPN) treatment	"mmu_circ_0001223 expression was greatly decreased in CUMS mice, but significantly elevated by SLPN treatment"	30298999
13338	Mouse	mmu_circ_0001320	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Parkinson's disease (PD) group	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	32344560
13339	Mouse	mmu_circ_0001336	circRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiac extracellular vesicles (EVs)	ischemia/reperfusion (I/R) treatment	dysregulated	31466885
13340	Mouse	mmu_circ_0001359	circRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	32018116
13341	Mouse	mmu_circ_0001454	circRNA	house dust mite (HDM)	allergic asthma (AA)	lung tissues	house dust mite allergen treatment	downregulated	33173985
13342	Mouse	mmu_circ_0001520	circRNA	concanamycin A (Con A)	autoimmune hepatitis (AIH)	liver tissues	concanavalin A (Con A) treatment	upregulated	32965791
13343	Mouse	mmu_circ_0001605	circRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse primary kidney GEC (C57-6014G) and mouse glomerular mesangial cells (GMC) (SV40 MES 13) and derived exosomes	high glucose (HG) treatment	downregulated	31497190
13344	Mouse	mmu_circ_0001632	circRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts	TGF-¦Â6 treatment	downregulated	32062386
13345	Mouse	mmu_circ_0001645	circRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts	TGF-¦Â4 treatment	downregulated	32062386
13346	Mouse	mmu_circ_000203	circRNA	angiotensin II (Ang II)	cardiac fibrosis	mouse cardiac fibroblasts	angiotensin II (Ang II) treatment	upregulated	28079129
13347	Mouse	mmu_circ_000203	circRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse ventricular cardiomyocytes (NMVCs)	angiotensin II (Ang II) treatment	CircRNA_000203 was found to be upregulated in the myocardium of Ang-II-infused mice and in the cytoplasma of Ang-II-treated neonatal mouse ventricular cardiomyocytes (NMVCs).	31397837
13348	Mouse	mmu_circ_0003292	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	striatum (ST)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	32344560
13349	Mouse	mmu_circ_0003865	circRNA	melatonin	osteoporosis	human bone marrow mesenchymal stem cell (hBMSC)	melatonin (MEL) treatment	Circ_0003865 expression in BMSCs was significantly decreased by MEL treatment.	33632317
13350	Mouse	mmu_circ_0004144	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Parkinson's disease (PD) group	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	32344560
13351	Mouse	mmu_circ_0004158	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with let-7k	31452702
13352	Mouse	mmu_circ_0004646	circRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	kidney tissues	ischemia/reperfusion (I/R) treatment	dysregulated	29245971
13353	Mouse	mmu_circ_0005324	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with let-7k	31452702
13354	Mouse	mmu_circ_0005477	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with miR-203-3p and miR-5128	31452702
13355	Mouse	mmu_circ_0005768	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with let-7k	31452702
13356	Mouse	mmu_circ_0007799	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with miR-5128	31452702
13357	Mouse	mmu_circ_0008737	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with let-7k	31452702
13358	Mouse	mmu_circ_001007	circRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiac extracellular vesicles (EVs)	ischemia/reperfusion (I/R) treatment	dysregulated	31466885
13359	Mouse	mmu_circ_0012530	circRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts	TGF-¦Â5 treatment	downregulated	32062386
13360	Mouse	mmu_circ_001265	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	downregulated	30614051
13361	Mouse	mmu_circ_0012698	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with miR-203-3p	31452702
13362	Mouse	mmu_circ_0013321	circRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Parkinson's disease (PD) group	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	32344560
13363	Mouse	mmu_circ_0013414	circRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	predicted to be ceRNAs that regulate angiogenesis-associated coding genes in ROP by competing with miR-203-3p	31452702
13364	Mouse	mmu_circ_001489	circRNA	"IFN-¦Ã, lipopolysaccharide (LPS) and IL-4"	macrophage differentiation and polarization	bone marrow-derived macrophages (BMDMs)	"M1 macrophages induced by interferon-¦Ã and LPS , M2 macrophages induced by interleukin-4"	differentlly regulated in M1 compared to M2	28075448
13365	Mouse	mmu_circ_001741	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	upregulated	31240833
13366	Mouse	mmu_circ_0019157	circRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	upregulated	32552669
13367	Mouse	mmu_circ_0020896	circRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	downregulated	32552669
13368	Mouse	mmu_circ_002581	circRNA	high concentration of free fatty acids	nonalcoholic steatohepatitis (NASH)	NCTC-1469 cells	high concentration of free fatty acids treatment	circRNA_002581 was upregulated in HFFA-induced NASH cell-like model.	32054840
13369	Mouse	mmu_circ_002813	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	downregulated	30614051
13370	Mouse	mmu_circ_002856	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	upregulated	30614051
13371	Mouse	mmu_circ_0029726	circRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	downregulated	32552669
13372	Mouse	mmu_circ_0032636	circRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	downregulated	32552669
13373	Mouse	mmu_circ_003410	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	downregulated	31240833
13374	Mouse	mmu_circ_003424	circRNA	"IFN-¦Ã, lipopolysaccharide (LPS) and IL-4"	macrophage differentiation and polarization	bone marrow-derived macrophages (BMDMs)	"M1 macrophages induced by interferon-¦Ã and LPS , M2 macrophages induced by interleukin-4"	differentlly regulated in M1 compared to M2	28075448
13375	Mouse	mmu_circ_0037128	circRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cells (MCs)	high glucose (HG) treatment	It was found that expression of circ_0037128 was significantly increased in mouse DN model and high glucose treated mesangial cells (MCs)	32860899
13376	Mouse	mmu_circ_003780	circRNA	"IFN-¦Ã, lipopolysaccharide (LPS) and IL-4"	macrophage differentiation and polarization	bone marrow-derived macrophages (BMDMs)	"M1 macrophages induced by interferon-¦Ã and LPS , M2 macrophages induced by interleukin-4"	differentlly regulated in M1 compared to M2	28075448
13377	Mouse	mmu_circ_0044226	circRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung lobes	bleomycin (BLM) treatment	upregulated	31786325
13378	Mouse	mmu_circ_004742	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	upregulated	30614051
13379	Mouse	mmu_circ_0047814	circRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal vessels	streptozotocin (STZ) treatment	upregulated	32343678
13380	Mouse	mmu_circ_005186	circRNA	ischemia/reperfusion (I/R) 	liver damage	mouse liver tissues	ischemia/reperfusion (I/R) treatment	mmu-circ_005186 dysregulated	30670716
13381	Mouse	mmu_circ_0054633	circRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	murine pulmonary microvascular endothelial cells (MPVECs)	lipopolysaccharide (LPS) treatment	Quietness of circ_0054633 alleviated LPS-induced ALI via NF-¦ÊB signaling pathway.	32950633
13382	Mouse	mmu_circ_0054633	circRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Primary murine pulmonary microvascular endothelial cells (MPVECs)	lipopolysaccharide (LPS) treatment	upregulated	32950633
13383	Mouse	mmu_circ_0061052	circRNA	cigarette smoke (CS)	epithelial-mesenchymal transition (EMT)	lung tissues	Cigarette smoke (CS) exposure	upregulated	32768781
13384	Mouse	mmu_circ_006636	circRNA	hypoxia	autophagy	primary mouse cardiomyocytes culture	hypoxia induce	circRNA_006636 inhibits autophagy and cell death in cardiomyocytes	30349076
13385	Mouse	mmu_circ_007845	circRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiac extracellular vesicles (EVs)	ischemia/reperfusion (I/R) treatment	dysregulated	31466885
13386	Mouse	mmu_circ_007893	circRNA	calcitonin gene-related peptide (CGRP)	inflammation	RAW264.7 macrophages	calcitonin gene-related peptide (CGRP) treatment	upregulated	29039515
13387	Mouse	mmu_circ_0080425	circRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse mesangial cells (MCs)	high glucose treatment	upregulated	31680239
13388	Mouse	mmu_circ_0080425	circRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	upregulated	31680239
13389	Mouse	mmu_circ_008228	circRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiac extracellular vesicles (EVs)	ischemia/reperfusion (I/R) treatment	dysregulated	31466885
13390	Mouse	mmu_circ_008351	circRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiac extracellular vesicles (EVs)	ischemia/reperfusion (I/R) treatment	dysregulated	31466885
13391	Mouse	mmu_circ_009056	circRNA	calcitonin gene-related peptide (CGRP)	osteogenesis	MC3T3 cells	calcitonin gene-related peptide (CGRP) treatment	"The expression of mmu_circ_009056 was upregulated in the CGRP-induced cells, whereas miR-22-3p was obviously decreased."	29709471
13392	Mouse	mmu_circ_009537	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	upregulated	30614051
13393	Mouse	mmu_circ_009839	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	upregulated	30614051
13394	Mouse	mmu_circ_010056	circRNA	"IFN-¦Ã, lipopolysaccharide (LPS) and IL-4"	macrophage differentiation and polarization	bone marrow-derived macrophages (BMDMs)	"M1 macrophages induced by interferon-¦Ã and LPS , M2 macrophages induced by interleukin-4"	differentlly regulated in M1 compared to M2	28075448
13395	Mouse	mmu_circ_010231	circRNA	"IFN-¦Ã, lipopolysaccharide (LPS) and IL-4"	macrophage differentiation and polarization	bone marrow-derived macrophages (BMDMs)	"M1 macrophages induced by interferon-¦Ã and LPS , M2 macrophages induced by interleukin-4"	differentlly regulated in M1 compared to M2	28075448
13396	Mouse	mmu_circ_010383	circRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells; mouse tubular epithelial cells	high glucose (HG) treatment	circRNA_010383 expression was markedly downregulated in tubular epithelial cells cultured in high-glucose conditions.	33203695
13397	Mouse	mmu_circ_010383	circRNA	high glucose (HG)	diabetic nephropathy (DN)	kidney tissues	high glucose (HG) treatment	"We found that circRNA_010383 expression was markedly downregulated in diabetic kidneys, mesangial cells, and tubular epithelial cells cultured in high-glucose conditions."	33472945
13398	Mouse	mmu_circ_010567	circRNA	angiotensin II (Ang II)	cardiac fibrosis	diabetic mice diabetic mice myocardium	angiotensin II (Ang II) treatment	upregulated	28412345
13399	Mouse	mmu_circ_012091	circRNA	SiO2	silicosis	L929 cells	SiO2 treatment	downregulated	30908929
13400	Mouse	mmu_circ_013120	circRNA	ischemia	brain injury after stroke	brain tissues	treat with focal cerebral ischemia	dysregulated	29156814
13401	Mouse	mmu_circ_013630	circRNA	"IFN-¦Ã, lipopolysaccharide (LPS) and IL-4"	macrophage differentiation and polarization	bone marrow-derived macrophages (BMDMs)	"M1 macrophages induced by interferon-¦Ã and LPS , M2 macrophages induced by interleukin-4"	differentlly regulated in M1 compared to M2	28075448
13402	Mouse	mmu_circ_013683	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	downregulated	30614051
13403	Mouse	mmu_circ_014015	circRNA	glyphosate	neurodevelopmental disorder	hippocampus tissues	glyphosate treatment	upregulated	29705695
13404	Mouse	mmu_circ_014193	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	upregulated	30614051
13405	Mouse	mmu_circ_015947	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuronal cell injury	hippocampal HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	26845359
13406	Mouse	mmu_circ_016719	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31698040
13407	Mouse	mmu_circ_016901	circRNA	ionizing radiation (IR)	cell damage	mouse bone mesenchymal stem cells (BMSCs)	irradiation treatment	Irradiation treatment upregulated the expression of circ-016901 and HIPK2 and downregulated miR-1249-5p expression.	33732328
13408	Mouse	mmu_circ_016901	circRNA	X-rays	radiation-induced injury	bone marrow stem cells	X-ray treatment	"mmu-circRNA_016901 affects the expression of TGF-¦Â3 through miRNA1249-5p, and thus participates in the regulation of the radiation damage mechanism of bone marrow mesenchymal stem cells"	32552977
13409	Mouse	mmu_circ_018127	circRNA	"IFN-¦Ã, lipopolysaccharide (LPS) and IL-4"	macrophage differentiation and polarization	bone marrow-derived macrophages (BMDMs)	"M1 macrophages induced by interferon-¦Ã and LPS , M2 macrophages induced by interleukin-4"	differentlly regulated in M1 compared to M2	28075448
13410	Mouse	mmu_circ_018331	circRNA	"3,4-benzopyrene/angiotensin II"	abdominal aortic aneurysm (AAA)	abdominal aortic tissues	"3,4-benzopyrene/angiotensin II induce"	downregulated	30614051
13411	Mouse	mmu_circ_018725	circRNA	alcohol	alcoholic hepatitis (AH)	Liver tissues	"The mice in the model group were fed with EtOH (5% v/v) liquid diet ad 88 libitum for 10 days, culminating with single dose binge alcohol administration (5 g/kg, body weight, 20% EtOH). All mice were killed 9 h after EtOH gavage."	circ_018725 was upregulated in the EtOH-fed mice.	31493407
13412	Mouse	mmu_circ_020563	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	upregulated	31240833
13413	Mouse	mmu_circ_040736	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	upregulated	31240833
13414	Mouse	mmu_circ_046163	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	upregulated	31240833
13415	Mouse	mmu_circ_085226	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	downregulated	31240833
13416	Mouse	mmu_circ_086093	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	downregulated	31240833
13417	Mouse	mmu_circ_09505	circRNA	bovine type II collagen	rheumatoid arthritis (RA)	synovial macrophages	bovine type II collagen induction	circRNA_09505 can function as a miR-6089 sponge and regulate inflammation via miR-6089/AKT1/NF-¦ÊB axis in collagen-induced arthritis (CIA) mice mice.	33028811
13418	Mouse	mmu_circ_095551	circRNA	electroacupuncture (EA)	morphine addiction	nucleus accumbens (NAc)	electroacupuncture (EA) treatment	downregulated	31240833
13419	Mouse	mmu_circ_10042	circRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis	Murine MC3T3-E1 osteoblastic cells	bone morphogenetic protein 2 (BMP2) treatment	upregulated	28395271
13420	Mouse	mmu_circ_101237	circRNA	anoxia/reoxygenation (A/R)	cardiovascular disease (CVD)	primary cardiomyocytes	anoxia/reoxygenation (A/R) treatment	upregulated	31894303
13421	Mouse	mmu_circ_101237	circRNA	anoxia/reoxygenation (A/R)	myocardial infarction (MI)	Primary cardiomyocyte	anoxia/reoxygenation (A/R) treatment	circRNA_101237 was induced by A/R injury in a time-dependent manner and that circRNA_101237 knockdown protected cardiomyocytes from A/R-mediated apoptosis.	31894303
13422	Mouse	mmu_circ_1045	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	upregulated	31782248
13423	Mouse	mmu_circ_1202	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	upregulated	31782248
13424	Mouse	mmu_circ_1350	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	downregulated	31782248
13425	Mouse	mmu_circ_1387	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	upregulated	31782248
13426	Mouse	mmu_circ_1528	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	upregulated	31782248
13427	Mouse	mmu_circ_1639	circRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	Kupffer cells from the livers and RAW 264.7 cells	ethanol treatment	upregulated	31325635
13428	Mouse	mmu_circ_1806	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	downregulated	31782248
13429	Mouse	mmu_circ_19142	circRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis	Murine MC3T3-E1 osteoblastic cells	bone morphogenetic protein 2 (BMP2) treatment	upregulated	28395271
13430	Mouse	mmu_circ_1983	circRNA	dicalcium silicate microparticle (C2S)	bone and dental tissue regenerative applications	mesenchymal stem cells (MSCs)	dicalcium silicate microparticle (C2S) treatment	"C2S-treatment upregulated the expression of circ_1983, Gas7, and Runx2 in BMSCs."	32463418
13431	Mouse	mmu_circ_2443	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	upregulated	29247798
13432	Mouse	mmu_circ_2483	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	downregulated	29247798
13433	Mouse	mmu_circ_28128	circRNA	glyphosate	neurodevelopmental disorder	hippocampus tissues	glyphosate treatment	upregulated	29705695
13434	Mouse	mmu_circ_28313	circRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL) and macrophage colony-stimulating factor (CSF1)	ovariectomized (OVX)-induced bone resorption	bone marrow monocyte/macrophage (BMM) cells	receptor activator of nuclear factor-¦ÊB ligand (RANKL) and macrophage colony-stimulating factor (CSF1) treatment	"circRNA_28313 was significantly induced by RANKL + CSF1 treatment circRNA_28313 knockdown significantly inhibited RANKL + CSF1-induced differentiation of osteoclasts within BMM cells?in vitro, while suppressed ovariectomized (OVX)-induced bone resorption in mice?in vivo"	31204558
13435	Mouse	mmu_circ_294	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	downregulated	31782248
13436	Mouse	mmu_circ_29837	circRNA	glyphosate	neurodevelopmental disorder	hippocampus tissues	glyphosate treatment	downregulated	29705695
13437	Mouse	mmu_circ_30365	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	downregulated	29247798
13438	Mouse	mmu_circ_30365	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	dysregulated	29247798
13439	Mouse	mmu_circ_30981	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	30118889
13440	Mouse	mmu_circ_33186	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	upregulated	29247798
13441	Mouse	mmu_circ_33186	circRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	circRNA.33186 was significantly upregulated in IL-1¦Â-treated chondrocytes and in cartilage tissues of a destabilized medial meniscus (DMM)-induced OA mouse model	30692016
13442	Mouse	mmu_circ_33594	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	30118889
13443	Mouse	mmu_circ_33594	circRNA	TGF-¦Â1	liver fibrosis	JS1 cells	TGF-¦Â1 treatment	upregulated	30118889
13444	Mouse	mmu_circ_33736	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	downregulated	29247798
13445	Mouse	mmu_circ_34116	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	30118889
13446	Mouse	mmu_circ_34116	circRNA	TGF-¦Â1	liver fibrosis	JS1 cells	TGF-¦Â1 treatment	downregulated	30118889
13447	Mouse	mmu_circ_344	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	downregulated	31782248
13448	Mouse	mmu_circ_35216	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	30118889
13449	Mouse	mmu_circ_35216	circRNA	TGF-¦Â1	liver fibrosis	JS1 cells	TGF-¦Â1 treatment	upregulated	30118889
13450	Mouse	mmu_circ_3591	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	downregulated	31782248
13451	Mouse	mmu_circ_36866	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	upregulated	29247798
13452	Mouse	mmu_circ_36866	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	dysregulated	29247798
13453	Mouse	mmu_circ_40001	circRNA	ischemia	brain injury after stroke	brain tissues	treat with focal cerebral ischemia	dysregulated	29156814
13454	Mouse	mmu_circ_40806	circRNA	ischemia	brain injury after stroke	brain tissues	treat with focal cerebral ischemia	dysregulated	29156814
13455	Mouse	mmu_circ_42398	circRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	30118889
13456	Mouse	mmu_circ_5846	circRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis	Murine MC3T3-E1 osteoblastic cells	bone morphogenetic protein 2 (BMP2) treatment	upregulated	28395271
13457	Mouse	mmu_circ_662	circRNA	astilbin	lung fibrosis	lung tissues	astilbin induce	dysregulated	31448882
13458	Mouse	mmu_circ_7063	circRNA	IL-1¦Â	osteoarthritis (OA)	mouse articular chondrocytes (MACs)	IL-1¦Â treatment	upregulated	29247798
13459	Mouse	mmu_circ_818	circRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	upregulated	31782248
13460	Mouse	mmu_circ_949	circRNA	astilbin	lung fibrosis	lung tissues	astilbin induce	dysregulated	31448882
13461	Mouse	mmu-let-7	miRNA	high tidal volume ventilation (HVTV)	lung injury	lung tissues	high tidal volume ventilation (HVTV) treatment	upregulated	22659882
13462	Mouse	mmu-let-7	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	tumorigenesis	brain and liver tissue cells	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) treatment"	downregulated	19270793
13463	Mouse	mmu-let-7	miRNA	morphine	contractility of  vascular smooth muscle cells	brain tissues	morphine treatment	morphine significantly upregulated let-7 expression in SH-SY5Y cells and in a mouse model of opioid tolerance.	20668208
13464	Mouse	mmu-let-7	miRNA	antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP)	diabetic nephropathy (DN)	diabetic CD-1 mice	antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) treatment	upregulated	24783220
13465	Mouse	mmu-let-7	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	downregulated	30692507
13466	Mouse	mmu-let-7	miRNA	concanamycin A (Con A)	hepatitis	mice liver tissues	con A infection	upregulated	23184091
13467	Mouse	mmu-let-7	miRNA	Staphylococcus aureus	inflammation	mouse mammary tissue	intramammary infection of Globally Staphylococcus aureus treatment	differently regulated	25075227
13468	Mouse	mmu-let-7	miRNA	maternal H. bakeri	maternal H. bakeri infection	brain tissues	maternal protein deficiency and/or nematode infection	upregulated in the developing fetal brain	28903026
13469	Mouse	mmu-let-7	miRNA	lipopolysaccharide (LPS)	regeneration of the intestinal epithelia	intestinal tissues	lipopolysaccharide (LPS) treatment	downregulated	29621481
13470	Mouse	mmu-let-7a	miRNA	high fat diet (HFD)	acute myocardial infarction (AMI)	liver tissue	high fat diet (HFD) feed	downregulated	19835573
13471	Mouse	mmu-let-7a	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	mouse mouse liver	ethanol treatment	downregulated in mouse liver	28536261
13472	Mouse	mmu-let-7a	miRNA	alcohol	alcoholic liver disease (ALD)	liver tissues	alcohol exposure	downregulated	31734308
13473	Mouse	mmu-let-7a	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	mice hepatocytes	EtOH treatment	downregulated	31734308
13474	Mouse	mmu-let-7a	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
13475	Mouse	mmu-let-7a	miRNA	blast	blast traumatic brain injury (bTBI)	Balb/c mice	blast treatment	dysregulated	29020847
13476	Mouse	mmu-let-7a	miRNA	diethylnitrosamine (DEN)	chronic cholestasis and cholangiocarcinoma	liver tissues	diethylnitrosamine (DEN) treatment	downregulated	21440549
13477	Mouse	mmu-let-7a	miRNA	estradiol	embryo implantation	mouse dormant blastocysts	estradiol treatment	downregulated	24419497
13478	Mouse	mmu-let-7a	miRNA	calcitonin (CT)	endometrial receptivity	uterine tissue	calcitonin (CT) treatment	upregulated	30536902
13479	Mouse	mmu-let-7a	miRNA	calcitonin (CT)	endometrial receptivity	uterine tissue samples	calcitonin (CT) treatment	CT injection increased the expression of LIF and miRNA Let-7a in ovarian stimulation similar to that in normal ovarian cycles.	30536902
13480	Mouse	mmu-let-7a	miRNA	dichloroacetate (DCA)	energy metabolism	MDA-MB-231 cells	dichloroacetate (DCA) treatment	upregulated	32248711
13481	Mouse	mmu-let-7a	miRNA	gold nanoparticles (AuNPs)	epithelial-mesenchymal transition and peritoneal fibrosis	liver and lung of mouse fetuses	gold nanoparticles (AuNP) treatment	upregulated	24004569
13482	Mouse	mmu-let-7a	miRNA	honeysuckle (HS)	enterovirus 71 (EV71) infection	brain tissues	Honeysuckle treatment	"Moreover, honeysuckle-induced?let-7a?suppression of EV71 RNA and protein expression as well as viral replication were investigated both in vitro and in vivo."	33669264
13483	Mouse	mmu-let-7a	miRNA	lipopolysaccharide (LPS)	inflammation	"Kupffer cells, RAW264.7 cells"	lipopolysaccharide (LPS) treatment	let-7a regulates LPS-induced inflammatory responses by targeting TLR4.	31344555
13484	Mouse	mmu-let-7a	miRNA	Japanese Encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	mouse neuronal (Neuro2a) cells or primary cortical neurons	Japanese Encephalitis virus (JEV) infection	upregulated	30556910
13485	Mouse	mmu-let-7a	miRNA	hypoxia	melanoma	Mouse melanoma B16-F0 cells	hypoxia induce	downregulated	30872795
13486	Mouse	mmu-let-7a	miRNA	hypoxia	melanoma	Mouse melanoma B16-F0 cell exosomes	hypoxia induce	upregulated	30872795
13487	Mouse	mmu-let-7a	miRNA	ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE)	metastasized melanoma	"B16F10 melanoma tissues, B16F10 melanoma lung metastasis in mice"	SLE treatment	upregulated	31514083
13488	Mouse	mmu-let-7a	miRNA	coronary artery ligation	myocardial ischaemic injury	heart	subjected to coronary artery ligation	downregulated	26655604
13489	Mouse	mmu-let-7a	miRNA	sevoflurane (SEV)	neurodegeneration (ND)	mouse embryonic stem cells (mESCs)	sevoflurane treatment	upregulated	27022747
13490	Mouse	mmu-let-7a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	31322277
13491	Mouse	mmu-let-7a	miRNA	¦Á-Synuclein (¦Á-Syn)	parkinson's disease (PD)	PD mice substantia nigra pars compacta (SNpc) or BV-2 microglia cells in vitro	¦Á-Synuclein (¦Á-Syn) treatment	downregulated	31547989
13492	Mouse	mmu-let-7a	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
13493	Mouse	mmu-let-7a	miRNA	testosterone	prostate cancer	female mouse liver	Testosterone treatment	"upregulation of the 6 miRNAs miR-22, miR-690, miR-122, let-7A, miR-30D and let-7D"	20600201
13494	Mouse	mmu-let-7a	miRNA	arsenite	lung fibrosis	murine bone marrow-derived macrophages (BMDMs)	arsenic (As) exposure	downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages.	33162208
13495	Mouse	mmu-let-7a	miRNA	arsenite	lung fibrosis	lung tissues; bone marrow-derived macrophages (BMDMs)	arsenite exposure	downregulated	33162208
13496	Mouse	mmu-let-7a	miRNA	laparotomy and exposure of the junc_x0002_tion between the large and small intestines	sepsis	mouse large and small intestines	laparotomy and exposure of the junc_x0002_tion between the large and small intestines treatment	downregulated	25043848
13497	Mouse	mmu-let-7a	miRNA	social defeat stress	sex differences of social defeat stress	female mice	social defeat stress treatment	upregulated	33358922
13498	Mouse	mmu-let-7a	miRNA	fludrocortisone	uterine receptivity	epithelial endometrium	fludrocortisone treatment	upregulated	30968418
13499	Mouse	mmu-let-7a	miRNA	bone morphogenetic protein 2 (BMP2)	chondrogenesis	Mouse embryonic fibroblasts (MEFs)	bone morphogenetic protein 2 (BMP2) treatment	upregulated	23519980
13500	Mouse	mmu-let-7a-1-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
13501	Mouse	mmu-let-7a-1-3p	miRNA	dexmedetomidine (DEX)	spinal cord ischemia/reperfusion injury (SCII)	hypoxia-induced isolated activated microglia from SCIRI mice	dexamethasone (DEX) treatment	upregulated	31190218
13502	Mouse	mmu-let-7a-1-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	spinal cord ischemia/reperfusion injury (SCII)	isolated activated microglia from SCIRI mice	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31190218
13503	Mouse	mmu-let-7a-2-3p	miRNA	dexmedetomidine (DEX)	spinal cord ischemia/reperfusion injury (SCII)	hypoxia-induced isolated activated microglia from SCIRI mice	dexamethasone (DEX) treatment	upregulated	31190218
13504	Mouse	mmu-let-7a-2-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	spinal cord ischemia/reperfusion injury (SCII)	isolated activated microglia from SCIRI mice	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31190218
13505	Mouse	mmu-let-7a-5p	miRNA	¦¤9-tetrahydrocannabinol (THC)	acute respiratory distress syndrome (ARDS)	lung-infiltrated mononuclear cells (MNCs)	¦¤9Tetrahydrocannabinol (THC) treatment	downregulated	32612530
13506	Mouse	mmu-let-7a-5p	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
13507	Mouse	mmu-let-7a-5p	miRNA	anoxia/reoxygenation (A/R)	cardiovascular disease (CVD)	primary cardiomyocytes	anoxia/reoxygenation (A/R) treatment	downregulated	31894303
13508	Mouse	mmu-let-7a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	catecholamine resistance	Adipocytes differentiated from 3T3-L1 preadipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30933434
13509	Mouse	mmu-let-7a-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	renal mesangial cells	high glucose treatment	downregulated	30896854
13510	Mouse	mmu-let-7a-5p	miRNA	fluke Fasciola gigantica (FgESPs)	F. gigantica infection	liver tissues	fluke Fasciola gigantica (FgESPs) infection	downregulated	33332355
13511	Mouse	mmu-let-7a-5p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	downregulated	32443549
13512	Mouse	mmu-let-7a-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32153563
13513	Mouse	mmu-let-7a-5p	miRNA	anoxia/reoxygenation (A/R)	myocardial infarction (MI)	Primary cardiomyocyte	anoxia/reoxygenation (A/R) treatment	"Let-7a-5p inhibition enhanced A/R-induced apoptosis, Let-7a-5p inhibits cardiomyocytes death by targeting IGF2BP3."	31894303
13514	Mouse	mmu-let-7a-5p	miRNA	Yiqi-Bushen-Tiaozhi (YBT)	nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)	liver tissues	Yiqi-Bushen-Tiaozhi (YBT) treatment	upregulated	33281601
13515	Mouse	mmu-let-7a-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13516	Mouse	mmu-let-7b	miRNA	high fat diet (HFD)	acute myocardial infarction (AMI)	liver tissue	high fat diet (HFD) feed	downregulated	19835573
13517	Mouse	mmu-let-7b	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	mouse mouse liver	ethanol treatment	downregulated in mouse liver	28536261
13518	Mouse	mmu-let-7b	miRNA	blast	blast traumatic brain injury (bTBI)	Balb/c mice	blast treatment	dysregulated	29020847
13519	Mouse	mmu-let-7b	miRNA	melatonin	cell proliferation	hippocampus dentate gyrus tissues	melatonin treatment	upregulated	31169197
13520	Mouse	mmu-let-7b	miRNA	TGF-¦Â	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	TGF-¦Â treatment	downregulated	25354942
13521	Mouse	mmu-let-7b	miRNA	trans-pellitorine	"fatty acid synthase, fatty acid uptake"	3T3-L1 cells	trans-pellitorine	upregulated	28620299
13522	Mouse	mmu-let-7b	miRNA	di(2-ethylhexyl) phthalate (DEHP)	follicular development	ovarian	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	29385306
13523	Mouse	mmu-let-7b	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
13524	Mouse	mmu-let-7b	miRNA	lithium (Li)	inflammation	primary cultures and in rat frontal cortex	Lithium?treatment	downregulated	21676127
13525	Mouse	mmu-let-7b	miRNA	Japanese Encephalitis virus (JEV)	Japanese Encephalitis virus (JEV) infection	mouse neuronal (Neuro2a) cells or primary cortical neurons	Japanese Encephalitis virus (JEV) infection	upregulated	30556910
13526	Mouse	mmu-let-7b	miRNA	epigallocatechin-3-gallate (EGCG)	melanoma	"Mouse melanoma B16, human melanoma Mewo and A375 cells"	Green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG) treatment	upregulated	26754091
13527	Mouse	mmu-let-7b	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	upregulated	18987751
13528	Mouse	mmu-let-7b	miRNA	arsenite	lung fibrosis	lung tissues	arsenite exposure	downregulated	33162208
13529	Mouse	mmu-let-7b-5p	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	plasma	acetaminophen (APAP) treatment	upregulated	30125006
13530	Mouse	mmu-let-7b-5p	miRNA	aerobic exercise	energy homeostasis	skeletal muscle	aerobic exercise training (AET) treatment	8 wk of aerobic training (Tr) markedly decreased let-7b-5p expression in murine skeletal muscle	32697599
13531	Mouse	mmu-let-7b-5p	miRNA	Yiqi-Bushen-Tiaozhi (YBT)	nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)	liver tissues	Yiqi-Bushen-Tiaozhi (YBT) treatment	upregulated	33281601
13532	Mouse	mmu-let-7b-5p	miRNA	bis-enoxacin	osteoclastogenesis	4T1 murine breast cancer cells	bis-enoxacin treatment	downregulated	30385810
13533	Mouse	mmu-let-7b-5p	miRNA	enoxacin	osteoclastogenesis	4T1 murine breast cancer cells	Enoxacin treatment	downregulated	30385810
13534	Mouse	mmu-let-7b-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13535	Mouse	mmu-let-7c	miRNA	high fat diet (HFD)	acute myocardial infarction (AMI)	liver tissue	high fat diet (HFD) feed	downregulated	19835573
13536	Mouse	mmu-let-7c	miRNA	angiotensin II (Ang II)	allergic airway inflammation	murine bone marrow-derived macrophages (BMDMs)	angiotensin II (Ang II) treatment	downregulated	32458348
13537	Mouse	mmu-let-7c	miRNA	lipoxin A4 (LXA4)	bronchopulmonary dysplasia (BPD)	mouse lung epithelial cells (MLE-12) cells	"5S,6R-methyl-LXA4 treatment"	upregulated	28819748
13538	Mouse	mmu-let-7c	miRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	alveolar macrophages	lipopolysaccharide (LPS) treatment	downregulated	26851791
13539	Mouse	mmu-let-7c	miRNA	TGF-¦Â	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	TGF-¦Â treatment	downregulated	25354942
13540	Mouse	mmu-let-7c	miRNA	lipopolysaccharide (LPS)	endometriosis	LPS-induced mouse endometritis tissues	lipopolysaccharide (LPS) treatment	downregulated	30406463
13541	Mouse	mmu-let-7c	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	"LPS , IFN-¦Ã treatment"	downregulated	25215948
13542	Mouse	mmu-let-7c	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cells	metformin treatment	upregulated	22245693
13543	Mouse	mmu-let-7c	miRNA	lithium (Li)	inflammation	primary cultures and in rat frontal cortex	Lithium?treatment	downregulated	21676127
13544	Mouse	mmu-let-7c-1-3p	miRNA	echinococcus multilocularis metacestodes	echinococcus multilocularis infection	RAW 264.7 cells	E. multilocularis metacestodes treatment	downregulated	30322806
13545	Mouse	mmu-let-7c-1-3p	miRNA	E. multilocularis metacestodes	infection and immunity of E. multilocularis	RAW264¡¤7 macrophage cells	E. multilocularis metacestodes for 6 and 12 h treatment	"upregulated (mmu-miR-378d,mmu-miR-155-5p, mmu-miR-146a-5p, mmu-miR-21a-5p , mmu-miR-125a-5p) and downregulated(mmu-miR-1981-5p , mmu-miR-let-7c-1-3p)"	28942753
13546	Mouse	mmu-let-7c-1-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
13547	Mouse	mmu-let-7c-5p	miRNA	quercetin	chronic inflammatory diseases	LPS-treated murine bone marrow¨Cderived DCs (BMDCs)	quercetin treatment	upregulated	31338984
13548	Mouse	mmu-let-7c-5p	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
13549	Mouse	mmu-let-7c-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13550	Mouse	mmu-let-7c-5p	miRNA	oxygen glucose deprivation (OGD)	stroke	microglia	oxygen-glucose deprivation (OGD) treatment	downregulated	25934573
13551	Mouse	mmu-let-7c-5p	miRNA	hypoxia	traumatic brain injury (TBI)	Primary mouse microglia	oxygen/glucose deprivation (OGD) treatment	downregulated	29408500
13552	Mouse	mmu-let-7c-5p	miRNA	lipopolysaccharide (LPS)	traumatic brain injury (TBI)	Primary mouse microglia	lipopolysaccharides (LPS) treatment	downregulated	29408500
13553	Mouse	mmu-let-7d	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
13554	Mouse	mmu-let-7d	miRNA	TGF-¦Â	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	TGF-¦Â treatment	downregulated	25354942
13555	Mouse	mmu-let-7d	miRNA	cyclosporine A (CsA)	nephrotoxicity	mouse kidney	cyclosporine A treatment	upregulated	28414804
13556	Mouse	mmu-let-7d	miRNA	berberine (BBR)	obesity	mouse primary preadipocytes isolated from epididymal white adipose tissue (eWAT)	berberine (BBR) treatment	upregulated	31527742
13557	Mouse	mmu-let-7d	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	MN9D Cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	29082467
13558	Mouse	mmu-let-7d	miRNA	testosterone	prostate cancer	female mouse liver	Testosterone treatment	"upregulation of the 6 miRNAs miR-22, miR-690, miR-122, let-7A, miR-30D and let-7D"	20600201
13559	Mouse	mmu-let-7d	miRNA	bleomycin (BLM)	lung fibrosis	exosomes of broncho-alveolar lavage fluids	bleomycin (BLM) treatment	downregulated	33179861
13560	Mouse	mmu-let-7d	miRNA	diesel exhaust particle (DEP)	pulmonary inflammatory response	lung tissues	diesel exhaust particle (DEP) exposure	downregulated	30172002
13561	Mouse	mmu-let-7d-3p	miRNA	licochalcone A (LA)	lung cancer	MLE-12 cells	Licochalcone A (lico A) treatment	upregulated	32505917
13562	Mouse	mmu-let-7d-5p	miRNA	nonivamide	adipogenesis	3T3©\L1 pre©\adipocytes cells	nonivamide treatment	upregulated	25704235
13563	Mouse	mmu-let-7d-5p	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	upregulated	32337768
13564	Mouse	mmu-let-7d-5p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	downregulated	32443549
13565	Mouse	mmu-let-7d-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13566	Mouse	mmu-let-7e	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
13567	Mouse	mmu-let-7e	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	bone marrow-derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	LPS-induced microRNA lethal-7e ( let-7e) expression was significantly increased in MK2 -/- macrophages.	29770701
13568	Mouse	mmu-let-7e	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues and bronchoalveolar lavage fluid (BALF)	lipopolysaccharide (LPS) treatment	upregulated	33392621
13569	Mouse	mmu-let-7e	miRNA	lipopolysaccharide (LPS)	cell proliferation	CD11b+ Gr1+ cells sorted from the bone marrow (BM)	lipopolysaccharide (LPS) treatment	upregulated	30221399
13570	Mouse	mmu-let-7e	miRNA	lipopolysaccharide (LPS)	immune response	Myeloid-derived suppressor cells (MDSCs)	lipopolysaccharide (LPS) treatment	"let-7e was highly upregulated in the LPS-treated group,"	30221399
13571	Mouse	mmu-let-7e	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	downregulated	22782705
13572	Mouse	mmu-let-7e-5p	miRNA	dexamethasone (DEX)	asthma	lung tissues	dexamethasone (Dex) treatment	let-7e-5p was downregulated in the Dex group compared with that in the Model group.	32222886
13573	Mouse	mmu-let-7e-5p	miRNA	¦Â-glycerophosphate (¦Â-GP) and pyruvic acid	coronary artery calcification (CAC)	mouse smooth muscle cell line (MOVAS-1)	¦Â-glycerophosphate (¦Â-GP) and pyruvic acid treatment	downregulated	31733402
13574	Mouse	mmu-let-7e-5p	miRNA	¦Â-glycerophosphate (¦Â-GP) and pyruvic acid	coronary artery calcification (CAC)	exosomes from mouse vascular smooth muscle cells line MOVAS-1	"To induce calcification, the MOVAS-1 cells were maintained in normal cell culture medium supplied with 10 mM ¦Â-glycerophosphate (¦Â-GP) (Sigma, UK) and 10 nM pyruvic acid for 21 d successively, and the culture medium was renewed every 3 d."	downregulated	31733402
13575	Mouse	mmu-let-7e-5p	miRNA	estradiol-17¦Â (E2)	systemic lupus erythematosus (SLE)	murine B cells	estradiol-17¦Â (E2) treatment	downegulated	25912736
13576	Mouse	mmu-let-7f	miRNA	ethanol (EtOH)	alcoholic liver injury	mouse	mitochondrial and cellular damage induced by repeated ethanol withdrawal (EW) treatment	upregulated	25406171
13577	Mouse	mmu-let-7f	miRNA	metformin (Met)	anti-cancer therapy	mice with 4-months-exposure of smoke	oral metformin was used at a dose of 800 mg/kg diet treatment	upregulated	24683044
13578	Mouse	mmu-let-7f	miRNA	high glucose (HG)	diabetic nephropathy (DN)	MPC5 cells	high glucose (HG) treatment	LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy	33232688
13579	Mouse	mmu-let-7f	miRNA	ischemia	ischemia/reperfusion (I/R) injury	cerebral cortex and hippocampus	Ischemic preconditioning and ischemic postconditioning (IPostC) treatment	downregulated	27485299
13580	Mouse	mmu-let-7f	miRNA	ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE)	metastasized melanoma	"B16F10 melanoma tissues, B16F10 melanoma lung metastasis in mice"	SLE treatment	upregulated	31514083
13581	Mouse	mmu-let-7f	miRNA	cigarette smoke (CS)	neovascularization	mouse ischemic muscles	cigarette smoke (CS)?exposure	downregulated	28345812
13582	Mouse	mmu-let-7f	miRNA	social defeat stress	sex differences of social defeat stress	female mice	social defeat stress treatment	upregulated	33358922
13583	Mouse	mmu-let-7f-2-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	upregulated	33224036
13584	Mouse	mmu-let-7f-5p	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colitis-associated colon cancer (CAC)	colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	downregulated	31275360
13585	Mouse	mmu-let-7f-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32153563
13586	Mouse	mmu-let-7f-5p	miRNA	polymethylmethacrylate (PMMA)	osteolysis	RAW264.7 cells	polymethylmethacrylate treatment	The expression of let-7f-5p was increased in the process of M1 macrophage polarization that induced by PMMA	30176162
13587	Mouse	mmu-let-7f-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13588	Mouse	mmu-let-7g	miRNA	blast	blast traumatic brain injury (bTBI)	Balb/c mice	blast treatment	dysregulated	29020847
13589	Mouse	mmu-let-7g	miRNA	house dust mite (HDM)	chronic allergic asthma	C57BL/6 mice	HDM treatment	downregulated	24610935
13590	Mouse	mmu-let-7g	miRNA	TGF-¦Â	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	TGF-¦Â treatment	downregulated	25354942
13591	Mouse	mmu-let-7g	miRNA	binase	lymphosarcoma	RLS40 cells	binase treatment	downregulated	33147876
13592	Mouse	mmu-let-7g	miRNA	doxorubicin (DOX)	myocardial injury	animal issues and cardiac cells	antibiotics treatment	The downregulated of let-7g in the myocardial-injury model suggests that let-7g may play an important role in the development of cardiac disease	22301161
13593	Mouse	mmu-let-7g	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
13594	Mouse	mmu-let-7g	miRNA	arsenite	lung fibrosis	lung tissues	arsenite exposure	downregulated	33162208
13595	Mouse	mmu-let-7g	miRNA	diesel exhaust particle (DEP)	pulmonary inflammatory response	lung tissues	diesel exhaust particle (DEP) exposure	downregulated	30172002
13596	Mouse	mmu-let-7g-3p	miRNA	Yiqi-Bushen-Tiaozhi (YBT)	nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)	liver tissues	Yiqi-Bushen-Tiaozhi (YBT) treatment	upregulated	33281601
13597	Mouse	mmu-let-7g-5p	miRNA	oxysterol 27-hydroxycholesterol (27-OHC)	Alzheimer's disease (AD)	brain tissues	oxysterol 27-hydroxycholesterol (27-OHC) treatment	downregulated	30582229
13598	Mouse	mmu-let-7g-5p	miRNA	ursolic acid (UA)	osteogenesis	RANKL-treated RAW264.7 cells	ursolic acid treatment	downregulated	30827108
13599	Mouse	mmu-let-7g-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13600	Mouse	mmu-let-7i	miRNA	TGF-¦Â	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	TGF-¦Â treatment	downregulated	25354942
13601	Mouse	mmu-let-7i	miRNA	arsenite	lung fibrosis	lung tissues	arsenite exposure	downregulated	33162208
13602	Mouse	mmu-let-7i	miRNA	cyclosporine A (CsA)	urinary tract infections (UTIs)	uropathogenic Escherichia coli (UPEC) infected kidneys	cyclosporine A treatment	upregulated	29069656
13603	Mouse	mmu-let-7i-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	upregulated	27322257
13604	Mouse	mmu-let-7i-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	29557526
13605	Mouse	mmu-let-7i-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13606	Mouse	mmu-let-7k	miRNA	Psychosocial stress	mesenchymal stem cell transplantation (MSCT)	mouse bone marrow mesenchymal stem cells (MSCs)	Psychosocial stress treatment	Psychological stress attenuates therapeutic effects of MSCT in a DSS-induced colitis mouse model by elevating the levels of exosomal Mir7k/mmu-let-7 k (microRNA 7 k) in circulation	32910719
13607	Mouse	mmu-let-7k	miRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	downregulated in the OIR samples	31452702
13608	Mouse	mmu-let-7k	miRNA	alpinia oxyphylla extract (AOE)	type 2 diabetes mellitus (T2DM)	db-/db- mouse kidney	A. oxyphylla extract (AOE) treatment	upregulated	28249617
13609	Mouse	mmu-miR-1	miRNA	heat stress	ischemia/reperfusion (I/R) injury	the hearts and livers tissue cells	heat-shock (HS)	"Mice subjected to cytoprotective heat-shock (HS) showed a significant increase of miRNA-1, miRNA-21 and miRNA-24 in the heart."	19041309
13610	Mouse	mmu-miR-1	miRNA	IFN-¦Â	autophagy	mouse cortical neurons	IFN-¦Â treatment	upregulated	31799933
13611	Mouse	mmu-miR-1	miRNA	2-acetyl-5-tetrahydroxybutyl imidazole (THI)	breast cancer	C2C12 cells	2-acetyl-5-tetrahydroxybutyl imidazole (THI) treatment	upregulated	24077965
13612	Mouse	mmu-miR-1	miRNA	sphingosine-1-phosphate (S1P)	breast cancer	C2C12 cells	sphingosine-1-phosphate (S1P) treatment	upregulated	24077965
13613	Mouse	mmu-miR-1	miRNA	metformin (Met)	cardiac conduction delay	cardiomyocytes; heart tissues	metformin (Met) treatment	Met can noticeably inhibit miR-1 upregulation.	32450177
13614	Mouse	mmu-miR-1	miRNA	doxorubicin (DOX)	cardiotoxicity	BALB/c mice injected C-26 tumor cells	doxorubicin treatment	upregulated	28560697
13615	Mouse	mmu-miR-1	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral palsy	N2A neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31500509
13616	Mouse	mmu-miR-1	miRNA	tamoxifen (TAM)	chronic pain	dorsal root ganglion (DRG) neurons	completed tamoxifen treatment	downregulated	27346077
13617	Mouse	mmu-miR-1	miRNA	bortezomib	congenital muscular dystrophy	dy(3K)/dy(3K) mice	bortezomib? treatment	downregulated	24631023
13618	Mouse	mmu-miR-1	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	downregulated	21584493
13619	Mouse	mmu-miR-1	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	CD1 mice of both genders	streptozocin (STZ) treatment	upregulated	24685144
13620	Mouse	mmu-miR-1	miRNA	lycium barbarum polysaccharide (LBP)	heart failure (HF)	neonatal rat ventricular cardiomyocytes (NRVCs)	lycium barbarum polysaccharides (LBPs) treatment	LBPs significantly reduced the expression of myocardial miR-1.	30117672
13621	Mouse	mmu-miR-1	miRNA	AICAR	hypertrophy	C2C12 cells	were incubat AMPK activator 5-aminoimidazole-4- carboxamide-1-_x0003-D-ribonucleoside treatment	upregulated	24347059
13622	Mouse	mmu-miR-1	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	mouse lung tissues	hypoxia treatment	downregulated in mouse lung tissues	29167124
13623	Mouse	mmu-miR-1	miRNA	synthetic Sulfonyl-Hydrazone-1	iPSC-derived cardiac differentiation	Murine fibroblast-derived iPSCs	Synthetic Sulfonyl-Hydrazone-1 treatment	"small chemical compounds, such as SHZ, can constitute a novel and clinically feasible strategy to improve iPSC-derived cardiac differentiation"	21445862
13624	Mouse	mmu-miR-1	miRNA	ischemia	ischemia/reperfusion (I/R) injury	cerebral cortex and hippocampus	Ischemic preconditioning and ischemic postconditioning (IPostC) treatment	downregulated	27485299
13625	Mouse	mmu-miR-1	miRNA	botulinum toxin A (BTXA)	muscle atrophy	quadriceps muscle	botulinum toxin A (BTXA) treatment	downregulated	30427927
13626	Mouse	mmu-miR-1	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
13627	Mouse	mmu-miR-1	miRNA	prolonged aerobic exercise	muscle hypertrophy	plasma	"impact of extended-duration, submaximal aerobic exercise treatment"	upregulated	24436293
13628	Mouse	mmu-miR-1	miRNA	heme oxygenase-1 (HMOX1)	myoblast differentiation	C2C12 cells	Heme oxygenase-1 (HMOX1) treatment	downregulated	21827279
13629	Mouse	mmu-miR-1	miRNA	Soluble epoxide hydrolase inhibitors (sEHIs)	myocardial infarction (MI)	MI mouse ischemic myocaridum	"sEHI t-AUCB (0.2, 1, 5 mg/L in drinking-water) was administered daily seven days before MI treatment"	downregulated in ischemic myocaridum	29212255
13630	Mouse	mmu-miR-1	miRNA	ischemia	myocardial ischaemic injury	mouse cardiomyocytes	ischemic pre-conditioning (IPC) treatment	"IPC-induced miRNAs trigger cardioprotection similar to the delayed phase of IPC, possibly through upregulating eNOS, HSP70, and the HSP70 transcription factor HSF-1."	19213952
13631	Mouse	mmu-miR-1	miRNA	sciatic nerve partial ligation	pain	mouse dorsal root ganglion (DRG)	sciatic nerve partial ligation therapy treatment	downregulated	21385380
13632	Mouse	mmu-miR-1	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	mouse lung tissues	hypoxia induce	downregulated	29167124
13633	Mouse	mmu-miR-1	miRNA	cyclopamine	regulating the activity of Shh signaling	embryonic lung cultures	cyclopamine treatment	dysregulated	24617895
13634	Mouse	mmu-miR-1	miRNA	statins	skeletal muscle injury	skeletal muscle cells	statins? treatment	"In cultured skeletal muscle cells, statin increased the levels of miR-1a but decreased the levels of mitogen-activated protein kinase kinase kinase 1 (MAP3K1) in a time or dose dependent manner"	33864447
13635	Mouse	mmu-miR-1	miRNA	astragalus Root dry extract (ARDE)	viral myocarditis (VM)	CVB3-infected mouse heart tissues and HL-1 cells	astragalus Root dry extract (ARDE) treatment	downregulated	30097120
13636	Mouse	mmu-miR-1	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	mouse heart tissues and HL-1 cells	CVB3 infection	upregulated	30097120
13637	Mouse	mmu-miR-100	miRNA	H2O2	apoptosis	cardiomyocytes	H2O2 treatment	upregulated	26191255
13638	Mouse	mmu-miR-100	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	mouse midbrain tissues	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	31298038
13639	Mouse	mmu-miR-100	miRNA	retinoic acid (RA)	cell proliferation	mouse spermatogonial stem cells (SSCs)	retinoic acid treatment	downregulated	28569396
13640	Mouse	mmu-miR-100-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	Cortexes of the brains	amyloid-¦Â (A¦Â) treatment	downregulated	26635599
13641	Mouse	mmu-miR-100-5p	miRNA	influenza virus	H5N2 influenza virus infection	lung tissues	H5N2 treatment	upregulated	25266911
13642	Mouse	mmu-miR-100a	miRNA	rapamycin	HIV-associated nephropathy(HIVAN)	mice renal tissues	Rapamycin treatment	downregulated	23611955
13643	Mouse	mmu-miR-101	miRNA	bleomycin (BLM)	acute lung injury (ALI)	lung	bleomycin (BLM) treatment	downregulated	26402323
13644	Mouse	mmu-miR-101	miRNA	celecoxib	anti-inflammatory responses	male A/J mice	"celecoxib (30 mg/kg/d, administered by gavage) treatment"	upregulated	27562754
13645	Mouse	mmu-miR-101	miRNA	geniposide (GEN)	atherosclerosis (AS)	LPS-treated RAW264.7 macrophage cell line	geniposide treatment	downregulated	30630636
13646	Mouse	mmu-miR-101	miRNA	geniposide (GEN)	atherosclerosis (AS)	Atherosclerosis (AS) mouse aorta tissues	geniposide treatment	downregulated	30630636
13647	Mouse	mmu-miR-101	miRNA	geniposide (GEN)	atherosclerosis (AS)	high fat diet fed ApoE-/- mice aorta tissues	geniposide (GEN) treatment	downregulated	30630636
13648	Mouse	mmu-miR-101	miRNA	high fat diet (HFD)	atherosclerosis (AS)	ApoE-/- mice aorta tissues	high fat diet (HFD) feed	upregulated	30630636
13649	Mouse	mmu-miR-101	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aorta tissues	high fat diet (HFD) feed	upregulated	30630636
13650	Mouse	mmu-miR-101	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	RAW264.7 macrophage cell line	lipopolysaccharide (LPS) treatment	upregulated	30630636
13651	Mouse	mmu-miR-101	miRNA	IL-10	colonic inflammation	colonic intraepithelial lymphocytes	IL-10 treatment	downregulated	22043014
13652	Mouse	mmu-miR-101	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
13653	Mouse	mmu-miR-101	miRNA	kaempferol	fracture healing	MC3T3-E1 cells	kaempferol treatment	upregulated	30942633
13654	Mouse	mmu-miR-101	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	?ATDC5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	?HULC protected ATDC5 cells against TNF-¦Á-induced inflammatory injury by repression of miR-101	30981080
13655	Mouse	mmu-miR-101	miRNA	phyllanthus emblica L (PEL) extract	precancerous lung lesion	male A/J mice	phyllanthus emblica L (PEL) extract treatment	upregulation	27562754
13656	Mouse	mmu-miR-101	miRNA	bleomycin (BLM)	lung fibrosis	mouse lung tissues	bleomycin (BLM) treatment	downregulated in lung tissues	28726637
13657	Mouse	mmu-miR-101	miRNA	salvianolic acid A (Sal A)	spinal cord injury (SCI)	RBMECs cells	Sal A treatment	upregulated	28011395
13658	Mouse	mmu-miR-101-3p	miRNA	Iodine-131 (131I)	papillary thyroid cancer (PTC)	PTC tissues	131I treatment	NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo.	30596336
13659	Mouse	mmu-miR-101-3p	miRNA	oxygen	bronchopulmonary dysplasia (BPD)	lung tissues	oxygen treatment	silencing of Xist suppressed BPD development by binding to miR-101-3p and downregulating HMGB3 and the TGF-b1/Smad3 axis.	33070148
13660	Mouse	mmu-miR-101-5p	miRNA	schisandrin B (Sch B)	liver fibrosis	liver tissues	Schisandrin B (Sch B) treatment	Sch B can attenuate liver fibrosis by upregulating the expression of miR-101-5p	31975615
13661	Mouse	mmu-miR-101a	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
13662	Mouse	mmu-miR-101a	miRNA	mangiferin	endoplasmic reticulum stress (ERS)	primary mouse hepatocytes	mangiferin treatment	downregulated	32413114
13663	Mouse	mmu-miR-101a	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	kidney tissues	angiotensin II (Ang II) treatment	downregulated	30304543
13664	Mouse	mmu-miR-101a	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	downregulated	20436259
13665	Mouse	mmu-miR-101a	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	liver damage	mouse liver cells	"2, 3, 7, 8-tetrachlorodi-benzo-p-dioxin (TCDD) treatment"	"TCDD dysregulates the expression of miR101a and miR122 and that COX-2, a target gene of miR101a, plays a significant role in liver damage in mice exposed to TCDD."	21602190
13666	Mouse	mmu-miR-101a	miRNA	IL-1¦Â	¦Â-cell dysfunction	MIN6 cells	IL-1¦Â treatment	upregulated	26367486
13667	Mouse	mmu-miR-101a-3p	miRNA	hypoxia	myocardial infarction (MI)	neonatal mice cardiomyocytes (NMCMs)	hypoxia treatment	downregulated	32315985
13668	Mouse	mmu-miR-101b	miRNA	oral gavage	anti-inflammatory responses	dextran sodium sulfate (DSS)-induced colitis-associated tumorigenesis Apc(Min/+) mouse	via oral gavage for 5 weeks treatment	upregulated	24817032
13669	Mouse	mmu-miR-101b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (MES13 cells)	high glucose (HG) treatment	circ_0000491 aggravates the extracellular matrix of diabetic nephropathy glomerular mesangial cells through suppressing miR-101b by targeting TGF¦ÂRI.	32901868
13670	Mouse	mmu-miR-101b	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	downregulated	20436259
13671	Mouse	mmu-miR-101b	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	downregulated	25672270
13672	Mouse	mmu-miR-101b	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	downregulated	25672270
13673	Mouse	mmu-miR-101b	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
13674	Mouse	mmu-miR-103	miRNA	tetrabromobisphenol-A (TBBPA)	adipogenesis	3T3-L1 and C3H10T1/2 cells	TBBPA treatment	upregulated	28329833
13675	Mouse	mmu-miR-103	miRNA	high fat diet (HFD)	adipose inflammation	mouse adipose tissues	high fat diet (HFD) feed	Overexpressing TRAF3 attenuated miR-103-induced inflammation by accelerating mitophagy.	30623853
13676	Mouse	mmu-miR-103	miRNA	adjuvant	adjuvant-induced arthritis (AIA)	cartilage	adjuvant treatment	Long noncoding RNA-GAS5 siRNA prevented cartilage destruction by inhibiting miR-103 expression.	33343265
13677	Mouse	mmu-miR-103	miRNA	baicalin (BAI)	asthma	ovalbumin (OVA)-induced asthma mouse lung tissues	baicalin (BAI) treatment	miR-103 was significantly upregulated after BA treatment.	33730981
13678	Mouse	mmu-miR-103	miRNA	baicalin (BAI)	asthma	mouse bronchial smooth muscle cells (SMCs)	baicalin (BAI) treatment	upregulated	33730981
13679	Mouse	mmu-miR-103	miRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	mouse bronchial smooth muscle cells (SMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	downregulated	33730981
13680	Mouse	mmu-miR-103	miRNA	high fat diet (HFD)	atherosclerosis (AS)	thoracic aorta	high fat diet (HFD) feed	upregulated	31232476
13681	Mouse	mmu-miR-103	miRNA	high fat diet (HFD)	atherosclerosis (AS)	Apolipoprotein E knockout (ApoE-/- ) mice thoracic aorta tissues	?high-fat-diet (HFD)?feed treatment	upregulated	31232476
13682	Mouse	mmu-miR-103	miRNA	carboxymethyllysine (CML)	diabetes mellitus (DM)	fibroblast cell line 3T3©\L1	carboxymethyllysine (CML) treatment	upregulated	27137869
13683	Mouse	mmu-miR-103	miRNA	trans-pellitorine	"fatty acid synthase, fatty acid uptake"	3T3-L1 cells	trans-pellitorine	upregulated	28620299
13684	Mouse	mmu-miR-103	miRNA	high fat diet (HFD)	inflammatory response	skeletal muscle of mice	high fat diet (HFD) feed	"miR-375, miR-29, miR-320, miR-103/107 and miR-126, play a crucial role in the regulation of glucose and lipid metabolism through the control of pancreatic islet cell function"	22395471
13685	Mouse	mmu-miR-103	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	murine hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGDR downregulated miR-103 and miR-107 to induce NKILA upregulation in neuronal cells	30007440
13686	Mouse	mmu-miR-103	miRNA	apigenin	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B cells	apigenin treatment	downregulated	23989853
13687	Mouse	mmu-miR-103	miRNA	resveratrol	hepatic steatosis	Sprague-Dawley rats	resveratrol (RS) treatment	downregulated	28375178
13688	Mouse	mmu-miR-103	miRNA	insulin-like growth factor 1 (IGF-1)	metastatic colorectal cancer (mCRC)	mouse intestinal crypt cells	insulin-like growth factors(IGF-1) treatment	downregulated	20886090
13689	Mouse	mmu-miR-103	miRNA	morphine	morphine tolerance	mouse brain	chronic morphine men treatment	upregulated	24302561
13690	Mouse	mmu-miR-103	miRNA	isoprenaline	myocardial infarction (MI)	hearts of the treated mice	isoprenaline treatment	Significant inhibition of miR-103 accompanied by increased FADD expression and markedly decreased expression of the other biomarkers were observed in the hearts of the treated mice.	33577038
13691	Mouse	mmu-miR-103	miRNA	high fat diet (HFD)	prenatal inflammation	ovarian tissue	high fat diet (HFD) feed	"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21"	23954404
13692	Mouse	mmu-miR-103-1-5p	miRNA	apigenin	acute myocardial infarction (AMI)	mouse myocardial cells	apigenin treatment	downregulated	32515357
13693	Mouse	mmu-miR-103-3p	miRNA	fenofibrate	obesity	C57BL/6J male mice visceral adipose tissue	fenofibrate treatment	upregulated	28926107
13694	Mouse	mmu-miR-103a	miRNA	cyclic mechanical stretch (CMS)	osteoblast differentiation and bone formation	bone	cyclic mechanical stretch (CMS) treatment	downregulated	25195535
13695	Mouse	mmu-miR-103a-3p	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
13696	Mouse	mmu-miR-103a-3p	miRNA	angiotensin II (Ang II)	renal inflammation and fibrosis	Urinary and serum	angiotensin II (Ang II) treatment	upregulated	31086184
13697	Mouse	mmu-miR-103a-3p	miRNA	lipopolysaccharide (LPS)	sepsis	Bone marrow-derived macrophages	lipopolysaccharide (LPS) treatment	downregulated	33333289
13698	Mouse	mmu-miR-103a-3p	miRNA	lipopolysaccharide (LPS)	sepsis	bone marrow-derived macrophages	lipopolysaccharide (LPS) treatment	miR-103a-3p was decreased while HMGB1 was increased in sepsis.	33333289
13699	Mouse	mmu-miR-103a-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced liver injury	liver tissues	lipopolysaccharide (LPS) treatment	miR-103a-3p was elevated in the septic liver of LPS-induced mice.	32369227
13700	Mouse	mmu-miR-105	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	26639663
13701	Mouse	mmu-miR-105	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
13702	Mouse	mmu-miR-106	miRNA	thyroid hormone	brain development	mouse fetal cortex	inject TH 12 h before sacrifice on GD 16 treatment	downregulated	24436321
13703	Mouse	mmu-miR-106	miRNA	bone morphogenetic protein 9 (BMP9)	osteogenesis	The conditionally immortalized mouse multipotent adipose-derived cells iMADs	bone morphogenetic protein 9 (BMP9) treatment	downregulated	31825894
13704	Mouse	mmu-miR-106a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse lung tissues and RAW264.7 cells	lipopolysaccharides (LPS) treatment	downregulated	31595149
13705	Mouse	mmu-miR-106a	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	27418244
13706	Mouse	mmu-miR-106a	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	upregulated	19462682
13707	Mouse	mmu-miR-106a	miRNA	streptozocin (STZ)	diabetic peripheral neuropathy (DPN)	mouse dorsal root ganglion (DRG)	STZ treatment	downregulated in dorsal root ganglion (DRG)	28393703
13708	Mouse	mmu-miR-106a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	colon tissues	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30327532
13709	Mouse	mmu-miR-106a	miRNA	high glucose (HG)	podocyte injury	MPC5 cells	high glucose (HG) treatment	MiR-106a was downregulated in HG-induced MPC5 podocytes.	33116706
13710	Mouse	mmu-miR-106a	miRNA	isoflurane	postoperative cognitive dysfunction (POCD)	hippocampus	isoflurane treatment	upregulated	31933141
13711	Mouse	mmu-miR-106a	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
13712	Mouse	mmu-miR-106a	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	TCMK-1 cells	lipopolysaccharides (LPS) treatment	upregulated	31432993
13713	Mouse	mmu-miR-106a-5p	miRNA	folic acid	Alzheimer's disease (AD)	APP/PS1 mice brains and N2a cells	Folic acid deficiency treatment	downregulated	26345540
13714	Mouse	mmu-miR-106a-5p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	downregulated	30883703
13715	Mouse	mmu-miR-106b	miRNA	high fat diet (HFD)	brown adipocyte differentiation	brown adipose tissues	high fat diet (HFD) feed	upregulated	23954633
13716	Mouse	mmu-miR-106b	miRNA	bovine type II collagen containing Freund's adjuvant	collagen-induced arthritis (CIA)	DAB/1 mice	bovine type II collagen containing Freund's adjuvant	upregulated	28957555
13717	Mouse	mmu-miR-106b	miRNA	high glucose (HG)	diabetes mellitus (DM)	mouse pancreatic beta-cell line NIT-1 cells	30 mM high glucose	downregulated	28436095
13718	Mouse	mmu-miR-106b	miRNA	isoflurane	drug-induced liver injury (DILI)	liver tissues	isoflurane treatment	downregulated	24598351
13719	Mouse	mmu-miR-106b	miRNA	isoniazid (INH)	liver damage	liver tissues	isoniazid (INH) treatment	upregulated	29554950
13720	Mouse	mmu-miR-106b	miRNA	glucocorticoid (GC)	osteoporosis	C57BL/6 mice	glucocorticoid	upregulated	28108317
13721	Mouse	mmu-miR-106b	miRNA	puerarin	osteoporosis	MC3T3-E1 cells	puerarin treatment	upregulated	29375675
13722	Mouse	mmu-miR-106b	miRNA	puerarin	osteoporosis	MC3T3-E1 cells	with 20 ?M puerarin treatment	upregulated	29375675
13723	Mouse	mmu-miR-106b	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
13724	Mouse	mmu-miR-106b	miRNA	collagen	rheumatoid arthritis (RA)	synovial fibroblasts (SFs)	collagen treatment	upregulated	32152704
13725	Mouse	mmu-miR-106b	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
13726	Mouse	mmu-miR-106b	miRNA	palmitic acid (PA)	skeletal muscle insulin resistance	C2C12 myocytes	palmitic acid (PA) treatment	upregulated	25529328
13727	Mouse	mmu-miR-106b-3p	miRNA	Yiqi-Bushen-Tiaozhi (YBT)	nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)	liver tissues	Yiqi-Bushen-Tiaozhi (YBT) treatment	downregulated	33281601
13728	Mouse	mmu-miR-106b-3p	miRNA	paraquat (PQ)	paraquat (PQ)-induced acute lung injury and pulmonary fibrosis	MLE-12 cells	paraquat (PQ) treatment	downregulated	32741895
13729	Mouse	mmu-miR-106b-5p	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	The present study revealed downregulated miR-106b-5p expression and upregulated SIX1 expression in asthmatic mice and TGF-¦Â1-induced BEAS-2B cells.	33495833
13730	Mouse	mmu-miR-106b-5p	miRNA	bone marrow transplantation (BMT)	diabetes mellitus (DM)	mice with insulin-deficient diabetes	bone marrow transplantation (BMT) treatment	upregulated	27974246
13731	Mouse	mmu-miR-106b-5p	miRNA	radiation	radiation-induced injury	blood	radiation treatment	downregulated	29799276
13732	Mouse	mmu-miR-107	miRNA	tetrabromobisphenol-A (TBBPA)	adipogenesis	3T3-L1 and C3H10T1/2 cells	TBBPA treatment	upregulated	28329833
13733	Mouse	mmu-miR-107	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	brain tissues	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	29286086
13734	Mouse	mmu-miR-107	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	mouse	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	29286086
13735	Mouse	mmu-miR-107	miRNA	high fat diet (HFD)	atherosclerosis (AS)	vascular endothelial cells (VECs) in coronary atherosclerosis mice	?high-fat-diet (HFD)?feed treatment	downregulated	30548623
13736	Mouse	mmu-miR-107	miRNA	high fat diet (HFD)	coronary atherosclerosis (CAS)	Vascular endothelial cells (VECs)	high fat diet (HFD) feed	downregulated	30548623
13737	Mouse	mmu-miR-107	miRNA	high fat diet (HFD)	inflammatory response	skeletal muscle of mice	high fat diet (HFD) feed	"miR-375, miR-29, miR-320, miR-103/107 and miR-126, play a crucial role in the regulation of glucose and lipid metabolism through the control of pancreatic islet cell function"	22395471
13738	Mouse	mmu-miR-107	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	murine hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGDR downregulated miR-103 and miR-107 to induce NKILA upregulation in neuronal cells	30007440
13739	Mouse	mmu-miR-107	miRNA	resveratrol	hepatic steatosis	Sprague-Dawley rats	resveratrol (RS) treatment	downregulated	28375178
13740	Mouse	mmu-miR-107	miRNA	morphine	morphine tolerance	mouse brain	chronic morphine men treatment	upregulated	24302561
13741	Mouse	mmu-miR-107	miRNA	177lu-octreotate	neuroendocrine tumors	Female BALB/c nude mice	"inject 1.3, 3.6, 14, 45, or 140 MBq 177Lu-octreotate treatment"	"miR-194, miR-107, miR-3090, and miR-3077 were commonly regulated"	25386939
13742	Mouse	mmu-miR-107	miRNA	oxygen glucose deprivation (OGD)	neuron apoptosis	HT-22 hippocampal neuron cell	oxygen-glucose deprivation (OGD) treatment	RMST/hnRNPK/p53/miR-107/Bcl2l2 axis plays an important role in regulating neuronal apoptosis	31852624
13743	Mouse	mmu-miR-107	miRNA	diet	obesity	murine hepatic cells	diet treatment	downregulated	21120623
13744	Mouse	mmu-miR-107	miRNA	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S2)	steroid-induced osteonecrosis of femoral head (ONFH)	femoral head tissues	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S2) treatment	APP-AW or S2 reversed the decreased miR- 107 level in rats suffering SANFH.	31786295
13745	Mouse	mmu-miR-107	miRNA	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S2)	steroid-induced osteonecrosis of femoral head (ONFH)	MC3T3-E1 cells	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S3) treatment	upregulated	31786295
13746	Mouse	mmu-miR-107	miRNA	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S2)	steroid-induced osteonecrosis of femoral head (ONFH)	dexamethasone (DEX)-treated MC3T3-E1 cells	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S4) treatment	upregulated	31786295
13747	Mouse	mmu-miR-107	miRNA	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S2)	steroid-induced osteonecrosis of femoral head (ONFH)	femoral head tissues	Agrimonia pilos polysaccharide (APP-AW)'s sulphated derivatives (S2) treatment	APP-AW or S2 reversed the decreased miR- 107 level in rats suffering SANFH.	31786295
13748	Mouse	mmu-miR-107	miRNA	agrimonia pilos polysaccharide (APP-AW) and its sulphated derivatives (S2)	steroid-induced osteonecrosis of femoral head (ONFH)	MC3T3-E1 cells	Agrimonia pilos polysaccharide (APP-AW)'s sulphated derivatives (S2) treatment	upregulated	31786295
13749	Mouse	mmu-miR-107	miRNA	dexamethasone (DEX)	steroid-induced osteonecrosis of femoral head (ONFH)	MC3T3-E1 cells	dexamethasone (DEX) treatment	downregulated	31786295
13750	Mouse	mmu-miR-107	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	downregulated	26426744
13751	Mouse	mmu-miR-10a	miRNA	high fat diet (HFD)	atherosclerosis (AS)	blood plasma from apolipoprotein E-deficient (ApoE-/-) mice	high fat diet (HFD) feed	downregulated	29459264
13752	Mouse	mmu-miR-10a	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	downregulated	19462682
13753	Mouse	mmu-miR-10a	miRNA	retinoic acid (RA)	cystic fibrosis (CF)	smooth muscle cell	retinoid acid treatment	downregulated	20118242
13754	Mouse	mmu-miR-10a	miRNA	neurotoxicant sodium valproate (VPA)	developmental toxicity	murine embryonic stem cells (mESCs)	neurotoxicant sodium valproate (VPA) treatment	upregulated	24896083
13755	Mouse	mmu-miR-10a	miRNA	concanamycin A (Con A)	fulminant hepatitis	Balb/c mice	conA injections of concanavalin A treatment	upregulation	25034766
13756	Mouse	mmu-miR-10a	miRNA	retinoic acid (RA)	host defense and immunoregulation	na?ve CD4+ T cells	retinoic acid treatment	upregulated	22544395
13757	Mouse	mmu-miR-10a	miRNA	angelica polysaccharide (AP)	inflammation	LPS-treated HT22 cells	angelica polysaccharide (AP) treatment	upregulated	31353963
13758	Mouse	mmu-miR-10a	miRNA	lipopolysaccharide (LPS)	inflammation	HT22 cells	lipopolysaccharide (LPS) treatment	downregulated	31353963
13759	Mouse	mmu-miR-10a	miRNA	olfactory discrimination training	olfactory discrimination	mouse hippocampal somatic cells	olfactory discrimination training treatment	dynamic and co-ordinated changes in miRNA expression accompany early stages of learning	20309390
13760	Mouse	mmu-miR-10a	miRNA	bone morphogenetic proteins (BMPs)	osteogenesis	pluripotent stem (iPS) cells	bone morphogenetic proteins (BMPs) treatment	downregulated	22937097
13761	Mouse	mmu-miR-10a	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	upregulated	19091803
13762	Mouse	mmu-miR-10a	miRNA	high fat diet (HFD) and streptozotocin (STZ)	type 2 diabetes mellitus (T2DM)	ICR strain mice	high fat diet (HFD); streptozotocin (STZ)  treatment	downregulated	27292126
13763	Mouse	mmu-miR-10a-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	ALI lung tissues and mouse pulmonary microvascular endothelial cells (MPMVECs)	lipopolysaccharides (LPS) treatment	downregulated	31174540
13764	Mouse	mmu-miR-10a-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	The mouse cardiomyocyte cell line HL-1 cells	hypoxia induce	"MIAT and EGR2 were subsequently determined to be highly-expressed, whereas miR-10a-5p was found to be poorly-expressed in cardiomyocytes exposed to hypoxia as well as in MI mice using RT-qPCR and Western blot assay."	33819189
13765	Mouse	mmu-miR-10a-5p	miRNA	high fat diet (HFD)	adipose tissue remodeling	adipose tissue macrophages (ATMs) in gonadal white adipose tissue (gWAT)	high fat diet (HFD) feed	downregulated	31668395
13766	Mouse	mmu-miR-10a-5p	miRNA	"¦Â3-adrenergic receptor agonist CL316,243 (CL)"	adipose tissue remodeling	adipose tissue macrophages (ATMs) and PDGFR¦Á+ adipocyte stem cells (ASCs) in gonadal white adipose tissue (gWAT)	"¦Â3-adrenergic receptor agonist CL316,243 (CL) treatment"	upregulated	31668395
13767	Mouse	mmu-miR-10a-5p	miRNA	fluke Fasciola gigantica (FgESPs)	F. gigantica infection	liver tissues	fluke Fasciola gigantica (FgESPs) infection	downregulated	33332355
13768	Mouse	mmu-miR-10a-5p	miRNA	gut bacterial metabolite Urolithin A (UA)	immune response	murine CD4+ T cells	gut bacterial metabolite Urolithin A (UA) treatment	upregulated	31417547
13769	Mouse	mmu-miR-10a-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
13770	Mouse	mmu-miR-10a-5p	miRNA	porcine hemagglutinating encephalomyelitis virus (PHEV)	porcine hemagglutinating encephalomyelitis virus (PHEV) infection	N2a cells; brain tissues	porcine hemagglutinating encephalomyelitis virus (PHEV) infection treatment	miR-10a-5p was constitutively upregulated by PHEV in both the N2a cells in vitro and mice brain in vivo	32153518
13771	Mouse	mmu-miR-10b	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	tumorigenesis	brain and liver tissue cells	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) treatment"	downregulated	19270793
13772	Mouse	mmu-miR-10b	miRNA	binase	lymphosarcoma	RLS40 cells	binase treatment	downregulated	33147876
13773	Mouse	mmu-miR-10b	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
13774	Mouse	mmu-miR-10b	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
13775	Mouse	mmu-miR-10b	miRNA	bone morphogenetic proteins (BMPs)	osteogenesis	pluripotent stem (iPS) cells	bone morphogenetic proteins (BMPs) treatment	downregulated	22937097
13776	Mouse	mmu-miR-10b	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	upregulated	19091803
13777	Mouse	mmu-miR-10b-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	ALI lung tissues and mouse pulmonary microvascular endothelial cells (MPMVECs)	lipopolysaccharides (LPS) treatment	downregulated	31174540
13778	Mouse	mmu-miR-10b-5p	miRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	downregulated	30820263
13779	Mouse	mmu-miR-10b-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
13780	Mouse	mmu-miR-10b-5p	miRNA	hypoxia	myocardial infarction (MI)	primary mouse cardiomyocyte	hypoxia induce	downregulated	31480879
13781	Mouse	mmu-miR-10b-5p	miRNA	oxygen glucose deprivation (OGD)	neuronal cell injury	HT22 hippocampal neurons	oxygen-glucose deprivation (OGD) treatment	upregulated	32323054
13782	Mouse	mmu-miR-10b-5p	miRNA	dexamethasone (DEX)	oxygen-glucose deprivation (OGD) induced neuron damage	HT22 hippocampal neurons	dexamethasone (Dex) treatment	downregulated	32323054
13783	Mouse	mmu-miR-1188	miRNA	clamping the renal pedicle	bilateral renal ischemia	C57Bl/6 mice plasma and kidneys	clamping the renal pedicle treatment	upregulated	24695114
13784	Mouse	mmu-miR-1192	miRNA	runt-related transcription factor-2 (Runx2)	tumorigenesis	C2C12 cells	Runt-related transcription factor-2 (Runx2) treatment	upregulated	24136232
13785	Mouse	mmu-miR-1192	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	downregulated	23716137
13786	Mouse	mmu-miR-1192	miRNA	swimming	myocardial infarction (MI)	hypoxia-induced neonatal cardiomyocytes	4-wk swim training treatment	upregulated	31733833
13787	Mouse	mmu-miR-1192	miRNA	swimming	myocardial infarction (MI)	plasma	swim training treatment	miR-1192 was increased after exercise	31733833
13788	Mouse	mmu-miR-1192	miRNA	estradiol	vulvovaginal candidiasis (VVC)	female mouse vaginal tissues	estradiol treatment	downregulated	30355939
13789	Mouse	mmu-miR-1192	miRNA	oil	vulvovaginal candidiasis (VVC)	female mouse vaginal tissues	oil treatment	downregulated	30355939
13790	Mouse	mmu-miR-1198	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
13791	Mouse	mmu-miR-1199-5p	miRNA	lipopolysaccharide (LPS)	neuroinflammation	BV2 cells	lipopolysaccharide (LPS) treatment	upregulated	33301806
13792	Mouse	mmu-miR-122	miRNA	"4-phenylbutyric acid (PBA, endoplasmic reticulum stress inhibitor)"	acute alcoholic liver injury	ethanol-treated mice serum exosomes	4-phenylbutyric acid (PBA) treatment	downregulated	31361816
13793	Mouse	mmu-miR-122	miRNA	ethanol (EtOH)	acute alcoholic liver injury	serum exosomes	ethanol treatment	upregulated	31361816
13794	Mouse	mmu-miR-122	miRNA	concanamycin A (Con A)	acute hepatitis	liver injury mice plasma	Con A (ConA) treatment	upregulated	30867286
13795	Mouse	mmu-miR-122	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	kidney	cisplatin treatment	downregulated	24759152
13796	Mouse	mmu-miR-122	miRNA	acetaminophen (APAP)	acute liver failure (ALF)	mouse liver tissues	acetaminophen (APAP) treatment	upregulated	28616908
13797	Mouse	mmu-miR-122	miRNA	acetaminophen (APAP)	acute liver failure (ALF)	mouse liver tissues	acetaminophen (APAP) treatment	upregulated in liver	28963035
13798	Mouse	mmu-miR-122	miRNA	alcohol	alcoholic hepatitis (AH)	sera	alcohol exposure	upregulated	26264599
13799	Mouse	mmu-miR-122	miRNA	alcohol	alcoholic liver disease (ALD)	mouse liver	Lieber-DeCarli alcohol treatment	downregulated in liver	28987423
13800	Mouse	mmu-miR-122	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	liver tissues	ethanol treatment	downregulated	28987423
13801	Mouse	mmu-miR-122	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	Kupffer cells from the livers and RAW 264.7 cells	ethanol treatment	downregulated	31325635
13802	Mouse	mmu-miR-122	miRNA	rhinoviruses (RVs)	asthma	infant mice lung tissues	rhinoviruses (RVs) infection treatment	"Here, we found that RV infection induced the expression of miRNA 122 (miR-122) in mouse lungs and in human airway epithelial cells"	33830082
13803	Mouse	mmu-miR-122	miRNA	high fat diet (HFD)	atherosclerosis (AS)	mouse aortic Endothelial cells	high fat diet (HFD) feed	upregulated	31228514
13804	Mouse	mmu-miR-122	miRNA	diethylnitrosamine (DEN)	chronic hepatitis	liver injury mice plasma	diethylnitrosamine (DEN) treatment	upregulated	30867286
13805	Mouse	mmu-miR-122	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	crohn disease (CD)	mice colitis tissues	"2,4,6-trinitro-benzene-sulfonic acid (TNBS) treatment"	downregulated	31019652
13806	Mouse	mmu-miR-122	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	upregulated	30095204
13807	Mouse	mmu-miR-122	miRNA	high doses of acetaminophen (APAP)	drug-induced liver injury (DILI)	mouse liver tissues	high doses of acetaminophen (APAP) treatment	upregulated	30381674
13808	Mouse	mmu-miR-122	miRNA	high fat diet (HFD)	epithelial-mesenchymal transition (EMT)	aortic tissues; serum	high fat diet (HFD) feed	MiR-122 is upregulated in aortic tissues of ApoE-/- mice fed with HFD.	33278397
13809	Mouse	mmu-miR-122	miRNA	short form augmenter of liver regeneration (sfALR)	fatty liver disease	The BALB/c mouse liver parenchymal cells	short form augmenter of liver regeneration (sfALR) treatment	upregulated	26476698
13810	Mouse	mmu-miR-122	miRNA	carbon tetrachloride (CCl4)	fibrosis	liver tissue of mice	CCl4 treatment	downregulated	23178710
13811	Mouse	mmu-miR-122	miRNA	ischemia	liver damage	liver tissues	serum levels hepatic ischaemia and reperfusion (I/R) injury treatment	upregulated	25039534
13812	Mouse	mmu-miR-122	miRNA	TGF-¦Â	hepatic fibrogenesis	"hepatic stellate cells (HSCs) and fibroblasts, the major sources of fibrogenic cells in liver tissues"	TNF-¦Átreatment treatment	downregulated	25909171
13813	Mouse	mmu-miR-122	miRNA	methionine choline-deficient diet (MCD)	liver damage	liver tissues	MCD treatment	upregulated	24217942
13814	Mouse	mmu-miR-122	miRNA	leptin	hepatic stellate cell (HSC) activation	hepatic stellate cell (HSC)	leptin treatment	leptin reduced miR-122 level.	29248466
13815	Mouse	mmu-miR-122	miRNA	ethanol (EtOH)	liver damage	liver mononuclear cells and Kupffer cells	ethanol treatment	upregulated	25973575
13816	Mouse	mmu-miR-122	miRNA	acetaminophen (APAP)	hepatotoxicity	C57BL/6J mice serum	acetaminophen (APAP) treatment	upregulated in early and progressively up to 6 h in the serum	28755860
13817	Mouse	mmu-miR-122	miRNA	paracetamol	hepatotoxicity	Pentoject-culled C57BL/6J mice serum	paracetamol treatment	upregulated in serum	30090508
13818	Mouse	mmu-miR-122	miRNA	high fat diet (HFD)	high fat diet?influence	liver tissue	high fat diet (HFD) feed	upregulated	19835573
13819	Mouse	mmu-miR-122	miRNA	angiotensin II (Ang II)	hypertension	kidney tissues	angiotensin II (Ang II) treatment	upregulated	30256768
13820	Mouse	mmu-miR-122	miRNA	lychee pulp phenolics (LPPs)	hypolipidemic mechanism	high-fat diet (HFD) mouse hepatocytes	lychee pulp phenolics (LPPs) treatment	downregulated in mouse hepatocytes	28121324
13821	Mouse	mmu-miR-122	miRNA	penetrating keratoplasty (PKP)	corneal transplantation rejection	BALB/c mice	"the recipients were BALB/s mice, and the donors were C57BL/6 mice. The diameter of the corneal graft was 2?mm treatment"	downregulated	28540063
13822	Mouse	mmu-miR-122	miRNA	lipopolysaccharide (LPS)	inflammation	blood	lipopolysaccharide (LPS) treatment	upregulated	27477940
13823	Mouse	mmu-miR-122	miRNA	dextran-iron	iron overload (IO)	C57BL/6 mice	feeding mice a 3% dextran-iron diet	downregulated	29176318
13824	Mouse	mmu-miR-122	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	mouse N2A neuroblastoma (N2A) cells	oxygen-glucose deprivation (OGD) treatment	miR-122 expression was significantly decreased in both N2A cells after OGD	29715465
13825	Mouse	mmu-miR-122	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	N2a cells	oxygen and glucose deprivation (OGD) treatment	downregulated	33177827
13826	Mouse	mmu-miR-122	miRNA	leishmania	leishmaniasis	"the liver and J774 macrophages, and in spleens from infected mice"	Leishmania infection	upregulated	29943317
13827	Mouse	mmu-miR-122	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	downregulated	20436259
13828	Mouse	mmu-miR-122	miRNA	silymarin (Sm)	liver damage	blood and liver tissues	silymarin (Sm) treatment	upregulated	31811641
13829	Mouse	mmu-miR-122	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	liver damage	mouse liver cells	"2, 3, 7, 8-tetrachlorodi-benzo-p-dioxin (TCDD) treatment"	"TCDD dysregulates the expression of miR101a and miR122 and that COX-2, a target gene of miR101a, plays a significant role in liver damage in mice exposed to TCDD."	21602190
13830	Mouse	mmu-miR-122	miRNA	leptin	liver fibrosis	HCS were isolated from adult Kunming mice	leptin treatment	downregulated	29054053
13831	Mouse	mmu-miR-122	miRNA	"1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP)"	liver growth	C57BL/6J male mice liver	"1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) treatment"	upregulated in liver	28095325
13832	Mouse	mmu-miR-122	miRNA	acetaminophen (APAP)	liver damage	liver tissues	acetaminophen (APAP) treatment	upregulated	19246379
13833	Mouse	mmu-miR-122	miRNA	bile duct ligation (BDL)	liver damage	Serum	bile-duct ligation (BDL) treatment	Serum miR-122 increased significantly after BDL-induced cholestatic injury	24086271
13834	Mouse	mmu-miR-122	miRNA	isoniazid (INH)	liver damage	liver tissues	isoniazid treatment	downregulated	26535639
13835	Mouse	mmu-miR-122	miRNA	isoniazid (INH)	liver damage	liver tissues	isoniazid (INH) treatment	downregulated	27446292
13836	Mouse	mmu-miR-122	miRNA	isoniazid (INH)	liver damage	liver tissues	isoniazid (INH) treatment	upregulated	29554950
13837	Mouse	mmu-miR-122	miRNA	resveratrol	hepatic steatosis	Sprague-Dawley rats	resveratrol (RS) treatment	downregulated	28375178
13838	Mouse	mmu-miR-122	miRNA	free fatty acids (FFAs) inducer CL316243	metabolic syndrome	C57BL/6 mice livers	CL316243 treatment	upregulated	28802563
13839	Mouse	mmu-miR-122	miRNA	ischemia/reperfusion (I/R) 	myocardial ischaemic injury	mouse plasma;Bone marrow-derived macrophage (BMDM);Rat neonatal CMs	ischemia/reperfusion (I/R) treatment	differently regulated	28768728
13840	Mouse	mmu-miR-122	miRNA	"berberis aristata, elaeis guineensis?and?coffea canephora"	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	"Berberis Aristata, Elaeis Guineensis?and?Coffea Canephora treatment"	both these miRNAs had similar levels to SD-mice in HFD+E-mice	33924725
13841	Mouse	mmu-miR-122	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31126802
13842	Mouse	mmu-miR-122	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	high fat diet (HFD) feed	both these miRNAs had similar levels to SD-mice in HFD+E-mice	33924725
13843	Mouse	mmu-miR-122	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic fatty liver disease (NAFLD)	liver tissue	methionine and choline-deficient treatment	MiR-122 levels increased	24217942
13844	Mouse	mmu-miR-122	miRNA	silybin	nonalcoholic fatty liver disease (NAFLD)	FaO cells	silybin treatment	upregulated	31816412
13845	Mouse	mmu-miR-122	miRNA	isochlorogenic acid B (ICAB)	nonalcoholic steatohepatitis (NASH)	NASH mouse liver tissues	Isochlorogenic acid B (ICAB) treatment	upregulated	30180301
13846	Mouse	mmu-miR-122	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	methionine- and choline-deficient (MCD) diet feed	downregulated	30180301
13847	Mouse	mmu-miR-122	miRNA	high concentration of free fatty acids	nonalcoholic steatohepatitis (NASH)	NCTC-1469 cells	high concentration of free fatty acids treatment	miR-122 levels was downregulated in HFFA-induced NASH cell-like model.	32054840
13848	Mouse	mmu-miR-122	miRNA	isochlorogenic acid B (ICAB)	nonalcoholic steatohepatitis (NASH)	non-alcoholic steatohepatitis (NASH) rats liver tissues	Isochlorogenic acid B (ICAB) treatment	upregulated	30180301
13849	Mouse	mmu-miR-122	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	downregulated	25672270
13850	Mouse	mmu-miR-122	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	methionine- and choline-deficient (MCD) diet feed	downregulated	30180301
13851	Mouse	mmu-miR-122	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	were fed a methionine-choline-deficient (MCD) diet for eight weeks treatment	upregulated	25269746
13852	Mouse	mmu-miR-122	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis (NASH)	high-fat diet mouse	STZ treatment	downregulated	29216638
13853	Mouse	mmu-miR-122	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
13854	Mouse	mmu-miR-122	miRNA	aerobic training	obesity	exosomes of serum	aerobic training	downregulated	32744099
13855	Mouse	mmu-miR-122	miRNA	monosodium glutamate (MSG)	obesity	liver tissues	monosodium glutamate (MSG)-injected mice with developed central obesity treatment	dysregulated	24465854
13856	Mouse	mmu-miR-122	miRNA	hepatocarcinogen diethylnitrosamine (DEN)	pathological changes in the brain	liver tissue of mice	hepatocarcinogen diethylnitrosamine (DEN) treatment	upregulated	24113455
13857	Mouse	mmu-miR-122	miRNA	testosterone	prostate cancer	female mouse liver	Testosterone treatment	"upregulation of the 6 miRNAs miR-22, miR-690, miR-122, let-7A, miR-30D and let-7D"	20600201
13858	Mouse	mmu-miR-122	miRNA	soluble egg antigen (SEA)of Schistosoma japonicum	schistosomiasis	mouse hepatocytes (AML12)	SEA treatment	upregulated	29469324
13859	Mouse	mmu-miR-122	miRNA	streptozocin (STZ)	smooth muscle cell differentiation	mouse liver	streptozotocin (STZ) treatment	Upregulation of miR-34a and downregulated of miR-122 was found in livers of STZ-induced diabetic mice	19372595
13860	Mouse	mmu-miR-122	miRNA	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)"	thymic atrophy and alterations in T cell differentiation	fetal thymocytes of mice	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) treatment"	upregulated	23024791
13861	Mouse	mmu-miR-122	miRNA	atorvastatin	type 2 diabetes mellitus (T2DM)	C57Bl/6 mice	injected once a day with 20 mg/kg atorvastatin intraperitoneally for 5 days	downregulated	27899485
13862	Mouse	mmu-miR-122-3p	miRNA	acetaminophen (APAP)	liver damage	mouse serum	acetaminophen (APAP) treatment	upregulated	30844585
13863	Mouse	mmu-miR-122-3p	miRNA	diosbuibin B (DB)	liver damage	mouse serum	diosbuibin B (DB) treatment	upregulated	30844585
13864	Mouse	mmu-miR-122-3p	miRNA	ethyl acetate fraction of airpotato yam	liver damage	ICR and C57BL/6 mice	treat with ethyl acetate fraction of airpotato yam	significantly upregulated with no significant elevation of serum ALT/AST activity	28844483
13865	Mouse	mmu-miR-122-3p	miRNA	monocrotaline (MCT)	liver damage	mouse serum	monocrotaline (MCT) treatment	upregulated	30844585
13866	Mouse	mmu-miR-122-3p	miRNA	toosendanin (TSN)	liver damage	mouse serum	toosendanin (TSN) treatment	upregulated	30844585
13867	Mouse	mmu-miR-1224	miRNA	alcohol	alcoholic liver disease (ALD)	mouse liver cells	Lieber-DeCarli alcohol treatment	upragulated	19572984
13868	Mouse	mmu-miR-1224	miRNA	methionine choline-deficient diet (MCD)	alcoholic liver disease (ALD)	liver tissues	methionine-choline-deficient (MCD) diets treatment	upragulated	19572984
13869	Mouse	mmu-miR-1224	miRNA	clamping the renal pedicle	bilateral renal ischemia	C57Bl/6 mice plasma and kidneys	clamping the renal pedicle treatment	upregulated	24695114
13870	Mouse	mmu-miR-1224	miRNA	lipopolysaccharide (LPS)	glioblastoma multiforme (GBM)	spleens of mice	lipopolysaccharide (LPS)? treatment	upregulated	21320120
13871	Mouse	mmu-miR-1224	miRNA	dopamine	neurodegeneration (ND)	N2a cells	dopamine treatment	downregulated	30738894
13872	Mouse	mmu-miR-1224	miRNA	total-body irradiation (TBI)	radiation nephropathy	mouse urinary	a single LD50 of total-body irradiation (TBI) or clinically relevant fractionated doses (2 Gy twice daily for 3 days) treatment	upregulated in mouse urinary	28977780
13873	Mouse	mmu-miR-1224-5p	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	bordetella pertussis infection	Pertussis Toxin (PTX) treated mice CD4+ T cells	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	downregulated	31681214
13874	Mouse	mmu-miR-1225-5p	miRNA	nuclear factor kappa-¦¢ ligand (RANKL)	osteoclastogenesis	bone marrow-derived macrophages (BMMs)	nuclear factor kappa-¦¢ ligand (RANKL) treatment	downregulated	31017694
13875	Mouse	mmu-miR-1225-5p	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	serum	streptozocin (STZ) treatment	Secretions of miR-1225-5p was significantly increased in streptozotocin-treated mice	29370422
13876	Mouse	mmu-miR-122-5p	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	serums	acetaminophen (APAP) treatment	upregulated	32779042
13877	Mouse	mmu-miR-122-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	renal cortex	lipopolysaccharide (LPS) treatment	upregulated	33782973
13878	Mouse	mmu-miR-122-5p	miRNA	concanamycin A (Con A)	acute liver failure (ALF)	RAW264.7 cells	concanavalin A (Con A) treatment	upregulated	32739513
13879	Mouse	mmu-miR-122-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Murine lung vascular endothelial cells (MLECs); lung tissues	lipopolysaccharide (LPS) treatment	upregulated	32470454
13880	Mouse	mmu-miR-122-5p	miRNA	apigenin	cardiac fibrosis	TGF-¦Â1-treated mouse cardiac fibroblasts	apigenin treatment	upregulated	33607460
13881	Mouse	mmu-miR-122-5p	miRNA	TGF-¦Â1	cardiac fibrosis	Mouse cardiac fibroblasts	TGF-¦Â1 treatment	downregulated	33607460
13882	Mouse	mmu-miR-122-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Plasma	doxorubicin (DOX) treatment	downregulated	30627229
13883	Mouse	mmu-miR-122-5p	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	plasma	acetaminophen (APAP) treatment	miR-122-5p and miR-192-5p were consistently upregulated in early to late stages of all the liver injury models.	30125006
13884	Mouse	mmu-miR-122-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	downregulated	31497013
13885	Mouse	mmu-miR-122-5p	miRNA	fluke Fasciola gigantica (FgESPs)	F. gigantica infection	liver tissues	fluke Fasciola gigantica (FgESPs) infection	downregulated	33332355
13886	Mouse	mmu-miR-122-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
13887	Mouse	mmu-miR-122-5p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
13888	Mouse	mmu-miR-122-5p	miRNA	cadmium (Cd)	toxic effects of cadmium	rat kidneys; NRK-52E	cadmium (Cd) treatment	upregulated	31626960
13889	Mouse	mmu-miR-122-5p	miRNA	5-chloro-N-[4-chloro-3-(trifluoromethyl)phenyl]thiophene-2-sulfonamide (FX5)	type 2 diabetes mellitus (T2DM)	mouse primary hepatocytes	5-chloro-N-[4-chloro-3-(trifluoromethyl)phenyl]thiophene-2-sulfonamide (FX5)  treatment	FX5 antagonized Dex or glucagon- induced enhancement on miR122-5p expression.	33316780
13890	Mouse	mmu-miR-122-5p	miRNA	dexamethasone (DEX)	type 2 diabetes mellitus (T2DM)	mouse primary hepatocytes	dexamethasone (DEX) treatment	upregulated	33316780
13891	Mouse	mmu-miR-122-5p	miRNA	glucagon	type 2 diabetes mellitus (T2DM)	mouse primary hepatocytes	glucagon treatment	upregulated	33316780
13892	Mouse	mmu-miR-122?5p	miRNA	carbon tetrachloride (CCl4)	hepatotoxicity	blood	carbon tetrachloride (CCl4) treatment	upregulated	32528856
13893	Mouse	mmu-miR-122a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intestinal inflammation	mice enterocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	21763238
13894	Mouse	mmu-miR-122a	miRNA	tert-butyl hydroperoxide (TBHP)	oxidative stress	adult male mice strain Balb/c	TBHP treatment	differently regulated	25141839
13895	Mouse	mmu-miR-124	miRNA	candida albicans (C. albicans)	acute kidney injury (AKI)	kidney tissues	candida albicans infection	downregulated	29568906
13896	Mouse	mmu-miR-124	miRNA	itraconazole (ITR)	acute kidney injury (AKI)	candidiasis-induced acute kidney injury (AKI) mouse kidney tissues	itraconazole (ITR) treatment	upregulated	29568906
13897	Mouse	mmu-miR-124	miRNA	d-galactosamine and lipopolysaccharide (LPS)	acute liver injury (ALI)	liver tissues and cells	d-galactosamine and lipopolysaccharide treatment	upregulated	31628693
13898	Mouse	mmu-miR-124	miRNA	sedum sarmentosum extract	acute liver injury (ALI)	liver tissues	S. sarmentosum extract treatment	miR-124 was increased in liver tissues after S sarmentosum extract was administered	32178661
13899	Mouse	mmu-miR-124	miRNA	forsythoside A (FA)	acute lung injury (ALI)	MLE-12 cells	forsythoside A (FA) treatment	miR-124 expression was upregulated after FA treatment.	32987027
13900	Mouse	mmu-miR-124	miRNA	H2O2	acute lung injury (ALI)	primary mouse lung epithelial cells (LECs)	H2O2 treatment	downregulated	31938089
13901	Mouse	mmu-miR-124	miRNA	hyperoxia	acute lung injury (ALI)	primary mouse lung epithelial cells (LECs)	hyperoxia treatment	downregulated	31938089
13902	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharides (LPS) treatment	downregulated	31476692
13903	Mouse	mmu-miR-124	miRNA	Mito-TEMPO	acute lung injury (ALI)	hyperoxia-/H2O2-treated primary mouse lung epithelial cells (LECs)	Mito-TEMPO treatment	upregulated	31938089
13904	Mouse	mmu-miR-124	miRNA	N-acetyl-L-cysteine (NAC)	acute lung injury (ALI)	hyperoxia-/H2O2-treated primary mouse lung epithelial cells (LECs)	N-acetyl-L-cysteine (NAC) treatment	upregulated	31938089
13905	Mouse	mmu-miR-124	miRNA	lithium (Li)	acute poststroke	brain tissues	lithium (1 mg/kg bolus followed by 2 mg/kg/day over up to 7 days) was intraperitoneally administered starting 0-9 h after reperfusion onset	upregulated in brain	27126323
13906	Mouse	mmu-miR-124	miRNA	insulin	adipogenesis	3T3-L1 cells	Insulin treatment	"insulin-induced miR-124 plays a pivotal role in post-transcriptional regulation of Dlx5 during adipogenic differentiation and that miR-124 exerts pro-adipogenic effects by targeting Dlx5, at least in part"	23648570
13907	Mouse	mmu-miR-124	miRNA	"3,4-dihydroxyphenylethanol (DOPET)"	Alzheimer's disease (AD)	oA42i (oligomeric amyloid ¦Â1-42 plus ibotenic acid) induced AD mouse hippocampi	"3,4-dihydroxyphenylethanol (DOPET) treatment"	upregulated	29901389
13908	Mouse	mmu-miR-124	miRNA	bilateral common carotid artery occlusion (2-VO)	Alzheimer's disease (AD)	hippocampus tissues of AD mouse	bilateral common carotid artery?occlusion (2VO) induce	The expression of miR-124 was significantly downregulated in 2VO-induced AD mice models	31743528
13909	Mouse	mmu-miR-124	miRNA	H2O2	Alzheimer's disease (AD)	N2a mouse neuroblastoma cells	Hydrogen peroxide (H2O2)?treatment	The expression of miR-124 was significantly downregulated in H2O2-treated N2a cells	31743528
13910	Mouse	mmu-miR-124	miRNA	oA42i (oligomeric amyloid ¦Â1-42 plus ibotenic acid)	Alzheimer's disease (AD)	hippocampi	oA42i (oligomeric amyloid ¦Â1-42 plus ibotenic acid) treatment	downregulated	29901389
13911	Mouse	mmu-miR-124	miRNA	streptozocin (STZ)	Alzheimer's disease (AD)	mouse brain tissues	streptozocin treatment	downregulated	31014193
13912	Mouse	mmu-miR-124	miRNA	H2O2	Alzheimer's disease (AD)	N2a cells	Hydrogen peroxide (H2O2 ) treatment	miR-124 expression level was upregulated in H2O2-treated N2a cells.	31743528
13913	Mouse	mmu-miR-124	miRNA	ischemia	apoptosis	brain tissues	ischemia?treatment	upregulated	23826665
13914	Mouse	mmu-miR-124	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
13915	Mouse	mmu-miR-124	miRNA	arsenite	arsenic induted deficits in differentiation	prenatal C57BL/6 mouse brain	arsenic (As) exposure	downregulated	27751817
13916	Mouse	mmu-miR-124	miRNA	metformin (Met)	atherosclerosis (AS)	carotid	Metformin treatment	Administration of metformin reduced miR-124 expression.	29502204
13917	Mouse	mmu-miR-124	miRNA	IL-4 and IL-13	breast cancer	macrophages	IL-4 and IL-13 treatment	upregulated	24358127
13918	Mouse	mmu-miR-124	miRNA	doxorubicin (DOX)	cardiac injury	heart sissues; primary cardiomyocytes	doxorubicin treatment	MiR-124 was downregulated in Dox-induced cardiac injury.	31672275
13919	Mouse	mmu-miR-124	miRNA	doxorubicin (DOX)	cardiotoxicity	heart tissues and primary cardiomyocytes	doxorubicin treatment	downregulated	31672275
13920	Mouse	mmu-miR-124	miRNA	melatonin	cell proliferation	hippocampus dentate gyrus tissues	melatonin treatment	upregulated	31169197
13921	Mouse	mmu-miR-124	miRNA	paclitaxel (PTX)	chemotherapy-induced peripheral neuropathy (CiPN)	mouse dorsal root ganglion (DRG) and sciatic nerve tissues	Paclitaxel treatment	upregulated	30677061
13922	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	cholinergic anti-inflammatory action	Mouse macrophage cell line RAW264.7 ;human HEK293 cell line	lipopolysaccharide (LPS) treatment	miR-124 is upregulated by cholinergic agonists in LPS-exposed cells and mice	23979021
13923	Mouse	mmu-miR-124	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	chondrogenesis	C3H10T1/2 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28979686
13924	Mouse	mmu-miR-124	miRNA	hypoxia	chondrogenesis	C3H10T1/2 cells	under hypoxic conditions (2% O2)	downregulated	28979686
13925	Mouse	mmu-miR-124	miRNA	collagen	collagen-induced arthritis (CIA)	synovial tissues	collagen treatment	downregulated	33337986
13926	Mouse	mmu-miR-124	miRNA	vitamin D	collagen-induced arthritis (CIA)	Th17 cells	vitamin D (VD) treatment	upregulated	30792721
13927	Mouse	mmu-miR-124	miRNA	kainic acid (KA)	convulsive seizures	hippocampal neural stem/progenitor cells (NSPCs)	kainic acid (KA) treatment	upregulated	30837840
13928	Mouse	mmu-miR-124	miRNA	oxidized low density lipoprotein (ox-LDL)	coronary artery disease (CAD)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32611832
13929	Mouse	mmu-miR-124	miRNA	resveratrol	experimental autoimmune encephalomyelitis (EAE)	encephalitogenic CD4+ T cells from EAE mice	"Resveratrol (3,5,4'-trihydroxy-trans-stilbene) (RES) treatment"	upregulated	30941623
13930	Mouse	mmu-miR-124	miRNA	TGF-¦Â1	fibrogenesis	Lung resident mesenchymal stem cells (LR-MSCs)	transforming growth factor (TGF)-¦Â1 treatment	upregulated	30802451
13931	Mouse	mmu-miR-124	miRNA	angiotensin II (Ang II)	heart failure (HF)	heart tissues	angiotensin II (Ang II) treatment	upregulated	29581851
13932	Mouse	mmu-miR-124	miRNA	shikonin	heart failure (HF)	heart tissues	Shikonin treatment	downregulated	31604527
13933	Mouse	mmu-miR-124	miRNA	morphine	immune response	microglia	morphine treatment	upregulated	25539811
13934	Mouse	mmu-miR-124	miRNA	IL-1¦Â	inflammation	ATDC5 cells	interleukin-1¦Â treatment	downregulated	31608709
13935	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	inflammation	Mouse macrophage cell line RAW264.7	lipopolysaccharide (LPS) treatment	upregulated	27063215
13936	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	inflammation	ATDC5 cells	lipopolysaccharide (LPS) treatment	downregulated	31190561
13937	Mouse	mmu-miR-124	miRNA	lycium barbarum polysaccharide (LBP)	inflammation	interleukin-1¦Â-treated ATDC5 cells	Lycium barbarum polysaccharide (LBP) treatment	upregulated	31608709
13938	Mouse	mmu-miR-124	miRNA	bacillus calmette-guerin (BCG)	inflammatory response	RAW264.7 AM cells	bacillus calmette-guerin (BCG) treatment	upregulated	24995397
13939	Mouse	mmu-miR-124	miRNA	ischemia	ischemia/reperfusion (I/R) injury	cerebral cortex and hippocampus	Ischemic preconditioning and ischemic postconditioning (IPostC) treatment	downregulated	27485299
13940	Mouse	mmu-miR-124	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	hippocampus tissues	chronic unpredictable mild stress (CUMS) treatment	downregulated	31626919
13941	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	major depressive disorder (MDD)	BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	31626919
13942	Mouse	mmu-miR-124	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	precursors	methamphetamine (METH) treatment	downregulated	29516602
13943	Mouse	mmu-miR-124	miRNA	mycobacterium bovis bacille Calmette-Gu¨¦rin (BCG)	mycobacterium tuberculosis (Mtb) infection	female C57/BL6 mice	infect with Mycobacterium bovis BCG treatment	upregulated in lungs	24705038
13944	Mouse	mmu-miR-124	miRNA	H2O2	myocardial infarction (MI)	neonatal rat ventricular myocytes (NRVMs)	H2O2 treatment	miR-124 was significantly upregulated in a mice model of MI and in neonatal rat ventricular myocytes (NRVMs) with H2O2 treatment.	30439699
13945	Mouse	mmu-miR-124	miRNA	H2O2	myocardial infarction (MI)	primary cardiomyocyte	H2O2 treatment	upregulated	31100313
13946	Mouse	mmu-miR-124	miRNA	hypoxia	myocardial infarction (MI)	primary cardiomyocyte	hypoxia induce	upregulated	31100313
13947	Mouse	mmu-miR-124	miRNA	hypoglossal nerve injury	nerve injury	injured hypoglossal motor neurons	injury mouse nerve treatment	downregulated	24184980
13948	Mouse	mmu-miR-124	miRNA	retinoic acid (RA)	cell differentiation	L929 cells	retinoic acid? treatment	upregulated	31823894
13949	Mouse	mmu-miR-124	miRNA	ketamine	neurodegeneration (ND)	murine hippocampus	high-dosage ketamine treatment	upregulated	24825585
13950	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	neuroinflammation	N9 microglia	lipopolysaccharide (LPS) treatment	downregulated	28096568
13951	Mouse	mmu-miR-124	miRNA	cocaine	neuronal adaptations	NG-108-15 cells£» HEK293T cells	cocaine treatment	"LV-miR-124 and let-7d expression in the NAc attenuates cocaine CPP, whereas LV-miR-181a enhances it"	21307844
13952	Mouse	mmu-miR-124	miRNA	cocaine	neuronal function	mouse nucleus accumbens (NAc)	cocaine treatment	cocaine treatment persistently downregulated miR-124 in NAc.	32641757
13953	Mouse	mmu-miR-124	miRNA	extra-virgin olive oil rich in phenols (H-EVOO)	neuronal function	cortex	H-EVOO treatment	upregulated	26695409
13954	Mouse	mmu-miR-124	miRNA	ketamine	neurotoxicity	Hippocampal	ketamine treatment	upregulated	24825585
13955	Mouse	mmu-miR-124	miRNA	morphine	opioid-induced damage to microglia	mouse BV2 cells	morphin treatment	upregulated	25539811
13956	Mouse	mmu-miR-124	miRNA	IL-6	osteoclastogenesis	M-CSF stimulated mouse bone marrow-derived macrophages	IL-6 treatment	downregulated	30547186
13957	Mouse	mmu-miR-124	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoclastogenesis	M-CSF stimulated mouse bone marrow-derived macrophages	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30547186
13958	Mouse	mmu-miR-124	miRNA	macrophage colony stimulating factor (M-CSF)	osteoporosis	bone marrow monocytes (BMMs) from OVX mice	co-cultured with RANKL (50 ng/ml) containing M-CSF (20ng/ml)	downregulated	29045940
13959	Mouse	mmu-miR-124	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	mouse brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30995872
13960	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	immortalized murine microglial cell line BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	30995872
13961	Mouse	mmu-miR-124	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brian tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated in the expression of brain-enriched miR-124	24792712
13962	Mouse	mmu-miR-124	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV2 cells	lipopolysaccharide (LPS) treatment	Brain-specific miR-124 was downregulated in the LPS- stimulated BV2 cells.	29329581
13963	Mouse	mmu-miR-124	miRNA	docosahexaenoic acid (DHA)	spinal cord injury (SCI)	BV-2 mouse microglial cells	Docosahexaenoic acid (DHA) treatment	upregulated	30972415
13964	Mouse	mmu-miR-124	miRNA	H2O2	spinal cord injury (SCI)	BV-2 cells	H2O2 treatment	downregulated	30720072
13965	Mouse	mmu-miR-124	miRNA	nicotine	ulcerative colitis (UC)	ulcerative colon	Nicotine treatment	upregulated	27709266
13966	Mouse	mmu-miR-124-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	32391561
13967	Mouse	mmu-miR-124-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	serum	lipopolysaccharide (LPS) treatment	downregulated	32934950
13968	Mouse	mmu-miR-124-3p	miRNA	myostatin	adipogenesis	3T3-L1 cells	myostatin treatment	upregulated	30576242
13969	Mouse	mmu-miR-124-3p	miRNA	myostatin	adipogenesis	3T3-L1 cells	myostatin treatment	upregulated	30576242
13970	Mouse	mmu-miR-124-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	30673982
13971	Mouse	mmu-miR-124-3p	miRNA	rosiglitazone	liver fibrosis	TGF-¦Â1 treated primary mouse hepatic stellate cells (HSCs)	Rosiglitazone (RGZ) treatment	upregulated	30673982
13972	Mouse	mmu-miR-124-3p	miRNA	rosiglitazone	liver fibrosis	carbon tetrachloride (CCl4) treated mouse liver tissues	Rosiglitazone (RGZ) treatment	upregulated	30673982
13973	Mouse	mmu-miR-124-3p	miRNA	TGF-¦Â1	liver fibrosis	Primary mouse hepatic stellate cells (HSCs)	TGF-¦Â1 treatment	downregulated	30673982
13974	Mouse	mmu-miR-124-3p	miRNA	repetitive traumatic brain injury (rTBI) mouse model brain extracts	nerve injury	BV2 microglia	repetitive traumatic brain injury (rTBI) mouse model brain extracts treatment	upregulated	31190315
13975	Mouse	mmu-miR-124-3p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	"In response to high-fat diet (HFD), expression of miR-124-3p was increased in the liver."	33324345
13976	Mouse	mmu-miR-124-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra (SN) area	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"?HOXA11-AS promoted MPTP-mediated SH-SY5Y neuronal injury and LPS-induced microglia activation, while miR-124-3p had the opposite effects."	33839699
13977	Mouse	mmu-miR-124-3p	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	33839699
13978	Mouse	mmu-miR-124-3p	miRNA	hypoxia	pulmonary hypertension (PH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	downregulated	33657879
13979	Mouse	mmu-miR-124-3p	miRNA	lipopolysaccharide (LPS)	severe community-acquired pneumonia (SCAP)	Ana-1 macrophages	lipopolysaccharide (LPS) treatment	downregulated	30535475
13980	Mouse	mmu-miR-124-3p	miRNA	lipopolysaccharide (LPS)	severe community-acquired pneumonia (SCAP)	Ana-1 macrophages	lipopolysaccharide (LPS) treatment	downregulated	30535475
13981	Mouse	mmu-miR-1244	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	mice	injected into the tumour centre at a concentration of 150 mg/kg treatment	dysregulated	24896104
13982	Mouse	mmu-miR-124-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse Alveolar Type 2 Epithelial Cells.	lipopolysaccharide (LPS) treatment	MiR-124-5p is increased in the LPS-induced ALI cell model.	32190682
13983	Mouse	mmu-miR-124-5p	miRNA	tanshinone IIA (Tan IIA)	acute myocardial infarction (AMI)	H9c2 cells	Tanshinone IIA (TSA) treatment	"TSA exerts the protective role against H/R induced apoptosis, oxidative and MMP loss of cardiomyocytes via regulating AK003290 and miR-124-5p signaling"	32220226
13984	Mouse	mmu-miR-124-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
13985	Mouse	mmu-miR-1246	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	"In ALI mice, miRNA-1246 expression is effectively upregulated."	30253370
13986	Mouse	mmu-miR-1246	miRNA	alcohol	alcoholic hepatitis (AH)	sera	alcohol exposure	upregulated	26264599
13987	Mouse	mmu-miR-1247	miRNA	carbon tetrachloride (CCl4)	acute kidney injury (AKI)	mouse liver	carbon tetrachloride (CCl4) treatment	upregulated	28285099
13988	Mouse	mmu-miR-1247-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	neuro2a (N2a) cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30779911
13989	Mouse	mmu-miR-1249	miRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	mouse aortic endothelial cells (MAECs)	chronic intermittent hypoxia (CIH) treatment	upregulated	29108914
13990	Mouse	mmu-miR-1249-5p	miRNA	Sphingosine-1-phosphate (S1P)	liver disease	liver tissues; liver macrophages	sphingosine 1-phosphate (S1P) treatment	downregulated	32672363
13991	Mouse	mmu-miR-1249-5p	miRNA	X-rays	radiation-induced injury	bone marrow stem cells	X-ray treatment	"mmu-circRNA_016901 affects the expression of TGF-¦Â3 through miRNA1249-5p, and thus participates in the regulation of the radiation damage mechanism of bone marrow mesenchymal stem cells"	32552977
13992	Mouse	mmu-miR-124a	miRNA	duloxetine	depression	frontal lobe and hippocampus	duloxetine treatment	downregulated	26823914
13993	Mouse	mmu-miR-124a	miRNA	neurotoxicant sodium valproate (VPA)	developmental toxicity	murine embryonic stem cells (mESCs)	neurotoxicant sodium valproate (VPA) treatment	downregulated	24896083
13994	Mouse	mmu-miR-124a	miRNA	exenatide (EXA)	insulin sensitivity	pancreas	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 375 in the pancreas were significantly increased in HFD control mice.These effects were reversed by treatment with exenatide."	26314504
13995	Mouse	mmu-miR-124a	miRNA	exenatide (EXA)	insulin sensitivity	liver	exenatide treatment	"the levels of miRNA-29c, 124a, and 146a in the liver were significantly increased. These effects were reversed by treatment with exenatide."	26314504
13996	Mouse	mmu-miR-124a	miRNA	exenatide (EXA)	insulin sensitivity	muscle	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 146a in the muscle were significantly increased. These effects were reversed by treatment with exenatide."	26314504
13997	Mouse	mmu-miR-124a	miRNA	exenatide (EXA)	insulin sensitivity	serum	exenatide treatment	"the levels of miRNA-15a, 29c, 124a, and 375 in the serum were significantly decreased. These effects were reversed by treatment with exenatide."	26314504
13998	Mouse	mmu-miR-124a	miRNA	high fat diet (HFD)	insulin sensitivity	pancreas	high fat diet (HFD) feed	upregulated	26314504
13999	Mouse	mmu-miR-124a	miRNA	high fat diet (HFD)	insulin sensitivity	liver	high fat diet (HFD) feed	upregulated	26314504
14000	Mouse	mmu-miR-124a	miRNA	high fat diet (HFD)	insulin sensitivity	muscle	high fat diet (HFD) feed	upregulated	26314504
14001	Mouse	mmu-miR-124a	miRNA	high fat diet (HFD)	insulin sensitivity	serum	high fat diet (HFD) feed	downregulated	26314504
14002	Mouse	mmu-miR-124a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	30861258
14003	Mouse	mmu-miR-124a	miRNA	liraglutide	nonalcoholic fatty liver disease (NAFLD)	high fat diet-fed mice liver tissues	liraglutide treatment	downregulated	30861258
14004	Mouse	mmu-miR-124a	miRNA	bone morphogenetic proteins (BMPs)	osteogenesis	pluripotent stem (iPS) cells	bone morphogenetic proteins (BMPs) treatment	downregulated	22937097
14005	Mouse	mmu-miR-125	miRNA	xanthomicrol	breast cancer	4T1 cells	xanthomicrol treatment	downregulated	33217075
14006	Mouse	mmu-miR-125	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic tissue	carbon tetrachloride (CCl4) treatment	Exos delivery of mmu_circ_0000623 inhibited liver fibrosis protein expression by promoting miR- 125/ATG4D-mediated autophagy.	32633558
14007	Mouse	mmu-miR-125a	miRNA	pristane (PS)	"acute ""SLE-like"" lung inflammation"	lung tissues	pristane treatment	downregulated	30089723
14008	Mouse	mmu-miR-125a	miRNA	candida albicans (C. albicans)	Alzheimer's disease (AD)	mouse macrophages	candida albicans infection	upregulated	21060679
14009	Mouse	mmu-miR-125a	miRNA	histone deacetylase inhibitors (HDIs) short-chain fatty acid (SCFA) butyrate	antibody-mediated systemic autoimmunity	B cells	SCFA HDI butyrate treatment	upregulated	32265934
14010	Mouse	mmu-miR-125a	miRNA	mycobacterium tuberculosis (Mtb)	autophagy	lungs tissues;spleens tissues;liver tissues	M. tuberculosis treatment	upregulated	25917095
14011	Mouse	mmu-miR-125a	miRNA	bilobalide (BB)	inflammation	IL-17-treated ATDC5 cells	bilobalide (BIL) treatment	downregulated	31593333
14012	Mouse	mmu-miR-125a	miRNA	IL-17	inflammation	ATDC5 cells	?interleukin (IL)-17 treatment	upregulated	31593333
14013	Mouse	mmu-miR-125a	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	miR-125a levels was downregulated in livers of mice fed chow or HF diet.	31988048
14014	Mouse	mmu-miR-125a	miRNA	high fat diet (HFD)	obesity	BALB/c and C57BL/6J mice adipose tissue	high fat diet (HFD) feed	upregulated	24675842
14015	Mouse	mmu-miR-125a	miRNA	bone morphogenetic protein 9 (BMP9)	osteogenesis	The conditionally immortalized mouse multipotent adipose-derived cells iMADs	bone morphogenetic protein 9 (BMP9) treatment	downregulated	31825894
14016	Mouse	mmu-miR-125a-3p	miRNA	MOG 35-55 peptide	experimental autoimmune encephalomyelitis (EAE)	oligodendrocyte precursor cells (OPCs)	MOG35-55 treatment	miR-125a-3p is upregulated in OPCs isolated from the spinal cord of chronic experimental autoimmune encephalomyelitis (EAE) mice.	32163190
14017	Mouse	mmu-miR-125a-3p	miRNA	Legionella pneumophila (L. pneumophila)	Legionella pneumophila (L. pneumophila) infection	WT and MyD88-/- murine bone marrow-derived macrophages (BMM)	infected with L. pneumophila	downregulated	28445535
14018	Mouse	mmu-miR-125a-3p	miRNA	urocortin 1 (Ucn-1)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R mosue	administration of Ucn-1 at the beginning of reperfusion treatment	upregulated	28827743
14019	Mouse	mmu-miR-125a-3p	miRNA	silica	lung fibrosis	lung tissues	silica treatment	downregulated	30658076
14020	Mouse	mmu-miR-125a-3p	miRNA	TGF-¦Â1	lung fibrosis	NIH/3T3 cells	TGF-¦Â1 treatment	downregulated	30658076
14021	Mouse	mmu-miR-125a-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	RAW264.7 macrophages	lipopolysaccharide (LPS) treatment	downregulated	32388658
14022	Mouse	mmu-miR-125a-5p	miRNA	inorganic nitrite	acute myocardial infarction (AMI)	heart tissues	single-dose of nitrite	downregulated	28090786
14023	Mouse	mmu-miR-125a-5p	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
14024	Mouse	mmu-miR-125a-5p	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
14025	Mouse	mmu-miR-125a-5p	miRNA	histone deacetylase inhibitor (HDACi)	B cell differentiation	B cells of C57BL/6J	"stimulated with LPS and IL-4 and treated with HDI (VPA, 500 ?M) or nil for 60 h"	upregulated	28994753
14026	Mouse	mmu-miR-125a-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	downregulated	30095204
14027	Mouse	mmu-miR-125a-5p	miRNA	echinococcus multilocularis metacestodes	echinococcus multilocularis infection	RAW 264.7 cells	E. multilocularis metacestodes treatment	upregulated	30322806
14028	Mouse	mmu-miR-125a-5p	miRNA	myelin oligodendrocyte glycoprotein	experimental autoimmune encephalomyelitis (EAE)	spinal ventral horn of EAE mice	myelin oligodendrocyte glycoprotein 35-55 peptides treatment	upregulated	31428926
14029	Mouse	mmu-miR-125a-5p	miRNA	myelin oligodendrocyte glycoprotein	experimental autoimmune encephalomyelitis (EAE)	lumbosacral spinal cord	myelin oligodendrocyte glycoprotein 35-55 peptides treatment	upregulated	31428926
14030	Mouse	mmu-miR-125a-5p	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
14031	Mouse	mmu-miR-125a-5p	miRNA	E. multilocularis metacestodes	infection and immunity of E. multilocularis	RAW264¡¤7 macrophage cells	E. multilocularis metacestodes for 6 and 12 h treatment	"upregulated (mmu-miR-378d,mmu-miR-155-5p, mmu-miR-146a-5p, mmu-miR-21a-5p , mmu-miR-125a-5p) and downregulated(mmu-miR-1981-5p , mmu-miR-let-7c-1-3p)"	28942753
14032	Mouse	mmu-miR-125a-5p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	mice	injected into the tumour centre at a concentration of 150 mg/kg treatment	dysregulated	24896104
14033	Mouse	mmu-miR-125a-5p	miRNA	gefitinib	nasopharyngeal carcinoma (NPC)	NPC tumor bearing-mice serum	geftinib treatment	upregulated	24602316
14034	Mouse	mmu-miR-125a-5p	miRNA	high fat diet (HFD)	obesity	obesity	high fat diet (HFD) feed	downregulated	29393878
14035	Mouse	mmu-miR-125a-5p	miRNA	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL)	osteoclastogenesis	RAW 264.7 osteoclast precursor cell	RANKL plus M-CSF treatment	upregulated	30976285
14036	Mouse	mmu-miR-125a-5p	miRNA	paraquat (PQ)	paraquat (PQ)-induced acute lung injury and pulmonary fibrosis	MLE-12 cells	paraquat (PQ) treatment	downregulated	32741895
14037	Mouse	mmu-miR-125a-5p	miRNA	anandamide (AEA)	pro-inflammatory activity	mouse	anandamide treatment	AEA differentil regulate the expression of miRNA	24699635
14038	Mouse	mmu-miR-125a-5p	miRNA	triptolide (TPL)	systemic lupus erythematosus (SLE)	MRL/lpr mice serum	triptolide (TPL) treatment	upregulated	30861393
14039	Mouse	mmu-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	high-fat diet-induced T2DM KK-Ay mice tissues	dioscin treatment	upregulated	31881477
14040	Mouse	mmu-miR-125a-5p	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	liver tissues	streptozotocin treatment	downregulated	31881477
14041	Mouse	mmu-miR-125a-5p	miRNA	palmitic acid (PA)	type 2 diabetes mellitus (T2DM)	AML12 cells	palmitic acid treatment	downregulated	30555566
14042	Mouse	mmu-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	AML12 cells	dioscin treatment	Dioscin was found to markedly elevate miR-125a-5p level and decrease STAT3 expression.	31881477
14043	Mouse	mmu-miR-125b	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	Mouse primary hippocampal neurons	amyloid-¦Â (A¦Â) treatment	upregulated	30706990
14044	Mouse	mmu-miR-125b	miRNA	melatonin	Alzheimer's disease (AD)	A¦Â-treated mouse primary hippocampal neurons	melatonin treatment	downregulated	30706990
14045	Mouse	mmu-miR-125b	miRNA	epigallocatechin-3-gallate (EGCG)	Alzheimer's disease (AD)	AD mouse serum	EGCG treatment groups (2 mg/kg/day)	upregulated	28731435
14046	Mouse	mmu-miR-125b	miRNA	estradiol-17¦Â (E2)	Alzheimer's disease (AD)	Primary cortical neurons	estradiol-17¦Â (E2) treatment	upregulated	27235580
14047	Mouse	mmu-miR-125b	miRNA	ethanol (EtOH)	apoptosis	neural crest cells (NCCs)	ethanol treatment	downregulated	26024858
14048	Mouse	mmu-miR-125b	miRNA	alcohol	brain injury and neurodegeneration	cerebral cortex	chronic alcohol administration	upregulated	30374194
14049	Mouse	mmu-miR-125b	miRNA	androgen receptor (ASC-J9 ?)	cardiac fibrosis	cardiac fibroblasts (CFs)	androgen receptor (ASC-J9 ?) treatment	ASC-J9 ? attenuates the expression of miR-125b.	30340830
14050	Mouse	mmu-miR-125b	miRNA	interleukin-1 receptor antagonist protein (IRAP)	cartilage impact injury	porcine knee joint	Interleukin-1 Receptor Antagonist Protein (IRAP) treatment	upregulated	26521750
14051	Mouse	mmu-miR-125b	miRNA	oxyELITE pro-new formula (OEP-NF)	drug-induced liver injury (DILI)	female B6C3F1 mice liver	administering 10X and 3X mouse-equivalent doses (MED) of OEP-NF treatment	upregulated in the liver	28843594
14052	Mouse	mmu-miR-125b	miRNA	cocaine	effects of cocaine action	dopaminergic neuronal cells and nucleus accumbens (NAc) of mice	acute and chronic cocaine exposure	downregulated	28828398
14053	Mouse	mmu-miR-125b	miRNA	cyclophosphamide	embryonic maldevelopment	the fore- and hindlimbs of mice	cyclophosphamide treatment	downregulated	20170545
14054	Mouse	mmu-miR-125b	miRNA	estrogen (ES)	hepatic steatosis	liver	estrogen treatment	upregulated	26272872
14055	Mouse	mmu-miR-125b	miRNA	ganoderma lucidum polysaccharides (GLPs)	hepatocellular carcinoma (HCC)	mouse hepatoma H22 cell line	Ganoderma lucidum polysaccharides (GLPS) treatment	upregulated	25889022
14056	Mouse	mmu-miR-125b	miRNA	aluminum-sulfate	inflammatory neurodegeneration	C57BL/6J mice blood	serum exposure to a standard mouse diet that included aluminum-sulfate	upregulated	29354323
14057	Mouse	mmu-miR-125b	miRNA	¦Ã-rays	irradiation-induced tumors	bone marrow (BM)	low-power long-term ¦Ã-irradiation	downregulated	32483710
14058	Mouse	mmu-miR-125b	miRNA	hypoxia	ischemic injury	bone marrow mesenchymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	30613290
14059	Mouse	mmu-miR-125b	miRNA	ultraviolet (UV) irradiation	ischemic tolerance	mouse embryonic fibroblast cells	ultraviolet radiation (UV) treatment	UV radiation induces upregulated of miR-125b	22854965
14060	Mouse	mmu-miR-125b	miRNA	isoniazid (INH)	liver damage	liver tissues	isoniazid (INH) treatment	upregulated	29554950
14061	Mouse	mmu-miR-125b	miRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	24576954
14062	Mouse	mmu-miR-125b	miRNA	retinoic acid (RA)	cell differentiation	Neuro-2A cells	retinoic acid? treatment	downregulated	31823894
14063	Mouse	mmu-miR-125b	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
14064	Mouse	mmu-miR-125b	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharides (LPS) treatment	downregulated	29550827
14065	Mouse	mmu-miR-125b	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	Overexpression of THRIL promoted LPS-induced ATDC5 cell inflammatory injury by down-regulating miR-125b and then activating JAK1/STAT3 and NF-¦ÊB pathways.	30521964
14066	Mouse	mmu-miR-125b	miRNA	H2O2	oxidative stress	mouse hippocampal HT22 cells	?H2O2 treatment	"Following stimulation with H2O2, we observed downregulated of miR-125b expression, upregulation of p53 expression, mitochondria were damaged and increased cell death"	33475982
14067	Mouse	mmu-miR-125b	miRNA	SDF-1¦Á analog CTCE-0214 (CTCE)	sepsis	mouse with polymicrobial sepsis	EPC therapy treatment	upregulated in endothelial progenitor cells (EPCs)	24707934
14068	Mouse	mmu-miR-125b	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	liver tissues	high fat diet (HFD) feed	upregulated	29319168
14069	Mouse	mmu-miR-125b-1-3p	miRNA	rutin (RUT)	pirarubicin (THP) cardiotoxicity	HL-1 cells	rutin (RUT) treatment	Rutin protects against pirarubicin-induced cardiotoxicity by adjusting microRNA-125b-1-3p-mediated JunD signaling pathway	32016695
14070	Mouse	mmu-miR-125b-5p	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	The mouse cardiomyocyte cell line HL-1	hypoxia/reperfusion induce	downregulated	32010261
14071	Mouse	mmu-miR-125b-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	primary mouse cortical neurons (MCN) and Neuro2a (N2a) cells	amyloid-¦Â (A¦Â) treatment	downregulated	32251872
14072	Mouse	mmu-miR-125b-5p	miRNA	melatonin	anti-inflammatory responses	RAW264.7 cells (a murine macrophage cell line) and mouse bone marrow-derived macrophages (BMDMs)	metformin treatment	Metformin might show anti-inflammatory effects in macrophages through the induction of Dicer and the subsequent upregulation of miR-34a-5p and miR-125b-5p.	31102492
14073	Mouse	mmu-miR-125b-5p	miRNA	brucella.suis	brucellosis	The RAW264.7 macrophage	Brucella infection treatment	downregulated	27473222
14074	Mouse	mmu-miR-125b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	downregulated	30095204
14075	Mouse	mmu-miR-125b-5p	miRNA	high fat diet (HFD)	insulin resistance (IR)	heart tissue	high fat diet (HFD) feed	downregulated	30632304
14076	Mouse	mmu-miR-125b-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HT-22 cells	oxygen-glucose deprivation treatment	Overexpression of circRNA circUCK2 Attenuates Cell Apoptosis in Cerebral Ischemia-Reperfusion Injury via miR-125b-5p/GDF11 Signaling	33230465
14077	Mouse	mmu-miR-125b-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	HL-1 cells	hypoxia/reoxygenation (H/R) treatment	LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5.	32010261
14078	Mouse	mmu-miR-125b-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
14079	Mouse	mmu-miR-125b-5p	miRNA	learning	persistent memory	C57BL/6J mouse hippocampal	Object-location memory task	upregulated	28927503
14080	Mouse	mmu-miR-125b-5p	miRNA	high fat diet (HFD) and streptozotocin (STZ)	type 2 diabetes mellitus (T2DM)	pancreatic ¦Â-cells	high-fat diet plus low dosage of streptozotocin treatment	downregulated	30684546
14081	Mouse	mmu-miR-125b-5p	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	RAW264.7 cells	metformin (Met) treatment	Metformin might show anti-inflammatory effects in macrophages through the induction of Dicer and the subsequent upregulation of miR-34a-5p and miR-125b-5p.	31102492
14082	Mouse	mmu-miR-126	miRNA	CTCE-0214 (CTCE)	acute respiratory distress syndrome (ARDS)	lung	CTCE-0214 (CTCE) treatment	upregulated	27031787
14083	Mouse	mmu-miR-126	miRNA	atorvastatin	atherosclerosis (AS)	ApoE-/- mice carotid arterial wall	atorvastatin treatment	upregulated in carotid arterial wall	26886754
14084	Mouse	mmu-miR-126	miRNA	cigarette smoke (CS)	atherosclerosis (AS)	aortic tissues of ApoE KO mice	cigarette smoke (CS) exposure	downregulated	29642385
14085	Mouse	mmu-miR-126	miRNA	high fat diet (HFD)	atherosclerosis (AS)	apolipoprotein E-knockout mice	high fat diet (HFD) feed	downregulated	28713948
14086	Mouse	mmu-miR-126	miRNA	notoginsenoside R1 (NGR1)	atherosclerosis (AS)	serum;aorta	notoginsenoside R1 (NGR3) treatment	downregulated	24933211
14087	Mouse	mmu-miR-126	miRNA	E26 transformation-specific variant 2 (ETV2; also known as ER71)	cardiovascular lineage development	mouse embryonic stem cells (mESCs)	E26 transformation-specific variant 2 (ETV2; also known as ER71) treatment	upregulated	31744543
14088	Mouse	mmu-miR-126	miRNA	training	dexamethasone (DEX)-induced microvascular rarefaction	muscle	training	upregulated	31991160
14089	Mouse	mmu-miR-126	miRNA	high glucose (HG)	diabetic atherosclerosis	aorta	high glucose treatment	downregulated	27993686
14090	Mouse	mmu-miR-126	miRNA	ischemia	diabetic retinopathy (DR)	retina tissues	ischemia induced	miR-126 was significantly decreased in retina from OIR mice	21586283
14091	Mouse	mmu-miR-126	miRNA	high glucose (HG)	inflammation	macrophage	high glucose treatment	downregulated	27827458
14092	Mouse	mmu-miR-126	miRNA	high glucose (HG)	inflammation	human gingival fibroblasts	high (25 mmol/L) glucose	downregulated	28598282
14093	Mouse	mmu-miR-126	miRNA	high fat diet (HFD)	inflammatory response	skeletal muscle of mice	high fat diet (HFD) feed	"miR-375, miR-29, miR-320, miR-103/107 and miR-126, play a crucial role in the regulation of glucose and lipid metabolism through the control of pancreatic islet cell function"	22395471
14094	Mouse	mmu-miR-126	miRNA	danhong injection (DHI)	myocardial infarction (MI)	myocardial infarction (MI) mouse heart tissues	danhong injection (DHI) treatment	upregulated	31629250
14095	Mouse	mmu-miR-126	miRNA	exercise training (ET)	myocardial infarction (MI)	Bone marrow-derived endothelial progenitor cells (EPCs) were isolated from the MI mice after 4 weeks of exercise	Exercise training (ET) induce	upregulated	29265525
14096	Mouse	mmu-miR-126	miRNA	exercise training (ET)	myocardial infarction (MI)	MI. C57BL/6 mice bone marrow-derived endothelial progenitor cells (EPCs)	r 4 weeks of exercise	upregulated	29265525
14097	Mouse	mmu-miR-126	miRNA	ischemia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Plasma	left anterior descending artery (LAD) ligation	HOTAIR aggravates myocardial IR by competitively binding SRSF1 with microRNA-126.	32964995
14098	Mouse	mmu-miR-126	miRNA	maternal diet	obesity and obesity-associated insulin resistance	adipose tissues	maternal diet-induced obesity on offspring adipose tissue insulin signalling treatment	expression in the aetiology of insulin resistance in later life is upregulated	24749062
14099	Mouse	mmu-miR-126	miRNA	exogenous ghrelin	peripheral arterial disease (PAD)	ischemic gastrocnemius tissues	exogenous ghrelin treatment	upregulated	32788622
14100	Mouse	mmu-miR-126	miRNA	mycobacterium tuberculosis (Mtb)	pulmonary tuberculosis (PTB)	lung tissues	mycobacterium tuberculosis (Mtb) treatment	downregulated	33089914
14101	Mouse	mmu-miR-126	miRNA	pSTAT3-specific inhibitor AG-490	pulmonary tuberculosis (PTB)	lung tissues	pSTAT3-specific inhibitor AG-490 treatment	upregulated	33089914
14102	Mouse	mmu-miR-126	miRNA	SDF-1¦Á analog CTCE-0214 (CTCE)	sepsis	mouse with polymicrobial sepsis	EPC therapy treatment	upregulated in endothelial progenitor cells (EPCs)	24707934
14103	Mouse	mmu-miR-126	miRNA	resveratrol	type 2 diabetes mellitus (T2DM)	mouse insulinoma cell line Min6	resveratrol (RSV) treatment	The expression level of miR-126 was upregulated by RSV	29710530
14104	Mouse	mmu-miR-1264	miRNA	ischemia/reperfusion (I/R) 	acute ischemic and hemorrhagic stroke	mouse circulation	ischemia/reperfusion (I/R) treatment	upregulated	28193834
14105	Mouse	mmu-miR-126-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	alveolar type II (ATII) cells	lipopolysaccharide (LPS) treatment	upregulated	27146208
14106	Mouse	mmu-miR-126-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
14107	Mouse	mmu-miR-126a	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	serial transverse aortic sections	Shexiang Tongxin dropping pill (STDP) treatment	downregulated	25449459
14108	Mouse	mmu-miR-126a	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	(ApoE(-/-)) mice aortic	STDP (30 mg/kg/day) on atherosclerotic lesions treatment	downregulated	25449459
14109	Mouse	mmu-miR-126a	miRNA	doxorubicin (DOX)	breast cancer	breast tumor-bearing mice	doxorubicin treatment	upregulated	27345402
14110	Mouse	mmu-miR-126a	miRNA	whole grain highland barley (WGH)	type 2 diabetes mellitus (T2DM)	liver tissues	whole grain highland barley (WGH) treatment	downregulated	33104141
14111	Mouse	mmu-miR-126a-3p	miRNA	lipopolysaccharide (LPS)	endotoxemia-induced vascular injury	aortas tissues	lipopolysaccharide (LPS) treatment	downregulated	26968021
14112	Mouse	mmu-miR-126a-5p	miRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	aortas	angiotensin II (Ang II) treatment	miR-126a-5p expression was significantly lower in AAA tissues than in control aortas.	32291538
14113	Mouse	mmu-miR-126a-5p	miRNA	ischemia/reperfusion (I/R) 	ischemia/reperfusion (I/R) injury	mouse serum	ischemia/reperfusion (I/R) treatment	upregulated in the serum	29212219
14114	Mouse	mmu-miR-127	miRNA	blast	blast traumatic brain injury (bTBI)	Balb/c mice	blast treatment	dysregulated	29020847
14115	Mouse	mmu-miR-127	miRNA	doxorubicin (DOX)	heart failure (HF)	myocardial tissues	doxorubicin (DOX) treatment	upregulated	30272299
14116	Mouse	mmu-miR-127	miRNA	ginkgo biloba extract (GBE)	hepatocellular carcinoma (HCC)	non-tumor (ENT) liver	ginkgo biloba extract (GBE) treatment	upregulated	32306082
14117	Mouse	mmu-miR-127	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	irritable bowel syndrome (IBS)	mouse interstitial cells of Cajal (ICC)	tumor necrosis factor alpha (TNF-¦Á) treatment	MiR-127 upregulated largely reversed the effects of TUG1 on TNF-¦Á-treated ICC.	30657572
14118	Mouse	mmu-miR-127	miRNA	lipopolysaccharide (LPS)	lung injury	"mouse bronchoalveolar lavage fluid, serum and lung tissue"	lipopolysaccharide (LPS) treatment	"upregulated in bronchoalveolar lavage fluid, serum and lung tissue"	28765901
14119	Mouse	mmu-miR-127	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	upregulated	25672270
14120	Mouse	mmu-miR-127	miRNA	piperine	osteoarthritis (OA)	ATDC5 cells	piperine treatment	Piperine reduced the expression of miR-127 in ATDC5 cells	29710511
14121	Mouse	mmu-miR-127	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	?PC-12 cell	lipopolysaccharide (LPS) treatment	"miR-127 was negatively regulated by TUG1. Effects of TUG1 on LPS-treated PC-12 cells were reversed by miR-127 overexpression. Besides, TUG1 inactivated NF-¦ÊB and p38MAPK pathways in LPS-treated PC-12 cells via down-regulating miR-127. Dynactin 4 and protein tyrosine phosphatase (PTP) were the target genes of miR-127. miR-127 regulated the NF-¦ÊB and p38MAPK pathways in PC-12 cells at least by targeting dynactin 4 and PTP."	31326411
14122	Mouse	mmu-miR-1271	miRNA	huaier extract	acute kidney injury (AKI)	kidney tissues	Huaier extract (HE) treatment	HE appreciably reduced the degree of kidney injury and fibrosis and restored the expression of the microRNA miR-1271 after IRI.	33457422
14123	Mouse	mmu-mir-127-3p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
14124	Mouse	mmu-miR-127-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Plasma	doxorubicin (DOX) treatment	downregulated	30627229
14125	Mouse	mmu-miR-127-5p	miRNA	arctigenin	endotoxic shock	Splenic myeloid-derived suppressor cells (MDSCs) were isolated from spleen of mice challenged by LPS (10 ¦Ìg/g)	arctigenin treatment	upregulated	30143931
14126	Mouse	mmu-miR-127-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
14127	Mouse	mmu-miR-1278	miRNA	H2O2	myocardial infarction (MI)	newborn murine ventricular cardiomyocytes (NMVCs)	H2O2 treatment	"miR-1278 is low in H2O2-treated NMVCs and post-MI cardiac tissues, and the overexpression of miR-1278 in these protects against cell death by modulating IL-22 and CXCL14 expression."	33275986
14128	Mouse	mmu-miR-1278	miRNA	H2O2	myocardial infarction (MI)	newborn murine ventricular cardiomyocytes (NMVCs)	H2O2 treatment	The levels of miR-1278 were reduced in the infarct regions of heart tissues of the MI mouse model and in H2O2-treated newborn murine ventricular cardiomyocytes (NMVCs) compared to those in the heart tissues of healthy mice and non-treated NMVCs.	33275986
14129	Mouse	mmu-miR-128	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
14130	Mouse	mmu-miR-128	miRNA	Staphylococcus aureus	acute lung injury (ALI)	mouse lung tissues and RAW264.7 cells	Staphylococcus aureus (S. aureus) infection treatment	downregulated	30802676
14131	Mouse	mmu-miR-128	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	primary mouse cortical neurons (MCN) and Neuro2a (N2a) cells	amyloid-¦Â (A¦Â) treatment	upregulated	30328325
14132	Mouse	mmu-miR-128	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	mouse macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
14133	Mouse	mmu-miR-128	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	peritoneal macrophages; Bone-marrow derived macrophages (BMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28882869
14134	Mouse	mmu-miR-128	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	miR-128 expression was remarkably decreased in ox-LDL-incubated RAW264.7 cells.	30203508
14135	Mouse	mmu-miR-128	miRNA	neurotoxicant sodium valproate (VPA)	developmental toxicity	murine embryonic stem cells (mESCs)	neurotoxicant sodium valproate (VPA) treatment	downregulated	24896083
14136	Mouse	mmu-miR-128	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	downregulated	30095204
14137	Mouse	mmu-miR-128	miRNA	dexmedetomidine (DEX)	hypoxic/ischemic brain damage (HIBD)	hypoxia induced neonatal mice brain tissues	dexamethasone (DEX) treatment	upregulated	30875657
14138	Mouse	mmu-miR-128	miRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	neonatal mice brain tissues	hypoxia induce	downregulated	30875657
14139	Mouse	mmu-miR-128	miRNA	methamphetamine (METH)	methamphetamine (METH)-induced locomotor sensitization	nucleus accumbens (NAc)	repeated-intermittent METH exposure	A significant increase of miR-128 in the NAc of mice upon repeated-intermittent METH exposure but not acute METH administration.	32058631
14140	Mouse	mmu-miR-128	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	upregulated	18987751
14141	Mouse	mmu-miR-128	miRNA	spinal cord segment-derived conditioned medium (CM) of SCI (CM-SCI)	neuropathic pain (NP)	mouse microglial cell line BV2	CM-SCI treatment	downregulated	28114268
14142	Mouse	mmu-miR-128	miRNA	methamphetamine (METH)	neuroplasticity	mouse nucleus accumbens (NAc)	Methamphetamine (METH) treatment	We identified a significant increase of miR-128 in the NAc of mice upon repeated-intermittent METH exposure but not acute METH administration.	32058631
14143	Mouse	mmu-miR-128	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31889412
14144	Mouse	mmu-miR-128	miRNA	hypoxia	stress response	mouse myogenic C2C12 cells	hypoxia (2% O2) for 4?h	downregulated	29138682
14145	Mouse	mmu-miR-1281	miRNA	mycobacterium tuberculosis (Mtb)	pulmonary tuberculosis (PTB)	lung tissues	mycobacterium tuberculosis (Mtb) treatment	downregulated	33089914
14146	Mouse	mmu-miR-1281	miRNA	pSTAT3-specific inhibitor AG-490	pulmonary tuberculosis (PTB)	lung tissues	pSTAT3-specific inhibitor AG-490 treatment	upregulated	33089914
14147	Mouse	mmu-miR-128-1-5p	miRNA	anandamide and norgestimate	depression	chronic mild stress (CMS) model of depression mouse	anandamide and norgestimate treatment	upregulated	28716528
14148	Mouse	mmu-miR-128-1-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
14149	Mouse	mmu-miR-128-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	TCMK-1 cells	lipopolysaccharide (LPS) treatment	upregulated	32500307
14150	Mouse	mmu-miR-128-3p	miRNA	angiotensin II (Ang II)	atrial fibrosis	mouse atrial tissues	angiotensin II (Ang II) treatment	LncRNA PVT1 promotes atrial fibrosis via miR-128-3p-SP1-TGF-¦Â1-Smad axis in atrial fibrillation.	30894138
14151	Mouse	mmu-miR-128-3p	miRNA	doxorubicin (DOX)	liver damage	Alpha mouse liver 12 (AML-12) cells	doxorubicin (Dox)?treatment	upregulated	31112750
14152	Mouse	mmu-miR-128-3p	miRNA	FTY720-C2	parkinson's disease (PD)	dopaminergic MN12D cells	FTY720-C2 treatment	upregulated	30359694
14153	Mouse	mmu-miR-128-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	hippocampus	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"We found that Axin1 was upregulated in hippocampal tissues and cells of the MPTP-lesioned mouse model of PD, while Hif1a and miR-128-3p were downregulated."	32167488
14154	Mouse	mmu-miR-128-3p	miRNA	FTY720-C2	parkinson's disease (PD)	MN9D cells	FTY720-C2 treatment	upregulated	30359694
14155	Mouse	mmu-miR-128-3p	miRNA	learning	persistent memory	C57BL/6J mouse hippocampal	Object-location memory task	upregulated	28927503
14156	Mouse	mmu-miR-1286	miRNA	GANT61	osteosarcoma (OS)	"OS cells (SaOS-2 , U2OS)"	GANT61 treatment	"In vivo experiments further confirmed that GANT61 inhibited tumor growth and RAB13 expression, but enhanced miRNA-1286. The study demonstrated that GANT61 inhibited cell aggressive phenotype and tumor growth by inducing oxidative stress through the miRNA-1286/RAB31 axis."	32936498
14157	Mouse	mmu-miR-129	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	brain tissues	amyloid-¦Â (A¦Â) 25-35 treatment	"Elevated H19, HMGB1 and decreased miR-129 were found in A¦Â25-35-treated PC12 cells as well as in brain tissues of AD mice."	33410377
14158	Mouse	mmu-miR-129	miRNA	dexamethasone (DEX)	Alzheimer's disease (AD)	hippocampal tissues	dexamethasone (DEX) treatment	Dex administration resulted in the enhancement of miR-129 expression with declined hippocampal neuron apoptosis and attenuated cognitive impairment in A¦Â1-42-injected mice.	32839917
14159	Mouse	mmu-miR-129	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	upregulated	19462682
14160	Mouse	mmu-miR-129	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	Wild-type (C57BL/6J) mice	angiotensin II (Ang II) treatment	downregulated	28213404
14161	Mouse	mmu-miR-129	miRNA	GYY4137	hypertensive nephropathy (HN)	Wild-type (C57BL/6J) mice	were treated with GYY4137 for 4 wk	upregulated	28213404
14162	Mouse	mmu-miR-129	miRNA	trinitrobenzene sulfonic acid (TNBS)	inflammatory bowel disease (IBD)	colon tissues	trinitrobenzene sulphonic acid (TNBS) treatment	downregulated	31945730
14163	Mouse	mmu-miR-129	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain samples	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30260025
14164	Mouse	mmu-miR-129	miRNA	resveratrol	parkinson's disease (PD)	Parkinson's disease (PD) mice midbrain samples	resveratrol (RS) treatment	upregulated	30260025
14165	Mouse	mmu-miR-129	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
14166	Mouse	mmu-miR-129	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
14167	Mouse	mmu-miR-1291	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
14168	Mouse	mmu-miR-129-1-3p	miRNA	doxycycline	c-Src-mediated tumor progression	HCT116 cells; HT29 cells	doxycycline treatment	c-Src promotes tumor progression through downregulated of microRNA-129-1-3p	31799727
14169	Mouse	mmu-miR-129-1-3p	miRNA	pirarubicin (THP)	pirarubicin (THP) cardiotoxicity	HL-1 cells	Pirarubicin (THP) treatment	downregulated	31957170
14170	Mouse	mmu-miR-129-1-3p	miRNA	alpinia oxyphylla extract (AOE)	type 2 diabetes mellitus (T2DM)	db-/db- mouse kidney	A. oxyphylla extract (AOE) treatment	downregulated	28249617
14171	Mouse	mmu-miR-129-3p	miRNA	osteopontin (OPN)	rheumatoid arthritis (RA)	Osteoblasts	Osteopontin (OPN)treatment	downregulated	27851983
14172	Mouse	mmu-miR-129-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	murine alveolar epithelial cell line (MLE)-12 cells	lipopolysaccharide (LPS) treatment	downregulated	32682121
14173	Mouse	mmu-miR-129-5p	miRNA	physical exercise	Alzheimer's disease (AD)	hippocampus	physical exercise treatment	miR-129-5p is significantly upregulated by physical exercise	32434194
14174	Mouse	mmu-miR-129-5p	miRNA	trichostatin A (TSA)	cell division	hearts	trichostatin A (TSA) treatment	upregulated	26946427
14175	Mouse	mmu-miR-129-5p	miRNA	ultraviolet (UV) irradiation	corneal epithelium impairment	corneal epithelial cells (CECs)	ultraviolet ray treatment	upregulated	30515795
14176	Mouse	mmu-miR-129-5p	miRNA	ultraviolet (UV) irradiation	corneal epithelium impairment	corneal epithelial cells (CECs)	ultraviolet ray treatment	upregulated	30515795
14177	Mouse	mmu-miR-129-5p	miRNA	anandamide and norgestimate	depression	chronic mild stress (CMS) model of depression mouse	anandamide and norgestimate treatment	downregulated	28716528
14178	Mouse	mmu-miR-129-5p	miRNA	lipopolysaccharide (LPS)	LPS-induced podocyte apoptosis	MPC5 cells	lipopolysaccharide (LPS) treatment	Podocytes with LPS significantly inhibits the expression of miR-129-5p.	33039954
14179	Mouse	mmu-miR-129-5p	miRNA	low choline (LC)	neural progenitor cell (NPC) self-renewal	Neural progenitor cells were isolated from embryonic ED 14 brains	low choline (LC) treatment	upregulated	30521373
14180	Mouse	mmu-miR-129-5p	miRNA	low choline (LC)	neurogenesis	cortical neural progenitor cell (NPC)	low choline (LC) treatment	upregulated	30521373
14181	Mouse	mmu-miR-129-5p	miRNA	alcohol	nonalcoholic fatty liver disease (NAFLD)	AML-12 cells	Lieber-DeCarli alcohol treatment	NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis	33228663
14182	Mouse	mmu-miR-129-5p	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	mouse liver tissues	methionine-choline-deficient (MCD) treatment	Liver tissues from mice fed a methionine-choline-deficient (MCD) diet exhibited increased expression of NEAT1 and PEG3 along with lower miR-129-5p expression.	33574830
14183	Mouse	mmu-miR-129-5p	miRNA	lipopolysaccharide (LPS)	secondary injury after spinal cord injury (SCI)	BV-2 cells	lipopolysaccharide (LPS) treatment	miR-129-5p alleviated SCI in mice via suppressing the apoptosis and inflammatory response through HMGB1//TLR4/NF-¦ÊB pathway.	32096822
14184	Mouse	mmu-miR-129-5p	miRNA	laparotomy and exposure of the junc_x0002_tion between the large and small intestines	sepsis	mouse large and small intestines	laparotomy and exposure of the junc_x0002_tion between the large and small intestines treatment	downregulated	25043848
14185	Mouse	mmu-miR-1297	miRNA	sevoflurane (SEV)	neurotoxicity	mouse neurons	sevoflurane treatment	"In sevoflurane-exposed mice, miR-1297 expression was upregulated compared with the control group"	33843359
14186	Mouse	mmu-miR-1298	miRNA	ischemia/reperfusion (I/R) 	acute ischemic and hemorrhagic stroke	mouse circulation	ischemia/reperfusion (I/R) treatment	upregulated	28193834
14187	Mouse	mmu-miR-130	miRNA	cyclosporine A (CsA)	nephrotoxicity	mouse kidney	cyclosporine A treatment	upregulated	28414804
14188	Mouse	mmu-miR-130	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	hepatocellular carcinoma (HCC)	white adipose tissues	TNF¦Á treatment	"Primary transcripts of miR-130 were increased after TNF¦Á stimulation,p65 binding to the promoter regions of miR-130 was enhanced after TNF¦Á treatment"	24396868
14189	Mouse	mmu-miR-1306-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
14190	Mouse	mmu-miR-130a	miRNA	alcohol	alcoholic hepatitis (AH)	sera	alcohol exposure	upregulated	26264599
14191	Mouse	mmu-miR-130a	miRNA	antibiotics	allergic airway diseases (AAD)	bronchoalveolar lavage fluid (BALF)	antibiotics treatment	downregulated	29702281
14192	Mouse	mmu-miR-130a	miRNA	angiotensin II (Ang II)	cardiac fibrosis	mice	angiotensin II (Ang II) treatment	upregulated	29114000
14193	Mouse	mmu-miR-130a	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	mouse enterocytes	adherent invasive escherichia coli (AIEC) treatment	upregulated	24148619
14194	Mouse	mmu-miR-130a	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart tissues	doxorubicin (Dox) treatment	The expression of miR-130a increases sharply upon Dox treatment.	29988029
14195	Mouse	mmu-miR-130a	miRNA	iron	iron deficiency	liver tissues	iron-deficient diet? treatment	liver expression of the microRNA is upregulated	25002578
14196	Mouse	mmu-miR-130a	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	cultured mouse primary hepatocytes	free fatty acid (FFA) treatment	downregulated	31064820
14197	Mouse	mmu-miR-130a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31064820
14198	Mouse	mmu-miR-130a	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	pulmonary arterial endothelial cells (PAEC)	MCT treated 3M	upregulated	28755990
14199	Mouse	mmu-miR-130a-3p	miRNA	ovalbumin (OVA)	asthma	pulmonary macrophages	ovalbumin (OVA) treatment	downregulated	32524675
14200	Mouse	mmu-miR-130a-3p	miRNA	high glucose (HG)	glomerulonephritis	Mice MPC5 podocytes	high glucose (HG) treatment	downregulated	29434693
14201	Mouse	mmu-miR-130a-3p	miRNA	paraquat (PQ)	paraquat (PQ)-induced acute lung injury and pulmonary fibrosis	MLE-12 cells	paraquat (PQ) treatment	downregulated	32741895
14202	Mouse	mmu-miR-130a-3p	miRNA	high glucose (HG)	podocyte injury	mouse podocytes	high glucose (HG) treatment	Ablation of lncRNA MIAT mitigates high glucose-stimulated inflammation and apoptosis of podocyte via miR-130a-3p/TLR4 signaling axis.	32972755
14203	Mouse	mmu-miR-130a-3p	miRNA	hypoxia	postmyocardial infarction	AC16 cells	hypoxia treatment	miR-130a-3p was underexpressed in post-MI myocardial cells.	29226319
14204	Mouse	mmu-miR-130a-3p	miRNA	oxygen	retinopathy of prematurity (ROP)	C57BL/6 neonatal mice retinal tissue	7-day-old mice were maintained in 75% oxygen conditions for 5 days treatment	dysregulatedin retinal tissue	27922698
14205	Mouse	mmu-miR-130a-5p	miRNA	influenza virus	H5N2 influenza virus infection	lung tissues	H5N2 treatment	upregulated	25266911
14206	Mouse	mmu-miR-130a-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	Mouse brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	downregulated	32627090
14207	Mouse	mmu-miR-130b	miRNA	H2O2	Alzheimer's disease (AD)	Primary hippocampal neuron cells	H2O2 treatment	upregulated	24423585
14208	Mouse	mmu-miR-130b	miRNA	H2O2	Alzheimer's disease (AD)	senescence accelerated mouse prone 8 (SAMP8) and prone 10 (SAMP10)	"different concentrations (0, 100, 200, 400 and 800 ¦ÌM) of H2O2 treatment"	upregulated	24423585
14209	Mouse	mmu-miR-130b	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
14210	Mouse	mmu-miR-130b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29172088
14211	Mouse	mmu-miR-130b	miRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	brain tissues	middle cerebral artery occlusion (MCAO) treatment	downregulated	28804561
14212	Mouse	mmu-miR-130b	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	glomerular mesangial cells (MC)	TGF-¦Â1 treatment	downregulated	25204661
14213	Mouse	mmu-miR-130b	miRNA	particle	osteolysis	MC3T3-E1 cells	particle treatment	upregulated	28382864
14214	Mouse	mmu-miR-130b	miRNA	ortho-silicic acid	osteoporosis	MC3T3-E1 cell; C2C12 cells	ortho-silicic acid treatment	MiR-130b is upregulated during the osteogenesis by the applicationof ortho-silicic acid.	33130075
14215	Mouse	mmu-miR-130b	miRNA	Co-Cr-Mo alloy particles	periprosthetic osteolysis	Raw264.7 cells and bone marrowderived macrophages (BMM)	Co-Cr-Mo alloy particles treatment	upregulated	30488739
14216	Mouse	mmu-miR-130b-3p	miRNA	extracellular cold-inducible RNA-binding protein (eCIRP)	inflammation	serum	extracellular cold-inducible RNA-binding protein (eCIRP) treatment	upregulated	31724825
14217	Mouse	mmu-miR-130b-3p	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	macrophage polarization	RAW 264.7 cells	interferon-¦Ã (IFN-¦Ã) and lipopolysaccharide (LPS) treatment	downregulated	32853398
14218	Mouse	mmu-miR-130b-3p	miRNA	aldosterone	renal fibrosis	mouse cortical collecting duct cells	aldosterone treatment (10-6 M; 3 days)	upregulated	29070573
14219	Mouse	mmu-miR-130b-3p	miRNA	aldosterone	renal fibrosis	mouse cortical collecting duct cells	aldosterone treatment (10-6 M; 3 days)	dysregulated	29070573
14220	Mouse	mmu-miR-132	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
14221	Mouse	mmu-miR-132	miRNA	soluble A¦Â oligomers	Alzheimer's disease (AD)	cultured primary neurons	soluble A¦Â oligomers treatment	downregulated	31669733
14222	Mouse	mmu-miR-132	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	primary neurons	amyloid-¦Â (A¦Â) treatment	Soluble A¦Â oligomers decreased miR-132 expression and increased HDAC3 levels in cultured primary neurons.	31669733
14223	Mouse	mmu-miR-132	miRNA	melatonin	Alzheimer's disease (AD)	primary cortical neurons	melatonin treatment	A¦Â25-35 exposure significantly decreased the expression of miR-132.	29322615
14224	Mouse	mmu-miR-132	miRNA	oleanolic acid (OLA)	anhedonic and anxiogenic behaviours	hippocampal neuronal	3-week oleanolic acid treatment	upregulated	25079084
14225	Mouse	mmu-miR-132	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	serial transverse aortic sections	Shexiang Tongxin dropping pill (STDP) treatment	downregulated	25449459
14226	Mouse	mmu-miR-132	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	(ApoE(-/-)) mice aortic	STDP (30 mg/kg/day) on atherosclerotic lesions treatment	downregulated	25449459
14227	Mouse	mmu-miR-132	miRNA	hypoxia	blood-brain barrier (BBB) dysfunction	mouse brain microvascular endothelial cells (BMEC)	hypoxia induce	upregulated	30617994
14228	Mouse	mmu-miR-132	miRNA	angiotensin II (Ang II)	cardiac remodeling	mice heart tissues	angiotensin II (Ang II) treatment	upregulated	31325434
14229	Mouse	mmu-miR-132	miRNA	klotho	cardiac remodeling	Ang II-treated mice heart tissues	klotho treatment	downregulated	31325434
14230	Mouse	mmu-miR-132	miRNA	TGF-¦Â1 inhibitor LY364947	cardiac remodeling	Ang II-treated mice heart tissues	TGF-¦Â1 inhibitor LY364947 treatment	downregulated	31325434
14231	Mouse	mmu-miR-132	miRNA	melatonin	cell proliferation	hippocampus dentate gyrus tissues	melatonin treatment	upregulated	31169197
14232	Mouse	mmu-miR-132	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	colitis-associated colon cancer (CAC)	"colon, spleen and lymph nodes"	"2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	29017096
14233	Mouse	mmu-miR-132	miRNA	"3,3'-diindolylmethane (DIM)"	colitis-associated colon cancer (CAC)	"mouse colon, spleen and lymph nodes"	"3,3'-diindolylmethane (DIM) treatment"	upregulated	29017096
14234	Mouse	mmu-miR-132	miRNA	duloxetine	depression	frontal lobe and hippocampus	duloxetine treatment	upregulated	26823914
14235	Mouse	mmu-miR-132	miRNA	lipopolysaccharide (LPS)	depression	lateral ventricle	lipopolysaccharide (LPS) treatment	downregulated	27378528
14236	Mouse	mmu-miR-132	miRNA	gallic acid (GA)	experimental autoimmune encephalomyelitis (EAE)	"The CD4+CD62L+ T cells were isolated from the spleen and cultured under Th17-polarizing conditions, and peritoneal macrophages were stimulated with LPS"	?gallic acid (GA)?treatment treatment	upregulated	31026283
14237	Mouse	mmu-miR-132	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	26639663
14238	Mouse	mmu-miR-132	miRNA	lipopolysaccharide (LPS)	inflammatory injury	HT-22 cells	lipopolysaccharide (LPS) treatment	miR-132 was downregulated by LPS in HT-22 cells	29377244
14239	Mouse	mmu-miR-132	miRNA	¦Ã-rays	ionizing radiation (IR) injury	mouse hippocampal neuronal HT22 cells	¦Ã-rays treatment	downregulated	25329592
14240	Mouse	mmu-miR-132	miRNA	ischemia	ischemic injury	mouse cortex	ischaemic preconditioning (IP) treatment	downregulated	20010955
14241	Mouse	mmu-miR-132	miRNA	deoxycorticosterone acetate (DOCA)	kidney damage	hypertensive mice kidneys and urine	injection of Deoxycorticosterone acetate (Doca)	upregulated in the kidneys and urine	29255279
14242	Mouse	mmu-miR-132	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	29100790
14243	Mouse	mmu-miR-132	miRNA	TGF-¦Â	liver fibrosis	Isolated primary cultured mouse hepatocytes	TGF-¦Â treatment	downregulated	29100790
14244	Mouse	mmu-miR-132	miRNA	cAMP-response element binding protein (CREB)	neuronal morphogenesis	PC12 cells and neonatal rat cortical neurons	cAMP-response element binding protein (CREB) treatment	CREB-regulated miRNA regulates neuronal morphogenesis by responding to extrinsic trophic cues	16260724
14245	Mouse	mmu-miR-132	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	C57bl/6J mice liver	high fat diet (HFD) feed	upregulated	28381526
14246	Mouse	mmu-miR-132	miRNA	H2O2	oxidative stress	mouse oocytes	were exposed to 25 ?M H2O2 treatment	downregulated	24963165
14247	Mouse	mmu-miR-132	miRNA	glutamate	pain	primary neurons in the spinal cord of mouse embryos	100 ¦Ìmol/L glutamate	upregulated	28244951
14248	Mouse	mmu-miR-132	miRNA	exogenous ghrelin	peripheral arterial disease (PAD)	ischemic gastrocnemius tissues	exogenous ghrelin treatment	upregulated	32788622
14249	Mouse	mmu-miR-132	miRNA	anandamide (AEA)	pro-inflammatory activity	mouse	anandamide treatment	AEA differentil regulate the expression of miRNA	24699635
14250	Mouse	mmu-miR-132	miRNA	CREB activator forskolin	renin-angiotensin-aldosterone system regulation	MMDD-1 cells	CREB activator Forskolin treatment	CREB activator Forskolin induces miR-132 expression after 24 h.	32409785
14251	Mouse	mmu-miR-132	miRNA	CREB-inhibitor 666-15	renin-angiotensin-aldosterone system regulation	MMDD-1 cells	CREB-inhibitor 666-15 treatment	CREB-inhibitor 666-15 reduces low salt induced miR-132 expression.	32409785
14252	Mouse	mmu-miR-132	miRNA	Salt inducible kinase inhibitor MRT67307	renin-angiotensin-aldosterone system regulation	MMDD-1 cells	Salt inducible kinase inhibitor MRT67307 treatment	Salt inducible kinase inhibitor MRT67307 increases high-salt-reduced miR-132 expression	32409785
14253	Mouse	mmu-miR-132	miRNA	brain-derived neurotrophic factor (BDNF)	retinocollicular/tectal map formation	retinal ganglion cell (RGC)	brain-derived neurotrophic factor (BDNF) treatment	upregulated	24431455
14254	Mouse	mmu-miR-132	miRNA	cigarette smoke (CS)	rheumatoid arthritis (RA)	Th17 cells	cigarette smoke (CS) exposure	CS markedly increased the expression of miR-132 in the Th17 cells from the lymph nodes of AIA mice.	33443169
14255	Mouse	mmu-miR-132	miRNA	cigarette smoke extract (CSE)	rheumatoid arthritis (RA)	Th17 cells	cigarette smoke extract (CSE) treatment	we show that?microRNA-132?is specifically induced in Th17 cells in the presence of either AhR agonist or CS-enriched medium.	33443169
14256	Mouse	mmu-miR-132-3p	miRNA	H2O2	acute myocardial infarction (AMI)	primary cardiomyocytes	H2O2 treatment	LncRNA TUG1 mediates ischemic myocardial injury by targeting miR-132-3p/HDAC3 axis.	31858814
14257	Mouse	mmu-miR-132-3p	miRNA	H2O2	acute myocardial infarction (AMI)	mouse primary cardiomyocytes	hydrogen peroxide (H2O2) treatment	"miR-132-3p was downregulated, whereas TUG1 upregulated in H2O2-challenged cardiomyocytes."	31858814
14258	Mouse	mmu-miR-132-3p	miRNA	gravitational mechanical unloading	disuse osteopenia	bone marrow-derived mesenchymal stem cells (BMSCs)	gravitational mechanical unloading	upregulated	32054528
14259	Mouse	mmu-miR-132-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32955644
14260	Mouse	mmu-miR-132-3p	miRNA	angiostrongylus cantonensis (A. cantonensis)	inflammation	male Balb/c mice	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24142285
14261	Mouse	mmu-miR-132-3p	miRNA	folic acid	kidney injury and fibrosis	kidney cortex	folic acid treatment	upregulated	26707937
14262	Mouse	mmu-miR-132-3p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
14263	Mouse	mmu-miR-133	miRNA	hydrocinnamoyl-L-valyl pyrrolidine (AS-1)	cardiac hypertrophy	hypertrophic cardiomyocytes	hydrocinnamoyl-L-valyl pyrrolidine (AS-1) treatment	downregulated	31015570
14264	Mouse	mmu-miR-133	miRNA	streptozocin (STZ)	congenital heart disease (CHD)	C57BL/6 mice blood	injection of streptozotocin before mating treatment	dysregulated	27998767
14265	Mouse	mmu-miR-133	miRNA	sEHI t-AUCB (trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid)	myocardial infarction (MI)	muscle	sEHI t-AUCB (trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid) treatment	downregulated	29843720
14266	Mouse	mmu-miR-133-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	upregulated	30453253
14267	Mouse	mmu-miR-133a	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
14268	Mouse	mmu-miR-133a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	TCMK-1 cells	lipopolysaccharide (LPS) treatment	The miR-133a expression was decreased in TCMK-1 cells treated with LPS.	32196613
14269	Mouse	mmu-miR-133a	miRNA	fluticasone	asthma	chronic asthma mouse	fluticasone treatment	downregulated	29191361
14270	Mouse	mmu-miR-133a	miRNA	ovalbumin (OVA)	asthma	lung tissues	Ovalbumin treatment	downregulated	30146725
14271	Mouse	mmu-miR-133a	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	miR-133a was downregulated in asthma.	30146725
14272	Mouse	mmu-miR-133a	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aortas	high fat diet (HFD) feed	downregulated	29268138
14273	Mouse	mmu-miR-133a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 and MOVAS cells	ox-LDL treatment	downregulated	29268138
14274	Mouse	mmu-miR-133a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells; MOVAS cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29268138
14275	Mouse	mmu-miR-133a	miRNA	reversine	browning of white adipocytes	differentiated adipocytes from 3T3©\L1 cells	reversine treatment	downregulated	30132867
14276	Mouse	mmu-miR-133a	miRNA	reversine	browning of white adipocytes	3T3©\L1 cells	reversine treatment	downregulated	30132867
14277	Mouse	mmu-miR-133a	miRNA	hydrogen sulfide (H2S)	cardiac hypertrophy	HL1 cardiomyocytes cell line	Na2S treatment	upregulated	28623294
14278	Mouse	mmu-miR-133a	miRNA	fibroblast growth factor 18 (FGF18)	cell differentiation	mouse preosteoblasts	collagen membranes (CMs) containing FGF-18 treatment	downregulated	29544382
14279	Mouse	mmu-miR-133a	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	airway epithelial cells	cigarette smoke (CS) exposure	upregulated	30341388
14280	Mouse	mmu-miR-133a	miRNA	high carbon dioxide (CO2)	chronic obstructive pulmonary disease (COPD)	mouse airway smooth muscle cells	High carbon dioxide (CO2) treatment	downregulated	30185650
14281	Mouse	mmu-miR-133a	miRNA	sevoflurane (SEV)	cognitive impairment	primary hippocampal neuron cells	sevoflurane exposure treatment	The expression of miR-133a was increased with increasing concentrations of sevoflurane exposure	31264218
14282	Mouse	mmu-miR-133a	miRNA	sevoflurane (SEV)	cognitive impairment	Primary hippocampal neuron cells	"To establish an in vitro sevoflurane©\ induced neurotoxicity model, the primary hippocampal neuron cells were treated with different concentrations of sevoflurane for 6 hr treatment"	"miR-133a was the direct target of lncRNA Gm15621 In addition, we also found that Sox4 was a downstream target of miR-133a and lncRNA Gm15621 exerted its biological functions by regulating the expression of Sox4 In summary, our findings revealed that lncRNA Gm15621 ameliorated the sevoflurane-induced neurotoxicity and the important role of Gm15621/miR-133a/Sox4 axis in cognitive disorder"	31264218
14283	Mouse	mmu-miR-133a	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	downregulated	24464560
14284	Mouse	mmu-miR-133a	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	downregulated	24464560
14285	Mouse	mmu-miR-133a	miRNA	bortezomib	congenital muscular dystrophy	dy(3K)/dy(3K) mice	bortezomib? treatment	downregulated	24631023
14286	Mouse	mmu-miR-133a	miRNA	TGF-¦Â	coronary heart disease (CHD)	primary murine HSC	TGF-¦Â treatment	Treatment of primary murine and human HSC with transforming growth factor (TGF)-¦Â resulted in a significant downregulated of miR-133a in these cells	23183523
14287	Mouse	mmu-miR-133a	miRNA	neurotoxicant sodium valproate (VPA)	developmental toxicity	murine embryonic stem cells (mESCs)	neurotoxicant sodium valproate (VPA) treatment	upregulated	24896083
14288	Mouse	mmu-miR-133a	miRNA	high glucose (HG)	diabetes mellitus (DM)	wild type (WT) mice smooth muscle	treated with 30 mM glucose (HG)	downregulated	28678840
14289	Mouse	mmu-miR-133a	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	heart	expression in the hearts of streptozotocin-induced diabetic animals treatment	downregulated in the hearts	24428157
14290	Mouse	mmu-miR-133a	miRNA	concanamycin A (Con A)	fulminant hepatitis	Balb/c mice	conA injections of concanavalin A treatment	dysregulated	25034766
14291	Mouse	mmu-miR-133a	miRNA	regular physical activity	healthy metabolic profile	circulating exosomes	regular physical activity treatment	upregulated	33199621
14292	Mouse	mmu-miR-133a	miRNA	castrated	impaired metabolic flexibility in elderly individuals	male C57BL/6J mice	castrated treatment	upregulated	24478708
14293	Mouse	mmu-miR-133a	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	C57BL/6 mice colonic tissue	dextran-sulfate-sodium (DSS) treatment	downregulated	28104982
14294	Mouse	mmu-miR-133a	miRNA	synthetic Sulfonyl-Hydrazone-1	iPSC-derived cardiac differentiation	Murine fibroblast-derived iPSCs	Synthetic Sulfonyl-Hydrazone-1 treatment	"small chemical compounds, such as SHZ, can constitute a novel and clinically feasible strategy to improve iPSC-derived cardiac differentiation"	21445862
14295	Mouse	mmu-miR-133a	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	lung injury	normal alveolar epithelial cells	alveolar epithelial cells GM-CSF during hyperoxia treatment	downregulated	24371146
14296	Mouse	mmu-miR-133a	miRNA	botulinum toxin A (BTXA)	muscle atrophy	quadriceps muscle	botulinum toxin A (BTXA) treatment	downregulated	30427927
14297	Mouse	mmu-miR-133a	miRNA	prolonged aerobic exercise	muscle hypertrophy	plasma	"impact of extended-duration, submaximal aerobic exercise treatment"	upregulated	24436293
14298	Mouse	mmu-miR-133a	miRNA	heme oxygenase-1 (HMOX1)	myoblast differentiation	C2C12 cells	Heme oxygenase-1 (HMOX1) treatment	downregulated	21827279
14299	Mouse	mmu-miR-133a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R mice myocardial tissues	The myocardial I/R injury was induced by temporary ligation of the left anterior descending coronary artery.	downregulated	31734557
14300	Mouse	mmu-miR-133a	miRNA	ischemia/reperfusion (I/R) 	myocardial ischaemic injury	mouse plasma;Bone marrow-derived macrophage (BMDM);Rat neonatal CMs	ischemia/reperfusion (I/R) treatment	differently regulated	28768728
14301	Mouse	mmu-miR-133a	miRNA	erythropoietin (EPO)	obesity and glucose homeostasis	high-fat diet (HFD) C57BL/6J mice	intraperitoneal injection of recombinant human EPO (200 IU/kg)thrice a week for four weeks	downregulated	28288167
14302	Mouse	mmu-miR-133a	miRNA	dietary methionine restriction (MR)	osteoblast differentiation and function	"male C57BL/6J mice bone marrow,plasma and liver"	fed diets containing 0.86% or 0.12% methionine for 5 weeks	"upregulated (miR-31 in plasma and liver, and miR-133a, miR-335-5p, and miR-204 in the bone marrow"	27191548
14303	Mouse	mmu-miR-133a	miRNA	Sodium Tanshinone IIA Sulfonate (STS)	peripheral arterial disease (PAD)	ischemic hindlimb in diabetic mice	Sodium Tanshinone IIA Sulfonate (STS) treatment	downregulated	31623833
14304	Mouse	mmu-miR-133a	miRNA	cecal ligation and puncture (CLP)	polymicrobial sepsis	C57Bl/6 mice	cecal ligation and puncture (CLP) treatment	different regulation	24413579
14305	Mouse	mmu-miR-133a	miRNA	progesterone (P4)	cell proliferation	mouse endometrial epithelial cells	progesterone treatment	upregulated	27458709
14306	Mouse	mmu-miR-133a	miRNA	progesterone (P4)	cell proliferation	endometrial epithelial cells	progesterone treatment	upregulated	27458709
14307	Mouse	mmu-miR-133a	miRNA	low salt (LS)	expression regulation	kidney tissues	low salt (LS) treatment	Expression of miR-133a was decreased in mice given LS.	33131307
14308	Mouse	mmu-miR-133a	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 macrophages	lipopolysaccharide (LPS) treatment	MiRNA-133a aggravates inflammatory responses in sepsis by targeting SIRT1.	32771944
14309	Mouse	mmu-miR-133a	miRNA	reversine	reversine-induced dedifferentiation	C2C12 murine myoblasts	reversine treatment	downregulated	24513286
14310	Mouse	mmu-miR-133a	miRNA	growth factor-1 receptor	vascular smooth muscle cell migration and proliferation	vascular smooth muscle cell	growth factor-1 receptor? treatment	"In atherosclerosis induced by ApoE deficiency, reduced miR-133a expression is associated with lower IGF-1R levels and suppressive VSMC growth"	24401233
14311	Mouse	mmu-miR-133a*	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	lung injury	normal alveolar epithelial cells	alveolar epithelial cells GM-CSF during hyperoxia treatment	downregulated	24371146
14312	Mouse	mmu-miR-133a*	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
14313	Mouse	mmu-mir-133a-1-3p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
14314	Mouse	mmu-mir-133a-1-5p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
14315	Mouse	mmu-mir-133a-2-3p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
14316	Mouse	mmu-miR-133a-3p	miRNA	intranasal instillation	asthma	lung and bronchial tissues	intranasal instillation treatment	downregulated	28267638
14317	Mouse	mmu-miR-133a-3p	miRNA	guanidinoacetic acid (GAA)	cell differentiation	C2C12 cells	Guanidinoacetic acid (GAA) treatment	downregulated	30235878
14318	Mouse	mmu-miR-133a-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Plasma	doxorubicin (DOX) treatment	downregulated	30627229
14319	Mouse	mmu-miR-133a-3p	miRNA	pilocarpine	epilepsy	blood and brain	pilocarpine treatment	upregulated	32590288
14320	Mouse	mmu-miR-133a-3p	miRNA	cold	obesity	brown adipose tissue (BAT)	cold treatment	downregulated	33015181
14321	Mouse	mmu-miR-133b	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	Nasal mucosa tissues;serum	intraperitoneal sensitization and intranasal challenge with ovalbumin (OVA)	downregulated	28662502
14322	Mouse	mmu-miR-133b	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation (OGD) treatment	"Circ_HECTD1 knockdown inhibited the expression of TRAF3 by targeting miR-133b, thereby attenuating neuronal injury caused by cerebral ischemia"	33148417
14323	Mouse	mmu-miR-133b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"The results showed that the expression of circ-HECTD1 and tumor necrosis factor receptor-associated factor 3 (TRAF3) was remarkably upregulated, while miR-133b was downregulated in oxygen-glucose deprivation (OGD)-induced HT22 cells and mouse middle cerebral artery occlusion (MCAO) model circ-HECTD1 knockdown relieved OGD-caused neuronal cell death in vitro Simultaneously, circ-HECTD1 knockdown improved cerebral infarction volume and neuronal apoptosis in MCAO mice"	33148417
14324	Mouse	mmu-miR-133b	miRNA	regular physical activity	healthy metabolic profile	circulating exosomes	regular physical activity treatment	upregulated	33199621
14325	Mouse	mmu-miR-133b	miRNA	low pH	hypoxia-induced extracellular acidosis	RAW 264.7 cells	low pH treatment	Only the upregulated of the miR-133b by low pH was seen in all normal cells.	30178347
14326	Mouse	mmu-miR-133b	miRNA	castrated	impaired metabolic flexibility in elderly individuals	male C57BL/6J mice	castrated treatment	upregulated	24478708
14327	Mouse	mmu-miR-133b	miRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	lung cancer cells	drug treatment	lung carcinogen NNK exposure changes the expression of serum miRNAs. Serum miR-206 and miR-133b could be associated with lung carcinogenesis induced by NNK	23337359
14328	Mouse	mmu-miR-133b	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF)	lung injury	normal alveolar epithelial cells	alveolar epithelial cells GM-CSF during hyperoxia treatment	downregulated	24371146
14329	Mouse	mmu-miR-133b	miRNA	botulinum toxin A (BTXA)	muscle atrophy	quadriceps muscle	botulinum toxin A (BTXA) treatment	downregulated	30427927
14330	Mouse	mmu-miR-133b	miRNA	heme oxygenase-1 (HMOX1)	myoblast differentiation	C2C12 cells	Heme oxygenase-1 (HMOX1) treatment	downregulated	21827279
14331	Mouse	mmu-miR-133b	miRNA	rotenone (ROT)	parkinson's disease (PD)	mouse MN9D cells	rotenone treatment	"Interference of SNHG14 reduced rotenone-induced DA neuron damage through miR-133b in MN9D cells and ¦Á-syn was responsible for the protective effect of miR-133b Similarly, interference of SNHG14 mitigated neuron injury in PD mouse model"	31683259
14332	Mouse	mmu-miR-133b	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	neonatal mouse cardiomyocytes	infect with CVB virus	downregulated	29096746
14333	Mouse	mmu-mir-133b-3p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
14334	Mouse	mmu-miR-133b-3p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	peripheral blood monocytes	murine cytomegalovirus (MCMV) infection	downregulated	33245094
14335	Mouse	mmu-miR-133b-3p	miRNA	perfluorooctanoic acid	testicular toxicity	BALB/c mice testes tissue	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	28126411
14336	Mouse	mmu-miR-134	miRNA	bisphenol A (BPA)	aging	mouse embryoid bodies (mEB)	bisphenol A (BPA) treatment	downregulated	24090592
14337	Mouse	mmu-miR-134	miRNA	hypoxia	cerebral ischemia injury (CII)	brain tissues	middle cerebral artery occlusion (MCAO) treatment	dysregulated	25003713
14338	Mouse	mmu-miR-134	miRNA	duloxetine	depression	frontal lobe and hippocampus	duloxetine treatment	downregulated	26823914
14339	Mouse	mmu-miR-134	miRNA	pilocarpine	epilepsy	hippocampus	pilocarpine treatment	upregulated	24874920
14340	Mouse	mmu-miR-134	miRNA	pilocarpine	epilepsy	intracerebroventricular	pilocarpine treatment	status epilepticus induced by pilocarpine was associated with upregulation of miR-134 within the hippocampus of mice	24874920
14341	Mouse	mmu-miR-134	miRNA	triclosan (TCS)	general cytotoxicity	mouse embryonic stem cells (mESC)	were acutely exposed to TCS for 24 h treatment	upregulated	24879426
14342	Mouse	mmu-miR-134	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse brain tissues	oxygen-glucose deprivation (OGD) treatment	upregulated	25304362
14343	Mouse	mmu-miR-134	miRNA	choline- and folate-deficient (CFD) diet	liver damage	plasma	choline- and folate-deficient (CFD) diet treatment	upregulated	26878785
14344	Mouse	mmu-miR-134	miRNA	prolonged aerobic exercise	muscle hypertrophy	plasma	"impact of extended-duration, submaximal aerobic exercise treatment"	upregulated	24436293
14345	Mouse	mmu-miR-134	miRNA	choline- and folate-deficient (CFD) diet	nonalcoholic fatty liver disease (NAFLD)	plasma	choline- and folate-deficient (CFD) treatment	upregulated	26878785
14346	Mouse	mmu-miR-134	miRNA	retinoic acid (RA)	susceptibility of tumour cells to natural killer cell-mediated cytotoxicity	mouse embryonic stem cells (mESCs)	?retinoic acid treatment	upregulated	17916804
14347	Mouse	mmu-miR-134-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	upregulated	32684588
14348	Mouse	mmu-miR-134-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	"ventral midbrains, mouse dopaminergic neuronal cell line MN9D"	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"circDLGAP4 exerted its functions via regulating miR-134-5p, circDLGAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway both in human and mouse."	31761328
14349	Mouse	mmu-miR-134-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	miR-134-5p was verified to be increased in PD animal.	31761328
14350	Mouse	mmu-miR-134-5p	miRNA	angiotensin II (Ang II)	thoracic aortic dissection (TAD)	aorta specimens	angiotensin II (Ang II) treatment	downregulated	30951965
14351	Mouse	mmu-miR-135-5p	miRNA	cold	obesity	brown adipose tissue (BAT)	cold treatment	downregulated	33015181
14352	Mouse	mmu-miR-135a	miRNA	chronic intermittent hypoxia (CIH)	aortic endothelial function	aortic endothelial cells	chronic intermittent hypoxia (CIH) treatment	MEG3 suppresses the apoptosis of aortic endothelial cells in mice with chronic intermittent hypoxia via downregulated of HIF-1¦Á by competitively binding to microRNA-135a.	32642094
14353	Mouse	mmu-miR-135a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29663503
14354	Mouse	mmu-miR-135a	miRNA	fibroblast growth factor 18 (FGF18)	cell differentiation	mouse preosteoblasts	collagen membranes (CMs) containing FGF-18 treatment	downregulated	29544382
14355	Mouse	mmu-miR-135a	miRNA	antidepressant	depression and anxiety disorders	adult mouse	antidepressant treatment	upregulated	24952960
14356	Mouse	mmu-miR-135a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells; mouse tubular epithelial cells	high glucose (HG) treatment	miR-135a expression was markedly upregulated in tubular epithelial cells cultured in high-glucose conditions.	33203695
14357	Mouse	mmu-miR-135a	miRNA	adriamycin (ADR)	focal segmental glomerulosclerosis (FSGS)	mouse	adriamycin (ADR) treatment	upregulated	28949388
14358	Mouse	mmu-miR-135a	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colon tissues	dextran sodium sulfate (DSS) treatment	downregulated	29636643
14359	Mouse	mmu-miR-135a	miRNA	H2O2	oxidative stress	hippocampal HT-22 cells	H2O2 treatment	upregulated	31728857
14360	Mouse	mmu-miR-135a	miRNA	paeoniflorin	oxidative stress	H2O2-treated hippocampal HT-22 cells	Paeoniflorin (PF) treatment	downregulated	31728857
14361	Mouse	mmu-miR-135a	miRNA	ovalbumin (OVA) and urban particulate matter (PM)	pulmonary arterial hypertension (PAH)	mouse lung	"exposure to combined Th2 antigen (Ovalbumin, OVA) and urban particulate matter (PM) treatment"	upregulated	28415675
14362	Mouse	mmu-miR-135a*	miRNA	nonylphenol (NP)	tumorigenesis	Sertoli TM5 cells	nonylphenol (NP) treatment	upregulated	21914226
14363	Mouse	mmu-miR-135a-1*	miRNA	H1N1 influenza virus	endometriosis and endometrial carcinoma	mouse lung?tissues	H1N1 influenza virus infection	upregulated	24066118
14364	Mouse	mmu-miR-135a-5p	miRNA	Physical exercise	age-related cognitive decline	neural precursor cells (NPCs) of the mouse dentate gyrus (DG)	Physical exercise treatment	downregulated	31130358
14365	Mouse	mmu-miR-135a-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	heart tissues	doxorubicin (DOX) treatment	CircRNA-Arhgap12 could sponge miR-135a-5p in mouse cardiomyocytes during DOX-induced cardiotoxicity.	33245966
14366	Mouse	mmu-miR-135a-5p	miRNA	hydrogen sulfide (H2S)	MPTP-induced mouse subacute	astrocytic	H2S treatment	downregulated	27842305
14367	Mouse	mmu-miR-135a-5p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
14368	Mouse	mmu-miR-135b	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	Neonatal mice cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	30037628
14369	Mouse	mmu-miR-135b	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	plasma and colon tissues	azoxymethane (AOM) treatment	upregulated	30311185
14370	Mouse	mmu-miR-135b	miRNA	lactobacillus acidophilus and bifidobacterium bifidum probiotics	colorectal cancer (CRC)	plasma and colon tissues from azoxymethane (AOM)-treated mice	Lactobacillus acidophilus and Bifidobacterium bifidum probiotics treatment	downregulated	30311185
14371	Mouse	mmu-miR-135b	miRNA	helicobacter pylori (H. pylori)	gastric MALT lymphoma (GML)	GML-developing d3Tx mice stomachs	infect with H. pylori	upregulated	28560185
14372	Mouse	mmu-miR-135b	miRNA	N-ethyl-N-nitrosourea (ENU)	hepatocellular carcinoma (HCC)	liver tissues	N-ethyl-N-nitrosourea (ENU) treatment	downregulated	21029445
14373	Mouse	mmu-miR-135b	miRNA	cigarette smoke or nontypeable Haemophilus influenzae (NTHi)	cell proliferation	lung tissue	cigarette smoke or nontypeable Haemophilus influenzae (NTHi) treatment	upregulated	23440414
14374	Mouse	mmu-miR-135b	miRNA	H2O2	myocardial infarction (MI)	Primary cultured neonatal mice ventricular cardiomyocytes (NMVCs)	hydrogen peroxide (H2O2) treatment	downregulated	31870781
14375	Mouse	mmu-miR-135b-5p	miRNA	dexamethasone (DEX)	asthma	lung tissues	dexamethasone (Dex) treatment	miR-135b-5p was upregulated in the Dex group compared with that in the Model group.	32222886
14376	Mouse	mmu-miR-135b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-135b-5p expression was significantly decreased in hippocampal neurons receiving OGD/R treatment	30002689
14377	Mouse	mmu-miR-135b-5p	miRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	mouse gastric tissue	Helicobacter pylori infection	upregulated	29985646
14378	Mouse	mmu-miR-135b-5p	miRNA	osteogenic differentiation medium	osteoporosis	MC3T3-E1 cells	osteogenic differentiation medium induction	downregulated	32010267
14379	Mouse	mmu-miR-135b-5p	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colonic tissues	dextran sulfate sodium (DSS) treatment	upregulated	32779953
14380	Mouse	mmu-miR-136	miRNA	high-content hydrogen water (HHW)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high-content hydrogen water (HHW) treatment	MiR-136 was downregulated in NAFLD mice model after HHW treatment.	29261513
14381	Mouse	mmu-miR-136	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	orchitis	testicular cells	poly I:C treatment	downregulated	31195953
14382	Mouse	mmu-miR-136	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	?murine chondrogenic ATDC5 cell	lipopolysaccharide (LPS) treatment	upregulated	30074264
14383	Mouse	mmu-miR-136-5p	miRNA	IL-17	inflammation	C57BL/6 mouse astrocytes	IL-17 (100ng/ml) for various periods of time (0-48 hours) and at various doses (0-200 ng)	upregulated	28355611
14384	Mouse	mmu-miR-136-5p	miRNA	barium chloride	muscle injury	C2C12 cells	barium chloride treatment	upregulated	32954829
14385	Mouse	mmu-miR-137	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	Mouse hippocampal neuron HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33746585
14386	Mouse	mmu-miR-137	miRNA	qingda granule (QDG)	ischemic stroke (IS)	oxygen-glucose deprivation/reoxygenation (OGD/R) treated HT22 cells	Qingda granule (QDG) treatment	upregulated	33746585
14387	Mouse	mmu-miR-137	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	Neuro2a (N2a) cells	amyloid-¦Â (A¦Â) treatment	downregulated	28655611
14388	Mouse	mmu-miR-137	miRNA	isorhapontigenin (ISO)	bladder cancer	Human bladder cancer cell line UMUC3	isorhapontigenin (ISO)treatment	upregulated	26832795
14389	Mouse	mmu-miR-137	miRNA	H2O2	cardiomyocyte apoptosis	cardiomyocyte	H2O2 treatment	upregulated	26566162
14390	Mouse	mmu-miR-137	miRNA	propofol (PPF)	cell apoptosis and autophagy	HT-22 cells	Propofol treatment	upregulated	31678238
14391	Mouse	mmu-miR-137	miRNA	kainic acid (KA)	convulsive seizures	hippocampal neural stem/progenitor cells (NSPCs)	kainic acid (KA) treatment	upregulated	30837840
14392	Mouse	mmu-miR-137	miRNA	neurotoxicant sodium valproate (VPA)	developmental toxicity	murine embryonic stem cells (mESCs)	neurotoxicant sodium valproate (VPA) treatment	downregulated	24896083
14393	Mouse	mmu-miR-137	miRNA	pentylenetetrazol (PTZ)	epilepsy	temporal neocortex; hippocampus	pentylenetetrazol (PTZ) treatment	downregulated	29894770
14394	Mouse	mmu-miR-137	miRNA	pilocarpine	epilepsy	temporal neocortex; hippocampus	pilocarpine treatment	downregulated	29894770
14395	Mouse	mmu-miR-137	miRNA	vaccinium bracteatum Thunb.(VBT)	gluconeogenesis	mouse liver	VBT treatment	downregulated in liver	28946187
14396	Mouse	mmu-miR-137	miRNA	olive leaf extract (OLE)	hypertension and inappropriate antidiuretic hormone secretion (SIADH)	kidneys tissues	Olive Leaf Extract (OLE) treatment	?In vivo experiments revealed that treatment with OLE increases the expression of the CaSR mRNA and decreases AQP2 mRNA paralleled by an increase of the AQP2-targeting miRNA-137.	33633156
14397	Mouse	mmu-miR-137	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse primary brain neurons	oxygen-glucose deprivation (OGD) treatment	miR-137 expression was significantly decreased in neurons exposed to OGD compared with their control groups	29307821
14398	Mouse	mmu-miR-137	miRNA	resveratrol	neuroblastoma (NB)	neuroblastoma cell line Neuro-2a (N-2a) cells	RSV treatment	upregulated	25505154
14399	Mouse	mmu-miR-137	miRNA	extra-virgin olive oil rich in phenols (H-EVOO)	neuronal function	cortex	H-EVOO treatment	upregulated	26695409
14400	Mouse	mmu-miR-137	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	mouse serum exosomes	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	31301273
14401	Mouse	mmu-miR-137	miRNA	H2O2	spinal cord injury (SCI)	C8-D1A and C8-B4 cells	hydrogen peroxide	downregulated	29125882
14402	Mouse	mmu-miR-137	miRNA	H2O2	spinal cord injury (SCI)	C8-D1A and C8-B4 cells	H2O2 treatment	downregulated	29125882
14403	Mouse	mmu-miR-137	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	downregulated	26426744
14404	Mouse	mmu-miR-137-3p	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	primary cardiomyocytes	oxygen glucose deprivation (OGD) treatment	downregulated	32371945
14405	Mouse	mmu-miR-137-3p	miRNA	bupivacaine	neurotoxicity	C57BL/6 mice dorsal root ganglion neurons (DRGNs)	bupivacaine treatment	downregulated	28899795
14406	Mouse	mmu-miR-138	miRNA	concanamycin A (Con A)	acute liver injury (ALI)	liver macrophage	Concanamycin A (Con A)?treatment	upregulated	31152110
14407	Mouse	mmu-miR-138	miRNA	H2O2	acute spinal cord injury (ASCI)	BV-2 cells	H2O2 treatment	"After treatment of various concentrations of H2O2, the cell viabilities were reduced, and miR-138 expression was downregulated."	29749242
14408	Mouse	mmu-miR-138	miRNA	coxsackievirus B3 (CVB3)	acute viral myocarditis (VM)	mouse myocardium; primary cardiomyocytes	Coxsackievirus B3 (CVB3) infection	lncRNA HIF1A-AS1 promotes NF-¦ÊB signaling and subsequently aggravates cardiomyocyte apoptosis and inflammation via targeting miR-138.	33224748
14409	Mouse	mmu-miR-138	miRNA	P. aeruginosa strain PAO1	bacterial infection	lung tissues	P. aeruginosa strain PAO1 treatment	upregulated	29945883
14410	Mouse	mmu-miR-138	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	H9C2 cells	hypoxia/reoxygenation (H/R) treatment	lncRNA ROR sponges miR-138 to aggravate H/R-induced myocardial cell injury by upregulating the expression of Mst1.	32240614
14411	Mouse	mmu-miR-138	miRNA	hyperoside	hypoxia-induced cardiac dysfunctions	H9C2 cells	Hyperoside (Hyp) treatment	The expression levels of miR-138 were increased in the hypoxic myocardium in the presence of Hyp	33649812
14412	Mouse	mmu-miR-138	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 macrophages	lipopolysaccharide (LPS) treatment	upregulated	30157481
14413	Mouse	mmu-miR-138	miRNA	morphine	morphine induced neuroinflammation	mouse primary astrocytes	morphine treatment	upregulated	33304479
14414	Mouse	mmu-miR-138	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	heart tissues	The left anterior descending branch of LCA was ligated.	downregulated	31602205
14415	Mouse	mmu-miR-138	miRNA	H2O2	osteoporotic injury of osteoblasts	MC3T3-E1 cells	H2O2 treatment	upregulated	29291636
14416	Mouse	mmu-miR-138-5p	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	27074385
14417	Mouse	mmu-miR-138-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	serum	lipopolysaccharide (LPS) treatment	upregulated	32934950
14418	Mouse	mmu-miR-138-5p	miRNA	propofol (PPF)	cognitive function	Primary neonatal mouse oligodendrocyte (OLGs)	propofol treatment	upregulated	33411226
14419	Mouse	mmu-miR-138-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	Primary astrocyte	oxygen-glucose deprivation (OGD)-induce treatment	downregulated	31485266
14420	Mouse	mmu-miR-138-5p	miRNA	cigarette smoke extract (CSE)	male infertility	Leydig and Sertoli cells	cigarette smoke?extract?(CSE) treatment	Quantitative polymerase chain reaction and Western blot assays showed a negative correlation between miR-138-5p and Caspase-3 expression.	33856081
14421	Mouse	mmu-miR-138-5p	miRNA	dexmedetomidine (DEX)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	mouse myocardial tissues	?dexmedetomidine (Dex)? treatment	"Dex improved cardiac function, alleviated myocardial damage, reduced inflammatory factor contents, collagen fibers, and Ltb4r1 expression while increased miR-138-5p expression in myocardial tissues of mice with MI/RI"	33509010
14422	Mouse	mmu-miR-138-5p	miRNA	high fat diet (HFD)	obesity	preadipocyte	high fat diet (HFD) feed	"CircSAMD4A regulated preadipocyte differentiation by acting as a miR-138-5p sponge, and thus increasing EZH2 expression."	32292524
14423	Mouse	mmu-miR-138-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	mouse chondrocytes	IL-1¦Â treatment	downregulated	29305974
14424	Mouse	mmu-miR-138-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	ATDC5 cells	IL-1¦Â treatment	MiR-138-5p was downregulated in ATDC5 cells.	31486753
14425	Mouse	mmu-miR-139	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	BV-2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-139 was significantly downregulated whereas c-Jun was obviously upregulated after OGD/R treatment.	32807449
14426	Mouse	mmu-miR-139	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
14427	Mouse	mmu-miR-139	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
14428	Mouse	mmu-miR-139-3p	miRNA	mechanical unloading	bone loss	MC3T3-E1 cells	Mechanical unloading treatment	LncRNA ODSM-mediated regulation of osteoblast apoptosis and differentiation partially depends on miR-139-3p under MG unloading conditions.	32071307
14429	Mouse	mmu-miR-139-3p	miRNA	urocortin 1 (Ucn-1)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R mosue	administration of Ucn-1 at the beginning of reperfusion treatment	downregulated	28827743
14430	Mouse	mmu-miR-139-5p	miRNA	high fat diet (HFD)	atherosclerosis (AS)	arterial tissues of mice	high fat diet (HFD) feed	downregulated	33331071
14431	Mouse	mmu-miR-139-5p	miRNA	Jiang Tang Xiao Ke Granule	diabetes mellitus (DM)	KKAy diabetic mice	Jiang Tang Xiao Ke Granule treatment	dysregulated	29163176
14432	Mouse	mmu-miR-139-5p	miRNA	high glucose (HG)	diabetes mellitus (DM)	Min6 cells	high glucose (HG) treatment	upregulated	31735337
14433	Mouse	mmu-miR-139-5p	miRNA	H1N1 influenza virus	endometriosis and endometrial carcinoma	mouse lung?tissues	H1N1 influenza virus infection	upregulated	24066118
14434	Mouse	mmu-miR-139-5p	miRNA	fructus meliae toosendan (FMT)	liver damage	eft lateral liver lobe	Fructus Meliae Toosendan (FMT) treatment	downregulated	26539117
14435	Mouse	mmu-miR-139-5p	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	upregulated	18987751
14436	Mouse	mmu-miR-139-5p	miRNA	25-hydroxycholesterol (25-HC)	osteoclastogenesis	mouse bone marrow macrophages (BMMs) cultured in receptor activator of NF-¦ÊB ligand (RANKL) and monocyte macrophage colony-stimulating factor (M-CSF)	25-hydroxycholesterol (25-HC) treatment	downregulated	28257846
14437	Mouse	mmu-miR-13a	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	plasma and colon tissues	azoxymethane (AOM) treatment	downregulated	30311185
14438	Mouse	mmu-miR-13a	miRNA	lactobacillus acidophilus and bifidobacterium bifidum probiotics	colorectal cancer (CRC)	plasma and colon tissues from azoxymethane (AOM)-treated mice	Lactobacillus acidophilus and Bifidobacterium bifidum probiotics treatment	upregulated	30311185
14439	Mouse	mmu-miR-1-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Plasma	doxorubicin (DOX) treatment	downregulated	30627229
14440	Mouse	mmu-miR-1-3p	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	plasma	acetaminophen (APAP) treatment	upregulated	30125006
14441	Mouse	mmu-miR-140	miRNA	ethanol (EtOH)	brain growth deficits associated with prenatal alcohol exposure	extracellular vesicles from neural stem cells (NSCs)	ethanol (EtOH) exposure	upregulated	31009095
14442	Mouse	mmu-miR-140	miRNA	TGF-¦Â3	cartilage defection	C3H10T1/2 mesenchymal stem cells (MSCs)	TGF-¦Â3 treatment	upregulated	29067438
14443	Mouse	mmu-miR-140	miRNA	interleukin-1 receptor antagonist protein (IRAP)	cartilage impact injury	porcine knee joint	Interleukin-1 Receptor Antagonist Protein (IRAP) treatment	upregulated	26521750
14444	Mouse	mmu-miR-140	miRNA	lipopolysaccharide (LPS)	hepatitis	liver tissues	lipopolysaccharide (LPS) treatment	?Microarray showed that lncRNA TUG1 was upregulated in LPS-induced hepatocyte inflammation.	33644034
14445	Mouse	mmu-miR-140	miRNA	high fat diet (HFD)	myofibroblast differentiation	mosue mammary adipose tissue	high fat diet (HFD) feed	downregulated in mammary adipose tissue	27895151
14446	Mouse	mmu-miR-140	miRNA	fluid shear stress (FSS)	osteoblastic differentiation	MC3T3-E1 cells	fluid shear stress (FSS)treatment	downregulated	23595392
14447	Mouse	mmu-miR-140	miRNA	endotoxin	sepsis	skeletal muscle tissue	endotoxin treatment	downregulated	31042421
14448	Mouse	mmu-miR-140-3p	miRNA	ovalbumin (OVA)	allergic bronchial asthma	bronchial smooth muscles (BSMs)	ovalbumin antigen treatment	downregulated	33121100
14449	Mouse	mmu-miR-140-3p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	downregulated	28396668
14450	Mouse	mmu-miR-140-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse ventricular cardiomyocytes (NMVCs)	angiotensin II (Ang II) treatment	miR-140-3p was markedly decreased in NMVCs with overexpression of circRNA_000203.	31397837
14451	Mouse	mmu-miR-140-3p	miRNA	ethanol (EtOH) and nicotine	chronic hepatitis C virus (HCV) infection	mouse fetal murine cerebral cortical	ethanol and nicotine treatment	downregulated	22458409
14452	Mouse	mmu-miR-140-3p	miRNA	lentivirus	collagen-induced arthritis (CIA)	synovial	lentivirus (LV) treatment	downregulated	26473405
14453	Mouse	mmu-miR-140-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	downregulated	30453253
14454	Mouse	mmu-miR-140-3p	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
14455	Mouse	mmu-miR-140-5p	miRNA	apigenin	acute kidney injury (AKI)	hypoxia/reoxygenation (H/R)-treated mouse renal tubular epithelial cells (mRTECs)	apigenin treatment	upregulated	33653497
14456	Mouse	mmu-miR-140-5p	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	mouse kidney	cisplatin treatment	upregulated	28928081
14457	Mouse	mmu-miR-140-5p	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	mouse renal tubular epithelial cells (mRTECs)	hypoxia/reoxygenation (H/R) treatment	downregulated	33653497
14458	Mouse	mmu-miR-140-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	30344669
14459	Mouse	mmu-miR-140-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	MLE-12 cells	lipopolysaccharide (LPS) treatment	downregulated	31769066
14460	Mouse	mmu-miR-140-5p	miRNA	shikonin	acute lung injury (ALI)	mouse MLE©\12 cell	Shikonin treatment	"Shikonin could improve acute lung injury induced by sepsis The mechanism might be correlation miRNA-140-5p expression increasing, and regulated targeted gene TLR4, with TLR4 expression depressing, the downstream myeloid differentiation protein 88 and nuclear factor ¦ÊB proteins expression were suppressed"	31769066
14461	Mouse	mmu-miR-140-5p	miRNA	shikonin	acute lung injury (ALI)	MLE-12 cells	Shikonin treatment	upregulated	31769066
14462	Mouse	mmu-miR-140-5p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	bone development	murine primary osteoblasts and MC3T3 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29604361
14463	Mouse	mmu-miR-140-5p	miRNA	lentivirus	collagen-induced arthritis (CIA)	synovial	lentivirus (LV) treatment	downregulated	26473405
14464	Mouse	mmu-miR-140-5p	miRNA	catalpol	diabetic cardiomyopathy (DCM)	high glucose (HG) treated mouse cardiomyocytes	catalpol treatment	"upregulated, overexpression of miR-140-5p or silencing of HDAC4 rescued Neat1-induced cardiomyocyte apoptosis"	31078585
14465	Mouse	mmu-miR-140-5p	miRNA	xuebijing (XBJ)	lung fibrosis	lung tissues	xuebijing (XBJ) treatment	XBJ administration upregulated miR-140-5p expression in mice with PQ-induced pulmonary fibrosis.	32462952
14466	Mouse	mmu-miR-140-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary mandibular condylar chondrocytes (MCCs)	IL-1¦Â treatment	upregulated	30728776
14467	Mouse	mmu-miR-140-5p	miRNA	fluid shear stress (FSS)	osteogenesis	MC3T3-E1 cells	Fluid shear stress (FSS)? treatment	miR-140-5p was significantly downregulated when MC3T3-E1 cells were exposed to FSS.	33588662
14468	Mouse	mmu-miR-140-5p	miRNA	Xuebijing (XBJ)	paraquat (PQ)-induced pulmonary fibrosis	lung tissues	Xuebijing (XBJ) treatment	XBJ administration upregulated miR-140-5p expression in mice with PQ-induced pulmonary fibrosis	32462952
14469	Mouse	mmu-miR-141	miRNA	melatonin	cardiac fibrosis	high glucose (HG)-treated cardiac fibroblasts (CFs)	Melatonin treatment	melatonin produces an antifibrotic effect via inhibiting lncR-MALAT1/miR-141-mediated NLRP3 inflammasome activation and TGF-¦Â1/Smads signaling	32067273
14470	Mouse	mmu-miR-141	miRNA	kainic acid (KA)	epilepsy	brain tissues	kainic acid treatment	miRNA-141 expression levels were increased in epilepsy mice.	30548678
14471	Mouse	mmu-miR-141	miRNA	shikonin	epithelial-mesenchymal transition (EMT)	mouse skin tissues	Shikonin treatment	downregulated	23861701
14472	Mouse	mmu-miR-141	miRNA	alcohol	intestinal injury and intestinal endotoxemia of alcoholic hepatitis	intestinal tissues	Lieber-Decarli alcohol feed	downregulated	31173169
14473	Mouse	mmu-miR-141	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	fed a methionine and choline deficient (MCD) diet for 2 week	upregulated in liver	29093267
14474	Mouse	mmu-miR-141	miRNA	bone morphogenetic protein 2 (BMP2)	preosteoblast differentiation	pre-osteoblast	bone morphogenetic protein 2 (BMP2) treatment	downregulated	19454767
14475	Mouse	mmu-miR-141	miRNA	X-rays	radiation-induced oral mucositis (RIOM)	tongue tissues	25 Gy X-ray irradiation treatment	upregulated	31346357
14476	Mouse	mmu-miR-141	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	diabetic heart tissues	?streptozotocin treatment	upregulated	23034391
14477	Mouse	mmu-miR-141	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	crohn disease (CD)	colon tissues	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated	24000293
14478	Mouse	mmu-miR-141-3p	miRNA	fatty acid amide hydrolase inhibitor (FAAH-II)	colitis	colitis mouse colon tissues	FAAH-II treatment	dysregulated	27327245
14479	Mouse	mmu-miR-141-3p	miRNA	aldose reductase	diabetic nephropathy (DN)	renal mesangial cells	aldose reductase treatment	upregulated	24161443
14480	Mouse	mmu-miR-141-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cells	high glucose (HG) treatment	LncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy.	32504027
14481	Mouse	mmu-miR-141-3p	miRNA	porcine cardiac myosin (PCM)	experimental autoimmune myocarditis (EAM)	heart tissues	porcine cardiac myosin (PCM) induce	downregulated	31225989
14482	Mouse	mmu-miR-141-3p	miRNA	D-glucose	osteoarthritis (OA)	ATDC5 cells	D-glucose treatment	downregulated	29319178
14483	Mouse	mmu-miR-141-3p	miRNA	coix seed Oil (CSO)	triple negative breast cancer (TNBC)	mouse triple-negative breast cancer (TNBC) tissues	coix Seed Oil (CSO) treatment	upregulated	33101013
14484	Mouse	mmu-miR-142	miRNA	Klebsiella pneumoniae	acute lung injury (ALI)	Bronchoalveolar lavage fluid (BALF) microvesicles (MVs)	Klebsiella pneumoniae infection	upregulated	31331947
14485	Mouse	mmu-miR-142	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Bronchoalveolar lavage fluid (BALF) microvesicles (MVs)	lipopolysaccharide (LPS) treatment	upregulated	31331947
14486	Mouse	mmu-miR-142	miRNA	amyloid-¦Â (A¦Â) 1-40	age-related macular degeneration (AMD)	C57BL/6 mice eye tissues	amyloid-¦Â (A¦Â) 1-40 treatment	upregulated	28324113
14487	Mouse	mmu-miR-142	miRNA	Glabridin (GLA)	breast cancer	MDA-MB-231 and BT-551 breast cancer cells	Glabridin (GLA) treatment	upregulation	24754877
14488	Mouse	mmu-miR-142	miRNA	doxycycline	colitis	colon tissues	doxycycline (DXC) treatment	upregulated	30076847
14489	Mouse	mmu-miR-142	miRNA	minocycline (MNC)	colitis	colon tissues	minocycline (MNC) treatment	upregulated	30076847
14490	Mouse	mmu-miR-142	miRNA	tigecycline (TGC)	colitis	colon tissues	tigecycline (TGC) treatment	upregulated	30076847
14491	Mouse	mmu-miR-142	miRNA	IL-15	innate immune response	type 1 innate lymphoid cells (ILCs) isolated from spleen tissues	Interleukin-15 (IL-15) treatment	upregulated	31402259
14492	Mouse	mmu-miR-142	miRNA	artesunate (ART)	ovarian cancer (OC)	peripheral CD4+ T cells and Th1 differentiation from CD4+ T cells	Artesunate treatment	upregulated	31038546
14493	Mouse	mmu-miR-142	miRNA	cecal ligation and puncture (CLP)	sepsis	mouse	cecal ligation and puncture (CLP) treatment	downregulated	29793310
14494	Mouse	mmu-miR-142	miRNA	catalpol	spinal cord injury (SCI)	BV2 cells	catalpol treatment	CTP was found to be upregulated miR-142 and the protective effects of CTP on apoptosis	33628189
14495	Mouse	mmu-miR-142-3p	miRNA	H2O2	acute myocardial infarction (AMI)	primary cultured cardiomyocytes	H2O2 treatment	downregulated	31145943
14496	Mouse	mmu-miR-142-3p	miRNA	borneol	asthma	CD4 + T cells	borneol treatment	Borneol inhibited CD4 + T cells infiltration in vivo and proliferation in vitro by downregulating miR-26a and miR-142-3p.	33272847
14497	Mouse	mmu-miR-142-3p	miRNA	borneol	asthma	CD4+ T cells isolated from the spleen of OVA-induced asthma mice	borneol treatment	Borneol inhibited CD4 + T cells infiltration in vivo and proliferation in vitro by downregulating miR-26a and miR-142-3p.	33272847
14498	Mouse	mmu-miR-142-3p	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin treatment	upregulated	29722559
14499	Mouse	mmu-miR-142-3p	miRNA	lipopolysaccharide (LPS)	cell death	BM cells	lipopolysaccharide (LPS) treatment	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality	21474672
14500	Mouse	mmu-miR-142-3p	miRNA	cholic acid (CA)	cholestasis	mouse liver	CA treatment	upregulated	28153841
14501	Mouse	mmu-miR-142-3p	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
14502	Mouse	mmu-miR-142-3p	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
14503	Mouse	mmu-miR-142-3p	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
14504	Mouse	mmu-miR-142-3p	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
14505	Mouse	mmu-miR-142-3p	miRNA	lipopolysaccharide (LPS)	hirschsprung's disease (HSCR)	neural precursor cells (NPCs)	lipopolysaccharides (LPS) treatment	downregulated	29956457
14506	Mouse	mmu-miR-142-3p	miRNA	flaxseed (FS)	inflammation	mouse exposed to X-ray	fed 10% FS or a 0% FS isocaloric control diet treatment	dysregulated	24755684
14507	Mouse	mmu-miR-142-3p	miRNA	histone deacetylase inhibitor trichostatin A (TSA)	inflammatory diseases	LPS-treated macrophages	histone deacetylase inhibitor trichostatin A treatment	upregulated	27788393
14508	Mouse	mmu-miR-142-3p	miRNA	licochalcone A (LA)	melanoma	B16 cells	licochalcone A (LCA) treatment	MiR- 142-3p level was significantly upregulated in LCA-treated B16 cells in a time- and dose-dependent manner	31793097
14509	Mouse	mmu-miR-142-3p	miRNA	ischemia/reperfusion (I/R) 	myocardial injury	cardiomyocyte M6200 cells	ischemia/reperfusion (I/R) treatment	downregulated	28025989
14510	Mouse	mmu-miR-142-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	chondrocytes	lipopolysaccharide (LPS) treatment	downregulated	27447821
14511	Mouse	mmu-miR-142-3p	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
14512	Mouse	mmu-miR-142-3p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
14513	Mouse	mmu-miR-142-3p	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell proliferation	mouse 3T3 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	25544846
14514	Mouse	mmu-miR-142-3p	miRNA	high inorganic phosphate (Pi)	uremia	blood of DBA/2 mice	high phosphate diet (HPD) feed	downregulated	30453118
14515	Mouse	mmu-miR-142-3p	miRNA	high inorganic phosphate (Pi)	vascular relaxation	blood of DBA/2 mice	high phosphate diet (HPD) feed	downregulated	30453118
14516	Mouse	mmu-miR-142-5p	miRNA	ovalbumin (OVA)	asthma	pulmonary macrophages	ovalbumin (OVA) treatment	upregulated	32524675
14517	Mouse	mmu-miR-142-5p	miRNA	oleanolic acid (OLA)	diabetic nephropathy (DN)	streptozotocin induced diabetic nephropathy (DN) mouse kidney tissues	oleanolic acid (OLA) treatment	downregulated	31410746
14518	Mouse	mmu-miR-142-5p	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
14519	Mouse	mmu-miR-142-5p	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
14520	Mouse	mmu-miR-142-5p	miRNA	pilocarpine	epilepsy	male NMRI mice	inject intraperitoneally with pilocarpine treatment	downregulated	25078263
14521	Mouse	mmu-miR-142-5p	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
14522	Mouse	mmu-miR-142-5p	miRNA	retinoid binding protein peptide 161-180	experimental autoimmune uveoretinitis (EAU)	ocular tissues	retinoid binding protein peptide 161-180 treatment	upregulated	20881307
14523	Mouse	mmu-miR-142-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31889412
14524	Mouse	mmu-miR-142-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31889412
14525	Mouse	mmu-miR-142-5p	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
14526	Mouse	mmu-miR-142-5p	miRNA	angiotensin II (Ang II)	cell proliferation	cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	downregulated	32268073
14527	Mouse	mmu-miR-142-5p	miRNA	TGF-¦Â1	cell proliferation	cardiac fibroblasts (CFs)	TGF-¦Â1 ttreatment treatment	downregulated	32268073
14528	Mouse	mmu-miR-142-5p	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	downregulated	22782705
14529	Mouse	mmu-miR-142-5p	miRNA	pilocarpine	temporal lobe epilepsy (TLE)	hippocampus	pilocarpine treatment	upregulated	32439493
14530	Mouse	mmu-miR-142a	miRNA	helicobacter pylori (H. pylori)	gastric MALT lymphoma (GML)	GML-developing d3Tx mice stomachs	infect with H. pylori	upregulated	28560185
14531	Mouse	mmu-miR-142a	miRNA	ischemia/reperfusion (I/R) 	myocardial ischaemic injury	mouse plasma;Bone marrow-derived macrophage (BMDM);Rat neonatal CMs	ischemia/reperfusion (I/R) treatment	differently regulated	28768728
14532	Mouse	mmu-miR-142a-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	ALI mice lung tissues and RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	31494298
14533	Mouse	mmu-miR-142a-3p	miRNA	methamphetamine (METH)	methamphetamine (METH)-mediated neurotoxicity	BV2 cells and mouse brain	Methamphetamine (METH) treatment	downregulated	30914375
14534	Mouse	mmu-miR-142a-5p	miRNA	genipin (GNP)	hyperlipidemia	obese mouse	GNP liver	upregulated	29197188
14535	Mouse	mmu-miR-142a-5p	miRNA	genipin (GNP)	hyperlipidemia	high fat diet-induced obese mice	genipin (GNP) treatment	upregulated	29197188
14536	Mouse	mmu-miR-143	miRNA	"3-Isobutyl_x0002_l-methylxanthine (MIX), dexamethasone (DEX)"	adipogenesis	3T3-L1cells	"adding 10 lg/ml insulin, 1 lM DEX, and 0.5 mM MIX treatment"	upregulated	25366176
14537	Mouse	mmu-miR-143	miRNA	angiotensin II (Ang II)	aortic dissection (AD)	mouse vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	downregulated	28167124
14538	Mouse	mmu-miR-143	miRNA	hepatic antigen S100	autoimmune hepatitis (AIH)	mouse liver tissues	hepatic antigen S100 treatment	Infection or transfection of mir-143 in mice or hepatocytes significantly attenuated the development of alleviation of hepatocyte injury.	31808606
14539	Mouse	mmu-miR-143	miRNA	estradiol-17¦Â (E2)	cervical cancer (CC)	Osteosarcoma Saos2 cell line	estradiol-17¦Â (E2) treatment	downregulated	27278606
14540	Mouse	mmu-miR-143	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues	dextran sodium sulfate (DSS) treatment	downregulated	29867475
14541	Mouse	mmu-miR-143	miRNA	probiotic Escherichia coli Nissle 1917 (EcN)	colitis	dextran sodium sulfate (DSS)-induced colitis mouse colon tissues	probiotic Escherichia coli Nissle 1917 (EcN) treatment	upregulated	29867475
14542	Mouse	mmu-miR-143	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	downregulated	24464560
14543	Mouse	mmu-miR-143	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	downregulated	24464560
14544	Mouse	mmu-miR-143	miRNA	high fat diet (HFD)	diabetes mellitus (DM)	mouse liver cells	high fat diet (HFD) treatment	downregulated	21441927
14545	Mouse	mmu-miR-143	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	downregulated	21584493
14546	Mouse	mmu-miR-143	miRNA	angelica polysaccharide (AP)	diabetes mellitus (DM)	TNF-¦Á-treated MIN6 cell line	angelica polysaccharide (AP) treatment	upregulated	31746030
14547	Mouse	mmu-miR-143	miRNA	carboxymethyllysine (CML)	diabetes mellitus (DM)	fibroblast cell line 3T3©\L1	carboxymethyllysine (CML) treatment	upregulated	27137869
14548	Mouse	mmu-miR-143	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetes mellitus (DM)	MIN6 cell line	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31746030
14549	Mouse	mmu-miR-143	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart tissues	doxorubicin (Dox) treatment	Doxorubicin treatment increased the expression of miR-143.	32170053
14550	Mouse	mmu-miR-143	miRNA	lipopolysaccharide (LPS)	hepatocyte injury	AML12 cells	lipopolysaccharide (LPS) treatment	Infection or transfection of mir-143 in mice or hepatocytes significantly attenuated the development of alleviation of hepatocyte injury.	31808606
14551	Mouse	mmu-miR-143	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colon tissues	dextran sulfate sodium (DSS) treatment	downregulated	30236870
14552	Mouse	mmu-miR-143	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary cortical neurons	oxygen-glucose deprivation (OGD) treatment	upregulated	30129112
14553	Mouse	mmu-miR-143	miRNA	listeria	Listeria infection	murine ileum tissues	Listeria infection	downregulated	24327339
14554	Mouse	mmu-miR-143	miRNA	high fat diet (HFD)	metastatic colorectal cancer (mCRC)	adipose tissue of mice	?high-fat diet treatment	the expression of miR-143 in the mesenteric fat was upregulated in mice fed a high-fat diet	18809385
14555	Mouse	mmu-miR-143	miRNA	6-Gingerol (6-G)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	HL-1 cells	6-Gingerol (6-G) treatment	we found that 6-G elevated cellular H19 expression in hypoxia/reoxygenation (H/R)-treated HL-1 cells.	33758383
14556	Mouse	mmu-miR-143	miRNA	methamphetamine (METH)	neuroinflammation	BV2 cells	Methamphetamine treatment	downregulated	30394308
14557	Mouse	mmu-miR-143	miRNA	methamphetamine (METH)	neuroinflammation	BV2 cells	methamphetamine (METH) treatment	downregulated	30394308
14558	Mouse	mmu-miR-143	miRNA	clozapine (CLZ)	phencyclidine-induced schizophrenia-related locomotor hyperactivity	"phencyclidine (PCP)-induced mice plasma, prefrontal cortex (PFC) and hippocampus"	clozapine treatment	upregulated	31233824
14559	Mouse	mmu-miR-143	miRNA	eticlopride	phencyclidine-induced schizophrenia-related locomotor hyperactivity	HT-22 neuronal cell line and primary cortical cultured neuronswere	eticlopride treatment	upregulated	31233824
14560	Mouse	mmu-miR-143	miRNA	phencyclidine (PCP)	phencyclidine-induced schizophrenia-related locomotor hyperactivity	"plasma, prefrontal cortex (PFC) and hippocampus"	phencyclidine (PCP) treatment	downregulated	31233824
14561	Mouse	mmu-miR-143	miRNA	quinpirole	phencyclidine-induced schizophrenia-related locomotor hyperactivity	HT-22 neuronal cell line and primary cortical cultured neuronswere	quinpirole treatment	downregulated	31233824
14562	Mouse	mmu-miR-143	miRNA	progesterone (P4)	cell proliferation	mouse endometrial epithelial cells	progesterone (P4) treatment	upregulated	29661100
14563	Mouse	mmu-miR-143	miRNA	cyclopamine	regulating the activity of Shh signaling	embryonic lung cultures	cyclopamine treatment	dysregulated	24617895
14564	Mouse	mmu-miR-143	miRNA	haloperidol	schizophrenia (SZ)	"phencyclidine (PCP)-induced mice plasma, prefrontal cortex (PFC) and hippocampus"	haloperidol treatment	upregulated	31233824
14565	Mouse	mmu-miR-143	miRNA	laparotomy and exposure of the junc_x0002_tion between the large and small intestines	sepsis	mouse large and small intestines	laparotomy and exposure of the junc_x0002_tion between the large and small intestines treatment	upregulated	25043848
14566	Mouse	mmu-miR-143	miRNA	radiation	thymic lymphoma (RITL)	BALB/c mice	radiation treatment	downregulated	28736328
14567	Mouse	mmu-miR-143	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	M(IL-4/IL-13) macrophages	Mycobacterium tuberculosis (Mtb) HN878 infection	upregulated	30941122
14568	Mouse	mmu-miR-143-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-143-3p was significantly upregulated during cerebral I/R injury both in vivo and in vitro	33709299
14569	Mouse	mmu-miR-143-3p	miRNA	"4,4'-methylenedianiline (MDA)"	cholestasis	plasma	"4,4'-Methylenedianiline (MDA) treatment"	upregulated	30125006
14570	Mouse	mmu-miR-143-3p	miRNA	thioacetamide (TAA)	cholestasis	plasma	thiacetamide (TAA) treatment	upregulated	30125006
14571	Mouse	mmu-miR-143-3p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	cholestasis	plasma	¦Á-naphthylisothiocyanate (ANIT) treatment	upregulated	30125006
14572	Mouse	mmu-miR-143-3p	miRNA	collagen	collagen-induced arthritis (CIA)	RA rats blood and the dorsal root ganglion (DRG)	collagen treatment	downregulated	30066874
14573	Mouse	mmu-miR-143-3p	miRNA	metformin (Met)	diabetic nephropathy (DN)	SV40-MES-13 cells	Metformin (MET) treatment	"Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-¦Â1 axis."	32391614
14574	Mouse	mmu-miR-143-3p	miRNA	fluke Fasciola gigantica (FgESPs)	F. gigantica infection	liver tissues	fluke Fasciola gigantica (FgESPs) infection	downregulated	33332355
14575	Mouse	mmu-miR-143-3p	miRNA	mycoplasma pneumoniae (M. pneumoniae)	fibromyalgia	lung tissues	Mycoplasma pneumoniae (MP) infection	"Compared with model group, model mice had upregulated miR-143-3p expression."	32597476
14576	Mouse	mmu-miR-143-3p	miRNA	hypoxanthine (HX)	hyperuricemia	renal tissues	The hyperuricemic mice mode were induced by combination of peritoneal injection of potassium oxonate (PO) at dose of 250 mg/kg and intragastric administration of hypoxanthine (HX) at dose of 300 mg/kg daily for 8 weeks.	downregulated	31378369
14577	Mouse	mmu-miR-143-3p	miRNA	potassium oxonate (PO)	hyperuricemia	renal tissues	The hyperuricemic mice mode were induced by combination of peritoneal injection of potassium oxonate (PO) at dose of 250 mg/kg and intragastric administration of hypoxanthine (HX) at dose of 300 mg/kg daily for 8 weeks.	downregulated	31378369
14578	Mouse	mmu-miR-143-3p	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
14579	Mouse	mmu-miR-143-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	29557526
14580	Mouse	mmu-miR-144	miRNA	angiotensin II (Ang II)	cardiac fibrosis	heart sissues	angiotensin II (Ang II) treatment	downregulated	32765685
14581	Mouse	mmu-miR-144	miRNA	erythropoietin (EPO)	chronic kidney disease (CKD)	renal fibroblasts	Erythropoietin (EPO) treatment	upregulated	26469975
14582	Mouse	mmu-miR-144	miRNA	cisplatin (DDP)	cisplatin (DDP)-induced nephrotoxicity	renal tissues	cisplatin treatment	downregulated	31781349
14583	Mouse	mmu-miR-144	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	heart sissues	streptozocin (STZ) treatment	MiR-144 was identified to be decreased in HG-induced cardiomyocytes and in streptozotocin (STZ)-challenged heart samples.	31907983
14584	Mouse	mmu-miR-144	miRNA	metformin (Met)	endometrial hyperplasia (EH)	endometrial tissues	metformin (Met) treatment	Met upregulateb the expression of miR-144 in a dose-dependent manner.	31894313
14585	Mouse	mmu-miR-144	miRNA	metformin (Met)	endometrial hyperplasia (EH)	endometrial hyperplasia (EH) mice uterus	metformin (Met) treatment	upregulated	31894313
14586	Mouse	mmu-miR-144	miRNA	tamoxifen (TAM)	endometrial hyperplasia (EH)	uterus	tamoxifen treatment	downregulated	31894313
14587	Mouse	mmu-miR-144	miRNA	streptozocin (STZ)	hyperglycemia	heart	STZ-induced diabetic mice treatment	downregulated	26164195
14588	Mouse	mmu-miR-144	miRNA	streptozocin (STZ)	hyperglycemia-induced cardiac dysfunction	heart tissues	streptozotocin (STZ) treatment	downregulated	31907983
14589	Mouse	mmu-miR-144	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	dorsal root ganglions (DRGs)	chronic constriction injury (CCI) treatment	downregulated	31737949
14590	Mouse	mmu-miR-144	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	upregulated	26426744
14591	Mouse	mmu-miR-144-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	miR-144-3p was upregulated at 24h.	32727087
14592	Mouse	mmu-miR-144-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	29492259
14593	Mouse	mmu-miR-144-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	miR-144-3p was upregulated while Caveolin-2 was downregulated in response to LPS treatment.	33418009
14594	Mouse	mmu-miR-144-3p	miRNA	7-chlorokynurenic acid (7-CTKA)	antidepressant	mouse	7-CTKA intraperitoneal injection	downregulated	25034119
14595	Mouse	mmu-miR-144-3p	miRNA	dietary zinc restriction	anxiety- and trauma-related disorders	C57BL/6 (BL6) mice	dietary zinc restriction	upregulated	28104225
14596	Mouse	mmu-miR-144-3p	miRNA	collagen	arthritis	mouse hind paws tissues	collagen treatment	downregulated	31396316
14597	Mouse	mmu-miR-144-3p	miRNA	moxibustion	collagen-induced arthritis (CIA)	CIA mouse hind paws tissues	Moxibustion treatment	upregulated	31396316
14598	Mouse	mmu-miR-144-3p	miRNA	chronic unpredictable mild stress (CUMS)	depression	prefrontal cortex	chronic unpredictable mild stress (CUMS) treatment	downregulated	27701406
14599	Mouse	mmu-miR-144-3p	miRNA	chronic unpredictable mild stress (CUMS)	depression	NAc tissue	chronic unpredictable mild stress (CUMS) treatment	upregulated	31430030
14600	Mouse	mmu-miR-144-3p	miRNA	electroacupuncture (EA)	electroacupuncture (EA)	CD4 T cells	electroacupuncture (EA) treatment	upregulated	32026263
14601	Mouse	mmu-miR-144-3p	miRNA	dietary zinc restriction	impaired fear extinction	basolateral amygdala	dietary zinc restriction	upregulated	28104225
14602	Mouse	mmu-miR-144-3p	miRNA	oxygen glucose deprivation (OGD)	ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation treatment	Overexpression of long non-coding RNA Rian attenuates cell apoptosis from cerebral ischemia-reperfusion injury via Rian/miR-144-3p/GATA3 signaling	33294587
14603	Mouse	mmu-miR-144-3p	miRNA	licochalcone A (LA)	lung cancer	MLE-12 cells	Licochalcone A (lico A) treatment	downregulated	32505917
14604	Mouse	mmu-miR-144-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
14605	Mouse	mmu-miR-144-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	HL-1 cardiomyocytes	hypoxia/reoxygenation (H/R) induce	downregulated	31227612
14606	Mouse	mmu-miR-144-3p	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	primary cardiomyocytes	oxygen glucose deprivation (OGD) treatment	downregulated	32371945
14607	Mouse	mmu-miR-144-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuronal cell injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29457851
14608	Mouse	mmu-miR-144-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	HL-1 cells	lipopolysaccharide (LPS) treatment	MiR-144-3p was downregulated in LPS-treated myocardial cells.	32016991
14609	Mouse	mmu-miR-144-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	macrophage RAW264.7 cells	Mycobacterium bovis Bacillus Calmette-Gu¨¦rin (BCG)	upregulated	28636635
14610	Mouse	mmu-miR-144-5p	miRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	aorta tissues	angiotensin II (Ang II) treatment	downregulated	32278833
14611	Mouse	mmu-miR-144-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	abdominal aortic aneurysm (AAA)	RAW 264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32278833
14612	Mouse	mmu-miR-145	miRNA	JWH-133	acute liver failure (ALF)	GalN/LPS-induced ALF	JWH-133 treatment	downregulated	25749929
14613	Mouse	mmu-miR-145	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	angiogenesis	mouse brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	the levels of lncRNA-MALAT1 and miR-145 were upregulated in OGD-induced BMECs miR-145 functioned as an anti-angiogenic and pro-apoptotic factor in OGD treated BMECs via down-regulating VEGF-A and ANGPT2 directly	30038058
14614	Mouse	mmu-miR-145	miRNA	angiotensin II (Ang II)	aortic dissection (AD)	mouse vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	downregulated	28167124
14615	Mouse	mmu-miR-145	miRNA	sevoflurane (SEV)	apoptosis	hippocampal neural cell line HT22	treat with 4.1% sevoflurane treatment	downregulated	31966430
14616	Mouse	mmu-miR-145	miRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblasts	angiotensin II (Ang II) treatment	downregulated	30146700
14617	Mouse	mmu-miR-145	miRNA	coronary artery ligation	cardiac fibrosis	heart	subjected to coronary artery ligation	miR-145 expression was downregulated at 3 days but was restored at 7 days	24001939
14618	Mouse	mmu-miR-145	miRNA	IL-10	cardiac fibrosis	mouse bone marrow fibroblast progenitor cells (BM-FPCs)	IL10 treatment	downregulated	28667100
14619	Mouse	mmu-miR-145	miRNA	doxorubicin (DOX)	cardiotoxicity	BALB/c mice injected C-26 tumor cells	doxorubicin treatment	upregulated	28560697
14620	Mouse	mmu-miR-145	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	MA-C cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"TUG1 could interact directly with miR-145, and downregulated of miR-145 could efficiently reverse the function of TUG1 siRNA on AQP4 expression"	31709761
14621	Mouse	mmu-miR-145	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	downregulated	24464560
14622	Mouse	mmu-miR-145	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	downregulated	24464560
14623	Mouse	mmu-miR-145	miRNA	myostatin	cell differentiation	C2C12 cells	1 ¦Ìg of recombinant myostatin	dysregulated	28691106
14624	Mouse	mmu-miR-145	miRNA	isoproterenol	extracellular matrices (ECMs) homeostasis	the hearts of TAC mice	isoproterenol treatment	downegulated	23624080
14625	Mouse	mmu-miR-145	miRNA	H2O2	granulosa cell (GC) apoptosis	mouse granulosa cells (mGCs)	H2O2 treatment	downregulated	28564582
14626	Mouse	mmu-miR-145	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	MA-C cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31709761
14627	Mouse	mmu-miR-145	miRNA	fentanyl	ischemia/reperfusion (I/R) injury	"HL-1, a cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte"	fentanyl treatment	upregulated	27862640
14628	Mouse	mmu-miR-145	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	downregulated	27289031
14629	Mouse	mmu-miR-145	miRNA	solar-simulated UV (ssUV)	melanogenesis	Murine melan-a melanocytes(from black mice)	solar-simulated UV (ssUV) treatment	downregulated	22895360
14630	Mouse	mmu-miR-145	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells;HL-1 cells	hypoxia treatment	upregulated	28980287
14631	Mouse	mmu-miR-145	miRNA	hypoxia	myocardial infarction (MI)	HL-1 cells	hypoxia induce	upregulated	28980287
14632	Mouse	mmu-miR-145	miRNA	hypoxia	myocardial infarction (MI)	cardiac fibroblasts	hypoxia treatment	downregulated	24001939
14633	Mouse	mmu-miR-145	miRNA	sevoflurane (SEV)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	myocardial tissues of ischemia/reperfusion (I/R) mice	sevoflurane treatment	upregulated	30873621
14634	Mouse	mmu-miR-145	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	HL-1 cells	hypoxia-reoxygenation (H/R)treatment	upregulated	27862640
14635	Mouse	mmu-miR-145	miRNA	salidroside (SAL)	osteoarthritis (OA)	LPS-induce inflammatory injury of ATDC5 cells	salidroside (SAL) treatment	"SAL significantly alleviated LPS-induced inflammatory injury Meanwhile, the expression of miR-145 was upregulated by SAL"	30586667
14636	Mouse	mmu-miR-145	miRNA	salidroside (SAL)	osteoarthritis (OA)	ATDC5 cells	salidroside (SAL) treatment	the expression of miR-145 was upregulated by SAL	30586667
14637	Mouse	mmu-miR-145	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	osteoclastogenesis	bone marrow-derived macrophages (BMDMs)	receptor activator of nuclear factor-kB ligand (RANKL) treatment	downregulated	29577879
14638	Mouse	mmu-miR-145	miRNA	oxygen	oxygen-induced retinopathy (OIR)	retinas tissues	neonatal mice with their nursing mother were exposed to 75% oxygen at P7 for 5 days and then returned to room air at P12. treatment	upregulated	30981984
14639	Mouse	mmu-miR-145	miRNA	progesterone (P4)	cell proliferation	mouse endometrial epithelial cells	progesterone (P4) treatment	upregulated	29661100
14640	Mouse	mmu-miR-145	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	?hypoxia treatment	upregulated	22715469
14641	Mouse	mmu-miR-145	miRNA	monocrotaline (MCT)	pulmonary hypertension (PH)	lung tissues	monocrotaline (MCT) treatment	upregulated	26980205
14642	Mouse	mmu-miR-145	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	30841464
14643	Mouse	mmu-miR-145	miRNA	hypoxia	stroke	mouse brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) induce	the levels of lncRNA-MALAT1 and miR-145 were upregulated in OGD-induced BMECs. miR-145 functioned as an anti-angiogenic and pro-apoptotic factor in OGD treated BMECs via down-regulating VEGF-A and ANGPT2 directly.	30038058
14644	Mouse	mmu-miR-145	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	upregulated	19091803
14645	Mouse	mmu-miR-145-5p	miRNA	H2O2	abdominal aortic aneurysm (AAA)	vascular smooth muscle cell (VSMC)	oxidative stress	Silencing of long non-coding RNA Sox2ot inhibits oxidative stress and inflammation of vascular smooth muscle cells in abdominal aortic aneurysm via microRNA-145-mediated Egr1 inhibition.	32629426
14646	Mouse	mmu-miR-145-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse lung tissues and mouse type II alveolar epithelial cells (AT II)	?lipopolysaccharide (LPS) treatment	downregulated	31353880
14647	Mouse	mmu-miR-145-5p	miRNA	house dust mite (HDM) extract	asthma	airway epithelial cells	house dust mite (HDM) extract exposure	upregulated	31264490
14648	Mouse	mmu-miR-145-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral infarction (CI)	BV-2 cells	oxygen/glucose deprivation (OGD) treatment	downregulated	28215748
14649	Mouse	mmu-miR-145-5p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissues	cigarette smoke (CS) exposure	upregulated	30595527
14650	Mouse	mmu-miR-145-5p	miRNA	fatty acid amide hydrolase inhibitor (FAAH-II)	colitis	colitis mouse colon tissues	FAAH-II treatment	dysregulated	27327245
14651	Mouse	mmu-miR-145-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	MicroRNA-145-5p attenuates high glucose-induced apoptosis by targeting the Notch signaling pathway in podocytes.	32104249
14652	Mouse	mmu-miR-145-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	?RGC-5 cells	high glucose treatment	upregulated	31272285
14653	Mouse	mmu-miR-145-5p	miRNA	fatty acid amide hydrolase (FAAH) blockade	experimental colitis	colon	Fatty acid amide hydrolase (FAAH) blockade treatment	upregulated	27327245
14654	Mouse	mmu-miR-145-5p	miRNA	mycobacterium tuberculosis (Mtb)	pulmonary tuberculosis (PTB)	RAW264.7 cells	mycobacterium tuberculosis (MTB) infection	miR-145-5p was lowly expressed in PTB.	33035634
14655	Mouse	mmu-miR-145a	miRNA	progesterone (P4)	anti-proliferative action	In endometrial epithelial cells from endometrial epithelium of ovariectomized mice	progesterone treatment	upregulation	24925854
14656	Mouse	mmu-miR-145a	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	26639663
14657	Mouse	mmu-miR-145a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	astrocyte cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MALAT1 promotes cerebral ischemia-reperfusion injury by affecting AQP4 expression through competitively binding miR-145	32138732
14658	Mouse	mmu-miR-145a	miRNA	lipopolysaccharide (LPS)	sepsis	Lung pericytes	lipopolysaccharide (LPS) treatment	miR-145a levels were decreased in lung pericytes in sepsis.	32285112
14659	Mouse	mmu-miR-145a-5p	miRNA	fractionated radiation	ionizing radiation (IR) injury	LLC1 cells	fractionated dose (FD) irradiation	upregulated	28599420
14660	Mouse	mmu-miR-145a-5p	miRNA	oxygen glucose deprivation (OGD)	neuroinflammation	BV-2 microglial cells	oxygen-glucose deprivation (OGD) induce treatment	downregulated	31551710
14661	Mouse	mmu-miR-145a-5p	miRNA	estradiol-17¦Â (E2)	systemic lupus erythematosus (SLE)	murine B cells	estradiol-17¦Â (E2) treatment	downegulated	25912736
14662	Mouse	mmu-miR-145b	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
14663	Mouse	mmu-miR-146	miRNA	high tidal volume ventilation (HVTV)	lung injury	lung tissues	high tidal volume ventilation (HVTV) treatment	upregulated	22659882
14664	Mouse	mmu-miR-146	miRNA	TGF-¦Â	acute contusion	mouse C2C12 myoblasts	TGF-¦Â treatment	downregulated	28510617
14665	Mouse	mmu-miR-146	miRNA	candida albicans (C. albicans)	Alzheimer's disease (AD)	mouse macrophages	candida albicans infection	upregulated	21060679
14666	Mouse	mmu-miR-146	miRNA	"retinoic acid (RA), leukemia inhibitory factor (LIF) and basic fibroblast growth factor (bFGF)"	cell differentiation	mouse bone marrow mesenchymal stem cells (BMSCs)	"retinoic acid (RA), leukemia inhibitory factor (LIF) and basic fibroblast growth factor (bFGF) treatment"	downregulated	32195202
14667	Mouse	mmu-miR-146	miRNA	retinoic acid (RA)	elevated level of homocysteine (Hcy)	spermatogonial	retinoic acid treatment	downregulated	20177001
14668	Mouse	mmu-miR-146	miRNA	lipopolysaccharide (LPS)	inner ear inflammatory	scala tympani	LPS was injected directly into treatment	upregulated	24470395
14669	Mouse	mmu-miR-146	miRNA	schistosoma japonicum	schistosomiasis	liver macrophage	exposed percutaneously to 16 S. japonicum cercaria treatment	downregulated	27780686
14670	Mouse	mmu-miR-146	miRNA	clostridium difficile	colitis	colonic lamina propria of mice	Clostridium difficile infection	upregulated	23071818
14671	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	bronchoalveolar lavage fluid (BALF)	lipopolysaccharide (LPS) treatment	upregulated	29863671
14672	Mouse	mmu-miR-146a	miRNA	¦Â-Patchoulene (¦Â-PAE)	acute lung injury (ALI)	lipopolysaccharide (LPS) treated mouse lung	¦Â-PAE pretreatment treatment	upregulated in lung	28711783
14673	Mouse	mmu-miR-146a	miRNA	acetaminophen (APAP)	alcoholic liver disease (ALD)	mouse liver tissues	acetaminophen(APAP) treatment	upregulated	22684891
14674	Mouse	mmu-miR-146a	miRNA	ovalbumin (OVA)	allergic asthma (AA)	Type II innate lymphoid cells (ILC2)?from asthma mice lung tissues	ovalbumin (OVA) treatment	upregulated	31435003
14675	Mouse	mmu-miR-146a	miRNA	ragweed (SRW)	allergic conjunctivitis (AC)	corneal epithelium and conjunctiva	ragweed (SRW) treatment	downregulated	26166175
14676	Mouse	mmu-miR-146a	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	AR mouse	ovalbumin (OVA) treatment	downregulated in nasal mucosa	26700406
14677	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	Alzheimer's disease (AD)	RAW264.7 cells	lipopolysaccharide (LPS) treatment	The isolated EVs derived from LPS-treated RAW cells contained significantly higher levels of miR-146a than those derived from PBS-treated RAW cells.	33185814
14678	Mouse	mmu-miR-146a	miRNA	sulforaphane (SFN)	Alzheimer's disease (AD)	temporal cortex and hippocampus	Sulforaphane treatment	downregulated	26827637
14679	Mouse	mmu-miR-146a	miRNA	"dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)"	anti-inflammatory responses	primary astrocyte cultures derived from C57BL/6 mouse stimulated with IL-1¦Â	"pretreat with DMF, MMF"	downregulated	28589165
14680	Mouse	mmu-miR-146a	miRNA	dexamethasone (DEX)	asthma	splenic CD4+ T lymphocytes	dexamethasone (DEX) treatment	downregulated	22580216
14681	Mouse	mmu-miR-146a	miRNA	"IL-33, TSLP, and IL-7"	asthma	ILC2s	"IL-33, TSLP, and IL-7 treatment"	"During stimulation of ILC2s, miR-146a expression gradually increased with a decrease of cell proliferation."	31435003
14682	Mouse	mmu-miR-146a	miRNA	ovalbumin (OVA)	asthma	lung tissues	OVA (ovalbumin) treatment	upregulated	31298396
14683	Mouse	mmu-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	mouse macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
14684	Mouse	mmu-miR-146a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	peritoneal macrophages; Bone-marrow derived macrophages (BMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28882869
14685	Mouse	mmu-miR-146a	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	atopic dermatitis (AD)	mouse skin	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	upregulated	31545496
14686	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	autoimmune lymphoproliferative syndrome	heart tissues;liver tissues;lung tissues;kidney tissues; spleen tissues;lymph nodes	lipopolysaccharide (LPS) treatment	upregulated	23645835
14687	Mouse	mmu-miR-146a	miRNA	hypoxia	autophagy	chondrocytes of C57BL/6J mouse	hypoxia treatment	upregulated	27845876
14688	Mouse	mmu-miR-146a	miRNA	hypoxia	autophagy	Chondrocytes	Hypoxia treatment	upregulated	26492575
14689	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	bone loss	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	30387844
14690	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	bone marrow transplantation	mouse hematopoietic stem/progenitor cells	lipopolysaccharide (LPS) treatment	upregulated	20933052
14691	Mouse	mmu-miR-146a	miRNA	hemoglobin (Hb)	brain inflammation	Primary microglial cells	hemoglobin (Hb) treatment	downregulated	32317924
14692	Mouse	mmu-miR-146a	miRNA	epstein-barr virus (EBV)	tumorigenesis	"Lymphocyte cell lines (IB4, X50-7, Rael, Akata, JY, JC5, P3HR1, Mutu, and BL30)"	Epstein-Barr virus (EBV) infection	upregulated	18057241
14693	Mouse	mmu-miR-146a	miRNA	celecoxib	tumorigenesis	wild-type (HPV16) mice	celecoxib treatment	upregulated	28551628
14694	Mouse	mmu-miR-146a	miRNA	angiotensin II (Ang II)	cell proliferation	Mouse aortic vascular smooth muscle cell (VSMC)	angiotensin II (Ang II) treatment	upregulated	31009837
14695	Mouse	mmu-miR-146a	miRNA	salvianolic acid B (Sal B)	cell proliferation	Ang II-treated mouse aortic vascular smooth muscle cell (VSMC)	salvianolic acid B (Sal B) treatment	downregulated	31009837
14696	Mouse	mmu-miR-146a	miRNA	porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS)	chronic apical periodontitis (CAP)	MC3T3-E1 cells	Porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS) treatment	upregulated	30125982
14697	Mouse	mmu-miR-146a	miRNA	porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS)	chronic apical periodontitis (CAP)	MC3T3-E1 cells	Porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS) treatment	upregulated	30125982
14698	Mouse	mmu-miR-146a	miRNA	borrelia burgdorferi	chronic infection	mouse joint tissue	infect Borrelia burgdorferi treatment	upregulated	24967703
14699	Mouse	mmu-miR-146a	miRNA	IL-1¦Â and TNF-¦Á	diabetes mellitus (DM)	MIN6 cells	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
14700	Mouse	mmu-miR-146a	miRNA	streptozocin (STZ)	diabetic osteoarthritis (OA)	cartilage tissues	streptozotocin (STZ) treatment	"PVT1 expression was significantly increased, whereas miR-146a was markedly decreased in diabetic OA mice than in non-diabetic OA and control"	33569722
14701	Mouse	mmu-miR-146a	miRNA	glucose	diabetic peripheral neuropathy (DPN)	DRG neurons	incubat high glucose (45 mM) for 24h treatment	downregulated	24316060
14702	Mouse	mmu-miR-146a	miRNA	high glucose (HG)	diabetic peripheral neuropathy (DPN)	macrophage	high glucose (HG) treatment	LncRNA HCG18 was highly expressed in DPN model and HG-induced macrophages.	32996080
14703	Mouse	mmu-miR-146a	miRNA	"(2E,6E)-2,6-bis(2-(trifluoromethyl)benzylidene)cyclohexanone (C66)"	diabetic wound healing	wounds	"(2 E,6 E)-2,6-bis(2-(trifluoromethyl)benzylidene)cyclohexanone (C66) treatment"	"miR-146a was significantly decreased in diabetic wounds, while C66 increased miR-146a in diabetic wounds."	32092902
14704	Mouse	mmu-miR-146a	miRNA	[6]-gingerol-fractions (GF)	diabetic wound healing	diabetic skin wounds	[6]-gingerol-fractions (GF) treatment	upregulated	31428171
14705	Mouse	mmu-miR-146a	miRNA	vitamin D	diabetic wound healing	diabetic skin wounds	vitamin D treatment	upregulated	31428171
14706	Mouse	mmu-miR-146a	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
14707	Mouse	mmu-miR-146a	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
14708	Mouse	mmu-miR-146a	miRNA	ischemia/reperfusion (I/R) 	intestinal ischemia/reperfusion (I/R) injury	m-ICcl2?cells	ischemia/reperfusion (I/R) treatment	downregulated	23143987
14709	Mouse	mmu-miR-146a	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
14710	Mouse	mmu-miR-146a	miRNA	high glucose (HG)	experimental diabetic peripheral neuropathy	dorsal root ganglion (DRG) neurons	high glucose treatment	downregulated	22499183
14711	Mouse	mmu-miR-146a	miRNA	azilsartan medoxomil (AZL-M)	heart failure (HF)	plasma	azilsartan medoxomil (AZL-M) treatment	"MiR-146a, miR-149, miR-150, and miR-342-3p were reproducibly reduced in the plasma of CSQ-tg mice."	27321284
14712	Mouse	mmu-miR-146a	miRNA	azilsartan medoxomil (AZL-M)	heart failure (HF)	calsequestrin (CSQ)-tg mouse	azilsartan medoxomil (AZL-M) treatment	upregulated	27321284
14713	Mouse	mmu-miR-146a	miRNA	lactoferrin (LF)	inflammation	lipopolysaccharide (LPS)-treated RAW264.7 cells	Lactoferrin treatment	"?LF could induce a decrease in inflammatory selected miRNAs,?mmu-mir-155, and?mmu-mir-146a expression."	33435756
14714	Mouse	mmu-miR-146a	miRNA	"limonin, (12S,12aS,Z)-8-((2-(diethylamino)ethoxy)imino)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldodecahydro-1H,3H-oxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,10(9aH)-dione (V-A-4)"	inflammation	lipopolysaccharide (LPS)-stimulated RAW264.7 cells	"limonin, (12S,12aS,Z)-8-((2-(diethylamino)ethoxy)imino)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldodecahydro-1H,3H-oxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,10(9aH)-dione (V-A-4) treatment"	upregulated	29477914
14715	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 macrophage cells	lipopolysaccharide (LPS) treatment	upregulated	23974950
14716	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
14717	Mouse	mmu-miR-146a	miRNA	rare ginsenoside from ginseng(Rg6)	inflammation	LPS treated bone marrow-derived macrophages (BMDMs)	Rg6 treatment	upregulated	30867482
14718	Mouse	mmu-miR-146a	miRNA	resveratrol and hydroxytyrosol	inflammation	LPS treated RAW 264.7	resveratrol and hydroxytyrosol 10¦ÌM treatment	downregulated	27998828
14719	Mouse	mmu-miR-146a	miRNA	resveratrol and hydroxytyrosol	inflammation	LPS treated RAW 264.7	resveratrol and hydroxytyrosol 10¦ÌM treatment	downregulated	27998828
14720	Mouse	mmu-miR-146a	miRNA	selenium (Se)	inflammation	mouse mammary epithelial cellsmouse mammary epithelial cells	Se treatment	upregulated	29340029
14721	Mouse	mmu-miR-146a	miRNA	¦¤9-tetrahydrocannabinol (THC)	inflammation	total lymph node cells and CD4(+) T cells	¦¤9-Tetrahydrocannabinol (THC) treatment	upregulated	27268054
14722	Mouse	mmu-miR-146a	miRNA	herpes simplex virus 1 (HSV-1)	inflammation and innate immunity	mouse brain tissue	infect with HSV-1	upregulated	28045967
14723	Mouse	mmu-miR-146a	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	3T3-L1 adipocytes;epididymal adipose tissue	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
14724	Mouse	mmu-miR-146a	miRNA	high fat diet (HFD)	obesity	C57BL/6J mice	high fat diet (HFD) feed	downregulated	28652200
14725	Mouse	mmu-miR-146a	miRNA	aluminum-sulfate	inflammatory neurodegeneration	C57BL/6J mice blood	serum exposure to a standard mouse diet that included aluminum-sulfate	upregulated	29354323
14726	Mouse	mmu-miR-146a	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	mouse lung tissues	Influenza A virus (IAV) infection	upregulated	30611999
14727	Mouse	mmu-miR-146a	miRNA	brucella.suis	innate immune response	RAW264.7 cells	brucella.suis infection	upregulated	29387067
14728	Mouse	mmu-miR-146a	miRNA	cannabinoids	innate immune response	LPS-treated BV-2 microglial cells	cannabinoids treatment	downregulated	30742662
14729	Mouse	mmu-miR-146a	miRNA	exenatide (EXA)	insulin sensitivity	liver	exenatide treatment	"the levels of miRNA-29c, 124a, and 146a in the liver were significantly increased. These effects were reversed by treatment with exenatide."	26314504
14730	Mouse	mmu-miR-146a	miRNA	exenatide (EXA)	insulin sensitivity	muscle	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 146a in the muscle were significantly increased. These effects were reversed by treatment with exenatide."	26314504
14731	Mouse	mmu-miR-146a	miRNA	high fat diet (HFD)	insulin sensitivity	liver	high fat diet (HFD) feed	upregulated	26314504
14732	Mouse	mmu-miR-146a	miRNA	high fat diet (HFD)	insulin sensitivity	muscle	high fat diet (HFD) feed	upregulated	26314504
14733	Mouse	mmu-miR-146a	miRNA	listeria monocytogenes (L. monocytogenes)	leishmaniasis	"macrophage-like cell line RAW264.7 and murine primary bone marrow-derive macrophages (BMDMs), mouse spleen and liver"	Listeria monocytogenes (L. monocytogenes) infection	upregulated	29587465
14734	Mouse	mmu-miR-146a	miRNA	integrin CD11b	liver fibrosis	"Dendritic cells (DCs),Bone marrow-derived DCs (BMDCs)"	Integrin CD11b?treatment	Integrin CD11b negatively regulates TLR9-triggered dendritic cell cross-priming by upregulating microRNA-146a	22551553
14735	Mouse	mmu-miR-146a	miRNA	ischemia/reperfusion (I/R) 	hepatic ischemia/reperfusion injury (HIRI)	mice Kupffer cells	ischemia/reperfusion (I/R) treatment	downregulated	24987958
14736	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	RAW264.7 macrophage cells	lipopolysaccharide (LPS) treatment	upregulated	22415194
14737	Mouse	mmu-miR-146a	miRNA	mycobacteria	inflammatory response	Mouse primary peritoneal macrophages and bone marrow-derived macrophages (BMDMs)	mycobacteria infection	mycobacteria-induced miR-146a could modulate inflammatoryresponse by targeting IRAK1 and TRAF6 and facilitate mycobacteria replication in macrophage	24358114
14738	Mouse	mmu-miR-146a	miRNA	calophyllum inophyllum Linn. (Guttiferae)	multiple myeloma (MM)	RAW264.7 cells	Calophyllum inophyllum L. treatment	downregulated	22735972
14739	Mouse	mmu-miR-146a	miRNA	"3,3'-diindolylmethane (DIM)"	multiple sclerosis (MS)	activated T cells during the development of experimental autoimmune encephalomyelitis (EAE)	"3,3'-Diindolylmethane (DIM) treatment"	upregulated	24898268
14740	Mouse	mmu-miR-146a	miRNA	cuprizone (CPZ)	multiple sclerosis (MS)	corpus callosum	cuprizone (CPZ) treatment	miR-146a was increasingly upregulated during CPZ-induced de- and remyelination.	29593734
14741	Mouse	mmu-miR-146a	miRNA	freeze-dried mouse spinal cord homogenate	multiple sclerosis (MS)	Biozzi ABH mice	experimental autoimmune encephalomyelitis treatment	upregulated	25515214
14742	Mouse	mmu-miR-146a	miRNA	amyloid-¦Â (A¦Â) 42	murine scrapie	murine brain	amyloid-¦Â (A¦Â) 43 peptide metal treatment	upregulated	22043907
14743	Mouse	mmu-miR-146a	miRNA	neurotoxic metal	murine scrapie	murine brain	neurotoxic metal treatment	upregulated	22043907
14744	Mouse	mmu-miR-146a	miRNA	proinflammatory cytokines	murine scrapie	murine brain	pro-inflammatory cytokine treatment	upregulated	22043907
14745	Mouse	mmu-miR-146a	miRNA	ischemia/reperfusion (I/R) 	myocardial ischaemic injury	mouse plasma;Bone marrow-derived macrophage (BMDM);Rat neonatal CMs	ischemia/reperfusion (I/R) treatment	differently regulated	28768728
14746	Mouse	mmu-miR-146a	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	upregulated	18987751
14747	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	neuroinflammation	N9 microglia	lipopolysaccharide (LPS) treatment	upregulated	28096568
14748	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	neuroinflammation	microvesicles (MVs) of BV2 cells treated with CHPG	lipopolysaccharide (LPS) treatment	downregulated in microvesicles (MVs) released	29170640
14749	Mouse	mmu-miR-146a	miRNA	mGlu5 receptor agonist CHPG	neuroinflammation	microvesicles (MVs) released from microglia BV2 cells	treat 24 h with the mGlu5 receptor agonist CHPG (200 ¦ÌM)	upregulated in microvesicles (MVs) released from microglia BV2 cells	29170640
14750	Mouse	mmu-miR-146a	miRNA	spirulina diet	neuroinflammation	cerebral cortex	spirulina diet treatment	Spirulina diet to lactating mothers preserved the LPS-induced increase in anti-inflammatory miR-146a	29845202
14751	Mouse	mmu-miR-146a	miRNA	Japanese encephalitis virus (JEV)	neuroinflammation	mouse microglial C8-B4 cells	infect with JEV	upregulated	28190197
14752	Mouse	mmu-miR-146a	miRNA	high fat diet (HFD)	obesity	nucleus accumbens	high fat diet (HFD) feed	Significant reductions in the levels of miR-155 (82%) and miR-146a (41%) levels were observed within the nucleus accumbens of HFD mice compared to CTL.	28652200
14753	Mouse	mmu-miR-146a	miRNA	hypoxia	osteoarthritis (OA)	Chondrocytes	hypoxia treatment	upregulated	26492575
14754	Mouse	mmu-miR-146a	miRNA	kaempferol	osteoarthritis (OA)	LPS-treated cultured chondrocyte-like ATDC5 cells	kaempferol treatment	downregulated	30776646
14755	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	29183039
14756	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	cultured chondrocyte-like ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	30776646
14757	Mouse	mmu-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoclast differentiation	RAW264.7 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23078176
14758	Mouse	mmu-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoporosis	MC3T3-E1 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	Rtn4-Exos attenuated TNF-¦Á-induced cytotoxicity and apoptosis in murine MC3T3-E1 cells by sponging miR-146a	32400849
14759	Mouse	mmu-miR-146a	miRNA	ovalbumin (OVA)	allergic inflammation of dendritic cells (DCs)	Bone marrow-derived DCs (BMDCs)	OVA treatment	OVA treatment significantly upregulated miR-146a in BMDCs in a dose- and time-dependent manner.	31957545
14760	Mouse	mmu-miR-146a	miRNA	CpG	autoimmune and inflammatory diseases	murine bone marrow-derived dendritic cells	?CpG treatment	upregulated	23244216
14761	Mouse	mmu-miR-146a	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
14762	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	postoperative cognitive dysfunction (POCD)	BV-2 microglial cells	lipopolysaccharide (LPS) treatment	upregulated	30685530
14763	Mouse	mmu-miR-146a	miRNA	probiotics (VSL#3)	postoperative cognitive dysfunction (POCD)	hippocampal tissues	probiotics (VSL#3)?treatment treatment	"Finally, VSL#3 treatment upregulated the expression of miR-146a to block BTG2/Bax axis and consequently inhibited neuronal apoptosis and reduced oxidative stress in POCD mice"	33725320
14764	Mouse	mmu-miR-146a	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
14765	Mouse	mmu-miR-146a	miRNA	prion	retinoblastoma (RB)	mouse brain tissues	prion treatment	over-expression	22363497
14766	Mouse	mmu-miR-146a	miRNA	collagen	rheumatoid arthritis (RA)	splenocytes	collagen treatment	downregulated	32938348
14767	Mouse	mmu-miR-146a	miRNA	Salmonella Typhimurium	salmonella typhimurium infection	Murine macrophages(murine RAW 264.7 cells)	Salmonella Typhimurium infection treatment	upregulated	21468030
14768	Mouse	mmu-miR-146a	miRNA	schistosomiasis	schistosomiasis liver inflammation	mouse liver tissues	schistosomiasis treatment	6W infected mice were significantly higher than those of the normal mice and of the 12W infected mice	25051829
14769	Mouse	mmu-miR-146a	miRNA	lipopolysaccharide (LPS)	sepsis	peritoneal macrophages	lipopolysaccharide (LPS) treatment	microRNA-146a was upregulated in macrophage stimulated by lipopolysaccharide.	30103197
14770	Mouse	mmu-miR-146a	miRNA	SiO2	silicosis	NR8383 cells	SiO2 treatment	upregulated	26239160
14771	Mouse	mmu-miR-146a	miRNA	aldara	skin inflammation	skin	aldara treatment	upregulated	25662483
14772	Mouse	mmu-miR-146a	miRNA	IL-17	skin inflammation	mouse keratinocytes	IL-17 treatment	upregulated	27568078
14773	Mouse	mmu-miR-146a	miRNA	sunitinib (SU)	sunitinib-induced cardiac dysfunction	the myocardium of sunitinib-treated mice	sunitinib treatment	downregulated	31507414
14774	Mouse	mmu-miR-146a	miRNA	mycobacteria	tuberculosis (TB)	RAW264.7 cells	mycobacterial treatment	upregulation	27025258
14775	Mouse	mmu-miR-146a	miRNA	antioxidant of bamboo leaves (AOB)	vascular development	embryoid bodies (EBs)	antioxidant of bamboo leaves (AOB) treatment	miR-146a was markedly downregulated following AOB treatment compared with the control.	29207159
14776	Mouse	mmu-miR-146a	miRNA	aerobic exercise	vascular injury	HUVECs	aerobic exercise training (AET) treatment	"aerobic exercise and statins may induce miR-146a expression, thereby reducing vascular TRAF and TLR4 signaling and vascular      inflammatory injury in AS."	24022569
14777	Mouse	mmu-miR-146a	miRNA	aerobic exercise	vascular injury	high-fat diet-E-null mice	aerobic exercise training (AET) treatment	aerobic exercise and statins may induce miR-146a expression	24022569
14778	Mouse	mmu-miR-146a	miRNA	live L. acidophilus	¦Â-lactoglobulin (¦Â-Lg) allergy	murine splenocytes	live L. acidophilus treatment	downregulated	30156972
14779	Mouse	mmu-miR-146a	miRNA	IL-6	osteoarthritis (OA)	ATDC5 cells	IL-6 treatment	miR©\146a level was negatively modulated by IL©\6 and lncRNA CHRF in ATDC5 cell	31026064
14780	Mouse	mmu-miR-146a	miRNA	dexamethasone (DEX)	osteonecrosis of femoral head (ONFH)	MC3T3-E1 cells from murine osteoblastic	dexamethasone (DEX) treatment	upregulated	28975995
14781	Mouse	mmu-miR-146a	miRNA	heme oxygenase-1 (HMOX1)	myoblast differentiation	C2C12 cells	Heme oxygenase-1 (HMOX1) treatment	upregulated	21827279
14782	Mouse	mmu-miR-146a-3p	miRNA	particulate matter (PM2.5)	macrophage polarization	RAW264.7 cells	Fine particulate matter (PM2.5) exposure treatment	upregulated	30911272
14783	Mouse	mmu-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	miR-146a-5p was upregulated at 6h and 48h.	32727087
14784	Mouse	mmu-miR-146a-5p	miRNA	house dust mite (HDM)	asthma	lung tissue	house dust mite allergen treatment	upregulated	31698144
14785	Mouse	mmu-miR-146a-5p	miRNA	long-chain polyunsaturated fatty acids (LCPUFAs)	asthma	HDM mice lung tissue	long-chain polyunsaturated fatty acids (LCPUFAs) treatment	downregulated	31698144
14786	Mouse	mmu-miR-146a-5p	miRNA	echinococcus multilocularis metacestodes	echinococcus multilocularis infection	RAW 264.7 cells	E. multilocularis metacestodes treatment	upregulated	30322806
14787	Mouse	mmu-miR-146a-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	brain cortices	ethanol treatment	upregulated	32937997
14788	Mouse	mmu-miR-146a-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
14789	Mouse	mmu-miR-146a-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	downregulated	31497013
14790	Mouse	mmu-miR-146a-5p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	downregulated	32443549
14791	Mouse	mmu-miR-146a-5p	miRNA	E. multilocularis metacestodes	infection and immunity of E. multilocularis	RAW264¡¤7 macrophage cells	E. multilocularis metacestodes for 6 and 12 h treatment	"upregulated (mmu-miR-378d,mmu-miR-155-5p, mmu-miR-146a-5p, mmu-miR-21a-5p , mmu-miR-125a-5p) and downregulated(mmu-miR-1981-5p , mmu-miR-let-7c-1-3p)"	28942753
14792	Mouse	mmu-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	inflammation	BV2 mouse microglial cells	lipopolysaccharide (LPS) treatment	upregulated	31530042
14793	Mouse	mmu-miR-146a-5p	miRNA	resveratrol	inflammation	LPS-treated BV2 mouse microglial cells	resveratrol (RSV) treatment	upregulated	31530042
14794	Mouse	mmu-miR-146a-5p	miRNA	angiostrongylus cantonensis (A. cantonensis)	inflammation	male Balb/c mice	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24142285
14795	Mouse	mmu-miR-146a-5p	miRNA	isosteviol Sodium (STV-Na)	ischemic stroke (IS)	microglia/macrophage polarization in ischemic stroke	Isosteviol Sodium (STV-Na) treatment	upregulated	31434993
14796	Mouse	mmu-miR-146a-5p	miRNA	Legionella pneumophila (L. pneumophila)	Legionella pneumophila (L. pneumophila) infection	WT and MyD88-/- murine bone marrow-derived macrophages (BMM)	infected with L. pneumophila	downregulated	28445535
14797	Mouse	mmu-miR-146a-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	high fat diet (HFD) feed	downregulated	31484042
14798	Mouse	mmu-miR-146a-5p	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	methionine-choline deficient (MCD) treatment	downregulated	26537990
14799	Mouse	mmu-miR-146a-5p	miRNA	bis-enoxacin	osteoclastogenesis	4T1 murine breast cancer cells	bis-enoxacin treatment	downregulated	30385810
14800	Mouse	mmu-miR-146a-5p	miRNA	enoxacin	osteoclastogenesis	4T1 murine breast cancer cells	Enoxacin treatment	downregulated	30385810
14801	Mouse	mmu-miR-146a-5p	miRNA	aldosterone	renal fibrosis	mouse cortical collecting duct cells	aldosterone treatment (10-6 M; 3 days)	downregulated	29070573
14802	Mouse	mmu-miR-146a-5p	miRNA	aldosterone	renal fibrosis	mouse cortical collecting duct cells	aldosterone treatment (10-6 M; 3 days)	dysregulated	29070573
14803	Mouse	mmu-miR-146a-5p	miRNA	cisplatin (DDP)	renal fibrosis	kidney tissues	cisplatin treatment	upregulated	33664736
14804	Mouse	mmu-miR-146a-5p	miRNA	TGF-¦Â1	renal fibrosis	mouse renal tubular epithelial cells (mRTECs)	TGF-¦Â1 treatment	upregulated	33664736
14805	Mouse	mmu-miR-146a-5p	miRNA	environmental toxin bisphenol A (BPA)	testicular steroidogenesis dysfuction	interstitial Leydig cells (LCs)	environmental toxin bisphenol A (BPA) treatment	upregulated	29746863
14806	Mouse	mmu-miR-146a-5p	miRNA	H2O2	thymic stromal cells senescence	thymic stromal cells	oxidative stress	downregulated	33002743
14807	Mouse	mmu-miR-146a-5p	miRNA	trinitrobenzene sulfonic acid (TNBS)	visceral pain in colitis	lumbosacral spinal cord	trinitrobenzene sulfonic acid (TNBS) treatment	upregulated	29550454
14808	Mouse	mmu-miR-146b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	"Bronchial alveolar lavage (BAL), peripheral blood isolated serum, splenocytes and lung tissues"	lipopolysaccharide (LPS) treatment	upregulated	30500983
14809	Mouse	mmu-miR-146b	miRNA	inorganic nitrite	acute myocardial infarction (AMI)	heart tissues	single-dose of nitrite	downregulated	28090786
14810	Mouse	mmu-miR-146b	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
14811	Mouse	mmu-miR-146b	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	"bronchial alveolar lavage (BAL) fluid, peripheral blood, splenocytes and lung tissues"	lipopolysaccharide (LPS) treatment	upregulated	30500983
14812	Mouse	mmu-miR-146b	miRNA	actinomycetemcomitans (Aa)	atherosclerosis (AS)	blood	actinomycetemcomitans (Aa) treatment	upregulated	25743474
14813	Mouse	mmu-miR-146b	miRNA	IL-1¦Â	atherosclerosis (AS)	mouse aortic smooth muscle cell lines	IL-1¦Â treatment	upregulated	33084403
14814	Mouse	mmu-miR-146b	miRNA	IL-6	atherosclerosis (AS)	mouse aortic smooth muscle cell lines	IL-6 treatment	upregulated	33084403
14815	Mouse	mmu-miR-146b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	mouse aortic smooth muscle cell lines	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	33084403
14816	Mouse	mmu-miR-146b	miRNA	calorie restriction (CR)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	calorie restriction (CR) treatment	upregulated	31863770
14817	Mouse	mmu-miR-146b	miRNA	exercise (Ex)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	exercise (Ex) treatment	upregulated	31863770
14818	Mouse	mmu-miR-146b	miRNA	high fat diet (HFD)	hepatic steatosis	liver tissues	high fat diet (HFD) feed	upregulated	30776032
14819	Mouse	mmu-miR-146b	miRNA	high fat diet (HFD)	hepatic steatosis	mice thyroid and liver tissues	high fat diet (HFD) feed	downregulated	31863770
14820	Mouse	mmu-miR-146b	miRNA	low fat diet (LFD)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	low-fat diet (LF) treatment	upregulated	31863770
14821	Mouse	mmu-miR-146b	miRNA	myricetin	hepatic steatosis	liver tissues	myricetin treatment	myricetin inhibited miR-146b upregulated induced by HFD.	30776032
14822	Mouse	mmu-miR-146b	miRNA	quercetin	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	quercetin (Que) treatment	upregulated	31863770
14823	Mouse	mmu-miR-146b	miRNA	ginkgo biloba extract (GBE)	hepatocellular carcinoma (HCC)	non-tumor (ENT) liver	ginkgo biloba extract (GBE) treatment	upregulated	32306082
14824	Mouse	mmu-miR-146b	miRNA	influenza A virus (IAV)	immune response	lung tissues	influenza A virus infection	downregulated	30513647
14825	Mouse	mmu-miR-146b	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
14826	Mouse	mmu-miR-146b	miRNA	deoxycorticosterone acetate (DOCA)	kidney damage	hypertensive mice kidneys and urine	injection of Deoxycorticosterone acetate (Doca)	upregulated in the kidneys and urine	29255279
14827	Mouse	mmu-miR-146b	miRNA	dextran sodium sulfate (DSS)	mucosal repair	"mucosa, lamina propria cells or epithelial cells"	dextran sulfate sodium (DSS) treatment	upregulated	30445446
14828	Mouse	mmu-miR-146b	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	downregulated	31863770
14829	Mouse	mmu-miR-146b	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	upregulated	31863770
14830	Mouse	mmu-miR-146b	miRNA	quercetin	obesity	thyroid	quercetin (QUE) treatment	upregulated	31863770
14831	Mouse	mmu-miR-146b	miRNA	zerumbone	obesity	3T3-L1 cells	zerumbone treatment	downregulated	28445161
14832	Mouse	mmu-miR-146b	miRNA	resveratrol	osteoarthritis (OA)	ATDC5 cells	resveratrol (Res) treatment	miR-146b was upregulated by RSV	29843156
14833	Mouse	mmu-miR-146b	miRNA	P. gingivalis	P. gingivalis infection	ApoE mice heart and aorta tissues	infect with P. gingivalis treatment	upregulated	28646427
14834	Mouse	mmu-miR-146b	miRNA	tanshinone IIA (Tan IIA)	P. gingivalis infection	ApoE mice serum and in heart	TSA (60 mg kg-/--/--1 day-1) treatment	downregulated	28646427
14835	Mouse	mmu-miR-146b	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
14836	Mouse	mmu-miR-146b	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
14837	Mouse	mmu-miR-146b	miRNA	schistosoma japonicum	schistosomiasis	murine liver	Schistosoma japonicum infection treatment	upregulated	23825609
14838	Mouse	mmu-miR-146b	miRNA	high fat diet (HFD)	visceral obesity and metabolic dysfunction	C57BL/6N mice	high fat diet (HFD) feed	upregulated	24931160
14839	Mouse	mmu-miR-146b	miRNA	dexamethasone (DEX)	asthma	splenic CD4+ T lymphocytes	dexamethasone (DEX) treatment	downregulated	22580216
14840	Mouse	mmu-miR-146b-3p	miRNA	influenza virus	H5N2 influenza virus infection	lung tissues	H5N2 treatment	upregulated	25266911
14841	Mouse	mmu-miR-146b-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32955644
14842	Mouse	mmu-miR-146b-5p	miRNA	3¦Â-hydroxycholest-5-en-7-one	anti-inflammatory responses	RAW 264.7 cells	3¦Â-hydroxycholest-5-en-7-one treatment	upregulated	32771556
14843	Mouse	mmu-miR-146b-5p	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	downregulated	32337768
14844	Mouse	mmu-miR-146b-5p	miRNA	tensile	cementoblastogenesis	cementoblast cell line OCCM-30 cells	tensile treatment	upregulated	27941605
14845	Mouse	mmu-miR-146b-5p	miRNA	folic acid	kidney injury and fibrosis	kidney cortex	folic acid treatment	upregulated	26707937
14846	Mouse	mmu-miR-146b-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	29557526
14847	Mouse	mmu-miR-146b-5p	miRNA	hypoxia	myocardial infarction (MI)	mouse infarcted myocardium	hypoxia treatment	"Herein, miR-146b-5p was found to be upregulated in the infarcted myocardium of mice and the serum of myocardial ischemia patients."	32845445
14848	Mouse	mmu-miR-146b-5p	miRNA	FTY720-C2	parkinson's disease (PD)	dopaminergic MN13D cells	FTY720-C2 treatment	upregulated	30359694
14849	Mouse	mmu-miR-146b-5p	miRNA	FTY720-C2	parkinson's disease (PD)	MN9D cells	FTY720-C2 treatment	upregulated	30359694
14850	Mouse	mmu-miR-146b-5p	miRNA	platelet-derived growth factor (PDGF)	vascular disease	Vascular smooth muscle cells (VSMCs)	PDGF treatment	upregulated	26722482
14851	Mouse	mmu-miR-147	miRNA	elastase	abdominal aortic aneurysm (AAA)	murine aortic tissues	elastase treatment	"A 10-fold upregulated of microRNA (miR)-147, a key mediator of macrophage inflammatory responses, was observed in murine aortic tissue in elastase-treated mice compared with controls on d 14."	29812968
14852	Mouse	mmu-miR-147	miRNA	norcantharidin (NCTD)	hepatocellular carcinoma (HCC)	liver tissues	intraperitoneal injection of different concentration of NCTD treatment	upregulated	24719559
14853	Mouse	mmu-miR-147	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	downregulated	23716137
14854	Mouse	mmu-miR-147-3p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
14855	Mouse	mmu-miR-147a	miRNA	sildenafil	diabetic peripheral neuropathy (DPN)	mouse	sildenafil at a dose of 10 mg/kg for 4 weeks treatment	upregulated	24316060
14856	Mouse	mmu-miR-147a	miRNA	praziquantel (PZQ)	inflammation	mouse liver	schistosomiasis treatment	increase in the PZQ-ed mice compared to the 12W infected mice	25051829
14857	Mouse	mmu-miR-147a	miRNA	thymosin ¦Â4 (T¦Â4)	neurological injury	mouse N20.1 OPC cell line	"T¦Â4, ranging from 25 to 100 ng/ml for 5 days treatment"	upregulation	24828500
14858	Mouse	mmu-miR-147a	miRNA	lipopolysaccharide (LPS)	pneumonia	TC-1 cells	lipopolysaccharide (LPS) treatment	downregulated	33318298
14859	Mouse	mmu-miR-148a	miRNA	cerulein	acute pancreatitis (AP)	pancreatic tissues of mice	cerulein treatment	downregulated	31122822
14860	Mouse	mmu-miR-148a	miRNA	ethanol (EtOH)	alcoholic hepatitis (AH)	"mouse liver tissues, AML cells, Mouse primary hepatocytes"	Lieber-DeCarli alcohol diet or binge alcohol exposure	downregulated	29475852
14861	Mouse	mmu-miR-148a	miRNA	alcohol	alcoholic liver disease (ALD)	cultured hepatocytes and mouse livers	alcohol exposure	downregulated	29475852
14862	Mouse	mmu-miR-148a	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	upregulated	22719926
14863	Mouse	mmu-miR-148a	miRNA	high methionine diet	atherosclerosis (AS)	ApoE mice	high methionine diet	upregulated	28472596
14864	Mouse	mmu-miR-148a	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	primary Kupffer cells (KCs)	hypoxia/reoxygenation (H/R) treatment	downregulated	30244246
14865	Mouse	mmu-miR-148a	miRNA	listeria	Listeria infection	murine ileum tissues	Listeria infection	downregulated	24327339
14866	Mouse	mmu-miR-148a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	30362572
14867	Mouse	mmu-miR-148a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	mouse liver tissue	carbon tetrachloride (CCl4) treatment	downregulated	30362572
14868	Mouse	mmu-miR-148a	miRNA	TGF-¦Â	liver fibrosis	"mouse Primary hepatic stellate cells (PHSCs), The human immortalized HSC line LX©\2,Human L©\02 hepatocytes"	TGF-¦Â treatment	downregulated	30362572
14869	Mouse	mmu-miR-148a	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra tissue	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	31059019
14870	Mouse	mmu-miR-148a	miRNA	lithium (Li)	parkinson's disease (PD)	substantia nigra tissues	Lithium treatment	downregulated	31059019
14871	Mouse	mmu-miR-148a-3p	miRNA	concanamycin A (Con A)	acute liver failure (ALF)	RAW264.7 cells	concanavalin A (Con A) treatment	upregulated	32739513
14872	Mouse	mmu-miR-148a-3p	miRNA	adipogenesis medium	adipocyte and osteoblast differentiation	ST2 or C3H10T1/2 cells	"adipogenic medium ((¦Á-MEM containing 10% FBS, 0.5 ¦ÌM dexamethasone, 0.25 mM methylisobutylxanthine, 5 ¦Ìg/ml insulin, and 50 ¦ÌM indomethacin) treatment"	upregulated	30728459
14873	Mouse	mmu-miR-148a-3p	miRNA	osteogenic differentiation medium	adipogenesis	ST2 or MC3T3-E1 cells	"osteogenic medium (¦Á-MEM containing 10% FBS, 50 ¦Ìg/ml ascorbic acid, and 5 mM ¦Â-glycerophosphate) treatment"	downregulated	30728459
14874	Mouse	mmu-miR-148a-3p	miRNA	lipopolysaccharide (LPS)	LPS-induced inflammation and sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	"In the LPS induced macrophages, the increasing of miR-148a-3p was milder in the RBP-J-/- macrophages than in the wild type macrophages."	32719678
14875	Mouse	mmu-miR-148a-3p	miRNA	metformin (Met)	oxidative stress	N2a cells	metformin treatment	metformin upregulated the expression of miR-148a-3p?in both MCAO/R-treated mice and OGD/R-treated N2a cells.	31934270
14876	Mouse	mmu-miR-148b	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
14877	Mouse	mmu-miR-148b-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-148b-3p expression was significantly decreased in neurons in response to OGD/R exposure.	31868937
14878	Mouse	mmu-miR-148b-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary mouse cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	miR-148b-3p expression was significantly upregulated in response to H/R treatment in cardiomyocytes.	30308185
14879	Mouse	mmu-miR-149	miRNA	arsenite	diabetes mellitus (DM)	Min6 cells	arsenite exposure	upregulated	29905828
14880	Mouse	mmu-miR-149	miRNA	azilsartan medoxomil (AZL-M)	heart failure (HF)	plasma	azilsartan medoxomil (AZL-M) treatment	"MiR-146a, miR-149, miR-150, and miR-342-3p were reproducibly reduced in the plasma of CSQ-tg mice."	27321284
14881	Mouse	mmu-miR-149	miRNA	melatonin	ischemic injury	Primary myoblast	Melatonin treatment	Melatonin increases mitochondrial function under oxidative stress conditions by upregulating miR-149.	32089265
14882	Mouse	mmu-miR-149	miRNA	silica dust	lung fibrosis	mouse lung tissues	silica dust treatment	downregulated	24641842
14883	Mouse	mmu-miR-149-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33216728
14884	Mouse	mmu-miR-149-3p	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
14885	Mouse	mmu-miR-149-5p	miRNA	3¦Â-hydroxycholest-5-en-7-one	anti-inflammatory responses	RAW 264.7 cells	3¦Â-hydroxycholest-5-en-7-one treatment	downregulated	32771556
14886	Mouse	mmu-miR-149-5p	miRNA	high glucose (HG)	diabetes mellitus (DM)	pancreatic beta cell line (MIN6 cells)	high-glucose (HG) treatment	downregulated	31260649
14887	Mouse	mmu-miR-149-5p	miRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	upregulated	30820263
14888	Mouse	mmu-miR-149-5p	miRNA	allopurinol	hyperuricemia	liver tissues	allopurinol treatment	"miR-149-5p was significantly upregulated in the livers of HFD-fed mice, while the expression was downregulated by allopurinol therapy."	32070295
14889	Mouse	mmu-miR-149-5p	miRNA	ursolic acid (UA)	hyperuricemia	AML-12 cells	uric acid treatment	MiR-149-5p expression was also significantly upregulated in uric acid-stimulated hepatocytes	32070295
14890	Mouse	mmu-miR-15	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	tumorigenesis	brain and liver tissue cells	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) treatment"	downregulated	19270793
14891	Mouse	mmu-miR-15	miRNA	monosodium luminol	neurodegeneration (ND)	central nervous system (CNS) tissues of?mice	Monosodium luminol treatment	downregulated	20201611
14892	Mouse	mmu-miR-150	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	31398659
14893	Mouse	mmu-miR-150	miRNA	celecoxib	tumorigenesis	wild-type (HPV16) mice	celecoxib treatment	upregulated	28551628
14894	Mouse	mmu-miR-150	miRNA	dextran sodium sulfate (DSS)	chronic inflammatory bowel diseases (IBDs)	colon tissue of DSS-treated mice	dextran sulphate sodium (DSS)? treatment	upregulated	21590770
14895	Mouse	mmu-miR-150	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	the lungs of CS-exposed mice	cigarette smoke (CS) exposure	downregulated	29205062
14896	Mouse	mmu-miR-150	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	mouse lungs	Cigarette smoke (CS) exposure	downregulated	29205062
14897	Mouse	mmu-miR-150	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues	dextran sodium sulfate (DSS) treatment	upregulated	29867475
14898	Mouse	mmu-miR-150	miRNA	probiotic Escherichia coli Nissle 1917 (EcN)	colitis	dextran sodium sulfate (DSS)-induced colitis mouse colon tissues	probiotic Escherichia coli Nissle 1917 (EcN) treatment	downregulated	29867475
14899	Mouse	mmu-miR-150	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	male B6C3F1 mice	were injected intravenously with 3mg/kg doxorubicin treatment	downregulated	25448438
14900	Mouse	mmu-miR-150	miRNA	adriamycin (ADR)	focal segmental glomerulosclerosis (FSGS)	renal tissues	adriamycin (ADR) treatment	upregulated	31787235
14901	Mouse	mmu-miR-150	miRNA	adriamycin (ADR)	focal segmental glomerulosclerosis (FSGS)	kidney tissues	adriamycin (ADR) treatment	Renal miR-150 increased in adriamycin-induced FSGS mice.	31787235
14902	Mouse	mmu-miR-150	miRNA	helicobacter pylori (H. pylori)	gastric MALT lymphoma (GML)	GML-developing d3Tx mice stomachs	infect with H. pylori	upregulated	28560185
14903	Mouse	mmu-miR-150	miRNA	azilsartan medoxomil (AZL-M)	heart failure (HF)	plasma	azilsartan medoxomil (AZL-M) treatment	"MiR-146a, miR-149, miR-150, and miR-342-3p were reproducibly reduced in the plasma of CSQ-tg mice."	27321284
14904	Mouse	mmu-miR-150	miRNA	hypoxia	hepatocyte proliferation	mice Primary hepatocytes	hypoxia treatment	miR-150 expression is subject to negative regulation by HIF-1¦Á	23715613
14905	Mouse	mmu-miR-150	miRNA	oxygen glucose deprivation (OGD)	hypoxic/ischemic brain damage (HIBD)	brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) treatment	OGD exposure augmented the level of Rmst while reduced the expression of miR-150 in bEnd3 cells	32728986
14906	Mouse	mmu-miR-150	miRNA	flaxseed (FS)	inflammation	mouse exposed to X-ray	fed 10% FS or a 0% FS isocaloric control diet treatment	dysregulated	24755684
14907	Mouse	mmu-miR-150	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	epididymal adipose tissue	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
14908	Mouse	mmu-miR-150	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse brain microvascular endothelial (bEnd.3) cells	oxygen-glucose deprivation (OGD) treatment	"SNHG12 expression was elevated, whereas miR-150 reduced in OGD-exposed bEnd.3 cells."	30193860
14909	Mouse	mmu-miR-150	miRNA	hypoxia	kidney damage	tubular epithelial cells (TECs)	hypoxia treatment	Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes.	32315664
14910	Mouse	mmu-miR-150	miRNA	¦Ã-rays	leukemia	the whole blood cells of mice	Gy ¦Ã-rays treatment	miRNA signatures induced by ionising radiation in mouse blood are radiation type- and radiation dose-specific	21271940
14911	Mouse	mmu-miR-150	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	CCl4 treatment	downregulated	30548190
14912	Mouse	mmu-miR-150	miRNA	IL-4	macrophage polarization	mouse peritoneal macrophages (MPMs) and MSF-differentiated mouse bone marrow-derived macrophages (BMDMs)	IL-4 treatment	upregulated	31647949
14913	Mouse	mmu-miR-150	miRNA	lipopolysaccharide (LPS)	macrophage polarization	mouse peritoneal macrophages (MPMs) and MSF-differentiated mouse bone marrow-derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	downregulated	31647949
14914	Mouse	mmu-miR-150	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse	high fat diet (HFD) feed	upregulated	31966555
14915	Mouse	mmu-miR-150	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver	high fat diet (HFD) feed	"HFD-fed mice had downregulated expression of miR-150, whereas the expression level was upregulated after MIM or NaB treatment."	33721354
14916	Mouse	mmu-miR-150	miRNA	metabolites of intestinal microflora (MIM)	nonalcoholic fatty liver disease (NAFLD)	mouse liver	metabolites of intestinal microflora (MIM) treatment	"HFD-fed mice had downregulated expression of miR-150, whereas the expression level was upregulated after MIM or NaB treatment."	33721354
14917	Mouse	mmu-miR-150	miRNA	Sodium butyrate (NaB)	nonalcoholic fatty liver disease (NAFLD)	mouse liver	Sodium butyrate (NaB) treatment	"HFD-fed mice had downregulated expression of miR-150, whereas the expression level was upregulated after MIM or NaB treatment"	33721354
14918	Mouse	mmu-miR-150	miRNA	IL-1	osteoarthritis (OA)	ATDC5 cells	Interleukin-1 (IL-1) treatment	upregulated	29996115
14919	Mouse	mmu-miR-150	miRNA	cecal ligation and puncture (CLP)	polymicrobial sepsis	C57Bl/6 mice	cecal ligation and puncture (CLP) treatment	different regulation	24413579
14920	Mouse	mmu-miR-150	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	splenocytes; islet ¦Â cells	streptozocin (STZ) treatment	downregulated	32360624
14921	Mouse	mmu-miR-150	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	blood; retina	high fat diet (HFD) feed	WT mice fed with an HFD for only 1?month had a significant decrease of miR-150 in the blood and retina.	32973073
14922	Mouse	mmu-miR-150-3p	miRNA	cold	obesity	brown adipose tissue (BAT)	cold treatment	downregulated	33015181
14923	Mouse	mmu-miR-150-5p	miRNA	high fat diet (HFD)	atherosclerosis (AS)	ApoE-/- mice heart tissues	high fat diet (HFD) feed	We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs.	33278458
14924	Mouse	mmu-miR-150-5p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	heart tissues	angiotensin II (Ang II) treatment	downregulated	31122130
14925	Mouse	mmu-miR-150-5p	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
14926	Mouse	mmu-miR-150-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	downregulated	31497013
14927	Mouse	mmu-miR-150-5p	miRNA	fluke Fasciola gigantica (FgESPs)	F. gigantica infection	liver tissues	fluke Fasciola gigantica (FgESPs) infection	upregulated	33332355
14928	Mouse	mmu-miR-150-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	33342075
14929	Mouse	mmu-miR-150-5p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	downregulated	32443549
14930	Mouse	mmu-miR-150-5p	miRNA	schistosomiasis japonica	hepatic fibrogenesis	serum	S. japonicum infection treatment	downregulated	30482723
14931	Mouse	mmu-miR-150-5p	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	inflammation	myeloid-derived suppressor cells (MDSCs)	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) treatment"	downregulated	31492743
14932	Mouse	mmu-miR-150-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	Liver tissue	carbon tetrachloride (CCl4) treatment	upregulated	31833387
14933	Mouse	mmu-miR-150-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	31833387
14934	Mouse	mmu-miR-150-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatocytes	carbon tetrachloride (CCl4) treatment	upregulated	31833387
14935	Mouse	mmu-miR-150-5p	miRNA	Rhein	uric acid nephropathy (UAN)	Mouse kidney epithelial cell line (TCMK-1)	Rhein treatment	rhein has a protective effect against UAN by inhibiting renal inflammatory injury via lincRNA-Cox2/miR-150-5p/STAT1 axis	32504995
14936	Mouse	mmu-miR-151	miRNA	di(2-ethylhexyl) phthalate (DEHP)	follicular development	ovarian	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	29385306
14937	Mouse	mmu-miR-151	miRNA	high-dose ascorbate bears cytotoxic	melanoma	human melanoma cells	with physiological (200 ¦ÌM) or pharmacological (8 mM) ascorbate for 1 h treatment	the expression of miRNAs was altered 12 h after ascorbate ment of BLM cells in physiological or pharmacological doses. Pharmacological doses upregulated 32 miRNAs	25202679
14938	Mouse	mmu-miR-151	miRNA	anandamide (AEA)	pro-inflammatory activity	mouse	anandamide treatment	AEA differentil regulate the expression of miRNA	24699635
14939	Mouse	mmu-miR-151-3p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	miR-151-3p was decresed on 6 weeks after S japonicum infection	32443549
14940	Mouse	mmu-miR-151-5p	miRNA	high fat diet (HFD)	erectile dysfunction (ED)	mouse	high fat diet (HFD) feed	dysregulated	25533598
14941	Mouse	mmu-miR-151a-3p	miRNA	deflazacort	inflammation	RAW 264.7 cells	deflazacort treatment	downregulated	32153563
14942	Mouse	mmu-miR-151a-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32153563
14943	Mouse	mmu-miR-151a-3p	miRNA	prednisolone	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32153563
14944	Mouse	mmu-miR-152	miRNA	hypoxia	activation of hepatic stellate cells (HSCs)	hepatic stellate cells (HSCs)	hypoxia treatment	Hypoxia induces the activation of hepatic stellate cells through the PVT1-miR-152-ATG14 signaling pathway.	31893334
14945	Mouse	mmu-miR-152	miRNA	salvia-Nelumbinis naturalis (SNN)	anti-inflammatory responses	Kupffer cells were isolated from C57BL/6 mice and treated with LPS	SNN treatment	upregulated	28167852
14946	Mouse	mmu-miR-152	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aortic tissues	high fat diet (HFD) feed	downregulated	30551500
14947	Mouse	mmu-miR-152	miRNA	high methionine diet	atherosclerosis (AS)	ApoE mice	high methionine diet	upregulated	28472596
14948	Mouse	mmu-miR-152	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cell	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30551500
14949	Mouse	mmu-miR-152	miRNA	high glucose (HG)	diabetes mellitus (DM)	Freshly isolated mouse pancreatic islets	high glucose treatment	upregulated	30106118
14950	Mouse	mmu-miR-152	miRNA	progesterone (P4)	early embryonic development and implantation	mouse endometrial epithelium	progesterone treatment	upregulated	30668148
14951	Mouse	mmu-miR-152	miRNA	progesterone (P4)	endometrial cancer (EC)	endometrial epithelial cells (EECs)	P4 treatment	upregulated	28122483
14952	Mouse	mmu-miR-152	miRNA	high fat diet (HFD)	hepatic insulin resistance	liver	high fat diet (HFD) feed	downregulated	26996529
14953	Mouse	mmu-miR-152	miRNA	hypoxia	hepatic stellate cell (HSC) activation	primary mouse HSCs	hypoxia induce	downregulated	31893334
14954	Mouse	mmu-miR-152	miRNA	glucose	high glucose impairment	mouse NCTC 1469 hepatocytes and mouse primary hepatocytes	following exposure to 25 mM glucose for 48 h treatment	downregulated	25070263
14955	Mouse	mmu-miR-152	miRNA	DNA methyltransferase 1	liver fibrosis	liver	DNA methyltransferase 1 treatment	"miR-152 induced by Sal B, contributed to DNMT1 downregulated and epigenetically regulated PTCH1, resulting in the inhibition of EMT in liver fibrosis."	26257392
14956	Mouse	mmu-miR-152	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	myocardial infarction (MI)	neonatal cardiomyocytes	poly (I:C) treatment	upregulated	29358670
14957	Mouse	mmu-miR-152	miRNA	gemcitabine (GEM)	osteosarcoma (OS)	MG63 cells	gemcitabine treatment	miR-152 level was significantly reduced in MG63/DOX cells.	30661902
14958	Mouse	mmu-miR-152	miRNA	"dietary 3,3'-diindolylmethane (DIM)"	pancreatic cancer (PC)	athymic BALB/c nude mice injected with PANC-1 and PANC-28 tumor cells	diet containing 2000 ppm of Bio-DIM for 6w	upregulated	28659310
14959	Mouse	mmu-miR-152	miRNA	ischemia	renal fibrosis	Renal tissues	the left ureter was ligated at the lower pole level of kidney for 7 days	downregulated	28285987
14960	Mouse	mmu-miR-152	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	upregulated	19091803
14961	Mouse	mmu-miR-152-3p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	upregulated	28396668
14962	Mouse	mmu-miR-152-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	Murine hippocampal HT22 neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31326116
14963	Mouse	mmu-miR-153	miRNA	isoflurane	neurotoxicity	mouse neurocyte	isoflurane induce	"In isoflurane-induced mice, miRNA-153 expression was downregulated compared with in the control group. downregulated of miRNA-153 induced neurocyte apoptosis, reduced cell growth and promoted oxidative stress in an in vitro model."	30896808
14964	Mouse	mmu-miR-153	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31889412
14965	Mouse	mmu-miR-153	miRNA	icariin (ICA)	osteoporosis	MC3T3-E1 cells	icariin treatment	upregulated	29904399
14966	Mouse	mmu-miR-153	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	oxygen-glucose deprivation/reoxygenation (OGD/R) injury	primary hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	28245071
14967	Mouse	mmu-miR-153	miRNA	laparotomy and exposure of the junc_x0002_tion between the large and small intestines	sepsis	mouse large and small intestines	laparotomy and exposure of the junc_x0002_tion between the large and small intestines treatment	upregulated	25043848
14968	Mouse	mmu-miR-153	miRNA	mifepristone (MIF)	triple negative breast cancer (TNBC)	patient-derived xenografts in NOD-SCID mice	mifepristone (MIF) treatment	upregulation in tumors	26941846
14969	Mouse	mmu-miR-153	miRNA	bilobalide (BB)	type 1 diabetes mellitus (T1DM)	TNF-¦Á-treated MIN6 cells	Bilobalide (BB) treatment	upregulated	31667906
14970	Mouse	mmu-miR-153	miRNA	bilobalide (BB)	type 1 diabetes mellitus (T1DM)	MIN6 cells	Bilobalide (BB) treatment	MiR-153 expression was elevated by BB when induced by TNF-¦Á.	31667906
14971	Mouse	mmu-miR-153	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	type 1 diabetes mellitus (T1DM)	MIN6 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31667906
14972	Mouse	mmu-miR-153-3p	miRNA	isoprenaline	cardiac hypertrophy	primary cardiac myocytes	Isoprenaline (ISO) treatment	ISO promoted mitochondrial fission and enhanced the expression of miR-153-3p in cardiomyocytes.	31903137
14973	Mouse	mmu-miR-153-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary mouse cerebral cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32912499
14974	Mouse	mmu-miR-154	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	alveolar type 2 cells (AT2)	hyperoxia treatment	Hyperoxia treatment maintains high levels of miR-154 in alveolar type 2 cells (AT2).	32252341
14975	Mouse	mmu-miR-154	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
14976	Mouse	mmu-miR-154-5p	miRNA	angiotensin II (Ang II)	cardiac remodeling	heart tissues	angiotensin II (Ang II) treatment	upregulated	31612078
14977	Mouse	mmu-miR-154-5p	miRNA	telmisartan	cardiac remodeling	Angiotensin II (AngII)-induced cardiomyocytes	telmisartan treatment	downregulated	31612078
14978	Mouse	mmu-miR-155	miRNA	trinitrobenzene sulfonic acid (TNBS)	colitis	colons and in cells of LNs	trinitrobenzene sulphonic acid (TNBS) treatment	upregulated	20143464
14979	Mouse	mmu-miR-155	miRNA	high tidal volume ventilation (HVTV)	lung injury	lung tissues	high tidal volume ventilation (HVTV) treatment	upregulated	22659882
14980	Mouse	mmu-miR-155	miRNA	IL-10	acquired Immune Deficiency Syndrome (AIDS)	TLR4-induced mouse B cells	IL-10 treatment	downregulated	25381386
14981	Mouse	mmu-miR-155	miRNA	monosodium urate (MSU)	acute gout	bone marrow-derived macrophages (BMDMs)	monosodium urate (MSU) treatment	MiR-155 expression was quickly upregulated in BMDMs from WT mice following MSU treatment in vitro.	29996893
14982	Mouse	mmu-miR-155	miRNA	chikusetsusaponin IVa (CsIVa)	acute inflammatory response	mouse liver; RAW264.7 cells	chikusetsusaponin IVa (CsIVa) treatment	"LPS induced high expression of miR-155, which was reversed by Chikusetsusaponin IVa (CsIVa)."	33110183
14983	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	acute inflammatory response	murine macrophages	lipopolysaccharide (LPS) treatment	upregulated	19596814
14984	Mouse	mmu-miR-155	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
14985	Mouse	mmu-miR-155	miRNA	concanamycin A (Con A)	acute liver injury (ALI)	liver tissues	concanavalin A (ConA) treatment	upregulated	29420849
14986	Mouse	mmu-miR-155	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver injury (ALI)	liver tissues	D-GalN/LPS treatment	upregulated	31061003
14987	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	acute liver injury (ALI)	Raw264.7 cells	LPS treatment	upregulated	31061003
14988	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	murine alveolar macrophage cell line MH-S	Isoflurane treatment	downregulated	25553444
14989	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	bronchoalveolar lavage fluid (BALF)	lipopolysaccharide (LPS) treatment	upregulated	29863671
14990	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	bone marrow-derived lymphocytes	lipopolysaccharide (LPS) treatment	miR-155 expressed in bone marrow-derived lymphocytes promoted LPS-induced ALI through the modulation of the Ang-2-Tie-2 pathway.	30717971
14991	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	macrophages	lipopolysaccharide (LPS) treatment	upregulated	27371731
14992	Mouse	mmu-miR-155	miRNA	caerulein (Cae)	acute pancreatitis (AP)	pancreatic tissue	caerulein (Cae) treatment	upregulated	29937734
14993	Mouse	mmu-miR-155	miRNA	citrus aurantium L. dry extracts (CAde)	adipogenesis	3T3-L1 pre-adipocytes	Citrus aurantium L. dry extracts (CAde) treatment	downregulated	31654716
14994	Mouse	mmu-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	adipogenesis	3T3-L1 preadipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	21986534
14995	Mouse	mmu-miR-155	miRNA	amyloid-¦Â (A¦Â) 1-40	age-related macular degeneration (AMD)	C57BL/6 mice eye tissues	amyloid-¦Â (A¦Â) 1-40 treatment	upregulated	28324113
14996	Mouse	mmu-miR-155	miRNA	acetaminophen (APAP)	alcoholic liver disease (ALD)	mouse liver tissues	acetaminophen(APAP) treatment	upregulated	22684891
14997	Mouse	mmu-miR-155	miRNA	alcohol	alcoholic liver disease (ALD)	liver tissue of mice	alcohol exposure	upregulated	21062749
14998	Mouse	mmu-miR-155	miRNA	alcohol	alcoholic liver disease (ALD)	liver tissues	alcohol exposure	upregulated	31090940
14999	Mouse	mmu-miR-155	miRNA	IL-33	allergic rhinitis (AR)	nasal mucosal	recombinant murine IL-33 treatment	upregulated	32946865
15000	Mouse	mmu-miR-155	miRNA	alogliptin	Alzheimer's disease (AD)	LPS-treated rats brain tissues	alogliptin treatment	downregulated	33125461
15001	Mouse	mmu-miR-155	miRNA	candida albicans (C. albicans)	Alzheimer's disease (AD)	mouse macrophages	candida albicans infection	upregulated	21060679
15002	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	Alzheimer's disease (AD)	brain tissues	lpopolysaccharide (LPS) treatment	upregulated	33125461
15003	Mouse	mmu-miR-155	miRNA	resveratrol	anti-adipogenic	3T3-L1 maturing pre-adipocytes	treat with 25 ¦ÌM of trans-resveratrol (RSV) treatment	upregulated	28953910
15004	Mouse	mmu-miR-155	miRNA	histone deacetylase inhibitors (HDIs) short-chain fatty acid (SCFA) butyrate	antibody-mediated systemic autoimmunity	B cells	SCFA HDI butyrate treatment	upregulated	32265934
15005	Mouse	mmu-miR-155	miRNA	"dimethyl fumarate (DMF) ,metabolite monomethyl fumarate (MMF)"	anti-inflammatory responses	primary astrocyte cultures derived from C57BL/6 mouse stimulated with IL-1¦Â	"pretreat with DMF, MMF"	downregulated	28589165
15006	Mouse	mmu-miR-155	miRNA	ginsenoside Rb1	anti-inflammatory responses	lipopolysaccharides (LPS) treated RAW264.7 cells	Ginsenoside Rb1 treatemnt	upregulated	28729651
15007	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	anti-inflammatory responses	mouse macrophage RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	24689881
15008	Mouse	mmu-miR-155	miRNA	mycobacterium bovis bacille Calmette-Gu¨¦rin (BCG)	anti-mycobacterial response	RAW264.7 cells	BCG infection treatment	upregulated	24937178
15009	Mouse	mmu-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	apoptosis	RAW264.7 cells	secreted antigenic target 6-kDa protein (ESAT-6) of Mycobacterium tuberculosis (Mtb)?treatment	upregulated	25721573
15010	Mouse	mmu-miR-155	miRNA	IL-33	asthma	type 2 innate lymphoid cells (ILC2s of wild-type (WT) mice	IL-33 treatment	upregulated	27492144
15011	Mouse	mmu-miR-155	miRNA	actinomycetemcomitans (Aa)	atherosclerosis (AS)	blood	actinomycetemcomitans (Aa) treatment	upregulated	25743474
15012	Mouse	mmu-miR-155	miRNA	cigarette smoke (CS)	atherosclerosis (AS)	aortic tissues of ApoE KO mice	cigarette smoke (CS) exposure	upregulated	29642385
15013	Mouse	mmu-miR-155	miRNA	conjugated linoleic acid (CLA)	atherosclerosis (AS)	aorta tissues	conjugated linoleic acid (CLA) treatment	1% cholesterol diet increased miR-155 expression while CLA blend supplementation decreased miR-155 expression in the aorta during atherosclerosis regression in vivo.	33391256
15014	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	atherosclerosis (AS)	apolipoprotein E knock-out (apoE) mice aortas	high fat diet (HFD) feed	upregulated	27856635
15015	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	26823719
15016	Mouse	mmu-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	26823719
15017	Mouse	mmu-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulation	27843203
15018	Mouse	mmu-miR-155	miRNA	paeonol (PAE)	atherosclerosis (AS)	M1 macrophage	Paeonol treatment	"Paeonol significantly reduced the LPS and IFN-¦Ã-induced high expression of F4/80 and CD86, the secretion of inflammatory factors IL-6 and TNF-¦Á(P<005 or P<001), decreased the expression level of miR-155"	32495566
15019	Mouse	mmu-miR-155	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	serial transverse aortic sections	Shexiang Tongxin dropping pill (STDP) treatment	downregulated	25449459
15020	Mouse	mmu-miR-155	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	(ApoE(-/-)) mice aortic	STDP (30 mg/kg/day) on atherosclerotic lesions treatment	downregulated	25449459
15021	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aortas	high fat diet (HFD) feed	upregulated	27856635
15022	Mouse	mmu-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular endothelial cells (VECs); vascular smooth muscle cells (VSMCs); RAW 264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	miR-155 inhibits oxidized low-density lipoprotein-induced apoptosis in different cell models by targeting the p85¦Á/AKT pathway	32081664
15023	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	?Mouse Monocyte	lipopolysaccharide (LPS) treatment	upregulated	24198819
15024	Mouse	mmu-miR-155	miRNA	concanamycin A (Con A)	autoimmune hepatitis (AIH)	liver tissues	concanavalin A (ConA) treatment	miR-155 was raised in liver tissues after 48 h exposure to ConA.	30290123
15025	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	autophagy	tibiae from LPS-injected mice and in osteoclasts (OC) stimulated by lipopolysaccharide (LPS)	lipopolysaccharides (LPS) treatment	upregulated	30144578
15026	Mouse	mmu-miR-155	miRNA	listeria monocytogenes (L. monocytogenes)	bacterial infection	brain tissues and microglia	Listeria monocytogenes infection	upregulated	30538705
15027	Mouse	mmu-miR-155	miRNA	bile acids	bile-containing gastroesophageal reflux	murine hypopharyngeal mucosa (HM)	bile acids treatment	upregulated	29529473
15028	Mouse	mmu-miR-155	miRNA	IFN-¦Á	biliary atresia (BA)	bile duct cells	IFN-¦Á treatment	upregulated	27817193
15029	Mouse	mmu-miR-155	miRNA	ischemia	blindness	retinal vascular networks	ischemia treatment	"Under ischemic conditions, dysregulated miR-155 and CCN1 expression increases the inflammatory load and microglial activation, prompting aberrant angiogenic responses"	26242736
15030	Mouse	mmu-miR-155	miRNA	selenium (Se)	bone infection or osteomyelitis	MC3T3-E1 cells	selenium treatment	downregulated	32511663
15031	Mouse	mmu-miR-155	miRNA	mycobacterium bovis bacille Calmette-Gu¨¦rin (BCG)	breast cancer	Murine macrophages	Mycobacterium bovis BCG infection	M. bovis BCG-driven miR-155 dictates cell fate decisions of infected macrophages	22473996
15032	Mouse	mmu-miR-155	miRNA	TGF-¦Â	breast cancer	normal murine mammary gland (NMuMG) epithelial cells	TGF-¦Â treatment	upregulated	18794355
15033	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	Raw264.7£» HEK293T cell lines	lipopolysaccharide (LPS) treatment	upregulated	24362029
15034	Mouse	mmu-miR-155	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cardiomyocyte	angiotensin II (Ang II) treatment	"CYTOR knockdown reduced IKKi protein levels while activated NF-kB signaling pathway, whereas miR-155 inhibition exerted an opposing effect; the effect of CYTOR could be partially attenuated by miR-155 inhibition."	30794866
15035	Mouse	mmu-miR-155	miRNA	polysaccharide from the roots of Actinidia eriantha (AEPS)	cell activation	RAW264.7 macrophages	AEPS treatment	"miR-155 inhibitor significantly downregulated the mRNA expression of proinflammatory factors (IL-1¦Â, IL-6, COX-2 and NOS2), and blocked the production of NO in RAW2647 cell induced by AEPS"	30914371
15036	Mouse	mmu-miR-155	miRNA	hypoxia	cerebral ischemia injury (CII)	N2a cells	oxygen-glucose deprivation/reoxygenation (OGD/R) induce	upregulated	29951932
15037	Mouse	mmu-miR-155	miRNA	minocycline (MNC)	cerebral ischemia injury (CII)	oxygen-glucose deprivation/reoxygenation (OGD/R) induced N2a cells	Minocycline treatment	downregulated	29951932
15038	Mouse	mmu-miR-155	miRNA	helicobacter pylori (H. pylori)	chronic gastritis and colitis	gastric mucosa of?mice	Helicobacter pylori infection	upregulated	21880981
15039	Mouse	mmu-miR-155	miRNA	hypoxia	chronic kidney disease (CKD)	renal tissues	chronic intermittent hypoxia (CIH) treatment	upregulated	29953588
15040	Mouse	mmu-miR-155	miRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	lung tissues; alveolar macrophages	cigarette smoke extract (CSE) exposure	upregulated	31819170
15041	Mouse	mmu-miR-155	miRNA	IL-10	clinical inflammatory lung disease	BAL cells and splenocytes	IL-10¨Csecreting M2-like macrophages	"we report that C/EBPb, a target molecule of miR-155, was upregulated and associated with IL-10 secretion and M2-like phenotype of macrophages"	23514739
15042	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues	dextran sodium sulfate (DSS) treatment	upregulated	29867475
15043	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues	dextran sulfate sodium (DSS) treatment	upregulated	33770552
15044	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	colitis	C57BL/6J mice colonic tissue	dextran-sulfate-sodium (DSS) treatment	upregulated	28752563
15045	Mouse	mmu-miR-155	miRNA	Lactobacillus fermentum (L. fermentum)	colitis	C57BL/7J mice colonic tissues	infect with L. fermentum	downregulated	28752563
15046	Mouse	mmu-miR-155	miRNA	pristimerin	colitis	DSS-induced colitis mice colon tissues	pristimerin (Pris) treatment	downregulated	33770552
15047	Mouse	mmu-miR-155	miRNA	probiotic Escherichia coli Nissle 1917 (EcN)	colitis	dextran sodium sulfate (DSS)-induced colitis mouse colon tissues	probiotic Escherichia coli Nissle 1917 (EcN) treatment	downregulated	29867475
15048	Mouse	mmu-miR-155	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	murine lymphocytes	ionizing radiation?treatment	upregulated	23496831
15049	Mouse	mmu-miR-155	miRNA	IL-10	colonic inflammation	colonic intraepithelial lymphocytes	IL-10 treatment	downregulated	22043014
15050	Mouse	mmu-miR-155	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	plasma and colon tissues	azoxymethane (AOM) treatment	upregulated	30311185
15051	Mouse	mmu-miR-155	miRNA	lactobacillus acidophilus and bifidobacterium bifidum probiotics	colorectal cancer (CRC)	plasma and colon tissues from azoxymethane (AOM)-treated mice	Lactobacillus acidophilus and Bifidobacterium bifidum probiotics treatment	downregulated	30311185
15052	Mouse	mmu-miR-155	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	coronary heart disease (CHD)	"HEK293T, L929 and RAW264.7 cells"	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	23436936
15053	Mouse	mmu-miR-155	miRNA	dengue virus (DENV)	dengue virus (DENV) infection	brain tissues	dengue virus (DENV) infection	miR-155 was time-dependently downregulated upon dengue virus (DENV) infection.	32277848
15054	Mouse	mmu-miR-155	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	"kidney, heart, PBMCs"	streptozotocin (STZ) treatment	downregulated	25929727
15055	Mouse	mmu-miR-155	miRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	"miRNA-155 was found to be highly expressed in serum and kidney tissue of mice with diabetic nephropathy and in cultured podocytes,"	33748285
15056	Mouse	mmu-miR-155	miRNA	[6]-gingerol-fractions (GF)	diabetic wound healing	diabetic skin wounds	[6]-gingerol-fractions (GF) treatment	downregulated	31428171
15057	Mouse	mmu-miR-155	miRNA	vitamin D	diabetic wound healing	diabetic skin wounds	vitamin D treatment	downregulated	31428171
15058	Mouse	mmu-miR-155	miRNA	adiponectin	metabolic processes	RAW 264.7 cells	adiponectin (ApN) treatment	upregulated	24084329
15059	Mouse	mmu-miR-155	miRNA	pristane (PS)	diffuse alveolar hemorrhage (DAH)	lung	pristane treatment	upregulated	26556607
15060	Mouse	mmu-miR-155	miRNA	IFN-¦Ã	inflammation	DJ-1-KO cells	IFN-¦Ã treatment	upregulated	24963279
15061	Mouse	mmu-miR-155	miRNA	cyclophosphamide	embryonic maldevelopment	the fore- and hindlimbs of mice	cyclophosphamide treatment	downregulated	20170545
15062	Mouse	mmu-miR-155	miRNA	kainic acid (KA)	epilepsy	brain tissues	kainic acid (KA) treatment	upregulated	30928987
15063	Mouse	mmu-miR-155	miRNA	progesterone (P4)	epithelial-mesenchymal transition (EMT)	The murine macrophage cell line RAW264.7	progesterone treatment	"progesterone suppresses TLRs-triggered immune response by regulating miR-155, and the decreased miR-155 contributes to inhibit TLR-induced IL-6 and IFN-¦Â via increased SOCS1 expression"	22546503
15064	Mouse	mmu-miR-155	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
15065	Mouse	mmu-miR-155	miRNA	ethanol (EtOH) and burn injury	ethanol and burn injury	mouse T cells	ethanol and burn injury treatment	downregulated	25126745
15066	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	experimental autoimmune prostatitis (EAP)	prostatic tissues	lipopolysaccharide (LPS) treatment	LPS enhanced the upregulation of miR-155.	32436368
15067	Mouse	mmu-miR-155	miRNA	staphylococcal enterotoxin B (SEB)	food poisoning	lung	exposure to SEB treatment	upregulated	24778118
15068	Mouse	mmu-miR-155	miRNA	helicobacter pylori (H. pylori)	gastric MALT lymphoma (GML)	GML-developing d3Tx mice stomachs	infect with H. pylori	upregulated	28560185
15069	Mouse	mmu-miR-155	miRNA	influenza virus	H9N2 influenza virus infection	Dendritic cells (DCs)	H9N2 avian influenza virus (H9N2 AIV) treatment	upregulated	27285980
15070	Mouse	mmu-miR-155	miRNA	vitamin C loaded human serum albumin (HSA) nanoparticles	healing of wounds	3T3 fibroblast cells	vitamin C loaded human serum albumin (HSA) nanoparticles treatment	downregulated	31035807
15071	Mouse	mmu-miR-155	miRNA	CoCl2	heart failure (HF)	cardiac stem cells (CSCs)	CoCl2 treatment	downregulated	30362213
15072	Mouse	mmu-miR-155	miRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	RAW264.7 cells	HBsAg treatment	upregulated	29349567
15073	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
15074	Mouse	mmu-miR-155	miRNA	norcantharidin (NCTD)	hepatocellular carcinoma (HCC)	liver tissues	intraperitoneal injection of different concentration of NCTD treatment	upregulated	24719559
15075	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	humoral autoimmune intestinal injury	Foxp3+ Treg cells	dextran sulfate sodium (DSS) treatment	upregulated	30927737
15076	Mouse	mmu-miR-155	miRNA	IL-10	immune response	mouse bone marrow-derived mast cells (BMMC)	IL-10 treatment	upregulated	27183599
15077	Mouse	mmu-miR-155	miRNA	streptococcus pneumoniae Endopeptidase O (PepO)	pneumococcal diseases	peritoneal exudate macrophages (PEMs)	PepO treatment	upregulated	28193634
15078	Mouse	mmu-miR-155	miRNA	corticosterone	immune response	100 ng/ml BAFF and 100 ng/ml IL4 in-vitro-induced germinal center B cells	corticosterone (CORT) treatment	downregulated	30414952
15079	Mouse	mmu-miR-155	miRNA	either yeasts or hyphal forms of Candida albicans	immune response	murine bone marrow-derived macrophages (BMDMs)	either yeasts or hyphal forms of Candida albicans	upregulated	27294852
15080	Mouse	mmu-miR-155	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-6	immune response	bone marrow cells	GM-CSF£¬ IL-6 treatment	upregulated	24391219
15081	Mouse	mmu-miR-155	miRNA	TGF-¦Â	immune response	bone marrow cells and spleen MDSC	TGF-¦Â treatment	upregulated	24391219
15082	Mouse	mmu-miR-155	miRNA	aflatoxin M1?(AFM1)	immunotoxicity	isolated T cells from spleens of mice	aflatoxin M1?(AFM1)?exposure	downregulated	30739504
15083	Mouse	mmu-miR-155	miRNA	"(R)-2-isobutyl 3-methyl 3,4-dihydro-1H-pyrido[3,4-b]indole-2,3(9H)-dicarboxylate"	inflammation	lipopolysaccharide (LPS)-stimulated RAW 264.7 cells	"(R)-2-isobutyl 3-methyl 3,4-dihydro-1H-pyrido[3,4-b]indole-2,3(9H)-dicarboxylate treatment"	downregulated	24299616
15084	Mouse	mmu-miR-155	miRNA	alcohol	inflammation	mouse	chronic alcohol administration	upregulated	28584078
15085	Mouse	mmu-miR-155	miRNA	CTB-UE	inflammation	H. pylori-induced gastric mouse	CTB-UE treatment	upregulated	25483699
15086	Mouse	mmu-miR-155	miRNA	curcumin (Cur)	inflammation	LPS-induced Raw264.7	curcumin treatment	downregulated	28264607
15087	Mouse	mmu-miR-155	miRNA	heat stress	inflammation	BV-2 microglial cells (BV-2 cells)	heat stress treatment	upregulated	30778287
15088	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	inflammation	ApoE-/- mice vessel segments	high fat diet (HFD) feed	upregulated	30765689
15089	Mouse	mmu-miR-155	miRNA	lactoferrin (LF)	inflammation	lipopolysaccharide (LPS)-treated RAW264.7 cells	Lactoferrin treatment	"?LF could induce a decrease in inflammatory selected miRNAs,?mmu-mir-155, and?mmu-mir-146a expression."	33435756
15090	Mouse	mmu-miR-155	miRNA	"limonin, (12S,12aS,Z)-8-((2-(diethylamino)ethoxy)imino)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldodecahydro-1H,3H-oxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,10(9aH)-dione (V-A-4)"	inflammation	lipopolysaccharide (LPS)-stimulated RAW264.7 cells	"limonin, (12S,12aS,Z)-8-((2-(diethylamino)ethoxy)imino)-12-(furan-3-yl)-6,6,8a,12a-tetramethyldodecahydro-1H,3H-oxireno[2,3-d]pyrano[4',3':3,3a]isobenzofuro[5,4-f]isochromene-3,10(9aH)-dione (V-A-4) treatment"	upregulated	29477914
15091	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	mice Bone marrow macrophage cells	LPS treatment	LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 pre-cursors in macrophages	19423639
15092	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	mouse macrophages	lipopolysaccharide (LPS) treatment	upregulated	29133016
15093	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	"the BV2 cells, primary microglia and the mouse cortex"	lipopolysaccharide (LPS) treatment	upregulated	29805490
15094	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	Raw264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	29854576
15095	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	bone marrow-derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	upregulated	30721702
15096	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	BV-2 microglial cells	lipopolysaccharide (LPS) treatment	upregulated	30720115
15097	Mouse	mmu-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28871950
15098	Mouse	mmu-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	RAW264.7 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29977930
15099	Mouse	mmu-miR-155	miRNA	tremella fuciformis polysaccharides (TFPS)	inflammation	LPS-treated Raw264.7 cells	Tremella fuciformis polysaccharides (TFPS)treatment treatment	downregulated	29854576
15100	Mouse	mmu-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	Vascular smooth muscle cells (VSMCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30765689
15101	Mouse	mmu-miR-155	miRNA	¦Á-mangostin	inflammation	macrophages	¦Á-mangostin treatment	downregulated	31806859
15102	Mouse	mmu-miR-155	miRNA	herpes simplex virus 1 (HSV-1)	inflammation and innate immunity	mouse brain tissue	infect with HSV-1	upregulated	28045967
15103	Mouse	mmu-miR-155	miRNA	"1,25-dihydroxyvitamin D (1,25(OH)2D)"	inflammation	3T3-L1 adipocytes; epididymal adipose tissue	"1,25-dihydroxyvitamin D (1,25(OH)2D) treatment"	downregulated	28055298
15104	Mouse	mmu-miR-155	miRNA	praziquantel (PZQ)	inflammation	mouse liver	schistosomiasis treatment	increase in the PZQ-ed mice compared to the 12W infected mice	25051829
15105	Mouse	mmu-miR-155	miRNA	influenza A virus (IAV)	inflammation	C57BL/6 mice lung	infect with influenza A/PR/8/34	upregulated	28193481
15106	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	obesity	C57BL/6J mice	high fat diet (HFD) feed	downregulated	28652200
15107	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colon tissues	dextran sodium sulfate (DSS) treatment	miR-155 expression was increased 4.74-fold in DSS-induced colon tissues compared with that in normal controls.	32713852
15108	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colon tissues	dextran sulfate sodium (DSS) treatment	upregulated	30236870
15109	Mouse	mmu-miR-155	miRNA	apigenin	inflammatory diseases	lungs from LPS-treated mice	dietary apigenin treatment	downregulated	25641956
15110	Mouse	mmu-miR-155	miRNA	resveratrol	inflammatory diseases	LPS-stimulated RAW264.7 murine macrophages	resveratrol (RS) treatment	downregulated	28004106
15111	Mouse	mmu-miR-155	miRNA	Sinomenine (SIN)	inflammatory diseases	RAW264.7 cells	Sinomenine (SIN) treatment	"SIN treatment significantly reduced LPS-induced inflammatory cytokine release, suppressed the expression of miR-155"	32116077
15112	Mouse	mmu-miR-155	miRNA	resveratrol	inflammatory response	lipopolysaccharide (LPS)-stimulated RAW264.7 murine macrophages	resveratrol (RS) treatment	downregulated	28004106
15113	Mouse	mmu-mir-155	miRNA	IL-10	inflammatory response	RAW264.7 cells	IL-10 treatment	upregulated	32324763
15114	Mouse	mmu-miR-155	miRNA	dexamethasone (DEX)	inflammatory therapeutics	Raw264.7 cells	dexamethasone (Dex) treatment	Dexamethasone decreased expression of pro-inflammatory microRNA-155 in exosomes from LPS-induced RAW264.7 macrophages.	31949716
15115	Mouse	mmu-miR-155	miRNA	cannabinoids	innate immune response	LPS-treated BV-2 microglial cells	cannabinoids treatment	downregulated	30742662
15116	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	inner ear inflammatory	scala tympani	LPS was injected directly into treatment	upregulated	24470395
15117	Mouse	mmu-miR-155	miRNA	alcohol	intestinal inflammation and barrier dysfunction	mouse	acute binge and chronic alcohol feeding in the small bowel (SB) in mice treatment	upregulated	25156614
15118	Mouse	mmu-miR-155	miRNA	dexamethasone (DEX)	intracerebral haemorrhage (ICH)	astrocytes	dexamethasone (DEX) treatment	downregulated	27601160
15119	Mouse	mmu-miR-155	miRNA	hypoxia	ischemic stroke (IS)	mouse brain tissues	middle cerebral artery occlusion (MCAO)	miR-155 is a direct target of lncRNA Oprm1. lncRNA Oprm1/miR-155/GATA3 axis plays an important role in cerebral I/R injury.	31187646
15120	Mouse	mmu-miR-155	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-155 is a direct target of lncRNA Oprm1 lncRNA Oprm1/miR-155/GATA3 axis plays an important role in cerebral I/R injury	31187646
15121	Mouse	mmu-miR-155	miRNA	gualou guizhi decoction (GLGZD)	ischemic brain injury	BV2 cells	GuaLou GuiZhi Decoction (GLGZD) treatment	GuaLou GuiZhi Decoction (GLGZD) might exert its anti-inflammatory action by inhibiting the expression of miR-155.	32173634
15122	Mouse	mmu-miR-155	miRNA	CoCl2	ischemic heart disease (IHD)	cardiac stem cells (CSCs)	CoCl 2 treatment	A dose-dependent decrease of miR-155 expression in CSCs treated with CoCl2.	30362213
15123	Mouse	mmu-miR-155	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues	infect with JEV treatment	upregulated	24522920
15124	Mouse	mmu-miR-155	miRNA	deoxycorticosterone acetate (DOCA)	kidney damage	hypertensive mice kidneys and urine	injection of Deoxycorticosterone acetate (Doca)	upregulated in the kidneys and urine	29255279
15125	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	kidney damage	mouse renal tissues	intraperitoneally injected with LPS	upregulated in renal tissues	31966808
15126	Mouse	mmu-miR-155	miRNA	leishmania	leishmaniasis	"the liver and J774 macrophages, and in spleens from infected mice"	Leishmania infection	upregulated	29943317
15127	Mouse	mmu-miR-155	miRNA	quercetin-3-glucuronide (Q3G)	leukemia	RAW264.7 macrophages	quercetin-3-glucuronide (Q3G) treatment	downregulated	20579867
15128	Mouse	mmu-miR-155	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	upregulated	20436259
15129	Mouse	mmu-miR-155	miRNA	acetaminophen (APAP)	liver damage	liver£¬blood	acetaminophen (APAP) treatment	upregulated	27673475
15130	Mouse	mmu-miR-155	miRNA	Triggering receptors expressed on myeloid cell-1 (TREM-1)	liver fibrosis	macrophages and lungs	Triggering receptors expressed on myeloid cell-1 (TREM-1) knockout treatment	downregulated	26684249
15131	Mouse	mmu-miR-155	miRNA	"(R)-2-isobutyl 3-methyl 3,4-dihydro-1H-pyrido[3,4-b]indole-2,3(9H)-dicarboxylate"	liver fibrosis	RAW 264.7 cells	"(R)-2-isobutyl 3-methyl 3,4-dihydro-1H-pyrido[3,4-b]indole-2,3(9H)-dicarboxylate (1) treatment"	downregulated	24299616
15132	Mouse	mmu-miR-155	miRNA	leishmania RNA virus 1 (LRV1)	leishmania RNA virus 1 (LRV1) infection	macrophage of naive mice	leishmania RNA virus 1 (LRV1) treatment	upregulated	27593513
15133	Mouse	mmu-miR-155	miRNA	binase	lymphosarcoma	RLS40 cells	binase treatment	downregulated	33147876
15134	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	RAW264.7 macrophage cells	lipopolysaccharide (LPS) treatment	upregulated	22415194
15135	Mouse	mmu-miR-155	miRNA	cypermethrin (CYM)	macrophage polarization	LPS-treated RAW264.7 cells	Cypermethrin (CYM) treatment	downregulated	29471534
15136	Mouse	mmu-miR-155	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	macrophage polarization	RAW264.7 cells	LPS/IFN-¦Ã treatment	upregulated	30384539
15137	Mouse	mmu-miR-155	miRNA	IL-4 and IL-13	macrophage polarization	RAW264.7 cells	IL-4 and IL-13 treatment	downregulated	30384539
15138	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	macrophage polarization	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	29471534
15139	Mouse	mmu-miR-155	miRNA	the fraction of Hedyotis diffusa and Scutellaria barbata herb couple(YDW11)	macrophage polarization	LPS/IFN-¦Ã-induced M1 macrophage (RAW264.7 cells)	the fraction of Hedyotis diffusa and Scutellaria barbata herb couple(YDW11) treatment	downregulated	30384539
15140	Mouse	mmu-miR-155	miRNA	the fraction of Hedyotis diffusa and Scutellaria barbata herb couple(YDW11)	macrophage polarization	IL-4/IL-13-induced M2 macrophage (RAW264.7 cells)	the fraction of Hedyotis diffusa and Scutellaria barbata herb couple(YDW11) treatment	upregulated	30384539
15141	Mouse	mmu-miR-155	miRNA	genetically attenuated parasites (GAP) that arrest in the liver	malaria	mouse liver	GAP-injected mice treatment	upregulated	25189739
15142	Mouse	mmu-miR-155	miRNA	selenium (Se)	mastitis	Staphylococcus aureus (S. aureus)-infected mouse mammary tissues and primary mouse mammary epithelial cells (MMECs)	Selenium (Se) supplementation treatment	downregulated	31545328
15143	Mouse	mmu-miR-155	miRNA	Staphylococcus aureus	mastitis	mouse mammary tissues and primary mouse mammary epithelial cells (MMECs)	Staphylococcus aureus (S. aureus) infection treatment	upregulated	31545328
15144	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	microglial activation	N9 microglial cells	lipopolysaccharide (LPS) treatment	upregulated	29410668
15145	Mouse	mmu-miR-155	miRNA	sulforaphane (SFN)	microglial activation	LPS-treated N9 microglial cells	Sulforaphane (SFN) treatment	downregulated	29410668
15146	Mouse	mmu-miR-155	miRNA	murine norovirus (MNV)	murine norovirus (MNV) infection	bone marrow derived macrophage (BMDM); RAW264.7 cells; BV-2 cells; caecum; colon tissues	murine norovirus (MNV) infection	downregulated	29900416
15147	Mouse	mmu-miR-155	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
15148	Mouse	mmu-miR-155	miRNA	sevoflurane (SEV)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	myocardial tissues	sevoflurane treatment	"The treatment of sevoflurane could reduce miR-155 expression and increased SIRT1 expression in the myocardial tissues, under which conditions, cardiac functions were promoted, accompanied by reduced infarct size and inhibited cardiomyocyte apoptosis"	31099069
15149	Mouse	mmu-miR-155	miRNA	3-acetyl-11-keto-¦Â-boswellic acid (AKBA) and dexamethasone (DEX)	neuroinflammation	brain tissues	3-acetyl-11-keto-¦Â-boswellic acid (AKBA) and dexamethasone (DEX) treatment	"The treatment of LPS-injected mice with either AKBA or DEX led to a signif- icant decrease in the relative miR-155 expression by 2.52 ¡À 0.33 and 3.78 ¡À 0.44, respectively, compared to LPS group."	29079998
15150	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	neuroinflammation	N9 microglia	lipopolysaccharide (LPS) treatment	upregulated	28096568
15151	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	neuroinflammation	BV2 microglia	lipopolysaccharides (LPS) treatment	upregulated	28875362
15152	Mouse	mmu-miR-155	miRNA	propofol (PPF)	neuroinflammation	LPS-treated BV2 microglia	Propofol treatment	downregulated	28875362
15153	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	neuroinflammation	mouse brain tissues	lipopolysaccharide (LPS) treatment	upregulated in the brain	29079998
15154	Mouse	mmu-miR-155	miRNA	alcohol	neuronal survival and neurite growth	primary or immortalized mouse microglia	alcohol exposure	upregulated	23951048
15155	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	BV-2 cells	lipopolysaccharide (LPS) treatment	"LPS induced M1 polarization in BV-2 cells with increasing of CD86, iNOS and miR-155."	32337959
15156	Mouse	mmu-miR-155	miRNA	phorbol-12-myristate-13-acetate(PMA)	neutrophil extracellular traps (NETs) generation	Neutrophils were separated from bone marrow cells	PMA treatment	upregulated	31736940
15157	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	26684249
15158	Mouse	mmu-miR-155	miRNA	green tea (GT)	obesity	adipose tissues	green tea (GT) treatment	GT reverses HFD-induced upregulated of miR-155 and -335 in epididymal adipose tissues.	29734116
15159	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	obesity	macrophage	high fat diet (HFD) feed	upregulated	27671445
15160	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	obesity	nucleus accumbens	high fat diet (HFD) feed	Significant reductions in the levels of miR-155 (82%) and miR-146a (41%) levels were observed within the nucleus accumbens of HFD mice compared to CTL.	28652200
15161	Mouse	mmu-miR-155	miRNA	high fat diet (HFD)	obesity	renal tissues	high fat diet (HFD) feed	upregulated	30715692
15162	Mouse	mmu-miR-155	miRNA	palmitic acid (PA)	obesity	The mouse renal microvascular endothelial cells (MECs)	palmitic acid (PA) treatment	upregulated	30715692
15163	Mouse	mmu-miR-155	miRNA	P. aeruginosa	ocular infection	Eight-week-old female C3H/HeJ mice corneas tissues	infect with ?P. aeruginosa treatment	?miR-155 expression was upregulated	24403554
15164	Mouse	mmu-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoclast differentiation	RAW264.7 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23078176
15165	Mouse	mmu-miR-155	miRNA	IFN-¦Â	osteoclast-mediated diseases	Murine macrophage cell line RAW26	Interferon-¦Â treatment	upregulated	22771905
15166	Mouse	mmu-miR-155	miRNA	alendronate	osteoporosis	Osteoporosis mice osteoclasts	alendronate treatment	downregulated	31317664
15167	Mouse	mmu-miR-155	miRNA	manganese (Mn)	oxidative stress	neuronal CATH.a cell line	Mn treatment	downregulated	30090472
15168	Mouse	mmu-miR-155	miRNA	P. gingivalis	P. gingivalis infection	ApoE mice heart and aorta tissues	infect with P. gingivalis treatment	upregulated	28646427
15169	Mouse	mmu-miR-155	miRNA	tanshinone IIA (Tan IIA)	P. gingivalis infection	ApoE mice serum and in heart	TSA (60 mg kg-/--/--1 day-1) treatment	downregulated	28646427
15170	Mouse	mmu-miR-155	miRNA	F. novicida	pancreatic cancer (PC)	L929 cells	F. novicida?infection	downregulated	20041145
15171	Mouse	mmu-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	periodontitis	OCCM-30 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28692806
15172	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	peripheral and CNS inflammation	primary murine microglia	lipopolysaccharide (LPS) treatment	upregulated	26134658
15173	Mouse	mmu-miR-155	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
15174	Mouse	mmu-miR-155	miRNA	cecal ligation and puncture (CLP)	polymicrobial sepsis	C57Bl/6 mice	cecal ligation and puncture (CLP) treatment	different regulation	24413579
15175	Mouse	mmu-miR-155	miRNA	dexamethasone (DEX)	preadipocyte differentiation	3T3-L1 preadipocytes	dexamethasone (Dex) treatment	miR-155 levels were upregulated (2.4-fold) by glucocorticoids in differentiating 3T3-L1 preadipocytes.	29352275
15176	Mouse	mmu-miR-155	miRNA	salmonella	programmed cell death	RAW 264.7 cells	salmonella treatment	upregulated	29608690
15177	Mouse	mmu-miR-155	miRNA	pseudomonas aeruginosa (PA)	pseudomonas aeruginosa lung infection	sorted lung macrophages	RP73 clinical strain of P. aeruginosa infection treatment	downregulated	28422188
15178	Mouse	mmu-miR-155	miRNA	resolvin D1 (RvD1)	pseudomonas aeruginosa lung infection	sorted lung macrophages from RP73 clinical strain of P. aeruginosa infected mouse	resolvin (Rv) D1 treatment	upregulated	28422188
15179	Mouse	mmu-miR-155	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
15180	Mouse	mmu-miR-155	miRNA	photo-oxidative damage (PD)	retinal degenerative diseases	retinal tissues; serum	photo-oxidative damage (PD) treatment	"Upregulation of miR-155 was detected in retinal tissue, serum and s-mEVs in response to photo-oxidative damage, localising to the nucleus of a subset of retinal ganglion cells and glial cells and in the cytoplasm of photoreceptors"	33037565
15181	Mouse	mmu-miR-155	miRNA	schistosoma japonicum	schistosomiasis	murine liver	Schistosoma japonicum infection treatment	upregulated	23825609
15182	Mouse	mmu-miR-155	miRNA	schistosomiasis	schistosomiasis liver inflammation	mouse liver tissues	schistosomiasis treatment	6W infected mice were significantly higher than those of the normal mice and of the 12W infected mice	25051829
15183	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	scleroderma fibrosis	RAW 264.7 and 293T cells	lipopolysaccharide (LPS) treatment	upregulated	18299402
15184	Mouse	mmu-miR-155	miRNA	dexamethasone (DEX)	sepsis	liver tissues	dexamethasone (DEX) treatment	downregulated	24244697
15185	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	sepsis	liver tissues	lipopolysaccharide (LPS) treatment	upregulated	24244697
15186	Mouse	mmu-miR-155	miRNA	SDF-1¦Á analog CTCE-0214 (CTCE)	sepsis	mouse with polymicrobial sepsis	EPC therapy treatment	upregulated in endothelial progenitor cells (EPCs)	24707934
15187	Mouse	mmu-miR-155	miRNA	lipopolysaccharide (LPS)	septic shock	Mouse Aorta and Left ventricular (LV)	lipopolysaccharide (LPS) treatment	upregulated	29979224
15188	Mouse	mmu-miR-155	miRNA	nuclear factor kappa-B (NF-¦ÊB) inhibitor Bay11-708211	supraesophageal bile reflux	hypopharyngeal mucosa	NF-¦ÊB inhibitor (BAY 11-7082) treatment	"Pre- but not post-application of NF-¦ÊB inhibitor, significantly blocks overexpression of Il6 and prostaglandin H synthases 2 (Ptgs2), and reverses miR-21, miR-155, miR-99a phenotypes."	32934775
15189	Mouse	mmu-miR-155	miRNA	T. gondii	T. gondii induced hepatic damage	liver tissues	T. gondii treatment	revealed a significant elevation in miRNA-155 expression and a significant reduction of BChE activity in all the infected untreated groups compared to the uninfected mice	33840057
15190	Mouse	mmu-miR-155	miRNA	lithium chloride and pilocarpine	temporal lobe epilepsy (TLE)	brain tissues	lithium-pilocarpine treatment	upregulated	27303295
15191	Mouse	mmu-miR-155	miRNA	controlled cortical impact (CCI)	traumatic brain injury (TBI)	mouse hippocampus	controlled cortical impact (CCI)	upregulated	28804446
15192	Mouse	mmu-miR-155	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	murine RAW264.7 cells and bone marrow-derived macrophages (BMDMs)	Mycobacterium tuberculosis (M.tb.)? infection	upregulated	22712528
15193	Mouse	mmu-miR-155	miRNA	triptolide (TPL)	ileocolonic anastomosis inflammation	lleum tissues; colon tissues	triptolide (TPL) treatment	downregulated	23911388
15194	Mouse	mmu-miR-155	miRNA	insulin	type 2 diabetes mellitus (T2DM)	liver tissues;adipose tissues;skeletal muscle tissues	?insulin? treatment	upregulated	27711113
15195	Mouse	mmu-miR-155	miRNA	artesunate (ART)	ulcerative colitis (UC)	RAW264.7 cells	artesunate (ART) treatment	ART treatment also reduced the expressions of pro-inflammatory factors and miR-155.	33524272
15196	Mouse	mmu-miR-155	miRNA	cinnamaldehyde (CA)	ulcerative colitis (UC)	RAW264.7 cells	Cinnamaldehyde (CA) treatment	downregulated	30530166
15197	Mouse	mmu-miR-155	miRNA	cinnamaldehyde (CA)	ulcerative colitis (UC)	colon tissues	Cinnamaldehyde (CA) treatment	downregulated	30530166
15198	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	DSS-induced mice colon tissues	Dextran sodium sulfate (DSS) treatment	upregulated	30530166
15199	Mouse	mmu-miR-155	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	mouse colon tissues	dextran-sulfate-sodium (DSS) treatment	upregulated	28888763
15200	Mouse	mmu-miR-155	miRNA	propofol (PPF)	unilateral ureteral obstruction (UUO)	UUO mouse	UUO mouse treatment	downregulated in kidney	27158339
15201	Mouse	mmu-miR-155	miRNA	live L. acidophilus	¦Â-lactoglobulin (¦Â-Lg) allergy	murine splenocytes	live L. acidophilus treatment	downregulated	30156972
15202	Mouse	mmu-miR-155	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	23797321
15203	Mouse	mmu-miR-155	miRNA	mycobacteria	depression	RAW264.7 cells	mycobacteria?infection	upregulated	24130493
15204	Mouse	mmu-miR-155	miRNA	IL-10	inflammation	BMDM	IL-10? treatment	downregulated	20435894
15205	Mouse	mmu-miR-155-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32955644
15206	Mouse	mmu-miR-155-5p	miRNA	angiostrongylus cantonensis (A. cantonensis)	angiostrongylus cantonensis (A. cantonensis) infection	mouse	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24682888
15207	Mouse	mmu-miR-155-5p	miRNA	"IL-4, IL-13 and IL-33"	allergic asthma (AA)	RAW264.7 cells	"IL-4,IL-13 and IL-33 treatment"	upregulated	29621782
15208	Mouse	mmu-mir-155-5p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
15209	Mouse	mmu-miR-155-5p	miRNA	histone deacetylase inhibitor (HDACi)	B cell differentiation	B cells of C57BL/6J	"stimulated with LPS and IL-4 and treated with HDI (VPA, 500 ?M) or nil for 60 h"	upregulated	28994753
15210	Mouse	mmu-miR-155-5p	miRNA	apigenin	cardiac fibrosis	TGF-¦Â1-treated mouse cardiac fibroblasts (M6300)	apigenin treatment	downregulated	32800930
15211	Mouse	mmu-miR-155-5p	miRNA	apigenin	cardiac fibrosis	M6300 cells	apigenin treatment	downregulated	32800930
15212	Mouse	mmu-miR-155-5p	miRNA	TGF-¦Â1	cardiac fibrosis	Mouse cardiac fibroblasts (M6300)	TGF-¦Â1 treatment	upregulated	32800930
15213	Mouse	mmu-miR-155-5p	miRNA	geniposide and ginsenoside Rg1	cerebral ischemia injury (CII)	oxygen-glucose deprivation (OGD) treated BV2 mouse microglial cells	Geniposide+Ginsenoside Rg1 dual treatment	downregulated	29257264
15214	Mouse	mmu-miR-155-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	BV2 mouse microglial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	29257264
15215	Mouse	mmu-miR-155-5p	miRNA	echinococcus multilocularis metacestodes	echinococcus multilocularis infection	RAW 264.7 cells	E. multilocularis metacestodes treatment	upregulated	30322806
15216	Mouse	mmu-miR-155-5p	miRNA	angiostrongylus cantonensis (A. cantonensis)	eosinophilic meningitis (EM)	murine microglial cell line N9	angiostrongylus cantonensis (A. cantonensis) infection	The current study confirmed that miR-155-5p peaked at 21 days after A. cantonensis infection.	32966836
15217	Mouse	mmu-miR-155-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	downregulated	31497013
15218	Mouse	mmu-miR-155-5p	miRNA	fluke Fasciola gigantica (FgESPs)	F. gigantica infection	liver tissues	fluke Fasciola gigantica (FgESPs) infection	upregulated	33332355
15219	Mouse	mmu-miR-155-5p	miRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	upregulated	31782248
15220	Mouse	mmu-miR-155-5p	miRNA	E. multilocularis metacestodes	infection and immunity of E. multilocularis	RAW264¡¤7 macrophage cells	E. multilocularis metacestodes for 6 and 12 h treatment	"upregulated (mmu-miR-378d,mmu-miR-155-5p, mmu-miR-146a-5p, mmu-miR-21a-5p , mmu-miR-125a-5p) and downregulated(mmu-miR-1981-5p , mmu-miR-let-7c-1-3p)"	28942753
15221	Mouse	mmu-miR-155-5p	miRNA	lactic acid (LA)	inflammation	bone marrow-derived mast cells (BMMC) of C57BL/6 mouse	lactic acid (LA) treatment	downregulated	27559047
15222	Mouse	mmu-miR-155-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32955644
15223	Mouse	mmu-miR-155-5p	miRNA	dexamethasone (DEX)	innate immune response	immature DCs (iDCs)	dexamethasone (DEX) treatment	downregulated	30174602
15224	Mouse	mmu-miR-155-5p	miRNA	IL-10	innate immune response	immature DCs (iDCs)	IL-10 treatment	downregulated	30174602
15225	Mouse	mmu-miR-155-5p	miRNA	methamphetamine (METH)	methamphetamine (METH)-mediated neurotoxicity	BV2 cells and mouse brain	Methamphetamine (METH) treatment	MiR-155-5p was significantly reduced by METH in vitro but increased in vivo.	30914375
15226	Mouse	mmu-miR-155-5p	miRNA	preformed fibrils (PFFs) of human wild-type ¦ÁSyn	microglial activation	Mouse primary microglia	preformed fibrils (PFFs) of human wild-type ¦ÁSyn treatment	upregulated	31182996
15227	Mouse	mmu-miR-155-5p	miRNA	triptolide (TPL)	microglial activation	preformed fibrils (PFFs) of human wild-type ¦ÁSyn-treated mouse primary microglia	triptolide (T10) treatment	downregulated	31182996
15228	Mouse	mmu-miR-155-5p	miRNA	neurotoxicant cuprizone (CPZ)	myelin abnormalities	myelin	Neurotoxicant cuprizone (CPZ) treatment	miR-155-5p and miR-20a-5p upregulations enhanced NgR induction through Smad 2 and Smad 4 suppression in demyelination.	31963761
15229	Mouse	mmu-miR-155-5p	miRNA	rosmarinic acid (RA)	parkinson's disease (PD)	ventral midbrain	rosmarinic acid (RA) treatment	MPTP injection increased the relative expression of miR-155-5p and RA treatment decreased its expression.	32946211
15230	Mouse	mmu-miR-155-5p	miRNA	geniposide and ginsenoside Rg3	stroke	BV2 mouse microglial cells	exposed to geniposide (40 ?g/ml) + ginsenoside Rg1 (8 ?g/ml)	upregulated	29257264
15231	Mouse	mmu-miR-155-5p	miRNA	"chlorpromazine, procainamide, manganese"	systemic lupus erythematosus (SLE)	mouse	"chlorpromazine, procainamide, manganese"	dysregulated	29349090
15232	Mouse	mmu-miR-155-5p	miRNA	T-2 toxin	T-2 toxin-induced inflammatory response	RAW264.7 cells	T-2 toxin treatment	upregulated	32240701
15233	Mouse	mmu-miR-15a	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	hippocampal neurons	amyloid-¦Â (A¦Â) 25-35 treatment	TUG1 knockdown restricts apoptosis of hippocampal neurons in AD by elevating miR-15a and suppressing ROCK1 expression.	32577774
15234	Mouse	mmu-miR-15a	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
15235	Mouse	mmu-miR-15a	miRNA	IL-22	colitis	CT-26 cells	Interleukin-22 (IL-22) treatment	downregulated	29023933
15236	Mouse	mmu-miR-15A	miRNA	IL-17A	colorectal cancer (CRC)	intestinal epithelial cells (IECs) of C57BL/B6 mice	IL17A treatment	downregulated	29031499
15237	Mouse	mmu-miR-15a	miRNA	[6]-gingerol-fractions (GF)	diabetic wound healing	diabetic skin wounds	[6]-gingerol-fractions (GF) treatment	upregulated	31428171
15238	Mouse	mmu-miR-15a	miRNA	vitamin D	diabetic wound healing	diabetic skin wounds	vitamin D treatment	upregulated	31428171
15239	Mouse	mmu-miR-15a	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	mouse lung tissues	bleomycin (BLM) treatment	downregulated	30644438
15240	Mouse	mmu-miR-15a	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	neonatal primary lung fibroblasts	transforming growth factor (TGF)-¦Â1 treatment	downregulated	30644438
15241	Mouse	mmu-miR-15a	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	mouse primary lung fibroblasts	TGF-¦Â1 treatment	"miR-15a antagonized the function of PFAR and inhibited PFAR induced extracellular collagen deposition, fibroblasts proliferation, migration and differentiation"	31273058
15242	Mouse	mmu-miR-15a	miRNA	exenatide (EXA)	insulin sensitivity	pancreas	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 375 in the pancreas were significantly increased in HFD control mice.These effects were reversed by treatment with exenatide."	26314504
15243	Mouse	mmu-miR-15a	miRNA	exenatide (EXA)	insulin sensitivity	muscle	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 146a in the muscle were significantly increased. These effects were reversed by treatment with exenatide."	26314504
15244	Mouse	mmu-miR-15a	miRNA	exenatide (EXA)	insulin sensitivity	serum	exenatide treatment	"the levels of miRNA-15a, 29c, 124a, and 375 in the serum were significantly decreased. These effects were reversed by treatment with exenatide."	26314504
15245	Mouse	mmu-miR-15a	miRNA	high fat diet (HFD)	insulin sensitivity	pancreas	high fat diet (HFD) feed	upregulated	26314504
15246	Mouse	mmu-miR-15a	miRNA	high fat diet (HFD)	insulin sensitivity	muscle	high fat diet (HFD) feed	upregulated	26314504
15247	Mouse	mmu-miR-15a	miRNA	high fat diet (HFD)	insulin sensitivity	serum	high fat diet (HFD) feed	downregulated	26314504
15248	Mouse	mmu-miR-15a	miRNA	ischemia/reperfusion (I/R) 	keratinocyte migration and boosts re-epithelialization during skin wound healing	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	22783320
15249	Mouse	mmu-miR-15a	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	downregulated	20436259
15250	Mouse	mmu-miR-15a	miRNA	concanamycin A (Con A)	liver damage	liver tissues	concanavalin A (ConA) treatment	downregulated	29023933
15251	Mouse	mmu-miR-15a	miRNA	high fat diet (HFD)	obesity	C57Bl/6 mice	high fat diet (HFD) feed	upregulated	28944834
15252	Mouse	mmu-miR-15a	miRNA	peroxisome proliferator-activated receptor delta (PPARdelta)	obstructive cholestasis	mouse Cerebral vascular endothelial cell (CEC)	peroxisome proliferator-activated receptor delta (PPARdelta)?treatment treatment	upregulation of PPARdelta can alleviate ODG-activated microRNA-15a (miR-15a) expression in CECs	20445066
15253	Mouse	mmu-miR-15a	miRNA	Tripterygium glycosides (TGs)	premature ovarian failure (POF)	ovarian granulosa cells (OGCs)	Tripterygium glycosides (TGs) treatment	upregulated	30092342
15254	Mouse	mmu-miR-15a	miRNA	radiation	radiation-induced fibrosis (RIF)	"CH3 mice muscle, skin, and subcutaneous tissue"	the right hind legs of 9-week old CH3 mice by a single-fraction dose of irradiation to 35 Gy treatment	dysregulated	24986745
15255	Mouse	mmu-miR-15a	miRNA	H2O2	spinal cord injury (SCI)	C8-D1A and C8B4 cells	H2O2 treatment	downregulated	31773669
15256	Mouse	mmu-miR-15a	miRNA	IFN	systemic lupus erythematosus (SLE)	splenic cellular and plasma	interferon treatment	upregulated	22578383
15257	Mouse	mmu-miR-15a*	miRNA	recombinant Adeno-Cre viruses (AdV-Cre)	lung adenocarcinoma (LUAD)	lung	recombinant Adeno-Cre viruses (AdV-Cre) treatment	upregulated	25359683
15258	Mouse	mmu-miR-15a-3p	miRNA	delvestidine (DLTD)	bone marrow-derived dendritic cells (BMDCs) maturity	bone marrow-derived dendritic cells (BMDCs)	Delvestidine (DLTD) treatment	upregulated	32871480
15259	Mouse	mmu-miR-15a-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Mouse podocytes (MPC5)	MPC5 were treated with 100 ng/mL LPS (Sigma-Aldrich) for 48 h	miR-15a-5p was significantly downregulated in LPS-treated MPCs.	31658856
15260	Mouse	mmu-miR-15a-5p	miRNA	ozone (O3)	asthma	CD4+ T cells and ASMCs	ozone treatment	lncRNA PVT1-miR-15a-5p/miR-29c-3p-PI3K-Akt-mTOR axis was implicated in ozone-induced asthma development by promoting ASMC proliferation and Th1/Th2 imbalance	33223504
15261	Mouse	mmu-miR-15a-5p	miRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes	phenylephrine [PE] treatment	upregulated	31889385
15262	Mouse	mmu-miR-15a-5p	miRNA	ischemia	cerebral ischemia injury (CII)	region of the gerbil hippocampus	transient common carotid artery occlusion (tCCAO) treatment	upregulated	25646661
15263	Mouse	mmu-miR-15b	miRNA	Bortezomib	acute allograft rejection (AR) after renal transplant	AR renal tissues	bortezomib? treatment	upregulated	31377589
15264	Mouse	mmu-miR-15b	miRNA	TNF	acute liver failure (ALF)	liver tissue	TNF treatment	upregulated	22374434
15265	Mouse	mmu-miR-15b	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
15266	Mouse	mmu-miR-15b	miRNA	puerarin	cardiac hypertrophy	Ang II-induced cardiac hypertrophy	Puerarin treatment	upregulated	27145790
15267	Mouse	mmu-miR-15b	miRNA	rosemary	colorectal cancer (CRC)	nude mice CRC tissues	rosemary treatment	downregulated	24892299
15268	Mouse	mmu-miR-15b	miRNA	herpes simplex virus 1 (HSV-1)	inflammation and innate immunity	mouse brain tissue	infect with HSV-1	upregulated	28045967
15269	Mouse	mmu-miR-15b	miRNA	epigallocatechin-3-gallate (EGCG)	inflammation	CD4 naive T cells isolated from C57BL/6 mice	10 ¦ÌM EGCG	upregulated	27851983
15270	Mouse	mmu-miR-15b	miRNA	ischemia/reperfusion (I/R) 	keratinocyte migration and boosts re-epithelialization during skin wound healing	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	22783320
15271	Mouse	mmu-miR-15b	miRNA	nicotine	neurobehavioral effects of nicotine	the spermatozoa of F0 mice;the brains of F1 mice	nicotine both the spermatozoa of F0 mice and the brains of F1 mice	downregulated in both the spermatozoa of F0 mice and the brains of F1 mice	28779169
15272	Mouse	mmu-miR-15b	miRNA	Japanese encephalitis virus (JEV)	neuroinflammation	glial cells and mouse brains	Japanese encephalitis virus (JEV) treatment	upregulated	26202983
15273	Mouse	mmu-miR-15b	miRNA	cigarette smoke (CS)	ovarian toxicity	ovarian tissues	cigarette smoke (CS) treatment	upregulated	29377183
15274	Mouse	mmu-miR-15b	miRNA	lipopolysaccharide (LPS)	sepsis and septic shock	blood cells	LPS treatment	upregulated	23395002
15275	Mouse	mmu-miR-15b	miRNA	cyclophosphamide (CP)	premature ovarian failure (POF)	mouse ovarian granulosa cells (mOGCs)	cyclophosphamide treatment	upregulated	31310795
15276	Mouse	mmu-miR-15b-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	prefrontal cortex	chronic unpredictable mild stress (CUMS) treatment	downregulated	27701406
15277	Mouse	mmu-miR-15b-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	NAc tissue	chronic unpredictable mild stress (CUMS) treatment	upregulated	31430030
15278	Mouse	mmu-miR-15b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	The mouse podocytes	high glucose (HG) treatment	downregulated	31025335
15279	Mouse	mmu-miR-15b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cells (MCs)	high glucose (HG) treatment	HG elevated miR-15b-5p expression.	31991106
15280	Mouse	mmu-miR-15b-5p	miRNA	sevoflurane (SEV)	endoplasmic reticulum stress (ERS)	HT22 cells	Sev treatment	upregulated	31966678
15281	Mouse	mmu-miR-15b-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	brain	chronic unpredictable mild stress (CUMS) treatment	"microRNA-15b-5p play a critical role in chronic stress-induced depression by decreasing synaptic proteins, innervations, and activities in the nucleus accumbens."	32209659
15282	Mouse	mmu-miR-15b-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29217406
15283	Mouse	mmu-miR-15b-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29217406
15284	Mouse	mmu-miR-1-5p	miRNA	lipopolysaccharide (LPS)	myocardial dysfunction	cardiomyocytes	lipopolysaccharide (LPS) treatment	The lncRNA RMRP axis acts as a sponge for miR-1-5p. RMRP inhibits LPS-induced apoptosis of cardiomyocytes and mitochondrial damage by suppressing the post-transcriptional regulatory function of miR-1-5p on HSPA4.	31900829
15285	Mouse	mmu-miR-16	miRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	C57BL/6 male mice	ischemia/reperfusion (I/R) treatment	upregulated	27297958
15286	Mouse	mmu-miR-16	miRNA	TNF	acute liver failure (ALF)	liver tissue	TNF treatment	upregulated	22374434
15287	Mouse	mmu-miR-16	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	30784935
15288	Mouse	mmu-miR-16	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
15289	Mouse	mmu-miR-16	miRNA	thyroid hormone	brain development	mouse fetal cortex	inject TH 12 h before sacrifice on GD 16 treatment	downregulated	24436321
15290	Mouse	mmu-miR-16	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	tumorigenesis	brain and liver tissue cells	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) treatment"	downregulated	19270793
15291	Mouse	mmu-miR-16	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	mouse VSMC line	angiotensin II (Ang II) treatment	downregulated	29104843
15292	Mouse	mmu-miR-16	miRNA	fluoxetine (Prozac)	colorectal cancer (CRC)	serotonergic raphe nuclei of mice	fluoxetine (Prozac) treatment	upregulated	20847275
15293	Mouse	mmu-miR-16	miRNA	fluoxetine (Prozac)	Dendritic cell cross-priming	serotonergic raphe neurons	fluoxetine (Prozac) treatment	"Fluoxetine, acting on serotonergic raphe neurons, decreases the amount of miR-16 in the hippocampus"	22833211
15294	Mouse	mmu-miR-16	miRNA	Deoxycorticosterone acetate (Doca)	hypertensive heart disease (HHD)	mouse HHD cells	injection of Deoxycorticosterone acetate (Doca)	upregulated in HHD cells	28531963
15295	Mouse	mmu-miR-16	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	sera	bleomycin (BLM) treatment	Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis.	33307020
15296	Mouse	mmu-miR-16	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	rectal mucosa	dextran sulfate sodium treatment	upregulated	32361613
15297	Mouse	mmu-miR-16	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	Liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	29080810
15298	Mouse	mmu-miR-16	miRNA	lipopolysaccharide (LPS)	lung injury	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	22185353
15299	Mouse	mmu-miR-16	miRNA	"3,3'-diindolylmethane (DIM)"	multiple sclerosis (MS)	activated T cells during the development of experimental autoimmune encephalomyelitis (EAE)	"3,3'-Diindolylmethane (DIM) treatment"	upregulated	24898268
15300	Mouse	mmu-miR-16	miRNA	monosodium glutamate (MSG)	obesity	liver tissues	monosodium glutamate (MSG)-injected mice with developed central obesity treatment	dysregulated	24465854
15301	Mouse	mmu-miR-16	miRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	mouse aortic endothelial cells (MAECs)	chronic intermittent hypoxia (CIH) treatment	downregulated	29108914
15302	Mouse	mmu-miR-16	miRNA	lipopolysaccharide (LPS)	sepsis and septic shock	blood cells	LPS treatment	upregulated	23395002
15303	Mouse	mmu-miR-16	miRNA	plasmodium	plasmodium infection	exosomes derived from the plasma	infect with Plasmodium treatment	upregulated	28650446
15304	Mouse	mmu-miR-16	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
15305	Mouse	mmu-miR-16	miRNA	epigallocatechin-3-gallate (EGCG)	breast cancer	"Murine breast cancer cell lines, 4T1"	Epigallocatechin gallate (EGCG)	EGCG upregulated miR-16 in 4T1 cells and in the exosomes	24044575
15306	Mouse	mmu-miR-16-1	miRNA	IL-22	colitis	CT-26 cells	Interleukin-22 (IL-22) treatment	downregulated	29023933
15307	Mouse	mmu-miR-16-1	miRNA	IL-17A	colorectal cancer (CRC)	intestinal epithelial cells (IECs) of C57BL/B6 mice	IL17A treatment	downregulated	29031499
15308	Mouse	mmu-miR-16-1	miRNA	triptolide (TPL)	crohn disease (CD)	IL-10-/- mice undergoing ileocecal resection (ICR)	triptolide (TPL) treatment	downregulated	28627592
15309	Mouse	mmu-miR-16-1	miRNA	concanamycin A (Con A)	liver damage	liver tissues	concanavalin A (ConA) treatment	downregulated	29023933
15310	Mouse	mmu-miR-16-2-3p	miRNA	delvestidine (DLTD)	bone marrow-derived dendritic cells (BMDCs) maturity	bone marrow-derived dendritic cells (BMDCs)	Delvestidine (DLTD) treatment	upregulated	32871480
15311	Mouse	mmu-miR-16-5p	miRNA	anandamide and norgestimate	depression	chronic mild stress (CMS) model of depression mouse	anandamide and norgestimate treatment	downregulated	28716528
15312	Mouse	mmu-miR-16-5p	miRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	two-week old Kunming (KM) mice muscle	intraperitoneally injected with high-virulence EV71 (GZ-CII strain)	upregulated	29180670
15313	Mouse	mmu-miR-16-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
15314	Mouse	mmu-miR-17	miRNA	hydrochloric acid	acute lung injury (ALI)	C57BL/6 mice microvesicle (MV)release from lung epithelium	"hydrochloric acid (0.1 N, pH 1.5) was intratracheally instilled into the mouse lung"	upregulated in microvesicle (MV)release from lung epithelium	28674181
15315	Mouse	mmu-miR-17	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	"Using a lipopolysaccharide (LPS)-induced ALI mouse model, it was observed that miR-17 was significantly downregulated in lung tissues"	32626914
15316	Mouse	mmu-miR-17	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	type II epithelial cells from 6-week-old mice	lipopolysaccharide (LPS) treatment	downregulated	24486549
15317	Mouse	mmu-miR-17	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	33143661
15318	Mouse	mmu-miR-17	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia (Hyp) treatment	Downregulated lncRNA H19 relieved pulmonary injury via targeting miR-17 to downregulate STAT3 and reduced inflammatory response caused by p-STAT3 in BPD newborn mice.	33285606
15319	Mouse	mmu-miR-17	miRNA	"retinoic acid (RA), leukemia inhibitory factor (LIF) and basic fibroblast growth factor (bFGF)"	cell differentiation	mouse bone marrow mesenchymal stem cells (BMSCs)	"retinoic acid (RA), leukemia inhibitory factor (LIF) and basic fibroblast growth factor (bFGF) treatment"	downregulated	32195202
15320	Mouse	mmu-miR-17	miRNA	high glucose (HG)	apoptosis	uteri	High glucose treatment	downregulated	26660634
15321	Mouse	mmu-miR-17	miRNA	ischemia/reperfusion (I/R) 	head and neck squamous cell carcinoma (HNSCC)	heart tissues	ischemia/reperfusion (I/R) treatment	the miR-17-92 cluster may protect the heart by diminishing the apoptosis and alleviating ischemia/reperfusion injury	23639284
15322	Mouse	mmu-miR-17	miRNA	high glucose (HG)	inflammation	RAW264.7 macrophages or mouse peritoneal macrophages	high glucose treatment	downregulated	29477089
15323	Mouse	mmu-miR-17	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 macrophages or mouse peritoneal macrophages	lipopolysaccharide (LPS) treatment	downregulated	29477089
15324	Mouse	mmu-miR-17	miRNA	¦¤9-tetrahydrocannabinol (THC)	inflammation	total lymph node cells and CD4(+) T cells	¦¤9-Tetrahydrocannabinol (THC) treatment	downregulated	27268054
15325	Mouse	mmu-miR-17	miRNA	retinoic acid (RA)	neuroblastoma (NB)	The SH-SY5Y cells	retinoic acid treatment	downregulated of miR-17 family	19666108
15326	Mouse	mmu-miR-17	miRNA	plasmodium	plasmodium infection	exosomes derived from the plasma	infect with Plasmodium treatment	upregulated	28650446
15327	Mouse	mmu-miR-17	miRNA	imiquimod (IMQ)	psoriasis-like dermatitis	the mouse skin tissues	IMQ treatment	dysregulated	27579777
15328	Mouse	mmu-miR-17	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
15329	Mouse	mmu-miR-17	miRNA	di(2-ethylhexyl) phthalate (DEHP)	skeletal muscle insulin resistance	skeletal muscle cells	di(2-ethylhexyl) phthalate (DEHP) treatment	The miR-17/Keap1-Nrf2/miR-200a axis contributed to DEHP-induced insulin resistance.	32802189
15330	Mouse	mmu-miR-17	miRNA	genistein	spermatogenesis	ICR mice testis	"different doses of GEN (0, 0.5, 5, 50 and 250 mg/kg/day) for 35 days"	upregulated	28938591
15331	Mouse	mmu-miR-17	miRNA	IFN-¦Ã	type 1 diabetes mellitus (T1DM)	¦Â-cells	IFN¦Ãtreatment	downregulated	26858253
15332	Mouse	mmu-miR-17	miRNA	cigarette smoke extract (CSE)	¦Â-cell dysfunction	MIN6 cells	cigarette smoke extract (CSE) treatment	"cigarette smoke extract (CSE) downregulated the levels of the transcription factor, mafA, and microRNA (miR)-17."	29856480
15333	Mouse	mmu-miR-17	miRNA	high glucose (HG)	neural tube defects (NTDs)	"C17.2 mouse neural stem cells, newborn mouse cerebellar progenitor cells"	High Glucose treatment	downregulated	26660634
15334	Mouse	mmu-miR-17-3p	miRNA	swimming	cardiac hypertrophy	C57BL/6 mice ventricle samples	starting swimming from 10 minutes twice daily with 10 minutes increase each day until 90 minutes reached 14 for 21 days treatment	upregulated in ventricle samples	28255358
15335	Mouse	mmu-miR-17-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cells (MCs)	high glucose (HG) treatment	It was found that expression of circ_0037128 was significantly increased in mouse DN model and high glucose treated mesangial cells (MCs)	32860899
15336	Mouse	mmu-miR-17-3p	miRNA	adrenaline	heart failure (HF)	Primary NMCMs (neonatal mouse cardiomyocytes)	adrenaline treatment	downregulated	31595165
15337	Mouse	mmu-miR-175p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29250806
15338	Mouse	mmu-miR-17-5p	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	spleen cells	ovalbumin (OVA) treatment	miR-17-5p expression was higher in the OVA group.	31999672
15339	Mouse	mmu-miR-17-5p	miRNA	high fat diet (HFD)	atherosclerosis (AS)	vascular smooth muscle cell (VSMC)	high fat diet (HFD) feed	"p53-dependent lincRNA-p21 expression downregulated miR-17-5p, whichconsequently protecting against AS progression via SIRT7 elevation."	33169349
15340	Mouse	mmu-miR-17-5p	miRNA	high-cholesterol diet	atherosclerosis (AS)	macrophages of ApoE-/- mice	high-cholesterol diet feed	upregulated	30850242
15341	Mouse	mmu-miR-17-5p	miRNA	high-cholesterol diet	atherosclerosis (AS)	macrophages of ApoE-/- mice fed with a high-cholesterol diet	high-cholesterol diet feed	upregulated	30850242
15342	Mouse	mmu-miR-17-5p	miRNA	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	dopaminergic (DA) neuron differentiation	neuro-2a cells	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment"	dysregulated	29250806
15343	Mouse	mmu-miR-17-5p	miRNA	dexmedetomidine (DEX)	doxorubicin (DOX)-induced cardiotoxicity	cardiomyocytes	dexmedetomidine (Dex) treatment	upregulated	32190669
15344	Mouse	mmu-miR-17-5p	miRNA	electroacupuncture (EA)	electroacupuncture (EA)	CD4 T cells	electroacupuncture (EA) treatment	upregulated	32026263
15345	Mouse	mmu-miR-17-5p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	follicular development	ovarian	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	29385306
15346	Mouse	mmu-miR-17-5p	miRNA	WY14643	hepatocellular carcinoma (HCC)	Mycfl/fl mice	"two days of Wy-14,643 treatment"	upregulated	24096051
15347	Mouse	mmu-miR-17-5p	miRNA	pinostilbene hydrate (PSH)	liver fibrosis	hepatic stellate cells (HSCs)	Pinostilbene hydrate (PSH) treatment	upregulated	32919323
15348	Mouse	mmu-miR-17-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29250806
15349	Mouse	mmu-miR-17-5p	miRNA	paraquat (PQ)	neurodegenerative diseases	N2a cells	paraquat (PQ) treatment	downregulated	29250806
15350	Mouse	mmu-miR-17-5p	miRNA	high fat diet (HFD)	obesity and obesity-associated insulin resistance	C57Bl/J mice	high fat diet (HFD) feed	downregulated	28265343
15351	Mouse	mmu-miR-17-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	murine induced pluripotent stem cell (miPSC)	IL-1¦Â treatment	"RNA-seq results show that miR-17-5p increase from 4 to 24 hours, but slightly decrease from 24 to 72 hours in IL-1¦Â stimulated pellets."	32767602
15352	Mouse	mmu-miR-17-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	murine induced pluripotent stem cell (miPSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	"RNA-seq results show that miR-17-5p increase from 4 to 24 hours, but slightly decrease from 24 to 72 hours in TNF-¦Á stimulated pellets"	32767602
15353	Mouse	mmu-miR-17-5p	miRNA	radiation	radiation-induced injury	blood	radiation treatment	downregulated	29799276
15354	Mouse	mmu-miR-17-5p	miRNA	lipopolysaccharide (LPS)	sepsis	Peripheral Blood Mononuclear Cells from mouse peripheral blood and Raw264.7 macrophages	lipopolysaccharide (LPS) treatment	downregulated	30506107
15355	Mouse	mmu-miR-17-5p	miRNA	schisandrin B (Sch B)	sepsis	LPS-treated mouse peripheral Blood Mononuclear Cells or Raw264.7 macrophages	Schisandrin B (Sch B) treatment	upregulated	30506107
15356	Mouse	mmu-miR-17-92	miRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	mouse renal tubular	ischemia/reperfusion (I/R) treatment	upregulated in renal tubular	29699633
15357	Mouse	mmu-miR-17-92	miRNA	mouse mammary tumor virus (MMTV)	breast cancer	mouse mammary HC11 cells	infect with MMTV	upregulated	29096160
15358	Mouse	mmu-miR-17-92	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	tumorigenesis	brain and liver tissue cells	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) treatment"	downregulated	19270793
15359	Mouse	mmu-miR-17-92	miRNA	streptozocin (STZ)	islet beta-cell repair	Islets	streptozotocin treatment	MiR-17-92¦ÂKO mice showed dramatically elevated fasting blood glucose and impaired glucose tolerance after streptozotocin treatment	32038500
15360	Mouse	mmu-miR-17-92	miRNA	grape seed procyanidin extract (GSPE)	lung cancer	A549 cells	grape seed procyanidin extract (GSE) treatment	downregulated	27289489
15361	Mouse	mmu-miR-17-92	miRNA	rapamycin	myocardial infarction (MI)	cardiomyocytes	rapamycin (RAPA) treatment	STAT3-miR-17/20 signalling axis plays a critical role in attenuating myocardial infarction following rapamycin treatment in diabetic mice	31738412
15362	Mouse	mmu-miR-18	miRNA	IL-1¦Â	diabetes mellitus (DM)	MIN6 cells	IL-1¦Â treatment	upregulated	31258677
15363	Mouse	mmu-miR-18	miRNA	gold nanoparticles (AuNPs)	epithelial-mesenchymal transition and peritoneal fibrosis	liver and lung of mouse fetuses	gold nanoparticles (AuNP) treatment	upregulated	24004569
15364	Mouse	mmu-miR-181	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	tumorigenesis	brain and liver tissue cells	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) treatment"	downregulated	19270793
15365	Mouse	mmu-miR-181a	miRNA	curcumin (Cur)	acute kidney injury (AKI)	kidney tissues	curcumin treatment	Curcumin treatment decreased miR-181a expression level.	32338107
15366	Mouse	mmu-miR-181a	miRNA	transglutaminase 2 (TG2)	allergic inflammation	B16F1 mouse melanoma cells	TGaseII treatment	downregulated	25202021
15367	Mouse	mmu-miR-181a	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	primary hippocampal cells	amyloid-¦Â (A¦Â) treatment	A¦Â treatment inhibited cLTP-dependent induction of translin and subsequent reduction of miR-181a.	32087004
15368	Mouse	mmu-miR-181a	miRNA	IL-1¦Â	Alzheimer's disease (AD)	primary murine astrocyte and neuron co-culture	IL-1¦Â treatment	microRNA-181a was significantly decreased following the IL-1¦Â treatment.	29710703
15369	Mouse	mmu-miR-181a	miRNA	histone deacetylase inhibitors (HDIs) short-chain fatty acid (SCFA) butyrate	antibody-mediated systemic autoimmunity	B cells	SCFA HDI butyrate treatment	upregulated	32265934
15370	Mouse	mmu-miR-181a	miRNA	dexamethasone (DEX)	asthma	splenic CD4+ T lymphocytes	dexamethasone (DEX) treatment	downregulated	22580216
15371	Mouse	mmu-miR-181a	miRNA	TGF-¦Â	cirrhosis and hepatocellular cancer	liver	TGF-¦Â treatment	upregulated	24576072
15372	Mouse	mmu-miR-181a	miRNA	streptozocin (STZ)	diabetic corneal nerve	trigeminal ganglion tissue (TG)	streptozotocin (STZ) treatment		31926967
15373	Mouse	mmu-miR-181a	miRNA	cocaine and amphetamines	drug-induced synaptic plasticity	Primary neuronal cells; synaptoneurosomes tissues	cocaine and amphetamines treatment	dysregulated	22144581
15374	Mouse	mmu-miR-181a	miRNA	MOG 35-55 peptide emulsified and pertussis toxin	"experimental autoimmune encephalomyelitis (EAE),multiple sclerosis (MS)"	brain tissues	wereinjected subcutaneously with MOG 35-55 peptide emulsified and pertussis toxin	downregulated in brain	28769921
15375	Mouse	mmu-miR-181a	miRNA	di(2-ethylhexyl) phthalate (DEHP)	follicular development	ovarian	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	29385306
15376	Mouse	mmu-miR-181a	miRNA	oxidized low density lipoprotein (ox-LDL)	hyperlipidemia	dendritic cells (DCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	22956783
15377	Mouse	mmu-miR-181a	miRNA	lipopolysaccharide (LPS)	inflammation	blood	lipopolysaccharides (LPS) or streptozotocin treatment	upregulated	23220232
15378	Mouse	mmu-miR-181a	miRNA	streptozocin (STZ)	inflammation	blood	lipopolysaccharides (LPS) or streptozotocin treatment	upregulated	23220232
15379	Mouse	mmu-miR-181a	miRNA	brucella.suis	innate immune response	RAW264.7 cells	brucella.suis infection	upregulated	29387067
15380	Mouse	mmu-miR-181a	miRNA	morphine	neurogenesis	mouse	morphine treatment	upregulated	24964978
15381	Mouse	mmu-miR-181a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	primary mouse hepatocytes (PMH)	palmitic acid (PA) treatment	upregulated	30558790
15382	Mouse	mmu-miR-181a	miRNA	bone morphogenetic proteins (BMPs)	osteogenesis	pluripotent stem (iPS) cells	bone morphogenetic proteins (BMPs) treatment	downregulated	22937097
15383	Mouse	mmu-miR-181a	miRNA	3-nitropropionic acid	oxidative stress	ovary tissues	3-nitropropionic acid treatment	upregulated	31359035
15384	Mouse	mmu-miR-181a	miRNA	H2O2	oxidative stress	primary mouse mGC	H2O2	upregulated	28981116
15385	Mouse	mmu-miR-181a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	oxidative stress	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30949956
15386	Mouse	mmu-miR-181a	miRNA	sphingosine-1-phosphate (S1P)	oxidative stress	H2O2 treated primary mouse GCs (mGCs)	sphingosine-1-phosphate (S1P) treatment	downregulated	31359035
15387	Mouse	mmu-miR-181a	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
15388	Mouse	mmu-miR-181a	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
15389	Mouse	mmu-miR-181a	miRNA	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)"	thymic atrophy and alterations in T cell differentiation	fetal thymocytes of mice	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) treatment"	upregulated	23024791
15390	Mouse	mmu-miR-181a	miRNA	high glucose (HG)	wound healing	granulation tissues	streptozocin (STZ) treatment	miR-181a was upregulated in the diabetic wound healing mouse model.	30565672
15391	Mouse	mmu-miR-181a-1	miRNA	¦Â-elemene	oxygen-induced retinopathy (OIR)	Retinas tissues	¦Â-elemene treatment	upregulated	30664207
15392	Mouse	mmu-miR-181a-1-3p	miRNA	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2)"	liver damage	bone marrow (BM)-derived macrophage (BMM) of liver injury mouse	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2) treatment"	upregulated	28748390
15393	Mouse	mmu-miR-181a-5p	miRNA	brucella abortus	brucellosis	"bone marrow-derived macrophages, spleens"	brucella abortus infection	upregulated	29942317
15394	Mouse	mmu-miR-181a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	Mouse N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"?miR-181a-5p was highly expressed in serum of ACI patients, MCAO mice, and OGD/R-induced N2a cells"	33360253
15395	Mouse	mmu-miR-181a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-181a-5p was highly expressed in OGD/R-induced N2a cells	33360253
15396	Mouse	mmu-miR-181a-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiomyocytes	high glucose (HG) treatment	downregulated	31353329
15397	Mouse	mmu-miR-181a-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	primary cultured cardiomyocyte	high glucose treatment	downregulated	31353329
15398	Mouse	mmu-miR-181a-5p	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	myocardium	streptozocin treatment	downregulated	31353329
15399	Mouse	mmu-miR-181a-5p	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	myocardial tissues	streptozotocin (STZ) treatment	downregulated	31353329
15400	Mouse	mmu-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	31844680
15401	Mouse	mmu-miR-181a-5p	miRNA	social defeat stress	sex differences of social defeat stress	female mice	social defeat stress treatment	upregulated	33358922
15402	Mouse	mmu-miR-181b	miRNA	high fat diet (HFD)	nervous and immune system diseases	the aortic intima and plasma in mice	high fat diet (HFD) feed	MiR-181b expression was reduced in the aortic intima and plasma in apolipoprotein E-deficient mice fed a high-fat diet	24084690
15403	Mouse	mmu-miR-181b	miRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	vascular smooth muscle cell and mouse-aorta-origin vascular smooth muscle (MOVAS) cells	angiotensin II (Ang II) treatment	upregulated	30417353
15404	Mouse	mmu-miR-181b	miRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	angiotensin II (AngII) treated mouse-aorta-origin vascular smooth muscle (MOVAS) cells	angiotensin II (Ang II) treatment	upregulated	30417353
15405	Mouse	mmu-miR-181b	miRNA	licochalcone A (LA)	abdominal aortic aneurysm (AAA)	angiotensin II (AngII)-treated mouse vascular smooth muscle cell and mouse-aorta-origin vascular smooth muscle (MOVAS) cells	Licochalcone A (LA) treatment	downregulated	30417353
15406	Mouse	mmu-miR-181b	miRNA	licochalcone A (LA)	abdominal aortic aneurysm (AAA)	Mouse-aorta-origin vascular smooth muscle (MOVAS) cells	Licochalcone A (LA) treatment	downregulated	30417353
15407	Mouse	mmu-miR-181b	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	miR-181b was found to be downregulated in lung tissues in the OVA-challenged mice.	33640857
15408	Mouse	mmu-miR-181b	miRNA	high fat diet (HFD)	atherosclerosis (AS)	mouse	high fat diet (HFD) feed	downregulated	24084690
15409	Mouse	mmu-miR-181b	miRNA	oxygen glucose deprivation (OGD)	cerebral artery occlusion	HT22 cell	oxygen-glucose deprivation (OGD) treatment	downregulated	27642276
15410	Mouse	mmu-miR-181b	miRNA	CoCl2	cerebral ischemic stroke (CIS)	N2A neuroblastoma cells	CoCl2 treatment	miR-181b expression was significantly decreased in N2A neuroblastoma cells after CoCl 2-induced hypoxic injury in vitro.	29807144
15411	Mouse	mmu-miR-181b	miRNA	estrogen (ES)	renal fibrosis	mouse uterus tissues	Estrogen treatment	mirn451 was significantly increased by estrogen administration whereas mirn181b and mirn204 expression was significantly reduced	20720260
15412	Mouse	mmu-miR-181b	miRNA	high-fat/high-cholesterol diet or a high-protein diet	dyslipidemia	DO mice	a high-fat/high-cholesterol diet or a high-protein diet for 18 wk	dysregulated	28916633
15413	Mouse	mmu-miR-181b	miRNA	brucella.suis	innate immune response	RAW264.7 cells	brucella.suis infection	upregulated	29387067
15414	Mouse	mmu-miR-181b	miRNA	erythrocyte lysates	intracerebral haemorrhage (ICH)	Primary cortical neurons from C57BL/6 mice	erythrocyte lysates treatment	downregulated	30503822
15415	Mouse	mmu-miR-181b	miRNA	erythrocyte lysates	intracerebral haemorrhage (ICH)	Primary cortical neurons from C57BL/6 mice	erythrocyte lysates treatment	downregulated	30503822
15416	Mouse	mmu-miR-181b	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	31790896
15417	Mouse	mmu-miR-181b	miRNA	liquiritigenin (LQ)	liver fibrosis	carbon tetrachloride (CCl4)-treated mice liver tissues	Liquiritigenin (LQ) treatment	downregulated	31790896
15418	Mouse	mmu-miR-181b	miRNA	liquiritigenin (LQ)	liver fibrosis	hepatic stellate cells (HSC)	Liquiritigenin (LQ) treatment	LQ led to a significant reduction in miR-181b expression.	31790896
15419	Mouse	mmu-miR-181b	miRNA	hypoxia	apoptosis	brain tissues	MCAO surgical procedure	downregulated	27642276
15420	Mouse	mmu-miR-181b	miRNA	sevoflurane (SEV)	neurotoxicity	HT22 cells	Sevoflurane treatment	downregulated	32150149
15421	Mouse	mmu-miR-181b	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse	high fat diet (HFD) feed	upregulated	28899784
15422	Mouse	mmu-miR-181b	miRNA	tert-butyl hydroperoxide (TBHP)	oxidative stress	adult male mice strain Balb/c	TBHP treatment	differently regulated	25141839
15423	Mouse	mmu-miR-181b	miRNA	cecal ligation and puncture (CLP)	sepsis	late sepsis	cecal ligation and puncture (CLP) treatment	upregulated	24980967
15424	Mouse	mmu-miR-181b	miRNA	SiO2	silicosis	NR8383 cells	SiO2 treatment	downregulated	26239160
15425	Mouse	mmu-miR-181-b	miRNA	MOG 35-55 peptide emulsified and pertussis toxin	"experimental autoimmune encephalomyelitis (EAE),multiple sclerosis (MS)"	brain tissues	wereinjected subcutaneously with MOG 35-55 peptide emulsified and pertussis toxin	downregulated in brain	28769921
15426	Mouse	mmu-miR-181b	miRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	BV2 cells	?lipopolysaccharide (LPS) treatment	"In this study, we found that lncRNA p21 and tumor necrosis factor alpha-induced protein 1 (Tnfaip1) expression were upregulated and miR-181b expression was downregulated in lipopolysaccharide (LPS)-induced and activated BV-2 microglia"	33774143
15427	Mouse	mmu-miR-181b1	miRNA	neuraminidase (NA)	H9N2 influenza virus infection	Dendritic cells (DCs)	Neuraminidase (NA) treatment	downregulated	27285980
15428	Mouse	mmu-miR-181b-5p	miRNA	histone deacetylase inhibitor (HDACi)	B cell differentiation	B cells of C57BL/6J	"stimulated with LPS and IL-4 and treated with HDI (VPA, 500 ?M) or nil for 60 h"	upregulated	28994753
15429	Mouse	mmu-miR-181b-5p	miRNA	high fat diet (HFD)	hepatic insulin resistance	serum and livers of diabetic mice	high fat diet (HFD) feed	downregulated	30627917
15430	Mouse	mmu-miR-181b-5p	miRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	downregulated	31782248
15431	Mouse	mmu-miR-181b-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	mouse cementoblast cell line OCCM©\30	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31131439
15432	Mouse	mmu-miR-181b-5p	miRNA	lipopolysaccharide (LPS)	postoperative cognitive dysfunction (POCD)	BV-2 cell lines	lipopolysaccharide (LPS) treatment	downregulated	31003188
15433	Mouse	mmu-miR-181c	miRNA	H2O2	acute ischemic stroke (AIS)	BV2 microglia	H2O2 treatment	miR-181c reduced proliferation but increased the apoptosis of these cells with or without LPS/H2O2 treatment.	28053821
15434	Mouse	mmu-miR-181c	miRNA	lipopolysaccharide (LPS)	acute ischemic stroke (AIS)	BV2 microglia	lipopolysaccharide (LPS) treatment	miR-181c reduced proliferation but increased the apoptosis of these cells with or without LPS/H2O2 treatment.	28053821
15435	Mouse	mmu-miR-181c	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
15436	Mouse	mmu-miR-181c	miRNA	hypoxia	cerebral hypoxic diseases	primary microglia	hypoxia treatment	downregulated	25545945
15437	Mouse	mmu-miR-181c	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	mouse	cigarette smoke (CS) exposure	downregulated	28806967
15438	Mouse	mmu-miR-181c	miRNA	high glucose (HG)	diabetes mellitus (DM)	endothelial cells (MAECs and END-D)	high glucose	downregulated	28223216
15439	Mouse	mmu-miR-181c	miRNA	myelin oligodendrocyte glycoprotein	experimental autoimmune encephalomyelitis (EAE)	CD4+ T cells	(MOG residues 35-55 treatment	miR-181c expression was significantly increased in EAE mice.	29545117
15440	Mouse	mmu-miR-181c	miRNA	high fat diet (HFD)	obesity-induced cardiac dysfunction	heart sissues	high fat diet (HFD) feed	HFD significantly upregulated heart levels of miR-181c and led to cardiac hypertrophy in wild-type mice.	32442661
15441	Mouse	mmu-miR-181c-5p	miRNA	reconstituted high-density lipoproteins (rHDL)	diabetes-impaired angiogenesis	diabetic mice ischaemic hindlimb	reconstituted high-density lipoproteins (rHDL) treatment	downregulated	30206364
15442	Mouse	mmu-miR-181c-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary neuronal cells	oxygen glucose deprivation (OGD)-induce treatment	downregulated	31334597
15443	Mouse	mmu-miR-181c-5p	miRNA	berberine (BBR)	post-stroke inflammation	ipsilateral cortex tissues	berberine (BBR) treatment	Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation.	31431734
15444	Mouse	mmu-miR-181c-5p	miRNA	berberine (BBR)	post-stroke inflammation	MCAO treated ipsilateral cortex tissues	?berberine (BBR)?treatment treatment	upregulated	31431734
15445	Mouse	mmu-miR-181d	miRNA	coxsackievirus B3 (CVB3)	acute viral myocarditis (VM)	mouse heart tissues	Coxsackievirus B3 (CVB3) infection	upregulated	30915768
15446	Mouse	mmu-miR-181d	miRNA	losartan	diabetic nephropathy (DN)	kidney tissues	losartan treatment	downregulated	27770539
15447	Mouse	mmu-miR-181d	miRNA	lipopolysaccharide (LPS)	inflammation	C57BL/6 mouse	lipopolysaccharide (LPS) treatment	downregulated	24416377
15448	Mouse	mmu-miR-181d	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
15449	Mouse	mmu-miR-181d-5p	miRNA	acupuncture with low-frequency electrical stimulation (Acu/LFES)	muscle atrophy	serum exosome	acupuncture with low-frequency electrical stimulation (Acu/LFES) treatment	miR-181d-5p is increased in the serum exosome of Acu/LFES-treated mice.	30132347
15450	Mouse	mmu-miR-182	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	RAW264.7 cells	lipopolysaccharide (LPS) treatment	miR-182 is inhibited in RAW264.7 cells stimulated with LPS.	32003008
15451	Mouse	mmu-miR-182	miRNA	alcohol	alcoholic liver disease (ALD)	mouse liver cells	Lieber-DeCarli alcohol treatment	downregulated	19572984
15452	Mouse	mmu-miR-182	miRNA	methionine choline-deficient diet (MCD)	alcoholic liver disease (ALD)	liver tissues	methionine-choline-deficient (MCD) diets treatment	downregulated	19572984
15453	Mouse	mmu-miR-182	miRNA	CTLA4-Ig	alloimmune	CD4CD44 T cells	CTLA4-Ig	downregulated	27893611
15454	Mouse	mmu-miR-182	miRNA	oxygen glucose deprivation (OGD)	blood-brain barrier (BBB) dysfunction	N2a cells	oxygen glucose deprivation (OGD) treatment	MiR-182 expression was markedly upregulated and arrived at a peak 2 hours after OGD in N2a cells and was later downregulated.	32808351
15455	Mouse	mmu-miR-182	miRNA	oxygen glucose deprivation (OGD)	blood-brain barrier (BBB) dysfunction	bEnd.3 cells	oxygen glucose deprivation (OGD) treatment	"miR-182 in bEnd.3 cells began to increase at 4 hours after OGD, remained el- evated until 8 hours with a peak at 6 hours."	32808351
15456	Mouse	mmu-miR-182	miRNA	oxygen glucose deprivation (OGD)	blood-brain barrier (BBB) dysfunction	microglia; brain vascular pericytes	oxygen glucose deprivation (OGD) treatment	The level of miR-182 in microglia and brain vascular pericytes gradually decreased with the OGD time extension when compared with the respective control groups.	32808351
15457	Mouse	mmu-miR-182	miRNA	alcohol	brain injury and neurodegeneration	cerebral cortex	chronic alcohol administration	downregulated	30374194
15458	Mouse	mmu-miR-182	miRNA	dexamethasone (DEX)	catabolic diseases	mouse C2C12 myoblasts	dexamethasone (Dex) treatment	downregulated	24871856
15459	Mouse	mmu-miR-182	miRNA	tetramethylpyrazine (TMP)	glaucoma	mouse primary retinal ganglion cells (RGCs)	Tetramethylpyrazine (TMP) treatment	upregulated	31173163
15460	Mouse	mmu-miR-182	miRNA	cisplatin (DDP)	hearing loss	cochlea	cisplatin treatment	upregulated	27607577
15461	Mouse	mmu-miR-182	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
15462	Mouse	mmu-miR-182	miRNA	lipopolysaccharide (LPS)	innate immune response	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	30625496
15463	Mouse	mmu-miR-182	miRNA	pseudomonas aeruginosa (PA)	innate immune response	RAW264.7 cells	Pseudomonas aeruginosa (PA) infection treatment	upregulated	30625496
15464	Mouse	mmu-miR-182	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	intestinal ischemia/reperfusion (I/R) injury	mice intestinal mucosa epithelial (MIME) cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31593847
15465	Mouse	mmu-miR-182	miRNA	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)"	kaposi's sarcoma (KS)	fetal thymocytes of mice	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) treatment"	downregulated	23024791
15466	Mouse	mmu-miR-182	miRNA	narrow band noise	noise-induced deafness	outer hair cells	2-4 kHz narrow band noise at 100 dB SPL 6h per day for 3 consecutive days treatment	downregulated	25026825
15467	Mouse	mmu-miR-182	miRNA	perfluorooctanoic acid	perfluorooctanoic acid toxicity	mouse liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	25092180
15468	Mouse	mmu-miR-182	miRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	upregulated	25827714
15469	Mouse	mmu-miR-182	miRNA	soluble egg antigen (SEA)of Schistosoma japonicum	schistosomiasis	mouse hepatocytes (AML12)	SEA treatment	downregulated	29469324
15470	Mouse	mmu-miR-182-5p	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	kidney tissues	cisplatin treatment	upregulated	33647908
15471	Mouse	mmu-miR-182-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; bronchoalveolar lavage fluid (BALF); RAW264.7 cells	lipopolysaccharide (LPS) treatment	"miR-182-5p was significantly downregulated in lung tissue and bronchoalveolar lavage fluid (BALF), as well as decreased in LPS-treated RAW264.7 cells."	31949658
15472	Mouse	mmu-miR-182-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	asthma	airway smooth muscle (ASM) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á stimulation markedly reduced miR-182-5p expression in ASM cells	32283508
15473	Mouse	mmu-miR-182-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	BV2 cells	oxygen-glucose deprivation (OGD) treatment	downregulated	30292407
15474	Mouse	mmu-miR-182-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 (mouse hippocampal neuronal cells)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA SNHG14 promotes OGD/R-induced neuron injury by inducing excessive mitophagy via miR-182-5p/BINP3 axis in HT22 mouse hippocampal neuronal cells	32912324
15475	Mouse	mmu-miR-182-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
15476	Mouse	mmu-miR-182-5p	miRNA	fatty acid amide hydrolase (FAAH) blockade	experimental colitis	colon	Fatty acid amide hydrolase (FAAH) blockade treatment	upregulated	27327245
15477	Mouse	mmu-miR-182-5p	miRNA	microcystin (MC)	female mammals' reproductive toxicity	mouse granulosa cells (mGCs)	microcystin-LR (MC-LR) for 48 h	dysregulated	28161121
15478	Mouse	mmu-miR-182-5p	miRNA	trichloroethylene (TCE)	hepatocarcinogenesis	mouse liver tissues	Trichloroethylene (TCE) treatment	upregulated	31524101
15479	Mouse	mmu-miR-182-5p	miRNA	trichloroethylene (TCE)	hepatocellular carcinoma (HCC)	mouse liver cell lines (BNL CL.2 and Hepa1-6)	TCE at non-toxic doses (0.1 and/or 0.3 mM) treatment	upregulated	28013219
15480	Mouse	mmu-miR-182-5p	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	pulmonary tissues	bleomycin (BLM) treatment	upregulated	31884830
15481	Mouse	mmu-miR-182-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
15482	Mouse	mmu-miR-182-5p	miRNA	cyclosporine A (CsA)	liver toxicity	mouse hepatocytes	cyclosporine A treatment	upregulated	25047351
15483	Mouse	mmu-miR-182-5p	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	miR-182-5p was upregulated in pulmonary fibrosis.	31884830
15484	Mouse	mmu-miR-182-5p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	cardiac tissue	murine cytomegalovirus (MCMV) infection	downregulated	33245094
15485	Mouse	mmu-miR-182-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	primary midbrain neurons (PMNs)	glial cell line-derived neurotrophic factor (GDNF) treatment	upregulated	29858093
15486	Mouse	mmu-miR-182-5p	miRNA	staphylococcus aureus pneumonia	sepsis	?intestinal tissues	Staphylococcus aureus pneumonia infection treatment	upregulated	31318050
15487	Mouse	mmu-miR-182-5p	miRNA	H2O2	spinal cord injury (SCI)	C8-D1A cells	H2O2 treatment	miR-182-5p was significantly reduced in a dose dependent manner under dif- ferent concentrations of H2O2 stimulation.	31938420
15488	Mouse	mmu-miR-182-5p	miRNA	cyclophosphamide (CP)	systemic lupus erythematosus (SLE)	C3.MRL-Faslpr/J mice	C3.MRL-Faslpr/J mice treatment	downregulated	27924862
15489	Mouse	mmu-miR-182-5p	miRNA	trichloroethylene (TCE)	trichloroethylene (TCE) hepatocarcinogenesis	liver tissues	Trichloroethylene (TCE) treatment	downregulated of lncRNA BACE1-AS inhibits iNOS activation in the substantial nigra and improve oxidative stress injury in PD rats by upregulating miR-34b-5p and downregulating BACE1	31942800
15490	Mouse	mmu-miR-1827	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
15491	Mouse	mmu-miR-183	miRNA	alcohol	alcoholic liver disease (ALD)	mouse liver cells	Lieber-DeCarli alcohol treatment	downregulated	19572984
15492	Mouse	mmu-miR-183	miRNA	methionine choline-deficient diet (MCD)	alcoholic liver disease (ALD)	liver tissues	methionine-choline-deficient (MCD) diets treatment	downregulated	19572984
15493	Mouse	mmu-miR-183	miRNA	HO-1 inducers	bone resorption	Raw264.7 cells	HO-1 inducers treatment	downregulated	26163109
15494	Mouse	mmu-miR-183	miRNA	alcohol	brain injury and neurodegeneration	cerebral cortex	chronic alcohol administration	downregulated	30374194
15495	Mouse	mmu-miR-183	miRNA	gentamicin	hearing restoration	hair cells from mouse cochlea.	Gentamicin treatment	downregulated	29901127
15496	Mouse	mmu-miR-183	miRNA	lipopolysaccharide (LPS)	innate immune response	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	30625496
15497	Mouse	mmu-miR-183	miRNA	pseudomonas aeruginosa (PA)	innate immune response	RAW264.7 cells	Pseudomonas aeruginosa (PA) infection treatment	upregulated	30625496
15498	Mouse	mmu-miR-183	miRNA	narrow band noise	noise-induced deafness	outer hair cells	2-4 kHz narrow band noise at 100 dB SPL 6h per day for 3 consecutive days treatment	downregulated	25026825
15499	Mouse	mmu-miR-183	miRNA	perfluorooctanoic acid	perfluorooctanoic acid toxicity	mouse liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	25092180
15500	Mouse	mmu-miR-183-5p	miRNA	brucella.suis	brucellosis	CD14 knock-down RAW264.7 (224.3) macrophages	brucella infection	upregulated	28443393
15501	Mouse	mmu-miR-183-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	N2a cells	oxygen glucose deprivation (OGD) treatment	downregulated	32901892
15502	Mouse	mmu-miR-183-5p	miRNA	Sinomenine (SIN)	cerebral ischemia/reperfusion (I/R) injury	BV-2 cells	sinomenine treatment	Sinomenine pre- treatment increased miRNA-183-5p	30084807
15503	Mouse	mmu-miR-183-5p	miRNA	adenine	chronic kidney disease (CKD)	kidney tissues	adenine treatment	upregulated	32526762
15504	Mouse	mmu-miR-183-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
15505	Mouse	mmu-miR-183-5p	miRNA	collagenase VII-S	intracerebral haemorrhage (ICH)	brain tissues	collagenase VII-Streatment	downregulated	32602850
15506	Mouse	mmu-miR-183-5p	miRNA	X rays	ionizing radiation (IR) injury	male Kunming mice blood	0.5-2 Gy total-body carbon-ion irradiation treatment	dysregulatedin blood	28632432
15507	Mouse	mmu-miR-183-5p	miRNA	palmitic acid (PA)	myogenic differentiation	C2C12 cells	Long-chain SFA palmitic acid (PA) treatment	miR-183-5p expression was found to be increased significantly in PA-treated C2C12 myo- blasts	33148375
15508	Mouse	mmu-miR-183-5p	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	AML12 cell	palmitic acid (PA) treatment	Expression of miR-183-5p was increased in the livers of three murine models and also in the AML12 cell model	33421522
15509	Mouse	mmu-miR-183-5p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	Female BALB/c mice blood	"4,4'-methylene diphenyl diisocyanate (MDI) exposure"	upregulated	30074411
15510	Mouse	mmu-miR-183-5p	miRNA	"diisocyanate, 4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	Female BALB/c mice blood	Female BALB/c mice were exposed to one of three exposure regimens: dermal exposure to 1% MDI in acetone; nose-only exposure to 4580?¡À?1497?¦Ìg/m3 MDI-aerosol for 60?minutes; or MDI dermal exposure/sensitization followed by MDI-aerosol inhalation challenge.	upregulated	30074411
15511	Mouse	mmu-miR-183-5p	miRNA	glial cell-derived neurotrophic factor (GDNF)	parkinson's disease (PD)	primary midbrain neurons (PMNs)	glial cell line-derived neurotrophic factor (GDNF) treatment	upregulated	29858093
15512	Mouse	mmu-miR-183c	miRNA	dihydroartemisinin (DHA)	asthma	asthma mice lung tissues	dihydroartemisinin (DHA) treatment	downregulated	31115390
15513	Mouse	mmu-miR-183c	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	31115390
15514	Mouse	mmu-miR-184	miRNA	BAM8-22	bone cancer pain (BCP)	LPS-treated BV-2 mouse microglial cells	BAM8-22 treatment	upregulated	31833017
15515	Mouse	mmu-miR-184	miRNA	lipopolysaccharide (LPS)	bone cancer pain (BCP)	BV-2 mouse microglial cells	lipopolysaccharide (LPS) treatment	downregulated	31833017
15516	Mouse	mmu-miR-184	miRNA	lipopolysaccharide (LPS)	bone cancer pain (BCP)	BV-2 cells	lipopolysaccharide (LPS) treatment	"After BAM8-22 treatment, increased miR-184 level was observed in both BCP mice and LPS-treated BV-2 cells."	31833017
15517	Mouse	mmu-miR-184	miRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes	phenylephrine (PE) treatment	miR-184 was downregulated in the cardiomyocytes treated with phenylephrine (PE)	29616999
15518	Mouse	mmu-miR-184	miRNA	high fat diet (HFD)	diabetic cardiomyopathy (DCM)	heart sissues	high fat diet (HFD) feed	miR-184 decreased significantly during the 24 weeks of high fat diet exposure.	32229289
15519	Mouse	mmu-miR-184	miRNA	ketogenic	insulin resistance (IR)	pancreatic ¦Â cell	ketogenic diet treatment	upregulated	24361012
15520	Mouse	mmu-miR-184	miRNA	huagan tongluo Fang (HGTLF)	liver fibrosis	CD4+ T cells	Huagan tongluo Fang (HGTLF) treatment	miR-184 was most significantly expressed after HGTLF drug stimulation.	32380055
15521	Mouse	mmu-miR-184	miRNA	ischemia	oxygen-induced retinopathy (OIR)	retinas tissues	ischemia treatment	downregulated	25796186
15522	Mouse	mmu-miR-184	miRNA	ischemia	renal fibrosis	mouse renal tissues	left anterior descending artery (LAD) ligation	upregulated	30536131
15523	Mouse	mmu-miR-184	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	upregulated	26426744
15524	Mouse	mmu-miR-1843-3p	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	upregulated	30242182
15525	Mouse	mmu-miR-184-3p	miRNA	3¦Â-hydroxycholest-5-en-7-one	anti-inflammatory responses	RAW 264.7 cells	3¦Â-hydroxycholest-5-en-7-one treatment	downregulated	32771556
15526	Mouse	mmu-miR-184-3p	miRNA	microcystin-leucine arginine (MC-LR)	male infertility	Primary sertoli cells (SC) were isolated from 14-day-old ICR mouse testes	Microcystin-leucine-arginine (MC-LR) treatment	downregulated	29071384
15527	Mouse	mmu-miR-184-3p	miRNA	microcystin-leucine arginine (MC-LR)	male reproductive disorders	primary SC were isolated from 14-day-old ICR mouse	MC-LR at 500 nM on day 4	downregulated	29071384
15528	Mouse	mmu-miR-184-5p	miRNA	streptozocin (STZ)	diabetic neuropathic pain (DNP)	mouse lumbar spinal dorsal horn	STZ treatment	differently regulated	25498543
15529	Mouse	mmu-miR-184-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary brain microvascular endothelial cells (bEnd.3)	oxygen-glucose deprivation (OGD) treatment	LncOGD-1006 might act as a ceRNA to inhibit apoptosis in bEnd3 cells by targeting miR-184-5p/CAAP1 pathway	33336752
15530	Mouse	mmu-miR-185	miRNA	resveratrol	acute liver injury (ALI)	liver mononuclear cells (MNCs)	resveratrol (Res) treatment	downregulated	30619104
15531	Mouse	mmu-miR-185	miRNA	hyperoxia	acute lung injury (ALI)	mouse primary lung epithelial cells	mouse primary lung epithelial cells treatment	upregulated	26747785
15532	Mouse	mmu-miR-185	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	mouse macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
15533	Mouse	mmu-miR-185	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	peritoneal macrophages; Bone-marrow derived macrophages (BMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28882869
15534	Mouse	mmu-miR-185	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	CCl4 treatment	downregulated	29499960
15535	Mouse	mmu-miR-185	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	intraperitoneally injected with CCl4 (0.5 mL/kg body weight) three times a week for 4 weeks	downregulated	29499960
15536	Mouse	mmu-miR-185-5p	miRNA	Jiang Tang Xiao Ke Granule	diabetes mellitus (DM)	liver tissues	Jiang Tang Xiao Ke treatment	downregulated	32210802
15537	Mouse	mmu-miR-185-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cell	?high glucose (HG)?treatment treatment	The expression of Gm26917 was induced by HG but weakened by RSG	33790061
15538	Mouse	mmu-miR-185-5p	miRNA	rosiglitazone	diabetic nephropathy (DN)	mesangial cell	Rosiglitazone (RSG) treatment	The expression of Gm26917 was induced by HG but weakened by RSG	33790061
15539	Mouse	mmu-miR-185-5p	miRNA	acetaminophen (APAP)	liver damage	AML12 cells	acetaminophen (APAP) treatment	circ-CBFB acts as a miRNA sponge of miR-185-5p to mediate p66Shc in APAP-induced liver injury.	33159035
15540	Mouse	mmu-miR-186	miRNA	dexamethasone (DEX)	glucocorticoid-induced osteoporosis (GIOP)	tibia of GIOP mice	dexamethasone (DEX) treatment	downregulated in the tibia of GIOP mice	29257214
15541	Mouse	mmu-miR-186	miRNA	icariin (ICA)	glucocorticoid-induced osteoporosis (GIOP)	tibia	icariin treatment	upregulated	29257214
15542	Mouse	mmu-miR-186	miRNA	monosodium glutamate (MSG)	obesity	liver tissues	monosodium glutamate (MSG)-injected mice with developed central obesity treatment	dysregulated	24465854
15543	Mouse	mmu-miR-186	miRNA	papain	osteoarthritis (OA)	OA cartilages	papain treatment	downregulated	30500068
15544	Mouse	mmu-miR-186	miRNA	papain	osteoarthritis (OA)	OA cartilages	intra-articular injection of papain into mice	downregulated	30500068
15545	Mouse	mmu-miR-186	miRNA	complete freund's adjuvant (CFA)	trigeminal neuropathic pain	trigeminal ganglions (TGs)	complete Freund's adjuvant (CFA) treatment	downregulated	30020320
15546	Mouse	mmu-miR-186	miRNA	aerobic exercise	vascular cognitive impairment (VCI)	HT22 cells	aerobic exercise training (AET) treatment	"Aerobic exercise could shorten the average time that mice reached the platform in the Morris water maze, increase the expression level of circRIMS2 and BDNF, reduce miR-186 expression, and inhibit neuronal apoptosis."	33413076
15547	Mouse	mmu-miR-186-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	BV2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33516048
15548	Mouse	mmu-miR-186-5p	miRNA	fractionated radiation	ionizing radiation (IR) injury	LLC1 cells	fractionated dose (FD) irradiation	upregulated	28599420
15549	Mouse	mmu-miR-187	miRNA	glutamate	oxidative stress	RGC-5 cells	glutamate treatment	downregulated	30170060
15550	Mouse	mmu-miR-187	miRNA	H2O2	oxidative stress	RGC-5 cells	H2O2 treatment	downregulated	30170060
15551	Mouse	mmu-miR-188	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	BV2;N2a cells	amyloid-¦Â (A¦Â) treatment	downregulated	32779043
15552	Mouse	mmu-miR-188	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
15553	Mouse	mmu-miR-188	miRNA	homocysteine (Hcy)	cardiac hypertrophy	HL-1 cell line	homocysteine treatment	downregulated	19669742
15554	Mouse	mmu-miR-188	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	miR-188 was upregulated in the liver of obese mice.	32252024
15555	Mouse	mmu-miR-188-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocytes	angiotensin II (Ang II) treatment	DSCAM-AS1 mediates pro-hypertrophy role of GRK2 in cardiac hypertrophy aggravation via absorbing miR-188-5p.	32377998
15556	Mouse	mmu-miR-188-5p	miRNA	hypoxia	choroidal neovascularization (CNV)-related diseases	"bone marrow-derived cells (BMCs), including mesenchymal stem cells (MSCs)"	hypoxia induce	downregulated	29908885
15557	Mouse	mmu-miR-188-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	upregulated	27322257
15558	Mouse	mmu-miR-1894-5p	miRNA	delvestidine (DLTD)	bone marrow-derived dendritic cells (BMDCs) maturity	bone marrow-derived dendritic cells (BMDCs)	Delvestidine (DLTD) treatment	downregulated	32871480
15559	Mouse	mmu-miR-1896	miRNA	IL-17	experimental autoimmune encephalomyelitis (EAE)	astrocytes from EAE mice	interleukin-17 (IL-17) treatment	upregulated	30294880
15560	Mouse	mmu-miR-1896	miRNA	IL-17	multiple sclerosis (MS)	Primary mouse astrocytes	interleukin-17 (IL-17) treatment	upregulated	30294880
15561	Mouse	mmu-miR-1897-3p	miRNA	clamping the renal pedicle	bilateral renal ischemia	C57Bl/6 mice plasma and kidneys	clamping the renal pedicle treatment	upregulated	24695114
15562	Mouse	mmu-miR-1897-5p	miRNA	cigarette smoke (CS)	ovarian toxicity	ovarian tissues	cigarette smoke (CS) treatment	upregulated	29377183
15563	Mouse	mmu-miR-18a	miRNA	polyphyllin VI (PP-VI)	breast cancer	mouse mammary carcinoma 4T1	Polyphyllin VI (PP-VI) treatment	downregulated	30817902
15564	Mouse	mmu-miR-18a	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	33143661
15565	Mouse	mmu-miR-18a	miRNA	panax notoginseng saponins (PNS)	comanifestation of cancer	heart tissues	PNS treatment	reduced expression of miR-18a in tumor and upregulated expression of miR-18a in heart	24903055
15566	Mouse	mmu-miR-18a	miRNA	duloxetine	depression	frontal lobe and hippocampus	duloxetine treatment	upregulated	26823914
15567	Mouse	mmu-miR-18a	miRNA	hyperoxia	hyperoxia-induced acute lung injury (HALI)	MLE-12 cells	hyperoxia treatment	downregulated	32084370
15568	Mouse	mmu-miR-18a	miRNA	¦¤9-tetrahydrocannabinol (THC)	inflammatory lung injury	splenocytes	¦¤(9) tetrahydrocannabinol (THC) treatment	upregulated	25425209
15569	Mouse	mmu-miR-18a	miRNA	panax notoginseng saponins (PNS)	breast cancer	mammary carcinoma 4T1 cells	Panax Notoginseng Saponins (PNS) treatment	downregulated	27641158
15570	Mouse	mmu-miR-18a	miRNA	TGF-¦Â	myofibroblast formation	cortical bone derived stem cells (CBSCs)	TGF-¦Â treatment	The upregulation of miR-18a was validated in adult fibroblasts treated with CBSCs compared to control cells	32656212
15571	Mouse	mmu-miR-18a	miRNA	oxygen glucose deprivation (OGD)	neuronal cell injury	Neuro-2a (N2a)	oxygen-glucose deprivation (OGD) treatment	"Silencing of SNHG15 led to CXCL13 upregulation through sequestering miR-18a and the following ERK/MEK activation, thus enhancing viability while reducing apoptosis of N2a cells."	32862188
15572	Mouse	mmu-miR-18a	miRNA	acetylcholine (ACh)	peripheral nerve injury (PNI)	hematopoietic stem cells (HSCs)	acetylcholine (ACh) treatment	"The therapeutic agents can thus be targeted to the enzyme protein, its encoding mRNA transcripts, or the regulator microRNA-132, opening new venues for therapeutic interference with multiple nervous and immune system diseases"	22448158
15573	Mouse	mmu-miR-18a	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	RAW264.7 cells and secreted exosomes	Mycobacterium tuberculosis (Mtb) infection	upregulated	31845528
15574	Mouse	mmu-miR-18a	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	RAW264.7 cells	mycobacterium tuberculosis (Mtb) treatment	miR-18a was induced both in Mtb-infected RAW264.7 cells and its derived exosomes compared with the controls.	31845528
15575	Mouse	mmu-mir-18a-5p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
15576	Mouse	mmu-miR-18a-5p	miRNA	resveratrol	chronically diabetic nephropathy	db/db mice renal tissues	resveratrol (Res) treatment	upregulated	29164562
15577	Mouse	mmu-miR-18a-5p	miRNA	folic acid	kidney injury and fibrosis	kidney cortex	folic acid treatment	upregulated	26707937
15578	Mouse	mmu-miR-18a-5p	miRNA	oxygen	proliferative retinopathy (OIR)	retinal tissues	oxygen treatment	upregulated	32210827
15579	Mouse	mmu-miR-18b	miRNA	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)"	kaposi's sarcoma (KS)	fetal thymocytes of mice	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) treatment"	downregulated	23024791
15580	Mouse	mmu-miR-19	miRNA	imiquimod (IMQ)	psoriasis-like dermatitis	the mouse skin tissues	IMQ treatment	dysregulated	27579777
15581	Mouse	mmu-miR-190	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra pars compacta (SNpc)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31232472
15582	Mouse	mmu-miR-190	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	31232472
15583	Mouse	mmu-miR-190	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	downregulated	26426744
15584	Mouse	mmu-miR-1902	miRNA	lipopolysaccharide (LPS)	bacterial infection	"the whole blood, serum and white blood cells (WBCs) of C57BL/6 and Tlr2-/- mice"	lipopolysaccharide (LPS) treatment	upregulated	23286671
15585	Mouse	mmu-miR-1903	miRNA	walnut	colorectal cancer (CRC)	colorectal tumor tissue	walnut-containing diet treatment	downregulated	25882694
15586	Mouse	mmu-miR-1904	miRNA	lipopolysaccharide (LPS)	bacterial infection	"the whole blood, serum and white blood cells (WBCs) of C57BL/6 and Tlr2-/- mice"	lipopolysaccharide (LPS) treatment	upregulated	23286671
15587	Mouse	mmu-miR-1906	miRNA	microcystin (MC)	female mammals' reproductive toxicity	mouse granulosa cells (mGCs)	microcystin-LR (MC-LR) for 48 h	dysregulated	28161121
15588	Mouse	mmu-miR-1907	miRNA	high fat diet (HFD)	atherosclerosis (AS)	ApoE (-/-) mice endothelial cell	high fat diet (HFD) feed	upregulated	28804559
15589	Mouse	mmu-miR-190a-5p	miRNA	streptozocin (STZ)	diabetic neuropathic pain (DNP)	mouse lumbar spinal dorsal horn	STZ treatment	differently regulated	25498543
15590	Mouse	mmu-miR-190b	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	29575055
15591	Mouse	mmu-miR-190b	miRNA	¦Â-elemene	oxygen-induced retinopathy (OIR)	Retinas tissues	¦Â-elemene treatment	upregulated	30664207
15592	Mouse	mmu-miR-191	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
15593	Mouse	mmu-miR-191	miRNA	arsenite	arsenicism	liver tissues	arsenite exposure	upregulated	33743404
15594	Mouse	mmu-miR-191*	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	downregulated	22782705
15595	Mouse	mmu-miR-1912-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
15596	Mouse	mmu-miR-191-5p	miRNA	amyloid-¦Â (A¦Â) 1-40	age-related macular degeneration (AMD)	retinal pigment epithelium (RPE) cell	amyloid-¦Â (A¦Â) 1-40 treatment	A¦Â1-40?-mediated RPE damage by inducing a decrease in endogenous miR-191-5p expression.	33715208
15597	Mouse	mmu-miR-191-5p	miRNA	epigallocatechin-3-gallate (EGCG)	Alzheimer's disease (AD)	AD mouse serum	EGCG treatment groups (2 mg/kg/day)	upregulated	28731435
15598	Mouse	mmu-miR-191-5p	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
15599	Mouse	mmu-miR-192	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
15600	Mouse	mmu-miR-192	miRNA	acetaminophen (APAP)	acute liver failure (ALF)	mouse liver tissues	acetaminophen (APAP) treatment	upregulated	28616908
15601	Mouse	mmu-miR-192	miRNA	alcohol	alcoholic hepatitis (AH)	sera	alcohol exposure	upregulated	26264599
15602	Mouse	mmu-miR-192	miRNA	TGF-¦Â	chronic hepatitis C virus (HCV) infection	Primary mouse MCs (MMCs) were cultured from renal glomeruli	Transforming growth factor-¦Â treatment	upregulated	23649518
15603	Mouse	mmu-miR-192	miRNA	alcohol extract of coreopsis tinctoria Nutt (AC)	diabetic nephropathy (DN)	db/db (DN) mice	alcohol extract of Coreopsis tinctoria Nutt (AC) treatment	downregulated	31032350
15604	Mouse	mmu-miR-192	miRNA	TGF-¦Â	diabetic nephropathy (DN)	diabetic glomeruli	TGF-¦Â treatment	upregulated	17360662
15605	Mouse	mmu-miR-192	miRNA	TGF-¦Â	DNA damage	tubular epithelial cells	TGF-¦Â treatment	downregulated	23207693
15606	Mouse	mmu-miR-192	miRNA	oxyELITE pro-new formula (OEP-NF)	drug-induced liver injury (DILI)	female B6C3F1 mice liver	administering 10X and 3X mouse-equivalent doses (MED) of OEP-NF treatment	upregulated in the liver	28843594
15607	Mouse	mmu-miR-192	miRNA	bisphenol A (BPA)	hepatic steatosis and lipid accumulation	male post-weaning C57BL/6 mice liver	bisphenol A (BPA) treatment	downregulated mouse liver	28483554
15608	Mouse	mmu-miR-192	miRNA	high fat diet (HFD)	high fat diet?influence	liver tissue	high fat diet (HFD) feed	upregulated	19835573
15609	Mouse	mmu-miR-192	miRNA	Sinomenine (SIN)	inflammation	ATDC5 cells injured by lipopolysaccharides (LPS)	Sinomenine (SIN) treatment	miR-192 was downregulated by SIN treatment	31094031
15610	Mouse	mmu-miR-192	miRNA	silymarin (Sm)	liver damage	blood and liver tissues	silymarin (Sm) treatment	upregulated	31811641
15611	Mouse	mmu-miR-192	miRNA	acetaminophen (APAP)	liver damage	liver tissues	acetaminophen (APAP) treatment	upregulated	19246379
15612	Mouse	mmu-miR-192	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
15613	Mouse	mmu-miR-192	miRNA	cyclosporine A (CsA)	nephrotoxicity	mouse kidney	cyclosporine A treatment	upregulated	28414804
15614	Mouse	mmu-miR-192	miRNA	pioglitazone	nonalcoholic fatty liver disease (NAFLD)	liver tissues of adiponectin knockout (adipoKO) mouse	pioglitazone treatment	resistance to pioglitazone treatment in adipoKO mice was associated with increased expression of miR-192	31176759
15615	Mouse	mmu-miR-192	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
15616	Mouse	mmu-miR-192	miRNA	aerobic training	obesity	exosomes of serum	aerobic training	downregulated	32744099
15617	Mouse	mmu-miR-192	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cells	metformin treatment	upregulated	22245693
15618	Mouse	mmu-miR-192	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
15619	Mouse	mmu-miR-192	miRNA	TGF-¦Â1	renal fibrosis	kidneys of diabetic mice	TGF-¦Â1 treatment	TGF-¦Â1 upregulates microRNA-192 (miR-192) in cultured glomerular mesangial cells	22223877
15620	Mouse	mmu-miR-192-5p	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	downregulated	31918268
15621	Mouse	mmu-miR-192-5p	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
15622	Mouse	mmu-miR-192-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	Hippocampus	chronic unpredictable mild stress (CUMS) treatment	downregulated	30118321
15623	Mouse	mmu-miR-192-5p	miRNA	Jiang Tang Xiao Ke Granule	diabetes mellitus (DM)	KKAy diabetic mice	Jiang Tang Xiao Ke Granule treatment	dysregulated	29163176
15624	Mouse	mmu-miR-192-5p	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	plasma	acetaminophen (APAP) treatment	miR-122-5p and miR-192-5p were consistently upregulated in early to late stages of all the liver injury models.	30125006
15625	Mouse	mmu-miR-192-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
15626	Mouse	mmu-miR-192-5p	miRNA	hypoxia	immunological tumor escape	B16F10	hypoxia treatment	upregulated	33066331
15627	Mouse	mmu-miR-192-5p	miRNA	carbon tetrachloride (CCl4)	liver damage	liver	CCl4 treatment	upregulated	27129188
15628	Mouse	mmu-miR-192?5p	miRNA	carbon tetrachloride (CCl4)	hepatotoxicity	blood	carbon tetrachloride (CCl4) treatment	upregulated	32528856
15629	Mouse	mmu-miR-1929-3p	miRNA	murine cytomegalovirus (MCMV)	essential hypertension (EH)	blood vessel	murine cytomegalovirus (MCMV) infection	"MCMV infection increased the blood pressure, promoted vascular remodeling, caused endothelial cell injury, and downregulated miR-1929-3p."	33416142
15630	Mouse	mmu-miR-1929-3p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	thoracic aorta	murine cytomegalovirus (MCMV) infection	downregulated	33245094
15631	Mouse	mmu-miR-1929-3p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	cardiac tissue	murine cytomegalovirus (MCMV) infection	downregulated	33245094
15632	Mouse	mmu-miR-1929-3p	miRNA	murine cytomegalovirus (MCMV)	vascular remodeling	blood vessels	murine cytomegalovirus (MCMV) infection	"MCMV infection increased the blood pressure, promoted vascular remodeling, caused endothelial cell injury, and downregulated miR-1929-3p."	33416142
15633	Mouse	mmu-miR-193	miRNA	high fat diet (HFD)	chondrogenesis	white adipose tissues	high fat diet (HFD) feed	downregulated	22496873
15634	Mouse	mmu-miR-193	miRNA	TGF-¦Â	liver fibrosis	liver	TGF-¦Â treatment	downregulated	26120970
15635	Mouse	mmu-miR-193	miRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	mouse aortic endothelial cells (MAECs)	chronic intermittent hypoxia (CIH) treatment	upregulated	29108914
15636	Mouse	mmu-miR-193	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
15637	Mouse	mmu-miR-193*	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
15638	Mouse	mmu-miR-1930-5p	miRNA	oxygen glucose deprivation (OGD)	intracerebral haemorrhage (ICH)	Primary brain microvascular endothelial cells (BMECs)	oxygen-and-glucose-deprivation (OGD) treatment	downregulated	33836898
15639	Mouse	mmu-miR-193-3p	miRNA	apolipoprotein A-I mimetic peptide 4F	pulmonary arterial hypertension (PAH)	hypoxia mouse model lung tissue and serum	apolipoprotein A-I mimetic peptide 4F treatment	downregulated	24963038
15640	Mouse	mmu-miR-1934	miRNA	stretch	myoblast proliferation	C2C12 myoblasts	stretch treatment	downregulated	27840929
15641	Mouse	mmu-miR-193-5p	miRNA	adenine	chronic kidney disease (CKD)	kidney tissues	adenine treatment	upregulated	32526762
15642	Mouse	mmu-miR-1937a	miRNA	high fat diet (HFD)	erectile dysfunction (ED)	mouse	high fat diet (HFD) feed	dysregulated	25533598
15643	Mouse	mmu-miR-1937c	miRNA	high fat diet (HFD)	erectile dysfunction (ED)	mouse	high fat diet (HFD) feed	dysregulated	25533598
15644	Mouse	mmu-miR-193a	miRNA	insulin-like growth factor 2 (IGF-2)	cell proliferation	C-kit-positive cardiac stem cells (CSCs)	Insulin-like growth factor (IGF)-1 treatment	downregulated	29467020
15645	Mouse	mmu-miR-193a	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	lumbar spinal dorsal horn	streptozocin (STZ) treatment	downregulated	31665716
15646	Mouse	mmu-miR-193a	miRNA	oxyELITE pro-new formula (OEP-NF)	drug-induced liver injury (DILI)	female B6C3F1 mice liver	administering 10X and 3X mouse-equivalent doses (MED) of OEP-NF treatment	upregulated in the liver	28843594
15647	Mouse	mmu-miR-193a	miRNA	melatonin	leukemia	U937T cells	melatonin (MLT) treatment	upregulated	31119862
15648	Mouse	mmu-miR-193a	miRNA	ligustrazine (Lig)	lung fibrosis	paraquat (PQ)-exposed mice lung tissues	Ligustrazine (Lig) treatment	upregulated	30744607
15649	Mouse	mmu-miR-193a	miRNA	paraquat (PQ)	lung fibrosis	lung tissues	paraquat (PQ) exposure	downregulated	30744607
15650	Mouse	mmu-miR-193a-3p	miRNA	concanamycin A (Con A)	liver fibrosis	liver tissues	concanavalin A (ConA) treatment	downregulated	30945448
15651	Mouse	mmu-miR-193a-3p	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
15652	Mouse	mmu-miR-193a-5p	miRNA	resveratrol	acute lung injury (ALI)	lung tissues	resveratrol (Res) treatment	miR-193a was strongly induced by SEB and was downregulated by RES treatment	29512867
15653	Mouse	mmu-miR-193a-5p	miRNA	diethylnitrosamine (DEN)	hepatocellular carcinoma (HCC)	liver tissues	diethylnitrosamine (DEN) treatment	downregulated	30165047
15654	Mouse	mmu-miR-193a-5p	miRNA	diethylnitrosamine (DEN)	hepatocellular carcinoma (HCC)	liver tissues	diethylnitrosamine (DEN) treatment	downregulated	30165047
15655	Mouse	mmu-miR-193b	miRNA	H2O2	Alzheimer's disease (AD)	Primary hippocampal neuron cells	H2O2 treatment	upregulated	24423585
15656	Mouse	mmu-miR-193b	miRNA	H2O2	Alzheimer's disease (AD)	senescence accelerated mouse prone 8 (SAMP8) and prone 10 (SAMP10)	"different concentrations (0, 100, 200, 400 and 800 ¦ÌM) of H2O2 treatment"	upregulated	24423585
15657	Mouse	mmu-miR-193b	miRNA	luteinising hormone (LH)	functions of Leydig cells	mouse TM3 Leydig cells	luteinising hormone (LH) treatment	upregulated	28762514
15658	Mouse	mmu-miR-193b	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
15659	Mouse	mmu-miR-193b	miRNA	luteinising hormone (LH)	steroidogenesis	mouse TM3 Leydig cells	luteinising hormone(LH) treatment	dysregulated	28762514
15660	Mouse	mmu-miR-193b*	miRNA	cecal ligation and puncture (CLP)	polymicrobial sepsis	C57Bl/6 mice	cecal ligation and puncture (CLP) treatment	different regulation	24413579
15661	Mouse	mmu-miR-193b-3p	miRNA	concanamycin A (Con A)	autoimmune hepatitis (AIH)	liver tissues	concanavalin A (Con A) treatment	downregulated	32965791
15662	Mouse	mmu-mir-193b-3p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
15663	Mouse	mmu-miR-193b-3p	miRNA	concanamycin A (Con A)	liver fibrosis	liver tissues	concanavalin A (ConA) treatment	downregulated	30945448
15664	Mouse	mmu-miR-194	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	31496625
15665	Mouse	mmu-miR-194	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	32522221
15666	Mouse	mmu-miR-194	miRNA	high fat diet (HFD)	acute myocardial infarction (AMI)	liver tissue	high fat diet (HFD) feed	downregulated	19835573
15667	Mouse	mmu-miR-194	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	liver tissues	ethanol treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)."	33068587
15668	Mouse	mmu-miR-194	miRNA	yangonin (Yan)	alcoholic liver disease (ALD)	ethanol-induced liver injury rats liver tissues	Yangonin (Yan) treatment	"MiR-194 was upregulated in the alcoholic liver disease, which was significantly suppressed by Yangonin (Yan)"	33068587
15669	Mouse	mmu-miR-194	miRNA	bupivacaine	bupivacaine-induced neurotoxicity	mouse DRG neurons	bupivacaine treatment	lincRNA PADNA/miR-194/FBXW7 axis plays an important role in the neurotoxicity process.	32791990
15670	Mouse	mmu-miR-194	miRNA	replicative senescence and stress	cell senescence	NIH/3T3 cells	replicative senescence and stress treatment	upregulated	27981676
15671	Mouse	mmu-miR-194	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	26639663
15672	Mouse	mmu-miR-194	miRNA	silymarin (Sm)	liver damage	blood and liver tissues	silymarin (Sm) treatment	upregulated	31811641
15673	Mouse	mmu-miR-194	miRNA	177lu-octreotate	neuroendocrine tumors	Female BALB/c nude mice	"inject 1.3, 3.6, 14, 45, or 140 MBq 177Lu-octreotate treatment"	"miR-194, miR-107, miR-3090, and miR-3077 were commonly regulated"	25386939
15674	Mouse	mmu-miR-194	miRNA	green tea (GT)	nonalcoholic fatty liver disease (NAFLD)	liver tissues from Male C57Bl/6 mice were fed with a high-fat diet for 4 weeks	green tea (GT) treatment	upregulated	31885789
15675	Mouse	mmu-miR-194	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	male C57BL/6J mice liver	high fat diet (HFD) feed	upregulated	28951211
15676	Mouse	mmu-miR-194	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31885789
15677	Mouse	mmu-miR-194	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	downregulated	25672270
15678	Mouse	mmu-miR-1941	miRNA	stretch	myoblast proliferation	C2C12 myoblasts	stretch treatment	upregulated	27840929
15679	Mouse	mmu-miR-194-5p	miRNA	ethyl acetate fraction of airpotato yam	liver damage	ICR and C57BL/6 mice	treat with ethyl acetate fraction of airpotato yam	significantly upregulated with no significant elevation of serum ALT/AST activity	28844483
15680	Mouse	mmu-miR-194-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
15681	Mouse	mmu-miR-194-5p	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	whole bone marrow exosomes	liraglutide 0.2 mg/kg for 2 months	dysregulated	29133778
15682	Mouse	mmu-miR-1946a	miRNA	alcohol	lung injury	lung tissues; murine primary lung fibroblasts	chronic alcohol administration	Chronic alcohol ingestion attenuates miR-1946a in the murine lung.	33154445
15683	Mouse	mmu-miR-195	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
15684	Mouse	mmu-miR-195	miRNA	carbon tetrachloride (CCl4)	acute liver injury (ALI)	liver tissues	carbon tetrachloride (CCl4) treatment	miR-195 was markedly increased in CCl4-induced ALI.	32277959
15685	Mouse	mmu-miR-195	miRNA	angiotensin II (Ang II)	aortic aneurysmal disease	C57BL6 mice	angiotensin II (Ang II) treatment	downregulated	25201911
15686	Mouse	mmu-miR-195	miRNA	palmitate	apoptosis	neonatal mouse cardiomyocytes	palmitate drug treatment	upregulated	21622680
15687	Mouse	mmu-miR-195	miRNA	streptozocin (STZ)	apoptosis	mouse podocytes?(diabetic nephropathy)	streptozocin (STZ) treatment	upregulated	22123611
15688	Mouse	mmu-miR-195	miRNA	oxytocin (OT)	breast cancer	Mouse mammary adenocarcinoma tumors	Oxytocin (OT) treatment	upregulated	30076862
15689	Mouse	mmu-miR-195	miRNA	puerarin	cardiac hypertrophy	Ang II-induced cardiac hypertrophy	Puerarin treatment	upregulated	27145790
15690	Mouse	mmu-miR-195	miRNA	thyroid stimulating hormone	cell proliferation	Rat FRTL-5 thyroid cells	thyroid stimulating hormone treatment	downregulated	22301781
15691	Mouse	mmu-miR-195	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissues	cigarette smoke (CS) exposure	upregulated	29223853
15692	Mouse	mmu-miR-195	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	mouse lung	cigarette smoke (CS) exposure	upregulated in the lung	29223853
15693	Mouse	mmu-miR-195	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
15694	Mouse	mmu-miR-195	miRNA	IFN-¦Â	liver fibrosis	hepatic stellate cells (HSCs)	interferon-¦Â treatment	upregulated	21792910
15695	Mouse	mmu-miR-195	miRNA	saturated fatty acid (SFA) and high fat diet (HFD)	hepatic insulin sensitivity	hepatocytes	saturated fatty acid (SFA) and high fat diet (HFD) treatment	significantly induce miR-195 expression in hepatocytes	25240198
15696	Mouse	mmu-miR-195	miRNA	diethylnitrosamine (DEN)	hepatocellular carcinoma (HCC)	liver tissues	diethylnitrosamine (DEN) treatment	upregulated	32216509
15697	Mouse	mmu-miR-195	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	muscle cell proliferation and differentiation	mouse skeletal myoblast C2C12 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28255268
15698	Mouse	mmu-miR-195	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	31059087
15699	Mouse	mmu-miR-195	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
15700	Mouse	mmu-miR-1953	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	33524472
15701	Mouse	mmu-miR-1954	miRNA	angiotensin II (Ang II)	cardiac fibrosis	heart tissues	angiotensin II (Ang II) treatment	downregulated	31640463
15702	Mouse	mmu-miR-195-5p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	30942447
15703	Mouse	mmu-miR-195-5p	miRNA	orthodontic mechanical loading	osteogenic differentiation and bone formation	periodontal tissues of mice	orthodontic mechanical loading	downregulated	28181691
15704	Mouse	mmu-miR-1959	miRNA	eimeria papillata	eimeria papillata infection	mouse jejunum	Eimeria papillata infection	upregulated	21093440
15705	Mouse	mmu-miR-195a-3p	miRNA	hypoxia	angiogenesis	mesenchymal stem cells (MSCs)	hypoxia treatment	downregulated	26989874
15706	Mouse	mmu-miR-195a-3p	miRNA	heat shock factor 1 (HSF1)	cardiac remodeling	heart tissues and endothelial cells (ECs)	Heat shock transcription factor 1 (HSF1) deficiency	upregulated	29626503
15707	Mouse	mmu-miR-196	miRNA	hypoxic/ischemic	hypoxic/ischemic brain damage (HIBD)	primary hippocampal cells	hypoxic/ischemic stress	"Snhg3 acted as the sponge of miR-196 in the hippocampal cells by regulating the expression of miR-196 target genes, XIAP and CAAP1."	31751562
15708	Mouse	mmu-miR-1960	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
15709	Mouse	mmu-miR-196a	miRNA	"AhR agonists benzo[a]pyrene (B[a]P) and FICZ, AhR antagonist CH-223191"	aryl hydrocarbon receptor (AhR)	AhR(+/+) mouse lung fibroblasts	"B[a]P and FICZ ,CH-223191 treatment"	downregulated	25178717
15710	Mouse	mmu-miR-196a	miRNA	¦Â-adrenergic	brown adipogenesis	WAT-progenitor cells	¦Â-adrenergic treatment	upregulated	22545021
15711	Mouse	mmu-miR-196a	miRNA	losartan	diabetic nephropathy (DN)	kidney tissues	losartan treatment	downregulated	27770539
15712	Mouse	mmu-miR-196a	miRNA	progesterone (P4)	infertility	uterine horn of 6-week-old female mice (C57BL/6)	progesterone treatment	dysregulated	30603515
15713	Mouse	mmu-miR-197	miRNA	lipopolysaccharide (LPS)	inflammation	The mouse immortalized podocyte cell line MPC5	lipopolysaccharide (LPS) treatment	upregulated	31115515
15714	Mouse	mmu-miR-1971	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	27074385
15715	Mouse	mmu-miR-1971	miRNA	fluoxetine (Prozac)	post-traumatic stress disorder (PTSD)	mouse prefrontal cortices (PFCs)	Fluoxetine treatment	downregulated	23847554
15716	Mouse	mmu-miR-1981	miRNA	brucella.suis	chronic infection	RAW264.7 cells	brucella infection	upregulated	22904669
15717	Mouse	mmu-miR-1981-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	downregulated	33224036
15718	Mouse	mmu-miR-1981-5p	miRNA	echinococcus multilocularis metacestodes	echinococcus multilocularis infection	RAW 264.7 cells	E. multilocularis metacestodes treatment	downregulated	30322806
15719	Mouse	mmu-miR-1981-5p	miRNA	E. multilocularis metacestodes	infection and immunity of E. multilocularis	RAW264¡¤7 macrophage cells	E. multilocularis metacestodes for 6 and 12 h treatment	"upregulated (mmu-miR-378d,mmu-miR-155-5p, mmu-miR-146a-5p, mmu-miR-21a-5p , mmu-miR-125a-5p) and downregulated(mmu-miR-1981-5p , mmu-miR-let-7c-1-3p)"	28942753
15720	Mouse	mmu-miR-1983	miRNA	adiponectin	frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)	?adipose tissue (AT)	adiponectin (ApN) treatment	downregulated	23015294
15721	Mouse	mmu-miR-199	miRNA	sodium arsenite (NaAsO2)	arsenic inhibited cellular differentiation	pluripotent P19 mouse embryonal carcinoma cells	sodium arsenite treatment	downregulated	29121352
15722	Mouse	mmu-miR-199	miRNA	glucose	diabetes mellitus (DM)	mouse insulinoma cells (MIN6) and mouse pancreatic beta-cells	glucose treatment	upregulated	31882540
15723	Mouse	mmu-miR-199	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	BNL-CL2	hypoxia induce	downregulated	31827704
15724	Mouse	mmu-miR-199-3p	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	nasal tissues	ovalbumin (OVA) treatment	upregulated	31124216
15725	Mouse	mmu-miR-199-3p	miRNA	high glucose (HG)	pancreatic ¦Â-cell dysfunction	mouse islets; mouse insulinoma cells (MIN6)	high glucose (HG) treatment	upregulated	31882540
15726	Mouse	mmu-miR-199-5p	miRNA	high-fat high-fructose diet (HFHFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	High-fatty and high-frutose-diet feed	upregulated	30347922
15727	Mouse	mmu-miR-199-5p	miRNA	total saponins of Panax japonicas(TPSJ)	nonalcoholic fatty liver disease (NAFLD)	NAFLD mouse liver tissues	total saponins of Panax japonicas(TPSJ) treatment	downregulated	30347922
15728	Mouse	mmu-miR-199-5p	miRNA	high glucose (HG)	pancreatic ¦Â-cell dysfunction	mouse islets; mouse insulinoma cells (MIN6)	high glucose (HG) treatment	upregulated	31882540
15729	Mouse	mmu-miR-199a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells	32069473
15730	Mouse	mmu-miR-199a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	brain microvascular endothelial cell injury	brain microvascular endothelial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30233065
15731	Mouse	mmu-miR-199a	miRNA	tough decoys (TuDs)	cardiac hypertrophy	cardiac samples	tough decoys (TuDs) treatment	upregulated	33473326
15732	Mouse	mmu-miR-199a	miRNA	high-fat/high-cholesterol diet or a high-protein diet	dyslipidemia	DO mice	a high-fat/high-cholesterol diet or a high-protein diet for 18 wk	dysregulated	28916633
15733	Mouse	mmu-miR-199a	miRNA	rapamycin	HIV-associated nephropathy(HIVAN)	mice renal tissues	Rapamycin treatment	downregulated	23611955
15734	Mouse	mmu-miR-199a	miRNA	progesterone (P4)	infertility	uterine horn of 6-week-old female mice (C57BL/6)	progesterone treatment	dysregulated	30603515
15735	Mouse	mmu-miR-199a	miRNA	hypoxia	ischemic stroke (IS)	primary neuronal cells and N2a cells	oxygen-glucose deprivation (OGD) treatment	downregulated	30144542
15736	Mouse	mmu-miR-199a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29883549
15737	Mouse	mmu-miR-199a	miRNA	lipopolysaccharide (LPS)	lung injury	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	22185353
15738	Mouse	mmu-miR-199a	miRNA	pristane (PS)	lupus nephritis (LN)	kidney tissues	pristane treatment	upregulated	30316188
15739	Mouse	mmu-miR-199a	miRNA	carbon tetrachloride (CCl4)	multiple myeloma (MM)	liver tissue of mouse	CCl4 treatment	upregulated	21283674
15740	Mouse	mmu-miR-199a	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute respiratory distress syndrome	mouse alveolar macrophages	?LPS?treatment treatment	upregulated	29351405
15741	Mouse	mmu-miR-199a*	miRNA	carbon tetrachloride (CCl4)	multiple myeloma (MM)	liver tissue of mouse	CCl4 treatment	upregulated	21283674
15742	Mouse	mmu-miR-199a-3p	miRNA	high fat diet (HFD)	adipogenesis	mouse adipose tissue	high fat diet (HFD) feed	downregulated in adipose tissue	28803985
15743	Mouse	mmu-miR-199a-3p	miRNA	alcohol	alcoholic liver disease (ALD)	mouse liver cells	Lieber-DeCarli alcohol treatment	downregulated	19572984
15744	Mouse	mmu-miR-199a-3p	miRNA	methionine choline-deficient diet (MCD)	alcoholic liver disease (ALD)	liver tissues	methionine-choline-deficient (MCD) diets treatment	downregulated	19572984
15745	Mouse	mmu-miR-199a-3p	miRNA	estradiol-17¦Â (E2)	autophagy	mouse osteocyte-like MLO-Y4 cells	estradiol-17¦Â (E2) treatment	downregulated	28708244
15746	Mouse	mmu-miR-199a-3p	miRNA	CL 316243 disodium salt	brown adipocyte differentiation	mouse interscapular brown brown adipose tissues (iBAT)	CL 316243 disodium salt treatment	downregulated	29753771
15747	Mouse	mmu-miR-199a-3p	miRNA	cold	brown adipocyte differentiation	mouse interscapular brown brown adipose tissues (iBAT)	cold induce	downregulated	29753771
15748	Mouse	mmu-miR-199a-3p	miRNA	brucella.suis	brucellosis	CD14 knock-down RAW264.7 (224.3) macrophages	brucella infection	upregulated	28443393
15749	Mouse	mmu-miR-199a-3p	miRNA	lipopolysaccharide (LPS)	cervical remodeling	cervical samples	lipopolysaccharide (LPS) treatment	downregulated	32468045
15750	Mouse	mmu-miR-199a-3p	miRNA	sarpogrelate and telmisartan	chronic kidney disease (CKD)	urinary	sarpogrelate and telmisartan treatment	miR-199a-3p was commonly reduced by sarpogrelate and telmisartan treatment	33359069
15751	Mouse	mmu-miR-199a-3p	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
15752	Mouse	mmu-miR-199a-3p	miRNA	¦Â-hydroxy-¦Â-methylbutyrate (HMB)	cell differentiation	muscle	¦Â-hydroxy-¦Â-methylbutyrate (HMB) treatment	upregulated	31891490
15753	Mouse	mmu-miR-199a-3p	miRNA	low-protein diet (LP0.5)	glucose homeostasis	¦Â cells	low-protein diet (LP0.5)	downregulated	25180600
15754	Mouse	mmu-miR-199a-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	29557526
15755	Mouse	mmu-miR-199a-3p	miRNA	¦Â-hydroxy-¦Â-methylbutyrate (HMB)	myofiber specification	"gastrocnemius, soleus muscle and C2C12 myotubes"	¦Â-hydroxy-¦Â-methylbutyrate (HMB) treatment	upregulated	31891490
15756	Mouse	mmu-miR-199a-3p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	C57BL/6J mice liver	high fat diet (HFD) feed	downregulated in the livers	28469795
15757	Mouse	mmu-miR-199a-5p	miRNA	qiliqiangxin (QL)	acute myocardial infarction (AMI)	PE induced cardiomyocytes	Qiliqiangxin (QL) treatment	the increase of miR-199a-5p in PE-treated cardiomyocytes was reversed by the treatment with QL	27161004
15758	Mouse	mmu-miR-199a-5p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	upregulated	28396668
15759	Mouse	mmu-miR-199a-5p	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	cell differentiation	bone marrow macrophages (BMMs) and RAW 264.7 cells	receptor activator of nuclear factor kappa-B ligand (RANKL) treatment	upregulated	30387167
15760	Mouse	mmu-miR-199a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31990992
15761	Mouse	mmu-miR-199a-5p	miRNA	resolvin D1 (RvD1)	extracellular matrix synthesis	macrophages	resolvin D1 (RvD1) treatment	upregulated	24249635
15762	Mouse	mmu-miR-199a-5p	miRNA	hyperoxia	hyperoxia-induced acute lung injury (HALI)	mice lungs and lung epithelial cells (MLE12)	hyperoxia induce	upregulated	31390652
15763	Mouse	mmu-miR-199a-5p	miRNA	resolvin D1 (RvD1)	insulin resistance and nonalcoholic steatohepatitis (NASH)	obese mice with NASH	resolvin D1 (RvD1) treatment	upregulated	24249635
15764	Mouse	mmu-miR-199a-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	N-2a cells	oxygen and glucose deprivation treatment	ANRIL protects N-2a cells against ischemia induced injury by elevated CAV-1 by competitively interacting with miR-199a-5p	31907708
15765	Mouse	mmu-miR-199a-5p	miRNA	¦Á-Tocotrienol (TCT)	ischemic stroke (IS)	primary cortical neuronal cells	¦Á-Tocotrienol (TCT)?treatment treatment	downregulated	21719775
15766	Mouse	mmu-miR-199a-5p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
15767	Mouse	mmu-miR-199a-5p	miRNA	fructus meliae toosendan (FMT)	liver damage	eft lateral liver lobe	Fructus Meliae Toosendan (FMT) treatment	downregulated	26539117
15768	Mouse	mmu-miR-199a-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	adipose tissues	high fat diet (HFD) feed	microRNA 199a-5p (miR-199a-5p) was significantly upregulated in high fat diet-induced steatosis mouse model.	33037981
15769	Mouse	mmu-miR-199a-5p	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	were fed a methionine-choline-deficient (MCD) diet for eight weeks treatment	upregulated	25269746
15770	Mouse	mmu-miR-199a-5p	miRNA	dexamethasone (DEX)	osteoporosis	osteoblasts	dexamethasone (Dex) treatment	upregulated	25878056
15771	Mouse	mmu-miR-199a-5p	miRNA	bile acids	sustained endoplasmic reticulum stress	mouse liver tissue	bile acids treatment	upregulated	23598416
15772	Mouse	mmu-miR-199b-3p	miRNA	hypoxia	ischemic stroke (IS)	?brain tissues	middle cerebral artery occlusion-reperfusion (MCAO-R)?induce	downregulated	31204565
15773	Mouse	mmu-miR-199b-5p	miRNA	atrasentan	diabetic nephropathy (DN)	mice renal proximal tubular epithelial cells	atractylon (Atr)?treatment	downregulated	29623952
15774	Mouse	mmu-miR-199b-5p	miRNA	hypoxia	myocardial infarction (MI)	heart tiisues	permanent ligation of the left coronary artery	upregulated in heart	30159417
15775	Mouse	mmu-miR-199b-5p	miRNA	curcumin (Cur)	neuroinflammation	LPS-treated BV2 microglial cells	curcumin treatment	upregulated	31862869
15776	Mouse	mmu-miR-199b-5p	miRNA	lipopolysaccharide (LPS)	neuroinflammation	BV2 microglial cells	lipopolysaccharide (LPS) treatment	downregulated	31862869
15777	Mouse	mmu-miR-199b-5p	miRNA	partial pancreatectomy (PPx)	cell proliferation	pancreas	partial pancreatectomy (PPx) treatment	upregulated	27280801
15778	Mouse	mmu-miR-19a	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	33143661
15779	Mouse	mmu-miR-19a	miRNA	high glucose (HG)	cardiomyocyte senescence	Neonatal mouse ventricular cells (NMVCs)	high glucose (HG) treatment	downregulated	33664669
15780	Mouse	mmu-miR-19a	miRNA	IL-10	colonic inflammation	colonic intraepithelial lymphocytes	IL-10 treatment	downregulated	22043014
15781	Mouse	mmu-miR-19a	miRNA	lipopolysaccharide (LPS)	endometriosis	uterine tissues	lipopolysaccharide (LPS) treatment	downregulated	30673803
15782	Mouse	mmu-miR-19a	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
15783	Mouse	mmu-miR-19a	miRNA	ischemia	ischemia/reperfusion (I/R) injury	cerebral cortex and hippocampus	Ischemic preconditioning and ischemic postconditioning (IPostC) treatment	upregulated	27485299
15784	Mouse	mmu-miR-19a	miRNA	grape seed procyanidin extract (GSPE)	lung cancer	A549 cells	grape seed procyanidin extract (GSE) treatment	downregulated	27289489
15785	Mouse	mmu-miR-19a	miRNA	microwave	microwave-induced adverse health outcomes 	mouse hippocampus	7 days after 30 mW/cm microwave exposure treatment	downregulated	24748327
15786	Mouse	mmu-miR-19a	miRNA	bleomycin and silica	lung fibrosis	fibroblasts	bleomycin and silica treatment	"qPCR revealed a significant increase of miR-19a, 19b, and 20a-expression in activated fibroblasts in the early phase of bleomycin and silica models."	29923329
15787	Mouse	mmu-miR-19a	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	downregulated	22782705
15788	Mouse	mmu-miR-19a-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse cardiomyocytes (NMCMs)	angiotensin II (Ang II) treatment	downregulated	29664809
15789	Mouse	mmu-miR-19a-3p	miRNA	H2O2	myocardial infarction (MI)	Primary neonatal mice cardiomyocytes (NMCMs)	H2O2 treatment	miR-19a-3p level was upregulated in response to H2O2 treatment.	33352533
15790	Mouse	mmu-miR-19b	miRNA	short ragweed pollen	allergic conjunctivitis (AC)	conjunctiva; cornea; cervical lymph nodes (CLN)	short ragweed pollen treatment	"In the murine AC model, miR-19b was aberrantly downregulated"	32150250
15791	Mouse	mmu-miR-19b	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	33143661
15792	Mouse	mmu-miR-19b	miRNA	diosgenin (DIO)	cholesterol metabolism and atherogenesis	THP-1 macrophages	diosgenin (DIO) treatment	downregulated	25765596
15793	Mouse	mmu-miR-19b	miRNA	pectin (fermented to butyrate in the colon) (FPA)	colon tumorigenesis	colonic stem cells	(fermented to butyrate in the colon) (FPA) treatment	upregulated	26493444
15794	Mouse	mmu-miR-19b	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	mouse liver	?acetaminophen (APAP) treatment	downregulated	31077331
15795	Mouse	mmu-miR-19b	miRNA	myelin oligodendrocyte glycoprotein	experimental autoimmune encephalomyelitis (EAE)	EAE mouse brain tissues	myelin oligodendrocyte glycoprotein (MOG35- 55) treatment	downregulated	30289071
15796	Mouse	mmu-miR-19b	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	balb/c nu-nu mice injected with 107 GC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
15797	Mouse	mmu-miR-19b	miRNA	fibrinogen	haemorrhagic shock	lung tissue	fibrinogen treatment	"Pulmonary microRNA-19b was increased after haemorrhagic shock and lactated Ringers, but reduced to sham levels by plasma and fibrinogen."	33539284
15798	Mouse	mmu-miR-19b	miRNA	Deoxycorticosterone acetate (Doca)	hypertensive heart disease (HHD)	mouse HHD cells	injection of Deoxycorticosterone acetate (Doca)	upregulated in HHD cells	28531963
15799	Mouse	mmu-miR-19b	miRNA	hypoxia	hypoxia-induced injury	BV2 cells	hypoxia induce	downregulated	30767206
15800	Mouse	mmu-miR-19b	miRNA	recombinant Adeno-Cre viruses (AdV-Cre)	lung adenocarcinoma (LUAD)	lung	recombinant Adeno-Cre viruses (AdV-Cre) treatment	downregulated	25359683
15801	Mouse	mmu-miR-19b	miRNA	grape seed procyanidin extract (GSPE)	lung cancer	A549 cells	grape seed procyanidin extract (GSE) treatment	downregulated	27289489
15802	Mouse	mmu-miR-19b	miRNA	dexamethasone (DEX)	metabolic disease	murine adipocytes	dexamethasone (Dex) treatment	"DEX treatment elevated miR-19b expression in SAT-and VAT-derived differentiated cells in a dose-dependent manner, and peak levels were observed at 1 ¦ÌM."	29077919
15803	Mouse	mmu-miR-19b	miRNA	fluid shear stress (FSS)	osteoblastic differentiation	MC3T3-E1 cells	fluid shear stress (FSS)treatment	downregulated	23595392
15804	Mouse	mmu-miR-19b	miRNA	bone morphogenetic proteins (BMPs)	osteogenesis	pluripotent stem (iPS) cells	bone morphogenetic proteins (BMPs) treatment	downregulated	22937097
15805	Mouse	mmu-miR-19b	miRNA	bleomycin and silica	lung fibrosis	fibroblasts	bleomycin and silica treatment	"qPCR revealed a significant increase of miR-19a, 19b, and 20a-expression in activated fibroblasts in the early phase of bleomycin and silica models."	29923329
15806	Mouse	mmu-miR-19b	miRNA	monocrotaline (MCT)	pulmonary hypertension (PH)	lung tissues	monocrotaline (MCT) treatment	upregulated	26980205
15807	Mouse	mmu-miR-19b	miRNA	mycobacterium tuberculosis (Mtb)	pulmonary tuberculosis (PTB)	lung tissues	mycobacterium tuberculosis (Mtb) treatment	downregulated	33089914
15808	Mouse	mmu-miR-19b	miRNA	pSTAT3-specific inhibitor AG-490	pulmonary tuberculosis (PTB)	lung tissues	pSTAT3-specific inhibitor AG-490 treatment	upregulated	33089914
15809	Mouse	mmu-miR-19b-1	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	mice heart tissues in vivo and primary murine cardiomyocytes in vitro	hypoxia induce	downregulated	30607541
15810	Mouse	mmu-miR-19b-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	tubular epithelial cells (TECs)-derived exosomes	lipopolysaccharide (LPS) treatment	upregulated	31097789
15811	Mouse	mmu-miR-19b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse cardiomyocytes (NMCMs)	angiotensin II (Ang II) treatment	downregulated	29664809
15812	Mouse	mmu-miR-19b-3p	miRNA	adriamycin (ADR)	chronic proteinuric kidney	tubular epithelial cells (TECs)-derived exosomes	adriamycin (ADR) treatment	upregulated	31097789
15813	Mouse	mmu-miR-19b-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	29572892
15814	Mouse	mmu-miR-19b-3p	miRNA	glyphosate	neurodevelopmental disorder	prefrontal cortex of mouse offspring	glyphosate	dysregulated	29467848
15815	Mouse	mmu-miR-19b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Murine ATDC5 cells	IL-1¦Â treatment	downregulated	31227976
15816	Mouse	mmu-miR-19b-3p	miRNA	paraquat (PQ)	paraquat (PQ)-induced acute lung injury and pulmonary fibrosis	MLE-12 cells	paraquat (PQ) treatment	downregulated	32741895
15817	Mouse	mmu-miR-19b-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	mouse pulmonary microvascular endothelial cells (PMVECs)	lipopolysaccharide (LPS) treatment	The level of miR-19b-3p was determined to be downregulated in vitro and in vivo	33760339
15818	Mouse	mmu-miR-19b-3p	miRNA	lipopolysaccharide (LPS)	tubulointerstitial inflammation	renal exosomes; tubule-derived exosomes	lipopolysaccharide (LPS) treatment	upregulated	31097789
15819	Mouse	mmu-miR-1a	miRNA	urethane	lung cancer	mouse lung tissue cells	urethane via ip injection treatment	downregulated	23761296
15820	Mouse	mmu-miR-1a	miRNA	high fat diet (HFD)	obesity	C57BL/6J male mice skeletal muscle	high fat diet (HFD) feed	upregulated	28926107
15821	Mouse	mmu-miR-1a-1-5p	miRNA	streptozocin (STZ)	diabetic pregnancy	female mice hyperglycemic ED9.5 embryos	streptozotocin treatment	dysregulatedin hyperglycemic ED95 embryos	27908722
15822	Mouse	mmu-miR-1a-3p	miRNA	guanidinoacetic acid (GAA)	cell differentiation	C2C12 cells	Guanidinoacetic acid (GAA) treatment	downregulated	30235878
15823	Mouse	mmu-miR-1a-3p	miRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	downregulated	30820263
15824	Mouse	mmu-miR-2	miRNA	torasemide	cardiac fibrosis	cardiac fibroblasts	Torasemide treatment	upregulated	26047574
15825	Mouse	mmu-miR-20	miRNA	western diet	coronary artery disease (CAD)	mouse	fed with western diet treatment	downregulated	28888922
15826	Mouse	mmu-miR-20	miRNA	Staphylococcus aureus	inflammation	mouse mammary tissue	intramammary infection of Globally Staphylococcus aureus treatment	differently regulated	25075227
15827	Mouse	mmu-miR-200	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	Kidneys tissue	TGF-¦Â1 treatment	downregulated	22012804
15828	Mouse	mmu-miR-200	miRNA	rapamycin	HIV-associated nephropathy(HIVAN)	mice renal tissues	Rapamycin treatment	downregulated	23611955
15829	Mouse	mmu-miR-200	miRNA	cyclosporine A (CsA)	nephrotoxicity	mouse kidney	cyclosporine A treatment	upregulated	28414804
15830	Mouse	mmu-miR-200	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	serum	high fat diet (HFD) feed	upregulated	32324317
15831	Mouse	mmu-miR-200a	miRNA	H2O2	acute myocardial infarction (AMI)	mouse cardiomyocytes	H2O2 treatment	The expression of miR-200a was upregulated in H 2O 2-treated cardiomyocytes.	31896068
15832	Mouse	mmu-miR-200a	miRNA	H2O2	acute myocardial infarction (AMI)	primary cultured mouse?cardiomyocytes	H2O2 treatment	upregulated	31896068
15833	Mouse	mmu-miR-200a	miRNA	isorhynchophylline (IRN)	asthma	ovalbumin (OVA)-induced asthma mice lung tissues	Isorhynchophylline (IRN) treatment	upregulated	31733831
15834	Mouse	mmu-miR-200a	miRNA	isorhynchophylline (IRN)	asthma	TGF-¦Â1-treated airway smooth muscle cells (ASMCs)	Isorhynchophylline (IRN) treatment	upregulated	31733831
15835	Mouse	mmu-miR-200a	miRNA	isorhynchophylline (IRN)	asthma	airway smooth muscle cells (ASMCs)	Isorhynchophylline (IRN) treatment	IRN administration inhibited miR-200a expression level.	31733831
15836	Mouse	mmu-miR-200a	miRNA	ovalbumin (OVA)	asthma	airway smooth muscle cells (ASMCs)	ovalbumin (OVA) treatment	upregulated	30423573
15837	Mouse	mmu-miR-200a	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	downregulated	31733831
15838	Mouse	mmu-miR-200a	miRNA	TGF-¦Â1	asthma	airway smooth muscle cells (ASMCs)	TGF-¦Â1 treatment	downregulated	31733831
15839	Mouse	mmu-miR-200a	miRNA	piceatannol (PIC)	atherosclerosis (AS)	RAW 264.7 cells	piceatannol (PIC) treatment	PIC increased miR-200a level in RAW2647 cells	32886103
15840	Mouse	mmu-miR-200a	miRNA	alcohol	brain injury and neurodegeneration	cerebral cortex	chronic alcohol administration	downregulated	30374194
15841	Mouse	mmu-miR-200a	miRNA	Glabridin (GLA)	breast cancer	MDA-MB-231 and BT-549 breast cancer cells	Glabridin (GLA) treatment	upregulation	24754877
15842	Mouse	mmu-miR-200a	miRNA	rosiglitazone	cardiac hypertrophy	adipocytes	rosiglitazone (RSG) treatment	upregulated	27734035
15843	Mouse	mmu-miR-200a	miRNA	doxorubicin (DOX)	cardiotoxicity	primary cultured cardiomyocyte	Doxorubicin (DOX) treatment	downregulated	31781322
15844	Mouse	mmu-miR-200a	miRNA	all-trans retinoic acid (ATRA)	cell differentiation	mouse hepatic progenitor cells (HPCs)	all-trans retinoic acid (ATRA) treatment	upregulated	31515718
15845	Mouse	mmu-miR-200a	miRNA	astaxanthin	colorectal cancer (CRC)	Mouse colon cancer cell CT26	astaxanthin (ATX) treatment	upregulated	31263239
15846	Mouse	mmu-miR-200a	miRNA	dexamethasone (DEX)	endometrial receptivity	endometrium tissues	dexamethasone (DEX) treatment	upregulated	30993706
15847	Mouse	mmu-miR-200a	miRNA	high glucose (HG)	endothelial dysfunction	aortic endothelial cells (ECs)	high glucose (HG) treatment	High glucose (HG) reduced miR-200a levels.	32031966
15848	Mouse	mmu-miR-200a	miRNA	shikonin	epithelial-mesenchymal transition (EMT)	mouse skin tissues	Shikonin treatment	downregulated	23861701
15849	Mouse	mmu-miR-200a	miRNA	calorie restriction (CR)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	calorie restriction (CR) treatment	upregulated	31863770
15850	Mouse	mmu-miR-200a	miRNA	exercise (Ex)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	exercise (Ex) treatment	upregulated	31863770
15851	Mouse	mmu-miR-200a	miRNA	high fat diet (HFD)	hepatic steatosis	mice thyroid and liver tissues	high fat diet (HFD) feed	downregulated	31863770
15852	Mouse	mmu-miR-200a	miRNA	low fat diet (LFD)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	low-fat diet (LF) treatment	upregulated	31863770
15853	Mouse	mmu-miR-200a	miRNA	quercetin	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	quercetin (Que) treatment	upregulated	31863770
15854	Mouse	mmu-miR-200a	miRNA	progesterone (P4)	infertility	uterine horn of 6-week-old female mice (C57BL/6)	progesterone treatment	dysregulated	30603515
15855	Mouse	mmu-miR-200a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	miR-200a was significantly reduced in liver tissues of a carbon tetrachloride (CCl4)-induced rat model.	32319630
15856	Mouse	mmu-miR-200a	miRNA	triptolide (TPL)	male hypogonadism	MLTC-1 cells	triptolide (TPL) treatment	downregulated of miR-200a could protect MLTC-1 cells against TP by inducing autophagy	33204070
15857	Mouse	mmu-miR-200a	miRNA	high glucose (HG)	cell differentiation	neural stem cells (NSCs)	high glucose treatment	downregulated	23776576
15858	Mouse	mmu-miR-200a	miRNA	fructose	metabolic disorders	C57BL/6JNju mice	fructose treatment	upregulated	28732575
15859	Mouse	mmu-miR-200a	miRNA	fructose	metabolic disorders	human-derived HepG2 cells	fructose treatment	upregulated	28732575
15860	Mouse	mmu-miR-200a	miRNA	carbon tetrachloride (CCl4)	multiple myeloma (MM)	liver tissue of mouse	CCl4 treatment	upregulated	21283674
15861	Mouse	mmu-miR-200a	miRNA	leptin	obesity	hypothalamus?tissues	leptin treatment	downregulated	24394757
15862	Mouse	mmu-miR-200a	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	downregulated	31863770
15863	Mouse	mmu-miR-200a	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	upregulated	31863770
15864	Mouse	mmu-miR-200a	miRNA	monosodium glutamate (MSG)	obesity	liver tissues	monosodium glutamate (MSG)-injected mice with developed central obesity treatment	dysregulated	24465854
15865	Mouse	mmu-miR-200a	miRNA	quercetin	obesity	thyroid	quercetin (QUE) treatment	upregulated	31863770
15866	Mouse	mmu-miR-200a	miRNA	growth hormone (GH)	osteosarcoma (OS)	LM8 cells	growth hormone (GH) treatment	downregulated	26289744
15867	Mouse	mmu-miR-200a	miRNA	bone morphogenetic protein 2 (BMP2)	preosteoblast differentiation	pre-osteoblast	bone morphogenetic protein-2 treatment	downregulated	19454767
15868	Mouse	mmu-miR-200a	miRNA	X-rays	radiation-induced oral mucositis (RIOM)	tongue tissues	25 Gy X-ray irradiation treatment	upregulated	31346357
15869	Mouse	mmu-miR-200a	miRNA	di(2-ethylhexyl) phthalate (DEHP)	skeletal muscle insulin resistance	skeletal muscle cells	di(2-ethylhexyl) phthalate (DEHP) treatment	The miR-17/Keap1-Nrf2/miR-200a axis contributed to DEHP-induced insulin resistance.	32802189
15870	Mouse	mmu-miR-200a	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
15871	Mouse	mmu-miR-200a-3	miRNA	7-chlorokynurenic acid (7-CTKA)	antidepressant	mouse	7-CTKA intraperitoneal injection	downregulated	25034119
15872	Mouse	mmu-miR-200a-3p	miRNA	TGF-¦Â	breast cancer	normal murine mammary gland epithelial (NMuMG) cells	transforming growth factor (TGF)¦Â treatment	downregulated	30285803
15873	Mouse	mmu-miR-200a-3p	miRNA	aldose reductase	diabetic nephropathy (DN)	renal mesangial cells	aldose reductase treatment	upregulated	24161443
15874	Mouse	mmu-miR-200a-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	SV40-MES-13?cells	high glucose treatment	downregulated	31630796
15875	Mouse	mmu-miR-200a-3p	miRNA	ethyl acetate extract isolated from rhizoma dioscoreae bulbifera	hepatotoxicity	mouse liver tissues	treat with ethyl acetate extract isolated from rhizoma dioscoreae bulbifera (450 mg/kg)	dysregulated	27609015
15876	Mouse	mmu-miR-200a-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis		carbon tetrachloride (CCl4) treatment	lncRNA Gpr137b-ps/miR-200a-3p/CXCL14 axis that modulates HSC activation and might exert an effect on the pathogenesis of liver fibrosis.	33069761
15877	Mouse	mmu-miR-200a-3p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
15878	Mouse	mmu-miR-200a-3p	miRNA	"chlorpromazine, procainamide, manganese"	systemic lupus erythematosus (SLE)	mouse	"chlorpromazine, procainamide, manganese"	dysregulated	29349090
15879	Mouse	mmu-miR-200a-3p	miRNA	coix seed Oil (CSO)	triple negative breast cancer (TNBC)	mouse triple-negative breast cancer (TNBC) tissues	coix Seed Oil (CSO) treatment	upregulated	33101013
15880	Mouse	mmu-miR-200b	miRNA	nicotine	abnormal migration and proliferation	mouse primary VSMCs	nicotine treatment	upregulated	28252009
15881	Mouse	mmu-miR-200b	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	murine primary neurons	amyloid-¦Â (A¦Â) treatment	upregulated	29738527
15882	Mouse	mmu-miR-200b	miRNA	alcohol	brain injury and neurodegeneration	cerebral cortex	chronic alcohol administration	downregulated	30374194
15883	Mouse	mmu-miR-200b	miRNA	aspergillus fumigatus (A. fumigatus)	bronchial asthma	bronchoalveolar lavage cells	aspergillus fumigatus infection	downregulated	29778524
15884	Mouse	mmu-miR-200b	miRNA	ovalbumin (OVA)	bronchial asthma	bronchoalveolar lavage cells	ovalbumin (OVA) treatment	downregulated	29778524
15885	Mouse	mmu-miR-200b	miRNA	hypertonicity	cellular responses to osmotic stress	mouse renal medulla	hypertonicity-induced induction	upregulated	20852262
15886	Mouse	mmu-miR-200b	miRNA	high fat diet (HFD)	chondrogenesis	white adipose tissues	high fat diet (HFD) feed	downregulated	22496873
15887	Mouse	mmu-miR-200b	miRNA	bone morphogenetic protein 2 (BMP2)	chronic pancreatitis (CP)	AR42J cells	bone morphogenetic protein 2 (BMP2) treatment	upregulated	29303912
15888	Mouse	mmu-miR-200b	miRNA	cerulein	chronic pancreatitis (CP)	pancreas	cerulein treatment	downregulated	29303912
15889	Mouse	mmu-miR-200b	miRNA	TGF-¦Â1	chronic pancreatitis (CP)	AR42J cells	TGF-¦Â1 treatment	downregulated	29303912
15890	Mouse	mmu-miR-200b	miRNA	monocrotaline (MCT)	cor pulmonale	"lungs, right ventricle (RV) and left ventricle (LV) tissues"	monocrotaline (MCT) treatment	downregulated	31730233
15891	Mouse	mmu-miR-200b	miRNA	alcohol extract of coreopsis tinctoria Nutt (AC)	diabetic nephropathy (DN)	db/db (DN) mice	alcohol extract of Coreopsis tinctoria Nutt (AC) treatment	downregulated	31032350
15892	Mouse	mmu-miR-200b	miRNA	retinoic acid (RA)	cell differentiation	embryonic stem cells (mESCs)	retinoic acid (RA) treatment	downregulated	26162091
15893	Mouse	mmu-miR-200b	miRNA	shikonin	epithelial-mesenchymal transition (EMT)	mouse skin tissues	Shikonin treatment	downregulated	23861701
15894	Mouse	mmu-miR-200b	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic tissues	carbon tetrachloride (CCl4) treatment	downregulated	30924172
15895	Mouse	mmu-miR-200b	miRNA	listeria	Listeria infection	murine ileum tissues	Listeria infection	downregulated	24327339
15896	Mouse	mmu-miR-200b	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	upregulated	20436259
15897	Mouse	mmu-miR-200b	miRNA	high glucose (HG)	cell differentiation	neural stem cells (NSCs)	high glucose treatment	downregulated	23776576
15898	Mouse	mmu-miR-200b	miRNA	leptin	obesity	hypothalamus?tissues	leptin treatment	downregulated	24394757
15899	Mouse	mmu-miR-200b	miRNA	lipopolysaccharide (LPS)	lung fibrosis	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	29200203
15900	Mouse	mmu-miR-200b	miRNA	X-rays	radiation-induced oral mucositis (RIOM)	tongue tissues	25 Gy X-ray irradiation treatment	upregulated	31346357
15901	Mouse	mmu-miR-200b	miRNA	carbon tetrachloride (CCl4)	multiple myeloma (MM)	liver tissue of mouse	CCl4 treatment	upregulated	21283674
15902	Mouse	mmu-miR-200b-3p	miRNA	folic acid	Alzheimer's disease (AD)	APP/PS1 mice brains and N2a cells	Folic acid deficiency treatment	downregulated	26345540
15903	Mouse	mmu-miR-200b-3p	miRNA	TGF-¦Â	breast cancer	normal murine mammary gland epithelial (NMuMG) cells	transforming growth factor (TGF)¦Â treatment	downregulated	30285803
15904	Mouse	mmu-miR-200b-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal microvascular endothelial cells (RMECs)	high glucose treatment	downregulated	31313295
15905	Mouse	mmu-miR-200b-3p	miRNA	streptozotocin injection and a high-glucose/high-fat diet	diabetic retinopathy (DR)	retinal microvascular endothelial cells (RMECs)	streptozotocin injection and a high-glucose/high-fat diet treatment	"YAP1 may exert some promotive effects on the development of DR through its regulation of the MALAT1/miR-200b-3p/VEGFA axis, highlighting that YAP1 silencing may be instrumental for the therapeutic targeting of DR"	31313295
15906	Mouse	mmu-miR-200b-3p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	downregulated	32443549
15907	Mouse	mmu-miR-200b-3p	miRNA	schistosomiasis japonica	hepatic fibrogenesis	serum	S. japonicum infection treatment	downregulated	30482723
15908	Mouse	mmu-miR-200b-3p	miRNA	arginine vasopressin	osmoregulation	mIMCD3 cells	exposure to arginine vasopressin treatment	downregulated	24389345
15909	Mouse	mmu-miR-200b-5p	miRNA	fatty acid amide hydrolase inhibitor (FAAH-II)	colitis	colitis mouse colon tissues	FAAH-II treatment	dysregulated	27327245
15910	Mouse	mmu-miR-200b-5p	miRNA	fatty acid amide hydrolase (FAAH) blockade	experimental colitis	colon	Fatty acid amide hydrolase (FAAH) blockade treatment	upregulated	27327245
15911	Mouse	mmu-miR-200b-5p	miRNA	X rays	ionizing radiation (IR) injury	male Kunming mice blood	0.5-2 Gy total-body carbon-ion irradiation treatment	dysregulatedin blood	28632432
15912	Mouse	mmu-miR-200b-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
15913	Mouse	mmu-miR-200c	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
15914	Mouse	mmu-miR-200c	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	murine primary neurons	amyloid-¦Â (A¦Â) treatment	upregulated	29738527
15915	Mouse	mmu-miR-200c	miRNA	Glabridin (GLA)	breast cancer	MDA-MB-231 and BT-550 breast cancer cells	Glabridin (GLA) treatment	upregulation	24754877
15916	Mouse	mmu-miR-200c	miRNA	aspergillus fumigatus (A. fumigatus)	bronchial asthma	bronchoalveolar lavage cells	aspergillus fumigatus infection	downregulated	29778524
15917	Mouse	mmu-miR-200c	miRNA	ovalbumin (OVA)	bronchial asthma	bronchoalveolar lavage cells	ovalbumin (OVA) treatment	downregulated	29778524
15918	Mouse	mmu-miR-200c	miRNA	R715 (B1R antagonist)	cerebral ischemia/reperfusion (I/R) injury	miR-200c in N9 cell and N9-derived MVs	R715 (B1R antagonist) (500 ¦Ìg/kg) treatment	downregulated in microvesicles (MVs)	28398146
15919	Mouse	mmu-miR-200c	miRNA	high fat diet (HFD)	chondrogenesis	white adipose tissues	high fat diet (HFD) feed	downregulated	22496873
15920	Mouse	mmu-miR-200c	miRNA	high glucose (HG)	diabetic vasculopathy	H5V cells	high glucose stimulation	upregulated	28627674
15921	Mouse	mmu-miR-200c	miRNA	retinoic acid (RA)	cell differentiation	embryonic stem cells (mESCs)	retinoic acid (RA) treatment	downregulated	26162091
15922	Mouse	mmu-miR-200c	miRNA	shikonin	epithelial-mesenchymal transition (EMT)	mouse skin tissues	Shikonin treatment	downregulated	23861701
15923	Mouse	mmu-miR-200c	miRNA	silica particle	epithelial-mesenchymal transition (EMT)	lung tissues	silica particles treatment	miR-200c expression levels were decreased on days 14 and 28 compared with those in the saline group	30010033
15924	Mouse	mmu-miR-200c	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	downregulated	26728044
15925	Mouse	mmu-miR-200c	miRNA	listeria	Listeria infection	murine ileum tissues	Listeria infection	downregulated	24327339
15926	Mouse	mmu-miR-200c	miRNA	"3,3'-diindolylmethane (DIM)"	multiple sclerosis (MS)	activated T cells during the development of experimental autoimmune encephalomyelitis (EAE)	"3,3'-Diindolylmethane (DIM) treatment"	upregulated	24898268
15927	Mouse	mmu-miR-200c	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	fed a methionine and choline deficient (MCD) diet for 2 week	upregulated in liver	29093267
15928	Mouse	mmu-miR-200c	miRNA	Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS)	periodontitis in obese subjects (PiOSs)	gingival; adipose tissues	Porphyromonas gingivalis?lipopolysaccharide (Pg-LPS) treatment	downregulated	33664998
15929	Mouse	mmu-miR-200c	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	upregulated	30242182
15930	Mouse	mmu-miR-200c	miRNA	lipopolysaccharide (LPS)	lung fibrosis	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	29200203
15931	Mouse	mmu-miR-200c	miRNA	X-rays	radiation-induced oral mucositis (RIOM)	tongue tissues	25 Gy X-ray irradiation treatment	upregulated	31346357
15932	Mouse	mmu-miR-200c	miRNA	reactive oxygen species (ROS)	spinal cord injury (SCI)	BV-2 cells	ROS treatment	upregulated	26503985
15933	Mouse	mmu-miR-200c	miRNA	split radiation	thymic lymphoma (RITL)	RITL samples	split radiation treatment	downregulated	25359176
15934	Mouse	mmu-miR-200c	miRNA	wound back skin	wound healing	8-week-old and 2-year-old mice	full-thickness 3 mm wound was introduced by punch biopsy onto back skin treatment	downregulated	28607463
15935	Mouse	mmu-miR-200c	miRNA	wound back skin	wound healing	8-week-old mice aged skin	full-thickness 3 mm wound was introduced by punch biopsy onto back skin treatment	upregulated at the early phase of wound healing in aged skin	28607463
15936	Mouse	mmu-miR-200c	miRNA	resveratrol	colorectal cancer (CRC)	HCT-116 Colorectal Cancer Cells	resveratrol (RS) treatment	upregulated	27918105
15937	Mouse	mmu-miR-200c*	miRNA	neuregulin-1£¨NRG1£©	cell differentiation	murine embryonic stem cell	neuregulin-1£¨NRG1£©	upregulated	21451102
15938	Mouse	mmu-miR-200c-3p	miRNA	IL-1B	intestinal inflammation	enterocytes	IL-1B treatment	Compared with mice given vehicle; enterocytes isolated from mice given IL1B had increased expression of MIR200C-3p	32569770
15939	Mouse	mmu-miR-200c-3p	miRNA	coix seed Oil (CSO)	triple negative breast cancer (TNBC)	mouse triple-negative breast cancer (TNBC) tissues	coix Seed Oil (CSO) treatment	upregulated	33101013
15940	Mouse	mmu-miR-200c-5p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	downregulated	28396668
15941	Mouse	mmu-miR-200s	miRNA	IL-6	insulin resistance (IR)	hepatocytes of mice	IL-6 treatment	downregulated	23798681
15942	Mouse	mmu-miR-202-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	downregulated	27322257
15943	Mouse	mmu-miR-203	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
15944	Mouse	mmu-miR-203	miRNA	alcohol	alcoholic liver disease (ALD)	liver tissues and AML-12 cell lines	alcohol exposure	downregulated	29670525
15945	Mouse	mmu-miR-203	miRNA	xiaoxianggou	atherosclerosis (AS)	serum	xiaoxianggou treatment	"Xiaoxianggou reverses the reduced miR-203 expression and the elevated Ets-2 expression induced by AngII,"	27470353
15946	Mouse	mmu-miR-203	miRNA	pectin (fermented to butyrate in the colon) (FPA)	colon tumorigenesis	colonic stem cells	(fermented to butyrate in the colon) (FPA) treatment	upregulated	26493444
15947	Mouse	mmu-miR-203	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse glomerular mesangial cells?M4200 cells	high glucose treatment	downregulated	30229838
15948	Mouse	mmu-miR-203	miRNA	estradiol	differentiation capacity in mouse embryoid bodies	vascular smooth muscle cells (VSMC)	estradiol treatment	upregulated	23175673
15949	Mouse	mmu-miR-203	miRNA	sodium arsenite (NaAsO2)	DNA methylation	liver tissues	sodium arsenite treatment	upregulated	32068019
15950	Mouse	mmu-miR-203	miRNA	eimeria papillata	eimeria papillata infection	mouse jejunum	Eimeria papillata infection	upregulated	21093440
15951	Mouse	mmu-miR-203	miRNA	high fat diet (HFD)	glucose homeostasis	adipose tissue	high fat diet (HFD) feed	downregulated	31327757
15952	Mouse	mmu-miR-203	miRNA	helicobacter pylori (H. pylori)	hepatic insulin resistance	primary hepatocytes	H. pylori infection	downregulated	25689935
15953	Mouse	mmu-miR-203	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung tissues	bleomycin (BLM) treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2.	32694556
15954	Mouse	mmu-miR-203	miRNA	bacillus calmette-guerin (BCG)	inflammatory response	macrophage RAW264.7 cells	bacille calmette-guerin (BCG) treatment	upregulated	23522925
15955	Mouse	mmu-miR-203	miRNA	lipopolysaccharide (LPS)	inflammatory response	macrophage RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	23522925
15956	Mouse	mmu-miR-203	miRNA	recombinant Adeno-Cre viruses (AdV-Cre)	lung adenocarcinoma (LUAD)	lung	recombinant Adeno-Cre viruses (AdV-Cre) treatment	upregulated	25359683
15957	Mouse	mmu-miR-203	miRNA	astragaloside IV (AS-IV)	osteoarthritis (OA)	ATDC5 cells	astragaloside IV (AS-IV) treatment	"AS-IV significantly reduces LPS-induced viability, apoptosis and the release of TNF-¦Á, IL-6 and iNOS mainly through up-regulating miR-203."	31906765
15958	Mouse	mmu-miR-203	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	29432995
15959	Mouse	mmu-miR-203	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	30550887
15960	Mouse	mmu-miR-203	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	mouse chondrogenic ATDC5 cells	lipopolysaccharide (LPS) treatment	miR-203 overexpression partially abolished the chondroprotective effects of PMS2L2.	30550887
15961	Mouse	mmu-miR-203	miRNA	IL-17	psoriasis	mouse ears	IL-17 treatment	upregulated	29039484
15962	Mouse	mmu-miR-203	miRNA	butyric acid (BA)	skin cancer	mouse skin	butyric acid (BA) treatment	upregulated	24792773
15963	Mouse	mmu-miR-203	miRNA	calcium glucarate (CAG)	skin cancer	mouse skin	calcium glucarate (CAG) treatment	upregulated	24792773
15964	Mouse	mmu-miR-203	miRNA	nicotinamide	skin cancer	mouse skin	nicotinamide(NA) treatment	upregulated	24792773
15965	Mouse	mmu-miR-203-3p	miRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	downregulated in the OIR samples	31452702
15966	Mouse	mmu-miR-203-3p	miRNA	alpinia oxyphylla extract (AOE)	type 2 diabetes mellitus (T2DM)	db-/db- mouse kidney	A. oxyphylla extract (AOE) treatment	downregulated	28249617
15967	Mouse	mmu-miR-203-3p	miRNA	aerobic exercise	whole-body metabolic adaptations	adipocytes	aerobic exercise training (AET) treatment	upregulated	32900951
15968	Mouse	mmu-miR-203a-3p	miRNA	oxygen	diabetic retinopathy (DR)	mouse retinal tissues	oxygen induce treatment	downregulated	31689123
15969	Mouse	mmu-miR-203a-3p	miRNA	oxygen	diabetic retinopathy (DR)	retinal tissues	oxygen treatment	MALAT1 affect angiogenesis by sponging miR-203a-3p in DR	31689123
15970	Mouse	mmu-miR-203a-3p	miRNA	carbon tetrachloride (CCl4)	epithelial-mesenchymal transition (EMT)	liver tissues	carbon tetrachloride (CCl4) treatment	miR-203a-3p was significantly downregulated in mice with liver fibrosis.	32659284
15971	Mouse	mmu-miR-203a-3p	miRNA	carnosic acid (CA)	liver fibrosis	liver tissues	carnosic acid (CA) treatment	Inhibition of p66Shc Oxidative Signaling via CA-Induced Upregulation of miR-203a-3p Alleviates Liver Fibrosis Progression.	32781430
15972	Mouse	mmu-miR-204	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
15973	Mouse	mmu-miR-204	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
15974	Mouse	mmu-miR-204	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	mouse Raw264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	MEG3 sponged miR-204 in Raw264.7 cells treated with ox-LDL. MEG3 exerted its function via the regulation of the MEG3/miR-204/CDKN2A regulatory axis in Raw264.7 cells treated with ox-LDL.	30672051
15975	Mouse	mmu-miR-204	miRNA	puerarin	autophagy	MC3T3-E1 cells	puerarin treatment	The expression level of miR-204 was decreased by puerarin	32010248
15976	Mouse	mmu-miR-204	miRNA	puerarin	cell differentiation	MC3T3-E1 cells	Puerarin treatment	downregulated	32010248
15977	Mouse	mmu-miR-204	miRNA	puerarin	cell proliferation	MC3T3-E1 cells	Puerarin treatment	downregulated	29368357
15978	Mouse	mmu-miR-204	miRNA	puerarin	cell viability	mouse MC3T3-E1 osteoblast-like cells	0.1 mg/ml puerarin for 48 h treatment	downregulated	28901520
15979	Mouse	mmu-miR-204	miRNA	estrogen (ES)	renal fibrosis	mouse uterus tissues	Estrogen treatment	mirn451 was significantly increased by estrogen administration whereas mirn181b and mirn204 expression was significantly reduced	20720260
15980	Mouse	mmu-miR-204	miRNA	¦Â-glycerophosphate (¦Â-GP)	colorectal cancer (CRC)	mouse aortic VSMCs	¦Â-glycerophosphate treatment	miR-204 was suppressed in mouse aortic VSMCs during ¦Â-glycerophosphate-induced calcification	22871591
15981	Mouse	mmu-miR-204	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart tissues	doxorubicin (DOX) treatment	downregulated	33274007
15982	Mouse	mmu-miR-204	miRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	mouse endothelial cells	tunicamycin (TM) treatment	upregulated	28839162
15983	Mouse	mmu-miR-204	miRNA	high fat diet (HFD)	endoplasmic reticulum stress (ERS)	C57Bl/6 mouse vascular	high fat diet (HFD) feed	upregulated	28181559
15984	Mouse	mmu-miR-204	miRNA	high glucose (HG)	obesity	3T3-L1 cells	high glucose treatment	LncRNA TUG1 could negatively regulate miR-204 to alleviate inflammation and insulin tolerance via promoting SIRT1/GLUT4/PPAR¦Ã/AKT pathway.	32888158
15985	Mouse	mmu-miR-204	miRNA	dietary methionine restriction (MR)	osteoblast differentiation and function	"male C57BL/6J mice bone marrow,plasma and liver"	fed diets containing 0.86% or 0.12% methionine for 5 weeks	"upregulated (miR-31 in plasma and liver, and miR-133a, miR-335-5p, and miR-204 in the bone marrow"	27191548
15986	Mouse	mmu-miR-204	miRNA	oxaliplatin	oxaliplatin induced-neuropathy	primary cultured dorsal root ganglia neurons	oxaliplatin treatment	upregulated	30031110
15987	Mouse	mmu-miR-204	miRNA	oxibendazole (OBZ)	prostate cancer	22Rv1 tumors in nude mice	treated with OBZ (25 mg/kg/day) treatment	upregulated	29434928
15988	Mouse	mmu-miR-204	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	neuronal cells	hypoxia treatment	upregulated	26350953
15989	Mouse	mmu-miR-204	miRNA	candida albicans (C. albicans)	systemic Candidiasis	C57BL/6 mice	candida albicans infection	downregulated	24641951
15990	Mouse	mmu-miR-204	miRNA	high fat diet (HFD)	chondrogenesis	white adipose tissues	high fat diet (HFD) feed	downregulated	22496873
15991	Mouse	mmu-miR-204-3p	miRNA	methamphetamine (METH)	drug addiction	nucleus accumbens (NAc)	methamphetamine (METH) treatment	upregulated	31153969
15992	Mouse	mmu-miR-204-3p	miRNA	high glucose (HG)	renal and podocytes injuries	MPC5 cells	high glucose treatment	downregulated	29940664
15993	Mouse	mmu-miR-204-5p	miRNA	IL-11	aplastic anemia (AA)	mouse hematopoietic stem cell (HSC)	IL-11 treatment	downregulated	29217821
15994	Mouse	mmu-miR-204-5p	miRNA	melatonin	calcific aortic valve disease (CAVD)	valvular interstitial cells	melatonin treatment	melatonin ameliorates aortic valve calcification via the regulation of CircRIC3/miR-204-5p/DPP4 signaling in hVICs	32369647
15995	Mouse	mmu-miR-204-5p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	peripheral blood monocytes	murine cytomegalovirus (MCMV) infection	downregulated	33245094
15996	Mouse	mmu-miR-204-5p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary cultured cardiomyocyte	hypoxia induce	downregulated	31644943
15997	Mouse	mmu-miR-204-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	"KCNQ1OT1 could promote the LGALS3 expression by binding to miR-204-5p, which led to aggravated myocardial IR injury."	31644943
15998	Mouse	mmu-miR-204-5p	miRNA	high fat diet (HFD)	obesity	fat tissues from obese mice fed long-term with a high-fat diet (HFD)	high fat diet (HFD) feed	downregulated	29775748
15999	Mouse	mmu-miR-204-5p	miRNA	morphine	painful or stressful conditions	hippocampal	Morphine treatment	downregulated	25844808
16000	Mouse	mmu-miR-204-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	serum and substantia nigra (SN)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	31572127
16001	Mouse	mmu-miR-204c	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
16002	Mouse	mmu-miR-204e	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
16003	Mouse	mmu-miR-205	miRNA	garcinol	acute myocardial infarction (AMI)	AMI mouse blood; heart tissues	Garcinol treatment	upregulated	33809417
16004	Mouse	mmu-miR-205	miRNA	isoproterenol	acute myocardial infarction (AMI)	blood; heart tissues	isoproterenol treatment	downregulated	33809417
16005	Mouse	mmu-miR-205	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	"SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice."	33170429
16006	Mouse	mmu-miR-205	miRNA	sodium arsenite (NaAsO2)	DNA methylation	liver tissues	sodium arsenite treatment	upregulated	32068019
16007	Mouse	mmu-miR-205	miRNA	shikonin	epithelial-mesenchymal transition (EMT)	mouse skin tissues	Shikonin treatment	downregulated	23861701
16008	Mouse	mmu-miR-205	miRNA	high fat diet (HFD)	erectile dysfunction (ED)	mouse	high fat diet (HFD) feed	dysregulated	25533598
16009	Mouse	mmu-miR-205	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	high fat diet (HFD) feed	upregulated	31799678
16010	Mouse	mmu-miR-205	miRNA	oleacein (OA)	nonalcoholic fatty liver disease (NAFLD)	mouse primary hepatocytes (PH)	oleic acid (OA) treatment	upregulated	31799678
16011	Mouse	mmu-miR-205	miRNA	erlotinib	non-small cell lung cancer (NSCLC)	murine NSCLC xenograft models	erlotinib treatment	downregulated	24911146
16012	Mouse	mmu-miR-205	miRNA	gefitinib	non-small cell lung cancer (NSCLC)	murine NSCLC xenograft models	gefitinib treatment	downregulated	24911146
16013	Mouse	mmu-miR-205	miRNA	kanamycin-furosemide	ototoxic effects of kanamycin-furosemide	serum	kanamycin-furosemide treatment	upregulated	30235835
16014	Mouse	mmu-miR-205	miRNA	baicalin (BAI)	type 1 diabetes mellitus (T1DM)	TNF-¦Á-treated pancreatic ¦Â-cell line Min6	baicalin (BAI) treatment	upregulated	30058243
16015	Mouse	mmu-miR-205	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	type 1 diabetes mellitus (T1DM)	pancreatic ¦Â-cell line Min6	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30058243
16016	Mouse	mmu-miR-205	miRNA	IL-32	vascular injury	hIL-32¦Á-Tg and ApoE /hIL-32¦Á-Tg mice	IL-32 treatment	downregulated	28740544
16017	Mouse	mmu-miR-205	miRNA	high glucose (HG)	diabetic nephropathy (DN)	The mouse mesangial SV40©\Mes13 cells	"SV40©\Mes13 cells were cultured under normal glucose condition (Con, 5.5 mM glucose), mannitol condition (MN, 5.5 mM glucose + 24.5 mM mannitol), or HG condition (30 mM glucose) for 24 hr. treatment"	"miR-205 inhibits HG©\induced proliferation, oxidative stress, ECM accumulation, and inflammation in mesangial cells via targeting HMGB1"	31087368
16018	Mouse	mmu-miR-205-3p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	bEnd.3 cells	Oxygen-glucose deprivation (OGD) treatment	Long noncoding RNA MALAT1 regulates apoptosis in ischemic stroke by sponging miR-205-3p and modulating PTEN expression	32655805
16019	Mouse	mmu-miR-205-5p	miRNA	curcumin (Cur)	melanoma	B78H1 cells	curcumin treatment	miRNA expression signature in tumors was substantially altered by curcumin intake with mmu-miR-205-5p over 100 times higher expressed when compared to controls.	24349037
16020	Mouse	mmu-miR-205-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	"The expression levels of MALAT1 and leucine-rich repeat kinase (LRRK2) were increased, and that of miR-205-5p was decreased in the midbrains of mice in which PD was induced by MPTP."	29511451
16021	Mouse	mmu-miR-205-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	lung tissue	hypoxia induce	downregulated	30853343
16022	Mouse	mmu-miR-205-5p	miRNA	coix seed Oil (CSO)	triple negative breast cancer (TNBC)	mouse triple-negative breast cancer (TNBC) tissues	coix Seed Oil (CSO) treatment	miR-205-5p was substantially altered in CSO treated tumor tissues.	33101013
16023	Mouse	mmu-miR-206	miRNA	lipopolysaccharide (LPS)	Alzheimer's disease (AD)	microglial BV-2 cells	lipopolysaccharide (LPS) treatment	upregulated	27277332
16024	Mouse	mmu-miR-206	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	"The expression of RMRP and CCL2 was elevated, while miR-206 was reduced in OVA-induced mice."	33511814
16025	Mouse	mmu-miR-206	miRNA	particulate matter (PM2.5)	bronchial asthma	lung tissue	PM2.5 exposure treatment	upregulated	31520993
16026	Mouse	mmu-miR-206	miRNA	Yes-associated protein (YAP)	cardiac hypertrophy	cardiomyocytes	Yes-associated protein (YAP) treatment	upregulated	26333362
16027	Mouse	mmu-miR-206	miRNA	neurotoxicant sodium valproate (VPA)	developmental toxicity	murine embryonic stem cells (mESCs)	neurotoxicant sodium valproate (VPA) treatment	upregulated	24896083
16028	Mouse	mmu-miR-206	miRNA	ethanol (EtOH)	drinking	"mouse different brain regions, including medial prefrontal cortex (mPFC) , central amygdala (CeA), and hippocampus (HPC)"	ethanol treatment	upregulated	30790666
16029	Mouse	mmu-miR-206	miRNA	forced swim stress (FSS)	drinking	"mouse different brain regions, including medial prefrontal cortex (mPFC) , central amygdala (CeA), and hippocampus (HPC)"	the mice received either a single or 5 daily 10-min FSS sessions	upregulated	30790666
16030	Mouse	mmu-miR-206	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	C2C12 cells	TGF-¦Â treatment	downregulated	21324893
16031	Mouse	mmu-miR-206	miRNA	"fasting, denervation, diabetes, and cancer cachexia"	fine-tuning the atrophy program	mouse muscles	"mouse muscles under wasting conditions such as fasting, denervation, diabetes, and cancer cachexia treatment"	wasting conditions showed an induction of miRNA-206 and miRNA-21 expression	24891504
16032	Mouse	mmu-miR-206	miRNA	adriamycin (ADR)	focal segmental glomerulosclerosis (FSGS)	glomeruli	adriamycin (ADR) treatment	upregulated	27056206
16033	Mouse	mmu-miR-206	miRNA	high fat diet (HFD)	hepatosteatosis and hyperglycemia	mouse fatty livers	high fat diet (HFD) feed	downregulated	28025059
16034	Mouse	mmu-miR-206	miRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	lung cancer cells	drug treatment	lung carcinogen NNK exposure changes the expression of serum miRNAs. Serum miR-206 and miR-133b could be associated with lung carcinogenesis induced by NNK	23337359
16035	Mouse	mmu-miR-206	miRNA	botulinum toxin A (BTXA)	muscle atrophy	quadriceps muscle	botulinum toxin A (BTXA) treatment	upregulated	30427927
16036	Mouse	mmu-miR-206	miRNA	heme oxygenase-1 (HMOX1)	myoblast differentiation	C2C12 cells	Heme oxygenase-1 (HMOX1) treatment	downregulated	21827279
16037	Mouse	mmu-miR-206	miRNA	sciatic nerve partial ligation	pain	mouse dorsal root ganglion (DRG)	sciatic nerve partial ligation therapy treatment	downregulated	21385380
16038	Mouse	mmu-miR-206	miRNA	"pioglitazone and L-buthionine-S,R-sulfoximine"	skeletal muscle injury	C57BL/6J mice plasma	"pioglitazone with L-buthionine-S,R-sulfoximine, to C57BL/6J mice for 2days treatment"	upregulated in plasma	28263783
16039	Mouse	mmu-miR-206	miRNA	6-bromoindirubin-3'-oxime (BIO)	skeletal muscle differentiation	C2C12 cells	6-bromoindirubin-3'-oxime (BIO) treatment	upregulated	31792344
16040	Mouse	mmu-miR-206-3p	miRNA	angiostrongylus cantonensis (A. cantonensis)	angiostrongylus cantonensis (A. cantonensis) infection	mouse	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24682888
16041	Mouse	mmu-miR-206-3p	miRNA	donepezil	Alzheimer's disease (AD)	APP/PS1 mice	donepezil treatment	downregulated in the hippocampus and cortex	28123152
16042	Mouse	mmu-miR-206-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
16043	Mouse	mmu-miR-206-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	Female BALB/c mice blood	"4,4'-methylene diphenyl diisocyanate (MDI) exposure"	downregulated	30074411
16044	Mouse	mmu-miR-206-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	bronchoalveolar lavage cells (BALCs)	"4,4'-methylene diphenyl diisocyanate (MDI) treatment"	downregulated	31609387
16045	Mouse	mmu-miR-206-3p	miRNA	"diisocyanate, 4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	Female BALB/c mice blood	Female BALB/c mice were exposed to one of three exposure regimens: dermal exposure to 1% MDI in acetone; nose-only exposure to 4580?¡À?1497?¦Ìg/m3 MDI-aerosol for 60?minutes; or MDI dermal exposure/sensitization followed by MDI-aerosol inhalation challenge.	downregulated	30074411
16046	Mouse	mmu-miR-206a-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	upregulated	30883703
16047	Mouse	mmu-miR-208	miRNA	IL-10	cardiac fibrosis	mouse bone marrow fibroblast progenitor cells (BM-FPCs)	IL10 treatment	downregulated	28667100
16048	Mouse	mmu-miR-208	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
16049	Mouse	mmu-miR-208	miRNA	bone morphogenetic protein 2 (BMP2)	impaired osteogenic differentiation	MC3T3-E1 cells; Primary murine osteoblast cells	bone morphogenetic protein 2 (BMP2) treatment	downregulated	20576608
16050	Mouse	mmu-miR-208	miRNA	cardiac ischemia reperfusion (CIR)	ischemia/reperfusion (I/R) injury	mouse	cardiac ischemia reperfusion (CIR) treatment	downregulated	29442001
16051	Mouse	mmu-miR-208a	miRNA	doxorubicin (DOX)	cardiomyocyte apoptosis	cardiomyocyte	doxorubicin treatment	upregulated	26137188
16052	Mouse	mmu-miR-208a	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	CD1 mice of both genders	streptozocin (STZ) treatment	upregulated	24685144
16053	Mouse	mmu-miR-208a	miRNA	high glucose (HG)	diabetes-induced cardiac remodelling	HL-1 cardiomyocytes	high-glucose (HG) treatment	upregulated	30696455
16054	Mouse	mmu-miR-208a	miRNA	synthetic Sulfonyl-Hydrazone-1	iPSC-derived cardiac differentiation	Murine fibroblast-derived iPSCs	Synthetic Sulfonyl-Hydrazone-1 treatment	"small chemical compounds, such as SHZ, can constitute a novel and clinically feasible strategy to improve iPSC-derived cardiac differentiation"	21445862
16055	Mouse	mmu-miR-208a	miRNA	isoproterenol	isoproterenol-induced cardiac injury	heart tissues	ISO treatment	upregulated	24713317
16056	Mouse	mmu-miR-208a	miRNA	prolonged aerobic exercise	muscle hypertrophy	plasma	"impact of extended-duration, submaximal aerobic exercise treatment"	upregulated	24436293
16057	Mouse	mmu-miR-208a	miRNA	ischemia/reperfusion (I/R) 	myocardial ischaemic injury	mouse plasma;Bone marrow-derived macrophage (BMDM);Rat neonatal CMs	ischemia/reperfusion (I/R) treatment	differently regulated	28768728
16058	Mouse	mmu-miR-208a	miRNA	angiotensin II (Ang II)	weight gain	HL-1 cells	angiotensin II (Ang II) treatment	upregulated	26381051
16059	Mouse	mmu-miR-208b-3p	miRNA	luteolin	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	Luteolin (LUT) treatment	downregulated	26658785
16060	Mouse	mmu-miR-20a	miRNA	H2O2	Alzheimer's disease (AD)	Primary hippocampal neuron cells	H2O2 treatment	upregulated	24423585
16061	Mouse	mmu-miR-20a	miRNA	H2O2	Alzheimer's disease (AD)	senescence accelerated mouse prone 8 (SAMP8) and prone 10 (SAMP10)	"different concentrations (0, 100, 200, 400 and 800 ¦ÌM) of H2O2 treatment"	upregulated	24423585
16062	Mouse	mmu-miR-20a	miRNA	notoginsenoside R1 (NGR1)	atherosclerosis (AS)	serum;aorta	notoginsenoside R1 (NGR4) treatment	upregulated	24933211
16063	Mouse	mmu-miR-20a	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	serial transverse aortic sections	Shexiang Tongxin dropping pill (STDP) treatment	upregulated	25449459
16064	Mouse	mmu-miR-20a	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	(ApoE(-/-)) mice aortic	STDP (30 mg/kg/day) on atherosclerotic lesions treatment	upregulated	25449459
16065	Mouse	mmu-miR-20a	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	33143661
16066	Mouse	mmu-miR-20a	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	downregulated	21584493
16067	Mouse	mmu-miR-20a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Mouse-derived retinal microvascular endothelial cells (RMECs)	high glucose (HG) treatment	miR-20a was significantly downregulated in HG-treated RMECs.	32776826
16068	Mouse	mmu-miR-20a	miRNA	mangiferin	endoplasmic reticulum stress (ERS)	primary mouse hepatocytes	mangiferin treatment	downregulated	32413114
16069	Mouse	mmu-miR-20a	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	downregulated	26728044
16070	Mouse	mmu-miR-20a	miRNA	progesterone (P4)	infertility	uterine horn of 6-week-old female mice (C57BL/6)	progesterone treatment	dysregulated	30603515
16071	Mouse	mmu-miR-20a	miRNA	fluid shear stress (FSS)	osteoblastic differentiation	MC3T3-E1 cells	fluid shear stress (FSS)treatment	downregulated	23595392
16072	Mouse	mmu-miR-20a	miRNA	hypoxia	osteoclast differentiation	RAW264.7 cells	"hypoxia caused induction of autophagy and osteoclast differentiation markers in . In addition, was significantly repressed treatment"	downregulated	25485521
16073	Mouse	mmu-miR-20a	miRNA	bleomycin and silica	lung fibrosis	fibroblasts	bleomycin and silica treatment	"qPCR revealed a significant increase of miR-19a, 19b, and 20a-expression in activated fibroblasts in the early phase of bleomycin and silica models."	29923329
16074	Mouse	mmu-miR-20a	miRNA	hypoxia	pulmonary hypertension (PH)	right ventricular and pulmonary arterial vascular	Hypoxia treatment	upregulated	22450430
16075	Mouse	mmu-miR-20a	miRNA	monocrotaline (MCT)	pulmonary hypertension (PH)	lung tissues	monocrotaline (MCT) treatment	upregulated	26980205
16076	Mouse	mmu-miR-20a	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
16077	Mouse	mmu-miR-20a	miRNA	genistein	spermatogenesis	ICR mice testis	"different doses of GEN (0, 0.5, 5, 50 and 250 mg/kg/day) for 35 days"	upregulated	28938591
16078	Mouse	mmu-miR-20a*	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
16079	Mouse	mmu-miR-20a-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	downregulated	30883703
16080	Mouse	mmu-miR-20a-5p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	downregulated	30883703
16081	Mouse	mmu-miR-20a-5p	miRNA	high glucose (HG)	hepatic glycogen synthesis	NCTC1469 cells and Hep1-6 cells	high glucose treatment	downregulated	27019188
16082	Mouse	mmu-miR-20a-5p	miRNA	licochalcone A (LA)	lung cancer	MLE-12 cells	Licochalcone A (lico A) treatment	downregulated	32505917
16083	Mouse	mmu-miR-20a-5p	miRNA	neurotoxicant cuprizone (CPZ)	myelin abnormalities	myelin	Neurotoxicant cuprizone (CPZ) treatment	miR-155-5p and miR-20a-5p upregulations enhanced NgR induction through Smad 2 and Smad 4 suppression in demyelination.	31963761
16084	Mouse	mmu-miR-20a-5p	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	primary mouse hepatocytes	free fatty acid (FFA) treatment	downregulated	33344451
16085	Mouse	mmu-miR-20a-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	murine induced pluripotent stem cell (miPSC)	IL-1¦Â treatment	"RNA-seq results show that miR-20a-5p increase from 4 to 24 hours, but slightly decrease from 24 to 72 hours in IL-1¦Âstimulated pellets."	32767602
16086	Mouse	mmu-miR-20a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	murine induced pluripotent stem cell (miPSC)	tumor necrosis factor alpha (TNF-¦Á) treatment	"RNA-seq results show that miR-20a-5p increase from 4 to 24 hours, but slightly decrease from 24 to 72 hours in TNF-¦Á stimulated pellets"	32767602
16087	Mouse	mmu-miR-20a-5p	miRNA	radiation	radiation-induced injury	blood	radiation treatment	downregulated	29799276
16088	Mouse	mmu-miR-20b	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
16089	Mouse	mmu-miR-20b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	immortalized mouse podocytes	HG	upregulated	28849008
16090	Mouse	mmu-miR-20b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	downregulated	30883703
16091	Mouse	mmu-miR-20b	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	32315726
16092	Mouse	mmu-miR-20b	miRNA	monocrotaline (MCT)	pulmonary hypertension (PH)	lung tissues	monocrotaline (MCT) treatment	upregulated	26980205
16093	Mouse	mmu-miR-20b	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
16094	Mouse	mmu-miR-20b	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	mouse mouse heart tissues	infect with CVB3	upregulated	28247213
16095	Mouse	mmu-miR-20b2	miRNA	tuberculosis (MTB)	inflammation	mouse lung	infect with TB treatment	downregulated in lung	28606793
16096	Mouse	mmu-miR-20b-5p	miRNA	H2O2	hepatic ischemia/reperfusion injury (HIRI)	Primary mouse hepatocytes culture	H2O2 treatment	?HOTAIR regulates autophagy via the miR-20b-5p/ATG7 axis in hepatic I/R injury	30367982
16097	Mouse	mmu-miR-20b-5p	miRNA	ischemia/reperfusion (I/R) 	myocardial ischemia/reperfusion (I/R) injury (MIRI)	mouse cardiomyocytes	ischemia/reperfusion (I/R) treatment	The expression of circHIPK3 was upregulated during myocardial I/R injury and hypoxia/reoxygenation (H/R) injury of cardiomyocytes.	33824287
16098	Mouse	mmu-miR-20b-5p	miRNA	radiation	radiation-induced injury	blood	radiation treatment	downregulated	29799276
16099	Mouse	mmu-miR-20b-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	RAW 264.7 macrophages	Mycobacterium tuberculosis (Mtb) infection	downregulated	30378171
16100	Mouse	mmu-miR-20b-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	RAW 264.7 macrophages	Mycobacterium tuberculosis (Mtb) infection	downregulated	30378171
16101	Mouse	mmu-miR-21	miRNA	TGF-¦Â	pancreatic cancer (PC)	mouse primary fibroblasts	TGF¦Â treatment	upregulated	23469132
16102	Mouse	mmu-miR-21	miRNA	hypoxia	Alzheimer's disease (AD)	exosomes derived from mesenchymal stromal cells (MSCs)	hypoxia induce	upregulated	28970251
16103	Mouse	mmu-miR-21	miRNA	red mud	biological effects of red mud	"CBA/Ca mice liver, spleen, lung, kidney and lymph nodes"	"1, 3, 6 and 24 h after a single intraperitoneal injection of red mud treatment"	"upregulated , but the level and the peak of the alteration differed according to examined tissue"	24425836
16104	Mouse	mmu-miR-21	miRNA	Tungsten carbide-cobalt (WC-Co) nanoparticle composites	bipolar disorder type I (BD-I)	JB6 P+ cells	Tungsten carbide-cobalt (WC-Co) nanoparticle composites? treatment	WC-Co nanoparticles induce miR-21 generation	23758151
16105	Mouse	mmu-miR-21	miRNA	high tidal volume ventilation (HVTV)	lung injury	lung tissues	high tidal volume ventilation (HVTV) treatment	upregulated	22659882
16106	Mouse	mmu-miR-21	miRNA	talcum powder	atrial fibrillation (AF)	heart	talcum powder treatment	upregulated	27406600
16107	Mouse	mmu-miR-21	miRNA	oxygen glucose deprivation (OGD)	acute cerebral infarction	mouse N2A neuroblastoma cells (N2A)	oxygen-and-glucose-deprivation (OGD) treatment	upregulated	24841240
16108	Mouse	mmu-miR-21	miRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	C57BL/6J mice	ischemia/reperfusion (I/R) treatment	upregulation in samples of kidney	26149640
16109	Mouse	mmu-miR-21	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
16110	Mouse	mmu-miR-21	miRNA	ischemia	acute kidney injury (AKI)	kidney tissues	subjected to 35 min occlusion of bilateral renal pedicles 4 days following preconditioning	upregulated	28677811
16111	Mouse	mmu-miR-21	miRNA	xenon (Xe)	acute kidney injury (AKI)	kidney	Xenon treatment	upregulated	25844699
16112	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	acute liver injury (ALI)	liver tissues	lipopolysaccharide (LPS) treatment	miR-21 exacerbate acute liver injury in sepsis mice by inhibiting PPAR¦Á expression.	33424957
16113	Mouse	mmu-miR-21	miRNA	Liang-Ge-San (LGS)	acute lung injury (ALI)	LPS-induced murine RAW264.7 cells	Liang-Ge-San (LGS) treatment	upregulated	31803051
16114	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Murine RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	31803051
16115	Mouse	mmu-miR-21	miRNA	caerulein (Cae)	acute pancreatitis (AP)	pancreata	caerulein (Cae) treatment	miR-21 was significantly lower following caerulein treatment.	30537729
16116	Mouse	mmu-miR-21	miRNA	ethanol (EtOH)	alcoholic liver injury	liver	ethanol treatment	upregulated	25118289
16117	Mouse	mmu-miR-21	miRNA	flavonol icariin	apoptosis	mouse pronuclear embryos	icariin treatment	upregulated	24948525
16118	Mouse	mmu-miR-21	miRNA	mouse growth differentiation factor-9 (GDF-9) or in pig oocyte-conditioned medium (POCM)	apoptosis	mouse oocytectomized cumulus oophorus complexes (OOXs)	cultured with GDF-9 or in POCM	upregulated	28486664
16119	Mouse	mmu-miR-21	miRNA	¦Á-MEM medium	apoptosis	mouse oocytectomized cumulus oophorus complexes (OOXs)	¦Á-MEM medium treatment	downregulated	28486664
16120	Mouse	mmu-miR-21	miRNA	budesonide	asthma	OVA-challenged asthma mice lung tissues	budesonide treatment	downregulated	29854030
16121	Mouse	mmu-miR-21	miRNA	calcitriol	asthma	OVA-challenged asthma mice lung tissues	calcitrioltreatment	downregulated	29854030
16122	Mouse	mmu-miR-21	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	29854030
16123	Mouse	mmu-miR-21	miRNA	bosentan	atherosclerosis (AS)	endothelial cell from apolipoprotein E-deficient (ApoE-/-) mouse model of atherosclerosis	bosentan treatment	upregulated	31886257
16124	Mouse	mmu-miR-21	miRNA	cigarette smoke (CS)	atherosclerosis (AS)	aortic tissues of ApoE KO mice	cigarette smoke (CS) exposure	upregulated	29642385
16125	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	RAW 264.7;macrophage-like cell line	lipopolysaccharide (LPS) treatment	upregulated	24502419
16126	Mouse	mmu-miR-21	miRNA	notoginsenoside R1 (NGR1)	atherosclerosis (AS)	serum;aorta	notoginsenoside R1 (NGR1) treatment	downregulated	24933211
16127	Mouse	mmu-miR-21	miRNA	high glucose (HG)	autophagy	murine podocytes cell (MPC) lines	high glucose	upregulated	26567247
16128	Mouse	mmu-miR-21	miRNA	deoxycholic acid (DCA)	bile acid-associated liver pathologies	primary rat hepatocytes	deoxycholic acid (DCA) treatment	downregulated	26621219
16129	Mouse	mmu-miR-21	miRNA	bile acids	bile-containing gastroesophageal reflux	murine hypopharyngeal mucosa (HM)	bile acids treatment	upregulated	29529473
16130	Mouse	mmu-miR-21	miRNA	saline	bile-containing gastroesophageal reflux	murine hypopharyngeal mucosa (HM)	saline treatment	upregulated	29529473
16131	Mouse	mmu-miR-21	miRNA	fludioxonil andfenhexamid	breast cancer	MCF-7;T47D; MDA-MB-231 human breast cancer cells	Fludioxonil and Fenhexamid treatment	downregulated	23052036
16132	Mouse	mmu-miR-21	miRNA	xanthomicrol	breast cancer	4T1 cells	xanthomicrol treatment	downregulated	33217075
16133	Mouse	mmu-miR-21	miRNA	doxorubicin (DOX)	cardiac cytotoxicity	heart tissue and H9C2 cells	doxorubicin (DOX) treatment	upregulated	26132560
16134	Mouse	mmu-miR-21	miRNA	angiotensin II (Ang II)	cardiac fibroblast migration	primary mouse cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	upregulated	24447911
16135	Mouse	mmu-miR-21	miRNA	IL-10	cardiac fibrosis	mouse bone marrow fibroblast progenitor cells (BM-FPCs)	IL10 treatment	downregulated	28667100
16136	Mouse	mmu-miR-21	miRNA	streptozocin (STZ)	cardiac fibrosis	myocardium of T1DM mice	streptozotocin treatment	upregulated	31680453
16137	Mouse	mmu-miR-21	miRNA	doxorubicin (DOX)	cardiotoxicity	BALB/c mice injected C-26 tumor cells	doxorubicin treatment	upregulated	28560697
16138	Mouse	mmu-miR-21	miRNA	collagen IV and vascular endothelial growth factor (VEGF)	cardiovascular regeneration	induced pluripotent stem cells (iPSC)	collagen IV and VEGF treatment	upregulated	24356956
16139	Mouse	mmu-miR-21	miRNA	IL-6	cell apoptosis in early mouse embryo development	mouse blastocyst stage embryos cells	interleukin-6 (IL-6) treatment	"the induction of the Stat3 anti-apoptotic pathway by IL-6 is linked to miRNA-21 expression, which possibly results in the regulation of cell apoptosis in early mouse embryo development"	19437447
16140	Mouse	mmu-miR-21	miRNA	substance P (SP)	cell proliferation	Colonic epithelial exosomes were isolated from mice	substance P (SP) treatment	upregulated	31545921
16141	Mouse	mmu-miR-21	miRNA	hypoxia	cerebral ischemic stroke (CIS)	C57BL/6 J mice	MCAO treatment	downregulated	29238035
16142	Mouse	mmu-miR-21	miRNA	estradiol-17¦Â (E2)	cervical cancer (CC)	Osteosarcoma Saos2 cell line	estradiol-17¦Â (E2) treatment	downregulated	27278606
16143	Mouse	mmu-miR-21	miRNA	bile duct ligation (BDL)	cholestasis	wild-type (WT) mice	bile duct ligation (BDL)treatment	upregulated BDL wild-type (WT) mice	29229992
16144	Mouse	mmu-miR-21	miRNA	hyperoxia	chronic lung disease (CLD)	Lung and serum samples	Hyperoxic exposure	upregulated	32191117
16145	Mouse	mmu-miR-21	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissues	cigarette smoke (CS) treatment	miR-21 was upregulated relative to the control in CS-exposed lungs.	30555555
16146	Mouse	mmu-miR-21	miRNA	cerulein	chronic pancreatitis (CP)	pancreas	cerulein treatment	upregulated	29303912
16147	Mouse	mmu-miR-21	miRNA	genistein	chronic vascular inflammation	aortae of LPS-treated mice	genistein (GEN) treatment	downregulated	33495831
16148	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	chronic vascular inflammation	aortae of LPS-treated mice	lipopolysaccharide (LPS) treatment	upregulated	33495831
16149	Mouse	mmu-miR-21	miRNA	trinitrobenzene sulfonic acid (TNBS)	colitis	colon tissues	trinitrobenzene sulfonic acid (TNBS) treatment	upregulated	29788092
16150	Mouse	mmu-miR-21	miRNA	ionizing radiation (IR)	colorectal cancer (CRC)	mouse hippocampal cells;brain tissues	ionizing radiation treatment	upregulated	21986536
16151	Mouse	mmu-miR-21	miRNA	IL-10	colonic inflammation	colonic intraepithelial lymphocytes	IL-10 treatment	downregulated	22043014
16152	Mouse	mmu-miR-21	miRNA	NaOH	corneal alkali burn	Corneal neovascularization	applying a paper disc (2.0-mm diameter) soaked with 2 ¦Ìl of 0.5 M NaOH in the right eye	upregulated	28052006
16153	Mouse	mmu-miR-21	miRNA	coxsackievirus B3 (CVB3)	coxsackievirus B3 (CVB3) infection disease	male A/J mice	intraperitoneally inoculation with 5¡Á103 plaque-forming unit (pfu) of CVB3 treatment	upregulated	24722419
16154	Mouse	mmu-miR-21	miRNA	hypoxia	Dendritic cell (DC) maturation	mouse bone marrow-derived DCs (BMDCs)	hypoxia induce	upregulated	30840288
16155	Mouse	mmu-miR-21	miRNA	IL-1¦Â and TNF-¦Á	diabetes mellitus (DM)	MIN6 cells	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
16156	Mouse	mmu-miR-21	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
16157	Mouse	mmu-miR-21	miRNA	TGF-¦Â	diabetic glomerulopathy	murine podocytes	TGF-¦Â treatment	upregulated	25145934
16158	Mouse	mmu-miR-21	miRNA	losartan	diabetic nephropathy (DN)	kidney tissues	losartan treatment	downregulated	27770539
16159	Mouse	mmu-miR-21	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	renal tissues	streptozotocin (STZ) treatment	upregulated	31655195
16160	Mouse	mmu-miR-21	miRNA	TGF-¦Â1	diabetic foot ulcer (DFU)	NIH-3T3 cells that are subjected to high glucose environment	TGF¦Â1 treatment	upregulated	25130469
16161	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	diabetic wound impairment	RAW264.7 cells	lipopolysaccharide (LPS) treatment	MiR-21 was highly induced in M1 macrophages.	32397166
16162	Mouse	mmu-miR-21	miRNA	delayed ischemic preconditioning	differentiation and contractile phenotype of smooth muscle cells (SMCs)	mouse kidney	Delayed ischemic preconditioning treatment	upregulated	22785173
16163	Mouse	mmu-miR-21	miRNA	TGF-¦Â	DNA damage	tubular epithelial cells	TGF-¦Â treatment	downregulated	23207693
16164	Mouse	mmu-miR-21	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	downregulated	30692507
16165	Mouse	mmu-miR-21	miRNA	high-fat/high-cholesterol diet or a high-protein diet	dyslipidemia	DO mice	a high-fat/high-cholesterol diet or a high-protein diet for 18 wk	dysregulated	28916633
16166	Mouse	mmu-miR-21	miRNA	eimeria papillata	eimeria papillata infection	mouse jejunum	Eimeria papillata infection	upregulated	21093440
16167	Mouse	mmu-miR-21	miRNA	¦Ã-rays	epithelial-mesenchymal transition (EMT)	lung tissue	irradiation with a single dose (20 Gy) of 60Co ¦Ã-rays.	upregulated	31160967
16168	Mouse	mmu-miR-21	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
16169	Mouse	mmu-miR-21	miRNA	retinoid binding protein peptide 161-180	experimental autoimmune uveoretinitis (EAU)	ocular tissues	retinoid binding protein peptide 161-180 treatment	upregulated	20881307
16170	Mouse	mmu-miR-21	miRNA	ginsenoside Rg3	gastric precancerous lesions (GPLs)	stomach samples	Ginsenoside Rg3 (Rg3) treatment	Rg3 Ameliorates Gastric Precancerous Lesions in Atp4a -/- Mice via Inhibition of Glycolysis through PI3K/AKT/miRNA-21 Pathway	32076440
16171	Mouse	mmu-miR-21	miRNA	high fat diet (HFD)	glioblastoma multiforme (GBM)	white adipose tissues	high fat diet (HFD) feed	upregulated	21381024
16172	Mouse	mmu-miR-21	miRNA	astragaloside IV (AS-IV)	glomerular diseases	mesangial cell (MC); primary mouse podocytes; serum; kidney tissues	astragaloside IV (AS-IV) treatment	AS-IV decreased miR-21 levels.	30122901
16173	Mouse	mmu-miR-21	miRNA	sophocarpine (SC)	head and neck squamous cell carcinoma (HNSCC)	nude mouse injected with UM-SCC-22B cells	"100 mm3, SC (5 mg/kg) was intravenously injection treatment"	downregulated	28571917
16174	Mouse	mmu-miR-21	miRNA	X-rays	hematopoietic toxicity following irradiation	"spleen, thymus, bone marrow, small intestine, liver, lung, brain tissues"	Mice were subjected to total body irradiation (TBI) at a dose of 6.5 Gy using a Pantak H-320 (320kV) Precision X-Ray	"miR-21 expression was increased in radiosensitive tissues, but not in radioinsensitive tissues following TBI in wild-type mice, suggesting it may have a critical function in the normal tissue response to irradiation."	31039423
16175	Mouse	mmu-miR-21	miRNA	arsenite	liver fibrosis	primary hepatocytes ; L-02 cells	arsenic (As) exposure	The levels of miR-21 and HIF-1¦Á were also enhanced in primary hepatocytes and L-02 cells exposed to arsenite.	33310519
16176	Mouse	mmu-miR-21	miRNA	corilagin	liver fibrosis	liver tissue	cordycepin treatment	downregulated	26946098
16177	Mouse	mmu-miR-21	miRNA	bromodichloromethane (BDCM)	hepatic fibrogenesis	high-fat (60% kcal) diet-fed chronic mouse	BDCM 2.0 mmol/kg treatment	upregulated	25501551
16178	Mouse	mmu-miR-21	miRNA	leptin	hepatic fibrogenesis	liver tissues	leptin treatment	upregulated	25501551
16179	Mouse	mmu-miR-21	miRNA	betulinic acid (BA)	hepatocellular carcinoma (HCC)	HCC cells	betulinic acid (BA) treatment	upregulated	26222667
16180	Mouse	mmu-miR-21	miRNA	dehydroepiandrosterone (DHEA)	hepatocellular carcinoma (HCC)	mouse mouse liver	DHEA treatment	upregulated	24845419
16181	Mouse	mmu-miR-21	miRNA	high inorganic phosphate (Pi)	hyperphosphatemia	Mouse myocardial endothelial cells (MEC)	high Pi treatment	High Pi induced MEC apoptosis and upregulated microRNA-21 expression.	30257106
16182	Mouse	mmu-miR-21	miRNA	angiotensin II (Ang II)	hypertension	ACE2 knockout mouse kidney	angiotensin II (Ang II) treatment	upregulated in the mouse kidney	28808068
16183	Mouse	mmu-miR-21	miRNA	angiotensin II (Ang II)	hypertensive heart disease (HHD)	heart sissues	angiotensin II (Ang II) treatment	MiR-21 expression levels were significantly upregulated in the mice hearts after angiotensin II (Ang II) infusion.	32040481
16184	Mouse	mmu-miR-21	miRNA	rapamycin	hypoxia/reoxygenation (H/R) injury	islet	rapamycin treatment	upregulated	27683229
16185	Mouse	mmu-miR-21	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	myofibroblasts	bleomycin (BLM) treatment	upregulated	20643828
16186	Mouse	mmu-miR-21	miRNA	granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-6	immune response	bone marrow cells	GM-CSF£¬ IL-6 treatment	upregulated	24391219
16187	Mouse	mmu-miR-21	miRNA	TGF-¦Â	immune response	bone marrow cells and spleen MDSC	TGF-¦Â treatment	upregulated	24391219
16188	Mouse	mmu-miR-21	miRNA	progesterone (P4)	infertility	uterine horn of 6-week-old female mice (C57BL/6)	progesterone treatment	dysregulated	30603515
16189	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	inflammation	postefferocytotic peripheral blood monocyte-derived macrophages	lipopolysaccharide (LPS) treatment	upregulated	24391209
16190	Mouse	mmu-miR-21	miRNA	pentraxin 3 (PTX3)	inflammation	wild-type brown adipocytes	pentraxin 3 (PTX3) treatment	"PTX3 plays an anti-inflammatory role, in part through regulating miR-21 expression and secretion"	31898407
16191	Mouse	mmu-miR-21	miRNA	sodium sulfide (Na2S)	ischemic injury	mouse heart	Na2S treatment	upregulated	24825878
16192	Mouse	mmu-miR-21	miRNA	intense light	ischemic preconditioning (IPC)	mouse cardiac tissues	expose mice to intense light	upregulated in cardiac tissue	28448534
16193	Mouse	mmu-miR-21	miRNA	rapamycin	islets hypoxia/reoxygenation (H/R) injury	male C57BL/6 islets with hypoxia/reoxygenation (H/R) injury	rapamycin treatment	upregulated	27683229
16194	Mouse	mmu-miR-21	miRNA	rosiglitazone	kidney fibrosis	obesity mouse kidney	rosiglitazone treatment	downregulated	28588299
16195	Mouse	mmu-miR-21	miRNA	deoxycorticosterone acetate (DOCA)	kidney damage	hypertensive mice kidneys and urine	injection of Deoxycorticosterone acetate (Doca)	upregulated in the kidneys and urine	29255279
16196	Mouse	mmu-miR-21	miRNA	hypoxia	kidney ischemia injury	mouse renal tubular epithelial cells (RTECs)	hypoxia treatment	upregulated	31632533
16197	Mouse	mmu-miR-21	miRNA	chlorogenic acid (CGA)	liver fibrosis	schistosome-infected mice hepatic tissue	Chlorogenic acid (CGA) treatment	downregulated in hepatic tissue	27872076
16198	Mouse	mmu-miR-21	miRNA	tamoxifen (TAM)	liver regeneration	liver tissues	tamoxifen-induced Dicer1 deletion treatment	upregulated	31306658
16199	Mouse	mmu-miR-21	miRNA	nitric oxide synthase (NOS2)	lung cancer	lung tissues	nitric oxide synthase (NOS2) treatment	downregulated	22618808
16200	Mouse	mmu-miR-21	miRNA	nickel nanoparticles (nano-Ni)	lung fibrosis	lung tissues	nickel nanoparticles (Nano-Ni) treatment	Nano-Ni resulted in upregulation of miR-21.	32924694
16201	Mouse	mmu-miR-21	miRNA	inositol hexaphosphate (IP6)	lung tumorigenesis	F1 mice lung tumor	"Balb/c mice were exposed to the N-ethyl-N-nitrosourea (ENU) intraperitoneally on the 17th day of gestation. After weaning, half of the litters were fed with oral 2% IP6."	downregulated	30806292
16202	Mouse	mmu-miR-21	miRNA	N-ethyl-N-nitrosourea (ENU)	lung tumorigenesis	F1 mice lung tumor	Balb/c mice were exposed to the N-ethyl-N-nitrosourea (ENU) intraperitoneally on the 17th day of gestation.	upregulated	30806292
16203	Mouse	mmu-miR-21	miRNA	rapamycin	lymphangioleiomyomatosis (LAM)	mouse embryonic fibroblasts	medicine treatment	MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM)The regulation of miR-21 by Rapamycin is cell type independent	23555865
16204	Mouse	mmu-miR-21	miRNA	binase	lymphosarcoma	RLS40 cells	binase treatment	downregulated	33147876
16205	Mouse	mmu-miR-21	miRNA	high glucose (HG)	macrophage apoptosis	Raw 264.7 macrophages	high glucose treatment	"miR-21 is sensitive to high-concentration glucose treatment in macrophages, and appears to have a protective effect in macrophage apoptosis induced by high concentrations of glucose via PDCD4."	25738901
16206	Mouse	mmu-miR-21	miRNA	interval exercise training with tamoxifen	breast cancer	Mouse mammary adenocarcinoma cell line (MC4-L2)	interval exercise training with tamoxifen treatment	downregulated	26300395
16207	Mouse	mmu-miR-21	miRNA	curcumin analog EF24	melanoma	B16 murine melanoma cells	EF24? treatment	downregulated	23940701
16208	Mouse	mmu-miR-21	miRNA	high intensity focused ultrasound (HIFU)	melanoma	melanoma cell	High intensity focused ultrasound (HIFU) treatment	downregulated	27391071
16209	Mouse	mmu-miR-21	miRNA	ischemia	myocardial apoptosis	myocardial of mice	Ischemic postconditioning (IPost)	upregulated	24098402
16210	Mouse	mmu-miR-21	miRNA	hypoxia	myocardial infarction (MI)	mouse infarcted zone	left anterior descending coronary artery was permanently ligated	upregulated in the infarcted zone	28817807
16211	Mouse	mmu-miR-21	miRNA	ischemia	myocardial ischaemic injury	mouse cardiomyocytes	ischemic pre-conditioning (IPC) treatment	"IPC-induced miRNAs trigger cardioprotection similar to the delayed phase of IPC, possibly through upregulating eNOS, HSP70, and the HSP70 transcription factor HSF-1."	19213952
16212	Mouse	mmu-miR-21	miRNA	cyclosporine A (CsA)	nephrotoxicity	mouse kidney	cyclosporine A treatment	upregulated	28414804
16213	Mouse	mmu-miR-21	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	renal tissues	high fat diet (HFD) feed	upregulated	29660503
16214	Mouse	mmu-miR-21	miRNA	high fructose	nonalcoholic fatty liver disease (NAFLD)	plasma	High fructose feed	upregulated	31030166
16215	Mouse	mmu-miR-21	miRNA	lycopene	nonalcoholic fatty liver disease (NAFLD)	mice liver tissue	Lycopene treatment	downregulated	22968990
16216	Mouse	mmu-miR-21	miRNA	microcystin (MC)	nonalcoholic fatty liver disease (NAFLD)	high-fat (60% KCal) supplemented methionine-choline-deficient (MCD-HFD) diet-induced NAFLD mice liver tissue	microcystin (MC) treatment	upregulated	31393787
16217	Mouse	mmu-miR-21	miRNA	microcystin-leucine arginine (MC-LR)	nonalcoholic fatty liver disease (NAFLD)	mouse kidney tissues and CRL-1927 cells	Microcystin-LR (MC) treatment	upregulated	31706246
16218	Mouse	mmu-miR-21	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) toxicity	Primary proximal tubular epithelial cell	ochratoxin A treatment	upregulated	28710020
16219	Mouse	mmu-miR-21	miRNA	astragaloside IV (AS-IV)	optic nerve injury	RGC-5 cells	astragaloside (AS-IV) treatment	The expression of miR-21 was significantly upregulated in OGD and AST-treated RGC-5 cells.	30551437
16220	Mouse	mmu-miR-21	miRNA	fluid shear stress (FSS)	osteoblastic differentiation	MC3T3-E1 cells	fluid shear stress (FSS)treatment	downregulated	23595392
16221	Mouse	mmu-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoclast differentiation	RAW264.7 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23078176
16222	Mouse	mmu-miR-21	miRNA	estrogen (ES)	osteoclastic apoptosis	Primary mouse bone marrow-derived monocyte£»macrophage precursors (BMMs)	Estrogen treatment	downregulated	23238785
16223	Mouse	mmu-miR-21	miRNA	anthracycline glycoside aloin	osteoclastogenesis	Raw264.7 cells	anthracycline glycoside aloin treatment	downregulated	30116953
16224	Mouse	mmu-miR-21	miRNA	particle	osteolysis	osteoclast	particle treatment	upregulated	22508494
16225	Mouse	mmu-miR-21	miRNA	aloin	osteopenic disorders	RAW 264.7 cells	aloin treatment	Aloin caused a dose-dependent decrease in the expression of all forms of miR-21.	30116953
16226	Mouse	mmu-miR-21	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	MES23.5 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31555359
16227	Mouse	mmu-miR-21	miRNA	porphyromonas endodontalis lipopolysaccharide ( P. endodontalis LPS)	periodontitis	RAW264.7 and bone marrow derived macrophages (BMDM)	Porphyromonas gingivalis (P. gingivalis) lipopolysaccharide (LPS) treatment	upregulated	29884447
16228	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	peritoneal fibrosis	peritoneal mesothelial cells	lipopolysaccharide (LPS) treatment	upregulated	29207016
16229	Mouse	mmu-miR-21	miRNA	ZCL-082	premature ovarian failure (POF)	female germline stem cell (FGSC)	ZCL-082 treatment	upregulated	31319247
16230	Mouse	mmu-miR-21	miRNA	globular adiponectin	programmed cell death	RAW 264.7 macrophages	Globular adiponectin treatment	upregulated	23597671
16231	Mouse	mmu-miR-21	miRNA	astragalus saponin IV	cell proliferation	bone marrow mesenchymal cells(BMSCs)	astragalus saponin IV(AS- IV) treatment	upregulated	32381364
16232	Mouse	mmu-miR-21	miRNA	curcumin analog EF24	prostate cancer	DU145 human prostate cancer cells	EF24? treatment	downregulated	23940701
16233	Mouse	mmu-miR-21	miRNA	castration	prostate cancer	CWR22 human prostate cancer xenograft mouse	castration treatment	downregulated	25216674
16234	Mouse	mmu-miR-21	miRNA	pseudomonas aeruginosa (PA)	pseudomonas aeruginosa lung infection	sorted lung macrophages	RP73 clinical strain of P. aeruginosa infection treatment	downregulated	28422188
16235	Mouse	mmu-miR-21	miRNA	resolvin D1 (RvD1)	pseudomonas aeruginosa lung infection	sorted lung macrophages from RP73 clinical strain of P. aeruginosa infected mouse	resolvin (Rv) D1 treatment	upregulated	28422188
16236	Mouse	mmu-miR-21	miRNA	hypoxia	pulmonary vascular remodeling	lung tissues	chronic hypoxia treatment	upregulated	22227207
16237	Mouse	mmu-miR-21	miRNA	total-body irradiation (TBI)	radiation nephropathy	mouse urinary	a single LD50 of total-body irradiation (TBI) or clinically relevant fractionated doses (2 Gy twice daily for 3 days) treatment	upregulated in mouse urinary	28977780
16238	Mouse	mmu-miR-21	miRNA	radiation	radiation-induced fibrosis (RIF)	"CH3 mice muscle, skin, and subcutaneous tissue"	the right hind legs of 9-week old CH3 mice by a single-fraction dose of irradiation to 35 Gy treatment	dysregulated	24986745
16239	Mouse	mmu-miR-21	miRNA	¦Ã-rays	radiation-induced pulmonary fibrosis (RIPF)	lung tissue	irradiation with a single dose (20 Gy) of 60Co ¦Ã-rays.	upregulated	31160967
16240	Mouse	mmu-miR-21	miRNA	CoCl2	renal ischemia/reperfusion (I/R) injury	renal I/R in mice	CoCl2 was pretreated intraperitoneally 24 hours before renal I/R in mice	upregulated	28737660
16241	Mouse	mmu-miR-21	miRNA	hypoxia/reoxygenation (H/R)	renal ischemia/reperfusion (I/R) injury	bone marrow-derived dendritic cells (BMDCs)	hypoxia/reoxygenation (H/R) treatment	"Treatment with hypoxia/reoxygenation (H/R) suppressed miR-21 expression in bone marrow-derived dendritic cells (BMDCs),"	32667078
16242	Mouse	mmu-miR-21	miRNA	total flavonoids (TFs)	renal tubulointerstitial fibrosis (TIF)	mouse tubular epithelial cells (mTECs)	total flavonoids (TFs) treatment	TFs reduced miR-21 expression in a time- and dose-dependent manner in mTECs.	30212825
16243	Mouse	mmu-miR-21	miRNA	Salmonella Typhimurium	salmonella typhimurium infection	Murine macrophages(murine RAW 264.7 cells)	Salmonella Typhimurium infection treatment	upregulated	21468030
16244	Mouse	mmu-miR-21	miRNA	praziquantel (PZQ)	schistosomiasis	M1-type macrophages	Praziquantel (PZQ) treatment	PZQ inhibited NLRP3 inflammasome in M1 macrophages and reduced the expression of miR-21	32118052
16245	Mouse	mmu-miR-21	miRNA	cecal ligation and puncture (CLP)	sepsis	late sepsis	cecal ligation and puncture (CLP) treatment	upregulated	24980967
16246	Mouse	mmu-miR-21	miRNA	IL-1¦Â	sepsis	macrophages	IL-1¦Â treatment	Exosomal miR-21 secreted by IL-1¦Â-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis.	33115604
16247	Mouse	mmu-miR-21	miRNA	lipopolysaccharide (LPS)	septic shock	bone marrow derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	"miR-21 deficiency inhibited the ASC pyroptosome, which restrained caspase-1 activation and GSDMD cleavage, thereby preventing LPS-induced pyroptosis and septic shock."	31189875
16248	Mouse	mmu-miR-21	miRNA	"chlamydia, haemophilus influenzae, influenza, and respiratory syncytial virus"	steroid-insensitive allergic airway disease (SSIAAD)	BALB/c mice lung	infect with virus respiratory tract infections and ovalbumin	upregulated in the lung	27448447
16249	Mouse	mmu-miR-21	miRNA	nuclear factor kappa-B (NF-¦ÊB) inhibitor Bay11-708211	supraesophageal bile reflux	hypopharyngeal mucosa	NF-¦ÊB inhibitor (BAY 11-7082) treatment	"Pre- but not post-application of NF-¦ÊB inhibitor, significantly blocks overexpression of Il6 and prostaglandin H synthases 2 (Ptgs2), and reverses miR-21, miR-155, miR-99a phenotypes."	32934775
16250	Mouse	mmu-miR-21	miRNA	angiotensin II (Ang II)	thoracic aortic aneurysm and dissection (TAAD)	Smad3 (mothers against decapentaplegic homolog 3) heterozygous (S3+/-) mice	angiotensin II (Ang II) treatment	upregulated	29519942
16251	Mouse	mmu-miR-21	miRNA	radiation	thymic lymphoma (RITL)	thymic lymphoma tissue samples	radiation treatment	upregulated	21494432
16252	Mouse	mmu-miR-21	miRNA	controlled cortical impact (CCI)	traumatic brain injury (TBI)	adult (5-6 months) and aged (22-24 months) C57/BL6 mice	controlled cortical impact (CCI)	upregulated	25277076
16253	Mouse	mmu-miR-21	miRNA	controlled cortical impact (CCI)	traumatic brain injury (TBI)	mouse hippocampus	controlled cortical impact (CCI)	upregulated	28804446
16254	Mouse	mmu-miR-21	miRNA	bone morphogenetic proteins (BMPs)	trichofolliculoma-like hair follicle-derived tumours	Primary mouse epidermal keratinocytes (PMEKs)	bone morphogenetic proteins (BMPs) treatment	downregulated	21984808
16255	Mouse	mmu-miR-21	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	NOD mice islets beta cell	streptozocin (STZ) treatment	upregulated in islets beta cell	28280903
16256	Mouse	mmu-miR-21	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	mouse	high fat diet (HFD) feed	downregulated	28627440
16257	Mouse	mmu-miR-21	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	ulcerative colitis (UC)	colon tissues	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	upregulated	31378906
16258	Mouse	mmu-miR-21	miRNA	azacitidine (AZA)	ulcerative colitis (UC)	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol-induced ulcerative colitis (UC) mice colon tissues"	azacitidine (AZA) treatment	downregulated	31378906
16259	Mouse	mmu-miR-21	miRNA	cinnamaldehyde (CA)	ulcerative colitis (UC)	RAW264.7 cells	Cinnamaldehyde (CA) treatment	downregulated	30530166
16260	Mouse	mmu-miR-21	miRNA	cinnamaldehyde (CA)	ulcerative colitis (UC)	colon tissues	Cinnamaldehyde (CA) treatment	downregulated	30530166
16261	Mouse	mmu-miR-21	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	DSS-induced mice colon tissues	Dextran sodium sulfate (DSS) treatment	upregulated	30530166
16262	Mouse	mmu-miR-21	miRNA	mesalazine (MSLZ)	ulcerative colitis (UC)	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol-induced ulcerative colitis (UC) mice colon tissues"	mesalazine (MSLZ) treatment	downregulated	31378906
16263	Mouse	mmu-miR-21	miRNA	centrin gene deleted Leishmania donovani parasites (LdCen?/?)	visceral leishmaniasis	murine DC cells	LdCen-/- parasites infection	LdCen-/- infection suppresses the expression of microRNA-21 (miR-21) in human macrophages compared to LdWT infection.	31608064
16264	Mouse	mmu-miR-21	miRNA	hypoxia	wound healing	Corneal epithelial cells	hypoxia induce	upregulated	31529118
16265	Mouse	mmu-miR-21	miRNA	TGF-¦Â1	wound healing	Corneal epithelial cells	TGF-¦Â1?treatment treatment	upregulated	31529118
16266	Mouse	mmu-miR-21	miRNA	xenon (Xe)	xenon-conferred	renal?of mice	xenon treatment	Xenon preconditioning significantly increased the expression of miR-21 in the mouse kidney	23681145
16267	Mouse	mmu-miR-21	miRNA	live L. acidophilus	¦Â-lactoglobulin (¦Â-Lg) allergy	murine splenocytes	live L. acidophilus treatment	downregulated	30156972
16268	Mouse	mmu-miR-21	miRNA	"fasting, denervation, diabetes, and cancer cachexia"	fine-tuning the atrophy program	mouse muscles	"mouse muscles under wasting conditions such as fasting, denervation, diabetes, and cancer cachexia treatment"	wasting conditions showed an induction of miRNA-206 and miRNA-21 expression	24891504
16269	Mouse	mmu-miR-21	miRNA	high fat diet (HFD)	prenatal inflammation	ovarian tissue	high fat diet (HFD) feed	"Obese mouse ovaries had decreased Irs1, Foxo3a, Cyp2e1, MiR-103, and MiR-21"	23954404
16270	Mouse	mmu-miR-21?	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	miR-21 expression was upregulated in HG-treated podocytes.	30212710
16271	Mouse	mmu-miR-21*	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	upregulated	26426744
16272	Mouse	mmu-miR-210	miRNA	hypoxia	acute ischemic stroke (AIS)	brain tissues	middle cerebral artery occlusion (MCAO) treatment	upregulated in the brain	29111308
16273	Mouse	mmu-miR-210	miRNA	hypoxia	acute peripheral ischemia	skeletal muscle of mice	hypoxia treatment	upregulated	23931770
16274	Mouse	mmu-miR-210	miRNA	"toluene 2,4-diisocyanate (TDI)"	allergic disease	draining lymph node (dLN) and Treg subsets	Toluene diisocyanate (TDI) treatment	upregulated	28035981
16275	Mouse	mmu-miR-210	miRNA	hypoxia	apoptosis	mouse GC-2spd (GC-2) cells	hypoxia induce	upregulated	30431115
16276	Mouse	mmu-miR-210	miRNA	hypoxia	apoptosis	A mouse neuroblastoma neuro-2a cell	hypoxia treatment	upregulated	23108914
16277	Mouse	mmu-miR-210	miRNA	high fat diet (HFD)	atherosclerosis (AS)	purified CD31+ endothelial cells from mouse aorta	high fat diet (HFD) feed	upregulated in purified CD31+ endothelial cells from mouse aorta	28536634
16278	Mouse	mmu-miR-210	miRNA	diethylnitrosamine (DEN)	chronic cholestasis and cholangiocarcinoma	liver tissues	diethylnitrosamine (DEN) treatment	upregulated	21440549
16279	Mouse	mmu-miR-210	miRNA	bupivacaine	dorsal root ganglion	neurons	bupivacaine treatment	downregulated	26708520
16280	Mouse	mmu-miR-210	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	primary mouse hepatocytes	hypoxia treatment	downregulated	32155285
16281	Mouse	mmu-miR-210	miRNA	hypoxia	hypoxia-induced injury	mouse GC-2spd (GC-2) cells	hypoxia induce	upregulated	30431115
16282	Mouse	mmu-miR-210	miRNA	epigallocatechin-3-gallate (EGCG)	lung cancer	lung cancer cells	Green tea polyphenol EGCG treatment	upregulated	21965273
16283	Mouse	mmu-miR-210	miRNA	hypoxia	myocardial infarction (MI)	mouse bone marrow-derived MSCs exosomes	cultured under hypoxia for 24 h	upregulated in exosomes from hypoxia-treated MSCs	29141446
16284	Mouse	mmu-miR-210	miRNA	cardiac shock wave therapy (SWT)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	murine adult cardiomyocyte cell line HL-1	Cardiac shock wave therapy (SWT) treatment	upregulated	31974607
16285	Mouse	mmu-miR-210	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	murine adult cardiomyocyte cell line HL-1	hypoxia induce	upregulated	31974607
16286	Mouse	mmu-miR-210	miRNA	hypoxia	myocardial repair	mesenchymal stem cells (MSCs)	hypoxia treatment	upregulated	29141446
16287	Mouse	mmu-miR-210	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	mice	injected into the tumour centre at a concentration of 150 mg/kg treatment	dysregulated	24896104
16288	Mouse	mmu-miR-210	miRNA	hypoxic/ischemic	neonatal hypoxic-ischemic brain damage	mouse pups tissues	hypoxic-ischemic (HI) treatment	"HI insult significantly upregulated miR-210, downregulated TET2 protein abundance, and increased NF-¦ÊB subunit p65 acetylation level and its DNA binding capacity to the interleukin 1 beta (IL-1¦Â) promoter in the brain of mouse pups."	33402183
16289	Mouse	mmu-miR-210	miRNA	bupivacaine	neurotoxicity	dorsal root ganglia	bupivacaine treatment	downregulated	26708520
16290	Mouse	mmu-miR-210	miRNA	erythropoietin (EPO)	erythroid maturation	mouse fetal liver cells	erythropoietin treatment	upregulated	18492109
16291	Mouse	mmu-miR-210	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoclast differentiation	RAW264.7 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23078176
16292	Mouse	mmu-miR-210	miRNA	lipopolysaccharide (LPS)	production of proinflammatory cytokines	murine macrophages	lipopolysaccharide (LPS) treatment	upregulated	22575656
16293	Mouse	mmu-miR-210	miRNA	IL-23	psoriasis	skin lesions	IL-23 treatment	upregulated	29757188
16294	Mouse	mmu-miR-210	miRNA	imiquimod (IMQ)	psoriasis	skin lesions	imiquimod treatment	upregulated	29757188
16295	Mouse	mmu-miR-210	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	exosome of RAW 264.7 cells	high glucose (HG) treatment	miR-210 was highly expressed in exosomes derived from high glucose-induced macrophage RAW264.7 cells.	32258168
16296	Mouse	mmu-miR-210-3p	miRNA	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	dopaminergic (DA) neuron differentiation	neuro-2a cells	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment"	dysregulated	29250806
16297	Mouse	mmu-miR-210-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29250806
16298	Mouse	mmu-miR-210-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29250806
16299	Mouse	mmu-miR-210-3p	miRNA	paraquat (PQ)	neurodegenerative diseases	N2a cells	paraquat (PQ) treatment	downregulated	29250806
16300	Mouse	mmu-miR-210-3p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
16301	Mouse	mmu-miR-210-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
16302	Mouse	mmu-miR-211	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
16303	Mouse	mmu-miR-211	miRNA	hypoxia	hypoxic/ischemic injury	Neuro2A cells	hypoxia treatment	miR-211 was upregulated in OGD-induced ischemic injury of Neuro2A cells.	30563429
16304	Mouse	mmu-miR-211	miRNA	cecal ligation and puncture (CLP)	sepsis	Monocytes were isolated from the spleens	cecal ligation and puncture induce	downregulated	31656541
16305	Mouse	mmu-miR-211	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated of NEAT1 level and downregulated of miR-495-3p/miR-211 level could aggravate inflammation in LPS-treated RAW264.7 cells.	31812793
16306	Mouse	mmu-miR-211	miRNA	candida albicans (C. albicans)	systemic Candidiasis	C57BL/6 mice	candida albicans infection	downregulated	24641951
16307	Mouse	mmu-miR-211-5p	miRNA	atractylon (Atr)	asthma	asthma mouse lung tissues; TGF-¦Â1-treated TC-1 cells	atractylon (Atr)?treatment	Atr treatment suppressed OVA-induced circRNA-0000981 and TGFBR2 expression but promoted miR-211-5p expression.	33855682
16308	Mouse	mmu-miR-211-5p	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	downregulated	33855682
16309	Mouse	mmu-miR-211-5p	miRNA	TGF-¦Â1	asthma	TC-1 cells	TGF-¦Â1 treatment	downregulated	33855682
16310	Mouse	mmu-miR-211-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
16311	Mouse	mmu-miR-211-5p	miRNA	alpinetin (ALP)	oral squamous cell carcinoma (OSCC)	OSCC tumor tissues	alpinetin (ALP) treatment	miR-211-5p expression was significantly increased under ALP treatment in com- parison with control mice.	31403340
16312	Mouse	mmu-miR-211-5p	miRNA	insulin-transferrin-selenite (ITS)	osteoarthritis (OA)	ATDC5 cells	insulin-transferrin-selenite (ITS) treatment	upregulated	31396630
16313	Mouse	mmu-miR-212	miRNA	high fat diet (HFD)	atherosclerosis (AS)	atherosclerotic lesions and macrophages from apoE-/- mice	high fat diet (HFD) feed	downregulated	29174964
16314	Mouse	mmu-miR-212	miRNA	high fat diet (HFD)	atherosclerosis (AS)	apoE mice macrophages	high fat diet (HFD) feed	downregulated	29174964
16315	Mouse	mmu-miR-212	miRNA	hypoxia	blood-brain barrier (BBB) dysfunction	mouse brain microvascular endothelial cells (BMEC)	hypoxia induce	upregulated	30617994
16316	Mouse	mmu-miR-212	miRNA	adenine	chronic kidney disease (CKD)	kidney tissues	adenine treatment	upregulated	32526762
16317	Mouse	mmu-miR-212	miRNA	gallic acid (GA)	experimental autoimmune encephalomyelitis (EAE)	"The CD4+CD62L+ T cells were isolated from the spleen and cultured under Th17-polarizing conditions, and peritoneal macrophages were stimulated with LPS"	?gallic acid (GA)?treatment treatment	upregulated	31026283
16318	Mouse	mmu-miR-212	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
16319	Mouse	mmu-miR-212	miRNA	alcohol	leaky gut	intestinal	alcohol exposure	overexpression	26207424
16320	Mouse	mmu-miR-212	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	precursors	methamphetamine (METH) treatment	downregulated	29516602
16321	Mouse	mmu-miR-212	miRNA	glucose deprivation (GD)	neurodegeneration (ND)	cortical neuronal cultures from mouse brains at embryonic day 15.5	glucose deprivation treatment	downregulated	28855274
16322	Mouse	mmu-miR-212	miRNA	fatty acid	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	fatty acid treatment	upregulated	26648452
16323	Mouse	mmu-miR-212	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse	high fat diet (HFD) feed	upregulated	26648452
16324	Mouse	mmu-miR-212	miRNA	long-chain fatty acid	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	long-chain fatty acid treatment	upregulated	26648452
16325	Mouse	mmu-miR-212	miRNA	running	nonalcoholic fatty liver disease (NAFLD)	HF mouse liver	HF mouse treatment	downregulated in liver	26648452
16326	Mouse	mmu-miR-212	miRNA	glutamate	pain	primary neurons in the spinal cord of mouse embryos	100 ¦Ìmol/L glutamate	upregulated	28244951
16327	Mouse	mmu-miR-212-3p	miRNA	quercetin	chronic inflammatory diseases	LPS-treated murine bone marrow¨Cderived DCs (BMDCs)	quercetin treatment	upregulated	31338984
16328	Mouse	mmu-miR-212-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	downregulated	27322257
16329	Mouse	mmu-miR-212-3p	miRNA	angiostrongylus cantonensis (A. cantonensis)	inflammation	male Balb/c mice	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24142285
16330	Mouse	mmu-miR-212-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	29557526
16331	Mouse	mmu-miR-212-3p	miRNA	hepatitis B virus (HBV)	liver damage	RAW264.7 cells	HBeAg treatment	miR-212-3p expression was significantly elevated in HBeAg-treated macrophages.	32767729
16332	Mouse	mmu-miR-212-3p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	27940320
16333	Mouse	mmu-miR-212-5p	miRNA	immunoglobulin E (IgE)	asthma-induced hypotension	primary arterial smooth muscle cell (ASMC) of WT or Fc¦ÅR1-/- mice	IgE treatment	upregulated	28988887
16334	Mouse	mmu-miR-212-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
16335	Mouse	mmu-miR-212-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	hippocampus	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30364275
16336	Mouse	mmu-miR-212-5p	miRNA	angiotensin II (Ang II)	cell proliferation	cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	downregulated	32268073
16337	Mouse	mmu-miR-212-5p	miRNA	TGF-¦Â1	cell proliferation	cardiac fibroblasts (CFs)	TGF-¦Â1 ttreatment treatment	downregulated	32268073
16338	Mouse	mmu-miR-2137	miRNA	H1N1 influenza virus	endometriosis and endometrial carcinoma	mouse lung?tissues	H1N1 influenza virus infection	upregulated	24066118
16339	Mouse	mmu-miR-2137	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	upregulated	26426744
16340	Mouse	mmu-miR-21-3p	miRNA	caerulein and aurolithocholic acid 3-sulfate (TLC-S)	acute pancreatitis (AP)	mouse pancreatic acinar cells	caerulein and TLC-S treatment	upregulated	27686613
16341	Mouse	mmu-mir-21-3p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
16342	Mouse	mmu-miR-21-3p	miRNA	nicotine	atherosclerosis (AS)	Raw264.7 cells	nicotine treatment	upregulated	31660076
16343	Mouse	mmu-miR-21-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	blood-brain barrier (BBB) dysfunction	bEnd.3 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	29695199
16344	Mouse	mmu-miR-21-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	mouse	angiotensin II (Ang II) treatment	downregulated	25504627
16345	Mouse	mmu-miR-21-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocyte	angiotensin II (Ang II) treatment	downregulated	24743145
16346	Mouse	mmu-miR-21-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
16347	Mouse	mmu-miR-21-3p	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
16348	Mouse	mmu-miR-21-3p	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
16349	Mouse	mmu-miR-21-3p	miRNA	oxygen glucose deprivation (OGD)	traumatic brain injury (TBI)	bEnd.3 cells	oxygen-glucose deprivation (OGD) treatment	miR-21-3p level in bEnd.3 cells with OGD treatment was increased after injury.	29695199
16350	Mouse	mmu-miR-21-3p	miRNA	wire-induced injury to carotid arteries	vessel stenosis	apolipoprotein E knockout (Apoe ) mice	injury to carotid arteries of treatment	upregulated	27622243
16351	Mouse	mmu-miR-214	miRNA	D-galactosamine (D-GalN) and TNF-¦Á	acute liver failure (ALF)	BNLCL2 cells	D-galactosamine (D-GalN) andTnF-¦Á treatment	miR214 was downregulated in D-GalN/LPS-stimulated mice and D-GalN/TNF-¦Á-stimulated BNLCL2 cells.	32377732
16352	Mouse	mmu-miR-214	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver failure (ALF)	liver tissues	D-galactosamine (D-GalN) and lipopolysaccharide (LPS) treatment	miR214 was downregulated in D-GalN/LPS-stimulated mice and D-GalN/TNF-¦Á-stimulated BNLCL2 cells.	32377732
16353	Mouse	mmu-miR-214	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	29499950
16354	Mouse	mmu-miR-214	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse cardiomyocytes (NMCMs)	angiotensin II (Ang II) treatment	MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction	33247214
16355	Mouse	mmu-miR-214	miRNA	ginkgolide B (GB)	cisplatin (DDP)-induced nephrotoxicity	cisplatin-treated HEI-OC1 auditory cells	cisplatin-treated HEI-OC1 auditory cells treatment	upregulation	26768586
16356	Mouse	mmu-miR-214	miRNA	high glucose (HG) and lipopolysaccharide (LPS)	diabetes-associated periodontitis	MC3T3-E1 cells	high glucose and lipopolysaccharide (LPS) co-stimulated	upregulated	31090954
16357	Mouse	mmu-miR-214	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse proximal tubular epithelial cells MCT	high glucose (HG) treatment	upregulated	31240704
16358	Mouse	mmu-miR-214	miRNA	indoxyl sulfate (IS)	endothelial cell injury	mouse aortic endothelial cells (MAECs)	indoxyl sulfate (IS) treatment	"Following IS treatment, miR-214 was significantly downregulated in MAECs in line with enhanced cell apoptosis."	31820187
16359	Mouse	mmu-miR-214	miRNA	ethanol (EtOH)	fibrosis	primary mouse HSC	ethanol treatment	downregulated	24122827
16360	Mouse	mmu-miR-214	miRNA	H2O2	fragility fracture	MC3T3-E1 cells	treat with 400 ¦ÌM H2O2	downregulated	291645892
16361	Mouse	mmu-miR-214	miRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	downregulated	30431065
16362	Mouse	mmu-miR-214	miRNA	palmitate	hepatic insulin resistance	mouse primary hepatocytes	palmitate treatment	downregulated	30431065
16363	Mouse	mmu-miR-214	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	mouse hepatocyte AML12	hypoxia induce	downregulated	30560327
16364	Mouse	mmu-miR-214	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	mouse hepatocyte AML12	hypoxia induce	downregulated	30560327
16365	Mouse	mmu-miR-214	miRNA	norcantharidin (NCTD)	hepatocellular carcinoma (HCC)	liver tissues	intraperitoneal injection of different concentration of NCTD treatment	upregulated	24719559
16366	Mouse	mmu-miR-214	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	mouse lungs; primary lung fibroblasts	bleomycin (BLM) treatment	FENDRR reduced pulmonary fibrosis by inhibiting fibroblast activation by reducing iron concentration and acting as a competing endogenous RNA of the profibrotic microRNA-214.	31697569
16367	Mouse	mmu-miR-214	miRNA	high fat diet (HFD)	liver fibrosis	liver tissues	high fat diet (HFD) feed	upregulated	29915227
16368	Mouse	mmu-miR-214	miRNA	sildenafil	metabolic and functional derangements in the heart	heart sissues	sildenafil treatment	Co-ingestion with sildenafil blunted the alcohol-induced increase in miR-214	32535704
16369	Mouse	mmu-miR-214	miRNA	methylglyoxal (MGO)	MGO-induced endothelial insulin-resistance	mouse aortic endothelial cells (MAECs)	methylglyoxal (MGO) treatment	downregulated	29425121
16370	Mouse	mmu-miR-214	miRNA	exercise (Ex)	osteoporosis	tibia tissues and primary osteoblasts	mice were run on treadmill at moderate-intensity for five weeks or Flexcell-5000C? Tension System	downregulated	31639865
16371	Mouse	mmu-miR-214	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	26349993
16372	Mouse	mmu-miR-214	miRNA	angiotensin II (Ang II)	pathological perivascular fibrosis in hypertension	perivascular tissue	angiotensin II (Ang II) treatment	miR-214 is increased in the vasculature in Ang II-induced hypertension.	32065054
16373	Mouse	mmu-miR-214	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	testicular ischemia-reperfusion injury (IRI)	GC-1 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29870987
16374	Mouse	mmu-miR-214	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon tissues	dextran sodiumsulfate (DSS) treatment	upregulated	31382166
16375	Mouse	mmu-miR-214	miRNA	limonin	ulcerative colitis (UC)	Ulcerative colitis (UC) mice colon tissues	limonin treatment	downregulated	31382166
16376	Mouse	mmu-miR-214	miRNA	sulfasalazine	ulcerative colitis (UC)	Ulcerative colitis (UC) mice colon tissues	sulfasalazine (SASP) treatment	downregulated	31382166
16377	Mouse	mmu-miR-214	miRNA	mechanical ventilation (MV)	ventilator-induced lung injury (VILI)	lung tissues; macrophages; fibroblasts; epithelial cells; endothelial cells	mechanical ventilation (MV) treatment	"The expression of miR-214 was increased in lung tissues and macrophages, fibroblasts, epithelial cells, and endothelial cells isolated from lung tissues in VILI mice."	33389067
16378	Mouse	mmu-miR-214-3p	miRNA	high fat diet (HFD) and sodium taurocholic	acute pancreatitis (AP)	kidney tissues	high-fat diet and sodium taurocholic injection	MiR-214-3p exacerbates kidney damages and inflammation induced by hyperlipidemic pancreatitis complicated with acute renal injury.	31790686
16379	Mouse	mmu-miR-214-3p	miRNA	streptozocin (STZ)	brain injury in diabetes mellitus (DM)	brain tissues	streptozocin (STZ) treatment	MicroRNA-214-3p (miR-214-3p) was decreased in DM mice.	32910484
16380	Mouse	mmu-miR-214-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	myofibroblasts	angiotensin II (Ang II) treatment	downregulated	27823969
16381	Mouse	mmu-miR-214-3p	miRNA	TGF-¦Â1	cardiac fibrosis	primary cultured myofibroblasts	TGF-¦Â1 treatment	downregulated	31434695
16382	Mouse	mmu-miR-214-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	hypertrophic myocardium	angiotensin II (Ang II) treatment	upregulated	27796324
16383	Mouse	mmu-miR-214-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiac tissues	high glucose (HG) treatment	miR-214-3p was decreased in the HG-treated cardiac fibroblasts.	30250027
16384	Mouse	mmu-miR-214-3p	miRNA	chronic social defeat stress (CSDS)	major depressive disorder (MDD)	medial prefrontal cortex (mPFC) tissues	chronic social defeat stress (CSDS) induce	upregulated	29522177
16385	Mouse	mmu-miR-214-3p	miRNA	luteolin exerts	obesity-associated comorbidities	mesenteric vessels	luteolin exerts treatment	"In HFD mice, luteolin counteracted significantly the decreased expression of miR-214-3p."	30319424
16386	Mouse	mmu-miR-214-3p	miRNA	bis-enoxacin	osteoclastogenesis	4T1 murine breast cancer cells	bis-enoxacin treatment	upregulated	30385810
16387	Mouse	mmu-miR-214-3p	miRNA	enoxacin	osteoclastogenesis	4T1 murine breast cancer cells	Enoxacin treatment	upregulated	30385810
16388	Mouse	mmu-miR-214-3p	miRNA	high glucose (HG)	osteogenesis	bone marrow mesenchymal stem cells (BMSCs)	high glucose (HG) treatment	upregulated	31728209
16389	Mouse	mmu-miR-214-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	33071725
16390	Mouse	mmu-miR-214-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	Primary Neuron	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	33071725
16391	Mouse	mmu-miR-214-5p	miRNA	pressure overload	heart failure (HF)	heart sissues	pressure overload treatment	upregulated	33224746
16392	Mouse	mmu-miR-214-5p	miRNA	lipopolysaccharide (LPS)	inflammation	BV2 microglia	lipopolysaccharide (LPS) treatment	downregulated	30584538
16393	Mouse	mmu-miR-215	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	mouse mesangial cell (MMC)	TGF-¦Â1 treatment	upregulated	23554908
16394	Mouse	mmu-miR-215	miRNA	sodium arsenite (NaAsO2)	DNA methylation	liver tissues	sodium arsenite treatment	upregulated	32068019
16395	Mouse	mmu-miR-215	miRNA	hypoxia	ischemic stroke (IS)	brain tissses	middle cerebral artery occlusion (MCAO) treatment	downregulated	29080697
16396	Mouse	mmu-mir-215-5p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
16397	Mouse	mmu-miR-215-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Plasma	doxorubicin (DOX) treatment	downregulated	30627229
16398	Mouse	mmu-miR-21-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	serum	lipopolysaccharide (LPS) treatment	upregulated	32934950
16399	Mouse	mmu-miR-21-5p	miRNA	tacrolimus (FK506)	chronic allograft dysfunction	renal proximal tubular epithelial cells (RPTECs)	tacrolimus treatment	upregulated	29362864
16400	Mouse	mmu-miR-21-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	plasma exosomes	ethanol treatment	downregulated	32937997
16401	Mouse	mmu-miR-21-5p	miRNA	ethanol (EtOH)	ethanol-induced neuroinflammation and brain damage	brain cortices	ethanol treatment	upregulated	32937997
16402	Mouse	mmu-miR-21-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32153563
16403	Mouse	mmu-miR-21-5p	miRNA	gastrodin and rhynchophylline	ischemia/reperfusion (I/R) injury	hypoxia-induced mouse brain tissues and BV2 cells	combination of gastrodin and rhynchophylline treatment	upregulated	31610203
16404	Mouse	mmu-miR-21-5p	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	mouse brain tissues and BV2 cells	Middle cerebral artery occlusion (MCAO) mice and oxygen glucose deprivation (OGD)-treated BV2 cells were used as in vivo and in vitro models of ischaemia	downregulated	31610203
16405	Mouse	mmu-miR-21-5p	miRNA	hypoxia	lung ischemia/reperfusion (I/R) injury	mesenchymal stromal cell-secreted exosomes (MSC-Exo)	hypoxia induce	upregulated	30682335
16406	Mouse	mmu-miR-21-5p	miRNA	lipopolysaccharide (LPS)	neuroinflammation	BV2 cells	lipopolysaccharide (LPS) treatment	upregulated	31707083
16407	Mouse	mmu-miR-21-5p	miRNA	icariin (ICA)	osteogenesis	MC3T3-E1 cells	icariin treatment	upregulated	29500883
16408	Mouse	mmu-miR-21-5p	miRNA	titanium (Ti)	osteogenesis	MC3T3-E1 cells	titanium (Ti) particle treatment	downregulated	29500883
16409	Mouse	mmu-miR-21-5p	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
16410	Mouse	mmu-miR-21-5p	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
16411	Mouse	mmu-miR-21-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	BV2 cells	lipopolysaccharide (LPS) treatment	upregulated	32572900
16412	Mouse	mmu-miR-21-5p	miRNA	TGF-¦Â1	spinal cord injury (SCI)	Primary mouse spinal fibroblasts	transforming growth factor (TGF)-¦Â1 treatment	upregulated	29483836
16413	Mouse	mmu-miR-21-5p	miRNA	"IL-1¦Â, IFN-¦Ã and TNF-¦Á"	type 1 diabetes mellitus (T1DM)	MIN6 cells	"a mixture containing 10 ng/mL each of IL-1¦Â, IFN-¦Ã, and TNF-¦Á for 24 h"	upregulated	29445851
16414	Mouse	mmu-miR-216	miRNA	cerulean	acute pancreatitis (AP)	mouse serum and pancreatic tissues	cerulean treatment	"upregulation of miR-216a and miR-216b in the serum, downregulated of miR-216a in pancreatic tissues"	28183420
16415	Mouse	mmu-miR-216	miRNA	amyloid-¦Â (A¦Â) 1-40	age-related macular degeneration (AMD)	C57BL/6 mice eye tissues	amyloid-¦Â (A¦Â) 1-40 treatment	upregulated	28324113
16416	Mouse	mmu-miR-216a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse lung tissues	lipopolysaccharide (LPS) treatment	downregulated	31784954
16417	Mouse	mmu-miR-216a	miRNA	cerulean	acute pancreatitis (AP)	serum	cerulean treatment	upregulated	28183420
16418	Mouse	mmu-miR-216a	miRNA	cerulean	acute pancreatitis (AP)	pancreatic	cerulean treatment	downregulated	28183420
16419	Mouse	mmu-miR-216a	miRNA	TGF-¦Â	cardiac fibrosis	Adult mouse cardiac fibroblasts	TGF-¦Â treatment	upregulated	31059054
16420	Mouse	mmu-miR-216a	miRNA	TGF-¦Â	diabetic nephropathy (DN)	glomerular mesangial cells	TGF-¦Â treatment	upregulated	19543271
16421	Mouse	mmu-miR-216a	miRNA	TGF-¦Â	vascular smooth muscle cell calcification	kidney cells	TGF-¦Â treatment	upregulated	20713358
16422	Mouse	mmu-miR-216b	miRNA	cerulean	acute pancreatitis (AP)	serum	cerulean treatment	upregulated	28183420
16423	Mouse	mmu-miR-216b	miRNA	glyoxylate	kidney tubular cell injury	renal tubular epithelial cell	glyoxylate treatment	downregulated	31735555
16424	Mouse	mmu-miR-216b	miRNA	glyoxylate	kidney tubular cell injury	oxidative stress	glyoxylate treatment	downregulated	31735555
16425	Mouse	mmu-miR-217	miRNA	silk ascending aorta proximal	cardiac hypertrophy	C57BL/6J mice cardiomyocytes	silk suture was tightened around the ascending aorta proximal to the brachiocephalic trunk treatment	downregulated in cardiomyocytes	27893464
16426	Mouse	mmu-miR-217	miRNA	fatty acid amide hydrolase inhibitor (FAAH-II)	colitis	colitis mouse colon tissues	FAAH-II treatment	dysregulated	27327245
16427	Mouse	mmu-miR-217	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	skin	streptozotocin (STZ) treatment	"GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model."	33865922
16428	Mouse	mmu-miR-217	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	feed with HG	upregulated	28017719
16429	Mouse	mmu-miR-217	miRNA	TGF-¦Â	diabetic nephropathy (DN)	glomerular mesangial cells	TGF-¦Â treatment	upregulated	19543271
16430	Mouse	mmu-miR-217	miRNA	sodium arsenite (NaAsO2)	DNA methylation	liver tissues	sodium arsenite treatment	downregulated	32068019
16431	Mouse	mmu-miR-217	miRNA	ethanol (EtOH)	genotoxic damage? cancer	The mouse AML-12 hepatocyte cell line and mice liver tisssue	ethanol treatment	"In AML-12 hepatocytes and in mouse livers, chronic ethanol exposure drastically and specifically induced miR-217 levels and caused excess fat accumulation"	22308024
16432	Mouse	mmu-miR-217	miRNA	ethanol (EtOH)	steatotic hepatocytes	Kupffer cells	ethanol treatment	upregulated	25797648
16433	Mouse	mmu-miR-217	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	peripheral blood and myocardial tissues of viral myocarditis mice and in CVB3-infected cardiomyocytes	Coxsackievirus B3 (CVB3) infection	upregulated	31894309
16434	Mouse	mmu-miR-217	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	peripheral blood; myocardial tissues; cardiomyocytes.	Coxsackievirus B3 (CVB3) infection	upregulated	31894309
16435	Mouse	mmu-miR-217-5p	miRNA	high fat diet (HFD)	atherosclerosis (AS)	atherosclerotic endothelial cells from apolipo protein E knockout ApoE(-/-) mice	high fat diet (HFD) feed	downregulated	31744714
16436	Mouse	mmu-miR-218	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	MH-S cells; RAW264.7 cells	lipopolysaccharide (LPS) treatment	MicroRNA-218 was significantly downregulated in cells treated with LPS.	30556885
16437	Mouse	mmu-miR-218	miRNA	transglutaminase 2 (TG2)	allergic inflammation	B16F1 mouse melanoma cells	TGaseII treatment	downregulated	25202021
16438	Mouse	mmu-miR-218	miRNA	intermittent hypoxia (IH)	apoptosis	normal mice aortic endothelial cells	under IH condition	upregulated	29262646
16439	Mouse	mmu-miR-218	miRNA	high glucose (HG)	diabetic nephropathy (DN)	murine podocyte	high glucose (HG) treatment	downregulated	31549412
16440	Mouse	mmu-miR-218	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose treatment	downregulated	31549412
16441	Mouse	mmu-miR-218	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin (STZ) treatment	downregulated	31549412
16442	Mouse	mmu-miR-218	miRNA	lopinavir/ritonavir (LPV/RTV)	lipogenesis	3T3-L1 cells	lopinavir/ritonavir (LPV/RTV) treatment	upregulated	31133852
16443	Mouse	mmu-miR-218	miRNA	amphetamine regimen	mesocortical dopamine development in adolescence	male mice dopamine neurons	amphetamine regimen treatment	upregulated	31192517
16444	Mouse	mmu-miR-218	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
16445	Mouse	mmu-miR-218	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	methionine-choline-deficient (MCD) diet feed	downregulated	31850710
16446	Mouse	mmu-miR-218	miRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	mouse aortic endothelial cells (MAECs)	chronic intermittent hypoxia (CIH) treatment	upregulated	29108914
16447	Mouse	mmu-miR-218	miRNA	oxygen	oxygen-induced retinopathy (OIR)	retinal tissues	Oxygen treatment	downregulated	27824019
16448	Mouse	mmu-miR-218	miRNA	RANKL (receptor activator of nuclear factor ¦ÊB ligand)	postmenopausal osteoporosis (PMOP)	osteoclastogenesis of RAW264.7 cells	50ng/mL RANKL treatment	downregulated	29271983
16449	Mouse	mmu-miR-218	miRNA	oxygen	retinal neovascularization (RNV)	retinal tissues	oxygen treatment	downregulated	26935869
16450	Mouse	mmu-miR-218	miRNA	laparotomy and exposure of the junc_x0002_tion between the large and small intestines	sepsis	mouse large and small intestines	laparotomy and exposure of the junc_x0002_tion between the large and small intestines treatment	downregulated	25043848
16451	Mouse	mmu-miR-218	miRNA	Src tyrosine kinase (Src)	tumorigenesis	The nontransformed and v-Src-transformed mouse embryonic Cx43Ko brain cells	Src tyrosine kinase (Src) treatment	downregulated	19767772
16452	Mouse	mmu-miR-218	miRNA	glucose	type 2 diabetes mellitus (T2DM)	isolated mouse islets	exposed to high levels of glucose within 1 h treatment	downregulated	25489007
16453	Mouse	mmu-miR-218-1-3p	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	27074385
16454	Mouse	mmu-miR-218-2*	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
16455	Mouse	mmu-miR-218-2*	miRNA	olanzapine (OLP)	psychotic disorders	brain tissues	clozapine treatment	upregulated	23318695
16456	Mouse	mmu-miR-218-5p	miRNA	honokiol	sepsis-induced acute kidney injury	renal tissues of sepsis-induced acute kidney injury (AKI) rats	honokiol treatment	downregulated	30833971
16457	Mouse	mmu-miR-218-5p	miRNA	ovalbumin (OVA)	asthma	Lung tissues	ovalbumin (OVA) treatment	downregulated	31520422
16458	Mouse	mmu-miR-218a-5p	miRNA	"4,4'-methylenedianiline (MDA)"	cholestasis	plasma	"4,4'-Methylenedianiline (MDA) treatment"	upregulated	30125006
16459	Mouse	mmu-miR-218a-5p	miRNA	¦Á-naphthylisothiocyanate (ANIT)	cholestasis	plasma	¦Á-naphthylisothiocyanate (ANIT) treatment	upregulated	30125006
16460	Mouse	mmu-miR-219	miRNA	arsenite	arsenic-induced neurotoxicity	hippocampus	arsenic (As) exposure	subchronic arsenic exposure induced impairment of learning and memory and significantly upregulated miRNA-219 (miR-219) expression in the mouse hippocampus.	29478199
16461	Mouse	mmu-miR-219	miRNA	complete freund's adjuvant (CFA)	chronic inflammatory pain	spinal neurons	complete Freund's adjuvant (CFA) treatment	downregulated	25031391
16462	Mouse	mmu-miR-219	miRNA	kainic acid (KA)	epilepsy	Hippocampal neurons	kainic acid (KA) treatment	downregulated	25394384
16463	Mouse	mmu-miR-219	miRNA	kainic acid (KA)	epilepsy	Hippocampal neurons	KA treatment	downregulated	25394384
16464	Mouse	mmu-miR-219	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	CCl4 treatment	downregulated	30592264
16465	Mouse	mmu-miR-219-5p	miRNA	resolvin D1 (RvD1)	extracellular matrix synthesis	macrophages	resolvin D1 (RvD1) treatment	upregulated	24249635
16466	Mouse	mmu-miR-219-5p	miRNA	resolvin D1 (RvD1)	insulin resistance and nonalcoholic steatohepatitis (NASH)	obese mice with NASH	resolvin D1 (RvD1) treatment	upregulated	24249635
16467	Mouse	mmu-miR-219-5p	miRNA	morphine	macrophage apoptosis	RAW264.7 cells	morphine treatment	downregulated	27253431
16468	Mouse	mmu-miR-219-5p	miRNA	microwave	microwave-induced adverse health outcomes 	mouse hippocampus	7 days after 30 mW/cm microwave exposure treatment	downregulated	24748327
16469	Mouse	mmu-miR-219a-2	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	HL-1 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	32682013
16470	Mouse	mmu-miR-219a-5p	miRNA	ethanol (EtOH)	chronic alcoholic liver disease (ALD)	AML-12 cells	Ethanol exposure	downregulated	31428222
16471	Mouse	mmu-miR-219a-5p	miRNA	protocatechuic acid (PCA)	chronic alcoholic liver disease (ALD)	AML-12 cells	Protocatechuic acid (PCA) treatment	upregulated	31428222
16472	Mouse	mmu-miR-219a-5p	miRNA	anandamide and norgestimate	depression	chronic mild stress (CMS) model of depression mouse	anandamide and norgestimate treatment	downregulated	28716528
16473	Mouse	mmu-miR-219a-5p	miRNA	H2O2	hepatic ischemia/reperfusion injury (HIRI)	AML-12 and NCTC1469 cells	H2O2 treatment	downregulated	30796685
16474	Mouse	mmu-miR-219b-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
16475	Mouse	mmu-miR-21a	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	serial transverse aortic sections	Shexiang Tongxin dropping pill (STDP) treatment	downregulated	25449459
16476	Mouse	mmu-miR-21a	miRNA	Shexiang Tongxin dropping pill (STDP)	atherosclerosis (AS)	(ApoE(-/-)) mice aortic	STDP (30 mg/kg/day) on atherosclerotic lesions treatment	downregulated	25449459
16477	Mouse	mmu-miR-21a	miRNA	helicobacter pylori (H. pylori)	gastric MALT lymphoma (GML)	GML-developing d3Tx mice stomachs	infect with H. pylori	upregulated	28560185
16478	Mouse	mmu-miR-21a-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	upregulated	32727087
16479	Mouse	mmu-miR-21a-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Mouse primary pulmonary Telocytes (TCs)	lipopolysaccharide (LPS) treatment	upregulated	31878977
16480	Mouse	mmu-miR-21a-3p	miRNA	fructus meliae toosendan (FMT)	liver damage	eft lateral liver lobe	Fructus Meliae Toosendan (FMT) treatment	upregulated	26539117
16481	Mouse	mmu-miR-21a-5p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	miR-21a-5p was upregulated at 24h and 48h.	32727087
16482	Mouse	mmu-miR-21a-5p	miRNA	brucella abortus	brucellosis	"bone marrow-derived macrophages, spleens"	brucella abortus infection	downregulated	29942317
16483	Mouse	mmu-miR-21a-5p	miRNA	kidney transplantation	chronic renal allograft dysfunction (CAD)	mouse kidney tissues	allogenic kidney transplantation treatment	upregulated in the mouse kidney	28396121
16484	Mouse	mmu-miR-21a-5p	miRNA	echinococcus multilocularis metacestodes	echinococcus multilocularis infection	RAW 264.7 cells	E. multilocularis metacestodes treatment	upregulated	30322806
16485	Mouse	mmu-miR-21a-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	downregulated	31497013
16486	Mouse	mmu-miR-21a-5p	miRNA	E. multilocularis metacestodes	infection and immunity of E. multilocularis	RAW264¡¤7 macrophage cells	E. multilocularis metacestodes for 6 and 12 h treatment	"upregulated (mmu-miR-378d,mmu-miR-155-5p, mmu-miR-146a-5p, mmu-miR-21a-5p , mmu-miR-125a-5p) and downregulated(mmu-miR-1981-5p , mmu-miR-let-7c-1-3p)"	28942753
16487	Mouse	mmu-miR-21a-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
16488	Mouse	mmu-miR-21a-5p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
16489	Mouse	mmu-miR-21a-5p	miRNA	polymethylmethacrylate (PMMA)	particle-induced osteolysis (PIO)	primary bone marrow-derived macrophages (BMMs)	polymethylmethacrylate (PMMA) treatment	miR-21a-5p expression was promoted in PMMA-induced cells	29252185
16490	Mouse	mmu-miR-21a-5p	miRNA	alpinia oxyphylla extract (AOE)	type 2 diabetes mellitus (T2DM)	db-/db- mouse kidney	A. oxyphylla extract (AOE) treatment	downregulated	28249617
16491	Mouse	mmu-miR-21b-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	NS2OY cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31217870
16492	Mouse	mmu-miR-22	miRNA	simvastatin	atherosclerosis (AS)	RAW264.7 macrophages	simvastatin treatment	miR-22 was found to be one of the most significantly upregulated miRNAs in LPS-stimulated RAW2647 macrophages after treatment with simvastatin	31949780
16493	Mouse	mmu-miR-22	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	?Mouse Monocyte	lipopolysaccharide (LPS) treatment	upregulated	24198819
16494	Mouse	mmu-miR-22	miRNA	ultraviolet (UV) irradiation	bacterial pneumonia	Mouse embryonic fibroblast cells	UV radiation treatment	?UV radiation induces a significant increase of miR-22 expression	22166214
16495	Mouse	mmu-miR-22	miRNA	Rhesus Rotavirus (RRV)	biliary atresia (BA)	mouse	infect with Rhesus Rotavirus (RRV) treatment	upregulated	24569080
16496	Mouse	mmu-miR-22	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse cardiac myocytes	angiotensin II (Ang II) treatment	The expression of lnc-FTX was associated with reduced hypertrophy of neonatal mouse cardiac myocytes and regulated the PTEN/PI3K/Akt signaling pathway by sponging miRNA-22	31840653
16497	Mouse	mmu-miR-22	miRNA	isoproterenol	cardiac hypertrophy	heart tissues	prolongation of isoproterenol intervention treatment	downregulated	24504502
16498	Mouse	mmu-miR-22	miRNA	doxorubicin (DOX)	cardiotoxicity	heart tissues	"Mice were exposed to reduplicative injections of Dox (i.p., 4?mg/kg) weekly for consecutive 4 weeks to generate Dox-induced cardiotoxicity."	upregulated	31677784
16499	Mouse	mmu-miR-22	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	mouse cardiomyocytes	high glucose (HG) treatment	MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy.	33097254
16500	Mouse	mmu-miR-22	miRNA	phosphodiesterase 5 (PDE5) inhibitor	diabetic nephropathy (DN)	diabetic kidney injury mouse	PDE5is treatment	downregulated	28294194
16501	Mouse	mmu-miR-22	miRNA	tongxinluo (TXL)	diabetic nephropathy (DN)	C57BL/6J mice	TXL treatment	downregulated	24370588
16502	Mouse	mmu-miR-22	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart tissues	doxorubicin (Dox) treatment	MicroRNA-22 inhibition prevents doxorubicin-induced cardiotoxicity via upregulating SIRT1.	31677784
16503	Mouse	mmu-miR-22	miRNA	puerarin	facilitates t-tubule development	murine embryonic stem cell-derived cardiomyocytes	puerarin treatment	downregulated	25059232
16504	Mouse	mmu-miR-22	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	sera	bleomycin (BLM) treatment	Exosomal miR-22 modulates fibroblast-to-myofibroblast differentiation.	31776321
16505	Mouse	mmu-miR-22	miRNA	"3,3'-diindolylmethane (DIM)"	multiple sclerosis (MS)	activated T cells during the development of experimental autoimmune encephalomyelitis (EAE)	"3,3'-Diindolylmethane (DIM) treatment"	upregulated	24898268
16506	Mouse	mmu-miR-22	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	33159388
16507	Mouse	mmu-miR-22	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
16508	Mouse	mmu-miR-22	miRNA	aerobic training	obesity	exosomes of serum	aerobic training	downregulated	32744099
16509	Mouse	mmu-miR-22	miRNA	high fat diet (HFD)	obesity	mouse brown adipose tissue (BAT)	high fat diet (HFD) feed	"Here, we show that miR-22 expression is induced during white, beige, and brown adipocyte differentiation in vitro."	33549579
16510	Mouse	mmu-miR-22	miRNA	dexamethasone (DEX)	osteoporosis	murine osteoblastic MC3T3-E1 cells	dexamethasone (DEX) treatment	The results demonstrated that miR-22 expression was upregulated in DEX-treated osteoblastic cells compared with the control group.	33732309
16511	Mouse	mmu-miR-22	miRNA	¦Â-elemene	oxygen-induced retinopathy (OIR)	Retinas tissues	¦Â-elemene treatment	upregulated	30664207
16512	Mouse	mmu-miR-22	miRNA	testosterone	prostate cancer	female mouse liver	Testosterone treatment	"upregulation of the 6 miRNAs miR-22, miR-690, miR-122, let-7A, miR-30D and let-7D"	20600201
16513	Mouse	mmu-miR-22	miRNA	haloperidol	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
16514	Mouse	mmu-miR-22	miRNA	olanzapine (OLP)	psychotic disorders	brain tissues	clozapine treatment	upregulated	23318695
16515	Mouse	mmu-miR-22	miRNA	bleomycin (BLM)	lung fibrosis	human lung fibroblasts	bleomycin (BLM) treatment	upregulated	31776321
16516	Mouse	mmu-miR-22	miRNA	TGF-¦Â1	skeletal muscle myogenesis	mouse myoblast cell (C2C12 myoblast cell line)	transforming growth factor beta 1 (TGF-¦Â1) treatment	downregulated	29588073
16517	Mouse	mmu-miR-220b	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	downregulated	21584493
16518	Mouse	mmu-miR-221	miRNA	red mud	biological effects of red mud	"CBA/Ca mice liver, spleen, lung, kidney and lymph nodes"	"1, 3, 6 and 24 h after a single intraperitoneal injection of red mud treatment"	"upregulated , but the level and the peak of the alteration differed according to examined tissue"	24425836
16519	Mouse	mmu-miR-221	miRNA	hydrochloric acid	acute lung injury (ALI)	C57BL/6 mice microvesicle (MV)release from lung epithelium	"hydrochloric acid (0.1 N, pH 1.5) was intratracheally instilled into the mouse lung"	upregulated in microvesicle (MV)release from lung epithelium	28674181
16520	Mouse	mmu-miR-221	miRNA	lipopolysaccharide (LPS)	asthma	P815 mast cells	lipopolysaccharide (LPS) treatment	upregulated	26901347
16521	Mouse	mmu-miR-221	miRNA	ovalbumin (OVA)	asthma	mouse lung tissue cells	OVA treatment	miRNA-221 blockade resulted in a reduction of airway inflammation in the OV A-induced murine asthma model	22572970
16522	Mouse	mmu-miR-221	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	32714925
16523	Mouse	mmu-miR-221	miRNA	lipopolysaccharide (LPS)	bacterial pneumonia	RAW 264.7 derived extracellular vesicles (EVs)	lipopolysaccharide (LPS) treatment	upregulated	28274991
16524	Mouse	mmu-miR-221	miRNA	bile acids	bronchial epithelial inflammation in asthma	EAC cells	bile acids treatment	upregulated	23933602
16525	Mouse	mmu-miR-221	miRNA	angiotensin II (Ang II)	cardiac electrical remodeling	heart tissues	angiotensin II (Ang II) treatment	upregulated	31312877
16526	Mouse	mmu-miR-221	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	heart sissues	angiotensin II (Ang II) treatment	upregulated	31312877
16527	Mouse	mmu-miR-221	miRNA	adenine	chronic kidney disease (CKD)	kidney tissues	adenine treatment	upregulated	32526762
16528	Mouse	mmu-miR-221	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
16529	Mouse	mmu-miR-221	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hippocampal neuron	streptozotocin induce treatment	"miR-221 was highly expressed in the diabetic mice miR-221 could bind with both lincRNA p21 and FOS miR-221 silencing in the diabetes mice reduced the cell apoptosis rate, and the expression of Bax and cleaved Caspase-3, whereas increase the Bcl-2 expression"	31081202
16530	Mouse	mmu-miR-221	miRNA	hypoxia	hypoxia-induced injury	mouse hippocampal HT22 cells	hypoxia treatment	downregulated	31512791
16531	Mouse	mmu-miR-221	miRNA	magnesium (Mg2+ )	hypoxia-induced injury	hypoxia-induced mouse hippocampal HT22 cells	Magnesium (Mg2+ ) treatment	upregulated	31512791
16532	Mouse	mmu-miR-221	miRNA	extracts from wild bitter gourd fruit (WBGE)	inflammation	TNF-¦Á-mouse lung tissues	extracts from wild bitter gourd fruit (WBGE) treatment	upregulated	29655703
16533	Mouse	mmu-miR-221	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	lung tissues	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29655703
16534	Mouse	mmu-miR-221	miRNA	TGF-¦Â1	inflammation	intestinal Th17 cells	TGF-¦Â1 treatment	Expression of miR-221 and miR-222 was induced by proinflammatory cytokines and repressed by the cytokine TGF-¦Â	33657395
16535	Mouse	mmu-miR-221	miRNA	vesicular stomatitis virus (VSV)	innate immune response	peritoneal macrophages	vesicular stomatitis virus (VSV) infection treatment	upregulated	30089112
16536	Mouse	mmu-miR-221	miRNA	high fat diet (HFD)	insulin resistance (IR)	C57BL/6 male mice liver and muscle	high fat diet (HFD) feed	upregulated	24130336
16537	Mouse	mmu-miR-221	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	upregulated	20436259
16538	Mouse	mmu-miR-221	miRNA	nerve growth factor (NGF)	neuronal differentiation	rat pheochromocytoma PC12 cells	nerve growth factor (NGF) regulated	miR-221 was drastically upregulated	22465943
16539	Mouse	mmu-miR-221	miRNA	carbon tetrachloride (CCl4)	nonalcoholic steatohepatitis (NASH)	liver tissues	carbon tetrachloride (CCl4) treatment	Liver miR-221 was significantly increased in both fibrosis models compared to control mice.	30528086
16540	Mouse	mmu-miR-221	miRNA	choline deficient diet (MCDD)	nonalcoholic steatohepatitis (NASH)	liver tissues	choline deficient diet (MCDD) treatment	Liver miR-221 was significantly increased in both fibrosis models compared to control mice.	30528086
16541	Mouse	mmu-miR-221	miRNA	high fat diet (HFD)	obesity	obese adipose tissue	high fat diet (HFD) feed	upregulated	29236311
16542	Mouse	mmu-miR-221/222	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	MN9D dopaminergic neurons	N-methyl-4-phenylpyridinium (MPP +) treatment	downregulated	31499060
16543	Mouse	mmu-miR-221-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	31208297
16544	Mouse	mmu-miR-221-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	RAW 264.7 macrophages	lipopolysaccharide (LPS) treatment	LncRNA TUG1 reverses LPS-induced cell apoptosis and inflammation of macrophage via targeting MiR-221-3p/SPRED2 axis	32841583
16545	Mouse	mmu-miR-221-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW 264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL treatment remarkably suppressed the expression of miR-221-3p in a concentration-dependent and time-dependent manner.	30362166
16546	Mouse	mmu-miR-221-3p	miRNA	"carbon-tetrachloride- and 3,5-di-diethoxycarbonyl-1,4-dihydrocollidine"	liver fibrosis	mouse hepatocytes	"carbon-tetrachloride- and 3,5-di-diethoxycarbonyl-1,4-dihydrocollidine induce"	upregulated	30582979
16547	Mouse	mmu-miR-221-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	oxidative stress	The RAW264.7 cell line	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30362166
16548	Mouse	mmu-miR-221-5p	miRNA	3¦Â-hydroxycholest-5-en-7-one	anti-inflammatory responses	RAW 264.7 cells	3¦Â-hydroxycholest-5-en-7-one treatment	upregulated	32771556
16549	Mouse	mmu-miR-222	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
16550	Mouse	mmu-miR-222	miRNA	staphylococcal enterotoxin B (SEB)	acute lung injury (ALI)	lung-infiltrating mononuclear cells	staphylococcal enterotoxin B (SEB) treatment	upregulated	26818958
16551	Mouse	mmu-miR-222	miRNA	staphylococcal enterotoxin B (SEB)	acute lung injury (ALI)	lung infiltrating mononuclear cells	staphylococcal Enterotoxin B (SEB) treatment	MiR-222 was upregulated in SEB-induced inflammatory ALI.	32457280
16552	Mouse	mmu-miR-222	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
16553	Mouse	mmu-miR-222	miRNA	lipopolysaccharide (LPS)	bacterial pneumonia	RAW 264.7 derived extracellular vesicles (EVs)	lipopolysaccharide (LPS) treatment	upregulated	28274991
16554	Mouse	mmu-miR-222	miRNA	celecoxib	breast cancer	ovariectomized athymic mice transplanted MCF-7 cells	celecoxib treatment	upregulated	24923427
16555	Mouse	mmu-miR-222	miRNA	bile acids	bronchial epithelial inflammation in asthma	EAC cells	bile acids treatment	upregulated	23933602
16556	Mouse	mmu-miR-222	miRNA	angiotensin II (Ang II)	cardiac electrical remodeling	heart tissues	angiotensin II (Ang II) treatment	upregulated	31312877
16557	Mouse	mmu-miR-222	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	heart sissues	angiotensin II (Ang II) treatment	upregulated	31312877
16558	Mouse	mmu-miR-222	miRNA	high glucose (HG)	cardiac remodeling	mouse heart endothelial cells	high glucose (HG) treatment	downregulated	32396525
16559	Mouse	mmu-miR-222	miRNA	streptozocin (STZ)	cardiac remodeling	heart sissues	streptozocin (STZ) treatment	downregulated	32396525
16560	Mouse	mmu-miR-222	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	heart tissues	streptozotocin (STZ) treatment	downregulated	31389030
16561	Mouse	mmu-miR-222	miRNA	gastrin	gastric cancer (GC)	AGSGR cells	Gastrin treatment	upregulated	27323780
16562	Mouse	mmu-miR-222	miRNA	¦Ã-rays	gastrointestinal acute radiation syndrome	Macrophages (M?) with the M2b phenotype (Pheno2b-M?)	7-10 Gy of gamma rays treatment	upregulated	29743312
16563	Mouse	mmu-miR-222	miRNA	estradiol-17¦Â (E2)	gestational diabetes mellitus (GDM)	3T3-L1 adipocytes	estradiol-17¦Â (E2) treatment	upregulated	24601884
16564	Mouse	mmu-miR-222	miRNA	streptozocin (STZ)	gestational diabetes mellitus (GDM)	placenta tissues	streptozocin treatment	MiR-222 was increased while CXCR4 was decreased in GDM patients and mice	33278386
16565	Mouse	mmu-miR-222	miRNA	exercise (Ex)	heart capacity	heart	Exercise treatment	upregulated	25863248
16566	Mouse	mmu-miR-222	miRNA	fructus meliae toosendan (FMT)	herb-induced liver injury (HILI)	serum exosome	Fructus Meliae Toosendan (FMT) treatment	downregulated	31855734
16567	Mouse	mmu-miR-222	miRNA	fructus meliae toosendan (FMT)	herb-induced liver injury (HILI)	mouse serum exosomes	Fructus Meliae Toosendan (FMT) treatment	downregulated	31855734
16568	Mouse	mmu-miR-222	miRNA	extracts from wild bitter gourd fruit (WBGE)	inflammation	TNF-¦Á-mouse lung tissues	extracts from wild bitter gourd fruit (WBGE) treatment	upregulated	29655703
16569	Mouse	mmu-miR-222	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
16570	Mouse	mmu-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	lung tissues	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29655703
16571	Mouse	mmu-miR-222	miRNA	TGF-¦Â1	inflammation	intestinal Th17 cells	TGF-¦Â1 treatment	Expression of miR-221 and miR-222 was induced by proinflammatory cytokines and repressed by the cytokine TGF-¦Â	33657395
16572	Mouse	mmu-miR-222	miRNA	panax notoginseng saponins (PNS)	lung cancer	Lewis lung carcinoma (LLC) cell line	Panax notoginseng saponins (PNS) treatment	downregulated	27566197
16573	Mouse	mmu-miR-222	miRNA	"arsenic (As), cadmium (Cd), and lead (Pb) (As-Cd-Pb)"	metal-induced carcinogenesis	Balb/c 3T3 cell	As-Cd-Pb exposure	upregulated	31769258
16574	Mouse	mmu-miR-222	miRNA	genistein	muscle health	C2C12 myoblasts	genistein treatment	The expression of miR-222 was decreased by genistein.	32361609
16575	Mouse	mmu-miR-222	miRNA	genistein	myoblast differentiation	C2C12 cells	Genistein treatment	Genistein treatment also downregulated the expression of miR-222.	29171786
16576	Mouse	mmu-miR-222	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	neonatal necrotizing enterocolitis (NEC)	M1 macrophages	tumor necrosis factor alpha (TNF-¦Á) treatment	We found that TNF-¦Á upregulated the expression of miRNA-222 and inhibited the expression of c-kit	33564933
16577	Mouse	mmu-miR-222	miRNA	carbon tetrachloride (CCl4)	nonalcoholic steatohepatitis (NASH)	liver tissues	carbon tetrachloride (CCl4) treatment	Liver miR-222 was significantly increased in both fibrosis models compared to control mice.	30528086
16578	Mouse	mmu-miR-222	miRNA	choline deficient diet (MCDD)	nonalcoholic steatohepatitis (NASH)	liver tissues	choline deficient diet (MCDD) treatment	Liver miR-222 was significantly increased in both fibrosis models compared to control mice.	30528086
16579	Mouse	mmu-miR-222	miRNA	high fat diet (HFD)	obesity	white adipose tissue	high fat diet (HFD) feed	upregulated	22496873
16580	Mouse	mmu-miR-222	miRNA	genistein	obesity and diabetes	mouse adipose tissues	genistein treatment	Genistein can inhibit obesity and downregulate the expression of miR-222 in mouse adipose tissue and 3T3-L1 cells.	32129363
16581	Mouse	mmu-miR-222	miRNA	genistein	obesity and diabetes	T3-L1 preadipocytes	genistein treatment	downregulated	32129363
16582	Mouse	mmu-miR-222	miRNA	wire-induced injury to carotid arteries	vessel stenosis	apolipoprotein E knockout (Apoe ) mice	injury to carotid arteries of treatment	upregulated	27622243
16583	Mouse	mmu-miR-222	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	mouse cardiomyocytes	Coxsachievirus B3 infection	upregulated	30669342
16584	Mouse	mmu-miR-222-3p	miRNA	bone marrow transplantation (BMT)	diabetes mellitus (DM)	mice with insulin-deficient diabetes	bone marrow transplantation (BMT) treatment	upregulated	27974246
16585	Mouse	mmu-miR-222-3p	miRNA	high fat diet (HFD)	insulin resistance (IR)	obese mice soleus muscle tissues	high fat diet (HFD) feed	upregulated	31770568
16586	Mouse	mmu-miR-222-3p	miRNA	pioglitazone	insulin resistance (IR)	obese mice soleus muscle tissues	pioglitazone (PGZ) treatment	downregulated	31770568
16587	Mouse	mmu-miR-222-3p	miRNA	hypoxia	cardiomyocytes injury	HL-1 Cells	hypoxia exposure	miR-222-3p could resume the functions of GAS5 in cell viabilities and apoptosis through protein regulation in PI3K and AKT signaling pathways.	32240616
16588	Mouse	mmu-miR-222-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
16589	Mouse	mmu-miR-222-5p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
16590	Mouse	mmu-miR-223	miRNA	hypoxia and load	pulmonary hypertension (PH)	murine lung;right ventricle	hypoxia and load treatment	downregulated	27013635
16591	Mouse	mmu-miR-223	miRNA	concanamycin A (Con A)	acute liver failure (ALF)	mouse	Con A treatment	dysregulated	25562161
16592	Mouse	mmu-miR-223	miRNA	Klebsiella pneumoniae	acute lung injury (ALI)	Bronchoalveolar lavage fluid (BALF) microvesicles (MVs)	Klebsiella pneumoniae infection	upregulated	31331947
16593	Mouse	mmu-miR-223	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	30747229
16594	Mouse	mmu-miR-223	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Bronchoalveolar lavage fluid (BALF) microvesicles (MVs)	lipopolysaccharide (LPS) treatment	upregulated	31331947
16595	Mouse	mmu-miR-223	miRNA	differentiation medium (DM)	adipogenesis	3T3-L1 cells	"3T3-L1 cells were incubated in differentiation medium (DM) supplemented with 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine, 250 nM dexamethasone, and 160 nM insulin."	downregulated	31828146
16596	Mouse	mmu-miR-223	miRNA	amyloid-¦Â (A¦Â) 1-40	age-related macular degeneration (AMD)	C57BL/6 mice eye tissues	amyloid-¦Â (A¦Â) 1-40 treatment	upregulated	28324113
16597	Mouse	mmu-miR-223	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	mouse both serum and neutrophils	chronic-plus-binge ethanol feeding	upregulated in both serum and neutrophils	27679493
16598	Mouse	mmu-miR-223	miRNA	vesicular stomatitis virus (VSV)	antiviral immune response	murine macrophages	vesicular stomatitis virus (VSV) treatment	upregulated	27226534
16599	Mouse	mmu-miR-223	miRNA	high fat diet (HFD)	atherosclerosis (AS)	endothelium	high fat diet (HFD) feed	miR-223 was remarkably upregulated in the melatonin-treated HFD group.	29024030
16600	Mouse	mmu-miR-223	miRNA	lipopolysaccharide (LPS)	atherosclerosis (AS)	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	26492242
16601	Mouse	mmu-miR-223	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	male C57BL/6J mice	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	25463083
16602	Mouse	mmu-miR-223	miRNA	sevelamer	chronic kidney disease (CKD)	CKD mice	sevelamer treatment	upregulation	24140891
16603	Mouse	mmu-miR-223	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues	dextran sodium sulfate (DSS) treatment	upregulated	29867475
16604	Mouse	mmu-miR-223	miRNA	dextran sodium sulfate (DSS)	colitis	C57BL/6J mice colonic tissue	dextran-sulfate-sodium (DSS) treatment	upregulated	28752563
16605	Mouse	mmu-miR-223	miRNA	Lactobacillus fermentum (L. fermentum)	colitis	C57BL/7J mice colonic tissues	infect with L. fermentum	downregulated	28752563
16606	Mouse	mmu-miR-223	miRNA	probiotic Escherichia coli Nissle 1917 (EcN)	colitis	dextran sodium sulfate (DSS)-induced colitis mouse colon tissues	probiotic Escherichia coli Nissle 1917 (EcN) treatment	downregulated	29867475
16607	Mouse	mmu-miR-223	miRNA	IL-10	colonic inflammation	colonic intraepithelial lymphocytes	IL-10 treatment	downregulated	22043014
16608	Mouse	mmu-miR-223	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	upregulated	24464560
16609	Mouse	mmu-miR-223	miRNA	high glucose (HG)	diabetes mellitus (DM)	murine Min6 ¦Â-cells	high glucose (HG) treatment	upregulated	31118273
16610	Mouse	mmu-miR-223	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetes mellitus (DM)	murine Min6 ¦Â-cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31118273
16611	Mouse	mmu-miR-223	miRNA	H1N1 influenza virus	endometriosis and endometrial carcinoma	mouse lung?tissues	H1N1 influenza virus infection	upregulated	24066118
16612	Mouse	mmu-miR-223	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
16613	Mouse	mmu-miR-223	miRNA	lipopolysaccharide (LPS)	inflammation	ATDC5 cells	lipopolysaccharide (LPS) treatment	downregulated	30791741
16614	Mouse	mmu-miR-223	miRNA	tripterine	inflammation	LPS-treated ATDC5 cells	Tripterine treatment	upregulated	30791741
16615	Mouse	mmu-miR-223	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	terminal ileum; colon	dextran sodium sulfate (DSS) treatment	miR-223 expression in the terminal ileum and colon was increased in the DSS group.	33332758
16616	Mouse	mmu-miR-223	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colon tissues	dextran sulfate sodium (DSS) treatment	upregulated	30236870
16617	Mouse	mmu-miR-223	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	terminal ileum and colon	dextran sodium sulfate (DSS) treatment	miR-223 expression in the terminal ileum and colon was increased in the DSS group compared with the WT group.	33332758
16618	Mouse	mmu-miR-223	miRNA	histone deacetylase inhibitor trichostatin A (TSA)	inflammatory diseases	TLR-triggered RAW264.7 cells	increased expression obviously in	upregulated	28881218
16619	Mouse	mmu-miR-223	miRNA	schistosoma japonicum	japonicum infection	serum	japonicum infection	upregulated	24330517
16620	Mouse	mmu-miR-223	miRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	mouse neutrophils	acetaminophen (APAP) treatment	upregulated in neutrophils	28295449
16621	Mouse	mmu-miR-223	miRNA	dexamethasone (DEX)	macrophage inflammatory response	Mouse bone marrow-derived macrophages (BMDMs)	dexamethasone (DEX) treatment	upregulated	31262200
16622	Mouse	mmu-miR-223	miRNA	IFN-¦Ã	macrophage inflammatory response	Mouse bone marrow-derived macrophages (BMDMs)	IFN-¦Ã treatment	downregulated	31262200
16623	Mouse	mmu-miR-223	miRNA	IL-10	macrophage inflammatory response	Mouse bone marrow-derived macrophages (BMDMs)	IL-10 treatment	upregulated	31262200
16624	Mouse	mmu-miR-223	miRNA	IL-4	macrophage inflammatory response	Mouse bone marrow-derived macrophages (BMDMs)	IL-4 treatment	upregulated	31262200
16625	Mouse	mmu-miR-223	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	Mouse bone marrow-derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	downregulated	31262200
16626	Mouse	mmu-miR-223	miRNA	rosiglitazone	macrophage inflammatory response	Mouse bone marrow-derived macrophages (BMDMs)	rosiglitazone treatment	upregulated	31262200
16627	Mouse	mmu-miR-223	miRNA	H2O2	myocardial infarction (MI)	Primarily cultured cardiomyocytes	H2O2 treatment	upregulated	30280799
16628	Mouse	mmu-miR-223	miRNA	ovalbumin (OVA)	neutrophilic asthma	lung tissues	OVA/CFA treatment	The expression of miR-223 was upregulated in lung tissues of experimental mice model.	32423405
16629	Mouse	mmu-miR-223	miRNA	high fat diet (HFD)	nonalcoholic steatohepatitis (NASH)	hepatocytes in HFD-fed mice	high fat diet (HFD) feed	upregulated	30964207
16630	Mouse	mmu-miR-223	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
16631	Mouse	mmu-miR-223	miRNA	olanzapine (OLP)	psychotic disorders	brain tissues	clozapine treatment	upregulated	23318695
16632	Mouse	mmu-miR-223	miRNA	photo-oxidative damage (PD)	retinal degenerative diseases	retina	photo-oxidative damage (PD) treatment	"During photo-oxidative damage (PD) in wild-type (WT) mice, miR-223 in the retina is significantly upregulated between 3 and 7 days, peaking at 5 days (P < 005), compared to dim-reared control levels"	32671067
16633	Mouse	mmu-miR-223	miRNA	leptin	age-associated loss of muscle mass	skeletal muscle	?leptin treatment	?leptin treatment increased the expression of miR-31 and miR-223	20800581
16634	Mouse	mmu-miR-223	miRNA	cecal ligation and puncture (CLP)	sepsis	mouse kidney homogenate	cecal ligation and puncture (CLP) treatment	upregulated in kidney homogenate	28515178
16635	Mouse	mmu-miR-223	miRNA	controlled cortical impact (CCI)	traumatic brain injury (TBI)	mouse hippocampus	controlled cortical impact (CCI)	upregulated	28804446
16636	Mouse	mmu-miR-223	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	heart tissues and heart-infiltrating macrophages	Coxsackievirus B3 (CVB3) infection	downregulated	29524390
16637	Mouse	mmu-miR-223	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	macrophages	coxsackievirus B3 (CVB3) treatment	"downregulated of MEG3 leads to the inhibition of inflammation and induces M2 macrophage polarization via miR-223/TRAF6/NF-¦ÊB axis, thus alleviating VMC."	33047847
16638	Mouse	mmu-miR-223*-5p	miRNA	ecal ligation and puncture (CLP)	severe septic	mouse	ligation and puncture treatment	downregulated	24486439
16639	Mouse	mmu-miR-223-3p	miRNA	angiostrongylus cantonensis (A. cantonensis)	angiostrongylus cantonensis (A. cantonensis) infection	mouse	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24682888
16640	Mouse	mmu-miR-223-3p	miRNA	"fatty acid esters of 3-chloro-1, 2-propanediol (3-MCPD)"	acute kidney injury (AKI)	kidney tissues	"Fatty acid esters of 3-chloro-1, 2-propanediol (3-MCPD) treatment"	upregulated	29860048
16641	Mouse	mmu-miR-223-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	miR-223-3p was upregulated at 1.5h and 24h.	32727087
16642	Mouse	mmu-miR-223-3p	miRNA	ovalbumin (OVA)	asthma	bone marrow-derived DCs (BMDCs)	ovalbumin (OVA) treatment	OVA treatment significantly downregulated miR-223-3p in BMDCs.	32656268
16643	Mouse	mmu-miR-223-3p	miRNA	¦Á-myosin H-chain peptide	autoimmune myocarditis	serum	¦Á-myosin H-chain peptide treatment	miR-223-3p expression was significantly lower in EAM mice than that in normal mice	31743855
16644	Mouse	mmu-miR-223-3p	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colitis-associated colon cancer (CAC)	colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	upregulated	31275360
16645	Mouse	mmu-miR-223-3p	miRNA	pedunculoside	colitis-associated colon cancer (CAC)	CAC mice colon tissues	pedunculoside treatment	downregulated	31275360
16646	Mouse	mmu-miR-223-3p	miRNA	reconstituted high-density lipoproteins (rHDL)	diabetes-impaired angiogenesis	diabetic mice HDL fraction	reconstituted high-density lipoproteins (rHDL) treatment	upregulated	30206364
16647	Mouse	mmu-miR-223-3p	miRNA	reconstituted high-density lipoproteins (rHDL)	diabetes-impaired angiogenesis	diabetic mice plasma	reconstituted high-density lipoproteins (rHDL) treatment	downregulated	30206364
16648	Mouse	mmu-miR-223-3p	miRNA	dexamethasone (DEX)	endometrial receptivity	endometrium tissues	dexamethasone (DEX) treatment	upregulated	30993706
16649	Mouse	mmu-miR-223-3p	miRNA	¦Á-myosin H-chain peptide	experimental autoimmune myocarditis (EAM)	EAM mice serum	¦Á-myosin H-chain peptide treatment	downregulated	31743855
16650	Mouse	mmu-miR-223-3p	miRNA	monosodium urate (MSU)	gouty inflammation	mice air pouch synovium	monosodium urate treatment	downregulated	33650318
16651	Mouse	mmu-miR-223-3p	miRNA	dexamethasone (DEX)	innate immune response	immature DCs (iDCs)	dexamethasone (DEX) treatment	upregulated	30174602
16652	Mouse	mmu-miR-223-3p	miRNA	low chromium (Cr)	insulin resistance (IR)	liver	fed a control or LC diet for 13 weeks	dysregulatedin liver	29286159
16653	Mouse	mmu-miR-223-3p	miRNA	candida albicans (C. albicans)	kaposi's sarcoma (KS)	serum	candida albicans infection	upregulated	31396494
16654	Mouse	mmu-miR-223-3p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
16655	Mouse	mmu-miR-223-3p	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
16656	Mouse	mmu-miR-223-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	Murine primary chondrocytes were isolated from postnatal mice	IL-1¦Â treatment	downregulated	30847744
16657	Mouse	mmu-miR-223-3p	miRNA	Sinomenine (SIN)	osteoarthritis (OA)	IL-1¦Â-treated murine primary chondrocytes were isolated from postnatal mice	Sinomenine (SIN) treatment	upregulated	30847744
16658	Mouse	mmu-miR-223-3p	miRNA	rotenone (ROT)	parkinson's disease (PD)	brain tissues	rotenone treatment	downregulated	32470877
16659	Mouse	mmu-miR-223-3p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
16660	Mouse	mmu-miR-223-3p	miRNA	?-glucan	rheumatoid arthritis (RA)	SKG mice plasma	injection of ?-glucan treatment	upregulated in plasma	28056105
16661	Mouse	mmu-miR-223-3p	miRNA	ecal ligation and puncture (CLP)	severe septic	mouse	ligation and puncture treatment	downregulated	24486439
16662	Mouse	mmu-miR-223-3p	miRNA	H2O2	spinal cord injury (SCI)	primary spinal neurons culture	H2O2 treatment	downregulated	30821011
16663	Mouse	mmu-miR-223-3p	miRNA	necrostatin-1 (Nec-1)	spinal cord injury (SCI)	H2O2 treated primary spinal neurons	Necrostatin-1 (Nec-1) treatment	upregulated	30821011
16664	Mouse	mmu-miR-223-3p	miRNA	PP242	uterine receptivity	epithelial endometrium	PP242 treatment	upregulated	30968418
16665	Mouse	mmu-miR-223-5p	miRNA	IL-4	spinal cord injury (SCI)	Microglia were first isolated from neonate rats	interleukin-4 (IL-4) treatment	downregulated	31799641
16666	Mouse	mmu-miR-223-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	Microglia were first isolated from neonate rats	lipopolysaccharide (LPS) treatment	upregulated	31799641
16667	Mouse	mmu-miR-22-3p	miRNA	light	age-related macular degeneration (AMD)	retinal tissues	"high©\intensity (5,000 lux) blue©\light with the wavelength ranging from 460 to 490 nm exposure"	downregulated	30927257
16668	Mouse	mmu-miR-22-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	Cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	downregulated	32329883
16669	Mouse	mmu-miR-22-3p	miRNA	nine hepatotoxic non-genotoxins (NGTXs)	genotoxicity	liver tissues	nine hepatotoxic non-genotoxins (NGTXs) treatment	downregulated	29777724
16670	Mouse	mmu-miR-22-3p	miRNA	nine hepatotoxic non-genotoxins (NGTXs)	genotoxicity	plasma	nine hepatotoxic non-genotoxins (NGTXs) treatment	upregulated	29777724
16671	Mouse	mmu-miR-22-3p	miRNA	monosodium urate (MSU)	gouty inflammation	mice air pouch synovium	monosodium urate treatment	downregulated	33650318
16672	Mouse	mmu-miR-22-3p	miRNA	calcitonin gene-related peptide (CGRP)	osteogenesis	MC3T3 cells	calcitonin gene-related peptide (CGRP) treatment	"The expression of mm9_circ_009056 was upregulated in the CGRP-induced cells, whereas miR-22-3p was obviously decreased."	29709471
16673	Mouse	mmu-miR-224	miRNA	angiotensin II (Ang II)	cardiac fibrosis	rat cardiac fibroblasts	angiotensin II (Ang II) treatment	upregulated	24649028
16674	Mouse	mmu-miR-224	miRNA	lipopolysaccharide (LPS)	inner ear inflammatory	scala tympani	LPS was injected directly into treatment	upregulated	24470395
16675	Mouse	mmu-miR-224	miRNA	ischemic brain extract (IBE)	ischemic injury	Neuro-2a mouse neuronal cells	IBE treatment	upregulated	24999036
16676	Mouse	mmu-miR-224	miRNA	TGF-¦Â1	ovulation and subsequent embryo development	mouse mural GCs and cumulus-oocyte complexes (COCs)	"by TGF-¦Â1 , which was partially mediated by treatment"	downregulated	24145127
16677	Mouse	mmu-miR-224	miRNA	Src tyrosine kinase (Src)	tumorigenesis	The nontransformed and v-Src-transformed mouse embryonic Cx43Ko brain cells	Src tyrosine kinase (Src) treatment	downregulated	19767772
16678	Mouse	mmu-mir-224-2	miRNA	bone morphogenetic protein 4 (BMP4)	apoptosis	mouse embryonic stem cells (ESCs)	bone morphogenetic protein 4 (BMP4) treatment	upregulated	25476774
16679	Mouse	mmu-miR-224-3p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	Oxygen glucose deprivation treatment	downregulated	31134677
16680	Mouse	mmu-miR-224-5p	miRNA	pyrrolidinedithiocarbamic acid (PDTC)	adipocyte apoptosis	3T3-L1 adipocytes	"pyrrolidinedithiocarbamic acid (PDTC, 60??M) treatment"	downregulated	28488777
16681	Mouse	mmu-miR-224-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	adipocyte apoptosis	3T3-L1 adipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	miRNA-224-5p (miR-224) was upregulated by TNF¦Á exposure	28488777
16682	Mouse	mmu-miR-224-5p	miRNA	pyrrolidinedithiocarbamic acid (PDTC)	apoptosis	3T3-L1 adipocytes	"Pyrrolidinedithiocarbamic acid (PDTC, 60 ?M) treatment"	downregulated	28488777
16683	Mouse	mmu-miR-224-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	3T3-L1 adipocytes	TNF¦Á (20 ng/mL) treatment	upregulated	28488777
16684	Mouse	mmu-mir-227a	miRNA	bone morphogenetic protein 4 (BMP4)	apoptosis	mouse embryonic stem cells (ESCs)	bone morphogenetic protein 4 (BMP4) treatment	upregulated	25476774
16685	Mouse	mmu-miR-23	miRNA	laser	angiogenesis	endothelial cells and highly vascularized tissues	laser treatment	upregulated	21536891
16686	Mouse	mmu-miR-23	miRNA	streptozocin (STZ)	congenital heart disease (CHD)	C57BL/6 mice blood	injection of streptozotocin before mating treatment	dysregulated	27998767
16687	Mouse	mmu-miR-23	miRNA	pioglitazone	macrophage polarization	bone marrow-derived macrophages (BMDM)	pioglitazone (PGZ) treatment	upregulated	31091119
16688	Mouse	mmu-mir-23a	miRNA	bone morphogenetic protein 4 (BMP4)	apoptosis	mouse embryonic stem cells (ESCs)	bone morphogenetic protein 4 (BMP4) treatment	upregulated	25476774
16689	Mouse	mmu-miR-23a	miRNA	conjugated linoleic acid (CLA)	apoptosis	3T3-L1 adipocytes	Conjugated linoleic acids (CLAs) treatment	downregulated	27898407
16690	Mouse	mmu-miR-23a	miRNA	angiotensin II (Ang II)	macrophage polarization	RAW264.7 macrophages	angiotensin II (Ang II) treatment	NRON promotes M2 macrophage polarization and alleviates atrial fibrosis through suppressing exosomal miR-23a derived from atrial myocytes.	33246743
16691	Mouse	mmu-miR-23a	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
16692	Mouse	mmu-miR-23a	miRNA	isoproterenol hydrochloride	cardiac hypertrophy	left ventricular specimens	isoproterenol hydrochloride treatment	upregulated	32023551
16693	Mouse	mmu-miR-23a	miRNA	resistance exercise training	chronic kidney disease (CKD)	CKD mice	muscle overload treatment	upregulated	28400445
16694	Mouse	mmu-miR-23a	miRNA	myostatin	cell differentiation	C2C12 cells	1 ¦Ìg of recombinant myostatin	dysregulated	28691106
16695	Mouse	mmu-miR-23a	miRNA	kainic acid (KA)	epilepsy	hippocampus	kainic acid (KA) treatment	upregulated	31336125
16696	Mouse	mmu-miR-23a	miRNA	pilocarpine	epilepsy	hippocampal tissues	pilocarpine treatment	upregulated	31114485
16697	Mouse	mmu-miR-23a	miRNA	berberine (BBR)	inflammation	LPS-treated RAW 264.7 macrophages	berberine (BBR) treatment	upregulated	30240693
16698	Mouse	mmu-miR-23a	miRNA	endothelin-1 (ET-1)	inflammation	herat of mice	endothelin-1 treatment	upregulated	22084234
16699	Mouse	mmu-miR-23a	miRNA	NQDI1 (apoptosis signal-regulating kinase 1 (ASK1) inhibitor)	inflammation	LPS-treated RAW 264.7 macrophages	NQDI1 treatment	upregulated	30240693
16700	Mouse	mmu-miR-23a	miRNA	phenylephrine (PE)	inflammation	herat of mice	phenylephrine treatment	upregulated	22084234
16701	Mouse	mmu-miR-23a	miRNA	TNF-¦Á and lipopolysaccharide (LPS)	inflammation	RAW 264.7 macrophages	TNF-¦Á and lipopolysaccharide (LPS) treatment	downregulated	30240693
16702	Mouse	mmu-miR-23a	miRNA	chlorogenic acid (CGA)	intestinal diseases	intestinal epithelial cells	chlorogenic acid (CGA) treatment	CGA promotes autophagy and inhibits ST infection through the GAS5/miR-23a/PTEN axis and the p38 MAPK pathway.	33240872
16703	Mouse	mmu-miR-23a	miRNA	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)"	kaposi's sarcoma (KS)	fetal thymocytes of mice	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) treatment"	downregulated	23024791
16704	Mouse	mmu-miR-23a	miRNA	delphinidin	muscle atrophy	dexamethasone-treated C2C12 cells	delphinidin treatment	upregulated	28000445
16705	Mouse	mmu-miR-23a	miRNA	berberine coated mannosylated liposomes (ML-BBR)	osteoclastogenesis	RANKL-stimulated bone marrow-derived monocytes/macrophages (BMMs)	berberine coated mannosylated liposomes (ML-BBR) treatment	upregulated	31261037
16706	Mouse	mmu-miR-23a	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	osteoclastogenesis	bone marrow-derived monocytes/macrophages (BMMs)	RANKL treatment	downregulated	31261037
16707	Mouse	mmu-miR-23a	miRNA	bupivacaine	painful diabetic neuropathy (PDN)	mouse microglia	bupivacaine treatment	Low concentration of Bupivacaine inhibited inflammation and promoted miR-23a expression in mice with painful diabetic neuropathy and in microglia induced by HIGH GLUCOSE.	33144067
16708	Mouse	mmu-miR-23a	miRNA	notoginsenoside R1 (NGR1)	preosteoblast differentiation	MC3T3-E1 cells	Notoginsenoside R1 (NGR1) treatment	upregulated	30831034
16709	Mouse	mmu-miR-23a	miRNA	bovine type II collagen	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLSs)	bovine type II collagen induction	PBMC-derived exos contributes to RA development with the involvement of the miR-23a/MDM2/SIRT6 axis.	33042992
16710	Mouse	mmu-miR-23a	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLSs)	Lipopolysaccharide (LPS) treatment	LncRNA NEAT1 shuttled by PBMC-derived exos promoted FLS proliferation and inflammation through regulating the MDM2/SIRT6 axis.	33042992
16711	Mouse	mmu-miR-23a	miRNA	controlled cortical impact (CCI)	traumatic brain injury (TBI)	mouse brain	controlled cortical impact (CCI)	downregulated	25057207
16712	Mouse	mmu-miR-23a	miRNA	etoposide (VP-16)	traumatic brain injury (TBI)	mouse primary cortical neurons	etoposide treatment	downregulated	31818176
16713	Mouse	mmu-miR-23a	miRNA	hypoxia	tubulointerstitial inflammation	mouse tubular epithelial cells	hypoxia induce	upregulated	30551896
16714	Mouse	mmu-miR-23a	miRNA	hypoxia	tubulointerstitial inflammation	mouse tubular epithelial cells (mTECs)	hypoxia treatment	upregulated	30551896
16715	Mouse	mmu-miR-23a-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	downregulated	32552669
16716	Mouse	mmu-miR-23a-3p	miRNA	hypoxia	oxidative stress	C57/BL6 mice	transient middle cerebral artery occlusion (MCAO) for 1h treatment	upregulated	25280466
16717	Mouse	mmu-miR-23a-3p	miRNA	dexamethasone (DEX)	stress response	mouse C2C12 myotubes	dexamethasone (DEX) treatment	downregulated	31138100
16718	Mouse	mmu-miR-23a-5p	miRNA	high NaCl	hypertonic stress	mouse inner medullary collecting duct cells (mIMCD3)	high NaCl treatment	The downregulated of miR-23a-5p facilitates cellular adaptation to hypertonic stress in mammalian renal cells through modulating HSPA1B.	33206547
16719	Mouse	mmu-miR-23a-5p	miRNA	prostaglandin E2 (PGE2)	liver fibrosis	TGF-¦Â1-treated primary hepatic stellate cells (HSCs)	PGE2 treatment	downregulated	29109031
16720	Mouse	mmu-miR-23a-5p	miRNA	TGF-¦Â1	liver fibrosis	primary hepatic stellate cells (HSCs)	TGF-¦Â1 treatment	upregulated	29109031
16721	Mouse	mmu-miR-23a-5p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	murine RAW264.7 cells	Mycobacterium tuberculosis (M.tb) infection	upregulated	28327409
16722	Mouse	mmu-miR-23a-5p	miRNA	ganoderma lucidum extract (GLE)	hepatocellular carcinoma (HCC)	Hepa 1-6 cells	Ganoderma lucidum extract (GLE) treatment	upregulated	32106374
16723	Mouse	mmu-miR-23b	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	C57BL/6J mice kindey	streptozocin (STZ) treatment	downregulated in peripheral blood	26839366
16724	Mouse	mmu-miR-23b	miRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	mouse aortic vascular smooth muscle cell (VSMC); ApoE-/-?mouse aortas	angiotensin II (Ang II) treatment	The expression of miR-23b was significantly reduced in the aorta during the early onset of AAA in angiotensin II-treated ApoE-/-?mice and in human AAA samples.	33737086
16725	Mouse	mmu-miR-23b	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
16726	Mouse	mmu-miR-23b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	murine alveolar macrophage cell line MH-S	lipopolysaccharide (LPS) treatment	LPS treatment inhibited miR-23b expression	33415668
16727	Mouse	mmu-miR-23b	miRNA	alcohol	alcoholic liver fibrosis (ALF)	mouse primary hepatic stellate cells	alcohol treatment	upregulated	29935035
16728	Mouse	mmu-miR-23b	miRNA	TGF-¦Â1	asthma	mouse airway smooth muscle cells (ASMCs)	TGF-¦Â1 treatment	upregulated	28062322
16729	Mouse	mmu-miR-23b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	kidney tissues of db/db mice	high glucose (HG) treatment	downregulated	26646104
16730	Mouse	mmu-miR-23b	miRNA	myostatin	cell differentiation	C2C12 cells	1 ¦Ìg of recombinant myostatin	dysregulated	28691106
16731	Mouse	mmu-miR-23b	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	MS-1 mouse pancreatic microvascular endothelial cells	TGF-¦Â treatment	upregulated	28338957
16732	Mouse	mmu-miR-23b	miRNA	hemin	neuroinflammation	BV2 cells	hemin treatment	downregulated	31536904
16733	Mouse	mmu-miR-23b	miRNA	bone morphogenetic protein 9 (BMP9)	ossification	C2C12 myoblasts	bone morphogenetic protein 9 (BMP9) treatment	downregulated	26820568
16734	Mouse	mmu-miR-23b	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	MiR-23b was downregulated after LPS treatment.	29922435
16735	Mouse	mmu-miR-23b	miRNA	IL-17	osteoclastogenesis	mouse primary kidney cells	IL-17 treatment	downregulated	22660635
16736	Mouse	mmu-miR-23b	miRNA	lipopolysaccharide (LPS)	osteogenesis	preosteoblast MC3T3-E1 cells	lipopolysaccharide (LPS) treatment	downregulated	26961602
16737	Mouse	mmu-miR-23b	miRNA	soluble egg antigen (SEA)of Schistosoma japonicum	schistosomiasis	mouse hepatocytes (AML12)	SEA treatment	downregulated	29469324
16738	Mouse	mmu-miR-23b	miRNA	H2O2	spinal cord injury (SCI)	BV2 cells	H2O2 treatment	Treatment of BV-2 cells with H2O2 decreased the levels of miR-23b.	31949662
16739	Mouse	mmu-miR-23b	miRNA	retinoic acid (RA)	rhinovirus 1B (RV1B) infection	L929cells	Retinoic acid treatment	downregulated	21642441
16740	Mouse	mmu-miR-23b	miRNA	ovalbumin (OVA)	tolerogenic properties of dendritic cells	Bone marrow-derived dendritic cells (BMDCs)	ovalbumin (OVA) treatment	upregulated	22229716
16741	Mouse	mmu-miR-23b-3p	miRNA	high fat diet (HFD)	insulin resistance (IR)	soleus muscle tissues	high fat diet (HFD) feed	upregulated	31770568
16742	Mouse	mmu-miR-23b-3p	miRNA	pioglitazone	insulin resistance (IR)	soleus muscle tissues	pioglitazone (PGZ) treatment	downregulated	31770568
16743	Mouse	mmu-miR-23b-3p	miRNA	androgen	muscle atrophy	skeletal muscles	androgen treatment	downregulated	31958315
16744	Mouse	mmu-miR-23b-3p	miRNA	paraquat (PQ)	paraquat (PQ)-induced acute lung injury and pulmonary fibrosis	MLE-12 cells	paraquat (PQ) treatment	downregulated	32741895
16745	Mouse	mmu-miR-23b-3p	miRNA	dexamethasone (DEX)	stress response	mouse C2C12 myotubes	dexamethasone (DEX) treatment	downregulated	31138100
16746	Mouse	mmu-miR-23b-5p	miRNA	hypoxia	cardiac hypertrophy	heart tissues	thoracic aortic constriction (TAC) induce	upregulated	31103821
16747	Mouse	mmu-miR-23b-5p	miRNA	Jiang Tang Xiao Ke Granule	diabetes mellitus (DM)	liver tissues	Jiang Tang Xiao Ke treatment	downregulated	32210802
16748	Mouse	mmu-miR-23b-5p	miRNA	cold	obesity	brown adipose tissue (BAT)	cold treatment	downregulated	33015181
16749	Mouse	mmu-miR-24	miRNA	heat stress	ischemia/reperfusion (I/R) injury	the hearts and livers tissue cells	heat-shock (HS)	"Mice subjected to cytoprotective heat-shock (HS) showed a significant increase of miRNA-1, miRNA-21 and miRNA-24 in the heart."	19041309
16750	Mouse	mmu-miR-24	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
16751	Mouse	mmu-miR-24	miRNA	oxygen glucose deprivation (OGD)	acute cerebral infarction	mouse N2A neuroblastoma cells (N2A)	oxygen-and-glucose-deprivation (OGD) treatment	upregulated	24841240
16752	Mouse	mmu-miR-24	miRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	mouse kidney tissues	ischemia/reperfusion (I/R) treatment	upregulated	24854275
16753	Mouse	mmu-miR-24	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver failure (ALF)	mouse	intraperitoneal injection of D-galactosamine/lipopolysaccharide (D-GalN/LPS)	downregulated	29218090
16754	Mouse	mmu-miR-24	miRNA	alcohol	alcoholic liver fibrosis (ALF)	mouse primary hepatic stellate cells	alcohol treatment	upregulated	29935035
16755	Mouse	mmu-miR-24	miRNA	TGF-¦Â	cardiac fibrosis	cardiac fibroblasts (CFs)	TGF-¦Â treatment	upregulated	22260784
16756	Mouse	mmu-miR-24	miRNA	cholesterol	cholesterol-induced inhibition of insulin secretion	MIN6 cells	cholesterol treatment	upregulated	31173188
16757	Mouse	mmu-miR-24	miRNA	brucella.suis	chronic brucella infection	murine bone marrow derived macro- phages (BMDM)	brucella infection	Brucella infection upregulates miR-24.	33108406
16758	Mouse	mmu-miR-24	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
16759	Mouse	mmu-miR-24	miRNA	hyperglycemia	diabetes mellitus (DM)	plasma	hyperglycemia treatment	downregulated	25814526
16760	Mouse	mmu-miR-24	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	downregulated	30095204
16761	Mouse	mmu-miR-24	miRNA	high-fat/high-cholesterol diet or a high-protein diet	dyslipidemia	DO mice	a high-fat/high-cholesterol diet or a high-protein diet for 18 wk	dysregulated	28916633
16762	Mouse	mmu-miR-24	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
16763	Mouse	mmu-miR-24	miRNA	ischemia	myocardial ischaemic injury	mouse cardiomyocytes	ischemic pre-conditioning (IPC) treatment	"IPC-induced miRNAs trigger cardioprotection similar to the delayed phase of IPC, possibly through upregulating eNOS, HSP70, and the HSP70 transcription factor HSF-1."	19213952
16764	Mouse	mmu-miR-24	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver	high fat diet (HFD) feed	microRNA-24 is significantly upregulated in the livers	24677249
16765	Mouse	mmu-miR-24	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	29787826
16766	Mouse	mmu-miR-24	miRNA	acetylcholine (ACh)	peripheral nerve injury (PNI)	hematopoietic stem cells (HSCs)	acetylcholine (ACh) treatment	"The therapeutic agents can thus be targeted to the enzyme protein, its encoding mRNA transcripts, or the regulator microRNA-132, opening new venues for therapeutic interference with multiple nervous and immune system diseases"	22448158
16767	Mouse	mmu-miR-24	miRNA	Staphylococcus aureus	staphylococcus aureus infection	mouse macrophage cell lines	infect with S. aureus treatment	downregulated	28303416
16768	Mouse	mmu-miR-24-1	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	MS-1 mouse pancreatic microvascular endothelial cells	TGF-¦Â treatment	upregulated	28338957
16769	Mouse	mmu-miR-24-1-5p	miRNA	black raspberry (BRB) anthocyanins	colorectal cancer (CRC)	colon tissue of azoxymethane/dextran sulphate sodium-induced mice	black raspberry anthocyanins feed	upregulated	30375302
16770	Mouse	mmu-miR-24-2*	miRNA	H2O2	chronic inflammatory airway diseases	RAW 264.7 cells	H2O2 treatment	downregulated	21350856
16771	Mouse	mmu-miR-24-2-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
16772	Mouse	mmu-miR-24-3p	miRNA	leishmania major (MRHO/IR/75/ER)	cutaneous Leishmaniasis (CL)	RAW264.7 cells	leishmania major (MRHO/IR/75/ER) treatment	miR-24-3p was upregulated in L. major infectioned macrophages.	33082797
16773	Mouse	mmu-miR-24-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse mesangial cells (MCs)	high glucose treatment	downregulated	31680239
16774	Mouse	mmu-miR-24-3p	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	downregulated	31680239
16775	Mouse	mmu-miR-24-3p	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	mouse primary cardiomyocytes	hypoxia induce	downregulated	30622671
16776	Mouse	mmu-miR-24-3p	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	liver tissues	"mice were ischemic for 1 h, and followed by reperfusion for 3, 6, 9, 12 h as needed."	downregulated	31735332
16777	Mouse	mmu-miR-24-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	downregulated	32552669
16778	Mouse	mmu-miR-25	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampal tissues and cells	amyloid ¦Â (A¦Â) peptide fragment 1 to 42 (A¦Â1-42) treatment	upregulated	31144355
16779	Mouse	mmu-miR-25	miRNA	corticosterone	apoptosis	Primary mouse vascular smooth muscle cells (VSMCs)	corticosterone (CORT) treatment	downregulated	30992737
16780	Mouse	mmu-miR-25	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse glomerular mesangial cells (MMCs)	high glucose (HG) treatment	upregulated	27941951
16781	Mouse	mmu-miR-25	miRNA	TGF-¦Â	diabetic nephropathy (DN)	mouse glomerular mesangial cells (MMCs)	TGF-¦Â treatment	upregulated	27941951
16782	Mouse	mmu-miR-25	miRNA	alcohol	fetal alcohol spectrum disorders (FASD)	brain tissues	alcohol exposure	downregulated	23580197
16783	Mouse	mmu-miR-25	miRNA	hypoxia	heart failure (HF)	heart tissues	transverse aortic constriction (TAC) surgery	upregulated	30771307
16784	Mouse	mmu-miR-25	miRNA	oxygen glucose deprivation (OGD)	oxidative stress	mouse retinal pigment epithelium (RPE)	oxygen-and-glucose-deprivation (OGD) treatment	upregulated	29210651
16785	Mouse	mmu-miR-25	miRNA	lipopolysaccharide (LPS)	sepsis and septic shock	blood cells	LPS treatment	upregulated	23395002
16786	Mouse	mmu-miR-25	miRNA	ginkgolide A (GA)	sepsis-induced renal injury	kidney tissues	Ginkgolide A (GA) treatment	The sepsis-induced decrease of miR-25 was enhanced by GA treatment.	33677255
16787	Mouse	mmu-miR-25	miRNA	lipopolysaccharide (LPS)	sepsis-induced renal injury	kidney tissues	lipopolysaccharide (LPS) treatment	The sepsis-induced decrease of miR-25 was enhanced by GA treatment.	33677255
16788	Mouse	mmu-miR-25	miRNA	laminectomy at the Th9 spinal vertebra	spinal cord injury (SCI)	spinal cords	laminectomy at the Th9 spinal vertebra	downregulated in injured spinal cords	28605990
16789	Mouse	mmu-miR-25-3p	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Primarily isolated coronary vascular endothelial cell (CVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31632389
16790	Mouse	mmu-miR-25-3p	miRNA	thrombin	atherosclerosis (AS)	peripheral blood platelet exosomes (PLT-Exo)	thrombin treatment	upregulated	31632389
16791	Mouse	mmu-miR-25-3p	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	primary cardiomyocytes	oxygen glucose deprivation (OGD) treatment	downregulated	32371945
16792	Mouse	mmu-miR-25-5p	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
16793	Mouse	mmu-miR-25-6p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	mice	injected into the tumour centre at a concentration of 150 mg/kg treatment	dysregulated	24896104
16794	Mouse	mmu-miR-26	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	tumorigenesis	brain and liver tissue cells	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) treatment"	downregulated	19270793
16795	Mouse	mmu-miR-26	miRNA	bushen yijing decoction (BSYJ)	systemic sclerosis (SSc)	skin tissues	Bushen Yijing decoction (BSYJ)? treatment	BSYJ-containing rat serum suppressed miR-26a expression	33843426
16796	Mouse	mmu-miR-26a	miRNA	oxytocin (OT)	"1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP)-induced neurotoxicity"	brain tissues	Oxytocin (OXT) treatment	The loss of miR-26a in MPTP mice 568 was fully restored by OXT	32083584
16797	Mouse	mmu-miR-26a	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	kidney tissues	cisplatin treatment	downregulated	31887787
16798	Mouse	mmu-miR-26a	miRNA	H2O2	acute myocardial infarction (AMI)	Neonatal mice cardiomyocytes (NMCMs)	hydrogen peroxid (H2O2) treatment	"forced expression of 2810403D21Rik/Mirf downregulated Mir26a to inhibit autophagy. In contrast, loss of 2810403D21Rik/Mirf resulted in upregulation of Mir26a to promote autophagy and alleviate cardiac injury, which in turn improved cardiac function in MI mice."	31512556
16799	Mouse	mmu-miR-26a	miRNA	H2O2	acute myocardial infarction (AMI)	primary neonatal mice ventricular cardiomyocytes	H2O2 treatment	MIRF contributed to cardiomyocyte apoptosis through modulating Bak1 by regulation of miR-26a.	32464547
16800	Mouse	mmu-miR-26a	miRNA	high fat diet (HFD)	acute myocardial infarction (AMI)	liver tissue	high fat diet (HFD) feed	downregulated	19835573
16801	Mouse	mmu-miR-26a	miRNA	estrogen (ES)	antibody-mediated systemic autoimmunity	B cells	estrogen treatment	downregulated	32265934
16802	Mouse	mmu-miR-26a	miRNA	histone deacetylase inhibitors (HDIs) short-chain fatty acid (SCFA) butyrate	antibody-mediated systemic autoimmunity	B cells	SCFA HDI butyrate treatment	upregulated	32265934
16803	Mouse	mmu-miR-26a	miRNA	borneol	asthma	CD4+ T cells isolated from the spleen of OVA-induced asthma mice	borneol treatment	Borneol inhibited CD4 + T cells infiltration in vivo and proliferation in vitro by downregulating miR-26a and miR-142-3p.	33272847
16804	Mouse	mmu-miR-26a	miRNA	borneol	asthma	CD4 + T cells	borneol treatment	Borneol inhibited CD4 + T cells infiltration in vivo and proliferation in vitro by downregulating miR-26a and miR-142-3p.	33272847
16805	Mouse	mmu-miR-26a	miRNA	ovalbumin (OVA)	asthma	lung tissues	OVA (ovalbumin) treatment	upregulated	31298396
16806	Mouse	mmu-miR-26a	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aortic intima	high fat diet (HFD) feed	downregulated	25801675
16807	Mouse	mmu-miR-26a	miRNA	notoginsenoside R1 (NGR1)	atherosclerosis (AS)	serum;aorta	notoginsenoside R1 (NGR2) treatment	downregulated	24933211
16808	Mouse	mmu-miR-26a	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	C57BL/6 mice lung	bleomycin (BLM) treatment	downregulated	24594795
16809	Mouse	mmu-miR-26a	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	lung tissues; pulmonary fibroblasts	TGF-¦Â1 treatment	downregulated	29952219
16810	Mouse	mmu-miR-26a	miRNA	puromycin	autoimmune glomerulonephritis	mouse podocytes	puromycin treatment	downregulated	25329154
16811	Mouse	mmu-miR-26a	miRNA	bleomycin (BLM)	lung injury	lung tissues	bleomycin (BLM) treatment	Lung miR-26a was significantly decreased 7 days after bleomycin injury.	30024304
16812	Mouse	mmu-miR-26a	miRNA	ginsenoside Rg3	male hypogonadism	MLTC-1 cells	Ginsenoside Rg3 treatment	downregulated	31296984
16813	Mouse	mmu-miR-26a	miRNA	triptolide (TPL)	male hypogonadism	MLTC-1 cells	triptolide (TPL) treatment	upregulated	31296984
16814	Mouse	mmu-miR-26a	miRNA	RANKL (receptor activator of nuclear factor ¦ÊB ligand)	cell differentiation	Murine osteoclasts	RANKL ischemia-reperfusion (I/R) treatment	upregulated	25518928
16815	Mouse	mmu-miR-26a	miRNA	bupivacaine	nerve injury	mouse dorsal root ganglia (DRG) neurons	bupivacaine treatment	downregulated	25808510
16816	Mouse	mmu-miR-26a	miRNA	A23187	nonalcoholic fatty liver disease (NAFLD)	Murine primary hepatocytes (MPHs)	A23187 treatment	upregulated	32567701
16817	Mouse	mmu-miR-26a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) treatment	upregulated	32567701
16818	Mouse	mmu-miR-26a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	"Combining miRNA dot blot array and quantitative PCR, we find that miR-26a is specifically induced by ER stress in liver cells."	32567701
16819	Mouse	mmu-miR-26a	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	Murine primary hepatocytes (MPHs)	oleate acid (OA) treatment	upregulated	32567701
16820	Mouse	mmu-miR-26a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	Murine primary hepatocytes (MPHs)	palmitate acid (PA) treatment	upregulated	32567701
16821	Mouse	mmu-miR-26a	miRNA	thapsigargin (Tg)	nonalcoholic fatty liver disease (NAFLD)	Murine primary hepatocytes (MPHs)	thapsigargin (Tg) treatment	upregulated	32567701
16822	Mouse	mmu-miR-26a	miRNA	tunicamycin (TM)	nonalcoholic fatty liver disease (NAFLD)	Murine primary hepatocytes (MPHs)	tunicamycin (Tu) treatment	upregulated	32567701
16823	Mouse	mmu-miR-26a	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
16824	Mouse	mmu-miR-26a	miRNA	high fat diet (HFD)	obesity	adipose tissue	high fat diet (HFD) feed	downregulated	31488578
16825	Mouse	mmu-miR-26a	miRNA	polyinosinic-polycytidilic acid (Poly(I:C))	orchitis	testicular cells	poly I:C treatment	downregulated	31195953
16826	Mouse	mmu-miR-26a	miRNA	metformin (Met)	pancreatic cancer (PC)	human pancreatic cancer cells	metformin treatment	upregulated	22245693
16827	Mouse	mmu-miR-26a	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	30718039
16828	Mouse	mmu-miR-26a	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
16829	Mouse	mmu-miR-26a	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
16830	Mouse	mmu-miR-26a	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	mouse serum and islets	high fat diet (HFD) feed	downregulated in the serum and islets	29191656
16831	Mouse	mmu-miR-26a	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	serum and islets	high fat diet (HFD) feed	downregulated	29191656
16832	Mouse	mmu-miR-26a	miRNA	whole grain highland barley (WGH)	type 2 diabetes mellitus (T2DM)	liver tissues	whole grain highland barley (WGH) treatment	upregulated	33104141
16833	Mouse	mmu-miR-26a-1	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
16834	Mouse	mmu-miR-26a-5p	miRNA	histone deacetylase inhibitor (HDACi)	B cell differentiation	B cells of C57BL/6J	"stimulated with LPS and IL-4 and treated with HDI (VPA, 500 ?M) or nil for 60 h"	upregulated	28994753
16835	Mouse	mmu-miR-26a-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	MP5 cells	high glucose (HG) treatment	downregulated	32580945
16836	Mouse	mmu-miR-26a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	neuro-2A (N2a) neuroblastoma cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30703362
16837	Mouse	mmu-miR-26a-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	downregulated	31994603
16838	Mouse	mmu-miR-26b	miRNA	isoproterenol	cardiac fibrosis	cardiac tissues; cardiac fibroblasts (CFs)	isoprenaline (ISO) tteatment	downregulated	33209126
16839	Mouse	mmu-miR-26b	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse ventricular cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	31966813
16840	Mouse	mmu-miR-26b	miRNA	pectin (fermented to butyrate in the colon) (FPA)	colon tumorigenesis	colonic stem cells	(fermented to butyrate in the colon) (FPA) treatment	upregulated	26493444
16841	Mouse	mmu-miR-26b	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	plasma and colon tissues	azoxymethane (AOM) treatment	downregulated	30311185
16842	Mouse	mmu-miR-26b	miRNA	lactobacillus acidophilus and bifidobacterium bifidum probiotics	colorectal cancer (CRC)	plasma and colon tissues from azoxymethane (AOM)-treated mice	Lactobacillus acidophilus and Bifidobacterium bifidum probiotics treatment	upregulated	30311185
16843	Mouse	mmu-miR-26b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	brain microvascular endothelial cell (BMEC) of C57BL/6J mice	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	28433650
16844	Mouse	mmu-miR-26b	miRNA	arsenite	liver fibrosis	mouse liver tissues	arsenite exposure	microRNA-26b is the target regulatory point of MALAT1	31513886
16845	Mouse	mmu-miR-26b	miRNA	hypoxia	pulmonary hypertension (PH)	mouse PASMCs	hypoxia treatment	downregulated	28816418
16846	Mouse	mmu-miR-26b	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
16847	Mouse	mmu-miR-26b-3p	miRNA	bone morphogenetic protein 2 (BMP2)	cell differentiation	MC3T3-E1 cells	bone morphogenetic protein 2 (BMP2) treatment	downregulated	29981839
16848	Mouse	mmu-miR-26b-3p	miRNA	bone morphogenetic protein 2 (BMP2)	cell differentiation	MC3T3-E1 cells	bone morphogenetic protein 2 (BMP2) treatment	downregulated	29981839
16849	Mouse	mmu-miR-26b-3p	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	primary cardiomyocytes	oxygen glucose deprivation (OGD) treatment	downregulated	32371945
16850	Mouse	mmu-miR-26b-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal mouse ventricular cardiomyocytes (NMVCs)	angiotensin II (Ang II) treatment	miR-26b-5p was markedly decreased in NMVCs with overexpression of circRNA_000203.	31397837
16851	Mouse	mmu-miR-26b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Mouse N2a neuroblastoma cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31751592
16852	Mouse	mmu-miR-26b-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
16853	Mouse	mmu-miR-26b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	intestinal hypoxia/reoxygenation injury	intestinal mucosa	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	We found that the expression of miR-26b-5p in intestinal mucosa was markedly decreased during I/R injury	33839982
16854	Mouse	mmu-miR-26b-5p	miRNA	methionine-choline-deficient and high-fat diet (MCDHF)	liver fibrosis	PDGFR-¦Â+ cells in the mouse fibrotic liver	methionine-choline-deficient and high-fat (MCDHF) diet treatment	downregulated	30901579
16855	Mouse	mmu-miR-26b-5p	miRNA	hypoxia	phenotypic switching of VSMCs	mouse vascular smooth muscle cells(mVSMCs)	hypoxia treatment	downregulated	28487943
16856	Mouse	mmu-miR-27	miRNA	flavonoid derivative (Fla-CN)	adipogenesis	3T3-L1 cells	Fla-CN treatment	upregulated	28088385
16857	Mouse	mmu-miR-27	miRNA	persimmon tannin	adipogenesis	3T3-L1 preadipocytes	persimmon tannin treatment	upregulated	25510894
16858	Mouse	mmu-miR-27	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	adipogenesis	mouse embryonic fibroblast-derived 3T3-L1 preadipocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	24903074
16859	Mouse	mmu-miR-27	miRNA	laser	angiogenesis	endothelial cells and highly vascularized tissues	laser treatment	upregulated	21536891
16860	Mouse	mmu-miR-27	miRNA	high fat diet (HFD)	atherosclerosis (AS)	ApoE-/- mice serum	high fat diet (HFD) feed	downregulated	30041636
16861	Mouse	mmu-miR-27	miRNA	xanthomicrol	breast cancer	4T1 cells	xanthomicrol treatment	downregulated	33217075
16862	Mouse	mmu-miR-27	miRNA	IL-1¦Â and IFN-¦Ã	cytomegalovirus infection	NIH-3T3;SVEC4-10;C127;TCMK-1 cells;Bone marrow-derived macrophages	cytomegalovirus infection	downregulated	20047990
16863	Mouse	mmu-miR-27	miRNA	granulocyte colony-stimulating factor (CSF3)	cell differentiation	32D.cl3 cell	granulocyte colony-stimulating factor (CSF3) treatment	upregulated	19298589
16864	Mouse	mmu-miR-27	miRNA	cold	metabolic disease	mouse BAT and subcutaneous white adipose tissue (SAT)	cold exposure treatment	downregulated	24238035
16865	Mouse	mmu-miR-27	miRNA	extra-virgin olive oil rich in phenols (H-EVOO)	neuronal function	cortex	H-EVOO treatment	upregulated	26695409
16866	Mouse	mmu-miR-27	miRNA	flavonoid derivative (Fla-CN)	obesity	liver and adipose	Fla-CN treatment	upregulated	26598088
16867	Mouse	mmu-miR-27-3p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	alveolar macrophages (AMs) and the lung tissues	cigarette smoke (CS) exposure	upregulated	29572385
16868	Mouse	mmu-miR-27-3p	miRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	alveolar macrophages (AMs) and the lung tissues	lipopolysaccharide (LPS) treatment	upregulated	29572385
16869	Mouse	mmu-miR-27-3p	miRNA	andrographolide	osteoarthritis (OA)	primary chondrocytes	andrographolide (And) treatment	"miR-27-3p was significant decrease in the mice with OA, but And treatment reversed OA-induced the downregulated of miR-27-3p."	32196852
16870	Mouse	mmu-miR-27a	miRNA	red mud	biological effects of red mud	"CBA/Ca mice liver, spleen, lung, kidney and lymph nodes"	"1, 3, 6 and 24 h after a single intraperitoneal injection of red mud treatment"	"upregulated , but the level and the peak of the alteration differed according to examined tissue"	24425836
16871	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
16872	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	30231673
16873	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse lung tissues	lipopolysaccharide (LPS) treatment	downregulated	31173183
16874	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; bronchoalveolar lavage fluid (BALF); splenocytes	lipopolysaccharide (LPS) treatment	downregulated	31938423
16875	Mouse	mmu-miR-27a	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	LPS-induced mice lung tissues	sevoflurane treatment	upregulated	31173183
16876	Mouse	mmu-miR-27a	miRNA	CoCl2	adipogenesis	murine preadipocyte 3T3-L1 cells	CoCl2 treatment	upregulated	27939617
16877	Mouse	mmu-miR-27a	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 macrophage	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31518965
16878	Mouse	mmu-miR-27a	miRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	Primary vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	upregulated	30654940
16879	Mouse	mmu-miR-27a	miRNA	leucine	cell proliferation	The mouse myoblast cell line C2C12 (CRL-1772)	Leucine treatment	upregulated	23880856
16880	Mouse	mmu-miR-27a	miRNA	resistance exercise training	chronic kidney disease (CKD)	CKD mice	muscle overload treatment	upregulated	28400445
16881	Mouse	mmu-miR-27a	miRNA	curcumin and 3 acetyl-11-keto-¦Â-boswellic acid (AKBA)	colorectal cancer (CRC)	colorectal cancer cells	curcumin and 3 acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment	downregulated	25712055
16882	Mouse	mmu-miR-27a	miRNA	chronic social defeat stress (CSDS)	depression	serum or hippocampus	chronic social defeat stress (CSDS) induce	downregulated	33402173
16883	Mouse	mmu-miR-27a	miRNA	isoliquiritin	depression	hippocampus of LPS-treated mice	isoliquiritin treatment	upregulated	33402173
16884	Mouse	mmu-miR-27a	miRNA	isoliquiritin	depression	hippocampus of chronic social defeat stress (CSDS)-induced mice	isoliquiritin treatment	upregulated	33402173
16885	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	depression	serum or hippocampus	lipopolysaccharide (LPS) treatment	downregulated	33402173
16886	Mouse	mmu-miR-27a	miRNA	high glucose (HG)	diabetic embryopathy	C17.2 mouse neural stem cells	high glucose diet	upregulated	29100869
16887	Mouse	mmu-miR-27a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	murine podocyte cell line	high glucose(30?mM)	upregulated	28277542
16888	Mouse	mmu-miR-27a	miRNA	high-fat/high-cholesterol diet or a high-protein diet	dyslipidemia	DO mice	a high-fat/high-cholesterol diet or a high-protein diet for 18 wk	dysregulated	28916633
16889	Mouse	mmu-miR-27a	miRNA	lithocholic acid (LCA)	glutathione synthesis and antioxidant capacity	Huh-7 cells	lithocholic acid (LCA) treatment	upregulated	25226451
16890	Mouse	mmu-miR-27a	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	AML12 cells	hypoxia induce	upregulated	31485635
16891	Mouse	mmu-miR-27a	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
16892	Mouse	mmu-miR-27a	miRNA	cerasus humilis polyphenol (CHP)	HFD-induced obesity	retroperitoneal white adipocytes	cerasus humilis polyphenol (CHP) treatment	CHP significantly inhibited the expression of miR-27a/b in mice retroperitoneal white adipocytes.	32227855
16893	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	inflammation	BMDMs	lipopolysaccharide (LPS) treatment	downregulated	24835395
16894	Mouse	mmu-miR-27a	miRNA	high fat diet (HFD)	obesity	male C57BL/6 J mice serum	high fat diet (HFD) feed	upregulated	28365247
16895	Mouse	mmu-miR-27a	miRNA	mycobacterium avium subspecies paratuberculosis (MAP)	innate immune response	"RAW264.7 and bone marrow-derived macrophage in vitro, intestine and spleen tissues in vivo"	Mycobacterium avium subspecies paratuberculosis (MAP) infection	downregulated	29375563
16896	Mouse	mmu-miR-27a	miRNA	Pam3Cys-Ser-(Lys)4 [PAM toll-like receptor (TLR)1/2 agonist]	innate immune response	RAW264.7 and bone marrow-derived macrophage	Pam3Cys-Ser-(Lys)4 [PAM toll-like receptor (TLR)1/2 agonist] treatment	downregulated	29375563
16897	Mouse	mmu-miR-27a	miRNA	high fat diet (HFD)	insulin resistance (IR)	"pancreas, liver, and white adipose tissue"	high fat diet (HFD) feed	upregulated	31562809
16898	Mouse	mmu-miR-27a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	insulin resistance (IR)	3T3-L1 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31562809
16899	Mouse	mmu-miR-27a	miRNA	high fructose	lipid metabolism	hepatic tissues	High fructose feed	upregulated	31030166
16900	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	liver damage	liver tissues	lipopolysaccharide (LPS) treatment	"miR-27a was approximately 5-fold downregulated in LPS group, compared with the sham group."	29156532
16901	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS) and paclitaxel	liver damage	liver tissues	lipopolysaccharide (LPS) and paclitaxel treatment	"when paclitaxel was applied to septic mice (paclitaxel + LPS group), an approximately 4-fold increase of miR-27a was observed when compared with LPS group."	29156532
16902	Mouse	mmu-miR-27a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31889412
16903	Mouse	mmu-miR-27a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31889412
16904	Mouse	mmu-miR-27a	miRNA	berberine (BBR)	obesity	3T3-L1 cells	berberine (BBR) treatment	upregulated	27484069
16905	Mouse	mmu-miR-27a	miRNA	high fat diet (HFD)	obesity	"serum, skeletal muscle"	high fat diet (HFD) feed	upregulated	29721071
16906	Mouse	mmu-miR-27a	miRNA	palmitate	obesity	3T3-L1 adipocytes	palmitate treatment	upregulated	29721071
16907	Mouse	mmu-miR-27a	miRNA	persimmon tannin	obesity	3T3-L1 preadipocytes	Persimmon tannin treatment	upregulated	25510894
16908	Mouse	mmu-miR-27a	miRNA	Satb2	osteoblast differentiation and bone formation	bone marrow stromal cells (BMSCs)	Satb2 treatment	downregulated	27142530
16909	Mouse	mmu-miR-27a	miRNA	¦Â-elemene	oxygen-induced retinopathy (OIR)	Retinas tissues	¦Â-elemene treatment	upregulated	30664207
16910	Mouse	mmu-miR-27a	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
16911	Mouse	mmu-miR-27a	miRNA	hypoxia	pulmonary hypertension (PH)	mouse lung tissues	hypoxia treatment	downregulated	24244514
16912	Mouse	mmu-miR-27a	miRNA	Fc	sepsis	LPS induced sepsis mice model	Fc treatment	downregulated	26171875
16913	Mouse	mmu-miR-27a	miRNA	laparotomy and exposure of the junc_x0002_tion between the large and small intestines	sepsis	mouse large and small intestines	laparotomy and exposure of the junc_x0002_tion between the large and small intestines treatment	upregulated	25043848
16914	Mouse	mmu-miR-27a	miRNA	lipopolysaccharide (LPS)	sepsis	liver tissues	lipopolysaccharide (LPS) treatment	downregulated	29156532
16915	Mouse	mmu-miR-27a	miRNA	paclitaxel (PTX)	sepsis	mouse liver tissues	paclitaxel treatment	upregulated	29156532
16916	Mouse	mmu-miR-27a	miRNA	controlled cortical impact (CCI)	traumatic brain injury (TBI)	mouse brain	controlled cortical impact (CCI)	downregulated	25057207
16917	Mouse	mmu-miR-27a	miRNA	high glucose (HG)	type 1 diabetic embryopathy	C17.2 neural stem cells	High-glucose treatment	upregulated	29100869
16918	Mouse	mmu-miR-27a	miRNA	streptozocin (STZ)	type 1 diabetic embryopathy	embryos on embryonic day 8.5 from diabetic dams	streptozotocin (STZ) treatment	upregulated	29100869
16919	Mouse	mmu-miR-27a*	miRNA	H2O2	chronic inflammatory airway diseases	RAW 264.7 cells	H2O2 treatment	downregulated	21350856
16920	Mouse	mmu-miR-27a*	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	RAW264.7 macrophage cells	lipopolysaccharide (LPS) treatment	downregulated	22415194
16921	Mouse	mmu-miR-27a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral infarction (CI)	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Circ_HECTD1 and FSTL1 were highly expressed, and miR-27a-3p was decreased in OGD/R-treated HT22 cells"	33843447
16922	Mouse	mmu-miR-27a-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	4930556M19Rik overexpression slowed HG-induced podocyte injury by downregulating miR-27a-3p and upregulating TIMP3.	32896839
16923	Mouse	mmu-miR-27a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-27a-3p was downregulated in OGD/R-treated HT22 cells	33875617
16924	Mouse	mmu-miR-27a-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	downregulated	32552669
16925	Mouse	mmu-miR-27a-3p	miRNA	leptin	liver fibrosis	primary cultured hepatic stellate cell (HSC)	leptin treatment	upregulated	29548749
16926	Mouse	mmu-miR-27a-3p	miRNA	sevoflurane (SEV)	neurotoxicity	neonatal mice	sevoflurane treatment	upregulated	28881034
16927	Mouse	mmu-miR-27a-3p	miRNA	brown rice	obesity	serum; white adipose tissue (WAT); lleum	brown rice treatment	downregulated	32975270
16928	Mouse	mmu-miR-27a-3p	miRNA	brown rice	obesity	liver tissues	brown rice treatment	upregulated	32975270
16929	Mouse	mmu-miR-27a-3p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
16930	Mouse	mmu-miR-27a-3p	miRNA	whole grain diets	obesity	serum; white adipose tissue (WAT); lleum	whole grain diets treatment	downregulated	32975270
16931	Mouse	mmu-miR-27a-3p	miRNA	whole grain diets	obesity	liver tissues	whole grain diets treatment	upregulated	32975270
16932	Mouse	mmu-miR-27a-3p	miRNA	melatonin	protecting neural stem cells (NSCs) from reactive oxygen species (ROS)	neural stem cells	Melatonin treatment	melatonin appeared to protect NSCs from H2O2-induced ROS by modification of the MEG3/miRNA-27a-3p/MAP2K4 axis.	32599124
16933	Mouse	mmu-miR-27a-3p	miRNA	H2O2	spinal cord injury (SCI)	C8-D1A and C8-B4 cells	hydrogen peroxide (H2O2) treatment	downregulated	30229811
16934	Mouse	mmu-miR-27a-5p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	upregulated	30883703
16935	Mouse	mmu-miR-27a-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	dysregulated	24792623
16936	Mouse	mmu-miR-27b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	bronchoalveolar lavage fluid (BALF)	lipopolysaccharides (LPS) treatment	upregulated	30584668
16937	Mouse	mmu-miR-27b	miRNA	CoCl2	adipogenesis	murine preadipocyte 3T3-L1 cells	CoCl2 treatment	upregulated	27939617
16938	Mouse	mmu-miR-27b	miRNA	alcohol	alcoholic liver fibrosis (ALF)	mouse primary hepatic stellate cells	alcohol treatment	upregulated	29935035
16939	Mouse	mmu-miR-27b	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 macrophage	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31518965
16940	Mouse	mmu-miR-27b	miRNA	palmitic acid (PA)	atrial arrhythmia	atrial cardiomyocytes	palmitic acid (PA) treatment	upregulated	26654778
16941	Mouse	mmu-miR-27b	miRNA	angiotensin II (Ang II)	atrial fibrosis	left atrium	angiotensin II (Ang II) treatment	The expression of miR-27b was significantly reduced after angiotensin II (AngII) infusion.	29671258
16942	Mouse	mmu-miR-27b	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary neonatal mouse cardiomyocytes (NMCMs)	angiotensin II (Ang II) treatment	MiR-27b was downregulated in cardiomyocyte was subjected to AngII treatment.	32439330
16943	Mouse	mmu-miR-27b	miRNA	interleukin-1 receptor antagonist protein (IRAP)	cartilage impact injury	porcine knee joint	Interleukin-1 Receptor Antagonist Protein (IRAP) treatment	upregulated	26521750
16944	Mouse	mmu-miR-27b	miRNA	dexamethasone (DEX)	central fat accumulation	primary SVF cells derived from mouse SAT and VAT	dexamethasone (DEX) treatment	upregulated	25187367
16945	Mouse	mmu-miR-27b	miRNA	IFN-¦Ã	chronic inflammatory diseases	liver epithelial cells	IFN-¦Ãtreatment	downregulated	26631623
16946	Mouse	mmu-miR-27b	miRNA	cerulein	chronic pancreatitis (CP)	pancreas	cerulein treatment	downregulated	29303912
16947	Mouse	mmu-miR-27b	miRNA	streptozocin (STZ)	critical limb ischemia (CLI) in diabetes mellitus	ischemic hindlimbs	streptozotocin (STZ) treatment	downregulated	30972183
16948	Mouse	mmu-miR-27b	miRNA	nitric oxide (NO)	duchenne muscular dystrophy (DMD)	FAP cells	nitric oxide (NO) treatment	upregulated	24170326
16949	Mouse	mmu-miR-27b	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	MS-1 mouse pancreatic microvascular endothelial cells	TGF-¦Â treatment	upregulated	28338957
16950	Mouse	mmu-miR-27b	miRNA	complement C3a	focal segmental glomerulosclerosis (FSGS)	tubular cells	C3a treatment	downregulated	30679767
16951	Mouse	mmu-miR-27b	miRNA	lithocholic acid (LCA)	glutathione synthesis and antioxidant capacity	Huh-7 cells	lithocholic acid (LCA) treatment	upregulated	25226451
16952	Mouse	mmu-miR-27b	miRNA	cerasus humilis polyphenol (CHP)	HFD-induced obesity	retroperitoneal white adipocytes	cerasus humilis polyphenol (CHP) treatment	CHP significantly inhibited the expression of miR-27a/b in mice retroperitoneal white adipocytes.	32227855
16953	Mouse	mmu-miR-27b	miRNA	mycobacterium tuberculosis (Mtb)	innate immune response	murine BMDMs and macrophage-like RAW264.7 cells	Mycobacterium tuberculosis infection	upregulated	29661829
16954	Mouse	mmu-miR-27b	miRNA	high fat diet (HFD)	insulin resistance (IR)	Epididymal white adipose tissue (eWAT)	high fat diet (HFD) feed	upregulated	29455245
16955	Mouse	mmu-miR-27b	miRNA	insulin	insulin resistance (IR)	The mouse 3T3-L1 preadipocyte cell line	insulin treatment	upregulated	29455245
16956	Mouse	mmu-miR-27b	miRNA	ischemic brain extract (IBE)	ischemic injury	Neuro-2a mouse neuronal cells	IBE treatment	downregulated	24999036
16957	Mouse	mmu-miR-27b	miRNA	ionizing radiation (IR)	leukemia	C57BL/6 mouse thymus tissue	IR treatment	downregulated	24974217
16958	Mouse	mmu-miR-27b	miRNA	berberine (BBR)	obesity	3T3-L1 cells	berberine (BBR) treatment	upregulated	27484069
16959	Mouse	mmu-miR-27b	miRNA	persimmon tannin	obesity	3T3-L1 preadipocytes	Persimmon tannin treatment	upregulated	25510894
16960	Mouse	mmu-miR-27b	miRNA	puromycin aminonucleoside (PAN)	podocyte protection	non-human primates (NHPs)	puromycin aminonucleoside (PAN) treatment	"In NHP primary podocyte culture, significant downregulated of miR-27b was observed during treatment of puromycin aminonucleoside (PAN), a classic nephrotoxin"	30429458
16961	Mouse	mmu-miR-27b	miRNA	ginsenoside Rb1	adipogenesis	3T3-L1 cells	Ginsenoside-Rb1? treatment	downregulated	22893262
16962	Mouse	mmu-miR-27b	miRNA	soluble egg antigen (SEA)of Schistosoma japonicum	schistosomiasis	mouse hepatocytes (AML12)	SEA treatment	downregulated	29469324
16963	Mouse	mmu-miR-27b	miRNA	methylglyoxal (MGO)	type 2 diabetes mellitus (T2DM)	mouse bone marrow progenitor cell (BMPCs )	24 h of exposure to methylglyoxal (MGO) or oxidized low-density lipoprotein	downregulated	28698281
16964	Mouse	mmu-miR-27b	miRNA	oxidized low density lipoprotein (ox-LDL)	type 2 diabetes mellitus (T2DM)	mouse bone marrow progenitor cell (BMPCs )	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28698281
16965	Mouse	mmu-miR-27b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	30584668
16966	Mouse	mmu-miR-27b	miRNA	cryptosporidium parvum	cryptosporidium parvum infection	biliary epithelial cells	cryptosporidium parvum? infection	upregulated	22615562
16967	Mouse	mmu-miR-27b*	miRNA	H2O2	chronic inflammatory airway diseases	RAW 264.7 cells	H2O2 treatment	downregulated	21350856
16968	Mouse	mmu-miR-27b-3p	miRNA	reconstituted high-density lipoproteins (rHDL)	diabetes-impaired angiogenesis	diabetic mice HDL fraction	reconstituted high-density lipoproteins (rHDL) treatment	upregulated	30206364
16969	Mouse	mmu-miR-27b-3p	miRNA	reconstituted high-density lipoproteins (rHDL)	diabetes-impaired angiogenesis	diabetic mice plasma	reconstituted high-density lipoproteins (rHDL) treatment	downregulated	30206364
16970	Mouse	mmu-miR-27b-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mice mesangial cells	high glucose (HG) treatment	downregulated	30549040
16971	Mouse	mmu-miR-27b-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mice mesangial cells	high glucose (HG) treatment	miR-27b-3p was decreased in high-glucose-induced mice mesangial cells.	30549040
16972	Mouse	mmu-miR-27b-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	upregulated	30883703
16973	Mouse	mmu-miR-27b-3p	miRNA	Rg3-enhanced red ginseng extract (Rg3E)	endometriosis	endometriosis mose endometriotic tissue	8 weeks of Rg3E treatment	downregulated in endometriotic tissue	29247225
16974	Mouse	mmu-miR-27b-3p	miRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	mice mesangial cells	high glucose (HG) treatment	downregulated	30549040
16975	Mouse	mmu-miR-27b-3p	miRNA	high glucose (HG)	fibrosis	mice mesangial cells	high glucose (HG) treatment	downregulated	30549040
16976	Mouse	mmu-miR-27b-3p	miRNA	leptin	liver fibrosis	primary cultured hepatic stellate cell (HSC)	leptin treatment	upregulated	29548749
16977	Mouse	mmu-miR-27b-3p	miRNA	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2)"	liver damage	bone marrow (BM)-derived macrophage (BMM) of liver injury mouse	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2) treatment"	upregulated	28748390
16978	Mouse	mmu-miR-27b-3p	miRNA	retinoic acid (RA)	myogenic hypoplasia	C2C12 cells	retinoic acid (RA) treatment	upregulated	27889377
16979	Mouse	mmu-miR-27b-3p	miRNA	retinoic acid (RA)	myogenic hypoplasia	C2C12 cells	retinoic acid (RA) treatment	upregulated	27889377
16980	Mouse	mmu-miR-27b-3p	miRNA	high fat diet (HFD)	obesity	mice epididymal white adipose tissue (eWAT)	high fat diet (HFD) feed	upregulated	30778336
16981	Mouse	mmu-miR-27b-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	downregulated	31497013
16982	Mouse	mmu-miR-28	miRNA	H2O2	cardiovascular disease (CVD)	cardiomyocytes	H2O2 treatment	upregulated	26364613
16983	Mouse	mmu-miR-281	miRNA	platelet derived growth factor-BB (PDGF-BB)	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	platelet-derived growth factor (PDGF)-BB treatment	downregulated	29514810
16984	Mouse	mmu-miR-28-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
16985	Mouse	mmu-miR-28-5p	miRNA	dexamethasone (DEX)	stress response	mouse C2C12 myotubes	dexamethasone (DEX) treatment	downregulated	31138100
16986	Mouse	mmu-miR-2861	miRNA	Silica nanoparticles (SiNPs)	apoptosis	Primary mouse spermatocyte cells (GC-2spd)	SiNPs treatment	"SiNPs could cause apoptosis of spermatocyte cells by inhibiting the expression of miRNA-2861, thereby resulting in the upregulation of mRNA expression of fas/fasl/ripk1 and activating the death receptor pathway of spermatocyte cells"	31071558
16987	Mouse	mmu-miR-28a-5p	miRNA	prostaglandin E2 (PGE2)	liver fibrosis	TGF-¦Â1-treated primary hepatic stellate cells (HSCs)	PGE2 treatment	downregulated	29109031
16988	Mouse	mmu-miR-28a-5p	miRNA	TGF-¦Â1	liver fibrosis	primary hepatic stellate cells (HSCs)	TGF-¦Â1 treatment	upregulated	29109031
16989	Mouse	mmu-miR-29	miRNA	bleomycin (BLM)	apoptosis	lung tissues	bleomycin (BLM) treatment	miR-29 was a downstream target gene of Smad3 and negatively regulated by TGF-¦Â/Smad signaling in fibrosis	22395530
16990	Mouse	mmu-miR-29	miRNA	2-acetyl-5-tetrahydroxybutyl imidazole (THI)	breast cancer	C2C12 cells	2-acetyl-5-tetrahydroxybutyl imidazole (THI) treatment	upregulated	24077965
16991	Mouse	mmu-miR-29	miRNA	lipopolysaccharide (LPS)	breast cancer	lung tissues	lipopolysaccharide (LPS) treatment	micro-RNA-29 decreased	22718803
16992	Mouse	mmu-miR-29	miRNA	sphingosine-1-phosphate (S1P)	breast cancer	C2C12 cells	sphingosine-1-phosphate (S1P) treatment	upregulated	24077965
16993	Mouse	mmu-miR-29	miRNA	xanthomicrol	breast cancer	4T1 cells	xanthomicrol treatment	upregulated	33217075
16994	Mouse	mmu-miR-29	miRNA	fundus photocoagulation with a krypton red laser	choroidal neovascularization (CNV)	C57BL/6 mice	fundus photocoagulation with a krypton red laser treatment	downregulated	24886609
16995	Mouse	mmu-miR-29	miRNA	dipeptidyl peptidase-4 (DPP-4)	diabetes mellitus (DM)	Streptozotocin-induced diabetic CD-1 mice	DPP-4 treatment	downregulated	24574044
16996	Mouse	mmu-miR-29	miRNA	IL-6	diabetic cardiomyopathy (DCM)	heart tissues	IL-6 treatment	downregulated	26972749
16997	Mouse	mmu-miR-29	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	Mouse retinal tissues	"Mice in the normal group were raised with normal diet each day, and those in the model group were fed with high-fat diet for 4 weeks. Then, mice in the normal group were intraperitoneally injected with normal saline and those in the model group were injected with 100 mg/kg STZ (streptozocin), for 4 consecutive weeks. treatment"	downregulated	31114980
16998	Mouse	mmu-miR-29	miRNA	2-acetyl-5-tetrahydroxybutyl imidazole (THI)	duchenne muscular dystrophy (DMD)	mdx mice	2-acetyl-5-tetrahydroxybutyl imidazole (THI) treatment	downregulated	24077965
16999	Mouse	mmu-miR-29	miRNA	high fat diet (HFD)	inflammatory response	skeletal muscle of mice	high fat diet (HFD) feed	"miR-375, miR-29, miR-320, miR-103/107 and miR-126, play a crucial role in the regulation of glucose and lipid metabolism through the control of pancreatic islet cell function"	22395471
17000	Mouse	mmu-miR-29	miRNA	baicalin (BAI)	keloids	NIH-3T3 cells	baicalin (BAI) treatment	upregulated	31081145
17001	Mouse	mmu-miR-29	miRNA	estradiol	liver fibrosis	mice liver cells	estradiol treatment	estrogen can inhibit CCl4-induced hepatic injury through the induction of hepatic miR-29.	22393047
17002	Mouse	mmu-miR-29	miRNA	carbon tetrachloride (CCl4)	liver inflammation and fibrogenesis	macrophages	carbon tetrachloride (CCl4) treatment	Both HuR and miR-29s regulate expression of CB1 involved in infiltration of bone marrow monocyte/macrophage in chronic liver injury	31495934
17003	Mouse	mmu-miR-29	miRNA	cyclosporine A (CsA)	nephrotoxicity	mouse kidney	cyclosporine A treatment	upregulated	28414804
17004	Mouse	mmu-miR-29	miRNA	angiotensin II (Ang II)	osteogenesis	heart tissues	angiotensin II (Ang II) treatment	Smad7 plays a protective role in AngII-mediated cardiac remodeling via mechanisms involving the Sp1-TGF-¦Â/Smad3-NF.¦ÊB-miR-29 regulatory network	23894614
17005	Mouse	mmu-miR-29	miRNA	16¦Á-hydroxyestrone (16¦ÁOHE)	pulmonary arterial hypertension (PAH)	lung tissues	16¦Á-hydroxyestrone (16¦ÁOHE) treatment	upregulated	26487756
17006	Mouse	mmu-miR-29	miRNA	ionizing radiation (IR)	pulmonary arterial hypertension (PAH)	fibroblasts	ionizing radiation treatment	miR-29 family members were downregulated in irradiated mouse fibroblasts.	29230533
17007	Mouse	mmu-miR-29	miRNA	synthetic RNA duplexes	lung fibrosis	adult male C56Bl6 mice lung	intravenous injection treatment	upregulated	25239947
17008	Mouse	mmu-miR-29	miRNA	ionizing radiation (IR)	radiation-induced fibrosis (RIF)	mouse fibroblasts	ionizing radiation treatment	downregulated	29230533
17009	Mouse	mmu-miR-29	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	female C57BL/6J mice	high fat diet (HFD) feed	upregulated	24722248
17010	Mouse	mmu-miR-29	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	C2C12 cells	TGF-¦Â treatment	downregulated	21324893
17011	Mouse	mmu-miR-290	miRNA	folate	cervical cancer (CC)	mouse embryonic stem cells (mESCs	folate deficiency induced	downregulated	22828209
17012	Mouse	mmu-miR-290-5p	miRNA	dextran sodium sulfate (DSS)	crohn disease (CD)	mouse peripheral blood CD4+ T cells	dextran sodium salt (DSS) treatment	downregulated	24356810
17013	Mouse	mmu-miR-290-5p	miRNA	propofol (PPF)	sepsis-induced renal injury	kidney tissues	Propofol treatment	Propofol increased miR-290-5p expression and decreased CCL-2 and inflammatory cytokines levels in the kidney for septic mice	30328934
17014	Mouse	mmu-miR-290b-5p	miRNA	embryo	embryo implantation	mouse uterine	embryo implantation	downregulated	29096585
17015	Mouse	mmu-miR-291	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	neuronal cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31658060
17016	Mouse	mmu-miR-2911	miRNA	honeysuckle (HS)	influenza A virus (IAV) infection	mouse mouse peripheral blood and lung	drinking or gavage feeding of HS treatment	upregulated	25287280
17017	Mouse	mmu-miR-291a	miRNA	sodium arsenite (NaAsO2)	arsenic inhibited cellular differentiation	pluripotent P19 mouse embryonal carcinoma cells	sodium arsenite treatment	upregulated	29121352
17018	Mouse	mmu-miR-291a-3p	miRNA	Jiang Tang Xiao Ke Granule	diabetes mellitus (DM)	KKAy diabetic mice	Jiang Tang Xiao Ke Granule treatment	dysregulated	29163176
17019	Mouse	mmu-miR-291b	miRNA	hyaluronic acid 35 (HA35)	alcoholic liver disease (ALD)	C57BL6/J mice pretreate with ethanol Kupffer cells	15?mg/kg HA35 in sterile saline during the last three days of feeding	downregulated	29142263
17020	Mouse	mmu-miR-291b-3p	miRNA	metformin (Met)	fatty liver disease	liver tissues	metformin treatment	downregulated	27013659
17021	Mouse	mmu-miR-291b-3p	miRNA	high fat diet (HFD)	hyperglycemia and insulin resistance	C57BL/6 J mouse liver	high fat diet (HFD) feed	upregulated in liver	28054586
17022	Mouse	mmu-miR-291b-3p	miRNA	H2O2	oxdative stress	EOMA mouse endothelial cells	H2O2 treatment	upregulated	30106126
17023	Mouse	mmu-miR-291b-5p	miRNA	polyphenols	cell function	mice liver cells	Polyphenols treatment	downregulated	22253797
17024	Mouse	mmu-miR-292	miRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	upregulated	25827714
17025	Mouse	mmu-miR-292-3p	miRNA	engrafting E6.5 embryos (wildtype or Gtl2((-/+)))	teratomas	mice	engrafting E6.5 embryos (wildtype or Gtl2((-/+))) treatment	downregulated	25355544
17026	Mouse	mmu-miR-293	miRNA	engrafting E6.5 embryos (wildtype or Gtl2((-/+)))	teratomas	mice	engrafting E6.5 embryos (wildtype or Gtl2((-/+))) treatment	downregulated	25355544
17027	Mouse	mmu-miR-294	miRNA	recombinant Adeno-Cre viruses (AdV-Cre)	lung adenocarcinoma (LUAD)	lung	recombinant Adeno-Cre viruses (AdV-Cre) treatment	upregulated	25359683
17028	Mouse	mmu-miR-294-3p	miRNA	leishmania	leishmaniasis	Bone marrowderived macrophages (BMDMs)	Leishmania infection	upregulated	30949455
17029	Mouse	mmu-miR-295	miRNA	engrafting E6.5 embryos (wildtype or Gtl2((-/+)))	teratomas	mice	engrafting E6.5 embryos (wildtype or Gtl2((-/+))) treatment	downregulated	25355544
17030	Mouse	mmu-miR-295*	miRNA	recombinant Adeno-Cre viruses (AdV-Cre)	lung adenocarcinoma (LUAD)	lung	recombinant Adeno-Cre viruses (AdV-Cre) treatment	upregulated	25359683
17031	Mouse	mmu-miR-295-5p	miRNA	dendrobine	liver damage	liver tissues	dendrobine treatment	Dendrobine downregulated the levels of mmu-miR-295-5p	32633153
17032	Mouse	mmu-miR-296	miRNA	H2O2	Alzheimer's disease (AD)	Primary hippocampal neuron cells	H2O2 treatment	upregulated	24423585
17033	Mouse	mmu-miR-296	miRNA	H2O2	Alzheimer's disease (AD)	senescence accelerated mouse prone 8 (SAMP8) and prone 10 (SAMP10)	"different concentrations (0, 100, 200, 400 and 800 ¦ÌM) of H2O2 treatment"	upregulated	24423585
17034	Mouse	mmu-miR-296	miRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	upregulated	25827714
17035	Mouse	mmu-miR-296	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
17036	Mouse	mmu-miR-296-3p	miRNA	neuregulin-1£¨NRG1£©	cell differentiation	murine embryonic stem cell	neuregulin-1£¨NRG1£©	upregulated	21451102
17037	Mouse	mmu-miR-296-3p	miRNA	destabilization of medial meniscus (DMM)	osteoarthritis (OA)	artilage tissues	destabilization of medial meniscus (DMM) treatment	CircCDH13 contributes to OA pathogenesis by functioning as a sponge of miR-296-3p and regulating the miR-296-3p-PTEN pathway.	33037617
17038	Mouse	mmu-miR-296-5p	miRNA	polyphenols	cell function	mice liver cells	Polyphenols treatment	downregulated	22253797
17039	Mouse	mmu-miR-296-5p	miRNA	barium chloride	muscle injury	C2C12 cells	barium chloride treatment	upregulated	32954829
17040	Mouse	mmu-miR-297	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	serum	lipopolysaccharide (LPS) treatment	downregulated	31945608
17041	Mouse	mmu-miR-297	miRNA	Aluminum oxide nanoparticles (Al2O3 NPs)	pulmonary inflammation	bronchoalveolar lavage fluid (BALF)	aluminum oxide nanoparticles (Al2O3 NPs) treatment	upregulated	31918133
17042	Mouse	mmu-miR-297a	miRNA	hypoxia/reoxygenation (H/R)	myocardial injury	HL-1 cells	hypoxia/reoxygenation (H/R) treatment	1700020I14Rik/miR-297a/CGRP axis suppressed myocardial cell apoptosis in myocardial I/R injury.	32298875
17043	Mouse	mmu-miR-297b-5p	miRNA	palmitic acid (PA)	impaired insulin secretion	¦Â-TC-6 cells	palmitic acid treatment	downregulated	32302972
17044	Mouse	mmu-miR-297b-5p	miRNA	stearic acid	impaired insulin secretion	¦Â-TC-6 cells	stearic acid treatment	downregulated	32302972
17045	Mouse	mmu-miR-297b-5p	miRNA	stearic acid	type 2 diabetes mellitus (T2DM)	¦Â-TC6 cells; mouse islets	stearic acid (C18:0) treatment	miR-297b-5p expression was significantly lower in ¦Â-TC6 cells and mouse islets in stearic acid than in control group	31961705
17046	Mouse	mmu-miR-298	miRNA	hypoxia	ischemic stroke (IS)	N2a cells	hypoxia induce	downregulated	30021197
17047	Mouse	mmu-mir-298-5p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
17048	Mouse	mmu-miR-298-5p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
17049	Mouse	mmu-miR-299-5p	miRNA	starvation	Alzheimer's disease (AD)	Hippocampal	starvation treatment	downregulated	27080144
17050	Mouse	mmu-miR-299a-3p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
17051	Mouse	mmu-miR-29a	miRNA	lipopolysaccharide (LPS)	sepsis	myocardial tissue and heart infiltrating macrophages	lipopolysaccharide (LPS) treatment	downregulated	33840587
17052	Mouse	mmu-miR-29a	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	liver tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-29a was upregulated in the liver tissues of female mice.	32871758
17053	Mouse	mmu-miR-29a	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	spleen tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-29a was downregulated in the spleen tissues of male mice.	32871758
17054	Mouse	mmu-miR-29a	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
17055	Mouse	mmu-miR-29a	miRNA	cholesterol	atherosclerosis (AS)	"apoE-/- mice serum, endothelial, macrophages"	cholesterol feed	downregulated	29074464
17056	Mouse	mmu-miR-29a	miRNA	IFN-¦Á	autocrine and paracrine modulation	thymic epithelial cell	IFN-¦Á treatment	The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-¦Á receptor	22179202
17057	Mouse	mmu-miR-29a	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues of neonatal mice with hyperoxia-induced BPD and mouse alveolar epithelial cells (MLE-12)	hyperoxia induce	upregulated	31892308
17058	Mouse	mmu-miR-29a	miRNA	curcumin (Cur)	cell proliferation	TGF¦Â1-induced NIH-3T3 cells	curcumin (CUR) treatment	upregulated	31710976
17059	Mouse	mmu-miR-29a	miRNA	TGF-¦Â1	cell proliferation	NIH-3T3 cells	Transforming growth factor-¦Â (TGF¦Â1) treatment	downregulated	31710976
17060	Mouse	mmu-miR-29a	miRNA	hyperglycemia	diabetes mellitus (DM)	streptozotocin-induced diabetic mice	hyperglycemia treatment	downregulated	24578127
17061	Mouse	mmu-miR-29a	miRNA	insulin	diabetes mellitus (DM)	mouse cardiomyocyte HL-1 cells	insulin treatment	downregulated	25062042
17062	Mouse	mmu-miR-29a	miRNA	rapamycin	diabetes mellitus (DM)	mouse cardiomyocyte HL-1 cells	rapamycin (Rap) treatment	upregulated	25062042
17063	Mouse	mmu-miR-29a	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	downregulated	21584493
17064	Mouse	mmu-miR-29a	miRNA	notoginsenoside R1 (NGR1)	diabetes mellitus (DM)	TNF-¦Á-treated Min6 cells	Notoginsenoside R1 (NGR1) treatment	upregulated	31184222
17065	Mouse	mmu-miR-29a	miRNA	notoginsenoside R1 (NGR1)	diabetes mellitus (DM)	TNF-¦Á-treated rat primary islets ¦Â cells	Notoginsenoside R1 (NGR1) treatment	upregulated	31184222
17066	Mouse	mmu-miR-29a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetes mellitus (DM)	Min6 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31184222
17067	Mouse	mmu-miR-29a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetes mellitus (DM)	rat primary islets ¦Â cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31184222
17068	Mouse	mmu-miR-29a	miRNA	streptozocin (STZ)	diabetic glomerulopathy	glomeruli tissues	streptozotocin (STZ) treatment	downregulated	30642005
17069	Mouse	mmu-miR-29a	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT	33324218
17070	Mouse	mmu-miR-29a	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina	streptozocin (STZ) treatment	downregulated	32182570
17071	Mouse	mmu-miR-29a	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	diarrhea-predominant irritable bowel syndrome (IBS-D)	Intestinal mucosa	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	Inhibition of miRNA-29a regulates intestinal barrier function in diarrhea-predominant irritable bowel syndrome by upregulating ZO-1 and CLDN1	33093893
17072	Mouse	mmu-miR-29a	miRNA	polychlorinated biphenyls (PCBs)	cell differentiation	P19 mouse embryonal carcinoma cells	polychlorinated biphenyls (PCBs) treatment	upregulated	23443104
17073	Mouse	mmu-miR-29a	miRNA	high glucose (HG)	high glucose (HG)-induced apoptosis	mouse podocytes	high glucose (HG) treatment	The expression of miR-29a was significantly decreased in the HG-treated podocytes.	30575934
17074	Mouse	mmu-miR-29a	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	28811129
17075	Mouse	mmu-miR-29a	miRNA	glucocorticoid (GC)	inflammatory diseases	Murine osteoblast	glucocorticoid treatment	upregulated	24096265
17076	Mouse	mmu-miR-29a	miRNA	saturated fatty acids (SFA) palmitate (PA)	insulin resistance (IR)	L6 GLUT4myc	saturated fatty acids (SFA) palmitate (PA) treatment	upregulated	24844433
17077	Mouse	mmu-miR-29a	miRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 myotubes	palmitic acid (PA) treatment	PA treatment increased the expression of miR-29a in a time-and dose-dependent manner	29693165
17078	Mouse	mmu-miR-29a	miRNA	water avoidance stress (WAS)	irritable bowel syndrome (IBS)	mouse intestinal tissues	water avoidance stress (WAS) induce treatment	upregulated	30827505
17079	Mouse	mmu-miR-29a	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	irritable bowel syndrome with diarrhea (IBS-D)	C57BL/6 strain mouse	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	upregulated	25277410
17080	Mouse	mmu-miR-29a	miRNA	angiotensin II (Ang II)	left ventricular (LV) remodeling	heart sissues	angiotensin II (Ang II) treatment	"MicroRNA-29a attenuates angiotensin-II induced-left ventricular remodeling by inhibiting collagen, TGF-¦Â and SMAD2/3 expression"	32165882
17081	Mouse	mmu-miR-29a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	intraperitoneal injection of CCl4	upregulated	28768954
17082	Mouse	mmu-miR-29a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	CCl? treatment	downregulated	30781750
17083	Mouse	mmu-miR-29a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	hepatic tissue	high fat diet (HFD) feed	downregulated	31652636
17084	Mouse	mmu-miR-29a	miRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	liver tissues	methionine-choline-deficient (MCD) diet feed	downregulated	30917489
17085	Mouse	mmu-miR-29a	miRNA	IL-2¦Â	osteoarthritis (OA)	cultured chondrocyte-like ATDC5 cells	?IL-1¦Â treatment	downregulated	30993110
17086	Mouse	mmu-miR-29a	miRNA	hypoxia	oxidative stress	Primary cultures of neonatal mouse cardiomyocytes	hypoxia induce	downregulated	31885817
17087	Mouse	mmu-miR-29a	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
17088	Mouse	mmu-miR-29a	miRNA	fibroblast growth factor 2 (FGF2)	regeneration of skeletal muscle	Skeletal muscle	fibroblast growth factor-2 (FGF2) treatment	we demonstrate using microRNA (miRNA) profiling in mouse and human myoblasts that the capacity of FGF2 to stimulate myoblast proliferation is mediated by miR-29a. FGF2 induces miR-29a expression and inhibition of miR-29a using pharmacological or genetic deletion decreases myoblast proliferation.	26731484
17089	Mouse	mmu-miR-29a	miRNA	streptozocin (STZ)	renal fibrosis	glomeruli	streptozocin (STZ) treatment	downregulated	27460630
17090	Mouse	mmu-miR-29a	miRNA	retinoic acid (RA)	retinal degenerative diseases	primary retinal progenitor cells (RPCs)	retinoic acid (RA) treatment	upregulated	29670089
17091	Mouse	mmu-miR-29a	miRNA	whole grain highland barley (WGH)	type 2 diabetes mellitus (T2DM)	liver tissues	whole grain highland barley (WGH) treatment	downregulated	33104141
17092	Mouse	mmu-miR-29a	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	mouse	dextran sodium sulfate (DSS) treatment	upregulated	25674218
17093	Mouse	mmu-miR-29a	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon tissues	dextran sulfate sodium treatment	upregulated	29916896
17094	Mouse	mmu-miR-29a-3p	miRNA	angiotensin II (Ang II)	myocardial infarction (MI)	neonatal mouse cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	downregulated	33235025
17095	Mouse	mmu-miR-29a-3p	miRNA	leonurine (LE)	myocardial infarction (MI)	myocardial infarction (MI) mouse heart tissues; angiotensin II (AngII)-treated neonatal mouse cardiac fibroblasts (CFs)	leonurine (LE)?treatment	upregulated	33235025
17096	Mouse	mmu-miR-29a-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	serum	lipopolysaccharide (LPS) treatment	upregulated	32934950
17097	Mouse	mmu-miR-29a-3p	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	MLE-12 cells	hyperoxia treatment	upregulated	33194901
17098	Mouse	mmu-miR-29a-3p	miRNA	hypoxia	cell differentiation	mouse (GL261 and G422) glioma cell lines	hypoxia induce	upregulated	30536597
17099	Mouse	mmu-miR-29a-3p	miRNA	astaxanthin	colorectal cancer (CRC)	Mouse colon cancer cell CT26	astaxanthin (ATX) treatment	upregulated	31263239
17100	Mouse	mmu-miR-29a-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal vessels	streptozotocin (STZ) treatment	downregulated	32343678
17101	Mouse	mmu-miR-29a-3p	miRNA	fluke Fasciola gigantica (FgESPs)	F. gigantica infection	liver tissues	fluke Fasciola gigantica (FgESPs) infection	downregulated	33332355
17102	Mouse	mmu-miR-29a-3p	miRNA	microcystin (MC)	female mammals' reproductive toxicity	mouse granulosa cells (mGCs)	microcystin-LR (MC-LR) for 48 h	dysregulated	28161121
17103	Mouse	mmu-miR-29a-3p	miRNA	paraquat (PQ)	paraquat (PQ)-induced acute lung injury and pulmonary fibrosis	MLE-12 cells	paraquat (PQ) treatment	downregulated	32741895
17104	Mouse	mmu-miR-29a-c	miRNA	angiotensin II (Ang II)	cardiac fibrosis	mouse heart	angiotensin II (Ang II) treatment	downregulated	24569834
17105	Mouse	mmu-miR-29a-c	miRNA	high glucose (HG)	hepatic gluconeogenesis	primary mouse hepatocytes	diet-induced obese (DIO)	"Adenovirus-mediated overexpression of miR-29a-c in the livers of db/m, db/db, and DIO mice decreased fasting blood glucose levels and improved glucose tolerance"	23111009
17106	Mouse	mmu-miR-29b	miRNA	high fat diet (HFD)	apoptosis	apoE knock-out mice	high fat diet (HFD) feed	upregulated	25131924
17107	Mouse	mmu-miR-29b	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
17108	Mouse	mmu-miR-29b	miRNA	ovalbumin (OVA)	asthma	lung and spleen tissues	OVA treatment	downregulated	31412349
17109	Mouse	mmu-miR-29b	miRNA	high fat diet (HFD)	atherosclerosis (AS)	serum	high fat diet (HFD) feed	upregulated	29398368
17110	Mouse	mmu-miR-29b	miRNA	insulin-like growth factor binding protein-related protein 1 (IGFBPrP1)	autophagy	hepatic stellate cell (HSC)	IGFBPrP1 treatment	downregulated	31610195
17111	Mouse	mmu-miR-29b	miRNA	TGF-¦Â	bone marrow transplantation	mouse alveolar macrophage	TGF-¦Â treatment	upregulated	25361568
17112	Mouse	mmu-miR-29b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30233687
17113	Mouse	mmu-miR-29b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-29b in N2a neuroblastoma cells decreased following oxygen and glucose deprivation/reperfusion (OGD/R) treatment	29399057
17114	Mouse	mmu-miR-29b	miRNA	insulin	diabetes mellitus (DM)	mouse cardiomyocyte HL-1 cells	insulin treatment	downregulated	25062042
17115	Mouse	mmu-miR-29b	miRNA	rapamycin	diabetes mellitus (DM)	mouse cardiomyocyte HL-1 cells	rapamycin (Rap) treatment	upregulated	25062042
17116	Mouse	mmu-miR-29b	miRNA	resveratrol	diabetic retinopathy (DR)	retinal cells	resveratrol (Res) treatment	diabetes-induced downregulated expression of miR-29b and upregulated expression of SP1 could be rescued by RSV in vivo and in vitro (P < 005)	27311771
17117	Mouse	mmu-miR-29b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	mouse retion	STZ treatment	downregulated	28246353
17118	Mouse	mmu-miR-29b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal tissues	streptozotocin (STZ) treatment	downregulated	32497630
17119	Mouse	mmu-miR-29b	miRNA	TGF-¦Â	DNA damage	tubular epithelial cells	TGF-¦Â treatment	downregulated	23207693
17120	Mouse	mmu-miR-29b	miRNA	carbon tetrachloride (CCl4)	extracellular-matrix (ECM) and fibril formation	mouse	CCl4 treatment	downregulated	24650661
17121	Mouse	mmu-miR-29b	miRNA	repeated social defeat (RSD)	gastric cancer (GC)	"male C57BL/6 (5 ¨C 6 weeks old) and CD-1 (12 months old, retired breeders) mice"	intruder attack mice treatment	significantly upregulated expression	25317829
17122	Mouse	mmu-miR-29b	miRNA	supercritical-carbon dioxide fluid of C. indicum (CISCFE)	hepatocellular carcinoma (HCC)	mouse H22	CISCFE combined with Bleomycin (BLM) treatment	upregulated	28245556
17123	Mouse	mmu-miR-29b	miRNA	scald	hypertrophic scars (HS)	mouse thermal injury tissue	scald skin treatment	downregulated in thermal injury tissue	28092445
17124	Mouse	mmu-miR-29b	miRNA	ICAT (inhibitor of ¦Â-catenin and T cell factor)	fetal mouse neurogenesis	neural stem cells (NSCs)	ICAT treatment	upregulated	25321480
17125	Mouse	mmu-miR-29b	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	irritable bowel syndrome with diarrhea (IBS-D)	C57BL/6 strain mouse	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	upregulated	25277410
17126	Mouse	mmu-miR-29b	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HT22 cells	oxygen-glucose deprivation (OGD) treatment	Long non-coding RNA H19 inhibition ameliorates oxygen-glucose deprivation-induced cell apoptosis and inflammatory cytokine expression by regulating the microRNA-29b/SIRT1/PGC-1¦Á axis	33313940
17127	Mouse	mmu-miR-29b	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	Mouse microglia cell line (BV-2)	Japanese encephalitis virus (JEV) treatment	significant upregulated of miR-29b in JEV-infected mouse microglial cell line (BV-2) and primary microglial cells.	24236890
17128	Mouse	mmu-miR-29b	miRNA	TGF-¦Â	liver fibrosis	primary hepatic stellate cells (HSCs)	TGF-¦Â treatment	downregulated	32893175
17129	Mouse	mmu-miR-29b	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	precursors	methamphetamine (METH) treatment	downregulated	29516602
17130	Mouse	mmu-miR-29b	miRNA	Japanese encephalitis virus (JEV)	microglial activation	mouse microglial cell line (BV-2)	JEV infected treatment	upregulated	24236890
17131	Mouse	mmu-miR-29b	miRNA	urethane	mouse lung tumors	lung tissues	urethane treatment	downregulated	24361357
17132	Mouse	mmu-miR-29b	miRNA	angiotensin II (Ang II)	muscle atrophy	C2C12 cells	angiotensin II (Ang II) treatment	miR-29b is elevated in AngII-induced muscle atrophy.	33614226
17133	Mouse	mmu-miR-29b	miRNA	high fat diet (HFD)	myocardial dysfunction	heart tissues	high fat diet (HFD) feed	miRNA-29b was reduced in the heart of HF diet-fed mice.	30362585
17134	Mouse	mmu-miR-29b	miRNA	berberine (BBR)	myocardial infarction (MI)	MI C57BL6 mice	berberine (BBR) treatment	upregulated	28722488
17135	Mouse	mmu-miR-29b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuroblastoma (NB)	N2a neuroblastoma cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29399057
17136	Mouse	mmu-miR-29b	miRNA	high fat diet (HFD)	obesity	mouse heart tissues	high fat diet (HFD) feed	downregulated	30362585
17137	Mouse	mmu-miR-29b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoclast differentiation	RAW264.7 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	23078176
17138	Mouse	mmu-miR-29b	miRNA	lipopolysaccharide (LPS)	osteoclastogenesis	mouse tibiae and cultured osteoclasts (OCs)	lipopolysaccharide (LPS) treatment	upregulated	31093317
17139	Mouse	mmu-miR-29b	miRNA	PD fluid (PDF)	peritoneal fibrosis	mosue renal tissue	PDF day 14 treatment	downregulated	25046436
17140	Mouse	mmu-miR-29b	miRNA	platelet derived growth factor-BB (PDGF-BB)	proliferative vascular diseases	primary vascular smooth muscle cells (VSMCs) of aorta in mice	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	30231015
17141	Mouse	mmu-miR-29b	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary artery tissues	hypoxia induce	downregulated	29662889
17142	Mouse	mmu-miR-29b	miRNA	astilbin	lung fibrosis	lung tissues	astilbin induce	"miR©\29b©\2©\5p increased under astilbin treatment compared with BLM treatment, Its expression was inversely correlated with circRNAs©\949 and 662."	31448882
17143	Mouse	mmu-miR-29b	miRNA	angiotensin II (Ang II)	renal inflammation and fibrosis	kidney of mice	angiotensin II (Ang II) treatment	downregulated	23301086
17144	Mouse	mmu-miR-29b	miRNA	di-n-butyl phthalate (DBP)	reproductive toxicity	"The mouse spermatogenesis pathway cell lines, GC-1 spg (catalog number: CRL-2053) and GC-2 spd (catalog number: CRL-2196)"	Di-n-butyl phthalate (DBP) treatment	upregulated	30952838
17145	Mouse	mmu-miR-29b	miRNA	supernatants from silica-treated macrophages	silicosis	NIH-3T3 and MRC-5	supernatants from silica-treated macrophages treatment	downregulated	30090550
17146	Mouse	mmu-miR-29b	miRNA	silica	silicosis	lung tissue	silica treatment	downregulated	30529807
17147	Mouse	mmu-miR-29b	miRNA	brucea javanica oil (BJO)	temporal lobe epilepsy (TLE)	HT22 cells	brucea javanica oil (BJO) treatment	BJO and BE-BJO significantly induced H22 cell apoptosis by upregulating the miRNA-29b gene level.	33341052
17148	Mouse	mmu-miR-29b*	miRNA	H2O2	chronic inflammatory airway diseases	RAW 264.7 cells	H2O2 treatment	downregulated	21350856
17149	Mouse	mmu-miR-29b-1*	miRNA	H1N1 influenza virus	endometriosis and endometrial carcinoma	mouse lung?tissues	H1N1 influenza virus infection	upregulated	24066118
17150	Mouse	mmu-miR-29b-1-5p	miRNA	H2O2	cardiovascular disease (CVD)	cardiomyocytes	hydrogen peroxide (H2O2 ) treatment	The expression of miR-29b-1-5p was upregulated in I/R injured hearts and in hydrogen peroxide treated cardiomyocytes.	29117536
17151	Mouse	mmu-miR-29b-1-5p	miRNA	methimazole (MTZ)	liver damage	liver tissues	methimazole (MTZ) treatment	upregulated	27421576
17152	Mouse	mmu-miR-29b-3	miRNA	cigarette smoke (CS)	renal fibrosis	5/6th partial nephrectomy (PNx) surgery	5/6th partial nephrectomy (PNx) surgery treatment	downregulated in renal and cardiac	27789733
17153	Mouse	mmu-miR-29b-3p	miRNA	"1,2-dichloroethane (1,2-DCE)"	brain edema	brain parenchyma and around the vessels of the cerebral cortex	"1,2-dichloroethane (1,2-DCE) treatment"	upregulated	31734271
17154	Mouse	mmu-miR-29b-3p	miRNA	"1,2-dichloroethane (1,2-DCE)"	brain edema	brain cortex	"1,2-dichloroethane (1,2-DCE) treatment"	upregulated	31734271
17155	Mouse	mmu-miR-29b-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	"?miR-29b-3p-induced inhibition of CFs proliferation and migration and alters the expression levels of miR-29b-3p targeting genes (a-SMA, COL1A1, COL3A1) in vitro."	30967276
17156	Mouse	mmu-miR-29b-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	myocardium of Ang-II-infused migration inhibitory factor (MIF)-KO mice	angiotensin II (Ang II) treatment	downregulated	31175931
17157	Mouse	mmu-miR-29b-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	mouse cardiac fibroblasts (CFs) with MIF overexpression or by treatment with MIF protein	angiotensin II (Ang II) treatment	upregulated	31175931
17158	Mouse	mmu-miR-29b-3p	miRNA	microcystin (MC)	female mammals' reproductive toxicity	mouse granulosa cells (mGCs)	microcystin-LR (MC-LR) for 48 h	dysregulated	28161121
17159	Mouse	mmu-miR-29b-3p	miRNA	luteinising hormone (LH)	functions of Leydig cells	mouse TM3 Leydig cells	luteinising hormone (LH) treatment	upregulated	28762514
17160	Mouse	mmu-miR-29b-3p	miRNA	schistosoma japonicum	liver fibrosis	liver tissues	Schistosoma japonicum infection treatment	downregulated	29091295
17161	Mouse	mmu-miR-29b-3p	miRNA	IL-1¦Â	osteoarthritis (OA)	ATDC5 cells	IL-1¦Â treatment	OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models.	32037864
17162	Mouse	mmu-miR-29b-3p	miRNA	cigarette smoke extract (CSE)	smoke-induced lung injury (SILI)	lung tissues	cigarette smoke extract (CSE) treatment	upregulated	33523607
17163	Mouse	mmu-miR-29b-3p	miRNA	Rb3	smoke-induced lung injury (SILI)	lung tissues	Rb3 treatment	downregulated	33523607
17164	Mouse	mmu-miR-29b-3p	miRNA	luteinising hormone (LH)	steroidogenesis	mouse TM3 Leydig cells	luteinising hormone(LH) treatment	dysregulated	28762514
17165	Mouse	mmu-miR-29b-3p	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon	dextran sodium sulfate (DSS) exposure	TUG1 inhibits IEC apoptosis and UC progression by regulating the balance of HuR and miR-29b-3p.	33047284
17166	Mouse	mmu-miR-29b-3p	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon tissues	dextran sodium sulfate (DSS) treatment	upregulated	33047284
17167	Mouse	mmu-miR-29b-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	YAMC cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TUG1 inhibits IEC apoptosis and UC progression by regulating the balance of HuR and miR-29b-3p	33047284
17168	Mouse	mmu-miR-29b-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	murine colonic epithelial YAMC cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	33047284
17169	Mouse	mmu-miR-29c	miRNA	lipopolysaccharide (LPS)	cardiac fibrosis	C57/Bl6 mice heart	LPS (10 mg/kg)were injected intraperitoneally once a week for 1-4 weeks treatment	downregulated	25233448
17170	Mouse	mmu-miR-29c	miRNA	panax notoginseng saponins (PNS)	cardiovascular disease (CVD)	hearts	Panax notoginseng saponins (PNS) treatment	upregulated	28017695
17171	Mouse	mmu-miR-29c	miRNA	insulin	diabetes mellitus (DM)	mouse cardiomyocyte HL-1 cells	insulin treatment	downregulated	25062042
17172	Mouse	mmu-miR-29c	miRNA	rapamycin	diabetes mellitus (DM)	mouse cardiomyocyte HL-1 cells	rapamycin (Rap) treatment	upregulated	25062042
17173	Mouse	mmu-miR-29c	miRNA	hypoxia inducible factor (HIF)-1	heart failure (HF)	heart tissues	hypoxia-inducible factor (HIF)-1 induce	upregulated	30575439
17174	Mouse	mmu-miR-29c	miRNA	influenza A virus (IAV)	immune response	lung tissues	influenza A virus infection	downregulated	30513647
17175	Mouse	mmu-miR-29c	miRNA	exenatide (EXA)	insulin sensitivity	pancreas	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 375 in the pancreas were significantly increased in HFD control mice.These effects were reversed by treatment with exenatide."	26314504
17176	Mouse	mmu-miR-29c	miRNA	exenatide (EXA)	insulin sensitivity	liver	exenatide treatment	"the levels of miRNA-29c, 124a, and 146a in the liver were significantly increased. These effects were reversed by treatment with exenatide."	26314504
17177	Mouse	mmu-miR-29c	miRNA	exenatide (EXA)	insulin sensitivity	muscle	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 146a in the muscle were significantly increased. These effects were reversed by treatment with exenatide."	26314504
17178	Mouse	mmu-miR-29c	miRNA	exenatide (EXA)	insulin sensitivity	serum	exenatide treatment	"the levels of miRNA-15a, 29c, 124a, and 375 in the serum were significantly decreased. These effects were reversed by treatment with exenatide."	26314504
17179	Mouse	mmu-miR-29c	miRNA	high fat diet (HFD)	insulin sensitivity	pancreas	high fat diet (HFD) feed	upregulated	26314504
17180	Mouse	mmu-miR-29c	miRNA	high fat diet (HFD)	insulin sensitivity	muscle	high fat diet (HFD) feed	upregulated	26314504
17181	Mouse	mmu-miR-29c	miRNA	high fat diet (HFD)	insulin sensitivity	serum	high fat diet (HFD) feed	downregulated	26314504
17182	Mouse	mmu-miR-29c	miRNA	high fat diet (HFD)	insulin sensitivity	liver	high fat diet (HFD) feed	upregulated	26314504
17183	Mouse	mmu-miR-29c	miRNA	panax notoginseng saponins (PNS)	myocardial injury	myocardial injury C57BL/6J mice	panax notoginseng saponins (PNS) treatment	upregulated	28017695
17184	Mouse	mmu-miR-29c	miRNA	isoproterenol	myocardial injury	heart tissues	isoproterenol (ISO) treatment	downregulated	28017695
17185	Mouse	mmu-miR-29c	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra pars compacta (SNpc)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31732967
17186	Mouse	mmu-miR-29c	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra pars compacta (SNpc)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	miR-29c was down-expressed but SP1 was high-expressed in substantia nigra pars compacta (SNpc) of MPTP-induced PD mice.	31732967
17187	Mouse	mmu-miR-29c	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV-2 cells	lipopolysaccharide (LPS) treatment	miR-29c was downregulated in LPS-induced BV-2 cells.	32160394
17188	Mouse	mmu-miR-29c	miRNA	silica	silicosis	lung tissues	silica treatment	downregulated	29216763
17189	Mouse	mmu-miR-29c	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31698040
17190	Mouse	mmu-miR-29c	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
17191	Mouse	mmu-miR-29c*	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
17192	Mouse	mmu-miR-29c-3p	miRNA	ozone (O3)	asthma	CD4+ T cells and ASMCs	ozone treatment	lncRNA PVT1-miR-15a-5p/miR-29c-3p-PI3K-Akt-mTOR axis was implicated in ozone-induced asthma development by promoting ASMC proliferation and Th1/Th2 imbalance	33223504
17193	Mouse	mmu-miR-29c-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	myocardium of Ang-II-infused migration inhibitory factor (MIF)-KO mice	angiotensin II (Ang II) treatment	downregulated	31175931
17194	Mouse	mmu-miR-29c-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	mouse cardiac fibroblasts (CFs) with MIF overexpression or by treatment with MIF protein	angiotensin II (Ang II) treatment	upregulated	31175931
17195	Mouse	mmu-miR-29c-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse primary kidney GEC (C57-6014G) and mouse glomerular mesangial cells (GMC) (SV40 MES 13) and derived exosomes	high glucose (HG) treatment	upregulated	31497190
17196	Mouse	mmu-miR-29c-3p	miRNA	high glucose (HG)	dysfunction of endothelial progenitor cells (EPCs)	EPCs	high glucose (HG) treatment	TUG1 restores high glucose-treated EPC function by regulating miR-29c-3p/PDGF-BB/Wnt signaling.	33059750
17197	Mouse	mmu-miR-29c-3p	miRNA	microcystin (MC)	female mammals' reproductive toxicity	mouse granulosa cells (mGCs)	microcystin-LR (MC-LR) for 48 h	dysregulated	28161121
17198	Mouse	mmu-miR-29c-3p	miRNA	carbon tetrachloride (CCl4)	hepatotoxicity	blood	carbon tetrachloride (CCl4) treatment	upregulated	32528856
17199	Mouse	mmu-miR-29c-3p	miRNA	licochalcone A (LA)	lung cancer	MLE-12 cells	Licochalcone A (lico A) treatment	downregulated	32505917
17200	Mouse	mmu-miR-29c-3p	miRNA	alpinia oxyphylla extract (AOE)	type 2 diabetes mellitus (T2DM)	db-/db- mouse kidney	A. oxyphylla extract (AOE) treatment	downregulated	28249617
17201	Mouse	mmu-miR-30	miRNA	TGF-¦Â	renal fibrosis	podocytes in normal mice	TGF-¦Â treatment	downregulated	24086574
17202	Mouse	mmu-miR-30	miRNA	high fat diet (HFD)	atherosclerosis (AS)	endothelial cell	high fat diet (HFD) feed	upregulated	26488467
17203	Mouse	mmu-miR-30	miRNA	melatonin	breast cancer	mouse breast cancer cell lines 4T1 and MA-891	Melatonin treatment	upregulated	31955008
17204	Mouse	mmu-miR-30	miRNA	melatonin	breast cancer	?4T1 cells; 891 cells	Melatonin treatment	Melatonin regulated breast cancer progression by the lnc010561/miR-30/FKBP3 axis.	31955008
17205	Mouse	mmu-miR-30	miRNA	streptozocin (STZ)	congenital heart disease (CHD)	C57BL/6 mice blood	injection of streptozotocin before mating treatment	dysregulated	27998767
17206	Mouse	mmu-miR-30	miRNA	chronic social defeat stress (CSDS)	depression	neurogenic dentate gyrus (DG) region	chronic social defeat stress (CSDS) induce	downregulated	31440139
17207	Mouse	mmu-miR-30	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	hepatocyte	TGF-¦Â1 treatment	downregulated	22227196
17208	Mouse	mmu-miR-30	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	CCl4 treatment	downregulated	25912033
17209	Mouse	mmu-miR-30	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated in	28592847
17210	Mouse	mmu-miR-30	miRNA	TGF-¦Â	liver fibrosis	liver	TGF-¦Â treatment	downregulated	26120970
17211	Mouse	mmu-miR-30	miRNA	cyclosporine A (CsA)	nephrotoxicity	mouse kidney	cyclosporine A treatment	upregulated	28414804
17212	Mouse	mmu-miR-30	miRNA	extra-virgin olive oil rich in phenols (H-EVOO)	neuronal function	cortex	H-EVOO treatment	upregulated	26695409
17213	Mouse	mmu-miR-30	miRNA	angiotensin II (Ang II)	podocyte injury	mouse podocytes	angiotensin II (Ang II) treatment	downregulated in the podocytes	28540409
17214	Mouse	mmu-miR-30	miRNA	lipopolysaccharide (LPS)	podocytopathy	podocytes	lipopolysaccharide (LPS) treatment	downregulated	31127093
17215	Mouse	mmu-miR-300	miRNA	lipopolysaccharide (LPS)	inflammation	mouse blood	lipopolysaccharide (LPS) treatment	upregulated in the blood samples	29441890
17216	Mouse	mmu-miR-300	miRNA	dopamine	neurodegeneration (ND)	N2a cells	dopamine treatment	downregulated	30738894
17217	Mouse	mmu-miR-300	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	upregulated	25672270
17218	Mouse	mmu-miR-301a	miRNA	notoginsenoside R1 (NGR1)	ankylosing spondylitis (AS)	ATDC5 cells	Notoginsenoside R1 (NG-R1) treatment	Notoginsenoside R1 suppresses miR-301a via NF-¦ÊB pathway in lipopolysaccharide-treated ATDC5 cells.	31837326
17219	Mouse	mmu-miR-301a	miRNA	lipopolysaccharide (LPS)	inflammation	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	31837326
17220	Mouse	mmu-miR-301a	miRNA	notoginsenoside R1 (NGR1)	inflammation	LPS-treated ATDC5 cells	Notoginsenoside R1 (NG-R1) treatment	downregulated	31837326
17221	Mouse	mmu-miR-301a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	CD4+ T cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26338824
17222	Mouse	mmu-miR-301a	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	mouse hippocampal neuronal cell line HT22	JEV (strain GP78) infection	upregulated	28196914
17223	Mouse	mmu-miR-301a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	murine chondrogenic ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	31966769
17224	Mouse	mmu-miR-301a	miRNA	anandamide (AEA)	pro-inflammatory activity	mouse	anandamide treatment	AEA differentil regulate the expression of miRNA	24699635
17225	Mouse	mmu-miR-301a	miRNA	TGF-¦Â	lung fibrosis	mouse embryonic fibroblasts (MEFs)	TGF-¦Â treatment	upregulated	32585629
17226	Mouse	mmu-miR-301a	miRNA	Japanese encephalitis virus (JEV)	viral-induced neuroinflammation	BV2 cells and primary microglial cells were isolated from postnatal day 0 (P0) to P2 BALB/c mouse pups	Japanese encephalitis virus (JEV) infection	upregulated	31527198
17227	Mouse	mmu-miR-301a-3p	miRNA	electroacupuncture (EA)	electroacupuncture (EA)	CD4 T cells	electroacupuncture (EA) treatment	upregulated	32026263
17228	Mouse	mmu-miR-301a-3p	miRNA	high glucose (HG)	glomerulonephritis	Mice MPC5 podocytes	high glucose (HG) treatment	downregulated	29434693
17229	Mouse	mmu-miR-301a-3p	miRNA	brucella.suis	innate immune response	RAW264.7 cells	brucella.suis infection	upregulated	29387067
17230	Mouse	mmu-miR-301b-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	upregulated	30453253
17231	Mouse	mmu-miR-301b-3p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	dopaminergic neuron	6-hydroxydopamine (6-OHDA) treatment	LncRNA H19 diminishes dopaminergic neuron loss by mediating microRNA-301b-3p in Parkinson's disease via the HPRT1-mediated Wnt/¦Â-catenin signaling pathway.	32434961
17232	Mouse	mmu-miR-302	miRNA	Streptococcus pneumoniae (Sp)	bacterial pneumonia	alveolar epithelial cells (AEC)	Streptococcus pneumoniae (Sp) infection treatment	upregulated	30971494
17233	Mouse	mmu-miR-302	miRNA	alpinetin (ALP)	colitis	CD4+ T cells and colons of dextran sulfate sodium (DSS)-induced colitis mice	alpinetin (ALP) treatment	upregulated	30166541
17234	Mouse	mmu-miR-302a	miRNA	folate	cervical cancer (CC)	mouse embryonic stem cells (mESCs	folate deficiency induced	downregulated	22828209
17235	Mouse	mmu-miR-302a	miRNA	folate	apoptosis	mouse embryonic stem cells	folate treatment	MicroRNA-302a is involved in folate deficiency-induced apoptosis through the AKT-FOXO1-BIM pathway in mouse embryonic stem cells	33372619
17236	Mouse	mmu-miR-302a	miRNA	engrafting E6.5 embryos (wildtype or Gtl2((-/+)))	teratomas	mice	engrafting E6.5 embryos (wildtype or Gtl2((-/+))) treatment	downregulated	25355544
17237	Mouse	mmu-miR-302a-3p	miRNA	high glucagon	diabetes mellitus (DM)	primary hepatocytes	high glucagon treatment	Hmigh glucagon treatment could time-dependently decrease the mRNA expression of miR-302a-3p.	30260029
17238	Mouse	mmu-miR-302a-3p	miRNA	high glucagon	hepatic gluconeogenesis	mouse primary hepatocytes	high glucagon treatment	"MEG3 served as a competing endogenous RNA (ceRNA) to upregulate CRTC2 by targeting miR-302a-3p in primary hepatocytes, thereby increasing PGC-1¦Á-PEPCK/G6Pc."	30260029
17239	Mouse	mmu-miR-302a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"The SNHG15 and STAT1/NF-¦ÊB pathways were both distinctly upregulated, while miR-302a-3p was notably downregulated in the ischemia cortex"	33779086
17240	Mouse	mmu-miR-302a-3p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
17241	Mouse	mmu-miR-302a-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	mouse cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	MiR-302a-3p expression was significantly upregulated in mice subjected to MIRI and in H/R-treated mouse cardiomyocytes.	32866521
17242	Mouse	mmu-miR-302b	miRNA	monosodium urate (MSU)	gouty arthritis	mouse air membranes	monosodium urate (MSU) crystal treatment	upregulated	29482609
17243	Mouse	mmu-miR-302b	miRNA	pseudomonas aeruginosa (PA)	respiratory bacterial infection	alveolar macrophages (AMs) were obtained from bronchoalveolar lavage (BAL) of C57BL/6 mice	Gram-negative bacterium Pseudomonas aeruginosa infection treatment	upregulated	24717937
17244	Mouse	mmu-miR-302b-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	miR-302b-5p expression was remarkably decreased after the treatment of MPTP in comparison with Normal tissues.	32474958
17245	Mouse	mmu-miR-302c	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	Induction of E6AP by microRNA-302c dysregulation inhibits TGF-¦Â-dependent fibrogenesis in hepatic stellate cells.	33037648
17246	Mouse	mmu-miR-302c	miRNA	engrafting E6.5 embryos (wildtype or Gtl2((-/+)))	teratomas	mice	engrafting E6.5 embryos (wildtype or Gtl2((-/+))) treatment	downregulated	25355544
17247	Mouse	mmu-miR-302d-3p	miRNA	leishmania	leishmaniasis	Bone marrowderived macrophages (BMDMs)	Leishmania infection	upregulated	30949455
17248	Mouse	mmu-miR-302e	miRNA	lipopolysaccharide (LPS)	infantile pneumonia (IP)	Lung tissue from 1 week old C57BL/6 mice	lipopolysaccharides (LPS) treatment	downregulated	31115487
17249	Mouse	mmu-miR-3061-3p	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
17250	Mouse	mmu-miR-3068	miRNA	walnut	colorectal cancer (CRC)	colorectal tumor tissue	walnut-containing diet treatment	downregulated	25882694
17251	Mouse	mmu-miR-3070-2-3p	miRNA	high fat diet (HFD)	compensatory hyperplasia of islets	hepatocellular extracellular vesicles (EVs)	?high-fat diet (HFD) feed treatment	downregulated	31284955
17252	Mouse	mmu-miR-3075-5p	miRNA	vorinostat (SAHA)	atherosclerosis (AS)	aortic tissues	vorinostat treatment	downregulated	30284929
17253	Mouse	mmu-miR-3077	miRNA	177lu-octreotate	neuroendocrine tumors	Female BALB/c nude mice	"inject 1.3, 3.6, 14, 45, or 140 MBq 177Lu-octreotate treatment"	"miR-194, miR-107, miR-3090, and miR-3077 were commonly regulated"	25386939
17254	Mouse	mmu-miR-3082-5p	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	bordetella pertussis infection	Pertussis Toxin (PTX) treated mice CD4+ T cells	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	31681214
17255	Mouse	mmu-miR-3082-5p	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
17256	Mouse	mmu-miR-3090	miRNA	177lu-octreotate	neuroendocrine tumors	Female BALB/c nude mice	"inject 1.3, 3.6, 14, 45, or 140 MBq 177Lu-octreotate treatment"	"miR-194, miR-107, miR-3090, and miR-3077 were commonly regulated"	25386939
17257	Mouse	mmu-miR-3090-5p	miRNA	poly(ethylenimine) (PEI)	cell death	MEF cells	poly(ethylenimine) (PEI) treatment	upregulated	26158199
17258	Mouse	mmu-miR-30a	miRNA	coxsackievirus B3 (CVB3)	acute viral myocarditis (VM)	mouse heart tissues	Coxsackievirus B3 (CVB3) infection	upregulated	30915768
17259	Mouse	mmu-miR-30a	miRNA	alcohol	alcoholic hepatitis (AH)	sera	alcohol exposure	upregulated	26264599
17260	Mouse	mmu-miR-30a	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	downregulated	31748850
17261	Mouse	mmu-miR-30a	miRNA	diethylstilbestrol (DES)	diethylstilbestrol (DES) triggers thymic atrophy	mouse thymocytes	Diethylstilbestrol (DES) treatment	downregulated	30153466
17262	Mouse	mmu-miR-30a	miRNA	hypoxia	ischemic brain injury	Neuronal Cells	middle cerebral artery occlusion (MCAO) treatment	downregulated	28854438
17263	Mouse	mmu-miR-30a	miRNA	hypoxia	ischemic stroke (IS)	brain tissues	6 h middle cerebral artery occlusion without reperfusion treatment	upregulation in the brain of mice	24771295
17264	Mouse	mmu-miR-30a	miRNA	hypoxia	ischemic stroke (IS)	brain and N2A cells	peri-infarct region of mice with 1 h MCAO/24 h reperfusion and in N2A cells after 1 h OGD/6-48 h reoxygenation treatment	significantly downregulated	24771295
17265	Mouse	mmu-miR-30a	miRNA	angiotensin-(1-7)	mitochondrial fission	HG-induced podocytes	angiotensin-(1-7) treatment	upregulated	27789249
17266	Mouse	mmu-miR-30a	miRNA	oxygen glucose deprivation (OGD)	neural ischemic injury	cortical neurons	oxygen-glucose deprivation (OGD) treatment	downregulated	26301516
17267	Mouse	mmu-miR-30a	miRNA	RANKL (receptor activator of nuclear factor ¦ÊB ligand)	osteoclastogenesis	mouse bone marrow-derived monocytes (BMMs)	30 ng/ml M-CSF and 100 ng/ml RANKL for 4 days treatment	downregulated	29312525
17268	Mouse	mmu-miR-30a	miRNA	Vaccination during Crisis of Plasmodium chabaudi Blood-Stage Malaria	plasmodium chabaudi infection	Balb/c Mice liver	infect with Vaccination treatment	downregulated in the Liver	28123381
17269	Mouse	mmu-miR-30a	miRNA	radiation	radiation-induced fibrosis (RIF)	"CH3 mice muscle, skin, and subcutaneous tissue"	the right hind legs of 9-week old CH3 mice by a single-fraction dose of irradiation to 35 Gy treatment	dysregulated	24986745
17270	Mouse	mmu-miR-30a	miRNA	ischemia	renal fibrosis	Renal tissues	the left ureter was ligated at the lower pole level of kidney for 7 days	downregulated	28285987
17271	Mouse	mmu-miR-30a*	miRNA	high fat diet (HFD)	chondrogenesis	white adipose tissues	high fat diet (HFD) feed	downregulated	22496873
17272	Mouse	mmu-miR-30a-3p	miRNA	deoxycorticosterone acetate-salt hypertension	hypertensive nephropathy (HN)	kidney tissues	deoxycorticosterone acetate-salt hypertension treatment	downregulated	31782248
17273	Mouse	mmu-miR-30a-3p	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	upregulated	19091803
17274	Mouse	mmu-miR-30a-5p	miRNA	alcohol	alcohol toxicity	male C57BL/6J mice	mimics binge alcohol drinking in humans treatment	upregulated	25330738
17275	Mouse	mmu-miR-30a-5p	miRNA	pentachlorophenol (PCP)	developmental toxicity	pregnancy ICR mice placental chorionic villi	Pentachlorophenol (PCP) exposure treatment	downregulated	30597782
17276	Mouse	mmu-miR-30a-5p	miRNA	pilocarpine	epilepsy	male NMRI mice	inject intraperitoneally with pilocarpine treatment	downregulated	25078263
17277	Mouse	mmu-miR-30a-5p	miRNA	alcohol	excessive alcohol intake	medial PFC (mPFC)	alcohol exposure	upregulated	25330738
17278	Mouse	mmu-miR-30a-5p	miRNA	high fat diet (HFD)	obesity	adipose tissue macrophages (ATMs)	high fat diet (HFD) feed	downregulated	29899524
17279	Mouse	mmu-miR-30a-5p	miRNA	Co-Cr-Mo metal particles (CoPs)	particle-induced osteolysis (PIO)	MC3T3-E1 cells	Co-Cr-Mo metal particles (CoPs) treatment	"CoPs could up-regulate TSIX level, down-regulate miR-30a-5p expression."	29260905
17280	Mouse	mmu-miR-30a-5p	miRNA	Co-Cr-Mo metal particles (CoPs)	particle-induced osteolysis (PIO)	MC3T3-E1 cells	Co-Cr-Mo metal particles (CoPs) treatment	downregulated	29260905
17281	Mouse	mmu-miR-30a-5p	miRNA	pentachlorophenol (PCP)	pentachlorophenol (PCP) developmental toxicity	pregnancy ICR mice placenta	Pentachlorophenol (PCP) treatment	downregulated	30597782
17282	Mouse	mmu-miR-30a-5p	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	heart tissues	coxsackievirus B3 (CVB3) treatment	miR-30a-5p was found to be highly expressed in VMC mice.	33416455
17283	Mouse	mmu-miR-30b	miRNA	alcohol	alcoholic hepatitis (AH)	sera	alcohol exposure	upregulated	26264599
17284	Mouse	mmu-miR-30b	miRNA	metformin (Met)	anti-cancer therapy	mice with 4-months-exposure of smoke	oral metformin was used at a dose of 800 mg/kg diet treatment	upregulated	24683044
17285	Mouse	mmu-miR-30b	miRNA	fish oil	brown adipose tissue thermogenesis	brown adipocytes	fish oil treatment	upregulated	27489163
17286	Mouse	mmu-miR-30b	miRNA	TGF-¦Â1	chondrocyte differentiation	mouse embryo-derived stem cells C3H10T1/2	TGF-¦Â3 treatment	downregulated	29285169
17287	Mouse	mmu-miR-30b	miRNA	mechanical unloading	disuse osteoporosis (DOP)	MC3T3-E1 cells	Mechanical unloading treatment	upregulated	31757419
17288	Mouse	mmu-miR-30b	miRNA	high glucose (HG)	neural tube defects (NTDs)	neural stem cells (NSCs) isolated from the forebrain of diabetic pregnancy embryos	exposed to low or high glucose or hypoxia	upregulated	28798665
17289	Mouse	mmu-miR-30b	miRNA	hypoxia	neural tube defects (NTDs)	neural stem cells (NSCs) isolated from the forebrain of diabetic pregnancy embryos	exposed to low or high glucose or hypoxia	upregulated	28798665
17290	Mouse	mmu-miR-30b	miRNA	low glucose (LG)	neural tube defects (NTDs)	neural stem cells (NSCs) isolated from the forebrain of diabetic pregnancy embryos	exposed to low or high glucose or hypoxia	upregulated	28798665
17291	Mouse	mmu-miR-30b	miRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	mouse aortic endothelial cells (MAECs)	chronic intermittent hypoxia (CIH) treatment	upregulated	29108914
17292	Mouse	mmu-miR-30b	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	ADTC5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	27941314
17293	Mouse	mmu-miR-30b	miRNA	IL-1¦Â	¦Â-cell dysfunction	MIN6 cells	IL-1¦Â treatment	upregulated	26367486
17294	Mouse	mmu-miR-30b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	HL-1 cells	angiotensin II (Ang II) treatment	downregulated	33130312
17295	Mouse	mmu-miR-30b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	The cardiomyocyte-like HL-1 cell lines	angiotensin II (Ang II) treatment	downregulated	33130312
17296	Mouse	mmu-miR-30b-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	"lung tissue, serum, and bronchoalveolar lavage fluid of mice"	lipopolysaccharide (LPS) treatment	downregulated	30600796
17297	Mouse	mmu-miR-30b-5p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	Cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	downregulated	32329883
17298	Mouse	mmu-miR-30b-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	renal tissues	high glucose (HG) treatment	"In high glucose induced HK-2 cells, expression levels of miR-30b-5p and E-cadherin were decreased, while SNAI1, a-SMA and Vimentin were increased."	33383483
17299	Mouse	mmu-miR-30c	miRNA	adherent-invasive escherichia coli (AIEC)	crohn disease (CD)	mouse enterocytes	adherent invasive escherichia coli (AIEC) treatment	upregulated	24148619
17300	Mouse	mmu-miR-30c	miRNA	mechanical unloading	disuse osteoporosis (DOP)	MC3T3-E1 cells	Mechanical unloading treatment	upregulated	31757419
17301	Mouse	mmu-miR-30c-1*	miRNA	polyphenols	cell function	mice liver cells	Polyphenols treatment	downregulated	22253797
17302	Mouse	mmu-miR-30c-1*	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
17303	Mouse	mmu-miR-30c-1-3p	miRNA	benzo(a)pyrene (BaP)	lung fibrosis	lung tissues	benzo(a)pyrene (BaP) exposure	downregulated	30543962
17304	Mouse	mmu-miR-30c-1-3p	miRNA	benzo(a)pyrene (BaP)	lung fibrosis	lung tissues	benzo(a)pyrene (BaP) exposure	downregulated	30543962
17305	Mouse	mmu-miR-30c-1-3p	miRNA	sulfur dioxide (SO2)	lung fibrosis	lung tissues	SO2 treatment	downregulated	30543962
17306	Mouse	mmu-miR-30c-1-3p	miRNA	sulfur dioxide (SO2)	lung fibrosis	lung tissues	sulfur dioxide (SO2)?exposure treatment	downregulated	30543962
17307	Mouse	mmu-miR-30c-2-3p	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	upregulated	32337768
17308	Mouse	mmu-miR-30c-5p	miRNA	cocaine	cocaine abuse-related cardiovascular disease	aortic smooth muscle cells	Cocaine treatment	upregulated	29483230
17309	Mouse	mmu-miR-30c-5p	miRNA	cryptococcosis	cryptococcal meningitis	BV2 cells	cryptococcosis infection	downregulated	31958475
17310	Mouse	mmu-miR-30c-5p	miRNA	high fat diet (HFD)	obesity	adipose tissue macrophages (ATMs)	high fat diet (HFD) feed	downregulated	29899524
17311	Mouse	mmu-miR-30d	miRNA	mechanical unloading	disuse osteoporosis (DOP)	MC3T3-E1 cells	Mechanical unloading treatment	upregulated	31757419
17312	Mouse	mmu-miR-30d	miRNA	lipopolysaccharide (LPS)	epithelial-mesenchymal transition (EMT)	hippocampus	lipopolysaccharide (LPS) treatment	LPS administration in mice significantly decreased miR-30d expression in the hippocampus.	29260931
17313	Mouse	mmu-miR-30D	miRNA	testosterone	prostate cancer	female mouse liver	Testosterone treatment	"upregulation of the 6 miRNAs miR-22, miR-690, miR-122, let-7A, miR-30D and let-7D"	20600201
17314	Mouse	mmu-miR-30d	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	islet ¦Â-cell	streptozotocin (STZ) treatment	downregulated	29663360
17315	Mouse	mmu-miR-30d-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Mouse N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33833132
17316	Mouse	mmu-miR-30d-5p	miRNA	FTY720-mitoxy	parkinson's disease (PD)	dopaminergic MN16D cells	FTY720-Mitoxy treatment	upregulated	30359694
17317	Mouse	mmu-miR-30d-5p	miRNA	FTY720-Mitoxy	parkinson's disease (PD)	MN9D cells	FTY720-Mitoxy treatment	upregulated	30359694
17318	Mouse	mmu-miR-30e	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
17319	Mouse	mmu-miR-30e	miRNA	mechanical unloading	disuse osteoporosis (DOP)	MC3T3-E1 cells	Mechanical unloading treatment	upregulated	31757419
17320	Mouse	mmu-miR-30e	miRNA	TGF-¦Â1	kidney fibrosis	tubular epithelial cell	TGF-¦Â1 treatment	downregulated	23515048
17321	Mouse	mmu-miR-30e	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	mouse substantia nigra pars compacta (SNpc)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated in substantia nigra pars compacta (SNpc)	29274035
17322	Mouse	mmu-miR-30e	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra pars compacta (SNpc)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29274035
17323	Mouse	mmu-miR-30e	miRNA	microwave	microwave-induced adverse health outcomes 	mouse hippocampus	7 days after 30 mW/cm microwave exposure treatment	downregulated	24748327
17324	Mouse	mmu-miR-30e	miRNA	aldosterone	podocyte apoptosis and mitochondrial dysfunction	mouse proximal tubule cells (MPC5)	aldosterone treatment	downregulated	27974319
17325	Mouse	mmu-miR-30e	miRNA	anandamide (AEA)	pro-inflammatory activity	mouse	anandamide treatment	AEA differentil regulate the expression of miRNA	24699635
17326	Mouse	mmu-miR-30e	miRNA	melatonin	radiation-induced injury	15 Gy irradiation exposured RAW 264.7 cells	Melatonin treatment	upregulated	30755784
17327	Mouse	mmu-miR-30e	miRNA	¦Ã-rays	radiation-induced injury	RAW 264.7 cells	15 Gy irradiation exposure treatment	downregulated	30755784
17328	Mouse	mmu-miR-30e*	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
17329	Mouse	mmu-miR-30e*	miRNA	high fat diet (HFD)	chondrogenesis	white adipose tissues	high fat diet (HFD) feed	downregulated	22496873
17330	Mouse	mmu-miR-30e-5p	miRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	lung tissues; blood; RAW264.7 cells	Fine particulate matter (PM2.5) treatment	downregulated	32707273
17331	Mouse	mmu-miR-30e-5p	miRNA	"CB1 antagonist, AM251"	diet-induced obesity (DIO)	F4/80+ cells from stromal vascular fractions (SVF) of epididymal fat	"CB1 antagonist, AM251 treatment"	upregulated	31134094
17332	Mouse	mmu-miR-30e-5p	miRNA	deflazacort	inflammation	RAW 264.7 cells	deflazacort treatment	downregulated	32153563
17333	Mouse	mmu-miR-30e-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32153563
17334	Mouse	mmu-miR-30e-5p	miRNA	prednisolone	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32153563
17335	Mouse	mmu-miR-30e-5p	miRNA	leishmania	leishmaniasis	Bone marrowderived macrophages (BMDMs)	Leishmania infection	upregulated	30949455
17336	Mouse	mmu-miR-30e-5p	miRNA	high fat diet (HFD)	obesity	adipose tissue macrophages (ATMs)	high fat diet (HFD) feed	downregulated	29899524
17337	Mouse	mmu-miR-30e-5p	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
17338	Mouse	mmu-miR-31	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
17339	Mouse	mmu-miR-31	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	nasal mucosa	ovalbumin (OVA) treatment	The expression levels of miR-31 were significantly decreased in the nasal mucosa of the AR group compared with those in the control group.	33179116
17340	Mouse	mmu-miR-31	miRNA	ovalbumin (OVA)	asthma	lung tissues	OVA (ovalbumin) treatment	upregulated	31298396
17341	Mouse	mmu-miR-31	miRNA	cerulein	chronic pancreatitis (CP)	pancreas	cerulein treatment	upregulated	29303912
17342	Mouse	mmu-miR-31	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	CD4+ T cells	"2,4,6-Trinitrobenzenesulfonic acid solution (TNBS) treatment"	upregulated	31730734
17343	Mouse	mmu-miR-31	miRNA	resveratrol	colitis	CD4+ T cells	resveratrol (RS) treatment	downregulated	31730734
17344	Mouse	mmu-miR-31	miRNA	resveratrol	colitis	mesenteric lymph node (MLN)	resveratrol (RS) treatment	Resveratrol Downregulates miR-31 to Promote T Regulatory Cells during Prevention of TNBS-Induced Colitis	31730734
17345	Mouse	mmu-miR-31	miRNA	IL-10	colonic inflammation	colonic intraepithelial lymphocytes	IL-10 treatment	downregulated	22043014
17346	Mouse	mmu-miR-31	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
17347	Mouse	mmu-miR-31	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
17348	Mouse	mmu-miR-31	miRNA	angiotensin II (Ang II)	hypertension	"the aorta, splenic CD4+ T cells, and kidney leukocytes"	angiotensin II (Ang II) treatment	upregulated	30929511
17349	Mouse	mmu-miR-31	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse brain and astrocytes	"C57BL/6J mice were used to establish the middle cerebral artery occlusion (MCAO) model. Following the establishment of an oxygen-glucose deprivation (OGD) model, the astrocytes were cocultured with neuronal OGD.? treatment"	downregulated	31517390
17350	Mouse	mmu-miR-31	miRNA	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)"	kaposi's sarcoma (KS)	fetal thymocytes of mice	"TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) treatment"	downregulated	23024791
17351	Mouse	mmu-miR-31	miRNA	"indole-3-carbinol (I3C) and 3,3'-diindolylmethane (DIM)"	liver damage	SEB into D-galactosamine-sensitized female C57BL/6 mice	"indole-3-carbinol (I3C) and 3,3'-diindolylmethane (DIM) treatment"	downregulated	25706292
17352	Mouse	mmu-miR-31	miRNA	binase	lymphosarcoma	RLS40 cells	binase treatment	downregulated	33147876
17353	Mouse	mmu-miR-31	miRNA	stretch	myoblast proliferation	C2C12 myoblasts	stretch treatment	downregulated	27840929
17354	Mouse	mmu-miR-31	miRNA	dietary methionine restriction (MR)	osteoblast differentiation and function	"male C57BL/6J mice bone marrow,plasma and liver"	fed diets containing 0.86% or 0.12% methionine for 5 weeks	"upregulated (miR-31 in plasma and liver, and miR-133a, miR-335-5p, and miR-204 in the bone marrow"	27191548
17355	Mouse	mmu-miR-31	miRNA	nuclear factor kappa-B (NF-¦ÊB)	psoriatic	keratinocytes	NF-¦ÊB treatment	upregulated	26138368
17356	Mouse	mmu-miR-31	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
17357	Mouse	mmu-miR-31	miRNA	leptin	age-associated loss of muscle mass	skeletal muscle	?leptin treatment	?leptin treatment increased the expression of miR-31 and miR-223	20800581
17358	Mouse	mmu-miR-31	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	ulcerative colitis (UC)	colon tissues	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	upregulated	31378906
17359	Mouse	mmu-miR-31	miRNA	azacitidine (AZA)	ulcerative colitis (UC)	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol-induced ulcerative colitis (UC) mice colon tissues"	azacitidine (AZA) treatment	downregulated	31378906
17360	Mouse	mmu-miR-31	miRNA	mesalazine (MSLZ)	ulcerative colitis (UC)	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol-induced ulcerative colitis (UC) mice colon tissues"	mesalazine (MSLZ) treatment	downregulated	31378906
17361	Mouse	mmu-miR-3100-5p	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	upregulated	30242182
17362	Mouse	mmu-miR-3102-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	upregulated	32552669
17363	Mouse	mmu-miR-3102-3p	miRNA	ganoderma lucidum extract (GLE)	hepatocellular carcinoma (HCC)	Hepa 1-6 cells	Ganoderma lucidum extract (GLE) treatment	upregulated	32106374
17364	Mouse	mmu-miR-3104-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
17365	Mouse	mmu-miR-3107*	miRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol (ISO) treatment	downregulated	27174579
17366	Mouse	mmu-miR-3113	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) treatment	upregulated in colon samples	29066742
17367	Mouse	mmu-miR-31-3p	miRNA	dextran sodium sulfate (DSS)	colitis	male C57BL/6J mice colon	DSS treatment	upregulated	29253460
17368	Mouse	mmu-miR-31-3p	miRNA	trinitrobenzene sulfonic acid (TNBS)	colitis	male C57BL/6J mice colon	TNBS treatment	upregulated	29253460
17369	Mouse	mmu-miR-31-5p	miRNA	astaxanthin	neuroinflammation	Lipopolysaccharide (LPS)-treated BV2 cells	astaxanthin (ATX) treatment	downregulated	33359248
17370	Mouse	mmu-miR-31-5p	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colitis-associated colon cancer (CAC)	colon tissue	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	upregulated	31100679
17371	Mouse	mmu-miR-31-5p	miRNA	azoxymethane (AOM) and dextran sulfate sodium (DSS)	colitis-associated colon cancer (CAC)	colon tissues	azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment	upregulated	31275360
17372	Mouse	mmu-miR-31-5p	miRNA	pedunculoside	colitis-associated colon cancer (CAC)	CAC mice colon tissues	pedunculoside treatment	downregulated	31275360
17373	Mouse	mmu-miR-31-5p	miRNA	water extract of I. rotunda (WIR)	colitis-associated colon cancer (CAC)	CAC mice colon tissue	water extract of I. rotunda (WIR) treatment	downregulated	31100679
17374	Mouse	mmu-miR-31-5p	miRNA	solar particle event (SPE)	colorectal cancer (CRC)	plasma of a colorectal cancer susceptible mouse	solar particle event (SPE) treatment	downregulated	26432591
17375	Mouse	mmu-miR-31-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	downregulated	31497013
17376	Mouse	mmu-miR-31-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
17377	Mouse	mmu-miR-31-5p	miRNA	barium chloride	muscle injury	C2C12 cells	barium chloride treatment	upregulated	32954829
17378	Mouse	mmu-miR-31-5p	miRNA	retinoic acid (RA)	cell proliferation	embryonic tongue and C2C12 myoblasts	retinoid acid treatment	upregulated	28526071
17379	Mouse	mmu-miR-31-5p	miRNA	imiquimod (IMQ)	psoriasis	skin tissues	imiquimod (IMQ) treatment	upregulated	31278779
17380	Mouse	mmu-miR-31-5p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	"NEAT1 and POU domain class 2 transcription factor 1 (POU2F1) were highly expressed in LPS-induced septic RAW264.7 cells, opposite to miR-31-5p expression."	33710444
17381	Mouse	mmu-miR-31-5p	miRNA	L©\arginine	severe acute pancreatitis (SAP)	pancreatic tissues	L-arginine treatment	downregulated	33122522
17382	Mouse	mmu-miR-3162-3p	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin treatment	upregulated	32610326
17383	Mouse	mmu-miR-3185	miRNA	mechanical asphyxia	asphyxial death	heart tissues	mechanical asphyxia treatment	miR-3185 was upregulated in cardiac tissues among cases of mechanical asphyxia.	32320934
17384	Mouse	mmu-miR-32	miRNA	high glucose (HG)	liver fibrosis	AML12 cells	high glucose (HG) treatment	upregulated	30816482
17385	Mouse	mmu-miR-32	miRNA	high glucose (HG)	mesenchymal stem cells (MSCs) dysfunction	mice bone marrow-derived mesenchymal stem cells	high glucose treatment	downregulated	23524257
17386	Mouse	mmu-miR-32	miRNA	microwave	microwave-induced adverse health outcomes 	mouse hippocampus	7 days after 30 mW/cm microwave exposure treatment	downregulated	24748327
17387	Mouse	mmu-miR-320	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	upregulated	19462682
17388	Mouse	mmu-miR-320	miRNA	palmitic acid (PA)	inflammation	mature 3T3-L1 adipocytes	palmitic acid (PA) treatment	upregulated	31634961
17389	Mouse	mmu-miR-320	miRNA	high fat diet (HFD)	inflammatory response	skeletal muscle of mice	high fat diet (HFD) feed	"miR-375, miR-29, miR-320, miR-103/107 and miR-126, play a crucial role in the regulation of glucose and lipid metabolism through the control of pancreatic islet cell function"	22395471
17390	Mouse	mmu-miR-320	miRNA	metformin (Met)	insulin resistance (IR)	3T3L1 cells	Metformin treatment	IR adipocytes downregulated miR-320 in response to Metformin graded concentrations.	32367399
17391	Mouse	mmu-miR-320	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	upregulated	18987751
17392	Mouse	mmu-miR-320	miRNA	pregnant mare serum gonadotropin	reproduction and some steroid-related disorders	mouse ovarian granulosa cells	pregnant mare serum gonadotropin treatment	suppression of miR-320 expression in a time-dependent manner	24828505
17393	Mouse	mmu-miR-3202	miRNA	high glucose (HG)	apoptosis	endothelial cell line H5V	high-glucose	upregulated	28228635
17394	Mouse	mmu-miR-320-3p	miRNA	Jiang Tang Xiao Ke Granule	diabetes mellitus (DM)	KKAy diabetic mice	Jiang Tang Xiao Ke Granule treatment	dysregulated	29163176
17395	Mouse	mmu-miR-320-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	newborn mouse cardiomyocyte (NMC)	high glucose (HG) treatment	Gas5/miR-320-3p/Tcf3 pathway was found to modulate the apoptosis of NMC.	32003049
17396	Mouse	mmu-miR-320-3p	miRNA	glyphosate	neurodevelopmental disorder	prefrontal cortex of mouse offspring	glyphosate	dysregulated	29467848
17397	Mouse	mmu-miR-320-3p	miRNA	busulphan	sertoli cells-only syndrome (SCOS)	murine testis	busulphan treatment	upregulated	30237478
17398	Mouse	mmu-miR-320-3p	miRNA	carbon tetrachloride (CCl4)	steatosis	plasma	carbon tetrachloride (CCl4) treatment	upregulated	30125006
17399	Mouse	mmu-miR-320-3p	miRNA	dexamethasone (DEX)	steatosis	plasma	dexamethasone (DEX) treatment	upregulated	30125006
17400	Mouse	mmu-miR-320a	miRNA	hypoxia	diabetic retinopathy (DR)	Mu?ller cells	hypoxia treatment	miR-320a was reduced by hypoixa treatment.	32830348
17401	Mouse	mmu-miR-320a	miRNA	IL-33	inflammatory bowel disease (IBD)	intestinal epithelial cell (IEC) isolated from IL-33-treated dextran sodium sulfate (DSS) colitic mice	IL-33 treatment	upregulated	30224451
17402	Mouse	mmu-miR-320c	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	serum	streptozocin (STZ) treatment	Secretions of miR-320c was significantly increased in streptozotocin-treated mice	29370422
17403	Mouse	mmu-miR-322	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	cardiomyocytes	hypoxia treatment	upregulated	27398164
17404	Mouse	mmu-miR-322	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	27986864
17405	Mouse	mmu-miR-322	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
17406	Mouse	mmu-miR-322	miRNA	plasmodium	plasmodium infection	exosomes derived from the plasma	infect with Plasmodium treatment	upregulated	28650446
17407	Mouse	mmu-miR-322	miRNA	glucose	type 2 diabetes mellitus (T2DM)	isolated mouse islets	exposed to high levels of glucose within 1 h treatment	downregulated	25489007
17408	Mouse	mmu-miR-322/424	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	mouse liver tissue	CCl4 treatment	"miR-322/424 level in liver cirrhosis patients, mouse liver fibrosis induced by CCl4?and BDL, and rat liver fibrosis induced by CCl4?and dimethylnitrosamine was increased."	33333053
17409	Mouse	mmu-miR-322-3p	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	whole bone marrow exosomes	liraglutide 0.2 mg/kg for 2 months	dysregulated	29133778
17410	Mouse	mmu-miR-322-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cardiomyocytes (PCM)	angiotensin II (Ang II) treatment	downregulated	32436661
17411	Mouse	mmu-miR-322-5p	miRNA	glyphosate	neurodevelopmental disorder	prefrontal cortex of mouse offspring	glyphosate	dysregulated	29467848
17412	Mouse	mmu-miR-322-5p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
17413	Mouse	mmu-miR-324-3p	miRNA	¦Â-glycerophosphate (¦Â-GP) and pyruvic acid	coronary artery calcification (CAC)	mouse smooth muscle cell line (MOVAS-1)	¦Â-glycerophosphate (¦Â-GP) and pyruvic acid treatment	upregulated	31733402
17414	Mouse	mmu-miR-324-3p	miRNA	¦Â-glycerophosphate (¦Â-GP) and pyruvic acid	coronary artery calcification (CAC)	exosomes from mouse vascular smooth muscle cells line MOVAS-1	"To induce calcification, the MOVAS-1 cells were maintained in normal cell culture medium supplied with 10 mM ¦Â-glycerophosphate (¦Â-GP) (Sigma, UK) and 10 nM pyruvic acid for 21 d successively, and the culture medium was renewed every 3 d."	upregulated	31733402
17415	Mouse	mmu-miR-324-3p	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
17416	Mouse	mmu-miR-324-3p	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
17417	Mouse	mmu-miR-324-3p	miRNA	urocortin 1 (Ucn-1)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R mosue	administration of Ucn-1 at the beginning of reperfusion treatment	upregulated	28827743
17418	Mouse	mmu-miR-324-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	upregulated	30095204
17419	Mouse	mmu-miR-324-5p	miRNA	polychlorinated biphenyls (PCBs)	cell differentiation	P19 mouse embryonal carcinoma cells	polychlorinated biphenyls (PCBs) treatment	downregulated	23443104
17420	Mouse	mmu-miR-325	miRNA	anoxia/reoxygenation (A/R)	heart failure (HF)	cardiomyocytes were isolated from 1-2 days old mice	anoxia(5% CO2 and 95% N2 )and subjected to reoxygenation (95% O2 and 5% CO2) treatment	upregulated	24531537
17421	Mouse	mmu-miR-325	miRNA	ischemia/reperfusion (I/R) 	heart failure (HF)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	24531537
17422	Mouse	mmu-miR-325-3p	miRNA	IL-1¦Â	cementum regeneration	"The cementoblast cell line, named OCCM©\30"	interleukin 1¦Â (IL1¦Â) treatment	upregulated	31680324
17423	Mouse	mmu-miR-325-3p	miRNA	hypoxia	myocardial infarction (MI)	primary cultured cardiomyocytes	hypoxia induce	downregulated	31248365
17424	Mouse	mmu-miR-325-3p	miRNA	chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004)	plvic inflammatory disease	mouse	two Chlamydia muridarum variants (C. muridarum Var001 [CmVar001] and CmVar004) infection	were upregulated during CmVar004 infection compared to CmVar001 infection	24961692
17425	Mouse	mmu-miR-325-3p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary microglia/BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	30911940
17426	Mouse	mmu-miR-325-3p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	BV2 cells	lipopolysaccharides (LPS) treatment	LncRNA H19 Regulates Lipopolysaccharide (LPS)-Induced Apoptosis and Inflammation of BV2 Microglia Cells Through Targeting miR-325-3p/NEUROD4 Axis.	33205379
17427	Mouse	mmu-miR-325-3p	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	RAW 264.7 cells	M. tuberculosis infection	microRNA-325-3p (miR-325-3p) is upregulated after M. tuberculosis infection.	32487755
17428	Mouse	mmu-miR-325-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
17429	Mouse	mmu-miR-32-5p	miRNA	lipopolysaccharide (LPS)	depression	hippocampus and prefrontal cortex	lipopolysaccharide (LPS) treatment	upregulated	31698013
17430	Mouse	mmu-miR-32-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	upregulated	30453253
17431	Mouse	mmu-miR-32-5p	miRNA	perfluorooctanoic acid	hepatotoxicity	liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	24459700
17432	Mouse	mmu-miR-326	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	29727715
17433	Mouse	mmu-miR-326	miRNA	0.05% NaI	autoimmune thyroiditis (AIT)	thyroid tissues	0.05% NaI treatment	upregulated	29181619
17434	Mouse	mmu-miR-326	miRNA	NaI	autoimmune thyroiditis (AIT)	spleen tissues	0.05% NaI treatment	upregulated	29181619
17435	Mouse	mmu-miR-326	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
17436	Mouse	mmu-miR-326	miRNA	IL-10	epithelial-mesenchymal transition (EMT)	colonic intraepithelial lymphocytes	IL-10 treatment	upregulated	22043014
17437	Mouse	mmu-miR-326	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	CCl4 treatment	downregulated	31692098
17438	Mouse	mmu-miR-326	miRNA	natalizumab	multiple sclerosis (MS)	MS mouse CD4(+) T cells	natalizumab treatment	downregulated	25642434
17439	Mouse	mmu-miR-326	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Parkinson's disease (PD)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31135066
17440	Mouse	mmu-miR-326	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	Parkinson's disease (PD)	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31270675
17441	Mouse	mmu-miR-326	miRNA	natalizumab	relapsing-remitting multiple sclerosis (RRMS)	splenocytes	natalizumab treatment	downregulated	25642434
17442	Mouse	mmu-miR-326	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	murine lungs; RAW264.7	lipopolysaccharide (LPS) treatment	miR-326 was downregulated in murine lungs and macrophages upon lipopolysaccharide (LPS) stimulation.	32530324
17443	Mouse	mmu-miR-326	miRNA	silicon dioxide (SiO2)	silicosis	HBE and A549 cells	silicon dioxide (SiO2) treatment	"miR-326 is downregulated in the fibrotic lung tissues of silica-treated mice, while increased expression of miR-326 attenuates silica-induced pulmonary fibrosis in vivo"	31642316
17444	Mouse	mmu-miR-326-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	brain tissues; BV2 cells	Japanese encephalitis virus (JEV) infection	downregulated	32552669
17445	Mouse	mmu-miR-326-3p	miRNA	cadmium (Cd)	toxic effects of cadmium	rat kidneys; NRK-52E	cadmium (Cd) treatment	upregulated	31626960
17446	Mouse	mmu-miR-326-5p	miRNA	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2)"	liver damage	bone marrow (BM)-derived macrophage (BMM) of liver injury mouse	"15-deoxy-¦¤12, 14-prostaglandin J2 (15d-PGJ2) treatment"	upregulated	28748390
17447	Mouse	mmu-miR-327	miRNA	low chromium (Cr)	insulin resistance (IR)	liver	fed a control or LC diet for 13 weeks	dysregulatedin liver	29286159
17448	Mouse	mmu-miR-328	miRNA	isoproterenol	cardiac hypertrophy	heart tissues	ISO treatment	upregulated	24631114
17449	Mouse	mmu-miR-328	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	upregulated	18987751
17450	Mouse	mmu-miR-328-3p	miRNA	dietary methionine restriction (MR)	diet-induced obesity (DIO)	high-fat-diet-induced obesity (DIO) mouse liver tissues	dietary methionine restriction (MR) treatment	upregulated	30512228
17451	Mouse	mmu-miR-328-3p	miRNA	high fat diet (HFD)	diet-induced obesity (DIO)	liver tissues	high fat diet (HFD) feed	downregulated	30512228
17452	Mouse	mmu-miR-328-3p	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	"Lower expression of miR-328-3p were observed in iPAH-PASMCs and relevant HPH models. Upregulation of lncRNA-MEG3 sequesters cytoplasmic miR-328-3p, eventually leading to expression of IGF1R, revealing a regulatory mechanism by lncRNAs in hypoxia-induced PASMC proliferation."	31477557
17453	Mouse	mmu-miR-328-3p	miRNA	licochalcone A (LA)	lung cancer	MLE-12 cells	Licochalcone A (lico A) treatment	upregulated	32505917
17454	Mouse	mmu-miR-328-3p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	cardiac tissue	murine cytomegalovirus (MCMV) infection	downregulated	33245094
17455	Mouse	mmu-miR-329	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver injury (ALI)	liver tissues	D-GalN/LPS treatment	downregulated	31061003
17456	Mouse	mmu-miR-329	miRNA	H2O2	Alzheimer's disease (AD)	Primary hippocampal neuron cells	H2O2 treatment	upregulated	24423585
17457	Mouse	mmu-miR-329	miRNA	H2O2	Alzheimer's disease (AD)	senescence accelerated mouse prone 8 (SAMP8) and prone 10 (SAMP10)	"different concentrations (0, 100, 200, 400 and 800 ¦ÌM) of H2O2 treatment"	upregulated	24423585
17458	Mouse	mmu-miR-329	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
17459	Mouse	mmu-miR-329-3p	miRNA	microcystin-leucine arginine (MC-LR)	male infertility	GT1-7 cells	Microcystin-leucine arginine (MC-LR) treatment	downregulated	30064084
17460	Mouse	mmu-miR-33	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Pulmonary microvascular endothelial cells (PMVECs)	lipopolysaccharide (LPS) treatment	downregulated	30761836
17461	Mouse	mmu-miR-33	miRNA	farnesoid X receptor (FXR)	cholesterol homeostasis	hepatic	farnesoid X receptor (FXR) treatment	upregulated	25593129
17462	Mouse	mmu-miR-33	miRNA	averrhoa carambola free phenolic extract (ACF)	hepatic steatosis	leptin receptor-deficient (db/db) mice	averrhoa carambola free phenolic extract (ACF) treatment	downregulated	29090700
17463	Mouse	mmu-miR-33	miRNA	lychee pulp phenolics (LPPs)	hypolipidemic mechanism	high-fat diet (HFD) mouse hepatocytes	lychee pulp phenolics (LPPs) treatment	downregulated in mouse hepatocytes	28121324
17464	Mouse	mmu-miR-33	miRNA	glucagon-like peptide-1 (GLP-1)	lipotoxic oxidative stress	FFA-treated INS-1 cells	GLP-1	downregulated	27956176
17465	Mouse	mmu-miR-33	miRNA	lonicera caerulea berry polyphenols (LCBP)	macrophage foam cell formation	ox-LDL-treated RAW264.7	Lonicera caerulea berry polyphenols (LCBP) treatment	downregulated	31146527
17466	Mouse	mmu-miR-33	miRNA	oxidized low density lipoprotein (ox-LDL)	macrophage foam cell formation	RAW264.7	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31146527
17467	Mouse	mmu-miR-33	miRNA	high glucose (HG) and cholesterol-lowering drugs atorvastatin and pitavastatin	metabolic syndrome	Murine macrophage cell line RAW264.7	high glucose and cholesterol-lowering drugs atorvastatin and pitavastatin treatment	upregulated	27139226
17468	Mouse	mmu-miR-33	miRNA	aerobic exercise	nonalcoholic fatty liver disease (NAFLD)	non-alcoholic fatty liver disease (NAFLD) mouse liver tissues	aerobic exercise training (AET) treatment	upregulated	28163011
17469	Mouse	mmu-miR-33	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	high fat diet (HFD) feed	downregulated	28163011
17470	Mouse	mmu-miR-33	miRNA	high fat diet (HFD)	obesity	mouse	high fat diet (HFD) feed	downregulated	28163011
17471	Mouse	mmu-miR-33	miRNA	training	obesity	obesity mouse liver	continuous endurance training treatment	upregulated	28163011
17472	Mouse	mmu-miR-33	miRNA	fructo-oligosaccharides (FOS)	tubulointerstitial fibrosis (TIF)	liver tissue of mice	?fructo-oligosaccharides (FOS)treatment treatment	upregulated	23203768
17473	Mouse	mmu-miR-330	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	liver tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-330 was upregulated in the liver tissues of male mice.	32871758
17474	Mouse	mmu-miR-330	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	kidneny tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-330 was upregulated in the kidney tissues of female mice.	32871758
17475	Mouse	mmu-miR-330	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	kidneny tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-330 was downregulated in the kidney tissues of male mice.	32871758
17476	Mouse	mmu-miR-330	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	primary microglial cells	lipopolysaccharide (LPS) treatment	The expression of microRNA-330 increased in the first 4 days and reached a plateau subsequently after LPS treatment	33325083
17477	Mouse	mmu-miR-330-3p	miRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes	phenylephrine (PE) treatment	downregulated	30297107
17478	Mouse	mmu-miR-330-3p	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	AML12 cells	hypoxia treatment	downregulated	30269356
17479	Mouse	mmu-miR-330-3p	miRNA	mineral oil	hepatic ischemia/reperfusion injury (HIRI)	AML12 cells	mineral oil treatment	downregulated	30269356
17480	Mouse	mmu-miR-330-5p	miRNA	lipopolysaccharide (LPS)	pulmonary vascular endothelial cell (PVEC) injury	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	"PRNCR1 and TLR4 levels were significantly upregulated in LPS-treated PVEC, both in vivo and in vitro, while miR-330-5p were downregulated. Inhibiting PRNCR1 or overexpressing miR-330-5p markedly attenuated LPS-induced PVEC injury."	33049095
17481	Mouse	mmu-miR-330-5p	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	HL-1 cells	lipopolysaccharide (LPS) treatment	LncRNA MIAT Promotes Inflammation and Oxidative Stress in Sepsis-Induced Cardiac Injury by Targeting miR-330-5p/TRAF6/NF-¦ÊB Axis	32556678
17482	Mouse	mmu-miR-330-5p	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	isolated adipose tissue macrophages	high fat diet (HFD) feed	upregulated	29433065
17483	Mouse	mmu-miR-331	miRNA	stretch	myoblast proliferation	C2C12 myoblasts	stretch treatment	downregulated	27840929
17484	Mouse	mmu-miR-331-3p	miRNA	pilocarpine	epilepsy	male NMRI mice	inject intraperitoneally with pilocarpine treatment	downregulated	25078263
17485	Mouse	mmu-miR-331-3p	miRNA	hemin	intracerebral haemorrhage (ICH)	BV2 cells	hemin treatment	downregulated	32596340
17486	Mouse	mmu-miR-331-5p	miRNA	gastrodin and rhynchophylline	ischemia/reperfusion (I/R) injury	hypoxia-induced mouse brain tissues and BV2 cells	combination of gastrodin and rhynchophylline treatment	upregulated	31610203
17487	Mouse	mmu-miR-331-5p	miRNA	oxygen glucose deprivation (OGD)	ischemia/reperfusion (I/R) injury	mouse brain tissues and BV2 cells	Middle cerebral artery occlusion (MCAO) mice and oxygen glucose deprivation (OGD)-treated BV2 cells were used as in vivo and in vitro models of ischaemia treatment	downregulated	31610203
17488	Mouse	mmu-miR-33-3p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	downregulated	28396668
17489	Mouse	mmu-miR-335	miRNA	C-phycocyanin (CPC)	Alzheimer's disease (AD)	hippocampal tissues	C-phycocyanin (CPC) treatment	downregulated	33312721
17490	Mouse	mmu-miR-335	miRNA	green tea (GT)	obesity	adipose tissues	green tea (GT) treatment	GT reverses HFD-induced upregulated of miR-155 and -335 in epididymal adipose tissues.	29734116
17491	Mouse	mmu-miR-335	miRNA	traditional Chinese medicine Changqin NO. 1	traumatic brain injury (TBI)	brain tissues and primary neurons	traditional Chinese medicine Changqin NO. 1 treatment	Changqin NO 1 promoted neuroprotective effects by inhibiting neuronal apoptosis via the GAS5/miR-335/Rasa1 axis in TBI	30653462
17492	Mouse	mmu-miR-335-3p	miRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	upregulated	30820263
17493	Mouse	mmu-miR-335-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
17494	Mouse	mmu-miR-335-5p	miRNA	high glucose (HG)	diabetic osteoporosis	MC3T3-E1 osteoblast cell line	high glucose treatment	downregulated	26986081
17495	Mouse	mmu-miR-335-5p	miRNA	streptozocin (STZ)	gestational diabetes mellitus (GDM)	pancreatic islet ¦Â-cells	streptozotocin (STZ) treatment	upregulated	30341900
17496	Mouse	mmu-miR-335-5p	miRNA	spatial learning	impairment in long-term memory	CD1 male mice	spatial learning with morris water maze treatment	downregulated in hippocampal	28039088
17497	Mouse	mmu-miR-335-5p	miRNA	dietary methionine restriction (MR)	osteoblast differentiation and function	"male C57BL/6J mice bone marrow,plasma and liver"	fed diets containing 0.86% or 0.12% methionine for 5 weeks	"upregulated (miR-31 in plasma and liver, and miR-133a, miR-335-5p, and miR-204 in the bone marrow"	27191548
17498	Mouse	mmu-miR-335-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	MC3T3-E1 cells; primary calvarial osteoblasts	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	32468044
17499	Mouse	mmu-miR-335-5p	miRNA	¦Â-elemene	oxygen-induced retinopathy (OIR)	Retinas tissues	¦Â-elemene treatment	upregulated	30664207
17500	Mouse	mmu-miR-33-5p	miRNA	bupivacaine	apoptosis	dorsal root ganglion (DRG) cells	bupivacaine treatment	upregulated	30617464
17501	Mouse	mmu-miR-337-3p	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	downregulated	18987751
17502	Mouse	mmu-miR-337-3p	miRNA	ganoderma lucidum extract (GLE)	hepatocellular carcinoma (HCC)	Hepa 1-6 cells	Ganoderma lucidum extract (GLE) treatment	upregulated	32106374
17503	Mouse	mmu-miR-337-5p	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
17504	Mouse	mmu-miR-338	miRNA	anoxia/reoxygenation (A/R)	autophagy	cardiomyocytes	anoxia/reoxygenation (A/R) treatment	miR-338 was significantly downregulated in cardiomyocytes in response to A/R.	29247537
17505	Mouse	mmu-miR-338	miRNA	oxygen glucose deprivation (OGD)	brain vascular dysfunction	brain microvascular endothelial cell (BMEC)	oxygen-glucose deprivation (OGD) treatment	SNHG1 and miR-338 were upregulated in OGD induced BMEC.	30414401
17506	Mouse	mmu-miR-338	miRNA	bisphenol A (BPA)	glucose homeostasis	mice (4 wk old)	bisphenol A (BPA) treatment	downregulated	28774890
17507	Mouse	mmu-miR-338	miRNA	bisphenol A (BPA)	glucose homeostasis	mice (4 wk old)	bisphenol A (BPA) treatment	long-term BPA exposure upregulated miR-338	28774890
17508	Mouse	mmu-miR-338	miRNA	hypoxia	ischemic stroke (IS)	Mice primary brain microvascular endothelial cells (BMEC)	oxygen/glucose-deprived (OGD)?treatment	upregulated	30414401
17509	Mouse	mmu-miR-338	miRNA	microwave	microwave-induced adverse health outcomes 	mouse hippocampus	7 days after 30 mW/cm microwave exposure treatment	downregulated	24748327
17510	Mouse	mmu-miR-338-3p	miRNA	N-acetyl-p-aminophenol (APAP)	acute liver injury (ALI)	liver tissues	N-acetyl-p-aminophenol (APAP) treatment	The results revealed that miR-338-3p was significantly upregulated following the intraperitoneal administration of APAP.	32331846
17511	Mouse	mmu-miR-338-3p	miRNA	paeonol (PAE)	atherosclerosis (AS)	vascular endothelial cells (VECs)	Paeonol treatment	Paeonol regulated VEC development via downregulating miR-338-3p expression	32770325
17512	Mouse	mmu-miR-338-3p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	gluconeogenesis	the livers of mice and in mouse HEPA1-6 hepatocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30132533
17513	Mouse	mmu-miR-338-3p	miRNA	perfluoroalkyl chemicals (PFASs)	hepatotoxicity	male BALB/c mice liver	PFASs treatment	downregulated	25181679
17514	Mouse	mmu-miR-338-3p	miRNA	N-acetyl-p-aminophenol (APAP)	liver damage	liver tissues	N-acetyl-p-aminophenol (APAP) treatment	upregulated	32331846
17515	Mouse	mmu-miR-338-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
17516	Mouse	mmu-miR-338-3p	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	downregulated	18987751
17517	Mouse	mmu-miR-338-3p	miRNA	dexamethasone (DEX)	osteoclast differentiation	osteoclast	dexamethasone (DEX) treatment	downregulated	27706599
17518	Mouse	mmu-miR-338-3p	miRNA	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL)	osteoclastogenesis	murine RAW264.7 cells	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL) treatment	upregulated	30716449
17519	Mouse	mmu-miR-338-3p	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoporosis	BALB/c mice bone marrow cell	ovariectomized (OVX) treatment	upregulated	24648262
17520	Mouse	mmu-miR-338-3p	miRNA	bleomycin (BLM)	lung fibrosis	fibroblast	bleomycin (BLM) treatment	downregulated	30796204
17521	Mouse	mmu-miR-338-3p	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	C57BL/6J mice livers	high fat diet (HFD) feed	downregulated	28467989
17522	Mouse	mmu-miR-339	miRNA	calorie restriction (CR)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	calorie restriction (CR) treatment	upregulated	31863770
17523	Mouse	mmu-miR-339	miRNA	exercise (Ex)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	exercise (Ex) treatment	upregulated	31863770
17524	Mouse	mmu-miR-339	miRNA	high fat diet (HFD)	hepatic steatosis	mice thyroid and liver tissues	high fat diet (HFD) feed	downregulated	31863770
17525	Mouse	mmu-miR-339	miRNA	low fat diet (LFD)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	low-fat diet (LF) treatment	upregulated	31863770
17526	Mouse	mmu-miR-339	miRNA	quercetin	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	quercetin (Que) treatment	upregulated	31863770
17527	Mouse	mmu-miR-339	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	downregulated	31863770
17528	Mouse	mmu-miR-339	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	upregulated	31863770
17529	Mouse	mmu-miR-339	miRNA	quercetin	obesity	thyroid	quercetin (QUE) treatment	upregulated	31863770
17530	Mouse	mmu-miR-339	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
17531	Mouse	mmu-miR-339-3p	miRNA	inorganic nitrite	acute myocardial infarction (AMI)	heart tissues	single-dose of nitrite	downregulated	28090786
17532	Mouse	mmu-miR-339-3p	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
17533	Mouse	mmu-miR-339-3p	miRNA	morphine and fentanyl	¦Ì-Opioid receptor (MOR) biosynthesis	hippocampal?tissues	morphine and fentanyl treatment	upregulated	23085997
17534	Mouse	mmu-miR-339-5p	miRNA	folic acid	Alzheimer's disease (AD)	APP/PS1 mice brains and N2a cells	Folic acid deficiency treatment	downregulated	26345540
17535	Mouse	mmu-miR-339-5p	miRNA	alcohol	brain-inflammation	mouse brain tissue and isolated microglial cells	alcohol exposure	upregulated	25172655
17536	Mouse	mmu-miR-339-5p	miRNA	oxygen glucose deprivation (OGD)	hypoxic/ischemic brain damage (HIBD)	primary mouse hippocampal neurons cells	Oxygen-glucose deprivation (OGD) treatment	lncRNA NEAT1 upregulated HOXA1 to alleviate HIBD in mice by binding to miR-339-5p	32163893
17537	Mouse	mmu-miR-339-5p	miRNA	olanzapine (OLP)	psychotic disorders	brain tissues	clozapine treatment	upregulated	23318695
17538	Mouse	mmu-miR-339-5p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	31852965
17539	Mouse	mmu-miR-339-5p	miRNA	paeonol (PAE)	sepsis	LPS-treated RAW264.7 cells	paeonol treatment	upregulated	31852965
17540	Mouse	mmu-miR-33a	miRNA	high fructose	adipogenesis	white adipose tissue	High fructose feed	downregulated	31030166
17541	Mouse	mmu-miR-33a	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
17542	Mouse	mmu-miR-33a	miRNA	urolithin A (UA)	endothelial dysfunction	RAW264.7 cells	Urolithin A (UA) treatment	Urolithin A attenuated ox-LDL-induced cholesterol accumulation in macrophages partly through regulating miR-33a and ERK/AMPK/SREBP1 signaling pathways	32236173
17543	Mouse	mmu-miR-33a	miRNA	high fat diet (HFD)	fatty liver disease	liver tissues	high fat diet (HFD) feed	Treatment with HFD significantly increased the expression of miR-33a in liver tissues.	30324697
17544	Mouse	mmu-miR-33a	miRNA	palmitic acid (PA)	fatty liver disease	mouse primary hepatocytes	palmitic acid (PA) treatment	Treatment with palmitic acid (PA) increased the expression of miR-33a in hepatocytes	30324697
17545	Mouse	mmu-miR-33a	miRNA	IL-6	gallbladder cancer (GBC)	gastric cancer SGC-7902 cells	IL-6 treatment	downregulated	27769047
17546	Mouse	mmu-miR-33a	miRNA	TGF-¦Â1	liver fibrosis	hepatic stellate cells (HSC) from C57BL/6 mice	TGF-¦Â1 treatment	upregulated	25155445
17547	Mouse	mmu-miR-33a-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteogenesis	mBMSCs	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	26785690
17548	Mouse	mmu-miR-34	miRNA	xanthomicrol	breast cancer	4T1 cells	xanthomicrol treatment	upregulated	33217075
17549	Mouse	mmu-miR-34	miRNA	cyclophosphamide	embryonic maldevelopment	the fore- and hindlimbs of mice	cyclophosphamide treatment	upregulated	20170545
17550	Mouse	mmu-miR-34	miRNA	adenoviral and lentiviral	lung cancer	KrasG12D/?;Trp53 lung epithelial cell lines	adenoviral and lentiviral treatment	In vivo treatment with miR-34a prevented tumor formation and progression in KrasLSL-G12D/?;Trp53LSL-R172H/?mice.	22964582
17551	Mouse	mmu-miR-34	miRNA	extra-virgin olive oil rich in phenols (H-EVOO)	neuronal function	cortex	H-EVOO treatment	upregulated	26695409
17552	Mouse	mmu-miR-340	miRNA	repeated social defeat (RSD)	gastric cancer (GC)	"male C57BL/6 (5 ¨C 6 weeks old) and CD-1 (12 months old, retired breeders) mice"	intruder attack mice treatment	significantly upregulated expression	25317829
17553	Mouse	mmu-miR-340	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	downregulated	33164260
17554	Mouse	mmu-miR-340	miRNA	dexmedetomidine (DEX)	neuroinflammation	BV2 cells	dexamethasone (DEX) treatment	upregulated	31631971
17555	Mouse	mmu-miR-340	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
17556	Mouse	mmu-miR-340	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
17557	Mouse	mmu-miR-340-5p	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	downregulated	26728044
17558	Mouse	mmu-miR-340-5p	miRNA	lipopolysaccharide (LPS)	intracerebral haemorrhage (ICH)	BV-2 cells	lipopolysaccharide (LPS) treatment	downregulated	33176298
17559	Mouse	mmu-mir-341-3p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
17560	Mouse	mmu-miR-342	miRNA	low-protein diet (LP0.5)	glucose homeostasis	¦Â cells	low-protein diet (LP0.5)	downregulated	25180600
17561	Mouse	mmu-miR-342	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	microglial neuroinflammation	Murine N9 microglia cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á stimulation induced the upregulation of miR-342	32488063
17562	Mouse	mmu-miR-342-3p	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	27484068
17563	Mouse	mmu-miR-342-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse renal mesangial cells (MCs)	high-glucose treatment	downregulated	31746345
17564	Mouse	mmu-miR-342-3p	miRNA	azilsartan medoxomil (AZL-M)	heart failure (HF)	plasma	azilsartan medoxomil (AZL-M) treatment	"MiR-146a, miR-149, miR-150, and miR-342-3p were reproducibly reduced in the plasma of CSQ-tg mice."	27321284
17565	Mouse	mmu-miR-342-3p	miRNA	azilsartan medoxomil (AZL-M)	heart failure (HF)	calsequestrin (CSQ)-tg mouse	azilsartan medoxomil (AZL-M) treatment	upregulated	27321284
17566	Mouse	mmu-miR-342-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	upregulated	27322257
17567	Mouse	mmu-miR-342-3p	miRNA	X rays	ionizing radiation (IR) injury	male Kunming mice blood	0.5-2 Gy total-body carbon-ion irradiation treatment	dysregulatedin blood	28632432
17568	Mouse	mmu-miR-342-3p	miRNA	prion	neurodegeneration (ND)	the brains tissues	prion infection treatment	upregulated	18987751
17569	Mouse	mmu-miR-342-3p	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	upregulated	25672270
17570	Mouse	mmu-miR-342-5p	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	primary type II alveolar epithelial cell (T2AEC); MLE12 cells and neonatal mouse lungs	hyperoxia induce	"Hyperoxia decreased miR-342-5p levels in primary T2AECs, MLE12 cells and neonatal mouse lungs."	33434946
17571	Mouse	mmu-miR-342-5p	miRNA	osteogenic differentiation medium	cell differentiation	MC3T3-E1 cells	"n osteogenic differentiation media that consisted of ¦Á-MEM, 10% FBS, 10 mM ¦Â-glycerophosphate, 50 ¦Ìg/mL ascorbic acid treatment"	downregulated	31398664
17572	Mouse	mmu-miR-342-5p	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
17573	Mouse	mmu-miR-343	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
17574	Mouse	mmu-miR-344	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
17575	Mouse	mmu-miR-344f-3p	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
17576	Mouse	mmu-miR-344g-5p	miRNA	delvestidine (DLTD)	bone marrow-derived dendritic cells (BMDCs) maturity	bone marrow-derived dendritic cells (BMDCs)	Delvestidine (DLTD) treatment	upregulated	32871480
17577	Mouse	mmu-miR-345-5p	miRNA	lipopolysaccharide (LPS)	resistant depression (TRD)	BV2 cells	lipopolysaccharide (LPS) treatment	upregulated	32730696
17578	Mouse	mmu-miR-34-5p	miRNA	¦¤9-tetrahydrocannabinol (THC)	acute respiratory distress syndrome (ARDS)	lung-infiltrated mononuclear cells (MNCs)	¦¤9Tetrahydrocannabinol (THC) treatment	downregulated	32612530
17579	Mouse	mmu-miR-346	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
17580	Mouse	mmu-miR-346	miRNA	cigarette smoke (CS)	rheumatoid arthritis (RA)	Th17 cells	cigarette smoke (CS) exposure	CS markedly increased the expression of miR-346 in the Th17 cells from the lymph nodes of AIA mice.	33443169
17581	Mouse	mmu-miR-346	miRNA	cigarette smoke extract (CSE)	rheumatoid arthritis (RA)	Th17 cells	cigarette smoke extract (CSE) treatment	upregulated	33443169
17582	Mouse	mmu-miR-346	miRNA	lipopolysaccharide (LPS)	sepsis	mouse macrophage cell line RAW264.7	lipopolysaccharide (LPS) treatment	"MALAT1 inhibited RAW264.7?cell proliferation, while miR-346 promoted its proliferation."	31494280
17583	Mouse	mmu-miR-346-3p	miRNA	poly(ethylenimine) (PEI)	cell death	MEF cells	poly(ethylenimine) (PEI) treatment	upregulated	26158199
17584	Mouse	mmu-miR-3472	miRNA	cyclophosphamide (CP)	chronic ovarian dysfunction	ovarian tissues	cyclophosphamide (CP) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice."	33318603
17585	Mouse	mmu-miR-3472	miRNA	samul-tang (SM)	chronic ovarian dysfunction	ovarian tissues	samul-tang (SM) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice"	33318603
17586	Mouse	mmu-miR-3473a	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
17587	Mouse	mmu-miR-3473b	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
17588	Mouse	mmu-miR-3473b	miRNA	hypoxia	stroke	primary cultured mouse neurons	oxygen-glucose deprivation (OGD) treatment	upregulated	29317607
17589	Mouse	mmu-miR-3473b	miRNA	lipopolysaccharide (LPS)	stroke	BV2 microglial cells	lipopolysaccharide (LPS) treatment	upregulated	29317607
17590	Mouse	mmu-miR-3473g	miRNA	microcystin-leucine arginine (MC-LR)	effects of microcystin-leucine arginine (MC-LR) on fertility	mouse granulosa	microcystin-leucine arginine (MC-LR) treatment	MC-LR inhibited miR-3473g expression of mouse granulosa cells both in vitro and in vivo.	31710595
17591	Mouse	mmu-miR-3474	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	downregulated	33224036
17592	Mouse	mmu-miR-34a	miRNA	staphylococcal enterotoxin B (SEB)	acute inflammatory lung injury	lung	staphylococcal enterotoxin B treatment	upregulated	25564423
17593	Mouse	mmu-miR-34a	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	kidney	cisplatin treatment	upregulated	24759152
17594	Mouse	mmu-miR-34a	miRNA	hyperoxia	acute lung injury (ALI)	"whole lungs, isolated endothelial cells (ECs) from lungs"	hyperoxia induce	upregulated	30512967
17595	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lungs tissues;endothelial cells (ECs)	lipopolysaccharide (LPS) treatment	upregulated	30512967
17596	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse alveolar type II epithelial (AT-II) cells	lipopolysaccharide (LPS) treatment	upregulated	28321785
17597	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung macrophages	lipopolysaccharides (LPS) treatment	upregulated	32825525
17598	Mouse	mmu-miR-34a	miRNA	¦Â-cypermethrin (¦Â-CYP)	adipogenesis	3T3-L1 cells	¦Â-cypermethrin (¦Â-CYP) treatment	downregulated	32637997
17599	Mouse	mmu-miR-34a	miRNA	alcohol	alcoholic liver disease (ALD)	mouse	chronic alcohol administration	upregulated	29128099
17600	Mouse	mmu-miR-34a	miRNA	resveratrol	allergic asthma (AA)	pulmonary inflammatory cells	resveratrol (RSV) treatment	Resveratrol attenuates allergic asthma by downregulating miR-34a that induces increased expression of FOXP3.	30619345
17601	Mouse	mmu-miR-34a	miRNA	tiaoxin recipe	Alzheimer's disease (AD)	cortex and hippocampus of APPswe/PS1¦¤E9 (APP/PS1) double transgenic mice	Tiaoxin Recipe treatment	downregulated	31548147
17602	Mouse	mmu-miR-34a	miRNA	aluminum (Al)	Alzheimer's disease (AD)	murine microglial cell line	aluminum treatment	downregulated	23778113
17603	Mouse	mmu-miR-34a	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	cortical neurons	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	26459758
17604	Mouse	mmu-miR-34a	miRNA	ketamine	apoptosis	one-month old C57/BL6 mice hippocampal	"received daily intraperitoneal injection of anesthesia (ketamine, 50 mg/kg) for 7 days treatment"	upregulated	25400756
17605	Mouse	mmu-miR-34a	miRNA	palmitate	apoptosis	Min6 pancreatic ¦Â -cell	palmitate treatment	upregulated	24829923
17606	Mouse	mmu-miR-34a	miRNA	folate	apoptosis	mouse embryonic stem cells (mESCs)	folate deficiency induced	upregulated	22828209
17607	Mouse	mmu-miR-34a	miRNA	kanamycin	apoptosis	inner ear tissues	kanamycin treatment	strong upregulated of miR-34a and miR-34c	21067520
17608	Mouse	mmu-miR-34a	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aortic arch	high fat diet (HFD) feed	upregulated	29704100
17609	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	Dendritic cell (DC) maturation	?Mouse Monocyte	lipopolysaccharide (LPS) treatment	upregulated	24198819
17610	Mouse	mmu-miR-34a	miRNA	melatonin	Benzo(a)pyrene (BaP)-induced hepatotoxicity	liver tissues	melatonin treatment	Exposure of mice to 20 mg/kg of melatonin resulted in a significant decrease in hepatic miR-34a expression (1.2-fold) compared with the BaP treated mice.	32247962
17611	Mouse	mmu-miR-34a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	bone regeneration	bone marrow mesenchymal stromal cells (BMSCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31308031
17612	Mouse	mmu-miR-34a	miRNA	D-galactose (D-Gal)	brain aging	brain tissues	D-Galactose treatment	upregulated	31420820
17613	Mouse	mmu-miR-34a	miRNA	urolithin A (UA)	brain aging	D-gal-induced brain aging mice brain tissues	?urolithin A treatment	downregulated	31420820
17614	Mouse	mmu-miR-34a	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	platelet-derived growth factor receptor (PDGFR)¦Á-expressing myofibroblasts	hyperoxia induce	upregulated	30770339
17615	Mouse	mmu-miR-34a	miRNA	myostatin	browning of white adipocytes	C2C12 myoblasts	myostatin treatment	upregulated	27297797
17616	Mouse	mmu-miR-34a	miRNA	N-ethyl-N-nitrosourea (ENU)	tumorigenesis	spleen tissues	N-ethyl-N-nitrosourea (ENU) treatment	upregulated	22297810
17617	Mouse	mmu-miR-34a	miRNA	TGF-¦Â1	cardiac fibrosis	cardiac fibroblasts	TGF-¦Â1 treatment	upregulated	25322725
17618	Mouse	mmu-miR-34a	miRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes; cardiac fibroblasts	phenylephrine (PE) treatment	LncRNA TUG1 alleviates cardiac hypertrophy by targeting miR©\34a/DKK1/Wnt©\¦Â©\catenin signalling	32057178
17619	Mouse	mmu-miR-34a	miRNA	programmed death-1 (PD-1) inhibitor	cardiac injury	HL-1 cells	programmed death-1 (PD-1) inhibitor treatment	upregulated	32709878
17620	Mouse	mmu-miR-34a	miRNA	aldosterone	cardiovascular disease (CVD)	primary mouse cardiomyocytes or mouse heart tissues	aldosterone treatment	TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling	32776109
17621	Mouse	mmu-miR-34a	miRNA	quercetin	apoptosis	HepG2 and Huh7 cells	quercetin treatment	upregulated	25896587
17622	Mouse	mmu-miR-34a	miRNA	diethylnitrosamine (DEN)	chronic cholestasis and cholangiocarcinoma	liver tissues	diethylnitrosamine (DEN) treatment	downregulated	21440549
17623	Mouse	mmu-miR-34a	miRNA	trichostatin A (TSA)	chronic obstructive pulmonary disease (COPD)	lung tissue of rats	trichostatin A (TSA) treatment	upregulated	21224215
17624	Mouse	mmu-miR-34a	miRNA	curcumin and 3 acetyl-11-keto-¦Â-boswellic acid (AKBA)	colorectal cancer (CRC)	colorectal cancer cells	curcumin and 3 acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment	upregulated	25712055
17625	Mouse	mmu-miR-34a	miRNA	chronic stress	depression	ouse raphe nuclei	chronic stress exposure	upregulated	31482401
17626	Mouse	mmu-miR-34a	miRNA	chronic stress	depression	raphe nuclei	chronic stress exposure	"microRNA-34a, under chronic stress, is significantly upregulated in the mouse raphe nuclei."	31482401
17627	Mouse	mmu-miR-34a	miRNA	IL-1¦Â and TNF-¦Á	diabetes mellitus (DM)	MIN6 cells	IL-1¦Â and TNF-¦Á treatment	upregulated	20086228
17628	Mouse	mmu-miR-34a	miRNA	streptozocin (STZ)	diabetes-induced testicular apoptotic cell death (TACD)	testes	streptozotocin (STZ) treatment	upregulated	30030567
17629	Mouse	mmu-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose (HG) treatment	miR-34a was upregulated in HG-stimulated H9c2.	30216438
17630	Mouse	mmu-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiomyocytes	high glucose treatment	upregulated	32212062
17631	Mouse	mmu-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	primary mouse cardiac fibroblasts (CFs)	high glucose (HG) treatment	The HG stimulation of CFs for 48?h significantly downregulated the expression level of miR-34a.	33289184
17632	Mouse	mmu-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiac tissues	high glucose (HG) treatment	"The HG stimulation of CFs for 48 h significantly downregulated the expression level of miR-34a and was associated with increased Type I collagen expression, cell viability, and migration and decreased apoptosis."	33289184
17633	Mouse	mmu-miR-34a	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	mouse heart tissues	streptozotocin (STZ) treatment	HOTAIR protected against DCM via activation of the SIRT1 expression by sponging miR-34a	30216438
17634	Mouse	mmu-miR-34a	miRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	primary cultured endothelial cells (ECs)	high glucose (HG) treatment	upregulated	30793480
17635	Mouse	mmu-miR-34a	miRNA	pifithrin-¦Á (PFT-¦Á)	diabetes-associated endothelial dysfunction	high glucose (HG)-treated primary cultured endothelial cells (ECs)	pifithrin-¦Á (PFT-¦Á) treatment	downregulated	30793480
17636	Mouse	mmu-miR-34a	miRNA	hyperoside	diabetic nephropathy (DN)	SV40-MES13 cells	hyperoside treatment	Hyperoside inhibits the proliferation of SV40-MES13 cells through the suppression of the ERK/CREB/miRNA-34a signaling pathway.	32774360
17637	Mouse	mmu-miR-34a	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	serum	streptozotocin (STZ) treatment	"The expression of acetylated p53 and miR-34a was upregulated, SIRT1was downregulated in glomeruli from patients with DN and STZ induced diabetic mice, as well as in human podocytes treated with advanced glycation end (AGE)"	33932899
17638	Mouse	mmu-miR-34a	miRNA	high glucose (HG)	diabetic vasculopathy	"MMECs, mouse micro vascular endothelial cells originated from mouse pancreas"	high glucose (HG) treatment	upregulated	26582729
17639	Mouse	mmu-miR-34a	miRNA	¦Ã-rays	DNA damage	Hematopoietic stem cells (HSCs)	Mice were exposed to various doses of total bodyirradiation (TBI) in a [60Co]¦Ã-irradiator	downregulated	30922079
17640	Mouse	mmu-miR-34a	miRNA	sodium arsenite (NaAsO2)	DNA methylation	liver tissues	sodium arsenite treatment	upregulated	32068019
17641	Mouse	mmu-miR-34a	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	male B6C3F1 mice	were injected intravenously with 3mg/kg doxorubicin treatment	upregulated	25448438
17642	Mouse	mmu-miR-34a	miRNA	kainic acid (KA)	epilepsy	mouse intraamygdala	intraamygdala microinjection of kainic acid	upregulated	22436728
17643	Mouse	mmu-miR-34a	miRNA	"dibenz[a,h]anthracene"	glucose homeostasis	liver tissue of mice	"dibenz[a,h]anthracene treatment"	upregulated	23793610
17644	Mouse	mmu-miR-34a	miRNA	ischemia	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hepatic ischemia-reperfusion (HIR)	downregulated	28708282
17645	Mouse	mmu-miR-34a	miRNA	averrhoa carambola free phenolic extract (ACF)	hepatic steatosis	leptin receptor-deficient (db/db) mice	averrhoa carambola free phenolic extract (ACF) treatment	downregulated	29090700
17646	Mouse	mmu-miR-34a	miRNA	high fat diet (HFD)	hepatic steatosis	hepatic	high fat diet (HFD) feed	upregulated	26608583
17647	Mouse	mmu-miR-34a	miRNA	perfluoroalkyl chemicals (PFASs)	hepatotoxicity	male BALB/c mice liver	PFASs treatment	upregulated	25181679
17648	Mouse	mmu-miR-34a	miRNA	perfluorooctanoic acid	hepatotoxicity	mouse liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	30342367
17649	Mouse	mmu-miR-34a	miRNA	high methionine diet	hyperhomocysteinemia (HHcy)	ApoE mice	feed with high methionine diet	downregulated	28485501
17650	Mouse	mmu-miR-34a	miRNA	hyperoxia	hyperoxia-induced acute lung injury (HALI)	neonatal mice lungs	exposed to hyperoxia	upregulated	29079808
17651	Mouse	mmu-miR-34a	miRNA	administering adenine and allantoxanic acid potassium salt	hyperuricemia	renal tissues	administering adenine and allantoxanic acid potassium salt treatment	upregulated	25535087
17652	Mouse	mmu-miR-34a	miRNA	Xie-Zhuo-Chu-Bi-Fang (XZCBF)	hyperuricemia	mouse	XZCBF for 15 days treatment	upregulated	25535087
17653	Mouse	mmu-miR-34a	miRNA	"bleomycin, cigarette smoke, silica, or sepsis"	idiopathic pulmonary fibrosis (IPF)	mouse lung tissues	caveolin-2 scaffolding domain peptide (CSP) treatment	upregulated	28273432
17654	Mouse	mmu-miR-34a	miRNA	caveolin-1 scaffolding domain peptide (CSP)	idiopathic pulmonary fibrosis (IPF)	mouse lung tissues	caveolin-1 scaffolding domain peptide (CSP) treatment	downregulated	28273432
17655	Mouse	mmu-miR-34a	miRNA	complete freund's adjuvant (CFA)	inflammation	spinal cord	complete Freund's adjuvant (CFA) treatment	upregulated	31296380
17656	Mouse	mmu-miR-34a	miRNA	flaxseed (FS)	inflammation	mouse exposed to X-ray	fed 10% FS or a 0% FS isocaloric control diet treatment	dysregulated	24755684
17657	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	inflammation	J774A.1 (mouse macrophage cell line)	lipopolysaccharide (LPS) treatment	downregulated	29773953
17658	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	inflammatory response	Murine macrophage cell line RAW264.7	lipopolysaccharide (LPS) treatment	downregulated	22483937
17659	Mouse	mmu-miR-34a	miRNA	cannabinoids	innate immune response	LPS-treated BV-2 microglial cells	cannabinoids treatment	upregulated	30742662
17660	Mouse	mmu-miR-34a	miRNA	carbon monoxide (CO)	ischemia/reperfusion (I/R) injury	hepatocytes	carbon monoxide (CO) treatment	downregulated	25916635
17661	Mouse	mmu-miR-34a	miRNA	tubulointerstitial spaces	kidney fibrosis	microvesicles isolated from obstructed kidney	tubulointerstitial spaces treatment	upregulated	25107369
17662	Mouse	mmu-miR-34a	miRNA	ionizing radiation (IR)	leukemia	mouse thymus and spleen tissue cells	irradiated	upregulated	18823940
17663	Mouse	mmu-miR-34a	miRNA	low frequency magnetic fields (LF-MF)	Lewis lung cancer	lung cancer cells	"exposed to a LF-MF (0.4T, 7.5 Hz) for 35 days"	upregulated	28389657
17664	Mouse	mmu-miR-34a	miRNA	resistin	lipid metabolism	male C57BL/6 mice liver	resistin treatment	upregulated in the liver	29197627
17665	Mouse	mmu-miR-34a	miRNA	dietary methyl deficiency	hepatocellular carcinoma (HCC)	the liver tissues	Dietary methyl deficiency treatment	upregulated	20436259
17666	Mouse	mmu-miR-34a	miRNA	bleomycin (BLM)	lung fibrosis	RLE/Abca3 cells	bleomycin (BLM) treatment	upregulated	28408209
17667	Mouse	mmu-miR-34a	miRNA	methotrexate (MTX)	lung fibrosis	RLE/Abca3 cells	methotrexate (MTX) treatment	upregulated	28408209
17668	Mouse	mmu-miR-34a	miRNA	TGF-¦Â1	lung fibrosis	RLE/Abca3 cells	TGF-¦Â1 treatment	upregulated	28408209
17669	Mouse	mmu-miR-34a	miRNA	crocin	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R-induced primary cardiomyocytes	crocin treatment	downregulated	29424794
17670	Mouse	mmu-miR-34a	miRNA	ischemia/reperfusion (I/R) 	myocardial ischaemic injury	mouse plasma;Bone marrow-derived macrophage (BMDM);Rat neonatal CMs	ischemia/reperfusion (I/R) treatment	differently regulated	28768728
17671	Mouse	mmu-miR-34a	miRNA	cadmium (Cd)	nephrotoxicity	mouse kidney	cadmium (Cd) treatment	"Furthermore, Cd-caused detrimental changes through inducing inflammation and apoptosis via the miR-34a/Sirt1/p53 axis."	33823310
17672	Mouse	mmu-miR-34a	miRNA	human immunodeficiency virus (HIV)-1 Tat	neuroinflammation	mouse microglia	Human immunodeficiency virus (HIV)-1 Tat treatment	upregulated	30872089
17673	Mouse	mmu-miR-34a	miRNA	berberine (BBR)	nonalcoholic fatty liver disease (NAFLD)	mouse liver	berberine (BBR) treatment	BBR's beneficial effects are linked with the downregulated of microRNA34a and long noncoding RNA H19	33494295
17674	Mouse	mmu-miR-34a	miRNA	"berberis aristata, elaeis guineensis?and?coffea canephora"	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	"Berberis Aristata, Elaeis Guineensis?and?Coffea Canephora treatment"	both these miRNAs had similar levels to SD-mice in HFD+E-mice	33924725
17675	Mouse	mmu-miR-34a	miRNA	green tea (GT)	nonalcoholic fatty liver disease (NAFLD)	liver tissues from Male C57Bl/6 mice were fed with a high-fat diet for 4 weeks	green tea (GT) treatment	downregulated	31885789
17676	Mouse	mmu-miR-34a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	hepatocytes	high fat diet (HFD) feed	upregulated	26330104
17677	Mouse	mmu-miR-34a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31885789
17678	Mouse	mmu-miR-34a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	high fat diet (HFD) feed	both these miRNAs had similar levels to SD-mice in HFD+E-mice	33924725
17679	Mouse	mmu-miR-34a	miRNA	palmitate	nonalcoholic fatty liver disease (NAFLD)	cholangiocytes of C57BL/6J mice	PA treatment	upregulated	28250026
17680	Mouse	mmu-miR-34a	miRNA	palmitic acid (PA)	nonalcoholic fatty liver disease (NAFLD)	C2C12 muscle cells	palmitic acid (PA) treatment	upregulated	31139863
17681	Mouse	mmu-miR-34a	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	upregulated	25672270
17682	Mouse	mmu-miR-34a	miRNA	cisplatin (DDP)	ochratoxin A (OTA) nephrotoxicity	HEI-OC1 auditory cells	cisplatin treatment	upregulated	24922076
17683	Mouse	mmu-miR-34a	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) toxicity	Primary proximal tubular epithelial cell	ochratoxin A treatment	upregulated	28710020
17684	Mouse	mmu-miR-34a	miRNA	fluid shear stress (FSS)	osteoblastic differentiation	MC3T3-E1 cells	fluid shear stress (FSS)treatment	downregulated	23595392
17685	Mouse	mmu-miR-34a	miRNA	tert-butyl hydroperoxide (TBHP)	oxidative stress	adult male mice strain Balb/c	TBHP treatment	differently regulated	25141839
17686	Mouse	mmu-miR-34a	miRNA	perfluorooctanoic acid	perfluorooctanoic acid (PFOA)-induced liver toxicity	mouse liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	30342367
17687	Mouse	mmu-miR-34a	miRNA	apigenin	peritoneal fibrosis	mouse mesothelial peritoneal cells (MMCs)	apigenin treatment	"Apigenin treatment induced a significant decrease in miR34a expression levels in HG-treated MMCs. Moreover, both apigenin treatment and miR34a depletion."	30474876
17688	Mouse	mmu-miR-34a	miRNA	radiation	radiation-induced fibrosis (RIF)	"CH3 mice muscle, skin, and subcutaneous tissue"	the right hind legs of 9-week old CH3 mice by a single-fraction dose of irradiation to 35 Gy treatment	dysregulated	24986745
17689	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	regeneration of the intestinal epithelia	intestinal tissues	lipopolysaccharide (LPS) treatment	downregulated	29621481
17690	Mouse	mmu-miR-34a	miRNA	SDF-1¦Á analog CTCE-0214 (CTCE)	sepsis	mouse with polymicrobial sepsis	EPC therapy treatment	upregulated in endothelial progenitor cells (EPCs)	24707934
17691	Mouse	mmu-miR-34a	miRNA	streptozocin (STZ)	smooth muscle cell differentiation	mouse liver	streptozotocin (STZ) treatment	Upregulation of miR-34a and downregulated of miR-122 was found in livers of STZ-induced diabetic mice	19372595
17692	Mouse	mmu-miR-34a	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	BV-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32096191
17693	Mouse	mmu-miR-34a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	teratogenesis	mouse and rat limb buds	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-34 family members are the most upregulated miRNAs	24623309
17694	Mouse	mmu-miR-34a	miRNA	dasatinib and quercetin	uterine fibrosis	uterine	dasatinib plus quercetin treatment	D+Q treatment decreased miR-34a.	31955151
17695	Mouse	mmu-miR-34a	miRNA	H2O2	cardiomyocyte apoptosis	bone marrow-derived mononuclear cells (BMCs)	H(2)O(2) treatment	upregulated	22403243
17696	Mouse	mmu-miR-34a	miRNA	insulin-like growth factor 1 (IGF-1)	leukemia	bone marrow-derived mononuclear cells (BMCs)	?IGF-1(insulin-like growth factors-1) treatment	downregulated	22403243
17697	Mouse	mmu-miR-34a-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	primary mouse cortical neurons (MCN) and Neuro2a (N2a) cells	amyloid-¦Â (A¦Â) treatment	downregulated	32251872
17698	Mouse	mmu-miR-34a-5p	miRNA	7-chlorokynurenic acid (7-CTKA)	antidepressant	mouse	7-CTKA intraperitoneal injection	downregulated	25034119
17699	Mouse	mmu-miR-34a-5p	miRNA	melatonin	anti-inflammatory responses	RAW264.7 cells (a murine macrophage cell line) and mouse bone marrow-derived macrophages (BMDMs)	metformin treatment	Metformin might show anti-inflammatory effects in macrophages through the induction of Dicer and the subsequent upregulation of miR-34a-5p and miR-125b-5p.	31102492
17700	Mouse	mmu-miR-34a-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	"plasma and heart, HL-1 cells"	doxorubicin (DOX) treatment	upregulated	30453253
17701	Mouse	mmu-miR-34a-5p	miRNA	total abdominal irradiation (TAI)	cognitive deficits	mouse small intestine tissues and peripheral blood (PD)	TAI treatment	upregulated in small intestine tissues and peripheral blood (PD)	28668331
17702	Mouse	mmu-miR-34a-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	upregulated	30453253
17703	Mouse	mmu-miR-34a-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Plasma	doxorubicin (DOX) treatment	upregulated	30627229
17704	Mouse	mmu-miR-34a-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	upregulated	27322257
17705	Mouse	mmu-miR-34a-5p	miRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	upregulated	30820263
17706	Mouse	mmu-miR-34a-5p	miRNA	dexamethasone (DEX)	innate immune response	immature DCs (iDCs)	dexamethasone (DEX) treatment	downregulated	30174602
17707	Mouse	mmu-miR-34a-5p	miRNA	X-rays	intestinal damage	small intestine	X-ray exposure	upregulated	32323814
17708	Mouse	mmu-miR-34a-5p	miRNA	ischemia/reperfusion (I/R) 	intestinal hypoxia/reoxygenation injury	C57BL/6 mice were induced	ischemia/reperfusion (I/R) treatment	upregulation	26935288
17709	Mouse	mmu-miR-34a-5p	miRNA	stearic acid	lipotoxicity	INS-1 cells	stearic-acid treatment	upregulated	26969487
17710	Mouse	mmu-miR-34a-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	29957876
17711	Mouse	mmu-miR-34a-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
17712	Mouse	mmu-miR-34a-5p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	mitophagy	mouse livers	"2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) treatment"	upregulated	31838391
17713	Mouse	mmu-miR-34a-5p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	mitophagy	Hepa1-6 cells	"2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) treatment"	upregulated	31838391
17714	Mouse	mmu-miR-34a-5p	miRNA	hypoxia	myocardial infarction (MI)	HL-1 cells	hypoxia induce	upregulated	30312158
17715	Mouse	mmu-miR-34a-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissue	high fat diet (HFD) feed	upregulated	30898698
17716	Mouse	mmu-miR-34a-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31500354
17717	Mouse	mmu-miR-34a-5p	miRNA	melatonin	nonalcoholic fatty liver disease (NAFLD)	high-fat diet (HFD)-fed mice liver tissues	melatonin treatment	downregulated	31500354
17718	Mouse	mmu-miR-34a-5p	miRNA	enoxacin	obesity	white subcutaneous (9W)	enoxacin treatment	Enoxacin led to a reduction of miR-34a-5p expression.	33268375
17719	Mouse	mmu-miR-34a-5p	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	RAW264.7 cells	metformin (Met) treatment	Metformin might show anti-inflammatory effects in macrophages through the induction of Dicer and the subsequent upregulation of miR-34a-5p and miR-125b-5p.	31102492
17720	Mouse	mmu-miR-34b	miRNA	doxorubicin (DOX)	cardiotoxicity	HL-1 cells	Doxorubicin (DOX) treatment	upregulated	31627713
17721	Mouse	mmu-miR-34b	miRNA	si-jun-zi-tang (SJZT)	melanoma	B16 cells	Si-Jun-Zi-Tang (SJZT) treatment	"Mechanistic investigations revealed that SJZT elevated miR-34b (a tumor suppressing miRNA), and lowered c-Met (a miR-34b target gene) and ¦Â-catenin (a downstream molecule of c-Met signaling) expression levels in the B16 tumors."	32505839
17722	Mouse	mmu-miR-34b	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegeneration (ND)	mouse primary cortical neurons	ELF-MFs	downregulated	29039021
17723	Mouse	mmu-miR-34b	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegenerative diseases	mouse primary cortical neurons	extremely low-frequency magnetic fields (ELF-MFs) treatment	downregulated	29039021
17724	Mouse	mmu-miR-34b	miRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	primary cultured mouse vascular smooth muscle cells (VSMCs) or mouse arteries derived from 5/6 nephrectomy	high inorganic phosphate (Pi) treatment	downregulated	31129659
17725	Mouse	mmu-miR-34b-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	HL-1 cells	high glucose (HG) treatment	LncRNA GAS5 inhibits NLRP3 inflammasome activation-mediated pyroptosis in diabetic cardiomyopathy by targeting miR-34b-3p/AHR	33092444
17726	Mouse	mmu-miR-34b-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	upregulated	30453253
17727	Mouse	mmu-miR-34b-3p	miRNA	single dose irradiation	ionizing radiation (IR) injury	LLC1 cells	single dose (SD) irradiation treatment	upregulated	28599420
17728	Mouse	mmu-miR-34b-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
17729	Mouse	mmu-miR-34b-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	29150939
17730	Mouse	mmu-miR-34b-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; primary murine pulmonary microvascular endothelial cells (PMVECs)	lipopolysaccharide (LPS) treatment	upregulated	32087725
17731	Mouse	mmu-miR-34b-5p	miRNA	pressure overload	heart failure (HF)	heart sissues	pressure overload treatment	upregulated	33224746
17732	Mouse	mmu-miR-34b-5p	miRNA	N-ethyl-N-nitrosourea (ENU)	hepatocellular carcinoma (HCC)	liver tissues	N-ethyl-N-nitrosourea (ENU) treatment	upragulated	21029445
17733	Mouse	mmu-miR-34b-5p	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	30915776
17734	Mouse	mmu-miR-34b-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
17735	Mouse	mmu-miR-34b-5p	miRNA	glyphosate	neurodevelopmental disorder	prefrontal cortex of mouse offspring	glyphosate	dysregulated	29467848
17736	Mouse	mmu-miR-34c	miRNA	kanamycin	apoptosis	inner ear tissues	kanamycin treatment	strong upregulated of miR-34a and miR-34c	21067520
17737	Mouse	mmu-miR-34c	miRNA	doxorubicin (DOX)	cardiotoxicity	HL-1 cells	Doxorubicin (DOX) treatment	upregulated	31627713
17738	Mouse	mmu-miR-34c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	podocyte	high glucose treatment	downregulated	26191142
17739	Mouse	mmu-miR-34c	miRNA	streptozocin (STZ)	diabetic peripheral neuropathy (DPN)	trigeminal ganglion (TG) tissue	streptozotocin (STZ) treatment	upregulated	30601927
17740	Mouse	mmu-miR-34c	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegeneration (ND)	mouse primary cortical neurons	ELF-MFs	downregulated	29039021
17741	Mouse	mmu-miR-34c	miRNA	extremely low-frequency magnetic fields (ELF-MFs)	neurodegenerative diseases	mouse primary cortical neurons	extremely low-frequency magnetic fields (ELF-MFs) treatment	downregulated	29039021
17742	Mouse	mmu-miR-34c	miRNA	ketamine	neurotoxicity	hippocampal	Ketamine treatment	upregulated	25052764
17743	Mouse	mmu-miR-34c	miRNA	fluid shear stress (FSS)	osteoblastic differentiation	MC3T3-E1 cells	fluid shear stress (FSS)treatment	downregulated	23595392
17744	Mouse	mmu-miR-34c	miRNA	icariin (ICA)	osteoporosis	(LPS)-induced bone loss via an osteogenic	Icariine treatment	"MiRNA-34c was dramatically upregulated after LPS stimulation; however, Icariine preincubation reversed miRNA-34c level."	27492554
17745	Mouse	mmu-miR-34c-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse alveolar macrophages (MH-S) and lung tissues	lipopolysaccharide (LPS) treatment	lncRNA SNHG14 silencing alleviated inflammation in LPS-induced ALI through miR-34c-3p-mediated inhibition of WISP1.	31660971
17746	Mouse	mmu-miR-34c-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	upregulated	30453253
17747	Mouse	mmu-miR-34c-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
17748	Mouse	mmu-miR-34c-5p	miRNA	single dose irradiation	ionizing radiation (IR) injury	LLC1 cells	single dose (SD) irradiation treatment	upregulated	28599420
17749	Mouse	mmu-miR-34c-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
17750	Mouse	mmu-miR-34c-5p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
17751	Mouse	mmu-miR-34c-5p	miRNA	aldosterone	renal fibrosis	mouse cortical collecting duct cells	aldosterone treatment (10-6 M; 3 days)	downregulated	29070573
17752	Mouse	mmu-miR-34c-5p	miRNA	aldosterone	renal fibrosis	mouse cortical collecting duct cells	aldosterone treatment (10-6 M; 3 days)	dysregulated	29070573
17753	Mouse	mmu-miR-350	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	downregulated	22782705
17754	Mouse	mmu-miR-351	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
17755	Mouse	mmu-miR-351	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	upregulated	30095204
17756	Mouse	mmu-miR-351	miRNA	streptozocin (STZ)	gestational diabetes mellitus (GDM)	liver tissues	streptozotocin (STZ) treatment	downregulated	31287224
17757	Mouse	mmu-miR-351	miRNA	Schistosoma	liver fibrosis	primary hepatic stellate cells (HSCs)	Schistosoma infection treatment	"the expr+B5808:J5808ession of host miR-351 in HSCs was markedly reduced during the early stage of Schistosoma infection However, this expression was significantly increased during the later stage of infection (after 52 d of infection)"	29255036
17758	Mouse	mmu-miR-351	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
17759	Mouse	mmu-miR-351	miRNA	prion	pancreatic cancer (PC)	The mouse neuroblastoma cell line N2a	prion treatment	downregulated of mmu-miR-351 and mmu-miR-542-5p	22985096
17760	Mouse	mmu-miR-351	miRNA	lipopolysaccharide (LPS)	sepsis-induced skeletal muscle wasting	long extensor muscle tissues of the toes	lipopolysaccharide (LPS) treatment	downregulated	30040486
17761	Mouse	mmu-miR-351-5p	miRNA	histone deacetylase inhibitor (HDACi)	B cell differentiation	B cells of C57BL/6J	"stimulated with LPS and IL-4 and treated with HDI (VPA, 500 ?M) or nil for 60 h"	upregulated	28994753
17762	Mouse	mmu-miR-351-5p	miRNA	brucella.suis	innate immune response	RAW264.7 cells	brucella.suis infection	upregulated	29387067
17763	Mouse	mmu-miR-351-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
17764	Mouse	mmu-miR-361	miRNA	histone deacetylase inhibitors (HDIs) short-chain fatty acid (SCFA) butyrate	antibody-mediated systemic autoimmunity	B cells	SCFA HDI butyrate treatment	upregulated	32265934
17765	Mouse	mmu-miR-361	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	upregulated	22719926
17766	Mouse	mmu-miR-361-3p	miRNA	nonylphenol (NP)	male infertility	GC-1 spermatogonia cell line	high concentration of NP	downregulated	29024157
17767	Mouse	mmu-miR-361-5p	miRNA	histone deacetylase inhibitor (HDACi)	B cell differentiation	B cells of C57BL/6J	"stimulated with LPS and IL-4 and treated with HDI (VPA, 500 ?M) or nil for 60 h"	upregulated	28994753
17768	Mouse	mmu-miR-361-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	Cardiomyocytes isolated from newborn mouse hearts	angiotensin II (Ang II) treatment	STAT3-inducetd upregulation of lncRNA MEG3 controls cardiac hypertrophy by regulating miR-362-5p/HDAC9 axis.	30679521
17769	Mouse	mmu-miR-361-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	30309516
17770	Mouse	mmu-miR-362	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
17771	Mouse	mmu-miR-362-3p	miRNA	curcumin (Cur)	anti-inflammatory responses	BV2 cells	curcumin treatment	miR-362-3p expression was upregulated by curcumin.	32472295
17772	Mouse	mmu-miR-362-3p	miRNA	perfluoroalkyl chemicals (PFASs)	hepatotoxicity	male BALB/c mice liver	PFASs treatment	downregulated	25181679
17773	Mouse	mmu-miR-363	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	downregulated	19462682
17774	Mouse	mmu-miR-363	miRNA	Staphylococcus aureus	inflammation	mouse mammary tissue	intramammary infection of Globally Staphylococcus aureus treatment	differently regulated	25075227
17775	Mouse	mmu-miR-363-3p	miRNA	resveratrol	hepatic insulin resistance	HepG2 cells	resveratrol (Res) treatment	RSV improves insulin resistance by upregulating miRNA mmu-miR-363-3p via the PI3K-Akt pathway	32104036
17776	Mouse	mmu-miR-365	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	mouse macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
17777	Mouse	mmu-miR-365	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	peritoneal macrophages; Bone-marrow derived macrophages (BMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28882869
17778	Mouse	mmu-miR-365	miRNA	dexamethasone (DEX)	osteoporosis	MC3T3-E1 osteoblasts	dexamethasone (DEX) treatment	downregulated	28471397
17779	Mouse	mmu-miR-365	miRNA	type II collagen and freund's adjuvant	rheumatoid arthritis (RA)	synovial tissues	type II collagen and freund's adjuvant treatment	MiR-365 expression decreased in synovial tissues of RA mice	31881377
17780	Mouse	mmu-miR-365	miRNA	curcumin (Cur)	secondary osteoporosis	bone	curcumin treatment	downregulated	26884838
17781	Mouse	mmu-miR-365	miRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	M(IL-4/IL-13) macrophages	Mycobacterium tuberculosis (Mtb) HN878 infection	upregulated	30941122
17782	Mouse	mmu-miR-365-1-5p	miRNA	cyclophosphamide (CP)	chronic ovarian dysfunction	ovarian tissues	cyclophosphamide (CP) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice."	33318603
17783	Mouse	mmu-miR-365-1-5p	miRNA	samul-tang (SM)	chronic ovarian dysfunction	ovarian tissues	samul-tang (SM) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice"	33318603
17784	Mouse	mmu-miR-3653-3p	miRNA	melatonin	osteoporosis	human bone marrow mesenchymal stem cell (hBMSC)	melatonin (MEL) treatment	Circ_0003865 expression in BMSCs was significantly decreased by MEL treatment.	33632317
17785	Mouse	mmu-miR-365-3p	miRNA	complete freund's adjuvant (CFA)	chronic inflammatory pain	spinal cord	complete Freund's adjuvant (CFA) treatment	A significant increase in miR-365-3p expression was observed from day 1 to day 7 after CFA in- jection.	31914601
17786	Mouse	mmu-miR-367	miRNA	engrafting E6.5 embryos (wildtype or Gtl2((-/+)))	teratomas	mice	engrafting E6.5 embryos (wildtype or Gtl2((-/+))) treatment	downregulated	25355544
17787	Mouse	mmu-miR-367-3p	miRNA	toosendanin (TSN)	liver damage	mouse serum	toosendanin (TSN) treatment	upregulated	30844585
17788	Mouse	mmu-miR-369-3p	miRNA	quercetin	chronic inflammatory diseases	LPS-treated murine bone marrow¨Cderived DCs (BMDCs)	quercetin treatment	upregulated	31338984
17789	Mouse	mmu-miR-369-3p	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues and isolated CD11c+ cells from colon	dextran-sulfate-sodium (DSS) treatment	downregulated	31338984
17790	Mouse	mmu-miR-369-3p	miRNA	quercetin	colitis	DSS-induced colitis mice colon tissues and isolated CD11c+ cells from colon	quercetin treatment	upregulated	31338984
17791	Mouse	mmu-miR-369-3p	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	A549 cells	bleomycin (BLM) treatment	TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells. DLEU2 directly targeted miR-369-3p.	33760118
17792	Mouse	mmu-miR-369-3p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â1 treatment	TRIM2 expression was increased and miR-369-3p expression was decreased in the lung tissues of mice with BLM-induced fibrosis and in TGF-¦Â1-stimulated A549 cells DLEU2 directly targeted miR-369-3p	33760118
17793	Mouse	mmu-miR-3695	miRNA	luteinising hormone (LH)	functions of Leydig cells	mouse TM3 Leydig cells	luteinising hormone (LH) treatment	upregulated	28762514
17794	Mouse	mmu-miR-3695	miRNA	luteinising hormone (LH)	steroidogenesis	mouse TM3 Leydig cells	luteinising hormone(LH) treatment	dysregulated	28762514
17795	Mouse	mmu-miR-369-5p	miRNA	alcohol	fetal alcohol spectrum disorders (FASD)	brain tissues	alcohol exposure	downregulated	23580197
17796	Mouse	mmu-miR-369-5p	miRNA	N-ethyl-N-nitrosourea (ENU)	hepatocellular carcinoma (HCC)	liver tissues	N-ethyl-N-nitrosourea (ENU) treatment	downregulated	21029445
17797	Mouse	mmu-miR-370	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	upregulated	30095204
17798	Mouse	mmu-miR-370	miRNA	ischemia	hepatic ischemia/reperfusion injury (HIRI)	male C57BL/6 mice	hepatic ischemia-reperfusion (HIR)	upregulated	24351048
17799	Mouse	mmu-miR-370	miRNA	ischemia/reperfusion (I/R) 	hepatic ischemia/reperfusion injury (HIRI)	liver tissues	ischemia/reperfusion (I/R) treatment	upregulated	28043920
17800	Mouse	mmu-miR-370	miRNA	glucagon-like peptide-1 (GLP-1)	lipotoxic oxidative stress	FFA-treated INS-1 cells	GLP-1	downregulated	27956176
17801	Mouse	mmu-miR-370	miRNA	ischemia/reperfusion (I/R) 	hepatic ischemia/reperfusion injury (HIRI)	C57BL/6 mice liver	ischemia/reperfusion (I/R) treatment	upregulated	28043920
17802	Mouse	mmu-miR-370	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	"The left anterior descending coronary artery was ligated with 6-0 sutures ?1.5 mm from the tip of the left auricle with a hollow plastic tube. After 30 min of ischemia, the hollow plastic tube was cut and blood flow was restored"	downregulated	30856533
17803	Mouse	mmu-miR-370	miRNA	sevoflurane (SEV)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	sevoflurane anesthetic preconditioning (SAP) treatment	upregulated	30856533
17804	Mouse	mmu-miR-370	miRNA	salidroside (SAL)	type 2 diabetes mellitus (T2DM)	liver tissue of mice	Salidroside treatment	downregulated	26948318
17805	Mouse	mmu-miR-370-3p	miRNA	fructus meliae toosendan (FMT)	liver damage	serum	Fructus Meliae Toosendan water extract (FMT) treatment	downregulated	29434260
17806	Mouse	mmu-miR-370-3p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW 264.7	lipopolysaccharide (LPS) treatment	LncRNA NEAT1 promoted the inflammation and apoptosis while restrained the proliferation of LPS-stimulated RAW 264.7 cells through the miR-370-3p/TSP-1 axis.	31957847
17807	Mouse	mmu-miR-370-3p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW 264.7 cells; HL-1 cells	lipopolysaccharides (LPS) treatment	downregulated	34004695
17808	Mouse	mmu-miR-371	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	balb/c nu-nu mice injected with 107 GC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
17809	Mouse	mmu-miR-371-5p	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
17810	Mouse	mmu-miR-373	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	downregulated	21584493
17811	Mouse	mmu-miR-374	miRNA	histone deacetylase inhibitor (HDACi)	hypercalciuric diseases	mouse	HDAC inhibitors treatment	upregulated	25071082
17812	Mouse	mmu-miR-374	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	heart tissues	The left anterior descending branch of LCA was ligated.	downregulated	30565678
17813	Mouse	mmu-miR-374	miRNA	thoracic epidural anesthesia (TEA)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	myocardial I/R mice heart tissues	thoracic epidural anesthesia (TEA) treatment	upregulated	30565678
17814	Mouse	mmu-miR-374	miRNA	anandamide (AEA)	pro-inflammatory activity	mouse	anandamide treatment	AEA differentil regulate the expression of miRNA	24699635
17815	Mouse	mmu-miR-374	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	upregulated	30242182
17816	Mouse	mmu-miR-374*	miRNA	polyphenols	cell function	mice liver cells	Polyphenols treatment	downregulated	22253797
17817	Mouse	mmu-miR-374*	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
17818	Mouse	mmu-miR-374-5p	miRNA	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	dopaminergic (DA) neuron differentiation	neuro-2a cells	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment"	dysregulated	29250806
17819	Mouse	mmu-miR-374-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29250806
17820	Mouse	mmu-miR-374-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29250806
17821	Mouse	mmu-miR-374-5p	miRNA	paraquat (PQ)	neurodegenerative diseases	N2a cells	paraquat (PQ) treatment	downregulated	29250806
17822	Mouse	mmu-miR-374a-5p	miRNA	lipopolysaccharide (LPS)	neonatal hypoxic-ischemic encephalopathy 	BV-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32464126
17823	Mouse	mmu-miR-374b	miRNA	¦¤9-tetrahydrocannabinol (THC)	inflammation	total lymph node cells and CD4(+) T cells	¦¤9-Tetrahydrocannabinol (THC) treatment	downregulated	27268054
17824	Mouse	mmu-miR-374b-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	BV2 cells	amyloid-¦Â (A¦Â) 25-35 treatment	"The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35."	33279663
17825	Mouse	mmu-miR-374b-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	BV2 cells	amyloid-¦Â (A¦Â) 25-35 treatment	MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells.	33279663
17826	Mouse	mmu-miR-374c	miRNA	myelin oligodendrocyte glycoprotein	experimental autoimmune encephalomyelitis (EAE)	spleen and brain tissues	myelin oligodendrocyte glycoprotein treatment	downregulated	31756487
17827	Mouse	mmu-miR-374c	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxic treatment	mmu_circ_0000790 Is Involved in Pulmonary Vascular Remodeling in Mice with HPH via MicroRNA-374c-Mediated FOXC1.	32199127
17828	Mouse	mmu-miR-374c-5p	miRNA	palmitic acid (PA)	impaired insulin secretion	¦Â-TC-6 cells	palmitic acid treatment	upregulated	32302972
17829	Mouse	mmu-miR-374c-5p	miRNA	stearic acid	impaired insulin secretion	¦Â-TC-6 cells	stearic acid treatment	upregulated	32302972
17830	Mouse	mmu-miR-375	miRNA	streptozocin (STZ)	¦Â-cell death and diabetes	mice ?peripheral blood and mice islets	?streptozotocin (STZ) treatment	"High-dose STZ administration dramatically increased circulating miR-375 levels, prior to the onset of hyperglycemia"	23321698
17831	Mouse	mmu-miR-375	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	the epithelia of nasal mucosa of allergic rhinitis mice	ovalbumin (OVA) treatment	downregulated	29677549
17832	Mouse	mmu-miR-375	miRNA	liraglutide	apoptosis	"mouse pancreatic ¦Á-cell line, ¦Á-TC1-6, and mouse pancreatic ¦Â-cell line, ¦Â-TC-tet"	could increase the level of and cell in pancreatic ¦Á-cells	upregulated	29225111
17833	Mouse	mmu-miR-375	miRNA	high fat diet (HFD)	atherosclerosis (AS)	heart tissues of ApoE-/- mice	high fat diet (HFD) feed	upregulated	30870679
17834	Mouse	mmu-miR-375	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	heart tissues of high-fat diet (HFD) fed ApoE-/- mice	Tanshinone IIA (TNA) treatment	downregulated	30870679
17835	Mouse	mmu-miR-375	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues	dextran sodium sulfate (DSS) treatment	downregulated	29867475
17836	Mouse	mmu-miR-375	miRNA	doxycycline	colitis	colon tissues	doxycycline (DXC) treatment	upregulated	30076847
17837	Mouse	mmu-miR-375	miRNA	minocycline (MNC)	colitis	colon tissues	minocycline (MNC) treatment	upregulated	30076847
17838	Mouse	mmu-miR-375	miRNA	tetracycline (TTC)	colitis	colon tissues	tetracycline (TTC) treatment	upregulated	30076847
17839	Mouse	mmu-miR-375	miRNA	tigecycline (TGC)	colitis	colon tissues	tigecycline (TGC) treatment	upregulated	30076847
17840	Mouse	mmu-miR-375	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	proximal colon myenteric plexus	streptozotocin (STZ) treatment	upregulated	30140011
17841	Mouse	mmu-miR-375	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colon tissues	dextran sulfate sodium (DSS) treatment	downregulated	30236870
17842	Mouse	mmu-miR-375	miRNA	high fat diet (HFD)	inflammatory response	skeletal muscle of mice	high fat diet (HFD) feed	"miR-375, miR-29, miR-320, miR-103/107 and miR-126, play a crucial role in the regulation of glucose and lipid metabolism through the control of pancreatic islet cell function"	22395471
17843	Mouse	mmu-miR-375	miRNA	high fat diet (HFD)	insulin resistance (IR)	Fecal exosomes released from intestinal epithelial cells (IECs)	?high-fat diet?feed treatment	We report that HFD feeding increased the expression of AhR and inhibited the expression of miR-375 and VAMP7	33754048
17844	Mouse	mmu-miR-375	miRNA	exenatide (EXA)	insulin sensitivity	pancreas	exenatide treatment	"The levels of miRNA-15a, 29c, 124a, and 375 in the pancreas were significantly increased in HFD control mice.These effects were reversed by treatment with exenatide."	26314504
17845	Mouse	mmu-miR-375	miRNA	exenatide (EXA)	insulin sensitivity	serum	exenatide treatment	"the levels of miRNA-15a, 29c, 124a, and 375 in the serum were significantly decreased. These effects were reversed by treatment with exenatide."	26314504
17846	Mouse	mmu-miR-375	miRNA	high fat diet (HFD)	insulin sensitivity	pancreas	high fat diet (HFD) feed	upregulated	26314504
17847	Mouse	mmu-miR-375	miRNA	high fat diet (HFD)	insulin sensitivity	serum	high fat diet (HFD) feed	downregulated	26314504
17848	Mouse	mmu-miR-375	miRNA	human islet grafts of adoptive lymphocyte transfer (ALT)	islets of Langerhans	mouse circulation	ALT	upregulated	27700000
17849	Mouse	mmu-miR-375	miRNA	concanamycin A (Con A)	liver damage	primary Kupffer cells	concanavalin A (ConA) treatment	upregulated	30206980
17850	Mouse	mmu-miR-375	miRNA	concanamycin A (Con A)	liver damage	liver tissues	concanavalin A (ConA) treatment	upregulated	30206980
17851	Mouse	mmu-miR-375	miRNA	streptozocin (STZ)	loss and apoptosis of beta cell	mouse blood plasma	STZ treatment	upregulated in blood plasma	29040320
17852	Mouse	mmu-miR-375	miRNA	morphine	morphine tolerance	CD-1 mice dorsal root ganglia (DRG)	chronic morphine treatment	downregulated in mouse dorsal root ganglia (DRG)	28603428
17853	Mouse	mmu-miR-375	miRNA	hypoxia	myocardial infarction (MI)	neonatal mouse ventricular cardiomyocytes (NMCMs)	hypoxia treatment	LNC_000898 could protect the heart against MI injury by regulating miR-375/PDK1.	32398474
17854	Mouse	mmu-miR-375	miRNA	cisplatin (DDP)	nephrotoxicity	mouse kidney proximal tubular cells	cisplatin treatment	upregulated	28119452
17855	Mouse	mmu-miR-375	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	29569260
17856	Mouse	mmu-miR-375	miRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	upregulated	32045921
17857	Mouse	mmu-miR-375	miRNA	astaxanthin	prostate cancer	Pca mouse tumor tissues	intragastrically administered 100 mg/kg astaxanthin (HA)	upregulated	28282880
17858	Mouse	mmu-miR-375	miRNA	kainic acid (KA)	temporal lobe epilepsy (TLE)	hippocampal tissues	kainic acid (KA) treatment	UCA1 was overexpressed in mice and the overexpression of UCA1 significantly reversed the abnormal proliferation of hippocampal neurons in epilepsy mice.	33829718
17859	Mouse	mmu-miR-375	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	"mouse pancreatic ¦Á-cell line, ¦Á-TC1-6"	liraglutide treatment	upregulated	29225111
17860	Mouse	mmu-miR-375	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	"mouse pancreatic ¦Â-cell line, ¦Â-TC-tet"	liraglutide treatment	downregulated	29225111
17861	Mouse	mmu-miR-375-3p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	upregulated	28396668
17862	Mouse	mmu-miR-375-3p	miRNA	solar particle event (SPE)	colorectal cancer (CRC)	plasma of a colorectal cancer susceptible mouse	solar particle event (SPE) treatment	downregulated	26432591
17863	Mouse	mmu-miR-375-3p	miRNA	streptozocin (STZ)	islets damage	serum exosomes	streptozocin (STZ) treatment	Exosomal mmu-miR-375-3p dramatically increased in serum of STZ treated mouse prior to the disturbance of blood glucose and insulin	30552311
17864	Mouse	mmu-miR-375-3p	miRNA	X-rays	vulvovaginal candidiasis (VVC)	serum	mouse whole body exposure to 7?Gy of X-rays. treatment	upregulated	29358747
17865	Mouse	mmu-miR-376	miRNA	antioxidant of bamboo leaves (AOB)	vascular development	embryoid bodies (EBs)	antioxidant of bamboo leaves (AOB) treatment	miR-376 was markedly downregulated following AOB treatment compared with the control.	29207159
17866	Mouse	mmu-miR-376a	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	upregulated	25672270
17867	Mouse	mmu-miR-376b-3p	miRNA	dihydroartemisinin (DHA)	inflammation	Mouse aortic vascular smooth muscle cells (VSMCs)	dihydroartemisinin (DHA) treatment	DHA was observed to directly depress the HG-induced expression of miR-376b-3p.	32753318
17868	Mouse	mmu-miR-376b-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
17869	Mouse	mmu-miR-376b-3p	miRNA	FTY-720	parkinson's disease (PD)	dopaminergic MN9D cells	FTY720 treatment	upregulated	30359694
17870	Mouse	mmu-miR-376b-3p	miRNA	FTY720-C2	parkinson's disease (PD)	dopaminergic MN10D cells	FTY720-C2 treatment	upregulated	30359694
17871	Mouse	mmu-miR-376b-3p	miRNA	FTY720-mitoxy	parkinson's disease (PD)	dopaminergic MN11D cells	FTY720-Mitoxy treatment	upregulated	30359694
17872	Mouse	mmu-miR-376b-3p	miRNA	FTY720-C2	parkinson's disease (PD)	MN9D cells	FTY720-C2 treatment	upregulated	30359694
17873	Mouse	mmu-miR-377	miRNA	cyclosporine A (CsA)	cardiomyocyte apoptosis	cardiomyocytes	cyclosporine A treatment	the expression of microRNA (miR)-377 was regulated by CsA.	26948033
17874	Mouse	mmu-miR-377	miRNA	hypoxia	cerebral ischemia injury (CII)	mouse brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) induce	"lncRNA NEAT1 facilitated the survival and angiogenesis of OGD-induced BMECs via targeting miR-377 and promoting the expression of VEGFA, SIRT1, and BCL-XL."	30408478
17875	Mouse	mmu-miR-377	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) treatment	Upregulation of lncRNA NEAT1 and downregulated of miR-377 were also observed under OGD conditions	30408478
17876	Mouse	mmu-miR-377	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cells	high glucose treatment	upregulated	18716028
17877	Mouse	mmu-miR-377	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	upregulated	30095204
17878	Mouse	mmu-miR-377	miRNA	TGF-¦Â	diabetic nephropathy (DN)	mesangial cells	transforming growth factor-¦Â treatment	?upregulated	18716028
17879	Mouse	mmu-miR-377	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
17880	Mouse	mmu-miR-377	miRNA	IFN-¦Ã	sj?gren's syndrome (SS)	salivary gland epithelial cells (SGECs)	interferon gamma (IFN-¦Ã) treatment	downregulated	31198060
17881	Mouse	mmu-miR-377-3p	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aorta tissues	high fat diet (HFD) feed	Deletion of ApoE and HFD treatment significantly downregulated miR-377-3p levels in aorta tissues.	32373927
17882	Mouse	mmu-miR-377-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
17883	Mouse	mmu-miR-378	miRNA	coenzyme Q10 (CoQ10)	atherosclerosis (AS)	mouse J774.A1 THP-1 macrophages	CoQ10 treatment	downregulated	24675662
17884	Mouse	mmu-miR-378	miRNA	oxygen glucose deprivation (OGD)	autophagy	primary neurons; brain tissues	oxygen glucose deprivation (OGD) treatment	downregulated	32605923
17885	Mouse	mmu-miR-378	miRNA	fish oil	brown adipose tissue thermogenesis	brown adipocytes	fish oil treatment	upregulated	27489163
17886	Mouse	mmu-miR-378	miRNA	TGF-¦Â1	cardiac fibrosis	mouse cardiac fibroblasts (CFs)	TGF-¦Â1 treatment	downregulated	31220469
17887	Mouse	mmu-miR-378	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiate	angiotensin II (Ang II) treatment	upregulated	25104350
17888	Mouse	mmu-miR-378	miRNA	high fat diet (HFD)	chondrogenesis	white adipose tissues	high fat diet (HFD) feed	downregulated	22496873
17889	Mouse	mmu-miR-378	miRNA	astragaloside IV (AS-IV)	diabetic nephropathy (DN)	high glucose-treated the mouse podocyte clone 5 (MPC5) cells	astragaloside (AS-IV) treatment	upregulated	29792879
17890	Mouse	mmu-miR-378	miRNA	high glucose (HG)	diabetic nephropathy (DN)	The mouse podocyte clone 5 (MPC5) cells	high glucose (HG) treatment	downregulated	29792879
17891	Mouse	mmu-miR-378	miRNA	fish oil	hepatosteatosis	mice liver tissues	Fisetin treatment	downregulated	23818290
17892	Mouse	mmu-miR-378	miRNA	ischemia	intestinal ischemia/reperfusion (I/R) injury	?intestinal mucosal cell	intestinal ischemia/reperfusion (I/R)	downregulated	29022896
17893	Mouse	mmu-miR-378	miRNA	electrical stimulation (EleS)	ischemic heart disease (IHD)	cardiac stem cells (CSCs)	electrical stimulation (EleS) treatment	miR-378 as a potential Ctgf regulator in (EleS)CSCs	24067999
17894	Mouse	mmu-miR-378	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	N2A cells	oxygen-glucose deprivation (OGD) treatment	downregulated	27598143
17895	Mouse	mmu-miR-378	miRNA	listeria	Listeria infection	murine ileum tissues	Listeria infection	downregulated	24327339
17896	Mouse	mmu-miR-378	miRNA	stretch	myoblast proliferation	C2C12 myoblasts	stretch treatment	downregulated	27840929
17897	Mouse	mmu-miR-378	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	miR-378 was significantly increased in fatty livers of dietary obese mice and human hepatoma HepG2 cells with accumulated lipid.	29625129
17898	Mouse	mmu-miR-378	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver	high fat diet (HFD) feed	upregulated	30218679
17899	Mouse	mmu-miR-378	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	30281809
17900	Mouse	mmu-miR-378	miRNA	high glucose (HG)	osteogenesis	mouse osteoblastic cell line MC3T3-E1	"high glucose (15.5, 25.5 or 35.5 mM) treatment"	upregulated	25400823
17901	Mouse	mmu-miR-378	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	upregulated	30242182
17902	Mouse	mmu-miR-378	miRNA	olanzapine (OLP)	psychotic disorders	brain tissues	clozapine treatment	upregulated	23318695
17903	Mouse	mmu-miR-378	miRNA	mycobacterium tuberculosis (Mtb)	pulmonary tuberculosis (PTB)	lung tissues	mycobacterium tuberculosis (Mtb) treatment	downregulated	33089914
17904	Mouse	mmu-miR-378	miRNA	pSTAT3-specific inhibitor AG-490	pulmonary tuberculosis (PTB)	lung tissues	pSTAT3-specific inhibitor AG-490 treatment	upregulated	33089914
17905	Mouse	mmu-miR-378-3p	miRNA	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	dopaminergic (DA) neuron differentiation	neuro-2a cells	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment"	dysregulated	29250806
17906	Mouse	mmu-miR-378-3p	miRNA	morphine	morphine tolerance	brainstem	morphine treatment	Chronic morphine treatment significantly increased the miR-378-3p level in the brainstem of the morphine tolerant mice.	31999011
17907	Mouse	mmu-miR-378-3p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29250806
17908	Mouse	mmu-miR-378-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29250806
17909	Mouse	mmu-miR-378a	miRNA	lipopolysaccharide (LPS)	acute aortic dissection (AAD)	aorta	lipopolysaccharide (LPS) treatment	downregulated	32634201
17910	Mouse	mmu-miR-378a	miRNA	high fat diet (HFD)	atherosclerosis (AS)	the aorta of ApoE-/- mice	high fat diet (HFD) feed	downregulated	30929259
17911	Mouse	mmu-miR-378a	miRNA	nano-titanium dioxide (nano-TiO2)	cardiovascular function	mouse heart tissues	Nano-titanium dioxide (nano-TiO2) treatment	upregulated	30704319
17912	Mouse	mmu-miR-378a-3p	miRNA	ionizing radiation (IR)	abdominal cancer	small intestines	ionizing radiation (IR) treatment	miR-378a-3p was markedly upregulated in the small intestines of mice after total abdominal irradiation.	32800335
17913	Mouse	mmu-miR-378a-3p	miRNA	high fat diet (HFD)	adipogenesis	mouse	high fat diet (HFD) feed	upregulated	25529446
17914	Mouse	mmu-miR-378a-3p	miRNA	high fat diet (HFD)	adipogenesis and obesity	adipose	high fat diet (HFD) feed	upregulated	25529446
17915	Mouse	mmu-miR-378a-3p	miRNA	Jiang Tang Xiao Ke Granule	diabetes mellitus (DM)	KKAy diabetic mice	Jiang Tang Xiao Ke Granule treatment	dysregulated	29163176
17916	Mouse	mmu-miR-378a-3p	miRNA	carbon tetrachloride (CCl4)	hepatic fibrogenesis	hepatic stellate cells (HSCs)	CCl4 treatment	downregulated	27001906
17917	Mouse	mmu-miR-378a-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	downregulated	27322257
17918	Mouse	mmu-miR-378a-3p	miRNA	high fat diet (HFD)	hyperlipidemia	fatty livers	high fat diet (HFD) feed	Activation of microRNA-378a-3p biogenesis promotes hepatic secretion of VLDL and hyperlipidemia by modulating ApoB100-Sortilin1 axis	32226531
17919	Mouse	mmu-miR-378a-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	primary hepatic stellate cell (HSC)	CCl4 treatment	downregulated	31272073
17920	Mouse	mmu-miR-378a-5p	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	upregulated	32337768
17921	Mouse	mmu-miR-378b	miRNA	luteinising hormone (LH)	functions of Leydig cells	mouse TM3 Leydig cells	luteinising hormone (LH) treatment	upregulated	28762514
17922	Mouse	mmu-miR-378b	miRNA	carbon tetrachloride (CCl4)	hepatic fibrogenesis	hepatic stellate cells (HSCs)	CCl4 treatment	downregulated	27001906
17923	Mouse	mmu-miR-378b	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	downregulated	27322257
17924	Mouse	mmu-miR-378b	miRNA	luteinising hormone (LH)	steroidogenesis	mouse TM3 Leydig cells	luteinising hormone(LH) treatment	dysregulated	28762514
17925	Mouse	mmu-miR-378c	miRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	upregulated	32337768
17926	Mouse	mmu-miR-378d	miRNA	echinococcus multilocularis metacestodes	echinococcus multilocularis infection	RAW 264.7 cells	E. multilocularis metacestodes treatment	upregulated	30322806
17927	Mouse	mmu-miR-378d	miRNA	carbon tetrachloride (CCl4)	hepatic fibrogenesis	hepatic stellate cells (HSCs)	CCl4 treatment	downregulated	27001906
17928	Mouse	mmu-miR-378d	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	downregulated	27322257
17929	Mouse	mmu-miR-378d	miRNA	E. multilocularis metacestodes	infection and immunity of E. multilocularis	RAW264¡¤7 macrophage cells	E. multilocularis metacestodes for 6 and 12 h treatment	"upregulated (mmu-miR-378d,mmu-miR-155-5p, mmu-miR-146a-5p, mmu-miR-21a-5p , mmu-miR-125a-5p) and downregulated(mmu-miR-1981-5p , mmu-miR-let-7c-1-3p)"	28942753
17930	Mouse	mmu-miR-378d	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	upregulated	30936699
17931	Mouse	mmu-miR-378d	miRNA	alpinia oxyphylla extract (AOE)	type 2 diabetes mellitus (T2DM)	db-/db- mouse kidney	A. oxyphylla extract (AOE) treatment	upregulated	28249617
17932	Mouse	mmu-miR-379	miRNA	dexamethasone (DEX)	duchenne muscular dystrophy (DMD)	muscle	dexamethasone (DEX) treatment	dexamethasone resulted in reduced muscle expression of miR-379.	32499563
17933	Mouse	mmu-miR-379	miRNA	cigarette smoke (CS)	ovarian toxicity	ovarian tissues	cigarette smoke (CS) treatment	downregulated	29377183
17934	Mouse	mmu-miR-379-5p	miRNA	arsenite	arsenite-induced liver damage	liver tissue	arsenite exposure	downregulated	30643918
17935	Mouse	mmu-miR-379-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	high glucose (HG) treatment	downregulated	31485601
17936	Mouse	mmu-miR-380-3p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissue and alveolar macrophages	cigarette smoke (CS) exposure	upregulated	31819170
17937	Mouse	mmu-miR-380-3p	miRNA	paraquat (PQ)	paraquat (PQ)-induced toxicity	mouse neuroblastoma (N2a) cells or tert-Butylhydroquinone (TBHQ)-treated N2a cells	paraquat (PQ) exposure	downregulated	31368498
17938	Mouse	mmu-miR-380-3p	miRNA	tert-butyl hydroperoxide (TBHP)	paraquat (PQ)-induced toxicity	mouse neuroblastoma (N2a) cells	tert-Butylhydroquinone (TBHQ) treatment	upregulated	31368498
17939	Mouse	mmu-miR-381	miRNA	dexmedetomidine (DEX)	acute lung injury (ALI)	LPS-induced acute lung injury mouse lung tissues	dexmedetomidine (Dex) treatment	upregulated	30102002
17940	Mouse	mmu-miR-381	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	30102002
17941	Mouse	mmu-miR-381	miRNA	H2O2	myocardial infarction (MI)	Primary cultured cardiomyocyte	H2O2 treatment	upregulated	30105734
17942	Mouse	mmu-miR-381	miRNA	hypoxia	myocardial infarction (MI)	Primary cultured cardiomyocyte	hypoxia induce	upregulated	30105734
17943	Mouse	mmu-miR-381-3p	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	E13.5 and E14.5 fetal palates	"On embryonic day 10.5 (E10.5), the pregnant mice in TCDD group were orally administrated with TCDD at dosage of 28 ¦Ìg/kg, while the pregnant mice in control group received equivalent corn oil. The pregnant mice in each group were sacrificed on E13.5 and E14.5, fetal palates were collected for analysis."	downregulated	31512462
17944	Mouse	mmu-miR-381-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina and serum of diabetic mice	streptozotocin treatment	upregulated	30883703
17945	Mouse	mmu-miR-381-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	Female BALB/c mice blood	"4,4'-methylene diphenyl diisocyanate (MDI) exposure"	downregulated	30074411
17946	Mouse	mmu-miR-381-3p	miRNA	"4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	bronchoalveolar lavage cells (BALCs)	"4,4'-methylene diphenyl diisocyanate (MDI) treatment"	downregulated	31609387
17947	Mouse	mmu-miR-381-3p	miRNA	"diisocyanate, 4,4'-methylene diphenyl diisocyanate (MDI)"	occupational asthma (OA)	Female BALB/c mice blood	Female BALB/c mice were exposed to one of three exposure regimens: dermal exposure to 1% MDI in acetone; nose-only exposure to 4580?¡À?1497?¦Ìg/m3 MDI-aerosol for 60?minutes; or MDI dermal exposure/sensitization followed by MDI-aerosol inhalation challenge.	downregulated	30074411
17948	Mouse	mmu-miR-382	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	renal tissues	streptozotocin (STZ) treatment	upregulated	29701296
17949	Mouse	mmu-miR-382	miRNA	¦Â-lapachone (BLC)	obesity	white adipose	¦Â-lapachone (BLC) treatment	downregulated	27246910
17950	Mouse	mmu-miR-382	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) toxicity	Primary proximal tubular epithelial cell	ochratoxin A treatment	upregulated	28710020
17951	Mouse	mmu-miR-382-3p	miRNA	exercise (Ex)	insulin resistance (IR)	serum from IR mouse	swimming	upregulated	31479923
17952	Mouse	mmu-miR-382-5p	miRNA	anandamide and norgestimate	depression	chronic mild stress (CMS) model of depression mouse	anandamide and norgestimate treatment	upregulated	28716528
17953	Mouse	mmu-miR-383	miRNA	calorie restriction (CR)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	calorie restriction (CR) treatment	upregulated	31863770
17954	Mouse	mmu-miR-383	miRNA	exercise (Ex)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	exercise (Ex) treatment	upregulated	31863770
17955	Mouse	mmu-miR-383	miRNA	high fat diet (HFD)	hepatic steatosis	mice thyroid and liver tissues	high fat diet (HFD) feed	downregulated	31863770
17956	Mouse	mmu-miR-383	miRNA	low fat diet (LFD)	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	low-fat diet (LF) treatment	upregulated	31863770
17957	Mouse	mmu-miR-383	miRNA	quercetin	hepatic steatosis	high-fat (HF) diet-induced obesity prone (OP) mice thyroid and liver tissues	quercetin (Que) treatment	upregulated	31863770
17958	Mouse	mmu-miR-383	miRNA	high glucose (HG)	high-fat induced diabetes	Islet beta-cell	high glucose (HG) treatment	miR-383 ameliorates high glucose-induced ¦Â-cells apoptosis and hyperglycemia in high-fat induced diabetic mice.	33058915
17959	Mouse	mmu-miR-383	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	26639663
17960	Mouse	mmu-miR-383	miRNA	methyltransferase G9a	liver mature	liver tissues from liver-specific knockout (Liv-KO) of G9a mice	liver-specific knockout (Liv-KO) of G9a	upregulated	29912608
17961	Mouse	mmu-miR-383	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	downregulated	31863770
17962	Mouse	mmu-miR-383	miRNA	low fat diet (LFD)	obesity	thyroid	low fat diet (LFD) treatment	upregulated	31863770
17963	Mouse	mmu-miR-383	miRNA	quercetin	obesity	thyroid	quercetin (QUE) treatment	upregulated	31863770
17964	Mouse	mmu-miR-383-5p	miRNA	delvestidine (DLTD)	bone marrow-derived dendritic cells (BMDCs) maturity	bone marrow-derived dendritic cells (BMDCs)	Delvestidine (DLTD) treatment	upregulated	32871480
17965	Mouse	mmu-miR-383-5p	miRNA	resveratrol	diabetic nephropathy (DN)	db/db mice podocyte	resveratrol (RS) treatment	downregulated	28374806
17966	Mouse	mmu-miR-384	miRNA	ovalbumin (OVA)	asthma	mouse purified airway smooth muscle cells	OVA treatment	downregulated	28978085
17967	Mouse	mmu-miR-384	miRNA	hypoxia	ischemic brain injury	HT22 cells and hippocampal tissues	hypoxia induce	upregulated	31165722
17968	Mouse	mmu-miR-384-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal tissues	streptozotocin (STZ) treatment	downregulated	30191948
17969	Mouse	mmu-miR-384-3p	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	upregulated	30242182
17970	Mouse	mmu-miR-384-5p	miRNA	high fat diet (HFD)	atherosclerosis (AS)	macrophages	high fat diet (HFD) feed	upregulated	27158352
17971	Mouse	mmu-miR-384-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cardiomyocytes (PCM)	angiotensin II (Ang II) treatment	downregulated	32436661
17972	Mouse	mmu-miR-384-5p	miRNA	streptozocin (STZ)	diabetic encephalopathy	Inflammatory macrophages were isolated from the brain of the mice	streptozotocin (STZ) treatment	downregulated	29511445
17973	Mouse	mmu-miR-392	miRNA	mycobacterium tuberculosis (Mtb)	pulmonary tuberculosis (PTB)	lung tissues	mycobacterium tuberculosis (Mtb) treatment	downregulated	33089914
17974	Mouse	mmu-miR-392	miRNA	pSTAT3-specific inhibitor AG-490	pulmonary tuberculosis (PTB)	lung tissues	pSTAT3-specific inhibitor AG-490 treatment	upregulated	33089914
17975	Mouse	mmu-miR-3963	miRNA	bilateral surgical destabilization of the medial meniscus (DMM)	osteoarthritis (OA)	male C57BL6 mice	bilateral surgical destabilization of the medial meniscus (DMM) treatment	dysregulated	29255152
17976	Mouse	mmu-miR-3p	miRNA	ultraviolet (UV) irradiation	skin inflammation	epidermis	UV exposure treatment	upregulated	27250636
17977	Mouse	mmu-miR-409-3p	miRNA	chronic social instability stress	embryonic development	sperm	chronic social instability stress treatment	"we found that exposure of male mice to chronic social instability stress, which leads to elevated anxiety in their female offspring across at least three generations through the paternal lineage, elevates sperm miR-409-3p levels not only in exposed males, but also in sperm of their F1 and F2 male offspring."	32333826
17978	Mouse	mmu-miR-409-3p	miRNA	IL-17	experimental autoimmune encephalomyelitis (EAE)	astrocytes from EAE mice	interleukin-17 (IL-17) treatment	upregulated	30294880
17979	Mouse	mmu-miR-409-3p	miRNA	nine hepatotoxic non-genotoxins (NGTXs)	genotoxicity	liver tissues	nine hepatotoxic non-genotoxins (NGTXs) treatment	downregulated	29777724
17980	Mouse	mmu-miR-409-3p	miRNA	nine hepatotoxic non-genotoxins (NGTXs)	genotoxicity	plasma	nine hepatotoxic non-genotoxins (NGTXs) treatment	upregulated	29777724
17981	Mouse	mmu-miR-409-3p	miRNA	choline- and folate-deficient (CFD) diet	liver damage	plasma	choline- and folate-deficient (CFD) diet treatment	upregulated	26878785
17982	Mouse	mmu-miR-409-3p	miRNA	IL-17	multiple sclerosis (MS)	Primary mouse astrocytes	interleukin-17 (IL-17) treatment	upregulated	30294880
17983	Mouse	mmu-miR-409-3p	miRNA	choline- and folate-deficient (CFD) diet	nonalcoholic fatty liver disease (NAFLD)	plasma	choline- and folate-deficient (CFD) treatment	upregulated	26878785
17984	Mouse	mmu-miR-409-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	mice cortexes	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	31849582
17985	Mouse	mmu-miR-409-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal microvascular endothelial cells (RMECs)	high glucose (HG) treatment	upregulated	32292119
17986	Mouse	mmu-miR-409-5p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal tissues	high glucose (HG) treatment	upregulated	32292119
17987	Mouse	mmu-miR-410	miRNA	hesperetin	acute lung injury (ALI)	lung tissues	Hesperetin (Hesp) treatment	MicroRNA-410 (miR-410) levels were significantly lower in the lung tissues of ALI mice and were reversed after Hesp treatment.	32762101
17988	Mouse	mmu-miR-410	miRNA	Tangeretin	gastric cancer (GC)	gastric cancer cells	Tangeretin treatment	upregulated	25998143
17989	Mouse	mmu-miR-410	miRNA	choline- and folate-deficient (CFD) diet	liver damage	plasma	choline- and folate-deficient (CFD) diet treatment	upregulated	26878785
17990	Mouse	mmu-miR-410	miRNA	choline- and folate-deficient (CFD) diet	nonalcoholic fatty liver disease (NAFLD)	plasma	choline- and folate-deficient (CFD) treatment	upregulated	26878785
17991	Mouse	mmu-miR-410	miRNA	olanzapine (OLP)	psychotic disorders	brain tissues	clozapine treatment	upregulated	23318695
17992	Mouse	mmu-miR-410	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	lung tissues	hypoxia induce	downregulated	31289307
17993	Mouse	mmu-miR-410-3p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	chondrocytes	lipopolysaccharide (LPS) treatment	downregulated	32709223
17994	Mouse	mmu-miR-410-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	cardiomyocytes	lipopolysaccharide (LPS) treatment	"miR-410-3p was downregulated, while TLR2 was upregulated in LPS-induced mice and cardiomyocytes."	33230433
17995	Mouse	mmu-miR-411-5p	miRNA	Ultra-high molecular weight polyethylene (UHMWPE)	particle-induced osteolysis (PIO)	mesenchymal stem cells (MSCs)	Ultra-high molecular weight polyethylene (UHMWPE) treatment	The expression of miR-411-5p was decreased in osteolysis mice and UHMWPE-induced mMSCs	32061766
17996	Mouse	mmu-miR-412-5p	miRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	downregulated in the OIR samples	31452702
17997	Mouse	mmu-miR-421	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia induce	upregulated	31144392
17998	Mouse	mmu-miR-421	miRNA	¦¤9-tetrahydrocannabinol (THC)	inflammation	total lymph node cells and CD4(+) T cells	¦¤9-Tetrahydrocannabinol (THC) treatment	downregulated	27268054
17999	Mouse	mmu-miR-421	miRNA	cortisone	rheumatoid arthritis (RA)	synovial tissues	cortisone treatment	downregulated	31646548
18000	Mouse	mmu-miR-422a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuron apoptosis	primary murine neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32999283
18001	Mouse	mmu-miR-423-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	immortalized mouse podocyte cell line (MPC5)	high glucose (HG) treatment	downregulated	30245133
18002	Mouse	mmu-miR-423?5p	miRNA	carbon tetrachloride (CCl4)	hepatotoxicity	blood	carbon tetrachloride (CCl4) treatment	upregulated	32528856
18003	Mouse	mmu-miR-423?5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32153563
18004	Mouse	mmu-miR-424	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Mouse pulmonary microvascular endothelial cells (MPVECs)	lipopolysaccharide (LPS) treatment	downregulated	32818819
18005	Mouse	mmu-miR-424	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	THRIL accelerates sepsis-induced lung injury by sponging miR-424 and further restoring ROCK2.	32818819
18006	Mouse	mmu-miR-424	miRNA	tanshinone IIA (Tan IIA)	fracture healing	mouse pre-osteoblast MC3T3-E1 cells	Tanshinone IIA (Tan IIA) treatment	downregulated	31306638
18007	Mouse	mmu-miR-424	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	Proximal kidney tubular cells	hypoxia induce	upregulated	31105811
18008	Mouse	mmu-miR-424	miRNA	ischemia/reperfusion (I/R) 	transient cerebral ischemia	peri-infarct cortex	ischemia/reperfusion (I/R) treatment	MiR-424 levels in the peri-infarct cortex increased at 1 and 4 hours then decreased 24 hours after reperfusion	25523055
18009	Mouse	mmu-miR-424	miRNA	transient cerebral ischemia	transient cerebral ischemia/reperfusion injury	C57/BL6 mice the peri infarct cortex	middle cerebral artery occlusion for 1 hour followed by reperfusion (ischemia/reperfusion) treatment	upregulated at 1 and 4 hours then downregulated 24 hours after reperfusion	25523055
18010	Mouse	mmu-miR-424-5p	miRNA	saturated fatty acids (SFA) palmitate (PA)	obesity-induced hepatic insulin resistance	liver tissues	saturated fatty acids (SFA) palmitate (PA) treatment	miR-424-5p was upregulated in both PA-treated HFD-fed mice	30033101
18011	Mouse	mmu-miR-425	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart sissues	doxorubicin (DOX) treatment	DOX resulted in a remarkable decrease of miR-425 in heart tissues.	32092815
18012	Mouse	mmu-miR-425	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	substantia nigra tissue	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	31383850
18013	Mouse	mmu-miR-425-3p	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	myocardial tissues	Coxsackievirus B3 (CVB3) infection	miR-425-3p was lowly expressed in myocardial tissues of mice with viral myocarditis.	33332750
18014	Mouse	mmu-miR-425-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse brain microvascular endothelial cell (BMEC)	oxygen-glucose deprivation (OGD) treatment	upregulated	33491845
18015	Mouse	mmu-miR-425-5p	miRNA	lipopolysaccharide (LPS)	sepsis	liver tissues	lipopolysaccharide (LPS) treatment	downregulated	32002587
18016	Mouse	mmu-miR-4262	miRNA	angiotensin-converting enzyme 2 (ACE2)	acute lung injury (ALI)	lung	angiotensin converting enzyme 2 (ACE2) treatment	ACE2 appeared to significantly suppress the upregulation of miR-4262 in mouse lung after ALI	26356266
18017	Mouse	mmu-miR-429	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	MLE-12 cells; lung tissues	lipopolysaccharide (LPS) treatment	miR-429 was increased in lung tissues from LPS-induced ALI mice and LPS-treated MLE-12 cells.	31837322
18018	Mouse	mmu-miR-429	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	murine alveolar epithelial cell line MLE-12	lipopolysaccharide (LPS) treatment	GAS5 suppresses inflammatory responses and apoptosis of alveolar epithelial cell MLE-12 by targeting miR-429/DUSP1 axis.	31837322
18019	Mouse	mmu-miR-429	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	primary mouse cortical neurons	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	30264333
18020	Mouse	mmu-miR-429	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Mouse brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32404105
18021	Mouse	mmu-miR-429	miRNA	dextran sodium sulfate (DSS)	colitis	colons	dextran sulphate sodium [DSS] treatment	downregulated	26818658
18022	Mouse	mmu-miR-429	miRNA	dextran sodium sulfate (DSS)	colitis	colon tissues	dextran sulfate sodium (DSS) treatment	downregulated	30334065
18023	Mouse	mmu-miR-429	miRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	mouse primary hippocampal neurons	hypoxia induce	downregulated	31185248
18024	Mouse	mmu-miR-429	miRNA	lipopolysaccharide (LPS)	microglial neuroinflammation	BV-2 microglia	lipopolysaccharide (LPS) treatment	upregulated	31896511
18025	Mouse	mmu-miR-429	miRNA	anoxia/reoxygenation (A/R)	myocardial infarction (MI)	primary cultured cardiomyocytes	anoxia/reoxygenation (AR) treatment	downregulated	31494170
18026	Mouse	mmu-miR-429	miRNA	leptin	obesity	hypothalamus?tissues	leptin treatment	downregulated	24394757
18027	Mouse	mmu-miR-429	miRNA	CoCl2	osteoblastic differentiation	MC3T3-E1 cells	CoCl2 treatment	upregulated	27576955
18028	Mouse	mmu-miR-429	miRNA	lipopolysaccharide (LPS)	traumatic brain injury (TBI)	BV-2 cells	lipopolysaccharide (LPS) treatment	LPS and TBI significantly induce the up-expression of miR-429.	31896511
18029	Mouse	mmu-miR-429	miRNA	insulin-like growth factor 1 (IGF-1)	unilateral ureteral obstruction (UUO)	mouse renal epithelial cells	insulin-like growth factor-1 (IGF-1) treatment	downregulated	27301852
18030	Mouse	mmu-miR-429-3p	miRNA	TGF-¦Â	breast cancer	normal murine mammary gland epithelial (NMuMG) cells	transforming growth factor (TGF)¦Â treatment	downregulated	30285803
18031	Mouse	mmu-miR-429-3p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
18032	Mouse	mmu-miR-429-3p	miRNA	coix seed Oil (CSO)	triple negative breast cancer (TNBC)	mouse triple-negative breast cancer (TNBC) tissues	coix Seed Oil (CSO) treatment	upregulated	33101013
18033	Mouse	mmu-miR-431-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	downregulated	30453253
18034	Mouse	mmu-miR-431-5p	miRNA	angiotensin II (Ang II)	hypertension	mesenteric arteries	angiotensin II (Ang II) treatment	upregulated	30929512
18035	Mouse	mmu-miR-432	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
18036	Mouse	mmu-miR-432-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocyte	angiotensin II (Ang II) treatment	downregulated	29966657
18037	Mouse	mmu-miR-433	miRNA	inorganic nitrite	acute myocardial infarction (AMI)	heart tissues	single-dose of nitrite	downregulated	28090786
18038	Mouse	mmu-miR-433	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
18039	Mouse	mmu-miR-433	miRNA	amyloid-¦Â (A¦Â) 1-40	age-related macular degeneration (AMD)	C57BL/6 mice eye tissues	amyloid-¦Â (A¦Â) 1-40 treatment	downregulated	28324113
18040	Mouse	mmu-miR-433	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	SH-SY5Y cells; SK-N-SH cells	amyloid-¦Â (A¦Â) treatment	downregulated	32871216
18041	Mouse	mmu-miR-433	miRNA	TGF-¦Â	cardiac fibrosis	primary adult cardiac fibroblasts	TGF-¦Â treatment	"Inhibition of miR-433 attenuated cardiac fibroblast proliferation and myofibroblast differentiation in murine post-MI models and in fibroblasts induced by TGF-¦Â and AngII stimulation In contrast, upregulation of miR-433 promoted cardiac fibrotic response CircNFIB acts as a competing endogenous RNA for miR-433"	31316543
18042	Mouse	mmu-miR-433	miRNA	high glucose (HG)	diabetes mellitus (DM)	Min-6 pancreatic ¦Â cells	high-glucose medium	downregulated	28713945
18043	Mouse	mmu-miR-433	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	balb/c nu-nu mice injected with 107 GC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
18044	Mouse	mmu-miR-433-3p	miRNA	ginkgo biloba extract (GBE)	hepatocellular carcinoma (HCC)	non-tumor (ENT) liver	ginkgo biloba extract (GBE) treatment	upregulated	32306082
18045	Mouse	mmu-mir-434-3p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
18046	Mouse	mmu-miR-434-3p	miRNA	long-term bed rest	disuse muscle atrophy	mouse both serum and muscle	long-term bed rest	downregulated	28329037
18047	Mouse	mmu-miR-434-3p	miRNA	pilocarpine	epilepsy	blood and brain	pilocarpine treatment	upregulated	32590288
18048	Mouse	mmu-miR-434-3p	miRNA	Ultra-high molecular weight polyethylene (UHMWPE)	particle-induced osteolysis (PIO)	mesenchymal stem cells (MSCs)	Ultra-high molecular weight polyethylene (UHMWPE) treatment	The expression of miR-434-3p was decreased in osteolysis mice and UHMWPE-induced mMSCs	32061766
18049	Mouse	mmu-miR-434-5p	miRNA	olanzapine (OLP)	psychotic disorders	brain tissues	clozapine treatment	upregulated	23318695
18050	Mouse	mmu-miR-448	miRNA	ischemia/reperfusion (I/R) 	acute ischemic and hemorrhagic stroke	mouse circulation	ischemia/reperfusion (I/R) treatment	upregulated	28193834
18051	Mouse	mmu-miR-448	miRNA	high fat diet (HFD)	atherosclerosis (AS)	aortic smooth muscle cell (ASMCs)	high fat diet (HFD) feed	miR-448 was highly expressed in aortic smooth muscle of AS model mice.	32848826
18052	Mouse	mmu-miR-448	miRNA	lipopolysaccharide (LPS)	endometriosis	uterine tissue	lipopolysaccharides (LPS) treatment	downregulated	31674024
18053	Mouse	mmu-miR-448	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung tissues	bleomycin (BLM) treatment	downregulated	31506947
18054	Mouse	mmu-miR-448	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	T2D mice-derived macrophages	high fat diet (HFD) feed	downregulated	30536833
18055	Mouse	mmu-miR-448	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	T2D mice-derived macrophages	streptozotocin (STZ) treatment	downregulated	30536833
18056	Mouse	mmu-miR-448	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	T2D mice-derived macrophages	Type 2 diabetes models in C57BL/6J mice were generated by a combination administration of streptozotocin (STZ) and a high-fat diet (HFD) treatment	downregulated	30536833
18057	Mouse	mmu-miR-448-5p	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin solution treatment	downregulated	30362537
18058	Mouse	mmu-miR-448-5p	miRNA	morphine	painful or stressful conditions	hippocampal	Morphine treatment	downregulated	25844808
18059	Mouse	mmu-miR-449	miRNA	cyclopamine	regulating the activity of Shh signaling	embryonic lung cultures	cyclopamine treatment	dysregulated	24617895
18060	Mouse	mmu-miR-449a	miRNA	histone deacetylase (HDAC)	diabetes mellitus (DM)	C2C12 cells	histone deacetylase (HDAC) treatment	upregulated	27184529
18061	Mouse	mmu-miR-449a	miRNA	bone morphogenetic protein 9 (BMP9)	osteogenesis	The conditionally immortalized mouse multipotent adipose-derived cells iMADs	bone morphogenetic protein 9 (BMP9) treatment	downregulated	31825894
18062	Mouse	mmu-miR-449a	miRNA	silica	silicosis	lung	silica treatment	downregulated	27351886
18063	Mouse	mmu-miR-449a-5p	miRNA	methimazole (MTZ)	liver damage	liver tissues	methimazole (MTZ) treatment	upregulated	27421576
18064	Mouse	mmu-miR-449b	miRNA	bone morphogenetic protein 9 (BMP9)	osteogenesis	The conditionally immortalized mouse multipotent adipose-derived cells iMADs	bone morphogenetic protein 9 (BMP9) treatment	downregulated	31825894
18065	Mouse	mmu-miR-450b-3p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
18066	Mouse	mmu-miR-450b-3p	miRNA	Silica nanoparticles (SiNPs)	reproductive toxicity	testis; GC-2spd cells	Silica nanoparticles (SiNPs) treatment	"The results showed that SiNPs induced the apoptosis of spermatogenic cells, decreased the quantity and quality of the sperm, reduced the expressions of miR-450 b-3p"	33652185
18067	Mouse	mmu-miR-450b-5p	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung fibroblasts	bleomycin (BLM) treatment	downregulated	32848140
18068	Mouse	mmu-miR-450b-5p	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
18069	Mouse	mmu-miR-451	miRNA	aspergillus fumigatus (A. fumigatus)	asthma	lung tissues	Aspergillus fumigatus (DRA) treatment	downregulated	32159972
18070	Mouse	mmu-miR-451	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	mouse lung endothelial cells (MLECs); lung tissues	hyperoxia treatment	Increased expression of miR-451 was noted in MLECs exposed to hyperoxia and in lungs of BPD mice.	32321512
18071	Mouse	mmu-miR-451	miRNA	genistein	cardiac hypertrophy	isoproterenol-treated mice heart tissues	genistein treatment	upregulated	30798118
18072	Mouse	mmu-miR-451	miRNA	isoproterenol	cardiac hypertrophy	heart tissues	isoprenaline (ISO) tteatment	downregulated	30798118
18073	Mouse	mmu-miR-451	miRNA	doxorubicin (DOX)	cardiotoxicity	heart tissues and cardiomyocytes	doxorubicin treatment	upregulated	31355248
18074	Mouse	mmu-miR-451	miRNA	complete freund's adjuvant (CFA)	chronic inflammatory pain	spinal dorsal horn and spinal microglia	complete Freund's adjuvant (CFA) treatment	downregulated	30069596
18075	Mouse	mmu-miR-451	miRNA	estrogen (ES)	renal fibrosis	mouse uterus tissues	Estrogen treatment	mirn451 was significantly increased by estrogen administration whereas mirn181b and mirn204 expression was significantly reduced	20720260
18076	Mouse	mmu-miR-451	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	heart tissues	streptozotocin (STZ) treatment	upregulated	30872181
18077	Mouse	mmu-miR-451	miRNA	kainic acid (KA)	epilepsy	hippocampus	kainic acid (KA) treatment	upregulated	31870266
18078	Mouse	mmu-miR-451	miRNA	lipopolysaccharide (LPS)	bacterial infection	"the whole blood, serum and white blood cells (WBCs) of C57BL/6 and Tlr2-/- mice"	lipopolysaccharide (LPS) treatment	upregulated	23286671
18079	Mouse	mmu-miR-451	miRNA	high glucose (HG)	inflammation	glomerular mesangial cells (SV40-MES-13)	high glucose (HG) treatment	upregulated	31652441
18080	Mouse	mmu-miR-451	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver	high fat diet (HFD) feed	downregulated	25957914
18081	Mouse	mmu-miR-451	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31396337
18082	Mouse	mmu-miR-451	miRNA	swimming	nonalcoholic fatty liver disease (NAFLD)	high fat diet (HFD)-fed mice liver tissues	swim training induce treatment	upregulated	31396337
18083	Mouse	mmu-miR-451	miRNA	lipopolysaccharide (LPS)	nonalcoholic steatohepatitis (NASH)	NCTC1469 cells and Raw264.7 cells	LPS (Lipopolysaccharide) treatment	downregulated	31816816
18084	Mouse	mmu-miR-451	miRNA	genistein	obesity and diabetes	mouse adipose tissues	genistein treatment	upregulated	32129363
18085	Mouse	mmu-miR-451	miRNA	monocrotaline (MCT)	pulmonary hypertension (PH)	plasma	monocrotaline (MCT) treatment	downregulated	29795360
18086	Mouse	mmu-miR-451	miRNA	cecal ligation and puncture (CLP)	sepsis	whole blood	cecal ligation and puncture (CLP) treatment	upregulated	24205035
18087	Mouse	mmu-miR-451	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	upregulated	26426744
18088	Mouse	mmu-miR-451	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	type 2 DM mouse hearts	high fat diet (HFD) feed	upregulated	25362209
18089	Mouse	mmu-miR-451	miRNA	whole grain highland barley (WGH)	type 2 diabetes mellitus (T2DM)	liver tissues	whole grain highland barley (WGH) treatment	upregulated	33104141
18090	Mouse	mmu-miR-451a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	miR-451a was upregulated at 24h.	32727087
18091	Mouse	mmu-miR-451a	miRNA	3¦Â-hydroxycholest-5-en-7-one	anti-inflammatory responses	RAW 264.7 cells	3¦Â-hydroxycholest-5-en-7-one treatment	upregulated	32771556
18092	Mouse	mmu-miR-451a	miRNA	ovalbumin (OVA)	asthma	airway epithelium	ovalbumin (OVA) treatment	downregulated	32234673
18093	Mouse	mmu-miR-451a	miRNA	doxorubicin (DOX)	cardiotoxicity	"plasma and heart, HL-1 cells"	doxorubicin (DOX) treatment	downregulated	30453253
18094	Mouse	mmu-miR-451a	miRNA	quercetin	chronic inflammatory diseases	LPS-treated murine bone marrow¨Cderived DCs (BMDCs)	quercetin treatment	upregulated	31338984
18095	Mouse	mmu-miR-451a	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	downregulated	30453253
18096	Mouse	mmu-miR-451a	miRNA	electroacupuncture (EA)	electroacupuncture (EA)	CD4 T cells	electroacupuncture (EA) treatment	upregulated	32026263
18097	Mouse	mmu-miR-451a	miRNA	"1,2-Dichloroethane (1,2-DCE)"	glucose homeostasis	NIH Swiss mice	"1,2-dichloroethane (1,2-DCE) treatment"	upregulated in the livers	28960355
18098	Mouse	mmu-miR-451a	miRNA	"1,2-dichloroethane (1,2-DCE)"	glycerol gluconeogenesis	liver tissues	"1,2-dichloroethane (1,2-DCE) treatment"	"miR-451a was significantly upregulated in the liver tissue of mice exposed to 700 mg m -3 1,2-DCE."	28960355
18099	Mouse	mmu-miR-451a	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	26639663
18100	Mouse	mmu-miR-451a	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	AML12 cells	"free fatty acids (FFAs; oleate/palmitate, 2:1 ratio) treatment"	downregulated	29604329
18101	Mouse	mmu-miR-451a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	29604329
18102	Mouse	mmu-miR-451a	miRNA	parathyroid hormone (PTH)	osteoblastic differentiation	mice calvarial osteoblasts (MCOs)	parathyroid hormone (PTH) treatment	PTH promotes glucose dependent miR-451a expression which stimulates osteoblast differentiation	30218791
18103	Mouse	mmu-miR-452	miRNA	hypoxia	sleep apnea syndrome (SAS)	mouse 3T3-L1 cells	hypoxia treatment	downregulated	31013606
18104	Mouse	mmu-miR-454	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	26741509
18105	Mouse	mmu-miR-455	miRNA	candida albicans (C. albicans)	Alzheimer's disease (AD)	mouse macrophages	candida albicans infection	upregulated	21060679
18106	Mouse	mmu-miR-455	miRNA	oral gavage	anti-inflammatory responses	dextran sodium sulfate (DSS)-induced colitis-associated tumorigenesis Apc(Min/+) mouse	via oral gavage for 5 weeks treatment	upregulated	24817032
18107	Mouse	mmu-miR-455	miRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiomyocytes of C57BL/6 mice	angiotensin II (Ang II) treatment	downregulated	28753062
18108	Mouse	mmu-miR-455	miRNA	norcantharidin (NCTD)	hepatocellular carcinoma (HCC)	liver tissues	intraperitoneal injection of different concentration of NCTD treatment	upregulated	24719559
18109	Mouse	mmu-miR-455-3p	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	pulmonary fbrotic tissues	bleomycin (BLM) treatment	upregulated	33549106
18110	Mouse	mmu-miR-455-3p	miRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	Primary mouse lung fbroblasts	TGF-¦Â1 treatment	downregulated	33549106
18111	Mouse	mmu-miR-455-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	mouse neuroblastoma cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	28934394
18112	Mouse	mmu-miR-455-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	SV40-MES13 cells	high-glucose (HG) treatment	downregulated	31934070
18113	Mouse	mmu-miR-455-3p	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
18114	Mouse	mmu-miR-455-3p	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
18115	Mouse	mmu-miR-455-3p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse neuronal cells	oxygen-glucose deprivation (OGD) treatment	downregulated	33738662
18116	Mouse	mmu-miR-455-3p	miRNA	bile duct ligation (BDL)	liver fibrosis	liver tissues	bile duct ligation (BDL) treatment	downregulated	31150929
18117	Mouse	mmu-miR-455-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	31150929
18118	Mouse	mmu-miR-455-3p	miRNA	high fat diet (HFD)	liver fibrosis	liver tissues	high fat diet (HFD) feed	downregulated	31150929
18119	Mouse	mmu-miR-455-3p	miRNA	ferric ammonium citrate (FAC)	osteoporosis	osteoblast cell lines MC3T3-E1	ferric ammonium citrate (FAC) treatment	downregulated	29042277
18120	Mouse	mmu-miR-455-3p	miRNA	ferric ammonium citrate (FAC)	oxidative stress	osteoblast cell lines MC3T3-E1	FAC	downregulated	29042277
18121	Mouse	mmu-miR-455-3p	miRNA	morphine	painful or stressful conditions	hippocampal	Morphine treatment	downregulated	25844808
18122	Mouse	mmu-miR-455-3p	miRNA	cinnamic acid (CNA)	traumatic brain injury (TBI)	dendritic spines from TBI mice	cinnamic acid (CNA) treatment	upregulated	31473194
18123	Mouse	mmu-miR-455-5p	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
18124	Mouse	mmu-miR-455-5p	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
18125	Mouse	mmu-miR-455-5p	miRNA	cold	obesity	brown adipose tissue (BAT)	cold treatment	downregulated	33015181
18126	Mouse	mmu-miR-463-3p	miRNA	hypoxia	tibial nerve regeneration	primary tibial nerve cells	oxygen-glucose deprivation treatment	upregulated	31468997
18127	Mouse	mmu-miR-464	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
18128	Mouse	mmu-miR-465b-5p	miRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	palate	all-trans retinoic acid (ATRA) treatment	?NONMMUT004850.2/NONMMUT024276.2-miR-741-3p/miR-465b-5p-Prkar1¦Á?could potentially serve as an important regulatory mechanism of palatal fusion in the development of the cleft palate.	32042778
18129	Mouse	mmu-miR-465b-5p	miRNA	neuregulin-1£¨NRG1£©	cell differentiation	murine embryonic stem cell	neuregulin-1£¨NRG1£©	downregulated	21451102
18130	Mouse	mmu-miR-465d	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
18131	Mouse	mmu-miR-466	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	bronchoalveolar lavage fluid (BALF)	lipopolysaccharide (LPS) treatment	upregulated	31221118
18132	Mouse	mmu-miR-466	miRNA	cannabinoid receptor 1 (CB1) antagonists SR141716A	diet-induced obesity (DIO)	mouse adipose tissue macrophage (ATM)	SR141716A treatment	downregulated	30910812
18133	Mouse	mmu-miR-466a-3p	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	nasal mucosa tissues	ovalbumin (OVA) treatment	downregulated	31081939
18134	Mouse	mmu-miR-466a-3p	miRNA	high glucose (HG)	cell differentiation	neural stem cells (NSCs)	high glucose treatment	downregulated	23776576
18135	Mouse	mmu-miR-466a-3p	miRNA	arginine vasopressin	osmoregulation	mIMCD3 cells	exposure to arginine vasopressin treatment	downregulated	24389345
18136	Mouse	mmu-miR-466b-3p	miRNA	arginine vasopressin	osmoregulation	mIMCD3 cells	exposure to arginine vasopressin treatment	downregulated	24389345
18137	Mouse	mmu-miR-466c-3p	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	downregulated	23716137
18138	Mouse	mmu-miR-466c-3p	miRNA	arginine vasopressin	osmoregulation	mIMCD3 cells	exposure to arginine vasopressin treatment	downregulated	24389345
18139	Mouse	mmu-miR-466d-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18140	Mouse	mmu-miR-466d-3p	miRNA	high glucose (HG)	cell differentiation	neural stem cells (NSCs)	high glucose treatment	downregulated	23776576
18141	Mouse	mmu-miR-466d-3p	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
18142	Mouse	mmu-miR-466d-5p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18143	Mouse	mmu-miR-466d-6p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18144	Mouse	mmu-miR-466e	miRNA	high fat diet (HFD)	chronic oxidative stress	mouse exposed to X-rays	high fat diet (HFD) feed	upregulated	25171162
18145	Mouse	mmu-miR-466e-3p	miRNA	arginine vasopressin	osmoregulation	mIMCD3 cells	exposure to arginine vasopressin treatment	downregulated	24389345
18146	Mouse	mmu-miR-466f	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
18147	Mouse	mmu-miR-466f-3p	miRNA	low chromium (Cr)	insulin resistance (IR)	liver	fed a control or LC diet for 13 weeks	dysregulatedin liver	29286159
18148	Mouse	mmu-miR-466h-5p	miRNA	H1N1 influenza virus	endometriosis and endometrial carcinoma	mouse lung?tissues	H1N1 influenza virus infection	upregulated	24066118
18149	Mouse	mmu-miR-466i-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	upregulated	27322257
18150	Mouse	mmu-miR-466j	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
18151	Mouse	mmu-miR-466m-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	MLE-12 cells	lipopolysaccharide (LPS) treatment	Hsp4 alleviates lipopolysaccharide-induced apoptosis of lung epithelial cells via miRNA-466m-3p/DNAjb6 axis.	32976821
18152	Mouse	mmu-miR-466p-3p	miRNA	arginine vasopressin	osmoregulation	mIMCD3 cells	exposure to arginine vasopressin treatment	downregulated	24389345
18153	Mouse	mmu-miR-467a	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	upregulated	22719926
18154	Mouse	mmu-miR-467a	miRNA	radiation	radiocarcinogenesis	mouse thymic lymphoma tissues	radiation treatment	upregulated	25552935
18155	Mouse	mmu-miR-467a*	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	downregulated	23716137
18156	Mouse	mmu-miR-467a-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18157	Mouse	mmu-miR-467a-3p	miRNA	ganoderma lucidum extract (GLE)	hepatocellular carcinoma (HCC)	Hepa 1-6 cells	Ganoderma lucidum extract (GLE) treatment	upregulated	32106374
18158	Mouse	mmu-miR-467a-5p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18159	Mouse	mmu-miR-467b	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mice liver cells	high fat diet (HFD) feed	downregulated	21986524
18160	Mouse	mmu-miR-467b*	miRNA	polyphenols	cell function	mice liver cells	Polyphenols treatment	downregulated	22253797
18161	Mouse	mmu-miR-467c	miRNA	walnut	colorectal cancer (CRC)	colorectal tumor tissue	walnut-containing diet treatment	downregulated	25882694
18162	Mouse	mmu-miR-468-3p	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
18163	Mouse	mmu-miR-471-3p	miRNA	advanced glycation end product (AGE)	diabetic cardiomyopathy (DCM)	RAW264.7 cells	advanced glycation end products (AGEs) treatment	"Meanwhile, miR-471-3p was significantly upregulated in RAW264.7 cells induced by AGEs and inhibition of miR-471-3p could reduce the inflammatory polarization of macrophages."	33417962
18164	Mouse	mmu-miR-483	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
18165	Mouse	mmu-miR-483	miRNA	recombinant Adeno-Cre viruses (AdV-Cre)	lung adenocarcinoma (LUAD)	lung	recombinant Adeno-Cre viruses (AdV-Cre) treatment	downregulated	25359683
18166	Mouse	mmu-miR-483*	miRNA	high fat diet (HFD)	acute myocardial infarction (AMI)	liver tissue	high fat diet (HFD) feed	downregulated	19835573
18167	Mouse	mmu-miR-483-3p	miRNA	black raspberry (BRB) anthocyanins	colorectal cancer (CRC)	colon tissues	black raspberry (BRB) anthocyanins treatment	downregulated	31763724
18168	Mouse	mmu-miR-483-3p	miRNA	black raspberry (BRB) anthocyanins	colorectal cancer (CRC)	azoxymethane (AOM)/dextran sulphate sodium (DSS)-induced CRC mouse	black raspberry (BRB) anthocyanins treatment	downregulated	31763724
18169	Mouse	mmu-miR-483-3p	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	cardiomyocyte	streptozotocin treatment	upregulated	27346130
18170	Mouse	mmu-miR-483-5p	miRNA	grape seed procyanidin B2 (GSP)	adipogenesis	3T3-L1 preadipocyte cell line	3T3-L1 preadipocyte cell line treatment	downregulated	28011376
18171	Mouse	mmu-miR-483-5p	miRNA	grape seed procyanidin B2 (GSP)	adipogenesis	3T3-L1 cells	GSP (dissolved in deionized water) (10¨C200 ug/ml)	downregulated	28011376
18172	Mouse	mmu-miR-483-5p	miRNA	rapamycin complex 1 (mTORC1)	osteoarthritis (OA)	Col2a1TSC1KO mice chondrocytes	rapamycin complex 1 (mTORC1) deficiency treatment	upregulated	30145794
18173	Mouse	mmu-miR-484	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
18174	Mouse	mmu-miR-484	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
18175	Mouse	mmu-miR-484	miRNA	extra-virgin olive oil rich in phenols (H-EVOO)	neuronal function	cortex	H-EVOO treatment	upregulated	26695409
18176	Mouse	mmu-miR-485	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	downregulated	30463065
18177	Mouse	mmu-miR-485	miRNA	oxygen glucose deprivation (OGD)	brain ischemia-reperfusion (I/R) injury	N2a cells	oxygen and glucose deprivation (OGD) treatment	downregulated	32860611
18178	Mouse	mmu-miR-485-3p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	BV2 cells	amyloid-¦Â (A¦Â) treatment	upregulated	33220166
18179	Mouse	mmu-miR-485-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	BV2 cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	33220166
18180	Mouse	mmu-miR-486	miRNA	low frequency magnetic fields (LF-MF)	cell proliferation and migration	"293T cells and Lung cancer cell lines (A549, LLC)"	LF-MFs treatment	upregulated	28924214
18181	Mouse	mmu-miR-486	miRNA	radiation	thymic lymphoma (RITL)	mouse lymphoma cells line (EL4)	radiation treatment	"Based on this network, we identified a critical miRNA, miR-486, which was the most downregulated in the radiation-induced carcinogenesis"	33692937
18182	Mouse	mmu-miR-486-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharides (LPS) treatment	upregulated	31940107
18183	Mouse	mmu-miR-486-5p	miRNA	(-)-epigallocatechin gallate (EGCG)	aging	C2C12 cells	(-)-Epigallocatechin gallate (EGCG) treatment	EGCG stimulated AKT phosphorylation and inhibited FoxO1a-mediated MuRF1 and Atrogin-1 transcription via up-regulating the expression of miR-486 in skeletal muscle of 40-wk-old SAMP8 mice as well as late passage C2C12 cells.	32710883
18184	Mouse	mmu-miR-486-5p	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	miR-486-5p was significantly upregulated in LPS-induced ATDC5 cells.	32705174
18185	Mouse	mmu-miR-486a-3p	miRNA	sublytic complement C5b-9 (sC5b-9)	renal inflammatory diseases	MPC5 cells	sublytic complement C5b-9 (sC5b-9) treatment	downregulated	33296289
18186	Mouse	mmu-miR-486a-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
18187	Mouse	mmu-miR-486a-5p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
18188	Mouse	mmu-miR-486b-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	RAW264.7 cells	lipopolysaccharide (LPS) treatment	miR-476 486b-3p levels decreased with exposure to LPS.	32421439
18189	Mouse	mmu-miR-487b	miRNA	lipopolysaccharide (LPS)	macrophage homeostasis	mouse bone marrow-derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	downregulated	26936882
18190	Mouse	mmu-miR-487b	miRNA	astaxanthin	prostate cancer	Pca mouse tumor tissues	intragastrically administered 100 mg/kg astaxanthin (HA)	upregulated	28282880
18191	Mouse	mmu-miR-488	miRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	upregulated	25827714
18192	Mouse	mmu-miR-488-3p	miRNA	hypoxia	acute myocardial infarction (AMI)	primary cardiomyocytes;MCM cells	hypoxia induce	miRNA-488-3p expression decreased in hypoxia-preconditioning primary cardiomyocytes or MCM cells in a time-dependent manner.	31210328
18193	Mouse	mmu-miR-488-3p	miRNA	hypoxia	acute myocardial infarction (AMI)	mouse heart tissues	ligation of the anterior descending coronary artery (LAD) treatment	downregulated	31210328
18194	Mouse	mmu-miR-489	miRNA	isoproterenol	cardiac fibrosis	heart tissue and cardiac fibroblasts (CFs)	isoprenaline (ISO) tteatment	downregulated	32104288
18195	Mouse	mmu-miR-489	miRNA	silica	lung fibrosis	lung	silica treatment	downregulated	27506999
18196	Mouse	mmu-miR-489	miRNA	silica	lung fibrosis	C57BL/6 male mice lung tissues	silica treatment	upregulated in lung tissues	28780788
18197	Mouse	mmu-miR-490-3p	miRNA	pilocarpine	epilepsy	hippocampal tissues	pilocarpine treatment	"Psmd11 was upregulated by Peg13 at a miR-490-3p dependent way, thus inactivating the Wnt/¦Â-catenin pathway and alleviating epilepsy course in mice"	33437373
18198	Mouse	mmu-miR-490-3p	miRNA	N-methyl-N-nitrosourea (MNU)	gastric cancer (GC)	gastric cancer cells	N-methyl-N-nitrosourea (MNU) treatment	downregulated	25503559
18199	Mouse	mmu-miR-490-3p	miRNA	silica	silicosis	lung tissues	silica treatment	MiR-490-3p was significantly downregulated in silica-induced fibrotic mouse lung tissues and TGF-¦Â1 treated fibroblasts	33482250
18200	Mouse	mmu-miR-490-3p	miRNA	H2O2	spinal cord injury (SCI)	C8-D1A cells; C8-B4 cells	H2O2 treatment	downregulated	30575927
18201	Mouse	mmu-miR-491	miRNA	tumour-derived TGF-¦Â	anti-cancer therapy	mouse CD8+T cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulation	27484289
18202	Mouse	mmu-miR-491	miRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	mice xenograft models	arsenic trioxide (As2O3) treatment	upregulated	25304214
18203	Mouse	mmu-miR-491	miRNA	anandamide (AEA)	pro-inflammatory activity	mouse	anandamide treatment	AEA differentil regulate the expression of miRNA	24699635
18204	Mouse	mmu-miR-491-5p	miRNA	anti-fas receptor antibodies	acute liver injury (ALI)	Hep G2 cells	anti-fas receptor antibodies	upregulated	20015148
18205	Mouse	mmu-miR-491-5p	miRNA	cold	obesity	brown adipose tissue (BAT)	cold treatment	downregulated	33015181
18206	Mouse	mmu-miR-493-5p	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	downregulated	19462682
18207	Mouse	mmu-miR-494	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	mouse C2C12 myotubes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	24349514
18208	Mouse	mmu-miR-494	miRNA	staphylococcal enterotoxin B (SEB)	acute lung injury (ALI)	lung-infiltrating mononuclear cells	staphylococcal enterotoxin B (SEB) treatment	upregulated	26818958
18209	Mouse	mmu-miR-494	miRNA	high fat diet (HFD)	acute myocardial infarction (AMI)	liver tissue	high fat diet (HFD) feed	downregulated	19835573
18210	Mouse	mmu-miR-494	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	vascular smooth muscle cells (VSMCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	30942414
18211	Mouse	mmu-miR-494	miRNA	"N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99)"	arthritis	Murine monocyte/macrophage cell line RAW264.7	"N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine (FC-99) treatment"	upregulated	31881378
18212	Mouse	mmu-miR-494	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	upregulated	19462682
18213	Mouse	mmu-miR-494	miRNA	silica nanoparticles (SiNPs) mycin	cell toxicity	mouse spermatocyte cells (GC-2spd cells)	SiNPs treatment	"inhibitor of miRNA-494 could attenuate the expression levels of AMPK, TSC, LC3¢ò and alleviate the decreased of AKT, mTOR, p-mTOR induced by SiNPs"	31541822
18214	Mouse	mmu-miR-494	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	mouse colon tissues	azoxymethane (AOM) treatment	upregulated in colon samples	29066742
18215	Mouse	mmu-miR-494	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	Primary cultured cortical neuronal	OGD treatment	miR-494 levels were reduced in neurons but increased in the medium after OGD	31510852
18216	Mouse	mmu-miR-494	miRNA	cyclosporine A (CsA)	nephrotoxicity	tubular epithelial cell	cyclosporine A treatment	upregulated	25854542
18217	Mouse	mmu-miR-494	miRNA	"FC-99 (N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine)"	rheumatoid arthritis (RA)	macrophages	"FC-99 (N1-[(4-methoxy)methyl]-4-methyl-1,2-Benzenediamine) treatment"	FC-99 relieved macrophages inflammation via the miR-494/TN-C/NF-¦ÊB pathway	31881378
18218	Mouse	mmu-miR-494-3p	miRNA	rice bran phenolic extract (RBPE)	alcoholic liver disease (ALD)	liver tissues	rice bran phenolic extract (RBPE) treatment	Rice Bran Phenolic Extract Confers Protective Effects against Alcoholic Liver Disease in Mice by Alleviating Mitochondrial Dysfunction via the PGC-1¦Á-TFAM Pathway Mediated by microRNA-494-3p	33094608
18219	Mouse	mmu-miR-494-3p	miRNA	poly(ethylenimine) (PEI)	cell death	MEF cells	poly(ethylenimine) (PEI) treatment	upregulated	26158199
18220	Mouse	mmu-miR-494-3p	miRNA	compression force (CF)	cell proliferation	"MC3T3-E1, a pre-osteoblastic cell line"	Compressive force treatment	upregulated	25795570
18221	Mouse	mmu-miR-494-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 macrophages	lipopolysaccharide?(LPS) treatment	upregulated	30942409
18222	Mouse	mmu-miR-494-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharides (LPS) treatment	downregulated	31002148
18223	Mouse	mmu-miR-494-3p	miRNA	high fat diet (HFD)	obesity	mice heart tissues	high fat diet (HFD) feed	downregulated	30629164
18224	Mouse	mmu-miR-495	miRNA	ovalbumin (OVA)	allergic rhinitis (AR)	CD4+ Th2 cells	ovalbumin induction	downregulated	32242002
18225	Mouse	mmu-miR-495	miRNA	alcohol	fetal alcohol spectrum disorders (FASD)	brain tissues	alcohol exposure	downregulated	23580197
18226	Mouse	mmu-miR-495	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colitis tissues	dextran sulfate sodium (DSS) treatment	miR-495 was lowly expressed in the DSS-induced colitis tissues.	31251902
18227	Mouse	mmu-miR-495	miRNA	choline- and folate-deficient (CFD) diet	liver damage	plasma	choline- and folate-deficient (CFD) diet treatment	upregulated	26878785
18228	Mouse	mmu-miR-495	miRNA	choline- and folate-deficient (CFD) diet	nonalcoholic fatty liver disease (NAFLD)	plasma	choline- and folate-deficient (CFD) treatment	upregulated	26878785
18229	Mouse	mmu-miR-495	miRNA	H2O2	spinal cord injury (SCI)	mouse SCNs	H2O2 treatment	"Interestingly, the expression of miR-495 was markedly suppressed when SCNs were exposed to H2O2."	33850858
18230	Mouse	mmu-miR-495	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	mouse peritoneal macrophages	high fat diet (HFD) feed	upregulated	31709454
18231	Mouse	mmu-miR-495-3p	miRNA	ischemia/reperfusion (I/R) 	intestinal hypoxia/reoxygenation injury	C57BL/6 mice were induced	ischemia/reperfusion (I/R) treatment	upregulation	26935288
18232	Mouse	mmu-miR-495-3p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	31812793
18233	Mouse	mmu-miR-495-3p	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated of NEAT1 level and downregulated of miR-495-3p/miR-211 level could aggravate inflammation in LPS-treated RAW264.7 cells.	31812793
18234	Mouse	mmu-miR-496	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	downregulated	19091803
18235	Mouse	mmu-miR-497	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
18236	Mouse	mmu-miR-497	miRNA	melatonin	chronic liver disease	C57BL/6 wild type (WT) mice pretreat with alcohol	melatonin (10 mg/kg body weight) supplemented by daily oral gavage at 09:00 hr during the last 2 weeks	upregulated	28095641
18237	Mouse	mmu-miR-497	miRNA	streptozocin (STZ)	diabetic foot ulcer (DFU)	wound lesion of diabetic mice	streptozotocin treatment	downregulated	31707336
18238	Mouse	mmu-miR-497	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	skin tissues	streptozotocin treatment	downregulated	31707336
18239	Mouse	mmu-miR-497	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
18240	Mouse	mmu-miR-497	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
18241	Mouse	mmu-miR-497	miRNA	IL-17	encephalomyelitis (EAE)	astrocytes in EAE mice	IL-17 treatment	downregulated	28458392
18242	Mouse	mmu-miR-497	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	muscle cell proliferation and differentiation	mouse skeletal myoblast C2C12 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28255268
18243	Mouse	mmu-miR-497	miRNA	plasmodium	plasmodium infection	exosomes derived from the plasma	infect with Plasmodium treatment	upregulated	28650446
18244	Mouse	mmu-miR-497a-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	31148190
18245	Mouse	mmu-miR-497a-5p	miRNA	alloxan	diabetic retinopathy (DR)	renal tissues	alloxan treatment	downregulated	29312507
18246	Mouse	mmu-miR-497a-5p	miRNA	metformin (Met)	diabetic retinopathy (DR)	renal tissues	metformin treatment	upregulated	29312507
18247	Mouse	mmu-miR-498	miRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	16HBE-T cells	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	upregulated	19462682
18248	Mouse	mmu-miR-498	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol) analogue EB1089"	estrogen-sensitive tumors	mouse	"1,25-dihydroxyvitamin D 3 (calcitriol) analogue EB1089 treatment"	upregulated	25252917
18249	Mouse	mmu-miR-499	miRNA	influenza virus	H9N2 influenza virus infection	Dendritic cells (DCs)	H9N2 avian influenza virus (H9N2 AIV) treatment	upregulated	27285980
18250	Mouse	mmu-miR-499	miRNA	puromycin aminonucleoside (PAN)	minimal change disease (MCD)	kidney tissues	puromycin aminonucleoside (PAN) treatment	PAN exposure reduced miR-499 expression in the kidneys of mice	29448244
18251	Mouse	mmu-miR-499	miRNA	conjugated linoleic acid (cLA) and nitrite	myocardial infarction (MI)	myocardial infarction	conjugated linoleic acid (cLA) and nitrite treatment	upregulated	24363996
18252	Mouse	mmu-miR-499	miRNA	insulin	obesity	mouse skeletal muscle satellite cells (SMSCs)	insulin treatment	downregulated	30097922
18253	Mouse	mmu-miR-499-3p	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
18254	Mouse	mmu-miR-499-5p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	miR-499-5p was upregulated in LPS-treated lung tissues.	33307898
18255	Mouse	mmu-miR-499-5p	miRNA	high glucose (HG)	cardiac hypertrophy	HL-1 cells	high glucose (HG) treatment	downregulated	32269707
18256	Mouse	mmu-miR-499-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	upregulated	30453253
18257	Mouse	mmu-miR-499¨C5p	miRNA	prolonged aerobic exercise	muscle hypertrophy	plasma	"impact of extended-duration, submaximal aerobic exercise treatment"	upregulated	24436293
18258	Mouse	mmu-miR-499a-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Plasma	doxorubicin (DOX) treatment	downregulated	30627229
18259	Mouse	mmu-miR-499a-5p	miRNA	IL-3¦Â	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cell	?IL-1¦Â treatment	"XIST expression was upregulated in the NP tissues of patients with IDD, and IL-1¦Â treatment resulted in a degradation of NPCs"	33722663
18260	Mouse	mmu-miR-500	miRNA	stretch	myoblast proliferation	C2C12 myoblasts	stretch treatment	downregulated	27840929
18261	Mouse	mmu-miR-501	miRNA	cardiotoxin (CTX)	skeletal muscle regeneration	myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs)	cardiotoxin (CTX) treatment	"In the mdx mouse model, which models a pathological disease state, not only was miR-501 induced in regenerating skeletal muscle, but also its serum levels were increased, which correlated with the disease state of the animals."	27707793
18262	Mouse	mmu-miR-501-5p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
18263	Mouse	mmu-miR-503	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	mouse macrophages atherogenic Evs	oxidized low-density lipoprotein (ox-LDL) treatment	enrichment in atherogenic EVs	28882869
18264	Mouse	mmu-miR-503	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	peritoneal macrophages; Bone-marrow derived macrophages (BMDMs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28882869
18265	Mouse	mmu-miR-503	miRNA	photobiomodulation therapy (PBMT)	cell proliferation	mouse pre-osteoblast cell line MC3T3-E1	"Photobiomodulation therapy (PBMT) (The PBMT parameters were as follows: 808 nm continuous wavelength, 0.401 W output power, 0.042 W/cm2 power density, 9.6 cm2 spot size, 36 J energy, 3.75 J/cm2 energy density, 90 s irradiation for three times per 12 h, 14.5 cm distance of the laser source and the angle of divergence of the laser beam was 7¡ã) treatment"	downregulated	30218348
18266	Mouse	mmu-miR-503	miRNA	photobiomodulation therapy (PBMT)	cell proliferation	mouse pre-osteoblast cell line MC3T3-E1	"The PBMT parameters were as follows: 808 nm continuous wavelength, 0.401 W output power, 0.042 W/cm2 power density, 9.6 cm2 spot size, 36 J energy, 3.75 J/cm2 energy density, 90 s irradiation for three times per 12 h, 14.5 cm distance of the laser source and the angle of divergence of the laser beam was 7¡ã. treatment"	downregulated	30218348
18267	Mouse	mmu-miR-503	miRNA	losartan	diabetic nephropathy (DN)	kidney tissues	losartan treatment	downregulated	27770539
18268	Mouse	mmu-miR-503	miRNA	hypoxia	ischemic injury	mouse bone marrow derived endothelial progenitor cells (EPCs)	hypoxia induce	downregulated	29800588
18269	Mouse	mmu-miR-503	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
18270	Mouse	mmu-miR-503	miRNA	oleanolic acid (OLA)	osteoclastogenesis	RANKL-induced RAW264.7 cells	oleanolic acid (OLA) treatment	upregulated	31176167
18271	Mouse	mmu-miR-503	miRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	osteoclastogenesis	RAW264.7 cells	RANKL treatment	downregulated	31176167
18272	Mouse	mmu-miR-503	miRNA	silica	lung fibrosis	mouse lung tissues	silica treatment	downregulated in	28900284
18273	Mouse	mmu-miR-503*	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
18274	Mouse	mmu-miR-503-5p	miRNA	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	dopaminergic (DA) neuron differentiation	neuro-2a cells	"paraquat (PQ) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment"	dysregulated	29250806
18275	Mouse	mmu-miR-503-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
18276	Mouse	mmu-miR-503-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29250806
18277	Mouse	mmu-miR-503-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	neurodegenerative diseases	N2a cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	29250806
18278	Mouse	mmu-miR-503-5p	miRNA	paraquat (PQ)	neurodegenerative diseases	N2a cells	paraquat (PQ) treatment	downregulated	29250806
18279	Mouse	mmu-miR-504-3p	miRNA	high fat diet (HFD)	compensatory hyperplasia of islets	hepatocellular extracellular vesicles (EVs)	?high-fat diet (HFD) feed treatment	downregulated	31284955
18280	Mouse	mmu-miR-505-5p	miRNA	streptozocin (STZ)	diabetic pregnancy	female mice hyperglycemic ED9.5 embryos	streptozotocin treatment	dysregulatedin hyperglycemic ED95 embryos	27908722
18281	Mouse	mmu-miR-505-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
18282	Mouse	mmu-miR-506	miRNA	lipopolysaccharide (LPS)	lung fibrosis	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	31214773
18283	Mouse	mmu-miR-5097	miRNA	stretch	myoblast proliferation	C2C12 myoblasts	stretch treatment	downregulated	27840929
18284	Mouse	mmu-miR-5107-5p	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
18285	Mouse	mmu-miR-5107-5p	miRNA	oxygen	retinopathy of prematurity (ROP)	C57BL/6 neonatal mice retinal tissue	7-day-old mice were maintained in 75% oxygen conditions for 5 days treatment	dysregulatedin retinal tissue	27922698
18286	Mouse	mmu-miR-511	miRNA	¦Ã-rays	leukemia	the whole blood cells of mice	Gy ¦Ã-rays treatment	miRNA signatures induced by ionising radiation in mouse blood are radiation type- and radiation dose-specific	21271940
18287	Mouse	mmu-miR-5112	miRNA	hypoxia	ischemic injury	bone marrow mesenchymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	30613290
18288	Mouse	mmu-miR-5112	miRNA	chronic sleep fragmentation (SF)	obstructive sleep apnea (OSA)	C57/B6 mice	chronic sleep treatment	"upregulation(mmu-miR-5128,mmu-miR-6366), downregulated(mmu-miR-5112) in plasma-derived exosomes"	27419627
18289	Mouse	mmu-miR-511-3p	miRNA	angiostrongylus cantonensis (A. cantonensis)	angiostrongylus cantonensis (A. cantonensis) infection	mouse	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24682888
18290	Mouse	mmu-mir-511-3p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
18291	Mouse	mmu-miR-511-3p	miRNA	delvestidine (DLTD)	bone marrow-derived dendritic cells (BMDCs) maturity	bone marrow-derived dendritic cells (BMDCs)	Delvestidine (DLTD) treatment	upregulated	32871480
18292	Mouse	mmu-miR-5115	miRNA	ischemia	acute kidney injury (AKI)	renal tubules	ischemia treatment	upregulated	27959449
18293	Mouse	mmu-miR-511-5p	miRNA	angiostrongylus cantonensis (A. cantonensis)	angiostrongylus cantonensis (A. cantonensis) infection	mouse	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24682888
18294	Mouse	mmu-miR-5119	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	upregulated	27322257
18295	Mouse	mmu-miR-5128	miRNA	chronic sleep fragmentation (SF)	obstructive sleep apnea (OSA)	C57/B6 mice	chronic sleep treatment	"upregulation(mmu-miR-5128,mmu-miR-6366), downregulated(mmu-miR-5112) in plasma-derived exosomes"	27419627
18296	Mouse	mmu-miR-5128	miRNA	oxygen	retinopathy of prematurity (ROP)	retinas tissue	"For OIR model construction, 7-day-old mice and their nursing mothers were maintained in 75% oxygen for 5 continuous days. On postnatal day (P) 12, the pups were returned to normoxic air and kept with their mothers for another 5 days. treatment"	downregulated in the OIR samples	31452702
18297	Mouse	mmu-miR-5129-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
18298	Mouse	mmu-miR-5130	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
18299	Mouse	mmu-miR-51302	miRNA	ethyl acetate extract isolated from rhizoma dioscoreae bulbifera	hepatotoxicity	mouse liver tissues	treat with ethyl acetate extract isolated from rhizoma dioscoreae bulbifera (450 mg/kg)	dysregulated	27609015
18300	Mouse	mmu-miR-5132-5p	miRNA	ethyl acetate extract isolated from rhizoma dioscoreae bulbifera	hepatotoxicity	mouse liver tissues	treat with ethyl acetate extract isolated from rhizoma dioscoreae bulbifera (450 mg/kg)	dysregulated	27609015
18301	Mouse	mmu-miR-5132-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
18302	Mouse	mmu-miR-515-5p	miRNA	cigarette smoke (CS)	epithelial-mesenchymal transition (EMT)	lung tissues	Cigarette smoke (CS) exposure	downregulated	32768781
18303	Mouse	mmu-miR-515-5p	miRNA	H2O2	ischemia/reperfusion (I/R) injury	Primary cardiomyocytes	H2O2 treatment	LINC00511 accelerates the proliferation of cardiomyocytes after I/R by targeting miRNA-515-5p.	32141575
18304	Mouse	mmu-miR-520h	miRNA	high glucose (HG)	diabetic nephropathy (DN)	SV40-MES-13?cells	high glucose (HG) treatment	downregulated	31630796
18305	Mouse	mmu-miR-525-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	Cardiomyocytes were isolated from the neonatal mouse	angiotensin II (Ang II) treatment	SP1-induced upregulation of lncRNA SYNE1-AS1 promoted CH via miR-525-5p/SP1 axis.	30652310
18306	Mouse	mmu-miR-526b	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung tissues	bleomycin (BLM) treatment	circTADA2A repressed lung-fibroblasts activation via miR-526b/Cav1 and reduced lung-fibroblasts proliferation via miR-203/Cav2.	32694556
18307	Mouse	mmu-miR-526b-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	heart sissues	doxorubicin (DOX) treatment	Cardiac miR-526b-3p presented the most significant elevation responding to DOX treatment in mice.	31958751
18308	Mouse	mmu-miR-532	miRNA	high glucose (HG)	diabetic foot ulcer (DFU)	AC-16 cells	high glucose (HG) treatment	High glucose significantly upregulated miR-532 expression in the cardiomyocytes after 48 h.	32418060
18309	Mouse	mmu-miR-532-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
18310	Mouse	mmu-miR-532-5p	miRNA	adiponectin	frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)	?adipose tissue (AT)	adiponectin (ApN) treatment	downregulated	23015294
18311	Mouse	mmu-miR-532-5p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	"miR-532-5p was decresed on 4 and 6 weeks after S japonicum infection, while increased on 9 weeks"	32443549
18312	Mouse	mmu-miR-532-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	N2a cells	oxygen-glucose deprivation (OGD) treatment	miR-532-5p level was decreased and the PTEN level was increased in OGD-treated N2a cells in vitro.	32086725
18313	Mouse	mmu-miR-532-5p	miRNA	lipopolysaccharide (LPS)	macrophage inflammatory response	RAW264.7 macrophage cells	lipopolysaccharide (LPS) treatment	downregulated	22415194
18314	Mouse	mmu-miR-532-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	hippocampus	chronic unpredictable mild stress (CUMS) treatment	MiR-532-5p was significantly reduced in the hippocampus of mice treated with CUMS.	33209030
18315	Mouse	mmu-miR-532-5p	miRNA	lipopolysaccharide (LPS)	major depressive disorder (MDD)	BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	33209030
18316	Mouse	mmu-miR-532-5p	miRNA	high fat diet (HFD)	obesity	liver tissues	high fat diet (HFD) feed	upregulated	32593682
18317	Mouse	mmu-miR-539-5p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	primary murine pulmonary microvascular endothelial cells (MPVECs)	lipopolysaccharide (LPS) treatment	downregulated	31825519
18318	Mouse	mmu-miR-540	miRNA	augmenter of liver regeneration (ALR)	hepatic steatosis	mouse liver tissues and primary hepatocytes	augmenter of liver regeneration (ALR) treatment	upregulated	30540918
18319	Mouse	mmu-miR-540	miRNA	augmenter of liver regeneration (ALR)	steatosis	hepatocytes	augmenter of liver regeneration (ALR) deficiency	upregulated	30540918
18320	Mouse	mmu-miR-540-3p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18321	Mouse	mmu-miR-541	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	mouse cardio myocytes	angiotensin II (Ang II) treatment	downregulated	24722296
18322	Mouse	mmu-miR-541	miRNA	microcystin-leucine arginine (MC-LR)	decline in sperm quality and damage to testicular structure	Mouse GC-1 cells	Microcystin-leucine arginine (MC-LR)? treatment	upregulated	27608041
18323	Mouse	mmu-miR-541	miRNA	cortical impact	traumatic brain injury (TBI)	cortex	cortical impact	downregulated	26426744
18324	Mouse	mmu-mir-541-5p	miRNA	second-hand smoke (SHS)	asthma	lung	second-hand smoke (SHS) treatment	upregulated	26859758
18325	Mouse	mmu-miR-542-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	30368874
18326	Mouse	mmu-miR-542-5p	miRNA	pristimerin	glioblastoma multiforme (GBM)	mouse GL261 glioma cells	Pristimerin treatment	downregulated	31015365
18327	Mouse	mmu-miR-542-5p	miRNA	oleic acid (OA)	hyperglycemia and hyperlipoidemia	hepatocytes; AML-12 cells	oleate treatment	downregulated	32882762
18328	Mouse	mmu-miR-542-5p	miRNA	silica suspension	lung fibrosis	lung tissues	silica suspension treatment	downregulated	30467286
18329	Mouse	mmu-miR-542-5p	miRNA	TGF-¦Â1	lung fibrosis	mouse fibroblast (NIH-3T3)	transforming growth factor ¦Â1 (TGF-¦Â1) treatment	downregulated	30467286
18330	Mouse	mmu-miR-542-5p	miRNA	L©\arginine	severe acute pancreatitis (SAP)	lung tissues	"the SAP group (WT mice were intraperitoneally injected with 8% L©\arginine (4 mg/g) once per hour, twice in total, with the time of the second L©\arginine injection defined as day 0, and the mice were killed in a humane manner at day 3)"	downregulated	30216510
18331	Mouse	mmu-miR-542-5p	miRNA	prion	pancreatic cancer (PC)	N2a cells	prion treatment	downregulated of mmu-miR-351 and mmu-miR-542-5p	22985096
18332	Mouse	mmu-miR-543	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	peripheral blood and myocardial tissues of viral myocarditis mice and in CVB3-infected cardiomyocytes	Coxsackievirus B3 (CVB3) infection	upregulated	31894309
18333	Mouse	mmu-miR-543	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	peripheral blood; myocardial tissues; cardiomyocytes.	Coxsackievirus B3 (CVB3) infection	upregulated	31894309
18334	Mouse	mmu-miR-543-3p	miRNA	nine hepatotoxic non-genotoxins (NGTXs)	genotoxicity	liver tissues	nine hepatotoxic non-genotoxins (NGTXs) treatment	downregulated	29777724
18335	Mouse	mmu-miR-543-3p	miRNA	nine hepatotoxic non-genotoxins (NGTXs)	genotoxicity	plasma	nine hepatotoxic non-genotoxins (NGTXs) treatment	upregulated	29777724
18336	Mouse	mmu-miR-543-3p	miRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	inflammation	myeloid-derived suppressor cells (MDSCs)	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) treatment"	downregulated	31492743
18337	Mouse	mmu-miR-544	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
18338	Mouse	mmu-miR-5622-3p	miRNA	high fat diet (HFD)	compensatory hyperplasia of islets	hepatocellular extracellular vesicles (EVs)	?high-fat diet (HFD) feed treatment	downregulated	31284955
18339	Mouse	mmu-miR-5709-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
18340	Mouse	mmu-miR-574-3p	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
18341	Mouse	mmu-miR-574-3p	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
18342	Mouse	mmu-miR-574-3p	miRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	mice	injected into the tumour centre at a concentration of 150 mg/kg treatment	dysregulated	24896104
18343	Mouse	mmu-miR-574-3p	miRNA	morphine	painful or stressful conditions	hippocampal	Morphine treatment	downregulated	25844808
18344	Mouse	mmu-miR-574-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	"In ARDS models, microRNA-574-5p (miR-574-5p) expression could be induced by the TLR4/NF-¦ÊB pathway upon LPS stimulation."	33202146
18345	Mouse	mmu-miR-574-5p	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
18346	Mouse	mmu-miR-574-5p	miRNA	cyclophosphamide (CP)	chronic ovarian dysfunction	ovarian tissues	cyclophosphamide (CP) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice."	33318603
18347	Mouse	mmu-miR-574-5p	miRNA	samul-tang (SM)	chronic ovarian dysfunction	ovarian tissues	samul-tang (SM) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice"	33318603
18348	Mouse	mmu-miR-574-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver	CCl4 treatment	upregulated	27322257
18349	Mouse	mmu-miR-574-5p	miRNA	X rays	ionizing radiation (IR) injury	male Kunming mice blood	0.5-2 Gy total-body carbon-ion irradiation treatment	dysregulatedin blood	28632432
18350	Mouse	mmu-miR-574-5p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18351	Mouse	mmu-miR-574-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
18352	Mouse	mmu-miR-574-5p	miRNA	particulate matter (PM2.5)	neuroinflammation	C57BL/6 mice	received oropharyngeal aspiration ofPM2.5 treatment	downregulated	28851397
18353	Mouse	mmu-miR-575	miRNA	l-lysine	hemin-insulted mouse cortical neurons	cortical neurons	l-lysine treatment	miR-575 expression was increased in L-lysine treated group.	31987833
18354	Mouse	mmu-miR-577	miRNA	hypoxia	myocardial infarction (MI)	myocardial tissues; primary cardiomyocytes;MCM cells	hypoxia induce	downregulated	31773708
18355	Mouse	mmu-miR-582-5p	miRNA	hypoxia	cerebral ischemic stroke (CIS)	N2A cells	oxygen-glucose deprivation/reoxygenation (OGD/R) induce	downregulated	30327244
18356	Mouse	mmu-miR-582-5p	miRNA	hypoxia	cerebral ischemic stroke (CIS)	N2A cells	oxygen-glucose deprivation/reoxygenation (OGD/R) treatment	downregulated	30327244
18357	Mouse	mmu-miR-582-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	NAc tissue	chronic unpredictable mild stress (CUMS) treatment	upregulated	31430030
18358	Mouse	mmu-miR-582-5p	miRNA	electroacupuncture (EA)	electroacupuncture (EA)	CD4 T cells	electroacupuncture (EA) treatment	upregulated	32026263
18359	Mouse	mmu-miR-584	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
18360	Mouse	mmu-miR-590	miRNA	high fat diet (HFD)	atherosclerosis (AS)	ApoE-/- mice aorta tissues	high fat diet (HFD) feed	downregulated	30799593
18361	Mouse	mmu-miR-590	miRNA	zingerone	cell differentiation	mouse mesenchymal stem cells (mMSCs)	Zingerone treatment	upregulated	31091349
18362	Mouse	mmu-miR-590-3p	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Mouse podocytes (MPC5) and kidney tissues	lipopolysaccharide (LPS) treatment	downregulated	30392071
18363	Mouse	mmu-miR-590-3p	miRNA	YKL-40	rheumatoid arthritis (RA)	mouse osteoblastic cell line MC3T3-E1	stimulated with YKL-40 for 24 h treatment	downregulated	28448439
18364	Mouse	mmu-miR-590-5p	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	colon tissues	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated	29912317
18365	Mouse	mmu-miR-590-5p	miRNA	high glucose (HG)	diabetic osteoporosis	MC3T3-E1 cell	high glucose (HG) treatment	downregulated	30803283
18366	Mouse	mmu-miR-590-5p	miRNA	lipopolysaccharide (LPS)	intracerebral haemorrhage (ICH)	Primary microglia cells	lipopolysaccharide (LPS) treatment	downregulated	30190124
18367	Mouse	mmu-miR-592	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
18368	Mouse	mmu-miR-592-5p	miRNA	quercetin	chronic inflammatory diseases	LPS-treated murine bone marrow¨Cderived DCs (BMDCs)	quercetin treatment	upregulated	31338984
18369	Mouse	mmu-miR-592-5p	miRNA	high fat diet (HFD)	hepatic insulin resistance	mouse liver tissues	high fat diet (HFD) feed	downregulated	30820263
18370	Mouse	mmu-miR-592-5p	miRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	hippocampal neuronal in a neonatal mouse	hypoxia induce	downregulated	29402808
18371	Mouse	mmu-miR-596	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
18372	Mouse	mmu-miR-602	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
18373	Mouse	mmu-miR-6089	miRNA	bovine type II collagen	rheumatoid arthritis (RA)	synovial macrophages	bovine type II collagen induction	circRNA_09505 can function as a miR-6089 sponge and regulate inflammation via miR-6089/AKT1/NF-¦ÊB axis in collagen-induced arthritis (CIA) mice mice.	33028811
18374	Mouse	mmu-miR-615-3p	miRNA	hypoxia	cell proliferation	brain tissue of micce	hypoxia treatment	downregulated	22171942
18375	Mouse	mmu-miR-615-5p	miRNA	adriamycin (ADR)	focal segmental glomerulosclerosis (FSGS)	kidney tissues	adriamycin (ADR) treatment	downregulated	32800553
18376	Mouse	mmu-miR-615-5p	miRNA	recombinant Adeno-Cre viruses (AdV-Cre)	lung adenocarcinoma (LUAD)	lung	recombinant Adeno-Cre viruses (AdV-Cre) treatment	downregulated	25359683
18377	Mouse	mmu-miR-618	miRNA	RANKL (receptor activator of nuclear factor ¦ÊB ligand)	postmenopausal osteoporosis (PMOP)	osteoclastogenesis of RAW264.7 cells	50ng/mL RANKL treatment	downregulated	29271983
18378	Mouse	mmu-miR-630	miRNA	bone morphogenetic protein 4 (BMP4) and TGF-¦Â2	heterotopic ossification (HO)	BALB/c-nu mice	bone morphogenetic protein 4 (BMP4) and TGF-¦Â2 treatment	downregulated	26940839
18379	Mouse	mmu-miR-6366	miRNA	chronic sleep fragmentation (SF)	obstructive sleep apnea (OSA)	C57/B6 mice	chronic sleep treatment	"upregulation(mmu-miR-5128,mmu-miR-6366), downregulated(mmu-miR-5112) in plasma-derived exosomes"	27419627
18380	Mouse	mmu-miR-640	miRNA	sevoflurane (SEV)	sevoflurane-induced abnormal cognition	primary hippocampal neurons	sevoflurane treatment	Overexpression of lncRNA Gm43050 alleviates apoptosis and inflammation response induced by sevoflurane treatment by regulating miR-640/ZFP91	32913509
18381	Mouse	mmu-miR-650	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon tissues	dextran sulfate sodium (DSS) treatment	upregulated	31399193
18382	Mouse	mmu-miR-6516-3p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
18383	Mouse	mmu-miR-652	miRNA	prednisolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	prednisolone treatment	downregulated	29883261
18384	Mouse	mmu-miR-652	miRNA	vamorolone	duchenne muscular dystrophy (DMD)	diaphragm muscle	vamorolone treatment	downregulated	29883261
18385	Mouse	mmu-miR-652	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	intraperitoneal injection of CCl4	upregulated	28768954
18386	Mouse	mmu-miR-652-3p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	oxygen glucose deprivation (OGD) treatment	upregulation of lncRNA HCP5 may exacerbate cerebral ischemic reperfusion injury by sponging miR-652-3p	32657103
18387	Mouse	mmu-miR-652-5p	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
18388	Mouse	mmu-miR-653-5p	miRNA	IL-1¦Â	chondrocyte apoptosis	ATDC5	IL-1¦Â treatment	upregulated	32517436
18389	Mouse	mmu-miR-6538	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	downregulated	33224036
18390	Mouse	mmu-miR-654-5p	miRNA	Tripterysium Glycosides Tablets (TGT)	rheumatoid arthritis (RA)	peripheral blood	Tripterysium Glycosides Tablets (TGT) treatment	upregulated	33135351
18391	Mouse	mmu-miR-660-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	It showed that the expression levels of hsa-miR- 660-3p significantly increased over time upon CCl4 injection.	32584784
18392	Mouse	mmu-miR-665	miRNA	phenylephrine (PE)	heart failure (HF)	cultured cardiomyocytes	phenylephrine (PE) treatment	upregulated	31664601
18393	Mouse	mmu-miR-665	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	C57BL/6 mice colonic mucosal tissues	dextran sodium sulfate (DSS) treatment	upregulated in colonic mucosal tissues	28333149
18394	Mouse	mmu-miR-665	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
18395	Mouse	mmu-miR-665-3p	miRNA	Sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	skin tissues	Sheng-ji Hua-yu (SJHY) treatment	upregulated	33271241
18396	Mouse	mmu-miR-665-3p	miRNA	Sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	ulceration surface	sheng-ji Hua-yu (SJHY) formula treatment	"RNA-seq identified 11 DE circRNAs and 476 DE mRNAs between SJHY formula-treated and diabetic mice, including 4 upregulated and 7 downregulated circRNAs, 311 upregulated and 165 downregulated mRNAs CircRNA-Krt13/miR-665-3p/Itga3 and circRNA-Krt14/miR-706/Mylk4 pathways were built, which may contribute to the healing of SJHY formula-treated diabetic wounds"	33271241
18397	Mouse	mmu-miR-665-3p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	BV2 cells	oxygen-glucose deprivation (OGD) treatment	downregulated	32512270
18398	Mouse	mmu-miR-667-3p	miRNA	cyclophosphamide (CP)	chronic ovarian dysfunction	ovarian tissues	cyclophosphamide (CP) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice."	33318603
18399	Mouse	mmu-miR-667-3p	miRNA	samul-tang (SM)	chronic ovarian dysfunction	ovarian tissues	samul-tang (SM) treatment	"CP treatment decreased the expression of miR-365-1-5p and miR-574-5p and increased that of miR-3472 and miR-667-3p, whereas SM administration restored the expression levels of these microRNAs to those in the Con mice"	33318603
18400	Mouse	mmu-miR-668	miRNA	lipopolysaccharide (LPS)	bacterial infection	"the whole blood, serum and white blood cells (WBCs) of C57BL/6 and Tlr2-/- mice"	lipopolysaccharide (LPS) treatment	upregulated	23286671
18401	Mouse	mmu-miR-668	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	peripheral blood of mice	smoking treatment	upregulated	22782705
18402	Mouse	mmu-miR-668	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	upregulated	22782705
18403	Mouse	mmu-miR-669a-5p	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
18404	Mouse	mmu-miR-669b-5p	miRNA	D-mannose	adipogenesis	adipose tissue-derived stem cells (ADSCs)	D-Mannose treatment	miR669b-5p expression level was significantly upregulated in the D-mannose group.	33376493
18405	Mouse	mmu-miR-669b-5p	miRNA	manganese (Mn)	parkinson's disease (PD)	MN9D dopaminergic cell exosomes	Mn exposure (300¦ÌM MnCl2) for 24h	upregulated in exosomes	28450057
18406	Mouse	mmu-miR-669c-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	primary microglial cultures	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-669c-3p expression is increased in primary cortical neurons exposed to excitotoxic injury.	32560730
18407	Mouse	mmu-miR-669n	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
18408	Mouse	mmu-miR-669n	miRNA	chloroquine	macrophage activation	LPS-treated RAW264.7 cells	Chloroquine (CQ) treatment	downregulated	26807181
18409	Mouse	mmu-miR-669n	miRNA	¦Â-elemene	oxygen-induced retinopathy (OIR)	Retinas tissues	¦Â-elemene treatment	upregulated	30664207
18410	Mouse	mmu-miR-669o-5p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	downregulated	28396668
18411	Mouse	mmu-miR-670	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Mouse N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Our results showed that after ischemia/reperfusion injury, miR-670 expression was obviously increased"	33269746
18412	Mouse	mmu-miR-671	miRNA	lead (Pb)	lead (Pb) toxicity	mouse neuroblastoma N2a cells	PbAc treatment	downregulated	27604105
18413	Mouse	mmu-miR-671-5p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
18414	Mouse	mmu-miR-674	miRNA	influenza virus	H9N2 influenza virus infection	Dendritic cells (DCs)	H9N2 avian influenza virus (H9N2 AIV) treatment	upregulated	27285980
18415	Mouse	mmu-miR-674-5p	miRNA	Japanese encephalitis virus (JEV)	Japanese encephalitis virus (JEV) infection	BV-2 cells; mouse neuroblastoma cell line NA; mouse brain endothelial cell line bEnd.3 	Japanese encephalitis virus (JEV) infection	downregulated	32461319
18416	Mouse	mmu-miR-675	miRNA	TGF-¦Â1	cardiac fibrosis	Cardiac fibroblasts (CFs)	transforming growth factor beta 1 (TGF¦Â1) treatment	downregulated	30953355
18417	Mouse	mmu-miR-675	miRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	upregulated	30692507
18418	Mouse	mmu-mir-676-3p	miRNA	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29)	bacterial infection	blood	recombinant-specific gram-negative pathogen Escherichia coli (Xen14) and gram-positive pathogen Staphylococcus aureus (Xen29) treatment	upregulated	25563241
18419	Mouse	mmu-miR-677	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
18420	Mouse	mmu-miR-677-5p	miRNA	TGF-¦Â1	ischemia-reperfusion (IR)-induced late fibrosis of kidney	kidney tissues	TGF-¦Â1 treatment	LncRNA (Gm12840) could act as a sponge for miR-677-5p to mediate fibroblast activation induced by TGF-¦Â1 via the WISP1/PKB (Akt) signaling pathway	33351669
18421	Mouse	mmu-miR-679	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
18422	Mouse	mmu-miR-682	miRNA	ischemia	intestinal ischemia/reperfusion (I/R) injury	intestinal epithelial cells	intestinal I/R injury	upregulation	27124584
18423	Mouse	mmu-miR-682	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
18424	Mouse	mmu-miR-687	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	renal tubular epithelial (PTEC) cells	lipopolysaccharide (LPS) treatment	upregulated	32655407
18425	Mouse	mmu-miR-690	miRNA	angiotensin II (Ang II)	obesity	3T3-L1 cells	angiotensin II (Ang II) treatment	upregulated	32466437
18426	Mouse	mmu-miR-690	miRNA	testosterone	prostate cancer	female mouse liver	Testosterone treatment	"upregulation of the 6 miRNAs miR-22, miR-690, miR-122, let-7A, miR-30D and let-7D"	20600201
18427	Mouse	mmu-miR-690	miRNA	clozapine (CLZ)	psychotic disorders	mouse brain	clozapine treatment	upregulated	23318695
18428	Mouse	mmu-miR-690	miRNA	¦¤9-tetrahydrocannabinol (THC)	¦¤9-tetrahydrocannabinol toxicity	CD11b£«Gr-1£«MDSCs	¦¤9-Tetrahydrocannabinol (THC) treatment	upregulated	24202177
18429	Mouse	mmu-miR-6906-5p	miRNA	indole-3-carbinol (I3C)	colitis	Mesenteric lymph nodes	Indole-3-carbinol (I3C) treatment	downregulated	32921956
18430	Mouse	mmu-miR-691	miRNA	cigarette smoke (CS)	ovarian toxicity	ovarian tissues	cigarette smoke (CS) treatment	upregulated	29377183
18431	Mouse	mmu-miR-691	miRNA	particulate matter (PM2.5)	PM2.5 exposure	mosue bronchoalveolar lavage fluid (BALF)	"were subjected to intratracheal instillation of 2.5, 10, or 20mg/kg PM2.5 treatment"	upregulated in bronchoalveolar lavage fluid (BALF)	29107863
18432	Mouse	mmu-miR-691	miRNA	particulate matter (PM2.5)	pulmonary toxicological	lung tissues	particulate matter (PM2.5) exposure treatment	upregulated	29107863
18433	Mouse	mmu-miR-691	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colonic tissues	dextran sulfate sodium (DSS) treatment	upregulated	32779953
18434	Mouse	mmu-miR-6914-5p	miRNA	mesalamine	inflammatory bowel disease (IBD)	DSS-induced IBD mouse colon tissues	"Mesalazine (5-aminosalicylic acid, 5-ASA) treatment"	"The network analysis of circRNA-miRNA-mRNAs identified an important pathway, i.e., chr10:115386962-115390436+/mmu-miR-6914-5p/Atg7, which is related to autophagy."	33819198
18435	Mouse	mmu-miR-692	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	upregulated	27609015
18436	Mouse	mmu-miR-6931	miRNA	dicalcium silicate microparticle (C2S)	bone and dental tissue regenerative applications	mesenchymal stem cells (MSCs)	dicalcium silicate microparticle (C2S) treatment	downregulated	32463418
18437	Mouse	mmu-miR-693-3p	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
18438	Mouse	mmu-miR-694	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
18439	Mouse	mmu-miR-696	miRNA	resistin	ectopic deposition of lipids	C2C12 cells	resistin treatment	upregulated	25962325
18440	Mouse	mmu-miR-696	miRNA	AICAR	metabolic syndrome	C2C12 cells	AMP-activated protein kinase (AMPK) activator AICAR treatment	upregulated	33812060
18441	Mouse	mmu-miR-696	miRNA	high fat diet (HFD)	metabolic syndrome	Tibialis anterior (TA) and extensor digitorum longus (EDL) muscles	high fat diet (HFD) feed	we found that miR-696 was highly expressed in the skeletal muscle of STZ-induced diabetic mice and chronic high-fat-fed mice.	33812060
18442	Mouse	mmu-miR-696	miRNA	palmitic acid (PA)	metabolic syndrome	C2C12 muscle cells	palmitic acid (PA) treatment	upregulated	33812060
18443	Mouse	mmu-miR-696	miRNA	streptozocin (STZ)	metabolic syndrome	Tibialis anterior (TA) muscle	streptozotocin (STZ) treatment	miR-696 was highly expressed in the skeletal muscle of STZ-induced diabetic mice and chronic high-fat-fed mice.	33812060
18444	Mouse	mmu-miR-698	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver injury (ALI)	liver tissues	D-GalN/LPS treatment	downregulated	31061003
18445	Mouse	mmu-miR-7	miRNA	high fat diet (HFD)	Alzheimer's disease (AD)	brain tissues	high fat diet (HFD) feed	upregulated	31501273
18446	Mouse	mmu-miR-7	miRNA	insulin	Alzheimer's disease (AD)	N2a cells	insulin treatment	upregulated	31501273
18447	Mouse	mmu-miR-7	miRNA	oxygen glucose deprivation (OGD)	brain ischemic injury	astrocytes	oxygen-glucose deprivation (OGD) treatment	downregulated	26961366
18448	Mouse	mmu-miR-7	miRNA	lipopolysaccharide (LPS)	brain tissue inflammation (BTI)	brain tissues	lipopolysaccharide (LPS) treatment	upregulated	31959187
18449	Mouse	mmu-miR-7	miRNA	lipopolysaccharide (LPS)	cerebral hemorrhage	BV2 microglia	lipopolysaccharides (LPS) treatment	downregulated	30229834
18450	Mouse	mmu-miR-7	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung lobes	bleomycin (BLM) treatment	downregulated	31786325
18451	Mouse	mmu-miR-7	miRNA	trinitrobenzene sulfonic acid (TNBS)	inflammatory bowel disease (IBD)	intestinal tissues	TNBS treatment	upregulated	31494796
18452	Mouse	mmu-miR-7	miRNA	ionizing radiation (IR)	leukemia	mouse thymus and spleen tissue cells	irradiated	downregulated	18823940
18453	Mouse	mmu-miR-7	miRNA	focal brain irradiation	radiation induced bystander effect (RIBE)	mouse	"10 Gy or sham irradiation of mice brains, lung tissues"	upregulated	29104495
18454	Mouse	mmu-miR-7	miRNA	silica	silicosis	lung tissues	silica treatment	miR-7 is downregulated in lung tissues during silica-induced pulmonary fibrosis	30202956
18455	Mouse	mmu-miR-700	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
18456	Mouse	mmu-miR-700	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	peripheral blood of mice	smoking treatment	upregulated	22782705
18457	Mouse	mmu-miR-700	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	upregulated	22782705
18458	Mouse	mmu-miR-7025	miRNA	hypoxia	ischemic injury	bone marrow mesenchymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	30613290
18459	Mouse	mmu-miR-702-5p	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
18460	Mouse	mmu-miR-7045	miRNA	hypoxia	ischemic injury	bone marrow mesenchymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	30613290
18461	Mouse	mmu-miR-705	miRNA	alcohol	alcoholic liver disease (ALD)	mouse liver cells	Lieber-DeCarli alcohol treatment	upragulated	19572984
18462	Mouse	mmu-miR-705	miRNA	methionine choline-deficient diet (MCD)	alcoholic liver disease (ALD)	liver tissues	methionine-choline-deficient (MCD) diets treatment	upragulated	19572984
18463	Mouse	mmu-miR-705	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hearts of diabetic mice	streptozotocin (STZ) treatment	upregulated	21584493
18464	Mouse	mmu-miR-705	miRNA	metformin (Met)	nonalcoholic steatohepatitis (NASH)	liver tissues	metformin treatment	downregulated	25672270
18465	Mouse	mmu-miR-706	miRNA	laboratory-attenuated vesicular stomatitis virus	apoptosis	The baby hamster kidney (BHK-21) cell lin	laboratory-attenuated vesicular stomatitis virus treatment	upregulated	20625776
18466	Mouse	mmu-miR-706	miRNA	Sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	skin tissues	Sheng-ji Hua-yu (SJHY) treatment	upregulated	33271241
18467	Mouse	mmu-miR-706	miRNA	Sheng-ji Hua-yu (SJHY) formula	diabetic foot ulcer (DFU)	ulceration surface	sheng-ji Hua-yu (SJHY) formula treatment	"RNA-seq identified 11 DE circRNAs and 476 DE mRNAs between SJHY formula-treated and diabetic mice, including 4 upregulated and 7 downregulated circRNAs, 311 upregulated and 165 downregulated mRNAs CircRNA-Krt13/miR-665-3p/Itga3 and circRNA-Krt14/miR-706/Mylk4 pathways were built, which may contribute to the healing of SJHY formula-treated diabetic wounds"	33271241
18468	Mouse	mmu-miR-706	miRNA	low glucose (LG)	endoplasmic reticulum stress (ERS)	NIH3T3 cells	low glucose media treatment	upregulated	31863666
18469	Mouse	mmu-miR-706	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	NIH3T3 cells	thapsigargin (Tg) treatment	upregulated	31863666
18470	Mouse	mmu-miR-706	miRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	AML12 mouse hepatic cells	thapsigargin (Tg) treatment	upregulated	31863666
18471	Mouse	mmu-miR-706	miRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	NIH3T3 cells	tunicamycin (TM) treatment	upregulated	31863666
18472	Mouse	mmu-miR-706	miRNA	H2O2	hepatic fibrogenesis	liver fibrogenic cells	oxidative stress	downregulated	27876854
18473	Mouse	mmu-miR-706-5p	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	upregulated	31497013
18474	Mouse	mmu-miR-708	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	downregulated	23716137
18475	Mouse	mmu-miR-708	miRNA	dexamethasone (DEX)	ovarian cancer (OC)	C57BL/6-derived ovarian cancer ID-8 cells	dexamethasone (DEX) treatment	upregulated	28591224
18476	Mouse	mmu-miR-708	miRNA	low glucose (LG)	¦Â-cell apoptosis	mouse pancreatic islets	low glucose concentrations	upregulated	28970284
18477	Mouse	mmu-miR-708-3p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
18478	Mouse	mmu-miR-708-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
18479	Mouse	mmu-miR-709	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	mouse proximal tubular cells (PTCs)	cisplatin treatment	upregulated	29042455
18480	Mouse	mmu-miR-709	miRNA	aldosterone	argonaute protein induct kidney	murine inner medullary collecting duct (mIMCD-3) cell line	aldosterone treatment	downregulated	24632479
18481	Mouse	mmu-miR-709	miRNA	sodium arsenite (NaAsO2)	arsenic inhibited cellular differentiation	pluripotent P19 mouse embryonal carcinoma cells	sodium arsenite treatment	upregulated	29121352
18482	Mouse	mmu-miR-709	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
18483	Mouse	mmu-miR-709	miRNA	high fat diet (HFD)	high fat diet?influence	liver tissue	high fat diet (HFD) feed	upregulated	19835573
18484	Mouse	mmu-miR-709	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	27232654
18485	Mouse	mmu-miR-709	miRNA	cisplatin (DDP)	mitochondrial dysfunction	proximal tubular cells (PTCs)	cisplatin (DPP) treatment	upregulated	29042455
18486	Mouse	mmu-miR-711	miRNA	hypoxia	ischemic injury	bone marrow mesenchymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	30613290
18487	Mouse	mmu-miR-711	miRNA	ionizing radiation (IR)	ionizing radiation (IR) injury	hippocampus; neurons	ionizing radiation (IR) treatment	"miR-711 was upregulated in the cortex at all time points and in the hippocampus and isolated neurons at 6 h, 24 h and 7 d after IR exposure."	32718090
18488	Mouse	mmu-miR-7116	miRNA	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD)	experimental autoimmune encephalomyelitis (EAE)	murine brain-derived CD4+ T cells	¦¤9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) combination treatment	upregulated	31497013
18489	Mouse	mmu-miR-7116-5p	miRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	downregulated	28543680
18490	Mouse	mmu-miR-712	miRNA	TGF-¦Â1	chronic inflammatory diseases	RAW 264.7 mouse macrophages	LPS and IFN-¦Ã treatment	downregulated	27992764
18491	Mouse	mmu-miR-712	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	insulin sensitivity	RAW 264.7	LPS? treatment	downregulated	27992764
18492	Mouse	mmu-miR-712	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
18493	Mouse	mmu-miR-712-5p	miRNA	tanshinone IIA (Tan IIA)	inflammation	Mouse aortic vascular smooth muscle cell (VSMC)	Tanshinone ¢òA (Tan ¢òA) treatment	Tan IIA inhibits VSMC inflammation via suppressing miR-712-5p upregulation by TNF-¦Á	32387370
18494	Mouse	mmu-miR-7-1-3p	miRNA	lipopolysaccharide (LPS)	autophagy	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	29845275
18495	Mouse	mmu-miR-714	miRNA	clamping the renal pedicle	bilateral renal ischemia	C57Bl/6 mice plasma and kidneys	clamping the renal pedicle treatment	upregulated	24695114
18496	Mouse	mmu-miR-717	miRNA	hypertonicity	cellular responses to osmotic stress	mouse renal medulla	hypertonicity-induced induction	upregulated	20852262
18497	Mouse	mmu-miR-718	miRNA	lipopolysaccharide (LPS)	inflammation	mouse spleens	lipopolysaccharide (LPS) treatment	upregulated	28209713
18498	Mouse	mmu-miR-718	miRNA	dioscorea bulbifera (DB)	liver damage	livers	dioscoreae bulbifera (EF) treatment	downregulated	27609015
18499	Mouse	mmu-miR-718	miRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	mouse aortic endothelial cells (MAECs)	chronic intermittent hypoxia (CIH) treatment	downregulated	29108914
18500	Mouse	mmu-miR-719	miRNA	arsenite	atherosclerosis (AS)	liver	arsenic (As) exposure	downregulated	22719926
18501	Mouse	mmu-miR-720	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver injury (ALI)	liver tissues	D-GalN/LPS treatment	downregulated	31061003
18502	Mouse	mmu-miR-720	miRNA	high fat diet (HFD)	erectile dysfunction (ED)	mouse	high fat diet (HFD) feed	dysregulated	25533598
18503	Mouse	mmu-miR-720	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	downregulated	26728044
18504	Mouse	mmu-miR-721	miRNA	enterovirus 71 (EV71)	enterovirus 71 (EV71) infection	mouse	infect with EV71	downregulated	28469998
18505	Mouse	mmu-miR-7218-5p	miRNA	high fat diet (HFD)	compensatory hyperplasia of islets	hepatocellular extracellular vesicles (EVs)	?high-fat diet (HFD) feed treatment	downregulated	31284955
18506	Mouse	mmu-miR-7219-5p	miRNA	high fat diet (HFD)	compensatory hyperplasia of islets	hepatocellular extracellular vesicles (EVs)	?high-fat diet (HFD) feed treatment	downregulated	31284955
18507	Mouse	mmu-miR-7224-3p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	downregulated	33224036
18508	Mouse	mmu-miR-7239-5p	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colonic tissues	dextran sulfate sodium (DSS) treatment	upregulated	32779953
18509	Mouse	mmu-miR-7240-5p	miRNA	subchronic deoxynivalenol (DON)	liver damage	liver tissues; Hepa 1-6 cells	subchronic deoxynivalenol (DON) exposure treatment	downregulated	32439590
18510	Mouse	mmu-miR-741-3p	miRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	palate	all-trans retinoic acid (ATRA) treatment	?NONMMUT004850.2/NONMMUT024276.2-miR-741-3p/miR-465b-5p-Prkar1¦Á?could potentially serve as an important regulatory mechanism of palatal fusion in the development of the cleft palate.	32042778
18511	Mouse	mmu-miR-741-3p	miRNA	pressure overload	heart failure (HF)	heart sissues	pressure overload treatment	downregulated	33224746
18512	Mouse	mmu-miR-741-3p	miRNA	radiation	radiation-induced brain injury (RBI)	hippocampus	radiation treatment	"microRNA sequencing was used to discover differential miRNAs in the hippocampus of RBI-modeled mice, which suggested that miR-741-3p was most significantly upregulated"	33544844
18513	Mouse	mmu-miR-744	miRNA	alcohol	alcoholic hepatitis (AH)	sera	alcohol exposure	upregulated	26264599
18514	Mouse	mmu-miR-744	miRNA	carbon tetrachloride (CCl4)	liver cirrhosis	sera and livers	CCl4 treatment	downregulated	31643031
18515	Mouse	mmu-miR-744-3p	miRNA	X-rays	bystander effect	C57BL/6 mice extracellular vesicles (EVs)	otal-body irradiated with X-rays	downregulated	28396668
18516	Mouse	mmu-miR-7-5p	miRNA	hyperoxia	experimental retinopathy	C57BL/6J mice endothelial cells	"exposed to hyperoxia (75% oxygen) in an incubation chamber (Stuart Scientific, Redhill, UK) with their nursing mothers for 5 days and then returned to ambient air"	upregulated	28353063
18517	Mouse	mmu-miR-7-5p	miRNA	diosbuibin B (DB)	gastric cancer (GC)	"human gastric cancer cell lines (MGC803, BGC-823 and SGC7901)"	Diosbulbin-B (DB)?treatment	knock-down of CircRNA CDR1as specifically promoted the cytotoxic effects of low-dose DB on GC cells instead of hepatocytes by regulating miR-7-5p/REG¦Ã axis.	31542615
18518	Mouse	mmu-miR-761	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	HL-1 Cells	hypoxia/reoxygenation (H/R) treatment	ZFAS1 was upregulated and miR-761 was downregulated in the serum of patients with AMI and H/R-induced HL-1 cells.	32833901
18519	Mouse	mmu-miR-761	miRNA	angiotensin II (Ang II)	atherosclerosis and restenosis	SMCs	angiotensin II (Ang II) treatment	downregulated	26444612
18520	Mouse	mmu-miR-762	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues	lipopolysaccharide (LPS) treatment	miR-762 was upregulated at 6h.	32727087
18521	Mouse	mmu-miR-762	miRNA	house dust mite (HDM)	asthma	C57BL/6J mice airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	HDM treatment	dysregulated in airway-secreted EVs (AEVs) were isolated from bronchoalveolar lavage fluid (BALF)	28859242
18522	Mouse	mmu-miR-762	miRNA	thyroxine T4	cardiac hypertrophy	heart tissues	thyroxine T4 treatment	downregulated	31522342
18523	Mouse	mmu-miR-762	miRNA	cannabinoid receptor 1 (CB1) antagonists SR141716A	diet-induced obesity (DIO)	mouse adipose tissue macrophage (ATM)	SR141716A treatment	downregulated	30910812
18524	Mouse	mmu-miR-762	miRNA	polychlorinated biphenyls (PCBs)	cell differentiation	P19 mouse embryonal carcinoma cells	polychlorinated biphenyls (PCBs) treatment	downregulated	23443104
18525	Mouse	mmu-miR-762	miRNA	anoxia/reoxygenation (A/R)	myocardial infarction (MI)	Neonatal mouse cardiomyocytes	anoxia/reoxygenation (A/R) treatment	miR-762 predominantly translocated in the mitochondria and was significantly upregulated upon anoxia/reoxygenation (A/R) treatment.	31235686
18526	Mouse	mmu-miR-764-3p	miRNA	TGF-¦Â1	treat steroid-related diseases	ovarian granulosa cells	TGF-¦Â1 treatment	upregulated	26676955
18527	Mouse	mmu-miR-765	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33068927
18528	Mouse	mmu-miR-7654-3p	miRNA	high fat diet (HFD)	compensatory hyperplasia of islets	hepatocellular extracellular vesicles (EVs)	?high-fat diet (HFD) feed treatment	downregulated	31284955
18529	Mouse	mmu-miR-766-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Gm11974/miR-766-3p/NR3C2 axis plays important role in cerebral I/R injury	31556305
18530	Mouse	mmu-miR-7670-3p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary astrocytes	oxygen glucose deprivation (OGD) treatment	circSHOC2 in IPAS-EXOs suppressed neuronal apoptosis and ameliorated neuronal damage by regulating autophagy and acting on the miR-7670-3p/SIRT1 axis	33230464
18531	Mouse	mmu-miR-770-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	In vitro podocyte model of DN was conducted by treatment conditionally immortalized mouse podocytes with HG (30 mM D-glucose).	upregulated	30779094
18532	Mouse	mmu-miR-770-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocytes	high glucose (HG) treatment	MiR-770-5p was upregulated and TIMP3 was downregulated in DN kidney tissues and HG-stimulated podocytes.	32309847
18533	Mouse	mmu-miR-770-5p	miRNA	streptozocin (STZ)	diabetic pregnancy	female mice hyperglycemic ED9.5 embryos	streptozotocin treatment	dysregulatedin hyperglycemic ED95 embryos	27908722
18534	Mouse	mmu-miR-770-5p	miRNA	H2O2	ischemia/reperfusion (I/R) injury	cardiomyocytes	H2O2 treatment	NHG16 accelerates the proliferative ability of cardiomyocytes following IRI by negatively regulating miRNA-770-5p.	32855691
18535	Mouse	mmu-miR-784	miRNA	indole-3-carbinol (I3C)	colitis	Mesenteric lymph nodes	Indole-3-carbinol (I3C) treatment	downregulated	32921956
18536	Mouse	mmu-miR-7a	miRNA	sevoflurane (SEV)	effects of sevoflurane during early development	mouse embryonic stem cells	Sevoflurane treatment	upregulated	27535693
18537	Mouse	mmu-miR-7a	miRNA	H1N1 influenza virus	endometriosis and endometrial carcinoma	mouse lung?tissues	H1N1 influenza virus infection	upregulated	24066118
18538	Mouse	mmu-miR-7a	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	NIH 3T3 cells;TCMK-1 cells	Murine cytomegalovirus treatment	downregulated	22442111
18539	Mouse	mmu-miR-7a	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	downregulated	23716137
18540	Mouse	mmu-miR-7a	miRNA	curcumin (Cur)	myocardial infarction (MI)	cardiac myocytes	curcumin treatment	upregulated	27261602
18541	Mouse	mmu-miR-7a	miRNA	hypoxia	myocardial infarction (MI)	cardiomyocytes	hypoxia treatment	upregulated	26998750
18542	Mouse	mmu-miR-7a-1	miRNA	"3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)"	sclerosing cholangitis	ngn-3-heterozygous (+/-) mice	were subjected to DDC feeding (a model of sclerosing cholangitis) treatment	upregulated	24925797
18543	Mouse	mmu-miR-7a-2	miRNA	"3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)"	sclerosing cholangitis	ngn-3-heterozygous (+/-) mice	were subjected to DDC feeding (a model of sclerosing cholangitis) treatment	upregulated	24925797
18544	Mouse	mmu-miR-7a-2-3p	miRNA	chronic unpredictable mild stress (CUMS)	major depressive disorder (MDD)	nucleus accumbens (NAc) tissues	chronic unpredictable mild stress (CUMS) induce	downregulated	30936699
18545	Mouse	mmu-miR-7a-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	serum	lipopolysaccharide (LPS) treatment	upregulated	32934950
18546	Mouse	mmu-miR-7a-5p	miRNA	lipopolysaccharide (LPS)	cardiomyocytes injury	Mouse cardiomyocytes MCM cells	lipopolysaccharide (LPS) treatment	The expression of miR-7a-5p was significantly reduced in myocardial cells in the LPS group.	33029099
18547	Mouse	mmu-miR-7a-5p	miRNA	butyrate	diabetic nephropathy (DN)	SV40-MES-13 cells	butyrate treatment	"miR-7a-5p was significantly decreased in the HG-induced SV40-MES-13 cells, while giving butyrate reversed this change."	32539181
18548	Mouse	mmu-miR-7a-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
18549	Mouse	mmu-miR-7a-5p	miRNA	FTY720-C2	parkinson's disease (PD)	dopaminergic MN14D cells	FTY720-C2 treatment	upregulated	30359694
18550	Mouse	mmu-miR-7a-5p	miRNA	FTY720-C2	parkinson's disease (PD)	MN9D cells	FTY720-C2 treatment	upregulated	30359694
18551	Mouse	mmu-miR-7a-5p	miRNA	lipopolysaccharide + ATP	traumatic brain injury (TBI)	microglia	lipopolysaccharide + ATP treatment	downregulated	33189612
18552	Mouse	mmu-miR-7a-5p	miRNA	alpinia oxyphylla extract (AOE)	type 2 diabetes mellitus (T2DM)	db-/db- mouse kidney	A. oxyphylla extract (AOE) treatment	downregulated	28249617
18553	Mouse	mmu-miR-7b	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	serum	lipopolysaccharide (LPS) treatment	upregulated	32934950
18554	Mouse	mmu-miR-7b	miRNA	angiotensin II (Ang II)	chronic heart failure (CHF)	NG108 cells	angiotensin II (Ang II) treatment	upregulated	26699387
18555	Mouse	mmu-miR-7b	miRNA	sevoflurane (SEV)	effects of sevoflurane during early development	mouse embryonic stem cells	Sevoflurane treatment	upregulated	27535693
18556	Mouse	mmu-miR-7b	miRNA	curcumin (Cur)	myocardial infarction (MI)	cardiac myocytes	curcumin treatment	upregulated	27261602
18557	Mouse	mmu-miR-7b	miRNA	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL)	osteoclast-related bone disorders	RAW264.7 cells	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL) treatment	downregulated	25123438
18558	Mouse	mmu-miR-7b-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	32955644
18559	Mouse	mmu-miR-7c	miRNA	coronary artery ligation	myocardial ischaemic injury	heart	subjected to coronary artery ligation	downregulated	26655604
18560	Mouse	mmu-miR-7c-5p	miRNA	learning	persistent memory	C57BL/6J mouse hippocampal	Object-location memory task	upregulated	28927503
18561	Mouse	mmu-miR-7g	miRNA	coronary artery ligation	myocardial ischaemic injury	heart	subjected to coronary artery ligation	downregulated	26655604
18562	Mouse	mmu-miR-802	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues and RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	31696241
18563	Mouse	mmu-miR-802	miRNA	high fat diet (HFD)	insulin resistance (IR)	mice liver tissues	high fat diet (HFD) treatment	upregulated	23389544
18564	Mouse	mmu-miR-802	miRNA	high fat diet (HFD)	insulin resistance (IR)	liver tissues	high fat diet (HFD) feed	upregulated	31173239
18565	Mouse	mmu-miR-802	miRNA	particulate matter (PM2.5)	malignant pulmonary disorders	serum	PM2.5 treatment	downregulated	27144337
18566	Mouse	mmu-miR-802	miRNA	high fat diet (HFD)	obesity	renal tissues	high fat diet (HFD) feed	upregulated	30729676
18567	Mouse	mmu-miR-802	miRNA	obeticholic acid	obesity	mouse liver tissue	obeticholic acid treatment	"In obese mice, activation of FXR by obeticholic acid treatment reduced miR-802 levels and improved insulin resistance and hepatosteatosis"	33328206
18568	Mouse	mmu-miR-802	miRNA	obeticholic acid	obesity-related diseases	liver tissues	obeticholic acid treatment	Activation of FXR by obeticholic acid treatment reduced miR-802 levels.	33328206
18569	Mouse	mmu-miR-82-5p	miRNA	fatty acid amide hydrolase inhibitor (FAAH-II)	colitis	colitis mouse colon tissues	FAAH-II treatment	dysregulated	27327245
18570	Mouse	mmu-miR-872	miRNA	dexamethasone (DEX)	muscle atrophy	Murine C2C12 myoblast cells	dexamethasone (DEX) treatment	upregulated	23716137
18571	Mouse	mmu-miR-872	miRNA	cigarette smoke (CS)	ovarian toxicity	ovarian tissues	cigarette smoke (CS) treatment	upregulated	29377183
18572	Mouse	mmu-miR-873	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocytes (MPC5)	high glucose treatment	upregulated	30095204
18573	Mouse	mmu-miR-873	miRNA	IL-17	multiple sclerosis (MS)	mouse primary astrocytes	stimulat IL-17 treatment	upregulated	25183005
18574	Mouse	mmu-miR-873-5p	miRNA	colistin	colistin-induced kidney injury	Mouse renal tubular epithelial cells (mRTECs)	colistin treatment	downregulated	31156435
18575	Mouse	mmu-miR-873-5p	miRNA	medium deficient in methionine and choline (MDMC)	nonalcoholic fatty liver disease (NAFLD)	Mouse primary hepatocytes	medium deficient in methionine and choline (MDMC) treatment	upregulated	31668391
18576	Mouse	mmu-miR-873-5p	miRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	Mouse primary hepatocytes	oleic acid (OA) treatment	upregulated	31668391
18577	Mouse	mmu-miR-873a-5p	miRNA	morphine	morphine tolerance	spinal cord	?morphine?treatment treatment	upregulated	31024249
18578	Mouse	mmu-miR-874	miRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocyte	high glucose treatment	downregulated	30171701
18579	Mouse	mmu-miR-874	miRNA	ischemia	intestinal ischemic injury	C57BL/6 mice	abdomen was opened and the superior mesenteric artery (SMA) treatment	upregulated	24462679
18580	Mouse	mmu-miR-874	miRNA	lipopolysaccharide (LPS)	sepsis	mice cardiomyocytes UL-1 cells	lipopolysaccharide (LPS) treatment	upregulated	30021355
18581	Mouse	mmu-miR-874-3p	miRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	kidney tissues	ischemia/reperfusion (I/R) treatment	dysregulated	29245971
18582	Mouse	mmu-miR-874-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced renal podocyte injury	mouse primary podocytes; kidney tissues	doxorubicin (DOX) treatment	upregulated	32908641
18583	Mouse	mmu-miR-874-3p	miRNA	lipopolysaccharide (LPS)	major depressive disorder (MDD)	prefrontal cortex (PFC)	lipopolysaccharide (LPS) treatment	LPS upregulated miR-874-3p concomitantly with increase in IDO1 expression in the prefrontal cortex (PFC).	33095942
18584	Mouse	mmu-miR-874-3p	miRNA	testosterone	polycystic ovarian syndrome (PCOS)	granulosa cell (GC)	?testosterone treatment	"Compared with vehicle-treated GCs, miR-874-3p expression levels were significantly increased in testosterone-treated GCs"	33732332
18585	Mouse	mmu-miR-875-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	Mouse liver tissues and primary hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	downregulated	31617598
18586	Mouse	mmu-miR-875-5p	miRNA	icariin (ICA)	liver fibrosis	primary hepatic stellate cells (HSCs)	icariin treatment	upregulated	31617598
18587	Mouse	mmu-miR-875-5p	miRNA	icariin (ICA)	liver fibrosis	mouse primary hepatic stellate cells (HSCs)	Icariin treatment	Icariin induced miR-875-5p upregulation.	31617598
18588	Mouse	mmu-miR-876	miRNA	high fat diet (HFD)	atherosclerosis (AS)	apoE (-/-) mice endothelial cells	high fat diet (HFD) feed	upregulated	28723693
18589	Mouse	mmu-miR-877*	miRNA	clamping the renal pedicle	bilateral renal ischemia	C57Bl/6 mice plasma and kidneys	clamping the renal pedicle treatment	upregulated	24695114
18590	Mouse	mmu-miR-877-3p	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	H2O2 treatment	upregulated	31284127
18591	Mouse	mmu-miR-877-5p	miRNA	Trovafloxacin	liver damage	liver	Trovafloxacin treatment	upregulated	27713024
18592	Mouse	mmu-miR-877-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	primary mouse chondrocytes	IL-1¦Â treatment	miR-877-5p expression levels significantly declined in IL- 1¦Â-stimulated chondrocytes in a concentration-dependent manner.	32584470
18593	Mouse	mmu-miR-879-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	NAc tissue	chronic unpredictable mild stress (CUMS) treatment	upregulated	31430030
18594	Mouse	mmu-miR-882	miRNA	melatonin	osteoporosis	Raw264.7 cells	Melatonin treatment	Melatonin downregulates miR-882 expression in RANKL-induced Raw264.7 cells.	33416111
18595	Mouse	mmu-miR-882	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	upregulated	30242182
18596	Mouse	mmu-miR-9	miRNA	baicalin (BAI)	aberrant scar	NIH-3T3 cells	baicalin (BAI) treatment	upregulated	31362535
18597	Mouse	mmu-miR-9	miRNA	differentiation medium (DM)	adipogenesis	3T3-L1 cells	"3T3-L1 cells were incubated in differentiation medium (DM) supplemented with 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine, 250 nM dexamethasone, and 160 nM insulin."	upregulated	31759991
18598	Mouse	mmu-miR-9	miRNA	epigallocatechin-3-gallate (EGCG)	Alzheimer's disease (AD)	AD mouse serum	EGCG treatment groups (2 mg/kg/day)	upregulated	28731435
18599	Mouse	mmu-miR-9	miRNA	osthole	Alzheimer's disease (AD)	NSCs isolated from the SVZ region of newborn (0¨C2 days) C57BL/6 mice	osthole treatment	upregulated	28659755
18600	Mouse	mmu-miR-9	miRNA	arsenite	arsenic induted deficits in differentiation	prenatal C57BL/6 mouse brain	arsenic (As) exposure	downregulated	27751817
18601	Mouse	mmu-miR-9	miRNA	sodium arsenite (NaAsO2)	arsenic inhibited cellular differentiation	pluripotent P19 mouse embryonal carcinoma cells	sodium arsenite treatment	downregulated	29121352
18602	Mouse	mmu-miR-9	miRNA	IFN-¦Ã and lipopolysaccharide (LPS)	asthma	lung tissues	"IFN-¦Ã,LPS treatment"	upregulated	25772595
18603	Mouse	mmu-miR-9	miRNA	isoflurane	central nervous system of the developing fetus	mouse embryonic stem cell (mES cell)	isoflurane treatment	upregulated	25892252
18604	Mouse	mmu-miR-9	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	mouse primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31837324
18605	Mouse	mmu-miR-9	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31837324
18606	Mouse	mmu-miR-9	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	balb/c nu-nu mice injected with 107 GC cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	25270964
18607	Mouse	mmu-miR-9	miRNA	histone deacetylase inhibitor (HDACi)	hypercalciuric diseases	mouse	HDAC inhibitors treatment	upregulated	25071082
18608	Mouse	mmu-miR-9	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung tissues	bleomycin (BLM) treatment	upregulated	30144053
18609	Mouse	mmu-miR-9	miRNA	lipopolysaccharide (LPS)	inflammation	Raw264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	30552873
18610	Mouse	mmu-miR-9	miRNA	lipopolysaccharide (LPS)	inflammation	macrophages	lipopolysaccharide (LPS) treatment	upregulated	30552873
18611	Mouse	mmu-miR-9	miRNA	lipopolysaccharide (LPS)	inflammation	Kupffer cells or RAW 264.7 macrophages	lipopolysaccharide (LPS) treatment	upregulated	31099043
18612	Mouse	mmu-miR-9	miRNA	aluminum-sulfate	inflammatory neurodegeneration	C57BL/6J mice blood	serum exposure to a standard mouse diet that included aluminum-sulfate	upregulated	29354323
18613	Mouse	mmu-miR-9	miRNA	CCL2	macrophage polarization	CC chemokine 2(CCL2) pre-treated mouse bone marrow-derived macrophages (BMDMs)	CCL2 treatment	upregulated	28242024
18614	Mouse	mmu-miR-9	miRNA	chronic unpredictable stress (CUMS) and lipopolysaccharide (LPS)	major depressive disorder (MDD)	plasma; hippocampus	chronic unpredictable stress (CUS) and lipopolysaccharide (LPS) treatment	upregulated	30413800
18615	Mouse	mmu-miR-9	miRNA	retinoic acid (RA)	cell differentiation	Neuro-2A cells	retinoic acid? treatment	upregulated	31823894
18616	Mouse	mmu-miR-9	miRNA	green tea polyphenols (GTP)	osteoarthritis (OA)	LPS treated ATDC5 cells	green tea polyphenols (GTP) treatment	upregulated	31102286
18617	Mouse	mmu-miR-9	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	31102286
18618	Mouse	mmu-miR-9	miRNA	resveratrol	osteoarthritis (OA)	mouse chondrocytes	resveratrol (Res) treatment	The relative expression level of miR-9 significantly increased following treatment with Res in a dose-dependent manner	32104302
18619	Mouse	mmu-miR-9	miRNA	microwave	microwave-induced adverse health outcomes 	mouse hippocampus	7 days after 30 mW/cm microwave exposure treatment	downregulated	24748327
18620	Mouse	mmu-miR-9	miRNA	bone morphogenetic protein 2 (BMP2)	repair of spinal cord injury	pre-osteoblast cell line MC3T3-E1	bone morphogenetic protein 2 (BMP2) treatment	downregulated	26359086
18621	Mouse	mmu-miR-9	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	31174089
18622	Mouse	mmu-miR-9	miRNA	ethanol (EtOH)	teratogenesis	fetal brains of mice	Ethanol?treatment	upregulated	19091803
18623	Mouse	mmu-miR-9	miRNA	zika virus (ZIKV)	Zika virus (ZIKV) infection	embryonic mouse cortex	Zika virus (ZIKV) infection treatment	upregulated	30264295
18624	Mouse	mmu-miR-9	miRNA	live L. acidophilus	¦Â-lactoglobulin (¦Â-Lg) allergy	murine splenocytes	live L. acidophilus treatment	downregulated	30156972
18625	Mouse	mmu-miR-9*	miRNA	arsenite	arsenic induted deficits in differentiation	prenatal C57BL/6 mouse brain	arsenic (As) exposure	downregulated	27751817
18626	Mouse	mmu-miR-90-3p	miRNA	N-ethyl-N-nitrosourea (ENU)	hepatocellular carcinoma (HCC)	liver tissues	N-ethyl-N-nitrosourea (ENU) treatment	upragulated	21029445
18627	Mouse	mmu-miR-9-1	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	liver tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-1 was downregulated in the liver tissues od female mice.	32871758
18628	Mouse	mmu-miR-9-1	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	liver tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-1 was downregulated in the liver tissues of male mice.	32871758
18629	Mouse	mmu-miR-9-1	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	kidneny tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-1 was upregulated in the kidney tissues od female mice.	32871758
18630	Mouse	mmu-miR-9-1	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	kidneny tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-1 wasdownregulated in the kidney tissues of male mice.	32871758
18631	Mouse	mmu-miR-9-1	miRNA	VitB12	methylmalonic acidemia (MMA)	newborn BalB/C mice	VitB12 treatment	downregulated	24390963
18632	Mouse	mmu-miR-92	miRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	33143661
18633	Mouse	mmu-miR-92	miRNA	contextual fear conditioning	contextual fear conditioning	mouse hippocampus	training mice in contextual fear conditioning treatment	upregulated	24990518
18634	Mouse	mmu-miR-92	miRNA	ischemia/reperfusion (I/R) 	head and neck squamous cell carcinoma (HNSCC)	heart tissues	ischemia/reperfusion (I/R) treatment	the miR-17-92 cluster may protect the heart by diminishing the apoptosis and alleviating ischemia/reperfusion injury	23639284
18635	Mouse	mmu-miR-92	miRNA	¦¤9-tetrahydrocannabinol (THC)	inflammation	total lymph node cells and CD4(+) T cells	¦¤9-Tetrahydrocannabinol (THC) treatment	downregulated	27268054
18636	Mouse	mmu-miR-92	miRNA	imiquimod (IMQ)	psoriasis-like dermatitis	the mouse skin tissues	IMQ treatment	dysregulated	27579777
18637	Mouse	mmu-miR-92a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; splenocytes; bronchoalveolar lavage fluid (BALF)	lipopolysaccharide (LPS) treatment	miR-92a was markedly upregulated in the lung tissues of ALI mice.	30138892
18638	Mouse	mmu-miR-92a	miRNA	sodium arsenite (NaAsO2)	arsenic inhibited cellular differentiation	pluripotent P19 mouse embryonal carcinoma cells	sodium arsenite treatment	upregulated	29121352
18639	Mouse	mmu-miR-92a	miRNA	high methionine diet	atherosclerosis (AS)	aorta	high-methionine diet treatment	downregulated	33045026
18640	Mouse	mmu-miR-92a	miRNA	ML-7 (an inhibitor of myosin light chain kinase)	atherosclerosis (AS)	atherosclerosis mice aortic vessels	ML-7 (an inhibitor of myosin light chain kinase) treatment	downregulated	30907506
18641	Mouse	mmu-miR-92a	miRNA	berberine (BBR)	beige adipogenesis	Mouse 3T3-L1 pre-adipocytes	berberine (BBR) treatment	downregulated	31234575
18642	Mouse	mmu-miR-92a	miRNA	high glucose (HG)	diabetes mellitus (DM)	Min-6 mouse pancreatic b cells	high glucose (HG) treatment	The expression of miRNA-92a was significantly increased.	29660330
18643	Mouse	mmu-miR-92a	miRNA	astragalus polysaccharide (APS)	inflammation	LPS-treated ATDC5 cells	astragalus polysaccharide (APS) treatment	downregulated	31302422
18644	Mouse	mmu-miR-92a	miRNA	lipopolysaccharide (LPS)	inflammation	ATDC5 cells	lipopolysaccharide (LPS) treatment	upregulated	31302422
18645	Mouse	mmu-miR-92a	miRNA	vesicular stomatitis virus (VSV)	innate immune response	mice peritoneal macrophages	vesicular stomatitis virus (VSV) infection	upregulated	30160073
18646	Mouse	mmu-miR-92a	miRNA	hypoxia	ischemic injury	bone marrow mesenchymal stem cells (BM-MSCs)	hypoxia treatment	upregulated	30613290
18647	Mouse	mmu-miR-92a	miRNA	hypoxia	myogenic-lineage differentiation	?hypoxia-primed embryoid bodies (Hyp-EBs)	hypoxia treatment	hypoxic priming enhances EB commitment to the myogenic lineage through miR-92a/Sp1/MyoD regulatory axis.	31606324
18648	Mouse	mmu-miR-92a	miRNA	hypoxia	myogenic-lineage differentiation	embryoid bodies	hypoxia induce	downregulated	31606324
18649	Mouse	mmu-miR-92a	miRNA	ethanol (EtOH)	oxidative stress	MH-S cells	ethanol treatment	downregulated	33278514
18650	Mouse	mmu-miR-92a-2-5p	miRNA	schistosoma japonicum	liver fibrosis	mouse liver tissues	Schistosoma japonicum infection treatment	downregulated	30708193
18651	Mouse	mmu-miR-92a-3p	miRNA	hypoxia	cell differentiation	mouse (GL261 and G422) glioma cell lines	hypoxia induce	upregulated	30536597
18652	Mouse	mmu-miR-92a-3p	miRNA	reconstituted high-density lipoproteins (rHDL)	diabetes-impaired angiogenesis	diabetic mice HDL fraction	reconstituted high-density lipoproteins (rHDL) treatment	upregulated	30206364
18653	Mouse	mmu-miR-92a-3p	miRNA	reconstituted high-density lipoproteins (rHDL)	diabetes-impaired angiogenesis	diabetic mice plasma	reconstituted high-density lipoproteins (rHDL) treatment	downregulated	30206364
18654	Mouse	mmu-miR-92a-3p	miRNA	schistosoma japonicum	liver fibrosis	serum exosomes	S. japonicum infection treatment	miR-92a-3p was decresed on 6 weeks after S japonicum infection	32443549
18655	Mouse	mmu-miR-92b	miRNA	histone deacetylase inhibitors (HDIs) short-chain fatty acid (SCFA) butyrate	antibody-mediated systemic autoimmunity	B cells	SCFA HDI butyrate treatment	upregulated	32265934
18656	Mouse	mmu-miR-92b	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	peripheral blood of mice	smoking treatment	upregulated	22782705
18657	Mouse	mmu-miR-92b	miRNA	smoking	smoking-related interstitial fibrosis (SRIF)	C57 mice circulating	6 months of chronic mainstream smoking exposure treatment	upregulated	22782705
18658	Mouse	mmu-miR-92b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	mouse	angiotensin II (Ang II) treatment	upregulated	29190899
18659	Mouse	mmu-miR-92b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	Neonatal mouse ventricular cells (NMVCs)	angiotensin II (Ang II) treatment	upregulated	31283925
18660	Mouse	mmu-miR-92b-3p	miRNA	advanced glycation end product (AGE)	diabetic nephropathy (DN)	kidney tissues	advanced glycation end products (AGEs) treatment	MiR-92b-3p is Induced by Advanced Glycation End Products and Involved in the Pathogenesis of Diabetic Nephropathy.	32215042
18661	Mouse	mmu-miR-92b-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells (HSCs)	carbon tetrachloride (CCl4) treatment	"For instance, the expression of circPSD3, a circRNA derived from the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene, was considerably downregulated in primary hepatic stellate cells (HSCs) and liver tissues of mice with CCl4-induced HF compared to those in the vehicle group."	33614234
18662	Mouse	mmu-miR-92b-3p	miRNA	dipogenic differentiation mixture (MDI)	liver fibrosis	LX-2 cells	dipogenic differentiation mixture (MDI) treatment	"We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1. However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)."	33618248
18663	Mouse	mmu-miR-92b-3p	miRNA	TGF-¦Â1	liver fibrosis	LX-2 cells	TGF-¦Â1 treatment	"We found that miR-92b-3p was highly expressed both in fibrotic liver tissues from patients and model mice and in activated LX-2 cells stimulated with TGF-¦Â1 However, the expression of miR-92b-3p was downregulated in inactivated LX-2 cells treated with adipogenic differentiation mixture (MDI)"	33618248
18664	Mouse	mmu-miR-93	miRNA	red mud	biological effects of red mud	"CBA/Ca mice liver, spleen, lung, kidney and lymph nodes"	"1, 3, 6 and 24 h after a single intraperitoneal injection of red mud treatment"	"upregulated , but the level and the peak of the alteration differed according to examined tissue"	24425836
18665	Mouse	mmu-miR-93	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; bronchoalveolar lavage fluid (BALF)	lipopolysaccharide (LPS) treatment	downregulated	32468034
18666	Mouse	mmu-miR-93	miRNA	high fat diet (HFD)	brown adipocyte differentiation	brown adipose tissues	high fat diet (HFD) feed	upregulated	23954633
18667	Mouse	mmu-miR-93	miRNA	isoprenaline	cardiac hypertrophy	primary cardiomyocytes	isoprenaline (ISO) tteatment	CHRF expression was upregulated and miR-93 expression was downregulated in mice and cellular models of cardiac hypertrophy.	29747050
18668	Mouse	mmu-miR-93	miRNA	cigarette smoke (CS)	emphysema	lung tissues	Cigarette smoke (CS) exposure	upregulated	33660100
18669	Mouse	mmu-miR-93	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	downregulated	26728044
18670	Mouse	mmu-miR-93	miRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	MLE- 12 cells	influenza A virus (IAV) infection	influenza A virus (IAV) infection significantly inhibited miR-93 expression in alveolar epithelial type II cells through RIG-I/JNK pathway.	32652502
18671	Mouse	mmu-miR-93	miRNA	"3,3'-diindolylmethane (DIM)"	multiple sclerosis (MS)	activated T cells during the development of experimental autoimmune encephalomyelitis (EAE)	"3,3'-Diindolylmethane (DIM) treatment"	upregulated	24898268
18672	Mouse	mmu-miR-93	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	primary chondrocytes	lipopolysaccharide (LPS) treatment	downregulated	30569118
18673	Mouse	mmu-miR-93	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	primary chondrocytes	lipopolysaccharide (LPS) treatment	miR-93 levels wsa downregulated in a dose-dependent manner by lipopolysaccharide (LPS) treatment.	30569118
18674	Mouse	mmu-miR-93	miRNA	¦Â-elemene	oxygen-induced retinopathy (OIR)	Retinas tissues	¦Â-elemene treatment	upregulated	30664207
18675	Mouse	mmu-miR-93	miRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV2 cells	lipopolysaccharide (LPS) treatment	?It was found that the expression of miR-93 was downregulated in LPS-exposed BV2 cells.	33900518
18676	Mouse	mmu-miR-93	miRNA	curcumin (Cur)	peripheral arterial disease (PAD)	muscle tissues	curcumin treatment	upregulated	30651865
18677	Mouse	mmu-miR-93	miRNA	curcumin (Cur)	peripheral arterial disease (PAD)	ischemic muscle tissues	curcumin treatment	upregulated	30651865
18678	Mouse	mmu-miR-9-3	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	liver tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-3 was upregulated in the liver tissues of female mice.	32871758
18679	Mouse	mmu-miR-9-3	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	liver tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-3 was downregulated in the liver tissues of male mice.	32871758
18680	Mouse	mmu-miR-9-3	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	spleen tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-3 was upregulated in the spleen tissues of female mice.	32871758
18681	Mouse	mmu-miR-9-3	miRNA	"7,12-dimethylbenz(¦Á)anthracene (DMBA)"	"7,12-dimethylbenz(¦Á)anthracene (DMBA) toxicity"	kidneny tissues	"7,12-dimethylbenz(¦Á)anthracene (DMBA) treatment"	miR-9-3 was upregulated in the lkidney tissues of female mice.	32871758
18682	Mouse	mmu-miR-93-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse primary kidney GEC (C57-6014G) and mouse glomerular mesangial cells (GMC) (SV40 MES 13)-derived exosomes	high glucose (HG) treatment	upregulated	31497190
18683	Mouse	mmu-miR-93-5p	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	mouse renal tissues	streptozotocin (STZ) treatment	silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN	31545928
18684	Mouse	mmu-miR-93-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	plasma	doxorubicin (DOX) treatment	downregulated	30453253
18685	Mouse	mmu-miR-93-5p	miRNA	ultraviolet (UV) irradiation	skin damage	primary murine skin fibroblasts	UVB treatment	he Meg3 functioned as a competing endogenous RNA (ceRNA) that acted as a sponge for miR-93-5p and thereby modulated the expression of Epiregulin (Ereg)	31761787
18686	Mouse	mmu-miR-9-3p	miRNA	dexamethasone (DEX)	innate immune response	immature DCs (iDCs)	dexamethasone (DEX) treatment	downregulated	30174602
18687	Mouse	mmu-miR-9-3p	miRNA	IL-10	innate immune response	immature DCs (iDCs)	IL-10 treatment	downregulated	30174602
18688	Mouse	mmu-miR-9-3p	miRNA	X rays	ionizing radiation (IR) injury	male Kunming mice blood	0.5-2 Gy total-body carbon-ion irradiation treatment	dysregulatedin blood	28632432
18689	Mouse	mmu-miR-9-3p	miRNA	bone morphogenetic proteins (BMPs)	osteogenesis	pluripotent stem (iPS) cells	bone morphogenetic proteins (BMPs) treatment	downregulated	22937097
18690	Mouse	mmu-miR-9-3p	miRNA	learning	persistent memory	C57BL/6J mouse hippocampal	Object-location memory task	upregulated	28927503
18691	Mouse	mmu-miR-943-3p	miRNA	ovalbumin (OVA)	allergic asthma (AA)	lung tissues	ovalbumin (OVA) induce	upregulated	31101982
18692	Mouse	mmu-miR-9-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	HT22 cells	amyloid-¦Â (A¦Â) 25-35 treatment	MiR-9-5p was downregulated in A¦Â25-35-induced HT22 cells.	32713252
18693	Mouse	mmu-miR-9-5p	miRNA	oxygen glucose deprivation (OGD)	angiogenesis	Brain microvascular endothelial cells (BMECs)	an oxygen glucose deprivation (OGD) treatment	miRNA-9-5p was significantly increased in the traumatic foci after TBI	32502567
18694	Mouse	mmu-miR-9-5p	miRNA	anandamide and norgestimate	depression	chronic mild stress (CMS) model of depression mouse	anandamide and norgestimate treatment	upregulated	28716528
18695	Mouse	mmu-miR-9-5p	miRNA	dexamethasone (DEX)	innate immune response	immature DCs (iDCs)	dexamethasone (DEX) treatment	downregulated	30174602
18696	Mouse	mmu-miR-9-5p	miRNA	IL-10	innate immune response	immature DCs (iDCs)	IL-10 treatment	downregulated	30174602
18697	Mouse	mmu-miR-9-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	"CHON-001, ATDC5 cells"	IL-1¦Â treatment	"MEG3 expression in chondrocytes was downregulated by the stimulation of IL-1¦Â, and MEG3 negatively regulated miR-9-5p expression but positively regulated KLF4 expression."	33776787
18698	Mouse	mmu-miR-9-5p	miRNA	FTY720-C2	parkinson's disease (PD)	dopaminergic MN15D cells	FTY720-C2 treatment	upregulated	30359694
18699	Mouse	mmu-miR-9-5p	miRNA	FTY720-C2	parkinson's disease (PD)	MN9D cells	FTY720-C2 treatment	upregulated	30359694
18700	Mouse	mmu-miR-96	miRNA	emulsion (proteoglycan)	ankylosing spondylitis (AS)	cartilage tissues	emulsion (proteoglycan) treatment	upregulated	31111563
18701	Mouse	mmu-miR-96	miRNA	angiotensin II (Ang II)	atrial fibrosis	atrial tissues	angiotensin II (Ang II) treatment	upregulated	32034721
18702	Mouse	mmu-miR-96	miRNA	alcohol	brain injury and neurodegeneration	cerebral cortex	chronic alcohol administration	downregulated	30374194
18703	Mouse	mmu-miR-96	miRNA	resveratrol	colorectal cancer (CRC)	mouse colorectal carcinoma (CRC) tissues	resveratrol (RS) treatment	upregulated	25280562
18704	Mouse	mmu-miR-96	miRNA	microcystin-leucine arginine (MC-LR)	cytotoxicity	GC-1 cells	Microcystin (MC)-LR treatment	miR-96 was downregulated most dramatically	24803159
18705	Mouse	mmu-miR-96	miRNA	grape seed proanthocyandin extract (GSPE)	dyslipidemia	high-fat diet (HFD)-fed mice liver tissues	grape seed proanthocyanidins extracts (GSPE) treatment	downregulated	30848548
18706	Mouse	mmu-miR-96	miRNA	high fat diet (HFD)	dyslipidemia	liver tissues	high fat diet (HFD) feed	upregulated	30848548
18707	Mouse	mmu-miR-96	miRNA	TGF-¦Â1	liver fibrosis	hepaticstellatecells(HSCs)	TGF-¦Â1 treatment	Exogenous expression of TGF-¦Â1 in mouse primary HSCs significantly increased expression of miR-96 in a concentration- and time-dependent manner	30406154
18708	Mouse	mmu-miR-96	miRNA	lipopolysaccharide (LPS)	inflammation	BV2 cells	lipopolysaccharide (LPS) treatment	downregulated	31150368
18709	Mouse	mmu-miR-96	miRNA	triptolide (TPL)	inflammation	LPS-treated BV2 cells	triptolide treatment	upregulated	31150368
18710	Mouse	mmu-miR-96	miRNA	lipopolysaccharide (LPS)	innate immune response	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	30625496
18711	Mouse	mmu-miR-96	miRNA	pseudomonas aeruginosa (PA)	innate immune response	RAW264.7 cells	Pseudomonas aeruginosa (PA) infection treatment	upregulated	30625496
18712	Mouse	mmu-miR-96	miRNA	narrow band noise	noise-induced deafness	outer hair cells	2-4 kHz narrow band noise at 100 dB SPL 6h per day for 3 consecutive days treatment	downregulated	25026825
18713	Mouse	mmu-miR-96	miRNA	perfluorooctanoic acid	perfluorooctanoic acid toxicity	mouse liver tissues	Perfluorooctanoic acid (PFOA) exposure treatment	upregulated	25092180
18714	Mouse	mmu-miR-96	miRNA	schistosoma	schistosomiasis hepatic fibrosis	hepaticstellatecells(HSCs)	Schistosoma infection treatment	"Schistosoma induces the expression of transforming growth factor ¦Â1 (TGF-¦Â1), which in turn upregulates the expression of miR-96 through SMAD2/3-DROSHA-mediated post-transcriptional regulation"	30406154
18715	Mouse	mmu-miR-96	miRNA	high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	pancreatic ¦Â cells	high fat diet (HFD) feed	upregulated	31506178
18716	Mouse	mmu-miR-96	miRNA	high glucose (HG)	type 2 diabetes mellitus (T2DM)	MIN6 cells	high glucose treatment	upregulated	31506178
18717	Mouse	mmu-miR-96	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	type 2 diabetes mellitus (T2DM)	MIN6 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	31506178
18718	Mouse	mmu-miR-96-5p	miRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 cells	lipopolysaccharide (LPS) treatment	downregulated	32955644
18719	Mouse	mmu-miR-96-5p	miRNA	FTY720-mitoxy	multiple system atrophy (MSA)	brain tissues	FTY720-Mitoxy treatment	downregulated	31751571
18720	Mouse	mmu-miR-96-5p	miRNA	palmitic acid (PA)	myogenesis and muscle homeostasis	C2C12 cells	Long-chain SFA palmitic acid (PA) treatment	upregulated	33322515
18721	Mouse	mmu-miR-96-5p	miRNA	lipopolysaccharide (LPS)	neonatal sepsis (NS)	RAW264.7 cells	lipopolysaccharide (LPS) treatment	The expression of miR-96-5p was decreased in LPS-induced inflammatory responses.	32618342
18722	Mouse	mmu-miR-96-5p	miRNA	high fat diet (HFD) and streptozotocin (STZ)	renal fibrosis	kidney tissues	high fat diet (HFD) and streptozotocin (STZ) treatment	miR-96-5p was downregulated in the renal tissues of DM mice.	31810140
18723	Mouse	mmu-miR-96-5p	miRNA	cyclophosphamide (CP)	systemic lupus erythematosus (SLE)	C3.MRL-Faslpr/J mice	C3.MRL-Faslpr/J mice treatment	downregulated	27924862
18724	Mouse	mmu-miR-98	miRNA	ischemia	acute myocardial infarction (AMI)	neonatal rat ventricular myocytes (NRVCs)	LAD artery	downregulated	28784995
18725	Mouse	mmu-miR-98	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28090786
18726	Mouse	mmu-miR-98	miRNA	scopolamine	Alzheimer's disease (AD)	brain tissues and hippocampal neurons	scopolamine treatment	downregulated	30365070
18727	Mouse	mmu-miR-98	miRNA	scopolamine	Alzheimer's disease (AD)	brain tissues and hippocampal neurons	scopolamine treatment	downregulated	30365070
18728	Mouse	mmu-miR-98	miRNA	nicotine	asthma	lung fibroblast (LF)	nicotine treatment	downregulated	33082140
18729	Mouse	mmu-miR-98	miRNA	rosiglitazone	asthma	lung fibroblast (LF)	rosiglitazone treatment	upregulated	33082140
18730	Mouse	mmu-miR-98	miRNA	lipopolysaccharide (LPS)	hepatocellular carcinoma (HCC)	RAW 264.7 cell line	LPS treatment	miR-98 expression in macrophages significantly decreased following LPS stimulation	21609717
18731	Mouse	mmu-miR-98	miRNA	cardiac ¦Á-myosin heavy chain peptides (MyHC-¦Á)	myocarditis	BALB/c mice B cells isolated from the mouse hearts	MyHC-¦Á treatment	upregulated in B cells isolated from the mouse hearts	27913008
18732	Mouse	mmu-miR-98	miRNA	IL-1¦Â	osteoarthritis (OA)	C57BL/6 mice OA chondrocytes	IL-1¦Â treatment	upregulated	28765925
18733	Mouse	mmu-miR-98	miRNA	plasmodium chabaudi malaria	peak parasitemia	liver of mice	Plasmodium chabaudi malaria infection treatment	downregulated	21085987
18734	Mouse	mmu-miR-98	miRNA	propofol (PPF)	propofol-induced developmental neurotoxicity	hippocampus	propofol treatment	downregulated	30242182
18735	Mouse	mmu-miR-98	miRNA	vitamin D	prostate cancer	LNCaP cells	vitamin D treatment	"the finding that growth inhibitive miR-98 is induced by 1,25-VD provides a potential therapeutic target for prostate cancer and a potential biomarker for 1,25-VD anti-tumor action"	23188821
18736	Mouse	mmu-miR-98	miRNA	sevoflurane (SEV)	cognitive impairment	adult mice	1 or 2 minimal alveolar concentrations sevoflurane for 4 or 8 h treatment	upregulated	28260068
18737	Mouse	mmu-miR-98	miRNA	hypoxia	pulmonary hypertension (PH)	lung tissues	hypoxia treatment	downregulated	26098770
18738	Mouse	mmu-miR-98-5p	miRNA	3¦Â-hydroxycholest-5-en-7-one	anti-inflammatory responses	RAW 264.7 cells	3¦Â-hydroxycholest-5-en-7-one treatment	downregulated	32771556
18739	Mouse	mmu-miR-98-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-98-5p expression is decreased in response to OGD/R treatment in neurons	30449595
18740	Mouse	mmu-miR-98-5p	miRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	colonic tissues	dextran sulphate sodium (DSS) treatment	miR-98-5p expression in the colonic tissues of mice was upregulated.	32242402
18741	Mouse	mmu-miR-98-5p	miRNA	estradiol-17¦Â (E2)	systemic lupus erythematosus (SLE)	murine B cells	estradiol-17¦Â (E2) treatment	downegulated	25912736
18742	Mouse	mmu-miR-99	miRNA	streptozocin (STZ)	congenital heart disease (CHD)	C57BL/6 mice blood	injection of streptozotocin before mating treatment	dysregulated	27998767
18743	Mouse	mmu-miR-99a	miRNA	angiotensin II (Ang II)	allergic airway inflammation	murine bone marrow-derived macrophages (BMDMs)	angiotensin II (Ang II) treatment	downregulated	32458348
18744	Mouse	mmu-miR-99a	miRNA	TGF-¦Â	hepatic genotoxicity	normal murine mammary gland cells	TGF-¦Â treatment	mir-99a and mir-99b may function as modulators within a complex network of factors regulating TGF-¦Â induced breast epithelial to mesenchymal transition	22299047
18745	Mouse	mmu-miR-99a	miRNA	rapamycin	HIV-associated nephropathy(HIVAN)	mice renal tissues	Rapamycin treatment	downregulated	23611955
18746	Mouse	mmu-miR-99a	miRNA	nuclear factor kappa-B (NF-¦ÊB) inhibitor Bay11-708211	supraesophageal bile reflux	hypopharyngeal mucosa	NF-¦ÊB inhibitor (BAY 11-7082) treatment	"Pre- but not post-application of NF-¦ÊB inhibitor, significantly blocks overexpression of Il6 and prostaglandin H synthases 2 (Ptgs2), and reverses miR-21, miR-155, miR-99a phenotypes."	32934775
18747	Mouse	mmu-miR-99a-5p	miRNA	high fat diet (HFD)	atherosclerosis (AS)	Apolipoprotein E knockout mice heart tissues	high fat diet (HFD) feed	downregulated	31325426
18748	Mouse	mmu-miR-99b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	32360624
18749	Mouse	mmu-miR-99b	miRNA	high fat diet (HFD)	hepatocellular carcinoma (HCC)	plasma and hepatic tissues	high fat diet (HFD) feed	upregulated	26728044
18750	Mouse	mmu-miR-99b	miRNA	mycobacterium tuberculosis (Mtb)	immune responses	dendritic cells (DCs) and macrophages	Mycobacterium tuberculosis infection	upregulated	23233675
18751	Mouse	mmu-miR-99b	miRNA	streptozocin (STZ)	nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC)	high fat dietmouse liver	STZ treatment	upregulated in liver	28345673
18752	Mouse	mmu-miR-99b	miRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	27538453
18753	Mouse	mmu-miR-99b	miRNA	TGF-¦Â	hepatic genotoxicity	normal murine mammary gland cells	TGF-¦Â treatment	mir-99a and mir-99b may function as modulators within a complex network of factors regulating TGF-¦Â induced breast epithelial to mesenchymal transition	22299047
18754	Mouse	mmu-miR-99b-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	heart tissue	angiotensin II (Ang II) treatment	We showed that Ang II infusion induced cardiac disfunction and fibrosis accompanied by markedly increased expression level of miR-99b-3p in heart tissues.	32814818
18755	Mouse	mmu-miR-99b-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	heart sissues	angiotensin II (Ang II) treatment	upregulated	32814818
18756	Mouse	mmu-miR-99b-5p	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	Cortexes of the brains	amyloid-¦Â (A¦Â) treatment	downregulated	26635599
18757	Mouse	mmu-miR-9a-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	serum	lipopolysaccharide (LPS) treatment	upregulated	32934950
18758	Mouse	mmu-miR-9a-5p	miRNA	static water pressure	liver fibrosis	hepatic stellate cells (HSCs)	static water pressure treatment	upregulated	26379395
18759	Mouse	mmu-miR-9a-5p	miRNA	liraglutide	type 2 diabetes mellitus (T2DM)	whole bone marrow exosomes	liraglutide 0.2 mg/kg for 2 months	dysregulated	29133778
18760	Mouse	mmu-miR-BART13	miRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	Mutu I and Mutu III cell lines	infection with EBV treatment	upregulated	25213622
18761	Mouse	mmu-miR-BART3	miRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	Mutu I and Mutu III cell lines	infection with EBV treatment	upregulated	25213622
18762	Mouse	mmu-miR-BART7	miRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	Mutu I and Mutu III cell lines	infection with EBV treatment	upregulated	25213622
18763	Mouse	mmu-miR-PC-5P-12969	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	mouse primary hippocampal neuronal cells (HT22)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30953313
18764	Mouse	Morrbid	lncRNA	hyperglycemia	myeloid neoplasms	C57/B6 mice	hyperglycemia treatment	"RNA-Seq revealed that this was due in part to upregulation of proinflammatory pathways, thereby generating a feed-forward loop, including expression of the antiapoptotic, long noncoding RNA (lncRNA) Morrbid."	33090974
18765	Mouse	MRAK017168	lncRNA	subarachnoid hemorrhage (SAH)	early brain injury (EBI)	brain	subarachnoid hemorrhage (SAH) treatment	downregulated	25777551
18766	Mouse	MRAK038897	lncRNA	subarachnoid hemorrhage (SAH)	early brain injury (EBI)	brain	subarachnoid hemorrhage (SAH) treatment	downregulated	25777551
18767	Mouse	mrhl	lncRNA	Wnt3a ligand	spermatogenesis	Gc1-Spg cells	Wnt3a ligand treatment	downregulated	25584904
18768	Mouse	MSTRG.13399.1	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	fetal mice palates	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	31961203
18769	Mouse	MSTRG.1991.1	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	fetal mice palates	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	31961203
18770	Mouse	MSTRG.38487.1	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	fetal mice palates	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	downregulated	31961203
18771	Mouse	MSTRG.40182.1	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	fetal mice palates	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	downregulated	31961203
18772	Mouse	MSTRG.51656.1	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	fetal mice palates	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	downregulated	31961203
18773	Mouse	MSTRG.56310.1	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	cleft palate (CP)	fetal mice palates	"2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) treatment"	upregulated	31961203
18774	Mouse	N54010	lncRNA	Japanese encephalitis virus (JEV)	neuroinflammation	mouse brain	infect with JEV	dysregulated	29033949
18775	Mouse	NEAT1	lncRNA	Iodine-131 (131I)	papillary thyroid cancer (PTC)	PTC tissues	131I treatment	NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo.	30596336
18776	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	RAW264.7 macrophages	lipopolysaccharide (LPS) treatment	upregulated	32388658
18777	Mouse	NEAT1	lncRNA	streptozocin (STZ)	Alzheimer's disease (AD)	mouse brain tissues	streptozocin treatment	upregulated	31014193
18778	Mouse	NEAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 was elevated by ox-LDL in a dose-dependent and time-dependent manner.	30203508
18779	Mouse	NEAT1	lncRNA	insulin-like growth factor binding protein-related protein 1 (IGFBPrP1)	autophagy	hepatic stellate cell (HSC)	IGFBPrP1 treatment	upregulated	31610195
18780	Mouse	NEAT1	lncRNA	hypoxia	cerebral ischemia injury (CII)	mouse brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) induce	"lncRNA NEAT1 facilitated the survival and angiogenesis of OGD-induced BMECs via targeting miR-377 and promoting the expression of VEGFA, SIRT1, and BCL-XL."	30408478
18781	Mouse	NEAT1	lncRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) treatment	Upregulation of lncRNA NEAT1 and downregulated of miR-377 were also observed under OGD conditions	30408478
18782	Mouse	NEAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	BV2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33184298
18783	Mouse	NEAT1	lncRNA	5-aminolevulinic acid photodynamic therapy(ALA-PDT)	colitis	colon tissues	5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment	downregulated	30385297
18784	Mouse	NEAT1	lncRNA	catalpol	diabetic cardiomyopathy (DCM)	high glucose (HG) treated mouse cardiomyocytes	catalpol treatment	Catalpol attenuated HG-induced long noncoding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (Neat1) expression in mouse cardiomyocytes.	31078585
18785	Mouse	NEAT1	lncRNA	glucose	diabetic nephropathy (DN)	mice mesangial cells	glucose treatment	upregulated	30515796
18786	Mouse	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mice mesangial cells	high glucose (HG) treatment	upregulated	30549040
18787	Mouse	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mice mesangial cells	high glucose (HG) treatment	NEAT1 was significantly increased in high-glucose-induced mice mesangial cells.	30549040
18788	Mouse	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (MMCs) (SV40 MES13 cells)	high glucose (HG) treatment	upregulated	31933932
18789	Mouse	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse mesangial cells (MMCs)	high glucose (HG) treatment	The enrichment of NEAT1 was elevated in MMCs induced by high concentration of glucose.	32096162
18790	Mouse	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	kidney tissues	high glucose (HG) treatment	NEAT1 was greatly upregulated in DM rats.	30515796
18791	Mouse	NEAT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	mouse mesangial cells	streptozocin (STZ) treatment	NEAT1 was greatly upregulated in high glucose treated mouse mesangial cells	30515796
18792	Mouse	NEAT1	lncRNA	"insulin, dexamethasone, isobutylmethyxanthine (IBMX)"	cell differentiation	3T3-L1 cells	IBMX treatment	downregulated	25437750
18793	Mouse	NEAT1	lncRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	mice mesangial cells	high glucose (HG) treatment	upregulated	30549040
18794	Mouse	NEAT1	lncRNA	high glucose (HG)	fibrosis	mice mesangial cells	high glucose (HG) treatment	upregulated	30549040
18795	Mouse	NEAT1	lncRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	mouse embryonic fibroblast (MEF) cells	infect with HSV-1	upregulated	27783096
18796	Mouse	NEAT1	lncRNA	oxygen glucose deprivation (OGD)	hypoxic/ischemic brain damage (HIBD)	primary mouse hippocampal neurons cells	Oxygen-glucose deprivation (OGD) treatment	lncRNA NEAT1 upregulated HOXA1 to alleviate HIBD in mice by binding to miR-339-5p	32163893
18797	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	"Kupffer cells, RAW264.7 cells"	lipopolysaccharide (LPS) treatment	LPS induces an inflammatory response by upregulating the expression of lncRNA NEAT1.	31344555
18798	Mouse	NEAT1	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	mouse	carbon tetrachloride (CCl4) treatment	upregulated	28864835
18799	Mouse	NEAT1	lncRNA	alcohol	nonalcoholic fatty liver disease (NAFLD)	AML-12 cells	Lieber-DeCarli alcohol treatment	NEAT1/microRNA-129-5p/SOCS2 axis regulates liver fibrosis in alcoholic steatohepatitis	33228663
18800	Mouse	NEAT1	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	mouse liver tissues	high fat diet (HFD) feed	upregulated	31484042
18801	Mouse	NEAT1	lncRNA	methionine choline-deficient diet (MCD)	nonalcoholic steatohepatitis (NASH)	mouse liver tissues	methionine-choline-deficient (MCD) treatment	Liver tissues from mice fed a methionine-choline-deficient (MCD) diet exhibited increased expression of NEAT1 and PEG3 along with lower miR-129-5p expression.	33574830
18802	Mouse	NEAT1	lncRNA	lithium chloride (LiCl)	obesity	3T3L1 cells	Lithium chloride (LiCl) treatment	downregulated	33288642
18803	Mouse	NEAT1	lncRNA	resveratrol	osteoarthritis (OA)	mouse chondrocytes	resveratrol (Res) treatment	"The relative mRNA expression levels of MALAT1 and NF-¦ÊB1 were significantly increased, while treatment with Res partially reversed the mRNA expression levels of MALAT1"	32104302
18804	Mouse	NEAT1	lncRNA	catalpol	oxidative stress	mouse primary cardiomyocytes	catalpol treatment	downregulated	31736383
18805	Mouse	NEAT1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29287722
18806	Mouse	NEAT1	lncRNA	bovine type II collagen	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLSs)	bovine type II collagen induction	PBMC-derived exos contributes to RA development with the involvement of the miR-23a/MDM2/SIRT6 axis.	33042992
18807	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLSs)	Lipopolysaccharide (LPS) treatment	LncRNA NEAT1 shuttled by PBMC-derived exos promoted FLS proliferation and inflammation through regulating the MDM2/SIRT6 axis.	33042992
18808	Mouse	NEAT1	lncRNA	methamphetamine (METH) and MK801	schizophrenia (SZ)	prefrontal cortex (PFC)	methamphetamine (METH) and MK801 treatment	downregulated	30243133
18809	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated	31812793
18810	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	RAW 264.7	lipopolysaccharide (LPS) treatment	LncRNA NEAT1 promoted the inflammation and apoptosis while restrained the proliferation of LPS-stimulated RAW 264.7 cells through the miR-370-3p/TSP-1 axis.	31957847
18811	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	RAW 264.7 cells; HL-1 cells	lipopolysaccharide (LPS) treatment	NEAT1 and Irak2 were upregulated in sepsis tissues and LPS-induced RAW 264.7 and HL-1 cells.	32414769
18812	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	"NEAT1 and POU domain class 2 transcription factor 1 (POU2F1) were highly expressed in LPS-induced septic RAW264.7 cells, opposite to miR-31-5p expression."	33710444
18813	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	upregulated of NEAT1 level and downregulated of miR-495-3p/miR-211 level could aggravate inflammation in LPS-treated RAW264.7 cells.	31812793
18814	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	RAW 264.7 cells; HL-1 cells	lipopolysaccharides (LPS) treatment	upregulated	34004695
18815	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	32089649
18816	Mouse	NEAT1	lncRNA	cecal ligation and puncture (CLP)	sepsis-induced brain injury (SIBI)	brain tissues	cecal ligation and puncture (CLP) treatment	upregulated	31115021
18817	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	HL-1 cells	lipopolysaccharide (LPS) treatment	NEAT1 was upregulated in LPS-treated myocardial cells.	32016991
18818	Mouse	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	mouse heart tissues	lipopolysaccharides (LPS) treatment	NEAT1 knockdown can improve LPS-induced myocardial injury in mice by inhibiting the TLR2/NF-¦ÊB signaling pathway.	31210324
18819	Mouse	NEAT1	lncRNA	controlled cortical impact (CCI)	traumatic brain injury (TBI)	C57BL/6J mice	controlled cortical impact (CCI)	upregulated	28483659
18820	Mouse	NEAT2	lncRNA	methamphetamine (METH) and MK801	schizophrenia (SZ)	prefrontal cortex (PFC)	methamphetamine (METH) and MK801 treatment	downregulated	30243133
18821	Mouse	NEF	lncRNA	Hyperoxia	lung injury	RLE-6TNcells; MLE-12 cells	Hyperoxia treatment	LncRNA-NEF regulated the hyperoxia-induced injury of lung epithelial cells by FOXA2	33042438
18822	Mouse	Nespas	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse BV2 cells	oxygen-glucose deprivation treatment	upregulated	31167620
18823	Mouse	NKILA	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	murine hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGDR downregulated miR-103 and miR-107 to induce NKILA upregulation in neuronal cells	30007440
18824	Mouse	NONMMUG002873	lncRNA	high fat diet (HFD)	cholesterol biosynthesis	liver tissues	high fat diet (HFD) feed	upregulated	30504232
18825	Mouse	NONMMUG002873	lncRNA	palmitic acid (PA)	cholesterol biosynthesis	AML12 cells	palmitic acid (PA) treatment	upregulated	30504232
18826	Mouse	NONMMUG002873	lncRNA	WY14643	cholesterol biosynthesis	AML12 cells	WY14643 treatment	upregulated	30504232
18827	Mouse	NONMMUG027912	lncRNA	high fat diet (HFD)	cholesterol biosynthesis	liver tissues	high fat diet (HFD) feed	upregulated	30504232
18828	Mouse	NONMMUG027912	lncRNA	palmitic acid (PA)	cholesterol biosynthesis	AML12 cells	palmitic acid (PA) treatment	upregulated	30504232
18829	Mouse	NONMMUG027912	lncRNA	WY14643	cholesterol biosynthesis	AML12 cells	WY14643 treatment	upregulated	30504232
18830	Mouse	NONMMUG043402	lncRNA	high fat diet (HFD)	cholesterol biosynthesis	liver tissues	high fat diet (HFD) feed	upregulated	30504232
18831	Mouse	NONMMUG043402	lncRNA	palmitic acid (PA)	cholesterol biosynthesis	AML12 cells	palmitic acid (PA) treatment	upregulated	30504232
18832	Mouse	NONMMUG043402	lncRNA	WY14643	cholesterol biosynthesis	AML12 cells	WY14643 treatment	upregulated	30504232
18833	Mouse	NONMMUG043404	lncRNA	high fat diet (HFD)	cholesterol biosynthesis	liver tissues	high fat diet (HFD) feed	upregulated	30504232
18834	Mouse	NONMMUG043404	lncRNA	palmitic acid (PA)	cholesterol biosynthesis	AML12 cells	palmitic acid (PA) treatment	upregulated	30504232
18835	Mouse	NONMMUG043404	lncRNA	WY14643	cholesterol biosynthesis	AML12 cells	WY14643 treatment	upregulated	30504232
18836	Mouse	NONMMUGO11496	lncRNA	toxoplasma gondii (T. gondii)	T. gondii induced neurological disorder	brain tissues	toxoplasma gondii (T. gondii) infection treatment	downregulated lncRNA NONMMUG011496 (lncRNA-11496) was identified in the brains of mice infected with T gondii	32499679
18837	Mouse	NONMMUT004850.2	lncRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	palate	all-trans retinoic acid (ATRA) treatment	?NONMMUT004850.2/NONMMUT024276.2-miR-741-3p/miR-465b-5p-Prkar1¦Á?could potentially serve as an important regulatory mechanism of palatal fusion in the development of the cleft palate.	32042778
18838	Mouse	NONMMUT005697	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	upregulated	29986645
18839	Mouse	NONMMUT016106	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	upregulated	29986645
18840	Mouse	NONMMUT021632	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	placenta	high fat diet (HFD) feed	downregulated	29986645
18841	Mouse	NONMMUT022554	lncRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	fibrotic lung tissues of mice and pulmonary fibroblasts	TGF-¦Â1 treatment	lncRNA NONMMUT022554 was increased in fibrotic lung tissues of mice and pulmonary fibroblasts exposed to transforming growth factor (TGF)-¦Â1	29952219
18842	Mouse	NONMMUT024276.2	lncRNA	all-trans retinoic acid (ATRA)	cleft palate (CP)	palate	all-trans retinoic acid (ATRA) treatment	?NONMMUT004850.2/NONMMUT024276.2-miR-741-3p/miR-465b-5p-Prkar1¦Á?could potentially serve as an important regulatory mechanism of palatal fusion in the development of the cleft palate.	32042778
18843	Mouse	NONMMUT033416.2	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	upregulated	31833538
18844	Mouse	NONMMUT040834	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	upregulated	29986645
18845	Mouse	NONMMUT063872	lncRNA	codonopsis pilosula	anti-aging effect of Codonopsis pilosula	lung tissues	codonopsis pilosula treatment	NONMMUT063872 was significantly increased in the model group compared with the control group and was significantly decreased in the high-dose Codonopsis pilosula treatment (HC) group compared with the model group.	32049955
18846	Mouse	NONMMUT065582	lncRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung fibrosis tissues	bleomycin (BLM) treatment	NONMMUT065582 is upregulated in the lungs of mice.	30025992
18847	Mouse	NONMMUT065582	lncRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	primary mouse lung fibroblasts	TGF-¦Â1 treatment	NONMMUT065582 is upregulated in fibrotic lung fibroblasts	30025992
18848	Mouse	NONMMUT068202	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	placenta	high fat diet (HFD) feed	upregulated	29986645
18849	Mouse	NONMMUT068206	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	placenta	high fat diet (HFD) feed	upregulated	29986645
18850	Mouse	NONMMUT068207	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	placenta	high fat diet (HFD) feed	upregulated	29986645
18851	Mouse	NONMMUT073434	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	placenta	high fat diet (HFD) feed	upregulated	29986645
18852	Mouse	NONMMUT080010.1	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	downregulated	31833538
18853	Mouse	NONMMUT124495.1	lncRNA	palmitic acid (PA)	insulin resistance (IR)	C2C12 cells	palmitic acid treatment	upregulated	31833538
18854	Mouse	NORAD	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	SV40-MES-13?cells	high glucose (HG) treatment	upregulated	31630796
18855	Mouse	NR_002854.2	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	downregulated	32626785
18856	Mouse	NR_015555.1	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	downregulated	32626785
18857	Mouse	NR_024118	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cell line	lipopolysaccharide (LPS) treatment	downregulated	31485657
18858	Mouse	NR_024118	lncRNA	shikonin	rheumatoid arthritis (RA)	RA synovial fibroblasts	Shikonin treatment	upregulated	26640499
18859	Mouse	NR_027710	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	NR_027710 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
18860	Mouse	NR_027710	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	downregulated	29115403
18861	Mouse	NR_027710	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	NR_027710 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
18862	Mouse	NR_030715	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	NR_030715 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
18863	Mouse	NR_030715	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	downregulated	29115403
18864	Mouse	NR_030715	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	NR_030715 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
18865	Mouse	NR_030777	lncRNA	paraquat (PQ)	parkinson's disease (PD)	Neuro-2a; N2a cells	paraquat (PQ) treatment	NR_030777 Alleviates Paraquat-Induced Neurotoxicity by Regulating Zfp326 and Cpne5	32735315
18866	Mouse	NRON	lncRNA	angiotensin II (Ang II)	atrial fibrosis	mouse primary cultured atrial myocytes	angiotensin II (Ang II) treatment	LncRNA NRON suppresses inflammatory response in Ang II-treated atrial myocytes	31693733
18867	Mouse	NRON	lncRNA	angiotensin II (Ang II)	macrophage polarization	RAW264.7 macrophages	angiotensin II (Ang II) treatment	NRON promotes M2 macrophage polarization and alleviates atrial fibrosis through suppressing exosomal miR-23a derived from atrial myocytes.	33246743
18868	Mouse	Gm15154-201	lncRNA	fasciola gigantica excretory/secretory products (ESP)	macrophage activation and polarization	M2 macrophages	fasciola gigantica excretory/secretory products (ESP) treatment	upregulated	29794463
18869	Mouse	Gm15765-201	lncRNA	fasciola gigantica excretory/secretory products (ESP)	macrophage activation and polarization	M2 macrophages	fasciola gigantica excretory/secretory products (ESP) treatment	upregulated	29794463
18870	Mouse	Ube4bos2-201	lncRNA	fasciola gigantica excretory/secretory products (ESP)	macrophage activation and polarization	M2 macrophages	fasciola gigantica excretory/secretory products (ESP) treatment	upregulated	29794463
18871	Mouse	Gm17233-201	lncRNA	fasciola gigantica excretory/secretory products (ESP)	macrophage activation and polarization	M2 macrophages	fasciola gigantica excretory/secretory products (ESP) treatment	upregulated	29794463
18872	Mouse	NUNMMUT016103	lncRNA	sodium butyrate (NaB)	asthma	nasal mucosa	sodium butyrate (NaB) treatment	NUNMMUT016103 was downregulated after sodium butyrate (NaB) treatment.	32124940
18873	Mouse	OAD	lncRNA	bone morphogenetic protein 2 (BMP2)	osteoblastic differentiation	"C3H10T1/2 mesenchymal stem cells , MC3T3-E1 preosteoblast cells"	bone morphogenetic protein 2 (BMP2) treatment	Lnc-OAD expression was increased during BMP-2-induced osteoblast differentiation in C3H10T1/2 mesenchymal stem cells and MC3T3-E1 preosteoblast cells.	33816629
18874	Mouse	Obox4-ps35	lncRNA	triptolide (TPL)	reproductive toxicity	GC2 cells	triptolide (TPL) treatment	Obox4-ps35 knock-out aggravated triptonide-induced cytotoxicity by decreasing cell survival and increasing apoptosis and autophagy rates	33045310
18875	Mouse	ODSM	lncRNA	mechanical unloading	bone loss	MC3T3-E1 cells	Mechanical unloading treatment	Overexpression of the lncRNA ODSM partially reduces apoptosis and promotes differentiation in MC3T3-E1 cells under MG unloading conditions.	32071307
18876	Mouse	OGD-1006	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary brain microvascular endothelial cells (bEnd.3)	oxygen-glucose deprivation (OGD) treatment	LncOGD-1006 might act as a ceRNA to inhibit apoptosis in bEnd3 cells by targeting miR-184-5p/CAAP1 pathway	33336752
18877	Mouse	OIP5-AS1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	BV2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33516048
18878	Mouse	OIP5-AS1	lncRNA	IL-1¦Â	osteoarthritis (OA)	ATDC5 cells	IL-1¦Â treatment	OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models.	32037864
18879	Mouse	Oprm1	lncRNA	hypoxia	ischemic stroke (IS)	mouse brain tissues	middle cerebral artery occlusion (MCAO)	Infarct size was distinctly decreased in the lncRNA Oprm1-overexpression group.	31187646
18880	Mouse	Oprm1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Overexpression of lncRNA Oprm1 alleviated the apoptosis induced by oxygen-glucose deprivation and significantly reduced cleaved caspase-3 levels	31187646
18881	Mouse	linc-p21	lncRNA	hypoxia	acute respiratory distress syndrome (ARDS)	mouse mesenchymal stem cells (MSCs)	hypoxia treatment	MSCs induced by hypoxic preconditioning evoked an increase in expression of LincRNA-p21.	30359325
18882	Mouse	linc-p21	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung fibroblasts	lipopolysaccharide (LPS) treatment	upregulated	27392907
18883	Mouse	linc-p21	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	mouse alveolar macrophages (AMs); MH-S cells	lipopolysaccharide (LPS) treatment	Elevated lincRNA-p21 levels were observed in both LPS-induced ARDS mice and LPS-treated MH-S cells.	32362153
18884	Mouse	linc-p21	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	vascular smooth muscle cell (VSMC)	high fat diet (HFD) feed	"p53-dependent lincRNA-p21 expression downregulated miR-17-5p, whichconsequently protecting against AS progression via SIRT7 elevation."	33169349
18885	Mouse	linc-p21	lncRNA	doxorubicin (DOX)	cardiotoxicity	HL-1 murine cardiomyocytes2	doxorubicin treatment	upregulated	29207090
18886	Mouse	linc-p21	lncRNA	furan	cell proliferation	mice liver cells	Furan treatment	lncRNAs are transcriptional targets of furan exposures associated with levels of furan that are cytotoxic and induce cell proliferation.	23853263
18887	Mouse	linc-p21	lncRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	HL-1 cells	doxorubicin (Dox) treatment	p21 was highly expressed in Dox-treated HL-1 murine cardiomyocytes.	29207090
18888	Mouse	linc-p21	lncRNA	salvianolic acid B (Sal B)	hepatic stellate cell (HSC) activation	HSCs isolated from C57BL/6J mice	treat with Sal B treatment	upregulated	28391277
18889	Mouse	linc-p21	lncRNA	¦Ã-rays	irradiation-induced tumors	bone marrow (BM)	low-power long-term ¦Ã-irradiation	downregulated	32483710
18890	Mouse	linc-p21	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated in hepatocytes	28592847
18891	Mouse	linc-p21	lncRNA	thymosin ¦Â4 (T¦Â4)	liver damage	hepatic tissues ; hepatic stellate cells (HSCs)	Thymosin ¦Â4 (T¦Â4) treatment	T¦Â4 inhibited the increased expression of lincRNA-p21 by transfection of Ad-p21	32649978
18892	Mouse	linc-p21	lncRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	BV2 cells	?lipopolysaccharide (LPS) treatment	"In this study, we found that lncRNA p21 and tumor necrosis factor alpha-induced protein 1 (Tnfaip1) expression were upregulated and miR-181b expression was downregulated in lipopolysaccharide (LPS)-induced and activated BV-2 microglia"	33774143
18893	Mouse	linc-p21	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	30671473
18894	Mouse	linc-p21	lncRNA	astragaloside IV (AS-IV)	parkinson's disease (PD)	MN9D cells; brain tissues	astragaloside IV (AS-IV) treatment	AS-IV inhibit the expression of lincRNA-p21. in PD mice and PD cells.	32511947
18895	Mouse	linc-p21	lncRNA	ultraviolet (UV) irradiation	skin cancer	keratinocytes	UVB-irradiated treatment	lincRNA-p21 is highly inducible by UVB	25789975
18896	Mouse	PADNA	lncRNA	bupivacaine	bupivacaine-induced neurotoxicity	mouse DRG neurons	bupivacaine treatment	lincRNA PADNA/miR-194/FBXW7 axis plays an important role in the neurotoxicity process.	32791990
18897	Mouse	PAX8-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	MPC5 cells	high glucose (HG) treatment	Inhibition of lncRNA-PAX8-AS1-N directly associated with VEGF/TGF-¦Â1/8-OhdG enhances podocyte apoptosis in diabetic nephropathy.	32633379
18898	Mouse	PCAI	lncRNA	lipopolysaccharide (LPS)	postoperative cognitive dysfunction (POCD)	BV-2 cells	lipopolysaccharide (LPS) treatment	Overexpression of lncRNA PCAI can promote the cell death and inflammation response induced by LPS.	32247002
18899	Mouse	PCAT29	lncRNA	silica	lung fibrosis	pulmonary fibroblasts	silica treatment	lncRNAPCAT29 were downregulated within interstitial lung cells from mice with silica-induced pulmonary fibrosis.	29620190
18900	Mouse	PCFL	lncRNA	TGF-¦Â1	cardiac fibrosis	mouse cardiac fibroblasts (CFs)	TGF-¦Â1 treatment	upregulated	31220469
18901	Mouse	PEG10	lncRNA	phenylephrine (PE)	cardiac hypertrophy	mouse primary cardiomyocytes	phenylephrine (PE) treatment	upregulated	31389601
18902	Mouse	PFAR	lncRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	mouse primary lung fibroblasts	TGF-¦Â1 treatment	silencing PFAR attenuated TGF-¦Â1 induced fibrogenesis in primary lung fibroblasts	31273058
18903	Mouse	PGC1¦Â-OT1	lncRNA	adipogenesis medium	adipocyte and osteoblast differentiation	ST2 or C3H10T1/2 cells	"adipogenic medium ((¦Á-MEM containing 10% FBS, 0.5 ¦ÌM dexamethasone, 0.25 mM methylisobutylxanthine, 5 ¦Ìg/ml insulin, and 50 ¦ÌM indomethacin) treatment"	downregulated	30728459
18904	Mouse	PGC1¦Â-OT1	lncRNA	osteogenic differentiation medium	adipogenesis	ST2 or MC3T3-E1 cells	"osteogenic medium (¦Á-MEM containing 10% FBS, 50 ¦Ìg/ml ascorbic acid, and 5 mM ¦Â-glycerophosphate) treatment"	upregulated	30728459
18905	Mouse	Pirb	lncRNA	tanshinone IIA (Tan IIA)	atherosclerosis (AS)	RAW 264.7 cells	Tanshinone IIA (Tan) treatment	downregulated	32337768
18906	Mouse	Plscr4	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocytes	angiotensin II (Ang II) treatment	lncRNA Plscr4 was upregulated in hypertrophic mice hearts and in angiotensin II (Ang II)-treated cardiomyocytes.	29499950
18907	Mouse	Plscr4	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	mouse cardiomyocytes	angiotensin II (Ang II) treatment	upregulated	29499950
18908	Mouse	PMS2L2	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	PMS2L2 expression was downregulated following LPS stimulation.	30550887
18909	Mouse	PMS2L2	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	mouse chondrogenic ATDC5 cells	lipopolysaccharide (LPS) treatment	"PMS2L2 expression was downregulated following LPS stimulation. PMS2L2 protected ATDC5 cells against LPS-induced injury by increasing cell viability, decreasing apoptosis, and repressing the release of pro-inflammatory factors."	30550887
18910	Mouse	PRINS	lncRNA	hypoxia	acute kidney injury (AKI)	renal tubular cells	hypoxia treatment	upregulated	26725683
18911	Mouse	PRINS	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mouse podocyte cells	high glucose (HG) treatment	upregulated	30936994
18912	Mouse	PRNCR1	lncRNA	cisplatin (DDP)	acute kidney injury (AKI)	kidney tissues	cisplatin treatment	downregulated	33647908
18913	Mouse	PRNCR1	lncRNA	lipopolysaccharide (LPS)	pulmonary vascular endothelial cell (PVEC) injury	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	"PRNCR1 and TLR4 levels were significantly upregulated in LPS-treated PVEC, both in vivo and in vitro, while miR-330-5p were downregulated. Inhibiting PRNCR1 or overexpressing miR-330-5p markedly attenuated LPS-induced PVEC injury."	33049095
18914	Mouse	Psmd11	lncRNA	pilocarpine	epilepsy	hippocampal tissues	pilocarpine treatment	"Psmd11 was upregulated by Peg13 at a miR-490-3p dependent way, thus inactivating the Wnt/¦Â-catenin pathway and alleviating epilepsy course in mice"	33437373
18915	Mouse	PTPRE-AS1	lncRNA	IL-4	macrophage activation	Mouse bone marrow-derived macrophages (BMDMs)	IL-4 treatment	upregulated	31844669
18916	Mouse	PU.1-AS	lncRNA	arsenite	arsenite-induced abnormal lipid metabolism	liver tissues	arsenic exposure	upregulated	31471020
18917	Mouse	PVT1	lncRNA	lipopolysaccharide (LPS)	sepsis	myocardial tissue and heart infiltrating macrophages	lipopolysaccharide (LPS) treatment	upregulated	33840587
18918	Mouse	PVT1	lncRNA	angiotensin II (Ang II)	abdominal aortic aneurysm (AAA)	Apolipoprotein E-deficient (ApoE-/-) male mice abdominal aortic tissues	angiotensin II (Ang II) treatment	upregulated	30726659
18919	Mouse	PVT1	lncRNA	hypoxia	activation of hepatic stellate cells (HSCs)	hepatic stellate cells (HSCs)	hypoxia treatment	Hypoxia induces the activation of hepatic stellate cells through the PVT1-miR-152-ATG14 signaling pathway.	31893334
18920	Mouse	PVT1	lncRNA	ozone (O3)	asthma	CD4+ T cells and ASMCs	ozone treatment	lncRNA PVT1-miR-15a-5p/miR-29c-3p-PI3K-Akt-mTOR axis was implicated in ozone-induced asthma development by promoting ASMC proliferation and Th1/Th2 imbalance	33223504
18921	Mouse	PVT1	lncRNA	angiotensin II (Ang II)	atrial fibrosis	mouse atrial tissues	angiotensin II (Ang II) treatment	"upregulated, PVT1 knockdown attenuated the Ang-II-induced mouse atrial fibrosis."	30894138
18922	Mouse	PVT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Mouse podocyte clone 5 (MPC5) podocytes and primary podocytes	high glucose (HG) treatment	upregulated	31371698
18923	Mouse	PVT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	upregulated	31371698
18924	Mouse	PVT1	lncRNA	streptozocin (STZ)	diabetic osteoarthritis (OA)	cartilage tissues	streptozotocin (STZ) treatment	"PVT1 expression was significantly increased, whereas miR-146a was markedly decreased in diabetic OA mice than in non-diabetic OA and control"	33569722
18925	Mouse	PVT1	lncRNA	hypoxia	hepatic stellate cell (HSC) activation	primary mouse HSCs	hypoxia induce	upregulated	31893334
18926	Mouse	PVT1	lncRNA	hypoxia	immunosuppression	MDSCs;granulocytic MDSCs (G-MDSCs)	O2 < 0.1 induce	upregulated	30925926
18927	Mouse	PVT1	lncRNA	IL-6 and granulocyte-macrophage colony stimulating factor (GM-CSF)	immunosuppression	MDSCs or granulocytic MDSCs (G-MDSCs)	?IL-6 and GM-CSF induce treatment	upregulated	30925926
18928	Mouse	PVT1	lncRNA	unmethylated cytosine followed by guanine (CpG ODN)	macrophage activation	RAW264.7 cells	unmethylated cytosine followed by guanine (CpG ODN) treatment	upregulated	32626785
18929	Mouse	Rian	lncRNA	oxygen glucose deprivation (OGD)	ischemia/reperfusion (I/R) injury	N2a cells	oxygen-glucose deprivation treatment	Overexpression of long non-coding RNA Rian attenuates cell apoptosis from cerebral ischemia-reperfusion injury via Rian/miR-144-3p/GATA3 signaling	33294587
18930	Mouse	RMRP	lncRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	"The expression of RMRP and CCL2 was elevated, while miR-206 was reduced in OVA-induced mice."	33511814
18931	Mouse	RMRP	lncRNA	valproic acid (VPA)	ischemic stroke (IS)	BV2 cells	valproate (VPA) treatment	Valproate improves middle cerebral artery occlusion-induced ischemic cerebral disorders in mice and oxygen-glucose deprivation-induced injuries in microglia by modulating RMRP/PI3K/Akt axis	32745656
18932	Mouse	RMRP	lncRNA	lipopolysaccharide (LPS)	myocardial dysfunction	cardiomyocytes	lipopolysaccharide (LPS) treatment	The lncRNA RMRP axis acts as a sponge for miR-1-5p. RMRP inhibits LPS-induced apoptosis of cardiomyocytes and mitochondrial damage by suppressing the post-transcriptional regulatory function of miR-1-5p on HSPA4.	31900829
18933	Mouse	Rmst	lncRNA	oxygen glucose deprivation (OGD)	hypoxic/ischemic brain damage (HIBD)	brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) treatment	OGD exposure augmented the level of Rmst while reduced the expression of miR-150 in bEnd3 cells	32728986
18934	Mouse	RMST	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary hippocampal neuron	oxygen-glucose deprivation (OGD) treatment	upregulated	29258823
18935	Mouse	RMST	lncRNA	hypoxia	ischemic stroke (IS)	hippocampal neuron tissues	middle cerebral artery occlusion (MCAO) treatment	upregulated	29258823
18936	Mouse	RMST	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	Mouse microglial BV2 cells	oxygen-glucose deprivation (OGD) induce treatment	upregulated	31329361
18937	Mouse	RMST	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HT-22?hippocampal neuron cells	oxygen-glucose-deprivation (OGD) treatment	RMST was highly expressed in OGD-treated HT-22?hippocampal neuron cells	31852624
18938	Mouse	RMST	lncRNA	oxygen glucose deprivation (OGD)	neuron apoptosis	HT-22 hippocampal neuron cell	oxygen-glucose deprivation (OGD) treatment	RMST/hnRNPK/p53/miR-107/Bcl2l2 axis plays an important role in regulating neuronal apoptosis	31852624
18939	Mouse	Rmst	lncRNA	bone morphogenetic protein 9 (BMP9)	osteogenesis	The conditionally immortalized mouse multipotent adipose-derived cells iMADs	bone morphogenetic protein 9 (BMP9) treatment	upregulated	31825894
18940	Mouse	RNCR2	lncRNA	oxygen	pathological neovascularization	mouse ocular neovascularization	exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment	dysregulated	24623407
18941	Mouse	RNCR3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	plasma	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	27253412
18942	Mouse	RNCR3	lncRNA	high glucose (HG)	retinal microvascular abnormality	RF/6A cells	high glucose treatment	upregulated	27876564
18943	Mouse	RNCR4	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	C57BL/6 mice	intraperitoneal injection of STZ(77 70 mg/kg B.W.) treatment	upregulated	27876564
18944	Mouse	ROR	lncRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	H9C2 cells	hypoxia/reoxygenation (H/R) treatment	lncRNA ROR sponges miR-138 to aggravate H/R-induced myocardial cell injury by upregulating the expression of Mst1.	32240614
18945	Mouse	RP23-430H21.1	lncRNA	propofol (PPF)	propofol-induced neurotoxicity	hippocampus	propofol treatment	downregulated	29628875
18946	Mouse	Rpa	lncRNA	lead (Pb)	lead (Pb) toxicity	mouse neuroblastoma N2a cells	PbAc treatment	upregulated	27604105
18947	Mouse	Rps4l	lncRNA	hypoxia	pulmonary hypertension (PH)	arteries; pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	Rps4l expression was significantly reduced in PH-model mice and hypoxic PASMCs.	32772647
18948	Mouse	RUNXOR	lncRNA	cytarabine (Ara-C)	leukemia	Leuke mic K562 cells	exposure to a low dose of the antileu_x0002_kemic drug by Ara-C treatment	upregulated	24752773
18949	Mouse	SETD5-AS1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SETD5-AS1 was highly expressed in the ischemia-reperfusion injury model	30280788
18950	Mouse	SHNG16	lncRNA	oxygen glucose deprivation (OGD)	neuronal cell injury	HT22 hippocampal neurons	oxygen-glucose deprivation (OGD) treatment	downregulated	32323054
18951	Mouse	SHNG16	lncRNA	dexamethasone (DEX)	oxygen-glucose deprivation (OGD) induced neuron damage	HT22 hippocampal neurons	dexamethasone (Dex) treatment	upregulated	32323054
18952	Mouse	SIAH1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29217406
18953	Mouse	Six3OS	lncRNA	oxygen	pathological neovascularization	mouse ocular neovascularization	exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment	dysregulated	24623407
18954	Mouse	Smad7	lncRNA	TGF-¦Â	breast cancer	mouse mammary gland epithelial cells and breast cancer cell lines	mouse mammary gland epithelial cells continuously with TGF-¦Â treatment	upregulation	24863656
18955	Mouse	SNHG1	lncRNA	oxygen glucose deprivation (OGD)	brain vascular dysfunction	brain microvascular endothelial cell (BMEC)	oxygen-glucose deprivation (OGD) treatment	SNHG1 and miR-338 were upregulated in OGD induced BMEC.	30414401
18956	Mouse	SNHG1	lncRNA	phenylephrine (PE)	cardiac hypertrophy	neonatal mouse cardiomyocytes	phenylephrine [PE] treatment	downregulated	31889385
18957	Mouse	SNHG1	lncRNA	hypoxia	ischemic stroke (IS)	Mice primary brain microvascular endothelial cells (BMEC)	oxygen/glucose-deprived (OGD)?treatment	upregulated	30414401
18958	Mouse	Snhg1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGD/R induces the expression of Snhg1	29883549
18959	Mouse	SNHG1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	bEnd3 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG1 and salt-induced kinase 1 (SIK1) were upregulated in oxygen-glucose deprivation/reperfusion (OGD/R)-induced bEnd3 cells	33677804
18960	Mouse	SNHG1	lncRNA	sevoflurane (SEV)	neurotoxicity	HT22 cells	Sevoflurane treatment	upregulated	32150149
18961	Mouse	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	MN9D dopaminergic neurons	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	31499060
18962	Mouse	SNHG1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29217406
18963	Mouse	SNHG1	lncRNA	lipopolysaccharide (LPS)	parkinson's disease (PD)	BV2 cells	lipopolysaccharide (LPS) treatment	"Snhg1 expression was elevated, whereas miR-7 reduced in LPS-induced BV2 cells."	30031125
18964	Mouse	SNHG12	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	brain microvascular endothelial cell injury	brain microvascular endothelial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG12 levels in brain microvascular endothelial cells increased with respect to OGD exposure time	30233065
18965	Mouse	SNHG12	lncRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	brain tissues	middle cerebral artery occlusion/reperfusion (MCAO/R) injury	upregulated	31056262
18966	Mouse	SNHG12	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	primary neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31469718
18967	Mouse	SNHG12	lncRNA	hypoxia	ischemic stroke (IS)	primary neuronal cells and N2a cells	oxygen-glucose deprivation (OGD) treatment	upregulated	30144542
18968	Mouse	SNHG12	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	primary neuronal cells and N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG12 was upregulated in primary neuronal cells and N2a cells and peaked at 12?h and 24?h after OGD/R treatment	30144542
18969	Mouse	SNHG12	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse brain microvascular endothelial (bEnd.3) cells	oxygen-glucose deprivation (OGD) treatment	"SNHG12 expression was elevated, whereas miR-150 reduced in OGD-exposed bEnd.3 cells."	30193860
18970	Mouse	SNHG12	lncRNA	2/3 partial hepatectomy (PH)	liver regeneration	mouse liver tissues	2/3 partial hepatectomy (PH) treatment	upregulated	31894329
18971	Mouse	SNHG12	lncRNA	hepatocyte growth factor (HGF)	liver regeneration	primary mouse hepatocytes	hepatocyte growth factor (HGF) treatment	The expression of SNHG12 was also increased in normal liver cell lines treated with different concentrations of hepatocyte growth factor (HGF).	31894329
18972	Mouse	SNHG12	lncRNA	hepatocyte growth factor (HGF)	liver regeneration	Mouse primary hepatocytes and e NCTC 1469 and BNL CL.2 mouse hepatocyte cell lines	hepatocyte growth factor (HGF) (PH) treatment	upregulated	31894329
18973	Mouse	SNHG12	lncRNA	angiotensin II (Ang II)	vascular endothelial injury	aortic primary endothelial cells	angiotensin II (Ang II) treatment	"As a result, LncRNA SNHG12 was downregulated in aortic primary ECs isolated from Ang II-induced hypertensive mice and 1 kidney/deoxycorticosterone acetate/salt-induced hypertensive mice."	33464650
18974	Mouse	SNHG14	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	mouse alveolar macrophages (MH-S) and lung tissues	lipopolysaccharide (LPS) treatment	lncRNA SNHG14 silencing alleviated inflammation in LPS-induced ALI through miR-34c-3p-mediated inhibition of WISP1.	31660971
18975	Mouse	SNHG14	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cardiomyocytes (PCM)	angiotensin II (Ang II) treatment	upregulated	32436661
18976	Mouse	SNHG14	lncRNA	oxygen glucose deprivation (OGD)	cerebral infarction (CI)	BV-2 cells	oxygen/glucose deprivation (OGD) treatment	upregulated	28215748
18977	Mouse	SNHG14	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	HT22 (mouse hippocampal neuronal cells)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA SNHG14 promotes OGD/R-induced neuron injury by inducing excessive mitophagy via miR-182-5p/BINP3 axis in HT22 mouse hippocampal neuronal cells	32912324
18978	Mouse	SNHG14	lncRNA	rotenone (ROT)	parkinson's disease (PD)	mouse MN9D cells	rotenone treatment	"In MN9D cells, the rotenone treatment (1¦Ìmol/L) enhanced the binding between transcriptional factor SP-1 and SNHG14 promoter, thus promoting SNHG14 expression"	31683259
18979	Mouse	SNHG14	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	midbrain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	33071725
18980	Mouse	SNHG14	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	primary Neuron	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	33071725
18981	Mouse	SNHG14	lncRNA	dexmedetomidine (DEX)	spinal cord ischemia/reperfusion injury (SCII)	primary microglia	dexamethasone (DEX) treatment	DEX inhibited microglial activation and downregulated SNHG14 expression in SCIRI mice and oxygen and glucose deprivation/reoxygenation (OGD/R)-treated primary microglia.	33045891
18982	Mouse	SNHG15	lncRNA	streptozocin (STZ)	diabetes mellitus (DM)	gastrocnemius tissues; endothelial cells isolated from gastrocnemius tissues	Streptozocin (STZ) treatment	downregulated	33636173
18983	Mouse	SNHG15	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	HT22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"The SNHG15 and STAT1/NF-¦ÊB pathways were both distinctly upregulated, while miR-302a-3p was notably downregulated in the ischemia cortex"	33779086
18984	Mouse	SNHG15	lncRNA	oxygen glucose deprivation (OGD)	neuronal cell injury	Neuro-2a (N2a)	oxygen-glucose deprivation (OGD) treatment	"Silencing of SNHG15 led to CXCL13 upregulation through sequestering miR-18a and the following ERK/MEK activation, thus enhancing viability while reducing apoptosis of N2a cells."	32862188
18985	Mouse	SNHG16	lncRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	pulmonary fbrotic tissues	bleomycin (BLM) treatment	upregulated	33549106
18986	Mouse	SNHG16	lncRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	Primary mouse lung fbroblasts	TGF-¦Â1 treatment	downregulated	33549106
18987	Mouse	SNHG16	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	mesangial cells	high glucose (HG) treatment	LncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy.	32504027
18988	Mouse	SNHG16	lncRNA	H2O2	ischemia/reperfusion (I/R) injury	cardiomyocytes	H2O2 treatment	NHG16 accelerates the proliferative ability of cardiomyocytes following IRI by negatively regulating miRNA-770-5p.	32855691
18989	Mouse	SNHG16	lncRNA	high glucose (HG)	podocyte injury	MPC5 cells	high glucose (HG) treatment	SNHG16 was significantly upregulated in HG-induced podocytes	33116706
18990	Mouse	SNHG17	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	MPC5	high glucose (HG) treatment	lncRNA SNHG17 knockdown promotes Parkin-dependent mitophagy and reduces apoptosis of podocytes through regulating the degradation of Mst1.	32627655
18991	Mouse	SNHG20	lncRNA	diethylnitrosamine (DEN)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	diethyl nitrosamine (DEN) treatment	upregulated	31408278
18992	Mouse	SNHG20	lncRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31408278
18993	Mouse	SNHG3	lncRNA	oxygen glucose deprivation (OGD)	brain ischemia-reperfusion (I/R) injury	N2a cells	oxygen and glucose deprivation (OGD) treatment	upregulated	32860611
18994	Mouse	SNHG3	lncRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	primary hippocampal cells	hypoxia induce	downregulated	31751562
18995	Mouse	SNHG3	lncRNA	hypoxic/ischemic	hypoxic/ischemic brain damage (HIBD)	primary hippocampal cells	hypoxic/ischemic stress	"Snhg3 acted as the sponge of miR-196 in the hippocampal cells by regulating the expression of miR-196 target genes, XIAP and CAAP1."	31751562
18996	Mouse	SNHG5	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	"SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice."	33170429
18997	Mouse	SNHG5	lncRNA	5-aminolevulinic acid photodynamic therapy(ALA-PDT)	colitis	colon tissues	5-Aminolevulinic acid photodynamic therapy(ALA-PDT) treatment	downregulated	30385297
18998	Mouse	SNHG6	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary neuronal cells	oxygen glucose deprivation (OGD)-induce treatment	upregulated	31334597
18999	Mouse	SNHG7	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	primary hepatic stellate cell (HSC)	CCl4 treatment	upregulated	31272073
19000	Mouse	SNHG7	lncRNA	TGF-¦Â	liver fibrosis	primary hepatic stellate cells (HSCs)	TGF-¦Â treatment	SNHG7 was signally increased in liver tissue and HSCs of liver fibrosis model of mice	32893175
19001	Mouse	SNHG8	lncRNA	hypoxia	ischemic brain injury	?HT22 cells and hippocampal tissues	hypoxia induce	downregulated	31165722
19002	Mouse	SNHG8	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cell (BMEC)	oxygen-glucose deprivation (OGD) treatment	downregulated	33491845
19003	Mouse	sONE	lncRNA	high salt diet	hypertension	systolic blood pressure	high salt diet treatment	downregulated	26261587
19004	Mouse	SOX2OT	lncRNA	H2O2	abdominal aortic aneurysm (AAA)	vascular smooth muscle cell (VSMC)	oxidative stress	Silencing of long non-coding RNA Sox2ot inhibits oxidative stress and inflammation of vascular smooth muscle cells in abdominal aortic aneurysm via microRNA-145-mediated Egr1 inhibition.	32629426
19005	Mouse	SOX2OT	lncRNA	H2O2	diabetes-induced retinal neurodegeneration	retinal ganglion cell (RGC)	H2O2 treatment	upregulated	27193103
19006	Mouse	SOX2OT	lncRNA	high glucose (HG)	diabetes-induced retinal neurodegeneration	retinal ganglion cell (RGC)	high glucose (HG) treatment	upregulated	27193103
19007	Mouse	SOX2OT	lncRNA	streptozocin (STZ)	diabetes-induced retinal neurodegeneration	renal tissues	streptozocin (STZ) treatment	downregulated	27193103
19008	Mouse	SOX2OT	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	temozolomide (TMZ) treatment	"LncRNA SOX2OT inhibited cell apoptosis, promoted cell proliferation, and TMZ resistance by upregulating SOX2 expression, which activated the Wnt5a/¦Â-catenin signaling pathway"	32439916
19009	Mouse	SOX2OT	lncRNA	isoprenaline	cardiac fibrosis	cardiac fibroblasts (CFs)	isoprenaline (ISO) tteatment	LncRNA SOX2OT/Smad3 feedback loop promotes myocardial fibrosis in heart failure.	32959533
19010	Mouse	SOX2OT	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	mouse heart tissues	lipopolysaccharide (LPS) treatment	upregulated	31618067
19011	Mouse	Spry1	lncRNA	TGF-¦Â	cell proliferation	NMuMG mammary epithelial cells	TGF-¦Â treatment	downregulated	28186499
19012	Mouse	SRA	lncRNA	dehydroepiandrosterone (DHEA)	polycystic ovarian syndrome (PCOS)	ovary tissues	DHEA treatment	Silencing of lncRNA Steroid Receptor RNA Activator (SRA) attenuates polycystic ovary syndrome (PCOS) in mice.	30391287
19013	Mouse	SRA	lncRNA	dehydroepiandrosterone (DHEA)	polycystic ovarian syndrome (PCOS)	mouse primary granulosa cell culture	DHEA treatment	Silencing of lncRNA Steroid Receptor RNA Activator (SRA) attenuates polycystic ovary syndrome (PCOS) in mice.	30391287
19014	Mouse	SRA	lncRNA	dehydroepiandrosterone (DHEA)	polycystic ovarian syndrome (PCOS)	ovary	DHEA treatment	upregulated	30391287
19015	Mouse	SRAs	lncRNA	IL-2	type 1 diabetes mellitus (T1DM)	MIN6 ¦Â-cells	IL-2 treatment	downregulated	33572095
19016	Mouse	SYNE1-AS1	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	Cardiomyocytes were isolated from the neonatal mouse	angiotensin II (Ang II) treatment	the hypertrophic responses were attenuated by SYNE1-AS1 knockdown.	30652310
19017	Mouse	TCONS_00019174	lncRNA	chronic ultra-mild stress	depression	hippocampus	chronic ultra-mild stress treatment	mice exposed to chronic ultra-mild stress displayed apparent depression-like behaviors and decreased expression of long non-coding RNA TCONS_00019174 in hippocampus.	29036835
19018	Mouse	THOR	lncRNA	H2O2	glaucoma	RGCs	H2O2 treatment	?The expression of THOR was reduced in H2O2-induced RGCs.	33811613
19019	Mouse	THRIL	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	THRIL was highly expressed in the lung of sepsis mice.	32818819
19020	Mouse	THRIL	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	LPS significantly induced ATDC5 cell inflammatory injury and upregulated the expression of THRIL.	30521964
19021	Mouse	THRIL	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	ATDC5 cells	lipopolysaccharide (LPS) treatment	LPS significantly induced ATDC5 cell inflammatory injury and upregulated the expression of THRIL.	30521964
19022	Mouse	TINCR	lncRNA	Tri-DAP	inflammation	3T3-L1 adipocytes	Tri-DAP treatment	upregulated	30851423
19023	Mouse	Tnfaip3	lncRNA	lipopolysaccharide (LPS)	inflammation	RAW264.7 mouse macrophage cells	lipopolysaccharide (LPS) treatment	upregulated	27979905
19024	Mouse	TSIX	lncRNA	Co-Cr-Mo metal particles (CoPs)	particle-induced osteolysis (PIO)	MC3T3-E1 cells	Co-Cr-Mo metal particles (CoPs) treatment	upregulated	29260905
19025	Mouse	Ttc3-209	lncRNA	hank's balanced salt solution containing 10 ?M antimycin A	retinal ischemia reperfusion injury (RIR)	primary mouse retinal ganglion cells	Hank's balanced salt solution containing 10 ?M antimycin A treatment	lncRNA Ttc3-209 was significantly upregulated after I/R injury and played a proapoptotic role in RGCs during I/R-induced apoptosis.	33687475
19026	Mouse	TUG1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Mouse cardiomyocytes HL-1 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The expression of TUG1 was significantly upregulated in OGD/R-induced myocardial HL-1 cells The overexpression of TUG1-induced inflammation and apoptosis in OGD-R-induced myocardial HL-1 cells Knock down of TUG1 protected OGD/R-induced myocardial I/R injury by inhibiting HMGB1 expression Suppression of lncRNA TUG1 may prevent myocardial I/R injury following acute myocardial infarction via inhibiting HMGB1 expression	31432688
19027	Mouse	TUG1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; primary murine pulmonary microvascular endothelial cells (PMVECs)	lipopolysaccharide (LPS) treatment	downregulated	32087725
19028	Mouse	TUG1	lncRNA	H2O2	acute myocardial infarction (AMI)	primary cultured cardiomyocytes	H2O2 treatment	upregulated	31145943
19029	Mouse	TUG1	lncRNA	H2O2	acute myocardial infarction (AMI)	primary cardiomyocytes	H2O2 treatment	LncRNA TUG1 mediates ischemic myocardial injury by targeting miR-132-3p/HDAC3 axis.	31858814
19030	Mouse	TUG1	lncRNA	H2O2	acute myocardial infarction (AMI)	mouse primary cardiomyocytes	hydrogen peroxide (H2O2) treatment	"miR-132-3p was downregulated, whereas TUG1 upregulated in H2O2-challenged cardiomyocytes."	31858814
19031	Mouse	TUG1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	RAW 264.7 cells	lipopolysaccharide (LPS) treatment	LncRNA TUG1 reverses LPS-induced cell apoptosis and inflammation of macrophage via targeting MiR-221-3p/SPRED2 axis	32841583
19032	Mouse	TUG1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	hippocampal neurons	amyloid-¦Â (A¦Â) 25-35 treatment	TUG1 knockdown restricts apoptosis of hippocampal neurons in AD by elevating miR-15a and suppressing ROCK1 expression.	32577774
19033	Mouse	TUG1	lncRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	33640857
19034	Mouse	TUG1	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	aortas	high fat diet (HFD) feed	upregulated	29268138
19035	Mouse	TUG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 cells; MOVAS cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29268138
19036	Mouse	TUG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	RAW264.7 and MOVAS cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29268138
19037	Mouse	TUG1	lncRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	MLE-12 cells	hyperoxia treatment	downregulated	33194901
19038	Mouse	TUG1	lncRNA	hypoxia	cardiac fibroblast-myofibroblast transformation (FMT)	heart tissues	hypoxia treatment	upregulated	30066872
19039	Mouse	TUG1	lncRNA	high glucose (HG)	cardiac hypertrophy	HL-1 cells	high glucose (HG) treatment	upregulated	32269707
19040	Mouse	TUG1	lncRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes; cardiac fibroblasts	phenylephrine (PE) treatment	LncRNA TUG1 alleviates cardiac hypertrophy by targeting miR©\34a/DKK1/Wnt©\¦Â©\catenin signalling	32057178
19041	Mouse	TUG1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	MA-C cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	LncRNA TUG1 expression was significantly upregulated in cultured MA-C cells exposed to OGD/R injury	31709761
19042	Mouse	TUG1	lncRNA	astragaloside IV (AS-IV)	diabetic nephropathy (DN)	MPC5 cells	astragaloside (AS-IV) treatment	"TUG1 was downregulated and TRAF5 was upregulated in high-glucose-treated MPC5 cells, and AS-IV ameliorated the TUG1 level."	30233141
19043	Mouse	TUG1	lncRNA	high glucose (HG)	dysfunction of endothelial progenitor cells (EPCs)	EPCs	high glucose (HG) treatment	TUG1 restores high glucose-treated EPC function by regulating miR-29c-3p/PDGF-BB/Wnt signaling.	33059750
19044	Mouse	TUG1	lncRNA	chlorogenic acid (CGA)	glaucoma	retinal tissues	Chlorogenic acid (CGA) treatment	"IPL thickness and lncRNA TUG1 expression were significantly decreased in glaucoma mice model, and CGA treatment increased IPL thickness and lncRNA TUG1 expression."	31055996
19045	Mouse	TUG1	lncRNA	chlorogenic acid (CGA)	glaucoma	mouse retinal ganglion cell (RGC)	Chlorogenic acid (CGA) treatment	"IPL thickness and lncRNA TUG1 expression were significantly decreased in glaucoma mice model, and CGA treatment increased IPL thickness and lncRNA TUG1 expression."	31055996
19046	Mouse	TUG1	lncRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	Mouse hepatic cell line AML12	hypoxia induce	upregulated	31297532
19047	Mouse	TUG1	lncRNA	propofol (PPF)	hepatic ischemia/reperfusion injury (HIRI)	Mouse hepatic cell	Propofol induce treatment	Propofol increases cell viability and lncRNA-TUG1 expression level in H/R-treated hepatic cells	31297532
19048	Mouse	TUG1	lncRNA	lipopolysaccharide (LPS)	inflammation	The mouse immortalized podocyte cell line MPC5	lipopolysaccharide (LPS) treatment	downregulated	31115515
19049	Mouse	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	irritable bowel syndrome (IBS)	mouse interstitial cells of Cajal (ICC)	tumor necrosis factor alpha (TNF-¦Á) treatment	TUG1 was downregulated in TNF-¦Á-treated ICC.	30657572
19050	Mouse	TUG1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	MA-C cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	LncRNA TUG1 expression was significantly upregulated in cultured MA-C cells exposed to OGD/R injury	31709761
19051	Mouse	TUG1	lncRNA	cold	liver damage	livers	cold treatment	downregulated	26785829
19052	Mouse	TUG1	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues; primary mouse HSCs	carbon tetrachloride (CCl4) treatment	Tug1 expression was significantly upregulated in fibrotic livers.	29904430
19053	Mouse	TUG1	lncRNA	TGF-¦Â	liver fibrosis	primary mouse HSCs	TGF-¦Â treatment	upregulated	29904430
19054	Mouse	TUG1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	The expression of TUG1 was significantly increased in the I/R cardiomyocyte injury models.	33164260
19055	Mouse	TUG1	lncRNA	oxygen glucose deprivation (OGD)	neuroinflammation	BV-2 microglial cells	oxygen-glucose deprivation (OGD) induce treatment	upregulated	31551710
19056	Mouse	TUG1	lncRNA	high glucose (HG)	obesity	3T3-L1 cells	high glucose treatment	LncRNA TUG1 could negatively regulate miR-204 to alleviate inflammation and insulin tolerance via promoting SIRT1/GLUT4/PPAR¦Ã/AKT pathway.	32888158
19057	Mouse	TUG1	lncRNA	emodin	osteoarthritis (OA)	ATDC5 cells	emodin treatment	TUG1 was upregulated by emodin.	29710506
19058	Mouse	TUG1	lncRNA	oxygen	pathological neovascularization	mouse ocular neovascularization	exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment	dysregulated	24623407
19059	Mouse	TUG1	lncRNA	pyrrolidinedithiocarbamic acid (PDTC)	pristine-induced systemic lupus erythematosus (SLE)	kidney tissues	pyrrolidine dithiocarbamate (PDTC) treatment	NF-¦ÊB inhibition with PDTC protected against the kidney injury of pristine-induced SLE mice possibly via up-regulating lncRNA TUG1	31930775
19060	Mouse	TUG1	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arteries tissues	hypoxia induce	upregulated	31679623
19061	Mouse	TUG1	lncRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon	dextran sodium sulfate (DSS) treatment	TUG1 inhibits IEC apoptosis and UC progression by regulating the balance of HuR and miR-29b-3p.	33047284
19062	Mouse	TUG1	lncRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon tissues	dextran sodium sulfate (DSS) treatment	downregulated	33047284
19063	Mouse	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	YAMC cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TUG1 inhibits IEC apoptosis and UC progression by regulating the balance of HuR and miR-29b-3p	33047284
19064	Mouse	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	murine colonic epithelial YAMC cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	33047284
19065	Mouse	TUG1	lncRNA	oxygen glucose deprivation (OGD)	vascular cognitive impairment (VCI)	HT22 cells	oxygen and glucose deprivation-induced treatment	"knockdown of TUG1 reduced hippocampal neuronal apoptosis and participates in the aerobic exercise-alleviated VCI, which was partly through regulating BDNF"	33213523
19066	Mouse	TUG1	lncRNA	lipopolysaccharide (LPS)	hepatitis	liver tissues	lipopolysaccharide (LPS) treatment	?Microarray showed that lncRNA TUG1 was upregulated in LPS-induced hepatocyte inflammation.	33644034
19067	Mouse	Uc.173	lncRNA	lead (Pb)	nerve injury	hippocampus	lead treatment	downregulated	26683706
19068	Mouse	uc.323	lncRNA	phenylephrine (PE)	cardiac hypertrophy	Primary cultures of neonatal rat ventricular myocytes	phenylephrine treatment	downregulated	31735087
19069	Mouse	uc.333	lncRNA	high fat diet (HFD)	insulin resistance (IR)	liver tissues	high fat diet (HFD) feed	downregulated	32303004
19070	Mouse	uc.333	lncRNA	IL-6	insulin resistance (IR)	liver tissues	IL-6 treatment	downregulated	32303004
19071	Mouse	uc.333	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	insulin resistance (IR)	liver tissues	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	32303004
19072	Mouse	uc.418	lncRNA	high fat diet (HFD)	insulin resistance (IR)	liver tissues	high fat diet (HFD) feed	downregulated	32303004
19073	Mouse	uc.420	lncRNA	high fat diet (HFD)	insulin resistance (IR)	liver tissues	high fat diet (HFD) feed	downregulated	32303004
19074	Mouse	uc.48+	lncRNA	P2X3 receptor	diabetic neuropathic pain (DNP)	dorsal root ganglia	serum treatment	upregulated	26686228
19075	Mouse	uc.48+	lncRNA	high glucose and free fatty acids (HG-FFA)	type 2 diabetes mellitus (T2DM)	RAW264.7 cells	high glucose and high plasma free fatty acids (FFAs) treatment	"It was found that treatment of RAW264.7 cells with high glucose and FFAs, which exhibited increased expression of uc.48+."	29750294
19076	Mouse	uc.77	lncRNA	paraquat (PQ)	idiopathic pulmonary fibrosis (IPF)	alveolar epithelial cells	paraquat (PQ) treatment	upregulated	26824344
19077	Mouse	uc007coi.2	lncRNA	cigarette smoke (CS)	airway inflammation	C57BL/6 mice lung tissue	cigarette smoke (CS) exposure	dysregulated	29383188
19078	Mouse	uc007dlv	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	decreased	25827714
19079	Mouse	uc007eib	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	upregulated	25827714
19080	Mouse	uc008hps.1	lncRNA	fasciola gigantica excretory/secretory products (ESP)	macrophage activation and polarization	M2 macrophages	fasciola gigantica excretory/secretory products (ESP) treatment	upregulated	29794463
19081	Mouse	uc008pwj	lncRNA	peritoneal dialysis fluid (PDF)	peritoneal fibrosis	peritoneal tissues	peritoneal dialysis fluid (PDF) treatment	decreased	25827714
19082	Mouse	uc008tgd.1	lncRNA	cigarette smoke (CS)	airway inflammation	C57BL/6 mice lung tissue	cigarette smoke (CS) exposure	dysregulated	29383188
19083	Mouse	uc009njr.1	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	uc009njr.1 was upregulated in the primary mouse hepatocytes treated by cyclic adenosine monophosphate (cAMP).	29115403
19084	Mouse	uc009njr.1	lncRNA	cyclic adenosine monophosphate (cAMP)	gluconeogenesis	primary mouse hepatocytes	cyclic adenosine monophosphate (cAMP) treatment	downregulated	29115403
19085	Mouse	uc009njr.1	lncRNA	metformin (Met)	gluconeogenesis	primary mouse hepatocytes	metformin (Met) treatment	uc009njr.1 was downregulated in the primary mouse hepatocytes treated by metformin (Met) when compared with cyclic adenosine monophosphate (cAMP) treated group.	29115403
19086	Mouse	uc011wph.1	lncRNA	cigarette smoke (CS)	airway inflammation	C57BL/6 mice lung tissue	cigarette smoke (CS) exposure	dysregulated	29383188
19087	Mouse	UCA1	lncRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes	phenylephrine (PE) treatment	lncRNA UCA1 was highly expressed in the cardiomyocytes treated with phenylephrine (PE)	29616999
19088	Mouse	UCA1	lncRNA	metformin (Met)	endometrial hyperplasia (EH)	endometrial hyperplasia (EH) mice uterus	metformin (Met) treatment	downregulated	31894313
19089	Mouse	UCA1	lncRNA	tamoxifen (TAM)	endometrial hyperplasia (EH)	uterus	tamoxifen treatment	upregulated	31894313
19090	Mouse	UCA1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	30536337
19091	Mouse	UCA1	lncRNA	kainic acid (KA)	temporal lobe epilepsy (TLE)	hippocampal tissues	kainic acid (KA) treatment	UCA1 was overexpressed in mice and the overexpression of UCA1 significantly reversed the abnormal proliferation of hippocampal neurons in epilepsy mice.	33829718
19092	Mouse	Vax2os1	lncRNA	oxygen	pathological neovascularization	mouse ocular neovascularization	exposure of mice to 75 % oxygen from the postnatal day7 (P7) to P12 and then room air until P17 treatment	dysregulated	24623407
19093	Mouse	Wfdc21	lncRNA	lipopolysaccharide (LPS)	sepsis	RAW264.7 cells	lipopolysaccharide (LPS) treatment	Wfdc21 level was elevated in LPS-treated RAW264.7 cells.	29900929
19094	Mouse	XIST	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Mouse podocytes (MPC5)	MPC5 were treated with 100 ng/mL LPS (Sigma-Aldrich) for 48 h	lncRNA XIST was significantly upregulated in LPS-treated MPCs.	31658856
19095	Mouse	XIST	lncRNA	H2O2	Alzheimer's disease (AD)	N2a cells	Hydrogen peroxide (H2O2 ) treatment	The expression of lncRNA XIST was significantly upregulated in H2O2-treated N2a cells.	31743528
19096	Mouse	XIST	lncRNA	oxygen	bronchopulmonary dysplasia (BPD)	lung tissues	oxygen treatment	silencing of Xist suppressed BPD development by binding to miR-101-3p and downregulating HMGB3 and the TGF-b1/Smad3 axis.	33070148
19097	Mouse	XIST	lncRNA	phenylephrine (PE)	cardiac hypertrophy	cardiomyocytes	phenylephrine (PE) treatment	(XIST) was upregulated in hypertrophic cardiac of mice and phenylephrine (PE)-treated cardiomyocytes	30297107
19098	Mouse	XIST	lncRNA	lipopolysaccharide (LPS)	cardiomyocytes injury	Mouse cardiomyocytes MCM cells	lipopolysaccharide (LPS) treatment	The level of xist in the myocardial cells was markedly higher in the LPS group compared with the control group.	33029099
19099	Mouse	XIST	lncRNA	IL-1¦Â	chondrocyte apoptosis	ATDC5	IL-1¦Â treatment	downregulated	32517436
19100	Mouse	XIST	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	mouse renal tissues	streptozotocin (STZ) treatment	silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN	31545928
19101	Mouse	XIST	lncRNA	lipopolysaccharide (LPS)	inflammation	J774A.1 (mouse macrophage cell line)	lipopolysaccharides (LPS) treatment	upregulated	29773953
19102	Mouse	XIST	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	mouse neuronal cells	oxygen-glucose deprivation (OGD) treatment	upregulated	33738662
19103	Mouse	XIST	lncRNA	lipopolysaccharide (LPS)	membranous nephropathy (MN)	mouse podocyte cell line	with lipopolysaccharides treatment	upregulated	25157805
19104	Mouse	XIST	lncRNA	hypoxia	myocardial infarction (MI)	neonatal mice cardiomyocytes (NMCMs)	hypoxia treatment	XIST was upregulated in NMCMs under anoxia condition.	32315985
19105	Mouse	XIST	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R mice myocardial tissues	The myocardial I/R injury was induced by temporary ligation of the left anterior descending coronary artery.	upregulated	31734557
19106	Mouse	XIST	lncRNA	hypoxia	postmyocardial infarction	AC16 cells	hypoxia treatment	"XIST and PDE4D were overexpressed in post-MI myocardial cells, whereas miR-130a-3p was underexpressed in post-MI myocardial cells."	29226319
19107	Mouse	XIST	lncRNA	bilateral common carotid artery occlusion (2-VO)	Alzheimer's disease (AD)	hippocampus tissues of AD mouse	bilateral common carotid artery?occlusion (2VO) induce	The expression of lncRNA XIST was significantly upregulated in 2VO-induced AD mice models	31743528
19108	Mouse	XIST	lncRNA	H2O2	Alzheimer's disease (AD)	N2a mouse neuroblastoma cells	Hydrogen peroxide (H2O2)?treatment	The expression of lncRNA XIST was significantly upregulated in H2O2-treated N2a cells	31743528
19109	Mouse	XLOC_015129	lncRNA	high fat diet (HFD)	cholesterol biosynthesis	liver tissues	high fat diet (HFD) feed	upregulated	30504232
19110	Mouse	XLOC_015129	lncRNA	palmitic acid (PA)	cholesterol biosynthesis	AML12 cells	palmitic acid (PA) treatment	upregulated	30504232
19111	Mouse	XLOC_015129	lncRNA	WY14643	cholesterol biosynthesis	AML12 cells	WY14643 treatment	upregulated	30504232
19112	Mouse	XLOC_032768	lncRNA	cisplatin (DDP)	cisplatin (DDP)-induced nephrotoxicity	renal tubular epithelial cells	cisplatin treatment	lncRNA XLOC_032768 expression was significantly repressed by cisplatin treatment.	32278129
19113	Mouse	XR_006756	lncRNA	subarachnoid hemorrhage (SAH)	early brain injury (EBI)	brain	subarachnoid hemorrhage (SAH) treatment	downregulated	25777551
19114	Mouse	XR_140468	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	placenta	high fat diet (HFD) feed	downregulated	29986645
19115	Mouse	XR_141088	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	downregulated	29986645
19116	Mouse	XR_141492	lncRNA	high fat diet (HFD)	gestational diabetes mellitus (GDM)	gonadal fat tissues	high fat diet (HFD) feed	downregulated	29986645
19117	Mouse	ZEB2-AS1	lncRNA	phenylephrine (PE)	cardiac hypertrophy	primary cardiomyocytes	phenylephrine (PE) treatment	lncRNA ZEB2-AS1 may influence the progression of CH by downregulating PTEN	32973941
19118	Mouse	ZFAS1	lncRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	HL-1 Cells	hypoxia/reoxygenation (H/R) treatment	ZFAS1 was upregulated and miR-761 was downregulated in the serum of patients with AMI and H/R-induced HL-1 cells.	32833901
19119	Mouse	ZFAS1	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	BV2 cells	lipopolysaccharide (LPS) treatment	?ZFAS1 was identified to be upregulated in spinal cord tissues of SCI mice.	33524472
19120	Mouse	ZFAS1	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	ApoE-/- mice heart tissues	high fat diet (HFD) feed	We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs.	33278458
19121	Mouse	ZNF593-AS	lncRNA	phenylephrine (PE)	dilated cardiomyopathy (DCM)	cardiomyocytes	phenylephrine treatment	"ZNF593-AS, which mainly localized in the cytoplasm of cardiomyocytes, was robustly decreased in the failing heart of DCM patients, as well as in phenylephrine-treated human cardiomyocytes"	33550812
19122	Murine cytomegalovirus	mcmv-miR-m01-4-3p	miRNA	diosbuibin B (DB)	liver damage	mouse serum	diosbuibin B (DB) treatment	upregulated	30844585
19123	Murine cytomegalovirus	mcmv-miR-m01-4-3p	miRNA	monocrotaline (MCT)	liver damage	mouse serum	monocrotaline (MCT) treatment	upregulated	30844585
19124	Murine cytomegalovirus	mcmv-miR-m01-4-3p	miRNA	toosendanin (TSN)	liver damage	mouse serum	toosendanin (TSN) treatment	upregulated	30844585
19125	Murine cytomegalovirus	mcmv-miR-m01-4-5p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	peripheral blood monocytes	murine cytomegalovirus (MCMV) infection	upregulated	33245094
19126	Murine cytomegalovirus	mcmv-miR-m01-4-5p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	thoracic aorta	murine cytomegalovirus (MCMV) infection	upregulated	33245094
19127	Murine cytomegalovirus	mcmv-miR-m01-4-5p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	cardiac tissue	murine cytomegalovirus (MCMV) infection	upregulated	33245094
19128	Murine cytomegalovirus	mcmv-miR-m88-1-3p	miRNA	murine cytomegalovirus (MCMV)	murine cytomegalovirus (MCMV) infection	cardiac tissue	murine cytomegalovirus (MCMV) infection	downregulated	33245094
374	Nicotiana benthamiana	nbe-miR-168	miRNA	beet necrotic yellow vein virus (BNYVV)	beet necrotic yellow vein virus (BNYVV) infection	N. benthamiana	beet necrotic yellow vein virus (BNYVV) infection	upregulated	32178444
375	Nicotiana benthamiana	nbe-miR-398	miRNA	beet necrotic yellow vein virus (BNYVV)	beet necrotic yellow vein virus (BNYVV) infection	N. benthamiana	beet necrotic yellow vein virus (BNYVV) infection	upregulated	32178444
24058	Oreochromis niloticus	oni-miR-122	miRNA	high fat diet (HFD)	fatty liver disease	liver tissues	high fat diet (HFD) feed	upregulated	30344495
24059	Oreochromis niloticus	oni-miR-127	miRNA	streptococcus iniae	streptococcus infection	peritoneal exudate macrophages (PEMs)	infect with Streptococcus iniae treatment	upregulated	28219342
24060	Oreochromis niloticus	oni-miR-145-5p	miRNA	high fat diet (HFD)	fatty liver disease	farmed tilapia liver	high fat diet (HFD) feed	dysregulated	28838655
24061	Oreochromis niloticus	oni-miR-146-3p	miRNA	streptococcus iniae	streptococcus infection	peritoneal exudate macrophages (PEMs)	infect with Streptococcus iniae treatment	downregulated	28219342
24062	Oreochromis niloticus	oni-miR-205-5p	miRNA	high fat diet (HFD)	fatty liver disease	farmed tilapia liver	high fat diet (HFD) feed	dysregulated	28838655
24063	Oreochromis niloticus	oni-miR-23a-3p	miRNA	high fat diet (HFD)	fatty liver disease	farmed tilapia liver	high fat diet (HFD) feed	dysregulated	28838655
24064	Oreochromis niloticus	oni-miR-29a	miRNA	high fat diet (HFD)	fatty liver disease	farmed tilapia liver	high fat diet (HFD) feed	dysregulated	28838655
24065	Oreochromis niloticus	oni-miR-30a-5p	miRNA	high fat diet (HFD)	fatty liver disease	farmed tilapia liver	high fat diet (HFD) feed	dysregulated	28838655
24066	Oreochromis niloticus	oni-miR-310-3p	miRNA	streptococcus iniae	streptococcus infection	peritoneal exudate macrophages (PEMs)	infect with Streptococcus iniae treatment	upregulated	28219342
24067	Oreochromis niloticus	oni-miR-34a	miRNA	high fat diet (HFD)	fatty liver disease	farmed tilapia liver	high fat diet (HFD) feed	dysregulated	28838655
24068	Oreochromis niloticus	oni-miR-375-5p	miRNA	streptococcus iniae	streptococcus infection	peritoneal exudate macrophages (PEMs)	infect with Streptococcus iniae treatment	downregulated	28219342
24069	Oreochromis niloticus	oni-miR-694	miRNA	streptococcus iniae	streptococcus infection	peritoneal exudate macrophages (PEMs)	infect with Streptococcus iniae treatment	downregulated	28219342
24070	Oreochromis niloticus	oni-miR-92	miRNA	streptococcus iniae	streptococcus infection	peritoneal exudate macrophages (PEMs)	infect with Streptococcus iniae treatment	upregulated	28219342
24071	Oreochromis niloticus	oni-miR-92d-3p	miRNA	streptococcus iniae	streptococcus infection	peritoneal exudate macrophages (PEMs)	infect with Streptococcus iniae treatment	downregulated	28219342
19131	Paralichthys olivaceus	pol-miR-3p-2	miRNA	Edwardsiella tarda	edwardsiella tarda infection	spleen tissues; liver tissues; gill tissues	Edwardsiella tarda infection	upregulated	31668931
19132	Pea	psa-miR398a	miRNA	dehydration	water deficit	pea roots and shoots	dehydration treatment	downregulated	25064597
19133	Pea	psa-miR398b	miRNA	dehydration	water deficit	pea roots and shoots	dehydration treatment	downregulated	25064597
19134	Pea	psa-miR408	miRNA	dehydration	water deficit	pea roots and shoots	dehydration treatment	downregulated	25064597
19135	Peach	ppe-miR156	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19136	Peach	ppe-miR160	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19137	Peach	ppe-miR166	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19138	Peach	ppe-miR167	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19139	Peach	ppe-miR2118	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19140	Peach	ppe-miR390	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19141	Peach	ppe-miR393	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19142	Peach	ppe-miR398	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	upregulated	29236054
19143	Peach	ppe-miR408b	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	upregulated	29236054
19144	Peach	ppe-miR482	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19145	Peach	ppe-miR535	miRNA	synthetic auxin ¦Á-naphthylacetic acid (NAA)	fruit development	mesocarp at the hard core stage following treatment of the peach (Prunus persica L.) fruit	NAA treatment	downregulated	29236054
19146	Phaseolus vulgaris	gma-miR1157	miRNA	salt	salt stress	drought-tolerant bean cv. Yakutiye and drought-sensitive bean cv. Zulbiye	"surface sterilization in a solution containing 5% (v/v) hypochlorite for 5 min, and were grown hydroponically in pots containing 0.2L of 1/10 Hoagland¡¯s solution"	dysregulated	28955602
19147	Phaseolus vulgaris	gma-miR159f-3p	miRNA	drought	drought resistance	common bean (Phaseolus vulgaris L.)	drought treatments	dysregulated	28711666
19148	Phaseolus vulgaris	gma-miR169u	miRNA	drought	drought resistance	common bean (Phaseolus vulgaris L.)	drought treatments	dysregulated	28711666
19149	Phaseolus vulgaris	gma-miR396f	miRNA	drought	drought resistance	common bean (Phaseolus vulgaris L.)	drought treatments	dysregulated	28711666
19150	Phaseolus vulgaris	gma-miR4415a-3p	miRNA	drought	drought resistance	common bean (Phaseolus vulgaris L.)	drought treatments	dysregulated	28711666
19151	Phaseolus vulgaris	gma-miR5286	miRNA	salt	salt stress	drought-tolerant bean cv. Yakutiye and drought-sensitive bean cv. Zulbiye	"surface sterilization in a solution containing 5% (v/v) hypochlorite for 5 min, and were grown hydroponically in pots containing 0.2L of 1/10 Hoagland¡¯s solution"	dysregulated	28955602
19152	Phaseolus vulgaris	gma-miR5660	miRNA	salt	salt stress	drought-tolerant bean cv. Yakutiye and drought-sensitive bean cv. Zulbiye	"surface sterilization in a solution containing 5% (v/v) hypochlorite for 5 min, and were grown hydroponically in pots containing 0.2L of 1/10 Hoagland¡¯s solution"	dysregulated	28955602
19153	Phaseolus vulgaris	gma-miR5769	miRNA	salt	salt stress	drought-tolerant bean cv. Yakutiye and drought-sensitive bean cv. Zulbiye	"surface sterilization in a solution containing 5% (v/v) hypochlorite for 5 min, and were grown hydroponically in pots containing 0.2L of 1/10 Hoagland¡¯s solution"	dysregulated	28955602
19154	Phaseolus vulgaris	gma-miR5770b	miRNA	drought	drought resistance	common bean (Phaseolus vulgaris L.)	drought treatments	dysregulated	28711666
19155	Phaseolus vulgaris	gma-miR8120	miRNA	salt	salt stress	drought-tolerant bean cv. Yakutiye and drought-sensitive bean cv. Zulbiye	"surface sterilization in a solution containing 5% (v/v) hypochlorite for 5 min, and were grown hydroponically in pots containing 0.2L of 1/10 Hoagland¡¯s solution"	dysregulated	28955602
19169	Pig	ALDBSSCT0000001353	lncRNA	baicalin (BAI)	H. parasuis infection	porcine aortic vascular endothelial cells (PAVECs)	baicalin (BAI) treatment	"The expression levels of lncRNA ALD was significantly upregulated after H. parasuis stimulation ( p < 0.05); however, after baicalin pretreatment, the expression levels was significantly downregulated."	32096672
19170	Pig	ALDBSSCT0000001677	lncRNA	baicalin (BAI)	H. parasuis infection	porcine aortic vascular endothelial cells (PAVECs)	baicalin (BAI) treatment	"The expression levels of lncRNA ALDBSSCT0000001677 was significantly upregulated after H. parasuis stimulation ( p < 0.05); however, after baicalin pretreatment, the expression levels of it was significantly downregulated."	32096672
19171	Pig	ALDBSSCT0000010434	lncRNA	baicalin (BAI)	H. parasuis infection	porcine aortic vascular endothelial cells (PAVECs)	baicalin (BAI) treatment	"The expression levels of lncRNA ALDBSSCT0000010434 was significantly upregulated after H. parasuis stimulation ( p < 0.05); however, after baicalin pretreatment, the expression levels was significantly downregulated."	32096672
19172	Pig	circCDR1as	circRNA	bufalin	cardiac remodeling and heart failure	heart tissues	bufalin treatment	Bufalin treatment additionally led to increased expression of CDR1as of the AMI region.	32823854
19173	Pig	circEZH2	circRNA	transmissible gastroenteritis virus (TGEV)	transmissible gastroenteritis (TGE)	porcine intestinal epithelial cell line (IPEC-J2)	TGEV infection treatment	mPTP opening of IPEC-J2 was occured during TGEV infection and suppressed by circEZH2 via attaching miR-22	31592229
19174	Pig	ENSSSCG00000034497	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	downregulated	32605750
19175	Pig	ENSSSCG00000035352	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	downregulated	32605750
19176	Pig	ENSSSCG00000035593	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	downregulated	32605750
19177	Pig	ENSSSCG00000039062	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	downregulated	32605750
19178	Pig	ENSSSCG00000039561	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	downregulated	32605750
19179	Pig	FDNCR1	lncRNA	TGF-¦Â1	adipogenesis	porcine preadipocytes	TGF-¦Â1 treatment	TGF-¦Â1-Mediated FDNCR1 Regulates Porcine Preadipocyte Differentiation via the TGF-¦Â Signaling Pathway	32796679
19180	Pig	ITSN1-OT1	lncRNA	dextran sodium sulfate (DSS)	intestinal barrier dysfunction	IPEC-J2 cells	Dextran sulfate sodium treatment	Atractylodis macrocephalae polysaccharides protect against DSS-induced intestinal injury through a novel lncRNA ITSN1-OT1.	33248053
19181	Pig	MSTRG.10724.2	lncRNA	baicalin (BAI)	H. parasuis infection	porcine aortic vascular endothelial cells (PAVECs)	baicalin (BAI) treatment	"The expression levels of lncRNA MSTRG.10724.2 was significantly upregulated after H. parasuis stimulation ( p < 0.05); however, after baicalin pretreatment, the expression levels was significantly downregulated."	32096672
19182	Pig	MSTRG.14711.2	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19183	Pig	MSTRG.18940.1	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	downregulated	32605750
19184	Pig	MSTRG.211821	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19185	Pig	MSTRG.21517.1	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19186	Pig	MSTRG.2441.1	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19187	Pig	MSTRG.27544.1	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19188	Pig	MSTRG.35452.15	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19189	Pig	MSTRG.36907.1	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19190	Pig	MSTRG.3767.1	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19191	Pig	MSTRG.3767.2	lncRNA	Seneca Valley virus (SVV)	seneca valley virus (SVV) infection	ST cells	Seneca Valley virus (SVV) treatment	upregulated	32605750
19192	Pig	MSTRG.41924.1	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	upregulated	31214284
19193	Pig	MSTRG.50562.2	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	upregulated	31214284
19194	Pig	MSTRG.51205.3	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	upregulated	31214284
19195	Pig	MSTRG.61844.8	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	upregulated	31214284
19196	Pig	MSTRG.68556.2	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	downregulated	31214284
19197	Pig	MSTRG.82168.2	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	downregulated	31214284
19198	Pig	MSTRG.86425.1	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	upregulated	31214284
19199	Pig	MSTRG.9629.1	lncRNA	baicalin (BAI)	H. parasuis infection	porcine aortic vascular endothelial cells (PAVECs)	baicalin (BAI) treatment	"The expression levels of lncRNA ALD was significantly upregulated after H. parasuis stimulation ( p < 0.05); however, after baicalin pretreatment, the expression levels was significantly downregulated."	32096672
19200	Pig	MSTRG.98845.2	lncRNA	diquat	oxidative stress	piglets liver tissues	diquat treatment	upregulated	31214284
19201	Pig	ssc-let-7b	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	innate immunity	porcine alveolar macrophages	infect with PRRSV treatment	upregulated	29387185
19202	Pig	ssc-let-7b	miRNA	respiratory syndrome virus (PRRSV)	respiratory syndrome virus (PRRSV) infection	primary porcine alveolar macrophages (PAMs)	respiratory syndrome virus (PRRSV) treatment	upregulated	29387185
19203	Pig	ssc-let-7f-5p	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	indigenous Chinese Tongcheng pigs alveolar macrophages	infect with PRRSV treatment	dysregulatedin alveolar macrophages	28971377
19204	Pig	ssc-miR-1	miRNA	conjugated linoleic acid (CLA)	lipogenesis	pigs fat tissues	1.5% CLA to the pig diet	dysregulatedin fat tissues	29027986
19205	Pig	ssc-miR-1	miRNA	sildenafil	ventricular fibrillation	cardiac	sildenafil treatment	"sildenafil treatment inhibited the increases in the microRNA-1 levels, but alleviated the decreases in the microRNA-133a levels"	26040988
19206	Pig	ssc-miR-10a-5p	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	indigenous Chinese Tongcheng pigs alveolar macrophages	infect with PRRSV treatment	dysregulatedin alveolar macrophages	28971377
19207	Pig	ssc-miR-122	miRNA	lipopolysaccharide (LPS)	gastrocnemius muscle inflammation	gastrocnemius muscle	lipopolysaccharide (LPS) treatment	downregulated	33232194
19208	Pig	ssc-miR-124	miRNA	herpes simplex virus 2 (HSV-2)	genital herpes	epithelial tissues from guinea pigs	infect with HSV2	upregulated	28962197
19209	Pig	ssc-miR-1245b-3p	miRNA	herpes simplex virus 2 (HSV-2)	genital herpes	epithelial tissues from guinea pigs	infect with HSV2	upregulated	28962197
19210	Pig	ssc-miR-1245b-5p	miRNA	herpes simplex virus 2 (HSV-2)	genital herpes	epithelial tissues from guinea pigs	infect with HSV2	upregulated	28962197
19211	Pig	ssc-miR-125b	miRNA	hyaluronan (HA)	acute cartilage injury	acute cartilage injury porcine	acute cartilage injury porcine treatment	upregulated	29986604
19212	Pig	ssc-miR-125b-5p	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	indigenous Chinese Tongcheng pigs alveolar macrophages	infect with PRRSV treatment	dysregulatedin alveolar macrophages	28971377
19213	Pig	ssc-miR-127	miRNA	3-isobutyl-1-methylxanthine (IBMX)-dexamethasone-insulin cocktail	adipogenesis	Porcine preadipocyte	3©\isobutyl©\1©\methylxanthine (IBMX)©\dexamethasone©\insulin cocktail treatment	miR-127 expression levels decreased during cell proliferation.	31206669
19214	Pig	ssc-miR-127	miRNA	insulin	adipogenesis	Porcine preadipocyte	insulin treatment	"miR©\127 levels increased in the early period (days 0¨C2) of cell differentiation, before dropping dramatically."	31206669
19215	Pig	ssc-miR-127	miRNA	cardio-pulmonary bypass (CPB)	lung injury	lung	cardiopulmonary bypass (CPB) treatment	dysregulated	25347932
19216	Pig	ssc-miR-128	miRNA	dexamethasone (DEX)	abnormal lipid accumulation	pig preadipocytes	dexamethasone (Dex) treatment	upregulated	30394333
19217	Pig	ssc-miR-128	miRNA	dexamethasone (DEX)	lipid accumulation	pig preadipocytes	dexamethasone (DEX) treatment	upregulated	30394333
19218	Pig	ssc-miR-1307	miRNA	foot-and-mouth disease virus (FMDV)	foot-and-mouth disease (FMD)	porcine kidney cell line PK-15	foot-and-mouth disease virus (FMDV) infection	upregulated	31306911
19219	Pig	ssc-miR-130a-3p	miRNA	brucella.suis	innate immune response	porcine alveolar macrophages (PAMs)	brucella.suis infection	upregulated	29387067
19220	Pig	ssc-miR-130b	miRNA	dexamethasone (DEX)	lipid accumulation	porcine preadipocytes	dexamethasone (DEX) treatment	upregulated	29152131
19221	Pig	ssc-miR-132	miRNA	lipopolysaccharide (LPS)	gastrocnemius muscle inflammation	gastrocnemius muscle	lipopolysaccharide (LPS) treatment	upregulated	33232194
19222	Pig	ssc-miR-132	miRNA	ochratoxin A (OTA)	toxic effects in renal proximal tubular epithelial cells	porcine renal proximal tubular cells	Ochratoxin A (OTA) treatment	upregulated	23281030
19223	Pig	ssc-miR-133a	miRNA	sildenafil	ventricular fibrillation	cardiac	sildenafil treatment	"sildenafil treatment inhibited the increases in the microRNA-1 levels, but alleviated the decreases in the microRNA-133a levels"	26040988
19224	Pig	ssc-miR-135a	miRNA	lipopolysaccharide (LPS)	gastrocnemius muscle inflammation	gastrocnemius muscle	lipopolysaccharide (LPS) treatment	downregulated	33232194
19225	Pig	ssc-miR-136	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	downregulated	28968594
19226	Pig	ssc-miR-140	miRNA	hyaluronan (HA)	acute cartilage injury	acute cartilage injury porcine	acute cartilage injury porcine treatment	upregulated	29986604
19227	Pig	ssc-miR-140-5p	miRNA	clostridium perfringens (C. perfringens) type C	piglet diarrhea	IPEC-J2 cells	Clostridium perfringens (C. perfringens) type C infection	ssc-miR-140-5p was significantly increased in piglets with diarrhea.	32905904
19228	Pig	ssc-miR-142-3p	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	downregulated	28968594
19229	Pig	ssc-miR-142-5p	miRNA	actinobacillus pleuropneumoniae	actinobacillus pleuropneumoniae infection	lung tissue	Actinobacillus pleuropneumoniae infection	downregulated	22953717
19230	Pig	ssc-miR-143-3p	miRNA	actinobacillus pleuropneumoniae	actinobacillus pleuropneumoniae infection	lung tissue	Actinobacillus pleuropneumoniae infection	downregulated	22953717
19231	Pig	ssc-miR-145	miRNA	lipopolysaccharide (LPS)	gastrocnemius muscle inflammation	gastrocnemius muscle	lipopolysaccharide (LPS) treatment	upregulated	33232194
19232	Pig	ssc-miR-145	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	innate immunity	porcine alveolar macrophages	infect with PRRSV treatment	upregulated	29387185
19233	Pig	ssc-miR-145	miRNA	cardio-pulmonary bypass (CPB)	lung injury	lung	cardiopulmonary bypass (CPB) treatment	dysregulated	25347932
19234	Pig	ssc-miR-145	miRNA	respiratory syndrome virus (PRRSV)	respiratory syndrome virus (PRRSV) infection	primary porcine alveolar macrophages (PAMs)	respiratory syndrome virus (PRRSV) treatment	upregulated	29387185
19235	Pig	ssc-miR-145-5p	miRNA	conjugated linoleic acid (CLA)	lipogenesis	pigs fat tissues	1.5% CLA to the pig diet	dysregulatedin fat tissues	29027986
19236	Pig	ssc-miR-146a	miRNA	hyaluronan (HA)	acute cartilage injury	acute cartilage injury porcine	acute cartilage injury porcine treatment	upregulated	29986604
19237	Pig	ssc-miR-146a	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	26505891
19238	Pig	ssc-miR-146a	miRNA	brucella.suis	innate immune response	chondrocytes	brucella.suis infection	upregulated	29387067
19239	Pig	ssc-miR-146a	miRNA	inflammatory cytokines	osteoarthritis (OA)	bone tissues	Inflammatory cytokines treatment	upregulated	26505891
19240	Pig	ssc-miR-146a-5p	miRNA	conjugated linoleic acid (CLA)	lipogenesis	pigs fat tissues	1.5% CLA to the pig diet	dysregulatedin fat tissues	29027986
19241	Pig	ssc-miR-146a-5p	miRNA	lipopolysaccharide (LPS)	skeletal muscle development and disease	weaned pig skeletal muscle	lipopolysaccharide (LPS) treatment	upregulated	26389897
19242	Pig	ssc-miR-146b	miRNA	conjugated linoleic acid (CLA)	lipogenesis	pigs fat tissues	1.5% CLA to the pig diet	dysregulatedin fat tissues	29027986
19243	Pig	ssc-miR-147	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	porcine alveolar macrophages (PAMs)	Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infection treatment	downregulated	24339989
19244	Pig	ssc-miR-148a	miRNA	actinobacillus pleuropneumoniae	actinobacillus pleuropneumoniae infection	lung tissue	Actinobacillus pleuropneumoniae infection	downregulated	22953717
19245	Pig	ssc-miR-150	miRNA	herpes simplex virus 2 (HSV-2)	genital herpes	epithelial tissues from guinea pigs	infect with HSV2	upregulated	28962197
19246	Pig	ssc-miR-150	miRNA	2-hydroxy-(4-methylthio)butanoic acid (HMB)	hyperhomocysteinemia (HHcy)	liver	2-hydroxy-(4-methylthio)butanoic acid (HMB) treatment	downregulated	27648945
19247	Pig	ssc-miR-155-5p	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	innate immune response	rotavirus (RV)-infected DLY pig jejunum tissues and IPEC-J2 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	31330869
19248	Pig	ssc-miR-155-5p	miRNA	rotavirus (RV)	innate immune response	DLY pig jejunum tissues and IPEC-J2 cells	rotavirus (RV) infection treatment	upregulated	31330869
19249	Pig	ssc-miR-17-5pi	miRNA	vacuum sealing drainage (VSD)	seawater-immersed blast-injury wounds (SIBIW)	seawater-immersed blast-injury wounds (SIBIW) pigs SIBIW granulation tissues	VSD treatment	upregulated in SIBIW granulation tissues	28450946
19250	Pig	ssc-miR-181	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	indigenous Chinese Tongcheng pigs alveolar macrophages	infect with PRRSV treatment	dysregulatedin alveolar macrophages	28971377
19251	Pig	ssc-miR-181a	miRNA	TGF-¦Â3	chondrogenesis	peripheral blood mesenchymal stem cell (PBMSCs)	TGF-¦Â3 treatment	upregulated	31938188
19252	Pig	ssc-miR-181a	miRNA	brucella.suis	innate immune response	porcine alveolar macrophages (PAMs)	brucella.suis infection	upregulated	29387067
19253	Pig	ssc-miR-181b	miRNA	brucella.suis	innate immune response	porcine alveolar macrophages (PAMs)	brucella.suis infection	upregulated	29387067
19254	Pig	ssc-miR-181d-5p	miRNA	2-hydroxy-(4-methylthio)butanoic acid (HMB)	hyperhomocysteinemia (HHcy)	liver	2-hydroxy-(4-methylthio)butanoic acid (HMB) treatment	downregulated	27648945
19255	Pig	ssc-miR-183	miRNA	lipopolysaccharide (LPS)	oxidative stress	hippocampus	lipopolysaccharide (LPS) treatment	LPS-treated piglets had lower expression of miR-183.	32165261
19256	Pig	ssc-miR-200c	miRNA	ochratoxin A (OTA)	toxic effects in renal proximal tubular epithelial cells	porcine renal proximal tubular cells	Ochratoxin A (OTA) treatment	upregulated	23281030
19257	Pig	ssc-miR-204	miRNA	cardio-pulmonary bypass (CPB)	lung injury	lung	cardiopulmonary bypass (CPB) treatment	dysregulated	25347932
19258	Pig	ssc-miR-205	miRNA	brain-derived neurotrophic factor (BDNF)	maturation of oocytes	oocytes	brain-derived neurotrophic factor (BDNF) treatment	downregulated	26838466
19259	Pig	ssc-miR-206	miRNA	conjugated linoleic acid (CLA)	lipogenesis	pigs fat tissues	1.5% CLA to the pig diet	dysregulatedin fat tissues	29027986
19260	Pig	ssc-miR-20a	miRNA	growth hormone releasing hormone (GHRH)	growth hormone (GH)?secretion regulation	Primary porcine anterior pituitary cells	were 10 nmol/L GHRH or 100 nmol/L CST treatment	downregulated	25613666
19261	Pig	ssc-miR-21	miRNA	conjugated linoleic acid (CLA)	lipogenesis	pigs fat tissues	1.5% CLA to the pig diet	dysregulatedin fat tissues	29027986
19262	Pig	ssc-miR-21	miRNA	cardio-pulmonary bypass (CPB)	lung injury	lung	cardiopulmonary bypass (CPB) treatment	dysregulated	25347932
19263	Pig	ssc-miR-21	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	LLC-PK1 cell line2	OTA treatment	upregulated	28089712
19264	Pig	ssc-miR-22	miRNA	hyaluronan (HA)	acute cartilage injury	acute cartilage injury porcine	acute cartilage injury porcine treatment	upregulated	29986604
19265	Pig	ssc-miR-22	miRNA	transmissible gastroenteritis virus (TGEV)	transmissible gastroenteritis (TGE)	porcine intestinal epithelial cell line (IPEC-J2)	TGEV infection treatment	mPTP opening of IPEC-J2 was occured during TGEV infection and suppressed by circEZH2 via attaching miR-22	31592229
19266	Pig	ssc-miR-221-3p	miRNA	avian leukosis virus (ALV-J)	avian influenza virus (AIV) infection	porcine alveolar macrophage (PAM)	avian leukosis virus (ALV-J) inhection	downregulated	32907982
19267	Pig	ssc-miR-221-5p	miRNA	lipopolysaccharide (LPS)	skeletal muscle development and disease	weaned pig skeletal muscle	lipopolysaccharide (LPS) treatment	upregulated	26389897
19268	Pig	ssc-miR-222	miRNA	avian leukosis virus (ALV-J)	avian influenza virus (AIV) infection	porcine alveolar macrophage (PAM)	avian leukosis virus (ALV-J) inhection	downregulated	32907982
19269	Pig	ssc-miR-222	miRNA	transmissible gastroenteritis virus (TGEV)	transmissible gastroenteritis virus (TGEV) infection	PK-15 cells	Transmissible gastroenteritis virus (TGEV) infection treatment	upregulated	30257878
19270	Pig	ssc-miR-223	miRNA	selenium (Se)	vascular disease	aorta	Selenium (Se) treatment	Se deficiency in porcine arteries can induce inflammation through miR-223/NLRP3	33241567
19271	Pig	ssc-miR-224	miRNA	lipopolysaccharide (LPS)	gastrocnemius muscle inflammation	gastrocnemius muscle	lipopolysaccharide (LPS) treatment	upregulated	33232194
19272	Pig	ssc-miR-23-3p	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	indigenous Chinese Tongcheng pigs alveolar macrophages	infect with PRRSV treatment	dysregulatedin alveolar macrophages	28971377
19273	Pig	ssc-miR-24-3p	miRNA	growth hormone releasing hormone (GHRH)	growth hormone (GH)?secretion regulation	Primary porcine anterior pituitary cells	were 10 nmol/L GHRH or 100 nmol/L CST treatment	downregulated	25613666
19274	Pig	ssc-miR-26a	miRNA	growth hormone releasing hormone (GHRH)	growth hormone (GH)?secretion regulation	Primary porcine anterior pituitary cells	were 10 nmol/L GHRH or 100 nmol/L CST treatment	downregulated	25613666
19275	Pig	ssc-miR-26a	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	innate immunity	porcine alveolar macrophages	infect with PRRSV treatment	upregulated	29387185
19276	Pig	ssc-miR-26a	miRNA	respiratory syndrome virus (PRRSV)	respiratory syndrome virus (PRRSV) infection	primary porcine alveolar macrophages (PAMs)	respiratory syndrome virus (PRRSV) treatment	upregulated	29387185
19277	Pig	ssc-miR-26a-5p	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	indigenous Chinese Tongcheng pigs alveolar macrophages	infect with PRRSV treatment	dysregulatedin alveolar macrophages	28971377
19278	Pig	ssc-miR-27a	miRNA	leucine	skeletal muscle development	Porcine myoblasts	leucine treatment	downregulated	30449288
19279	Pig	ssc-miR-27b	miRNA	hyaluronan (HA)	acute cartilage injury	acute cartilage injury porcine	acute cartilage injury porcine treatment	upregulated	29986604
19280	Pig	ssc-miR-27b	miRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	downregulated	26505891
19281	Pig	ssc-miR-27b	miRNA	inflammatory cytokines	osteoarthritis (OA)	chondrocytes	Inflammatory cytokines treatment	upregulated	26505891
19282	Pig	ssc-miR-296-3p	miRNA	2-hydroxy-(4-methylthio)butanoic acid (HMB)	hyperhomocysteinemia (HHcy)	liver	2-hydroxy-(4-methylthio)butanoic acid (HMB) treatment	downregulated	27648945
19283	Pig	ssc-miR-29c	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	LLC-PK1 cell line2	OTA treatment	downregulated	28089712
19284	Pig	ssc-miR-301a-3p	miRNA	brucella.suis	innate immune response	porcine alveolar macrophages (PAMs)	brucella.suis infection	upregulated	29387067
19285	Pig	ssc-miR-30c	miRNA	iohexol	contrast-induced acute kidney injury (CIAKI)	kidney tissues	iohexol treatment	upregulated	32682254
19286	Pig	ssc-miR-30c-3p	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19287	Pig	ssc-miR-323	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19288	Pig	ssc-miR-338	miRNA	lipopolysaccharide (LPS)	porcine adrenal gland inflammation	adrenal gland tissues	lipopolysaccharide (LPS) treatment	Treatment with LPS alone extremely significantly decreased ssc-miR-338 levels.	32671106
19289	Pig	ssc-miR-342-5p	miRNA	herpes simplex virus 2 (HSV-2)	genital herpes	epithelial tissues from guinea pigs	infect with HSV2	upregulated	28962197
19290	Pig	ssc-miR-34a	miRNA	hyaluronan (HA)	acute cartilage injury	acute cartilage injury porcine	acute cartilage injury porcine treatment	upregulated	29986604
19291	Pig	ssc-miR-34a	miRNA	lipopolysaccharide (LPS)	gastrocnemius muscle inflammation	gastrocnemius muscle	lipopolysaccharide (LPS) treatment	upregulated	33232194
19292	Pig	ssc-miR-34a	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	innate immunity	porcine alveolar macrophages	infect with PRRSV treatment	upregulated	29387185
19293	Pig	ssc-miR-34a	miRNA	respiratory syndrome virus (PRRSV)	respiratory syndrome virus (PRRSV) infection	primary porcine alveolar macrophages (PAMs)	respiratory syndrome virus (PRRSV) treatment	upregulated	29387185
19294	Pig	ssc-miR-361-3p	miRNA	hypothalamic gonadotropin-releasing hormone (GnRH)	pituitary gonadotrope FSH secretion	pituitary cells	Hypothalamic gonadotropin-releasing hormone (GnRH)?treatment	downregulated	23451171
19295	Pig	ssc-miR-370	miRNA	lipopolysaccharide (LPS)	gastrocnemius muscle inflammation	gastrocnemius muscle	lipopolysaccharide (LPS) treatment	downregulated	33232194
19296	Pig	ssc-miR-370	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19297	Pig	ssc-miR-374	miRNA	dexamethasone (DEX)	primary cultures of porcine adipocytes	primary porcine preadipocytes	dexamethasone (DEX) treatment	upregulated	23468252
19298	Pig	ssc-miR-376a-5p	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19299	Pig	ssc-miR-378-3p	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	indigenous Chinese Tongcheng pigs alveolar macrophages	infect with PRRSV treatment	dysregulatedin alveolar macrophages	28971377
19300	Pig	ssc-miR-425-3p	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19301	Pig	ssc-miR-4331	miRNA	transmissible gastroenteritis virus (TGEV)	transmissible gastroenteritis virus (TGEV) infection	porcine kidney (PK-15) cells	infect with TGEV treatment	upregulated	29217619
19302	Pig	ssc-miR-4331-5p	miRNA	foot-and-mouth disease virus (FMDV)	foot-and-mouth disease (FMD)	PK-15 cells	foot and mouth virus (FMDV) treatment	FMDV infection directly upregulates miR-4331-5p expression.	32574680
19303	Pig	ssc-miR-491	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19304	Pig	ssc-miR-493-5p	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19305	Pig	ssc-miR-592	miRNA	herpes simplex virus 2 (HSV-2)	genital herpes	epithelial tissues from guinea pigs	infect with HSV2	upregulated	28962197
19306	Pig	ssc-miR-874	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19307	Pig	ssc-miR-92b-5p	miRNA	coronary microembolization (CME)	"proliferation, apoptosis, coronary microembolization"	Bama mini-pigs	CME treatment	upregulated	28968594
19308	Pig	ssc-miR-c89	miRNA	porcine reproductive and respiratory syndrome virus (PRRSV)	porcine reproductive and respiratory syndrome virus (PRRSV) infection	porcine alveolar macrophages (PAMs)	porcine reproductive and respiratory syndrome virus (PRRSV) infection treatment	upregulated	31478827
19309	Pig	TCONS_00036806	lncRNA	4-tert-octylphenol (OP)	rheumatoid arthritis (RA)	ovaries	4-tert-octylphenol (OP) treatment	downregulated	32450468
19310	Pig	TCONS_00058367	lncRNA	transmissible gastroenteritis virus (TGEV)	inflammation	porcine intestinal epithelial cell-jejunum 2 (IPEC-J2) cell line	Transmissible gastroenteritis virus (TGEV) infection treatment	the dysregulated lncRNA TCONS_00058367 might lead to a reduction of phosphorylation of transcription factor p65 (p-p65) in TGEV-infected IPEC-J2 cells by negatively regulating its antisense gene promyelocytic leukemia (PML)	31684870
23959	Pig	ssc-miR-106-5p	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23960	Pig	ssc-miR-1249	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	upregulated	31242957
23961	Pig	ssc-miR-127	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23962	Pig	ssc-miR-199a-3p	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23963	Pig	ssc-miR-199a-5p	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23964	Pig	ssc-miR-199b-3p	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23965	Pig	ssc-miR-199b-5p	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23966	Pig	ssc-miR-370	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23967	Pig	ssc-miR-493-5p	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23968	Pig	ssc-miR-758	miRNA	lipopolysaccharide (LPS)	bacterial-induced endometritis	sow endometrial epithelial cells (EECs)	lipopolysaccharide (LPS) treatment	downregulated	31242957
23993	Pig	ALDBSSCT0000002830	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	downregulated	32122616
23994	Pig	ALDBSSCT0000002830	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	downregulated	32122616
23995	Pig	ALDBSSCT0000002870	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	downregulated	32122616
23996	Pig	ALDBSSCT0000002870	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	downregulated	32122616
23997	Pig	ALDBSSCT0000003044	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
23998	Pig	ALDBSSCT0000003044	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
23999	Pig	ALDBSSCT0000003405	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24000	Pig	ALDBSSCT0000003405	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24001	Pig	ALDBSSCT0000004845	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	downregulated	32122616
24002	Pig	ALDBSSCT0000004845	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	downregulated	32122616
24003	Pig	ALDBSSCT0000006627	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	downregulated	32122616
24004	Pig	ALDBSSCT0000006627	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	downregulated	32122616
24005	Pig	ALDBSSCT0000010381	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	downregulated	32122616
24006	Pig	ALDBSSCT0000010381	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	downregulated	32122616
24007	Pig	ALDBSSCT0000018610	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	downregulated	32122616
24008	Pig	ALDBSSCT0000018610	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	downregulated	32122616
24009	Pig	ENSSSCT00000033557	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24010	Pig	ENSSSCT00000033557	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24011	Pig	LNC_000206	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24012	Pig	LNC_000206	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24013	Pig	LNC_000237	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24014	Pig	LNC_000237	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24015	Pig	LNC_000293	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24016	Pig	LNC_000293	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24017	Pig	LNC_000342	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24018	Pig	LNC_000342	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24019	Pig	LNC_000597	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	downregulated	32122616
24020	Pig	LNC_000597	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	downregulated	32122616
24021	Pig	LNC_001246	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24022	Pig	LNC_001246	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24023	Pig	LNC_001319	lncRNA	gE/TK deficient (gE-TK-PRV) PRV-II	antiviral immune response	PK-15 cells	gE/TK deficient (gE-TK-PRV) PRV-II infection	upregulated	32122616
24024	Pig	LNC_001319	lncRNA	pseudorabies virus type II (PRV-II)	antiviral immune response	PK-15 cells	pseudorabies virus type II (PRV-II) infection treatment	upregulated	32122616
24025	Pig	ssc-miR-140	miRNA	classical swine fever virus (CSFV)	classical swine fever virus (CSFV) infection	swine umbilical vein endothelial cells (SUVEC)	Classical swine fever virus (CSFV) infection	downregulated	32114898
19156	Podophyllum	she-miR1438	miRNA	methyl jasmonate (MeJA)	oxygen species (ROS)	podophyllum hexandrum	methyl jasmonate (MeJA) treatment	downregulated	28261233
19157	Podophyllum	she-miR172i	miRNA	methyl jasmonate (MeJA)	oxygen species (ROS)	podophyllum hexandrum	methyl jasmonate (MeJA) treatment	downregulated	28261233
19158	Podophyllum	she-miR2275	miRNA	methyl jasmonate (MeJA)	oxygen species (ROS)	podophyllum hexandrum	methyl jasmonate (MeJA) treatment	downregulated	28261233
19159	Podophyllum	she-miR35	miRNA	methyl jasmonate (MeJA)	oxygen species (ROS)	podophyllum hexandrum	methyl jasmonate (MeJA) treatment	downregulated	28261233
19160	Podophyllum	she-miR8291	miRNA	methyl jasmonate (MeJA)	oxygen species (ROS)	podophyllum hexandrum	methyl jasmonate (MeJA) treatment	downregulated	28261233
19164	Populus	pto-miR156k	miRNA	cold	populus under cold stress	Populus plantlets	Populus plantlets grown in vitro were treated with cold (4 ¡ãC for 8 h)	downregulated	30912003
19165	Populus	pto-miR167a-d	miRNA	cold	populus under cold stress	Populus plantlets	Populus plantlets grown in vitro were treated with cold (4 ¡ãC for 8 h)	upregulated	30912003
19166	Populus	pto-miR167f/g	miRNA	cold	populus under cold stress	Populus plantlets	Populus plantlets grown in vitro were treated with cold (4 ¡ãC for 8 h)	upregulated	30912003
19167	Populus	pto-miR169i-m	miRNA	cold	populus under cold stress	Populus plantlets	Populus plantlets grown in vitro were treated with cold (4 ¡ãC for 8 h)	downregulated	30912003
19168	Populus	pto-miR394a-5p/b-5p	miRNA	cold	populus under cold stress	Populus plantlets	Populus plantlets grown in vitro were treated with cold (4 ¡ãC for 8 h)	downregulated	30912003
19161	Populus tomentosa	ptc-miR6437a	miRNA	indole-3-acetic acid (IAA)	growth of P. tomentosa	1-year-old poplar clones	indole-3-acetic acid (IAA) treatment	upregulated	31324970
19162	Populus tomentosa	TCONS_00003480	lncRNA	indole-3-acetic acid (IAA)	growth of P. tomentosa	1-year-old poplar clones	indole-3-acetic acid (IAA) treatment	downregulated	31324970
19163	Populus tomentosa	TCONS_00004832	lncRNA	indole-3-acetic acid (IAA)	growth of P. tomentosa	1-year-old poplar clones	indole-3-acetic acid (IAA) treatment	downregulated	31324970
23873	Pyrus?pyrifolia	pyr-miR156a	miRNA	bagging treatments	red peel coloration and anthocyanin accumulation	Red Chinese sand pear (Pyrus pyrifolia) fruits	bagging treatments	downregulated	28824447
23874	Pyrus?pyrifolia	pyr-miR156ba	miRNA	bagging treatments	red peel coloration and anthocyanin accumulation	Red Chinese sand pear (Pyrus pyrifolia) fruits	bagging treatments	downregulated	28824447
23875	Pyrus?pyrifolia	pyr-miR156g	miRNA	bagging treatments	red peel coloration and anthocyanin accumulation	Red Chinese sand pear (Pyrus pyrifolia) fruits	bagging treatments	downregulated	28824447
23876	Pyrus?pyrifolia	pyr-miR156s	miRNA	bagging treatments	red peel coloration and anthocyanin accumulation	Red Chinese sand pear (Pyrus pyrifolia) fruits	bagging treatments	downregulated	28824447
23877	Pyrus?pyrifolia	pyr-miR156sa	miRNA	bagging treatments	red peel coloration and anthocyanin accumulation	Red Chinese sand pear (Pyrus pyrifolia) fruits	bagging treatments	downregulated	28824447
19311	Rabbit	MEG3	lncRNA	methylene blue (MB)	osteoarthritis (OA)	knee joint	methylene blue (MB) treatment	MEG3 was significantly increased following treatment with MB.	29581742
19312	Rabbit	MSTRG.10603.16	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	carotid arteries	high fat diet (HFD) feed	dysregulated	31392586
19313	Rabbit	MSTRG.1124.1	lncRNA	T. mentagrophytes	dermatophytosis lesional	skin	T. mentagrophytes treatment	downregulated	29560532
19314	Rabbit	MSTRG.12022.1	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	carotid arteries	high fat diet (HFD) feed	dysregulated	31392586
19315	Rabbit	MSTRG.12250.4	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	carotid arteries	high fat diet (HFD) feed	dysregulated	31392586
19316	Rabbit	MSTRG.12799.3	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	carotid arteries	high fat diet (HFD) feed	dysregulated	31392586
19317	Rabbit	MSTRG.14353.1	lncRNA	T. mentagrophytes	dermatophytosis lesional	skin	T. mentagrophytes treatment	downregulated	29560532
19318	Rabbit	MSTRG.14801.3	lncRNA	T. mentagrophytes	dermatophytosis lesional	skin	T. mentagrophytes treatment	upregulated	29560532
19319	Rabbit	MSTRG.3615.1	lncRNA	T. mentagrophytes	dermatophytosis lesional	skin	T. mentagrophytes treatment	upregulated	29560532
19320	Rabbit	MSTRG.5258.4	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	carotid arteries	high fat diet (HFD) feed	dysregulated	31392586
19321	Rabbit	MSTRG.5352.1	lncRNA	high fat diet (HFD)	atherosclerosis (AS)	carotid arteries	high fat diet (HFD) feed	dysregulated	31392586
19322	Rabbit	MSTRG.6673.1	lncRNA	T. mentagrophytes	dermatophytosis lesional	skin	T. mentagrophytes treatment	upregulated	29560532
19323	Rabbit	MSTRG.7195.4	lncRNA	T. mentagrophytes	dermatophytosis lesional	skin	T. mentagrophytes treatment	upregulated	29560532
19324	Rabbit	ocu-miR-133	miRNA	Krebs-Henseleit solution with 1 ?mol L(-1) atrial natriuretic peptide	myocardial reperfusion injury	rabbit heart tissues	Krebs-Henseleit solution with 1 ?mol L(-1) atrial natriuretic peptide treatment	upregulated	24585906
19325	Rabbit	ocu-miR-133b-3p	miRNA	glucocorticoid (GC)	non-traumatic osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMMSCs)	glucocorticoid treatment	downregulated	33176873
19326	Rabbit	ocu-miR-182	miRNA	N-methyl-D-aspartate (NMDA)	inner retinal injury	plasma	N-methyl-D-aspartate (NMDA) treatment	"Compared to pre-dosing values, the plasma levels at 4 hr after dosing with NMDA were significantly higher both for miR-182 (P < 0.05) and miR-183."	32404558
19327	Rabbit	ocu-miR-183	miRNA	N-methyl-D-aspartate (NMDA)	inner retinal injury	plasma	N-methyl-D-aspartate (NMDA) treatment	"Compared to pre-dosing values, the plasma levels at 4 hr after dosing with NMDA were significantly higher both for miR-182 (P < 0.05) and miR-183."	32404558
19328	Rabbit	ocu-miR-20a	miRNA	naringin	osteoblastic differentiation and inhibition of adipocyte formation	bone marrow stem cells	Naringin treatment	upregulated	26126997
19329	Rabbit	ocu-miR-26b	miRNA	leptin	Alzheimer's disease (AD)	Frontal Cortex tissues	cholesterol fed rabbit model for AD treatment	upregulated	24754001
19330	Rabbit	ocu-miR-451-5p	miRNA	glucocorticoid (GC)	non-traumatic osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMMSCs)	glucocorticoid treatment	upregulated	33176873
19336	Rainbow trout	omy-miR-122b	miRNA	insulin	postprandial lipogenesis	rainbow trout liver cells	insulin treatment	upregulated	24333236
19337	Rainbow trout	omy-miR-133	miRNA	estradiol-17¦Â (E2)	apoptosis	juvenile rainbow trout	estradiol-17¦Â (E2) treatment	upregulated	28011237
19338	Rainbow trout	omy-miR-145	miRNA	estradiol-17¦Â (E2)	apoptosis	juvenile rainbow trout	estradiol-17¦Â (E2) treatment	downregulated	28011237
19339	Rainbow trout	omy-miR-206	miRNA	estradiol-17¦Â (E2)	apoptosis	juvenile rainbow trout	estradiol-17¦Â (E2) treatment	upregulated	28011237
19340	Rainbow trout	omy-miR-499	miRNA	estradiol-17¦Â (E2)	apoptosis	juvenile rainbow trout	estradiol-17¦Â (E2) treatment	downregulated	28011237
24181	rainbow trout	omy-mir-122	miRNA	insulin	hepatic lipogenesis	rainbow trout hepatocytes	Insulin treatment	upregulation	24333236
19341	Rat	AABR07037489.1	lncRNA	nickel	steroidogenesis disturbance	Leydig cells	NiSO4 induce	dysregulated	31734292
19342	Rat	AABR07037489.1	lncRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	downregulated	31734292
19343	Rat	AABR07070307.1	lncRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	downregulated	31734292
19344	Rat	Abcf2-004	lncRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	upregulated	29505837
19345	Rat	Adgrv1-003	lncRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	upregulated	29505837
19346	Rat	AF159100	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	Sprague-Dawley (SD) rats	angiotensin II (Ang II) treatment	upregulated	24817929
19347	Rat	AF230638	lncRNA	aldosterone	chronic kidney disease (CKD)	mesangial cells (MCs)	aldosterone treatment	downregulated	28849035
19348	Rat	AF336872	lncRNA	aldosterone	chronic kidney disease (CKD)	mesangial cells (MCs)	aldosterone treatment	upregulated	28849035
19349	Rat	AJ005396	lncRNA	bleomycin (BLM)	lung fibrosis	fibrotic lung tissues	bleomycin (BLM) treatment	upregulated	23732278
19350	Rat	AK003290	lncRNA	tanshinone IIA (Tan IIA)	acute myocardial infarction (AMI)	H9c2 cells	Tanshinone IIA (TSA) treatment	"TSA exerts the protective role against H/R induced apoptosis, oxidative and MMP loss of cardiomyocytes via regulating AK003290 and miR-124-5p signaling"	32220226
19351	Rat	AK046177	lncRNA	Safflor yellow B (SYB)	stroke	cortical cells	Safflor yellow B (SYB) treatment	Safflor Yellow B Attenuates Ischemic Brain Injury via downregulated of Long Noncoding AK046177 and Inhibition of MicroRNA-134 Expression in Rats	32566081
19352	Rat	AK12348	lncRNA	anoxia/reoxygenation (A/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	anoxia/reoxygenation (A/R) treatment	"The relative level of lncRNA AK12348, LDH release and cell apoptotic rate in A/R cardiomyocytes was significantly higher than that in normal cardiomyocytes."	29398472
19353	Rat	AK12348	lncRNA	anoxia/reoxygenation (A/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat cardiomyocyte H9C2	anoxia/reoxygenation (A/R) treatment	upregulated	29398472
19354	Rat	AK123702	lncRNA	hypoxia	gastric cancer (GC)	GC cells	hypoxia treatment	upregulated	26884908
19355	Rat	AK139128	lncRNA	hypoxia	myocardial infarction (MI)	cardiomyocytes	hypoxia treatment	hypoxia upregulated the level of AK139128 in CMs and exosomes and exosomal AK139128 derived from hypoxic CMs modulated cellular activities of CFs in vitro and in vivo.	32494135
19356	Rat	ANRIL	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	upregulated	31264206
19357	Rat	ANRIL	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	ANRIL plays a protective part in hypoxia-induced H9c2 cell injury via modulating the miR-7-5p/SIRT1 axis	31264206
19358	Rat	ANRIL	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	rat adrenal medulla-derived pheochromocytoma cell line PC-12	oxygen-glucose deprivation (OGD) induce treatment	OGD-induced PC-12 cell injury and decreased ANRIL expression	31174432
19359	Rat	Atat1	lncRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	downregulated	31948324
19360	Rat	ATB	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12 cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â 25-35-induced injury in PC12 cells and increased the expression of lncRNA-ATB.	30248538
19361	Rat	AX765700	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	Sprague-Dawley (SD) rats	angiotensin II (Ang II) treatment	upregulated	24817929
19362	Rat	AY325162	lncRNA	aldosterone	chronic kidney disease (CKD)	mesangial cells (MCs)	aldosterone treatment	upregulated	28849035
19363	Rat	BACE1-AS	lncRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	substantia nigra	6-hydroxydopamine (6-OHDA) treatment	downregulated of lncRNA BACE1-AS inhibits iNOS activation in the substantial nigra and improve oxidative stress injury in PD rats by upregulating miR-34b-5p and downregulating BACE1.	32308102
19364	Rat	BC079195	lncRNA	manganese (Mn)	neurotoxicity	hippocampal neurons	Manganese (Mn) treatment	upregulated	26745496
19365	Rat	BC086588	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	Sprague-Dawley (SD) rats	angiotensin II (Ang II) treatment	upregulated	24817929
19366	Rat	BC088254	lncRNA	aldosterone	chronic kidney disease (CKD)	mesangial cells (MCs)	aldosterone treatment	upregulated	28849035
19367	Rat	BC089928	lncRNA	manganese (Mn)	neurotoxicity	hippocampal neurons	Manganese (Mn) treatment	downregulated	26745496
19368	Rat	BC092207	lncRNA	subarachnoid hemorrhage (SAH)	early brain injury (EBI)	brain	subarachnoid hemorrhage (SAH) treatment	upregulated	25777551
19369	Rat	BC167085	lncRNA	aldosterone	chronic kidney disease (CKD)	mesangial cells (MCs)	aldosterone treatment	downregulated	28849035
19370	Rat	BC168211	lncRNA	aldosterone	chronic kidney disease (CKD)	mesangial cells (MCs)	aldosterone treatment	upregulated	28849035
19371	Rat	BC168687	lncRNA	aldosterone	chronic kidney disease (CKD)	mesangial cells (MCs)	aldosterone treatment	upregulated	28849035
19372	Rat	BC168687	lncRNA	streptozocin (STZ)	diabetic neuropathic pain (DNP)	rats DRG	injected intraperitoneally with a dosage of 30?mg/kg streptozotocin (STZ) solution treatment	upregulated	29204447
19373	Rat	BCYRN1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	airway smooth muscle cells (ASMCs) isolated from SD rat	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulation	27648131
19374	Rat	BDNF-AS	lncRNA	hypoxia	acute spinal cord injury (ASCI)	AGE1.HN cells; PC12 cells	hypoxia treatment	"BDNF-AS, PRDM5 and c-caspase 3 expression were significantly upregulated, while miR-130b-5p was suppressed in the ASCI group and neuronal cells following hypoxia treatment."	29995562
19375	Rat	BDNF-AS	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12 cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â 25-35 apparently increased BDNF-AS but decreased BDNF in PC12 cells.	29902125
19376	Rat	BDNF-AS	lncRNA	lithium (Li)	spinal cord injury (SCI)	spinal cord	lithium treatment	"Furthermore, lithium treatment alleviated the inflammatory response by inactivating the nuclear factor-kappa B (NF-¦ÊB) pathway and inhibited the expression of lncRNA brain-derived neurotrophic factor antisense (BDNF-AS) in SCI rats."	33464390
19377	Rat	BLACAT1	lncRNA	IL-6	osteogenesis	bone marrow stromal stem cells (BMSCs)	IL-6 treatment	"BLACAT1 expression was increased in inflammatory BMSCs, and knockdown of BLACAT1 promoted proliferation and osteogenic differentiation of BMSCs targeting miR-142-5p."	32271407
19378	Rat	Blnc1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	renal tissues	streptozotocin (STZ) treatment	upregulated	31632538
19379	Rat	Bmncr	lncRNA	macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-¦ÊB ligand (RANKL)	osteoporosis	Bone marrow mesenchymal stem cells (BMMs) isolated from rats undergoing ovariectomy (OVX)	RANKL (50 ng/mL) and M-CSF (50 ng/mL) for 120 h treatment	Bmncr expression gradually downregulated during RANKL-induced in vitro osteoclast differentiation	31773670
19380	Rat	CASC2	lncRNA	pentylenetetrazol (PTZ)	epilepsy	hippocampus tissues	pentylenetetrazol (PTZ) treatment	lncRNA CASC2 was time-dependently downregulated in the epileptic groups compared with the control group	31958564
19381	Rat	CASC2	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary arterial tissues and pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30857524
19382	Rat	CASC9	lncRNA	lipopolysaccharide (LPS)	lung injury	lung tissues	Lipopolysaccharide (LPS) treatment	CASC9 was markedly downregulated while miR-195-5p was significantly upregulated in HSAECs treated by LPS and lung tissues of rats with sepsis.	32221619
19383	Rat	CASC9	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	The results showed that lncRNA CASC9 was downregulated and miR-383-5p was upregulated in SCI rats and LPS-induced PC12 cells.	33438067
19384	Rat	CCAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	spinal cord injury (SCI)	astrocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	CCAT1 Protects Astrocytes Against OGD/R-Induced Damage by Targeting the miR-218/NFAT5-Signaling Axis	32239388
19385	Rat	CD36-005	lncRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	upregulated	29505837
19386	Rat	Cdkn1	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac	angiotensin II (Ang II) treatment	downregulated	25979571
19387	Rat	Cdkn1	lncRNA	losartan	cardiac fibrosis	heart tissues	Losartan treatment	"losartan (AT1 blocker) nearly completely reversed the decrease of lncRNA-NR024118 and partly reversed the decrease of Cdkn1c induced by Ang II in adult rat cardiac fibroblasts,"	25979571
19388	Rat	CHAR	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal rat ventricular cells (NRVCs)	angiotensin II (Ang II) treatment	CHAR was also down©\regulated in AngII©\treated NRVCs. CHAR participates in pathological cardiac hypertrophy in vitro. CHAR regulates cardiac hypertrophy via the miR©\20b/PTEN/AKT pathway.	31465630
19389	Rat	chr1:142682098|142682602	circRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	31961470
19390	Rat	chr1:87010380|87010777	circRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	31961470
19391	Rat	chr15:67588477|67588841	circRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	31961470
19392	Rat	chr18:49891333|49891588	circRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	31961470
19393	Rat	chr19:9683854|9684128	circRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	31961470
19394	Rat	chr5:90817794|90827570	circRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	rat coronary artery endothelial cells (CAEC)	TGF-¦Â1 treatment	upregulated	29521313
19395	Rat	chr6:22033342|22038870	circRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	rat coronary artery endothelial cells (CAEC)	TGF-¦Â1 treatment	upregulated	29521313
19396	Rat	chr8:71336875|71337745	circRNA	hyperoxia	bronchopulmonary dysplasia (BPD)	lung tissues	hyperoxia treatment	downregulated	31961470
19397	Rat	chr8:71336875|71337745	circRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	rat coronary artery endothelial cells (CAEC)	TGF-¦Â1 treatment	upregulated	29521313
19398	Rat	CHRF	lncRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	"?Silence of lncRNA CHRF impeded the LPS injury to H9c2 cells, as cell viability was increased, apoptosis was inhibited, ROS generation was decreased, and the expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-¦Á was suppressed. However, silence of lncRNA CHRF had no impacts on normal H9c2 cells growth."	30695715
19399	Rat	circANKRD36	circRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	upregulated	31442445
19400	Rat	circANXA2	circRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	The expression of CircANXA2 was upregulated in H/R-treated H9c2 cells.	32685535
19401	Rat	circANXA2	circRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32685535
19402	Rat	circBNIP3	circRNA	hypoxia	hypoxia-induced injury	H9c2 cell	hypoxia induce	upregulated	31923741
19403	Rat	circCamk4	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary neuronal cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32332879
19404	Rat	circCDR1as	circRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	32889692
19405	Rat	circCDR1as	circRNA	exendin-4 (Ex-4)	parkinson's disease (PD)	1-methyl-4-phenylpyridinium (MPP+)-treated PC12 cells	Exendin-4 (Ex-4)?treatment	downregulated	32889692
19406	Rat	circCDR1as	circRNA	exendin-4 (Ex-4)	neuronal cell injury	PC12 cells	Exendin-4 (Ex-4) treatment	Ex-4 downregulated 1-methyl-4 phenyl-pyridine ion (MPP+) -induced CDR1as expression in PC12 cells and upregulated miR-671 expression.	32889692
19407	Rat	circDENND2A	circRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	rat H9c2 cells	oxygen glucose deprivation (OGD) treatment	OGD upregulated circDENND2A expression in H9c2 cells	31878833
19408	Rat	circDENND2A	circRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	H9c2 cells	oxygen glucose deprivation (OGD) treatment	circDENND2A overexpression enhanced OGD-inhibited cell viability and migration but declined OGD-promoted apoptosis by downregulating miR-34a and via ¦Â-catenin and Ras/Raf/MEK/ERK pathways	31878833
19409	Rat	circDENND4C	circRNA	oxygen glucose deprivation (OGD)	ischemic heart disease (IHD)	H9c2 cells	oxygen and glucose deprivation (OGD) treatment	CircRNA-DENND4C was upregulated after OGD/R stimulation	33090893
19410	Rat	circDNMT3B	circRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinas tissues	streptozotocin treatment	downregulated	31636010
19411	Rat	circEIF4G2	circRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E cells	high glucose (HG) treatment	upregulated	33615661
19412	Rat	circFADS2	circRNA	lipopolysaccharide (LPS)	cell proliferation	chondrocytes	lipopolysaccharide (LPS) treatment	upregulated	31141496
19413	Rat	circHIPK3	circRNA	caerulein (Cae)	acute pancreatitis (AP)	AR42J cells	caerulein treatment	"circHIPK3 promotes pyroptosis in acinar cells through regulation of the miR-193a-5p/GSDMD axis, which eventually aggravates AP disease."	32318575
19414	Rat	circHIPK3	circRNA	CoCl2	spinal cord injury (SCI)	PC12 cells	CoCl2 treatment	circ-HIPK3 relieves the neuronal cell apoptosis through regulating miR-588/DPYSL5 axis in SCI.	32247616
19415	Rat	circITCH	circRNA	H2O2	cardiovascular disease (CVD)	H9c2 cells	H2O2 treatment	downregulated	33350543
19416	Rat	circLRP6	circRNA	streptozocin (STZ)	diabetes mellitus (DM)	INS-1 cells	streptozotocin (STZ) treatment	The expression of circLRP6 was elevated while cell viability was decreased after INS-1 cells were exposed to STZ.	33826088
19417	Rat	circMAT2B	circRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	H9c2 cells	Oxygen-glucose deprivation (OGD) treatment	circMAT2B knockdown works as an inflammatory inhibitor in OGD-induced H9c2 cells inflammatory injury through up-regulating miR-133	32897801
19418	Rat	circNCX1	circRNA	H2O2	ischemic heart disease (IHD)	H9c2 cells	H2O2 treatment	A time-dependent increase in circNCX1 level was observed in H9c2 cells upon treatment with 100 ¦ÌM H2O2.	30187887
19419	Rat	circNFIX	circRNA	H2O2	myocardial infarction (MI)	H9c2 cells	oxidative stress treatment	The expression of circNFIX was significantly downregulated in cardiomyocytes subjected to oxidative stress.	33067659
19420	Rat	circPan3	circRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (Dox) treatment	downregulated	32135167
19421	Rat	circPlekha7	circRNA	Smad3 inhibitor (SIS3)	intrauterine adhesion (IUA)	endometrial stromal cell (ESC)	SIS3 treatment	CircPlekha7 was identified as one of the significantly upregulated circRNAs in the SIS3 group	32801258
19422	Rat	circPTK2	circRNA	oxygen glucose deprivation (OGD)	neuron apoptosis	rat primary hippocampal microglial cells	oxygen-glucose deprivation (OGD) induce treatment	upregulated	30742923
19423	Rat	circPVT1	circRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow-derived mesenchymal stem cells (BMSCs)	Glucocorticoid (GC)?treatment	"We found that CircPVT1 was decreased in the femoral head of SIONFH rats and GC-treated BMSCs, while miR-21-5p was markedly upregulated."	33733589
19424	Rat	circSAMD4A	circRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	circSAMD4A were upregulated after H/R induction.	33219594
19425	Rat	circSamd4a	circRNA	inorganic phosphate (Pi)	vascular calcification (VC)	rat vascular smooth muscle cells	inorganic phosphate treatment	"circSamd4a was downregulated after vascular calcification induction. While silencing circSamd4a promoted vascular calcification, overexpressing it reduced vascular calcification in calcium assay and Alizarin red S (ARS) staining."	31790973
19426	Rat	circSamd4a	circRNA	inorganic phosphate (Pi)	vascular calcification (VC)	Vascular Smooth Muscle Cells	Inorganic phosphate (Pi) treatment	downregulated	31790973
19427	Rat	circShank3	circRNA	dexmedetomidine (DEX)	postoperative cognitive dysfunction (POCD)	Hippocampus	dexmedetomidine (Dex) treatment	circ-Shank3 participate in the process of Dex improved POCD through regulating the P53 and NF-¦ÊB signaling pathways.	32226705
19428	Rat	circTtc3	circRNA	hypoxia	apoptosis	Neonatal rat ventricular myocytes (NRVMs) and fibroblasts	hypoxia induce	upregulated	30876857
19429	Rat	circTtc3	circRNA	TGF-¦Â1	apoptosis	Neonatal rat ventricular fibroblasts	TGF-¦Â1 treatment	upregulated	30876857
19430	Rat	circTTC3	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary neural stem cells (NSCs) were obtained from rat embryos	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	the expression of circTTC3 was elevated in the MCAO/R mice and oxygen and glucose deprivation (OGD)-treated astrocytes	33579365
19431	Rat	circZNF292	circRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	hypoxic-ischemic encephalopathy (HIE)	neural stem cells (NSCs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32052645
19432	Rat	circZNF292	circRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cells	hypoxia treatment	"The production of the circZNF292 was promoted by OGD. Abundant circZNF292 released OGD-induced damage by up-regulating cell viability and Wnt3a/¦Â-catenin or mTOR proteins, but down-regulating apoptosis and autophagy."	31607209
19433	Rat	CPS1©\IT	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary artery tissues	hypoxia induce	downregulated	30982984
19434	Rat	CRNDE	lncRNA	lipopolysaccharide (LPS)	intrauterine infection	brain tissues	lipopolysaccharide (LPS) treatment	CRNDE deteriorates intrauterine infection-induced neonatal brain injury	32234564
19435	Rat	CRNDE	lncRNA	lipopolysaccharide (LPS)	myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	CRNDE/miR-29a/SIRT1 network regulated sepsis-induced myocardial injury.	32473249
19436	Rat	CRNDE	lncRNA	platelet derived growth factor-BB (PDGF-BB)	restenosis after angioplasty or stent	rat carotid artery and vascular smooth muscle cells (VSMCs)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	30740670
19437	Rat	CRNDE	lncRNA	feeney's freefall impact	traumatic brain injury (TBI)	brain tissues	Feeney's freefall impact induce	upregulated	31345079
19438	Rat	CTPB1-AS2	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	The neonatal rat ventricular myocytes (NRVMs)	angiotensin II (Ang II) treatment	upregulated	31220774
19439	Rat	CUST-2117-PI428311958	lncRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	upregulated	28761781
19440	Rat	CUST-4640-PI428311958	lncRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	upregulated	28761781
19441	Rat	CUST-5105-PI428311958	lncRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	upregulated	28761781
19442	Rat	CUST-6638-PI428311958	lncRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	upregulated	28761781
19443	Rat	CUST-9613-PI428311958	lncRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	upregulated	28761781
19444	Rat	CYTOR	lncRNA	lipopolysaccharide (LPS)	myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	upregulated	32181504
19445	Rat	DANCR	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	DANCR alleviated hypoxia-caused H9c2 cells damage through positive regulation of HIF-1¦Á.	33426962
19446	Rat	DANCR	lncRNA	compression force (CF)	cell differentiation	human periodontal ligament (PDL) cells	compression force (CF) treatment	upregulated	31213122
19447	Rat	DANCR	lncRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	H9c2 cells	tunicamycin treatment	lncRNA Dancr overexpression protected cardiomyocytes against ERS injury via sponging miR-6324.	33300079
19448	Rat	DANCR	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cell (BMEC)	oxygen glucose deprivation (OGD) treatment	"DANCR expression significantly increased at 2, 4, 6, 8, and 10 h after OGD."	31986122
19449	Rat	DCRF	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	neonatal rats cardiomyocytes	high glucose (HG) treatment	High glucose increased DCRF expression and induced autophagy in cardiomyocytes.	31285779
19450	Rat	DCRF	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	rat heart tissues	streptozotocin treatment	"DCRF knockdown reduced cardiomyocyte autophagy, attenuated myocardial fibrosis, and improved cardiac function in diabetic rats"	31285779
19451	Rat	DGCR5	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	downregulated	31826181
19452	Rat	DGCR5	lncRNA	polydatin (PD)	myocardial infarction (MI)	hypoxia-induced H9c2 cells	Polydatin (PD) treatment	upregulated	31826181
19453	Rat	DGCR5	lncRNA	hypoxia	spinal cord injury (SCI)	PC12 cells	hypoxia treatment	DGCR5 was downregulated in PC12 cells treated with hypoxia.	30146926
19454	Rat	Dlg4	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19455	Rat	EFNA3	lncRNA	hypoxia	cerebral ischemia injury (CII)	hypoxia-injured rat adrenal pheochromocytoma (PC-12) cells	hypoxia induce	"?lncRNA EFNA3 was highly expressed in response to hypoxia. Deletion of lncRNA EFNA3 significantly aggravated hypoxia-induced injury in PC-12 cells, as the impairment of cell viability, migration, and invasion, and the inducement of apoptosis. LncRNA EFNA3 worked as a sponging molecule for miR-101a and miR-101a suppression-protected PC-12 cells against hypoxia-induced injury even when lncRNA EFNA3 was silenced."	30125989
19456	Rat	EFNA3	lncRNA	hypoxia	cerebral ischemia injury (CII)	PC-12 cells	hypoxia treatment	lncRNA EFNA3 was highly expressed in response to hypoxia.	30125989
19457	Rat	EGOT	lncRNA	recombinant human brain natriuretic peptide (rhBNP)	hypoxia-induced injury	H9c2 cells	recombinant human brain natriuretic peptide (rhBNP) treatment	Hypoxia significantly induced injury in H9c2 cells (inhibited cell viability and promoted cell apoptosis and autophagy) and decreased the expression of EGOT	30031611
19458	Rat	Eif4g2	lncRNA	palmitate	pancreatic ¦Â-cell dysfunction	INS-1E cells	palmitate treatment	lncEif4g2 is able to indirectly regulate the expression of CREB via targeting miR-3074-5p in INS-1E cells and mouse islets	32956705
19459	Rat	Ell2	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19460	Rat	ENSRNOG00000037522	lncRNA	streptozocin (STZ)	epithelial-mesenchymal transition (EMT)	kidney tissues	streptozocin (STZ) treatment	ENSRNOG00000037522 was significantly increased in kidney tissues	29436579
19461	Rat	ENSRNOT00000065561	lncRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnea-induced cardiovascular disease	heart tissues	chronic intermittent hypoxia (CIH) treatment	upregulated	30535531
19462	Rat	ENST00000052577	lncRNA	A2B5+ cell transplantation	traumatic brain injury (TBI)	TBI Sprague-Dawley rats	A2B5+ cell transplantation	upregulated	29251113
19463	Rat	ENST00000446135	lncRNA	cadmium (Cd)	cadmium-induced toxicity	lung tissues	cadmium (Cd) treatment	upregulated	33447366
19464	Rat	FAF	lncRNA	hypoxia	acute myocardial infarction (AMI)	Cardiomyocytes were isolated from 1©\ to 3©\day©\old rats	hypoxia induce	downregulated	31093967
19465	Rat	FAF	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblasts (CFs); heart tissues	angiotensin II (Ang II) treatment	lncRNA FAF was decreased in heart tissues and CFs treated with Ang II compared with the control.	31708099
19466	Rat	FAM83H-AS1	lncRNA	advanced glycation end product (AGE)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	advanced glycation end products (AGEs) treatment	downregulated	33313263
19467	Rat	Fendrr	lncRNA	caerulein (Cae)	acute pancreatitis (AP)	AR42J cells	caerulein (Cae) treatment	LncRNA Fendrr was also upregulated in AP cell model and directly bound ANXA2 protein.	30474876
19468	Rat	Fendrr	lncRNA	hypoxia	cardiomyocyte apoptosis	H9c2 cells	hypoxia treatment	LncRNA Fendrr inhibits hypoxia/reoxygenation-induced cardiomyocyte apoptosis by downregulating p53 expression.	32537758
19469	Rat	FGD5-AS1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	primary cortical neuron culture	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	FGD5-AS1 may protect the neuron against OGD/R injury via acting as a ceRNA for miR-223 to mediate IGF1R expression	32337949
19470	Rat	FIRRE	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	primary microglial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	FIRRE was upregulated in OGD/R-treated microglial cells	29715458
19471	Rat	FOXD3-AS1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31632535
19472	Rat	FTX	lncRNA	lithium chloride and pilocarpine	epilepsy	hippocampal neuron	lithium chloride and pilocarpine induce	"?FTX is notably reduced in the hippocampus of SE rat model. Moreover, the in?vivo overexpression of FTX inhibited SE-induced hippocampus neuron apoptosis."	30871773
19473	Rat	FTX	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia/reoxygenation (H/R) treatment	FTX alleviates hypoxia/reoxygenation-induced cardiomyocyte injury via miR-410-3p/Fmr1 axis	31957854
19474	Rat	FTX	lncRNA	Nogo-66	neurite outgrowth	PC12 cells	Nogo-66 treatment	LncRNA FTX Involves in the Nogo-66-Induced Inhibition of Neurite Outgrowth Through Regulating PDK1/PKB/GSK-3¦Â Pathway.	32107749
19475	Rat	Gadd45a	lncRNA	sevoflurane (SEV)	sevoflurane-induced neurotoxicity	neural stem cells (NSCs)	sevoflurane treatment	lncRNA Gadd45a were positively coupregulated in rat NSCs fol- lowing exposure to sevoflurane	29521679
19476	Rat	gadd7	lncRNA	agmatine (AGM)	hyperoxia-induced acute lung injury (HALI)	rat lung tissues	agmatine (AGM) treatment	"AGM decreased the upregulated expression of lncRNA gadd7 caused by hyperoxia and due to the presence of the competitive binding of lncRNA gadd7 and MFN1 to miR-125a, AGM indirectly decreased MFN1 protein expression to inhibit the cells apoptosis."	31196629
19477	Rat	GAS5	lncRNA	isoproterenol	acute myocardial infarction (AMI)	rat myocardial tissues	subcutaneous injection of isoproterenol (ISO)	"SiRNA GAS5 can enhance the cardiac function of AMI model rats, relieve pathological damage, reduce myocardial cell apoptosis, and inhibit the occurrence of myocardial fibrosis. The possible underlying mechanism may be associated with upregulated of miR-21."	31646590
19478	Rat	GAS5	lncRNA	bisphenol A (BPA)	bisphenol A (BPA) induced neurotoxicity	PC12cells	bisphenol A (BPA) treatment	GAS5 was downregulated in PC12 cells induced by BPA.	29552716
19479	Rat	GAS5	lncRNA	hypoxia/reoxygenation (H/R)	cardiomyocyte apoptosis	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	"LncRNA-GAS5 regulates PDCD4 expression to mediate MI-induced cardiomyocyte apoptosis via targeting miR-21, suggesting that GAS5 could be a therapeutic target for MI."	32308118
19480	Rat	GAS5	lncRNA	homocysteine (Hcy)	cell damage	primary cardiac microvascular endothelial cells (CMECs)	homocysteine (HCY) treatment	downregulated	30825202
19481	Rat	GAS5	lncRNA	deep hypothermic circulatory arrest	cerebral injury	rat hippocampal tissues	deep hypothermic circulatory arrest treatment	upregulated	30824348
19482	Rat	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cardiomyocytes	high glucose (HG) treatment	GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model	33682891
19483	Rat	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose (HG) treatment	"GAS5 downregulated high blood glucose concentrations in STZ-induced diabetic rats, however its expression levels decreased in both HG-processed H9C2 cells and the myocardium of DM model rats."	33313941
19484	Rat	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose (HG) treatment	downregulated	33313941
19485	Rat	GAS5	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	H9c2 cells	streptozotocin (STZ) treatment	"GAS5 downregulated high blood glucose concentrations in STZ-induced diabetic rats, however its expression levels decreased in both HG-processed H9C2 cells and the myocardium of DM model rats"	33313941
19486	Rat	GAS5	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	myocardium	streptozotocin (STZ) treatment	downregulated	33313941
19487	Rat	GAS5	lncRNA	kainic acid (KA)	epilepsy	primary hippocampal neuron	kainic acid (KA) treatment	"lncRNA GAS5 functions as a competitive endogenous RNA of miR-135a-5p to increase expression of KCNQ3, and lncRNA GAS5 silencing inhibited the occurrence and progression of epilepsy."	31373759
19488	Rat	GAS5	lncRNA	astragaloside IV (AS-IV)	heart failure (HF)	hypoxia-treated cardiomyoblast H9c2 cells	astragaloside IV (AS-IV) treatment	"we found that lncRNA GAS5 expression was downregulated by AS-IV treatment, and AS-IV might affect hypoxia-stimulated H9c2 cells through lncRNA GAS5."	31136949
19489	Rat	GAS5	lncRNA	hypoxia	heart failure (HF)	H9c2 cells	hypoxia induce	"silence of lncRNA GAS5 attenuated hypoxia-triggered cell death, silence of lncRNA GAS5 protected H9c2 cells against hypoxia-induced injury possibly via sponging miR-142-5p."	31085811
19490	Rat	GAS5	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	Liver tissues	carbon tetrachloride (CCl4) treatment	lncRNA GAS5 can be used as a sponge platform for miR-23a to decrease miR-23a expression levels competitively.	30735452
19491	Rat	GAS5	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	brain tissues	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	GAS5 and PTEN expression levels were elevated in brain tissues of MCAO rats and OGD/R-induced PC12 cells	33309710
19492	Rat	GAS5	lncRNA	hypoxia	myocardial infarction (MI)	myocardial cell line H9c2	hypoxia induce	upregulated	31429119
19493	Rat	GAS5	lncRNA	norepinephrine (NE)	myocardial infarction (MI)	H9c2 cells	Norepinephrine (NE) treatment	upregulated	30099044
19494	Rat	GAS5	lncRNA	anoxia/reoxygenation (A/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	anoxia/reoxygenation (A/R) treatment	lncRNA GAS5 in H9c2 cells treated with anoxia and reoxygenation was significantly upregulated.	31985016
19495	Rat	GAS5	lncRNA	palmitic acid (PA)	myocardial lipotoxic injury	H9c2 cells	palmitic acid (PA) treatment	GAS5 was significantly upregulated in cardiomyocytes following treatment with PA	30365114
19496	Rat	GAS5	lncRNA	cocaine	neural function	nucleus accumbens (NAc)	cocaine treatment	downregulated	32711952
19497	Rat	GAS5	lncRNA	methamphetamine (METH)	neurotoxicity	prefrontal cortical neurons	Methamphetamine treatment	upregulated	28619521
19498	Rat	GAS5	lncRNA	curcumin (Cur)	post-stroke depression (PSD)	hippocampus	curcumin treatment	upregulated	32627518
19499	Rat	GAS5	lncRNA	hypoxia	stroke	rat brain tissues	Transient focal ischemia was induced by intraluminal occlusion of the right Middle cerebral artery occlusion (MCAO)	"GAS5 was upregulated in MCAO rats and in vitro hypoxia cell model while miR-221 expression was decreased in vitro hypoxia cell model. GAS5 promoted cells apoptosis, while miR-221 inhibited cell apoptosis through regulation of PUMA and downstream JNK/H2AX signaling."	31878844
19500	Rat	Giver	lncRNA	angiotensin II (Ang II)	hypertension	Rat vascular smooth muscle cell (VSMC)	angiotensin II (Ang II) treatment	upregulated	30566058
19501	Rat	Giver	lncRNA	angiotensin II (Ang II)	hypertension	vascular smooth muscle cell (VSMC)	angiotensin II (Ang II) treatment	AngII increased the expression of Giver.	30566058
19502	Rat	Gm2691	lncRNA	hypoxia	acute myocardial infarction (AMI)	neonatal rat ventricular cardiomyocytes	AnaeroPack anaerobic system treatment	LncRNA Gm2691 improved the cardiac function and attenuated the inflammatory response in vivo	31169981
19503	Rat	Gm4419	lncRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	BRL-3A cells	hypoxia-reoxygenation (H/R) treatment	lncRNA Gm4419 accelerates hepatic I/R injury by targeting the miR-455-SOX6 axis.	32114773
19504	Rat	Gm4419	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	microglial cells from SD rat	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	28476620
19505	Rat	Gm4419	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H92c cells	hypoxia/reoxygenation treatment	upregulated	32590403
19506	Rat	Gpr19	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute myocardial infarction (AMI)	rat ventricular cardiomyocytes (NRCMs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31622017
19507	Rat	Gpr19	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Neonatal rat ventricular cardiomyocytes (NRCMs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Inhibition of the LncRNA Gpr19 attenuates ischemia-reperfusion injury after acute myocardial infarction by inhibiting apoptosis and oxidative stress via the miR-324-5p/Mtfr1 axis.	31622017
19508	Rat	Grik2-001	lncRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	downregulated	29505837
19509	Rat	H19	lncRNA	hypoxia	acute myocardial infarction (AMI)	rat H9c2 cells	hypoxia	upregulated	29179202
19510	Rat	H19	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	"The expression of H19 and FOXA1 was significantly upregulated, while the expression of miR-423-5p was downregulated in LPS-induced ARDS rats."	33629893
19511	Rat	H19	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12 cells	amyloid-¦Â (A¦Â) 25-35 treatment	"Elevated H19, HMGB1 and decreased miR-129 were found in A¦Â25-35-treated PC12 cells as well as in brain tissues of AD mice."	33410377
19512	Rat	H19	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	ancestral TCDD exposure	ovary of TCDD treated F3 female rats	Pregnant Sprague-Dawley female rats (F0) were given with either vehicle or TCDD (100 or 500?ng/kg BW/day) by gavages during days 8-14 of gestation.	upregulated	31629011
19513	Rat	H19	lncRNA	hypoxia	cardiac rehabilitation	H9c2 cells	hypoxic preconditioning (HPC) treatment	"HPC treatment protected H9c2 cells against H2O2-induced injury, upregulated the level of long noncoding RNA (lncRNA) H19."	33197240
19514	Rat	H19	lncRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	brain tissues	(lncRNA H19) was found to be upregulated by hypoxia	upregulated	28203482
19515	Rat	H19	lncRNA	streptozocin (STZ)	diabetes mellitus (DM)	rats renal tubular epithelial cells	streptozotocin treatment	upregulated	29029394
19516	Rat	H19	lncRNA	high glucose (HG) and lipid diet	diabetic foot ulcer (DFU)	ulcer tissues	high glucose and lipid diet	lncRNA H19 accelerated wound healing in DFU through elevation of CTGF and activation of the MAPK signaling pathway.	32698141
19517	Rat	H19	lncRNA	adriamycin (ADR)	dilated cardiomyopathy (DCM)	rats?myocardial tissue	adriamycin (ADR) treatment	upregulated	28430627
19518	Rat	H19	lncRNA	hindlimb unloading (HLU)	disuse osteoporosis (DOP)	rats	HLU treatment	downregulated	28447380
19519	Rat	H19	lncRNA	intra-amygdala kainic acid	epilepsy	hippocampus	intra-amygdala kainic acid treatment	H19 is involved in astrocyte activation in the hippocampus of epileptic rats.	30314521
19520	Rat	H19	lncRNA	kainic acid (KA)	epilepsy	rat hippocampus neurons	kainic acid treatment	LncRNA H19 could competitively bind to let-7b to promote hippocampal glial cell activation and epileptic seizures by targeting Stat3 in a rat model of temporal lobe epilepsy.	32648622
19521	Rat	H19	lncRNA	hypoxia	hypoxic brain injury	PC-12 cell	hypoxia induce	"Hypoxia-induced cell damage was aggravated by lncRNA H19 overexpression, while was alleviated by lncRNA H19 silence."	30312698
19522	Rat	H19	lncRNA	geniposide (GEN)	hypoxic/ischemic brain damage (HIBD)	oxygen and glucose deprivation (OGD)-treated PC-12 cells	Geniposide (GEN) treatment	upregulated	30472296
19523	Rat	H19	lncRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	PC-12 cells	oxygen and glucose deprivation (OGD)	downregulated	30472296
19524	Rat	H19	lncRNA	geniposide (GEN)	hypoxic-ischemic encephalopathy (HIE)	PC-12 cells	geniposide (GEN) treatment	H19 expression was upregulated by GEN.	30472296
19525	Rat	H19	lncRNA	hypoxia	ischemic stroke (IS)	rat brain tissues	middle cerebral artery occlusion/reperfusion (MCAO/R) injury	upregulated	31170091
19526	Rat	H19	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	rat neuronal cells	oxygen glucose deprivation (OGD) treatment	upregulated	31170091
19527	Rat	H19	lncRNA	hypoxia	myocardial infarction (MI)	rat cardiomyocyte	hypoxia treatment	Downregulated H19 and upregulated CYP1B1 were observed in MI patients.	33389498
19528	Rat	H19	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia treatment	upregulated	32319634
19529	Rat	H19	lncRNA	H2O2	myocardial ischemic preconditioning (IP)	H9c2 cells	H2O2 treatment	H19 overexpression enhanced the protective role of H2 O2 -PC in cardiomyocytes.	31975412
19530	Rat	H19	lncRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	Schwann cells	chronic constriction injury (CCI) induce	Silencing H19 inhibited NP by suppressing CDK5/p35 and p-CREB phosphorylation via the miR-196a-5p/CDK5 axis.	32903807
19531	Rat	H19	lncRNA	"2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)"	ovary development and functions	female offspring rats (F1) ovary	the pregnant rats were treated with TCDD (100?ng/kg/day or 500?ng/kg/day) or only vehicle and corn oil on the day 8-14 of gestation through the gavage with a stainless-steel feeding needle. The vaginal opening time and estrous cycle of female offspring rats (F1) were monitored twice a day.	downregulated	31063829
19532	Rat	H19	lncRNA	metformin (Met)	polycystic ovarian syndrome (PCOS)	ovary tissues	Metformin (Met) treatment	downregulated	30989649
19533	Rat	H19	lncRNA	estrogen (ES)	postmenopausal osteoporosis (PMOP)	bone tissues	estrogen treatment	upregulated	33577975
19534	Rat	H19	lncRNA	IL-1¦Â	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	IL-1¦Â treatment	upregulated	30547791
19535	Rat	H19	lncRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	serum; lungs tissues	monocrotaline (MCT) treatment	H19 was highly expressed in the serum and lungs of MCT-induced models.	30547791
19536	Rat	H19	lncRNA	platelet derived growth factor-BB (PDGF-BB)	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	30547791
19537	Rat	H19	lncRNA	3-methyladenine (3-MA)	repair of epidermal growth factor (EGF)	IEC-6 cells	3-methyladenine (3-MA) treatment	downregulated	32301281
19538	Rat	H19	lncRNA	rapamycin	repair of epidermal growth factor (EGF)	IEC-6 cells	Rapamycin treatment	upregulated	32301281
19539	Rat	H19	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	"H19 and SORBS2 were downregulated in H9C2 cells following LPS treatment, while miR-93-5p was upregulated."	32996061
19540	Rat	H19	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	H9C2 cells	lipopolysaccharide (LPS) treatment	H19 attenuated the development of sepsis-induced myocardial injury in vitro via modulation of the miR-93-5p/SORBS2 axis.	32996061
19541	Rat	H19	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary spinal neurons	lipopolysaccharide (LPS) treatment	SCI resulted in lncRNA H19 higher expression and miR-370-3p lower expression.	33708438
19542	Rat	H19	lncRNA	metformin and sitagliptin	polycystic ovarian syndrome (PCOS)	primary ovarian granulosa cells?culture	metformin (DMBG) and sitagliptin (TECOS) treatment	co-treatment with TECOS and DMBG induced H19 expression via suppressing the PI3K/AKT-DNMT1 pathway.	31405334
19543	Rat	HCG18	lncRNA	high glucose (HG)	diabetic peripheral neuropathy (DPN)	macrophage	high glucose (HG) treatment	LncRNA HCG18 was highly expressed in DPN model and HG-induced macrophages.	32996080
19544	Rat	HIF1A-AS2	lncRNA	hypoxia	ischemic stroke (IS)	HUVECs	pMCAO treatment	upregulated in infraction areas	28985553
19545	Rat	HOTAIR	lncRNA	sepsis	acute kidney injury (AKI)	?kidney tissues	cecal ligation puncture induced sepsis treatment	lncRNA HOTAIR mimics could remarkably improve the renal function of sepsis rats	31081107
19546	Rat	HOTAIR	lncRNA	hypoxia	acute myocardial infarction (AMI)	neonatal rat cardiomyocytes	hypoxia treatment	downregulated	29258067
19547	Rat	HOTAIR	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9C2 cells	hypoxia induce	upregulated	30468490
19548	Rat	HOTAIR	lncRNA	bisphenol-A (BPA) and diethylstilbestrol (DES)	breast cancer	mammary glands of rat	BPA and DES treatment	upregulated	24533974
19549	Rat	HOTAIR	lncRNA	exenatide (EXA)	cirrhotic cardiomyopathy	thioacetamide (TAA)-treated rats cardiac tissue	exenatide (EXA) treatment	upregulated	31100415
19550	Rat	HOTAIR	lncRNA	thioacetamide (TAA)	cirrhotic cardiomyopathy	cardiac tissue	thioacetamide (TAA) treatment	downregulated	31100415
19551	Rat	HOTAIR	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	?high glucose (HG) induce	HOTAIR protected against DCM via activation of the SIRT1 expression by sponging miR-34a.	30216438
19552	Rat	HOTAIR	lncRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	heart tissues	streptozotocin (STZ) treatment	HOTAIR was downregulated in the diabetic hearts	30216438
19553	Rat	HOTAIR	lncRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	chondrocytes obtained from SD rats	lipopolysaccharide (LPS) treatment	downregulated	28732288
19554	Rat	HOTAIR	lncRNA	H2O2	ischemia/reperfusion (I/R) injury	H9c2 cells	H2O2 treatment	HOTAIR was significantly downregulated in H9c2 cells in response to oxidative stimuli.	30239560
19555	Rat	HOTAIR	lncRNA	sulfasalazine	multiple sclerosis (MS)	OLN-93 cells	sulfasalazine (SF) treatment	SF downregulated lncRNA HOTAIR but upregulated miR-136-5p	29944870
19556	Rat	HOTAIR	lncRNA	hypoxia	myocardial infarction (MI)	rat heart tissues	permanent ligation of the left anterior descending (LAD) coronary artery induce	downregulated	30607799
19557	Rat	HOTAIR	lncRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H2O2 treatment	HOTAIR aggravates myocardial IR by competitively binding SRSF1 with microRNA-126.	32964995
19558	Rat	HOTAIR	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32256945
19559	Rat	HOTAIR	lncRNA	matrine	oxidative stress	H9c2 cells	matrine treatment	Matrine modulated H2O2-induced myocardial oxidative stress repair through HOTAIR/miR-106b-5p axis via AKT and STAT3 signaling pathway.	32395744
19560	Rat	HOTAIR	lncRNA	dehydro-isoandrosterone	polycystic ovarian syndrome (PCOS)	ovarian tissues and granulosa cells	dehydro-isoandrosterone treatment	LncRNA HOTAIR up-regulates the expression of IGF1 and aggravates the endocrine disorders and granulosa cell apoptosis through competitive binding to miR-130a in rat models of PCOS.	31733099
19561	Rat	HOTAIR	lncRNA	dehydro-isoandrosterone	polycystic ovarian syndrome (PCOS)	ovarian tissues	dehydro-isoandrosterone treatment	upregulated	31733099
19562	Rat	HOTAIR	lncRNA	paeonol (PAE)	renal interstitial fibrosis (RIF)	renal tissues or NRK-49F cells	paeonol (PAE) treatment	PAE was found to decrease HOTAIR and Notch1 expression but to increase the miR-124 expression in RIF rats.	30714138
19563	Rat	HOTAIR	lncRNA	sevoflurane (SEV)	sevoflurane anesthesia-mediated cognitive dysfunction	hippocampus	sevoflurane treatment	upregulated	29352445
19564	Rat	HOTTIP	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina tissues	streptozocin (STZ) treatment	upregulated	29863235
19565	Rat	HOXA-AS2	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin (STZ) treatment	HOXA-AS2 was downregulated in STZ-induced DN rats	32432759
19566	Rat	HOXB-AS3	lncRNA	doxorubicin (DOX)	cardiotoxicity	H9c2 cells	Doxorubicin (DOX) treatment	Relative level of HOXB-AS3 was upregulated in DOX-treated cardiomyocytes. Silence of HOXB-AS3 in cardiomyocytes undergoing DOX treatment markedly elevated their proliferative ability.	32010313
19567	Rat	HOXB-AS3	lncRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (DOX) treatment	Relative level of HOXB-AS3 was upregulated in DOX-treated cardiomyocytes.	32010313
19568	Rat	HULC	lncRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	32674625
19569	Rat	HULC	lncRNA	dimethylnitrosamine (DMN)	liver cirrhosis	liver tissues	dimethylnitrosamine (DMN) treatment	upregulated	31933850
19570	Rat	IFNG-AS1	lncRNA	vildagliptin (Vilda)	ulcerative colitis (UC)	colon tissues	Vildagliptin (Vilda) treatment	"Vilda hsa markedly inhibited the expression of lncRNA IFNG-AS1 and miR-146a, as well as PI3K/Akt/NF¦ÊB pathway"	33434756
19571	Rat	ILF3-AS1	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	ILF3-AS1 was downregulated by hypoxia.	32196615
19572	Rat	JHDM1D-AS1	lncRNA	H2O2	periodontal ligament repair	rat periodontal ligament stem cells (PDLSCs)	H2O2 treatment	downregulated	31276733
19573	Rat	KCNA2-AS	lncRNA	varicella zoster virus (VZV)	postherpetic neuralgia (PHN)	spinal cord tissue	Varicella zoster virus (VZV) treatment	KCNA2-AS was highly expressed in the spinal cord tissue of PHN model rats	33225882
19574	Rat	KCNQ1OT1	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	"Kcnq1ot1 sponged miR-466k and miR-466i-5p to up-regulate Tead1, thus triggering cardiomyocyte injury in the process of AMI."	32422306
19575	Rat	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic corneal endothelial keratopathy	rat corneal endothelial cells	high glucose treatment	upregulated	31693400
19576	Rat	KCNQ1OT1	lncRNA	streptozocin (STZ)	diabetic corneal endothelial keratopathy	corneal endothelial cells	streptozotocin (STZ) treatment	upregulated	31693400
19577	Rat	KCNQ1OT1	lncRNA	ketamine	ketamine-induced neurotoxicity	neurons of the hippocampus; PC-12 cells	ketamine treatment	LncRNA KCNQ1OT1 Sponges miR-206 to Ameliorate Neural Injury Induced by Anesthesia via Up-Regulating BDNF.	33204065
19578	Rat	KCNQ1OT1	lncRNA	lipopolysaccharide (LPS)	myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated of KCNQ1OT1 advances cardiac injury through regulating miR-192-5p/XIAP axis during sepsis.	32102564
19579	Rat	L20992	lncRNA	lead (Pb)	lead-induced neurotoxicity	PC12 cells	lead treatment	lncRNAL20992 was significantly upregulated in a lead-induced neuronal-injury cell model.	29029323
19580	Rat	LEF1-AS1	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary microglial cells	lipopolysaccharide (LPS) treatment	"We revealed that LncRNA LEF1-AS1 was distinctly upregulated, whereas miR-222-5p was significantly downregulated in LPS-treated SCI and microglial cells."	33407665
19581	Rat	LEGLTBC	lncRNA	high glucose (HG) and palmitate (HG/PA)	type 2 diabetes mellitus (T2DM)	INS-1 cells	high glucose and palmitate (HG/PA) treatment	downregulated	31737170
19582	Rat	LET	lncRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cells	hypoxia treatment	downregulated	31222827
19583	Rat	LET	lncRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cells	hypoxia induce	The expression of lncRNA-LET was repressed by hypoxia. Overexpression of lncRNA-LET attenuated hypoxia-induced injury in H9c2 cells.	31222827
19584	Rat	Lin28	lncRNA	"2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)"	colorectal cancer (CRC)	rat tumors; colonic mucosa tissues	"2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) treatment"	the let-7/c-Myc/Lin28 axis is dysregulated in heterocyclic amine-induced colon carcinogenesis	22641368
19585	Rat	LINC00261	lncRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R)-mediated acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	The expression of LINC00261 was significantly downregulated in H9C2 cells.	32558131
19586	Rat	LINC00339	lncRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	primary cultured myocardial cells (PC); H9c2 cells	doxorubicin (DOX) treatment	Primary cultured myocardial cell (PC) and H9C2 cell line were treated with different concentrations of DOX and the expression of LINC00339 were markedly upregulated.	30170730
19587	Rat	LINC00472	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute hepatic injury	liver tissues	Lipopolysaccharide (LPS) treatment	upregulated	33129786
19588	Rat	LINC00707	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	LINC00707 alleviates LPS-induced inflammation and apoptosis in PC-12 cells by targeting miR-30a-5p/Neurod 1	31272297
19589	Rat	LINC00961	lncRNA	hypoxia	myocardial infarction (MI)	cardiomyocytes H9c2	hypoxia induce	upregulated	30887575
19590	Rat	LINC01614	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32231469
19591	Rat	LNC_000343	lncRNA	iohexol	contrast-induced acute kidney injury (CIAKI)	Renal tissue	"Animals were dehydrated for 48 h and then underwent furosemide (10 mL/kg; Harvest Pharmaceutical, Shanghai, China) injection 30 min before administration of iohexol (15 mL/kg, group CI-AKI; iodine, 350 mg/mL; GE Healthcare, Shanghai, China) or 0.9% normal saline (15 mL/kg, control group)."	lncRNA LNC_000343 was downregulated in Contrast-induced acute kidney injury (CI-AKI).	31234008
19592	Rat	lnc000908	lncRNA	isoproterenol	cardiac fibrosis	heart tissues	isoproterenol treatment	upregulated	31297954
19593	Rat	lncRNA00654	lncRNA	pentoxifylline (PTX)	cardiac injury	heart sissues	Pentoxifylline (PTX) treatment	Pentoxifylline (PTX) treatment produced a dose-dependent decrease in lncRNA-00654 expressions	31972363
19594	Rat	lncRNA5657	lncRNA	lipopolysaccharide (LPS)	sepsis-induced lung injury	NR8383 cells	lipopolysaccharide (LPS) treatment	upregulated	32866783
19595	Rat	LOC102546452	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19596	Rat	LOC102547847	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19597	Rat	LOC102549714	lncRNA	silica	silicosis	lung tissues	silica treatment	upregulated	32028236
19598	Rat	LOC102549714	lncRNA	TGF-¦Â1	silicosis	rat lung fibroblasts (FBs)	TGF-¦Â1 treatment	upregulated	32028236
19599	Rat	LOC102549726	lncRNA	nickel	steroidogenesis disturbance	Leydig cells	NiSO4 induce	dysregulated	31734292
19600	Rat	LOC102549726	lncRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	upregulated	31734292
19601	Rat	LOC102550137	lncRNA	silica	silicosis	lung tissues	silica treatment	upregulated	32028236
19602	Rat	LOC102550137	lncRNA	TGF-¦Â1	silicosis	rat lung fibroblasts (FBs)	TGF-¦Â1 treatment	upregulated	32028236
19603	Rat	LOC102551149	lncRNA	platelet-derived growth factor (PDGF)	liver fibrosis	hepatic stellate cells (HSCs)	platelet-derived growth factor (PDGF) treatment	downregulated	32306379
19604	Rat	LOC102553339	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19605	Rat	LOC103690121	lncRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	rat hippocampal neurons (RN-h cells)	high glucose treatment	upregulated	30851305
19606	Rat	LOC103690121	lncRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	hippocampal tissues	streptozotocin (STZ) treatment	upregulated	30851305
19607	Rat	LOC103691197	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19608	Rat	LOC103691336	lncRNA	MgSO4	osteogenesis	rat primary bone marrow stromal cells	MgSO4 treatment	upregulated	31081160
19609	Rat	LOC103691771	lncRNA	silica	silicosis	lung tissues	silica treatment	upregulated	32028236
19610	Rat	LOC103691771	lncRNA	TGF-¦Â1	silicosis	rat lung fibroblasts (FBs)	TGF-¦Â1 treatment	upregulated	32028236
19611	Rat	LOC103692016	lncRNA	silica	silicosis	lung tissues	silica treatment	downregulated	32028236
19612	Rat	LOC103692016	lncRNA	TGF-¦Â1	silicosis	rat lung fibroblasts (FBs)	TGF-¦Â1 treatment	downregulated	32028236
19613	Rat	LOC103692656	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19614	Rat	LOC103693125	lncRNA	silica	silicosis	lung tissues	silica treatment	downregulated	32028236
19615	Rat	LOC103693125	lncRNA	TGF-¦Â1	silicosis	rat lung fibroblasts (FBs)	TGF-¦Â1 treatment	downregulated	32028236
19616	Rat	Lrrc75a-as1	lncRNA	inorganic phosphate (Pi)	vascular calcification (VC)	rat vascular smooth muscle cells (VSMCs)	inorganic phosphate treatment	downregulated	30971745
19617	Rat	MAGI1-IT1	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	downregulated	31222747
19618	Rat	MAGI1-IT1	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	MAGI1-IT1 functioned as a negative regulator in CH through inactivating Wnt/beta-catenin pathway via targeting miR-302e/DKK1 axis	31222747
19619	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues; NRK-52E cells	lipopolysaccharide (LPS) treatment	upregulated	29115409
19620	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	NRK-52E cells	lipopolysaccharide (LPS) treatment	upregulated	29115409
19621	Rat	MALAT1	lncRNA	"5(S), 6(R),7-trihydroxyheptanoic acid methyl ester (BML-111)"	acute lung injury (ALI)	lung tissues	BML-111 treatment	upregulated	29704485
19622	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	MALAT1 was upregulated and mir-146a was downregulated in lps-induced ALI rat model.	29649906
19623	Rat	MALAT1	lncRNA	hyperbaric oxygen (HBO)	acute myocardial infarction (AMI)	Rat cardiac myocytes	Hyperbaric oxygen (HBO) treatment	HBO significantly increased MALAT1 expression in cardiac myocytes.	32939962
19624	Rat	MALAT1	lncRNA	hypoxia	acute myocardial infarction (AMI)	heart tissues	ligation of the left anterior descending coronary artery	upregulated	32010261
19625	Rat	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute myocardial infarction (AMI)	H9c2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31669130
19626	Rat	MALAT1	lncRNA	caerulein (Cae)	acute pancreatitis (AP)	"AR42J, a rat pancreatic acinar cell line"	caerulein (Cae) treatment	upregulated	31518341
19627	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	33407436
19628	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute spinal cord injury (ASCI)	primary microglia	lipopolysaccharide (LPS) treatment	"Upon treatment with LPS, MALAT1 expression dramatically increased in the microglia in vitro."	29631367
19629	Rat	MALAT1	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	nerve growth factor (NGF) stimulated PC 12 cells and primary cerebral cortex neurons of rat embryo	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	31345147
19630	Rat	MALAT1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12; C6 cells	amyloid-¦Â (A¦Â) 25-35 treatment	MALAT1 could promote neuronal recovery following AD through the miR-30b/CNR1 network and the PI3K/AKT signaling activation.	32976819
19631	Rat	MALAT1	lncRNA	fluid-percussion injury (FPI)	brain edema	astrocyte	fluid percussion injury (FPI) induce	downregulated	31218751
19632	Rat	MALAT1	lncRNA	cadmium (Cd)	cadmium-induced toxicity	rats lung	cadmium (Cd) treatment	upregulated in the lung	30090506
19633	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	cell differentiation	differentiated BM-MSCs	lipopolysaccharide (LPS) treatment	"In hepatocytes differentiated from BM-MSCs, miR-217 was downregulated and lncRNA MALAT1 was upregulated. RIP analysis showed MALAT1 was physically associated with miR-217 and might function in the regulation of ZEB-1, further enhancing the expression of TERT so as to augment telomerase activity."	30658864
19634	Rat	MALAT1	lncRNA	aerobic exercise	chronic heart failure (CHF)	myocardial tissues	aerobic exercise training (AET) treatment	upregulated	33708967
19635	Rat	MALAT1	lncRNA	streptozocin (STZ)	diabetes-related microvascular complications	diabetic rats retinal endothelial cell	STZ treatment	upregulated	25356875
19636	Rat	MALAT1	lncRNA	streptozocin (STZ)	diabetic gastroparesis (DGP)	stomach	streptozocin (STZ) treatment	MALAT1 was upregulated in rat model of DGP	29317209
19637	Rat	MALAT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	rats renal tubular epithelial cells	streptozotocin treatment	upregulated	27964927
19638	Rat	MALAT1	lncRNA	angiotensin II (Ang II)	hypertension	rat vascular tissues	angiotensin II (Ang II) treatment	upregulated	31343412
19639	Rat	MALAT1	lncRNA	hypoxia	hypoxia-induced injury	PC12 cells	hypoxia treatment	upregulated	29360503
19640	Rat	MALAT1	lncRNA	H2O2	myocardial infarction (MI)	H9C2 cells	H2O2 treatment	upregulated	30841417
19641	Rat	MALAT1	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	Hypoxia significantly enhanced the expression of Malat1. Knockdown of Malat1 aggravated hypoxia-induced H9c2 cell injury.	30843674
19642	Rat	MALAT1	lncRNA	isoproterenol	myocardial infarction (MI)	heart tissues	isoproterenol (ISO) treatment	LncRNA MALAT1 was upregulated in the myocardial infarction areas.	30536615
19643	Rat	MALAT1	lncRNA	isoproterenol	myocardial infarction (MI)	rat H9C2 cells	isoproterenol (ISO) treatment	lncRNA MALAT1 protected cardiomyocytes from ISO-induced apoptosis by sponging miR-558 thus promoting ULK1-dependent autophagy.	30536615
19644	Rat	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cardiomyocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31823095
19645	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated	31027517
19646	Rat	MALAT1	lncRNA	myricetin	myocarditis	LPS-treated H9c2 cells	myricetin treatment	upregulated	31027517
19647	Rat	MALAT1	lncRNA	brachial plexus avulsion	neuropathic pain (NP)	spinal cords	brachial plexus avulsion induce	downregulated	31114309
19648	Rat	MALAT1	lncRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	L4©\L6 dorsal spinal cord of rats	chronic constriction injury (CCI) induce	upregulated	30740678
19649	Rat	MALAT1	lncRNA	sevoflurane (SEV)	neurotoxicity	rat hippocampal tissues	Sevoflurane exposure treatment	"Suppression of MALAT1 can reduce the apoptosis of hippocampal neurons induced by sevoflurane anesthesia, improve the capability of spatial learning, and memory function and alleviate the loss of hippocampal nerve cells in developing rats"	31190336
19650	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	rat chondrocytes	lipopolysaccharide (LPS) treatment	MALAT1 was upregulated in chondrocytes induced by LPS.	31472145
19651	Rat	MALAT1	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	Isolated rat chondrocytes	lipopolysaccharide (LPS) treatment	"In OA patients and OA cell model, the expression of MALAT1 and PI3K was clearly reduced. Following with MALAT1 silencing, the generation of Cyclooxygenase-2 (COX-2), Interleukin-6 (IL-6) and Matrix metallopeptidase-13 (MMP-13) were promoted, while the level of type II collagen (COL2) was inhibited. Moreover, MALAT1 silencing caused a significant reduction in the proliferative rate of LPS-treated chondrocytes through inducing apoptosis."	31472145
19652	Rat	MALAT1	lncRNA	green tea polyphenols (GTP)	oxidative stress	PC12 cells	PC12 cells were preincubated with GTP prior to H2O2 stimulation	upregulated	31456460
19653	Rat	MALAT1	lncRNA	uterine perfusion pressure (RUPP)	pregnancy-induced hypertension (PIH)	aortic endothelial cells (ECs)	uterine perfusion pressure (RUPP) treatment	upregulated	32351607
19654	Rat	MALAT1	lncRNA	resveratrol	pulmonary embolism	pulmonary embolism (PE) induced heart tissues	resveratrol (Res) treatment	downregulated	31573048
19655	Rat	MALAT1	lncRNA	high glucose (HG)	pyroptosis	H9c2 cells	high glucose (HG) treatment	"MALAT1 mRNA expression levels were significantly increased, whereas miR-141-3p expression levels were significantly decreased in HG-treated H9C2 cells compared with the NG group."	33576445
19656	Rat	MALAT1	lncRNA	sinapic acid (SA)	pyroptosis	macrophages	sinapic acid (SA) treatment	downregulated	29095793
19657	Rat	MALAT1	lncRNA	ginkgo biloba extract (GBE)	renal injury	methotrexate (MTX)-induce rat renal tissues	Ginkgo biloba extract (GB) treatment	downregulated	31684190
19658	Rat	MALAT1	lncRNA	methotrexate (MTX)	renal injury	renal tissues	Methotrexate (MTX) treatment	upregulated	31684190
19659	Rat	MALAT1	lncRNA	cecal ligation and puncture (CLP)	sepsis	rats	cecal ligation and puncture (CLP) treatment	upregulated	29227823
19660	Rat	MALAT-1	lncRNA	IL-1¦Â	articular cartilage inflammation	primary articular chondrocytes culture	IL-1¦Â?treatmrnt	"In response to IL-1¦Â induction, articular chondrocytes showed reduced MALAT-1 expression; moreover, obvious cartilage injury was observed with decreased chondrocyte viability and Col II expression and elevated chondrocyte apoptosis, MMP-13 expression, and p-JNK expression."	31111559
19661	Rat	MALAT1EZH2	lncRNA	cecal ligation and puncture (CLP)	sepsis	Sprague-Dawley (SD) rats	cecal ligation and puncture (CLP) treatment	upregulated	28831768
19662	Rat	MALAT1EZH2	lncRNA	lipopolysaccharide (LPS)	sepsis	cardiac microvascular endothelial cells (CMVECs)	lipopolysaccharide (LPS) treatment	upregulated	28831769
19663	Rat	MANTIS	lncRNA	monocrotaline (MCT)	idiopathic pulmonary arterial hypertension	human umbilical vein endothelial cells	monocrotaline treatment	downregulated	28351900
19664	Rat	MEG3	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	upregulated	28731278
19665	Rat	MEG3	lncRNA	hypoxia	acute myocardial infarction (AMI)	rat cardiomyocyte-drived H9c2 cells	hypoxia	upregulated	28731278
19666	Rat	MEG3	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	"The expression levels of MEG3 and TRPV4 were significantly increased, whereas miR-325-3p expression levels were significantly decreased in hypoxic H9c2 cells compared with normoxic H9c2 cells."	33179099
19667	Rat	MEG3	lncRNA	oxygen glucose deprivation (OGD)	apoptosis	H9c2 cells	oxygen and glucose deprivation (OGD) induce treatment	upregulated	31184214
19668	Rat	MEG3	lncRNA	salvianolic acid B (Sal B)	apoptosis	hypoxia-induced H9c2 cells	?Salvianolic acid B (Sal-B) treatment	downregulated	31184214
19669	Rat	MEG3	lncRNA	high glucose (HG)	cardiomyocytes injury	Primary cultures of ventricular myocytes	high glucose (HG) treatment	The downregulated of MEG3 could attenuate cardiomyocytes injury and apoptosis induced by HG.	31539151
19670	Rat	MEG3	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral infarction (CI)	rat brain microvascular endothelial cells (RBMVECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	28634073
19671	Rat	MEG3	lncRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	brain tissues	middle cerebral artery occlusion (MCAO) induce	upregulated	30841460
19672	Rat	MEG3	lncRNA	N-acetyl-L-cysteine (NAC)	cirrhotic neuropathy	thiacetamide (TAA)-treated rats liver tissues and sciatic nerve	N-acetylcysteine (NAC) treatment	downregulated	31751619
19673	Rat	MEG3	lncRNA	thioacetamide (TAA)	cirrhotic neuropathy	liver tissues and sciatic nerve	thiacetamide (TAA) treatment	upregulated	31751619
19674	Rat	MEG3	lncRNA	streptozocin (STZ)	diabetes-related cognitive impairments	PC12 cells	streptozotocin (STZ) treatment	"Here, it was observed that MEG3 was significantly downregulated in STZ (streptozotocin)-induced diabetic rats"	33843209
19675	Rat	MEG3	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	rat kidney tissues	streptozotocin treatment	downregulated	31799068
19676	Rat	MEG3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	microvascular endothelial cells	high glucose (HG) treatment	DNMT1-mediated lncRNA MEG3 methylation accelerates endothelial-mesenchymal transition in diabetic retinopathy through the PI3K/Akt/mTOR signaling pathway	33284093
19677	Rat	MEG3	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal lesions	streptozotocin treatment	DNMT1-mediated lncRNA MEG3 methylation accelerates endothelial-mesenchymal transition in diabetic retinopathy through the PI3K/Akt/mTOR signaling pathway	33284093
19678	Rat	MEG3	lncRNA	hypoxia	hypoxia-induced injury	pheochromocytoma-12 (PC12) cell	hypoxia induce	upregulated	31392726
19679	Rat	MEG3	lncRNA	hypoxia	hypoxia-induced injury	PC12 cells	hypoxia treatment	MEG3 silencing suppresses hypoxia-induced PC12 cell injury by inhibiting TIMP2 promoter methylation.	31392726
19680	Rat	MEG3	lncRNA	hyperoxia	hypoxic/ischemic brain damage (HIBD)	PC12 cells	hypoxia treatment	Silencing MEG3 protects PC12 cells from hypoxic injury by targeting miR-21.	32050796
19681	Rat	MEG3	lncRNA	platelet-derived growth factor (PDGF)	intimal hyperplasia (IH)	vascular smooth muscle cell (VSMCs)	Platelet derived growth factor (PDGF)-BB treatment	PDGF-BB decreasedthe expression of MEG3	30156956
19682	Rat	MEG3	lncRNA	hypoxia	ischemic stroke (IS)	mouse brain tissues	middle cerebral artery occlusion (MCAO)	upregulated	31794744
19683	Rat	MEG3	lncRNA	platelet derived growth factor-BB (PDGF-BB)	ischemia/reperfusion (I/R) injury	vascular smooth muscle cell (VSMCs)	Platelet derived growth factor (PDGF)-BB treatment	downregulated	30156956
19684	Rat	MEG3	lncRNA	hypoxia	ischemic stroke (IS)	Sprague¨CDawley rats brain tissues	middle cerebral artery occlusion (MCAO) treatment	downregulated in brain tissues	27900677
19685	Rat	MEG3	lncRNA	thioacetamide (TAA)	liver cirrhosis	liver tissues	thiacetamide (TAA) treatment	upregulated	31751619
19686	Rat	MEG3	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat H9C2 cells	hypoxia induce	downregulated of MEG3 protects myocardial cells against I/R-induced apoptosis through miR-7-5p/PARP1 pathway	31366567
19687	Rat	MEG3	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	The myocardial A10 cell lines	hypoxia induce	upregulated	31389596
19688	Rat	MEG3	lncRNA	IL-1¦Â	osteoarthritis (OA)	rat chondrocytes	IL-1¦Â treatment	downregulated	31253047
19689	Rat	MEG3	lncRNA	nickel oxide nanoparticles (NiO NPs)	lung fibrosis	lung tissues	Nickel oxide nanoparticles (NiO NPs) treatment	downregulated	33547861
19690	Rat	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	rheumatoid arthritis (RA)	synovial tissues and fibroblast-like synoviocytes (FLSs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	30644097
19691	Rat	MEG3	lncRNA	complete freund's adjuvant (CFA)	rheumatoid arthritis (RA)	synovial tissues and fibroblast-like synoviocytes (FLSs)	complete Freund's adjuvant (CFA) treatment	downregulated	30644097
19692	Rat	MEG3	lncRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	chondrocyte	lipopolysaccharide (LPS) treatment	MEG3 was downregulated evidently in lipopolysaccharide (LPS)-treated chondrocyte. upregulated MEG3 resulted in an increase the level of Ki67.	31411001
19693	Rat	MEG3	lncRNA	lithium chloride and pilocarpine	temporal lobe epilepsy (TLE)	hippocampal neuronal	lithium chloride and pilocarpine treatment	"MEG3 reduced proinflammatory cytokines, oxidative stress, and apoptosis rate of hippocampal neuron and enhanced cell viability through the activation of the PI3K/AKT/mTOR pathway in SREDs and rats with TLE."	33149593
19694	Rat	MEG3	lncRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	ulcerative colitis (UC)	colon tissues	"2, 4, 6-Trinitrobenzenesulfonic acid solution (TNBS) treatment"	downregulated	33394187
19695	Rat	MHRT	lncRNA	H2O2	cardiomyocytes against H2O2-Induced Apoptosis	cardiac myocytes	H2O2 treatment	upregulated	26759697
19696	Rat	Mhrt	lncRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced dysfunction	cardiomyocytes	doxorubicin (DOX) treatment	upregulated	27261628
19697	Rat	MIAT	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33745924
19698	Rat	MIAT	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocytes isolated from 1 to 2-day-old Wistar rats	angiotensin II (Ang II) treatment	upregulated	29157986
19699	Rat	MIAT	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocytes	angiotensin II (Ang II) treatment	MIAT was upregulated and miR-93 was downregulated in AngII-treated cardiomyocytes.	29673400
19700	Rat	MIAT	lncRNA	isoprenaline	cardiac hypertrophy	rat primary cardiomyocytes	isoprenaline induction	upregulated	33013286
19701	Rat	MIAT	lncRNA	isoproterenol	cardiac hypertrophy	Neonatal rat ventricular myocytes (NRVMs)	isoproterenol (ISO) treatment	upregulated	29786749
19702	Rat	MIAT	lncRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	primary cultured cerebral microvascular endothelial cell (CMEC)	oxygen glucose deprivation (OGD) treatment	upregulated	31628679
19703	Rat	MIAT	lncRNA	oxygen glucose deprivation (OGD)	cerebral microvascular endothelial cell (CMEC) injury	cerebral microvascular endothelial cell (CMEC)	oxygen glucose deprivation (OGD) treatment	upregulated	31628679
19704	Rat	MIAT	lncRNA	glucose	diabetic cardiomyopathy (DCM)	neonatal cardiomyocytes of rats	treat with high glucose	upregulated	28703801
19705	Rat	MIAT	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	rat retinal M¨¹ller cells (rMC-1) cells	high glucose	upregulated	28246353
19706	Rat	MIAT	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	M¨¹ller cells	high glucose treatment	upregulated	31344482
19707	Rat	MIAT	lncRNA	berberine (BBR)	cardiac hypertrophy	rat heart tissues	berberine (BBR) treatment	downregulated	31612504
19708	Rat	MIAT	lncRNA	hypoxia	hypoxic/ischemic injury	striatal tissues	hypoxia treatment	lncRNA MIAT was downregulated in striatal tissues of neonatal rats in HI group.	30563429
19709	Rat	MIAT	lncRNA	low selenium	Kashin-Beck Disease (KBD)	serum	low selenium and/or T-2 toxin treatment	"LncRNA MIAT regulated by selenium and T-2 toxin increases NF-¦ÊB-p65 activation, promoting the progress of Kashin-Beck Disease"	33233966
19710	Rat	MIAT	lncRNA	T-2 toxin	Kashin-Beck Disease (KBD)	serum	low selenium and/or T-2 toxin treatment	"LncRNA MIAT regulated by selenium and T-2 toxin increases NF-¦ÊB-p65 activation, promoting the progress of Kashin-Beck Disease"	33233966
19711	Rat	MIAT	lncRNA	electrode	cardiac fibrosis	atrium tissues of rats	electrode stimulation	upregulated	32130618
19712	Rat	MIAT	lncRNA	catechin	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	catechin treatment	Catechin relieved H/R-induced myocardial cell apoptosis through regulating CREB/lncRNA MIAT/Akt/Gsk-3¦Â pathway.	31955523
19713	Rat	MIAT	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia induce	"targeting MIAT remarkably enhanced H9c2 cell viability, decreased H/R-induced cell apoptosis and LDH leakage and significantly decreased I/R-induced myocardial infarct size, reduced myocardial apoptosis and enhanced the heart function."	30971184
19714	Rat	MIAT	lncRNA	hypoxic/ischemic	neonatal cerebral palsy	striatal tissues	hypoxic-ischemic (HI) treatment	"MIAT overexpression reduced apoptosis of Neuro2A cells through miR-211/GDNF, which relieved HI injury of neonatal rats."	30563429
19715	Rat	MIAT	lncRNA	huo xue tong luo capsule (HXTL capsule)	osteogenesis	Rat bone marrow mesenchymal stem cells (rMSCs)	Huo Xue Tong Luo capsule (HXTL capsule) treatment	downregulated	30970282
19716	Rat	MIAT	lncRNA	sepsis	renal injury	?kidney tissues	cecal ligation puncture induced sepsis treatment	lincRNA-MIAT increased in the sepsis-induced kidney injury model	31858562
19717	Rat	MIAT	lncRNA	high glucose (HG)	renal tubules injury	tubules	high glucose treatment	downregulated	26551455
19718	Rat	Mirt1	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	diabetic rats heart tissues	"The rats were fixed in supine position, intubated through right common carotid artery, and connected with a pressure transducer."	upregulated	30611788
19719	Rat	Mirt2	lncRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	33199822
19720	Rat	Mirt2	lncRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia reoxygenation (H/R) treatment	Mirt2 participated in the regulation of MI through the miR-764/PDK1 axis.	33199822
19721	Rat	Mirt2	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC12 cell	lipopolysaccharide (LPS) treatment	?lncRNA Mirt2 was upregulated in LPS-stimulated PC12 cells. Overexpression of lncRNA Mirt2 protected PC12 cells against LPS-induced injuries.	31309444
19722	Rat	MRAK134679	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	Sprague-Dawley (SD) rats	angiotensin II (Ang II) treatment	upregulated	24817929
19723	Rat	MRAK154943	lncRNA	ischemia	stroke	rat cortical tissues	focal ischemia treatment	upregulated	24063527
19724	Rat	MRAK159688	lncRNA	ischemia	stroke	rat cortical tissues	focal ischemia treatment	upregulated	24063527
19725	Rat	MRNR026574	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	Sprague-Dawley (SD) rats	angiotensin II (Ang II) treatment	upregulated	24817929
19726	Rat	MRuc008hvl	lncRNA	subarachnoid hemorrhage (SAH)	early brain injury (EBI)	brain	subarachnoid hemorrhage (SAH) treatment	upregulated	25777551
19727	Rat	MSTRG.11559	lncRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
19728	Rat	MSTRG.11560	lncRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
19729	Rat	MSTRG.15160	lncRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
19730	Rat	MSTRG.199	lncRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
19731	Rat	MSTRG.30244	lncRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	downregulated	33193637
19732	Rat	MSTRG.34031.1	lncRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
19733	Rat	MSTRG.4076.1	lncRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
19734	Rat	MSTRG.48686.2	lncRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
19735	Rat	MSTRG.89940.1	lncRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	upregulated	33343808
19736	Rat	N1LR	lncRNA	ischemia/reperfusion (I/R) 	ischemia/reperfusion (I/R) injury	brain tissues	ischemia/reperfusion (I/R) treatment	upregulated	27844279
19737	Rat	NEAT1	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	upregulated	30950059
19738	Rat	NEAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	rat mesangial cells (RMCs)	lipopolysaccharide (LPS) treatment	upregulated	29669307
19739	Rat	NEAT1	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	PC-12 cells	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	31014193
19740	Rat	NEAT1	lncRNA	phenylephrine (PE)	cardiac hypertrophy	primary cardiomyocytes; myocardium	phenylephrine (PE) treatment	NEAT1 was highly expressed in myocardium of rats with cardiac hypertrophy and PE-induced primary cardiomyocytes	32096186
19741	Rat	NEAT1	lncRNA	hypoxia	cardiomyocyte apoptosis	H9c2 cardiomyocyte cell line	hypoxia induce	upregulated	31410172
19742	Rat	NEAT1	lncRNA	arsenic trioxide (ATO)	cardiac injury	H9c2 cells	arsenic trioxide (As2O3) treatment	NEAT1 regulated the expression of inflammatory factors to protect cardiomyocytes from As2O3 damage by inhibiting miR-124/NF-kappa B signaling pathway.	32096187
19743	Rat	NEAT1	lncRNA	doxorubicin (DOX)	cardiotoxicity	H9c2 cells	doxorubicin (Dox)?treatment	upregulation of miRNA let-7f-2-3p by long noncoding RNA (lncRNA) NEAT1 inhibits exportin-1 (XPO1)-mediated nuclear export of hematopoietic-substrate-1 associated protein X-1 (HAX-1) in Dox-induced cardiotoxicity.	31570982
19744	Rat	NEAT1	lncRNA	gastrodin (GAS)	cerebral ischemia/reperfusion (I/R) injury	OGD/R-treated rat primary cortical neurons	gastrodin (GAS) treatment	downregulated	33839999
19745	Rat	NEAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Rat primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33839999
19746	Rat	NEAT1	lncRNA	nimodipine	cognitive impairment	brain tissues	nimodipine treatment	Nimodipine can improve CI after SAH in rats through the lncRNA NEAT1/miR-27a/MAPT axis.	32606599
19747	Rat	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	rat glomerular mesangial cell line (HBZY-1)	high glucose (HG) treatment	upregulated	32721950
19748	Rat	NEAT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozocin (STZ) treatment	NEAT1 was significantly increased in streptozotocin-induced DN rat models	30549040
19749	Rat	NEAT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	rat kidney tissues	streptozotocin (STZ) treatment	upregulated	30549040
19750	Rat	NEAT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozocin (STZ) treatment	NEAT1 in the kidney was upregulated in the STZ-induced DN rats.	32721950
19751	Rat	NEAT1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	upregulated	30515796
19752	Rat	NEAT1	lncRNA	IL-1¦Â	epilepsy	CTX-TNA cells	IL-1¦Â treatment	upregulated	31948324
19753	Rat	NEAT1	lncRNA	ischemia/reperfusion (I/R) 	ischemia/reperfusion (I/R) injury	PC12 cells	ischemia/reperfusion (I/R) treatment	LncRNA NEAT1 aggravates cerebral I/R injury by suppressing miR-874-3p expression.	32329323
19754	Rat	NEAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	Rat primary microglial cell culture	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	YY1-induced upregulation of NEAT1 contributed to the OGD/R injury and neuroinflammation damage of microglial cells via Wnt/¦Â-catenin signaling pathway	31286366
19755	Rat	NEAT1	lncRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	H2O2 treatment	upregulated	31347173
19756	Rat	NEAT1	lncRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H2O2 treatment	NEAT1 contributed to M-I/R injury via the modulation of miR-495-3p and MAPK6.	31347173
19757	Rat	NEAT1	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	BRL3A cell	free fatty acid (FFA) treatment	upregulated	31957704
19758	Rat	NEAT1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	brain tissues	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	29575151
19759	Rat	NEAT1	lncRNA	hypoxia	reperfusion injury	rat cardiomyocytes	hypoxia treatment	downregulated	32826883
19760	Rat	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	H9c2 cells	lipopolysaccharide (LPS) treatment	lncRNA NEAT1 accelerated apoptosis and inflammation in LPS-stimulated H9c2 cells via sponging miR-590-3p.	32855700
19761	Rat	NEAT1	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharides (LPS) treatment	High NEAT1 levels can increase LPS-induced injury in PC-12 cells through the miR-29a/BCL2L11 pathway.	32776916
19762	Rat	NKILA	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischaemic injury	H9C2 cells	hypoxia/reoxygenation (H/R) treatment	NKILA enhanced the expression of myocardin via inhibiting the NF-¦ÊB signalling pathway and preventing cell apoptosis and the inflammatory response of cardiomyocytes.	31838061
19763	Rat	NKILA	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 rat myoblasts	hypoxia induce	downregulated	31838061
19764	Rat	NONRATT002335	lncRNA	bile duct ligation (BDL)	jaundice	Sprague-Dawley rats	the common bile duct was located and ligated using 4-0 silk at two points anterior to the pancreas and posterior to the hilum of the liver	upregulated	29285317
19765	Rat	NONRATT004911.2	lncRNA	liraglutide	type 2 diabetes mellitus (T2DM)	pancreases	Liraglutide treatment	downregulated	32238798
19766	Rat	NONRATT005195.2	lncRNA	adriamycin (ADR)	chronic glomerulonephritis (CGN)	glomerular tissues	adriamycin (ADR) treatment	downregulated	30458286
19767	Rat	NONRATT008453.2	lncRNA	dibutyl phthalate (DBP)	hypospadias	genital tubercle (GT)	dibutyl phthalate (DBP) treatment	"Furthermore, out of the 103 putative autophagy©\related lncRNAs, NONRATT008453.2 was the highest expressed lncRNA in the DBP©\treated group compared with the controls."	33452730
19768	Rat	NONRATT009003.2	lncRNA	adriamycin (ADR)	chronic glomerulonephritis (CGN)	glomerular tissues	adriamycin (ADR) treatment	downregulated	30458286
19769	Rat	NONRATT009208.2	lncRNA	adriamycin (ADR)	chronic glomerulonephritis (CGN)	glomerular tissues	adriamycin (ADR) treatment	downregulated	30458286
19770	Rat	NONRATT009275.2	lncRNA	adriamycin (ADR)	chronic glomerulonephritis (CGN)	glomerular tissues	adriamycin (ADR) treatment	upregulated	30458286
19771	Rat	NONRATT009530.2	lncRNA	adriamycin (ADR)	chronic glomerulonephritis (CGN)	glomerular tissues	adriamycin (ADR) treatment	upregulated	30458286
19772	Rat	NONRATT010788.2	lncRNA	lithium chloride and pilocarpine	status epilepticus (SE)	hippocampus	lithium/pilocarpine treatment		31738000
19773	Rat	NONRATT015587.2	lncRNA	metformin (Met)	pulmonary arterial hypertension (PAH)	PAH rat pulmonary arterial tissues	metformin treatment	downregulated	31060005
19774	Rat	NONRATT015587.2	lncRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	rat pulmonary arterial tissues	monocrotaline treatment	upregulated	31060005
19775	Rat	NONRATT015614.2	lncRNA	liraglutide	type 2 diabetes mellitus (T2DM)	pancreases	Liraglutide treatment	downregulated	32238798
19776	Rat	NONRATT018085	lncRNA	bile duct ligation (BDL)	jaundice	Sprague-Dawley rats	the common bile duct was located and ligated using 4-0 silk at two points anterior to the pancreas and posterior to the hilum of the liver	upregulated	29285317
19777	Rat	NONRATT018630.2	lncRNA	liraglutide	type 2 diabetes mellitus (T2DM)	pancreases	Liraglutide treatment	downregulated	32238798
19778	Rat	NONRATT021972	lncRNA	high glucose and free fatty acids (HG-FFA)	diabetic cardiac autonomic neuropathy (DCAN)	sympathetic neuronal-like PC12 cells	high glucose (HG) and high FFAs (HF) treatment	upregulated	27519467
19779	Rat	NONRATT021972	lncRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	rats DRG	intraperitoneal injection of STZ with 30 mg/kg treatment	upregulated in	26742527
19780	Rat	NONRATT023402.2	lncRNA	levodopa	levodopa-induced dyskinesia (LID)	PC1 2cells	Levodopa treatment	downregulated	31929116
19781	Rat	NONRATT024782.2	lncRNA	liraglutide	type 2 diabetes mellitus (T2DM)	pancreases	Liraglutide treatment	upregulated	32238798
19782	Rat	NONRATT025388	lncRNA	bile duct ligation (BDL)	jaundice	Sprague-Dawley rats	the common bile duct was located and ligated using 4-0 silk at two points anterior to the pancreas and posterior to the hilum of the liver	downregulated	29285317
19783	Rat	NONRATT025409	lncRNA	bile duct ligation (BDL)	jaundice	Sprague-Dawley rats	the common bile duct was located and ligated using 4-0 silk at two points anterior to the pancreas and posterior to the hilum of the liver	downregulated	29285317
19784	Rat	NONRATT025415	lncRNA	bile duct ligation (BDL)	jaundice	Sprague-Dawley rats	the common bile duct was located and ligated using 4-0 silk at two points anterior to the pancreas and posterior to the hilum of the liver	downregulated	29285317
19785	Rat	NONRATT026027.2	lncRNA	liraglutide	type 2 diabetes mellitus (T2DM)	pancreases	Liraglutide treatment	downregulated	32238798
19786	Rat	NONRATT026805.2	lncRNA	adriamycin (ADR)	chronic glomerulonephritis (CGN)	glomerular tissues	adriamycin (ADR) treatment	upregulated	30458286
19787	Rat	NONRATT029906.2	lncRNA	liraglutide	type 2 diabetes mellitus (T2DM)	pancreases	Liraglutide treatment	upregulated	32238798
19788	Rat	NR_002155.1	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	29749545
19789	Rat	NR_024118	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac	angiotensin II (Ang II) treatment	downregulated	25979571
19790	Rat	NR_024118	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	Sprague-Dawley (SD) rats	angiotensin II (Ang II) treatment	upregulated	24817929
19791	Rat	NR_024118	lncRNA	losartan	cardiac fibrosis	heart tissues	Losartan treatment	losartan (AT1 blocker) nearly completely reversed the decrease of lncRNA-NR024118 and partly reversed the decrease of Cdkn1c induced by Ang II in adult rat cardiac fibroblasts	25979571
19792	Rat	NR_026689	lncRNA	NNK	lung cancer	lung tissues	NNK treatment	upregulated	26908441
19793	Rat	NR_027943	lncRNA	methamphetamine (METH)	neurotoxicity	prefrontal cortical neurons	Methamphetamine treatment	upregulated	28619521
19794	Rat	NR_031896.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
19795	Rat	NR_038323	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinas tissues	streptozotocin treatment	upregulated	31430717
19796	Rat	NR_046239.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
19797	Rat	NR_046246.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
19798	Rat	NR_110713	lncRNA	methamphetamine (METH)	neurotoxicity	prefrontal cortical neurons	Methamphetamine treatment	upregulated	28619521
19799	Rat	Nrf2	lncRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced dysfunction	cardiomyocytes	doxorubicin (DOX) treatment	upregulated	27261628
19800	Rat	Nup214	lncRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	upregulated	31734292
19801	Rat	OGRU	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	M¨¹ller cells	high glucose (HG) treatment	DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals. Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas	33762162
19802	Rat	OIP5-AS1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose treatment	OIP5-AS1 overexpression promotes viability and inhibits high glucose-induced oxidative stress of cardiomyocytes by targeting microRNA-34a/SIRT1 axis in diabetic cardiomyopathy.	33380310
19803	Rat	Oip5-as1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Oip5-as1 suppresses miR-29a leading to activation of the SIRT1/AMPK/PGC1¦Á pathway, which attenuates mitochondria-mediated apoptosis during MI/R injury"	32468629
19804	Rat	OIP5-AS1	lncRNA	freund¡¯s complete adjuvant (FCA)	rheumatoid arthritis (RA)	synovial tissues	Freund¡¯s complete adjuvant (FCA) treatment	lncRNA OIP5-AS1 may mitigate RA progression through the miR-448-PON1 axis and through the inactivation of the TLR3-NF-¦ÊB signalling pathway.	32770578
19805	Rat	PACER	lncRNA	dexmedetomidine (DEX)	chronic obstructive pulmonary disease (COPD)	primary rat alveolar epithelial cells	dexmedetomidine (Dex) treatment	"DEX induction decreased PACER expression, and proliferative and migratory abilities in primary rat alveolar epithelial cells harvested from COPD rats."	33378047
19806	Rat	PEAMIR	lncRNA	particulate matter (PM2.5)	ischemia/reperfusion (I/R) injury	H9c2 cells	PM2.5 exposure treatment	LncRNA NR_136400 Suppresses Cell Proliferation and Invasion by Acting as a ceRNA of TUSC5 That Is Modulated by miR-8081 in Osteosarcoma	32100595
19807	Rat	PEBP1P2	lncRNA	platelet derived growth factor-BB (PDGF-BB)	proliferative vascular diseases	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor BB (PDGF-BB) treatment	downregulated	32916601
19808	Rat	PEG10	lncRNA	H2O2	spinal cord injury (SCI)	rat PC-12 cells	H2O2 treatment	Knockdown PEG10 deteriorated H2O2-injury.	31835090
19809	Rat	PEG10	lncRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	H2O2 treatment	Knockdown PEG10 remitted H2O2-injury of PC-12 cells by targeting miR-34a-5p/TLX.	31835090
19810	Rat	PTENP1	lncRNA	lipopolysaccharide (LPS)	cardiac dysfunction	H9C2 cells	lipopolysaccharide (LPS) treatment	upregulated	33341669
19811	Rat	PTENP1	lncRNA	matrine	cardiac dysfunction	LPS-treated H9C2 cells	matrine treatment	downregulated	33341669
19812	Rat	PTENP1	lncRNA	matrine	cardiac dysfunction	H9c2 cells	Matrine treatment	downregulated	33341669
19813	Rat	PVT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute ischemic stroke (AIS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32827544
19814	Rat	PVT1	lncRNA	curcumin (Cur)	acute kidney injury (AKI)	NRK cells	curcumin treatment	Curcumin decreased PVT1 expression in LPS-induced septic acute kidney tissues and reduced LPS-induced septic acute kidney injury in mice.	31972207
19815	Rat	PVT1	lncRNA	respiratory syncytial virus (RSV)	asthma	Sprague-Dawley rat	respiratory syncytial virus (RSV) infection treatment	upregulated	28510638
19816	Rat	PVT1	lncRNA	doxorubicin (DOX)	cardiotoxicity	H9c2 cells	Doxorubicin (DOX) treatment	Doxorubicin promotes H9c2 apoptosis and increased PVT1 expression in cardiomyocytes.	31786333
19817	Rat	PVT1	lncRNA	streptozocin (STZ)	diabetes mellitus (DM)	rat insulinoma (INS-1) cells	streptozotocin (STZ) treatment	Silencing of lncRNA PVT1 ameliorates streptozotocin-induced pancreatic ¦Â cell injury and enhances insulin secretory capacity by regulating miR-181a-5p	32758099
19818	Rat	PVT1	lncRNA	danggui buxue tang (DBT)	diabetic nephropathy (DN)	rats	danggui buxue tang (DBT) treatment	downregulated	28861164
19819	Rat	PVT1	lncRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (DOX) treatment	Doxorubicin promotes H9c2 apoptosis and increased PVT1 expression in cardiomyocytes.	31786333
19820	Rat	PVT1	lncRNA	lithium chloride and pilocarpine	epilepsy	hippocampus tissues	lithium chloride-pilocarpine treatment	upregulated	30805931
19821	Rat	PVT1	lncRNA	complete freund's adjuvant (CFA)	rheumatoid arthritis (RA)	synovial tissues and RA fibroblast-like synoviocyte (RA-FLS)	complete Freund¡¯s adjuvant (CFA) treatment	upregulated	31303891
19822	Rat	RGD1566344	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32424772
19823	Rat	RGD1566344	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"In this study, we found that RGD1566344 levels were elevated in the ischemic infarct and penumbra regions 12 h after middle cerebral artery occlusion/reperfusion (MCAO/R) in male mice and in PC12 cells with oxygen glucose deprivation/reperfusion (OGD/R)"	32424772
19824	Rat	Rian	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	upregulated	32187165
19825	Rat	RMRP	lncRNA	abdominal aortic coarctation	cardiac fibrosis	heart tissues	abdominal aortic banding treatment	lncRNA RMRP expression was upregulated in the presence of cardiac fibrosis in an abdominal aortic banding-treated rat model.	31485650
19826	Rat	RMRP	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblast	angiotensin II (Ang II) treatment	"Treatment with angiotensin II increased RMRP expression in cardiac fibroblasts, while the knockdown of RMRP by small-interfering RNA inhibited cardiac fibroblast proliferation, differentiation and collagen accumulation."	31485650
19827	Rat	RMRP	lncRNA	hypoxia	myocardial injury	H9c2 cells	hypoxia exposure	LncRNA RMRP accelerates hypoxia-induced injury by targeting miR-214-5p in H9c2 cells.	31839421
19828	Rat	RMRP	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	The H9c2 cardiomyocytes	hypoxia induce	upregulated	30551524
19829	Rat	RMRP	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia treatment	Hypoxia promoted the expression of RMRP in H9c2 cells.	30551524
19830	Rat	Rn50_X_0711.1	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
19831	Rat	RNF7	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblasts	angiotensin II (Ang II) treatment	RNF7 promotes the cardiac fibrosis in rat model via miR-543/THBS1 axis and TGF¦Â1 activation.	31913855
19832	Rat	rno_circ_0000064	circRNA	salidroside (SAL)	ischemia/reperfusion (I/R) injury	rat heart	salidroside (SAL) treatment	Sal treatment attenuated autophagy by up-regulating the expression of hsa_circ_0000064 (circ-0000064) and Rapamycin (RAPA) treatment abolished it	32858179
19833	Rat	rno_circ_0002074	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19834	Rat	rno_circ_0002322	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19835	Rat	rno_circ_0002640	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19836	Rat	rno_circ_0003331	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19837	Rat	rno_circ_0004153	circRNA	iohexol	contrast-induced acute kidney injury (CIAKI)	Renal tissue	"Animals were dehydrated for 48 h and then underwent furosemide (10 mL/kg; Harvest Pharmaceutical, Shanghai, China) injection 30 min before administration of iohexol (15 mL/kg, group CI-AKI; iodine, 350 mg/mL; GE Healthcare, Shanghai, China) or 0.9% normal saline (15 mL/kg, control group)."	circRNA circ_0004153 was significantly upregulated in Contrast-induced acute kidney injury (CI-AKI).	31234008
19838	Rat	rno_circ_0004699	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19839	Rat	rno_circ_0004849	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19840	Rat	rno_circ_0004938	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19841	Rat	rno_circ_0005139	circRNA	2-imidazolidinethione	anorectal malformations (ARM)	Intestinal epithelial cells; IECs and anorectal tissues	2-imidazolidinethione treatment	"Rno_circ_0005139 influences cell proliferation and apoptosis by acting as a miR-324-3p sponge, thereby downregulating Wnt5a in ARM."	32848333
19842	Rat	rno_circ_0005972	circRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	upregulated	31923741
19843	Rat	rno_circ_0006385	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19844	Rat	rno_circ_0006567	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19845	Rat	rno_circ_0007717	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19846	Rat	rno_circ_0008082	circRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19847	Rat	rno_circ_001372	circRNA	propofol (PPF)	propofol-induced neurotoxicity and neuroinflammation	brain tissues; PC-12 cells	propofol treatment	The propofol anesthesia decreases the levels of rno_circ_001372 in vitro and vivo	32506974
19848	Rat	rno_circ_001555	circRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	29706607
19849	Rat	rno_circ_002948	circRNA	laminectomy plus contusion	spinal cord injury (SCI)	spinal cord	laminectomy plus contusion treatment	downregulated	30756390
19850	Rat	rno_circ_003593	circRNA	Malva sylvestris L. (MS)	ischemic heart disease (IHD)	heart sissues	Malva sylvestris L. (MS) treatment	We noted that rat_circ_003593 (circ003593) was upregulated by I/ R injury and downregulated by MS pre-treatment.	33101012
19851	Rat	rno_circ_004806	circRNA	lipopolysaccharide (LPS)	sepsis	aortic tissues	lipopolysaccharide (LPS) treatment	upregulated	32452125
19852	Rat	rno_circ_004930	circRNA	lipopolysaccharide (LPS)	sepsis	aortic tissues	lipopolysaccharide (LPS) treatment	downregulated	32452125
19853	Rat	rno_circ_00534	circRNA	laminectomy plus contusion	spinal cord injury (SCI)	spinal cord	laminectomy plus contusion treatment	downregulated	30756390
19854	Rat	rno_circ_005442	circRNA	kaempferol	depression	hippocampus	Kaempferol (Kae) treatment	downregulated	31898506
19855	Rat	rno_circ_0054633	circRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	32950633
19856	Rat	rno_circ_005564	circRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	rats lung tissues	lipopolysaccharide (LPS) treatment	dysregulated	28864418
19857	Rat	rno_circ_006096	circRNA	laminectomy plus contusion	spinal cord injury (SCI)	spinal cord	laminectomy plus contusion treatment	downregulated	30756390
19858	Rat	rno_circ_0062389	circRNA	hypoxia/reoxygenation (H/R)	heart failure (HF)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	Silencing circ_0062389 alleviates cardiomyocyte apoptosis in heart failure rats via modulating TGF-¦Â1/Smad3 signaling pathway	32949699
19859	Rat	rno_circ_008634	circRNA	lipopolysaccharide (LPS)	sepsis	aortic tissues	lipopolysaccharide (LPS) treatment	downregulated	32452125
19860	Rat	rno_circ_008728	circRNA	lipopolysaccharide (LPS)	sepsis	aortic tissues	lipopolysaccharide (LPS) treatment	upregulated	32452125
19861	Rat	rno_circ_010219	circRNA	lipopolysaccharide (LPS)	sepsis	aortic tissues	lipopolysaccharide (LPS) treatment	downregulated	32452125
19862	Rat	rno_circ_010489	circRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	rats lung tissues	lipopolysaccharide (LPS) treatment	dysregulated	28864418
19863	Rat	rno_circ_010684	circRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	29706607
19864	Rat	rno_circ_011426	circRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	rats lung tissues	lipopolysaccharide (LPS) treatment	dysregulated	28864418
19865	Rat	rno_circ_013017	circRNA	laminectomy plus contusion	spinal cord injury (SCI)	spinal cord	laminectomy plus contusion treatment	downregulated	30756390
19866	Rat	rno_circ_013981	circRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	29706607
19867	Rat	rno_circ_014900	circRNA	kaempferol	depression	hippocampus	Kaempferol (Kae) treatment	upregulated	31898506
19868	Rat	rno_circ_015513	circRNA	laminectomy plus contusion	spinal cord injury (SCI)	spinal cord	laminectomy plus contusion treatment	downregulated	30756390
19869	Rat	rno_circ_016014	circRNA	lipopolysaccharide (LPS)	sepsis	aortic tissues	lipopolysaccharide (LPS) treatment	upregulated	32452125
19870	Rat	rno_circ_017418	circRNA	lipopolysaccharide (LPS)	sepsis	aortic tissues	lipopolysaccharide (LPS) treatment	downregulated	32452125
19871	Rat	rno_circ_017759	circRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	29706607
19872	Rat	rno_circ_19423	circRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	rats lung tissues	lipopolysaccharide (LPS) treatment	dysregulated	28864418
19873	Rat	rno_circ_30664	circRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	rats lung tissues	lipopolysaccharide (LPS) treatment	dysregulated	28864418
19874	Rat	rno_circ_68566	circRNA	ischemia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	ischemia buffer treatment	circ-0068566 inhibited the development of myocardial ischemia reperfusion injury by regulating hsa-miR-6322/PARP2 signal pathway.	32633392
19875	Rat	rno-let-7	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	endotoxin treatment	upregulated	26137246
19876	Rat	rno-let-7	miRNA	"2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)"	colorectal cancer (CRC)	rat tumors; colonic mucosa tissues	"2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) treatment"	the let-7/c-Myc/Lin28 axis is dysregulated in heterocyclic amine-induced colon carcinogenesis	22641368
19877	Rat	rno-let-7	miRNA	pilocarpine	epilepsy	adult male rats brain tissue and heart tissue	50 days of pilocarpine treatment	downregulated in heart tissue	24530830
19878	Rat	rno-let-7	miRNA	curcumin (Cur)	neuroinflammation	neuroinflammatory rat	"co- of both compounds (Cur or VPA, 200 mg/kg) for 4 weeks treatment"	upregulated	25374508
19879	Rat	rno-let-7a	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	lung tissues	sevoflurane treatment	downregulated	28617947
19880	Rat	rno-let-7a	miRNA	infarct the LV free wall	acute myocardial infarction (AMI)	heart tissues	left anterior descending coronary artery (LAD) was ligated using a 5/0 silk thread treatment	downregulated	24758696
19881	Rat	rno-let-7a	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal rat ventricular myocytes (NRVMs)	angiotensin II (Ang II) treatment	downregulated	28123343
19882	Rat	rno-let-7a	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	downregulated	24304932
19883	Rat	rno-let-7a	miRNA	vein graft model	intimal hyperplasia (IH)	rat	vein graft treatment	downregulated	24953987
19884	Rat	rno-let-7a	miRNA	enoxacin	major depressive disorder (MDD)	rats	with 10 or 25 mg/kg enoxacin for 1 week treatment	upregulated	24575053
19885	Rat	rno-let-7a	miRNA	hypoxia	myocardial ischaemic injury	neonatal rat ventricular myocytes	hypoxia treatment	downregulated	26655604
19886	Rat	rno-let-7a	miRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	dysregulated	24517225
19887	Rat	rno-let-7a	miRNA	rotenone (ROT)	parkinson's disease (PD)	striatum of parkinsonian rats	rotenone exposure treatment	upregulated	30267378
19888	Rat	rno-let-7a	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
19889	Rat	rno-let-7a-1	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
19890	Rat	rno-let-7a-2-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
19891	Rat	rno-let-7a-5p	miRNA	alcohol	brain damage due to chronic heavy alcohol	hippocampal tissues	chronic alcohol administration	upregulated	33228793
19892	Rat	rno-let-7a-5p	miRNA	high fat diet (HFD)	obesity	white adipose tissues	high fat diet (HFD) feed	upregulated	32366215
19893	Rat	rno-let-7a-5p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	downregulated	28560399
19894	Rat	rno-let-7a-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
19895	Rat	rno-let-7b	miRNA	oxygen	oxygen-induced retinopathy (OIR)	choroid and the retinal pigment epithelium	oxygen treatment	upregulated	31430465
19896	Rat	rno-let-7b	miRNA	burn injury	burn-induced hyperglycemia	rats serum	30% total body surface area (TBSA)	upregulated	29069833
19897	Rat	rno-let-7b	miRNA	adriamycin (ADR)	chronic myeloid leukemia (CML)	K562 cells; KA cells	adriamycin (ADR) treatment	let-7b was downregulated in K562/ADM (KA) cells.	32856506
19898	Rat	rno-let-7b	miRNA	cisplatin (DDP)	cisplatin (DDP)-induced nephrotoxicity	renal tissue homogenate	cisplatin treatment	downregulated	32777238
19899	Rat	rno-let-7b	miRNA	pentoxifylline (PTX)	cisplatin (DDP)-induced nephrotoxicity	renal tissue homogenate	pentoxifylline (PTX) treatment	upregulated	32777238
19900	Rat	rno-let-7b	miRNA	antibiotics	dysbacteria	Sprague Dawley (SD) rats faeces	treat with a combination of antibiotics for 8 week	downregulated	29264965
19901	Rat	rno-let-7b	miRNA	kainic acid (KA)	epilepsy	rat hippocampus neurons	kainic acid treatment	LncRNA H19 could competitively bind to let-7b to promote hippocampal glial cell activation and epileptic seizures by targeting Stat3 in a rat model of temporal lobe epilepsy.	32648622
19902	Rat	rno-let-7b	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	lung tissues and pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	upregulated	30628484
19903	Rat	rno-let-7b	miRNA	verapamil	male fertility	testis	verapamil treatment	downregulated	32725937
19904	Rat	rno-let-7b	miRNA	ethanol (EtOH)	neuroimmune	rat hippocampal-entorhinal cortex (HEC)	ethanol treatment	upregulated	28118842
19905	Rat	rno-let-7b	miRNA	estradiol-17¦Â (E2)	osteogenesis	primary bone marrow mesenchymal stem cells from rats (rBMSCs)	estradiol-17¦Â (E2) treatment	upregulated	31089333
19906	Rat	rno-let-7b	miRNA	hypoxia	pulmonary hypertension (PH)	Sprague-Dawley (SD) rats remodeled pulmonary artery	were exposed to hypoxia (10% O2) for 21days	downregulated in remodeled pulmonary artery	27889560
19907	Rat	rno-let-7b	miRNA	TGF-¦Â1	renal fibrosis	Rat proximal tubular epithelial cells (NRK52E)	Transforming growth factor-¦Â1 treatment	downregulated	24088962
19908	Rat	rno-let-7b	miRNA	TGF-¦Â1	renal fibrosis	NRK52E cells	TGF-¦Â1 treatment	downregulated	24088962
19909	Rat	rno-let-7b-5p	miRNA	"2,5-hexanedione (HD)"	"2,5-hexanedione (HD) toxicity"	spinal cord tissues	"2,5-hexanedione (HD) treatment"	upregulated	31760062
19910	Rat	rno-let-7b-5p	miRNA	electroacupuncture (EA)	analgesic effects	brain tissues	Electroacupuncture (EA) treatment	MicroRNA Let-7b-5p Induces Electroacupuncture Tolerance by Downregulating the MKP-1 Gene in Rats Subjected to CFA-induced Inflammatory Nociception.	32240501
19911	Rat	rno-let-7b-5p	miRNA	electroacupuncture (EA)	chronic nociception	hypothalamus	electroacupuncture (EA) treatment	Let-7b-5p promotes electroacupuncture tolerance by downregulating Penk1 gene in CFA-induced inflammatory nociception rats.	32184167
19912	Rat	rno-let-7b-5p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	upregulated	26997989
19913	Rat	rno-let-7b-5p	miRNA	smoking	smoke inhalation injury (SII)	bronchoalveolar lavage fluid (BALF)	Smoke inhalation treatment	upregulated	30139538
19914	Rat	rno-let-7c	miRNA	infarct the LV free wall	acute myocardial infarction (AMI)	heart tissues	left anterior descending coronary artery (LAD) was ligated using a 5/0 silk thread treatment	downregulated	24758696
19915	Rat	rno-let-7c	miRNA	aluminum (Al)	Alzheimer's disease (AD)	PC-12 cells	aluminum treatment	downregulated	28222524
19916	Rat	rno-let-7c	miRNA	curcumin (Cur)	Alzheimer's disease (AD)	aluminum-induced PC-12 cells	curcumin treatment	upregulated	28222524
19917	Rat	rno-let-7c	miRNA	resveratrol	Alzheimer's disease (AD)	aluminum-induced PC-12 cells	resveratrol treatment	upregulated	28222524
19918	Rat	rno-let-7c	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	downregulated	24304932
19919	Rat	rno-let-7c	miRNA	collagenase	intracerebral haemorrhage (ICH)	brain tissues	harvested hemorrhagic brain 24 hours aftercollagenase induced ICH in the rat treatment	upregulated	24959881
19920	Rat	rno-let-7c	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	mesenchymal stem cell (MSC) exosome	hypoxia-reoxygenation (H/R) treatment	upregulated	32719674
19921	Rat	rno-let-7c	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
19922	Rat	rno-let-7c-1-3p	miRNA	methylprednisolone	steroid-induced osteonecrosis of femoral head (ONFH)	bone microvascular endothelial cells (BMECs)	methylprednisolone treatment	downregulated	29408208
19923	Rat	rno-let-7c-5p	miRNA	lipopolysaccharide (LPS)	pulpitis	Dental pulp stem cells (DPSCs)	lipopolysaccharide (LPS) treatment	downregulated	30238933
19924	Rat	rno-let-7c-5p	miRNA	lipopolysaccharide (LPS)	pulpitis	dental pulp stem cells (DPSCs)	lipopolysaccharide (LPS) treatment	downregulated	30575977
19925	Rat	rno-let-7c-5p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	upregulated	26997989
19926	Rat	rno-let-7c-5p	miRNA	smoking	smoke inhalation injury (SII)	bronchoalveolar lavage fluid (BALF)	Smoke inhalation treatment	upregulated	30139538
19927	Rat	rno-let-7d	miRNA	infarct the LV free wall	acute myocardial infarction (AMI)	heart tissues	left anterior descending coronary artery (LAD) was ligated using a 5/0 silk thread treatment	downregulated	24758696
19928	Rat	rno-let-7d	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	NRK-52E cells	TGF-¦Â1 treatment	downregulated	27693697
19929	Rat	rno-let-7d	miRNA	ethanol (EtOH)	ethanol-related behaviors	NAc tissues	ethanol treatment	Lentiviral-mediated upregulated of let-7d microRNA decreases alcohol intake through down-regulating the dopamine D3 receptor	32646740
19930	Rat	rno-let-7d	miRNA	high amplitude mechanical stretching	lung fibrosis	alveolar type II (ATII) cells and lung fibroblasts	high amplitude mechanical stretching treatment	upregulated	31290711
19931	Rat	rno-let-7d-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
19932	Rat	rno-let-7e	miRNA	infarct the LV free wall	acute myocardial infarction (AMI)	heart tissues	left anterior descending coronary artery (LAD) was ligated using a 5/0 silk thread treatment	downregulated	24758696
19933	Rat	rno-let-7e	miRNA	paraquat (PQ)	apoptosis	PC 12 cells	paraquat (PQ) treatment	downregulated	25174400
19934	Rat	rno-let-7e	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
19935	Rat	rno-let-7e-5p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	upregulated	27919821
19936	Rat	rno-let-7f	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	downregulated	24304932
19937	Rat	rno-let-7f-1-3p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
19938	Rat	rno-let-7f-2-3p	miRNA	doxorubicin (DOX)	cardiotoxicity	H9c2 cells	doxorubicin (Dox)?treatment	"let-7f-2-3p inhibition in mice alleviated Dox-induced cardiotoxicity and preserved the antitumor efficacy. Together, let-7f-2-3p regulated by lncRNA NEAT1 aggravates Dox-induced cardiotoxicity through inhibiting XPO1-mediated HAX-1 nuclear export"	31570982
19939	Rat	rno-let-7f-5p	miRNA	plastrum testudinis extracts (PTE)	osteogenesis	bone marrow mesenchymal stem cells (BMSCs)	plastrum testudinis extracts (PTE) treatment	upregulated	29975930
19940	Rat	rno-let-7g	miRNA	hypoxia	pulmonary hypertension (PH)	PASMCs	hypoxia treatment	downregulated	27889560
19941	Rat	rno-let-7g	miRNA	hypoxia	pulmonary hypertension (PH)	Sprague-Dawley (SD) rats remodeled pulmonary artery	were exposed to hypoxia (10% O2) for 21days	downregulated in remodeled pulmonary artery	27889560
19942	Rat	rno-let-7g	miRNA	hypoxia	pulmonary hypertension (PH)	SD Rats pulmonary arteries	"were exposed to hypoxia (10% O2, 3 weeks)"	downregulated in pulmonary arteries	28108289
19943	Rat	rno-let-7g	miRNA	rapamycin	repair of epidermal growth factor (EGF)	IEC-6 cells	Rapamycin treatment	downregulated	32301281
19944	Rat	rno-let-7g-5p	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	33263228
19945	Rat	rno-let-7i	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	lung tissues	sevoflurane treatment	downregulated	28617947
19946	Rat	rno-let-7i	miRNA	infarct the LV free wall	acute myocardial infarction (AMI)	heart tissues	left anterior descending coronary artery (LAD) was ligated using a 5/0 silk thread treatment	downregulated	24758696
19947	Rat	rno-let-7i	miRNA	icariside II (ICA II)	erectile dysfunction (ED)	adipose tissue-derived stem cells (ADSCs)	IcarisideII (ICAII) treatment	downregulated	31581950
19948	Rat	rno-let-7i	miRNA	dioscin	liver fibrosis	NRK-52E and HK-2 cells	dioscin treatment	upregulated	27431331
19949	Rat	rno-let-7i	miRNA	penetrating ballistic-like brain injury	penetrating ballistic-like brain injury (PBBI)	male Sprague-Dawley rats brain tissue	a unilateral frontal 10% PBBI treatment	upregulated in brain tissue	28452880
19950	Rat	rno-let-7i	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
19951	Rat	rno-let-7i	miRNA	blast	traumatic brain injury (TBI)	Blood and cerebrospinal fluid of rats	blast treatment	upregulated	22352906
19952	Rat	rno-let-8	miRNA	lipopolysaccharide (LPS)	neuroinflammation	neuroinflammatory rat	injection of (250 ¦Ìg/kg) lipopolysaccharide-stimulated neuroinflammatory rat treatment	downregulated	25374508
19953	Rat	rno-miR-1	miRNA	infusion of oleic acid (OA)	acute lung injury (ALI)	lung tissues	OA (200 ?l/kg) suspended in 20% ethyl alcohol was injected through the tail vein for 20 min treatment	dysregulated	24736893
19954	Rat	rno-miR-1	miRNA	coronary artery ligation	acute myocardial infarction (AMI)	heart	subjected to coronary artery ligation	"serum miR-1 is quickly increased after AMI with a peak at 6 h, in which an increase in miR-1 of over 200-fold was demonstrated."	20218970
19955	Rat	rno-miR-1	miRNA	glucose	apoptosis	?rat cardiomyocyte cell line H9C2	glucose treatment	upregulated	18801338
19956	Rat	rno-miR-1	miRNA	doxycycline	atrial fibrillation (AF)	heart tissues	doxycycline treatment	downregulated	30470910
19957	Rat	rno-miR-1	miRNA	doxycycline	atrial fibrillation (AF)	heart sissues	doxycycline treatment	upregulated	30470910
19958	Rat	rno-miR-1	miRNA	astragaloside IV (AS-IV)	cardiac dysfunction	heart tissue of rats treated with LPS	astragaloside (AS-IV) treatment	downregulated	33774032
19959	Rat	rno-miR-1	miRNA	lipopolysaccharide (LPS)	cardiac dysfunction	heart tissue	lipopolysaccharide (LPS) treatment	upregulated	33774032
19960	Rat	rno-miR-1	miRNA	angiotensin II (Ang II)	cardiac fibroblast proliferation	primary ventricular fibroblasts	angiotensin II (Ang II) treatment	downregulated	31157242
19961	Rat	rno-miR-1	miRNA	TGF-¦Â	cardiac fibroblast proliferation	adult rat ventricular fibroblasts	TGF¦Â treatment	downregulated	31157242
19962	Rat	rno-miR-1	miRNA	T3	cardiac hypertrophy	neonatal rat cardiac myocytes (NRCMs)	treat with T3 for 24 hr treatment	upregulated	28063219
19963	Rat	rno-miR-1	miRNA	hexabromocyclododecane (HBCD)	cardiac hypertrophy and arrhythmia	rat cardiomyocyte cells	Hexabromocyclododecane (HBCD) treatment	"miR-1, which was depressed by Nkx2.5, might play a fundamental role in mediating cardiac hypertrophy and arrhythmia via its target genes Mef2a and Irx5 after HBCD treatment"	26476318
19964	Rat	rno-miR-1	miRNA	ionizing radiation (IR)	cardiogenic stress	hearts	ionizing radiation treatment	downregulated	27643935
19965	Rat	rno-miR-1	miRNA	doxorubicin (DOX)	cardiomyocyte apoptosis	H9c2 cells	doxorubicin treatment	upregulated	27284328
19966	Rat	rno-miR-1	miRNA	ischemia	cardiomyocyte apoptosis	cardiomyocytes	Ischemic postconditioning (IPost)treatment	upregulated	21406115
19967	Rat	rno-miR-1	miRNA	daunorubicin	cardiomyopathy	rats	"daunorubicin (DAU-A, 3 mg/kg, every 48 h)"	downregulated	28303410
19968	Rat	rno-miR-1	miRNA	acute and long-term aerobic exercise	cardiorespiratory fitness	young men	acute and long-term aerobic exercise treatment	downregulated	27895662
19969	Rat	rno-miR-1	miRNA	isoproterenol and doxorubicin	cardiotoxicity	rats plasma	isoproterenol and doxorubicin treatment	upregulated after treatment with doxorubicin	25092230
19970	Rat	rno-miR-1	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose (HG) treatment	upregulated	30186406
19971	Rat	rno-miR-1	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiomyocytes	high glucose (HG) treatment	upregulated	27306406
19972	Rat	rno-miR-1	miRNA	ivabradine	electrophysiological cardiac remodelling	heart of rat	?ivabradine treatment	upregulated	21838751
19973	Rat	rno-miR-1	miRNA	pilocarpine	epilepsy	adult male rats brain tissue and heart tissue	50 days of pilocarpine treatment	downregulated in heart tissue	24530830
19974	Rat	rno-miR-1	miRNA	angiotensin II (Ang II)	hemorrhagic shock	vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	AngII treatment reverses the upregulated of miR-1.	30419280
19975	Rat	rno-miR-1	miRNA	angiotensin II (Ang II)	hemorrhagic shock	hypoxia-induced vascular smooth muscle cells (VSMCs)	angiotensin II (Ang II) treatment	downregulated	30419280
19976	Rat	rno-miR-1	miRNA	hypoxia	hemorrhagic shock	vascular smooth muscle cells (VSMCs)	hypoxia induce	upregulated	30419280
19977	Rat	rno-miR-1	miRNA	aloe-emodin (AE)	HFD-induced cardiac electrical remodeling	high-fat diet (HFD) rats hearts	intragastrically administered with 100 mg/kg AE each day for 6 weeks	downregulated in the hearts	29055952
19978	Rat	rno-miR-1	miRNA	ionizing radiation (IR)	irradiation-induced heart damage	rat myocardium	Single irradiation of 10 Gy (4¨C5 Gy/min.) of rat¡¯s mediastinum area	upregulated	30830529
19979	Rat	rno-miR-1	miRNA	molecular hydrogen-rich water (HRW)	irradiation-induced heart damage	irradiation-induced rat myocardium	molecular hydrogen-rich water (HRW) treatment	downregulated	30830529
19980	Rat	rno-miR-1	miRNA	tanshinone IIA (Tan IIA)	ischemic arrhythmias	?rat isolated ventricular myocytes	Tanshinone IIA? treatment	downregulated	19775284
19981	Rat	rno-miR-1	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	primary cultured cardiomyocyte	hypoxia induce	upregulated	31369209
19982	Rat	rno-miR-1	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	cardiomyocytes of neonatal rats	hypoxia/reoxygenation (HR) injury treatment	upregulated	25008997
19983	Rat	rno-miR-1	miRNA	losartan	ischemia/reperfusion (I/R) injury	heart tissues	losartan treatment	upregulated	26168042
19984	Rat	rno-miR-1	miRNA	telmisartan	ischemia/reperfusion (I/R) injury	hypoxia-induced primary cultured cardiomyocyte	telmisartan treatment	downregulated	31369209
19985	Rat	rno-miR-1	miRNA	dantonic	isoproterenol-induced myocardial ischemia (ISO-AMI)	plasma	dantonic treatment	miR-1 level was significantly lower in both dantonic-administrated groups compared to LAD- AMI group.	30319429
19986	Rat	rno-miR-1	miRNA	scopolamine	memory loss	"prefrontal cortex (PFC), the hippocampus and the amygdala tissues"	scopolamine treatment	upregulated	31400468
19987	Rat	rno-miR-1	miRNA	carvedilol	myocardial infarction (MI)	H2O2 treated primary cultured cardiomyocyte	carvedilol treatment	downregulated	30896796
19988	Rat	rno-miR-1	miRNA	H2O2	myocardial infarction (MI)	primary cultured cardiomyocyte	H2O2 treatment	upregulated	30896796
19989	Rat	rno-miR-1	miRNA	H2O2	myocardial infarction (MI)	primary cultured rat?cardiomyocytes	H2O2 treatment	upregulated	31702064
19990	Rat	rno-miR-1	miRNA	metoprolol	myocardial infarction (MI)	cardiomyocytes; heart tissues	metoprolol treatment	Pretreatment of metoprolol reversed these changes by decreasing miR-1 and increasing Cx43 expression.	31702064
19991	Rat	rno-miR-1	miRNA	metoprolol	myocardial infarction (MI)	H2O2 treated primary cultured rat?cardiomyocytes	Metoprolol treatment	downregulated	31702064
19992	Rat	rno-miR-1	miRNA	hypoxia	myocardial ischaemic injury	H9c2 cells	hypoxia treatment	downregulated	32030815
19993	Rat	rno-miR-1	miRNA	sciatic nerve partial ligation	peripheral nerve injury (PNI)	dorsal root ganglion (DRG)	sciatic nerve partial ligation therapy treatment	downregulated in the injured nerve	27381812
19994	Rat	rno-miR-1	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	lung tissues	hypoxia induce	upregulated	29717493
19995	Rat	rno-miR-1	miRNA	Su5416	pulmonary arterial hypertension (PAH)	lung tissues	Su5416 treatment	upregulated	29717493
19996	Rat	rno-miR-1	miRNA	exercise training (ET)	pulmonary arterial stenosis (PAS)	PAS rats	PAS rats treatment	miR-1 downregulated and miR-21 upregulation	27994552
19997	Rat	rno-miR-1	miRNA	hypoxia/reoxygenation (H/R)	pyroptosis	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	MiRNA-1 promoted pyroptosis of cardiomyocytes and release of inflammatory factors by downregulating the expression level of PIK3R1.	33215443
19998	Rat	rno-miR-1	miRNA	aerobic exercise	sinus bradycardia	rats	aerobic exercise training (AET) treatment	upregulated	24825544
19999	Rat	rno-miR-1	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 13) treatment	different expression	24420840
20000	Rat	rno-miR-1	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	downregulated	22847192
20001	Rat	rno-miR-10	miRNA	scopolamine	memory loss	"prefrontal cortex (PFC), the hippocampus and the amygdala tissues"	scopolamine treatment	upregulated	31400468
20002	Rat	rno-miR-100	miRNA	TGF-¦Â	adaptation of tendons to mechanical loading	rat Tendon fibroblasts	Transforming growth factor-¦Â(TGF-¦Â) treatment	upregulated	22539168
20003	Rat	rno-miR-100	miRNA	isoproterenol	cardiac hypertrophy	H9c2 cells	isoproterenol treatment	miR-100 was upregulated during ISO- induced pathological hypertrophy.	29481791
20004	Rat	rno-miR-100	miRNA	H2O2	glaucoma	Rat RGC-5 cells	H2O2 was added to induce oxidative stress treatment	upregulated	25406880
20005	Rat	rno-miR-100	miRNA	phosphodiesterase 5 (PDE5) inhibitor	nonalcoholic fatty liver disease (NAFLD)	plasma exosomes	phosphodiesterase 5 (PDE5) inhibitor treatment	upregulated	33396535
20006	Rat	rno-miR-100	miRNA	hypoxia	pulmonary hypertension (PH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	downregulated	26409044
20007	Rat	rno-miR-100	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary cultured microglia were extracted from 3-day-old neonatal rats	lipopolysaccharide (LPS) treatment	downregulated	31696457
20008	Rat	rno-miR-101	miRNA	hypoxia/reoxygenation (H/R)	autophagy	H9c2 cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	"the inhibition of miR-101 attenuated H/R-induced apoptosis, at least partially, via the induction of autophagy."	25606826
20009	Rat	rno-miR-101	miRNA	hypoxia	bladder fibrosis	Bladder Smooth Muscle Cells	hypoxia treatment	Hypoxia could promote the expression of extracellular matrix subtypes and microRNA-101 in BSMCs.	30549198
20010	Rat	rno-miR-101	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	hypertrophic cardiac myocytes	angiotensin II (Ang II) treatment	downregulated	25850725
20011	Rat	rno-miR-101	miRNA	chronic unpredictable mild stress (CUMS)	depression	rats ventrolateral orbital cortex (VLO)	chronic unpredictable mild stress (CUMS) treatment	downregulated in ventrolateral orbital cortex (VLO)	28549965
20012	Rat	rno-miR-101	miRNA	hypoxia	fibrosis	bladder smooth muscle cells (BSMCs)	hypoxia induce	upregulated	30549198
20013	Rat	rno-miR-101	miRNA	hypoxia	myocardial infarction (MI)	H9C2 cells	hypoxia treatment	downregulated	32072912
20014	Rat	rno-miR-101	miRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	rat spinal microglia cells	lipopolysaccharide (LPS) treatment	downregulated	31526851
20015	Rat	rno-miR-101	miRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	Rat spinal microglia cells	lipopolysaccharide (LPS) treatment	downregulated	31526851
20016	Rat	rno-miR-101	miRNA	IL-1¦Â	osteoarthritis (OA)	Chondrocytes	IL-1¦Â treatment	The expression of Sox9 was likewise negatively regulated by miR-101 in rat chondrocytes	23227940
20017	Rat	rno-miR-101	miRNA	salvianolic acid A (Sal A)	spinal cord injury (SCI)	RBMECs under hypoxia	RBMECs under hypoxia treatment	upregulation	28011395
20018	Rat	rno-miR-101-1	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
20019	Rat	rno-miR-101-3p	miRNA	complete freund's adjuvant (CFA)	adjuvant-induced arthritis (AIA)	Synovium and fibroblast-like synoviocytes (FLS)	complete Freund¡¯s adjuvant treatment	downregulated	29626254
20020	Rat	rno-miR-101-3p	miRNA	type II collagen	rheumatoid arthritis (RA)	synovial tissues	type II collagen treatment	miR-101-3p was highly expressed in synovial tissues of RA rats.	31894846
20021	Rat	rno-miR-101-3p	miRNA	zinc	testicular ischemia-reperfusion injury (IRI)	rat testicular tissue	Zinc treatment	downregulated	31692452
20022	Rat	rno-miR-101a	miRNA	infusion of oleic acid (OA)	acute lung injury (ALI)	lung tissues	OA (200 ?l/kg) suspended in 20% ethyl alcohol was injected through the tail vein for 20 min treatment	dysregulated	24736893
20023	Rat	rno-miR-101a	miRNA	hypoxia	cerebral ischemia injury (CII)	hypoxia-injured rat adrenal pheochromocytoma (PC-12) cells	hypoxia induce	"?lncRNA EFNA3 was highly expressed in response to hypoxia. Deletion of lncRNA EFNA3 significantly aggravated hypoxia-induced injury in PC-12 cells, as the impairment of cell viability, migration, and invasion, and the inducement of apoptosis. LncRNA EFNA3 worked as a sponging molecule for miR-101a and miR-101a suppression-protected PC-12 cells against hypoxia-induced injury even when lncRNA EFNA3 was silenced."	30125989
20024	Rat	rno-miR-101a	miRNA	mongolian medicine warm acupuncture	insomnia	rats brain tissues	Mongolian medicine warm acupuncture treatment	upregulated in the brain tissue	28672928
20025	Rat	rno-miR-101a	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
20026	Rat	rno-miR-101a	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H2O2 treatment	MiR-101a was upregulated in H9c2 cell after H2O2 treatment.	32655807
20027	Rat	rno-miR-101a	miRNA	hypoxia	cerebral ischemia injury (CII)	PC-12 cells	hypoxia treatment	downregulated	30125989
20028	Rat	rno-miR-101a-3p	miRNA	pilocarpine	epilepsy	hippocampus tissues	pilocarpine treatment	MiR-101a-3p was downregulated while c-FOS was increased in hippocampus tissues of Rat model of pilocarpine-induced epilepsy	33559830
20029	Rat	rno-miR-101a-3p	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	31746349
20030	Rat	rno-miR-101a-3p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cell	hypoxia induce	upregulated	31746349
20031	Rat	rno-miR-101a-3p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	upregulated	26997989
20032	Rat	rno-miR-101b	miRNA	hypoxia	cortical injury	rat cortex tisssues	hypoxia treatment	downregulated	23272113
20033	Rat	rno-miR-101b	miRNA	TGF-¦Â1	diabetic nephropathy (DN)	rat renal mesangial cells (MCs)	Transforming growth factor-¦Â1 (TGF-¦Â) trreatment treatment	upregulated	31266808
20034	Rat	rno-miR-101b	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
20035	Rat	rno-miR-101b	miRNA	WNT family of secreted lipoglycoproteins(Wnt-5a)	Wnt-5a effect on hippocampal neurons	primary hippocampal neurons of 18-day-old Sprague-Dawley rat embryos	Wnt-5a treatment	downregulated	26895946
20036	Rat	rno-miR-101b-3p	miRNA	monocrotaline (MCT)	liver sinusoidal endothelial cells (LSEC) injury	serum	monocrotaline treatment	upregulated	30019166
20037	Rat	rno-miR-101b-3p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	upregulated	28560399
20038	Rat	rno-miR-103	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cultured myocardial cells from neonatal rats	angiotensin II (Ang II) treatment	downregulated	30604587
20039	Rat	rno-miR-103	miRNA	6-Gingerol (6-G)	cerebral ischemia injury (CII)	PC-12 cells	6-Gingerols (6G) treatment	hypoxia administration upregulated miR-103 expression and 6G could further increase miR-103 expression in hypoxia-stimulated PC-12 cells.	31043087
20040	Rat	rno-miR-103	miRNA	hypoxia	cerebral ischemia injury (CII)	rat PC-12 cells	hypoxia induce	upregulated	31043087
20041	Rat	rno-miR-103	miRNA	repeated binge-EtOH exposure	ethanol addiction	dorsal and ventral hippocampus of male Wistar rats	repeated binge-EtOH exposure treatment	different regulation	24416161
20042	Rat	rno-miR-103	miRNA	acetaminophen (APAP)	liver damage	plasma of rats	acetaminophen (APAP) treatment	miR-103 as suitable reference gene for plasma miRNAs analysis for acetaminophen-induced liver injury.	23558424
20043	Rat	rno-miR-103	miRNA	ethanol (EtOH)	liver regeneration	rat liver tissue	Chronic Ethanol Feeding treatment	upregulated	22823254
20044	Rat	rno-miR-103	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
20045	Rat	rno-miR-103	miRNA	high fat diet (HFD) and streptozotocin (STZ)	prediabetes state	Peripheral blood mononuclear cells (PBMCs)	high fat diet/streptozotocin (STZ) treatment	upregulated	26164754
20046	Rat	rno-miR-103	miRNA	zinc oxide nanoparticles (ZnONPs) and DPP-IV inhibitor (Vildagliptin)	type 2 diabetes mellitus (T2DM)	type 2 diabetes rats	type 2 diabetes rats treatment	downregulated	27723572
20047	Rat	rno-miR-103/107	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	PASMCs	hypoxia treatment	downregulated	26827991
20048	Rat	rno-miR-103a	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) treatment	downregulated of microRNA-103a reduces microvascular endothelial cell injury in a rat model of cerebral ischemia by targeting AXIN2	31650542
20049	Rat	rno-miR-103a	miRNA	hypoxia	cerebral ischemia injury (CII)	brain microvascular endothelial cells (BMECs)	middle cerebral artery occlusion (MCAO) induce	upregulated	31650542
20050	Rat	rno-miR-103a	miRNA	lithium chloride and pilocarpine	epilepsy	hippocampus tissues of epilepsy rats	lithium chloride-pilocarpine treatment	upregulated	31049031
20051	Rat	rno-miR-106a	miRNA	tamoxifen (TAM)	hepatocellular carcinoma (HCC)	rat liver	tamoxifen? treatment	upregulated	17343880
20052	Rat	rno-miR-106b-5p	miRNA	lipopolysaccharide (LPS)	cardiac dysfunction	H9C2 cells	lipopolysaccharide (LPS) treatment	downregulated	33341669
20053	Rat	rno-miR-106b-5p	miRNA	matrine	cardiac dysfunction	LPS-treated H9C2 cells	matrine treatment	upregulated	33341669
20054	Rat	rno-miR-106b-5p	miRNA	matrine	cardiac dysfunction	H9c2 cells	Matrine treatment	upregulated	33341669
20055	Rat	rno-miR-106b-5p	miRNA	pentylenetetrazol (PTZ)	epilepsy	brain tissues	pentylenetetrazol (PTZ) treatment	upregulated	32779334
20056	Rat	rno-miR-106b-5p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	upregulated	28560399
20057	Rat	rno-miR-106b-5p	miRNA	matrine	oxidative stress	H9c2 cells	matrine treatment	Matrine modulated H2O2-induced myocardial oxidative stress repair through HOTAIR/miR-106b-5p axis via AKT and STAT3 signaling pathway.	32395744
20058	Rat	rno-miR-107	miRNA	6-hydroxydopamine (6-OHDA)	Alzheimer's disease (AD)	PC12 cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	31778666
20059	Rat	rno-miR-107	miRNA	6-hydroxydopamine (6-OHDA)	Alzheimer's disease (AD)	PC-12 cells	6-hydroxydopamine (6-OHDA) treatment	6-OHDA suppressed miR-107 expression.	31778666
20060	Rat	rno-miR-107	miRNA	osthole	Alzheimer's disease (AD)	hippocampal and cortex region of the brain	osthole treatment	upregulated	27143098
20061	Rat	rno-miR-107	miRNA	ketamine	anesthesia-induced neural cytotoxicity	rat brain embryonic stem cell (ESC)-derived neurons	Ketamine treatment	upregulated	30308117
20062	Rat	rno-miR-107	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	male Wistar rats inflamed colon	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated in inflamed colon	28572713
20063	Rat	rno-miR-107	miRNA	ketamine	ketamine-induced neurotoxicity	rat brain embryonic stem cell (ESC)-derived neurons	ketamine treatment	"Ketamine induced apoptosis, neurite degeneration, and upregulated miR-107 in NSC-derived neurons."	30308117
20064	Rat	rno-miR-107	miRNA	ethanol (EtOH)	liver regeneration	rat liver tissue	Chronic Ethanol Feeding treatment	upregulated	22823254
20065	Rat	rno-miR-107	miRNA	penetrating ballistic-like brain injury	penetrating ballistic-like brain injury (PBBI)	male Sprague-Dawley rats brain tissue	a unilateral frontal 10% PBBI treatment	upregulated in brain tissue	28452880
20066	Rat	rno-miR-107	miRNA	doxorubicin (DOX)	renal interstitial fibrosis (RIF)	kidneys	doxorubicin (ADR) induction	downregulated	32606425
20067	Rat	rno-miR-107	miRNA	"kangxianling (KXL, anti-fibrin)"	renal interstitial fibrosis (RIF)	kidneys	"Kangxianling (KXL, anti-fibrin) treatment"	upregulated	32606425
20068	Rat	rno-miR-107-3p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
20069	Rat	rno-miR-107-5p	miRNA	hypoxia	stroke	middle cerebral artery occlusion (MCAO) Sprague-Dawley rat	middle cerebral artery occlusion (MCAO) treatment	upregulated	29113076
20070	Rat	rno-miR-10a	miRNA	retinoic acid receptor-¦Á (RAR¦Á)- and retinoid X receptor-¦Á (RXR¦Á)-specific agonists	atherosclerosis (AS)	inner curvature (OS region) of aortic arch in rats	retinoic acid receptor-¦Á (RAR¦Á)- and retinoid X receptor-¦Á (RXR¦Á)-specific agonists dual treatment	upregulated	29459264
20071	Rat	rno-miR-10a	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal rat cardiomyocytes	angiotensin II (Ang II) treatment	upregulated	28100873
20072	Rat	rno-miR-10a	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	downregulated	22156553
20073	Rat	rno-miR-10a	miRNA	verapamil	male fertility	testis	verapamil treatment	downregulated	32725937
20074	Rat	rno-miR-10a	miRNA	naringin	renal ischemia/reperfusion (I/R) injury	IR injury rat renal tissues	naringin (NAR) treatment	downregulated	30780111
20075	Rat	rno-miR-10a	miRNA	trimetazidine (TMZ)	renal ischemia/reperfusion (I/R) injury	IR injury rat renal tissues	trimetazidine (TMZ) treatment	downregulated	30780111
20076	Rat	rno-miR-10a	miRNA	pegylated rat leptin antagonist (pRLA)	type 2 diabetes mellitus (T2DM)	rat muscle and liver	pegylated rat leptin antagonist (pRLA) treatment	"upregulation of rno-miR-10a at d28 and rno-miR-200a, rno-miR-409-5p, and rno-miR-125a-3p following HFD challenge"	23576026
20077	Rat	rno-miR-10a	miRNA	"high concentrations of lipid and glucose, and cytokines"	vascular hyper-reactivity	VSMC	"incubat high glucose (25mmol/L) or lipid (palmitic acid 50 ¦Ì mol/L) and 200ng/ml of TNF-¦Á,IL-1¦Â and IL-6 for 24h treatment"	downregulated	25425000
20078	Rat	rno-miR-10a-5p	miRNA	acarbose	diabetes mellitus (DM)	blood	acarbose? treatment	upregulated	24260283
20079	Rat	rno-miR-10a-5p	miRNA	repeated binge-EtOH exposure	ethanol addiction	dorsal and ventral hippocampus of male Wistar rats	repeated binge-EtOH exposure treatment	different regulation	24416161
20080	Rat	rno-miR-10a-5p	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
20081	Rat	rno-miR-10a-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
20082	Rat	rno-miR-10a-5p	miRNA	fluorine combined with aluminum (FA)	neurotoxicity	hippocampi in the offspring of rats	fluorine combined with aluminum (FA) exposure	upregulated	30033483
20083	Rat	rno-miR-10a-5p	miRNA	steroids	osteonecrosis of femoral head (ONFH)	serum	steroid treatment	upregulated	29887962
20084	Rat	rno-miR-10b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	downregulated	22156553
20085	Rat	rno-miR-10b	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	downregulated	24304932
20086	Rat	rno-miR-10b	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
20087	Rat	rno-miR-10b	miRNA	ferulic acid (FA)	oxidative stress	PC-12 cells	Ferulic Acid (FA) treatment	"miR-10b was induced by H2O2 in PC12 cells, whereas FA inhibited H2O2-induced miR-10b."	33379243
20088	Rat	rno-miR-10b	miRNA	bisphenol S (BPS)	pheochromocytoma (PCC)	PC12 cells	bisphenol S (BPS) treatment	upregulated	30140998
20089	Rat	rno-miR-10b	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	downregulated	21094214
20090	Rat	rno-miR-10b-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	rat hippocampal tissues	amyloid ¦Â1-42?(A¦Â) treatment	"MiR-10b-5p was upregulated while HOXD10 was downregulated, and the Rho/ROCK signalling pathway was activated in hippocampal tissues of rats with AD."	33307856
20091	Rat	rno-miR-10b-5p	miRNA	anisakis complete extract (CE)	anisakiasis	sera	anisakis complete extract (CE) treatment	"mmu-miR-1b-5p and mmu-miR-10b-5p (a cancer-related miRNA) were significantly decreased (P?<?.05) in sera from the rats inoculated with Anisakis CE, compared with control rats inoculated with saline."	30006808
20092	Rat	rno-miR-10b-5p	miRNA	cadmium (Cd)	cadmium (Cd)-induced reproductive toxicity	testes	cadmium (Cd) treatment	"For the expression of miR-10b-5p, at PND 21, the expression of miR-10b-5p in the testes of the F1 rats was significantly upregulated in the 2.0 mg/kg Cd treatment group. At PND 56, the expression of miR-10b-5p was significantly increased in the 8.0 mg/kg Cd treatment group."	31654709
20093	Rat	rno-miR-10b-5p	miRNA	dexamethasone (DEX)	neuronal cell injury	brain tissues	dexamethasone (Dex) treatment	downregulated	32323054
20094	Rat	rno-miR-10b-5p	miRNA	hypoxia	neuronal cell injury	brain tissues	middle cerebral artery occlusion (MCAO) surgery	upregulated	32323054
20095	Rat	rno-miR-10b-5p	miRNA	escitalopram	stress-induced depression	nucleus accumbens (NAc) tissues	escitalopram treatment	dysregulated	31856805
20096	Rat	rno-miR-1193-3p	miRNA	TGF-¦Â1	lung fibrosis	lung fibroblasts	TGF-¦Â1 treatment	downregulated	32464548
20097	Rat	rno-miR-1207-5p	miRNA	lipopolysaccharide (LPS)	steroid-induced necrosis of femoral head (SNFH)	necrotic femoral head tissue	lipopolysaccharide treatment	upregulated	31002120
20098	Rat	rno-miR-1207-5p	miRNA	methylprednisolone	steroid-induced necrosis of femoral head (SNFH)	necrotic femoral head tissue	methylprednisolone treatment	upregulated	31002120
20099	Rat	rno-miR-122	miRNA	ethanol (EtOH)	acute alcoholic liver injury	liver tissues	50% ethanol at 8 mL/kg treatment	upregulated	31398934
20100	Rat	rno-miR-122	miRNA	portulaca oleracea extract (POE)	acute alcoholic liver injury	acute alcoholic liver injury rats liver tissues	Portulaca oleracea extract (POE) treatment	downregulated	31398934
20101	Rat	rno-miR-122	miRNA	carbon tetrachloride (CCl4)	acute liver failure (ALF)	rats	CCl4 treatment	upregulated	28616908
20102	Rat	rno-miR-122	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	upregulated	30458344
20103	Rat	rno-miR-122	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	upregulated	30458344
20104	Rat	rno-miR-122	miRNA	lycium barbarum polysaccharide (LBP)	acute myocardial infarction (AMI)	hypoxia-induced H9c2 cells	Lycium barbarum polysaccharides (LBPs) treatment	downregulated	30458344
20105	Rat	rno-miR-122	miRNA	lycium barbarum polysaccharide (LBP)	acute myocardial infarction (AMI)	hypoxia-induced H9c2 cells	Lycium barbarum polysaccharides (LBPs) treatment	downregulated	30458344
20106	Rat	rno-miR-122	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute myocardial infarction (AMI)	H9c2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31669130
20107	Rat	rno-miR-122	miRNA	grape seed proanthocyanidins (GSPs)	cardiovascular disease (CVD)	healthy rats liver	chronic (3 weeks) of grape seed proanthocyanidins (GSPE) treatment	downregulated	24445039
20108	Rat	rno-miR-122	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	colonic tissue of rat	azoxymethane (AOM) treatment	downregulated	23049818
20109	Rat	rno-miR-122	miRNA	high-copper diet	crohn disease (CD)	serum	high-copper diet?treatment	upregulated	23125884
20110	Rat	rno-miR-122	miRNA	exercise intervention	diabetes mellitus (DM)	liver tissues	exercise intervention treatment	upregulated	30318957
20111	Rat	rno-miR-122	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	serum	acetaminophen (APAP) treatment	dysregulated	22624025
20112	Rat	rno-miR-122	miRNA	dioscorea bulbifera (DB)	drug-induced liver injury (DILI)	serum	dioscorea bulbifera (DB) treatment	upregulated	22624025
20113	Rat	rno-miR-122	miRNA	cafeteria diet	dyslipidemia	liver of rat	cafeteria diet feed	upregulated	23922812
20114	Rat	rno-miR-122	miRNA	grape seed proanthocyandin extract (GSPE)	dysregulated fatty acid and cholesterol metabolism	rat liver cells	grape seed proanthocyanidins extracts (GSPE) treatment	downregulated	22965541
20115	Rat	rno-miR-122	miRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	rat hepatic stellate cells HSC-T6	TGF-¦Â1 treatment	miRNA-122 inhibit the activation and EMT of HSCs stimulated by TGF-¦Â1	30651793
20116	Rat	rno-miR-122	miRNA	chromium (Cr)	hepatic ischemia/reperfusion injury (HIRI)	serum	Cr treatment	downregulated	28963950
20117	Rat	rno-miR-122	miRNA	zinc sulfate (ZnSO4)	hepatic ischemia/reperfusion injury (HIRI)	ischemia-reperfusion (IR) injuried rats liver tissues	zinc sulfate (ZnSO4) treatment	downregulated	30014282
20118	Rat	rno-miR-122	miRNA	zinc sulfate (ZnSO4)	hepatic ischemia/reperfusion injury (HIRI)	ischemia-reperfusion (IR) rats serum	zinc sulfate (ZnSO4) treatment	downregulated	30014282
20119	Rat	rno-miR-122	miRNA	zinc sulfate (ZnSO4)	hepatic ischemia/reperfusion injury (HIRI)	serum	ZnSO4 treatment	downregulated	28963950
20120	Rat	rno-miR-122	miRNA	silybin	hepatic steatosis	oleate/palmitate induced FaO cells	silybin treatment	upregulated	31816412
20121	Rat	rno-miR-122	miRNA	¦Â-ionone (¦ÂI)	hepatocellular carcinoma (HCC)	rats hepatocyte	¦ÂI (16 mg/100 g body weight) treatment	"upregulated(miR-122 , miR-34a) ;downregulated (miR-181b , miR-708)"	27061051
20122	Rat	rno-miR-122	miRNA	bisphenol A (BPA)	hepatotoxicity	Wistar rats liver	bisphenol A (BPA) treatment	upregulated in liver	28689058
20123	Rat	rno-miR-122	miRNA	thioacetamide or carbon tetrachloride	hepatotoxicity	Adult male Wistar rats	thioacetamide or carbon tetrachloride treatment	downregulated	24388909
20124	Rat	rno-miR-122	miRNA	dexamethasone (DEX)	hormonal regulation	adrenals?tissues	dexamethasone (DEX) treatment	downregulated	24205079
20125	Rat	rno-miR-122	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
20126	Rat	rno-miR-122	miRNA	high fat diet (HFD)	hypercholesterolemia	liver tissues of IUGR female rats exposed to a maternal HFD	high fat diet (HFD) feed	upregulated	29896121
20127	Rat	rno-miR-122	miRNA	trichostatin A (TSA)	hepatocellular carcinoma (HCC)	rat primary hepatocytes	Trichostatin A (TSA)treatment treatment	"miR-122, miR-143 and miR-379 could be related to the inhibitory effects of TSA on hepatocellular proliferation"	21513791
20128	Rat	rno-miR-122	miRNA	silymarin (Sm)	liver damage	thioacetamide (TAA) treated rat Blood and liver tissues	silymarin (Sm) treatment	upregulated	31811641
20129	Rat	rno-miR-122	miRNA	thioacetamide (TAA)	liver damage	blood and liver tissues	thioacetamide (TAA) treatment	downregulated	31811641
20130	Rat	rno-miR-122	miRNA	atorvastatin	liver fibrosis	liver tissues	atorvastatin treatment	upregulated	32822719
20131	Rat	rno-miR-122	miRNA	curcumin (Cur)	liver fibrosis	liver tissues	curcumin treatment	upregulated	32822717
20132	Rat	rno-miR-122	miRNA	quercetin	liver fibrosis	liver tissues	quercetin treatment	upregulated	32822718
20133	Rat	rno-miR-122	miRNA	TGF-¦Â1	liver fibrosis	HSC-T6 cells	TGF-¦Â1 treatment	upregulated	30651793
20134	Rat	rno-miR-122	miRNA	acetaminophen (APAP) and methapyrilene (MP)	liver damage	rats pericentral and periportal regions	acetaminophen (APAP) and methapyrilene (MP) treatment	upregulated	24863736
20135	Rat	rno-miR-122	miRNA	lipopolysaccharide (LPS)	liver damage	plasma	lipopolysaccharide (LPS) treatment	upregulated	31026554
20136	Rat	rno-miR-122	miRNA	xian-Ling-Gu-Bao (XLGB)	liver damage	plasma	Xian-Ling-Gu-Bao (XLGB) treatment	upregulated	31026554
20137	Rat	rno-miR-122	miRNA	ethanol (EtOH)	liver regeneration	rat liver tissue	Chronic Ethanol Feeding treatment	upregulated	22823254
20138	Rat	rno-miR-122	miRNA	ellagic acid (EA)	breast cancer	female rat mammary tissue	ellagic acid treatment	"ellagic acid, which inhibited E2-induced mammary tumorigenesis in our previous study, reversed the dysregulation of miR-375, miR-206, miR-182, miR-122, miR-127 and miR-183 detected with E2treatment"	23791885
20139	Rat	rno-miR-122	miRNA	granulocyte-colony stimulating factor (G-CSF)	neuropathic pain (NP)	dorsal root ganglia (DRGs)	Granulocyte colony-stimulating factor?treatment	upregulated	32664488
20140	Rat	rno-miR-122	miRNA	high-fat high-fructose diet (HFHFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high-fat high-fructose diet (HFHFD) feed	downregulated	30318957
20141	Rat	rno-miR-122	miRNA	high-intensity interval training (HIIT)	nonalcoholic fatty liver disease (NAFLD)	diabetic rats liver tissues	high-intensity interval training (HIIT) treatment	upregulated	30318957
20142	Rat	rno-miR-122	miRNA	proanthocyanidin	obesity	livers of obese rats	proanthocyanidin treatment	3 weeks of supplementation with grape seed proanthocyanidin extract normalized the overexpression of miR-33a and miR-122 in obese rats' liver for all doses studied	25769350
20143	Rat	rno-miR-122	miRNA	grape seed proanthocyandin extract (GSPE)	obesity and metabolic syndrome	rat hepatoma Fao cells	grape seed proanthocyanidins extracts (GSPE) treatment	"although GSPE reduced both miR-122 and miR-33a levels, GPE reduced miR-122 but upregulated miR-33a expression. The expression of miR-122 and miR-33a was not altered by the DF fraction in either Fao or HepG2 cells"	24165878
20144	Rat	rno-miR-122	miRNA	phenobarbital (PB)	phenobarbital (PB)-mediated tumours	B13/H cells	Phenobarbital (PB) treatment	downregulated	27427493
20145	Rat	rno-miR-122	miRNA	grape seed proanthocyandin extract (GSPE)	reduced postprandial lipemia	rat liver tissues and lipid extraction	grape seed proanthocyanidins extracts (GSPE) treatment	GSPE repressed miR-33a and miR-122 liver expression and reduced postprandial lipemia in a dose-dependent manner.	24445039
20146	Rat	rno-miR-122	miRNA	high sodium/low potassium (Japanese-style) diet (JD)	stroke	spontaneously hypertensive rat (SHRSP) brain	high sodium/low potassium (Japanese-style) diet (JD) for one month	downregulated	28751928
20147	Rat	rno-miR-122	miRNA	proanthocyanidins or docosahexaenoic acid	dyslipidemia	liver of rat	proanthocyanidins or docosahexaenoic acid?treatment treatment	downregulated	23922812
20148	Rat	rno-miR-122-3p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	pulmonary metastatic tissue	sorafenib treatment	downregulated	26026584
20149	Rat	rno-miR-1224	miRNA	resveratrol	 lipogenesis	perirenal adipose tissue	resveratrol (RS) treatment	upregulated	26952965
20150	Rat	rno-miR-1225-5p	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	INS-1 cells	streptozocin (STZ) treatment	Secretions of miR-1225-5p was in streptozotocin-treated INS-1 cells	29370422
20151	Rat	rno-miR-122-5p	miRNA	hypoxia	cardiac injury	H9c2 cardiomyocyte	hypoxia induce	Hypoxic H9c2 cells demonstrated an increase in the extent of their apoptosis and expression of microRNA-122-5p.	31887421
20152	Rat	rno-miR-122-5p	miRNA	hypoxia	cardiac injury	H9c2 cells	hypoxia treatment	upregulated	31887421
20153	Rat	rno-miR-122-5p	miRNA	cisplatin and gentamicin	drug-induced acute kidney injury (DIKI)	plasma	"cisplatin (CSP, 6?mg/kg) and gentamicin (GEN, 120?mg/kg) treatment"	downregulated	30682439
20154	Rat	rno-miR-122-5p	miRNA	aflatoxin B1 (AFB1)	epatocarcinogenesis	serum	aflatoxin (AFB1 ) treatment	upregulated	31373075
20155	Rat	rno-miR-122-5p	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	F344 rats liver tissues	aflatoxin B1 (AFB2) treatment	upregulated	28218475
20156	Rat	rno-miR-122-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	pulmonary metastatic tissue	sorafenib treatment	downregulated	26026584
20157	Rat	rno-miR-122-5p	miRNA	perfluorooctane sulfonic acid (PFOS)	hepatotoxicity	liver tissues	Perfluorooctanesulfonate (PFOS) treatment	downregulated	26724606
20158	Rat	rno-miR-122-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
20159	Rat	rno-miR-122-5p	miRNA	high fat diet (HFD)	insulin resistance (IR)	liver tissues	high fat diet (HFD) feed	upregulated	30958584
20160	Rat	rno-miR-122-5p	miRNA	streptozocin (STZ)	insulin resistance (IR)	liver tissues	streptozotocin (STZ) treatment	upregulated	30958584
20161	Rat	rno-miR-122-5p	miRNA	cadmium (Cd)	kidney damage	NRK-52E cells	cadmium (Cd) treatment	miR-122-5p and miR-326-3p might enhance cadmium-induced NRK-52E cell apoptosis through downregulating PLD1 expression.	32697411
20162	Rat	rno-miR-122-5p	miRNA	perfluorooctane sulfonic acid (PFOS)	liver damage	liver tissues	Perfluorooctanesulfonate (PFOS) treatment	downregulated	26724606
20163	Rat	rno-miR-122-5p	miRNA	monocrotaline (MCT)	liver sinusoidal endothelial cells (LSEC) injury	serum	monocrotaline treatment	upregulated	30019166
20164	Rat	rno-miR-122-5p	miRNA	salvianolate	myocardial Infarction (MI)	MI rats myocardial tissues	salvianolate treatment	downregulated in rat myocardial tissues	29076429
20165	Rat	rno-miR-122-5p	miRNA	cadmium (Cd)	renal toxic	"NRK-52E cells, rat kidney, serum and urine samples"	cadmium (Cd) treatment	upregulated	31626960
20166	Rat	rno-miR-122-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20167	Rat	rno-miR-1236-3p	miRNA	Propylthiouracil	congenital hypothyroidism (CH)	Propylthiouracil (50 mg/day) was injected intraperitoneally into pregnant rats to generate pups with CH. hippocampus tissues of CH rats was collected.	Propylthiouracil treatment	upregulated	31885695
20168	Rat	rno-miR-124	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	upregulated	27535721
20169	Rat	rno-miR-124	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	PC-12 cells	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	31014193
20170	Rat	rno-miR-124	miRNA	astaxanthin	Alzheimer's disease (AD)	AD-like rats cortex and hippocampus	astaxanthin (ATX) treatment	upregulated	33575874
20171	Rat	rno-miR-124	miRNA	hydrated aluminum chloride (AlCl3.6H2O)	Alzheimer's disease (AD)	cortex and hippocampus	hydrated aluminum chloride (AlCl3.6H2O) treatment	downregulated	33575874
20172	Rat	rno-miR-124	miRNA	curcumin (Cur)	breast cancer	renal cortex of diabetic rats £» cultured podocytes	curcumin treatment	downregulated	24556741
20173	Rat	rno-miR-124	miRNA	arsenic trioxide (ATO)	cardiac injury	H9c2 cells	arsenic trioxide (As2O3) treatment	NEAT1 regulated the expression of inflammatory factors to protect cardiomyocytes from As2O3 damage by inhibiting miR-124/NF-kappa B signaling pathway.	32096187
20174	Rat	rno-miR-124	miRNA	hypoxia	cell damage	H9c2 cells	hypoxia treatment	upregulated	29864957
20175	Rat	rno-miR-124	miRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	brain tissue of rats	Middle cerebral artery occlusion (MCAO) treatment	upregulated	30906474
20176	Rat	rno-miR-124	miRNA	hepatocyte growth factor (HGF)	chemotactic migration	rat MSCs (rMSCs)	rat MSCs (rMSCs) treatment	downregulated	27377850
20177	Rat	rno-miR-124	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus	chronic unpredictable mild stress (CUMS) treatment	miR-124 expression was upregulated in the hippocampus of CUMS -induced depression model rats.	32189593
20178	Rat	rno-miR-124	miRNA	corticosterone	depression	prefrontal cortex	corticosterone (CORT) treatment	upregulated	26575223
20179	Rat	rno-miR-124	miRNA	amadori-glycated albumin (AGA)	diabetes mellitus (DM)	retinal ganglion cells (RGCs)	amadori-glycated albumin (AGA) treatment	downregulated	26348633
20180	Rat	rno-miR-124	miRNA	curcumin (Cur)	diabetic nephropathy (DN)	enal cortex of diabetic rats and podocytes	curcumin treatment	downregulated	24556741
20181	Rat	rno-miR-124	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	upregulated	22156553
20182	Rat	rno-miR-124	miRNA	streptozocin (STZ)	glaucoma	renal cortex cells	streptozotocin (STZ) treatment	miR-124 upregulated	24247359
20183	Rat	rno-miR-124	miRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	human hepatic L02 cells	hepatic ischemia-reperfusion (HIR)	downregulated	24875359
20184	Rat	rno-miR-124	miRNA	astragaloside IV (AS-IV)	hypoxia-induced injury	hypoxia-induced PC-12 cells	astragaloside IV (AS-IV) treatment	downregulated	29990829
20185	Rat	rno-miR-124	miRNA	hypoxia	hypoxia-induced injury	PC-12 cells	hypoxia induce	upregulated	29990829
20186	Rat	rno-miR-124	miRNA	ischemia	ichemia/reperfusion (I/R)-induced brain injury	brain tissues	2 h of MCAO using a nylon monofilament suture as described previously treatment	downregulated	24166354
20187	Rat	rno-miR-124	miRNA	collagenase	intracerebral haemorrhage (ICH)	plasma	collagenase treatment	"miR-124 was significantly elevated at the acute injury phase (day 1 and 2), gradually decreased during the delayed recovery phase (day 7, 14 and 30), and finally restored to normal levels at late recovery phase (day 60)."	29101647
20188	Rat	rno-miR-124	miRNA	collagenase	intracerebral haemorrhage (ICH)	rats plasma and brain tissue	collagenase treatment	dysregulated in rat plasma and brain tissue	29101647
20189	Rat	rno-miR-124	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	Primary cortical astrocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31004734
20190	Rat	rno-miR-124	miRNA	enoxacin	major depressive disorder (MDD)	rats	with 10 or 25 mg/kg enoxacin for 1 week treatment	upregulated	24575053
20191	Rat	rno-miR-124	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	rat neonatal cardiomyocytes(NCMs)	angiotensin II (Ang II) treatment	upregulated	28478799
20192	Rat	rno-miR-124	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary rat cardiomyocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31486506
20193	Rat	rno-miR-124	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	PC12 cells; Primary Cortical Neurons	oxygen glucose deprivation (OGD) treatment	downregulated	31916069
20194	Rat	rno-miR-124	miRNA	dexmedetomidine (DEX)	neuroinflammation	"adult Wistar rats brain ,plasma,"	dexmedetomidine (Dex) treatment	downregulated	28832497
20195	Rat	rno-miR-124	miRNA	high fat diet (HFD)	neuroinflammation	hippocampus	high fat diet (HFD) feed	upregulated	30134248
20196	Rat	rno-miR-124	miRNA	lipopolysaccharide (LPS)	neuroinflammation	adult Wistar rats brain regions	lipopolysaccharide (LPS) treatment	upregulated in both brain regions	28832497
20197	Rat	rno-miR-124	miRNA	isoflurane	neurological deficits	neonatal rats and primary hippocampal neurons	isoflurane exposure	downregulated	31131895
20198	Rat	rno-miR-124	miRNA	physical EE	neuropsychiatric disorders	hippocampal	physical EE treatment	upregulated	26132842
20199	Rat	rno-miR-124	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
20200	Rat	rno-miR-124	miRNA	platelet-derived growth factor (PDGF)	cell proliferation	pulmonary arterial smooth muscle cell (PASMC) of Sprague-Dawley rats	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	28867608
20201	Rat	rno-miR-124	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
20202	Rat	rno-miR-124	miRNA	paeonol (PAE)	renal interstitial fibrosis (RIF)	renal tissues or NRK-49F cells	paeonol (PAE) treatment	PAE was found to decrease HOTAIR and Notch1 expression but to increase the miR-124 expression in RIF rats.	30714138
20203	Rat	rno-miR-124	miRNA	docosahexaenoic acid (DHA)	spinal cord injury (SCI)	"rat spinal primary microglia cultures, SCI rats Iba1-positive or P2Y12-positive cells"	Docosahexaenoic acid (DHA) treatment	upregulated	30972415
20204	Rat	rno-miR-124-3p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	32391561
20205	Rat	rno-miR-124-3p	miRNA	ethanol (EtOH)	alcohol use disorders (AUDs)	nucleus accumbens shell (NAcsh)	ethanol treatment	upregulated	32353460
20206	Rat	rno-miR-124-3p	miRNA	ethanol (EtOH)	alcohol use disorders (AUDs)	nucleus accumbens core (NAcc)	ethanol treatment	upregulated	32353460
20207	Rat	rno-miR-124-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	29706607
20208	Rat	rno-miR-124-3p	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	H9C2 cells	hypoxia induce	upregulated	31432169
20209	Rat	rno-miR-124-3p	miRNA	chronic exogenous corticosterone (CORT)	major depressive disorder (MDD)	Sprague¨CDawley rats	CORT-treated (50?mg/kg; intraperitoneal injections for 21 days; n=9) rats	upregulated	27577603
20210	Rat	rno-miR-124-3p	miRNA	ischemia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	heart tissues	the proximal left anteriordescending coronaryartery (LAD) was loosely ligated by a 6¨C0 silk suture	"miR-124-3p was significantly downregulated in both MIRI rat model and H/R treated HCMs.?Overexpression of miR-124-3p reversed the H/R-induced cell apoptosis and upregulation of TNF-¦Á, IL-6, and IL-1¦Â."	31768721
20211	Rat	rno-miR-124-3p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	PC12 cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28543594
20212	Rat	rno-miR-124-3p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	PC12 cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	28543594
20213	Rat	rno-miR-124-3p	miRNA	Total glucosides of paeony (TGP)	renal ischemia/reperfusion (I/R) injury	NRK-52E?cells	Total glucosides of paeony (TGP) treatment	TGP inhibited XIST expression to modulate the miR-124-3p/ITGB1 axis	33299380
20214	Rat	rno-miR-124-3p	miRNA	N-methyl-N-nitrosourea (MNU)	retinal lesions	serum	N-methyl-N-nitrosourea (MNU) treatment	"MNU at 50?mg/kg induced photoreceptor cell death, with elevation in serum miR-124-3p levels."	30336191
20215	Rat	rno-miR-124-3p	miRNA	N-methyl-D-aspartate (NMDA)	retinal toxicity	serum	N-methyl-d-aspartate (NMDA) treatment	upregulated	30336191
20216	Rat	rno-miR-124-3p	miRNA	N-methyl-N-nitrosourea (MNU)	retinal toxicity	serum	N-methyl-N-nitrosourea (MNU) treatment	upregulated	30336191
20217	Rat	rno-miR-124-4p	miRNA	fluoxetine (Prozac)	major depressive disorder (MDD)	Sprague¨CDawley rats	"were treated with fluoxetine (10?mg/kg, intraperitoneal for 60 days; n=5)"	downregulated	27577603
20218	Rat	rno-miR-124-5p	miRNA	tanshinone IIA (Tan IIA)	acute myocardial infarction (AMI)	H9c2 cells	Tanshinone IIA (TSA) treatment	"TSA exerts the protective role against H/R induced apoptosis, oxidative and MMP loss of cardiomyocytes via regulating AK003290 and miR-124-5p signaling"	32220226
20219	Rat	rno-miR-1247	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
20220	Rat	rno-miR-1247-5p	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
20221	Rat	rno-miR-1249	miRNA	hypoxia	apoptosis	myocardial tissue and H9C2 cells	Chronic intermittent hypoxia (CIH) induce	upregulated	30293354
20222	Rat	rno-miR-1249	miRNA	grape seed procyanidin extract (GSPE)	pancreatic islet injury	rat islets	grape seed procyanidin extract (GSPE)treatment	"GSPE altered significantly the expression of miR-1249, miR-483, miR-30c-1*, and miR-3544."	23215023
20223	Rat	rno-miR-124a	miRNA	forced swim stress (FSS)	acute stress	Wistar rats hippocampus	forced swim stress (FSS; 15 min in 25¡ãC water)	upregulated in the hippocampus	27054829
20224	Rat	rno-miR-124a	miRNA	all-trans retinoic acid (ATRA)	congenital spina bifida	rats	all-trans retinoic acid (ATRA) treatment	downregulated	26611840
20225	Rat	rno-miR-124a	miRNA	all-trans retinoic acid (ATRA)	congenital spina bifida	spina	all-trans retinoic acid (ATRA) treatment	downregulated	26611840
20226	Rat	rno-miR-124a	miRNA	dexamethasone (DEX)	depression	prefrontal cortex and hippocampus of adolescent rats	dexamethasone (DEX) treatment	upregulated	30469088
20227	Rat	rno-miR-124a	miRNA	dexamethasone (DEX)	depression	prefrontal cortex and hippocampus of adolescent rats	dexamethasone (DEX) treatment	upregulated	30469088
20228	Rat	rno-miR-124a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	rat podocytes	high glucose (HG) treatment	upregulated	31190436
20229	Rat	rno-miR-124a	miRNA	alcohol	ethanol addiction	rat dorsal striatum tissue	alcohol exposure	miR124a was downregulated in the dorso-lateral striatum (DLS) following alcohol drinking. brain-derived neurotrophic factor (BDNF) as a direct target of miR124a	23601049
20230	Rat	rno-miR-124a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	upregulated	31190436
20231	Rat	rno-miR-124a	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
20232	Rat	rno-miR-124a	miRNA	penetrating ballistic-like brain injury	penetrating ballistic-like brain injury (PBBI)	male Sprague-Dawley rats brain tissue	a unilateral frontal 10% PBBI treatment	upregulated in brain tissue	28452880
20233	Rat	rno-miR-124a	miRNA	chronic unpredictable mild stress (CUMS)	permanent depressive-like behaviours and memory impairment	adolescent rats basolateral amygdala (BLA)	chronic unpredictable mild stress (CUMS) treatment	upregulated in the basolateral amygdala (BLA)	28826069
20234	Rat	rno-miR-124a	miRNA	retinal toxicant pan-CDK inhibitors	retinal toxicity	rats in renal	a single intravitreal (IVT) injection treatment	upregulated	24114799
20235	Rat	rno-miR-124a	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	BALB/c rats hearts	lipopolysaccharide (LPS) treatment	downregulated in hearts	28560580
20236	Rat	rno-miR-124a	miRNA	retinoic acid (RA)	spina bifida	spinal cord of rat	Retinoic acid treatment	downregulated	17962954
20237	Rat	rno-miR-124a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
20238	Rat	rno-miR-124a	miRNA	D-4F	type 1 diabetes mellitus (T1DM)	T1DM rats	D-4F (1 mg/kg i.p.)	upregulated	29221142
20239	Rat	rno-miR-124a	miRNA	exercise training (ET)	vascular relaxation	arteries	exercise training	downregulated	32301852
20240	Rat	rno-miR-125	miRNA	H2O2	ischemia/reperfusion (I/R) injury	H9c2 cells	H2O2 treatment	miR-125 expression level was significantly increased after H2O2 treatment in a dose-dependent manner.	30239560
20241	Rat	rno-miR-125-3p	miRNA	light	focal retinal degeneration	right eye	light treatment	upregulated	25921151
20242	Rat	rno-miR-125-3p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline treatment	downregulated	28000863
20243	Rat	rno-miR-125-5p	miRNA	platelet-derived growth factor (PDGF)	intimal hyperplasia (IH)	vascular smooth muscle cell (VSMCs)	Platelet derived growth factor (PDGF)-BB treatment	PDGF-BB increased the expressionof miR-125a-5p and HDAC4	30156956
20244	Rat	rno-miR-125a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	endotoxin treatment	upregulated	26137246
20245	Rat	rno-miR-125a	miRNA	high glucose (HG)	atherosclerosis (AS)	vascular smooth muscle cells (VSMC)	high glucose treatment	MicroRNA-125a-mediated regulation of the mevalonate signaling pathway contributes to high glucose-induced proliferation and migration of vascular smooth muscle cells.	32319638
20246	Rat	rno-miR-125a	miRNA	agmatine (AGM)	hyperoxia-induced acute lung injury (HALI)	rat lung tissues	agmatine (AGM) treatment	"AGM decreased the upregulated expression of lncRNA gadd7 caused by hyperoxia and due to the presence of the competitive binding of lncRNA gadd7 and MFN1 to miR-125a, AGM indirectly decreased MFN1 protein expression to inhibit the cells apoptosis."	31196629
20247	Rat	rno-miR-125a	miRNA	massive small bowel resection	lung cancer	rat jejunum and IEC-6 cells	massive small bowel resection treatment	upregulated	22418008
20248	Rat	rno-miR-125a	miRNA	glucagon-like peptide-2 (GLP-2)	short bowel syndrome (SBS)	intestinal exosomes	Glucagon-like peptide-2 (GLP-2) treatment	downregulated	32685005
20249	Rat	rno-miR-125a	miRNA	H2O2	spinal cord injury (SCI)	rat PC-12 cells	H2O2 treatment	upregulated	28609843
20250	Rat	rno-miR-125a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
20251	Rat	rno-miR-125a	miRNA	hypoxia	stroke	brain tissues	middle cerebral artery occlusion (MCAO) treatment	upregulated	29039453
20252	Rat	rno-miR-125a-3p	miRNA	"2,5-hexanedione (HD)"	"2,5-hexanedione (HD) toxicity"	spinal cord tissues	"2,5-hexanedione (HD) treatment"	downregulated	31760062
20253	Rat	rno-miR-125a-3p	miRNA	alcohol	brain damage due to chronic heavy alcohol	hippocampal tissues	chronic alcohol administration	upregulated	33228793
20254	Rat	rno-miR-125a-3p	miRNA	complete freund's adjuvant (CFA)	orofacial inflammatory pain	male Sprague¨CDawley rats	CFA treatment	downregulated	25380251
20255	Rat	rno-miR-125a-3p	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 10) treatment	different expression	24420840
20256	Rat	rno-miR-125a-3p	miRNA	pegylated rat leptin antagonist (pRLA)	type 2 diabetes mellitus (T2DM)	rat muscle and liver	pegylated rat leptin antagonist (pRLA) treatment	"upregulation of rno-miR-10a at d28 and rno-miR-200a, rno-miR-409-5p, and rno-miR-125a-3p following HFD challenge"	23576026
20257	Rat	rno-miR-125a-3p	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	Vascular Smooth Muscle Cells	Inorganic phosphate (Pi) treatment	upregulated	31790973
20258	Rat	rno-miR-125a-5p	miRNA	CoCl2	blood-spinal cord barrier (BSCB)	Rat spinal cord microvascular endothelial cells (SCMECs) and astrocyte	"CoCl2 was added to the medium in the upper chambers at a final concentration of 200 ¦ÌM to induce chemical hypoxia, and the cells were incubated for 24 h."	downregulated	31696327
20259	Rat	rno-miR-125a-5p	miRNA	hypoxia	disruption of the blood-spinal cord barrier (BSCB)	rat spinal cord microvascular endothelial cells (SCMECs)	hypoxia treatment	"MiRNA-125a-5p appears to reduce the permeability of the BSCB by up regulating the expression of ZO-1, occludin, and VE-cadherin and their mRNA, and against hypoxia-induced apoptosis of spinal cord microvascular endothelial cells."	31696327
20260	Rat	rno-miR-125a-5p	miRNA	Pentylenetetrazol (PTZ)	epilepsy	hippocampus tissues	Pentylenetetrazol (PTZ) treatment	downregulated	31490757
20261	Rat	rno-miR-125a-5p	miRNA	platelet derived growth factor-BB (PDGF-BB)	ischemia/reperfusion (I/R) injury	vascular smooth muscle cell (VSMCs)	Platelet derived growth factor (PDGF)-BB treatment	upregulated	30156956
20262	Rat	rno-miR-125a-5p	miRNA	enoxacin	major depressive disorder (MDD)	rats	with 10 or 25 mg/kg enoxacin for 1 week treatment	upregulated	24575053
20263	Rat	rno-miR-125a-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial hypoxia/reoxygenation (H/R) injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	"Compared with the blank control group, the expression of miR-125a-5p in the hypoxia/reoxygenation group was significantly increased."	32820512
20264	Rat	rno-miR-125a-5p	miRNA	binge drinking	neurodegeneration (ND)	rats	binge drinking treatment	downregulated in prefrontal cortex (PFC)	27085842
20265	Rat	rno-miR-125a-5p	miRNA	high fat diet (HFD)	obesity	white adipose tissues	high fat diet (HFD) feed	upregulated	32366215
20266	Rat	rno-miR-125a-5p	miRNA	IL-6	pulmonary arterial hypertension (PAH)	rat pulmonary artery smooth muscle cells (PASMCs)	IL-6 treatment	upregulated	29700287
20267	Rat	rno-miR-125a-5p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	pulmonary artery (PA) tissues and rat pulmonary artery smooth muscle cells (PASMCs)	monocrotaline (MCT) treatment	downregulated	29700287
20268	Rat	rno-miR-125a-5p	miRNA	TGF-¦Â1	pulmonary arterial hypertension (PAH)	rat pulmonary artery smooth muscle cells (PASMCs)	TGF-¦Â1 treatment	upregulated	29700287
20269	Rat	rno-miR-125a-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	stroke-prone spontaneously hypertensive	rat VECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	20531225
20270	Rat	rno-miR-125a-5p	miRNA	dioscin	type 2 diabetes mellitus (T2DM)	high-fat diet- and streptozotocin- induced T2DM rats liver tissues	dioscin treatment	upregulated	31881477
20271	Rat	rno-miR-125a-5p	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	liver tissues	streptozotocin treatment	downregulated	31881477
20272	Rat	rno-miR-125b	miRNA	hypoxia	acute myocardial infarction (AMI)	Neonatal rat cardiomyocytes	hypoxia induce	downregulated	31595551
20273	Rat	rno-miR-125b	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	nerve growth factor (NGF) stimulated PC 12 cells and primary cerebral cortex neurons of rat embryo	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	31345147
20274	Rat	rno-miR-125b	miRNA	¦Â-mercaptoethanol (BME)	cell differentiation	rat bone marrow mesenchymal stem cells (BMSCs)	¦Â-mercaptoethanol (BME) treatment	miR-125b can promote BME to induce rat BMSCs differentiation into neuron-like cells	23536218
20275	Rat	rno-miR-125b	miRNA	hypoxia	cardiac injury	H9c2 cells	hypoxia exposure	upregulated	32415544
20276	Rat	rno-miR-125b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	29510389
20277	Rat	rno-miR-125b	miRNA	hypoxia	dementia	brain tissues	hypoxia induce	downregulated	31000329
20278	Rat	rno-miR-125b	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
20279	Rat	rno-miR-125b	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	CCl4 treatment	downregulated	31548167
20280	Rat	rno-miR-125b	miRNA	cecal ligation and puncture (CLP)	sepsis	rats	cecal ligation and puncture (CLP) treatment	downregulated	29227823
20281	Rat	rno-miR-125b	miRNA	retinoic acid (RA)	spina bifida	spinal cord of rat	Retinoic acid treatment	downregulated	17962954
20282	Rat	rno-miR-125b	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
20283	Rat	rno-miR-125b	miRNA	phosphorus (Pi)	vascular calcification (VC)	rat aortic vascular smooth muscle cells	high levels of phosphate treatment	downregulated	28522697
20284	Rat	rno-miR-125b-1-3p	miRNA	prenatal stress (PNS)	schizophrenia (SZ)	hippocampus tissue	"pregnant dams, during the last week of gestation, were restrained in a transparent Plexiglas cylinder, under bright light, for 45 min, three times a day for 1 week. Control pregnant females were left undisturbed in their home cages."	downregulated	30057098
20285	Rat	rno-miR-125b-2-3p	miRNA	ethylenethiourea (ETU)	anorectal malformations (ARM)	Hindgut tissue was isolated from the gestational day 14 and day 15 fetuses	ethylenethiourea (ETU) treatment	upregulated	30106085
20286	Rat	rno-miR-125b-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis and hypertension	cardiac fibroblasts (CFs) of rats	angiotensin II (Ang II) treatment	upregulated	23007623
20287	Rat	rno-miR-125b-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	heart tissues	ligation of the left anterior descending coronary artery	downregulated	32010261
20288	Rat	rno-miR-125b-5p	miRNA	¦Â3-adrenoceptors(¦Â3-AR) inhibitor SR 59230A	chronic heart failure (CHF)	CHF rats	1 ml SR 59230A(85 mmoL/L in 0.9% saline)twice a day for seven weeks by intraperitoneal injection treatment	upregulated	29926593
20289	Rat	rno-miR-125b-5p	miRNA	sevoflurane (SEV)	cognitive impairment	rats hippocampus tissue	Sevoflurane treatment	upregulated	31490755
20290	Rat	rno-miR-125b-5p	miRNA	dexmedetomidine (DEX)	diabetic nephropathy (DN)	PC-12 cells	dexamethasone (DEX) treatment	DEX displays neuroprotective effects on PC-12 cells under high glucose through regulating miR-125b-5p/VDR axis.	32538430
20291	Rat	rno-miR-125b-5p	miRNA	palmitate	insulin resistance (IR)	H9c2 cardiomyoblasts	palmitate treatment	downregulated	30632304
20292	Rat	rno-miR-125b-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	PC-12?cells	oxygen and glucose deprivation (OGD) treatment	upregulated	29777774
20293	Rat	rno-miR-125b-5p	miRNA	oxidized low density lipoprotein (ox-LDL)	stroke-prone spontaneously hypertensive	rat VECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	20531225
20294	Rat	rno-miR-126	miRNA	CoCl2	acute myocardial infarction (AMI)	rat embryonic heart-derived H9c2 cells	CoCl2 treatment	upregulated	30597234
20295	Rat	rno-miR-126	miRNA	CoCl2	acute myocardial infarction (AMI)	H9C2 rat cardiomyocytes	CoCl2 treatment	upregulated	30597234
20296	Rat	rno-miR-126	miRNA	H2O2	acute myocardial infarction (AMI)	H9C2 rat cardiomyocytes	H2O2 treatment	upregulated	30597234
20297	Rat	rno-miR-126	miRNA	H2O2	acute myocardial infarction (AMI)	rat embryonic heart-derived H9c2 cells	H2O2 treatment	upregulated	30597234
20298	Rat	rno-miR-126	miRNA	H2O2	acute myocardial infarction (AMI)	bone marrow-derived endothelial progenitor cells	H2O2 treatment	Treatment with H2O2 decreased miR-126 expression in EPCs in a dose-dependent manner.	31999938
20299	Rat	rno-miR-126	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	allergic contact dermatitis (ACD)	ear tissues of rats with allergic contact dermatitis	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	upregulated	30186504
20300	Rat	rno-miR-126	miRNA	IgE	allergic contact dermatitis (ACD)	rat peritoneal mast cells (RPMCs)	IgE treatment	upregulated	30186504
20301	Rat	rno-miR-126	miRNA	swimming	angiogenesis	the heart and soleus muscle tissue of rat	Swimming Training treatment	upregulated	22330028
20302	Rat	rno-miR-126	miRNA	heat stress	apoptosis	primary cultured cardiomyocytes	heat stress induce	upregulated	30296408
20303	Rat	rno-miR-126	miRNA	crocin	cardiovascular disease (CVD)	Wistar rats heart tissue	crocin treatment	upregulated	28678929
20304	Rat	rno-miR-126	miRNA	high-intensity interval training (HIIT)	diabetes mellitus (DM)	heart sissues	high-intensity interval training (HIIT) treatment	HIIT gave rise to a significant enhancement in expression of miR-126 heart tissues.	33520826
20305	Rat	rno-miR-126	miRNA	alloxan	diabetes mellitus (DM)	plasma	alloxan treatment	downregulated	31508175
20306	Rat	rno-miR-126	miRNA	gambogic acid (GA)	diabetes mellitus (DM)	plasma	Gallic acid (GA) treatment	upregulated	31508175
20307	Rat	rno-miR-126	miRNA	garlic	diabetes mellitus (DM)	myocardium	garlic feed	upregulated	30570073
20308	Rat	rno-miR-126	miRNA	garlic	diabetes mellitus (DM)	diabetic rats heart tissues	Garlic treatment	upregulated	30570073
20309	Rat	rno-miR-126	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	heart tissues	streptozotocin (STZ) treatment	downregulated	30570073
20310	Rat	rno-miR-126	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	myocardium	streptozotocin treatment	downregulated	30570073
20311	Rat	rno-miR-126	miRNA	voluntary exercise	diabetes mellitus (DM)	myocardium	voluntary exercise treatment	upregulated	30570073
20312	Rat	rno-miR-126	miRNA	voluntary exercise	diabetes mellitus (DM)	diabetic rats heart tissues	voluntary exercise treatment	upregulated	30570073
20313	Rat	rno-miR-126	miRNA	testosterone	diabetic cardiomyopathy (DCM)	type 1 diabetic rats	testosterone and exercise treatment	upregulated	31149186
20314	Rat	rno-miR-126	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin (STZ) treatment	"miR-126 expression was downregulated in model of diabetic nephropathy, compared with control group"	32449863
20315	Rat	rno-miR-126	miRNA	hypoxia	diabetic retinopathy (DR)	RF/6A cells	Hypoxia treatment	The expression of miR-126 was also reduced in the retina tissue of streptozotocin-induced dia-betic rats.	24396282
20316	Rat	rno-miR-126	miRNA	hypoxia	diabetic retinopathy (DR)	chorioretinal vessel endothelial cells	Hypoxia treatment	A significantly decreased expression of miR-126 was found in hypoxia-treated RF/6A cells in a time-dependent manner compared with normoxic condition.	24396282
20317	Rat	rno-miR-126	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal tissue	streptozotocin (STZ) treatment	The diabetic rats were found to exhibit downregulated serum and retinal miR-126 levels compared with the non-diabetic rats	33416109
20318	Rat	rno-miR-126	miRNA	negative pressure wound therapy	diabetic wound repair	diabetic wound repair	Negative pressure wound therapy treatment	"In the NPWT group, miR-126 expression was significantly increased on days 3, 5, 7, and 9 (P<0.05)."	31564936
20319	Rat	rno-miR-126	miRNA	trimetazidine (TMZ)	endothelial dysfunction	plasma	Trimetazidine (TMZ) treatment	"Trimetazidine Increases Plasma MicroRNA-24 and MicroRNA-126 Levels and Improves Dyslipidemia, Inflammation and Hypotension in Diabetic Rats"	33680027
20320	Rat	rno-miR-126	miRNA	hypoxia	F. novicida?infection	rat cardiac myocytes	Hypoxia treatment	upregulated	23201405
20321	Rat	rno-miR-126	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	downregulated	24304932
20322	Rat	rno-miR-126	miRNA	collagenase	intracerebral haemorrhage (ICH)	rats	intracerebral injection of collagenase	downregulated	28112373
20323	Rat	rno-miR-126	miRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	rat lung tissue	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment	downregulated	18780894
20324	Rat	rno-miR-126	miRNA	TGF-¦Â1	lung cancer	rat bone marrow-derived EPCs	TGF¦Â1?treatment treatment	downregulated	24349482
20325	Rat	rno-miR-126	miRNA	exercise training (ET)	myocardial angiogenesis	heart sissues	Exercise training (ET)	4-week ET could significantly increase the expression of HIF-1¦Á and miR-126.	32939968
20326	Rat	rno-miR-126	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H2O2 treatment	HOTAIR aggravates myocardial IR by competitively binding SRSF1 with microRNA-126.	32964995
20327	Rat	rno-miR-126	miRNA	hypoxia/reoxygenation (H/R)	perivascular fibrosis	NRK52E cells	hypoxia/reoxygenation (H/R) treatment	MiR-126 was downregulated in NRK52E cells subjected to hypoxia/reoxygenation (H/R).	31862188
20328	Rat	rno-miR-126	miRNA	contrast medium (CM)	preeclampsia (PE)	preeclampsia rats placenta and fetuses	contrast-enhanced ultrasound treatment	downregulated	24239158
20329	Rat	rno-miR-126	miRNA	ginkgolide B (GB)	cell proliferation	endothelial progenitor cells (EPCs) of Sprague-Dawley rats	"various concentrations of ginkgolide B (0, 1.25, 5, 20, 80 or 160 ?g/ml) for 24 or 48 h"	upregulated	28849170
20330	Rat	rno-miR-126	miRNA	carbon black (CB) particles	lung fibrosis	rat lung tissues	carbon black (CB) particles treatment	downregulated	31502903
20331	Rat	rno-miR-126	miRNA	Yishen Huoxue prescription	renal fibrosis	unilateral ureteral obstruction (UUO) rats renal tissues	Yishen Huoxue prescription treatment	upregulated	30439324
20332	Rat	rno-miR-126	miRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	NRK52E cells	hypoxia induce	downregulated	31862188
20333	Rat	rno-miR-126	miRNA	hesperidin	testicular toxicity	testicular	hesperidin (HSP) treatment	upregulated	32050098
20334	Rat	rno-miR-1262	miRNA	diethylnitrosamine and 2-acetylaminofluorene	precancerous lesion (PCL)	liver tissues	diethylnitrosamine and 2-acetylaminofluorene treatment	downregulated	31009125
20335	Rat	rno-miR-1262	miRNA	pantoprazole	precancerous lesion (PCL)	liver tissues	pantoprazole treatment	upregulated	31009125
20336	Rat	rno-miR-126-3p	miRNA	Type VII collagenase	intracerebral haemorrhage (ICH)	serum and hemorrhagic area	Type VII collagenase treatment	downregulated	31474826
20337	Rat	rno-miR-126-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	downregulated	33365067
20338	Rat	rno-miR-126-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A.	33365067
20339	Rat	rno-miR-126-5p	miRNA	dehydroepiandrosterone (DHEA)	polycystic ovarian syndrome (PCOS)	rats' ovarian tissues	DHEA treatment	downregulated in rats' ovarian tissues	28673204
20340	Rat	rno-miR-126a	miRNA	NOX inhibitor VAS2870	acute ischemic stroke (AIS)	tMCAO rats	intravenous treatment with NOX inhibitor VAS2870	upregulated	27325364
20341	Rat	rno-miR-126a-3p	miRNA	estradiol benzoate (EB)	chronic inflammatory diseases	dorsolateral prostate	estradiol benzoate (EB) treatment	upregulated	33332750
20342	Rat	rno-miR-126a-3p	miRNA	L-nitro-arginine methylester	preeclampsia (PE)	placenta of pre-eclampsia-like female rats	L-nitro-arginine methylester treatment	downregulated	31789346
20343	Rat	rno-miR-126a-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20344	Rat	rno-miR-126a-5p	miRNA	hypoxia	persistent pulmonary hypertension of the newborn (PPHN)	newborn rats lung tissues	exposed to hypoxia (10-12%) or room air for 2 weeks	upregulated in lung tissue	28148930
20345	Rat	rno-miR-127	miRNA	taurocholate	acute pancreatitis (AP) with lung injury (LI)	rats lungs	administrated with retrograde cholangiopancreatography injection of 0.5% or 3.5% sodium taurocholate to induce AP with mild or severe LI treatment	upregulated in the lungs	29434409
20346	Rat	rno-miR-127	miRNA	circadian disruption (CD)	breast cancer	mammary	circadian disruption (CD) treatment	downregulated	26097876
20347	Rat	rno-miR-127	miRNA	methyl-deficient diet	hepatocellular carcinoma (HCC)	liver tissues	methyl-deficient diet feed	downregulated	18942116
20348	Rat	rno-miR-127	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	rat adrenal medulla-derived pheochromocytoma cell line PC-12	oxygen-glucose deprivation (OGD) induce treatment	"Furthermore, ANRIL negatively regulated miR-127 expression miR-127 overexpression significantly enhanced OGD-induced PC-12 cell injury"	31174432
20349	Rat	rno-miR-127	miRNA	SiO2	lung injury	lung	SiO2 treatment	upregulated	27689473
20350	Rat	rno-miR-127	miRNA	ellagic acid (EA)	breast cancer	female rat mammary tissue	ellagic acid treatment	"ellagic acid, which inhibited E2-induced mammary tumorigenesis in our previous study, reversed the dysregulation of miR-375, miR-206, miR-182, miR-122, miR-127 and miR-183 detected with E2treatment"	23791885
20351	Rat	rno-miR-127	miRNA	astragalus polysaccharide (APS)	myocarditis	H9c2 cells	astragalus polysaccharide (APS) treatment	"APS could protect H9c2 cells against LPS-induced inflammation injury, which might be partially due to miR-127 downregulated and regulation of NF-¦ÊB, JNK, and PI3K/AKT signaling pathways."	29451405
20352	Rat	rno-miR-127	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
20353	Rat	rno-miR-127	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	upregulated	29198922
20354	Rat	rno-miR-1273g-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	DR rat retinal pigment epithelial (RPE) cells	streptozotocin (STZ) treatment	upregulated	29197896
20355	Rat	rno-miR-127-5p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
20356	Rat	rno-miR-128	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	upregulated	30265647
20357	Rat	rno-miR-128	miRNA	HspB1	breast cancer	cortical neurons of rats	HspB1 treatment	upregulated	24141048
20358	Rat	rno-miR-128	miRNA	hypoxia/reoxygenation (H/R)	cardiac injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	30372838
20359	Rat	rno-miR-128	miRNA	homocysteine (Hcy)	cardiac microvascular endothelial cells (CMECs) injury	cardiac microvascular endothelial cells (CMECs)	homocysteine (HCY) treatment	downregulated	30701536
20360	Rat	rno-miR-128	miRNA	astragaloside IV (AS-IV)	diabetes mellitus (DM)	retinal pigment epithelial (RPE) cells	astragaloside IV (AS-IV) treatment	"miR-128 expression in RPE cells from dM rats treated with AIV (60 mg/kg) for 11 weeks increased significantly, compared with that in RPE cells from rats with dM."	32626913
20361	Rat	rno-miR-128	miRNA	"(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC)"	epilepsy	hippocampus	"(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC) treatment"	"2R,4R-APDC upregulated miR-128 expression levels in the hippocampus."	29497903
20362	Rat	rno-miR-128	miRNA	lithium chloride (LiCl)	epilepsy	hippocampus	lithium chloride treatment	upregulated	31173166
20363	Rat	rno-miR-128	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Antimycin A-treated H9c2 cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31902745
20364	Rat	rno-miR-128	miRNA	antimycin A (AA)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	antimycin A (AA) treatment	downregulated	31902745
20365	Rat	rno-miR-128-3p	miRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	brain tissues and primary cultured neural stem cells (NSCs)	hypoxia induce	upregulated	31638230
20366	Rat	rno-miR-128-3p	miRNA	theaflavin (TF)	cerebral ischemia/reperfusion (I/R) injury	hypoxia-induced brain tissues and primary cultured neural stem cells (NSCs)	Theaflavin treatment	downregulated	31638230
20367	Rat	rno-miR-128-3p	miRNA	melamine and cyanuric acid (MEL&CYA)	kidney damage	serum	melamine and cyanuric acid (MEL&CYA) treatment	downregulated	27621052
20368	Rat	rno-miR-128-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20369	Rat	rno-miR-128-3p	miRNA	electroacupuncture (EA)	spinal cord injury (SCI)	spinal cords	electroacupuncture (EA) treatment	downregulated	32468009
20370	Rat	rno-miR-128-3p	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	islet tissues	"Rats in the T2DM group were fed with a high sugar and high fat diet containing 20% sucrose, 10% lard, 2.5% cholesterol, 1.0% bile salts, and 66.5% normal diets. After 4 weeks of feeding with a high sugar and high fat diet for rats in the T2DM group and a fast for 12 hr, the rats in the T2DM group were injected with 2% streptozotocin. treatment"	upregulated	30341898
20371	Rat	rno-miR-128-3p	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	islet tissues	streptozotocin (STZ) treatment	upregulated	30341898
20372	Rat	rno-miR-128a-3p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
20373	Rat	rno-miR-128a-3p	miRNA	¦Ä-opioid receptor (DOR)	hypoxic/ischemic injury	hearts	¦Ä-opioid receptor (DOR) activation treatment	upregulated	27576463
20374	Rat	rno-miR-128a-3p	miRNA	pilocarpine	mesial temporal lobe epilepsy (MTLE)	hippocampi	pilocarpine treatment	downregulated	27695061
20375	Rat	rno-miR-129	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12 cells	amyloid-¦Â (A¦Â) 25-35 treatment	"Elevated H19, HMGB1 and decreased miR-129 were found in A¦Â25-35-treated PC12 cells as well as in brain tissues of AD mice."	33410377
20376	Rat	rno-miR-129	miRNA	resveratrol	breast cancer	matched tumor/normal tissues	resveratrol (RS) treatment	upregulated	24447120
20377	Rat	rno-miR-129	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	kidney?tissues	OTA nephrotoxicity treatment	suppressed in mid dose but then elevated in high dose	24885635
20378	Rat	rno-miR-129-1-3p	miRNA	cyclic mechanical stretch (CMS)	cell differentiation	Bone marrow-derived Endothelial progenitor cells (EPCs)	Bone marrow-derived EPCs were exposed to cyclic stretch with a magnitude of 5% (which mimics physiological mechanical stress) at a constant frequency of 1.25?Hz for 24?hours.	downregulated	30320897
20379	Rat	rno-miR-129-1-3p	miRNA	pirarubicin (THP)	pirarubicin (THP) cardiotoxicity	H9c2 cells	Pirarubicin (THP) treatment	downregulated	31957170
20380	Rat	rno-miR-129-1-3p	miRNA	cyclic mechanical stretch (CMS)	vessel injury	Endothelial progenitor cells (EPCs)	cyclic stretch treatment	Cyclic stretch significantly decreased miR-129-1-3p expression.	30320897
20381	Rat	rno-miR-129-3p	miRNA	palmitic acid (PA)	inflammation	H9c2 cells	palmitic acid (PA) treatment	upregulated	30820195
20382	Rat	rno-miR-129-3p	miRNA	tetrahydroxy stilbene glucoside (TSG)	inflammation	palmitic acid (PA)-treated H9c2 cells	Tetrahydroxy stilbene glucoside (TSG) treatment	downregulated	30820195
20383	Rat	rno-miR-129-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	brain tissues	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	31564203
20384	Rat	rno-miR-129-5p	miRNA	IL-1¦Â	epilepsy	CTX-TNA cells	IL-1¦Â treatment	The expression of miR-129-5p was decreased in the model cells compared with normal astrocytes.	31948324
20385	Rat	rno-miR-129-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	serum	carbon tetrachloride (CCl4) treatment	RT-qPCR revealed that miR-129-5p was poorly expressed and PEG3 was highly expressed in hepatic fibrosis tissues.	33743102
20386	Rat	rno-miR-129-5p	miRNA	collagenase	intracerebral haemorrhage (ICH)	Sprague Dawley (SD) rats brain	collagenase treatment	downregulated	28645008
20387	Rat	rno-miR-129-5p	miRNA	H2O2	ischemic heart disease (IHD)	H9c2 cells	H2O2 treatment	downregulated	30348524
20388	Rat	rno-miR-1298	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
20389	Rat	rno-miR-1298	miRNA	Diethylnitrosamine and 2-acetylaminofluorene	hepatic precancerous lesion (HPC)	Liver tissues and blood samples	diethylnitrosamine and 2-acetylaminofluorene treatment	downregulated	31489981
20390	Rat	rno-miR-1298	miRNA	hesperidin	hepatic precancerous lesion (HPC)	hepatic precancerous lesion (HPC) rat liver tissues and blood samples	Hesperidin treatment	upregulated	31489981
20391	Rat	rno-miR-130	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	upregulated	29761875
20392	Rat	rno-miR-130a	miRNA	molidustat	anemia	plasma samples	Molidustat treatment	upregulated	30657053
20393	Rat	rno-miR-130a	miRNA	thrombin	acute spontaneous intracerebral hemorrhage (ICH)	primary brain microvascular endothelial cells (BMECs) of Sprague-Dawley rats	primary brain microvascular endothelial cells (BMECs) of Sprague-Dawley rats treatment	upregulation	25631713
20394	Rat	rno-miR-130a	miRNA	nicotine	allergic asthma (AA)	lung tissues	nicotine injections	downregulated	28381639
20395	Rat	rno-miR-130a	miRNA	hypoxia	apoptosis	H9C2 cells	hypoxia induce	upregulated	29399759
20396	Rat	rno-miR-130a	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	upregulated	28352363
20397	Rat	rno-miR-130a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells or brain tissues	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31226635
20398	Rat	rno-miR-130a	miRNA	hypoxia/reoxygenation (H/R)	myocardial hypoxia/reoxygenation (H/R) injury	rat cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	upregulated	28352363
20399	Rat	rno-miR-130a	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	kidney?tissues	OTA nephrotoxicity treatment	suppressed in mid dose but then elevated in high dose	24885635
20400	Rat	rno-miR-130a	miRNA	dehydro-isoandrosterone	polycystic ovarian syndrome (PCOS)	ovarian tissues and granulosa cells	dehydro-isoandrosterone treatment	LncRNA HOTAIR up-regulates the expression of IGF1 and aggravates the endocrine disorders and granulosa cell apoptosis through competitive binding to miR-130a in rat models of PCOS.	31733099
20401	Rat	rno-miR-130a	miRNA	dehydro-isoandrosterone	polycystic ovarian syndrome (PCOS)	ovarian tissues	dehydro-isoandrosterone treatment	downregulated	31733099
20402	Rat	rno-miR-130a	miRNA	hypoxia	cell proliferation	pulmonary smooth muscle cell	hypoxia treatment	miRNA family miR-130 plays an important role in the repression of CDKN1A by hypoxia. miR-130 enhances hypoxia-induced smooth muscle proliferation and might be involved in the development of right ventricular hypertrophy and vascular remodeling in pulmonary hypertension.	25681685
20403	Rat	rno-miR-130a	miRNA	metformin (Met)	vascular endothelial dysfunction	palmitic acid (PA)-treated bone marrow-derived endothelial progenitor cells (EPCs)	metformin treatment	upregulated	30896786
20404	Rat	rno-miR-130a	miRNA	palmitic acid (PA)	vascular endothelial dysfunction	bone marrow-derived endothelial progenitor cells (EPCs)	palmitic acid (PA) treatment	downregulated	30896786
20405	Rat	rno-miR-130a-3p	miRNA	norepinephrine (NE)	cardiac hypertrophy	rat cardiomyocytes (NRCMs); H9c2 cells	norepinephrine (NE) treatment	downregulated	32329288
20406	Rat	rno-miR-130a-3p	miRNA	aflatoxin B1 (AFB1)	hepatotoxicant and genotoxicant	liver	aflatoxin B1 (AFB1) treatment	downregulated	26385312
20407	Rat	rno-miR-130a-5p	miRNA	nitrofen	congenital diaphragmatic hernia (CDH)	fetal lungs	"Nitrofen was orally administrated on embryonic day (E) 8.5 to establish a rat CDH model, and fetal lungs were collected on E13.5, E15.5, E17.5, E19.5 and E21.5."	upregulated	31843527
20408	Rat	rno-miR-130a-5p	miRNA	high fat diet (HFD)	obesity	white adipose tissues	high fat diet (HFD) feed	upregulated	32366215
20409	Rat	rno-miR-130b	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia/reperfusion (I/R) injury	primary astrocytes	anoxic conditions (1% O2) for 6 h (OGD) treatment	downregulated	28804561
20410	Rat	rno-miR-130b	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	kidney?tissues	OTA nephrotoxicity treatment	suppressed in mid dose but then elevated in high dose	24885635
20411	Rat	rno-miR-130b	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
20412	Rat	rno-miR-130b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	renal fibrosis	kidney tissues of streptozotocin-induced diabetic nephropathy (DN) rats	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	31781203
20413	Rat	rno-miR-130b	miRNA	TGF-¦Â1	renal fibrosis	kidney tissues of streptozotocin-induced diabetic nephropathy (DN) rats	TGF-¦Â1 treatment	downregulated	31781203
20414	Rat	rno-miR-130b-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	downregulated	32192351
20415	Rat	rno-miR-130b-5p	miRNA	ginsenoside Rb1	spinal cord injury (SCI)	?spinal cord injury (SCI) rat spinal cord tissues; oxygen-glucose deprivation/reoxygenation (OGD/R)-treated microglia cell	Ginsenoside Rb1 (GRb1) treatment	upregulated	32761843
20416	Rat	rno-miR-130b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	spinal cord injury (SCI)	Rat immortalized microglia cell line highly aggressively proliferating immortalized (HAPI)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32761843
20417	Rat	rno-miR-130b-5p	miRNA	hypoxia	acute spinal cord injury (ASCI)	AGE1.HN cells; PC12 cells	hypoxia treatment	"BDNF-AS, PRDM5 and c-caspase 3 expression were significantly upregulated, while miR-130b-5p was suppressed in the ASCI group and neuronal cells following hypoxia treatment."	29995562
20418	Rat	rno-miR-130b-5p	miRNA	ginsenoside Rb1	spinal cord injury (SCI)	Rat immortalized micro- glia cells	Ginsenoside Rb1 (GRb1) treatment	GRb1 alleviated SCI through inhibiting neuronal apoptosis and proinflammatory factor expression via increasing miR-130b-5p.	32761843
20419	Rat	rno-miR-132	miRNA	NOX inhibitor VAS2870	acute ischemic stroke (AIS)	tMCAO rats	intravenous treatment with NOX inhibitor VAS2870	upregulated	27325364
20420	Rat	rno-miR-132	miRNA	isoproterenol	agonism	heart tissues	isoproterenol treatment	upregulated	25925428
20421	Rat	rno-miR-132	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	Primary hippocampal neuron	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â25-35 treatment decreased miR-132 expression.	31949779
20422	Rat	rno-miR-132	miRNA	angiotensin II (Ang II)	atrial fibrillation (AF)	cardiac fibroblasts of adult rats	angiotensin II (Ang II) treatment	upregulated	28731126
20423	Rat	rno-miR-132	miRNA	angiotensin II (Ang II)	cardiac fibrosis	heart tissues	angiotensin II (Ang II) treatment	MicroRNA-132 attenuated cardiac fibrosis in myocardial infarction-induced heart failure rats	32885809
20424	Rat	rno-miR-132	miRNA	angiotensin II (Ang II)	cardiac fibrosis and hypertension	cardiac fibroblasts (CFs) of rats	angiotensin II (Ang II) treatment	upregulated	23007623
20425	Rat	rno-miR-132	miRNA	CREB-inhibitor 666-15	cardiac hypertrophy	H2O2-treated primary cultured cardiomyocytes	The CREB inhibitor 666-15 treatment	downregulated	30403388
20426	Rat	rno-miR-132	miRNA	H2O2	cardiac hypertrophy	primary cultured cardiomyocytes	H2O2 treatment	upregulated	30403388
20427	Rat	rno-miR-132	miRNA	isoproterenol	cardiac hypertrophy	primary cultured cardiomyocytes	Isoproterenol (ISO) treatment	upregulated	30403388
20428	Rat	rno-miR-132	miRNA	mitochondrial ATP-dependent K+ channel (mitoKATP) channel-opener Dzx	cardiac hypertrophy	Isoproterenol (ISO)-treated primary cultured cardiomyocytes	The mitochondrial ATP-dependent K+ channel (mitoKATP) channel-opener Dzx treatment	downregulated	30403388
20429	Rat	rno-miR-132	miRNA	angiotensin II (Ang II)	cardiac remodeling	cultured cardiomyocytes and cardiac fibroblasts	angiotensin II (Ang II) treatment	upregulated	31325434
20430	Rat	rno-miR-132	miRNA	klotho	cardiac remodeling	Ang II-treated cultured cardiomyocytes and cardiac fibroblasts	klotho treatment	downregulated	31325434
20431	Rat	rno-miR-132	miRNA	TGF-¦Â1 inhibitor LY364947	cardiac remodeling	Ang II-treated cultured cardiomyocytes and cardiac fibroblasts	TGF-¦Â1 inhibitor LY364947 treatment	downregulated	31325434
20432	Rat	rno-miR-132	miRNA	high glucose (HG)	cardiovascular disease (CVD)	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	downregulated	31257477
20433	Rat	rno-miR-132	miRNA	nimodipine	chronic cerebral hypoperfusion (CCH)	Chronic cerebral hypofusion (CCH) rats hippocampus tissues	Nimodipine treatment	upregulated	29042207
20434	Rat	rno-miR-132	miRNA	nimodipine	chronic cerebral hypoperfusion (CCH)	brain tissues	nimodipine treatment	downregulated	29042207
20435	Rat	rno-miR-132	miRNA	permanent bilateral common carotid artery occlusion (2VO)	chronic cerebral hypoperfusion (CCH)	rats hippocampus and cortex	2VO treatment	upregulated in the hippocampus and cortex	29090669
20436	Rat	rno-miR-132	miRNA	hypoxia	chronic cerebral hypoperfusion (CCH)-induced learning and memory impairments	hippocampus and cortex	bilateral common carotid artery occlusion (2VO) induce	downregulated	30885820
20437	Rat	rno-miR-132	miRNA	cocaine hydrochloride	cocaine addiction	rats brain structures	cocaine hydrochloride was dissolved in sterile 0.9 % NaCl and administered intravenously	upregulated	26944283
20438	Rat	rno-miR-132	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	rat colon Epithelial cells	azoxymethane (AOM) treatment	"Of the 27 miRNAs expressed at higher (P < 0.05) levels in tumors, miR-34a, 132, 223 and 224 were overexpressed at >10-fold. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (?0.32-fold) in adenocarcinomas."	19825969
20439	Rat	rno-miR-132	miRNA	doxorubicin (DOX)	dilated cardiomyopathy (DCM)	heart tissues	doxorubicin treatment	downregulated	30216493
20440	Rat	rno-miR-132	miRNA	testosterone	heart angiogenesis	heart tissue	testosterone treatment	upregulated	30907089
20441	Rat	rno-miR-132	miRNA	H2O2	heart failure (HF)	H9c2 cells	H2O2 treatment	downregulated	29682535
20442	Rat	rno-miR-132	miRNA	luteolin	hepatitis C virus (HCV) infection	PC12 cells	Luteolin treatment	upregulated	22916239
20443	Rat	rno-miR-132	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	upregulated	24205079
20444	Rat	rno-miR-132	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	upregulated	24205079
20445	Rat	rno-miR-132	miRNA	angiotensin II (Ang II)	hypertension	heart tissues	angiotensin II (Ang II) treatment	upregulated	23712358
20446	Rat	rno-miR-132	miRNA	oxygen glucose deprivation (OGD)	hypoxic/ischemic brain damage (HIBD)	fetal rat hippocampal neurons	oxygen-glucose deprivation (OGD) treatment	upregulated	28627974
20447	Rat	rno-miR-132	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
20448	Rat	rno-miR-132	miRNA	propofol (PPF)	learning and memory deficits	neonatal rats hippocampus	propofol treatment	downregulated in the hippocampus	28109866
20449	Rat	rno-miR-132	miRNA	enoxacin	major depressive disorder (MDD)	rats	with 10 or 25 mg/kg enoxacin for 1 week treatment	upregulated	24575053
20450	Rat	rno-miR-132	miRNA	hypoxia	myocardial infarction (MI)	cardiomyocyte	The left anterior descending branch of LCA was ligated.	downregulated	31621911
20451	Rat	rno-miR-132	miRNA	oxygen glucose deprivation (OGD)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	oxygen-glucose deprivation (OGD) treatment	upregulated	31210352
20452	Rat	rno-miR-132	miRNA	oxygen glucose deprivation (OGD)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	oxygen glucose deprivation (OGD) treatment	OGD disposition obviously enhanced miR-132 expression in H9c2 cells.	31210352
20453	Rat	rno-miR-132	miRNA	hypoxia	nerve injury	Schwann cells (SCs) after peripheral nerve injury	Hypoxia treatment	upregulated	26399639
20454	Rat	rno-miR-132	miRNA	dexmedetomidine (DEX)	neuroinflammation	"adult Wistar rats brain ,plasma,"	dexmedetomidine (Dex) treatment	downregulated	28832497
20455	Rat	rno-miR-132	miRNA	high fat diet (HFD)	neuroinflammation	hippocampus	high fat diet (HFD) feed	downregulated	30134248
20456	Rat	rno-miR-132	miRNA	lipopolysaccharide (LPS)	neuroinflammation	adult Wistar rats brain regions	lipopolysaccharide (LPS) treatment	upregulated in both brain regions	28832497
20457	Rat	rno-miR-132	miRNA	dexamethasone (DEX)	neuronal function	cortical neurons	dexamethasone (DEX) treatment	downregulated	19958814
20458	Rat	rno-miR-132	miRNA	physical EE	neuropsychiatric disorders	hippocampal	physical EE treatment	upregulated	26132842
20459	Rat	rno-miR-132	miRNA	polychlorinated biphenyls (PCBs)	neuropsychological disorders	postnatal day 1¨C2 (P1¨CP2) Sprague¨CDawley rats hippocampal cultures	nanomolar concentrations of PCB 95 treatment	upregulated	24431430
20460	Rat	rno-miR-132	miRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	dysregulated	24517225
20461	Rat	rno-miR-132	miRNA	glucagon-like peptide-1 (GLP-1)	pancreatic ¦Â-cell dysfunction	INS-1 832/3 cells	glucagon-like peptide 1 (GLP-1) treatment	upregulated	26218441
20462	Rat	rno-miR-132	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung and pulmonary arterial tissues	monocrotaline treatment	upregulated	30896881
20463	Rat	rno-miR-132	miRNA	IL-6 and TNF-¦Á	rheumatoid arthritis (RA)	Schwann cells	0.1 ng/mL IL-6 and 20 ng/mL TNF-¦Á treatment	downregulated	30456455
20464	Rat	rno-miR-132	miRNA	sciatic nerve partial ligation	nerve regeneration	dorsal root ganglion (DRG)	sciatic nerve partial ligation therapy treatment	upregulation	26399639
20465	Rat	rno-miR-132	miRNA	lipopolysaccharide (LPS)	sepsis-induced lung injury	rat alveolar macrophage cell line NR8383	lipopolysaccharide (LPS) treatment	upregulated	26052826
20466	Rat	rno-miR-132	miRNA	sevoflurane (SEV)	sevoflurane-induced neuronal apoptosis	brain tissues	sevoflurane treatment	miRNA-132 was downregulated in sevoflurane-induced rats	30272258
20467	Rat	rno-miR-132	miRNA	aluminum (Al)	spatial learning and memory impairment	offspring rats hippocampus	exposure to aluminium during the embryonic stage	upregulated	30172012
20468	Rat	rno-miR-132	miRNA	fluoride	spatial learning and memory impairment	offspring rats hippocampus	exposure to fluorine during the embryonic stage	upregulated	30172012
20469	Rat	rno-miR-132	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	downregulated	30691440
20470	Rat	rno-miR-132	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cell	lipopolysaccharide (LPS) treatment	downregulated	31062615
20471	Rat	rno-miR-132	miRNA	notoginsenoside R1 (NGR1)	spinal cord injury (SCI)	LPS-treated PC-12 cell	notoginsenoside R1 (NGR1) treatment	upregulated	31062615
20472	Rat	rno-miR-132	miRNA	resveratrol	spinal cord injury (SCI)	LPS-treated PC-12 cells	resveratrol (RSV) treatment	upregulated	30691440
20473	Rat	rno-miR-132	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
20474	Rat	rno-miR-132	miRNA	lithium chloride (LiCl)	temporal lobe epilepsy (TLE)	Temporal lobe? tissues	TGF-¦Â treatment	upregulated	24995086
20475	Rat	rno-miR-132	miRNA	cilostazol	vascular smooth muscle cell (VSMC) differentiation	vascular smooth muscle cell (VSMC)	cilostazol treatment	Treatment of cultured rat VSMCs with cilostazol resulted in the upregulated of PTEN mRNA and the downregulated of miR-132.	29738818
20476	Rat	rno-miR-132	miRNA	brain-derived neurotrophic factor (BDNF)	neuronal function	cortical neurons	brain-derived neurotrophic factor (BDNF) treatment	upregulated	19958814
20477	Rat	rno-miR-132-3p	miRNA	angiostrongylus cantonensis (A. cantonensis)	inflammation	healthy male SD rats	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24142286
20478	Rat	rno-miR-132-3p	miRNA	N-methyl-D-aspartate receptor	long-term potentiation (LTP) persistence	rat dentate gyrus	rat dentate gyrus 20 min post-LTP induction in vivo treatment	downregulated	25538559
20479	Rat	rno-miR-132-3p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	female Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	28192093
20480	Rat	rno-miR-132-3p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	male Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	downregulated	28192093
20481	Rat	rno-miR-132-3p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31915454
20482	Rat	rno-miR-132-3p	miRNA	Shenling Baizhu San (SLBZS)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	Shenling Baizhu San (SLBZS) treatment	the expression levels were reversed by SLBZS administration	31915454
20483	Rat	rno-miR-132-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20484	Rat	rno-miR-132-3p	miRNA	methylprednisolone	steroid-induced osteonecrosis of femoral head (ONFH)	bone microvascular endothelial cells (BMECs)	methylprednisolone treatment	upregulated	29408208
20485	Rat	rno-miR-132-5p	miRNA	nicotine	neuroprotective effects	PC12 cells	nicotine treatment	miR-132-5p was increased upon nicotine treatment.	32174265
20486	Rat	rno-miR-132-5p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	female Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	28192093
20487	Rat	rno-miR-132-5p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	male Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	downregulated	28192093
20488	Rat	rno-miR-132-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20489	Rat	rno-miR-132-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	downregulated	28246536
20490	Rat	rno-miR-133	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	downregulated	29938673
20491	Rat	rno-miR-133	miRNA	human growth hormone (hGH)	cardiac hypertrophy	ventricular muscle	recombinant human growth hormone (r-hGH) treatment	upregulated	30842884
20492	Rat	rno-miR-133	miRNA	human growth hormone (hGH)	cardiac hypertrophy	heart tissues	swimming exercise plus r-hGH treatment	upregulated	30842884
20493	Rat	rno-miR-133	miRNA	swimming	cardiac hypertrophy	ventricular muscle	swimming induce treatment	upregulated	30842884
20494	Rat	rno-miR-133	miRNA	swimming	cardiac hypertrophy	heart tissues	The exercise groups completed a 1-h swimming exercise 5 times a week for 8 weeks. treatment	upregulated	30842884
20495	Rat	rno-miR-133	miRNA	thyroid hormone	cardiac hypertrophy	Cardiomyocytes	thyroid hormone (TH) treatment	downregulated	26202011
20496	Rat	rno-miR-133	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	renal tissue	streptozotocin (STZ) treatment	upregulated	31858564
20497	Rat	rno-miR-133	miRNA	ivabradine	electrophysiological cardiac remodelling	heart of rat	?ivabradine treatment	upregulated	21838751
20498	Rat	rno-miR-133	miRNA	tanshinone IIA (Tan IIA)	H2O2-induced cell death	H9c2 cells	tanshinone IIA treatment	downregulated	27446335
20499	Rat	rno-miR-133	miRNA	aloe-emodin (AE)	myocardial infarction (MI)	H2O2-treated neonatal rat ventricular myocytes (NRVMs)	aloe-emodin (AE) treatment	upregulated	31207343
20500	Rat	rno-miR-133	miRNA	H2O2	myocardial infarction (MI)	neonatal rat ventricular myocytes (NRVMs)	H2O2 treatment	downregulated	31207343
20501	Rat	rno-miR-133	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	H9c2 cells	Oxygen-glucose deprivation (OGD) treatment	circMAT2B knockdown works as an inflammatory inhibitor in OGD-induced H9c2 cells inflammatory injury through up-regulating miR-133	32897801
20502	Rat	rno-miR-133	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	The expression of miR-133 was significantly decreased in H/R-treated H9c2 cells.	32685535
20503	Rat	rno-miR-133	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	32685535
20504	Rat	rno-miR-133	miRNA	doxorubicin (DOX)	oxidative stress	rat heart cell H9c2	doxorubicin (DOX) treatment	downregulated	28867607
20505	Rat	rno-miR-133	miRNA	H2O2	oxidative stress	rat heart cell H9c2	H2O2 treatment	downregulated	28867607
20506	Rat	rno-miR-133	miRNA	tanshinone IIA (Tan IIA)	oxidative stress	rat heart cell H9c2 treated by either H2O2 or doxorubicin (DOX)	Tanshinone ¢òA treatment	upregulated	28867607
20507	Rat	rno-miR-133a	miRNA	doxycycline	atrial fibrillation (AF)	heart tissues	doxycycline treatment	downregulated	30470910
20508	Rat	rno-miR-133a	miRNA	doxycycline	atrial fibrillation (AF)	heart sissues	doxycycline treatment	upregulated	30470910
20509	Rat	rno-miR-133a	miRNA	TGF-¦Â1	bladder outlet obstruction (BOO)	bladder smooth muscle cells (BSMCs)	TGF-¦Â1 treatment	downregulated	25451078
20510	Rat	rno-miR-133a	miRNA	"3,5-diiodo-L-thyronine (T2)"	browning of white adipocytes	subcutaneous white adipose tissue (sWAT)	receiving a high fat diet for 10 weeks and being subsequently treated for four weeks with an HFD together with the administration of T?	downregulated	30889829
20511	Rat	rno-miR-133a	miRNA	high fat diet (HFD)	browning of white adipocytes	subcutaneous white adipose tissue (sWAT)	high fat diet (HFD) feed	upregulated	30889829
20512	Rat	rno-miR-133a	miRNA	norepinephrine (NE)	cardiac hypertrophy	neonatal rat ventricular cardiomyocytes	norepinephrine treatment	downregulated	28795305
20513	Rat	rno-miR-133a	miRNA	phenanthrene (Phe)	cardiac hypertrophy	H9C2 cells	phenanthrene (Phe) treatment	downregulated	26830171
20514	Rat	rno-miR-133a	miRNA	ischemia	cardiomyocyte apoptosis	cardiomyocytes	Ischemic postconditioning (IPost)treatment	upregulated	21406115
20515	Rat	rno-miR-133a	miRNA	daunorubicin	cardiomyopathy	rats	"daunorubicin (DAU-A, 3 mg/kg, every 48 h)"	downregulated	28303410
20516	Rat	rno-miR-133a	miRNA	acute and long-term aerobic exercise	cardiorespiratory fitness	young men	acute and long-term aerobic exercise treatment	downregulated	27895662
20517	Rat	rno-miR-133a	miRNA	isoproterenol and doxorubicin	cardiotoxicity	rats plasma	isoproterenol and doxorubicin treatment	upregulated after treatment with doxorubicin	25092230
20518	Rat	rno-miR-133a	miRNA	dexamethasone (DEX)	glucocorticoid-induced osteoporosis (GIOP)	mesenchymal stem cells (MSCs)	dexamethasone (DEX) treatment	qRT-PCR analysis indicated that glucocorticoid induced high miR-133a expression in MSCs and animal models.	33781345
20519	Rat	rno-miR-133a	miRNA	losartan	ischemia/reperfusion (I/R) injury	heart tissues	losartan treatment	upregulated	26168042
20520	Rat	rno-miR-133a	miRNA	hypoxia	myocardial hypoxia injury	H9c2 cells	hypoxia treatment	downregulated	25421410
20521	Rat	rno-miR-133a	miRNA	hydrogen sulfide (H2S)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R-induced H9c2 cells	hydrogen sulfide (H2S) treatment	upregulated	30326468
20522	Rat	rno-miR-133a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	downregulated	30326468
20523	Rat	rno-miR-133a	miRNA	hydrogen sulfide (H2S)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hydrogen sulfide (H2S) treatment	miR-133a expression levels were significantly lower than those in the control group.	30326468
20524	Rat	rno-miR-133a	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia/reoxygenation (H/R) induce	downregulated	31734557
20525	Rat	rno-miR-133a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
20526	Rat	rno-miR-133a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC-12 cells	MPP+ (1-methyl-4-phenylpyridinium) treatment	Low miR-133a expression was detected in a cell model of MPP?-induced PD.	32713934
20527	Rat	rno-miR-133a	miRNA	epigallocatechin-3-gallate (EGCG)	prostatic hyperplasia (BPH)	prostatic hyperplasia (BPH) rats prostate tissue	Epigallocatechin-3-gallate (EGCG) treatment	upregulated	30179845
20528	Rat	rno-miR-133a	miRNA	testosterone	prostatic hyperplasia (BPH)	Prostate tissue	testosterone treatment	downregulated	30179845
20529	Rat	rno-miR-133a	miRNA	estrogen (ES)	pulmonary arterial hypertension (PAH)	"PAH rats blood vessels, rat pulmonary smooth muscle cell (RPASMC)"	estrogen (ES) treatment	upregulated	31562386
20530	Rat	rno-miR-133a	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	blood vessels	monocrotaline (MCT) treatment	downregulated	31562386
20531	Rat	rno-miR-133a	miRNA	quinone compounds P3H4	renal cell carcinoma (RCC)	renal cancer tissue	P3H4 treatment	miR-133a was significantly upregulated in rat renal cancer tissue after the treatment of P3H4	30178839
20532	Rat	rno-miR-133a	miRNA	berberine (BBR)	vascular dementia in diabetes	diabetic rats vascular endothelium	berberine (BBR) treatment	downregulated	30472896
20533	Rat	rno-miR-133a	miRNA	berberine (BBR)	vascular dementia in diabetes	diabetic rats vascular endothelium	berberine (BBR) treatment	downregulated	30472896
20534	Rat	rno-miR-133a	miRNA	streptozocin (STZ)	vascular dementia in diabetes	vascular endothelium	streptozotocin (STZ) treatment	upregulated	30472896
20535	Rat	rno-miR-133a	miRNA	streptozocin (STZ)	vascular dementia in diabetes	vascular endothelium	streptozotocin treatment	upregulated	30472896
20536	Rat	rno-miR-133a3p	miRNA	muscle contraction	diabetes mellitus (DM)	muscle tissues	"stimulated to contract in vitro for twitch tension analysis (0.5 Hz), 30 min later for tetanic analysis (100 Hz)"	upregulated	28000044
20537	Rat	rno-miR-133a-3p	miRNA	pentoxifylline (PTX)	cardiac injury	heart sissues	Pentoxifylline (PTX) treatment	Pentoxifylline (PTX) treatment produced a dose-dependent increase in miRNA-133a-3p expressions	31972363
20538	Rat	rno-miR-133a-3p	miRNA	ioversol	contrast-induced nephropathy (CIN)	kidney tissues	ioversol treatment	downregulated	33387208
20539	Rat	rno-miR-133a-3p	miRNA	H2O2	coronary artery disease (CAD)	H9c2 cells	H2O2 treatment	Lower miR-133a-3p level was found in H2O2-induced H9c2 cells.	32764884
20540	Rat	rno-miR-133a-3p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	downregulated	32893733
20541	Rat	rno-miR-133a-3p	miRNA	electrode	cardiac fibrosis	atrium tissues of rats	electrode stimulation	downregulated	32130618
20542	Rat	rno-miR-133a-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20543	Rat	rno-miR-133a-3p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
20544	Rat	rno-miR-133a-5p	miRNA	methamphetamine (METH)	drug addiction	heart tissues	Methamphetamine treatment	downregulated	31825931
20545	Rat	rno-miR-133a-5p	miRNA	Rhynchophylline	drug addiction	methamphetamine-treated rats heart tissues	Rhynchophylline treatment	upregulated	31825931
20546	Rat	rno-miR-133a-5p	miRNA	Rhynchophylline	drug addiction	heart sissues	Rhynchophylline treatment	Rhynchophylline could significantly increase the expression of miR-133a-5p	31825931
20547	Rat	rno-miR-133a-5p	miRNA	ischemia	hepatic ischemia/reperfusion injury (HIRI)	liver tissues	ischemia for 1 h and reperfusion for 2 h	downregulated	28198596
20548	Rat	rno-miR-133a-5p	miRNA	propofol (PPF)	hepatic ischemia/reperfusion injury (HIRI)	Sprague-Dawley rats liver	(I/R) injury rats treatment	upregulated	28198596
20549	Rat	rno-miR-133a-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20550	Rat	rno-miR-133b	miRNA	Sodium iodate (NaIO3)	retinal injury	eyes tissues	Sodium iodate (NaIO3) treatment	upregulated	23143922
20551	Rat	rno-miR-133b	miRNA	TGF-¦Â1	bladder outlet obstruction (BOO)	bladder smooth muscle cells (BSMCs)	TGF-¦Â1 treatment	downregulated	25451078
20552	Rat	rno-miR-133b	miRNA	vitamin D receptor activators (VDRAs)	chronic renal failure (CRF)	nephrectomized Wistar rats	equivalent doses of two VDRAs: calcitriol and paricalcitol treatment	upregulated	28460073
20553	Rat	rno-miR-133b	miRNA	caffeic acid	diabetic nephropathy (DN)	high-fat diet and streptozotocin-induced (HFD-STZ) diabetic rats	caffeic acid (CA) treatment	downregulated	28536471
20554	Rat	rno-miR-133b	miRNA	morphine	dopaminergic (DA) neuron differentiation	mature rat hippocampal neurons	Morphine treatment	downregulated	20716624
20555	Rat	rno-miR-133b	miRNA	hypoxia	hypoxia-induced injury	H9c2 cell	hypoxia induce	downregulated of miR-133b aggravated the cell injury induced by hypoxia.	31885905
20556	Rat	rno-miR-133b	miRNA	losartan	ischemia/reperfusion (I/R) injury	heart tissues	losartan treatment	upregulated	26168042
20557	Rat	rno-miR-133b	miRNA	epigallocatechin-3-gallate (EGCG)	prostatic hyperplasia (BPH)	prostatic hyperplasia (BPH) rats prostate tissue	Epigallocatechin-3-gallate (EGCG) treatment	upregulated	30179845
20558	Rat	rno-miR-133b	miRNA	testosterone	prostatic hyperplasia (BPH)	Prostate tissue	testosterone treatment	downregulated	30179845
20559	Rat	rno-miR-133b	miRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle	high-phosphorous treatment	downregulated	26187577
20560	Rat	rno-miR-133b	miRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle	high-phosphorous treatment	lower levels of miR-133b and miR-211 and higher levels of miR-29b	26187577
20561	Rat	rno-miR-133b-3p	miRNA	muscle contraction	diabetes mellitus (DM)	muscle tissues	"stimulated to contract in vitro for twitch tension analysis (0.5 Hz), 30 min later for tetanic analysis (100 Hz)"	upregulated	28000044
20562	Rat	rno-miR-133b-3p	miRNA	cannabinoid receptor type II (CB2R)	parkinson's disease (PD)	PC12 cells	cannabinoid receptor type II (CB2R) treatment	CB2 receptor agonist AM1241 alleviated PD via regulation of the Xist/miR-133b-3p/Pitx3 axis.	31989652
20563	Rat	rno-miR-133b-3p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
20564	Rat	rno-miR-133b-5p	miRNA	morphine	cardiomyocytes against H/R injury	H9c2 cells	morphine treatment	upregulated	26919791
20565	Rat	rno-miR-133b-5p	miRNA	hypoxia	HPC-induced cardioprotection	rat cardiomyocytes	hypoxia preconditioning (HPC) treatment	upregulated	29568969
20566	Rat	rno-miR-133b-5p	miRNA	hypoxia/reoxygenation (H/R)	HPC-induced cardioprotection	rat cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	downregulated	29568969
20567	Rat	rno-miR-133b-5p	miRNA	morphine	hypoxia/reoxygenation (H/R) injury	cardiomyocytes	morphine treatment	"After H/R injury, the decrease in miR-133b-5p and a contemporaneous rise in Fas mRNA and protein levels in adult rat cardiomyocytes were prevented by MPC treatment."	26919791
20568	Rat	rno-miR-133b-5p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	downregulated	27919821
20569	Rat	rno-miR-133b-5p	miRNA	human immunodeficiency virus (HIV)-1 gp120 V3 Loop peptide	neuron apoptosis	cortical neurons	HIV-1 gp120 V3 Loop peptide treatment	upregulated	26280272
20570	Rat	rno-miR-133b-5p	miRNA	human immunodeficiency virus (HIV)-1	neuronal cell dysfunction and apoptosis	primary rat cortical neurons	HIV-1 treatment	upregulated	26280272
20571	Rat	rno-miR-133c	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	downregulated	32893733
20572	Rat	rno-mir-133c	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20573	Rat	rno-miR-134	miRNA	CoCl2	autophagy	PC12 cells	CoCl2 treatment	downregulated	33410125
20574	Rat	rno-miR-134	miRNA	propofol (PPF)	autophagy	CoCl2-treated PC12 cells	propofol treatment	upregulated	33410125
20575	Rat	rno-miR-134	miRNA	soluble ¦Â-amyloid (sA¦Â) oligomers	Alzheimer's disease (AD)	cortical neurons were isolated from E17 embryos of Sprague Dawley rats	sA¦Â treatment	upregulated	24595404
20576	Rat	rno-miR-134	miRNA	adeno-associated virus (AAV)	cerebral ischemia injury (CII)	neuron death induced by OGD/reoxygenation	adeno-associated virus (AAV) Doxorubicin (DOX)	upregulated	25316150
20577	Rat	rno-miR-134	miRNA	resveratrol	cognitive impairment	primary cultured hippocampus neurons	resveratrol (RS) treatment	downregulated	29715537
20578	Rat	rno-miR-134	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampal tissues	chronic unpredictable mild stress (CUMS) treatment	upregulated	30716615
20579	Rat	rno-miR-134	miRNA	enriched environment (EE)	depression	Chronic unpredictable mild stress (CUMS) treated rat hippocampal tissues	Enriched environment (EE) treatment	downregulated	30716615
20580	Rat	rno-miR-134	miRNA	ginsenoside Rg1	depression	basolateral amygdala (BLA)	Ginsenoside Rg1 treatment	upregulated	30121663
20581	Rat	rno-miR-134	miRNA	unpredictable chronic mild stress (UCMS)	depression	ventromedial prefrontal cortex (vmPFC)	unpredictable chronic mild stress (UCMS) induce treatment	upregulated	29329879
20582	Rat	rno-miR-134	miRNA	kainic acid (KA)	epilepsy	brain tissue and serum	kainic acid treatment	downregulated	29917202
20583	Rat	rno-miR-134	miRNA	kainic acid (KA)	epilepsy	hippocampus tissue	kainic acid (KA) treatment	upregulated	31031600
20584	Rat	rno-miR-134	miRNA	ethylene glycol monomethyl ether (EGME)	hyperglycemia	?testicle of rat	Ethylene glycol monomethyl ether (EGME) treatment	"miR-449a and miR-92a decreased obviously and, miR-320, miR-134 and miR-188 increased"	22008535
20585	Rat	rno-miR-134	miRNA	brain-derived neurotrophic factor (BDNF)	hypoxic/ischemic brain damage (HIBD)	rats hippocampalwith hypoxic-hypoglycemic neuron injury	brain-derived neurotrophic factor (BDNF) treatment	downregulated	28343294
20586	Rat	rno-miR-134	miRNA	freund¡¯s complete adjuvant (FCA)	Insulin resistance and nonalcoholic steatohepatitis (NASH)	rat dorsal root ganglia (DRG)	Freund's adjuvant (CFA) treatment	downregulated of miR-134 and upregulated of MOR1	22865422
20587	Rat	rno-miR-134	miRNA	electroacupuncture (EA)	ischemic stroke (IS)	middle cerebral artery occlusion induced cognitive deficit (MICD) rats hippocampal	electroacupuncture (EA) treatment	downregulated	28116173
20588	Rat	rno-miR-134	miRNA	bile duct ligation (BDL)	liver fibrosis	liver tissues	bile duct ligation (BDL) treatment	downregulated	30645141
20589	Rat	rno-miR-134	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	30645141
20590	Rat	rno-miR-134	miRNA	dimethylnitrosamine (DMN)	liver fibrosis	liver tissues	dimethylnitrosamine (DMN) treatment	downregulated	30645141
20591	Rat	rno-miR-134	miRNA	TGF-¦Â1	liver fibrosis	The rat hepatic stellate cell line HSC-T6	TGF-¦Â1 treatment	downregulated	30645141
20592	Rat	rno-miR-134	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia/reoxygenation (H/R) induce	upregulated	31618402
20593	Rat	rno-miR-134	miRNA	dexmedetomidine (DEX)	neuroinflammation	"adult Wistar rats brain ,plasma,"	dexmedetomidine (Dex) treatment	downregulated	28832497
20594	Rat	rno-miR-134	miRNA	lipopolysaccharide (LPS)	neuroinflammation	adult Wistar rats brain regions	lipopolysaccharide (LPS) treatment	upregulated in both brain regions	28832497
20595	Rat	rno-miR-134	miRNA	H2O2	neuron survival	retinal ganglion cell (RGC)	H2O2 treatment	upregulated	25744098
20596	Rat	rno-miR-134	miRNA	magnesium (Mg2+ )	neuroprotective effects	hippocampus of the SE rats	low Mg2+-exposed	upregulated	28942448
20597	Rat	rno-miR-134	miRNA	propofol (PPF)	neuroprotective effects	primary hippocampal neurons under OGD condition	propofol treatment	downregulated	26884981
20598	Rat	rno-miR-134	miRNA	paliperidone	neurotoxicity	SH-SY5Y cells	SH-SY5Y cells treatment	downregulated	26055227
20599	Rat	rno-miR-134	miRNA	magnesium (Mg2+ )	satus epilepticus (SE)	rat hippocampal neurons	low Mg2+ treatment	upregulated	24810882
20600	Rat	rno-miR-134	miRNA	Safflor yellow B (SYB)	stroke	cortical cells	Safflor yellow B (SYB) treatment	Safflor Yellow B Attenuates Ischemic Brain Injury via downregulated of Long Noncoding AK046177 and Inhibition of MicroRNA-134 Expression in Rats	32566081
20601	Rat	rno-miR-134	miRNA	"fenoldopam, dopamine and midodrine"	vascular injury	rat mesentery cells	"Fenoldopam, dopamine and midodrine treatment"	upregulated	22627061
20602	Rat	rno-miR-134-5p	miRNA	H2O2	acute myocardial infarction (AMI)	H9c2 cells	H2O2 treatment	H2O2-induced cardiomyocyte injury upregulated miR-134-5p expression.	32689640
20603	Rat	rno-miR-134-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	Hypoxia-induced cardiomyocyte injury upregulated miR-134-5p expression.	32689640
20604	Rat	rno-miR-134-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus tissues	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	31625272
20605	Rat	rno-miR-134-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	31625272
20606	Rat	rno-miR-134-5p	miRNA	potentiates inorganic phosphate (Pi)	calcium deposition	A10 cells	potentiates inorganic phosphate (Pi) treatment	upregulated	32783377
20607	Rat	rno-miR-134-5p	miRNA	¦Ä-opioid receptor (DOR)	hypoxic/ischemic injury	hearts	¦Ä-opioid receptor (DOR) activation treatment	upregulated	27576463
20608	Rat	rno-miR-134-5p	miRNA	oxygen glucose deprivation (OGD)	hypoxic/ischemic brain damage (HIBD)	PC-12 cells	oxygen glucose deprivation (OGD) treatment	The expression of miR-134-5p was elevated in PC12 cells following OGD.	32814091
20609	Rat	rno-miR-134-5p	miRNA	X-rays	large intestine cancer	SW620 cells; HT29 cells	X-ray radiation treatment	LncRNA TTN-AS1/miR-134-5p/PAK3 axis regulates the radiosensitivity of human large intestine cancer cells through the P21 pathway and AKT/GSK-3¦Â/¦Â-catenin pathway	32749739
20610	Rat	rno-miR-134-5p	miRNA	permanent bilateral common carotid artery occlusion (2VO)	vascular dementia (VD)	brain cortex tissues	Permanent bilateral occlusion of the common carotid artery (2-VO) induce treatment	upregulated	31545395
20611	Rat	rno-miR-135a	miRNA	cerulein	acute pancreatitis (AP)	AR42J cells	cerulein treatment	upregulated	31729558
20612	Rat	rno-miR-135a	miRNA	schisandrin B (Sch B)	asthma	lung	Schisandrin B treatment	upregulated	26916957
20613	Rat	rno-miR-135a	miRNA	Streptococcus pneumoniae (Sp)	bacterial meningitis (BM)	astrocytes	Streptococcus pneumoniae?infection treatment	downregulated	30726113
20614	Rat	rno-miR-135a	miRNA	astragaloside IV (AS-IV)	cardiac fibrosis	heart tissues	astragaloside IV (AS-IV) treatment	upregulated	31739105
20615	Rat	rno-miR-135a	miRNA	isoproterenol	cardiac fibrosis	cardiac fibroblasts (CFs)	isoprenaline (ISO) tteatment	downregulated	29775892
20616	Rat	rno-miR-135a	miRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	Primary rat cerebral cortical neurons	hypoxia induce	downregulated	29719095
20617	Rat	rno-miR-135a	miRNA	pilocarpine	epilepsy	adult male rats brain tissue and heart tissue	50 days of pilocarpine treatment	downregulated in the brain tissue	24530830
20618	Rat	rno-miR-135a	miRNA	¦Ä-opioid receptor (DOR)	hypoxic/ischemic injury	hearts	¦Ä-opioid receptor (DOR) activation treatment	upregulated	27576463
20619	Rat	rno-miR-135a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	downregulated	30644128
20620	Rat	rno-miR-135a	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	neurotoxicity	brain tissues of rats	RDX at a dose(47 mg/kg) for 48 h treatment	upregulated	25559034
20621	Rat	rno-miR-135a	miRNA	H2O2	oxidative stress	rat cardiomyoblast cells H9c2	H2O2	upregulated	28123342
20622	Rat	rno-miR-135a	miRNA	stress	post-traumatic stress disorder (PTSD)	Wistar rats HIP	controlled lighting (light on 07:00¨C19:00 hr) and temperature (25 ¡À 2¡ãC) conditions with ad libitum access to food and water treatment	upregulated	28944448
20623	Rat	rno-miR-135a	miRNA	"paroxetine hydrochloride and corticotropin-releasing factor antagonist (CP-154,526)"	post-traumatic stress disorder (PTSD)	PTSD Wistar rats HIP	"CP-154,526 treatment"	downregulated	28944448
20624	Rat	rno-miR-135a	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline (MCT) treatment	upregulated	31773709
20625	Rat	rno-miR-135a	miRNA	acute stress (AS) and chronic stress (CS)	stress-induced myocardial injury	rat	Rats were bound and suspended treatment	downregulated	24669248
20626	Rat	rno-miR-135a-5p	miRNA	kainic acid (KA)	epilepsy	primary hippocampal neuron	kainic acid (KA) treatment	"lncRNA GAS5 functions as a competitive endogenous RNA of miR-135a-5p to increase expression of KCNQ3, and lncRNA GAS5 silencing inhibited the occurrence and progression of epilepsy."	31373759
20627	Rat	rno-miR-135a-5p	miRNA	magnesium-free extracellular fluid	epilepsy	primary hippocampal neurons from newborn rats	magnesium-free medium culture	upregulated	31091851
20628	Rat	rno-miR-135a-5p	miRNA	magnesium-free extracellular fluid	epilepsy	primary hippocampal neuron	magnesium-free extracellular fluid culture	"lncRNA GAS5 functions as a competitive endogenous RNA of miR-135a-5p to increase expression of KCNQ3, and lncRNA GAS5 silencing inhibited the occurrence and progression of epilepsy."	31373759
20629	Rat	rno-miR-135a-5p	miRNA	hypoxia	ischemic stroke (IS)	PC12 cells	hypoxia induce	downregulated	31632583
20630	Rat	rno-miR-135a-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30038339
20631	Rat	rno-miR-135a-5p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline (MCT) treatment	downregulated	30038339
20632	Rat	rno-miR-135a-5p	miRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	H2O2 treatment	downregulated	33294293
20633	Rat	rno-miR-135a-5p	miRNA	Jianpi Xiaoke (JPXK)	type 2 diabetes mellitus (T2DM)	rat	Jianpi Xiaoke (JPXK) treatment	downregulated	33456489
20634	Rat	rno-miR-135b	miRNA	radiation	breast cancer	rat mammary cancer tissues	radiation treatment	upregulated	23273170
20635	Rat	rno-miR-135b	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	rat PC-12 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	31036506
20636	Rat	rno-miR-135b-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
20637	Rat	rno-miR-136	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
20638	Rat	rno-miR-136-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	29706607
20639	Rat	rno-miR-136-3p	miRNA	high fat diet (HFD) and injection of pituitrin	coronary artery disease (CAD)	myocardial tissues	high-fat diet and injection of pituitrin	downregulated	32434208
20640	Rat	rno-miR-136-3p	miRNA	homocysteine (Hcy)	coronary artery disease (CAD)	cardiac microvascular endothelial cells (CMECs)	homocysteine (HCY) treatmemt	downregulated	32434208
20641	Rat	rno-miR-136-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30546117
20642	Rat	rno-miR-136-5p	miRNA	sulfasalazine	multiple sclerosis (MS)	OLN-93 cells	sulfasalazine (SF) treatment	SF downregulated lncRNA HOTAIR but upregulated miR-136-5p	29944870
20643	Rat	rno-miR-136-5p	miRNA	electroacupuncture (EA)	spinal cord injury (SCI)	spinal cords	electroacupuncture (EA) treatment	downregulated	32468009
20644	Rat	rno-miR-137	miRNA	ethanol (EtOH)	alcohol exposure	amygdala tissues	Adolescent rats were exposed to 2 g/kg ethanol (2 d on/off; AIE) or adolescent intermittent saline (AIS) during postnatal days (PND)28-PND41 and allowed to grow to adulthood.	upregulated	31740576
20645	Rat	rno-miR-137	miRNA	hypoxia	apoptosis	GC-5 cells; HEK-293 cells	"5% O2, 90% N2 and 5% CO2,"	downregulated	29286063
20646	Rat	rno-miR-137	miRNA	hypoxia	apoptosis	The rat retinal ganglion cell line RGC-5	hypoxia induce	downregulated	29286063
20647	Rat	rno-miR-137	miRNA	propofol (PPF)	cell apoptosis and autophagy	PC-12 cells	Propofol treatment	upregulated	31678238
20648	Rat	rno-miR-137	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozocin (STZ) treatment	downregulated	28695984
20649	Rat	rno-miR-137	miRNA	triptolide (TPL)	diabetic nephropathy (DN)	the kidney tissues of the diabetic rats	triptolide (TPL) treatment	upregulated	28695984
20650	Rat	rno-miR-137	miRNA	ketamine	hippocampal neurodegeneration	hippocampal neurons	administrat ketamine (75 mg/kg) for 3 days treatment	downregulated	25197371
20651	Rat	rno-miR-137	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic injury	rat hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-137 expression reduced in hippocampal neurons after OGD treatment.	31961204
20652	Rat	rno-miR-137	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neural ischemia/reperfusion (I/R) injury	hippocampal neurons isolated from neonatal Sprague-Dawley rats	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	28132879
20653	Rat	rno-miR-137	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	rats	chronic constriction injury (CCI) induce	downregulated	29115665
20654	Rat	rno-miR-137	miRNA	heme oxygenase-1 (HMOX1)	oxidative stress	primary spinal cord neurons of E16 rat embryos	HO-1	upregulated	27864650
20655	Rat	rno-miR-137	miRNA	lead (Pb)	spatial memory impairment	hippocampal tissues	developmental lead (Pb) exposure	upregulated	31511494
20656	Rat	rno-miR-137	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC12 cells	lipopolysaccharide (LPS) treatment	miR-137 effectively inhibited the apoptosis of LPS-challenged PC12 cells	33499717
20657	Rat	rno-miR-137-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary microglia were isolated from the spinal cord of newborn rats	lipopolysaccharide (LPS) treatment	downregulated	31210303
20658	Rat	rno-miR-138	miRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cells	hypoxia induce	"miR-138 was a downstream effector of lncRNA-LET, that miR-138 was highly expressed in lncRNA-LET-overexpressed cell. The cardioprotective effects of lncRNA-LET were abolished when miR-138 was silenced."	31222827
20659	Rat	rno-miR-138	miRNA	hypoxia	psoriasis	H9C2 cells	hypoxia treatment	upregulated	24211202
20660	Rat	rno-miR-138	miRNA	IL-6 and lipopolysaccharide (LPS)	advanced periodontal disease	periodontal ligament (PDL) cells	IL-6 and lipopolysaccharide (LPS) treatment	upregulated	26518300
20661	Rat	rno-miR-138	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	hippocampus primary neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29614311
20662	Rat	rno-miR-138	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cardiomyocytes	high glucose (HG) treatment	GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model	33682891
20663	Rat	rno-miR-138	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
20664	Rat	rno-miR-138	miRNA	hyperoside	hypoxia-induced cardiac dysfunctions	H9C2 cells	Hyperoside (Hyp) treatment	The expression levels of miR-138 were increased in the hypoxic myocardium in the presence of Hyp	33649812
20665	Rat	rno-miR-138	miRNA	astragalus polysaccharide (APS)	hypoxia-induced injury	hypoxia-induced neural stem cells (NSCs)	astragalus polysaccharide (APS) treatment	upregulated	29567543
20666	Rat	rno-miR-138	miRNA	hypoxia	hypoxia-induced injury	neural stem cells (NSCs)	hypoxia induce	upregulated	29567543
20667	Rat	rno-miR-138	miRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cells	hypoxia treatment	upregulated	31222827
20668	Rat	rno-miR-138	miRNA	emodin	myocardial infarction (MI)	hypoxia-induced H9c2 cells	emodin treatment	upregulated	30810622
20669	Rat	rno-miR-138	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	downregulated	30810622
20670	Rat	rno-miR-138	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated	31442445
20671	Rat	rno-miR-138-5p	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	MiR-138-5p was downregulated in H/R-induced H9C2 cells.	33219594
20672	Rat	rno-miR-138-5p	miRNA	metformin (Met)	acute respiratory distress syndrome (ARDS)	NR8383 cells	metformin treatment	downregulated	30178862
20673	Rat	rno-miR-138-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2cells	hypoxia/reoxygenation (H/R) treatment	downregulated	32231469
20674	Rat	rno-miR-138-5p	miRNA	gan-jiang-ling-zhu decoction (GJLZ)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	Gan-Jiang-Ling-Zhu decoction (GJLZ) treatment	"MiR-138?5p expression was significantly increased in the model group, and GJLZ decoction downregulated the expression."	32325349
20675	Rat	rno-miR-138-5p	miRNA	MgSO4	osteogenesis	rat primary bone marrow stromal cells	MgSO4 treatment	downregulated	31081160
20676	Rat	rno-miR-138-5p	miRNA	insulin-like growth factor 1 (IGF-1)	spinal cord injury (SCI)	Neural stem cells were obtained from E15 fetal rat cerebral cortex cultured supernatant exosomes	insulin growth factor-1 (IFG-1) treatment	upregulated	31848325
20677	Rat	rno-miR-139	miRNA	monomethyl fumarate (MF)	intracerebral haemorrhage (ICH)	intracerebral hemorrhage (ICH) rat brain tissues	Monomethyl fumarate (MF) treatment	upregulated	31210338
20678	Rat	rno-miR-139-3p	miRNA	acute eccentric exercise	exercise-induced muscle damage (EIMD)	Sprague-Dawley (SD) rats	a downhill running treatment at -16? gradient	dysregulated	28638919
20679	Rat	rno-miR-139-5p	miRNA	hypoxic/ischemic	neuron apoptosis	neurons;rat brain tissues	hypoxia-ischemia treatment	downregulated	24333693
20680	Rat	rno-miR-139-5p	miRNA	liraglutide	antiapoptotic	INS-1 cells	liraglutide (100 nM) for 48 h	downregulated	28346520
20681	Rat	rno-miR-139-5p	miRNA	spontaneous recurrent epileptiform discharges (SREDs)	epilepsy	rat primary hippocampal neurons	spontaneous recurrent epileptiform discharges (SREDs) treatment	miR-139-5p upregulation alleviated SREDs-induced oxidative stress and cell apoptosis via regulating the Notch pathway	33247610
20682	Rat	rno-miR-139-5p	miRNA	phenylephrine (PE)	refractory epilepsy	hippocampus	phenobarbitone injection treatment	microRNA-139-5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1	31750616
20683	Rat	rno-miR-139-5p	miRNA	fluid-percussion injury (FPI)	traumatic brain injury (TBI)	Sprague-Dawley rats	FPI	downregulated	28273100
20684	Rat	rno-miR-139-5-p	miRNA	H2O2	cardiomyocytes injury	H9c2 cells	H2O2 treatment	downregulated	26884911
20685	Rat	rno-miR-139b	miRNA	"high concentrations of lipid and glucose, and cytokines"	vascular hyper-reactivity	VSMC	"incubat high glucose (25mmol/L) or lipid (palmitic acid 50 ¦Ì mol/L) and 200ng/ml of TNF-¦Á,IL-1¦Â and IL-6 for 25h treatment"	downregulated	25425000
20686	Rat	rno-miR-1-3p	miRNA	isoproterenol	acute cardiac injury	heart tissues	isoproterenol treatment	upregulated	27605421
20687	Rat	rno-miR-1-3p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	downregulated	27535721
20688	Rat	rno-miR-1-3p	miRNA	muscle contraction	diabetes mellitus (DM)	muscle tissues	"stimulated to contract in vitro for twitch tension analysis (0.5 Hz), 30 min later for tetanic analysis (100 Hz)"	upregulated	28000044
20689	Rat	rno-miR-1-3p	miRNA	butorphanol	ischemic arrhythmias	myocardial tissues	butorphanol treatment	Butorphanol significantly reduced the level of miR-1-3p in myocardium.	33210593
20690	Rat	rno-miR-1-3p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
20691	Rat	rno-miR-1-3p	miRNA	Jianpi Xiaoke (JPXK)	type 2 diabetes mellitus (T2DM)	rat	Jianpi Xiaoke (JPXK) treatment	upregulated	33456489
20692	Rat	rno-miR-140	miRNA	paclitaxel (PTX)	lung fibrosis	lung tisssue of rats	paclitaxel? treatment	low-dose PTX prevents pulmonary fibrosis by suppressing the TGF-¦Â1/Smad3 pathway via upregulating miR-140	23967091
20693	Rat	rno-miR-140	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	plasma and lungs	lipopolysaccharide (LPS) treatment	downregulated	30233718
20694	Rat	rno-miR-140	miRNA	food restriction	malnutrition	rats serum	10 days of 40% food restriction (RES) treatment	downregulated	24456162
20695	Rat	rno-miR-140	miRNA	ormeloxifene	ormeloxifene-induced inhibition of embryo implantation	uterine tissues	ormeloxifene treatment	miR-140 expression was found to be elevated in ormeloxifene administered groups.	29330027
20696	Rat	rno-miR-140	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
20697	Rat	rno-miR-140	miRNA	atorvastatin	pericardial patch angioplasty	patch isolated from surrounding vascular tissue	atorvastatin treatment	upregulated	30662650
20698	Rat	rno-miR-140*	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	7-week-old Fischer344 male rats liver	aflatoxin B1 (AFB6) treatment	upregulated	24472605
20699	Rat	rno-miR-140*	miRNA	nicotine	nicotine addiction	rat PC12 cell	nicotine treatment	upregulated	18845019
20700	Rat	rno-miR-140-3p	miRNA	fetal bovine serum (FBS)	liver fibrosis	HSC-T6 cells	Cells were incubated with 5% FBS for 48 h	upregulated	31124340
20701	Rat	rno-miR-140-3p	miRNA	platelet derived growth factor-BB (PDGF-BB)	liver fibrosis	HSC-T6 cells	Cells were treated with 10 ng/mL of PDGF-BB for 48 h treatment	upregulated	31124340
20702	Rat	rno-miR-140-3p	miRNA	TGF-¦Â1	liver fibrosis	HSC-T6 cells	TGF-¦Â2 treatment	upregulated	31124340
20703	Rat	rno-miR-140-5p	miRNA	shikonin	acute lung injury (ALI)	rat lung tissues	Shikonin treatment	Shikonin has effective treatment effects on acute lung injury via regulation of microRNA-140-5p/toll-like receptor 4 (miRNA-140-5p/TLR4) in the in vivo study	31769066
20704	Rat	rno-miR-140-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (DOX) treatment	upregulated	29304479
20705	Rat	rno-miR-140-5p	miRNA	dioscin	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	dioscin treatment	downregulated	29524841
20706	Rat	rno-miR-140-5p	miRNA	dexmedetomidine (DEX)	hypoxic/ischemic brain damage (HIBD)	Hypoxia-ischaemia (HI)-treated neonatal rats?brain tissues	dexamethasone (DEX) treatment	upregulated	29536658
20707	Rat	rno-miR-140-5p	miRNA	doxorubicin (DOX)	cardiomyocytes injury	SD rats heart tissue	treat with DOX	upregulated	29304479
20708	Rat	rno-miR-140-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	The expression of miR-140-5p in H/R-induced H9c2 cells was higher than that in the control group.	32572928
20709	Rat	rno-miR-140-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	rats pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30367500
20710	Rat	rno-miR-140-5p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline (MCT) treatment	downregulated	30367500
20711	Rat	rno-miR-141	miRNA	paraquat (PQ)	lung injury	lung tissues; RLE-6TN cells	paraquat (PQ) treatment	downregulated	33015978
20712	Rat	rno-miR-141	miRNA	thalidomide	lung injury	lung tissues; RLE-6TN cells	thalidomide treatment	upregulated	33015978
20713	Rat	rno-miR-141	miRNA	glucose fluctuations (GF)	cardiovascular complications of diabetes mellitus (DM)	heart	glucose fluctuations (GF) treatment	upregulated	26497329
20714	Rat	rno-miR-141	miRNA	N-acetyl-L-cysteine (NAC)	chronic nonbacterial prostatitis (CNP)	carrageenan-induced CNP rats	N-acetyl-L-cysteine (NAC) treatment	upregulation	26941030
20715	Rat	rno-miR-141	miRNA	antibiotics	dysbacteria	Sprague Dawley (SD) rats faeces	treat with a combination of antibiotics for 8 week	downregulated	29264965
20716	Rat	rno-miR-141	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
20717	Rat	rno-miR-141	miRNA	hypoxia	hypoxia-induced injury	PC12 cells	hypoxia induce	downregulated	31273531
20718	Rat	rno-miR-141	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
20719	Rat	rno-miR-141	miRNA	TGF-¦Â1	liver fibrosis	HSC-T6 cells	TGF-¦Â1 treatment	downregulated of miR-141 deactivates hepatic stellate cells by targeting the PTEN/AKT/mTOR pathway	32319536
20720	Rat	rno-miR-141	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	dorsal root ganglion	chronic constriction injury (CCI) treatment	downregulated	26398163
20721	Rat	rno-miR-141	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	kidney?tissues	OTA nephrotoxicity treatment	suppressed in mid dose but then elevated in high dose	24885635
20722	Rat	rno-miR-141	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12 cells	N-methyl-4-phenylpyridinium (MPP +) treatment	"MPP+ toxicity significantly caused upregulated in miR-34a, miR-141, and miR-9."	29631008
20723	Rat	rno-miR-141	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	chondrocyte	lipopolysaccharide (LPS) treatment	"miR-141 was upregulated in LPS-treated chondrocyte. Inhibitory effects of MEG3 overexpression, mentioned above, were partially abolished by overexpressed miR-141."	31411001
20724	Rat	rno-miR-141	miRNA	dexamethasone (DEX)	steroid-induced avascular necrosis of femoral head (SANFH)	Bone marrow mesenchymal stem cells (BMSC)	dexamethasone (DEX) treatment	The mRNA expression of miR-141 was higher in the DEX group compared with the control group.	31916393
20725	Rat	rno-miR-141	miRNA	acute stress (AS) and chronic stress (CS)	stress-induced myocardial injury	rat	Rats were bound and suspended treatment	upregulated	24669248
20726	Rat	rno-miR-141-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	downregulated	32192351
20727	Rat	rno-miR-141-3p	miRNA	high fat diet (HFD)	cardiac dysfunction	myocardium	high fat diet (HFD) feed	upregulated	32346302
20728	Rat	rno-miR-141-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	H/R remarkably reduces the expression of miR-141-3p.	32123560
20729	Rat	rno-miR-141-3p	miRNA	propofol (PPF)	neurodegeneration (ND)	rats neural stem cells (NSCs)	propofol treatment	upregulated	27796156
20730	Rat	rno-miR-141-3p	miRNA	propofol (PPF)	neurodegenerative diseases	neural stem cells (NSCs)	propofol treatment	upregulated	27796156
20731	Rat	rno-miR-141-3p	miRNA	hypoxia	oxidative stress	H9c2 rat cardiomyoblasts	hypoxia induce	upregulated	31532760
20732	Rat	rno-miR-141-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC-12 cells	MPP+ (1-methyl-4-phenylpyridinium) treatment	miR-141-3p was upregulated in MPP+-treated PC12 cells.	33204711
20733	Rat	rno-miR-141-3p	miRNA	letrozole	polycystic ovarian syndrome (PCOS)	Ovary?tissues	letrozole treatment	dysregulated	26745201
20734	Rat	rno-miR-141-3p	miRNA	phthalate mixture	prostate development	Pregnant females filial generation rat prostate	Pregnant females were divided into 4 groups and orally dosed daily from GD10 to PND21 with corn oil (Control:C) or the phthalate mixture at three doses (20?¦Ìg/kg/d:T1; 200?¦Ìg/kg/d:T2; 200?mg/kg/d:T3). treatment	upregulated	31199487
20735	Rat	rno-miR-141-3p	miRNA	bleomycin (BLM)	lung fibrosis	rat lung tissues	bleomycin (BLM) treatment	downregulated	30755599
20736	Rat	rno-miR-141-3p	miRNA	TGF-¦Â1	lung fibrosis	RLE-6TN cells	TGF-¦Â1 treatment	downregulated	30755599
20737	Rat	rno-miR-141-3p	miRNA	high glucose (HG)	pyroptosis	H9c2 cells	high glucose (HG) treatment	"MALAT1 mRNA expression levels were significantly increased, whereas miR-141-3p expression levels were significantly decreased in HG-treated H9C2 cells compared with the NG group."	33576445
20738	Rat	rno-miR-142	miRNA	electroacupuncture (EA)	hyperactivity of the HPA axis induced by hepatectomy	rats	electroacupuncture (EA) treatment	upregulated	29021740
20739	Rat	rno-miR-142	miRNA	hepatectomy	hyperactivity of the HPA axis induced by hepatectomy	rats hypothalamic	hepatectomy	downregulated	29021740
20740	Rat	rno-miR-142-3p	miRNA	TGF-¦Â3	blood-testis barrier (BTB) impairment	Primary Sertoli cell	TGF-¦Â3 treatment	downregulated	29590647
20741	Rat	rno-miR-142-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	cultured neonatal rat cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	30372837
20742	Rat	rno-miR-142-3p	miRNA	citrate	cardiomyocyte autophagy	cardiomyocytes	citrate treatment	"The level of miR-142-3p was downregulated in H/R model, but upregulated in cardiomyocytes following citrate treatment."	32456513
20743	Rat	rno-miR-142-3p	miRNA	isoproterenol	drug-induced cardiac injury (DICI)	heart tissues	isoproterenol treatment	upregulated	29355689
20744	Rat	rno-miR-142-3p	miRNA	TGF-¦Â	liver cirrhosis	rat primary HSCs	TGF-¦Â treatment	downregulated	28823564
20745	Rat	rno-miR-142-3p	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	mesenchymal stem cell (MSC) exosome	hypoxia-reoxygenation (H/R) treatment	upregulated	32719674
20746	Rat	rno-miR-142-3p	miRNA	phosphodiesterase 5 (PDE5) inhibitor	nonalcoholic fatty liver disease (NAFLD)	plasma exosomes	phosphodiesterase 5 (PDE5) inhibitor treatment	upregulated	33396535
20747	Rat	rno-miR-142-3p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	upregulated	28560399
20748	Rat	rno-miR-142-3p	miRNA	X-rays	radiosensitivity	786-O and A549 cells	786-O and A549 cells treatment	dysregulated	27527863
20749	Rat	rno-miR-142-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	reperfusion/ischemia brain injury	Primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-142-3p expression was downregulated in neurons when exposed to oxygen-glucose deprivation/re-oxygenation.	32246643
20750	Rat	rno-miR-142-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	rat mesangial cells (RMCs)	lipopolysaccharide (LPS) treatment	upregulated	30834562
20751	Rat	rno-miR-142-5p	miRNA	acute stressor modulates	acute stress	male Fisher 344 rats	expose to an acute stressor modulates treatment	downregulated	25259839
20752	Rat	rno-miR-142-5p	miRNA	oleanolic acid (OLA)	diabetic nephropathy (DN)	high glucose-induced NRK-52E cells	oleanolic acid (OLA) treatment	downregulated	31410746
20753	Rat	rno-miR-142-5p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal tissues	streptozocin (STZ) treatment	miR-142-5p level was downregulated in retinal tissues of DR rats.	32116075
20754	Rat	rno-miR-142-5p	miRNA	hypoxia	heart failure (HF)	H9c2 cells	hypoxia induce	"silence of lncRNA GAS5 attenuated hypoxia-triggered cell death, silence of lncRNA GAS5 protected H9c2 cells against hypoxia-induced injury possibly via sponging miR-142-5p."	31085811
20755	Rat	rno-miR-142-5p	miRNA	Smad3 inhibitor (SIS3)	intrauterine adhesion (IUA)	endometrial stromal cells (ESCs)	Smad3 inhibitor (SIS3) treatment	upregulated	32447720
20756	Rat	rno-miR-142-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	rat hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	28320085
20757	Rat	rno-miR-142-5p	miRNA	hypoxia	ischemic heart disease (IHD)	H9C2 cardiomyoblasts	hypoxia treatment	downregulated	28772218
20758	Rat	rno-miR-142-5p	miRNA	IL-6	osteogenesis	bone marrow stromal stem cells (BMSCs)	IL-6 treatment	"BLACAT1 expression was increased in inflammatory BMSCs, and knockdown of BLACAT1 promoted proliferation and osteogenic differentiation of BMSCs targeting miR-142-5p."	32271407
20759	Rat	rno-miR-142-5p	miRNA	triclosan (TCS)	testosterone	R2C cells; testis; Leydig cells	Triclosan (TCS) treatment	"TCS treatment upregulated miR-142-5p expressions in Leydig cells, with the maximum inductive effect observed in R2C cells treated with 10 ¦ÌM of TCS"	32084696
20760	Rat	rno-miR-143	miRNA	plum polyphenols	aberrant crypt foci	colon tissues	plum polyphenols treatment	upregulated	27865352
20761	Rat	rno-miR-143	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	male Wistar rats inflamed colon	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated in inflamed colon	28572713
20762	Rat	rno-miR-143	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (Dox) treatment	Doxorubicin treatment increased the expression of miR-143.	32170053
20763	Rat	rno-miR-143	miRNA	stimulation electrode	epilepsy	Adult male Sprague Dawley rats blood	A bipolar stimulation electrode (distance between tips 500 ?m) was implanted in the angular bundle treatment	dysregulated	24184920
20764	Rat	rno-miR-143	miRNA	myocardin	hepatitis C virus (HCV) infection	rat primary aortic SMCs	myocardin treatment	myocardin coordinate smooth muscle differentiation by inducing transcription of microRNA-143	20489207
20765	Rat	rno-miR-143	miRNA	activin A	insulin action in cardiomyocytes	primary adult rat cardiomyocytes (ARC)	activin A treatment	downregulated	23812417
20766	Rat	rno-miR-143	miRNA	aerobic exercise	left ventricular hypertrophy (LVH)	left ventricular	aerobic exercise training (AET) treatment	downregulated	21709209
20767	Rat	rno-miR-143	miRNA	trichostatin A (TSA)	hepatocellular carcinoma (HCC)	rat primary hepatocytes	Trichostatin A (TSA)treatment treatment	"miR-122, miR-143 and miR-379 could be related to the inhibitory effects of TSA on hepatocellular proliferation"	21513791
20768	Rat	rno-miR-143	miRNA	hypoxia	myocardial infarction (MI)	neonatal rat cardiomyocytes	hypoxia induce	upregulated	30998966
20769	Rat	rno-miR-143	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	lncUCA1 might protect cardiomyocyte against H/R induced apoptosis by suppressing miR-143 and modulated the following downstream MDM2/p53 signaling pathway.	30998966
20770	Rat	rno-miR-143	miRNA	high fat diet (HFD)	obesity	adipose tissues	high fat diet (HFD) feed	"The obese rats in the HFD group, compared with rats in the NFD group, demonstrated a significant decrease in the expression of miR-27a (p < 0.05) and a significant increase in the expression of miR-143."	30411548
20771	Rat	rno-miR-143	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	lung tissues	hypoxia treatment	upregulated	30195228
20772	Rat	rno-miR-143	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
20773	Rat	rno-miR-143	miRNA	zinc oxide nanoparticles (ZnONPs) and DPP-IV inhibitor (Vildagliptin)	type 2 diabetes mellitus (T2DM)	type 2 diabetes rats	type 2 diabetes rats treatment	downregulated	27723572
20774	Rat	rno-miR-143	miRNA	high fat diet (HFD)	weight gain	end epididymal fat	high fat diet (HFD) feed	upregulated	29023027
20775	Rat	rno-miR-143-3p	miRNA	atorvastatin	cardiac fibrosis	cardiac fibroblasts (CFs)	atorvastatin treatment	Atorvastatin suppressed the levels of miR-143-3p.	31758917
20776	Rat	rno-miR-143-3p	miRNA	TGF-¦Â1	cardiac fibrosis	cultured?cardiac fibroblasts (CFs)	TGF-¦Â1	upregulated	31758917
20777	Rat	rno-miR-143-3p	miRNA	¦Â3-adrenoceptors(¦Â3-AR) inhibitor SR 59230A	chronic heart failure (CHF)	CHF rats	1 ml SR 59230A(85 mmoL/L in 0.9% saline)twice a day for seven weeks by intraperitoneal injection treatment	upregulated	29926593
20778	Rat	rno-miR-143-3p	miRNA	cisplatin and gentamicin	drug-induced acute kidney injury (DIKI)	plasma	"cisplatin (CSP, 6?mg/kg) and gentamicin (GEN, 120?mg/kg) treatment"	downregulated	30682439
20779	Rat	rno-miR-143-3p	miRNA	gypenoside A (GP)	ischemia/reperfusion (I/R) injury	H9c2 cells	Gypenoside A (GP) treatment	Administration of GP decresed the expression of miR-143-3p.	31889343
20780	Rat	rno-miR-143-3p	miRNA	angiotensin II (Ang II)	left ventricular hypertrophy (LVH)	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	30119211
20781	Rat	rno-miR-143-3p	miRNA	atorvastatin	left ventricular hypertrophy (LVH)	angiotensin II (Ang II)-treated H9c2 cells	atorvastatin treatment	downregulated	30119211
20782	Rat	rno-miR-143-3p	miRNA	H2O2	cardiac hypertrophy	H9c2 cells	H2O2 treatment	H2O2 administration increased the levels of miR-143-3p.	30203887
20783	Rat	rno-miR-143-3p	miRNA	gypenoside A (GP)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced H9c2 cell line	Gypenoside A (GP) treatment	downregulated	31889343
20784	Rat	rno-miR-143-3p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cell line	hypoxia induce	upregulated	31889343
20785	Rat	rno-miR-143-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20786	Rat	rno-miR-143-5p	miRNA	propofol (PPF)	neurotoxicity	primary cultured neural stem cells (NSCs)	propofol treatment	upregulated	29679758
20787	Rat	rno-miR-144	miRNA	ginsenoside Rg1	apoptosis	hypoxia-induced PC12 cells	Ginsenoside Rg1 treatment	downregulated	30262824
20788	Rat	rno-miR-144	miRNA	hypoxia	apoptosis	PC12 cells	OGD/R treatment	upregulated	30262824
20789	Rat	rno-miR-144	miRNA	isoprenaline	cardiac hypertrophy	rat primary cardiomyocytes	isoprenaline induction	downregulated	33013286
20790	Rat	rno-miR-144	miRNA	hypoxia	cardioprotective therapy	bone marrow mesenchymal stem cell (MSC)-derived exosomes	hypoxia treatment	upregulated	31973741
20791	Rat	rno-miR-144	miRNA	human immunodeficiency virus (HIV)-1	chronic human immunodeficiency virus (HIV) infection	alveolar epithelial cell (AEC)	Human immunodeficiency virus (HIV)-1 infection	upregulated	31091144
20792	Rat	rno-miR-144	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells; Neonatal rat cardiomyocytes (NRCMs)	high glucose (HG) treatment	downregulated	31907983
20793	Rat	rno-miR-144	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	downregulated	22156553
20794	Rat	rno-miR-144	miRNA	high glucose (HG)	hyperglycemia-induced cardiac dysfunction	"Neonatal rat cardiomyocytes (NRCMs), rat H9c2 cells"	high glucose treatment	downregulated	31907983
20795	Rat	rno-miR-144	miRNA	ginsenoside Rg1	ischemia/reperfusion (I/R) injury	OGD/R-treated PC-12 cell	Ginsenoside Rg1 (Rg1) treatment	downregulated	30262824
20796	Rat	rno-miR-144	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	PC-12 cells	oxygen-glucose deprivation/reperfusion (OGD/R) treatment	upregulated	30262824
20797	Rat	rno-miR-144	miRNA	swimming	left ventricular hypertrophy (LVH)	rat left ventricular	Swimming exercise training treatment	upregulated	23812090
20798	Rat	rno-miR-144	miRNA	SiO2	lung injury	lung	SiO2 treatment	upregulated	27689473
20799	Rat	rno-miR-144	miRNA	4-vinylcyclohexene diepoxide (VCD)	premature ovarian failure (POF)	ovarian	4-vinylcyclohexene diepoxide (VCD) tretament	downregulated	24188450
20800	Rat	rno-miR-144	miRNA	botulinum neurotoxin (BoNT)	nerve sprouting	spinal cord anterior horn	botulinum neurotoxin (BoNT) treatment	downregulated	32083076
20801	Rat	rno-miR-144	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
20802	Rat	rno-miR-144	miRNA	4-vinylcyclohexene diepoxide (VCD)	premature ovarian failure (POF)	rat POF tissues	VCD treatment	downregulated	24188450
20803	Rat	rno-miR-144	miRNA	american ginseng root's	premature ovarian failure (POF)		4-Vinylcyclohexene diepoxide (VCD) treatment	upregulated	25705687
20804	Rat	rno-miR-144-3p	miRNA	high fat diet (HFD)	cardiac dysfunction	myocardium	high fat diet (HFD) feed	upregulated	32346302
20805	Rat	rno-miR-144-3p	miRNA	rapamycin	cardiac fibrosis	heart tissues	rapamycin (Rap) treatment	downregulated	30647817
20806	Rat	rno-miR-144-3p	miRNA	iohexol	contrast-induced acute kidney injury (CIAKI)	Renal tissue	"Animals were dehydrated for 48 h and then underwent furosemide (10 mL/kg; Harvest Pharmaceutical, Shanghai, China) injection 30 min before administration of iohexol (15 mL/kg, group CI-AKI; iodine, 350 mg/mL; GE Healthcare, Shanghai, China) or 0.9% normal saline (15 mL/kg, control group)."	miR-144-3p was downregulated in Contrast-induced acute kidney injury (CI-AKI).	31234008
20807	Rat	rno-miR-144-3p	miRNA	oxyhemoglobin (OxyHb)	intracerebral hemorrhage (ICH)-induced secondary brain injury (SBI)	primary rat cortical neurons	oxyhemoglobin (OxyHb) treatment	"Following ICH induction, we found miRNA-144-3p expression to increase."	30511586
20808	Rat	rno-miR-144-3p	miRNA	intracerebral hemorrhage (ICH)	secondary brain injury (SBI)	primary rat cortical neurons	oxyhemoglobin (OxyHb) treatment	"miRNA-144-3p aggravated ICH-induced SBI by targeting and downregulating FPR2, thereby contributing to neurological dysfunction and neural apoptosis via PI3K/AKT pathway activation."	30511586
20809	Rat	rno-miR-144-5p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	downregulated	32893733
20810	Rat	rno-miR-145	miRNA	ethanol (EtOH)	acute gastric mucosal injury	gastric tissues?of rat	oral administration of ethanol	upregulated	23830200
20811	Rat	rno-miR-145	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	The miR-145 was downregulated in the LPS-induced ARDS lung	33505551
20812	Rat	rno-miR-145	miRNA	soluble ¦Â-amyloid (sA¦Â) oligomers	Alzheimer's disease (AD)	cortical neurons were isolated from E17 embryos of Sprague Dawley rats	sA¦Â treatment	upregulated	24595404
20813	Rat	rno-miR-145	miRNA	reactive oxygen species (ROS)	cadmium-induced toxicity	neonatal rat cardiomyocytes	reactive oxygen species (ROS) treatment	miR-145 regulates reactive oxygen species (ROS)-induced Ca2+overload in cardiomyocytes	23702479
20814	Rat	rno-miR-145	miRNA	high glucose (HG)	cardiomyocyte apoptosis	rat cardiomyocytes	high glucose concentration (25 mmol/L)	downregulated	29178342
20815	Rat	rno-miR-145	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemic stroke (CIS)	rats astrocytes	oxygen-glucose deprivation (OGD) treatment	downregulated	29057271
20816	Rat	rno-miR-145	miRNA	hypoxia	chronic hypoxic heart disease (CHD)	H9c2 cells	hypoxia induce	"miR©\145 was repressed by hypoxia,miR©\145 overexpression caused an inhibition in viability and facilitation in apoptosis"	31190357
20817	Rat	rno-miR-145	miRNA	estradiol benzoate (EB)	chronic inflammatory diseases	dorsolateral prostate	estradiol benzoate (EB) treatment	upregulated	33332750
20818	Rat	rno-miR-145	miRNA	pomegranate beverage (PG)	colitis	dextran sodium sulfate (DSS) induced colitis rats	PG treatment	upregulated	28282584
20819	Rat	rno-miR-145	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose (HG) treatment	"In the HG group, miR-145 expression was significantly decreased and ARF6 expression significantly increased compared with controls."	33763154
20820	Rat	rno-miR-145	miRNA	lithium chloride and pilocarpine	epilepsy	hippocampus	lithium chloride-pilocarpine treatment	upregulated	30465949
20821	Rat	rno-miR-145	miRNA	lithium chloride and pilocarpine	epilepsy	hippocampus	lithium chloride-pilocarpine treatment	upregulated	30465949
20822	Rat	rno-miR-145	miRNA	emodin	hepatitis	LPS-treated primary hepatocyte	Emodin treatment	upregulated	31079494
20823	Rat	rno-miR-145	miRNA	lipopolysaccharide (LPS)	hepatitis	primary hepatocyte	lipopolysaccharide (LPS) treatment	downregulated	31079494
20824	Rat	rno-miR-145	miRNA	diethylnitrosamine (DEN)	hepatocellular carcinoma (HCC)	liver tissues	diethylnitrosamine (DEN) treatment	upregulated	30412748
20825	Rat	rno-miR-145	miRNA	pomegranate fruit aqueous extract (PGE)	insulin sensitivity	Alloxan-diabetic Wistar rats plasma and homogenized suspension of liver and skeletal muscle tissues	long-term PGE treatment	downregulated in plasma and homogenized suspension of liver and skeletal muscle tissues	29105385
20826	Rat	rno-miR-145	miRNA	swimming	left ventricular hypertrophy (LVH)	rat left ventricular	Swimming exercise training treatment	upregulated	23812090
20827	Rat	rno-miR-145	miRNA	TGF-¦Â	liver fibrosis	rat primary HSCs	10?ng/mL TGF- treatment	upregulated	28091538
20828	Rat	rno-miR-145	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	upregulated	28980287
20829	Rat	rno-miR-145	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	upregulated	29055960
20830	Rat	rno-miR-145	miRNA	ischemia	myocardial infarction (MI)	rats heart tissues	left anterior descending artery (LAD) ligation	downregulated in heart	29218098
20831	Rat	rno-miR-145	miRNA	hypoxia	myocardial ischaemic injury	rat cardiomyocytes	hypoxia treatment	The hypoxic insult led to the suppression of miR-145 expression in cultured rat cardiomyocytes in a concentration-dependent manner.	32138537
20832	Rat	rno-miR-145	miRNA	Fibroblast growth factor 21 (FGF21)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced H9c2 cells	Fibroblast growth factor 21 (FGF21) treatment	upregulated	30662618
20833	Rat	rno-miR-145	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	downregulated	30662618
20834	Rat	rno-miR-145	miRNA	geniposide (GEN)	myocarditis	H9c2 cells	geniposide (GEN) treatment	upregulated	29611016
20835	Rat	rno-miR-145	miRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	dysregulated	24517225
20836	Rat	rno-miR-145	miRNA	hypoxia	obstructive sleep apnea (OSA)	Sprague Dawley rats Vascular smooth muscle cells (VSMCs)	hypoxia treatment	downregulated	28465478
20837	Rat	rno-miR-145	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	experimental OA in rats	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29072705
20838	Rat	rno-miR-145	miRNA	angiotensin II (Ang II)	oxidative stress	primary cultured rat cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	29178342
20839	Rat	rno-miR-145	miRNA	H2O2	oxidative stress	HaCaT cells	H2O2 treatment	Anti-antioxidant impacts of circZNF609 silence in HaCaT cells through regulating miR-145	33821719
20840	Rat	rno-miR-145	miRNA	high glucose (HG)	oxidative stress	primary cultured rat cardiomyocytes	Sustained high glucose concentration (25 mmol/L) treatment	downregulated	29178342
20841	Rat	rno-miR-145	miRNA	pomegranate fruit aqueous extract (PGE)	oxidative stress	plasma and liver and skeletal muscle tissues	pomegranate fruit aqueous extract (PGE) treatment	upregulated	29105385
20842	Rat	rno-miR-145	miRNA	streptozocin (STZ)	painful diabetic neuropathy (PDN)	L3-5 DRG neurons	streptozocin (STZ) treatment	downregulated	33185386
20843	Rat	rno-miR-145	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
20844	Rat	rno-miR-145	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
20845	Rat	rno-miR-145	miRNA	TGF-¦Â	acute myocardial infarction (AMI)	mesenchymal stem cells (MSC)	TGF-¦Â(1) treatment	upregulated	21762377
20846	Rat	rno-miR-145-5p	miRNA	cationic bovine serum albumin (C-BSA)	chronic glomerulonephritis (CGN)	rats renal mesangial cells	C-BSA treatment	upregulated in renal mesangial cells	29030988
20847	Rat	rno-miR-145-5p	miRNA	¦Â3-adrenoceptors(¦Â3-AR) inhibitor SR 59230A	chronic heart failure (CHF)	CHF rats	1 ml SR 59230A(85 mmoL/L in 0.9% saline)twice a day for seven weeks by intraperitoneal injection treatment	upregulated	29926593
20848	Rat	rno-miR-145-5p	miRNA	puerarin	diabetic nephropathy (DN)	Renal Tissue	puerarin treatment	upregulated	33122931
20849	Rat	rno-miR-145-5p	miRNA	dioscin	hepatorenal damages	L-02;NRK-52E cells	dioscin treatment	Dioscin reduced the expression levels of miR-145-5p which directly targeted Sirt5	33836263
20850	Rat	rno-miR-145-5p	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	cardiac microvascular endothelial cells (CMEC)	hypoxia/reoxygenation (H/R) treatment	The injured CMECs showed significantly lower miR-145-5p expression than normal ones.	32432764
20851	Rat	rno-miR-145-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
20852	Rat	rno-miR-145-5p	miRNA	hypoxia	myocardial hypoxic/ischemic injury	H9c2 cardiac cells	hypoxia treatment	downregulated	28281187
20853	Rat	rno-miR-145-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20854	Rat	rno-miR-145-5p	miRNA	geniposide (GEN)	spinal cord injury (SCI)	LPS-treated PC12 cells	Geniposide treatment	upregulated	31307231
20855	Rat	rno-miR-145-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC12 cells	lipopolysaccharide (LPS) treatment	downregulated	31307231
20856	Rat	rno-miR-146	miRNA	hypoxia	apoptosis	H9c2 rat myocardial cells	oxygen-glucose deprivation/recovery (OGD/R) treatment	downregulated	29257202
20857	Rat	rno-miR-146	miRNA	carbamylated albumin	renal cell carcinoma (RCC)	rat mesangial cells (RMCs)	Carbamylated albumin treatment	upregulated	21472233
20858	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	kidney tissues; NRK-52E cells	lipopolysaccharide (LPS) treatment	downregulated	29115409
20859	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	NRK-52E cells	lipopolysaccharide (LPS) treatment	downregulated	29115409
20860	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	endotoxin treatment	upregulated	26137246
20861	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	MALAT1 was upregulated and mir-146a was downregulated in lps-induced ALI rat model.	29649906
20862	Rat	rno-miR-146a	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	lung tissues	sevoflurane treatment	downregulated	28617947
20863	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	acute Lung Injury (ALI)/acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	23848342
20864	Rat	rno-miR-146a	miRNA	streptozocin (STZ)	aorta inflammation	male Wistar rats diabetic aorta	streptozocin (STZ) treatment	downregulated	24824805
20865	Rat	rno-miR-146a	miRNA	acupuncture	chronic atrophic gastritis (CAG)	gastric	acupuncture treatment	downregulated	27293468
20866	Rat	rno-miR-146a	miRNA	dexmedetomidine (DEX)	chronic obstructive pulmonary disease (COPD)	lung	dexmedetomidine (Dex) treatment	downregulated	27677199
20867	Rat	rno-miR-146a	miRNA	running	diabetes mellitus (DM)	rats kidney	exposed to 5 days of consecutive treadmill exercise for 60 min/day with the 22 m/min speed for 60 days treatment	upregulated	28858844
20868	Rat	rno-miR-146a	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	rats kindey	streptozocin (STZ) treatment	downregulated	28858844
20869	Rat	rno-miR-146a	miRNA	inorganic arsenic (iAs)	diabetes mellitus (DM)	rat insulinoma cells	inorganic arsenic (iAs) exposure	upregulated	31555879
20870	Rat	rno-miR-146a	miRNA	streptozocin (STZ)	diabetes-related cognitive impairments	serum from STZ/CC rats	streptozotocin (STZ) treatment	downregulated	30240403
20871	Rat	rno-miR-146a	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney?of rat	streptozotocin treatment	upregulated	24057185
20872	Rat	rno-miR-146a	miRNA	high glucose (HG)	diabetic peripheral neuropathy (DPN)	macrophage	high glucose (HG) treatment	LncRNA HCG18 was highly expressed in DPN model and HG-induced macrophages.	32996080
20873	Rat	rno-miR-146a	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	sciatic nerve	streptozotocin treatment	upregulated	25567745
20874	Rat	rno-miR-146a	miRNA	mitomycin C-polylactic acid ( MMC-PLA) film	epidural scar hyperplasia and adhesion	post-laminectomy rat scar tissues	25 mg of PLA film containing 0.01% MMC was implanted on the laminectomy area	upregulated	28617531
20875	Rat	rno-miR-146a	miRNA	lithium chloride and pilocarpine	epilepsy	brain tissues	lithium-pilocarpine treatment	dysregulated	29363732
20876	Rat	rno-miR-146a	miRNA	pilocarpine	epilepsy	adult male rats brain tissue and heart tissue	50 days of pilocarpine treatment	downregulated in the brain tissue	24530830
20877	Rat	rno-miR-146a	miRNA	sleep deprivation	epilepsy	adult male rats	total sleep deprivation (TSD 6 h) and paradoxical sleep deprivation (PSD 24 h) treatment	significant increase of miR-146a expression	24530830
20878	Rat	rno-miR-146a	miRNA	ulinastatin	hemorrhagic shock	hemorrhagic shock rats lung tissues	ulinastatin treatment	upregulated	31801723
20879	Rat	rno-miR-146a	miRNA	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)	hypertension	heart tissues	deoxycorticosterone acetate (DOCA) -salt (sodium chloride) treatment	downregulated	30290168
20880	Rat	rno-miR-146a	miRNA	metformin (Met)	hypertension	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)-induced hypertension rats heart tissues	metformin (MF) treatment	upregulated	30290168
20881	Rat	rno-miR-146a	miRNA	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)	hypertension-induced cardiac dysfunction	heart tissues	deoxycorticosterone acetate (DOCA) -salt (sodium chloride) treatment	downregulated	30290168
20882	Rat	rno-miR-146a	miRNA	metformin (Met)	hypertension-induced cardiac dysfunction	heart tissues	Metformin treatment	upregulated	30290168
20883	Rat	rno-miR-146a	miRNA	thymosin ¦Â4 (T¦Â4)	hypoxic brain injury	Coronal cerebellar	T¦Â4 treatment	microRNA 146a expression was found to have increased in Tβ4-treated BV-2 cells	26457369
20884	Rat	rno-miR-146a	miRNA	complete freund's adjuvant (CFA)	inflammatory pain	dorsal root ganglion (DRG)	complete Freund's adjuvant (CFA) treatment	The expression of miR-146a was decreased in CFA rats.	30129228
20885	Rat	rno-miR-146a	miRNA	fagellin (FLA)	intestinal inflammation	IEC18 cells	fagellin (FLA) treatment	upregulated	30478292
20886	Rat	rno-miR-146a	miRNA	IL-1¦Â	intestinal inflammation	IEC18 cells	IL-1¦Â treatment	upregulated	30478292
20887	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	intestinal inflammation	IEC18 cells	lipopolysaccharide (LPS) treatment	upregulated	30478292
20888	Rat	rno-miR-146a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intestinal inflammation	IEC18 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30478292
20889	Rat	rno-miR-146a	miRNA	collagenase VII	intracerebral haemorrhage (ICH)	brain tissues	The ICH model was constructed via the stereotaxic intrastriatal injection of collagenase type VII	miR-146a was significantly downregulated in ICH rats	31656540
20890	Rat	rno-miR-146a	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
20891	Rat	rno-miR-146a	miRNA	spirulina diet	lactogenesis	brains	Spirulina-enriched diet treatment	upregulated	27571388
20892	Rat	rno-miR-146a	miRNA	heat stress	lung cancer	lung	Heating System 2.2 (THS2.2) treatment	downregulated	27866933
20893	Rat	rno-miR-146a	miRNA	rotenone (ROT)	mitochondrial dysfunction	brain tissues	rotenone treatment	Coordinated Action of miR-146a and Parkin Gene Regulate Rotenone-induced Neurodegeneration.	32392329
20894	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	myocardial dysfunction	H9c2 cells	lipopolysaccharide (LPS) treatment	LPS Induces Oxidative Injury and miR146a Upregulation in H9C2 Cells.	30224945
20895	Rat	rno-miR-146a	miRNA	angiotensin II (Ang II)	myocardial infarction (MI)	primary neonatal rat cardiac fibroblasts (CFs) and cardiomyocytes	angiotensin II (Ang II) treatment	inhibition of miR-146a improved cardiac dysfunction and cardiac remodeling in heart failure rats.	31763669
20896	Rat	rno-miR-146a	miRNA	thymosin ¦Â4 (T¦Â4)	neurological injury	rat oligodendrocyte progenitor cells (OPCs)	"T¦Â4, ranging from 25 to 100 ng/ml for 4 days treatment"	upregulation	24828499
20897	Rat	rno-miR-146a	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	rat	high fat diet (HFD) feed	upregulated	25562147
20898	Rat	rno-miR-146a	miRNA	high fat diet (HFD)	obesity	lung tissue	high fat diet (HFD) feed	upregulated	30521085
20899	Rat	rno-miR-146a	miRNA	high fat diet (HFD)	obesity	lung tissues	OVA-sensitized with high-fat diet treatment	in the S + HFD group the mRNA expression levels of miRNA-146a increased in the lung tissues.	30521085
20900	Rat	rno-miR-146a	miRNA	ovalbumin (OVA)	obesity	lung tissue	ovalbumin (OVA) treatment	upregulated	30521085
20901	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	rat chondrocytes	lipopolysaccharide (LPS) treatment	The levels of miR-146a in chondrocytes treated with LPS were reduced.	31472145
20902	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	Isolated rat chondrocytes	lipopolysaccharide (LPS) treatment	"In OA cell model, the expression of miR-146a was clearly increased."	31472145
20903	Rat	rno-miR-146a	miRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis	rats adipose-derived mesenchymal stem cells (ADSCs)	bone morphogenetic protein 2 (BMP2) treatment	downregulated	28205638
20904	Rat	rno-miR-146a	miRNA	resveratrol	osteonecrosis	rat bone marrow mesenchymal stem cells (BMMSCs)	resveratrol (Res) treatment	"Res application was associated with elevated microRNA-146a (miR-146a) expression, osteogenic differentiation, and suppressed osteoclastic differentiation, which were markedly reversed by miR-146a inhibitor"	33454992
20905	Rat	rno-miR-146a	miRNA	H2O2	oxidative stress	neuronal spinal cord (RN-sc) cells	H2O2 treatment	upregulated	26323253
20906	Rat	rno-miR-146a	miRNA	H2O2	oxidative stress	PC12 cells	PC12 cells were stimulated with 200 ¦ÌM of H2O2	upregulated	29484526
20907	Rat	rno-miR-146a	miRNA	high fat diet (HFD)	pulmonary inflammation	lung tissues	high fat diet (HFD) feed	upregulated	31473901
20908	Rat	rno-miR-146a	miRNA	Trans-chalcone	pulmonary inflammation	High-fat diet (HFD)-fed rats lung tissues	Trans-chalcone treatment	downregulated	31473901
20909	Rat	rno-miR-146a	miRNA	collagen	rheumatoid arthritis (RA)	synovial tissue	collagen treatment	downregulated	32662411
20910	Rat	rno-miR-146a	miRNA	iguratimod	rheumatoid arthritis (RA)	synovial tissue of collagen-induced arthritis (CIA) rat	iguratimod treatment	upregulated	32662411
20911	Rat	rno-miR-146a	miRNA	dexamethasone (DEX)	sepsis-induced acute kidney injury	renal tissues	dexamethasone (DEX) treatment	miR-146a in the renal tissues was upregulated in Dex treated group.	32415933
20912	Rat	rno-miR-146a	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	myocardial tissue	lipopolysaccharide (LPS) treatment	upregulated	31281454
20913	Rat	rno-miR-146a	miRNA	silicon dioxide (SiO2)	silicosis	fibrotic lungs	silicon dioxide (SiO2) treatment	upregulated	26239160
20914	Rat	rno-miR-146a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	brain tissues	lithium-pilocarpine treatment	upregulated	28474544
20915	Rat	rno-miR-146a	miRNA	hypoxia	stroke	brain tissues	middle cerebral artery occlusion (MCAO) treatment	upregulation in the corpus callosum and subventricular zone (SVZ)	26738853
20916	Rat	rno-miR-146a	miRNA	SHENMAI	toxicokinetic of SHENMAI	rats serum	inject with SHENMAI treatment	upregulated	24747029
20917	Rat	rno-miR-146a	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	hippocampus and cerebral cortex	streptozocin (STZ) treatment	downregulated	29867484
20918	Rat	rno-miR-146a	miRNA	Thymoquinone (TQ)	type 2 diabetes mellitus (T2DM)	Type 2 diabetes mellitus (T2DM) rats hippocampus and cerebral cortex	Thymoquinone (TQ) treatment	upregulated	29867484
20919	Rat	rno-miR-146a	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	ulcerative colitis (UC)	rat intestinal tissues	"2,4,6-Trinitrobenzenesulfonic acid (TNBS) treatment"	upregulated	30915760
20920	Rat	rno-miR-146a	miRNA	vildagliptin (Vilda)	ulcerative colitis (UC)	colon tissues	Vildagliptin (Vilda) treatment	"Vilda hsa markedly inhibited the expression of lncRNA IFNG-AS1 and miR-146a, as well as PI3K/Akt/NF¦ÊB pathway"	33434756
20921	Rat	rno-miR-146a	miRNA	IL-4¦Â	mesial temporal lobe epilepsy (MTLE)	hippocampi of immature rats	?IL-1¦Â treatment	upregulated	22708826
20922	Rat	rno-miR-146a-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	Reduced SIRT1 and raised miR-146a-3p were found in LPS-induced BEAS-2B cells and ALI rats.	33185125
20923	Rat	rno-miR-146a-3p	miRNA	dexmedetomidine (DEX)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	dexamethasone (DEX) treatment	Dexmedetomidine upregulated expression of miR-146a-3p.	33220608
20924	Rat	rno-miR-146a-5p	miRNA	zhenbao pill	acute spinal cord injury (ASCI)	ASCI rat neuron	zhenbao pill treatment	upregulated	29187582
20925	Rat	rno-miR-146a-5p	miRNA	lithium chloride and pilocarpine	epilepsy	rat cortex and hippocampus tissues	lithium chloride-pilocarpine treatment	upregulated	31061316
20926	Rat	rno-miR-146a-5p	miRNA	intermittent hypoxia (IH)	hypoxia-induced injury	H9c2 cells	intermittent hypoxia(IH) induced	upregulated	31205587
20927	Rat	rno-miR-146a-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	rats liver	CCl4 treatment	upregulated	28739486
20928	Rat	rno-miR-146a-5p	miRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	condylar chondrocytes	IL-1¦Â and TNF-¦Á treatment	upregulated	33147588
20929	Rat	rno-miR-146a-5p	miRNA	steroids	osteonecrosis	osteoblasts	steroid treatment	downregulated	27378744
20930	Rat	rno-miR-146a-5p	miRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	downregulated	29505837
20931	Rat	rno-miR-146a-6p	miRNA	angiostrongylus cantonensis (A. cantonensis)	inflammation	healthy male SD rats	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24142286
20932	Rat	rno-miR-146b	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	bone marrow MSCs (rMSCs)	cisplatin treatment	downregulated	27400799
20933	Rat	rno-miR-146b	miRNA	circadian disruption (CD)	breast cancer	mammary	circadian disruption (CD) treatment	downregulated	26097876
20934	Rat	rno-miR-146b	miRNA	angiotensin II (Ang II)	cardiac fibrosis and hypertension	cardiac fibroblasts (CFs) of rats	angiotensin II (Ang II) treatment	upregulated	23007623
20935	Rat	rno-miR-146b	miRNA	TGF-¦Â	liver fibrosis	hepatic stellate cells (HSCs)	TGF-¦Â treatment	upregulated	27740527
20936	Rat	rno-miR-146b	miRNA	aspirin-triggered resolvin D1 (AT-RvD1)	hepatic ischemia/reperfusion injury (HIRI)	liver ischemia/reperfusion (I/R) Sprague-Dawley rats liver	aspirin-triggered resolvin D1 (AT-RvD1) treatment	upregulated	28837866
20937	Rat	rno-miR-146b	miRNA	electroacupuncture (EA)	ischemic stroke (IS)	Primary stem cells	electroacupuncture (EA) treatment	EA increased miR-146b expression.	32792909
20938	Rat	rno-miR-146b	miRNA	porcine serum	liver fibrosis	rat liver tissues	porcine serum treatment	upregulation	24927615
20939	Rat	rno-miR-146b	miRNA	heat stress	lung cancer	lung	Heating System 2.2 (THS2.2) treatment	downregulated	27866933
20940	Rat	rno-miR-146b	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	downregulated	24886372
20941	Rat	rno-miR-146b-3p	miRNA	high fat diet (HFD)	cardiac remodeling	heart tissues	high fat diet (HFD) feed	upregulated	29884823
20942	Rat	rno-miR-146b-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20943	Rat	rno-miR-146b-5p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31899128
20944	Rat	rno-miR-146b-5p	miRNA	cadmium (Cd)	cadmium (Cd)-induced kidney injury	renal cortex	cadmium (Cd) treatment	upregulated	29543730
20945	Rat	rno-miR-146b-5p	miRNA	estradiol benzoate (EB) and testosterone (T)/E	chronic inflammatory diseases	dorsolateral prostate	estradiol benzoate (EB) and testosterone (T)/E treatment	upregulated	33332750
20946	Rat	rno-miR-146b-5p	miRNA	lipopolysaccharide (LPS)	intestinal sepsis	IEC-6 cells	lipopolysaccharide (LPS) treatment	rno-miR-146b-5p may play a vital role in the development of sepsis intestinal injury through targeting Klf4 expression and affecting promoter activity of Ccnd2.	33200654
20947	Rat	rno-miR-146b-5p	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	PC-12 cells	oxygen glucose deprivation (OGD) treatment	miR-146b-5p was lower in PC12 cells upon OGD insult.	32734729
20948	Rat	rno-miR-146b-5p	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic brain damage	oligodendrocyte precursor cells (OPCs)	oxygen/glucose deprivation (OGD) induce treatment	downregulated	31003769
20949	Rat	rno-miR-146b-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31915454
20950	Rat	rno-miR-146b-5p	miRNA	Shenling Baizhu San (SLBZS)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	Shenling Baizhu San (SLBZS) treatment	the expression levels were reversed by SLBZS administration	31915454
20951	Rat	rno-miR-146b-5p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	downregulated	26997989
20952	Rat	rno-miR-146b-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20953	Rat	rno-miR-147	miRNA	H2O2	acute myocardial infarction (AMI)	H9c2 cells	H2O2 treatment	MiR-147 expression was significantly decreased in H2O2 treated H9c2 cells.	32572895
20954	Rat	rno-miR-147	miRNA	mcyclic mechanical stretch	endoplasmic reticulum stress (ERS)	rat L6 myoblasts	mcyclic mechanical stretch treatment	downregulated	31628639
20955	Rat	rno-miR-147	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	pristane (PS)-treated ATCC? CRL-2192TM cells (rat macrophage cells)	methotrexate treatment	upregulated	31105830
20956	Rat	rno-miR-147	miRNA	pristane (PS)	rheumatoid arthritis (RA)	ATCC? CRL-2192TM cells (rat macrophage cells)	pristane (PS) treatment	downregulated	31105830
20957	Rat	rno-mir-147	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20958	Rat	rno-miR-147b	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	MiR-147b was downregulated in lipopolysaccharide (LPS)-induced ALI rats and LPS-treated A549 cells	33660808
20959	Rat	rno-miR-147b	miRNA	H2O2	heart failure (HF)	rat H9c2 cardiomyocytes	H2O2 treatment	upregulated	29377979
20960	Rat	rno-miR-148-3p	miRNA	loureirin B	liver fibrosis	Hepatic stellate cells (HSCs)	loureirin B treatment	upregulated	30123297
20961	Rat	rno-miR-148-3p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline treatment	downregulated	28000863
20962	Rat	rno-miR-148a	miRNA	cerulein	acute pancreatitis (AP)	The rat pancreatic acinar cell line AR42J	cerulein treatment	downregulated	31122822
20963	Rat	rno-miR-148a-3p	miRNA	steroids	osteonecrosis	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	26459755
20964	Rat	rno-miR-148b	miRNA	angiotensin II (Ang II)	cardiac fibrosis	Cardiac myofibroblasts	angiotensin II (Ang II) treatment	"Ang-II downregulated the miR-148b expression, which was reversed by SRA1 siRNA, suggesting the regulation of SRA1 on miR-148b."	30694702
20965	Rat	rno-miR-148b	miRNA	hypoxia	ischemic stroke (IS)	rats subventricular zone (SVZ)	middle cerebral artery occlusion (MCAO) treatment	upregulated	29104534
20966	Rat	rno-miR-148b	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia/reoxygenation (H/R) induce	upregulated	30820984
20967	Rat	rno-miR-148b-3p	miRNA	ginsenoside Rg1	apoptosis	hypoxia-induced male rat bone marrow mesenchymal stem cells (rBMSCs)	Ginsenoside Rg1 treatment	upregulated	29307726
20968	Rat	rno-miR-148b-3p	miRNA	hypoxia	apoptosis	Male rat bone marrow mesenchymal stem cells (rBMSCs)	hypoxia induce	downregulated	29307726
20969	Rat	rno-miR-148b-3p	miRNA	pentylenetetrazol (PTZ)	epilepsy	brain tissues	pentylenetetrazol (PTZ) treatment	downregulated	32779334
20970	Rat	rno-miR-148b-5p	miRNA	ginsenoside Rg1	apoptosis	hypoxia-induced male rat bone marrow mesenchymal stem cells (rBMSCs)	Ginsenoside Rg1 treatment	upregulated	29307726
20971	Rat	rno-miR-148b-5p	miRNA	hypoxia	apoptosis	Male rat bone marrow mesenchymal stem cells (rBMSCs)	hypoxia induce	downregulated	29307726
20972	Rat	rno-miR-149	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia induce	upregulated	31741467
20973	Rat	rno-miR-149	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	osteogenesis	rat mesenchymal stem cells (MSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31206187
20974	Rat	rno-miR-149-5p	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	downregulated	31263091
20975	Rat	rno-miR-149-5p	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	mesenchymal stem cell (MSC) exosome	hypoxia-reoxygenation (H/R) treatment	upregulated	32719674
20976	Rat	rno-miR-149-5p	miRNA	resveratrol	ischemic stroke (IS)	rat cerebral tissue	resveratrol (RS) treatment	decreased p53 protein expression and increased miR-149-5p activity on sirtuin1 (Sirt1) activation with resveratrol after 24 h following MCAO	31866350
20977	Rat	rno-miR-149-5p	miRNA	resveratrol	ischemic stroke (IS)	brain tissues	resveratrol (RS) treatment	upregulated of Sirt1/miR-149-5p signaling may play a role in resveratrol induced protection against ischemia via p53 in rat brain	31866350
20978	Rat	rno-miR-149-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
20979	Rat	rno-miR-15	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
20980	Rat	rno-miR-15	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	H9c2 cells	Coxsackievirus B3 (CVB3) treatment	MiR-15 expression was significantly upregulated in H9c2 cells after CVB3 infection.	32099552
20981	Rat	rno-miR-150	miRNA	H2O2	acute myocardial infarction (AMI)	H9c2 cells	H2O2 treatment	FTX relieves H2O2-induced cardiomyocyte injury by increasing KLF13 expression via depletion of miR-150.	33817286
20982	Rat	rno-miR-150	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	downregulated	27649667
20983	Rat	rno-miR-150	miRNA	H2O2	cardiac injury	cardiac myocytes	?H2O2 treatment	upregulated	23824072
20984	Rat	rno-miR-150	miRNA	high glucose (HG)	cardiac hypertrophy	rat cardiac cells	high glucose treatment	downregulated	23211718
20985	Rat	rno-miR-150	miRNA	¦Â-arrestin1-biased ¦Â1-adrenergic receptor	ischemic injury	embryonic ventricular cardiomyocyte H9c2 cells	¦Â-arrestin1-biased ¦Â1-adrenergic receptor treatment	upregulated	25824147
20986	Rat	rno-miR-150	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
20987	Rat	rno-miR-150	miRNA	H2O2	oxidative stress	neuronal spinal cord (RN-sc) cells	H2O2 treatment	upregulated	26323253
20988	Rat	rno-miR-150	miRNA	tetramethylpyrazine (TMP)	parkinson's disease (PD)	hippocampu	Tetramethylpyrazine (TMP) treatment	Tetramethylpyrazine ameliorates isoflurane-induced cognitive dysfunction by inhibiting neuroinflammation via miR-150 in rats	32855738
20989	Rat	rno-miR-150	miRNA	hypoxia	pulmonary hypertension (PH)	lung tissue and plasma	hypoxia induce	downregulated	30551428
20990	Rat	rno-miR-150	miRNA	hypoxia	pulmonary hypertension (PH)	lung tissue and plasma	hypoxia treatment	miR-150 level was reduced in the lung tissue and plasma of hypoxia-treated rats.	30551428
20991	Rat	rno-miR-150	miRNA	lipopolysaccharide (LPS)	septic shock	Wistar rats serum	LPS (10 mg/kg) treatment	upregulated	24915805
20992	Rat	rno-miR-150	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
20993	Rat	rno-miR-1502	miRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
20994	Rat	rno-miR-150-3p	miRNA	CP (cyclophosphamide)	cyclophosphamide (CP)-induced lung toxicity	lung tissues	CP (cyclophosphamide) treatment	Single treatment with CP caused a significant increase in the relative gene expression of miR-150-3p compared to control rats.	32747644
20995	Rat	rno-miR-150-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
20996	Rat	rno-miR-150-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	"XIST protects cardiomyocytes from hypoxia-induced injury by mediating miR-150-5p/Bax axis, suggesting that XIST is an important target for AMI treatment."	32096185
20997	Rat	rno-miR-150-5p	miRNA	isoproterenol	cardiac hypertrophy	Neonatal rat ventricular myocytes (NRVMs)	isoproterenol (ISO) treatment	downregulated	29786749
20998	Rat	rno-miR-150-5p	miRNA	fish oil (FO) and olive oil (OO)	cardiovascular responses	heart sissues	Fish oil (FO) and olive oil (OO) treatment	O 3-induced upregulated of miR-150-5p and miR-208a-5p were attenuated by FO and/or OO.	33091443
20999	Rat	rno-miR-150-5p	miRNA	chronic heart failure (CHF)	chronic heart failure (CHF)	myocardial tissues	aerobic exercise treatment	downregulated	33708967
21000	Rat	rno-miR-150-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiac fibroblasts (CFs)	high glucose (HG) treatment	upregulated	31710102
21001	Rat	rno-miR-150-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiac fibroblasts (CFs)	high-glucose (HG) treatment	upregulated	31710102
21002	Rat	rno-miR-150-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	miR-150-5p was upregulated on carbon tetrachloride (CCl4) injection for 8 weeks.	31833387
21003	Rat	rno-miR-150-5p	miRNA	uterine perfusion pressure (RUPP)	pregnancy-induced hypertension (PIH)	aortic endothelial cells (ECs)	uterine perfusion pressure (RUPP) treatment	downregulated	32800559
21004	Rat	rno-miR-150-5p	miRNA	lipopolysaccharide (LPS)	sepsis	H9c2 cells; heart tissues	lipopolysaccharide (LPS) treatment	downregulated	32908879
21005	Rat	rno-miR-150-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21006	Rat	rno-miR-151	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
21007	Rat	rno-miR-151*	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	7-week-old Fischer344 male rats liver	aflatoxin B1 (AFB5) treatment	upregulated	24472605
21008	Rat	rno-miR-151-3p	miRNA	dexamethasone (DEX)	Alzheimer's disease (AD)	PC12 cells	dexamethasone (DEX) treatment	upregulated of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against ¦Â-amyloid by targeting DAPK-1 and TP53.	33275947
21009	Rat	rno-miR-151-3p	miRNA	cold	cold stress	rats serum	cold conditions (4¡æ for 12h)	downregulated	28477904
21010	Rat	rno-miR-151-3p	miRNA	long-term potentiation(LTP)	long-term potentiation (LTP) persistence	Sprague-Dawley rats Dentate Gyrus Neuropil	unilaterally at perforant path-dentate gyrus synapses	upregulated in Dentate Gyrus Neuropil	28125614
21011	Rat	rno-miR-151-5p	miRNA	house dust mite (HDM) extract	allergic airway inflammation	adipose tissue and lungs	house dust mite extract treatment	upregulated	32887419
21012	Rat	rno-miR-152	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	31258681
21013	Rat	rno-miR-152	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	rat	high fat diet (HFD) feed	upregulated	25562147
21014	Rat	rno-miR-152	miRNA	astragalus polysaccharide (APS)	osteogenesis	marrow mesenchymal stem cells (MSCs)	Astragalus polysaccharide (APS) treatment	downregulated	31071509
21015	Rat	rno-miR-152	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	rheumatoid arthritis (RA)	synovium	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	26093272
21016	Rat	rno-miR-152-3p	miRNA	pentylenetetrazol (PTZ)	epilepsy	brain tissues	pentylenetetrazol (PTZ) treatment	downregulated	32779334
21017	Rat	rno-miR-152-3p	miRNA	tanshinone IIA (Tan IIA)	heart failure (HF)	H9C2 cells	tanshinone IIA treatment	upregulated	27508033
21018	Rat	rno-miR-153	miRNA	H2O2	cardiovascular disease (CVD)	primary culture of rat ventricular cardiomyocytes	primary culture of rat ventricular cardiomyocytes treatment	upregulated	27220418
21019	Rat	rno-miR-153	miRNA	hypoxia	hypoxia-induced injury	rat pheochromocytoma (PC-12) cells	hypoxia induce	downregulated	30579328
21020	Rat	rno-miR-153	miRNA	propofol (PPF)	hypoxia-induced injury	?hypoxia-induced rat pheochromocytoma (PC-12) cells	propofol treatment	upregulated	30579328
21021	Rat	rno-miR-153	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
21022	Rat	rno-miR-153	miRNA	lead acetate (PbAc)	lead-induced hepatotoxicity	liver tissues and primary cultured hepatocytes	lead acetate (PbAc) treatment	upregulated	29175668
21023	Rat	rno-miR-153	miRNA	grape seed proanthocyanidins (GSPs)	lepatotoxicity	lead acetate (PbAc)-treated rats liver tissues and primary cultured hepatocytes	Grape seed procyanidin extract (GSPE) treatment	downregulated	29175668
21024	Rat	rno-miR-153	miRNA	grape seed procyanidin extract (GSPE)	liver damage	rat primary hepatocytes pretreated with PbAc (100 ¦ÌM)	GSPE (100 ¦Ìg/ml)	downregulated	29175668
21025	Rat	rno-miR-153	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary cultured rat cardiomyocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31037501
21026	Rat	rno-miR-153	miRNA	grape seed procyanidin extract (GSPE)	nephrotoxicity	Pb induced nephrotoxicity rat	vemurafenib	downregulated	28178683
21027	Rat	rno-miR-153-3p	miRNA	hypoxia	ischemic stroke (IS)	HUVECs	pMCAO treatment	downregulated in infraction areas	28985553
21028	Rat	rno-miR-154-3p	miRNA	IL-6	skeletal muscle regeneration	rat primary skeletal muscle cells (RSkMC)	IL-6 treatment	upregulated	31820147
21029	Rat	rno-miR-154-3p	miRNA	IL-6	skeletal muscle regeneration	rat primary skeletal muscle cells (RSkMC)	IL-6 treatment	upregulated	31820147
21030	Rat	rno-miR-155	miRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	IL-1¦Â treatment	downregulated	29852820
21031	Rat	rno-miR-155	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	29852820
21032	Rat	rno-miR-155	miRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	NRK-52E cells	hypoxia-reoxygeneration (H/R) induce	upregulated	31216555
21033	Rat	rno-miR-155	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	endotoxin treatment	upregulated	26137246
21034	Rat	rno-miR-155	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	lung tissues	sevoflurane treatment	downregulated	28617947
21035	Rat	rno-miR-155	miRNA	H2O2	acute myocardial infarction (AMI)	neonatal rat ventricular cardiomyocyte (NRVM)	H2O2 treatment	upregulated	31191799
21036	Rat	rno-miR-155	miRNA	galantamine	adjuvant-induced arthritis (AIA)	joint	galantamine treatment	miR-155 was downregulated in galantamine treated group when compared with AA mice.	32621912
21037	Rat	rno-miR-155	miRNA	ovalbumin (OVA)	asthma	lung tissues	ovalbumin (OVA) treatment	upregulated	29938673
21038	Rat	rno-miR-155	miRNA	gold nanoparticles (AuNPs)	AuNP-induced lung pathogenesis	lung tissues	gold nanoparticles (AuNPs) treatment	upregulated	31413563
21039	Rat	rno-miR-155	miRNA	high glucose (HG)	cardiac fibrosis	H9c2 cells	high glucose (HG) treatment	HG treatment resulted in increased miR-155 expression.	32901848
21040	Rat	rno-miR-155	miRNA	docosahexaenoic acid (DHA)	carotid restenosis	VSMCs	docosahexaenoic acid (DHA) treatment	Docosahexaenoic acid inhibits vascular smooth muscle cell migration and proliferation by decreasing microRNA-155 expression levels	32945419
21041	Rat	rno-miR-155	miRNA	valproic acid (VPA)	cerebral ischemia injury (CII)	rat cortical neuronal cells	valproic acid treatment	upregulated	22937209
21042	Rat	rno-miR-155	miRNA	acupuncture	chronic atrophic gastritis (CAG)	gastric	acupuncture treatment	downregulated	27293468
21043	Rat	rno-miR-155	miRNA	paradoxical sleep deprivation (PSD)	cognitive impairment	Hippocampal tissues	paradoxical sleep deprivation (PSD) induce treatment	upregulated	31279826
21044	Rat	rno-miR-155	miRNA	saikosaponin d (SSd)	depression	hippocampal neurons	saikosaponin d (SSd) treatment	"SSd could ameliorate depression-like behaviors in the rats treated with UCMS by downregulating NF-¦ÊB and miR-155, and upregulating FGF2"	31926302
21045	Rat	rno-miR-155	miRNA	tetrandrine	diabetes mellitus (DM)	rat pancreatic islet caused by alloxan	Tetrandrine treatment	downregulated	26064305
21046	Rat	rno-miR-155	miRNA	ibuprofen	diabetic nephropathy (DN)	spinal tissues	ibuprofen treatment	downregulated	27392937
21047	Rat	rno-miR-155	miRNA	L©\arginine	diabetic nephropathy (DN)	spinal	L-arginine treatment	downregulated	27392937
21048	Rat	rno-miR-155	miRNA	glucose	diabetic peripheral neuropathy (DPN)	rat Schwann cells (SCs)	5.5 mM glucose treatment	"miR-155 antagomir-induced inhibition increased MNCV and SNCV, strengthened angiogenesis and alleviated inflammation in DPN rats."	31404910
21049	Rat	rno-miR-155	miRNA	atorvastatin	endothelial dysfunction	erectile tissue of the aged rat	atorvastatin treatment	downregulated	29686722
21050	Rat	rno-miR-155	miRNA	Saikosaponin a (Ssa)	epilepsy	hippocampus	Ssa treatment	downregulated	28958944
21051	Rat	rno-miR-155	miRNA	light	focal retinal degeneration	right eye	light treatment	upregulated	25921151
21052	Rat	rno-miR-155	miRNA	electroacupuncture (EA)	head and neck squamous cell carcinoma (HNSCC)	rat peritoneal mast cells (RPMCs)	electro-acupuncture (EA) treatment	downregulated	29404871
21053	Rat	rno-miR-155	miRNA	perfluorooctane sulfonic acid (PFOS)	hepatomegaly	HepG2 cells	perfluorooctane sulfonate (PFOS) treatment	upregulated	26844784
21054	Rat	rno-miR-155	miRNA	asiaticoside	hyperoxia-induced bronchopulmonary dysplasia	lung tissues	asiaticoside treatment	Asiaticoside downregulated the expression of miR-155.	31948528
21055	Rat	rno-miR-155	miRNA	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)	hypertension	heart tissues	deoxycorticosterone acetate (DOCA) -salt (sodium chloride) treatment	upregulated	30290168
21056	Rat	rno-miR-155	miRNA	metformin (Met)	hypertension	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)-induced hypertension rats heart tissues	metformin (MF) treatment	downregulated	30290168
21057	Rat	rno-miR-155	miRNA	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)	hypertension-induced cardiac dysfunction	heart tissues	deoxycorticosterone acetate (DOCA) -salt (sodium chloride) treatment	upregulated	30290168
21058	Rat	rno-miR-155	miRNA	metformin (Met)	hypertension-induced cardiac dysfunction	heart tissues	Metformin treatment	downregulated	30290168
21059	Rat	rno-miR-155	miRNA	lipopolysaccharide (LPS)	inflammation	rat alveolar macrophages NR8383	lipopolysaccharide (LPS) treatment	upregulated	30541646
21060	Rat	rno-miR-155	miRNA	gualou guizhi decoction (GLGZD)	ischemic stroke (IS)	brain tissues	Gualou Guizhi Decoction (GLGZD) treatment	"GLGZD was able to inhibit miR-155 upregulation, resulting in downregulated of miR155-targeted molecules in MCAO rats"	33081480
21061	Rat	rno-miR-155	miRNA	lipopolysaccharide (LPS)	hepatocellular carcinoma (HCC)	rat spleen myeloid cells	lipopolysaccharide (LPS) treatment	mature miR-155 is overexpressed in rat spleen myeloid cells treated with LPS	23329697
21062	Rat	rno-miR-155	miRNA	acetaminophen (APAP)	liver damage	liver tissues	acetaminophen (APAP) treatment	"miR-155 and miR-21 were evaluated as makers of inflammation and regeneration, respectively, to characterize liver status."	27051339
21063	Rat	rno-miR-155	miRNA	dexmedetomidine (DEX)	LPS-induced neuroinflammation	"adult Wistar rats brain ,plasma,"	dexmedetomidine (Dex) treatment	downregulated	28832497
21064	Rat	rno-miR-155	miRNA	lipopolysaccharide (LPS)	myocardial infarction (MI)	rat bone marrow derived macrophages (BMDMs)	lipopolysaccharide (LPS) treatment	upregulated	31207208
21065	Rat	rno-miR-155	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cell	hypoxia/reoxygenation (H/R) induce	upregulated	31807249
21066	Rat	rno-miR-155	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	miR-155 was markedly upregulated in the H/R model.	31922242
21067	Rat	rno-miR-155	miRNA	lipopolysaccharide (LPS)	neuroinflammation	adult Wistar rats brain regions	lipopolysaccharide (LPS) treatment	upregulated in both brain regions	28832497
21068	Rat	rno-miR-155	miRNA	bortezomib	neuropathic pain (NP)	L5-L6 spinal cord dorsal horn	bortezomib? treatment	Inhibition of microRNA-155 Reduces Neuropathic Pain During Chemotherapeutic Bortezomib via Engagement of Neuroinflammation.	32296644
21069	Rat	rno-miR-155	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
21070	Rat	rno-miR-155	miRNA	myo-inositol	polycystic ovarian syndrome (PCOS)	ovaries	Myo-inositol treatment	downregulated of miR-155 was detected with myo-inositol supplementation.	32045334
21071	Rat	rno-miR-155	miRNA	N-3 polyunsaturated fatty acids (PUFA)	post-menopausal depression	brain tissues	N-3 polyunsaturated fatty acids (PUFA) treatment	"N-3 PUFA decreased blood levels of adrenocorticotropic hormone and corticosterone, and brain expressions of corticotropin-releasing factor and miRNA-218, which increased the expression of the glucocorticoid receptor. N-3 PUFA decreased the expression of tumor necrosis factor-¦Á, interleukin (IL)-6, IL-1¦Â, and prostaglandin E2, while increased the expression of miRNA-155."	33548474
21072	Rat	rno-miR-155	miRNA	nitric oxide synthase inhibitor L-NAME	pregnancy-induced hypertension (PIH)	pregnant female rats placental tissues	nitric oxide synthase inhibitor L-NAME treatment	upregulated	30402830
21073	Rat	rno-miR-155	miRNA	ischemia/reperfusion (I/R) 	renal ischemia/reperfusion (I/R) injury	kidney tissues	ischemia/reperfusion (I/R) treatment	upregulated	28006785
21074	Rat	rno-miR-155	miRNA	lipopolysaccharide (LPS)	rheumatoid arthritis (RA)	rat synoviocytes	lipopolysaccharide (LPS) treatment	upregulated	31258713
21075	Rat	rno-miR-155	miRNA	lipopolysaccharide (LPS)	sepsis-induced lung injury	NR8383 macrophages	lipopolysaccharide (LPS) treatment	upregulated	28125526
21076	Rat	rno-miR-155	miRNA	kainic acid (KA)	status epilepticus (SE)	hippocampus	kainic acidtreatment	upregulated	30006293
21077	Rat	rno-miR-155	miRNA	gualou guizhi decoction (GLGZD)	stroke	ischemic hemisphere	Gualou Guizhi Decoction (GLGZD) treatment	GLGZD was able to inhibit miR-155 upregulation.	33081480
21078	Rat	rno-miR-155	miRNA	exercise training (ET)	vascular relaxation	arteries	exercise training	downregulated	32301852
21079	Rat	rno-miR-155-3p	miRNA	puerarin	bone graft defects	bone mesenchymal stem cells (BMSCs)	puerarin treatment	miR-155-3p expression was increased by puerarin in BMScs	32377717
21080	Rat	rno-miR-155-3p	miRNA	TGF-¦Â1	lung fibrosis	lung fibroblasts	TGF-¦Â1 treatment	downregulated	32464548
21081	Rat	rno-miR-155-3p	miRNA	TGF-¦Â1	lung fibrosis	lung fibroblasts	TGF-¦Â1 treatment	upregulated	32464548
21082	Rat	rno-miR-155-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21083	Rat	rno-miR-155-3p	miRNA	diosgenin glucoside (DG)	spinal cord injury (SCI)	Spinal cord injury (SCI) rats spinal cord tissue	Diosgenin glucoside (DG) treatment	downregulated	30072674
21084	Rat	rno-miR-155-5p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31899128
21085	Rat	rno-miR-155-5p	miRNA	alcohol	alcoholic cardiomyopathy (ACM)	heart tissues	alcohol exposure	alcohol drinking significantly upregulated miR-155-5p level	33868799
21086	Rat	rno-miR-155-5p	miRNA	rapamycin	cardiac fibrosis	heart tissues	rapamycin (Rap) treatment	upregulated	30647817
21087	Rat	rno-miR-155-5p	miRNA	valproic acid (VPA)	cell differentiation	primary cultured neural stem cells (NSCs)	valproate (VPA) treatment	upregulated	29575035
21088	Rat	rno-miR-155-5p	miRNA	geniposide and ginsenoside Rg1	cerebral ischemia injury (CII)	middle cerebral artery occlusion treated rats brain tissues	Geniposide+Ginsenoside Rg1 dual treatment	downregulated	29257264
21089	Rat	rno-miR-155-5p	miRNA	dihydromyricetin (DHM)	diabetic nephropathy (DN)	NRK-52E?cells; kidney tissues	high glucose (HG) treatment	"MiR-155-5p expression was increased, while PTEN expression was decreased in DN rat and cell model, and DHM reversed both effects."	31668144
21090	Rat	rno-miR-155-5p	miRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E?cells	high glucose (HG) treatment	upregulated	31668144
21091	Rat	rno-miR-155-5p	miRNA	isoproterenol	drug-induced cardiac injury (DICI)	heart tissues	isoproterenol treatment	upregulated	29355689
21092	Rat	rno-miR-155-5p	miRNA	pilocarpine	epilepsy	hippocampus	pilocarpine treatment	upregulated	29191771
21093	Rat	rno-miR-155-5p	miRNA	plasminogen activator (tPA)	neuropathy-induced blood-nerve barrier (BNB) opening	sciatic nerve from male rats	plasminogen activator (tPA) treatment	upregulated	30625382
21094	Rat	rno-miR-155-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31915454
21095	Rat	rno-miR-155-5p	miRNA	Shenling Baizhu San (SLBZS)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	Shenling Baizhu San (SLBZS) treatment	the expression levels were reversed by SLBZS administration	31915454
21096	Rat	rno-miR-155-5p	miRNA	group A streptococci	rheumatic heart disease (RHD)	valve tissues and serum exosomes	an RHD rat model was induced by inactivated Group A streptococci and complete Freund's adjuvant.	upregulated	31894293
21097	Rat	rno-miR-155-5p	miRNA	group A streptococci and complete Freund's adjuvant	rheumatic heart disease (RHD)	valve tissues; serum exosomes	group A streptococci and complete Freund's adjuvant treatment	The expression of miR-155-5p in valve tissues and serum exosomes was increased.	31894293
21098	Rat	rno-miR-155-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21099	Rat	rno-miR-155-5p	miRNA	silica	silicosis	rats lung tissues	silica treatment	upregulated	31877411
21100	Rat	rno-miR-155-5p	miRNA	silica	silicosis	lung tissues	silica treatment	upregulated	31877411
21101	Rat	rno-miR-155-5p	miRNA	geniposide and ginsenoside Rg2	stroke	middle cerebral artery occlusion rats	"geniposide (30 mg/kg, tail vein injection)+ ginsenoside Rg1 (6 mg/kg, tail vein injection)"	upregulated	29257264
21102	Rat	rno-miR-155-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	subacute thyroiditis	rat thyroid follicle FRTL-5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30399324
21103	Rat	rno-miR-155-5p	miRNA	pilocarpine	temporal lobe epilepsy (TLE)	rats hippocampus	pilocarpine treatment	upregulated in hippocampus	29191771
21104	Rat	rno-miR-155-5p	miRNA	cadmium (Cd)	vascular calcification (VC)	rat vascular smooth muscle cells (rVSMCs)	CaCl2 treatment	miR-155-5p was decreased in the rat vascular smooth muscle cells (rVSMCs) undergoing calcification in vitro.	32345535
21105	Rat	rno-miR-156	miRNA	dexmedetomidine (DEX)	neuroinflammation	"adult Wistar rats brain ,plasma,"	dexmedetomidine (Dex) treatment	downregulated	28832497
21106	Rat	rno-miR-15a	miRNA	ischemia/reperfusion (I/R) 	apoptosis	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	24043355
21107	Rat	rno-miR-15a	miRNA	freund¡¯s complete adjuvant (FCA)	arthritis	Sprague-Dawley rats	injected with Freund's complete adjuvant	downregulated	28877850
21108	Rat	rno-miR-15a	miRNA	gabapentin	arthritis	Sprague-Dawley rats	administered intraperitoneally gabapentin for 8 days	upregulated	28877850
21109	Rat	rno-miR-15a	miRNA	hypoxia	glial scars	DI TNC1 cells	hypoxia treatment	upregulated	27460735
21110	Rat	rno-miR-15a	miRNA	insulin	glucose homeostasis	L6 rat skeletal muscle cells	insulin treatment	upregulated	31594761
21111	Rat	rno-miR-15a	miRNA	hypoxia	hypoxia-induced injury	PC-12 cells	hypoxia induce	upregulated	30395900
21112	Rat	rno-miR-15a	miRNA	sappanone A	hypoxia-induced injury	hypoxia-induced PC-12 cells	sappanone A treatment	downregulated	30395900
21113	Rat	rno-miR-15a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic brain injury	primary cortical neu- rons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-15a expression level in OGD/R group was increased.	31631531
21114	Rat	rno-miR-15a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic brain injury	primary cortical neurons separated from rats	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31631531
21115	Rat	rno-miR-15a	miRNA	hypoxia	neurological injury	PC-12 cells	hypoxia induce	upregulated	30395900
21116	Rat	rno-miR-15a	miRNA	Sappanone A	neurological injury	hypoxia-induced PC-12 cells	Sappanone A treatment	downregulated	30395900
21117	Rat	rno-miR-15a	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	Rat lumbar spinal cord tissues	chronic constriction injury (CCI) induce	downregulated	31736006
21118	Rat	rno-miR-15a	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
21119	Rat	rno-miR-15a	miRNA	pilocarpine	temporal lobe epilepsy (TLE)	TLE tissues	pilocarpine treatment	mir-15a was significantly downregulated in the TLE tissues	32945401
21120	Rat	rno-miR-15a-5p	miRNA	methylprednisolone	femoral head necrosis (FHN)	femoral head tissues	methylpred-nisolone treatment	upregulated	30957181
21121	Rat	rno-miR-15a-5p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline (MCT) treatment	upregulated	31894295
21122	Rat	rno-miR-15b	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	"In H9c2 cells, hypoxia/reoxygenation induced increased miRNA-15b expression and augmented cardiomyocyte apoptosis observed at 24?hours after 24-hour hypoxia."	28814571
21123	Rat	rno-miR-15b	miRNA	ischemia/reperfusion (I/R) 	acute myocardial infarction (AMI)	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	28814571
21124	Rat	rno-miR-15b	miRNA	glycochenodeoxycholate (GCDC)	apoptosis	liver tissues	glycochenodeoxycholate (GCDC) treatment	upregulated	31152635
21125	Rat	rno-miR-15b	miRNA	hypoxia	apoptosis	Neonatal rat ventricular myocytes (NRVMs) and fibroblasts	hypoxia induce	downregulated	30876857
21126	Rat	rno-miR-15b	miRNA	ischemia/reperfusion (I/R) 	apoptosis	heart tissues	ischemia/reperfusion (I/R) treatment	upregulated	24043355
21127	Rat	rno-miR-15b	miRNA	tauroursodeoxycholate (TUDC)	apoptosis	glycochenodeoxycholate (GCDC)-induced rats liver tissues	Tauroursodeoxycholate (TUDC) treatment	downregulated	31152635
21128	Rat	rno-miR-15b	miRNA	TGF-¦Â1	apoptosis	Neonatal rat ventricular fibroblasts	TGF-¦Â1 treatment	downregulated	30876857
21129	Rat	rno-miR-15b	miRNA	allopurinol	cardiac fibrosis	fructose-treated rats heart tissues and H9c2 cells	allopurinol treatment	upregulated	31871537
21130	Rat	rno-miR-15b	miRNA	fructose	cardiac fibrosis	rats heart tissues and H9c2 cells	fructose treatment	downregulated	31871537
21131	Rat	rno-miR-15b	miRNA	Pterostilbene	cardiac fibrosis	fructose-treated rats heart tissues and H9c2 cells	Pterostilbene treatment	upregulated	31871537
21132	Rat	rno-miR-15b	miRNA	mild hypothermia	cerebral ischemia injury (CII)	brain tissues	applying ice packs around the neck and head	downregulated	30276328
21133	Rat	rno-miR-15b	miRNA	oxaliplatin	chronic neuropathic pain	rats dorsal root ganglion (DRG)	injections of oxaliplatin (2 mg¡¤kg-1 ) for five consecutive days	upregulated in the dorsal root ganglion (DRG)	28012171
21134	Rat	rno-miR-15b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal capillary endothelial cells and pericytes	streptozotocin treatment	downregulated	31364104
21135	Rat	rno-miR-15b	miRNA	ionizing radiation (IR)	irradiation-induced heart damage	rat myocardium	Single irradiation of 10 Gy (4¨C5 Gy/min.) of rat¡¯s mediastinum area	downregulated	30830529
21136	Rat	rno-miR-15b	miRNA	molecular hydrogen-rich water (HRW)	irradiation-induced heart damage	irradiation-induced rat myocardium	molecular hydrogen-rich water (HRW) treatment	upregulated	30830529
21137	Rat	rno-miR-15b	miRNA	losartan	ischemia/reperfusion (I/R) injury	heart tissues	losartan treatment	upregulated	26168042
21138	Rat	rno-miR-15b	miRNA	kaempferol	ischemic heart disease (IHD)	H9c2 cells	Kaempferol (Kae) treatment	Kae exposure promoted downregulated of miR-15b.	32418959
21139	Rat	rno-miR-15b	miRNA	apigenin	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced H9C2 cells	apigenin treatment	downregulated	30983593
21140	Rat	rno-miR-15b	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia induce	upregulated	30983593
21141	Rat	rno-miR-15b	miRNA	"quinacrine, erythromycin and tetracycline"	non-surgical sterilization	Wistar albino 12-14 week old female rats	"quinacrine, erythromycin , tetracycline treatment"	upregulated	25195052
21142	Rat	rno-miR-15b	miRNA	high amplitude mechanical stretching	lung fibrosis	alveolar type II (ATII) cells and lung fibroblasts	high amplitude mechanical stretching treatment	upregulated	31290711
21143	Rat	rno-miR-15b	miRNA	doxorubicin (DOX)	renal interstitial fibrosis (RIF)	kidneys	doxorubicin (ADR) induction	upregulated	32606425
21144	Rat	rno-miR-15b	miRNA	"kangxianling (KXL, anti-fibrin)"	renal interstitial fibrosis (RIF)	kidneys	"Kangxianling (KXL, anti-fibrin) treatment"	downregulated	32606425
21145	Rat	rno-miR-16	miRNA	nicotine	allergic asthma (AA)	lung tissues	nicotine injections	upregulated	28381639
21146	Rat	rno-miR-16	miRNA	amyloid-¦Â (A¦Â)	Alzheimer's disease (AD)	PC12 cells	amyloid-¦Â (A¦Â) treatment	downregulated	30142113
21147	Rat	rno-miR-16	miRNA	glycochenodeoxycholate (GCDC)	apoptosis	liver tissues	glycochenodeoxycholate (GCDC) treatment	upregulated	31152635
21148	Rat	rno-miR-16	miRNA	hypoxia	apoptosis	Bone marrow-derived mesenchymal stem cells (BM-MSCs)	hypoxia/serum deprivation (SD) induce	upregulated	29767235
21149	Rat	rno-miR-16	miRNA	partial hepatectomy (PH)	apoptosis	wistar rats liver tissues	PHS (70% PH); PHP (70% PH of an organ perfused and preserved for 24 hours) treatment	downregulated	25131054
21150	Rat	rno-miR-16	miRNA	tauroursodeoxycholate (TUDC)	apoptosis	glycochenodeoxycholate (GCDC)-induced rats liver tissues	Tauroursodeoxycholate (TUDC) treatment	downregulated	31152635
21151	Rat	rno-miR-16	miRNA	valsartan (VAL)	arrhythmogenesis	H9c2	valsartan treatment	downregulated	26654716
21152	Rat	rno-miR-16	miRNA	H2O2	cardiomyocyte oxidative injury	neonatal rat ventricular cells (NRVCs)	hydrogen peroxide	upregulated	28423616
21153	Rat	rno-miR-16	miRNA	thyroglobulin (Tg)	cell proliferation	rat FRTL-5 thyroid cells	Tg treatment	upregulated	24479877
21154	Rat	rno-miR-16	miRNA	chronic unpredictable mild stress (CUMS)	depression	cerebrospinal fluid (CSF) and raphe	chronic unpredictable mild stress (CUMS) treatment	downregulated	29957478
21155	Rat	rno-miR-16	miRNA	dingzhi Xiaowan (DZ)	depression	unpredictable mild moderate stimulation (CUMS)-induced depression rats hippocampus	Dingzhi Xiaowan (DZ) treatment	upregulated	30347920
21156	Rat	rno-miR-16	miRNA	mitomycin C-polylactic acid ( MMC-PLA) film	epidural scar hyperplasia and adhesion	post-laminectomy rat scar tissues	25 mg of PLA film containing 0.01% MMC was implanted on the laminectomy area	downregulated	28617531
21157	Rat	rno-miR-16	miRNA	hypoxia	glial scars	DI TNC1 cells	hypoxia treatment	upregulated	27460735
21158	Rat	rno-miR-16	miRNA	"acetaminophen, carbon tetrachloride, D-galactosamine and thioacetamide"	hepatotoxicity	rat liver cells	hepatotoxins treatment	"the combination of MicroRNA-16/5S Ribosomal RNA and Beta 2 Microglobulin/18S Ribosomal RNA were validated as optimal reference genes for microRNA and mRNA quantification, respectively, in rat models of acute hepatotoxicity."	22563491
21159	Rat	rno-miR-16	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	NP cells	lipopolysaccharide (LPS) treatment	MiR-16 was downregulated in NP cells after LPS induction.	33747285
21160	Rat	rno-miR-16	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
21161	Rat	rno-miR-16	miRNA	hypoxia	myocardial hypoxia/reoxygenation (H/R) injury	H9c2(2-1) cells	hypoxia induce	upregulated	31432171
21162	Rat	rno-miR-16	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated	31777165
21163	Rat	rno-miR-16	miRNA	lipopolysaccharide (LPS)	myocarditis	H9C2 cells	lipopolysaccharide (LPS) treatment	upregulation of miR-16 has a protective effect on LPS-damaged H9c2 cells.	31777165
21164	Rat	rno-miR-16	miRNA	destabilization of medial meniscus (DMM)	osteoarthritis (OA)	male Sprague¨CDawley rats OA cartilage tissues	destabilization of medial meniscus (DMM) treatment	upregulated	29255591
21165	Rat	rno-miR-16	miRNA	destabilization of medial meniscus (DMM)	osteogenesis	bone marrow mesenchymal stem cells (BMSCs)	MgCl2 treatment	MgCl2 causes the decreases of miR-16 levels.	32411326
21166	Rat	rno-miR-16	miRNA	stress	post-traumatic stress disorder (PTSD)	Wistar rats HIP	controlled lighting (light on 07:00¨C19:00 hr) and temperature (25 ¡À 2¡ãC) conditions with ad libitum access to food and water treatment	upregulated	28944448
21167	Rat	rno-miR-16	miRNA	"paroxetine hydrochloride and corticotropin-releasing factor antagonist (CP-154,526)"	post-traumatic stress disorder (PTSD)	PTSD Wistar rats HIP	"CP-154,526 treatment"	downregulated	28944448
21168	Rat	rno-miR-16	miRNA	sitagliptin	renal interstitial inflammatory	type II diabetic Goto-Kakizaki (GK)	sitagliptin treatment	upregulated	28652790
21169	Rat	rno-miR-16	miRNA	cronobacter sakazakii	septicemia	amygdala	cronobacter sakazakii treatment	upregulated	26388777
21170	Rat	rno-miR-16	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 11) treatment	different expression	24420840
21171	Rat	rno-miR-16-3p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
21172	Rat	rno-miR-16-5p	miRNA	isoproterenol	acute cardiac injury	blood	isoproterenol treatment	upregulated	27605421
21173	Rat	rno-miR-16-5p	miRNA	"2,3,5,6-tetramethylpyrazine (TMP)"	creeclampsia (PE)	trophoblast cells of placental tissue of PE rats	"2,3,5,6-tetramethylpyrazine (TMP) treatment"	TMP inhibits trophoblast cell autophagy and promotes its viability and migration in PE rat model through regulating the miR-16-5p/IGF-2 axis.	33112793
21174	Rat	rno-miR-16-5p	miRNA	octreotide (OCT)	neuroendocrine tumors	INS-1 cells	octreotide treatment	upregulated	33045023
21175	Rat	rno-miR-17	miRNA	ethanol (EtOH)	acute gastric mucosal injury	gastric tissues?of rat	oral administration of ethanol	downregulated	23830200
21176	Rat	rno-miR-17	miRNA	butyrylated high-amylose maize starch (HAMSB)	colorectal cancer (CRC)	high-protein meat diet (HPM) fed rat colonic tissue	butyrylated high-amylose maize starch (HAMSB) feed	downregulated	31052187
21177	Rat	rno-miR-17	miRNA	high-amylose potato starch (HAPS)	colorectal cancer (CRC)	high-protein meat diet (HPM) fed rat colonic tissue	high-amylose potato starch (HAPS) feed	downregulated	31052187
21178	Rat	rno-miR-17	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	upregulated	28199183
21179	Rat	rno-miR-17	miRNA	resveratrol	cardiac fibrosis	cardiac fibroblasts (CFs)	resveratrol (Res) treatment	"Resveratrol decreased the levels of miR-17,in TGF- ¦Â1-treated CFs"	30648109
21180	Rat	rno-miR-17	miRNA	high fat diet (HFD) and streptozotocin (STZ)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD); streptozotocin (STZ)  treatment	downregulated	30338914
21181	Rat	rno-miR-17	miRNA	"1,3,5-tris-4-propyl-1H-pyrazole"	spinal cord injury (SCI)	VSC4.1 motoneurons	ER agonists treatment	upregulated	24157932
21182	Rat	rno-miR-17	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	retina tissues	streptozotocin (STZ) treatment	upregulated	30170066
21183	Rat	rno-miR-17-1	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
21184	Rat	rno-miR-17-3p	miRNA	dexamethasone (DEX)	ischemia/reperfusion (I/R) injury	H9c2 cells	dexamethasone (DEX) treatment	"A concentration of 0.1-10 ?mol/l Dex attenuated H/R injury, which was accompanied by increased miR-17-3p levels."	32742334
21185	Rat	rno-miR-17-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31730378
21186	Rat	rno-miR-17-3p	miRNA	rosuvastatin	myocardial ischemia/reperfusion (I/R) injury (MIRI)	oxygen-glucose deprivation/reoxygenation (OGD/R) induced H9C2 cells	Rosuvastatin (RS) treatment	upregulated	31730378
21187	Rat	rno-miR-17-3p	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 9) treatment	different expression	24420840
21188	Rat	rno-miR-17-5p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	downregulated	27535721
21189	Rat	rno-miR-17-5p	miRNA	H2O2	cardiovascular disease (CVD)	H9c2 cells	H2O2 treatment	upregulated	33350543
21190	Rat	rno-miR-17-5p	miRNA	hypoxia	glial scars	DI TNC1 cells	hypoxia treatment	upregulated	27460735
21191	Rat	rno-miR-17-5p	miRNA	H2O2	ischemia/reperfusion (I/R) injury	neonatal rat ventricular cardiomyocytes (NRVCs)	oxidative stress treatment	upregulated	25200830
21192	Rat	rno-miR-17-5p	miRNA	hypoxia	ischemic acute kidney injury	rat kidney proximal tubular cell (RPTC) line	hypoxia treatment	upregulated	27622990
21193	Rat	rno-miR-17-5p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cell (HSC)	CCl4 treatment	upregulated	25915722
21194	Rat	rno-miR-17-5p	miRNA	Salvianolic acid B (Sal B)	liver fibrosis	hepatic stellate cell (HSC)	Salvianolic acid B (Sal B) treatment	downregulated	26637809
21195	Rat	rno-miR-17-5p	miRNA	diosmin (Dios)	oxidative stress	rats	100 mg¡¤(kg body mass)-1¡¤day-1 (per oral) of Dios	downregulated	28177765
21196	Rat	rno-miR-17-5p	miRNA	ionizing radiation (IR)	oxidative stress	liver tissues	overall dose of 12 Gy on 6 fractions of 2 Gy each	upregulated	28177765
21197	Rat	rno-miR-17-5p	miRNA	X-rays	radiation-induced skin injury	rats irradiated skin	45-Gy electron beam treatment	downregulated	24447893
21198	Rat	rno-miR-17-5p	miRNA	beta-phenethyl isothiocyanate (PEITC)	sciatic nerve conditioning injury	Primary Sensory Neurons	beta-phenethyl isothiocyanate (PEITC) treatment	downregulated	29877111
21199	Rat	rno-miR-181	miRNA	"2,5-hexanedione (HD)"	"2,5-hexanedione (HD) toxicity"	spinal cord tissues	"2,5-hexanedione (HD) treatment"	upregulated	31760062
21200	Rat	rno-miR-181	miRNA	DF3016A	ischemic neuroinflammatory injury	OGD/R treated primary cultured neurons	oxygen-glucose deprivation-reoxygenation (OGD/R) treatment	downregulated	30953275
21201	Rat	rno-miR-181	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuroinflammatory injury	Primary Cultured neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30953275
21202	Rat	rno-miR-181	miRNA	angiotensin II (Ang II)	renal fibrosis	NRK49F cells	angiotensin II (Ang II) treatment	downregulated	30816527
21203	Rat	rno-miR-181a	miRNA	ethanol (EtOH)	acute gastric mucosal injury	gastric tissues?of rat	oral administration of ethanol	downregulated	23830200
21204	Rat	rno-miR-181a	miRNA	adriamycin (ADR)	anthracycline-induced cardiomyocyte apoptosis	"rat myocardial cell line, H9c2, and primary cardiomyocytes"	adriamycin (ADR) treatment	upregulated	29849870
21205	Rat	rno-miR-181a	miRNA	propofol (PPF)	anthracycline-induced cardiomyocyte apoptosis	"Adriamycin? (ADM)-treated rat myocardial cell line, H9c2, and primary cardiomyocytes"	propofol treatment	downregulated	29849870
21206	Rat	rno-miR-181a	miRNA	H2O2	antiapoptotic	mesenchymal stem cells (MSCs)	H2O2 treatment	upregulated	26283227
21207	Rat	rno-miR-181a	miRNA	GW0742	astrocytic injury	rat hippocampal astrocytes	GW0742	upregulated	27789312
21208	Rat	rno-miR-181a	miRNA	sevoflurane (SEV)	cerebral ischemia/reperfusion (I/R) injury	"primary cortical neurons after OGD, rat brain after MCAO"	sevoflurane (SEVO) treatment	downregulated	31170386
21209	Rat	rno-miR-181a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiomyocytes	high glucose treatment	upregulated	27221738
21210	Rat	rno-miR-181a	miRNA	TGF-¦Â	diabetic nephropathy (DN)	Rat glomerular mesangial cells	TGF¦Â treatment	upregulated	29397070
21211	Rat	rno-miR-181a	miRNA	dapagliflozin	drug-induced acute kidney injury (DIKI)	rat kidney tissues	Dapagliflozin (DAPA) treatment	upregulated	31075409
21212	Rat	rno-miR-181a	miRNA	dapagliflozin	drug-induced acute kidney injury (DIKI)	GNT-treated rat kidney tissues	Dapagliflozin (DAPA) treatment	downregulated	31075409
21213	Rat	rno-miR-181a	miRNA	gentamicin	drug-induced acute kidney injury (DIKI)	rat kidney tissues	gentamicin (GNT) treatment	upregulated	31075409
21214	Rat	rno-miR-181a	miRNA	pentylenetetrazol (PTZ)	epilepsy	hippocampal tissues	pentylenetetrazol (PTZ) treatment	upregulated	26722477
21215	Rat	rno-miR-181a	miRNA	perinatal nicotine	health effects of E-cigarette and other novel electronic nicotine delivery systems (ENDS)	heart tissues	perinatal nicotine exposure (PNE) treatment	PNE could induce a reprogramming of cardiac miR-181a expression/DNA methylation pattern	33052248
21216	Rat	rno-miR-181a	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
21217	Rat	rno-miR-181a	miRNA	resveratrol	cardiac fibrosis	cardiac fibroblasts (CFs)	resveratrol (Res) treatment	Resveratrol decreased the levels of miR-181a in TGF- ¦Â1-treated CFs	30648109
21218	Rat	rno-miR-181a	miRNA	abdominal aortic coarctation	cardiac hypertrophy	rats cardiac tissues	abdominal aortic coarctation treatment	downregulated in cardiac tissues	29243791
21219	Rat	rno-miR-181a	miRNA	H2O2	oxidative stress	H9c2 rat cardiomyocyte cell line	H2O2 treatment	upregulated	24683439
21220	Rat	rno-miR-181a	miRNA	retinal toxicant pan-CDK inhibitors	retinal toxicity	rats in renal	a single intravitreal (IVT) injection treatment	upregulated	24114799
21221	Rat	rno-miR-181a	miRNA	hesperidin	testicular toxicity	testicular	hesperidin (HSP) treatment	upregulated	32050098
21222	Rat	rno-miR-181a/b-5p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline (MCT) treatment	downregulated	31637717
21223	Rat	rno-miR-181a/b-5p	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	pulmonary arterial hypertension (PAH)	primary rat pulmonary arterial endothelial cells (rPAECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	31637717
21224	Rat	rno-miR-181a-2-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	29706607
21225	Rat	rno-miR-181a-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	33407436
21226	Rat	rno-miR-181a-5p	miRNA	methamphetamine (METH)	addiction	nucleus accumbens tissues	Methamphetamine treatment	dysregulated	28681200
21227	Rat	rno-miR-181a-5p	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	rat insulinoma (INS-1) cells	streptozotocin (STZ) treatment	Silencing of lncRNA PVT1 ameliorates streptozotocin-induced pancreatic ¦Â cell injury and enhances insulin secretory capacity by regulating miR-181a-5p	32758099
21228	Rat	rno-miR-181a-5p	miRNA	liraglutide	endothelial dysfunction	aortic endothelial in diabetic rats	liraglutide treatment	downregulated	30863684
21229	Rat	rno-miR-181a-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
21230	Rat	rno-miR-181a-5p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	downregulated	27919821
21231	Rat	rno-miR-181a-5p	miRNA	high mobility group box-1 protein (HMGB1)	sepsis	rats dendritic cell (DC)	HMGB1	upregulated	28947753
21232	Rat	rno-miR-181a-5p	miRNA	CXCR4 agonist AMD3100	severe acute pancreatitis (SAP)	Severe acute pancreatitis (SAP) rats pancreas and serum	CXCR4 agonist AMD3100 treatment	downregulated	31654716
21233	Rat	rno-miR-181a-5p	miRNA	Sodium taurocholate	Severe acute pancreatitis (SAP)	pancreas and serum	Sodium taurocholate treatment	downregulated	31654716
21234	Rat	rno-miR-181a-5p	miRNA	lithium chloride and pilocarpine	temporal lobe epilepsy (TLE)	hippocampus	lithium-pilocarpine treatment	miR-181a-5p was increased in the hippocampus.	32461588
21235	Rat	rno-miR-181b	miRNA	angiotensin II (Ang II)	cardiac fibrosis and hypertension	cardiac fibroblasts (CFs) of rats	angiotensin II (Ang II) treatment	downregulated	23007623
21236	Rat	rno-miR-181b	miRNA	kainic acid (KA)	epilepsy	hippocampus of KA-induced juvenile epileptic rats	kainic acid (KA) treatment	downregulated	29808547
21237	Rat	rno-miR-181b	miRNA	magnesium-free extracellular fluid	epilepsy	hippocampal neurons	magnesium-free treatment	MiR-181b suppressed the progression of epilepsy via regulation of RASSF1A and lncRNA ZNF883.	32655808
21238	Rat	rno-miR-181b	miRNA	gleditsia sinensis extract (GSE)	hepatocellular carcinoma (HCC)	HCC liver	Gleditsia sinensis extract (GSE) treatment	upregulated	30940289
21239	Rat	rno-miR-181b	miRNA	¦Â-ionone (¦ÂI)	hepatocellular carcinoma (HCC)	rats hepatocyte	¦ÂI (16 mg/100 g body weight) treatment	"upregulated(miR-122 , miR-34a) ;downregulated (miR-181b , miR-708)"	27061051
21240	Rat	rno-miR-181b	miRNA	hypoxia	hypertensive disorders complicating pregnancy (HDCP)	primary cardiomyocytes	hypoxia treatment	downregulated	28912851
21241	Rat	rno-miR-181b	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	male Sprague¨CDawley (180¨C220 g) rats	CCl4 treatment	upregulated	25148875
21242	Rat	rno-miR-181b	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC-12 cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	The expression of miR-181b was downregulated by the change in MPP+ concentration.	29608948
21243	Rat	rno-miR-181b	miRNA	panax notoginseng saponins (PNS)	severe acute pancreatitis (SAP)	taurocholate-induced severe acute pancreatitis (SAP) rats pancreas tissues	Panax notoginseng saponins treatment	upregulated	29402262
21244	Rat	rno-miR-181b	miRNA	taurocholate	severe acute pancreatitis (SAP)	pancreas tissues	taurocholate treatment	downregulated	29402262
21245	Rat	rno-miR-181b	miRNA	silicon dioxide (SiO2)	silicosis	fibrotic lungs	silicon dioxide (SiO2) treatment	downregulated	26239160
21246	Rat	rno-miR-181b	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	downregulated	21094214
21247	Rat	rno-miR-181b-1	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
21248	Rat	rno-miR-181b-1-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21249	Rat	rno-miR-181b-3p	miRNA	hyaluronic acid 35 (HA35)	ethanol-induced liver and intestinal injury	Kupffer cells isolated from ethanol-fed rats	HA35 for 5 h	upregulated	28257601
21250	Rat	rno-miR-181b-5p	miRNA	earle's balanced salt solution (EBSS)	autophagy	H9c2 cardiomyocytes and neonatal rat ventricular myocytes (NRVMs)	"H9c2 cardiomyocytes and neonatal rat ventricular myocytes (NRVMs) were glucose-starved in Earle's Balanced Salt Solution (EBSS) for different periods of time (0, 2, 4, 6 and 8 h)"	downregulated	30431062
21251	Rat	rno-miR-181b-5p	miRNA	glucose starvation	cardiomyocyte autophagy	H9c2 cardiomyocytes and neonatal rat ventricular myocytes (NRVMs)	glucose-starved in Earle's Balanced Salt Solution (EBSS) induce	downregulated	30431062
21252	Rat	rno-miR-181b-5p	miRNA	monocrotaline (MCT)	epithelial-mesenchymal transition (EMT)	rat pulmonary arterial	monocrotaline (MCT) treatment	downregulated	31734320
21253	Rat	rno-miR-181b-5p	miRNA	"TNF-¦Á, TGF¦Â1 and IL-1¦Â in combination"	epithelial-mesenchymal transition (EMT)	primary rat pulmonary arterial endothelial cells (rPAECs)	"TNF-¦Á, TGF¦Â1 and IL-1¦Â in combination treatment"	downregulated	31734320
21254	Rat	rno-miR-181b-5p	miRNA	hypoxia	ischemic heart disease (IHD)	H9C2 myocardial cells	hypoxia induce	upregulated	31297863
21255	Rat	rno-miR-181b-5p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	rat pulmonary arterial	monocrotaline (MCT) treatment	downregulated	31734320
21256	Rat	rno-miR-181b-5p	miRNA	"TNF-¦Á, TGF¦Â1 and IL-1¦Â in combination"	pulmonary arterial hypertension (PAH)	primary rat pulmonary arterial endothelial cells (rPAECs)	"TNF-¦Á, TGF¦Â1 and IL-1¦Â in combination treatment"	downregulated	31734320
21257	Rat	rno-miR-181b-5p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	downregulated	26997989
21258	Rat	rno-miR-181b-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21259	Rat	rno-miR-181b-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	?Bioinformatics prediction and luciferase reporter assay demonstrated that miR-181b-5p could directly bind to SNHG14.	33791006
21260	Rat	rno-miR-181c	miRNA	IL-6	apoptosis	INS-1 beta cells	IL-6 treatment	downregulated	30974824
21261	Rat	rno-miR-181c	miRNA	valproic acid (VPA)	autism spectrum disorder (ASD)	amygdala	valproic acid treatment	upregulated	25986729
21262	Rat	rno-miR-181c	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	primary hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-181c was significantly decreased in OGD/reoxygenation-treated hippocampal neurons.	32213240
21263	Rat	rno-miR-181c	miRNA	bilateral common carotid artery occlusion (2-VO)	chronic cerebral hypoperfusion (CCH)	rats	bilateral common carotid artery?occlusion (2VO) induce	downregulated	27933582
21264	Rat	rno-miR-181c	miRNA	ischemia/hypoxia (IH)	chronic cerebral hypoperfusion (CCH)	hippocampus	ischemia/hypoxia treatment	downregulated	27933582
21265	Rat	rno-miR-181c	miRNA	H2O2	craniofacial defect	Bone mesenchymal stem cell (BMSC)	H2O2 treatment	downregulated	33111200
21266	Rat	rno-miR-181c	miRNA	H2O2	craniofacial defect reconstruction	Bone mesenchymal stem cell (BMSC)	hydrogen peroxide (H2O2) treatment	downregulated	31578723
21267	Rat	rno-miR-181c	miRNA	hypoxia/reoxygenation (H/R)	doxorubicin (DOX)-induced cardiotoxicity	H9C2 cells	hypoxia /reoxygenation (H/R) treatment	MiR-181c protects cardiomyocyte injury by preventing cell apoptosis through PI3K/Akt signaling pathway	32968640
21268	Rat	rno-miR-181c	miRNA	methamphetamine (METH)	intestinal barrier dysfunction	IEC-6 cells (rat small intestine epithelial cells)	Methamphetamine treatment	downregulated	31862507
21269	Rat	rno-miR-181c	miRNA	H2O2	oxidative stress	Bone mesenchymal stem cells (BMSC)	H2O2 treatment	downregulated	31466503
21270	Rat	rno-miR-181c	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	28770951
21271	Rat	rno-miR-181c	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	downregulated	21094214
21272	Rat	rno-miR-181c-3p	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	primary cortical neurons?and secreted exosomes	oxygen and glucose deprivation (OGD) treatment	downregulated	31665717
21273	Rat	rno-miR-181c-5p	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	F344 rats liver tissues	aflatoxin B1 (AFB3) treatment	upregulated	28218475
21274	Rat	rno-miR-181c-5p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	?H9C2 cells	hypoxia induce	upregulated	31178952
21275	Rat	rno-miR-181d-5p	miRNA	Jianpi Xiaoke (JPXK)	type 2 diabetes mellitus (T2DM)	rat	Jianpi Xiaoke (JPXK) treatment	upregulated	33456489
21276	Rat	rno-miR-182	miRNA	hypoxia	acute kidney injury (AKI)	NRK-52E cells	hypoxia induce	upregulated	29733821
21277	Rat	rno-miR-182	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31899128
21278	Rat	rno-miR-182	miRNA	vitamin D3	arterial calcification	rat calcified arterial tissues	vitamin D3 treatment	downregulated	29196163
21279	Rat	rno-miR-182	miRNA	vitamin D3 and ¦Â-glycerophosphate	arterial calcification	Sprague Dawley (SD) rats calcified arterial tissues	vitamin D3 and ¦Â-glycerophosphate treatment	downregulated in calcified arterial tissues	29196163
21280	Rat	rno-miR-182	miRNA	¦Â-glycerophosphate (¦Â-GP)	arterial calcification	vascular smooth muscle cells (VSMCs)	¦Â-glycerophosphate treatment	downregulated	29196163
21281	Rat	rno-miR-182	miRNA	hypoxia	cyanotic congenital heart disease (CCHD)	H9c2 cells	hypoxia induce	downregulated	30107165
21282	Rat	rno-miR-182	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	upregulated	22156553
21283	Rat	rno-miR-182	miRNA	aflatoxin B1 (AFB1)	epatocarcinogenesis	serum	aflatoxin (AFB1 ) treatment	upregulated	31373075
21284	Rat	rno-miR-182	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
21285	Rat	rno-miR-182	miRNA	rapid ventricular pacing	heart failure (HF)	rat heart tissues	rapid ventricular pacing induce treatment	downregulated	31210325
21286	Rat	rno-miR-182	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	upregulated	24205079
21287	Rat	rno-miR-182	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	upregulated	24205079
21288	Rat	rno-miR-182	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	downregulated	29262398
21289	Rat	rno-miR-182	miRNA	schistosomiasis japonica	liver fibrosis	hepatic fibrosis tissues	Schistosomiasis japonica infection treatment	upregulated	29323718
21290	Rat	rno-miR-182	miRNA	heat stress	lung cancer	lung	Heating System 2.2 (THS2.2) treatment	downregulated	27866933
21291	Rat	rno-miR-182	miRNA	ellagic acid (EA)	breast cancer	female rat mammary tissue	ellagic acid treatment	"ellagic acid, which inhibited E2-induced mammary tumorigenesis in our previous study, reversed the dysregulation of miR-375, miR-206, miR-182, miR-122, miR-127 and miR-183 detected with E2treatment"	23791885
21292	Rat	rno-miR-182	miRNA	fluorine combined with aluminum (FA)	neurotoxicity	hippocampi in the offspring of rats	fluorine combined with aluminum (FA) exposure	upregulated	30033483
21293	Rat	rno-miR-182	miRNA	oxymatrine	nonalcoholic fatty liver disease (NAFLD)	liver tissues	oxymatrine treatment	upregulated	32679144
21294	Rat	rno-miR-182	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
21295	Rat	rno-miR-182	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	downregulated	26997989
21296	Rat	rno-miR-182	miRNA	retinal toxicant pan-CDK inhibitors	retinal toxicity	rats in renal	a single intravitreal (IVT) injection treatment	upregulated	24114799
21297	Rat	rno-miR-182	miRNA	activated protein C(APC)	sepsis	rats blood and liver tissue	activated protein C treatment	aPC treatment coordinates beneficial cytoprotective effects during sepsis by modulating miRNA expression	22940033
21298	Rat	rno-miR-182	miRNA	colesevelam	zucker diabetic fatty (ZDF)	liver tissues	colesevelam treatment	upregulated	30160993
21299	Rat	rno-miR-182-5p	miRNA	ganoderic acid A (GAA)	hypoxia-induced cardiac dysfunctions	H9c2 cells	Ganoderic acid A (GAA) treatment	GAA obviously enhanced the expression level of miR-182-5p in H9c2 cells.	30415259
21300	Rat	rno-miR-182-5p	miRNA	diethylnitrosamine (DEN)	liver fibrosis	liver tissues	diethylnitrosamine (DEN) treatment	upregulated	29236317
21301	Rat	rno-miR-182-5p	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	upregulated	29671338
21302	Rat	rno-miR-182-5p	miRNA	aldosterone	osteoporosis	Osteoporosis (OP) rats left femurs	alendronate treatment	downregulated	30413613
21303	Rat	rno-miR-182-5p	miRNA	palmitate	type 2 diabetes mellitus (T2DM)	INS-1 cells	palmitate (Pal) treatment	upregulated	30546417
21304	Rat	rno-miR-183	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	downregulated	28731278
21305	Rat	rno-miR-183	miRNA	hypoxia	acute myocardial infarction (AMI)	rat cardiomyocyte-drived H9c2 cells	hypoxia	downregulated	28731278
21306	Rat	rno-miR-183	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	upregulated	22156553
21307	Rat	rno-miR-183	miRNA	gleditsia sinensis extract (GSE)	hepatocellular carcinoma (HCC)	HCC liver	Gleditsia sinensis extract (GSE) treatment	upregulated	30940289
21308	Rat	rno-miR-183	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	upregulated	24205079
21309	Rat	rno-miR-183	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	upregulated	24205079
21310	Rat	rno-miR-183	miRNA	ellagic acid (EA)	breast cancer	female rat mammary tissue	ellagic acid treatment	"ellagic acid, which inhibited E2-induced mammary tumorigenesis in our previous study, reversed the dysregulation of miR-375, miR-206, miR-182, miR-122, miR-127 and miR-183 detected with E2treatment"	23791885
21311	Rat	rno-miR-183	miRNA	retinal toxicant pan-CDK inhibitors	retinal toxicity	rats in renal	a single intravitreal (IVT) injection treatment	upregulated	24114799
21312	Rat	rno-miR-183	miRNA	colesevelam	zucker diabetic fatty (ZDF)	liver tissues	colesevelam treatment	upregulated	30160993
21313	Rat	rno-miR-183	miRNA	dexamethasone (DEX)	hormonal regulation	adrenals?tissues	dexamethasone (DEX) treatment	upregulated	24205079
21314	Rat	rno-miR-183-3p	miRNA	vagus nerve stimulation (VNS)	chronic systolic heart failure (CSHF)	heart tissues	vagus nerve stimulation (VNS) stimulation treatment	upregulated	31629817
21315	Rat	rno-miR-183-3p	miRNA	vagus nerve stimulation (VNS)	chronic systolic heart failure (CSHF)	heart tissues	vagus nerve stimulation (VNS) treatment	MicroRNA-183-3p upregulated by vagus nerve stimulation mitigates chronic systolic heart failure via the reduction of BNIP3L-mediated autophagy	31629817
21316	Rat	rno-miR-183-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus tissues	chronic unpredictable mild stressed (CUMS) treatment	upregulated	28083819
21317	Rat	rno-miR-183-5p	miRNA	hronic unpredictable mild stressed (CUMS)	depression	rats hippocampal tissues	stimulated daily with randomly applied mild stressors from among 14 different mild stressors	upregulated	28083819
21318	Rat	rno-miR-183-5p	miRNA	diethylnitrosamine (DEN)	liver fibrosis	liver tissues	diethylnitrosamine (DEN) treatment	upregulated	29236317
21319	Rat	rno-miR-183-5p	miRNA	anoxia/reoxygenation (A/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	anoxia/reoxygenation (A/R) treatment	downregulated	31618500
21320	Rat	rno-miR-183-5p	miRNA	oxymatrine	nonalcoholic fatty liver disease (NAFLD)	liver tissues	oxymatrine treatment	upregulated	32679144
21321	Rat	rno-miR-183-5p	miRNA	N-methyl-N-nitrosourea (MNU)	retinal lesions	serum	N-methyl-N-nitrosourea (MNU) treatment	"MNU at 50?mg/kg induced photoreceptor cell death, with elevation in serum miR-183-5p levels."	30336191
21322	Rat	rno-miR-183-5p	miRNA	N-methyl-N-nitrosourea (MNU)	retinal toxicity	serum	N-methyl-N-nitrosourea (MNU) treatment	upregulated	30336191
21323	Rat	rno-miR-184	miRNA	palmitic acid (PA)	diabetic cardiomyopathy (DCM)	H9c2 cells	palmitic acid treatment	The expression of miR-184 was significantly decreased in H9c2 cardiomyoblast treated by palmitic acid	32229289
21324	Rat	rno-miR-184	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
21325	Rat	rno-miR-184	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
21326	Rat	rno-miR-184	miRNA	H2O2	myocardial infarction (MI)	H9c2 cells	H2O2 treatment	MiR-184 expression was significantly increased in H2O2-induced H9c2 cell injury model.	33215444
21327	Rat	rno-miR-184	miRNA	phthalate mixture	prostate development	Pregnant females filial generation rat prostate	Pregnant females were divided into 4 groups and orally dosed daily from GD10 to PND21 with corn oil (Control:C) or the phthalate mixture at three doses (20?¦Ìg/kg/d:T1; 200?¦Ìg/kg/d:T2; 200?mg/kg/d:T3). treatment	upregulated	31199487
21328	Rat	rno-miR-184	miRNA	angiotensin II (Ang II)	renal fibrosis	NRK49F cells	angiotensin II (Ang II) treatment	upregulated	30536131
21329	Rat	rno-mir-184	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21330	Rat	rno-miR-184	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	Sprague-Dawley (SD) rats colon tissues in the colon tissues	dextran sulfate sodium (DSS)	upregulated( miR-149-5p) downregulated (miR-184) in the colon tissues in the colon tissues	28246536
21331	Rat	rno-miR-184	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
21332	Rat	rno-miR-185	miRNA	tunicamycin (TM) or thapsigargin (TG)	cardiomyocyte apoptosis	neonatal rat ventricular myocytes (NRVMs)	neonatal rat ventricular myocytes (NRVMs) treatment	downregulated	26521941
21333	Rat	rno-miR-185	miRNA	rotenone (ROT)	parkinson's disease (PD)	rats substantia nigra (SN) and striatum (ST) tissues	rotenone treatment	downregulated	31814881
21334	Rat	rno-miR-186	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	rat primary cardiomyocytes	10¦Ìg/ml or 50¦Ìg/ml TNF¦Á stimulation for 24h treatment	downregulated	28233577
21335	Rat	rno-miR-186	miRNA	GYKI-52466 and MK-801	homeostatic synaptic scaling	hippocampal neurons	Blockade of AMPARs and NMDARs with 50 ¦ÌM GYKI-52466 and 10 ¦ÌM MK-801 for 24h	synaptic activity blockade persistently down-regulates miR-186-5p.	30808806
21336	Rat	rno-miR-187	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	upregulated	28199183
21337	Rat	rno-miR-187	miRNA	IL-10	epilepsy	hippocampal tissues	IL-10 treatment	downregulated	26696826
21338	Rat	rno-miR-187-3p	miRNA	doxorubicin (DOX)	cardiotoxicity	H9c2 cells	Doxorubicin (DOX) treatment	miR-187-3p inhibitor significantly reduced PVT1-knockdown H9c2 cell viability and promoted apoptosis	31786333
21339	Rat	rno-miR-187-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (DOX) treatment	"ncRNA PVT1 adsorbs miR-187-3p by sponge action, reducing miR-187-3p levels."	31786333
21340	Rat	rno-miR-188	miRNA	iodixanol	contrast-induced acute kidney injury (CIAKI)	rat renal tissues	iodixanol treatment	upregulated	31555692
21341	Rat	rno-miR-188	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	upregulated	28199183
21342	Rat	rno-miR-188	miRNA	ethylene glycol monomethyl ether (EGME)	hyperglycemia	?testicle of rat	Ethylene glycol monomethyl ether (EGME) treatment	"miR-449a and miR-92a decreased obviously and, miR-320, miR-134 and miR-188 increased"	22008535
21343	Rat	rno-miR-188-3p	miRNA	sevoflurane (SEV)	cognitive impairment	rat brain tissues	sevoflurane treatment	upregulated	29344658
21344	Rat	rno-miR-188-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	primary hippocampal neuron	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	27708404
21345	Rat	rno-miR-18a	miRNA	hypoxia	acute myocardial infarction (AMI)	cardiac tissues and H9c2 cells	hypoxia induce	upregulated	31168354
21346	Rat	rno-miR-18a	miRNA	(E)-1-(4'-aminophenyl)-3-phenylprop-2-en-1-one (APE)	breast cancer	plasma	(E)-1-(4'-aminophenyl)-3-phenylprop-2-en-1-one (APE) treatment	APE can decrease miR-18a and MMP-9 expressions and increase Dicer1 expression in rat mammary cancer.	32458624
21347	Rat	rno-miR-18a	miRNA	blueberry	breast cancer	estrogen-mediated rats breast cancer	blueberry-supplemented diet treatment	upregulated	24245576
21348	Rat	rno-miR-18a	miRNA	dexamethasone (DEX)	depression	prefrontal cortex and hippocampus of adolescent rats	dexamethasone (DEX) treatment	upregulated	30469088
21349	Rat	rno-miR-18a	miRNA	dexamethasone (DEX)	depression	prefrontal cortex and hippocampus of adolescent rats	dexamethasone (DEX) treatment	upregulated	30469088
21350	Rat	rno-miR-18a	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
21351	Rat	rno-miR-18a	miRNA	hypoxia	hypoxia-induced injury	neuronal pheochromocytoma (PC)-12 cells	hypoxia treatment	downregulated	319666702
21352	Rat	rno-miR-18a	miRNA	isoflurane	oxidative stress	H9c2 cells	Isoflurane treatment	downregulated	29627934
21353	Rat	rno-miR-18a	miRNA	nanosized SiO2	pulmonary injury	liver tissues	nanosized SiO2 treatment	upregulated	27689473
21354	Rat	rno-miR-18a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32815784
21355	Rat	rno-miR-19	miRNA	TGF-¦Â1	renal fibrosis	NRK-52E cells	TGF-¦Â1 treatment	miR-19 was significantly increased in cells treated with TGF-¦Â1	32355512
21356	Rat	rno-miR-190	miRNA	fish oil and pectin	colorectal cancer (CRC)	colon tissue of rats	corn oil ¡À fish oil with pectin ¡À cellulose	upregulated	21406606
21357	Rat	rno-miR-190	miRNA	fentanyl	fentanyl toxicity	rat primary hippocampal neuron cultures	fentanyl	downregulated	20457614
21358	Rat	rno-miR-190	miRNA	4-vinylcyclohexene diepoxide (VCD)	premature ovarian failure (POF)	ovarian	4-vinylcyclohexene diepoxide (VCD) tretament	upregulated	24188450
21359	Rat	rno-miR-190	miRNA	fentanyl	smooth muscle cell differentiation	rat hippocampal neurons	fentanyl treatment	downregulated	19854889
21360	Rat	rno-miR-190a	miRNA	dichlorodiphenyltrichloroethane (DDT)	dichlorodiphenyltrichloroethane (DDT) exposure	"liver, uterus, ovaries and mammary gland of female Wistar rats"	dichlorodiphenyltrichloroethane (DDT) exposure	upregulated	30421125
21361	Rat	rno-miR-190a	miRNA	isoflurane and sevoflurane	postoperative cognitive dysfunction (POCD)	Wistar rats hippocampus	exposed to isoflurane and sevoflurane for 2 or 4h	downregulated in the hippocampus	28669717
21362	Rat	rno-miR-190b	miRNA	dichlorodiphenyltrichloroethane (DDT)	dichlorodiphenyltrichloroethane (DDT) exposure	"liver, uterus, ovaries and mammary gland of female Wistar rats"	dichlorodiphenyltrichloroethane (DDT) exposure	upregulated	30421125
21363	Rat	rno-miR-190b	miRNA	isoflurane and sevoflurane	postoperative cognitive dysfunction (POCD)	Wistar rats hippocampus	exposed to isoflurane and sevoflurane for 2 or 4h	downregulated in the hippocampus	28669717
21364	Rat	rno-miR-1912-3p	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
21365	Rat	rno-miR-191a-5p	miRNA	paradoxical sleep deprivation (PSD)	cognitive impairment	Hippocampal tissues	paradoxical sleep deprivation (PSD) induce treatment	upregulated	31279826
21366	Rat	rno-miR-191b	miRNA	hypoxia	stroke	middle cerebral artery occlusion (MCAO) Sprague-Dawley rat	middle cerebral artery occlusion (MCAO) treatment	upregulated	29113076
21367	Rat	rno-miR-192	miRNA	connective tissue growth factor (CTGF)	gastric cancer (GC)	NRK-52E cells	CTGF treatment	downregulated	20393144
21368	Rat	rno-miR-192	miRNA	TGF-¦Â	gastric cancer (GC)	NRK-52E cells	TGF-¦Â treatment	downregulated	20393144
21369	Rat	rno-miR-192	miRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	rats plasma	ischemia/reperfusion (I/R) treatment	upregulated by fourfold in the plasma and downregulatedd by about 40% in the kidney	28035621
21370	Rat	rno-miR-192	miRNA	carbon tetrachloride (CCl4)	acute liver failure (ALF)	rats	CCl4 treatment	upregulated	28616908
21371	Rat	rno-miR-192	miRNA	epigallocatechin-3-gallate (EGCG)	chronic renal injury	cadmium (Cd) pretreated Wistar albino rats	EGCG treatment	"decreased miR-21 and miR-192, enhanced miR-29a/b/c in kidney samples"	27474435
21372	Rat	rno-miR-192	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	male Wistar rats inflamed colon	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated in inflamed colon	28572713
21373	Rat	rno-miR-192	miRNA	exercise (Ex)	diabetes mellitus (DM)	Streptozotocin- induced diabetic rats	exercise treatment	upregulated	25789230
21374	Rat	rno-miR-192	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Rat glomerular mesangial cells	high glucose (HG) treatment	upregulated	30827272
21375	Rat	rno-miR-192	miRNA	astragaloside IV (AS-IV)	diabetic nephropathy (DN)	high glucose treated rat mesangial cells (RMCs)	astragaloside (AS-IV) treatment	downregulated	31572545
21376	Rat	rno-miR-192	miRNA	captopril	diabetic nephropathy (DN)	diabetes rats kidney tissue	captopril treatment	downregulated	31433203
21377	Rat	rno-miR-192	miRNA	high glucose (HG)	diabetic nephropathy (DN)	rat mesangial cells (RMCs)	high glucose (HG) treatment	upregulated	31572545
21378	Rat	rno-miR-192	miRNA	spironolactone	diabetic nephropathy (DN)	diabetes rats kidney tissue	spironolactone treatment	downregulated	31433203
21379	Rat	rno-miR-192	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissue	streptozotocin (STZ) treatment	upregulated	31433203
21380	Rat	rno-miR-192	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	serum	acetaminophen (APAP) treatment	dysregulated	22624025
21381	Rat	rno-miR-192	miRNA	dioscorea bulbifera (DB)	drug-induced liver injury (DILI)	serum	dioscorea bulbifera (DB) treatment	upregulated	22624025
21382	Rat	rno-miR-192	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	H9C2 cells	hypoxia induce	upregulated	30280798
21383	Rat	rno-miR-192	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
21384	Rat	rno-miR-192	miRNA	silymarin (Sm)	liver damage	thioacetamide (TAA) treated rat Blood and liver tissues	silymarin (Sm) treatment	upregulated	31811641
21385	Rat	rno-miR-192	miRNA	thioacetamide (TAA)	liver damage	blood and liver tissues	thioacetamide (TAA) treatment	downregulated	31811641
21386	Rat	rno-miR-192	miRNA	radiation	breast cancer	rat mammary cancer tissues	radiation treatment	upregulated	23273170
21387	Rat	rno-miR-192	miRNA	paclitaxel (PTX)	pancreatic cancer (PC)	renal tissue of rats	paclitaxel?treatment treatment	downregulated	21984124
21388	Rat	rno-miR-192	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	serum	streptozotocin (STZ) treatment	upregulated	30186503
21389	Rat	rno-miR-192-5p	miRNA	isoproterenol	acute cardiac injury	urine tissues	isoproterenol treatment	upregulated	27605421
21390	Rat	rno-miR-192-5p	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	33263228
21391	Rat	rno-miR-192-5p	miRNA	hypoxia/reoxygenation (H/R)	cardiomyocyte apoptosis	H9c2 cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	upregulated	27780314
21392	Rat	rno-miR-192-5p	miRNA	methane	diabetic retinopathy (DR)	Retinal?tissues	methane treatment	upregulated	26363454
21393	Rat	rno-miR-192-5p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
21394	Rat	rno-miR-192-5p	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	27780314
21395	Rat	rno-miR-192-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
21396	Rat	rno-miR-192-5p	miRNA	ischemia/reperfusion (I/R) 	kidney damage	Sprague-Dawley rats urine	ischemia/reperfusion (I/R) treatment	upregulated	28056546
21397	Rat	rno-miR-192-5p	miRNA	monocrotaline (MCT)	liver sinusoidal endothelial cells (LSEC) injury	serum	monocrotaline treatment	upregulated	30019166
21398	Rat	rno-miR-192-5p	miRNA	lipopolysaccharide (LPS)	myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated of KCNQ1OT1 advances cardiac injury through regulating miR-192-5p/XIAP axis during sepsis.	32102564
21399	Rat	rno-miR-192-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	Sprague Dawley rats liver	high fat diet (HFD) feed	upregulated in liver	29290651
21400	Rat	rno-miR-192-5p	miRNA	liraglutide	nonalcoholic fatty liver disease (NAFLD)	HDF rats liver	injection of liraglutide	downregulated in liver	29290651
21401	Rat	rno-miR-192-5p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	rat pheochromocytoma PC12 cells	6-hydroxydopamine (6-OHDA) treatment	upregulated	30552896
21402	Rat	rno-miR-192-5p	miRNA	baicalin (BAI)	parkinson's disease (PD)	6-hydroxydopamine (6-OHDA)-treated rat pheochromocytoma PC12 cells	baicalin (BAI) treatment	downregulated	30552896
21403	Rat	rno-miR-192-5p	miRNA	baicalin (BAI)	parkinson's disease (PD)	PC-12 cells	baicalin (BAI) treatment	Baicalin alleviates 6-hydroxydopamine-induced neurotoxicity in PC12 cells by downregulated of microRNA-192-5p.	30552896
21404	Rat	rno-miR-193	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	serum	acetaminophen (APAP) treatment	dysregulated	22624025
21405	Rat	rno-miR-193	miRNA	dioscorea bulbifera (DB)	drug-induced liver injury (DILI)	serum	dioscorea bulbifera (DB) treatment	upregulated	22624025
21406	Rat	rno-miR-193	miRNA	pilocarpine	epilepsy	adult male rats brain tissue and heart tissue	50 days of pilocarpine treatment	downregulated in the brain tissue	24530830
21407	Rat	rno-miR-193	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
21408	Rat	rno-miR-193	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
21409	Rat	rno-miR-193	miRNA	cadmium (Cd)	ovary structure and function	Wistar rats	cadmium (Cd) treatment	upregulated	24462979
21410	Rat	rno-miR-193	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline treatment	downregulated	28000863
21411	Rat	rno-miR-193-3p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31899128
21412	Rat	rno-miR-193-3p	miRNA	apolipoprotein A-I mimetic peptide 4F	pulmonary arterial hypertension (PAH)	monocrotaline rat lung tissue and serum	apolipoprotein A-I mimetic peptide 4F treatment	miR193 downregulated	24963038
21413	Rat	rno-miR-193a	miRNA	fish oil and pectin	colorectal cancer (CRC)	colon tissue of rats	corn oil ¡À fish oil with pectin ¡À cellulose	upregulated	21406606
21414	Rat	rno-miR-193a	miRNA	fructose	renal dysfunction	rat glomeruli and cultured differentiated podocytes	fructose treatment	upregulated	31085161
21415	Rat	rno-miR-193a	miRNA	Magnesium isoglycyrrhizinate (MgIG)	renal dysfunction	fructose-treated rat glomeruli and cultured differentiated podocytes	Magnesium isoglycyrrhizinate (MgIG) treatment	downregulated	31085161
21416	Rat	rno-miR-193a-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; NR8383 cells	lipopolysaccharide (LPS) treatment	rats in LPS group also resulted in a decrease in ZFAS1 expression and increase in miR-193a-3p expression in lung tissues	33848686
21417	Rat	rno-miR-193a-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12 cells	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31857133
21418	Rat	rno-miR-193a-3p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC-12 cells	amyloid-¦Â (A¦Â) 25-35 treatment	miR-193a-3p was significantly downregulated in PC-12 cells.	31857133
21419	Rat	rno-miR-193a-3p	miRNA	¦Ä-opioid receptor (DOR)	hypoxic/ischemic injury	hearts	¦Ä-opioid receptor (DOR) activation treatment	upregulated	27576463
21420	Rat	rno-miR-193a-3p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	upregulated	28560399
21421	Rat	rno-miR-193a-5p	miRNA	caerulein (Cae)	acute pancreatitis (AP)	AR42J cells	caerulein treatment	"circHIPK3 promotes pyroptosis in acinar cells through regulation of the miR-193a-5p/GSDMD axis, which eventually aggravates AP disease."	32318575
21422	Rat	rno-miR-193b-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-193b-3p has a potentially neuroprotective effect on focal cerebral I/R-induced injury by inhibiting 5-LOX expression	32032565
21423	Rat	rno-miR-19-3p	miRNA	sevoflurane (SEV)	neuron proliferation	primary cultured neonatal rats neurons	?sevoflurane (SEVO) treatment	upregulated	30540563
21424	Rat	rno-miR-194	miRNA	caerulein (Cae)	acute pancreatitis (AP)	"AR42J, a rat pancreatic acinar cell line"	caerulein (Cae) treatment	downregulated	31518341
21425	Rat	rno-miR-194	miRNA	burn injury	burn-induced hyperglycemia	rats	serum from burn rats treatment	miR-194 expression was significantly elevated	25186839
21426	Rat	rno-miR-194	miRNA	serum	burn-induced hyperglycemia	Rat myoblast L6 cells	serum from burn rats treatment	miR-194 expression was significantly elevated	25186839
21427	Rat	rno-miR-194	miRNA	citrulline	gastrointestinal toxicity	rats	citrulline treatment	"Fecal miR-194 levels upregulated,"	27189632
21428	Rat	rno-miR-194	miRNA	palmitate and palmitate plus oleate.	insulin resistance (IR)	mouse myoblasts	palmitate and palmitate plus oleate treatment	upregulated	21183973
21429	Rat	rno-miR-194	miRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	NP cells	lipopolysaccharide (LPS) treatment	MiR-194 expression was reduced in LPS-induced NP cells.	29745371
21430	Rat	rno-miR-194	miRNA	silymarin (Sm)	liver damage	thioacetamide (TAA) treated rat Blood and liver tissues	silymarin (Sm) treatment	upregulated	31811641
21431	Rat	rno-miR-194	miRNA	thioacetamide (TAA)	liver damage	blood and liver tissues	thioacetamide (TAA) treatment	downregulated	31811641
21432	Rat	rno-miR-194	miRNA	radiation	breast cancer	rat mammary cancer tissues	radiation treatment	upregulated	23273170
21433	Rat	rno-miR-194	miRNA	lipopolysaccharide (LPS)	myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	The expression level of microRNA-194 was increased in LPS-induced H9c2 cardiomyocytes injury model in a time-dependent manner.	29687865
21434	Rat	rno-miR-194	miRNA	lycium barbarum polysaccharide (LBP)	spinal cord injury (SCI)	PC-12 cells	Lycium barbarum polysaccharides (LBPs) treatment	downregulated	30308510
21435	Rat	rno-miR-194-1	miRNA	hypoxia	stroke	middle cerebral artery occlusion (MCAO) Sprague-Dawley rat	middle cerebral artery occlusion (MCAO) treatment	downregulated	29113076
21436	Rat	rno-miR-194-3p	miRNA	propofol (PPF)	neurotoxicity	primary cultured neural stem cells (NSCs)	propofol treatment	upregulated	29679758
21437	Rat	rno-miR-194-5p	miRNA	methamphetamine (METH)	addiction	nucleus accumbens tissues	Methamphetamine treatment	dysregulated	28681200
21438	Rat	rno-miR-194-5p	miRNA	hypothermia oxygen glucose deprivation	stroke	primary neuron tisssues	hypothermia oxygen glucose deprivation treatment	miR-194-5p expression was significantly downregulated in hypothermia oxygen glucose deprivation-treated neurons in vitro.	30232383
21439	Rat	rno-miR-195	miRNA	hypoxia/reoxygenation (H/R)	cardiomyocyte apoptosis	H9c2 cells	hypoxia/reoxygenation (H/R) injury treatment	upregulated	27608900
21440	Rat	rno-miR-195	miRNA	isoprenaline	cardiac hypertrophy	neonatal rat ventricular myocytes	isoprenaline treatment	upregulated	25100012
21441	Rat	rno-miR-195	miRNA	thyroglobulin (Tg)	cell proliferation	rat FRTL-5 thyroid cells	Tg treatment	upregulated	24479877
21442	Rat	rno-miR-195	miRNA	hypoxia	cerebral ischemia injury (CII)	brain tissues	middle cerebral artery occlusion (MCAO) treatment	downregulated in rat brain samples	28849133
21443	Rat	rno-miR-195	miRNA	chronic brain hypoperfusion (CBH)	dementia	neurons? cells	chronic brain hypoperfusion (CBH) treatment	downregulated	23447608
21444	Rat	rno-miR-195	miRNA	high-fat high-fructose diet (HFHFD)	diabetic cardiomyopathy (DCM)	heart tissues	high-fat high-fructose diet (HFHFD) feed	upregulated	30320520
21445	Rat	rno-miR-195	miRNA	high-intensity interval training (HIIT)	diabetic cardiomyopathy (DCM)	diabetic rats heart tissues	high-intensity interval training (HIIT) treatment	downregulated	30320520
21446	Rat	rno-miR-195	miRNA	high-intensity interval training (HIIT)	diabetic cardiomyopathy (DCM)	heart sissues	high-intensity interval training (HIIT)	HIIT effectively decreases the expression of miR-195 and increases the expression of Sirt1 and BCL-2 in diabetic rats compared with continuous endurance training (CET).	30320520
21447	Rat	rno-miR-195	miRNA	astragalus polysaccharide (APS)	diabetic retinopathy (DR)	high glucose (HG)-treated rat primary retinal pigment epithelium (RPE) cells	astragalus polysaccharide (APS) treatment	downregulated	31117931
21448	Rat	rno-miR-195	miRNA	high glucose (HG)	diabetic retinopathy (DR)	rat primary retinal pigment epithelium (RPE) cells	high glucose (HG) treatment	upregulated	31117931
21449	Rat	rno-miR-195	miRNA	L5 spinal nerve ligation (SNL)	duchenne muscular dystrophy (DMD)	spinal nerve ligation and spinal microglia	L5 spinal nerve ligation (SNL) treatment	that miR-195 levels were markedly increased in rats subjected to L5 spinal nerve ligation (SNL);Upregulated miR-195 was also found in spinal microglia of rats with SNL	23361941
21450	Rat	rno-miR-195	miRNA	hypoxia	glycolysis	cardiomyocytes	hypoxia treatment	"Meanwhile, miR-27 and miR-195 were also upregulated in hypoxia-induced cardiomyocytes."	33819184
21451	Rat	rno-miR-195	miRNA	oxymatrine	hepatic stellate cell (HSC) activation	TGF-¦Â1-treated HSC-T6 cells	Oxymatrine (OM) treatment	downregulated	31221141
21452	Rat	rno-miR-195	miRNA	TGF-¦Â1	hepatic stellate cell (HSC) activation	HSC-T6 cells	TGF-¦Â1 treatment	upregulated	31221141
21453	Rat	rno-miR-195	miRNA	diethylnitrosamine (DEN)	liver fibrosis	rats	diethyl nitrosamine (DEN) treatment	upregulated	28929107
21454	Rat	rno-miR-195	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
21455	Rat	rno-miR-195-5p	miRNA	hypoxia	acute kidney injury (AKI)	NRK-52E cells	hypoxia treatment	miR-195-5p was found to be markedly reduced under hypoxic conditions.	32492657
21456	Rat	rno-miR-195-5p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	upregulated	32192351
21457	Rat	rno-miR-195-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cardiomyocytes	angiotensin II (Ang II) treatment	upregulated	31341888
21458	Rat	rno-miR-195-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	rat cardiomyocytes	high glucose (HG) treatment	upregulated	31729781
21459	Rat	rno-miR-195-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	Neonatal rat ventricular myocyte	high glucose treatment	upregulated	31729781
21460	Rat	rno-miR-195-5p	miRNA	lipopolysaccharide (LPS)	lung injury	lung tissues	Lipopolysaccharide (LPS) treatment	CASC9 was markedly downregulated while miR-195-5p was significantly upregulated in HSAECs treated by LPS and lung tissues of rats with sepsis.	32221619
21461	Rat	rno-miR-195-5p	miRNA	hypoxia	cell proliferation and migration	apoptosis-resistant pulmonary microvascular endothelial cells (PVECs/AR)	hypoxia treatment	upregulated	28862358
21462	Rat	rno-miR-195-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	rats pulmonary microvascular endothelial cells (PVECs/AR)	exposure to hypoxia for 12 or 24 h	upregulated	28862358
21463	Rat	rno-miR-1956-5p	miRNA	iohexol	contrast-induced acute kidney injury (CIAKI)	Renal tissue	"Animals were dehydrated for 48 h and then underwent furosemide (10 mL/kg; Harvest Pharmaceutical, Shanghai, China) injection 30 min before administration of iohexol (15 mL/kg, group CI-AKI; iodine, 350 mg/mL; GE Healthcare, Shanghai, China) or 0.9% normal saline (15 mL/kg, control group)."	miR-1956-5p was significantly upregulated in Contrast-induced acute kidney injury (CI-AKI).	31234008
21464	Rat	rno-miR-196-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21465	Rat	rno-miR-196a	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	hippocampus tissues	amyloid-¦Â (A¦Â) 25-35 treatment	downregulated	31119777
21466	Rat	rno-miR-196a	miRNA	"3,5-diiodo-L-thyronine (T2)"	browning of white adipocytes	subcutaneous white adipose tissue (sWAT)	receiving a high fat diet for 10 weeks and being subsequently treated for four weeks with an HFD together with the administration of T?	upregulated	30889829
21467	Rat	rno-miR-196a	miRNA	high fat diet (HFD)	browning of white adipocytes	subcutaneous white adipose tissue (sWAT)	high fat diet (HFD) feed	downregulated	30889829
21468	Rat	rno-miR-196a	miRNA	¦Ä-opioid receptor (DOR)	hypoxic/ischemic injury	hearts	¦Ä-opioid receptor (DOR) activation treatment	upregulated	27576463
21469	Rat	rno-miR-196a	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	cultured neonatal rat cortical neurons	oxygen-glucose deprivation (OGD) induce treatment	upregulated	30720182
21470	Rat	rno-miR-196a-5p	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	Schwann cells	chronic constriction injury (CCI) induce	Silencing H19 inhibited NP by suppressing CDK5/p35 and p-CREB phosphorylation via the miR-196a-5p/CDK5 axis.	32903807
21471	Rat	rno-miR-196a-5p	miRNA	steroids	osteonecrosis	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	26459755
21472	Rat	rno-miR-196b	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
21473	Rat	rno-miR-196b-5p	miRNA	pilocarpine	mesial temporal lobe epilepsy (MTLE)	hippocampi	pilocarpine treatment	upregulated	27695061
21474	Rat	rno-miR-196b-5p	miRNA	hypoxia	stroke	middle cerebral artery occlusion (MCAO) Sprague-Dawley rat	middle cerebral artery occlusion (MCAO) treatment	upregulated	29113076
21475	Rat	rno-miR-199a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	autophagy	PC-12 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	MPP+ decreased miR-199a expression in PC12 cells in a concentration-dependent manner.	32151238
21476	Rat	rno-miR-199a	miRNA	isoproterenol	cardiac fibrosis	cardiac fibroblasts (CFs)	isoproterenol (ISO) treatment	upregulated	31115026
21477	Rat	rno-miR-199a	miRNA	estradiol-17¦Â (E2)	embryo implantation	rat uterine horns	estradiol-17¦Â (E2) treatment	downregulated	24149516
21478	Rat	rno-miR-199a	miRNA	Safflor yellow B (SYB)	hypoxia-induced injury	rats RAECs	SYB (0.8 mM) treatment	upregulated	29212172
21479	Rat	rno-miR-199a	miRNA	hypoxia	hypoxia-induced injury	H9c2 cells	hypoxia induce	upregulated	31307244
21480	Rat	rno-miR-199a	miRNA	quercetin	hypoxia-induced injury	hypoxia-induced H9c2 cells	Quercetin treatment	downregulated	31307244
21481	Rat	rno-miR-199a	miRNA	3-nitropropionic acid	liver cirrhosis	brain tissue of rats	3-nitropropionic acid treatment	downregulated	22079324
21482	Rat	rno-miR-199a	miRNA	nicotine	nicotine intake	female rats prefrontal cortex (PFC) tissues	nicotine exposure	upregulated	30504847
21483	Rat	rno-miR-199a	miRNA	dexamethasone (DEX)	osteogenesis	bone marrow mesenchymal stem cells (BMSCs)	dexamethasone (DEX) treatment	"miR-199a was upregulated during OD of BMSCs, while DEX treatment caused a significant reduction in miR-199a."	32869899
21484	Rat	rno-miR-199a	miRNA	dexamethasone (DEX)	oxidative stress	PC-12 cells	dexamethasone (DEX) treatment	Dex attenuated H 2O2-induced oxidative damage in PC12 cells by down-regulating miR-199a expression.	32024386
21485	Rat	rno-miR-199a	miRNA	estradiol-17¦Â (E2)	pseudopregnant	rat uterine horns	estradiol-17¦Â (E2) treatment	Treatmentwith17b-estradiol or both 17b-estradiol and progesterone significantly diminished miR199a levels	24149516
21486	Rat	rno-miR-199a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
21487	Rat	rno-miR-199a	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	upregulated	22847192
21488	Rat	rno-miR-199a-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	upregulated	32192351
21489	Rat	rno-miR-199a-3p	miRNA	palmitate	diabetes mellitus (DM)	INS-1 cells	palmitate (Pal) treatment	upregulated	30131392
21490	Rat	rno-miR-199a-3p	miRNA	hepatitis B virus (HBV) and TGF-¦Â1	hepatic progenitor cells (HPCs) transformation	Hepatic stem-like epithelial cells (LE/6)	HBx and TGF-¦Â1 exposure	upregulated	31740785
21491	Rat	rno-miR-199a-3p	miRNA	hypoxia	neuronal cell injury	C6 glioma cells	hypoxia treatment	upregulated	33110474
21492	Rat	rno-miR-199a-3p	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC-12 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	33494069
21493	Rat	rno-miR-199a-3p	miRNA	mono-n-butyl phthalate (MBP)	precocious puberty and testicular tumors	testicular Sertoli cells (SCs)	mono-n-butyl phthalate (MBP) treatment	upregulated	29162477
21494	Rat	rno-miR-199a-3p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	downregulated	26997989
21495	Rat	rno-miR-199a-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	downregulated	22156553
21496	Rat	rno-miR-199a-5p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	upregulated	27535721
21497	Rat	rno-miR-199a-5p	miRNA	high glucose (HG)	apoptosis	INS-1 rat pancreatic ¦Â-cells	high glucose (HG) treatment	upregulated	28338182
21498	Rat	rno-miR-199a-5p	miRNA	lithium chloride and pilocarpine	epilepsy	Hippocampal	lithium-pilocarpine treatment	upregulated	26945677
21499	Rat	rno-miR-199a-5p	miRNA	angiotensin II (Ang II)	heart failure (HF)	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	29703907
21500	Rat	rno-miR-199a-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31059047
21501	Rat	rno-miR-199a-5p	miRNA	lidocaine	neurotoxicity	spinal cord of rats	Lidocaine treatment	Increased expression of miR-199a-5p in the spinal cord of rats treated with 10 % lidocaine was assessed by qRT-PCR.	33166664
21502	Rat	rno-miR-199a-5p	miRNA	activated protein C(APC)	sepsis	rats blood and liver tissue	activated protein C treatment	aPC treatment coordinates beneficial cytoprotective effects during sepsis by modulating miRNA expression	22940033
21503	Rat	rno-miR-199a-5p	miRNA	lidocaine	spinal cord neurotoxicity	spinal cord white matter	lidocaine treatment	upregulated	33166664
21504	Rat	rno-miR-199b-5p	miRNA	lipopolysaccharide (LPS)	rejection after lung transplantation	allograft tissues	lipopolysaccharide (LPS) treatment	downregulated	29779167
21505	Rat	rno-miR-19a	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	H9C2 cells	hypoxia-reoxygeneration (H/R) treatment	downregulated	29054970
21506	Rat	rno-miR-19a	miRNA	ethanol (EtOH)	acute gastric mucosal injury	gastric tissues?of rat	oral administration of ethanol	downregulated	23830200
21507	Rat	rno-miR-19a	miRNA	hypoxia	acute myocardial infarction (AMI)	heart tissues and primary cardiomyocytes in vitro	hypoxia induce	downregulated	31633225
21508	Rat	rno-miR-19a	miRNA	propofol (PPF)	cerebral injury	PC12 cells	Propofol treatment	"propofol relieved Glu-triggered apoptosis and autophagy of PC12, and activated AMPK and mTOR pathways by suppressing miR-19a expression"	31913544
21509	Rat	rno-miR-19a	miRNA	hypoxia	coronary microvascular obstruction injury	cardiac myocytes	hypoxia treatment	miR-19a was gradually reduced as time increased in primary cardiomyocytes after hypoxia stimulation.	31633225
21510	Rat	rno-miR-19a	miRNA	dexamethasone (DEX)	hormonal regulation	adrenals?tissues	dexamethasone (DEX) treatment	downregulated	24205079
21511	Rat	rno-miR-19a	miRNA	hypoxia	hypoxia-induced injury	primary cardiomyocytes	hypoxia treatment	miR-19a was gradually reduced as time increased in primary cardiomyocytes after hypoxia stimulation.	31633225
21512	Rat	rno-miR-19a	miRNA	hypoxia	ischemic stroke (IS)	rat brain tissues	middle cerebral artery occlusion/reperfusion (MCAO/R) injury	downregulated	31170091
21513	Rat	rno-miR-19a	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	rat neuronal cells	oxygen glucose deprivation (OGD) treatment	downregulated	31170091
21514	Rat	rno-miR-19a	miRNA	hypoxia	microvascular obstruction (MO)	cardiomyocytes	hypoxia treatment	downregulated	27220268
21515	Rat	rno-miR-19a-3p	miRNA	phenylephrine (PE)	cardiac hypertrophy	primary cardiomyocytes; myocardium	phenylephrine (PE) treatment	downregulated	32096186
21516	Rat	rno-miR-19a-3p	miRNA	isoproterenol	drug-induced cardiac injury (DICI)	heart tissues	isoproterenol treatment	upregulated	29355689
21517	Rat	rno-miR-19a-3p	miRNA	Shenfu Injection (SFI)	cardiac hypertrophy	abdominal aortic constriction-induced myocardial hypertrophic rats cardiomyocytes	Shenfu Injection (SFI) treatment	upregulated	29549288
21518	Rat	rno-miR-19a-3p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	Primary neurons	oxygen-glucose deprivation (OGD) treatment	upregulated	31168302
21519	Rat	rno-miR-19b	miRNA	glucagon-like peptide-1 (GLP-1)	cholesterol-induced lipotoxicity	liver tissues	Glucagon-like peptide-1 (GLP-1) treatment	downregulated	30308521
21520	Rat	rno-miR-19b	miRNA	TGF-¦Â1	liver fibrosis	Primary hepatocytes and hepatic stellate cells (HSCs)	transforming growth factor beta 1 (TGF-¦Â1) treatment	downregulated	29281894
21521	Rat	rno-miR-19b	miRNA	hypoxia	hypoxia-induced injury	PC12 cells	hypoxia induce	downregulated	30767206
21522	Rat	rno-miR-19b	miRNA	alcohol	liver damage	hepatic stellate cell (HSC)	alcohol exposure	downregulated	27291156
21523	Rat	rno-miR-19b	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H2O2 treatment	downregulated	26918829
21524	Rat	rno-miR-19b	miRNA	irisin	"myocardial remodeling,apoptosis"	embryonic rat cardiac myoblast H9c2 cell line	irisin treatment	upregulated	31966617
21525	Rat	rno-miR-19b	miRNA	angiotensin II (Ang II)	expression regulation	Cardiomyocytes isolated from 1- to 3-day-old neonatal rats	angiotensin II (Ang II) treatment	downregulated	24296617
21526	Rat	rno-miR-19b	miRNA	angiotensin II (Ang II)	expression regulation	Cardiomyocytes from neonatal rats	angiotensin II (Ang II) treatment	downregulated	23951138
21527	Rat	rno-miR-19b	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 15) treatment	different expression	24420840
21528	Rat	rno-miR-19b	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 7) treatment	different expression	24420840
21529	Rat	rno-miR-19b-1	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
21530	Rat	rno-miR-19b-3p	miRNA	cyclic mechanical stretch (CMS)	hypertension-induced vascular remodeling	vascular smooth muscle cells (VSMCs) were harvested from rat thoracic aorta	15% cyclic stretch induce	downregulated	30690026
21531	Rat	rno-miR-19b-3p	miRNA	rosmarinic acid (RA)	irradiation-induced pulmonary fibrosis	lung regions	rosmarinic acid (RA) treatment	"RA attenuated RhoA/Rock signaling through upregulating miR-19b-3p, leading to the inhibition of fibrosis."	33149731
21532	Rat	rno-miR-1a	miRNA	quinone compounds P3H4	renal cell carcinoma (RCC)	renal cancer tissue	P3H4 treatment	miR-1a was significantly upregulated in rat renal cancer tissue after the treatment of P3H4	30178839
21533	Rat	rno-miR-1a-3p	miRNA	H2O2	ischemia/reperfusion (I/R) injury	neonatal rat ventricular cells (NRVCs)	H2O2 treatment	upregulated	30292140
21534	Rat	rno-miR-1a-3p	miRNA	metformin (Met)	ischemia/reperfusion (I/R) injury	H2O2-treated neonatal rat ventricular cells (NRVCs)	Metformin treatment	downregulated	30292140
21535	Rat	rno-miR-1b	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	downregulated	32893733
21536	Rat	rno-miR-1b-5p	miRNA	anisakis complete extract (CE)	anisakiasis	sera	anisakis complete extract (CE) treatment	"mmu-miR-1b-5p and mmu-miR-10b-5p (a cancer-related miRNA) were significantly decreased (P?<?.05) in sera from the rats inoculated with Anisakis CE, compared with control rats inoculated with saline."	30006808
21537	Rat	rno-miR-20	miRNA	perillyle alcohol (PA)	pulmonary arterial hypertension (PAH)	lung tissues	Perillyle alcohol (PA) treatment	upregulated	32660602
21538	Rat	rno-miR-20	miRNA	quercetin	pulmonary arterial hypertension (PAH)	lung tissues	Quercetin (QS) treatment	upregulated	32660602
21539	Rat	rno-miR-200	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	Kidneys tissue	TGF-¦Â1 treatment	downregulated	22012804
21540	Rat	rno-miR-200	miRNA	mitomycin C-polylactic acid ( MMC-PLA) film	epidural scar hyperplasia and adhesion	post-laminectomy rat scar tissues	25 mg of PLA film containing 0.01% MMC was implanted on the laminectomy area	upregulated	28617531
21541	Rat	rno-miR-200	miRNA	perfluorooctane sulfonic acid (PFOS)	hepatotoxicity	liver tissues	Perfluorooctanesulfonate (PFOS) treatment	upregulated	26724606
21542	Rat	rno-miR-200	miRNA	perfluorooctane sulfonic acid (PFOS)	liver damage	liver tissues	Perfluorooctanesulfonate (PFOS) treatment	upregulated	26724606
21543	Rat	rno-miR-200	miRNA	ferulic acid (FA)	liver fibrosis	liver tissues	ferulic acid treatment	upregulated	32278740
21544	Rat	rno-miR-200	miRNA	gallic acid (GA)	liver fibrosis	liver tissues	gallic acid treatment	upregulated	32278740
21545	Rat	rno-miR-200a	miRNA	IL-22	liver fibrosis	rat liver tissues	IL-22 treatment	upregulated	27819314
21546	Rat	rno-miR-200a	miRNA	doxorubicin (DOX)	cardiotoxicity	H9c2 cells	Doxorubicin (DOX) treatment	downregulated	31781322
21547	Rat	rno-miR-200a	miRNA	TGF-¦Â1	cerebral vascular endothelial injury	proximal-tubular epithelial cells (NRK52E)	TGF-¦Â1 treatment	downregulated	20952520
21548	Rat	rno-miR-200a	miRNA	TGF-¦Â2	cerebral vascular endothelial injury	proximal-tubular epithelial cells (NRK52E)	TGF-¦Â2 treatment	downregulated	20952520
21549	Rat	rno-miR-200a	miRNA	antibiotics	dysbacteria	Sprague Dawley (SD) rats faeces	treat with a combination of antibiotics for 8 week	downregulated	29264965
21550	Rat	rno-miR-200a	miRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	rats pancreatic stellate cells	TGF-¦Â1 at a concentration of 10 ng/ml treatment	downregulated	28281184
21551	Rat	rno-miR-200a	miRNA	allopurinol	fructose-induced hepatic inflammation	fructose-induced rats liver tissues and Buffalo rat liver cell line (BRL-3?A)	allopurinol treatemnt	upregulated	30248460
21552	Rat	rno-miR-200a	miRNA	curcumin (Cur)	fructose-induced hepatic inflammation	fructose-induced rats liver tissues and Buffalo rat liver cell line (BRL-3?A)	curcumin treatment	upregulated	30248460
21553	Rat	rno-miR-200a	miRNA	fructose	fructose-induced hepatic inflammation	liver tissues and Buffalo rat liver cell line (BRL-3?A)	fructose treatment	downregulated	30248460
21554	Rat	rno-miR-200a	miRNA	TGF-¦Â1	liver fibrosis	HSC-T6 cells	TGF-¦Â1 treatment	downregulated	24242045
21555	Rat	rno-miR-200a	miRNA	furan	hepatotoxicity	liver	Furan treatment	upregulated	27371368
21556	Rat	rno-miR-200a	miRNA	diethylnitrosamine (DEN)	hepatocellular carcinoma (HCC)	F344 rat	diethylnitrosamine abdominal injection treatment	downregulated	25203708
21557	Rat	rno-miR-200a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	serum	CCl4 treatment	downregulated	30254303
21558	Rat	rno-miR-200a	miRNA	carvedilol	liver fibrosis	CCl4-induced liver fibrosis rats serum	carvedilol treatment	upregulated	30254303
21559	Rat	rno-miR-200a	miRNA	phenobarbital (PB)	liver homeostasis	liver tissues	phenobarbital (PB) treatment	upregulated	24157574
21560	Rat	rno-miR-200a	miRNA	thymosin ¦Â4 (T¦Â4)	cell differentiation	brain progenitor cells	Thymosin beta 4 (T¦Â4) treatment	upregulated	26466330
21561	Rat	rno-miR-200a	miRNA	thymosin ¦Â4 (T¦Â4)	neurological injury	brain progenitor cells	Thymosin beta 4 (T¦Â4) treatment	upregulated	26466330
21562	Rat	rno-miR-200a	miRNA	CoCl2	neuron apoptosis	PC12 cells	cobalt chloride (CoCl2) treatment	downregulated	32004541
21563	Rat	rno-miR-200a	miRNA	high fructose	nonalcoholic fatty liver disease (NAFLD)	liver tissues and BRL-3A cells	high fructose treatment	downregulated	30014902
21564	Rat	rno-miR-200a	miRNA	polydatin (PD)	nonalcoholic fatty liver disease (NAFLD)	high fructose-induced rats liver tissues and BRL-3A cells	"Polydatin (3,4',5-trihydroxy-stilbene-3-¦Â-D-glucoside) treatment"	upregulated	30014902
21565	Rat	rno-miR-200a	miRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	dysregulated	24517225
21566	Rat	rno-miR-200a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12 cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30712312
21567	Rat	rno-miR-200a	miRNA	TGF-¦Â1	peritoneal fibrosis	peritoneal mesothelial cells	?transforming growth factor beta 1 (TGF-¦Â1) treatment	downregulated	30888602
21568	Rat	rno-miR-200a	miRNA	pegylated rat leptin antagonist (pRLA)	type 2 diabetes mellitus (T2DM)	rat muscle and liver	pegylated rat leptin antagonist (pRLA) treatment	"upregulation of rno-miR-10a at d28 and rno-miR-200a, rno-miR-409-5p, and rno-miR-125a-3p following HFD challenge"	23576026
21569	Rat	rno-miR-200a-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	downregulated	32192351
21570	Rat	rno-miR-200a-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31651553
21571	Rat	rno-miR-200a-3p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
21572	Rat	rno-miR-200a-3p	miRNA	enterococcus faecalis supernatants	migration of bone marrow mesenchymal stem cells (BMSCs)	bone marrow mesenchymal stem cells (BMSCs)	Enterococcus faecalis supernatants treatment	upregulated	32711573
21573	Rat	rno-miR-200a-3p	miRNA	H2O2	myocardial infarction (MI)	H9C2 cells	H2O2 treatment	downregulated	30841417
21574	Rat	rno-miR-200a-3p	miRNA	letrozole	polycystic ovarian syndrome (PCOS)	Ovary?tissues	letrozole treatment	dysregulated	26745201
21575	Rat	rno-miR-200a-3P	miRNA	X-rays	radiation-induced myocardial fibrosis (RIMF)	primary rat cardiac fibroblasts	X-ray irradiation treatment	downregulated	32382291
21576	Rat	rno-miR-200a-3p	miRNA	thymosin ¦Â4 (T¦Â4)	traumatic brain injury (TBI)	plasma	thymosin beta 4 (T¦Â4) treatment	T¦Â4 treatment significantly increased plasma levels of miR-200a-3p and miR-200b-3p	29873258
21577	Rat	rno-miR-200a-3p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
21578	Rat	rno-miR-200a-5P	miRNA	X-rays	radiation-induced myocardial fibrosis (RIMF)	primary rat cardiac fibroblasts	X-ray irradiation treatment	downregulated	32382291
21579	Rat	rno-miR-200a-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21580	Rat	rno-miR-200b	miRNA	high glucose (HG)	blood-brain barrier (BBB) dysfunction	rat brain microvascular endothelial cells (RBMECs)	rat brain microvascular endothelial cells (RBMECs) treatment	downregulated	27497919
21581	Rat	rno-miR-200b	miRNA	Salvianolic acid B (Sal B)	blood-brain barrier (BBB) dysfunction	high-glucose treated rat brain microvascular endothelial cells (RBMECs)	high-glucose treated rat brain microvascular endothelial cells (RBMECs) treatment	upregulation	27497919
21582	Rat	rno-miR-200b	miRNA	comfrey	tumorigenesis	rat liver	comfrey treatment	upragulated	21370286
21583	Rat	rno-miR-200b	miRNA	hypertonic saline (HS)	cerebral edema	right-sided middle cerebral artery occlusion (MCAO) treated rat brian tissues;hypoxia-induced primary microglial cells	Hypertonic saline (HS) treatment	downregulated	29577903
21584	Rat	rno-miR-200b	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	male Wistar rats inflamed colon	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated in inflamed colon	28572713
21585	Rat	rno-miR-200b	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Rat glomerular mesangial cells	high glucose (HG) treatment	upregulated	30827272
21586	Rat	rno-miR-200b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina	streptozocin (STZ) treatment	downregulated	33324202
21587	Rat	rno-miR-200b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	Wistar male rats retion	STZ treatment	downregulated	28122882
21588	Rat	rno-miR-200b	miRNA	methyl-deficient diet	hepatocellular carcinoma (HCC)	liver tissues	methyl-deficient diet feed	downregulated	18942116
21589	Rat	rno-miR-200b	miRNA	furan	hepatotoxicity	liver	Furan treatment	upregulated	27371368
21590	Rat	rno-miR-200b	miRNA	dexamethasone (DEX)	hormonal regulation	adrenals?tissues	dexamethasone (DEX) treatment	downregulated	24205079
21591	Rat	rno-miR-200b	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
21592	Rat	rno-miR-200b	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
21593	Rat	rno-miR-200b	miRNA	phenobarbital (PB)	liver homeostasis	liver tissues	phenobarbital (PB) treatment	upregulated	24157574
21594	Rat	rno-miR-200b	miRNA	CoCl2	neuron apoptosis	PC12 cells	cobalt chloride (CoCl2) treatment	downregulated	32004541
21595	Rat	rno-miR-200b	miRNA	nitrofen	pulmonary hypoplasia	lung tissues	nitrofen treatment	upregulated	29135495
21596	Rat	rno-miR-200b-3p	miRNA	methamphetamine (METH)	addiction	nucleus accumbens tissues	Methamphetamine treatment	dysregulated	28681200
21597	Rat	rno-miR-200b-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cell line	high glucose treatment	downregulated	30506990
21598	Rat	rno-miR-200b-3p	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	heart tissues	streptozotocin (STZ) treatment	downregulated	30506990
21599	Rat	rno-miR-200b-3p	miRNA	aflatoxin B1 (AFB1)	hepatotoxicant and genotoxicant	liver	aflatoxin B1 (AFB1) treatment	upregulated	26385312
21600	Rat	rno-miR-200b-3p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
21601	Rat	rno-miR-200b-3p	miRNA	hypoxic/ischemic	hypoxic/ischemic brain damage (HIBD)	brain tissues	hypoxia-ischemic treatment	miR-200b-3p was upregulated in rat brains at the early stage following hypoxia-ischemic treatment.	31964527
21602	Rat	rno-miR-200b-3p	miRNA	enterococcus faecalis supernatants	migration of bone marrow mesenchymal stem cells (BMSCs)	bone marrow mesenchymal stem cells (BMSCs)	Enterococcus faecalis supernatants treatment	upregulated	32711573
21603	Rat	rno-miR-200b-3p	miRNA	thymosin ¦Â4 (T¦Â4)	traumatic brain injury (TBI)	plasma	thymosin beta 4 (T¦Â4) treatment	T¦Â4 treatment significantly increased plasma levels of miR-200a-3p and miR-200b-3p	29873258
21604	Rat	rno-miR-200b-3p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
21605	Rat	rno-miR-200c	miRNA	ethanol (EtOH)	acute gastric mucosal injury	gastric tissues?of rat	oral administration of ethanol	downregulated	23830200
21606	Rat	rno-miR-200c	miRNA	SZ-685C	apoptosis	"A rat prolactinoma cell line, MMQ"	SZ-685C treatment	downregulated	23317100
21607	Rat	rno-miR-200c	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal rat cardiomyocytes (NCMs)	angiotensin II (Ang II) treatment	upregulated	30680929
21608	Rat	rno-miR-200c	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 rat cardiomyocytes	H2O2 treatment	upregulated	28770953
21609	Rat	rno-miR-200c	miRNA	glucose fluctuations (GF)	cardiovascular complications of diabetes mellitus (DM)	heart	glucose fluctuations (GF) treatment	upregulated	26497329
21610	Rat	rno-miR-200c	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	rat neonatal cardiomyocytes	high-glucose (HG)	upregulated	27696308
21611	Rat	rno-miR-200c	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	high-fat diet cardiomyocytes	streptozotocin high-fat diet treatment	upregulated	27696308
21612	Rat	rno-miR-200c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Rat glomerular mesangial cells	high glucose (HG) treatment	upregulated	30827272
21613	Rat	rno-miR-200c	miRNA	ethanol (EtOH)	fetal alcohol spectrum disorders (FASD)	Sprague-Dawley rats	were exposed to 5.25 g/kg/day ethanol from postnatal days (PD) 4-9 via intubation	upregulated	28433422
21614	Rat	rno-miR-200c	miRNA	(+)-cholesten-3-one (CN)	osteogenesis	Sprague-Dawley rats mesenchymal stem cells (MSCs)	(+)-cholesten-3-one treatment	upregulated	29218094
21615	Rat	rno-miR-200c	miRNA	artesunate (ART) and bromocriptine (BRC)	pituitary adenoma	rat pituitary adenoma cell lines GH3 and MMQ	artesunate (ART) and bromocriptine (BRC) treatment	downregulated	28501857
21616	Rat	rno-miR-200c	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 14) treatment	different expression	24420840
21617	Rat	rno-miR-200c-3p	miRNA	lithium chloride and pilocarpine	epilepsy	hippocampus tissues	lithium chloride-pilocarpine treatment	upregulated	31018114
21618	Rat	rno-miR-200c-3p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
21619	Rat	rno-miR-200c-3p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	31881206
21620	Rat	rno-miR-200c-3p	miRNA	angiotensin II (Ang II)	renal vascular endothelial dysfunction	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	31881206
21621	Rat	rno-miR-201-5p	miRNA	letrozole	polycystic ovarian syndrome (PCOS)	Ovary?tissues	letrozole treatment	dysregulated	26745201
21622	Rat	rno-miR-201-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21623	Rat	rno-miR-202-3p	miRNA	chronic mild unpredictable mild stimulation (CUMS)	depression	hippocampus	chronic mild unpredictable mild stimulation (CUMS) treatment	upregulated	32425535
21624	Rat	rno-miR-202-3p	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus tissues	chronic unpredictable mild stressed (CUMS) treatment	upregulated	28083819
21625	Rat	rno-miR-202-3p	miRNA	hronic unpredictable mild stressed (CUMS)	depression	rats hippocampal tissues	stimulated daily with randomly applied mild stressors from among 14 different mild stressors	upregulated	28083819
21626	Rat	rno-miR-202-3p	miRNA	IL-1¦Â	multiple sclerosis (MS)	oligodendrocyte precursor cells (OPCs)	IL-1¦Â treatment	IL-1¦Â markedly decreased the expression of miR-202-3p.	32582975
21627	Rat	rno-miR-202-5p	miRNA	hypoxia	apoptosis	rat embryonic ventricular cardiomyocyte-derived H9c2 cells	hypoxia induce	upregulated	31966756
21628	Rat	rno-miR-202-5p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	downregulated	32893733
21629	Rat	rno-miR-202-5p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	neonatal rats cardiomyocytes	hypoxia/reoxygenation-induce	downregulated	31062423
21630	Rat	rno-miR-203	miRNA	acute stressor modulates	acute stress	male Fisher 344 rats	expose to an acute stressor modulates treatment	downregulated	25259839
21631	Rat	rno-miR-203	miRNA	comfrey	tumorigenesis	rat liver	comfrey treatment	downregulated	21370286
21632	Rat	rno-miR-203	miRNA	streptozocin (STZ)	diabetic foot ulcer (DFU)	?skin tissues	streptozotocin treatment	upregulated	31707396
21633	Rat	rno-miR-203	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	miR-203 expression in rat PASMCs was significantly lower than that in normoxia control group at 24 h and 48 h after hypoxic treatment.	29680463
21634	Rat	rno-miR-203	miRNA	lipopolysaccharide (LPS)	myocarditis	Cardiomyocyte H9c2	lipopolysaccharide (LPS) treatment	upregulated	30484891
21635	Rat	rno-miR-203	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	upregulated	30484891
21636	Rat	rno-miR-203	miRNA	Riboflavin (RF)	neuroprotective effects	rat model of cerebral ischemia	RF treatment	upregulated	24884571
21637	Rat	rno-miR-203	miRNA	monosodium iodoacetate	postmenopausal osteoarthritis	cartilage tissues	A combined protocol of the bilateral ovariectomy and the intra-articular monosodium iodoacetate injection was applied to establish a postmenopausal OA model in rats.	upregulated	31711313
21638	Rat	rno-miR-203	miRNA	activated protein C(APC)	sepsis	rats blood and liver tissue	activated protein C treatment	aPC treatment coordinates beneficial cytoprotective effects during sepsis by modulating miRNA expression	22940033
21639	Rat	rno-miR-203a	miRNA	respiratory syncytial virus (RSV)	asthma	Sprague-Dawley rat	respiratory syncytial virus (RSV) infection treatment	downregulated	28510638
21640	Rat	rno-miR-203a	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	31725080
21641	Rat	rno-miR-203a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
21642	Rat	rno-miR-203a-3p	miRNA	acidosis	acidosis	Walker-256 mammary carcinoma cells	incubated at pH 6.6	downregulated	28685435
21643	Rat	rno-miR-203a-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	rat retinal	streptozotocin (STZ)-induced diabetic rat treatment	differential expressions	24502381
21644	Rat	rno-miR-203a-3p	miRNA	atorvastatin	endothelial senescence	high-fat diet-induced hyperlipidemic rats plasma	atorvastatin treatment	downregulated	29248491
21645	Rat	rno-miR-203a-3p	miRNA	high fat diet (HFD)	endothelial senescence	plasma	high fat diet (HFD) feed	upregulated	29248491
21646	Rat	rno-miR-203a-3p	miRNA	high fat diet (HFD)	hyperlipidemia	rats plasma	high fat diet (HFD) feed	upregulated	29248491
21647	Rat	rno-miR-203a-3p	miRNA	hypoxia	hypoxic lung injury		hypoxia treatment	downregulated of lung miR-203a-3p expression by high-altitude hypoxia enhances VEGF/Notch signaling	32112644
21648	Rat	rno-miR-203a-3p	miRNA	astragalus polysaccharide (APS)	insulin resistance (IR)	liver tissues	astragalus polysaccharide (APS) treatment	miR-203a-3p was upregulated following APS treatment.	29257218
21649	Rat	rno-miR-203a-3p	miRNA	teriparatide (TP)	postmenopausal osteoporosis (PMOP)	serum and femoral head from ovariectomy rat	teriparatide treatment	upregulated	31683019
21650	Rat	rno-miR-203a-3p	miRNA	zoledronate	postmenopausal osteoporosis (PMOP)	serum and femoral head from ovariectomy rat	zoledronate treatment	upregulated	31683019
21651	Rat	rno-miR-203a-3p	miRNA	oxygen	proliferative diabetic retinopathy (PDR)	retina of oxygen-induced retinopathy rats	"Pups and their mothers were exposed between postnatal day (P) 0 to P11 in 80% O 2 for 21 hours/day and 20% O2 for 3 hours/day. Then, rats were placed in room air from P12 to P18. treatment"	downregulated	31408201
21652	Rat	rno-miR-203a-3p	miRNA	loureirin A	skin wound healing	hair follicle stem cells (HFSCs)	loureirin A treatment	Microarray and quantitative real time polymerase chain reaction analyses demonstrated that miR-203a-3p was upregulated in differentiated HFSCs induced by loureirin A.	32589363
21653	Rat	rno-miR-203a-3p	miRNA	astragalus polysaccharide (APS)	type 2 diabetes mellitus (T2DM)	T2DM Goto Kakizaki (GK) rats liver	astragalus polysaccharide (APS) treatment	upregulated in the liver	29257218
21654	Rat	rno-miR-203a-5p	miRNA	TGF-¦Â1	bone development and bone remodeling	rat osteoblasts	TGF-¦Â1 treatment	downregulated	30951775
21655	Rat	rno-miR-204	miRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	rat mesangial cells (RMCs)	lipopolysaccharide (LPS) treatment	downregulated	29669307
21656	Rat	rno-miR-204	miRNA	resveratrol	breast cancer	matched tumor/normal tissues	resveratrol (RS) treatment	upregulated	24447120
21657	Rat	rno-miR-204	miRNA	aldosterone	cardiac hypertrophy	isolated neonatal rat cardiomyocytes	aldosterone treatment	upregulated	30262720
21658	Rat	rno-miR-204	miRNA	nicotine	cognitive impairment	choroid plexus and CSF	nicotine treatment	upregulated	31119189
21659	Rat	rno-miR-204	miRNA	thioredoxin-interacting protein (TXNIP)	diabetes mellitus (DM)	INS-1 beta cells	TXNIP treatment	upregulated	25391656
21660	Rat	rno-miR-204	miRNA	palmitate	diabetes mellitus (DM)	INS-1 cells	palmitate (Pal) treatment	downregulated	30131392
21661	Rat	rno-miR-204	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	upregulated	22156553
21662	Rat	rno-miR-204	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (DOX) treatment	downregulated	33274007
21663	Rat	rno-miR-204	miRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	10-day-old pup rats brain tissues	hypoxia induce	downregulated	31602202
21664	Rat	rno-miR-204	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	miR-204 was significantly downregulated after H/R treatment.	29371766
21665	Rat	rno-miR-204	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
21666	Rat	rno-miR-204	miRNA	lead (Pb)	nervous system diseases	rats hippocampus	chronic lead exposure treatment	upregulated	24960059
21667	Rat	rno-miR-204	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12 cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30712312
21668	Rat	rno-miR-204	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	pulmonary arterial hypertension (PAH)	rat pulmonary arterial endothelial cells (PAECs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29196166
21669	Rat	rno-miR-204	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	pulmonary arterial hypertension (PAH)	rat pulmonary arterial endothelial cells (PAECs)	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	29196166
21670	Rat	rno-miR-204	miRNA	hypoxia	pulmonary hypertension (PH)	rat pulmonary arterial intima	hypoxia induce	downregulated	31542480
21671	Rat	rno-miR-204	miRNA	aluminum (Al)	spatial learning and memory impairment	offspring rats hippocampus	exposure to aluminium during the embryonic stage	upregulated	30172012
21672	Rat	rno-miR-204	miRNA	fluoride	spatial learning and memory impairment	offspring rats hippocampus	exposure to fluorine during the embryonic stage	upregulated	30172012
21673	Rat	rno-miR-204	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN;PC12 cells	hypoxia	upregulated	28714326
21674	Rat	rno-miR-204	miRNA	magnesium-free extracellular fluid	status epilepticus (SE)	hippocampal neurons	Mg(2+)-free treatment	downregulated	26947618
21675	Rat	rno-miR-204	miRNA	phosphorus (Pi)	vascular calcification (VC)	Primary rat vascular smooth muscle cells (VSMCs)	high Pi exposure treatment	downregulated	30867423
21676	Rat	rno-miR-204	miRNA	triptolide (TPL)	vascular calcification (VC)	aorta	triptolide (TPL) treatment	MiRNA-204 expression was increased in the TP-treated groups compared with VC controls	33597871
21677	Rat	rno-miR-204*	miRNA	angiotensin II (Ang II)	cardiac fibrosis and hypertension	cardiac fibroblasts (CFs) of rats	angiotensin II (Ang II) treatment	downregulated	23007623
21678	Rat	rno-miR-204-3p	miRNA	Smad3 inhibitor (SIS3)	intrauterine adhesion (IUA)	endometrial stromal cells (ESCs)	Smad3 inhibitor (SIS3) treatment	upregulated	32447720
21679	Rat	rno-miR-204-5p	miRNA	cadmium (Cd)	cadmium-induced toxicity	rat ovarian granulosa cells (OGCs)	cadmium (Cd) treatment	MicroRNA-204-5p regulates apoptosis by targeting Bcl2 in rat ovarian granulosa cells exposed to cadmium.	32500147
21680	Rat	rno-miR-204-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral ischemia injury (CII)	primary cultured cerebral microvascular endothelial cell (CMEC)	oxygen glucose deprivation (OGD) treatment	downregulated	31628679
21681	Rat	rno-miR-204-5p	miRNA	oxygen glucose deprivation (OGD)	cerebral microvascular endothelial cell (CMEC) injury	cerebral microvascular endothelial cell (CMEC)	oxygen glucose deprivation (OGD) treatment	downregulated	31628679
21682	Rat	rno-miR-204-5p	miRNA	isoflurane	cognitive impairment	hippocampal tissue of rats	isoflurane exposure	"Isoflurane could significantly induce neuroinflammation, and the expression of miR-204-5p was increased in the hippocampal tissue of rats exposed to isoflurane."	33878909
21683	Rat	rno-miR-204-5p	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
21684	Rat	rno-miR-205	miRNA	TGF-¦Â	adaptation of tendons to mechanical loading	rat Tendon fibroblasts	Transforming growth factor-¦Â(TGF-¦Â) treatment	upregulated	22539168
21685	Rat	rno-miR-205	miRNA	apomorphine (APO)	diabetes mellitus-induced erectile dysfunction (DMED)	diabetes mellitus (DM) rats cavernous bodies	apomorphine (APO) treatment	upregulated	30729682
21686	Rat	rno-miR-205	miRNA	short-term vagus nerve stimulation (VNS)	myocardial apoptosis	rats with chronic heart failure	VNS treatment	downregulated	28849082
21687	Rat	rno-miR-205	miRNA	high glucose (HG)	neuron protection	astrocytes	high glucose (HG) treatment	upregulated	32168096
21688	Rat	rno-miR-205	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
21689	Rat	rno-miR-205	miRNA	bleomycin (BLM)	lung fibrosis	pulmonary fibrosis tissues	bleomycin (BLM) treatment	downregulated	31820686
21690	Rat	rno-miR-205	miRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	rat renal tissues	hypoxia treatment	downregulated	31934284
21691	Rat	rno-miR-205	miRNA	smoking	smoke inhalation injury (SII)	bronchoalveolar lavage fluid (BALF)	Smoke inhalation treatment	upregulated	30139538
21692	Rat	rno-miR-206	miRNA	isoproterenol and doxorubicin	cardiotoxicity	rats plasma	isoproterenol and doxorubicin treatment	upregulated after treatment with doxorubicin	25092230
21693	Rat	rno-miR-206	miRNA	dexamethasone (DEX)	cartilage injury	articular cartilage	dexamethasone (DEX) treatment	miR-206 was downregulated compared with control group.	29207029
21694	Rat	rno-miR-206	miRNA	icariin (ICA)	cartilage injury	articular chondrocytes	icariin treatment	upregulated	29207029
21695	Rat	rno-miR-206	miRNA	TGF-¦Â1	cell proliferation	primary cultured airway smooth muscle cells (ASMCs)	transforming growth factor ¦Â1 (TGF-¦Â1) treatment	downregulated	29483552
21696	Rat	rno-miR-206	miRNA	ketamine	depression	rat hippocampus	ketamine (15 mg/kg) treatment	miR-206 was downregulated in hippocampus of rats	24839168
21697	Rat	rno-miR-206	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiomyocytes	high glucose (HG) treatment	upregulated	27306406
21698	Rat	rno-miR-206	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	H9c2 cells	hypoxia-reoxygeneration (H/R) treatment	downregulated	29237256
21699	Rat	rno-miR-206	miRNA	ketamine	ketamine-induced neurotoxicity	neurons of the hippocampus; PC-12 cells	ketamine treatment	LncRNA KCNQ1OT1 Sponges miR-206 to Ameliorate Neural Injury Induced by Anesthesia via Up-Regulating BDNF.	33204065
21700	Rat	rno-miR-206	miRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	male F344 rats	was induc systemic NNK treatment	upregulated	24553369
21701	Rat	rno-miR-206	miRNA	ellagic acid (EA)	breast cancer	female rat mammary tissue	ellagic acid treatment	"ellagic acid, which inhibited E2-induced mammary tumorigenesis in our previous study, reversed the dysregulation of miR-375, miR-206, miR-182, miR-122, miR-127 and miR-183 detected with E2treatment"	23791885
21702	Rat	rno-miR-206	miRNA	repair of exercise	muscle injury	agile male rats	agile male rats treatment	upregulation in rat skeletal muscle	277067322
21703	Rat	rno-miR-206	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	The H9c2 cardiomyocytes	hypoxia induce	downregulated	30551524
21704	Rat	rno-miR-206	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia treatment	downregulated	30551524
21705	Rat	rno-miR-206	miRNA	methylmercury (MeHg)	neuronal cell death	primary rat cortical neurons	Methylmercury (MeHg) exposure	downregulated	29522201
21706	Rat	rno-miR-206	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	rats dorsal root ganglion (DRG)	chronic constriction injury (CCI) induce	downregulated in the dorsal root ganglion (DRG)	28130187
21707	Rat	rno-miR-206	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	L4©\L6 dorsal spinal cord of rats	chronic constriction injury (CCI) induce	downregulated	30740678
21708	Rat	rno-miR-206	miRNA	curcumin (Cur)	podocyte injury	podocyte	curcumin treatment	upregulated	26395192
21709	Rat	rno-miR-206	miRNA	TGF-¦Â1	post-angioplasty restenosis	vascular smooth muscle cells (VSMCs) VSMCs isolated from Sprague-Dawley rats	TGF-¦Â1 treatment	downregulated	28328152
21710	Rat	rno-miR-206	miRNA	H2O2	cell senescence	Bone marrow-derived mesenchymal stem cells (MSCs)	H2O2 treatment	miR-206 was upregulated in the senescent MSCs induced by H2O2.	32148656
21711	Rat	rno-miR-206	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	alveolar type II epithelial cells (ATII)	lipopolysaccharide treatment	downregulated	31258665
21712	Rat	rno-miR-206	miRNA	"muscle toxicant 2,3,5,6-tetramethyl-p-phenylenediamine (TMPD)"	skeletal muscle injury	serum	"muscle toxicant 2,3,5,6-tetramethyl-p-phenylenediamine (TMPD) treatment"	Serum miR-206 levels significantly increased after treatment with TMPD.	32741900
21713	Rat	rno-miR-206	miRNA	"1,3,5-tris-4-propyl-1H-pyrazole"	spinal cord injury (SCI)	VSC4.1 motoneurons	ER agonists treatment	upregulated	24157932
21714	Rat	rno-miR-206	miRNA	"high concentrations of lipid and glucose, and cytokines"	vascular hyper-reactivity	VSMC	"incubat high glucose (25mmol/L) or lipid (palmitic acid 50 ¦Ì mol/L) and 200ng/ml of TNF-¦Á,IL-1¦Â and IL-6 for 26h treatment"	downregulated	25425000
21715	Rat	rno-miR-206-3p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	upregulated	29706607
21716	Rat	rno-miR-206-3p	miRNA	acute eccentric exercise	exercise-induced muscle damage (EIMD)	Sprague-Dawley (SD) rats	a downhill running treatment at -16? gradient	dysregulated	28638919
21717	Rat	rno-miR-206-3p	miRNA	steroids	osteonecrosis	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	26459755
21718	Rat	rno-miR-206-3p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
21719	Rat	rno-miR-206-3p	miRNA	Jianpi Xiaoke (JPXK)	type 2 diabetes mellitus (T2DM)	rat	Jianpi Xiaoke (JPXK) treatment	upregulated	33456489
21720	Rat	rno-miR-207	miRNA	light	focal retinal degeneration	right eye	light treatment	upregulated	25921151
21721	Rat	rno-miR-207	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
21722	Rat	rno-miR-207	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	downregulated	28560399
21723	Rat	rno-miR-207	miRNA	ischemia	periodontitis	Serum	Ligation around teeth treatment	upregulated	26910654
21724	Rat	rno-miR-208	miRNA	angiotensin II (Ang II)	apoptosis	H9c2 cells	angiotensin II (Ang II) treatment	downregulated	30244257
21725	Rat	rno-miR-208	miRNA	ghrelin	apoptosis	angiotensin II (Ang II)-induced H9c2 cells	ghrelin treatment	upregulated	30244257
21726	Rat	rno-miR-208	miRNA	daunorubicin	cardiomyopathy	rats	"daunorubicin (DAU-A, 3 mg/kg, every 48 h)"	downregulated	28303410
21727	Rat	rno-miR-208	miRNA	insulin	cell proliferation	vascular smooth muscle cell	Insulin?treatment	insulin increased VSMC proliferation and miR-208 expression	21720271
21728	Rat	rno-miR-208	miRNA	isoproterenol	myocardial injury	Plasma	isoproterenol treatment	upregulated	19696117
21729	Rat	rno-miR-208	miRNA	nanosized SiO2	pulmonary injury	liver tissues	nanosized SiO2 treatment	upregulated	27689473
21730	Rat	rno-miR-208a	miRNA	ischemia	acute myocardial infarction (AMI)	heart tissues	Ligation of the proximal left anterior descending artery to induce AMI treatment	upregulated	25936493
21731	Rat	rno-miR-208a	miRNA	H2O2	apoptosis	primary cultured neonatal rat cardiomyocyte	H2O2 treatment	downregulated	29877301
21732	Rat	rno-miR-208a	miRNA	exercise training (ET)	cardiac hypertrophy	heart tissues	Exercise training (ET)	downregulated	29746886
21733	Rat	rno-miR-208a	miRNA	thyroid hormone	cardiac hypertrophy	rat cardiac tissue	thyroid hormone treatment	"AT1R mediates the hyperthyroidism-induced increase on cardiac miRNA-208a/a-MHC levels, while does not influence on the reduction of miRNA-208b/b-MHC levels."	23623871
21734	Rat	rno-miR-208a	miRNA	doxorubicin (DOX)	cardiotoxicity	Wistar rats left atrium (LA)/ventricle (LV)	doxorubicin (DOX) and liposomal doxorubicin (L-DOX) administration	downregulated in left atrium (LA)/ventricle (LV)	27990619
21735	Rat	rno-miR-208a	miRNA	aorta-caval shunt	cardiovascular disease (CVD)	adult Sprague-Dawley rats	AV shunt from 3 to 14 days treatment	upregulated	24392114
21736	Rat	rno-miR-208a	miRNA	conditioned media (CM)	diabetes-related heart disease	primary adult rat cardiomyocytes	CM-EAT-T2D	upregulated	27864612
21737	Rat	rno-miR-208a	miRNA	mechanical stress	hypertrophy	Neonatal rat cardiomyocytes	Mechanical stretch treatment	upregulated	24120154
21738	Rat	rno-miR-208a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	H9c2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"in H9c2 cells after simulated I/R injury, miR-208a was upregulated"	29681568
21739	Rat	rno-miR-208a	miRNA	ketamine	ketamine-induced cardiotoxicity	heart tissues	Ketamine treatment	upregulated	30923228
21740	Rat	rno-miR-208a	miRNA	ketamine	ketamine-induced cardiotoxicity	heart tissues	ketamine treatment	upregulated	30923228
21741	Rat	rno-miR-208a	miRNA	H2O2	myocardial injury	H9C2 cardiomyocytes	H2O2 treatment	"miR-208a mimic aggravated H2O2-induced apoptosis and oxidative injury in cardiomyocytes, while miR-208a inhibitor hadan inverse effect."	31545986
21742	Rat	rno-miR-208a	miRNA	Calhex-231 (Cal)	traumatic hemorrhagic shock (THS)	vascular smooth muscle cells (VSMCs)	Calhex-231 (Cal) treatment	The Calcilytic Drug Calhex-231 Ameliorates Vascular Hyporesponsiveness in Traumatic Hemorrhagic Shock by Inhibiting Oxidative Stress and miR-208a-Mediated Mitochondrial Fission.	33343806
21743	Rat	rno-miR-208a-3p	miRNA	isoproterenol	acute cardiac injury	heart tissues	isoproterenol treatment	upregulated	27605421
21744	Rat	rno-miR-208a-3p	miRNA	allylamine (AAM)	drug-induced cardiac injury (DICI)	plasma	allylamine (AAM) treatment	upregulated	26454886
21745	Rat	rno-miR-208a-3p	miRNA	isoproterenol	drug-induced cardiac injury (DICI)	"Heart tissues, plasma"	isoproterenol (ISO) treatment	upregulated	26454886
21746	Rat	rno-miR-208a-5p	miRNA	fish oil (FO) and olive oil (OO)	cardiovascular responses	heart sissues	Fish oil (FO) and olive oil (OO) treatment	O 3-induced upregulated of miR-150-5p and miR-208a-5p were attenuated by FO and/or OO.	33091443
21747	Rat	rno-miR-208b	miRNA	thyroid hormone	cardiac hypertrophy	rat cardiac tissue	thyroid hormone treatment	"AT1R mediates the hyperthyroidism-induced increase on cardiac miRNA-208a/a-MHC levels, while does not influence on the reduction of miRNA-208b/b-MHC levels."	23623871
21748	Rat	rno-miR-208b	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	upregulated	30119250
21749	Rat	rno-miR-208b	miRNA	doxorubicin (DOX)	cardiac injury	?rat heart	doxorubicin treatment	upregulated	22859947
21750	Rat	rno-miR-208b-3p	miRNA	isoproterenol	drug-induced cardiac injury (DICI)	heart tissues	isoproterenol treatment	upregulated	29355689
21751	Rat	rno-miR-208b-3p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
21752	Rat	rno-miR-20a	miRNA	HspB1	breast cancer	cortical neurons of rats	HspB1 treatment	upregulated	24141048
21753	Rat	rno-miR-20a	miRNA	ischemia/reperfusion (I/R) 	cardiomyocyte apoptosis	neonatal rat cardiomyocytes (NRCM)	ischemia/reperfusion (I/R) treatment	upregulated	22182733
21754	Rat	rno-miR-20a	miRNA	resveratrol	liver fibrosis	HSC-T6 cells	Resveratrol (RSV) treatment	RSV induces autophagy and activates the miR-20a-mediated PTEN/PI3K/AKT signaling pathway to attenuate LF	33125088
21755	Rat	rno-miR-20a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	downregulated	31444671
21756	Rat	rno-miR-20a	miRNA	high fat diet (HFD) and streptozotocin (STZ)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD); streptozotocin (STZ)  treatment	downregulated	30338914
21757	Rat	rno-miR-20a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
21758	Rat	rno-miR-20a-5p	miRNA	pentylenetetrazol (PTZ)	epilepsy	brain tissues	pentylenetetrazol (PTZ) treatment	upregulated	32779334
21759	Rat	rno-miR-20a-5p	miRNA	diosgenin (DIO)	osteoprotective effect of diosgenin (DIO)	tibias	diosgenin (DIO) treatment	DIO might exert an anti-osteoclastogenic effect on OVX rats by upregulating the expression of miR-20a-5p in circulation and bone tissue.	32210807
21760	Rat	rno-miR-20b	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal rat ventricular cells (NRVCs)	angiotensin II (Ang II) treatment	"miR©\20b participates in cardiac hypertrophy, PTEN/AKT as a mediator of miR-20b action. CHAR regulates cardiac hypertrophy via the miR©\20b/PTEN/AKT pathway."	31465630
21761	Rat	rno-miR-20b	miRNA	resveratrol	cardiomyocyte apoptosis	Cardiomyocytes	resveratrol treatment	downregulated	22050707
21762	Rat	rno-miR-20b	miRNA	¦Ã-tocotrienol	cardiomyocyte apoptosis	Cardiomyocytes	¦Ã-tocotrienol treatment	downregulated	22050707
21763	Rat	rno-miR-20b	miRNA	methylprednisolone	steroid-induced necrosis of femoral head (SNFH)	bone tissues	methylprednisolone treatment	upregulated	31210286
21764	Rat	rno-miR-20b-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21765	Rat	rno-miR-20b-5p	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12 cells	amyloid-¦Â (A¦Â) 25-35 treatment	Inhibition of miR-20b-5p attenuates apoptosis induced by A¦Â25-35 in PC12 cells through targeting RhoC.	33278507
21766	Rat	rno-miR-20b-5p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinas tissues	streptozotocin treatment	upregulated	31636010
21767	Rat	rno-miR-20b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cardiomyocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31823095
21768	Rat	rno-miR-20b-5p	miRNA	Chronic constriction injury (CCI)	neuropathic pain (NP)	spinal dorsal horm and isolated primary microglia	chronic constriction injury (CCI) induce	downregulated	31381191
21769	Rat	rno-miR-21	miRNA	molidustat	anemia	plasma samples	Molidustat treatment	upregulated	30657053
21770	Rat	rno-miR-21	miRNA	ethanol (EtOH)	acute gastric mucosal injury	gastric tissues?of rat	oral administration of ethanol	downregulated	23830200
21771	Rat	rno-miR-21	miRNA	hyperoxia	acute lung injury (ALI)	Sprague-Dawley (SD) rats left lung tissues	hyperoxia	downregulated	28627345
21772	Rat	rno-miR-21	miRNA	infusion of oleic acid (OA)	acute lung injury (ALI)	lung tissues	OA (200 ?l/kg) suspended in 20% ethyl alcohol was injected through the tail vein for 20 min treatment	dysregulated	24736893
21773	Rat	rno-miR-21	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lungs of LPS-induced ALI rats and NR8383 alveolar macrophages (AMs)	lipopolysaccharide (LPS) treatment	upregulated	30542412
21774	Rat	rno-miR-21	miRNA	isoproterenol	acute myocardial infarction (AMI)	rat myocardial tissues	subcutaneous injection of isoproterenol (ISO)	"SiRNA GAS5 can enhance the cardiac function of AMI model rats, relieve pathological damage, reduce myocardial cell apoptosis, and inhibit the occurrence of myocardial fibrosis. The possible underlying mechanism may be associated with upregulated of miR-21."	31646590
21775	Rat	rno-miR-21	miRNA	curcumin (Cur)	acute pulmonary embolism (APE)	acute pulmonary embolism (APE) rats lung tissues	curcumin?treatment	Curcumin decreased miR-21 expression by downregulating Sp1 to upregulate PTEN.	33730297
21776	Rat	rno-miR-21	miRNA	TGF-¦Â	adaptation of tendons to mechanical loading	rat Tendon fibroblasts	Transforming growth factor-¦Â(TGF-¦Â) treatment	upregulated	22539168
21777	Rat	rno-miR-21	miRNA	berberine (BBR)	allergic contact dermatitis (ACD)	ear tissues; Rat Peritoneal Mast Cells (RPMCs)	berberine (BBR) treatment	Berberine treatment inhibited miR-21 expression.	29282578
21778	Rat	rno-miR-21	miRNA	trimetazidine (TMZ)	angina	rat RV myocardial cells (RVMCs)	Trimetazidine treatment	downregulated	22842854
21779	Rat	rno-miR-21	miRNA	H2O2	apoptosis	C-kit(+) cardiac stem cells isolated from SD rats	H2O2 treatment	downregulated	29166725
21780	Rat	rno-miR-21	miRNA	hypoxia	apoptosis	Rat cardiomyocyte line H9c2 and primary cardiomyocytes	oxygen-glucose deprivation (OGD) treatment	downregulated	30552708
21781	Rat	rno-miR-21	miRNA	hypoxia- and serum deprivation	apoptosis	bone marrow mesenchymal stem cell- (MSC)	Hypoxia- and Serum Deprivation treatment	downregulated	21698002
21782	Rat	rno-miR-21	miRNA	hypoxia/reoxygenation (H/R)	apoptosis	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	27680680
21783	Rat	rno-miR-21	miRNA	IL-6	apoptosis	rats DRG neurons	IL-6 treatment	upregulated	24279830
21784	Rat	rno-miR-21	miRNA	notoginsenoside R1 (NGR1)	apoptosis	oxygen-glucose deprivation (OGD) treated rat cardiomyocyte line H9c2 and primary cardiomyocytes	Notoginsenoside R1 (NG-R1) treatment	upregulated	30552708
21785	Rat	rno-miR-21	miRNA	TGF-¦Â1	asthma	rat airway smooth muscle cell (ASMC)	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30132829
21786	Rat	rno-miR-21	miRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	rat vascular endothelial cells (VECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	24562307
21787	Rat	rno-miR-21	miRNA	ursodeoxycholic acid (UDCA)	atherosclerosis and restenosis	vascular smooth muscle cells (VSMCs)	ursodeoxycholic acid (UDCA) treatment	UDCA inhibited intimal hyperplasia and VSMCs excessive migration and proliferation via blocking miR-21/PTEN/AKT/mTOR signaling pathway	32202193
21788	Rat	rno-miR-21	miRNA	doxycycline	atrial fibrillation (AF)	heart tissues	doxycycline treatment	"Doxycycline treatment attenuated CIH-induced atrial fibrosis, reduced microRNA-21 and PI3K."	30098136
21789	Rat	rno-miR-21	miRNA	doxycycline	atrial fibrillation (AF)	heart tissues	doxycycline treatment	downregulated	30470910
21790	Rat	rno-miR-21	miRNA	doxycycline	atrial fibrillation (AF)	heart sissues	doxycycline treatment	upregulated	30470910
21791	Rat	rno-miR-21	miRNA	hypoxia	atrial fibrillation (AF)	atrial interstitial	chronic intermittent hypoxia (CIH) treatment	upregulated	30203914
21792	Rat	rno-miR-21	miRNA	tolvaptan	atrial fibrillation (AF)	chronic intermittent hypoxia (CIH) treated rats atrial interstitial	tolvaptan treatment	downregulated	30203914
21793	Rat	rno-miR-21	miRNA	hypoxia	atrial remodeling	atrial interstitial	chronic intermittent hypoxia (CIH)-induce	upregulated	31434432
21794	Rat	rno-miR-21	miRNA	tolvaptan	atrial remodeling	chronic intermittent hypoxia (CIH)-induced atrial interstitial	tolvaptan treatment	downregulated	31434432
21795	Rat	rno-miR-21	miRNA	glucose	autophagy	mesangial cells	glucose treatment	"Ursolic acid inhibits the glucose-induced upregulated of mesangial cell miRNA-21 expression, up-regulates PTEN expression,"	25689721
21796	Rat	rno-miR-21	miRNA	axotomy	peripheral nerve injury (PNI)	adult rat DRG neurons	axotomy treatment	upregulated	21853131
21797	Rat	rno-miR-21	miRNA	N-methyl-N-nitrosourea (MNU)	breast cancer	rats with experimental breast cancer Thoracic Duct Lymph	N-Methyl-N-Nitrosourea	dysregulatedin Thoracic Duct Lymph	28091921
21798	Rat	rno-miR-21	miRNA	resveratrol	breast cancer	matched tumor/normal tissues	resveratrol (RS) treatment	upregulated	24447120
21799	Rat	rno-miR-21	miRNA	high glucose (HG)	cardiac fibrosis	rat cardiac fibroblasts	high glucose treatment	upregulated	25418215
21800	Rat	rno-miR-21	miRNA	hydrogen sulfide (H2S)	cardiac fibrosis	thyroxine-induced rats myocardial tissues	Hydrogen sulfide (H2S) treatment	downregulated	29743447
21801	Rat	rno-miR-21	miRNA	radix angelica sinensis and radix hedysari ultrafiltration extract (RAS-RH)	cardiac fibrosis	primary rat cardiac fibroblasts	Radix Angelica Sinensis and Radix Hedysari ultrafiltration extract (RAS-RH) treatment	"TBI resulted in an increase in the expression of miRNA-21 in primary rat cardiac fibroblasts, and RAS-RH mitigated the TBI-induced increased expression of miRNA-21."	30780109
21802	Rat	rno-miR-21	miRNA	thyroxine	cardiac fibrosis	myocardial tissues	thyroxine treatment	upregulated	29743447
21803	Rat	rno-miR-21	miRNA	total-body irradiation (TBI)	cardiac fibrosis	primary rat cardiac fibroblasts	a single dose of total body irradiation (TBI) at 8?Gy treatment	"TBI resulted in an increase in the expression of miRNA-21 in primary rat cardiac fibroblasts, and RAS-RH mitigated the TBI-induced increased expression of miRNA-21"	30780109
21804	Rat	rno-miR-21	miRNA	human growth hormone (hGH)	cardiac hypertrophy	ventricular muscle	recombinant human growth hormone (r-hGH) treatment	upregulated	30842884
21805	Rat	rno-miR-21	miRNA	human growth hormone (hGH)	cardiac hypertrophy	heart tissues	swimming exercise plus r-hGH treatment	upregulated	30842884
21806	Rat	rno-miR-21	miRNA	swimming	cardiac hypertrophy	ventricular muscle	swimming induce treatment	upregulated	30842884
21807	Rat	rno-miR-21	miRNA	swimming	cardiac hypertrophy	heart tissues	The exercise groups completed a 1-h swimming exercise 5 times a week for 8 weeks. treatment	upregulated	30842884
21808	Rat	rno-miR-21	miRNA	aldosterone	cardiac injury	Sprague-Dawley rats	alendronate treatment	upregulated	28368454
21809	Rat	rno-miR-21	miRNA	H2O2	cardiac injury	eonatal rat cardiac ventricular myocytes	H2O2 treatment	upregulated	19336275
21810	Rat	rno-miR-21	miRNA	hypoxia/reoxygenation (H/R)	cardiomyocyte apoptosis	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	"LncRNA-GAS5 regulates PDCD4 expression to mediate MI-induced cardiomyocyte apoptosis via targeting miR-21, suggesting that GAS5 could be a therapeutic target for MI."	32308118
21811	Rat	rno-miR-21	miRNA	palmitate	cardiomyocyte apoptosis	H9c2 cells	palmitate exposure treatment	Palmitate exposure greatly reduced miR-21 expression in cardiomyocytes	30504734
21812	Rat	rno-miR-21	miRNA	SN50 (a selective cell permeable peptide inhibitor of NF- ¦Ê B)	cardiomyocyte apoptosis	rats neonatal cardiomyocytes	SN50 treatment	downregulated	24237305
21813	Rat	rno-miR-21	miRNA	hypoxia	cardiomyocytes injury	Rat cardiomyocyte line H9c2 and primary cardiomyocytes	oxygen-glucose deprivation (OGD) treatment	downregulated	30552708
21814	Rat	rno-miR-21	miRNA	notoginsenoside R1 (NGR1)	cardiomyocytes injury	oxygen-glucose deprivation (OGD) treated rat cardiomyocyte line H9c2 and primary cardiomyocytes	Notoginsenoside R1 (NG-R1) treatment	upregulated	30552708
21815	Rat	rno-miR-21	miRNA	fish oil (FO) and olive oil (OO)	cardiovascular responses	heart sissues	Fish oil (FO) and olive oil (OO) treatment	miR-21 was upregulated by both FO and OO after O 3 exposure.	33091443
21816	Rat	rno-miR-21	miRNA	amlodipine	cell differentiation	plasma and aortic vessels	?amlodipine?treatment treatment	upregulated	30927374
21817	Rat	rno-miR-21	miRNA	hypoxia	cerebral ischemia injury (CII)	rats neural stem/progenitor cells (NSPCs)	hypoxia treatment	upregulated	28939387
21818	Rat	rno-miR-21	miRNA	rosuvastatin	cholestatic liver injury	cholestatic liver injury rat liver tissues	rosuvastatin (Rvs) treatment	downregulated	30203151
21819	Rat	rno-miR-21	miRNA	acupuncture	chronic atrophic gastritis (CAG)	gastric	acupuncture treatment	downregulated	27293468
21820	Rat	rno-miR-21	miRNA	ischemia	chronic constriction injury	rat spinal cord	ligation of the sciatic nerve treatment	"The expression levels of a large number of miRNAs in the dorsal horn of the spinal cord in CCI rats changed (miR-500, -221 and -21)"	23124577
21821	Rat	rno-miR-21	miRNA	doxycycline	chronic intermittent hypoxia (CIH)-induced atrial fibrosis	heart tissues	doxycycline treatment	downregulated	29380561
21822	Rat	rno-miR-21	miRNA	ochratoxin A (OTA)	chronic nephropathy	rat renal proximal tubule cells (NRK-52E) co-cultured with renal fibroblasts (NRK-49F)	Ochratoxin A (OTA) treatment	upregulated	31415839
21823	Rat	rno-miR-21	miRNA	epigallocatechin-3-gallate (EGCG)	chronic renal injury	cadmium (Cd) pretreated Wistar albino rats	EGCG treatment	"decreased miR-21 and miR-192, enhanced miR-29a/b/c in kidney samples"	27474435
21824	Rat	rno-miR-21	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	upregulated	28199183
21825	Rat	rno-miR-21	miRNA	chaihuang Yishen granule (CHYS)	diabetic nephropathy (DN)	type 1 DN Wistar rats	CHYS at a dose of 0.56 g/kg body weight treatment	upregulated	24646636
21826	Rat	rno-miR-21	miRNA	geraniol	diabetic nephropathy (DN)	kidney tissues	Geraniol treatment	downregulated	32666288
21827	Rat	rno-miR-21	miRNA	high glucose (HG)	diabetic nephropathy (DN)	human kidney glomerular mesangial cells	high glucose treatment	"In renal mesangial cells, high glucose increased the expression of miR-21"	21613227
21828	Rat	rno-miR-21	miRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E cells	high glucose (HG) treatment	upregulated	30847937
21829	Rat	rno-miR-21	miRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E cells	high glucose treatment	upregulated	31655195
21830	Rat	rno-miR-21	miRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E cells	high glucose treatment	upregulated	31933879
21831	Rat	rno-miR-21	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinal tissues of DR rats	"rats were fed with a high-sugar and high-fat diet for 8 weeks, during which, the rats were rendered diabetic with an intraperitoneal injection of 2% streptozotocin (STZ) at a concentration of 60 mg/kg. treatment"	upregulated	31759996
21832	Rat	rno-miR-21	miRNA	nucleolin	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	nucleolin treatment	Nucleolin upregulates microRNA(miRNA)-21 expression in vivo and in vitro.	29968904
21833	Rat	rno-miR-21	miRNA	dapagliflozin	drug-induced acute kidney injury (DIKI)	rat kidney tissues	Dapagliflozin (DAPA) treatment	downregulated	31075409
21834	Rat	rno-miR-21	miRNA	dapagliflozin	drug-induced acute kidney injury (DIKI)	GNT-treated rat kidney tissues	Dapagliflozin (DAPA) treatment	upregulated	31075409
21835	Rat	rno-miR-21	miRNA	gentamicin	drug-induced acute kidney injury (DIKI)	rat kidney tissues	gentamicin (GNT) treatment	downregulated	31075409
21836	Rat	rno-miR-21	miRNA	pilocarpine	epilepsy	hippocampi	pilocarpine treatment	upregulated	27725160
21837	Rat	rno-miR-21	miRNA	stimulation electrode	epilepsy	Adult male Sprague Dawley rats blood	A bipolar stimulation electrode (distance between tips 500 ?m) was implanted in the angular bundle treatment	dysregulated	24184920
21838	Rat	rno-miR-21	miRNA	aldosterone	fibrotic remodeling of the atrial myocardium	rat cardiomyocytes of 5-day-old neonatal Sprague-Dawley rat hearts	aldosterone treatment	upregulated	24469458
21839	Rat	rno-miR-21	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	downregulated	24304932
21840	Rat	rno-miR-21	miRNA	aristolochic acid	genotoxic and carcinogenic	tissues from transgenic Big Blue rats liver and kidney	aristolochic acid (AA) treatment	"dysregulated in the kidney, miR-34a was dysregulated in the liver"	25106556
21841	Rat	rno-miR-21	miRNA	quercetin	liver damage	liver tissues	quercetin (QUR) treatment	QUR significantly lowered levels of miR-21 and increased the protein levels and activity of Nrf2	33733575
21842	Rat	rno-miR-21	miRNA	methyl helicterate (MH)	liver fibrosis	liver tissues	methyl helicterate (MH) treatment	MH treatment significantly decreased miR-21 expression.	30419452
21843	Rat	rno-miR-21	miRNA	diethylnitrosamine (DEN)	hepatocellular carcinoma (HCC)	liver tissues	diethylnitrosamine (DEN) treatment	downregulated	30412748
21844	Rat	rno-miR-21	miRNA	gleditsia sinensis extract (GSE)	hepatocellular carcinoma (HCC)	HCC liver	Gleditsia sinensis extract (GSE) treatment	upregulated	30940289
21845	Rat	rno-miR-21	miRNA	high glucose (HG)	hyperglycemia	Rat kidney glomerular mesangial cells	high glucose treatment	"In renal mesangial cells, high glucose increased the expression of miR-21"	21613227
21846	Rat	rno-miR-21	miRNA	hypoxia	hypoxia-induced injury	H9c2 rat cardiomyocytes	hypoxia induce	downregulated	30680008
21847	Rat	rno-miR-21	miRNA	loperamide	hypoxia-induced injury	hypoxia-induced H9c2 rat cardiomyocytes	loperamide treatment	upregulated	30680008
21848	Rat	rno-miR-21	miRNA	puerarin	hypoxia-induced injury	H/R-treated H9c2 cells	Puerarin treatment	upregulated	31115556
21849	Rat	rno-miR-21	miRNA	hyperoxia	hypoxic/ischemic brain damage (HIBD)	PC12 cells	hypoxia treatment	Silencing MEG3 protects PC12 cells from hypoxic injury by targeting miR-21.	32050796
21850	Rat	rno-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	rat kidney IMCD cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28214900
21851	Rat	rno-miR-21	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	IEC-6 cells	hypoxia treatment	upregulated	29170412
21852	Rat	rno-miR-21	miRNA	radiation	ionizing radiation (IR) injury	cardiac fibroblasts (CFs)	radiation treatment	"Upregulation of miR-21 in irradiated CFs, which persistently increased up to 7 days after 85 Gy irradiation"	33354435
21853	Rat	rno-miR-21	miRNA	ionizing radiation (IR)	irradiation-induced heart damage	rat myocardium	Single irradiation of 10 Gy (4¨C5 Gy/min.) of rat¡¯s mediastinum area	upregulated	30830529
21854	Rat	rno-miR-21	miRNA	molecular hydrogen-rich water (HRW)	irradiation-induced heart damage	irradiation-induced rat myocardium	molecular hydrogen-rich water (HRW) treatment	downregulated	30830529
21855	Rat	rno-miR-21	miRNA	ischemia	ischemic heart disease (IHD)	?rat hearts	ischaemic preconditioning (IP) treatment	upregulated	20219857
21856	Rat	rno-miR-21	miRNA	isoflurane	ischemia/reperfusion (I/R) injury	cardiomyocytes	isoflurane treatment	upregulated	25536091
21857	Rat	rno-miR-21	miRNA	kaempferol	ischemia/reperfusion (I/R) injury	H9c2 cells	Kaempferol treatment	Kaempferol enhanced miR-21 level in H9c2 cells exposed to H/R.	33151961
21858	Rat	rno-miR-21	miRNA	sodium hydrosulfide (NaHS)	ischemia/reperfusion (I/R) injury	?rat liver (BRL) cells	sodium hydrosulfide (NaHS) treatment	upregulated	29187695
21859	Rat	rno-miR-21	miRNA	trimetazidine (TMZ)	ischemia/reperfusion (I/R) injury	rat heart	Trimetazidine treatment	upregulated	27666568
21860	Rat	rno-miR-21	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
21861	Rat	rno-miR-21	miRNA	H2O2	ischemic cerebrovascular disease (ICVD)	PC-12 cells	H2O2 treatment	downregulated	30802826
21862	Rat	rno-miR-21	miRNA	luteolin	ischemic cerebrovascular disease (ICVD)	H2O2 treated PC-12 cells	luteolin treatment	upregulated	30802826
21863	Rat	rno-miR-21	miRNA	sodium sulfide (Na2S)	ischemic injury	adult primary rat cardiomyocytes	Na2S treatment	upregulated	24825878
21864	Rat	rno-miR-21	miRNA	cecal ligation and puncture (CLP)	kidney damage	Wistar rats	cecal ligation and puncture (CLP) treatment	upregulated	28821165
21865	Rat	rno-miR-21	miRNA	cisplatin (DDP)	kidney damage	male Wistar rats	cisplatin treatment	upregulated	24880025
21866	Rat	rno-miR-21	miRNA	vitamin D3 (Vit D) and erythropoietin (EPO)	kidney ischemia reperfusion (IR) injury	renal cells	vitamin D3 (Vit D) and erythropoietin (EPO) treatment	upregulated	33262439
21867	Rat	rno-miR-21	miRNA	swimming	left ventricular hypertrophy (LVH)	rat left ventricular	Swimming exercise training treatment	upregulated	23812090
21868	Rat	rno-miR-21	miRNA	atorvastatin	liver fibrosis	liver tissues	atorvastatin treatment	downregulated	32822716
21869	Rat	rno-miR-21	miRNA	corilagin	liver fibrosis	CCl4-induced liver fibrosis rats liver tissues	Corilagin treatment	downregulated	31752524
21870	Rat	rno-miR-21	miRNA	curcumin (Cur)	liver fibrosis	liver tissues	curcumin treatment	downregulated	32822714
21871	Rat	rno-miR-21	miRNA	"DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane)"	liver fibrosis	liver tissues	"DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane) treatment"	Long-term DDT exposure increased micro RNA-21 (miR-21) level.	32508177
21872	Rat	rno-miR-21	miRNA	ferulic acid (FA)	liver fibrosis	liver tissues	ferulic acid treatment	downregulated	32278740
21873	Rat	rno-miR-21	miRNA	gallic acid (GA)	liver fibrosis	liver tissues	gallic acid treatment	downregulated	32278740
21874	Rat	rno-miR-21	miRNA	methyl helicterate (MH)	liver fibrosis	HSC-T6 cells	Methyl helicterate (MH) treatment	downregulated	30419452
21875	Rat	rno-miR-21	miRNA	quercetin	liver fibrosis	liver tissues	quercetin treatment	downregulated	32822715
21876	Rat	rno-miR-21	miRNA	acetaminophen (APAP)	liver damage	liver tissues	acetaminophen (APAP) treatment	"miR-155 and miR-21 were evaluated as makers of inflammation and regeneration, respectively, to characterize liver status."	27051339
21877	Rat	rno-miR-21	miRNA	methotrexate (MTX)	liver damage	liver tissues	methotrexate (MTX) treatment	upregulated	33349067
21878	Rat	rno-miR-21	miRNA	GYY4137	hepatic ischemia/reperfusion injury (HIRI)	Wistar rats liver	"undergoing hepatic I/R for 30 min, followed by a 3-h reperfusion"	upregulated	29187695
21879	Rat	rno-miR-21	miRNA	partial hepatectomy (PH)	liver regeneration	primary rat hepatocytes	?partial hepatectomy (PH) treatment	upregulated	20689055
21880	Rat	rno-miR-21	miRNA	"DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane), benzo[a]pyrene (BP), and 3-methylcholanthrene (MC)"	post-transcriptional regulation	?the livers and ovaries of chemically induced rats	"DDT, benzo[a]pyrene (BP), and 3-methylcholanthrene (MC) treatment"	downregulated	24727239
21881	Rat	rno-miR-21	miRNA	angiotensin II (Ang II)	lung fibrosis	rats	angiotensin II (Ang II) treatment	upregulated	29084974
21882	Rat	rno-miR-21	miRNA	angiotensin-(1-7)	lung fibrosis	rats	angiotensin-(1-7) treatment	downregulated	29084974
21883	Rat	rno-miR-21	miRNA	TGF-¦Â1	cardiac fibrosis	primary rat cardiomyocytes	TGF-¦Â1 treatment	microRNA-21 were Upregulated in Fibrotic Primary Rat Cardiomyocytes Induced by TGF-¦Â1	30058694
21884	Rat	rno-miR-21	miRNA	ginsenoside Rb1	myocardial infarction (MI)	hypoxia-induced neonatal rat cardiomyocytes	Ginsenoside Rb1 (GS-Rb1) treatment	upregulated	30988756
21885	Rat	rno-miR-21	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	downregulated	30861181
21886	Rat	rno-miR-21	miRNA	hypoxia	myocardial infarction (MI)	neonatal rat cardiomyocytes	hypoxia induce	downregulated	30988756
21887	Rat	rno-miR-21	miRNA	indoxyl sulfate (IS)	myocardial infarction (MI)	cardiac fibroblasts	indoxyl sulfate (IS) treatment	upregulated	25896982
21888	Rat	rno-miR-21	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	"cardiomyocytes, cardiac fibroblasts, and conditioned medium (CM) derived from cardiomyocytes"	Oxygen-glucose-deprivation (OGD) treatment	upregulated	31430983
21889	Rat	rno-miR-21	miRNA	TGF-¦Â1	myocardial infarction (MI)	primary cardiac fibroblasts (CFs) isolated from 1 to 3-day-old Sprague-Dawley rats	TGF-¦Â1 treatment	upregulated	28817807
21890	Rat	rno-miR-21	miRNA	gastrodin (GAS)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-treated H9c2 cells	gastrodin (GSTD) treatment	upregulated	30684569
21891	Rat	rno-miR-21	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	upregulated	30684569
21892	Rat	rno-miR-21	miRNA	extracellular superoxide dismutase (SOD3)	myocardial reperfusion injury	hind limb of rats	Extracellular superoxide dismutase (SOD3) treatment	upregulated	21909393
21893	Rat	rno-miR-21	miRNA	baicalin (BAI)	myocarditis	H9c2 cells	baicalin (BAI) treatment	The enhanced expression of miR-21 triggered by LPS was further elevated by Baicalin.	31984561
21894	Rat	rno-miR-21	miRNA	xenon (Xe)	nephrotoxicity	kidney tissues	Xenon (Xe)? treatment	upregulated	23737979
21895	Rat	rno-miR-21	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
21896	Rat	rno-miR-21	miRNA	hypoxic/ischemic	neuronal cell death	Primary microglial cells	Hypoxia/Ischemia treatment	downregulated	22907769
21897	Rat	rno-miR-21	miRNA	apocynin	nonalcoholic fatty liver disease (NAFLD)	Immortalized rat Kupffer cell line (SV40)	apocynin treatment	downregulated	31393787
21898	Rat	rno-miR-21	miRNA	microcystin (MC)	nonalcoholic fatty liver disease (NAFLD)	Immortalized rat Kupffer cell line (SV40)	microcystin (MC) treatment	upregulated	31393787
21899	Rat	rno-miR-21	miRNA	"nitrone spin trap 5,5 dimethyl-1- pyrroline N-oxide (DMPO)"	nonalcoholic fatty liver disease (NAFLD)	Immortalized rat Kupffer cell line (SV40)	"nitrone spin trap 5,5 dimethyl-1- pyrroline N-oxide (DMPO) treatment"	downregulated	31393787
21900	Rat	rno-miR-21	miRNA	"quinacrine, erythromycin and tetracycline"	non-surgical sterilization	Wistar albino 12-14 week old female rats	"quinacrine, erythromycin , tetracycline treatment"	upregulated	25195052
21901	Rat	rno-miR-21	miRNA	"3,6-dihydroxyflavone (3,6-DHF)"	obesity	breast?of rats	"3,6-dihydroxyflavone (3,6-DHF) treatment"	"the global upregulation of miR-21 and downregulated of miR-34a in breast carcinogenesis could be reversed by 3,6-DHF"	22616882
21902	Rat	rno-miR-21	miRNA	H2O2	oxidative stress	neuronal spinal cord (RN-sc) cells	H2O2 treatment	upregulated	26323253
21903	Rat	rno-miR-21	miRNA	H2O2	oxidative stress	exosomes derived from bone marrow mesenchymal stem cells (MSCs)	H2O2 treatment	upregulated	29444190
21904	Rat	rno-miR-21	miRNA	glucagon-like peptide-1 (GLP-1)	pancreatic ¦Â-cell dysfunction	INS-1 832/3 cells	glucagon-like peptide 1 (GLP-1) treatment	upregulated	26218441
21905	Rat	rno-miR-21	miRNA	penetrating ballistic-like brain injury	penetrating ballistic-like brain injury (PBBI)	male Sprague-Dawley rats brain tissue	a unilateral frontal 10% PBBI treatment	upregulated in brain tissue	28452880
21906	Rat	rno-miR-21	miRNA	high glucose (HG)	peritoneal fibrosis	"Peritoneal tissues in fibrosis rats, peritoneal mesothelial cells"	high glucose treatment	upregulated	30515805
21907	Rat	rno-miR-21	miRNA	high glucose (HG)	peritoneal fibrosis	peritoneal mesothelial cells	high glucose (HG) treatment	upregulated	30515805
21908	Rat	rno-miR-21	miRNA	angiotensin II type I receptor agonistic autoantibodies (AT1-AA)	preeclampsia (PE)	neonatal rat cardiomyocytes	Angiotensin II type I receptor agonistic autoantibodies (AT1-AA) treatment	downregulated	31105840
21909	Rat	rno-miR-21	miRNA	amniotic fluid mesenchymal stem cells (AFMSCs)	premature ovarian dysfunction (POD)	ovarian lysate	amniotic fluid mesenchymal stem cells (AFMSCs) treatment	miRNA-21 allowed regeneration by modulating PTEN and caspase 3 apoptotic pathways.	33049041
21910	Rat	rno-miR-21	miRNA	propofol (PPF)	prostate cancer	vascular smooth muscle cells	?propofol treatment	upregulated	21263323
21911	Rat	rno-miR-21	miRNA	osthole	pulmonary arterial hypertension (PAH)	blood	osthole treatment	osthole hsa a role of metabolic regulator to potentially treat PAH by targeting inhibition of Sphk1/S1P via microRNA-21-PI3K/Akt/mTOR signal pathway.	32402408
21912	Rat	rno-miR-21	miRNA	platelet-derived growth factor (PDGF)	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cell (PASMC)	platelet-derived growth factor (PDGF) treatment	upregulated	30453304
21913	Rat	rno-miR-21	miRNA	exercise training (ET)	pulmonary arterial stenosis (PAS)	PAS rats	PAS rats treatment	miR-1 downregulated and miR-21 upregulation	27994552
21914	Rat	rno-miR-21	miRNA	baicalin (BAI)	lung fibrosis	lung tissue of rats	baicalin (BAI) treatment	downregulated	23523661
21915	Rat	rno-miR-21	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	?bleomycin (BLM)?treatment treatment	upregulated	29843043
21916	Rat	rno-miR-21	miRNA	resveratrol	lung fibrosis	?bleomycin (BLM)-induced pulmonary fibrosis (PF) rats lung tissues	resveratrol (Res) treatment	downregulated	29843043
21917	Rat	rno-miR-21	miRNA	IFN-¦Ã	lung fibrosis	lung tissues	interferon gamma (IFN-¦Ã) treatment	downregulated	25704671
21918	Rat	rno-miR-21	miRNA	antigen	pulmonary inflammation	plasma and lavaged lung	antigen treatment	upregulated	27075111
21919	Rat	rno-miR-21	miRNA	aspirin	radiation-induced heart disease (RIHD)	left ventricle (LV)	male Wistar rats were subjected to a single sub-lethal dose of chest radiation at 25 Gy and treated with aspirin (3 mg/day) for six weeks.	downregulated	29642568
21920	Rat	rno-miR-21	miRNA	atorvastatin	radiation-induced heart disease (RIHD)	left ventricle (LV)	male Wistar rats were subjected to a single sub-lethal dose of chest radiation at 25 Gy and treated with atorvastatin (0.25 mg/day) for six weeks.	upregulated	29642568
21921	Rat	rno-miR-21	miRNA	X rays	radiation-induced heart disease (RIHD)	left ventricle (LV)	male Wistar rats were subjected to a single sub-lethal dose of chest radiation at 25 Gy treatment	upregulated	29642568
21922	Rat	rno-miR-21	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	downregulated	24886372
21923	Rat	rno-miR-21	miRNA	X-rays	radiation-induced skin injury	rats irradiated skin	45-Gy electron beam treatment	upregulated	24447893
21924	Rat	rno-miR-21	miRNA	TGF-¦Â1	renal fibrosis	NRK-49F cells	TGF-¦Â1 treatment	upregulated	29361523
21925	Rat	rno-miR-21	miRNA	TGF-¦Â	renal injury	rat tubular epithelial cells (NRK52E)	Transforming growth factor (TGF)-¦Â? treatment	upregulated	21704009
21926	Rat	rno-miR-21	miRNA	doxorubicin (DOX)	renal interstitial fibrosis (RIF)	kidneys	doxorubicin (ADR) induction	upregulated	32606425
21927	Rat	rno-miR-21	miRNA	fuzheng huayu recipe (FZHY)	renal interstitial fibrosis (RIF)	kidney tissues	Fuzheng Huayu recipe (FZHY) treatment	miR-21 is the key fibrosis-related miRNA regulated by FZHY	32912827
21928	Rat	rno-miR-21	miRNA	"kangxianling (KXL, anti-fibrin)"	renal interstitial fibrosis (RIF)	kidneys	"Kangxianling (KXL, anti-fibrin) treatment"	downregulated	32606425
21929	Rat	rno-miR-21	miRNA	norepinephrine (NE)	rheumatoid arthritis (RA)	rats primary granulosa cells	norepinephrine treatment	downregulated	28473352
21930	Rat	rno-miR-21	miRNA	astragalus polysaccharide (APS)	rheumatoid arthritis (RA)	adjuvant arthritis (AA) rats cardiac tissues	astragalus polysaccharides (APS) treatment	downregulated	31495827
21931	Rat	rno-miR-21	miRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	adjuvant arthritis (AA) rats cardiac tissues	methotrexate (MTX) treatment	downregulated	31495827
21932	Rat	rno-miR-21	miRNA	triptolide (TPL)	rheumatoid arthritis (RA)	adjuvant arthritis (AA) rats cardiac tissues	triptolide (TPL) treatment	downregulated	31495827
21933	Rat	rno-miR-21	miRNA	xinfeng capsules (XFC)	rheumatoid arthritis (RA)	cardiac tissues	xinfeng capsules (XFC) treatment	upregulated	31495827
21934	Rat	rno-miR-21	miRNA	Xinfeng capsules (XFC)	rheumatoid arthritis (RA)	adjuvant arthritis (AA) rats cardiac tissues	Xinfeng capsules (XFC) treatment	downregulated	31495827
21935	Rat	rno-miR-21	miRNA	morphine	spinal cord injury (SCI)	rats brain tissues	morphine at either 2 or 15 days post-SCI treatment	upregulated	24867772
21936	Rat	rno-miR-21	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	downregulated	21094214
21937	Rat	rno-miR-21	miRNA	"1,1-trichloro-2,2-di(4-chlorophenyl)ethane (DDT)"	toxic effects of DDT	Wistar rats livers	"1,1-trichloro-2,2-di(4-chlorophenyl)ethane (DDT) treatment"	downregulated	28900085
21938	Rat	rno-miR-21	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	transplant vasculopathy	VSMCs isolated from rat aorta	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28415796
21939	Rat	rno-miR-21	miRNA	hydrogen gas (H2)	traumatic brain injury (TBI)	traumatic brain injury (TBI) rats brain tissues	H2 treatment was given by exposure to 2% H2 from 30 min to 5?h after TBI operation	upregulated	29028768
21940	Rat	rno-miR-21	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	blood	streptozotocin (STZ) treatment	upregulated	32233625
21941	Rat	rno-miR-21	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	downregulated	22847192
21942	Rat	rno-miR-21	miRNA	high salt (HS)	hypertension	aorta of? rats	high salt (HS) treatment	downregulated	24161401
21943	Rat	rno-miR-21?	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	Streptozotocin (STZ) treatment	miR-21 expression was upregulated in kidney tissues of STZ-induced DN rats	30212710
21944	Rat	rno-miR-21*	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 8) treatment	different expression	24420840
21945	Rat	rno-miR-210	miRNA	soluble ¦Â-amyloid (sA¦Â) oligomers	Alzheimer's disease (AD)	cortical neurons were isolated from E17 embryos of Sprague Dawley rats	sA¦Â treatment	upregulated	24595404
21946	Rat	rno-miR-210	miRNA	hypoxia- and serum deprivation	apoptosis	bone marrow mesenchymal stem cell- (MSC)	Hypoxia- and Serum Deprivation treatment	downregulated	21698002
21947	Rat	rno-miR-210	miRNA	hypobaric hypoxia (HH)	brain injury	hippocampus tissues	hypobaric hypoxia (HH) induce	downregulated	30878546
21948	Rat	rno-miR-210	miRNA	Rhodiola crenulata aqueous extract (RCAE)	brain injury	hippocampus tissues	Rhodiola crenulata aqueous extract (RCAE) treatment	upregulated	30878546
21949	Rat	rno-miR-210	miRNA	H2O2	cardiomyocyte apoptosis	Rat cardiomyoblast H9c2 cells	H2O2 treatment	upregulated	25968948
21950	Rat	rno-miR-210	miRNA	crocin	cardiovascular disease (CVD)	Wistar rats heart tissue	crocin treatment	upregulated	28678929
21951	Rat	rno-miR-210	miRNA	immunoregulatory molecule soluble HLA-G (sHLA-G)	CD4+ T cells proliferation	CD4+ T cells	immunoregulatory molecule soluble HLA-G (sHLA-G) treatment	"sHLA-G triggered a modulation of miRNA expression that may in turn modulate downstream gene expression, thus affecting CD4+ T -cell function."	23220581
21952	Rat	rno-miR-210	miRNA	hypoxia	cytoprotective effects	H9c2 cells (ATTC)	Hypoxia treatment	upregulated	21841015
21953	Rat	rno-miR-210	miRNA	garlic	diabetes mellitus (DM)	myocardium	garlic feed	downregulated	30570073
21954	Rat	rno-miR-210	miRNA	garlic	diabetes mellitus (DM)	diabetic rats heart tissues	Garlic treatment	downregulated	30570073
21955	Rat	rno-miR-210	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	heart tissues	streptozotocin (STZ) treatment	upregulated	30570073
21956	Rat	rno-miR-210	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	myocardium	streptozotocin treatment	upregulated	30570073
21957	Rat	rno-miR-210	miRNA	voluntary exercise	diabetes mellitus (DM)	myocardium	voluntary exercise treatment	downregulated	30570073
21958	Rat	rno-miR-210	miRNA	voluntary exercise	diabetes mellitus (DM)	diabetic rats heart tissues	voluntary exercise treatment	downregulated	30570073
21959	Rat	rno-miR-210	miRNA	paraquat (PQ)	epithelial-mesenchymal transition (EMT)	rat alveolar type II cells (RLE-6TN)	paraquat (PQ) treatment	upregulated	28699704
21960	Rat	rno-miR-210	miRNA	hypoxia	fetal hypoxia	cardiomyocytes	hypoxia treatment	upregulated	29113299
21961	Rat	rno-miR-210	miRNA	hypoxia	hypoxia-induced injury	cardiac stem cells (CSCs) were isolated from rat ventricular wall and cultured until passage 4	hypoxia induce	upregulated	30668175
21962	Rat	rno-miR-210	miRNA	hypoxia	hypoxia-induced renal tubular cell apoptosis	rats renal tubular cells	hypoxia treatment	upregulated in renal tubular cells	29387863
21963	Rat	rno-miR-210	miRNA	hypoxia	hypoxia-induced injury	PC-12 cells	hypoxia treatment	upregulated	29018330
21964	Rat	rno-miR-210	miRNA	nicotine	hypoxic/ischemic injury	hypoxic-ischemic (HI) injury neonates brain	nicotine exposure in perinatal rats	upregulated in brain	28123348
21965	Rat	rno-miR-210	miRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	microglia in the neonatal brain	hypoxia induce	upregulated	31300734
21966	Rat	rno-miR-210	miRNA	hypoxic/ischemic	hypoxic-ischemic brain edema	left brain	hypoxia-ischemia (HI) treatment	downregulated	27530798
21967	Rat	rno-miR-210	miRNA	hypoxic/ischemic	hypoxic-ischemic encephalopathy (HIE)	brain tissues	hypoxic-ischemic? treatment	downregulated	24089674
21968	Rat	rno-miR-210	miRNA	oxygen glucose deprivation (OGD)	hypoxic-ischemic encephalopathy (HIE)	PC12 cells	oxygen and glucose deprivation-induced treatment	upregulated	25323830
21969	Rat	rno-miR-210	miRNA	losartan	ischemia/reperfusion (I/R) injury	heart tissues	losartan treatment	upregulated	26168042
21970	Rat	rno-miR-210	miRNA	Vagus nerve stimulation (VNS)	ischemia/reperfusion (I/R) injury	brain matrix	Vagus nerve stimulation (VNS) treatment	upregulated	25783636
21971	Rat	rno-miR-210	miRNA	oxygen glucose deprivation (OGD)	ischemic hypoxia (IH)	PC12 rat pheochromocytoma cells	OGD treatment	upregulated	25323830
21972	Rat	rno-miR-210	miRNA	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	lung cancer	male F344 rats	was induc systemic NNK treatment	downregulated	24553369
21973	Rat	rno-miR-210	miRNA	Hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	upregulated	29710553
21974	Rat	rno-miR-210	miRNA	CoCl2	myocardial injury	H9c2 cells	CoCl2 treatment	MiR-210 suppressed autophagy by upregulating p62 and downregulating LC3II/I in hypoxic H9C2 cells.	33234216
21975	Rat	rno-miR-210	miRNA	cardiac shock wave therapy (SWT)	myocardial ischaemic injury	HL-1 cells	Cardiac shock wave therapy (SWT) treatment	Cardiac shock wave therapy protects cardiomyocytes from hypoxia-induced injury by modulating miR-210	31974607
21976	Rat	rno-miR-210	miRNA	hypoxia	neonatal brain hypoxia	neural stem cells (NSCs) derived from embryo 14 Sprague-Dawley rats	hypoxia induce	downregulated	29864934
21977	Rat	rno-miR-210	miRNA	salidroside (SAL)	neonatal brain hypoxia	hypoxia-induced neural stem cells (NSCs)	Salidroside treatment	upregulated	29864934
21978	Rat	rno-miR-210	miRNA	hypoxic/ischemic	neonatal hypoxic-ischemic brain damage	brain tissues	hypoxic/ischemic treatment	upregulated in the neonatal rat brain	28672801
21979	Rat	rno-miR-210	miRNA	hypoxia	neurilemmoma	schwannoma RT4-D6P2T cells	1% O2 tri-gas incubator	upregulated	28440459
21980	Rat	rno-miR-210	miRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	chondrocytes	lipopolysaccharide (LPS) treatment	downregulated	26244598
21981	Rat	rno-miR-210	miRNA	H2O2	oxidative stress	H9c2 cells	H2O2 for 48 h	upregulated	28661226
21982	Rat	rno-miR-210-3p	miRNA	docosahexaenoic Acid (DHA)	apoptosis	H9C2 cardiomyocyte	Docosahexaenoic Acid (DHA) treatment	upregulated	33791918
21983	Rat	rno-miR-210-3p	miRNA	valproic acid (VPA)	cell differentiation	primary cultured neural stem cells (NSCs)	valproate (VPA) treatment	upregulated	29575035
21984	Rat	rno-miR-210-3p	miRNA	cold	cold stress	rats serum	cold conditions (4¡æ for 12h)	downregulated	28477904
21985	Rat	rno-miR-210-3p	miRNA	melamine and cyanuric acid (MEL&CYA)	kidney damage	serum	melamine and cyanuric acid (MEL&CYA) treatment	downregulated	27621052
21986	Rat	rno-miR-210-3p	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	downregulated	32187165
21987	Rat	rno-miR-210-3p	miRNA	CoCl2	neural stem cells (NSCs) injury	neural stem cells (NSCs)	Cobalt chloride treatment	miR-210-3p was significantly higher in the cobalt chloride-induced hypoxia group.	33000190
21988	Rat	rno-miR-210-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
21989	Rat	rno-miR-211	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	bronchoalveolar lavage fluid (BALF)-derived macrophages	lipopolysaccharide (LPS) treatment	upregulated	29402831
21990	Rat	rno-miR-211	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-211 expression was significantly downregulated in PC12 cells in response to OGD/R	32050841
21991	Rat	rno-miR-211	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	upregulated	22156553
21992	Rat	rno-miR-211	miRNA	hypoxia	hypoxic/ischemic injury	striatal tissues	hypoxia treatment	miR-211 was upregulated in striatal tissues of HI group.	30563429
21993	Rat	rno-miR-211	miRNA	radiation	breast cancer	rat mammary cancer tissues	radiation treatment	upregulated	23273170
21994	Rat	rno-miR-211	miRNA	hypoxic/ischemic	neonatal cerebral palsy	striatal tissues	hypoxic-ischemic (HI) treatment	"MIAT overexpression reduced apoptosis of Neuro2A cells through miR-211/GDNF, which relieved HI injury of neonatal rats."	30563429
21995	Rat	rno-miR-211	miRNA	lead (Pb)	nervous system diseases	rats hippocampus	chronic lead exposure treatment	upregulated	24960059
21996	Rat	rno-miR-211	miRNA	tougu xiaotong capsule (TXC)	osteoarthritis (OA)	chondrocyte cells	Tougu Xiaotong capsule (TXC) treatment	upregulated	30342192
21997	Rat	rno-miR-211	miRNA	tougu xiaotong capsule (TXC)	osteoarthritis (OA)	tunicamycin-treated primary chondrocytes	Tougu Xiaotong capsule (TXC) treatment	upregulated	30342192
21998	Rat	rno-miR-211	miRNA	tunicamycin (TM)	osteoarthritis (OA)	primary chondrocytes	tunicamycin (TM) treatment	downregulated	30342192
21999	Rat	rno-miR-211	miRNA	activated protein C(APC)	sepsis	rats blood and liver tissue	activated protein C treatment	aPC treatment coordinates beneficial cytoprotective effects during sepsis by modulating miRNA expression	22940033
22000	Rat	rno-miR-211	miRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	hydrogen peroxide (H2O2 ) treatment	downregulated	30145837
22001	Rat	rno-miR-211	miRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle	high-phosphorous treatment	downregulated	26187577
22002	Rat	rno-miR-211	miRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle	high-phosphorous treatment	lower levels of miR-133b and miR-211 and higher levels of miR-29b	26187577
22003	Rat	rno-miR-211-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-211-5p expression significantly increased in OGD-treated PC12 cells and peaked at 24 h.	32311346
22004	Rat	rno-miR-211-5p	miRNA	dexmedetomidine (DEX)	chronic inflammatory visceral pain (CIVP)	trinitrobenzene sulfonic acid (TNBS)-induced chronic inflammatory visceral pain (CIVP) rats spinal cord	dexamethasone (DEX) treatment	upregulated	30874971
22005	Rat	rno-miR-211-5p	miRNA	trinitrobenzene sulfonic acid (TNBS)	chronic inflammatory visceral pain (CIVP)	spinal cord	trinitrobenzene sulfonic acid (TNBS) treatment	downregulated	30874971
22006	Rat	rno-miR-212	miRNA	cocaine hydrochloride	cocaine addiction	rats brain structures	cocaine hydrochloride was dissolved in sterile 0.9 % NaCl and administered intravenously	upregulated	26944283
22007	Rat	rno-miR-212	miRNA	electroconvulsive stimulation (ECS)	depression	rat brain tissue cells and whole blood cells	electroconvulsive stimulation (ECS) treatment	upregulated	23721784
22008	Rat	rno-miR-212	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	upregulated	24304932
22009	Rat	rno-miR-212	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	upregulated	24205079
22010	Rat	rno-miR-212	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	upregulated	24205079
22011	Rat	rno-miR-212	miRNA	angiotensin II (Ang II)	hypertension	heart tissues	angiotensin II (Ang II) treatment	upregulated	23712358
22012	Rat	rno-miR-212	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic brain injury	Primary cerebral cortical neuronal cultures	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31651707
22013	Rat	rno-miR-212	miRNA	SiO2	lung injury	lung	SiO2 treatment	upregulated	27689473
22014	Rat	rno-miR-212	miRNA	nanosized SiO2	pulmonary injury	liver tissues	nanosized SiO2 treatment	upregulated	27689473
22015	Rat	rno-miR-212	miRNA	ionizing radiation (IR)	radiation-induced heart disease (RIHD)	heart tissues	ionizing radiation (IR) treatment	upregulated	31380269
22016	Rat	rno-miR-212	miRNA	angiotensin II (Ang II)	renal interstitial fibrosis (RIF)	NRK49F cells	angiotensin II (Ang II) treatment	upregulated	33495813
22017	Rat	rno-miR-212	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	NRK49F cells	TGF-¦Â1 treatment	upregulated	33495813
22018	Rat	rno-miR-212	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	upregulated	22847192
22019	Rat	rno-miR-212	miRNA	propranolol (PRO)	¦Â-adrenoceptor intervention	rat heart	propranolol (PRO) treatment	downregulated	22847192
22020	Rat	rno-miR-212-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	rat retinal	streptozotocin (STZ)-induced diabetic rat treatment	differential expressions	24502381
22021	Rat	rno-miR-212-3p	miRNA	angiostrongylus cantonensis (A. cantonensis)	inflammation	healthy male SD rats	angiostrongylus cantonensis (A. cantonensis) infection	upregulated	24142286
22022	Rat	rno-miR-212-3p	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	upregulated	32196615
22023	Rat	rno-miR-212-3p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	female Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	28192093
22024	Rat	rno-miR-212-3p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	male Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	downregulated	28192093
22025	Rat	rno-miR-212-5p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	female Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	upregulated	28192093
22026	Rat	rno-miR-212-5p	miRNA	di(2-ethylhexyl) phthalate (DEHP)	neurotoxicity	male Long Evans rats hippocampal	di(2-ethylhexyl) phthalate (DEHP) treatment	downregulated	28192093
22027	Rat	rno-miR-212-5p	miRNA	lipopolysaccharide (LPS)	sepsis	?H9c2 cells	?lipopolysaccharide (LPS) treatment	downregulated	31806569
22028	Rat	rno-miR-213	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
22029	Rat	rno-miR-21-3p	miRNA	aristolochic acid	acute kidney injury (AKI)	rats kidney	aristolochic acid (AA) treatment	upregulated	27422293
22030	Rat	rno-miR-21-3p	miRNA	aristolochic acid	acute kidney injury (AKI)	kidney	aristolochic acid (AA) treatment	upregulated	27422293
22031	Rat	rno-miR-21-3p	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	33263228
22032	Rat	rno-miR-21-3p	miRNA	Yiqifumai Injection (YQFM)	chronic heart failure (CHF)	H9c2 cells	Yiqifumai Injection (YQFM) treatment	upregulated	29467665
22033	Rat	rno-miR-21-3p	miRNA	high glucose (HG)	diabetic cardiac fibrosis	cardiac fibroblasts	high glucose (HG) treatment	miR-21-3p level was upregulated in high glucose-induced cardiac fibroblasts.	33385416
22034	Rat	rno-miR-21-3p	miRNA	streptozocin (STZ)	diabetic cardiac fibrosis	heart sissues	streptozocin (STZ) treatment	miR-21-3p level was upregulated in STZ-induced diabetic cardiac fibrosis tissues.	33385416
22035	Rat	rno-miR-21-3p	miRNA	steroids	osteonecrosis	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	26459755
22036	Rat	rno-miR-21-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22037	Rat	rno-miR-21-3p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	downregulated	30595983
22038	Rat	rno-miR-214	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute ischemic stroke (AIS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32827544
22039	Rat	rno-miR-214	miRNA	D-galactosamine/lipopolysaccharide (D-GalN/LPS)	acute liver injury (ALI)	hepatic tissues of ALF rats	D©\galactose+LPS treatment	upregulated	30938885
22040	Rat	rno-miR-214	miRNA	zhenbao pill	acute spinal cord injury (ASCI)	cultured CD4+ T cells	Zhenbao Pill treatment	downregulated	30287503
22041	Rat	rno-miR-214	miRNA	isoproterenol	agonism	heart tissues	isoproterenol treatment	upregulated	25925428
22042	Rat	rno-miR-214	miRNA	isoflurane	Alzheimer's disease (AD)	primary cultured rat hippocampal neurons	Isoflurane treatment	downregulated	23408966
22043	Rat	rno-miR-214	miRNA	hydrogen sulfide (H2S)	cardiac fibrosis	thyroxine-induced rats myocardial tissues	Hydrogen sulfide (H2S) treatment	downregulated	29743447
22044	Rat	rno-miR-214	miRNA	isoproterenol	cardiac fibrosis	cardiac fibroblast (CF)	"isoproterenol (ISO, a ¦Â-AR agonist) treatment"	upregulated	26692091
22045	Rat	rno-miR-214	miRNA	thyroxine	cardiac fibrosis	myocardial tissues	thyroxine treatment	upregulated	29743447
22046	Rat	rno-miR-214	miRNA	fish oil and pectin	colorectal cancer (CRC)	colon tissue of rats	corn oil ¡À fish oil with pectin ¡À cellulose	upregulated	21406606
22047	Rat	rno-miR-214	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	downregulated	28199183
22048	Rat	rno-miR-214	miRNA	streptozocin (STZ)	diabetic corneal endothelial keratopathy	corneal endothelial cells	streptozotocin (STZ) treatment	downregulated	31693400
22049	Rat	rno-miR-214	miRNA	Xuesaitong (XST)	diabetic nephropathy (DN)	glomeruli	Xuesaitong (XST) treatment	XST significantly reduced the miR-214 mRNA expression in diabetic glomeruli	32051833
22050	Rat	rno-miR-214	miRNA	high glucose (HG)	diabetic nephropathy (DN)	rat glomerular MCs	25 mM glucose for 24 h	upregulated	28701356
22051	Rat	rno-miR-214	miRNA	desflurane	cell differentiation	primary rat hippocampal neurons	desflurane treatment	downregulated	24021802
22052	Rat	rno-miR-214	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	downregulated	24205079
22053	Rat	rno-miR-214	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
22054	Rat	rno-miR-214	miRNA	hypoxia	hypoxia-induced injury	neural stem cells (NSCs)	hypoxia induce	upregulated	31282213
22055	Rat	rno-miR-214	miRNA	puerarin	hypoxia-induced injury	hypoxia-induced neural stem cells (NSCs)	Puerarin treatment	further upregulated	31282213
22056	Rat	rno-miR-214	miRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cells	hypoxia induce	downregulated	31220945
22057	Rat	rno-miR-214	miRNA	oridonin	ischemic heart disease (IHD)	hypoxia-induced H9c2 cells	Oridonin (Orid) treatment	upregulated	31220945
22058	Rat	rno-miR-214	miRNA	H2O2	apoptosis	L6 SKM cells	H2O2 treatment	H2O2 could significantly increase miR-214 gene expression in L6 SKM.	32131653
22059	Rat	rno-miR-214	miRNA	ketamine	learning and memory impairment and neurodegeneration	brain tissues	ketamine administered at a dose of 80 mg/kg treatment	downregulated	24914689
22060	Rat	rno-miR-214	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	29915227
22061	Rat	rno-miR-214	miRNA	sevoflurane (SEV)	liver damage	BRL-3a cells	sevoflurane treatment	Exposure to sevoflurane upregulated the expression level of miR-214	29226348
22062	Rat	rno-miR-214	miRNA	massive small bowel resection	lung cancer	rat jejunum and IEC-6 cells	massive small bowel resection treatment	upregulated	22418008
22063	Rat	rno-miR-214	miRNA	nicotine	nicotine intake	female rats prefrontal cortex (PFC) tissues	nicotine exposure	upregulated	30504847
22064	Rat	rno-miR-214	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22065	Rat	rno-miR-214	miRNA	propofol (PPF)	propofol-induced neuroapoptosis	serum	propofol treatment	The serum level of miR-214 expression was observed to be significantly upregulated in propofol-induced neuroapoptosis rats	30106086
22066	Rat	rno-miR-214	miRNA	X-rays	radiation-induced skin injury	rats irradiated skin	45-Gy electron beam treatment	upregulated	24447893
22067	Rat	rno-miR-214	miRNA	H2O2	reactive oxygen species (ROS)-induced cardiac myocyte injury	Sprague¨CDawley rats cardiac myocytes	H2O2 treatment	upregulated	23904244
22068	Rat	rno-miR-214	miRNA	TGF-¦Â	renal injury	rat tubular epithelial cells (NRK52E)	Transforming growth factor (TGF)-¦Â? treatment	upregulated	21704009
22069	Rat	rno-miR-214	miRNA	electroacupuncture (EA)	spinal cord injury (SCI)	SCI rats	electroacupuncture (EA) treatment	upregulated	28298073
22070	Rat	rno-miR-214	miRNA	hypoxia/reoxygenation (H/R)	spinal cord ischemia/reperfusion injury (SCII)	PC12 cells	hypoxia/reoxygenation (H/R) treatment	Foxd3 induces spinal cord ischemia-reperfusion injury by potentiating microRNA-214-dependent inhibition of Kcnk2	31959866
22071	Rat	rno-miR-214	miRNA	CoCl2	vascular senescence	Rat aortic vascular smooth muscle cell (A7r5)	CoCl2 treatment	miR-214 level was elevated in both intracellular and exosome samples of VSMCs after CoCl2 treatment.	32410577
22072	Rat	rno-miR-214	miRNA	exercise training (ET)	ventricular contractile dysfunction	cardiac	exercise training treatment	exercise training restores microRNA-1 and -214 expression levels	26646371
22073	Rat	rno-miR-214	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	upregulated	22847192
22074	Rat	rno-miR-214-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	upregulated	32192351
22075	Rat	rno-miR-214-3p	miRNA	estradiol benzoate (EB)	chronic inflammatory diseases	dorsolateral prostate	estradiol benzoate (EB) treatment	upregulated	33332750
22076	Rat	rno-miR-214-3p	miRNA	testosterone	chronic inflammatory diseases	dorsolateral prostate	estradiol benzoate (EB) treatment	downregulated	33332750
22077	Rat	rno-miR-214-3p	miRNA	high glucose (HG)	diabetic corneal endothelial keratopathy	rat corneal endothelial cells	high glucose treatment	downregulated	31693400
22078	Rat	rno-miR-214-3p	miRNA	high fat diet (HFD)	hyperlipidemic pancreatitis (HP)	"kidney, pancreas and serum"	high fat diet (HFD) feed	upregulated	31790686
22079	Rat	rno-miR-214-3p	miRNA	Sodium taurocholate	hyperlipidemic pancreatitis (HP)	"kidney, pancreas and serum"	long-term high-fat diet and sodium taurocholic injection treatment	upregulated	31790686
22080	Rat	rno-miR-214-3p	miRNA	salt	hypertension	renal outer medulla	salt treatment	miR-214-3p in the renal outer medulla was significantly more abundant in SS rats on the 4% NaCl diet compared with SS13BN26 rats	30049682
22081	Rat	rno-miR-214-3p	miRNA	hypoxia	pulmonary hypertension (PH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	upregulated	31373336
22082	Rat	rno-miR-214-3p	miRNA	tetramethylpyrazine (TMP)	spinal cord injury (SCI)	SCI Sprague-Dawley rats spinal cord	TMP treatment	downregulated	28802236
22083	Rat	rno-miR-214-3p	miRNA	escitalopram	stress-induced depression	nucleus accumbens (NAc) tissues	Escitalopram treatment	dysregulated	31856805
22084	Rat	rno-miR-214-5p	miRNA	hypoxia	myocardial injury	H9c2 cells	hypoxia exposure	LncRNA RMRP accelerates hypoxia-induced injury by targeting miR-214-5p in H9c2 cells.	31839421
22085	Rat	rno-miR-214-5p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	downregulated	32864001
22086	Rat	rno-miR-215	miRNA	doxorubicin (DOX)	cardiac injury	?rat heart	doxorubicin treatment	upregulated	22859947
22087	Rat	rno-miR-215	miRNA	connective tissue growth factor (CTGF)	gastric cancer (GC)	NRK-52E cells	CTGF treatment	downregulated	20393144
22088	Rat	rno-miR-215	miRNA	TGF-¦Â	gastric cancer (GC)	NRK-52E cells	TGF-¦Â treatment	downregulated	20393144
22089	Rat	rno-miR-215	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	downregulated	27535721
22090	Rat	rno-miR-215	miRNA	fish oil and pectin	colorectal cancer (CRC)	colon tissue of rats	corn oil ¡À fish oil with pectin ¡À cellulose	upregulated	21406606
22091	Rat	rno-miR-215	miRNA	citrulline	gastrointestinal toxicity	rats	citrulline treatment	"Fecal miR-215 levels upregulated, and plasma miR-215 downregulatedd"	27189632
22092	Rat	rno-miR-215	miRNA	high fat diet (HFD)	hepatic insulin resistance	liver tissues	high fat diet (HFD) feed	upregulated	30896868
22093	Rat	rno-miR-215	miRNA	ethanol (EtOH)	oxidative stress	rat normal hepatocyte (BRL)	ethanol treatment	upregulated	23905774
22094	Rat	rno-miR-215	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	downregulated	21094214
22095	Rat	rno-miR-215	miRNA	Jianpi Xiaoke (JPXK)	type 2 diabetes mellitus (T2DM)	rat	Jianpi Xiaoke (JPXK) treatment	downregulated	33456489
22096	Rat	rno-miR-215-5p	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	MiR-215-5p was overtly downregulated in LPS-treated H9c2 cells.	31806569
22097	Rat	rno-miR-21-5p	miRNA	cadmium (Cd)	cadmium (Cd)-induced kidney injury	renal cortex	cadmium (Cd) treatment	upregulated	29543730
22098	Rat	rno-miR-21-5p	miRNA	rapamycin	cardiac fibrosis	heart tissues	rapamycin (Rap) treatment	upregulated	30647817
22099	Rat	rno-miR-21-5p	miRNA	hypoxia	cardiac injury	Rat H9C2 cells and isolated primary cardiomyocytes	hypoxia induce	downregulated	31782491
22100	Rat	rno-miR-21-5p	miRNA	prostaglandin E1 (PGE1)	cardiac injury	hypoxia/reoxygenation (H/R)-induced?rat H9C2 cells and isolated primary cardiomyocytes	Prostaglandin-E1 (PGE1) treatment	upregulated	31782491
22101	Rat	rno-miR-21-5p	miRNA	high glucose (HG)	diabetes mellitus-induced erectile dysfunction (DMED)	corpus cavernosum smooth muscle cells (CCSMCs)	high glucose (HG) treatment	downregulated	32808325
22102	Rat	rno-miR-21-5p	miRNA	allylamine (AAM)	drug-induced cardiac injury (DICI)	heart tissues	allylamine treatment	upregulated	29355689
22103	Rat	rno-miR-21-5p	miRNA	isoproterenol	drug-induced cardiac injury (DICI)	heart tissues	isoproterenol treatment	upregulated	29355689
22104	Rat	rno-miR-21-5p	miRNA	atorvastatin	endothelial senescence	high-fat diet-induced hyperlipidemic rats plasma	atorvastatin treatment	downregulated	29248491
22105	Rat	rno-miR-21-5p	miRNA	high fat diet (HFD)	endothelial senescence	plasma	high fat diet (HFD) feed	upregulated	29248491
22106	Rat	rno-miR-21-5p	miRNA	kainic acid (KA)	epilepsy	hippocampus	kainic acid treatment	upregulated	29751355
22107	Rat	rno-miR-21-5p	miRNA	lithium chloride and pilocarpine	epilepsy	hippocampal neuron	lithium chloride and pilocarpine induce	"?FTX is notably reduced in the hippocampus of SE rat model. Moreover, the in?vivo overexpression of FTX inhibited SE-induced hippocampus neuron apoptosis."	30871773
22108	Rat	rno-miR-21-5p	miRNA	melatonin	fibroblast-myofibroblast transdifferentiation (FMT)	NRK-49F cells	Melatonin treatment	Melatonin remarkably attenuated the expression of miR-21-5p.	32243691
22109	Rat	rno-miR-21-5p	miRNA	perfluorooctane sulfonic acid (PFOS)	hepatotoxicity	liver tissues	Perfluorooctanesulfonate (PFOS) treatment	downregulated	26724606
22110	Rat	rno-miR-21-5p	miRNA	high fat diet (HFD)	hyperlipidemia	rats plasma	high fat diet (HFD) feed	upregulated	29248491
22111	Rat	rno-miR-21-5p	miRNA	H2O2	hyperoxia-induced acute lung injury (HALI)	rat type II alveolar epithelial cells (AECII)	hydrogen peroxide (H2O2) treatment	downregulated	29436647
22112	Rat	rno-miR-21-5p	miRNA	perfluorooctane sulfonic acid (PFOS)	liver damage	liver tissues	Perfluorooctanesulfonate (PFOS) treatment	downregulated	26724606
22113	Rat	rno-miR-21-5p	miRNA	steroids	osteonecrosis of femoral head (ONFH)	serum	steroid treatment	upregulated	29887962
22114	Rat	rno-miR-21-5p	miRNA	bortezomib	peripheral neuropathy	PC12 cells	bortezomib treatment	downregulated	31979371
22115	Rat	rno-miR-21-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22116	Rat	rno-miR-21-5p	miRNA	glucocorticoid (GC)	steroid-induced osteonecrosis of femoral head (ONFH)	bone marrow-derived mesenchymal stem cells (BMSCs)	Glucocorticoid (GC)? treatment	"We found that CircPVT1 was decreased in the femoral head of SIONFH rats and GC-treated BMSCs, while miR-21-5p was markedly upregulated."	33733589
22117	Rat	rno-miR-216a	miRNA	TGF-¦Â	acute pancreatitis (AP)	AR42J cells	TGF-¦Â treatment	upregulated	25501921
22118	Rat	rno-miR-216a	miRNA	cerulein or cyanohydroxybutene (CHB)	exocrine pancreatic injury (EPIJ)	serum	cerulein or cyanohydroxybutene (CHB) treatment	upregulated	24285669
22119	Rat	rno-miR-216a	miRNA	cerulein or cyanohydroxybutene (CHB)	exocrine pancreatic injury (EPIJ)	serum	rats were administered cerulein or CHB to induce EPIJ treatment	upregulated	24285669
22120	Rat	rno-miR-216a	miRNA	TGF-¦Â	liver cirrhosis	Rat pluripotent LPC-like WB-F344 cells	Hepatic transforming growth factor beta?treatment treatment	TGF-¦Â-induced Akt activation and LPC transformation was mediated by microRNA-216a-modulated phosphatase and tensin homolog deleted on chromosome 10 (PTEN) suppression	22898879
22121	Rat	rno-miR-216a	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	NRK-52E cells	Transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	31378905
22122	Rat	rno-miR-216a	miRNA	yttrium aluminium garnet (YAG) laser	retinal injury	retinal tissue	yttrium aluminium garnet (YAG) laser treatment	downregulated	30541958
22123	Rat	rno-miR-216a-5p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	rat retinal	streptozotocin (STZ)-induced diabetic rat treatment	differential expressions	24502381
22124	Rat	rno-miR-216a-5p	miRNA	ginsenoside Rg1	spinal cord injury (SCI)	H2O2-treated PC-12 cell	Ginsenoside Rg1 treatment	upregulated	31605711
22125	Rat	rno-miR-216a-5p	miRNA	H2O2	spinal cord injury (SCI)	PC-12 cell	H2O2 treatment	downregulated	31605711
22126	Rat	rno-miR-216b	miRNA	doxorubicin (DOX)	cardiac injury	?rat heart	doxorubicin treatment	upregulated	22859947
22127	Rat	rno-miR-216b-5p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	upregulated	32893733
22128	Rat	rno-miR-217	miRNA	streptozocin (STZ)	atherosclerosis (AS)	aortic	streptozocin (STZ) treatment	downregulated	33283391
22129	Rat	rno-miR-217	miRNA	silk ascending aorta proximal	cardiac hypertrophy	Sprague Dawley rats cardiomyocytes	silk suture was tightened around the ascending aorta proximal to the brachiocephalic trunk treatment	downregulated in cardiomyocytes	27893464
22130	Rat	rno-miR-217	miRNA	lipopolysaccharide (LPS)	cell differentiation	differentiated BM-MSCs	lipopolysaccharide (LPS) treatment	"In hepatocytes differentiated from BM-MSCs, miR-217 was downregulated and lncRNA MALAT1 was upregulated. RIP analysis showed MALAT1 was physically associated with miR-217 and might function in the regulation of ZEB-1, further enhancing the expression of TERT so as to augment telomerase activity."	30658864
22131	Rat	rno-miR-217	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Primary rat cerebral cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31173187
22132	Rat	rno-miR-217	miRNA	streptozocin (STZ)	diabetic foot ulcer (DFU)	serum	streptozotocin (STZ) treatment	upregulated	31079353
22133	Rat	rno-miR-217	miRNA	carbon tetrachloride (CCl4)	liver damage	hepatocytes	carbon tetrachloride (CCl4) treatment	upregulated	30417525
22134	Rat	rno-miR-217	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	The expression of miR-217 was significantly decreased after hypoxia treatment.	30843674
22135	Rat	rno-miR-217-5p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	upregulated	32893733
22136	Rat	rno-miR-218	miRNA	bleomycin and IgG IC	acute lung injury (ALI)	lung tissues	bleomycin and IgG IC treatment	MicroRNA-218 was significantly downregulated in bleomycin and IgG IC-induced lung injury rat model.	30556885
22137	Rat	rno-miR-218	miRNA	homocysteine (Hcy)	coronary artery disease (CAD)	cardiac microvascular endothelial cells (CMECs)	homocysteine (HCY) treatment	downregulated	31566720
22138	Rat	rno-miR-218	miRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E cells	high glucose (HG) treatment	downregulated	33615661
22139	Rat	rno-miR-218	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	downregulated	31549412
22140	Rat	rno-miR-218	miRNA	mixture of oleate and palmitate	nonalcoholic steatohepatitis (NASH)	BRL-3A cells	mixture of oleate and palmitate treatment	downregulated	31850710
22141	Rat	rno-miR-218	miRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	dysregulated	24517225
22142	Rat	rno-miR-218	miRNA	N-3 polyunsaturated fatty acids (PUFA)	post-menopausal depression	brain tissues	N-3 polyunsaturated fatty acids (PUFA) treatment	"N-3 PUFA decreased blood levels of adrenocorticotropic hormone and corticosterone, and brain expressions of corticotropin-releasing factor and miRNA-218, which increased the expression of the glucocorticoid receptor. N-3 PUFA decreased the expression of tumor necrosis factor-¦Á, interleukin (IL)-6, IL-1¦Â, and prostaglandin E2, while increased the expression of miRNA-155."	33548474
22143	Rat	rno-miR-218	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	spinal cord injury (SCI)	astrocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	CCAT1 Protects Astrocytes Against OGD/R-Induced Damage by Targeting the miR-218/NFAT5-Signaling Axis	32239388
22144	Rat	rno-miR-218-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute ischemic stroke (AIS)	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-218-5p level was notably increased in OGD/R injured PC12 cells	32048632
22145	Rat	rno-miR-218a-2-3p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	downregulated	28560399
22146	Rat	rno-miR-218a-5p	miRNA	emodin	intestinal dysfunction	intestinal tract	Emodin treatment	emodin reduced the expression of miR-218a-5p in the intestinal tract.	32664763
22147	Rat	rno-miR-218a-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22148	Rat	rno-miR-218b	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	kidney?tissues	OTA nephrotoxicity treatment	suppressed in mid dose but then elevated in high dose	24885635
22149	Rat	rno-mir-218b	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22150	Rat	rno-miR-219	miRNA	angiotensin II (Ang II)	liver fibrosis	Hepatic stellate cells (HSCs)	angiotensin II (Ang II) treatment	downregulated	30592264
22151	Rat	rno-miR-219-2-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	downregulated	22156553
22152	Rat	rno-miR-219-5p	miRNA	hypoxia	congenital heart disease (CHD)	H9C2 cells	hypoxia induce	The data showed that miR-219-5p expression was higher in patients with cyanotic CHD compared with patients with acyanotic CHD gradually increased in H9C2 cells with prolonged hypoxia time.	33262822
22153	Rat	rno-miR-219-5p	miRNA	morphine	morphine tolerance	spinal cord of rats	10 ¦Ìg morphine sulfate (in a volume of 10 ¦ÌL) was delivered via an intrathecal catheter twice daily for 7 d	downregulated in spinal cord of rats	28423675
22154	Rat	rno-miR-219-5p	miRNA	pulsed electromagnetic field (PEMF)	spinal cord injury (SCI)	primary oligodendrocyte precursor cells (OPCs)	?low frequency pulsed electromagnetic field (PEMF)?treatment treatment	upregulated	30885522
22155	Rat	rno-miR-219-5p	miRNA	acute stress (AS) and chronic stress (CS)	stress-induced myocardial injury	rat	Rats were bound and suspended treatment	upregulated	24669248
22156	Rat	rno-miR-219a-1-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22157	Rat	rno-miR-219a-2-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	inflammation	primary brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"?In particular, the expression levels of rno-miR-666-3p, rno-miR-92a-2-5p, and rno-miR-219a-2-3p decreased in OGD/R-exposed cells compared with those in the control"	33745435
22158	Rat	rno-miR-219a-2-3p	miRNA	insulin-like growth factor 1 (IGF-1)	spinal cord injury (SCI)	Neural stem cells were obtained from E15 fetal rat cerebral cortex cultured supernatant exosomes	insulin growth factor-1 (IFG-1) treatment	upregulated	31848325
22159	Rat	rno-miR-219a-5p	miRNA	ethanol (EtOH)	chronic alcoholic liver disease (ALD)	liver tissues	Ethanol exposure	downregulated	31428222
22160	Rat	rno-miR-219a-5p	miRNA	protocatechuic acid (PCA)	chronic alcoholic liver disease (ALD)	liver tissues	Protocatechuic acid (PCA) treatment	upregulated	31428222
22161	Rat	rno-miR-219a-5p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	nucleus accumbens (NAc) was isolated from rat whole brain	methamphetamine (METH) self-administration (SA)	upregulated	30867225
22162	Rat	rno-miR-219a-5p	miRNA	electroacupuncture (EA)	spinal cord injury (SCI)	spinal cords	electroacupuncture (EA) treatment	downregulated	32468009
22163	Rat	rno-miR-22	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	hippocampus	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	30672441
22164	Rat	rno-miR-22	miRNA	caerulein (Cae)	apoptosis	AR42J cells	caerulein (Cae) treatment	upregulated	30568389
22165	Rat	rno-miR-22	miRNA	angiotensin II (Ang II)	cardiac fibrosis	neonatal rat cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	upregulated	29486470
22166	Rat	rno-miR-22	miRNA	2-acetylaminofluorene	hepatocellular carcinoma (HCC)	liver tissue of rats	2-acetylaminofluorene treatment	downregulated	22213190
22167	Rat	rno-miR-22	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
22168	Rat	rno-miR-22	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	hypoxic-ischemic encephalopathy (HIE)	neural stem cells (NSCs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32052645
22169	Rat	rno-miR-22	miRNA	ionizing radiation (IR)	ionizing radiation (IR) injury	Bone marrow mesenchymal stromal cells (BMSCs)	"The cells were subjected to IR (electrons) using 6 MeV (Precise Treatment System, Elekta, Sweden) at a dosage of 6 Gy and a dose rate of 600 Mu."	upregulated	30846680
22170	Rat	rno-miR-22	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-22 expression was significantly downregulated in the PC12 cells subjected to I/R.	32065044
22171	Rat	rno-miR-22	miRNA	ischemia/reperfusion (I/R) 	ischemia/reperfusion (I/R) injury	myocardial in rats	ischemia/reperfusion (I/R) treatment	upregulated	24338162
22172	Rat	rno-miR-22	miRNA	hypoxia/reoxygenation (H/R)	ischemic heart disease (IHD)	Neonatal rat ventricular cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	downregulated	26707060
22173	Rat	rno-miR-22	miRNA	starvation	ischemic heart disease (IHD)	cardiomyocytes (NRCMs)	starvation treatment	downregulated	27544030
22174	Rat	rno-miR-22	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	PC12 cells (a rat pheochromocytoma cell line)	oxygen glucose deprivation (OGD) treatment	downregulated	31115561
22175	Rat	rno-miR-22	miRNA	angelica polysaccharide (AP)	myocardial infarction (MI)	H9c2 cells	angelica polysaccharide (AP) treatment	ASP pretreatment attenuated hypoxia-induced H9c2 cell injury.	29960169
22176	Rat	rno-miR-22	miRNA	hypoxia	myocardial infarction (MI)	Primary neonatal rat ventricular cardiomyocytes (PNCM) and H9C2 cells	hypoxia induce	upregulated	31581847
22177	Rat	rno-miR-22	miRNA	lentinan (LNT)	myocardial infarction (MI)	hypoxia-induced primary neonatal rat ventricular cardiomyocytes (PNCM) and H9C2 cells	Lentinan (LEN) treatment	downregulated	31581847
22178	Rat	rno-miR-22	miRNA	curcumin (Cur)	neointimal hyperplasia	vascular smooth muscle cells (VSMC)	curcumin treatment	Curcumin increased the expression of miR-22.	32631202
22179	Rat	rno-miR-22	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22180	Rat	rno-miR-22	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	PC12 cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	27631550
22181	Rat	rno-miR-22	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
22182	Rat	rno-miR-22	miRNA	high glucose (HG)	renal tubulointerstitial fibrosis (TIF)	NRK-52E cells	high glucose (HG) treatment	upregulated	29850604
22183	Rat	rno-miR-22	miRNA	streptozocin (STZ)	renal tubulointerstitial fibrosis (TIF)	renal Tissues	streptozocin (STZ) treatment	upregulated	29850604
22184	Rat	rno-mir-22	miRNA	hypoxia/reoxygenation (H/R)	reperfusion injury	rat cardiomyocytes;	hypoxia and hypoxia-reoxygenation treatment	upregulated	32826883
22185	Rat	rno-miR-22	miRNA	escherichia coli (E.coli)	sepsis-induced acute kidney injury	kidney tissues	Escherichia coli infection	"TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway."	30666657
22186	Rat	rno-miR-22	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
22187	Rat	rno-miR-22	miRNA	scratch	traumatic brain injury (TBI)	neuronal cell	scratch treatment	downregulated	27186313
22188	Rat	rno-miR-22	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	upregulated	22847192
22189	Rat	rno-miR-221	miRNA	TGF-¦Â	adaptation of tendons to mechanical loading	rat Tendon fibroblasts	Transforming growth factor-¦Â(TGF-¦Â) treatment	upregulated	22539168
22190	Rat	rno-miR-221	miRNA	nicotine	allergic asthma (AA)	lung tissues	nicotine injections	upregulated	28381639
22191	Rat	rno-miR-221	miRNA	L©\arginine	atherosclerosis (AS)	endothelial cells	L-Arginine treatment	L-Arginine Ameliorates High-Fat Diet-Induced Atherosclerosis by Downregulating miR-221.	32090093
22192	Rat	rno-miR-221	miRNA	TGF-¦Â1	bladder cancer	Human bladder cancer cell lines (RT4 and T24)	TGF-¦Â1 treatment	upregulated	25928257
22193	Rat	rno-miR-221	miRNA	N-methyl-N-nitrosourea (MNU)	breast cancer	rats with experimental breast cancer Thoracic Duct Lymph	N-Methyl-N-Nitrosourea	dysregulatedin Thoracic Duct Lymph	28091921
22194	Rat	rno-miR-221	miRNA	hydrogen sulfide (H2S)	cardiac fibrosis	thyroxine-induced rats myocardial tissues	Hydrogen sulfide (H2S) treatment	upregulated	29743447
22195	Rat	rno-miR-221	miRNA	thyroxine	cardiac fibrosis	myocardial tissues	thyroxine treatment	downregulated	29743447
22196	Rat	rno-miR-221	miRNA	ischemia	chronic constriction injury	rat spinal cord	ligation of the sciatic nerve treatment	"The expression levels of a large number of miRNAs in the dorsal horn of the spinal cord in CCI rats changed (miR-500, -221 and -21)"	23124577
22197	Rat	rno-miR-221	miRNA	mitomycin C-polylactic acid ( MMC-PLA) film	epidural scar hyperplasia and adhesion	post-laminectomy rat scar tissues	25 mg of PLA film containing 0.01% MMC was implanted on the laminectomy area	downregulated	28617531
22198	Rat	rno-miR-221	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	rat INS-1?cell	high glucose (HG) treatment	downregulated	31587871
22199	Rat	rno-miR-221	miRNA	diethylnitrosamine (DEN)	hepatocellular carcinoma (HCC)	liver tissues and HepG2 cells	diethylnitrosamine (DEN) treatment	upregulated	31801250
22200	Rat	rno-miR-221	miRNA	oroxin B (OB)	hepatocellular carcinoma (HCC)	DEN-treated liver tissues and HepG2 cells	Oroxin B (OB) treatment	downregulated	31801250
22201	Rat	rno-miR-221	miRNA	overfeeding	insulin resistance (IR)	liver tissues	overfeeding treatment	Overfeeding induces hepatic miR-221 expression.	32305038
22202	Rat	rno-miR-221	miRNA	"DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane), benzo[a]pyrene (BP), and 3-methylcholanthrene (MC)"	post-transcriptional regulation	?the livers and ovaries of chemically induced rats	"DDT, benzo[a]pyrene (BP), and 3-methylcholanthrene (MC) treatment"	downregulated	24727239
22203	Rat	rno-miR-221	miRNA	propofol (PPF)	mast cell degranulation	RBL-2H3 cells	Propofol treatment	Propofol inhibited miR-221 expression in a dose-dependent manner	30116391
22204	Rat	rno-miR-221	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	H9c2 and rat cardiac fibroblast (cFB)	hypoxia and reoxygenation (H/R) induce	downregulated	31261033
22205	Rat	rno-miR-221	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	"?miR-221 was negatively regulated by lncRNA CHRF. LncRNA CHRF silence did not protect H9c2 cells against LPS when miR-221 was suppressed. Also, the inhibitory effects of lncRNA CHRF silence on the activation of NF-¦ÊB and JNK pathways were flattened by miR-221 suppression."	30695715
22206	Rat	rno-miR-221	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	spinal cord and the isolated microglia	chronic constrictive injury (CCI) treatment	upregulated	27059231
22207	Rat	rno-miR-221	miRNA	estradiol	obesity	high fat (HF) diet-induced obesity rats liver tissues	estradiol treatment	upregulated	29957877
22208	Rat	rno-miR-221	miRNA	postnatal overfeeding	obesity	rat liver tissue	postnatal overfeeding treatment	We first report postnatal overfeeding induces hepatic miR-221 expression	32305038
22209	Rat	rno-miR-221	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22210	Rat	rno-miR-221	miRNA	cadmium (Cd)	ovary structure and function	Wistar rats	cadmium (Cd) treatment	upregulated	24462979
22211	Rat	rno-miR-221	miRNA	estradiol-17¦Â (E2)	oxidative stress	liver tissues	estradiol-17¦Â (E2) treatment	downregulated	30574741
22212	Rat	rno-miR-221	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	PC12 cells	6-hydroxydopamine (6-OHDA) treatment	miRNA-221 is significantly lower in 6-OHDA treated PC12 pheochromocytoma cells compared to the normal cells.	29405726
22213	Rat	rno-miR-221	miRNA	crocin	parkinson's disease (PD)	striatal tissueS	crocin treatment	Crocin upregulated the expression of miRNA-221.	31811872
22214	Rat	rno-miR-221	miRNA	rotenone (ROT)	parkinson's disease (PD)	striatal tissueS	rotenone (ROT) treatment	miRNA-221 was significantly repressed upon ROT treatment	31811872
22215	Rat	rno-miR-221	miRNA	rotenone (ROT)	parkinson's disease (PD)	striatal tissueS	rotenone (ROT) treatment	miRNA-7 was significantly repressed upon ROT treatment	31811872
22216	Rat	rno-miR-221	miRNA	angiotensin II (Ang II)	renal fibrosis	rat kidney interstitial fibroblast (NRK-49F) cells	angiotensin II (Ang II) treatment	upregulated	25228106
22217	Rat	rno-miR-221	miRNA	hypoxia	stroke	rat brain tissues	Transient focal ischemia was induced by intraluminal occlusion of the right Middle cerebral artery occlusion (MCAO)	"GAS5 was upregulated in MCAO rats and in vitro hypoxia cell model while miR-221 expression was decreased in vitro hypoxia cell model. GAS5 promoted cells apoptosis, while miR-221 inhibited cell apoptosis through regulation of PUMA and downstream JNK/H2AX signaling."	31878844
22218	Rat	rno-miR-221-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	myocardium	high glucose (HG) treatment	upregulated	33313941
22219	Rat	rno-miR-221-3p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose (HG) treatment	"GAS5 downregulated high blood glucose concentrations in STZ-induced diabetic rats, however its expression levels decreased in both HG-processed H9C2 cells and the myocardium of DM model rats."	33313941
22220	Rat	rno-miR-221-3p	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	myocardium	streptozotocin (STZ) treatment	upregulated	33313941
22221	Rat	rno-miR-221-3p	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	H9c2 cells	streptozotocin (STZ) treatment	"GAS5 downregulated high blood glucose concentrations in STZ-induced diabetic rats, however its expression levels decreased in both HG-processed H9C2 cells and the myocardium of DM model rats"	33313941
22222	Rat	rno-miR-221-3p	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H2O2 treatment	The expression of miR-221-3p was elevated in H2O2-incubated cells.	29693157
22223	Rat	rno-miR-2218	miRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
22224	Rat	rno-miR-222	miRNA	TGF-¦Â	adaptation of tendons to mechanical loading	rat Tendon fibroblasts	Transforming growth factor-¦Â(TGF-¦Â) treatment	upregulated	22539168
22225	Rat	rno-miR-222	miRNA	N-methyl-N-nitrosourea (MNU)	breast cancer	rats with experimental breast cancer Thoracic Duct Lymph	N-Methyl-N-Nitrosourea	dysregulatedin Thoracic Duct Lymph	28091921
22226	Rat	rno-miR-222	miRNA	"DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane), benzo[a]pyrene (BP), and 3-methylcholanthrene (MC)"	post-transcriptional regulation	?the livers and ovaries of chemically induced rats	"DDT, benzo[a]pyrene (BP), and 3-methylcholanthrene (MC) treatment"	downregulated	24727239
22227	Rat	rno-miR-222	miRNA	nickel	muscle tumor	rat muscle tumor tissue	nickel treatment	upregulated	23447020
22228	Rat	rno-miR-222	miRNA	cadmium (Cd)	ovary structure and function	Wistar rats	cadmium (Cd) treatment	upregulated	24462979
22229	Rat	rno-miR-222	miRNA	activated protein C(APC)	sepsis	rats blood and liver tissue	activated protein C treatment	aPC treatment coordinates beneficial cytoprotective effects during sepsis by modulating miRNA expression	22940033
22230	Rat	rno-miR-222	miRNA	"high concentrations of lipid and glucose, and cytokines"	vascular hyper-reactivity	VSMC	"incubat high glucose (25mmol/L) or lipid (palmitic acid 50 ¦Ì mol/L) and 200ng/ml of TNF-¦Á,IL-1¦Â and IL-6 for 27h treatment"	downregulated	25425000
22231	Rat	rno-miR-222-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary microglial cells	lipopolysaccharide (LPS) treatment	"We revealed that LncRNA LEF1-AS1 was distinctly upregulated, whereas miR-222-5p was significantly downregulated in LPS-treated SCI and microglial cells."	33407665
22232	Rat	rno-miR-223	miRNA	TGF-¦Â1	asthma	airway smooth muscle cells (ASMCs)	TGF-¦Â1 treatment	TGF-¦Â1 stimulation lowers the expression of miR-223.	29636864
22233	Rat	rno-miR-223	miRNA	paeonol (PAE)	atherosclerosis (AS)	plasma-derived exosome	Paeonol (Pae) treatment	Pae-exo successfully increased the expression of exosomal miR-223 and relieved inflammatory secretion	32800809
22234	Rat	rno-miR-223	miRNA	phenylephrine (PE)	cardiac hypertrophy	neonatal rat cardiomyocytes (NRCs)	phenylephrine (PE) treatment	downregulated	29110214
22235	Rat	rno-miR-223	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-223 was significantly over-expressed after OGD/R treatment	29663740
22236	Rat	rno-miR-223	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	rat colon Epithelial cells	azoxymethane (AOM) treatment	"Of the 27 miRNAs expressed at higher (P < 0.05) levels in tumors, miR-34a, 132, 223 and 224 were overexpressed at >10-fold. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (?0.32-fold) in adenocarcinomas."	19825969
22237	Rat	rno-miR-223	miRNA	heat stress	febrile seizure (FS)	hippocampus tissues	hot water-bath induce	downregulated	30947016
22238	Rat	rno-mir-223	miRNA	phenylephrine (PE)	hypertrophy	neonatal rat cardiomyocytes (HNRCs)	phenylephrine (PE) treatment	downregulated	29110214
22239	Rat	rno-miR-223	miRNA	lipopolysaccharide (LPS)	inflammation	Isolated rat nucleus pulposus (NP) cells	lipopolysaccharide (LPS) treatment	downregulated	29707878
22240	Rat	rno-miR-223	miRNA	ischemic brain extract (IBE)	ischemic injury	"C6 rat astrocytoma cells, and primary rat MSCc (rMSCs)"	IBE treatment	upregulated	24999035
22241	Rat	rno-miR-223	miRNA	electroacupuncture (EA)	ischemic stroke (IS)	subventricular zone (SVZ) and hippocampus tissues	electroacupuncture (EA) treatment	upregulated	31883264
22242	Rat	rno-miR-223	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	primary cortical neuron culture	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	FGD5-AS1 may protect the neuron against OGD/R injury via acting as a ceRNA for miR-223 to mediate IGF1R expression	32337949
22243	Rat	rno-miR-223	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	upregulated	29608885
22244	Rat	rno-miR-223	miRNA	TGF-¦Â1	myocardial infarction (MI)	Cultured cardiac fibroblasts (CFs)	TGF-¦Â1 treatment	upregulated	29689569
22245	Rat	rno-miR-223	miRNA	emodin	myocarditis	LPS-treated H9c2 cells	Emodin treatment	downregulated	30745529
22246	Rat	rno-miR-223	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	upregulated	30745529
22247	Rat	rno-miR-223	miRNA	2-methoxyestradiol (2-Me)	obstructive sleep apnea (OSA)	pulmonary artery smooth muscle cells (PASMCs); lung tissues	2-methoxyestradiol (2-Me) treatment	"Chronic intermittent hypoxia (CIH) decreased the expression of miR-223, whereas 2-Me reversed the downregulated of miR-223 both in vivo and in vitro."	30246291
22248	Rat	rno-miR-223	miRNA	2-methoxyestradiol (2-Me)	pulmonary hypertension (PH)	Chronic intermittent hypoxia (CIH) model rat lung tissues	2-methoxyestradiol (2-Me) treatment	upregulated	30246291
22249	Rat	rno-miR-223	miRNA	hypoxia	pulmonary hypertension (PH)	lung tissues	Chronic intermittent hypoxia (CIH) induce	downregulated	30246291
22250	Rat	rno-miR-223	miRNA	X-rays	radiation-induced skin injury	rats irradiated skin	45-Gy electron beam treatment	upregulated	24447893
22251	Rat	rno-miR-223	miRNA	lipopolysaccharide (LPS)	septic shock	Wistar rats serum	LPS (10 mg/kg) treatment	upregulated	24915805
22252	Rat	rno-miR-223	miRNA	angelica polysaccharide (AP)	spinal cord injury (SCI)	PC-12 cells	angelica polysaccharide (AP) treatment	AP pre-treatment attenuated LPS-induced miR-223 expression level increase in PC-12 cells.	30372834
22253	Rat	rno-miR-223	miRNA	electroacupuncture (EA)	stroke	cortex tissues	Electroacupuncture (EA) treatment	upregulated	31237865
22254	Rat	rno-miR-223	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	colon tissues	dextran sulfate sodium (DSS) treatment	upregulated	31210320
22255	Rat	rno-miR-223	miRNA	methylglyoxal (MGO)	vascular tones	A10 cells	methylglyoxal (MGO) treatment	miR-223 expression in the cultured SMCs after 300 ¦ÌM MGO exposure by 5-6 folds.	32151743
22256	Rat	rno-miR-223	miRNA	naringenin	spinal cord injury (SCI)	spinal cords	Naringenin (NR)treatment	downregulated	27432064
22257	Rat	rno-miR-223-3p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31899128
22258	Rat	rno-miR-223-3p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
22259	Rat	rno-miR-223-3p	miRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cells	hypoxia induce	upregulated	30336138
22260	Rat	rno-miR-223-3p	miRNA	sevoflurane (SEV)	learning and memory deficits	rat neuron cells	sevoflurane (SEVO) treatment	upregulated	31450504
22261	Rat	rno-miR-223-3p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30507047
22262	Rat	rno-miR-223-3p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	primary rat pulmonary arterial smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30507047
22263	Rat	rno-miR-223-3p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	pulmonary artery;right ventricle	monocrotaline (MCT) treatment	downregulated	30507047
22264	Rat	rno-miR-223-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22265	Rat	rno-miR-223-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22266	Rat	rno-miR-22-3p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	upregulated	27535721
22267	Rat	rno-miR-22-3p	miRNA	gastrodin (GAS)	cerebral ischemia/reperfusion (I/R) injury	OGD/R-treated rat primary cortical neurons	gastrodin (GAS) treatment	upregulated	33839999
22268	Rat	rno-miR-22-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	Rat primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33839999
22269	Rat	rno-miR-22-3p	miRNA	berberine (BBR)	hepatocellular carcinoma (HCC)	HepG2 cells	berberine (BBR) treatment	upregulated	27904693
22270	Rat	rno-miR-22-3p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	downregulated	27919821
22271	Rat	rno-miR-22-3p	miRNA	resveratrol	pulmonary embolism	pulmonary embolism (PE) induced heart tissues	resveratrol (Res) treatment	upregulated	31573048
22272	Rat	rno-miR-22-3p	miRNA	angiotensin II (Ang II)	thoracic aortic aneurysm (TAA)	thoracic aorta	angiotensin II (Ang II) treatment	The expression of miR-22-3p in Ang II group was significantly lower than that in the normal group.	32633388
22273	Rat	rno-miR-224	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	rat colon Epithelial cells	azoxymethane (AOM) treatment	"Of the 27 miRNAs expressed at higher (P < 0.05) levels in tumors, miR-34a, 132, 223 and 224 were overexpressed at >10-fold. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (?0.32-fold) in adenocarcinomas."	19825969
22274	Rat	rno-miR-224	miRNA	furan	hepatotoxicity	liver	Furan treatment	upregulated	27371368
22275	Rat	rno-miR-224	miRNA	lead acetate (PbAc)	lead (Pb) acetate-induced thyrotoxicity	thyroid tissues	lead (Pb) exposure	upregulated	29665650
22276	Rat	rno-miR-224	miRNA	selenium nanoparticles (SeNPs)	lead (Pb) acetate-induced thyrotoxicity	lead (Pb) acetate-exposured rats thyroid tissues	Selenium nanoparticles (Se-NPs) treatment	downregulated	29665650
22277	Rat	rno-miR-224-5p	miRNA	cadmium (Cd)	cadmium (Cd)-induced kidney injury	renal cortex	cadmium (Cd) treatment	upregulated	29543730
22278	Rat	rno-miR-224-5p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	hypothyroidism	liver tissues and H4-II-E cells	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	downregulated	31901531
22279	Rat	rno-miR-224-5p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	hypothyroidism	H4-II-E cells	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	rno-miR-224-5p level was decreased by BDE47 in a dose-dependent manner.	31901531
22280	Rat	rno-miR-224-5p	miRNA	glucocorticoid (GC)	osteonecrosis of femoral head (ONFH)	rat bone marrow stromal stem cells (BMSCs)	glucocorticoids (GCs) treatment	"In the present study, we demonstrated that miR-224-5p was upregulated in GC-treated BMSCs"	33453444
22281	Rat	rno-miR-224-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
22282	Rat	rno-miR-22-5p	miRNA	pirarubicin (THP)	cardiomyocytes injury	rat cardiomyocytes	pirarubicin (THP) treatment	"In this study, we developed an microRNA (miRNA) chip by replicating the rat model of THP-induced myocardial injury and identified miR-22-5p and the RAP1-member of RAS oncogene family/extracellular regulated protein kinases (RAP1/ERK) signaling pathway as an object of study"	32864822
22283	Rat	rno-miR-22-5p	miRNA	rutin (RUT)	cardiomyocytes injury	rat cardiomyocytes	rutin (RUT) treatment	"In this study, we developed an microRNA (miRNA) chip by replicating the rat model of THP-induced myocardial injury and identified miR-22-5p and the RAP1-member of RAS oncogene family/extracellular regulated protein kinases (RAP1/ERK) signaling pathway as an object of study"	32864822
22284	Rat	rno-miR-22-5p	miRNA	rutin (RUT)	pirarubicin (THP)-induced myocardial damage	myocardial tissues	rutin (RUT) treatment	"RUT significantly improved THP-induced myocardial damage , increased the expression of miR-22-5p"	32864822
22285	Rat	rno-miR-22a-3p	miRNA	"3,5-diiodo-L-thyronine (T2)"	glucose homeostasis	serum from high fat diet fed rats	"3,5-diiodo-L-thyronine (T2) treatment"	downregulated	31719576
22286	Rat	rno-miR-23	miRNA	isoflurane	oxidative stress	H9c2 cells	Isoflurane treatment	downregulated	29627934
22287	Rat	rno-miR-23a	miRNA	lipopolysaccharide (LPS)	sepsis	myocardial and kidney tissues	lipopolysaccharide (LPS) treatment	downregulated	33538509
22288	Rat	rno-miR-23a	miRNA	streptozocin (STZ)	acute diabete	rats gastrocnemius	streptozotocin treatment	downregulated	24336651
22289	Rat	rno-miR-23a	miRNA	H2O2	acute myocardial infarction (AMI)	H9c2 cells	H2O2 treatment	upregulated	29488607
22290	Rat	rno-miR-23a	miRNA	bone marrow mesenchymal stem cells (BMSCs)	apoptosis	infarcted rats myocardium	bone marrow mesenchymal stem cells (BMSCs) treatment	downregulated	28662151
22291	Rat	rno-miR-23a	miRNA	hypoxia- and serum deprivation	apoptosis	bone marrow mesenchymal stem cell- (MSC)	Hypoxia- and Serum Deprivation treatment	downregulated	21698002
22292	Rat	rno-miR-23a	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	mesenchymal stem cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	24269648
22293	Rat	rno-miR-23a	miRNA	ovalbumin (OVA)	asthma	lung tissues	OVA treatment	upregulated	31020662
22294	Rat	rno-miR-23a	miRNA	isoproterenol and aldosterone	cardiac hypertrophy	Neonatal rat cardiomyocytes	isoproterenol and aldosterone treatment	upregulated	19574461
22295	Rat	rno-miR-23a	miRNA	doxorubicin (DOX)	cardiotoxicity	primary neonatal rat ventricular myocytes (NRVMs)	Doxorubicin (DOX) treatment	upregulated	30831132
22296	Rat	rno-miR-23a	miRNA	deep hypothermic circulatory arrest	cerebral injury	rat hippocampal tissues	deep hypothermic circulatory arrest treatment	downregulated	30824348
22297	Rat	rno-miR-23a	miRNA	ginsenoside Rg1	diabetic foot ulcer (DFU)	diabetic rats?incision area and tissue	Ginsenoside Rg1 treatment	downregulated	31158376
22298	Rat	rno-miR-23a	miRNA	stimulation electrode	epilepsy	Adult male Sprague Dawley rats blood	A bipolar stimulation electrode (distance between tips 500 ?m) was implanted in the angular bundle treatment	dysregulated	24184920
22299	Rat	rno-miR-23a	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	downregulated	24304932
22300	Rat	rno-miR-23a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	Liver tissues	carbon tetrachloride (CCl4) treatment	miR-23a expression increased significantly in hepatic fibrosis tissues.	30735452
22301	Rat	rno-miR-23a	miRNA	berberine (BBR)	inflammation	LPS-treated adjuvant-induced arthritic synovial macrophages (AA-SM)	berberine (BBR) treatment	upregulated	30240693
22302	Rat	rno-miR-23a	miRNA	NQDI1 (apoptosis signal-regulating kinase 1 (ASK1) inhibitor)	inflammation	LPS-treated adjuvant-induced arthritic synovial macrophages (AA-SM)	NQDI1 treatment	upregulated	30240693
22303	Rat	rno-miR-23a	miRNA	TNF-¦Á and lipopolysaccharide (LPS)	inflammation	adjuvant-induced arthritic synovial macrophages (AA-SM)	TNF-¦Á and lipopolysaccharide (LPS) treatment	downregulated	30240693
22304	Rat	rno-miR-23a	miRNA	H2O2	ischemia/reperfusion (I/R) injury	H9c2 rat myocardial cell	H2O2	downregulated	29272015
22305	Rat	rno-miR-23a	miRNA	hypoxia	neuron apoptosis	SH-SY5Y cells	1% O2 hypoxia	upregulated	28529459
22306	Rat	rno-miR-23a	miRNA	hypoxia	neuron apoptosis	brain tissues	chronic hypobaric hypoxia rat model as well as a tissue culture model where were exposed to	upregulated	28529459
22307	Rat	rno-miR-23a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22308	Rat	rno-miR-23a-3p	miRNA	acupuncture	intracerebral haemorrhage (ICH)	brain tissues	acupuncture?treatment	Acupuncture also alleviated ferroptosis and decreased miR-23a-3p expression	33403590
22309	Rat	rno-miR-23a-3p	miRNA	long-term potentiation(LTP)	long-term potentiation (LTP) persistence	Sprague-Dawley rats Dentate Gyrus Neuropil	unilaterally at perforant path-dentate gyrus synapses	upregulated in Dentate Gyrus Neuropil	28125614
22310	Rat	rno-miR-23a-3p	miRNA	high glucose (HG)	maternal hyperglycemia	H9c2 cells	high glucose (HG) treatment	Upregulation of miRNA-23a-3p rescues high glucose-induced cell apoptosis and proliferation inhibition in cardiomyocytes	33197036
22311	Rat	rno-miR-23a-3p	miRNA	ionizing radiation (IR)	radiation-induced central nervous system toxicity	Primary cortical neurons	ionizing radiation (IR) treatment	miR-23a-3p is rapidly decreased after neuronal irradiation.	32456284
22312	Rat	rno-miR-23a-5p	miRNA	platelet-derived growth factor (PDGF)	liver fibrosis	hepatic stellate cells (HSCs)	platelet-derived growth factor (PDGF) treatment	upregulated	32306379
22313	Rat	rno-miR-23b	miRNA	lipopolysaccharide (LPS)	cardiomyopathy induced by sepsis	H9C2 cardiomyoblasts	lipopolysaccharide (LPS) treatment	upregulated	30734878
22314	Rat	rno-miR-23b	miRNA	hypoxia	congenital heart disease (CHD)	H9C2 cells	prolonged hypoxia	upregulated	29078258
22315	Rat	rno-miR-23b	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22316	Rat	rno-miR-23b	miRNA	lipopolysaccharide (LPS)	sepsis	vascular endothelial cells (VECs)	lipopolysaccharide (LPS) treatment	Endothelial microvesicles (EMVs) play an important role in pulmonary vascular leakage and lung injury during sepsis by transferring functional miR-23b.	32766250
22317	Rat	rno-miR-23b-3p	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	hippocampus tissues	streptozocin (STZ) treatment	miRNA-23b-3p expression was upregulated in cognitive impairment of diabetic rats	30282005
22318	Rat	rno-miR-23b-3p	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R)-mediated acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32558131
22319	Rat	rno-miR-23b-3p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	upregulated	26997989
22320	Rat	rno-miR-23b-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9C2 cells	angiotensin II (Ang II) treatment	upregulated	31103821
22321	Rat	rno-miR-23c	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	rats renal tubular epithelial cells	streptozotocin treatment	downregulated	27964927
22322	Rat	rno-miR-24	miRNA	hypoxia	cardiomyocyte apoptosis	acute myocardial infarction (AMI) rat myocardium	hypoxia induce	upregulated	31378912
22323	Rat	rno-miR-24	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	LPS-induced lung injury in neonatal rats and resulted in significant downregulated of miR-24 expression.	30600184
22324	Rat	rno-miR-24	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	30600184
22325	Rat	rno-miR-24	miRNA	taurolithocholic acid-3 sulfate	acute pancreatitis (AP)	rat pancreatic acinar AR42J cells	taurolithocholic acid-3 sulfate treatment	dysregulated	28849189
22326	Rat	rno-miR-24	miRNA	thyroglobulin (Tg)	cell proliferation	rat FRTL-5 thyroid cells	Tg treatment	upregulated	24479877
22327	Rat	rno-miR-24	miRNA	high-salt/low-potassium diet	cerebral and renal vascular injuries	stroke-prone spontaneously hypertensive rats	high-salt/low-potassium diet treatment	downregulated	23297375
22328	Rat	rno-miR-24	miRNA	alloxan	diabetes mellitus (DM)	plasma	alloxan treatment	downregulated	31508175
22329	Rat	rno-miR-24	miRNA	gambogic acid (GA)	diabetes mellitus (DM)	plasma	Gallic acid (GA) treatment	upregulated	31508175
22330	Rat	rno-miR-24	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	vascular smooth muscle cells (VSMCs)	high glucose (HG) treatment	downregulated	31005375
22331	Rat	rno-miR-24	miRNA	trimetazidine (TMZ)	endothelial dysfunction	plasma	Trimetazidine (TMZ) treatment	"Trimetazidine Increases Plasma MicroRNA-24 and MicroRNA-126 Levels and Improves Dyslipidemia, Inflammation and Hypotension in Diabetic Rats"	33680027
22332	Rat	rno-miR-24	miRNA	stimulation electrode	epilepsy	Adult male Sprague Dawley rats blood	A bipolar stimulation electrode (distance between tips 500 ?m) was implanted in the angular bundle treatment	dysregulated	24184920
22333	Rat	rno-miR-24	miRNA	lingguizhugan decoction (LGZG)	heart failure (HF)	heart tissues	doxorubicin (DOX)-treated rats	downregulated	31829159
22334	Rat	rno-miR-24	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	H/R exposure decreased the expression of miR-24 in rat cardiomyocytes.	32728001
22335	Rat	rno-miR-24	miRNA	lycium barbarum polysaccharide (LBP)	hypoxia-induced injury	oxygen and glucose deprivation (OGD)-treated PC-12 cells	Lycium barbarum polysaccharides (LBPs) treatment	upregulated	31588805
22336	Rat	rno-miR-24	miRNA	oxygen glucose deprivation (OGD)	hypoxia-induced injury	PC-12 cells	oxygen and glucose deprivation (OGD) treatment	downregulated	31588805
22337	Rat	rno-miR-24	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	bleomycin-injured rats lung tissues	bleomycin (BLM) treatment	downregulated	30446578
22338	Rat	rno-miR-24	miRNA	bleomycin (BLM)	idiopathic pulmonary fibrosis (IPF)	lung tissues	bleomycin (BLM) treatment	downregulated	30446578
22339	Rat	rno-miR-24	miRNA	isoflurane	isoflurane-induced neurotoxicity	hippocampus	isoflurane treatment	downregulated	31533001
22340	Rat	rno-miR-24	miRNA	lipopolysaccharide (LPS)	myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated	32181504
22341	Rat	rno-miR-24	miRNA	high glucose (HG)	oxidative stress	vascular smooth muscle cells (VSMCs) isolated from the thoracic aorta	high glucose (HG) treatment	downregulated	31539718
22342	Rat	rno-miR-24	miRNA	isoflurane	oxidative stress	H9c2 cells	Isoflurane treatment	downregulated	29627934
22343	Rat	rno-miR-24	miRNA	thrombin	post-intracerebral hemorrhage (ICH)	endothelial cells	thrombin injection treatment	thrombin reduces HIF-1¦Á degradation and initiates angiogenesis by increasing miR-24	32413855
22344	Rat	rno-miR-24	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
22345	Rat	rno-miR-24	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	upregulated	22847192
22346	Rat	rno-miR-24	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	cancer and inflammation	rat cardiomyocytes	HIF-1 treatment	upregulated	23098654
22347	Rat	rno-miR-24-1	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22348	Rat	rno-miR-24-1-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22349	Rat	rno-miR-24-1-5p	miRNA	hypoxia	stroke	middle cerebral artery occlusion (MCAO) Sprague-Dawley rat	middle cerebral artery occlusion (MCAO) treatment	upregulated	29113076
22350	Rat	rno-miR-2424	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
22351	Rat	rno-miR-24-2-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22352	Rat	rno-miR-24-3p	miRNA	estradiol benzoate (EB)	chronic inflammatory diseases	dorsolateral prostate	estradiol benzoate (EB) treatment	upregulated	33332750
22353	Rat	rno-miR-24-3p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	downregulated	27919821
22354	Rat	rno-miR-24-3p	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	H9C2 cardiomyocyte cell line	hypoxia induce	downregulated	30622671
22355	Rat	rno-miR-24-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22356	Rat	rno-miR-2467-3p	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	Urinary; blood; kidney tissues	streptozotocin (STZ) treatment	STZ-induced type 1 diabetic rat exhibit the reduction both of urinary and circulating miR-2467-3p	32050151
22357	Rat	rno-miR-24a	miRNA	dexamethasone (DEX)	acute diabete	C2C12 myotubes	dexamethasone (DEX) treatment	downregulated	24336651
22358	Rat	rno-miR-25	miRNA	hypoxia	cardiomyocytes proliferation and migration	heart tissues; primary neonatal;adult cardiomyocytes	hypoxia induce	downregulated	31058341
22359	Rat	rno-miR-25	miRNA	repetitive transcranial magnetic stimulation (rTMS)	focal cerebral ischemia	Sprague-Dawley rats ischemic cortex	rTMS treatment	upregulated	25302788
22360	Rat	rno-miR-25	miRNA	emodin	hypoxic brain injury	hypoxia-induced PC-12 cells	Emodin (EMO) treatment	upregulated	31257935
22361	Rat	rno-miR-25	miRNA	hypoxia	hypoxic brain injury	PC-12 cells	hypoxia induce	downregulated	31257935
22362	Rat	rno-miR-25	miRNA	estradiol-17¦Â (E2)	osteogenesis	primary bone marrow mesenchymal stem cells from rats (rBMSCs)	estradiol-17¦Â (E2) treatment	upregulated	31089333
22363	Rat	rno-miR-25	miRNA	cholesterol-enriched diet	oxidative stress	Serum and tissue of rat	cholesterol-enriched diet treatment	upregulated	23722270
22364	Rat	rno-miR-25	miRNA	high amplitude mechanical stretching	lung fibrosis	alveolar type II (ATII) cells and lung fibroblasts	high amplitude mechanical stretching treatment	upregulated	31290711
22365	Rat	rno-miR-25	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	cardiac H9C2 cell line	lipopolysaccharide (LPS) treatment	downregulated	29440462
22366	Rat	rno-miR-25	miRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	?H2O2 treatment	downregulated	28605990
22367	Rat	rno-miR-25	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	downregulated	21094214
22368	Rat	rno-miR-25-3p	miRNA	hypoxia	cyanotic congenital heart disease (CCHD)	H9c2 cells	hypoxia induce	"SNHG14 and KLF4 were upregulated, whereas miR-25-3p was downregulated in hypoxia-induced H9c2 cells and cardiac tissues of patients with CCHD compared with their controls."	33278191
22369	Rat	rno-miR-25-3p	miRNA	kainic acid (KA)	epilepsy	rats hippocampi; hippocampal neurons	Kainic acid (KA) induction	downregulated	31954517
22370	Rat	rno-miR-25-3p	miRNA	magnesium-free extracellular fluid	epilepsy	rats hippocampi; hippocampal neurons	Mg2+-free solution	downregulated	31954517
22371	Rat	rno-miR-25-3p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
22372	Rat	rno-miR-25-5p	miRNA	serotonin	smooth muscle cell differentiation	brown Norway rat BMSCs	serotonin treatment	downregulated	24595007
22373	Rat	rno-miR-25-5p	miRNA	insulin-like growth factor 1 (IGF-1)	spinal cord injury (SCI)	Neural stem cells were obtained from E15 fetal rat cerebral cortex cultured supernatant exosomes	insulin growth factor-1 (IFG-1) treatment	upregulated	31848325
22374	Rat	rno-miR-26-3p	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	33263228
22375	Rat	rno-miR-26a	miRNA	methotrexate (MTX)	arthritis	rat macrophage line NR8383 cells	methotrexate treatment	downregulated	24423102
22376	Rat	rno-miR-26a	miRNA	pristane (PS)	arthritis	NR8383 cells	pristane treatment	downregulated	24423102
22377	Rat	rno-miR-26a	miRNA	CoCl2	cardiac arrest-induced brain damage	Neural stem cells (NSCs)	CoCl2 treatment to induce hypoxia injury model	downregulated	30992390
22378	Rat	rno-miR-26a	miRNA	H2O2	cytotoxicity	RGC-5 cells	H2O2 treatment	downregulated	25757910
22379	Rat	rno-miR-26a	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	rat heart tissues	streptozotocin (STZ) treatment	downregulated	31389595
22380	Rat	rno-miR-26a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	Rat glomerular mesangial cells	High glucose treatment	upregulated	25797045
22381	Rat	rno-miR-26a	miRNA	repeated binge-EtOH exposure	ethanol addiction	dorsal and ventral hippocampus of male Wistar rats	repeated binge-EtOH exposure treatment	different regulation	24416161
22382	Rat	rno-miR-26a	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	vascular tissues	abdominal incision induce	downregulated	30132885
22383	Rat	rno-miR-26a	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	H9c2 cells	oxygen glucose deprivation (OGD) treatment	miR-26a was downregulated in oxygen-glucose deprivation (OGD)-treated H9c2 cells.	31990056
22384	Rat	rno-miR-26a	miRNA	rotenone (ROT)	parkinson's disease (PD)	striatum of parkinsonian rats	rotenone exposure treatment	upregulated	30267378
22385	Rat	rno-miR-26a	miRNA	antigen	pulmonary inflammation	plasma and lavaged lung	antigen treatment	upregulated	27075111
22386	Rat	rno-miR-26a	miRNA	TGF-¦Â1	renal fibrosis	renal tubular epithelial cells (NRK-52E)	TGF-¦Â1 treatment	downregulated	27874055
22387	Rat	rno-miR-26a	miRNA	type II collagen	rheumatoid arthritis (RA)	cartilage tissues and inflammatory articular chondrocytes of RA rats	type II collagen treatment	downregulated	31267533
22388	Rat	rno-miR-26a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
22389	Rat	rno-miR-26a	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 12) treatment	different expression	24420840
22390	Rat	rno-miR-26a-1-5p	miRNA	H2O2	abdominal aortic aneurysm (AAA)	primary vascular smooth muscle cells (VSMCs)	H2O2 treatment	downregulated	29956734
22391	Rat	rno-miR-26a-5p	miRNA	¦Â3-adrenoceptors(¦Â3-AR) inhibitor SR 59230A	chronic heart failure (CHF)	CHF rats	1 ml SR 59230A(85 mmoL/L in 0.9% saline)twice a day for seven weeks by intraperitoneal injection treatment	upregulated	29926593
22392	Rat	rno-miR-26a-5p	miRNA	liraglutide	endothelial dysfunction	aortic endothelial in diabetic rats	liraglutide treatment	upregulated	30863684
22393	Rat	rno-miR-26a-5p	miRNA	hemin	intracerebral haemorrhage (ICH)	PC-12 cells	hemin treatment	downregulated	33000559
22394	Rat	rno-miR-26b	miRNA	cisplatin (DDP)	cisplatin (DDP)-induced nephrotoxicity	renal tissue homogenate	cisplatin treatment	downregulated	32777238
22395	Rat	rno-miR-26b	miRNA	pentoxifylline (PTX)	cisplatin (DDP)-induced nephrotoxicity	renal tissue homogenate	pentoxifylline (PTX) treatment	downregulated	32777238
22396	Rat	rno-miR-26b	miRNA	intermittent hypoxia (IH)	cognitive impairment	rats hippocampus	intermittent hypoxia (IH) treatment	downregulated in hippocampus	28647595
22397	Rat	rno-miR-26b	miRNA	high salt (HS)	hypertension	aorta of? rats	high salt (HS) treatment	downregulated	24161401
22398	Rat	rno-miR-26b	miRNA	osteoactivin (OA)	osteogenesis	bone marrow-derived mesenchymal stem cells (BMSCs)	Osteoactivin (OA) treatment	upregulated	30768922
22399	Rat	rno-miR-26b	miRNA	hypoxia	pulmonary hypertension (PH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia treatment	Hypoxia-induced microRNA-26b inhibition contributes to hypoxic pulmonary hypertension via CTGF.	28816418
22400	Rat	rno-miR-26b	miRNA	glycine	subarachnoid hemorrhage (SAH)	Cultured cortical neurons and microglia	Glycine treatment	upregulated	31612303
22401	Rat	rno-miR-26b	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	brain tissues	"orally and daily administrated 2.0 ml NSO, 100 mg metformin (MT)"	downregulated in the brain	28505155
22402	Rat	rno-miR-26b-3p	miRNA	rapamycin	cardiac fibrosis	heart tissues	rapamycin (Rap) treatment	upregulated	30647817
22403	Rat	rno-miR-26b-3p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
22404	Rat	rno-miR-26b-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Our results showed that miR-26b-5p was downregulated in OGD/R-induced PC12 cells	33559506
22405	Rat	rno-miR-26b-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
22406	Rat	rno-miR-27	miRNA	hypoxia	glycolysis	cardiomyocytes	hypoxia treatment	"Meanwhile, miR-27 and miR-195 were also upregulated in hypoxia-induced cardiomyocytes."	33819184
22407	Rat	rno-miR-27	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated	31576518
22408	Rat	rno-miR-27	miRNA	isoflurane	oxidative stress	H9c2 cells	Isoflurane treatment	upregulated	29627934
22409	Rat	rno-miR-27a	miRNA	chronic brain hypoperfusion (CBH)	apoptosis	rats	chronic brain hypoperfusion (CBH) treatment	upregulated	26993299
22410	Rat	rno-miR-27a	miRNA	nimodipine	cognitive impairment	brain tissues	nimodipine treatment	Nimodipine can improve CI after SAH in rats through the lncRNA NEAT1/miR-27a/MAPT axis.	32606599
22411	Rat	rno-miR-27a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	rat MC line (HBZY-1)	rat MC line (HBZY-1) treatment	upregulated	27184517
22412	Rat	rno-miR-27a	miRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E cells	high glucose (HG) treatment	upregulated	32484208
22413	Rat	rno-miR-27a	miRNA	omentin-1	diabetic nephropathy (DN)	HBZY-1 cells	omentin-1 treatment	downregulated	30103116
22414	Rat	rno-miR-27a	miRNA	cyclic mechanical stretch (CMS)	cell proliferation	primary rat aortic ECs	15% cyclic stretch	upregulated in vascular smooth muscle cells -derived microparticles (VSMC-MPs)	28106155
22415	Rat	rno-miR-27a	miRNA	stimulation electrode	epilepsy	Adult male Sprague Dawley rats blood	A bipolar stimulation electrode (distance between tips 500 ?m) was implanted in the angular bundle treatment	dysregulated	24184920
22416	Rat	rno-miR-27a	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	downregulated	24205079
22417	Rat	rno-miR-27a	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
22418	Rat	rno-miR-27a	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	renal tissues	"rats were anesthetized following the inhalation of 2% isoflurane. Subsequently, an abdominal incision was created, and the renal pedicle was clamped for 45 min with a microaneurysm clamp."	downregulated	31173204
22419	Rat	rno-miR-27a	miRNA	aerobic exercise	left ventricular hypertrophy (LVH)	left ventricular	aerobic exercise training (AET) treatment	upregulated	21709209
22420	Rat	rno-miR-27a	miRNA	glucagon-like peptide-1 (GLP-1)	lipotoxicity	INS-1 pancreatic ¦Â-cell line derived from rat insulinoma	10 nmol/L GLP-1 for 24 h	downregulated	29032333
22421	Rat	rno-miR-27a	miRNA	porcine serum	liver fibrosis	rat liver tissues	porcine serum treatment	upregulation	24927615
22422	Rat	rno-miR-27a	miRNA	lipopolysaccharide (LPS)	microglial neuroinflammation	primary microglial cells	lipopolysaccharide (LPS) treatment	downregulated	26971344
22423	Rat	rno-miR-27a	miRNA	bilobalide (BB)	myocardial infarction (MI)	hypoxia-induced H9C2 cells	bilobalide treatment	upregulated	31322008
22424	Rat	rno-miR-27a	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	H9C2 cells	oxygen-glucose deprivation (OGD)-induce treatment	downregulated	31322008
22425	Rat	rno-miR-27a	miRNA	high fat diet (HFD)	obesity	adipose tissues	high fat diet (HFD) feed	"The obese rats in the HFD group, compared with rats in the NFD group, demonstrated a significant decrease in the expression of miR-27a (p < 0.05) and a significant increase in the expression of miR-143."	30411548
22426	Rat	rno-miR-27a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22427	Rat	rno-miR-27a	miRNA	endothelin-1 (ET-1)	pulmonary hypertension (PH)	primary cultured rat PASMC	endothelin-1 (ET-1) treatment	upregulated	28484848
22428	Rat	rno-miR-27a	miRNA	H2O2	spinal cord injury (SCI)	primary rat neurons	H2O2 treatment	downregulated	32679145
22429	Rat	rno-miR-27a	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	microglial cells	lipopolysaccharide (LPS) treatment	miR-27a was lowly expressed in LPS-induced microglial cells.	31778769
22430	Rat	rno-miR-27a	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	mouse primary microglial cells	lipopolysaccharide (LPS) treatment	"higher level of XIST and Smurf1, but lower level of miR-27a in SCI rats and lipopolysaccharide (LPS)-induced primary microglial cells."	31778769
22431	Rat	rno-miR-27a	miRNA	dexamethasone (DEX)	steroid-induced osteonecrosis of femoral head (ONFH)	serum	dexamethasone (DEX) treatment	downregulated	30535438
22432	Rat	rno-miR-27a	miRNA	dexamethasone (DEX)	steroid-induced osteonecrosis of femoral head (ONFH)	ONFH rats serum	dexamethasone (DEX) treatment	downregulated	30535438
22433	Rat	rno-miR-27a	miRNA	high fat diet (HFD)	weight gain	end epididymal fat	high fat diet (HFD) feed	downregulated	29023027
22434	Rat	rno-miR-27a	miRNA	dexamethasone (DEX)	hormonal regulation	adrenals?tissues	dexamethasone (DEX) treatment	downregulated	24205079
22435	Rat	rno-miR-27a-3p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	downregulated	31923741
22436	Rat	rno-miR-27a-3p	miRNA	kainic acid (KA)	epilepsy	rat neuronal cells	kainic acid (KA) treatment	upregulated	31710596
22437	Rat	rno-miR-27a-3p	miRNA	hypoxia	hypoxia-induced injury	H9c2 cell	hypoxia induce	downregulated	31923741
22438	Rat	rno-miR-27a-3p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	downregulated	28560399
22439	Rat	rno-miR-27a-3p	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin A5 treatment	downregulated	32538751
22440	Rat	rno-miR-27a-3p	miRNA	bleomycin (BLM)	renal ischemia/reperfusion (I/R) injury	NRK-52E cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32084559
22441	Rat	rno-miR-27a-3p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	upregulated	26997989
22442	Rat	rno-miR-27a-3p	miRNA	phosphorus (Pi)	vascular calcification (VC)	A10 cells	Pi treatment	downregulated	33230462
22443	Rat	rno-miR-27a-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	rat cardiomyoblast cells (H9c2)	hypoxia induce	downregulated	31100777
22444	Rat	rno-miR-27a-5p	miRNA	caerulein (Cae)	acute pancreatitis (AP)	Rat pancreatic acinar cell line AR42J	caerulein (Cae) treatment	downregulated	31106896
22445	Rat	rno-miR-27a-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22446	Rat	rno-miR-27ab	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	neurotoxicity	brain tissues of rats	RDX at a dose(47 mg/kg) for 48 h treatment	upregulated	25559034
22447	Rat	rno-miR-27b	miRNA	angiotensin II (Ang II)	cardiac fibrosis	rat neonatal cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	upregulated	31881012
22448	Rat	rno-miR-27b	miRNA	collagenase	intracerebral haemorrhage (ICH)	rats striatum	collagenase treatment	downregulated	29050310
22449	Rat	rno-miR-27b	miRNA	ischemic brain extract (IBE)	ischemic injury	"C6 rat astrocytoma cells, and primary rat MSCc (rMSCs)"	IBE treatment	downregulated	24999035
22450	Rat	rno-miR-27b	miRNA	sevoflurane (SEV)	learning deficits and abnormal social behaviors	brain	sevoflurane treatment	upregulated	27973945
22451	Rat	rno-miR-27b	miRNA	aerobic exercise	left ventricular hypertrophy (LVH)	left ventricular	aerobic exercise training (AET) treatment	upregulated	21709209
22452	Rat	rno-miR-27b	miRNA	4-vinylcyclohexene diepoxide (VCD)	premature ovarian failure (POF)	ovarian	4-vinylcyclohexene diepoxide (VCD) tretament	upregulated	24188450
22453	Rat	rno-miR-27b	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22454	Rat	rno-miR-27b	miRNA	puromycin aminonucleoside (PAN)	podocyte protection	non-human primates (NHPs)	puromycin aminonucleoside (PAN) treatment	"In NHP primary podocyte culture, significant downregulated of miR-27b was observed during treatment of puromycin aminonucleoside (PAN), a classic nephrotoxin"	30429458
22455	Rat	rno-miR-27b	miRNA	endothelin-1 (ET-1)	pulmonary hypertension (PH)	primary cultured rat PASMC	endothelin-1 (ET-1) treatment	upregulated	28484848
22456	Rat	rno-miR-27b	miRNA	sitagliptin	renal interstitial inflammatory	type II diabetic Goto-Kakizaki (GK)	sitagliptin treatment	upregulated	28652790
22457	Rat	rno-miR-27b	miRNA	isoproterenol	¦Â-adrenoceptor intervention	rat heart tissues	isoproterenol (ISO)  treatment	downregulated	22847192
22458	Rat	rno-miR-27b-3p	miRNA	guarana	adipogenesis	3T3L1 cells	guarana	downregulated	28632199
22459	Rat	rno-miR-27b-3p	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozocin (STZ) treatment	miR-27b-3p was decreased in DN rats and high-glucose-induced mice mesangial cells	30549040
22460	Rat	rno-miR-27b-3p	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	rat kidney tissues	streptozotocin (STZ) treatment	downregulated	30549040
22461	Rat	rno-miR-28	miRNA	hypoxia	cerebral ischemia injury (CII)	Rat pheochomocytoma PC-12?cells	hypoxia induce	upregulated	31002779
22462	Rat	rno-miR-28	miRNA	tanshinone IIA (Tan IIA)	cerebral ischemia injury (CII)	hypoxia induced Rat pheochomocytoma PC-12?cells	Tanshinone IIA treatment	downregulated	31002779
22463	Rat	rno-miR-28	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
22464	Rat	rno-miR-28	miRNA	hypoxia	hypoxic brain injury	PC-12 cell	hypoxia induce	"lncRNA H19 downregulated miR-28 expression, which in turn preventing SP1 from degradation by miR-28, and ultimately deactivated PDK/AKT and JAK/STAT signaling pathways."	30312698
22465	Rat	rno-miR-28*	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	7-week-old Fischer344 male rats liver	aflatoxin B1 (AFB7) treatment	upregulated	24472605
22466	Rat	rno-miR-28-3p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	upregulated	32893733
22467	Rat	rno-miR-28-5p	miRNA	phosgene	acute lung injury (ALI)	Lung-derived exosomes	phosgene induce treatment	upregulated	31707339
22468	Rat	rno-miR-28-5p	miRNA	dexamethasone (DEX)	cartilage injury	articular cartilage	dexamethasone (DEX) treatment	miR-28-5p was downregulated compared with control group.	29207029
22469	Rat	rno-miR-29	miRNA	cigarette/nicotine	cardiac dysfunction	primary neonatal rat cardiac fibroblasts	cigarette/nicotine exposure	downregulated	32795172
22470	Rat	rno-miR-29	miRNA	aerobic exercise	cardiac hypertrophy	rat cardiac muscle tissues	aerobic exercise training (AET) treatment	aerobic training increase miR-29 expression in the heart	21447748
22471	Rat	rno-miR-29	miRNA	combined resistance-endurance (RE) training	cardiovascular disease risk in women during menopause	ovariectomy (OVX) rats heart tissues	combined resistance-endurance (RE) training treatment	upregulated	30766462
22472	Rat	rno-miR-29	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	rat isolated dorsal root ganglion (DRG) neurons	STZ treatment	downregulated	24819309
22473	Rat	rno-miR-29	miRNA	TGF-¦Â	erythroid cell differentiation	Rat tubular epithelial cells (NRK52E)	TGF-¦Â treatment	downregulated	24103556
22474	Rat	rno-miR-29	miRNA	dexamethasone (DEX)	excess of glucocorticoids (GCs)	pregnant rats	dexamethasone (DEX) treatment	upregulated	24253049
22475	Rat	rno-miR-29	miRNA	hepatocyte growth factor (HGF)	hepatic stellate cells (HSC) transdifferentiate into myofibroblasts	rat hepatic stellate cells (HSC)	Hepatocyte growth factor (HGF) treatment	upregulated	21931759
22476	Rat	rno-miR-29	miRNA	TGF-¦Â	hepatic stellate cells (HSC) transdifferentiate into myofibroblasts	rat hepatic stellate cells (HSC)	transforming growth factor-¦Â (TGF-¦Â) treatment	downregulated	21931759
22477	Rat	rno-miR-29	miRNA	dexamethasone (DEX)	maternal undernutrition (MUN) during pregnancy	fetal rat lung fibroblasts	dexamethasone (DEX) treatment	Dexamethasone treatment of cultured fetal rat lung fibroblasts significantly induced miR-29 expression.	30088984
22478	Rat	rno-miR-29	miRNA	ginkgolide B (GB)	myocardial infarction (MI)	H9c2 cells	Ginkgolide B treatment	Hypoxia-induced apoptosis of cardiomyocytes is restricted by ginkgolide B-downregulated microRNA-29.	32295500
22479	Rat	rno-miR-29	miRNA	PPAR-¦Ãagonist	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat left ventricl tissue	PPAR-¦Ãagonist treatment	downregulated	20164119
22480	Rat	rno-miR-29	miRNA	cisplatin (DDP)	nephrotoxicity	male Sprague-Dawley (SD) rats urine	cisplatin treatment	upregulated	24863737
22481	Rat	rno-miR-29	miRNA	dexamethasone (DEX)	vascular smooth muscle cell proliferation	Blood samples	dexamethasone (Dex) treatment	upregulated	24253049
22482	Rat	rno-miR-29	miRNA	hepatitis C virus (HCV)	hepatitis C virus (HCV) infection	primary rat hepatocytes	hepatitis C virus (HCV) infection	downregulated	21606534
22483	Rat	rno-miR-291a-3p	miRNA	"2,5-hexanedione (HD)"	"2,5-hexanedione (HD) toxicity"	spinal cord tissues	"2,5-hexanedione (HD) treatment"	upregulated	31760062
22484	Rat	rno-miR-291a-3p	miRNA	dexamethasone (DEX)	osteoporosis	bone marrow-derived mesenchymal stem cells (BMSCs)	dexamethasone (Dex) treatment	DEX (DEX) inhibited cell viability and decreased the expression of miR-291a-3p in BMSCs.	31729834
22485	Rat	rno-miR-291a-3p	miRNA	dexamethasone (DEX)	osteoporosis	Primary rat bone marrow-derived mesenchymal stem cells (BMSCs)	dexamethasone (DEX) treatment	"miRNA-291a-3p could improve the cell viability, osteogenic differentiation, and ALP activity, which are suppressed by DEX in BMSCs."	31729834
22486	Rat	rno-miR-291b	miRNA	ethanol (EtOH)	alcoholic liver disease (ALD)	male Wistar rats Kupffer cells	ethanol treatment	upregulated in Kupffer cells	29142263
22487	Rat	rno-miR-29-3p	miRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	hypoxic pulmonary hypertension (HPH)	pulmonary adventitial fibroblasts	hypoxia-inducible factor-1 ¦Á treatment	downregulated	25421979
22488	Rat	rno-miR-294	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	mesenchymal stem cell (MSC) exosome	hypoxia-reoxygenation (H/R) treatment	upregulated	32719674
22489	Rat	rno-miR-296	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
22490	Rat	rno-miR-296	miRNA	acute stress (AS) and chronic stress (CS)	stress-induced myocardial injury	rat	Rats were bound and suspended treatment	upregulated	24669248
22491	Rat	rno-miR-296-5p	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	colonic tissue of rat	azoxymethane (AOM) treatment	downregulated	23049818
22492	Rat	rno-miR-297	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal rat cardiomyocytes (NCMs)	angiotensin II (Ang II) treatment	upregulated	28286226
22493	Rat	rno-miR-297	miRNA	perfluorooctane sulfonic acid (PFOS)	neural dysfunctions	rat brains	perfluorooctane sulfonic acid (PFOS) treatment	downregulated	22594572
22494	Rat	rno-miR-297	miRNA	lipopolysaccharide (LPS)	septic shock	Wistar rats serum	LPS (10 mg/kg) treatment	upregulated	24915805
22495	Rat	rno-miR-297a	miRNA	valproic acid (VPA)	cerebral ischemia injury (CII)	rat cortical neuronal cells	valproic acid treatment	upregulated	22937209
22496	Rat	rno-miR-298	miRNA	hypoxia	cortical injury	rat cortex tisssues	hypoxia treatment	downregulated	23272113
22497	Rat	rno-miR-298	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cardiomyocytes	hypoxia induce	upregulated	31138376
22498	Rat	rno-miR-298	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
22499	Rat	rno-miR-298	miRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
22500	Rat	rno-miR-29a	miRNA	L©\arginine	acute edematous pancreatitis (AEP)	AR42J cell	L-arginine treatment	upregulated	27239114
22501	Rat	rno-miR-29a	miRNA	NOX inhibitor VAS2870	acute ischemic stroke (AIS)	tMCAO rats	intravenous treatment with NOX inhibitor VAS2870	upregulated	27325364
22502	Rat	rno-miR-29a	miRNA	deoxycholic acid (DCA)	acute pancreatitis (AP)	AR42J cells	deoxycholic acid (DCA) treatment	upregulated	30554587
22503	Rat	rno-miR-29a	miRNA	VEGF-A	cardiac fibrosis	rat cardiac fibroblasts	VEGF-A treatment	downregulated	27060017
22504	Rat	rno-miR-29a	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31162869
22505	Rat	rno-miR-29a	miRNA	angiotensin II (Ang II)	cell proliferation and collagen synthesis	cardiac fibroblasts of Sprague-Dawley rats	angiotensin II (Ang II) treatment	downregulated	28615545
22506	Rat	rno-miR-29a	miRNA	infrasound	cell proliferation and collagen synthesis	cardiac fibroblasts of Sprague-Dawley rats pre-treat with Ang II	infrasound treatment	upregulated	28615545
22507	Rat	rno-miR-29a	miRNA	epigallocatechin-3-gallate (EGCG)	chronic renal injury	cadmium (Cd) pretreated Wistar albino rats	EGCG treatment	"decreased miR-21 and miR-192, enhanced miR-29a/b/c in kidney samples"	27474435
22508	Rat	rno-miR-29a	miRNA	follicle stimulating hormone (FSH)	colorectal cancer (CRC)	rat granulosa cells	Follicle-stimulating hormone (FSH)treatment	downregulated	20734245
22509	Rat	rno-miR-29a	miRNA	streptozocin (STZ)	diabetic cataract (DC)	lens epithelial cells (LECs)	Streptozotocin (STZ) treatment	downregulated	28003969
22510	Rat	rno-miR-29a	miRNA	captopril	diabetic nephropathy (DN)	diabetes rats kidney tissue	captopril treatment	upregulated	31433203
22511	Rat	rno-miR-29a	miRNA	spironolactone	diabetic nephropathy (DN)	diabetes rats kidney tissue	spironolactone treatment	upregulated	31433203
22512	Rat	rno-miR-29a	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissue	streptozotocin (STZ) treatment	downregulated	31433203
22513	Rat	rno-miR-29a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	rat retinal M¨¹ller cells	high glucose treatment	downregulated	29409329
22514	Rat	rno-miR-29a	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	rat retinal tissues	streptozotocin (STZ) treatment	downregulated	29409329
22515	Rat	rno-miR-29a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	hypothermic Circulatory Arrest (DHCA)-associated neural injury	HT-22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29623838
22516	Rat	rno-miR-29a	miRNA	hypoxic/ischemic	hypoxic/ischemic injury	rat kidneys tissue cells	Hypoxia/Ischemia treatment	upregulated	23596515
22517	Rat	rno-miR-29a	miRNA	clamping both renal arteries	ischemia/reperfusion (I/R) injury	male rats	clamping both renal arteries for 45 min	upregulated	28129785
22518	Rat	rno-miR-29a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	primary astrocyte cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30628716
22519	Rat	rno-miR-29a	miRNA	corticotrophin releasing factor (CRF) receptor I antagonist (BMS-764459)	hepatocellular carcinoma (HCC)	rat liver cells	"The corticotrophin releasing factor (CRF) receptor I antagonist, BMS-764459 treatment"	"MiR-680 and miR-29a were identified as potential regulators and biomarkers of atypical CYP1A1 induction by regulating Abcc3, CYP3A and CYP2B as well as a number of AhR targeted genes"	23831372
22520	Rat	rno-miR-29a	miRNA	4-vinylcyclohexene diepoxide (VCD)	premature ovarian failure (POF)	ovarian	4-vinylcyclohexene diepoxide (VCD) tretament	downregulated	24188450
22521	Rat	rno-miR-29a	miRNA	swimming	myocardial infarction (MI)	myocardial-Infarcted Rats BR and RM	ST consisted of 60 min/day/10 weeks and began four weeks after MI treatment	upregulated	24642957
22522	Rat	rno-miR-29a	miRNA	lipopolysaccharide (LPS)	myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	CRNDE/miR-29a/SIRT1 network regulated sepsis-induced myocardial injury.	32473249
22523	Rat	rno-miR-29a	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Oip5-as1 suppresses miR-29a leading to activation of the SIRT1/AMPK/PGC1¦Á pathway, which attenuates mitochondria-mediated apoptosis during MI/R injury"	32468629
22524	Rat	rno-miR-29a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 myocardial cells	hypoxia induce	upregulated	31481517
22525	Rat	rno-miR-29a	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	31481517
22526	Rat	rno-miR-29a	miRNA	arbutin (ARB)	optic nerve injury	H2O2 treated rat primary retinal ganglion cells (RGCs)	arbutin (ARB) treatment	upregulated	30970524
22527	Rat	rno-miR-29a	miRNA	H2O2	optic nerve injury	rat primary retinal ganglion cells (RGCs)	H2O2 treatment	downregulated	30970524
22528	Rat	rno-miR-29a	miRNA	"5,7,3',4'-tetramethoxyflavone (TMF)"	osteoarthritis (OA)	chondrocytes isolated from the rat cartilages	"5,7,3',4'-tetramethoxyflavone (TMF) treatment"	downregulated	31354246
22529	Rat	rno-miR-29a	miRNA	4-vinylcyclohexene diepoxide (VCD)	premature ovarian failure (POF)	rat POF tissues	VCD treatment	downregulated	24188450
22530	Rat	rno-miR-29a	miRNA	american ginseng root's	premature ovarian failure (POF)		4-Vinylcyclohexene diepoxide (VCD) treatment	upregulated	25705687
22531	Rat	rno-miR-29a	miRNA	sepsis	renal injury	?kidney tissues	cecal ligation puncture induced sepsis treatment	the expression of miR-29a was prominently decreased in the sepsis-induced kidney injury model	31858562
22532	Rat	rno-miR-29a	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharides (LPS) treatment	High NEAT1 levels can increase LPS-induced injury in PC-12 cells through the miR-29a/BCL2L11 pathway.	32776916
22533	Rat	rno-miR-29a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	downregulated	21094214
22534	Rat	rno-miR-29a-3p	miRNA	endothelin-1 (ET-1)	cardiac hypertrophy	H9c2	endothelin-1 (ET-1) treatment	downregulated	26992639
22535	Rat	rno-miR-29a-3p	miRNA	Neuropeptide Y (NPY)	cardiac hypertrophy	Neonatal Rat Cardiomyocytes	Neuropeptide Y (NPY) treatment	NPY leads to downregulated of miR-29a-3p expression.	32297569
22536	Rat	rno-miR-29a-3p	miRNA	muscle contraction	diabetes mellitus (DM)	muscle tissues	"stimulated to contract in vitro for twitch tension analysis (0.5 Hz), 30 min later for tetanic analysis (100 Hz)"	upregulated	28000044
22537	Rat	rno-miR-29a-3p	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary adventitial fibroblast	hypoxia treatment	downregulated	25421979
22538	Rat	rno-miR-29a-3p	miRNA	dexamethasone (DEX)	hypoxic/ischemic brain damage (HIBD)	hippocampus	dexamethasone (DEX) treatment	Dex treatment increased miR-29a-3p expression and decreased HDAC4 expression.	33232741
22539	Rat	rno-miR-29a-3p	miRNA	high fat diet (HFD)	osteogenesis	rat bone marrow mesenchymal stem cells (BMSCs)	high fat diet (HFD) feed	downregulated	31168988
22540	Rat	rno-miR-29a-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	oxygen-glucose deprivation/reoxygenation (OGD/R) injury	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MiR-29a-3p Enhances the Viability of Rat Neuronal Cells that Injured by Oxygen-Glucose Deprivation/Reoxygenation Treatment Through Targeting TNFRSF1A and Regulating NF-¦ÊB Signaling Pathway	33066952
22541	Rat	rno-miR-29a-3p	miRNA	angiotensin II (Ang II)	renal glomerular and tubulo-interstitial fibrosis	renal tubules	angiotensin II (Ang II) treatment	downregulated	26700017
22542	Rat	rno-miR-29a-3p	miRNA	yunpiheluo (YPHL) decoction	type 2 diabetes mellitus (T2DM)	Zucker diabetic fatty (ZDF) rats liver tissues	Yunpiheluo (YPHL) decoction treatment	"YPHL decoction attenuated IR in T2DM probably by down-regulating or maintaining the miR-29a-3p level, increasing the expression of IRS1 mRNA and its phosphorylated proteins, and regulating the expression of insulin receptor signaling-related proteins"	31128151
22543	Rat	rno-miR-29a-3p	miRNA	cyclic mechanical stretch (CMS)	vein graft restenosis	Venous vascular smooth muscle cells	Venous VSMCs exposed to 10%-1.25Hz cyclic stretch by using the Flexcell system were used to simulate arterial mechanical conditions in vitro.	upregulated	31513704
22544	Rat	rno-miR-29a-5p	miRNA	valproic acid (VPA)	cell differentiation	primary cultured neural stem cells (NSCs)	valproate (VPA) treatment	upregulated	29575035
22545	Rat	rno-miR-29a-5p	miRNA	dehydroepiandrosterone (DHEA)	polycystic ovarian syndrome (PCOS)	rats' ovarian tissues	DHEA treatment	downregulated in rats' ovarian tissues	28673204
22546	Rat	rno-miR-29b	miRNA	chitosan	achilles tendon injury	rats fibroblasts	chitosan treatment	upregulated	25674210
22547	Rat	rno-miR-29b	miRNA	carvedilol	alcohol addiction	LV myocardium of rat	carvedilol treatment	upregulated	24086569
22548	Rat	rno-miR-29b	miRNA	warfarin plus vitamin K	calcific aortic valve disease (CAVD)	aorta; plasma	warfarin plus vitamin K treatment	upregulated	32845082
22549	Rat	rno-miR-29b	miRNA	tanshinone IIA (Tan IIA)	cardiac fibrosis	cardiac fibroblast (CF)	Tanshinone IIA (TSN) treatment	upregulated	25636075
22550	Rat	rno-miR-29b	miRNA	complete freund's adjuvant (CFA)	chronic pain	L4-6 dorsal root ganglions (DRGs)	complete Freund's adjuvant (CFA) treatment	CFA leads to the upregulation of miR-29b level.	31980031
22551	Rat	rno-miR-29b	miRNA	vitamin D receptor activators (VDRAs)	chronic renal failure (CRF)	nephrectomized Wistar rats	equivalent doses of two VDRAs: calcitriol and paricalcitol treatment	upregulated	28460073
22552	Rat	rno-miR-29b	miRNA	epigallocatechin-3-gallate (EGCG)	chronic renal injury	cadmium (Cd) pretreated Wistar albino rats	EGCG treatment	"decreased miR-21 and miR-192, enhanced miR-29a/b/c in kidney samples"	27474435
22553	Rat	rno-miR-29b	miRNA	hypoxia	cortical injury	rat cortex tisssues	hypoxia treatment	downregulated	23272113
22554	Rat	rno-miR-29b	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	the retinal ganglion cells (RGCs) ;the cells of the inner nuclear layer (INL)	streptozotocin (STZ) injection treatment	upregulated	21897745
22555	Rat	rno-miR-29b	miRNA	captopril	diabetic nephropathy (DN)	diabetes rats kidney tissue	captopril treatment	upregulated	31433203
22556	Rat	rno-miR-29b	miRNA	spironolactone	diabetic nephropathy (DN)	diabetes rats kidney tissue	spironolactone treatment	upregulated	31433203
22557	Rat	rno-miR-29b	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissue	streptozotocin (STZ) treatment	downregulated	31433203
22558	Rat	rno-miR-29b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	rat retinal M¨¹ller cells	high glucose treatment	downregulated	29409329
22559	Rat	rno-miR-29b	miRNA	resveratrol	diabetic retinopathy (DR)	diabetic rats retina	RSV (5 and 10 mg/kg/day)s at 1-7 months treatment	upregulated	27311771
22560	Rat	rno-miR-29b	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	rat retinal tissues	streptozotocin (STZ) treatment	downregulated	29409329
22561	Rat	rno-miR-29b	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	Cardiomyocytes	doxorubicin (Dox) treatment	upregulated	30025410
22562	Rat	rno-miR-29b	miRNA	angiotensin II (Ang II)	epithelial-mesenchymal transition (EMT)	spontaneously hypertensive rats (SHRs) and age-matched Wistar-Kyoto (WKY) rats	angiotensin II (Ang II) treatment	downregulated	25231273
22563	Rat	rno-miR-29b	miRNA	cyclosporine A (CsA)	gingival overgrowth	gingival fibroblasts	cyclosporine A treatment	downregulated	26738448
22564	Rat	rno-miR-29b	miRNA	2-acetylaminofluorene	hepatocellular carcinoma (HCC)	liver tissue of rats	2-acetylaminofluorene treatment	downregulated	22213190
22565	Rat	rno-miR-29b	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	hypothermic Circulatory Arrest (DHCA)-associated neural injury	HT-22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29623838
22566	Rat	rno-miR-29b	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
22567	Rat	rno-miR-29b	miRNA	curcumin (Cur)	liver fibrosis	HSC-T6 cells	curcumin treatment	upregulated	24138392
22568	Rat	rno-miR-29b	miRNA	phenobarbital (PB)	liver homeostasis	liver tissues	phenobarbital (PB) treatment	upregulated	24157574
22569	Rat	rno-miR-29b	miRNA	hypoxia/reoxygenation (H/R)	myocardial dysfunction	H9c2 cells	hypoxia-reoxygenation (H/R) treatment	hypoxia-reoxygenation (H/R) reduced the expression of miRNA-29b in cardiomyoblasts cultures.	30362585
22570	Rat	rno-miR-29b	miRNA	indoxyl sulfate (IS)	myocardial infarction (MI)	cardiac fibroblasts	indoxyl sulfate (IS) treatment	downregulated	25896982
22571	Rat	rno-miR-29b	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia induce	downregulated	30362585
22572	Rat	rno-miR-29b	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	upregulated	29518613
22573	Rat	rno-miR-29b	miRNA	oxygen glucose deprivation (OGD)	neuron apoptosis	rat primary hippocampal microglial cells	oxygen-glucose deprivation (OGD) induce treatment	downregulated	30742923
22574	Rat	rno-miR-29b	miRNA	isoflurane	oxidative stress	H9c2 cells	Isoflurane treatment	upregulated	29627934
22575	Rat	rno-miR-29b	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
22576	Rat	rno-miR-29b	miRNA	angiotensin II (Ang II)	renal interstitial fibrosis (RIF)	NRK-52E cells	angiotensin II (Ang II) treatment	downregulated	29568897
22577	Rat	rno-miR-29b	miRNA	activated protein C(APC)	sepsis	rats blood and liver tissue	activated protein C treatment	aPC treatment coordinates beneficial cytoprotective effects during sepsis by modulating miRNA expression	22940033
22578	Rat	rno-miR-29b	miRNA	silica	silicosis	RLE-6TN cells (rat type II alveolar epithelial cell line)	supernatant of RAW264.7 cells stimulated by 50 mg/mL silica treatment	downregulated	30529807
22579	Rat	rno-miR-29b	miRNA	silica	silicosis	RLE-6TN cells	treatment treatment	Exposure of RLE-6TN cells to silica for 48 hr also resulted in EMT and a decrease in miR-29b gene expression	30529807
22580	Rat	rno-miR-29b	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
22581	Rat	rno-miR-29b	miRNA	angiotensin II (Ang II)	unilateral ureteral obstruction (UUO)	NRK-52E cells	angiotensin II (Ang II) treatment	"?In this study, loss of miR-29b accompanied with increased epithelial-mesenchymal transition (EMT) was observed in renal tubules of mice after UUO and cultured NRK-52E cells exposed to AngII."	33742315
22582	Rat	rno-miR-29b	miRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle	high-phosphorous treatment	upregulated	26187577
22583	Rat	rno-miR-29b	miRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle	high-phosphorous treatment	lower levels of miR-133b and miR-211 and higher levels of miR-29b	26187577
22584	Rat	rno-miR-29b-3p	miRNA	cholecalciferol	arterial calcification	Sprague Dawley rats calcified arterial tissues	subcutaneous injection of a toxic dose of cholecalciferol	downregulated in calcified arterial tissues	28164126
22585	Rat	rno-miR-29b-3p	miRNA	"1,2-dichloroethane (1,2-DCE)"	brain edema	brain parenchyma and around the vessels of the cerebral cortex	"1,2-dichloroethane (1,2-DCE) treatment"	upregulated	31734271
22586	Rat	rno-miR-29b-3p	miRNA	"1,2-dichloroethane (1,2-DCE)"	brain edema	brain cortex	"1,2-dichloroethane (1,2-DCE) treatment"	upregulated	31734271
22587	Rat	rno-miR-29b-3p	miRNA	TGF-¦Â1	cardiac fibrosis	Cardiac fibrosis	TGF-¦Â1 treatment	TGF-¦Â1 treatment dose-dependently curbed miR-29b-3p expression in CFs	32812641
22588	Rat	rno-miR-29b-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	TUG1 functioned as a positive modulator of cardiac hypertrophy via sponging miR-29b-3p	31183682
22589	Rat	rno-miR-29b-3p	miRNA	Na/K-ATPase	chronic kidney disease (CKD)	cardiac fibroblasts	Na/K-ATPase treatment	"a specific Na/K-ATPase signaling antagonist, pNaKtide, prevented ouabain-induced increases in collagen synthesis and decreases in miR-29b-3p expression in these cells"	26702050
22590	Rat	rno-miR-29b-3p	miRNA	ketamine	depression	prefrontal cortex of the normal rats	Ketamine treatment	upregulated	30369596
22591	Rat	rno-miR-29b-3p	miRNA	muscle contraction	diabetes mellitus (DM)	muscle tissues	"stimulated to contract in vitro for twitch tension analysis (0.5 Hz), 30 min later for tetanic analysis (100 Hz)"	downregulated	28000044
22592	Rat	rno-miR-29b-3p	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
22593	Rat	rno-miR-29b-3p	miRNA	hypoxia	heart failure (HF)	H9c2 cells	hypoxia induce	downregulated	30560317
22594	Rat	rno-miR-29b-3p	miRNA	hypoxia	heart failure (HF)	H9c2 cells	hypoxia induce	downregulated	30560317
22595	Rat	rno-miR-29b-3p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
22596	Rat	rno-miR-29b-3p	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	IEC-6 cells	hypoxia induce	downregulated	31167039
22597	Rat	rno-miR-29b-3p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	upregulated	27919821
22598	Rat	rno-miR-29b-3p	miRNA	particulate matter (PM2.5)	ischemia/reperfusion (I/R) injury	H9c2 cells	PM2.5 exposure treatment	LncRNA NR_136400 Suppresses Cell Proliferation and Invasion by Acting as a ceRNA of TUSC5 That Is Modulated by miR-8081 in Osteosarcoma	32100595
22599	Rat	rno-miR-29b-3p	miRNA	metformin (Met)	polycystic ovarian syndrome (PCOS)	ovary tissues	Metformin (Met) treatment	upregulated	30989649
22600	Rat	rno-miR-29c	miRNA	NOX inhibitor VAS2870	acute ischemic stroke (AIS)	tMCAO rats	intravenous treatment with NOX inhibitor VAS2870	upregulated	27325364
22601	Rat	rno-miR-29c	miRNA	fastigial nucleus stimulation (FNS)	brain injury	left intracerebroventricular	fastigial nucleus stimulation (FNS)treatment	downregulated	25678279
22602	Rat	rno-miR-29c	miRNA	exercise training (ET)	cardiac remodeling and cardiac dysfunction	obese Zucker rats carsiac	"exercise training (AET) consisted of 10 weeks of 60-min swimming sessions, and 5 days/week"	downregulated and miR-1 was upregulated compared with the control lean rats in carsiac	29138674
22603	Rat	rno-miR-29c	miRNA	epigallocatechin-3-gallate (EGCG)	chronic renal injury	cadmium (Cd) pretreated Wistar albino rats	EGCG treatment	"decreased miR-21 and miR-192, enhanced miR-29a/b/c in kidney samples"	27474435
22604	Rat	rno-miR-29c	miRNA	streptozocin (STZ)	diabetic cataract (DC)	lens epithelial cells (LECs)	Streptozotocin (STZ) treatment	downregulated	28003969
22605	Rat	rno-miR-29c	miRNA	captopril	diabetic nephropathy (DN)	diabetes rats kidney tissue	captopril treatment	upregulated	31433203
22606	Rat	rno-miR-29c	miRNA	spironolactone	diabetic nephropathy (DN)	diabetes rats kidney tissue	spironolactone treatment	upregulated	31433203
22607	Rat	rno-miR-29c	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin (STZ) treatment	upregulated	31364127
22608	Rat	rno-miR-29c	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissue	streptozotocin (STZ) treatment	downregulated	31433203
22609	Rat	rno-miR-29c	miRNA	mithramycin A and decitabine	glucocorticoids effects	rat aortic smooth muscle cells	mithramycin A and decitabine treatment	upregulated	28801263
22610	Rat	rno-miR-29c	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	hypothermic Circulatory Arrest (DHCA)-associated neural injury	HT-22 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	29623838
22611	Rat	rno-miR-29c	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
22612	Rat	rno-miR-29c	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
22613	Rat	rno-miR-29c	miRNA	Specificity protein 1 (Sp1)	renal fibrosis	Rat proximal tubular epithelial cell (NRK-52E)	Specificity protein 1 (Sp1) treatment	downregulated	23806282
22614	Rat	rno-miR-29c	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	NRK-49F cells	TGF-¦Â1 treatment	MiR-29c expression was downregulated in TGF-¦Â1-treated NRK-49F cells	32346368
22615	Rat	rno-miR-29c	miRNA	SiO2	trans-differentiation of pulmonary fibroblasts into myofibroblasts	Fibroblasts which were co-cultured with pulmonary macrophages (NR8383)	SiO2 treatment	downregulated	31177707
22616	Rat	rno-miR-29c-3p	miRNA	lipopolysaccharide (LPS)	epilepsy	CTX-TNA2 (CRL-2006) astrocyte cell line	lipopolysaccharide (LPS) treatment	downregulated	33776905
22617	Rat	rno-miR-29c-3p	miRNA	pentylenetetrazol (PTZ)	epilepsy	dorsal hippocampus	pentylenetetrazol treatment	downregulated	33776905
22618	Rat	rno-miR-29c-3p	miRNA	high glucose (HG)	functions of cardiac fibroblasts	primary cardiac fibroblasts	high glucose (HG) treatment	"MiR-29c-3p was downregulated, and STAT3 was upregulated in HG-induced cardiac fibroblasts."	32720796
22619	Rat	rno-miR-29c-3p	miRNA	fish oil	nonalcoholic fatty liver disease (NAFLD)	high-fat high-cholesterol diet rats	supplemented with fish oil (FOH)	dysregulated	28691019
22620	Rat	rno-miR-30	miRNA	doxorubicin (DOX)	cardiomyopathy	Adult rat ventricular cardiomyocytes (ARVCM)	doxorubicin treatment	downregulated	25950484
22621	Rat	rno-miR-30	miRNA	angiotensin II (Ang II)	chronic kidney disease (CKD)	neonatal rat ventricular myocytes (NRVMs)	angiotensin II (Ang II) treatment	"?Furthermore, CKD-related detrimental factors, such as fibroblast growth factor-23 (FGF-23), uraemic toxin, angiotensin-II (Ang-II) and transforming growth factor-¦Â (TGF-¦Â), suppress cardiac miRNA-30 expression"	33848263
22622	Rat	rno-miR-30	miRNA	fibroblast growth factor 23 (FGF23)	chronic kidney disease (CKD)	neonatal rat ventricular myocytes (NRVMs)	fibroblast growth factor-23 (FGF-23) treatment	"?Furthermore, CKD-related detrimental factors, such as fibroblast growth factor-23 (FGF-23), uraemic toxin, angiotensin-II (Ang-II) and transforming growth factor-¦Â (TGF-¦Â), suppress cardiac miRNA-30 expression"	33848263
22623	Rat	rno-miR-30	miRNA	indoxyl sulfate (IS)	chronic kidney disease (CKD)	neonatal rat ventricular myocytes (NRVMs)	indoxyl sulfate (IS) treatment	"?Furthermore, CKD-related detrimental factors, such as fibroblast growth factor-23 (FGF-23), uraemic toxin, angiotensin-II (Ang-II) and transforming growth factor-¦Â (TGF-¦Â), suppress cardiac miRNA-30 expression"	33848263
22624	Rat	rno-miR-30	miRNA	TGF-¦Â	chronic kidney disease (CKD)	neonatal rat ventricular myocytes (NRVMs)	TGF-¦Â treatment	"?Furthermore, CKD-related detrimental factors, such as fibroblast growth factor-23 (FGF-23), uraemic toxin, angiotensin-II (Ang-II) and transforming growth factor-¦Â (TGF-¦Â), suppress cardiac miRNA-30 expression"	33848263
22625	Rat	rno-miR-30	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	glomeruli	streptozotocin (STZ) treatment	downregulated	33490186
22626	Rat	rno-miR-30	miRNA	angiotensin-converting enzyme 2 (ACE2)	doxorubicin (DOX)-induced cardiotoxicity	Primary cardiomyocytes and H9C2 cell line	ACE2 (angiotensin-converting enzyme 2) treatment	upregulated	27633839
22627	Rat	rno-miR-30	miRNA	ferulic acid (FA)	liver fibrosis	liver tissues	ferulic acid treatment	upregulated	32278740
22628	Rat	rno-miR-30	miRNA	gallic acid (GA)	liver fibrosis	liver tissues	gallic acid treatment	upregulated	32278740
22629	Rat	rno-miR-30	miRNA	folic acid	renal fibrosis	kidney tissues	folic acid treatment	downregulated	29158184
22630	Rat	rno-miR-30	miRNA	TGF-¦Â1	renal fibrosis	rat kidney fibroblast cell NRK-49F and renal tubular epithelial cell NRK-52E	TGF-¦Â1 treatment	downregulated	29158184
22631	Rat	rno-miR-30	miRNA	TGF-¦Â1	renal fibrosis	Rat kidney fibroblast cell NRK-49F and renal tubular epithelial cell NRK-52E	TGF-¦Â1 treatment	downregulated	29158184
22632	Rat	rno-miR-30	miRNA	angiotensin II (Ang II)	WC-Co-induced carcinogenesis	Cardiomyocyte	angiotensin II (Ang II) treatment	Angiotensin II induces downregulated of miR-30 in cardiomyocytes	23326547
22633	Rat	rno-miR-300-3p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
22634	Rat	rno-miR-300-5p	miRNA	angiotensin II (Ang II)	cardiac fibrosis and hypertension	cardiac fibroblasts (CFs) of rats	angiotensin II (Ang II) treatment	downregulated	23007623
22635	Rat	rno-miR-301a	miRNA	glycine	neuronal cell injury	cortical neurons	Glycine treatment	upregulated	27230112
22636	Rat	rno-miR-301a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22637	Rat	rno-miR-301b-3p	miRNA	mono-n-butyl phthalate (MBP)	cell proliferation	rat juvenile Sertoli cells (SCs)	treat with 0.1mM MBP	upregulated	29162477
22638	Rat	rno-miR-302	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31845077
22639	Rat	rno-miR-302a	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31845077
22640	Rat	rno-miR-302b	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31845077
22641	Rat	rno-miR-302b-3p	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin (STZ) treatment	upregulated	32432759
22642	Rat	rno-miR-302b-3p	miRNA	isoflurane	neuronal cell injury	primary hippocampal neurons	Isoflurane (ISO) treatment	ISO stimulation led to miR-302b-3p upregulation and neuronal injury.	33370590
22643	Rat	rno-miR-302b-3p	miRNA	isoflurane	neuronal cell injury	rat hippocampal neurons	Isoflurane (ISO) treatment	?We discovered that ISO stimulation led to miR-302b-3p upregulation and neuronal injury.	33370590
22644	Rat	rno-miR-302c	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31845077
22645	Rat	rno-miR-302c	miRNA	high glucose (HG)	mesothelial/epithelial-mesenchymal transition (MMT/EMT)	mouse peritoneum	high glucose peritoneal dialysate induce	downregulated	30693641
22646	Rat	rno-miR-302d	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31845077
22647	Rat	rno-miR-302e	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31222747
22648	Rat	rno-miR-302e	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	MAGI1-IT1 functioned as a negative regulator in CH through inactivating Wnt/beta-catenin pathway via targeting miR-302e/DKK1 axis	31222747
22649	Rat	rno-miR-30-3p	miRNA	hypoxia	myocardial infarction (MI)	H9C2 cells	"cobalt chloride solution as 1000 ?mol/L, hypoxia for 12 hours"	miRNA-30-3p had the effect of improving cell apoptosis induced by myocardial ischemia in vitro and in vivo studies by the regulation of the PTEN/PI3K/AKT pathway.	31131466
22650	Rat	rno-miR-3068-3p	miRNA	glutamate	ischemic stroke (IS)	rat primary cortical neurons	glutamate treatment	upregulated	31792968
22651	Rat	rno-mir-3074	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22652	Rat	rno-miR-3074-5p	miRNA	palmitate	pancreatic ¦Â-cell dysfunction	INS-1E cells	palmitate treatment	lncEif4g2 is able to indirectly regulate the expression of CREB via targeting miR-3074-5p in INS-1E cells and mouse islets	32956705
22653	Rat	rno-miR-3084a-3p	miRNA	cadmium (Cd)	cadmium (Cd)-induced kidney injury	renal cortex	cadmium (Cd) treatment	upregulated	29543730
22654	Rat	rno-miR-3084c-3p	miRNA	cadmium (Cd)	cadmium (Cd)-induced kidney injury	renal cortex	cadmium (Cd) treatment	upregulated	29543730
22655	Rat	rno-miR-30a	miRNA	paeonol (PAE)	atherosclerosis (AS)	vascular endothelial cells (VECs)	paeonol treatment	"ox-LDL decreased miR-30a and increased Beclin-1 expression, pretreatment with paeonol could reverse the process of regulation in dose-dependent manners"	29472864
22656	Rat	rno-miR-30a	miRNA	triiodo-l-thyronine (T3)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	primary cardiomyocyte of neonatal rats with hypoxia	T3 treatment	upregulated	25137026
22657	Rat	rno-miR-30a	miRNA	phenylephrine (PE)	cardiac hypertrophy	H9c2 cells	phenylephrine treatment	downregulated	23660952
22658	Rat	rno-miR-30a	miRNA	rapamycin	cell senescence	vascular smooth muscle cells (VSMCs)	rapamycin treatment	downregulated	30747228
22659	Rat	rno-miR-30a	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	male Wistar rats inflamed colon	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated in inflamed colon	28572713
22660	Rat	rno-miR-30a	miRNA	caffeic acid	diabetic nephropathy (DN)	high-fat diet and streptozotocin-induced (HFD-STZ) diabetic rats	caffeic acid (CA) treatment	downregulated	28536471
22661	Rat	rno-miR-30a	miRNA	S100A12	diabetic retinopathy (DR)	Retinal microglia	S100A12 treatment	downregulated	31199706
22662	Rat	rno-miR-30a	miRNA	TGF-¦Â1	insulin resistance (IR)	peritoneal tissue in a rat	TGF-¦Â1 treatment	downregulated	24378208
22663	Rat	rno-miR-30a	miRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepS cells	cis-dichloro-diamine platinum (cis-DDP) treatment	upregulated	22157765
22664	Rat	rno-miR-30a	miRNA	taxol	hepatocellular carcinoma (HCC)	HepS cells	Taxol treatment	upregulated	22157765
22665	Rat	rno-miR-30a	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	downregulated	29587268
22666	Rat	rno-miR-30a	miRNA	melatonin	malignant arrhythmias	older obese female rat hearts	melatonin treatment	downregulated	30446908
22667	Rat	rno-miR-30a	miRNA	melatonin	malignant arrhythmias	high-sucrose-induced left ventricles of female rat hearts	Melatonin treatment	downregulated	30446908
22668	Rat	rno-miR-30a	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	malignant arrhythmias	older obese female rat hearts	omega-3 polyunsaturated fatty acids treatment	downregulated	30446908
22669	Rat	rno-miR-30a	miRNA	omega-3 polyunsaturated fatty acids (¦Ø-3 PUFA)	malignant arrhythmias	high-sucrose-induced left ventricles of female rat hearts	omega-3 polyunsaturated fatty acids treatment	downregulated	30446908
22670	Rat	rno-miR-30a	miRNA	substance P (SP)	malignant arrhythmias	left ventricles of female rat hearts	sucrose treatment	upregulated	30446908
22671	Rat	rno-miR-30a	miRNA	sucrose	malignant arrhythmias	older obese female rat hearts	sucrose treatment	upregulated	30446908
22672	Rat	rno-miR-30a	miRNA	angiotensin II (Ang II)	myocardial injury	rats primary cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	25501305
22673	Rat	rno-miR-30a	miRNA	epigallocatechin-3-gallate (EGCG)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced H9c2 cardiomyocytes	EGCG treatment	upregulated	31029907
22674	Rat	rno-miR-30a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cardiomyocytes	hypoxia induce	downregulated	31029907
22675	Rat	rno-miR-30a	miRNA	osthole	myocardial ischemia/reperfusion (I/R) injury (MIRI)	I/R in rat heart tissues and hypoxia/reoxygenation (H/R) in myocardial cells in vitro	osthole treatment	downregulated	31017665
22676	Rat	rno-miR-30a	miRNA	H2O2	oxidative stress	cardiovascular cells NRVCs and RAVSMCs	H2O2 treatment	downregulated	24612558
22677	Rat	rno-miR-30a	miRNA	isoflurane and sevoflurane	postoperative cognitive dysfunction (POCD)	Wistar rats hippocampus	exposed to isoflurane and sevoflurane for 2 or 4h	downregulated in the hippocampus	28669717
22678	Rat	rno-miR-30a	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
22679	Rat	rno-miR-30a	miRNA	grape seed proanthocyanidins (GSPs)	prostatic deficits	prostate	orally given for 20 weeks	upregulated	28499242
22680	Rat	rno-miR-30a*	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
22681	Rat	rno-miR-30a-3p	miRNA	compound 21 (C21)	cardiac hypertrophy	Zucker diabetic fatty (ZDF) rats heart tissues	Compound 21 (C21) treatment	downregulated	30187136
22682	Rat	rno-miR-30a-3p	miRNA	losartan	cardiac hypertrophy	Zucker diabetic fatty (ZDF) rats heart tissues	losartan treatment	downregulated	30187136
22683	Rat	rno-miR-30a-3p	miRNA	compound 21 (C21)	cardiac hypertrophy	heart tissues	Compound 21 (C21) treatment	downregulated	30187136
22684	Rat	rno-miR-30a-3p	miRNA	losartan	cardiac hypertrophy	heart tissues	losartan treatment	downregulated	30187136
22685	Rat	rno-miR-30a-5p	miRNA	¦Â3-adrenoceptors(¦Â3-AR) inhibitor SR 59230A	chronic heart failure (CHF)	CHF rats	1 ml SR 59230A(85 mmoL/L in 0.9% saline)twice a day for seven weeks by intraperitoneal injection treatment	upregulated	29926593
22686	Rat	rno-miR-30a-5p	miRNA	glucose	glucotoxicity	rat islets and INS-1 cells	glucose treatment	upregulated	23338554
22687	Rat	rno-miR-30a-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	Hypoxia/reoxygenation (H/R) remarkably raised the level of miR-30a-5p in H9c2 cardiomyocytes.	33058540
22688	Rat	rno-miR-30a-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	LINC00707 alleviates LPS-induced inflammation and apoptosis in PC-12 cells by targeting miR-30a-5p/Neurod 1	31272297
22689	Rat	rno-miR-30b	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	PC12; C6 cells	amyloid-¦Â (A¦Â) 25-35 treatment	MALAT1 could promote neuronal recovery following AD through the miR-30b/CNR1 network and the PI3K/AKT signaling activation.	32976819
22690	Rat	rno-miR-30b	miRNA	angiotensin II (Ang II)	cardiomyocytes cell death	rat neonatal cardiomyocytes	angiotensin II (Ang II) treatment	dysregulated	24178239
22691	Rat	rno-miR-30b	miRNA	hypoxia/reoxygenation (H/R)	cardiomyopathy	H9C2 cell line	hypoxia/re-oxygenation treatment	downregulated	27294099
22692	Rat	rno-miR-30b	miRNA	high glucose (HG)	diabetic retinopathy (DR)	rat retinal M¨¹ller cells (rMC-1) cells	high glucose	downregulated	28246353
22693	Rat	rno-miR-30b	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	30721562
22694	Rat	rno-miR-30b	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22695	Rat	rno-miR-30b	miRNA	H2O2	oxidative stress	cardiovascular cells NRVCs and RAVSMCs	H2O2 treatment	downregulated	24612558
22696	Rat	rno-miR-30b	miRNA	grape seed proanthocyanidins (GSPs)	prostatic deficits	prostate	orally given for 20 weeks	upregulated	28499242
22697	Rat	rno-miR-30b-3p	miRNA	triptolide (TPL)	nephropathy	blood and renal tissues	rats with adriamycin-induced nephropathy treatment	triptolide treatment reversed the increase in the expression of these two miRNAs	26078766
22698	Rat	rno-miR-30b-5p	miRNA	estradiol-17¦Â (E2)	osteogenesis	primary bone marrow mesenchymal stem cells from rats (rBMSCs)	estradiol-17¦Â (E2) treatment	downregulated	31089333
22699	Rat	rno-miR-30b-5p	miRNA	oxaliplatin	peripheral neuropathic pain	dorsal root ganglion (DRG) tissues	oxaliplatin treatment	downregulated	31054938
22700	Rat	rno-miR-30b-5p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	upregulated	26997989
22701	Rat	rno-miR-30c	miRNA	TGF-¦Â1	atrial fibrosis	primary cultured neonatal cardiac fibroblasts (CFs)	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	29532993
22702	Rat	rno-miR-30c	miRNA	vitamin D receptor activators (VDRAs)	chronic renal failure (CRF)	nephrectomized Wistar rats	equivalent doses of two VDRAs: calcitriol and paricalcitol treatment	upregulated	28460073
22703	Rat	rno-miR-30c	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiomyocytes	high glucose treatment	upregulated	27221738
22704	Rat	rno-miR-30c	miRNA	palmitate	diabetic cardiomyopathy (DCM)	H9c2 cells and primary neonatal rat cardiomyocytes	palmitate treatment	downregulated	30635067
22705	Rat	rno-miR-30c	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	cardiomyocytes	low-dose streptozotocin-high-fat diet treatment	downregulated	25781190
22706	Rat	rno-miR-30c	miRNA	pilocarpine	epilepsy	adult male rats brain tissue and heart tissue	50 days of pilocarpine treatment	downregulated in heart tissue	24530830
22707	Rat	rno-miR-30c	miRNA	hydrogen sulfide (H2S)	ischemia/reperfusion (I/R) injury	spinal cord infarct zone	Hydrogen sulfide (H2S) treatment	downregulated	26149869
22708	Rat	rno-miR-30c	miRNA	angiotensin II (Ang II)	liver fibrosis/cirrhosis	hepatic stellate cells (HSCs)	angiotensin II (Ang II) treatment	downregulated	27142827
22709	Rat	rno-miR-30c	miRNA	cisplatin (DDP)	nephrotoxicity	rats renal tubules and epithelial cell	cisplatin treatment	downregulated	28796263
22710	Rat	rno-miR-30c	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
22711	Rat	rno-miR-30c	miRNA	grape seed proanthocyanidins (GSPs)	prostatic deficits	prostate	orally given for 20 weeks	upregulated	28499242
22712	Rat	rno-miR-30c	miRNA	TGF-¦Â1	renal fibrosis	renal tubular epithelial cells (NRK-52E)	TGF-¦Â1 treatment	downregulated	27874055
22713	Rat	rno-miR-30c	miRNA	oxygen glucose deprivation (OGD)	spinal cord ischemia/reperfusion injury (SCII)	PC12 cells	oxygen-glucose deprivation (OGD) treatment	upregulated	30776367
22714	Rat	rno-miR-30c	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
22715	Rat	rno-miR-30c	miRNA	propranolol (PRO)	¦Â-adrenoceptor intervention	rat heart	propranolol (PRO) treatment	upregulated	22847192
22716	Rat	rno-miR-30c-1*	miRNA	grape seed procyanidin extract (GSPE)	pancreatic islet injury	rat islets	grape seed procyanidin extract (GSPE)treatment	"GSPE altered significantly the expression of miR-1249, miR-483, miR-30c-1*, and miR-3544."	23215023
22717	Rat	rno-miR-30c-2*	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
22718	Rat	rno-miR-30c-5p	miRNA	ischemia/reperfusion (I/R) 	kidney damage	Sprague-Dawley rats urine	ischemia/reperfusion (I/R) treatment	upregulated	28056546
22719	Rat	rno-miR-30c-5p	miRNA	tert-butyl hydroperoxide (TBHP)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	tert- butyl hydroperoxide tBHP treatment	MiR-30c-5p mediates the effects of panax notoginseng saponins in myocardial ischemia reperfusion injury by inhibiting oxidative stress-induced cell damage.	32036220
22720	Rat	rno-miR-30c-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22721	Rat	rno-miR-30d	miRNA	valproic acid (VPA)	autism spectrum disorder (ASD)	amygdala	valproic acid treatment	upregulated	25986729
22722	Rat	rno-miR-30d	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal cardiomyocytes	angiotensin II (Ang II) treatment	upregulated	33860820
22723	Rat	rno-miR-30d	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	rats heart	STZ treatment	upregulated	25341033
22724	Rat	rno-miR-30d	miRNA	SGLT-2 inhibitors	diabetic cardiomyopathy (DCM)	heart tissues	SGLT-2 inhibitors treatment	SGLT-2 inhibitors prevented heart function decline in diabetic rats by inhibiting miR-30d	32572932
22725	Rat	rno-miR-30d	miRNA	TianMai Xiaoke tablet(TM)	type 2 diabetes mellitus (T2DM)	diabetic rats islet	TM treatment	upregulated	24812635
22726	Rat	rno-miR-30d	miRNA	follicle stimulating hormone (FSH)	colorectal cancer (CRC)	rat granulosa cells	Follicle-stimulating hormone (FSH)treatment	downregulated	20734245
22727	Rat	rno-miR-30d-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22728	Rat	rno-miR-30d-5p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	upregulated	27919821
22729	Rat	rno-miR-30d-5p	miRNA	fish oil	nonalcoholic fatty liver disease (NAFLD)	high-fat high-cholesterol diet rats	supplemented with fish oil (FOH)	dysregulated	28691019
22730	Rat	rno-miR-30d-5p	miRNA	follicle stimulating hormone (FSH)	polycystic ovarian syndrome (PCOS)	rat cultured granulosa cells	follicle stimulating hormone (FSH) treatment	upregulated	31853272
22731	Rat	rno-miR-30e	miRNA	isoproterenol	cardiac fibrosis	Sprague Dawley rats hearts	ISO treatment	downregulated in the hearts	28777253
22732	Rat	rno-miR-30e	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
22733	Rat	rno-miR-30e	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat myocardial tissues	hypoxia/reoxygenation injury (H/R)? treatment	Decreased miR-30e and increased SOX9 were found in myocardial tissues of MI/RI rats and H/R-treated cardiomyocytes.	33293097
22734	Rat	rno-miR-30e	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation injury (H/R) treatment	downregulated	33293097
22735	Rat	rno-miR-30e	miRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	dysregulated	24517225
22736	Rat	rno-miR-30e	miRNA	serum	cell proliferation	VSMCs isolated from normal aorta of adult male rats	were stimulated with 10% serum treatment	downregulated	28123167
22737	Rat	rno-miR-30e	miRNA	schisandrin B (Sch B)	tubulointerstitial fibrosis (TIF)	TGF-¦Â1-treated NRK-52e cells	Schisandrin B (Sch B) treatment	upregulated	31697999
22738	Rat	rno-miR-30e	miRNA	TGF-¦Â1	tubulointerstitial fibrosis (TIF)	NRK-52e cells	TGF-¦Â1 treatment	downregulated	31697999
22739	Rat	rno-miR-30e-3p	miRNA	rapamycin	cardiac fibrosis	heart tissues	rapamycin (Rap) treatment	upregulated	30647817
22740	Rat	rno-miR-31	miRNA	atorvastatin	cardiac hypertrophy	chronic intermittent hypoxia (CIH)-treated H9c2 cells	atorvastatin treatment	downregulated	30074205
22741	Rat	rno-miR-31	miRNA	hypoxia	cardiac hypertrophy	H9c2 cells	chronic intermittent hypoxia (CIH) induce	upregulated	30074205
22742	Rat	rno-miR-31	miRNA	hypoxia	myocardial infarction (MI)	heart tissues	MI was induced by ligation of the left anterior descending coronary artery (LAD)	upregulated	28865712
22743	Rat	rno-miR-31	miRNA	isoflurane and sevoflurane	postoperative cognitive dysfunction (POCD)	Wistar rats hippocampus	exposed to isoflurane and sevoflurane for 2 or 4h	downregulated in the hippocampus	28669717
22744	Rat	rno-miR-31-5p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (Dox) treatment	downregulated	32135167
22745	Rat	rno-miR-31a-5p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31899128
22746	Rat	rno-miR-31a-5p	miRNA	angiotensin II (Ang II)	heart failure (HF)	cardiac H9C2 cell line	angiotensin II (Ang II) treatment	downregulated	29286111
22747	Rat	rno-miR-31a-5p	miRNA	angiotensin II (Ang II)	heart failure (HF)	H9C2 cell line	angiotensin II (Ang II) treatment	downregulated	29286111
22748	Rat	rno-miR-31a-5p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	upregulated	32893733
22749	Rat	rno-miR-31b	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	upregulated	32893733
22750	Rat	rno-miR-31c	miRNA	H2O2	oxidative stress	cardiovascular cells NRVCs and RAVSMCs	H2O2 treatment	downregulated	24612558
22751	Rat	rno-miR-32	miRNA	streptozocin (STZ)	liver fibrosis	liver tissue	streptozotocin (STZ) treatment	upregulated	30816482
22752	Rat	rno-miR-320	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	downregulated	28199183
22753	Rat	rno-miR-320	miRNA	high glucose (HG)	diabetic retinopathy (DR)	M¨¹ller cells	high glucose (HG) treatment	DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals. Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas	33762162
22754	Rat	rno-miR-320	miRNA	ethylene glycol monomethyl ether (EGME)	hyperglycemia	?testicle of rat	Ethylene glycol monomethyl ether (EGME) treatment	"miR-449a and miR-92a decreased obviously and, miR-320, miR-134 and miR-188 increased"	22008535
22755	Rat	rno-miR-320	miRNA	high salt (HS)	hypertension	aorta of? rats	high salt (HS) treatment	upregulated	24161401
22756	Rat	rno-miR-320	miRNA	edaravone (ED)	intestinal mucosa barrier dysfunction after burn injury	intestinal mucosal tissue injury in burned rats	edaravone (ED) treatment	upregulated	31829167
22757	Rat	rno-miR-320	miRNA	oxygen glucose deprivation (OGD)	ischemic heart disease (IHD)	H9c2 cells	oxygen and glucose deprivation (OGD) treatment	Overexpressed circRNA-DENND4C in H9c2 cells attenuated OGD/R-induced injuries by the downregulated of miR-320 through the ERK and mTOR activation	33090893
22758	Rat	rno-miR-320	miRNA	verapamil	male fertility	testis	verapamil treatment	downregulated	32725937
22759	Rat	rno-miR-320	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cardiac myocytes	hypoxia induce	upregulated	29521436
22760	Rat	rno-miR-320	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	upregulated	30181740
22761	Rat	rno-miR-320	miRNA	insulin	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced H9C2 cardiac myocytes	insulin treatment	downregulated	29521436
22762	Rat	rno-miR-320	miRNA	luteolin	renal ischemia/reperfusion (I/R) injury	ischemia-reperfusion (I/R) injury rats kidney tissues	luteolin treatment	downregulated	31089916
22763	Rat	rno-miR-3202	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	rats bronchia	cigarette smoke (CS) treatment	downregulated in bronchia	29208459
22764	Rat	rno-miR-320-3p	miRNA	morphine	myocardial hypoxia/reoxygenation (H/R) injury	H9c2 cells	Morphine pre-conditioning (MPC)	The expression of miR-320-3p in the MPC+H/R group was significantly lower than that in the H/R group.	32468068
22765	Rat	rno-miR-320-5p	miRNA	¦Â3-adrenoceptors(¦Â3-AR) inhibitor SR 59230A	chronic heart failure (CHF)	CHF rats	1 ml SR 59230A(85 mmoL/L in 0.9% saline)twice a day for seven weeks by intraperitoneal injection treatment	upregulated	29926593
22766	Rat	rno-miR-320a	miRNA	insulin	polycystic ovarian syndrome (PCOS)	KGN cells	insulin treatment	upregulated	28849208
22767	Rat	rno-miR-320b	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
22768	Rat	rno-miR-320c	miRNA	streptozocin (STZ)	type 1 diabetes mellitus (T1DM)	INS-1 cells	streptozocin (STZ) treatment	Secretions of miR-320c was significantly increased in streptozotocin-treated INS-1 cells	29370422
22769	Rat	rno-miR-322	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	upregulated	28199183
22770	Rat	rno-miR-322	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	33333053
22771	Rat	rno-miR-322	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	rat liver tissue	CCl4 treatment	"miR-322/424 level in liver cirrhosis patients, mouse liver fibrosis induced by CCl4?and BDL, and rat liver fibrosis induced by CCl4?and dimethylnitrosamine was increased."	33333053
22772	Rat	rno-miR-322-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	downregulated	32436661
22773	Rat	rno-miR-322-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	rat vascular smooth muscle cells (VSMCs)	high glucose	downregulated	28536423
22774	Rat	rno-miR-322-5p	miRNA	bortezomib	peripheral neuropathy	PC12 cells	bortezomib treatment	downregulated	31979371
22775	Rat	rno-miR-322-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22776	Rat	rno-miR-323	miRNA	hypoxia	cerebral infarction (CI)	PC12 cells	hypoxia induce	upregulated	30535466
22777	Rat	rno-miR-323	miRNA	oxygen glucose deprivation (OGD)	neuronal cell death	primary hippocampal neuron	oxygen-glucose deprivation (OGD) treatment	upregulated	26617783
22778	Rat	rno-miR-323-3p	miRNA	H2O2	myocardial infarction (MI)	H9c2 cells	H2O2 treatment	downregulated	32633390
22779	Rat	rno-miR-323a-3p	miRNA	angiotensin II (Ang II)	cardiac fibrosis	rat cardiac fibroblasts (CFs)	angiotensin II (Ang II) treatment	MiR-323a-3p was found upregulated in CFs cultured with Angiotensin ¢ò (Ang ¢ò).	30551487
22780	Rat	rno-miR-324	miRNA	aerobic exercise	parkinson's disease (PD)	brain tissues	aerobic exercise training (AET) treatment	downregulated	31309116
22781	Rat	rno-miR-324-3p	miRNA	2-imidazolidinethione	anorectal malformations (ARM)	Intestinal epithelial cells; IECs and anorectal tissues	2-imidazolidinethione treatment	"Rno_circ_0005139 influences cell proliferation and apoptosis by acting as a miR-324-3p sponge, thereby downregulating Wnt5a in ARM."	32848333
22782	Rat	rno-miR-324-3p	miRNA	high fat diet (HFD)	cardiac remodeling	heart tissues	high fat diet (HFD) feed	upregulated	29884823
22783	Rat	rno-miR-324-3p	miRNA	hypoxia	cortical injury	rat cortex tisssues	hypoxia treatment	downregulated	23272113
22784	Rat	rno-miR-324-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retinas tissues	streptozotocin treatment	downregulated	31430717
22785	Rat	rno-miR-324-3p	miRNA	¦Ä-opioid receptor (DOR)	hypoxic/ischemic injury	hearts	¦Ä-opioid receptor (DOR) activation treatment	upregulated	27576463
22786	Rat	rno-miR-324-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute myocardial infarction (AMI)	rat ventricular cardiomyocytes (NRCMs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31622017
22787	Rat	rno-miR-324-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary rat neurons	oxygen-glucose deprivation (OGD) induce treatment	downregulated	31885705
22788	Rat	rno-miR-324-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary rat neurons	oxygen-glucose deprivation (OGD) treatment	Downregulated miRNA-324-5p aggravates neuronal injury induced by oxygen-glucose deprivation via modulating RAN	31885705
22789	Rat	rno-miR-324-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	Neonatal rat ventricular cardiomyocytes (NRCMs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Inhibition of the LncRNA Gpr19 attenuates ischemia-reperfusion injury after acute myocardial infarction by inhibiting apoptosis and oxidative stress via the miR-324-5p/Mtfr1 axis.	31622017
22790	Rat	rno-miR-325-3p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	"The expression levels of MEG3 and TRPV4 were significantly increased, whereas miR-325-3p expression levels were significantly decreased in hypoxic H9c2 cells compared with normoxic H9c2 cells."	33179099
22791	Rat	rno-miR-325-5p	miRNA	neonatal colonic inflammation (NCI)	chronic visceral hypersensitivity	colon-related dorsal root ganglia (DRGs)	neonatal colonic inflammation (NCI) induce	downregulated	30980241
22792	Rat	rno-miR-326	miRNA	alcohol	fetal alcohol exposure (FAE)	pregnant Fisher 344 rats pituitary	liquid diet containing 6.7% alcohol between gestational days 7-21 (AF)	upregulated	28710248
22793	Rat	rno-miR-326	miRNA	formaldehyde	formaldehyde inducted immune/inflammation	rats	were exposed to formaldehyde treatment	upregulated	24304932
22794	Rat	rno-miR-326	miRNA	oxygen glucose deprivation (OGD)	hypoxic/ischemic brain damage (HIBD)	PC-12 cells	oxygen glucose deprivation (OGD) treatment	The expression levels of miR-326 was significantly lower in the HIBD group.	32228617
22795	Rat	rno-miR-326-3p	miRNA	cadmium (Cd)	kidney damage	NRK-52E cells	cadmium (Cd) treatment	miR-122-5p and miR-326-3p might enhance cadmium-induced NRK-52E cell apoptosis through downregulating PLD1 expression.	32697411
22796	Rat	rno-miR-326-3p	miRNA	cadmium (Cd)	renal toxic	"NRK-52E cells, rat kidney, serum and urine samples"	cadmium (Cd) treatment	upregulated	31626960
22797	Rat	rno-miR-326-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary rat cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Mfn2 and miR-326-5p were reduced, and STAT3 was elevated in OGD-treated neurons and brain tissues of MCAO rats"	33877455
22798	Rat	rno-miR-327	miRNA	angiotensin II (Ang II)	cardiac hypertrophy and fibrosis	rat cardiac fibroblasts	angiotensin II (Ang II) treatment	miR-327 levels in fibroblasts were increased.	29393356
22799	Rat	rno-miR-327	miRNA	oxygen	lung injury	pregnant rats lung tissue	inspired oxygen of 10.5 or 23% for two days treatment	downregulated	25120593
22800	Rat	rno-miR-327	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H9c2 cells were exposed to hypoxia for 4?hr and reoxygenation for 12?hr to mimic I/R injury	upregulated	31587299
22801	Rat	rno-miR-327	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H92c cells	hypoxia/reoxygenation (H/R) treatment	Inhibition of microRNA-327 ameliorates ischemia/reperfusion injury-induced cardiomyocytes apoptosis through targeting apoptosis repressor with caspase recruitment domain	31587299
22802	Rat	rno-miR-328	miRNA	doxycycline	atrial fibrillation (AF)	heart tissues	doxycycline treatment	downregulated	30470910
22803	Rat	rno-miR-328	miRNA	doxycycline	atrial fibrillation (AF)	heart sissues	doxycycline treatment	upregulated	30470910
22804	Rat	rno-miR-328	miRNA	60 mmHg of pressure	renal fibrosis	rat renal tubular cells (NRK-52E)	culture under 60 mmHg of pressure treatment	downregulated	24919189
22805	Rat	rno-miR-328a	miRNA	high fat diet (HFD)	erectile dysfunction (ED)	rats	high fat diet (HFD) feed	corpus cavernosum (CC)	28970082
22806	Rat	rno-miR-328a-3p	miRNA	cold	cold stress	rats serum	cold conditions (4¡æ for 12h)	downregulated	28477904
22807	Rat	rno-miR-328a-3p	miRNA	fish oil	nonalcoholic fatty liver disease (NAFLD)	high-fat high-cholesterol diet rats	supplemented with fish oil (FOH)	dysregulated	28691019
22808	Rat	rno-miR-328a-5	miRNA	cadmium (Cd)	cadmium (Cd)-induced reproductive toxicity	testes	cadmium (Cd) treatment	"miR-328a-5p was significantly increased only in the 2.0 mg/kg Cd treatment group at PND 21. at PND 56, the expression of miR-328a-5p decreased in all of the Cd treatment groups (P < 0.05 and P < 0.01) and decreased to 0.4 in the 2.0 mg/kg Cd treatment group."	31654709
22809	Rat	rno-miR-329	miRNA	comfrey	tumorigenesis	rat liver	comfrey treatment	downregulated	21370286
22810	Rat	rno-miR-329-3p	miRNA	estradiol benzoate (EB) and testosterone (T)/E	chronic inflammatory diseases	dorsolateral prostate	estradiol benzoate (EB) and testosterone (T)/E treatment	downregulated	33332750
22811	Rat	rno-miR-32d	miRNA	H2O2	oxidative stress	cardiovascular cells NRVCs and RAVSMCs	H2O2 treatment	downregulated	24612558
22812	Rat	rno-miR-33	miRNA	grape seed proanthocyandin extract (GSPE)	dysregulated fatty acid and cholesterol metabolism	rat liver cells	grape seed proanthocyanidins extracts (GSPE) treatment	downregulated	22965541
22813	Rat	rno-miR-33	miRNA	icariside II (ICA II)	erectile dysfunction (ED)	Adipose derived stem cells (ADSCs)	Icariside II (ICA II) treatment	ICA II promoted the differentiation of ADSCs to SCs through downregulating miR-33.	32066039
22814	Rat	rno-miR-33	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
22815	Rat	rno-miR-33	miRNA	estradiol	metabolic effects of estrogen	liver tissues	estradiol treatment	upregulated	32045601
22816	Rat	rno-miR-33	miRNA	arterial mechanical stretch	neointimal hyperplasia	Sprague-Dawley rats venous smooth muscle cells (SMCs)	exposed to a 10%-1.25 Hz cyclic arterial stretch	downregulated	28137944
22817	Rat	rno-miR-330	miRNA	lipopolysaccharide (LPS)	disseminated intravascular coagulation (DIC)	liver tissues	lipopolysaccharide (LPS) treatment	upregulated	24806323
22818	Rat	rno-miR-330	miRNA	fructose	kidney damage	rats kidney cortex	fructose treatment	downregulated in kidney cortex	28205387
22819	Rat	rno-miR-330	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
22820	Rat	rno-miR-330-3p	miRNA	high glucose (HG)	gestational diabetes mellitus (GDM)	INS-1 cells	high glucose (HG) treatment	The miR-330-3p expression level positively correlated with blood glucoseand and it was highly expressed in glucose-treated INS-1 cells.	32202040
22821	Rat	rno-miR-330-5p	miRNA	H2O2	adipogenesis	mesenchymal stem cells (MSCs)	H2O2 treatment	downregulated	30015907
22822	Rat	rno-miR-330-5p	miRNA	high fat diet (HFD)	cardiac remodeling	heart tissues	high fat diet (HFD) feed	upregulated	29884823
22823	Rat	rno-miR-330-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22824	Rat	rno-miR-331-3p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	SOX2OT was elevated in SCI rat and cell models.	33340723
22825	Rat	rno-miR-331-5p	miRNA	ketamine	drug addiction	hippocampus tissues	ketamine treatment	downregulated	29476799
22826	Rat	rno-miR-331-5p	miRNA	rhynchophylline	drug addiction	ketamine-addicted rats hippocampus tissues	rhynchophylline treatment	downregulated	29476799
22827	Rat	rno-miR-335	miRNA	hypoxia	acute ischemic stroke (AIS)	brain tissues	Middle cerebral artery occlusion (MCAO) treatment	downregulated	30747210
22828	Rat	rno-miR-335	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31899128
22829	Rat	rno-miR-335	miRNA	methane	diabetic retinopathy (DR)	Retinal?tissues	methane treatment	upregulated	26363454
22830	Rat	rno-miR-335	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	miR-335 was significantly downregulat- ed in H/R-exposed cardiomyocytes.	30662652
22831	Rat	rno-miR-335	miRNA	glucocorticoid (GC)	osteonecrosis of femoral head (ONFH)	rat femoral head bone microvascular endothelial cells (BMECs)	glucocorticoids treatment	ICA could regulate the overexpression of miRNA-335 induced by glucocorticoids.	32911026
22832	Rat	rno-miR-335	miRNA	icariin (ICA)	osteonecrosis of femoral head (ONFH)	rat femoral head bone microvascular endothelial cells (BMECs)	Icariin (ICA) treatment	ICA could regulate the overexpression of miRNA-335 induced by glucocorticoids.	32911026
22833	Rat	rno-mir-335	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22834	Rat	rno-miR-335	miRNA	methylprednisolone	steroid-induced osteonecrosis of femoral head (ONFH)	bone microvascular endothelial cells (BMECs)	methylprednisolone treatment	upregulated	29408208
22835	Rat	rno-miR-335-3p	miRNA	chronic normobaric hypoxia (CNH)	pulmonary arterial hypertension (PAH)	lung tissues	chronic normobaric hypoxia (CNH) treatment	MiR-335-3p was significantly increased in lung tissue of CNH-induced PAH mice.	32015687
22836	Rat	rno-miR-33-5p	miRNA	fish oil	nonalcoholic fatty liver disease (NAFLD)	high-fat high-cholesterol diet rats	supplemented with fish oil (FOH)	dysregulated	28691019
22837	Rat	rno-miR-336-5p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	upregulated	27535721
22838	Rat	rno-miR-337	miRNA	"bone matrix gelatin ,collagen,and pristane"	chondrogenesis	rat cartilage	"bone matrix gelatin ,collagen,and pristane treatment"	downregulated	22425884
22839	Rat	rno-miR-337	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	neonatal rat ventricular cardiomyocytes	hypoxia induce	upregulated	31220137
22840	Rat	rno-miR-337	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary cultured astrocytes (AST)	lipopolysaccharide (LPS) treatment	upregulated	30257365
22841	Rat	rno-miR-337	miRNA	mulberrin (Mul)	spinal cord injury (SCI)	Spinal cord injury (SCI) rats spinal cord tissue	Mulberrin (Mul) treatment	downregulated	30257365
22842	Rat	rno-miR-337	miRNA	mulberrin (Mul)	spinal cord injury (SCI)	LPS-treated primary cultured astrocytes (AST)	Mulberrin (Mul) treatment	downregulated	30257365
22843	Rat	rno-miR-337-3p	miRNA	CoCl2	hypoxia-induced injury	PC12 cells	CoCl2 treatment	upregulated	31264277
22844	Rat	rno-miR-337-3p	miRNA	palmitate and palmitate plus oleate.	insulin resistance (IR)	mouse myoblasts	palmitate and palmitate plus oleate treatment	upregulated	21183973
22845	Rat	rno-miR-337-5p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
22846	Rat	rno-miR-338	miRNA	Tectorigenin	cell proliferation	rat pulmonary fibroblasts	Tectorigenin treatment	"Tectorigenin inhibits the proliferation of pulmonary fibroblasts in vitro and enhances miR-338* expression, which might in turn downregulate LPA1"	20600766
22847	Rat	rno-miR-338	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
22848	Rat	rno-miR-338	miRNA	¦Ä-opioid receptor (DOR)	hypoxic/ischemic injury	hearts	¦Ä-opioid receptor (DOR) activation treatment	upregulated	27576463
22849	Rat	rno-miR-338	miRNA	oxygen	lung injury	pregnant rats lung tissue	inspired oxygen of 10.5 or 24% for two days treatment	downregulated	25120593
22850	Rat	rno-miR-338	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	downregulated	22156553
22851	Rat	rno-miR-338-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	upregulated	32192351
22852	Rat	rno-miR-338-3p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa tissues	fine particulate matter (PM2.5) exposure treatment	The results showed that miR-338-3p was downregulated in both nasal mucosa of PM25-exacerbated AR rat models and PM25-treated RPMI-2650 cells	33770685
22853	Rat	rno-miR-338-3p	miRNA	IL-6	skeletal muscle regeneration	rat primary skeletal muscle cells (RSkMC)	IL-6 treatment	upregulated	31820147
22854	Rat	rno-miR-338-3p	miRNA	IL-6	skeletal muscle regeneration	rat primary skeletal muscle cells (RSkMC)	IL-6 treatment	upregulated	31820147
22855	Rat	rno-miR-339	miRNA	adenosine	effect of acupuncture	nerve growth factor-induced differentiated PC12 cells	adenosine treatment	downregulated	25199539
22856	Rat	rno-miR-339-3p	miRNA	sevoflurane (SEV)	neural function	left cortex of the brain	Sevoflurane treatment	significantly increased	26021509
22857	Rat	rno-miR-339-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22858	Rat	rno-miR-339-5p	miRNA	loureirin A	follicle stem cell (HFSC) differentiation	primary rat follicle stem cell (HFSC)	loureirin A treatment	downregulated	29901112
22859	Rat	rno-miR-33a	miRNA	grape seed proanthocyanidins (GSPs)	cardiovascular disease (CVD)	healthy rats liver	chronic (3 weeks) of grape seed proanthocyanidins (GSPE) treatment	downregulated	24445039
22860	Rat	rno-miR-33a	miRNA	cafeteria diet	dyslipidemia	liver of rat	cafeteria diet feed	upregulated	23922812
22861	Rat	rno-miR-33a	miRNA	proanthocyanidins or docosahexaenoic acid	dyslipidemia	liver of rat	proanthocyanidins or docosahexaenoic acid?treatment treatment	downregulated	23922812
22862	Rat	rno-miR-33a	miRNA	tanshinone IIA (Tan IIA)	hyperlipidemia	liver tissues	Tanshinone IIA treatment	downregulated	27082100
22863	Rat	rno-miR-33a	miRNA	proanthocyanidin	obesity	livers of obese rats	proanthocyanidin treatment	3 weeks of supplementation with grape seed proanthocyanidin extract normalized the overexpression of miR-33a and miR-122 in obese rats' liver for all doses studied	25769350
22864	Rat	rno-miR-33a	miRNA	grape seed proanthocyandin extract (GSPE)	obesity and metabolic syndrome	rat hepatoma Fao cells	grape seed proanthocyanidins extracts (GSPE) treatment	"although GSPE reduced both miR-122 and miR-33a levels, GPE reduced miR-122 but upregulated miR-33a expression. The expression of miR-122 and miR-33a was not altered by the DF fraction in either Fao or HepG2 cells"	24165878
22865	Rat	rno-miR-33a	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
22866	Rat	rno-miR-33a	miRNA	grape seed proanthocyanidins (GSPs)	reduced postprandial lipemia	rat liver tissues and lipid extraction	grape seed proanthocyanidins (GSPE) treatment	GSPE repressed miR-33a and miR-122 liver expression and reduced postprandial lipemia in a dose-dependent manner.	24445039
22867	Rat	rno-miR-33a	miRNA	ghrelin	type 2 diabetes mellitus (T2DM)	diabetes rat liver tissues	ghrelin treatment	downregulated	31468622
22868	Rat	rno-miR-33a	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	rat liver tissues	streptozotocin treatment	upregulated	31468622
22869	Rat	rno-miR-33a-3p	miRNA	"3,5-diiodo-L-thyronine (T2)"	glucose homeostasis	serum from high fat diet fed rats	"3,5-diiodo-L-thyronine (T2) treatment"	downregulated	31719576
22870	Rat	rno-miR-33a-5p	miRNA	homocysteine (Hcy)	cell damage	primary cardiac microvascular endothelial cells (CMECs)	homocysteine (HCY) treatment	upregulated	30825202
22871	Rat	rno-miR-33a-5p	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cell (BMEC)	oxygen glucose deprivation (OGD) treatment	miR-33a-5p expression was the lowest at 4 h and the highest at 10 h after OGD treatment.	31986122
22872	Rat	rno-miR-33b	miRNA	lovastatin	medulloblastoma	c-Myc-null rat fibroblast Rat1 cells (clone HO15.19)	lovastatin? treatment	upregulated	22887866
22873	Rat	rno-miR-33e	miRNA	H2O2	oxidative stress	cardiovascular cells NRVCs and RAVSMCs	H2O2 treatment	downregulated	24612558
22874	Rat	rno-miR-34	miRNA	dimethylnitrosamine (DMN)	liver fibrosis	rat hepatic fibrosis tissue	dimethylnitrosamine (DMN) treatment	upregulated	21366874
22875	Rat	rno-miR-34	miRNA	tamoxifen (TAM)	hepatocellular carcinoma (HCC)	rat liver	tamoxifen? treatment	upregulated	17343880
22876	Rat	rno-miR-340-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22877	Rat	rno-miR-340-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute ischemic stroke (AIS)	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The expression levels of miR-340-5p were decreased in PC12 cells following OGD/R induction.	32468054
22878	Rat	rno-miR-340-5p	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	lung tissues	sevoflurane treatment	downregulated	28617947
22879	Rat	rno-miR-340-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	acute myocardial infarction (AMI)	H9C2 cardiomyocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30989715
22880	Rat	rno-miR-340-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	rat hippocampal neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	31870893
22881	Rat	rno-miR-340-5p	miRNA	oxygen glucose deprivation (OGD)	depression	primary hippocampal neurons	oxygen glucose deprivation (OGD) treatment	miR-340-5p was poorly expressed in these neurons after OGDR stimulation.	31870893
22882	Rat	rno-miR-340-5p	miRNA	collagenase VII	intracerebral haemorrhage (ICH)	brain tissues	collagenase VII treatment	downregulated	33176298
22883	Rat	rno-miR-340-5p	miRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	spinal cord tissues and isolated microglial cells	chronic constriction injury (CCI) induce	downregulated	30848438
22884	Rat	rno-miR-341	miRNA	huoxue jiedu formula (HXJDF)	diabetic retinopathy (DR)	retinal tissues	HuoXue JieDu Formula (HXJDF) treatment	miR-341 was downregulated in HuoXue JieDu Formula (HXJDF) treated group when compared with diabetic mice.	33271246
22885	Rat	rno-miR-341	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
22886	Rat	rno-miR-342	miRNA	caffeic acid	diabetic nephropathy (DN)	high-fat diet and streptozotocin-induced (HFD-STZ) diabetic rats	caffeic acid (CA) treatment	downregulated	28536471
22887	Rat	rno-miR-342-5p	miRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	HNE1cells; CNE2 cells	cisplatin treatment	LINC00346 regulates the cisplatin resistance of NPC cells by inhibiting miR-342-5p.	32397872
22888	Rat	rno-miR-344b-1-3p	miRNA	aspergillus fumigatus (A. fumigatus)	autophagy	"A rat alveolar macrophage cell line, NR8383"	aspergillus fumigatus infection	downregulated	31258647
22889	Rat	rno-miR-344b-1-3p	miRNA	smoking	chronic obstructive pulmonary disease (COPD)	rats alveolar macrophages (AMs)	smoke inhalation treatment	upregulated in alveolar macrophages (AMs)	28243080
22890	Rat	rno-miR-344b-3p	miRNA	triptolide (TPL)	nephropathy	blood and renal tissues	rats with adriamycin-induced nephropathy treatment	triptolide treatment reversed the increase in the expression of these two miRNAs	26078766
22891	Rat	rno-miR-345	miRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
22892	Rat	rno-miR-346	miRNA	H2O2	acute myocardial infarction (AMI)	H9c2 cells	H2O2 treatment	MiR-346 was significantly upregulated in H2O2-treated H9c2 cells.	33275244
22893	Rat	rno-miR-346-3p	miRNA	dexmedetomidine (DEX)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat cardiomyocytes	dexamethasone (DEX) treatment	DEX promoted miR-346-3p expression in MI/R rats	33731281
22894	Rat	rno-miR-347	miRNA	hypoxia	cortical injury	rat cortex tisssues	hypoxia treatment	downregulated	23272113
22895	Rat	rno-miR-347	miRNA	light	focal retinal degeneration	right eye	light treatment	upregulated	25921151
22896	Rat	rno-miR-3473	miRNA	cisplatin and gentamicin	drug-induced acute kidney injury (DIKI)	plasma	"cisplatin (CSP, 6?mg/kg) and gentamicin (GEN, 120?mg/kg) treatment"	miR-3473 was specifically upregulated in the glomerular injury models.	30682439
22897	Rat	rno-mir-3473	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
22898	Rat	rno-miR-3473	miRNA	Jianpi Xiaoke (JPXK)	type 2 diabetes mellitus (T2DM)	rat	Jianpi Xiaoke (JPXK) treatment	upregulated	33456489
22899	Rat	rno-miR-34a	miRNA	betanin (BET)	liver damage	cisplatin (DDP)-induced liver injury rats liver tissues	betanin (BET) treatment	downregulated	33661552
22900	Rat	rno-miR-34a	miRNA	cisplatin (DDP)	liver damage	liver tissues	cisplatin treatment	upregulated	33661552
22901	Rat	rno-miR-34a	miRNA	sepsis	acute kidney injury (AKI)	?kidney tissues	cecal ligation puncture induced sepsis treatment	MiR-34a level in kidney tissues was upregulated in the sepsis-induced AKI model	31081107
22902	Rat	rno-miR-34a	miRNA	diclofenac (Diclo)	acute kidney injury (AKI)	kidney tissues	diclofenac (Diclo) treatment	Diclo administration caused a significant reduction of mitofusin-2 (Mfn2) and increase of microRNA-34a (miR-34a) mRNA expressions.	33165700
22903	Rat	rno-miR-34a	miRNA	Thymoquinone (TQ)	acute kidney injury (AKI)	kidney tissues	thymoquinone treatment	downregulated	33165700
22904	Rat	rno-miR-34a	miRNA	D-galactosamine (D-GalN)	aging	hippocampus	D-gal treatment	upregulated	27780933
22905	Rat	rno-miR-34a	miRNA	alcohol	alcoholic liver disease (ALD)	liver tissues	alcohol exposure	upregulated	29873178
22906	Rat	rno-miR-34a	miRNA	valproic acid (VPA)	autism spectrum disorder (ASD)	ASD rats cerebellar cortex and primary cerebellar cortical neuronal cells	VPA treatment	upregulated in cerebellar cortex and primary cerebellar cortical neuronal cells	28803955
22907	Rat	rno-miR-34a	miRNA	low temperature	breast cancer	neural stem cells (NSCs)	low temperatures treatment	downregulated	23354401
22908	Rat	rno-miR-34a	miRNA	comfrey	tumorigenesis	rat liver	comfrey treatment	upragulated	21370286
22909	Rat	rno-miR-34a	miRNA	doxorubicin (DOX)	cardiac injury	cardiac cells	doxorubicin (DOXO) treatment	upregulated	27694688
22910	Rat	rno-miR-34a	miRNA	hydrogen sulfide (H2S)	cardiac fibrosis	thyroxine-induced rats myocardial tissues	Hydrogen sulfide (H2S) treatment	downregulated	29743447
22911	Rat	rno-miR-34a	miRNA	TGF-¦Â1	cardiac fibrosis	primary rat cardiac fibroblasts	TGF-¦Â1 treatment	upregulated	29551367
22912	Rat	rno-miR-34a	miRNA	thyroxine	cardiac fibrosis	myocardial tissues	thyroxine treatment	upregulated	29743447
22913	Rat	rno-miR-34a	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	rat cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	24728149
22914	Rat	rno-miR-34a	miRNA	high glucose (HG)	cardiomyocyte apoptosis	H9c2 tissues	High Glucose treatment	miR-34a contributes to high glucose-induced decreases in Bcl-2 expression and subsequent cardiomyocyte apoptosis	24339958
22915	Rat	rno-miR-34a	miRNA	paraquat (PQ)	apoptosis	PC 12 cells	paraquat (PQ) treatment	upregulated	25174400
22916	Rat	rno-miR-34a	miRNA	X-rays	cell cycle arrest	rats	X-ray exposure treatment	upregulated	25594002
22917	Rat	rno-miR-34a	miRNA	high-salt/low-potassium diet	cerebral and renal vascular injuries	stroke-prone spontaneously hypertensive rats	high-salt/low-potassium diet treatment	downregulated	23297375
22918	Rat	rno-miR-34a	miRNA	typhae pollen polysaccharides (TPP)	cerebral ischemia injury (CII)	PC12 cells	typhae pollen polysaccharides (TPP) treatment	TPP downregulated miR-34a expression	32635836
22919	Rat	rno-miR-34a	miRNA	furan	cholangiocarcinoma and hepatocellular tumors	liver	furan treatment	upregulated	26194646
22920	Rat	rno-miR-34a	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	chronic inflammatory visceral pain (CIVP)	spinal cord tissues of rats	"2,4,6-Trinitrobenzenesulfonic acid (TNBS) treatment"	downregulated	31324142
22921	Rat	rno-miR-34a	miRNA	dexmedetomidine (DEX)	chronic inflammatory visceral pain (CIVP)	spinal cord tissues of (TNBS)-induced chronic inflammatory visceral pain (CIVP) rats	dexamethasone (DEX) treatment	upregulated	31324142
22922	Rat	rno-miR-34a	miRNA	cisplatin (DDP)	cisplatin (DDP)-induced nephrotoxicity	renal tissue homogenate	cisplatin treatment	upregulated	32777238
22923	Rat	rno-miR-34a	miRNA	pentoxifylline (PTX)	cisplatin (DDP)-induced nephrotoxicity	renal tissue homogenate	pentoxifylline (PTX) treatment	downregulated	32777238
22924	Rat	rno-miR-34a	miRNA	urolithin A (UA)	cognitive impairment	H2O2-induced PC12 cell	?urolithin A treatment	downregulated	31420820
22925	Rat	rno-miR-34a	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	rat colon Epithelial cells	azoxymethane (AOM) treatment	"Of the 27 miRNAs expressed at higher (P < 0.05) levels in tumors, miR-34a, 132, 223 and 224 were overexpressed at >10-fold. In contrast, the expression levels of miR-192, 194, 215 and 375 were dramatically reduced (?0.32-fold) in adenocarcinomas."	19825969
22926	Rat	rno-miR-34a	miRNA	fish oil and pectin	colorectal cancer (CRC)	colon tissue of rats	corn oil ¡À fish oil with pectin ¡À cellulose	upregulated	21406606
22927	Rat	rno-miR-34a	miRNA	palmitate	diabetes mellitus (DM)	INS-1 cells	palmitate (Pal) treatment	upregulated	30131392
22928	Rat	rno-miR-34a	miRNA	astragaloside IV (AS-IV)	diabetic cardiomyopathy (DCM)	High glucose (HG)-treated rat cardiomyocytes (H9C2(2-1))	astragaloside IV (AS-IV) treatment	downregulated	31713440
22929	Rat	rno-miR-34a	miRNA	granulocyte-colony stimulating factor (G-CSF)	diabetic cardiomyopathy (DCM)	H9c2 cells	Granulocyte colony-stimulating factor?treatment	G-CSF treatment significantly decreased apoptosis and reduced miR-34a expression in diabetic myocardium and H9c2 cells under the HG condition.	31237127
22930	Rat	rno-miR-34a	miRNA	granulocyte-colony stimulating factor (G-CSF)	diabetic cardiomyopathy (DCM)	high glucose (HG)-induced H9c2 cells	Granulocyte colony-stimulating factor?treatment	downregulated	31237127
22931	Rat	rno-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	?high glucose (HG) induce	HOTAIR protected against DCM via activation of the SIRT1 expression by sponging miR-34a.	30216438
22932	Rat	rno-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	rat cardiomyocytes (H9C2(2-1))	high glucose (HG) treatment	upregulated	31713440
22933	Rat	rno-miR-34a	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9c2 cells	high glucose treatment	OIP5-AS1 overexpression promotes viability and inhibits high glucose-induced oxidative stress of cardiomyocytes by targeting microRNA-34a/SIRT1 axis in diabetic cardiomyopathy.	33380310
22934	Rat	rno-miR-34a	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	upregulated	28199183
22935	Rat	rno-miR-34a	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	heart tissues	streptozotocin (STZ) treatment	miR-34a was upregulated in the diabetic hearts	30216438
22936	Rat	rno-miR-34a	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Rat retinal vascular endothelial cells (RVECs)	high glucose (HG) treatment	MicroRNA-34a promotes apoptosis of retinal vascular endothelial cells by targeting SIRT1 in rats with diabetic retinopathy.	31863767
22937	Rat	rno-miR-34a	miRNA	mitomycin C-polylactic acid ( MMC-PLA) film	epidural scar hyperplasia and adhesion	post-laminectomy rat scar tissues	25 mg of PLA film containing 0.01% MMC was implanted on the laminectomy area	upregulated	28617531
22938	Rat	rno-miR-34a	miRNA	magnesium (Mg2+ )	epilepsy	rat hippocampal neuronal cells	"To induce the hippocampal neuronal spontaneous recurrent epileptiform discharges (SREDs) pattern, the neuronal cultures had been treated with a solution containing no added MgCl2 (Mg2+-free) for 3?h on the 14th day"	SREDs Induces Increase of?miR-34a Expression and?Decrease of?Notch Pathway Expression	30877521
22939	Rat	rno-miR-34a	miRNA	pterostilbene	fructose-induced hepatic lipid accumulation	BRL-3A cells	Pterostilbene treatment	Pterostilbene recovered the fructose-disturbed miR-34a expression	31927917
22940	Rat	rno-miR-34a	miRNA	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)	gastric cancer (GC)	rat gastric tissue	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment	downregulated	31648165
22941	Rat	rno-miR-34a	miRNA	Weipixiao (WPX) decoction	gastric cancer (GC)	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treated rat gastric tissue	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment	upregulated	31648165
22942	Rat	rno-miR-34a	miRNA	aristolochic acid	genotoxic and carcinogenic	tissues from transgenic Big Blue rats liver and kidney	aristolochic acid (AA) treatment	"dysregulated in the kidney, miR-34a was dysregulated in the liver"	25106556
22943	Rat	rno-miR-34a	miRNA	chromium (Cr)	hepatic ischemia/reperfusion injury (HIRI)	serum	Cr treatment	downregulated	28963950
22944	Rat	rno-miR-34a	miRNA	zinc sulfate (ZnSO4)	hepatic ischemia/reperfusion injury (HIRI)	ischemia-reperfusion (IR) injuried rats liver tissues	zinc sulfate (ZnSO4) treatment	downregulated	30014282
22945	Rat	rno-miR-34a	miRNA	zinc sulfate (ZnSO4)	hepatic ischemia/reperfusion injury (HIRI)	ischemia-reperfusion (IR) rats serum	zinc sulfate (ZnSO4) treatment	downregulated	30014282
22946	Rat	rno-miR-34a	miRNA	zinc sulfate (ZnSO4)	hepatic ischemia/reperfusion injury (HIRI)	serum	ZnSO4 treatment	downregulated	28963950
22947	Rat	rno-miR-34a	miRNA	methyl-deficient diet	hepatocellular carcinoma (HCC)	liver tissues	methyl-deficient diet feed	downregulated	18942116
22948	Rat	rno-miR-34a	miRNA	¦Â-ionone (¦ÂI)	hepatocellular carcinoma (HCC)	rats hepatocyte	¦ÂI (16 mg/100 g body weight) treatment	"upregulated(miR-122 , miR-34a) ;downregulated (miR-181b , miR-708)"	27061051
22949	Rat	rno-miR-34a	miRNA	furan	hepatotoxicity	liver	Furan treatment	upregulated	27371368
22950	Rat	rno-miR-34a	miRNA	streptozocin (STZ)	hyperglycemia-induced vascular endothelial cell damage	thoracic aorta tissues	streptozotocin (STZ) treatment	upregulated	29529692
22951	Rat	rno-miR-34a	miRNA	clamping both renal arteries	ischemia/reperfusion (I/R) injury	male rats	clamping both renal arteries for 45 min	upregulated	28129785
22952	Rat	rno-miR-34a	miRNA	ischemia/reperfusion (I/R) 	ischemia/reperfusion (I/R) injury	cardiomyocytes (NRCMs)	ischemia/reperfusion (I/R) treatment	upregulated	28599575
22953	Rat	rno-miR-34a	miRNA	hypoxia	ischemic injury	cardiomyocytes of 1-3 day-old male Wistar rats	long-term (4 h) exposure to hypoxia followed by 6 h of reoxygenation	upregulated	28709867
22954	Rat	rno-miR-34a	miRNA	hypoxia	ischemic injury	cardiomyocytes	hypoxia treatment	upregulated	28709867
22955	Rat	rno-miR-34a	miRNA	TGF-¦Â1	kidney fibrosis	rat renal fibroblast cell line (NRK-49F)	TGF-¦Â1-ed fibroblasts treatment	miR-34a is markedly upregulated in microvesicles isolated from the cell culture medium	25107369
22956	Rat	rno-miR-34a	miRNA	fructose	liver fibrosis	rats liver tissues and BRL-3A cells	fructose treatment	upregulated	30632134
22957	Rat	rno-miR-34a	miRNA	Pterostilbene	liver fibrosis	fructose-treated rats liver tissues and BRL-3A cells	Pterostilbene treatment	downregulated	30632134
22958	Rat	rno-miR-34a	miRNA	estradiol	metabolic effects of estrogen	liver tissues	estradiol treatment	downregulated	32045601
22959	Rat	rno-miR-34a	miRNA	deoxycholic acid (DCA)	apoptosis	primary rat hepatocytes	deoxycholic acid (DCA) treatment	upregulated	24421392
22960	Rat	rno-miR-34a	miRNA	resveratrol	cardiac fibrosis	cardiac fibroblasts (CFs)	resveratrol (Res) treatment	Resveratrol decreased the levels of miR-34ain TGF- ¦Â1-treated CFs	30648109
22961	Rat	rno-miR-34a	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	rat H9c2 cells	oxygen glucose deprivation (OGD) treatment	circDENND2A negatively regulated miR-34a miR-34a overexpression weakened the protective effects of circDENND2A in OGD-injury	31878833
22962	Rat	rno-miR-34a	miRNA	oxygen glucose deprivation (OGD)	myocardial infarction (MI)	H9c2 cells	oxygen glucose deprivation (OGD) treatment	circDENND2A overexpression enhanced OGD-inhibited cell viability and migration but declined OGD-promoted apoptosis by downregulating miR-34a and via ¦Â-catenin and Ras/Raf/MEK/ERK pathways	31878833
22963	Rat	rno-miR-34a	miRNA	silymarin (Sm)	myocardial infarction (MI)	heart sissues	Silymarin (SM) treatment	miRNA-34a was downregulated in SM-treated rats	31974855
22964	Rat	rno-miR-34a	miRNA	isoproterenol	myocardial injury	heart tissues	isoproterenol (ISO) treatment	upregulated	31794687
22965	Rat	rno-miR-34a	miRNA	resveratrol	myocardial injury	isoproterenol-induced rat heart tissues	resveratrol (RS) treatment	downregulated	31794687
22966	Rat	rno-miR-34a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	1%O	upregulated	28894025
22967	Rat	rno-miR-34a	miRNA	luteolin	neuritogenesis	PC12 cells	Luteolin treatment	upregulated	25865700
22968	Rat	rno-miR-34a	miRNA	nerve growth factor (NGF)	neuronal differentiation	differentiating PC12 cells	nerve growth factor (NGF) treatment	upregulated	28084588
22969	Rat	rno-miR-34a	miRNA	lidocaine	neurotoxicity	dorsal root ganglia neurons (DRGNs)	lidocaine treatment	downregulated	26455477
22970	Rat	rno-miR-34a	miRNA	fish oil	nonalcoholic fatty liver disease (NAFLD)	high-fat high-cholesterol diet rats	supplemented with fish oil (FOH)	dysregulated	28691019
22971	Rat	rno-miR-34a	miRNA	"quinacrine, erythromycin and tetracycline"	non-surgical sterilization	Wistar albino 12-14 week old female rats	"quinacrine, erythromycin , tetracycline treatment"	upregulated	25195052
22972	Rat	rno-miR-34a	miRNA	"3,6-dihydroxyflavone (3,6-DHF)"	obesity	breast?of rats	"3,6-dihydroxyflavone (3,6-DHF) treatment"	"the global upregulation of miR-21 and downregulated of miR-34a in breast carcinogenesis could be reversed by 3,6-DHF"	22616882
22973	Rat	rno-miR-34a	miRNA	IL-1¦Â	osteoarthritis (OA)	rat Articular chondrocytes	IL-1¦Â treatment	Silencing of miR-34a by LNA-modified anti-sense could effectively reduce rat chondrocyte apoptosis induced by IL-1¦Â	20675358
22974	Rat	rno-miR-34a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
22975	Rat	rno-miR-34a	miRNA	oxygen	oxygen-induced retinopathy (OIR)	retinas tissues	oxygen induce treatment	downregulated	30571142
22976	Rat	rno-miR-34a	miRNA	rotenone (ROT)	parkinson's disease (PD)	striatum of parkinsonian rats	rotenone exposure treatment	upregulated	30267378
22977	Rat	rno-miR-34a	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12 cells	N-methyl-4-phenylpyridinium (MPP +) treatment	"MPP+ toxicity significantly caused upregulated in miR-34a, miR-141, and miR-9."	29631008
22978	Rat	rno-miR-34a	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
22979	Rat	rno-miR-34a	miRNA	dioscin	renal injury	cisplatin (CDDP)-induced rats nephrotoxicity	dioscin treatment	downregulated	28514495
22980	Rat	rno-miR-34a	miRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	Rat proximal tubular epithelial cell line (NRK-52E) secreted microvesicles (MVs)	TGF-¦Â1 treatment	upregulated	30867715
22981	Rat	rno-miR-34a	miRNA	diclofenac (Diclo)	renal oxidative damage	kidney tissues	diclofenac (Diclo) treatment	Diclo administration caused a significant reduction of mitofusin-2 (Mfn2) and increase of microRNA-34a (miR-34a) mRNA expressions.	33165700
22982	Rat	rno-miR-34a	miRNA	oxygen	retinal angiogenesis	retina of oxygen-induced retinopathy rats	oxygen induce treatment	downregulated	30571142
22983	Rat	rno-miR-34a	miRNA	lipopolysaccharide (LPS)	sepsis	plasma and renal tissue	lipopolysaccharide (LPS) treatment	upregulated	29663998
22984	Rat	rno-miR-34a	miRNA	lipopolysaccharide (LPS)	sepsis	pulmonary macrophages	lipopolysaccharide (LPS) treatment	miR-34a was upregulated in Lipopolysaccharide (LPS)-induced pulmonary macrophages.	30021364
22985	Rat	rno-miR-34a	miRNA	allen's weight-drop method	spinal cord injury (SCI)	spinal neuron	allen's weight-drop method treatment	downregulated	31490756
22986	Rat	rno-miR-34a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
22987	Rat	rno-miR-34a	miRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	teratogenesis	mouse and rat limb buds	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	miR-34 family members are the most upregulated miRNAs	24623309
22988	Rat	rno-miR-34a	miRNA	cyclosporine A (CsA)	testicular damage	testis	cyclosporine A (CsA) treatment	Exposure to CsA increased the expression of mir-34a.	32569592
22989	Rat	rno-miR-34a	miRNA	high glucose and palmitate (HG/PA)	type 2 diabetes mellitus (T2DM)	INS-1 cells	high glucose and palmitate (HG/PA) treatment	upregulated	31737170
22990	Rat	rno-miR-34a	miRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	brain tissues	"orally and daily administrated 2.0 ml NSO, 100 mg metformin (MT)"	downregulated in the brain	28505155
22991	Rat	rno-miR-34a	miRNA	coxsackievirus B3 (CVB3)	viral myocarditis (VM)	rat primary cultured cardiomyocytes	Coxsackievirus B3 (CVB3) infection	upregulated	30968966
22992	Rat	rno-miR-34a-3p	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	lung tissues	Sevoflurane (Sev) treatment	"sevoflurane reduces inflammatory factor expression, increases lung cell viability and inhibits lung cell apoptosis in ALI through upregulation of miR-34a-3p"	32147387
22993	Rat	rno-miR-34a-3p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	serum	monocrotaline (MCT) treatment	downregulated	29431643
22994	Rat	rno-miR-34a-5p	miRNA	cadmium (Cd)	cadmium (Cd)-induced kidney injury	renal cortex	cadmium (Cd) treatment	upregulated	29543730
22995	Rat	rno-miR-34a-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	rat cardiomyocyte H9c2 cells	doxorubicin treatment	upregulated	28928469
22996	Rat	rno-miR-34a-5p	miRNA	liraglutide	endothelial dysfunction	aortic endothelial in diabetic rats	liraglutide treatment	downregulated	30863684
22997	Rat	rno-miR-34a-5p	miRNA	aflatoxin B1 (AFB1)	hepatocellular carcinoma (HCC)	F344 rats liver tissues	aflatoxin B1 (AFB4) treatment	upregulated	28218475
22998	Rat	rno-miR-34a-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	pulmonary metastatic tissue	sorafenib treatment	upregulated	26026584
22999	Rat	rno-miR-34a-5p	miRNA	aflatoxin B1 (AFB1)	hepatotoxicant and genotoxicant	liver	aflatoxin B1 (AFB1) treatment	upregulated	26385312
23000	Rat	rno-miR-34a-5p	miRNA	sevoflurane (SEV)	hypoxia-induced injury	H9c2 cells	sevoflurane treatment	downregulated	29554593
23001	Rat	rno-miR-34a-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	downregulated	29262398
23002	Rat	rno-miR-34a-5p	miRNA	thioacetamide (TAA)	liver toxicity	Sprague-Dawley rats livers	"treat with TAA at three doses (4.5, 15 and 45 mg/kg) and four time points (3-, 7-, 14- and 28-days) treatment"	dysregulatedin livers	28596526
23003	Rat	rno-miR-34a-5p	miRNA	N-methyl-D-aspartate receptor	long-term potentiation (LTP) persistence	rat dentate gyrus	rat dentate gyrus 20 min post-LTP induction in vivo treatment	downregulated	25538559
23004	Rat	rno-miR-34a-5p	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	upregulated	30312158
23005	Rat	rno-miR-34a-5p	miRNA	high fat diet (HFD)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31915454
23006	Rat	rno-miR-34a-5p	miRNA	Shenling Baizhu San (SLBZS)	nonalcoholic fatty liver disease (NAFLD)	liver tissues	Shenling Baizhu San (SLBZS) treatment	the expression levels were reversed by SLBZS administration	31915454
23007	Rat	rno-miR-34a-5p	miRNA	H2O2	spinal cord injury (SCI)	rat PC-12 cells	H2O2 treatment	miR-34a-5p was confirmed as a target of PEG10 and miR-34a-5p inhibitor remitted PEG10-induced H2O2-injury.	31835090
23008	Rat	rno-miR-34a-5p	miRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	H2O2 treatment	Knockdown PEG10 remitted H2O2-injury of PC-12 cells by targeting miR-34a-5p/TLX.	31835090
23009	Rat	rno-miR-34b	miRNA	H2O2	cerebral ischemia/reperfusion (I/R) injury	rat neuroblast B35 cells	H2O2 treatment	downregulated	30539753
23010	Rat	rno-miR-34b	miRNA	nitrate	fertility parameters	testicular	Nitrate treatment	Nitrate administration in the DN group also decreased miR-34b.	32129362
23011	Rat	rno-miR-34b	miRNA	H2O2	ischemic stroke (IS)	rat neuroblast B35 cells	H2O2 treatment	downregulated	30539753
23012	Rat	rno-miR-34b	miRNA	hypoxia	ischemic stroke (IS)	brain tissue	Middle cerebral artery occlusion (MCAO) treatment	downregulated	30539753
23013	Rat	rno-miR-34b	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	neonatal rat ventricular cardiomyocytes	hypoxia induce	upregulated	31220137
23014	Rat	rno-miR-34b	miRNA	lead (Pb)	nervous system diseases	rats hippocampus	chronic lead exposure treatment	upregulated	24960059
23015	Rat	rno-miR-34b-3p	miRNA	rapamycin	cardiac fibrosis	heart tissues	rapamycin (Rap) treatment	upregulated	30647817
23016	Rat	rno-miR-34b-3p	miRNA	steroids	osteonecrosis	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	26459755
23017	Rat	rno-miR-34b-3p	miRNA	smoking	smoke inhalation injury (SII)	bronchoalveolar lavage fluid (BALF)	Smoke inhalation treatment	upregulated	30139538
23018	Rat	rno-miR-34b-5p	miRNA	guarana	adipogenesis	3T3L1 cells	guarana	downregulated	28632199
23019	Rat	rno-miR-34b-5p	miRNA	flurothyl	brain injury	hippocampus	flurothyl treatment	upregulated	27514646
23020	Rat	rno-miR-34b-5p	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
23021	Rat	rno-miR-34b-5p	miRNA	fluorine combined with aluminum (FA)	neurotoxicity	hippocampi in the offspring of rats	fluorine combined with aluminum (FA) exposure	upregulated	30033483
23022	Rat	rno-miR-34b-5p	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	substantia nigra	6-hydroxydopamine (6-OHDA) treatment	downregulated of lncRNA BACE1-AS inhibits iNOS activation in the substantial nigra and improve oxidative stress injury in PD rats by upregulating miR-34b-5p and downregulating BACE1.	32308102
23023	Rat	rno-miR-34b-5p	miRNA	letrozole	polycystic ovarian syndrome (PCOS)	Ovary?tissues	letrozole treatment	dysregulated	26745201
23024	Rat	rno-miR-34c	miRNA	doxorubicin (DOX)	cardiac injury	?rat heart	doxorubicin treatment	upregulated	22859947
23025	Rat	rno-miR-34c	miRNA	blueberry	breast cancer	estrogen-mediated rats breast cancer	blueberry-supplemented diet treatment	upregulated	24245576
23026	Rat	rno-miR-34c	miRNA	high glucose (HG)	diabetic nephropathy (DN)	rat glomerular mesangial cell line (HBZY-1)	high glucose (HG) treatment	downregulated	32721950
23027	Rat	rno-miR-34c	miRNA	pentylenetetrazol (PTZ)	epilepsy	brain tissues	pentylenetetrazol (PTZ) treatment	upregulated	29344671
23028	Rat	rno-miR-34c	miRNA	lead (Pb)	nervous system diseases	rats hippocampus	chronic lead exposure treatment	upregulated	24960059
23029	Rat	rno-miR-34c	miRNA	lidocaine	neurotoxicity	dorsal root ganglia neurons (DRGNs)	lidocaine treatment	downregulated	26455477
23030	Rat	rno-miR-34c	miRNA	catheter injury	pathologic cardiovascular	carotid artery	catheter injury treatment	upregulated	25683915
23031	Rat	rno-miR-34c-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary cortical neurons	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	the expression levels of miR-34c-5p were significantly reduced in MCAO rats and OGD/RP cells	33842985
23032	Rat	rno-miR-34c-5p	miRNA	cigarette smoke (CS)	chronic obstructive pulmonary disease (COPD)	lung tissues	cigarette smoke exposure	downregulated	31032652
23033	Rat	rno-miR-34c-5p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	rat retinal	streptozotocin (STZ)-induced diabetic rat treatment	differential expressions	24502381
23034	Rat	rno-miR-34c-5p	miRNA	"3,5-diiodo-L-thyronine (T2)"	glucose homeostasis	serum from high fat diet fed rats	"3,5-diiodo-L-thyronine (T2) treatment"	downregulated	31719576
23035	Rat	rno-miR-34c-5p	miRNA	H2O2	hyperoxia-induced acute lung injury (HALI)	rat type II alveolar epithelial cells (AECII)	hydrogen peroxide (H2O2) treatment	downregulated	29436647
23036	Rat	rno-miR-34c-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
23037	Rat	rno-miR-34c-5p	miRNA	steroids	osteonecrosis	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	26459755
23038	Rat	rno-miR-34c-5p	miRNA	smoking	smoke inhalation injury (SII)	bronchoalveolar lavage fluid (BALF)	Smoke inhalation treatment	upregulated	30139538
23039	Rat	rno-miR-350	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	upregulated	27535721
23040	Rat	rno-miR-350	miRNA	triiodo-l-thyronine (T3)	liver fibrosis	cardiomyocytes	triiodothyronine (T?) treatment	upregulated	22525353
23041	Rat	rno-miR-351	miRNA	light	focal retinal degeneration	right eye	light treatment	upregulated	25921151
23042	Rat	rno-miR-351-5p	miRNA	dioscin	intestinal ischemia/reperfusion (I/R) injury	hypoxia-induced IEC-6 cells	dioscin treatment	downregulated	30503840
23043	Rat	rno-miR-351-5p	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	IEC-6 cells	hypoxia induce	upregulated	30503840
23044	Rat	rno-miR-351-5p	miRNA	dioscin	intestinal ischemia/reperfusion (I/R) injury	hypoxia-induced IEC-6 cells	dioscin treatment	downregulated	30240824
23045	Rat	rno-miR-351-5p	miRNA	hypoxia	intestinal ischemia/reperfusion (I/R) injury	IEC-6 cells	hypoxia induce	upregulated	30240824
23046	Rat	rno-mir-351-5p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	downregulated	26997989
23047	Rat	rno-miR-351-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
23048	Rat	rno-miR-352	miRNA	elevated fluid shear stress (FSS)	improved collateral circulation	rat hind limbs	elevated fluid shear stress (FSS)	downregulated	28751690
23049	Rat	rno-miR-352	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	upregulated	27919821
23050	Rat	rno-miR-352	miRNA	pilocarpine	mesial temporal lobe epilepsy (MTLE)	hippocampi	pilocarpine treatment	upregulated	27695061
23051	Rat	rno-miR-3541	miRNA	alcohol	brain damage due to chronic heavy alcohol	hippocampal tissues	chronic alcohol administration	upregulated	33228793
23052	Rat	rno-miR-3544	miRNA	grape seed procyanidin extract (GSPE)	pancreatic islet injury	rat islets	grape seed procyanidin extract (GSPE)treatment	"GSPE altered significantly the expression of miR-1249, miR-483, miR-30c-1*, and miR-3544."	23215023
23053	Rat	rno-mir-3548	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23054	Rat	rno-miR-3552	miRNA	hypoxia	stroke	middle cerebral artery occlusion (MCAO) Sprague-Dawley rat	middle cerebral artery occlusion (MCAO) treatment	upregulated	29113076
23055	Rat	rno-miR-3557	miRNA	aerobic exercise	parkinson's disease (PD)	brain tissues	aerobic exercise training (AET) treatment	upregulated	31309116
23056	Rat	rno-miR-3557-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23057	Rat	rno-miR-3559-5p	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
23058	Rat	rno-miR-3559-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
23059	Rat	rno-miR-3562	miRNA	huoxue jiedu formula (HXJDF)	diabetic retinopathy (DR)	retinal tissues	HuoXue JieDu Formula (HXJDF) treatment	miR-3562 was downregulated in HuoXue JieDu Formula (HXJDF) treated group when compared with diabetic mice.	33271246
23060	Rat	rno-miR-3573-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus tissues	chronic unpredictable mild stressed (CUMS) treatment	upregulated	28083819
23061	Rat	rno-miR-3573-5p	miRNA	hronic unpredictable mild stressed (CUMS)	depression	rats hippocampal tissues	stimulated daily with randomly applied mild stressors from among 14 different mild stressors	upregulated	28083819
23062	Rat	rno-miR-3574	miRNA	intermittent hypoxia (IH)	cardiac injury	H9C2 cells	intermittent hypoxia (IH) treatment	"We confirmed that IH inhibited cell viability, induced cell apoptosis and suppressed miR-3574 expression in the H9c2."	33582657
23063	Rat	rno-mir-3574	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23064	Rat	rno-miR-3578	miRNA	Smad3 inhibitor (SIS3)	intrauterine adhesion (IUA)	endometrial stromal cells (ESCs)	Smad3 inhibitor (SIS3) treatment	upregulated	32447720
23065	Rat	rno-mir-3578	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23066	Rat	rno-miR-3583-3p	miRNA	high fat diet (HFD)	cardiac remodeling	heart tissues	high fat diet (HFD) feed	upregulated	29884823
23067	Rat	rno-miR-3583-3p	miRNA	propofol (PPF)	neurotoxicity	primary cultured neural stem cells (NSCs)	propofol treatment	downregulated	29679758
23068	Rat	rno-miR-3584-5p	miRNA	propofol (PPF)	neural function	left cortex of the brain	Propofol treatment	significantly increased	26021509
23069	Rat	rno-miR-3584-5p	miRNA	mono-n-butyl phthalate (MBP)	precocious puberty and testicular tumors	testicular Sertoli cells (SCs)	mono-n-butyl phthalate (MBP) treatment	upregulated	29162477
23070	Rat	rno-miR-3584-5p	miRNA	mono-n-butyl phthalate (MBP)	cell proliferation	rat juvenile Sertoli cells (SCs)	treat with 0.1mM MBP	upregulated	29162477
23071	Rat	rno-miR-3586-3p	miRNA	Smad3 inhibitor (SIS3)	intrauterine adhesion (IUA)	endometrial stromal cells (ESCs)	Smad3 inhibitor (SIS3) treatment	downregulated	32447720
23072	Rat	rno-miR-3588	miRNA	huoxue jiedu formula (HXJDF)	diabetic retinopathy (DR)	retinal tissues	HuoXue JieDu Formula (HXJDF) treatment	miR-3588 was downregulated in HuoXue JieDu Formula (HXJDF) treated group when compared with diabetic mice.	33271246
23073	Rat	rno-miR-3588	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23074	Rat	rno-miR-3588	miRNA	ochratoxin A (OTA)	ochratoxin A (OTA) nephrotoxicity	kidney?tissues	OTA nephrotoxicity treatment	suppressed in mid dose but then elevated in high dose	24885635
23075	Rat	rno-miR-3590-3p	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
23076	Rat	rno-mir-3591	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23077	Rat	rno-miR-3595	miRNA	baicalin (BAI)	liver fibrosis	platelet-derived growth factor-BB-treated HSC-T6 cells	baicalin (BAI) treatment	upregulated	29393361
23078	Rat	rno-miR-3595	miRNA	platelet derived growth factor-BB (PDGF-BB)	liver fibrosis	HSC-T6 cells	platelet-derived growth factor-BB treatment	downregulated	29393361
23079	Rat	rno-miR-3596b	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
23080	Rat	rno-miR-361	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	Protective Role of Astrocyte-Derived Exosomal microRNA-361 in Cerebral Ischemic-Reperfusion Injury by Regulating the AMPK/mTOR Signaling Pathway and Targeting CTSB	32801720
23081	Rat	rno-miR-361	miRNA	palmitate and palmitate plus oleate.	insulin resistance (IR)	mouse myoblasts	palmitate and palmitate plus oleate treatment	upregulated	21183973
23082	Rat	rno-miR-361	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
23083	Rat	rno-miR-361-5p	miRNA	dexmedetomidine (DEX)	osteoporosis	human umbilical vein endothelial cells (HUVECs)	dexamethasone (DEX) treatment	"After Dex treatment, the expressions of miR-361-5p, VEGFA, BMD related indexes were increased in OP rats."	33631172
23084	Rat	rno-miR-362*	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
23085	Rat	rno-miR-362-3p	miRNA	palmitate	diabetes mellitus (DM)	INS-1 cells	palmitate (Pal) treatment	downregulated	30131392
23086	Rat	rno-miR-362-3p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	"SNHG1 regulated cell viability, apoptosis and autophagy in LPS-treated PC12 cells"	33515352
23087	Rat	rno-miR-362-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23088	Rat	rno-miR-363	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23089	Rat	rno-miR-363	miRNA	hypoxia	myocardial infarction (MI)	rat myocardium-derived H9C2 and 293T cells	1% O2 at 37 _x0002_C for 24 h	upregulated	28402919
23090	Rat	rno-miR-363	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	Bladder Detrusor Tissues	streptozocin (STZ) treatment	miR-363 is Downregulated in STZ-Induced T2DM.	33294298
23091	Rat	rno-miR-365	miRNA	dexamethasone (DEX)	cartilage injury	articular cartilage	dexamethasone (DEX) treatment	miR-365 was downregulated compared with control group.	29207029
23092	Rat	rno-miR-365	miRNA	cyclic mechanical stretch (CMS)	cell differentiation	bone marrow-derived mesenchymal stem cells (BMSCs)	Cyclic tensile strain (CTS) treatment	upregulated	31276691
23093	Rat	rno-miR-365	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	retina tissues	streptozotocin (STZ) treatment	upregulated	29196060
23094	Rat	rno-miR-365	miRNA	H2O2	ischemic neuroinflammatory injury	primary cultured neurons	H2O2 treatment	upregulated	30977043
23095	Rat	rno-miR-365	miRNA	morphine	morphine tolerance	neurons of the spinal cord	rats treatment treatment	downregulated	27922111
23096	Rat	rno-miR-365	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
23097	Rat	rno-miR-3657	miRNA	apatinib	advanced gastric cancers (AGCs)	BGC-823 and HGC-27	apatinib treatment	Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7	32139670
23098	Rat	rno-miR-367	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	31845077
23099	Rat	rno-miR-367	miRNA	doxorubicin (DOX)	cardiac injury	?rat heart	doxorubicin treatment	upregulated	22859947
23100	Rat	rno-miR-369	miRNA	hypoxia	myocardial infarction (MI)	rat myocardial tissues	hypoxia treatment	Our data indicated that miR-369 expression was significantly downregulated and TRPV3 was significantly upregulated in myocardial tissue after MI in rats and in hypoxic-treated neonatal rat cardiomyocytes (NRCMs).	33470394
23101	Rat	rno-miR-369-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23102	Rat	rno-miR-370	miRNA	TGF-¦Â1	hepatic fibrogenesis	hepatic stellate cells (HSCs)	TGF-¦Â1 treatment	downregulated	25686745
23103	Rat	rno-miR-370	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	upregulated	24205079
23104	Rat	rno-miR-370	miRNA	H2O2	myocardial infarction (MI)	H9C2 cells	hydrogen peroxide (H2O2) treatment	downregulated	31555385
23105	Rat	rno-miR-370	miRNA	hypoxia	myocardial infarction (MI)	Sprague-Dawley rats border area	anterior descending artery was ligated with 7¨C0 ligation line 2 mm at the lower edge of the right in the left atrial appendage	downregulated	28350072
23106	Rat	rno-miR-370-3p	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus tissues	chronic unpredictable mild stressed (CUMS) treatment	downregulated	28083819
23107	Rat	rno-miR-370-3p	miRNA	hronic unpredictable mild stressed (CUMS)	depression	rats hippocampal tissues	stimulated daily with randomly applied mild stressors from among 14 different mild stressors	downregulated	28083819
23108	Rat	rno-miR-370-3p	miRNA	TGF-¦Â1	lung fibrosis	lung fibroblasts	TGF-¦Â1 treatment	downregulated	32464548
23109	Rat	rno-miR-370-3p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	primary spinal neurons	lipopolysaccharide (LPS) treatment	SCI resulted in lncRNA H19 higher expression and miR-370-3p lower expression.	33708438
23110	Rat	rno-miR-371b-5p	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	lung tissues	monocrotaline treatment	miR-371b-5p was downregulated in PAH rats compared with the control group.	30387816
23111	Rat	rno-miR-372	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	PC-12 cells	hypoxia induce	upregulated	30298297
23112	Rat	rno-miR-372-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	primary neural stem cells (NSCs) were obtained from rat embryos	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33579365
23113	Rat	rno-miR-373-3p	miRNA	lipopolysaccharide (LPS)	sepsis-induced acute hepatic injury	liver tissues	Lipopolysaccharide (LPS) treatment	downregulated	33129786
23114	Rat	rno-miR-374	miRNA	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)	gastric cancer (GC)	rats mesenchymal stem cells (MSCs) from the gastric tissues	treat with MNNG	upregulated in mesenchymal stem cells (MSCs) from the gastric tissues	28731132
23115	Rat	rno-miR-374	miRNA	sevoflurane (SEV)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	ischemia-reperfusion (I/R) injuried rats heart tissues	sevoflurane treatment	upregulated	29689553
23116	Rat	rno-miR-374-5p	miRNA	hypothermia	fatal hypothermia	iliopsoas muscle	hypothermia treatment	Mex3B expression was regulated by rno-miR-374-5p and decreased with decreasing body temperature.	32963265
23117	Rat	rno-miR-374a	miRNA	CoCl2	hypoxia-induced injury	PC-12 cells	CoCl2 treatment	downregulated	29247275
23118	Rat	rno-miR-374a	miRNA	fortunellin	inflammatory bowel disease (IBD)	rat coliti	Fortunellin treatment	Fortunellin increased mir-374a expression.	29472916
23119	Rat	rno-miR-374a	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	?hypoxia/reoxygenation (H/R) induce	downregulated	31265855
23120	Rat	rno-miR-374a-5p	miRNA	oxygen glucose deprivation (OGD)	apoptosis	PC12 cells	oxygen/glucose deprivation (OGD) induce treatment	downregulated	31127537
23121	Rat	rno-miR-375	miRNA	doxorubicin (DOX)	aoxorubicin-induced myocardial toxicity	H9c2 cells	Doxorubicin treatment	Doxorubicin significantly upregulated miR-375 expression in vitro and in vivo.	32186283
23122	Rat	rno-miR-375	miRNA	diethylnitrosamine (DEN)	carcinogen-initiated hepatocytes	resistant-hepatocyte (R-H) rat	diethyl nitrosamine (DEN) treatment	downregulated	25010260
23123	Rat	rno-miR-375	miRNA	hepatocyte growth factor (HGF)	cell migration	mesenchymal stem cells (MSCs)	hepatocyte growth factor (HGF) treatment	downregulated	29322249
23124	Rat	rno-miR-375	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	colitis	male Wistar rats inflamed colon	"2,4,6-trinitrobenzene sulfonic acid (TNBS)/ethanol treatment"	downregulated in inflamed colon	28572713
23125	Rat	rno-miR-375	miRNA	palmitate	enteric neurons and gastrointestinal motility	immorto postnatal enteric neuronal (IM-PEN) cell line	palmitate treatment	upregulated	24507550
23126	Rat	rno-miR-375	miRNA	cerulein or cyanohydroxybutene (CHB)	exocrine pancreatic injury (EPIJ)	serum	cerulein or cyanohydroxybutene (CHB) treatment	upregulated	24285669
23127	Rat	rno-miR-375	miRNA	cerulein or cyanohydroxybutene (CHB)	exocrine pancreatic injury (EPIJ)	serum	rats were administered cerulein or CHB to induce EPIJ treatment	upregulated	24285669
23128	Rat	rno-miR-375	miRNA	hypoxia	hepatocellular carcinoma (HCC)	HCCs	hypoxia treatment	"MiR-375 presented an obviously differential expression in human HCCs versus background livers (BLs) and HCCs versus normal liver tissues (NLTs). In rat models, miR-375 was gradually declined during hepatocarcinogenesis."	32215815
23129	Rat	rno-miR-375	miRNA	furan	hepatotoxicity	liver	Furan treatment	downregulated	27371368
23130	Rat	rno-miR-375	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23131	Rat	rno-miR-375	miRNA	ellagic acid (EA)	breast cancer	female rat mammary tissue	ellagic acid treatment	"ellagic acid, which inhibited E2-induced mammary tumorigenesis in our previous study, reversed the dysregulation of miR-375, miR-206, miR-182, miR-122, miR-127 and miR-183 detected with E2treatment"	23791885
23132	Rat	rno-miR-375	miRNA	lipopolysaccharide (LPS)	neuronal cell injury	N9 cells	endotoxin treatment	upregulated	26631961
23133	Rat	rno-miR-375	miRNA	calycosin	neuroprotective effects	middle cerebral artery occlusion (MCAO) rats	calycosin treatment	upregulated	24548484
23134	Rat	rno-miR-375	miRNA	streptozocin (STZ)	pancreatic injury	acinar cells	Streptozotocin (STZ) treatment	upregulated	27521901
23135	Rat	rno-miR-375	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	substantia nigra	6-hydroxydopamine (6-OHDA) treatment	"Compared with the normal group, the expression of miR-375 in the substantia nigra of rats in the model group was decreased."	33245094
23136	Rat	rno-miR-375	miRNA	adjuvant	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLS)	adjuvant treatment	downregulated	25619565
23137	Rat	rno-miR-375	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
23138	Rat	rno-miR-375	miRNA	immobilization (IMO) stress	synthesis and secretion of catecholamines	Wistar rats adrenal medulla chromaffin cells	exposed to IMO stress	downregulated in rat adrenal medulla chromaffin cells	28356269
23139	Rat	rno-miR-375	miRNA	TianMai Xiaoke tablet(TM)	type 2 diabetes mellitus (T2DM)	diabetic rats islet	TM treatment	upregulated	24812635
23140	Rat	rno-miR-375-3p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cardiomyocyte	angiotensin II (Ang II) treatment	upregulated	30618075
23141	Rat	rno-miR-375-3p	miRNA	ionizing radiation (IR)	cell death	?rat pancreatic ¦Â cell line RIN-5F	7 Gy irradiation exposure	upregulated	30930975
23142	Rat	rno-miR-375-3p	miRNA	streptozocin (STZ)	cell death	?rat pancreatic ¦Â cell line RIN-5F	streptozotocin (STZ) treatment	upregulated	30930975
23143	Rat	rno-miR-375-3p	miRNA	hypoxia	congenital heart disease (CHD)	H9C2 cells	hypoxia induce	miR-375-3p was upregulated and FOXP1/Bcl2l2 was downregulated in maternal serum of women with fetal CHD and hypoxia-induced rat cardiomyocyte h9c2 cells.	33128129
23144	Rat	rno-miR-375-3p	miRNA	hypoxia	congenital heart disease (CHD)	H9c2 cells	hypoxia treatment	miR-375-3p was upregulated in hypoxia-induced rat cardiomyocyte h9c2 cells.	33128129
23145	Rat	rno-miR-375-3p	miRNA	high fructose	liver fibrosis	rat liver tissues and BRL-3A cells and/or primary rat hepatocytes	high fructose treatment	downregulated	30568253
23146	Rat	rno-miR-375-3p	miRNA	Magnesium isoglycyrrhizinate (MgIG)	liver fibrosis	high fructose-treated rat liver tissues and BRL-3A cells and/or primary rat hepatocytes	Magnesium isoglycyrrhizinate treatment	magnesium isoglycyrrhizinate increased miR-375-3p expression to suppress the JAK2/STAT3 pathway and TGF-¦Â1/Smad signaling in these animal and cell models.	30568253
23147	Rat	rno-miR-375-3p	miRNA	Magnesium isoglycyrrhizinate (MgIG)	liver fibrosis	liver tissues; BRL-3A cells; primary rat hepatocytes	magnesium isoglycyrrhizinate treatment	magnesium isoglycyrrhizinate increased miR-375-3p expression in liver fibrosis models.	30568253
23148	Rat	rno-miR-375-3p	miRNA	hypoxia	pulmonary microvascular endothelial cells (PMECs) injury	Pulmonary microvascular endothelial cells (PMECs)	hypoxia treatment	The expression of miR-375-3p and Notch1 in the PMECs was significantly downregulated and upregulated during hypoxia.	32644005
23149	Rat	rno-miR-376a	miRNA	human chorionic gonadotrophin (hCG)	expression regulation	Female 21-day-old Wistar rats	12 h after with (hCG) treatment	upregulated	25279841
23150	Rat	rno-miR-376a-3p	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
23151	Rat	rno-miR-376b-3p	miRNA	noradrenaline (NA)	cardiac hypertrophy	neonatal rat ventricular cells (NRVCs)	noradrenaline (NA) treatment	downregulated	29570827
23152	Rat	rno-miR-376b-3p	miRNA	ischemia	periodontitis	Serum	Ligation around teeth treatment	upregulated	26910654
23153	Rat	rno-miR-376c	miRNA	electroacupuncture (EA)	hyperactivity of the HPA axis induced by hepatectomy	rats	electroacupuncture (EA) treatment	upregulated	29021740
23154	Rat	rno-miR-376c-3p	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	PC-12 cells	oxygen-glucose deprivation (OGD) treatment	downregulated	31844418
23155	Rat	rno-miR-377	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32674625
23156	Rat	rno-miR-377	miRNA	fructose	glomerular podocyte injury	kidney cortex tissues	fructose-fed treatment	upregulated	25746774
23157	Rat	rno-miR-377	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	upregulated	24205079
23158	Rat	rno-miR-377	miRNA	hypoxia	ischemic stroke (IS)	Primary rat microglial cells and brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) treatment	downregulated	28569430
23159	Rat	rno-miR-377	miRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	primary rat microglial cells and brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation (OGD) treatment	downregulated	28569430
23160	Rat	rno-miR-377*	miRNA	oxygen	lung injury	pregnant rats lung tissue	inspired oxygen of 10.5 or 22% for two days treatment	upregulated	25120593
23161	Rat	rno-miR-377-5p	miRNA	propofol (PPF)	neurotoxicity	primary cultured neural stem cells (NSCs)	propofol treatment	upregulated	29679758
23162	Rat	rno-miR-378	miRNA	TGF-¦Â	adaptation of tendons to mechanical loading	rat Tendon fibroblasts	Transforming growth factor-¦Â(TGF-¦Â) treatment	upregulated	22539168
23163	Rat	rno-miR-378	miRNA	astragaloside IV (AS-IV)	diabetic nephropathy (DN)	diabetic rats kidney tissues	astragaloside (AS-IV) treatment	upregulated	29792879
23164	Rat	rno-miR-378	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin (STZ) treatment	downregulated	29792879
23165	Rat	rno-miR-378	miRNA	TGF-¦Â1	kidney fibrosis and mesangial hypertrophy	NRK52E and mesangial cells	TGF-¦Â1 treatment	downregulated	28053239
23166	Rat	rno-miR-378	miRNA	hypoxia	vascularization	Sprague-Dawley rats mesenchymal stem cells (MSCs)	hypoxia treatment	downregulated	25418617
23167	Rat	rno-miR-378a	miRNA	mitomycin C-polylactic acid ( MMC-PLA) film	epidural scar hyperplasia and adhesion	post-laminectomy rat scar tissues	25 mg of PLA film containing 0.01% MMC was implanted on the laminectomy area	downregulated	28617531
23168	Rat	rno-miR-378a	miRNA	cisplatin (DDP)	liver damage	urine	cisplatin treatment	upregulated	27397436
23169	Rat	rno-miR-378a	miRNA	cisplatin (DDP)	nephrotoxicity	rats	cisplatin treatment	upregulated	27397436
23170	Rat	rno-miR-378a-3p	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	33263228
23171	Rat	rno-miR-378a-3p	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	rat liver tissues	acetaminophen (APAP) treatment	downregulated	31468699
23172	Rat	rno-miR-378a-3p	miRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	liver tissues	acetaminophen (APAP) treatment	CYP2E1 and miRNA-378a-3p contribute to acetaminophen- or tripterygium glycosides-induced hepatotoxicity.	31468699
23173	Rat	rno-miR-378a-3p	miRNA	chlormethiazole (CMZ)	drug-induced liver injury (DILI)	rat liver tissues	chlormethiazole (CMZ) treatment	downregulated	31468699
23174	Rat	rno-miR-378a-3p	miRNA	Tripterygium glycosides (TGs)	drug-induced liver injury (DILI)	rat liver tissues	tripterygium glycosides (TG) treatment	downregulated	31468699
23175	Rat	rno-miR-378a-3p	miRNA	Tripterygium glycosides (TGs)	drug-induced liver injury (DILI)	liver tissues	tripterygium glycosides (TG) treatment	CYP2E1 and miRNA-378a-3p contribute to acetaminophen- or tripterygium glycosides-induced hepatotoxicity.	31468699
23176	Rat	rno-miR-378a-3p	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	upregulated	27919821
23177	Rat	rno-miR-378a-3p	miRNA	ischemia/reperfusion (I/R) 	kidney damage	Sprague-Dawley rats urine	ischemia/reperfusion (I/R) treatment	upregulated	28056546
23178	Rat	rno-miR-378a-3p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
23179	Rat	rno-miR-378a-5p	miRNA	alcohol	alcoholic cardiomyopathy (ACM)	primary rat cardiomyocytes	alcohol exposure	upregulated	28160209
23180	Rat	rno-miR-378a-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23181	Rat	rno-miR-378b	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	downregulated	27919821
23182	Rat	rno-miR-378b	miRNA	hypoxia	obesity	dietary-induced obese SD rats	hypoxia exercise training treatment	downregulated	25183036
23183	Rat	rno-mir-378b	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23184	Rat	rno-miR-379	miRNA	trichostatin A (TSA)	hepatocellular carcinoma (HCC)	rat primary hepatocytes	Trichostatin A (TSA)treatment treatment	"miR-122, miR-143 and miR-379 could be related to the inhibitory effects of TSA on hepatocellular proliferation"	21513791
23185	Rat	rno-miR-379	miRNA	SiO2	lung injury	lung	SiO2 treatment	upregulated	27689473
23186	Rat	rno-miR-379	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
23187	Rat	rno-miR-379-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23188	Rat	rno-miR-380-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23189	Rat	rno-miR-381	miRNA	dexmedetomidine (DEX)	cerebral ischemia injury (CII)	OGD/R-treated rat neuron cells	dexmedetomidine (Dex) treatment	upregulated	33314611
23190	Rat	rno-miR-381	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	neuron cells were isolated from the hippocampus of rats	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33314611
23191	Rat	rno-miR-381	miRNA	dexmedetomidine (DEX)	cerebral ischemia injury (CII)	brain tissues	dexmedetomidine (Dex) treatment	Dex was found to increase the miR-381 expression.	33314611
23192	Rat	rno-miR-381	miRNA	dexmedetomidine (DEX)	ropivacaine induced neurocyte injury	PC12 cells	dexamethasone (DEX) treatment	"Dexmedetomidine reversed role of ropivacaine (0 mM, 0.1 mM, 0.5 mM, 1 mM) by upragulating the expression of miR-381 and suppressing the expression of LRRC4 in PC12 cells."	32467829
23193	Rat	rno-miR-381-3p	miRNA	lipopolysaccharide (LPS)	acute spinal cord injury (ASCI)	Microglial BV2 cells	Lipopolysaccharide (LPS) treatment	downregulated	30229813
23194	Rat	rno-miR-382	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23195	Rat	rno-miR-382	miRNA	alcohol	myocardial infarction (MI)	the nucleus accumbens (NAc)	alcohol exposure	upregulated	23873704
23196	Rat	rno-miR-382	miRNA	acute stress (AS) and chronic stress (CS)	stress-induced myocardial injury	rat	Rats were bound and suspended treatment	upregulated	24669248
23197	Rat	rno-miR-382	miRNA	phosphorus (Pi)	vascular calcification (VC)	rat aortic vascular smooth muscle cells	high levels of phosphate treatment	downregulated	28522697
23198	Rat	rno-miR-382*	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23199	Rat	rno-miR-382-3p	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus tissues	chronic unpredictable mild stressed (CUMS) treatment	upregulated	28083819
23200	Rat	rno-miR-382-3p	miRNA	hronic unpredictable mild stressed (CUMS)	depression	rats hippocampal tissues	stimulated daily with randomly applied mild stressors from among 14 different mild stressors	upregulated	28083819
23201	Rat	rno-miR-382-5p	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus	chronic unpredictable mild stress (CUMS) treatment	upregulated	32982244
23202	Rat	rno-miR-383	miRNA	propofol (PPF)	anesthesia-induced cognitive impairment	hippocampus	propofol treatment	Propofol treatment significantly reduced the relative mRNA expression of miR-383	29545833
23203	Rat	rno-miR-383	miRNA	piperine	myocardial ischemia/reperfusion (I/R) injury (MIRI)	heart tissues	Piperine (PIP) treatment	MIRI-caused elevation of miR-383 and decrease of RP105/PI3K/AKT pathway were reverted by PIP treatment	33219747
23204	Rat	rno-miR-383	miRNA	piperine	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat cardiomyocytes	Piperine (PIP) treatment	?MIRI-caused elevation of miR-383 and decrease of RP105/PI3K/AKT pathway were reverted by PIP treatment	33219747
23205	Rat	rno-miR-383-3p	miRNA	high fat diet (HFD)	coronary atherosclerosis (CAS)	myocardial tissues	high fat diet (HFD) feed	MiR-383-3p was downregulated in myocardial tissues of AS rats.	29693751
23206	Rat	rno-miR-383-5p	miRNA	cold	cold stress	rats serum	cold conditions (4¡æ for 12h)	downregulated	28477904
23207	Rat	rno-miR-383-5p	miRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	pulmonary metastatic tissue	sorafenib treatment	upregulated	26026584
23208	Rat	rno-miR-383-5p	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	The results showed that lncRNA CASC9 was downregulated and miR-383-5p was upregulated in SCI rats and LPS-induced PC12 cells.	33438067
23209	Rat	rno-miR-383-5p	miRNA	hypoxia	stroke	middle cerebral artery occlusion (MCAO) Sprague-Dawley rat	middle cerebral artery occlusion (MCAO) treatment	upregulated	29113076
23210	Rat	rno-miR-384	miRNA	epigallocatechin-3-gallate (EGCG)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia-induced H9c2 cell lines	EGCG treatment	upregulated	31802847
23211	Rat	rno-miR-384	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cell lines	hypoxia induce	downregulated	31802847
23212	Rat	rno-miR-384	miRNA	oxygen glucose deprivation (OGD)	neonatal hypoxic-ischemic encephalopathy 	Neonatal rat primary microglia cells	oxygen-glucose deprivation (OGD) treatment	The expression of miR-384 was decreased in the serum of HIE newborns and OGD-induced activated microglia.	32621118
23213	Rat	rno-miR-384-5p	miRNA	TGF-¦Â	cardiac fibrosis	Primary cardiac fibroblasts (CFs)	TGF-¦Â treatment	downregulated	30206318
23214	Rat	rno-miR-384-5p	miRNA	TGF-¦Â	cardiac fibrosis	cardiac fibroblasts (CFs)	TGF-¦Â treatment	TGF-¦Â treatment also significantly decreased the expression of miR-384-5p in CFs	30206318
23215	Rat	rno-miR-384-5p	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	downregulated	32436661
23216	Rat	rno-miR-384-5p	miRNA	trimethyltin (TMT)	neurotoxicity	rats serum	were given a single administration of TMT treatment	upregulated	24777749
23217	Rat	rno-miR-384-5p	miRNA	ischemia	myogenic differentiation	ischemic myocardium of rats;H9c2 cells	ischemia treatment	downregulated	23315007
23218	Rat	rno-miR-39a	miRNA	high fat diet (HFD)	insulin resistance (IR)	C57BL/6 mice	high fat diet (HFD) feed	upregulated	24844433
23219	Rat	rno-miR-409	miRNA	isoflurane	isoflurane-induced neurotoxicity	hippocampal neurons; PC-12 cells	isoflurane treatment	Vitexin could significantly increase the expression of miR-409.	32011832
23220	Rat	rno-miR-409-5p	miRNA	hypoxia	myocardial hypoxic/ischemic injury	H92c cells	hypoxia treatment	USP7 expression was markedly elevated while miR-409-5p expression was significantly downregulated in H9c2 cells under hypoxic culture.	33241864
23221	Rat	rno-miR-409-5p	miRNA	pegylated rat leptin antagonist (pRLA)	type 2 diabetes mellitus (T2DM)	rat muscle and liver	pegylated rat leptin antagonist (pRLA) treatment	"upregulation of rno-miR-10a at d28 and rno-miR-200a, rno-miR-409-5p, and rno-miR-125a-3p following HFD challenge"	23576026
23222	Rat	rno-miR-409a-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23223	Rat	rno-miR-409a-5p	miRNA	TGF-¦Â1	lung fibrosis	lung fibroblasts	TGF-¦Â1 treatment	downregulated	32464548
23224	Rat	rno-mir-409b	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23225	Rat	rno-miR-410	miRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	PC12 cells	6-hydroxydopamine (6-OHDA) treatment	downregulated	31067440
23226	Rat	rno-miR-410	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin A5 treatment	upregulated	30157485
23227	Rat	rno-miR-410	miRNA	bleomycin (BLM)	lung fibrosis	pulmonary fibrosis rats lung tissues	Prodigiosin (PG) treatment	downregulated	30157485
23228	Rat	rno-miR-410-3p	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	rat retinal	streptozotocin (STZ)-induced diabetic rat treatment	differential expressions	24502381
23229	Rat	rno-miR-410-3p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia/reoxygenation (H/R) treatment	FTX alleviates hypoxia/reoxygenation-induced cardiomyocyte injury via miR-410-3p/Fmr1 axis	31957854
23230	Rat	rno-miR-410-3p	miRNA	sevoflurane (SEV)	postoperative cognitive dysfunction (POCD)	hippocampal neuron	sevoflurane anesthesia-induce treatment	downregulated	31350734
23231	Rat	rno-miR-410-5p	miRNA	high fat diet (HFD)	cardiac remodeling	heart tissues	high fat diet (HFD) feed	upregulated	29884823
23232	Rat	rno-miR-410-5p	miRNA	propofol (PPF)	neurotoxicity	primary cultured neural stem cells (NSCs)	propofol treatment	downregulated	29679758
23233	Rat	rno-miR-411	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	microglia	lipopolysaccharide (LPS) treatment	MiRNA-411 increase ameliorates the inflammatory microglia-induced neurological lesion and promotes neural recovery by JNK pathway inhibition via negative targeting IL-18 in SCI.	32016950
23234	Rat	rno-miR-411-3p	miRNA	silica	lung fibrosis	lung tissues	silica treatment	downregulated	32004504
23235	Rat	rno-miR-411-3p	miRNA	TGF-¦Â1	lung fibrosis	primary fibroblasts	TGF-¦Â1 treatment	downregulated	32004504
23236	Rat	rno-miR-411-3p	miRNA	TGF-¦Â1	lung fibrosis	lung fibroblasts	TGF-¦Â1 treatment	downregulated	32464548
23237	Rat	rno-miR-411-3p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
23238	Rat	rno-miR-421	miRNA	hypoxia	hypoxia-induced injury	H9c2 cells	hypoxia induce	upregulated	31469043
23239	Rat	rno-miR-421	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H92c cells	hypoxia/reoxygenation treatment	MiR-421 inhibition protects H9c2 cells against hypoxia/reoxygenation-induced oxidative stress and apoptosis by targeting Sirt3.	31469043
23240	Rat	rno-miR-423-3p	miRNA	house dust mite (HDM) extract	allergic airway inflammation	adipose tissue and lungs	house dust mite extract treatment	upregulated	32887419
23241	Rat	rno-miR-423-5p	miRNA	ischemia/reperfusion (I/R) 	acute kidney injury (AKI)	rats kidney tissues	ischemia/reperfusion (I/R) treatment	upregulated in rat kidneys	29137244
23242	Rat	rno-miR-423-5p	miRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	lung tissues	lipopolysaccharide (LPS) treatment	"The expression of H19 and FOXA1 was significantly upregulated, while the expression of miR-423-5p was downregulated in LPS-induced ARDS rats."	33629893
23243	Rat	rno-miR-423-5p	miRNA	huoxue jiedu formula (HXJDF)	diabetic retinopathy (DR)	retinal tissues	HuoXue JieDu Formula (HXJDF) treatment	miR-423-4p was downregulated in HuoXue JieDu Formula (HXJDF) treated group when compared with diabetic mice.	33271246
23244	Rat	rno-miR-423-5p	miRNA	hypoxia	hypoxia-induced injury	H9C2 cells	hypoxia induce	upregulated	31074036
23245	Rat	rno-miR-423-5p	miRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	H2O2 treatment	upregulated	30977409
23246	Rat	rno-miR-424	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	downregulated	30637733
23247	Rat	rno-miR-424	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	upregulated	33333053
23248	Rat	rno-miR-424	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	rat liver tissue	CCl4 treatment	"miR-322/424 level in liver cirrhosis patients, mouse liver fibrosis induced by CCl4?and BDL, and rat liver fibrosis induced by CCl4?and dimethylnitrosamine was increased."	33333053
23249	Rat	rno-miR-425	miRNA	sevoflurane (SEV)	acute lung injury (ALI)	lung tissues	sevoflurane treatment	downregulated	28617947
23250	Rat	rno-miR-425-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23251	Rat	rno-miR-425-5p	miRNA	cold	cold stress	rats serum	cold conditions (4¡æ for 12h)	downregulated	28477904
23252	Rat	rno-miR-4262	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	chondrocytes were separated from Sprague-Dawley rats	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29434702
23253	Rat	rno-miR-4262	miRNA	tumor necrosis factor alpha (TNF-¦Á) 	osteoarthritis (OA)	Primary chondrocytes	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	29434702
23254	Rat	rno-miR-429	miRNA	N-methyl-N-nitrosourea (MNU)	breast cancer	rats with experimental breast cancer Thoracic Duct Lymph	N-Methyl-N-Nitrosourea	dysregulatedin Thoracic Duct Lymph	28091921
23255	Rat	rno-miR-429	miRNA	comfrey	tumorigenesis	rat liver	comfrey treatment	upragulated	21370286
23256	Rat	rno-miR-429	miRNA	angiotensin II (Ang II)	epithelial-mesenchymal transition (EMT)	NRK-52E cells	angiotensin II (Ang II) treatment	downregulated	30132344
23257	Rat	rno-miR-429	miRNA	aflatoxin B1 (AFB1)	hepatotoxicant and genotoxicant	liver	aflatoxin B1 (AFB1) treatment	upregulated	26385312
23258	Rat	rno-miR-429	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
23259	Rat	rno-miR-429	miRNA	"DDT (2,2-dichlorodiphenyl-1,1,1-trichloroethane), benzo[a]pyrene (BP), and 3-methylcholanthrene (MC)"	post-transcriptional regulation	?the livers and ovaries of chemically induced rats	"DDT, benzo[a]pyrene (BP), and 3-methylcholanthrene (MC) treatment"	downregulated	24727239
23260	Rat	rno-miR-429	miRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	upregulated	31876239
23261	Rat	rno-miR-429	miRNA	swainsonine (SW)	myocarditis	LPS-treated H9c2 cells	Swainsonine (SW) treatment	downregulated	31876239
23262	Rat	rno-miR-429	miRNA	CoCl2	neuron apoptosis	PC12 cells	cobalt chloride (CoCl2) treatment	downregulated	32004541
23263	Rat	rno-miR-429	miRNA	ketamine	neurotoxicity	PC12 cells	Ketamine treatment	miR-429 attenuates ketamine-induced neurotoxicity in PC12 cells by the downregulated of BAG5.	33283947
23264	Rat	rno-miR-429	miRNA	ketamine	neurotoxicity	PC12 cells	ketamine treatment	The qRT-PCR results showed that miR-429 expression was downregulated by treatment of ketamine in a dose-dependent manner.? Overexpression of miR-429 alleviated ketamine-induced neurotoxicity in PC12 cells.	33283947
23265	Rat	rno-miR-429	miRNA	swainsonine (SW)	pediatric myocarditis (PM)	H9c2 cells	swainsonine (SW) treatment	MiR-429 expression was elevated by LPS and suppressed by SW	31876239
23266	Rat	rno-miR-429	miRNA	high salt (HS)	salt-sensitive hypertension	Sprague-Dawley rats renal medullary tissues	high-salt diet (8% NaCl)	upregulated	28445205
23267	Rat	rno-miR-429	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC13 cell	lipopolysaccharide (LPS) treatment	?miR-429 was downregulated in LPS-stimulated PC12 cells. Overexpression of miR-429 contributed to LPS-induced PC12 injuries.	31309444
23268	Rat	rno-miR-429-3p	miRNA	dexmedetomidine (DEX)	chemotherapy-induced cognitive impairment (CICI)	brain tissues	dexmedetomidine (Dex) treatment	Dexmedetomidine attenuates cisplatin-induced cognitive impairment by modulating miR-429-3p expression in rats	32411568
23269	Rat	rno-miR-431	miRNA	H2O2	acute myocardial infarction (AMI)	H9c2 cells	H2O2 treatment	We revealed that miR-431 expression was decreased in H2O2-treated H9c2 cells and myocardium of MI rats.	33660818
23270	Rat	rno-miR-432-5p	miRNA	high fat diet (HFD)	insulin resistance (IR)	liver tissues	high fat diet (HFD) feed	upregulated	29802941
23271	Rat	rno-miR-432-5p	miRNA	physical exercise	insulin resistance (IR)	diet-induced obesity rats liver tissues	physical exercise treatment	downregulated	29802941
23272	Rat	rno-miR-434	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23273	Rat	rno-miR-434-3p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
23274	Rat	rno-miR-434-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23275	Rat	rno-miR-434-5p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
23276	Rat	rno-miR-448	miRNA	lead (Pb)	nervous system diseases	rats hippocampus	chronic lead exposure treatment	upregulated	24960059
23277	Rat	rno-miR-448	miRNA	sevoflurane (SEV)	neural function	left cortex of the brain	Sevoflurane treatment	significantly increased	26021509
23278	Rat	rno-miR-448	miRNA	isoflurane	neuron apoptosis	Sprague-Dawley rats hippocampus tissues	isoflurane treatment	upregulated in rat hippocampus tissue	29067448
23279	Rat	rno-miR-448	miRNA	freund¡¯s complete adjuvant (FCA)	rheumatoid arthritis (RA)	synovial tissues	Freund¡¯s complete adjuvant (FCA) treatment	lncRNA OIP5-AS1 may mitigate RA progression through the miR-448-PON1 axis and through the inactivation of the TLR3-NF-¦ÊB signalling pathway.	32770578
23280	Rat	rno-miR-448	miRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	PC12 cells	hypoxia induce	upregulated	29561961
23281	Rat	rno-miR-448-3p	miRNA	high glucose (HG)	diabetes-associated endothelial dysfunction	rat aortic endothelial cells	high glucose (HG) treatment	downregulated	32542696
23282	Rat	rno-miR-448-3p	miRNA	streptozocin (STZ)	diabetes-associated endothelial dysfunction	aorta	streptozocin (STZ) treatment	downregulated	32542696
23283	Rat	rno-miR-448-3p	miRNA	fluorine combined with aluminum (FA)	fluorine combined with aluminum (FA)-induced developmental neurotoxicity	hippocampi	fluorine combined with aluminum (FA) treatment	upregulated	30033483
23284	Rat	rno-miR-448-5p	miRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	downregulated	29505837
23285	Rat	rno-miR-449	miRNA	cisplatin (DDP)	acute kidney injury (AKI)	NRK-52E cells	cisplatin treatment	upregulated	26968221
23286	Rat	rno-miR-449a	miRNA	hypoxia	cardiomyocytes injury	H9c2 cells	hypoxia induce	upregulated	30770559
23287	Rat	rno-miR-449a	miRNA	tetramethylpyrazine (TMP)	cardiomyocytes injury	hypoxia-induced H9c2 cells	Tetramethylpyrazine treatment	downregulated	30770559
23288	Rat	rno-miR-449a	miRNA	sodium nitrate	diabetic testicular disorder	diabetic rats testis tissues	sodium nitrate feed treatment	upregulated	30952494
23289	Rat	rno-miR-449a	miRNA	streptozocin (STZ)	diabetic testicular disorder	testis tissues	streptozotocin (STZ) treatment	downregulated	30952494
23290	Rat	rno-miR-449a	miRNA	light	focal retinal degeneration	right eye	light treatment	upregulated	25921151
23291	Rat	rno-miR-449a	miRNA	ethylene glycol monomethyl ether (EGME)	hyperglycemia	?testicle of rat	Ethylene glycol monomethyl ether (EGME) treatment	"miR-449a and miR-92a decreased obviously and, miR-320, miR-134 and miR-188 increased"	22008535
23292	Rat	rno-miR-449a	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	neonatal rat ventricular myocytes and H9C2 cells	hypoxia induce	upregulated	29758550
23293	Rat	rno-miR-449a	miRNA	lead (Pb)	nervous system diseases	rats hippocampus	chronic lead exposure treatment	upregulated	24960059
23294	Rat	rno-miR-449a	miRNA	electroacupuncture (EA)	spinal cord injury (SCI)	SCI rats	modified Allen's method	downregulated	28507480
23295	Rat	rno-miR-449a	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	spinal cord tissues; HAPI cells	lipopolysaccharide (LPS) treatment	upregulated	30119293
23296	Rat	rno-miR-449a-5p	miRNA	H2O2	hyperoxia-induced acute lung injury (HALI)	rat type II alveolar epithelial cells (AECII)	hydrogen peroxide (H2O2) treatment	downregulated	29436647
23297	Rat	rno-miR-449a-5p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary arterial smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30715622
23298	Rat	rno-miR-450a	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
23299	Rat	rno-miR-451	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor type BB (PDGF-BB) treatment	downregulated	30930138
23300	Rat	rno-miR-451	miRNA	genistein	cardiac hypertrophy	isoproterenol-treated H9C2 cells	genistein treatment	upregulated	30798118
23301	Rat	rno-miR-451	miRNA	isoproterenol	cardiac hypertrophy	H9C2 cells	isoprenaline (ISO) tteatment	downregulated	30798118
23302	Rat	rno-miR-451	miRNA	immunoregulatory molecule soluble HLA-G (sHLA-G)	CD4+ T cells proliferation	CD4+ T cells	immunoregulatory molecule soluble HLA-G (sHLA-G) treatment	"sHLA-G triggered a modulation of miRNA expression that may in turn modulate downstream gene expression, thus affecting CD4+ T -cell function."	23220581
23303	Rat	rno-miR-451	miRNA	trans-chalcone	hepatoprotective action of trans-chalcone	liver tissues	trans-chalcone treatment	Trans-chalcone increased hepatic level of miR-451 and reduced hepatic IL-8 as well as AST and ALT aft er 6 weeks	29453920
23304	Rat	rno-miR-451	miRNA	propofol (PPF)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	hypoxia treated H9C2 cells	Propofol treatment	upregulated	31188485
23305	Rat	rno-miR-451	miRNA	anoxia/reoxygenation (A/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	neonatal rat ventricular cardiomyocytes	anoxia/reoxygenation (A/R) treatment	downregulated	27121079
23306	Rat	rno-miR-451	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	32256945
23307	Rat	rno-miR-451	miRNA	palmitic acid (PA)	obesity and diabetes	cardiac myocytes	high-fat diet (HFD) treatment	upregulated	25362209
23308	Rat	rno-miR-451	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
23309	Rat	rno-miR-451	miRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonate (PFOS)-induced toxic action	rat liver tissue	dams received 3.2 mg/kg PFOS in their feed from gestational day 1 (GD1) to postnatal day 7 (PND 16) treatment	different expression	24420840
23310	Rat	rno-miR-451	miRNA	Silica nanoparticles (SiNPs)	vascular endothelial dysfunction	aortic arch	Silica nanoparticles (SiNPs) treatment	downregulated	30975181
23311	Rat	rno-miR-451	miRNA	heat stress	vascular permeability	lung endothelial cells	heat treatment	"MiRNA-451 was upregulated in the lung endothelial cells of the rat model, and contributed to increase lung endothelial cell permeability."	33269809
23312	Rat	rno-miR-451-5p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	downregulated	32893733
23313	Rat	rno-miR-454	miRNA	carbon tetrachloride (CCl4)	liver cirrhosis	liver tissues	CCl4 treatment	downregulated	30535384
23314	Rat	rno-miR-454	miRNA	TGF-¦Â1	liver cirrhosis	HSC-T6 cells	transforming growth factor (TGF)-¦Â1 treatment	downregulated	30535384
23315	Rat	rno-miR-454	miRNA	pioglitazone	oxygen glucose deprivation (OGD)-induced myocardial cell injury	H9c2 cells	pioglitazone treatment	Pioglitazone significantly upregulated miR-454 expression in OGD-injured cells	30524679
23316	Rat	rno-miR-455	miRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	BRL-3A cells	hypoxia-reoxygenation (H/R) treatment	lncRNA Gm4419 accelerates hepatic I/R injury by targeting the miR-455-SOX6 axis.	32114773
23317	Rat	rno-miR-455-3p	miRNA	cadmium (Cd)	cadmium (Cd)-induced kidney injury	renal cortex	cadmium (Cd) treatment	downregulated	29543730
23318	Rat	rno-miR-455-3p	miRNA	bicyclol	idiopathic pulmonary fibrosis (IPF)	IPF rat lung tissues	bicyclol treatment	upregulated	31407409
23319	Rat	rno-miR-455-3p	miRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	mesenchymal stem cell (MSC) exosome	hypoxia-reoxygenation (H/R) treatment	upregulated	32719674
23320	Rat	rno-miR-455-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33528807
23321	Rat	rno-miR-455-3p	miRNA	TGF-¦Â1	liver fibrosis	hepatic stellate cells (HSC-T6)	transforming growth factor ¦Â1 (TGF-¦Â1) treatment	downregulated	31150929
23322	Rat	rno-miR-455-3p	miRNA	thioacetamide (TAA)	liver toxicity	Sprague-Dawley rats livers	"treat with TAA at three doses (4.5, 15 and 45 mg/kg) and four time points (3-, 7-, 14- and 28-days) treatment"	dysregulatedin livers	28596526
23323	Rat	rno-miR-455-5p	miRNA	Smad3 inhibitor (SIS3)	intrauterine adhesion (IUA)	endometrial stromal cells (ESCs)	Smad3 inhibitor (SIS3) treatment	downregulated	32447720
23324	Rat	rno-miR-455-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	brain tissues	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	miR-455-5p expression was reduced in brain tissues of MCAO rats and OGD/R-induced PC12 cells	33309710
23325	Rat	rno-miR-465*	miRNA	oxygen	lung injury	pregnant rats lung tissue	inspired oxygen of 10.5 or 21% for two days treatment	upregulated	25120593
23326	Rat	rno-miR-466	miRNA	single dose irradiation	radiation-induced lung injury (RILI)	male Wistar rats lung tissues	subjected to single dose irradiation with 20 Gy using 6 MV x-rays to the right lung treatment	upregulated	24886372
23327	Rat	rno-miR-466b	miRNA	hypoxia	cortical injury	rat cortex tisssues	hypoxia treatment	downregulated	23272113
23328	Rat	rno-miR-466b	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	downregulated	24205079
23329	Rat	rno-miR-466b	miRNA	dexamethasone (DEX)	hormonal regulation	adrenals?tissues	dexamethasone (DEX) treatment	downregulated	24205079
23330	Rat	rno-miR-466b	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
23331	Rat	rno-miR-466b	miRNA	perfluorooctane sulfonic acid (PFOS)	neural dysfunctions	rat brains	perfluorooctane sulfonic acid (PFOS) treatment	downregulated	22594572
23332	Rat	rno-miR-466b	miRNA	acute stress (AS) and chronic stress (CS)	stress-induced myocardial injury	rat	Rats were bound and suspended treatment	downregulated	24669248
23333	Rat	rno-miR-466b-1FNx01	miRNA	propofol (PPF)	neural function	left cortex of the brain	Propofol treatment	significantly increased	26021509
23334	Rat	rno-miR-466b-1FNx01	miRNA	sevoflurane (SEV)	neural function	left cortex of the brain	Sevoflurane treatment	significantly increased	26021509
23335	Rat	rno-miR-466b-2-3p	miRNA	methylprednisolone	steroid-induced osteonecrosis of femoral head (ONFH)	bone microvascular endothelial cells (BMECs)	methylprednisolone treatment	downregulated	29408208
23336	Rat	rno-miR-466b-5p	miRNA	propofol (PPF)	neurotoxicity	primary cultured neural stem cells (NSCs)	propofol treatment	downregulated	29679758
23337	Rat	rno-miR-466b-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23338	Rat	rno-miR-466c-5p	miRNA	vitamin A	congenital scoliosis (CS)	Embryos	Vitamin A deficiency treatment	upregulated	31044535
23339	Rat	rno-miR-466f	miRNA	valproic acid (VPA)	cerebral ischemia injury (CII)	rat cortical neuronal cells	valproic acid treatment	upregulated	22937209
23340	Rat	rno-miR-466i	miRNA	palmitate and palmitate plus oleate.	insulin resistance (IR)	mouse myoblasts	palmitate and palmitate plus oleate treatment	upregulated	21183973
23341	Rat	rno-miR-466i-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	"Kcnq1ot1 sponged miR-466k and miR-466i-5p to up-regulate Tead1, thus triggering cardiomyocyte injury in the process of AMI."	32422306
23342	Rat	rno-miR-466k	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	"Kcnq1ot1 sponged miR-466k and miR-466i-5p to up-regulate Tead1, thus triggering cardiomyocyte injury in the process of AMI."	32422306
23343	Rat	rno-miR-4728-5p	miRNA	H2O2	age-related cataract (ARC)	human lens epithelial cells (LECs)	oxidative stress	NONHSAT143692.2 is involved in oxidative DNA damage repair in the lens by regulating the miR-4728-5p/OGG1 axis.	33000245
23344	Rat	rno-miR-483	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23345	Rat	rno-miR-483	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
23346	Rat	rno-miR-483	miRNA	grape seed procyanidin extract (GSPE)	pancreatic islet injury	rat islets	grape seed procyanidin extract (GSPE)treatment	"GSPE altered significantly the expression of miR-1249, miR-483, miR-30c-1*, and miR-3544."	23215023
23347	Rat	rno-miR-483-5p	miRNA	palmitate	diabetes mellitus (DM)	INS-1 cells	palmitate (Pal) treatment	upregulated	30131392
23348	Rat	rno-miR-483-5p	miRNA	inorganic phosphate (Pi)	vascular calcification (VC)	Vascular Smooth Muscle Cells	Inorganic phosphate (Pi) treatment	upregulated	31790973
23349	Rat	rno-miR-484	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	primary cultured myocardial cells (PC); H9c2 cells	doxorubicin (DOX) treatment	downregulated	30170730
23350	Rat	rno-miR-485	miRNA	hypoxia	ischemic stroke (IS)	mouse brain tissues	middle cerebral artery occlusion (MCAO)	downregulated	31794744
23351	Rat	rno-miR-485-3p	miRNA	FK506	osteogenesis	rat bone marrow stromal cells (BMSCs)	FK506 treatment	upregulated	28560399
23352	Rat	rno-miR-485-5p	miRNA	complete freund's adjuvant (CFA)	inflammatory pain	L4-6 dorsal root ganglion (DRG)	complete Freund's adjuvant (CFA) treatment	The miRNA-485-5p expression level clearly decreased while the ASIC1 expression level was upregulated in the L4-6 dorsal root ganglion (DRG) of CFA rats.	33239909
23353	Rat	rno-miR-486	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	downregulated	30121658
23354	Rat	rno-miR-486	miRNA	acute and long-term aerobic exercise	cardiorespiratory fitness	young men	acute and long-term aerobic exercise treatment	downregulated	27895662
23355	Rat	rno-miR-486	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	27910957
23356	Rat	rno-miR-486	miRNA	chronic hypoxia-hypercapnia (CHH)	skeletal muscle atrophy	gastrocnemius muscles	chronic hypoxia-hypercapnia (CHH) treatment	downregulated	30654931
23357	Rat	rno-miR-486	miRNA	neuromuscular electrical stimulation (NMES)	skeletal muscle atrophy	gastrocnemius muscles	Neuromuscular Electrical Stimulation (NMES) treatment	upregulated	30654931
23358	Rat	rno-miR-486-3p	miRNA	high glucose (HG)	diabetic retinopathy (DR)	Muller cells	high glucose (HG) treatment	Bone marrow mesenchymal stem cells-induced exosomal microRNA-486-3p protects against diabetic retinopathy through TLR4/NF-¦ÊB axis repression.	32979189
23359	Rat	rno-miR-486-5p	miRNA	hypoxia	cyanotic congenital heart disease (CCHD)	H9C2 cells	hypoxia induce	upregulated	31934081
23360	Rat	rno-miR-487b	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23361	Rat	rno-miR-487b-3p	miRNA	"2,5-hexanedione (HD)"	"2,5-hexanedione (HD) toxicity"	spinal cord tissues	"2,5-hexanedione (HD) treatment"	upregulated	31760062
23362	Rat	rno-miR-488	miRNA	psoralen	osteogenesis	bone marrow mesenchymal stem cells (BMSCs)	psoralen treatment	downregulated	31485621
23363	Rat	rno-miR-489	miRNA	gentamicin	acute kidney injury (AKI)	urine	gentamicin treatment	upregulated	27074385
23364	Rat	rno-miR-489	miRNA	resveratrol	breast cancer	matched tumor/normal tissues	resveratrol (RS) treatment	upregulated	24447120
23365	Rat	rno-miR-489	miRNA	H2O2	myocardial infarction (MI)	H9c2 cells	H2O2 treatment	miR-489 expression was increased in H2O2-treated H9c2 cardiomyocytes	32880387
23366	Rat	rno-miR-489	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) induce	upregulated	31378911
23367	Rat	rno-miR-489-3p	miRNA	carbon tetrachloride (CCl4)	liver fibrosis	liver tissues	carbon tetrachloride (CCl4) treatment	miR-489-3p was significantly downregulated in liver fibrotic tissues compared with the control group.	32144602
23368	Rat	rno-miR-490-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	downregulated	33456519
23369	Rat	rno-miR-490-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	The results revealed that miR-490-3p was markedly downregulated in an LPS-induced rat ALI model	33456519
23370	Rat	rno-miR-490-5p	miRNA	sevoflurane (SEV)	brain injury	rat middle cerebral artery occlusion model rats brain tissues	Sevoflurane (SEV)??treatment treatment	Sevo raised miR-490-5p and decreased CDK1 to improve neurological deficits	33513398
23371	Rat	rno-miR-490-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23372	Rat	rno-miR-490-5p	miRNA	dextran sodium sulfate (DSS)	ulcerative colitis (UC)	Sprague-Dawley (SD) rats colon tissues in the colon tissues	dextran sulfate sodium (DSS)	upregulated( miR-149-5p) downregulated (miR-184) in the colon tissues in the colon tissues	28246536
23373	Rat	rno-miR-490-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	downregulated	28246536
23374	Rat	rno-miR-493	miRNA	oxygen glucose deprivation (OGD)	stroke	rat brain microvascular endothelial cells (RBMECs)	oxygen and glucose deprivation-induced treatment	downregulated	26929185
23375	Rat	rno-miR-493-3p	miRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus tissues	chronic unpredictable mild stressed (CUMS) treatment	upregulated	28083819
23376	Rat	rno-miR-493-3p	miRNA	hronic unpredictable mild stressed (CUMS)	depression	rats hippocampal tissues	stimulated daily with randomly applied mild stressors from among 14 different mild stressors	upregulated	28083819
23377	Rat	rno-miR-493-5p	miRNA	"2,5-hexanedione (HD)"	"2,5-hexanedione (HD) toxicity"	spinal cord tissues	"2,5-hexanedione (HD) treatment"	upregulated	31760062
23378	Rat	rno-miR-494	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	33174056
23379	Rat	rno-miR-494	miRNA	ethanol (EtOH)	alcohol-induced anxiolysis	Amygdaloid	ethanol treatment	downregulated	26786313
23380	Rat	rno-miR-494	miRNA	ethanol (EtOH)	anxiolysis	amygdaloid	ethanol treatment	downregulated	26786313
23381	Rat	rno-miR-494	miRNA	lithium chloride and pilocarpine	epilepsy	hippocampus	lithium chloride-pilocarpine treatment	downregulated	32308116
23382	Rat	rno-miR-494	miRNA	propofol (PPF)	hepatic ischemia/reperfusion injury (HIRI)	myocardial cell	propofol treatment	miR-494 levels were suppressed in the propofol group compared with the I/R group	33682507
23383	Rat	rno-miR-494	miRNA	atropine sulfate	myocardial infarction (MI)	rat heart tissues	atropine sulfate treatment	downregulated	31541797
23384	Rat	rno-miR-494	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	downregulated	30170481
23385	Rat	rno-miR-494	miRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	Rat pheochomocytoma PC-12?cells	lipopolysaccharide (LPS) treatment	upregulated	30816451
23386	Rat	rno-miR-494-3p	miRNA	ginsenoside Rg1	apoptosis	hypoxia-induced male rat bone marrow mesenchymal stem cells (rBMSCs)	Ginsenoside Rg1 treatment	upregulated	29307726
23387	Rat	rno-miR-494-3p	miRNA	hypoxia	apoptosis	Male rat bone marrow mesenchymal stem cells (rBMSCs)	hypoxia induce	downregulated	29307726
23388	Rat	rno-miR-494-3p	miRNA	angiotensin II (Ang II)	hypertensive nephropathy (HN)	rat renal artery endothelial cells (RRAECs)	angiotensin II (Ang II) treatment	upregulated	32346437
23389	Rat	rno-miR-494-3p	miRNA	Sera from patients with septic shock	cardiomyocytes injury	Rat cardiomyocytes (M6200)	Sera from patients with septic shock treatment	downregulated	30783439
23390	Rat	rno-miR-495	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	MiR-495 expression was remarkably increased in H9c2 cells treated with hypoxia.	33506922
23391	Rat	rno-miR-495	miRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal ganglion cells (RGCs)	high glucose (HG) treatment	miR-495 was significantly upregulated in HG-treated RGCs.	30119264
23392	Rat	rno-miR-495	miRNA	pilocarpine	epilepsy	hippocampus; hippocampal neurons	pilocarpine treatment	"The lncRNA UCA1 and Nrf2 were downregulated in epileptiform hippocampal tissues and neurons, while the miR-495 was upregulated"	29608952
23393	Rat	rno-miR-495	miRNA	repeated binge-EtOH exposure	ethanol addiction	dorsal and ventral hippocampus of male Wistar rats	repeated binge-EtOH exposure treatment	different regulation	24416161
23394	Rat	rno-miR-495	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23395	Rat	rno-miR-495	miRNA	ischemia	periodontitis	Serum	Ligation around teeth treatment	upregulated	26910654
23396	Rat	rno-miR-495	miRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	PAH rats right ventricular (RV) tissues	monocrotaline (MCT) treatment	upregulated	29566365
23397	Rat	rno-miR-495	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
23398	Rat	rno-miR-495-3p	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	Alveolar macrophages (NR8383)	lipopolysaccharide (LPS) treatment	"methylation of the miR-495 promoter could downregulate miR-495, whose elevation could attenuate the activation of the NLRP3 inflammasome to protect against ALI"	31734560
23399	Rat	rno-miR-495-3p	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	H2O2 treatment	downregulated	31347173
23400	Rat	rno-miR-495-3p	miRNA	H2O2	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	H2O2 treatment	NEAT1 contributed to M-I/R injury via the modulation of miR-495-3p and MAPK6.	31347173
23401	Rat	rno-miR-496	miRNA	hypoxia	cerebral ischemia/reperfusion (I/R) injury	Middle cerebral	middle cerebral artery occlusion/reperfusion (MCAO/R) induce	downregulated	30597231
23402	Rat	rno-miR-496	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	H92c cells	hypoxia/reoxygenation (H/R) treatment	miR-496 was lowly expressed in H/R-treated H9c2 cells.	31436348
23403	Rat	rno-miR-496	miRNA	hypoxia	myocardial injury	The H9c2 rat cardiomyocyte cells	hypoxia induce	"with Hook3 functionality's aid, miR-496 upregulation defends cells from H/R-induced apoptosis and stimulates cell proliferation."	31436348
23404	Rat	rno-miR-496-3p	miRNA	methamphetamine (METH)	addiction	nucleus accumbens tissues	Methamphetamine treatment	dysregulated	28681200
23405	Rat	rno-miR-497	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	Primary cardiomyocytes	angiotensin II (Ang II) treatment	Our data indicated that TUG1 was upregulated and miR-497 was downregulated in the TAC rat model and Ang II-induced cardiomyocytes.	33817315
23406	Rat	rno-miR-497	miRNA	bone matrix gelatin	chondrogenesis	chondrocytes	bone matrix gelatin treatment	downregulated	30156864
23407	Rat	rno-miR-497	miRNA	high glucose (HG)	diabetic retinopathy (DR)	M¨¹ller cells	high glucose (HG) treatment	miR-497 was significantly increased in high glucose-treated M¨¹ller cells	29383970
23408	Rat	rno-miR-497	miRNA	exercise training (ET)	myocardial infarction (MI)	heart sissues; serum	exercise training (ET)	ET reduced the infarct size in MI rats and inhibited the levels of miR-497.	32162294
23409	Rat	rno-miR-497	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
23410	Rat	rno-miR-497-5p	miRNA	"2,5-hexanedione (HD)"	"2,5-hexanedione (HD) toxicity"	spinal cord tissues	"2,5-hexanedione (HD) treatment"	downregulated	31760062
23411	Rat	rno-miR-498	miRNA	lipopolysaccharide (LPS)	cell proliferation	chondrocytes	lipopolysaccharide (LPS) treatment	downregulated	31141496
23412	Rat	rno-miR-499	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (HX/R) treatment	upregulated	31270949
23413	Rat	rno-miR-499	miRNA	mechanical stress	apoptosis	rat cardiomyocytes	mechanical stress treatment	downregulated	26859150
23414	Rat	rno-miR-499	miRNA	hypoxia/reoxygenation (H/R)	cardiomyocytes injury	H9c2 cells	hypoxia/reoxygenation (H/R) induce	downregulated	31076992
23415	Rat	rno-miR-499	miRNA	daunorubicin	cardiomyopathy	rats	"daunorubicin (DAU-A, 3 mg/kg, every 48 h)"	downregulated	28303410
23416	Rat	rno-miR-499	miRNA	losartan	ischemia/reperfusion (I/R) injury	heart tissues	losartan treatment	upregulated	26168042
23417	Rat	rno-miR-499	miRNA	myricetin	myofiber type transition	soleus and gastrocnemius muscles	myricetin treatment	upregulated	31073320
23418	Rat	rno-miR-499	miRNA	lipopolysaccharide (LPS)	sepsis	cardiomyocytes	lipopolysaccharide (LPS) treatment	upregulated	26659076
23419	Rat	rno-miR-499-5p	miRNA	isoproterenol	acute cardiac injury	heart tissues	isoproterenol treatment	upregulated	27605421
23420	Rat	rno-miR-499-5p	miRNA	hyperoxia	acute myocardial infarction (AMI)	neonatal rat cardiomyocytes	hyperoxia treatment	upregulated	27231854
23421	Rat	rno-miR-499-5p	miRNA	hypoxia	hypoxic-ischemic encephalopathy (HIE)	neonatal rats brain tissues	hypoxia induce	downregulated	31812653
23422	Rat	rno-miR-499-5p	miRNA	notexin	skeletal muscle atrophy	plasma	notexin treatment	upregulated	26952641
23423	Rat	rno-miR-499a-5p	miRNA	doxorubicin (DOX)	cardiotoxicity	left ventricular samples	Doxorubicin (DOX) treatment	upregulated	31048226
23424	Rat	rno-miR-499a-5p	miRNA	high-intensity interval training (HIIT)	cardiotoxicity	DOX-induced rats left ventricular samples	high-intensity interval training (HIIT) treatment	downregulated	31048226
23425	Rat	rno-miR-499a-5p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	downregulated	31452254
23426	Rat	rno-miR-500	miRNA	ischemia	chronic constriction injury	rat spinal cord	ligation of the sciatic nerve treatment	"The expression levels of a large number of miRNAs in the dorsal horn of the spinal cord in CCI rats changed (miR-500, -221 and -21)"	23124577
23427	Rat	rno-miR-500-3p	miRNA	huoxue jiedu formula (HXJDF)	diabetic retinopathy (DR)	retinal tissues	HuoXue JieDu Formula (HXJDF) treatment	miR-500-3p was downregulated in HuoXue JieDu Formula (HXJDF) treated group when compared with diabetic mice.	33271246
23428	Rat	rno-miR-503	miRNA	hypoxia	apoptosis	H9c2 rat myocardial cells	hypoxia induce	upregulated	30404731
23429	Rat	rno-miR-503	miRNA	azoxymethane (AOM)	colorectal cancer (CRC)	colonic tissue of rat	azoxymethane (AOM) treatment	downregulated	23049818
23430	Rat	rno-miR-503	miRNA	high glucose (HG)	diabetic peripheral neuropathy (DPN)	RSC96 cells	high glucose (HG) treatment	upregulated	31581849
23431	Rat	rno-miR-503	miRNA	notoginsenoside R1 (NGR1)	diabetic peripheral neuropathy (DPN)	high glucose-treated RSC96 cells	Notoginsenoside R1 (NGR1) treatment	downregulated	31581849
23432	Rat	rno-miR-503	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	downregulated	24205079
23433	Rat	rno-miR-503	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	downregulated	24205079
23434	Rat	rno-miR-503-5p	miRNA	mechanical stretch	bone formation	RBMSCs	Flexcell FX-5000TM Tension System	downregulated	27862699
23435	Rat	rno-miR-503-5p	miRNA	cyclic mechanical stretch (CMS)	orthodontic	bone mesenchymal stem cells (BMSCs)	Cyclical stretch treatment	downregulated	27862699
23436	Rat	rno-miR-503-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23437	Rat	rno-miR-506	miRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	BRL3A cell	free fatty acid (FFA) treatment	downregulated	31957704
23438	Rat	rno-miR-506	miRNA	lipopolysaccharide (LPS)	pulpitis	dental pulp stem cells (DPSCs)	lipopolysaccharide (LPS) treatment	upregulated	31877121
23439	Rat	rno-miR-511	miRNA	dexamethasone (DEX)	depression	prefrontal cortex of adolescent rats	dexamethasone (DEX) treatment	downregulated	30469088
23440	Rat	rno-miR-511	miRNA	dexamethasone (DEX)	depression	prefrontal cortex of adult rats	dexamethasone (DEX) treatment	downregulated	30469088
23441	Rat	rno-miR-511-3p	miRNA	monocrotaline (MCT)	sinusoidal obstruction syndrome	plasma	monocrotaline treatment	upregulated	29353062
23442	Rat	rno-miR-519d-3p	miRNA	hypoxia	myocardial infarction (MI)	rat heart tissues	permanent ligation of the left anterior descending (LAD) coronary artery induce	upregulated	30607799
23443	Rat	rno-miR-520a	miRNA	hypoxia	cardiomyocyte apoptosis	H9c2 cardiomyocyte cell line	hypoxia induce	downregulated	31410172
23444	Rat	rno-miR-525-5p	miRNA	oxygen glucose deprivation (OGD)	brain injury	neurons	oxygen-glucose deprivation (OGD) treatment	downregulated	26770408
23445	Rat	rno-miR-525-5p	miRNA	hypoxia	myocardial infarction (MI)	myocardial cell line H9c2	hypoxia induce	downregulated	31429119
23446	Rat	rno-miR-532	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	upregulated	28199183
23447	Rat	rno-miR-532-3p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	upregulated	27535721
23448	Rat	rno-miR-532-3p	miRNA	estrogen (ES)	postmenopausal osteoporosis (PMOP)	bone tissues	estrogen treatment	downregulated	33577975
23449	Rat	rno-miR-532-5p	miRNA	parathyroid hormone (PTH)	bone remodeling	rat osteoblasts	Parathyroid hormone (PTH) treatment	downregulated	29626351
23450	Rat	rno-miR-532-5p	miRNA	hypoxia	cardiomyocytes injury	H9c2 cells	hypoxia treatment	miR-532-5p was downregulated in hypoxia-exposed H9c2 cells.	29958954
23451	Rat	rno-miR-532-5p	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
23452	Rat	rno-miR-532-5p	miRNA	anoxia/reoxygenation (A/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	anoxia/reoxygenation (A/R) treatment	downregulated	31985016
23453	Rat	rno-miR-532-5p	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	TUG1 silence ameliorated H/R-induced cardiomyocytes injury through regulating miR-532-5p/Sox8 axis.	32833900
23454	Rat	rno-miR-532-5p	miRNA	bortezomib	peripheral neuropathy	PC12 cells	bortezomib treatment	downregulated	31979371
23455	Rat	rno-miR-539	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	The rat microvascular endothelial cell line bEND.3	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	30276507
23456	Rat	rno-miR-539	miRNA	chronic constriction injury (CCI)	neuronal mechanisms	Sprague-Dawley rats anterior cingulate cortex (ACC)	chronic constriction injury (CCI) induce	downregulated	28379535
23457	Rat	rno-miR-539-5p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	downregulated	27535721
23458	Rat	rno-miR-539-5p	miRNA	bushen huoxue decoction (BHD)	bone fractures	rat mesenchymal stem cells (rMSCs)	bushen huoxue decoction (BHD) treatment	downregulated	31341413
23459	Rat	rno-miR-539-5p	miRNA	laser photocoagulation	experimental choroidal neovascularization	retinal pigment epithelial/choroid/sclera tissues of laser-injured eyes	laser photocoagulation treatment	downregulated	29146732
23460	Rat	rno-miR-541	miRNA	SiO2	lung injury	lung	SiO2 treatment	downregulated	27689473
23461	Rat	rno-miR-541-5p	miRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	pulmonary fibrosis rats	treat with TGF-¦Â treatment	downregulated	28816543
23462	Rat	rno-miR-542-3p	miRNA	Yiqifumai Injection (YQFM)	chronic heart failure (CHF)	H9c2 cells	Yiqifumai Injection (YQFM) treatment	upregulated	29467665
23463	Rat	rno-miR-542-3p	miRNA	kainic acid (KA)	epilepsy	hippocampal tissues	kainic acid (KA) treatment	downregulated	31702493
23464	Rat	rno-miR-542-3p	miRNA	light	focal retinal degeneration	right eye	light treatment	upregulated	25921151
23465	Rat	rno-miR-542-3p	miRNA	TGF-¦Â1	liver fibrosis	HSC©\T6 cells	transforming growth factor ¦Â1 (TGF¦Â1) treatment	upregulated	30368874
23466	Rat	rno-miR-542-5p	miRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	we found that the miR-542-5p expression and the autophagy activation were significantly increased in H9c2 cells after H/R injury.	33394350
23467	Rat	rno-miR-543	miRNA	angiotensin II (Ang II)	cardiac fibrosis	cardiac fibroblasts	angiotensin II (Ang II) treatment	RNF7 promotes the cardiac fibrosis in rat model via miR-543/THBS1 axis and TGF¦Â1 activation.	31913855
23468	Rat	rno-miR-547*	miRNA	"3,3'-iminodipropionitrile (IDPN)"	neurotoxicity	pons and medulla	"3,3'-iminodipropionitrile (IDPN) treatment"	upregulated	27821907
23469	Rat	rno-miR-547-3p	miRNA	methamphetamine (METH)	methamphetamine (METH) addiction	brain tissues	Methamphetamine (METH) treatment	upregulated	32893733
23470	Rat	rno-miR-547-3p	miRNA	Jianpi Xiaoke (JPXK)	type 2 diabetes mellitus (T2DM)	rat	Jianpi Xiaoke (JPXK) treatment	upregulated	33456489
23471	Rat	rno-miR-551b	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
23472	Rat	rno-miR-551b-5p	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	neonatal rats cardiomyocytes	high glucose (HG) treatment	"DCRF can act as a competing endogenous RNA to increase PCDH17 expression by sponging miR-551b-5p, thus contributing to increased cardiomyocyte autophagy in DCM."	31285779
23473	Rat	rno-miR-551b-5p	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	rat heart tissues	streptozotocin treatment	"DCRF can act as a competing endogenous RNA to increase PCDH17 expression by sponging miR-551b-5p, thus contributing to increased cardiomyocyte autophagy in DCM"	31285779
23474	Rat	rno-miR-558	miRNA	isoproterenol	myocardial infarction (MI)	rat H9C2 cells	isoproterenol (ISO) treatment	lncRNA MALAT1 protected cardiomyocytes from ISO-induced apoptosis by sponging miR-558 thus promoting ULK1-dependent autophagy.	30536615
23475	Rat	rno-miR-558	miRNA	CoCl2	spinal cord injury (SCI)	PC12 cells	CoCl2 treatment	circ-HIPK3 relieves the neuronal cell apoptosis through regulating miR-588/DPYSL5 axis in SCI.	32247616
23476	Rat	rno-miR-582-5p	miRNA	propofol (PPF)	propofol-induced neurotoxicity	primary rat hippocampal neurons	Propofol treatment	miR-582-5p were decreased in a time-dependent manner after propofol treatment	32031069
23477	Rat	rno-miR-590	miRNA	ferulic acid (FA)	spinal cord injury (SCI)	neural stem cells (NSCs) of SCI rat	FA	downregulated	28642684
23478	Rat	rno-miR-590-3p	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	"ZFAS1 was upregulated in H9c2 cells subjected to I/R injury, and that ZFAS1 knockdown protected against I/R-induced myocardial cell apoptosis by directly interacting with miR-590-3p, via the NF-¦ÊB pathway."	32705215
23479	Rat	rno-miR-590-3p	miRNA	nuclear factor kappa-B (NF-¦ÊB)	myocarditis and heart dysfunction	heart tissues	NF-¦ÊB treatment	downregulated	26278103
23480	Rat	rno-miR-590-3p	miRNA	lipopolysaccharide (LPS)	sepsis	H9c2 cells	lipopolysaccharide (LPS) treatment	lncRNA NEAT1 accelerated apoptosis and inflammation in LPS-stimulated H9c2 cells via sponging miR-590-3p.	32855700
23481	Rat	rno-miR-592	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	astrocytes (ASTs) from AD rats	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	31759899
23482	Rat	rno-miR-592	miRNA	D-galactose (D-Gal)	Alzheimer's disease (AD)	astrocytes (ASTs) from AD rats	D-galactose treatment	upregulated	31759899
23483	Rat	rno-miR-592	miRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	hippocampus tissues	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	31759899
23484	Rat	rno-miR-593-5p	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	lung tissues and pulmonary arterial smooth muscle cells (PASMCs)	hypoxia induce	downregulated	31081105
23485	Rat	rno-miR-612	miRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	VSMCs isolated from the thoracic aortas of rat	platelet-derived growth factor-BB (PDGF-BB) treatment	downregulated	29399059
23486	Rat	rno-miR-612	miRNA	dexamethasone (DEX)	cartilage injury	articular cartilage	dexamethasone (DEX) treatment	miR-612 was downregulated compared with control group.	29207029
23487	Rat	rno-miR-612	miRNA	platelet derived growth factor-BB (PDGF-BB)	neointimal formation	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor (PDGF)-BB treatment	"PDGF-BB significantly promoted the proliferation and migration of VSMCs, and decreased miR-612 levels in VSMCs"	29399059
23488	Rat	rno-miR-6215	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	downregulated	27919821
23489	Rat	rno-miR-6216	miRNA	doxorubicin (DOX)	ischemia/reperfusion (I/R) injury	rats cardiomyocytes	doxorubicin treatment	upregulated	27919821
23490	Rat	rno-miR-6216	miRNA	doxorubicin (DOX)	renal interstitial fibrosis (RIF)	kidneys	doxorubicin (ADR) induction	upregulated	32606425
23491	Rat	rno-miR-6216	miRNA	"kangxianling (KXL, anti-fibrin)"	renal interstitial fibrosis (RIF)	kidneys	"Kangxianling (KXL, anti-fibrin) treatment"	downregulated	32606425
23492	Rat	rno-miR-628	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	downregulated	27535721
23493	Rat	rno-miR-628	miRNA	burn injury	burn-induced skeletal muscle atrophy	rats	burn treatment	upregulated	27766036
23494	Rat	rno-mir-6314	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23495	Rat	rno-miR-6322	miRNA	ischemia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	ischemia buffer treatment	Hsa-circ-0068566 inhibited the development of myocardial ischemia reperfusion injury by regulating hsa-miR-6322/PARP2 signal pathway.	32633392
23496	Rat	rno-miR-6324	miRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	H9c2 cells	tunicamycin treatment	lncRNA Dancr overexpression protected cardiomyocytes against ERS injury via sponging miR-6324.	33300079
23497	Rat	rno-mir-6329	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23498	Rat	rno-miR-636	miRNA	caffeic acid	diabetic nephropathy (DN)	liver tissues	caffeic acid (CA) treatment	caffeic acid down regulates miR-636 expression level.	31391719
23499	Rat	rno-miR-636	miRNA	caffeic acid	diabetic nephropathy (DN)	kidney tissues	caffeic acid (CA) treatment	downregulated	31391719
23500	Rat	rno-miR-636	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin treatment	upregulated	31391719
23501	Rat	rno-miR-638	miRNA	resveratrol	pulmonary arterial hypertension (PAH)	rat pulmonary arterial smooth muscle cells (PASMCs)	resveratrol (RS) treatment	"MCT resulted in significant pulmonary vascular remodeling and downregulated of miR-638, which could be suppressed by resveratrol"	32057731
23502	Rat	rno-miR-652	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	PC12 cells; brain tissues	oxygen-glucose deprivation (OGD treatment	"The transcription factor NR4A2 mediates the expression of Mul1 through transcriptional repression of miR-652, thus promoting ischemic brain injury"	33116527
23503	Rat	rno-miR-652-3p	miRNA	valproic acid (VPA)	cell differentiation	primary cultured neural stem cells (NSCs)	valproate (VPA) treatment	upregulated	29575035
23504	Rat	rno-miR-652-3p	miRNA	huoxue jiedu formula (HXJDF)	diabetic retinopathy (DR)	retinal tissues	HuoXue JieDu Formula (HXJDF) treatment	miR-652-3p was upregulated in HuoXue JieDu Formula (HXJDF) treated group when compared with control mice.	33271246
23505	Rat	rno-miR-652-5p	miRNA	steroids	osteonecrosis	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	upregulated	26459755
23506	Rat	rno-miR-659-3p	miRNA	hypoxia	familial frontotemporal lobar degeneration (FTLD)	?rat cortices	Hypoxia treatment	downregulated	27199656
23507	Rat	rno-miR-663b	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	miR-663b inhibition protected cardiomyocytes against hypoxia-induced injury by targeting BCL2L1.	32346421
23508	Rat	rno-miR-664	miRNA	acarbose	diabetes mellitus (DM)	blood	acarbose? treatment	upregulated	24260283
23509	Rat	rno-miR-664-2	miRNA	danazol	precocious puberty (PP)	rat hypothalamus tissues	Danazol treatment	downregulated	30916745
23510	Rat	rno-miR-665	miRNA	propofol (PPF)	central nervous system (CNS) development	astroglia	propofol treatment	downregulated	26083276
23511	Rat	rno-miR-665	miRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	32132320
23512	Rat	rno-miR-666-3p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	inflammation	primary brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"?In particular, the expression levels of rno-miR-666-3p, rno-miR-92a-2-5p, and rno-miR-219a-2-3p decreased in OGD/R-exposed cells compared with those in the control"	33745435
23513	Rat	rno-miR-668	miRNA	hypoxia	acute kidney injury (AKI)	rat proximal tubular cells (RPTC)	hypoxia induce	upregulated	30325740
23514	Rat	rno-miR-668	miRNA	erythropoietin (EPO)	hydrocephalus	kaolin-induced obstructive hydrocephalus rats periventricular ependymal lining and cultured astrocytes	erythropoietin (EPO) treatment	downregulated	29982881
23515	Rat	rno-miR-668	miRNA	kaolin	hydrocephalus	periventricular ependymal lining and cultured astrocytes	kaolin treatment	upregulated	29982881
23516	Rat	rno-miR-671	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated	32889692
23517	Rat	rno-miR-671	miRNA	exendin-4 (Ex-4)	parkinson's disease (PD)	1-methyl-4-phenylpyridinium (MPP+)-treated PC12 cells	Exendin-4 (Ex-4)?treatment	upregulated	32889692
23518	Rat	rno-miR-671	miRNA	exendin-4 (Ex-4)	neuronal cell injury	PC12 cells	Exendin-4 (Ex-4) treatment	Ex-4 downregulated 1-methyl-4 phenyl-pyridine ion (MPP+) -induced CDR1as expression in PC12 cells and upregulated miR-671 expression.	32889692
23519	Rat	rno-miR-672	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cultured rat cardiomyocytes	angiotensin II (Ang II) treatment	downregulated	29339068
23520	Rat	rno-miR-672	miRNA	insulin-like growth factor 1 (IGF-1)	cardiac hypertrophy	primary cultured rat cardiomyocytes	insulin-like growth factor 1 treatment	downregulated	29339068
23521	Rat	rno-miR-672	miRNA	phenylephrine (PE)	cardiac hypertrophy	primary cultured rat cardiomyocytes	phenylephrine treatment	downregulated	29339068
23522	Rat	rno-miR-672	miRNA	perfluorooctane sulfonic acid (PFOS)	neural dysfunctions	rat brains	perfluorooctane sulfonic acid (PFOS) treatment	downregulated	22594572
23523	Rat	rno-miR-672-5p	miRNA	steroids	osteonecrosis	osteoblasts	steroid treatment	upregulated	27378744
23524	Rat	rno-miR-674-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23525	Rat	rno-miR-674-3p	miRNA	insulin-like growth factor 1 (IGF-1)	spinal cord injury (SCI)	Neural stem cells were obtained from E15 fetal rat cerebral cortex cultured supernatant exosomes	insulin growth factor-1 (IFG-1) treatment	upregulated	31848325
23526	Rat	rno-miR-674-5p	miRNA	valproic acid (VPA)	cell differentiation	primary cultured neural stem cells (NSCs)	valproate (VPA) treatment	upregulated	29575035
23527	Rat	rno-miR-675	miRNA	H2O2	aging-induced vascular dysfunction	H9C2 cells	H2O2 treatment	downregulated	30889706
23528	Rat	rno-miR-675	miRNA	adriamycin (ADR)	dilated cardiomyopathy (DCM)	rats?myocardial tissue	adriamycin (ADR) treatment	downregulated	28430627
23529	Rat	rno-miR-676	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
23530	Rat	rno-mir-676	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23531	Rat	rno-miR-676-1	miRNA	fastigial nucleus stimulation (FNS)	focal cerebral ischemia	rat brain	fastigial nucleus stimulation (FNS)?treatment	upregulated	25783478
23532	Rat	rno-miR-680	miRNA	corticotrophin releasing factor (CRF) receptor I antagonist (BMS-764459)	hepatocellular carcinoma (HCC)	rat liver cells	"The corticotrophin releasing factor (CRF) receptor I antagonist, BMS-764459 treatment"	"MiR-680 and miR-29a were identified as potential regulators and biomarkers of atypical CYP1A1 induction by regulating Abcc3, CYP3A and CYP2B as well as a number of AhR targeted genes"	23831372
23533	Rat	rno-miR-682	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H92c cells	hypoxia/reoxygenation treatment	downregulated	32590403
23534	Rat	rno-miR-691	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
23535	Rat	rno-miR-7	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	primary isolated endothelial cell (EC) and retinal pericyte (RP)	streptozotocin (STZ) treatment	downregulated	30058674
23536	Rat	rno-miR-7	miRNA	tricin	glioblastoma multiforme (GBM)	C6 glioma cells	tricin treatment	upregulated	29877083
23537	Rat	rno-miR-7	miRNA	hypoxia	ischemic stroke (IS)	hippocampal CA1 neurons	hypoxia induce	upregulated	30305621
23538	Rat	rno-miR-7	miRNA	atrazine (2-chloro-4-ethylamino-6-isopropylamino-s-triazine; ATR)	parkinson's disease (PD)	peripheral blood and brain tissue in a rat model of PD	Atrazine (2-chloro-4-ethylamino-6-isopropylamino-s-triazine; ATR) treatment	miR-7 was upregulated in brain tissue but downregulated in peripheral blood of rats with ATR-induced PD.	31185338
23539	Rat	rno-miR-7	miRNA	rotenone (ROT)	parkinson's disease (PD)	striatum of parkinsonian rats	rotenone exposure treatment	upregulated	30267378
23540	Rat	rno-miR-7	miRNA	crocin	parkinson's disease (PD)	striatal tissueS	crocin treatment	Crocin upregulated the expression of miRNA-7.	31811872
23541	Rat	rno-miR-702-3p	miRNA	SiO2	lung injury	lung	SiO2 treatment	upregulated	27689473
23542	Rat	rno-miR-702-3p	miRNA	propofol (PPF)	neural function	left cortex of the brain	Propofol treatment	significantly increased	26021509
23543	Rat	rno-miR-706	miRNA	palmitate and palmitate plus oleate.	insulin resistance (IR)	mouse myoblasts	palmitate and palmitate plus oleate treatment	upregulated	21183973
23544	Rat	rno-miR-708	miRNA	¦Â-ionone (¦ÂI)	hepatocellular carcinoma (HCC)	rats hepatocyte	¦ÂI (16 mg/100 g body weight) treatment	"upregulated(miR-122 , miR-34a) ;downregulated (miR-181b , miR-708)"	27061051
23545	Rat	rno-miR-708-3p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23546	Rat	rno-miR-708-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23547	Rat	rno-miR-708-5p	miRNA	nickel	steroidogenesis disturbance	Leydig cells	NiSO4 induce	dysregulated	31734292
23548	Rat	rno-miR-708-5p	miRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	upregulated	31948324
23549	Rat	rno-miR-709	miRNA	acetaminophen (APAP) and methapyrilene (MP)	liver damage	rats pericentral and periportal regions	acetaminophen (APAP) and methapyrilene (MP) treatment	upregulated	24863736
23550	Rat	rno-miR-709	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
23551	Rat	rno-miR-71	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	neurotoxicity	brain tissues of rats	RDX at a dose(47 mg/kg) for 48 h treatment	upregulated	25559034
23552	Rat	rno-miR-7-1	miRNA	"1,3,5-tris-4-propyl-1H-pyrazole"	spinal cord injury (SCI)	VSC4.1 motoneurons	ER agonists treatment	upregulated	24157932
23553	Rat	rno-miR-711	miRNA	palmitate and palmitate plus oleate.	insulin resistance (IR)	mouse myoblasts	palmitate and palmitate plus oleate treatment	upregulated	21183973
23554	Rat	rno-miR-711	miRNA	pioglitazone	myocardial infarction (MI)	rat cardiac fibroblasts	pioglitazone treatment	upregulated	23633075
23555	Rat	rno-miR-711	miRNA	antimycin A (AA)	oxidative stress	H9c2 cells	antimycin A (AA) treatment	upregulated	32308692
23556	Rat	rno-miR-711	miRNA	CoCl2	oxidative stress	H9c2 cells	CoCl2 treatment	upregulated	32308692
23557	Rat	rno-miR-711	miRNA	H2O2	oxidative stress	H9c2 cells	H2O2 treatment	upregulated	32308692
23558	Rat	rno-miR-711	miRNA	hypoxia/reoxygenation (H/R)	oxidative stress	H9c2 cells	hypoxia/reoxygenation (H/R)) treatment	upregulated	32308692
23559	Rat	rno-miR-711	miRNA	etoposide (VP-16)	spinal cord injury (SCI)	primary cultured cortical neurons	etoposide treatment	upregulated	31685802
23560	Rat	rno-miR-711	miRNA	staurosporine	spinal cord injury (SCI)	primary cultured cortical neurons	staurosporine treatment	upregulated	31685802
23561	Rat	rno-miR-7134-5p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
23562	Rat	rno-miR-714	miRNA	dexamethasone (DEX)	cartilage injury	articular cartilage	dexamethasone (DEX) treatment	miR-714was downregulated compared with control group.	29207029
23563	Rat	rno-miR-720	miRNA	acetaminophen (APAP) and methapyrilene (MP)	liver damage	rats pericentral and periportal regions	acetaminophen (APAP) and methapyrilene (MP) treatment	upregulated	24863736
23564	Rat	rno-miR-743b-5p	miRNA	artemisinin (ART)	ventricular arrhythmias (VA)	transverse aortic constriction (TAC) surgery treated rats left ventricle (LV) tissues	artemisinin (ART) treatment	upregulated	30595983
23565	Rat	rno-miR-7-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia induce	downregulated	31264206
23566	Rat	rno-miR-7-5p	miRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	ANRIL plays a protective part in hypoxia-induced H9c2 cell injury via modulating the miR-7-5p/SIRT1 axis	31264206
23567	Rat	rno-miR-7-5p	miRNA	icariside II (ICA II)	hypoxia-induced injury	H9c2 cells	Icariside II (ICS II) treatment	upregulated	32945347
23568	Rat	rno-miR-7-5p	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat H9C2 cells	hypoxia induce	downregulated of MEG3 protects myocardial cells against I/R-induced apoptosis through miR-7-5p/PARP1 pathway	31366567
23569	Rat	rno-miR-760	miRNA	verapamil	male fertility	testis	verapamil treatment	downregulated	32725937
23570	Rat	rno-miR-760	miRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	miR-760 was downregulated in H9C2 cells exposed to H/R.	32160475
23571	Rat	rno-miR-760-3p	miRNA	nickel	steroidogenesis disturbance	Leydig cells	NiSO4 induce	dysregulated	31734292
23572	Rat	rno-miR-760-3p	miRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	downregulated	31948324
23573	Rat	rno-miR-760-5p	miRNA	guarana	adipogenesis	3T3L1 cells	guarana	downregulated	28632199
23574	Rat	rno-miR-764	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	downregulated	33199822
23575	Rat	rno-miR-764	miRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia reoxygenation (H/R) treatment	Mirt2 participated in the regulation of MI through the miR-764/PDK1 axis.	33199822
23576	Rat	rno-miR-764-5p	miRNA	high fat diet (HFD)	cardiac remodeling	heart tissues	high fat diet (HFD) feed	upregulated	29884823
23577	Rat	rno-miR-766-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	33791020
23578	Rat	rno-miR-7a	miRNA	dexamethasone (DEX)	cartilage injury	articular cartilage	dexamethasone (DEX) treatment	miR-7a was downregulated compared with control group.	29207029
23579	Rat	rno-miR-7a	miRNA	palmitate and palmitate plus oleate.	insulin resistance (IR)	mouse myoblasts	palmitate and palmitate plus oleate treatment	upregulated	21183973
23580	Rat	rno-miR-7a-5p	miRNA	hypoxia	hypoxic/ischemic injury	Male Sprague Dawley rats	"were exposed to hypoxia (9.5-10% O2) for 1, 5, or 10 days"	upregulated	29262398
23581	Rat	rno-miR-7a-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23582	Rat	rno-miR-7a-5p	miRNA	recurrent insulin-induced hypoglycemia (RH)	sympathoadrenal response	ventromedial hypothalamus (VMH)	recurrent insulin-induced hypoglycemia (RH) treatment	downregulated	31619588
23583	Rat	rno-miR-7b	miRNA	hypoxia	acute myocardial infarction (AMI)	rat cardiomyoblast cells (H9c2)	hypoxia induce	downregulated	30548297
23584	Rat	rno-miR-7b	miRNA	ischemia	chronic heart failure (CHF)	Plasma	Ligation of the left anterior descendent coronary artery treatment	upregulated	26699387
23585	Rat	rno-miR-7b	miRNA	hypoxia	ischemia/reperfusion (I/R) injury	H9C2 cells	hypoxia induce	downregulated	30548297
23586	Rat	rno-miR-7b	miRNA	electroacupuncture (EA)	spinal cord injury (SCI)	spinal cords	electroacupuncture (EA) treatment	downregulated	32468009
23587	Rat	rno-miR-7c	miRNA	hypoxia	myocardial ischaemic injury	neonatal rat ventricular myocytes	hypoxia treatment	downregulated	26655604
23588	Rat	rno-miR-7g	miRNA	hypoxia	myocardial ischaemic injury	neonatal rat ventricular myocytes	hypoxia treatment	downregulated	26655604
23589	Rat	rno-miR-802	miRNA	palmitate	type 2 diabetes mellitus (T2DM)	INS-1 rat insulinoma cell line	palmitate for 48 h treatment	upregulated	31966484
23590	Rat	rno-miR-871-3p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31899128
23591	Rat	rno-miR-873	miRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	downregulated	31570671
23592	Rat	rno-miR-873-5p	miRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	PC12 cells	amyloid ¦Â1-42?(A¦Â) treatment	downregulated	29926354
23593	Rat	rno-miR-873-5p	miRNA	ginsenoside Rg1 (GRg1) and acori graminei Rhizoma (AGR)	Alzheimer's disease (AD)	A¦Â1-42-treated PC12 cells	Ginsenoside Rg1 (GRg1)/Acori graminei Rhizoma (AGR) treatment	upregulated	29926354
23594	Rat	rno-miR-874	miRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozotocin (STZ) treatment	downregulated	30171701
23595	Rat	rno-miR-874-3p	miRNA	streptozocin (STZ)	diabetes mellitus-induced erectile dysfunction (DMED)	Rat cavernosum tissues	streptozocin treatment	downregulated	31914690
23596	Rat	rno-miR-874-3p	miRNA	streptozocin (STZ)	diabetes mellitus-induced erectile dysfunction (DMED)	cavernosum tissues	streptozotocin (STZ) treatment	Epigenetic silencing of microRNA-874-3p implicates in erectile dysfunction in diabetic rats by activating the Nupr1/Chop-mediated pathway	31914690
23597	Rat	rno-miR-874-3p	miRNA	ischemia/reperfusion (I/R) 	ischemia/reperfusion (I/R) injury	PC12 cells	ischemia/reperfusion (I/R) treatment	LncRNA NEAT1 aggravates cerebral I/R injury by suppressing miR-874-3p expression.	32329323
23598	Rat	rno-miR-874-3p	miRNA	hypoxia	ischemic stroke (IS)	brain tissues	middle cerebral artery occlusion/reperfusion (MCAO/R) treatment	downregulated	31200256
23599	Rat	rno-miR-874-5p	miRNA	hypoxia	autophagy	Pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	miR-874-5p was upregulated following hypoxia.	32805255
23600	Rat	rno-miR-875-3p	miRNA	doxorubicin (DOX)	cardiotoxicity	H9c2 cells	Doxorubicin (DOX) treatment	Knockdown of miRNA-875-3p decreased the proliferative ability of cardiomyocytes.	32010313
23601	Rat	rno-miR-875-3p	miRNA	doxorubicin (DOX)	doxorubicin (DOX)-induced cardiotoxicity	H9c2 cells	doxorubicin (DOX) treatment	downregulated	32010313
23602	Rat	rno-miR-877	miRNA	streptozocin (STZ)	diabetic cardiomyopathy (DCM)	Wistar rats left ventricle (LV)	STZ treatment	downregulated	28199183
23603	Rat	rno-mir-877	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23604	Rat	rno-miR-881-3p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	upregulated	31899128
23605	Rat	rno-miR-9	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	endotoxin treatment	upregulated	26137246
23606	Rat	rno-miR-9	miRNA	epigallocatechin-3-gallate (EGCG)	chronic kidney disease (CKD)	NRK-49F cells	EGCG treatment	EGCG upregulated the Expression of MiR-9.	30468495
23607	Rat	rno-miR-9	miRNA	hypoxia	congenital heart disease (CHD)	H9c2 cells	hypoxia induce	upregulated	30639391
23608	Rat	rno-miR-9	miRNA	occlusion of the bilateral common carotid artery (2VO)	"dementia ,learning and memory"	hippocampus; cortex	occlusion of the bilateral common carotid artery (2VO) treatment	upregulated in both the hippocampus and cortex	28683457
23609	Rat	rno-miR-9	miRNA	emodin	diabetic foot ulcer (DFU)	PC-12 cells	emodin treatment	miR-9 was highly expressed in response to emodin treatment.	29577942
23610	Rat	rno-miR-9	miRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	H9C2 cells	high glucose treatment	downregulated	26898797
23611	Rat	rno-miR-9	miRNA	alcohol	fetal alcohol exposure (FAE)	pregnant Fisher 344 rats pituitary	liquid diet containing 6.7% alcohol between gestational days 7-21 (AF)	upregulated	28710248
23612	Rat	rno-miR-9	miRNA	serum	hepatopulmonary syndrome (HPS)	pulmonary artery smooth muscle cell (PASMC)	serum treatment	upregulated	26147104
23613	Rat	rno-miR-9	miRNA	hypoxia	hypoxia-induced cardiac dysfunctions	H9c2 cells	hypoxia treatment	"We found that miR-9 was increased, while CDK8 was decreased in hypoxia-treated H9c2 cells."	33737500
23614	Rat	rno-miR-9	miRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	brain tissues	8% O2 + 92% N2 and sugar-free medium for 60 minutes treatment	downregulated	25206848
23615	Rat	rno-miR-9	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	upregulated	27074745
23616	Rat	rno-miR-9	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG7 was downregulated and miR-9 was upregulated by OGD/R treatment in PC12 cells	33262598
23617	Rat	rno-miR-9	miRNA	hypoxia	neonatal hypoxic-ischemic brain damage	PC12 cells; hippocampus	hypoxia treatment	upregulated	32470970
23618	Rat	rno-miR-9	miRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC12 cells	N-methyl-4-phenylpyridinium (MPP +) treatment	"MPP+ toxicity significantly caused upregulated in miR-34a, miR-141, and miR-9."	29631008
23619	Rat	rno-miR-9	miRNA	hypoxia	phenotypic switch of PASMCs	rats pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	upregulated	24615545
23620	Rat	rno-miR-9	miRNA	retinoic acid (RA)	spina bifida	spinal cord of rat	Retinoic acid treatment	downregulated	17962954
23621	Rat	rno-miR-9	miRNA	matrine	spinal cord injury (SCI)	PC-12 cells	Matrine treatment	LPS reduced miR-9 expression about 60%.	32297823
23622	Rat	rno-miR-9*	miRNA	trimethyltin (TMT)	neurotoxicity	rats serum	were given a single administration of TMT treatment	upregulated	24777749
23623	Rat	rno-miR-9*	miRNA	high fat diet (HFD)	obesity	rats	high fat diet (HFD) feed	dysregulated	24517225
23624	Rat	rno-miR-9*	miRNA	retinoic acid (RA)	spina bifida	spinal cord of rat	Retinoic acid treatment	downregulated	17962954
23625	Rat	rno-miR-9119	miRNA	human chorionic gonadotrophin (hCG)	polycystic ovarian syndrome (PCOS)	ovarian granulosa cells (GCs)	human chorionic gonadotrophin (hCG) treatment	upregulated	31894528
23626	Rat	rno-miR-92	miRNA	butyrylated high-amylose maize starch (HAMSB)	colorectal cancer (CRC)	high-protein meat diet (HPM) fed rat colonic tissue	butyrylated high-amylose maize starch (HAMSB) feed	downregulated	31052187
23627	Rat	rno-miR-92	miRNA	high-amylose potato starch (HAPS)	colorectal cancer (CRC)	high-protein meat diet (HPM) fed rat colonic tissue	high-amylose potato starch (HAPS) feed	downregulated	31052187
23628	Rat	rno-miR-92a	miRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues	lipopolysaccharide (LPS) treatment	upregulated	33015189
23629	Rat	rno-miR-92a	miRNA	hyperbaric oxygen (HBO)	acute myocardial infarction (AMI)	Rat cardiac myocytes	Hyperbaric oxygen (HBO) treatment	HBO-induced exosomes post-MI significantly reduced miR-92a expression compared with AMI alone at 14 days.	32939962
23630	Rat	rno-miR-92a	miRNA	bone marrow mesenchymal stem cells (BMSCs)	apoptosis	infarcted rats myocardium	bone marrow mesenchymal stem cells (BMSCs) treatment	downregulated	28662151
23631	Rat	rno-miR-92a	miRNA	H2O2	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs) were primarily cultured from rat thoracic aortas	hydrogen peroxide (H2O2) treatment	downregulated	29115493
23632	Rat	rno-miR-92a	miRNA	adenine	chronic kidney disease (CKD)	rats aortas; serum	adenine	upregulated	28696247
23633	Rat	rno-miR-92a	miRNA	tetrodotoxin and AP5	effect of tetrodotoxin and AP5	rats hippocampal neurons	tetrodotoxin and AP5 treatment	downregulated	25017011
23634	Rat	rno-miR-92a	miRNA	ethylene glycol monomethyl ether (EGME)	hyperglycemia	?testicle of rat	Ethylene glycol monomethyl ether (EGME) treatment	"miR-449a and miR-92a decreased obviously and, miR-320, miR-134 and miR-188 increased"	22008535
23635	Rat	rno-miR-92a	miRNA	losartan	ischemia/reperfusion (I/R) injury	heart tissues	losartan treatment	upregulated	26168042
23636	Rat	rno-miR-92a	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	"Hypoxia stimulation significantly inhibited H9c2 cell viability and proliferation, induced cell apoptosis and upregulated miR-92a expression."	31949700
23637	Rat	rno-miR-92a-1-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23638	Rat	rno-miR-92a-2-5p	miRNA	ethylenethiourea (ETU)	anorectal malformations (ARM)	Hindgut tissue was isolated from the gestational day 14 fetuses	ethylenethiourea (ETU) treatment	upregulated	30106085
23639	Rat	rno-miR-92a-2-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	inflammation	primary brain microvascular endothelial cells (BMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"?In particular, the expression levels of rno-miR-666-3p, rno-miR-92a-2-5p, and rno-miR-219a-2-3p decreased in OGD/R-exposed cells compared with those in the control"	33745435
23640	Rat	rno-miR-92a-3p	miRNA	cold	cold stress	rats serum	cold conditions (4¡æ for 12h)	downregulated	28477904
23641	Rat	rno-miR-92a-3p	miRNA	smoking	smoke inhalation injury (SII)	bronchoalveolar lavage fluid (BALF)	Smoke inhalation treatment	upregulated	30139538
23642	Rat	rno-miR-92b	miRNA	adriamycin (ADR)	nephrotic syndrome (NS)	kidney tissues	adriamycin (ADR) treatment	upregulated	30551379
23643	Rat	rno-miR-92b	miRNA	zhen-wu-tang (ZWT)	nephrotic syndrome (NS)	kidney tissues	Zhen-wu-tang (ZWT) treatment	downregulated	30551379
23644	Rat	rno-miR-92b	miRNA	zhen-wu-tang (ZWT)	nephrotic syndrome (NS)	kidney tissues	zhen-wu-tang (ZWT) treatment	ZWT can decrease the expression of miR-92b and reverse the effect of miR-92b on AQP2 in vitro.	30551379
23645	Rat	rno-miR-92b	miRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
23646	Rat	rno-miR-92b	miRNA	insulin-like growth factor 1 (IGF-1)	post-stroke	brain tissues	Post-stroke ICV administration of IGF-1 to middle-aged female rats treatment	downregulated	24618563
23647	Rat	rno-miR-92b	miRNA	insulin-like growth factor 1 (IGF-1)	spinal cord injury (SCI)	Neural stem cells were obtained from E15 fetal rat cerebral cortex cultured supernatant exosomes	insulin growth factor-1 (IFG-1) treatment	upregulated	31848325
23648	Rat	rno-miR-92b-3p	miRNA	resveratrol	osteoporosis	rat bone marrow mesenchymal stem cells (BMSCs)	resveratrol (Res) treatment	upregulated	32674689
23649	Rat	rno-miR-92b-3p	miRNA	hypoxia	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia induce	downregulated	30149918
23650	Rat	rno-miR-92b-3p	miRNA	smoking	smoke inhalation injury (SII)	bronchoalveolar lavage fluid (BALF)	Smoke inhalation treatment	upregulated	30139538
23651	Rat	rno-miR-92b-3p	miRNA	insulin-like growth factor 1 (IGF-1)	spinal cord injury (SCI)	Neural stem cells were obtained from E15 fetal rat cerebral cortex cultured supernatant exosomes	insulin growth factor-1 (IFG-1) treatment	upregulated	31848325
23652	Rat	rno-miR-92b-3p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
23653	Rat	rno-miR-93	miRNA	17-AAG (tanespimycin)	apoptosis	tunicamycin-treated primary neonatal rat cardiomyocytes	?17-AAG (tanespimycin) treatment	upregulated	30556167
23654	Rat	rno-miR-93	miRNA	tunicamycin (TM)	apoptosis	primary neonatal rat cardiomyocytes	tunicamycin treatment	downregulated	30556167
23655	Rat	rno-miR-93	miRNA	estradiol-17¦Â (E2)	breast cancer	mammary tissues	estradiol-17¦Â (E2) treatment	upregulated	23492819
23656	Rat	rno-miR-93	miRNA	vitamin C	breast cancer	mammary tissues	vitamin C treatment	downregulated	23492819
23657	Rat	rno-miR-93	miRNA	TGF-¦Â1	cardiac fibrosis	primary rat cardiac fibroblasts	TGF-¦Â1 treatment	upregulated	29551367
23658	Rat	rno-miR-93	miRNA	angiotensin II (Ang II)	cardiac hypertrophy	cardiomyocytes	angiotensin II (Ang II) treatment	MIAT was upregulated and miR-93 was downregulated in AngII-treated cardiomyocytes.	29673400
23659	Rat	rno-miR-93	miRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation and migration	rats vascular smooth muscle cell (VSMC)	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	31754334
23660	Rat	rno-miR-93	miRNA	lipopolysaccharide (LPS)	endotoxin-induced uveitis (EIU)	macrophages	lipopolysaccharide (LPS) treatment	downregulated	24642374
23661	Rat	rno-miR-93	miRNA	furan	hepatotoxicity	liver	Furan treatment	upregulated	27371368
23662	Rat	rno-miR-93	miRNA	nerve growth factor (Ngf)	neurodegenerative diseases	PC12 cells	100 ng/ml Ngf treatment	different regulation	24492999
23663	Rat	rno-miR-93	miRNA	dopamine agonist (DA)	prolactinoma	MMQ cells; GH3 cells	dopamine agonist (DA) treatment	miRNA-93 expression was elevated in DA-resistant prolactinomas.	30389900
23664	Rat	rno-miR-93-3p	miRNA	lipopolysaccharide (LPS)	inflammation	H9c2 cells	lipopolysaccharide (LPS) treatment	downregulated	30195636
23665	Rat	rno-miR-93-5p	miRNA	insert a cannula connected with a saline container into the anterior chamber	acute ocular hypertension (AOH)	adult albino rats retinal ganglion cells (RGCs) and microglial cells	insert a cannula connected with a saline container into the anterior chamber	downregulated	27535721
23666	Rat	rno-miR-93-5p	miRNA	liraglutide	endothelial dysfunction	aortic endothelial in diabetic rats	liraglutide treatment	downregulated	30863684
23667	Rat	rno-miR-93-5p	miRNA	N-methyl-D-aspartate (NMDA)	glaucoma	rat retinal ganglion cells	N-me- thyl-D-aspartate (NMDA) treatment	The level of miR-93-5p in the retina of rats with injection of NMDA was gradually declined over time.	29421576
23668	Rat	rno-miR-93-5p	miRNA	IL-1¦Â	osteoarthritis (OA)	rat chondrocytes	IL-1¦Â treatment	upregulated	31253047
23669	Rat	rno-miR-93-5p	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	H9c2 cells	lipopolysaccharide (LPS) treatment	"H19 and SORBS2 were downregulated in H9C2 cells following LPS treatment, while miR-93-5p was upregulated."	32996061
23670	Rat	rno-miR-93-5p	miRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	H9C2 cells	lipopolysaccharide (LPS) treatment	H19 attenuated the development of sepsis-induced myocardial injury in vitro via modulation of the miR-93-5p/SORBS2 axis.	32996061
23671	Rat	rno-miR-93-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23672	Rat	rno-miR-939	miRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cardiac muscle cells	hypoxia induce	downregulated	31321998
23673	Rat	rno-miR-93a-5p	miRNA	high fat diet (HFD)	obesity	white adipose tissues	high fat diet (HFD) feed	upregulated	32366215
23674	Rat	rno-miR-942-5p	miRNA	doxorubicin (DOX)	cardiomyocyte apoptosis	Primary cardiomyocytes	?doxorubicin (DOX) treatment	"SOX2-OT and DP5 were highly expressed, while miR-942-5p was downregulated in DOX-treated primary cardiomyocytes and rat model"	33603338
23675	Rat	rno-miR-9-5p	miRNA	streptozocin (STZ)	diabetes mellitus (DM)	INS-1 cells	streptozotocin (STZ) treatment	downregulated	33826088
23676	Rat	rno-miR-9-5p	miRNA	sevoflurane (SEV)	hepatic ischemia/reperfusion injury (HIRI)	liver ischemia/reperfusion (IR) rats liver tissues	sevoflurane treatment	upregulated	30906455
23677	Rat	rno-miR-9-5p	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	downregulated	30101604
23678	Rat	rno-miR-9-5p	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	forced expression of miR-9-5p in H9c2 cells is concurrent with diminished expression of Fstl1 and vice versa.	30101604
23679	Rat	rno-miR-9-5p	miRNA	IL-6 and TNF-¦Á	rheumatoid arthritis (RA)	Schwann cells	TNF-¦Á treatment	"In IL-6- and TNF-¦Á-stimulated Schwann cells, apoptosis was induced, while the cell viability and level of miR-9-5p were inhibited."	30456455
23680	Rat	rno-miR-9-5p	miRNA	IL-6 and TNF-¦Á	rheumatoid arthritis (RA)	Schwann cells	0.1 ng/mL IL-6 and 20 ng/mL TNF-¦Á treatment	downregulated	30456455
23681	Rat	rno-miR-9-5p	miRNA	lithium (Li)	spinal cord injury (SCI)	spinal cord	lithium treatment	"Furthermore, lithium treatment alleviated the inflammatory response by inactivating the nuclear factor-kappa B (NF-¦ÊB) pathway and inhibited the expression of lncRNA brain-derived neurotrophic factor antisense (BDNF-AS) in SCI rats."	33464390
23682	Rat	rno-miR-9-5p	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	traumatic brain injury (TBI)	brain microvascular endothelial cells (BMECs); astrocytes	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"upregulated of miRNA-9-5p alleviates BBB damage and neuroinflammatory responses by activating the Hedgehog pathway and inhibiting NF-¦ÊB/MMP-9 pathway, which promotes the recovery of neurological function after TBI"	33236776
23683	Rat	rno-miR-96	miRNA	sevoflurane (SEV)	cognitive impairment	hippocampus	sevoflurane treatment	upregulated	30217735
23684	Rat	rno-miR-96	miRNA	sevoflurane (SEV)	cognitive impairment	neonatal rats hippocampal neuron	sevoflurane treatment	upregulated	30217735
23685	Rat	rno-miR-96	miRNA	high fat diet (HFD)	diabetic peripheral neuropathy (DPN)	sciatic nerve tissues	high fat diet (HFD) feed	downregulated	29689688
23686	Rat	rno-miR-96	miRNA	streptozocin (STZ)	diabetic peripheral neuropathy (DPN)	sciatic nerve tissues	streptozotocin (STZ) treatment	downregulated	29689688
23687	Rat	rno-miR-96	miRNA	swimming	diabetic peripheral neuropathy (DPN)	diabetic rats sciatic nerve tissues	swimming exercise induce treatment	upregulated	29689688
23688	Rat	rno-miR-96	miRNA	streptozocin (STZ)	diabetic retinopathy (DR)	?retinas?tissues	streptozotocin (STZ) treatment	upregulated	22156553
23689	Rat	rno-miR-96	miRNA	lipopolysaccharide (LPS)	disseminated intravascular coagulation (DIC)	liver tissues	lipopolysaccharide (LPS) treatment	upregulated	24806323
23690	Rat	rno-miR-96	miRNA	adreno-cortico-tropic-hormone (ACTH)	hormonal regulation	adrenals?tissues	adreno-cortico-tropic-hormone (ACTH) treatment	upregulated	24205079
23691	Rat	rno-miR-96	miRNA	estradiol-17¦Â (E2)	hormonal regulation	adrenals?tissues	estradiol-17¦Â (E2) treatment	upregulated	24205079
23692	Rat	rno-miR-96	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	downregulated	27041227
23693	Rat	rno-miR-96	miRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	hypoxic/ischemic brain damage (HIBD)	PC12 cell	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	28721600
23694	Rat	rno-miR-96	miRNA	carbon black nanoparticle (CBNP)	lung fibrosis	lung tissues and whole lung lavage fluid (WLL)	carbon black nanoparticle (CBNP) treatment	downregulated	31683435
23695	Rat	rno-miR-96	miRNA	retinal toxicant pan-CDK inhibitors	retinal toxicity	rats in renal	a single intravitreal (IVT) injection treatment	upregulated	24114799
23696	Rat	rno-miR-96	miRNA	colesevelam	zucker diabetic fatty (ZDF)	liver tissues	colesevelam treatment	upregulated	30160993
23697	Rat	rno-miR-96-5p	miRNA	high fat diet (HFD)	aging-related non-alcoholic fatty liver disease (NAFLD)	liver tissues	high fat diet (HFD) feed	downregulated	31899128
23698	Rat	rno-miR-96-5p	miRNA	particulate matter (PM2.5)	allergic rhinitis (AR)	nasal mucosa	particulate matter 2.5 (PM2.5) treatment	downregulated	32192351
23699	Rat	rno-miR-96-5p	miRNA	diethylnitrosamine (DEN)	liver fibrosis	liver tissues	diethylnitrosamine (DEN) treatment	upregulated	29236317
23700	Rat	rno-miR-96-5p	miRNA	oxymatrine	nonalcoholic fatty liver disease (NAFLD)	liver tissues	oxymatrine treatment	upregulated	32679144
23701	Rat	rno-miR-96-5p	miRNA	N-methyl-N-nitrosourea (MNU)	retinal lesions	serum	N-methyl-N-nitrosourea (MNU) treatment	"MNU at 50?mg/kg induced photoreceptor cell death, with elevation in serum miR-96-5p levels."	30336191
23702	Rat	rno-miR-96-5p	miRNA	N-methyl-N-nitrosourea (MNU)	retinal toxicity	serum	N-methyl-N-nitrosourea (MNU) treatment	upregulated	30336191
23703	Rat	rno-miR-97	miRNA	quercetin	oxidative stress	PC-12 cells	Quercetin treatment	downregulated	33343808
23704	Rat	rno-miR-98	miRNA	H2O2	acute myocardial infarction (AMI)	neonatal rat ventricular myocytes (NRVCs)	H2O2 treatment	downregulated	28784995
23705	Rat	rno-miR-98	miRNA	doxorubicin (DOX)	cardiotoxicity	neonatal rat ventricular myocytes	doxorubicin (DOX) treatment	we observed a significant increase in miR-98 expression in neonatal rat ventricular myocytes after DOX treatment	33617954
23706	Rat	rno-miR-98	miRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	lung tissue and pulmonary artery (PA) smooth muscle cells (PASMCs)	hypoxia induce	downregulated	31322216
23707	Rat	rno-miR-98	miRNA	oxygen glucose deprivation (OGD)	ischemic brain injury	Hippocampal neuronal	oxygen-glucose deprivation (OGD) treatment	downregulated	27074745
23708	Rat	rno-miR-98	miRNA	"hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)"	neurotoxicity	brain tissues of rats	RDX at a dose(47 mg/kg) for 48 h treatment	upregulated	25559034
23709	Rat	rno-miR-98	miRNA	"quinacrine, erythromycin and tetracycline"	non-surgical sterilization	Wistar albino 12-14 week old female rats	"quinacrine, erythromycin , tetracycline treatment"	upregulated	25195052
23710	Rat	rno-miR-98	miRNA	steroids	osteonecrosis of femoral head (ONFH)	bone marrow mesenchymal stem cells (BMSCs)	steroid treatment	downregulated	27910957
23711	Rat	rno-miR-98	miRNA	sevoflurane (SEV)	cognitive impairment	BRL rat hepatocyte cell line	1 or 2 minimal alveolar concentrations sevoflurane for 4 or 8 h treatment	upregulated	28260068
23712	Rat	rno-miR-98	miRNA	arsenic trioxide (ATO)	lung fibrosis	PF rat	arsenic trioxide (As2O3) treatment	upregulated	25123535
23713	Rat	rno-miR-98	miRNA	streptozocin (STZ)	type 2 diabetes mellitus (T2DM)	aortas	streptozotocin (STZ) treatment	downregulated	26840039
23714	Rat	rno-miR-98-3p	miRNA	¦Á-Lipoic acid (LA)	longevity and neuroprotection	cerebral cortex	¦Á-Lipoic acid (LA) treatment	upregulated	26694192
23715	Rat	rno-miR-98-5p	miRNA	cold	cold stress	rats serum	cold conditions (4¡æ for 12h)	downregulated	28477904
23716	Rat	rno-miR-98-5p	miRNA	"2,4,6-trinitrobenzene sulfonic acid (TNBS)"	ulcerative colitis (UC)	colon tissues	"2, 4, 6-Trinitrobenzenesulfonic acid solution (TNBS) treatment"	upregulated	33394187
23717	Rat	rno-miR-98-5p	miRNA	herb-partitioned moxibustion	ulcerative colitis (UC)	UC rats colon tissues	herb-partitioned moxibustion	upregulated	28246536
23718	Rat	rno-miR-9995-3p	miRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	33193637
23719	Rat	rno-miR-99a	miRNA	isoproterenol	cardiac hypertrophy	H9c2 cells	isoproterenol treatment	miR-99a was upregulated during ISO- induced pathological hypertrophy.	29481791
23720	Rat	rno-miR-99a	miRNA	nitrofen	hypoplastic lung	lung tissues	nitrofen treatment	upregulated	27041227
23721	Rat	rno-miR-99a	miRNA	hypoxia	myocardial infarction (MI)	H9C2 cells	hypoxia induce	downregulated	29745968
23722	Rat	rno-miR-99a	miRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	Hypoxia induced an increase of THRIL but a reduction of miR-99a and Brg1.	29745968
23723	Rat	rno-miR-99a	miRNA	isoflurane	oxidative stress	H9c2 cells	Isoflurane treatment	upregulated	29627934
23724	Rat	rno-miR-99a	miRNA	lithium chloride and pilocarpine	status epilepticus (SE)	rat hippocampus tissues	lithium-pilocarpine treatment	upregulated	21094214
23725	Rat	rno-miR-99a-5p	miRNA	ethylenethiourea (ETU)	anorectal malformations (ARM)	Hindgut tissue was isolated from the gestational day 14 and day 16 fetuses	ethylenethiourea (ETU) treatment	upregulated	30106085
23726	Rat	rno-miR-99a-5p	miRNA	steroids	osteonecrosis of femoral head (ONFH)	serum	steroid treatment	upregulated	29887962
23727	Rat	rno-miR-99a-5p	miRNA	lipopolysaccharide (LPS)	septic shock	heart tissue	lipopolysaccharide (LPS) treatment	dysregulated	31332662
23728	Rat	rno-miR-99b	miRNA	isoproterenol	cardiac hypertrophy	H9c2 cells	isoproterenol treatment	miR-99b was upregulated during ISO- induced pathological hypertrophy.	29481791
23729	Rat	rno-miR-99b	miRNA	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)	hypertension	heart tissues	deoxycorticosterone acetate (DOCA) -salt (sodium chloride) treatment	downregulated	30290168
23730	Rat	rno-miR-99b	miRNA	metformin (Met)	hypertension	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)-induced hypertension rats heart tissues	metformin (MF) treatment	upregulated	30290168
23731	Rat	rno-miR-99b	miRNA	deoxycorticosterone acetate (DOCA) -salt (sodium chloride)	hypertension-induced cardiac dysfunction	heart tissues	deoxycorticosterone acetate (DOCA) -salt (sodium chloride) treatment	downregulated	30290168
23732	Rat	rno-miR-99b	miRNA	metformin (Met)	hypertension-induced cardiac dysfunction	heart tissues	Metformin treatment	upregulated	30290168
23733	Rat	rno-miR-99b	miRNA	phosphodiesterase 5 (PDE5) inhibitor	nonalcoholic fatty liver disease (NAFLD)	plasma exosomes	phosphodiesterase 5 (PDE5) inhibitor treatment	upregulated	33396535
23734	Rat	rno-miR-99b-5p	miRNA	glucocorticoid (GC)	respiratory distress syndrome	lung	Glucocorticoids treatment	downregulated	26997989
23735	Rat	rno-miR-9a-5p	miRNA	hypoxia	cerebral ischemia injury (CII)	rats ischemic region	middle cerebral artery occlusion (MCAO) treatment	downregulated in the ischemic region	29316542
23736	Rat	rno-miR-9a-5p	miRNA	H2O2	myocardial infarction (MI)	cultured cardiomyocytes	H2O2 treatment	downregulated	31787746
23737	Rat	ROR	lncRNA	hypoxia	chronic hypoxic heart disease (CHD)	H9c2 cells	hypoxia induce	"We found that lncRNA-ROR was elevated by hypoxia in H9c2 cells. LncRNA-ROR overexpression was able to relieve the damages of H9c2 cells induced by hypoxia through rescuing viability, suppressing apoptosis, and blocking Cytochrome c release"	31190357
23738	Rat	ROR	lncRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	lncRNA-ROR was upregulated in H9c2 cells.	29694511
23739	Rat	ROR	lncRNA	hypoxia	ischemic stroke (IS)	PC12 cells	hypoxia induce	upregulated	31632583
23740	Rat	ROR	lncRNA	Skullcapflavone I (SF I)	myocardial infarction (MI)	hypoxia-stimulated H9c2 cells and primary cardiomyocytes.	Skullcapflavone I (SF I) treatment	SF I promoted the hypoxia-caused upregulated of lincRNA-ROR in H9c2 cells and primary cardiomyocytes	31220954
23741	Rat	ROR	lncRNA	ischemia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	heart tissues	the proximal left anteriordescending coronaryartery (LAD) was loosely ligated by a 6¨C0 silk suture	lncRNA ROR were upregulated in both MIRI rat model and H/R treated HCMs.	31768721
23742	Rat	RP11-513I15.6	lncRNA	diethylnitrosamine and 2-acetylaminofluorene	precancerous lesion (PCL)	liver tissues	diethylnitrosamine and 2-acetylaminofluorene treatment	upregulated	31009125
23743	Rat	RP11-513I15.6	lncRNA	pantoprazole	precancerous lesion (PCL)	liver tissues	pantoprazole treatment	downregulated	31009125
23744	Rat	RP11-583F2.2	lncRNA	diethylnitrosamine and 2-acetylaminofluorene	hepatic ischemia/reperfusion injury (HIRI)	Liver tissues and blood samples	diethylnitrosamine and 2-acetylaminofluorene treatment	upregulated	31489981
23745	Rat	RP11-583F2.2	lncRNA	hesperidin	hepatic precancerous lesion (HPC)	hepatic precancerous lesion (HPC) rat liver tissues and blood samples	Hesperidin treatment	downregulated	31489981
23746	Rat	RP4	lncRNA	hypoxia	ischemic heart disease (IHD)	H9c2 cardiac muscle cells	hypoxia induce	upregulated	31321998
23747	Rat	RPT	lncRNA	monocrotaline (MCT)	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	monocrotaline (MCT) treatment	downregulated of LnRPT was also observed in the pulmonary arteries of rats with monocrotaline-induced PAH.	28915060
23748	Rat	RPT	lncRNA	platelet derived growth factor-BB (PDGF-BB)	pulmonary arterial hypertension (PAH)	pulmonary artery smooth muscle cells (PASMCs)	platelet-derived growth factor (PDGF)-BB treatment	LnRPT was downregulated significantly in responding PDGF-BB	28915060
23749	Rat	rPvt1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	rat heart samples	lipopolysaccharide (LPS) treatment	lncRNA rPvt1 showed significant upregulation in the sepsis group	31472370
23750	Rat	RT1-CE5-002	lncRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	upregulated	29505837
23751	Rat	RT1-M3-1-002	lncRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	upregulated	29505837
23752	Rat	S69206	lncRNA	bleomycin (BLM)	lung fibrosis	fibrotic lung tissues	bleomycin (BLM) treatment	upregulated	23732278
23753	Rat	SHNG16	lncRNA	dexamethasone (DEX)	neuronal cell injury	brain tissues	dexamethasone (Dex) treatment	upregulated	32323054
23754	Rat	SHNG16	lncRNA	hypoxia	neuronal cell injury	brain tissues	middle cerebral artery occlusion (MCAO) surgery	downregulated	32323054
23755	Rat	sirt1-AS	lncRNA	astragaloside IV (AS-IV)	idiopathic pulmonary fibrosis (IPF)	RLE-6TN	astragaloside IV (AS-IV) treatment	upregulated	32139663
23756	Rat	Slc25a52	lncRNA	lipopolysaccharide (LPS)	hepatocarcinogenesis	WB-F344 cells	lipopolysaccharide (LPS) treatment	upregulated	31065105
23757	Rat	SNHG1	lncRNA	kainic acid (KA)	epilepsy	CTX-TNA2 cells	kainic acid (KA) treatment	SNHG1 expression was downregulated in EP tissues and kainic acid (KA)-induced CTX-TNA2 cells.	33359246
23758	Rat	SNHG1	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	"SNHG1 regulated cell viability, apoptosis and autophagy in LPS-treated PC12 cells"	33515352
23759	Rat	SNHG12	lncRNA	hypoxia	ischemia/reperfusion (I/R) injury	rat brain microvascular endothelial cells (BMECs)	hypoxia induce	upregulated	31293373
23760	Rat	SNHG12	lncRNA	H2O2	ischemia/reperfusion (I/R) injury	HT22 cells	oxidative stress treatment	lncRNA SNHG12 increased cell activity and inhibited oxidative stress through inhibition of SIRT1/FOXO3a signaling-mediated autophagy in HT22 cells of I/R model.	32718291
23761	Rat	SNHG12	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia-reoxygenation (H/R) treatment	"Here, we found the increase of the SNHG12 level in hypoxia-reoxygenation (H/R)-injured-H9c2 cells."	33589923
23762	Rat	SNHG14	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	upregulated	32436661
23763	Rat	SNHG14	lncRNA	hypoxia	cyanotic congenital heart disease (CCHD)	H9c2 cells	hypoxia induce	"SNHG14 and KLF4 were upregulated, whereas miR-25-3p was downregulated in hypoxia-induced H9c2 cells and cardiac tissues of patients with CCHD compared with their controls."	33278191
23764	Rat	SNHG14	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	?lncRNA-small nucleolar RNA host gene 14 (SNHG14) was found upregulated oxygen-glucose deprivation and reoxygenation (OGD/R) treated PC-12 cells	30546117
23765	Rat	SNHG14	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC-12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA-small nucleolar RNA host gene 14 (SNHG14) was found upregulated in oxygen-glucose deprivation and reoxygenation (OGD/R) treated PC-12 cells	30546117
23766	Rat	SNHG14	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	?Bioinformatics prediction and luciferase reporter assay demonstrated that miR-181b-5p could directly bind to SNHG14.	33791006
23767	Rat	SNHG15	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33528807
23768	Rat	SNHG16	lncRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	H2O2 treatment	downregulated	30977409
23769	Rat	SNHG3	lncRNA	oxygen glucose deprivation (OGD)	intracerebral haemorrhage (ICH)	primary brain microvascular endothelial cells (BMVECs)	oxygen-and-glucose-deprivation (OGD) plus hemin induce treatment	"In ICH rats, downregulated of Snhg3 by siRNA injection improved behavioral and histological manifestations, including number of right turns, limb placement score, integrity of blood-brain barrier (BBB), brain water content and cell apoptosis in vivo"	31610210
23770	Rat	SNHG4	lncRNA	puromycin aminonucleoside (PAN)	glomerular injury	primary rat podocytes	puromycin aminonucleoside (PAN) treatment	upregulated	30597036
23771	Rat	SNHG7	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	neonatal rat cardiomyocytes (NRCMs)	angiotensin II (Ang II) treatment	upregulated	31026094
23772	Rat	SNHG7	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG7 was downregulated and miR-9 was upregulated by OGD/R treatment in PC12 cells	33262598
23773	Rat	SNHG8	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	lncRNA SNHG8 affected myocardial infarction by affecting hypoxia-induced cardiomyocyte injury via regulation of the NF-kappaB pathway.	32772038
23774	Rat	SOX2OT	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	H9c2 (rat cardiomyocyte cell line)	lipopolysaccharide (LPS) treatment	upregulated	31618067
23775	Rat	SOX2OT	lncRNA	H2O2	spinal cord injury (SCI)	PC-12 cells	hydrogen peroxide (H2O2 ) treatment	Sox2ot expression was significantly increased after H2O2 treatment compared with control.	30145837
23776	Rat	SOX2OT	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	PC-12 cells	lipopolysaccharide (LPS) treatment	SOX2OT was elevated in SCI rat and cell models.	33340723
23777	Rat	SOX2OT	lncRNA	doxorubicin (DOX)	cardiomyocyte apoptosis	Primary cardiomyocytes	?doxorubicin (DOX) treatment	"SOX2-OT and DP5 were highly expressed, while miR-942-5p was downregulated in DOX-treated primary cardiomyocytes and rat model"	33603338
23778	Rat	SRA1	lncRNA	angiotensin II (Ang II)	cardiac fibrosis	Cardiac myofibroblasts	angiotensin II (Ang II) treatment	"Ang-II treatment increased the SRA1 expression of cardiac myofibroblasts, whereas SRA1 knockdown by siRNA inhibited the proliferation, myofibroblast conversion, and collagen production of cardiac myofibroblasts induced by Ang-II."	30694702
23779	Rat	SRA1	lncRNA	hypoxia	hypoxia-induced injury	H9c2 cells	hypoxia treatment	hypoxia resulted in a decreased expression of SRA1 in H9c2 cardiomyocytes.	31949848
23780	Rat	SULT1C2A	lncRNA	vitamin A	congenital scoliosis (CS)	Embryos	Vitamin A deficiency treatment	downregulated	31044535
23781	Rat	TALNEC2	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	upregulated	30861181
23782	Rat	Tap1	lncRNA	NiSO4	steroidogenesis disturbance	rat Leydig cells	NiSO4 treatment	downregulated	31948324
23783	Rat	TapSAKI	lncRNA	escherichia coli (E.coli)	sepsis-induced acute kidney injury	kidney tissues	Escherichia coli infection	"TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway."	30666657
23784	Rat	TCF7	lncRNA	hypoxia	myocardial infarction (MI)	Mesenchymal stem cells (MSCs)	hypoxia induce	upregulated	30814673
23785	Rat	TCF7	lncRNA	integrin-linked kinase (ILK)	myocardial infarction (MI)	Mesenchymal stem cells (MSCs)	integrin-linked kinase (ILK) overexpression	upregulated	30814673
23786	Rat	TCONS_00041960	lncRNA	glucocorticoid (GC)	adipogenic and osteogenic differentiation	bone marrow mesenchymal stem cells (BMSCs)	glucocorticoid treatment	we found downregulated of TCONS_00041960 during adipogenic and osteogenic differentiation of glucocorticoid-treated bone marrow mesenchymal stem cells (BMSCs).	29319166
23787	Rat	TCONS_00052110	lncRNA	lipopolysaccharide (LPS)	heart failure (HF)	myocardium	lipopolysaccharide (LPS) treatment	upregulated	30119177
23788	Rat	TCONS_00201718	lncRNA	lipopolysaccharide (LPS)	heart failure (HF)	myocardium	lipopolysaccharide (LPS) treatment	upregulated	30119177
23789	Rat	TCONS_00202959	lncRNA	acetylcholine-CaCl2 solution	atrial fibrillation (AF)	heart tissues	acetylcholine-CaCl2 solution treatment	The expression of lncRNA TCONS_00202959 was decreased in the AF group compared to the control group.	30575932
23790	Rat	TCONS_00296056	lncRNA	lipopolysaccharide (LPS)	heart failure (HF)	myocardium	lipopolysaccharide (LPS) treatment	downregulated	30119177
23791	Rat	TCONS-00088786	lncRNA	TGF-¦Â	renal fibrosis	rat renal tubular epithelial NRK-52E cells	TGF-¦Â treatment	upregulated	28912732
23792	Rat	TCONS-01496394	lncRNA	TGF-¦Â	renal fibrosis	rat renal tubular epithelial NRK-52E cells	TGF-¦Â treatment	upregulated	28912732
23793	Rat	THRIL	lncRNA	geniposide (GEN)	myocardial infarction (MI)	H9c2 cells	Geniposide (GEN) treatment	downregulated	30953616
23794	Rat	THRIL	lncRNA	hypoxia	myocardial infarction (MI)	H9C2 cells	hypoxia induce	upregulated	29745968
23795	Rat	THRIL	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia treatment	Hypoxia induced an increase of THRIL but a reduction of miR-99a and Brg1.	29745968
23796	Rat	THRIL	lncRNA	hypoxia	myocardial infarction (MI)	H9c2 cells	hypoxia induce	upregulated	30953616
23797	Rat	TINCR	lncRNA	doxorubicin (DOX)	cardiotoxicity	Primary neonatal rat cardiomyocytes (PNRC) and H9c2 cells	Doxorubicin (DOX) treatment	upregulated	31445005
23798	Rat	TINCR	lncRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	"MpostC-induced upregulated of TINCR protects cardiomyocytes from I/R injury via inhibiting degradation and ubiquitination of FGF1, and subsequently activating PKC¦Å signaling pathway."	32176291
23799	Rat	TNFRSF17	lncRNA	hypoxia	hypoxic/ischemic brain damage (HIBD)	neonatal rat brain after HIBD	hypoxia induce	downregulated	31949607
23800	Rat	TTTY15	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	PC12 cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The results of the present study revealed that TTTY15 expression was upregulated in OGD/R-treated PC12 cells	33791020
23801	Rat	TUG1	lncRNA	diosmetin (DIOS)	acute kidney injury (AKI)	RMC cells	diosmetin (DIOS) treatment	upregulated	33182044
23802	Rat	TUG1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	RMC cells	lipopolysaccharide (LPS) treatment	downregulated	33182044
23803	Rat	TUG1	lncRNA	zhenbao pill	acute spinal cord injury (ASCI)	cultured CD4+ T cells	Zhenbao Pill treatment	upregulated	30287503
23804	Rat	TUG1	lncRNA	metformin (Met)	atherosclerosis (AS)	aortic root tissue	Metformin treatment	Metformin prevent AS by activating the AMPK/mTOR pathway via lncRNA TUG1.	32099330
23805	Rat	TUG1	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	H9c2 cells	angiotensin II (Ang II) treatment	Silencing TUG1 attenuated Ang II-induced cardiac hypertrophy.	31183682
23806	Rat	TUG1	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	Primary cardiomyocytes	angiotensin II (Ang II) treatment	Our data indicated that TUG1 was upregulated and miR-497 was downregulated in the TAC rat model and Ang II-induced cardiomyocytes.	33817315
23807	Rat	TUG1	lncRNA	hypoxia	cell damage	H9c2 cells	hypoxia treatment	downregulated	29864957
23808	Rat	TUG1	lncRNA	sacubitril/valsartan (LCZ696)	chemotherapy-induced testicular atrophy	testicular	LCZ696 treatment	"LCZ696 increased lncRNA TUG1 expression, improved sperm characteristics, hormonal profile, testicular function, antioxidant defences, and Bcl-2"	32197949
23809	Rat	TUG1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Mesangial cells	high glucose treatment	downregulated	31539141
23810	Rat	TUG1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	NRK-52E cells	high glucose treatment	downregulated	31933879
23811	Rat	TUG1	lncRNA	streptozocin (STZ)	diabetic nephropathy (DN)	kidney tissues	streptozocin (STZ) treatment	downregulated	31539141
23812	Rat	TUG1	lncRNA	hypoxia	hypoxia-induced cardiac dysfunctions	H9c2 cells	hypoxia treatment	Hypoxia treatment significantly increased the expression level of TUG1.	29207102
23813	Rat	TUG1	lncRNA	H2O2	myocardial infarction (MI)	cultured cardiomyocytes	H2O2 treatment	upregulated	31787746
23814	Rat	TUG1	lncRNA	hypoxia	myocardial ischaemic injury	cardiomyocyte cell line H9c2	hypoxia	upregulated	29207102
23815	Rat	TUG1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	TUG1 silence ameliorated H/R-induced cardiomyocytes injury through regulating miR-532-5p/Sox8 axis.	32833900
23816	Rat	TUG1	lncRNA	lipopolysaccharide (LPS)	myocarditis	H9c2 cells	lipopolysaccharide (LPS) treatment	TUG1 expression was downregulated in LPS-injured H9c2 cells.	29518613
23817	Rat	TUG1	lncRNA	ketamine	neurotoxicity	primary rat hippocampal neurons	Ketamine (KET) treatment	"small interfering TUG1 (siTUG1) decreased KET-induced hippocampal neurons apoptosis and ROS level, and increased hippocampal neurons viability."	30995880
23818	Rat	TUG1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	rat mesangial cells (RMCs)	lipopolysaccharide (LPS) treatment	downregulated	30834562
23819	Rat	TUG1	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	?PC-12 cell	lipopolysaccharide (LPS) treatment	"?LPS-induced decrease of cell viability, increase of apoptosis and release of IL-6 and TNF-¦Á were mitigated by TUG1 overexpression."	31326411
23820	Rat	uc.229	lncRNA	manganese (Mn)	neurotoxicity	hippocampal neurons	Manganese (Mn) treatment	downregulated	26745496
23821	Rat	uc.242	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	Primary cardiomyocytes	angiotensin II (Ang II) treatment	upregulated	33229398
23822	Rat	uc.242	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	primary cardiomyocytes	angiotensin II (Ang II) treatment	upregulated	33229398
23823	Rat	uc.412	lncRNA	TGF-¦Â1	cell proliferation	The rat mesangial cell line RMC	transforming growth factor ¦Â1 treatment	upregulated	31638227
23824	Rat	uc.48	lncRNA	high fat diet (HFD)	diabetic neuropathic pain (DNP)	Sprague-Dawley rats	high fat diet (HFD) feed	upregulated	31966886
23825	Rat	uc.48+	lncRNA	high fat diet (HFD)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	rat myocardium	high fat diet (HFD) feed	upregulated	30417395
23826	Rat	uc.48+	lncRNA	hypoxia	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9c2 cells	hypoxia induce	upregulated	30417395
23827	Rat	uc.48+	lncRNA	high fat diet (HFD)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	left ventricular tissue	high fat diet (HFD) feed	uc.48+ was upregulated in HFD I/R myocardium.	30417395
23828	Rat	uc.80-	lncRNA	chronic unpredictable mild stress (CUMS)	depression	hippocampus	chronic unpredictable mild stress (CUMS) treatment	uc.80- was downregulated in hippocampus of depressed rats.	32780551
23829	Rat	UCA1	lncRNA	lithium chloride and pilocarpine	epilepsy	brain tissues	lithium chloride-pilocarpine treatment	upregulated	28742194
23830	Rat	UCA1	lncRNA	pilocarpine	epilepsy	hippocampus; hippocampal neurons	pilocarpine treatment	"The lncRNA UCA1 and Nrf2 were downregulated in epileptiform hippocampal tissues and neurons, while the miR-495 was upregulated"	29608952
23831	Rat	UCA1	lncRNA	hypoxia	hypoxia-induced injury	neuronal pheochromocytoma (PC)-12 cells	hypoxia treatment	upregulated	319666702
23832	Rat	UCA1	lncRNA	hypoxia	ischemia/reperfusion (I/R) injury	H9C2 cells	hypoxia induce	downregulated	30877641
23833	Rat	UCA1	lncRNA	hypoxia	myocardial infarction (MI)	neonatal rat cardiomyocytes	hypoxia induce	downregulated	30998966
23834	Rat	UCA1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial infarction (MI)	cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	lncUCA1 might protect cardiomyocyte against H/R induced apoptosis by suppressing miR-143 and modulated the following downstream MDM2/p53 signaling pathway.	30998966
23835	Rat	UCA1	lncRNA	6-hydroxydopamine (6-OHDA)	parkinson's disease (PD)	dopaminergic neurons	6-hydroxydopamine (6-OHDA) treatment	upregulated	31301558
23836	Rat	UCA1	lncRNA	kainic acid (KA)	temporal lobe epilepsy (TLE)	hippocampal astrocyte	kainic acid (KA) treatment	UCA1 inhibited hippocampal astrocyte activation and JAK/STAT/GLAST expression in TLE rats and improved the adverse reactions caused by epilepsy.	31909503
23837	Rat	Urgcp-002	lncRNA	letrozole	polycystic ovarian syndrome (PCOS)	ovarian tissues	letrozole treatment	upregulated	29505837
23838	Rat	URIDS	lncRNA	advanced glycation end product (AGE)	diabetic foot ulcer (DFU)	dermal fibroblasts	advanced glycation end products (AGEs) treatment	lnc-URIDS was highly expressed in diabetic skin and dermal fibroblasts treated with advanced glycation end products (AGEs).	32801140
23839	Rat	XIST	lncRNA	hypoxia	cardiac injury	H9c2 cells	hypoxia induce	Hypoxic H9c2 cells demonstrated a decrease in their migration and invasion abilities and lncRNA XIST expression.	31887421
23840	Rat	XIST	lncRNA	hypoxia	acute myocardial infarction (AMI)	H9c2 cells	hypoxia treatment	"XIST protects cardiomyocytes from hypoxia-induced injury by mediating miR-150-5p/Bax axis, suggesting that XIST is an important target for AMI treatment."	32096185
23841	Rat	XIST	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	Primary hippocampal neuron	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â25-35 treatment increased XIST expression in hippocampal neurons.	31949779
23842	Rat	XIST	lncRNA	hypoxia	cardiac injury	H9c2 cells	hypoxia treatment	Hypoxic H9c2 cells demonstrated a decrease in XIST expression.	31887421
23843	Rat	XIST	lncRNA	hypoxia	cardiac injury	H9c2 cells	hypoxia exposure	"XIST expressions of cardiomyocyte line, H9c2 were apparently suppressed by long-time hypoxia exposure under low glucose supply."	32415544
23844	Rat	XIST	lncRNA	ioversol	contrast-induced nephropathy (CIN)	kidney tissues	ioversol treatment	upregulated	33387208
23845	Rat	XIST	lncRNA	lipopolysaccharide (LPS)	epilepsy	CTX-TNA2 (CRL-2006) astrocyte cell line	lipopolysaccharide (LPS) treatment	upregulated	33776905
23846	Rat	XIST	lncRNA	pentylenetetrazol (PTZ)	epilepsy	dorsal hippocampus	pentylenetetrazol treatment	upregulated	33776905
23847	Rat	XIST	lncRNA	phenylephrine (PE)	hypertrophy	cardiomyoblast H9c2 cells	phenylephrine (PE) induce treatment	The expression of XIST was significantly upregulated in PE-treated cardiomyocytes Knockdown of XIST attenuated PE-induced cardiomyocyte hypertrophy	30605239
23848	Rat	XIST	lncRNA	complete freund's adjuvant (CFA)	inflammatory pain	dorsal root ganglion (DRG)	complete Freund's adjuvant (CFA) treatment	upregulated	30129228
23849	Rat	XIST	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	H9C2 cells	hypoxia/reoxygenation (H/R) induce	upregulated	31734557
23850	Rat	XIST	lncRNA	chronic constriction injury (CCI)	neuropathic pain (NP)	rats	chronic constriction injury (CCI) induce	upregulated	29115665
23851	Rat	XIST	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	PC-12 cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	33494069
23852	Rat	XIST	lncRNA	cannabinoid receptor type II (CB2R)	parkinson's disease (PD)	PC12 cells	cannabinoid receptor type II (CB2R) treatment	CB2 receptor agonist AM1241 alleviated PD via regulation of the Xist/miR-133b-3p/Pitx3 axis.	31989652
23853	Rat	XIST	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	microglial cells	lipopolysaccharide (LPS) treatment	XIST was significantly higher in LPS-induced primary microglial cells.	31778769
23854	Rat	XIST	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	mouse primary microglial cells	lipopolysaccharide (LPS) treatment	"higher level of XIST and Smurf1, but lower level of miR-27a in SCI rats and lipopolysaccharide (LPS)-induced primary microglial cells."	31778769
23855	Rat	XR_005513	lncRNA	ischemia	stroke	rat cortical tissues	focal ischemia treatment	upregulated	24063527
23856	Rat	XR_007793	lncRNA	platelet derived growth factor-BB (PDGF-BB)	neointimal formation	rat aortic smooth muscle cells	platelet-derived growth factor (PDGF)-BB treatment	XR007793 expression was significantly increased in the injured carotid artery of Sprague-Dawley rats and platelet-derived growth factor-BB induced rat aortic smooth muscle cells	30141428
23857	Rat	XR_007793	lncRNA	pathological hypertensive cyclic strain	cell proliferation and migration	vascular smooth muscle cells (VSMCs) of spontaneously hypertensive rats and Wistar-Kyoto rats	Flexcell-4000T treatment	upregulated	28319593
23858	Rat	XR_086062.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
23859	Rat	XR_145872.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
23860	Rat	XR_145894.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
23861	Rat	XR_146480.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	downregulated	30373531
23862	Rat	XR_146737.1	lncRNA	(+)-cholesten-3-one (CN)	osteoblastic differentiation	mesenchymal stem cells (MSCs)	(+)-cholesten-3-one (CN) treatment	upregulated	30373531
23863	Rat	XR_344474	lncRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnea-induced cardiovascular disease	heart tissues	chronic intermittent hypoxia (CIH) treatment	upregulated	30535531
23864	Rat	XR_590196	lncRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnea-induced cardiovascular disease	heart tissues	chronic intermittent hypoxia (CIH) treatment	downregulated	30535531
23865	Rat	XR_596701	lncRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnea-induced cardiovascular disease	heart tissues	chronic intermittent hypoxia (CIH) treatment	upregulated	30535531
23866	Rat	XR_597099	lncRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnea-induced cardiovascular disease	heart tissues	chronic intermittent hypoxia (CIH) treatment	downregulated	30535531
23867	Rat	XR_600374	lncRNA	chronic intermittent hypoxia (CIH)	obstructive sleep apnea-induced cardiovascular disease	heart tissues	chronic intermittent hypoxia (CIH) treatment	downregulated	30535531
23868	Rat	ZEB1-AS1	lncRNA	bleomycin (BLM)	lung fibrosis	rat lung tissues	bleomycin (BLM) treatment	upregulated	30755599
23869	Rat	ZEB1-AS1	lncRNA	TGF-¦Â1	lung fibrosis	RLE-6TN cells	TGF-¦Â1 treatment	upregulated	30755599
23870	Rat	ZFAS1	lncRNA	hypoxia/reoxygenation (H/R)	acute myocardial infarction (AMI)	H9c2 cells	hypoxia/reoxygenation (H/R) treatment	"ZFAS1 was upregulated in H9c2 cells subjected to I/R injury, and that ZFAS1 knockdown protected against I/R-induced myocardial cell apoptosis by directly interacting with miR-590-3p, via the NF-¦ÊB pathway."	32705215
23871	Rat	ZFAS1	lncRNA	bleomycin (BLM)	lung fibrosis	lung tissues	bleomycin (BLM) treatment	upregulated	32453709
23872	Rat	ZFAS1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	lung tissues; NR8383 cells	lipopolysaccharide (LPS) treatment	rats in LPS group also resulted in a decrease in ZFAS1 expression and increase in miR-193a-3p expression in lung tissues	33848686
12603	Rhesus monkey	mml-miR-10a	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	Proximal duodenal	¦¤9-tetrahydrocannabinol (¦¤9-THC) treatment	upregulated	25378491
12604	Rhesus monkey	mml-miR-145	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	Proximal duodenal	¦¤9-tetrahydrocannabinol (¦¤9-THC) treatment	upregulated	25378491
12605	Rhesus monkey	mml-miR-149	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	Proximal duodenal	¦¤9-tetrahydrocannabinol (¦¤9-THC) treatment	upregulated	25378491
12606	Rhesus monkey	mml-miR-187	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	Proximal duodenal	¦¤9-tetrahydrocannabinol (¦¤9-THC) treatment	upregulated	25378491
12607	Rhesus monkey	mml-miR-24	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	Proximal duodenal	¦¤9-tetrahydrocannabinol (¦¤9-THC) treatment	upregulated	25378491
12608	Rhesus monkey	mml-miR-99b	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	Proximal duodenal	¦¤9-tetrahydrocannabinol (¦¤9-THC) treatment	upregulated	25378491
12610	Rhesus monkey	mml-miR-126	miRNA	¦Ã-rays	tissue toxicity of radiation	male and female rhesus macaques (Macaca mulatta) NHPs	¦Ã-rays treatment	"downregulated (miR-126, miR-144, miR-21) and upregulation( miR-1-3p , miR-206 )"	27907140
12611	Rhesus monkey	mml-miR-1-3p	miRNA	¦Ã-rays	tissue toxicity of radiation	male and female rhesus macaques (Macaca mulatta) NHPs	¦Ã-rays treatment	"downregulated (miR-126, miR-144, miR-21) and upregulation( miR-1-3p , miR-206 )"	27907140
12612	Rhesus monkey	mml-miR-144	miRNA	¦Ã-rays	tissue toxicity of radiation	male and female rhesus macaques (Macaca mulatta) NHPs	¦Ã-rays treatment	"downregulated (miR-126, miR-144, miR-21) and upregulation( miR-1-3p , miR-206 )"	27907140
12613	Rhesus monkey	mml-miR-206	miRNA	¦Ã-rays	tissue toxicity of radiation	male and female rhesus macaques (Macaca mulatta) NHPs	¦Ã-rays treatment	"downregulated (miR-126, miR-144, miR-21) and upregulation( miR-1-3p , miR-206 )"	27907140
12614	Rhesus monkey	mml-miR-21	miRNA	¦Ã-rays	tissue toxicity of radiation	male and female rhesus macaques (Macaca mulatta) NHPs	¦Ã-rays treatment	"downregulated (miR-126, miR-144, miR-21) and upregulation( miR-1-3p , miR-206 )"	27907140
12615	Rhesus monkey	mml-miR-574-5p	miRNA	¦Ã-rays	tissue toxicity of radiation	male and female rhesus macaques (Macaca mulatta) NHPs	¦Ã-rays treatment	upregulated	27907140
12646	Rhesus monkey	mml-let-7f	miRNA	simian immunodeficiency virus (SIV)	acquired Immune Deficiency Syndrome (AIDS)	Adult male rhesus macaques	infect with SIV treatment	downregulated	24672033
12649	Rhesus monkey	mml-miR-143	miRNA	simian immunodeficiency virus (SIV)	acquired Immune Deficiency Syndrome (AIDS)	Adult male rhesus macaques	infect with SIV treatment	downregulated	24672033
12650	Rhesus monkey	mml-miR-145	miRNA	simian immunodeficiency virus (SIV)	acquired Immune Deficiency Syndrome (AIDS)	Adult male rhesus macaques	infect with SIV treatment	downregulated	24672033
12653	Rhesus monkey	mml-miR-194	miRNA	simian immunodeficiency virus (SIV)	acquired Immune Deficiency Syndrome (AIDS)	Adult male rhesus macaques	infect with SIV treatment	downregulated	24672033
12655	Rhesus monkey	mml-miR-21	miRNA	simian immunodeficiency virus (SIV)	acquired Immune Deficiency Syndrome (AIDS)	Adult male rhesus macaques	infect with SIV treatment	downregulated	24672033
23878	Rhesus monkey	mml-miR-10a	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	acute simian immunodeficiency virus infection of rhesus macaques	¦¤9-THC treatment	upregulated	25378491
23879	Rhesus monkey	mml-miR-125a-5p	miRNA	calorie restriction (CR)	delayed aging	rhesus monkeys	calorie restriction (CR) treatment	downregulated	28677323
23880	Rhesus monkey	mml-miR-130a	miRNA	simian immunodeficiency virus (SIV)	intestinal barrier dysfunction	colonic epithelium (CE)	Simian Immunodeficiency Virus (SIV) infection treatment	upregulated	29514950
23881	Rhesus monkey	mml-miR-145	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	acute simian immunodeficiency virus infection of rhesus macaques	¦¤9-THC treatment	upregulated	25378491
23882	Rhesus monkey	mml-miR-149	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	acute simian immunodeficiency virus infection of rhesus macaques	¦¤9-THC treatment	upregulated	25378491
23883	Rhesus monkey	mml-miR-155	miRNA	alcohol	hyperglycemia-induced beta-cell dysfunction	colon tissues	chronic alcohol administration	upregulated	24329418
23884	Rhesus monkey	mml-miR-155	miRNA	alcohol	systemic and mucosal infections	"rhesus macaques colon,PBMC"	chronic alcohol administration	upregulated	24329418
23885	Rhesus monkey	mml-miR-181a	miRNA	alcohol	both systemic and mucosal infections	PBMC	chronic alcohol administration	upregulated	24329418
23886	Rhesus monkey	mml-miR-181a	miRNA	alcohol	systemic and mucosal infections	"rhesus macaques colon,PBMC"	chronic alcohol administration	upregulated	24329418
23887	Rhesus monkey	mml-miR-187	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	acute simian immunodeficiency virus infection of rhesus macaques	¦¤9-THC treatment	upregulated	25378491
23888	Rhesus monkey	mml-miR-206	miRNA	simian immunodeficiency virus (SIV)	simian immunodeficiency virus (SIV) infection	Indian-derived male rhesus macaques myoblasts	infect with SIV treatment	downregulated in myoblasts	28637658
23889	Rhesus monkey	mml-miR-206	miRNA	simian immunodeficiency virus (SIV)	simian immunodeficiency virus (SIV) infection	Indian-derived male rhesus macaques plasma and muscle	daily 30-min intragastric infusions of alcohol and infect with SIV treatment	downregulated in plasma and muscle	28637658
23890	Rhesus monkey	mml-miR-212	miRNA	simian immunodeficiency virus (SIV)	intestinal barrier dysfunction	colonic epithelium (CE)	Simian Immunodeficiency Virus (SIV) infection treatment	upregulated	29514950
23891	Rhesus monkey	mml-miR-221	miRNA	alcohol	both systemic and mucosal infections	PBMC	chronic alcohol administration	upregulated	24329418
23892	Rhesus monkey	mml-miR-221	miRNA	alcohol	systemic and mucosal infections	"rhesus macaques colon,PBMC"	chronic alcohol administration	upregulated	24329418
23893	Rhesus monkey	mml-miR-24	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	acute simian immunodeficiency virus infection of rhesus macaques	¦¤9-THC treatment	upregulated	25378491
23894	Rhesus monkey	mml-miR-6790	miRNA	environmental tobacco smoke (ETS)	age-related macular degeneration (AMD)	plasma	environmental tobacco smoke (ETS) treatment	downregulated	30294202
23895	Rhesus monkey	mml-miR-6794	miRNA	environmental tobacco smoke (ETS)	age-related macular degeneration (AMD)	plasma	environmental tobacco smoke (ETS) treatment	downregulated	30294202
23896	Rhesus monkey	mml-miR-7	miRNA	rotavirus (RV)	rotavirus (RV) infection	MA104 cells	Rotavirus (RV) infection treatment	miR-7 is upregulated during Rotavirus (RV) replication	32069901
23897	Rhesus monkey	mml-miR-99b	miRNA	¦¤9-tetrahydrocannabinol (THC)	intestinal inflammation	acute simian immunodeficiency virus infection of rhesus macaques	¦¤9-THC treatment	upregulated	25378491
23898	Rice	osa-miR1425	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) and susceptible (Vandana) rice cultivars	short and prolonged heat stress and recovery	upregulated	28407080
23899	Rice	osa-miR1439	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23900	Rice	osa-miR159a	miRNA	hydrogen gas (H2)	aluminum (Al) toxicity	germinating rice seeds treated with aluminum (Al)	H2	"compared with Al alone, transcripts of miR-398a and miR-159a were downregulated by H2"	28756251
23901	Rice	osa-miR159f	miRNA	drought	cultivar-specific drought responsive (CSDR)	rice	drought treatments	upregulated	29133823
23902	Rice	osa-miR162	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) and susceptible (Vandana) rice cultivars	short and prolonged heat stress and recovery	upregulated	28407080
23903	Rice	osa-miR164a	miRNA	magnaporthe oryzae strain Guy11	magnaporthe oryzae (M. oryzae) infection	rice	magnaporthe oryzae strain Guy11 infection	osa-miR164a expression reduced upon Guy11 infection at both early and late stages.	29775494
23904	Rice	osa-miR166	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) and susceptible (Vandana) rice cultivars	short and prolonged heat stress and recovery	upregulated	28407080
23905	Rice	osa-miR167d	miRNA	magnaporthe oryzae (M. oryzae)	magnaporthe oryzae (M. oryzae) infection	rice	M. oryzae infection	"The expression of Osa-miR167d was significantly suppressed in a resistant accession at and after 24?h post inoculation (hpi), however, its expression was significantly increased at 24 hpi in the susceptible accession upon M. oryzae infection."	31001874
23906	Rice	osa-miR168	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) and susceptible (Vandana) rice cultivars	short and prolonged heat stress and recovery	upregulated	28407080
23907	Rice	osa-miR171	miRNA	chromium (Cr)	signalling pathway in rice during Cr stress	rice	chromium (Cr) treatment	"miR171 was downregulated after 7h treatment by chromium (Cr), while it was upregulated after prolonged Cr exposure (7 days)."	31792790
23908	Rice	osa-miR1848	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23909	Rice	osa-miR1862	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) and susceptible (Vandana) rice cultivars	short and prolonged heat stress and recovery	upregulated	28407080
23910	Rice	osa-miR1871	miRNA	drought	cultivar-specific drought responsive (CSDR)	rice	drought treatments	upregulated	29133823
23911	Rice	osa-miR1876	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) and susceptible (Vandana) rice cultivars	short and prolonged heat stress and recovery	upregulated	28407080
23912	Rice	osa-miR1883	miRNA	chromium (Cr)	signalling pathway in rice during Cr stress	rice	chromium (Cr) treatment	osa-miR1883 was was significantly decreased immediately after Cr exposure (24 h).	31792790
23913	Rice	osa-miR2096	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23914	Rice	osa-miR2106	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23915	Rice	osa-MIR268	miRNA	cadmium (Cd)	cadmium stress	seedlings	cadmium (Cd) treatment	upregulated	28657742
23916	Rice	osa-miR2875	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23917	Rice	osa-miR2878-5p	miRNA	drought	cultivar-specific drought responsive (CSDR)	rice	drought treatments	upregulated	29133823
23918	Rice	osa-miR396	miRNA	chromium (Cr)	signalling pathway in rice during Cr stress	rice	chromium (Cr) treatment	osa-miR396 was was significantly increased immediately after Cr exposure (24 h) and significantly reduced after prolonged Cr exposure (7 days).	31792790
23919	Rice	osa-miR397a	miRNA	drought	cultivar-specific drought responsive (CSDR)	rice	drought treatments	upregulated	29133823
23920	Rice	osa-miR3981	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23921	Rice	osa-miR398a	miRNA	hydrogen gas (H2)	aluminum (Al) toxicity	germinating rice seeds treated with aluminum (Al)	H2	"compared with Al alone, transcripts of miR-398a and miR-159a were downregulated by H2"	28756251
23922	Rice	osa-miR398b	miRNA	drought	cultivar-specific drought responsive (CSDR)	rice	drought treatments	upregulated	29133823
23923	Rice	osa-miR408-3p	miRNA	drought	cultivar-specific drought responsive (CSDR)	rice	drought treatments	upregulated	29133823
23924	Rice	osa-miR5072	miRNA	chromium (Cr)	signalling pathway in rice during Cr stress	rice	chromium (Cr) treatment	osa-miR5072 was was significantly increased immediately after Cr exposure (24 h) and significantly reduced after prolonged Cr exposure (7 days).	31792790
23925	Rice	osa-miR5079	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23926	Rice	osa-miR5151	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23927	Rice	osa-miR528-5p	miRNA	drought	cultivar-specific drought responsive (CSDR)	rice	drought treatments	upregulated	29133823
23928	Rice	osa-miR529	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) and susceptible (Vandana) rice cultivars	short and prolonged heat stress and recovery	upregulated	28407080
23929	Rice	osa-miR5484	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23930	Rice	osa-miR5485	miRNA	drought	drought resistance	"rice lines with contrasting levels of drought tolerance: IR77298-14-1-2-10, IR87705-7-15-B , IR64"	plants at booting stage by discontinuing watering	dysregulated	29045473
23931	Rice	osa-miR5487	miRNA	drought	drought resistance	"rice lines with contrasting levels of drought tolerance: IR77298-14-1-2-10, IR87705-7-15-B , IR64"	plants at booting stage by discontinuing watering	dysregulated	29045473
23932	Rice	osa-miR5492	miRNA	drought	drought resistance	"rice lines with contrasting levels of drought tolerance: IR77298-14-1-2-10, IR87705-7-15-B , IR64"	plants at booting stage by discontinuing watering	dysregulated	29045473
23933	Rice	osa-miR5517	miRNA	drought	drought resistance	"rice lines with contrasting levels of drought tolerance: IR77298-14-1-2-10, IR87705-7-15-B , IR64"	plants at booting stage by discontinuing watering	dysregulated	29045473
23934	Rice	osa-miR5792	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23935	Rice	osa-miR5812	miRNA	heat stress	oxidative stress	tolerant (Nagina 22) rice cultivars	short and prolonged heat stress and recovery	dysregulated	28407080
23936	Rubber tree	hbr-miR159	miRNA	ethylene	bark dryness syndrome	bark of rubber tree	ethylene treatment	downregulated	25289520
23937	Rubber tree	hbr-miR166	miRNA	ethylene	bark dryness syndrome	bark of rubber tree	ethylene treatment	downregulated	25289520
23938	Schistosoma japonicum	sja-miR-2162	miRNA	schistosoma japonicum	liver fibrosis	hepatic stellate cells (HSCs)	Schistosoma japonicum (S. japonicum) infection treatment	upregulated	31738999
23939	Schistosoma japonicum	sja-miR-2162	miRNA	schistosoma japonicum	liver fibrosis	hepatic stellate cells 52 (HSCs)	schistosoma japonicum (S. japonicum) infection treatment	upregulated	31738999
23940	Sheep	oar-miR-1246	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	sheep lung and spleen	infect with PPR treatment	dysregulated in lung and spleen	28694795
23941	Sheep	oar-miR-125a-5p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23942	Sheep	oar-miR-125b-5p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23943	Sheep	oar-miR-126-3p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23944	Sheep	oar-miR-133b-3p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23945	Sheep	oar-miR-208b-3p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23946	Sheep	oar-miR-210	miRNA	hypoxia	preeclampsia (PE)	pregnant sheep uterine arteries	maintain at low altitude or exposed to high altitude hypoxia for 110 days	upregulated	28739977
23947	Sheep	oar-miR-210-3p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23948	Sheep	oar-miR-21-3p	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	sheep lung and spleen	infect with PPR treatment	dysregulated in lung and spleen	28694795
23949	Sheep	oar-miR-21-5p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23950	Sheep	oar-miR-27a-5p	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	sheep lung and spleen	infect with PPR treatment	dysregulated in lung and spleen	28694795
23951	Sheep	oar-miR-29a-3p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23952	Sheep	oar-miR-320a	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23953	Sheep	oar-miR-320a	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	sheep lung and spleen	infect with PPR treatment	dysregulated in lung and spleen	28694795
23954	Sheep	oar-miR-363	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	sheep lung and spleen	infect with PPR treatment	dysregulated in lung and spleen	28694795
23955	Sheep	oar-miR-494-3p	miRNA	heart failure (HF) surgery	heart failure (HF)	ovine left ventricular (LV) tissue	7 French His-bundle electrode was implanted subepicardially in the LV wall for subsequent pacing	upregulated in left ventricular (LV) tissue	28811555
23956	Sheep	oar-miR-760-3p	miRNA	peste des petits ruminants virus (PPRV)	peste des petits ruminants (PPR) virus infection	sheep lung and spleen	infect with PPR treatment	dysregulated in lung and spleen	28694795
23969	Soybean	gma-miR169c	miRNA	high N	soybean nodulation	soybean	high N treatment	miR169c expression was induced by high N treatment.	33245793
23970	Soybean	gso-miR156hk-3p	miRNA	salt	salt stress	soybean	salt stress treatment	upregulated	32947244
23971	Soybean	gso-miR156hk-3p	miRNA	polyethylene glycol	salt stress	soybean	Polyethylene glycol treatment	downregulated	32947244
23972	Soybean	gso-miR166i-5p	miRNA	polyethylene glycol	salt stress	soybean	Polyethylene glycol treatment	downregulated	32947244
23973	Soybean	gso-miR319b-5p	miRNA	salt	salt stress	soybean	salt stress treatment	upregulated	32947244
23974	Soybean	gso-miR4414a-5p	miRNA	salt	salt stress	soybean	salt stress treatment	downregulated	32947244
23975	Soybean	gso-miR482bd-5p	miRNA	salt	salt stress	soybean	salt stress treatment	downregulated	32947244
23976	Soybean	gso-miR482bd-5p	miRNA	polyethylene glycol	salt stress	soybean	Polyethylene glycol treatment	downregulated	32947244
23977	Soybean	gso-miR6300-3p	miRNA	salt	salt stress	soybean	salt stress treatment	upregulated	32947244
23978	Soybean	gso-miR9726-3p	miRNA	salt	salt stress	soybean	salt stress treatment	upregulated	32947244
23979	Spartina alterniflora	sal-miR164	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23980	Spartina alterniflora	sal-miR168	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23981	Spartina alterniflora	sal-miR169	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23982	Spartina alterniflora	sal-miR171	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23983	Spartina alterniflora	sal-miR393	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23984	Spartina alterniflora	sal-miR395	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23985	Spartina alterniflora	sal-miR396	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23986	Spartina alterniflora	sal-miR399	miRNA	Salt	plant growth and development	Spartina alterniflora (S. alterniflora)	Salt stress treatment	downregulated	26353690
23987	Spodoptera frugiperda	Sf-miR-31	miRNA	¦Ã-rays	cell death	Sf9 cell line	¦Ã-radiation treatment	upregulated	26514984
23988	Strawberry	fan-miR73	miRNA	abscisic acid (ABA)	fruit ripening and adaptive stress responses	"Roots, stems, leaves and flowers"	abscisic acid (ABA) treatment	downregulated	27325048
23989	Sugarcane	sof-miR408	miRNA	acidovorax avenae	acidovorax avenae infection	sugarcane	acidovorax avenae infection	downregulated	29657296
23990	Sweet orange	csi-miR156	miRNA	citrus psorosis virus (CPsV)	citrus psorosis virus (CPsV) infection	sweet orange plants	Citrus psorosis virus (CPsV) treatment	downregulated	26033697
23991	Sweet orange	csi-miR167	miRNA	citrus psorosis virus (CPsV)	citrus psorosis virus (CPsV) infection	sweet orange plants	Citrus psorosis virus (CPsV) treatment	downregulated	26033697
23992	Sweet orange	csi-miR171	miRNA	citrus psorosis virus (CPsV)	citrus psorosis virus (CPsV) infection	sweet orange plants	Citrus psorosis virus (CPsV) treatment	downregulated	26033697
24026	Switchgrass	pvi-miR393a	miRNA	cold	cold stress	switchgrass (Panicum virgatum L.)	old treatment at 4¡æ for twenty days	upregulated	29069481
24027	Switchgrass	pvi-miR393a	miRNA	1-naphthaleneacetic acid (NAA)	tillering	switchgrass (Panicum virgatum L.)	1-naphthaleneacetic acid (NAA) treatment	downregulated	29069481
402	Syrian hamster	mau-miR-3470b	miRNA	bovine ephemeral fever virus (BEFV)	bovine ephemeral fever virus (BEFV) infection	Baby Hamster Syrian Kidney cells (BHK-21)	bovine ephemeral fever virus (BEFV) infection	upregulated	30587113
403	Syrian hamster	mau-miR-486	miRNA	hyperlipidemic (HL) diet	hyperlipidemia	liver and plasma	"hyperlipidemic (HL) diet (standard chow plus 3% cholesterol and 15% butter, 10 weeks) feed"	upregulated	29725814
404	Syrian hamster	mau-miR-92a	miRNA	hyperlipidemic (HL) diet	hyperlipidemia	liver and plasma	"hyperlipidemic (HL) diet (standard chow plus 3% cholesterol and 15% butter, 10 weeks) feed"	upregulated	29725814
24028	Syrian hamster	mau-miR-133a	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	downregulated	28265775
24029	Syrian hamster	mau-miR-141	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24030	Syrian hamster	mau-miR-181a	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	downregulated	28265775
24031	Syrian hamster	mau-miR-200a	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24032	Syrian hamster	mau-miR-200b	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24033	Syrian hamster	mau-miR-200c	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24034	Syrian hamster	mau-miR-21	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24035	Syrian hamster	mau-miR-29a	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24036	Syrian hamster	mau-miR-29b	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24037	Syrian hamster	mau-miR-429	miRNA	diethylstilbestrol (DES)	dysplasia/neoplasia phenomenon	neonatal Syrian golden hamsters	diethylstilbestrol (DES) treatment	upregulated	28265775
24038	Syrian hamster	mau-miR-455-5p	miRNA	pentagalloylglucose (PGG)	viral replication	rabies virus (RABV)-infected BHK-21 cells	pentagalloylglucose (PGG) treatment	downregulated	31243136
24039	Syrian hamster	mau-miR-455-5p	miRNA	rabies virus (RABV)	viral replication	BHK-21 cells	rabies virus (RABV) infection treatment	upregulated	31243136
24040	Taenia crassiceps	tcr-miR7b	miRNA	praziquantel (PZQ)	cysticercosis	T. crassiceps cysticerci	praziquantel treatment	upregulated	28526608
270	Taxus?chinensis	tch-miR1310	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ)treatment	downregulated	19393185
271	Taxus?chinensis	tch-miR156	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ)treatment	downregulated	19393185
272	Taxus?chinensis	tch-miR164	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ) treatment	upregulated	19393185
273	Taxus?chinensis	tch-miR168	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ)treatment	downregulated	19393185
274	Taxus?chinensis	tch-miR169	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ)treatment	downregulated	19393185
275	Taxus?chinensis	tch-miR172	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ)treatment	downregulated	19393185
276	Taxus?chinensis	tch-miR390	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ) treatment	upregulated	19393185
277	Taxus?chinensis	tch-miR396	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ)treatment	downregulated	19393185
278	Taxus?chinensis	tch-miR480	miRNA	methyl jasmonate (MeJA)	taxus chinensis development	Taxus chinensis (T. chinensis) cells	methyl jasmonate (MJ)treatment	downregulated	19393185
24041	Tegillarca granosa	tgr-miR-184b	miRNA	cadmium (Cd)	toxic effects of cadmium	blood clam Tegillarca granosa	cadmium (Cd) treatment	dysregulated	24690903
24042	Tegillarca granosa	tgr-miR-21	miRNA	cadmium (Cd)	toxic effects of cadmium	blood clam Tegillarca granosa	cadmium (Cd) treatment	dysregulated	24690903
24043	Tegillarca granosa	tgr-miR-2a	miRNA	cadmium (Cd)	toxic effects of cadmium	blood clam Tegillarca granosa	cadmium (Cd) treatment	dysregulated	24690903
24044	Tegillarca granosa	tgr-miR-33-5p	miRNA	cadmium (Cd)	toxic effects of cadmium	blood clam Tegillarca granosa	cadmium (Cd) treatment	dysregulated	24690903
24045	Tegillarca granosa	tgr-miR-8	miRNA	cadmium (Cd)	toxic effects of cadmium	blood clam Tegillarca granosa	cadmium (Cd) treatment	dysregulated	24690903
24046	Tibetan schizothoracine fish	tst-miR-124c-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24047	Tibetan schizothoracine fish	tst-miR-125c-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24048	Tibetan schizothoracine fish	tst-miR-130c-5p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24049	Tibetan schizothoracine fish	tst-miR-139-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24050	Tibetan schizothoracine fish	tst-miR-145	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24051	Tibetan schizothoracine fish	tst-miR-145-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24052	Tibetan schizothoracine fish	tst-miR-25-5p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24053	Tibetan schizothoracine fish	tst-miR-3-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24054	Tibetan schizothoracine fish	tst-miR-738	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24055	Tibetan schizothoracine fish	tst-miR-7a-2-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24056	Tibetan schizothoracine fish	tst-miR-7c-1-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
24057	Tibetan schizothoracine fish	tst-miR-7d-3p	miRNA	thermal acclimation	thermal acclimation	Tibetan Schizothoracine fish	exposed to 24¡ãC of 12 hours with heating rate of ~ 0.8¡ãC/h treatment	dysregulated	29045433
318	Tobacco	nta-miR156	miRNA	3-acetonyl-3-hydroxyoxindole (AHO)	systemic acquired resistance (SAR)	Nicotiana	3-acetonyl-3-hydroxyoxindole (AHO) treatment	upregulated	28970509
319	Tobacco	nta-miR172f	miRNA	3-acetonyl-3-hydroxyoxindole (AHO)	systemic acquired resistance (SAR)	Nicotiana	3-acetonyl-3-hydroxyoxindole (AHO) treatment	upregulated	28970509
320	Tobacco	nta-miR172g	miRNA	3-acetonyl-3-hydroxyoxindole (AHO)	systemic acquired resistance (SAR)	Nicotiana	3-acetonyl-3-hydroxyoxindole (AHO) treatment	upregulated	28970509
321	Tobacco	nta-miR408a	miRNA	3-acetonyl-3-hydroxyoxindole (AHO)	systemic acquired resistance (SAR)	Nicotiana	3-acetonyl-3-hydroxyoxindole (AHO) treatment	downregulated	28970509
24072	Tobacco	nta-miR156i	miRNA	mock- grown (CK) and 20 % polyethylene glycol	pEG resistance of tobacco	tobacco roots	PEG treatment	upregulated	24664280
24073	Tobacco	nta-miR160a	miRNA	mock- grown (CK) and 20 % polyethylene glycol	pEG resistance of tobacco	tobacco roots	PEG treatment	upregulated	24664280
24074	Tobacco	nta-miR162	miRNA	drought	drought stress	tobacco	drought treatments	dysregulated	28068898
24075	Tobacco	nta-miR166	miRNA	drought	drought stress	tobacco	drought treatments	dysregulated	28068898
24076	Tobacco	nta-miR168	miRNA	drought	drought stress	tobacco	drought treatments	dysregulated	28068898
24077	Tobacco	nta-miR172b	miRNA	mock- grown (CK) and 20 % polyethylene glycol	pEG resistance of tobacco	tobacco roots	PEG treatment	upregulated	24664280
24078	Tobacco	nta-miR390	miRNA	drought	drought stress	tobacco	drought treatments	dysregulated	28068898
24079	Tobacco	nta-miR395	miRNA	titanium dioxide (TiO(2))	tobacco growth and development	tobacco	low concentrations (0.1 and 1 %) of TiO(2) nanoparticles treatment	upregulated	24132512
24080	Tobacco	nta-miR398	miRNA	drought	drought stress	tobacco	drought treatments	dysregulated	28068898
24081	Tobacco	nta-miR399	miRNA	titanium dioxide (TiO(2))	tobacco growth and development	tobacco	low concentrations (0.1 and 1 %) of TiO(2) nanoparticles treatment	upregulated	24132512
24082	Tomato	lncRNA39026	lncRNA	Phytophthora infestans (P. infestans)	resistance to P. infestans	tomato plants	Phytophthora infestans infection treatment	"lncRNA39026 might function to decoy miR168a and affect the expression of PR genes in tomato plants, increasing resistance to disease"	31876247
24083	Tomato	lncRNA44664	lncRNA	Pseudomonas putida Sneb821	root-knot nematodes (RKNs) infection	tomato root	Pseudomonas putida Sneb821 treatment	downregulated	32019153
24084	Tomato	lncRNA48734	lncRNA	Pseudomonas putida Sneb821	root-knot nematodes (RKNs) infection	tomato root	Pseudomonas putida Sneb821 treatment	upregulated	32019153
24085	Tomato	sly-circRNA45	circRNA	Phytophthora infestans (P. infestans)	tomato resistance	tomato	Phytophthora infestans (P. infestans) infection treatment	"Upon P infestans infection, the relative expression of circRNA45 was continuously downregulated from 0 to 36 h post infection (hpi), subsequently upregulated at 48 hpi, and reached the peak at 72 hpi, eventually downregulated at 96 hpi"	32259631
24086	Tomato	sly-circRNA47	circRNA	Phytophthora infestans (P. infestans)	tomato resistance	tomato	Phytophthora infestans (P. infestans) infection treatment	"circRNA47 was persistently downregulated from 0 to 24 hpi, then upregulated from 36 to 72 hpi, finally downregulated at 96 hpi"	32259631
24087	Tomato	sly-miR1127-3p	miRNA	botrytis cinerea (B. cinerea)	botrytis cinerea (B. cinerea) infection	tomato	botryosphaeria dothidea infection	downregulated	29079899
24088	Tomato	sly-miR156d	lncRNA	Pseudomonas putida Sneb821	root-knot nematodes (RKNs) infection	tomato root	Pseudomonas putida Sneb821 treatment	downregulated	32019153
24089	Tomato	sly-miR156e-5p	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	upregulated	29096602
24090	Tomato	sly-mir159	miRNA	Tomato leaf curl virus (ToLCV)	leaf curl disease	the leaves of tomato	Tomato leaf curl virus (ToLCV) infection treatment	upregulated	20973960
24091	Tomato	sly-miR160	miRNA	hydrogen sulfide (H2S) and H2O2	lateral root formation	tomato lateral root	hydrogen sulfide (H2S) and hydrogen peroxide (H2O2)	upregulated	29029623
24092	Tomato	sly-miR160a	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	upregulated	29096602
24093	Tomato	sly-miR164a-5p	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	upregulated	29096602
24094	Tomato	sly-miR168a	miRNA	Phytophthora infestans (P. infestans)	resistance to P. infestans	tomato plants	Phytophthora infestans infection treatment	"lncRNA39026 might function to decoy miR168a and affect the expression of PR genes in tomato plants, increasing resistance to disease"	31876247
24095	Tomato	sly-mir172	miRNA	Tomato leaf curl virus (ToLCV)	leaf curl disease	the leaves of tomato	Tomato leaf curl virus (ToLCV) infection treatment	upregulated	20973960
24096	Tomato	sly-miR27	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	downregulated	29096602
24097	Tomato	sly-mir319	miRNA	Tomato leaf curl virus (ToLCV)	leaf curl disease	the leaves of tomato	Tomato leaf curl virus (ToLCV) infection treatment	upregulated	20973960
24098	Tomato	sly-miR390a	miRNA	hydrogen sulfide (H2S) and H2O2	lateral root formation	tomato lateral root	hydrogen sulfide (H2S) and hydrogen peroxide (H2O2)	upregulated	29029623
24099	Tomato	sly-miR393-5p	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	upregulated	29096602
24100	Tomato	sly-miR395a	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	downregulated	29096602
24101	Tomato	sly-miR396a	lncRNA	Pseudomonas putida Sneb821	root-knot nematodes (RKNs) infection	tomato root	Pseudomonas putida Sneb821 treatment	upregulated	32019153
24102	Tomato	sly-miR397-5p	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	downregulated	29096602
24103	Tomato	sly-miR397¨C5p	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	upregulated	29096602
24104	Tomato	sly-miR398b-3p	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	upregulated	29096602
24105	Tomato	sly-miR398b-3p	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	downregulated	29096602
24106	Tomato	sly-miR477-3p	miRNA	Phytophthora infestans (P. infestans)	tomato resistance	tomato	Phytophthora infestans (P. infestans) infection treatment	downregulated	32259631
24107	Tomato	sly-miR7b	miRNA	high temperature	heat stress	tomato cultivar ¡°Micro-Tom¡±	plants were exposed to 35 ¡À 1 ¡ãC/30 ¡À 1 ¡ãC (16 h day/ 8 h night) for 12 d	upregulated	29096602
24108	Vigna mungo	vmu-miR1511	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24109	Vigna mungo	vmu-miR1514	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24110	Vigna mungo	vmu-miR156	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24111	Vigna mungo	vmu-miR159	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24112	Vigna mungo	vmu-miR160	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24113	Vigna mungo	vmu-miR166	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24114	Vigna mungo	vmu-miR2118	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24115	Vigna mungo	vmu-miR398	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24116	Vigna mungo	vmu-miRn13	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24117	Vigna mungo	vmu-miRn14	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24118	Vigna mungo	vmu-miRn7	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
24119	Vigna mungo	vmu-miRn8	miRNA	Mungbean Yellow Mosaic India Virus (MYMIV)	Mungbean Yellow Mosaic India Virus (MYMIV) infection	blackgram (Vigna mungo)	infect with MYMIV	dysregulated	28224923
143	Water buffalo	bbu-miR-106a	miRNA	"glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF) 2, and epidermal growth factor (EGF)"	self-renewal and maintenance of spermatogonial stem cells	spermatogonial stem cells (SSCs)	(20?ng mL-1 GDNF +10?ng mL-1 FGF2?+?10?ng mL-1 EGF) treatment	upregulated	30589561
144	Water buffalo	bbu-miR-106a	miRNA	"glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF) 2, and epidermal growth factor (EGF)"	self-renewal and maintenance of spermatogonial stem cells	spermatogonial stem cells (SSCs)	"Glial Cell Line-Derived Neurotrophic Factor, Fibroblast Growth Factor 2, and Epidermal Growth Factor (GDNF+FGF2+EGF) treatment"	upregulated	30589561
145	Water buffalo	bbu-miR-20b	miRNA	"glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF) 2, and epidermal growth factor (EGF)"	self-renewal and maintenance of spermatogonial stem cells	spermatogonial stem cells (SSCs)	(20?ng mL-1 GDNF +10?ng mL-1 FGF2?+?10?ng mL-1 EGF) treatment	upregulated	30589561
146	Water buffalo	bbu-miR-20b	miRNA	"glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF) 2, and epidermal growth factor (EGF)"	self-renewal and maintenance of spermatogonial stem cells	spermatogonial stem cells (SSCs)	"Glial Cell Line-Derived Neurotrophic Factor, Fibroblast Growth Factor 2, and Epidermal Growth Factor (GDNF+FGF2+EGF) treatment"	upregulated	30589561
147	Water buffalo	bbu-miR-21	miRNA	"glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF) 2, and epidermal growth factor (EGF)"	self-renewal and maintenance of spermatogonial stem cells	spermatogonial stem cells (SSCs)	(20?ng mL-1 GDNF +10?ng mL-1 FGF2?+?10?ng mL-1 EGF) treatment	upregulated	30589561
148	Water buffalo	bbu-miR-21	miRNA	"glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF) 2, and epidermal growth factor (EGF)"	self-renewal and maintenance of spermatogonial stem cells	spermatogonial stem cells (SSCs)	"Glial Cell Line-Derived Neurotrophic Factor, Fibroblast Growth Factor 2, and Epidermal Growth Factor (GDNF+FGF2+EGF) treatment"	upregulated	30589561
24160	Yellow catfish	pfu-miR-141-3p	miRNA	17¦Á-ethinylestradiol (EE2)	testis development and spermatogenesis	one-year-old male yellow catfish	intraperitoneal inject 17¦Á-ethinylestradiol (EE2) at a dose of 10 ?g/g body weight treatment	upregulated	25229553
24161	Yellow catfish	pfu-miR-200a-3p	miRNA	17¦Á-ethinylestradiol (EE2)	testis development and spermatogenesis	one-year-old male yellow catfish	intraperitoneal inject 17¦Á-ethinylestradiol (EE2) at a dose of 10 ?g/g body weight treatment	upregulated	25229553
24162	Yellow catfish	pfu-miR200b-3p	miRNA	17¦Á-ethinylestradiol (EE2)	testis development and spermatogenesis	one-year-old male yellow catfish	intraperitoneal inject 17¦Á-ethinylestradiol (EE2) at a dose of 10 ?g/g body weight treatment	upregulated	25229553
24163	Yellow catfish	pfu-miR-200c-3p	miRNA	17¦Á-ethinylestradiol (EE2)	testis development and spermatogenesis	one-year-old male yellow catfish	intraperitoneal inject 17¦Á-ethinylestradiol (EE2) at a dose of 10 ?g/g body weight treatment	upregulated	25229553
24164	Yellow catfish	pfu-miR-429b-3p	miRNA	17¦Á-ethinylestradiol (EE2)	testis development and spermatogenesis	one-year-old male yellow catfish	intraperitoneal inject 17¦Á-ethinylestradiol (EE2) at a dose of 10 ?g/g body weight treatment	upregulated	25229553
24165	Zebrafish	dre-let-7	miRNA	copper (Cu)	olfactory injury	zebrafish tissue	copper (Cu) treatment	"the epigenetic regulatory mechanisms of metal-induced neurotoxicity of the fish olfactory system, and identify novel miRNA biomarkers of metal exposures."	23745839
24166	Zebrafish	dre-let-7b	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	upregulated	28215799
24167	Zebrafish	dre-let-7d	miRNA	fasted and fluoxetine (FLX)	fluoxetine exposure	zebrafish	FLX treatment	upregulated	24751937
24168	Zebrafish	dre-let-7d	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24169	Zebrafish	dre-let-7i	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	downregulated	28215799
24170	Zebrafish	dre-miR-1	miRNA	phenylephrine (PE)	myocardium hypertrophy	zebrafish hearts	phenylephrine (PE) treatment	downregulated	32681863
24171	Zebrafish	dre-miR-101b	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24172	Zebrafish	dre-miR-107	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24173	Zebrafish	dre-miR-122	miRNA	AgNO3	detoxification pathway of heavy metal ions	zebrafish fibroblasts (ZF4) cells	AgNO3 exposure	downregulated	31617658
24174	Zebrafish	dre-miR-122	miRNA	lead (Pb)	detoxification pathway of heavy metal ions	zebrafish fibroblasts (ZF4) cells	Pb(NO3 )2 exposure	downregulated	31617658
24175	Zebrafish	dre-miR-122	miRNA	ochratoxin A (OTA)	hepatocyte proliferation	embryonic zebrafish liver tissues	OTA treatment	downregulated in liver	29274910
24176	Zebrafish	dre-miR-122	miRNA	crude microcystins	hepatosis	the liver tissues	crude microcystins treatment	downregulated	23851223
24177	Zebrafish	dre-miR-122	miRNA	triptolide (TPL)	hepatotoxicity	zebrafish larvae	triptolide (TPL) treatment	downregulated	28962522
24178	Zebrafish	dre-miR-122	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	upregulated	28215799
24179	Zebrafish	dre-miR-122	miRNA	paracetamol	liver disease	zebrafish liver	17b-estradiol (E18) treatment	miRNA was substantially upregulated by paracetamol 24 h after exposure	24625211
24180	Zebrafish	dre-miR-122	miRNA	valproic acid (VPA)	teratogenesis	zebrafish embryos	valproic acid treatment	exposure to teratogens such as valproic acid alters microRNA expression profiles in developing embryos	24126255
24182	Zebrafish	dre-miR-123	miRNA	acetylcysteine	liver disease	zebrafish(3 h poststart of paracetamol exposure)	3 h poststart of paracetamol exposure treatment	upregulated	24625211
24183	Zebrafish	dre-mir-125	miRNA	triclosan (TCS)	toxicity of Triclosan (TCS)	zebrafish larvae	Triclosan (TCS) treatment	upregulated	31627110
24184	Zebrafish	dre-miR-125a	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24185	Zebrafish	dre-miR-125b	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24186	Zebrafish	dre-miR-125b	miRNA	¦Â-diketone antibiotic (DKAs)	liver disease	zebrafish	¦Â-Diketone antibiotics (DKAs) treatment	DKA-exposure at 125 and 25?mg/L significantly increased the expressions of miR-144 and miR-125b	30121499
24187	Zebrafish	dre-miR-125b	miRNA	triclosan (TCS)	triclosan (TCS) exposure	zebrafish (Danio rerio)	TCS treatment	dysregulated	29121543
24188	Zebrafish	dre-miR-125b	miRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	vitamin D-sensitive mRNA concentrations	zebrafish	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	24650217
24189	Zebrafish	dre-miR-126	miRNA	AgNO3	detoxification pathway of heavy metal ions	zebrafish fibroblasts (ZF4) cells	AgNO3 exposure	downregulated	31617658
24190	Zebrafish	dre-miR-126	miRNA	lead (Pb)	detoxification pathway of heavy metal ions	zebrafish fibroblasts (ZF4) cells	Pb(NO3 )2 exposure	downregulated	31617658
24191	Zebrafish	dre-miR-126	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24192	Zebrafish	dre-miR-126*	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24193	Zebrafish	dre-miR-128	miRNA	copper (Cu)	olfactory injury	zebrafish tissue	copper (Cu) treatment	"the epigenetic regulatory mechanisms of metal-induced neurotoxicity of the fish olfactory system, and identify novel miRNA biomarkers of metal exposures."	23745839
24194	Zebrafish	dre-miR-132	miRNA	morphine	morphine addiction	embryos of wild-type AB zebrafish line	morphine treatment	"decreases miR-212 , upregulates miR-132"	26947007
24195	Zebrafish	dre-miR-132	miRNA	valproic acid (VPA)	teratogenesis	zebrafish embryos	valproic acid treatment	exposure to teratogens such as valproic acid alters microRNA expression profiles in developing embryos	24126255
24196	Zebrafish	dre-miR-133a	miRNA	phenylephrine (PE)	myocardium hypertrophy	zebrafish hearts	phenylephrine (PE) treatment	downregulated	32681863
24197	Zebrafish	dre-miR-135a	miRNA	ethanol (EtOH)	ethanol-induced apoptosis	zebrafish embryos; neural crest cells (NCCs)	ethanol treatment	downregulated	33134300
24198	Zebrafish	dre-miR-137	miRNA	triclosan (TCS)	neurotoxicity	brain tissues	Triclosan (TCS) exposure treatment	upregulated	30496951
24199	Zebrafish	dre-miR-138	miRNA	copper (Cu)	olfactory injury	zebrafish tissue	copper (Cu) treatment	"the epigenetic regulatory mechanisms of metal-induced neurotoxicity of the fish olfactory system, and identify novel miRNA biomarkers of metal exposures."	23745839
24200	Zebrafish	dre-miR-140	miRNA	ethanol (EtOH)	alcohol-related tissue damage	muscle	ethanol treatment	downregulated	27671199
24201	Zebrafish	dre-miR-140-5p	miRNA	fasted and fluoxetine (FLX)	fluoxetine exposure	zebrafish	FLX treatment	upregulated	24751937
24202	Zebrafish	dre-miR-142a	miRNA	triclosan (TCS)	triclosan (TCS) exposure	zebrafish (Danio rerio)	TCS treatment	dysregulated	29121543
24203	Zebrafish	dre-miR-142a-5p	miRNA	RPS24 morpholino	diamond-Blackfan anemia (DBA)	zebrafish	RPS24 morpholino treatment	upregulated	25189322
24204	Zebrafish	dre-miR-142b-5p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	neurotoxicity	zebrafish larvae	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	downregulated	280728662
24205	Zebrafish	dre-miR-143	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24206	Zebrafish	dre-miR-144	miRNA	¦Â-diketone antibiotic (DKAs)	liver disease	zebrafish	¦Â-Diketone antibiotics (DKAs) treatment	DKA-exposure at 125 and 25?mg/L significantly increased the expressions of miR-144 and miR-125b	30121499
24207	Zebrafish	dre-miR-145	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24208	Zebrafish	dre-miR-146a	miRNA	aeromonas hydrophila and edwardsiella piscicida	edwardsiella piscicida infections	zebrafish	aeromonas hydrophila and edwardsiella piscicida infections	Intraperitoneally (i.p.) injected A. hydrophila and E. piscicida into adult zebrafish showed significant upregulation of miR-146a in gills.	32067211
24209	Zebrafish	dre-miR-146a	miRNA	E. piscicida	edwardsiella piscicida infections	zebrafish larvae	E. piscicida infection	The expression of miR-146a was significantly increased in larvae when exposed to E. piscicida infection at 24 and 48 h post exposure (hpe).	32067211
24210	Zebrafish	dre-miR-148	miRNA	crude microcystins	hepatosis	the liver tissues	crude microcystins treatment	downregulated	23851223
24211	Zebrafish	dre-miR-153b-3p	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	upregulated	28215799
24212	Zebrafish	dre-miR-155	miRNA	RPS24 morpholino	diamond-Blackfan anemia (DBA)	zebrafish	RPS24 morpholino treatment	upregulated	25189322
24213	Zebrafish	dre-miR-15b	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	Zebrafish embryos	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
24214	Zebrafish	dre-miR-16a	miRNA	valproic acid (VPA)	teratogenesis	zebrafish embryos	valproic acid treatment	exposure to teratogens such as valproic acid alters microRNA expression profiles in developing embryos	24126255
24215	Zebrafish	dre-miR-17a	miRNA	human chorionic gonadotrophin (hCG)	lung cancer	follicular cells	human chorionic gonadotropin treatment	downregulated	23453964
24216	Zebrafish	dre-miR-182	miRNA	light	circadian clockwork	zebrafish pineal gland	light- and dark-ed fish at six circadian times treatment	upregulated	24423866
24217	Zebrafish	dre-miR-182	miRNA	neomycin	neomycin-induced ototoxicity	hair cells	neomycin treatment	upregulated	29214789
24218	Zebrafish	dre-miR-183	miRNA	light	circadian clockwork	zebrafish pineal gland	light- and dark-ed fish at six circadian times treatment	upregulated	24423866
24219	Zebrafish	dre-miR-183	miRNA	neomycin	neomycin-induced ototoxicity	hair cells	neomycin treatment	upregulated	29214789
24220	Zebrafish	dre-miR-184	miRNA	¦Â-diketone antibiotic (DKAs)	chronic ototoxicity	otoliths during embryonic-larval development	¦Â-diketone antibiotics (DKAs) exposure treatment	downregulated	30265930
24221	Zebrafish	dre-miR-18c	miRNA	valproic acid (VPA)	teratogenesis	zebrafish embryos	valproic acid treatment	exposure to teratogens such as valproic acid alters microRNA expression profiles in developing embryos	24126255
24222	Zebrafish	dre-mir-193b	miRNA	bisphenol S (BPS)	Bisphenol S (BPS) toxicity	male zebrafish gonad	bisphenol S (BPS) treatment	upregulated	29180064
24223	Zebrafish	dre-mir-193b	miRNA	bisphenol S (BPS)	BPS-induced toxicity	male zebrafish	bisphenol S (BPS) treatment	dysregulated	29180064
24224	Zebrafish	dre-miR-199	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24225	Zebrafish	dre-miR-19a-3p	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	downregulated	28215799
24226	Zebrafish	dre-miR-19b-3p	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	downregulated	28215799
24227	Zebrafish	dre-miR-203a	miRNA	triclosan (TCS)	triclosan (TCS) exposure	zebrafish (Danio rerio)	TCS treatment	dysregulated	29121543
24228	Zebrafish	dre-miR-205	miRNA	triclosan (TCS)	triclosan (TCS) exposure	zebrafish (Danio rerio)	TCS treatment	dysregulated	29121543
24229	Zebrafish	dre-miR-21	miRNA	crude microcystins	hepatosis	the liver tissues	crude microcystins treatment	upregulated	23851223
24230	Zebrafish	dre-miR-21	miRNA	polychlorinated biphenyls (PCBs)	skeletal deficiencies	zebrafish embryos	PCB1254 treatment	upregulated	27761858
24231	Zebrafish	dre-miR-212	miRNA	MAPK inhibition (U0126)	drug addiction	Zebrafish embryos	MAPK inhibition (U0126) treatment	downregulated	30251655
24232	Zebrafish	dre-miR-212	miRNA	morphine	drug addiction	Zebrafish embryos	morphine treatment	downregulated	30251655
24233	Zebrafish	dre-miR-212	miRNA	"N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butylester (DAPT)"	drug addiction	Zebrafish embryos	"N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butylester (DAPT) treatment"	upregulated	30251655
24234	Zebrafish	dre-miR-212	miRNA	morphine	morphine addiction	embryos of wild-type AB zebrafish line	morphine treatment	"decreases miR-212 , upregulates miR-132"	26947007
24235	Zebrafish	dre-miR-214	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	Zebrafish embryos	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
24236	Zebrafish	dre-miR-217	miRNA	"triazophos (phenyl-1,2,4-triazolyl-3-(o,o-diethyl thionophosphate))"	toluene-induced toxicity	adult zebrafish (Danio rerio)	"triazophos (phenyl-1,2,4-triazolyl-3-(o,o-diethyl thionophosphate)) exposure treatment"	upregulated	30310668
24237	Zebrafish	dre-mir-223	miRNA	bisphenol S (BPS)	Bisphenol S (BPS) toxicity	male zebrafish gonad	bisphenol S (BPS) treatment	downregulated	29180064
24238	Zebrafish	dre-mir-223	miRNA	bisphenol S (BPS)	BPS-induced toxicity	male zebrafish	bisphenol S (BPS) treatment	dysregulated	29180064
24239	Zebrafish	dre-miR-223	miRNA	RPS24 morpholino	diamond-Blackfan anemia (DBA)	zebrafish	RPS24 morpholino treatment	upregulated	25189322
24240	Zebrafish	dre-miR-23a	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	Zebrafish embryos	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
24241	Zebrafish	dre-miR-24	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	upregulated	28215799
24242	Zebrafish	dre-miR-26a	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24243	Zebrafish	dre-miR-26b	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24244	Zebrafish	dre-miR-27b	miRNA	crude microcystins	hepatosis	the liver tissues	crude microcystins treatment	upregulated	23851223
24245	Zebrafish	dre-miR-29a	miRNA	RPS24 morpholino	diamond-Blackfan anemia (DBA)	zebrafish	RPS24 morpholino treatment	upregulated	25189322
24246	Zebrafish	dre-miR-301b-3p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	neurotoxicity	zebrafish larvae	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	downregulated	280728662
24247	Zebrafish	dre-mir-33	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	neurotoxicity	zebrafish larvae	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	downregulated	280728662
24248	Zebrafish	dre-miR-33-5p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	neurotoxicity	zebrafish larvae	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	downregulated	280728662
24249	Zebrafish	dre-miR-338	miRNA	RPS24 morpholino	diamond-Blackfan anemia (DBA)	zebrafish	RPS24 morpholino treatment	upregulated	25189322
24250	Zebrafish	dre-miR-338	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24251	Zebrafish	dre-mir-363	miRNA	bisphenol S (BPS)	Bisphenol S (BPS) toxicity	male zebrafish gonad	bisphenol S (BPS) treatment	downregulated	29180064
24252	Zebrafish	dre-mir-363	miRNA	bisphenol S (BPS)	BPS-induced toxicity	male zebrafish	bisphenol S (BPS) treatment	dysregulated	29180064
24253	Zebrafish	dre-miR-377	miRNA	Korean Red ginseng extract (KRGE)	angiogenesis	Zebrafish embryos	korean red ginseng extract (KRGE)? treatment	downregulated	29021694
24254	Zebrafish	dre-miR-430b	miRNA	human chorionic gonadotrophin (hCG)	lung cancer	follicular cells	human chorionic gonadotropin treatment	downregulated	23453964
24255	Zebrafish	dre-miR-457a	miRNA	RPS24 morpholino	diamond-Blackfan anemia (DBA)	zebrafish	RPS24 morpholino treatment	upregulated	25189322
24256	Zebrafish	dre-miR-459-5p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	neurotoxicity	zebrafish larvae	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	downregulated	280728662
24257	Zebrafish	dre-miR-462	miRNA	hypoxia	embryonic development	"notochord, pharyngeal arch, liver, and gut regions"	Hypoxia treatment	upregulated	26265472
24258	Zebrafish	dre-mir-499	miRNA	bisphenol S (BPS)	Bisphenol S (BPS) toxicity	male zebrafish gonad	bisphenol S (BPS) treatment	downregulated	29180064
24259	Zebrafish	dre-mir-499	miRNA	bisphenol S (BPS)	BPS-induced toxicity	male zebrafish	bisphenol S (BPS) treatment	dysregulated	29180064
24260	Zebrafish	dre-miR-57b	miRNA	valproic acid (VPA)	teratogenesis	zebrafish embryos	valproic acid treatment	exposure to teratogens such as valproic acid alters microRNA expression profiles in developing embryos	24126255
24261	Zebrafish	dre-miR-731	miRNA	hypoxia	embryonic development	"notochord, pharyngeal arch, liver, and gut regions"	Hypoxia treatment	upregulated	26265472
24262	Zebrafish	dre-miR-731	miRNA	ochratoxin A (OTA)	intracerebral haemorrhage (ICH)	zebrafish embryos	Ochratoxin A (OTA) treatment	upregulated	31675585
24263	Zebrafish	dre-miR-731	miRNA	mycotoxin ochratoxin A (OTA)	renal development	embryos	Mycotoxin ochratoxin A (OTA) treatment	upregulated	30090366
24264	Zebrafish	dre-miR-733	miRNA	estradiol-17¦Â (E2)	liver disease	zebrafish liver	estradiol-17¦Â (E2) treatment	downregulated	23767875
24265	Zebrafish	dre-miR-735-3p	miRNA	"2,2',4,4'-tetrabromodiphenyl ether (BDE47)"	neurotoxicity	zebrafish larvae	"2,2',4,4'-tetrabromodiphenyl ether (BDE47) treatment"	upregulated	280728662
24266	Zebrafish	dre-miR-7a	miRNA	particulate matter (PM2.5)	"hypertension, atherosclerosis and myocardial infarction"	zebrafish (Danio rerio)	fertilized embryos (50 per replicate) were exposed to PM2.5 for 6¨C120 h post-fertilization treatment	downregulated	28215799
24267	Zebrafish	dre-miR-7a	miRNA	copper (Cu)	olfactory injury	zebrafish tissue	copper (Cu) treatment	"the epigenetic regulatory mechanisms of metal-induced neurotoxicity of the fish olfactory system, and identify novel miRNA biomarkers of metal exposures."	23745839
24268	Zebrafish	dre-miR-96	miRNA	¦Â-diketone antibiotic (DKAs)	chronic ototoxicity	otoliths during embryonic-larval development	¦Â-diketone antibiotics (DKAs) exposure treatment	downregulated	30265930
24269	Zebrafish	dre-miR-96	miRNA	neomycin	neomycin-induced ototoxicity	hair cells	neomycin treatment	upregulated	29214789
24270	Zebrafish	dre-miR-965	miRNA	light	circadian clockwork	zebrafish pineal gland	light- and dark-ed fish at six circadian times treatment	upregulated	24423866
24271	Zebrafish	MALAT1	lncRNA	mercury	mercury toxicity in zebrafish embryos	"the brain region, eyes, and notochord of developing zebrafish embryos"	mercury exposure	upregulated	30912647
24272	Zebrafish	TCONS00017790	lncRNA	¦Â-diketone antibiotic (DKAs)	chronic ¦Â-diketone antibiotic (DKAs) exposure	zebrafish	exposure to DKAs treatment	dysregulated	27951453
24273	Zebrafish	TCONS00027240	lncRNA	¦Â-diketone antibiotic (DKAs)	chronic ¦Â-diketone antibiotic (DKAs) exposure	zebrafish	exposure to DKAs treatment	dysregulated	27951453
24274	Zebrafish	TCONS00129029	lncRNA	¦Â-diketone antibiotic (DKAs)	chronic ¦Â-diketone antibiotic (DKAs) exposure	zebrafish	exposure to DKAs treatment	dysregulated	27951453